drug_id	drug_name	drug_synonyms	drug_cas_number	drug_pubchem_cid	drug_pubchem_sid	target_id	target_name	target_synonyms	target_uniprot_id	target_entrez_id	target_ensembl_id	interaction_type
DCL000569	MK-1775	N/A	501-36-0	445154	49734167	TTDC00256	Wee1-like protein kinase	Wee1A kinase;WEE1hu	P30291	7465	ENSG00000166483	inhibitor
DAP000044	Dutasteride	AC1L49EM; NSC740477; Dutasteride; GG-745; FT-0080365; GI-198745; C27H30F6N2O2; CHEMBL283245; DB01126; Avolve; CID9914880; Avodart; GI 198745; AC1OCF98; MolPort-003-847-041; CID152945; GI-198745X; N-[2,5-bis(trifluoromethyl)phenyl]-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxamide; 1H-Indeno(5,4-f)quinoline-7-carboxamide, N-(2,5-bis(trifluoromethyl)phenyl)-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-4a,6a-dimethyl-2-oxo-, (4aR,4bS,6aS,7S,9aS,9bS,11aR)-; Duagen; CHEBI:132773; alpha,alpha,alpha,alpha',alpha',alpha'-Hexafluoro-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxy-2',5'-xylidide; Dutasteride [USAN]; 164656-23-9; (1S,3aS,3bS,5aR,9aR,9bS,11aS)-N-[2,5-bis(trifluoromethyl)phenyl]-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide; Avodart (TN); Bio-0167; Dutasteride (JAN/USAN/INN); Avodart, Dutasteride; D03820; (5alpha,17beta)-N-(2,5-Bis(trifluoromethyl)phenyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide; GG 745; MolPort-003-666-660; S1202_Selleck; (1S,3aS,3bS,5aR,9aR,11aS)-N-[2,5-bis(trifluoromethyl)phenyl]-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide; (5.alpha.,17.beta.)-N-{2,5 bis(trifluoromethyl)phenyl}-3-oxo-4-azaandrost-1-ene-17-carboxamide;dutasteride;Avodart;; CID6918296; LS-173584; ZINC03932831; UNII-O0J6XJN02I; CHEMBL1200969	164656-23-9	152945	730446	TTDS00240	5-alpha reductase	5 alpha-reductase;Hepatic 5-alpha reductase	N/A	N/A	N/A	inhibitor
DCL000519	Dutasteride & tamsulosin	N/A	N/A	N/A	N/A	TTDS00240	5-alpha reductase	5 alpha-reductase;Hepatic 5-alpha reductase	N/A	N/A	N/A	inhibitor
DAP000045	Finasteride	DB01216; F1293_SIGMA; Proscar (TN); HMS2051F09; Proscar, Propecia, Finasteride; BSPBio_000933; D00321; BPBio1_001027; 34202_RIEDEL; MLS001165768; Prestwick1_000717; S1197_Selleck; (5alpha,17beta)-(1,1-Dimethylethyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide; MK-906; DB07774; MK-0906; Merck Brand 2 of Finasteride; AC1L1MUF; Prestwick0_000717; HMS2090G22; SAM001246541; N-tert-Butyl-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxamide; Merck Frosst Brand 1 of Finasteride; Propecia; Finasterida; CHEBI:5062; N-(2-methyl-2-propyl)-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxamide; CCRIS 7438; MK906; Finasterida [INN-Spanish]; 4-Azaandrost-1-ene-17-carboxamide, N-(1,1-dimethylethyl)-3-oxo-, (5alpha,17beta)-; 98319-26-7; MSD Brand of Finasteride; BRN 4269024; ZINC03782599; MK 0906; HSDB 6793; SMR000466304; Merck Sharp & Dohme Brand 1 of Finasteride; MK 906; CHEMBL710; Finastid; KS-1058; 17beta-(N-tert-butylcarbamoyl)-4-aza-5 alpha-androst-1-en-3-one; Finpecia; L-652,931; Finasteridum; AB00513901; N-tert-Butyl-3-oxo-4-aza-5alpha-androst-1-en-17beta-carboxamide; Prostide; finasteride; HMS1570O15; BRD-K01095011-001-03-5; 4-azaandrost-1-ene-17-carboxamide, N-(1,1-dimethylethyl)-3-oxo-, (5alpha, 17beta)-; CPD000466304; Finasteride (USP/INN); Finasteride [USAN:INN:BAN]; Prestwick3_000717; (4aR,4bS,6aS,7S,9aS,9bS,11aR)-N-(1,1-dimethylethyl)-4a,6a-dimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide; Chibro Proscar; FT-0082891; AC1Q5L2C; FIT; LS-7397; SPBio_002854; Prestwick2_000717; UNII-57GNO57U7G; 34202_FLUKA; Merck Sharp & Dhome Brand 2 of Finasteride; MSD Chibropharm Brand of Finasteride; MolPort-002-500-272; Lipha Brand of Finasteride; MLS001424046; (1S,3aS,3bS,5aR,9aR,9bS,11aS)-N-tert-butyl-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide; Propeshia; Merck Brand 1 of Finasteride; YM-152; Merck Frosst Brand 2 of Finasteride; N-(2-Methyl-2-propyl)-3-oxo-4-aza-5-alpha-androst-1-ene-17-beta-carboxamide; Chibro-Proscar; Eucoprost; Andozac; Frosst Iberica Brand of Finasteride; MLS000759404; D018120; Finasteridum [INN-Latin]; Cahill May Roberts Brand of Finasteride; Proscar; CID57363; C23H36N2O2; 4-azaandrost-1-ene-17-carboxamide, N -(1,1-dimethylethyl)-3-oxo-,(5(alpha),17(beta))-; Propecia (TN); (4aR,4bS,6aS,7S,9aS,9bS,11aR)-N-(tert-butyl)-4a,6a-dimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide	98319-26-7	57363	194453	TTDS00240	5-alpha reductase	5 alpha-reductase;Hepatic 5-alpha reductase	N/A	N/A	N/A	inhibitor
DAP000889	Azelaic Acid	azelaic acid; Azelaic polyanhydride; CHEMBL1238; KBio2_000437; NINDS_000532; KBio1_000532; 19619-43-3 (unspecified potassium salt); 1tuf; Emerox 1144; Finacea; Heptanedicarboxylic acid; NCGC00093565-03; 17356-30-8 (mono-hydrochloride salt); LMFA01170054; C9H16O4; n-Nonanedioic acid; Azelex; CID2266; DB00548; ZK-62498; acidum azelaicum; 458317_ALDRICH; Spectrum_000057; 38900-29-7 (di-lithium salt); MolPort-001-779-873; SMR000059164; MLS001148615; 27825-99-6 (unspecified hydrochloride salt); NONANEDIOIC ACID; 32733-99-6; MLS000069659; AKOS000120052; 246379_ALDRICH; AI3-06299; 123-99-9; LS-22779; KBioSS_000437; NCGC00093565-01; AZELAIC ACID, 95%; 0C50D8EC-0DB0-4F24-8EFC-2919E1F0D9BF; KBio3_001256; I04-0585; KBio2_003005; NCGC00093565-04; SPECTRUM1500648; HMS2092E22; HMS501K14; Emery's L-110; Acido azelaico [Spanish]; Emerox 1110; Lopac-246379; Azleaic Acid; A-9800; HSDB 7659; 17265-13-3 (di-hydrochloride salt); Spectrum5_001304; NCGC00093565-05; Spectrum3_000278; CHEBI:48131; EINECS 204-669-1; AGN-191861; NCGC00093565-02; SDCCGMLS-0066619.P001; D03034; Azalaic Acid; Lepargylic acid; Azelaic; BIDD:GT0315; KBioGR_000662; IDI1_000532; 52457-54-2 (di-potassium salt); NCGC00093565-07; NCGC00014993-02; Azelex (TN); Nonanedioic acid, homopolymer; Azelaic acid polyanhydride; AZ1; AC1L1DAO; NSC 19493; A0561; 1,7-Heptanedicarboxylic acid; Finevin; Anchoic acid; STL059432; Acidum azelaicum [Latin]; InChI=1/C9H16O4/c10-8(11)6-4-2-1-3-5-7-9(12)13/h1-7H2,(H,10,11)(H,12,13; 26776-28-3; NCGC00014993-09; Azelaic acid [USAN:INN]; HMS1921O11; Azelainic acid; KBio2_005573; Finacea (TN); Acide azelaique [French]; Dicarboxylic acid C9; Nonanedioic acid; AZA; Lopac0_000051; AC1Q75FC; SBB060279; 1,9-Nonanedioic acid; UNII-F2VW3D43YT; Polyazelaic anhydride; Acido azelaico; Skinoren; SH-441; C08261; EU-0100051; A96150_ALDRICH; SPBio_001089; DivK1c_000532; NCGC00093565-06; Azelaic acid (USAN/INN); acide azelaique; 4-02-00-02055 (Beilstein Handbook Reference); BSPBio_001756; BRN 1101094; NSC19493; Azelaic acid, technical grade; Spectrum2_000995; Poly(azelaic anhydride); ZK 62498; Spectrum4_000401; Skinorem; NCGC00014993-01	123-99-9	2266	10460	TTDS00240	5-alpha reductase	5 alpha-reductase;Hepatic 5-alpha reductase	N/A	N/A	N/A	inhibitor
DCL000106	DG051	N/A	149409-57-4	119382	29300276	TTDC00130	Leukotriene A-4 hydrolase	Leukotriene A(4) hydrolase;Leukotriene A(4)Leukotriene A-4 hydrolase hydrolase;Leukotriene A4 hydrolase;LTA-4 hydrolase;LTA4H;LTA-H	P09960	4048	ENSG00000111144	inhibitor
DCL000786	E 7080	6-Quinolinecarboxamide, 4-(3-chloro-4-     (((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-; E-7080, E7080; 942407-57-0; 417716-92-8; E7080; S1164_Selleck; 4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxy-quinoline-6-carboxamide; CID9823820	204460-24-2	213050	30417287	TTDS00008	Vascular endothelial growth factor receptor 2	Fetal liver kinase 1;Kinase insert domain receptor;Kinase NYK;Protein-tyrosine kinase receptor Flk-1;VEGFR-2	P35968	3791	ENSG00000128052	inhibitor
DCL000355	KRN633	KRN-633; S1557_Selleck; KRN633, KRN-633, KRN 633; VEGF Receptor Tyrosine Kinase Inhibitor III, KRN633; CHEMBL406381; N-(2-Chloro-4-((6,7-dimethoxy-4-quinazolinyl)oxy)phenyl)-N&prime;-propylurea; K00589a; CID9549295	N/A	N/A	N/A	TTDS00008	Vascular endothelial growth factor receptor 2	Fetal liver kinase 1;Kinase insert domain receptor;Kinase NYK;Protein-tyrosine kinase receptor Flk-1;VEGFR-2	P35968	3791	ENSG00000128052	inhibitor
DCL000354	Cediranib	D08881; EC-000.2328; AZD2171, Recentin, Cediranib; 288383-20-0; 790713-41-6; AZD2171; ZD-2171; UNII-NQU9IPY4K9; NSC-732208; AZD-2171; AKOS005145767; 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline; Cediranib; Quinazoline, 4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxy-7-(3-(1-pyrrolidinyl)propoxy)-; AZD 2171; CID9933475; Recentin; Cediranib (USAN/INN); S1017_Selleck; M6294; CHEMBL491473; 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline; Kinome_3318	N/A	9933475	26746631	TTDS00008	Vascular endothelial growth factor receptor 2	Fetal liver kinase 1;Kinase insert domain receptor;Kinase NYK;Protein-tyrosine kinase receptor Flk-1;VEGFR-2	P35968	3791	ENSG00000128052	inhibitor
DCL000263	XL647	N/A	168626-94-6	5712	49684198	TTDS00008	Vascular endothelial growth factor receptor 2	Fetal liver kinase 1;Kinase insert domain receptor;Kinase NYK;Protein-tyrosine kinase receptor Flk-1;VEGFR-2	P35968	3791	ENSG00000128052	inhibitor
DCL000356	BAY-57-9352	2-Pyridinecarboxamide, 4-(((4-((4-chlorophenyl)amino)furo(2,3-d)pyridazin-7-yl)oxy)methyl)-N-methyl-; Bay 57-9352; UNII-18P7197Q7J; 332012-40-5; CID 9808844; CID9808844; Telatinib	332012-40-5 	9808844	75059184	TTDS00008	Vascular endothelial growth factor receptor 2	Fetal liver kinase 1;Kinase insert domain receptor;Kinase NYK;Protein-tyrosine kinase receptor Flk-1;VEGFR-2	P35968	3791	ENSG00000128052	inhibitor
DCL000353	Axitinib	ST51054130; ZINC03816287; Benzamide, N-methyl-2-((3-((1E)-2-(2-pyridinyl)ethenyl)-1H-indazo)-6-yl)thio)-; 319460-85-0; AC1O51X3; I14-1971; N-methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-indazol-6-yl)sulfanyl)benzamide; N-methyl-2-[[3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]sulfanyl]benzamide; AG 013736; C503983; Axitinib; MolPort-006-392-413; AC-1539; AG013736; UNII-C9LVQ0YUXG; S1005_Selleck; AG-013736, Axitinib; AG-013736; EC-000.2322; CID6450551; Benzamide, N-methyl-2-[[3-[(1E)-2-(2-pyridinyl)ethenyl]-1H-indazol-6-yl]thio]-; AG-13736; 790713-39-2	319460-85-0	6450551	3889615	TTDS00008	Vascular endothelial growth factor receptor 2	Fetal liver kinase 1;Kinase insert domain receptor;Kinase NYK;Protein-tyrosine kinase receptor Flk-1;VEGFR-2	P35968	3791	ENSG00000128052	inhibitor
DAP000005	Sunitinib	PDGF TK antagonist; 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-; AC1NS62J; SU 11248; 5-(5-FLUORO-2-OXO-1,2-DIHYDRO-INDOL-3-YLIDENEMETHYL)-2,4-DIMETHYL-1H-PYRROLE-3-CARBOXYLIC ACID (2-DIETHYLAMINO-ETHYL)-AMIDE; NSC736511; SU-11248J; 326914-13-0; NSC750690; K00588a; Su-011248; Sunitinib; SU-12662; KS-5022; CHEMBL535; UNII-V99T50803M; Sunitanib; 557795-19-4; N-(2-diethylaminoethyl)-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; NCGC00164631-01; SU11248; 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)- (5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-; LS-187023; DB01268; I01-1229; CID5329102; SU-11248; CHEBI:38940; sunitinibum; DB07417; LS-187648; N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; FT-0083556; Sutent; D08552; Sunitinib (free base); Sunitinib (INN); EN002687; 1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-	557795-19-4	5329102	14830382	TTDS00008	Vascular endothelial growth factor receptor 2	Fetal liver kinase 1;Kinase insert domain receptor;Kinase NYK;Protein-tyrosine kinase receptor Flk-1;VEGFR-2	P35968	3791	ENSG00000128052	inhibitor
DCL000578	Motesanib	453562-69-1; UNII-U1JK633AYI; ZINC18710082; CID11667893; AMG706; AKOS005146333; N-(3,3-dimethyl-2,3-dihydro-1H-indol-6-yl)-2-[(pyridin-4-ylmethyl)amino]pyridine-3-carboxamide; N-(2,3-dihydro-3,3-dimethyl-1H-indol-6-yl)-2-((4-pyridinylmethyl)amino)-3-pyridinecarboxamide; D06678; Motesanib; CHEMBL572881; AMG-706; AMG 706; CHEBI:51098	453562-69-1	11667893	47208329	TTDS00008	Vascular endothelial growth factor receptor 2	Fetal liver kinase 1;Kinase insert domain receptor;Kinase NYK;Protein-tyrosine kinase receptor Flk-1;VEGFR-2	P35968	3791	ENSG00000128052	inhibitor
DCL000348	PTK787/ZK 222584	N/A	212141-54-3	151194	791590	TTDS00008	Vascular endothelial growth factor receptor 2	Fetal liver kinase 1;Kinase insert domain receptor;Kinase NYK;Protein-tyrosine kinase receptor Flk-1;VEGFR-2	P35968	3791	ENSG00000128052	inhibitor
DCL000646	Sunitinib malate	SU010398; N-(2-diethylaminoethyl)-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; (2S)-2-hydroxybutanedioic acid; PNU-290940AD; SU011248; SU-010398; PHA-290940AD; AKOS005145765; FT-0083555; Sunitinib malate [USAN]; Sutent, SU-11248; D06402; SU-011248 L-malate salt; Sunitinib malate; N-(2-(Diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (2S)-hydroxybutanedioate; ST51053712; Sutent (TN); AC1O5CMQ; CHEMBL1567; 341031-54-7; LS-186078; 1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-,     (2S)-hydroxybutanedioate (1:1); CHEBI:550864; MolPort-003-986-763; 1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1); SU011248 L-malate salt; TL8002546; Sunitinib malate (JAN/USAN); UNII-LVX8N1UT73; CID6456015; Butanedioic acid, hydroxy-, (2S)-, compd. with N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (1:1); SU-11248 L-malate salt; SU 011248; S1042_Selleck	557795-19-4	5329102	14830382	TTDS00008	Vascular endothelial growth factor receptor 2	Fetal liver kinase 1;Kinase insert domain receptor;Kinase NYK;Protein-tyrosine kinase receptor Flk-1;VEGFR-2	P35968	3791	ENSG00000128052	inhibitor
DAP001550	Pazopanib HCl	N/A	N/A	N/A	N/A	TTDS00008	Vascular endothelial growth factor receptor 2	Fetal liver kinase 1;Kinase insert domain receptor;Kinase NYK;Protein-tyrosine kinase receptor Flk-1;VEGFR-2	P35968	3791	ENSG00000128052	inhibitor
DCL001168	Cabozantinib	N/A	N/A	N/A	N/A	TTDS00008	Vascular endothelial growth factor receptor 2	Fetal liver kinase 1;Kinase insert domain receptor;Kinase NYK;Protein-tyrosine kinase receptor Flk-1;VEGFR-2	P35968	3791	ENSG00000128052	inhibitor
DCL001128	4SC-203	N/A	N/A	N/A	N/A	TTDS00008	Vascular endothelial growth factor receptor 2	Fetal liver kinase 1;Kinase insert domain receptor;Kinase NYK;Protein-tyrosine kinase receptor Flk-1;VEGFR-2	P35968	3791	ENSG00000128052	inhibitor
DCL000352	OSI-930	3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide; 728033-96-3; OSI 930; S1220_Selleck; CID9868037; OSI930; OSI-930; OSI-930 is a multi-targeted tyrosine kinase inhibitor	N/A	9868037	50086917	TTDS00008	Vascular endothelial growth factor receptor 2	Fetal liver kinase 1;Kinase insert domain receptor;Kinase NYK;Protein-tyrosine kinase receptor Flk-1;VEGFR-2	P35968	3791	ENSG00000128052	inhibitor
DCL000349	CP-547632	CP 547632; CP-547,632; BFF; CHEMBL253969; Kinome_3755; CP-547632; 252003-65-9; CID9811611; 4-Isothiazolecarboxamide, 3-((4-bromo-2,6-difluorophenyl)methoxy)-5-((((4-(1-pyrrolidinyl)butyl)amino)carbonyl)amino)-; MolPort-006-827-159; 3-(4-Bromo-2,6-difluorobenzyloxy)-5-(3-(4-pyrrolidin-1-ylbutyl)ureido)isothiazole-4-carboxylic acid amide; CID 9811611	252003-65-9	9811611	56374257	TTDS00008	Vascular endothelial growth factor receptor 2	Fetal liver kinase 1;Kinase insert domain receptor;Kinase NYK;Protein-tyrosine kinase receptor Flk-1;VEGFR-2	P35968	3791	ENSG00000128052	inhibitor
DCL000011	XL999	N/A	N/A	N/A	N/A	TTDS00008	Vascular endothelial growth factor receptor 2	Fetal liver kinase 1;Kinase insert domain receptor;Kinase NYK;Protein-tyrosine kinase receptor Flk-1;VEGFR-2	P35968	3791	ENSG00000128052	inhibitor
DCL000362	CEP-7055	3-{9-oxo-13-[(propan-2-yloxy)methyl]-4,9,10,11-tetrahydro-3h-indeno[2,1-a]pyrrolo[3,4-c]carbazol-3-yl}propyl n,n-dimethylglycinate; AR-1F1464; CID216386; AC1L50N0; CEP-7055; LS-181899; AC1Q670P; Glycine, N,N-dimethyl-, 3-(5,6,7,13-tetrahydro-9-((1-methylethoxy)methyl)-5-oxo-12H-indeno(2,1-a)pyrrolo(3,4-c)carbazol-12-yl)propyl ester	133364-63-3	444266	789567	TTDS00008	Vascular endothelial growth factor receptor 2	Fetal liver kinase 1;Kinase insert domain receptor;Kinase NYK;Protein-tyrosine kinase receptor Flk-1;VEGFR-2	P35968	3791	ENSG00000128052	inhibitor
DCL000350	Vandetanib	DB08764; UNII-YO460OQ37K; 338992-00-0; CHEMBL24828; AC1MIWRU; Zactima, ZD6474; ||Zactima; CH 331; ZD 6474|; Vandetanib; Quinazolin-4-amine, N-(4-bromo-2-fluorophenyl)-6-mthoxy-7-[(1-methyl-4-piperidinyl)methoxy]-; C452423; Kinome_3316; LS-184394; N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methyl-4-piperidinyl)methoxy)-4-quinazolinamine; 4-Quninazolinamine, N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methyl-4-piperidinyl)methoxy)-; EN002713; NCGC00167513-01; CID3081361; N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-amine; NSC744325; ZD 6474; N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine; Zactima; EC-000.2359; AZD-6474; 443913-73-3; Vandetanib, Zactima, ZD6474; MolPort-005-942-399; S1046_Selleck; ZD-6474; F9995-0087; 4-(4-Bromo-2-fluoroanilino)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazoline; Vandetanib [INN]; AC-5251; CH-331; CHEBI:49960; 4-Quinazolinamine, N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-; I14-1942; Vandetanib (JAN/INN); D06407; 2ivu; ZD6474	443913-73-3	3081361	3882431	TTDS00008	Vascular endothelial growth factor receptor 2	Fetal liver kinase 1;Kinase insert domain receptor;Kinase NYK;Protein-tyrosine kinase receptor Flk-1;VEGFR-2	P35968	3791	ENSG00000128052	inhibitor
DCL000579	Motesanib diphosphate	S1032_Selleck; Motesanib diphosphate; Motesanib diphosphate [USAN]; D08947; 857876-30-3; Motesanib diphosphate (USAN); UNII-T6Q3060U91; AMG-706. Motesanib Diphosphate; EC-000.2343	850649-62-6	11450633	22395889	TTDS00008	Vascular endothelial growth factor receptor 2	Fetal liver kinase 1;Kinase insert domain receptor;Kinase NYK;Protein-tyrosine kinase receptor Flk-1;VEGFR-2	P35968	3791	ENSG00000128052	inhibitor
DCL000010	CYC116	N/A	N/A	N/A	N/A	TTDS00008	Vascular endothelial growth factor receptor 2	Fetal liver kinase 1;Kinase insert domain receptor;Kinase NYK;Protein-tyrosine kinase receptor Flk-1;VEGFR-2	P35968	3791	ENSG00000128052	inhibitor
DCL000683	Aflibercept	N/A	845771-78-0	N/A	85150458	TTDS00008	Vascular endothelial growth factor receptor 2	Fetal liver kinase 1;Kinase insert domain receptor;Kinase NYK;Protein-tyrosine kinase receptor Flk-1;VEGFR-2	P35968	3791	ENSG00000128052	inhibitor
DCL000342	SU-6668	N/A	N/A	5329099	12015385	TTDS00008	Vascular endothelial growth factor receptor 2	Fetal liver kinase 1;Kinase insert domain receptor;Kinase NYK;Protein-tyrosine kinase receptor Flk-1;VEGFR-2	P35968	3791	ENSG00000128052	inhibitor
DCL000357	SU-14813	CID 10225366; SU-14813; 1H-Pyrrole-3-carboxamide, 5-((5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-N-((2S)-2-hydroxy-3-(4-morpholinyl)propyl)-2,4-dimethyl-; 627908-92-3; SU 14813; SU14813; CID10138259; 5-((5-Fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl)-N-(2-hydroxy-3-morpholin-4-ylpropyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide	627908-92-3	10138259	77465073	TTDS00008	Vascular endothelial growth factor receptor 2	Fetal liver kinase 1;Kinase insert domain receptor;Kinase NYK;Protein-tyrosine kinase receptor Flk-1;VEGFR-2	P35968	3791	ENSG00000128052	inhibitor
DCL000096	CT-322	N/A	N/A	N/A	N/A	TTDS00008	Vascular endothelial growth factor receptor 2	Fetal liver kinase 1;Kinase insert domain receptor;Kinase NYK;Protein-tyrosine kinase receptor Flk-1;VEGFR-2	P35968	3791	ENSG00000128052	inhibitor
DCL000265	XL880	CHEMBL1230609; S1111_Selleck; XL880; GSK1363089; 88Z; GSK 1363089; EC-000.2326; 937176-80-2; XL 880; GSK 089; GSK1363089, GSK089, foretinib, EXEL-2880, XL880	N/A	N/A	N/A	TTDS00008	Vascular endothelial growth factor receptor 2	Fetal liver kinase 1;Kinase insert domain receptor;Kinase NYK;Protein-tyrosine kinase receptor Flk-1;VEGFR-2	P35968	3791	ENSG00000128052	inhibitor
DCL000351	Pazopanib	Pazopanib; CID10113978; GW-786034; I09-0358; 790713-33-6; 5-[[4-[(2,3-Dimethyl-2H-indazol-6-yl)(methyl)amino]pyrimidin-2-yl]amino]-2-methylbenzenesulfonami; GW786034; 444731-52-6; 5-[[4-[(2,3-dimethylindazol-6-yl)-methyl-amino]pyrimidin-2-yl]amino]-2-methyl-benzenesulfonamide; AKOS005145819; UNII-7RN5DR86CK; ST51053493; CHEMBL477772; MolPort-006-827-156; Votrient; GW 786034; Kinome_3790; Benzenesulfonamide, 5-((4-((2,3-dimethyl-2H-indazol-6-yl)methylamino)-2-pyrimidinyl)amino)-2-methyl-; Pazopanib [INN]; Benzenesulfonamide, 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-	444731-52-6	11525740	22395868	TTDS00008	Vascular endothelial growth factor receptor 2	Fetal liver kinase 1;Kinase insert domain receptor;Kinase NYK;Protein-tyrosine kinase receptor Flk-1;VEGFR-2	P35968	3791	ENSG00000128052	inhibitor
DAP000656	Rifabutin	(9S,12E,14S,15R,16S,17R,18R,19R,20S,21S,22E,24Z)-6,18,20-trihydroxy-1'-isobutyl-14-methoxy-7,9,15,17,19,21,25-heptamethyl-5,10,26-trioxo-3,5,9,10-tetrahydrospiro[9,4-(epoxypentadeca[1,11,13]trienoimino)furo[2',3':7,8]naphtho[1,2-d]imidazole-2,4'-piperidin; (9S,12E,14S,15R,16S,17R,18R,19R,20S,21S,22E,24Z)-6-16,18,20-Tetrahydroxy-1'-isobutyl-14-methoxy-7,9,15,17,19,21,25-heptamethylspiro(9,4-(epoxypentadeca(1,11,13)trienimino)-2H-furo(2',3':7,8)naphth(1,2-d)imidazole-2,4'-piperidine)-5,10,26(3H,9H)-trione,16-acetate; Rifabutinum [Latin]; RBT; HSDB 3577; 4-N-isobutylspiropiperidylrifamycin S; MolPort-005-938-065; Ansamycin; LM-427; BRN 3584778; D00424; UNII-1W306TDA6S; Mycobutin, Ansamycin, LM 427, Ansatipine, Rifabutin; Spiro[9,4-(epoxypentadeca[1,11,13]trienimino)-2H-furo[2',3':7,8]naphth[1,2-d]imidazole-2,4'-piperidine]-5,10,26(3H,9H)-trione, 16-(acetyloxy)-6,18,20-trihydroxy-14-methoxy-7,9,15,17,19,21,25-heptameth; CHEBI:45367; Rifabutina; 4-Deoxo-3,4-(2-spiro(N-isobutyl-4-piperidyl)-2,5-dihydro-1H-imidazo)-rifamycin S; LM 427; LS-143839; CHEMBL444633; Antibiotic LM 427; Rifabutin Pfizer Brand; SAM002589970; yl-1'-(2-methylpropyl)-, (9S,12E,14S,15R,16S,17R,18R,19R,20S,21S,22E,24Z)-; DRG-0085; SMR001227203; LM427; Rifamycin XIV, 1,4-dihydro-1-deoxy-1',4-didehydro-5'-(2-methylpropyl)-1-oxo-; MLS000759428; Rifabutin [USAN:BAN:INN]; C07235; Kenfarma Brand of Rifabutin; Prestwick2_001109; SMR000466322; Ansatipin; Ansatipine; S1741_Selleck; AC-19109; Alfacid; Rifabutine [French]; Mycobutin; NCGC00090762-01; Grunenthal Brand of Rifabutin; Rifabutine; RIFABUTIN; (9S,12E,14S,15R,16S,17R,18R,19R,20S,21S,22E,24Z)-6-16,18,20- TETRAHYDROXY-1'-ISOBUTYL-14-METHOXY-7,9,15,17,19,21,25- HEPTAMETHYLSPIRO(9,4-(EPOXYPENTADECA(1,11,13)TRIENIMINO)-2H- FURO(2',3':7,8)NAPHTH(1,2-D)IMIDAZOLE-2,4'-PIPERIDINE)- 5,10,26(3H,9H)-TRIONE,16-ACETATE; D017828; DB00615; Rifamycin XIV, 1',4-didehydro-1-deoxy-1,4-dihydro-5'-(2-methylpropyl)-1-oxo-; Pfizer Brand of Rifabutin; HMS1571M20; CID6323490; Rifabutina [Spanish]; MLS001061256; Ambap72559-06-9; C46H62N4O11; Rifabutinum; CPD001227203; 1,4-Dihydro-1-deoxy-1',4-didehydro-5'-(2-methylpropyl)-1-oxorifamycin XIV; 72559-06-9; Mycobutin (TN); Assatipin; Rifabutin (JAN/USP/INN)	72559-06-9	6323490	189788	TTDS00222	DNA-dependent RNA polymerase at the beta subunit	N/A	Q7X2I2	N/A	N/A	inhibitor
DAP001008	Fusidic Acid	Fusidate; fusidic acid; SMR000857101; (2Z)-2-[(3alpha,4alpha,5alpha,8alpha,9beta,11alpha,13alpha,14beta,16beta,17Z)-16-(acetyloxy)-3,11-dihydroxy-4,8,10,14-tetramethylgonan-17-ylidene]-6-methylhept-5-enoic acid; 3.alpha.,11.alpha.,16.beta.-Trihydroxy-29-nor-8.alpha.,9.beta.,13.alpha.,14.beta.-dammara-17(20),24-dien-21-oic acid 16-acetate; Fucidate; CHEBI:29013; 6990-06-3; Fucidin Cream 2%; 16-(Acetyloxy)-3,11-dihydroxy-29-nordammara-17(20),24-dien-21-oic acid; DB02703; NSC56192; D04281; CID3000226; Diethanolamine fusidate; Fusidine; AKOS005146257; Fucidin acid; Fusidate sodium; Fucithalmic; 29-Nordammara-17(20),24-dien-21-oic acid, 16-(acetyloxy)-3,11-dihydroxy-, (3a,4a,8a,9b,11a,13a,14b,16b,17Z)-; 29-Nor-8.alpha.,9.beta.,13.alpha.,14.beta.-dammara-17(20),24-dien-21-oic acid, 3.alpha.,11.alpha.,16.beta.-trihydroxy-, 16-acetate, (Z)-; 1qca; Fucidate Sodium; CHEMBL374975; MLS001332649; MLS001332650; F0756_SIAL; Fucidic acid; C.A.S. 62,602; (2Z)-2-[(17Z)-16beta-acetoxy-3alpha,11alpha-dihydroxy-4alpha,8alpha,10,14beta-tetramethyl-5alpha,9beta,13alpha-gonan-17-ylidene]-6-methylhept-5-enoic acid; MLS002207094; Prestwick2_000390; (2Z)-2-[(3R,4S,5S,8S,9S,10S,11R,13R,14S,16S)-16-acetyloxy-3,11-dihydroxy-4,8,10,14-tetramethyl-2,3,4,5,6,7,9,11,12,13,15,16-dodecahydro-1H-cyclopenta[a]phenanthren-17-ylidene]-6-methylhept-5-enoic acid; Fusidic acid (USAN/INN); FUCIDIN; CPD0-1606; C06694; F0756_SIGMA; AC1MHD21; LMPR0106040001; nchembio.341-comp2; Ramycin; 29-Nordammara-17(20),24-dien-21-oic acid, 16-(acetyloxy)-3,11-dihydroxy-, (3.alpha.,4.alpha.,8.alpha.,9.beta.,11.alpha.,13.alpha.,14.beta.,16.beta.,17Z)-; SQ 16,603	6990-06-3	3000226	8919	TTDS00436	Elongation factor G	EF-G	Q97SQ3	N/A	N/A	inhibitor
DCL000297	CS-8958	Inavir; CID9847629; CID 9847629; CS-8958; CHEMBL467058; R-118958; Laninamivir octanoate	N/A	N/A	N/A	TTDS00174	Neuraminidase	N-acylneuraminate glycohydrolase;NANase;Sialidase;STNA	P29768	N/A	N/A	inhibitor
DCL000286	Peramivir	Cyclopentanecarboxylic acid, 3-((1S)-1-(acetylamino)-2-ethylbutyl)-4-((aminoiminomethyl)amino)-2-hydroxy-, (1S,2S,3R,4R)-; S-021812; AC1L4BWX; CID151164; CID154234; BCX1812; RWJ270201; 3-(1-ACETYLAMINO-2-ETHYL-BUTYL)-4-GUANIDINO-2-HYDROXY-CYCLOPENTANECARBOXYLIC ACID; (1S,2S,3S,4R)-3-(1-acetamido-2-ethylbutyl)-4-(diaminomethylideneamino)-2-hydroxycyclopentane-1-carboxylic acid; UNII-QW7Y7ZR15U; BCX 1812; Cyclopentanecarboxylic acid, 3-[(1S)-1-(acetylamino)-2-ethylbutyl]-4-[(aminoiminomethyl)amino]-2-hydroxy-, (1S,2S,3R,4R)-; 330600-85-6; CHEBI:292932; RWJ 270201; RWJ-270201; Cyclopentanecarboxylic acid, 3-((1R)-1-(acetylamino)-2-ethylbutyl)-4-((aminoiminomethyl)amino)-2-hydroxy-, (1R,2R,3S,4S)-rel-; (1S,2S,3S,4R)-3-[(1S)-1-acetamido-2-ethylbutyl]-4-(diaminomethylideneamino)-2-hydroxycyclopentane-1-carboxylic acid; Rapiacta; CHEBI:41095; Peramivir; 1A5BB290; 229614-56-6; PeramiFlu; CHEMBL139367; CHEMBL332608; 3-(1'-acetylamino-2'-ethyl)butyl-4-((aminoimino)methyl)amino-2-hydroxycyclopentane-1-carboxylic acid; BCZ; 229614-55-5; AC1L45SI; BCX-1812	229614-55-5	151164	17397915	TTDS00174	Neuraminidase	N-acylneuraminate glycohydrolase;NANase;Sialidase;STNA	P29768	N/A	N/A	inhibitor
DAP000715	Zanamivir	BIDD:GT0349; GR121167X; SAM001246788; 5-Acetamido-2,6-anhydro-3,4,5-trideoxy-4-guanidino-D-glycero-D-galacto-non-2-enonic acid; 139110-80-8; CHEBI:50663; GG167; D00902; Zanamivir (USAN/INN); Relenza; (2R,3R,4S)-3-acetamido-4-(diaminomethylideneamino)-2-[(1R,2R)-1,2,3-trihydroxypropyl]-3,4-dihydro-2H-pyran-6-carboxylic acid; CID60855; GANA; ZMR; AC1L1U2A; DB00558; zanamivir; GG-167; C08095; 4-Guanidino-NeueAc2en; CPD000469215; MODIFIED SIALIC ACID; 2qwe; Relenza (TN); CHEMBL222813; 1a4g; GNA; 5-(acetylamino)-4-{[amino(imino)methyl]amino}-2,6-anhydro-3,4,5-trideoxy-D-glycero-D-galacto-non-2-enonic acid; GR-121167X; Zanamavir; Zanamivir hydrate	139110-80-8	60855	197092	TTDS00174	Neuraminidase	N-acylneuraminate glycohydrolase;NANase;Sialidase;STNA	P29768	N/A	N/A	inhibitor
DAP000714	Oseltamivir	Ro-64-0796; 1-Cyclohexene-1-carboxylic acid, 4-(acetylamino)-5-amino-3-(1-ethylpropoxy)-, ethyl ester, (3R-(3alpha,4beta,5alpha))-; C08092; ethyl (3R,4R,5S)-4-acetamido-5-amino-3-pentan-3-yloxycyclohexene-1-carboxylate; GS 4104; Oseltamivir (INN); (-)-oseltamivir; MolPort-005-933-026; GS-4104; D08306; BRD-K76011241-045-01-5; FT-0082384; ethyl (3R,4R,5S)-4-acetamido-5-amino-3-(pentan-3-yloxy)cyclohex-1-ene-1-carboxylate; BIDD:GT0426; (3R,4R,5S)-4-acetamido-5-amino-3-(pentan-3-yloxy)cyclohex-1-enecarboxylic acid; UNII-20O93L6F9H; DB00198; Agucort (TN); Ro-640796; HMS2090C11; 204255-11-8; Agucort; GS4104; CID65028; 4-Acetylamino-5-amino-3-(1-ethyl-propoxy)-cyclohex-1-enecarboxylic acid; Tamiflu-Free; oseltamivirum; oseltamivir; 196618-13-0; AC1L22FK; Tamvir; CHEMBL1229; AC1Q63H0; Oseltamivir [INN:BAN]; NCGC00178698-01; CHEBI:7798; Ethyl (5S,3R,4R)-4-(acetylamino)-5-amino-3-(ethylpropoxy)cyclohex-1-enecarboxylate; 1-Cyclohexene-1-carboxylic acid, 4-(acetylamino)-5-amino-3-(1-ethylpropoxy)-, ethyl ester, (3R,4R,5S)-; Ethyl (3R,4R,5S)-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate; LS-57422; Tamiflu (*Phosphate salt 1:1*); (3R,4R,5S)-4-Acetylamino-5-amino-3-(1-ethyl-propoxy)-cyclohex-1-enecarboxylic acid; HSDB 7433	204255-11-8	65028	626306	TTDS00174	Neuraminidase	N-acylneuraminate glycohydrolase;NANase;Sialidase;STNA	P29768	N/A	N/A	inhibitor
DCL000182	NXN-188	N/A	64815-81-2	123853	29304035	TTDC00063	Nitric-oxide synthase, brain	BNOS;Constitutive NOS;NC-NOS;Neuronal NOS;NNOS;N-NOS;NOS, type I	P29475	4842	ENSG00000089250	inhibitor
DAP001095	Efalizumab	Raptiva; Efalizumab; Efalizumab (USAN/INN); Raptiva (TN); 214745-43-4; D03959	214745-43-4	11151	47205946	TTDS00444	Lymphocyte function-associated antigen 1	CD11a;Integrin alpha-L;Leukocyte adhesion glycoprotein LFA-1 alpha chain;Leukocyte function associated molecule 1, alpha chain;LFA-1;LFA-1A;Lymphocyte Function-associated Antigen-1	Q9UBC8	N/A	N/A	antibody
DCL000132	Ilepatril	N/A	N/A	1641	48259452	TTDS00449	Neprilysin	CALLA;CD10;Common acute lymphocytic leukemia antigen;Enkephalinase;NEP;Neutral endopeptidase;Neutral endopeptidase 24.11	P08473	4311	ENSG00000196549	inhibitor
DCL000926	Pfizer 4	N/A	N/A	N/A	N/A	TTDS00449	Neprilysin	CALLA;CD10;Common acute lymphocytic leukemia antigen;Enkephalinase;NEP;Neutral endopeptidase;Neutral endopeptidase 24.11	P08473	4311	ENSG00000196549	inhibitor
DAP001145	Candoxatril	Candoxatril (JAN/USAN/INN); Candoxatril; D01070; 4-[[1-[3-(2,3-dihydro-1H-inden-5-yloxy)-2-(2-methoxyethoxymethyl)-3-oxopropyl]cyclopentanecarbonyl]amino]cyclohexane-1-carboxylic acid; Cyclohexanecarboxylic acid, 4-(((1-(3-((2,3-dihydro-1H-inden-5-yl)oxy)-2-((2-methoxyethoxy)methyl)-3-oxopropyl)cyclopentyl)carbonyl)amino)-; LS-172554; CHEBI:288288; Cyclohexanecarboxylic acid, 4-(((1-(2-carboxy-3-(2-methoxyethoxy)propyl)cyclopentyl)carbonyl)amino)-, (4(S)-cis)-; CID122116; CHEMBL326116; 3-(1-((4-Carboxycyclohexyl)carbamoyl)cyclopentyl)-2-(2-methoxyethoxymethyl)propanoic acid 5-indanyl ester; CID5362417; C29H41NO7; C062766; UK-79,300; cis-4-{[(1-{(2S)-3-(2,3-dihydro-1H-inden-5-yloxy)-2-[(2-methoxyethoxy)methyl]-3-oxopropyl}cyclopentyl)carbonyl]amino}cyclohexanecarboxylic acid; AC1NSFYL; 4-[[1-[(2S)-3-(2,3-dihydro-1H-inden-5-yloxy)-2-(2-methoxyethoxymethyl)-3-oxopropyl]cyclopentanecarbonyl]amino]cyclohexane-1-carboxylic acid; DB00616; [4(S)-cis]-4-[[[1-[3-[(2,3-dihydro-1H-indeb5-yl)oxy]-2-[(2-methoxyethoxy)methyl]-3-oxopropyl]cyclopentyl]carbonyl]amino]cyclohexanecarboxylic acid; (alphaS)-1-((cis-4-Carboxycyclohexyl)carbamoyl)-alpha-((2-methoxyethoxy)methyl)cyclopentanepropionic acid; AC1L3U07; 123122-55-4; LS-172390; UK 79300; Candoxatril [USAN:INN:BAN]; 118785-03-8; CHEBI:3353; Cyclohexanecarboxylic acid, 4-(((1-(2-carboxy-3-(2-methoxyethoxy)propyl)cyclopentyl)carbonyl)-amino)-, (4(S)-cis)	118785-03-8	5362417	13887	TTDS00449	Neprilysin	CALLA;CD10;Common acute lymphocytic leukemia antigen;Enkephalinase;NEP;Neutral endopeptidase;Neutral endopeptidase 24.11	P08473	4311	ENSG00000196549	inhibitor
DCL000024	GSK 796406	N/A	N/A	1234	48258991	TTDS00449	Neprilysin	CALLA;CD10;Common acute lymphocytic leukemia antigen;Enkephalinase;NEP;Neutral endopeptidase;Neutral endopeptidase 24.11	P08473	4311	ENSG00000196549	inhibitor
DCL000188	Omapatrilat	CID656629; (4S,7S,10aS)-5-oxo-4-[[(2S)-3-phenyl-2-sulfanylpropanoyl]amino]-2,3,4,7,8,9,10,10a-octahydropyrido[2,1-b][1,3]thiazepine-7-carboxylic acid; 167305-00-2; Omapatrilat (JAN/USAN/INN); AC1LCVB7; BMS-186716; Omapatrilat; CHEBI:159756; D01970; CHEMBL289556	167305-00-2	656629	12014939	TTDS00449	Neprilysin	CALLA;CD10;Common acute lymphocytic leukemia antigen;Enkephalinase;NEP;Neutral endopeptidase;Neutral endopeptidase 24.11	P08473	4311	ENSG00000196549	inhibitor
DCL001178	Debio 0827	N/A	N/A	N/A	N/A	TTDS00449	Neprilysin	CALLA;CD10;Common acute lymphocytic leukemia antigen;Enkephalinase;NEP;Neutral endopeptidase;Neutral endopeptidase 24.11	P08473	4311	ENSG00000196549	inhibitor
DCL000160	M100,240	142695-08-7; AC1L33RX; MDL-100240; Mdl 100240; (4S,7S,12bR)-7-[[(2S)-2-acetylsulfanyl-3-phenylpropanoyl]amino]-6-oxo-2,3,4,7,8,12b-hexahydro-1H-pyrido[2,1-a][2]benzazepine-4-carboxylic acid; Mdl 100,142; M-100240; Pyrido(2,1-a)(2)benzazepine-4-carboxylic acid, 7-((2-(acetylthio)-1-oxo-3-phenylpropyl)amino)-1,2,3,4,6,7,8,12b-octahydro-6-oxo-, (4S-(4alph,7alpha(R*),12bbeta))-; CID133985; Mdl 100,240	177172-49-5	158797	47207678	TTDS00449	Neprilysin	CALLA;CD10;Common acute lymphocytic leukemia antigen;Enkephalinase;NEP;Neutral endopeptidase;Neutral endopeptidase 24.11	P08473	4311	ENSG00000196549	inhibitor
DCL000230	SLV 306	N/A	N/A	N/A	N/A	TTDS00449	Neprilysin	CALLA;CD10;Common acute lymphocytic leukemia antigen;Enkephalinase;NEP;Neutral endopeptidase;Neutral endopeptidase 24.11	P08473	4311	ENSG00000196549	inhibitor
DAP001486	Ispaghula	Psyllium seed husk; Psyllium seed gum; Metamucil; Plantaglucide; Ispaghula; Psyllium gum; PSYLLIUM; 8063-16-9; Psyllium Husk [USP]; Fiberall	9034-32-6	N/A	167336	TTDS00001	Muscarinic acetylcholine receptor	(m)AChR;MAChR	N/A	N/A	N/A	antagonist
DAP001112	Ipratropium	Prestwick0_000575; Bitrop; X8M; BRD-A37432947-004-02-5; Apovent; (3-endo,8-syn)-3-(3-Hydroxy-1-oxo-2-phenylpropoxy)-8-methyl-8-(1-methylethyl)-8-azoniabicyclo(3.2.1)octane; Spectrum_000803; Atrovent Aerosol; MolPort-006-830-024; BPBio1_000430; KBio2_001283; AC1NWANU; Rinoberen; DB00332; Rhinotrop; SPBio_001270; ZINC13907155; L000784; CAS-22254-24-6; (8-methyl-8-propan-2-yl-8-azoniabicyclo[3.2.1]octan-3-yl) 3-hydroxy-2-phenylpropanoate; DivK1c_000201; LS-187697; NINDS_000201; IDI1_000201; CPD001906775; CHEBI:5956; UNII-GR88G0I6UL; ipratropium; Spectrum3_000471; Atrovent Hfa; KBio2_003851; (+-)-Ipratropine; 8-Azoniabicyclo(3.2.1)octane, 3-(3-hydroxy-1-oxo-2-phenylpropoxy)-8-methyl-8-(1-methylethyl)-, (endo,syn)-(+-)-; Vagos; BSPBio_000390; Ipatropium Bromide; N-Isopropylatropine; KBio2_006419; Tocris-0692; ZINC13782937; KBioSS_001283; NCGC00163226-01; LS-187321; BRD-A07029265-004-02-9; NCGC00018212-01; 3-[(3-hydroxy-2-phenylpropanoyl)oxy]-8-methyl-8-(propan-2-yl)-8-azoniabicyclo[3.2.1]octane; NCGC00178765-01; C07052; Narilet; Aerodose; NCGC00179574-01; AB00513864; AC1Q6241; CID3746; Atrovent Nasal; KBio3_001422; CID43232; Spectrum2_001275; Spectrum5_000874; NCGC00024735-01; 3-(3-Hydroxy-1-oxo-2-phenylpropoxy)-8-methyl-8-(1-methylethyl)-8-azoniabicyclo(3.2.1)octane (3-endo,8-syn)-; [(1R,5S)-8-methyl-8-propan-2-yl-8-azoniabicyclo[3.2.1]octan-3-yl] (2R)-3-hydroxy-2-phenylpropanoate; LS-182152; Kendral-Ipratropium; Rhinovent; Ipvent; BSPBio_002202; BRD-A05352148-004-02-0; 22254-24-6 (bromide); Atrovent; 8-Azoniabicyclo(3.2.1)octane, 3-(3-hydroxy-1-oxo-2-phenylpropoxy)-8-methyl-8-(1-methylethyl)-, (endo,syn)-; Prestwick1_000575; Prestwick2_000575; Spectrum4_000021; Atronase; Rinovagos; SPBio_002609; Rinatec; Prestwick3_000575; (3-endo,8-syn)-3-[(3-hydroxy-2-phenylpropanoyl)oxy]-8-isopropyl-8-methyl-8-azoniabicyclo[3.2.1]octane; 60205-81-4; CID657309; CID5702074; Disne-Asmol; NCGC00016761-01; [(1R,5R)-8-methyl-8-propan-2-yl-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate; Aerovent; SAM002564215; AC1L1GMB; Ipravent; AC1O7GEJ; Apo-Ipravent; [(5R)-8-methyl-8-propan-2-yl-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate; AR-1F0540; ipratropium bromide; KBio1_000201; BIDD:GT0659; AC1LCWC1; CID6604365; [(1R,5S)-8-methyl-8-propan-2-yl-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate; HMS2089K19; KBioGR_000421; AC1L29FR	60205-81-4	43232	183666	TTDS00001	Muscarinic acetylcholine receptor	(m)AChR;MAChR	N/A	N/A	N/A	antagonist
DAP000342	Trospium	Trospium; 8-Benziloyloxy-6,10-ethano-5-azoniaspiro(4.5)decane chloride; MolPort-003-850-800; spiro[8-azoniabicyclo[3.2.1]octane-8,1'-azolidin-1-ium]-3-yl 2-hydroxy-2,2-diphenylacetate chloride; I06-0400; AC1Q1SI9; DB00209; spiro[8-azoniabicyclo[3.2.1]octane-8,1'-azolidin-1-ium]-3-yl 2-hydroxy-2,2-diphenylacetate; AC1L1KP8; Spasmex (TN); Spiro(8-azoniabicyclo(3.2.1)octane-8,1'-pyrrolidinium), 3-hydroxy-, chloride, benzilate; CID107979; Spasmoplex; Trospium chloride (JAN/USAN/INN); AR-1L7894; Spasmoplex (TN); CHEMBL1200605; trospium chloride; L001322; 3-Hydroxyspiro(8-azoniabicyclo(3.2.1)octane-8,1'-pyrrolidinium) chloride benzilate; D01103; LS-145788; AC1L333K; 6,10-Ethano-5-azoniaspiro(4.5)decan-8-ol, chloride, benzilate; Trosec; 10405-02-4; Spasmex; CID5596; ST51052756; IP-631	10405-02-4	5596	4894299	TTDS00001	Muscarinic acetylcholine receptor	(m)AChR;MAChR	N/A	N/A	N/A	antagonist
DAP001113	Pilocarpine	L001181; Ocusert; AC1Q6MOP; NINDS_000358; ZINC00075008; CHEBI:39460; STOCK1N-18408; Pilokarpol; NCGC00023339-03; Spectrum5_001379; Ocusert pilo-20 (TN); HSDB 3163; DB01085; Pilocarpine chloride; 2(3H)-Furanone, 3-ethyldihydro-4-[(1-methyl-1H-imidazol-5-yl)methyl]-, (3S-cis)-; (3S,4R)-3-ethyl-4-[(1-methyl-1H-imidazol-5-yl)methyl]dihydrofuran-2(3H)-one; KBio2_004155; 3-Ethyl-4-[(1-methyl-1H-imidazol-5-yl)methyl]dihydro-2(3H)-furanone; Ocu-Carpine; Spersacarpine; Salagen; pilocarpine; AR-1F3128; Pilocarpine (JAN/USP); KBioSS_001587; (3S-cis)-3-Ethyldihydro-4-((1-methyl-1H-imidazol-5-yl)methyl)-2(3H)-furanone; Spectrum_001107; Pilagan; AC1L1J0W; Lopac0_000950; KBioGR_000956; Pilocarpine-; DivK1c_000358; 3-ethyl-4-[(3-methylimidazol-4-yl)methyl]oxolan-2-one; LS-187208; SPBio_001287; P.V. Carpine Liquifilm; Pilocarpine nitrate; Spectrum4_000478; Piloptic-4; Prestwick3_000449; 54-71-7; Pilocarpine [USAN:BAN:JAN]; Pilokarpin; (+)-Pilocarpine; Syncarpine; 91484-73-0; CID5910; nchembio.78-comp9; Epicar; Piloptic-2; AI3-50523; KBio2_001587; NCGC00023339-06; Tocris-0694; Pilocarpine Mononitrate, (3S-cis)-Isomer; NCGC00023339-13; Piloptic-1; IDI1_000358; (3S-cis)-3-ethyldihydro-4-[(1-methyl-1H-imidazol-5-yl)methyl]-2(3H)-furanone; NCGC00023339-07; BSPBio_002191; 3-Ethyl-4-(3-methyl-3H-imidazol-4-ylmethyl)dihydrofuran-2-one; Pilocarpine HCl; 3-ethyl-4-((1-methyl-1H-imidazol-5-yl)methyl)dihydro-2(3H)-furanone; NSC5746; Adsorbocarpine; NCGC00023339-12; Amistura P; 2(3H)-Furanone, 3-ethyldihydro-4-((1-methyl-1H-imidazol-5-yl)methyl)-, (3S-cis)-; Piloptic-3; MolPort-002-512-506; isopilocarpine; Mi-Pilo; (3S,4R)-3-ethyl-4-[(3-methylimidazol-4-yl)methyl]oxolan-2-one; Miocarpine; KBio2_006723; Piloptic-6; C07474; 2(3H)-Furanone, 3-ethyldihydro-4-((1-methyl-1H-imidazol-5-yl)methyl)-, (3S,4R)-; KBio3_001691; D00525; Imidazole-5-butyric acid, alpha-ethyl-beta-(hydroxymethyl)-1-methyl-, gamma-lactone; NCGC00023339-08; EINECS 202-128-4; Prestwick2_000449; Almocarpine; CHEMBL550; HMS2089K17; Ocusert pilo; Prestwick0_000449; Spectrum2_001284; Piloptic-1/2; Isopto carpine; SDCCGMLS-0003164.P005; CID4819; Isoptocarpine; Pilostat; 92-13-7; BPBio1_000548; NCGC00023339-09; beta-Pilocarpine hydrochloride; Pilocarpine, Monohydrochloride, (3S-cis)-Isomer; Ocusert P 20; SPBio_002437; Minims Pilocarpine; Pilocarpol; AC1L1LEF; NCI60_004403; Prestwick1_000449; BRD-K85090592-008-05-2; (3S,4R)-3-ethyldihydro-4-((1-methyl-1H-imidazol-5-yl)methyl)-2(3H)-furanone; Spectrum3_000546; BSPBio_000498; KBio1_000358; Pilocarpin; Ocusert Pilo-40; Ocusert pilo-20; CHEBI:8207; 3-Ethyl-4-[(1-methyl-1H-imidazol-5-yl)methyl]dihydrofuran-2(3H)-one; Lopac0_000960; UNII-01MI4Q9DI3; LS-7661; BIDD:GT0217	54-71-7	5910	7847591	TTDS00001	Muscarinic acetylcholine receptor	(m)AChR;MAChR	N/A	N/A	N/A	agonist
DAP001111	Cyclopentolate	Cyclopentoiate; beta-dimethylaminoethyl (1-hydroxycyclopentyl)phenylacetate; Cyclopentylate; Prestwick3_001095; Benzeneacetic acid, .alpha.-(1-hydroxycyclopentyl)-, 2-(dimethylamino)ethyl ester; AR-1H7796; beta-(Dimethylamino)ethyl (1-hydroxycyclopentyl)phenylacetate; IDI1_000610; Cyclopentolate [INN:BAN]; CID2905; AC1Q67OG; C06932; Bell Pentolate (TN); BRD-A77291778-003-05-5; KBioSS_001336; 2-dimethylaminoethyl 2-(1-hydroxycyclopentyl)-2-phenylacetate; D07759; Cylate; alpha-(1-hydroxycyclopentyl)benzeneacetic acid 2-(dimethylamino)ethyl ester; KBio1_000610; Cyclopentolatum; (+-)-cyclopentolate; SPBio_003055; Spectrum_000856; Spectrum4_000303; Bell Pentolate; Spectrum3_000369; BSPBio_002097; 2-(Dimethylamino)ethyl (1-hydroxycyclopentyl)(phenyl)acetate; Prestwick0_001095; KBio2_001336; DivK1c_000610; Prestwick1_001095; AB00053445; 2-(Dimethylamino)ethyl 1-hydroxy-alpha-phenylcyclopentaneacetate; BPBio1_001288; Cyclopentolate (INN); Spectrum5_000793; NINDS_000610; AC1L1EQK; MolPort-005-935-560; KBio3_001317; CHEBI:4024; 1-hydroxy-alpha-phenylcyclopentaneacetic acid 2-(dimethylamino)ethyl ester; KBio2_006472; 2-(dimethylamino)ethyl 2-(1-hydroxycyclopentyl)-2-phenylacetate; Ciclopentolato [INN-Spanish]; DB00979; b-dimethylaminoethyl(1-hydroxycyclopentyl)phenylacetate; 2-Dimethylaminoethyl 2-(1-hydroxycyclopentyl)-2-phenylacetat; Cyclopentolatum [INN-Latin]; Minims Cyclopentolate; SPBio_000983; cyclopentolate; KBioGR_000886; 2-phenyl-2-(1-hydroxycyclopentyl)ethanoic acid beta-(dimethylamino)ethyl ester; EINECS 208-136-4; Ciclopentolato; Spectrum2_001122; KBio2_003904; Ocu-Pentolate; 512-15-2; Mydrilate; BSPBio_001170; Diopentolate; AC-15991; L000802; Benzeneacetic acid, alpha-(1-hydroxycyclopentyl)-, 2-(dimethylamino)ethyl ester; Prestwick2_001095; nchembio747-comp4; UNII-I76F4SHP7J; LS-175236	512-15-2	2905	9149	TTDS00001	Muscarinic acetylcholine receptor	(m)AChR;MAChR	N/A	N/A	N/A	antagonist
DAP001110	Procyclidine	Prestwick2_000844; NSC169103; 77-37-2; Prosyklidin; BSPBio_000827; SPBio_002748; AC1Q76Z5; BPBio1_000911; KBio1_000429; AR-1L1798; EINECS 201-023-0; Spectrum3_000557; 1-cyclohexyl-1-phenyl-3-pyrrolidin-1-ylpropan-1-ol; Prestwick0_000844; NINDS_000429; Prestwick3_000844; Triciclidina; 1-Cyclohexyl-1-phenyl-3-(1-pyrrolidinyl)-1-propanol; AC1L1J8M; Triciloid; Spectrum4_000489; Procidlidina; DivK1c_000429; Vagosin; 1-PYRROLIDINEPROPANOL, alpha-CYCLOHEXYL-alpha-PHENYL-; Spectrum_000862; WLN: T5NTJ A2XQR&- AL6TJ; 5-20-01-00250 (Beilstein Handbook Reference); BRD-A31800922-003-05-3; Tricoloid; IDI1_000429; AB00053533; Kemadrin; KBio2_001342; Procyclidine (INN); NSC 169103; Metanin; D08425; 1-Cyclohexyl-1-phenyl-3-pyrrolidino-1-propanol; KBio2_003910; DB00387; AC1Q77DP; Osnervan; Spectrum5_001224; Kemadrine; KBioSS_001342; CHEBI:8448; Procyclidine [INN:BAN]; SPBio_001335; KBioGR_000977; Elorine; KBio2_006478; Prociclidina [INN-Spanish]; LS-138139; BRN 0088563; 56172-67-9; Spectrum2_001298; Spamol; UNII-C6QE1Q1TKR; KBio3_001733; CID4919; procyclidine; Lergine; Procyclidinum [INN-Latin]; Procyklidin; BSPBio_002233; C07378; Procyclidinum; 107661-03-0; Prociclidina; Arpicolin; 1-Pyrrolidinepropanol, .alpha.-cyclohexyl-.alpha.-phenyl-; Tricyclamol; L001290; Prestwick1_000844; Procyclid	77-37-2	4919	9582	TTDS00001	Muscarinic acetylcholine receptor	(m)AChR;MAChR	N/A	N/A	N/A	antagonist
DAP001532	Trihexyphenidyl HCl	MolPort-003-666-299; 144-11-6 (Parent); C20H31NO; 1-cyclohexyl-1-phenyl-3-piperidin-1-ylpropan-1-ol hydrochloride; Parcopane; Trihexyphenidyl hydrochloride [JAN]; MLS001148658; 3-(1-Piperidyl)-1-cyclohexyl-1-phenyl-1-propanol hydrochloride; SMR000058515; 52-49-3; T1516_SIGMA; 1-Piperidinepropanol, alpha-cyclohexyl-alpha-phenyl-, hydrochloride; CHEMBL1092; Benzhexol hydrochloride; Artane hydrochloride; Benzhexol chloride; CPD000058515; Parkopan; Pipanol; CID66007; alpha-Cyclohexyl-alpha-phenyl-1-piperidinepropanol hydrochloride; Artane (TN); LS-116014; AC1L24EZ; Romparkin; Cyclodolum; HMS1570M03; NCGC00094393-01; AC-4520; Prestwick_133; Pargitan; Artane; 1-Piperidinepropanol, alpha-cyclohexyl-alpha-phenyl-, hydrochloride, (+-)-; (+-)-alpha-Cyclohexyl-alpha-phenyl-1-piperidinepropanol hydrochloride; ST51015131; Paralest; D00787; LS-116011; NCGC00094393-02; Peragit; Trihexyphenidyl hydrochloride (JP15/USP); HMS1921G17; T 1516; NCGC00094393-04; SAM002264652; Trihexyphenidyl-D,L Hydrochloride; Cyclodol; Triesifenidile; 1-Phenyl-1-cyclohexyl-3-piperidyl-1-propanol hydrochloride; SPECTRUM1500592; MLS000069670; UNII-AO61G82577; DL-TRIHEXYPHENIDYL; NCGC00094393-03; Pacitane; TL8003459; Tsiklodol; NCGC00094393-05; EU-0101125; DL-TRIHEXYPHENIDYL HYDROCHLORIDE; Trihexyphenidyl hydrochloride; Triexifenidila; EINECS 200-142-5; Trihexyphenidyl HCl; Tremin; WIN 511; 58947-95-8	58947-95-8	5572	46507717	TTDS00001	Muscarinic acetylcholine receptor	(m)AChR;MAChR	N/A	N/A	N/A	antagonist
DCL000750	CHF 5407	N/A	N/A	N/A	N/A	TTDS00001	Muscarinic acetylcholine receptor	(m)AChR;MAChR	N/A	N/A	N/A	antagonist
DAP001114	Flavoxate	Flavoxate HCI; 4H-1-Benzopyran-8-carboxylic acid, 3-methyl-4-oxo-2-phenyl-, 2-(1-piperidinyl)ethyl ester; Flavoxato; Bladuril; Prestwick0_000242; DW-61; BPBio1_000028; LS-39215; 15301-69-6; CHEBI:5088; BSPBio_000024; NSC114649; EINECS 239-337-5; zopyran-8-carboxylate; Piperidinoethyl-3-methylflavone-8-carboxylate; Bladuril (TN); Urispas; AK 123; CID3354; AC1L1FQT; Flavoxatum; D07961; Flavoxatum [INN-Latin]; 2-Piperidinoethyl 3-methyl-4-oxo-2-phenyl-4H-1-benzopyran-8-carboxylat; UNII-3E74Y80MEY; Prestwick1_000242; Spasuret hydrochloride; TL8001137; SPIUTQOUKAMGCX-UHFFFAOYSA-; Flavoxato [INN-Spanish]; CAS-3717-88-2; BRD-K47639036-003-03-3; NCGC00016636-01; 2-(piperidin-1-yl)ethyl 3-methyl-4-oxo-2-phenyl-4H-chromene-8-carboxylate; Flavossato; 2-Piperidinoethyl 3-methyl-4-oxo-2-phenyl-4H-1-benzopyran-8-carboxylate; Prestwick2_000242; C07809; Flavoxate HCL; Prestwick3_000242; Flavoxate (INN); L001104; SPBio_002243; beta-piperidinoethyl 3-methylflavone-8-carboxylate; InChI=1/C24H25NO4/c1-17-21(26)19-11-8-12-20(23(19)29-22(17)18-9-4-2-5-10-18)24(27)28-16-15-25-13-6-3-7-14-25/h2,4-5,8-12H,3,6-7,13-16H2,1H3; 2-(1-Piperidinyl)ethyl 3-methyl-4-oxo-2-phenyl-4H-chromene-8-carboxylate; Oprea1_293788; 2-piperidinoethyl 3-methylflavone-8-carboxylate; Flavossato [DCIT]; 2-piperidin-1-ylethyl 3-methyl-4-oxo-2-phenylchromene-8-carboxylate; 2-(1-Piperidinyl)ethyl 3-methyl-4-oxo-2-phenyl-4H-chromene-8-carboxylate; 1-Piperidinoethanol, 3-methyl-4-oxo-2-phenyl-4H-1-benzopyran-8-carboxylate; 2-Piperidinoethyl-3-methyl-4-oxo-2-phenyl-4H-1-ben; Flavoxate [INN:BAN]; 2-piperidin-1-ylethyl 3-methyl-4-oxo-2-phenyl-4H-chromene-8-carboxylate; flavoxate; DB01148	15301-69-6	3354	10011	TTDS00001	Muscarinic acetylcholine receptor	(m)AChR;MAChR	N/A	N/A	N/A	antagonist
DAP000837	Anisotropine Methylbromide	D00232; C17H32NO2; UNII-62M960DHIL; ANISOTROPINE METHYLBROMIDE; Octatropone Bromide; 8-Azoniabicyclo(3.2.1)octane, 8,8-dimethyl-3-((1-oxo-2-propylpentyl)oxy)-, bromide, endo-; 1alphaH,5alphaH-Tropanium, 3alpha-hydroxy-8-methyl-, bromide, 2-propylvalerate; CHEMBL1578; 8-Methyl-3-(2-propylpentanoyloxy)tropinium bromide; A5181_SIGMA; DB00517; Valpin (TN); Anisotropine methylbromide (USAN); 80-50-2; MLS001146935; Metilbromuro de octatropina [INN-Spanish]; Anisotropine methyl bromide; (1r,5r)-8,8-dimethyl-3-[(2-propylpentanoyl)oxy]-8-azoniabicyclo[3.2.1]octane bromide; Methylbromure d'octatropine; AR-1A1324; 1-alpha-H,5-alpha-H-Tropanium, 3-alpha-hydroxy-8-methyl-, bromide, 2-propylvalerate; 3-alpha-Hydroxy-8-methyl-1-alpha-H,5-alpha-H-tropanium bromide 2-propylvalerate; C06830; Octatropini methylbromidum [INN-Latin]; anisotropine methylbromide, (endo)-isomer; Endovalpin; AC1Q1RH2; Methylbromure d'octatropine [INN-French]; [(1R,5S)-8,8-dimethyl-8-azoniabicyclo[3.2.1]octan-3-yl] 2-propylpentanoate bromide; 8-Methyltropinium bromide 2-propylvalerate; endo-8,8-Dimethyl-3-((1-oxo-2-propylpentyl)oxy)-8-azoniabicyclo(3.2.1)octane bromide; 8,8-dimethyl-3-[(2-propylpentanoyl)oxy]-8-azoniabicyclo[3.2.1]octane bromide; Octatropine methylbromide; EINECS 201-285-6; SMR000058851; KST-1A8552; AC1L1MZS; [(1R,5R)-8,8-dimethyl-8-azoniabicyclo[3.2.1]octan-3-yl] 2-propylpentanoate bromide; Methyloctatropine bromide (JAN); CID6647; Valpin 50; 3alpha-Hydroxy-8-methyl-1alphaH,5alphaH-tropanium bromide 2-propylvalerate; Octatropini methylbromidum; MolPort-003-940-196; Metilbromuro de octatropina; Anisotropine; Anisotropine methylbromide [USAN:JAN]; CHEBI:2739; Lytispasm; Anisotropine methobromide; HSDB 3010; Valpin; 8-Methyltropinium bromide 2-propylpentanoate; MLS000028664; (3-endo)-8,8-dimethyl-3-[(2-propylpentanoyl)oxy]-8-azoniabicyclo[3.2.1]octane bromide; methyloctatropine bromide; AC1LCW69; Octatropine methylbromide (INN); LS-157873; 2-Propylpentanoyltropinium methylbromide; Valpin 50 (TN); CID657201	80-50-2	6647	9048	TTDS00001	Muscarinic acetylcholine receptor	(m)AChR;MAChR	N/A	N/A	N/A	binder
DAP001494	Mebeverine	thoxy-.alpha.-methylphenethyl)amino]-, butyl ester-; Mebeverine (USAN)(*hydrochloride*); Spectrum5_001315; C25H35NO5; Mebeverina; 2753-45-9 (HYDROCHLORIDE); KBio1_000045; Mebeverinum; Prestwick3_000310; Arluy (TN); LS-162044; 4-(Ethyl(2-(4-methoxyphenyl)-1-methylethyl)amino)butyl 3,4-dimethoxybenzoate; Benzoic acid, 3,4-dimethoxy-, {4-[ethyl[2-(4-methoxyphenyl)-1-methylethyl]amino]butyl} ester; Veratric acid, 4-[ethyl(p-me; Mebeverina [INN-Spanish]; EINECS 222-830-4; Arluy; Spectrum3_000918; SPBio_002499; Mebeverine (INN); NINDS_000045; BRD-A09467419-003-04-2; Veratric acid, 4-((ethyl(p-methoxy-alpha-methylphenethyl))amino)butyl ester; 4-(ethyl{1-methyl-2-[4-(methyloxy)phenyl]ethyl}amino)butyl 3,4-bis(methyloxy)benzoate; Spectrum4_001017; KBio2_003483; 4-(ethyl-(4-methoxy-alpha-methylphenethyl)aminobutyl) veratrate; KBio2_000915; DivK1c_000045; BSPBio_000280; NSC169101; D08160; KBio2_006051; SPBio_001448; Spectrum2_001404; AB00053597; 4-[ethyl-[1-(4-methoxyphenyl)propan-2-yl]amino]butyl 3,4-dimethoxybenzoate; KBio3_001896; CHEMBL282121; Benzoic acid, 3,4-dimethoxy-, 4-(ethyl(2-(4-methoxyphenyl)-1-methylethyl)amino)butyl ester; BRN 2783282; Prestwick2_000310; Veratric acid, 4-((ethyl(p-methoxy-.alpha.-methylphenethyl))amino)butyl ester; KBioGR_001513; Prestwick0_000310; Benzoic acid, 3,4-dimethoxy-, 4-[ethyl[2-(4-methoxyphenyl)-1-methylethyl]amino]butyl ester; KBioSS_000915; CID4031; BPBio1_000308; Mebeverinum [INN-Latin]; Mebeverine [INN:BAN]; mebeverine; IDI1_000045; Prestwick1_000310; 3625-06-7; Spectrum_000435; AC1L1H9B	3625-06-7	62887	48416197	TTDS00001	Muscarinic acetylcholine receptor	(m)AChR;MAChR	N/A	N/A	N/A	antagonist
DAP001108	Hyoscyamine	CID3661; (+/-)-Atropine; R-(+)-Hyoscyamine; DL-Tropanyl 2-hydroxy-1-phenylpropionate; 28905-40-0; AR-1H4769; AC1Q3ZKH; ST057178; C02046; Atropen; CID154417; EU-0100567; BRD-A27290375-001-01-8; OIN; 1892-81-5; TL80090722; NCGC00161600-03; A0132_SIGMA; Scopolia extract; HSDB 2199; D00113; Peptard; Oprea1_442738; NCGC00015026-12; MLS000069795; Atropine Sulfate S.O.P.; Minims; AI3-60219; SMP1_000031; Prestwick3_000233; Atropair; L001264; Protamine & Atropine; ATROPINE; BPBio1_000386; C17H23NO3; 101-31-5; I06-2035; Symax SL; IDI1_000558; NCGC00015026-03; Gastrosed; KBioSS_001393; NCGC00161600-02; (+/-)-Hyoscyamine; Urised; SPBio_002569; AB00514677; Spectrum2_000112; NCGC00142514-01; Atropin; (-)-Hyoscyamine; BRN 0091258; Hyoscyamine (D)-; Neo-Diophen; Atropine, 3(S)-endo-Isomer; A0754; l-Atropine; DivK1c_000558; NCGC00142514-03; KBioGR_002450; NCGC00093951-03; EINECS 202-933-0; AC1L4C8O; (+-)-atropine; Hyoscyamine [BAN]; IDI1_000505; Belladenal; (+)-HYOSCYAMINE; Atropina; AC1L5AX3; NCGC00161600-01; Hyospaz; AC1L21QZ; Atropt; HSDB 3552; Levsinex SR; BSPBio_000350; DB00572; Spectrum_001159; SPBio_000124; Isopto-atropine; bmse000649; HMS2089A16; MLS002695888; Hyosyne; 47170-56-9; KBio2_003961; 8000-07-5; NCGC00093951-04; Egacene; NINDS_000558; Lopac0_000042; Symax Duotab; Hyocyamine; Spectrum4_000961; Donnamar; (S)-(-)-Hyoscyamine; AC-15995; (-)-Tropic Acid Ester with Tropine; NP-010662; SDCCGMLS-0066623.P001; Eyesules; SPECTRUM1500346; BRD-A78303415-001-02-7; CHEBI:16684; 38411-64-2; NCGC00015026-13; Spectrum3_000464; Hyoscyamine sulfate; Atropin [German]; Symax SR; 1-Hyoscyamine; Daturine; KBio2_001639; KBio1_000558; BSPBio_001874; STOCK1N-53442; UNII-PX44XO846X; MLS002222193; Atrosulf; Spectrum_000913; Tropine, tropate (ester); Atropin-flexiolen; DB00424; B785FB93-7373-4673-9EFB-E49344DB621C; NCGC00179608-01; I-Tropine; Duboisine; Nulev; MolPort-003-666-207; MLS001148094; Buwecon; Hyoscyamine (L); NCGC00178783-01; CID5318386; HMS501J07; Tropine, (-)-tropate; Atropine Care; MolPort-001-779-638; Troyl tropate; MLS001304011; SDCCGMLS-0066590.P001; Atropen (TN); CID64692; KBioSS_001639; Tropic acid, 3-alpha-tropanyl ester; Levsin; Tropic acid, (-)-, ester with tropine; NCGC00093951-01; Symax; SPBio_000048; CID174174; MEGxp0_001878; KBio1_000505; HMS2091L21; Prestwick2_000565; Spectrum4_001813; dl-Hyoscyamine; DL -Hyoscyamine; NCGC00094699-02; Prestwick1_000565; Ocu-Tropine; L-Hyoscyamine hydrobromide; hyoscyamine; HYOSCYAMINE HCl; H0450; Hyoscyamine (USP); Atropina [Italian]; AC1L1GFK; nchembio.307-comp21; UNII-7C0697DR9I; Egazil; NINDS_000505; SMR000058248; Spectrum2_000094; SAM002554885; (+-)-hyoscyamine; Ambotz51-55-8; 51-55-8; MolPort-002-526-676; Prestwick3_000565; KBio2_006775; Spectrum3_000307; D00147; CID25817; AC1L19TF; L-Hyoscamine; LS-7203; CHEBI:17486; Bellergal-S; Hyoscyamine, (-)-; KBio2_004207; Cytospaz; MLS002154242; Isopto Atropine; Levsin SL; NCGC00093951-02; AC1NSWSM; l-Hyopscyamine; Atropine (USP); Prestwick_273; A2468_SIGMA; Hyoscyamine, (+)-; Tropine, (-)-tropate (ester); MolPort-001-742-593; UPCMLD-DP018; UPCMLD-DP018:001; Atropine [BAN]; KBio2_001393; BSPBio_002168; KBio2_006529; Tropic acid, ester with tropine; HMS1920F13; Lopac0_000567; Atropinol; SMR000718747; CHEMBL9751; L-Hyoscyamine; BSPBio_000305; BPBio1_000337; 13269-35-7; CHEBI:537621; dl-Tropyltropate; (S)-Atropine; L-Tropine tropate; KBio3_001388; Minims Atropine; DivK1c_000505; C01479; 2arm; CHEMBL1234973; Levsinex; Hyoscyamine, l-; LS-77527; Prestwick0_000565; Spectrum5_000545; Neoquess; Tropine (+/-)-tropate; I06-0059; CCRIS 3080; Tropine tropate; (+)-Atropine; HSDB 3553; KBioGR_001301; (-)-Atropine; CPD001906768; LS-77526; BRD-K40530731-001-02-5; H 9002; KBio3_001374; Spectrum5_000840; Anaspaz; Levbid; AC1Q3XL2; DL-Tropyl tropate; NCGC00094699-01; ACon1_000046; Cystospaz; EINECS 200-104-8; (+,-)-Tropyl tropate	101-31-5	64692	206628	TTDS00001	Muscarinic acetylcholine receptor	(m)AChR;MAChR	N/A	N/A	N/A	antagonist
DCL000913	OrM3	N/A	N/A	N/A	N/A	TTDS00001	Muscarinic acetylcholine receptor	(m)AChR;MAChR	N/A	N/A	N/A	antagonist
DAP000836	Tridihexethyl	NCGC00179360-01; Prestwick2_001042; BPBio1_001062; Prestwick1_001042; SPBio_002902; AC1Q76YT; BSPBio_000964; C07861; CID20299; Tridihexethyl; 3-cyclohexyl-N,N,N-triethyl-3-hydroxy-3-phenylpropan-1-aminium; Pathilon; Prestwick0_001042; CHEBI:9701; AC1L2FZA; AB00514015; UNII-7HE50A367X; 60-49-1; Benzenepropanaminium, gamma-cyclohexyl-N,N,N-triethyl-gamma-hydroxy-; L001320; (3-cyclohexyl-3-hydroxy-3-phenylpropyl)-triethylazanium; Prestwick3_001042; 4310-35-4 (chloride); Propethonum; 125-99-5 (iodide); DB00505	60-49-1	20299	10063	TTDS00001	Muscarinic acetylcholine receptor	(m)AChR;MAChR	N/A	N/A	N/A	binder
DCL000823	GSK233705	N/A	N/A	N/A	N/A	TTDS00001	Muscarinic acetylcholine receptor	(m)AChR;MAChR	N/A	N/A	N/A	antagonist
DCL000911	Org-23366	N/A	187673-38-7	6324648	42973616	TTDS00001	Muscarinic acetylcholine receptor	(m)AChR;MAChR	N/A	N/A	N/A	antagonist
DAP000263	Bethanechol	Amidopropyldimethylbetaine; Bethanecol; Carbamoyl-beta-methylcholine; C06850; KBio2_000504; Prestwick1_001073; BPBio1_001196; KBio2_003072; Lopac0_000304; DivK1c_000179; 2-carbamoyloxypropyl-trimethylazanium; IDI1_000179; 674-38-4; 1-Propanaminium, 2-((aminocarbonyl)oxy)-N,N,N-trimethyl-; 1-Propanaminium, 2-((aminocarbonyl)oxy)-N,N,N-trimethyl- (9CI); SPBio_000204; CID2370; Spectrum4_000255; Spectrum2_000132; 590-63-6 (chloride); KBio3_001402; bethanechol; NCGC00015245-06; CHEMBL1482; NCGC00089770-02; LS-18498; Carbamyl-beta-methylcholine; UNII-004F72P8F4; BSPBio_001086; BRN 1773706; KBio1_000179; 2-carbamoyloxypropyl(trimethyl)azanium; Prestwick3_001073; Ammonium, (2-hydroxypropyl)trimethyl-, carbamate (ester); NCGC00163217-01; AB00053794; Spectrum3_000311; DB01019; AC1L1DJ2; KBioSS_000504; 2-(carbamoyloxy)-N,N,N-trimethylpropan-1-aminium; SPBio_002993; NINDS_000179; CHEBI:3084; C7H17N2O2; 2-((Aminocarbonyl)oxy)-N,N,N-trimethyl-1-propanaminium; KBioGR_000690; KBio2_005640; Spectrum5_000892; HMS2089I08; Prestwick0_001073; (2-Hydroxypropyl)trimethylammonium carbamate; Myotonine chloride; Prestwick2_001073; Urabeth; Spectrum_000084; BSPBio_001902	674-38-4	2370	9068	TTDS00001	Muscarinic acetylcholine receptor	(m)AChR;MAChR	N/A	N/A	N/A	agonist
DCL000901	NVA237	GLYCOPYRROLATE; AC1LAW54; Bromure de glycopyrronium [INN-French]; Bromuro de glicopirronio; Pyrrolidinium, 1,1-dimethyl-3-hydroxy-, bromide, alpha-cyclopentylmandelate; UNII-V92SO9WP2I; Bromure de glycopyrronium; Cuvposa; Pyrrolidinium, 3-hydroxy-1,1-dimethyl-, bromide, alpha-cyclopentylmandelate (8CI); Glycopyrronii bromidum; C19H28NO3; Glycopyrrolate bromide; 3-Hydroxy-1,1-dimethylpyrrolidinium bromide alpha-cyclopentylmandelate; Ritropirronium bromide; AC1Q1RGS; 1-Methyl-3-pyrrolidinyl .alpha.-phenylcyclopentaneglycolate methobromide; Ritropirronium bromide [INN]; NSC 251252; Pyrrolidinium, 3-hydroxy-1,1-dimethyl-, bromide, .alpha.-cyclopentylmandelate; ROBINUL FORTE; Bromuro de glicopirronio [INN-Spanish]; Glycopyrronium; Robinul (TN); glycopyrronium bromide; CHEMBL1201027; 53808-86-9; Robanul; Glycopyrroni bromidum; HMS2094A05; 3-Hydroxy-1,1-dimethylpyrrolidinium bromide .alpha.-cyclopentylmandelate; Gastrodyn; NSC 251251; Tarodyn; 3-(erythro-2-Cyclopentyl-2-hydroxy-2-phenylacetoxy)-1,1-dimethylpyrrolidiniumbromid; MolPort-002-885-831; I14-3643; .beta.-1-Methyl-3-pyrrolidyl-.alpha.-cyclopentylmandelate methobromide; NSC251251; 596-51-0; CPD000469282; Pyrrolidinium, 3-[(cyclopentylhydroxyphenylacetyl)oxy]-1,1-dimethyl-, bromide; Tarodyl; NVA-237; NSC251252; Robinul; HMS1570E14; 1,1-Dimethyl-3-hydroxypyrrolidinium bromide .alpha.-cyclopentylmandelate; Copyrrolate; NSC 250836; 1-Methyl-3-pyrrolidyl alpha-phenylcyclopentaneglycolate methobromide; Asecryl; Glycopyrrolate [USAN]; Pyrrolidinium, 3-((cyclopentylhydroxyphenylacetyl)oxy)-1,1-dimethyl-, bromide; Bromure de ritropirronium; 3-Hydroxy-1,1-dimethylpyrrolidinium bromide-.alpha.-cyclopentylmandelate; AC1L1XX0; Glycopyrrolate (USP); D00540; AHR 504; SMR000469282; EINECS 209-887-0; MLS002222301; Glycopyrronium bromide (JAN/INN); NSC250836; Mandelic acid, .alpha.-cyclopentyl-, ester with 3-hydroxy-1,1-dimethylpyrrolidinium bromide; WLN: T5KTJ A1 A1 COVXQR&- AL5TJ &Q &E; LS-138344; SAM002589987; HMS2051P12; AC-15990; Bromure de ritropirronio; PT-001; (1,1-dimethylpyrrolidin-1-ium-3-yl) 2-cyclopentyl-2-hydroxy-2-phenylacetate bromide; Glycopyrronii bromidum [INN-Latin]; NVA 237; 1,1-Dimethyl-3-hydroxypyrrolidinium bromide alpha-cyclopentylmandelate; Pyrrolidinium, 3-hydroxy-1,1-dimethyl-, bromide, alpha-cyclopentylmandelate; Nodapton; AD-237; CID11693; AHR-504; SAM001246629; MLS001424112; ST51054976	N/A	N/A	N/A	TTDS00001	Muscarinic acetylcholine receptor	(m)AChR;MAChR	N/A	N/A	N/A	antagonist
DCL000677	Aclidinium bromide	UNII-UQW7UF9N91; Aclidinium bromide; 320345-99-1; CID11519741; 1-Azoniabicyclo(2.2.2)octane, 3-((hydroxydi-2-thienylacetyl)oxy)-1-(3-phenoxypropyl)-, bromide, (3R)-; Bretaris; Eklira; LAS-W-330; CHEMBL551466; [1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]oct-8-yl] 2-hydroxy-2,2-dithiophen-2-yl-acetate Bromide; LAS-34273; CHEBI:662404	320345-99-1	35766	34677294	TTDS00001	Muscarinic acetylcholine receptor	(m)AChR;MAChR	N/A	N/A	N/A	antagonist
DAP001109	Methantheline	AC1Q65RT; diethyl-methyl-[2-(9H-xanthene-9-carbonyloxy)ethyl]azanium; CAS-53-46-3; Prestwick0_001066; NCGC00016239-01; N,N-Diethyl-N-methyl-2-[(9H-xanthen-9-ylcarbonyl)oxy]ethanaminium; Methanthelinium; Prestwick3_001066; Prestwick1_001066; L000712; Methanthine bromide; BPBio1_001158; BSPBio_001052; Ethanaminium, N,N-diethyl-N-methyl-2-((9H-xanthen-9-ylcarbonyl)oxy)-; methantheline; Mantheline; Prestwick2_001066; Gastrin I; Gastrin-1 Human; BRD-K09859624-004-03-9; SPBio_002966; C07849; Banthine bromide; Methanide; nchembio747-comp13; AB00514028; CID4097; DB00940; Methanthelinum; AC1L1HEM; AR-1J4187	5818-17-7	4097	10051	TTDS00001	Muscarinic acetylcholine receptor	(m)AChR;MAChR	N/A	N/A	N/A	antagonist
DAP000835	Oxyphencyclimine	Oxiphencycliminum; Spectrum3_001806; Spectrum_001606; (1-methyl-5,6-dihydro-4H-pyrimidin-2-yl)methyl 2-cyclohexyl-2-hydroxy-2-phenylacetate; UNII-4V44H1O8XI; 1-Methyl-1,4,5,6-tetrahydro-2-pyrimidinylmethyl-alpha-cyclohexylmandelat; Zamanil; KBio2_007222; Oxyphencycliminum; 125-52-0 (mono-hydrochloride); 1,4,5,6-Tetrahydro-1-methyl-2-pyrimidinylmethyl alpha-cyclohexyl-alpha-phenylglycolat; Antulcus; AC1L1IMJ; KBio2_002086; Oxifencicliminum [INN-Spanish]; Daricol; Caridan; Oxyphencycliminum [INN-Latin]; Spectrum4_000234; Spectrum2_001600; Spectrum5_001499; D08325; C20H28N2O3; DivK1c_000876; Manir; C07851; Oxyphencyclimine [INN:BAN]; KBio3_002894; KBioGR_000927; SPBio_001600; 1,4,5,6-Tetrahydro-1-methyl-2-pyrimidinemethanol-alpha-phenylcyclohexaneglycolate; (1-methyl-1,4,5,6-tetrahydropyrimidin-2-yl)methyl cyclohexyl(hydroxy)phenylacetate; IDI1_000876; KBioSS_002086; EINECS 204-743-3; KBio1_000876; DB00383; Oxifencicliminum; 125-53-1; NINDS_000876; KBio2_004654; AC1Q65P8; Benzeneacetic acid, .alpha.-cyclohexyl-.alpha.-hydroxy-, (1,4,5,6-tetrahydro-1-methyl-2-pyrimidinyl)methyl ester; CHEMBL1495; LS-172612; Naridan; CID4642; AR-1J3862; oxyphencyclimine; L000910; Oxyphencyclimine (INN); BSPBio_003391	125-53-1	4642	10053	TTDS00001	Muscarinic acetylcholine receptor	(m)AChR;MAChR	N/A	N/A	N/A	binder
DAP001115	Mepenzolate	1-Methyl-3-piperidyl benzilate methyl bromide; SAM002554910; UNII-ONW3LB39P7; Glycophenylate; CID4057; Spectrum2_001042; LS-116643; Piperidinium, 3-[(hydroxydiphenylacetyl)oxy]-1,1-dimethyl-; Gastropidil; Spectrum5_000948; Piperidinium, 3-((hydroxydiphenylacetyl)oxy)-1,1-dimethyl- (VAN); Benzilic acid, ester with 3-hydroxy-1,1-dimethylpiperidinium bromide; C21H26NO3; AC1Q61DQ; KBio2_004033; KBio2_006601; Piperidinium, 3-[(hydroxydiphenylacetyl)oxy]-1,1-dimethyl-, bromide; Cantril; Mepenzolate bromide (JP15/INN); NCGC00094716-01; 1-Methyl-3-piperidyl benzilate methylbromide; N-methyl-3-piperidylbenzilate methyl bromide; SPECTRUM1500383; 88215-34-3; BSPBio_001959; AC-15989; Colopiril; Prestwick2_000653; Spectrum4_000042; MolPort-003-848-491; Bromuro de mepenzolato; Bromure de mepenzolate; AC1L1MKX; BPBio1_000755; AR-1D5362; HMS1920L05; Eftoron; KBio2_001465; Benzilic acid, 1-methyl-3-piperidyl ester methobromide; UNII-APX8D32IX1; NCGC00094716-02; mepenzolic acid, bromine salt; CHEMBL1724; NCGC00178896-01; (1,1-dimethylpiperidin-1-ium-3-yl) 2-hydroxy-2,2-diphenylacetate; Trokonil; MLS002222165; NINDS_000636; Bromure de mepenzolate [INN-French]; Prestwick0_000653; Mepenzolon; Delevil; BRD-A62421304-004-05-6; JB 340; Spectrum_000985; SMR000058832; DB04843; AC1L2HSA; MolPort-003-666-226; Cantilaque; AC1Q1R9F; 3-((Hydroxydiphenylacetyl)oxy)-1,1-dimethylpiperidinium bromide; HMS2091B18; MEPENZOLATE BROMIDE; Piperidinium, 3-((hydroxydiphenylacetyl)oxy)-1,1-dimethyl-, bromide; Prestwick1_000653; Mepenzolate Methylbromide; AB00053804; 25990-43-6; WLN: T6KTJ A1 A1 COVXQR&R &E; Mepenzolic acid; KBioSS_001465; 76-90-4 (BROMIDE); SPBio_002606; 3-{[hydroxy(diphenyl)acetyl]oxy}-1,1-dimethylpiperidinium bromide; CPD000058832; AC1L1HBG; CID6461; 2-(1,1-dimethylpiperidin-1-ium-3-yl)oxy-2-oxo-1,1-diphenylethanolate; Cantilon; KBio1_000636; Mepenzolati bromidum [INN-Latin]; NSC4358; Colibantil; Mepenzolati bromidum; LS-174120; C07818; CID72288; SPBio_000964; HMS1570C07; Piperidinium, 3-hydroxy-1,1-dimethyl-, benzilate (ester); 76-90-4; 2-[(1,1-dimethylpiperidinium-3-yl)oxy]-2-oxo-1,1-diphenylethanolate; Piperidinium, 3-hydroxy-1,1-dimethyl-, bromide, benzilate; N-Methyl-3-piperidyldiphenylglycolate methobromide; Mepenzolone Bromide; DivK1c_000636; Cantil; Mepenzolate bromide [INN:BAN:JAN]; N-Methyl-3-piperidyl benzilate methobromide; EINECS 200-992-7; BSPBio_000685; Trancolon; 3-Hydroxy-1,1-dimethylpiperidinium bromide benzilate; KBioGR_000503; mepenzolate; Cantil (TN); Spectrum3_000490; (1,1-dimethylpiperidin-1-ium-3-yl) 2-hydroxy-2,2-diphenylacetate bromide; HMS501P18; Tralanta; Colum; Prestwick3_000653; MLS001076678; CHEBI:654127; NCGC00178896-02; Bromuro de mepenzolato [INN-Spanish]; 25990-43-6 (Parent); D00720; KBio3_001459; IDI1_000636; NSC 4358; N-Methyl-3-piperidyl benzilate methyl bromide; Prestwick_100	25990-43-6	4057	10020	TTDS00001	Muscarinic acetylcholine receptor	(m)AChR;MAChR	N/A	N/A	N/A	antagonist
DAP000389	Daclizumab	N/A	152923-56-3	N/A	46504469	TTDS00139	Interleukin-2 receptor	IL-2R	P14784	3560	ENSG00000100385	antibody
DAP001098	Denileukin diftitox	N/A	173146-27-5	N/A	46506950	TTDS00139	Interleukin-2 receptor	IL-2R	P14784	3560	ENSG00000100385	binder
DAP001099	Aldesleukin	N/A	85898-30-2	N/A	46508054	TTDS00139	Interleukin-2 receptor	IL-2R	P14784	3560	ENSG00000100385	modulator
DCL000847	Inolimomab	N/A	152981-31-2	5785	3817314	TTDS00139	Interleukin-2 receptor	IL-2R	P14784	3560	ENSG00000100385	antagonist
DAP000388	Basiliximab	N/A	152923-56-3	N/A	46505169	TTDS00139	Interleukin-2 receptor	IL-2R	P14784	3560	ENSG00000100385	antibody
DCL000927	PG-116800	PGE 530742; 4-Hexynoic acid, 2-(((4-((4-methoxybenzoyl)amino)phenyl)sulfonyl)amino)-6-(4-morpholinyl)-; PG 530742; PGE 7113313; 291533-11-4; 668998-02-5; PG-116800; PG 116800	N/A	N/A	N/A	TTDC00105	Stromelysin-1	Matrix metalloproteinase 3;Matrix metalloproteinase-3;MMP-3;SL-1;Transin-1	P08254	4314	ENSG00000149968; ENSG00000263313	inhibitor
DCL000002	PG-530742	PGE 530742; 4-Hexynoic acid, 2-(((4-((4-methoxybenzoyl)amino)phenyl)sulfonyl)amino)-6-(4-morpholinyl)-; PG 530742; PGE 7113313; 291533-11-4; 668998-02-5; PG-116800; PG 116800	291533-11-4	44150852	85149997	TTDC00105	Stromelysin-1	Matrix metalloproteinase 3;Matrix metalloproteinase-3;MMP-3;SL-1;Transin-1	P08254	4314	ENSG00000149968; ENSG00000263313	inhibitor
DPR000165	Galardin	KBio3_000797; MolPort-006-822-517; HMS1792E21; Butanediamide, N4-hydroxy-N1-((1S)-1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl)-2-(2-methylpropyl)-, (2R)-; KBio3_000798; KBio2_000419; (2R)-N'-hydroxy-N-[(2S)-3-(1H-indol-3-yl)-1-(methylamino)-1-oxopropan-2-yl]-2-(2-methylpropyl)butanediamide; Ilomastat; Ilomastat [USAN]; KBioGR_000419; KBio2_005555; HMS1362E21; CS-610; BSPBio_001079; Galardin MPI; NCGC00163450-03; DB02255; AC1L314S; SMP2_000212; CS 610; Bio2_000370; LS-186959; IDI1_002125; Bio1_000658; (S-(R*,S*))-N(sup 4)-Hydroxy-N(sup 1)-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl)-2-(2-methylopropyl)butanediamide; CHEBI:42919; Bio2_000850; CBiol_001883; NSC727632; CHEMBL19611; LS-187605; Bio1_001147; NCGC00163450-01; Ilomastat (USAN/INN); (R)-N(sup 1)-Hydroxy-N-((S)-2-indol-3-yl-1-(methylcarbamoyl)ethyl)-2-isobutylsuccinamide; HMS1990E21; KBioSS_000419; NCGC00163450-02; Galardin; 142880-36-2; Bio1_000169; D03793; CHEBI:123466; Butanediamide, N4-hydroxy-N1-(1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl)-2-(2-methylpropyl)-, (S-(R*,S*))-; BCBcMAP01_000057; KBio2_002987; CID132519; N-[(2R)-2-(Hydroxamidocarbonylmethyl)-4-methylpentanoyl]-L-tryptophan Methylamide; GM 6001	N/A	N/A	N/A	TTDC00105	Stromelysin-1	Matrix metalloproteinase 3;Matrix metalloproteinase-3;MMP-3;SL-1;Transin-1	P08254	4314	ENSG00000149968; ENSG00000263313	inhibitor
DAP001534	Tropisetron	D02130; TKT; (3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl 1H-indole-3-carboxylate; CHEBI:188800; CID656665; Lopac-T-104; AC1LCVDG; C13666; PDSP1_000776; [(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] 1H-indole-3-carboxylate; Navoban; NCGC00161414-01; NCGC00015984-01; MolPort-006-823-819; PDSP2_000764; HMS2090D16; CHEMBL56564; Tropisetron (INN); ICS-205930; tropisetron; Novaban; Navoban (TN)	89565-68-4	5595	24278133	TTDS00399	5-hydroxytryptamine receptor 3A	5-HT-3;5-HT3A;5HT3R;5-HT3R;HTR3;HTR3A;Serotonin receptor 3A;Serotonin-gated ion channel receptor	P46098	3359	ENSG00000166736	antagonist
DCL000702	Arverapamil	N/A	123932-43-4	N/A	N/A	TTDS00399	5-hydroxytryptamine receptor 3A	5-HT-3;5-HT3A;5HT3R;5-HT3R;HTR3;HTR3A;Serotonin receptor 3A;Serotonin-gated ion channel receptor	P46098	3359	ENSG00000166736	antagonist
DAP000368	Dolasetron	AC1L1FA2; AR-1F4842; Dolasetron [INN:BAN]; CID3033818; AC1Q6P89; LS-172300; CHEMBL523689; CID60654; 115956-12-2; CID11503972; UNII-82WI2L7Q6E; BIDD:GT0287; MolPort-006-393-891; D07867; C07866; DB00757; HSDB 7565; AC1L1TNT; Dolasetronum; 3-oxooctahydro-2h-2,6-methanoquinolizin-8-yl 1h-indole-3-carboxylate; Dolasteron; dolasetron; CHEBI:253226; CID3148; AC1Q6P88; Dolasetron (INN); AC1MHWDD; 1H-Indole-3-carboxylic acid, octahydro-3-oxo-2,6-methano-2H-quinolizin-8-yl ester, (2alpha,6alpha,8alpha,9abeta)-; Dolasetronum [INN-Latin]	115956-12-2	60654	210767	TTDS00399	5-hydroxytryptamine receptor 3A	5-HT-3;5-HT3A;5HT3R;5-HT3R;HTR3;HTR3A;Serotonin receptor 3A;Serotonin-gated ion channel receptor	P46098	3359	ENSG00000166736	antagonist
DAP000367	Palonosetron	RS-25259-198; RS 25259-198; Palonosetron [INN]; DB00377; AC1L3WNN; 2-Qhbiqo; 135729-61-2; (S-(R*,R*))-2-(1-Azabicyclo(2.2.2)oct-3-yl)-2,3,3a,4,5,6-hexahydro-1H-benz(de)isoquinolin-1-one; 1H-Benz(de)isoquinolin-1-one, 2-(1-azabicyclo(2.2.2)oct-3-yl)-2,3,3a,4,5,6-hexahydro-, (S-(R*,R*))-; CID148211; UNII-5D06587D6R; RS-25259-197; LS-187778; Aloxi; NCGC00166415-02; Onicit; RS-25233-198; NCGC00166415-01; LS-186967; RS 25233-197; RS-25233-197; RS 25259-197; 135729-56-5; 2-(1-Azabicyclo(2.2.2)oct-3-yl)-2,3,3a,4,5,6-hexahydro-1H-benz(de)isoquinolin-1-one; RS 25233-198; (3aR)-2-[(3S)-1-azabicyclo[2.2.2]octan-3-yl]-3a,4,5,6-tetrahydro-3H-benzo[de]isoquinolin-1-one; Palonosetron	119904-90-4	148211	725898	TTDS00399	5-hydroxytryptamine receptor 3A	5-HT-3;5-HT3A;5HT3R;5-HT3R;HTR3;HTR3A;Serotonin receptor 3A;Serotonin-gated ion channel receptor	P46098	3359	ENSG00000166736	antagonist
DAP000296	Procaine	CHEBI:8430; SPBio_001331; p-Aminobenzoyldiethylaminoethanol; DivK1c_000120; CID4914; Gerovital; Procaine [INN:BAN]; beta-(Diethylamino)ethyl p-aminobenzoate; p-Aminobenzyoyldiethylaminoethanol; Scurocaine; AC1Q2ZE2; Procaina; Nissocaine; 91484-72-9; beta-Diethylaminoethyl 4-aminobenzoate; Jenacaine; KBioSS_001318; I06-1439; KBioGR_000975; Vitamin H3; Norocaine; AKOS000115407; IDI1_000120; MolPort-000-889-177; 4-14-00-01138 (Beilstein Handbook Reference); 2-Diethylaminoethyl p-aminobenzoate; 4-Aminobenzoic acid 2-(diethylamino) ethyl ester; 2-(Diethylamino)ethyl 4-aminobenzoate; procaine; Novocain; Procaine, base; 4-Aminobenzoic acid diethylaminoethyl ester; .beta.-Diethylaminoethyl 4-aminobenzoate; Spectrum4_000488; CHEMBL569; BRD-K24616672-003-05-2; BSPBio_000161; AB00053531; LS-35778; Spinocaine; Anticort; CAS-51-05-8; Diethylaminoethyl p-aminobenzoate; Stoff H3; Prestwick3_000041; InChI=1/C13H20N2O2/c1-3-15(4-2)9-10-17-13(16)11-5-7-12(14)8-6-11/h5-8H,3-4,9-10,14H2,1-2H; SP01A; DB00721; Spectrum2_001296; SP-01A; KBio2_003886; C07375; 2-Diethylaminoethylester kyseliny p-aminobenzoove [Czech]; Spectrum5_001186; Gerokit; KBio3_001731; Procaine (INN); SPBio_002082; STOCK2S-12721; BPBio1_000179; NINDS_000120; Duracaine; NCGC00015864-02; Benzoic acid, p-amino-, 2-(diethylamino)ethyl ester; Procainum [INN-Latin]; beta-(Diethylamino)ethyl 4-aminobenzoate; Anuject; 2-Diethylaminoethylester kyseliny p-aminobenzoove; Anticort (TM); BSPBio_002231; Gerovital H-3; Prestwick1_000041; SP01; KBio2_001318; Factor H3; 59-46-1; KBio1_000120; Spectrum3_000556; HSDB 3388; Solution of novocain (TN); 4-Aminobenzoesaeure-beta-diethylaminoethylester; KBio2_006454; NCGC00162298-01; Lopac0_000966; UNII-4Z8Y51M438; D08422; NSC 169497; Jenacain; Allocaine; NSC169497; 2-(Diethylamino)ethyl-4-aminobenzoate; Procainum; p-Aminobenzoic acid 2-diethylaminoethyl ester; WLN: ZR DVO2N2&2; NCGC00015864-04; Spectrum_000838; Benzoic acid, 4-amino-, 2-(diethylamino)ethyl ester; Lopac-P-9879; Prestwick2_000041; NCGC00015864-01; AC1L1J8C; 2-(Diethylamino)ethyl p-aminobenzoate; 2-Diethylaminoethyl 4-aminobenzoate; Prestwick0_000041; Solution of novocain; BENZOIC ACID,4-AMINO,2-DIETHYLAMINOETHYL ESTER   PROCAIN BASE; BRN 0913480; Procain; .beta.-(Diethylamino)ethyl p-aminobenzoate; STK177303; EINECS 200-426-9; Procaina [INN-Spanish]; Novocaine	59-46-1	4914	9579	TTDS00399	5-hydroxytryptamine receptor 3A	5-HT-3;5-HT3A;5HT3R;5-HT3R;HTR3;HTR3A;Serotonin receptor 3A;Serotonin-gated ion channel receptor	P46098	3359	ENSG00000166736	antagonist
DAP001489	Levetriacetam	N/A	102767-28-2	5284583	48416166	TTDS00399	5-hydroxytryptamine receptor 3A	5-HT-3;5-HT3A;5HT3R;5-HT3R;HTR3;HTR3A;Serotonin receptor 3A;Serotonin-gated ion channel receptor	P46098	3359	ENSG00000166736	antagonist
DAP000369	Alosetron	1H-Pyrido(4,3-b)indol-1-one, 2,3,4,5-tetrahydro-5-methyl-2-((5-methyl-1H-imidazol-4-yl)methyl)-, monohydrochloride; GR-68755C; GR68755; LS-172542; alosetron monohydrochloride; MolPort-006-391-882; Alosetron (INN); HSDB 7055; CHEMBL1200885; CHEMBL1110; ALOSETRON HYDROCHLORIDE; GR 68755c; D02829; ZINC13537284; ST51051100; ||GR 68755; Alosetron HCl; 2,3,4,5-tetrahydro-5-methyl-2-((5-methylimidazol-4-yl)methyl)-1H-pyridol(4,3-b)indol-1-one monohydrochloride; LS-172541; Lotronex; AC1L1CX0; LS-187763; 122852-42-0; AC-022; 1H-Pyrido[4,3-b]indol-1-one, 2,3,4,5-tetrahydro-5-methyl-2-[(5-methyl-1H-imidazol; C17H18N4O.HCl; D07129; MolPort-005-934-855; UNII-13Z9HTH115; Lotrpnex (TN); SAM001246782; GR 68755X; I01-2212; UNII-2F5R1A46YW; AC1Q3EM0; 1H-Pyrido[4,3-b]indol-1-one, 2,3,4,5-tetrahydro-5-methyl-2-[(4-methyl-1H-imidazol-5-yl)methyl]-; Alosetron hydrochloride (USAN); Lotrpnex; Alosetron [INN:BAN]; Alosetron hydrochloride [USAN]; CID2099; 5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indol-1-one hydrochloride; 1H-Pyrido[4,3-b]indol-1-one, 2,3,4,5-tetrahydro-5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]- (9CI)|; AC1L1TV5; 1H-Pyrido[4,3-b]indol-1-one, 2,3,4,5-tetrahydro-5-methyl-2-[(4-methyl-1H-imidazol-5-yl)methyl]-, hydrochloride (1:1); NCGC00167528-01; 5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-3,4-dihydropyrido[4,3-b]indol-1-one hydrochloride; -4-yl)methyl]-, monohydrochloride (9CI); I06-2291; CPD000469211; CHEBI:253342; 5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indol-1-one; 1H-Pyrido(4,3-b)indol-1-one, 2,3,4,5-tetrahydro-5-methyl-2-((5-methyl-1H-imidazol-4-yl)methyl)-; 5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-3,4-dihydropyrido[4,3-b]indol-1-one; 2,3,4,5-Tetrahydro-5-methyl-2-((5-methylimidazol-4-yl)methyl)-1H-pyrido(4,3-b)indol-1-one monohydrochloride; 2,3,4,5-Tetrahydro-5-methyl-2-((5-methyl-1H-imidazol-4-yl)methyl)-1H-pyrido(4,3-b)indol-1-one; alosetron; 2,3,4,5-tetrahydro-5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-1H-pyrido[4,3-b]indol-1-one, monohydrochloride; 1H-Pyrido(4,3-b)indol-1-one, 2,3,4,5-tetrahydro-5-methyl-2((5-methyl-1H-imidazol-4-yl)methyl)-, monohydrochloride; CHEBI:53783; MLS001401464; SMR000469211; CID60758; DB00969; GR 68755; 122852-69-1	122852-42-0	2099	655047	TTDS00399	5-hydroxytryptamine receptor 3A	5-HT-3;5-HT3A;5HT3R;5-HT3R;HTR3;HTR3A;Serotonin receptor 3A;Serotonin-gated ion channel receptor	P46098	3359	ENSG00000166736	antagonist
DPR000016	ATI-17000	N/A	N/A	5311194	49684203	TTDS00399	5-hydroxytryptamine receptor 3A	5-HT-3;5-HT3A;5HT3R;5-HT3R;HTR3;HTR3A;Serotonin receptor 3A;Serotonin-gated ion channel receptor	P46098	3359	ENSG00000166736	antagonist
DCL000954	Renzapride	4-amino-N-[(4S,5S)-1-azabicyclo[3.3.1]nonan-4-yl]-5-chloro-2-methoxybenzamide; Benzamide, 4-amino-N-1-azabicyclo(3.3.1)non-4-yl-5-chloro-2-methoxy-, endo-; CID3086547; (( -)-endo)-4-Amino-5-chloro-2-methoxy-N-(1-azabicyclo(3.3.1)non-4-yl)benzamide; AC1MJ6DN; 109828-31-1; 112727-80-7; Renzapridum [INN-Latin]; Renzaprida; 125636-29-5; LS-186857; Renzaprida [INN-Spanish]; Renzapridum; Renzapride; 4-Amino-N-1-azabicyclo(3.3.1)non-4-yl-5-chloro-2-methoxybenzamide endo-; Renzapride [INN]; LS-187513	112727-80-7	3035241	47208053	TTDS00399	5-hydroxytryptamine receptor 3A	5-HT-3;5-HT3A;5HT3R;5-HT3R;HTR3;HTR3A;Serotonin receptor 3A;Serotonin-gated ion channel receptor	P46098	3359	ENSG00000166736	antagonist
DCL000766	DDP-225	AA-10021; AC1OCF4Z; AA-10025; 4-(2-fluorophenyl)-6-methyl-2-piperazin-1-ylthieno[2,3-d]pyrimidine hydrate hydrochloride; AA-10026; CID6918194; DDP-225	135991-48-9	127912	12014606	TTDS00399	5-hydroxytryptamine receptor 3A	5-HT-3;5-HT3A;5HT3R;5-HT3R;HTR3;HTR3A;Serotonin receptor 3A;Serotonin-gated ion channel receptor	P46098	3359	ENSG00000166736	antagonist
DCL000338	Benoxaprofen	Benoxaprofen; Oraflex; 5-Benzoxazoleacetic acid, 2-(4-chlorophenyl)-alpha-methyl, (+-)-; dl-Benoxaprofen; Benoxaprofeno; ( -)-2-(4-Chlorophenyl)-alpha-methyl-5-benzoxazoleacetic acid; 67434-14-4; 5-Benzoxazoleacetic acid, 2-(4-chlorophenyl)-.alpha.-methyl-; Compound 90459; Opren; 51234-86-7 (mono-hydrochloride salt); NSC299582; ( -)-Benoxaprofen; AC1L22RI; Inflamid; Benoxaprofen [USAN:INN:BAN]; Lilly 90459; 2-(2-(4-Chlorophenyl)-1,3-benzoxazol-5-yl)propanoic acid; 2-(p-Chlorophenyl)-.alpha.-methyl-5-benzoxazoleacetic acid; 5-Benzoxazoleacetic acid, 2-(4-chlorophenyl)-.alpha.-methyl-; Oraflex (TN); Benoxaprofene [INN-French]; Uniprofen; 2-(2-(4-Chlorophenyl)-1,3-benzoxazol-5-yl)propanoic acid; AC1Q5RRV; (1)-2-(4-Chlorophenyl)benzoxazole-5-propionic acid; Coxigon; (+-)-2-(p-Chlorophenyl)-alpha-methyl-5-benzoxazoleacetic acid; EINECS 257-069-7; 51234-28-7; CID39941; Benoxaprofenum; UNII-17SZX404IM; DB04812; 5-benzoxazoleacetic acid, 2-(4-chlorophenyl)-a-methyl-; CHEMBL340978; LS-42081; 2-(4-Chlorophenyl)-alpha-methyl-5-benzoxazoleacetic acid; LRCL 3794; NSC 299582; D03080; C16H12ClNO3; Benoxaprofenum [INN-Latin]; BRN 1085080; 2-(p-Chlorophenyl)-.alpha.-methyl-5-benzoxazoleacetic acid; 5-Benzoxazoleacetic acid, 2-(4-chlorophenyl)-alpha-methyl-; Benoxaprofeno [INN-Spanish]; Benoxaprofene; 2-[2-(4-Chlorophenyl)-1,3-benzoxazol-5-yl]propanoic acid; Benoxaprofen (USAN/INN); 70062-36-1 (ammonium salt); EINECS 266-692-3	51234-28-7	39941	10465284	TTDC00313	Acetyl-CoA acetyltransferase, mitochondrial	Acetoacetyl-CoA thiolase;T2	P24752	38	ENSG00000075239	inhibitor
DCL000503	CAT-354	N/A	3625-06-7	4031	49698915	TTDC00177	Interleukin-13	IL-13	P35225	3596	ENSG00000169194	antibody
DCL000433	Anti-IL13	N/A	145258-61-3	N/A	47206399	TTDC00177	Interleukin-13	IL-13	P35225	3596	ENSG00000169194	inhibitor
DAP000359	Alprostadil	BML1-F06; HMS1571K17; CID5280723; BRD-K52459643-001-06-0; l-Prostaglandin E1; PGE1; Alprostadil (JP15/USP/INN); AB00514004; D00180; Muse; NCGC00025234-03; LMFA03010134; Vitaros; (11alpha,13E,15S)-11,15-dihydroxy-9-oxoprost-13-en-1-oic acid; Caverject; HMS1791K10; NCGC00025234-04; U-10136; SAM001247093; SAM001246845; AC-6095; Prostaglandin E1; 745-65-3; CPD000112594; MolPort-003-939-183; BSPBio_001175; FemLife; AC1NQXHQ; P5515_SIAL; SMP2_000271; Sugiran; Befar (TN); alprostadil; SMR000112594; Topiglan; P7527_SIGMA; MLS001424250; P5515_SIGMA; Edex; 82474_FLUKA; HMS1361K10; MLS000758964; Prostavasin; Prestwick2_001018; Viridal; Alista; Prestwick3_001018; Prost-13-en-1-oic acid, 11,15-dihydroxy-9-oxo-, (11alpha,13E,15S)-, homopolymer; MR-256; BSPBio_001488; NCGC00025234-05; Prink; HMS1989K10; P8908_SIGMA; Alprox-TD; A0593_SIAL; 119314-69-1; PGE1 Oligomer; SAM001246840; Prostin VR Pediatric; Prink (TN); C04741; BIDD:GT0747; DB00770; Befar; CHEBI:15544; MR 256; Prostin VR pediatric (TN); Prostin VR; HEI-507; (13E,15S)-11alpha,15-dihydroxy-9-oxoprost-13-en-1-oic acid; NCGC00025234-02; Femprox; IDI1_033958; Alprostadilum; RayVa; CHEMBL495; ST50826271; Alprostadil Prostoglandin E1; 7-[(1R,2R,3R)-3-hydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]heptanoic acid; (11alpha,13E,15S)-11,15-Dihydroxy-9-oxoprost-13-enoic acid; HMS2090L08; HMS2052L11; BPBio1_001293; (13E)-(15S)-11alpha,15-Dihydroxy-9-oxoprost-13-enoate	745-65-3	149351	7312	TTDS00168	Prostaglandin E2 receptor, EP2 subtype	EP2 receptor;PGE receptor, EP2 subtype;Prostanoid EP2 receptor	P43116	5732	ENSG00000125384	antagonist
DAP000273	Iloprost	(E)-(3aS,4R,5R,6aS)-Hexahydro-5-hydroxy-4-((E)-(3S,4RS)-3-hydroxy-4-methyl-1-octen-6-ynyl)-delta(sup 2(1H),delta)-pentalenevaleric acid; AC1Q1J28; (5E)-5-[(3aS,4R,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-ylidene]pentanoic acid; (5E)-5-[(3aS,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-ylidene]pentanoic acid; CID6435378; Iloprostum [Latin]; (5E)-5-[(3aS,5R,6aS)-5-hydroxy-4-[(1E,3S)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl]hexahydropentalen-2(1H)-ylidene]pentanoic acid; L000996; C22H32O4; Iloprost [BAN:INN]; Ventavis; ZK 36374; AC1O5JP3; (5Z)-5-[(3aS,5R,6aS)-5-hydroxy-4-[(E,3R)-3-hydroxy-4-methyloct-1-en-6-ynyl]-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-ylidene]pentanoic acid; Iloprost (INN); HMS2090A19; CID10937300; UNII-JED5K35YGL; Ilomedine; (16R,S)-Methyl-18,18,19,19-tetradehydro-6a-carbaprostaglandin I(sub 2); PDSP2_001536; 73873-87-7; (E)-5-(3aS,4R,5R,6aS)-5-Hydroxy-4((E)-(3S,4RS)-3-hydroxy-4-methyl-1-octen-6-inyl)perhydropentalen-2-yliden)valeriansaeure; CHEMBL494; Ciloprost; LS-101845; Ventavis (TN); Ilomedin; NCGC00181784-01; Pentanoic acid, 5-(hexahydro-5-hydroxy-4-(3-hydroxy-4-methyl-1-octen-6-ynyl)-2(1H)-pentalenylidene)-; CID11639089; CID9885245; CID6435293; CID9975807; ZK-36374; AC1NSK5T; Endoprost; SH-401; AC1O5JIJ; D02721; [3H]-Iloprost; 78919-13-8; E-1030; ZK-363775; Iloprostum; ILOPROST; CHEMBL236025; CHEMBL138694; CID5311181	78919-13-8	6443959	772634	TTDS00168	Prostaglandin E2 receptor, EP2 subtype	EP2 receptor;PGE receptor, EP2 subtype;Prostanoid EP2 receptor	P43116	5732	ENSG00000125384	agonist
DAP001215	Carboprost Tromethamine	Prosta-5,13-dien-1-oic acid, 9,11,15-trihydroxy-15-methyl-, (5Z,9-alpha,11-alpha,13E,15S)-,compd. with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1); U 32921E; 15-methylprostaglandin F2alpha-tromethamine; (15S)-15-Methylprostaglandin F(sub 2alpha) tromethamine; C21H36O5; 58551-69-2; I06-1950; Hemabate; (Z)-7-((1R,2R,3R,5S)-3,5-Dihydroxy-2-((E)-(3S)-3-hydroxy-3-methyl-1-octenyl)cyclopentyl)-5-heptenoic acid compound with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1); 15(S)15-Methyl pgf2-alpha tromethamine salt; Carboprost tromethamine [USAN]; CARBOPROST TROMETHAMINE; Carboprost Trometanol; AC1O5I8V; (15S)-15-Methylprostaglandin F2alpha tromethamine; CHEMBL1200954; 2-amino-2-(hydroxymethyl)propane-1,3-diol; (E)-7-[(1S,3S,5R)-3,5-dihydroxy-2-[(Z,3S)-3-hydroxy-3-methyloct-1-enyl]cyclopentyl]hept-5-enoic acid; ST51053306; 15(S)15-Methyl prostaglandin F2-alpha tromethamine; CID6434572; carboprost trometamol; Prosta-5,13-dien-1-oic acid, 9,11,15-trihydroxy-15-methyl-, (5Z,9-alpha,11-alpha,13E,15S)-, compd. with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1); U-32921E; UNII-U4526F86FJ; Prostin / 15M; LS-125842	58551-69-2	5284525	7853872	TTDS00168	Prostaglandin E2 receptor, EP2 subtype	EP2 receptor;PGE receptor, EP2 subtype;Prostanoid EP2 receptor	P43116	5732	ENSG00000125384	binder
DCL000505	CP-533536	CP-533536; 2-[3-[[pyridin-3-ylsulfonyl-[(4-tert-butylphenyl)methyl]amino]methyl]phenoxy]acetic Acid; CHEBI:659503; CHEMBL563646; UNII-L266R6E31E; Acetic acid, 2-(3-((((4-(1,1-dimethylethyl)phenyl)methyl)(3-pyridinylsulfonyl)amino)methyl)phenoxy)-; CID9890801; 2-(3-((((4-(1,1-dimethylethyl)phenyl)methyl)(pyridin-3-ylsulfonyl)amino)methyl)phenoxy)acetic acid; 223488-57-1; MolPort-005-942-744; Evatanepag; CP-533,536	N/A	9890801	49684229	TTDS00168	Prostaglandin E2 receptor, EP2 subtype	EP2 receptor;PGE receptor, EP2 subtype;Prostanoid EP2 receptor	P43116	5732	ENSG00000125384	agonist
DAP001490	Lipo-alprostadil	N/A	745-65-3	5280723	48415538	TTDS00168	Prostaglandin E2 receptor, EP2 subtype	EP2 receptor;PGE receptor, EP2 subtype;Prostanoid EP2 receptor	P43116	5732	ENSG00000125384	agonist
DAP000360	Dinoprostone	D015232; nchembio.106-comp6; 5-Heptenoic acid, 7-(3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxocyclopentyl)-, l-; (5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprosta-5,13-dienoate; 7-(3-Hydroxy-2-(3-hydroxy-1-octenyl)-5-oxocyclopentyl)-5-heptenoic acid; Propess; [3H]PGE2; Prostaglandin E2; Dinoprostone; HMS1791K12; PGE2; Cervidil; l-7-(3-Hydroxy-2-(3-hydroxy-1-octenyl)-5-oxocyclopentyl)-5-heptenoic acid; 5-Heptenoic acid, 7-(3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxocyclopentyl)- (8CI); Prostenon; NCGC00092361-03; Prestwick_793; Prostaglandin E2alpha; (5Z,11alpha,13E,15S)-11,15-dihydroxy-9-oxoprosta-5,13-dien-1-oic acid; HMS1989K12; CHEMBL548; NSC 165560; Prostin E; (Z)-7-[(1R,2R,3R)-3-Hydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]hept-5-enoic acid; ST50826265; U-12062; l-Prostaglandin E2; Dinoprostone; NCGC00092361-01; Dinoprostone beta-Cyclodextrin Clathrate; Dinoprostone [USAN:INN:BAN:JAN]; Prepidil; Dinoprostonum [INN-Latin]; PGE2alpha; NSC 196514; Dinoproston; D00079; NCGC00092361-02; EINECS 206-656-6; NCGC00092361-05; Prostin; MolPort-003-939-184; DB00917; E2, Prostaglandin; E2alpha, Prostaglandin; nchembio.147-comp12; Prostarmon E2; (5Z,11alpha,13E,15S)-11,15-Dihydroxy-9-oxoprosta-5,13-dienoic acid; IDI1_033960; l-PGE2; Prepidil Gel; 5-Heptenoic acid, 7-(3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxocyclopentyl)-; CID5280360; AC-6098; Prepidil (TN); P0409_SIGMA; LMFA03010003; E2 alpha, Prostaglandin; Prostaglandin E2 alpha; Cervidil (TN); 05D31BD5-818B-4A92-8CFC-BEC19926A5B3; Dinoprostona; HMS1361K12; PGE2 alpha; (5Z,11.alpha.,13E,15S)-11,15-Dihydroxy-9-oxoprosta-5,13-dien-1-oic acid; Dinoprostona [INN-Spanish]; Dinoprostonum; NCGC00092361-04; Dinoprostone Prostaglandin E2; Prostaglandin E2; Prostarmon E; (5Z,11-alpha,13E,15S)-11,15-Dihydroxy-9-oxoprosta-5,13-dien-1-oic acid; alpha, PGE2; (5Z,13E,15S)-11alpha,15-dihydroxy-9-oxoprosta-5,13-dien-1-oic acid; (15S)-Prostaglandin E2; AC1NQWXW; alpha, Prostaglandin E2; BML1-F07; Minprostin E2; (5Z,11alpha,13E,15S)-11,15-Dihydroxy-9-oxoprosta-5,13-dien-1-oic; BMS-279654 & PGE2; (5Z,13E)-(15S)-11alpha,15-Dihydroxy-9-oxoprost-13-enoate; (E,Z)-(1R,2R,3R)-7-(3-Hydroxy-2-((3S)-(3-hydroxy-1-octenyl))-5-oxocyclopentyl)-5-heptenoic acid; Prostin E2; LS-125823; BSPBio_001490; P6532_SIGMA; 363-24-6; UNII-K7Q1JQR04M; HMS2089D17; CHEBI:15551; Prostin E2 (TN); Minprositin E2; BRD-K26521938-001-04-9; C00584; Prosta-5,13-dien-1-oic acid, 11,15-dihydroxy-9-oxo-, (5Z,11alpha,13E,15S)-; P5640_SIGMA; Dinoprostone (JAN/USP/INN); SMP2_000056; U 12062; Gel, Prepidil; Prosta-5,13-dien-1-oic acid, (5Z,11-alpha,13E,15S)-11,15-dihydroxy-9-oxo-	363-24-6	5280360	7847147	TTDS00168	Prostaglandin E2 receptor, EP2 subtype	EP2 receptor;PGE receptor, EP2 subtype;Prostanoid EP2 receptor	P43116	5732	ENSG00000125384	antagonist
DCL001184	EZN-4176	N/A	N/A	N/A	N/A	TTDC00332	mRNA of androgen receptor	mRNA of Dihydrotestosterone receptor;mRNA of Nuclear receptor subfamily 3 group C member 4	P10275	367	ENSG00000169083	antisense
DCL000165	Midostaurin	PKC412; 120685-11-2; C411007; Midostaurin; CHEMBL608533; Midostaurin (USAN/INN); CHEMBL338448; CID9829523; NSC656576; N-Benzoylstaurosporine; CPG 41251; D05029; Benzamide, N-[(9S,10R,11R,13R)-2,3,10,11,12,13- hexahydro-10-methoxy-9-methyl-1-oxo-9,13-epoxy-1H,9H- diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazonin-11-yl]-N-methyl-; PKC-412; HMS3229K17	120685-11-2	9829523	48426267	TTDC00015	Protein kinase C gamma type	PKCG;PKC-gamma;PRKCG	P05129	5582	ENSG00000126583	inhibitor
DCL001230	Rontalizumab	N/A	N/A	N/A	N/A	TTDR00332	Interferon alpha	B-cell interferon;Buffy coat interferon;Foreign cell-induced interferon;IFN-alpha;Leukocyte interferon;Lymphoblast interferon;Lymphoblastoid interferon;Namalwa interferon;PH2-stable interferon;RSV-induced factor;Type-1 interferon	N/A	N/A	N/A	antibody
DCL000819	GPI-1485	N/A	848859-43-8	N/A	85152636	TTDC00307	FK506-binding protein 1A	12 kDa FKBP;FK-binding protein 12;FKBP-12;Immunophilin FKBP12;Immunophillin FKBP;Peptidyl-prolyl cis-trans isomerase;PPIase;Rotamase	P20071	N/A	N/A	N/A
DCL000550	ISIS-CRP	N/A	N/A	4878	47959550	TTDC00216	mRNA of C-reactive protein	CRP	P02741	1401	ENSG00000132693	antisense
DCL000449	AVE5026	N/A	N/A	N/A	N/A	TTDS00203	Coagulation factor Xa	Activated coagulation factor X;Factor Xa;Fxa	P00742	2159	ENSG00000126218	inhibitor
DAP000964	Coagulation Factor IX	N/A	9001-28-9	N/A	5997	TTDS00203	Coagulation factor Xa	Activated coagulation factor X;Factor Xa;Fxa	P00742	2159	ENSG00000126218	activator
DCL000586	Otamixaban	CID5496659; 2-(3-Carbamimidoylbenzyl)-3-(4-(1-oxypyridin-4-yl)benzoylamino)butyric acid methyl ester; Methyl 2-[(3-carbamimidoylphenyl)methyl]-3-[[4-(1-oxidopyridin-4-yl)benzoyl]amino]butanoate; CHEBI:167105; 193153-04-7; methyl (2R,3R)-2-[(3-carbamimidoylphenyl)methyl]-3-[[4-(1-oxidopyridin-1-ium-4-yl)benzoyl]amino]butanoate; 1ksn; AC1NUYXM; CHEMBL46618; Otamixaban	193153-04-7	N/A	10549646	TTDS00203	Coagulation factor Xa	Activated coagulation factor X;Factor Xa;Fxa	P00742	2159	ENSG00000126218	inhibitor
DAP001363	Danaparoid	N/A	83513-48-8	N/A	3820671	TTDS00203	Coagulation factor Xa	Activated coagulation factor X;Factor Xa;Fxa	P00742	2159	ENSG00000126218	inhibitor
DCL000184	Octopamine	alpha-(aminomethyl)-4-hydroxybenzenemethanol; LS-42692; Norsympathol; Norden; AKOS000123349; Spectrum_000201; STK801377; SPBio_003077; Prestwick2_000949; SMP1_000221; KBio3_001250; DivK1c_000245; PDSP1_001544; Octopaminum [INN-Latin]; Lopac0_000932; BPBio1_001010; Benzenemethanol, alpha-(aminomethyl)-4-hydroxy-; Benzyl alcohol, alpha-(aminomethyl)-p-hydroxy-; p-Hydroxyphenylethanolamine; NCGC00091918-04; 4-Octopamine; 1-(p-Hydroxyphenyl)-2-aminoethanol; KBio2_005817; NCGC00015760-08; 64C59BC0-9C98-49EF-A853-8849F02ABAAC; beta-hydroxytyramine; KBio1_000245; SDCCGMLS-0066599.P001; Octopamine hydrochloride; p-Norsynephrin; BRN 1211019; Octopaminum [Latin]; 4-(2-Amino-1-hydroxyethyl)phenol; KBioGR_000664; AB00053571; Benzenemethanol, .alpha.-(aminomethyl)-4-hydroxy-; alpha-Aminoethyl-4-hydroxybenzylalkohol; alpha-(Aminoethyl)-4-hydroxybenzenemethanol; Prestwick0_000949; ND 50; IDI1_000245; NINDS_000245; AC1L1IHG; KBio2_003249; Norfen; alpha-(Aminomethyl)-p-hydroxybenzyl alcohol; octopaminum; CID4581; Paraoxyphenyl aminoethanol; Norsynephrine; KBioSS_000681; 4-13-00-02656 (Beilstein Handbook Reference); TBB066518; octopamine; Octopamine [INN]; Prestwick3_000949; PDSP2_001528; p-Octopamine; Spectrum2_000222; EINECS 203-179-5; Octopamina [INN-Spanish]; KBio2_000681; Analet; Octopamin; WIN 5512; BSPBio_001750; NCGC00091918-03; Prestwick1_000949; SPBio_000263; MolPort-002-052-044; Norphen; CHEMBL53929; Spectrum4_000402; WV 569; alpha-(Aminoethyl)-p-hydroxybenzyl alcohol; Spectrum3_000275; Norsympatol; CHEBI:17134; 104-14-3; Spectrum5_001543; UNII-14O50WS8JD; Octopamina [Spanish]; para-Octopamine; Octopamina; BSPBio_000918; Octapamine	N/A	5311213	39340921	TTDS00203	Coagulation factor Xa	Activated coagulation factor X;Factor Xa;Fxa	P00742	2159	ENSG00000126218	inhibitor
DAP000616	Enoxaparin	PK-10169; Heparin, Low Molecular Weight; PK10,169; EMT 966; D017984; DB00407; Heparin, Low-Molecular-Weight; Low molecular weight heparin sodium; CID772; D006495; 6-[6-[6-[5-acetamido-4,6-dihydroxy-2-(sulfooxymethyl)oxan-3-yl]oxy-2-carboxy-4-hydroxy-5-sulfooxyoxan-3-yl]oxy-2-(hydroxymethyl)-5-(sulfoamino)-4-sulfooxyoxan-3-yl]oxy-3,4-dihydroxy-5-sulfooxyoxane-2-carboxylic acid; 2-o-sulfohexopyranuronosyl-(1->4)-2-deoxy-3-o-sulfo-2-(sulfoamino)hexopyranosyl-(1->4)-2-o-sulfohexopyranuronosyl-(1->4)-2-acetamido-2-deoxy-6-o-sulfohexopyranose; Lovenox; PK 10,169; Lovenox HP; LMWH; PK-10,169; Clexane; EMT-967; EMT-966; Low-Molecular-Weight Heparin; enoxaparin; DB01225; EMT967; AR-1E4539; EMT 967; AC1L19ZN; PK10169; Low molecular weight heparin; Enoxaparine; EMT966	9005-49-6	772	2789	TTDS00203	Coagulation factor Xa	Activated coagulation factor X;Factor Xa;Fxa	P00742	2159	ENSG00000126218	inhibitor
DCL000591	PD-348292	N-(4-Chlorophenyl)-N-(2-fluoro-4-(2-oxopyridin-1(2H)-yl)phenyl)-4-methoxypyrrolidiine-1,2-dicarboxamide; UNII-5FCH6YDY7Z; DB06920; CID 11634458; 2phb; 536748-46-6; eribaxaban; CHEMBL476186; PD 348292; Eribaxaban (USAN); PD0348292; D08913; CID11634458; PD-0348292; CHEBI:597500; PD 0348292	536748-46-6	11634458	85149732	TTDS00203	Coagulation factor Xa	Activated coagulation factor X;Factor Xa;Fxa	P00742	2159	ENSG00000126218	inhibitor
DAP000812	Fondaparinux sodium	decasodium (2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5R,6R)-6-[(2R,3S,4S,5R,6R)-2-carboxylato-4-hydroxy-6-[(2R,3S,4R,5R,6S)-4-hydroxy-6-methoxy-5-(sulfonatoamino)-2-(sulfonatooxymethyl)oxan-3-yl]oxy-5-sulfonatooxyoxan-3-yl]oxy-5-(sulfonatoamino)-4-sulfonatooxy-2-(sulfonatooxymethyl)oxan-3-yl]oxy-3-[(2R,3R,4R,5S,6R)-4,5-dihydroxy-3-(sulfonatoamino)-6-(sulfonatooxymethyl)oxan-2-yl]oxy-4,5-dihydroxyoxane-2-carboxylate; CID636380; GSK-576428; D01844; SR-90107; Fondaparinux sodium; Arixtra (TN); DB00569; Quixidar; 114870-03-0; Arixtra; AKOS005146286; CHEMBL1200644; Org-31540; Fondaparinux sodium (JAN/USAN/INN); AC1LCS4W; I06-1946; Fondaparin sodium; SR-90107A	114870-03-0	636380	7848906	TTDS00203	Coagulation factor Xa	Activated coagulation factor X;Factor Xa;Fxa	P00742	2159	ENSG00000126218	inhibitor
DCL000233	SR-123781A	N/A	232602-93-6	N/A	N/A	TTDS00203	Coagulation factor Xa	Activated coagulation factor X;Factor Xa;Fxa	P00742	2159	ENSG00000126218	inhibitor
DCL000651	TAK-442	CID 11641515; CHEBI:728723; CHEMBL1095032; TAK-442; CID11641515	N/A	626522	43456077	TTDS00203	Coagulation factor Xa	Activated coagulation factor X;Factor Xa;Fxa	P00742	2159	ENSG00000126218	inhibitor
DCL000537	Idraparinux	SR 34006; LS-191667; alpha-D-Glucopyranoside, methyl O-2,3,4-tri-O-methyl-6-O-sulfo-alpha-D-glucopyranosyl-(1-4)-O-2,3-di-O-methyl-beta-D-glucopyranuronosyl-(1-4)-O-2,3,6-tri-O-sulfo-alpha-D-lucopyranosyl-(1-4)-O-2,3-di-O-methyl-alpha-L-idopyranuronosyl-(1-4)-, tris(hydrogen sulfate); CID3083445; AC1MJ0N7; CID 9942027; C479958; 162610-17-5; SR-34006; (2S,3S,4S,5R,6R)-6-[(2R,3R,4S,5R,6R)-6-[(2R,3S,4S,5R,6R)-2-carboxy-4,5-dimethoxy-6-[(2R,3R,4S,5R,6S)-6-methoxy-4,5-disulfooxy-2-(sulfooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-disulfooxy-2-(sulfooxymethyl)oxan-3-yl]oxy-4,5-dimethoxy-3-[(2R,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(sulfooxymethyl)oxan-2-yl]oxyoxane-2-carboxylic acid; Idraparinux	162610-17-5	3083445	85149566	TTDS00203	Coagulation factor Xa	Activated coagulation factor X;Factor Xa;Fxa	P00742	2159	ENSG00000126218	inhibitor
DCL000438	Apixaban	S1593_Selleck; 503612-47-3; BMS 562247-01; 1H-Pyrazolo(3,4-c)pyridine-3-carboxamide, 4,5,6,7-tetrahydro-1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxo-1-piperidinyl)phenyl)-; 1H-Pyrazolo[3,4-c]pyridine-3-carboxamide, 4,5,6,7-tetrahydro-1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxo-1-piperidinyl)phenyl]-; DB07828; CHEMBL231779; ro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid amide; D03213; GG2; Apixaban; AKOS005146204; 1-(4-Methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetrahyd; 2p16; BMS-562247-01, Apixaban; CHEBI:49620; UNII-3Z9Y7UWC1J; CID10182969; BMS-562247-01; Apixaban (JAN/USAN/INN); BMS-562247	N/A	10182969	46519072	TTDS00203	Coagulation factor Xa	Activated coagulation factor X;Factor Xa;Fxa	P00742	2159	ENSG00000126218	inhibitor
DAP000545	Succinic acid	110-15-6; AI3-06297; HOOC-CH2-CH2-COOH; Asuccin; LS-147378; nchembio856-comp9; Kyselina jantarova [Czech]; bmse000183; AKOS000118899; NCGC00159372-02; Potassium Succinate; Succinicun acidum; Bernsteinsaure [German]; Ethanedicarboxylic acid; STK387105; Acid of amber; Bernsteinsaeure; NSC25949; SUCCINIC ACID, ACS; butanedioic acid; Bernsteinsaure; Spirit of amber; I04-1083; 1cze; Butandisaeure; DB00139; NSC106449; C00042; succinic acid; Wormwood acid; 1,4-BUTANEDIOIC ACID  (SUCCINIC ACID); S9512_SIGMA; AC1L1AQW; 37E8FFFB-70DA-4399-B724-476BD8715EF0; W502715_ALDRICH; nchembio.2007.47-comp2; A 12084; Wormwood; SBB040562; Succinic acid (8CI); Ethylene dicarboxylic acid; ethylenesuccinic acid; S7501_SIAL; Butanedionic acid; 14079_FLUKA; BRN 1754069; Butanedioic acid diammonium salt; LMFA01170043; 4-02-00-01908 (Beilstein Handbook Reference); nchembio.186-comp50; 14079_SIAL; Succinicum acidum; nchembio.198-comp17; Amber acid; 398055_SIAL; Katasuccin; W502707_ALDRICH; acide succinique; NCGC00159372-03; nchembio.266-comp26; succinate, 9; 1,2-Ethanedicarboxylic acid; 6283-68-7; NSC 106449; AC1Q757B; 14078_FLUKA; 623158-99-6; InChI=1/C4H6O4/c5-3(6)1-2-4(7)8/h1-2H2,(H,5,6)(H,7,8; Kyselina jantarova; MolPort-000-871-623; 1,4-Butanedioic acid; Sal succini; acide butanedioique; S3674_SIAL; S0100; Ethylene succinic acid; SIN; CHEMBL576; CHEBI:15741; WLN: QV2VQ; C4H6O4; EINECS 203-740-4; Acidum succinicum; CID1110; Amber acid, Butanedioic acid, Ethylenesuccinic acid; Butanedioic acid (9CI); Succinellite; UNII-AB6MNQ6J6L; succ; HSDB 791; Dihydrofumaric acid	110-15-6	1110	3344	TTDS00054	Succinate semialdehyde dehydrogenase, mitochondrial	NAD(+)-dependent succinic semialdehyde dehydrogenase;Succinic dehydrogenase	P51649	7915	ENSG00000112294	inhibitor
DAP000754	Chlormerodrin	Chlormerodrin Hg 197 (USAN); AC1Q5OOC; KST-1A2974; AR-1A8894; Neohydrin-203 (TN); MolPort-001-783-408; CID11954348; AC1L4XDH; Chloromeridin; loro-}; Mercury, {[3-[(aminocarbonyl)amino]-2-methoxypropyl]chloro-}; Urea, (2-methoxypropyl)-, mercury complex; Urea, (3-(chloromercuri)-2-methoxypropyl)-; Urea, (3-(chloromercurio)-2-methoxypropyl)-; D03465; [3-(carbamoylamino)-2-methoxypropyl](chloro)(203hg)mercury; Hg-203 chlormerodrin; CHEBI:59462; CHEMBL1201095; AC1Q5OOB; [3-(carbamoylamino)-2-methoxypropyl]-chloromercury; AC1Q44GD; Neogidrin; [3-(carbamoylamino)-2-methoxypropyl](chloro)mercury; Chlormerodrin (197Hg) (INN); chloro(2-methoxy-3-ureidopropyl)((203)Hg)mercury(II); AC1L1EAZ; UNII-1D6EFC579A; Chlormerodrin (197Hg); Chlormerodrin Hg 197 (TN); 23495-28-5; D03466; 10375-56-1; AC1L18NP; chlormerodrin; 3-ureido-2-methoxypropyl((203)Hg)mercury(II) chloride; CHEBI:59445; DB00534; Chlormerodrin Hg 203 (USAN); ; {[3-(Chloromercuri)-2-methoxypropyl]urea}; {[3-[(Aminocarbonyl)amino]-2-hydroxypropyl]chloromercury}; NSC19911; CID193986; chlormerodrin (203Hg); AR-1A3788; Chlormerodrin Hg 197 [USAN:USP XX]; 3-Chloromercuri-2-methoxypropylurea; Mercury, [3-[(aminocarbonyl)amino]-2-methoxypropyl]chloro; Mercury, chloro(2-methoxy-3-ureidopropyl)-; Mercury, {[3-[(aminocarbonyl)amino]-2-methoxypropyl-C1,O3]ch; [3-(carbamoylamino)-2-methoxypropyl](chloro)((203)Hg)mercury; KST-1A9137; Chlormerodrin Hg 197; Chlormerodrin Hg 203; (3-(Chloromercuri)-2-methoxypropyl)urea; chlormerodrina; CID25210; Neohydrin-203; [3-(carbamoylamino)-2-methoxypropyl]-chloromercury-203	62-37-3	2716	541660	TTDS00054	Succinate semialdehyde dehydrogenase, mitochondrial	NAD(+)-dependent succinic semialdehyde dehydrogenase;Succinic dehydrogenase	P51649	7915	ENSG00000112294	inhibitor
DAP000781	Amantadine	Spectrum3_000291; MolPort-001-661-700; 1-Adamantanamine (8CI); EINECS 212-201-2; Adamantanamine; CHEMBL660; KBio3_001322; Lopac0_000004; NSC83653; KBio2_000390; 1-Aminoadamantane; BSPBio_001822; BSPBio_000334; NSC341865; BIDD:GT0757; CHEBI:2618; Lopac-A-1260; ADAMANTANE,1-AMINO; MolPort-001-760-587; HSDB 3202; Spectrum5_000772; D07441; IDI1_000815; KBioSS_000390; 1-Adamantanamine; Symadine; BIA4304; L000868; C10H17N; STK298781; KBio2_005526; AC1Q5396; tricyclo[3.3.1.1(3,7)]decane-1-amine; LS-157049; adamantan-1-amine; Pk-merz; Amantadine [INN:BAN]; InChI=1/C10H17N/c11-10-4-7-1-8(5-10)3-9(2-7)6-10/h7-9H,1-6,11H; Prestwick1_000407; Tricyclo(3.3.1.1(3,7))-decan-1-amine; Amantadinum; Symmetrel; Mantadine; UNII-BF4C9Z1J53; amantadine; HMS1791O12; AB00514655; Amantadina; NCIOpen2_001059; Amant; OR14310; HMS1989O12; AKOS000113994; BPBio1_000368; NCGC00179597-01; Gen-Amantadine; 1-Aminotricyclo(3.3.1.1(sup 3,7))decane; Spectrum4_000134; Amantadinum [INN-Latin]; NINDS_000815; TL8005280; AC1L1CZI; SPBio_002273; KBio1_000815; MolPort-001-791-102; Tricyclo(3.3.1.1(sup 3,7))decan-1-amine; 768-94-5; CID2130; Tricyclo[3.3.1.1(3,7)]decan-1-amine; Tricyclo[3.3.1.1^3,7]decan-1-amine; Tricyclo[3.3.1.1(sup3,7)]decan-1-amine; BRN 2204333; tricyclo[3.3.1.1~3,7~]decan-1-amine; Spectrum_000030; NCGC00162039-04; Aminoadamantane; 665-66-7 (hydrochloride); C06818; Endantadine; Adamantamine; Prestwick3_000407; Amantadine (INN); NCGC00162039-03; Adamantylamine; Prestwick2_000407; Oprea1_248648; BSPBio_001570; NCGC00015036-01; adamantan-1-ylamine; DivK1c_000815; NCGC00015036-07; Amantidine; SPBio_000002; I14-1101; NSC 341865; Spectrum2_000081; Amantadina [INN-Spanish]; DB00915; AC-11992; NCGC00162039-02; Wiregyt; Amantadine Base; KBioGR_000548; TCMDC-125869; WLN: L66 B6 A B- C 1B ITJ BZ; tricyclo[3.3.1.1(3,7)]decan-1-ylamine; Tricyclo(3.3.1.1(sup 3.7))decan-1-amine; KBio2_002958; Tricyclo(3.3.1.13,7)decan-1-amine; Prestwick0_000407; AC1Q4UAF; 138576_ALDRICH; 1-Adamantamine; AKOS000119324; Bio-0821; NCGC00162039-01; 1-Adamantylamine; Ambap768-94-5	768-94-5	2130	9036	TTDS00175	Influenza A virus M2 protein	M2 proton channel;Matrix protein M2	P63231	N/A	N/A	inhibitor
DAP001087	Rimantadine	13392-28-4; NCGC00159491-02; IDI1_007990; Riamantadine; MolPort-000-892-068; Rimantadine (INN); 1-Adamantan-1-yl-ethylamine; HSDB 7438; Tricyclo(3.3.1.13,7)decane-1-methanamine, alpha-methyl-; Rimantadina; UNII-0T2EF4JQTU; STK177253; BRN 2715740; AC1L1JJO; Tricyclo(3.3.1.1^3,7)decane-1-methanamine, .alpha.-methyl-; alpha-Methyl-1-adamantanemethylamine; MolPort-001-794-501; Oprea1_602732; Remantadine; 1-(1-adamantyl)ethylamine; LS-15019; Rimantidine & .alpha.IFN; .alpha.-Methyladamantanemethylamine; CID5071; Rimantadinum [INN-Latin]; 1-(adamantan-1-yl)ethan-1-amine; Rimant & .alpha. IFN; HMS1410F13; Enamine_005755; CHEMBL959; Rimant; AC1Q2B57; rimantadine; alpha-Methyladamantanemethylamine; 1-(1-Adamantyl)ethylamin; 1-(tricyclo[3.3.1.1~3,7~]dec-1-yl)ethanamine; Rimantadine [INN:BAN]; Maybridge1_002066; 1-Adamantan-1-ylethylamine; alpha-Methyl-1-adamantanemethylamine; Tricyclo(3.3.1.1^3,7)decane-1-methanamine, .alpha.-methyl- & IFN.alpha; Rimantadinum; D08483; HMS2090L19; 1-Adamantanemethylamine, .alpha.-methyl-; AC1Q2BAB; DB00478; NCGC00159491-03; STOCK4S-93186; C07236; 1-tricyclo[3.3.1.1~3,7~]dec-1-ylethanamine; Tricyclo(3.3.1.1(sup 3,7))decane-1-methanamine, alpha-methyl-; Ambap13392-28-4; AKOS000264537; 1-ADAMANTANEMETHYLAMINE, alpha-METHYL-; 1-(1-Adamantyl)ethanamine; 1-(1-adamantyl)-ethylamine; Rimantadina [INN-Spanish]	13392-28-4	5071	9445	TTDS00175	Influenza A virus M2 protein	M2 proton channel;Matrix protein M2	P63231	N/A	N/A	inhibitor
DAP000931	Flunitrazepam	LS-34296; betapharm Brand of Flunitrazepam; F9261_SIGMA; DivK1c_000981; nchembio747-comp30; 1622-62-4; ct-Arzneimittel Brand of Flunitrazepam; HSDB 6960; Roche Brand of Flunitrazepam; Flunitrazepam neuraxpharm; Flunitrazepam ratiopharm; MolPort-003-941-406; 5-(o-Fluorophenyl)-1,3-dihydro-1-methyl-7-nitro-2H-1,4-benzodiazepin-2-one; 5-(2-Fluorophenyl)-1-methyl-7-nitro-1,3-dihydro-2H-1,4-benzodiazepin-2-one; DB01544; Fluridrazepam; 5-24-04-00350 (Beilstein Handbook Reference); 5-(2-Fluorophenyl)-1-methyl-7-nitro-3H-1,4-benzodiazepin-2(1H)-one; HMS503E03; AKOS005066009; Rohypnol (TN); 1A Brand of Flunitrazepam; Flunitrazepam (JP15/USAN/INN); DEA No. 2763; ct Arzneimittel Brand of Flunitrazepam; flunizep von ct; 1,3-Dihydro-5-(o-fluorophenyl)-1-methyl-7-nitro-2H-1,4-benzodiazepin-2-one; NSC708829; CCRIS 5287; Hexal Brand of Flunitrazepam; ratiopharm Brand of Flunitrazepam; Flunitrazepamum; Flunibeta; 2H-1,4-BENZODIAZEPIN-2-ONE, 1,3-DIHYDRO-5-(2-FLUOROPHENYL)-1-METHYL-7-NITRO-; 2H-1,4-Benzodiazepin-2-one, 5-(2-fluorophenyl)-1,3-dihydro-1-methyl-7-nitro-; Flunimerck; RO54200; ZINC03812994; Teva Brand of Flunitrazepam; Merck dura Brand of Flunitrazepam; 1-Methyl-7-nitro-5-(2-fluorophenyl)-3H-1,4-benzodiazepin-2(1H)-one; NINDS_000981; Ro 5-4200; [3H]flunitrazepam; AC1L1FSZ; IDI1_000981; Primun; Narcozep; Flunitrazepam [USAN:INN:BAN:JAN]; Flunitrazepamum [INN-Latin]; Fluni 1A Pharma; Flunitrazepam-neuraxpharm; D005445; EINECS 216-597-8; flunitrazepam; 5-(2-fluorophenyl)-1-methyl-7-nitro-3H-1,4-benzodiazepin-2-one; Roipnol; Flunitrazepam-Teva; Fluninoc; RO-5-4200; Rohypnol; CID3380; KBio1_000981; D01230; Flunitrazepam Teva; CHEMBL13280; BRN 0702691; neuraxpharm Brand of Flunitrazepam; Rohipnol; Flunitrazepam-ratiopharm	1622-62-4	3380	10476153	TTDS00374	Benzodiazepine receptor	N/A	N/A	N/A	N/A	agonist
DAP000930	Estazolam	Estazolam (JP15/USAN/INN); DB01215; Julodin; 8-Chloro-6-phenyl-4H-s-triazolo(4,3-a)(1,4)benzodiazepine; BIDD:GT0481; LS-7378; Takeda Brand of Estazolam; BRN 1220868; ProSom; CID3261; AKOS005064373; Abbott Brand of Estazolam; Prosom (TN); Tasedan; Estazolam [USAN:INN:JAN]; I06-0352; DEA No. 2756; AC1L1FJ8; 4H-s-Triazolo(4,3-a)(1,4)benzodiazepine, 8-chloro-6-phenyl-; Eurodin; Somnatrol; InChI=1/C16H11ClN4/c17-12-6-7-14-13(8-12)16(11-4-2-1-3-5-11)18-9-15-20-19-10-21(14)15/h1-8,10H,9H2; 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-6-phenyl-; D004949; Estazolamum [INN-Latin]; D00311; UNII-36S3EQV54C; ZINC00001370; 8-Chloro-6-phenyl-4H-s-triazolo[4,3-a][1,4]benzodiazepine; MolPort-003-941-274; CHEMBL285674; D40TA; CCRIS 1955; E3638_SIGMA; C16H11ClN4; U 33737; D-40TA; Hormona Brand of Estazolam; 4H-(1,2,4)Triazolo(4,3-a)(1,4)benzodiazepine, 8-chloro-6-phenyl-; D 40TA; estazolam; Nuctalon; 8-Chloro-6-phenyl-4H-(1,2,4)triazolo-(4,3-a)(1,4)benzodiazepine; NSC290818; Estazolamum; 8-chloro-6-phenyl-4H-s-triazolo[4,3-(alpha)] [1,4]benzodiazepine; CDCHDCWJMGXXRH-UHFFFAOYSA-; 4H-s-Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-6-phenyl-; 29975-16-4; NCGC00168250-01; CHEBI:4858; NSC 290818; Abbott 47631; Esilgan; 4H-(1,2,4)Triazolo(4,3-a)(1,4)benzodiazepine, 8-chloro-6-phenyl; EINECS 249-982-4; Nemurel; WLN: T B576 BN DNN HN GHJ IR& LG; 8-Chloro-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine; 8-Chloro-6-phenyl-4H-s-triazolo(4,3-a)(1,4)benzodiazepine (IUPAC); Cannoc	29975-16-4	3261	9195	TTDS00374	Benzodiazepine receptor	N/A	N/A	N/A	N/A	agonist
DAP000243	Oxazepam	CID4616; Abboxampam; DF2371850; NSC169448; Nesontil; D00464; Oxazepam (JAN/USP/INN); Ossazepam [DCIT]; Z 10 tr; (+-)-7-Chloro-1,3-dihydro-3-hydroxy-5-phenyl-2H-1,4-benzodiazepin-2-one; Azutranguil; (RS)-Oxazepam; Abboxapam; Sobril; nchembio747-comp28; Psicopax; D010076; WLN: T67 GMV JN IHJ CG IQ KR; 7-chloro-3-hydroxy-5-phenyl-1,3-dihydro-1,4-benzodiazepin-2-one; Murelax; Psiquiwas; Praxiten; EINECS 210-076-9; Hi-Long; UNII-6GOW6DWN2A; WY-3498; Hilong; Droxacepam; Quilibrex; Ro 5-6789; Seresta; Sigacalm; Serax (TN); 2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-3-hydroxy-5-phenyl-; 35295-88-6; Serenid-D; Tarchomin; InChI=1/C15H11ClN2O2/c16-10-6-7-12-11(8-10)13(9-4-2-1-3-5-9)18-15(20)14(19)17-12/h1-8,15,20H,(H,17,19); 7-Chloro-1,3-dihydro-3-hydroxy-5-phenyl-2H-1,4-benzodiazepine-2-one; Wy-3498 stic; Noctazepam; DEA No. 2835; C07359; NINDS_000986; Isodin; Serenid; MolPort-001-729-110; Apo-astress; Tacepam; Alepam; (+-)-Oxazepam; QUEN; Serax; Aplakil; Oxazepam [USAN:INN:BAN:JAN]; 2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-3-hydroxy-5-phenyl-, (+-)-; Oxazepamum [INN-Latin]; Serepax; Oxozepam; CHEMBL568; 7-Chloro-1,3-dihydro-3-hydroxy-5-phenyl-2H-1,4-benzodiazepin-2-one; Uskan; Zaxopam; Tazepam; Ossazepam; Astress; 1,3-Dihydro-7-chloro-3-hydroxy-5-phenyl-3H-1,4-benzodiazepin-2-one; NSC 169448; LS-44; Tranquo-buscopan-wirkstoff; tranquo-buscopan- wirkstoff; 7-Chloro-1,3-dihydro-3-hydroxy-5-phenyl-1,4(2H)-benzodiazepin-2-one; Pacienx; 7-Chloro-3-hydroxy-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one; O5254_SIGMA; Serpax; Durazepam; Z10-Tr; CCRIS 488; 1,3-Dihydro-7-chloro-3-hydroxy-5-phenyl-2H-1,4-benzodiazepin-2-one; Adumbran; Wy 3498; Nortemazepam; Vaben; Oxazipam; Oxa-puren; Propax; Limbial; Anxiolit retard; N-Desmethyltemazepam; NIOSH/DF2371850; Anxiolit; HSDB 3140; DivK1c_000986; Sedigoa; KBio1_000986; Azutranquil; oxazepam; LS-34236; HMS503E13; Bonare; AC1L1IKD; DB00842; CHEBI:7823; Oxazepamum; Rondar; Oxanid; CB 8092; ADIMAYPTOBDMTL-UHFFFAOYSA-; Drimuel; 604-75-1; Oprea1_501459; Ansioxacepam; IDI1_000986; 3H-1,4-Benzodiazepin-2-one, 1,3-dihydro-7-chloro-3-hydroxy-5-phenyl-; NCGC00159323-02; Nozepam; Serenal; Lederpam; 61036-43-9; p acienx	604-75-1	4616	9563	TTDS00374	Benzodiazepine receptor	N/A	N/A	N/A	N/A	agonist
DAP000241	Midazolam	Midazolam Base; UC429_SIGMA; 4H-Imidazo[1,5-a][1,4]benzodiazepine, 8-chloro-6-(2-fluoro-phenyl)-1-methyl-, (Z)-2-butenedioate; 8-Chlor-6-(2-fluorphenyl)-1-methyl-4H-imidazo(1,5-a)(1,4)benzodiazepin; Midanium; 59467-70-8; Midosed; Midazolamum; UNII-R60L0SM5BC; Dazolam; Dormicum (TN); ZINC00001732; AC-18749; CHEMBL655; 8-Chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5a][1,4]benzodiazepine hydrochloride; AC1L1HMA; 8-Chloro-6-(o-fluorophenyl)-1-methyl-4H-imidazo(1,5-a)(1,4)benzodiazepine; Ro 21-3981; BRN 0625572; MolPort-003-849-219; 8-Chloro-6-(O-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]-benzodiazepine; Midazolam [INN:BAN:JAN]; LS-77780; C07524; BIDD:GT0647; Versed; TL8003787; EINECS 261-774-5; CID4192; DEA No. 2884; 8-Chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]benzodiazepine; midazolam; C18H13ClFN3; DB00683; 4H-Imidazo[1,5-a][1,4]benzodiazepine, 8-chloro-6-(2-fluorophenyl)-1-methyl-; D00550; NCGC00168254-01; Dormicum; Midazolam (JAN/INN); nchembio747-comp32; 4H-Imidazo(1,5-a)(1,4)benzodiazepine, 8-chloro-6-(2-fluorophenyl)-1-methyl-; Midazolamum [INN-Latin]	59467-70-8	4192	183492	TTDS00374	Benzodiazepine receptor	N/A	N/A	N/A	N/A	agonist
DAP000244	Triazolam	Apotex Brand of Triazolam; 8-Chloro-6-(o-chlorophenyl)-1-methyl-4H-s-triazolo[4,3-a][1,4]benzodiazepine; DEA No. 2887; Halcion; Clorazolam; CCRIS 1932; Apo-Triazo; Novodorm; C17H12Cl2N4; CHEBI:9674; Hypnostat; 4H-(1,2,4)Triazolo(4,3-a)(1,4)benzodiazepine, 8-chloro-6-(2-chlorophenyl)-1-methyl-; NCGC00168258-01; Alti-Triazolam; Triazolam (JAN/USP/INN); EINECS 249-307-3; 28911-01-5; L000796; Triazolam Pfizer Brand; DB00897; Triazolamum [INN-Latin]; 8-Chloro-6-(2-chlorophenyl)-1-methyl-4H-(1,2,4)triazolo(4,3-a)(1,4)benzodiazepine; 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-6-(2-chlorophenyl)-1-methyl-; AC1L1KLZ; Novo-Triolam; Genpharm Brand of Triazolam; T9772_SIGMA; Gen Triazolam; Pfizer Brand of Triazolam; Songar; D014229; U-33,030; 4H-s-Triazolo(4,3-a)(1,4)benzodiazepine, 8-chloro-6-(o-chlorophenyl)-1-methyl-; U33,030; U 33,030; Novidorm; nchembio747-comp15; U-33030; Gen-Triazolam; U 33030; 8-Chloro-6-(2-chlorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine; MolPort-003-959-834; BRN 1226643; D00387; Triazolamum; Gerard Brand of Triazolam; 8-Chloro-6-(o-chlorophenyl)-1-methyl-4H-s-triazolo(4,3-a)(1,4)benzodiazepine; HSDB 6759; Halcion (TN); ZINC00002212; Apo Triazo; CHEMBL646; Triazolam [USAN:BAN:INN:JAN]; TGAR01H; CID5556; triazolam; UNII-1HM943223R; LS-156323; 8-Chloro-6-[2-chlorophenyl]-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine; Halcion (triazolam); Trilam	28911-01-5	5556	7847453	TTDS00374	Benzodiazepine receptor	N/A	N/A	N/A	N/A	agonist
DAP000932	Clotiazepam	5-(2-chlorophenyl)-7-ethyl-1-methyl-1,3-dihydro-2H-thieno[2,3-e][1,4]diazepin-2-one; D01328; AC1L1EIT; Rise; DEA No. 2752; Rizen; C16H15ClN2OS; 2H-Thieno(2,3e)(1,4)-diazepin-2-one, 5-(o-chlorophenyl)-7-ethyl-1,3-dihydro-1-methyl- (8CI); Trecalmo; Distensan; 5-(2-chlorophenyl)-7-ethyl-1-methyl-3H-thieno[2,3-e][1,4]diazepin-2-one; Clotiazepam (JP15/INN); clotiazepam; Rize; 33671-46-4; BRN 0623332; Rize (TN); ZINC00001207; Clozan; 2H-Thieno[2,3-e]-1,4-diazepin-2-one, 5-(2-chlorophenyl)-7-ethyl-1,3-dihydro-1-methyl-; AKOS005065735; Clotiazepamum [INN-Latin]; EINECS 251-627-3; Veratran; Clotiazepam [INN:JAN]; MolPort-004-285-852; CID2811; 2H-Thieno(2,3e)(1,4)-diazepin-2-one, 5-(o-chlorophenyl)-7-ethyl-1,3-dihydro-1-methyl-; 5-(o-Chlorophenyl)-7-ethyl-1,3-dihydro-1-methyl-2H-thieno(2,3-e)-1,4-diazepin-2-one; Y-6047; 5-(2-Chlorophenyl)-7-ethyl-1-methyl-1,3-dihydro-2H-thieno(2,3-e)(1,4)diazepin-2-one; Tienor; Y 6047; 2H-Thieno(2,3-e)(1,4)diazepin-2-one, 1,3-dihydro-5-(o-chlorophenyl)-7-ethyl-1-methyl-; UNII-ZCN055599V; DB01559; Clotiazepamum; LS-152361	33671-46-4	2811	10472457	TTDS00374	Benzodiazepine receptor	N/A	N/A	N/A	N/A	agonist
DAP000239	Alprazolam	Zolarem; U 31889; Zopax; U-31,889; MLS000759485; 8-Chloro-1-methyl-6-phenyl-4H-s-triazolo(4,3-alpha)(1,4)benzodiazepine; CHEBI:2611; D65MT; CPD000149316; Ksalol; Gen-Alprazolan; 8-Chloro-1-methyl-6-(phenyl-d5)-4H-(1,2,4)triazolo[4,3-a][1,4]benzodiazepine; C06817; Prazam; Tensivan; Zaxan; Arzneimittelwerk Dresden Brand of Alprazolam; Alprazolam Nu-Pharm Brand; NCGC00159466-03; EINECS 249-349-2; Zolam; Ralozam; 28981-97-7; HSDB 7207; Anpress; Solanax; STK590494; Alprazolam Novopharm Brand; Alpronax; AKOS005066050; Alprazolam extended release tablets; DEA No. 2882; Alzam; A6551_SIGMA; Alviz; NCGC00159466-02; Panistat; Cassadan; Alprazolam Pfizer Brand; DB00404; Apotex Brand of Alprazolam; Xanax; Restyl; CHEMBL661; CID2118; ZINC00000903; D00225; Pfizer Brand of Alprazolam; MLS000559000; U31,889; Nu Alpraz; Tafil D; AC-18721; Nu-Pharm Brand of Alprazolam; TUS-1; Apo Alpraz; Helex; NuAlpraz; A6551_FLUKA; Alprazolan; Novo Alprazol; Zolan; Alpaz; UNII-YU55MQ3IZY; Alprazolam Temmler Brand; Alprazolam Apotex Brand; 4H-(1,2,4)Triazolo(4,3-a)(1,4)benzodiazepine, 8-chloro-1-methyl-6-phenyl-; Apo-Alpraz; Alpram; Frontal; Algad; BIDD:GT0475; Zacetin; D 65MT; Xanagis; Zoldax; Alzon; AC1L1CYL; U-31889; A8800_SIGMA; Trankimazin; 8-Chloro-1-methyl-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine; D-65MT; Xanax TS; SMR000149316; Xanax (TN); ApoAlpraz; Panix; 8-Chloro-1-methyl-6-phenyl-4H-s-triazolo[4,3-a][1,4]benzodiazepine; 4H-s-Triazolo(4,3-a)(1,4)benzodiazepine, 8-chloro-1-methyl-6-phenyl-; Staccato-alprazolam; Zenax; NovoAlprazol; SAM001246696; Alprazolam intensol; I14-7472; Kenral Brand of Alprazolam; Alprazolam Alphapharm Brand; Alprox; Tus 1; Xanor; Temmler Brand of Alprazolam; BRN 1223125; Alprazolam-d5; Niravam; Mialin; Valeans; Nu-Alpraz; Alplax; Alprazolam Kenral Brand; Alcelam; LS-156344; Alphapharm Brand of Alprazolam; 4H-(1,2,4)Triazolo(4,3-alpha)(1,4)benzodiazepine, 8-chloro-1-methyl-6-phenyl-; 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-1-methyl-6-phenyl-; 611026_ALDRICH; Alprax; Novo-Alprazol; nchembio747-comp35; Alprazolam solution; 8-Chloro-1-methyl-6-phenyl-4H-s-triazolo(4,3-a)(1,4)benzodiazepine; Relaxol; alprazolam; Alprazolam [USAN:INN:BAN:JAN]; Nu Pharm Brand of Alprazolam; Zotran; Unilan; Esparon; Azor; Neurol; TGAR01P; BIDD:PXR0150; Pharnax; Tafil; Xanolam; Tranquinal; Bestrol; Alprazolam (JP15/USP/INN); AP-1002; MolPort-002-507-836; Zoldac; Prinox; Alprazolam Orion Brand; Tranax; Zopic; 611026_FLUKA; Tricalma; D000525; Alprazolamum [INN-Latin]; HMS2051A10; Zanapam; Alprazolamum; Bio-0790; Prazolan; Xanax XR; Intensol; Novopharm Brand of Alprazolam; Constan; AZ-002; Alzolam; Orion Brand of Alprazolam	28981-97-7	2118	176116	TTDS00374	Benzodiazepine receptor	N/A	N/A	N/A	N/A	agonist
DAP000933	Eszopiclone	CHEBI:53760; NCGC00159515-02; AC1LJ6QN; SEP-0227018; SEP-225441; (+)-Zopiclone; Lunesta; (+)-(5S)-6-(5-Chloropyridin-2-yl)-7-oxo-6,7-dihydro-5H-pyrrolo(3,4-b)pyrazin-5-yl 4-methylpiperazine-1-carboxylate; 1-Piperazinecarboxylic acid, 4-methyl-, (5S)-6-(5-chloro-2-pyridinyl)-6,7-dihydro-7-oxo-5H-pyrrolo(3,4-b)pyrazin-5-yl ester; D02624; CID969472; SEP-190; MolPort-003-666-599; 138729-47-2; KS-1055; CHEMBL1522; AC1Q3ZTD; UNII-UZX80K71OE; CPD000550478; HSDB 7472; Estorra; Lunivia; DB00402; ZINC19632834; ( )-Zopiclone; MLS001165744; Eszopiclone; MolPort-002-885-823; Eszopiclone (JAN/USAN/INN); Lunesta (TN); AC-5546; Eszopiclone [USAN:INN]; (plus)-Zopiclone; (S)-Zopiclone; SMR000550478; LS-186538; (5S)-6-(5-chloropyridin-2-yl)-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazin-5-yl 4-methylpiperazine-1-carboxylate; [(7S)-6-(5-chloropyridin-2-yl)-5-oxo-7H-pyrrolo[3,4-b]pyrazin-7-yl] 4-methylpiperazine-1-carboxylate; LS-187790; Estorra (TN); Esopiclone; LS-187032; (5S)-6-(5-Chloropyridin-2-yl)-7-oxo-6,7-dihydro-5H-pyrrolo(3,4-b)pyrazin-5-yl 4-methylpiperazine-1-carboxylate; SAM002548982; (5S)-6-(5-chloropyridin-2-yl)-7-oxo-5H,6H,7H-pyrrolo[3,4-b]pyrazin-5-yl 4-methylpiperazine-1-carboxylate; SEP-0227108; SPECTRUM1505188	138729-47-2	969472	734464	TTDS00374	Benzodiazepine receptor	N/A	N/A	N/A	N/A	agonist
DAP000240	Clorazepate	23887-31-2; Novo-Clopate; 20432-69-3; Tranxene /Cherazepate dipotasium/; AC1L1EIN; 7-Chloro-2,3-dihydro-2,2-dihydroxy-5-phenyl-1H-1,4-benzodiazepine-3-carboxylic acid; LS-187760; DEA No. 2768; Clorazepic acid [BAN]; Cchlorazepic acid; nchembio747-comp25; Gen-xene; clorazepate; LS-182361; AR-1H3291; EINECS 245-926-8; 7-chloro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine-3-carboxylic acid; 28425-34-5; MolPort-004-285-851; AC1Q3S8C; CID2809; UNII-D51WO0G0L4; Tranxene; CHEMBL1213252; Chlorazepic acid; C06921; HSDB 3041; Clorazepate dipotassium; 7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepine-3-carboxylic acid; 1H-1,4-Benzodiazepine-3-carboxylic acid, 7-chloro-2,3-dihydro-2-oxo-5-phenyl-; (Chloromethyl)(dimethyl)(tridecyloxy)silane; DB00628; CHEBI:3761; Chlorazepate; Clorazepic acid	23887-31-2	2809	9138	TTDS00374	Benzodiazepine receptor	N/A	N/A	N/A	N/A	agonist
DAP000238	Temazepam	Methyloxazepam; Scheffler Brand of Temazepam; Nocturne; LS-7712; Orion Brand of Temazepam; 846-50-4; 5-25-02-00242 (Beilstein Handbook Reference); Temaz; Temazepam, pharmaceutical grade; Dasuen; Normitab; Signopam; Temazepamum; Desitin Brand of Temazepam; Katwijk Brand of Temazepam; NSC 246303; Temaze; SaH 47-603; Sigma Brand of Temazepam; 7-Chloro-3-hydroxy-1-methyl-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one; Temazepamum [INN-Latin]; Perdorm; K3917; Restoril (TN); temazep von ct; Remestan; Planum; AHP Brand of Temazepam; ER 115; Wy-3917; CID5391; Levanzene; 3 Hydroxydiazepam; T8275_SIGMA; Euipnos; Knoll Brand of Temazepam; MolPort-002-051-814; NINDS_000989; Neodorm SP; Restoril; Nu Temazepam; Temazepam [USAN:INN:BAN]; Wyeth Brand of Temazepam; Nu-Temazepam; UNII-CHB1QD2QSS; DEA No. 2925; PMS Temazepam; Ro-5-5345; temazepam; EINECS 212-688-1; Alphapharm Brand of Temazepam; Uvamin Retard; Tema, Norkotral; WY 2917; WLN: T67 GNV JN IHJ CG G1 IQ KR; CCRIS 1954; NCGC00159440-02; ICN Brand of Temazepam; Hydroxydiazepam; ct Arzneimittel Brand of Temazepam; NSC246303; Nomapam; T8275_FLUKA; Ro 5-5345; WY 3917; Tenox; Nu Pharm Brand of Temazepam; Nu-Pharm Brand of Temazepam; Temazepam (USP/INN); DB00231; Gen-Temazepam; ct-Arzneimittel Brand of Temazepam; K-3917; BRN 0759300; DivK1c_000989; 7-CHLORO-1,3-DIHYDRO-3-HYDROXY-1-METHYL-5-PHENYL-2H-1,4-BENZODIAZEPIN-2-ONE; Gelthix; Apo Temazepam; Genopharm Brand of Temazepam; Levanxol; Cerepax; HMS503E19; SaH 47 603; Genpharm Brand of Temazepam; CHEMBL967; 7-chloro-3-hydroxy-1-methyl-5-phenyl-3H-1,4-benzodiazepin-2-one; Pronervon T; Apotex Brand of Temazepam; AC1L1K92; Lenal; Novo-Temazepam; SaH 47603; WY3917; 2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-3-hydroxy-1-methyl-5-phenyl-; Novo Temazepam; PMS-Temazepam; Temtabs; Novartis Brand of Temazepam; Norkotral Tema; Pfizer Brand 1 of Temazepam; Gen Temazepam; Normison; Mabertin; D013693; Euhypnos; Nortem; Oxydiazepam; Norton Brand of Temazepam; KBio1_000989; Ro55345; N-Methyloxazepam; 3-Hydroxydiazepam; D00370; 1,3-Dihydro-7-chloro-3-hydroxy-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one; Levanxene; Ro 5 5345; Temador; Apo-Temazepam; Crisonar; Pharmascience Brand of Temazepam; IDI1_000989; Novopharm Brand of Temazepam; Mallinckrodt Brand of Temazepam; Pfizer Brand 2 of Temazepam	846-50-4	5391	156664	TTDS00374	Benzodiazepine receptor	N/A	N/A	N/A	N/A	agonist
DAP000934	Fludiazepam	ID-540; UNII-7F64A2K16Z; 7-Chloro-5-(2-fluorophenyl)-1,3-dihydro-1-methyl-2H-1,4-benzodiazepin-2-one; 7-Chloro-5-(2-fluorophenyl)-1-methyl-1H-1,4-benzodiazepin-2(3H)-one; fludiazepam; 2H-1,4-Benzodiazepin-2-one, 7-chloro-5-(2-fluorophenyl)-1,3-dihydro-1-methyl- (9CI); 2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-7-chloro-5-(o-fluorophenyl)-1-methyl-; CHEBI:31618; ID 540; DB01567; 2H-1,4-Benzodiazepin-2-one, 7-chloro-5-(o-fluorophenyl)-1,3-dihydro-1-methyl-; LS-185079; CHEMBL13291; DEA No. 2759; 2H-1,4-Benzodiazepin-2-one, 7-chloro-5-(2-fluorophenyl)-1,3-dihydro-1-methyl-; ZINC00001460; MolPort-004-285-858; D01354; 7-Chloro-5-(2-fluorophenyl)-1-methyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one; CID3369; Fludiazepamum; BRN 0686115; Fludiazepamum [INN-Latin]; 5-24-04-00320 (Beilstein Handbook Reference); Erispan; Erispan (TN); 7-chloro-5-(2-fluorophenyl)-1-methyl-3H-1,4-benzodiazepin-2-one; Fludiazepam (JP15/INN); 60918-52-7; Fludiazepam [INN:JAN]; AC1L1FS2; 7-Chloro-5-(o-Fluorophenyl)-1,3-dihydro-1-methyl-2H-1,4-benzodiazepin-2-one; 3900-31-0	3900-31-0	3369	10469517	TTDS00374	Benzodiazepine receptor	N/A	N/A	N/A	N/A	agonist
DAP000084	Chlordiazepoxide	Disarim; AR-1L8290; CHEBI:3611; 7-chloro-4-hydroxy-N-methyl-5-phenyl-3H-1,4-benzodiazepin-2-imine; Chlordiazepoxide Base; Chlordiazepoxidum; C16H14ClN3.H2O; Mesural; chlordiazepoxide; Spectrum4_000578; KBio1_000995; Eden-psich; AC-13012; Psicosan; Clordiazepoxido; Apo-Chlordiazepoxide; Novo-Poxide; 58-25-3; Librelease; MolPort-002-051-367; CHEMBL451; Chloridiazepoxide; nchembio747-comp24; Chlordiazepoxid; Clordiazepossido [Italian]; Abboxide; Clordiazepossido; HMS2052C19; Radepur; MLS001424220; Clordiazepoxido [INN-Spanish]; KBioGR_001016; Ifibrium; 7-Chloro-2-(methylamino)-5-phenyl-3H-1,4-benzodiazepine 4-oxide; Kalmocaps; Viopsicol; 438-41-5; Decacil; Chlordiazepoxide (JP15/USP/INN); I06-0193; Chloridazepoxide; Bio-0792; Chlordiazepoxydum; HSDB 3028; Napoton; STK597142; LS-168455; SMR000469226; Chloridiazepide; Control; Napton; Silibrin; DivK1c_000995; LS-34063; Zetran; Libritabs; MolPort-004-285-850; Librium; Chloradiazepoxide; Eden; Spectrum2_001157; Multum; Helogaphen; 7-Chlor-2-methylamino-5-phenyl-3H-1,4-benzodiazepin-4-oxid; Balance (pharmaceutical); UNII-6RZ6XEZ3CR; Lygen; MLS001066622; Mildmen; 7-Chloro-N-methyl-5-phenyl-3H-1,4-benzodiazepin-2-amine 4-oxide; 7-Cloro-2-metilamino-5-fenil-3H-1,4-benzodiazepina 4-ossido [Italian]; Methaminodiazepoxide; DEA No. 2744; Librinin; CPD000469226; Zeisin; DB00475; Elenium; Balance; IDI1_000995; Chlozepid; AC1L1EAN; Sonimen; Risolid; 3H-1,4-Benzodiazepine, 7-chloro-2-(methylamino)-5-phenyl-, 4-oxide; Chlordiazachel; 7-Cloro-2-metilamino-5-fenil-3H-1,4-benzodiazepina 4-ossido; MENRIUM 5-4; NINDS_000995; Chlordiazepoxide [USAN:INN:BAN:JAN]; 3H-1,4-benzodiazepin-2-amine,7-chloro-N-methyl-5-phenyl-,4-oxide; ZINC19632917; D00267; A-Poxide; Spectrum5_001623; CID2712; SPBio_001113; Clopoxide; HMS503G11; Tropium; 3H-1,4-Benzodiazepin-2-amine, 7-chloro-N-methyl-5-phenyl-, 4-oxide; EINECS 200-371-0; Chlorodiazepoxide; SAM001246815; MENRIUM 10-4; 3H-1,4-Benzodiazepin-2-amine, 7-chloro-N-methyl-5-phenyl, 4-oxide; 7-Chlor-2-methylamino-5-phenyl-3H-1,4-benzodiazepin-4-oxid [German]; Chlordiazepoxidum [INN-Latin]; Libritabs (TN); Menrium	58-25-3	2712	148862	TTDS00374	Benzodiazepine receptor	N/A	N/A	N/A	N/A	agonist
DAP000242	Flurazepam	Ro-5-6901/3; NCGC00164573-01; Flurazepam hydrochloride; Felmane; C21H23ClFN3O; Insumin; Dalmadorm; Noctosom; Dalmane; 2H-1,4-Benzodiazepin-2-one, 7-chloro-1-[2-(diethylamino)ethyl]-5-(2-fluorophenyl)-1,3-dihydro-, dihydrochloride; BRN 0767925; 2H-1,4-Benzodiazepin-2-one, 7-chloro-1-[2-(diethylamino)ethyl]-5-(o-fluorophenyl)-1,3-dihydro-; 2H-1,4-Benzodiazepin-2-one, 7-chloro-1-[2-(diethylamino)ethyl]-5-(2-fluorophenyl)-1,3-dihydro-; DEA No. 2767; MolPort-004-285-859; Flurazepam HCL; 7-Chloro-1-(2-(diethylamino)ethyl)-5-(2-fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one; LS-34188; UNII-IHP475989U; Flurazepamum; Flurazepamum [INN-Latin]; Felison; CHEMBL968; 17617-23-1; HSDB 3085; 2H-1,4-Benzodiazepin-2-one, 7-chloro-1-(2-(diethylamino)ethyl)-5-(2-fluorophenyl)-1,3-dihydro-; Stauroderm; Flurazepam [INN:BAN:JAN]; 7-chloro-1-(2-diethylaminoethyl)-5-(2-fluorophenyl)-3H-1,4-benzodiazepin-2-one; Insumin (TN); D00329; Flurazepam (JP15/INN); 2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-7-chloro-1-(2-(diethylamino)ethyl)-5-(o-fluorophenyl)-; 5-24-04-00322 (Beilstein Handbook Reference); 7-Chloro-1-[2-(diethylamino)ethyl]-5-(2-fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one; 36105-20-1 (mono-hydrochloride); 1172-18-5 (di-hydrochloride); EINECS 241-591-7; Valdorm; Paxane; Dalmane-R; CID3393; AC1L1FU2; flurazepam; DB00690; 7-Chloro-1-(2-(diethylamino)ethyl)-5-(2-fluorophenyl)-1H-1,4-benzodiazepin-2(3H)-one; Flunox; Somnol	17617-23-1	3393	7847395	TTDS00374	Benzodiazepine receptor	N/A	N/A	N/A	N/A	agonist
DAP000237	Lorazepam	Emotion; Equitam; Lorafen; Lorazep; Lorazepam Fabra; Nervistopl; Loraz; Lorazon; L1764_SIGMA; Lorenin; Lorazepam Medical; Lorat; Lorazepam Baxter Brand; Lorzem; WLN: T67 GMV JN IHJ CG IQ KR BG; Wyeth Brand of Lorazepam; ApoLorazepam; Lorivan; Idalprem; D008140; Tavor; o-Chlorooxazepam; Lorapam; Lorazepam Apotex Brand; Laubeel; Tranqipam; Lorazepam ratiopharm Brand; Alzapam; Lorazepam Riemser Brand; Lorazepam Desitin Brand; Lorazin; Tolid; 2H-1,4-Benzodiazepin-2-one, 7-chloro-5-(o-chlorophenyl)-1,3-dihydro-3-hydroxy-; Demethyllormetazepam; o-Chloroxazepam; Larpose; LS-34141; NSC 289758; Orfidal Wyeth; KBio1_000965; Pro dorm; Lomesta; lorazepam; Rocosgen; Durazolam; Lorazepam-Efeka; Temesta; Lorazepam (JP15/USP/INN); Lorazepam neuraxpharm; Lorazepamum [INN-Latin]; 2H-1,4-Benzodiazepin-2-one, 7-chloro-5-(2-chlorophenyl)-1,3-dihydro-3-hydroxy-; Aplacassee; Lorazepam preservative free; Apo Lorazepam; Merlit; NSC289758; Bonton; Aripax; Quait; Sedizepan; Baxter Brand of Lorazepam; Lorazepam Intensol; SAM001246833; Lorazepam-neuraxpharm; IDI1_000965; Donix; Punktyl; neuraxpharm Brand of Lorazepam; 7-Chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-2H-1,4-benzodiazepin-2-one; Duralozam; Sedicepan; Nu-Loraz; Medical, Lorazepam; Novolorazem; BRN 0759084; 2H-1,4-Benzodiazepin-2-one, 7-chloro-5-(2-chlorophenyl)-1,3-dihydro-3-hydroxy-, (+-)-; Nu Pharm Brand of Lorazepam; Loridem; AC1L1H3H; Novhepar; EINECS 212-687-6; 7-Chloro-5-(o-chlorophenyl)-1,3-dihydro-3-hydroxy-2H-1,4-benzodiazepin-2-one; lorazep von ct; Lorans; Wy 4036; (+/-)-Lorazepam; DivK1c_000965; Nu-Pharm Brand of Lorazepam; Novartis Brand of Lorazepam; Silence; 5-25-02-00248 (Beilstein Handbook Reference); (+-)-7-Chloro-5-(o-chlorophenyl)-1,3-dihydro-3-hydroxy-2H-1,4-benzodiazepin-2-one; Lozepam; 7-Chloro-5-(2-chlorophenyl)-3-hydroxy-1H-1,4-benzodiazepin-2(3H)-one; Lorazepam Genericon; Anzepam; Kalmalin; Desitin Brand of Lorazepam; Lorazepam Novartis Brand; Novo Lorazem; NINDS_000965; Lorazepam Dolorgiet Brand; Wy-4036; HMS503A11; CPD000058410; Lorazepam neuraxpharm Brand; Medical Brand of Lorazepam; Lorazepamum; DEA No. 2885; ct Arzneimittel Brand of Lorazepam; Novopharm Brand of Lorazepam; DB00186; Nervistop L; ratiopharm Brand of Lorazepam; Norlormetazepam; Renaquil; Lopam; Wyeth, Orfidal; lorazepam (Ativan); Lorazepam Nu-Pharm Brand; nchembio747-comp26; Riemser Brand of Lorazepam; Llorens Brand of Lorazepam; Merck dura Brand of Lorazepam; Max Pax; Lorazepam Llorens Brand; Lorazepam Wyeth Brand; Lorazepam [USAN:INN:BAN:JAN]; UNII-O26FZP769L; 2H,1,4-Benzodiazepin-2-one, 7-chloro-5-(o-chlorophenyl)-1,3-dihydro-3-hydroxy-; Anxiedin; D00365; Sinestron; Lorsilan; Sedazin; Ativan (TN); Emotival; NCGC00159439-02; HMS2052H07; Aplacasse; Anxira; Apotex Brand of Lorazepam; Lorazepam AHP Brand; 7-Chloro-5-(2-chlorophenyl)-1,3-dihydro-3-hydroxy-2H-1,4-benzodiazepin-2-one; Upan; Lorazepam Novopharm Brand; Lorabenz; NuLoraz; Medix Brand of Lorazepam; ct-Arzneimittel Brand of Lorazepam; Loram; Bonatranquan; CID3958; Azurogen; Sedatival; 7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one; Trapax; Nu Loraz; Orfidal; Vigiten; Serra Pamies Brand of Lorazepam; Sidenar; Delormetazepam; Stapam; Lorazepam Medix Brand; AHP Brand of Lorazepam; Almazine; Lorazepam-ratiopharm; Apo-Lorazepam; Efasedan; Lorazene; Lorsedal; Lorazepam ct-Arzneimittel Brand; MolPort-002-051-769; Lorazepam Lannacher; Lorazepan Richet; Lorazepam ratiopharm; Securit; 846-49-1; Wypax; CHEBI:116959; Somagerol; Novo-Lorazem; Lorazepan Chobet; Lorax; Lorazepam Medical Brand; Ativan; CHEMBL580; WY4036; Dolorgiet Brand of Lorazepam	846-49-1	3958	156663	TTDS00374	Benzodiazepine receptor	N/A	N/A	N/A	N/A	agonist
DCL000924	PF-00547659	N/A	N/A	9865554	49684245	TTDC00248	Mucosal addressin cell adhesion molecule 1	hMAdCAM-1;MAdCAM-1	Q13477	8174	ENSG00000099866	antibody
DCL000216	RhuDex	N/A	N/A	N/A	N/A	TTDS00453	T-lymphocyte activation antigen CD80	Activation B7-1 antigen;B7;BB1;CD28LG;CD28LG1;CD80;CTLA-4 counter-receptor B7.1;LAB7	P33681	941	ENSG00000121594	inhibitor
DAP000867	Abatacept	N/A	332348-12-6	10237	46509198	TTDS00453	T-lymphocyte activation antigen CD80	Activation B7-1 antigen;B7;BB1;CD28LG;CD28LG1;CD80;CTLA-4 counter-receptor B7.1;LAB7	P33681	941	ENSG00000121594	binder
DCL001058	AP12009	N/A	N/A	N/A	N/A	TTDC00272	Transforming growth factor beta 2	BSC-1 cell growth inhibitor;Cetermin;Glioblastoma-derived T-cell suppressor factor;G-TSF;Polyergin;TGF-beta 2	P61812	7042	ENSG00000092969	antisense
DCL001199	ISIS-APOCIII	N/A	N/A	N/A	N/A	TTDC00328	mRNA of ApoC-III	mRNA of Apo-CIII;mRNA of ApoC-III;mRNA of Apolipoprotein C3	P02656	345	ENSG00000110245	antisense
DAP000184	Nevirapine	MLS000084585; C07263; CHEMBL57; MLS001055309; 11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[2,3-e:3',2'-b][1,4]diazepin-6-one & PRO 140 (Anti-CCR5 monoclonal antibody); HMS2051J09; NCGC00065890-02; CPD000048458; BIRG-0587; Nevirapine & PRO 140; 1vrt; 129618-40-2; SAM001246551; 11-Cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido(3,2-b:2',3'-e)(1,4)diazepin-6-one; HSDB 7164; BI RG 587; STK580320; BI-RG-587; DB08311; N11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e]-[1,4]diazepin-6-one & CD4-immunoadhesin; BIDD:GT0326; MLS000759409; UNII-99DK7FVK1H; NVP; NON-NUCLEOSIDE RT INHIBITOR NEVIRAPINE; NEV; Nevirapine (JAN/USP/INN); D00435; BI-RG-587 & CD4-IgG; NSC641530; S1742_Selleck; Cahill May Roberts Brand of Nevirapine; SMR000048458; BIRG-587; Promeco Brand of Nevirapine; BIRG587; DB00238; I02-0310; 2hny; nevirapine; Viramune (TN); Bio-0789; 11-CYCLOPROPYL-5,11-DIHYDRO-4-METHYL-6H-DIPYRIDO[3,2-B:2',3'-E][1,4]DIAZEPIN-6-ONE; CHEBI:44659; 11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[2,3-e:3',2'-b][1,4]diazepin-6-one; LS-2289; CID4463; Viramune, BI-RG 587, Nevirapine; AC-643; 11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one; Viramune; BIRG 0587; C15H14N4O; ZINC00004778; 6H-Dipyrido(3,2-b:2',3'-e)(1,4)diazepin-6-one, 11-cyclopropyl-5,11-dihydro-4-methyl-; 5H-Dipyrido(3,2-b:2',3'-e)(1,4)diazepin-6-one, 5,11-dihydro-11-cyclopropyl-4-methyl-; D019829; Nevirapine & CD4-IgG; BIRG 587; Nevirapine [USAN:INN]; Viramune(TM); AC1L1I81; MolPort-002-507-817; MLS001201730; NSC 641530	129618-40-2	4463	197039	TTDS00317	HIV-1 reverse transcriptase	HIV-1 RT;Human immunodeficiency virus type 1 reverse transcriptase	Q69617	N/A	N/A	inhibitor
DAP001084	Emtricitabine	DRG-0208; 524W91; UNII-G70B4ETF4S; (-)-2',3'-Dideoxy-5-fluoro-3'-thiacytidine; 2'-Deoxy-5-fluoro-3'-thiacytidine; 2-FTC; HMS2089I05; (-)-cis-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one; (2R-cis)-4-Amino-5-fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1H)-pyrimidinone; 4-amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one; FTC, (-)-; 2',3'-Dideoxy-5-fluoro-3'-thiacytidine; Coviracil(TM); BW 524W91; 145213-48-5; LS-173184; beta-L-2',3'-dideoxy-5-fluoro-3'-thiacytidine; 2',3',5-FTC; DB00879; 2(1H)-Pyrimidinone, 4-amino-5-fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-, cis-; Emtricitabine; HSDB 7337; TL8000958; 1-(2-(Hydroxymethyl)oxathiolan-5-yl)-5-fluorocytosine; 2(1H)-Pyrimidinone, 4-amino-5-fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-, (2R-cis)-; AC1L1U3I; .beta.-L-(-)-(2R,5S)-5-Fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine; 4-Amino-5-fluoro-1-[(2R,5S)-(hydroxymethyl)-1,3-oxathiolan-5-yl]-2(1H)-pyrimidinone; (-)-.beta.-L-FTC; ZINC03629271; (-)-(2R,5S)-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine; BW524W91; Emtriva (TN); AC1Q4KUB; D01199; NCGC00164564-01; 143491-54-7; Emtriva; 2(1H)-Pyrimidinone, 4-amino-5-fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-, cis-(+-)-; 143491-57-0; 5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)[1,3]oxathiolan-5-yl]cytosine; CHEBI:31536; SBB066061; Coviracil; Emtriva(TM); C12599; (-)-FTC; C122114; FT-0080009; 4-amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2(1H)-one; BW 1592; RCV; C8H10FN3O3S; LS-135838; CHEMBL885; (-)-2'-Deoxy-5-fluoro-3'-thiacytidine; CID60877; Emtricitabine (JAN/USAN/INN); dOTFC; 3'-Thia-2'.3'-dideoxy-5-fluorocytidine; 2'-Deoxy-5-fluoro-3'-oxa-4'-thiocytidine; 5-Fluoro-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine; (-)-beta-2',3'-dideoxy-5-fluoro-3'-thiacytidine; BW-524W91; 2(1H)-Pyrimidinone, 4-amino-5-fluoro-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-, rel-; Racivir; 5-Fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine	143491-57-0	60877	207107	TTDS00317	HIV-1 reverse transcriptase	HIV-1 RT;Human immunodeficiency virus type 1 reverse transcriptase	Q69617	N/A	N/A	inhibitor
DCL000540	IDX899	N/A	N/A	N/A	N/A	TTDS00317	HIV-1 reverse transcriptase	HIV-1 RT;Human immunodeficiency virus type 1 reverse transcriptase	Q69617	N/A	N/A	inhibitor
DAP001430	Tenofovir disoproxil	Bis(isopropyloxymethylcarbonyl) 9-(2-phosphonomethoxypropyl)adenine; LS-187786; PMPA prodrug; ST51052782; GS 4331-05 (*1:1 Fumarate salt*); Tenofovir disoproxil; CID5481350; TDF; 9-((R)-2-((Bis(((isopropoxycarbonyl)oxy)methoxy)phosphinyl)methoxy)propyl)adenine; LS-187012; 201341-05-1; Bis(POC)PMPA; AC1NUKHG; Viread(TM) (*1:1 Fumarate salt*); [[(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethyl-(propan-2-yloxycarbonyloxymethoxy)phosphoryl]oxymethyl propan-2-yl carbonate; Bis(isopropyloxymethylcarbonyl)PMPA; CHEMBL1538; 9-[(R)-2-[[Bis[[(isopropoxycarbonyl)oxy] methoxy]phosphinyl]methoxy]propyl]adenine	201341-05-1	5481350	696535	TTDS00317	HIV-1 reverse transcriptase	HIV-1 RT;Human immunodeficiency virus type 1 reverse transcriptase	Q69617	N/A	N/A	inhibitor
DAP000183	Delavirdine	N-[2-[4-[3-(propan-2-ylamino)pyridin-2-yl]piperazine-1-carbonyl]-1H-indol-5-yl]methanesulfonamide; UNII-DOL5F9JD3E; N-[2-({4-[3-(propan-2-ylamino)pyridin-2-yl]piperazin-1-yl}carbonyl)-1H-indol-5-yl]methanesulfonamide; Delavirdine (*Mesylate salt*); 147221-93-0; Delavirdine (INN); DELAVIRDINE MESYLATE; CID5625; N-(2-(1-(3-(isopropylamino)pyridin-2-yl)piperazine-4-carbonyl)-1H-indol-5-yl)methanesulfonamide; DLV; LS-172972; CHEBI:119573; DB08563; MolPort-003-846-188; Piperazine, 1-[3-[(1-methylethyl)amino]-2-pyridinyl]-4-[[5-[(methylsulfonyl)amino]-1H-indol-2-yl]carbonyl]-; 1-(5-Methanesulphonamido)-1H-indol-2-yl-carbonyl)-4-[3-(isopropylamino)-2-pyridinyl]piperaz; HMS2089F20; N-{2-[(4-{3-[(1-methylethyl)amino]pyridin-2-yl}piperazin-1-yl)carbonyl]-1H-indol-5-yl}methanesulfonamide; Piperazine, 1-[3-[(1-methylethyl)amino]-2-pyridinyl]-4-[[5-[(methylsulfonyl)amino]-1H-indol-2-yl]carbonyl]- & alpha-Interferon; Delavirdine [INN]; U90152S (*Mesylate salt*); Delavirdine; CHEMBL593; 147221-93-0 (mesylate); 1-(3-((1-Methylethyl)amino)-2-pyridinyl)-4-((5-((methylsulfonyl)amino)-1H-indol-2-yl)carbonyl)piperazine; D07782; u-90152; N-{2-[4-(3-Isopropylamino-pyridin-2-yl)-piperazine-1-carbonyl]-1H-indol-5-yl}-methanesulfonamide; U 90152; SPP; 2-(4-(5-Methanesulfonamido-1H-indol-2-ylcarbonyl)-1-piperazinyl)-N-(1-methylethyl)-3-pyridinamine; PNU-90152-T; (N-[2-[4-[3-(1-methylethylamino)pyridin-2-yl]piperazin-1-yl]carbonyl-1H-indol-5-yl] methanesulfonamide); (1-(5-METHANSULPHONAMIDO-1H-INDOL-2-YL-CARBONYL)4-[METHYLAMINO)PYRIDINYL]PIPERAZINE; C06941; 136817-59-9; Delavirdine(U-90152) & .a.IFN; Rescriptor (TM); DB00705; Rescriptor; AC1L1KRN; NCGC00168776-01; C22H28N6O3S; U-90152S; ZINC18516586; BHAP-U 90152	136817-59-9	5625	206947	TTDS00317	HIV-1 reverse transcriptase	HIV-1 RT;Human immunodeficiency virus type 1 reverse transcriptase	Q69617	N/A	N/A	inhibitor
DAP001476	Etravirine	D04112; 4-({6-AMINO-5-BROMO-2-[(4-CYANOPHENYL)AMINO]PYRIMIDIN-4-YL}OXY)-3,5-DIMETHYLBENZONITRILE; TMC 125; Etravirine (JAN/USAN/INN); UNII-0C50HW4FO1; 4-[6-amino-5-bromo-2-(4-cyanoanilino)pyrimidin-4-yl]oxy-3,5-dimethylbenzonitrile; R 165335; R165335-TMC125; DB07191; R165335; Intelence(TM); TMC-125/R-165335; Benzonitrile, 4-[[6-amino-5-bromo-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl-; I06-1887; ST51053273; R-165335; 269055-15-4; CID193962; CHEMBL308954; 394729-17-0; 65B; Benzonitrile, 4-((6-amino-5-bromo-2-((4-cyanophenyl)amino)-4-pyrimidinyl)oxy)-3,5-dimethyl-; TMC125; DAPY deriv; CHEBI:213138; ZINC00602632; Intelence (TN); AC1L4XC5; Etravirine; TMC-125; Diaminopyrimidine deriv; 4-((6-amino-5-bromo-2-((4-cyanophenyl)amino)-4-pyrimidinyl)oxy)-3,5-dimethyl-benzonitrile; Intelence	269055-15-4	193962	47206062	TTDS00317	HIV-1 reverse transcriptase	HIV-1 RT;Human immunodeficiency virus type 1 reverse transcriptase	Q69617	N/A	N/A	inhibitor
DCL000765	Dapivirine	TMC120-R147681; 4-[4-(2,4,6-TRIMETHYL-PHENYLAMINO)-PYRIMIDIN-2-YLAMINO]-BENZONITRILE; CHEMBL70663; TMC-120; TMC120; Dapivirine; 4-((4-((2,4,6-Trimethylphenyl)amino)pyrimidin-2-yl)amino)benzonitrile; CID214347; CHEBI:46180; SBB062853; ZINC00007761; UNII-TCN4MG2VXS; 4-[[4-(2,4,6-trimethylanilino)pyrimidin-2-yl]amino]benzonitrile; TMC-120/R-147681; R-147681; AC1Q4RF3; R147681; AC1L4WO4; MolPort-000-003-506; 4-({4-[(2,4,6-Trimethylphenyl)amino]pyrimidin-2-yl}amino)benzenecarbonitrile; DB08639; R 147681; AR-1I3460; dapivirinum; TMC 120; GEL-002	244767-67-7	208898	787916	TTDS00317	HIV-1 reverse transcriptase	HIV-1 RT;Human immunodeficiency virus type 1 reverse transcriptase	Q69617	N/A	N/A	inhibitor
DAP000709	Efavirenz	DB00625; 2H-3,1-Benzoxazin-2-one, 6-chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-, (4S)- (9; HSDB 7163; CPD000466351; (S)-6-Chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one; MLS001424087; 2H-3,1-Benzoxazin-2-one, 6-chloro-4-(2-cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-, (4S)-; (S)-6-Chloro-4-(2-cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-ben; DB07709; L-743725; D00896; Efavirenz (JAN/INN); CID64139; SBB066062; DMP-266; Met-Stromal Cell-derived Factor-1.beta. (Human) & Efavirenz; Eravirenz; CHEMBL223228; SMR000466351; MolPort-003-983-924; efavirenz; zoxazin-2-one; 2H-3,1-Benzoxazin-2-one, 6-chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-, (4S)-; Stocrin; MLS000759465; L-743,726; L-741211; (-)-Efavirenz; HMS2090N16; L-743726; Sustiva (TN); (4S)-6-chloro-4-(2-cyclopropylethynyl)-4-(trifluoromethyl)-1H-3,1-benzoxazin-2-one; L 743726; Sustiva (TM); DMP 266; 1ikv; (4S)-6-Chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one; AC1L20IX; Sustiva; BIDD:GT0383; EFV; efavirenz, (S)-isomer; Strocin (TM); EFZ; 154598-52-4; HMS2051J08; Met-SDF-1.beta. & Efavirenz; UNII-JE6H2O27P8; AC-19049; SAM001246667; LS-173464; NSC742403; 1ikw; CHEBI:119486; ZINC02020233; 6-chloro-4-(2-cyclopropyl-1-ethynyl)-4-trifluoromethyl-(4S)-1,4-dihydro-2H-benzo[d][1,3]oxazin-2-one; 2H-3,1-Benzoxazin-2-one, 6-chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-, (S)-; C08088; (S)-6-Chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one; C14H9ClF3NO2; 2H-3,1-Benzoxazin-2-one, 6-chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-, (4S)-; (4S)-6-Chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one; (4S)-6-chloro-4-(cyclopropylethynyl)-4-(trifluoromethyl)-1,4-dihydro-2H-3,1-benzoxazin-2-one	154598-52-4	64139	206181	TTDS00317	HIV-1 reverse transcriptase	HIV-1 RT;Human immunodeficiency virus type 1 reverse transcriptase	Q69617	N/A	N/A	inhibitor
DPR000060	IDDB-41331	N/A	N/A	N/A	N/A	TTDR00131	Melanin-concentrating hormone receptor	MCH receptor	N/A	N/A	N/A	antagonist
DAP001336	Hydroxocobalamin	CHEMBL1200742; Neo-cytamen; Cobinamide dihydroxide dihydrogen phosphate (ester), mono(inner salt), 3'-ester with 5,6-dimethyl-1-alpha-D-ribofuranosylbenzimidazole; CID11953898; Codroxomin; Vitamin B12b; Hydroxy vitamin B12; Coalpha-[alpha-(5,6-dimethylbenzimidazolyl)]-Cobeta-hydroxocobamide; Ducobee-Hy; EINECS 236-533-2; Axion; OH-Duphar; Hydroxocobalamin acetate; Cobinamide hydroxide phosphate 3'-ester with 5,6-dimethyl-1-alpha-D-ribofuranosylbenzimidazole inner salt; Benzimidazolyl ribofuranosyl phosphate deriv.; D01027; Hydroxycobalamine; Hydroxocobalamine; Primabalt RP; Neo-macrabin; S1668_Selleck; Vitamin B12a; Hidroxocobalamina [INN-Spanish]; Hydroxocobalamin [USAN:INN:BAN:JAN]; AlphaRedisol; Vitamin B(sub 12a); Docevita; HSDB 3342; 78091-12-0; Cyanokit (TN); UNII-Q40X8H422O; Hidroxocobalamina; AlphaRedisol (TN); Vitadurin; Oxolamine (arcum); Hydroxy Cobal; Docelvita; Hydroxocobalaminacetat; Cobalex; Duradoce; Hydroxocobalamin(alkaline soln.), OH- replaces CN- in Cyanocobalamin); vitamin B-12b; Neo-rojamin; Depogamma; Hyxobamine; 22465-48-1; Cobinamide, dihydroxide, dihydrogen phosphate (ester), mono(inner salt), 3'-ester with 5,6-dimethyl-1-alpha-D-ribofuranosyl-1H-benzimidazole; Hydroxomin; CID6474319; Hydrocobalamin; Sytobex-H; alpha Cobione; CID11622291; CHEMBL235822; C62H85CoN13O15P; Hydroxocobalamin monohydrochloride; Docelan; Acti-B12; Hydroxocobalaminum [INN-Latin]; Hydroxocobemine; Cobinamide, dihydroxide, dihydrogen phosphate (ester), mono (inner salt), 3'- ester with 5,6-dimethyl-1-alpha-D-ribofuranosylbenzimidazole; Redisol-H; Lyovit-H; Cobinamide, Co-hydroxy-, dihydrogen phosphate (ester), inner salt, 3'-ester with (5,6-dimethyl-1-alpha-D-ribofuranosyl-1H-benzimidazole-kappaN3); alpha-(5,6-Dimethylbenzimidazolyl)hydroxocobamide; Hydroxocobalamin (JAN/USP/INN); Vibeden; 8017-22-9; OH-Cbl; Cobinamide, hydroxide, dihydrogen phosphate (ester), inner salt, 3'-ester with 5,6-dimethyl-1-alpha-D-ribofuranosyl-1H-benzimidazole; Cobinamide, Co-hydroxy-, f-(dihydrogen phosphate), inner salt, 3'-ester with (5,6-dimethyl-1-alpha-D-ribofuranosyl-1H-benzimidazole-kappaN3); Idrossocobalamina [DCIT]; Cyanokit; Ohb12; Hydro Cobex; Cobalamin, hydroxo-; Ciplamin H; Axlon; Hydroxycobalamin; Idrogrisevit; DB00200; CID5460373; Oxobemin; Hydroxycob(lll)alamin; Neo-Betalin 12; Hydrovit; Docclan; Idrossocobalamina; Hydrobamine; Duralta-12; CHEBI:27786; 13422-51-0; Hydrogrisevit; Hydroxocobalamin Vitamin B12; Hydroxocobalaminum; CID6433575; LS-54607; Hydroxocobalamine [INN-French]; C08230; HYDROXOCOBALAMIN	13422-51-0	11953898	10429	TTDS00482	Methylmalonyl-CoA mutase	MCM;Methylmalonyl-CoA isomerase;MUT	P22033	4594	ENSG00000146085	cofactor
DCL000060	AVT-02 UE	N/A	N/A	N/A	N/A	TTDC00113	STAT-1 transcription factor	P91;Signal transducers and activators of transcription factor;STAT-1	P42224	6772	ENSG00000115415	inhibitor
DCL001053	Mipomersen	N/A	1000120-98-8	N/A	N/A	TTDC00236	mRNA of ApoB-100	N/A	N/A	N/A	N/A	antisense
DCL000851	ISIS 301012	N/A	287714-14-4	10607	49698638	TTDC00236	mRNA of ApoB-100	N/A	N/A	N/A	N/A	antisense
DCL001170	Cenderitide	N/A	N/A	N/A	N/A	TTDS00478	Atrial natriuretic peptide receptor A	ANP-A;ANPRA;Atrial natriuretic peptide A-type receptor;GC-A;Guanylate cyclase;NPR1;NPR-A	P16066	4881	ENSG00000169418	agonist
DAP001320	Nesiritide	N/A	124584-08-3	9881506	47206871	TTDS00478	Atrial natriuretic peptide receptor A	ANP-A;ANPRA;Atrial natriuretic peptide A-type receptor;GC-A;Guanylate cyclase;NPR1;NPR-A	P16066	4881	ENSG00000169418	binder
DCL000440	Ataciguat	UNII-QP166M390Q; 5-Chloro-2-((5-chloro-2-thienyl)sulfonylamino)-N-(4-(morpholin-4-ylsulfonyl)phenyl)benzamide; AR-1G7683; HMR-1766; Ataciguat [INN]; MolPort-006-392-391; 5-Chloro-2-(5-chlorothiophene-2-sulfonylamino)-N-(4-(morpholine-4-sulfonyl)phenyl)benzamide; HMR 1766; AC1Q6UV8; 5-chloro-2-[(5-chlorothiophen-2-yl)sulfonylamino]-N-(4-morpholin-4-ylsulfonylphenyl)benzamide; AC1L4U4P; CID213037; Ataciguat	N/A	213037	49684236	TTDS00478	Atrial natriuretic peptide receptor A	ANP-A;ANPRA;Atrial natriuretic peptide A-type receptor;GC-A;Guanylate cyclase;NPR1;NPR-A	P16066	4881	ENSG00000169418	activator
DCL000982	Seletracetam	UCB-44212; 357336-74-4; UCB 44212; Seletracetam; UNII-RFR2CH3QZK; 1-Pyrrolidineacetamide, 4-(2,2-difluoroethenyl)-alpha-ethyl-2-oxo-, (alphaS,4S)-; 2-[4-(2,2-difluoroethenyl)-2-oxo-pyrrolidin-1-yl]butanamide; CID9942725	357336-74-4	16058810	47207478	TTDC00246	Synaptic vesicle glycoprotein 2A	N/A	Q7L0J3	9900	ENSG00000159164	binder
DCL000730	Brivaracetam	Rikelta; 357336-20-0; D08879; Brivaracetam; CHEMBL607400; UCB-34714; Brivaracetam (USAN/INN); CID9837243	357336-20-0	9837243	22395457	TTDC00246	Synaptic vesicle glycoprotein 2A	N/A	Q7L0J3	9900	ENSG00000159164	inhibitor
DCL000760	CX-516	1-(6-Quinoxalinylcarbonyl)piperidine; ST51054897; Ampalex; LS-113469; C13675; AC1L3WLW; CX516; 1-(6-quinoxalinylcarbonyl)-Piperidine; C097396; CHEMBL136800; Piperidine, 1-(6-quinoxalinylcarbonyl)-; 1-(quinoxalin-6-ylcarbonyl)piperidine; CX-516; I14-13059; I14-3265; 173047-75-1; ZINC00006489; VU0430675-1; MolPort-005-942-523; SPD-420; Jsp003008; EN003057; CID148184; BDP 12; 154235-83-3; CHEBI:326603; piperidin-1-yl(quinoxalin-6-yl)methanone; 6-(piperidin-1-ylcarbonyl)quinoxaline; BDP-12; AC-001; CX 516	154235-83-3	9049	586267	TTDS00121	Glutamate receptor AMPA subtype	AMPA receptor;AMPA selective glutamate receptor;GluR;Glutamate receptor;Glutamate receptor ionotropic, AMPA	N/A	N/A	N/A	modulator
DPR000057	GYKI-47261	GYKI 47261; EC-000.2407	220445-20-5	N/A	N/A	TTDS00121	Glutamate receptor AMPA subtype	AMPA receptor;AMPA selective glutamate receptor;GluR;Glutamate receptor;Glutamate receptor ionotropic, AMPA	N/A	N/A	N/A	antagonist
DAP000799	Enflurane	AC1L1FGH; Enflurane (JP15/USP/INN); NCGC00167422-01; CID3226; DB00228; Enflurano [INN-Spanish]; C07516; BRN 1903921; Efrane; NSC-115944; NSC115944; D004737; Enflurano; (+-)-2-Chloro-1,1,2-trifluoroethyl difluoromethyl ether; Anesthetic Compound No. 347; EINECS 237-553-4; Compound 347; CHEMBL1257; Enflurane [USAN:BAN:INN:JAN]; Baxter Anaesthesia Brand of Enflurane; Ethane, 2-chloro-1-(difluoromethoxy)-1,1,2-trifluoro-; UNII-91I69L5AY5; AstraZeneca Brand of Enflurane; Zeneca Brand of Enflurane; Abbott Brand of Enflurane; 13838-16-9; CHEBI:4792; Ethrane; Enflurane [Anaesthetics, volatile]; Ethane, 2-chloro-1-(difluoromethoxy)-1,1,2-trifluoro-, (+-)-; ST51041446; Enfluranum; 2-Chloro-1-(difluoromethoxy)-1,1,2-trifluoroethane; Pisa Brand of Enflurane; C 347; Enlirane; enflurane; WLN: GYFXFFOYFF; Enfluranum [INN-Latin]; Ether, 2-chloro-1,1,2-trifluoroethyl difluoromethyl; Enfran; Alyrane; MolPort-001-773-112; LS-7376; Methylflurether; OHIO 347; D00543; Anesthetic 347; Ethrane (TN); 2-Chloro-1,1,2-trifluoroethyl difluoromethyl ether; Etran	13838-16-9	3226	169039	TTDS00121	Glutamate receptor AMPA subtype	AMPA receptor;AMPA selective glutamate receptor;GluR;Glutamate receptor;Glutamate receptor ionotropic, AMPA	N/A	N/A	N/A	N/A
DCL000723	Bicifadine	N/A	71195-57-8	449171	12015676	TTDS00121	Glutamate receptor AMPA subtype	AMPA receptor;AMPA selective glutamate receptor;GluR;Glutamate receptor;Glutamate receptor ionotropic, AMPA	N/A	N/A	N/A	antagonist
DCL000715	Becampanel	AMP-397A; AMP-397; UNII-X3D0O800AJ; AMP397; 188696-80-2; CID5491960; Becampanel; CHEBI:235507; [(7-nitro-2,3-dioxo-1,4-dihydroquinoxalin-5-yl)methylamino]methylphosphonic acid; AC1NUSQV; CHEMBL84775	188696-80-2	5491960	12015413	TTDS00121	Glutamate receptor AMPA subtype	AMPA receptor;AMPA selective glutamate receptor;GluR;Glutamate receptor;Glutamate receptor ionotropic, AMPA	N/A	N/A	N/A	antagonist
DAP000693	Desflurane	Suprane; CHEMBL1200733; UNII-CRS35BZ94Q; DB01189; AC1L274J; LS-65505; PC6781E; Desflurane (JAN/USP/INN); Desflurano; Desflurane [USAN:INN]; DESFLURANE; (+-)-2-Difluoromethyl 1,2,2,2-tetrafluoroethyl ether; C3H2F6O; Ethane, 2-(difluoromethoxy)-1,1,1,2-tetrafluoro-, (+-)-; CID42113; D00546; MolPort-001-776-387; 2-(difluoromethoxy)-1,1,1,2-tetrafluoroethane; r-e 236ea1; difluoromethyl 1,2,2,2-tetrafluoroethyl ether; Suprane (TN); Ethane, 2-(difluoromethoxy)-1,1,1,2-tetrafluoro-; I-653; Desfluranum [INN-Latin]; Desfluranum; CHEBI:4445; AC1Q4ICY; 1,1,1,2-tetrafluoro-2-(difluoromethoxy)ethane; I653; C07519; 57041-67-5; I 653; Desflurano [INN-Spanish]	57041-67-5	42113	9722	TTDS00121	Glutamate receptor AMPA subtype	AMPA receptor;AMPA selective glutamate receptor;GluR;Glutamate receptor;Glutamate receptor ionotropic, AMPA	N/A	N/A	N/A	antagonist
DAP000692	Halothane	Rhodialothan; NCGC00090868-01; NSC143490; Ftuorotan; Halsan; Narkotan; BRN 1736947; Halothane (JP15/USP/INN); UNII-UQT9G45D1P; Bromochlorotrifluoroethane; BCQZXOMGPXTTIC-UHFFFAOYSA-; Ftorotan; InChI=1/C2HBrClF3/c3-1(4)2(5,6)7/h1H; Halotan; 2-BROMO-2-CHLORO-1,1,1-TRIFLUOROETHANE; NSC 143490; Ethane, 1-bromo-1-chloro-2,2,2-trifluoro-; Narcotan; AC1L1G7T; C2HBrClF3; Narcotann ne-spofa; HSDB 6753; 2,2,2-Trifluoro-1-chloro-1-bromoethane; Narcotane; HMS2094K17; Alotano; Freon 123B1; Halothane [INN:BAN:JAN]; Halothane [Anaesthetics, volatile]; CHEMBL931; Ethane, 2-bromo-2-chloro-1,1,1-trifluoro-, (+-)-; WLN: GYEXFFF; 1,1,1-Trifluoro-2-bromo-2-chloroethane; D006221; Bromchlortrifluoraethanum; Halan; Halotano [INN-Spanish]; Fluothane (TN); Alotano [DCIT]; 2-Brom-2-chlor-1,1,1-trifluorethan; Halothanum; LS-881; halothane; CHEBI:5615; Fluktan; Ftorotan [Russian]; Narcotann NE-spofa [Russian]; Phthorothanum; (+-)-2-Bromo-2-chloro-1,1,1-trifluoroethane; CCRIS 6244; D00542; Anestan; MolPort-001-772-004; Fluorotane; Halotano; C07515; 1-Bromo-1-chloro-2,2,2-trifluoroethane; CF3CHClBr; DB01159; 16730_FLUKA; Fluothane; B4388_SIGMA; Halothanum [INN-Latin]; EINECS 205-796-5; 151-67-7; Chalothane; 1,1,1-Trifluoro-2-chloro-2-bromoethane; CID3562; Halothan; Ethane, 2-bromo-2-chloro-1,1,1-trifluoro-	151-67-7	3562	7847608	TTDS00121	Glutamate receptor AMPA subtype	AMPA receptor;AMPA selective glutamate receptor;GluR;Glutamate receptor;Glutamate receptor ionotropic, AMPA	N/A	N/A	N/A	antagonist
DCL001120	S-18986	N/A	N/A	N/A	N/A	TTDS00121	Glutamate receptor AMPA subtype	AMPA receptor;AMPA selective glutamate receptor;GluR;Glutamate receptor;Glutamate receptor ionotropic, AMPA	N/A	N/A	N/A	modulator
DCL001013	Talampanel	Talampanel; C13670; AC1L4UWP; (8R)-7-acetyl-5-(4-aminophenyl)-8,9-dihydro-8-methyl-7H-1,3-dioxolo[4,5-h][2,3]benzodiazepine; (R)-(-)-1-(4-Aminophenyl)-3-acetyl-4-methyl-7,8-methylenedioxy-3,4-dihydro-5H-2,3-benzodiazepine; KST-1A2491; LS-62670; AR-1A7825; NSC729898; CHEMBL61872; IDR-53773; CID164509; GYKI 53773; D02696; (R)-7-Acetyl-5-(p-aminophenyl)-8,9-dihydro-8-methyl-7H-1,3-dioxolo(4,5-h)(2,3)benzodiazepine; Kinampa; AC1Q5KPR; (R)-7-acetyl-5-(p-aminophenyl)-8,9-dihydro-8-methyl-7H-1,3-dioxolo[4,5-h][2,3]benzodiazepine; GYKI-53773; 7H-1,3-Dioxolo(4,5-h)(2,3)benzodiazepine, 7-acetyl-5-(4-aminophenyl)-8,9-dihydro-8-methyl-, (8R)-; Ampanel; Talampanel (INN); LY-300164; 7H-1,3-Dioxolo(4,5-h)(2,3)benzodiazepine, 7-acetyl-5-(4-aminophenyl)-8,9-dihydro-8-methyl-, (R)-; LY 300164; 161832-65-1; 7H-1,3-Dioxolo(4,5-h)(2,3)benzodiazepine, 8,9-dihydro-7-acetyl-5-(4-aminophenyl)-8-methyl-, (R)-	161832-65-1	164509	48428354	TTDS00121	Glutamate receptor AMPA subtype	AMPA receptor;AMPA selective glutamate receptor;GluR;Glutamate receptor;Glutamate receptor ionotropic, AMPA	N/A	N/A	N/A	antagonist
DCL000899	NS 1209	CHEMBL387049; CID6918411; NS-1209; 2-[[5-[4-(dimethylsulfamoyl)phenyl]-8-methyl-2-oxo-7,9-dihydro-6H-pyrrolo[3,2-h]isoquinolin-3-yl]amino]oxy-4-hydroxybutanoic acid; MolPort-005-943-190; CHEBI:460191; SPD-502; AC1OCFEG	205645-02-9	129869	3820489	TTDS00121	Glutamate receptor AMPA subtype	AMPA receptor;AMPA selective glutamate receptor;GluR;Glutamate receptor;Glutamate receptor ionotropic, AMPA	N/A	N/A	N/A	antagonist
DCL001025	TRO-19622	N/A	22033-87-0	6918486	43529856	TTDS00121	Glutamate receptor AMPA subtype	AMPA receptor;AMPA selective glutamate receptor;GluR;Glutamate receptor;Glutamate receptor ionotropic, AMPA	N/A	N/A	N/A	antagonist
DAP000694	Sevoflurane	ETHER, FLUOROMETHYL 2,2,2-TRIFLUORO-1-(TRIFLUOROMETHYL)ETHYL-; Sevofluranum [INN-Latin]; MolPort-001-775-746; NCGC00167421-01; UNII-38LVP0K73A; Ultane; fluoromethyl-2,2,2-trifluoro-1-(trifluoromethyl)ethyl ether; fluoromethyl hexafluoroisopropyl ether; Sojourn; BRN 2041023; DB01236; MR6S4; Sevoflurano [INN-Spanish]; F0691; Sevoflurane (JAN/USAN/INN); Fluoromethyl 1,1,1,3,3,3-Hexafluoroisopropyl Ether; Sevofluran; C4H3F7O; D00547; Sevofluranum; Fluoromethyl 2,2,2-trifluoro-1-(trifluoromethyl)ethyl ether; AC-15484; MR_6S4; ZINC01530810; Sevofrane; Ultane (TN); 1,1,1,3,3,3-Hexafluoro-2-(fluoromethoxy)propane; PC4681; Sevoflurane [USAN:INN:BAN:JAN]; Bax 3084; CHEBI:9130; Sevoflurano; sevoflurane; CID5206; CHEMBL1200694; 28523-86-6; Propane, 1,1,1,3,3,3-hexafluoro-2-(fluoromethoxy)-; C009250; LS-67851; Sevorane; AC1L1JU0; C07520; I14-13357	28523-86-6	5206	9723	TTDS00121	Glutamate receptor AMPA subtype	AMPA receptor;AMPA selective glutamate receptor;GluR;Glutamate receptor;Glutamate receptor ionotropic, AMPA	N/A	N/A	N/A	antagonist
DCL000761	CX717	N/A	N/A	N/A	N/A	TTDS00121	Glutamate receptor AMPA subtype	AMPA receptor;AMPA selective glutamate receptor;GluR;Glutamate receptor;Glutamate receptor ionotropic, AMPA	N/A	N/A	N/A	agonist
DCL000390	GSK729327	N/A	57599-91-4	151780	729327	TTDS00121	Glutamate receptor AMPA subtype	AMPA receptor;AMPA selective glutamate receptor;GluR;Glutamate receptor;Glutamate receptor ionotropic, AMPA	N/A	N/A	N/A	modulator
DAP000684	Thiamylal	C07846; DivK1c_000990; 5-Allyl-5-(1-methylbutyl)-2-thioxodihydro-4,6(1H,5H)-pyrimidinedione; Dihydro-5-(1-methylbutyl)-5-(2-propenyl)-2-thioxo-4,6-(1H,5H)-pyrimidinedione; CHEMBL440; Barbituric acid, 5-allyl-5-(1-methylbutyl)-2-thio- (VAN) (8CI); Spectrum2_000384; 5-allyl-5-(1-methylbutyl)-2-thioxodihydropyrimidine-4,6(1H,5H)-dione; NSC 120815; 1340-07-4; AC1MHTV0; SPBio_000567; 77-27-0; IDI1_000990; CID3032285; 5-(pentan-2-yl)-5-(prop-2-en-1-yl)-2-sulfanylidenedihydropyrimidine-4,6(1H,5H)-dione; NSC120815; 5-Allyl-5-(1-methylbutyl)-2-thiobarbitursaeure; EINECS 201-018-3; KBio1_000990; Barbituric acid, 5-allyl-5-(1-methylbutyl)-2-thio- (VAN); KBio2_002305; KBio2_004873; MolPort-002-070-546; 4,6(1H,5H)-Pyrimidinedione, dihydro-5-(1-methylbutyl)-5-(2-propenyl)-2-thioxo-; Spectrum5_001901; Thiamylal [USAN]; 5-pentan-2-yl-5-prop-2-enyl-2-sulfanylidene-1,3-diazinane-4,6-dione; Thioquinalbarbitone; CHEBI:9536; KBio2_007441; Spectrum4_000577; 5-Allyl-5-(1-methylbutyl)-2-thiobarbituric acid; T9799_SIGMA; Thioseconal; Spectrum3_001782; D06106; NINDS_000990; Barbituric acid, 5-allyl-5-(1-methylbutyl)-2-thio-; KBioGR_001014; Surital; Spectrum_001812; BSPBio_003303; LS-177327; 7187-63-5; UNII-01T23W89FR; thiamylal; T9799_FLUKA; 4,6(1H,5H)-Pyrimidinedione, dihydro-5-(1-methylbutyl)-5-(2-propenyl)-2-thioxo- (9CI); KBio3_002805; dihydro-5-(1-methylbutyl)-5-(2-propenyl)-2-thioxo-4,6(1H,5H)-pyrimidinedione; KBioSS_002307; BRD-A23970436-236-02-6; DB01154; AC1Q2UJP; C12H18N2O2S	77-27-0	3032285	10048	TTDS00403	Gamma-aminobutyric acid receptor subunit alpha-1	GABA(A) receptor subunit alpha-1;GABRA1	P14867	2554	ENSG00000022355	antagonist
DAP000690	Quazepam	36735-22-5; LS-34123; Dormalin; Quazepam [USAN:BAN:INN]; AC1L1JE0; Quazepam (JAN/USP); quazepam; 5-24-04-00356 (Beilstein Handbook Reference); 7-chloro-5-(2-fluorophenyl)-1-(2,2,2-trifluoroethyl)-3H-1,4-benzodiazepine-2-thione; Selepam; Oniria; DB01589; Sch 16134; Quazapam; Quazepamum; BRN 0901084; CHEMBL1200472; NSC309702; ZINC00538266; Sch-16134; 2H-1,4-Benzodiazepine-2-thione, 7-chloro-5-(2-fluorophenyl)-1,3-dihydro-1-(2,2,2-trifluoroethyl)-; UNII-JF8V0828ZI; Quazium; NSC 309702; Cetrane; Quazepam (JAN/USP/INN); EINECS 253-179-4; Quazepamum [INN-Latin]; Doral (TN); CID4999; MolPort-004-286-004; C07336; 7-Chloro-5-(2-fluorophenyl)-1,3-dihydro-1-(2,2,2-trifluoroethyl)-2H-1,4-benzodiazepine-2-thione; C17H11ClF4N2S; D00457; 7-Chloro-5-(o-fluorophenyl)-1,3-dihydro-1-(2,2,2-trifluoroethyl)-2H-1,4-benzodiazepine-2-thione; Prosedar; Doral; DEA No. 2881; Sch-161	36735-22-5	4999	12012678	TTDS00403	Gamma-aminobutyric acid receptor subunit alpha-1	GABA(A) receptor subunit alpha-1;GABRA1	P14867	2554	ENSG00000022355	antagonist
DAP000668	Butalbital	Itobarbital; 5-Allyl-5-(2-methylpropyl)barbituric acid; 5-(2-methylpropyl)-5-prop-2-enyl-1,3-diazinane-2,4,6-trione; 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-(2-methylpropyl)-5-(2-propenyl)-; Butalbitalum [INN-Latin]; CHEMBL454; Butalbitale [DCIT]; CID2481; ZINC03830347; MolPort-003-940-483; Butalbitalum; Allylisobutylbarbital; Butalbarbital; 5-Allyl-5-isobutyl-2,4,6(1H,3H,5H)-pyrimidinetrione; BARBITURIC ACID, 5-ALLYL-5-ISOBUTYL-; AKOS003398680; D03182; 5-(2-methylpropyl)-5-prop-2-en-1-ylpyrimidine-2,4,6(1H,3H,5H)-trione; Allylbarbital; Butalbital [USAN:INN]; DivK1c_000970; NINDS_000970; Butalbital (USP/INN); Butalbitale; AC1Q1P7F; Alisobumal; CHEBI:102524; 77-26-9; Allylbarbitone; Iso-butylallylbarbituric acid; UNII-KHS0AZ4JVK; 5-Allyl-5-isobutylbarbituric acid; Sandoptal (TN); Profundal; 5-(2-methylpropyl)-5-(prop-2-en-1-yl)pyrimidine-2,4,6(1H,3H,5H)-trione; LS-23742; KBio1_000970; IBS-L0126512; IDI1_000970; 5-Allyl-5-(2'-methyl-n-propyl) barbituric acid; HMS503A21; 23554-70-3 (mono-hydrochloride salt); EINECS 201-017-8; 5-Allyl-5-isobutyl-pyrimidine-2,4,6-trione; Allylisobutylbarbiturate; Sandoptal; Tetrallobarbital; Alisobumalum; butalbital; DB00241; AC1L1DRZ	77-26-9	2481	149431	TTDS00403	Gamma-aminobutyric acid receptor subunit alpha-1	GABA(A) receptor subunit alpha-1;GABRA1	P14867	2554	ENSG00000022355	antagonist
DAP000673	Meprobamate	Milprem-200; Prequil; Appetrol-Sr; Lepenil; Sedoselecta; component of Milprem; Cirpon; Sowell; PMB-200; Meprosin; Meprodiol; Tranquinol; Ayermate; Margonil; Meprosan; ZINC01530701; Placidon; Q-Gesic; Quietidon; Procalmadiol; Meprobamate and Aspirin Tablets; Apo-Meprobamate; Ecuanil; Arcoban; Perquietil; Meprospan-200; Larten; Meprocon CMC; Epicur; Meprin (VAN); Meprobamat; Letyl; Metractyl; Erina; Ansil; Pertranquil; Perequil; component of Equalysen; Pensive; Diron; Mepamtin; Miltown; Calmadin; DEA No. 2820; Ataraxine; Meproten; Miltown 600; component of PMB-400; Meproleaf; Mepranil; NCGC00091031-01; Quaname; Bamo 400; Shalvaton; Procalmadol; Probamato; Amosene; M2392_SIGMA; Ansietan; Neo-Tran; Biobamat; Edenal; AC1L1HC1; Fas-Cile; Anastress; Aneusral; Tensonal; Tensol; Pan-tranquil; Stensolo; Nephentine; Gadexyl; Meprotanum; Spantran; Brobamate; Libiolan; WLN: ZVO1X3&1&1OVZ; Reostral; Ipsotian; Kessobamate; Andaksin; Oasil; Meprocon; Protran; Ayeramate; Meprotil; Orolevol; Wyseals; Diurnaldiverondormabrol; Miltaun; Meprospan; Procarbamide; Dormabrol; Optarket; Perequietil; Selene; Quanil; Trancot; Meprol; Anathylmon; Orlevol; Sedanyl; EINECS 200-337-5; Micrainin; Equanil suspension; Lepetown; Tamate; Cap-O-Tran; Sedanil; BRN 1788882; Tranquiline; 1,3-Propanediol, 2-methyl-2-propyl-, dicarbamate; AKOS003617983; 2-Metil-2-n-propil-1,3-propanediol dicarbamato [Spanish]; Miltuan; Restenyl; MolPort-001-783-402; Panediol; Mepriam; Equanil; Meprobamatum [INN-Latin]; Carbamic acid 2-methyl-2-propyltrimethylene ester; Dapaz; Nervonus; Meprobamate (JAN/USP/INN); Tranquilsan; Restinal; 2-Methyl-2-propyl-1,3-propanediol dicarbamate; Meprotan; 2-Methyl-2-n-propyl-1,3-propanediol dicarbamate; Meptran; Equazine-M; meprobamate; Meprobamato [Italian]; 2-[(carbamoyloxy)methyl]-2-methylpentyl carbamate; Aneurol; Seril; Mendel; Anxietil; Aneuxal; Estasil; Harmonin; Calmiren; 2,2-Di(carbamoyloxymethyl)pentane; Restinil; Tranmep; Meproban; Mar-Bate; Dicandiol; Epikur; Miltamato; Arpon; I14-2779; Carbaxin; Meprin; Restenil; Meptranactylmilprem; Wardamate; Aneural; 57-53-4; Placitate; Equinil; Miltwon; Proquanil; [2-(carbamoyloxymethyl)-2-methylpentyl] carbamate; Meprobamato; Promato; Tranquilate; Mepro-Aspirin; Pimal; Misedant; PMB 400; Biobamate; Gagexyl; 2-Methyl-2-propyltrimethylene carbamate; Sedabamate; Morbam; Appetrol; Cyrpon; CHEMBL979; Sadanyl; component of Milpath; Meprovanmeprozine; Quanane; Meprodil; Multaun; 1,3-Propanediol, 2-methyl-2-propyl-, 1,3-dicarbamate; NSC30418; Meprobamatum; Tranquilax; Sedoquil; Milpath; Scolazil; Coprobate; Enorden; Apasil; Atraxin; Procalmidol; Miltann; component of Bamadex; Fas-Cile 200; Equilium; Sedazil; Meprovan; Pankalma; Meprozine; Klort; C9H18N2O4; Meprosa; AC1Q2UIX; UNII-9I7LNY769Q; Pancalma; Meprocompren; Milprem-400; Holbamate; Hartol; Bamd 400; Paxin; My-trans; Tranquiline (Intra); Trelmar; Anzil; Tranlisant; Equitar; Probate; Cirponyl; Milprem; 2-Methyl-2-propylpropane-1,3-diol dicarbamate; Ansiowas; Mepro-analgesic; LS-120649; Meprindon; Bamate; D00376; Meprobam; Meprobamato [INN-Spanish]; Robamate; Apascil; Meprotabs; Cypron; Miltown (TN); Promate; Meprobamic acid; Tranquilan; 3P Bamate; Deprol; Equatrate; HSDB 3117; Mepavlon; Canquil-400; Despasmol; Meposed; Vio-Bamate; Meprobamat [German]; Probamyl; Amepromat; {2-[(carbamoyloxy)methyl]-2-methylpentyl} carbamate; Anatimon; Calmax; Meprobamate [USAN:INN:BAN:JAN]; Vistabamate; SK-Bamate; Diurnal; PMB 200; Equanil (TN); component of Miltrate; Kesso-Bamate; Ansiatan; Anural; Artolon; Auxietil; PMB-400; DB00371; M2392_FLUKA; Canquil 400; Urbil; component of Appetrol; Mepiosine; Diveron; Aneuxral; Quivet; Crestanil; CID4064; Solevione anastress; Neuramate; Setran; Zirpon; Pathibamate; Meprospan-400; Andaxin; Carbamic acid, 2-methyl-2-propyltrimethylene ester; Urbilat; Trankvilan; 2-Metil-2-n-propil-1,3-propanediol dicarbamato; Metranquil; Mepantin; Rastenil	57-53-4	4064	7847442	TTDS00403	Gamma-aminobutyric acid receptor subunit alpha-1	GABA(A) receptor subunit alpha-1;GABRA1	P14867	2554	ENSG00000022355	antagonist
DAP000672	Clobazam	7-Chloro-1-methyl-5-phenyl-1H-1,5-benzodiazepine-2,4(3H,5H)-dione; NSC 336279; nchembio747-comp39; 1-phenyl-5-methyl-8-chloro-1,2,4,5- tetrahydro-2,4-diketo-3H-1,5-benzodiazepine; 22316-47-8; Ambap22316-47-8; Noiafren; MolPort-003-940-848; 1H-1,5-Benzodiazepine-2,4(3H,5H)-dione, 7-chloro-1-methyl-5-phenyl-; 7-chloro-1-methyl-5-phenyl-1,5-benzodiazepine-2,4-dione; Caastilium; Clobazamum; 5-24-08-00034 (Beilstein Handbook Reference); DB00349; DEA No. 2751; Urbadan; Odipam; RU-4723; 1-Phenyl-5-methyl-8-chloro-1,2,4,5-tetrahydro-2,4-dioxo-3H-1,5-benzodiazepine; Clobazamum [INN-Latin]; Clobazam (JAN/USAN/INN); 1H-1,5-Benzodiazepine-2,4(3H,5H)-dione, 7-chloro-1-methyl-5-phenyl-; 1-Phenyl-5-methyl-8-chloro-1,2,4,5-tetrahydro-2,4-dioxo-3H-1, 5-benzodiazepine; 7-Chloro-1-methyl-5-phenyl-1H-1,5-benzodiazepine-2,; CID2789; AC1L1EGZ; CCRIS 7506; UNII-2MRO291B4U; Urbanil; NSC336279; Clorepin; Mystan (TN); Chlorepin; Mystan; Urbanyl; AC-273; BRN 0758410; ZINC00001175; 7-Chloro-1-methyl-5-phenyl-1H-1,5-benzodiazepine-2,4-(3H,5H)-dione; HR 376; LM 2717; LS-34098; C8414_SIGMA; CHEBI:31413; Frisium; 4(3H,5H)-dione; 7-Chloro-1-methyl-5-phenyl-1H-1,5-benzodiazepine-2,4-(3H,5H)-dione; H 4723; C012255; 1-Phenyl-5-methyl-8-chloro-1,2,4,5-tetrahydro-2,4-diketo-3H-1,5-benzodiazepine; EINECS 244-908-7; Clobazam; Clobazam [USAN:BAN:INN]; D01253; H-4723; LM-2717; NCGC00168249-01; CHEMBL70418; WLN: T67 GNV JVN IHJ CG G1 KR	22316-47-8	2789	583072	TTDS00403	Gamma-aminobutyric acid receptor subunit alpha-1	GABA(A) receptor subunit alpha-1;GABRA1	P14867	2554	ENSG00000022355	antagonist
DAP000670	Talbutal	5-(1-methylpropyl)-5-prop-2-en-1-ylpyrimidine-2,4,6(1H,3H,5H)-trione; 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-(1-methypropyl)-5-(2-propenyl)-; Lotusate (TN); 115-44-6; Profundol; AC1L1QN8; CHEMBL1200802; LS-23680; 5-Isobutyl-5-allylbarbituric acid; Lotusate; TALBUTAL; 5-(1-Methylpropyl)-5-(2-propenyl)-2,4,6(1H,3H,5H)-pyrimidinetrione; HSDB 3397; 5-Allyl-5-(1-methylpropyl) barbituric acid; Talbutalum; Talbutal [INN]; Barbituric acid, 5-allyl-5-sec-butyl-; 5-butan-2-yl-5-prop-2-enyl-1,3-diazinane-2,4,6-trione; sec-Butyl allyl barbituric acid; UNII-4YIR8202AX; Talbumalum; D06887; Talbutale; Talbutale [DCIT]; WIN 5095; Talbutalum [INN-Latin]; MolPort-004-286-010; CID8275; 5-Allyl-5-sec-butylbarbituric acid; 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-(1-methylpropyl)-5-(2-propenyl)-; EINECS 204-090-4; Talbutal (INN)	115-44-6	606974	10444920	TTDS00403	Gamma-aminobutyric acid receptor subunit alpha-1	GABA(A) receptor subunit alpha-1;GABRA1	P14867	2554	ENSG00000022355	antagonist
DAP000677	Methohexital	Barbituric acid, 5-allyl-1-methyl-5-(1-methyl-2-pentynyl)-; Methohexital, Monosodium Salt; Enallynymalum; Methohexitone; EINECS 205-798-6; Brietal; 5-Allyl-5-(3-hexyn-2-yl)-1-methylbarbituric acid; 5-Allyl-1-methyl-5-(1-methyl-2-pentynyl)-2,4,6(1H,3H,5H)-pyrimidinetrione; .alpha.-DL-1-Methyl-5-allyl-5-(1'-methylpentyn-2-yl)barbituric acid; 5-Allyl-1-methyl-5-(1-methyl-pent-2-ynyl)-pyrimidine-2,4,6-trione; LS-173735; Metohexital; Metoesital [DCIT]; Barbituric acid, 5-allyl-1-methyl-5-(1-methyl-2-pentynyl)-, (.+/-.)-; Compound 25398; 7187-72-6; (+-)-5-Allyl-1-methyl-5-(1-methyl-2-pentynyl)barbituric acid; Compound 22451; C07844; 5-hex-3-yn-2-yl-1-methyl-5-prop-2-enyl-1,3-diazinane-2,4,6-trione; C14H18N2O3; Methohexital (USP/INN); METHOHEXITAL; CID9034; Metohexital [INN-Spanish]; DEA No. 2264; CHEBI:102216; AC1L1S67; 18652-93-2; Methohexitalum [INN-Latin]; MolPort-004-285-965; Enallynymall; 1-methyl-5-(1-methylpent-2-yn-1-yl)-5-prop-2-en-1-ylpyrimidine-2,4,6(1H,3H,5H)-trione; 2,4,6(1H,3H,5H)-Pyrimidinetrione, 1-methyl-5-(1-methyl-2-pentynyl)-5-(2-propenyl)-, (.+/-.)-; DB00474; alpha-DL-1-Methyl-5-allyl-5-(1'-methylpentyn-2-yl)barbituric acid; CHEMBL7413; UNII-E5B8ND5IPE; Brevital; 151-83-7; 1-methyl-5-(1-methylpent-2-yn-1-yl)-5-(prop-2-en-1-yl)pyrimidine-2,4,6(1H,3H,5H)-trione; D04985; Metoesital; Methodrexitone; 115621-33-5; Methohexitalum	151-83-7	9034	10046	TTDS00403	Gamma-aminobutyric acid receptor subunit alpha-1	GABA(A) receptor subunit alpha-1;GABRA1	P14867	2554	ENSG00000022355	antagonist
DAP000688	Hexobarbital	NSC71929; Barbituric acid, 5-(1-cyclohexen-1-yl)-1,5-dimethyl-; CID3608; C11723; 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-(1-cyclohexen-1-yl)-1,5-dimethyl-, (+-)-; Evipan; Methylhexabital; 5-(.delta.-1,2-cyclohexenyl)-5-methyl-N-methyl-barbitursaeure; 5-(1-Cyclohexen-1-yl)-1,5-dimethyl-2,4,6(1H,3H,5H)-pyrimidinetrione; Hexobarbital [INN:JAN]; 5-cyclohex-1-en-1-yl-2-hydroxy-1,5-dimethylpyrimidine-4,6(1H,5H)-dione; 5-(delta-1,2-cyclohexenyl)-5-methyl-N-methyl-barbitursaeure; Sombucaps; Hexobarbital; Enhexymal; NCGC00159430-02; Noctivane; MolPort-001-783-664; LS-24041; 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-(1-cyclohexen-1-yl)-1,5-dimethyl-; AI3-61892; Enhexymalum; 5-(1-Cyclohexenyl-1)-1-methyl-5-methylbarbituric acid; Oprea1_350917; Cyclopan; Cyclonal; 5-(1-CYCLOHEXEN-1-YL)-1,5-DIMETHYLBARBITURIC ACID; Sombulex; 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-(1-cyclohexen-1-yl)-1,5-dimethyl; 1,5-Dimethyl-5-(1-cyclohexenyl)barbituric acid; AC1L1GB8; AKOS000355976; 5-cyclohex-1-en-1-yl-1,5-dimethylpyrimidine-2,4,6(1H,3H,5H)-trione; Somnalert; Hexobarbitalum; 5-(cyclohexen-1-yl)-1,5-dimethyl-1,3-diazinane-2,4,6-trione; 5-(1-Cyclohexenyl)-1,5-dimethylbarbituric acid; MolPort-002-070-456; N-Methyl-5-cyclohexenyl-5-methylbarbituric acid; Evipal; (+-)-Hexobarbital; H1005_SIGMA; STK696034; Esobarbitale [DCIT]; H1005_FLUKA; Hexenal (barbiturate); Methexenyl; 5-(delta-1,2-Cyclohexenyl)-5-methyl-N-methyl-barbitursaeure [German]; Dorico; MLS001143909; 7200-11-5; 5-(cyclohex-1-en-1-yl)-1,5-dimethylpyrimidine-2,4,6(1H,3H,5H)-trione; Barbidorm; Methylhexabarbital; Hexobarbital (VAN); D01071; Hexobarbitonum; Esobarbitale [Italian]; WLN: T6VMVNV FHJ D1 F1 F- AL6UTJ; Hexobarbital (JAN/INN); Hexanastab oral; Narcosan; Hexobarbitalum [INN-Latin]; Citopan; UNII-AL8Z8K3P6S; NSC 71929; NCGC00159430-03; Hexobarbitone; 56-29-1; DB01355; CHEMBL7728; EINECS 200-264-9; Sodium hexobarbital; Citodon; Hexabarbital; SMR000473348; AC-16076; CHEBI:5706; Esobarbitale	56-29-1	3608	7848134	TTDS00403	Gamma-aminobutyric acid receptor subunit alpha-1	GABA(A) receptor subunit alpha-1;GABRA1	P14867	2554	ENSG00000022355	antagonist
DAP000681	Ethanol	8000-16-6; WLN: Q2; Alcohols, C1-3; 02857_SIAL; Tecsol; Alcohol, Grain; Spirt; Ethyloxy Group; 24102_SIAL; Alcohol, anhydrous; Ethanol, undenatured; Fermentation alcohol; 71329-38-9; 02858_FLUKA; 02891_SIAL; Methylcarbinol; 459828_ALDRICH; QMHAIh@; bmse000297; C00469; 24105_RIEDEL; CDA 19; C2H6O; 02865_SIAL; 270741_ALDRICH; Infinity Pure; Alcool ethylique; Ethylalcohol; 02877_FLUKA; 245119_ALDRICH; Alcohol [USP]; Alcohol, dehydrated; Etanolo [Italian]; IMS 99; nchembio.552-comp10; 32205_RIEDEL; 121182-78-3; Distilled spirits; E2385_SIGMA; 277649_SIAL; Alcool etilico; Alcohols; D00068; Sekundasprit; 277649_ALDRICH; 02875_FLUKA; FEMA No. 2419; 459836_ALDRICH; Ethanol Absolute; 458600_SIAL; 245119_SIAL; E7148_SIAL; 24194_SIAL; 32205_SIAL; Synasol; Caswell No. 430; 459844_SIAL; 02884_FLUKA; 64-17-5; Molasses alcohol; 02483_FLUKA; Ru-Tuss Expectorant; AI3-01706; Thanol; 02858_SIAL; Hydroxyethane; Methylated spirit; Anhydrol; 32294_SIAL; Ethyl hydrate; Dehydrated alcohol; 02883_FLUKA; FEMA Number 2419; Aethylalkohol; 24106_SIAL; CDA 19-200; Cologne Spirit; CID702; etanol; 02856_SIAL; Ethylalcohol [Dutch]; LTBB002977; ALCOHOL 5% IN D5-W; Aethanol; LS-1539; Etylowy alkohol; 2858_SIGMA; UNII-3K9958V90M; 02860_FLUKA; Ethylol; Ethanol [JAN]; 24103_SIAL; 100C.NPA; Alcohols, C6-9; 24106_RIEDEL; Anhydrous ethanol; 02890_FLUKA; 493546_ALDRICH; Spirits of wine; 24105_SIAL; 02855_FLUKA; AHD 2000; Alcohol, Absolute; Tecsol C; 493511_SIAL; Ethanol (9CI); 34963_RIEDEL; 40210_ALDRICH; C2H5OH; Denatured ethanol; 32221_RIEDEL; Hinetoless; SY Fresh M; Alkohol [German]; 02870_SIAL; I14-12648; Dehydrated ethanol; 8024-45-1; 02882_SIAL; Cologne spirits; Ethanol Vapor; HSDB 82; E7023_SIAL; CHEBI:16236; alcohol; Alcohols, C30; Ethanol solution; Etanolo; MolPort-001-785-844; 29221_FLUKA; 02865_FLUKA; AC1L19TW; 270741_SIAL; Esumiru WK 88; Aethanol [German]; 493546_SIAL; Ethyl hydroxide; 24103_RIEDEL; 24194_RIEDEL; EINECS 200-578-6; 02857_FLUKA; SDA 3A; Ethicap; 02851_FLUKA; E7023_ALDRICH; Desinfektol EL; 493538_SIAL; grain alcohol; EOX; Alkohol; AC1Q31MM; NCI-C03134; Jaysol; 187380_ALDRICH; 32221_SIAL; Ethanol Anhydrous; Alcare Hand Degermer; Ethanolum anhydricum; 41322_FLUKA; Potato alcohol; SDM No. 37; 71076-86-3; Absolute ethanol; 32294_RIEDEL; Anhydrol PM 4085; CCRIS 945; Spirit; Ethanol Absolute Bp; 24102_RIEDEL; 459836_SIAL; Anhydrous alcohol; 02856_FLUKA; 40210_RIEDEL; (C6-C9)Alkyl alcohol; D000431; EtOH; Alcohol (USP); E7517_SIGMA; Reagent Alcohol; EOH; Ethanol Extra Pure; CHEMBL545; Ethyl alc; Ethanol 200 proof; NSC 85228; SDA 40-2; ethanol; 34870_SIAL; alcohol etilico; EINECS 270-649-4; 02890_SIAL; 02853_FLUKA; nchem.651-comp3c; nchembio.94-comp20; 676829_SIAL; 187380_SIAL; Denatured alcohol; E7148_ALDRICH; 02891_FLUKA; 39278_FLUKA; Alcohol anhydrous; Alkoholu etylowego; Alcohol dehydrated; absolute alcohol; NCGC00091458-01; 458600_ALDRICH; 68475-56-9; NSC85228; spiritus vini; 1-Hydroxyethane; 48075_SUPELCO; Oxydimethylene Group; 459828_SIAL; 02870_FLUKA; 02854_FLUKA; Alcohol, ethyl; DB00898; 493538_ALDRICH; 02878_FLUKA; Jaysol S; Algrain; 02882_FLUKA; HYDROXYETHYL GROUP; ethyl alcohol; Ethyl alcohol usp; Alcohol, diluted	64-17-5	702	3752	TTDS00403	Gamma-aminobutyric acid receptor subunit alpha-1	GABA(A) receptor subunit alpha-1;GABRA1	P14867	2554	ENSG00000022355	antagonist
DAP000674	Secobarbital	Quinalbarbital; C12H18N2O3; DEA No. 2315; (+-)-5-Allyl-5-(1-methylbutyl)-barbituric acid; S4006_SIGMA; Seconal; CID5193; CHEMBL447; 29071-21-4; Secobarbitalum; 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-(1-methylbutyl)-5-(2-propenyl)-, (+-)- (9CI); Secobarbitale [DCIT]; Barbosec; 5-24-09-00235 (Beilstein Handbook Reference); 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-(1-methylbutyl)-5-(2-propenyl)-, (+-)-; Meballymalum; 5-Allyl-5-(1-methylbutyl)malonylurea; Secobarbital (USP/INN); 5-(pentan-2-yl)-5-(prop-2-en-1-yl)-pyrimidine-2,4,6(1H,3H,5H)-trione; Seconal (TN); Secobarbital solution; Meballymal; Barbituric acid, 5-allyl-5-(1-methylbutyl)-; Secobarbitale; 76-73-3; Somosal; 5-ALLYL-5-(1-METHYLBUTYL)BARBITURIC ACID; LS-23756; (+-)-Secobarbital; Hypotrol; BRN 0225330; MolPort-003-959-501; BARBITURIC ACID, 5-ALLYL-5-(1-METHYLBUTYL)-, (+-)-; 5-allyl-5-(1-methylbutyl)pyrimidine-2,4,6(1H,3H,5H)-trione; AC1L1JT0; 5-(1-methylbutyl)-5-(2-propenyl)-2,4,6(1H,3H,5H)-pyrimidinetrione; UNII-1P7H87IN75; Secobarbital [USAN:INN]; EINECS 200-982-2; LS-23757; Secobarbital suppository dosage form; S1503_FLUKA; S1503_SIGMA; AC1Q2UJO; 5-Allyl-5-(1-methylbutyl)-2,4,6(1H,3H,5H)-pyrimidinetrione; secobarbital; Seotal; DEA No. 2316; Evronal; Quinalbarbitone; CHEBI:9073; 5-pentan-2-yl-5-prop-2-enyl-1,3-diazinane-2,4,6-trione; D00430; Hyptran; Secobarbitalum [INN-Latin]; Secobarbitone; S4006_FLUKA; 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-(1-methylbutyl)-5-(2-propenyl)-; Pramil; 5-Allyl-5-(1-methylbutyl)barbiturate; HSDB 3182	76-73-3	31143	173168	TTDS00403	Gamma-aminobutyric acid receptor subunit alpha-1	GABA(A) receptor subunit alpha-1;GABRA1	P14867	2554	ENSG00000022355	antagonist
DAP001351	Barbituric acid	Barbiturate; 678184-94-6; 914348-20-2; Pyrimidinetrione; C032232; AC1Q6GAK; 223674-02-0; Malonylurea; 42910-84-9; Barbituric acid (VAN) (8CI); InChI=1/C4H4N2O3/c7-2-1-3(8)6-4(9)5-2/h1H2,(H2,5,6,7,8,9; 16564-27-5; 160336-60-7; 117491-80-2; 888733-51-5; Malonylharnstoff; 860760-03-8; 253678-06-7; Urea, N,N'-(1,3-dioxo-1,3-propanediyl)-; AC1L1M19; MolPort-000-998-466; 774592-06-2; hexahydro-pyrimidine-2,4,6-trione; 253678-08-9; CHEBI:669285; Sodium barbiturate; AG-670/31547005; Barbitursaeure; 11709_FLUKA; BARBITURIC ACID; S03-0134; 4390-16-3 (mono-hydrochloride salt); 408335-37-5; 2,4,6(1H,3H,5H)-Pyrimidinetrione; 32267-40-6; 118738-52-6; 2,4,6-Pyrimidinetriol; CHEMBL574699; 67-52-7; EINECS 200-658-0; Pyrimidinetriol; Barbituric acid (VAN); AR-1H7693; 1,3-diazinane-2,4,6-trione; STK317809; CHEBI:16294; 2,4,6-(1H,3H,5H)-Pyrimidinetrione; 2,4,6-Trioxohexahydropyrimidine; pyrimidine-2,4,6(1H,3H,5H)-trione; 20964-57-2; AI3-02724; AKOS000288853; C00813; 53853-41-1; 1194-23-6; Hexahydropyrimidine-2,4,6-trione; LS-7209; bmse000346; CID6211; 2,4,6-Pyrimidinetrione; 2,4,6-Trihydroxypyrimidine; Hydrouracil, 6-hydroxy-; 944357-77-1; 477705-05-8; 6-Hydroxyuracil; 154254-45-2; 465532-08-5; NSC 7889; 185698_SIAL; 1,2,3,4,5,6-Hexahydro-2,4,6-pyrimidinetrione; 51159-18-3; 158217-19-7; NSC7889; 253678-07-8; 4A0BDFFD-9542-4996-A89F-E5A55D03B250	67-52-7	6211	4071	TTDS00403	Gamma-aminobutyric acid receptor subunit alpha-1	GABA(A) receptor subunit alpha-1;GABRA1	P14867	2554	ENSG00000022355	antagonist
DAP000687	Butethal	AC1L1MLX; NSC229336; Meonal; Hyperbutal; Sonerile; Soneryl; Neonal; 77-28-1; Butabarbitol; Monodorm; LS-23929; 5-Butyl-5-ethyl-2,4,6(1H,3H,5H)-pyrimidinetrione; Butobarbital (BAN); 5-24-09-00161 (Beilstein Handbook Reference); BRN 0201786; Butobarbitone; 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-butyl-5-ethyl- (9CI); MolPort-004-285-848; Longanoct; 5-butyl-5-ethyl-1,3-diazinane-2,4,6-trione; CHEMBL404422; Butobarbitalum; Etoval; 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-butyl-5-ethyl-; NSC 229336; Barbituric acid, 5-butyl-5-ethyl-; D02618; 5-Ethyl-5-butylbarbituric acid; Budorm; Butobarbitural; Neonal (TN); Butethal; Butyl,5-ethylbarbituric acid; 5-Ethyl-5-n-butylbarbituric acid; Butobarbital [BAN]; 5-BUTYL-5-ETHYLBARBITURIC ACID; WLN: T6VMVMV FHJ F4 F2; EINECS 201-019-9; CID6473; Aethylbutylbarbitursaeure; DB01353; ZINC05514900; 35763-44-1 (mono-hydrochloride salt); Butobarbital	77-28-1	6473	10413788	TTDS00403	Gamma-aminobutyric acid receptor subunit alpha-1	GABA(A) receptor subunit alpha-1;GABRA1	P14867	2554	ENSG00000022355	antagonist
DAP000682	Methoxyflurane	Methyl 1,1-difluoro-2,2-dichloroethyl ether; 2,2-Dichloro-1,1-difluoroethyl methyl ether; D00544; WLN: GYGXFFO1; DB01028; CHEMBL1341; Metofane (VAN); UNII-30905R8O7B; Ether, 2,2-dichloro-1,1-difluoroethyl methyl; LS-1693; 2,2-Dichloro-1,1-difluoro-1-methoxyethane; CID4116; Ingalan; Metossiflurano; Methoflurane; Metoxifluran; C3H4Cl2F2O; Metossiflurano [DCIT]; Inhalan; NSC110432; Methoxyfluorane; MolPort-000-153-984; methoxyflurane; Metoxiflurano; Methoxyflurane [USAN:INN:BAN]; Metofane; Pentran; C07517; NSC-110432; NCGC00168747-01; HSDB 7201; Methofane; Pentrane; Methoxyfluran; Methoxane; Methoxyflurane (USP/INN); Metoxfluran; AC1L1HG4; Penthrane (VAN); Methofluranum; D008733; Metoxiflurano [INN-Spanish]; Ethane, 2,2-dichloro-1,1-difluoro-1-methoxy-; ZINC00896988; Methoxyfluoran; Analgizer; AC1Q44GN; Methoxyfluranum [INN-Latin]; (2,2-dichloro-1,1-difluoroethyl) methyl ether; Penthrane; ST51041742; 76-38-0; Methoxiflurane; Methoxifluranum; Penthrane (TN); CCRIS 5840; Methoxyflurane [Anaesthetics, volatile]; BRN 1737766; EINECS 200-956-0; Anecotan; Methoxyfluranum	76-38-0	4116	149389	TTDS00403	Gamma-aminobutyric acid receptor subunit alpha-1	GABA(A) receptor subunit alpha-1;GABRA1	P14867	2554	ENSG00000022355	antagonist
DAP000667	Butabarbital	125-40-6; Butrate; Unicelles; 5-SEC-BUTYL-5-ETHYL-BARBITURIC ACID; NSC 27517; BRN 0199734; 5-Ethyl-5-isobutylbarbituric acid; 1135-61-1; Secbutabarbital [INN]; LS-23930; NSC27517; BRN 0199127; 97164-73-3; Sodium butabarbital; 5-Sec-butyl-5-ethyl-2,4,6(1H,3H,5H)-pyrimidinetrione; Secbutabarbitalum; Butisol sodium; Butabarbital [USAN]; CHEBI:3228; Butabarbital (VAN); HSDB 3018; Secbutabarbitalum [INN-Latin]; Butatal; Butabarbital (USP); sec-Butobarbitone; 5-Ethyl-5-(1-methylpropyl)barbituric acid; 5-Ethyl-5-(1-methylpropyl)-2,4,6(1H,3H,5H)-pyrimidinetrione; 5-butan-2-yl-5-ethyl-1,3-diazinane-2,4,6-trione; Butatab; Nilox; Secbutabarbital; EINECS 204-738-6; MolPort-004-285-873; AC-16078; 5-Ethyl-5-(1-methylpropyl)barbiturate; D03180; 5-(butan-2-yl)-5-ethylpyrimidine-2,4,6(1H,3H,5H)-trione; UNII-P0078O25A9; Butabarb; Sarisol; Butabarbitone; Buticaps; Medarsed; WLN: T6VMVMV FHJ FY2 & 1 F2; Barbituric acid, 5-ethyl-5-isobutyl-; 5-sec-butyl-5-ethylpyrimidine-2,4,6(1H,3H,5H)-trione; CHEMBL449; Secbutobarbital; Secbutobarbitone; C07827; Barbituric acid, 5-sec-butyl-5-ethyl-; CID2479; LS-24330; butabarbital; AC1L1DRT; DB00237; 5-sec-Butyl-5-ethylmalonyl urea; 5-ethyl-5-(1-methylpropyl)pyrimidine-2,4,6(1H,3H,5H)-trione; 5-sec-Butyl-5-ethylbarbituric acid; 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-5-(1-methylpropyl)-; Secbutabarbitale [DCIT]; Butalan; Secbubarbital; Butisol; Secbutabarbitale	125-40-6	2479	10029	TTDS00403	Gamma-aminobutyric acid receptor subunit alpha-1	GABA(A) receptor subunit alpha-1;GABRA1	P14867	2554	ENSG00000022355	antagonist
DAP000678	Primidone	Cyral; Spectrum_000832; Prysoline; KBio3_001725; NCGC00015834-02; CHEMBL856; Misolyne; MLS001055411; BRN 0218034; 5-Ethyldihydro-5-phenyl-4,6(1H,5H)-pyrimidinedione; WLN: T6MV DVMTJ C2 CR; 5-Ethyl-5-phenylhexahydropyrimidine-4,6-dione; NCGC00016377-01; Majsolin; SMR000058501; 5-Phenyl-5-aethylhexahydropyrimidindion-(4,6); 5-ethyl-5-phenyl-1,3-diazinane-4,6-dione; Sanofi-Synthelabo Brand of Primidone; KBioGR_000969; Hexadiona; Spectrum4_000485; Primidone Methanol Solution; Tocris-0830; BSPBio_002225; BIDD:GT0319; Primidone (primaclone); Pyrimidone Medi-pets; Spectrum2_001293; KBio1_000324; BSPBio_000866; NCGC00015834-14; Astra Brand of Primidone; MLS000028593; Desoxyphenobarbitone; NCGC00023254-06; 5-Aethyl-5-phenyl-hexahydropyrimidin-4,6-dion; Hexamidine (the antispasmodic); NCGC00023254-10; 4,6(1H,5H)-Pyrimidinedione, 5-ethyldihydro-5-phenyl-; SPECTRUM1500501; Mizolin; Lepimidin; NCI-C56360; Liskantin; KBio2_003880; SMP1_000135; Misodine; Primidona; EINECS 204-737-0; NCGC00015834-01; Xcel Brand of Primidone; Hexamidine(the antispasmodic); 4,4'-(Hexamethylenedioxy)dibenzamidine; D011324; BPBio1_000859; P7295_FLUKA; P7295_SIGMA; 5-Ethylhexahydro-5-phenylpyrimidine-4,6-dione; ZINC00001979; BPBio1_000954; Prestwick2_000933; Primidonum; Draxis Brand of Primidone; NCGC00023254-04; UNII-13AFD7670Q; SPBio_001325; Spectrum3_000553; Prilepsin; Mysoline (TN); NCGC00023254-07; BRD-K32247306-001-05-4; Desitin Brand of Primidone; 2-Desoxyphenobarbital; primidone; hexamidine (the  antispasmodic); Mysedon; Apo-Primidone; Lopac-P-7295; Biomol-NT_000261; NCGC00015834-07; KBio2_006448; Primidon; AKOS003368409; Lepsiral; Milepsin; C07371; EU-0101021; NSC 41701; MolPort-001-783-659; CPD000058501; Mizodin; 5-ethyl-5-phenyldihydropyrimidine-4,6(1H,5H)-dione; Primidona [INN-Spanish]; IDI1_000324; KBioSS_001312; Prestwick1_000933; Mylepsin; Myidone; 5-24-08-00102 (Beilstein Handbook Reference); DB00794; NCGC00023254-08; Prestwick0_000933; Apotex Brand of Primidone; 2-Deoxyphenobarbital; Roe 101; AstraZeneca Brand of Primidone; Pms Primidone; Medi-Pets; CID4909; Primoline; SPBio_003035; Prestwick3_000933; Primidon Holsten; AB00052079; HMS501A06; SAM002554925; Primacone; Neurosyn; NINDS_000324; 5-Phenyl-5-ethyl-hexahydropyrimidine-4,6-dione; ST076725; NCGC00023254-09; Mysoline; Primidonum [INN-Latin]; Lopac0_001021; Pyrimidone "Medi-pets"; Primakton; HMS1920J20; Mylepsinum; P 7295; Primacione; NCGC00023254-02; HSDB 3169; 5-ethylhe xahydro-4,6-dioxo-5-phenylpyrimidine; 125-33-7; Desoxyphenobarbital; Midone; NSC41701; Resimatil; DivK1c_000324; KBio2_001312; Primidone (JP15/USP/INN); 5-Aethyl-5-phenyl-hexahydropyrimidin-4,6-dion [German]; 5-Phenyl-5-aethylhexahydropyrimidindion-(4,6) [German]; HMS1570L08; Primaclone; NCGC00023254-05; S1965_Selleck; 5-Ethylhexahydro-4,6-dioxo-5-phenylpyrimidine; HMS2092A21; Spectrum5_001144; AC1L1J82; MLS001074125; Sertan; Holsten Brand of Primidone; Zeneca Brand of Primidone; CCRIS 54; Primidone [USAN:INN:BAN:JAN]; LS-48; CAS-125-33-7; D00474; I06-0632	125-33-7	4909	173378	TTDS00403	Gamma-aminobutyric acid receptor subunit alpha-1	GABA(A) receptor subunit alpha-1;GABRA1	P14867	2554	ENSG00000022355	antagonist
DAP000683	Methyprylon	CHEMBL1200790; 125-64-4; Ro 1-6463; Methprylon; 2,4-Dioxy-3,3-diethyl-5-methylpiperidine; HSDB 3128; methyprylon; AC1L1HJV; Dimerin; Methyprylon (JAN/INN); Nodular; Metiprilone; D01150; LS-115204; BRN 0082860; NSC 30442; CID4162; DB01107; C10H17NO2; 2,4-Piperidinedione, 3,3-diethyl-5-methyl-; Metiprilona [INN-Spanish]; Metiprilona; Methyprylon [INN]; UNII-CUT48I42ON; Noludar; Methyprylone [INN-French]; Methyprylonum; Methyprolon; Noludar (TN); 3,3-Diethyl-5-methylpiperidine-2,4-dione; MolPort-001-783-609; WLN: T6MV DVTJ C2 C2 E1; Methyprylonum [INN-Latin]; DEA No. 2575; NSC30442; EINECS 204-745-4; 2,4-Dioxo-3,3-diethyl-5-methylpiperidine; Methyprylone; 3,3-Diethyl-2,4-dioxo-5-methylpiperidine; Metiprilon; Noctan; 3,3-Diethyl-5-methyl-2,4-piperidinedione	125-64-4	4162	582940	TTDS00403	Gamma-aminobutyric acid receptor subunit alpha-1	GABA(A) receptor subunit alpha-1;GABRA1	P14867	2554	ENSG00000022355	antagonist
DAP000676	Picrotoxin	NSC 403139; CID6473767; Indian berry; Caswell No. 663A; P1675_SIGMA; AC1L1LDB; Picrotin, compd. with picrotoxinin (1:1); Picrotin - Picrotoxinin; Sesquiterpene; PICROTOXIN; Lopac0_000916; AC1LAQW2; 3,6-Methano-8H-1,5,7-trioxacyclopenta(ij)cycloprop(a)azulene-4,8(3H)-dione, hexahydro-2a-hydroxy-9-(1-hydroxy-1-methylethyl)-8b-methyl-, (1aR-(1aalpha,2abeta,3beta,6beta,6abeta,8aS*,8bbeta,9S*))-, compd. with (1aR-(1aalpha,2abeta,3beta,6beta,6; NCGC00094227-01; Picrotoxinum; SAM001246993; CPD000469289; )-hexahydro-2a-hydroxy-8b-methyl-9-(1-methylethenyl)-3,6-methano-8H-1,5,7-trioxacyclopenta[ij]cycloprop[a]azulene-4,8(3H)-dione (1:1); 124-87-8; NSC403139; Oriental berry; Picrotoxin (Compound of one mole Picrotoxinin and one mole Picrotin); Cocculin; MLS001423995; AI3-17689; Coques du levant [French]; SMR000469289; 3,6-Methano-8H-1,5,7-trioxacyclopenta(ij)cycloprop(a)azulene-4,8(3H)-dione, hexahydro-2a-hydroxy-9-(1-hydroxy-1-methylethyl)-8b-methyl-, (1aR-(1aalpha,2abeta,3beta,6beta,6abeta,8aS*,8bbeta,9S*))-, compd. with (1aR-(1aalpha,2abeta,3beta,6beta,6abeta,8aS*,8bbeta,9R*))-hexahydro-2a-hydroxy-8b-methyl-9-(1-methylethenyl)-3,6-methano-8H-1,5,7-trioxacyclopenta(ij)cycloprop(a)azulene-4,8(3H)-dione (1:1); HSDB 6385; Picrotin, compound with picrotoxinin (1:1); Ambap124-87-8; EU-0100916; CID518601; C15H16O6.C15H18O7; MolPort-003-800-101; Picrotoxine; Picrotoxinin, compd. with picrotin (1:1); HMS2051E09; CID31304; 3,6-Methano-8H-1,5,7-trioxacyclopenta(ij)cycloprop(a)azulene-4,8(3H)-dione, hexahydro-2a-hydroxy-9-(1-hydroxy-1-methylethyl)-8b-methyl-, (1aR-(1aalpha,2abeta,3beta,6beta,6abeta,8aS*,8bbeta,9S*))-, compd with (1aR-(1aalpha,2abeta,3beta,6beta,6abeta,8aS*,8bbeta,9R*))-hexahydro-2a-hydroxy-8b-methyl-9-(1-methylethenyl)-3,6-methano-8H-1,5,7-trioxacyclopenta(ij)cycloprop(a)azulene-4,8(3H)-dione; 3,6-Methano-8H-1,5,7-trioxacyclopenta[ij]cycloprop[a]azulene-4,8(3H)-dione, hexahydro-2a-hydroxy-9-(1-hydroxy-1-methylethyl)-8b-methyl-, (1aR,2aR,3S,6R,6aS,8aS,8bR,9S)- & (1aR,2aR,3S,6R,6aS,8aS,8bR,9R; CHEMBL506977; MolPort-003-894-698; Cocculus; LS-109760; EINECS 204-716-6; Fish berry; EPA Pesticide Chemical Code 002301; P 1675; Coques du levant; 3,6-Methano-8H-1,5,7-trioxacyclopenta(ij)cycloprop(a)azulene-4,8(3H)-dione, hexahydro-2a-hydroxy-9-(1-hydroxy-1-methylethyl)-8b-methyl-, (1aR,2aR,3S,6R,6aS,8aS,8bR,9S)-, compd. with (1aR,2aR,3S,6R,6aS,8aS,8bR,9R)-hexahydro-2a-hydroxy-8b-methyl-9-(1-methylethenyl)-3,6-methano-8H-1,5,7-trioxacyclopenta(ij)cycloprop(a)azulene-4,8(3H)-dione (1:1); 3,6-Methano-8H-1,5,7-trioxacyclopenta[ij]cycloprop[a]azulene-4,8(3H)-dione, hexahydro-2a-hydroxy-9-(1-hydroxy-1-methylethyl)-8b-methyl-, [1aR-(1a.alpha.,2; Picrotoxinin - picrotin; 80410_FLUKA; Picrotox; DB00466	124-87-8	31304	173365	TTDS00403	Gamma-aminobutyric acid receptor subunit alpha-1	GABA(A) receptor subunit alpha-1;GABRA1	P14867	2554	ENSG00000022355	antagonist
DAP000680	Methylphenobarbital	Mephobarbitone; 5-Ethyl-1-methyl-5-phenyl-2,4,6(1H,3H,5H)-pyrimidinetrione; 5-ethyl-1-methyl-5-phenylpyrimidine-2,4,6(1H,3H,5H)-trione; 5-ethyl-1-methyl-5-phenyl-1,3-diazinane-2,4,6-trione; N-Methylethylphenylbarbituric acid; Mebroin; Metylfenemal; Mebaral; Methyl-calminal; AKOS002254670; 115-38-8; Mephobarbital (JAN/USP); Enphenemalum; N-Methyl-5-phenyl-5-ethylbarbital; Phemetone; C07829; 5-Ethyl-1-methyl-5-phenylbarbituric acid; Metyna; ALARQZQTBTVLJV-UHFFFAOYSA-; Methyl phenobarbitone; Methylphenylbarbituric acid; NCGC00159357-02; AC-16075; Prominaletten; 1-Methylphenobarbital; InChI=1/C13H14N2O3/c1-3-13(9-7-5-4-6-8-9)10(16)14-12(18)15(2)11(13)17/h4-8H,3H2,1-2H3,(H,14,16,18); Metilfenobarbital [INN-Spanish]; N-Methylphenobarbital; AC1L1QMW; BRN 0256144; Meberal; CHEBI:6758; Isonal (roussel); Metilfenobarbitale [DCIT]; NCGC00159357-03; 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-1-methyl-5-phenyl-; Methylphenobarbital (INN); Methylphenobarbitonum; 5-Ethyl-N-methyl-5-phenylbarbituric acid; Phemiton; 1-Methyl-5-phenyl-5-ethylbarbituric acid; Sanofi Brand of Mephobarbital; N-Ethylmethylphenylbarbituric acid; Metilfenobarbitale; Sanofi Synthelabo Brand of Mephobarbital; DB00849; Mephobarbital [JAN]; D00700; 5-Phenyl-5-ethyl-3-methylbarbituric acid; Methylphenobarbitalum; MolPort-000-839-979; STK732046; Methylphenobarbitone; Phemitone; Prominalum; Methylphenolbarbital; Mephobarbital; Mephytal; Oprea1_133475; LS-24423; Enfenemal; D008618; EINECS 204-085-7; MolPort-002-537-654; Phenmiton; CID8271; Methylphenobarbitalum [INN-Latin]; Metilfenobarbital; Barbituric acid, 5-ethyl-1-methyl-5-phenyl-; 1-Methyl-5-ethyl-5-phenylbarbituric acid; Enphenemal; CHEMBL45029; Menta-Bal; N-Methylphenolbarbitol; Morbusan; 5-24-09-00294 (Beilstein Handbook Reference); UNII-5NC67NU76B; DEA No. 2250; Prominal; METHYLPHENOBARBITAL; HSDB 3579; Bio-0356; Mebaral (TN); 5-Ethyl-5-phenyl-N-methyl-bartituric acid	115-38-8	8271	7847765	TTDS00403	Gamma-aminobutyric acid receptor subunit alpha-1	GABA(A) receptor subunit alpha-1;GABRA1	P14867	2554	ENSG00000022355	antagonist
DAP000686	Amobarbital	VIROVYVQCGLCII-UHFFFAOYSA-; component of Dexamyl; Talamo; Eunoctal; Amytal; Dormytal; ZINC04811698; Amobarbitalum [INN-Latin]; Amital; Sumital; 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-5-(3-methylbutyl)-; Isomyl; NSC120800; Binoctal; Amobarbital [INN:JAN]; Amobarbitone; Amospan; Oprea1_587446; 5-Ethyl-5-isopentylbarbituric acid; Amylobarbitone; 5-Ethyl-5-isopentylbarbitursaeure; Amylobarbital; CCRIS 5454; IDI1_000994; MolPort-004-285-843; amobarbital; DB01351; Isoamylethylbarbituric acid; DivK1c_000994; component of Amo-Dextrosule; Amobarbitalum; Somnal; CBDivE_006514; Amobarbitale [DCIT]; 5-Ethyl-5-isoamylmalonyl urea; KBio1_000994; 64-43-7 (hydrochloride); D00555; AMAL; UNII-GWH6IJ239E; 5-ethyl-5-(3-methylbutyl)-1,3-diazinane-2,4,6-trione; 5-Ethyl-5-(3-methylbutyl)-2,4,6(1H,3H,5H)-pyrimidinetrione; Barbamyl; Mylodorm; CID2164; LS-7196; Amybal; Dorlotyn; 5-Isoamyl-5-ethylbarbituric acid; Amobarbitale; Schiwanox; NSC 10815; NINDS_000994; HSDB 3286; Pentymal; NSC32406; DEA No. 2126; InChI=1/C11H18N2O3/c1-4-11(6-5-7(2)3)8(14)12-10(16)13-9(11)15/h7H,4-6H2,1-3H3,(H2,12,13,14,15,16); NSC10815; Barbamil; 57-43-2; Isomytal (TN); Amobarbital suppository dosage form; Stadadorm; ZINC04811699; CHEMBL267894; component of Q-Caps; Isomytal; EINECS 200-330-7; Robarb; Amasust; Amylbarbitone; component of 15-90; Amobarbital (JP15/INN); 5-Ethyl-5-(3-methylbutyl)barbituric acid; Barbamyl acid; WLN: T6VMVMV FHJ F2 F2Y1&1; Sednotic; Barbituric acid, 5-ethyl-5-isopentyl-; Pentymalum; AC1L1D2C; C07536; Ethylisopentylbarbituric acid; BIDD:PXR0091; 5-Ethyl-5-isoamylbarbituric acid; CHEBI:2673; 5-ethyl-5-(3-methylbutyl)pyrimidine-2,4,6(1H,3H,5H)-trione	57-43-2	2164	7847621	TTDS00403	Gamma-aminobutyric acid receptor subunit alpha-1	GABA(A) receptor subunit alpha-1;GABRA1	P14867	2554	ENSG00000022355	antagonist
DAP000669	Etomidate	1-(alpha-Methylbenzyl)-1H-imidazole-5-carboxylic acid ethyl ester; Prestwick0_001041; 1H-Imidazole-5-carboxylic acid, 1-((1R)-1-phenylethyl)-, ethyl ester; Ethyl 1-(1-phenylethyl)-1H-imidazole-5-carboxylate; Etomidate [USAN:BAN:INN]; Radenarcon; HMS1571A04; C14H16N2O2; CHEBI:129025; R-26490; S1329_Selleck; R-(+)-Ethyl 1-(1-phenylethyl)-1H-imidazole-5-carboxylate; UNII-Z22628B598; 1H-Imidazole-5-carboxylic acid, 1-(1-phenylethyl)-, ethyl ester, (+-)-; Etomidate (USAN/INN); SBB066197; 1-(1-Phenylethyl)-1H-imidazole-5-carboxylic acid ethyl ester; CHEMBL23731; Etomidate; Prestwick1_001041; R 16659; Etomidatum [INN-Latin]; R 26490; HMS1612G10; C07522; Amidate, Etomidate; ethyl 3-(1-phenylethyl)imidazole-4-carboxylate; MolPort-000-917-569; 15301-65-2; HMS2093P17; LS-78232; D-Etomidate; BRN 0665833; D005045; CID36339; (+)-Etomidate; CPD000010931; Hypnomidate; R26490; 3-(1-Phenyl-ethyl)-3H-imidazole-4-carboxylic acid ethyl ester; Etomidatum; AC1Q64LP; SPBio_002901; Amidate (pharmaceutical); MLS000034952; Etomidic acid; BAS 01947657; (+)-Ethyl 1-(alpha-methylbenzyl)imidazole-5-carboxylate; (d)-Etomidate; AC1Q34BV; Radenarkon; Ethomidate; Ethnor; D00548; AKOS000548952; MLS001240191; (R)-(+)-1-(alpha-Methylbenzyl)imidazole-5-carboxylic acid ethyl ester; Amidate; AC1L1VLF; EINECS 251-385-9; DB00292; Imidazole-5-carboxylic acid, 1-(alpha-methylbenzyl)-, ethyl ester, (R)-(+)-; Etomidato; Amidate (TN); Prestwick2_001041; Etomidato [INN-Spanish]; SAM002548930; Absele; 33125-97-2; 1H-Imidazole-5-carboxylic acid, 1-(1-phenylethyl)-, ethyl ester, (R)-; 1-(1-Phenylethyl)-imidazole-5-carboxylic acid, ethyl ester; SMR000010931; 1H-Imidazole-5-carboxylic acid, 1-(1-phenylethyl)-, ethyl ester, (+)-; AC-5898	33125-97-2	36339	9725	TTDS00403	Gamma-aminobutyric acid receptor subunit alpha-1	GABA(A) receptor subunit alpha-1;GABRA1	P14867	2554	ENSG00000022355	antagonist
DAP000679	Halazepam	Schering 12041; EINECS 245-425-4; Halazepam [USAN:BAN:INN]; BRN 0898553; 7-chloro-5-phenyl-1-(2,2,2-trifluoroethyl)-3H-1,4-benzodiazepin-2-one; D00338; AC1L1M12; DEA No. 2762; nchembio747-comp33; 7-Chloro-1,3-dihydro-5-phenyl-1-(2,2,2-trifluoroethyl)-2H-1,4-benzodiazepin-2-one; C17H12ClF3N2O; Pacinone; LS-34273; 5-24-04-00303 (Beilstein Handbook Reference); Halazepam; 7-Chloro-5-phenyl-1-(2,2,2-trifluoroethyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one; MolPort-004-285-861; Halazepam (USAN/INN); AC1Q4K6Z; Halazepamum [INN-Latin]; Sch-12041; 2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-5-phenyl-1-(2,2,2-trifluoroethyl)-; UNII-320YC168LF; CHEMBL970; Paxipam (TN); 2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-7-chloro-5-phenyl-1-(2,2,2-trifluoroethyl)-; DB00801; ZINC00537811; Paxipam; Halazepamum; Sch 12041; CID31640; 23092-17-3; 7=Chlor-5-phenyl-1-(2,2,2-trifluorethyl)-1H-1,4-benzodiazepin-2(3H)-on	23092-17-3	31640	7847404	TTDS00403	Gamma-aminobutyric acid receptor subunit alpha-1	GABA(A) receptor subunit alpha-1;GABRA1	P14867	2554	ENSG00000022355	antagonist
DAP000675	Metharbital	2,4,6(1H,3H,5H)-Pyrimidinetrione, 5,5-diethyl-1-methyl-; 5-24-09-00144 (Beilstein Handbook Reference); 5,5-Diethyl-1-methylbarbituric acid; 5,5-diethyl-1-methylpyrimidine-2,4,6(1H,3H,5H)-trione; AC1L1HES; Gemonal; 5,5-Diethyl-1-methyl-2,4,6(1H,3H,5H)-pyrimidinetrione; C9H14N2O3; 5,5-diethyl-1-methyl-1,3-diazinane-2,4,6-trione; Methabarbital; Methabarbitone; Methylbarbital; AN 23; Metharbitalum [INN-Latin]; Metharbital [INN:JAN]; Endiemal; EINECS 200-011-2; BRN 0184688; Gemonil (TN); Metarbital [INN-Spanish]; D01382; N-Methylbarbital; metharbital; Metarbitale [DCIT]; Metabarbital; 1-Methylbarbital; Sch 412; Gemonit; Metarbitale; MolPort-004-920-887; ZINC05508997; DB00463; Metharbutal; LS-24178; Metarbital; Barbituric acid, 5,5-diethyl-1-methyl-; WLN: T6VMVNV FHJ D1 F2 F2; 50-11-3; NCGC00181148-01; NSC27156; Metharbitalum; Metharbital (JAN/INN); UNII-02OS7K758T; Endiemalum; NSC 27156; Metharbitone; Gemonil; CID4099; CHEMBL450	50-11-3	4099	583209	TTDS00403	Gamma-aminobutyric acid receptor subunit alpha-1	GABA(A) receptor subunit alpha-1;GABRA1	P14867	2554	ENSG00000022355	antagonist
DAP000685	Flumazenil	UPCMLD-DP137; Flumazenilo; Flumazenilo [Spanish]; Ethyl 8-fluoro-5-methyl-6-oxo-5,6-dihydro-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylate; Mazicon; F 6300; EU-0100506; AC1Q33UE; CID3373; NCGC00025116-02; Romazicon; PDSP2_001761; Flumazenilum [Latin]; ZINC00001464; Ethyl 8-fluoro-5,6-dihydro-5-methyl-6-oxo-4H-imidazo(1,5-a)(1,4)benzodiazepine-3-carboxylate; NCGC00015439-07; 4H-Imidazo(1,5-a)(1,4)benzodiazepine-3-carboxylic acid, 8-fluoro-5,6-dihydro-5-methyl-6-oxo-, ethyl ester; SBB063113; PDSP1_001778; Flumazenil [USAN:BAN:INN]; ethyl 8-fluoro-5-methyl-6-oxo-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylate; nchembio747-comp37; CPD000058450; Ro15-1788; NCGC00025116-01; Flumazepil, Ro 15-1788, Anexate, Lanexat, Mazicon, Roma,Flumazenil; NCGC00025116-04; Ro 151788; SAM001246763; C15H14FN3O3; S1332_Selleck; Ethyl 8-fluoro-5-methyl-5,6-dihydro-6-oxo-4H-imidazo(1,5-a)(1,4)benzodiazepine-3-carboxylate; AC1L1FSE; NCGC00015439-03; DB01205; BRN 4763661; MolPort-003-666-855; [3H]Ro15-1788; F6300_SIGMA; Flumazepil; Hoffman La Roche Brand of Flumazenil; Flumazenilum; MLS000028850; I01-0379; UPCMLD-DP137:001; NCGC00025116-05; HMS2089B15; MLS000759529; HMS2051D17; UNII-40P7XK9392; 8-Fluoro-5,6-dihydro-5-methyl-6-oxo-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylic acid ethyl ester; Lopac0_000506; 78755-81-4; Biomol-NT_000285; Ro 15-1788; Ro-15-1788; Lopac-F-6300; BIDD:GT0766; C07825; D005442; AC-6846; BRD-K98769987-001-01-3; CHEMBL407; LS-77778; Lanexat; Tocris-1328; RO-151788; CHEBI:5103; flumazenil; BPBio1_001190; Ro 15 1788; Roche Brand of Flumazenil; Romazicon (TN); NCGC00025116-03; MLS001076354; Flumazenil (JAN/USP/INN); Hoffman-La Roche Brand of Flumazenil; Ro-?15-1788; SMR000058450; NCGC00015439-01; TL8005362; D00697; Anexate	78755-81-4	3373	10027	TTDS00403	Gamma-aminobutyric acid receptor subunit alpha-1	GABA(A) receptor subunit alpha-1;GABRA1	P14867	2554	ENSG00000022355	antagonist
DAP001350	Barbital	Barbital [INN:JAN]; NSC 31352; Dormonal; AI3-02727; LS-24148; Barbital (JP15/INN); Uronal; Barbitalum; CHEMBL444; MolPort-003-890-764; 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5,5-diethyl-; DEBA; CHEBI:31252; Diemal; Veroletten; Oprea1_497227; Barbitone; DB01483; Diemalum; Barbital Faes Brand; Hypnogene; Dormileno; Oprea1_012884; ZINC13545632; Veronal; Diethylmalonylurea; D01740; 7979P; Barbitale; Kyselina 5,5-diethylbarbiturova; barbital; InChI=1/C8H12N2O3/c1-3-8(4-2)5(11)9-7(13)10-6(8)12/h3-4H2,1-2H3,(H2,9,10,11,12,13; Barbituric acid, 5,5-diethyl-; BRN 0163999; B0375_SIGMA; Faes Brand of Barbital; Diethylbarbitone; Verolettin; Barbitonum; 57-44-3; Barbital (VAN); NCGC00159419-03; 5,5-Diethylbarbituric acid; Ethylbarbital; Malonal; CID2294; Barbital (TN); 5-24-09-00137 (Beilstein Handbook Reference); D001462; Barbitalum [INN-Latin]; Vesperal; 5,5-diethyl-1,3-diazinane-2,4,6-trione; NCGC00159419-02; 31995_SIGMA; Sedeval; EINECS 200-331-2; Barbitale [DCIT]; 31995_FLUKA; 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5,5-diethyl- (9CI); 5,5-Diethyl-2,4,6(1H,3H,5H)-pyrimidinetrione; CCRIS 7420; Diethylbarbituric acid; NSC31352; Kyselina 5,5-diethylbarbiturova [Czech]; Medinal; 5,5-diethylpyrimidine-2,4,6(1H,3H,5H)-trione; MolPort-001-783-065; WLN: T6VMVMV FHJ F2 F2; AC1L1DCX; C8H12N2O3; DEA No. 2145; UNII-5WZ53ENE2P	57-44-3	2294	7848803	TTDS00403	Gamma-aminobutyric acid receptor subunit alpha-1	GABA(A) receptor subunit alpha-1;GABRA1	P14867	2554	ENSG00000022355	antagonist
DAP000689	Prazepam	2955-38-6; MolPort-003-959-240; 2H-1,4-Benzodiazepin-2-one, 7-chloro-1-(cyclopropylmethyl)-1,3-dihydro-5-phenyl-; Prazene; W-4020; 7-chloro-1-(cyclopropylmethyl)-5-phenyl-3H-1,4-benzodiazepin-2-one; 7-Chloro-1-(cyclopropylmethyl)-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one; Trepidan; 7-Chloro-1-cyclopropylmethyl-5-phenyl-1H-1,4-benzodiazepin-2(3H)-one; Prazepamum; D00470; NSC277179; Verstran; 7-Chloro-1-(cyclopropylmethyl)-1,3-dihydro-5-phenyl-2H-1,4-benzodiazepin-2-one; Settima; Centrax; Prazepam [USAN:INN:BAN:JAN]; NCGC00168256-01; W 4020; DEA No. 2764; C07366; Centrax (TN); UNII-Q30VCC064M; Prazeene; Sedapran; 2H-1,4-BENZODIAZEPIN-2-ONE, 1,3-DIHYDRO-7-CHLORO-1-(CYCLOPROPYLMETHYL)-5-PHENYL-; Lysanxia; BRN 0895797; K-373; AC1L1J6K; EINECS 220-975-8; P3654_SIGMA; DB01588; CHEMBL969; CID4890; NSC 277179; WLN: T67 GNV JN IHJ CG KR& G1- AL3TJ; Prazepam (JP15/USAN/INN); LS-7667; Demetrin; ZINC00001971; Prazepamum [INN-Latin]; prazepam; C19H17ClN2O	2955-38-6	4890	10468346	TTDS00403	Gamma-aminobutyric acid receptor subunit alpha-1	GABA(A) receptor subunit alpha-1;GABRA1	P14867	2554	ENSG00000022355	antagonist
DAP000163	Ethchlorvynol	Ethchlorvinol; DEA No. 2540; Placidyl (TN); LS-102223; Ethclorvynol; Aethyl-chlorvynol; Ethchlorvinyl; Ethchlorvynol (JAN/USP/INN); Serenesil; HSDB 3079; A 71; Roeridorm; AR-1I7766; 3-(beta-Chlorovinyl)-1-pentyn-3-ol; 5-Chloro-3-ethylpent-1-yn-4-en-3-ol; beta-Chlorvinyl ethyl ethynyl carbinol; Ethchlorovynol; AC1NQXZT; Etchlorvinolo; Placidil; Serenil; Alvinol; Etclorvinol; D00704; Serensil; Ethyl beta-chlorovinyl ethynyl carbinol; Ethychlorvynol; 113-18-8; beta-Chlorovinyl ethyl ethynyl carbinol; CHEMBL591; 1-Chloro-3-ethyl-1-penten-4-yn-3-ol; Ethochlorvynol; MolPort-004-285-854; 1-Penten-4-yn-3-ol, 1-chloro-3-ethyl-; Normosan; DB00189; CHEBI:4882; Ethchlorvynolum; NSC 30372; Ethchlorvynolum [INN-Latin]; UNII-6EIM3851UZ; C7H9ClO; Placidyl; C07833; Nromoson; ethchlorvynol; Normoson; Arvynol; CID5281077; BRN 1702245; 1-chloro-3-ethylpent-1-en-4-yn-3-ol; Ethchlorvynol [USAN:INN:BAN]; AC1Q3HC3; (E)-1-chloro-3-ethylpent-1-en-4-yn-3-ol; Etclorvinol [INN-Spanish]; AI3-23721; 1-Chloro-3-ethylpent-1-4-yn-3-ol; Normonson; Nostel; Serensiloline	113-18-8	3281	10035	TTDS00403	Gamma-aminobutyric acid receptor subunit alpha-1	GABA(A) receptor subunit alpha-1;GABRA1	P14867	2554	ENSG00000022355	antagonist
DAP000671	Pentobarbital	Pentabarbitone; UNII-I4744080IR; DivK1c_000992; AC1L1IUE; D00499; Pentobarbitalum; Pentobarbital [USP:INN]; Spectrum5_001705; BSPBio_003305; 5-24-09-00168 (Beilstein Handbook Reference); Pentobarbital (USP/INN); Pentabarbital; Mebubarbital; Pentobarbital suppository dosage form; Pentobarbitale [DCIT]; Spectrum4_000574; HSDB 3151; Pentobarbitone; Etaminal; 5-Ethyl-5-(1-methylbutyl)malonylurea; (+-)-5-Ethyl-5-(1-methylbutyl)barbituric acid; KBio2_004834; KBio3_002807; Spectrum2_001991; CHEMBL448; 57-33-0 (mono-hydrochloride salt); Mebumal; KBioSS_002267; Neodorm (new); Oprea1_143902; Pentobarbital (VAN); Spectrum3_001783; Pentobarbiturate; KBio2_007402; HMS2094E21; LS-24385; SPECTRUM1900006; Ethaminal; Pentobarbitale; NINDS_000992; WLN: T6VMVMV FHJ FY3&1 F2; 5-ethyl-5-(pentan-2-yl)pyrimidine-2,4,6(1H,3H,5H)-trione; 5-Ethyl-5-(sec-pentyl)barbituric acid; NCGC00096074-01; MolPort-001-785-697; CCRIS 7089; SPBio_002201; C07422; 76-74-4; KBioGR_001008; Barbituric acid, 5-ethyl-5-(1-methylbutyl)-; CHEBI:7983; Nebralin; DEA No. 2270; Nembutal (TN); 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-5-(1-methylbutyl)-, (+-)-; Pentobarbitalum [INN-Latin]; Neodorm; 5-Ethyl-5-(1-methylbutyl)barbituric acid; Spectrum_001783; 5-ethyl-2-hydroxy-5-(1-methylbutyl)pyrimidine-4,6(1H,5H)-dione; IDI1_000992; Nembutal (VAN); AKOS000277861; Aethaminalum; MolPort-003-666-760; NSC 28708; KBio1_000992; Dorsital; HMS503G05; 5-ethyl-5-pentan-2-yl-1,3-diazinane-2,4,6-trione; Pentobarbital calcium; Ethyl-propylmethylcarbinylbarbituric acid; Pentobarbituric acid; DB00312; Neodorm (VAN); Rivadorm; EINECS 200-983-8; 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-5-(1-methylbutyl)-; Pentobarbital, Monosodium Salt; BRN 0087067; pentobarbital; KBio2_002266; AC1Q2UJM; Barbituric acid, 5-ethyl-5-(2-pentyl)-; NCGC00096074-02; Oprea1_775730; CID4737; 5-Ethyl-5-(1-methylbutyl)-2,4,6(1H,3H,5H)-pyrimidinetrione; Pentobarbitone (VAN); NSC28708; Nembutal	76-74-4	4737	9626	TTDS00403	Gamma-aminobutyric acid receptor subunit alpha-1	GABA(A) receptor subunit alpha-1;GABRA1	P14867	2554	ENSG00000022355	antagonist
DAP000691	Nitrazepam	Mogadon; Bio-0690; Allphar Brand of Nitrazepam; Benzalin (TN); Nelmat; S 2000; Epibenzalin; Wernigerode Brand of Nitrazepam; Relact; Megadon; InChI=1/C15H11N3O3/c19-14-9-16-15(10-4-2-1-3-5-10)12-8-11(18(20)21)6-7-13(12)17-14/h1-8H,9H2,(H,17,19); Mogadan; 1,3-Dihydro-7-nitro-5-phenyl-2H-1,4-benzodiazepin-2-one; CCRIS 1931; Nitrazepam-neuraxpharm; Ibrovek; STK806322; Ipersed; 2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-7-nitro-5-phenyl-; NSC58775; PDSP1_000120; Magadon; neuraxpharm Brand of Nitrazepam; Somnite; NCGC00159358-02; HMS2051F19; Trazenin; Somnibel; Somnased; Alter Brand of Nitrazepam; Dormalon; Aliud Brand of Nitrazepam; Serenade; N-Desmethylnimetazepam; Ro 4-5360; Scheurich Brand of Nitrazepam; Nitrazepam-5; LA 1 (VAN); Mitidin; Remnos; MolPort-000-302-259; C15H11N3O3; KJONHKAYOJNZEC-UHFFFAOYSA-; Neuchlonic; Sonebon Tofraniln A; Nitrenpax; Cerson; SMR000058302; Apodorm; Gerson; MolPort-000-699-491; Sonebon; CHEMBL13209; D00531; Dormo-Puren; 146-22-5; Desitin Brand of Nitrazepam; Noctesed; 7-nitro-5-phenyl-1,3-dihydro-1,4-benzodiazepin-2-one; Calsamin; 5-24-04-00344 (Beilstein Handbook Reference); Ro 53-60; ct-Arzneimittel Brand of Nitrazepam; Sandoz nitrazepam; DB01595; C07487; Neozepam; Norgine Brand of Nitrazepam; Calsmin; DDSA Brand of Nitrazepam; LA 1; Nitrazepam (TN); Ro 5-3059; Hipnax; D009567; Nitrazepamum; Dormicum (anticonvulsant); Rhoxal-nitrazepam; nchembio747-comp31; ChemDiv1_022312; NSC-58775; Apo-nitrazepam tablets BP; Dermatech Brand of Nitrazepam; Eatan N; Pfleger Brand of Nitrazepam; Nitrazepam [USAN:INN:BAN:JAN]; Nitrazepam (JP15/USAN/INN); NSC 58775; Unisomnia; DEA No. 2834; Benzalin; Taurus Brand of Nitrazepam; Epinelbon; EINECS 205-665-2; Pacisyn; Nitrazep; Imesont; Dumolid; CPD000058302; 2,3-Dihydro-7-nitro-5-phenyl-1H-1,4-benzodiazepin-2-on; Imadorm; Persopit; Eatan; LS-34311; Pelson; Mogadone; HMS650G04; nitrazepam; ZINC04311748; Nelbon; ISOPROPYLACETATE/NITRAZEPAM; Protea Brand of Nitrazepam; Nitrazepam-10; 7-Nitro-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one; Nitravet; MLS001304053; United Drug Brand of Nitrazepam; Dormin-5; SAM001246711; 7-Nitro-1,3-dihydro-5-phenyl-2H-1,4-benzodiazepin-2-one; CHEBI:111745; CID4506; Alphapharma Brand of Nitrazepam; CSP Brand of Nitrazepam; Eunoktin; Imeson; AKOS002254707; 1, 3-Dihydro-7-nitro-5-phenyl-2H-1,4-benzodiazepin-2-one; Alodorm; Rhoxalpharma Brand of Nitrazepam; Nitrazepam AL; I06-0805; Radedorm; PDSP2_000120; Hipsal; AC1Q1XWD; AC-4537; Nitrados; Paxisyn; BRN 0757185; Nitrempax; Oprea1_476234; ICN Brand of Nitrazepam; Nitrodiazepam; Nitrazepamum [INN-Latin]; Eunoctin; Novanox; Alpharma Brand of Nitrazepam; Somitran; Dormicum Brand of Nitrazepam; WLN: T67 GMV JN IHJ CNW KR; Nitrazadon; 7-Nitro-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-2-one; N3889_SIGMA; Surem; AC1L1IBJ; Sonnolin	146-22-5	4506	10470563	TTDS00403	Gamma-aminobutyric acid receptor subunit alpha-1	GABA(A) receptor subunit alpha-1;GABRA1	P14867	2554	ENSG00000022355	antagonist
DPR000178	ISIS-GCCR	N/A	N/A	N/A	N/A	TTDR01436	mRNA of glucocorticoid receptor	mRNA of GR;mRNA of Nuclear receptor subfamily 3 group C member 1;mRNA of NR3C1;mRNA of GRL	P04150	2908	ENSG00000113580	antisense
DPR000119	VT-111	N/A	N/A	N/A	N/A	TTDR01271	Serine protease	N/A	N/A	N/A	N/A	inhibitor
DPR000083	ONO-5046	sodium 2-[[2-[[4-(2,2-dimethylpropanoyloxy)phenyl]sulfonylamino]benzoyl]amino]acetate tetrahydrate; LY 544349; 201677-61-4; Sivelestat sodium hydrate (JAN); 127373-66-4; MolPort-005-935-338; UNII-DWI62G0P59; CID107706; Sivelestat; CHEBI:222423; Elastase Inhibitor IV; CID158792; C20H22N2O7S; Glycine, N-(2-(((4-(2,2-dimethyl-1-oxopropoxy)phenyl)sulfonyl)amino)benzoyl)-; LY544349 Sodium Hydrate; EI-546; Elaspol (TN); Sivelestat (USAN/INN); N-(o-(p-Pivaloyloxybenzene)sulfonylaminobenzoyl)glycine; UNII-737RR8Y409; Sivelestat sodium (USAN); Ono 5046; CHEMBL76688; AC1L4KMF; D01918; AC-1291; EI 546; Sivelestat sodium; LS-172679; Elaspol; IN1349; D03788; Sodium  ((2-(((4-((2,2-dimethylpropanoyl)oxy)phenyl)sulfonyl)amino)benzoyl)amino)acetate  tetrahydrate; o-(p-Hydroxybenzenesulfonamido)hippuric acid, pivalate (ester); N-(2-(4-(2,2-Dimethylpropionyloxy)phenylsulfonylamino)benzoyl)aminoacetic acid; Ono-5046; ONO5046; 2-[[2-[[4-(2,2-dimethylpropanoyloxy)phenyl]sulfonylamino]benzoyl]amino]acetic acid; ONO-5046.Na; sivelestat sodium hydrate; Glycine, N-(2-(((4-(2,2-dimethyl-1-oxopropoxy)phenyl)sulfonyl)amino)benzoyl)-, monosodium salt, tetrahydrate; AC1L32LG; Sivelestat [USAN]	201677-61-4	131682	46519220	TTDR01271	Serine protease	N/A	N/A	N/A	N/A	inhibitor
DCL001169	Canagliflozin	N/A	N/A	N/A	N/A	TTDC00158	Sodium/glucose cotransporter 2	Low affinity sodium-glucose cotransporter;Na(+)/glucose cotransporter 2;SGLT2;Sodium dependent glucose transporter 2	P31639	6524	ENSG00000140675	blocker
DCL000619	Remogliflozin etabonate	442201-24-3; KGT-1681; CID9871420; CID 9871420; GSK-189075; remogliflozin etabonate; GSK-189075A	442201-24-3	N/A	N/A	TTDC00158	Sodium/glucose cotransporter 2	Low affinity sodium-glucose cotransporter;Na(+)/glucose cotransporter 2;SGLT2;Sodium dependent glucose transporter 2	P31639	6524	ENSG00000140675	blocker
DCL000549	ISIS-5GLT2rx	N/A	72702-95-5	5278	47364952	TTDC00158	Sodium/glucose cotransporter 2	Low affinity sodium-glucose cotransporter;Na(+)/glucose cotransporter 2;SGLT2;Sodium dependent glucose transporter 2	P31639	6524	ENSG00000140675	blocker
DCL000101	Dapagliflozin	AKOS005145763; 2-(3-(4-Ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol; Dapagliflozin (INN/USAN); Dapagliflozin; D-Glucitol, 1,5-anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-, (1S)-; D08897; BMS-512148; CID9887712; BMS-512148, Dapagliflozin; 461432-26-8; D-Glucitol, 1,5-anhydro-1-C-(4-chloro-3-((4-ethoxyphenyl)methyl)phenyl)-, (1S)-; BMS 512148; CHEMBL429910; S1548_Selleck	N/A	9887712	49688954	TTDC00158	Sodium/glucose cotransporter 2	Low affinity sodium-glucose cotransporter;Na(+)/glucose cotransporter 2;SGLT2;Sodium dependent glucose transporter 2	P31639	6524	ENSG00000140675	blocker
DAP000039	Lamotrigine	Desitin Brand of Lamotrigine; CHEBI:138727; EINECS 281-901-8; Faes Brand of Lamotrigine; Juste Brand of Lamotrigine; Lamitor; HMS2093P21; Lamictal ODT; NCGC00015605-02; Lopac-L-3791; BW-430C; GW 273293; D00354; ZINC00013156; NCGC00015605-08; CHEMBL741; CID3878; Crisomet; EUR-1048; 6-(2,3-Dichlorophenyl)-1,2,4-triazine-3,5-diyldiamine; EU-0100688; Lamictin; Lamotrigina; lamotrigine; STK628377; Tocris-1611; Lamictal Cd; L3791_SIGMA; 84057-84-1; NCGC00015605-01; 3,5-Diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine; SAM001246697; BIDD:GT0794; HMS2051C10; Lamotrigina [Spanish]; NCGC00022936-05; L 3791; GI 267119X; NCGC00015605-06; C047781; UNII-U3H27498KS; Lamiktal; Lamotrigine [USAN:INN:BAN]; BW 430C; Lamictal XR; Lamotriginum [Latin]; CPD000058464; 3,5-Diamino-6-(2,3-dichlorophenyl)-as-triazine; HSDB 7526; MolPort-003-666-744; CHEBI:6367; Lamotriginum; MLS000069685; AC1L1GWT; Lamotrigine (JAN/USAN/INN); Lamictal (TN); DB00555; Glaxo Wellcome Brand of Lamotrigine; Bio-0056; MLS001077325; GI 267119X; 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine; SMP2_000303; AC-10298; Labileno; 3,5-diamino-6-(2,3-dichlorophenyl)- as -triazine; NCGC00022936-02; Lopac0_000688; NSC746307; GlaxoSmithKline Brand of Lamotrigine; MLS000759486; HMS2089M08; Lamictal; LS-155249; SMR000058464; 1,2,4-Triazine-3,5-diamine, 6-(2,3-dichlorophenyl)-; NCGC00022936-04; 6-(2,3-Dichlorophenyl)-1,2,4-triazine-3,5-diamine	84057-84-1	3878	7847420	TTDS00156	Voltage-gated sodium channel	Voltage-sensitive sodium channel	Q8NDX3	N/A	N/A	blocker
DAP000121	Lidocaine	KBio1_000174; LS-805; UNII-98PI200987; CPD000058189; NSC 40030; Xylocaine (TN); AC-10282; BSPBio_000179; Rucaina; KBioGR_000599; DB00281; AC1Q2Z7J; MLS001074177; Lidoject-2; LQZ; Xylocaine Test Dose; Lopac0_000669; Duncaine; HMS548M19; Lidocaine [USAN:INN:JAN]; Prestwick1_000050; SPBio_001525; lidocaine; Lidocaine (VAN); nchembio.65-comp16; I01-2704; After Burn Double Strength Gel; KBio2_001598; NCGC00022176-06; AB00053581; Dilocaine; Octocaine; Lidocaine Monohydrochloride; L7757_SIGMA; D00358; Xylocitin; NINDS_000174; Dalcaine; Octocaine-100; KBio2_002647; 137-58-6; Leostesin; 4-12-00-02538 (Beilstein Handbook Reference); Lidocaina [INN-Spanish]; Octocaine-50; CDS1_000283; Acetamide, 2-(diethylamino)-N-(2,6-dimethylphenyl)-; Xylocain; Xilocaina [Italian]; CAS-73-78-9; NSC40030; BRN 2215784; Spectrum_001118; BRD-K52662033-001-02-6; Lida-Mantle; Isicaina; SAM001247018; ARONIS23855; MolPort-001-783-478; Bio2_000079; NCGC00015611-02; CHEBI:6456; Alphacaine; Prestwick0_000050; NCGC00022176-07; Lidocaine Hydrocarbonate; Lanabiotic; Bio1_000868; KBio3_000158; Spectrum4_000070; Xylocaine; KBio2_005215; HMS2051C21; 2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide; BPBio1_000197; KBioSS_001598; Xylocaine CO2; Lignocainum; WLN: 2N2 & 1VMR B1 F1; 2',6'-Acetoxylidide, 2-(diethylamino)-; alfa-Dietilamino-2,6-dimetilacetanilide; 6108-05-0 (mono-hydrochloride, mono-hydrate); Xylocaine-Mpf; L1026_SIGMA; Prestwick3_000050; Maricaine; Solcain; NCGC00015611-03; KBioSS_000079; Lidocaina; 2-(Diethylamino)-2',6'-acetoxylidide; NCGC00022176-05; BIDD:GT0342; KBio2_006734; STK552033; KBio2_004166; After Burn Double Strength Spray; IDI1_000174; Lidocainum; IDI1_033829; L0156; After Burn Spray; Xylocaine-Mpf with Glucose; CID3676; Xilocaina; alpha-Diethylamino-2,6-dimethylacetanilide; CHEMBL79; alfa-Dietilamino-2,6-dimetilacetanilide [Italian]; HMS1989D21; Lidocaine Carbonate; 2-Diethylamino-N-(2,6-dimethylphenyl)acetamide; Zilactin-L; .alpha.-Diethylaminoaceto-2,6-xylidide; Zingo; KBioGR_000079; Solarcaine aloe extra burn relief cream; Dentipatch (TN); Xyloneural (free base); Rocephin Kit; After Burn Gel; Isicaine; BRD-K52662033-003-05-5; BSPBio_003004; SMR000058189; Spectrum3_001392; .omega.-Diethylamino-2,6-dimethylacetanilide; C07073; KBio3_002224; Bio1_001357; Diethylaminoaceto-2,6-xylidide; Spectrum2_001343; Xylocaine Dental Ointment; Maybridge1_002571; Xylotox; NCGC00022176-08; BSPBio_001359; Esracaine; NCGC00015611-04; .alpha.-(Diethylamino)-2,6-acetoxylidide; EINECS 205-302-8; Bio1_000379; N-(2,6-dimethylphenyl)-N(2),N(2)-diethylglycinamide; 73-78-9 (mono-hydrochloride); Xylocaine 5% Spinal; Xylocaine Viscous; .alpha.-Diethylamino-2,6-dimethylacetanilide; LIDOCAINE (73-58-6 (MONOHYDROCHLORIDE); 6108-05-0 (MONOHYDROCHLORIDE MONOHYDRATE)); FT-0082378; ELA-Max; Bio-0767; Xylocard; HMS1791D21; Cuivasil; Jetocaine; NCGC00015611-14; Spectrum5_001549; Gravocain; Xycaine; Xylestesin; KBio3_000157; MLS000069724; Prestwick2_000050; Xylesthesin; AC1L1GGQ; S1357_Selleck; Emla Cream; NCGC00022176-09; C14H22N2O; Lidoderm; Anestacon; EMBOLEX; L-Caine; SPBio_002100; Bio2_000559; Lingocaine; Xilina; Dentipatch; DivK1c_000174; Remicaine; Lidocaine (JP15/USP/INN); Lignocaine; Lidocaton; N-(2,6-dimethylphenyl)-N~2~,N~2~-diethylglycinamide; DivK1c_001323; DermaFlex; 2-Diethylamino-N-(2,6-dimethyl-phenyl)-acetamide; HMS2089E15; Lopac-L-5647; HSDB 3350; MLS000758263; Norwood Sunburn Spray; LIDOPEN; Lidocainum [INN-Latin]; KBio2_000079; AKOS001026768; Cappicaine; NCGC00015611-01; Xylocaine Endotracheal; Cito optadren; Lidoject-1; Xllina; Anestacon Jelly	137-58-6	3676	151886	TTDS00156	Voltage-gated sodium channel	Voltage-sensitive sodium channel	Q8NDX3	N/A	N/A	blocker
DAP000527	Riluzole	RP-54274; NCGC00015882-03; BB_SC-4839; NCGC00015882-11; EU-0101064; I01-2084; Bio1_000416; 2-Benzothiazolamine, 6-(trifluoromethoxy)-; S1614_Selleck; R-116; SPBio_000599; BENZOTHIAZOLE, 2-AMINO-6-TRIFLUOROMETHOXY-; ZINC00006481; SMR000058231; UNII-7LJ087RS6F; Lopac0_001064; 6-(trifluoromethoxy)-1,3-benzothiazol-2-amine; ZERO/001785; Rilutek; BRD-K21283037-003-03-9; 6-(trifluoromethoxy)benzo[d]thiazol-2-amine; Spectrum2_000550; LS-40688; 1744-22-5; 2-Amino-6-trifluoro- methoxybenzothiazole; HMS2094G07; HMS2089O19; 2-amino-6-(trifluoromethoxyl)benzothiazole; Prestwick2_000167; AC-730; R116_SIGMA; SPBio_001954; AKOS000265071; Bio1_001394; NCGC00023141-04; AC1Q530H; 6-Trifluoromethoxy-benzothiazol-2-ylamine; Amino-2 trifluoromethoxy-6 benzothiazole; Tocris-0768; AC1L1JJL; MLS000069369; 2-Amino-6-(trifluoromethoxy)benzothiazole; CID5070; BPBio1_000837; FT-0082997; NCGC00015882-01; Prestwick0_000167; Lopac-R-116; NCGC00023141-06; BF-37; Prestwick3_000167; Riluzol [INN-Spanish]; Amino-2 trifluoromethoxy-6 benzothiazole [French]; Riluzole [USAN:INN]; NCGC00023141-05; Biomol-NT_000245; STK503686; PK-26124, RP-54274, Rilutek, Riluzole; C07937; 2-amino-6-(trifluoromethoxy)benzo[d]thiazole; 2-amino-6-trifluoromethoxybenzothiazole; Bio1_000905; BIDD:GT0055; MolPort-000-151-262; BSPBio_000033; NCGC00015882-02; Riluzolum; BPBio1_000037; ALBB-006046; Riluzole HCl; CHEMBL744; DB00740; NCGC00023141-02; riluzole; 2-Amino-6-(trifluoromethoxy)-benzothiazole; Prestwick-03A08; 2-amino-6-(trifluoromethoxy)-1,3-benzothiazole; Rilutek (TN); Prestwick1_000167; 6-trifluoromethoxybenzothiazole-2-yl-amine; HMS1773G08; NCGC00015882-07; Riluzole (JAN/USAN/INN); Riluzolum [INN-Latin]; RP 54274; PK-26124; Riluzol; D00775; BRD-K21283037-001-02-5; C8H5F3N2OS	1744-22-5	5070	7847840	TTDS00156	Voltage-gated sodium channel	Voltage-sensitive sodium channel	Q8NDX3	N/A	N/A	blocker
DCL000837	HP-184	1H-Indol-1-amine, N-(3-fluoro-4-pyridinyl)-3-methyl-N-propyl-, monohydrochloride; 119229-64-0; N-(3-fluoropyridin-4-yl)-3-methyl-N-propylindol-1-amine; EN002124; HP-184; N-(3-Fluoro-4-pyridinyl)-3-methyl-N-propyl-1H-indol-1-amine; 119229-65-1; Nerispirdine; 1H-Indol-1-amine, N-(3-fluoro-4-pyridinyl)-3-methyl-N-propyl-; CID3081185; UNII-G7M7YWO6CG; Nerispirdine hydrochloride; AC1MIWGX; HP 184; N-(n-Propyl)-3-fluoro-4-pyridinyl-1H-3-methylindol-1-amine hydrochloride	119229-65-1	10302451	3882236	TTDS00156	Voltage-gated sodium channel	Voltage-sensitive sodium channel	Q8NDX3	N/A	N/A	blocker
DAP000528	Oxcarbazepine	HMS2090F13; D00533; BIDD:GT0078; MLS000759520; KIN-493; 5-oxo-6H-benzo[b][1]benzazepine-11-carboxamide; SMR000048684; UNII-VZI5B1W380; Oxcarbazepime; Spectrum4_000634; 10,11-Dihydro-10-oxo-5H-dibenz(b,f)azepine-5-carboxamide; AC1L1RCU; Spectrum5_001869; Epliga; 10,11-Dihydro-10-oxo-5H-debenz(b,f)azepine-5-carboxamide; Oxacarbazepine; AB1004555; KBio3_002677; C07492; EINECS 249-188-8; Trileptal; I06-0072; HSDB 7524; CPD000048684; KBio2_004723; MolPort-001-685-316; AC1Q6NA8; S1391_Selleck; 5H-Dibenz[b,f]azepine-5-carboxamide, 10,11-dihydro-10-oxo-; SPN-804; LS-60365; 5H-Dibenz(b,f)azepine-5-carboxamide, 10,11-dihydro-10-oxo-; Oxcarbazepinum; GP-47680; CHEMBL1068; Oxcarbazepina [INN-Spanish]; NCGC00065934-02; KBio2_007291; Oxcarbazepine [INN]; AC-3483; Oxcarbazepina; 10,11-Dihydro-10-oxo-5h-dibenz[b,f]azepine-5-carboxamide; Oxacarbazepine; NCGC00065934-03; Epilexter; 10,11-Dihydro-10-oxo-5H-dibenz[b,f]azepine-5-carboxamide; 10-Oxo-10,11-dihydro-5H-dibenzo[b,f]azepine-5-carboxamide; DB00776; BSPBio_003457; Spectrum3_001669; O3764_SIGMA; SPECTRUM1504243; Trileptal (TN); Novartis brand of oxcarbazepine; C036006; KBio2_002155; Oxcarbazepine (USAN/INN); KBioGR_001248; SAM001246754; STK594696; NCGC00065934-04; Spectrum_001675; GP 47680; CID34312; MLS001201742; ZINC00004724; MLS000084586; OXCARBAZEPINE; Spectrum2_000483; Oxcarbamazepine; Desitin brand of oxcarbazepine; 10,11-Dihydro-10-oxo-5H-dibenzo[b,f]azepine-5-carboxamide; HMS2051O04; 28721-07-5; Oxcarbazepinum [INN-Latin]; HMS2093E10; HMS1922H17; O0363; Bio-0527; KBioSS_002155; Timox; SPBio_000345	28721-07-5	34312	9695	TTDS00156	Voltage-gated sodium channel	Voltage-sensitive sodium channel	Q8NDX3	N/A	N/A	blocker
DCL000858	Lacosamide	AKOS005146274; SPM-929; Lacosamide; LS-185541; Propanamide, 2-(acetylamino)-3-methoxy-N-(phenylmethyl)-, (2R)-; AC1L560M; Erlosamide; Lacosamide [USAN]; D07299; SPM-927; 175481-36-4; ZINC00007673; S1253_Selleck; CHEBI:188739; SPM 927; Vimpat; Erlosamide, Vimpat, Lacosamide; CHEMBL58323; Erlosamide [INN]; I01-7424; (2R)-2-acetamido-N-benzyl-3-methoxypropanamide; ( )-(2R)-2-(acetylamino)-N-benzyl-3-methoxypropanamide; Harkoseride; CID219078; Lacosamide (USAN/INN); (2R)-2-(Acetylamino)-N-benzyl-3-methoxypropanamide; 2-(Acetylamino)-3-methoxy-N-(phenylmethyl)propanamide, (2R)-; ADD 234037; ADD-234037	175481-36-4	219078	12015335	TTDS00156	Voltage-gated sodium channel	Voltage-sensitive sodium channel	Q8NDX3	N/A	N/A	N/A
DAP000868	Oxtriphylline	Cholini theophyllinas [INN-Latin]; Theophyllinate de choline; Theophylline cholinate; 1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl-, ion(1-), 2-hydroxy-N,N,N-trimethylethanaminium; Theophylline, compd. with choline; Theophylline salt of choline; Zy 15061; OXTRIPHYLLINE; 13930-27-3; AC1L2GKJ; Cholini theophyllinas; Oxtriphylline pediatric; (2-Hydroxyethyl)trimethylammonium compound with theophylline; Colina teofillinato [DCIT]; 56553-57-2; Teofilinato de colina [INN-Spanish]; Choline, compd. with theophylline (1:1); 146-71-4; Filoral; Sabidal; Cholinophyllin; 1,3-dimethyl-7H-purine-2,6-dione; 2-hydroxyethyl(trimethyl)azanium; CID20585; Choline, hydroxide, compd. with theophylline (1:1); Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with 3,7-dihydro-1,3-dimethylpurine-2,6-dione; Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with 3,7-dihydro-1,3-dimethyl-1H-purine-2,6-dione (1:1); UNII-3K045XR58X; Theophyllinate de choline [INN-French]; Choline salt with theophylline (1:1); Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with 3,7-dihydro-1,3-dimethyl-1H-purine-2,6-dione; Colina teofillinato; LS-53330; Cholinophylline; EINECS 224-798-7; LS-185028; Soliphylline; Teofilinato de colina; Teofilcolina; Choledyl SA 400; Choline theophylline salt; Theoxylline; Choledyl; Oxtriphylline [USAN]; Oxtrimethylline; Teokolin; Cholegyl	4499-40-5	656652	7849079	TTDS00499	Type IV phosphodiesterase	DPDE3;PDE43;PDE4D	Q08499	5144	ENSG00000113448	inhibitor
DCL000362	CEP-7055	3-{9-oxo-13-[(propan-2-yloxy)methyl]-4,9,10,11-tetrahydro-3h-indeno[2,1-a]pyrrolo[3,4-c]carbazol-3-yl}propyl n,n-dimethylglycinate; AR-1F1464; CID216386; AC1L50N0; CEP-7055; LS-181899; AC1Q670P; Glycine, N,N-dimethyl-, 3-(5,6,7,13-tetrahydro-9-((1-methylethoxy)methyl)-5-oxo-12H-indeno(2,1-a)pyrrolo(3,4-c)carbazol-12-yl)propyl ester	133364-63-3	444266	789567	TTDC00161	Angiopoietin 1 receptor	CD202b antigen;Endothelial Cell-Specific Receptor TIE-2;P140 TEK;Tunica interna endothelial cell kinase;Tyrosine-protein kinase receptor TEK;Tyrosine-protein kinase receptor TIE-2	Q02763	7010	ENSG00000120156	inhibitor
DCL000753	Cizolirtine	CID132412; CHEMBL90544; CHEMBL92357; AC1L30XJ; 142155-43-9; Cizolirtine [INN]; MolPort-005-942-571; Cizolirtine; AC1MI3GX; UNII-SMP167WV5D; CID3037765; N,N-dimethyl-2-[(R)-(2-methylpyrazol-3-yl)-phenylmethoxy]ethanamine; CHEMBL92501; N,N-dimethyl-2-[(2-methylpyrazol-3-yl)-phenylmethoxy]ethanamine; CID10220803	142155-44-0	5360545	771338	TTDC00017	Calcitonin gene-related peptide 1	Alpha-type CGRP;CALC1;CALCA;Calcitonin gene-related peptide I;CGRP-I	P06881	796	ENSG00000110680; ENSG00000262933	inhibitor
DCL000187	Olcegepant	BIBN-4096BS; Olcegepant; BIBN 4096 BS; AC1OCFIR; N-((1R)-2-(((1S)-5-Amino-1-((4-(pyridin-4-yl)piperazin-1-yl)carbonyl)pentyl)amino)-1-(3,5-dibromo-4-hydroxybenzyl)-2-oxoethyl)-4-(2-oxo-1,4-dihydroquinazolin-3(2H)-yl)piperidine-1-carboxamide; CID6918509; BIBN 4096; CHEBI:446036; 204697-65-4; BIBN-4096; Olcegepant [INN]; N-[(2R)-1-[[(2S)-6-amino-1-oxo-1-(4-pyridin-4-ylpiperazin-1-yl)hexan-2-yl]amino]-3-(3,5-dibromo-4-hydroxyphenyl)-1-oxopropan-2-yl]-4-(2-oxo-1,4-dihydroquinazolin-3-yl)piperidine-1-carboxamide; LS-184037; C492454; CHEMBL207197	N/A	3025955	12015401	TTDC00017	Calcitonin gene-related peptide 1	Alpha-type CGRP;CALC1;CALCA;Calcitonin gene-related peptide I;CGRP-I	P06881	796	ENSG00000110680; ENSG00000262933	inhibitor
DCL000465	AZD3241	N/A	N/A	N/A	N/A	TTDC00199	Myeloperoxidase	MPO	P05164	4353	ENSG00000005381	inhibitor
DCL000471	AZD5904	N/A	157341-41-8	177992	33501323	TTDC00199	Myeloperoxidase	MPO	P05164	4353	ENSG00000005381	inhibitor
DAP000426	Rifapentine	SAM001246620; 3-(4-Cyclopentyl-1-piperazinyl)iminomethylrifamycin SV; MDL473; CID6323497; DL 473; Cyclopentylrifampicin; HMS2051D16; 3-(((4-cyclopentyl-1-piperazinyl)imino)methyl)rifamycin SV; CHEMBL1660; EINECS 262-743-9; Rifapentinum; Ambap127923-87-9; RPE; 3-(((4-Cyclopentyl-1-piperazinyl)imino)methyl)rifamycin; Antibiotic DL 473IT; MDL-473; CPD001906779; Rifapentine (USAN/INN); C08059; DL-473; 3-(N-(4-Cyclopentyl-1-piperazinyl)formimidoyl)rifamycin; Rifapentina; UNII-XJM390A33U; (2S,12Z,14E,16S,17S,18R,19R,20R,21S,22R,23S,24E)-8-{(E)-[(4-cyclopentylpiperazin-1-yl)imino]methyl}-5,6,9,17,19-pentahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-1,11-dioxo-1,2-dihydro-2,7-(epoxypentadeca[1,11,13]trienoimino)naphtho[2,1-b]furan-21-yl acetate; R-773; 71950-35-1; Priftin (TN); CHEBI:45304; MLS001424209; 61379-65-5; 3-[N-(4-Cyclopentyl-1-piperazinyl)formimidoyl]rifamycin; C47H64N4O12; Rifapentin; CID6434610; DL473; M000473; SMR000466332; DB01201; BIDD:GT0669; S1760_Selleck; (2R,16S,17R,18R,19R,20S,21S,22S,23S)-8-{[(4-CYCLOPENTYLPIPERAZIN-1-YL)IMINO]METHYL}-5,6,9,17,19-PENTAHYDROXY-23-METHOXY-2,4,12,16,18,20,22-HEPTAMETHYL-1,11-DIOXO-1,2-DIHYDRO-2,7-(EPOXYPENTADECA[1,11,13]TRIENOIMINO)NAPHTHO[2,1-B]FURAN-21-YL ACETATE; DL-4-73; DL 473-IT; Priftin, Cyclopentylrifampicin, Rifapentine; RPT; RIFAPENTINE; SAM002589953; CID9919168; R 77-3; D00879; Cyclopentyl rifampin; DRG-0283; LS-143825; NCGC00167431-01; MLS000759441; CPD000466332; KTC 1; Rifamycin AF/ACPP; CID6835847; MDL 473; Rifapentina [Spanish]; Rifamycin, 3-(((4-cyclopentyl-1-piperazinyl)imino)methyl)-; Rifapentinum [Latin]; Rifapentine [USAN:BAN:INN]; Priftin	61379-65-5	6323497	11533327	TTDS00225	DNA-dependent RNA polymerase	N/A	N/A	N/A	N/A	binder
DCL000783	Dronedarone	141626-36-0; L001445; SR 33589B; AKOS005145680; Multaq; AC-5012; CID208898; CHEMBL184412; N-[2-butyl-3-{4-[3-(dibutylamino)propoxy]benzoyl}-1-benzofuran-5-yl]methanesulfonamide; N-(2-butyl-3-(4-(3-(dibutylamino)propoxy)benzoyl)-5-benzofuranyl)-methanesulfonamide; D02537; N-[2-butyl-3-[4-[3-(dibutylamino)propoxy]benzoyl]-1-benzofuran-5-yl]methanesulfonamide; SR 33589; C118667; AC1L4LKA; Sanofi-Aventis brand of dronedarone; Methanesulfonamide, N-[2-butyl-3-[4-[3-(dibutylamino)propoxy]benzoyl]-5-benzofuranyl]-; UNII-JQZ1L091Y2; LS-90090; Dronedarone [INN]; CHEBI:50659; Methanesulfonamide, N-(2-butyl-3-(4-(3-(dibutylamino)propoxy)benzoyl)-5-benzofuranyl)-; Dronedarone; N-(2-Butyl-3-(p-(3-(dibutylamino)propoxy)benzoyl)-5-benzofuranyl)methanesulfonamide; I06-2091; Dronedarone (INN)	141625-93-6	154087	17396708	TTDC00303	Potassium voltage-gated channel subfamily A member 5	02-Sensitive Potassium Channel Kv1.5;HK2;HPCN1;Potassium channel Kv1.5;Voltage-gated potassium channel subunit Kv1.5	P22460	3741	ENSG00000130037	blocker
DCL000671	4-Aminopyridine	UNII-BH3B64OKL9; NINDS_000572; UPCMLD-DP125:001; p-Aminopyridine [UN2671] [Poison]; AKOS000119896; Fampridine-PR; 36687_FLUKA; 504-24-5; IDI1_034032; 4-Pyridinamine; SDCCGMLS-0066228.P001; Fampridine [USAN:INN]; KBio2_000635; Spectrum2_001413; 275875_ALDRICH; Bio1_000842; VMI103; NCGC00024890-04; KBioSS_000635; Phillips 1861; EU-0100032; Dalfampridine; InChI=1/C5H6N2/c6-5-1-3-7-4-2-5/h1-4H,(H2,6,7; KBioSS_000282; p-Aminopyridine; 4-AP; Spectrum5_001501; Lopac0_000032; KBio1_000572; LS-130202; 4-Aminopyridine Sustained Release; Amaya; Avitrol; NSC 15041; UPCMLD-DP125; Avitrol 200; NCGC00024890-01; Bio1_001331; KBio3_001888; Ampyra; NSC15041; Pymadin; KBio3_000564; Pymadine; NCGC00024890-09; Fampridine; EINECS 207-987-9; Prc 1237; Spectrum4_001013; Fampridine SR; NCGC00024890-07; NCGC00024890-02; NCGC00015009-12; 4 AP; Bio2_000762; A 0152; NCGC00024890-10; IDI1_000572; CID1727; CHEBI:34385; VMI 10-3; Fampridine (USAN/INN); HMS2092F05; NCGC00015009-03; SPECTRUM1501130; DivK1c_000572; Spectrum3_000914; Neurelan; Caswell No. 038; AC1L1C3R; 4-Aminopyridine 10; 4 Aminopyridine; Bio2_000282; Ampydin; [J.Pharmacol.Exp.Ther. 275:864 (1995)]; KBioGR_001505; VMI-103; HMS1361O04; AC1Q52BM; A78403_ALDRICH; EL-970; Compound 1861; KBio2_005418; BSPBio_001562; Mi-W-3; HC150041; pyridin-4-amine; AI3-52547; .gamma.-Aminopyridine; Bio1_000353; KBio2_002850; HMS1791O04; 4 Aminopyridine Sustained Release; Neurelan (TN); SMR000058211; BRN 0105782; NCGC00024890-05; MolPort-000-146-022; D04127; CHEMBL284348; KBio2_005771; MLS000069400; Sustained Release, 4-Aminopyridine; pyridin-4-ylamine; Pimadin (free base); NCGC00024890-08; C5H6N2; 4-aminopyridine; PYRIDINE,4-AMINO; nchem.892-comp4; KBio2_003203; gamma-Aminopyridine; KBio3_000563; AC-907/25014071; 4-Pyridylamine; FT-0083754; VMI-10-3; D015761; C13728; STK298717; Amino-4 pyridine; A0414; 5-22-09-00106 (Beilstein Handbook Reference); Philips 1861; KBioGR_000282; NCGC00015009-01; BB_SC-6974; RCRA waste no. P008; HMS1989O04; VMI 103; SPBio_001486; 36687_RIEDEL; Spectrum_000155; WLN: T6NJ DZ; Tocris-0940; Fampridine-SR; Amino-4-Pyridine; 4-Pyridinamine; Fampridine; HMS501M14; HMS1921H15; Lopac-A-0152; NCGC00024890-06; NCGC00024890-03; AB1004971; p-Aminopyridine [UN2671]  [Poison]; KBio2_000282; Pyridine, 4-amino-; TL8003344; EPA Pesticide Chemical Code 069201; HSDB 6037	504-24-5	1727	48421296	TTDC00303	Potassium voltage-gated channel subfamily A member 5	02-Sensitive Potassium Channel Kv1.5;HK2;HPCN1;Potassium channel Kv1.5;Voltage-gated potassium channel subunit Kv1.5	P22460	3741	ENSG00000130037	blocker
DCL000713	Azimilide	149908-53-2; 2,4-Imidazolidinedione, 1-(((5-(4-chlorophenyl)-2-furanyl)methylene)amino)-3-(4-(4-methyl-1-piperazinyl)butyl)-; CHEMBL123558; MolPort-005-933-014; LS-173360; C23H28ClN5O3; AZIMILIDE; CID9571004; LS-187295; C13777; 1-({[5-(4-chlorophenyl)furan-2-yl]methylidene}amino)-3-[4-(4-methylpiperazin-1-yl)butyl]imidazolidine-2,4-dione; UNII-74QU6P2934; CHEBI:308679; Azimilide [INN:BAN]; AC1Q3T08	149908-53-2	6918236	7978750	TTDC00303	Potassium voltage-gated channel subfamily A member 5	02-Sensitive Potassium Channel Kv1.5;HK2;HPCN1;Potassium channel Kv1.5;Voltage-gated potassium channel subunit Kv1.5	P22460	3741	ENSG00000130037	blocker
DAP000660	Pyrazinamide	MLS000069730; CID1046; Farmizina; BSPBio_000467; Pyrazinoic acid amide, Pezetamid, Pyrafat, Zinamide, Tebrazid, Pyrafat, Pyrazinamide; NCGC00090695-07; CHEMBL614; IDI1_000241; Braccopiral; HMS2092E09; Spectrum_000902; 2-Pyrazinecarboxamide; Aldinamid; 98-96-4; Zinamide; AC1Q4ZGM; MolPort-001-770-770; BIDD:GT0228; Aldinamide; AC1L1ALT; Spectrum2_001305; ZINC00002005; pyrazine-2-carboxamide; Pyrazinecarboxylic acid amide; NCGC00090695-01; Tisamid; EINECS 202-717-6; pyrazinoic acid amide; MLS002222347; KBio2_001382; KBio2_003950; Pharozinamide; Pyrazinamide (TN); BSPBio_002572; DB00339; PZA; Pyrazinamdie; Pirazinamida; pms-Pyrazinamide; D00144; Lynamide; KBio3_001792; Tebrazid; CAS- 98-96-4; HMS1920N08; Pezetamid; P0633; AB00052083; T 165; HMS1569H09; S1762_Selleck; Rozide; Pirazinamide [DCIT]; 5-25-04-00178 (Beilstein Handbook Reference); NCGC00090695-06; CPD000036662; Tebrazio; EU-0101011; 82612_FLUKA; InChI=1/C5H5N3O/c6-5(9)4-3-7-1-2-8-4/h1-3H,(H2,6,9; Novamid; Pyrazinoic acid amide; pyrazinamide; PZA; D-50 (VAN); Prestwick2_000514; NCGC00015833-10; BB_SC-1250; Corsazinmid; STK801661; BRN 0112306; NCGC00015833-01; Spectrum5_001026; MK 56; Pyrazinamidum; Prestwick0_000514; SMR000036662; Pyrazineamide; Prestwick3_000514; NCGC00090695-03; UNII-2KNI5N06TI; Pyrazinamide [INN:BAN:JAN]; C5H5N3O; D-50; Spectrum4_001186; NSC 14911; Zinastat; Pirazimida; NCGC00015833-02; P ezetamid; SPBio_002388; Pyrafat; BPBio1_000515; KBioSS_001382; Pyrazinoic acid am ide; CCRIS 545; 2-Carbamylpyrazine; DivK1c_000241; 2-carbamyl pyrazine; SPBio_001369; Eprazin; Pyrazine carboxamide; HMS500M03; NCGC00090695-05; Prazina; Piraldina; CHEBI:45285; AKOS000120280; Prestwick1_000514; Pyramide; pyrazinecarboxamide; SAM002554927; Prestwick_811; NCGC00015833-05; NSC14911; LS-2053; Pirazinamide; Lopac0_001011; NINDS_000241; KBioGR_001851; Pyrazide; SPECTRUM1500518; Pyrazinamidum [INN-Latin]; D011718; Pyrazinamide BP 2000; pyrazine carboxylamide; Dipimide; Spectrum3_001046; WLN: T6N DNJ BVZ; AC-907/25014068; Pirazinamida [INN-Spanish]; KBio2_006518; KBio1_000241; NCGC00090695-04; Isopas; Pirazinamid; Lopac-P-7136; NCI-C01785; HSDB 3576; P7136_SIGMA; C01956; I14-6758; P 7136; Unipyranamide; AZT + Pyrazinamide combination; pyrazinamide; DRG 0124; Pyrazinamide (JP15/USP/INN)	98-96-4	1046	5057	TTDS00386	Fatty acid synthase subunit beta	Fatty acid synthetase I	P34731	N/A	N/A	inhibitor
DCL000224	SB-743921	N-[1-(3-benzyl-7-chloro-4-oxo-quinazolin-2-yl)propyl]-4-bromo-N-(3-dimethylaminopropyl)benzamide; 336115-72-1; CID11261882; CHEMBL1164552; EN002661; SB-743921	N/A	N/A	N/A	TTDC00143	Kinesin-like protein KIF11	Eg5;Kinesin-like protein 1;Kinesin-like spindle protein HKSP;Kinesin-related motor protein Eg5;Thyroid receptor interacting protein 5;TRIP5	P52732	3832	ENSG00000138160	inhibitor
DCL000139	Ispinesib	CHEMBL228814; 336113-53-2; Ispinesib (SB-715992 /CK0238273); Benzamide, N-(3-aminopropyl)-N-((1R)-1-(7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl)-2-methylpropyl)-4-methyl-; UNII-BKT5F9C2NI; CID6851740; nchembio.2007.34-comp1; SB-715992, CK0238273, Ispinesib; EN002662; N-(3-aminopropyl)-N-[(1R)-1-(3-benzyl-7-chloro-4-oxoquinazolin-2-yl)-2-methylpropyl]-4-methylbenzamide; MolPort-006-394-712; AC1OA9A4; SB-715992; S1452_Selleck; Ispinesib	514820-03-2	6851740	26683880	TTDC00143	Kinesin-like protein KIF11	Eg5;Kinesin-like protein 1;Kinesin-like spindle protein HKSP;Kinesin-related motor protein Eg5;Thyroid receptor interacting protein 5;TRIP5	P52732	3832	ENSG00000138160	inhibitor
DCL001129	4SC-205	N/A	N/A	N/A	N/A	TTDC00143	Kinesin-like protein KIF11	Eg5;Kinesin-like protein 1;Kinesin-like spindle protein HKSP;Kinesin-related motor protein Eg5;Thyroid receptor interacting protein 5;TRIP5	P52732	3832	ENSG00000138160	inhibitor
DCL000053	ARRY-520	N/A	N/A	N/A	N/A	TTDC00143	Kinesin-like protein KIF11	Eg5;Kinesin-like protein 1;Kinesin-like spindle protein HKSP;Kinesin-related motor protein Eg5;Thyroid receptor interacting protein 5;TRIP5	P52732	3832	ENSG00000138160	inhibitor
DCL001254	VX-500	N/A	N/A	N/A	N/A	TTDS00320	HIV protease	N/A	N/A	N/A	N/A	inhibitor
DAP000171	Saquinavir	2fgv; Saquinavir (JAN/USP/INN); AKOS000280831; NCGC00091469-02; AC1L9ATC; Ro 31-8959; Invirase(TM)(monomesylate); Ro-31-8959; Prestwick0_001114; Fortovase; Prestwick1_001114; (2S)-N-[(2S,3R)-4-[(3S,4aS,8aS)-3-(tert-butylcarbamoyl)-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinolin-2-yl]-3-hydroxy-1-phenylbutan-2-yl]-2-(quinoline-2-carbonylamino)butanediamide; CID441243; saguinavir; Ambap127779-20-8; AB00514056; MLS001195635; SAQUINAVIR; CHEBI:45279; LS-187081; (2s)-N-[(2s,3r)-4-[(2s,3s,4as,8as)-3-(Tert-Butylcarbamoyl)-3,4,4a,5,6,7,8,8a-Octahydro-1h-Isoquinolin-2-Yl]-3-Hydroxy-1-Phenyl-Butan-2-Yl]-2-(Quinolin-2-Ylcarbonylamino)butanediamide; ROC; SQV; NSC722663; Prestwick2_001114; MLS001304735; 127779-20-8; MolPort-000-883-824; SMR000469157; BPBio1_001373; BIDD:GT0323; BSPBio_001248; Fortovase(TM); CHEMBL114; Prestwick3_001114; D00429; CIS-N-TERT-BUTYL-DECAHYDRO-2-[2(R)-HYDROXY-4-PHENYL-3(S)-[[N-2-QUINOLYLCARBONYL-L-ASPARAGINYL]AMINO]BUTYL]-(4AS)-ISOQUINOLINE-3(S)-CARBOXAMIDE; 2fgu; Ro 318959; AC-16711; Fortovase (TN); BIDD:PXR0010; BRD-K09963420-066-03-4; 1hxb; QNC-ASN-HPH-DIQ-NTB; Invirase; SPBio_003114	127779-20-8	60787	197032	TTDS00320	HIV protease	N/A	N/A	N/A	N/A	inhibitor
DAP000168	Indinavir	1sdv; L-735,524; N-[2(R)-HYDROXY-1(S)-INDANYL]-5-[(2(S)-TERTIARY BUTYLAMINOCARBONYL)-4(3-PYRIDYLMETHYL)PIPERAZINO]-4(S)-HYDROXY-2(R)-PHENYLMETHYLPENTANAMIDE; 1sdt; Indinavir (*1:1 Sulfate salt*); Crixivan (TM); L 735524; C07051; 1hsg; NCGC00159460-02; 2avv; RS-253; D-erythro-Pentonamide, 2,3,5-trideoxy-N-((1S,2R)-2,3-dihydro-2-hydroxy-1H-inden-1-yl)-5-((2S)-2-(((1,1-dimethylethyl)amino)carbonyl)-4-(3-pyridinylmethyl)-1-piperazinyl)-2-(phenylmethyl)-; 1sgu; Crixivan; Indinavir, Sulfate (1:1); (1(1S,2R),5(S))-2,3,5-Trideoxy-N-(2,3-dihydro-2-hydroxy-1H-inden-1-yl)-5-(2-(((1,1-dimethylethyl)amino)carbonyl)-4-(3-pyridinylmethyl)-1-piperazinyl)-2-(phenylmethyl)-D-erythro-Pentonamide; 1k6c; 1c6y; L-735524; 157810-81-6; (2S)-1-[(2S,4S)-4-benzyl-2-hydroxy-5-[[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]amino]-5-oxopentyl]-N-tert-butyl-4-(pyridin-3-ylmethyl)piperazine-2-carboxamide; 1hsh; 1sdu; MK-639; 166746-42-5; L-735 524; 2avo; Compound J; BIDD:GT0378; 216884-06-9; D-erythro-Pentonamide, 2,3,5-trideoxy-N-(2,3-dihydro-2-hydroxy-1H-inden-1-yl)-5-(2-(((1,1-dimethylethyl)amino)carbonyl)-4-(3-pyridinylmethyl)-1-piperazinyl)-2-(phenylmethyl)-, (1(1S,2R),5(S))-; AC-20034; UNII-9MG78X43ZT; 150378-17-9; IDV; DB00224; AKOS000280989; Indinavir [USAN]; indinavir; AC1L1U7I; NSC697197; C36H47N5O4; Propolis & 4-Hydroxy-N-(2-hydroxy-2,3-dihydro-1H-1-indanyl)-N'-(1,1-dimethylethyl)-2-phenylmethyl-5-[4-(3-pyridylmethyl)-1-piperzinyl]hexanediamide; BIDD:PXR0141; 2bpx; 157810-81-6 (sulfate (1:1) (salt)); LS-173382; MolPort-000-883-804; 2avs; CHEBI:44032; Propolis+Indinavir	150378-17-9	5362440	197165	TTDS00320	HIV protease	N/A	N/A	N/A	N/A	inhibitor
DCL001190	GS-9256	N/A	N/A	N/A	N/A	TTDS00320	HIV protease	N/A	N/A	N/A	N/A	inhibitor
DCL001247	TMC435	N/A	N/A	N/A	N/A	TTDS00320	HIV protease	N/A	N/A	N/A	N/A	inhibitor
DCL001160	BMS 650032	N/A	N/A	N/A	N/A	TTDS00320	HIV protease	N/A	N/A	N/A	N/A	inhibitor
DCL001132	ABT-450	N/A	N/A	N/A	N/A	TTDS00320	HIV protease	N/A	N/A	N/A	N/A	inhibitor
DCL001176	Danoprevir	N/A	N/A	N/A	N/A	TTDS00320	HIV protease	N/A	N/A	N/A	N/A	inhibitor
DCL001135	ACH-1625	N/A	N/A	N/A	N/A	TTDS00320	HIV protease	N/A	N/A	N/A	N/A	inhibitor
DAP000170	Amprenavir	HSDB 7157; Vertex VX478; CID65016; C25H35N3O6S; HHA & Amprenavir; 1t7j; {3-[(4-AMINO-BENZENESULFONYL)-ISOBUTYL-AMINO]-1-BENZYL-2-HYDROXY-PROPYL}-CARBAMIC ACID TETRAHYDRO-FURAN-3-YL ESTER; KVX-478; Agenerase; HMS2090N10; LS-173559; C08086; S1639_Selleck; AKOS000280844; DB00701; (3S)-Tetrahydro-3-furyl ((alphaS)-alpha-((1R-1-hydroxy-2-(N(sup 1)-isobutylsulfanilamido)ethyl)phenethyl)carbamate; Vertex; [(3S)-oxolan-3-yl] N-[(2S,3R)-4-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-3-hydroxy-1-phenylbutan-2-yl]carbamate; 141W94; CHEMBL116; UNII-5S0W860XNR; Amprenavir [USAN]; ZINC03809192; (3S)-tetrahydro-3-furyl N-[(1S,2R)-3-(4-amino-N-isobutylbenzenesulfonamido)-1-benzyl-2-hydroxy-propyl]carbamate; 161814-49-9; 4-Amino-N-((2 syn,3S)-2-hydroxy-4-phenyl-3-((S)-tetrahydrofuran-3-yloxycarbonylamino)-butyl)-N-isobutyl-benzenesulfonamide; VX-478; Carbamic acid, ((1S,2R)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)-, (3S)-tetrahydro-3-furanyl ester & Hippeastrum hybrid agglutinin( HHA); NCGC00159461-03; Carbamic acid, (3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)-, tetrahydro-3-furanyl ester, (3S-(3R*(1S*,2R*)))-; amprenavir[usan]; amprenavir; DRG-0258; (3S)-Tetrahydro-3-furanyl ((1S,2R)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)carbamate; NCGC00159461-02; GNA & Amprenavir; FT-0082731; Carbamic acid, ((1S,2R)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)-, (3S)-tetrahydro-3-furanyl ester & Galanthus nivalis agglutinin (GNA); Amprenavir (JAN/USAN/INN); Carbamic acid, ((1S,2R)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)-, (3S)-tetrahydro-3-furanyl ester; CHEBI:40050; AC1Q5X5K; VX 478; Prozei; AMV; Agenerase (TM); Tetrahydro-3-furyl N-(3-(4-amino-N-isobutylbenzenesulfonamido)-1-benzyl-2-hydroxypropyl)carbamate; VX478; AC1L22EW; D00894; MolPort-000-883-856; 1hpv; (3S-(3R*(1R*,2S*)))-(3-(((4-Aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl) tetrahydro-3-furanyl carbamate; BIDD:GT0398; Agenerase (TN)	161814-49-9	65016	7847958	TTDS00320	HIV protease	N/A	N/A	N/A	N/A	inhibitor
DCL001157	BI 201335	N/A	N/A	N/A	N/A	TTDS00320	HIV protease	N/A	N/A	N/A	N/A	inhibitor
DAP000169	Ritonavir	1,3-thiazol-5-ylmethyl N-[(2S,3S,5S)-3-hydroxy-5-[[(2S)-3-methyl-2-[[methyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate; A-84538; 538, ABT; 5-Thiazolylmethyl ((alphaS)-alpha-((1S,3S-1-hydroxy-3-((2S)-2-(3-((2-isopropyl-4-thiazolyl)methyl)-3-methylureido)-3-methylbutyramido)-4-phenylbutyl)phenethyl)carbamate; MolPort-000-883-877; 5-Thiazolylmethyl ((alphaS)-alpha-((1S,3S)-1-hydroxy-3-((2S)-2-(3-((2-isopropyl-4-thiazolyl)methyl)-3-methylureido)-3-methylbutyramido)-4-phenylbutyl)phenethyl)carbamate; BIDD:GT0387; 1sh9; LS-148860; 155213-67-5; ritonavir; Norvir (TN); Norvir (TM); D00427; CPD000466395; Bio-0093; RTV; Abbott 84538; 2,4,7,12-Tetraazatridecan-13-oic acid, 10-hydroxy-2-methyl-5-(1-methylethyl)-1-(2-(1-methylethyl)-4-thiazolyl)-3,6-dioxo-8,11-bis(phenylmethyl)-, 5-thiazolylmethyl ester,(5S,8S,10S,11S)-; Ritonavir [USAN]; CHEBI:45409; ZINC03944422; MLS001424063; 1hxw; ABBOTT-84538; Norvir Sec; ABT538; AC1L94GB; S1185_Selleck; Ritonavir is an inhibitor of HIV protease used to treat HIV infection and AIDS.; RIT; STK634209; N-[(2S,4S,5S)-4-hydroxy-1,6-diphenyl-5-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}hexan-2-yl]-N~2~-(methyl{[2-(propan-2-yl)-1,3-thiazol-4-yl]methyl}carbamoyl)-L-valinamide; Ritonavir (JAN/USAN/INN); SMR000466395; DB00503; AKOS000280930; ABT-538; Norvir; 2,4,7,12-Tetraazatridecan-13-oic acid, 10-hydroxy-2-methyl-5-(1-methylethyl)-1-[2-(1-methylethyl)-4-thiazolyl]-3,6-dioxo-8,11-bis(phenylmethyl)-, 5-thiazolylmethyl ester, [5S-(5R*,8R*,10R*,11R*)]-; C07240; 2,4,7,12-Tetraazatridecan-13-oic acid, 10-hydroxy-2-methyl-5-(1-methylethyl)-1-(2-(1-methylethyl)-4-thiazolyl)-3,6-dioxo-8,11-bis(phenylmethyl)-, 5-thiazolylmethyl ester, (5S-(5R*,8R*,10R*,11R*))-; AC-733; BIDD:PXR0023; HMS2051B08; ABT 84538; C37H48N6O5S2; CID392622; HSDB 7160; CHEMBL163; MLS000759541; NSC693184; ABT 538; FT-0082824; D019438; NCGC00159462-02; SAM001246783; DRG-0244	155213-67-5	392622	612199	TTDS00320	HIV protease	N/A	N/A	N/A	N/A	inhibitor
DCL001159	BIT225	N/A	N/A	N/A	N/A	TTDS00320	HIV protease	N/A	N/A	N/A	N/A	inhibitor
DCL000616	R7227	N/A	N/A	5353955	47499145	TTDS00320	HIV protease	N/A	N/A	N/A	N/A	inhibitor
DCL001216	MK-5172	N/A	N/A	N/A	N/A	TTDS00320	HIV protease	N/A	N/A	N/A	N/A	inhibitor
DCL001250	Vaniprevir	N/A	N/A	N/A	N/A	TTDS00320	HIV protease	N/A	N/A	N/A	N/A	inhibitor
DAP001345	Almogran	Spectrum5_001554; KBio2_004976; Spectrum4_001134; Almotriptan (USAN); CID123606; KBio2_007544; KBio3_001951; AC1L3WYP; NCGC00095135-02; Almotriptan; 1-(((3-(2-(Dimethylamino)ethyl)indol-5-yl)methyl)sulfonyl)pyrrolidine; Almotriptan [USAN:INN:BAN]; PNU-180638; BIDD:GT0048; HMS1922L13; SPECTRUM1505204; KBioSS_002414; BRD-K67601717-001-02-0; 154323-57-6; UNII-1O4XL5SN61; BSPBio_002731; C17H27N3O2S; NCGC00095135-03; L000846; I06-0492; Spectrum2_000498; Spectrum3_001006; Spectrum_001884; N,N-dimethyl-2-[5-(pyrrolidin-1-ylsulfonylmethyl)-1H-indol-3-yl]ethanamine; N,N-dimethyl-2-{5-[(pyrrolidin-1-ylsulfonyl)methyl]-1H-indol-3-yl}ethanamine; NCGC00095135-01; CHEBI:520985; Axert; D02824; DB00918; MolPort-003-666-604; Almogran; LS-173461; CHEMBL1505; KBioGR_001647; Pyrrolidine, 1-(((3-(2-(dimethylamino)ethyl)-1H-indol-5-yl)methyl)sulfonyl)-; SPBio_000395; LAS-31416; KBio2_002408	154323-57-6	123606	12014867	TTDS00100	5-hydroxytryptamine 1D receptor	5HT1D;5-HT-1D;5-HT1D receptor;5-HT-1D-alpha;5-hydroxytryptamine receptor 1D;Serotonin receptor;Serotonin receptor 1D	P28221	3352	ENSG00000179546	agonist
DAP000077	Zolmitriptan	CPD000449310; Spectrum2_000728; 4-[[3-(2-dimethylaminoethyl)-1H-indol-5-yl]methyl]oxazolidin-2-one; Zomig ZMT; 2-Oxazolidinone, 4-((3-(2-(dimethylamino)ethyl)-1H-indol-5-yl)methyl)-, (S)-; SPECTRUM1505281; MLS000758208; 311C90; Zomig Nasal Spray; CID60857; (S)-4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-2-oxazolidinone; Zomigon; Zomig; SAM001246841; Zomig-ZMT; (S)-4-((3-(2-(Dimethylamino)ethyl)-1H-indol-5-yl)methyl)-2-oxazolidinone; SAM001247064; SMR000449310; zolmitriptanum; Zolmitriptan [USAN]; Flezol; zolmitriptan; Zomig, Zomigon, AscoTopand, Zomigoro,  Zolmitriptan; SPBio_000656; S1649_Selleck; CHEBI:10124; BW-311C90; C07218; HMS2052K17; (4S)-4-[[3-(2-dimethylaminoethyl)-1H-indol-5-yl]methyl]-1,3-oxazolidin-2-one; LS-100559; (S)-4-[3-(2-Dimethylamino-ethyl)-1H-indol-5-ylmethyl]-oxazolidin-2-one; (4S)-4-({3-[2-(dimethylamino)ethyl]-1H-indol-5-yl}methyl)-1,3-oxazolidin-2-one; AC1L1U2E; HMS1922B04; CHEMBL1185; MLS001424172; zolmitriptane; 4-((3-(2-(Dimethylamino)ethyl)-1H-indol-5-yl)methyl)-2-oxazolidinone; 139264-17-8; HMS2093O14; BIDD:GT0040; AscoTop; KS-5072; Zolmitriptan RapidFilm; UNII-2FS66TH3YW; MolPort-003-666-626; (S)-4-((3-(2-(Dimethylamino)ethyl)indol-5-yl)methyl)-2-oxazolidinone; C16H21N3O2	139264-17-8	441240	7847481	TTDS00100	5-hydroxytryptamine 1D receptor	5HT1D;5-HT-1D;5-HT1D receptor;5-HT-1D-alpha;5-hydroxytryptamine receptor 1D;Serotonin receptor;Serotonin receptor 1D	P28221	3352	ENSG00000179546	agonist
DAP000063	Frovatriptan	UNII-H82Q2D5WA7; (6R)-6-(methylamino)-6,7,8,9-tetrahydro-5H-carbazole-3-carboxamide; SB 209509; Frovatriptan (INN); Allegro; Migard; HSDB 7363; 158747-02-5; CHEBI:350328; MolPort-005-932-844; Allergo filmtabletten (TN); Miguard; CHEMBL1279; Frova; BIDD:PXR0142; Rilamig; (R)-5,6,7,8-Tetrahydro-6-(methylamino)carbazole-3-carboxamide; Auradol; DB00998; AC1L2U95; CID77992; 1H-Carbazole-6-carboxamide, 2,3,4,9-tetrahydro-3-(methylamino)-, (R)-; LS-186996; Frovatriptan; (3R)-3-(methylamino)-2,3,4,9-tetrahydro-1H-carbazole-6-carboxamide; Allergo filmtabletten; D07997; Frovelan; LS-187764; SB-209509; 1H-Carbazole-6-carboxamide, 2,3,4,9-tetrahydro-3-(methylamino)-, (3R)-	158747-02-5	77992	655050	TTDS00100	5-hydroxytryptamine 1D receptor	5HT1D;5-HT-1D;5-HT1D receptor;5-HT-1D-alpha;5-hydroxytryptamine receptor 1D;Serotonin receptor;Serotonin receptor 1D	P28221	3352	ENSG00000179546	agonist
DAP000220	Rizatriptan	C093622; UNII-51086HBW8G; SPECTRUM1505189; Risatriptan; L000812; rizatriptan; D08485; AC1L1JK9; CHEBI:48273; N,N-dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]-ethanamine; MK 462 free base; N,N-dimethyl-2-[5-(1H-1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethanamine; Rizatriptan (INN); TL8000966; BIDD:GT0361; CID5078; AC-1712; NCGC00095899-01; Rizatriptan [INN:BAN]; N,N-Dimethyl-2-[5-(1H-1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethylamine; DB00953; Rizatriptan benzoat; I06-2272; CHEMBL905; 144034-80-0; N,N-dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethanamine; LS-83053; 1H-Indole-3-ethanamine, N,N-dimethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-; rizatriptanum; MolPort-003-666-600; N,N-Dimethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-1H-indole-3-ethanamine	145202-66-0	5078	7854588	TTDS00100	5-hydroxytryptamine 1D receptor	5HT1D;5-HT-1D;5-HT1D receptor;5-HT-1D-alpha;5-hydroxytryptamine receptor 1D;Serotonin receptor;Serotonin receptor 1D	P28221	3352	ENSG00000179546	agonist
DAP000008	Eletriptan	(R)-3-[(1-Methyl-2-pyrrolidinyl)methyl]-5-[2-(phenylsulfonyl)ethyl]-1H-Indole; (R)-5-[2-(Benzenesulfonyl)ethyl]-3-[(N-methylpyrrolidin-2-yl)methyl]-1H-indole; Eletriptan; UK116044; 3-(((R)-1-Methyl-2-pyrrolidinyl)methyl)-5-(2-(phenylsulfonyl)ethyl)indole; UK 116044; Eletriptan (INN); UK-116044-04; AC1L2U98; D07887; UK-116044; 5-[2-(benzenesulfonyl)ethyl]-3-[[(2R)-1-methylpyrrolidin-2-yl]methyl]-1H-indole; UNII-22QOO9B8KI; AB1004885; DB00216; CHEMBL1510; CID77993; AC-3397; eletriptanum; Eletriptan; CHEBI:50922; AKOS005145842; 1H-Indole, 3-(((2R)-1-methyl-2-pyrrolidinyl)methyl)-5-(2-(phenylsulfonyl)ethyl)ethyl)-; 3-{[(2R)-1-methylpyrrolidin-2-yl]methyl}-5-[2-(phenylsulfonyl)ethyl]-1H-indole; Eletriptan [INN:BAN]; NCGC00181130-01; LS-186998; MolPort-005-940-717; LS-187637; 143322-58-1; Relpax	143322-58-1	77993	655051	TTDS00100	5-hydroxytryptamine 1D receptor	5HT1D;5-HT-1D;5-HT1D receptor;5-HT-1D-alpha;5-hydroxytryptamine receptor 1D;Serotonin receptor;Serotonin receptor 1D	P28221	3352	ENSG00000179546	agonist
DCL000793	Elzasonan hydrochloride	AC1O5TUJ; Elzasonan hydrochloride; D03983; UNII-X38F62RR8L; (2E)-4-(3,4-dichlorophenyl)-2-[[2-(4-methylpiperazin-1-yl)phenyl]methylidene]thiomorpholin-3-one hydrochloride; 220322-05-4; CID6440591; Elzasonan HCl; AC1O6SNF; (2Z)-4-(3,4-dichlorophenyl)-2-[[2-(4-methylpiperazin-1-yl)phenyl]methylidene]thiomorpholin-3-one hydrochloride; Elzasonan hydrochloride (USAN); CP 448187-01; CID6506051	220322-05-4	6473739	47205966	TTDS00100	5-hydroxytryptamine 1D receptor	5HT1D;5-HT-1D;5-HT1D receptor;5-HT-1D-alpha;5-hydroxytryptamine receptor 1D;Serotonin receptor;Serotonin receptor 1D	P28221	3352	ENSG00000179546	antagonist
DAP000219	Sumatriptan	103628-46-2; UNII-8R78F6L9VO; Imitrex (TN); MLS001195659; Sumatriptanum; GR 43175X; BRD-K50938287-001-01-7; D00451; SMR000596517; MLS001304742; Sumax; 1H-Indole-5-methanesulfonamide, 3-(2-(dimethylamino)ethyl)-N-methyl-; KS-1116; BRN 6930870; AC1L1K6B; (3-[2-(Dimethylamino)ethyl]-1H-indol-5-yl)-N-methylmethanesulfonamide; CHEBI:10650; CHEMBL128; CID5358; 1-[3-(2-dimethylaminoethyl)-1H-indol-5-yl]-N-methylmethanesulfonamide; DB00669; MolPort-002-885-863; NP101; sumatriptan; I06-0076; 1-[3-(2-dimethylaminoethyl)-1H-indol-5-yl]-N-methyl-methanesulfonamide; 3-(2-(Dimethylamino)ethyl)-N-methyl-1H-indole-5-methanesulfonamide; SPECTRUM1505372; BSPBio_002304; Sumatriptanum [INN-Latin]; NCGC00095838-01; Imitrex; LS-83175; L000584; C07319; 103628-48-4 (succinate); Imigran; GR 43175; Imigran (TN); 1H-Indole-5-methanesulfonamide, 3-[2-(dimethylamino)ethyl]-N-methyl-; NCGC00095838-02; Sumatran; BIDD:GT0248; C14H21N3O2S; 3-[2-(Dimethylamino)ethyl]-N-methyl-1H-indole-5-methanesulfonamide; 1-{3-[2-(dimethylamino)ethyl]-1H-indol-5-yl}-N-methylmethanesulfonamide; GR-43175; Ambap103628-46-2; Sumatriptan (JAN/USP/INN); 3-[2-(Dimethylamino)ethyl]-N-methylindole-5-methanesulfonamide	103628-46-2	5358	7847517	TTDS00100	5-hydroxytryptamine 1D receptor	5HT1D;5-HT-1D;5-HT1D receptor;5-HT-1D-alpha;5-hydroxytryptamine receptor 1D;Serotonin receptor;Serotonin receptor 1D	P28221	3352	ENSG00000179546	agonist
DCL000533	IAP Antagonist	N/A	26305-03-3	5478883	49699079	TTDS00256	Alkaline phosphatase, tissue-nonspecific	AP-TNAP;Liver/bone/kidney isozyme;TNSALP	P05186	249	ENSG00000162551	inhibitor
DAP000570	Levamisole	NSC177023; Tetramisol; SPBio_002024; D08114; AC1L1C2T; KBio1_000667; Imidazo(2,1-b)thiazole, 2,3,5,6-tetrahydro-6-phenyl-, (S)-; dl-Tetramisole; levamisole; KBio3_001783; 2,3,5,6-Tetrahydro-6-phenyl-imidazo[2,1-b]thiazole, (S)-; Levamisolum; Levamisole Base; CHEMBL1454; Ketrax; Levamisole (INN); KBio2_002089; DivK1c_000667; Levotetramisole; SPBio_000909; Imidazo(2,1-b)thiazole, 2,3,5,6-tetrahydro-6-phenyl-, (6S)-; KBio2_004657; (-)-Tetramisole; EINECS 238-836-5; L(-)-Levamisole; Spectrum4_001078; NINDS_000667; 16595-80-5 (hydrochloride); BSPBio_002563; KBioGR_001436; C07070; NCGC00162225-03; NCI60_001476; 14769-73-4; AC-18929; Lepuron; IDI1_000667; P00039; Nilverm base; TL8001042; BIDD:GT0372; NCGC00162225-02; L-Tetramisole; LS-80639; KBioSS_002089; UNII-2880D3468G; Ketrax (TN); Lopac0_000690; HMS2090O04; Levamisolum [INN-Latin]; L-2,3,5,6-Tetrahyro-6-phenylimidazo(2,1-b)thiazole; AC1Q1I73; 53096-13-2; BRD-K73107279-003-03-4; Spectrum2_000865; Prestwick0_000182; (6S)-6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazole; TCMDC-125847; C11H12N2S; Wormicid; Spectrum3_000962; KBio2_007225; Prestwick2_000182; Levamisol; Levamisol [INN-Spanish]; Spectrum5_001645; CHEBI:484948; LEVOMYSOL; (S)-(-)-Levamisole; Prestwick1_000182; CID26879; MolPort-001-794-629; Levamisole [INN:BAN]; Spectrum_001609; DB00848; AKOS001637203; Vermisol 150; 16595-80-5; dl-Tetramisol	14769-73-4	26879	9282	TTDS00256	Alkaline phosphatase, tissue-nonspecific	AP-TNAP;Liver/bone/kidney isozyme;TNSALP	P05186	249	ENSG00000162551	inhibitor
DCL000498	BIBW 2992	Tovok; Afatinib; FT-0083487; CID 10184653; 915958-11-1; CID10184653; Tovok, BIBW2992; 2-Butenamide, N-(4-((3-chloro-4-fluorophenyl)amino)-7-(((3S)-tetrahydro-3-furanyl)oxy)-6-quinazolinyl)-4-(dimethylamino)-; S1011_Selleck; BIBW-2992; 439081-18-2; CHEBI:61390; CHEMBL1173655; BIBW 2992; Tomtovok; (2E)-N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[(3S)-tetrahydrofuran-3-yloxy]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide; CHEBI:750126	N/A	N/A	N/A	TTDS00355	Epidermal growth factor receptor	EGFR;EGFR-TK;Epidermal growth factor receptor ErbB-1;Epidermal growth factor receptor-tyrosine kinase;Receptor protein-tyrosine kinase ErbB-1	P00533	1956	ENSG00000146648	inhibitor
DCL000263	XL647	N/A	168626-94-6	5712	49684198	TTDS00355	Epidermal growth factor receptor	EGFR;EGFR-TK;Epidermal growth factor receptor ErbB-1;Epidermal growth factor receptor-tyrosine kinase;Receptor protein-tyrosine kinase ErbB-1	P00533	1956	ENSG00000146648	inhibitor
DCL001231	S-222611	N/A	N/A	N/A	N/A	TTDS00355	Epidermal growth factor receptor	EGFR;EGFR-TK;Epidermal growth factor receptor ErbB-1;Epidermal growth factor receptor-tyrosine kinase;Receptor protein-tyrosine kinase ErbB-1	P00533	1956	ENSG00000146648	inhibitor
DCL000495	Bevacizumab+Erlotinib	N/A	N/A	N/A	N/A	TTDS00355	Epidermal growth factor receptor	EGFR;EGFR-TK;Epidermal growth factor receptor ErbB-1;Epidermal growth factor receptor-tyrosine kinase;Receptor protein-tyrosine kinase ErbB-1	P00533	1956	ENSG00000146648	inhibitor
DAP001010	Erlotinib	[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; Erlotinib, OS-774; 4-Quinazolinamine, N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-; CP-358,774; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; CID176870; Erlotinib(Tarceva); N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; CHEMBL553; R 1415; Kinome_3317; AQ4; CP 358,774; NCGC00164574-01; OSI 744; ZINC01546066; HMS2089F05; AB1004620; Erlotinib; 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline; SR-05000001460; Tarceva; EN002711; BCB03_000783; AKOS000282911; CP-358774; K00241; NSC 718781; [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; LS-184395; UNII-J4T82NDH7E; AC1L42EI; DB00530; STK623143; SR-05000001460-2; C400278; 4-[(3-ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline; n-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine; N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-Quinazolinamine; Erlotinin; Erlotinib Base; 183321-74-6; CHEBI:114785; I01-1241; AC-399; FT-0083688; nchembio866-comp3; MolPort-003-847-084	183321-74-6	176870	7885946	TTDS00355	Epidermal growth factor receptor	EGFR;EGFR-TK;Epidermal growth factor receptor ErbB-1;Epidermal growth factor receptor-tyrosine kinase;Receptor protein-tyrosine kinase ErbB-1	P00533	1956	ENSG00000146648	inhibitor
DCL000346	HKI-272	N/A	698387-09-6	9915743	76593408	TTDS00355	Epidermal growth factor receptor	EGFR;EGFR-TK;Epidermal growth factor receptor ErbB-1;Epidermal growth factor receptor-tyrosine kinase;Receptor protein-tyrosine kinase ErbB-1	P00533	1956	ENSG00000146648	inhibitor
DCL000596	PF-299804	N/A	599179-03-0	3009355	47207954	TTDS00355	Epidermal growth factor receptor	EGFR;EGFR-TK;Epidermal growth factor receptor ErbB-1;Epidermal growth factor receptor-tyrosine kinase;Receptor protein-tyrosine kinase ErbB-1	P00533	1956	ENSG00000146648	inhibitor
DAP000657	Gefitinib	C419708; EN002708; CHEMBL939; NCGC00159455-03; AC-1556; CHEBI:49668; UNII-S65743JHBS; KBioSS_002241; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamide; MolPort-000-883-335; NSC715055; 6-(3-morpholinopropoxy)-N-(3-chloro-4-fluorophenyl)-7-methoxyquinazolin-4-amine; ZD-1839, Iressa, Gefitinib; D01977; 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-4-morpholin)propoxy)-; Iressa; I01-1227; N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine; Gefitinib; Iressa (TN); N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine; Kinome_3321; nchembio866-comp14; CID123631; ZD1839; DB00317; Bio-0046; nchembio.117-comp18; BCB03_000781; Gefitinib [USAN]; Iressa(TM); DB07998; Gefitinib, Iressa, ZD1839; IRE; Kinome_3322; LS-139916; STK621310; 4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline; 184475-35-2; ZD 1839; 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholinyl)propoxy]-; K00240; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(morpholin-4-yl)propoxy]quinazolin-4-amine; CCRIS 9011; Gefitini; Iressa; Irressat; FT-0081035; S1025_Selleck; NCGC00159455-02; CU-00000000396-1; ZINC19632614; 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-; AKOS000280752; AC1L3X0A; N-(3-Chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine; Gefitinib (JAN/USAN/INN); EC-000.2409; ZD-1839; HMS2089B19	184475-35-2	123631	7849039	TTDS00355	Epidermal growth factor receptor	EGFR;EGFR-TK;Epidermal growth factor receptor ErbB-1;Epidermal growth factor receptor-tyrosine kinase;Receptor protein-tyrosine kinase ErbB-1	P00533	1956	ENSG00000146648	inhibitor
DAP001009	Panitumumab	Panitumumab (USAN/INN); Panitumumab (genetical recombination) (JAN); Panitumumab (genetical recombination); D05350; 339177-26-3; Panitumumab; Vectibix (TN); Vectibix	339177-26-3	N/A	47207035	TTDS00355	Epidermal growth factor receptor	EGFR;EGFR-TK;Epidermal growth factor receptor ErbB-1;Epidermal growth factor receptor-tyrosine kinase;Receptor protein-tyrosine kinase ErbB-1	P00533	1956	ENSG00000146648	N/A
DAP001472	DWP-401	N/A	55-63-0	4510	48420963	TTDS00355	Epidermal growth factor receptor	EGFR;EGFR-TK;Epidermal growth factor receptor ErbB-1;Epidermal growth factor receptor-tyrosine kinase;Receptor protein-tyrosine kinase ErbB-1	P00533	1956	ENSG00000146648	activator
DCL000086	CI-1033	S1019_Selleck; N-(4-((3-Chloro-4-fluorophenyl)amino)-7-(3-(morpholin-4-yl)propoxy)quinazolin-6-yl)prop-2-enamide; Canertinib HCl; N-[4-(3-chloro-4-fluoroanilino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]prop-2-enamide dihydrochloride; 2-Propenamide, N-(4-((3-chloro-4-fluorophenyl) amino)-7-(3-(4-morpholinyl) propoxy)-6-quinazolinyl)-, dihydrochloride; CI-1033; UNII-C78W1K5ASF; D03350; AC1L4G5R; I14-8433; 2-Propenamide, N-(4-((3-chloro-4-fluorophenyl)amino)-7-(3-(4-morpholinyl)propoxy)-6-quinazolinyl)-, dihydrochloride; EC-000.2258; 267243-28-7; CI1033; PD-0183805; 289499-45-2; CHEMBL545315; PD 183805; CHEMBL31965; CID156413; CHEBI:61399; N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(morpholin-4-yl)propoxy]quinazolin-6-yl}prop-2-enamide; LS-185636; Canertinib dihydrochloride; N-[4-(3-Chloro-4-fluorophenylamino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]acrylamide dihydrochloride; N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl]-2-propenamide dihydrochloride; Canertinib, PD-183805, CI1033, PD183805; AKOS005145818; Canertinib dihydrochloride [USAN]; Canertinib; CID156414; AC-2414; I06-1255; CI 1033; N-[4-(3-chloro-4-fluoroanilino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]prop-2-enamide; Canertinib dihydrochloride (USAN); AB1004832; Canertinib dihydrochloride; PD-183805; AC1L4G5O; UNII-ICJ93X8X90; N-(4-(3-chloro-4-fluorophenyl)amino)-7-(3-morpholin-4-yl)propoxy)quinazolin-6-yl)prop-2-enamide dihydrochloride	289499-45-2	156414	12015296	TTDS00355	Epidermal growth factor receptor	EGFR;EGFR-TK;Epidermal growth factor receptor ErbB-1;Epidermal growth factor receptor-tyrosine kinase;Receptor protein-tyrosine kinase ErbB-1	P00533	1956	ENSG00000146648	inhibitor
DCL000350	Vandetanib	DB08764; UNII-YO460OQ37K; 338992-00-0; CHEMBL24828; AC1MIWRU; Zactima, ZD6474; ||Zactima; CH 331; ZD 6474|; Vandetanib; Quinazolin-4-amine, N-(4-bromo-2-fluorophenyl)-6-mthoxy-7-[(1-methyl-4-piperidinyl)methoxy]-; C452423; Kinome_3316; LS-184394; N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methyl-4-piperidinyl)methoxy)-4-quinazolinamine; 4-Quninazolinamine, N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methyl-4-piperidinyl)methoxy)-; EN002713; NCGC00167513-01; CID3081361; N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-amine; NSC744325; ZD 6474; N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine; Zactima; EC-000.2359; AZD-6474; 443913-73-3; Vandetanib, Zactima, ZD6474; MolPort-005-942-399; S1046_Selleck; ZD-6474; F9995-0087; 4-(4-Bromo-2-fluoroanilino)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazoline; Vandetanib [INN]; AC-5251; CH-331; CHEBI:49960; 4-Quinazolinamine, N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-; I14-1942; Vandetanib (JAN/INN); D06407; 2ivu; ZD6474	443913-73-3	3081361	3882431	TTDS00355	Epidermal growth factor receptor	EGFR;EGFR-TK;Epidermal growth factor receptor ErbB-1;Epidermal growth factor receptor-tyrosine kinase;Receptor protein-tyrosine kinase ErbB-1	P00533	1956	ENSG00000146648	inhibitor
DAP001451	Tyverb/Tykerb	N/A	198821-22-6	11557040	12015501	TTDS00355	Epidermal growth factor receptor	EGFR;EGFR-TK;Epidermal growth factor receptor ErbB-1;Epidermal growth factor receptor-tyrosine kinase;Receptor protein-tyrosine kinase ErbB-1	P00533	1956	ENSG00000146648	inhibitor
DCL000523	Erlotinib+Bevacizumab	N/A	N/A	N/A	N/A	TTDS00355	Epidermal growth factor receptor	EGFR;EGFR-TK;Epidermal growth factor receptor ErbB-1;Epidermal growth factor receptor-tyrosine kinase;Receptor protein-tyrosine kinase ErbB-1	P00533	1956	ENSG00000146648	inhibitor
DCL000468	AZD4769	N/A	127481-29-2	124437	29304468	TTDS00355	Epidermal growth factor receptor	EGFR;EGFR-TK;Epidermal growth factor receptor ErbB-1;Epidermal growth factor receptor-tyrosine kinase;Receptor protein-tyrosine kinase ErbB-1	P00533	1956	ENSG00000146648	inhibitor
DCL000343	BMS-599626	N/A	N/A	N/A	N/A	TTDS00355	Epidermal growth factor receptor	EGFR;EGFR-TK;Epidermal growth factor receptor ErbB-1;Epidermal growth factor receptor-tyrosine kinase;Receptor protein-tyrosine kinase ErbB-1	P00533	1956	ENSG00000146648	inhibitor
DAP000853	Lapatinib	FMM; I01-1247; LS-187029; Tycerb; AC1L4LL4; TL80090051; CHEMBL554; EN002712; 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-; DB02584; GW 572016; Lapatinib (INN); Lapatinib [INN]; CHEBI:49603; Lapatinib tosilate hydrate; Lapatinib Ditosylate; AKOS005145766; AC-1314; 4-[[3-Chloro-4-(3-fluorobenzyloxy)phenyl]amino]-6-[5-[[(2-methanesulfonylethyl)amino]methyl]furan-2-yl]quinazoline; GSK572016; GW 572016; GW 572016X; Lapatinib; N-(3-Chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-((2-methylsulfonylethylamino)methyl)-2-furyl)quinazolin-4-amine; NCGC00167507-01; HMS2089H10; N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine; 388082-78-8; N-(3-Chloro-4-{[(3-fluorophenyl)methyl]oxy}phenyl)-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furanyl]-4-quinazolinamine; CID208908; LS-187771; Kinome_3685; Lapatinib, Tykerb, GW572016; 231277-92-2; D08108; nchembio866-comp20; AB1004631; 4-Quinazolinamine, N-(3-chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl)-; Lapatinib; GW 572016X; Kinome_3684; NSC745750; DB01259; UNII-0VUA21238F; GW572016; GSK 572016; 1xkk; N-{3-CHLORO-4-[(3-FLUOROBENZYL)OXY]PHENYL}-6-[5-({[2-(METHYLSULFONYL)ETHYL]AMINO}METHYL)-2-FURYL]-4-QUINAZOLINAMINE	388082-78-8	208908	14911387	TTDS00355	Epidermal growth factor receptor	EGFR;EGFR-TK;Epidermal growth factor receptor ErbB-1;Epidermal growth factor receptor-tyrosine kinase;Receptor protein-tyrosine kinase ErbB-1	P00533	1956	ENSG00000146648	inhibitor
DAP000394	Cetuximab	Cetuximab; Erbitux (TN); 205923-56-4; D03455; Cetuximab (genetical recombination) (JAN); Cetuximab (USAN/INN); Erbitux; Cetuximab (genetical recombination)	205923-56-4	2333	46507042	TTDS00355	Epidermal growth factor receptor	EGFR;EGFR-TK;Epidermal growth factor receptor ErbB-1;Epidermal growth factor receptor-tyrosine kinase;Receptor protein-tyrosine kinase ErbB-1	P00533	1956	ENSG00000146648	antibody
DCL000347	TAK165	Mubritinib (USAN/INN); I14-8814; UNII-V734AZP9BR; 1H-1,2,3-triazole, 1-(4-(4-((2-((1E)-2-(4-(trifluoromethyl)phenyl)ethenyl)-4-oxazolyl)methoxy)phenyl)butyl)-; AC1O61A3; Mubritinib; D04025; TAK 165; CID6444692; 4-[[4-[4-(triazol-1-yl)butyl]phenoxy]methyl]-2-[(E)-2-[4-(trifluoromethyl)phenyl]ethenyl]-1,3-oxazole; AC-5248; 366017-09-6	366017-09-6	6444692	50490680	TTDS00355	Epidermal growth factor receptor	EGFR;EGFR-TK;Epidermal growth factor receptor ErbB-1;Epidermal growth factor receptor-tyrosine kinase;Receptor protein-tyrosine kinase ErbB-1	P00533	1956	ENSG00000146648	inhibitor
DCL000589	Pazopanib + Tyverb/Tykerb	N/A	N/A	443391	36886718	TTDS00355	Epidermal growth factor receptor	EGFR;EGFR-TK;Epidermal growth factor receptor ErbB-1;Epidermal growth factor receptor-tyrosine kinase;Receptor protein-tyrosine kinase ErbB-1	P00533	1956	ENSG00000146648	inhibitor
DAP001482	HEGF	N/A	62253-63-8	N/A	3747909	TTDS00355	Epidermal growth factor receptor	EGFR;EGFR-TK;Epidermal growth factor receptor ErbB-1;Epidermal growth factor receptor-tyrosine kinase;Receptor protein-tyrosine kinase ErbB-1	P00533	1956	ENSG00000146648	activator
DCL000344	Tykerb	CID11557040; CHEMBL1201179; Lapatinib ditosylate (USAN); GW-572016F; GW-572016; Lapatinib tosilate hydrate (JAN); Lapatinib tosilate hydrate; Lapatinib Ditosylate; LAPATINIB DITOSYLATE MONOHYDRATE; Tykerb (TN); Tykerb; Tyverb; D04024; GW-2016; 388082-78-8	388082-78-8	208908	783738	TTDS00355	Epidermal growth factor receptor	EGFR;EGFR-TK;Epidermal growth factor receptor ErbB-1;Epidermal growth factor receptor-tyrosine kinase;Receptor protein-tyrosine kinase ErbB-1	P00533	1956	ENSG00000146648	inhibitor
DCL001145	Anti-HER3/EGFR DAF	N/A	N/A	N/A	N/A	TTDS00355	Epidermal growth factor receptor	EGFR;EGFR-TK;Epidermal growth factor receptor ErbB-1;Epidermal growth factor receptor-tyrosine kinase;Receptor protein-tyrosine kinase ErbB-1	P00533	1956	ENSG00000146648	antibody
DCL000195	PG-490-88	195883-09-1; Omtriptolide sodium (USAN); Omtriptolide sodium; TriptoSar; CID6918521; D06625; YM-274; PG490-88Na; F-60008; PG-490-88	N/A	6918522	12015431	TTDC00046	Nuclear factor NF-kappa-B	DNA-binding factor KBF2;H2TF1;Lymphocyte translocation chromosome 10;Lyt10;NFKB2;Nuclear factor NF-kappa-B p52 subunit;Oncogene Lyt-10	Q00653	4791	ENSG00000077150	inhibitor
DCL000254	Tyloxapol	Superiuone [French]; formaldehyde; oxirane; 4-(2,4,4-trimethylpentan-2-yl)phenol; component of Alevaire; CID71388; Tyloxapol [USAN:BAN:INN]; WLN: /QR DX1&1&1X1&1&1/ &/*O2*/ &/*O1*/; Superinone; Triton W.R.1339; Triton WR 1339; AR-1J0912; Tyloxapol; Triton WR-1339; NSC 90255; Phenol, 4-(1,1,3,3-tetramethylbutyl)-, polymer with formaldehyde and oxirane; 25301-02-4; Formaldehyde, polymer with oxirane and 4-(1,1,3,3-tetra methylbutyl)phenol; 9014-66-8; Phenol, p-(1,1,3,3-tetramethylbutyl)-, polymer with ethylene oxide and formaldehyde; Tiloxapol [INN-Spanish]; 9014-50-0; Triton A-20; Formaldehyde, polymer with oxirane and 4-(1,1,3,3-tetramethylbutyl)phenol; p-(1,1,3,3-Tetramethylbutyl)phenol polymer with ethylene oxide and formaldehyde; Poly(oxy-1,2-ethanediyl), alpha,alpha',alpha'',alpha'''-(5,11,17,23-tetrakis(1,1,3,3-tetramethylbutyl)pentacyclo(19.3.1.13,7.19,13.115,19)octacosa-1(25),3,5,7(28),9,11,13(27),15,17,19(26),21,23-dodecaene-25,26,27,28-tetrayl)tetrakis(omega-hydroxy-; Superiuone; NSC90255; Oxyethylated tertiary octyl-phenol-formaldehyde polymer; Tyloxypal; Alevaire; Tyloxapolum [INN-Latin]; Tyloxapolum; UNII-Y27PUL9H56; Tiloxapol; AC1L2G2K; formaldehyde; oxirane; 4-(1,1,3,3-tetramethylbutyl)phenol; 51273-01-9; Ethylene oxide-formaldehyde-p-octylphenol copolymer; LS-105149; Macrocyclon; Enuclene; 4-(1,1,3,3-Tetramethylbutyl)phenol, polymer with formaldehyde & oxirane; 4-(1,1,3,3-Tetramethylbutyl)phenol, polymer with formaldehyde  oxirane; AC1Q6918; p-Isooctylpolyoxyethylenephenol formaldehyde polymer	N/A	71388	24900557	TTDC00046	Nuclear factor NF-kappa-B	DNA-binding factor KBF2;H2TF1;Lymphocyte translocation chromosome 10;Lyt10;NFKB2;Nuclear factor NF-kappa-B p52 subunit;Oncogene Lyt-10	Q00653	4791	ENSG00000077150	inhibitor
DCL000120	GMX1777	N/A	N/A	N/A	N/A	TTDC00046	Nuclear factor NF-kappa-B	DNA-binding factor KBF2;H2TF1;Lymphocyte translocation chromosome 10;Lyt10;NFKB2;Nuclear factor NF-kappa-B p52 subunit;Oncogene Lyt-10	Q00653	4791	ENSG00000077150	inhibitor
DCL000015	Curaxin CBLC102	N/A	N/A	6427053	43021080	TTDC00046	Nuclear factor NF-kappa-B	DNA-binding factor KBF2;H2TF1;Lymphocyte translocation chromosome 10;Lyt10;NFKB2;Nuclear factor NF-kappa-B p52 subunit;Oncogene Lyt-10	Q00653	4791	ENSG00000077150	inhibitor
DCL001005	Sulfasalizine	N/A	599-79-1	5359476	48425604	TTDC00046	Nuclear factor NF-kappa-B	DNA-binding factor KBF2;H2TF1;Lymphocyte translocation chromosome 10;Lyt10;NFKB2;Nuclear factor NF-kappa-B p52 subunit;Oncogene Lyt-10	Q00653	4791	ENSG00000077150	activator
DCL000294	Cetilistat	D09208; Cametor; MolPort-005-943-563; 2-(Hexadecyloxy)-6-methyl-4H-3,1-benzoxazin-4-one; Cetilistat; 282526-98-1 (Parent); ATL-962; I14-6098; Cetilistat [INN]; 335149-24-1; ATL 962; Cetilistat (JAN/USAN/INN); AC-219; 282526-98-1; UNII-LC5G1JUA39; ATL962; C520092; CID9952916	282526-98-1	9952916	46049526	TTDS00064	Lipase	N/A	N/A	N/A	N/A	inhibitor
DCL000322	GT-389255	N/A	162394-19-6	N/A	47207024	TTDS00064	Lipase	N/A	N/A	N/A	N/A	inhibitor
DPR000022	Bisquaternary salt	N/A	N/A	N/A	N/A	TTDS00064	Lipase	N/A	N/A	N/A	N/A	inhibitor
DAP000053	Orlistat	C055122; N-Formyl-L-leucine (1S)-1-[[(2S,3S)-3-hexyl-4-oxo-2-oxetanyl]methyl]dodecyl ester; R-212; Orlipastat; Alli, Xenical, Tetrahydrolipstatin, Orlistat; L-Leucine,N-formyl-, (1S)-1-(((2S,3S)-3-hexyl-4-oxo-2-oxetanyl)methyl)dodecyl ester; UNII-95M8R751W8; THLP; CPD000466339; Roche brand of orlistat; (-)-Tetrahydrolipstatin; Orlipastatum; LS-178328; CID3034010; NCGC00165856-01; DB01083; C29H53NO5; Ro-18-0647; O4139_SIGMA; Ro 18-0647/008; SMR000466339; BIDD:GT0853; Xenical; Tetrahydrolipstatin; 111397-16-1; Alli; GlaxoSmithKline brand of orlistat; MLS000759448; MLS001423955; D04028; L-Leucine, N-formyl-, 1-((3-hexyl-4-oxo-2-oxetanyl)methyl)dodecyl ester, (2S-(2alpha(R*),3beta))-; Orlipastatum [INN-Latin]; MLS002207022; CHEMBL175247; Orlistat (USAN/INN); AC-19012; S1629_Selleck; N-Formyl-L-leucine, ester with (3S,4S)-3-hexyl-4-((2S)-2-hydroxytridecyl)-2-oxetanone; Xenical (TN); 1-((3-hexyl-4-oxo-2-oxetanyl)methyl)dodecyl-2-formamido-4-methylvalerate; Hoffmann-La Roche brand of orlistat; Orlistat [USAN:INN]; nchembio.129-comp24; L-Leucine, N-formyl-, (1S)-1-(((2S,3S)-3-hexyl-4-oxo-2-oxetanyl)methyl)dodecyl ester; FT-0082584; HMS2051I08; orlistat; Ro 18-0647/002; [(2S)-1-[(2S,3S)-3-hexyl-4-oxooxetan-2-yl]tridecan-2-yl] (2S)-2-formamido-4-methylpentanoate; 96829-58-2; SAM001246637; KS-1183; MolPort-005-938-035; AC1MHWQP	96829-58-2	3034010	213522	TTDS00064	Lipase	N/A	N/A	N/A	N/A	inhibitor
DPR000116	Tanaproget	304853-42-7; T98; DB04787; AC1NA08O; 1H-Pyrrole-2-carbonitrile, 5-(1,4-dihydro-4,4-dimethyl-2-thioxo-2H-3,1-benzoxazin-6-yl)-1-methyl-; Tanaproget (USAN/INN); 1zuc; NSP-989; NSP 989; D06003; UNII-W9F9H8GXWR; CID4369524; CHEMBL539163; 5-(4,4-dimethyl-2-sulfanylidene-1H-3,1-benzoxazin-6-yl)-1-methylpyrrole-2-carbonitrile; Tanaproget; 5-(4,4-Dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-1-methyl-1H-pyrrole-2-carbonitrile	304853-42-7	4369524	47207661	TTDC00085	Complement C1s component	C1 esterase;C1-esterase	P09871	716	ENSG00000182326	inhibitor
DCL000953	Recombinant human C1 inhibitor	N/A	139755-83-2	5212	48416538	TTDC00085	Complement C1s component	C1 esterase;C1-esterase	P09871	716	ENSG00000182326	inhibitor
DCL000629	Romiplostim	N/A	N/A	5329098	49674962	TTDC00085	Complement C1s component	C1 esterase;C1-esterase	P09871	716	ENSG00000182326	inhibitor
DAP001545	Cinryze	N/A	N/A	N/A	N/A	TTDC00085	Complement C1s component	C1 esterase;C1-esterase	P09871	716	ENSG00000182326	inhibitor
DCL000075	C1-INH	N/A	N/A	N/A	N/A	TTDC00085	Complement C1s component	C1 esterase;C1-esterase	P09871	716	ENSG00000182326	inhibitor
DPR000096	Rhucin	N/A	N/A	N/A	N/A	TTDC00085	Complement C1s component	C1 esterase;C1-esterase	P09871	716	ENSG00000182326	inhibitor
DAP000569	Sulindac	Spectrum5_001024; cMAP_000021; Chibret; Copals; Z-5-Fluoro-2-methyl-1-[p-(methlsulfinyl)benzylidene]indene-3-acetic acid; cis-5-Fluoro-2-methyl-1-((4-(methylsulfinyl)phenyl)methylene)-1H-indene-3-acetic acid; KBio2_004888; STK802068; SPBio_002206; HMS1921C11; (E)-(1)-5-Fluoro-2-methyl-1-((4-(methylsulphinyl)phenyl)methylene)-1H-indene-3-acetic acid; Spectrum3_001365; 1H-Indene-3-acetic acid, 5-fluoro-2-methyl-1-((4-(methylsulfinyl)phenyl)methylene)-, (Z)-; Sulindacum; S2007_Selleck; C20H17FO3S; Gum copal; AC1Q6YHK; (Z)-5-Fluoro-2-methyl-1-[[4-(methyl-sulfinyl)phenyl]methylene]-1H-indene-3-acetic acid; NCGC00025268-01; KST-1B6530; AB00513800; Lopac-S-8139; Klinoril; Tocris-1707; KBioGR_001571; AR-1A9609; Prestwick_456; NCGC00015970-08; EU-0101070; Clinoril (TN); KBioSS_002322; Clinoril; UNII-M5221THD3M; {(1E)-5-fluoro-2-methyl-1-[4-(methylsulfinyl)benzylidene]-1H-inden-3-yl}acetic acid; Novo-Sundac; HMS2092K15; EINECS 253-819-2; KBio2_007456; Sulindac (JAN/USP/INN); Kendrick Brand of Sulindac; Sulindaco [INN-Spanish]; Sulindac [USAN:BAN:INN:JAN]; NCGC00094349-02; Apo Sulin; EINECS 250-893-8; 6301-55-9; Novopharm Brand of Sulindac; Apo-Sulin; Merck Brand of Sulindac; SPECTRUM1500556; NCGC00025268-03; D013467; C01531; Spectrum4_000876; 38194-50-2; CPD000326718; 5-Fluoro-2-methyl-1-((4-(methylsulphinyl)phenyl)methylene)-1H-indene-3-acetic acid; CID5352; IDI1_000601; Sulindaco; CID1548885; Chemia Brand of Sulindac; Sulindal; Prestwick2_000073; MK 231; (Z)-5-Fluoro-2-methyl-1-((p-(methylsulfinyl)phenyl)methylene)-1H-indene-3-acetic acid; Aflodac; SPBio_001451; KBioSS_001506; BRN 2951842; Lopac0_001070; {(1Z)-5-fluoro-2-methyl-1-[4-(methylsulfinyl)benzylidene]-1H-inden-3-yl}acetic acid; Aclin; CHEBI:9352; BRD-A03427350-001-01-3; Copal rosin varnish; 9000-14-0; Nu Sulindac; KBio2_001506; Prestwick1_000073; Cahill May Roberts Brand of Sulindac; 32004-68-5; 53933-60-1; MolPort-002-507-760; Novo Sundac; BSPBio_002890; KBio2_006642; HMS501O03; KBio2_002320; Alphapharm Brand of Sulindac; Sulindacum [INN-Latin]; 2-[6-fluoro-2-methyl-3-[(4-methylsulfinylphenyl)methylidene]inden-1-yl]acetic acid; AC1LU7GY; Copal resin; DivK1c_000601; DB00605; D00120; CAS-38194-50-2; UNM-0000306136; NCGC00015970-03; MK-231; KBio2_004074; BB_SC-1128; S8139_SIAL; KBioGR_002320; Apotex Brand of Sulindac; SAM002554933; CID1548887; [(1E)-5-fluoro-2-methyl-1-{[4-(methylsulfinyl)phenyl]methylidene}-1H-inden-3-yl]acetic acid; Arthrocine; BPBio1_000315; Copal; EINECS 258-873-0; (Z)-5-Fluoro-2-methyl-1-[p-(methylsulfinyl)benzylidene]indene-3-acetic acid; cis-5-Fluoro-2-methyl-1-((p-methylsulfinyl)benzylidene)indene-3-acetic acid; S8139_SIGMA; NCGC00094349-01; sulindac; Arthrobid; MLS001304027; KBio1_000601; MLS001056554; CHEMBL1376; UNII-184SNS8VUH; AC-4550; Nu Pharm Brand of Sulindac; MK231; NCGC00015970-01; LS-81610; S 8139; KBio3_002800; AC1L1K5T; AKOS004119989; HMS2089J04; SMR000326718; KBio3_002110; Nu-Pharm Brand of Sulindac; 2-[(3E)-6-fluoro-2-methyl-3-[(4-methylsulfinylphenyl)methylidene]inden-1-yl]acetic acid; SMR000043852; Spectrum2_001326; HMS1568O07; Spectrum_001026; Prestwick3_000073; Sulindac sulfoxide; EINECS 232-527-9; I06-0523; NCGC00015970-02; Resin copal; Kenalin; 2-[(3Z)-6-fluoro-2-methyl-3-[(4-methylsulfinylphenyl)methylidene]inden-1-yl]acetic acid; S4429_SIAL; CCRIS 3305; {5-fluoro-2-methyl-1-[4-(methylsulfinyl)benzylidene]-1h-inden-3-yl}acetic acid; AC1LU7GU; Nu-Sulindac; MolPort-003-666-287; SBB058181; NCGC00025268-02; Merck Sharp & Dohme Brand of Sulindac; BSPBio_000285; Mobilin; NINDS_000601; MLS002207124; Prestwick0_000073; BRD-A13946108-001-04-9	38194-50-2	5352	4693	TTDS00115	Aldose reductase	Aldehyde reductase;AR	P15121	231	ENSG00000085662	inhibitor
DCL000311	Fidarestat	AC1L4MX5; Aldos; (2S,4S)-2-AMINOFORMYL-6-FLUORO-SPIRO[CHROMAN-4,4'-IMIDAZOLIDINE]-2',5'-DIONE; AR-1A0129; 136087-85-9; Spiro(4H-1-benzopyran-4,4'-imidazolidine)-2-carboxamide, 6-fluoro-2,3-dihydro-2',5'-dioxo-, (2S-cis)-; SNK-860; FID; AR-1A0128; Fidaresstat; CHEMBL84446; Spiro(4H-1-benzopyran-4,4'-imidazolidine)-2-carboxamide, 2,3-dihydro-2',5'-dioxo-6-fluoro-, (2S-cis)-; Fidarestat; 158271-18-2; 105300-43-4; C12H10FN3O4; D01842; (+)-(2s,4s)-6-fluoro-2',5'-dioxospiro[chroman-4,4'-imidazolidine]-2-carboxamide; SK 860; (2S,4S)-6-fluoro-2',5'-dioxospiro[2,3-dihydrochromene-4,4'-imidazolidine]-2-carboxamide; KST-1A1767; (+)-(2S,4S)-6-Fluoro-2',5'-dioxospiro(chroman-4,4'-imidazolidine)-2-carboxamide; Fidarestat (JAN/INN); LS-145864; (2S,4S)-6-Fluoro-2',5'-dioxospiro(3,4-dihydro-2H-1-benzopyran-4,4'-imidazolidine)-2-carboxamide; CID160024; (2S,4S)-6-fluoro-2',5'-dioxospiro(chroman-4,4'-imidazolidine)-2-carboxamide; C077139; Aldos (TN); UNII-8SH8T1164U; Snk 860; 15825-24-8; AC1Q4OK0; ZINC03789766; KST-1A1766	136087-85-9	160024	10253854	TTDS00115	Aldose reductase	Aldehyde reductase;AR	P15121	231	ENSG00000085662	inhibitor
DAP001376	Epalrestat	LS-151103; Ono-2235; 5-((1Z,2E)-2-Methyl-3-phenylpropenylidene)-4-oxo-2-thioxo-3-thiazolidineacetic acid; 2-((z)-5-((e)-2-methyl-3-phenylallylidene)-4-oxo-2-thioxothiazolidin-3-yl)acetic acid; 2-[(5Z)-5-[(E)-2-methyl-3-phenylprop-2-enylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]acetic acid; D01688; {5-[(E)-2-Methyl-3-phenyl-prop-2-en-(Z)-ylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-acetic acid; Epalrestat (JAN/INN); Epalrestatum [Latin]; STK337187; SMR000414799; MolPort-000-436-626; 5-((Z,E)-beta-Methylcinnamylidene)-4-oxo-2-thioxo-3-thiazolidineacetic acid; ONO-2; UNII-424DV0807X; NCGC00164613-01; CHEMBL56337; I01-1929; AKOS000274207; {(5Z)-5-[(2E)-2-methyl-3-phenylprop-2-en-1-ylidene]-4-oxo-2-thioxo-1,3-thiazolidin-3-yl}acetic acid; ONO 2; MLS000806985; CID1549120; Kinedak (TN); (5-[(e)-2-methyl-3-phenyl-prop-2-en-(z)-ylidene]-4-oxo-2-thioxo-thiazolidin-3-yl)-acetic acid 82159-; Epalrestatum; 3-carboxymethyl-5-(methyl-3-phenylpropenylidene)rhodanine; AC1LU7S3; CHEBI:188882; 82159-09-9; Bio-0155; Kinedak; epalrestat; C15H13NO3S2; Ono 2235; 3-Thiazolidineacetic acid, 5-(2-methyl-3-phenyl-2-propenylidene)-4-oxo-2-thioxo-, (E,E)-; Epalrestat [INN]	82159-09-9	1549120	213475	TTDS00115	Aldose reductase	Aldehyde reductase;AR	P15121	231	ENSG00000085662	inhibitor
DCL000270	Sorbinil	Spiro(4H-1-benzopyran-4,4'-imidazolidine)-2',5'-dione, 6-fluoro-2,3-dihydro-, (S)-; MolPort-000-883-094; CHEMBL266497; Sorbinilo; Sorbinil (USAN/INN); Spiro[4H-1-benzopyran-4,4'-imidazolidine]-2',5'-dione, 6-fluoro-2,3-dihydro-; D05893; Sorbinil; CID337359; 68367-52-2; AKOS000280386; CP 45634; NSC 355082; DB02712; NCGC00159452-02; InChI=1/C11H9FN2O3/c12-6-1-2-8-7(5-6)11(3-4-17-8)9(15)13-10(16)14-11/h1-2,5H,3-4H2,(H2,13,14,15,16; Sorbinilum [Latin]; (4S)-6-fluoro-2,3-dihydro-2'H,5'H-spiro[chromene-4,4'-imidazolidine]-2',5'-dione; CP-45634; (4S)-6-fluorospiro[2,3-dihydrochromene-4,5'-imidazolidine]-2',4'-dione; NSC355082; AC1L7LJN; ZINC00002070; Sorbinilo [Spanish]; C026411; D-6-fluoro-spiro(chroman-4,4'-imidazolidine)-2',5'-dione; Sorbinilum; SBI	68367-52-2	337359	48416546	TTDS00115	Aldose reductase	Aldehyde reductase;AR	P15121	231	ENSG00000085662	inhibitor
DCL000283	Zenarestat	1(2H)-Quinazolineacetic acid, 3,4-dihydro-3-((4-bromo-2-fluorophenyl)methyl)-7-chloro-2,4-dioxo-; 2-[3-[(4-bromo-2-fluorophenyl)methyl]-7-chloro-2,4-dioxoquinazolin-1-yl]acetic acid; CID5724; CI 1014; Zenarestat; AC1Q260H; Zenarestatum; (3-(4-bromo-2-fluorobenzyl)-7-chloro-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-1-yl)acetic acid; FK 366; CI-1014; FR-74366; ZES; Fk366; KST-1A0661; 3-((4-Bromo-2-fluorophenyl)methyl)-7-chloro-3,4-dihydro-2,4-dioxo-1(2H)-quinazolineacetic acid; Zenarestatum [INN-Latin]; CHEMBL10413; Zenarestat (USAN/INN); [3-(4-BROMO-2-FLUORO-BENZYL)-7-CHLORO-2,4-DIOXO-3,4-DIHYDRO-2H-QUINAZOLIN-1-YL]-ACETIC ACID; DB02132; AR-1A8877; LS-139978; D03807; C17H11BrClFN2O4; Zenarestat [USAN:INN]; 1142-27-4; 2-(7-Chloro-3-(4-bromo-2-fluorobenzyl)-1,2,3,4-tetrahydro-2,4-dioxoquinazolin)-1-acetic acid; FR74366; UNII-180C9PJ8JT; FR 74366; 3-(4-Bromo-2-fluorobenzyl)-7-chloro-3,4-dihydro-2,4-dioxo-1(2H)-quinazolineacetic acid; 112733-06-9; FK-366; [3-(4-bromo-2-fluorobenzyl)-7-chloro-2,4-dioxo-3,4-dihydroquinazolin-1(2h)-yl]acetic acid; AC1L1KZW	112733-06-9	5724	46516730	TTDS00115	Aldose reductase	Aldehyde reductase;AR	P15121	231	ENSG00000085662	inhibitor
DAP000867	Abatacept	N/A	332348-12-6	10237	46509198	TTDS00490	T-lymphocyte activation antigen CD86	Activation B7-2 antigen;B70;BU63;CD28LG2;CD86;CTLA-4 counter-receptor B7.2;FUN-1	P42081	942	ENSG00000114013	binder
DCL001174	CM2489	N/A	N/A	N/A	N/A	TTDC00342	Calcium-release activated calcium channel	Calcium release-activated calcium channel protein 1;Protein orai-1;Transmembrane protein 142A;ORAI1	Q96D31	84876	ENSG00000182500	inhibitor
DAP001331	Natamycin	SMR000058788; Delvolan; Pimaricine; Pimaricin (JP15); CID657250; DB00826; MolPort-005-935-314; P9703_SIGMA; HMS1571M10; Tennecetin; P0440_SIGMA; Delvopos; MolPort-003-939-127; Stereoisomer of 22-((3-amino-3,6-dideoxy-beta-D-mannopyranosyl)oxy)-1,3,26-trihydroxy-12-methyl-10-oxo-6,11,28-trioxatricyclo(22.3.1.0(sup 5,7))octacosa-8,14,16,18,20-pentaene-25-carboxylic acid; D00884; Prestwick2_001104; Natamicina [INN-Spanish]; Natamycine; Natacyn (TN); Antibiotic A-5283; 6,11,28-Trioxatricyclo[22.3.1.05,7]octacosa-8,14,16,18,20-pentaene-25-carboxylic acid, 22-[(3-amino-3,6-dideoxy-.beta.-D-mannopyranosyl)oxy]-1,3,26-trihydroxy-12-methyl-10-oxo-, (1R,3S,5R,7R,8E,12R,14; NATAMYCIN; EINECS 231-683-5; Natamycin (USP/INN); AC1MC3GI; 7681-93-8; (1R,3S,5R,7R,8E,12R,14E,16E,18E,20E,22R,24S,25R,26S)-22-[(3-amino-3,6-dideoxy-beta-D-mannopyranosyl)oxy]-1,3,26-trihydroxy-12-methyl-10-oxo-6,11,28-trioxatricyclo[22.3.1.0~5,7~]octacosa-8,14,16,18,20-pentaene-25-carboxylic acid; CL 12,625; SMR000466358; pimaricin; Natamycinum; Pimarizin [German]; Pimaricin preparation; Delvocid; Natafucin; Pimarizin; Mycophyt; UNII-8O0C852CPO; MLS000069611; E,16E,18E,20E,22R,24S,25R,26S)-; CPD000466358; CL 12625; AC-15226; Natacyn; Myprozine; SMP1_000240; Natamicina; Pimafucin; Natamycin [USAN:INN:BAN]; Natamycinum [INN-Latin]; AC1LCW93; MLS000759475; 80482_FLUKA; Synogil; LS-7662; SAM001246683; C08073; Natamycine [INN-French]; CHEMBL1200656; CL-12625; Natamycin preparation; C33H47NO13; 16-(3-Amino-3,6-didesoxy-beta-D-mannopyranosyloxy)-5,6-epoxy-8,12,14-trihydroxy-26-methyl-2,10-dioxo-1-oxacyclohexacosa-3,17,19,21,23-pentaen-13-carbonsaeure	7681-93-8	5281099	10273	TTDS00463	Fungal outer membrane	N/A	N/A	N/A	N/A	binder
DAP001332	Haloprogin	M-1028 (Meiji); Haloprogin [USAN:INN:JAN]; NINDS_000762; Halotex; AC1L1G7Q; KBioSS_002369; M 1028; Haloprogin (JAN/USAN/INN); DivK1c_000762; C9H4Cl3IO; Benzene, 1,2,4-trichloro-5-((3-iodo-2-propynyl)oxy)-; BRN 1976771; Haloprogina [INN-Spanish]; Polik; UNII-AIU7053OWL; Haloprogine [INN-French]; WLN: I1UU2OR BG DG EG; Halotex (TN); CHEBI:353862; Mycanden; Haloproginum [INN-Latin]; KBio2_007501; NSC 100071; 777-11-7; NCGC00181134-01; Mycilan; Haloprogine; KBio2_004933; CHEMBL1289; Haloprogina; 3-Iodo-2-propynyl 2,4,5-trichlorophenyl ether; AC1Q3I91; 2,4,5-Trichlorophenyl-gamma-iodopropargyl ether; Ether, 3-iodo-2-propynyl 2,4,5-trichlorophenyl; 1,2,4-trichloro-5-(3-iodoprop-2-ynoxy)benzene; D00339; EINECS 212-286-6; DB00793; KBio1_000762; IDI1_000762; (3-Iod-2-propinyl)-(2,4,5-trichlorphenyl)ether; 2,4,5-Trichlorophenyl gamma-iodopropargil ether; 2,4,5-Trichlorophenyl .gamma.-iodopropargil ether; HMS502G04; CID3561; MolPort-003-666-198; Benzene,1,2,4-trichloro-5-[(3-iodo-2-propynyl)oxy]; 2,4,5-Trichlorophenyl iodopropargyl ether; 2,4,5-Trichlorophenyl .gamma.-iodopropargyl ether; component of Halotex; Prestwick_232; haloprogin; LS-67855; KBio2_002365; Benzene, 1,2,4-trichloro-5-[(3-iodo-2-propynyl)oxy]-; 1,2,4-trichloro-5-[(3-iodo-2-propynyl) oxy]benzene; Haloproginum; Spectrum_001852; NSC100071; aloprogen	777-11-7	3561	7847405	TTDS00463	Fungal outer membrane	N/A	N/A	N/A	N/A	binder
DAP001322	Amphotericin B	Amphotherizin [German]; Amphotericinum B; Prestwick0_000410; Amphotericin B, Streptomyces sp.; Amphotericin B, Lipid-based; Amphotericine B [INN-French]; Abelecet; SMR001566780; Fungisome; Fungizone (TN); NCI60_004288; NS 718; MolPort-006-392-260; NCGC00090808-01; LMPK06000002; CHEMBL1200646; Amphomoronal; NCI527017; C47H73NO17; Amphotericinum; Amfotericina B [INN-Spanish]; UNII-7XU7A7DROE; AC1NTQ32; MLS002702966; C06573; KBio2_003119; Amphotericin B Colloidal Dispersion; Amphotec (TN); amphotericin B liposomal; AB00513832; 12633-72-6; KBioGR_002298; D00203; AC1NY9JC; CHEMBL267345; AC1L70KF; CID6713692; SinuNase; Spectrum2_000818; AC1L24V6; Prestwick3_000410; NSC-527017; Amphotericine B; BIDD:GT0351; CHEBI:2682; 54482-28-9; HMS1569A22; Amphotericin B [USAN:INN:JAN]; CID10677275; Spectrum4_001779; Amfotericina B; CID10629638; Amphortericin B; NCGC00179595-01; CID10533925; 30782-62-8; CCRIS 5963; Ambisome; Amphotericin B Cholesterol Dispersion; NSC 527017; LS-187721; Amphozone; NCGC00098014-01; CID9919339; EINECS 215-742-2; KBioSS_000551; Prestwick1_000410; SPBio_002279; Fungizone; Amphotericinum B [INN-Latin]; CID352546; AC1L1CN2; SPBio_000715; Amphotherizin; ST50999656; NSC527017; ABLC; Abelcet; Amphotericin; AC1O8PFK; 1397-89-3; AC1L73U6; amophotericin B; Fungilin; Amphocin; Ambap1397-89-3; AI3-26528; CID6604295; Amphotericin B (JP15/USP/INN); amphotericin b; I06-0257; DB00681; Liposomal Amphotericin B; BPBio1_000374; 5-18-10-00525 (Beilstein Handbook Reference); Prestwick2_000410; CID5280965; CID1972; Halizon; AMPH-B; KBio2_005687; AC1O7GCZ; AC1O8FQV; AmBisome (TN); CID14956; HSDB 3008; Amphotec; SMP1_000302; Amphotericin-B; AC1NUQG4; CID5386092; Ampho-Moronal; CID5771695; CID5458486; CID6708817; KBio2_000551; HSDB 3008 IAB; 8055-20-7; Fungisone; Prestwick_721; LNS-AmB; CID354192; NCGC00014913; NKTR-024; LS-93; AC1NQXTD; SpecPlus_000949; BSPBio_000340; DivK1c_007045; Spectrum_000111; NCIStruc2_000920; NCIStruc1_001042; Amphotericin .BETA.; BRN 0078342; KBio1_001989; Mysteclin-F	1397-89-3	14956	8802	TTDS00463	Fungal outer membrane	N/A	N/A	N/A	N/A	binder
DAP000879	Nystatin	O-V Statin; EPA Pesticide Chemical Code 202800; Moronal; LS-187914; MolPort-003-938-857; Nilstat; Nystatine [INN-French]; Mycostatin Pastilles; Mykostatyna; Nyamyc; Nystatin LF (liposome); (1S,15S,16R,17R,18S,19E,21E,25E,27E,29E,31E)-33-[(3-amino-3,6-dideoxy-alpha-D-mannopyranosyl)oxy]-1,3,4,7,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,25,27,29,31-hexaene-36-carboxylic acid; Fungicidin; Nistatin; SMP1_000219; Mykinac; Nyotran; (4E,6E,8E,10E,14E,16E)-3-[(2R,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-19,25,27,29,32,33,35,37-octahydroxy-18,20,21-trimethyl-23-oxo-22,39-dioxabicyclo[33.3.1]nonatriaconta-4,6,8,10,14,16-hexaene-38-carboxylic acid; Nistatina [INN-Spanish]; BCBcMAP01_000244; Nystavescent; CID5311331; UNII-ZGT9EY838C; Nystatin A3; Nystatin preparation; HMS500N05; IDI1_000263; Spectrum5_001333; (4E,6E,8E,10E,14E,16E,18S,19R,21S,35S)-3-[(3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-19,25,27,29,32,33,35,37-octahydroxy-18,20,21-trimethyl-23-oxo-22,39-dioxabicyclo[33.3.1]nonatriaconta-4,6,8,10,14,16-hexaene-38-carboxylic acid; Nystatinum; Caswell No. 607B; Mycostatin 20; EINECS 215-749-0; Diastatin; Nystatin A1, A2, A3 complex; Nystatin A2; Myconystatin; MolPort-003-983-447; AC1NSKG2; Korostatin; CHEMBL229383; Nystop; N6261_SIGMA; CHEBI:473992; C47H75NO17; N4014_SIGMA; (1S,15S,16R,17R,18S,19E,21E,25E,27E,29E,31E)-33-[(3-amino-3,6-dideoxy-a-D-mannopyranosyl)oxy]-1,3,4,7,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,25,27,29,31-hexaene-36-carboxylic acid; Zydin E; AC1NWAPF; CID6433272; UNII-BDF1O1C72E; nystatin; Comycin; BSPBio_002119; HMS2091L08; SPECTRUM1500446; Mycostatin; Moronal (antibiotic); Candex Lotion; Nystatyna [Polish]; Stamycin; HMS1920D08; N1638_SIGMA; Terrastatin; Nystaform; Nystatin G; (4E,6E,8E,10E,14E,16E,18S,19R,20R,21S,35S)-3-[(2S,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-19,25,27,29,32,33,35,37-octahydroxy-18,20,21-trimethyl-23-oxo-22,39-dioxabicyclo[33.3.1]nonatriaconta-4,6,8,10,14,16-hexaene-38-carboxylic acid; N3503_SIGMA; HSDB 3138; CHEMBL1200650; CID5702099; Nystatinum [INN-Latin]; NSC 150817; LS-97612; MolPort-003-665-538; Nystatin [INN:BAN:JAN]; Nystatin A; Nistatina; Barstatin 100; Nystatyna; Candio-hermal; Nystatin A1; AI3-26526; Nystex; Stamicin; Herniocid; Nystatine; Biofanal; AC1O5FWI; Nystan	1400-61-9	11953884	8801	TTDS00463	Fungal outer membrane	N/A	N/A	N/A	N/A	binder
DAP001412	Olmesartan medoxomil	KBio3_002711; Olmesartan medoxomil (JAN/USAN); KBio2_007626; Cs 866; NCGC00095136-01; MolPort-005-935-047; LS-181818; AC1L2Y71; HMS1922L15; (5-methyl-2-oxo-1,3-dioxolen-4-yl)methoxy-4-(1-hydroxy-1-methylethyl)-2-propyl-1-(4-(2-(tetrazol-5-yl)phenyl)phenyl)methylimidazol-5-carboxylate; Olmesartan medoxomil; 1H-imidazole-5-carboxylic acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-,(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester; DE-092; BRD-K78485176-001-02-9; KS-1182; Olmesartan medoximil; CHEMBL1200692; Benicar (TN); Spectrum2_000506; DB00275; CS-866RN; CS-866; D01204; NCGC00095136-02; Sankyo Brand of Olmesartan Medoxomil; L001061; MolPort-003-666-605; KBio2_005058; BSPBio_003491; 144689-63-4; KBioSS_002498; Olvance; 1H-Imidazole-5-carboxylic acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester; SPBio_000431; Olmetec; KBioGR_001040; Forest Brand of Olmesartan Medoxomil; Spectrum3_001676; (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 5-(2-hydroxypropan-2-yl)-2-propyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxylate; HMS2089K18; Berlin-Chemie Brand of Olmesartan Medoxomil; CID130881; SPECTRUM1505205; S1587_Selleck; UNII-6M97XTV3HD; I06-0025; Benevas; Spectrum_001944; Spectrum5_001556; Bio-0071; Spectrum4_000740; KBio2_002490; C097933; CS-866DM; Olmetec (TN); Benicar, Olmetec,Olmesartan; AC-1601; HMS2093K16; Benicar; 1H-Imidazole-5-carboxylic acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-((2'-(1H-tetrazol-5-yl) (1,1'-biphenyl)-4-yl)methyl)-, (5-methyl-2-oxo-1,3-dioxol-4-yl) methyl ester	144689-63-4	130881	707351	TTDS00267	Type-1 angiotensin II receptor	Angiotensin 1 receptor;Angiotensin II receptor 1;AT1;AT1AR	P30556	185	ENSG00000144891	antagonist
DAP001258	Tasosartan	CID60919; DB01349, Tasosartan; 145733-36-4; 2,4-dimethyl-8-{[2'-(2h-tetrazol-5-yl)biphenyl-4-yl]methyl}-5,8-dihydropyrido[2,3-d]pyrimidin-7(6h)-one; Tasosartan (USAN/INN); AC1Q6LAA; CHEMBL432162; D06010; S1539_Selleck; ANA-756; CHEBI:215967; AKOS000278114; DB01349; TASOSARTAN; Verdia; WAY-ANA-756; L001443; WAY-126756; 2,4-dimethyl-8-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-5,6-dihydropyrido[2,3-d]pyrimidin-7-one; AC1L1U5X; Pyrido(2,3-d)pyrimidin-7(6H)-one, 5,8-dihydro-2,4-dimethyl-8-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-	145733-36-4	60919	12014735	TTDS00267	Type-1 angiotensin II receptor	Angiotensin 1 receptor;Angiotensin II receptor 1;AT1;AT1AR	P30556	185	ENSG00000144891	antagonist
DCL001236	S-474474	N/A	N/A	N/A	N/A	TTDS00267	Type-1 angiotensin II receptor	Angiotensin 1 receptor;Angiotensin II receptor 1;AT1;AT1AR	P30556	185	ENSG00000144891	blocker
DAP000908	Eprosartan	SK&F 108566; SKF-108566; CHEMBL813; (E)-alpha{[2-butyl-1-[(4-carboxyphenyl)methyl]-1H-imidazole-5-yl]methylene}-2-thiopheneproprionic acid; Eprosartan (USAN/INN); HMS2089O10; Eprosartan [USAN:BAN:INN]; L000248; TL8000785; 4-({2-butyl-5-[(1E)-2-carboxy-3-(2-thienyl)prop-1-en-1-yl]-1H-imidazol-1-yl}methyl)benzoic acid; CID5281037; AC1NQXXN; D04040; 2-Thiophenepropanoic acid, alpha-((2-butyl-1-((4-carboxyphenyl)methyl)-lH-imidazol-5-yl)methylene)-, (E)-; (4-carboxybenzyl)imidazole-5-acrylic acid; Eprosartan; C23H24N2O4S; (E)-2-Butyl-1-(p-carboxybenzyl)-alpha-2-thenylimidazole-5-acrylic acid; (E)-3-[2-n-butyl-1-{(4-carboxyphenyl)methyl}-1H-imidazol-5-yl]-2-(2-thienyl)methyl-2-propenoic acid; SK-108566; NCGC00164557-01; Bio-0035; SK&F-108566; CHEBI:4814; 4-[[2-butyl-5-[(E)-3-hydroxy-3-oxo-2-(thiophen-2-ylmethyl)prop-1-enyl]imidazol-1-yl]methyl]benzoic acid; C07467; 4-({2-butyl-5-[(1E)-2-carboxy-3-(thiophen-2-yl)prop-1-en-1-yl]-1H-imidazol-1-yl}methyl)benzoic acid; HSDB 7521; STK618317; BIDD:GT0030; 133040-01-4; MolPort-003-847-076; UNII-2KH13Z0S0Y; LS-172855	133040-01-4	5281037	9670	TTDS00267	Type-1 angiotensin II receptor	Angiotensin 1 receptor;Angiotensin II receptor 1;AT1;AT1AR	P30556	185	ENSG00000144891	antagonist
DCL000653	TAK-591	N/A	N/A	N/A	N/A	TTDS00267	Type-1 angiotensin II receptor	Angiotensin 1 receptor;Angiotensin II receptor 1;AT1;AT1AR	P30556	185	ENSG00000144891	antagonist
DAP000766	Telmisartan	BIDD:GT0365; 144701-48-4; 4'-((4-Methyl-6-(1-methyl-2-benzimidazolyl)-2-propyl-1-benzimidazolyl)methyl)-2-biphenylcarboxylic acid; Abbott brand of telmisartan; YM-086; C084178; NCGC00095150-02; NCGC00095150-03; CHEMBL1017; Spectrum3_001089; GlaxoSmithKline brand of telmisartan; BIBR-277-SE; BIBR 277SE; S1738_Selleck; AC-2013; AC1Q5U7O; BIBR-277SE; HSDB 7590; Bay 68-9291; 4'-[(1,7'-dimethyl-2'-propyl-1H,3'H-2,5'-bibenzimidazol-3'-yl)methyl]biphenyl-2-carboxylic acid; Spectrum5_001053; Micardis; 4'-[(1,7'-dimethyl-2'-propyl-1H,3'H-2,5'-bibenzimidazol-3'-yl)methyl][1,1'-biphenyl]-2-carboxylic acid; Boehringer Ingelheim brand of telmisartan; 4'-((1,4'-dimethyl-2'-propyl(2,6'-bi-1H-benzimidazol)-1'-yl)methyl)-(1,1'-biphenyl)-2-carboxylic acid; Telmisartan; Pritor; BSPBio_002738; BRD-K73999723-001-02-2; 2-[4-[[4-methyl-6-(1-methylbenzimidazol-2-yl)-2-propylbenzimidazol-1-yl]methyl]phenyl]benzoic acid; D00627; C33H30N4O2; Bio-0103; CHEBI:9434; (1,1'-Biphenyl)-2-carboxylic acid, 4'-((1,4'-dimethyl-2'-propyl(2,6'-bi-1H-benzimidazol)-1'-yl)methyl)-; Kinzalmono; BAY-68-9291; Telmisartan (JAN/USAN/INN); LS-44263; Glaxo Wellcome brand of telmisartan; SMR000466326; STK624049; I06-0281; HMS2051P16; 4'-((4-mehtyl-6-(1-methyl-2-benzimidazolyl)-2-propyl-1-benzimmidazolyl)methyl)-2-biphenylcarboxylic acid; SPECTRUM1505261; BIBR 277; HMS2093M22; Kinzal; 4'-[(1,4'-dimethyl-2'propyl[2,6'-bi-1H-benzimidazol]-1'-yl)methyl]-[1,1'-biphenyl]-2-carboxylic acid; BAY68-9291; HMS2090P17; MolPort-003-666-621; NCGC00095150-01; SAM001246602; CPD000466326; CID65999; Spectrum2_001976; BIBR-277; L001035; SPBio_002131; Micardis (TN); Spectrum4_001261; Telmisartan [USAN:INN]; TL8000991; DB00966; MLS001076687; KBioGR_001842; C07710; Micardis, Targit, Temax, BIBR277, Telmisartan; HMS1922P07; AC1L24EB; KBio3_001958; MLS000759432; UNII-U5SYW473RQ	144701-48-4	65999	9912	TTDS00267	Type-1 angiotensin II receptor	Angiotensin 1 receptor;Angiotensin II receptor 1;AT1;AT1AR	P30556	185	ENSG00000144891	antagonist
DAP000364	Irbesartan	AC-537; BMS-186295, SR-47436, Aprovel, Karvea, Irbesartan; MolPort-003-666-550; Aprovel; Karvea; KBio2_002231; Irbesarran; Avapro (TN); SPECTRUM1504259; DB01029; HMS2051L08; Spectrum3_000994; I06-0690; UNII-J0E2756Z7N; MLS001424099; S1507_Selleck; 2-butyl-3-{[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl}-1,3-diazaspiro[4.4]non-1-en-4-one; Lrbesartan; 2-butyl-3-[ p -( o -1 H -tetrazol-5-ylphenyl)benzyl]-1,3-diazaspiro[4,4]non-1-en-4-one; 1,3-Diazaspiro(4.4)non-1-en-4-one, 2-butyl-3-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-; Avapro; Spectrum_001751; 2-Butyl-3-(p-(o-1H-tetrazol-5-ylphenyl)benzyl)-1,3-diazaspiro(4.4)non-1-en-4-one; Bristol Myers Brand of Irbesartan; KBioSS_002231; Jsp002315; AC1L1GMK; Spectrum5_001288; Bio-0053; CHEBI:5959; 1,3-Diazaspiro[4.4]non-1-en-4-one, 2-butyl-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-; Sanofi Winthrop Brand of Irbesartan; 2-Butyl-3-[2'-(1H-tetrazol-5-yl)biphenyl-4-ylmethyl]1,3-diaza-spiro[4.4]non-1-en-4-one; CID3749; C25H28N6O; 2-butyl-3-[2'-(1h-tetrazol-5-yl)biphenyl-4-ylmethyl]1,3-diaza-spiro[; SAM001246548; HMS2093E16; BSPBio_002687; KBio2_007367; BRD-K60038276-001-02-5; SPBio_001889; SR-47436; NCGC00095122-02; L000319; NCGC00095122-01; Irbesartan (JAN/USAN/INN); 2-butyl-3-[p-(o-1H-tetrazol-5-ylphenyl)benzyl]-1,3-diazaspiro[4.4]non-1-en-4-one; 8-butyl-7-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-7,9-diazaspiro[4.4]non-8-en-6-one; TL8000875; SMR000466306; KBioGR_001603; HMS1922J05; 2-n-butyl-3-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-1,3-diazaspiro(4,4)non-1-en-4-one; 2-butyl-3-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1,3-diazaspiro[4.4]non-1-en-4-one; BIDD:GT0347; 2-butyl-3-[2'-(1h-tetrazol-5-yl)-biphenyl-4-ylmethyl]-1,3-diaza-spiro[; D00523; SR 47436; CPD000466306; BMS 186295; C081309; NCGC00095122-03; STK645362; 138402-11-6; C07469; LS-60064; KBio3_001907; CHEMBL1513; irbesartan; Irbesartan [USAN:INN]; Irbetan; Spectrum4_001122; BMS Brand of Irbesartan; MLS000759408; KBio2_004799; BMS-186295; Spectrum2_001675	138402-11-6	3749	7847589	TTDS00267	Type-1 angiotensin II receptor	Angiotensin 1 receptor;Angiotensin II receptor 1;AT1;AT1AR	P30556	185	ENSG00000144891	antagonist
DAP001367	Eprosartan mesylate	Eprosartan mesilate; LS-173203; 4-[[2-butyl-5-[(E)-3-hydroxy-3-oxo-2-(thiophen-2-ylmethyl)prop-1-enyl]imidazol-1-yl]methyl]benzoic acid; methanesulfonic acid; CHEMBL1200987; EPROSARTAN MESYLATE; Futuran; 144143-96-4; 2-Thiophenepropanoic acid, alpha-((2-butyl-1-((4-carboxyphenyl)methyl)-1H-imidazol-5-yl)methylene)-, (E)-, monomethanesulfonate; Eprosartan mesylate (USAN); Tevetenz; AC1NR04M; SK&F 108566-J; Navixen; SK&F-108566-J; (E)-2-butyl-1-(p-carboxybenzyl)-alpha-2-thienylimidazole-5-acrylic acid monomethanesulfonate; CHEBI:48409; (E)-2-Butyl-1-(p-carboxybenzyl)-alpha-2-thenylimidazole-5-acrylic acid, monomethanesulfonate; Teveten (TN); Eprosartan mesylate dihydrate; Eprosartan mesylate [USAN:BAN]; CID5282474; Epro-sartan mesylate dihydrate; UNII-8N2L1NX8S3; 4-({2-butyl-5-[(1E)-2-carboxy-3-(2-thienyl)prop-1-en-1-yl]-1H-imidazol-1-yl}methyl)benzoic acid methanesulfonate; (E)-alpha-((2-butyl-1-((4-carboxyphenyl)methyl)-1H-imidazol-5-yl)methylene)-2-thiophenepropanoic acid monomethanesulfonate; Teveten; C23H24N2O4S.CH4O3S; Teveten SB; Regulaten; D02082	144143-96-4	5282474	7849144	TTDS00267	Type-1 angiotensin II receptor	Angiotensin 1 receptor;Angiotensin II receptor 1;AT1;AT1AR	P30556	185	ENSG00000144891	antagonist
DAP000523	Losartan	AC1L1H3Q; HMS1922J13; DUP 89; Oprea1_644635; KBioSS_002193; Losartic; UNII-JMS50MPO89; BSPBio_002695; 114798-26-4; MK-954; KBio2_004761; (2-butyl-4-chloro-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-imidazol-5-yl)methanol; losartan; 2-Butyl-4-chloro-1-((2'-(1H-etrazol-5-yl) (1,1'-biphenyl)-4-yl)methyl)-1H-imidazole-5-methanol; LOSARTAN POTASSIUM; NCGC00095125-03; Spectrum_001713; D08146; LS-78746; Losartic (TN); [2-butyl-5-chloro-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol; Lortaan; 2-n-butyl-4-chloro-5-hydroxymethyl-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole; BRD-K76205745-001-02-5; DB00678; (2-butyl-4-chloro-1-{[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl}-1H-imidazol-5-yl)methanol; Hyzaar; 1H-imidazole-5-methanol, 2-butyl-4-chloro-1-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-; Spectrum2_001677; SPBio_001893; Jsp001094; 2-Butyl-4-chloro-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl-1H-imidazole-5-methanol; NCGC00095125-01; Spectrum4_001126; Cozaar; Losartan [INN:BAN]; CID3961; 1H-Imidazole-5-methanol, 2-butyl-4-chloro-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (9CI); Losartan monopotassium salt; Losartan (INN); 124750-99-8 (mono-potassium salt); CHEBI:6541; 2-n-butyl-4-chloro-5-hydroxymethyl-1-[[2'-(1H-tetrazol-5-yl)-biphenyl-4-yl]methyl]imidazole; 1H-Imidazole-5-methanol, 2-butyl-4-chloro-1-((2'-(1H-tetrazol-5-yl)(1,1'- biphenyl)-4-yl)methyl)-; BIDD:GT0286; HMS2093E22; KBio3_001915; KBio2_002193; L000351; SPECTRUM1504268; I14-9710; MK954; NCGC00095125-02; Spectrum3_000998; MolPort-003-666-553; Spectrum5_001466; CHEMBL191; C22H23ClN6O; KBioGR_001611; KBio2_007329; CL23623; 2-butyl-4-chloro-1-[p-(o-1H-tetrazol-5ylphenyl)benzyl]imidazole-5-methanol; DuP-753; C07072	114798-26-4	3961	205151	TTDS00267	Type-1 angiotensin II receptor	Angiotensin 1 receptor;Angiotensin II receptor 1;AT1;AT1AR	P30556	185	ENSG00000144891	antagonist
DAP001256	Forasartan	UNII-065F7WPT0B; Forasartan; 5-[(3,5-dibutyl-1,2,4-triazol-1-yl)methyl]-2-[2-(2H-tetrazol-5-yl)phenyl]pyridine; Pyridine, 5-((3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl)-2-(2-(1H-tetrazol-5-yl)phenyl)-; L007541; AC1L31G8; DB01342; 145216-43-9; Forasartan (USAN/INN); SC-52458; CHEBI:239233; 5-((3,5-Dibutyl-1H-1,2,4-triazol-1-yl)methyl)-2-(2-(1H-tetrazol-5-ylphenyl))pyridine; D04243; SC 52458; CHEMBL315021; CID132706	145216-43-9	132706	14904609	TTDS00267	Type-1 angiotensin II receptor	Angiotensin 1 receptor;Angiotensin II receptor 1;AT1;AT1AR	P30556	185	ENSG00000144891	antagonist
DAP000363	Valsartan	L-Valine, N-(1-oxopentyl)-N-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-; C081489; Spectrum4_000749; (s)-2-(n-((2'-(1h-tetrazol-5-yl)biphenyl-4-yl)methyl)pentanamido)-3-methylbutanoic acid; SMR000466318; CGP 48933; CID60846; CHEMBL1069; Spectrum_001796; MLS001424088; DB00177; (2S)-3-methyl-2-[pentanoyl-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]amino]butanoic acid; |Tareg; Kalpress; C24H29N5O3; KBio2_004855; UNII-80M03YXJ7I; KBio2_002287; Bio-0796; L-Valine, N-(1-oxopentyl)-N-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-; BSPBio_003501; L-Valine, N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (9CI); N-pentanoyl-N-{[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl}-L-valine; Sanol brand of valsartan; BIDD:GT0345; BRD-K45158365-001-02-3; AC1L1U1M; D00400; KBio3_003006; Miten; Spectrum2_001120; Valsartan (JAN/USAN/INN); MLS000759423; (S)-N-valeryl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]-methyl}-valine; MolPort-003-666-608; Diovan; SAM001246581; Nisis||; Diovan, Valsartan; AC-4543; Spectrum3_001831; CEPA brand of valsartan; HMS1922L21; Valsarran; Esteve brand of valsartan; KBioGR_001078; HMS2051L12; KBioSS_002289; CPD000466318; Vals; N-pentanoyl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-L-valine; Spectrum5_001582; Novartis brand of valsartan; HMS2093K22; MolPort-002-507-854; Valsartan [USAN:INN]; CGP-48933; SPBio_001260; TL8000869; Aventis brand of valsartan; HSDB 7519; CHEBI:9927; AC1Q5QIK; S1894_Selleck; Lacer brand of valsartan; (s)-3-methyl-2-(pentanoyl-[2'-(1h-tetrazol-5-yl)-biphenyl-4-ylmethyl]-amino)-butyric acid 137862-53-; KBio2_007423; N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-L-valine; Diovan (TN); SPECTRUM1505209; valsartan; N-(p-(o-1H-Tetrazol-5-ylphenyl)benzyl)-N-valeryl-L-valine; 137862-53-4; Schwarz brand of valsartan; Ambap137862-53-4; LS-161334; N-valeryl-N-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)valine; Provas; Tareg; Nisis; walsartan	137862-53-4	60846	197083	TTDS00267	Type-1 angiotensin II receptor	Angiotensin 1 receptor;Angiotensin II receptor 1;AT1;AT1AR	P30556	185	ENSG00000144891	antagonist
DAP001257	Saprisartan	3-[[3-bromo-2-[2-(trifluoromethylsulfonylamino)phenyl]-1-benzofuran-5-yl]methyl]-5-cyclopropyl-2-ethylimidazole-4-carboxamide; GR-138950X; L000533; Saprisartan potassium; AC1L1U60; AC1Q4KIE; Saprisartan; 1h-imidazole-5-carboxamide, 1-[[3-bromo-2-[2-[[(trifluoromethyl)sulfonyl]amino]phenyl]-5-benzofuranyl]methyl]-4-cyclopropyl-2-ethyl-; GR-138950; DB01347; GR-138950C; 146623-69-0; CHEMBL305544; CID60921; 1H-Imidazole-5-carboxamide, 1-((3-bromo-2-(2-(((trifluoromethyl)sulfonyl)amino)phenyl)-5-benzofuranyl)methyl)-4-cyclopropyl-2-ethyl-; GR 138950	146623-69-0	60921	12014753	TTDS00267	Type-1 angiotensin II receptor	Angiotensin 1 receptor;Angiotensin II receptor 1;AT1;AT1AR	P30556	185	ENSG00000144891	antagonist
DAP000524	Candesartan	2-ethoxy-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-benzimidazole-7-carboxylic acid; CV11974; candesartan; D00522; 1H-Benzimidazole-7-carboxylic acid, 2-ethoxy-1-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-; Candesartan [USAN:INN]; UNII-S8Q36MD2XX; Candesartan (USAN/INN); S1578_Selleck; KS-5003; 2-ethoxy-7-carboxy-1-(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methylbenzimidazole; Candesartan [BAN]; I01-0374; AC-203; HSDB 7520; 139481-59-7; MolPort-005-943-739; FT-0083585; 2-(ethyloxy)-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-benzimidazole-7-carboxylic acid; CID2541; 2-ethoxy-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4ethyl}-1H-benzimidazole-7-carboxylic acid; Atacand, Blopress, Amias, Ratacand,Candesartan; CV 11974; CV-11974; CHEBI:216848; C081643; Blopress (TN); NCGC00167474-01; 2-ethoxy-3-[[4-[2-(1h-tetrazol-5-yl)phenyl]phenyl]methyl]-3h-benzoimidazole-4-carboxylic acid; MolPort-003-845-570; CHEBI:3347; CHEMBL1016; LS-32740; C07468; 2-Ethoxy-3-[[4-[2-(1H-tetrazol-5-yl)phenyl]phenyl] methyl]-3H-benzoimidazole-4-carboxylic acid; 2-ethoxy-1-({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl)-1H-benzimidazole-7-carboxylic acid; C24H20N6O3; 2-Ethoxy-1-(p-(o-1H-tetrazol-5-ylphenyl)benzyl)-7-benzimidazolecarboxylic acid; Blopress; 2-ethoxy-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylic acid; TL8000897; AC1L1DWT; BIDD:GT0350; DB00796; L000156; 1H-Benzimidazole-7-carboxylic acid, 2-ethoxy-1-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-; HMS2089M22	139481-59-7	2541	208049	TTDS00267	Type-1 angiotensin II receptor	Angiotensin 1 receptor;Angiotensin II receptor 1;AT1;AT1AR	P30556	185	ENSG00000144891	antagonist
DAP000907	Olmesartan	D05246; C437965; Olmesartan (USAN/INN); RNH-6270; CS-088; 4-(1-hydroxy-1-methylethyl)-2-propyl-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-imidazole-5-carboxylic acid; MLS000759446; SMR000466337; 4-(1-hydroxy-1-methylethyl)-2-propyl-1-{[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl}-1H-imidazole-5-carboxylic acid; CID158781; CHEBI:48416; MolPort-003-666-606; HMS2051K12; CPD000466337; SAM001246634; 144689-24-7; UNII-8W1IQP3U10; CHEMBL1516; LS-181800; Olmesartan [USAN]; L001097; 1H-Imidazole-5-carboxylic acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-((2'-(1H-tetrazol-5-yl) (1,1'-biphenyl)-4-yl)methyl)-; MLS001424016; 4-(2-hydroxypropan-2-yl)-2-propyl-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-imidazole-5-carboxylic acid; RNH 6270; 5-(2-hydroxypropan-2-yl)-2-propyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxylic acid; Olmesartan; 4-(hydroxy-1-methylethyl)-2-propyl-1-{[2'-(1H-tetrazol-5-yl)-1,1'-biphenyl-4-yl]methyl}-1H-imidazole-5-carboxylic acid; 4-(hydroxy-1-methylethyl)-2-propyl-1-((2'-(1H-tetrazol-5-yl)-1,1'-biphenyl-4-yl)methyl)-1H-imidazole-5-carboxylic acid; I14-10085; omesartan; AC1L4KLS	144689-63-4	158781	707351	TTDS00267	Type-1 angiotensin II receptor	Angiotensin 1 receptor;Angiotensin II receptor 1;AT1;AT1AR	P30556	185	ENSG00000144891	antagonist
DCL000437	Apaziquone	AC1NXQZI; E-85/053; EOquin; EO9; Apaziquone; CHEMBL73822; 5-(aziridin-1-yl)-3-(hydroxymethyl)-2-[(E)-3-hydroxyprop-1-enyl]-1-methylindole-4,7-dione; LS-83017; NOR-701; EO-9; E-09; 1H-Indole-4,7-dione, 5-(1-aziridinyl)-3-(hydroxymethyl)-2-(3-hydroxy-1-propenyl)-1-methyl-,(E)-; C15H16N2O4; NSC 382,459; E-85/050; D02965; C060817; Apaziquonum [INN-Latin]; E 09; NSC 382459; Apaziquone (USAN/INN); 1H-Indole-4,7-dione, 5-(1-aziridinyl)-3-(hydroxymethyl)-2-(3-hydroxy-1-propenyl)-1-methyl-, (E)-; NSC-382456; EO 9; Neoquin; CID5813717; 1H-Indole-4,7-dione, 5-(1-aziridinyl)-3-(hydroxymethyl)-2- ((1E)-3-hydroxy-1-propenyl)-1-methyl-; Eoquin (TN); EO 9 (pharmaceutical); Apaziquone [USAN:INN]; MolPort-005-942-580; 114560-48-4; NSC 382456; 5-(Azridin-1-yl)-3-(hydroxymethyl)-2-((1E)-3-hydroxyprop-1-enyl)-methyl-1H-indole-4,7-dione; 1H-Indole-4,7-dione, 5-(1-aziridinyl)-3-(hydroxymethyl)-2-((1E)-3-hydroxy-1-propenyl)-1-methyl-; ZINC01536777; 3-hydroxymethyl-5-aziridinyl-1-methyl-2-(1H-indole-4,7-dione)prop-beta-en-alpha-ol; NSC-382459; Apaziquonum; (E)-5-(1-Azirinyl)-3-(hydroxymethyl)-2-(3-hydroxy-1-propenyl)-1-methyl-1H-indole-4,7-dione; UNII-H464ZO600O; E09	114560-48-4	5813717	17397122	TTDC00200	NAD(P)H dehydrogenase [quinone] 1	Azoreductase;DTD;DT-diaphorase;DT-diaphorase 1;Menadione reductase;NAD(P)H:quinone oxidoreductase 1;NQO1;Phylloqui reductase;Phylloquinone reductase;QR1;Qui reductase 1;Quinone reductase 1	P15559	1728	ENSG00000181019	activator
DCL000664	Xatral	Uroxatral, Alfuzosin hydrochloride; 2-Furancarboxamide, N-(3-((4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino)propyl)tetrahydro-, monohydrochloride (+-)-; 133880-44-1; SL 77499-10; SL-77499; Xatral OD; AR-1K4672; Alfuzosin hydrochloride (JAN/USAN); Uroxatral; MolPort-006-391-851; SL-77499-10; Uroxatral (TN); AC1Q5PED; N-[3-[4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro-2-furancarboxamide hydrochloride; CHEBI:32286; n-{3-[(4-amino-6,7-dimethoxychinazolin-2-yl)(methyl)amino]propyl}tetrahydrofuran-2-carboxamidhydrochlorid; SL-7749910; Xatral Retard; D01692; UNII-75046A1XTN; Alfuzosin HCl; CHEMBL1723; Xatral XL; Xatral SR; CID71764; Alfetim; Urion; (+-)-N-(3-((4-Amino-6,7-dimethoxy-2-quinazolinyl)methylamino)propyl)tetrahydro-2-furamide monohydrochloride; Alfoten; SL-77.0499-10; Xatral; S1409_Selleck; 81403-80-7 (Parent); HMS1569A05; LS-70107; Alfuzosin hydrochloride [USAN]; AC-1116; Alfuzosin Hydrochloride; SL 77 499-10; C19H27N5O4; AC1L2GRP; N-[3-[(4-amino-6,7-dimethoxyquinazolin-2-yl)-methylamino]propyl]oxolane-2-carboxamide hydrochloride	N/A	2092	12012888	TTDC00292	Alpha-1A adrenergic receptor	Alpha 1A-adrenoceptor;Alpha 1A-adrenoreceptor;Alpha adrenergic receptor 1c;Alpha-1C adrenergic receptor	P35348	148	ENSG00000120907	antagonist
DCL000519	Dutasteride & tamsulosin	N/A	N/A	N/A	N/A	TTDC00292	Alpha-1A adrenergic receptor	Alpha 1A-adrenoceptor;Alpha 1A-adrenoreceptor;Alpha adrenergic receptor 1c;Alpha-1C adrenergic receptor	P35348	148	ENSG00000120907	antagonist
DCL000405	GSK1265744	N/A	N/A	5288371	46508160	TTDC00211	HIV integrase	N/A	O56072	N/A	N/A	inhibitor
DCL001235	S-349572	N/A	N/A	N/A	N/A	TTDC00211	HIV integrase	N/A	O56072	N/A	N/A	inhibitor
DCL001233	S-265744 LAP	N/A	N/A	N/A	N/A	TTDC00211	HIV integrase	N/A	O56072	N/A	N/A	inhibitor
DCL000408	GSK1349572	GSK-1349572; CHEMBL1213165	N/A	N/A	N/A	TTDC00211	HIV integrase	N/A	O56072	N/A	N/A	inhibitor
DCL000052	ARQ 197	N/A	N/A	N/A	N/A	TTDC00110	Hepatocyte growth factor receptor	C-met;C-Met receptor tyrosine kinase;HGF receptor;HGF-SF receptor;Met proto-oncogene tyrosine kinase	P08581	4233	ENSG00000105976	inhibitor
DCL000430	Anti-cMet	N/A	N/A	N/A	N/A	TTDC00110	Hepatocyte growth factor receptor	C-met;C-Met receptor tyrosine kinase;HGF receptor;HGF-SF receptor;Met proto-oncogene tyrosine kinase	P08581	4233	ENSG00000105976	antibody
DCL000656	TAK-701	N/A	N/A	16760691	33932084	TTDC00110	Hepatocyte growth factor receptor	C-met;C-Met receptor tyrosine kinase;HGF receptor;HGF-SF receptor;Met proto-oncogene tyrosine kinase	P08581	4233	ENSG00000105976	antibody
DCL000265	XL880	CHEMBL1230609; S1111_Selleck; XL880; GSK1363089; 88Z; GSK 1363089; EC-000.2326; 937176-80-2; XL 880; GSK 089; GSK1363089, GSK089, foretinib, EXEL-2880, XL880	N/A	N/A	N/A	TTDC00110	Hepatocyte growth factor receptor	C-met;C-Met receptor tyrosine kinase;HGF receptor;HGF-SF receptor;Met proto-oncogene tyrosine kinase	P08581	4233	ENSG00000105976	inhibitor
DCL001168	Cabozantinib	N/A	N/A	N/A	N/A	TTDC00110	Hepatocyte growth factor receptor	C-met;C-Met receptor tyrosine kinase;HGF receptor;HGF-SF receptor;Met proto-oncogene tyrosine kinase	P08581	4233	ENSG00000105976	inhibitor
DCL000574	MK-8033	N/A	N/A	N/A	N/A	TTDC00110	Hepatocyte growth factor receptor	C-met;C-Met receptor tyrosine kinase;HGF receptor;HGF-SF receptor;Met proto-oncogene tyrosine kinase	P08581	4233	ENSG00000105976	inhibitor
DCL000229	SGX523	SGX523, SGX-523; CHEMBL1236107; S1112_Selleck; EC-000.2355; SGX-523; DB08584	N/A	N/A	N/A	TTDC00110	Hepatocyte growth factor receptor	C-met;C-Met receptor tyrosine kinase;HGF receptor;HGF-SF receptor;Met proto-oncogene tyrosine kinase	P08581	4233	ENSG00000105976	inhibitor
DPR000077	Mteron-F1	N/A	501081-76-1	N/A	47208286	TTDC00110	Hepatocyte growth factor receptor	C-met;C-Met receptor tyrosine kinase;HGF receptor;HGF-SF receptor;Met proto-oncogene tyrosine kinase	P08581	4233	ENSG00000105976	stimulator
DCL000171	MP470	N/A	850879-09-3	N/A	85151253	TTDC00110	Hepatocyte growth factor receptor	C-met;C-Met receptor tyrosine kinase;HGF receptor;HGF-SF receptor;Met proto-oncogene tyrosine kinase	P08581	4233	ENSG00000105976	inhibitor
DCL000562	MetMAb	N/A	N/A	N/A	N/A	TTDC00110	Hepatocyte growth factor receptor	C-met;C-Met receptor tyrosine kinase;HGF receptor;HGF-SF receptor;Met proto-oncogene tyrosine kinase	P08581	4233	ENSG00000105976	antibody
DCL000342	SU-6668	N/A	N/A	5329099	12015385	TTDC00024	Basic fibroblast growth factor receptor 1	bFGF-R;CD331 antigen;c-fgr;FGFR-1;Fms-like tyrosine kinase 2	P11362	2260	ENSG00000077782	inhibitor
DCL000113	FGF-1	N/A	106096-92-8	N/A	3808660	TTDC00024	Basic fibroblast growth factor receptor 1	bFGF-R;CD331 antigen;c-fgr;FGFR-1;Fms-like tyrosine kinase 2	P11362	2260	ENSG00000077782	binder
DAP000288	Glycine	NChemBio.2007.13-comp1; Glicoamin; (15N)Glycine; Glycine, non-medical; AR-1A0345; 6000-43-7 (hydrochloride); BPBio1_001222; Aciport; 33242-26-1 (calcium salt); Sucre de gelatine; 32817-15-5 (copper salt); an alpha amino acid ester; 7575-55-5; nchembio.266-comp30; 25718-94-9; Glycine (JP15/USP); glycine; Glyzin; CCRIS 5915; S04-0135; Glykokoll; Glycinum; 2-Aminoacetic acid; CHEBI:16228; CID750; nchem.554-comp2; Glycine iron sulphate (1:1); nchembio.198-comp12; Acidum aminoaceticum; Biomol-NT_000195; KST-1A2919; G0317; GLYCINE, ACS; MolPort-000-871-607; W328707_ALDRICH; 848646-45-7; Gyn-hydralin; 513-29-1 (sulfate (3:1)); nchembio.121-comp9; Glycin; Amitone; L-alpha-amino acids; AC1L19XW; Glycine-UL-14C hydrochloride; bmse000089; CHEMBL773; UNII-TE7660XO1C; G8790_SIGMA; Glicina [INN-Spanish]; EINECS 200-272-2; 15527_SIAL; gly; Glycocoll; AC1Q28JW; Acido aminoacetico; AKOS000119626; G7403_SIGMA; 15527_RIEDEL; AI3-04085; B72BA06C-60E9-4A83-A24A-A2D7F465BB65; Acide aminoacetique; Hgly; G5417_SIGMA; CPD-8569; AR-1A0532; Glicina; 7490-95-1 (hydrochloride (2:1); 2311-65-1; Acide aminoacetique [INN-French]; NCGC00024503-02; 410225_SIAL; Aminoazijnzuur; AMINOACETIC ACID 1.5% IN PLASTIC CONTAINER; G0099; Glycine [INN]; NCGC00024503-01; G5523_SIGMA; 50046_FLUKA; 87867-94-5; CHEBI:15705; Polyglycine II; AB1002628; WLN: Z1VQ; aminoacetic acid; Acetic acid, amino-; L-Glycine; CHEBI:15428; 18875-39-3; (1-13c)glycinato; Aminoethanoic acid; D00011; AC1Q53O0; 56-40-6; 6000-44-8 (mono-hydrochloride salt); 52955-63-2; Aminoacetic acid; Aminoethanoic acid; Glycocoll; 2,2-dialkylglycines; Aminoessigsaeure; Leimzucker; 63183-41-5 (hydrochloride hydrogen carbonate); 50046_SIGMA; Glycine, labeled with carbon-14; H-Gly-OH; NSC 25936; GLY (IUPAC abbrev); 17829-66-2 (cobalt salt); Glycinum [INN-Latin]; 29728-27-6 (monoammonium salt); Acidum aminoaceticum [INN-Latin]; KST-1A8102; AB-131/40217813; nchembio.145-comp33; 57678-19-0; Glycolixir; DB00145; FT-0083159; 33226_SIAL; 35947-07-0 (calcium salt (2:1)); Tocris-0219; FEMA No. 3287; Hampshire glycine; 33226_RIEDEL; Glycine, homopolymer (VAN); G8898_SIGMA; NSC25936; HSDB 495; C00037; LS-218; 7490-95-1 (hydrochloride (2:1)); nchembio.265-comp9; GLYCINE 1.5% IN PLASTIC CONTAINER; polyglycine; Corilin; InChI=1/C2H5NO2/c3-1-2(4)5/h1,3H2,(H,4,5; 15743-44-9 (mono-potassium salt); 71295-98-2 (phosphate (1:1)); Glycosthene; H2N-CH2-COOH; P8791_SIGMA; G7126_SIGMA; Acido aminoacetico [INN-Spanish]; L001246; Padil	56-40-6	750	3339	TTDS00123	Glutamate [NMDA] receptor subunit epsilon 1	HNR2A;NMDA receptor NR2A;NMDAR2A;N-methyl D-aspartate receptor subtype 2A;NR2A	Q12879	2903	ENSG00000183454	antagonist
DAP000160	Levofloxacin	(3S)-9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid; Cravit Ophthalmic; SMR000466387; Ofloxacin S-(-)-form; LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER; RWJ-25213; LEVOFLOXACIN; Spectrum3_000995; R-Ofloxacin; DR3355; CCRIS 4073; HR-355; Volequin; (R)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid; DR-3355: L-isomer of ofloxacin; KBioGR_001605; SAM001246758; HMS1922J07; Oftaquix; Leroxacin; MolPort-002-885-835; LS-133260; Spectrum4_001123; Nofaxin; Spectrum_001719; (&#8722;)-Ofloxacin; MLS001165709; Cravit (TN); KBio3_001909; Floxacin; LFX; Levofloxacin tablet, suspension or intravenous; NCGC00178529-01; KBio2_007335; AC-7593; (-)-(S)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid; Aeroquin; C18H20FN3O4.H2O; 100986-85-4; (-)-Ofloxacin; C07660; Levox; KBio2_004767; Levoxacin; 28266_FLUKA; Levofloxacine; Floxel; CHEMBL33; 100986-86-5; MLS001423977; Levofloxacinum; KBioSS_002199; DR-3355; Mosardal; Spectrum5_001438; Levofloxacino [INN-Spanish]; C18H20FN3O4; (-)-(S)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyridol[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid hemihydrate; L0193; Levofloxacin [USAN:INN:JAN]; KBio2_002199; HMS2090O10; (-)-(S)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7Hpyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid hemihydrate; 28266_SIGMA; Levofloxacine [INN-French]; Iquix; Reskuin; BRD-K09471561-001-06-7; Levokacin; Lesacin; (R)-isomer; 7H-Pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid, 2,3-dihydro-9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-, (S)-; CID149096; 7H-Pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid, 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-, (3S)-; CPD000466387; 7H-Pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid, 2,3-dihydro-9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-, hemihydrate, (S)-; LS-171761; AC1L3YF8; Spectrum2_001676; HMS2051G04; (S)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid; Cravit; (S)-(-)-Ofloxacin; Levaquin; S1940_Selleck; SPBio_001891; Levofloxacinum [INN-Latin]; HMS2093E18; (S)-Ofloxacin; LVX; Levofloxacin (INN); MP-376; DR 3354; HR 355; BSPBio_002689; Quixin; MLS000759524; SPECTRUM1504260; Elequine; D08120; S-(-)-Ofloxacin; d-Levofloxacin; Ambap100986-85-4; DB01137; Tavanic; RWJ 25213-097; L-Ofloxacin; Levofloxacino; CCRIS 4074	100986-85-4	149096	195031	TTDS00083	Topoisomerase IV	Topo IV	N/A	N/A	N/A	inhibitor
DAP000159	Gatifloxacin	CHEBI:5280; Kinome_3137; MLS000040259; BRD-A74980173-001-02-8; (+-)-1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; Gatifloxacin; SAM002589955; PD-135432; Zymaxid; KBio2_007578; 180200-66-2; 1-cyclopropyl-6-fluoro-8-methoxy-7-(3-methylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; MLS000759493; Tequin; SMR000043336; Spectrum3_000999; 112811-59-3; BMS-206584; AM 1155; 3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-; Gatiflo; 1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; AM-1155 (*Sesquihydrate*); Zymer; CG-5501; Gatifloxacin & Gamma Interferon; Gatifloxacin (TN); 160738-57-8; I06-2286; AM-1155; S1340_Sellekc; KBio3_001917; D08011; Spectrum2_000487; KBioGR_001613; NCGC00095126-02; 1-cyclopropyl-6-fluoro-8-methoxy-7-(3-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid; S1340_Selleck; Gatifloxacin [USAN:INN]; 1-Cyclopropyl-1,4-dihydro-6-fluoro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; MolPort-001-738-626; Spectrum_001909; NCGC00178525-01; Zymer (TN); TL8001438; HMS2090K10; BMS-206584-01; I06-2287; PD135432; CPD000043336; C07661; KBio2_002442; KBio2_005010; BSPBio_002697; AC1L1K82; Tequin in dextrose 5% in plastic container; FT-0082686; Zymar; Spectrum4_001127; KBioSS_002448; GTFX; Spectrum5_001468; HMS2093G06; HMS1922J15; NCGC00095126-01; Gatispan; CHEMBL31; CG 5501; PD 135432; Gatilox; STK801620; SAM001246715; AC-1944; Gatiflo,Tequin and Zymar,  Gatifloxacin; BMS 206584-01; AKOS004119932; BB_SC-1123; DB01044; SPBio_000353; SPECTRUM1504272; Gaity; Gatifloxacin (INN); Bonoq; CID5379; LS-184402; Gatiquin	112811-59-3	5379	9863	TTDS00083	Topoisomerase IV	Topo IV	N/A	N/A	N/A	inhibitor
DAP001360	ciprofloxacin	UNII-5E8K9I0O4U; CCRIS 5241; DivK1c_000095; Cipro I.V.; Ciprofloxacino; Cifloxin; 1-Cyclopropyl-6-fluoro-1,4-dihydro-7-(1-piperazinyl)-4-oxo-3-quinoline carboxylic acid; Fimoflox; Ciprodar; CPFX; Ciprofloxacino [INN-Spanish]; Prestwick1_000113; Cipro (TN); Proksi 500; Spectrum_000162; 17850_FLUKA; Cycin; Ciprecu; Spectrum3_001872; D00186; 3-Quinolinecarboxylic acid,1,4-dihydro-1-cyclopropyl-6-fluoro-4-oxo-7-(1-piperazinyl); AC-7613; 1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid; Quinolid; SMP1_000125; KBio2_003210; Cipromycin; Ciprofloxacinum [INN-Latin]; Ciprofloxacin monohydrochloride; 1-cyclopropyl-6-fluoro-7-hexahydro-1-pyrazinyl-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid; 33434_RIEDEL; 1-CYCLOPROPYL-6-FLUORO-4-OXO-7-PIPERAZIN-1-YL-1,4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID; CIPRO IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER; Ciprobay; 1-Cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydro-quinoline-3-carboxylic acid; 3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-; Baflox; Cipro IV; 1-Cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperzinyl)-3-quinolinecarboxylic acid HCl H2O; CHEBI:100241; 33434_FLUKA; Ciproxan; Ciproxina; BRN 3568352; AKOS000269653; Corsacin; Cipro XR; Rancif; Ciprocinol; 1-cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid; Ciprofloxacin Hydrchloride; Proksi 250; Cyprobay; Ciproquinol; Spectrum5_001089; Liposomal-ciprofloxacin; Prestwick2_000113; Proflaxin; NCGC00095058-01; Probiox; KBio2_000642; NCGC00178128-01; Quintor; CPF; CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER; Oprea1_313572; Bacquinor; Prestwick3_000113; Flociprin; Cipro XL; Ciprofloxacin HCl; NSC620634; Bernoflox; Zumaflox; Bay o 9867; Ciprofloxacinum; Roxytal; Ciprofloxacin dihydrochloride; NCGC00016959-01; Ciloxan (*Hydrochloride*); HMS500E17; Ciprinol; C17H18FN3O3; BAY q 3939; SPBio_002065; BRD-K04804440-311-02-3; ARONIS020379; ciprofloxacin; Bay-09867; Ciprofloxacin hydrochloride; Ciflox; BSPBio_003344; MLS001336035; BAY-Q-3939; HMS2093I03; KBio3_002846; Proflox; Ciprofloxacine; BIDD:GT0205; Cixan; Prestwick0_000113; Bi-Cipro; Alcon Cilox; IDI1_000095; KBioGR_001567; Velomonit; Ipiflox; NCGC00095058-02; Ciplus; AC1L1EEW; CAS-93107-08-5; CID2764; Ciprobay Uro; Sophixin Ofteno; KBio1_000095; Ciprolin; Superocin; HMS1922E18; Septicide; SPBio_001474; Ciprofloxacin (JAN/USP/INN); KBio2_005778; 1-Cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid; BAS 06989041; Ciprofloxacin [USAN:INN:BAN]; Ciprolon; HSDB 6987; 3-Quinolinecarboxylic acid, 1,4-dihydro-1-cyclopropyl-6-fluoro-4-oxo-7-(1-piperazinyl)-; Cilab; Ciprofloxacine [INN-French]; Spectrum2_001567; NINDS_000095; Ciprowin; CRL-1605 & Ciprofloxacin; HMS2090O07; BSPBio_000126; Eni; 85721-33-1; Bay o 9867 (*Hydrochloride*); MolPort-000-819-654; STK021082; Baycip; Ciproxine; Spitacin; BPBio1_000140; SPECTRUM1503614; Cipro; Ciproxin; BAYQ3939; CHEMBL8; Loxan; Cipro (*Hydrochloride*); Bio-0540; Unex; Ciprofloxacina; SMR000471901; LS-141563; Citopcin; DB00537; Spectrum4_000874; Ciprogis; nchembio820-comp1; Italnik; 1-Cyclopropyl-6-fluoro-4-oxo-7-(1-piperazinyl)-1,4-dihydro-3-quinolinecarboxylic acid; C05349; CBMicro_048498; Oprea1_008239; Ciriax; Ciproflox; KBioSS_000642	85721-33-1	2764	192835	TTDS00083	Topoisomerase IV	Topo IV	N/A	N/A	N/A	inhibitor
DAP000158	Moxifloxacin	DB00218; CHEMBL32; 186826-86-8; MXF; LS-141510; (1'S,6'S)-1-Cyclopropyl-7-(2,8-diazabicyclo[4.3.0]non-8-yl)-6-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; CID152946; 151096-09-2; AC1L49EP; moxifloxacin; I06-1961; Avelox I.V.; UNII-U188XYD42P; BAY 12-8039 (*Hydrochloride*); Actira (*Hydrochloride*); CCRIS 8690; Moxifloxacin [INN:BAN]; 3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-((4aS,7aS)-octahydro-6H-pyrrolo(3,4-b)pyridin-6-yl)-4-oxo-; MFX; Avelox (*Hydrochloride*); Vigamox; 192927-63-2; Avelox; 7-[(4aS,7aS)-1,2,3,4,4a,5,7,7a-octahydropyrrolo[3,4-b]pyridin-6-yl]-1-cyclopropyl-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid; 1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-((4aS,7aS)-octahydro-6H-pyrrolo(3,4-b)pyridin-6-yl)-4-oxo-3-quinolinecarboxylic acid; MXFX	354812-41-2	152946	730447	TTDS00083	Topoisomerase IV	Topo IV	N/A	N/A	N/A	inhibitor
DAP001387	Gatifloxacin	Kinome_3137; MLS000040259; (+-)-1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; Gatifloxacin; SAM002589955; PD-135432; 1-cyclopropyl-6-fluoro-8-methoxy-7-(3-methylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; MLS000759493; Spectrum3_000999; BMS-206584; AM 1155; Gatiflo; 1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; Gatifloxacin (TN); 160738-57-8; AM-1155; S1340_Sellekc; KBio3_001917; D08011; Spectrum2_000487; NCGC00095126-02; 1-cyclopropyl-6-fluoro-8-methoxy-7-(3-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid; S1340_Selleck; Zymer (TN); TL8001438; BMS-206584-01; PD135432; CPD000043336; KBio2_005010; AC1L1K82; Tequin in dextrose 5% in plastic container; FT-0082686; Zymar; Spectrum4_001127; KBioSS_002448; GTFX; HMS2093G06; Gatispan; Gatilox; AC-1944; AKOS004119932; SPBio_000353; Gatifloxacin (INN); CID5379; LS-184402; Gatiquin; CHEBI:5280; BRD-A74980173-001-02-8; Zymaxid; KBio2_007578; 180200-66-2; Tequin; SMR000043336; 112811-59-3; 3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-; AM-1155 (*Sesquihydrate*); Zymer; CG-5501; Gatifloxacin & Gamma Interferon; I06-2286; KBioGR_001613; Gatifloxacin [USAN:INN]; 1-Cyclopropyl-1,4-dihydro-6-fluoro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; MolPort-001-738-626; Spectrum_001909; NCGC00178525-01; HMS2090K10; I06-2287; C07661; KBio2_002442; BSPBio_002697; Spectrum5_001468; HMS1922J15; NCGC00095126-01; CHEMBL31; CG 5501; PD 135432; STK801620; SAM001246715; Gatiflo,Tequin and Zymar,  Gatifloxacin; BMS 206584-01; BB_SC-1123; DB01044; SPECTRUM1504272; Gaity; Bonoq	112811-59-3	5379	9863	TTDS00083	Topoisomerase IV	Topo IV	N/A	N/A	N/A	inhibitor
DAP000161	Sparfloxacin	Zagam (TN); PD131501; 3-Quinolinecarboxylic acid, 1,4-dihydro-5-amino-1-cyclopropyl-6,8-difluoro-7-(3,5-dimethyl-1-piperazinyl)-4-oxo-, cis-; PD 1315-1; 5-Amino-1-cyclohexyl-7-(cis-3,5-dimethylpiperazino)-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid; C19H22F2N4O3; Sparfloxacin [USAN:BAN:INN:JAN]; CI 978; 3-Quinolinecarboxylic acid, 5-amino-1-cyclopropyl-7-((3R,5S)-3,5-dimethyl-1-piperazinyl)-6,8-difluoro-1,4-dihydro-4-oxo-, rel-; D00590; MolPort-002-507-759; Sparfloxacinum [INN-Latin]; 5-Amino-1-cyclopropyl-7-(cis-3,5-dimethyl-1-piperazinyl)-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid; SPFX; 33967_FLUKA; Esparfloxacino; 3-Quinolinecarboxylic acid, 5-amino-1-cyclopropyl-7-(3,5-dimethyl-1-piperazinyl)-6,8-difluoro-1,4-dihydro-4-oxo-, cis-; 110871-86-8; sparfloxacin, cis-isomer; Sparfloxacin (JAN/USAN/INN); (cis)-5-amino-1-cyclopropyl-7-(3,5-dimethyl-1-piperazinyl)-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid; PD-131501; 111542-93-9; CHEBI:9212; DB01208; 5-amino-1-cyclopropyl-7-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-6,8-difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; Spara; HMS2090N19; STK802067; Liposome-encapsulated sparfloxacin; Sparfloxacinum; 56968_FLUKA; BB_SC-1127; BRN 3658018; Esparfloxacino [INN-Spanish]; Zagam; AT-4140; 33967_RIEDEL; SMR000466312; AT 4140; AC1Q29E9; CPD000466312; Sparfloxacine [INN-French]; CI-978; 5-Amino-1-cyclopropyl-7-(cis-3,5-dimethyl)-6,8- difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid & RU 40555; Sparfloxacin & RU 40555; CP-103826; CHEMBL850; AC1L1TB5; PD 131501; MLS000759417; C07662; 56968_SIGMA; AC-11574; Sparfloxacine; I06-1320; CP 103826; sparfloxacin; NCGC00166294-01; UNII-Q90AGA787L; 5-amino-1-cyclopropyl-7-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-6,8-difluoro-4-oxoquinoline-3-carboxylic acid; RP-64206; DRG-0143; LS-141521; CID60464; SAM001246566; 5-Amino-1-cyclopropyl-7-(cis-3,5-dimethyl-1-piperazinyl)- 6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid; cis-5-Amino-1-cyclopropyl-7-(3,5-dimethyl-1-piperazinyl)-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid	110871-86-8	60464	9864	TTDS00083	Topoisomerase IV	Topo IV	N/A	N/A	N/A	inhibitor
DCL000557	LY2275796	N/A	N/A	N/A	N/A	TTDC00228	mRNA of Eukaryotic translation initiation factor 4E	EIF4E;EIF-4E;EIF-4F 25 kDa subunit;MRNA cap-binding protein	P06730	1977	ENSG00000151247	antisense
DCL000336	AR-C69931 MX	D03361; 163706-36-3; CID5310955; AC1NSJQ8; CHEBI:726138; Cangrelor tetrasodium (USAN); CID10260031; AR-C69931; ARC-69931MX; CHEMBL1097279; Cangrelor tetrasodium; [(2R,3S,4R,5R)-3,4-dihydroxy-5-[6-(2-methylsulfanylethylamino)-2-(3,3,3-trifluoropropylsulfanyl)purin-9-yl]oxolan-2-yl]methyl dihydrogen phosphate; AR-C69931MX	163706-36-3	10260031	41245276	TTDS00113	P2Y purinoceptor 12	Adenosine P2Y12 receptor;ADP-glucose receptor;ADPG-R;ADP-receptor;Nucleotide P2Y(12) receptor;P2T(AC);P2Y(AC);P2Y(ADP);P2Y(ADP)P2Y purinoceptor 12;P2Y(cyc);P2Y12;P2Y12 platelet ADP receptor;SP1999	Q9H244	64805	ENSG00000169313	antagonist
DAP000178	Clopidogrel	SPBio_000463; AC1L1TKZ; CHEMBL1771; HMS502H09; STK580572; MLS001165708; TL8000400; (+)-Clopidogrel; D07729; CGE; 113665-84-2; SR 25990; Methyl (+)-(S)-alpha-(o-chlorophenyl)-6,7-dihydrothieno(3,2-c)pyridine-5(4H)-acetate; Spectrum4_000175; (S)-Methyl 2-(2-chlorophenyl)-2-(6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl)acetate; MLS001304711; AC-19024; MolPort-003-845-991; Clopidogrel (INN); CPD000550475; CLOPIDOGREL SULFATE; clopidogrel, (+)(S)-isomer; KBio3_002431; NINDS_000787; DivK1c_000787; NCGC00163329-02; IDI1_000787; Plavix; Clopidogrel [BAN:INN]; BRD-K27721098-065-02-9; KBio2_000545; (S)-Clopidogrel; Zyllt; ( )-(S)-Clopidogrel; Plavix (TN); KBio2_003113; KBioSS_000545; methyl (2S)-2-(2-chlorophenyl)-2-(6,7-dihydro-4H-thieno[3,2-c]pyridin-5-yl)acetate; BIDD:GT0284; AC1Q41I9; clopidogrel; HMS2090O21; MLS001195633; CHEBI:37941; C16H16ClNO2S; KBio2_005681; KBioGR_000689; KBio1_000787; MolPort-002-885-817; Spectrum3_001606; nchem.651-comp8; Clopidogrel (TN); Thieno(3,2-c)pyridine-5(4H)-acetic acid, alpha-(2-chlorophenyl)-6,7-dihydro-, methyl ester, (S)-; SMR000550475; UNII-A74586SNO7; Spectrum2_000512; Clopidogrelum; LS-172232; Clopidogrel [INN:BAN]; Spectrum_000105; STOCK5S-27782; BSPBio_003211; DB00758; CID60606; methyl (2S)-(2-chlorophenyl)(6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl)ethanoate; SAM002589956; HSDB 7430	113665-84-2	60606	196885	TTDS00113	P2Y purinoceptor 12	Adenosine P2Y12 receptor;ADP-glucose receptor;ADPG-R;ADP-receptor;Nucleotide P2Y(12) receptor;P2T(AC);P2Y(AC);P2Y(ADP);P2Y(ADP)P2Y purinoceptor 12;P2Y(cyc);P2Y12;P2Y12 platelet ADP receptor;SP1999	Q9H244	64805	ENSG00000169313	antagonist
DAP001548	Prasugrel	N/A	N/A	N/A	N/A	TTDS00113	P2Y purinoceptor 12	Adenosine P2Y12 receptor;ADP-glucose receptor;ADPG-R;ADP-receptor;Nucleotide P2Y(12) receptor;P2T(AC);P2Y(AC);P2Y(ADP);P2Y(ADP)P2Y purinoceptor 12;P2Y(cyc);P2Y12;P2Y12 platelet ADP receptor;SP1999	Q9H244	64805	ENSG00000169313	inhibitor
DAP000723	Ticlopidine	BPBio1_000191; ticlopidine; Ticlopidinum [INN-Latin]; Ticlopidin-Puren; NCGC00024361-04; Thieno[3,2-c]pyridine, 5-[(2-chlorophenyl)methyl]-4,5,6,7-tetrahydro-; Prestwick2_000047; STOCK5S-54105; CAS-53885-35-1; Ticlopidina [INN-Spanish]; DB00208; BIDD:PXR0169; C14H14ClNS; Ticlopidina; EINECS 259-498-5; Prestwick0_000047; 5-((2-Chlorophenyl)methyl)-4,5,6,7-tetrahydrothieno(3,2-c)pyridine; STK589340; LS-152434; Prestwick1_000047; CID5472; AC-15204; Thieno(3,2-c)pyridine, 5-((2-chlorophenyl)methyl)-4,5,6,7-tetrahydro-; 5-(2-Chlorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine; NCGC00016872-02; UNII-OM90ZUW7M1; 5-[(2-chlorophenyl)methyl]-6,7-dihydro-4H-thieno[3,2-c]pyridine; Ticlid; Prestwick3_000047; AC1L1KFB; PCR 5332; ZINC19594599; SPBio_002094; BRN 1216802; BSPBio_000173; HMS2089I18; Ticlopidin-Puren (TN); 5-[(2-chlorophenyl)methyl]-4,5,6,7-tetrahydrothieno[3,2-c]pyridine; MLS001201825; Thieno(3,2-c)pyridine, 4,5,6,7-tetrahydro-5-((2-chlorophenyl)methyl)-; L001108; NCGC00016872-01; Ticlopidine [INN:BAN]; 55142-85-3; C07140; D08594; Ticlopidine (INN); CHEBI:9588; BRD-K00603606-003-03-4; Ticlopidinum; CHEMBL833; SMR000641861; UNM-0000345023; MolPort-002-507-849	55142-85-3	5472	9349	TTDS00113	P2Y purinoceptor 12	Adenosine P2Y12 receptor;ADP-glucose receptor;ADPG-R;ADP-receptor;Nucleotide P2Y(12) receptor;P2T(AC);P2Y(AC);P2Y(ADP);P2Y(ADP)P2Y purinoceptor 12;P2Y(cyc);P2Y12;P2Y12 platelet ADP receptor;SP1999	Q9H244	64805	ENSG00000169313	antagonist
DCL000499	Brilinta	AR-C126532; CID9871419; Brilinta; 274693-27-5; AZD-6140; Ticagrelor (USAN/INN); Ticagrelor; Brilique; D09017; CHEMBL398435	N/A	N/A	N/A	TTDS00113	P2Y purinoceptor 12	Adenosine P2Y12 receptor;ADP-glucose receptor;ADPG-R;ADP-receptor;Nucleotide P2Y(12) receptor;P2T(AC);P2Y(AC);P2Y(ADP);P2Y(ADP)P2Y purinoceptor 12;P2Y(cyc);P2Y12;P2Y12 platelet ADP receptor;SP1999	Q9H244	64805	ENSG00000169313	antagonist
DPR000086	Organon-2	N/A	N/A	N/A	N/A	TTDC00227	Sodium- and chloride-dependent glycine transporter 1	Glycine transporter type 1;Glycine type-1 transporter;GlyT1;GlyT-1	P48067	6536	ENSG00000196517	blocker
DPR000087	Organon-3	N/A	N/A	N/A	N/A	TTDC00227	Sodium- and chloride-dependent glycine transporter 1	Glycine transporter type 1;Glycine type-1 transporter;GlyT1;GlyT-1	P48067	6536	ENSG00000196517	blocker
DPR000085	Organon	Gestanin; 17.alpha.-Allyl-3-deoxy-19-nortestosterone; Estr-4-en-17-ol, 17-(2-propenyl)-, (17beta)-; (8R,9S,10R,13S,14S,17R)-13-methyl-17-prop-2-enyl-2,3,6,7,8,9,10,11,12,14,15,16-dodecahydro-1H-cyclopenta[a]phenanthren-17-ol; Allilestrenolo [DCIT]; Turinal; 17-alpha-Allyl-4-oestrene-17-beta-ol; LMST02030125; CCRIS 9068; AR-1H6825; C21H32O; Alilestrenol [INN-Spanish]; 17alpha-Allylestr-4-en-17beta-ol; 3-Deoxy-17-alpha-allyl-19-nortestosterone; 17alpha-Allylestrenol; C12811; BRN 3148038; 17-alpha-Allyl-3-deoxy-19-nortestosterone; Allyloestrenol; ZINC04214767; WLN: L E5 B666 MUTJ E1 FQ F2U1; 19-Nor-17-alpha-preg-4-en-17-ol, 21-methylene-; allylestrenol(jan); 17alpha-Allyl-4-oestrene-17beta-ol; NSC 37723; 17-Hydroxy-17-alpha-allyl-4-estrene; Gestanon-r; 17-alpha-Allylhydroxy-19-nor-4-androstene; 17.alpha.-Allyl-17-.beta.-hydroxy-.delta.(sup 4)-estren; AC1L5VF2; 17alpha-Allyl-17beta-hydroxy-4-estrene; 17.alpha.-Allylestrenol; Estrenol, allyl-; ESTR-4-EN-17-beta-OL, 17-ALLYL-; 17-alpha-Allyl-17-beta-hydroxy-delta(sup 4)-estren; 17.alpha.-Allyl-4-estren-17.beta.-ol; Estr-4-en-17-ol, 17-(2-propenyl)-, (17.beta.)-; Estr-4-en-17beta-ol, 17-allyl-; EINECS 207-082-9; 17-alpha-Allylestr-4-en-17-beta-ol; Gestanyn; MolPort-003-986-853; 17alpha-Allyl-3-deoxy-19-nortestosterone; 17alpha-Allyl-4-destrene-17beta-ol; 17-alpha-Allyl-17-beta-hydroxy-4-estrene; Estr-4-en-17.beta.-ol, 17-allyl-; 17.alpha.-Allylestr-4-en-17.beta.-ol; 432-60-0; D01374; 17.alpha.-Allyl-17.beta.-hydroxy-4-estrene; Gestanon; Perselin; 17.alpha.-Allyl-4-oestrene-17.beta.-ol; Perselin (TN); 17.alpha.-Allyl-4-destrene-17.beta.-ol; Allylestrenol [INN:JAN]; Allyloestrenolum; Gestanol; Allylestrenolum [INN-Latin]; 21-Methylene-19-nor-17-alpha-preg-4-en-17-ol; DB01431; allylestrenol; Orageston; Allylestrenol (JAN/INN); CID235905; 17-(2-Propenyl)estr-4-en-17-ol; LS-64837; 17alpha-Allyl-4-estren-17beta-ol; Organon; NSC37723; TL8003047; (17beta)-17-prop-2-en-1-ylestr-4-en-17-ol; AC1Q59O7; 17alpha-Allyl-19-nor-delta-4-androstene-17beta-ol	432-60-0	1967	153117	TTDC00227	Sodium- and chloride-dependent glycine transporter 1	Glycine transporter type 1;Glycine type-1 transporter;GlyT1;GlyT-1	P48067	6536	ENSG00000196517	blocker
DPR000112	SSR-103800	N/A	N/A	N/A	N/A	TTDC00227	Sodium- and chloride-dependent glycine transporter 1	Glycine transporter type 1;Glycine type-1 transporter;GlyT1;GlyT-1	P48067	6536	ENSG00000196517	blocker
DPR000084	Org-24461	ORG-24461; CID10044846; CHEMBL59821	N/A	N/A	N/A	TTDC00227	Sodium- and chloride-dependent glycine transporter 1	Glycine transporter type 1;Glycine type-1 transporter;GlyT1;GlyT-1	P48067	6536	ENSG00000196517	blocker
DCL000401	GSK1018921	N/A	N/A	788325	1018921	TTDC00227	Sodium- and chloride-dependent glycine transporter 1	Glycine transporter type 1;Glycine type-1 transporter;GlyT1;GlyT-1	P48067	6536	ENSG00000196517	blocker
DCL000604	R1678	CHEMBL1171829; CHEBI:749450; R-1678; RG-1678	N/A	N/A	N/A	TTDC00227	Sodium- and chloride-dependent glycine transporter 1	Glycine transporter type 1;Glycine type-1 transporter;GlyT1;GlyT-1	P48067	6536	ENSG00000196517	blocker
DPR000113	SSR-504734	CID9954539; SSR-504734; 2-chloro-N-[(R)-phenyl-(2-piperidyl)methyl]-3-(trifluoromethyl)benzamide Hydrochloride	N/A	9954539	57304403	TTDC00227	Sodium- and chloride-dependent glycine transporter 1	Glycine transporter type 1;Glycine type-1 transporter;GlyT1;GlyT-1	P48067	6536	ENSG00000196517	blocker
DCL000690	ALX-5407	NFPS; 2-[[(3R)-3-(4-fluorophenyl)-3-(4-phenylphenoxy)propyl]-methylamino]acetic acid; AC1O7H1E; AC1NSKCW; CHEBI:131521; Tocris-1757; ALX5407; NCGC00025278-01; CID6604909; CHEMBL26512; CHEMBL180966; BRD-K53979406-003-01-0; 2-[[3-(4-fluorophenyl)-3-(4-phenylphenoxy)propyl]-methylamino]acetic acid; CHEBI:406688; ALX-5407; CID5311283	571147-18-7	6604909	57304382	TTDC00227	Sodium- and chloride-dependent glycine transporter 1	Glycine transporter type 1;Glycine type-1 transporter;GlyT1;GlyT-1	P48067	6536	ENSG00000196517	blocker
DCL000815	Gliatech	N/A	N/A	N/A	N/A	TTDC00227	Sodium- and chloride-dependent glycine transporter 1	Glycine transporter type 1;Glycine type-1 transporter;GlyT1;GlyT-1	P48067	6536	ENSG00000196517	blocker
DCL000824	GSK372475	N/A	N/A	N/A	N/A	TTDS00038	Noradrenergic re-uptake	Norepinephrine reuptake	N/A	N/A	N/A	inhibitor
DAP000864	Amitriptyline	Oprea1_479304; NCGC00024433-04; PDSP2_001548; 5-(gamma-Dimethylaminopropylidine)-5H-dibenzo(a,d)(1,4)cycloheptadiene; Amitriptylin; Laroxil; 3-(10,11-dihydro-5H-dibenzo[a,d][7]annulen-5-ylidene)-N,N-dimethylpropan-1-amine; NCGC00015095-02; CAS-549-18-8; Amitriptyline [INN:BAN]; Sylvemid; BRN 2217885; CID2160; Amitriptylin [German]; Triptilin; L001041; 5-(3-Dimethylaminopropylidene)-5H-dibenzo[a,d]-10,11-dihydrocycloheptene; Flavyl; DB00321; KBio2_002261; LS-60747; NCGC00015095-03; AKOS000512694; Amitriptilina [INN-Spanish]; Lopac0_000112; N 750; Adepress; Amitriprolidine; 5-(gamma-Dimethylaminopropylidene)-5H-dibenzo[a,d]10,11-dihydrocycloheptene; Prestwick1_000074; Amitriptylinum [INN-Latin]; Amitryptyline; Sarotex; AB00514631; BSPBio_000287; PDSP1_001564; STK525215; NINDS_000766; EINECS 200-041-6; KBio2_005560; STOCK1S-56825; KBio3_001336; Laroxyl; Spectrum4_000146; Amitriptylinum; Prestwick2_000074; Lopac-A-8404; 3-(10,11-Dihydro-5H-dibenzo(a,d)cyclohepten-5-yliden)-N,N-dimethylpropylamin; 5-(3-Dimethylaminopropylidene)-10,11-dihydro-5H-dibenzo(a,d)cycloheptatriene; Amitriptyline (INN); CHEBI:2666; NCGC00015095-01; BPBio1_000317; Elavil; Lantron; SPBio_002208; D07448; Triptisol; 30227-34-0 (maleate (1:1)); UNII-1806D8D52K; NSC169910; KBioSS_000424; MolPort-001-662-651; 17086-03-2 (pamoate (2:1)); KBioGR_000592; Elanil; Amytriptiline; Damilan; TP0; IDI1_000766; Spectrum_000044; Tryptanol; 5-(gamma-Dimethylaminopropylidene)-5H-dibenzo(a,d)(1,4)cycloheptadiene; Damilen; Laroxyl (TN); Spectrum3_000298; Amitryptiline; 5-(3'-Dimethylaminopropylidene)-dibenzo-[a,d][1,4]-cycloheptadiene; KBio2_002992; 5-(gamma-Dimethylaminopropylidene)-5H-Dibenzo[a,d][1,4]cycloheptadiene; 10,11-dihydro-5-(gamma-dimethylaminopropylidene)-5H-dibenzo[a,d]cycloheptene; KBioSS_002262; KBio1_000766; CHEMBL629; amitriptyline; AC1L1D20; CCRIS 9174; DivK1c_000766; 10,11-Dihydro-5-(gamma-dimethylaminopropylidene)-5H-dibenzo(a,d)cycloheptene; C06824; Amitriptilina; Amytriptylin; BIDD:GT0115; Spectrum5_000806; KBio2_004829; Amitriptilina [Italian]; 50-48-6; Amitril; KBioGR_002261; MK 230; 5-(3-dimethylaminopropylidene)dibenzo[a,d][1,4]-cycloheptadiene; Spectrum2_000101; Seroten; [3-(10,11-Dihydro-dibenzo[a,d]cyclohepten-5-ylidene)-propyl]-dimethyl-amine; Prestwick0_000074; SPBio_000082; BAS 00269727; Triptanol; BSPBio_001836; KBio3_002741; 10,11-Dihydro-N,N-dimethyl-5H-dibenzo(a,d)heptalene-delta(5),gamma-propylamine; 5-(3'-Dimethylaminopropylidene)-dibenzo-(a,d)(1,4)-cycloheptadiene; Redomex; Damitriptyline; KBio2_007397; Adepril; Ro 4-1575; Proheptadiene; KBio2_000424; BRD-K53737926-003-05-4; 5-(gamma-Dimethylaminopropylidene)-10,11-dihydro-5H-dibenzo(a,d)cycloheptene; 549-18-8 (hydrochloride); cMAP_000001; 5-(3-Dimethylaminopropylidene)-10,11-dihydro-5H-dibenzo(a,d)cycloheptene; Prestwick3_000074; NCGC00015095-10	50-48-6	2160	9042	TTDS00038	Noradrenergic re-uptake	Norepinephrine reuptake	N/A	N/A	N/A	inhibitor
DAP001154	Imipramine	Intalpram; 113-52-0 (mono-hydrochloride); 5-(3-(Dimethylamino)propyl)-10,11-dihydro-5H-dibenz(b,f)azepine; Norchlorimipramine; Oprea1_200908; KBio2_003963; MolPort-001-783-692; NCGC00024253-03; 1-(3-Dimethylaminopropyl)-4,5-dihydro-2,3,6,7-dibenzazepine; 5H-Dibenz(b,f)azepine-5-propanamine, 10,11-dihydro-N,N-dimethyl-; CHEBI:47499; CAS-113-52-0; L000739; UNII-OGG85SX4E4; CHEMBL11; Promiben; Dynaprin; 5H-Dibenz[b,f]azepine, 5-[3-(dimethylamino)propyl]-10,11-dihydro-; N-(gamma-Dimethylaminopropyl)iminodibenzyl; Imipramina; Spectrum2_000990; CPD-11438; N-(.gamma.-Dimethylaminopropyl)iminodibenzyl; Imipramin; HSDB 3100; Spectrum4_000016; Tofranil, base; Tofranil (TN); HMS2089G08; Eupramin; Spectrum_000915; NCGC00015563-01; 10,11-Dihydro-5-(3-(dimethylamino)propyl)-5H-dibenz[b,f]azepine; KBio3_001392; Lopac-I-7379; KBio1_000559; DivK1c_000559; DB08002; KBioGR_000391; NCGC00015563-09; SK-Pramine; Melipramine; NCGC00015563-03; CID3696; IDI1_000559; Imidobenzyle; 3-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethylpropan-1-amine; Irmin; Psychoforin; NCGC00015563-02; Tofranil (free base); Imiprin; 5H-Dibenz[b,f]azepine-5-propanamine, 10,11-dihydro-N,N-dimethyl-; Imipramine (INN); NSC 169866; BSPBio_000283; 5H-Dibenz(b,f)azepine, 10,11-dihydro-5-(3-(dimethylamino)propyl)-; Tofranil; Imipramine [INN:BAN]; BRN 0256892; Berkomine; nchembio747-comp8; Tofranil (hydrochloride); Imipramina [INN-Spanish]; Prestwick2_000072; KBioSS_001395; BIDD:GT0116; Imipraminum [INN-Latin]; Janimine; 5,6-Dihydro-N-[3-(dimethylamino)propyl]-11H-dibenz[b,e]azepine; CCRIS 9173; EINECS 200-042-1; G-22355; 2,2'-(3-Dimethylaminopropylimino)bibenzyl; Nelipramin; C07049; Censtim; KBio2_006531; Imizin; AC1L1GIE; Dpid; Imizinum; Janimine (hydrochloride); D08070; imipramine; KBio2_001395; Imavate; DB00458; NINDS_000559; 5,6-Dihydro-N-(3-(dimethylamino)propyl)-11H-dibenz(b,e)azepine; NCGC00024253-04; Censtin; Imipramina [Italian]; Spectrum5_000864; Prestwick1_000072; Antideprin; 2,2'-(3-Dimethylaminopropylimino)dibenzyl; Norfranil; Lopac0_000702; Impramine; NSC169866; AB00053486; WLN: T C676 BN&T&J B3N1&1; LS-60467; 10,11-Dihydro-N,N-dimethyl-5H-dibenz[b,f]azepine-5-propanamine; BRD-K38436528-003-05-5; Prestwick3_000072; 3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N-dimethylpropan-1-amine; Iramil; 5-(3-Dimethylaminopropyl)-10,11-dihydro-5H-dibenzo(b,f)azepine; Timolet; Dyna-zina; Spectrum3_000466; BSPBio_002172; SPBio_001059; 5H-Dibenz(b,f)azepine-5-propanamine, 10,11-dihydro-N,N-dimethyl- (9CI); Dimipressin; 5H-Dibenz(b,f)azepine, 5-(3-(dimethylamino)propyl)-10,11-dihydro-; Imipraminum; Tofraniln A; Melipramin; Prazepine; Declomipramine; 50-49-7; 5H-Dibenz(b,f)azepine,5-[3-(dimethylamino)propyl]-10,11-dihydro-mixed with ethyl alcohol; N-(3-Dimethylaminopropyl)-o-iminodibenzyl; InChI=1/C19H24N2/c1-20(2)14-7-15-21-18-10-5-3-8-16(18)12-13-17-9-4-6-11-19(17)21/h3-6,8-11H,7,12-15H2,1-2H; BPBio1_000313; Surplix; SPBio_002204; Pramine; Prestwick0_000072	50-49-7	3696	9261	TTDS00038	Noradrenergic re-uptake	Norepinephrine reuptake	N/A	N/A	N/A	inhibitor
DAP000863	Protriptyline	Novo-Tripramine; Lopac-P-8813; NCGC00024439-03; Protriptyline [INN:BAN]; Prestwick1_000930; AB00489964; Prestwick3_000930; Protriptilina; Vivactyl; L000913; 438-60-8; Rhotrimine; Novo-Doxepin; D08447; CID4976; DB00344; BRN 2217411; BIDD:PXR0157; BSPBio_000840; CHEBI:8597; N-Methyl-5H-dibenzo(a,d)cycloheptene-5-propylamine; 3-(5H-dibenzo[a,d][7]annulen-5-yl)-N-methylpropan-1-amine; C07408; Protriptylinum [INN-Latin]; UNII-4NDU154T12; nchembio747-comp7; protriptyline; AC1L1JCC; Impril; CAS-1225-55-4; Maximed; Vivactil; Novopramine; Triptil; 5-(3-Methylaminopropyl)-5H-dibenzo(a,d)cycloheptene; Triptil hydrochloride; MolPort-005-935-551; 5H-Dibenzo[a, d]cycloheptene-5-propanamine, N-methyl-, hydrochloride; SPBio_003019; Triadapin 5; 5-(3-Methylaminopropyl)-5H-Dibenzo[a,d]cycloheptene; Apo-Imipramine; BPBio1_000924; N-3-(5H-Dibenzo(a,d)cyclohepten-5-yl)propyl-N-methylamine; 1225-55-4; NCGC00015851-02; 5H-Dibenzo(a,d)cycloheptene-5-propanamine, N-methyl-; NCGC00015851-03; 7-(3-Methylaminopropyl)-1,2:5,6-dibenzocycloheptatriene; 1225-55-4 (HYDROCHLORIDE); BRD-K42098891-003-03-1; EINECS 207-119-9; 3-(5H-Dibenzo[a,d]cyclohepten-5-yl)-N-methyl-1-propanamine; PDSP1_001390; Amimetilina; NCGC00015851-07; Normethyl EX4442; Protriptilina [INN-Spanish]; CHEMBL668; Apo-Trimip; Lopac0_000974; Protryptyline; 5H-Dibenzo[a,d]cycloheptene-5-propanamine, N-methyl-; AC-15971; HSDB 3391; NCGC00015851-01; N-Methyl-5H-dibenzo[a,d]cycloheptene-5-propylamine; NSC169912; Protriptylinum; Prestwick2_000930; 5H-Dibenzo(a,d)cycloheptene-5-propylamine, N-methyl-; LS-60771; Triptyl; Protriptyline (INN); Prestwick0_000930; N-Methyl-5H-dibenzo[a,d]cycloheptene-5-propanamine; PDSP2_001374	438-60-8	4976	9612	TTDS00038	Noradrenergic re-uptake	Norepinephrine reuptake	N/A	N/A	N/A	inhibitor
DAP000860	Phenmetrazine	A 66; 2-Fenyl-3-methylmorfolin [Czech]; AC1L1IWB; 134-49-6; dl-2-Phenyl-3-methyltetrahydro-1,4-oxazine; 2-Phenyl-3-methylmorpholine; EINECS 205-143-4; LS-93169; Psychamine A 66; 3-Methyl-2-phenylmorpholine; 1707-14-8 (hydrochloride); AC-16023; Dexphenmetrazine; phenmetrazine; Fenmetrazin; DB00830; Phenmetrazinum [INN-Latin]; Preludin hydrochloride; MolPort-001-783-678; Fenmetrazina [INN-Spanish]; DEA No. 1631; NCGC00164535-01; Oxazimedrine; 2-Fenyl-3-methylmorfolin; Fenmetrazina; AKOS003662804; Phenmetrazin; Probese-P; BRN 0140490; CID4762; Defenmetrazin; Cafilon; Morpholine, 3-methyl-2-phenyl-; Phenmetrazinum; ST081100; UNII-XA501VL3VR; 21288-73-3; 154-40-5; C07432; Phenmetraline; 3-Methyl-2-phenyltetrahydro-2H-1,4-oxazine; Phenmetrazine [INN:BAN]; HSDB 3156	134-49-6	4762	9636	TTDS00038	Noradrenergic re-uptake	Norepinephrine reuptake	N/A	N/A	N/A	inhibitor
DAP001152	Nortriptyline	NINDS_000151; 3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine; 1-Propanamine, 3-(10,11-dihydro-5H-dibenzo(a,d)cyclohepten-5-ylidene)-N-methyl-; CAS-894-71-3; 10,11-dihydro-N-methyl-5H-dibenzo[a,d]cycloheptene-Delta(5,gamma)-propylamine; UNII-BL03SY4LXB; Desitriptyline; Nortriptilina; Sensival Ventyl; NCGC00014483-04; IDI1_000151; KBio2_004089; KBio2_006657; SPECTRUM1500442; NCGC00024261-06; Lopac-N-7261; NSC78248; Nortriptylinum [INN-Latin]; Lumbeck; BPBio1_000076; NSC169453; KBio1_000151; 5H-Dibenzo(a,d)cycloheptene-delta(sup 5),gamma-propylamine, 10,11-dihydro-N-methyl-; AVENTYL HCL; Desitriptilina; N-Methyl-3-(10,11-dihydro-5H-dibenzo(a,d)cyclohepten-5-yliden)propylamin; CCRIS 9175; NCGC00014483-03; Sesaval; Acetexa; Prestwick3_000254; BSPBio_002111; HMS500H13; 10,11-Dihydro-N-methyl-5H-dibenzo(a,d)cycloheptene-delta(5,gamma)-propylamine; HMS1920B20; Lopac0_000868; EINECS 200-788-8; Altilev; CHEMBL445; Prestwick1_000254; Spectrum5_001377; Amitryptyline, demethyl-; Spectrum_001041; KBioSS_001521; Nortrilen; Vividyl; 10,11-Dihydro-5-(3-methylaminopropylidene)-5H-dibenzo(a,d)(1,4)cycloheptene; Spectrum4_000455; Desmethylamitriptylin; 5-(3-(Methylamino)propylidene)dibenzo(a,e)cyclohepta(1,5)diene; BRN 2216786; BSPBio_000068; Avantyl; Demethylamitryptyline; DivK1c_000151; Nortryptiline; SPBio_002287; NCGC00014483-11; BIDD:PXR0187; Nortriptyline [INN:BAN]; Aventyl; KBioGR_000870; Ateben; LS-60753; CID4543; C07274; D08288; nchembio747-comp6; 5-(3-Methylaminopropylidene)-10,11-dihydro-5H-dibenzo(a,d)cycloheptene; 1-Propanamine, 3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-; Spectrum3_000526; NCIOpen2_004361; DB00540; 3-(10,11-dihydro-5H-dibenzo[a,d][7]annulen-5-ylidene)-N-methylpropan-1-amine; Pamelor hydrochloride; NCI169453; PDSP1_001805; BRD-K91263825-003-03-2; MolPort-003-666-245; PDSP2_001788; KBio2_001521; Nortrilen (TN); Desmethylamitriptyline; NCIStruc1_000856; Noramitriptyline; Nortriptyline (INN); Spectrum2_000997; Psychostyl; 894-71-3; NCGC00014483; HMS2091J20; NCGC00024261-03; Prestwick2_000254; Nortriptylene hydrochloride; NCGC00014483-02; Demethylamitriptyline; Prestwick0_000254; Demethylamitriptylene; QTL1_000063; NCGC00024261-05; NCIStruc2_000700; Nortryptyline; Sensaval; Nortriptylinum; KBio3_001611; AB00052061; 5-(alpha-Methylaminopropylidene)dibenzo(a,d)cyclohepta(1,4)diene; CHEBI:7640; Nortriptilina [DCIT]; Allegron; nortriptyline; NCI60_001354; 3-(10,11-Dihydro-5H-dibenzo(a,d)cyclohepten-5-ylidene)-N-methylpropylamine; Pamelor; 72-69-5; Noritren; 1-Propanamine, 3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-; (2)10,11-Dihydro-N-methyl-5H-dibenzo[a,d]cycloheptene-.delta.5.gamma.-propylamine; NCGC00024261-04; AC1L1IED; SPBio_001093; NSC-169453	72-69-5	4543	149239	TTDS00038	Noradrenergic re-uptake	Norepinephrine reuptake	N/A	N/A	N/A	inhibitor
DAP001469	Desvenalfaxine succinate	N/A	386750-22-7	125017	17396741	TTDS00038	Noradrenergic re-uptake	Norepinephrine reuptake	N/A	N/A	N/A	inhibitor
DCL000669	Reboxetine	98769-83-6; 71621-36-8; Reboxetine (INN); Reboxetine [INN]; LS-93003; AC1L2442; 98819-76-2; Edronax (TN); NCGC00025335-01; (S,S)-( )-Reboxetine; Morpholine, 2-((R)-(2-ethoxyphenoxy)phenylmethyl)-, (2R)-rel-; Prolift; 2-((2-ethoxyphenoxy)benzyl)morpholine methanesulfonate; MolPort-003-850-135; Reboxetine; DB00234; Esreboxetine; Edronax; CID5311403; UNII-947S0YZ36I; Davedax; (2S)-2-[(S)-(2-ethoxyphenoxy)-phenylmethyl]morpholine; Solvex; CID10403303; (+-)-(2R*)-2-((alphaR*)-alpha-(o-Ethoxyphenoxy)benzyl)morpholine; (S,S)-reboxetine; BRD-A43974499-066-01-1; MolPort-005-943-618; CHEMBL14370; AC1MIDJY; Esreboxetine (USAN/INN); D09340; CID65856; 71620-89-8; 2-[(2-ethoxyphenoxy)-phenylmethyl]morpholine; LS-178388; Tocris-1982; AC1NSKK9; AC-1247; CHEMBL593475; Reboxetine mesylate; CID10455311; CID127151; Reboxitine; (2R)-2-[(S)-(2-ethoxyphenoxy)-phenylmethyl]morpholine; Norebox; CID10245062; AC1L2RJ0; MolPort-005-942-846; Vestra; (2R)-2-[(R)-(2-ethoxyphenoxy)-phenylmethyl]morpholine; CHEBI:114263; 98769-81-4; CID3022645; D08472	98769-81-4	123628	42307133	TTDS00038	Noradrenergic re-uptake	Norepinephrine reuptake	N/A	N/A	N/A	inhibitor
DAP001153	Trimipramine	5H-Dibenz(b,f)azepine-5-propanamine, 10,11-dihydro-N,N,beta-trimethyl-, (+)- (9CI); AB00053646; BPBio1_000739; Trimipramine (USAN/INN); 1-(3-Dimethylamino-2-methylpropyl)-4,5-dihydro-2,3:6,7-dibenzazepine; Trimipraminum; 10,11 Dihydro-N,N,beta-trimethyl-5H-dibenz(b,f)azepine-5-propanamine; 10633 RP; Surmontyl; 5H-Dibenz(b,f)azepine, 5-(3-(dimethylamino)-2-methylpropyl)-10,11-dihydro-, (-)-; Prestwick3_000806; 5-(3-(Dimethylamino)-2-methylpropyl)-10,11-dihydro-5H-dibenz(b,f)azepine; KBioGR_001118; Spectrum3_001151; UNII-6S082C9NDT; 5H-Dibenz(b,f)azepine, 10,11-dihydro-5-(3-(dimethylamino)-2-methylpropyl)-; (+)-Trimipramine; trimipramine; KBio2_001902; Prestwick2_000806; NCGC00016013-03; LS-60464; Spectrum5_001052; 5H-Dibenz(b,f)azepine, 5-(3-(dimethylamino)-2-methylpropyl)-; ( )-Trimipramine; 5-(gamma-Dimethylamino-beta-methylpropyl)-10,11-dihydro-5H-dibenzo(b,f)azepine; KBio3_002201; Trimipramina; 5-(gamma-dimethylamino-beta-methylpropyl)-10,11-dihydro-5H-dibenzo[b,f]azepine; 5-[3-(dimethylamino)-2-methylpropyl]-10,11-dihydro-5H-dibenz[b,f]azepine; Trimipramine [USAN:INN:BAN]; CHEMBL644; BSPBio_000671; 5H-Dibenz(b,f)azepine-5-propanamine, 10,11-dihydro-N,N,beta-trimethyl-; Trimeprimine; DivK1c_000093; InChI=1/C20H26N2/c1-16(14-21(2)3)15-22-19-10-6-4-8-17(19)12-13-18-9-5-7-11-20(18)22/h4-11,16H,12-15H2,1-3H; 5H-Dibenz(b,f)azepine-5-propanamine, 10,11-dihydro-N,N,beta-trimethyl-, (-)- (9CI); 5H-Dibenz(b,f)azepine, 5-(3-(dimethylamino)-2-methylpropyl)-10,11-dihydro-, (+)-; 5H-Dibenz(b,f)azepine-5-propanamine, 10,11-dihydro-N,N,beta-trimethyl-, (+)-; SPBio_002592; LS-60463; 5H-Dibenz(b,f)azepine, 5-(3-(dimethylamino)-2-methylpropyl)-10,11-dihydro-; (-)-Trimipramine; L000969; KBioSS_001902; Lopac0_001156; Trimeproprimine; 3564-75-8; 5H-Dibenz(b,f)azepine, 10,11-dihydro-5-(3-(dimethylamino)-2-methylpropyl)-, (-)-; 521-78-8 (maleate (1:1)); Prestwick0_000806; 3564-66-7; Sapilent; Trimeproprimin; Trimipramine, (-)-Isomer; LS-60465; 7162 RP; 5-20-08-00099 (Beilstein Handbook Reference); CHEBI:9738; Surmontil; Prestwick1_000806; BSPBio_002701; Trimipraminum [INN-Latin]; Spectrum_001422; Trimipramina [INN-Spanish]; BRD-A19195498-050-05-9; AC-15969; Spectrum2_001530; Spectrum4_000759; Stangyl; 3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N,2-trimethylpropan-1-amine; 3589-21-7 (mono-hydrochloride); 5H-Dibenz[b,f]azepine-5-propanamine, 10,11-dihydro-N,N,.beta.-trimethyl-; NINDS_000093; 2'-Metil-3'-dimetilamino-propil-5-iminodibenzile; Trimeprimina [Italian]; KBio2_004470; IL-6001; RP-7162; D00394; SPBio_001320; EINECS 212-008-3; 5H-Dibenz(b,f)azepine, 10,11-dihydro-5-(3-(dimethylamino)-2-methylpropyl)-, (+)-; 10,11-dihydro-N,N,beta-trimethyl-5H-dibenz[b,f]azepine-5-propanamine; BRN 1321466; Trimeprimina; 25332-13-2 (mesylate); CID5584; KBio2_007038; DB00726; IDI1_000093; MolPort-005-935-550; Oprea1_375679; 739-71-9; NCGC00162356-01; 3-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N,2-trimethylpropan-1-amine; FI 6120; 2'-Metil-3'-dimetilamino-propil-5-iminodibenzile [Italian]; KBio1_000093; AC1L1KO8; 10645 RP; IL 6001; 10,11-Dihydro-5-(3-dimethylamino-2-methylpropyl)-5H-dibenz(b,f)azepine; beta-Methylimipramine	739-71-9	5584	156272	TTDS00038	Noradrenergic re-uptake	Norepinephrine reuptake	N/A	N/A	N/A	inhibitor
DAP000104	Trazodone	Trittico (TN); KBio2_001904; Desyrel Dividose; KBio3_002540; 19794-93-5; CHEMBL621; Lopac-T-6154; Trazodonum; DB00656; Trazodona [INN-Spanish]; LS-156735; Trazodona; NCGC00016035-09; 1,2,4-Triazolo[4,3-a]pyridin-3(2H)-one, 2-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-; Desyrel(trazodone hcl salt); CAS-25332-39-2; Lopac0_001159; Prestwick2_000292; 2-{3-[4-(3-chlorophenyl)piperazin-1-yl]propyl}[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one; EINECS 243-317-1; Trazodonum [Latin]; Oprea1_185901; Prestwick1_000292; CID5533; Trazodonum [INN-Latin]; Trazodone [INN:BAN]; BSPBio_000224; NINDS_000196; L000771; nchembio873-comp51; UNII-YBK48BXK30; Trazalon; trazodone (Desyrel); NCGC00016035-01; IDI1_000196; MLS000758230; Trazolan; BRD-K70778732-003-05-1; 1,2,4-Triazolo(4,3-a)pyridin-3(2H)-one, 2-(3-(4-(3-chlorophenyl)-1-piperazinyl)propyl)-; Trazodon; Trazodone Hcl; AC-6778; 2-(3-[4-(3-Chlorophenyl)-1-piperazinyl]propyl)[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one; KBioGR_001110; Spectrum4_000755; KBio2_007040; Spectrum2_000854; NCGC00024405-03; BPBio1_000248; Spectrum5_000974; AC1L1KK2; Desirel; Prestwick3_000292; Trazodil; Trazodone (INN); Sideril; 8-[3-[4-(3-Chlorophenyl)piperazin-1-yl]propyl]-1,7,8-triazabicyclo[4.3.0]nona-2,4,6-trien-9-one hydrochloride; Trittico; I06-1977; Tradozone; BSPBio_003040; Beneficat; Trazodona [Spanish]; s-Triazolo(4,3-a)pyridin-3(2H)-one, 2-(3-(4-(m-chlorophenyl)-1-piperazinyl)propyl)-; C07156; SPBio_002443; NCGC00016035-03; BRN 0628010; KBio1_000196; CHEBI:9654; 2-[3-[4-(3-chlorophenyl)piperazin-1-yl]propyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one; C19H22ClN5O; SPBio_000867; D08626; Trialodine; Trazonil; Spectrum3_001560; trazodone; Spectrum_001424; NCGC00016035-02; KBio2_004472; MolPort-003-850-601; DivK1c_000196; Prestwick0_000292; KBioSS_001904	19794-93-5	5533	172043	TTDS00038	Noradrenergic re-uptake	Norepinephrine reuptake	N/A	N/A	N/A	inhibitor
DAP001436	Ultracet	N/A	147630-09-9	44153587	85150200	TTDS00038	Noradrenergic re-uptake	Norepinephrine reuptake	N/A	N/A	N/A	inhibitor
DAP001150	Maprotiline	10262-69-8; HMS2089K11; MolPort-002-507-847; Spectrum2_000139; Spectrum3_000483; Prestwick1_000346; 9,10-Ethanoanthracene-9(10H)-propanamine, N-methyl-; BSPBio_001945; NCGC00015708-10; 3-(9,10-Dihydro-9,10-ethanoanthracen-9-yl)propylmethylamine; TBB066626; maprotiline; BSPBio_000411; Prestwick3_000346; SMR000641863; SMP1_000169; C07107; BPBio1_000453; DivK1c_000891; Prestwick2_000346; IDI1_000891; Maprotilinum [INN-Latin]; KBio3_001445; CID4011; 10347-81-6 (hydrochloride); 276-Ba; AC1L1H7N; Spectrum4_000035; AC-12507; CHEMBL21731; Maprotilina [INN-Spanish]; STOCK6S-18648; KBio1_000891; nchembio747-comp22; Maprotiline (USAN); Dibencycladine; KBio2_006503; 58902-67-3 (mesylate); D02566; EINECS 233-599-4; Maprotylina [Polish]; Maprotylina; KBio2_001367; LS-66338; KBio2_003935; BRD-K03319035-003-02-7; Spectrum5_000918; KBioGR_000469; BRD-K25433859-003-11-4; SPBio_002332; Ba-34,276; MLS001201766; Maprotiline [USAN:BAN:INN]; NCGC00024886-02; Tocris-0935; SPBio_000218; BA-34276; UNII-2U1W68TROF; NCGC00015708-01; N-Methyl-9,10-ethanoanthracene-9(10H)-propanamine; Lopac-M-9651; Spectrum_000887; STK711156; N-Methyl-9,10-ethanoanthracene-9(10H)-propylamine; MolPort-002-671-472; Lopac0_000812; NCGC00024886-03; NCGC00016691-01; Maprotilin; AB00514665; NCGC00018217-01; 3-(9,10-ethanoanthracen-9(10H)-yl)-N-methylpropan-1-amine; Deprilept; BRN 2385493; DB00934; L001173; CAS-10347-81-6; Maprotilinum; 9,10-Ethanoanthracene-9(10H)-propylamine, N-methyl-; NINDS_000891; NCGC00024886-01; KBioSS_001367; Maprotilina; Prestwick0_000346	10262-69-8	4011	9318	TTDS00038	Noradrenergic re-uptake	Norepinephrine reuptake	N/A	N/A	N/A	inhibitor
DAP000862	Diethylpropion	AC1L1NUD; Reginon; Silutin; MolPort-001-783-471; 4-14-00-00144 (Beilstein Handbook Reference); 2-(Diethylamino)propiophenone; Diethylcathinone; Obesitex; 2-(Diethylamino)-1-phenyl-1-propanone; 2-(diethylamino)-1-phenylpropan-1-one; Cegramine; Prefamone; Regenon; Tepanil; CHEBI:4530; Amfepramone (INN); C13H19NO; EINECS 202-019-1; Amfepramone HCL; Amfepramonum; Modulor; 1-Phenyl-2-diethylamino-1-propanone; Diethylpropione; 2-Diethylaminopropiophenone; UNII-Q94YYU22B8; Amfepramone; Anfamon; Amphepramon; Diethylpropion HCL; Tylinal; alpha-Diethylaminopropiophenone; Amfepramonum [INN-Latin]; C06954; Adiposon; Derfon; Parabolin; 90-84-6; DIETHYLPROPION; Keramik; Frekentine; Amfepramon; Anfepramona [INN-Spanish]; Amfepramone hydrochloride; DEA No. 1610; Magrene; Diethylpropion (BAN); Keramin; Amphepramone; AC-13099; Amphepramonum hydrochloride; Diethylpropione hydrochloride; DB00937; CID7029; Propiophenone, 2-diethylamino-; alpha-Benzoyltriethylamine; Dobesin; Fenyl-(1-diethylaminoethyl)keton; Phepranon; BRN 2804400; Propiophenone, 2-(diethylamino)-; D07444; LS-125137; HSDB 3059; Danylen; Nopropiophenone; Anfepramona; UR 1423; (+-)-diethylpropion; Neobes; 1-Propanone, 2-(diethylamino)-1-phenyl-; Anorex; Tenuate hydrochloride; Fenyl-(1-diethylaminoethyl)keton [Czech]; Amfepramone [INN]	134-80-5	7029	9169	TTDS00038	Noradrenergic re-uptake	Norepinephrine reuptake	N/A	N/A	N/A	inhibitor
DCL000769	Desvenlafaxine SR	N/A	93413-62-8	125017	701788	TTDS00038	Noradrenergic re-uptake	Norepinephrine reuptake	N/A	N/A	N/A	inhibitor
DAP001155	Milnacipran	1-phenyl-1-diethylaminocarbonyl-2-aminomethylcyclopropane HCl; AC1L2425; (-)-milnacipran; Milnacipran; F-2207; (+-)-cis-2-(Aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide; Milnacipran (INN); 92623-85-3; Midalcipran; LS-178180; 105310-09-6; Cyclopropanecarboxamide, 2-(aminomethyl)-N,N-diethyl-1-phenyl-, cis-(+-)-; Toledomin; ( -)-Milnacipran; DB04896; Milnacipran [INN]; Milnacipranum [Latin]; Ixel; NCGC00165825-01; (1R,2S)-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropane-1-carboxamide; Milnacipranum; F 2207; CHEMBL252923; UNII-G56VK1HF36; CID65833; D08222	92623-85-3	65833	15122095	TTDS00038	Noradrenergic re-uptake	Norepinephrine reuptake	N/A	N/A	N/A	inhibitor
DCL000968	R-sibutramine metabolite	N/A	N/A	N/A	N/A	TTDS00038	Noradrenergic re-uptake	Norepinephrine reuptake	N/A	N/A	N/A	inhibitor
DAP000719	Phentermine	alpha.,.alpha.-dimethyl-Benzeneethanamine; Phentermine HCl; Phentrol; Lipopill; MolPort-002-043-208; RCRA waste no. P046; CHEMBL1574; Ortetaminum; Phentercot; 2-methyl-1-phenylpropan-2-amine; UNII-VF4N11KKKR; Obermine; Adipex-P; Omnibex; AC1L1IX2; C07438; 9008-94-0; alpha,alpha-Dimethylphenethylamine; Normephentermine; Ortetamine [INN]; 35373-71-8; Phenterminum [INN-Latin]; Phenethylamine, alpha,alpha-dimethyl-; D05458; Phenyl-tertiary-butylamine; Fastin; Ionamine; 122-09-8; EINECS 204-522-1; 1,1-Dimethyl-2-phenylethylamine; BRN 0970319; HSDB 3158; Ortetamina; Ionamin; Phenterminum; Phentrol 3; 1-(2-Tolyl)-2-propylamine; Phentermine resin complex; DEA No. 1640; Lonamin; Wilpo; Duromine; 1197-21-3 (hydrochloride); CID4771; AmbkkkkK744; Pro-Fast; HMS2093B16; alpha-Benzylisopropylamine; Obenix; 2-Methyl-1-phenyl-2-propanamine; 2-Propylamine, 1-(2-methylphenyl)-; (alpha,alpha)-Dimethylphenethylamine; LS-103327; Phenyl-tert-butylamine; Fentermina; Phenethylamine, .alpha.,.alpha.-dimethyl-; Linyl; Ona Mast; Ortetamin; Ethanamine, 1,1-dimethyl-2-phenyl-; Phentermine [USAN:INN:BAN]; 2-Phenyl-tert-butylamine; Phentride; Benzeneethanamine, .alpha.,.alpha.-dimethyl-; AKOS004123261; Zantryl; CHEBI:8080; InChI=1/C10H15N/c1-10(2,11)8-9-6-4-3-5-7-9/h3-7H,8,11H2,1-2H; Phentrol 2; phentermine; Benzeneethanamine, alpha,alpha-dimethyl-; alpha,alpha-Dimethylbenzeneethanamine; 2-Amino-2-methyl-1-phenylpropane; 12674-13-4; UNII-C045TQL4WP; Phentermine Resin 30; alpha,alpha-Dimethyl-beta-phenylethylamine; Phentermine (USAN/INN); Mirapront; RCRA waste number P046; Phentrol 4; 1-(2-Methylphenyl)-2-propylamin; Inoamin; DB00191; Fentermina [INN-Spanish]; Oby-Trim	122-09-8	4771	9642	TTDS00038	Noradrenergic re-uptake	Norepinephrine reuptake	N/A	N/A	N/A	inhibitor
DAP001149	Amoxapine	NCGC00015004-03; CL-67772; EU-0100116; Ascendin; Defanyl; Spectrum4_001218; Moxadil; KBio2_006062; Spectrum5_001284; EINECS 237-867-1; NCGC00015004-06; NINDS_000236; Amoxapina [INN-Spanish]; KBio3_001874; Prestwick3_000102; Prestwick2_000102; Amoxan; SPBio_001150; Spectrum2_001245; CHEBI:2675; Dibenz[b,f][1,4]oxazepine, 2-chloro-11-(1-piperazinyl)-; Prestwick1_000102; Amoxapine (JP15/USP/INN); DivK1c_000236; IDI1_000236; Spectrum_000446; 2-Chloro-11-(1-piperazinyl)- dibenz[b,f][1,4]oxazepine; amoxapine; A-129; CL-67,772; 8-chloro-6-piperazin-1-ylbenzo[b][1,4]benzoxazepine; Amoxapine [USAN:BAN:INN:JAN]; 14028-44-5; BRN 0832057; NCGC00015004-10; C17H16ClN3O; MLS000069371; LS-61563; 2-Chloro-11-(1-piperazinyl)dibenz[b,f][1,4]oxazepine; 2-chloro-11-(piperazin-1-yl)dibenzo[b,f][1,4]oxazepine; I06-0520; Desmethylloxapine; L001293; Amoxepine; HMS500L18; Amoxapinum [INN-Latin]; 2-chloro-11-piperazin-1-yldibenzo[b,f][1,4]oxazepine; AC-5495; PDSP1_001609; KBio2_000926; SPECTRUM2300161; Asendin; HMS2093N08; KBioGR_001656; SMR000058416; D00228; HMS2089G10; Dibenzo[b,f][1,4]oxazepine, 2-chloro-11-(1-piperazinyl)-; 2-Chlor-11-(1-piperazinyl)dibenz(b,f)(1,4)oxazepin; Asendin (TN); NCGC00023887-03; SAM002564189; Prestwick_503; KBioSS_000926; BSPBio_000084; AC1L1D2U; NCGC00023887-04; KBio1_000236; NCGC00015004-02; NCGC00023887-05; 2-Chloro-11-(1-piperazinyl)dibenz(b,f)(1,4)oxazepine; Spectrum3_001067; DB00543; HMS1568E06; BRD-K02265150-001-05-9; CID2170; Lopac-A-129; CPD000058416; BPBio1_000094; DIBENZ(b,f)(1,4)OXAZEPINE, 2-CHLORO-11-(1-PIPERAZINYL)-; MolPort-003-666-768; SPBio_002023; PDSP2_001593; Demolox; UNII-R63VQ857OT; CAS-14028-44-5; KS-1197; Asendis; KBio2_003494; Amoxapinum; CHEMBL1113; CL 67772; Lopac0_000116; Amoxapina; NCGC00015004-01; Desmethylloxapin; BSPBio_002654; A129_SIGMA; Prestwick0_000102; NCGC00023887-06	14028-44-5	2170	7847295	TTDS00038	Noradrenergic re-uptake	Norepinephrine reuptake	N/A	N/A	N/A	inhibitor
DCL000779	DOV 21947	N/A	N/A	N/A	N/A	TTDS00038	Noradrenergic re-uptake	Norepinephrine reuptake	N/A	N/A	N/A	inhibitor
DCL000781	DOV-21947	N/A	N/A	N/A	N/A	TTDS00038	Noradrenergic re-uptake	Norepinephrine reuptake	N/A	N/A	N/A	inhibitor
DAP000176	Sibutramine	Butramin (TN); Spectrum4_001137; Spectrum_001961; MolPort-002-507-758; HMS2090N17; AKOS004119970; KBio2_005076; TL8000239; 106650-56-0; UNII-WV5EC51866; Sibutraminum [Latin]; Spectrum3_001009; Spectrum2_001686; N-1-(1-(4-chlorophenyl)cyclobutyl)-3-methylbutyl-N,N-dimethylamine HCl; SAM001247105; KBioSS_002516; Sibutraminum; NCGC00092357-02; CPD000238156; KBio2_002508; AC-15773; LS-172014; AC1L1JUC; Meridia; CID5210; I05-0006; Spectrum5_001440; SPBio_001612; CHEMBL1419; DEA No. 1675; 84485-00-7 (hydrochloride); Butramin; SMR000238156; Sibutramine (INN); MLS001401362; Reductil; FT-0082832; HMS2052P05; Sibutramine [INN:BAN]; 1-[1-(4-chlorophenyl)cyclobutyl]-N,N,3-trimethylbutan-1-amine; STK802066; D08513; Cyclobutanemethanamine, 1-(4-chlorophenyl)-N,N-dimethyl-alpha-(2-methylpropyl)-; sibutramine; Sibutramina [Spanish]; MLS001066619; Medaria; Sibutramina; STOCK4S-20116; C17H26ClN; KBio2_007644; KBio3_001957; DB01105; C07247; BSPBio_002737; KBioGR_001653; BTS-54524	106650-56-0	5210	206707	TTDS00038	Noradrenergic re-uptake	Norepinephrine reuptake	N/A	N/A	N/A	inhibitor
DCL000768	Desvenlafaxine	Phenol, 4-(2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl)-; ST51051296; MolPort-003-846-411; CID125017; WY-45,233; O-Desmethylvenlafaxine; LS-178212; Desvenlafaxine; CHEBI:261281; Desvenlafaxine [INN:BAN]; I06-2078; PDSP1_001804; PDSP2_001787; CHEMBL1118; DB06700; Norvenlafaxine; AC1L2NUV; 93413-62-8; O-DESMETHYLVENLAFAXINE (ODV); D07793; 4-[2-(Dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]phenol; UNII-NG99554ANW; WY 45,233; Desvenlafaxine (INN); DVS 233; 4-(2-(Dimethylamino)-1-(1-hydroxycyclohexyl)ethyl)phenol	93413-62-8	125017	701788	TTDS00038	Noradrenergic re-uptake	Norepinephrine reuptake	N/A	N/A	N/A	inhibitor
DAP000052	Bupropion	Bupropion Hcl; 34841-36-6 (hydrochloride); BSPBio_000038; AC1L198Y; KBioGR_001168; KBio2_004711; CPD000472526; (+-)-1-(3-chlorophenyl)-2-((1,1-dimethylethyl)amino)-1-propanone; Bupropion (Old RN); BRD-A05186015-003-05-7; UNII-01ZG3TPX31; SMR000472526; Elont; .alpha.-(tert-Butylamino)-m-chloropropiophenone; MolPort-003-845-432; (+-)-Bupropion; KBio1_001994; SAM001246699; L000725; ( -)-2-(tert-Butylamino)-3'-chlorpropiophenon; Amfebutamone; MLS001424015; Amfebutamona; BPBio1_000042; alpha-(tert-butylamino)-m-chloropropiophenone; BSPBio_002247; DB01156; 34911-55-2; 2-(Tert-Butylamino)-3'-chloropropiophenone; 1-Propanone, 1-(3-chlorophenyl)-2-[(1, 1-dimethylethyl)amino]-; Propiophenone, 2-(tert-butylamino)-3'-chloro-; KBio2_007279; Prestwick0_000249; Spectrum_001663; KBioSS_002143; D07591; Lopac0_000166; AMFEBUTAMONE HCl; Bupropion hydrocloride; CHEBI:3219; AC-197; Bupropion (USAN); Bupropion (INN); Amfebutamonum [INN-Latin]; Spectrum2_001659; Bupropion SR; NCGC00015122-06; Jsp006301; LS-122817; KBio3_001467; 1-Propanone, 1-(3-chlorophenyl)-2-((1,1-dimethylethyl)amino)-; Spectrum4_000614; BRN 2101062; TL8002604; Spectrum3_000644; Amfebutamona [INN-Spanish]; NCI60_002714; 2-(tert-butylamino)-1-(3-chlorophenyl)propan-1-one; Prestwick3_000249; 1-Propanone, 1-(3-chlorophenyl)-2-((1,1-dimethylethyl)amino)-, (+-)-; AB00053756; HMS2051G10; Amfebutamon; Bupropion [INN:BAN]; Prestwick1_000249; Spectrum5_001406; C06860; Prestwick2_000249; SPBio_001817; bupropion; CHEMBL894; CID444; KBio2_002143; 1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]-; amfebutamonum; SPBio_002257; 1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]-, ()-; DivK1c_007050; HMS2089G14; ( -)-2-(tert-Butylamino)-3'-chloropropiophenone; 34841-39-9; SpecPlus_000954; NCGC00089751-02; NSC315851; 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]propan-1-one	34841-39-9	444	178415	TTDS00038	Noradrenergic re-uptake	Norepinephrine reuptake	N/A	N/A	N/A	inhibitor
DCL000900	NS 2359	N/A	843660-54-8	N/A	N/A	TTDS00038	Noradrenergic re-uptake	Norepinephrine reuptake	N/A	N/A	N/A	inhibitor
DCL001023	Trazodone CR	N/A	19794-93-5	5533	172043	TTDS00038	Noradrenergic re-uptake	Norepinephrine reuptake	N/A	N/A	N/A	inhibitor
DAP000721	Atomoxetine	D07473; CHEMBL641; LS-187331; Tomoxetine [INN]; Tomoxetinum [Latin]; PDSP2_000502; DB00289; Atomoxetine (INN); CID54841; Tocris-2011; BRD-K20141153-003-03-8; Tomoxetine; NCGC00025345-01; (-)-Tomoxetine; HSDB 7352; 83015-26-3; Tomoxetina [Spanish]; PDSP1_000504; (3R)-N-methyl-3-(2-methylphenoxy)-3-phenylpropan-1-amine; Benzenepropanamine, N-methyl-gamma-(2-methylphenoxy)-, (gammaR)-; AC1Q57N5; Atomoxetine; UNII-ASW034S0B8; AC1L1HTI; CHEBI:127342; Tomoxetinum; AC-5316; MolPort-002-052-062; Tomoxetina	82248-59-7	54841	214424	TTDS00038	Noradrenergic re-uptake	Norepinephrine reuptake	N/A	N/A	N/A	inhibitor
DAP000494	Duloxetine	PDSP2_001369; PDSP2_000953; (3S)-N-methyl-3-naphthalen-1-yloxy-3-thiophen-2-ylpropan-1-amine; CHEMBL1175; (S)-Duloxetine; 116539-59-4; (S)-N-Methyl-gamma-(1-naphthalenyloxy)-2-thiophenepropanamine; MLS000758267; (3S)-N-methyl-3-(1-naphthyloxy)-3-(2-thienyl)propan-1-amine; LS-172322; SAM001247059; Cymbalta; CHEBI:36795; CPD000449282; (3S)-N-methyl-3-(naphthalen-1-yloxy)-3-(2-thienyl)propan-1-amine; AC-15704; C18H19NOS; PDSP1_001385; Yentreve; NCGC00164559-01; MolPort-003-847-038; AC1L1U0Q; CID60835; HSDB 7368; 2-Thiophenepropanamine, N-methyl-gamma-(1-naphthalenyloxy)-, (S)-; Duloxetine (INN); Yentreve (TN); AC1Q57H7; Duloxetine [INN:BAN]; UNII-O5TNM5N07U; duloxetine; LY 248686; 2-Thiophenepropanamine, N-methyl-gamma-(1-naphthalenyloxy)-, (gammaS)-; D07880; DB00476; PDSP1_000969; HMS2051I05; MLS001423946; SMR000449282; duloxetine, (+)-isomer	136434-34-9	60835	704934	TTDS00038	Noradrenergic re-uptake	Norepinephrine reuptake	N/A	N/A	N/A	inhibitor
DAP000722	Mazindol	Sanjorex; 3H-Imidazo(2,1-a)isoindol-5-ol, 2,5-dihydro-5-(4-chlorophenyl)-; SANOREX (TN); Searle Brand of Mazindol; CID4020; Magrilon; 5-p-Chlorophenyl-2,3-dihydro-5H-imidazo(2,1-a)isoindol-5-ol; SAH 42548; Mazindol Medix Brand; Teronak; 5-(4-chlorophenyl)-2,3-dihydroimidazo[1,2-b]isoindol-5-ol; Wyeth Brand of Mazindol; UNII-C56709M5NH; HSDB 3112; D00367; Diestet; Mazindol Searle Brand; Novartis Brand of Mazindol; BRN 0546547; AN 448; D008454; CHEMBL781; DB00579; LS-77865; Mazindol [USAN:BAN:INN]; 5-(4-Chlorophenyl)-2,3-dihydro-5-hydroxy-5H-imidazo(2,1-a)isoindole; Mazindol (JAN/USP/INN); 5-(p-Chlorophenyl)-2,5-dihydro-3H-imidazo(2,1-a)isoindol-5-ol; DEA No. 1605; Solucaps; Sanorex; I06-0844; AC1L1H8E; Mazildene; CHEBI:146385; EINECS 244-857-0; AN448; 3H-Imidazo(2,1-a)isoindol-5-ol, 5-(4-chlorophenyl)-2,5-dihydro-, (+-)-; mazindol; AC-12511; Mazindolum; 3H-Imidazo[2,1-a]isoindol-5-ol, 5-(4-chlorophenyl)-2,5-dihydro-; MolPort-003-958-662; 5H-Imidazo(2,1-a)isoindol-5-ol, 5-(4-chlorophenyl)-2,3-dihydro; Mazindol Wyeth Brand; Mazindol Novartis Brand; (+-)-5-(p-Chlorophenyl)-2,5-dihydro-3H-imidazo(2,1-a)isoindol-5-ol; Mazindolum [INN-Latin]; Terenac; 3H-Imidazo(2,1-a)isoindol-5-ol, 5-(4-chlorophenyl)-2,5-dihydro-; AN-448; SA 42-548; CCRIS 3152; 3H-Imidazo(2,1-a)isoindol-5-ol, 5-(p-chlorophenyl)-2,5-dihydro-; 22232-71-9; 5-(4-Chlorophenyl)-2,5-dihydro-3H-imidazo[2,1-a]isoindol-5-ol; S 42548; M2017_SIGMA; Dimagrir; Mazanor; Mazindole; Medix Brand of Mazindol; Teronac	22232-71-9	4020	7847433	TTDS00038	Noradrenergic re-uptake	Norepinephrine reuptake	N/A	N/A	N/A	inhibitor
DAP000054	Venlafaxine	SPBio_000583; AC1L1KU8; Venlafaxine ER; Cyclohexanol, 1-(2-(dimethylamino)-1-(4-methoxyphenyl)ethyl)-, (+-)-; Efectin (TN); LS-57095; STK621394; KBio3_001877; Venlafaxinum; UNII-GRZ5RCB1QG; SpecPlus_000842; KBioSS_002151; Spectrum_001671; D08670; KBioGR_001590; NCGC00095109-03; HMS2090F04; VenlafaxineXR; 1-{2-(dimethylamino)-1-[4-(methyloxy)phenyl]ethyl}cyclohexanol; Efectin; Elafax; Venlafaxina; NCGC00095109-04; CHEMBL637; DivK1c_006938; HMS1922F05; Venlafaxine [INN:BAN]; Spectrum2_000542; Venlafaxine [BAN:INN]; BRD-A51714012-003-01-1; 1-[2-(Dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexanol; venlafaxine (Effexor); Venlafaxina [INN-Spanish]; Spectrum3_000989; 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexan-1-ol; CID5656; Wy 45030; 93413-69-5; NCGC00095109-02; MolPort-003-666-534; HMS2093A12; KBio2_002151; N,N-dimethyl-2-(1-hydroxycyclohexyl)-2-(4-methoxyphenyl)ethylamine; 1-[2-dimethylamino-1-(4-methoxyphenyl)ethyl]cyclohexan-1-ol; 1-[(1R)-2-(Dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexanol; DB00285; BRD-A51714012-001-02-3; Spectrum4_001115; BSPBio_002657; Venlafaxine (INN); 99300-78-4 (hydrochloride); NCGC00095109-01; KBio2_004719; C07187; AB1004809; KBio1_001882; CHEBI:9943; Spectrum5_001516; KBio2_007287; venlafaxine; Venlafaxinum [INN-Latin]; AC-1547; SPECTRUM1504171	93413-69-5	5656	193901	TTDS00038	Noradrenergic re-uptake	Norepinephrine reuptake	N/A	N/A	N/A	inhibitor
DCL000780	DOV-216303	N/A	N/A	N/A	N/A	TTDS00038	Noradrenergic re-uptake	Norepinephrine reuptake	N/A	N/A	N/A	inhibitor
DAP001452	Amfepramone	AC1L1NUD; Reginon; Silutin; MolPort-001-783-471; 4-14-00-00144 (Beilstein Handbook Reference); 2-(Diethylamino)propiophenone; Diethylcathinone; Obesitex; 2-(Diethylamino)-1-phenyl-1-propanone; 2-(diethylamino)-1-phenylpropan-1-one; Cegramine; Prefamone; Regenon; Tepanil; CHEBI:4530; Amfepramone (INN); C13H19NO; EINECS 202-019-1; Amfepramone HCL; Amfepramonum; Modulor; 1-Phenyl-2-diethylamino-1-propanone; Diethylpropione; 2-Diethylaminopropiophenone; UNII-Q94YYU22B8; Amfepramone; Anfamon; Amphepramon; Diethylpropion HCL; Tylinal; alpha-Diethylaminopropiophenone; Amfepramonum [INN-Latin]; C06954; Adiposon; Derfon; Parabolin; 90-84-6; DIETHYLPROPION; Keramik; Frekentine; Amfepramon; Anfepramona [INN-Spanish]; Amfepramone hydrochloride; DEA No. 1610; Magrene; Diethylpropion (BAN); Keramin; Amphepramone; AC-13099; Amphepramonum hydrochloride; Diethylpropione hydrochloride; DB00937; CID7029; Propiophenone, 2-diethylamino-; alpha-Benzoyltriethylamine; Dobesin; Fenyl-(1-diethylaminoethyl)keton; Phepranon; BRN 2804400; Propiophenone, 2-(diethylamino)-; D07444; LS-125137; HSDB 3059; Danylen; Nopropiophenone; Anfepramona; UR 1423; (+-)-diethylpropion; Neobes; 1-Propanone, 2-(diethylamino)-1-phenyl-; Anorex; Tenuate hydrochloride; Fenyl-(1-diethylaminoethyl)keton [Czech]; Amfepramone [INN]	90-84-6	7029	150052	TTDS00038	Noradrenergic re-uptake	Norepinephrine reuptake	N/A	N/A	N/A	inhibitor
DAP001151	Desipramine	Prestwick1_000343; Sertofran; AC-15977; 5-(gamma-Methylaminopropyl)iminodibenzyl; 5H-Dibenz(b,f)azepine-5-propanamine, 10,11-dihydro-N-methyl-; KBio2_006057; DMI 50475; 10, 11-Dihydro-N-methyl-5H-dibez[b,f]azepine-5-propanamine; Desipramine (INN); Dimethylimipramine; desipraminum; Prestwick2_000343; KBioSS_000921; 50-47-5; Spectrum_000441; CHEBI:47781; Desimipramine; AB00053450; KBio1_000190; DivK1c_000190; KBio2_000921; Desipraminum [INN-Latin]; Desipramin; Lopac0_000358; Spectrum5_000833; Monodemethylimipramine; KBio3_001357; KBio2_003489; EINECS 200-040-0; Methylaminopropyliminodibenzyl; DMI (pharmaceutical); Lopac-D-3900; (3-(10H,11H-Dibenzo[b,f]azepin-5-yl)propyl)methylamine; 5H-Dibenz[b,f]azepine-5-propanamine, 10,11-dihydro-N-methyl-; Demethylimipramine; UNII-TG537D343B; Desipramina [INN-Spanish]; DB01151; D07791; Dezipramine; 3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N-methylpropan-1-amine; MolPort-002-051-955; Prestwick0_000343; Norimipramine; L001089; BRN 1432747; NCGC00015340-10; ZERO/006017; BSPBio_002137; C06943; BPBio1_000447; N-(3-Methylaminopropyl)iminobibenzyl; CHEMBL72; Spectrum2_000091; NCGC00015340-01; BSPBio_000405; NCGC00024375-04; Pertrofane; 5H-Dibenz(b,f)azepine, 10,11-dihydro-5-(3-(methylamino)propyl)-; NINDS_000190; STOCK2S-34822; Desipramine (D4); Desipramina; NCGC00015340-02; LS-60421; CCRIS 7091; SPBio_000042; SPBio_002326; KBioGR_000928; HSDB 3052; 10,11-Dihydro-5-(3-methylaminopropyl)-5H-dibenz(b,f)azepine; Norpramine; Desmethylimipramine; 5H-Dibenz[b,f]azepine-5-propanamine, 10,11-dihydro-N-methyl-; Spectrum3_000379; AC1L1EXQ; 58-28-6 (hydrochloride); desipramine; Prestwick3_000343; Spectrum4_000314; Pentofran; NCGC00015340-03; CAS-58-28-6; Imipramine, demethyl-; DB07682; Desimpramine; IDI1_000190; AKOS001681456; STK735144; Desipramine Hcl; 3-(10,11-DIHYDRO-5H-DIBENZO[B,F]AZEPIN-5-YL)-N-METHYLPROPAN-1-AMINE; Desipramine [INN:BAN]; CID2995	50-47-5	2995	148551	TTDS00038	Noradrenergic re-uptake	Norepinephrine reuptake	N/A	N/A	N/A	inhibitor
DAP000720	Reboxetine	98769-83-6; MolPort-005-943-618; 71621-36-8; Reboxetine (INN); Reboxetine [INN]; CHEMBL14370; LS-93003; AC1MIDJY; Esreboxetine (USAN/INN); D09340; CID65856; 71620-89-8; 2-[(2-ethoxyphenoxy)-phenylmethyl]morpholine; AC1L2442; LS-178388; Tocris-1982; 98819-76-2; Edronax (TN); NCGC00025335-01; (S,S)-( )-Reboxetine; AC1NSKK9; Morpholine, 2-((R)-(2-ethoxyphenoxy)phenylmethyl)-, (2R)-rel-; Prolift; AC-1247; 2-((2-ethoxyphenoxy)benzyl)morpholine methanesulfonate; CHEMBL593475; MolPort-003-850-135; Reboxetine mesylate; Reboxetine; CID10455311; DB00234; Esreboxetine; Edronax; CID5311403; UNII-947S0YZ36I; CID127151; Davedax; Reboxitine; (2S)-2-[(S)-(2-ethoxyphenoxy)-phenylmethyl]morpholine; Solvex; (2R)-2-[(S)-(2-ethoxyphenoxy)-phenylmethyl]morpholine; CID10403303; Norebox; CID10245062; (+-)-(2R*)-2-((alphaR*)-alpha-(o-Ethoxyphenoxy)benzyl)morpholine; AC1L2RJ0; MolPort-005-942-846; Vestra; (2R)-2-[(R)-(2-ethoxyphenoxy)-phenylmethyl]morpholine; CHEBI:114263; 98769-81-4; CID3022645; D08472; (S,S)-reboxetine; BRD-A43974499-066-01-1	98769-81-4	65856	207897	TTDS00038	Noradrenergic re-uptake	Norepinephrine reuptake	N/A	N/A	N/A	inhibitor
DAP000834	Cocaine	53-21-4 (hydrochloride); Snort; Allococaine; Cecil; Jam; (-)-Cocaine base; Charlie; methyl (1S,4R,5R)-3-benzoyloxy-8-methyl-8-azabicyclo[3.2.1]octane-4-carboxylate; Blow [Street Name]; SMR001338843; Depsococaine; MolPort-002-535-520; DB00907; Happy powder; Toke; Bernies; Cocktail; D00110; Gold dust [Street Name]; White girl or lady; Coca; Bernice; DEA No. 9041; Methyl 3beta-hydroxy-1alphaH,5alphaH-tropane-2beta-carboxylate benzoate (ester); Cocaine, l-; Blast; Trails; Eritroxilina; Sleighride; Sweet Stuff; Neurocaine; Delcaine; Flake [Street Name]; Lady [Street Name]; Ecgonine methyl ester benzoate; Carrie; Blow; CID11779748; Moonrocks; Burese; KBio1_000975; Kokayeen; Kokain; methyl 3-benzoyloxy-8-methyl-8-azabicyclo[3.2.1]octane-4-carboxylate; Florida Snow; Happy trails; Bernice [Street Name]; Cola; AC1L3U2D; 2-beta-Tropanecarboxylic acid, 3-beta-hydroxy-, methyl ester, benzoate (ester); Flake; C8912_SIGMA; AC1L1EK2; Cocaine [BAN]; STOCK1N-68258; d-Pseudococaine; Erytroxylin; (R)-Cocaine; CHEBI:27958; C01416; Ecgonine, methyl ester, benzoate (ester); (1R,2R,3S,5S)-2-Methoxycarbonyltropan-3-yl benzoate; Blizzard; Snow (birds); C" Carrie; 610089_FLUKA; AC-16037; Caviar; G-Rock; Badrock; 50-36-2; Prime Time; HSDB 6469; 1-Cocaine; cocainum; Dextrocaine; UNII-I5Y540LHVR; 2-beta-Carbomethoxy-3-beta-benzoxytropane; Flex; Rock [Street Name]; l-Cocain; Goofball; 2beta-Carbomethoxy-3beta-benzoxytropane; Isococain; Kokan; Benzoylethylecgonine; CID446220; Snow; Cocaine (TN); MLS002320697; DivK1c_000975; COC; methyl (3S,4R)-3-benzoyloxy-8-methyl-8-azabicyclo[3.2.1]octane-4-carboxylate; cocaine; Cholly; Methyl 3-(benzoyloxy)-8-methyl-8-azabicyclo[3.2.1]octane-2-carboxylate; Girl; Cocain; Crack cocaine; Heaven; L000836; 3beta-Hydroxy-2beta-tropanecarboxylic acid methyl ester benzoate (ester); Bouncing Powder; NCGC00159467-02; Gold dust; AC1L9JBL; Pseudococaine; Leaf; Star dust; Allopseudococaine; Cocaina; Toot; Rock; 1i7z; Cocaine (USP); Nose candy; CID5760; Dama blanca; NINDS_000975; nchembio.284-comp4; Foo Foo; L-Cocaine; 610089_ALDRICH; (1R,2R,3S,5S)-2-(methoxycarbonyl)tropan-3-yl benzoate; Chicken Scratch; Corine; Happy dust [Street Name]; Ecgonine methyl ester benzoate solution; Methyl Benzoylecgonine; MolPort-003-937-722; beta-Cocain; Crack; Isococaine; Pseudoallococaine; CPD-9776; Yeyo; Hell; Candy; Coke; AC1L1L2T; Cocaine solution; Happy dust; Cocaine free base; Star-spangled powder; Girl [Street Name]; Kibbles n' Bits; (-)-Cocaine; Benzoylmethylecgonine; IDI1_000975; Cocaine-M; 1q72; Bazooka; LS-157759; CID2826; 3-Tropanylbenzoate-2-carboxylic acid methyl ester; Pimp's drug; Toot [Street Name]; EINECS 200-032-7; Freeze; Cecil [Street Name]; Cabello; Lady; AC-20208; Green gold	50-36-2	5760	148543	TTDS00038	Noradrenergic re-uptake	Norepinephrine reuptake	N/A	N/A	N/A	inhibitor
DAP001552	Carglumic acid	N/A	N/A	N/A	N/A	TTDS00533	Carbamoyl-phosphate synthetase I	Carbamoyl-phosphate synthase [ammonia], mitochondrial;CPSase I;CPS1	P31327	1373	ENSG00000021826	activator
DAP000150	Milrinone	1,6-Dihydro-2-methyl-6-oxo-3,4-bipyridine-5-carbonitrile; Milrila; NCGC00015675-07; CHEMBL189; AC1Q2EBX; Primacor; Lopac-M-4659; D00417; NCGC00025189-02; Corotrop; 2-methyl-6-oxo-1,6-dihydro-3,4'-bipyridine-5-carbonitrile; Milrinonum; NCGC00015675-02; LS-44610; 3-Cyano-6-methyl-5-(4-pyridyl)-2-pyridone; HMS2090J14; CPD000058475; PRIMACOR IN DEXTROSE 5% IN PLASTIC CONTAINER; M4659_SIGMA; 111GE027; Milrinone [USAN:BAN:INN]; AB00514027; Prestwick2_001065; MLS000028818; C12H9N3O; SPBio_002965; UNII-JU9YAX04C7; CID4197; NCGC00025189-03; 1,6-Dihydro-2-methyl-6-oxo-(3,4'-bipyridine)-5-carbonitrile; SAM001246611; AC1L1HMP; NCGC00015675-01; HMS1571E12; 1,6-Dihydro-2-methyl-6-oxo(3,4'-bipyridine)-5-carbonitrile; AC-4730; NCGC00164390-01; Milrila (TN); Win-47203; Milrinone (JAN/USAN/INN); Prestwick0_001065; SMR000058475; 1,6-Dihydro-2-methyl-6-oxo-(3,4&prime;-bipyridine)-5-carbonitrile; BIDD:GT0197; Milrinona [Spanish]; WIN 47203-2; ZINC09224016; Milrinonum [Latin]; BSPBio_001050; C07224; Prestwick3_001065; 1,6-Dihydro-2-methyl-6-oxo-[3,4'-bipyridine]-5-carbonitrile; HMS2051L10; Tocris-1504; (3,4'-Bipyridine)-5-carbonitrile, 6-dihydro-2-methyl-6-oxo-; BRN 3546821; CAS-78415-72-2; Prestwick1_001065; NCGC00015675-04; Corotrope; DB00235; Win-47203-2; CHEBI:50693; YM 018; milrinone; I06-0259; S2484_Selleck; EN002063; MLS001424052; EU-0100737; Milrinona; M1663; 78415-72-2; BPBio1_001156; NCGC00025189-01; 6-methyl-2-oxo-5-pyridin-4-yl-1H-pyridine-3-carbonitrile; MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER; EINECS 278-903-6; Lopac0_000737; CCRIS 3795; M 4659; 6-Methyl-5-(4-pyridyl)-2-pyridone-3-carbonitrile; SBB055743; (3,4'-BIPYRIDINE)-5-CARBONITRILE, 1,6-DIHYDRO-2-METHYL-6-OXO-	78415-72-2	4197	9433	TTDS00390	CGMP-inhibited 3',5'-cyclic phosphodiesterase A	CGI-PDE A;Cyclic GMP inhibited phosphodiesterase A;Phosphodiesterase  3A	Q14432	5139	ENSG00000172572	inhibitor
DAP000613	Aminophylline	Theonite; Syntophyllin; Duraphyllin; Slo Phyllin; Theopek; 8013-40-9; BIDD:ER0557; Uni-Dur; ST50298884; Constant-T; DB00277; Euphyllinum; HMS1570D21; SPBio_002640; Theophyl-SR; Theo-Sav; Peterphyllin; Ethophylline; Cardiomin; Aminophyllin; Theolone; 12767-26-9; CPD-12479; Bronchoparat; DOBO; Norofilina; 5768-49-0; CID2153; NSC 7919; Theo-Nite; KBio2_006654; Eufilina; Theospan; KBio3_001583; Slo-bid; A1755_SIGMA; Theolix; Talotren; Lanophyllin; Elixicon; Uniphyl; MLS002153487; HSDB 3399; KBio2_004086; Theodrox; BIDD:GT0151; SMR000058537; Lixaminol; Theacitin; Aerolate SR; Teocen 200; Theo-24; SAM002554935; Teofyllamin; Lopac-A-1755; Physpan; Phyllotemp; D00227; 95646-60-9; Nuelin S.A.; MLS000069390; SloPhyllin; Theo-dur; C07130; CHEMBL1210; Optiphyllin; Doraphyllin; Euphyllin; Quibron T/SR; AC-20328; CCRIS 4729; Pro-vent; Asmalix; Nuelin S.A; Phyllindon; Elixophyllin; Vasofilina; NCI60_001736; Uniphyl (TN); 46157-00-0; Theodur; 80186-94-3; Quibron T-SR; 58-55-9; Theodur G; CID441189; CPD000058537; Theolair; Teofilina; Theochron; Nuelin SA; ct, theo von; Uniphyllin; Cardophylin; CHEMBL190; Aminocardol; SomophyllinT; Truphylline; Egifilin; Thephyldine; Theodrip; NSC2066; Theotard; Somophyllin; Theophyllin; Neophyiline; CAS-317-34-0; Constant T; Theodel; A 1755; Diaphyllin; Theomin; Theona P; SPBio_002866; Unifyl; Etheophyl; Austyn; Euphylong; 56645-32-0; Solosin; Elixomin; Nuelin; HMS2089A06; Theolamine; HSDB 221; PDSP1_001234; Xanthium; AC-11138; Theo24; T0179; Theo-11; HMS500K05; Bronkodyl SR; GS 2591A; Choledyl SA; Synophylate; Afonilm; Theoclear-80; Theophyldine; Uniphylline; Teonova; Quibron TSR; Theophyl; T1633_SIGMA; Bronkotabs; AC1L1T14; D013806; theo von ct; Theolair-SR; PDSP2_001218; NINDS_000203; Respid; AI3-50216; Asmax; SMP1_000291; Diuxanthine; CHEBI:28177; Accurbron; LS-241; Aerolate III; Tefamin; Quibron T SR; Quibron T; Theostat 80; Quibron-T; Elixex; HMS2092M05; Xantivent; Theocontin; Theoclear 80; Diophllin; T9031_SIGMA; Theobid; AC1L9AQ0; Eurphyllin; ConstantT; IDI1_000203; KBio1_000203; Theovent; Bio-0793; Diophyllin; Afonilum; KBio2_001518; CID9433; Carena; AB00052106; Theo-DS; UPCMLD-DP123; Tesona; Phylcardin; Theo 24; ZINC18043251; Mudrane; Unilong; Theophyl-225; Theophyline; T7770_SIGMA; LaBID; D00371; C7H8N4O2; Theofol; 2a3a; D05429; Linampheta; Lasodex; Cardophyllin; Aerolate; Sustaire; Maphylline; Armophylline; T4924_SIGMA; Euphylline; Theograd; Quibron-T/SR; Quibron; Theocin; Telb-DS; Aquaphyllin; Respbid; Metaphylline; Phyllocontin; EU-0100014; Miofilin; Aerobin; Metaphyllin; Hylate; Teosona; Theostat; Theoclear LA; PDSP2_001002; 317-34-0; Genophyllin; Theoclair-SR; Prestwick_93; PDSP1_001018; 75448-53-2; Aminodur; Cariomin; Theokin; Aminofillina; Inophylline; Theolixir; Acet-theocin; L000595; Parkophyllin; 442519-87-1; von ct, theo; Theobid Jr.; Bilordyl; T-Phyl; Euufillin; ST024762; Respicur; TH/100; Duraphyl; Theo-24 (TN); ST50298827; Theoplus; HMS1921E03; AC1L1D1F; Grifomin; SPBio_000823; THEOBID JR; LASMA; Euufilin; Diaphylline; Minaphil; Pulmidur; MLS002152943; Diaphilline; Cardiofilina; Theoclear; Diffumal; LS-149548; Ammophyllin; STK397040; NSC 2066; Medaphyllin; Theo Dur; Slo-phyllin; Teolair; Labophylline; X 115; theophylline; Bronkodyl; Stenovasan; DB01223; Aminofilina; 111079-49-3; BY 108	317-34-0	9433	152642	TTDS00390	CGMP-inhibited 3',5'-cyclic phosphodiesterase A	CGI-PDE A;Cyclic GMP inhibited phosphodiesterase A;Phosphodiesterase  3A	Q14432	5139	ENSG00000172572	inhibitor
DAP000612	Anagrelide	D07455; AC1L1D3U; 6,7-dichloro-1,5-dihydroimidazo[2,1-]quinazolin-2(3H)-one; Anagrelidum; UNII-K9X45X0051; AC-3401; Anagrelide [BAN:INN]; Imidazo(2,1-b)quinazolin-2(3H)-one, 6,7-dichloro-1,5-dihydro-; I14-11970; Anagrelida [INN-Spanish]; Anagrelidum [INN-Latin]; MolPort-005-934-314; Anagrelida; Anagrelide [INN:BAN]; 6,7-Dichlor-1,5-dihydroimidazo(2,1-b)chinazolin-2(3H)-on; HSDB 7325; MolPort-003-844-624; BL 416201; HMS2089D21; 6,7-Dichloro-1,5-dihydroimidazo(2,1-b)quinazolin-2(3H)-one; 6,7-dichloro-5,10-dihydro-3H-imidazo[2,1-b]quinazolin-2-one; CID2182; CHEBI:142290; Anagrelide (INN/BAN); anagrelide; LS-80464; 68475-42-3; ZINC03871541; BRN 0619582; NCGC00161408-01; CHEMBL760; C10H7Cl2N3O; BIDD:GT0711	68475-42-3	2182	660898	TTDS00390	CGMP-inhibited 3',5'-cyclic phosphodiesterase A	CGI-PDE A;Cyclic GMP inhibited phosphodiesterase A;Phosphodiesterase  3A	Q14432	5139	ENSG00000172572	inhibitor
DAP000191	Cilostazol	89332-50-3; SAM001247085; TL8005113; MLS000028470; 6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydro-2(1H)-quinolinone; AC1L1EE2; CL23867; cilostazol; 2(1H)-Quinolinone, 3,4-dihydro-6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-; C045645; Tocris-1692; CID2754; CHEBI:31401; NCGC00022153-06; Pletal; Pletaal; 2(1H)-Quionlinone, 6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydro-; EU-0100218; OPC 13013; LS-142693; CPD000058428; MLS000759507; 6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)-butoxy]-3,4-dihydro-2(1H)-quinolinone; AC-4334; C0737_SIGMA; C 0737; Pletal,  Cilostazol; SPBio_001256; MLS001076067; Spectrum3_001170; NCGC00022153-07; Pletal (TN); CHEMBL799; 3,4-Dihydro-6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-2(1H)-quinolinone; MLS002153891; HMS2093M14; D01896; NCGC00022153-02; KBioGR_001184; S1294_Selleck; 73963-72-1; Cilostazole; KBio3_002259; Cilostazol (JP15/USAN/INN); 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydroquinolin-2(1H)-one; NCGC00015207-01; ZINC01552174; 6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxyl)-3,4-dihydrocarobostyril; NCGC00015207-02; MLS000758281; BRN 3632107; NCGC00022153-04; SAM001246734; 6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydrocarbostyril; OPC 21; UNII-N7Z035406B; BSPBio_002759; Spectrum2_001118; OPC-21; C20H27N5O2; OPC 13013; OPC 21; Pletaal; BRD-K67017579-001-07-5; Lopac-C-0737; Otsuka brand of cilostazol; HMS1922N15; OPC-13013; Cilostazol [INN:JAN]; BRD-K67017579-001-04-2; MolPort-001-758-007; NCGC00015207-06; SPECTRUM1505230; BRD-K67017579-001-13-3; Cilostazolum [INN-Latin]; Lopac0_000218; BRD-K67017579-001-05-9; Spectrum4_000772; SMR000058428; Spectrum5_001762; NCGC00022153-05; DB01166; 6-[4-(1-cyclohexyltetrazol-5-yl)butoxy]-3,4-dihydro-1H-quinolin-2-one; Cilostazolum; NCGC00015207-10	73963-72-1	2754	190773	TTDS00390	CGMP-inhibited 3',5'-cyclic phosphodiesterase A	CGI-PDE A;Cyclic GMP inhibited phosphodiesterase A;Phosphodiesterase  3A	Q14432	5139	ENSG00000172572	inhibitor
DAP001442	Candesartan cilexetil	candesartan cilexitil; Kenzen; FT-0082579; SPECTRUM1504261; Candesartan cilexetil [USAN]; CHEMBL1014; 1-(cyclohexylocarbonyloxy)ethyl-2-ethoxy-1-(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)-1H-benzimidazole-7-carboxylate; KBio2_002187; 1-cyclohexyloxycarbonyloxyethyl 2-ethoxy-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylate; Atacand (TN); (+-)-1-Hydroxyethyl 2-ethoxy-1-(p-(o-1H-tetrazol-5-ylphenyl)benzyl)-7-benzimidazolecarboxylate, cyclohexyl carbonate (ester); 2-Ethoxy-3-[2'-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3H-benzoimidazole-4-carboxylic acid 1-cyclohexyloxycarbonyloxy-ethyl ester; 1-{[(cyclohexyloxy)carbonyl]oxy}ethyl 2-(ethyloxy)-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-benzimidazole-7-carboxylate; 1H-Benzimidazole-7-carboxylic acid, 2-ethoxy-1-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-, 1-[[(cyclohexyloxy)carbonyl]oxy]ethyl ester; Takeda brand of candesartan cilexetil; Spectrum4_001124; I06-0090; NCGC00095123-03; Spectrum2_000485; 2-ethoxy-3-[2'-(1h-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3h-benzoimidazole-4-carboxylic acid 1-cyclohe; Astra brand of candesartan cilexetil; Candesartan hexetil; NCGC00095123-01; L006257; D00626; Promed brand of candesartan cilexetil; HMS1922J09; Spectrum5_001462; Candesartan cilexetil (JAN/USAN); 1H-Benzimidazole-7-carboxylic acid, 2-ethoxy-1-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-, 1-(((cyclohexyloxy)carbonyl)oxy)ethyl ester, (+-)-; AstraZeneca brand of candesartan cilexetil; AC1L1DWQ; C07709; ST51052687; Racanda; CID2540; Candesartan cilexetil; TL8000995; H212/91; NCGC00095123-02; KBio2_007323; Parapres; KBio2_004755; TCV-116; CHEBI:216349; Spectrum3_000996; 145040-37-5; Spectrum_001707; KBioGR_001607; AC-204; 1H-Benzimidazole-7-carboxylic acid, 2-ethoxy-1-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-, 1-(((cyclohexyloxy)carbonyl)oxy)ethyl ester, ( -)-; KBio3_001911; C077793; HMS2093E20; TCV 116; ATACAND HCT; Amias; 1H-Benzimidazolium, 7-carboxy-1-(2-((cyclohexylcarbonyl)oxy)ethyl)-2-ethoxy-1-(2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)-, hydroxide, inner salt, (+-)-; MolPort-003-666-552; KBioSS_002187; UNII-R85M2X0D68; BRD-A65671304-001-02-6; SPBio_000349; Atacand; Almirall brand of candesartan cilexetil; LS-32741; C33H34N6O6; BSPBio_002691	145040-37-5	2540	48413371	TTDS00525	Type-2 angiotensin II receptor	Angiotensin II receptor 2;AT2	P50052	186	ENSG00000180772	antagonist
DCL000310	TAK-491	CID11238823; 863031-21-4; UNII-LL0G25K7I2; CID 11238823; TAK 491	N/A	N/A	N/A	TTDS00525	Type-2 angiotensin II receptor	Angiotensin II receptor 2;AT2	P50052	186	ENSG00000180772	antagonist
DCL000491	Azilsartan medoxomil	N/A	N/A	N/A	N/A	TTDS00525	Type-2 angiotensin II receptor	Angiotensin II receptor 2;AT2	P50052	186	ENSG00000180772	antagonist
DCL000653	TAK-591	N/A	N/A	N/A	N/A	TTDS00525	Type-2 angiotensin II receptor	Angiotensin II receptor 2;AT2	P50052	186	ENSG00000180772	antagonist
DCL000490	Azilsartan	CHEBI:187493; CID 9825285; 147403-03-0; L001451; CHEMBL57242; UNII-F9NUX55P23; Azilsartan; TAK 536; Azilsartan (INN/USAN); TAK-536; D08864; CID9825285	N/A	N/A	N/A	TTDS00525	Type-2 angiotensin II receptor	Angiotensin II receptor 2;AT2	P50052	186	ENSG00000180772	antagonist
DCL000299	PS433540	N/A	58944-73-3	65482	49738087	TTDS00525	Type-2 angiotensin II receptor	Angiotensin II receptor 2;AT2	P50052	186	ENSG00000180772	antagonist
DPR000135	ER-319711-15	N/A	N/A	N/A	N/A	TTDS00093	Dipeptidyl peptidase IV	ADABP;Adenosine deaminase complexing protein-2;DPP IV;DPP-IV;T-cell activation antigen CD26;TP103	P27487	1803	ENSG00000197635	inhibitor
DCL001110	IDDBCP161883	N/A	N/A	N/A	N/A	TTDS00093	Dipeptidyl peptidase IV	ADABP;Adenosine deaminase complexing protein-2;DPP IV;DPP-IV;T-cell activation antigen CD26;TP103	P27487	1803	ENSG00000197635	inhibitor
DPR000145	LY-2463665	N/A	N/A	N/A	N/A	TTDS00093	Dipeptidyl peptidase IV	ADABP;Adenosine deaminase complexing protein-2;DPP IV;DPP-IV;T-cell activation antigen CD26;TP103	P27487	1803	ENSG00000197635	inhibitor
DCL001121	SSR-162369	N/A	N/A	N/A	N/A	TTDS00093	Dipeptidyl peptidase IV	ADABP;Adenosine deaminase complexing protein-2;DPP IV;DPP-IV;T-cell activation antigen CD26;TP103	P27487	1803	ENSG00000197635	inhibitor
DAP000639	Sitagliptin	LS-187389; MolPort-003-666-756; Sitagliptin; CID4369359; Januvia (merck & Co.); (2R)-4-OXO-4-[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]-1-(2,4,5-TRIFLUOROPHENYL)BUTAN-2-AMINE; 1x70; Xelevia; Sitagliptin (Prop.INN); Sitagliptan; UNII-QFP0P1DV7Z; AB1004599; BSPBio_002262; 1,2,4-Triazolo(4,3-a)pyrazine, 7-((3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl)-5,6,7,8-tetrahydor-3-(trifluoromethyl)-; Sitagliptin phosphate; DB07214; BRD-K19416115-001-01-2; AC1N9ZYR; CHEBI:40237; DB01261; Januvia; (3R)-3-amino-1-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)butan-1-one; (3R)-3-Amino-1-[3-(trifluoromethyl)-5,6,7,8-tetrahydro-1,2,4-triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-1-one; HMS2093F20; CHEMBL1422; MK-0431; (3R)-3-amino-1-[3-(trifluoromethyl)-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-1-one; HSDB 7516; Janumet; 486460-32-6; D08516	486460-32-6	4369359	14904024	TTDS00093	Dipeptidyl peptidase IV	ADABP;Adenosine deaminase complexing protein-2;DPP IV;DPP-IV;T-cell activation antigen CD26;TP103	P27487	1803	ENSG00000197635	inhibitor
DPR000151	R-1438	N/A	N/A	N/A	N/A	TTDS00093	Dipeptidyl peptidase IV	ADABP;Adenosine deaminase complexing protein-2;DPP IV;DPP-IV;T-cell activation antigen CD26;TP103	P27487	1803	ENSG00000197635	inhibitor
DCL000647	SYR-472	N/A	18559-59-6	5581	47959946	TTDS00093	Dipeptidyl peptidase IV	ADABP;Adenosine deaminase complexing protein-2;DPP IV;DPP-IV;T-cell activation antigen CD26;TP103	P27487	1803	ENSG00000197635	inhibitor
DCL001101	ABT-279	ABT-279; LS-193221; CHEMBL386369	N/A	N/A	N/A	TTDS00093	Dipeptidyl peptidase IV	ADABP;Adenosine deaminase complexing protein-2;DPP IV;DPP-IV;T-cell activation antigen CD26;TP103	P27487	1803	ENSG00000197635	inhibitor
DCL000421	Alogliptin	2-({6-[(3r)-3-Aminopiperidin-1-Yl]-3-Methyl-2,4-Dioxo-3,4-Dihydropyrimidin-1(2h)-Yl}methyl)benzonitrile; MolPort-005-933-065; CHEMBL376359; 850649-61-5; CID11450633; UNII-JHC049LO86; Alogliptin	N/A	11450633	46516529	TTDS00093	Dipeptidyl peptidase IV	ADABP;Adenosine deaminase complexing protein-2;DPP IV;DPP-IV;T-cell activation antigen CD26;TP103	P27487	1803	ENSG00000197635	inhibitor
DCL000648	TAK-100	N/A	N/A	N/A	N/A	TTDS00093	Dipeptidyl peptidase IV	ADABP;Adenosine deaminase complexing protein-2;DPP IV;DPP-IV;T-cell activation antigen CD26;TP103	P27487	1803	ENSG00000197635	inhibitor
DPR000142	Isoleucine thiazolidide DPP IV	N/A	N/A	N/A	N/A	TTDS00093	Dipeptidyl peptidase IV	ADABP;Adenosine deaminase complexing protein-2;DPP IV;DPP-IV;T-cell activation antigen CD26;TP103	P27487	1803	ENSG00000197635	inhibitor
DCL001113	Melogliptin	N/A	N/A	N/A	N/A	TTDS00093	Dipeptidyl peptidase IV	ADABP;Adenosine deaminase complexing protein-2;DPP IV;DPP-IV;T-cell activation antigen CD26;TP103	P27487	1803	ENSG00000197635	inhibitor
DCL000553	Linagliptin	CHEBI:49403; BI-1356-BS; Ondero; CHEBI:499873; CHEMBL237500; Linagliptin; (R)-8-(3-Amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione; CID10096344; CID 10096344; 668270-12-0; BI 1356; BI-1356; 1H-Purine-2,6-dione, 8-((3R)-3-amino-1-piperidinyl)-7-(2-butynyl)-3,7-dihydro-3-methyl-1-((4-methyl-2-quinazolinyl)methyl)-	668270-12-0	10096344	N/A	TTDS00093	Dipeptidyl peptidase IV	ADABP;Adenosine deaminase complexing protein-2;DPP IV;DPP-IV;T-cell activation antigen CD26;TP103	P27487	1803	ENSG00000197635	inhibitor
DPR000133	Denagliptin	Denagliptin; 483369-58-0; (2S,4S)-1-[(2S)-2-amino-3,3-bis(4-fluorophenyl)propanoyl]-4-fluoro-pyrrolidine-2-carbonitrile; GW823093; CID9887755; UNII-DOS9ZOT21L; 2-Pyrrolidinecarbonitrile, 1-((2S)-2-amino-3,3-bis(4-fluorophenyl)-1-oxopropyl)-4-fluoro-, (2S,4S)-; GW 823093	N/A	N/A	N/A	TTDS00093	Dipeptidyl peptidase IV	ADABP;Adenosine deaminase complexing protein-2;DPP IV;DPP-IV;T-cell activation antigen CD26;TP103	P27487	1803	ENSG00000197635	inhibitor
DPR000129	ASP8497	N/A	N/A	N/A	N/A	TTDS00093	Dipeptidyl peptidase IV	ADABP;Adenosine deaminase complexing protein-2;DPP IV;DPP-IV;T-cell activation antigen CD26;TP103	P27487	1803	ENSG00000197635	inhibitor
DPR000149	NVP DPP728	CID9799555; NVP-DPP728	N/A	N/A	N/A	TTDS00093	Dipeptidyl peptidase IV	ADABP;Adenosine deaminase complexing protein-2;DPP IV;DPP-IV;T-cell activation antigen CD26;TP103	P27487	1803	ENSG00000197635	inhibitor
DCL000639	Saxagliptin	361442-04-8; 2-Azabicyclo[3.1.0]hexane-3-carbonitrile, 2-[(2S)-2-amino-2-(3-hydroxytricyclo[3.3.1.13,7]dec-1-yl)acetyl]-, (1S,3S,5S)-; AC-6008; Onglyza; (1S,5S)-2-[2-amino-2-(3-hydroxy-1-adamantyl)acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile; BMS 477118-11; Saxagliptin; CID11243969; CHEBI:460723; S1540_Selleck; .1.13,7]dec-1-yl)acetyl]-, (1S,3S,5S)- (9CI); BMS-477118; BMS-477118-11; OPC-262; 2-Azabicyclo[3.1.0]hexane-3-carbonitrile, 2-[(2S)-amino(3-hydroxytricyclo[3.3; DB06335; CHEMBL385517	N/A	11243969	46512075	TTDS00093	Dipeptidyl peptidase IV	ADABP;Adenosine deaminase complexing protein-2;DPP IV;DPP-IV;T-cell activation antigen CD26;TP103	P27487	1803	ENSG00000197635	inhibitor
DAP001544	Vildagliptin	LAF 237; Galvus; Xiliarx; (2S)-1-[2-[(3-hydroxy-1-adamantyl)amino]acetyl]pyrrolidine-2-carbonitrile; CHEMBL319819; CID6918537; Vildagliptin (JAN/USAN/INN); NVP-LAF237; 2-Pyrrolidinecarbonitrile, 1-[2-[(3-hydroxytricyclo[3.3.1.13,7]dec-1-yl)amino]acetyl]-, (2S)-; DB04876; AC1OCFK2; 2-Pyrrolidinecarbonitrile, 1-(((3-hydroxytricyclo(3.3.1.13,7)dec-1-yl)amino)acetyl)-, (2S)-; LAF-237; SBB066750; FT-0082760; Vidagliptin (see Vildagliptin); Vildagliptin; C502012; 1-[2-[(3-hydroxy-1-adamantyl)amino]acetyl]pyrrolidine-2-carbonitrile; 274901-16-5; CID5251896; AC1NQOUT; CID11077541; LAF237; UNII-I6B4B2U96P; Equa; s; LAF 237; NVP-LAF 237; (2S)-(((3-hydroxyadamantan-1-yl)amino)acetyl)pyrrolidine-2-carbonitrile; CHEBI:253127; Jalra; I11-0029; NVP-LAF-237; CHEMBL142703; D07080; LS-193227; 2-Pyrrolidinecarbonitrile, 1-[[(3-hydroxytricyclo[3.3.1.13,7]dec-1-yl)amino]acetyl]-, (2S)- (9CI); Galvu	N/A	N/A	N/A	TTDS00093	Dipeptidyl peptidase IV	ADABP;Adenosine deaminase complexing protein-2;DPP IV;DPP-IV;T-cell activation antigen CD26;TP103	P27487	1803	ENSG00000197635	inhibitor
DCL001123	TNX-355	N/A	N/A	N/A	N/A	TTDC00265	T-cell surface glycoprotein CD4	CD4;T-cell surface antigen T4/Leu-3	P01730	920	ENSG00000010610	binder
DCL000429	Anti-CD4	N/A	N/A	N/A	N/A	TTDC00265	T-cell surface glycoprotein CD4	CD4;T-cell surface antigen T4/Leu-3	P01730	920	ENSG00000010610	antibody
DPR000179	ISIS-GCGR	N/A	N/A	N/A	N/A	TTDC00286	mRNA of Glucagon receptor	N/A	N/A	N/A	N/A	antisense
DCL001062	ISIS 325568	N/A	N/A	N/A	N/A	TTDC00286	mRNA of Glucagon receptor	N/A	N/A	N/A	N/A	antisense
DAP001406	Motexafin gadolinium	Xcytrin (TN); Motexafin gadolinium; Xcytrin; GdT2B2; D05080; Gadolinium texaphyrin; gadolinium diacetate (1Z,7Z,12E,20E)-4,5-diethyl-9,24-bis(3-hydroxypropyl)-16,17-bis{2-[2-(2-methoxyethoxy)ethoxy]ethoxy}-10,23-dimethyl-13,20,25,26,27-pentaazapentacyclo[20.2.1.13,6.18,11.014,19]heptacosa-1,3,5,7,9,11(26),12,14,16,18,20,22(25),23-tridecaen-27-ide; PCI-0120; 156436-89-4; GD-Tex; Motexafin gadolinium (USAN)	156436-89-4	12047567	56313878	TTDS00421	Ribonucleoside-diphosphate reductase subunit M2	Ribonucleotide reductase small chain;Ribonucleotide reductase small subunit;RR2;RRM2	P31350	6241	ENSG00000171848	inhibitor
DAP000256	Cinacalcet	UNII-UAZ6V7728S; (R)-alpha-methyl-N-[3-[3-(trifluoromethyl)phenyl]propyl]-1-naphthalenemethane amine; N-[(1R)-1-(1-naphthyl)ethyl]-3-[3-(trifluoromethyl)phenyl]propan-1-amine; AMG073; MolPort-003-845-954; Cinacalcet [INN]; N-[(1R)-1-naphthalen-1-ylethyl]-3-[3-(trifluoromethyl)phenyl]propan-1-amine; N-((1R)-1-(Naphthalen-1-yl)ethyl)-3-(3-(trifluoromethyl)phenyl)propan-1-amine; N-((1R)-1-(1-Naphthyl)ethyl)-3-(3-(trifluoromethyl)phenyl)propan-1-amine; CHEBI:48390; Cinacalcet (USAN); AMG 073; CID156419; HSDB 7318; 364782-34-3 (Hydrochloride); DB01012; Cinacalcet; I14-3270; nchembio.2007.55-comp29; (R)-N-(1-(Naphthalen-1-yl)ethyl)-3-(3-(trifluoromethyl)phenyl)propan-1-amine; TL8001899; 226256-56-0; LS-187374; AC1L4G5X; D03504; NCGC00181002-01	226256-56-0	156419	783756	TTDS00164	Extracellular calcium-sensing receptor	CaSR;Parathyroid calcium receptor;Parathyroid cell calcium receptor;Parathyroid Cell calcium-sensing receptor	P41180	846	ENSG00000036828	agonist
DCL000630	Ronacaleret	N/A	753449-67-1	5329098	49674962	TTDS00164	Extracellular calcium-sensing receptor	CaSR;Parathyroid calcium receptor;Parathyroid cell calcium receptor;Parathyroid Cell calcium-sensing receptor	P41180	846	ENSG00000036828	antagonist
DCL000399	GSK1004723	N/A	N/A	5702160	49698346	TTDC00079	Histamine H3 receptor	G protein-coupled receptor 97;HH3R;Histamine receptor 3	Q9Y5N1	11255	ENSG00000101180	antagonist
DCL001192	HPP404	N/A	N/A	N/A	N/A	TTDC00079	Histamine H3 receptor	G protein-coupled receptor 97;HH3R;Histamine receptor 3	Q9Y5N1	11255	ENSG00000101180	antagonist
DCL000393	GSK835726	N/A	N/A	5311268	40722554	TTDC00079	Histamine H3 receptor	G protein-coupled receptor 97;HH3R;Histamine receptor 3	Q9Y5N1	11255	ENSG00000101180	antagonist
DCL000088	Cipralisant	CIPRALISANT; 5-[(1R,2R)-2-(5,5-dimethylhex-1-ynyl)cyclopropyl]-1H-imidazole; CHEMBL278462; 213027-19-1; UNII-309713XSKW; LS-191791; Cipralisant [INN]; CHEBI:122426; CID6450823; AC1O52EX	N/A	6433105	43026851	TTDC00079	Histamine H3 receptor	G protein-coupled receptor 97;HH3R;Histamine receptor 3	Q9Y5N1	11255	ENSG00000101180	N/A
DCL000028	ABT-239	CHEMBL351231; CHEBI:367366; 4-[2-[2-(2-methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl]benzonitrile; CID 10028119; CID9818903; CID11202447; ABT-239	N/A	N/A	N/A	TTDC00079	Histamine H3 receptor	G protein-coupled receptor 97;HH3R;Histamine receptor 3	Q9Y5N1	11255	ENSG00000101180	antagonist
DCL000634	SAR110894	N/A	N/A	N/A	N/A	TTDC00079	Histamine H3 receptor	G protein-coupled receptor 97;HH3R;Histamine receptor 3	Q9Y5N1	11255	ENSG00000101180	antagonist
DCL000374	GSK239512	N/A	N/A	N/A	N/A	TTDC00079	Histamine H3 receptor	G protein-coupled receptor 97;HH3R;Histamine receptor 3	Q9Y5N1	11255	ENSG00000101180	antagonist
DAP001317	Nitroprusside	13755-38-9 (di-hydrochloride salt, diH20); CHEMBL74115; UNII-169D1260KM; Ferrate(2-), pentakis(cyano-C)nitrosyl-, (OC-6-22)-; LS-187044; Nitroprusside; C07269; 14402-89-2 (di-hydrochloride salt); CID11953891; 15078-28-1	15078-28-1	11963622	8145943	TTDS00502	Inositol 1,4,5-trisphosphate receptor	InsP3R1;IP3 receptor isoform 1;IP3R;ITPR1;Type 1 inositol 1,4,5-trisphosphate receptor;Type 1 InsP3 receptor	Q14643	3708	ENSG00000150995	antagonist
DAP000132	Glimepiride	Glimepiride [USAN:BAN:INN]; NCGC00181757-01; Prestwick2_000651; TL8005924; MolPort-003-847-587; CPD000466368; Bio-0049; Glimepirida [Spanish]; LS-136752; AC1L1G0T; 93479-97-1; Glimepirida; Ratio-glimepiride; Glimepiride (JAN/USP/INN); MLS001076674; BRN 5365754; I06-2285; MolPort-005-941-721; SMR000466368; G2295_SIGMA; Prestwick0_000651; Glimer; Amaryl, Glista OD, Glimepiride; Glymepirid; glimepiride; 4-ethyl-3-methyl-N-[2-[4-[(4-methylcyclohexyl)carbamoylsulfamoyl]phenyl]ethyl]-5-oxo-2H-pyrrole-1-carboxamide; S1344_Selleck; Oprea1_382896; Prestwick3_000651; MolPort-003-987-461; CCRIS 7083; Hoe-490; 1-{[4-(2-{[(3-ethyl-4-methyl-2-oxo-2,5-dihydro-1H-pyrrol-1-yl)carbonyl]amino}ethyl)phenyl]sulfonyl}-3-(trans-4-methylcyclohexyl)urea; NCGC00161404-01; NCGC00016960-01; 64598P; Endial; HMS1570C03; BPBio1_000751; CHEBI:5383; SAM001246710; BSPBio_000681; Glimepride; Solosa; Glimepirid; Amaryl; MLS000759495; Amarel; Sandoz glimepiride; HOE 490; UNII-6KY687524K; D00593; Amaryl (TN); PMS-glimepiride; C07669; HMS2052L03; Glimepiridum; DB00222; 1H-Pyrrole-1-carboxamide, 3-ethyl-2,5-dihydro-4-methyl-N-(2-(4-(((((4-methylcyclohexyl)amino)carbonyl)amino)sulfonyl)phenyl)ethyl)-2-oxo-, trans-; ZINC00537791; CHEMBL1481; 1H-Pyrrole-1-carboxamide, 2,5-dihydro-3-ethyl-4-methyl-N-(2-(4-(((((4-methylcyclohexyl)amino)carbonyl)amino)sulfonyl)phenyl)ethyl)-2-oxo-, trans-; Glimepiridum [Latin]; BRD-K34776109-001-03-4; NCGC00161404-02; AB00513874; HMS2090K18; Roname; Novo-glimepiride; 1-((p-(2-(3-Ethyl-4-methyl-2-oxo-3-pyrroline-1-carboxamido)ethyl)phenyl)sulfonyl)-3-(trans-4-methylcyclohexyl)urea; C24H34N4O5S; BRD-K42693031-001-01-8; Prestwick1_000651; CAS-93479-97-1; 3-ethyl-4-methyl-N-[2-(4-{[(trans-4-methylcyclohexyl)carbamoyl]sulfamoyl}phenyl)ethyl]-2-oxo-2,5-dihydro-1H-pyrrole-1-carboxamide; SPBio_002602; AC-476; 3-ethyl-4-methyl-n-(4-(n-((1r,4r)-4-methylcyclohexylcarbamoyl)sulfamoyl)phenethyl)-2-oxo-2,5-dihydro; I06-0029; MLS001401419; CID3476	93479-97-1	3476	193913	TTDS00332	SUR2-type K(ATP) channel	Kir6.2/SUR2	N/A	N/A	N/A	blocker
DAP000133	Repaglinide	SAM001246546; NCGC00016978-01; Novo Nordisk brand of repaglinide; Glaxo Wellcome brand of replaginide; D00594; 135062-02-1; AC-726; C27H36N2O4; 2-ethoxy-N-(alpha-(2-methyl-1-propyl)-2-piperidinobenzyl)-4-carbamoylmethylbenzoic acid; MLS001076684; MolPort-003-850-140; Repaglinida [INN-Spanish]; AC1L24D5; (+)-2-Ethoxy-alpha-(((S)-alpha-isobutyl-o-piperidinobenzyl)carbamoyl)-p-toluic acid; CAS-135062-02-1; AG-EE 388; (S)-(+)-2-Ethoxy-4-[N-[1-(2-piperidinophenyl)-3-methyl-1-butyl]aminocarbonylmethyl]benzoic acid; Prestwick0_001046; GlucoNorm; AGEE-623ZW; Actulin; 2-ethoxy-4-[2-[[(1S)-3-methyl-1-(2-piperidin-1-ylphenyl)butyl]amino]-2-oxoethyl]benzoic acid; Repaglinide; SMP-508; AG-EE-388; (S)-2-Ethoxy-4-(2-((methyl-1-(2-(1-piperidinyl)phenyl)butyl)amino)-2-oxoethyl)-benzoic acid; MLS000759407; CID65981; AC1Q5TZW; Prestwick3_001046; SMR000466305; Repaglinidum; BPBio1_001070; Prandin, GlucoNorm, NovoNorm, Repaglinide; AG-EE-623 ZW; NCGC00016978-02; C07670; Repaglinide [USAN]; STK629501; LS-38509; Prestwick1_001046; NovoNorm; UNII-668Z8C33LU; repa-glinide; Prestwick2_001046; CHEBI:348669; DB00912; AG-EE 623 ZW; AG-EE 388 ZW; 2-ethoxy-4-(2-{[(1S)-3-methyl-1-(2-piperidin-1-ylphenyl)butyl]amino}-2-oxoethyl)benzoic acid; HMS2051N08; Bio-0087; Novo Nordisk brand 2 of repaglinide; BSPBio_000972; HMS1571A14; repaglinide, (+-)-isomer; 2-ethoxy-4-(2-((3-methyl-1-(2-(1-piperidinyl)phenyl)butyl)amino)-2-oxoethyl)benzoic acid; 2-ethoxy-4-[2-({(1S)-3-methyl-1-[2-(piperidin-1-yl)phenyl]butyl}amino)-2-oxoethyl]benzoic acid; HMS2094C07; Prandin; C072379; NN-623; Repaglinidum [INN-Latin]; Repaglinide (JAN/USP/INN); BIDD:GT0338; S1426_Selleck; CPD000466305; AB00514019; CHEMBL1272; R9028_SIGMA; SPBio_002906; (S)-2-ethoxy-4-(2-((3-methyl-1-(2-(1-piperidinyl)-phenyl)butyl)amino)-2-oxoethyl)-benzoic acid; 111GE012; BRD-K82846253-001-03-0; Prandin (TN); Benzoic acid, 2-ethoxy-4-(2-((3-methyl-1-(2-(1-piperidinyl)phenyl)butyl)amino)-2-oxoethyl)-, (S)-; Repaglinida	135062-02-1	65981	208038	TTDS00332	SUR2-type K(ATP) channel	Kir6.2/SUR2	N/A	N/A	N/A	blocker
DAP001417	Pinacidil	SPBio_001818; HMS1568B14; CBiol_001878; Spectrum5_001372; AKOS001637331; BPBio1_000036; (R,S)-Pinacidil; BCBcMAP01_000050; HMS2089C19; KBioSS_000867; KBio2_003435; Prestwick3_000246; Bio2_000661; SPECTRUM2300270; NCGC00025188-02; EINECS 262-294-9; NCGC00025188-08; KBio2_000867; S 1230; C13H19N5; KBioGR_000181; Bio1_001142; SMR000058360; Spectrum_000387; Bio2_000181; (+-)-Pinacidil; HMS2094G21; BSPBio_002360; Guanidine, N-cyano-N'-4-pyridinyl-N''-(1,2,2-trimethylpropyl)-, monohydrate; KBio2_006003; CHEMBL1159; NCGC00025188-03; P154_SIGMA; 60560-33-0; HMS1791J03; Spectrum2_001739; MLS000069377; Prestwick0_000246; Prestwick1_000246; Guanidine, 2-cyano-3-(4-pyridyl)-1-(1,2,2-trimethylpropyl)-, monohydrate; BSPBio_001461; NCGC00095199-04; KBio2_002749; KBio2_005317; LS-73486; KBioSS_000181; pinacidil; (+/-)-N-Cyano-N'-4-pyridinyl-N"-(1,2,2-trimethylpropyl)guanidine; AR-1C2481; P-154; Pinacidil (anhydrous); KBio3_000361; NCGC00095199-02; NCGC00025188-04; AC1Q4SLP; Bio1_000164; Pinacidilum; SpecPlus_000759; BRD-A43882281-001-06-4; 85371-64-8; EU-0101037; BSPBio_000032; NCGC00025188-05; ( inverted question mark)-N-Cyano-N'-4-pyridinyl-N''-(1,2,2-trimethylpropyl)-guanidine; BRD-A58207013-001-01-2; KBio1_001799; 85371-64-8 (Parent); 113563-69-2; KBio2_000181; 1-cyano-2-(3,3-dimethylbutan-2-yl)-3-pyridin-4-ylguanidine; Lopac0_001037; DivK1c_006855; NCGC00025188-06; AC1L1J1H; CHEBI:287515; NCGC00095199-01; Guanidine, N-cyano-N'-4-pyridinyl-N''-(1,2,2-trimethylpropyl)-; HMS1989J03; P 1134; Pinacidilum [INN-Latin]; Bio1_000653; MolPort-003-666-777; NCGC00025188-07; 2-Cyano-3-(4-pyridyl)-1-(1,2,2-trimethylpropyl)guanidine monohydrate; HMS1361J03; Prestwick2_000246; S-1230; SPBio_002251; IDI1_033931; NCGC00095199-03; KBio3_000362; MLS002154248; 2-Cyano-3-(4-pyridinyl)-1-(1,2,2-trimethylpropyl)guanidine; HMS1922L10; N-Cyano-N'-4-pyridinyl-N''-(1,2,2-trimethylpropyl)guanidine; Prestwick_396; CID4826	85371-64-8	55329	586318	TTDS00332	SUR2-type K(ATP) channel	Kir6.2/SUR2	N/A	N/A	N/A	activator
DAP001409	Nicorandil	2-Nicotinamidoethyl nitrate; Nicorandil Aventis Brand; LS-130673; N0837; SG 75; AC1Q5PMV; Aventis Pharma Brand of Nicorandil; Tocris-2147; AC1L2I8U; 65141-46-0; Bio-0696; MolPort-000-829-178; NCGC00025357-01; SG-75; MLS001424162; ZINC01533102; NICORANDIL; HMS2051N16; I06-0032; SAM001246701; HMS2089L12; 3-Pyridinecarboxamide, N-(2-(nitrooxy)ethyl)-; D020108; Merck Brand of Nicorandil; CHEMBL284906; 2-(Pyridine-3-carboxamido)ethyl Nitrate; 3-Pyridinecarboxamide, N-(2-(nitroxy)ethyl)-; N-(2-Hydroxyethyl)nicotinamide nitrate; 2-[(pyridin-3-ylcarbonyl)amino]ethylnitrat; MLS002222323; 2-Nicotinamidethyl Nitrate; 2-(Nicotinamido)ethyl nitrat; MLS000759488; Nicorandil Merck Brand; Nicorandilum [INN-Latin]; Ikorel; Sigmart (TN); Sigmart; TL8004616; ARONIS24318; BRN 0481451; S1971_Selleck; Rhone Poulenc Rorer Brand of Nicorandil; RP-46417; Nitrate, 2-Nicotinamidethyl; C8H9N3O4; EINECS 265-514-1; Adancor; Dancor; 2 Nicotinamidethyl Nitrate; AKOS001589705; Nicorandil (JP15/USAN/INN); SG75; C13280; Nicorandilum; 2 Nicotinamidoethyl Nitrate; AC-4690; SMR000466365; NCGC00025357-02; N-(2-Hydroxyethyl)nicotinamide nitrate (ester); CPD000466365; Nicorandil [USAN:BAN:INN:JAN]; Aventis Brand of Nicorandil; D01810; Merck Lipha Sante Brand of Nicorandil; Nitrate, 2-Nicotinamidoethyl; CID47528; BRD-K97752965-001-01-6; Rhone-Poulenc Rorer Brand of Nicorandil; N-[2-(Nitrooxy)ethyl]pyridine-3-carboxamide; 2-(pyridine-3-carbonylamino)ethyl nitrate	65141-46-0	47528	586024	TTDS00332	SUR2-type K(ATP) channel	Kir6.2/SUR2	N/A	N/A	N/A	activator
DAP000136	Tolbutamide	NCGC00015999-01; Tarasina; N-(4-Methylbenzenesulfonyl)-N'-butylurea; Urea, 1-butyl-3-(p-tolylsulfonyl)-; LS-278; KBioGR_000795; TL8000121; CHEBI:27999; KBio3_002755; NCGC00022721-05; D014044; Tolbutamide Aventis Brand; Toluvan; Mobenol; Tolylsulfonylbutylurea; Prestwick0_000190; toluran; KBio2_004843; NCGC00015999-14; N-(4-Methylphenylsulfonyl)-N'-butylurea; Apotex Brand of Tolbutamide; HMS501B03; NCGC00022721-08; NCGC00022721-04; NCGC00022721-09; KBio2_007411; N-4-Methylbenzolsulfonyl-N-butylurea; Orinaz; cMAP_000008; AB00052110; Tolbutamidum; U 2043; HSDB 3393; 100735-34-0; Diabuton; BRN 1984428; Glyconon; NSC23813; NCGC00015999-02; HMS1791L09; Tolbutamidum [INN-Latin]; N-Butyl-N'-(p-tolylsulfonyl)urea; Berlin-Chemie Brand of Tolbutamide; Bio1_000206; Tolbutamida; CCRIS 592; TOLBUTAMIDE USP; Lopac0_001154; KBio2_002795; Dolipol; KBio2_006063; T 0891; Drabet; Oramide; Tolbutamid R.A.N.; BPBio1_000131; NCGC00015999-07; Novo-Butamide; Valdecasas Brand of Tolbutamide; N-Butyl-N'-toluene-p-sulfonylurea; Pramidex; MLS001148399; 1-butyl-3-(4-methylphenyl)sulfonylurea; CAS-64-77-7; SPBio_002040; KBio2_000227; Lopac-T-0891; 3-(p-Tolyl-4-sulfonyl)-1-butylurea; KBio3_000454; tolbutamide; Prestwick2_000190; 1-Butyl-3-(4-methylphenylsulfonyl)urea; CPD000058363; Spectrum_000447; Tolbutamida [INN-Spanish]; Butamidum; MLS000028399; Berlin Chemie Brand of Tolbutamide; 3-[p-Tolyl-4-sulfonyl]-1-butylurea; BRD-K85119730-001-06-5; Arkozal; NCIOpen2_009592; Yamanouchi Brand of Tolbutamide; Willbutamide; NINDS_000341; Butamid; Toluina; Aglicid; CID5505; CBiol_001920; Diasulfon; SAM002554936; 1-Butyl-3-tosylurea; KBio3_000453; AC1L1KHP; Oralin; N-4-(Methylbenzolsulfonyl)-n-butylurea; Pfizer Brand of Tolbutamide; Restinon; BSPBio_001507; 1-Butyl-3-(p-methylphenylsulfonyl)urea; NSC 23813; 1-Butyl-3-(p-tolylsulfonyl)urea; D 860; Prestwick_471; Diabesan; KBioSS_002276; 46968_FLUKA; Tolbutamide Pfizer Brand; HMS1989L09; Spectrum5_001272; NCGC00022721-06; R.A.N. Brand of Tolbutamide; KBio2_005363; KBio2_003495; KBioSS_000927; KBioGR_000227; MLS002152944; Tolbutamide Butamide Brand; Diaval; IDI1_000341; KBioGR_002275; Prestwick1_000190; BSPBio_000119; Butamide; Orinase (TN); Tolbet; WLN: 4MVMSWR D1; HLS 831; Apo-Tolbutamide; SPBio_001000; Spectrum4_000358; DB01124; Sk-tolbutamide; KBio1_000341; Arcosal; N-(p-tolylsulfonyl)-N'-n-butylurea; AC-12490; ZINC01530703; HMS2089C17; Beglucin; AB1004876; NCI-C01763; Tolbutamide Hoechst Brand; BIM-0051121.0001; Tolumid; BSPBio_002078; NCGC00022721-10; KBio2_000927; AC1Q2X3T; Orabet; Artozin; Spectrum2_001210; D00380; Diaben; Hoechst Brand of Tolbutamide; HMS1361L09; SPECTRUM1500581; C12H18N2O3S; IDI1_033977; N-Butyl-N'-(4-methylphenylsulfonyl)urea; NCGC00022721-07; T0891_FLUKA; Prestwick3_000190; Rastinon; 1-p-Toluenesulfonyl-3-butylurea; Diabetamid; Butamide Brand of Tolbutamide; Bio2_000227; 64-77-7; N-Butyl-N'-p-toluenesulfonylurea; Spectrum3_000599; N-(p-Tolylsulfonyl)-N'-butylcarbamide; Bio1_000695; Tolbutamide [INN:BAN:JAN]; C07148; Bio2_000707; Tol-Tab; KBio3_001578; Tolbutone; Orinase; Diabetol; CHEMBL782; Tolbusal; 1-Butyl-3-(para-tolylsulfonyl) urea; EU-0101154; T0891_SIGMA; Orezan; Bio1_001184; Aventis Brand of Tolbutamide; NCGC00015999-03; UNII-982XCM1FOI; DivK1c_000341; NCGC00022721-03; Ipoglicone; N-n-Butyl-N'-tosylurea; KBioSS_000227; 46968_RIEDEL; 3-(p-tolylsulfonyl)-1-butylurea; Tolbutamide (JP15/USP/INN); HMS1568F21; Dirastan; KBio2_002275; Tolbutamid; EINECS 200-594-3; SMR000058363; Oterben; BIDD:PXR0179; HMS2092M21; MolPort-001-783-540; Artosin	64-77-7	5505	149066	TTDS00332	SUR2-type K(ATP) channel	Kir6.2/SUR2	N/A	N/A	N/A	blocker
DCL000512	Dalbavancin	D03640; Zeven; Zeven (TN); Dalbavancin (USAN/INN)	91097-81-3	122186	47205876	TTDC00295	Triacylglycerol lipase, pancreatic	Pancreatic lipase;PL	P16233	5406	ENSG00000175535	inhibitor
DCL001077	PF-477736	N/A	N/A	N/A	N/A	TTDC00005	Serine/threonine-protein kinase Chk1	Chk1	O14757	1111	ENSG00000149554	inhibitor
DCL001064	7-hydroxystaurosporine	(5s,6r,7r,9r,16r)-16-hydroxy-6-methoxy-5-methyl-7-(methylamino)-6,7,8,9,15,16-hexahydro-5h,14h-5,9-epoxy-4b,9a,15-triazadibenzo[b,h]cyclonona[1,2,3,4-jkl]cyclopenta[e]-as-indacen-14-one; KW-2401; UCN; AR-1A6540; 8,12-Epoxy-1H,8H-2,7b,12a-triazadibenzo(a,g)cyclonona(cde)triinden-1-one, 2,3,9,10,11,12-hexahydro-3-hydroxy-9-methoxy-8-methyl-10-(methylamino)-; KRX-0601; AC1Q6PB4; Ucn 01; NSC-638850; CPD-11911; LS-64044; 1okz; 98290-92-7; 9,13-Epoxy-1H,9H-diindolo(1,2,3-gh:3',2',1'-lm)pyrrolo(3,4-j)(1,7)benzodiazonin-1-one,2,3,10,11,12,13-hexahydro-3-hydroxy-10-methoxy-9-methyl-11-(methylamino)-, (3-alpha,9-beta,10-alpha,11-alpha,13-beta)-(+)-; C28H26N4O4; NSC 638850; UCN01; NSC638850; 7-hydroxystaurosporine (UCN-01); CHEBI:46153; NCI60_012974; 9,13-Epoxy-1H,9H-diindolo(1,2,3-gh:3',2',1'-lm)pyrrolo(3,4-j)(1,7)benzodiazonin-1-one, 2,3,10,11,12,13-hexahydro-3-hydroxy-10-methoxy-9-methyl-11-(methylamino)-, (3-alpha,9-beta,10-alpha,11-alpha,13-beta)-(+)-; CHEMBL1236539; UCN-02; KST-1A9223; UCN-01; 7-Hydroxystaurosporine; 112953-11-4; 9,13-Epoxy-1H,9H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one, 2,3,10,11,12,13-hexahydro-3-hydroxy-10-methoxy-9-methyl-11-(methylamino)-, (3R,9S,10R,11R,13R)-	N/A	72271	49965093	TTDC00005	Serine/threonine-protein kinase Chk1	Chk1	O14757	1111	ENSG00000149554	inhibitor
DCL000017	XL844	N/A	N/A	N/A	N/A	TTDC00005	Serine/threonine-protein kinase Chk1	Chk1	O14757	1111	ENSG00000149554	inhibitor
DCL000016	UCN-01	(5s,6r,7r,9r,16r)-16-hydroxy-6-methoxy-5-methyl-7-(methylamino)-6,7,8,9,15,16-hexahydro-5h,14h-5,9-epoxy-4b,9a,15-triazadibenzo[b,h]cyclonona[1,2,3,4-jkl]cyclopenta[e]-as-indacen-14-one; KW-2401; UCN; AR-1A6540; 8,12-Epoxy-1H,8H-2,7b,12a-triazadibenzo(a,g)cyclonona(cde)triinden-1-one, 2,3,9,10,11,12-hexahydro-3-hydroxy-9-methoxy-8-methyl-10-(methylamino)-; KRX-0601; AC1Q6PB4; Ucn 01; NSC-638850; CPD-11911; LS-64044; 1okz; 98290-92-7; 9,13-Epoxy-1H,9H-diindolo(1,2,3-gh:3',2',1'-lm)pyrrolo(3,4-j)(1,7)benzodiazonin-1-one,2,3,10,11,12,13-hexahydro-3-hydroxy-10-methoxy-9-methyl-11-(methylamino)-, (3-alpha,9-beta,10-alpha,11-alpha,13-beta)-(+)-; C28H26N4O4; NSC 638850; UCN01; NSC638850; 7-hydroxystaurosporine (UCN-01); CHEBI:46153; NCI60_012974; 9,13-Epoxy-1H,9H-diindolo(1,2,3-gh:3',2',1'-lm)pyrrolo(3,4-j)(1,7)benzodiazonin-1-one, 2,3,10,11,12,13-hexahydro-3-hydroxy-10-methoxy-9-methyl-11-(methylamino)-, (3-alpha,9-beta,10-alpha,11-alpha,13-beta)-(+)-; CHEMBL1236539; UCN-02; KST-1A9223; UCN-01; 7-Hydroxystaurosporine; 112953-11-4; 9,13-Epoxy-1H,9H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one, 2,3,10,11,12,13-hexahydro-3-hydroxy-10-methoxy-9-methyl-11-(methylamino)-, (3R,9S,10R,11R,13R)-	N/A	72271	46517284	TTDC00005	Serine/threonine-protein kinase Chk1	Chk1	O14757	1111	ENSG00000149554	inhibitor
DCL000480	AZD7762	N/A	175481-36-4	219078	46531903	TTDC00005	Serine/threonine-protein kinase Chk1	Chk1	O14757	1111	ENSG00000149554	inhibitor
DAP000915	Quinidine barbiturate	N/A	56-54-2	441074	46504552	TTDS00278	Bile salt export pump	ATP-binding cassette, sub-family B, member 11	O95342	8647	ENSG00000073734	inhibitor
DAP000916	Probucol	C07373; Bisbid; Probucol (JAN/USP/INN); Spectrum3_001438; BSPBio_003176; Spectrum2_001400; AC1L1J88; KBioSS_002399; Acetone bis(3,5-di-tert-butyl-4-hydroxyphenyl) mercaptole; SPBio_002488; AKOS001740866; Hoechst Brand of Probucol; NCGC00094895-03; Probucol [USAN:BAN:INN:JAN]; ST075698; Lesterol; LORELCO (TN); LS-13188; CAS-23288-49-5; DH 581; NINDS_000599; BRN 2026253; Phenol, 4,4'-[(1-methylethylidene)bis(thio)]bis[2,6-bis(1,1-dimethylethyl)-; Aventis Brand of Probucol; UNII-P3CTH044XJ; IDI1_000599; probucol; 2,6-ditert-butyl-4-[2-(3,5-ditert-butyl-4-hydroxyphenyl)sulfanylpropan-2-ylsulfanyl]phenol; NSC652160; CHEBI:122641; Probucolum [INN-Latin]; KBioGR_002394; SPBio_001420; HMS2092D05; KBio2_004962; Lursell; NSC 652160; SPECTRUM1501109; Prestwick1_000384; BPBio1_000625; Prestwick2_000384; 4,4'-(Isopropylidenedithio)bis(2,6-di-tert-butylphenol); P9672_SIGMA; cMAP_000039; D011341; Phenol, 4,4'-((1-methylethylidene)bis(thio))bis(2,6-bis(1,1-dimethylethyl))-; Prestwick0_000384; HMS1569M09; KBio1_000599; Biphenabid; Probucolum; ZERO/001429; P9672_FLUKA; Panavir; 4,4'-[(1-Methylethylidene)bis(thio)]bis-[2,6-bis(1,1-dimethylethyl)phenol]; DivK1c_000599; 4,4'- (Isopropylidenedithio)bis(2, 6-di-tert-butylphenol); 4,4'-(Isopropylidenedithio)bis[2, 6-di-tert-butylphenol]; NCGC00094895-02; KBio2_001776; 4,4'-(Isopropylidenedithio)bis(2, 6-di-tert-butylphenol); KBioSS_001776; D00476; DB01599; Superlipid; MolPort-002-042-265; KBio3_002873; KBioGR_000708; DH581; Acetone, bis(3,5-di-tert-butyl-4-hydroxyphenyl) mercaptole; Lurselle; CCRIS 7510; Acetone, bis (3,5-di-tert-butyl-4-hydroxyphenyl) mercaptole; KBio2_007530; C31H48O2S2; Lorelco; KBio2_006912; Phenol, 4,4'-((1-methylethylidene)bis(thio))bis(2,6-bis(1,1-dimethylethyl)-; AB00052202; Spectrum4_000414; STK762566; NCGC00094895-04; Spectrum5_001343; Almirall Brand of Probucol; DE-3872; NCGC00094895-01; CHEMBL608; BSPBio_000567; NCGC00016777-01; KBio3_002396; Prestwick3_000384; Bisphenabid; KBio2_004344; 4,4'-(propane-2,2-diyldisulfanediyl)bis(2,6-di-tert-butylphenol); Prestwick_408; CID4912; ZINC01530755; KBio2_002394; 4,4'-(Isopropylidenedithio)bis[2,6-di-tert-butylphenol]; HMS1921D21; NSC86225; MLS000028492; Sinlestal; NSC 86225; EINECS 245-560-9; HMS501N21; Spectrum_001296; SMR000058265; 23288-49-5; DH-581	23288-49-5	4912	10321432	TTDS00278	Bile salt export pump	ATP-binding cassette, sub-family B, member 11	O95342	8647	ENSG00000073734	inhibitor
DAP001521	SM-101	N/A	N/A	445629	48169378	TTDS00515	Low affinity immunoglobulin gamma Fc region receptor II-A	CD32;CDw32;Fc-gamma RII-a;FcgammaRIIa;Fc-gamma-RIIa;FcRII-a;IgG Fc receptor II-a	P12318	2212	ENSG00000143226	antagonist
DAP000743	Acitretin	55079-83-9; Soriatane, Acitretin; Acitretin; CHEBI:50173; U0279; MLS001076667; EINECS 259-474-4; 9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid; 54757-46-9; Acitretinum [Latin]; MolPort-003-925-892; CCRIS 5534; SAM002589973; Isoacitretin; 9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid; AC1Q5T6I; CPD000499573; Bio-0002; Acitretina; SBB064171; CID5284513; Ro 10-1670/000; Retinoid etretin; Neotigason; 2,4,6,8-Nonatetraenoic acid, 3,7-dimethyl-9-(4-methoxy-2,3,6-trimethylphenyl)-, (all-E)-; FT-0082892; Etretin; Spectrum5_002065; 2,4,6,8-Nonatetraenoic acid, 9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-; S1368_Selleck; all-trans-Acitretin; Acitretin [USAN:INN:BAN]; AC1NR4LJ; Ro 10-1670; Ro-10-1670; LS-96920; 44707_FLUKA; NCGC00163127-02; (2E,4E,6E,8E)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid; Acitretine [French]; AC-4702; Isoetretin; Soriatane; 2,4,6,8-Nonatetraenoic acid, 9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-, (all-E)-; HSDB 7187; Ro 13-7652; (2E,4E,6E,8E)-3,7-dimethyl-9-[2,3,6-trimethyl-4-(methyloxy)phenyl]nona-2,4,6,8-tetraenoic acid; Ro-10-1670/000; CHEMBL1131; Acitretina [Spanish]; Ro-13-7652; NCGC00163127-01; 44707_SIGMA; TMMP; BIDD:GT0617; D02754; Acitretin (USAN/INN); all-trans-3,7-Dimethyl-9-(4-methoxy-2,3,6-trimethylphenyl)-2,4,6,8-nonatetraenoic acid; UNII-LCH760E9T7; 13-cis-Acitretin; Acitretine; SMR000499573; Soriatane (TN); (all-E)-9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid; Acitretinum	55079-83-9	6437841	691722	TTDS00275	Signal transducer and activator of transcription 3	Stat3;Transcription factor STAT3	P40763	6774	ENSG00000168610	inhibitor
DCL000707	Atiprimod	123018-47-3; SKF-106615; 130065-61-1 (2HCl); SKF 106615; AC1L2WDB; UNII-MG7D3QD743; N,N-Diethyl-8,8-dipropyl-2-azaspiro(4.5)decane-2-propanamine; CHEMBL103735; CID129869; Atiprimod; 3-(8,8-dipropyl-3-azaspiro[4.5]decan-3-yl)-N,N-diethylpropan-1-amine; Atiprimod [INN]; 2-Azaspiro(4.5)decane-2-propanamine, N,N-diethyl-8,8-dipropyl-	123018-47-3	129869	706395	TTDS00275	Signal transducer and activator of transcription 3	Stat3;Transcription factor STAT3	P40763	6774	ENSG00000168610	inhibitor
DCL000217	RTA 402	N/A	N/A	N/A	N/A	TTDS00275	Signal transducer and activator of transcription 3	Stat3;Transcription factor STAT3	P40763	6774	ENSG00000168610	inhibitor
DAP000023	Goserelin	HS-2015; AC1NSK1T; HMS2089D16; ICI-118630; goserelin; ZD-9393; CID5311128; (2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[(carbamoylamino)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide; MolPort-006-823-831	65807-02-5	47725	186963	TTDS00244	Leutinizing-hormone-releasing hormone	N/A	N/A	N/A	N/A	activator
DAP000020	Leuprolide	5-oxoprolylhistidyltryptophylseryltyrosylleucylleucyl-n5-(diaminomethylidene)ornithyl-n-ethylprolinamide; L001094; CID3911; N-[1-[[1-[[1-[[1-[[1-[[1-[[5-(diaminomethylideneamino)-1-[2-(ethylcarbamoyl)pyrrolidin-1-yl]-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide; Enantone (TN); I04-0109; AC1L1GZK; D08113; C07612; leuprolide; NSC377526; AC1Q5OPO; L002030; AR-1G9354; Enantone; Leuprorelin (INN)	53714-56-0	3911	9814	TTDS00244	Leutinizing-hormone-releasing hormone	N/A	N/A	N/A	N/A	activator
DCL000418	Albiglutide	N/A	782500-75-8	N/A	85154136	TTDC00205	Glucagon-like peptide 1	GLP;GLP-1;Glucagon-like peptide-1(7-36)-amide	P41521	N/A	N/A	activator
DCL000444	AVE0010	N/A	N/A	4273754	49689354	TTDC00205	Glucagon-like peptide 1	GLP;GLP-1;Glucagon-like peptide-1(7-36)-amide	P41521	N/A	N/A	activator
DPR000031	CL-314698	N/A	138908-34-6	N/A	N/A	TTDC00184	Beta-3 adrenergic receptor	Beta-3 adrenoceptor;Beta-3 adrenoreceptor;Beta3AR;Beta3-AR	P13945	155	ENSG00000188778	agonist
DPR000066	L-751250	N/A	N/A	448991	49742670	TTDC00184	Beta-3 adrenergic receptor	Beta-3 adrenoceptor;Beta-3 adrenoreceptor;Beta3AR;Beta3-AR	P13945	155	ENSG00000188778	agonist
DCL000721	Beta3-adrenoceptor agonist	N/A	N/A	6439232	43032176	TTDC00184	Beta-3 adrenergic receptor	Beta-3 adrenoceptor;Beta-3 adrenoreceptor;Beta3AR;Beta3-AR	P13945	155	ENSG00000188778	agonist
DCL000695	Amibegron	CID 3035442; LS-187094; D08850; UNII-PDQ3ME68U3; 121524-08-1; amibegron; SR 58611; ethyl 2-[[(7S)-7-[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]-5,6,7,8-tetrahydronaphthalen-2-yl]oxy]acetate; AC1MHZDD; CID3035442; Amibegron (USAN/INN)	121524-08-1	121888	698388	TTDC00184	Beta-3 adrenergic receptor	Beta-3 adrenoceptor;Beta-3 adrenoreceptor;Beta3AR;Beta3-AR	P13945	155	ENSG00000188778	agonist
DPR000049	GCR-1087	N/A	N/A	N/A	N/A	TTDC00184	Beta-3 adrenergic receptor	Beta-3 adrenoceptor;Beta-3 adrenoreceptor;Beta3AR;Beta3-AR	P13945	155	ENSG00000188778	agonist
DPR000032	CP-114271	N/A	N/A	N/A	N/A	TTDC00184	Beta-3 adrenergic receptor	Beta-3 adrenoceptor;Beta-3 adrenoreceptor;Beta3AR;Beta3-AR	P13945	155	ENSG00000188778	agonist
DPR000069	LY-362884	N/A	N/A	N/A	N/A	TTDC00184	Beta-3 adrenergic receptor	Beta-3 adrenoceptor;Beta-3 adrenoreceptor;Beta3AR;Beta3-AR	P13945	155	ENSG00000188778	agonist
DPR000065	L-742791	N/A	N/A	4367562	46505031	TTDC00184	Beta-3 adrenergic receptor	Beta-3 adrenoceptor;Beta-3 adrenoreceptor;Beta3AR;Beta3-AR	P13945	155	ENSG00000188778	agonist
DCL000890	N-5984	N/A	N/A	N/A	N/A	TTDC00184	Beta-3 adrenergic receptor	Beta-3 adrenoceptor;Beta-3 adrenoreceptor;Beta3AR;Beta3-AR	P13945	155	ENSG00000188778	agonist
DPR000018	AZ-40140	N/A	N/A	N/A	N/A	TTDC00184	Beta-3 adrenergic receptor	Beta-3 adrenoceptor;Beta-3 adrenoreceptor;Beta3AR;Beta3-AR	P13945	155	ENSG00000188778	agonist
DCL000831	GW-427353	N/A	451470-34-1	9887812	47207540	TTDC00184	Beta-3 adrenergic receptor	Beta-3 adrenoceptor;Beta-3 adrenoreceptor;Beta3AR;Beta3-AR	P13945	155	ENSG00000188778	agonist
DCL000626	Rilotumumab	N/A	N/A	N/A	N/A	TTDC00194	Hepatocyte growth factor	Hepatopoeitin A;HGF;Scatter factor;SF	P14210	3082	ENSG00000019991	antibody
DCL000511	Dacetuzumab	N/A	N/A	9953592	49681647	TTDC00188	Tumor necrosis factor receptor superfamily member 5	B-cell surface antigen CD40;Bp50;CD40;CD40L receptor;CDw40	P25942	958	ENSG00000101017	antibody
DCL001195	IMO-2125	N/A	N/A	N/A	N/A	TTDC00107	Toll-like receptor 9	TLR-9	Q9NR96	54106	ENSG00000239732	agonist
DCL000249	TLR9 agonist	N/A	375815-87-5	444305	49740556	TTDC00107	Toll-like receptor 9	TLR-9	Q9NR96	54106	ENSG00000239732	agonist
DPR000176	IMO-2134	N/A	N/A	N/A	N/A	TTDC00107	Toll-like receptor 9	TLR-9	Q9NR96	54106	ENSG00000239732	agonist
DCL000446	AVE0675	N/A	N/A	N/A	N/A	TTDC00107	Toll-like receptor 9	TLR-9	Q9NR96	54106	ENSG00000239732	agonist
DCL001196	IMO-3100	N/A	N/A	N/A	N/A	TTDC00107	Toll-like receptor 9	TLR-9	Q9NR96	54106	ENSG00000239732	antagonist
DCL001194	IMO-2055	N/A	N/A	N/A	N/A	TTDC00107	Toll-like receptor 9	TLR-9	Q9NR96	54106	ENSG00000239732	agonist
DCL000020	CPG 52364	N/A	453562-69-1	11667893	47214228	TTDC00107	Toll-like receptor 9	TLR-9	Q9NR96	54106	ENSG00000239732	antagonist
DCL000417	Agatolimod	N/A	N/A	213043	49710126	TTDC00107	Toll-like receptor 9	TLR-9	Q9NR96	54106	ENSG00000239732	agonist
DAP000943	Arformoterol	formoterol; CHEMBL1363; Foradil; 289657-27-8; AC1MJ0T4; Formamide, N-(2-hydroxy-5-((1R)-1-hydroxy-2-(((1R)-2-(4-methoxyphenyl)-1-methylethyl)amino)ethyl)phenyl)-; (R,R)-Formoterol; CHEBI:408174; DB01274; (-)-Formoterol; 299964-45-7; Arformoterol (INN); MolPort-005-942-483; N-{2-hydroxy-5-[(1R)-1-hydroxy-2-({(1R)-1-methyl-2-[4-(methyloxy)phenyl]ethyl}amino)ethyl]phenyl}formamide; CID3083544; N-{2-hydroxy-5-[(1R)-1-hydroxy-2-{[(2R)-1-(4-methoxyphenyl)propan-2-yl]amino}ethyl]phenyl}formamide; 208102-40-3; D07463; 67346-49-0; Formamide, N-(2-hydroxy-5-(1-hydroxy-2-((2-(4-methoxyphenyl)-1-methylethyl)amino)ethyl)phenyl)-, (R-(R*,R*))-; UNII-F91H02EBWT; MolPort-003-847-486; N-[2-hydroxy-5-[(1R)-1-hydroxy-2-[[(2R)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]phenyl]formamide; Arformoterol; 73573-87-2	67346-49-0	3083544	3884858	TTDS00037	Beta-2 adrenergic receptor	Beta-2 adrenoceptor;Beta-2 adrenoreceptor	P07550	154	ENSG00000169252	agonist
DCL000846	Indacaterol	QAB-149; CID6918554; Indacaterol (USAN/INN); 5-(2-(5,6-Diethylindan-2-ylamino)-1-hydroxyethyl)-8-hydroxy-1H-quinolin-2-one; 312753-06-3; UNII-8OR09251MQ; CHEBI:725589; Indacaterol; D09318; CHEMBL1095777; 5-[(1R)-2-[(5,6-diethyl-2,3-dihydro-1H-inden-2-yl)amino]-1-hydroxyethyl]-8-hydroxy-1H-quinolin-2-one; AC1OCFKW	312753-06-3	6918554	12015479	TTDS00037	Beta-2 adrenergic receptor	Beta-2 adrenoceptor;Beta-2 adrenoreceptor	P07550	154	ENSG00000169252	agonist
DCL000983	Sibenadet	N/A	154189-24-9	443590	36886849	TTDS00037	Beta-2 adrenergic receptor	Beta-2 adrenoceptor;Beta-2 adrenoreceptor	P07550	154	ENSG00000169252	agonist
DAP000945	Clenbuterol	Clenbuterol (INN); KBio2_007180; 4-Amino-3,5-dichloro-alpha-(((1,1-dimethylethyl)amino)methyl)benzenemethanol; AB00053680; NCGC00163150-02; nchembio.307-comp6; SPBio_002330; 37148-27-9; KBioGR_001518; IDI1_000794; D07713; Spectrum4_001099; NCGC00163150-01; (+)-4-Amino-alpha-((tert-butylamino)methyl)-3,5-dichlorobenzyl alcohol; Planipart; 4-Amino-alpha-((tert-butylamino)methyl)-3,5-dichlorobenzyl alcohol; Clenbuterol [BAN:INN]; clenbuterol; Prestwick1_000345; Planipart [veterinary] (TN); CHEMBL49080; CID2783; AC1L1EGH; LS-30602; BRN 1076467; NCGC00163150-04; Clenbuterolum; MolPort-003-845-975; HMS2089I15; DB01407; NCGC00163150-03; UNII-XTZ6AXU7KN; Benzyl alcohol, 4-amino-alpha-((tert-butylamino)methyl)-3,5-dichloro-; (+-)-clenbuterol; KBioSS_002044; KBio3_001829; Benzenemethanol, 4-amino-3,5-dichloro-.alpha.-[[(1,1-dimethylethyl)amino]methyl]-; 1-(4-amino-3,5-dichlorophenyl)-2-[(1,1-dimethylethyl)amino]ethanol; KBio2_002044; BENZENEMETHANOL, 4-AMINO-3,5-DICHLORO-alpha-(((1,1-DIMETHYLETHYL)AMINO)METHYL)-; BPBio1_000451; KBio2_004612; Spectrum4_000743; Spectrum5_001497; NAB-365; 50306-03-1; BSPBio_002609; BSPBio_000409; Prestwick2_000345; (-)-4-Amino-alpha-((tert-butylamino)methyl)-3,5-dichlorobenzyl alcohol; 1-(4-Amino-3,5-dichloro-phenyl)-2-tert-butylamino-ethanol; C12H18Cl2N2O; KBio1_000794; AC-10284; Prestwick3_000345; 50499-60-0; BRD-A75726477-003-04-9; 1-(4-Amino-3,5-dichlorophenyl)-2-(tert-butylamino)ethanol; EINECS 253-366-0; NINDS_000794; DivK1c_000794; Prestwick0_000345; Contraspasmin (TN); Planipart [veterinary]; EINECS 256-608-3; Spectrum_001564; Spectrum3_000975; Clenbuterolum [INN-Latin]; CHEBI:174690; KBioGR_001066; EINECS 256-531-5; Contraspasmin	37148-27-9	2783	10366793	TTDS00037	Beta-2 adrenergic receptor	Beta-2 adrenoceptor;Beta-2 adrenoreceptor	P07550	154	ENSG00000169252	agonist
DCL001010	TA-2005	CID63951; CHF-4226; 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(2R)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]-1H-quinolin-2-one hydrochloride; 8-Hydroxy-5-(1-hydroxy-2-(N-(2-(4-methoxyphenyl)-1-methylethyl)amino)ethyl)carbostyril hydrochloride; AC1L204L; AC1Q3ER2; 100429-08-1; 8-Hydroxy-5-((1R)-1-hydroxy-2-(N-(1R)-2-(p-methoxyphenyl)isopropylamino)ethyl)carbostyril HCl; 8-hydroxy-5-[(1r)-1-hydroxy-2-{[(2r)-1-(4-methoxyphenyl)propan-2-yl]amino}ethyl]quinolin-2(1h)-one hydrochloride(1:1); Carmoterol hydrochloride; 2(1H)-Quinolinone, 8-hydroxy-5-(1-hydroxy-2-((2-(4-methoxyphenyl)-1-methylethyl)amino)ethyl)-, hydrochloride, (R-(R*,R*))-; LS-142795; 2(1H)-Quinolinone, 8-hydroxy-5-(1-hydroxy-2-((2-(4-methoxyphenyl)-1-methylethyl)amino)ethyl)-, monohydrochloride, (R-(R*,R*))-; CHF 4226.01; 137888-11-0; TA-2005	N/A	63952	49684190	TTDS00037	Beta-2 adrenergic receptor	Beta-2 adrenoceptor;Beta-2 adrenoreceptor	P07550	154	ENSG00000169252	agonist
DAP000248	Salbutamol	m-Xylene-alpha,alpha'-diol, alpha-((tert-butylamino)methyl)-4-hydroxy-; dl-Salbutamol; L000531; Salbuven; CHEBI:2549; alpha(sup 1)-((tert-Butylamino)methyl)-4-hydroxy-m-xylene-alpha,alpha'-diol; Albuterol (USP); (alpha1-((tert-butylamino)methyl)-4-hydroxy-m-xylene-alpha,alpha-diol); Salbutamolum [INN-Latin]; AH 3365; MLS000758199; Ventolin Rotacaps; albuterol; Alti-Salbutamol; Albuterol [USAN]; Salbulin; Ventamol; Salbetol; Prestwick_665; R,S-Albuterol; nchembio801-comp4; KBio1_000943; PDSP1_000623; UNII-QF8SVZ843E; Respolin; 4-[2-(tert-Butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol; Salmaplon; DL-N-tert-Butyl-2-(4-hydroxy-3-hydroxymethylphenyl)-2-hydroxyethylamine; Butotal; NCGC00015955-10; Ventoline; KBio2_005816; Salbutamol; to_000081; Salbron; AC1Q1MO0; Proventil HFA; Rotahaler; Salbutan; Novosalmol; Gerivent; NCGC00024698-04; Ecovent; Salamol; Mozal; LS-7693; BRD-A88254928-001-04-6; Prestwick3_000198; Volma; Buto-Asma; Asmaven; Salbusian; Salbutine; AB00052154; HMS2089I19; SBB066105; Vencronyl; Asthalin; Grafalin; SGCUT00011; alpha-[(t-Butylamino)methyl]-4-hydroxy-m-xylene-alpha,alpha -diol; DivK1c_000943; racemic-Salbutamol; PDSP2_000620; KBio2_003248; Spectrum2_001350; IDI1_000943; Parasma; Albuterol hemisulfate; Salbutamol Sulphate; Prestwick1_000198; HSDB 7206; Salvent; Salbutamolum; Albuterol Sulphate; (+-)-Albuterol; Sultanol N; Salbutamol sulfate; Prestwick0_000198; HMS2092I08; Pneumolat; Dilatamol; Sabutal; NCGC00024698-06; NINDS_000943; Lopac0_001098; NCGC00024698-02; Proventil Inhaler; BSPBio_000155; Bio1_000935; Ventalin inhaler; 1-(tert-Butylaminomethyl)-4-hydroxy-m-xylene-alpha1,alpha3-diol; DB01001; Salbutalan; NCGC00024698-05; Servitamol; Aerolin; HMS1568H17; Cobutolin; Bio1_000446; KBio2_000680; Asmasal; Prestwick2_000198; HMS1921C04; Saventol; NCGC00015955-04; Salomol; BCBcMAP01_000116; Farcolin; SMP1_000268; Libretin; Proventil; Anebron; SPBio_002076; 4-Hydroxy-3-hydroxymethyl-alpha-((tert-butylamino)methyl)benzyl alcohol; alpha'-((tert-Butylamino)methyl)-4-hydroxy-m-xylene-alpha,alpha'-diol; Volmax; BRN 2213614; Arubendol-Salbutamol; Cetsim; SPECTRUM1500677; m-Xylene-alpha,alpha'-diol, alpha'-((tert-butylamino)methyl)-4-hydroxy-; Salbuhexal; Buventol; Salbu-BASF; CHEMBL714; Almotex; 1,3-Benzenedimethanol, alpha1-(((1,1-dimethylethyl)amino)methyl)-4-hydroxy-; Sabutamol; Asmatol; Ventilan; Bio1_001424; Ventiloboi; SMR000058513; 46725_FLUKA; 2-t-Butylamino-1-(4-hydroxy-3-hydroxy-3-hydroxymethyl)phenylethanol; Asthavent; Tobybron; Salbu-Fatol; Asmadil; CID2083; S8260_SIGMA; Bronter; S 8260; 46725_RIEDEL; Spreor; 2-(tert-Butylamino)-1-(4-hydroxy-3-hydroxymethylphenyl)ethanol; NCGC00024698-07; Volare albuterol HFA; Bugonol; 4-{2-[(1,1-dimethylethyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol; Respax; Salbutol; Asmol Uni-Dose; ST024764; LS-29861; Sultanol; dl-Albuterol; I06-0331; ProAir; Salbupur; Airomir; Ventolin Inhaler; KBioGR_001294; KBioSS_000680; Spectrum5_001059; Spectrum_000200; Suxar; AC-10286; alpha-[(tert-Butylamino)methyl]-4-hydroxy-m-xylene-alpha,alpha'-diol; Butohaler; Asmanil; Proventil (TN); Asmidon; Lopac0_001090; D02147; HMS502P05; BPBio1_000171; Broncho-Spray; Bumol; EU-0101090; NCGC00015955-11; Butovent; 1,3-Benzenedimethanol, .alpha.1-[[(1,1-dimethylethyl)amino]methyl]-4-hydroxy-; Volare easi-breathe; 35763-26-9; Spectrum4_000887; 1,3-Benzenedimethanol, .alpha.(1)-[[(1,1-dimethylethyl)amino]methyl]-4-hydroxy-; Asmol; Zaperin; NCGC00024698-03; Theosal; Solbutamol; EINECS 242-424-0; MolPort-001-838-925; AC1L1CVO; Medolin; Ventodisks; 18559-94-9; (+-)-Salbutamol; SPBio_001539; Salbutard; Broncovaleas; Salbuvent; Butamol; Sallbupp; VU0243312-5; Suprasma	18559-94-9	2083	171517	TTDS00037	Beta-2 adrenergic receptor	Beta-2 adrenoceptor;Beta-2 adrenoreceptor	P07550	154	ENSG00000169252	agonist
DAP000247	Formoterol	49861-99-6; AC1Q6QRX; 67346-49-0; (+-)-2'-Hydroxy-5'-((RS)-1-hydroxy-2-(((RS)-p-methoxy-alpha-methylphenethyl)amino)ethyl)formanilide; Formoterolum [INN-Latin]; CID449974; Formoterolum; formoterol, ((R*,R*)-(+-))-isomer; HSDB 7287; Formamide, N-(2-hydroxy-5-(1-hydroxy-2-((2-(4-methoxyphenyl)-1-methylethyl)amino)ethyl)phenyl)-, (R-(R*,R*))-; CID3410; AC1MHY5S; UNII-F91H02EBWT; MolPort-003-847-486; formoterol; CHEMBL1363; CID3034756; MolPort-005-934-219; Foradil; eformoterol; Oxis; AC1L1FVE; 183814-29-1; 289657-27-8; NCGC00025167-01; AC1MJ0T4; Formamide, N-(2-hydroxy-5-((1R)-1-hydroxy-2-(((1R)-2-(4-methoxyphenyl)-1-methylethyl)amino)ethyl)phenyl)-; (R,R)-Formoterol; Formoterol tartrate; CHEBI:408174; AR-1K3797; Foradile; UNII-5ZZ84GCW8B; LS-187799; DB01274; 128954-45-0; D07990; FORMOTEROL FUMARATE; N-[2-hydroxy-5-[(1R)-1-hydroxy-2-[[(2R)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]phenyl]formamide; AC1MIIFN; Oxis (TN); AC-459; C07805; CID3045233; LS-187368; (-)-Formoterol; N-[2-hydroxy-5-[(1R)-1-hydroxy-2-[[(2S)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]phenyl]formamide; Arformoterol; LS-69501; Formoterol [USAN:INN:BAN]; 299964-45-7; 126587-85-7; BIDD:GT0743; Arformoterol (INN); Tocris-1448; N-[2-hydroxy-5-[1-hydroxy-2-[1-(4-methoxyphenyl)propan-2-ylamino]ethyl]phenyl]formamide; Oxeze Turbuhaler; Oxeze Turbuhaler Foradil; MOLI000351; 73573-87-2; N-[2-hydroxy-5-[(1S)-1-hydroxy-2-[[(2S)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]phenyl]formamide; NCGC00181126-01; MolPort-005-942-483; N-{2-hydroxy-5-[(1R)-1-hydroxy-2-({(1R)-1-methyl-2-[4-(methyloxy)phenyl]ethyl}amino)ethyl]phenyl}formamide; CID3083544; AC1L9NSS; Formoterol (INN); n-[2-hydroxy-5-(1-hydroxy-2-{[1-(4-methoxyphenyl)propan-2-yl]amino}ethyl)phenyl]formamide; 3-formylamino-4-hydroxy-alpha-(N-1-methyl-2-p-methoxyphenethylaminomethyl)benzyl alcohol.hemifumarate; N-{2-hydroxy-5-[(1R)-1-hydroxy-2-{[(2R)-1-(4-methoxyphenyl)propan-2-yl]amino}ethyl]phenyl}formamide; DB00983; L000259; 208102-40-3; CID9862958; D07463	73573-87-2	3410	10007	TTDS00037	Beta-2 adrenergic receptor	Beta-2 adrenoceptor;Beta-2 adrenoreceptor	P07550	154	ENSG00000169252	agonist
DCL000687	Albuterol sulfate	Broncho Inhalat; 4-[2-(tert-butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol; sulfuric acid; AH-3365; Aerotec; dl-Salbutamol sulfate; Ventolin Rotacaps; ALBUTEROL SULFATE; LS-29862; Amocasin; MolPort-003-933-916; Epaq; Accuvent; TQ-1016; 5-[2-(tert-Butylamino)-1-hydroxyethyl]-2-hydroxybenzyl Alcohol Hemisulfate; Sch 13949W sulfate; Proventil Repetabs, Solution, Syrup, and Tablets; S0531; Albuterol hemisulfate; D00683; Volare; 1,3-Benzenedimethanol, alpha(sup 1)-(((1,1-dimethylethyl)amino)methyl)-4-hydroxy-, sulfate (2:1) (salt); Venetlin; Salbutamol Easyhaler; NCGC00094370-01; S 5013; Emican; Ventolin Nebules; 46732_RIEDEL; 1,3-Benzenedimethanol, alpha1-(((1,1-dimethylethyl)amino)methyl)-4-hydroxy-, sulfate (2:1) (salt) (9CI); Bronchospray; AccuNeb; 1-(4-Hydroxy-3-hydroxymethylphenyl)-2-(tert-butylamino)ethanol sulfate; Buventol Easyhaler; Albuterol sulfate (USP); Pulvinal salbutamol; Proair HFA; 1,3-Benzenedimethanol, alpha(sup 1)-(((1,1-dimethylethyl)amino)methyl)-4-hydroxy-,sulfate (2:1) (salt); Accuneb (TN); UNII-021SEF3731; Salbutamol hemisulfate salt; 46732_FLUKA; Ventolin (TN); 2-(tert-Butylamino)-1-(4-hydroxy-3-hydroxymethylphenyl)ethanol Hemisulfate; Ventolin easy-breathe; Ventolin HFA; Proventil-HFA; C13H21NO3.H2O4S; Aloprol; 1,3-Benzenedimethanol, alpha1-(((1,1-dimethylethyl)amino)methyl)-4-hydroxy-, sulfate (2:1) (salt); 51022-70-9; EU-0101098; LS-162604; Fartolin; Salbutamol hemisulfate; Huma-Salmol; KS-5056; Loftan; S5013_SIGMA; 36519-31-0; Salbutamol sulfate; alpha-([t-Butylamino]methyl)-4-hydroxy-m-xylene-alpha,alpha'-diol; Ventolin; Broncodil; TL8003382; alpha1-[(tert-Butylamino)methyl]-4-hydroxy-1,3-benzenedimethanol hemisulfate salt; Pediavent; Salbutamol sulfate (JP15); Proventil Repetabs; NSC 289928; CID39859; alpha(sup 1)-((tert-Butylamino)methyl)-4-hydroxy-m-xylene-alpha,alpha'-diol sulfate (2:1) (salt); Salbutamol Diskus; Proventil (TN); AC1L22LX; Albuterol sulfate [USAN]; Inspiryl; Dipulmin; Bis((tert-butyl)(beta,3,4-trihydroxyphenethyl)ammonium) sulphate; EINECS 256-916-8; VoSpire ER	51022-70-9	2083	12014160	TTDS00037	Beta-2 adrenergic receptor	Beta-2 adrenoceptor;Beta-2 adrenoreceptor	P07550	154	ENSG00000169252	agonist
DCL000385	GW642444	N/A	N/A	6917655	49658596	TTDS00037	Beta-2 adrenergic receptor	Beta-2 adrenoceptor;Beta-2 adrenoreceptor	P07550	154	ENSG00000169252	agonist
DCL000882	Milveterol+Fluticasone	N/A	90566-53-3	62924	205110	TTDS00037	Beta-2 adrenergic receptor	Beta-2 adrenoceptor;Beta-2 adrenoreceptor	P07550	154	ENSG00000169252	agonist
DCL000822	GSK-159797	CID 11225217; 804518-03-4; D08945; Milveterol hydrochloride; TD-3327; CID11225217; GSK-159797; Milveterol hydrochloride (USAN)	N/A	5468287	49684261	TTDS00037	Beta-2 adrenergic receptor	Beta-2 adrenoceptor;Beta-2 adrenoreceptor	P07550	154	ENSG00000169252	agonist
DCL000740	Carmoterol	N/A	147568-66-9	6433087	10549575	TTDS00037	Beta-2 adrenergic receptor	Beta-2 adrenoceptor;Beta-2 adrenoreceptor	P07550	154	ENSG00000169252	agonist
DCL000563	Milveterol	N/A	N/A	N/A	N/A	TTDS00037	Beta-2 adrenergic receptor	Beta-2 adrenoceptor;Beta-2 adrenoreceptor	P07550	154	ENSG00000169252	agonist
DAP001426	Salmeterol xinafoate	Bio-0096; 94749-08-3; NCGC00094372-02; MLS001332577; UNII-6EW8Q962A5; CHEMBL1082607; Salmeterol xinafoate (JAN/USAN); Inaspir; C25H37NO4.C11H8O3; Betamican; Arial; NCGC00094372-01; NCGC00094372-04; Salmetedur; 89365-50-4 (Parent); AC1L1LPS; D00687; CID56801; 1,3-Benzenedimethanol, 4-hydroxy-alpha(sup 1)-(((6-(4-phenylbutoxy)hexyl)amino)methyl)-, (+-)-, 1-hydroxy-2-naphthalenecarboxylate (salt); salmeterol xinafoate; S5068_SIGMA; GR 33343 G; GR-33343 G; Serevent Inhaler and Disks; Serevent (TN); Dilamax; LS-94516; Salmeterol 1-hydroxy-2-naphthoate; Beglan; EU-0101100; (+/-) 4-Hydroxy-a1-[[[6-(4-phenylbutoxy)hexyl]amino]m-ethyl]-1,3-benzenedimethanol xinafoate; 2-(hydroxymethyl)-4-[1-hydroxy-2-[6-(4-phenylbutoxy)hexylamino]ethyl]phenol; 1-hydroxynaphthalene-2-carboxylic acid; (+-)-4-Hydroxy-alpha(sup 1)-(((6-(4-phenylbutoxy)hexyl)amino)methyl)-m-xylene-alpha,alpha'-diol 1-hydroxy-2-naphthoate (salt); Ultrabeta; MLS001332578; SMR000875207; GR 33343X xinafoate; Salmeterol xinafoate [USAN]; Asmerole; MolPort-003-850-218; Serevent diskus; NCGC00094372-03	94749-08-3	56801	194036	TTDS00037	Beta-2 adrenergic receptor	Beta-2 adrenoceptor;Beta-2 adrenoreceptor	P07550	154	ENSG00000169252	agonist
DAP000246	Terbutaline	Spectrum_001030; Spectrum2_001327; Spectrum5_001262; Terbutalinum; Prestwick3_000391; KWD-2019; Spectrum4_000870; 1,3-Benzenediol, 5-(2-((1,1-dimethylethyl)amino)-1-hydroxyethyl)-; DivK1c_000078; Oprea1_823972; 5-(2-((1,1-DIMETHYLETHYL)AMINO)-1-HYDROXYETHYL)-1,3-BENZENEDIOL; BRN 2370513; Terbutaline (INN); EINECS 245-385-8; BSPBio_000601; KBio2_001510; Prestwick2_000391; 23031-25-6; KBio1_000078; 5-{2-[(1,1-dimethylethyl)amino]-1-hydroxyethyl}benzene-1,3-diol; Terbutalinum [INN-Latin]; Brethaire; Brican; terbutaline; Lopac0_001126; 1,3-Benzenediol, 5-[2-[(1,1-dimethylethyl)amino]-1-hydroxyethyl]-; Bricaril; (+-)-5-(2-((1,1-Dimethylethyl)amino)-1-hydroxyethyl)-1,3-benzenediol; Benzyl alcohol, .alpha.-((t-butylamino)methyl)-3,5-dihydroxy-; SPBio_002522; Prestwick1_000391; SBB063955; DB00871; SPBio_001453; D08570; 46719-29-3; AC1L1KA2; KBioSS_001510; KWD 2019; UNII-N8ONU3L3PG; Asthmasian (TN); 23031-32-5 (Sulfate); Terbutalin; BPBio1_000663; Spectrum3_000593; Terbutaline sulfate; I01-3464; IDI1_000078; PDSP2_000157; CHEMBL1760; NCGC00089821-02; L000594; Prestwick0_000391; KBio2_004078; AB00053548; KBioGR_001539; LS-29961; (+-)-Terbutaline; Benzyl alcohol, alpha-((t-butylamino)methyl)-3,5-dihydroxy-; BSPBio_002066; Brethine; Bricanyl; 1,3-Benzenediol, 5-(2-((1,1-dimethylethyl)amino)-1-hydroxyethyl)-, (+-)-; NCGC00016010-06; Terbutalino [INN-Spanish]; PDSP1_000158; NINDS_000078; Terbutaline [INN:BAN]; KBio3_001566; 1,3-Benzenediol, 5-(2-((1,1-dimethylethyl)amino)-1-hydroxyethyl)- (9CI); BRD-A50157456-065-02-4; KBio2_006646; Bricyn; Asthmasian; Terbutalina; Bricar; Terbutalino; C07129; Terbutalina [DCIT]; MolPort-003-850-418; CID5403; LS-7713; 5-[2-(tert-butylamino)-1-hydroxyethyl]benzene-1,3-diol	23031-25-6	5403	9339	TTDS00037	Beta-2 adrenergic receptor	Beta-2 adrenoceptor;Beta-2 adrenoreceptor	P07550	154	ENSG00000169252	agonist
DAP000250	Bambuterol	terbutaline bis(dimethylcarbamate); SMR001233168; Prestwick0_000361; Bambuterol (INN); 5-[2-(tert-butylamino)-1-hydroxyethyl]benzene-1,3-diyl bis(dimethylcarbamate); Bambuterol [BAN:INN]; (+-)-5-(2-(tert-Butylamino)-1-hydroxyethyl)-m-phenylene bis(dimethylcarbamate); STK643808; NCGC00179546-01; BPBio1_000531; UNII-Y1850G1OVC; CHEMBL521589; MolPort-003-844-685; Bambuterol; KWD-2183; Bambuterolum [Latin]; HMS2089J18; 5-(2-(tert-butylamino)-1-hydroxyethyl)-3-phenylene bis(dimethylcarbamate); BRD-A17462676-003-03-3; CID54766; AC1Q60S0; LS-49501; Prestwick1_000361; SPBio_002402; Prestwick2_000361; BSPBio_000481; 81732-65-2; D07377; Prestwick3_000361; MLS002153785; C18H29N3O5; terbutaline bisdimethylcarbamate; Bambuterolum; DB01408; L004435; Bambec; [3-[2-(tert-butylamino)-1-hydroxyethyl]-5-(dimethylcarbamoyloxy)phenyl] N,N-dimethylcarbamate; Oxeol; CHEBI:553827; AC1L1HP6	81732-46-9	54766	11466389	TTDS00037	Beta-2 adrenergic receptor	Beta-2 adrenoceptor;Beta-2 adrenoreceptor	P07550	154	ENSG00000169252	agonist
DAP000249	Pirbuterol	38677-81-5; 38029-10-6 (di-hydrochloride); Pirbuterolum; Pirbuterol (INN); 65652-44-0 (acetate); LS-66540; CP-24,314-14; C12H20N2O3; 6-[2-(tert-butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)pyridin-3-ol; Pirbuterolum [INN-Latin]; NCI60_003197; Ethanol, 2-tert-butylamino-1-(5-hydroxy-6-hydroxymethyl-2-pyridyl)-; CHEMBL1094966; Pirbuterol [INN:BAN]; CID4845; pirbuterol acetate salt; CP 24315-1; C07807; AC1L1J32; 2-tert-Butylamino-1-(5-hydroxy-6-hydroxymethyl-2-pyridyl)ethanol; DB01291; Maxair; pyrbuterol; UNII-OG645J8RVW; 6-(2-(tert-butylamino)-1-hydroxyethyl)-2-(hydroxymethyl)-3-pyridinol; CP-24,314-1; L013424; 2-hydroxymethyl-3-hydroxy-6-(1-hydroxy-2-tert-butylamino ethyl)pyridine, dihydrochloride; CP-24315-1; PIRBUTEROL; D08387	38677-81-5	4845	10009	TTDS00037	Beta-2 adrenergic receptor	Beta-2 adrenoceptor;Beta-2 adrenoreceptor	P07550	154	ENSG00000169252	agonist
DAP000946	Fenoterol	Fenoterolum; Prestwick1_000282; CHEMBL32800; 1944-10-1; L000255; Lopac0_000544; Benzyl alcohol, 3,5-dihydroxy-alpha-(((p-hydroxy-alpha-methylphenethyl)amino)methyl)-; Berotek; Berotec; BPBio1_000204; AC1L1FPW; BSPBio_000184; SPBio_002403; BRD-A97104540-004-04-4; Spectrum3_000915; DivK1c_000405; KBio2_001726; NINDS_000405; Spectrum4_001014; KBioGR_001507; Fenoterol (USAN/INN); TH 1165; Phenoterol; Fenoterol [USAN:BAN:INN]; LS-42858; Benzyl alcohol, 3,5-dihydroxy-.alpha.-(((p-hydroxy-.alpha.-methylphenethyl)amino)methyl)-; Prestwick3_000282; TH 1165A; KBioSS_001726; 1,3-Benzenediol, 5-(1-hydroxy-2-((2-(4-hydroxyphenyl)-1-methylethyl)amino)ethyl)-; KBio2_006862; DB01288; 13392-18-2; CID3343; 5-(1-hydroxy-2-{[1-(4-hydroxyphenyl)propan-2-yl]amino}ethyl)benzene-1,3-diol; CHEBI:149226; AB00053590; Th-1165a; 5-[1-hydroxy-2-[1-(4-hydroxyphenyl)propan-2-ylamino]ethyl]benzene-1,3-diol; Spectrum2_001388; 1944-12-3 (hydrobromide); Spectrum_001246; fenoterol; MolPort-002-052-088; BRN 2157041; KBio2_004294; 1-(p-Hydroxyphenyl)-2-((beta-hydroxy-beta-(3',5'-dihydroxyphenyl))ethyl)aminopropane; 5-(1-hydroxy-2-{[2-(4-hydroxyphenyl)-1-methylethyl]amino}ethyl)benzene-1,3-diol; SPBio_001376; 1-(3,5-Dihydroxyphenyl)-1-hydroxy-2-((4-hydroxyphenyl)isopropylamino)ethane; KBio1_000405; Prestwick2_000282; AC-13630; NCGC00162181-01; NCGC00015430-03; D04157; IDI1_000405; UNII-22M9P70OQ9; Prestwick0_000282; p-Hydroxyphenyl-orciprenaline; 5-{1-Hydroxy-2-[2-(4-hydroxy-phenyl)-1-methyl-ethylamino]-ethyl}-benzene-1,3-diol; Spectrum5_001572; Fenoterolum [INN-Latin]; KBio3_001890; AC1Q79W3; AR-1L6635; 3,5-Dihydroxy-alpha-(((p-hydroxy-alpha-methylphenethyl)amino)methyl)benzyl alcohol; p-Hydroxyphenylorciprenaline	13392-18-2	3343	10445391	TTDS00037	Beta-2 adrenergic receptor	Beta-2 adrenoceptor;Beta-2 adrenoreceptor	P07550	154	ENSG00000169252	agonist
DCL000501	Budesonide & formoterol fumarate dihydrate	N/A	N/A	N/A	N/A	TTDS00037	Beta-2 adrenergic receptor	Beta-2 adrenoceptor;Beta-2 adrenoreceptor	P07550	154	ENSG00000169252	agonist
DAP000947	Salmeterol	Glaxo Wellcome brand of salmeterol xinafoate; MLS000759000; TL80090037; MLS001424322; BRD-A01320529-001-05-9; 1,3-Benzenedimethanol, 4-hydroxy-alpha(sup 1)-(((6-(4-phenylbutoxy)hexyl)amino)methyl-, (+-)-; Serevent; HSDB 7315; C07241; Prestwick3_000945; 94749-08-3 (xinafoate); CPD000466295; SMR000466295; AB00513972; Salmeterolum; 1,3-Benzenedimethanol, 4-hydroxy-alpha(sup 1)-(((6-(4-phenylbutoxy)hexyl)amino)methyl)-, (+-)-; BPBio1_001002; STK629186; UNII-2I4BC502BT; SALMATEROL; Salmeterol (USAN/INN); GR 33343X; Salmeterol; 89365-50-4; SAM001247096; Salmeterolum [Latin]; NCGC00025247-02; LS-29869; DB00938; S 2692; 2-(hydroxymethyl)-4-[1-hydroxy-2-({6-[(4-phenylbutyl)oxy]hexyl}amino)ethyl]phenol; AC1L1JPX; D05792; Lopac0_001100; L000532; HMS2090E17; HMS2052H13; 2-(hydroxymethyl)-4-[1-hydroxy-2-[6-(4-phenylbutoxy)hexylamino]ethyl]phenol; BSPBio_000910; CHEMBL1263; ( inverted question mark) 4-Hydroxy-a1-[[[6-(4-phenylbutoxy)hexyl]amino]m-ethyl]-1,3-benzenedimethanol; GR 33343X; (+-)-4-Hydroxy-alpha1-(((6-(4-phenylbutoxy)hexyl)amino)methyl)-1,3-benzenedimethanol; 2-(hydroxymethyl)-4-(1-hydroxy-2-{[6-(4-phenylbutoxy)hexyl]amino}ethyl)phenol; Salmeterol [USAN:BAN:INN]; (+-)-4-Hydroxy-alpha'-(((6-(4-phenylbutoxy)hexyl)amino)methyl)-m-xylene-alpha,alpha'-diol; GR-33343X; Aeromax; MolPort-005-933-084; CID5152; C057823; Astmerole; 1,3-Benzenedimethanol, 4-hydroxy-alpha1-(((6-(4-phenylbutoxy)hexyl)amino)methyl)-, (+-)-	89365-50-4	5152	205141	TTDS00037	Beta-2 adrenergic receptor	Beta-2 adrenoceptor;Beta-2 adrenoreceptor	P07550	154	ENSG00000169252	agonist
DAP001424	Salbutamol sulphate	m-Xylene-alpha,alpha'-diol, alpha-((tert-butylamino)methyl)-4-hydroxy-; Salbuven; alpha(sup 1)-((tert-Butylamino)methyl)-4-hydroxy-m-xylene-alpha,alpha'-diol; (alpha1-((tert-butylamino)methyl)-4-hydroxy-m-xylene-alpha,alpha-diol); AH 3365; Ventolin Rotacaps; Albuterol [USAN]; Salbulin; Ventamol; Prestwick_665; R,S-Albuterol; KBio1_000943; UNII-QF8SVZ843E; 4-[2-(tert-Butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol; Salmaplon; DL-N-tert-Butyl-2-(4-hydroxy-3-hydroxymethylphenyl)-2-hydroxyethylamine; Ventoline; KBio2_005816; to_000081; Salbutan; Salamol; Asmaven; Salbutine; HMS2089I19; SBB066105; Grafalin; alpha-[(t-Butylamino)methyl]-4-hydroxy-m-xylene-alpha,alpha -diol; KBio2_003248; Spectrum2_001350; Parasma; Albuterol hemisulfate; Prestwick1_000198; HSDB 7206; (+-)-Albuterol; Prestwick0_000198; Dilatamol; NINDS_000943; NCGC00024698-02; 1-(tert-Butylaminomethyl)-4-hydroxy-m-xylene-alpha1,alpha3-diol; DB01001; Salbutalan; Aerolin; HMS1568H17; Bio1_000446; KBio2_000680; Prestwick2_000198; BCBcMAP01_000116; Farcolin; SMP1_000268; Libretin; Anebron; SPBio_002076; 4-Hydroxy-3-hydroxymethyl-alpha-((tert-butylamino)methyl)benzyl alcohol; Cetsim; m-Xylene-alpha,alpha'-diol, alpha'-((tert-butylamino)methyl)-4-hydroxy-; Buventol; CHEMBL714; 1,3-Benzenedimethanol, alpha1-(((1,1-dimethylethyl)amino)methyl)-4-hydroxy-; Ventilan; Bio1_001424; 2-t-Butylamino-1-(4-hydroxy-3-hydroxy-3-hydroxymethyl)phenylethanol; Tobybron; Asmadil; CID2083; S8260_SIGMA; Bronter; 46725_RIEDEL; Spreor; Bugonol; Respax; Sultanol; dl-Albuterol; I06-0331; ProAir; Salbupur; Ventolin Inhaler; Suxar; Butohaler; D02147; EU-0101090; NCGC00015955-11; 1,3-Benzenedimethanol, .alpha.1-[[(1,1-dimethylethyl)amino]methyl]-4-hydroxy-; 35763-26-9; 1,3-Benzenedimethanol, .alpha.(1)-[[(1,1-dimethylethyl)amino]methyl]-4-hydroxy-; Asmol; NCGC00024698-03; Theosal; Solbutamol; EINECS 242-424-0; MolPort-001-838-925; Medolin; 18559-94-9; (+-)-Salbutamol; SPBio_001539; Salbutard; Broncovaleas; Butamol; VU0243312-5; dl-Salbutamol; L000531; CHEBI:2549; Albuterol (USP); Salbutamolum [INN-Latin]; MLS000758199; albuterol; Alti-Salbutamol; Salbetol; nchembio801-comp4; PDSP1_000623; Respolin; Butotal; NCGC00015955-10; Salbutamol; Salbron; AC1Q1MO0; Proventil HFA; Rotahaler; Novosalmol; Gerivent; NCGC00024698-04; Ecovent; Mozal; LS-7693; BRD-A88254928-001-04-6; Prestwick3_000198; Volma; Buto-Asma; Salbusian; AB00052154; Vencronyl; Asthalin; SGCUT00011; DivK1c_000943; racemic-Salbutamol; PDSP2_000620; IDI1_000943; Salbutamol Sulphate; Salvent; Salbutamolum; Albuterol Sulphate; Sultanol N; Salbutamol sulfate; HMS2092I08; Pneumolat; Sabutal; NCGC00024698-06; Lopac0_001098; Proventil Inhaler; BSPBio_000155; Bio1_000935; Ventalin inhaler; NCGC00024698-05; Servitamol; Cobutolin; Asmasal; HMS1921C04; Saventol; NCGC00015955-04; Salomol; Proventil; alpha'-((tert-Butylamino)methyl)-4-hydroxy-m-xylene-alpha,alpha'-diol; Volmax; BRN 2213614; Arubendol-Salbutamol; SPECTRUM1500677; Salbuhexal; Salbu-BASF; Almotex; Sabutamol; Asmatol; Ventiloboi; SMR000058513; 46725_FLUKA; Asthavent; Salbu-Fatol; S 8260; 2-(tert-Butylamino)-1-(4-hydroxy-3-hydroxymethylphenyl)ethanol; NCGC00024698-07; Volare albuterol HFA; 4-{2-[(1,1-dimethylethyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol; Salbutol; Asmol Uni-Dose; ST024764; LS-29861; Airomir; KBioGR_001294; KBioSS_000680; Spectrum5_001059; Spectrum_000200; AC-10286; alpha-[(tert-Butylamino)methyl]-4-hydroxy-m-xylene-alpha,alpha'-diol; Asmanil; Proventil (TN); Asmidon; Lopac0_001090; HMS502P05; BPBio1_000171; Broncho-Spray; Bumol; Butovent; Volare easi-breathe; Spectrum4_000887; Zaperin; AC1L1CVO; Ventodisks; Salbuvent; Sallbupp; Suprasma	51022-70-9	161912	739438	TTDS00037	Beta-2 adrenergic receptor	Beta-2 adrenoceptor;Beta-2 adrenoreceptor	P07550	154	ENSG00000169252	agonist
DCL000825	GSK642444	N/A	N/A	6918465	46517476	TTDS00037	Beta-2 adrenergic receptor	Beta-2 adrenoceptor;Beta-2 adrenoreceptor	P07550	154	ENSG00000169252	agonist
DCL000942	QVA-149	N/A	312753-06-3	6433117	10549776	TTDS00037	Beta-2 adrenergic receptor	Beta-2 adrenoceptor;Beta-2 adrenoreceptor	P07550	154	ENSG00000169252	agonist
DAP000944	Procaterol	Procaterolum; (R*,S*)-(+-)-8-Hydroxy-5-(1-hydroxy-2-((1-methylethyl)amino)butyl)-2(1H)-quinolinone; Procaterolum [INN-Latin]; SPBio_001400; BSPBio_003239; 8-Hydroxy-5-(1-hydroxy-2-((1-methylethyl)amino)butyl)-2(1H)-quinolinone (R*,S*)-(+-)-; NSC 308904; Spectrum3_001770; L023776; 72332-33-3; MolPort-005-934-511; CHEMBL160519; AC1L1J8G; LS-142797; 2(1H)-Quinolinone, 8-hydroxy-5-(1-hydroxy-2-((1-methylethyl)amino)butyl)-, (R*,S*)-(+-)-; D08424; Procaterol [INN:BAN]; 60443-17-6; AC-13705; OPC-2009; Spectrum2_001550; CID4916; AR-1J3938; AC1Q6I3X; PROCATEROL; Procaterolo; Procaterol (INN); CI-888; 8-hydroxy-5-[1-hydroxy-2-(propan-2-ylamino)butyl]-1H-quinolin-2-one; STK632659; BRD-A22684332-003-02-3; 62929-91-3 (mono-hydrochloride); Meptin (TN); 8-Hydroxy-5-(1-hydroxy-2-((1-methylethyl)amino)butyl)-2(1H)-quinolinone; Pro-Air; 5-[1-hydroxy-2-(propan-2-ylamino)butyl]quinoline-2,8-diol; NSC308904; Procaterol Monohydrochloride; 2(1H)-Quinolinone, 8-hydroxy-5-(1-hydroxy-2-((1-methylethyl)amino)butyl)-; Procaterolum [Latin]; Procaterolo [DCIT]; KBio3_002739; Meptin; EINECS 276-590-0	72332-33-3	688561	11113915	TTDS00037	Beta-2 adrenergic receptor	Beta-2 adrenoceptor;Beta-2 adrenoreceptor	P07550	154	ENSG00000169252	agonist
DAP000811	Orciprenaline	KBio2_001405; Orciprenalina [INN-Spanish]; Metaproterenol Polistirex (metaproterenol); CHEBI:144647; Spectrum2_000096; Spectrum3_000492; BSPBio_000429; Alotec; Astmopent; SAM002548965; Lopac0_000734; (RS)-1-(3,5-Dihydroxyphenyl)-2-isopropylaminoethanol; 586-06-1; KBioGR_000507; Orciprenalinum; 1,3-Benzenediol, 5-(1-hydroxy-2-((1-methylethyl)amino)ethyl)- (9CI); Spectrum5_000952; SPBio_000052; Benzyl alcohol, 3,5-dihydroxy-.alpha.-((isopropylamino)methyl)-; Orciprenalinum [INN-Latin]; HMS502A07; Orciprenaline (INN); Orciprenalina; BPBio1_000473; HMS1920L09; KBio3_001483; L000678; LS-42870; 3,5-Dihydroxy-alpha-((isopropylamino)methyl)benzyl alcohol; IDI1_000645; SPECTRUM1500390; Novasmasol; KBio2_006541; Prestwick3_000505; Orciprenaline [INN]; Benzyl alcohol, 3,5-dihydroxy-alpha-((isopropylamino)methyl)-; Prestwick0_000505; BRN 2807247; DB00816; Alupent; CHEMBL776; NCGC00015655-05; Spectrum4_000044; M-3070; 1,3-Benzenediol, 5-[1-hydroxy-2-[(1-methylethyl)amino]ethyl]-; Metaprel; Metaproterenol polistirex; D08300; CPD001453712; CCRIS 9017; KBio2_003973; MolPort-003-666-227; Prestwick1_000505; NCGC00094718-01; NINDS_000645; EINECS 209-569-1; Prometa; KBio1_000645; Prestwick2_000505; SPBio_002350; KBioSS_001405; AC1L1HDP; Spectrum_000925; ORCIPRENALINE; CID4086; DivK1c_000645; NCGC00094718-02; 5-[1-hydroxy-2-(propan-2-ylamino)ethyl]benzene-1,3-diol; BSPBio_001983; AB00052037; 1,3-Benzenediol, 5-(1-hydroxy-2-((1-methylethyl)amino)ethyl)-; UNII-53QOG569E0; Orciprenaline sulfate; NCGC00094718-03; C07144; metaproterenol; Metaproterenol sulfate; HMS2091D04	586-06-1	4086	9353	TTDS00037	Beta-2 adrenergic receptor	Beta-2 adrenoceptor;Beta-2 adrenoreceptor	P07550	154	ENSG00000169252	agonist
DCL000397	GSK961081	N/A	38398-32-2	6918305	47206230	TTDS00037	Beta-2 adrenergic receptor	Beta-2 adrenoceptor;Beta-2 adrenoreceptor	P07550	154	ENSG00000169252	agonist
DCL000370	GSK159802	N/A	N/A	N/A	N/A	TTDS00037	Beta-2 adrenergic receptor	Beta-2 adrenoceptor;Beta-2 adrenoreceptor	P07550	154	ENSG00000169252	agonist
DCL000645	Sulopenem IV	N/A	120788-07-0	N/A	N/A	TTDS00212	Penicillin binding protein 3	PBP 3;PBP-3;Penicillin-binding protein 3;Peptidoglycan glycosyltransferase 3;Peptidoglycan synthetase ftsI;PSPB20	P45059	N/A	N/A	inhibitor
DAP001178	Cefmenoxime	Cefmenoxima [INN-Spanish]; 65085-01-0; C16H17N9O5S3; Cefmax; LS-176426; Cefmenoxime (INN); (6R,7R)-7-[[(2E)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid (IUPAC); UNII-KBZ4844CXN; 75738-58-8 (hydrochloride (2:1)); Cefmenoxima; Tacef; (6R,7R)-7-((Z)-2-(2-Amino-4-thiazolyl)-2-methoxyiminoacetamido)-3-((1-methyl-1H-5-tetraazolylthio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-2-carbonsaeure; (6R,7R)-7-({(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(methyloxy)imino]acetyl}amino)-3-{[(1-methyl-1H-tetrazol-5-yl)thio]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; SCE 1365; Cefmenoximum [INN-Latin]; cefmenoxime; 7beta-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-3,4-didehydrocepham-4-carboxylic acid; AB 50912; (6R,7R)-(2-(2-Amino-4-thiazolyl)glyoxylamido)-3-(1-methyl-1H-tetrazol-5-yl)thiomethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-2-carbonsaeure-7-(Z)-(O-methyloxim); CHEBI:55490; Abbott-50192; 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2-amino-4-thiazolyl)(methoxyimino)acetyl)amino)-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-, (6R-(6alpha,7beta(Z)))-; A 50912; Cefmenoxime [INN]; Cefmenoxime Hydrochloride (2:1); (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; D07641; CID9570757; Cefmenoximum	65085-01-0	5361486	7853887	TTDS00212	Penicillin binding protein 3	PBP 3;PBP-3;Penicillin-binding protein 3;Peptidoglycan glycosyltransferase 3;Peptidoglycan synthetase ftsI;PSPB20	P45059	N/A	N/A	binder
DAP001179	Cefmetazole	I06-1563; U-72791A; U 72791; (6R,7S)-7-({[(cyanomethyl)sulfanyl]acetyl}amino)-7-methoxy-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; BSPBio_000859; 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((((cyanomethyl)thio)acetyl)amino)-7-methoxy-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-, (6R-cis)-; D00910; BRN 0634647; LS-150046; AC-13154; (6R,7S)-7-(2-((Cyanomethyl)thio)acetamido)-7-methoxy-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; Cefmetazole (USP/INN); (6R,7S)-7-[[2-(cyanomethylsulfanyl)acetyl]amino]-7-methoxy-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 56796-39-5 (mono-hydrochloride salt); CMZ; Prestwick2_000700; C15H17N7O5S3; Cefmetazolum; EINECS 260-384-2; DB00274; Prestwick3_000700; CS 1170; CHEBI:3489; Cefmetazolo; MolPort-005-934-200; 56796-20-4; Prestwick1_000700; Cefmetazolum [INN-Latin]; BPBio1_000945; Cefmetazolo [INN-Spanish]; Cefmetazole [USAN:INN]; (6R,7S)-7-({[(cyanomethyl)thio]acetyl}amino)-7-(methyloxy)-3-{[(1-methyl-1H-tetrazol-5-yl)thio]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; SKF 83088; CS-1170; UNII-3J962UJT8H; Prestwick0_000700; cefmetazole; SPBio_002780; Cefmetazole Monosodium Salt; (6R,7S)-7-(2-((Cyanomethyl)thio)acetamido)-7-methoxy-3-(((1-methyl-1H-tetrazol-5-yl)thiomethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, sodium salt; CID42008; Lopac0_000266; AC1L26WS; C08103; 6beta-{[(cyanomethyl)sulfanyl]acetamido}-6alpha-methoxy-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}ceph-3-em-4-carboxylic acid	56796-20-4	42008	10303	TTDS00212	Penicillin binding protein 3	PBP 3;PBP-3;Penicillin-binding protein 3;Peptidoglycan glycosyltransferase 3;Peptidoglycan synthetase ftsI;PSPB20	P45059	N/A	N/A	binder
DAP001181	Latamoxef	NINDS_000909; Spectrum_000971; Oxa-cephem; Sid 734787; EINECS 265-287-9; LMOX; SPBio_001054; SPBio_002638; Spectrum4_000064; CID47499; UNII-VUF6C936Z3; Latamoxefum [INN-Latin]; Lamoxactam; 79120-38-0; CHEMBL74632; Latamoxefum; AC1Q41EH; 5-Oxa-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((carboxy(4-hydroxyphenyl)acetyl)amino)-7-methoxy-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-; 75007-71-5; Prestwick0_000819; C20H20N6O9S; KBioGR_000587; Disodium Moxalactam; C07231; (6R,7R)-7-[[3-hydroxy-2-(4-hydroxyphenyl)-3-oxopropanoyl]amino]-7-methoxy-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; Lilly 127935; LS-98586; DB04570; KBioSS_001451; 7-((Carboxy(4-hydroxyphenyl)acetyl)amino)-7-methoxy-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-5-oxa-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid (6R-(6alpha,7alpha,7(S*)))-; SMP1_000200; KBio1_000909; Latamoxef [INN:BAN]; (6R-(6alpha,7alpha,7(S*)))-7-((Carboxy(4-hydroxyphenyl)acetyl)amino)-7-methoxy-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-5-oxa-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; KBio3_001539; Ly127935; Prestwick2_000819; DivK1c_000909; Latamoxef; 5-Oxa-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((carboxy(4-hydroxyphenyl)acetyl)amino)-7-methoxy-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-, (6R-(6alpha,7alpha,7(S*)))-; KBio2_006587; AC1Q6LO9; CHEBI:599928; KBio2_004019; Prestwick1_000819; BSPBio_002039; 7beta-(2-Carboxy-2-(4-hydroxyphenyl)acetamido)-7alpha-methoxy-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-1-oxa-1-dethia-3-cephem-4-carboxylic acid; 7b-[2-carboxy-2-(4-hydroxyphenyl)acetamido]-7a-methoxy-3-[[(1-methyl-1h-tetrazol-5-yl)thio]methyl]-1-oxa-1-dethia-3-cephem-4-carboxylic acid; S-6059; IDI1_000909; 64952-97-2; KBio2_001451; AC1L2I6O; 1-Oxacephalosporin; (6R,7R)-7-{[carboxy(4-hydroxyphenyl)acetyl]amino}-7-(methyloxy)-3-{[(1-methyl-1H-tetrazol-5-yl)thio]methyl}-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; Spectrum3_000510; (6R,7R)-7-{[carboxy(4-hydroxyphenyl)acetyl]amino}-7-methoxy-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 5-Oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[carboxy(4-hydroxyphenyl)acetyl]amino]-7methoxy-3-[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-8-oxo-; Spectrum5_001371; Festamoxin; Spectrum2_001067; moxalactam; D08109; Latamoxef (INN)	64952-97-2	47499	46505546	TTDS00212	Penicillin binding protein 3	PBP 3;PBP-3;Penicillin-binding protein 3;Peptidoglycan glycosyltransferase 3;Peptidoglycan synthetase ftsI;PSPB20	P45059	N/A	N/A	binder
DCL000644	Sulopenem	Sulopenem; KST-1A0914; CID71341; (5r,6s)-6-[(1r)-1-hydroxyethyl]-3-[(1-oxidotetrahydrothiophen-3-yl)sulfanyl]-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; CID6918095; AR-1A6480; AC1L2FZB; Sulopenem (USAN/INN); (5R,6S)-6-[(1R)-1-hydroxyethyl]-7-oxo-3-[(3S)-1-oxothiolan-3-yl]sulfanyl-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; CID9798461; (5R,6S)-6-[(1R)-1-hydroxyethyl]-7-oxo-3-(1-oxothiolan-3-yl)sulfanyl-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; CP 70429; 120788-07-0; CID9928329; AC1OCF0J; CP-65207-S; CID9950244; CP-70429; CID10427910; D05969; 12202-43-6	120788-07-0	6918095	47207627	TTDS00212	Penicillin binding protein 3	PBP 3;PBP-3;Penicillin-binding protein 3;Peptidoglycan glycosyltransferase 3;Peptidoglycan synthetase ftsI;PSPB20	P45059	N/A	N/A	inhibitor
DAP001180	Mezlocillin	(2S,5R,6R)-3,3-dimethyl-6-{[(2R)-2-({[3-(methylsulfonyl)-2-oxoimidazolidin-1-yl]carbonyl}amino)-2-phenylacetyl]amino}-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 6beta-{(2R)-2-[3-(methanesulfonyl)-2-oxoimidazolidine-1-carboxamido]-2-phenylacetamido}-2,2-dimethylpenam-3alpha-carboxylic acid; Mezlocillin (USAN/INN); AC1LCV44; C07221; MEZLOCILLIN; (2S,5R,6R)-3,3-dimethyl-6-[[(2R)-2-[(3-methylsulfonyl-2-oxoimidazolidine-1-carbonyl)amino]-2-phenylacetyl]amino]-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; Mezlocilina; 6beta-{(2R)-2-[3-(methanesulfonyl)-2-oxoimidazolidine-1-carboxamido]-2-phenylacetamido}penicillanic acid; CID656511; DB00948; NCGC00167470-01; D05021; CHEMBL1731; CHEBI:6919; 51481-65-3; Mezlin; Mezlocillinum	51481-65-3	656511	9430	TTDS00212	Penicillin binding protein 3	PBP 3;PBP-3;Penicillin-binding protein 3;Peptidoglycan glycosyltransferase 3;Peptidoglycan synthetase ftsI;PSPB20	P45059	N/A	N/A	binder
DAP001177	Cefotiam	CEFOTIAM HYDROCHLORIDE; Prestwick1_000482; 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2-amino-4-thiazolyl)acetyl)amino)-3-(((1-(2-(dimethylamino)ethyl)-1H-tetrazol-5-yl)thio)methyl)-8-oxo-, (6R-trans)-; CTM; Abbott-48999; SPBio_002264; BRD-K02275692-003-03-4; 7beta-(2-amino-1,3-thiazol-4-yl)acetamido-3-[({1-[2-(dimethylamino)ethyl]-1H-tetrazol-5-yl}sulfanyl)methyl]-3,4-didehydrocepham-4-carboxylic acid; (6R,7R)-7-[2-(2-Amino-thiazol-4-yl)-acetylamino]-3-[1-(2-dimethylamino-ethyl)-1H-tetrazol-5-ylsulfanylmethyl]-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid; BPBio1_000379; CHEMBL1296; DB00229; CID43708; Aspil (TN); C18H23N9O4S3; BSPBio_000343; 67356-92-7; SCE-963; Ceradolan; CGP-14221-E; AC1Q6LOO; Cefotiam [INN:BAN]; Cefotiamum [INN-Latin]; AB00514684; Prestwick0_000482; (6R,7R)-7-[[2-(2-amino-1,3-thiazol-4-yl)acetyl]amino]-3-[[1-(2-dimethylaminoethyl)tetrazol-5-yl]sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; UNII-91W6Z2N718; LS-149969; 7b-[2-(aminothiazol-4-yl)acetamido]-3-[[[1-(2-dimethylaminoethyl)-1h-tetrazol-5-yl]thio]methyl]ceph-3-em-4-carboxylic acid; Aspil; NCGC00179594-01; CGP 14221E; 70896-40-1; 61622-34-2; Cefotiam (INN); Cefotiamum; Haloapor; Prestwick3_000482; (6R,7R)-7-{[(2-amino-1,3-thiazol-4-yl)acetyl]amino}-3-[({1-[2-(dimethylamino)ethyl]-1H-tetrazol-5-yl}thio)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; D07648; AC1L2AFI; (6R,7R)-7-{[(2-amino-1,3-thiazol-4-yl)acetyl]amino}-3-[({1-[2-(dimethylamino)ethyl]-1H-tetrazol-5-yl}sulfanyl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; CHEBI:355510; Prestwick2_000482; cefotiam	61622-34-2	43708	7853895	TTDS00212	Penicillin binding protein 3	PBP 3;PBP-3;Penicillin-binding protein 3;Peptidoglycan glycosyltransferase 3;Peptidoglycan synthetase ftsI;PSPB20	P45059	N/A	N/A	binder
DAP000117	Aztreonam	78110-38-0; S1505_Selleck; CHEMBL158; NCGC00179656-01; Prestwick3_000185; 2-[(Z)-[1-(2-amino-1,3-thiazol-4-yl)-2-[[(2S,3S)-2-methyl-4-oxo-1-sulfoazetidin-3-yl]amino]-2-oxoethylidene]amino]oxy-2-methylpropanoic acid; 2-({[(1Z)-1-(2-amino-1,3-thiazol-4-yl)-2-{[(2S,3S)-2-methyl-4-oxo-1-sulfoazetidin-3-yl]amino}-2-oxoethylidene]amino}oxy)-2-methylpropanoic acid; Prestwick_914; CID5742832; AC1NX3U2; AC-4330; Ambap78110-38-0; BSPBio_000109; Prestwick2_000185; BPBio1_000121; HMS1568F11; Azactam; Monobactam, SQ 26776, Squibb 26776, Aztreonam; MolPort-003-886-345; [2S-[2alpha,3beta(Z)]]-2-[[[1-(2-Amino-4-thiazolyl)-2-[(2-methyl-4-oxo-1-sulfo-3-azetidinyl)amino]-2-oxoethylidene]amino]oxy]-2-methylpropanoic acid; NSC646279; SQ-26776; aztreonam; BRD-K62607865-001-03-0; HMS2090K09; Primbactam; CHEBI:161680; BIDD:GT0765	78110-38-0	5362041	9058	TTDS00212	Penicillin binding protein 3	PBP 3;PBP-3;Penicillin-binding protein 3;Peptidoglycan glycosyltransferase 3;Peptidoglycan synthetase ftsI;PSPB20	P45059	N/A	N/A	binder
DCL001202	ISIS-SGLT2	N/A	N/A	N/A	N/A	TTDC00336	mRNA of sodium-glucose transporter-2	mRNA of Sodium/glucose cotransporter 2;mRNA of Na(+)/glucose cotransporter 2;mRNA of Low affinity sodium-glucose cotransporter;mRNA of Solute carrier family 5 member 2;mRNA of SLC5A2;mRNA of SGLT2	P31639	6524	ENSG00000140675	antisense
DCL000007	SNS-032	CID3025986; S1145_Selleck; BMS-387032; Kinome_3820; AC-5242; I09-1579; CID6918586; LS-186036; BMS-387032, SNS-032; N-(5-(((5-(1,1-Dimethylethyl)-2-oxazolyl)methyl)thio)-2-thiazolyl)-4-piperidinecarboxamide; SNS-032; N-[5-[(5-tert-butyl-1,3-oxazol-2-yl)methylsulfanyl]-1,3-thiazol-2-yl]piperidine-4-carboxamide; (2R,3R)-2,3-dihydroxybutanedioic acid; MolPort-005-942-660; 345627-80-7; N-[5-[(5-tert-butyl-1,3-oxazol-2-yl)methylsulfanyl]-1,3-thiazol-2-yl]piperidine-4-carboxamide; AC1OCFM7; AC1MHGD4; CHEMBL296468; N-[5-[[[5-(1,1-Dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4-piperidinecarboxamide L-tartaric acid salt (2:1); 4-Piperidinecarboxamide, N-(5-(((5-(1,1-dimethylethyl)-2-oxazolyl)methyl)thio)-2-thiazolyl)-; BMS-387072	N/A	6918586	12015560	TTDC00088	Cell division protein kinase 2	CDK2;Cyclin-dependent kinase 2;P33 protein kinase;Sin3 associated polypeptide;SIN3-associated protein	P24941	1017	ENSG00000123374	inhibitor
DCL001079	R547	LS-193675; ZINC13983251; R547; DB08094; R-547; CHEMBL384304; [4-amino-2-[(1-methylsulfonylpiperidin-4-yl)amino]pyrimidin-5-yl]-(2,3-difluoro-6-methoxyphenyl)methanone; 2fvd; LIA; CID6918852; AC1OCFYV	N/A	N/A	N/A	TTDC00088	Cell division protein kinase 2	CDK2;Cyclin-dependent kinase 2;P33 protein kinase;Sin3 associated polypeptide;SIN3-associated protein	P24941	1017	ENSG00000123374	inhibitor
DCL001080	R-roscovitine	2a4l; AR-1A2673; LS-182554; AC-2416; CYC202; 3ddq; Seliciclib; CYC202, Seliciclib, R-roscovitine, Roscovitine; M02443; 1-Butanol, 2-((9-(1-methylethyl)-6-((phenylmethyl)amino)-9H-purin-2-yl)amino)-, (R)-; CBiol_002016; 1-Butanol, 2-((9-(1-methylethyl)-6-((phenylmethyl)amino)-9H-purin-2- yl)amino)-, (2R)-; HMS1362F19; IDI1_002134; BiomolKI2_000054; S1153_Selleck; HMS1990F19; NSC-701554; AC1L4NH4; R7772_SIGMA; MolPort-003-959-463; CYC 202; 186692-46-6; CYC-202; AR-1A2674; 1-Butanol, 2-((9-(1-methylethyl)-6-((phenylmethyl)amino)-9H-purin-2-yl)amino)-, (2R)-; 6-(Benzylamino)-2(R)-[[1-(hydroxymethyl)propyl]amino]-9-isopropylpurine; Bio1_000302; KBioGR_000418; Bio1_000791; BRD-K07691486-001-03-1; Rosco; AKOS005146319; (2R)-2-[[6-(benzylamino)-9-propan-2-ylpurin-2-yl]amino]butan-1-ol; RRC; CID160355; HMS3229N13; 1-Butanol, 2-((9-(1-methylethyl)-6-((phenylmethyl)amino)-9H-purin-2- yl)amino)-, (R)-; KST-1A2714; NCGC00094374-04; 1-Butanol, 2-[[9-(1-methylethyl)-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-, (2R)-; SMP1_000266; HMS1792F19; BMK1-E12; KBioSS_000418; NCGC00094374-01; NSC701554; BCBcMAP01_000013; BRD-K07691486-001-05-6; KBio2_000418; KST-1A2715; ZINC01649340; CHEMBL14762; R-Roscovitine; NCGC00094374-02; Lopac0_001102; 2-(R)-[[9-(1-Methylethyl)-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-1-butanol; 2-(R)-(1-Ethyl-2-hydroxyethylamino)-6-benzylamino-9-isopropylpurine; KBio3_000795; BiomolKI_000048; roscovitine; (R)-roscovitine; NCI60_036420; Bio1_001280; InSolution&trade; Roscovitine; KBio2_002986; BSPBio_001078; KBio2_005554; Ambotz186692-46-6; NSC 701554; NCGC00094374-03; 2-[[9-(1-Methylethyl)-6-[(phenylmethyl)amino]- 9H-purin-2-yl]amino]-(R)-1-butanol; HSCI1_000092; (2r)-2-{[6-(benzylamino)-9-isopropyl-9h-purin-2-yl]amino}-1-butanol; AC1Q4VI5; Bio2_000379; Bio2_000859; KBio3_000796	186692-46-6	160355 	737846	TTDC00088	Cell division protein kinase 2	CDK2;Cyclin-dependent kinase 2;P33 protein kinase;Sin3 associated polypeptide;SIN3-associated protein	P24941	1017	ENSG00000123374	inhibitor
DCL000227	Seliciclib	2a4l; AR-1A2673; LS-182554; AC-2416; CYC202; 3ddq; Seliciclib; CYC202, Seliciclib, R-roscovitine, Roscovitine; M02443; 1-Butanol, 2-((9-(1-methylethyl)-6-((phenylmethyl)amino)-9H-purin-2-yl)amino)-, (R)-; CBiol_002016; 1-Butanol, 2-((9-(1-methylethyl)-6-((phenylmethyl)amino)-9H-purin-2- yl)amino)-, (2R)-; HMS1362F19; IDI1_002134; BiomolKI2_000054; S1153_Selleck; HMS1990F19; NSC-701554; AC1L4NH4; R7772_SIGMA; MolPort-003-959-463; CYC 202; 186692-46-6; CYC-202; AR-1A2674; 1-Butanol, 2-((9-(1-methylethyl)-6-((phenylmethyl)amino)-9H-purin-2-yl)amino)-, (2R)-; 6-(Benzylamino)-2(R)-[[1-(hydroxymethyl)propyl]amino]-9-isopropylpurine; Bio1_000302; KBioGR_000418; Bio1_000791; BRD-K07691486-001-03-1; Rosco; AKOS005146319; (2R)-2-[[6-(benzylamino)-9-propan-2-ylpurin-2-yl]amino]butan-1-ol; RRC; CID160355; HMS3229N13; 1-Butanol, 2-((9-(1-methylethyl)-6-((phenylmethyl)amino)-9H-purin-2- yl)amino)-, (R)-; KST-1A2714; NCGC00094374-04; 1-Butanol, 2-[[9-(1-methylethyl)-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-, (2R)-; SMP1_000266; HMS1792F19; BMK1-E12; KBioSS_000418; NCGC00094374-01; NSC701554; BCBcMAP01_000013; BRD-K07691486-001-05-6; KBio2_000418; KST-1A2715; ZINC01649340; CHEMBL14762; R-Roscovitine; NCGC00094374-02; Lopac0_001102; 2-(R)-[[9-(1-Methylethyl)-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-1-butanol; 2-(R)-(1-Ethyl-2-hydroxyethylamino)-6-benzylamino-9-isopropylpurine; KBio3_000795; BiomolKI_000048; roscovitine; (R)-roscovitine; NCI60_036420; Bio1_001280; InSolution&trade; Roscovitine; KBio2_002986; BSPBio_001078; KBio2_005554; Ambotz186692-46-6; NSC 701554; NCGC00094374-03; 2-[[9-(1-Methylethyl)-6-[(phenylmethyl)amino]- 9H-purin-2-yl]amino]-(R)-1-butanol; HSCI1_000092; (2r)-2-{[6-(benzylamino)-9-isopropyl-9h-purin-2-yl]amino}-1-butanol; AC1Q4VI5; Bio2_000379; Bio2_000859; KBio3_000796	N/A	160355	12015583	TTDC00088	Cell division protein kinase 2	CDK2;Cyclin-dependent kinase 2;P33 protein kinase;Sin3 associated polypeptide;SIN3-associated protein	P24941	1017	ENSG00000123374	inhibitor
DCL001084	ZK 304709	N/A	N/A	N/A	N/A	TTDC00088	Cell division protein kinase 2	CDK2;Cyclin-dependent kinase 2;P33 protein kinase;Sin3 associated polypeptide;SIN3-associated protein	P24941	1017	ENSG00000123374	inhibitor
DCL000077	Capridine-beta	666854-78-0; CC-10004; UNII-UP7QBP99PN; CC 10004; Apremilast; D08860; CID11561674; Apremilast (USAN); CHEMBL514800; CHEBI:558773; N-[2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methylsulfonyl-ethyl]-1,3-dioxo-isoindol-4-yl]acetamide	N/A	N/A	N/A	TTDC00088	Cell division protein kinase 2	CDK2;Cyclin-dependent kinase 2;P33 protein kinase;Sin3 associated polypeptide;SIN3-associated protein	P24941	1017	ENSG00000123374	inhibitor
DCL000366	Ro 31-7453	AC1NS2UU; CID5327686; Bisindolylmaleimide deriv. 44; Ro-31-7453; 3-(1-methylindol-3-yl)-4-(1-methyl-6-nitroindol-3-yl)pyrrole-2,5-dione; MKC-1; CHEMBL52885	443912-18-3	N/A	3820971	TTDC00088	Cell division protein kinase 2	CDK2;Cyclin-dependent kinase 2;P33 protein kinase;Sin3 associated polypeptide;SIN3-associated protein	P24941	1017	ENSG00000123374	inhibitor
DCL001081	SCH 727965	Dinaciclib; SCH-727965	N/A	N/A	N/A	TTDC00088	Cell division protein kinase 2	CDK2;Cyclin-dependent kinase 2;P33 protein kinase;Sin3 associated polypeptide;SIN3-associated protein	P24941	1017	ENSG00000123374	inhibitor
DPR000124	AG-024322	N-[[5-[(3E)-3-(4,6-difluorobenzimidazol-2-ylidene)-1,2-dihydroindazol-5-yl]-4-methylpyridin-3-yl]methyl]ethanamine; AG-24322; AG-024322; AC1OCFY2; CID6918834	N/A	N/A	N/A	TTDC00088	Cell division protein kinase 2	CDK2;Cyclin-dependent kinase 2;P33 protein kinase;Sin3 associated polypeptide;SIN3-associated protein	P24941	1017	ENSG00000123374	inhibitor
DCL000116	Flavopiridol	UNII-45AD6X575G; S1230_Selleck; 2-(2-CHLORO-PHENYL)-5,7-DIHYDROXY-8-(3-HYDROXY-1-METHYL-PIPERIDIN-4-YL)-4H-BENZOPYRAN-4-ONE; Alvocidib; FLAVO; 131740-09-5; DB03496; HMR-1275, Alvocidib, L868275, Flavopiridol; Flavopiridol; 4H-1-Benzopyran-4-one, 2-(2-chlorophenyl)-5,7-dihydroxy-8-((3R,4S)-3-hydroxy-1-methyl-4-piperidinyl)-, rel-(-)-; 1e1y; CHEMBL428690; L 868275; CHEMBL8817; AC1NRALK; CID5287969; 4H-1-Benzopyran-4-one, 2-(2-chlorophenyl)-2,3-dihydro-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methyl-4-piperidinyl]-; L-868275; 1c8k; 358739-39-6; 4H-1-Benzopyran-4-one, 2-(2-chlorophenyl)-5,7-dihydroxy-8-(3-hydroxy-1-methyl-4-piperidinyl)-, cis-(-)-; 146426-40-6; Alvocidib [INN]; L86-8275; NSC649890; (-)cis-5,7-Dihydroxy-2-(2-chlorophenyl)-8-(4-(3-hydroxy-1-methyl)piperidinyl)-4H-1-benzopyran-4-one; 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]chromen-4-one; LS-173272; C21H20ClNO5; HMR-1275; Flavopiridol hydrochloride	131740-09-5	5287969	11041362	TTDC00088	Cell division protein kinase 2	CDK2;Cyclin-dependent kinase 2;P33 protein kinase;Sin3 associated polypeptide;SIN3-associated protein	P24941	1017	ENSG00000123374	inhibitor
DCL000058	AT7519	CHEMBL445813; 4-[(2,6-dichlorobenzoyl)amino]-N-(4-piperidyl)-2H-pyrazole-3-carboxamide; DB08142; CID11338033; AT 7519, AT7519; CHEMBL497478; S1524_Selleck; LZE; AT7519; AT-7519	252870-53-4	N/A	N/A	TTDC00088	Cell division protein kinase 2	CDK2;Cyclin-dependent kinase 2;P33 protein kinase;Sin3 associated polypeptide;SIN3-associated protein	P24941	1017	ENSG00000123374	inhibitor
DAP000499	Dantrolene	Dantrolenum [INN-Latin]; HMS1989B07; HSDB 3050; 2,4-Imidazolidinedione, 1-(((5-(4-nitrophenyl)-2-furanyl)methylene)amino)-; Prestwick2_000291; BRD-K81272440-236-05-1; IDI1_000898; Dantrium Intravenous; Spectrum5_001752; AC1OC9NE; F-368; nchembio.368-comp3; DANTROLENE SODIUM; BIDD:GT0187; 1-(((5-(4-Nitrophenyl)-2-furanyl)methylene)amino)-2,4-imidazolidinedione; C14H10N4O5; LS-76264; HMS1791B07; D02347; Dantroleno [INN-Spanish]; UNII-F64QU97QCR; DB01219; 1-[(E)-[5-(4-nitrophenyl)furan-2-yl]methylideneamino]imidazolidine-2,4-dione; C06939; Dantroleno; CHEMBL1201288; Dantrium; CHEBI:4317; MolPort-006-389-324; Hydantoin, 1-((5-(p-nitrophenyl)furfurylidene)amino)-; 2,4-Imidazolidinedione, 1-[[[5-(4-nitrophenyl)-2-furanyl]methylene]amino]-; Dantrolenum; ZINC26894874; CID6914273; 7261-97-4; EINECS 230-684-8; Prestwick3_000291; NCGC00163402-01; Lopac0_000424; IDI1_033775; NCGC00163132-01; 1-((5-(p-Nitrophenyl)furfurylidene)amino)hydantoin; dantrolene; BRD-K81272440-001-02-6; BRN 0705189; 1-({[5-(4-nitrophenyl)furan-2-yl]methylidene}amino)imidazolidine-2,4-dione; HMS1361B07; 1-({(1E)-[5-(4-nitrophenyl)furan-2-yl]methylidene}amino)imidazolidine-2,4-dione; BCBcMAP01_000067; BSPBio_000222; Dantrolene (USAN/INN); BSPBio_001305; Dantrolene [USAN:BAN:INN]; BSPBio_003074; BPBio1_000246; NCGC00163402-02	7261-97-4	2952	9154	TTDS00165	Ryanodine receptor	Brain ryanodine receptor-calcium release channel;Brain-type ryanodine receptor;Cardiac muscle ryanodine receptor-calcium release channel;Cardiac muscle-type ryanodine receptor;RyR;Skeletal muscle calcium release channel;Skeletal muscle-type ryanodine receptor	Q92736	6262	ENSG00000198626	antagonist
DCL001207	Mavrilimumab	N/A	N/A	N/A	N/A	TTDS00442	Granulocyte-macrophage colony-stimulating factor receptor alpha chain	CD116 antigen;CDw116;GM-CSFR;GM-CSF-R-alpha;GMR	P15509	1438	ENSG00000198223	antibody
DAP001053	Sargramostim	Sargramostim; Leukine (TN); Sargramostim (genetical recombination) (JAN); D05803; 123774-72-1; Leukine; Sargramostim (genetical recombination); Sargramostim (USAN/INN)	83869-56-1	N/A	47207464	TTDS00442	Granulocyte-macrophage colony-stimulating factor receptor alpha chain	CD116 antigen;CDw116;GM-CSFR;GM-CSF-R-alpha;GMR	P15509	1438	ENSG00000198223	binder
DAP001288	Quinupristin	CHEMBL1200649; Quinupristina; AC1L2FZ2; C08032; AC1Q6O3S; RP 57669; Quinupristine; CHEMBL1236119; 5delta-(3-quinuclidinyl)thiomethylpristinamycin IA; N-((6R,9S,10R,13S,15aS,18R,22S,24aS)-22-(p-(Dimethylamino)benzyl)-6-ethyldocosahydro-10,23-dimethyl-5,8,12,15,17,21,24-heptaoxo-13-phenyl-18-(((3S)-3-quinuclidinylthio)methyl)-12H-pyrido(2,1-f)pyrrolo(2,1-l)(1,4,7,10,13,16)oxapentaazacyclononadecin-9-yl)-3-hydroxypicolinamide; NCGC00181778-01; Quinupristin [USAN:INN]; CID5388937; LS-172437; AC1MHDYI; CID5496904; CID71338; CHEBI:45818; Quinupristine [INN-French]; CID11981004; Virginiamycin S1, 4-(4-(dimethylamino)-N-methyl-L-phenylalanine)-5-(5-((1-azabicyclo(2.2.2)oct-3-ylthio)methyl)-4-oxo-L-2-piperidinecarboxylic acid)-, (S)-; CID3001764; RP-57669; 120138-50-3; Quinupristin (JAN/USAN/INN); AR-1K4503; CID11979364; CID5311393; D00852; SYB; CID470126; UNII-23OW28RS7P; 4-[4-(DIMETHYLAMINO)-N-METHYL-L-PHENYLALANINE]-5-[(2S,5R)-5-[[[(3S)-1-AZABICYCLO-[2.2.2]OCT-3-YL]THIO]METHYL]-4-OXO-2-PIPERIDINECARBOXYLIC ACID]VIRGINIAMYCIN; Quinupristina [INN-Spanish]; AC1LAKMS; n-{18-[(1-azabicyclo[2.2.2]oct-3-ylsulfanyl)methyl]-22-[4-(dimethylamino)benzyl]-6-ethyl-10,23-dimethyl-5,8,12,15,17,21,24-heptaoxo-13-phenyldocosahydro-12h-pyrido[2,1-f]pyrrolo[2,1-l][1,4,7,10,13,16]oxapentaazacyclononadecin-9-yl}-3-hydroxypyridine-2-carboxamide; Quinupristin; Virginiamycin S1, 4-(4-(dimethylamino)-N-methyl-L-phenylalanine)-5-(5-((1-azabicycl- o(2.2.2)oct-3-ylthio)methyl)-4-oxo-L-2-piperidinecarboxylic acid)-, (S)-; Quinupristinum; Quinupristinum [INN-Latin]	120138-50-3	11953896	7847917	TTDS00510	Integral membrane protein LmrP	lmrP	Q9CDQ3	N/A	N/A	modulator
DCL000803	FG-3019	N/A	637334-45-3	N/A	47206937	TTDC00213	Connective tissue growth factor	CCN2;CTGF;Hypertrophic chondrocyte-specific protein 24;Long	P29279	1490	ENSG00000118523	inhibitor
DCL000951	RDEA 594	N/A	N/A	5312150	39341768	TTDC00243	Solute carrier family 22 member 12	Organic anion transporter 4-like protein;Renal-specific transporter;RST;Urate anion exchanger 1	Q96S37	116085	ENSG00000197891	blocker
DCL000883	MLN1202	N/A	960509-91-5	N/A	85153015	TTDC00122	C-C chemokine receptor type 2	C-C CKR-2;CC-CKR-2;CCR2;CCR-2;Chemokine receptor CCR2B;MCP-1-R;Monocyte chemoattractant protein 1 receptor	P41597	729230	ENSG00000121807	antagonist
DPR000072	MCP-1	N/A	N/A	N/A	623363	TTDC00122	C-C chemokine receptor type 2	C-C CKR-2;CC-CKR-2;CCR2;CCR-2;Chemokine receptor CCR2B;MCP-1-R;Monocyte chemoattractant protein 1 receptor	P41597	729230	ENSG00000121807	antagonist
DCL000845	INCB-3284	N/A	87667-21-8	2146	49601938	TTDC00122	C-C chemokine receptor type 2	C-C CKR-2;CC-CKR-2;CCR2;CCR-2;Chemokine receptor CCR2B;MCP-1-R;Monocyte chemoattractant protein 1 receptor	P41597	729230	ENSG00000121807	antagonist
DCL000546	INCB8696	N/A	N/A	N/A	N/A	TTDC00122	C-C chemokine receptor type 2	C-C CKR-2;CC-CKR-2;CCR2;CCR-2;Chemokine receptor CCR2B;MCP-1-R;Monocyte chemoattractant protein 1 receptor	P41597	729230	ENSG00000121807	antagonist
DPR000102	RS-504393	N/A	300816-15-3	N/A	N/A	TTDC00122	C-C chemokine receptor type 2	C-C CKR-2;CC-CKR-2;CCR2;CCR-2;Chemokine receptor CCR2B;MCP-1-R;Monocyte chemoattractant protein 1 receptor	P41597	729230	ENSG00000121807	antagonist
DCL000135	INCB3284	N/A	17617-45-7	442292	49681586	TTDC00122	C-C chemokine receptor type 2	C-C CKR-2;CC-CKR-2;CCR2;CCR-2;Chemokine receptor CCR2B;MCP-1-R;Monocyte chemoattractant protein 1 receptor	P41597	729230	ENSG00000121807	antagonist
DCL000080	CCX915	N/A	N/A	41214	34706879	TTDC00122	C-C chemokine receptor type 2	C-C CKR-2;CC-CKR-2;CCR2;CCR-2;Chemokine receptor CCR2B;MCP-1-R;Monocyte chemoattractant protein 1 receptor	P41597	729230	ENSG00000121807	antagonist
DCL001087	BKM120	N/A	N/A	N/A	N/A	TTDC00140	Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit, gamma isoform	Phosphoinositide 3-Kinase gamma;PI3K;PI3Kgamma;PI3-kinase p110 subunit gamma;PtdIns-3-kinase p110	P48736	5294	ENSG00000105851	inhibitor
DCL000264	XL765	N/A	210101-16-9	151171	47583799	TTDC00140	Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit, gamma isoform	Phosphoinositide 3-Kinase gamma;PI3K;PI3Kgamma;PI3-kinase p110 subunit gamma;PtdIns-3-kinase p110	P48736	5294	ENSG00000105851	inhibitor
DCL000600	LY294002	NCGC00025020-01; CID3973; EC-000.2341; Tocris-1130; 8-Phenyl-2-(morpholin-4-yl)-chromen-4-one; HSCI1_000206; NCGC00179253-01; KBioGR_000563; HMS3229G17; IDI1_002197; HMS1792M05; 2-morpholin-4-yl-8-phenyl-4H-chromen-4-one; Bio2_000442; NSC697286; 2-morpholin-4-yl-8-phenylchromen-4-one; BiomolKI_000029; CHEMBL98350; AC1Q6CLU; 4H-1-Benzopyran-4-one, 2-(4-morpholinyl)-8-phenyl-; NCGC00025020-04; Lopac0_000710; LY-294,002; HMS1990M05; LY2; KBio3_001006; 1yi3; H-1-Benzopyran-4-one, 2-(4-morpholinyl)-8-phenyl- (9CI); LY-294002; LS-39828; NCGC00025020-03; S1105_Selleck; NCGC00025020-02; Lopac-L-9908; KBio2_003131; DB02656; 2-MORPHOLIN-4-YL-7-PHENYL-4H-CHROMEN-4-ONE; Bio1_001310; 154447-36-6; KBio3_001005; IN1266; C15195; BSPBio_001223; 2-(4-Morpholinyl)-8-phenyl-4H-1-benzopyran-4-one; BMK1-D5; LY294002; HMS1362M05; LY 294002; 2-(4-Morpholino)-8-phenyl-4H-1-benzopyran-4-one; Kinome_3543; K00235; Bio1_000332; C085911; KBio2_000563; 4H-1-Benzopyran-4-one, 2-(4-morpholinyl)-8-phenyl; AC1L1H4N; LY 294002; BRD-K27305650-001-05-9; Bio1_000821; Bio2_000922; BiomolKI2_000037; nchembio790-comp36; AR-1J3542; NCGC00015622-01; IN1268; NCGC00015622-07; NCI60_034712; 4H-1-Benzopyran-4-one, 2-(4-morpholinyl)-8-phenyl- (9CI); ZINC00006014; InSolution&trade; LY 294002; BCBcMAP01_000117; CBiol_002046; Lys 294002; KBioSS_000563; KBio2_005699	N/A	100665	44430760	TTDC00140	Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit, gamma isoform	Phosphoinositide 3-Kinase gamma;PI3K;PI3Kgamma;PI3-kinase p110 subunit gamma;PtdIns-3-kinase p110	P48736	5294	ENSG00000105851	inhibitor
DCL000246	TG100-115	EN003068; TG100115, TG100-115; S1352_Selleck; 3,3'-(2,4-diaminopteridine-6,7-diyl)diphenol; CID10427712; TG-100115; CHEMBL230011; C539252; TG-100-115; 3-(2,4-diamino-6-(3-hydroxyphenyl)pteridin-7-yl)phenol; TG100-115; 3-[2,4-diamino-7-(3-hydroxyphenyl)pteridin-6-yl]phenol	N/A	N/A	N/A	TTDC00140	Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit, gamma isoform	Phosphoinositide 3-Kinase gamma;PI3K;PI3Kgamma;PI3-kinase p110 subunit gamma;PtdIns-3-kinase p110	P48736	5294	ENSG00000105851	inhibitor
DCL000601	PI3K alpha	N/A	N/A	N/A	N/A	TTDC00140	Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit, gamma isoform	Phosphoinositide 3-Kinase gamma;PI3K;PI3Kgamma;PI3-kinase p110 subunit gamma;PtdIns-3-kinase p110	P48736	5294	ENSG00000105851	inhibitor
DCL000476	AZD6482	N/A	N/A	N/A	N/A	TTDC00140	Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit, gamma isoform	Phosphoinositide 3-Kinase gamma;PI3K;PI3Kgamma;PI3-kinase p110 subunit gamma;PtdIns-3-kinase p110	P48736	5294	ENSG00000105851	inhibitor
DCL001090	PX-866	CHEMBL411907; CID9849735; PX-866; DJM-2-166; NSC-722134; DJM-166	N/A	N/A	N/A	TTDC00140	Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit, gamma isoform	Phosphoinositide 3-Kinase gamma;PI3K;PI3Kgamma;PI3-kinase p110 subunit gamma;PtdIns-3-kinase p110	P48736	5294	ENSG00000105851	inhibitor
DCL001086	BGT226	N/A	N/A	N/A	N/A	TTDC00140	Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit, gamma isoform	Phosphoinositide 3-Kinase gamma;PI3K;PI3Kgamma;PI3-kinase p110 subunit gamma;PtdIns-3-kinase p110	P48736	5294	ENSG00000105851	inhibitor
DCL001089	GSK1059615	N/A	N/A	N/A	N/A	TTDC00140	Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit, gamma isoform	Phosphoinositide 3-Kinase gamma;PI3K;PI3Kgamma;PI3-kinase p110 subunit gamma;PtdIns-3-kinase p110	P48736	5294	ENSG00000105851	inhibitor
DCL001085	BEZ235	BEZ235; NVP-BEZ235, BEZ235; CID11977753; EC-000.2325; BEZ-235; 2-(4-(2,3-dihydro-3-methyl-2-oxo-8-(quinolin-3-yl)imidazo[4,5-c]quinolin-1-yl)phenyl)-2-methylpropanenitrile; Kinome_2911; ZINC24760115; S14-0511; CID 11977753; NVP-BEZ-235; S1009_Selleck; nchembio.117-comp24; ST51056474; MolPort-005-737-784	N/A	N/A	N/A	TTDC00140	Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit, gamma isoform	Phosphoinositide 3-Kinase gamma;PI3K;PI3Kgamma;PI3-kinase p110 subunit gamma;PtdIns-3-kinase p110	P48736	5294	ENSG00000105851	inhibitor
DCL001091	CAL-101	N/A	N/A	N/A	N/A	TTDC00140	Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit, gamma isoform	Phosphoinositide 3-Kinase gamma;PI3K;PI3Kgamma;PI3-kinase p110 subunit gamma;PtdIns-3-kinase p110	P48736	5294	ENSG00000105851	inhibitor
DCL000228	SF1126	936487-67-1; CC-1126; SF1126; L-Serine, N2-(1,4-dioxo-4-((4-(4-oxo-8-phenyl-4H-1-benzopyran-2-yl)morpholinium-4-yl)methoxy)butyl)-L-arginylglycyl-L-alpha-aspartyl-, inner salt; SF-1126	145158-71-0	5362436	49681580	TTDC00140	Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit, gamma isoform	Phosphoinositide 3-Kinase gamma;PI3K;PI3Kgamma;PI3-kinase p110 subunit gamma;PtdIns-3-kinase p110	P48736	5294	ENSG00000105851	inhibitor
DCL001189	GDC-0980	N/A	N/A	N/A	N/A	TTDC00140	Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit, gamma isoform	Phosphoinositide 3-Kinase gamma;PI3K;PI3Kgamma;PI3-kinase p110 subunit gamma;PtdIns-3-kinase p110	P48736	5294	ENSG00000105851	inhibitor
DCL001088	GDC0941	GD9; 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine; EC-000.2335; 4-(2-(1H-Indazol-4-yl)-6-((4-(methylsulfonyl)piperazin-1-yl)methyl)thieno[3,2-d]pyrimidin-4-yl)morpholine; GDC-0941, GDC0941; GDC-0941; nchembio.293-comp12; C53216200; Kinome_3719; GDC 0941; GDC0941; CHEMBL521851; S1065_Selleck	N/A	N/A	N/A	TTDC00140	Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit, gamma isoform	Phosphoinositide 3-Kinase gamma;PI3K;PI3Kgamma;PI3-kinase p110 subunit gamma;PtdIns-3-kinase p110	P48736	5294	ENSG00000105851	inhibitor
DCL000262	XL147	AC1Q2LO8; Oprea1_361507; ZINC02267166; S1118_Selleck; CID1893730; EC-000.2364; SAR245408, XL-147, XL147; N-[3-(2,1,3-benzothiadiazol-5-ylamino)quinoxalin-2-yl]-4-methylbenzenesulfonamide; N-[3-(2; STOCK1S-43211; XL147; MolPort-001-844-503; AC1LZ6F0	N/A	N/A	N/A	TTDC00140	Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit, gamma isoform	Phosphoinositide 3-Kinase gamma;PI3K;PI3Kgamma;PI3-kinase p110 subunit gamma;PtdIns-3-kinase p110	P48736	5294	ENSG00000105851	inhibitor
DCL000526	Esreboxetine	Reboxetine [INN]; AC1L2442; 98819-76-2; NCGC00025335-01; (S,S)-( )-Reboxetine; Prolift; 2-((2-ethoxyphenoxy)benzyl)morpholine methanesulfonate; Reboxetine; DB00234; Esreboxetine; Davedax; (2S)-2-[(S)-(2-ethoxyphenoxy)-phenylmethyl]morpholine; Solvex; (+-)-(2R*)-2-((alphaR*)-alpha-(o-Ethoxyphenoxy)benzyl)morpholine; (S,S)-reboxetine; Esreboxetine (USAN/INN); D09340; CID65856; LS-178388; Tocris-1982; Reboxetine mesylate; Norebox; MolPort-005-942-846; Vestra; CHEBI:114263	N/A	4553	45642362	TTDC00304	Sodium-dependent noradrenaline transporter	NET;Norepinephrine transporter	P23975	6530	ENSG00000103546	blocker
DAP001547	Milnacipran HCl	N/A	N/A	N/A	N/A	TTDC00304	Sodium-dependent noradrenaline transporter	NET;Norepinephrine transporter	P23975	6530	ENSG00000103546	inhibitor
DPR000146	LY367265	MolPort-003-947-263; Lopac0_000648; NCGC00015600-04; LY-367,265; CHEBI:713416; NCGC00015600-02; AC1NDRET; MLS002172448; Lopac-L-2411; L 2411; CID4605800; L020228; EU-0100648; SMR001254083; CHEMBL1079460; NCGC00015600-01; NCGC00094014-01; NCGC00094014-02; L2411_SIGMA; 1-[2-[4-(6-fluoro-1H-indol-3-yl)-3,6-dihydro-1(2H)-pyridinyl]ethyl]-5,6-dihydro-1H,4H-[1,2,5]thiadiazolo[4.3.2-ij]quinoline-2,2-dioxide	N/A	N/A	N/A	TTDC00304	Sodium-dependent noradrenaline transporter	NET;Norepinephrine transporter	P23975	6530	ENSG00000103546	inhibitor
DCL000896	NERI IV	N/A	162401-32-3	449193	47207405	TTDC00304	Sodium-dependent noradrenaline transporter	NET;Norepinephrine transporter	P23975	6530	ENSG00000103546	blocker
DAP001304	Inulin	EINECS 232-684-3; 887747-94-6; AI3-19506; 189444-25-5; DB00638; Inulin from Jerusalem artichokes; Inulin USP 27; Inulin [BAN]; (2R,3R,4S,5S,6R)-2-[(2S,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethy; INULIN; LS-187349; Inulin and sodium chloride; CID24763; AC1L2NNM; LS-186416	9005-80-5	24763	6172	TTDS00511	Cycloinulo-oligosaccharide fructanotransferase	cft	Q9F0I5	N/A	N/A	binder
DCL000190	ONO-4819	ONO-4819CD; ONO-AE1-734; CHEMBL303960; ONO-4819; 256382-08-8; CHEBI:197869; CID9803828; AE1-734; ONO-4819.CD; Rivenprost	N/A	9803828	49684223	TTDC00151	Prostaglandin E2 receptor, EP4 subtype	EP sub 4 receptor;PGE receptor, EP4 subtype;Prostanoid EP4 receptor	P35408	5734	ENSG00000171522	agonist
DCL000734	Buproprion+zonisamide	N/A	31677-93-7	N/A	N/A	TTDS00504	Organic anion transporter 1	hOAT1;hPAHT;hROAT1;OAT1;PAH transporter;PAHT;Renal organic anion transporter 1;SLC22A6;Solute carrier family 22 member 6	Q4U2R8	9356	ENSG00000197901	blocker
DAP001292	Probenecid	Benemid; Biokanol Brand of Probenecid; SPBio_002504; P8761_SIGMA; Benuryl; Prestwick2_000542; AC1L1J86; BRD-K95237249-001-05-9; MLS001076472; C13H19NO4S; Spectrum2_001294; WLN: QVR DSWN3&3; DivK1c_000056; Probenemid; Spectrum5_001419; 4-[(dipropylamino)sulfonyl]benzoic acid; Valdecasas Brand of Probenecid; SAM002554923; Probecid; NCGC00023829-03; MolPort-000-145-935; Probenecid acid; Col-BENEMID; ColBenemid (component of); CPD000058280; Synergid R; Probenecid Major Brand; probenecid; Martec Brand of Probenecid; Proben; CHEBI:177474; Probenecide; Probenecid (JP15/USP/INN); CHEMBL897; Ophthalmic Brand of Probenecid; AC-2023; Tubophan; Probenecid Martec Brand; Spectrum_000834; NINDS_000056; Pro-Cid; KBioGR_000971; 57-66-9; NCGC00016251-01; NCGC00023829-04; NCGC00023829-05; 4-(Dipropylsulfamoyl)benzoic acid; HMS1920J22; BSPBio_002227; LS-33; AB00052080; Probenecid Weimer; KBio2_003882; SPBio_001327; AI3-50078; MLS000028496; p-(Dipropylsulfamoyl)benzoic acid; ICN Brand of Probenecid; Probenecid [INN:BAN:JAN]; AC1Q2XQM; Spectrum4_000486; Prestwick_809; p-[Dipropylsulfamoyl]benzoic acid; Probenecid Parmed Brand; NCGC00023829-06; 4-(N,N-Dipropylsulfamoyl)benzoesaeure; KBio3_001727; CAS-57-66-9; HMS1569N05; Probenecidum; Panuric; 4-((Dipropylamino)sulfonyl)benzoic acid; Polycillin-BRB; Parabenem; ColBenemid (co mponent of); I01-1905; Benemid (TN); Bencid; Probenecida; AC1Q2XQN; Spectrum3_000554; KBioSS_001314; D00475; Uricosid; probenicid; Probenecida [INN-Spanish]; Prestwick0_000542; DB01032; HMS500C18; Probenecidum [INN-Latin]; NSC18786; Probenecid Zenith Brand; KBio2_001314; C07372; SPECTRUM1500502; 4-(Di-n-propylsulfamoyl)benzoesaeure; IDIS Brand of Probenecid; Robenecid; Parmed Brand of Probenecid; Sulprin; p-(Dipropylsulfamyl)benzoic acid; Prestwick3_000542; Probexin; BRN 2815775; EINECS 200-344-3; NCI-C56097; KBio1_000056; Oprea1_416955; Merck Brand of Probenecid; IDI1_000056; Prolongine; CID4911; Benemide; NCGC00016251-02; UNII-PO572Z7917; Apurina; Prestwick1_000542; Polycillin-PRB (component of); BIDD:GT0626; Urocid; BSPBio_000583; Benzoic acid, p-(dipropylsulfamoyl)-; SBB028597; Probalan; BPBio1_000643; Probampacin; Probenid; SMR000058280; KBio2_006450; NSC 18786; AKOS000165123; Probenecide [INN-French]; Benzoic acid, 4-((dipropylamino)sulfonyl)-; BIDD:PXR0092; CCRIS 3643; Benzoic acid, 4-[(dipropylamino)sulfonyl]-; HMS2092C03; Major Brand of Probenecid; D011339; HSDB 3387; Benecid; Zenith Brand of Probenecid	57-66-9	4911	9576	TTDS00504	Organic anion transporter 1	hOAT1;hPAHT;hROAT1;OAT1;PAH transporter;PAHT;Renal organic anion transporter 1;SLC22A6;Solute carrier family 22 member 6	Q4U2R8	9356	ENSG00000197901	blocker
DAP000873	Ursodeoxycholic acid	Acido ursodeossicolico; U-9000; MolPort-005-932-884; 7beta-Hydroxylithocholic acid; MLS001066373; UDCS; Antigall; 3 alpha,7 beta-Dihydroxy-5 beta-cholan-24-oic Acid; Ursodiol [USAN]; 5-beta-Cholan-24-oic acid, 3-alpha,7-beta-dihydroxy-; ursodeoxycholate; Ursodeoxycholic acid (JP15/INN); Ursodiol (USP); Cholan-24-oic acid, 3,7-dihydroxy-, (3-alpha,5-beta,7-beta)- (9CI); URSODEOXYCHOLIC ACID; Lyeton; C07880; Acide ursodesoxycholique [INN-French]; NCI60_028904; CHEMBL73390; LS-53033; (3alpha,5beta,7beta)-3,7-dihydroxycholan-24-oic acid; 3alpha,7beta-Dihydroxy-5beta-cholan-24-oic acid; Cholit-ursan; Urso (TN); U0030; (4R)-4-[(3R,5S,7S,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid; ursodiol; chenodeoxycholic acid; BRN 3219888; 3-alpha,7-beta-Dioxycholanic acid; CHEBI:9907; Ursacol; Cholan-24-oic acid, 3,7-dihydroxy-, (3alpha,5beta,7beta)-; HMS1570P18; Solutrat; 3,7-Dihydroxycholan-24-oic acid; AB00513977; UrSO; Ursochol; Ursofalk; Urso 250; CID31401; Actigall; Ursobilin; Prestwick3_000958; 7-beta-Hydroxylithocholic acid; BB_NC-2372; 3alpha,7beta-Dihydroxy-5beta-cholanic acid; S1643_Selleck; NSC 657950; 3-alpha,7-beta-Dihydroxy-5-beta-cholanoic acid; 128-13-2; UDCA; EINECS 204-879-3; Dom-ursodiol c; UNII-724L30Y2QR; Urosiol; MolPort-001-794-630; CPD000058403; D00734; SMP2_000012; Ursolvan; 17-beta-(1-Methyl-3-carboxypropyl)etiocholane-3-alpha,7-beta-diol; AC-18919; Ursodamor; Delursan; SMR000058403; SPBio_003105; Urso Forte; ISO-URSODEOXYCHOLIC ACID; 80225-86-1; CPD-10534; Ursocholic acid, deoxy-; Ursosan; MLS000028461; Prestwick0_000958; Acido ursodeoxicolico; NSC 683769; 5beta-Cholan-24-oic acid-3alpha,7beta-diol; BSPBio_000956; C24H40O4; PMS-ursodiol c; Sodium Ursodeoxycholate; Cholan-24-oic acid, 3,7-dihydroxy-, (3-alpha,5-beta,7-beta)-; Acide ursodesoxycholique; CID11516715; Arsacol; PHL-ursodiol c; 4-10-00-01604 (Beilstein Handbook Reference); Acidum ursodeoxycholicum; Destolit; Acido ursodeoxicolico [INN-Spanish]; DB01586; Litursol; AC-2081; Ursacholic Acid; Actigall (TN); LMST04010033; Deoxyursocholic Acid; Urso DS; NCGC00179363-01; U5127_SIGMA; BPBio1_001052; Ursodesoxycholic acid; Acido ursodeossicolico [Italian]; CHEMBL1551; Prestwick2_000958; Deursil; Prestwick1_000958; Peptarom; Acidum ursodeoxycholicum [INN-Latin]; 5beta-Cholanic Acid-3alpha,7beta-diol; Ursodeoxy cholic acid; (3alpha,5beta,7beta,8xi)-3,7-dihydroxycholan-24-oic acid; 50809-41-1; Ursodexycholic Acid; SAM002264653; CCRIS 5502; IU5; AC1L1LJH; 3-alpha,7-beta-Dihydroxycholanic acid; Ursodeoxycholic acid, UDCA, Ursosan, Ursofalk, Urso Forte, Udiliv, Ursodiol	128-13-2	31401	7847799	TTDS00494	Biliverdin reductase A	Biliverdin-IX alpha-reductase;BLVR;BLVRA;BVR;BVR A	P53004	644	ENSG00000106605	activator
DCL000115	FK-228	Probes2_000337; CID5352062; HDInhib_000006; CHEMBL343448; L-Valine, N-(3-hydroxy-7-mercapto-1-oxo-4-heptenyl)-D-valyl-D-cysteinyl-(Z)-2,3-didehydro-2-aminobutanoyl-, xi-lactone, cyclic (1-2)-disulfide, (S-(E))-; Chromadax (TN); Istodax; CHEBI:61080; Cyclo((2Z)-2-amino-2-butenoyl-L-valyl-(3S,4E)-3-hydroxy-7-mercapto-4-heptenoyl-D-valyl-D-cysteinyl), cyclic (3?5)-disulfide"; AC1NS1N3; FR901228; NSC630176; NSC 630176; C087123; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone; Probes1_000153; FR-901228; FK 228; Chromadax; nchembio.313-comp2; D06637; (1S,4S,7Z,10S,16E,21R)-7-Ethylidene-4,21-bis(1-methylethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo(8.7.6)tricos-16-ene-3,6,9,19,22-pentone; FK-901228; LS-161318; Romidepsin (USAN); FK228; Antibiotic FR 901228; C24H36N4O6S2; L-Valine, N-((3S,4E)-3-hydroxy-7-mercapto-1-oxo-4-heptenyl)-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoxyl-, (4-1)-lactone, cyclic (1-2)-disulfide; Romidepsin; NSC-630176; 128517-07-7; FK-228; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone; FR 901228	128517-07-7	5352062	12014448	TTDC00159	Histone deacetylase 4	HDAC4	P56524	9759	ENSG00000068024	inhibitor
DCL000451	AZD0837	N/A	189357-33-3	451416	14910769	TTDS00202	Thrombin	Coagulation factor II;Prothrombin	P00734	2147	ENSG00000180210	inhibitor
DAP000758	Argatroban	(2R,4R)-4-Methyl-1-((S)-N(sup 2)-(((RS)-1,2,3,4-tetrahydro-3-methyl-8-quinolyl)sulfonyl)arginyl)pipecolic acid; MD-805; CID152951; Argatrobanum [Latin]; 121785-71-5; KST-1A8419; (2R,4R)-1-[(2S)-5-(diaminomethylideneamino)-2-[(3-methyl-1,2,3,4-tetrahydroquinolin-8-yl)sulfonylamino]pentanoyl]-4-methylpiperidine-2-carboxylic acid; MITSUBISHI INHIBITOR; Acova; LS-114621; Argatrobanum; MCI-9038; CPD000466348; Argatroban [INN:JAN]; CHEBI:288815; AC-15185; TL8005144; 82784-65-4; HMS2090L12; MLS001424093; CID445156; 21R-Argatroban; AC1L49F4; MPQA; 2-Piperidinecarboxylic acid, 1-((2S)-5-((aminoiminomethyl)amino)-1-oxo-2-(((1,2,3,4-tetrahydro-3-methyl-8-quinolinyl)sulfonyl)amino)pentyl)-4-methyl-, (2R,4R)-; 4-methyl-1-(N(2)-(3-methyl-1,2,3,4-tetrahydro-8-quinolinesulfonyl)-L-arginyl)-2-piperidinecarboxylic acid; AC1Q5QXC; MCI 9038; AR-1A3021; 74863-84-6; (2R,4R)-1-[(2S)-5-(diaminomethylideneamino)-2-[[(3R)-3-methyl-1,2,3,4-tetrahydroquinolin-8-yl]sulfonylamino]pentanoyl]-4-methylpiperidine-2-carboxylic acid; MMTQAP; AC1L3OPA; LS-114640; MD 805; UNII-OCY3U280Y3; MolPort-003-987-205; CID440542; (2r,4r)-4-methyl-1-[n2-(3-methyl-1,2,3,4-tetrahydro-8-quinolinesulfonyl)-l-arginyl]-2-piperidinecarboxylic acid; NCGC00164592-01; GN-1600; 1dwc; MQI-ARG-MCP; Novastan; SMR000466348; 2-Piperidinecarboxylic acid, 1-(5-((aminoiminomethyl)amino)-1-oxo-2-(((1,2,3,4-tetrahydro-3-methyl-8-quinolinyl)sulfonyl)amino)pentyl)-4-methyl-, (2R-(1(S*(R*)),2alpha,4beta))-; CHEMBL59461; CHEMBL1166; 2-Piperidinecarboxylic acid, 1-(5-((aminoiminomethyl)amino)-1-oxo-2-(((1,2,3,4-tetrahydro-3-methyl-8-quinolinyl)sulfonyl)amino)pentyl)-4-methyl-; MD805; (2R,4R)-1-[5-(diaminomethylideneamino)-2-[(3-methyl-1,2,3,4-tetrahydroquinolin-8-yl)sulfonylamino]pentanoyl]-4-methylpiperidine-2-carboxylic acid; C23H36N6O5S; HMS2051N07; BIDD:GT0748; Argatroban (anhydrous); CHEBI:194249; argatroban; (2R,4R)-1-[(2S)-5-(diaminomethylideneamino)-2-[[(3S)-3-methyl-1,2,3,4-tetrahydroquinolin-8-yl]sulfonylamino]pentanoyl]-4-methylpiperidine-2-carboxylic acid; C04931; MLS000759461; SAM001246661; AC1L99H9; NCGC00166413-01; CID92722; AC1L9HII; DB00278; (2R,4R)-4-Methyl-1[Nalpha-[(3-methyl-1,2,3,4-tetrahydro-8-quinolinyl)sulfonyl]-L-arginyl)]-2-piperadinecarboxylic acid	74863-84-6	152951	730451	TTDS00202	Thrombin	Coagulation factor II;Prothrombin	P00734	2147	ENSG00000180210	inhibitor
DAP000541	Lepirudin	Aventis Brand Lepirudin; LS-187612; 1-Leu-2-thr-63-desulfohirudin; Hirudin (Hirudo medicinalis isoform HV1), 1-L-leucine-2-L-threonine-63-desulfo-; C083544; Lepirudin recombinant; LS-186968; Aventis Pharma Brand of Lepirudin; Aventis Behring Brand of Lepirudin; Hbw 023; 1-L-Leucine-2-L-threonine-63-desulfohirudin (Hirudo medicinalis isoform HV1); Lepirudin; Refludin; Refludan; Pharmion Brand of Lepirudin; Berlex Brand of Lepirudin; Schering Brand of Lepirudin; 138068-37-8; UNII-Y43GF64R34; Hoechst Brand of Lepirudin; Hbw-023	120993-53-5	16132441	14818038	TTDS00202	Thrombin	Coagulation factor II;Prothrombin	P00734	2147	ENSG00000180210	inhibitor
DAP001218	Ximelagatran	H 376/95; Glycine, N-((1R)-1-cyclohexyl-2-((2S)-2-((((4-((hydroxyamino)iminomethyl)phenyl)methyl)amino)carbonyl)-1-azetidinyl)-2-oxoethyl)-, ester ester; Ethyl (((1R)-1-cyclohexyl-2-((2S)-2-((4-(hydroxycarbamimidoyl)benzyl)carbamoyl)azetidin-1-yl-2-oxoethyl)amino)acetate; LS-72418; xi-melagatran; Glycine, N-((1R)-1-cyclohexyl-2-((2S)-2-((((4-(hydroxyamino)iminomethyl)phenyl)methyl)amino)carbonyl)-1-azetidinyl)-2-oxoethyl)-, ethyl ester; glycine, N-((1R)1-cyclohexyl-2-((2S)-((((4-(amino(hydroxyimino)methyl)phenyl)methyl)amino)carbonyl)-1-azetidinyl)2-oxoethyl)-ethyl ester; Ximelagatran; C426686; CID9574101; MolPort-003-850-871; Exanta (TN); Exanta; H 37695; Exarta; Ximelagatran [USAN:INN]; Ximelagatran (JAN/USAN/INN); UNII-49HFB70472; H 376 95; DB04898; H 376-95; H-376/95; Glycine, N-((1)1-cyclohexyl-2-((2)-((((4-(amino(hydroxyimino)methyl)phenyl)methyl)amino)carbonyl)-1-azetidinyl)2-oxoethyl)-, ethyl ester; Glycine, N-((1)1-cyclohexyl-2-((2)-((((4-(amino(hydroxyimino)methyl)phenyl)methyl)amino)carbonyl)-1-azetidinyl)2-oxoethyl)-ethyl ester; D01981; 192939-46-1	192939-46-1	9574101	12015148	TTDS00202	Thrombin	Coagulation factor II;Prothrombin	P00734	2147	ENSG00000180210	inhibitor
DAP000542	Bivalirudin	Phe-Pro-Arg-Pro-(Gly)4-Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu; UNII-TN9BEX005G; DB02351; BG 8967; Hirulog; Phe-Pro-Arg-Pro-(Gly)4 desulfato-Tyr63'-hirugen; Phe-Pro-Arg-Pro-(Gly)4-desulfohirudin-(53-64); The Medicines Company brand of bivalirudin; CHEBI:59173; BG-8967; Bivalirudin [USAN:BAN:INN]; HS-2004; D-Phenylalanyl-L-prolyl-L-arginyl-L-prolylglycylglycylglycylglycyl-L-asparaginylglycyl-L-alpha-aspartyl-L-phenylalanyl-L-alpha-glutamyl-L-alpha-glutamyl-L-isoleucyl-L-prolyl-L-alpha-glutamyl-L-alpha-glutamyl-L-tyrosyl-L-leucine; BG8967; Hirulog-1; Bivalirudin; bivalirudine; Angiomax; 128270-60-0; LS-172701; L-Leucine, D-phenylalanyl-L-prolyl-L-arginyl-L-prolylglycylglycylglycylglycyl-L-asparaginylglycyl-L-alpha-aspartyl-L-phenylalanyl-L-alpha-glutamyl-L-alpha-glutamyl-L-isoleucyl-L-prolyl-L-alpha-glutamyl-L-alpha-glutamyl-L-tyrosyl-; C9H11NO.C2H6.CH4; C074619; (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-4-amino-2-[[2-[[2-[[2-[[2-[[(2S)-1-[(2S)-2-[[(2S)-1-[(2R)-2-amino-3-cyclohexylpropanoyl]pyrrolidine-2-carbonyl]amino]-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]acetyl]amino]acetyl]amino]acetyl]amino]-4-oxobutanoyl]amino]acetyl]amino]-4-hydroxy-4-oxobutanoyl]amino]-3-cyclohexylpropanoyl]amino]-5-hydroxy-5-oxopentanoyl]amino]-5-hydroxy-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbonyl]amino]-5-hydroxy-5-oxopentanoyl]amino]-5-hydroxy-5-oxopentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoic acid; bivalirudina; bivalirudinum	128270-60-0	16129704	214065	TTDS00202	Thrombin	Coagulation factor II;Prothrombin	P00734	2147	ENSG00000180210	inhibitor
DCL000019	Dermolastin	N/A	N/A	N/A	N/A	TTDS00202	Thrombin	Coagulation factor II;Prothrombin	P00734	2147	ENSG00000180210	inhibitor
DCL000233	SR-123781A	N/A	232602-93-6	N/A	N/A	TTDS00202	Thrombin	Coagulation factor II;Prothrombin	P00734	2147	ENSG00000180210	inhibitor
DAP001537	Ximelegatran	N/A	192939-46-1	448042	48259041	TTDS00202	Thrombin	Coagulation factor II;Prothrombin	P00734	2147	ENSG00000180210	inhibitor
DAP001555	Dabigatran	N/A	N/A	N/A	N/A	TTDS00202	Thrombin	Coagulation factor II;Prothrombin	P00734	2147	ENSG00000180210	inhibitor
DCL000033	Aerovant	N/A	N/A	N/A	N/A	TTDC00081	Interleukin-4 receptor alpha chain	CD124 antigen;IL-4R;IL-4R-alpha	P24394	3566	ENSG00000077238	antagonist
DCL000424	AMG 317	N/A	N/A	N/A	N/A	TTDC00081	Interleukin-4 receptor alpha chain	CD124 antigen;IL-4R;IL-4R-alpha	P24394	3566	ENSG00000077238	antagonist
DCL000199	PRX-321	N/A	N/A	N/A	N/A	TTDC00081	Interleukin-4 receptor alpha chain	CD124 antigen;IL-4R;IL-4R-alpha	P24394	3566	ENSG00000077238	agonist
DAP001132	Succinylcholine	trimethyl-[2-[4-oxo-4-[2-(trimethylazaniumyl)ethoxy]butanoyl]oxyethyl]azanium; DB00202; 306-40-1; Lysthenon; 2ha6; CHEBI:45652; Choline, succinate (ester); CHEMBL703; AC1L1K2T; trimethyl-[2-[4-oxo-4-(2-trimethylazaniumylethoxy)butanoyl]oxyethyl]azanium diio; Ethanaminium, 2,2'-((1,4-dioxo-1,4-butanediyl)bis(oxy))bis(N,N,N-trimethyl-; C07546; Suxamethonium; ST50437287; Choline, succinyl-; HMS2090P14; Dicholine succinate; NCGC00162336-01; Quelicin; Ditilin; 4-04-00-01451 (Beilstein Handbook Reference); Ethanaminium, 2,2'-((1,4-dioxo-1,4-butanediyl)bis(oxy))bis(N,N,N-trimethyl)-; C14H30N2O4; Succinic acid, diester with choline; 2,2'-[(1,4-DIOXOBUTANE-1,4-DIYL)BIS(OXY)]BIS(N,N,N-TRIMETHYLETHANAMINIUM); Succinic acid, diester with choline chloride; STK177290; Lopac-S-8251; LS-53328; L000926; succinylcholine; 55-94-7 (dibromide); Diacetylcholine; Ditiline; Succinylbischoline; Succinyldicholine; UNII-J2R869A8YF; Lopac0_001080; InChI=1/C14H30N2O4/c1-15(2,3)9-11-19-13(17)7-8-14(18)20-12-10-16(4,5)6/h7-12H2,1-6H3/q+2; Succinocholine; CID5314; Succinyl choline; HSDB 3254; MolPort-002-964-486; NCGC00015971-01; ZINC01530820; AXOIZCJOOAYSMI-UHFFFAOYSA-; Succinoylcholine; BRN 1805311; 71-27-2 (dichloride); Anectine; Sucostrin; SCK; 2ha2; 541-19-5 (diiodide); Succicuran; Choline, succinate (2:1) (ester); Listenon; NCGC00015971-03	306-40-1	5314	9749	TTDS00004	Muscarinic acetylcholine receptor M3	M3 receptor	P20309	1131	ENSG00000133019	antagonist
DAP000376	Tolterodine	MolPort-002-885-868; CID443879; 2-{(1R)-3-[bis(1-methylethyl)amino]-1-phenylpropyl}-4-methylphenol; MLS001304745; CHEBI:9622; Jsp001637; AC1L9FDR; Tolterodina; FT-0082998; SMR000596518; AC-3472; NCGC00159519-02; 2-[3-[Bis(1-methylethyl)amino]-1-phenylpropyl]-4-methylphenol; tolterodine; Kabi-2234; 2-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-methylphenol; FT-0082150; Tolterodinum; MLS001195620; MolPort-005-934-224; BIDD:GT0318; CHEMBL1382; 124937-51-5; LS-187278; 2-[(1R)-3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-methylphenol	124937-51-5	60774	197020	TTDS00004	Muscarinic acetylcholine receptor M3	M3 receptor	P20309	1131	ENSG00000133019	antagonist
DAP001128	Oxybutynin	HSDB 3270; Oxybutynin (USAN/INN); S1754_Selleck; oxybutynin; CID4634; I06-2117; Cystrin; Prestwick0_000287; 4-(Diethylamino)-2-butynyl alpha-phenylcyclohexaneglycolic acid ester; 1508-65-2 (hydrochloride); Oxybutyninum [INN-Latin]; Lopac0_000923; SPBio_002413; LS-28714; Oxybutynin Base; CHEMBL1231; Prestwick3_000287; L000923; transdermal patch; 4-(diethylamino)but-2-ynyl 2-cyclohexyl-2-hydroxy-2-phenylacetate; Ditropan; 5633-20-5; Oxytrol; FT-0082890; Oxibutinina [INN-Spanish]; BPBio1_000214; 4-Diethylamino-2-butinyl alpha-cyclohexylmandelat; NCGC00015767-06; Benzeneacetic acid, alpha-cyclohexyl-alpha-hydroxy-, 4-(diethylamino)-2-butynyl ester; Oxybutinin; Oxybutyninum; Oxybutynine [INN-French]; C07360; 4-(diethylamino)but-2-yn-1-yl cyclohexyl(hydroxy)phenylacetate; UNII-K9P6MC7092; 4-(diethylamino)-2-butynyl-alpha-cyclohexyl-alpha-hydroxybenzeneacetate; Oxibutinina; DB01062; Cyclohexaneglycolic acid, alpha-phenyl-, 4-(diethylamino)-2-butynyl ester; Prestwick1_000287; AC1L1ILV; oxybutynin topical gel; Cyclohexaneglycolic acid, .alpha.-phenyl-, 4-(diethylamino)-2-butynyl ester; D00465; Prestwick2_000287; 4-(diethylamino)-2-butynyl-alpha-phenylcyclohexaneglycolate; Ditropan, Lyrinel XL, Oxytrol, Oxybutynin; 4-Diethylamino-2-butynyl alpha-phenylcyclohexaneglycolate; CCRIS 1923; Oxybutynine; Oxibutyninum; CHEBI:7856; NCGC00089795-02; MolPort-003-849-741; AC-2153; Oxybutynin [USAN:INN:BAN]; Oxytrol (TN); Pollakisu; BRD-A65013509-003-03-8; BSPBio_000194	5633-20-5	4634	164556	TTDS00004	Muscarinic acetylcholine receptor M3	M3 receptor	P20309	1131	ENSG00000133019	antagonist
DAP001129	Solifenacin	Quinuclidin-3'-yl-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylatemonosuccinate; Vesikur; CHEMBL1734; 1-azabicyclo[2.2.2]octan-3-yl (1S)-1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylate; 242478-37-1; 242478-38-2; [(3R)-1-azabicyclo[2.2.2]octan-3-yl] (1S)-1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylate; butanedioic acid; CID216457; UNII-A8910SQJ1U; YM-905; AC1L9FFR; MolPort-003-850-268; LS-183550; Solifenacin succinate; DB01591; NCGC00168778-01; Butanedioic acid, cmpd. with (1S)-(3R)-1-azabicyclo(2.2.2)oct-3-yl 3,4-dihydro-1-phenyl-2(1H)-isoquinolinecarboxylate (1:1); CID154059; AR-1L5425; YM 905; 1-azabicyclo[2.2.2]oct-8-yl (1S)-1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylate; AC1L50Q6; Solifenacin (INN); CID443938; AC1L4BM3; Butanedioic acid, compd with (1S)-(3R)-1-azabicyclo(2.2.2)oct-3-yl 3,4-dihydro-1-phenyl-2(1H)-isoquinolinecarboxylate (1:1); 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-1-phenyl-,1-azabicyclo(2.2.2)oct-3-yl ester, (R-(R*,S*))-; Solifenacin [INN:BAN]; Solifenacin; 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-1-phenyl-, (3R)-1-azabicyclo(2.2.2)oct-3-yl ester, (1S)-, butanedioate (1:1); YM-67905; YM-53705; Vesicare; D08522; AC1Q5VRD; [(3R)-1-azabicyclo[2.2.2]octan-3-yl] (1S)-1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylate; UNII-KKA5DLD701; Solifenacin succinate [USAN]; CHEMBL1200803	242478-37-1	216457	12015109	TTDS00004	Muscarinic acetylcholine receptor M3	M3 receptor	P20309	1131	ENSG00000133019	antagonist
DCL000957	Revatropate	[(3R)-1-azabicyclo[2.2.2]octan-3-yl] (2R)-2-(hydroxymethyl)-4-methylsulfinyl-2-phenylbutanoate; CID3035836; CID6918246; UK-112166; CID9690123; UNII-3W7L15V40W; AC1OCF7F; CID9554797; AC1MI026; UK-112,166; [(3R)-1-azabicyclo[2.2.2]octan-3-yl] (2S)-2-(hydroxymethyl)-4-methylsulfinyl-2-phenylbutanoate; Revatropate; Benzenacetic acid, alpha-(hydroxymethyl)-alpha-(2-(methylsulfinyl)ethyl)-, 1-azabicyclo(2.2.2)oct-3-yl ester, (3R-(3R*(S*(R*))))-; (3R-(3R*(S*(R*))))-1-Azabicyclo(2.2.2)oct-3-yl alpha-(hydroxymethyl)-alpha-(2-(methylsulfinyl)ethyl)benzenacetate; UK-112166-04; 149926-91-0	149926-91-0	9690123	12014788	TTDS00004	Muscarinic acetylcholine receptor M3	M3 receptor	P20309	1131	ENSG00000133019	antagonist
DAP000075	Cevimeline	NCGC00181793-01; LS-145782; Spiro(1-azabicyclo(2.2.2)octane-3,5'-(1,3)-oxathiolane), 2'-methyl-, (2'R,3R)-rel-; Saligren (TN); (2R,5R)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane]; HSDB 7286; Cevimeline hydrochloride hemihydrate; LS-172037; Cevimeline.HCl; AF 102B; (2R,2'R)-2'-methylspiro[4-azabicyclo[2.2.2]octane-2,5'-[1,3]oxathiolane] dihydrochloride hydrate; CID83927; Spiro(1-azabicyclo(2.2.2)octane-3,5'-(1,3)-oxathiolane), 2'-methyl-, cis-; 2-Methyspiro(1,3-oxathiolane-5,3)quinuclidine; Cevimeline hydrochloride (USAN); SNI-2011; 153504-70-2; FKS-508; Cevimeline hydrochloride hydrate (JAN); SND 5008, AF-102B, FKS-508; AC1NR4MS; Fks 508; cevimeline hydrochloride hydrate; cis-2-Methylspiro(1,3-oxathiolane-5,3')quinuclidine hydrochloride hydrate (2:2:1); Saligren; Cevimeline (INN); AC1L36GD; Cevimeline hydrochloride [USAN]; UNII-P81Q6V85NP; BIDD:GT0265; Cevimeline; AF-102B; D00661; DB00185; Evoxac; (2R,5R)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane] hydrate hydrochloride; D07667; AC1OCEXD; UNII-K9V0CDQ56E; C10H17NOS; Evoxac (TN); (2R,5R)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane] hydrate dihydrochloride; CID83898; AC1L36EF; CID5284532; Cevimeline hydrochloride; CID6918023; AF102B; (+/-)cis-2-methylspiro(1-azabicyclo[2.2.2]octance-3,5'-(1,3)oxathiolane) hydrochloride hemihydrate; Spiro(1-azabicyclo(2.2.2)octane-3,5'-(1,3)oxathiolane), 2'-methyl-, hydrochloride, hydrate (2:1), cis-; Cevimeline [INN]; (+-)-cis-2-Methylspiro(1,3-oxathiolane-5,3'-quinuclidine) hydrochloride, hemihydrate; (2R,5R)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane] dihydrate hydrochloride; Cevimeline HCl 1/2H2O; 107233-08-9; SND-5008; SNK-508; CHEMBL1200362	107233-08-9	83898	660798	TTDS00004	Muscarinic acetylcholine receptor M3	M3 receptor	P20309	1131	ENSG00000133019	agonist
DAP001131	Darifenacin	NCGC00168775-01; DB00496; CID444031; STOCK6S-73577; Darifenacin; D03654; CHEBI:391960; MolPort-005-943-011; (S)-1-(2-(2,3-Dihydro-5-benzofuranyl)ethyl)-alpha,alpha-diphenyl-3-pyrrolidineacetamide; 2-[(3S)-1-[2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]pyrrolidin-3-yl]-2,2-diphenylacetamide; Emselex; 2-{(3S)-1-[2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]pyrrolidin-3-yl}-2,2-diphenylacetamide; AC1L9FKY; Darifenacin (USAN/INN); LS-187359; CHEMBL1346; AC-302; 133099-04-4	133099-04-4	444031	7979027	TTDS00004	Muscarinic acetylcholine receptor M3	M3 receptor	P20309	1131	ENSG00000133019	antagonist
DAP000344	Tiotropium	3-Oxa-9-azoniatricyclo(3,3.1.0(2,4))nonane, 7-((hydroxydi-2-thienylacetyl)oxy)-9,9-dimethyl-, bromide, (1alpha,2beta,4beta,5alpha,7beta)-; CID5487427; AC-1300; LS-172955; (1|A,2|A,4|A,5|A,7|A)-7-[(Hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatri-cyclo[3.3.1.02.4]nonane bromide; (1a,2,4,5a,7)-7-[(2-Hydroxy-2,2-di-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonane bromide; BA-679 BR; 186691-13-4; TIOTROPIUM BROMIDE; Spiriva Respimat; AC1L1U0B; MolPort-005-935-362; BA 679BR; MolPort-006-396-155; Tiotropium; 3-oxa-9-azoniatricyclo(3,3.1.0(2,4))nonane,7-((hydroxydi-2-thienylacetyl)oxy)9,9-dimethyl-,bromide,(1alpha,2beta,4beta,5alpha,7beta)-; BA-679-BR; HMS2090H20; 7-((Hydroxybis(2-thienyl)acetyl)oxy)-9,9-dimethyl-3-oxa-9-azoniatricyclo(3.3.1.0(2,4))nonane bromide; AC1Q1RHA; UNII-0EB439235F; Spiriva; BA 679 BR; C19H22NO4S2; Tiotropium bromide [USAN:INN]; Spiriva Handihaler; 7-{[hydroxy(dithiophen-2-yl)acetyl]oxy}-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonane bromide; UNII-XX112XZP0J; ZINC13900863; 136310-93-5; CID60830; NCGC00167971-01; AB1004875	186691-13-4	5487426	12014767	TTDS00004	Muscarinic acetylcholine receptor M3	M3 receptor	P20309	1131	ENSG00000133019	antagonist
DCL000861	LAS-34273	UNII-UQW7UF9N91; Aclidinium bromide; 320345-99-1; CID11519741; 1-Azoniabicyclo(2.2.2)octane, 3-((hydroxydi-2-thienylacetyl)oxy)-1-(3-phenoxypropyl)-, bromide, (3R)-; Bretaris; Eklira; LAS-W-330; CHEMBL551466; [1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]oct-8-yl] 2-hydroxy-2,2-dithiophen-2-yl-acetate Bromide; LAS-34273; CHEBI:662404	N/A	11434515	49684225	TTDS00004	Muscarinic acetylcholine receptor M3	M3 receptor	P20309	1131	ENSG00000133019	antagonist
DAP001130	Diphemanil Methylsulfate	Talpran; Diphemanil; UNII-W2ZG23MGYI; UNII-Q26TX1UD0W; Prentol; CID6126; Variton; SMR001233482; Prestwick_522; p-(.alpha.-Phenylbenzylidene)-1,1-dimethylpiperidinium methyl sulfate; 4-benzhydrylidene-1,1-dimethylpiperidin-1-ium; methyl sulfate; LS-116553; 4-(diphenylmethylidene)-1,1-dimethylpiperidinium methyl sulfate; Diphemanil metilsulfate (INN); MLS002154192; CHEBI:59782; Diphemanil metilsulfate; MolPort-003-666-719; AC1L1LUO; Prantal; Diphemanili metilsulfas; Metilsulfato de difemanilo; Diphenmethanil methyl sulfate; AR-1H7690; 62-97-5; N,N-Dimethyl-4-piperidylidene-1,1-diphenylmethane methylsulfate; NSC41725; 4-(Diphenylmethylene)-1,1-dimethylpiperidinium methyl sulfate; Metilsulfate de diphemanil; ban-guard; Diphemanil methyl sulfate; WLN: T6K DYTJ A1 A1 DUYR&R &WSO&O1; HMS1568O19; Prantal methylsulfate; Ban-Guard (Veterinary); EINECS 200-552-4; Diphenmanil methylsulfate; 4-(Diphenylmethylene)-1,1-dimethylpiperidinium methylsulfate; Metilsulfato de difemanilo [INN-Spanish]; Demotil; AC1Q22R8; Metilsulfate de diphemanil [INN-French]; D06878; Diphemanil methosulfate; Vagophemanil; C20H24N.CH4O4S; Prantal (TN); DIPHEMANIL METHYLSULFATE; Piperidinium, 4-(diphenylmethylene)-1,1-dimethyl-, methyl sulfate; Diphemanilum; Diphenmanil methyl sulfate; NSC 41725; p-(alpha-Phenylbenzylidene)-1,1-dimethylpiperidinium methyl sulfate; Diphenmethanil; Vagophemanil methyl sulfate; DB00729; Diphemanil methylsulphate; Nivelona; CHEMBL1200880; Diphemanil methylsulfate [INN:BAN]; Nivelon; Diphenatil; Diphemanili metilsulfas [INN-Latin]; Diphenmethanil methylsulfate; Prantil	62-97-5	6126	149020	TTDS00004	Muscarinic acetylcholine receptor M3	M3 receptor	P20309	1131	ENSG00000133019	antagonist
DAP001295	Doxapram	C24H30N2O2; CHEMBL1754; MolPort-005-933-844; 2-Pyrrolidinone, 1-ethyl-4-(2-(4-morpholinyl)ethyl)-3,3-diphenyl-; Docatone; LS-138811; CHEBI:681848; Dopram; 2-Pyrrolidinone, 1-ethyl-4-(2-(4-morpholinyl)ethyl)-3,3-diphenyl- (9CI); Oprea1_016788; 309-29-5; STK634791; Doxapram [USP:JAN]; Docatone (TN); UNII-94F3830Q73; 1-ethyl-4-(2-morpholin-4-ylethyl)-3,3-diphenylpyrrolidin-2-one; doxapram; HSDB 3318; AC-12510; 1-Ethyl-4-(2-morpholinoethyl)-3,3-diphenyl-2-pyrrolidinone; Doxapramum; 1-ethyl-4-[2-(morpholin-4-yl)ethyl]-3,3-diphenylpyrrolidin-2-one; Doxapram (INN); Doxapram hydrochloride; Doxapramum [INN-Latin]; BRN 0628691; 2-Pyrrolidinone, 1-ethyl-4-(2-morpholinoethyl)-3,3-diphenyl-; (+-)-doxapram; EINECS 206-216-3; DB00561; D07873; Doxapram HCL; 2-Pyrrolidinone, 1-ethyl-4-[2-(4-morpholinyl)ethyl]-3,3-diphenyl-; AC1L1FAQ; NCGC00167459-01; CID3156	309-29-5	3156	152600	TTDS00457	Peripheral carotid chemoreceptor	N/A	N/A	N/A	N/A	stimulator
DCL000665	Zibotentan	LS-194046; trans,trans-2(4-methoxyphenyl)-4-(1-3-benzodiazol-5-yl)-1-(dibutylaminocarbonylmethyl)pyrrolidine-3-carboxylic acid; Zibotentan (JAN/INN); CID9910224; ZINC01491485; ZD4054; C511404; ZD4054, Zibotentan; N-(3-methoxy-5-methyl-pyrazin-2-yl)-2-[4-(1,3,4-oxadiazol-2-yl)phenyl]pyridine-3-sulfonamide; 186497-07-4; MolPort-005-943-325; S1456_Selleck; Zibotentan; L001670; D07741; 3-Pyridinesulfonamide, N-(3-methoxy-5-methylpyrazinyl)-2-(4-(1,3,4-oxadiazol-2-yl)phenyl)-; ZD-4054	23713-49-7	23994	49745562	TTDS00198	Endothelin-1 receptor	Endothelin A receptor;Endothelin receptor A;ET-A;ETA receptor;ETA-R;HET-AR	P25101	1909	ENSG00000151617	antagonist
DCL000710	Avosentan	L001646; 5-methylpyridine-2-sulfonic acid (6-methoxy-5-(2-methoxyphenoxy)-2-(pyridin-4-yl)pyrimidin-4-yl)amide; UNII-L94KSX715K; Ro 67-0565; CID9912992; C484919; 2-Pyridinesulfonamide, N-(6-methoxy-5-(2-methoxyphenoxy)-2-(4-pyridinyl)-4-pyrimidinyl)-5-methyl-; N-[6-methoxy-5-(2-methoxyphenoxy)-2-pyridin-4-yl-pyrimidin-4-yl]-5-methyl-pyridine-2-sulfonamide; SPP301; 290815-26-8; Avosentan; SPP 301	290815-26-8	N/A	10549769	TTDS00198	Endothelin-1 receptor	Endothelin A receptor;Endothelin receptor A;ET-A;ETA receptor;ETA-R;HET-AR	P25101	1909	ENSG00000151617	antagonist
DCL000593	PF-1228305	MolPort-006-395-946; CID6918326; CID11477084; Sitaxentan sodium; PF-1228305; Thelin; Sitaxsentan sodium	N/A	9865554	49684245	TTDS00198	Endothelin-1 receptor	Endothelin A receptor;Endothelin receptor A;ET-A;ETA receptor;ETA-R;HET-AR	P25101	1909	ENSG00000151617	antagonist
DAP001441	Ambrisentan	2-[(4,6-dimethylpyrimidin-2-yl)oxy]-3-methoxy-3,3-diphenylpropanoic acid; AC1L53VT; NCGC00160662-01; MolPort-002-945-567; LS-186563; 177036-94-1; Letairis; BSF-208075; Ambrisentan [INN]; STK097095; Ambrisentan; 2-(4,6-dimethylpyrimidin-2-yl)oxy-3-methoxy-3,3-diphenylpropanoic acid; Benzenepropanoic acid, .alpha.-[(4,6-dimethyl-2-pyrimidinyl)oxy]-.beta.-methoxy-.beta.-phe; LU 208075; Gilead brand of ambrisentan; C467894; UNII-HW6NV07QEC; BSF 208075; (+-)-(2S)-2-((4,6-Dimethylpyrimidin-2-yl)oxy)-3-methoxy-3,3-diphenylpropanoic acid; LU-208075; nyl-, (S)-; MLS001195278; CHEBI:205299; ST51051295; LU208075; LS-187364; BSF208075; 2-(4,6-dimethylpyrimidin-2-yl)oxy-3-methoxy-3,3-diphenyl-propanoic acid; CID197712; CHEMBL302753; Benzenepropanoic acid, .alpha.-[(4,6-dimethyl-2-pyrimidinyl)oxy]-.beta.-methoxy-.beta.-phenyl-, (.alpha.S)-; I06-2077; SMR000502713	N/A	6918493	12015371	TTDS00198	Endothelin-1 receptor	Endothelin A receptor;Endothelin receptor A;ET-A;ETA receptor;ETA-R;HET-AR	P25101	1909	ENSG00000151617	antagonist
DCL000296	Atrasentan	LS-184352; A-127722.5; A-127722; A 127722; Xinlay; 3-Pyrrolidinecarboxylic acid, 4-(1,3-benzodioxol-5-yl)-1-(2-dibutylamino)-2-oxoethyl)-2-(4-methoxyphenyl)-, (2R-(2alpha,3beta,4alpha))-; 2-(4-methoxyphenyl)-4-(1,3-benzodioxol-5-yl)-1-(((dibutylamino)carbonyl)methyl)pyrrolidine-3-carboxylic acid; C098644; (11C)ABT-627; NSC720763; A 147627; (2R,3R,4S)-4-(1,3-benzodioxol-5-yl)-1-[2-(dibutylamino)-2-oxoethyl]-2-(4-methoxyphenyl)pyrrolidine-3-carboxylic acid; 2R-(4-methoxyphenyl)-4S(1,3-benzodioxol-5-yl)-1-(N,N-di(n-butyl)aminocarbonyl-methyl)-pyrrolidine-3R-carboxylic acid; 3-Pyrrolidinecarboxylic acid, 4-(1,3-benzodioxo-5-yl)-1-(2-(dibutylamino)-2-oxoethyl)-2-(4-methoxyphenyl)-, (2R,3R,4S)-; (+)-A-127722; ABT-627; Atrasentan [INN]; CHEBI:105200; CID159594; A-147627; UNII-V6D7VK2215; Atrasentan; 173937-91-2; ABT 627; AC1L4M3F; (+)-A 127722; CHEMBL9194	195733-43-8	159594	12014999	TTDS00198	Endothelin-1 receptor	Endothelin A receptor;Endothelin receptor A;ET-A;ETA receptor;ETA-R;HET-AR	P25101	1909	ENSG00000151617	antagonist
DAP001520	Sitaxsentan	3-Thiophenesulfonamide, N-(4-chloro-3-methyl-5-isoxazolyl)-2-((6-methyl-1,3-benzodioxol-5-yl)acetyl)-; 184036-34-8; TBC 11251; UNII-J9QH779MEM; CHEBI:123417; AR-1F5297; DB06268; Sitaxsentan; C106276; IPI 1040; Thelin; CHEMBL282724; N-(4-Chloro-3-methyl-5-isoxazolyl)-2-((2-methyl-4,5-methylenedioxyphenyl)acetyl)thiophene-3-sulfonamide; D07171; Sitaxentan (INN); TBC11251; AC1Q5G7P; N-(4-Chloro-3-methyl-5-isoxazolyl)-2-((3,4-(methylenedioxy)-6-methylphenyl)acetyl)-3-thiophenesulfonamide; Sitaxentan; CID216235; AC1L50C3; N-(4-chloro-3-methyl-1,2-oxazol-5-yl)-2-[2-(6-methyl-1,3-benzodioxol-5-yl)acetyl]thiophene-3-sulfonamide; TBC-11251	210421-64-0	6478419	789419	TTDS00198	Endothelin-1 receptor	Endothelin A receptor;Endothelin receptor A;ET-A;ETA receptor;ETA-R;HET-AR	P25101	1909	ENSG00000151617	antagonist
DAP000030	Bosentan	174227-18-0; TL8001039; -5-(o-methoxyphenoxy)-2-(2-pyrimidinyl)-4-pyrimidinyl]benzenesulfonamide; Bosentan [USAN:INN:BAN]; Bosentan (INN); Benzenesulfonamide, 4-(1,1-dimethylethyl)-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)(2,2'-bipyrimidin)-4-yl)-; Bosentan; Benzenesulfonamide, 4-(1,1-dimethylethyl)-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)[2,2'-bipyrimidin]-4-yl]-; AC1L2XN2; LS-31532; PDSP1_001731; I06-1873; Tracleer; AC-148; UNII-XUL93R30K2; 4-(1,1-Dimethylethyl)-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-(2,2'-bipyrimidin)-4-yl)benzenesulfornamide; bosentanum; p-tert-Butyl-N-[6-(2-hydroxyethoxy); p-tert-Butyl-N-(6-(2-hydroxyethoxy)-5-(o-methoxyphenoxy)-2-(2-pyrimidinyl)-4-pyrimidinyl)benzenesulfonamide; NCGC00167440-01; 4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-pyrimidin-2-ylpyrimidin-4-yl]benzenesulfonamide; Ro-47-0203/029; PDSP2_001714; CHEBI:51450; Ro 47-0203; CHEMBL957; 4-t-butyl-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2,2'-bipyrimidin-4-yl)benzenesulfonamide; 4-(1,1-Dimethylethyl)-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-(2,2'-bipyrimidin)-4-yl) benzenesulfornamide; CID104865; 4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2,2'-bipyrimidin-4-yl]benzenesulfonamide; D07538; 147536-97-8; KS-5062; DB00559; Ro-47-0203; MolPort-003-845-300; Actelion; C27H29N5O6S; L001086; EN002863; HMS2090N14; Ro-47-0203/039; Ro 47-0203/039	147536-97-8	104865	682323	TTDS00198	Endothelin-1 receptor	Endothelin A receptor;Endothelin receptor A;ET-A;ETA receptor;ETA-R;HET-AR	P25101	1909	ENSG00000151617	antagonist
DCL000862	LE-300	Tocris-1674; LE 300; NCGC00015614-03; MLS002153328; MolPort-003-958-572; Lopac0_000699; CID4350931; NCGC00025255-02; L 8401; NCGC00015614-01; CHEMBL441618; EU-0100699; BRD-K01648091-001-01-8; NCGC00025255-03; AC1N8VWD; NCGC00015614-05; 7-Methyl-6,7,8,9,14,15-hexahydro-5H-benz[d]indolo[2,3-g]azecine; NCGC00025255-01; L8401_SIGMA; CHEBI:200867; SMR001230741; Lopac-L-8401	274694-98-3	4350931	56463488	TTDS00015	D(1B) dopamine receptor	D(5) dopamine receptor;D(5)D(1B) dopamine receptor dopamine receptor;D1beta dopamine receptor;Dopamine receptor 5	P21918	1816	ENSG00000169676	antagonist
DAP000281	Apomorphine	Uprima (TN); nchembio.307-comp3; D07460; (R)-6-Methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol; PDSP2_001488; EINECS 200-360-0; Ixense; (6aR)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol; Prestwick2_000101; 314-19-2 (hydrochloride anhydrous); CID6005; AC1L1LLC; PDSP1_000780; 41372-20-7 (hydrochloride hemihydrate); apomorphine; Biomol-NT_000019; 4H-Dibenzo(de,g)quinoline-10,11-diol, 5,6,6a,7-tetrahydro-6-methyl-, (R)-; HMS2089C10; BSPBio_000082; NCGC00025349-01; LS-21474; Apokyn; 6abeta-Aporphine-10,11-diol; IV Apomorphine; STOCK1N-03149; Apomorphin; VR-400; Prestwick3_000101; Prestwick0_000101; CE0800000; Apomorphine hydrochloride hemihydrate; Apomorphinium chloride hemihydrate; (6aR)-5,6,6a,7-Tetrahydro-6-methyl-4H-dibenzo(de,g)chinolin-10,11-diol; Tocris-2073; 6a-beta-Aporphine-10,11-diol; VR004; Apomorfin; BRD-K76022557-001-01-3; BPBio1_001179; Apomorphine hydrochloride; R-(-)-Apomorphine; Prestwick1_000101; L-Apomorphine; SPBio_002021; 6a-beta-Aporphine-10,11-diol, hydrochloride, hemihydrate; (-)-10,11-Dihydroxyaporphine; CHEBI:48538; BPBio1_000092; SMP1_000027; UNII-N21FAR7B4S; (R)-5,6,6a,7-tetrahydro-6-methyl-4H-dibenzo[de,g]quinoline-10,11-diol; VR-040; 4H-Dibenzo(de,g)quinoline-10,11-diol, 5,6,6a,7-tetrahydro-6-methyl-, HCl, (R)-, hemihydrate; Apomorphine HCl hydrate; NIOSH/CE0800000; 58-00-4; C17H17NO2; NCGC00025349-02; HSDB 3289; Uprima; Apormorphine; nchembio873-comp6; Apomorphine (BAN); DB00714; 4H-Dibenzo(de,g)quinoline-10,11-diol, 5,6,6a,7-tetrahydro-6-methyl-, (R)- (9CI)	41372-20-7	6005	148852	TTDS00015	D(1B) dopamine receptor	D(5) dopamine receptor;D(5)D(1B) dopamine receptor dopamine receptor;D1beta dopamine receptor;Dopamine receptor 5	P21918	1816	ENSG00000169676	agonist
DCL000817	GMC-283	N/A	183140-98-9	N/A	N/A	TTDS00015	D(1B) dopamine receptor	D(5) dopamine receptor;D(5)D(1B) dopamine receptor dopamine receptor;D1beta dopamine receptor;Dopamine receptor 5	P21918	1816	ENSG00000169676	antagonist
DCL001042	ZD-3638	N/A	152352-44-8	447043	49718186	TTDS00015	D(1B) dopamine receptor	D(5) dopamine receptor;D(5)D(1B) dopamine receptor dopamine receptor;D1beta dopamine receptor;Dopamine receptor 5	P21918	1816	ENSG00000169676	binder
DCL001148	APC-100	N/A	N/A	N/A	N/A	TTDS00367	Androgen receptor	Dihydrotestosterone receptor;Testosterone receptor	P10275	367	ENSG00000169083	inhibitor
DAP000092	Bicalutamide	Cosudex; Casodex, Cosudex, Calutide, Kalumid, Bicalutamide; CPD000466329; CHEMBL409; I06-0480; Bicalutamide (JAN/USP/INN); MLS001424047; Raffolutil; CID2375; AC1L1DJE; SAM001246612; MolPort-006-808-679; SMR000466329; AstraZeneca brand of bicalutamide; ICI 176334; NCGC00167977-02; S1190_Selleck; LS-119125; NCGC00167977-01; Propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methyl-,; C053541; I06-0475; KS-1161; Astra brand of bicalutamide; 4'-cyano-3-(4-fluorophenylsulfonyl)-2-hydroxy-2-methyl-3'-(trifluoromethyl)propionanilide; FT-0080576; N-[4-cyano-3-(trifluoromethyl)phenyl]-3-(4-fluorophenyl)sulfonyl-2-hydroxy-2-methylpropanamide; MLS000759437; Propanamide, N-(4-cyano-3-(trifluoromethyl)phenyl)-3-((4-fluorophenyl)sulfonyl)-2-hydroxy-2-methyl-, (+-)-; 90357-06-5; C08160; Casodex; BRN 5364666; bicalutamide; C18H14F4N2O4S; ICI-176334; Propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methyl-; (+-)-4'-Cyano-alpha,alpha,alpha-trifluoro-3-((p-fluorophenyl)sulfonyl)-2-methyl-m-lactotoluidide; DB01128; MolPort-003-845-034; D00961; NSC722665; HMS2051B13; Zeneca brand of bicalutamide; Casodex (TN); Bicalutamide [USAN:INN:BAN]; TL8005814; propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methyl-,(+-); AC-4232; HMS2089N12	90357-06-5	56069	193420	TTDS00367	Androgen receptor	Dihydrotestosterone receptor;Testosterone receptor	P10275	367	ENSG00000169083	antagonist
DAP001391	Hydroxyflutamide	hydroxy-flutamide; Hydroxyniphtholide; Hydroxyflutamide; ZINC04655055; LS-119288; 2-Hydroxy-2-methyl-N-(4-nitro-3-(trifluoromethyl)phenyl)propanamide; Propanamide, 2-hydroxy-2-methyl-N-(4-nitro-3-(trifluoromethyl)phenyl)-; CHEMBL491; HFT; AC1Q1LI1; NCGC00091014-01; MLS001061267; AR-1E2288; MolPort-001-771-895; SMR001227196; 2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide; CID91649; OH-flutamide; 52806-53-8; CHEBI:106787; BIDD:ER0519; CHEBI:43064; Sch-16423; AC1L3MI1; alpha,alpha,alpha-Trifluoro-2-methyl-4'-nitro-m-lactotoluidide; FT-0080575; S2174_Selleck; C14204; PC1193; Sch 16423; EN001669; C014290; alpha, alpha, alpha-trifluoro-2-methyl-4'-nitro-m-lactotoluidide	52806-53-8	91649	7847014	TTDS00367	Androgen receptor	Dihydrotestosterone receptor;Testosterone receptor	P10275	367	ENSG00000169083	antagonist
DAP000841	Testosterone	D00075; Cristerona T; Synandrol F; Mertestate; Orquisteron; Andropatch; Testosterone;  4-Androsten-17?-ol-3-one;  17?-Hydroxy-4-androsten-3-one; HMS2052N11; Homosteron; Testim (TN); Testobase; Depotest; Halotensin; UNII-3XMK78S47O; Androst-4-en-3-one, 17-hydroxy-, (17beta)-; Andrusol; 4-Androsten-17beta-ol-3-one; NCGC00091018-01; DB00624; Neo-Hombreol F; Virormone; CPD000058344; T1500_SIGMA; Scheinpharm Testone-Cyp; S00309; MLS000563091; Testaqua; NSC 9700; Sustanon; Sustason 250; Testosterona; Testoject-50; Testosterone [INN:BAN]; Percutacrine androgenique; Testosteroid; Testosterone hydrate; 17beta-Hydroxy-delta(sup4)-androsten-3-one; Testostosterone; delta4-androsten-17b-ol-3-one; Perandren; 17beta-Hydroxyandrost-4-en-3-one; T5411_FLUKA; Testoviron T; Oreton-F; 17-beta-Hydroxy-delta(sup 4)-androsten-3-one; Testosteron; Androst-4-en-3-one, 17-beta-hydroxy-; Testolin; MolPort-002-506-901; 17beta-Hydroxyandrost-4-ene-3-one; Testoviron Schering; Primoteston; Primotest; SMR000058344; (8R,9S,10R,13S,14S,17S)-17-hydroxy-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one; Testro AQ; BIDD:ER0555; Oreton F; MLS001306401; Androst-4-en-3-one, 17-hydroxy, (17.beta.)-; Neotestis; Testopel Pellets; EINECS 200-370-5; 46923_FLUKA; CDB 111C; Geno-cristaux gremy; Testrin-P.A; Relibra; LS-148813; Sustanone; Virosterone; Malestrone (amps); Homosterone; 46923_RIEDEL; Androst-4-en-3-one, 17beta-hydroxy-; Andropository 200; AC1L1LM0; Androgel (TN); Andro 100; Testosteronum; Testim; SMR001261453; 17-beta-Hydroxyandrost-4-en-3-one; Androderm; Malogen in Oil; COL 1621; Striant; 4-androstene-17beta-ol-3-one; AndroGel; Neo-testis; Androst-4-en-17beta-ol-3-one; 17-Hydroxy-(17beta)-androst-4-en-3-one; (17beta)-17-Hydroxyandrost-4-en-3-one; C00535; Testosteronum [INN-Latin]; Testogel; Testiculosterone; trans-Testosterone; Testosterone solution; BIM-0061761.0001; 17b-hydroxy-4-androsten-3-one; LibiGel; Androst-4-en-3-one, 17-hydroxy-, (17-beta)-; Testosterone [Androgenic steroids, anabolic]; Teslen; Testosterone and its esters; MLS001032098; 7-beta-Hydroxyandrost-4-en-3-one; Testred Cypionate 200; 17-Hydroxy-(17-beta)-androst-4-en-3-one; Testosterona [INN-Spanish]; S2033_Selleck; testosterone; 58-22-0; Andryl 200; CID6013; Cristerone T; AC-14899; Oreton; CMC_13449; Andronaq; CP 601B; ZINC06500184; Testosterone (JAN/USP); Virilon IM; 17beta-Hydroxy-3-oxo-4-androstene; SAM001246921; Testrone; Bio-0678; Testoviron; beta testosterone; T-Cypionate; Intrinsa; CHEMBL386630; 17beta-Hydroxy-4-androsten-3-one; Malerone; Andronate 200; B5DEE83F-632B-48A1-A0ED-A51E7F13DF2E; CCRIS 574; delta4-Androsten-17beta-ol-3-one; Testoderm; Androderm (TN); T5411_SIGMA; Testopropon; HSDB 3398; Testamone 100; AA 2500; Everone 200; Testoderm Tts; LMST02020002; Malogen, aquaspension injection; Testryl; delta(sup 4)-Androsten-17(beta)-ol-3-one; Andronate 100; Striant (TN); Androsorb; Testandrone; MLS002174283; CHEBI:17347; Androlin	58-22-0	6013	7847143	TTDS00367	Androgen receptor	Dihydrotestosterone receptor;Testosterone receptor	P10275	367	ENSG00000169083	agonist
DAP000302	Nilutamide	5,5-Dimethyl-3-(4-nitro-3-(trifluoromethyl)phenyl)-2,4-imidazolidinedione; RU 23908; MLS002154066; SPBio_002125; BIDD:GT0683; NCGC00025280-03; SPBio_003015; Nilandrone; HMS1570J18; C021277; SPECTRUM1504152; KBio2_002105; Spectrum2_001973; 1-(3'-Trifluoromethyl-4'-nitrophenyl)-4,4-dimethylimidazolidine-2,5-dione; Anandron; Spectrum3_001633; Nilutamida [Spanish]; Prestwick1_000928; NCGC00025280-07; L000759; Prestwick3_000928; NCGC00025280-04; Tocris-1759; RU-23908; STK633161; BIDD:PXR0177; Nilutamide (USAN/INN); Lopac-N-8534; HMS1922F03; HMS2093A10; Bio-0070; DivK1c_006998; KBioGR_001100; CHEBI:7573; MolPort-003-666-533; DB00665; BPBio1_000920; SMR001233381; 5,5-Dimethyl-3-(alpha,alpha,alpha-trifluoro-4-nitro-m-tolyl)hydantoin; BSPBio_003325; Nilandron; NCGC00025280-01; D00965; UNII-51G6I8B902; N 8534; Nilutamide [USAN:BAN:INN]; KBio3_002545; 5,5-dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]imidazolidine-2,4-dione; CHEMBL1274; 2,4-Imidazolidinedione, 5,5-dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]-; NCGC00025280-06; Hoechst Brand of Nilutamide; NCGC00015754-02; C08164; Aventis Brand of Nilutamide; N8534_SIGMA; KBio2_004673; EU-0100879; BSPBio_000836; I14-2740; NCGC00025280-08; NCGC00025280-05; Spectrum4_000600; Aventis Behring Brand of Nilutamide; AC-5260; Spectrum_001625; SpecPlus_000902; NCGC00015754-01; BRN 0841906; 5,5-dimethyl-3-(4-nitro-3-(trifluoromethyl)phenyl)- 2,4-imidazolidinedione; AB00053180; 63612-50-0; CID4493; KBio2_007241; Lopac0_000879; Nilutamide [USAN:INN:BAN]; C12H10F3N3O4; KBioSS_002105; nilutamide; Prestwick2_000928; ZINC03874498; RU 23908-10; NCGC00015754-04; Spectrum5_001512; Nilutamidum [Latin]; BRD-K23566484-001-05-2; NCGC00015754-11; 5,5-Dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]-2,4-imidazolidinedione; NCGC00025280-02; Prestwick0_000928; MolPort-005-975-300; 2,4-IMIDAZOLIDINEDIONE, 5,5-DIMETHYL-3-(4-NITRO-3-(TRIFLUOROMETHYL)PHENYL)-; Nilutamida; KBio1_001942; FT-0080574; CAS-63612-50-0; AC1L1IAG; Nilutamidum; Nilandron (TN); LS-79181	63612-50-0	4493	7848028	TTDS00367	Androgen receptor	Dihydrotestosterone receptor;Testosterone receptor	P10275	367	ENSG00000169083	antagonist
DPR000088	Ostarine	N/A	401900-40-1	5478977	39469895	TTDS00367	Androgen receptor	Dihydrotestosterone receptor;Testosterone receptor	P10275	367	ENSG00000169083	modulator
DAP000903	Nandrolone	17beta-hydroxyestr-4-en-3-one; LMST02010044; 46476_FLUKA; Estr-4-en-3-one, 17beta-hydroxy-; MolPort-003-849-312; Norandrostenolon; nandrolone; D08250; MLS002222325; ZINC03814379; (8R,9S,10R,13S,14S,17S)-17-hydroxy-13-methyl-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-one; Nortestosteronum; Menidrabol; C18H26O2; Estr-4-en-3-one, 17-hydroxy-, (17-beta)- (9CI); LT03330030; Oestrenolon; HMS2051I04; AC1L1U32; CHEMBL757; EINECS 207-101-0; 434-22-0; 17-Hydroxy-Estr-4-Ene-3-One; Nandrolon; 17beta-Hydroxy-19-norandrost-4-en-3-one; 74640_ALDRICH; Nandrolonum [INN-Latin]; 4-Estren-17beta-ol-3-one; Nandrolona; Nadrolone; Nortestonate; 17beta-Hydroxy-19-nor-4-androsten-3-one; SMR000058610; 19-Nortestosterone; SAM001246751; Estr-4-en-3-one, 17-beta-hydroxy-; Estr-4-en-3-one, 17-hydroxy-, (17-beta)-; CHEBI:7466; Estr-4-en-3-one, 17-hydroxy-, (17beta)-; 19-Norandrostenolone; LS-64851; (17-beta)-17-Hydroxyestr-4-en-3-one; decadura (TN); Nandrolona [INN-Spanish]; Estr-4-en-3-one, 17beta-hydroxy- (8CI); 17-beta-Hydroestr-4-en-3-one; Norandrostenolone; HSDB 3368; Nortestosterone; UNII-6PG9VR430D; Estr-4-en-3-one, 17-hydroxy-, (17beta)- (9CI); 46476_RIEDEL; Nandrolonum; AC-15207; decadura; N7252_SIGMA; 17beta-Hydroxy-4-estren-3-one; 74640_FLUKA; C07254; (17beta)-17-hydroxyestr-4-en-3-one; NSC 3351; CPD000058610; Estrenolone; CID9904; (17beta)-17-hydroxyestr-4-en-3-one; 17beta-hydroxy-19-nor-4-androsten-3-one; 17beta-hydroxy-4-estren-3-one; 19-Norandrostenolone; 19-Nortestosterone; 4-estren-17beta-ol-3-one; Nandrolone; NCGC00159416-02; U 2410; Nandrolone (INN)	434-22-0	9904	14718104	TTDS00367	Androgen receptor	Dihydrotestosterone receptor;Testosterone receptor	P10275	367	ENSG00000169083	agonist
DAP000301	Flutamide	ZINC03812944; LS-2105; Prestwick2_000180; MLS000069634; UNII-76W6J0943E; CHEBI:5132; Oncosal; Flutamin; BSPBio_003122; Alphapharm Brand of Flutamide; KBioGR_001377; Spectrum_001210; Tedec Meiji Brand of Flutamide; NCGC00091460-08; Prostandril; SPBio_000982; KBio2_004258; NCGC00091460-04; Prostogenat; Prasfarma Brand of Flutamide; Gry Brand of Flutamide; C07653; Prestwick3_000180; CID3397; Juta Brand of Flutamide; Apotex Brand of Flutamide; Flumid; Schering-Plough Brand of Flutamide; Ipsen Brand of Flutamide; CCRIS 7246; Q-Pharm Brand of Flutamide; 37209-54-4; m-Propionotoluidide, alpha,alpha,alpha-trifluoro-2-methyl-4'-nitro-; KBioSS_001690; Testotard; Spectrum3_001421; Eulexin; PMS-Flutamide; Fluta GRY; Prestwick0_000180; SAM002264612; Fluta 1A Pharma; m-Propionotoluidide, .alpha.,.alpha.,.alpha.-trifluoro-2-methyl-4'-nitro-; cell pharm Brand of Flutamide; NSC215876; PMS Flutamide; FlutaGRY; CPD000058187; m-Propionotoluidide, 2-methyl-4'-nitro-alpha,alpha,alpha-triflouro-; Flutamidum; 4'-Nitro-3'-trifluoromethylisobutyranilide; niftolid; Flutamide (pubertal study); DB00499; ST058409; Prostica; D005485; F 9397; Prestwick_228; Propanamide, 2-methyl-N-(4-nitro-3-(trifluoromethyl)phenyl)-; Drogenil; Flulem; flutamide; Cebatrol; Flutacell; Flutaplex; BRN 2157663; Prestwick1_000180; NCGC00091460-05; Schering Brand of Flutamide; NCGC00091460-01; Niftholide; Novo-Flutamide; AC1L1FUE; PUBERTAL FLUTAMIDE STUDY (PUBERTAL STUDIES OF VINCLOZOLIN; METHOXYCHLOR; ETHINYL ESTRADIOL); HMS1568D21; IDI1_000459; BPBio1_000087; Flutamide USP25; Sch 13521; Flutamide [USAN:BAN:INN]; EINECS 236-341-9; NSC 215876; m-Propionotoluidide, 2-methyl-4'-nitro-.alpha.,.alpha.,.alpha.-trifluoro-; Flutamide (JAN/USP/INN); Fugerel; KBio3_002342; NCGC00091460-09; TAD Brand of Flutamide; Prostacur; 4-Nitro-3-(trifluoromethyl)isobutyranilide; KBio2_006826; AKOS001025465; NCGC00015452-02; 337962-98-8; 4'-Nitro-3'-(trifluoromethyl)isobutyranilide; BRD-K28307902-001-05-0; Flutamidum [INN-Latin]; Chephasaar Brand of Flutamide; Lemery Brand of Flutamide; NCGC00015452-04; NSC147834; Spectrum2_001201; Essex Brand of Flutamide; F9397_SIGMA; NCGC00091460-02; NCGC00015452-12; I01-2470; HMS2090I18; esparma Brand of Flutamide; NCGC00015452-01; MLS001065596; F0663; Chiron Brand of Flutamide; 4'-Nitro-3'-trifluoromethylisobutyramilide; NovoFlutamide; Eulexine; 13311-84-7; 2-Methyl-N-(4-nitro-3-[trifluoromethyl]phenyl)propanamide; KBio2_001690; Flutamida; KBio1_000459; Propanamide, 2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-; Apimid; Odyne; Fluken; Lopac-F-9397; HMS2092O14; alpha,alpha,alpha-Trifluoro-2-methyl-4'-nitro-m-propionotoluidide; Ham's F-12 medium; Sch-13521; ApoFlutamide; Kendrick Brand of Flutamide; SPECTRUM1500995; m-propionotoluidide,alpha,alpha,alpha-trifluoro-2-methyl-4'-nitro; Chimax; Lopac0_000557; Hexal Brand of Flutamide; MolPort-001-771-894; EU-0100557; SPBio_002000; Pharmascience Brand of Flutamide; Flutexin; m-Propionotoluidide, alpha,alpha,alpha-trifluoro-2-methyl-4'-nitro- (8CI); Schering Plough Brand of Flutamide; AB00052188; 2-Methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propionamide; Ciclum Brand of Flutamide; Azupharma Brand of Flutamide; Eulexin (TN); NCGC00091460-06; CHEMBL806; Cytamid; CAS-13311-84-7; Novo Flutamide; Flutandrona; Spectrum5_001450; BSPBio_000079; NCGC00091460-03; NCGC00091460-07; .alpha.,.alpha.,.alpha.-Trifluoro-2-methyl-4'-nitro-m-propionotoluidide; Niftolide; NFBA; AC-10517; Apogepha Brand of Flutamide; SCH13521; DivK1c_000459; 1A Brand of Flutamide; Spectrum4_000829; Apo-Flutamide; SMR000058187; Fluta cell; C11H11F3N2O3; Fluta-cell; Cebatrol, veterinary; S1908_Selleck; Flutamida [INN-Spanish]; HMS1921O16; Q Pharm Brand of Flutamide; NK-601; Inibsa Brand of Flutamide; NINDS_000459; D00586; Fluta-GRY; HMS501G21; Eulexin, Flutamin, Drogenil,Flutamide; Novopharm Brand of Flutamide; Apo Flutamide; 2-Methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide	13311-84-7	3397	9855	TTDS00367	Androgen receptor	Dihydrotestosterone receptor;Testosterone receptor	P10275	367	ENSG00000169083	antagonist
DAP000905	Oxandrolone	Ossandrolone [DCIT]; UNII-7H6TM3CT4L; Ossandrolone; CID5878; OXANDROLONE; LS-98540; EINECS 200-172-9; Oxandrolonum; Lonavar; Oxandrolona; Protivar; 2-Oxa-5alpha-androstan-3-one, 17beta-hydroxy-17-methyl- (8CI); 2-Oxaandrostan-3-one, 17-hydroxy-17-methyl-, (5alpha,17beta)-; AC1L1LBY; MolPort-003-986-935; Vasorome; 17-beta-hydroxy-17-methyl-2-oxa-androstan-3-one; 2-Oxaandrostan-3-one, 17-hydroxy-17-methyl-, (5-alpha,17-beta)- (9CI); (4aS,4bS,6aS,7S,9aS,9bR,11aS)-7-hydroxy-4a,6a,7-trimethyltetradecahydroindeno[4,5-h]isochromen-2(1H)-one; C19H30O3; CHEMBL1200436; Dodecahydro-3-hydroxy-6-(hydroxy-methyl)-3,3a,6-trimethyl-1H-benz(e)indene-7-acetic acid delta-lactone; 8075 C.B; 2-Oxa-5alpha-androstan-3-one, 17beta-hydroxy-17-methyl-; (1S,3aS,3bR,5aS,9aS,9bS,11aS)-1-hydroxy-1,9a,11a-trimethyl-2,3,3a,3b,4,5,5a,6,9,9b,10,11-dodecahydroindeno[4,5-h]isochromen-7-one; C07346; SC-11585; 8075 C. B.; ZINC03813047; 17beta-Hydroxy-17-methyl-2-oxa-5alpha-androstan-3-one; TL8003512; 8075 C.B.; Provitar; AC-14975; Oxandrin (TN); 17-beta-hydroxy-17-methyl-2-oxa-androstan-3-one (9CI); DB00621; CHEBI:7820; Oxandrolone (JAN/USP/INN); 8075 C. B; Oxandrin, Anavar, Oxandrolone; Anavar; SC 11585; 17beta-Hydroxy-17alpha-methyl-2-oxa-5alpha-androstan-3-one; Oxandrin; Oxandrolonum [INN-Latin]; 8075 CB; NSC 67068; 53-39-4; Oxandrolona [INN-Spanish]; D00462; S1753_Selleck; 2-Oxaandrostan-3-one, 17-hydroxy-17-methyl-, (5-alpha,17-beta)-; 2-Oxa-5-alpha-androstan-3-one, 17-beta-hydroxy-17-methyl-; Ambap53-39-4; HSDB 3373; Oxandrolone [USAN:INN:BAN:JAN]	53-39-4	5878	9553	TTDS00367	Androgen receptor	Dihydrotestosterone receptor;Testosterone receptor	P10275	367	ENSG00000169083	agonist
DAP000904	Fluoxymesterone	CCRIS 9036; 9alpha-Fluoro-17alpha-methyl-11beta,17-dihydroxy-4-androsten-3-one; Neo-Ormonal; fluoxymesterone; NSC 10704; 9alpha-Fluoro-11beta,17beta-dihydroxy-17alpha-methyl-4-androstene-3-one; NSC12165; Fluoximesteronum; Fluossimesterone; Fluoxymesteronum; Ora-Testryl; Testosterone, 9-fluoro-11.beta.-hydroxy-17-methyl-; Testoral; Flusteron; Anadroid-F; Fluoxymestrone; 11beta,17beta-Dihydroxy-9alpha-fluoro-17alpha-methyl-4-androster-3-one; (11beta,17beta)-9-fluoro-11,17-dihydroxy-17-methylandrost-4-en-3-one; CHEMBL1445; U 6040; 9.alpha.-Fluoro-11.beta.,17.beta.-dihydroxy-17.alpha.-methyl-4-androstene-3-one; Androst-4-en-3-one, 9-fluoro-11-beta,17-beta-dihydroxy-17-methyl-; Androst-4-en-3-one, 9-fluoro-11.beta.,17.beta.-dihydroxy-17-methyl-; CHEBI:5120; Fluoro-9-alpha dihydroxy-11-beta,17-beta methyl-17-alpha androstene-4 one-3; Androsterolo; Ora Testryl; 11beta,17beta-Dihydroxy-9alpha-fluoro-17alpha-methyl-4-androsten-3-one; NCGC00091037-01; 9alpha-Fluoro-11beta,17beta-dihydroxy-17alpha-methylandrost-4-en-3-one; Androfluorone; Fluoximesteron; 9.alpha.-Fluoro-11.beta.-hydroxy-17-methyltestosterone; LS-19496; 17alpha-Methyl-9alpha-fluoro-11beta-hydroxytesterone; 9-Fluoro-11-beta,17-beta-dihydroxy-17-methylandrost-4-en-3-one; Fluoximesterona; ZINC03875484; Flutestos; Testosterone, 9-fluoro-11beta-hydroxy-17-methyl-; 9-alpha-Fluoro-17-alpha-methyl-11-beta,17-dihydroxy-4-androsten-3-one; DB01185; 11-beta,17-beta-Dihydroxy-9-alpha-fluoro-17-alpha-methyl-4-androster-3-one; EINECS 200-961-8; Fluoximesterone; Androst-4-en-3-one, 9-fluoro-11beta,17beta-dihydroxy-17-methyl- (VAN) (8CI); Ultandren; BRN 2008796; HSDB 3333; Fluoro-9-alpha dihydroxy-11-beta,17-beta methyl-17-alpha androstene-4 one-3 [French]; 9alpha-Fluoro-11beta-hydroxy-17-methyltestosterone; Androst-4-en-3-one, 9-fluoro-11beta,17beta-dihydroxy-17-methyl-; 76-43-7; 9-Fluoro-11beta,17beta-dihydroxy-17-methylandrost-4-en-3-one; AI3-52940; (8S,9R,10S,11S,13S,14S,17S)-9-fluoro-11,17-dihydroxy-10,13,17-trimethyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one; Fluosterone; Fluossimesterone [DCIT]; UNII-9JU12S4YFY; MLS001055414; SMR000686158; 4-08-00-02057 (Beilstein Handbook Reference); Androst-4-en-3-one, 9-fluoro-11beta,17beta-dihydroxy-17-methyl- (VAN); 17-alpha-Methyl-9-alpha-fluoro-11-beta-hydroxytesterone; 9-fluoro-11beta,17beta-dihydroxy-17alpha-methylandrost-4-en-3-one; MolPort-004-285-946; LMST02020025; CID6446; Fluoxymesteronum [INN-Latin]; NSC-12165; Androst-4-en-3-one, 9-fluoro-11,17-dihydroxy-17-methyl-, (11.beta.,17.beta.)-; component of Halodrin; Fluoxymesterone [INN:BAN:JAN]; C20H29FO3; Androst-4-en-3-one, 9-fluoro-11,17-dihydroxy-17-methyl-, (11beta,17beta)-; Fluoximesterona [INN-Spanish]; 9-alpha-Fluoro-11-beta-hydroxy-17-methyltestosterone; Ultandrene; 9-alpha-Fluoro-11-beta,17-beta-dihydroxy-17-alpha-methyl-4-androstene-3-one; Android-f; Fluotestin; 9alpha-Fluoro-11beta-hydroxy-17alpha-methyltestosterone; Halotestin; AC1L1MJU; Oralsterone; NSC10704; F7751_SIGMA; Halotestin (TN); Oratestin; D00327; Androfluorene; Fluoxymesterone (JP15/USP/INN)	76-43-7	6446	7847393	TTDS00367	Androgen receptor	Dihydrotestosterone receptor;Testosterone receptor	P10275	367	ENSG00000169083	agonist
DAP000906	Cyproterone	Cyproterone [INN:BAN]; CID5284537; cyproterone; Novo-cyproterone; CHEMBL142130; KBioGR_001485; MolPort-003-981-177; Ciproterona [INN-Spanish]; Cyproteronum; KBio2_002052; CyPat; BAY 94-8367; AC1L1EZB; Cyproterone (INN); 6-Chlor-delta(sup 6)-1,2-alpha-methylen-17-alpha-hydroxyprogesteron; Spectrum_001572; SPBio_001594; HMS502H08; Spectrum3_001901; KBio1_000786; UNII-E61Q31EK2F; CID16417; Ciproterona; 6-chloro-17-hydroxy-1beta,2beta-dihydro-3'H-cyclopropa[1,2]pregna-4,6-diene-3,20-dione; Spectrum2_001597; IDI1_000786; Gen-Cyproterone; 6-Chlor-delta(sup 6)-1,2-alpha-methylen-17-alpha-hydroxyprogesteron [German]; 3'H-Cyclopropa(1,2)pregna-1,4,6-triene-3,20-dione, 6-chloro-1-beta,2-beta-dihydro-17-hydroxy-; Ciproterona Servycal (TN); KBioSS_002052; 3'H-Cyclopropa(1,2)pregna-1,4,6-triene-3,20-dione, 6-chloro-1,2-dihydro-17-hydroxy-, (1beta,2beta)-; Ciproterone [DCIT]; BAY94-8367; Ciproterone; Cyproteronum [INN-Latin]; LS-58798; (1R,3aS,3bR,7aR,8aS,8bS,8cS,10aS)-1-acetyl-5-chloro-1-hydroxy-8b,10a-dimethyl-2,3,3a,3b,7a,8,8a,8b,8c,9,10,10a-dodecahydrocyclopenta[a]cyclopropa[g]phenanthren-7(1H)-one; Spectrum4_000853; SPECTRUM1503921; Ciproterona Servycal; AC-6213; BSPBio_003462; Spectrum5_001362; Apo-cyproterone; C22H27ClO3; KBio2_004620; CID3015; SH 80881; 2098-66-0; NCGC00178048-01; MolPort-005-932-862; CHEBI:50742; D07766; DB04839; CID5702275; 6-Chlor-delta(6)-1,2-alpha-methylen-17-alpha-hydroxyprogesteron; DivK1c_000786; KBio3_002966; NINDS_000786; CID10044976; KBio2_007188; AC1L27WO; HMS1922K16; Cyproteron	2098-66-0	5284537	11039334	TTDS00367	Androgen receptor	Dihydrotestosterone receptor;Testosterone receptor	P10275	367	ENSG00000169083	antagonist
DAP000840	Dromostanolone	UNII-7DR7H00HDT; 2a-methylandrostan-17b-ol-3-one; dromostanolone; Drostanolonum; HSDB 3319; Drostanolo; 58-19-5; Medrotestron; Dihydro-2alpha-methyltestosterone; (2alpha,5alpha,17beta)-17-hydroxy-2-methylandrostan-3-one; 2-alpha-Methyldihydrotestosterone; Testosterone, 4,5.alpha.-dihydro-2.alpha.-methyl-; C14605; 17-beta-Hydroxy-2-alpha-methyl-5-alpha-androstan-3-one; 5alpha-Androstan-3-one, 17beta-hydroxy-2alpha-methyl-; Metholone; Medrosteron; CCRIS 2777; prometholone; CHEMBL1582; Drostanolona; 2.alpha.-Methyldihydrotestosterone; AC1L1LLU; Drostanolonum [INN-Latin]; Methalone; Drostanolone [INN:BAN]; LS-19397; CHEBI:34838; Testosterone, 4,5alpha-dihydro-2alpha-methyl-; Drostanolona [INN-Spanish]; EINECS 200-367-9; Androstan-3-one, 17-hydroxy-2-methyl-, (2alpha,5alpha,17beta)-; 5.alpha.-Androstan-3-one, 17.beta.-hydroxy-2.alpha.-methyl-; 2-alpha-Methyl-17-beta-hydroxy-5-alpha-androstan-3-one; Dihydro-2.alpha.-methyltestosterone; Androstan-3-one, 17-hydroxy-2-methyl-, (2.alpha.,5.alpha.,17.beta.)-; NSC26198; Drostanolone; Drostanolo [DCIT]; drostanolon; Androstan-3-one, 17-hydroxy-2-methyl-, (2alpha,5alpha,17beta)- (9CI); (2R,5S,8R,9S,10S,13S,14S,17S)-17-hydroxy-2,10,13-trimethyl-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-one; AI3-52812; 17 beta-hydroxy-2 alpha-methyl-5 alpha-androstan-3-one; 17beta-Hydroxy-2alpha-methyl-5alpha-androstan-3-one; AC1Q6OL6; Androstan-3-one, 17-hydroxy-2-methyl-, (2-alpha,5-alpha,17-beta)-; SKI 27719; CID6011; Dihydro-2-alpha-methyltestosterone; AR-1D8078; 5-alpha-Androstan-3-one, 17-beta-hydroxy-2-alpha-methyl-; 2alpha-Methyldihydrotestosterone	521-12-0	224004	7848597	TTDS00367	Androgen receptor	Dihydrotestosterone receptor;Testosterone receptor	P10275	367	ENSG00000169083	binder
DCL000176	ND1251	N/A	N/A	9844019	49684211	TTDC00057	Sphingomyelin phosphodiesterase 4	KIAA1418;Neutral sphingomyelinase 3;Neutral sphingomyelinase III;nSMase3;nSMase-3;SMPD4	Q9NXE4	55627	ENSG00000136699	inhibitor
DPR000125	TAK-779	TAK 779; dimethyl-[[4-[[3-(4-methylphenyl)-8,9-dihydro-7H-benzo[7]annulene-6-carbonyl]amino]phenyl]methyl]-(oxan-4-yl)azanium chloride; TAK 799; CID183789; N,N-Dimethyl-N-[4-[[[2-(4-methylphenyl)-6,7-dihydro-5H-benzohepten-8-yl]carbonyl]amino]benzyl]tetrahydro-2H-pyran-4-aminium & PRO 140 (Anti-CCR5 monoclonal antibody); CHEBI:158224; TAK 779 (Chloride); TAK779 & CD4 mAb; 263765-56-6; TAK-779 (*Chloride*); N,N-Dimethyl-N-(4-(((2-(4-methylphenyl)-6,7-dihydro-5H-benzohepten-8-yl)carbonyl)amino)benzyl)tetrahydro-2H-pyran-4-aminium; dimethyl-[[4-[[3-(4-methylphenyl)-8,9-dihydro-7H-benzo[7]annulene-6-carbonyl]amino]phenyl]methyl]-(oxan-4-yl)azanium; 2H-Oyran-4-aminium, N-((4-(((6,7-dihydro-2-(4-methylphenyl)-5H-benzocyclohepten-8-yl)carbonyl)amino)phenyl)methyl)tetrahydro-N,N-dimethyl-; TAK-779 & PA14; CHEMBL41275; N,N-Dimethyl-N-[4-[[[2-(4-methylphenyl)-6,7-dihydro-5H-benzohepten-8-yl]carbonyl]amino]benzyl]tetrahydro-2H-pyran-4-aminium; N,N-Dimethyl-N-[4-[[[2-(4-methylphenyl)-6,7-dihydro-5H-benzohepten-8-yl]carbonyl]amino]benzyl]tetrahydro-2H-pyran-4-aminium & Monoclonal antibody directed against CD4 receptor; E-921; L001057; N,N-Dimethyl-N-[4-[[[2-(4-methylphenyl)-6,7-dihydro-5H-benzohepten-8-yl]carbonyl]amino]benzyl]tetrahydro-2H-pyran-4-aminium PRO 140 (Anti-CCR5 monoclonal antibody); TAK799; LS-184219; CID183790; TAK-779; TAK-279 & PRO 140; AC1L4DMK; AC1L4DMN; E921/TAK-779; N,N-Dimethyl-N-(4-(((2-(4-methylphenyl)-6,7-dihydro-5H-benzocyclohepten-8-yl)carbonyl)amino)benzyl)tetrahydro-2H-pyran-4-aminium chloride; TAK779; TAK-779 (Chloride); TAK 779 (*Chloride*); 2H-Pyran-4-aminium, N,N-dimethyl-N-(4-(((2-(4-methylphenyl)-6,7-dihydro-5H-benzocyclohepten-8-yl)carbonyl)amino)benzyl)tetrahydro-, chloride; 229005-80-5	N/A	N/A	N/A	TTDS00326	C-C chemokine receptor type 5	C-C CKR-5;CC-CKR-5;CCR5;CCR-5;CD195 antigen;Chemokine receptor CCR5;CHEMR13;HIV-1 fusion coreceptor;HIV-1 fusion co-receptor	P51681	1234	ENSG00000160791	antagonist
DCL000281	Sch-351125	N/A	402567-16-2	9574343	45622034	TTDS00326	C-C chemokine receptor type 5	C-C CKR-5;CC-CKR-5;CCR5;CCR-5;CD195 antigen;Chemokine receptor CCR5;CHEMR13;HIV-1 fusion coreceptor;HIV-1 fusion co-receptor	P51681	1234	ENSG00000160791	antagonist
DCL000470	AZD5672	N/A	136668-50-3	11758240	42800261	TTDS00326	C-C chemokine receptor type 5	C-C CKR-5;CC-CKR-5;CCR5;CCR-5;CD195 antigen;Chemokine receptor CCR5;CHEMR13;HIV-1 fusion coreceptor;HIV-1 fusion co-receptor	P51681	1234	ENSG00000160791	antagonist
DCL000485	AZD8566	N/A	N/A	N/A	N/A	TTDS00326	C-C chemokine receptor type 5	C-C CKR-5;CC-CKR-5;CCR5;CCR-5;CD195 antigen;Chemokine receptor CCR5;CHEMR13;HIV-1 fusion coreceptor;HIV-1 fusion co-receptor	P51681	1234	ENSG00000160791	antagonist
DCL000274	Vicriviroc	CHEMBL82301; AC1MHPZN; Sch 417690; 1-((4,6-Dimethyl-5-pyrimidinyl)carbonyl)-4-(4-(2-methoxy-4-(trifluoromethyl)phenyl)ethyl-3-methyl-1-piperazinyl)-4-methylpiperidine; PRO 140 (Anti-CCR5 monoclonal antibody) & 1-[(4,6-Dimethyl-5-pyrimidinyl)carbonyl]-4-[4-{2-methoxy-1(R)-4-(trifluoromethyl)-phenyl}ethyl-3(S)-methyl-1-piperazinyl]-4-methylpiperidine; 306296-47-9; Vicriviroc; CHEBI:227116; (4,6-dimethylpyrimidin-5-yl)-[4-[(3S)-4-[(1R)-2-methoxy-1-[4-(trifluoromethyl)phenyl]ethyl]-3-methylpiperazin-1-yl]-4-methylpiperidin-1-yl]methanone; 1-[(4,6-Dimethyl-5-pyrimidinyl)carbonyl]-4-[4-{2-methoxy-1(R)-4-(trifluoromethyl)-phenyl}ethyl-3(S)-methyl-1-piperazinyl]-4-methylpiperidine; Sch-D compound; SCH-417690; UNII-TL515DW4QS; PRO 140 & Vicrivirac; CID3009355; SCH-D690; SchD; SCH-D	N/A	3009355	26683800	TTDS00326	C-C chemokine receptor type 5	C-C CKR-5;CC-CKR-5;CCR5;CCR-5;CD195 antigen;Chemokine receptor CCR5;CHEMR13;HIV-1 fusion coreceptor;HIV-1 fusion co-receptor	P51681	1234	ENSG00000160791	antagonist
DAP000308	Maraviroc	Celsentri(TM); 4,4-Difluoro-N-((1S)-3-(exo-3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo(3.2.1)oct-8-yl)-1-phenylpropyl)cyclohexanecarboxamide; Isopropyl, 4,4-difluoro-N-((1S)-3-{(1R,3s,5S)-3-(3-methyl-5-(propan-2-yl)-4H-1,2,4-triazol-4-yl)-8-azabicyclo(3.2.1)octan-8-yl}-1-phenylpropyl)cyclohexanecarboxamide; 376348-65-1; UK-427,857; UNII-MD6P741W8A; 674782-29-7; Celsentri; Selzentry(TM); exo-4,4-Difluoro-N-[3-[3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]oct-8-yl]-1(S)-phenylpropyl]cyclohexanecarboxamide; CHEMBL256907; 4,4-difluoro-N-[(1S)-3-[(1R,5S)-3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-phenylpropyl]cyclohexane-1-carboxamide; CHEMBL1201187; DB04835; Selzentry; UK-427,857 maraviroc (MVC); Maraviroc [USAN]; UK-427857; AC-558; Maraviroc; MVC; UK 427857; LS-182818; PRO 140 (Anti-CCR5 monoclonal antibody) & exo-4,4-Difluoro-N-[3-[3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]oct-8-yl]-1(S)-phenylpropyl]cyclohexanecarboxamide; AC1MHEFQ; Cyclohexanecarboxamide, 4,4-difluoro-N-((1S)-3-((3-exo)-3-(3-methyl-5-(1-methylethyl)-4H-1,2,4-triazol-4-yl)-8-azabicyclo(3.2.1)oct-8-yl)-1-phenylpropyl)-; CID3002977; CHEBI:537583; PRO 140 & Maraviroc	376348-65-1	3002977	12015618	TTDS00326	C-C chemokine receptor type 5	C-C CKR-5;CC-CKR-5;CCR5;CCR-5;CD195 antigen;Chemokine receptor CCR5;CHEMR13;HIV-1 fusion coreceptor;HIV-1 fusion co-receptor	P51681	1234	ENSG00000160791	antagonist
DCL000305	GW873140	GW 873140; GW-873140; 674782-28-6; ONO-4128; 461023-63-2; Benzoic acid, 4-[4-[[1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]- & Soluble CD4; UNII-04D148Z3VR; GSK873140; AK-602; CID6918686; CID3001322; Benzoic acid, 4-[4-[[1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-; UNII-98B425P30V; Benzoic acid, 4-(4-(((3R)-1-butyl-3-((R)-cyclohexylhydroxymethyl)-2,5-dioxo-1,4,9-triazaspiro(55)undec-9-yl)methyl)phenoxy)-; aplaviroc; AC1OCFQR; 4-[4-[[(9R)-11-butyl-9-[(R)-cyclohexyl(hydroxy)methyl]-7,10-dioxo-3,8,11-triazaspiro[5.5]undecan-3-yl]methyl]phenoxy]benzoic acid; 873140 Compound; GW873140; 675184-11-9; Aplaviroc hydrochloride (USAN); ONO 4128; AK602; AK 602; 4-[4-[[(9R)-11-butyl-9-[(R)-cyclohexyl(hydroxy)methyl]-7,10-dioxo-3,8,11-triazaspiro[5.5]undecan-3-yl]methyl]phenoxy]benzoic acid hydrochloride; 461443-59-4; Aplaviroc HCl; Aplaviroc hydrochloride; D06557; AC1MHDOS	675184-11-9	464989	3820990	TTDS00326	C-C chemokine receptor type 5	C-C CKR-5;CC-CKR-5;CCR5;CCR-5;CD195 antigen;Chemokine receptor CCR5;CHEMR13;HIV-1 fusion coreceptor;HIV-1 fusion co-receptor	P51681	1234	ENSG00000160791	binder
DPR000155	SCH-C	SCH-C; L023973; CID9574343; Methanone, (4-bromophenyl)[1'-[(2,4-dimethyl-3-pyridinyl)carbonyl]-4'-methyl[1,4'-bipiperidin]-4-yl]-, O-ethyloxime, (Z)-, N1-oxide; SCH-C & PA14; SCH-C & AOP-RANTES; Methanone, (4-bromophenyl)[1'-[(2,4-dimethyl-3-pyridinyl)carbonyl]-4'-methyl[1,4'-bipiperidin]-4-yl]-, O-ethyloxime, (Z)-, N1-oxide & AOP-RANTES; SCH-C  AOP-RANTES; SCH 351125  AOP-RANTES; CHEBI:226495; SCH-351125; 305792-46-5; Methanone, (4-bromophenyl)(1'-((2,4-dimethyl-3-pyridinyl)carbonyl)-4'-methyl(1,4'-bipiperidin)-4-yl)-, O-ethyloxime, (Z)-, N1-oxide  AOP-RANTES; Ancriviroc; (2,4-Dimethyl-1-oxy-pyridin-3-yl)-(4'-methyl-[1,4']bipiperidinyl-1'-yl)-methanone; Methanone, (4-bromophenyl)[1'-[(2,4-dimethyl-3-pyridinyl)carbonyl]-4'-methyl[1,4'-bipiperidin]-4-yl]-, O-ethyloxime, (Z)-, N1-oxide & PRO 140 (Anti-CCR5 monoclonal antibody); Methanone, (4-bromophenyl)(1'-((2,4-dimethyl-3-pyridinyl)carbonyl)-4'-methyl(1,4'-pipiperidin)-4-yl)-, O-ethyloxime, N1-oxide; C438583; CHEMBL78535; SCH351125; Methanone, (4-bromophenyl)(1'-((2,4-dimethyl-3-pyridinyl)carbonyl)-4'-methyl(1,4'-bipiperidin)-4-yl)-, O-ethyloxime, (Z)-, N1-oxide & AOP-RANTES; SCH C; 4-((4-bromophenyl)-(ethoxyimino)methyl)-1'-((2,4-dimethyl-3-pyridinyl)carbonyl)-4'-methyl-1,4'-bipiperidine N-oxide; SCH-C cpd; LS-183687; SCH 351125 & AOP-RANTES; SCH 351125 (non-stereospecific); AK671/SCH-C; 1'-[(2,4-Dimethyl-1-oxidopyridin-3-yl)carbonyl]-4'-methyl-1,4'-bipiperidine; SC-351125; SCH 351125	N/A	N/A	N/A	TTDS00326	C-C chemokine receptor type 5	C-C CKR-5;CC-CKR-5;CCR5;CCR-5;CD195 antigen;Chemokine receptor CCR5;CHEMR13;HIV-1 fusion coreceptor;HIV-1 fusion co-receptor	P51681	1234	ENSG00000160791	binder
DCL000541	INCB15050	N/A	N/A	N/A	N/A	TTDS00326	C-C chemokine receptor type 5	C-C CKR-5;CC-CKR-5;CCR5;CCR-5;CD195 antigen;Chemokine receptor CCR5;CHEMR13;HIV-1 fusion coreceptor;HIV-1 fusion co-receptor	P51681	1234	ENSG00000160791	antagonist
DCL001097	PRO 140	PRO 140 (Anti-CCR5 monoclonal antibody); PRO 140; PRO-140; PA 14; PA14	N/A	N/A	N/A	TTDS00326	C-C chemokine receptor type 5	C-C CKR-5;CC-CKR-5;CCR5;CCR-5;CD195 antigen;Chemokine receptor CCR5;CHEMR13;HIV-1 fusion coreceptor;HIV-1 fusion co-receptor	P51681	1234	ENSG00000160791	antibody
DCL000300	INCB9471	N/A	N/A	N/A	N/A	TTDS00326	C-C chemokine receptor type 5	C-C CKR-5;CC-CKR-5;CCR5;CCR-5;CD195 antigen;Chemokine receptor CCR5;CHEMR13;HIV-1 fusion coreceptor;HIV-1 fusion co-receptor	P51681	1234	ENSG00000160791	antagonist
DPR000158	Tak-220	CHEBI:446202; CID5275766; TAK220; TAK-220; L000798; AC1NQNHO; AIDS228341; CHEMBL207004; TBR220; 4-Piperidinecarboxamide, 1-acetyl-N-[3-[4-[[4-(aminocarbonyl)phenyl]methyl]-1-piperidinyl]propyl]-N-(3-chloro-4-methylphenyl)-; TBR-220; 1-acetyl-N-[3-[4-[(4-carbamoylphenyl)methyl]piperidin-1-yl]propyl]-N-(3-chloro-4-methylphenyl)piperidine-4-carboxamide	N/A	N/A	N/A	TTDS00326	C-C chemokine receptor type 5	C-C CKR-5;CC-CKR-5;CCR5;CCR-5;CD195 antigen;Chemokine receptor CCR5;CHEMR13;HIV-1 fusion coreceptor;HIV-1 fusion co-receptor	P51681	1234	ENSG00000160791	binder
DCL001096	SCH-D	CHEMBL82301; AC1MHPZN; Sch 417690; 1-((4,6-Dimethyl-5-pyrimidinyl)carbonyl)-4-(4-(2-methoxy-4-(trifluoromethyl)phenyl)ethyl-3-methyl-1-piperazinyl)-4-methylpiperidine; PRO 140 (Anti-CCR5 monoclonal antibody) & 1-[(4,6-Dimethyl-5-pyrimidinyl)carbonyl]-4-[4-{2-methoxy-1(R)-4-(trifluoromethyl)-phenyl}ethyl-3(S)-methyl-1-piperazinyl]-4-methylpiperidine; 306296-47-9; Vicriviroc; CHEBI:227116; (4,6-dimethylpyrimidin-5-yl)-[4-[(3S)-4-[(1R)-2-methoxy-1-[4-(trifluoromethyl)phenyl]ethyl]-3-methylpiperazin-1-yl]-4-methylpiperidin-1-yl]methanone; 1-[(4,6-Dimethyl-5-pyrimidinyl)carbonyl]-4-[4-{2-methoxy-1(R)-4-(trifluoromethyl)-phenyl}ethyl-3(S)-methyl-1-piperazinyl]-4-methylpiperidine; Sch-D compound; SCH-417690; UNII-TL515DW4QS; PRO 140 & Vicrivirac; CID3009355; SCH-D690; SchD; SCH-D	N/A	N/A	N/A	TTDS00326	C-C chemokine receptor type 5	C-C CKR-5;CC-CKR-5;CCR5;CCR-5;CD195 antigen;Chemokine receptor CCR5;CHEMR13;HIV-1 fusion coreceptor;HIV-1 fusion co-receptor	P51681	1234	ENSG00000160791	antagonist
DAP000549	Progesterone	Progestol; CHEBI:17026; SMR000653542; Prestwick2_000477; NCGC00022185-09; Progesteron; P7556_ALDRICH; Projestaject; Corluvite; Lucorteum; Lutin; BRD-K64994968-001-03-6; MLS002222367; ZINC04428529; Gynlutin; 3,20-Pregnene-4; Progesterone, water-soluble; Progesterona [INN-Spanish]; BIDD:PXR0094; Prestwick3_000477; Luteum; Luteocrin normale; D4-Pregnene-3,20-dione; delta(Sup4)-pregnene-3,20-dione; Gestormone; NSC64377; NSC-9704; 4-Pregnene-3,20-dione; P9776_SIGMA; BHR-100; Lutromone; Natural Progesterone; Progestogel; DB00396; BPBio1_000676; Piaponon; Progesterone [Progestins]; Pregn-4-ene-3,20-dione; NCGC00090798-02; Percutacrine Luteinique; WLN: L E5 B666 OV MUTJ A1 E1 FV1; 8023-13-0; 46665_FLUKA; FE-999913; Lutocuclin M; Corlutina; EINECS 200-350-6; CHEMBL103; P3972_SIGMA; Gestron; Gynoluton; Progesterone [INN:BAN:JAN]; Syngestrets; Cyclogesterin; S1705_Selleck; 46665_RIEDEL; Gelbkoerperhormon; (S)-Progesterone; Corporin; Prestwick_411; 8012-32-6; Membrettes; BSPBio_000614; Colprosterone; Lutinus; NCGC00022185-03; NSC 9704; Gynolutone; Luteinique; SMR000058345; Luteostab; Synovex S; HMS1569O16; Progestone; NCGC00022185-05; Gesterol 100; Lutocyclin; P7556_SIGMA; Utrogestan; Crinone; CID5994; U 3672; Lutociclina; S00293; SAM001247039; D00066; P6149_SIGMA; delta4-Pregnene-3,20-dione; Gestone; Utrogest; 17alpha-progesterone; 4-Pregnene-3,20-dione; Agolutin; Akrolutin; Crinone; Delta(4)-pregnene-3,20-dione; Gelbkoerperhormon; PROGESTERONE; Progesteron; Progesterone; corpus luteum hormone; luteohormone; progesterone; Prestwick1_000477; Corlutin; EU-0100895; AC1L1LKF; Progeffik; Methylpregnone; Glanducorpin; Prolidon; Protormone; Lipolutin; P0130_SIGMA; AI3-51682; Luteopur; LS-234; Fologenon; Prochieve; Luteal hormone; Primolut; Proluton; C00410; P0478; HSDB 3389; Prolutone; Progesteronum; Cyclogest; .delta.4-Pregnene-3,20-dione; MLS000028517; 1h60; NCGC00022185-06; Progesterone (JP15/USP/INN); Micronized Progesterone; NSC 64377; Lopac0_000895; CPD000058345; Lucorteum Sol; Prontogest; Pregnenedione; Progesterone; 4-Pregnene-3,20-dione; MLS001074187; Prometrium; HMS2051O05; 57-83-0; Luteol; Lutidon; DR-2011; Progesterol; 32104FB6-BF81-4F6E-83C2-024DEEAEB272; nchembio.2007.53-comp14; 1dbb; Lingusorbs; Luteogan; CCRIS 533; Luteodyn; Prolets; Progesteronum [INN-Latin]; Lutogyl; (S)-4-Pregnene-3,20-dione; MolPort-001-794-643; Spectrum5_002053; Vitarrine; AC-700; CMC_13406; Nalutron; Lutocyclin M; Flavolutan; Endometrin; Luteosan; Progestasert; SPBio_002553; BIDD:ER0547; 17alpha-Progesterone; component of Cyclogesterin; Percutacrine; Gesterol; 257630-50-5; 17.alpha.-Progesterone; Lutren; Luteohormone; Corpus luteum hormone; BB_NC-0185; Gestiron; Hormoflaveine; HMS2090J07; NCGC00022185-07; Gesterol 50; Hormoluton; Progestron; delta(sup 4)-Pregnene-3,20-dione; Lugesteron; Luteovis; Progesterone: HBC complex; SR-01000000088-5; P 0130; Delta(4)-pregnene-3,20-dione; Lutocylol; .delta.(sup4)-Pregnene-3,20-dione; ETI-411; (S)-Pregn-4-en-3,20-dione; Crinone (TN); progesterone; Pranone; NSC9704; Syngesterone; Progesterona; bmse000482; MLS000758277; Prolutin; NCGC00090798-01; Lipo-Lutin; Prometrium (TN); Luteol (VAN); NCGC00022185-08; Prestwick0_000477; Akrolutin; LMST02030159; UNII-4G7DS2Q64Y; 753497-20-0; Progekan; Progesterone-Water Soluble; Progestronol; Progestrel; Progestin; COL-1620; .beta.-Progesterone; Lutocylin; Bio-luton; Pregnene-3,20-dione; Syntolutan; P8783_SIGMA; Progestosol; NCI60_042166; NCGC00022185-04; Crinone progesterone gel; Lutex; SR-01000000088; Agolutin; Lutoform	57-83-0	5994	148842	TTDS00241	17 alpha-hydroxylase-C17, 20-lyase 	17 alpha-Hydroxylase/C17-20-lyase;CYP 17;CYPXVII;P450 17;P450c17;P450-C17;Steroid 17-alpha-hydroxylase/17,20 lyase	P05093	1586	ENSG00000148795	inhibitor
DAP000710	Bacitracin	n-{[2-(1-amino-2-methylbutyl)-4,5-dihydro-1,3-thiazol-4-yl]carbonyl}leucyl-|A-glutamyl-n-[3-(2-amino-2-oxoethyl)-18-(3-aminopropyl)-12-benzyl-15-(butan-2-yl)-6-(carboxymethyl)-9-(1h-imidazol-5-ylmethyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptaazacyclopentacosan-21-yl]isoleucinamide; 46084_RIEDEL; AC1Q6GKZ; (4R)-4-[[(2S)-2-[[2-(1-amino-2-methylbutyl)-4,5-dihydro-1,3-thiazole-4-carbonyl]amino]-4-methylpentanoyl]amino]-5-[[(2S,3S)-1-[[(3S,6R,9S,12R,15S,18R,21S)-3-(2-amino-2-oxoethyl)-18-(3-aminopropyl)-12-benzyl-15-[(2S)-butan-2-yl]-6-(carboxymethyl)-9-(1H-imidazol-5-ylmethyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclopentacos-21-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-5-oxopentanoic acid; AC1O6F67; partyl-, (10.4)-lactam; CHEMBL1200558; MolPort-003-926-019; AC1L22YV; CID10909430; Baciguent; MLS002695992; Citracin; BSPBio_000798; B0125_SIGMA; SPBio_002987; Baciquent; SMR001562136; CID65281; CID6714010; 11702_SIGMA; EINECS 245-115-9; Bacitracin F, 1-(N-((2-(1-amino-2-methylbutyl)-4,5-dihydro-4-thiazolyl)carbonyl)-L-leucine)-; bacitracin; HMS1570H20; LS-23608; AB00513964; Bacitracin A2a; Fortracin; 22601-59-8; Altracin; 11702_FLUKA; Bacitracin F, 1-[N-[[2-(1-amino-2-methylbutyl)-4,5-dihydro-4-thiazolyl]carbonyl]-L-leucine]-; CID6474109; (4R)-4-[[(2S)-2-[[(4R)-2-[(1S,2S)-1-amino-2-methylbutyl]-4,5-dihydro-1,3-thiazole-4-carbonyl]amino]-4-methylpentanoyl]amino]-5-[[(2S,3S)-1-[[(3S,6R,9S,12R,15R,18R,21S)-3-(2-amino-2-oxoethyl)-18-(3-aminopropyl)-12-benzyl-15-[(2S)-butan-2-yl]-6-(carboxymethyl)-9-(1H-imidazol-5-ylmethyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclopentacos-21-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-5-oxopentanoic acid; AC1O8Q0J; BPBio1_000878; Bacitracin A; Prestwick2_000919; Prestwick1_000919; 4-[[2-[[2-(1-amino-2-methylbutyl)-4,5-dihydro-1,3-thiazole-4-carbonyl]amino]-4-methylpentanoyl]amino]-5-[[1-[[3-(2-amino-2-oxoethyl)-18-(3-aminopropyl)-12-benzyl-15-butan-2-yl-6-(carboxymethyl)-9-(1H-imidazol-5-ylmethyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclopentacos-21-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-5-oxopentanoic acid; L-Asparagine, N-[[(4R)-2-[(1S,2S)-1-amino-2-methylbutyl]-4,5-dihydro-4-thiazolyl]carbonyl]-L-leucyl-D-.alpha.-glutamyl-L-isoleucyl-L-lysyl-D-ornithyl-L-isoleucyl-D-phenylalanyl-L-histidyl-D-.alpha.-as; NSC 45737; C15482; UNII-DDA3RRX0P7; Bacitracin A1; Prestwick3_000919; Solu-Tracin 50	1405-87-4	439542	4814	TTDS00134	Insulin-degrading Enzyme	IDE;Insulin protease;Insulinase;Insulysin	P14735	3416	ENSG00000119912	inhibitor
DCL001137	ALB-127158(a)	N/A	N/A	N/A	N/A	TTDC00133	Melanin-concentrating hormone receptor 1	G protein coupled receptor 24;MCH receptor 1;MCH(1) receptor;MCH1R;MCH-1R;MCHR;MCHR1;MCH-R1;MCHR-1;Melanin-concentrating hormone receptor subtype 1;SLC-1;Somatostatin receptor-like protein	Q99705	2847	ENSG00000128285	antagonist
DCL000177	NGD-4715	N/A	N/A	N/A	N/A	TTDC00133	Melanin-concentrating hormone receptor 1	G protein coupled receptor 24;MCH receptor 1;MCH(1) receptor;MCH1R;MCH-1R;MCHR;MCHR1;MCH-R1;MCHR-1;Melanin-concentrating hormone receptor subtype 1;SLC-1;Somatostatin receptor-like protein	Q99705	2847	ENSG00000128285	antagonist
DPR000109	SNAP-7941	SNAP-7941; Snap7941; CID11520238	387825-78-7	11520239	49684227	TTDC00133	Melanin-concentrating hormone receptor 1	G protein coupled receptor 24;MCH receptor 1;MCH(1) receptor;MCH1R;MCH-1R;MCHR;MCHR1;MCH-R1;MCHR-1;Melanin-concentrating hormone receptor subtype 1;SLC-1;Somatostatin receptor-like protein	Q99705	2847	ENSG00000128285	antagonist
DPR000071	MCH antagonist	N/A	N/A	N/A	N/A	TTDC00133	Melanin-concentrating hormone receptor 1	G protein coupled receptor 24;MCH receptor 1;MCH(1) receptor;MCH1R;MCH-1R;MCHR;MCHR1;MCH-R1;MCHR-1;Melanin-concentrating hormone receptor subtype 1;SLC-1;Somatostatin receptor-like protein	Q99705	2847	ENSG00000128285	antagonist
DCL000043	AMG 076	N/A	209799-67-7	444499	49689710	TTDC00133	Melanin-concentrating hormone receptor 1	G protein coupled receptor 24;MCH receptor 1;MCH(1) receptor;MCH1R;MCH-1R;MCHR;MCHR1;MCH-R1;MCHR-1;Melanin-concentrating hormone receptor subtype 1;SLC-1;Somatostatin receptor-like protein	Q99705	2847	ENSG00000128285	antagonist
DCL001164	BMS-830216	N/A	N/A	N/A	N/A	TTDC00133	Melanin-concentrating hormone receptor 1	G protein coupled receptor 24;MCH receptor 1;MCH(1) receptor;MCH1R;MCH-1R;MCHR;MCHR1;MCH-R1;MCHR-1;Melanin-concentrating hormone receptor subtype 1;SLC-1;Somatostatin receptor-like protein	Q99705	2847	ENSG00000128285	antagonist
DPR000114	T-226293	N/A	N/A	6536	29225504	TTDC00133	Melanin-concentrating hormone receptor 1	G protein coupled receptor 24;MCH receptor 1;MCH(1) receptor;MCH1R;MCH-1R;MCHR;MCHR1;MCH-R1;MCHR-1;Melanin-concentrating hormone receptor subtype 1;SLC-1;Somatostatin receptor-like protein	Q99705	2847	ENSG00000128285	antagonist
DPR000115	T-226296	PDSP1_000981; LS-44229; PDSP2_000965; CID9865843; T-226296; CHEMBL178707; LS-193063; CHEBI:400886	N/A	9865843	49684230	TTDC00133	Melanin-concentrating hormone receptor 1	G protein coupled receptor 24;MCH receptor 1;MCH(1) receptor;MCH1R;MCH-1R;MCHR;MCHR1;MCH-R1;MCHR-1;Melanin-concentrating hormone receptor subtype 1;SLC-1;Somatostatin receptor-like protein	Q99705	2847	ENSG00000128285	antagonist
DAP000978	Methylergonovine	479-03-8; 78207-86-0; Ryegonovin; BRD-K34685430-001-01-1; HSDB 3364; (8beta)-N-[(1S)-1-(hydroxymethyl)propyl]-6-methyl-9,10-didehydroergoline-8-carboxamide; Ergoline-8-beta-carboxamide, 9,10-didehydro-N-((S)-1-(hydroxymethyl)propyl)-6-methyl-; DivK1c_000357; Methergine; D08207; BPBio1_000581; Ergotyl (TN); SPBio_000546; KBioSS_000743; Methylergometrine maleate; Spametrin-M; DB00353; Methylergometrine [INN:BAN]; Metenarin; UNII-W53L6FE61V; Methylergometrinum [INN-Latin]; EINECS 204-027-0; IDI1_000357; Methergin; Methylergometrine (INN); NINDS_000357; CID8226; Prestwick3_000374; methylergonovine; 29589-73-9; BSPBio_002023; Metilergometrinio; N-(alpha-(Hydroxymethyl)propyl)-D-lysergamide; Ergoline-8-carboxamide, 9,10-didehydro-N-(1-(hydroxymethyl)propyl)-6-methyl-, (8beta(S))-; 9,10-Didehydro-N-(alpha-(hydroxymethyl)propyl)-6-methyl-ergoline-8-beta-carboxamide; Spectrum3_000502; D-Lysergic acid-(+)-butanolamide-(2); Methylergometrinum; Methylergometrin; BSPBio_000527; Biomol-NT_000154; Lysergic acid butanolamide; LS-64363; Partergin; Ergometrine, methyl-; KBio2_000743; KBio2_003311; Ergotyl; 113-42-8; Methylergometrine; Methergen; Methylergobasine; AC1L1QJP; Lopac0_000794; 9,10-Didehydro-N-(1-(hydroxymethyl)propyl)-6-methylergoline-8-carboxamide; Spectrum5_001879; Methylergobrevin; NCGC00024646-03; Methylergonovin; BPBio1_000442; NCGC00017258-05; Spectrum2_000613; D-Lysergic acid-dl-hydroxybutylamide-2; C20H25N3O2; 29477-86-9; ME 277; Spectrum_000263; KBio2_005879; KBio3_001523; AB00514664; Basofortina; Lysergamide, N-((S)-1-(hydroxymethyl)propyl)-; NCGC00024646-02; Metilergometrina; Metilergometrina [DCIT]; BRD-K34685430-050-04-2; Methylergobasin; KBio1_000357; Metilergometrinio [INN-Spanish]	113-42-8	8226	151359	TTDS00011	Dopamine D1 receptor	D(1) dopamine receptor;D(1A) dopamine receptor	P21728	1812	ENSG00000184845	antagonist
DPR000035	D1 agonist D2 antagonist	N/A	N/A	N/A	N/A	TTDS00011	Dopamine D1 receptor	D(1) dopamine receptor;D(1A) dopamine receptor	P21728	1812	ENSG00000184845	agonist
DAP000069	Pergolide	Lopac0_000984; (8beta)-8-[(methylthio)methyl]-6-propylergoline; ST057534; Permax (TN); KBio2_002127; CHEBI:112494; CHEMBL531; NINDS_000442; SPBio_002099; KBio2_004695; LS-64479; KBio1_000442; BIDD:GT0177; NCGC00142538-03; C19H26N2S; KBioGR_001409; pergolide; Ergoline, 8-((methylthio)methyl)-6-propyl-, (8beta)-; IDI1_000442; (6aR,9R,10aR)-9-(Methylthiomethyl)-7-propyl-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinoline; MolPort-003-849-834; Permax; Pergolide [INN:BAN]; InChI=1/C19H26N2S/c1-3-7-21-11-13(12-22-2)8-16-15-5-4-6-17-19(15)14(10-20-17)9-18(16)21/h4-6,10,13,16,18,20H,3,7-9,11-12H2,1-2H3/t13-,16-,18-/m1/s; nchembio873-comp45; KBioSS_002127; Pergolida [INN-Spanish]; LY-127,809; AC1L2IT3; BPBio1_000254; 66104-22-1; Spectrum4_000835; HMS2089C18; D08339; NCGC00142538-02; BPBio1_001211; C07425; Prestwick2_000295; Pergolidum; DB01186; Pergolide (INN); (8beta)-8-[(methylsulfanyl)methyl]-6-propylergoline; BSPBio_000230; SPBio_002449; 66104-23-2 (mesylate); AC1Q7DT2; Prestwick1_000295; DivK1c_000442; Spectrum2_001970; CID47811; Prestwick0_000295; BRD-K60770992-066-05-2; KBio2_007263; BSPBio_003156; UNII-24MJ822NZ9; NCGC00142538-01; Prestwick3_000295; Spectrum3_001588; Pergolidum [INN-Latin]; BRD-K60770992-001-01-8; Pergolida; NCGC00017366-05; Spectrum_001647; Biomol-NT_000025; Spectrum5_001649; KBio3_002656	66104-22-1	47811	9629	TTDS00011	Dopamine D1 receptor	D(1) dopamine receptor;D(1A) dopamine receptor	P21728	1812	ENSG00000184845	agonist
DCL000731	BSF-78438	N/A	N/A	N/A	N/A	TTDS00011	Dopamine D1 receptor	D(1) dopamine receptor;D(1A) dopamine receptor	P21728	1812	ENSG00000184845	binder
DAP000254	Fenoldopam	NCGC00025246-02; Fenoldopam (INN); AR-1L4264; 1H-3-Benzazepine-7,8-diol, 6-chloro-2,3,4,5-tetrahydro-1-(4-hydroxyphenyl)-; 67287-54-1 (hydrobromide); D07946; Carlacor (TN); Fenoldopamum [Latin]; Carlacor; CID3341; Fenoldopam [INN:BAN]; PDSP2_001645; 87900-90-1; CHEBI:5002; C07693; SKF-82526J; BPBio1_001265; LS-27993; DB00800; SKF 82526; CHEMBL588; fenoldopam; 9-chloro-5-(4-hydroxyphenyl)-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diol; Fenodopam mesylate; Fenoldopamum; AC1Q3LHG; Lopac0_000556; AC1L1FPQ; NCGC00025246-03; BRD-A50684349-001-01-5; PDSP1_001661; 6-chloro-1-(4-hydroxyphenyl)-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diol; SK&F-82526; 67227-57-0 (mesylate); HMS2090G16; SKF 82526-J; Biomol-NT_000042; 67227-56-9; L000254; NCGC00015444-05; UNII-INU8H2KAWG	67227-57-0	3341	188303	TTDS00011	Dopamine D1 receptor	D(1) dopamine receptor;D(1A) dopamine receptor	P21728	1812	ENSG00000184845	agonist
DCL000093	CRA-028129	N/A	N/A	16760355	26758426	TTDC00067	Cathepsin S	Cysteine protease cathepsin S	P25774	1520	ENSG00000163131	inhibitor
DAP000870	Vitamin B1	3-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-5-(2-hydroxyethyl)-4-methylthiazolium chloride; NSC 36226; CHEMBL1547; Prestwick1_000631; LT00233141; MLS001304099; [5-[[5-(2-hydroxyethyl)-4-methyl-1,3-thiazol-3-ium-3-yl]methyl]-2-methylpyrimidin-4-yl]azanium dichloride; Beivon; Thiamine [INN:BAN]; EINECS 200-641-8; 3-[(4-amino-2-methylpyrimidin-5-yl)methyl]-5-(2-hydroxyethyl)-4-methyl-1,3-thiazol-3-ium; Thiazolium, 3-((4-amino-2-methyl-5-pyrimidinyl)methyl)-5-(2-hydroxyethyl)-4-methyl- chloride; vitamin B1; B-Amin; Aneurine; CHEBI:49105; NSC36226; CHEMBL1588; BAS 00266240; 3-((4-Amino-2-methyl-5-pyrimidinyl)methyl)-5-(2-hydroxyethyl)-4-methylthiazolium chloride monohydrochloride; Prestwick0_000631; Tiamina; CHEBI:33283; AC1L1LOC; 100660-17-1; 2-[3-[(4-amino-2-methylpyrimidin-5-yl)methyl]-4-methyl-1,3-thiazol-3-ium-5-yl]ethanol chloride; BSPBio_000622; VIB; SBB058094; Prestwick3_000631; vitamin b1(thiamine); MolPort-000-722-048; Apatate drape; Vitaneurin; Thiamine chloride; AR-1L8201; 3[(4-Amino-2-methyl-5-pyrimidinyl)-methyl]-5-(2-hydroxyethyl)-4-methylthiazolium chloride; SPBio_002841; ZINC00049153; Thiamine dichloride; 67-03-8; thiamine(1+) ion; AC-11683; Thiamine hydrochloride [JAN]; THIAMIN, VITAMIN B1; Bethiamin; 3-[(4-amino-2-methylpyrimidin-5-yl)methyl]-5-(2-hydroxyethyl)-4-methyl-1,3-thiazol-3-ium chloride hydrochloride; Antiberiberi factor; SMP1_000084; MolPort-001-920-086; C00378; AC1L1ASK; Thiamine HCL; Thiazolium, 3-((4-amino-2-methyl-5-pyrimidinyl)methyl)-5-(2-hydroxyethyl)-4-methyl- chloride (1:1); AKOS000668650; Thiamine, monohydrochloride; 115461-66-0; nchembio.121-comp5; Thiazolium, 3-((4-amino-2-methyl-5-pyrimidinyl)methyl)-5-(2-hydroxyethyl)-4-m- ethyl, chloride, monohydrochloride; Prestwick2_000631; thiamine; NChemBio.2007.13-comp10; SMR000718788; 3-((4-Amino-2-methyl-5-pyrimidinyl)methyl)-5-(2-hydroxyethyl)-4-m- ethylthiazolium chloride, monohydrochloride; CID1130; Thiazolium, 3-((4-amino-2-methyl-5-pyrimidinyl)methyl)-5-(2-hydroxyethyl)-4-methyl-, chloride, monohydrochloride; Oryzanine; Thiamine chloride hydrochloride; Oryzanin; Thiamine (INN); AC1Q4V9Q; Thiamine monochloride; Betaxin; ST095175; 3-((4-Amino-2-methyl-5-pyrimidinyl)methyl)-5-(2-hydrox yethyl)-4-methylthiazolium chloride; 3-[(4-amino-2-methylpyrimidin-5-yl)methyl]-5-(2-hydroxyethyl)-4-methyl-1,3-thiazol-3-ium chloride; BPBio1_000686; CCRIS 5823; CHEBI:18385; 3-((4-Amino-2-methyl-5-pyrimidinyl)methyl)-5-(2-hydroxyethyl)-4-methylthiazolium chloride; Vitamin B1 (TN); Thiamine, chloride; Tiamina [INN-Spanish]; 1sbr; EINECS 200-425-3; I14-14339; Aneurin; THD; 55463-15-5; MolPort-002-052-059; Betalin S; TimTec1_000613; HSDB 220; FEMA No. 3322; Betabion; thiamin; Thiaminum [INN-Latin]; Biamine; CCRIS 1906; thiaminium; 59-43-8; UNII-X66NSO3N35; Thiamin dichloride; D08580; CID6042; AC1LAODT; AI3-18993; Thiazolium, 3-((4-amino-2-methyl-5-pyrimidinyl)methyl)-5-(2-hydroxyethyl)-4-methyl-chloride; Thiaminum; bmse000274; 57777-32-9; Bequin; DB00152; Thiaminium chloride hydrochloride; CID517305; C12H17N4OS; LS-3226; Vitaneuron; Thiadoxine; Thiamine, chloride, hydrochloride; 3-(4-AMINO-2-METHYL-PYRIMIDIN-5-YLMETHYL)-5-(2-HYDROXY-ETHYL)-4-METHYL-THIAZOL-3-IUM; 2-[3-[(4-amino-2-methylpyrimidin-5-yl)methyl]-4-methyl-1,3-thiazol-3-ium-5-yl]ethanol; Chloride-hydrochloride salt of thiamine; Thiamine monohydrochloride; Bewon; Vitamin B1 hydrochloride (VAN)	59-43-8	1130	3215	TTDS00530	Pyruvate decarboxylase	Pyruvate decarboxylase E1 component	P06958	N/A	N/A	cofactor
DCL000488	AZD9639	N/A	180916-16-9	216416	49688680	TTDS00347	Fusion glycoprotein	F protein;Fusion protein;Measles virus fusion protein;MV fusion protein	Q91MJ9	N/A	N/A	inhibitor
DCL000577	Motavizumab	D06621; Motavizumab (USAN/INN); MEDI-524; 677010-34-3; Motavizumab	677010-34-3	N/A	47208272	TTDS00347	Fusion glycoprotein	F protein;Fusion protein;Measles virus fusion protein;MV fusion protein	Q91MJ9	N/A	N/A	inhibitor
DAP000386	Palivizumab	Palivizumab (genetical recombination) (JAN); Palivizumab; 188039-54-5; Palivizumab (genetical recombination); Synagis; D02737; Palivizumab (INN); Synagis (TN)	188039-54-5	N/A	47205815	TTDS00347	Fusion glycoprotein	F protein;Fusion protein;Measles virus fusion protein;MV fusion protein	Q91MJ9	N/A	N/A	antibody
DPR000118	VP-14637	N/A	235106-62-4	6481192	26683772	TTDS00347	Fusion glycoprotein	F protein;Fusion protein;Measles virus fusion protein;MV fusion protein	Q91MJ9	N/A	N/A	inhibitor
DPR000094	RFI-641	RFI 641; RFI-641; CHEMBL409824; WAY-154641; CHEMBL425633; [1,1'-Biphenyl]-2,2'-disulfonic acid, 4,4'-bis[[4,6-bis[[3-[[bis(2-amino-2-oxoethyl)amino]sulfonyl]phenyl]amino]-1,3,5-triazin-2-yl]amino]-	197366-31-7	16130904	26683836	TTDS00347	Fusion glycoprotein	F protein;Fusion protein;Measles virus fusion protein;MV fusion protein	Q91MJ9	N/A	N/A	inhibitor
DCL001147	Anti-M1 prime	N/A	N/A	N/A	N/A	TTDC00323	M1 prime segment of membrane IgE	N/A	N/A	N/A	N/A	antibody
DAP000142	Flunarizine	1-[bis(4-fluorophenyl)methyl]-4-[(E)-3-phenylprop-2-enyl]piperazine; BPBio1_000336; DB04841; 30484-77-6 (di-hydrochloride); CID941361; Flunarizin; Novo-Flunarizine; HMS1989D03; Flunarizine (INN); CHEMBL30008; BRD-K12184470-300-01-8; 40218-96-0; Sibelium; HMS2089H21; HMS1791D03; Vertix; AC1LIZWP; NCGC00024308-06; D07971; NCGC00018102-09; NCGC00024308-04; Issium; NCGC00024308-07; AR-1B9446; EINECS 254-842-0; Spectrum5_001570; Apo-flunarizine capsules; Flunarizine [INN:BAN]; BRD-K29582677-001-02-7; Zinasen; 1-(Bis(4-fluorophenyl)methyl)-4-cinnamylpiperazine; EINECS 257-937-5; Flunarizinum; Piperazine, 1-(bis(4-fluorophenyl)methyl)-4-(3-phenyl-2-propenyl)-; HMS1361D03; LS-110464; BCBcMAP01_000120; BSPBio_000304; Lopac0_000527; NCGC00024308-05; Flunarizina [INN-Spanish]; CHEBI:138764; IDI1_000043; flunarizine; BRD-K29582677-300-05-6; Fluvert; Bio-0741; Piperazine, 1-[bis(4-fluorophenyl)methyl]-4-(3-phenyl-2-propenyl)-, (E)-; MolPort-000-732-712; 52468-60-7; 5343-57-7; Piperazine, 1-[bis(4-fluorophenyl)methyl]-4-[(2E)-3-phenyl-2-propenyl]-; AC1Q4NMD; Sibelium (TN); AC-1283; (E)-1-(Bis(4-fluorophenyl)methyl)-4-(3-phenyl-2-propenyl)piperazine; C26H26F2N2; KST-1B4966; Flunarizinum [INN-Latin]; R-14950; 1-[bis(4-fluorophenyl)methyl]-4-(3-phenylprop-2-en-1-yl)piperazine; Prestwick2_000312; BSPBio_003096; (E)-1-[Bis-(p-fluorophenyl)methyl]-4-cinnamylpiperazine; Flunarizina; Piperazine, 1-(bis(4-fluorophenyl)methyl)-4-(3-phenyl-2-propenyl)-, (E)-; IDI1_033811; Flufenal; BSPBio_001341; Prestwick3_000312	52468-60-7	941361	181267	TTDS00413	Voltage-dependent T-type calcium channel subunit alpha-1H	KCND3;Voltage-gated potassium channel subunit Kv4.3	O95180	8912	ENSG00000196557	blocker
DAP000128	Sodium bicarbonate	SODIUM BICARBONATE; Sodium bicarbonate (JP15/USP); 31437_RIEDEL; 5006-97-3; S8875_SIAL; D017693; S8761_SIGMA; AC1LANJA; NaHCO3; Sodium bicarbonate solution; Col-evac; S4019_SIGMA; 13433_SIAL; Sodium hydrocarbonate; Meylon (TN); E-Z-EM Prep Lyte; Sodium bicarbonate in plastic container; 151127-72-9; UNII-8MDF5V39QO; 246180-97-2; Carbonic acid, monosodium salt; Soludal; Gripe water; Sodium acid carbonate; S7277_SIGMA; Monosodium hydrogen carbonate; Meylon; 7542-12-3 (unspecified hydrochloride salt); Sandoz sodium bicarbonate; Natron; Sodium hydrogen carbonate; 196216-68-9; 144-55-8; Golytely; MolPort-003-926-303; Peg-lyte; Natrii hydrogencarbonas; Baking soda; Natrium bicarbonicum; Nulytely; Natrium hydrogencarbonicum; Sodium carbonate (Na(HCO3)); LS-2380; BSS plus; D01203; S5761_SIGMA; Sodium bicarbonate (1:1); Go-evac; 88208_FLUKA; C12603; Carbonic acid sodium salt (1:1); Soda (van); Caswell No. 747; Natrum bicarbonicum; Bicarbonate, Sodium; Glycoprep; Sodium bicarbonate liquid concentrate; S3817_SIGMA; CID8953; 13433_RIEDEL; HSDB 697; S6297_SIAL; Sodium bicarbonate [USAN:JAN]; Lithium bicarbonate; CHEBI:32139; 36486_FLUKA; DB01390; Hydrogen Carbonate, Sodium; 172672-17-2; 31437_SIAL; Sodium hydrogencarbonate; CID516892; EPA Pesticide Chemical Code 073505; EINECS 205-633-8; Carbonic acid monosodium salt; 800 Sodium Bicarbonate Powder; Monosodium carbonate; NSC 134031; CHEMBL1353; Sel De vichy; Hema BP-38; S4019_SIAL; Neut (TN); Natriumhydrogenkarbonat; Neut; Colovage; Jusonin; CCRIS 3064; Co-lav; 401676_SIAL; 199723-76-7; Soda Mint; Bicarbonate of soda; AC1Q1W5G; Soda, Baking; S6014_SIAL; Acidosan	144-55-8	8953	7848266	TTDS00413	Voltage-dependent T-type calcium channel subunit alpha-1H	KCND3;Voltage-gated potassium channel subunit Kv4.3	O95180	8912	ENSG00000196557	blocker
DCL001069	Bevasiranib	N/A	959961-96-7	N/A	N/A	TTDC00289	mRNA of Vascular endothelial growth factor A165 isoform	N/A	N/A	N/A	N/A	N/A
DAP000665	Gabapentin	NCGC00021545-04; HSDB 7364; NCGC00015466-09; LS-7194; Prestwick0_000861; G154_SIGMA; Novo-Gabapentin; 1-(Aminomethyl)-cyclohexaneacetic acid; DB00996; Prestwick_151; Gabapentin Stada; AC1L1FYE; gabapentinium; HMS1570N03; 2-[1-(aminomethyl)cyclohexyl]acetic acid; STK598009; DDS-2003; DM-1796; Cyclohexaneacetic acid, 1-(aminomethyl)-; BB_SC-1512; PMS-Gabapentin; Aclonium; Gabapentinum; NCGC00015466-01; Gabapentino; MolPort-000-883-862; 60142-96-3; Gabapentin-ratiopharm; Serada; G0318; gabapentin; CCRIS 7210; UNII-6CW7F3G59X; MLS000069358; I06-0677; Gabapentine; Vultin; AC-1485; Gabapentine [INN-French]; Pharmascience brand of gabapentin; Gabapetin; GOE 2450; NCGC00015466-02; NSC742194; Goe-3450; CAS-60142-96-3; Parke Davis brand of gabapentin; DM-5689; Prestwick3_000861; Apotex brand of gabapentin; Apo-Gabapentin; Gabapentino [Spanish]; Gabapentin [USAN:INN:BAN]; ratiopharm brand of gabapentin; NCGC00016891-01; Go 3450; NCGC00021545-05; Pfizer brand of gabapentin; Gabapentino [INN-Spanish]; Tocris-0806; C9H17NO2; EU-0100582; BRN 2359739; Gabapentin Hexal; Prestwick2_000861; BIDD:GT0656; CI-945; Gabapen; NCGC00021545-02; BPBio1_000993; SMR000058311; S2133_Selleck; Neurontin; C040029; gabapentina; CID3446; HMS2089J03; SPBio_002822; Gabapentin GR; Hexal brand of gabapentin; Lopac0_000582; NCGC00015466-06; Prestwick1_000861; CI 945; EINECS 262-076-3; [1-(AMINOMETHYL)CYCLOHEXYL]ACETIC ACID; Novopharm brand of gabapentin; Gabapentinum [INN-Latin]; 1-(Aminomethyl)cyclohexaneacetic acid; AC1Q53PH; TL8003814; L000733; G-154; AKOS000280865; CHEMBL940; Stadapharm brand of gabapentin; D00332; CHEBI:188316; Gabapentin (JAN/USAN/INN); GBN; gabapentin (Neurontin); Neurontin (TN); BSPBio_000901; Aventis brand of gabapentin; CHEBI:42797; Warner-Lambert brand of gabapentin; Lopac-G-154	60142-96-3	3446	183654	TTDS00022	Gamma-aminobutyric acid B receptor	GABA B receptor;GABA(B) receptor;GABAB receptor;Gamma-aminobutyric acid type b receptor	N/A	N/A	N/A	antagonist
DCL001098	SGS-742	145537-81-1; DVD-742; SGS-742; LS-173250; Cgp-36742; PDSP2_001463; CID130021; AC1L2WMW; (3-Aminopropyl)(n-butyl)phosphinic acid; 3-aminopropyl(butyl)phosphinic acid; CHEMBL112797; L000169; PDSP1_001479; CHEBI:285141; Cgp 36742; SGS 742; 123690-78-8; (3-Aminopropyl)butylphosphinic acid; Phosphinic acid, (3-aminopropyl)butyl-; LS-183981; C7H18NO2P	N/A	N/A	N/A	TTDS00022	Gamma-aminobutyric acid B receptor	GABA B receptor;GABA(B) receptor;GABAB receptor;Gamma-aminobutyric acid type b receptor	N/A	N/A	N/A	antagonist
DCL000466	AZD3355	N/A	N/A	N/A	N/A	TTDS00022	Gamma-aminobutyric acid B receptor	GABA B receptor;GABA(B) receptor;GABAB receptor;Gamma-aminobutyric acid type b receptor	N/A	N/A	N/A	agonist
DAP000258	Progabide	AC1OA7P1; Progabidum [INN-Latin]; LS-45438; Gabren; BRN 2339306; CHEBI:137067; D05621; Progabide; Halogabide; Progabida; Progabidum; CID5361323; Butyramide, 4-(alpha-(p-chlorophenyl)-5-fluoro-2-hydroxybenzylideneamino)-; AC1NSF62; AC1O3RGQ; DB00837; Gabren (TN); SL-76002; C17H16ClFN2O2; Progabide [USAN:BAN:INN]; CID6850568; Progabide [USAN:INN:BAN]; 4-(alpha-(p-Chlorophenyl)-5-fluoro-2-hydroxybenzylideneamino)butyramide; 4-((alpha-(p-Chlorophenyl)-5-fluorosalicylidene)amino)butyramide; CHEMBL287631; 4-[[(Z)-(4-chlorophenyl)-(3-fluoro-6-oxocyclohexa-2,4-dien-1-ylidene)methyl]amino]butanamide; SL 76002; 4-[[(E)-(4-chlorophenyl)-(3-fluoro-6-oxocyclohexa-2,4-dien-1-ylidene)methyl]amino]butanamide; CID6314395; EINECS 263-679-4; Gabrene; Progabide (USAN/INN); SL 76-002; 4-(((4-Chlorophenyl)(5-fluoro-2-hydroxyphenyl)methylene)amino)butanamide; 62666-20-0; C017985; Progabida [INN-Spanish]; 4-[[(4-chlorophenyl)-(3-fluoro-6-oxocyclohexa-2,4-dien-1-ylidene)methyl]amino]butanamide; BUTANAMIDE, 4-(((4-CHLOROPHENYL)(5-FLUORO-2-HYDROXYPHENYL)METHYLENE)AMINO)-	62666-20-0	5361323	184378	TTDS00022	Gamma-aminobutyric acid B receptor	GABA B receptor;GABA(B) receptor;GABAB receptor;Gamma-aminobutyric acid type b receptor	N/A	N/A	N/A	agonist
DAP000257	Baclofen	CCRIS 3722; DB00181; Nu Baclo; KBio2_003034; Kemstro (TN); STOCK2S-30552; BPBio1_000750; Baclofene Irex; MolPort-002-051-370; CHEMBL701; B5399_SIGMA; Baclofen Pharmascience Brand; Ba34647; Ba-34,647; Gen-Baclofen; Nu Pharm Brand of Baclofen; Ba34,647; STK535284; Baclofenum; KBioSS_000466; Apo Baclofen; AWD, Baclofen; Pms-Baclofen; Irex Brand of Baclofen; baclofen; 1134-47-0; NCGC00015156-12; Hydrocinnamic acid, .beta.-(aminomethyl)-p-chloro-; Lioresal (TN); Baclofeno; Isis Brand of Baclofen; 4-Amino-3-(4-chlorophenyl)butanoic acid; BaclofeneIrex; DL-Baclofen; KBio2_000466; Spectrum4_000245; Gabalon; NCGC00024579-04; BRD-A84174873-001-05-2; Baclofen (R,S); PCP-GABA; Baclofene-Irex; beta-(4-Chlorophenyl)gaba; NuBaclo; Apotex Brand of Baclofen; 4-Amino-3-(4-chlorophenyl)butyric acid; (+-)-Baclofen; AC-4530; Oprea1_440627; Nu-Pharm Brand of Baclofen; DL-4-Amino-3-p-chlorophenylbutanoic acid; Pharmascience Brand of Baclofen; Baclofenum [INN-Latin]; PMSBaclofen; Clofen; NSC329137; Benzenepropanoic acid, beta-(aminomethyl)-4-chloro-, (+-)-; Prestwick0_000085; Baclofeno [INN-Spanish]; (+/-)-BACLOFEN; Benzenepropanoic acid, beta-(aminomethyl)-4-chloro-(9CI); Baclofen Novartis Brand; CHEBI:2972; HMS1920E21; Nu-Baclo; Baclofen [USAN:INN:BAN:JAN]; KBio3_001380; Baclofen (JP15/USP/INN); AB00051921; Baclofene; CIBA-34,647-BA; C 34647Ba; Genpharm; Baclofen Isis Brand; KBio1_000001; L000002; Lioresal; Chlorophenyl GABA; Baclofen Nu-Pharm Brand; UPCMLD-DP142:001; Medtronic Brand of Baclofen; Baclofen AWD; Baclophen; PMS Baclofen; Novartis Brand of Baclofen; SMP1_000036; Ciba 34,647-Ba; 62594-36-9; ASTA Medica Brand of Baclofen; KBio2_005602; Baclofen Alphapharm Brand; Atrofen; Gen Baclofen; BPBio1_000012; HMS1568A12; AC1L1DC6; NCGC00024579-05; MLS000028480; HMS500A03; EINECS 214-486-9; BSPBio_001880; Ba 34647; KBioGR_000650; D001418; GABA, Chlorophenyl; HYDROCINNAMIC ACID, beta-(AMINOMETHYL)-p-CHLORO-; Prestwick2_000085; Prestwick1_000085; Prestwick3_000085; Baclofen Ciba-Geigy Brand; B 5399; Baclofen Apotex Brand; BSPBio_000010; EU-0100163; Biomol-NT_000251; Ba-34647; Alphapharm Brand of Baclofen; Lioresal Intrathecal; Spectrum2_000092; CIBA34,647BA; SPECTRUM1500135; Lopac0_000163; DivK1c_000001; NINDS_000001; Ciba-Geigy Brand of Baclofen; NCGC00023843-03; B3343; Baclofene [INN-French]; Benzenepropanoic acid, .beta.-(aminomethyl)-4-chloro-; GenBaclofen; Lebic; (?)-Baclofen; Benzenepropanoic acid, beta-(aminomethyl)-4-chloro-; UNII-H789N3FKE8; I01-1934; C10H12ClNO2; CID2284; Apo-Baclofen; Ashbourne Brand of Baclofen; Baclofen Medtronic Brand; ApoBaclofen; BRN 2104494; Baclofen Ashbourne Brand; Baclon; SMR000058294; Butanoic acid, 4-amino-3-(4-chlorophenyl)-; Kemstro; (+/-)-beta-(Aminomethyl)-4-chlorobenzenepropanoic acid; SPBio_000044; UPCMLD-DP142; SPBio_001949; Prestwick_85; NCGC00024579-06; NCGC00015156-05; D00241; Spectrum3_000310; ( inverted question mark)-Baclofen; beta-(Aminomethyl)-4-chlorobenzenepropanoic acid; gamma-Amino-beta-(p-chlorophenyl)butyric acid; Spectrum_000066; (+/-)- beta-(Aminoethyl)-4- chlorobenzenepropanoic acid; Spectrum5_000852; beta-(p-Chlorophenyl)-gamma-aminobutyric acid; Nu-Baclofen; Baclospas; NCGC00024579-03; beta-(Aminomethyl)-p-chlorohydrocinnamic acid; IDI1_000001; LS-77134; Baclofen Irex Brand; Baclofen Athena Brand; Ciba Geigy Brand of Baclofen; Athena Brand of Baclofen; HMS2091M03	1134-47-0	2284	9059	TTDS00022	Gamma-aminobutyric acid B receptor	GABA B receptor;GABA(B) receptor;GABAB receptor;Gamma-aminobutyric acid type b receptor	N/A	N/A	N/A	agonist
DAP000418	Flurandrenolide	Fluorandrenolone; Fludroxicortida [INN-Spanish]; 6alpha-Fluoro-16alpha-hydroxyhydrocortisone 16,17-acetonide; Fluradrenolide; Fludroxycortide; NCGC00023234-03; BRD-K00824317-001-03-0; 6alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxypregn-4-ene-3,20-dione, cyclic 16,17-acetal with acetone; Pregn-4-ene-3,20-dione, 6-fluoro-11,21-dihydroxy-16,17-((1-methylethylidene)bis(oxy))-, (6alpha,11beta,16alpha)-; ZINC04097308; Fludrossicortide; Floudroxycortide; Haldrone-F; Prestwick3_000645; Flurandrenolide (USP); CID15209; Flurandrenolone acetonide; MLS001148136; Pregn-4-ene-3,20-dione, 6alpha-fluoro-11beta,16alpha,17,21-tetrahydroxy-, cyclic 16,17-acetal with acetone; Haelan; Drenison; 1524-88-5; Fludroxicortida; CHEMBL1201012; MLS000069556; MolPort-005-943-436; Drocort; Flurandrenolide [USAN]; HMS1570A11; Flurandrenolone; Alondra-F; EINECS 216-196-8; Acetonide of 6alpha-fluoro-16alpha-hydroxyhydrocortisone; Pregn-4-ene-3,20-dione, 6-alpha-fluoro-11-beta,16-alpha,17,21-tetrahydroxy-, cyclic 16,17-acetal with acetone; DB00846; LS-118689; Fludroxycortidum; L 33379; Prestwick1_000645; 6alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxyprogesterone cyclic 16,17-acetal with acetone; Cordran; flurandrenolide; SPBio_002570; Fludrossicortide [DCIT]; Prestwick0_000645; Sermaka; CORDRAN SP; HSDB 3084; Fludroxycortide (JAN/INN); SMR000058825; Prestwick_1065; BPBio1_000715; UNII-8EUL29XUQT; BSPBio_000649; D00328; Fluorandrenolone acetonide; Fludroxicortidum; C24H33FO6; Fludroxycortidum [INN-Latin]; Prestwick2_000645; CORDRAN (TN); AC1L25EB	1524-88-5	15209	7847394	TTDS00068	Corticosteroid-binding globulin	CBG;Transcortin	P08185	866	ENSG00000170099	binder
DAP000416	Beclomethasone	CPD000466920; Beconasol; SMR000466920; NCGC00015136-01; MolPort-003-940-375; NCGC00162078-01; B0385_SIGMA; BCBcMAP01_000159; Beclometasona; Beclometasone (INN); Inalone; C22H29ClO5; SMP1_000039; NCGC00162078-02; Beclometasonum; Beclocort; UNII-KGZ1SLC28Z; NCGC00015136-02; Beclometasona [INN-Spanish]; MLS000028668; Lopac-B-0385; D07495; 9-Chloro-11beta,17,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione; MLS001076089; DB00394; 9alpha-Chloro-11beta,17alpha,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione; Beclometason; B 0385; Vancenase AQ; MLS002153387; Beclometason (TN); C06842; Viarex; 4419-39-0; AC1L2GBM; CID20469; CHEMBL1586; NCGC00164402-01; MolPort-003-844-701; ZINC04097285; NCGC00093647-01; CHEBI:3001; BMJ 5800; Becotide; MLS001333212; 9-chloro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; (11beta,16beta)-9-chloro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione; Lopac0_000159; AC1O7G0A; AC1L1DDX; Beclometasondipropionat Mikron; CID6603734; (8S,9R,10S,11S,13S,14S,16S,17R)-9-chloro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; Anceron; Becodisks; CID11957468; (8R,9S,10S,11S,13R,14R,16R,17R)-9-chloro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; Pregna-1,4-diene-3,20-dione, 9-chloro-11,17,21-trihydroxy-16-methyl-, (11beta,16beta)-; Becloval; EINECS 224-585-9; 9alpha-Chloro-16beta-methylprednisolone; MLS001333211; Beclometasonum [INN-Latin]; EU-0100159; MLS001424231; CID11407187; 9alpha-Chloro-16beta-methyl-1,4-pregnadiene-11beta,17alpha,21-triol-3,20-dione; BIDD:GT0556; Pregna-1,4-diene-3,20-dione, 9-chloro-11,17,21-trihydroxy-16-methyl-, (11.beta.,16.beta.)-; Beclometasone [INN]; HMS2052E17; LS-174992; SAM001246898; SMR000058899; CID2308; beclomethasone	4419-39-0	20469	9060	TTDS00068	Corticosteroid-binding globulin	CBG;Transcortin	P08185	866	ENSG00000170099	binder
DAP000814	Flumethasone Pivalate	MolPort-002-885-878; Locorten (TN); AC1L9FI1; CHEBI:31620; Flumetasone pivalate; 6,9-Difluoro-11,17-dihydroxy-16-methyl-3,20-dioxopregna-1,4-dien-21-yl pivalate; 6.Alpha.,9.alpha.-Difluoro-16.alpha.-methylprednisolone 21-pivalate; 6.Alpha.,9-Difluoro-11.beta.,17,21-trihydroxy-16.a; 6alpha,9-difluoro-11beta,17-dihydroxy-16alpha-methyl-3,20-dioxopregna-1,4-dien-21-yl 2,2-dimethylpropanoate; F0891_SIGMA; Locacorten; Lorinden; AC-2070; ZINC03977985; MLS001077304; Flumethasone pivalate (USP); Locorten; KS-1138; SMR000058824; DB00663; MLS000069558; CID443980; D01464; NSC107680; [2-[(6S,8S,9R,10S,11S,13S,14S,16R,17R)-6,9-difluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] 2,2-dimethylpropanoate; FLUMETHASONE PIVALATE; Flumetasone pivalate (JAN/BAN); lpha.-methylpregna-1,4-diene-3,20-dione 21-pivalate; Pregna-1,4-diene-3,20-dione, 21-(2,2-dimethyl-1-oxopropoxy)-6,9-difluoro-11, 17-dihydroxy-16-methyl-, (6.alpha.,11.beta.,16.alpha.)-; CHEMBL1200877; 6alpha,9-Difluoro-11beta,17,21-trihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione 21-(2,2-dimethylpropionate); 2002-29-1	2002-29-1	443980	7848527	TTDS00068	Corticosteroid-binding globulin	CBG;Transcortin	P08185	866	ENSG00000170099	binder
DAP000813	Fluocinolone Acetonide	Retisert (TN); Pregna-1,4-diene-3,20-dione, 6,9-difluoro-11,21-dihydroxy-16,17-((1-methylethylidene)bis(oxy))-, (6alpha,11beta,16alpha)-; Synalar-HP; Derma-smoothe/fs; AC1Q6ACL; D01825; FLUOCINOLONE ACETONIDE; NCGC00021301-04; Retisert; Synandrone; Acetonida de fluocinolona; Sinalar; Prodermin; 4b,12-Difluoro-6b-glycoloyl-5-hydroxy-4a,6a,8,8-tetramethyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one; 6.Alpha., 9.alpha.-Difluoro-16.alpha.-h; MLS001076276; Radiocin; Percutina; flucinolone; Omniderm; UNII-0CD5FD6S2M; DB00591; Fluovitif; NCI60_042042; AC-429; RS 1401AT; Neo-Synalar; CCRIS 3250; Medidur; FS; Fluocinolone 16,17-acetonide; 6.alpha.-Fluorotriamcinolone acetonide; Fluocinolone acetonide (JP15/USP/INN); F8880_FLUKA; Cortiplastol; AC1L1M1L; (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-difluoro-5-hydroxy-6b-(hydroxyacetyl)-4a,6a,8,8-tetramethyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one; 6alpha,9-Difluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione, cyclic 16,17-acetal with acetone; SMR000058329; Dermalar; Flucort; Synotic; Tefunote; Pregna-1,4-diene-3,20-dione, 6alpha,9-difluoro-11beta,16alpha,17,21-tetrahydroxy-, cyclic 16,17-acetal with acetone; Fluocinoloni acetonidum; CID6215; Pregna-1,4-diene-3,20-dione, 6,9-difluoro-11,21-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)-, (6.alpha.,11.beta.,16.alpha.)-; Acetonide de fluocinolone; NSC 92339; RS-1401 AT; STOCK1N-55828; WLN: T F5 E5 B666 GO IO RV AHTTTT&J A BF CQ E FVIQ H H OF -A&BHO -B&ACEF; 6.alpha.,9-Difluoro-11.beta.,16.alpha.,17,21-tetrahydroxypregna-1,4-diene-3,20-dione, cyclic 16,17-acetal with acetone; Synalar; Fluocinolonacetonidum; Synamol; HSDB 3083; F8880_SIGMA; Fluocinoloni acetonidum [INN-Latin]; Acetonida de fluocinolona [INN-Spanish]; Flupollon; 67-73-2; Synsac; Fluocinolone acetonide [USAN:INN:JAN]; Synandone; 6alpha,9alpha-Difluoro-16alpha-hydroxyprednisolone 16,17-acetonide; MolPort-002-528-328; 6-alpha,9-alpha-Difluoro-16-alpha-hydroxyprednisolone 16,17-acetonide; Pregna-1,4-diene-3,20-dione, 6,9-difluoro-11,12-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]-, (6.alpha.,11.beta.,16.alpha.)-; MLS000028545; S2470_Selleck; AR-1H0758; ydroxyprednisolone 16,17-acetonide; 6.Alpha.,9-Difluoro; Localyn Syntex; Fluocet; component of Neo-Synalar; Fluotrex; 6alpha,9alpha-Difluoro-11beta,16alpha,17alpha,21-tetrahydroxy-1,4-pregnadiene-3,20-dione 16,17-Acetonide; Flucinar; Fluocet (TN); SAM002564208; LS-118443; F0657; 6a,9a-difluoro-16a-hydroxyprednisolone 16,17-acetonide; Pregna-1,4-diene-3,20-dione, 6,9-difluoro-11,12-dihydroxy-16,17-((1-methylethylidene)bis(oxy))-, (6-alpha,11-beta,16-alpha)-; 6.alpha.,9.alpha.-Difluoro-16.alpha.-hydroxyprednisolone 16,17-acetonide; 6alpha,9alpha-Difluoro-11beta,16alpha,17alpha,21-tetrahydroxy-1,4-pregnadiene-3,20-dione; Coriphate; C24H30F2O6; Pregna-1,4-diene-3,20-dione, 6.alpha.,9-difluoro-11.beta.,16.alpha.,17,21-tetrahydroxy-, cyclic 16,17-acetal with acetone; Jellin; Synalar (TN); NSC92339; HMS2090I14; Synemol; Localyn; Fluonid; ZINC03977981; Dermatin (steroid); CHEMBL989; Fluocinolone acetonide [DCIT]; Acetonide de fluocinolone [INN-French]; Fs Shampoo; Pregna-1,4-diene-3,20-dione, 6,9-difluoro-11,21-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]-, (6.alpha.,11.beta.,16.alpha.)-; EINECS 200-668-5; 6alpha-Fluorotriamcinolone acetonide; CPD000058329; Pregna-1,4-diene-3,20-dione, 6alpha,9-difluoro-11beta,16alpha,17,21-tetrahydroxy-, cyclic 16,17-acetal with acetone (8CI); Fluortriamcinolone Acetonide	67-73-2	6215	7848887	TTDS00068	Corticosteroid-binding globulin	CBG;Transcortin	P08185	866	ENSG00000170099	binder
DAP000415	Alclometasone	UNII-136H45TB7B; CHEBI:53776; 67452-97-5; D07116; (7R,8S,9S,10R,11S,13S,14S,16R,17R)-7-chloro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one; CID5311000; AC1NSJSZ; (7alpha,11beta,16alpha)-7-chloro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione; Alclometasone [INN:BAN]; Aclometasone; Alclometasone (INN); alclometasone; 7alpha-Chloro-16alpha-methylprednisolone	66734-13-2	636374	7848882	TTDS00068	Corticosteroid-binding globulin	CBG;Transcortin	P08185	866	ENSG00000170099	binder
DAP000422	Paramethasone	paramethasone; Paramethasone [INN:BAN]; Dillar (TN); (6S,8S,9S,10R,11S,13S,14S,16R,17R)-6-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one; Pregna-1,4-diene-3,20-dione, 6alpha-fluoro-11beta,17,21-trihydroxy-16alpha-methyl-; Parametasone [DCIT]; (6alpha,11beta,16alpha)-6-fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione; Parametasona; CHEMBL1579; AC1L1LBS; Paramethasonum [INN-Latin]; 6alpha-Fluoro-16alpha-methylprednisolone; Flumethone; LS-175409; D07464; CS 1483; Pregna-1,4-diene-3,20-dione, 6-fluoro-11,17,21-trihydroxy-16-methyl-, (6alpha,11beta,16alpha)-; Parametasona [INN-Spanish]; Cassenne; 53-33-8; C07413; Paramethasone (INN); HSDB 3376; CID5875; Paramethasonum; EINECS 200-169-2; UNII-VFC6ZX3584; Metilar; Paramezone; Cortiden; 16alpha-Methyl-6alpha-fluoroprednisolone; DB01384; Dillar; Parametasone	53-33-8	5875	9617	TTDS00068	Corticosteroid-binding globulin	CBG;Transcortin	P08185	866	ENSG00000170099	binder
DAP000419	Prednisolone	Deltasolone; delta(sup 1)-Dehydrocortisol; Erbasona; Lentosone; Hydroretrocortine; Predisolone Sodium Phosphate; Hydeltrone; CO-Hydeltra; Sterane; Dicortol; Fernisolone-P; Eazolin D; DiAdresonF; Steran; Predate; Cotogesic; Delta-Cortef (TN); delta(1)-Hydrocortisone; Lite Pred; Prednisolonum [INN-Latin]; NSC 9120; Di-adreson F; CHEBI:8378; Delcortol; HMS1568H10; Predair A; Predcor-Tba; 1-Dehydrocortisol; Predniretard; Donisolone; Codelcortone; Fernisolone; Deltacortril; Poly-Pred; Ophtho-Tate; Articulose-50; delta(sup 1)-Dehydrohydrocortisone; .DELTA.1-Dehydrocortisol; Meticortelone; Predni-Dome; component of K-Predne-Dome; Deltahydrocortisone; Prednis; Precortisyl; Predonin; Ultracortene H; Bio-0666; UNII-9PHQ9Y1OLM; Delta(1)-dehydrohydrocortisone; Predcor-25; Rolisone; Deltisilone; Ultracorten H; BSPBio_000148; Metacortandralone; Prednisolonum; K 1557; .delta.-Stab; Paracortol; Prelone; .DELTA.1-Hydrocortisone; PRDL; Prednelan; Estilsona; Ak-Tate; delta(1)-Cortisol; Prednisolona [INN-Spanish]; BRN 1354103; Prestwick0_000274; Flamasone; Orapred; CPD000718761; Key-Pred; component of Ataraxoid; LS-7669; delta(sup 1)-Hydrocortisone; SPBio_002367; Prestwick_404; Delta-Cortef; HSDB 3385; delta(1)-Dehydrocortisol; Predate Tba; Hydroretrocortin; Sterolone; Predate-50; 46656_FLUKA; Prednisolona; Prednisolone (JP15/USP/INN); SAM002264639; Di-Adreson-F; C07369; D00472; Erbacort; Bubbli-Pred; Ultra Pred; Dexa-Cortidelt hostacortin H; D011239; Ultracortene-hydrogen; Derpo PD; 1-Dehydrohydrocortisone; .DELTA.1-Cortisol; EINECS 200-021-7; MLS001304083; Hydeltra; Cordrol; 50-24-8; Precortancyl; NCGC00179649-01; AC1L1L2E; Decaprednil; Neo-Delta-Cortef; BRD-K98039984-001-03-0; Precortilon; CCRIS 980; Predalone T.B.A.; Predonine; Hostacortin H; DB00860; Ulacort; Delta F; S1737_Selleck; ZINC03833821; Fernisolone P; Predniliderm; 46656_RIEDEL; NSC9900; MolPort-002-507-147; LMST02030179; Delta-Ef-Cortelan; Prednisolone [INN:BAN:JAN]; Prestwick2_000274; Supercortisol; Ocu-Pred; AC-1773; PRED-G; Dydeltrone; P6004_SIGMA; Hydrodeltisone; Ocu-Pred Forte; Scherisolon; MLS002207037; prednisolone; Delta-stab; Prenolone; 8056-11-9; Precortalon; Cortalone; Prednisolone (anhydrous); delta(sup 1)-Cortisol; Meti-Derm; Predcor-50; Nor-Pred T.B.A.; 1,2-Dehydrohydrocortisone; .delta.-Cortef; P0637; CHEMBL131; Solone; .DELTA.1-Dehydrohydrocortisone; Ultracortene-H; Klismacort; CID5755; Panafcortelone; Paracotol; Prestwick3_000274; Decortin H; 58201-11-9; Prestwick1_000274; Hydrodeltalone; Deltacortenol; NSC9120; Predne-Dome; Di Adreson F; Prednicen; Deltacortril Enteric; MLS002154250; Ak-Pred; HMS2090J05; Cotolone; I-Pred; Delta(1)-dehydrocortisol; Delta(1)-dehydrohydrocortisone; Delta(1)-hydrocortisone; Prednisolone; hydroretrocortine; metacortandralone; BPBio1_000164; P0152_SIGMA; SMR000718761	50-24-8	5755	148534	TTDS00068	Corticosteroid-binding globulin	CBG;Transcortin	P08185	866	ENSG00000170099	binder
DAP000421	Fluocinonide	LS-118446; Vanos (TN); Fluocinolone acetonide 21-acetate; Fluocinolide; UNII-2W4A77YPAN; BSPBio_000848; Fluocinonide [USAN:BAN:INN:JAN]; Fluocinonide (JP15/USP/INN); fluocinonide; Fluocinonide Emulsified Base; Lonide; Vanos; Cortalar; Prestwick3_000774; CPD000058331; Prestwick1_000774; AC1L1TI1; Pregna-1,4-diene-3,20-dione, 6alpha,9-difluoro-11beta,16alpha,17,21-tetrahydroxy-, cyclic 16,17-acetal with acetone, 21-acetate; BRD-K57886322-001-03-4; D00325; SMR000058331; Fluocinonidum; Prestwick0_000774; Fluocinolide acetate; AC-2071; NCGC00022398-03; DB01047; Fluocinonide [USAN:INN:BAN:JAN]; HMS1570K10; Straderm; MLS000028476; Topsyn; ZINC03977978; Lidex; Fluocinonide FAPG; MolPort-002-528-921; Fluonex; Prestwick_1066; Fluocinonido [INN-Spanish]; CID9642; Fluocinolone acetonide acetate; Pregna-1,4-diene-3,20-dione, 21-(acetyloxy)-6,9-difluoro-11-hydroxy-16,17-((1-methylethylidene)bis(oxy))-, (6alpha,11beta,16alpha)-; 356-12-7; LIDEX-E; Fluocinonido; EINECS 206-597-6; Prestwick2_000774; Metosyn; BPBio1_000934; Biscosal; Lyderm; LIDEX (TN); SPBio_002787; Pregna-1,4-diene-3,20-dione, 6alpha,9-difluoro-11beta,16alpha,17,21-tetrahydroxy-, cyclic 16,17-acetal with acetone, 21-acetate (8CI); Bestasone; CHEMBL1501; Pregna-1,4-diene-3,20-dione, 6-alpha, 9-difluoro-11-beta,16-alpha,17,21-tetrahydroxy-, cyclic17-acetal with acetone, 21-acetate; Fluzon; 6alpha,9-Difluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione, cyclic 16,17-acetal with acetone, 21-acetate; STOCK1N-56641; SAM002589945; NSC 101791; Fluocinonidum [INN-Latin]; Lidex E; Synalar acetate; Topsymin	356-12-7	9642	7847391	TTDS00068	Corticosteroid-binding globulin	CBG;Transcortin	P08185	866	ENSG00000170099	binder
DAP000417	Triamcinolone	EU-0101179; Triamcinolona [INN-Spanish]; nchembio.2007.53-comp7; Prestwick3_000120; Triamcinolone [USAN:INN:BAN:JAN]; Lopac0_001179; Triamcinolonum; NCI60_000750; Aristocort; Trilone; S1933_Selleck; NSC 13397; 11-beta,16-alpha,17-alpha,21-Tetrahydroxy-9-alpha-fluoro-1,4-pregnadiene-3,20-dione; Orion; SMP1_000300; NSC13397; Triamcinalone; Pregna-1,4-diene-3,20-dione, 9-fluoro-11-beta,16-alpha,17,21-tetrahydroxy-; Tiamcinolonum [INN-Latin]; NCGC00021580-06; MLS001066543; Cinolone-T; ZINC03882036; EINECS 204-718-7; Triamcinolon; D00385; 83474-03-7; Rodinolone; CL 19823; 124-94-7; T6376_SIGMA; Pregna-1,4-diene-3,20-dione, 9-fluoro-11beta,16alpha,17,21-tetrahydroxy-; 9alpha-Fluoro-16alpha-hydroxyprednisolone; Cinolone; Fougera; HMS1568G22; Bio-0662; SPBio_002079; 9.alpha.-Fluoro-16.alpha.-hydroxyprednisolone; NCGC00021580-03; Delphicort; 9alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxy-1,4-pregnadiene-3,20-dione; BRN 2341955; AC1Q5HJC; BRD-K77554836-001-03-3; Pregna-1,4-diene-3,20-dione, 9-fluoro-11beta,16alpha,17,21-tetrahydroxy- (8CI); Pregna-1,4-diene-3,20-dione, 9-fluoro-11.beta.,16.alpha.,17,21-tetrahydroxy-; Prestwick2_000120; 9.alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahydroxypregna-1,4-diene-3,20-dione; Kenacort; Omicilon; Volon; MLS000028542; Tiamcinolonum; NCGC00021580-04; HSDB 3194; CID31307; Prednisolone, 9-fluoro-16alpha-hydroxy-; Celeste; Triamcinlon; Prestwick1_000120; Pregna-1,4-diene-3,20-dione, 9-fluoro-11,16,17,21-tetrahydroxy-, (11-beta,16-alpha)-; 11.beta.,16.alpha.,17.alpha.,21-Tetrahydroxy-9.alpha.-fluoro-1,4-pregnadiene-3,20-dione; ne, 9-fluoro-11,16,17,21-tetrahydroxy-, (11.beta.,16.alpha.)-; 9-alpha-Fluoro-16-alpha-hydroxyprednisolone; D014221; Fluoxyprednisolone; DB00620; Tristoject; 4-08-00-03629 (Beilstein Handbook Reference); Pregna-1,4-diene-3,20-dione, 9-fluoro-11,16,17,21-tetrahydroxy-, (11.beta.,16.alpha.)-; Mycolog; 9.alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahydroxy-1,4-pregnadiene-3,20-dione; Triamcinolone (JP15/USP/INN); Adcortyl; Ledercort; WLN: L E5 B666 OV KU MUTJ A1 BF CQ E1 FV1Q FQ GQ; NCGC00021580-05; droxypregna-1,4-diene-3,20-dione; 9.Alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahydroxy-1,4-pregnadiene-3,20-dione; 9.Alpha.-Fluoro-11.beta.,16.alpha.,17.alpha., 21-tetrahydroxypregna-1,4-diene-3,20-d; Triamcinolonum [INN]; Prestwick_438; MLS002695935; Pregna-1,4-diene-3,20-dione, 9-fluoro-11,16,17,21-tetrahydroxy-, (11beta,16alpha); SMR000058333; Prestwick0_000120; TRIAMCINOLONE (SEE ALSO TRIAMCINOLONE ACETONIDE (76-25-5) AND TRIAMCINOLONE DIACETATE (67-78-7)); Triamcet; 9.alpha.-Fluoro-11.beta.,16.alpha.,17.alpha.,21-tetrahydroxypregna-1,4-diene-3,20-dione; Prednisolone, 9-fluoro-16.alpha.-hydroxy-; CHEMBL1451; NCGC00021580-07; (8S,9R,10S,11S,13S,14S,16R,17S)-9-fluoro-11,16,17-trihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; 9-Fluoro-11,16,17,21-tetrahydroxypregna-1,4-diene-3,20-dione; 11.Beta.,16.alpha.,17.alpha., 21-Tetrahydroxy-9.alpha.-fluoro-1,4-pregnadiene-3,20-dione; 9.Alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahy; BSPBio_000140; SK-Triamcinolone; Pregna-1,4-diene-3,20-dione, 9-fluoro-11,16,17,21-tetrahydroxy-, (11beta,16alpha)-; C21H27FO6; Aristocort Tablets; 9-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione; Kenacort-AG; Fluoxiprednisolone; ione; 9.Alpha.-Fluoro-16.alpha.-hydroxyprednisolone; Prednisolone, 9-fluoro-16.alpha.-hydroxy-; Pregna-1,4-diene-3, 20-dione, 9-fluoro-11.beta.,16.alpha.,17,21-tetrahydroxy-; Pregna-1,4-diene-3,20-dio; BPBio1_000154; Omcilon; LS-698; AC-2072; AC1L1LDH; 9-alpha-Fluoro-11-beta,16-alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione; MolPort-002-528-981; Triamcinolona; 9alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione; triamcinolone; Triam-Tablinen; Kenacort (TN); Tricortale; UNII-1ZK20VI6TY; HMS2090D12	124-94-7	31307	173366	TTDS00068	Corticosteroid-binding globulin	CBG;Transcortin	P08185	866	ENSG00000170099	binder
DAP000423	Ciclesonide	Ciclesonide [INN]; BTR-15; D01703; AC-1330; NCGC00167972-01; TBN-15; Alvesco; 126544-47-6; BYK-20426; Omnair; CID6918155; Osonase; Ciclesonide (JAN/USAN/INN); KS-1165; Alvesco HFA; Omnaris HFA; Ciclesonide; Osonide; LS-186047; 141845-82-1; Alvesco (TN); (R)-11beta,16alpha,17,21-Tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with cyclohexanecarboxaldehyde, 21-isobutyrate; BY-9010; B-9207-015; BTR-15K; UNII-S59502J185; RPR 251526; Omnaris; Pregna-1,4-diene-3,20-dione, 16,17-(((R)-cyclohexylmethylene)bis(oxy))-11-hydroxy-21-(2-methyl-1-oxopropoxy)-, (11beta,16alpha)-; MolPort-005-940-705; Pregna-1,4-diene-3,20-dione, 16,17-((cyclohexylmethylene)bis(oxy))-11-hydroxy-21-(2-methyl-1-oxopropoxy)-, (11beta,16alpha(R))-	141845-82-1	444033	10299472	TTDS00068	Corticosteroid-binding globulin	CBG;Transcortin	P08185	866	ENSG00000170099	binder
DAP000420	Rimexolone	HMS1571K21; Org-6216; Vexol (TN); BSPBio_001179; Prestwick0_001020; (8S,9S,10R,11S,13S,14S,16R,17S)-11-hydroxy-10,13,16,17-tetramethyl-17-propanoyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one; D05729; Rimexolone (USP/INN); Rimexel; Prestwick1_001020; Trimexolone; AL-2178; Prestwick2_001020; BPBio1_001297; MLS002154105; NCGC00179273-01; RIMEXOLONE; SMR001233413; Prestwick3_001020; 49697-38-3; CHEMBL1200617; AC1NSKKX; CID5311412; BRD-K31627533-001-03-8; AB00514006; SPBio_003050	49697-38-3	39507	180512	TTDS00068	Corticosteroid-binding globulin	CBG;Transcortin	P08185	866	ENSG00000170099	binder
DAP000119	Acetyldigitoxin	Digitoxin, alpha-acetyl-; Acetildigitoxina; Acetyldigitoxinum; 3beta-[3-O-acetyl-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyloxy]-14-hydroxy-5beta-card-20(22)-enolide; [(2R,3R,4S,6S)-3-hydroxy-6-[(2R,4S,6S)-4-hydroxy-6-[(2R,3S,4S,6R)-4-hydroxy-6-[[(5R,8R,9S,10S,13R,14S,17R)-14-hydroxy-10,13-dimethyl-17-(5-oxo-2H-furan-3-yl)-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-yl]oxy]-2-methyloxan-3-yl]oxy-2-methyloxan-3-yl]oxy-2-methyloxan-4-yl] acetate; C43H66O14; alpha-Acetyldigitoxins; [(2R,3R,4S,6S)-3-hydroxy-6-[(2R,3S,4S,6S)-4-hydroxy-6-[(2R,3S,4S,6R)-4-hydroxy-6-[[(3S,5R,8R,10S,13R,14S,17R)-14-hydroxy-10,13-dimethyl-17-(5-oxo-2H-furan-3-yl)-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-yl]oxy]-2-methyloxan-3-yl]oxy-2-methyloxan-3-yl]oxy-2-methyloxan-4-yl] acetate; CHEBI:53773; Digitoxin 3'''-acetate; Acetyldigitoxin [INN]; alpha-Acetyldigitoxin; Adicin; Acetyl-digitoxin-alpha; Acetyldiginatin; (3beta,5beta)-3-((O-3-O-Acetyl-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy)-14-hydroxycard-20(22)-enolide; CID10056176; LS-61949; (3beta,5beta)-3-{[3-O-acetyl-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl]oxy}-14-hydroxycard-20(22)-enolide; CID6324906; D06881; CID1997; Acylanid (TN); Acetyldigitoxinum [INN-Latin]; AC1L2AS7; Acylanid; [3-hydroxy-6-[4-hydroxy-6-[4-hydroxy-6-[[14-hydroxy-10,13-dimethyl-17-(5-oxo-2H-furan-3-yl)-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-yl]oxy]-2-methyloxan-3-yl]oxy-2-methyloxan-3-yl]oxy-2-methyloxan-4-yl] acetate; Desglucolanatoside A; AC1O44LA; acetyldigitoxin; BRN 0077291; Acigoxin; Acedigal; AC1L1CP2; CHEMBL1200634; UNII-0ZV4Q4L2FU; alpha-Monoacetyldigitoxin; AC1NR4LG; Digitoxin, acetate, alpha-; Card-20(22)-enolide, 3-((O-3-O-acetyl-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy)-14-hydroxy-, (3beta,5beta)-; 1111-39-3; CID5284512; Acetyldigitoxin (INN); DB00511; Acylanide; EINECS 214-178-4; [(2R,3R,4S,6S)-3-hydroxy-6-[(2R,3S,4S,6S)-4-hydroxy-6-[(2R,3S,4S,6R)-4-hydroxy-6-[[(3S,5R,8R,9S,10S,13R,14S,17R)-14-hydroxy-10,13-dimethyl-17-(5-oxo-2H-furan-3-yl)-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-yl]oxy]-2-methyloxan-3-yl]oxy-2-methyloxan-3-yl]oxy-2-methyloxan-4-yl] acetate; CID68949; Digitoxin, 3'''-acetate; Acetildigitoxina [INN-Spanish]; (3beta,5beta)-3-((O-3-O-Acetyl-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy)-14-hydroxycard-20(22)-enolide	25395-32-8	68949	211111	TTDS00046	Sodium/potassium-transporting ATPase	N/A	N/A	N/A	N/A	inhibitor
DAP000120	Digitoxin	DivK1c_000036; AC1NWALC; NSC7529; 71-63-6; Mono-digitoxid [German]; KBioGR_001087; HMS1920G12; Digimerck; Digitalin, crystalline; MolPort-003-665-570; NCGC00159428-02; Spectrum5_000903; KBioSS_001444; Glucodigin; AC1L1M6R; BSPBio_002205; Purodigin; Digitophyllin; Crystodigin (TN); Digitoxin; Digitoxoside; Digitoxigenin tridigitoxoside; NINDS_000036; CHEBI:28544; Digitoxinum; Digipural; LT00244784; Digilong; Unidigin; NCGC00178764-01; MEGxp0_001901; SDCCGMLS-0066602.P001; Digitaline nativelle; CID3061; UNII-E90NZP2L9U; Digitrin; Mono-digitoxid; Digitoxigenin-tridigitoxosid [German]; Spectrum_000964; Digitoxine [INN-French]; Cardidigin; NCI60_041649; Spectrum3_000393; Spectrum4_000514; Coramedan; BRN 0076678; MLS000069787; Lanatoxin; HMS2091M22; CID11968425; IDI1_000036; CID5351469; Mono-glycocard; SPBio_000259; Natigal; AC1L9AQX; Pandigal; Acedoxin; CID6432666; Carditalin; Digitoksin; 1339-93-1; MolPort-001-742-606; AC1L1F35; Monodigitoxoside; ACon1_000610; HSDB 215; SPECTRUM1500246; CID10078873; Digitoksim; SMP1_000096; CID11251271; Digisidin; KBio2_001444; CID5702041; DB01396; AR-1A5259; Tri-digitoxoside; CHEMBL254219; CCRIS 7116; 87112-48-9; Digitalinum verum; digitoxin; ACon0_000319; D0542; AC1NS0M9; Digitoxinum [INN-Latin]; 5.beta.-Card-20(22)-enolide, 3.beta.,14-dihydroxy-, 3-[tris-(digitoxoside)]; Digitossina; Digitoxin (JP15/USP/INN); A572A148-EC30-47D2-A32A-C9D8A93F8EFC; Digitoxine; C06955; NCGC00142623-03; Ditaven; Digitaline cristallisee; CID6281; Crystalline digitalin; NCGC00142623-01; Panlanat; Digitoxin [INN:BAN:JAN]; Cristapurat; Lanostabil; LMST01120018; KBio3_001425; Purodigin, crystalline; HMS500B18; Crystodigin; Digitoxina; Caswell No. 349; D5878_SIGMA; 1391-34-0; KST-1A8658; Crystodigin (TN); NSC 7529; inhibits Na+/K+ ATPase; BRD-A93236127-001-02-9; Digitoxosidum; Digimed; Digitoxina [INN-Spanish]; Digilanid; Digicor; Digitossina [DCIT]; EINECS 200-760-5; AR-1F1319; BRD-K63668566-001-01-7; Tri-digitoxoside [German]; De-Tone; ST072187; CID441207; KBio2_004012; C41H64O13; Carditoxin; Myodigin; AC1O5EQ0; Spectrum2_000070; Digitoxigenin-tridigitoxosid; Purpurid; EPA Pesticide Chemical Code 097002; KBio1_000036; D00297; SMR000058529; KBio2_006580; SR-01000721879-2; 8006-96-0; Digitoxoside; Cardiolanata; NCGC00142623-02; Tardigal; 1367-39-1; Cardigin; Asthenthilo; LS-61948	71-63-6	441207	7847363	TTDS00046	Sodium/potassium-transporting ATPase	N/A	N/A	N/A	N/A	inhibitor
DAP000744	Digoxin	3-[(3S,5R,8R,9S,10S,12R,13S,14S,17R)-3-[(2R,4S,5S,6R)-5-[(2S,4S,5S,6R)-5-[(2S,4S,5S,6R)-4,5-dihydroxy-6-methyloxan-2-yl]oxy-4-hydroxy-6-methyloxan-2-yl]oxy-4-hydroxy-6-methyloxan-2-yl]oxy-12,14-dihydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2H-furan-5-one; Prestwick3_000437; BPBio1_000500; CID2724385; HMS1569G16; SR-01000721866-3; D1828; D6003_FLUKA; MLS001076495; NCGC00090797-03; 4-[(1S,2S,5S,7R,10R,11S,14R,15S,16R)-5-{[(2R,4S,5S,6R)-5-{[(2S,4S,5S,6R)-5-{[(2S,4S,5S,6R)-4,5-dihydroxy-6-methyloxan-2-yl]oxy}-4-hydroxy-6-methyloxan-2-yl]oxy}-4-hydroxy-6-methyloxan-2-yl]oxy}-11,16-dihydroxy-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^; Prestwick1_000437; Lanoxin (TN); D00298; (3beta,5beta,12beta)-3-{[2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl]oxy}-12,14-dihydroxycard-20(22)-enolide; 12beta-Hydroxydigitoxin; SMR000653537; AC1Q29PT; BRD-K23478508-001-03-7; C06956; MolPort-002-536-760; ST069334; SMR000059217; nchembio.476-comp8; BSPBio_000454; NCGC00090797-02; CHEMBL1751; Lanoxicaps (TN); 20830-75-5; 0B9662A7-264E-4ACD-94B2-9E1138C0CA5A; Prestwick_170; Prestwick2_000437; digoxin; CHEBI:4551; D6003_SIGMA; Prestwick0_000437; STOCK1N-70146; BIDD:PXR0148; D6770_SIGMA; SPBio_002393; Digoxin (JP15/USP); MLS001055371; NCGC00090797-04; MLS000069819; NCGC00090797-01; AC1MC4TN	20830-75-5	30322	172469	TTDS00046	Sodium/potassium-transporting ATPase	N/A	N/A	N/A	N/A	inhibitor
DCL000973	Sarizotan	AC1MHW5N; 1-(3,4-dihydro-2H-chromen-2-yl)-N-[[5-(4-fluorophenyl)pyridin-3-yl]methyl]methanamine; CID3058747; L001578; UNII-467LU0UCUW; Sarizotan; N-((3,4-Dihydro-2H-1-benzopyran-2-yl)methyl)-5-(4-fluorophenyl)-3-pyridinemethanamine; EMD 128130; 177975-08-5; (-)-3-((((R)-2-Chromanylmethyl)amino)methyl)-5-(p-fluorophenyl)pyridine; Sarizotan [INN]; LS-192590	177976-12-4	3058747	3862729	TTDC00291	D(4) dopamine receptor	D(2C)D(4) dopamine receptor dopamine receptor;Dopamine D4 receptor	P21917	1815	ENSG00000069696	agonist
DPR000110	Sonepiprazole	Isochr-etpip-phso2NH2; AC1L2T0Q; CHEMBL69759; PDSP1_000467; CHEMBL146246; 4-[4-[2-[(1S)-3,4-dihydro-1H-isochromen-1-yl]ethyl]piperazin-1-yl]benzenesulfonamide; Benzenesulfonamide, 4-(4-(2-(3,4-dihydro-1H-2-benzopyran-1-yl)ethyl)-1-piperazinyl)-, (S)-; CID133079; AC1L3256; 4-[4-[2-(3,4-dihydro-1H-isochromen-1-yl)ethyl]piperazin-1-yl]benzenesulfonamide; U-101387; 170858-33-0; CHEBI:343832; CHEBI:204505; 4-(4-(2-(Isochroman-1-yl)ethyl)piperazin-1-yl)benzenesulfonamide; Sonepiprazole; UNII-O609V24217; CID128010; U 101387; PDSP2_000465; L000606	170858-34-1	5289469	46392990	TTDC00291	D(4) dopamine receptor	D(2C)D(4) dopamine receptor dopamine receptor;Dopamine D4 receptor	P21917	1815	ENSG00000069696	binder
DPR000019	Belaperidone	Belaperidone; AC1L4FOQ; 3-[2-[(1S,5R,6S)-6-(4-fluorophenyl)-3-azabicyclo[3.2.0]heptan-3-yl]ethyl]-1H-quinazoline-2,4-dione; 3-{2-[(1s,5r,6s)-6-(4-fluorophenyl)-3-azabicyclo[3.2.0]hept-3-yl]ethyl}quinazoline-2,4(1h,3h)-dione; Belaperidone [INN]; CID184841; LU 111995; AR-1F1378; 156862-51-0; AC1Q4NH6; LU-111995; 2,4(1H,3H)-Quinazolinedione, 3-(2-((1S,5R,6S)-6-(4-fluorophenyl)-3-azabicyclo(3.2.0)hept-3-yl)ethyl)-; UNII-4DN0TK4892; Balaperidone	208661-17-0	184841	12015111	TTDC00291	D(4) dopamine receptor	D(2C)D(4) dopamine receptor dopamine receptor;Dopamine D4 receptor	P21917	1815	ENSG00000069696	antagonist
DCL001029	U-99363E	U 99363E; CID133107; N-(1-benzylpiperidin-4-yl)-3-ethoxy-N-methylpyridin-2-amine; U 99363; U-99363E; 3-Ethoxy-N-methyl-N-(1-(phenylmethyl)-4-piperidinyl)-2-pyridinylamine; AC1L3270; 179556-82-2; U-99363	188989-96-0	133107	709406	TTDC00291	D(4) dopamine receptor	D(2C)D(4) dopamine receptor dopamine receptor;Dopamine D4 receptor	P21917	1815	ENSG00000069696	binder
DCL000836	HMR-2934	N/A	N/A	5330286	46394060	TTDC00291	D(4) dopamine receptor	D(2C)D(4) dopamine receptor dopamine receptor;Dopamine D4 receptor	P21917	1815	ENSG00000069696	antagonist
DCL000919	PD-165167	N/A	N/A	9887803	49684212	TTDC00291	D(4) dopamine receptor	D(2C)D(4) dopamine receptor dopamine receptor;Dopamine D4 receptor	P21917	1815	ENSG00000069696	antagonist
DCL000997	SPI-376	N/A	496921-73-4	68870	44945120	TTDC00291	D(4) dopamine receptor	D(2C)D(4) dopamine receptor dopamine receptor;Dopamine D4 receptor	P21917	1815	ENSG00000069696	binder
DCL000898	NGD 94-1	AR-1D7659; CID188942; 2-[4-[(2-phenyl-1H-imidazol-5-yl)methyl]piperazin-1-yl]pyrimidine; Ngd 94-1; PDSP2_001697; CHEBI:266379; Ngd-94-1; 2-{4-[(2-phenyl-1h-imidazol-4-yl)methyl]piperazin-1-yl}pyrimidine; AC1L4NQX; L000440; PDSP1_001714; AC1Q4X5G; CHEMBL103772; 2-Phenyl-4(5)-((4-(2-pyrimidinyl)-piperazin-1-yl)methyl)imidazole dimaleate	113082-98-7	60594	7980118	TTDC00291	D(4) dopamine receptor	D(2C)D(4) dopamine receptor dopamine receptor;Dopamine D4 receptor	P21917	1815	ENSG00000069696	antagonist
DCL000202	PSN357	N/A	127373-66-4	107706	46234170	TTDC00099	Glycogen phosphorylase, muscle form	Glycogen phosphorylase b;Muscle glycogen phosphorylase	P11217	5837	ENSG00000068976	inhibitor
DCL000012	JSM 6427	N/A	N/A	N/A	N/A	TTDC00020	Integrin alpha-5	CD49e antigen;Fibronectin receptor subunit alpha;FNRA;Integrin alpha-5 heavy chain;Integrin alpha-5 light chain;Integrin alpha-F;ITGA5;VLA-5	P08648	3678	ENSG00000161638	antagonist
DAP001190	Clocortolone	9-chloro-6alpha-fluoro-11beta,21-dihydroxy-16alpha-methyl-1,4-pregnadien-3,20-dione; (6S,8S,9R,10S,11S,13S,14S,16R,17S)-9-chloro-6-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-7,8,11,12,14,15,16,17-octahydro-6H-cyclopenta[a]phenanthren-3-one; 4828-27-7; MolPort-005-943-442; D07719; CID5311052; 9-chloro-6alpha-fluoro-11beta,21-dihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione; Clocortolona; AC1NSJWN; ZINC21981454; 9-chloro-6alpha-fluoro-16alpha-methyl-1,4-pregnadiene-11beta,21-diol-3,20-dione; CHEBI:59582; Clocortolonum; Clocortolone (INN); CLOCORTOLONE	34097-16-0	5282493	7849346	TTDS00065	Phospholipase A2	Group IB phospholipase A2;Phosphatidylcholine 2-acylhydrolase;Secreted phospholipase A(2)	P04054	5319	ENSG00000170890	inducer
DAP001187	Hydrocortamate	Hyddrocortison-21-(beta-diethylaminoacetat); Hydrocortamate; Hydrocortamate [INN]; AC1L36R1; Hydrocortamatum; LS-177227; UNII-Y3N00BK5WK; 11beta,17alpha,21-Trihydroxypregn-4-ene-3,20-dione 21-diethylaminoacetate; Glycine, N,N-diethyl-, 21-ester with cortisol; Hydrocortisone 21-(diethylamino)acetate; Hidrocortamato [INN-Spanish]; 11beta,17-dihydroxy-3,20-dioxopregn-4-en-21-yl N,N-diethylglycinate; EINECS 200-963-9; Idrocortamato; Glycine, N,N-diethyl-, (11beta)-11,17-dihydroxy-3,20-dioxopregn-4-en-21-yl ester; Hidrocortamato; 76-47-1; C27H41NO6; 17-Hydroxycorticosterone, 21-(diethylamino)acetate; 11beta,17-Dihydroxy-3,20-dioxo-4-pregnen-21-yl 2-(diethylamino)acetat; CHEBI:50851; Hydrocortamatum [INN-Latin]; CID84088; Magnacort; Idrocortamato [DCIT]; [2-[(8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-10,13-dimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] 2-(diethylamino)acetate	76-47-1	408334	10535192	TTDS00065	Phospholipase A2	Group IB phospholipase A2;Phosphatidylcholine 2-acylhydrolase;Secreted phospholipase A(2)	P04054	5319	ENSG00000170890	inhibitor
DAP001188	Desonide	16alpha,17alpha-isopropylidenedioxyprednisolone; Prednacinolone; I06-0284; desfluorotriamcinolone acetonide; S1701_Selleck; Locapred, Topifug, Tridesilon, Desonide; CID578798; Verdeso; Flusemidon; Desonidum; Prenacid; Desonide [USAN:INN:BAN]; Apolar; CHEBI:204734; ZINC04212851; Prednisolone-16,17-acetonide, 16-alpha-hydroxy-; Verdeso (TN); Topifug; Locapred; Sterax; Desowen (TN); CID5311066; CHEMBL987; 638-94-8; TL8004516; Pregna-1,4-diene-3,20-dione, 11,21-dihydroxy-16,17-((1-methylethylidene)bis(oxy))-, (11beta,16alpha)-; Desonida; D 2083; Pregna-1,4-diene-3,20-dione, 11,21-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]-, (11.beta.,16.alpha.)-; MolPort-003-666-875; DESONIDE; 16alpha-hydroxyprednisolone-16alpha,17-acetonide; CID12536; (4aR,4bS,5S,6aS,6bS,9aR,10aS,10bS)-5-hydroxy-6b-(hydroxyacetyl)-4a,6a,8,8-tetramethyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one; D-2083; Desonate; Zotinar; Tridesilon; AC1LB9FO; Steroderm; AC-2165; Desilux; DB01260; CHEMBL1201109; 11beta,21-dihydroxy-16alpha,17-isopropylidenedioxypregna-1,4-diene-3,20-dione; EINECS 211-351-6; LS-118407; 16-alpha-Hydroxyprednisole-16,17-acetonide; 11beta,21-dihydroxy-16alpha,17alpha-isopropylidenedioxypregna-1,4-diene-3,20-dione; 11beta,21-dihydroxy-16alpha,17-[(1-methylethylidene)bis(oxy)]pregna-1,4-diene-3,20-dione; Desonida [INN-Spanish]; MolPort-003-987-087; Desonide (USAN/INN); Reticus; UNII-J280872D1O; Tridesonit; 16alpha-hydroxyprednisole-16,17-acetonide; D03696; AC1L1ZT0; Hamiltoderm; DesOwen; 11beta,16alpha,17,21-Tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with acetone; Desonidum [INN-Latin]	638-94-8	5311066	17397789	TTDS00065	Phospholipase A2	Group IB phospholipase A2;Phosphatidylcholine 2-acylhydrolase;Secreted phospholipase A(2)	P04054	5319	ENSG00000170890	inhibitor
DAP001186	Halobetasol Propionate	AC1L2JJ6; CID48175; NCGC00167451-01; Ulobetasol propionate; Miracorten; 6 alpha-fluoroclobetasol 17-propionate; Halobetasol propionate [USAN]; Ultravate (TN); CGP 14458; Pregna-1,4-diene-3,20-dione, 21-chloro-6,9-difluoro-11-hydroxy-16-methyl-17-(1-oxopropoxy)-, (6alpha,11beta,16beta)-; Halobetasol; CGP-14458; CID6918178; [(6S,9R,16S,17R)-17-(2-chloroacetyl)-6,9-difluoro-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] propanoate; C25H31ClF2O5; DB00596; HALOBETASOL PROPIONATE; CHEMBL1200908; AC1OCF43; BMY-30056; 6-fluoroclobetasol 17-propionate; 21-Chloro-6alpha,9-difluoro-11beta,17-dihydroxy-16beta-methylpregna-1,4-diene-3,20-dione 17-propionate; Ulobetasol cream; [(6S,8S,9R,10S,11S,13S,14S,16S,17R)-17-(2-chloroacetyl)-6,9-difluoro-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] propanoate; D04409; Ultravate; LS-118431; BMY 30056; Pregna-1,4-diene-3,20-dione, 21-chloro-6,9-difluoro-11-hydroxy-16-methyl-17-(1-oxopropoxy)-,(6-alpha,11-beta,16-beta)-; 66852-54-8; UNII-91A0K1TY3Z; CGP 14 458; Halobetasol propionate (USAN)	66852-54-8	48175	187307	TTDS00065	Phospholipase A2	Group IB phospholipase A2;Phosphatidylcholine 2-acylhydrolase;Secreted phospholipase A(2)	P04054	5319	ENSG00000170890	inhibitor
DAP001183	Clobetasol	21-chloro-9-fluoro-11,17-dihydroxy-16-methylpregna-1,4-diene-3,20-dione; Pregna-1,4-diene-3,20-dione, 21-chloro-9-fluoro-11,17-dihydroxy-16-methyl-, (11beta,16beta)-; Clofenazon; LS-174086; CHEBI:205919; MolPort-005-909-335; CID5311051; Clobetasolum [INN-Latin]; UNII-ADN79D536H; Clobetasol (INN); Clobetasol [INN:BAN]; 21-Chloro-9-fluoro-11beta,17-dihydroxy-16beta-methylpregna-1,4-diene-3,20-dione; C22H28ClFO4; clobetasol; Clobetasolum; Clobecort Amex; CHEMBL1201362; NCGC00164580-01; (9R,17R)-17-(2-chloroacetyl)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; AC1NDRJ9; D07715; CID4630419; AC-1775; 17-(2-chloroacetyl)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; (11beta,16beta)-21-chloro-9-fluoro-11,17-dihydroxy-16-methylpregna-1,4-diene-3,20-dione; 25122-41-2; CID10341542; EINECS 246-633-8; AC1L1OG6; Clobecort Amex (TN); CID32797; AC1NSJWK; CID9844480; STK801976; ZINC26892643; BB_NC-1906; (8S,9R,10S,11S,13S,14S,16S,17R)-17-(2-chloroacetyl)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one	25122-46-7	32798	7848335	TTDS00065	Phospholipase A2	Group IB phospholipase A2;Phosphatidylcholine 2-acylhydrolase;Secreted phospholipase A(2)	P04054	5319	ENSG00000170890	inhibitor
DPR000076	Miltefosine	1-Hexadecylphosphorylcholine; HMS2089J15; n-Hexadecylphosphorylcholine; D18506; SPECTRUM1505329; D 18506; UNII-53EY29W7EC; AC1L1GAH; LS-65132; MolPort-003-665-519; C15H32.C7H17NO4P; Hexadecylphosphocholine; 4-04-00-01460 (Beilstein Handbook Reference); HePC; D-18506; ST51055612; Hexadecyl 2-(trimethyl-.lambda.~5~-azanyl)ethyl hydrogen phosphate; BRN 3690495; Miltefosinum; H-1850; Miltefosine; NSC605583; M-7200; Impavido; Prasfarma brand of miltefosine; Miltex; Miltefosine [INN:BAN]; Miltefosin C; Choline hydroxide, hexadecyl hydrogen phosphate, inner salt; 3,5-Dioxa-4-phosphaunacosan-1-aminium, 4-hydroxy-N,N,N-trimethyl-, hydroxide, inner salt, 4-oxide; NCGC00095169-03; Baxter brand of miltefosine; Miltefosinum [INN-Latin]; TF-002; CHEMBL125; HMS1922D16; Choline, hexadecyl hydrogen phosphate, inner salt; CHEBI:125047; NCGC00095169-02; Choline phosphate, hexadecyl ester, hydroxide, inner salt; Miltefosine (INN); 2-(((Hexadecyloxy)hydroxyphosphinyl)oxy)-N,N,N-trimethylethanaminium hydroxide, inner salt; Ethanaminium, 2-(((hexadecyloxy)hydroxyphosphinyl)oxy)-N,N,N-trimethyl-, hydroxide, inner salt; HDPC; hexadecyl 2-(trimethylazaniumyl)ethyl phosphate; C039128; NCGC00095169-01; Miltefosina; IN1227; Hexadecylphosphorylcholine; I14-7244; 58066-85-6; Miltefosina [INN-Spanish]; Ethanaminium, 2-(((hexadecyloxy)hydroxyphosphinyl)oxy)-N,N,N-trimethyl-, hydroxide, innner salt; Baxter Oncology brand of miltefosine; CID3599; Choline phosphate, hexadecyl ester, hydroxide, inner salt (6CI); D02494	58066-85-6	3600	26759174	TTDS00065	Phospholipase A2	Group IB phospholipase A2;Phosphatidylcholine 2-acylhydrolase;Secreted phospholipase A(2)	P04054	5319	ENSG00000170890	inhibitor
DAP000825	Quinacrine	Acridine, 6-chloro-9-[[4-(diethylamino)-1-methylbutyl]amino]-2-methoxy-; 83-89-6 (Parent); NCI60_000926; AC1NS008; Pentilen; acrichine; Erion; Haffkinine; GNF-PF-5448; CID149640; N4-(6-Chloro-2-methoxy-9-acridinyl)-N1,N1-diethyl-1,4-pentanediamine monoacetate; DB01103; AC1L3ZIX; Spectrum4_000496; RP-866 (Dihydrochloride dihydrate); acetic acid; N'-(6-chloro-2-methoxyacridin-9-yl)-N,N-diethylpentane-1,4-diamine; Italchin; BPBio1_000348; KBio1_000101; 866 R.P.; chinacrin; Mepacrina; BRD-A45889380-336-03-4; NSC14229; Quinacrine dihydrochloride dihydrate; NINDS_000101; 316-05-2 (dimesylate); AC1MBFYF; quinacrine; C23H30ClN3O.2HCl.2H2O; 2-Methoxy-6-chloro-9-diethylaminopentylaminoacridine; KBioGR_001011; EINECS 201-508-7; Spectrum5_001405; Quinacrine dihydrochloride mustard; MolPort-004-285-521; AC1L18SD; Arichin; Prestwick1_000318; EINECS 204-989-1; Metochin; Mepacrine (INN); Spectrum2_000888; BSPBio_000316; IDI1_000101; CHEBI:8711; MS-1557; KBio2_002507; NCGC00180969-01; TCMDC-125480; Quinacrine Dihydrochloride, Dihydrate; nchembio.215-comp6; MolPort-001-739-072; STL061087; Mepacrinum [INN-Latin]; CCRIS 8633; Mepacrina [INN-Spanish]; Acrinamine; KBioSS_001409; N~4~-[6-chloro-2-(methyloxy)acridin-9-yl]-N~1~,N~1~-diethylpentane-1,4-diamine; D08179; CID2725002; Mepacrinum; AC1Q2BPT; SPBio_000676; Methoquine; BSPBio_002112; LS-190025; 3-Chloro-7-methoxy-9-(1-methyl-4-diethylaminobutylamino)acridine; AB00053540; Quinactine; HMS2090L03; N(4)-(6-chloro-2-methoxy-9-acridinyl)-N(1),N(1)-diethyl-1,4-pentanediamine; Spectrum3_000606; KBio2_006545; BAS 00439963; Prestwick3_000318; Acirchine; KBio3_001612; Acridine, 6-chloro-9-((4-(diethylamino)-1-methylbutyl)amino)-2-methoxy-; 6151-30-0; Prestwick2_000318; St 439; N*4*-(6-Chloro-2-methoxy-acridin-9-yl)-N*1*,N*1*-diethyl-pentane-1,4-diamine; 130-42-7 (mono-hydrochloride); Atabrine dihydrochloride; 1,4-Pentanediamine, N4-(6-chloro-2-methoxy-9-acridinyl)-N1,N1-diethyl-; Italchine; mepacrine; 78901-94-7 (monoacetate); AI3-04467; SPBio_002535; Mepacrine hydrochloride dihydrate; Atebrine; acetic acid; 4-N-(6-chloro-2-methoxyacridin-9-yl)-1-N,1-N-diethylpentane-1,4-diamine; RP 866; Spectrum_000929; 69-05-6; Palusan; 4-N-(6-chloro-2-methoxyacridin-9-yl)-1-N,1-N-diethylpentane-1,4-diamine; N~4~-(6-chloro-2-methoxyacridin-9-yl)-N~1~,N~1~-diethylpentane-1,4-diamine; Erion Hydrochloride; Mepacrine [INN:BAN]; AKOS000541535; Malaricida; Prestwick0_000318; Quinacrin; N4-(6-Chloro-2-methoxy-9-acridinyl)-N1,N1-diethyl-1,4-pentanediamine; C07339; atebrin; NCGC00015874-04; KBio2_005075; KBio3_002985; LS-14294; HMS1568P18; 69-05-6 (di-hydrochloride); Prestwick_650; SAM001247040; CHEMBL7568; KBio2_001409; DivK1c_000101; Mecryl; KBioGR_002507; 130-42-7; SN-390 (Dihydrochloride dihydrate); CHEMBL546257; 6151-30-0 (di-hydrochloride, di-hydrate); KBio2_007643; NCGC00180899-01; atabrine; Lopac0_000970; CID5351141; 78901-94-7; Quinacrine acetate; Palacrin; KBioSS_002515; 83-89-6; Quinacrine hydrochloride dihydrate; Acriquine; cMAP_000067; KBio2_003977; AKOS004910405; HSDB 3253; Akrichin; Atabrine hydrochloride; CPD000449289; CID237; nchembio873-comp30; 6-Chloro-9-((4-(diethylamino)-1-methylbutyl)amino)-2-methoxyacridine; NCGC00162300-01; LS-14293; MLS000758289; Atabrine hydrochloride dihydrate; Antimalarina; WLN: T C666 BNJ EG IMY1&3N2&2 LO1 &GH 2; Mepacrine HCl; SMR000449289	83-89-6	237	9546	TTDS00065	Phospholipase A2	Group IB phospholipase A2;Phosphatidylcholine 2-acylhydrolase;Secreted phospholipase A(2)	P04054	5319	ENSG00000170890	inhibitor
DAP001185	Desoximetasone	SMR000058856; DB00547; ZINC04212854; MolPort-003-941-111; (8S,9R,10S,11S,13S,14S,16R,17S)-9-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-7,8,11,12,14,15,16,17-octahydro-6H-cyclopenta[a]phenanthren-3-one; (11beta,16alpha)-9-Fluoro-11,21-dihydroxy-16-methylpregna-1,4-diene-3,20-dione; Topicort (TN); Desoximetasona; CID5311067; SAM001246885; Topicort; AC1NSJXQ; 382-67-2; Desoximetasone (USP/INN); HMS2052C15; desoximetasone; CPD000058856; Desoximetasonum; NCGC00023648-03; 9-Fluoro-11beta,21-dihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione; CHEMBL1766; A-41-304; CHEBI:691037; HOE-304; R-2113; D03697; MLS001076073; 9alpha-fluoro-16alpha-methyl-Delta(1)-corticosterone; MLS000028654	382-67-2	5311067	855924	TTDS00065	Phospholipase A2	Group IB phospholipase A2;Phosphatidylcholine 2-acylhydrolase;Secreted phospholipase A(2)	P04054	5319	ENSG00000170890	inhibitor
DAP001189	Prednicarbate	AB00514017; [2-[(8S,9S,10R,11S,13S,14S,17R)-17-ethoxycarbonyloxy-11-hydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] propanoate; BSPBio_000968; 73771-04-7; PREDNICARBATE; S-770777; MLS002154121; AC-3521; AC1O8Q04; Prestwick2_001044; S-77 0777; HMS1571A10; Prednicarbate (USP/INN); Prestwick3_001044; Dermatop (TN); Prestwick1_001044; Dermatop; D05601; BRD-K46137903-001-03-3; SMR001233428; SPBio_002904; CHEMBL1200386; MolPort-005-943-424; Prestwick0_001044; BPBio1_001066; NCGC00179357-01; CID6714002; Hoe-777; Peitel; ZINC03938652	73771-04-7	52421	190435	TTDS00065	Phospholipase A2	Group IB phospholipase A2;Phosphatidylcholine 2-acylhydrolase;Secreted phospholipase A(2)	P04054	5319	ENSG00000170890	inducer
DAP001184	Diflorasone	EINECS 219-875-7; diflorasone; CID71415; U 34865; C22H28F2O5; 6a,9a-difluoro-16b-methylprednisolone; Diflorasona; 26259-77-8; AC1L2G4H; AC-2167; 6alpha,9-Difluoro-11beta,17,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione; ZINC05752191; AC1Q5HJB; Diflorasonum; Maxiflor; Murode; D07827; Murode (TN); UNII-T2DHJ9645W; Diflorasone (INN); AR-1H0759; (6alpha,11beta,16beta)-6,9-difluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione; MolPort-005-943-440; Diflorasona [INN-Spanish]; LS-174106; Diflorasonum [INN-Latin]; CHEBI:59750; (6S,8S,9R,10S,11S,13S,14S,16S,17R)-6,9-difluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; Diflorasone [INN:BAN]	2557-49-5	71414	7848390	TTDS00065	Phospholipase A2	Group IB phospholipase A2;Phosphatidylcholine 2-acylhydrolase;Secreted phospholipase A(2)	P04054	5319	ENSG00000170890	inhibitor
DAP000124	Guanethidine	Su 5864 sulfate (1:1); CAS-60-02-6; Oktatensin; IDI1_000539; Guanidine, (2-(hexahydro-1(2H)-azocinyl)ethyl)-; Guanethidine Sulphae; Guanidine, [2-(hexahydro-1(2H)-azocinyl)ethyl]-; Guanethidine Sulfate (1:1); Eutensol; KBio1_000539; NCGC00016272-02; Guanethidinum [INN-Latin]; Spectrum2_001103; Oktatenzin; Spectrum3_000446; Prestwick0_000317; Prestwick3_000317; Octadine; STK895063; 2-(1'-Azacyclooctyl)ethylguanidine; KBio2_006453; NCGC00016272-01; 60-02-6 (sulfate (2:1)); 1-(2-azocan-1-ylethyl)guanidine; 2-(1-N,N-Heptamethyleneimino)ethylguanidine; C07036; UNII-ZTI6C33Q2Q; Ismelin sulfate; Azocine, 1-((2-(aminoiminomethyl)amino)ethyl)octahydro-; KBioSS_001317; KBio2_001317; guanethidine sulfate; KBio2_003885; 1-[2-(azocan-1-yl)ethyl]guanidine; CID3518; 2-[2-(azocan-1-yl)ethyl]guanidine; AB00053479; (2-(Octahydro-1-azocinyl)ethyl)guanidine; N-(2-Perhydroazocin-1-ylethyl)guanidine; .Beta.-1-Azacyclooctylethylguanidine; Azocine, 1-(2-guanidinoethyl)octahydro-; Guanidine, N-[2-(hexahydro-1(2H)-azocinyl)ethyl]-; Oktadin; KBio3_001312; Dopom; Abapresin; 55-65-2; NINDS_000539; Isobarin; Octatensine; Guanethidine (INN); D08030; L000732; Prestwick2_000317; 645-43-2 (sulfate (1:1)); BPBio1_000346; KBioGR_000976; DivK1c_000539; ((2-Hexahydro-1(2H)-azocinyl)ethyl)guanidine; Spectrum_000837; Guanetidina; Heptamethylenimine, 1-(2-guanidinoethyl)-; DB01170; Guanethidine [INN:BAN]; GUANETHIDINE; HSDB 3092; Octadin; CHEBI:5557; C10H22N4; Guanethidinum; Spectrum5_000784; Prestwick1_000317; MolPort-001-783-613; Ismelin; Apo-Guanethidine; CHEMBL765; ST50819310; Azocine, 1-(2-guanidinoethyl)octahydro-; NCGC00016272-03; Guanethidine Sulfate (2:1); Sanotensin; Guanetidina [INN-Spanish]; BSPBio_000314; SPBio_001206; NSC29863; Spectrum4_000568; LS-73688; EINECS 200-241-3; SPBio_002533; Dopam; Octatensin; AC1L1G48; BSPBio_002092	645-43-2	3518	7854193	TTDS00527	Adrenergic neuron	N/A	N/A	N/A	N/A	blocker
DAP000125	Debrisoquin	Ro 5-3307/1; CAS-581-88-4; 1,2,3, 4-Tetrahydro-isoquinoline-2-carboxamidine sulfate; 2(1H)-Isoquinolinecarboxamidine, 3,4-dihydro-, sulfate (2:1); 2(1H)-Isoquinolinecarboximidamide, 3,4-dihydro-, sulfate (2:1); 3,4-Dihydro-2(1H; )-isoquinoline carboxamidine sulfate; 3,4-Dihydro-2(1H)-isoquinolinecarboxamidine sulfate (2:1); Sulfuric acid compound with 3,4-dihydro-2(1H)-isoquinolinecarboximidamide (1:1); 2(1H)-Isoquinolinecarboximidamide, 3,4-dihydro-; AKOS000225362; MolPort-000-912-053; Prestwick2_000372; 3,4-Dihydro-2(1H)-isoquinolinecarboximidamide; Debrisoquina; Debrisoquine; C10H13N3; 2-Amidino-1,2,3,4-tetrahydroisoquinoline; Isocaramidine; 3,4-Dihydro-2(1H)-isoquinolinecarboxamidine; Debrisoquin; UNII-X31CDK040E; D003647; NCGC00016513-01; STK232096; C13650; Debrisoquinum [INN-Latin]; 3,4-dihydro-1H-isoquinoline-2-carboximidamide; Lopac0_000326; CHEMBL169901; EINECS 214-470-1; SPBio_002444; Declinax; Debrisochinum; Prestwick0_000372; 1131-64-2; Debrisoquina [INN-Spanish]; DEBRISOQUIN SULFATE; Debrisoquinum; Prestwick1_000372; CID2966; NSC139330; AC1L1EVE; NCGC00016513-02; 3,4-dihydroisoquinoline-2(1H)-carboximidamide; Debrisoquine sulfate; Debrisoquine [INN:BAN]; NCGC00016513-03; Debrisoquin hemisulfate; STOCK5S-37991; HMS2089P09; CHEBI:34665; LS-172212; Prestwick3_000372; Isocaramidine sulfate; Equitonil; Tendor; DB04840; 2(1H)-Isoquinolinecarboxamidine, 3,4-dihydro- (7CI,8CI); BPBio1_000577; BSPBio_000523	1131-64-2	2966	7846928	TTDS00527	Adrenergic neuron	N/A	N/A	N/A	N/A	blocker
DCL000085	CHR-2797	CHR-2797; Tosedostat, CHR2797, CHR-2797; BB-76163; 238750-77-1; S1522_Selleck; Tosedostat; Benzeneacetic acid, alpha-(((2R)-2-((1S)-1-hydroxy-2-(hydroxyamino)-2-oxoethyl)-4-methyl-1-oxopentyl)amino)-, cyclopentyl ester, (alphaS)-	238750-77-1	N/A	85150391	TTDC00249	Puromycin-sensitive aminopeptidase	PSA	P55786	9520	ENSG00000141279	inhibitor
DCL001001	SSR149415	SSR149415; CHEMBL582857; CHEBI:672209; Nelivaptan; CID9895468; C456029; SR-149415; 1-(5-chloro-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-methoxyphenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl)-4-hydroxy-N,N-dimethyl-2-pyrrolidinecarboxamide; SSR 149415; SSR-149415	439687-69-1	23725053	47207847	TTDC00298	Vasopressin V1b receptor	Antidiuretic hormone receptor 1b;AVPR V1b;AVPR V3;V1bR;Vasopressin V(1b) Receptor;Vasopressin V3 receptor	P47901	553	ENSG00000198049	antagonist
DCL000579	Motesanib diphosphate	S1032_Selleck; Motesanib diphosphate; Motesanib diphosphate [USAN]; D08947; 857876-30-3; Motesanib diphosphate (USAN); UNII-T6Q3060U91; AMG-706. Motesanib Diphosphate; EC-000.2343	850649-62-6	11450633	22395889	TTDS00270	Mast/stem cell growth factor receptor	CD117 antigen;C-kit;KIT;Proto-oncogene tyrosine-protein kinase Kit;SCFR	P10721	3815	ENSG00000157404	inhibitor
DAP000179	Imatinib	AC-524; 4-[(4-methylpiperazin-1-yl)methyl]-N-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)benzamide; Cgp 57148; 152459-95-5; CHEMBL941; sti-571; I01-1232; nchembio.282-comp6; alpha-(4-Methyl-1-piperazinyl)-3'-((4-(3-pyridyl)-2-pyrimidinyl)amino)-p-tolu-p-toluidide; Imatinib (INN); Glamox; 4-(4-METHYL-PIPERAZIN-1-YLMETHYL)-N-[4-METHYL-3-(4-PYRIDIN-3-YL-PYRIMIDIN-2-YLAMINO)-PHENYL]-BENZAMIDE; Imatinib free base; BRD-K92723993-066-02-9; NCGC00159456-02; CID5291; MolPort-000-883-342; CCRIS 9076; benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-; Imatinib; BIDD:GT0047; N-(3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)-4-methylphenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; AKOS000280662; STK617705; CGP 57148B; nchembio.117-comp23; Benzamide, 4-((4-methyl)-1-piperazinyl)methyl)-N-(4-methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)phenyl)-; AC1L1K0Z; Imatinib [INN:BAN]; EN002706; nchembio.162-comp5; 4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide; LS-182208; DB00619; STI; FT-0083542; 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide methanesulfonate; Kinome_3724; NSC743414; 112GI019; NCGC00159456-04; 4-[(4-methylpiperazin-1-yl)methyl]-N-{4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl}benzamide; 1iep; CHEBI:45783; Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI); nchembio.83-comp14; D08066; Imatinib Methansulfonate; HMS2089D03; 1xbb; UNII-BKJ8M8G5HI; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-phenyl]benzamide; DB03261; NCGC00159456-03; LS-187106; Glamox (TN); STI571; STI 571	152459-95-5	5291	841977	TTDS00270	Mast/stem cell growth factor receptor	CD117 antigen;C-kit;KIT;Proto-oncogene tyrosine-protein kinase Kit;SCFR	P10721	3815	ENSG00000157404	inhibitor
DAP000005	Sunitinib	PDGF TK antagonist; 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-; AC1NS62J; SU 11248; 5-(5-FLUORO-2-OXO-1,2-DIHYDRO-INDOL-3-YLIDENEMETHYL)-2,4-DIMETHYL-1H-PYRROLE-3-CARBOXYLIC ACID (2-DIETHYLAMINO-ETHYL)-AMIDE; NSC736511; SU-11248J; 326914-13-0; NSC750690; K00588a; Su-011248; Sunitinib; SU-12662; KS-5022; CHEMBL535; UNII-V99T50803M; Sunitanib; 557795-19-4; N-(2-diethylaminoethyl)-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; NCGC00164631-01; SU11248; 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)- (5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-; LS-187023; DB01268; I01-1229; CID5329102; SU-11248; CHEBI:38940; sunitinibum; DB07417; LS-187648; N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; FT-0083556; Sutent; D08552; Sunitinib (free base); Sunitinib (INN); EN002687; 1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-	557795-19-4	5329102	14830382	TTDS00270	Mast/stem cell growth factor receptor	CD117 antigen;C-kit;KIT;Proto-oncogene tyrosine-protein kinase Kit;SCFR	P10721	3815	ENSG00000157404	inhibitor
DCL000578	Motesanib	453562-69-1; UNII-U1JK633AYI; ZINC18710082; CID11667893; AMG706; AKOS005146333; N-(3,3-dimethyl-2,3-dihydro-1H-indol-6-yl)-2-[(pyridin-4-ylmethyl)amino]pyridine-3-carboxamide; N-(2,3-dihydro-3,3-dimethyl-1H-indol-6-yl)-2-((4-pyridinylmethyl)amino)-3-pyridinecarboxamide; D06678; Motesanib; CHEMBL572881; AMG-706; AMG 706; CHEBI:51098	453562-69-1	11667893	47208329	TTDS00270	Mast/stem cell growth factor receptor	CD117 antigen;C-kit;KIT;Proto-oncogene tyrosine-protein kinase Kit;SCFR	P10721	3815	ENSG00000157404	inhibitor
DCL000646	Sunitinib malate	SU010398; N-(2-diethylaminoethyl)-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; (2S)-2-hydroxybutanedioic acid; PNU-290940AD; SU011248; SU-010398; PHA-290940AD; AKOS005145765; FT-0083555; Sunitinib malate [USAN]; Sutent, SU-11248; D06402; SU-011248 L-malate salt; Sunitinib malate; N-(2-(Diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (2S)-hydroxybutanedioate; ST51053712; Sutent (TN); AC1O5CMQ; CHEMBL1567; 341031-54-7; LS-186078; 1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-,     (2S)-hydroxybutanedioate (1:1); CHEBI:550864; MolPort-003-986-763; 1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1); SU011248 L-malate salt; TL8002546; Sunitinib malate (JAN/USAN); UNII-LVX8N1UT73; CID6456015; Butanedioic acid, hydroxy-, (2S)-, compd. with N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (1:1); SU-11248 L-malate salt; SU 011248; S1042_Selleck	557795-19-4	5329102	14830382	TTDS00270	Mast/stem cell growth factor receptor	CD117 antigen;C-kit;KIT;Proto-oncogene tyrosine-protein kinase Kit;SCFR	P10721	3815	ENSG00000157404	inhibitor
DAP001550	Pazopanib HCl	N/A	N/A	N/A	N/A	TTDS00270	Mast/stem cell growth factor receptor	CD117 antigen;C-kit;KIT;Proto-oncogene tyrosine-protein kinase Kit;SCFR	P10721	3815	ENSG00000157404	inhibitor
DCL000351	Pazopanib	Pazopanib; CID10113978; GW-786034; I09-0358; 790713-33-6; 5-[[4-[(2,3-Dimethyl-2H-indazol-6-yl)(methyl)amino]pyrimidin-2-yl]amino]-2-methylbenzenesulfonami; GW786034; 444731-52-6; 5-[[4-[(2,3-dimethylindazol-6-yl)-methyl-amino]pyrimidin-2-yl]amino]-2-methyl-benzenesulfonamide; AKOS005145819; UNII-7RN5DR86CK; ST51053493; CHEMBL477772; MolPort-006-827-156; Votrient; GW 786034; Kinome_3790; Benzenesulfonamide, 5-((4-((2,3-dimethyl-2H-indazol-6-yl)methylamino)-2-pyrimidinyl)amino)-2-methyl-; Pazopanib [INN]; Benzenesulfonamide, 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-	444731-52-6	11525740	22395868	TTDS00270	Mast/stem cell growth factor receptor	CD117 antigen;C-kit;KIT;Proto-oncogene tyrosine-protein kinase Kit;SCFR	P10721	3815	ENSG00000157404	inhibitor
DCL000352	OSI-930	3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide; 728033-96-3; OSI 930; S1220_Selleck; CID9868037; OSI930; OSI-930; OSI-930 is a multi-targeted tyrosine kinase inhibitor	N/A	9868037	50086917	TTDS00270	Mast/stem cell growth factor receptor	CD117 antigen;C-kit;KIT;Proto-oncogene tyrosine-protein kinase Kit;SCFR	P10721	3815	ENSG00000157404	inhibitor
DCL000171	MP470	N/A	850879-09-3	N/A	85151253	TTDS00270	Mast/stem cell growth factor receptor	CD117 antigen;C-kit;KIT;Proto-oncogene tyrosine-protein kinase Kit;SCFR	P10721	3815	ENSG00000157404	inhibitor
DCL000360	Nilotinib	4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazo; Benzamide, 4-methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-(4-(3-pyridinyl)-2-pyrimidinyl)amino)-; AKOS005063561; Nilotinib; 641571-10-0; 4-Methyl-N-[3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl]-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]benzamide; C498826; CHEBI:52172; CID644241; S1033_Selleck; 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide; NSC747599; 4-Methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide; NIL; CHEMBL255863; nilotinibum; Benzamide, 4-methyl-N-((3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-(4-(3-pyridinyl)-2-pyrimidinyl)amino)-; Benzamide, 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]- (9CI); 4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide; AMN 107; Nilotinib (INN/USAN); AMN-107; 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl]benzamide; AC-647; l-1-yl)-3-(trifluoromethyl)phenyl]benzamide; DB04868; Nilotinib, AMN107, Tasigna; I01-1225; D08953; 4-Methyl-3-(4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-[5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl]benzamide; AMN107; TL8004531; AC1LD8U3; Tasigna; EN002707; EC-000.2344; Tasigna (Novartis); MolPort-003-987-089; benzamide, 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-; Tasigna, AMN-107, Nilotinib; UNII-F41401512X	N/A	N/A	N/A	TTDS00270	Mast/stem cell growth factor receptor	CD117 antigen;C-kit;KIT;Proto-oncogene tyrosine-protein kinase Kit;SCFR	P10721	3815	ENSG00000157404	inhibitor
DCL000192	Ostabolin-C	N/A	N/A	N/A	N/A	TTDC00041	Parathyroid hormone receptor	PTH2 receptor;PTH2R;PTHR2	P49190	5746	ENSG00000144407	agonist
DCL000204	PTH 1-34	N/A	N/A	16129682	50067792	TTDC00041	Parathyroid hormone receptor	PTH2 receptor;PTH2R;PTHR2	P49190	5746	ENSG00000144407	agonist
DCL000379	GW468816	N/A	N/A	N/A	N/A	TTDC00039	Glycine receptor	GLR;Glycine receptor 58 kDa subunit	P48167	2743	ENSG00000109738	antagonist
DCL000126	GW 468816	N/A	339177-26-3	N/A	47207035	TTDC00039	Glycine receptor	GLR;Glycine receptor 58 kDa subunit	P48167	2743	ENSG00000109738	antagonist
DCL000288	Cilnidipine	3-O-(2-methoxyethyl) 5-O-[(E)-3-phenylprop-2-enyl] 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; 132203-70-4; Siscard; C1493_SIGMA; AC-270; C27H28N2O7; STK623341; Bio-0164; NCGC00162150-01; FRC-8653; CHEBI:31399; FRC 8653; I06-0491; BRD-A07875874-001-01-6; HMS2089J07; Cilnidipine [INN]; Cilnidipine (JAN/INN); CID5282138; Cinaldipine; CHEBI:438069; CHEMBL452076; Cinalong; Atelec; AC1NQZJB; cilnidipine; 2-methoxyethyl (2E)-3-phenylprop-2-en-1-yl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; LS-131293; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-methoxyethyl 3-phenyl-2-propenyl ester, (E)-(+-)-; Atelec (TN); D01173; 1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 2-methoxyethyl (2E)-3-phenyl-2-propenyl ester; NCGC00162150-02; NCGC00162150-03; MolPort-003-845-950; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-,2-methoxyethyl 3-phenyl-2-propenyl ester, (E)-(+-)-; (+-)-(E)-Cinnamyl 2-methoxyethyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate; S1293_Selleck	N/A	5282138	24892414	TTDS00160	Voltage-dependent L-type calcium channel	L-type Ca(2+) channel;L-type Ca2+ channel;L-type voltage-dependent Ca(2+) channel	N/A	N/A	N/A	blocker
DAP000525	Bepridil	Prestwick2_000368; KBio3_000042; Bio1_000877; Prestwick1_000368; IDI1_000110; KBioSS_002225; KBio2_002589; Prestwick3_000368; MolPort-005-935-595; NCGC00162097-04; HMS1989B03; KBio2_005157; AC-16059; KBio2_004793; BPBio1_000545; Bio2_000021; N-benzyl-N-[3-(2-methylpropoxy)-2-(pyrrolidin-1-yl)propyl]aniline; BSPBio_000495; LS-137756; BSPBio_002334; NCGC00015155-07; Bepadin; NCGC00162097-03; NINDS_000110; KBio2_000021; CERM 1978; BRD-A91008255-001-02-8; HMS1361B03; DivK1c_000110; BCBcMAP01_000130; bepridil; SPBio_000742; KBio3_000041; NCGC00162097-01; 68099-86-5 (mono-hydrochloride); Bio1_000388; HMS1791B03; N-Benzyl-N-[3-(2-methylpropoxy)-2-pyrrolidin-1-yl-propyl]aniline hydrochloride; 1-Pyrrolidineethanamine, beta-((2-methylpropoxy)methyl)-N-phenyl-N-(phenylmethyl)-; CHEBI:3061; AB00053643; Bepadin (TN); Spectrum4_000797; 64706-54-3; N-benzyl-N-[3-(2-methylpropoxy)-2-pyrrolidin-1-ylpropyl]aniline; NCGC00162097-02; 74764-40-2 (mono-hydrochloride, mono-hydrate); CHEMBL1008; AC1L1DHI; Bio1_001366; CID2351; KBio2_002225; Spectrum3_000747; Prestwick0_000368; KBioSS_000021; Bepridil (INN); C06847; D07520; KBio3_001554; IDI1_033771; nchembio873-comp28; HMS2089C05; KBio2_007361; DB01244; Lopac0_000222; Ambap64706-54-3; Spectrum2_000901; KBio1_000110; KBioGR_001274; N-{3-[(2-methylpropyl)oxy]-2-pyrrolidin-1-ylpropyl}-N-(phenylmethyl)aniline; beta-((2-Methylpropoxy)methyl)-N-phenyl-N-(phenylmethyl)-1-pyrrolidineethanamine; HSCI1_000377; Org 5730; KBioGR_000021; BSPBio_001301; Spectrum_001745; SPBio_002416; Bio2_000501; Spectrum5_000978; Vascor	64706-54-3	2351	186733	TTDS00160	Voltage-dependent L-type calcium channel	L-type Ca(2+) channel;L-type Ca2+ channel;L-type voltage-dependent Ca(2+) channel	N/A	N/A	N/A	blocker
DCL000931	Pinaverium bromide	LS-93532; PINAVERIUM BROMIDE; Bromuro de pinaverio; Dicetel; EINECS 258-450-0; C26H41BrNO4.HBr; AC1L24AM; D07094; Pinaverii bromidum; CID40703; MolPort-003-849-935; Bromuro de pinaverio [INN-Spanish]; Pinaverium bromide (INN); 53251-94-8; LAT 1717; Morpholinium, 4-(2-bromo-4,5-dimethoxy)benzyl-4-(2-(2-(6,6-dimethyl-2-norpinyl)ethoxy)ethyl)-, bromide; Pinaverii bromidum [INN-Latin]; Bromure de pinaverium; Bromure de pinaverium [INN-French]; 59995-65-2 (Parent); 4-(6-Bromoveratryl)-4-(2-(2-(6,6-dimethyl-2-norpinyl)ethoxy)ethyl)morpholinium bromide; Pinaverium bromide [INN]; I14-9199; 4-[(2-bromo-4,5-dimethoxyphenyl)methyl]-4-[2-[2-(6,6-dimethyl-4-bicyclo[3.1.1]heptanyl)ethoxy]ethyl]morpholin-4-ium bromide	53251-94-8	68736	48332100	TTDS00160	Voltage-dependent L-type calcium channel	L-type Ca(2+) channel;L-type Ca2+ channel;L-type voltage-dependent Ca(2+) channel	N/A	N/A	N/A	blocker
DAP000753	Terbinafine	NCGC00159346-03; Terbinafine [USAN:BAN:INN]; Lamisil AT; UNII-G7RIW8S0XP; HMS2089B20; AKOS001451917; MolPort-004-637-919; Terbinafine, SF-86-327, Lamisil, TBNF; 1-NAPHTHALENEMETHANAMINE, N-(6,6-DIMETHYL-2-HEPTEN-4-YNYL)-N-METHYL-, (E)-; (E)-N-(6,6-Dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphthalenemethylamine; LS-94722; C08079; Lamasil (TN); TerbiFoam; Lamisil Tablet; (E)-N-(6,6-dimethyl-2-heptenynyl)-N-methyl-1-naphthalenementhamin hydrochloride; (E)-N,6,6-trimethyl-N-(naphthalen-1-ylmethyl)hept-2-en-4-yn-1-amine; NCGC00159346-02; (E)-N-(6,6-Dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphthalene methanamine; BRN 4256376; Bramazil; AC-12049; Ternbinafine HCl; D02375; DB00857; terbinafine; Lamisil, Terbinex, Corbinal, Zabel,  Terbinafine; CHEMBL822; BIDD:GT0825; (2E)-N,6,6-trimethyl-N-(naphthalen-1-ylmethyl)hept-2-en-4-yn-1-amine; CID1549008; Lamasil; CHEBI:156831; STK802069; (2E)-N,6,6-trimethyl-N-(1-naphthylmethyl)-2-hepten-4-yn-1-amine; Terbinafine (USAN/INN); SF 86-327; Terbina; SF-86-327; AC1LU7MZ; 91161-71-6; S1725_Selleck; STOCK5S-43972; MolPort-002-507-761	91161-71-6	5402	7849434	TTDS00302	Squalene monooxygenase	ERG1;Oxidosqaulene cyclase;SE;Squalene epoxidase	Q14534	6713	ENSG00000104549	inhibitor
DAP001237	Tolnaftate	O-2-Naphthyl N,N-dimethylthiocarbanilate; NP27; Tinactin cream; Sporiline; Aftate for jock itch gel; IDI1_000334; Tolnaftat Purder N; CAS-2398-96-1; Spectrum_000963; Tniaderm; NP-27 Spray Powder; NCGC00016610-02; Tinactin (TN); Naphthiomate-T; Tinactin antifungal deodorant powder aerosol; Tinactin jock itch aerosol powder; KBio2_004011; Chinosol Brand of Tolnaftate; Ting; AC-5548; Tolnaftate Douglas Brand; 94256-64-1; C19H17NOS; Tinaderm; Tolnaftate (JP15/USP/INN); Timoped; Zenith Brand of Tolnaftate; NP-27 Cream; Breezee; Tinatox; HMS501A16; Tritin; BPBio1_000285; KBioGR_000799; Ony Clear; HMS2092O05; UNII-06KB629TKV; Essex Brand of Tolnaftate; Tolnaftato [DCIT]; 2-Naphthyl N-methyl-N-(3-tolyl)thionocarbamate; Aftate for athlete's foot sprinkle powder; LS-51199; Purder N, Tolnaftat; Tolnaftate Schering Brand; Prestwick0_000070; Methyl (3-methylphenyl)carbamothioic acid O-2-naphthalenyl ester; Tolnaftatum; Aftate for athlete's foot aerosol spray powder; CHEMBL83668; NCGC00023506-03; Tolnaftato [INN-Spanish]; Tinactin aerosol powder; Tinactin; Methyl-(3-methylphenyl)carbamothioic acid O-2-naphthyl ester; Wernigerode Brand of Tolnaftate; MLS000028526; Ting antifungal spray liquid; Spectrum4_000360; Naphthiomate T; ZINC00057522; HI-Alazin; Tinactin plus aerosol powder; SPBio_002180; Tolnaftate (JP14/USP); BRN 2752620; Sorgoa; Stiefel Brand of Tolnaftate; Fungistop; Tonoftal; D014047; tolnaftate; O-naphthalen-2-yl N-methyl-N-(3-methylphenyl)carbamothioate; Spectrum2_000950; BRD-K44273375-001-04-5; MLS001146910; N-Methyl-(3-methylphenyl)-carbamothioic acid, O-2-naphthalenyl ester; Ting antifungal powder; Tinactin powder; SMR000058288; Tolnaftate [USAN:INN:BAN:JAN]; Tolnaftatum [INN-Latin]; 2398-96-1; AB00052111; Aftate for jock itch aerosol spray powder; ZeaSorb; o-(2-Naphthyl) methyl(3-methylphenyl)thiocarbamate; Separin; O-2-Naphthyl m,N-dimethylthiocarbanilate; HMS1568M21; Ting Products; NP-27 Solution; O-naphthalen-2-yl methyl(3-methylphenyl)carbamothioate; Pedinol Brand 1 of Tolnaftate; Thompson Brand of Tolnaftate; Tinavet (Veterinary); Genaspor; Ting antifungal cream; CID5510; Tinactin aerosol liquid; DivK1c_000334; Tolnaphthate; Genaspore cream; Tolsanil; MolPort-002-893-958; D00381; Sch 10144; Dungistop; Spectrum5_001000; Douglas Brand of Tolnaftate; Micoisdin; Aftate; Tolnaftate(USAN); Tinavet; KBioSS_001443; ST51015151; Dr. Scholl's athlete's foot spray; Hi-alarzin; Pedinol Brand 2 of Tolnaftate; Chinofungin; Prestwick_472; SPECTRUM1500583; NSC233648; KBio1_000334; Dermoxin; Tolnaftate (JP15/USP); m,N-Dimethylthiocarbanilic acid O-2-naphthyl ester; Pitrex; Methyl-[3-methylphenyl]-carbamothioic acid O-2-naphthyl ester; Tinactin solution; Tolnaftato; Tinactin jock itch cream; Tolnaftate [USAN:BAN:INN:JAN]; Insight Brand of Tolnaftate; STL069548; Isdin Brand of Tolnaftate; NP-27 Powder; Tinactin jock itch spray powder; Focusan; NSC 233648; NCGC00016610-01; Prestwick2_000070; Carter Wallace Brand of Tolnaftate; Phytoderm; Schering-Plough Brand 1 of Tolnaftate; EINECS 219-266-6; Prestwick1_000070; Aftate for jock itch sprinkle powder; Pitrex cream; Prestwick3_000070; AKOS005111014; SPBio_000920; Separin (TN); KBio2_006579; HMS1921E21; Carbamothioic acid, N-methyl-N-(3-methylphenyl)-, O-2-naphthalenyl ester; DB00525; Aftate for athlete's foot aerosol spray liquid; Carbanilic acid, N,m-dimethylthio-, O-2-naphthyl ester; Carbamothioic acid, methyl(3-methylphenyl)-, O-2-naphthalenyl ester; Aftate for athlete's foot gel; Ting antifungal spray powder; NP 27; KBio2_001443; Carbanilic acid, m,N-dimethylthio-, O-2-naphthyl ester; Schering-Plough Brand 2 of Tolnaftate; NINDS_000334; Zeasorb-AF powder; T6638_SIGMA; Bioglan Brand of Tolnaftate; AC1L1KI4; Ony-Clear; BSPBio_000259; Schering Brand of Tolnaftate; Tinactin plus powder	2398-96-1	5510	10321471	TTDS00302	Squalene monooxygenase	ERG1;Oxidosqaulene cyclase;SE;Squalene epoxidase	Q14534	6713	ENSG00000104549	inhibitor
DAP001236	Butenafine	KBio2_007169; KBio2_004601; SpecPlus_000920; CHEBI:3238; CID2484; Spectrum_001553; Butenafinum [INN-Latin]; KP 363; Butenafina [INN-Spanish]; N-(p-tert-Butylbenzyl)-N-methyl-1-naphthalenemethylamine; BIDD:GT0236; Butenafine (INN); butenafine; N-p-tert-Butylbenzyl-N-methyl-1-naphthalenemethylamine; KBioSS_002033; N-4-tert-butylbenzyl-N-methyl-1-naphthalene methylamine hydrochloride; LS-171795; Butenafinum; CHEMBL990; NCGC00159511-03; D07596; Butenafine [INN]; KP-363; DivK1c_007016; I06-0093; Butenafine hydrochloride; KBio1_001960; AC1L1DS8; 101828-21-1; Mentax; UNII-91Y494NL0X; KBio2_002033; AC-13296; 4-tert-butylbenzyl(methyl)(1-naphthalenemethyl)amine; DB01091; Butenafina; 1-(4-tert-butylphenyl)-N-methyl-N-(naphthalen-1-ylmethyl)methanamine; C08067; C23H27N; NCGC00159511-02; MolPort-002-885-811; MolPort-005-934-260; Butenafine HCL; HMS2089O04	101828-21-1	2484	10267	TTDS00302	Squalene monooxygenase	ERG1;Oxidosqaulene cyclase;SE;Squalene epoxidase	Q14534	6713	ENSG00000104549	inhibitor
DAP000752	Naftifine	(E)-N-Cinnamyl-N-methyl-1-naphthalinmethylamin; LS-176454; CHEMBL626; DB00735; Naftifinum; UNII-4FB1TON47A; Naftifin; Prestwick3_001063; Naftifine (INN); (2E)-N-methyl-N-(1-naphthylmethyl)-3-phenyl-2-propen-1-amine; Naftifine HCl; MolPort-003-849-301; CHEBI:126722; (E)-N-Cinnamyl-N-methyl-1-naphthalenemethylamine; N-cinnamyl-N-methyl-1-naphthalenemethylamine hydrochloride; AR-1K5852; 1-Naphthalenemethanamine, N-methyl-N-(3-phenyl-2-propenyl)-, (E)-; Naftifinum [INN-Latin]; CID47641; 65472-88-0; NCGC00179332-01; BRD-K74141488-003-03-9; AB00514711; Naftifine [INN:BAN]; D08245; Naftifina; Naftifina [INN-Spanish]; AC1Q28IA; AC1L2IFX; (E)-N-Cinnamyl-N-methyl-1-naphthylmethylamin; N-Methyl-N-(1-naphthyl methyl)-3-phenyl-2-propen-1-amine(E), hydrochloride; SN 105-843; C08071; Prestwick2_001063; (E)-N-methyl-N-(naphthalen-1-ylmethyl)-3-phenylprop-2-en-1-amine; BSPBio_001046; Naftifine; BPBio1_001152	65472-88-0	73342	10271	TTDS00302	Squalene monooxygenase	ERG1;Oxidosqaulene cyclase;SE;Squalene epoxidase	Q14534	6713	ENSG00000104549	inhibitor
DAP000699	Amodiaquine	EINECS 201-669-3; Basoquin; Amodiaquine USP24; Camoquin; Miaquin; 86-42-0; 4-[(7-chloroquinolin-4-yl)amino]-2-(diethylaminomethyl)phenol; Prestwick0_000309; o-Cresol, 4-[(7-chloro-4-quinolyl)amino]-.alpha.-(diethylamino)-; NSC 13453; HSDB 7457; Phenol, 4-[(7-chloro-4-quinolinyl)amino]-2-[(diethylamino)methyl]-; 7-Chloro-4-(3-diethylaminomethyl-4-hydroxyphenylamino)quinoline; BRN 0300962; CID2165; 5-22-10-00283 (Beilstein Handbook Reference); BPBio1_000306; AKOS000538864; CHEMBL682; AC-13295; Oprea1_019229; Phenol, 4-((7-chloro-4-quinolinyl)amino)-2-((diethylamino)methyl)-; 7-Chloro-4-(3-diethylaminomethyl-4-hydroxyanilino); amodiaquine; Amodiaquina; D02922; o-Cresol, 4-[(7-chloro-4-quinolyl)amino]-.alpha.-(diethylamino)- (6CI,7CI,8CI); MolPort-001-924-563; AMODIAQUINE, FLAVOQUINE; WR-002977; C07626; C20H22ClN3O; ||SN 10,751; CAM-AQ 1; AC1L1D2F; S. N. 10751; Cam-AQ1; Amodiaquine, ring-closed; Sunoquine; 2aou; Flavoquin; SMR000718769; SN 10,751; DB00613; Amodiaquinum; o-Cresol, 4-((7-chloro-4-quinolyl)amino)-alpha-(diethylamino)-; Amodiaquina [INN-Spanish]; 4-((7-Chloro-4-quinolyl)amino)-alpha-(diethylamino)-o-cresol; Prestwick2_000309; Amodiaquine  (USAN/INN); Amodiaquin; 4-[(7-CHLOROQUINOLIN-4-YL)AMINO]-2-[(DIETHYLAMINO)METHYL]PHENOL; CQA; BAS 00327385; 4-(7-Chloro-quinolin-4-ylamino)-2-diethylaminomethyl-phenol; LS-55353; MLS001304065; Prestwick3_000309; Camoquine; SPBio_002497; SN 10751; Quinoline, 7-chloro-4-[[3-[(diethylamino)methyl]-4-hydroxyphenyl]amino]-|; CAM-AQI; Prestwick1_000309; Amodiachin; 4-((7-Chloro-4-quinolinyl)amino)-2-((diethylamino)methyl)phenol; Amodiaquine [USAN:INN:BAN]; Flavoquine; CPD-10889; CHEBI:2674; Amodiaquinum [INN-Latin]; CAM-AQI; Camochin; BSPBio_000278; UNII-220236ED28; 4-[(7-Chloro-4-quinolinyl)amino]-2-[(diethylamino)methyl]phenol; CCRIS 8486; 7-Chloro-4-(3-diethylaminomethyl-4-hydroxyanilino)quinoline; Amodiaquine hydrochloride; Bio-0471; NSC13453; Camochin; Camoquinal; Amodiachinum; Quinoline, 7-chloro-4-[[3-[(diethylamino)methyl]-4-hydroxyphenyl]amino]-	86-42-0	2165	9828	TTDS00089	Histamine N-methyltransferase	Histamine-N-methyltransferase;HMT	P50135	3176	ENSG00000150540	inhibitor
DAP001349	Eflornithine	C07997; AC-5497; BRN 2250529; CHEMBL536971; 96020-91-6; AC1L1EYW; D,L-alpha-Difluoromethylornithine; DFMO hydrochloride hydrate; Eflornithinum [Latin]; EINECS 269-532-0; CCRIS 3718; DL-alpha-Difluoromethylornithine hydrochloride hydrate; 2,5-diamino-2-(difluoromethyl)pentanoic acid; 70052-12-9; CCRIS 5805; DL-.alpha.-Difluoromethylornithine; NCGC00015316-03; D07883; CID57004; LS-98405; DL-alpha-Difluoromethylornithine; 2,5-diamino-2-(difluoromethyl)pentanoic acid hydrate hydrochloride; MDL 71782; DFMO (growth regulator); 2-(Difluoromethyl)-DL-ornithine monohydrochloride, monohydrate; Eflornithinum; Eflornithine [INN:BAN]; N-Difluoromethylornithine; DL-alpha-Difluoromethylornithine, Hydrochloride; 2-(Difluoromethyl)-DL-ornithine HCl; Difluromethylornithine; UNII-ZQN1G5V6SR; 2-(Difluoromethyl)-DL-ornithine; alpha-Difluoromethylornithine hydrochloride; MLS000069341; LS-178282; CID3009; AC-388; 70052-12-9 (Parent); CCRIS 3295; D00829; 2,5-diamino-2-(difluoromethyl)pentanoic acid hydrochloride; 67037-37-0; DL-alpha-Difluoromethylornithine hydrochloride; C6H12F2N2O2.HCl.H2O; CHEMBL1201037; CHEBI:41948; Lopac0_000429; NCGC00162152-01; Eflornithine (INN); D193_SIGMA; LS-185084; Ornithine, 2-(difluoromethyl)-, monohydrochloride; Ornithine, 2-(difluoromethyl)-; RMI 71782; DL-alpha-(Difluoromethyl)ornithine; EU-0100429; DL-Ornithine, 2-(difluoromethyl)-, monohydrochloride, monohydrate; Eflornitina [Spanish]; HSCI1_000267; D,L-alpha-Difluoromethylornithine hydrochloride; DL-Ornithine, 2-(difluoromethyl)-; 70050-56-5; Eflornitina; 2-(Difluoromethyl)-DL-ornithine monohydrochloride; LS-7332; DFMO hydrochloride; dfmo; Ornidyl (TN); 96020-91-6 (mono-hydrochloride, monohydrate); Ornidyl; 2-(Difluoromethyl)ornithine hydrochloride hydrate; NCGC00093850-01; AC1L9B1G; FT-0082608; Eflornithine hydrochloride hydrate; Eflornithine hydrochloride [USAN]; DL-Ornithine, 2-(difluoromethyl)-, monohydrochloride; 2-(Difluoromethyl)-DL-ornithine hydrochloride; alpha-Difluoromethylornithine; AC1L1M41; SMR000058442; EFLORNITHINE HYDROCHLORIDE; I06-0316; BMS 203522; Eflornithine HCl; CID441361; Vaniqa; NSC337250; MDL 71,782 A; I06-0530; RMI-71782; UNII-4NH22NDW9H; 2-(Difluoromethyl)-DL-ornithine monohydrochloride.monohydrate; alpha,delta-Diamino-alpha-(difluoromethyl)valeric acid; SBB066102; 68278-23-9; MolPort-003-940-991; CPP-1X; MDL-71782A; EFLORNITHINE; DFMO HCl; alpha-(Difluoromethyl)-DL-ornithine; Eflornithine hydrochloride (USAN); NSC270295; 2-(Difluoromethyl)ornithine; Difluoromethylornithine; MLS001332583; .alpha.-DFMO HCl; Eflornithine hydrochloride monohydrate; FT-0082826	70052-12-9	3009	48415938	TTDS00313	Ornithine decarboxylase	ODC	P11926	4953	ENSG00000115758	inhibitor
DCL001075	PD-0332991	EC-000.2350; 6-ACETYL-8-CYCLOPENTYL-5-METHYL-2-[(5-PIPERAZIN-1-YLPYRIDIN-2-YL)AMINO]PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE; PD-332991; CHEMBL189963; S1116_Selleck; CID5330286; Pyrido(2,3-d)pyrimidin-7(8H)-one, 6-acetyl-8-cyclopentyl-5-methyl-2-((5-(1-piperazinyl)-2-pyridinyl)amino)-; LQQ; 6-acetyl-8-cyclopentyl-5-methyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one; 2euf; Kinome_3823; 6-Acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-ylpyridin-2-ylamino)-8H-pyrido(2,3-d)pyrimidin-7-one; PD0332991; 571190-30-2; PD 332991, PD 0332991, PD0332991; AC1NS8RV; Kinome_3824; PD-0332991; PD 0332991	N/A	N/A	N/A	TTDC00165	Cell division protein kinase 4	CDK4;Cyclin-dependent kinase 4;PSK-J3	P11802	1019	ENSG00000135446	inhibitor
DCL001079	R547	LS-193675; ZINC13983251; R547; DB08094; R-547; CHEMBL384304; [4-amino-2-[(1-methylsulfonylpiperidin-4-yl)amino]pyrimidin-5-yl]-(2,3-difluoro-6-methoxyphenyl)methanone; 2fvd; LIA; CID6918852; AC1OCFYV	N/A	N/A	N/A	TTDC00165	Cell division protein kinase 4	CDK4;Cyclin-dependent kinase 4;PSK-J3	P11802	1019	ENSG00000135446	inhibitor
DCL001073	P1446A-05	N/A	N/A	N/A	N/A	TTDC00165	Cell division protein kinase 4	CDK4;Cyclin-dependent kinase 4;PSK-J3	P11802	1019	ENSG00000135446	inhibitor
DCL001074	P276-00	N/A	N/A	N/A	N/A	TTDC00165	Cell division protein kinase 4	CDK4;Cyclin-dependent kinase 4;PSK-J3	P11802	1019	ENSG00000135446	inhibitor
DCL000077	Capridine-beta	666854-78-0; CC-10004; UNII-UP7QBP99PN; CC 10004; Apremilast; D08860; CID11561674; Apremilast (USAN); CHEMBL514800; CHEBI:558773; N-[2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methylsulfonyl-ethyl]-1,3-dioxo-isoindol-4-yl]acetamide	N/A	N/A	N/A	TTDC00165	Cell division protein kinase 4	CDK4;Cyclin-dependent kinase 4;PSK-J3	P11802	1019	ENSG00000135446	inhibitor
DCL000366	Ro 31-7453	AC1NS2UU; CID5327686; Bisindolylmaleimide deriv. 44; Ro-31-7453; 3-(1-methylindol-3-yl)-4-(1-methyl-6-nitroindol-3-yl)pyrrole-2,5-dione; MKC-1; CHEMBL52885	443912-18-3	N/A	3820971	TTDC00165	Cell division protein kinase 4	CDK4;Cyclin-dependent kinase 4;PSK-J3	P11802	1019	ENSG00000135446	inhibitor
DCL001084	ZK 304709	N/A	N/A	N/A	N/A	TTDC00165	Cell division protein kinase 4	CDK4;Cyclin-dependent kinase 4;PSK-J3	P11802	1019	ENSG00000135446	inhibitor
DPR000124	AG-024322	N-[[5-[(3E)-3-(4,6-difluorobenzimidazol-2-ylidene)-1,2-dihydroindazol-5-yl]-4-methylpyridin-3-yl]methyl]ethanamine; AG-24322; AG-024322; AC1OCFY2; CID6918834	N/A	N/A	N/A	TTDC00165	Cell division protein kinase 4	CDK4;Cyclin-dependent kinase 4;PSK-J3	P11802	1019	ENSG00000135446	inhibitor
DCL000365	PD-332991	EC-000.2350; 6-ACETYL-8-CYCLOPENTYL-5-METHYL-2-[(5-PIPERAZIN-1-YLPYRIDIN-2-YL)AMINO]PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE; PD-332991; CHEMBL189963; S1116_Selleck; CID5330286; Pyrido(2,3-d)pyrimidin-7(8H)-one, 6-acetyl-8-cyclopentyl-5-methyl-2-((5-(1-piperazinyl)-2-pyridinyl)amino)-; LQQ; 6-acetyl-8-cyclopentyl-5-methyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one; 2euf; Kinome_3823; 6-Acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-ylpyridin-2-ylamino)-8H-pyrido(2,3-d)pyrimidin-7-one; PD0332991; 571190-30-2; PD 332991, PD 0332991, PD0332991; AC1NS8RV; Kinome_3824; PD-0332991; PD 0332991	571190-30-2	5005498	12015755	TTDC00165	Cell division protein kinase 4	CDK4;Cyclin-dependent kinase 4;PSK-J3	P11802	1019	ENSG00000135446	inhibitor
DAP000878	Hydroxychloroquine	IDI1_000942; SPBio_001116; UNII-4QWG6N8QKH; EINECS 204-249-8; Hydroxychlorochin; WIN 1258; Hydroxychloroguine; Hydroxychloroquine (INN); KBio1_000942; Spectrum5_001697; Quensyl; BRN 0253894; HCQ; Hydroxychloroquine [INN:BAN]; Oxychlorochin; 2-((4-((7-Chloro-4-quinolyl)amino)pentyl)ethylamino)ethanol; 747-36-4 (sulfate (1:1) salt); Oxichloroquine; Hydroxychloroquinum [INN-Latin]; hydroxychloroquine; NSC4375; 2-(N-(4-(7-Chlor-4-chinolylamino)-4-methylbutyl)ethylamino)ethanol; DB01611; Ethanol, 2-[[4-[(7-chloro-4-quinolinyl)amino]pentyl]ethylamino]-; Polirreumin; Ethanol, 2-((4-((7-chloro-4-quinolinyl)amino)pentyl)ethylamino)-; MolPort-003-847-792; C18H26ClN3O; Ethanol, 2-((4-((7-chloro-4-quinolyl)amino)pentyl)ethylamino)-; Hidroxicloroquina [INN-Spanish]; Oxichlorochinum; NCGC00159483-02; HMS502P04; 5-22-10-00280 (Beilstein Handbook Reference); Spectrum2_001238; Polirreumin (TN); C07043; Hidroxicloroquina; CID3652; Idrossiclorochina [DCIT]; CHEMBL1535; Hydroxychloroquinum; LS-66614; D08050; 118-42-3; Idrossiclorochina; DivK1c_000942; 2-[4-[(7-chloroquinolin-4-yl)amino]pentyl-ethylamino]ethanol; Oxychloroquine; Hydroxychloroquine Sulfate (1:1) Salt; AC1L1GEW; ST072188; 2-[{4-[(7-chloroquinolin-4-yl)amino]pentyl}(ethyl)amino]ethanol; 7-Chloro-4-(4-(ethyl(2-hydroxyethyl)amino)-1-methylbutylamino)quinoline; NINDS_000942; Gen-Hydroxychloroquine 200mg Tablets; 7-Chloro-4-(4-(N-ethyl-N-beta-hydroxyethylamino)-1-methylbutylamino)quinoline; 7-Chloro-4-(5-(N-ethyl-N-2-hydroxyethylamino)-2-pentyl)aminoquinoline	118-42-3	3652	9255	TTDS00311	Toll-like receptor 7	N/A	Q9NYK1	51284	ENSG00000196664	antagonist
DCL000323	Isatoribine	5-Amino-3-.beta.-D-ribofuranosylthiazolo[4,5]pyrimidine-2,7(3H,6H)-dione; 7-TOG; Isatoribine monohydrate; Immusine; NARI-10146; TOG; AC1L2HO7; Immusine (TN); Immunosine; 5-amino-3-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-4H-[1,3]thiazolo[4,5-d]pyrimidine-2,7-dione hydrate; 5-Amino-3-ribofuranosylthiazolo(4,5-d)pyrimidine-2,7(3H,6H)-dione; 5-amino-3-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-4H-[1,3]thiazolo[4,5-d]pyrimidine-2,7-dione; Isatoribine [USAN:INN]; ANA245; Isatorabine; CID172984; 7-Thia-8-oxoguanosine; 5-amino-3-(|A-d-ribofuranosyl)[1,3]thiazolo[4,5-d]pyrimidine-2,7(3h,4h)-dione; Satoribine; 7-Deaza-7-thia-8-oxoguanosine; Thiazolo(4,5-d)pyrimidine-2,7(3H,4H)-dione, 5-amino-3-beta-D-ribofuranosyl-; D04619; ANA-245; 198832-38-1; AR-1G7129; Isatoribine (USAN); CID72231; AC1Q6N18; ICN-10146; Isatoribine; N10146; AC1L59KV; ANA 245	122970-40-5	172984	47206462	TTDS00311	Toll-like receptor 7	N/A	Q9NYK1	51284	ENSG00000196664	agonist
DAP001249	Docosanol	Lidavol; NSC 8407; AC1Q7CQ8; DB00632; Erazaban; AC1Q2W4M; Docosanol [USAN]; Nacol 22-97; AI3-36489; S1637_Selleck; 1-DOCOSANOL; Behenyl alcohol; CCRIS 8943; BEHENYL ALCOHOL, 98%; Abreva (TN); Docosyl alcohol; NSC8407; D03884; Docosanol; NCGC00159370-03; CID12620; CPD-7845; Doconsanol; LS-174295; Behenyl alcohol, AI3-36489, Behenic alcohol, 1-Docosanol, Docosyl alcohol, IK-2, Tadenan; 661-19-8; IK 2; CHEMBL1200453; Behenyl alcohol, Abreva, 1-Docosanol, Docosanol; Debat; BRN 1770470; Abreva; AC1L1ZZI; Tadenan; AC-19852; LMFA05000008; Stenol 1822A; 43960_FLUKA; TL8004688; NAA 422; n-Docosanol; HSDB 5739; 4-01-00-01906 (Beilstein Handbook Reference); InChI=1/C22H46O/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23/h23H,2-22H2,1H; CHEBI:31000; EINECS 211-546-6; Lidakol; Herepair; docosan-1-ol; NCGC00159370-02; 30303-65-2; IK.2; Stenol 1822; 169102_ALDRICH; Docosanol (VAN); Healip; SBB060170; HMS2093P22; MolPort-003-666-887; LS-63381; C22H46O; UNII-9G1OE216XY; D0964; V-1326; Lanette 22; Docosanol (USAN); A3D72D45-625E-49B5-B0FC-394010B3485D; Behenic alcohol	30303-65-2	12620	207364	TTDS00311	Toll-like receptor 7	N/A	Q9NYK1	51284	ENSG00000196664	agonist
DAP000278	Imiquimod	Imiquimod acetate; 4-Amino-1-isobutyl-1H-imidazo[4,5-c]quinoline; CHEMBL1282; 3M Brand of Imiquimod; I5159_SIGMA; BB_SC-2107; STK583860; AC-529; DB00724; LS-178395; I06-2289; MTD-39; 1-(2-Methylpropyl)-1H-imidazole[4,5-c]quinoline-4-amine; S1211_Selleck; AC1Q4YO9; 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine; NSC369100; 1-(2-methylpropyl)imidazo[4,5-c]quinolin-4-amine; SMR000048307; I06-0624; UNII-P1QW714R7M; S 26308; Beselna; Imiquimod (JAN/USAN/INN); 4-Amino-1-isobutyl-1H-imidazo(4,5-c)quinoline; 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine; MolPort-002-507-845; Aldara; AC1L1N2I; R-837; S-26308; HMS2090M14; TL8006059; NCGC00070736-02; Imiquimod [USAN:INN]; 99011-02-6; IMIQUIMOD; 1-isobutyl-1H-imidazo(4,5-c)quinolin-4-amine; CID57469; FT-0080222; CHEBI:36704; Zyclara; MLS000083577; C056493; Aldara, Imiquimod; Zartra; DZ-2636; BIDD:GT0859; TMX-101; Aldara (TN); 1H-Imidazo[4,5-c]quinolin-4-amine, 1-(2-methylpropyl)-; R 837; D02500; ZINC19632912; 1H-Imidazo(4,5-c)quinolin-4-amine, 1-(2-methylpropyl)-; I0747	99011-02-6	57469	194523	TTDS00311	Toll-like receptor 7	N/A	Q9NYK1	51284	ENSG00000196664	agonist
DCL001196	IMO-3100	N/A	N/A	N/A	N/A	TTDS00311	Toll-like receptor 7	N/A	Q9NYK1	51284	ENSG00000196664	antagonist
DCL000215	Resiquimod	C099445; CHEMBL383322; AC1L4M46; S-28463; 1-[4-amino-2-(ethoxymethyl)imidazo[4,5-c]quinolin-1-yl]-2-methylpropan-2-ol; 4-amino-2-ethoxymethyl-alpha,alpha-dimethyl-1H-imidazo(4,5-c)quinoline-1-ethanol; CHEBI:36706; 1-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-2-methylpropan-2-ol; 4-amino-2-(ethoxymethyl)-a,a-dimethyl-1h-imidazo[4,5-c]quinoline-1-ethanol; 144875-48-9; 1H-Imidazo(4,5-c)quinoline-1-ethanol, 4-amino-2-(ethoxymethyl)-alpha,alpha-dimethyl-; Resiquimod; 171742-32-8; CID159603; R848; UNII-V3DMU7PVXF; Resiquimod [INN]; AC1Q4YO8; R 848; VML-600; AR-1G0546; MolPort-006-822-593; R-848; AR-1G0547; 1-(4-Amino-2-ethoxymethyl-imidazo[4,5-c]quinolin-1-yl)-2-methyl-propan-2-ol; C402365; S 28463; R848 compound	144875-48-9	159603	17425420	TTDS00311	Toll-like receptor 7	N/A	Q9NYK1	51284	ENSG00000196664	agonist
DCL000020	CPG 52364	N/A	453562-69-1	11667893	47214228	TTDS00311	Toll-like receptor 7	N/A	Q9NYK1	51284	ENSG00000196664	antagonist
DCL001140	ANA773	N/A	N/A	N/A	N/A	TTDS00311	Toll-like receptor 7	N/A	Q9NYK1	51284	ENSG00000196664	agonist
DCL000110	Exherin	NSC729477; CID9916058; Exherin; CID 9916058; ADH-10001; 229971-81-7; ADH-1; L-Cysteinamide, N-Acetyl-L-cysteinyl-L-hisitidyl-L-alanyl-L-valyl-, cyclic (1 5)-disulfide, trifluoroacetate (salt) hydrate	N/A	24203776	49684202	TTDC00137	Neural-cadherin	Cadherin-2;N-cadherin	P19022	1000	ENSG00000170558	binder
DCL000821	GRN163	N/A	N/A	N/A	N/A	TTDC00195	Telomerase	N/A	Q37967	N/A	N/A	inhibitor
DCL000583	Olaparib	4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; 937799-91-2; AZD2281; KU-0059436; AKOS005145764; Olaparib, KU-0059436, AZD2281, KU0059436,  AZD2281; S1060_Selleck; Olaparib; AZD-2281; AZD 2281; EC-000.2324; CHEMBL521686; EN002690; KU-59436; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one; 763113-22-0; FT-0083489; Acylpiperazine analogue, 47	N/A	N/A	N/A	TTDS00191	Poly [ADP-ribose] polymerase-1	ADPRT;NAD(+) ADP-ribosyltransferase-1;NAD(+)Poly [ADP-ribose] polymerase-1 ADP-ribosyltransferase-1;PARP-1;Poly(ADP-ribose)polymerase-1;Poly[ADP-ribose] synthetase-1	P09874	142	ENSG00000143799	inhibitor
DCL000500	BSI-201	SAR-240550; NSC-746045; INO2BA; IND-71677; EN002691; S1087_Selleck; 4-iodo-3-nitro-benzamide; Iniparib, NSC-746045, IND-71677, BSI201, BSI-201; BSI-201; CID9796068; CHEMBL1170047; 160003-66-7; Iniparib; NIBA; EC-000.2329; 4-Iodo-3-nitrobenzamide	N/A	6324636	42973608	TTDS00191	Poly [ADP-ribose] polymerase-1	ADPRT;NAD(+) ADP-ribosyltransferase-1;NAD(+)Poly [ADP-ribose] polymerase-1 ADP-ribosyltransferase-1;PARP-1;Poly(ADP-ribose)polymerase-1;Poly[ADP-ribose] synthetase-1	P09874	142	ENSG00000143799	inhibitor
DAP001410	Nicotinamide	MolMap_000061; CPD000058212; Aminicotin; Nicamindon; Nicotinamide, niacin, vitamin B3; Pyridine, 3-carbamoyl-; Niacinamide (USP); SGCUT00176; Amide PP; Vi-Nicotyl; Nikotinsaeureamid; Merck Brand of Niacinamide; 123574-63-0; 3 Pyridinecarboxamide; Witamina PP; Vitamin B (VAN); D009536; Austrovit PP; Nicovit; Pyridine-3-carboxylic acid amide; Amixicotyn; Nicotinamidum [INN-Latin]; Pharmagenix Brand of Niacinamide; Nicotylamidum; C6H6N2O; nchembio.154-comp4; N5535_SIAL; I02-1741; HMS2093H03; Nicotine acid amide; Niacevit; 1yc5; Benicot; N0636_SIGMA; 98-92-0; Nicovitina; Niacinamide Pharmagenix Brand; Niko-tamin; nchembio.73-comp6; 11032-50-1; 37321-14-5; Nicotinamide (JP15/INN); Vitamin H1; Nicosan 2; Vitamin B; 47865U_SUPELCO; Nicotinamida; Amid kyseliny nikotinove; niacin - Vitamin B3; Endobion; 3-Pyridinecarboxylic acid amide; 72347_FLUKA; to_000073; AC1L1ACZ; 55600-01-6; Niacinamide Astra Brand; pyridine-3-carboxamide; Nicamina; Nikotinsaeureamid [German]; Niacinamide Jenapharm Brand; Nicotilamide; Pelmin; B3, Vitamin; HMS2052M21; AC-907/25014114; Nicotinic amide; Pelmine; PP-Faktor; Nicobion; D00036; Savacotyl; N2142_SIGMA; NCGC00093354-04; Jenapharm Brand of Niacinamide; Delonin amide; Nicomidol; beta-Pyridinecarboxamide; 78731-47-2; Nicozymin; Nicotinsaureamid; CHEBI:17154; Vitamin B 3; m-(Aminocarbonyl)pyridine; Hansamid; Nikasan; CID936; Nicotylamide; NSC27452; 3-Pyridinecarboxamide; .beta.-Pyridinecarboxamide; C00153; Nicotinic acid amide; DEA No. 1405; Niacinamide [USAN]; NCGC00093354-03; EINECS 234-265-0; 72340_FLUKA; Pelonin amide; Nicotinsaureamid [German]; Nikotinamid; N3376_SIGMA; Nicotililamido; HMS2090B05; CCRIS 1901; Enduramide; Nicotol; niacinamide; MolPort-001-783-876; Astra Brand of Niacinamide; AI3-02906; Nicovitol; HSDB 1237; nicotinamide; Niacinamide, Nicotinic acid amide, Nicotinamide; 63748-44-7; 3-Carbamoylpyridine; UNII-25X51I8RD4; Nandervit-N; Niocinamide; Nikazan; SMR000058212; Nicasir; BB_NC-2290; Amnicotin; Niozymin; Mediatric; Nicogen; Niacotinamide; DB02701; Niamide; LS-2051; Nicotamide; Nicotinamida [INN-Spanish]; Dipegyl; Nicotinamide (Niacinamide); CHEMBL1140; ZINC00005878; Papulex; Nicotinamide-carbonyl-14C; Nicotinamidum; Factor pp; bmse000281; MLS000069714; Inovitan PP; vitamin PP; N0078; B 3, Vitamin; Niacinamide Merck Brand; NSC 13128; Niavit PP; InChI=1/C6H6N2O/c7-6(9)5-2-1-3-8-4-5/h1-4H,(H2,7,9; S1899_Selleck; EINECS 202-713-4; Nicotinsaureamid Jenapharm; Nicosylamide; Amid kyseliny nikotinove [Czech]; Nicotine amide; AC1Q4ZFV; Nicofort; WLN: T6NJ CVZ; NSC13128; 72340_SIGMA; Nicotinamid; Nicota; A186B02E-6C70-4E54-9739-79398D439AAA; I02-2250; Nicotinsaeureamid; Jenapharm, Nicotinsaureamid; SAM001246860	98-92-0	936	3453	TTDS00191	Poly [ADP-ribose] polymerase-1	ADPRT;NAD(+) ADP-ribosyltransferase-1;NAD(+)Poly [ADP-ribose] polymerase-1 ADP-ribosyltransferase-1;PARP-1;Poly(ADP-ribose)polymerase-1;Poly[ADP-ribose] synthetase-1	P09874	142	ENSG00000143799	binder
DCL000416	AG-14699	AG-014699; AG-14699; AG-014447; PF-01367338; EC-000.2323; S1098_Selleck; CID9931953; CID 9931953; AG-14447	83420-94-4	3035055	36078614	TTDS00191	Poly [ADP-ribose] polymerase-1	ADPRT;NAD(+) ADP-ribosyltransferase-1;NAD(+)Poly [ADP-ribose] polymerase-1 ADP-ribosyltransferase-1;PARP-1;Poly(ADP-ribose)polymerase-1;Poly[ADP-ribose] synthetase-1	P09874	142	ENSG00000143799	inhibitor
DCL000145	KU-0059436	4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; 937799-91-2; AZD2281; KU-0059436; AKOS005145764; Olaparib, KU-0059436, AZD2281, KU0059436,  AZD2281; S1060_Selleck; Olaparib; AZD-2281; AZD 2281; EC-000.2324; CHEMBL521686; EN002690; KU-59436; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one; 763113-22-0; FT-0083489; Acylpiperazine analogue, 47	937799-91-2	N/A	85154426	TTDS00191	Poly [ADP-ribose] polymerase-1	ADPRT;NAD(+) ADP-ribosyltransferase-1;NAD(+)Poly [ADP-ribose] polymerase-1 ADP-ribosyltransferase-1;PARP-1;Poly(ADP-ribose)polymerase-1;Poly[ADP-ribose] synthetase-1	P09874	142	ENSG00000143799	inhibitor
DCL000136	INO-1001	KBio2_002444; KBioSS_002450; AC1O8FMH; KBio2_007580; BSPBio_002719; Hypoxanthine arabinoside; SPECTRUM3100024; AC-3200; DivK1c_006781; Spectrum5_000469; KBio3_002219; SPBio_001977; 9-[(3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one; CHEMBL462399; Spectrum_001910; Spectrum3_001160; CID6708742; KBioGR_002372; KBio2_005012; LT00454797; KBio1_001725; INO-1001; Spectrum2_001939; SpecPlus_000685; Spectrum4_001795	55837-27-9	4849	49699267	TTDS00191	Poly [ADP-ribose] polymerase-1	ADPRT;NAD(+) ADP-ribosyltransferase-1;NAD(+)Poly [ADP-ribose] polymerase-1 ADP-ribosyltransferase-1;PARP-1;Poly(ADP-ribose)polymerase-1;Poly[ADP-ribose] synthetase-1	P09874	142	ENSG00000143799	inhibitor
DCL001102	AG140699	N/A	N/A	N/A	N/A	TTDS00191	Poly [ADP-ribose] polymerase-1	ADPRT;NAD(+) ADP-ribosyltransferase-1;NAD(+)Poly [ADP-ribose] polymerase-1 ADP-ribosyltransferase-1;PARP-1;Poly(ADP-ribose)polymerase-1;Poly[ADP-ribose] synthetase-1	P09874	142	ENSG00000143799	inhibitor
DCL000571	MK-4827	MK-4827; CHEBI:724225; CHEMBL1094636	N/A	9690123	47169651	TTDS00191	Poly [ADP-ribose] polymerase-1	ADPRT;NAD(+) ADP-ribosyltransferase-1;NAD(+)Poly [ADP-ribose] polymerase-1 ADP-ribosyltransferase-1;PARP-1;Poly(ADP-ribose)polymerase-1;Poly[ADP-ribose] synthetase-1	P09874	142	ENSG00000143799	inhibitor
DCL001118	Pro 542	N/A	N/A	N/A	N/A	TTDR00264	HIV envelope protein gp120	N/A	O40473	N/A	N/A	binder
DCL001105	BMS-488043	1-(4-benzoylpiperazin-1-yl)-2-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione; BMS-043; BMS043; CID507806; Piperazine, 1-benzoyl-4-[2-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)-1,2-dioxoethyl]-; CHEMBL238103; BMS488043; CHEBI:501787; AC1LA5X7; BMS-488043; AIDS171276	N/A	N/A	N/A	TTDR00264	HIV envelope protein gp120	N/A	O40473	N/A	N/A	binder
DCL001060	TV-1102	N/A	N/A	N/A	N/A	TTDC00282	mRNA of Integrin alpha V	N/A	N/A	N/A	N/A	antisense
DAP001302	Salmon Calcitonin	salmon calcitonin (1-32); EINECS 256-342-8; Staporos; Oseototal; Stalcin; synthetic salmon calcitonin; Porostenina; Calcitonina; Miacalcin (TN); Salmon calcitonin-(I-32); LS-48624; Miacalcic; Kalsimin; Biocalcin; Calcitonin salmon; TZ-CT; Ipocalcin; Miracalcic; Eptacalcin; Karil; Rulicalcin; Calcitonin salmon (USAN/INN); Calcitonin (salmon); C06865; Fortical (TN); Calogen; Isi-calcin; D00249; Salcat; Osteobion; Prontocalcin; Ostostabil; Calco; 47931-85-1; C145H239N43O48S2; Miacalcin; Calcitonin salmon (synthesis); Calcitonine de saumon; Calcitonin, salmar; recombinant salmon calcitonin; Quosten; UNII-7SFC6U2VI5; Calcimar (TN); Steocin; Fortical; Caltine; Calsynar; Cadens; Calcitonin-salmon; Tonocalcin; Calcimar; Cibacalcine; Casalm; Calcinil; Catonin; Calcitonin vom lachs; Calcimonta; Riostin; Ostosalm; Osteovis; Calcihexal; Bionocalcin; Calcitoran; Salmofar; Calcioton; Calcitonin,salmon; Osseocalcina; Ucecal; Salmocalcin; C028815; Salcatonin; Astronin; Thyrocalcitonin (salmon); CALCITONIN, SALMON; Salcatyn; Salmon calcitonin; Calcitonin salmon (synthesis) (JAN); Salmon calcitonin I; Calcitonin [USAN:INN:BAN:JAN]; Citonina; Cibacalcin; 135506-95-5; Calcitonin, salmon, for bioassay; Sical; Calciben; Calsynar Lyo L; Forcaltonin	47931-85-1	16129616	7847315	TTDS00485	Calcitonin receptor	CALCR;CT-R	P30988	799	ENSG00000004948	binder
DCL000877	MCI-186	MLS001146878; KBioGR_000575; D01552; DivK1c_001018; CI Developer 1; 1-Phenyl-3-methyl-5-oxo-2-pyrazoline; Bio2_000448; KBioSS_000747; 3-Methyl-1-phenyl-5-pyrazolone; LS-1892; KBio2_003315; 1-Phenyl-3-methylpyrazolone-5; Spectrum5_001217; EINECS 201-891-0; KBioGR_001502; HMS1990M17; C.I. Developer 1; 206195-95-1; HMS503K17; NCGC00022665-02; 68740_FLUKA; Radicut (TN); KBio2_000575; KBio2_005711; 5-Methyl-2-phenyl-2,4-dihydro-3H-pyrazol-3-one; Phenyl methyl pyrazolone; 5-Pyrazolone, 3-methyl-1-phenyl-; NINDS_001018; NCI-C03952; 72134-66-8; edarabone; Spectrum_000267; C13008; Spectrum3_000971; 5-methyl-2-phenyl-4H-pyrazol-3-one; MLS000069602; NCGC00164015-01; BRN 0609575; 1-Phenyl-3-methyl-5-pyrazolone; AE-641/00371017; MCI 186; KBioSS_000575; edaravone; M70800_ALDRICH; SPECTRUM1503635; S1326_Selleck; Monopyrazolone; BSPBio_001235; 2-Pyrazolin-5-one, 3-methyl-1-phenyl-; Norantipyrine; Spectrum4_001091; Tocris-0786; 1-Fenyl-3-methyl-2-pyrazolin-5-on [Czech]; IDI1_001018; 3-Methyl-1-phenylpyrazol-5-one; Bio1_001416; AC1Q2PHG; Methylphenylpyrazolone; Spectrum2_001574; Developer Z; WLN: T5NMV DHJ BR& E1; Bio2_000928; Norphenazone; IDI1_002203; edaravone(jan); AC-4745; NSC 12; 89-25-8; 1-Phenyl-3-methylpyrazolone; 1-Fenyl-3-methyl-2-pyrazolin-5-on; BSPBio_002601; 12235-58-4; 2,4-Dihydro-5-methyl-2-phenyl-3H-pyrazol-3-one; DivK1c_002026; C005435; I01-2810; KBio2_005883; 52224-17-6; MolPort-000-182-197; SPBio_001508; Radicut; KBio3_001029; AI3-03557; KBio3_001821; 115566-83-1; IN1263; KBio2_003143; KBio1_001018; HSDB 4102; NCGC00022665-06; NSC26139; MLS002415675; AR-1I7113; NSC2629; Maybridge1_005738; InChI=1/C10H10N2O/c1-8-7-10(13)12(11-8)9-5-3-2-4-6-9/h2-6H,7H2,1H; 3-METHYL-1-PHENYL-2-PYRAZOLIN-5-ONE; MCI-186; AC1L1H8H; NCGC00018218-01; CDS1_000986; BRD-K35458079-001-04-2; Bio1_000927; (MCI-186); 3H-Pyrazol-3-one, 2,4-dihydro-5-methyl-2-phenyl-; SMR000059020; 3-Methyl-1-phenyl-2-pyrazoline-5-one; NCGC00022665-05; Edaravone (JAN/INN); HMS1792M17; CCRIS 512; STK201315; AKOS000313817; 62495-97-0; CHEMBL290916; CHEBI:31530; Bio1_000438; Edaravone [INN]; AC1Q6EYP; BCBcMAP01_000127; Phenylmethylpyrazolone; HMS557M18; M0687; CID4021; BB_SC-0469; KBio2_000747; HMS1362M17; NCGC00022665-04; UNII-S798V6YJRP; KBio3_001030	89-25-8	4021	26759079	TTDC00319	Apoptosis regulator Bcl-2	Bcl-2	P10415	596	ENSG00000171791	N/A
DCL000903	Oblimersen	N/A	190977-41-4	N/A	47206935	TTDC00319	Apoptosis regulator Bcl-2	Bcl-2	P10415	596	ENSG00000171791	inhibitor
DCL000056	AT-101	Isosorbide (JP15/USP/INN); 1,4:3,6-dianhydrohexitol; Sorbid; CHEMBL1200660; Bio-0643; 50974-60-2; NCGC00160508-01; 1,4:3,6-Dianhydro-D-sorbitol; Isosorbida [INN-Spanish]; EINECS 211-492-3; Vascardin dinitrate; BRN 0080510; 652-67-5; Glucitol, 1,4:3,6-dianhydro-, D-; Oprea1_439690; Ismotic (TN); 2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3,6-diol; AC1Q79SL; 42750-75-4; Isosorbide [USAN:INN:BAN:JAN]; TL8004635; 67803-92-3; STK801813; I0407; HSDB 3105; AC1L4190; Isobide; SMP1_000177; EINECS 248-906-7; AR-1B7417; NSC 40725; EINECS 211-374-1; BIDD:GT0695; Devicoran; 49871-92-3; Isosorbidum [INN-Latin]; D-Sorbitol, 1,4:3,6-dianhydro(furo[3,2-b]furan-3,6-diol, hexahydro-); 24332-71-6; MolPort-001-783-404; I14-6752; 1,4:3,6-Dianhydroglucitol; LS-71370; Isobide (TN); NSC40725; D00347; UNII-WXR179L51S; D-Glucitol, 1,4:3,6-dianhydro-; D-Sorbitol, {1,4:3,6-dianhydro(furo[3,2-b]furan-3,6-diol,} hexahydro-); LS-89261; Hydronol; Sorbitol, 1,4:3,6-dianhydro-; Isosorbidum; 1,4:3,6-Dianhydromannitol; 151380-60-8; A912284D-27E1-4FB0-91B8-86C8AB905297; 5-19-03-00201 (Beilstein Handbook Reference); 641-74-7; NSC270938; 152881-21-5; Hydronol (VAN); Isomannide; D-1,4:3,6-Dianhydroglucitol; isosorbide; 1,4:3,6-Dianhydro-D-glucitol; (3S,3aR,6R,6aR)-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3,6-diol; Ismotic; (+)-D-Isosorbide; AT-101; CID99937; AC1L1ZXO; Dianhydrosorbitol; D-Mannitol, 1,4:3,6-dianhydro-; KST-1B7297; CID12597; AT 101; ZINC18284778; Isosorbida; D-Glucitol, 1,4:3,6-dianhydro-; 28218-68-0; MolPort-000-812-960; Mannitol, 1,4:3,6-dianhydro-; NSC231906; Dianhydro-D-glucitol; 1,4:3,6-Dianhydrosorbitol; 1,4-Dianhydrosorbitol	652-67-5	12597	26683984	TTDC00319	Apoptosis regulator Bcl-2	Bcl-2	P10415	596	ENSG00000171791	inhibitor
DCL000415	ABT-263	Navitoclax; ABT 263; 1000696-69-4; 923564-51-6; Benzamide, 4-(4-((2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohexen-1-yl)methyl)-1-piperazinyl)-N-((4-(((1R)-3-(4-morpholinyl)-1-((phenylthio)methyl)propyl)amino)-3-((trifluoromethyl)sulfonyl)phenyl)sulfonyl)-; CHEMBL443684; CHEBI:608147; ABT263, Navitoclax; I06-2050; S1001_Selleck; BRD-K82746043-001-03-7; BRD-K82746043-001-02-9; MolPort-006-391-499; 4-(4-{[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({4-({(1R)-3-morpholin-4-yl-1-[(phenylsulfanyl)methyl]propyl}amino)-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)benzamide; BRD-K82746043-001-01-1; ABT-263	119229-65-1	3081185	44854467	TTDC00319	Apoptosis regulator Bcl-2	Bcl-2	P10415	596	ENSG00000171791	inhibitor
DAP000182	Alendronate	(4-Amino-1-hydroxybutylidene)bisphosphonic acid; ST50036159; 4-Amino-1-hydroxybutane-1,1-diphosphonic Acid; Alendronic acid [INN:BAN]; MK 217; Oprea1_422906; 4-Amino-1-hydroxybutylidene-1,1-bis(phosphonic acid); Acide alendronique; SPECTRUM1505166; 4-Amino-1-hydroxybutylidene-1,1-bisphosphonate; alendronate; NCGC00096054-04; Acido alendronico; Arendal; (4-amino-1-hydroxybutane-1,1-diyl)bis(phosphonic acid); C07752; Acido alendronico [INN-Spanish]; (4-Amino-1-hydroxybutylidene)diphosphonic acid; MolPort-000-421-410; UNII-X1J18R4W8P; (4-amino-1-hydroxy-1-phosphonobutyl)phosphonic acid; D07119; 4-Amino-1-hydroxybutane-1,1-diphosphonate; Alendronic acid (INN); Acide alendronique [INN-French]; NCGC00096054-01; CHEBI:2567; Fosamax; 121268-17-5 (mono-hydrochloride salt, trihydrate); BIDD:GT0180; Phosphonic acid, (4-amino-1-hydroxybutylidene)bis-; Acidum alendronicum; Phosphonic acid, (4-amino-1-hydroxybutylidene)bis; Acidum alendronicum [INN-Latin]; ALENDRONATE SODIUM; ALENDRONIC ACID; AKOS001015793; LS-106421; AC1L1CW3; HSCI1_000337; 1yhm; DB00630; 66376-36-1; bisphosphonate, 65; CID2088; MK-217; NCGC00096054-03; CHEMBL870	66376-36-1	2088	9954	TTDS00360	Receptor-type protein-tyrosine phosphatase S	Protein-tyrosine phosphatase sigma;R-PTP-S;R-PTP-sigma	Q13332	5802	ENSG00000105426	inhibitor
DAP000827	Etidronic acid	Didronel IV; SPBio_002826; NSC 227995; MLS002207267; Acide etidronique; (1-Hydroxyethylene)diphosphonic acid; Dequest Z 010; Phosphonic acid, (1-hydroxyethylidene)bis-; Diphosphonate (base); HSDB 5898; EHDP; 1-Hydroxyethane-1,1-diphosphonate; 138360-84-6; (Hydroxyethylidene)diphosphonic acid; 1-Hydroxyethylidene 1,1-diphosphonic acid; (1-Hydroxyethylidene)diphoshonic acid; 129130-42-3; SMR000038750; MolPort-001-786-542; Ethane-1-hydroxy-1,1-diphosphonic acid; I14-1271; Acidum etidronicum; Prestwick0_000863; 51888-66-5; Acido etidronico; BSPBio_000905; 2809-21-4; (1-Hydroxyethylidene)bis(phosphonic acid); Jsp005415; 54342_FLUKA; 0-02-00-00171 (Beilstein Handbook Reference); Acide etidronique [INN-French]; (1-Hydroxyethylidene)bisphosphonic acid; Turpinal SL; H6773_ALDRICH; HEDP; (1-hydroxy-1-phosphonoethyl)phosphonic acid; Etidronic acid monohydrate; 1-Hydroxyethanediphosphonic acid; Oxyethylidenediphosphonic acid; Phosphonic acid, 1-hydroxy-1,1-ethanediyl ester; D02373; Ferrofos 510; Etidronic acid (USAN/INN); Cintichem Technetium 99m Hedspa; Bio-0708; 192526-55-9; STK721995; BRN 1789291; 1-Hydroxyethane-1,1-bisphosphonic acid; ethane-1-hydroxy-1,1-bisphosphonic acid; Ethane-1-hydroxy-1,1-bisphosphonate; CHEMBL871; 853028-38-3; MLS002695948; 103736-66-9; 86159-18-4; BPBio1_000997; C07736; 66216-98-6; Dequest 2010; etidronate; Dequest 2015; 1,1,1-Ethanetriol diphosphonate; 100511-44-2; Phosphonic acid, (1-hydroxyethylidene)di-; Etidronic acid [USAN:INN:BAN]; Phosphonic acid, P,P'-(1-hydroxyethylidene)bis-; 1-Hydroxyethylidene-1,1-biphosphonate; 1-HYDROXY-1,1-DIPHOSPHONOETHANE; 1-Hydroxyethylidene-1,1-diphosphonic acid; Acidum etidronicum [INN-Latin]; RP 61; EINECS 220-552-8; (1-hydroxyethane-1,1-diyl)bis(phosphonic acid); 14860-53-8 (tetra-potassium salt); Prestwick2_000863; CHEBI:170675; NSC227995; UNII-M2F465ROXU; Acido etidronico [INN-Spanish]; Etidronsaeure; Hydroxyethane-1,1-diphosphonic acid; Prestwick3_000863; Hydroxyethanediphosphonic acid; CHEBI:4907; 303177-33-5; 54342_ALDRICH; Prestwick1_000863; 106908-76-3; LS-106637; NCGC00159352-02; 1-Hydroxyethylidenediphosphonic acid; MPI Stannous Diphosphonate; 1-Hydroxyethane-1,1,-diphosphonic acid; H6773_SIGMA; Osteoscan; H0587; 85985-26-8; 1000SL; Ethane-1-hydroxy-1,1-diphosphonate; 1-Hydroxyethylidene-1,1-bisphosphonate; CID3305; Acetodiphosphonic acid; AC1L1FMT; DB01077; Etidronic acid; 1-Hydroxyethane-1,1-diphosphonic acid; (1-Hydroxyethylidene)diphosphonic acid	7414-83-7	3305	626344	TTDS00360	Receptor-type protein-tyrosine phosphatase S	Protein-tyrosine phosphatase sigma;R-PTP-S;R-PTP-sigma	Q13332	5802	ENSG00000105426	inhibitor
DCL000121	GRC-6211	N/A	14698-29-4	4628	49698382	TTDC00049	Transient receptor potential cation channel subfamily V member 1	Capsaicin receptor;Osm-9-like TRP channel 1;OTRPC1;TrpV1;Vanilloid receptor 1	Q8NER1	7442	ENSG00000196689	blocker
DCL000046	AMG-8563	N/A	N/A	N/A	N/A	TTDC00049	Transient receptor potential cation channel subfamily V member 1	Capsaicin receptor;Osm-9-like TRP channel 1;OTRPC1;TrpV1;Vanilloid receptor 1	Q8NER1	7442	ENSG00000196689	blocker
DCL000956	Resiniferatoxin	CID104826; Benzeneacetic acid, 4-hydroxy-3-methoxy-, ((2S,3aR,3bS,6aR,9aR,9bR,10R,11aR)-3a,3b,6,6a,9a,10,11,11a-octahydro-6a-hydroxy-8,10-dimethyl-11a-(1-methylethenyl)-7-oxo-2-(phenylmethyl)-7H-2,9b-epoxyazuleno(5,4-e)-1,3-benzodioxol-5-yl)methyl ester; NCGC00162396-01; CID2733497; CID6324660; CID5148108; CHEBI:556371; MolPort-005-940-882; ZINC04262463; RTX; AC1L2XKN; CHEMBL448382; Reciniferatoxin; 57444-62-9; LS-28836; CID5311411; CID5702546; MolPort-003-983-798; 6,7-Deepoxy-6,7-didehydro-5-deoxy-21-dephenyl-21-(phenylmethyl)daphnetoxin 20-(3-hydroxy-5-methoxybenzeneacetate); AC1MBZ1I; Resiniferatoxin	57444-62-9	104826	49688359	TTDC00049	Transient receptor potential cation channel subfamily V member 1	Capsaicin receptor;Osm-9-like TRP channel 1;OTRPC1;TrpV1;Vanilloid receptor 1	Q8NER1	7442	ENSG00000196689	activator
DCL000455	AZD1386	N/A	N/A	N/A	N/A	TTDC00049	Transient receptor potential cation channel subfamily V member 1	Capsaicin receptor;Osm-9-like TRP channel 1;OTRPC1;TrpV1;Vanilloid receptor 1	Q8NER1	7442	ENSG00000196689	blocker
DCL000223	SB-705498	SB-705498; CID9910486; CHEMBL207433	N/A	9910486	49688578	TTDC00049	Transient receptor potential cation channel subfamily V member 1	Capsaicin receptor;Osm-9-like TRP channel 1;OTRPC1;TrpV1;Vanilloid receptor 1	Q8NER1	7442	ENSG00000196689	blocker
DCL000044	AMG-517	BD-0082; AMG-517; AMG 517; CHEMBL229430	N/A	N/A	N/A	TTDC00049	Transient receptor potential cation channel subfamily V member 1	Capsaicin receptor;Osm-9-like TRP channel 1;OTRPC1;TrpV1;Vanilloid receptor 1	Q8NER1	7442	ENSG00000196689	blocker
DCL000178	NGD-8243	N/A	N/A	N/A	N/A	TTDC00049	Transient receptor potential cation channel subfamily V member 1	Capsaicin receptor;Osm-9-like TRP channel 1;OTRPC1;TrpV1;Vanilloid receptor 1	Q8NER1	7442	ENSG00000196689	blocker
DCL000737	Capsaicin	8 Methyl N Vanillyl 6 Nonenamide; Prestwick3_000879; Nonenamide, N-((4-hydroxy-3-methoxyphenyl)methyl)-8 -methyl-, (E)-; Antiphlogistine Rub A-535 Capsaicin; Zacin; CHEBI:3374; UPCMLD-DP092; Elan Brand of Capsaicin; Carter Horner Brand of Capsaicin; HMS1791N10; AC1Q46B3; NCI-C56564; FT-0082538; Capsaicin [USAN]; C-1700; NGX 4010; depletes Substance P; ZINC01530575; Capsicum Farmaya; NCGC00090853-07; NSC56353; C18H27NO3; Isodecenoic acid vanillylamide; Flemming Brand of Capsaicin; Axsain; 21748_SIGMA; D002211; TL8002946; 8-Methyl-N-Vanillyl-6-Nonenamide; MolPort-001-742-263; [(E)-N-(4-Hydroxy-3-methoxyphenyl)methyl]-8-methyl-6-nonenamide; UNII-S07O44R1ZM; Spectrum5_000538; Gelcen; ZOSTRIX (TN); NGX-1998; (E)-Capsaicin; HMS2089N11; Nonenamide, 8-methyl-N-vanillyl-, (E)-; Capsaicin (in oleoresin of capsicum); Medicis Brand of Capsaicin; I01-2469; (6E)-N-(4-hydroxy-3-methoxybenzyl)-8-methylnon-6-enamide; nchembio862-comp2; BRD-K50590187-001-06-6; Caswell No. 158; Capsaicin; NCGC00090853-02; NGX-4010; 6-Nonenamide, N-((4-hydroxy-3-methoxyphenyl)methyl)-8-methyl-, (6E)-; Zostrix; neurotoxic; CID1548943; trans-Capsaicin; C06866; Capzasin; Bio-0615; 21750_FLUKA; N-(4-Hydroxy-3-methoxybenzyl)-8-methylnon-trans-6-enamide; NGX4010; CAPSAICINE; Link Brand of Capsaicin; NCGC00090853-09; HMS1921H11; CCRIS 1588; 6-Nonenamide, N-[(4-hydroxy-3-methoxyphenyl)methyl]-8-methyl-, (E)-; Katrum; N-[(4-hydroxy-3-methoxy-phenyl)methyl]nonanamide; 21750_SIGMA; N-((4-Hydroxy-3-methoxyphenyl)methyl)-8-methyl-6-nonenamide, (E)-; trans-8-Methyl-N-vanillyl-6-nonenamide; HMS1570P19; 12084_FLUKA; Prestwick_204; HMS1361N10; Capsin; 360376_ALDRICH; Capsaicin Patch; BSPBio_001548; nchembio.146-comp1; HSDB 954; Capsidol; Transacin; BSPBio_002917; Prestwick2_000879; HMS2092D21; 912457-62-6; NCGC00090853-04; MLS002154049; BPBio1_001053; Capsaicin (JAN/USP); M2028_SIGMA; BSPBio_000957; LS-2138; HMS1989N10; IDI1_034018; Zostrix HP; Vinas Brand of Capsaicin; SDCCGMLS-0066678.P001; NGX-3781; M1149; 8-Methyl-N-vanillyl-trans-6-nonenamide; BRD-K37056290-001-01-1; NCGC00090853-03; MR3H3; HMS501B16; CHEMBL294199; 6-Nonenamide, 8-methyl-N-vanillyl-, (E)-; UPCMLD-DP092:002; IDI1_000354; BRN 2816484; CAPSAICIN (2444-46-4 NONIVAMIDE (SYNTHETIC CAPSAICIN)); Capsaicin [in oleoresin of capsicum]; (6E)-N-{[4-hydroxy-3-(methyloxy)phenyl]methyl}-8-methylnon-6-enamide; MEGxp0_001448; SPECTRUM1501128; Smaller Brand of Capsaicin; AC1LU7K3; Centrum Brand of Capsaicin; Qutenza; NCGC00090853-06; TQ-1018; 8-Methyl-N-vanillyl-6-nonenamide, (E)-; SMP2_000337; 6-Nonenamide, (E)-N-((4-hydroxy-3-methoxy-phenyl)methyl)-8-methyl; n-(4-hydroxy-3-methoxybenzyl)-8-methyl-6-nonenamide; EINECS 206-969-8; Styptysat; (E)-N-[(4-hydroxy-3-methoxyphenyl)methyl]-8-methylnon-6-enamide; EPA Pesticide Chemical Code 070701; (E)-8-Methyl-N-vanillyl-6-nonenamide; N-[(4-Hydroxy-3-methoxyphenyl)methyl]-8-methyl-6-nonenamide; D00250; 404-86-4; Capsaicin (Natural); S1990_Selleck; Alacan Brand of Capsaicin; Thompson Brand of Capsaicin; NSC 56353; FEMA No. 3404; NGX-7325; N-(4-hydroxy-3-methoxybenzyl)-8-methylnon-6-enamide; 360376_SIGMA; E-CAPSAICIN; 6-Nonenamide, 8-methyl-N-vanillyl-, (E)- (8CI); 21748_FLUKA; 6-Nonenamide, N-((4-hydroxy-3-methoxyphenyl)methyl)-8-methyl-, (E)-; NCGC00090853-01; (E)-N-((4-Hydroxy-3-methoxyphenyl)-methyl)-8-methyl-6-nonenamide; NCGC00090853-08; SMR000718774; UPCMLD-DP092:001	404-86-4	1548943	49688535	TTDC00049	Transient receptor potential cation channel subfamily V member 1	Capsaicin receptor;Osm-9-like TRP channel 1;OTRPC1;TrpV1;Vanilloid receptor 1	Q8NER1	7442	ENSG00000196689	activator
DCL000389	SB-705498	SB-705498; CID9910486; CHEMBL207433	N/A	9883933	45630877	TTDC00049	Transient receptor potential cation channel subfamily V member 1	Capsaicin receptor;Osm-9-like TRP channel 1;OTRPC1;TrpV1;Vanilloid receptor 1	Q8NER1	7442	ENSG00000196689	blocker
DCL000025	A-425619	CHEMBL104028; AC1OYT5J; T5512318; MolPort-004-096-542; ZINC06746067; CID8068410; C503120; LS-192912; A-425619; 1-isoquinolin-5-yl-3-(4-trifluoromethyl-benzyl)-urea; 1-isoquinolin-5-yl-3-[[4-(trifluoromethyl)phenyl]methyl]urea	N/A	8068410	49688408	TTDC00049	Transient receptor potential cation channel subfamily V member 1	Capsaicin receptor;Osm-9-like TRP channel 1;OTRPC1;TrpV1;Vanilloid receptor 1	Q8NER1	7442	ENSG00000196689	blocker
DCL000045	AMG-8562	N/A	N/A	N/A	N/A	TTDC00049	Transient receptor potential cation channel subfamily V member 1	Capsaicin receptor;Osm-9-like TRP channel 1;OTRPC1;TrpV1;Vanilloid receptor 1	Q8NER1	7442	ENSG00000196689	blocker
DCL000026	A-993610	N/A	N/A	N/A	N/A	TTDC00049	Transient receptor potential cation channel subfamily V member 1	Capsaicin receptor;Osm-9-like TRP channel 1;OTRPC1;TrpV1;Vanilloid receptor 1	Q8NER1	7442	ENSG00000196689	blocker
DCL000063	BCTC	N/A	24365-47-7	72429	48413940	TTDC00049	Transient receptor potential cation channel subfamily V member 1	Capsaicin receptor;Osm-9-like TRP channel 1;OTRPC1;TrpV1;Vanilloid receptor 1	Q8NER1	7442	ENSG00000196689	blocker
DCL000027	ABT-102	CID11256560; ABT-102; 3-(1H-indazol-4-yl)-1-(5-tert-butyl-2,3-dihydro-1H-inden-1-yl)urea; CHEMBL398338; CHEBI:518623	N/A	N/A	N/A	TTDC00049	Transient receptor potential cation channel subfamily V member 1	Capsaicin receptor;Osm-9-like TRP channel 1;OTRPC1;TrpV1;Vanilloid receptor 1	Q8NER1	7442	ENSG00000196689	blocker
DAP000767	Fosfomycin	[(2R,3S)-3-methyloxiran-2-yl]phosphonic acid; I06-1211; (1R,2S)(-)-(1,2-Epoxypropyl)phosphonic acid disodium salt; FOM-Na; AC1L2JXY; Phosphonomycin disodium salt; AR-1I6648; DB00828; CHEMBL1757; disodium [(2R,3S)-3-methyloxiran-2-yl]-dioxido-oxo-; CID446987; LS-106593; ZINC19594585; CPD0-1113; disodium[(2r,3s)-3-methyloxiran-2-yl]phosphonate; Fosfomycin sodium (JP15); L-cis-1,2-epoxypropylphosphonic acid; Phosphonomycin sodium; EINECS 247-409-2; 34089_FLUKA; Phosphomycin disodium salt; 6F066DFF-696A-4A94-AF78-A28430EBE5BA; Disodium phosphonomycin; 34089_RIEDEL; Fosfocina disodium salt; Fosfomycin (USAN/INN); NSC 136017; D04253; 26016-99-9; D02188; nchem.1024-comp6; Disodium (1R,2S)-(1,2-epoxypropyl)phosphonate; Phosphonic acid, (3-methyloxiranyl)-, disodium salt, (2R-cis)-; (-)-(1R,2S)-(1,2-Epoxypropyl)phosphonic acid; P5396_SIGMA; (1R,2S)-epoxypropylphosphonate; Phosphonic acid, (3-methyloxiranyl)-, disodium salt, (2R-cis)- (9CI); C06454; Phosphonomycin; Disodium fosfomycin; (1R,2S)-epoxypropylphosphonic acid; 23155-02-4; Fosmicin S (TN); (&#8722;)-(1R,2S)-(1,2-Epoxypropyl)phosphonic acid; AC1L9KC0; Fosfomycin disodium; Phosphonemycin; phosphomycin; Priomicina; MK 955; Fosfomycin sodium; CID73491; (2R-cis)-(3-Methyloxiranyl)phosphonic acid disodium salt; Fosfomycin disodium salt; FCM; Sodium fosfomycin; BRN 1680831, Fosfocina; AC1Q1URS; Fosfomycin sodium salt; FOSFOMYCIN; Fosmicin S; Veramina; CHEBI:681859; MolPort-003-847-502; BIDD:GT0448; Phosphonic acid, (1,2-epoxypropyl)-, disodium salt (1R,2S) (-)-	23155-02-4	446987	8687	TTDS00233	UDP-N-acetylglucosamine 1-carboxyvinyltransferase	Enoylpyruvate transferase;EPT;MurA;MurA protein;UDP-GlcNAc enolpyruvyl transferase;UDP-N-acetylglucosamine enolpyruvyl transferase	P28909	N/A	N/A	inhibitor
DAP000957	Perhexiline	IDI1_000542; D08340; Perhexilinum [INN-Latin]; Perhexilina [INN-Spanish]; (+)-2-(2,2-Dicyclohexylethyl)piperidine; KBio2_005489; MolPort-003-808-309; Perhexiline [INN:BAN]; KBio1_000542; CID4746; Perhexilene; perhexilline; BSPBio_000192; AB00053656; Spectrum4_000173; KBioGR_000685; KBioSS_000353; Prestwick1_000286; Spectrum2_001539; CHEBI:35553; PERHEXILINE; Piperidine, 2-(2,2-dicyclohexylethyl)-; EINECS 254-558-7; Oprea1_365504; 6621-47-2; Spectrum5_001084; Prestwick0_000286; DivK1c_000542; LS-176505; SPBio_002411; BSPBio_003118; CHEMBL75880; Spectrum_000013; AC1L1IV5; BPBio1_000212; SPBio_001358; Perhexilina; 39648-47-0; Perhexiline (INN); EINECS 254-559-2; D010480; EINECS 229-569-5; 2-(2,2-Dicyclohexylethyl)piperidine; DB01074; KBio2_002921; Prestwick3_000286; KBio2_000353; NINDS_000542; (-)-2-(2,2-Dicyclohexylethyl)piperidine; KBio3_002618; C19H35N; Spectrum3_001579; Prestwick2_000286; 39648-48-1; Perhexilinum	6621-47-2	4746	165685	TTDS00433	Carnitine O-palmitoyltransferase I	Carnitine o-palmitoyltransferase-1;Carnitine palmitoyltransferase I;Carnitine palmitoyl-transferase I;CPT;CPT I;CPT-1;CPTI-L	Q92523	1375	ENSG00000205560	inhibitor
DAP000958	L-Carnitine	HMS2093J13; Carnitene; Carniking 50; Carnovis; MLS001332549; (R)-Carnitine; Carnitor; Ammonium, (3-carboxy-2-hydroxypropyl)trimethyl-, hydroxide, inner salt, L-; c0049; ST 198; ARONIS24315; Carnitolo; Ammonium, (3-carboxy-2-hydroxypropyl)trimethyl-, hydroxide, inner salt, L- (8CI); Carrier; 44985-71-9; C00318; 1-Propanaminium, 3-carboxy-2-hydroxy-N,N,N-trimethyl-, hydroxide, inner salt, (R)-; C0158_SIGMA; DB00583; Carnitine, (-)-; HSDB 7588; CHEBI:16347; TL8003552; (L-3-Carboxy-2-hydroxypropyl)trimethylammonium hydroxide, inner salt; L-carnitine; Levocarnitine [USAN:INN]; SMR000112475; gamma-Trimethyl-ammonium-beta-hydroxybutirate; L-Carnitine inner salt; (-)-L-Carnitine; AC1L1W85; SBB058880; bmse000211; Levocarnitina; (R)-(3-Carboxy-2-hydroxypropyl)trimethylammonium hydroxide, inner salt; Levocarnitinum [Latin]; CID10917; MolPort-001-760-007; Karnitin; Lefcar; (S)-carnitine; vitamin BT; Levocarnitina [Spanish]; Levocarnitine; 3-Carboxy-2-hydroxy-N,N,N-trimethyl-1-propanaminium hydroxide, innersalt; (-)-L-Carnitin; carnitine (L-form); EINECS 208-768-0; 1-Propanaminium, 3-carboxy-2-hydroxy-N,N,N-trimethyl-, inner salt, (2R)-; MLS001332550; (R)-3-Hydroxy-4-(trimethylammonio)butyrate; (R)-(3-Carboxy-2-hydroxypropyl)trimethylammonium hydroxide; ZINC03079340; Levocarnitinum; Carnitor (TN); BIDD:GT0603; CHEMBL1149; (3-Carboxy-2-hydroxypropyl)trimethyl-ammonium hydroxide, inner salt; (-)-Carnitine; C8H18NO3; 3-Carboxy-2-hydroxy-N,N,N-trimethyl-1-propanaminium hydroxide, inner salt; L-carnitine Base; gamma-Trimethyl-beta-hydroxybutyrobetaine; vitamin B T; Levocarnitine (JAN/USP/INN); Ammonium, (3-carboxy-2-hydroxypropyl)trimethyl-, hydroxide,inner salt; R-(-)-3-hydroxy-4-trimethylaminobutyrate; Carnicor; Carniking; DRG-0211; C-1985; LS-17074; L-gamma-trimethyl-beta-hydroxybutyrobetaine; NSC741806; Carnilean; 7634-98-2; D02176; 1-CARNITINE; (-)-(R)-3-Hydroxy-4-(trimethylammonio)butyrate; bicarnesine; 541-15-1; 3-carboxy-2-hydroxy-N,N,N-trimethyl-1-propanaminium; 1-Propanaminium, 3-carboxy-2-hydroxy-N,N,N-trimethyl-, inner salt, (2R)- (9CI); (3R)-3-hydroxy-4-(trimethylazaniumyl)butanoate; (3R)-3-hydroxy-4-(trimethylammonio)butanoate; L-(-)-Carnitine; 1-Propanaminium, 3-carboxy-2-hydroxy-N,N,N-trimethyl-, inner salt, (R)-; Metina; UNII-0G389FZZ9M; (R)-3-Hydroxy-4-trimethylammoniobutyrate; Carnitine, L-; Carnitine; 1-Propanaminium, 3-carboxy-2-hydroxy-N,N,N-trimethyl-, hydroxide, inner salt	541-15-1	10917	7849237	TTDS00433	Carnitine O-palmitoyltransferase I	Carnitine o-palmitoyltransferase-1;Carnitine palmitoyltransferase I;Carnitine palmitoyl-transferase I;CPT;CPT I;CPT-1;CPTI-L	Q92523	1375	ENSG00000205560	activator
DAP000609	Miglustat	n-Butyl dnj; BuDNJ; CHEBI:50381; nchembio.81-comp12; CHEBI:49779; SC-48334; AC1L1BHJ; OGT-918; SC48334; Miglustat (USAN/INN); DB00419; NB-DNJ; 72599-27-0; Miglustat; CHEMBL1029; D05032; LS-116261; OGT 918; nchembio850-comp5; N-Butyl-DNJ; N-Butylmoranoline; N-Butyldeoxynojirimycin; 3,4,5-Piperidinetriol, 1-butyl-2-(hydroxymethyl)-, (2R-(2alpha,3beta,4alpha,5beta))-; Vevesca; Zavesca; Miglustat, Hydrochloride; UNII-ADN3S497AZ; miglustatum; n-Butyl deoxynojirimycin; N-butyl-1-deoxynojirimycin; Butyldeoxynojirimycin; 1,5-Dideoxy-1,5-N-butylimino-D-glucitol; N-(n-Butyl)deoxynojirimycin; 134282-77-2; N-(n-butyl)-1,5-dideoxy-1,5-imino-D-glucitol; Miglustat [USAN]; (2R,3R,4R,5S)-1-butyl-2-(hydroxymethyl)piperidine-3,4,5-triol; D-Glucitol, 1,5-(butylimino)-1,5-dideoxy-; N-Bu-DNJ; HMS2090N20; 3,4,5-Piperidinetriol, 1-butyl-2-(hydroxymethyl)-, (2R,3r,4R,5S)-; N-Butyl-deoxynojirimycin; CID51634; SC 48334; NBV; Zavesca (TN)	72599-27-0	51634	189803	TTDS00377	Ceramide glucosyltransferase	GCS;GLCT-1;Glucosylceramide synthase;UDP-glucose ceramide glucosyltransferase;UDP-glucose:N-acylsphingosine D-glucosyltransferase	Q16739	7357	ENSG00000148154	inhibitor
DAP001335	Cycloserine	C3H6N2O2; BSPBio_002121; NSC 154851; MolPort-000-858-643; D-cycloserine; 3-Isoxazolidinone, 4-amino-, d-; Serine, cyclo-; Wasserina; alpha-Cycloserine; 30020_FLUKA; KBio2_001340; 3-Isoxazolidinone, 4-amino-, (R); R-4-Amino-3-isoxazolidinone; D-4-amino-3-isoxazolidinone; UNII-95IK5KI84Z; Closina; Spectrum5_000797; DRG-0195; SAM001247014; 3-Isoxazolidinone, 4-amino-, (+)- (8CI); (+)-4-Amino-3-isoxazolidinone; (R)-(+)-4-Amino-3-isoxazolidinone; NCGC00093713-01; Lopac-C-3909; Seromycin (TN); NCGC00016306-05; 68-41-7; Cyclo-D-serine; Cyclorin; C7670_SIGMA; HSDB 3218; K-300; KBio1_000098; SPBio_003029; Oxamycin; 3-Isoxazolidinone, 4-amino-, (R)-; BIDD:GT0707; CAS-68-41-7; LMPK14000007; cycloserine; (R)-Cycloserine; BRN 0080798; MLS001423962; KBioSS_001340; Cycloserinum; Lopac-C-1159; D-4-Amino-3-isossazolidone; NCGC00016306-01; EINECS 200-688-4; C3909_SIGMA; Lopac-C-7005; AI3-50153; C-9390; D-4-amino-3-isoxazolidone; SC-49088; CID6234; AC1L1M33; Oxamicina; Spectrum4_000305; NINDS_000098; 3-Isoxazolidinone, 4-amino-, (+)-; Miroseryn; HMS500E20; AC1Q4UA7; Novoserin; IDI1_000098; Spectrum3_000371; EU-0100252; Prestwick0_001089; KBio2_003908; orientomycin; Miroserina; (R)-3-Isoxazolidinone, 4-amino-; 3-Isoxazolidinone, 4-amino-, (4R)- (9CI); (4R)-4-Amino-3-isoxazolidinone; Tebemicina; SPECTRUM1500215; 3-Isoxazolidinone, 4-amino-, D; Cycloserine [INN:BAN:JAN]; NCGC00093713-02; SAM002264599; Spectrum_000860; DB03123; (4R)-4-amino-1,2-oxazolidin-3-one; Lopac0_000252; NCGC00015213-01; SMR000058313; Cicloserina [Italian]; C 3909; SPBio_000008; HMS2091I14; Prestwick1_001089; 4AX; (R)-4-Amino-3-isoxazolidone; HMS2051C15; 4-27-00-05549 (Beilstein Handbook Reference); E-733-A; MLS000758215; PA 94; HMS1920C06; D-amino-3-isoxazolidinone; AC-4721; (R)-(+)-Cycloserine; CPD-2482; Prestwick2_001089; KBio2_006476; PA-94; CHEBI:40009; 1pb9; RO-1-9213; NCGC00016306-02; CAS-339-72-0; (4R)-4-aminoisoxazolidin-3-one; CPD000058313; Cicloserina; BB_NC-1631; S1998_Selleck; I-1431; FA6C7F8B-D080-4EA3-978F-1ECFB5A29D09; NCGC00015213-02; Spectrum2_000084; Tisomycin; BPBio1_001252; D-(+)-Cycloserine; (R)-4-AMINO-ISOXAZOLIDIN-3-ONE; AB00443920; Oxamicina [Italian]; C6880_SIGMA; Micoserina; CHEMBL771; D-CS; Prestwick3_001089; C-9400; D00877; KBio3_001341; Cycloserinum [INN-Latin]; Closerin; R-(+)-Cycloserine; Cycloserine (JP15/USP/INN); LS-86757; KBioGR_000890; Cicloserina [INN-Spanish]; R(+)-4-Amino-3-isoxazolidinone; HMS1571I20; SMP1_000167; NCGC00016306-03; NCGC00015213-03; Farmiserina; BSPBio_001138; (R)-4-Amino-3-isoxazolidinone; (+)-Cycloserine; D-4-Amino-3-isossazolidone [Italian]; Seromycin; C08057; 30020_SIGMA; DivK1c_000098	68-41-7	401	8907	TTDS00474	D-alanine-D-alanine ligase A	D-Ala-D-Ala ligase A;D-alanylalanine synthetase A;ddlA	P0A6J8	N/A	N/A	inhibitor
DCL000225	SCH-530348	CID10077130; CID 10028615; SCH-530348; CHEBI:586977; Vorapaxar; CHEMBL493982	618385-01-6	N/A	N/A	TTDC00071	Proteinase activated receptor 1	Coagulation factor II receptor;PAR-1;Protease activated receptor 1;Protease-activated receptor-1;Thrombin receptor	P25116	2149	ENSG00000181104	antagonist
DCL000304	Metoprine	SK 5265; BW50197; NSC 7364; METOPRINE, METHODICHLOROPHEN; Neuro_000005; NSC7364; C2M; TCMDC-123931; WLN: T6N CNJ BZ DZ ER CG DG& F1; 5-(3,4-Dichlorophenyl)-6-methyl-2,4-pyrimidinediamine; BW-197U; BW 197 U; CPD-10891; Pyrimidine, 2,4-diamino-5-(3,4-dichlorophenyl)-6-methyl-; Metoprine [USAN]; 5-(3,4-DICHLOROPHENYL)-6-METHYLPYRIMIDINE-2,4-DIAMINE; BW 197U; BW 50,197; AC1L2NGD; DDMP; DB04655; METOPRINE; NCIMech_000234; BW 50-197; AI3-26402; LS-135022; AC1Q2OZ6; BRN 0223622; 197U50; NSC 19494; 7761-45-7; BW 50197; 2aov; NCI60_041610; 2,4-Pyrimidinediamine, 5-(3,4-dichlorophenyl)-6-methyl-; CID24466; Metoprine (USAN); BW 1970; CHEMBL264373; 5-(3,4-Dichlorphenyl)-6-methyl-2,4-pyrimidindiamin; NSC19494; D00309; Methodichlorophen; U 197; C11H10Cl2N4; NSC-19494; 2,4-Diamino-5-(3',4'-dichlorophenyl)-6-methyl pyrimidine; SMR001565478; CHEBI:166251; 2,4-Diamino-5-(3,4-dichlorophenyl)-6-methylpyrimidine; MLS002701892; U-197	7761-45-7	24466	24714896	TTDS00208	Dihydrofolate reductase	N/A	Q9HBH1	64146	ENSG00000258429	inhibitor
DAP000927	Trimethoprim	T2286; NCGC00016055-01; NCGC00024707-05; Toprim; Primosept; KSC-4-158; Velaten; Trimethoprim (JAN/USP/INN); AC1Q48DF; Prestwick0_000208; Lagatrim; Trimethoprimum [INN-Latin]; Trimpex 200; Trimethoprim [USAN:BAN:INN:JAN]; Sinotrim; AC1L1KNQ; Trimetoprim [DCIT]; Spectrum4_000372; Zamboprim; Septrin DS; Proloprim; Omstat; Trimethoprim & VRC3375; Exbesul; Trimetoprima; Bactin; NCGC00024707-03; Polytrim; Bacta; Tocris-0650; Conprim; AB00052118; 92131_FLUKA; SPECTRUM1500595; Cotrimel; Septrin Forte; Trimanyl; BB_SC-2116; SPBio_002116; Bencole; Priloprim; KUC103659N; NCGC00016055-02; Methoprim; Trimetoprim; LS-1627; Urobactrim; CID5578; Bacterial [Antibiotic]; SPBio_000874; Bethaprim; Trimpex (TN); Trimexazole; BPBio1_000215; Resprim; UNII-AN164J8Y0X; Trimexol; EU-0101271; nchembio.221-comp23; HMS501N11; Briscotrim; Trimethopriom; Oraprim; Bacdan; Trimeth/Sulfa; Monoprim; Cidal; Colizole; Oprea1_495058; Sulfoxaprim; Trisul; AB1004879; NCGC00024707-07; trimethoprim; Spectrum2_000937; Trimogal; Futin; nchembio.215-comp11; MLS002303068; I06-0086; Spectrum5_001559; EINECS 212-006-2; Instalac; Roubal; NIH 204; Monotrimin; Fortrim; 46984_RIEDEL; Bacterial; KBio2_003215; Streptoplus; Bacidal; DB00440; Trimethoprimum; Alcorim-F; Wellcoprim; NCGC00024707-04; component of Bactrim; KBio1_000589; Trisulcom; Bactramin; CCRIS 2410; Stopan; Pancidim; Septrin S; D00145; C01965; Trimez-IFSA; CHEBI:45924; 46984_FLUKA; nchembio.108-comp1; Sulmeprim; BSPBio_000195; WR 5949; KBio3_001465; Antrimox; Protrin; Esbesul; Ikaprim; Salvatrim; MolPort-001-826-685; UPCMLD-DP132:001; Anitrim; T 7883; BW 56-72; HSDB 6781; MLS001201740; BRD-K07208025-001-06-5; Prestwick2_000208; Abaprim; Primsol; BW 5672; Trimezol; T7883_SIGMA; Triprim; AI3-52594; Colizole DS; CPD0-1581; ZINC06627681; Roubac; SMP2_000262; Uretrim; Setprin; component of Septra; CHEMBL22; BIDD:GT0190; CAS-738-70-5; IDI1_000589; Purbal; TCMDC-125538; BRN 0625127; Biosulten; HMS1921I03; Bacide; Monotrim; Syraprim; Trimopan; Utetrin; Metoprim; 92131_SIGMA; TL8005108; AKOS001650069; HMS2090D14; BSPBio_002245; HMS2092A10; STK177322; Deprim; ARONIS24118; Espectrin; Prestwick_485; Euctrim; Idotrim; Lagatrim Forte; Prestwick3_000208; Lopac-T-7883; Duocide; Sultrex; NCGC00024707-06; NSC 106568; Kombinax; NINDS_000589; Lopac0_001271; NCGC00024707-01; KBioSS_000647; Prestwick1_000208; KBio2_000647; Resprim Forte; Trimethoprime; KBioGR_000863; Sulfamar; Trimono; Trimetoprim [Polish]; NCGC00016055-06; Proloprim (TN); Sulfamethoprim; MLS000079023; TMP/SMX (MIXTURE)); Uro-D S; Spectrum_000167; Bacin; Lastrim; D014295; Bactoprim; SAM002264649; HMS1568J17; CPD000035999; Xeroprim; Chemotrin; Alprim; Spectrum3_000643; Trimethioprim; Trimpex; Sugaprim; AC-13572; Wellcoprin; Smz-Tmp; NCGC00016055-12; Tmp-Ratiopharm; 738-70-5; NSC-106568; DivK1c_000589; SMR000035999; NIH 204 (VAN); UPCMLD-DP132; Fermagex; AZT + TMP/SMX (mixture) combination; Trimetoprima [INN-Spanish]; Trisural; Trimethoprime [INN-French]; Apo-Sulfatrim; Sulthrim; Trimethopim(TMP); Novotrimel; Antrima; WLN: T6N CNJ BZ DZ E1R CO1 DO1 EO1; Co-Trimoxizole; U-Prin; Tiempe; KBio2_005783; BW-56-72; Bacticel; NCGC00024707-08; Sulfamethoxazole & Trimethoprim; NSC106568; Trisulfam	738-70-5	5578	156267	TTDS00208	Dihydrofolate reductase	N/A	Q9HBH1	64146	ENSG00000258429	inhibitor
DAP000633	Pyrimethamine	KBio2_003954; MLS002701881; Pyrimethamine (Pyr); CID4993; 2,4-Diamino-5-(p-chlorophenyl)-6-ethylpyrimidine; Primethamine; Prestwick_504; MLS002454446; 5-(4-chlorophenyl)-2,4-diamino-6-ethylpyrimidine; KBio2_001386; KBio1_000652; Malocide; GlaxoSmithKline Brand of Pyrimethamine; Pirimetamin; 46706_FLUKA; Daraprim; Spectrum_000906; NSC-3061; 5-(4'-Chlorophenyl)-2,4-diamino-6-ethylpyrimidine; Lactoferrin H & Pyrimethamine; IDI1_000652; UNII-Z3614QOX8W; BW 5063; CCRIS 546; Pirimecidan; Maloprim; WLN: T6N CNJ BZ DZ ER DG& F2; 2,4-Pyrimidinediamine, 5-(p-chlorophenyl)-6-ethyl-; Prestwick0_000037; SPECTRUM1500520; Spectrum5_001447; Lactoferrin B & Pyrimethamine; EXR-101; NSC3061; 5-(4-Chlorophenyl)-6-ethyl-2,4-diaminopyrimidine; S2006_Selleck; WR 2978; Pyrimethamine Hcl; 46706_RIEDEL; CHEMBL36; 4753 R.P.; Pyrimethaminum [INN-Latin]; BRN 0219864; Malocid; Chloridine; NCIOpen2_008313; NCGC00023188-05; NINDS_000652; Spectrum4_000494; Diaminopyritamin; Tindurine; Erbaprelina; TCMDC-125860; CP6; Daraclor; NCGC00023188-04; L000713; AZT + Pyrimethamine combination; Spectrum2_000886; Glaxo Wellcome Brand of Pyrimethamine; NCGC00016256-01; Pyrimidine, 2,4-diamino-5-(p-chlorophenyl)-6-ethyl-; Pirimetamina [Spanish]; 58-14-0; Pyrimethaminum; RP 4753; Pyremethamine; Fansidar (Pyrimethamine/Sulfadoxine); Daraprim (TN); NSC 3061; Chloridyn; KBioGR_001007; NCGC00023188-03; D011739; C07391; Pirimetamina; Malacid; SAM002554921; LS-238; DB00205; BRD-K88429204-001-05-4; BIDD:GT0149; NCGC00016256-02; C12H13ClN4; CD; Daraprin; CPD000058714; Darachlor; 5-(4-Chlorophenyl)-6-ethyl-2,4-pyrimidi nediamine; BSPBio_003282; 5-(p-chlorophenyl)-6-ethyl-2,4-diaminopyrimidine; nchembio.87-comp22; Prestwick1_000037; Tindurin; Khloridin; DivK1c_000652; Spectrum3_001701; 4753 r.p; KBio3_002502; MLS001148621; KBioSS_001386; AC1L1JDI; KBio2_006522; 5-(4-chlorophenyl)-6-ethylpyrimidine-2,4-diamine; SPBio_000672; MolPort-001-783-655; Wellcome Brand of Pyrimethamine; BW 50-63; HMS1568G15; ZINC00057464; AB00052084; D00488; BIDD:PXR0173; nchembio.215-comp13; CAS-58-14-0; SPBio_002054; MLS000028606; Ethylpyrimidine; NCI-C01683; Chloridin; TCMDC-123831; AC-7879; Pyrimethamine (JAN/USP/INN); Aventis Brand of Pyrimethamine; 2,4-Pyrimidinediamine, 5-(4-chlorophenyl)-6-ethyl-; HMS2092E13; m alocid; pyrimethamine; CRL-8142 & Pyrimethamine; 5-[4-Chlorophenyl]-6-ethyl-2,4-pyrimidinediamine; Prestwick3_000037; Pyrimethamine [USAN:INN:BAN:JAN]; BPBio1_000147; 2,4-Diamino-5-chlorophenyl-6-ethylpyrimidine; Prestwick2_000037; 5-(4-CHLOROPHENYL)-6-ETHYL-2,4-PYRIMIDINEDIAMINE; NCGC00023188-06; Tinduring; Daraprime; CRL-8131 & Pyrimethamine; NCGC00023188-07; HMS1920N12; Pirimetamina [INN-Spanish]; Pyrimethamin; 2,4-Diamino-5-(4-chlorophenyl)-6-ethylpyrimidine; BSPBio_000133; NCI60_002604; HMS502A14; EINECS 200-364-2; CHEBI:8673; SMR000058714; AI3-25005; 5-(4-CHLORO-PHENYL)-6-ETHYL-PYRIMIDINE-2,4-DIAMINE; Darapram	58-14-0	4993	9595	TTDS00208	Dihydrofolate reductase	N/A	Q9HBH1	64146	ENSG00000258429	inhibitor
DAP001464	Chlorproguanil	Biguanide, 1-(3,4-dichoro-phenyl)-5-isopropyl-; C11H15Cl2N5; UNII-8O3249M729; CID9571037; 537-21-3; CHEMBL1213553; Clorpreguanile; Chlorproguanilum; 6001-93-0 (mono-hydrochloride); Chlorproguanilum [INN-Latin]; Imidodicarbonimidic diamide, N-(3,4-dichlorophenyl)-N'-(1-methylethyl)-; Clorproguanil; Chlorproguanil; 1-(3,4-Dichlorophenyl)-5-isopropylbiguanide; LS-175481; Lapudrine; unspecified HCl of chlorproguanil; EINECS 208-660-3; Chlorproguanil [INN:BAN]; Clorpreguanile [DCIT]; 15537-76-5 (unspecified hydrochloride); Clorproguanil [INN-Spanish]; N-(3,4-dichlorophenyl)-N'-(1-methylethyl)imidodicarbonimidic diamide	537-21-3	151170	48415767	TTDS00208	Dihydrofolate reductase	N/A	Q9HBH1	64146	ENSG00000258429	inhibitor
DAP000634	Proguanil	N-(4-chlorophenyl)-N'-(propan-2-yl)imidodicarbonimidic diamide; Proguanil [INN:BAN]; SN-12837 (hydrochloride); CAS-637-32-1; Spectrum2_001135; Spectrum4_000622; Prestwick3_000999; Spectrum_001588; Proguanile [DCIT]; Prestwick2_000999; KBio2_007204; Tirian (hydrochloride); C11H16ClN5; Drinupal (hydrochloride); Spectrum3_001659; KBio1_001707; Proguanile; (hydrochloride); KBio2_004636; 637-32-1; UNII-S61K3P7B2V; BSPBio_001097; 1-Isopropyl-5-(4-chlorophenyl)biguanide; 4-12-00-01198 (Beilstein Handbook Reference); SPBio_001029; NCGC00016528-03; KBioSS_002068; Palusil (hydrochloride); M-4888 (hydrochloride); (1E)-1-[amino-(4-chloroanilino)methylidene]-2-propan-2-ylguanidine; 500-92-5; CID6178111; Prestwick0_000999; proguanil; DB01131; Paludrin; BIGUANIDE, 1-(p-CHLOROPHENYL)-5-ISOPROPYL-; NCGC00016528-01; Chlorguanid; BPBio1_001207; Paludrine (hydrochloride); Imidodicarbonimidic diamide, N-(4-chlorophenyl)-N'-(1-methylethyl)-; KBio2_002068; NSC12977; BRN 2811599; BIDD:GT0576; AB00053776; Bigumal; Diguanyl (hydrochloride); NCGC00016528-02; CHEBI:8455; LS-43869; 46920-30-3; BRD-K28183345-003-05-6; KBio3_002637; N-(4-Chlorophenyl)-N'-(1-methylethyl)imidodicarbonimidic diamide; Chlorguanide; KBioGR_001204; EINECS 207-915-6; SPBio_002988; 637-32-1 (HYDROCHLORIDE); DivK1c_006763; BSPBio_003417; CHEMBL1377; N-(4-Chlorophenyl)-N'-(isopropyl)-imidodicarbonimidic diamide; N1-p-Chlorophenyl-N5-isopropylbiguanide; RP-3359; 1-(p-Chlorophenyl)-5-isopropylbiguanide; Proguanilum [INN-Latin]; Chloriguane; Spectrum5_001384; Chloroguanide; AC1O1QGA; Prestwick1_000999; SpecPlus_000667; Proguanilum	500-92-5	4923	9833	TTDS00208	Dihydrofolate reductase	N/A	Q9HBH1	64146	ENSG00000258429	inhibitor
DAP000635	Trimetrexate	JB 11; D06238; NCGC00161419-02; TMQ; trimetrexate; 5-methyl-6-({[3,4,5-tris(methyloxy)phenyl]amino}methyl)quinazoline-2,4-diamine; DB01157; CI-898; Trimetrexatum; Trimetrexato; NSC249008; NCGC00161419-01; 2,4-Quinazolinediamine, 5-methyl-6-[[(3,4,5-trimethoxyphenyl)amino]methyl]-; 2,4-Quinazolinediamine, 5-methyl-6-(((3,4,5-trimethoxyphenyl)amino)methyl)-; Trimetrexate (USAN/INN); NSC-249008; Jb-11; 5-Methyl-6-(((3,4,5-trimethoxyphenyl)amino)methyl)-2,4-quinazolinediamine; C11154; AC1L1KO5; C19H23N5O3; HSDB 6545; BIDD:GT0129; NSC-328564; NSC 249008; Trimetrexatum [INN-Latin]; 6-[((3,4,5-Trimethoxyphenyl)amino)methyl]-5-methyl-2,4-quinazolinediamine; 5-methyl-6-[(3,4,5-trimethoxyanilino)methyl]quinazoline-2,4-diamine; UNII-UPN4ITI8T4; Trimetrexato [INN-Spanish]; 52128-35-5; CHEMBL119; 2,4-Diamino-5-methyl-6-((3,4,5-trimethoxyanilino)methyl)quinazoline; CID5583; LS-175340; Trimetrexate [USAN:BAN:INN]	52128-35-5	5583	181153	TTDS00208	Dihydrofolate reductase	N/A	Q9HBH1	64146	ENSG00000258429	inhibitor
DAP001549	Pralatrexate	N/A	N/A	N/A	N/A	TTDS00208	Dihydrofolate reductase	N/A	Q9HBH1	64146	ENSG00000258429	inhibitor
DCL000840	Iclaprim	AR-100; 5-[(2-cyclopropyl-7,8-dimethoxy-2h-chromen-5-yl)methyl]pyrimidine-2,4-diamine; CID213043; Iclaprim; Mersarex; 192314-93-5; AR-102; D08337; AC1L4U54; UNII-42445HUU0O; AR-101; 220629-90-3; AR-100.001; MolPort-006-823-580; 2,4-Pyrimidinediamine, 5-[(2-cyclopropyl-7,8-dimethoxy-2H-1-benzopyran-5-yl)methyl]-; 5-((2RS)-2-cyclopropyl-7,8-dimethoxy-2H-chromen-5-ylmethyl)pyrimidine-2,4-diamine; Iclaprim (USAN/INN); RO-48-2622; CHEMBL134561; Iclaprim [INN]; AR-1G6498; AC1Q4WM5	192314-93-5	213043	46518185	TTDS00208	Dihydrofolate reductase	N/A	Q9HBH1	64146	ENSG00000258429	binder
DAP001346	Aminopterin	Kyselina 4-aminopteroylglutamova [Czech]; EINECS 200-209-9; 4'-Amino-folsaeure; 4-Amino pteroylglutamic acid; SMR001230749; A5159_SIGMA; 4-Aminopteroyl-<R>glutamic acid; L-Glutamic acid, N-[4-[[(2,4-diamino-6-pteridinyl)methyl]amino]benzoyl]-,; KBio1_001939; NCGC00093553-06; Lopac-A-1784; CID2154; MolPort-001-684-171; Spectrum2_000893; N-(4-(((2,4-Diamino-6-pteridyl)-methyl)amino)benzoyl)-L-glutamic acid; 4-Amino-4-desoxy-pteroylglutaminsaeure; DivK1c_006995; NSC257456; SPBio_000706; BSPBio_002972; KBio3_002192; CHEBI:108080; C19H20N8O5; A-7170; KBioGR_001414; NCGC00015038-02; KBio2_002391; Kyselina N-(p-((2,4-diamino-6-pteridinyl)methyl)benzoyl)-L(+)-glutamova [Czech]; Kyselina 4-aminolistova [Czech]; 4-Aminopteroyl-L-glutamic acid; 4-Amino-4-deoxypteroylglutamate; Kyselina N-(p-((2,4-diamino-6-pteridinyl)methyl)benzoyl)-L(+)-glutamova; N-(4-(((2,4-Diamino-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid; CID169371; 58602-66-7; NCGC00093553-04; AC1MHTUI; NCGC00015038-09; BIDD:GT0600; LS-71805; APGA; 09328_FLUKA; SpecPlus_000899; Aminopteridine; AI3-26079; N-[(4-{[(2,4-diaminopteridin-6-yl)methyl]amino}phenyl)carbonyl]glutamic acid; Kyselina N-(p-((2,4-diamino-6-pteridinylmethyl)amino)benzoyl)-L(+)-glutamova; KBio2_004959; 31823-54-8 (hydrochloride salt); (2S)-2-[[4-[(2,4-diaminopteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid; KBio2_007527; NSC739; ENT-26079; (2R)-2-[[4-[(2,4-diaminopteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid; NCGC00093553-05; Folic acid, 4-amino-; Pteramina [Czech]; NCGC00093553-02; SPECTRUM1500679; NSC 739; Aminotrexate; Aminofolic acid, 4-; HMS1921C08; Glutamic acid, N-(p-(((2,4-diamino-6-pteridinyl)methyl)amino)benzoyl)-, L-; 54-62-6; N-(4-{[(2,4-diaminopteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid; Lopac0_000034; NSC-739; L-Glutamic acid, N-[4-[[(2,4-diamino-6-pteridinyl)methyl]amino]benzoyl]-; NCGC00093553-01; HSDB 6374; Spectrum5_000931; Kyselina 4-aminolistova; Aminopterine; Spectrum3_001386; Aminopterinum; A-Ninopterin; WLN: T66 BN DN GN JNJ CZ EZ H1MR DVMYVQ2VQ; 4-Aminofolic acid; Pteramina; 2-[[4-[(2,4-diaminopteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid; BRN 0069045; A 1784; aminopterin; MolPort-004-964-256; CHEMBL274619; KBioSS_002396; NCGC00093553-03; A3411_SIGMA; 4-Amino-PGA; CID3032277; 4-Aminopteroyl- glutamic acid; nchembio.215-comp16; FT-0082668; CHEMBL376180; 4'-Desoxy-4'-aminofolsaeure; Kyselina 4-aminopteroylglutamova; A1784_SIGMA; L-Glutamic acid, N-(4-(((2,4-diamino-6-pteridinyl)methyl)amino)benzoyl)-; Kyselina N-(p-((2,4-diamino-6-pteridinylmethyl)amino)benzoyl)-L(+)-glutamova [Czech]; 120382-78-7; 64801-55-4; N-(1-((2,4-Diamino-6-pteridinylmethyl)amino)benzoyl)glutaminsaeure; Spectrum_001874; NCGC00015038-01; MLS002153337; AR-1J8773; Spectrum4_000917; AC1L53MI; AC1L1D1I; 4-Aminopteroylglutamic acid; AC1Q5QRI; CHEBI:22526; 4-26-00-03831 (Beilstein Handbook Reference); EU-0100034; CCRIS 5856	54-62-6	2154	51072235	TTDS00208	Dihydrofolate reductase	N/A	Q9HBH1	64146	ENSG00000258429	inhibitor
DAP001507	Proquanil	Milprem-200; Prequil; Lepenil; Cirpon; Sowell; Meprosin; Meprosan; ZINC01530701; Placidon; Meprobamate and Aspirin Tablets; Apo-Meprobamate; Ecuanil; Meprobamat; Letyl; Ansil; Diron; Calmadin; DEA No. 2820; Ataraxine; Meproten; Meproleaf; Mepranil; NCGC00091031-01; Quaname; Bamo 400; Shalvaton; Procalmadol; Probamato; Amosene; Ansietan; Neo-Tran; Edenal; Aneusral; Tensonal; Stensolo; Gadexyl; Meprotanum; Spantran; Libiolan; Reostral; Kessobamate; Oasil; Ayeramate; Meprotil; Diurnaldiverondormabrol; Procarbamide; Dormabrol; Quanil; Meprol; Anathylmon; Orlevol; Sedanyl; Lepetown; Cap-O-Tran; Sedanil; BRN 1788882; AKOS003617983; 2-Metil-2-n-propil-1,3-propanediol dicarbamato [Spanish]; Miltuan; MolPort-001-783-402; Equanil; Carbamic acid 2-methyl-2-propyltrimethylene ester; Meprobamate (JAN/USP/INN); 2-Methyl-2-n-propyl-1,3-propanediol dicarbamate; meprobamate; 2-[(carbamoyloxy)methyl]-2-methylpentyl carbamate; Aneurol; Estasil; Calmiren; Restinil; Tranmep; Dicandiol; Arpon; Carbaxin; Placitate; Miltwon; [2-(carbamoyloxymethyl)-2-methylpentyl] carbamate; Tranquilate; Mepro-Aspirin; PMB 400; Sedabamate; component of Milpath; Meprodil; Sedoquil; Milpath; Enorden; Apasil; Atraxin; Procalmidol; Miltann; component of Bamadex; Fas-Cile 200; Equilium; Pankalma; Klort; C9H18N2O4; UNII-9I7LNY769Q; Pancalma; Holbamate; Paxin; My-trans; Trelmar; Tranlisant; Equitar; Probate; Milprem; LS-120649; Meprindon; Bamate; D00376; Meprobamato [INN-Spanish]; Apascil; Meprotabs; Cypron; Promate; Despasmol; Meprobamat [German]; Probamyl; Anatimon; Calmax; Diurnal; Equanil (TN); component of Miltrate; PMB-400; M2392_FLUKA; Canquil 400; Mepiosine; Aneuxral; Quivet; Crestanil; Neuramate; Andaxin; Carbamic acid, 2-methyl-2-propyltrimethylene ester; Urbilat; Trankvilan; Metranquil; Mepantin; Rastenil; Appetrol-Sr; Sedoselecta; component of Milprem; PMB-200; Meprodiol; Tranquinol; Ayermate; Margonil; Q-Gesic; Quietidon; Procalmadiol; Arcoban; Perquietil; Meprospan-200; Larten; Meprocon CMC; Epicur; Meprin (VAN); Metractyl; Erina; Pertranquil; Perequil; component of Equalysen; Pensive; Mepamtin; Miltown; Miltown 600; component of PMB-400; M2392_SIGMA; Biobamat; AC1L1HC1; Fas-Cile; Anastress; Tensol; Pan-tranquil; Nephentine; Brobamate; WLN: ZVO1X3&1&1OVZ; Ipsotian; Andaksin; Meprocon; Protran; Orolevol; Wyseals; Miltaun; Meprospan; Optarket; Perequietil; Selene; Trancot; EINECS 200-337-5; Micrainin; Equanil suspension; Tamate; Tranquiline; 1,3-Propanediol, 2-methyl-2-propyl-, dicarbamate; Restenyl; Panediol; Mepriam; Meprobamatum [INN-Latin]; Dapaz; Nervonus; Tranquilsan; Restinal; 2-Methyl-2-propyl-1,3-propanediol dicarbamate; Meprotan; Meptran; Equazine-M; Meprobamato [Italian]; Seril; Mendel; Anxietil; Aneuxal; Harmonin; 2,2-Di(carbamoyloxymethyl)pentane; Meproban; Mar-Bate; Epikur; Miltamato; I14-2779; Meprin; Restenil; Meptranactylmilprem; Wardamate; Aneural; 57-53-4; Equinil; Proquanil; Meprobamato; Promato; Pimal; Misedant; Biobamate; Gagexyl; 2-Methyl-2-propyltrimethylene carbamate; Morbam; Appetrol; Cyrpon; CHEMBL979; Sadanyl; Meprovanmeprozine; Quanane; Multaun; 1,3-Propanediol, 2-methyl-2-propyl-, 1,3-dicarbamate; NSC30418; Meprobamatum; Tranquilax; Scolazil; Coprobate; Sedazil; Meprovan; Meprozine; Meprosa; AC1Q2UIX; Meprocompren; Milprem-400; Hartol; Bamd 400; Tranquiline (Intra); Anzil; Cirponyl; 2-Methyl-2-propylpropane-1,3-diol dicarbamate; Ansiowas; Mepro-analgesic; Meprobam; Robamate; Miltown (TN); Meprobamic acid; Tranquilan; 3P Bamate; Deprol; Equatrate; HSDB 3117; Mepavlon; Canquil-400; Meposed; Vio-Bamate; Amepromat; {2-[(carbamoyloxy)methyl]-2-methylpentyl} carbamate; Meprobamate [USAN:INN:BAN:JAN]; Vistabamate; SK-Bamate; PMB 200; Kesso-Bamate; Ansiatan; Anural; Artolon; Auxietil; DB00371; Urbil; component of Appetrol; Diveron; CID4064; Solevione anastress; Setran; Zirpon; Pathibamate; Meprospan-400; 2-Metil-2-n-propil-1,3-propanediol dicarbamato	57-53-4	4064	89640	TTDS00208	Dihydrofolate reductase	N/A	Q9HBH1	64146	ENSG00000258429	inhibitor
DAP001493	MCB-3837	MCB-3837; Oxaquin	58-14-0	4993	48425587	TTDS00208	Dihydrofolate reductase	N/A	Q9HBH1	64146	ENSG00000258429	inhibitor
DCL000704	Asimadoline	Benzeneacetamide, N-(2-(3-hydroxy-1-pyrrolidinyl)-1-phenylethyl)-N-methyl-alpha-phenyl-, (S-(R*,R*))-; AC1L452B; EMD 61753; Benzeneacetamide, N-((1S)-2-((3S)-3-hydroxy-1-pyrrolidinyl)-1-phenylethyl)-N-methyl-alpha-phenyl-; 153205-46-0; UNII-D0VK52NV5M; CID179340; Asimadoline [INN]; Asimadoline; N-[(1S)-2-[(3S)-3-hydroxypyrrolidin-1-yl]-1-phenylethyl]-N-methyl-2,2-diphenylacetamide	153205-46-0	3037918	756584	TTDS00127	Kappa-type opioid receptor	Kappa opioid receptor;KOR;KOR-1;Opioid receptor Kappa	P41145	4986	ENSG00000082556	agonist
DPR000053	GNTI	G 3416; G3416_SIGMA; CID9853099; GNTI di-trifluoroacetate; SMR001338894; 5'-Guanidinonaltrindole di(trifluoroacetate) salt hydrate; Guanidinyl-naltrindole di-trifluoroacetate; NCGC00093944-01; 5'-Guanidinylnaltrindole dihydrochloride; EU-0100559; GNTI; MLS002320748	219655-56-8	9826034	24278454	TTDS00127	Kappa-type opioid receptor	Kappa opioid receptor;KOR;KOR-1;Opioid receptor Kappa	P41145	4986	ENSG00000082556	antagonist
DAP001100	Dezocine	CID4630917; Dezocinum [INN-Latin]; Wy-16225; CHEMBL1685; CHEBI:4474; Dezocine [USAN:INN]; DEZOCINE; WY 16,225; Dalgan (TN); CID3033053; CHEBI:618361; C08010; Wy-16,225; Dalgan; UNII-VHX8K5SV4X; Dezocina [INN-Spanish]; 5,11-Methanobenzocyclodecen-3-ol, 13-amino-5,6,7,8,9,10,11,12-octahydro-5-methyl-, (5alpha,11alpha,13S*)-, (-)-; L000770; DB01209; Dezocinum; (5R,11S,13S)-13-amino-5-methyl-5,6,7,8,9,10,11,12-octahydro-5,11-methanobenzocyclodecen-3-ol; (5R,11S,13S)-13-amino-5-methyl-5,6,7,8,9,10,11,12-octahydro-5,11-methanobenzo[10]annulen-3-ol; D00838; Dezocine (USAN); WY 16225; Dezocina; LS-90701; AC1NDSKX; 13-Amino-5,6,7,8,9,10,11,12-octahydro-5-methyl-5,11-methanobenzocyclodecenol; CID40841; 53648-55-8; AC1MHV5E; (-5alpha, 11alpha,13s)-13-amino-5,6,7,8,9,10,11,12-octahydro-5-methyl-5,11-methanobenzocyclodecen-3-ol; (-)-13beta-Amino-5,6,7,8,9,10,11alpha,12-octahydro-5alpha-methyl-5,11-methanobenzocyclodecen-3-ol; AC1L24L4	53648-55-8	40841	10210	TTDS00127	Kappa-type opioid receptor	Kappa opioid receptor;KOR;KOR-1;Opioid receptor Kappa	P41145	4986	ENSG00000082556	antagonist
DAP001271	Voriconazole	UNII-JFU09I87TR; (alphaR,betaS)-alpha-(2,4-difluorophenyl)-5-fluoro-beta-methyl-alpha(1H-1,2,4-triazol-1-ylmethyl)-4-pyrimidineethanol; AC1Q4O6I; MLS000759464; Vfend,  Voriconazole; C07622; HMS2051N09; D00578; SMR000466350; Vfend; ZINC00014864; CHEBI:10023; TL8000858; MLS001424082; UK-109,496; C102790; Voriconazole [USAN:INN:BAN]; (alphaR,betaS)-alpha-(2,4-Difluorophenyl)-5-fluoro-beta-methyl-alpha-(1H-1,2,4-triazol-1-ylmethyl)-4-pyrimidineethanol; UK 109496; DB00582; 137234-62-9; Vfend (TN); AKOS005145705; S1442_Selleck; (R-(R*,S*))-alpha-(2,4-difluorophenyl)-5-fluoro-beta-methyl-alpha-(1H-1,2,4-triazol-1-ylmethyl)-4-pyrimidineethanol; VCZ; SAM001246664; (2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol; Pfizer brand of voriconazole; UK-109496; AC1L2GHR; AC-823; (2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1,2,4-triazol-1-yl)butan-2-ol; 173967-54-9; LS-181799; UK 109,496; DRG-0301; VRC; MolPort-003-850-863; 4-Pyrimidineethanol, alpha-(2,4-difluorophenyl)-5-fluoro-beta-methyl-alpha-(1H-1,2,4-triazol-1-ylmethyl)-, (R-(R*,S*))-; Voriconazole (JAN/USAN/INN); Voriconazole; CHEMBL638; 4-Pyrimidineethanol, alpha-(2,4-difluorophenyl)-5-fluoro-beta-methyl-alpha-(1H-1,2,4-triazol-1-ylmethyl)-, (alphaR,betaS)-; CPD000466350; FT-0082604; Voriconazole in combination with MGCD290; CID71616	137234-62-9	71616	213886	TTDS00359	Fungal Cytochrome P450 51	CYPL1;CYPLI;Cyt P450 14DM;Cytochrome P-450 lanosterol 14-alpha-demethylase;Cytochrome P450-dependent lanosterol 14-demethylase;Erg11p;Lanosterol 14 alpha-demethylase;Lanosterol 14-alpha demethylase;LDM;P450-14DM;P450L1;P450LI;Sterol 14-alpha demethylase;Sterol 14alpha-demethylase	Q96W81	N/A	N/A	inhibitor
DAP001268	Tioconazole	DB01007; Tioconazol [INN-Spanish]; (+-)-1-[2-[(2-Chloro-3-thienyl)methoxy]-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole; Vagistat-1; HMS2090B12; 1H-Imidazole, 1-(2-((2-chloro-3-thienyl)methoxy)-2-(2,4-dichlorophenyl)ethyl)-; 65899-73-2; LS-78340; Fungibacid; C08082; tioconazole; (+-)-1-(2,4-Dichloro-beta-((2-chloro-3-ethenyl)oxy)phenethyl)imidazole; Monistat 1; Tioconazole [USAN:BAN:INN:JAN]; 1-(2,4-Dichloro-beta-((2-chloro-3-thenyl)-oxy)phenethyl)imidazole; D00890; Tioconazole (JAN/USP/INN); EINECS 265-973-8; BRN 0573867; UK 20349; HMS2093P11; AC-13425; Ambap65899-73-2; 1H-Imidazole, 1-[2-[(2-chloro-3-thienyl)methoxy]-2-(2,4-dichlorophenyl)ethyl]-; NCGC00167430-01; Vagistat; Trosyd; Vagistat-1 (TN); Gyno-trosyd; Zoniden; Tioconazol; UK-20349; CHEMBL1200438; GyneCure; UK 20,349; Trosyl; C16H13Cl3N2OS; Trosyd AF; 1-[2-[(2-chlorothiophen-3-yl)methoxy]-2-(2,4-dichlorophenyl)ethyl]imidazole; Tioconazolum; 1-(2,4-Dichloro-(beta-(2-chloro-3-thenyl)oxy)phenethyl)imidazole; Tz-3; AC1L1KG2; Tioconazolum [INN-Latin]; CID5482; 5-23-04-00324 (Beilstein Handbook Reference); Trosyd J; MolPort-003-666-711; UNII-S57Y5X1117	65899-73-2	5482	10282	TTDS00359	Fungal Cytochrome P450 51	CYPL1;CYPLI;Cyt P450 14DM;Cytochrome P-450 lanosterol 14-alpha-demethylase;Cytochrome P450-dependent lanosterol 14-demethylase;Erg11p;Lanosterol 14 alpha-demethylase;Lanosterol 14-alpha demethylase;LDM;P450-14DM;P450L1;P450LI;Sterol 14-alpha demethylase;Sterol 14alpha-demethylase	Q96W81	N/A	N/A	inhibitor
DAP001204	Oxiconazole	Oxiconazolum; MolPort-005-933-996; AC1NS4N5; LS-176356; AC-12722; (Z)-1-(2,4-dichlorophenyl)-2-(1H-imidazol-1-yl)-O-(2,4-dichlorobenzyl) ethanone oxime nitrate; C08074; oxyconazole; BRD-K56104152-008-02-5; 2',4'-Dichlor-O-(2,4-dichlorbenzyl)-2-(1-imidazolyl)-(Z)-acetophenonoxim; Oxiconazole [INN:BAN]; oxiconazole; CHEMBL1262; ZINC03873296; C18H13Cl4N3O; Oxiconazolum [INN-Latin]; Oxiconazole (INN); Oxiconazol [INN-Spanish]; 2',4'-Dichloro-2-imidazol-1-ylacetophenone (Z)-(O-(2,4-dichlorobenzyl)oxime); NCGC00177980-01; 1-(2,4-dichlorophenyl)-N-[(2,4-dichlorophenyl)methoxy]-2-imidazol-1-ylethanimine; CID5353853; Ro 13-8996; 64211-46-7 (NITRATE); UNII-C668Q9I33J; Oxiconazol; D08313; BIDD:GT0685; BSPBio_003582; HMS2090F15; 64211-45-6; RO-13-8996; Sgd 301-76; Ethanone, 1-(2,4-dichlorophenyl)-2-(1H-imidazol-1-yl)-, O-((2,4-dichlorophenyl)methyl)oxime, (Z)-	64211-46-7	5361463	668922	TTDS00359	Fungal Cytochrome P450 51	CYPL1;CYPLI;Cyt P450 14DM;Cytochrome P-450 lanosterol 14-alpha-demethylase;Cytochrome P450-dependent lanosterol 14-demethylase;Erg11p;Lanosterol 14 alpha-demethylase;Lanosterol 14-alpha demethylase;LDM;P450-14DM;P450L1;P450LI;Sterol 14-alpha demethylase;Sterol 14alpha-demethylase	Q96W81	N/A	N/A	inhibitor
DAP000154	Miconazole	Miconazolo [DCIT]; I14-14342; Dactarin; Spectrum_000965; 75319-47-0; Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)-; SPBio_002174; Miconasil Nitrate; Monistat Dual- PAK; Prestwick3_000067; D00416; Daktarin IV; imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl) methoxy)ethyl)- (9CI); NCI60_001353; KBio2_006581; Monista (nitrate); imidazole, 1-(2,4-dichloro-beta-((2,4-dichlorobenzyl)oxy) phenethyl)-; HMS2090B21; Monistat IV; SPBio_000976; 1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole; UNII-7NNO0D7S5M; Micantin (nitrate); Femizol-M; Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)- (9CI); Oprea1_091955; 22916-47-8; NCI60_001380; STOCK1S-93556; Conofite(nitrate); KBioGR_000581; NSC 170986; R-14,889; 1-[2-(2,4-dichlorophenyl)-2-{[(2,4-dichlorophenyl)methyl]oxy}ethyl]-1H-imidazole; NSC170986; 1H-Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)-; KBio2_001445; Miconazole nitrate salt; Micozole; BSPBio_000253; BRD-A82396632-008-02-7; NSC169434; Monistat; SMR001307249; Monistat-Derm; Zimycan; Miconazol [INN-Spanish]; Imidazole, 1-[2,4-dichloro-.beta.-[(2,4-dichlorobenzyl)oxy]phenethyl]-; Miconazolum; Prestwick1_000067; 1-(2,4-dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl) imidazole; CCRIS 7924; AKOS001574474; MolPort-002-557-553; NINDS_000156; STK834405; AB00053500; Miconazole [USAN:BAN:INN:JAN]; Monistat (TN); BRN 0965511; 1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole; Miconazole 3; KBio3_001533; HMS1568M15; CPD-4501; Monistat iv (TN); miconazole; R 18134; Prestwick2_000067; Albistat(nitrate); CHEMBL91; Prestwick_335; 1H-imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl) methoxy)ethyl)-; BRD-A82396632-001-03-0; IDI1_000156; Monistat 3 Dual-Pak; Prestwick0_000067; (+-)-1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole; 1-{2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole; Miconazole-7; Spectrum3_000507; AC1L1HM1; 1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole; Vusion; Monistat 1 Combination Pack; DB01110; Spectrum4_000061; KBio1_000156; Miconazole (JP15/USP/INN); Imidazole, 1-(2,4-dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)-; Spectrum5_001297; Monistat 5 Tampon; KBio2_004013; Minostate; Miconazolum [INN-Latin]; 1-[2,4-Dichloro- beta-([2,4-dichloro- benzyl]oxy)phenethyl]imidazole; Lotrimin AF(nitrate); KBioSS_001445; 1H-Imidazole, 1-2-((2,4-dichlorophenyl)-2-((2,4-dichlorophenyl))methoxy)ethyl)-, (+-)-; EINECS 245-324-5; Miconazolo; Monistat 7 Vaginal Suppositories; 1H-Imidazole, 1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-; CID4189; Monistat 7 Dual-Pak; MLS002222203; Florid(nitrate); Gyno-Daktar(nitrate); BSPBio_002033; CHEBI:6923; Novo-Miconazole Vaginal Ovules; Monistat 3 Vaginal Ovules; Epi-Monistat(nitrate); MCZ; LS-78378; MJR 1762; Spectrum2_001048; Miconazole 3 Combination Pack; 22832-87-7 (NITRATE); 1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole; Aflorix(nitrate); Miconazole 7 Combination Pack; BPBio1_000279; Monazole 7; Miconazol; DivK1c_000156; Andergin(nitrate)	22916-47-8	4189	602748	TTDS00359	Fungal Cytochrome P450 51	CYPL1;CYPLI;Cyt P450 14DM;Cytochrome P-450 lanosterol 14-alpha-demethylase;Cytochrome P450-dependent lanosterol 14-demethylase;Erg11p;Lanosterol 14 alpha-demethylase;Lanosterol 14-alpha demethylase;LDM;P450-14DM;P450L1;P450LI;Sterol 14-alpha demethylase;Sterol 14alpha-demethylase	Q96W81	N/A	N/A	inhibitor
DAP001269	Econazole	KBioSS_001703; Ecostatin; NINDS_000113; Spectrum_001223; KBio1_000113; SPBio_001578; Spectrum5_001033; KBioGR_000832; NSC243115; SQ 13050; I01-3539; AC1L1FE8; Econazole (USAN/INN); Spectrum3_001467; NCI60_001564; NSC187789; KBio2_006839; Prestwick1_000304; CID3198; BPBio1_000296; MolPort-005-933-574; Imidazole, 1-[2,4-dichloro-.beta.-[(p-chlorobenzyl)oxy]phenethyl]-; Spectrum4_000446; Gyno-pevaryl; 1-{2-[(4-chlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole; KBio2_004271; AB00053611; Ecostatin Vaginal Ovules; SPBio_002487; AC-1113; 1-{2-[(4-chlorophenyl)methoxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole; NCI60_001947; 27220-47-9; KBio2_001703; 1-[2-[(4-Chlorophenyl)methoxy]-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole; Pevaryl; AC1Q3JJ8; D03936; IDI1_000113; Palavale; BSPBio_000268; C08068; Prestwick3_000304; 1-[2-[(4-chlorophenyl)methoxy]-2-(2,4-dichlorophenyl)ethyl]imidazole; BRD-A51820102-008-05-7; Spectrum2_001439; Prestwick0_000304; 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole; KBio3_002493; Prestwick2_000304; LS-194478; CHEMBL808; BSPBio_002993; CHEBI:4754; econazole; Ecostatin cream; Spectazole cream; 1-[2,4-Dichloro-.beta.-[(p-chlorobenzyl)oxy]phenethyl]imidazole; DivK1c_000113; Gyno-Pevaryl 150; DB01127	27220-47-9	3198	10268	TTDS00359	Fungal Cytochrome P450 51	CYPL1;CYPLI;Cyt P450 14DM;Cytochrome P-450 lanosterol 14-alpha-demethylase;Cytochrome P450-dependent lanosterol 14-demethylase;Erg11p;Lanosterol 14 alpha-demethylase;Lanosterol 14-alpha demethylase;LDM;P450-14DM;P450L1;P450LI;Sterol 14-alpha demethylase;Sterol 14alpha-demethylase	Q96W81	N/A	N/A	inhibitor
DAP000877	Bifonazole	Canesten Extra Bifonazol; BRN 0618427; Bifonazol; Bioglan brand of bifonazole; EINECS 262-336-6; Spectrum2_000035; bifonazole; KBio3_002922; Moldina; STK618771; SMR000058970; 1-[phenyl-(4-phenylphenyl)methyl]imidazole; HMS2090K13; (+-)-1-(p,alpha-Diphenylbenzyl)imidazole; MLS000759537; Mycospor (TN); 1H-Imidazole, 1-((1,1'-biphenyl)-4-ylphenylmethyl)-, (+-)-; 60628-96-8; TL8003842; Bay-h-4502; Bifonazolum [INN-Latin]; LS-78073; MLS000028576; Trifonazole; Juventus brand of bifonazole; Bifonazol [INN-Spanish]; Inkeysa brand of bifonazole; SPECTRUM1505309; Bifonazolum; MolPort-003-666-632; Amycor; Bay H-4502; CHEBI:116973; Mycospor; BAY H 4502; Bio-0008; HMS1922B18; SAM001246775; Bifokey; MLS001074074; 1H-Imidazole, 1-((1,1'-biphenyl)-4-ylphenylmethyl)-; DB04794; CPD000058970; 1-(p,alpha-Diphenylbenzyl)imidazole; 5-23-04-00292 (Beilstein Handbook Reference); C036596; NCGC00089815-02; Spectrum3_001970; AC1L1DJN; Bifonazole (JP15/USAN/INN); BRD-A94543220-001-02-3; D01775; CHEMBL277535; NCGC00089815-03; HMS2051F04; 1H-Imidazole, 1-([1,1'-biphenyl]-4-ylphenylmethyl)-; Merck Lipha Sante brand of bifonazole; Azolmen; I01-2098; SPBio_000129; Bifon; CID2378; Dermapharm brand of bifonazole; NCGC00089815-04; Bifomyk; 1-((4-Biphenylyl)phenylmethyl)-1H-imidazole; 1-[4,alpha-Diphenylbenzyl]-imidazole; HMS2093B09; Bayer brand of bifonazole; 1-(alpha-(4-Biphenylyl)benzyl)imidazole; BSPBio_003570; Imidazole, 1-(alpha-(4-biphenylyl)benzyl)-; 1-[biphenyl-4-yl(phenyl)methyl]-1H-imidazole; C22H18N2; VU0239694-7; Canesten brand of bifonazole; AC-15414; (+-)1-([1,1'-Biphenyl]-4-ylphenylmethyl)-1H-imidazole; Bifonazole [USAN:BAN:INN:JAN]	60628-96-8	2378	10461678	TTDS00359	Fungal Cytochrome P450 51	CYPL1;CYPLI;Cyt P450 14DM;Cytochrome P-450 lanosterol 14-alpha-demethylase;Cytochrome P450-dependent lanosterol 14-demethylase;Erg11p;Lanosterol 14 alpha-demethylase;Lanosterol 14-alpha demethylase;LDM;P450-14DM;P450L1;P450LI;Sterol 14-alpha demethylase;Sterol 14alpha-demethylase	Q96W81	N/A	N/A	inhibitor
DAP000630	Ketoconazole	MLS002222255; 1-[4-[4-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]ethanone; ketoconazole; BRD-K29113274-001-03-6; Nizoral, Extina, Xolegel, Kuric, Ketoconazole; CID456201; NCGC00025000-03; Lopac0_000666; NCGC00025000-09; AC-15957; (+/-)-cis-1-Acetyl-4-[4-[[2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazine; CHEBI:48336; Prestwick2_000389; BIDD:GT0696; BPBio1_000635; KS-1205; Prestwick0_000389; MolPort-003-848-307; Piperazine, (+/-)-1-acetyl-4-[4-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-, rel-; HSDB 7447; (+)-Ketoconazole; UPCMLD-DP138:001; K1003_SIGMA; SMR000058460; cis-1-Acetyl-4-[4-[[2-(2,4-; BRN 4303081; cis-1-Acetyl-4-[4-[[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazine; K 1003; NSC 317629; 79156-75-5; UC280_SIGMA; R 41400; NCGC00025000-02; NSC317629; SAM001246983; Prestwick_744; MLS001146934; NCGC00025000-01; NCGC00025000-06; (+/-)-cis-1-Acetyl-4-(4-[(2-[2,4-dichlorophenyl]-2-[1H-imidazol-1-ylmethyl]-1,3-dioxolan-4-yl)-methoxy]phenyl)piperazine; Ketoconazole [USAN:INN:BAN:JAN]; R41,400; MLS002207053; KTZ; NCGC00025000-05; CIS-1-ACETYL-4-(4-((2-(2,4-DICHLOROPHENYL)-2-(1H-IMIDAZOL-1-YLMETHYL)-1,3-DIOXOLAN-4-YL)METHOXY)PHENYL)PIPERAZINE; Fungoral; MLS000758224; dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-piperazine; Tocris-1103; CPD000058460; BSPBio_000577; NCGC00025000-07; Prestwick3_000389; R-41400; KZ; KCZ; Ketoconazol; Piperazine, (+)-1-acetyl-4-[4-[[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-; MLS000069784; EINECS 265-667-4; R 41,400; SPBio_002498; HMS2051A19; S1353_Selleck; 65277-42-1; R41400; AC1L9UG3; Ketoderm; CHEMBL75; (+-)-cis-1-Acetyl-4-(p-((2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl)methoxy)phenyl)piperazine; KW-1414; Fungarest; HMS1569M19; 1-acetyl-4-(4-{[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine; BIM-0050645.0001; LS-110149; Piperazine, 1-acetyl-4-(4-((2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl)methoxy)phenyl)-, cis-; NCGC00025000-04; HMS2089N05; Prestwick1_000389; C26H28Cl2N4O4; EU-0100666; K0045; NCGC00025000-08; UPCMLD-DP138	65277-42-1	47576	186839	TTDS00359	Fungal Cytochrome P450 51	CYPL1;CYPLI;Cyt P450 14DM;Cytochrome P-450 lanosterol 14-alpha-demethylase;Cytochrome P450-dependent lanosterol 14-demethylase;Erg11p;Lanosterol 14 alpha-demethylase;Lanosterol 14-alpha demethylase;LDM;P450-14DM;P450L1;P450LI;Sterol 14-alpha demethylase;Sterol 14alpha-demethylase	Q96W81	N/A	N/A	inhibitor
DAP001267	Butoconazole	67085-14-7 (nitrate); AB00513831; Butoconazolum; NCGC00179596-01; DB00639; Prestwick1_000408; Femstat; UNII-0Q771797PH; AC1L2I4R; CID47472; BRD-A16665823-008-03-3; CHEBI:3240; Butoconazole; I14-1086; 1H-Imidazole, 1-(4-(4-chlorophenyl)-2-((2,6-dichlorophenyl)thio)butyl)-,; C08065; RS 35887-10-3; LS-176407; C19H17Cl3N2S; Gynofort (TN); 85496-23-7; CHEMBL1295; ( -)-1-((4-(p-Chlorophenyl)-2-((2,6-dichlorophenyl)thio)imidazole; Butaconazole; 1H-Imidazole, 1-[4-(4-chlorophenyl)-2-[(2,6-dichlorophenyl)thio]butyl]-, (1)-; duplicate RN for parent cpd; Butoconazole (INN); (+-)-1-[4-(4-Chlorophenyl)-2-[(2,6-dichlorophenyl)thio]butyl]-1H-imidazole; MolPort-003-666-530; Gynofort; Prestwick2_000408; Butoconazol [INN-Spanish]; Butoconazole [INN:BAN]; RS 35887; LS-176574; Prestwick3_000408; 67085-13-6; 1-(4-(4-Chlorophenyl)-2-(2,6-dichlorophenylthio)-n-butyl)-1H-imidazole; 1-[4-(4-chlorophenyl)-2-(2,6-dichlorophenyl)sulfanylbutyl]imidazole; 64872-76-0; Butoconazolum [INN-Latin]; Butoconazol; BSPBio_000336; SPBio_002275; Prestwick0_000408; (.+/-.)-1-[4-(p-Chlorophenyl)-2-[(2,6-dichlorophenyl)thio]butyl]imidazole; 1H-Imidazole, 1-(4-(4-chlorophenyl)-2-((2,6-dichlorophenyl)thio)butyl)-, nitrate; 1-{4-(4-chlorophenyl)-2-[(2,6-dichlorophenyl)sulfanyl]butyl}-1H-imidazole; AC1Q3NSJ; BPBio1_000370; 1H-Imidazole, 1-(4-(4-chlorophenyl)-2-((2,6-dichlorophenyl)thio)butyl)-, (+-)-; D07598; AC-15961	64872-77-1	47472	606881	TTDS00359	Fungal Cytochrome P450 51	CYPL1;CYPLI;Cyt P450 14DM;Cytochrome P-450 lanosterol 14-alpha-demethylase;Cytochrome P450-dependent lanosterol 14-demethylase;Erg11p;Lanosterol 14 alpha-demethylase;Lanosterol 14-alpha demethylase;LDM;P450-14DM;P450L1;P450LI;Sterol 14-alpha demethylase;Sterol 14alpha-demethylase	Q96W81	N/A	N/A	inhibitor
DAP000628	Fluconazole	nchembio.100-comp3; Triflucan; 86386-73-4; CCRIS 7211; DivK1c_001030; BRD-K05977355-001-02-6; Fuconal; ct Arzneimittel Brand of Fluconazole; UK49858; SMR000471882; UK 49858; KBio2_007270; FCZ; Diflazon; TL8005609; betapharm Brand of Fluconazole; I06-0069; Forcan; Loitin; KBioGR_000360; 2-(2,4-Difluoro-phenyl)-1,3-bis-[1,2,4]triazol-1-yl-propan-2-ol; Fluconazol von ct; 2-(2,4-difluorophenyl)-1,3-bis(1,2,4-triazol-1-yl)propan-2-ol; SPECTRUM1503975; AC-428; Vita Brand of Fluconazole; Bio-0041; 2-(2,4-DIFLUOROPHENYL)-1,3-DI(1H-1,2,4-TRIAZOL-1-YL)PROPAN-2-OL; Fluconazole (JAN/USAN/INN); NINDS_001030; HSDB 7420; FLCZ; Zoltec; Fluconazole & MC-510,011; Fluconazol-Isis; Dimycon; DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER; Flucytosine & Nyotran; KS-1059; D015725; STK619301; XMP.391 & Fluconazole; C13H12F2N6O; S1331_Selleck; NCGC00095089-01; TPF; Fluconazole in dextrose 5% in plastic container; DIFLUCAN IN SODIUM CHLORIDE 0.9%; CHEBI:46081; Flukezol; Elazor; MLS001165780; nchembio.65-comp15; Fluconazolum [Latin]; Biocanol; Oxifungol; Apo Fluconazole; Mutum; MLS001195645; Flunizol; Lesvi Brand of Fluconazole; Fluconazole & Bovine Lactoferrin; Spectrum2_001607; Fluzone; MolPort-000-883-859; Beagyne; Flucazol; ct-Arzneimittel Brand of Fluconazole; IDI1_001030; D00322; HMS1922O10; Fluconazol AL; SPBio_001613; Apo-Fluconazole; KBioSS_002134; Apotex Brand of Fluconazole; HMS2090I20; AC1L1FRQ; Effik Brand of Fluconazole; Lavisa; Baten; 2,4-Difluoro-alpha,alpha-bis(1H-1,2,4-triazol-1-ylmethyl)benzyl alcohol; Zonal; Pritenzol; Chemia Brand of Fluconazole; SAT Brand of Fluconazole; fluconazole; CID3365; Lichtenstein Brand of Fluconazole; Afungil; XMP.366 & Fluconazole; Flucostat; Alpharma Brand of Fluconazole; NCGC00095089-02; Stada Brand of Fluconazole; AC1Q77FV; CPD000471882; Silanes Brand of Fluconazole; UK-49858; DB00196; Fluconazol [Spanish]; Fluconazol ratiopharm; MLS001066394; SAM002589905; Fluconazol-ratiopharm; NCGC00095089-04; HMS503M21; Flunazul; Fluconazol AbZ; GL663142 & Fluconazole; KBio2_004702; KBio2_002134; Fluconazole [USAN:INN:BAN:JAN]; Fluconazolum; XMP.284 & Fluconazole; Diflucan (TN); KBio3_003009; Spectrum4_000090; Fluconazole in sodium chloride 0.9%; Flucytosine & Nyotran(Liposomal Nystatin); Diflucan, Trican, Alfumet, Fluconazole; Aliud Brand of Fluconazole; 2,4-difluoro-,1-bis(1H-1,2,4-triazol-1-ylmethyl)benzyl alcohol; Spectrum5_001277; CHEMBL106; Alflucoz; DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER; Zemyc; 2-(2,4-Difluorophenyl)-1,3-bis(1H-1,2,4-triazol-1-yl)propan-2-ol; Fluconazole in sodium chloride 0.9% in plastic container; MolPort-002-885-825; Fluconazole & Human recombinant granulocyte colony stimulating factor; ZINC00004009; Diflucan; UNII-8VZV102JFY; Fluconazole in combination with MGCD290; F0677; ratiopharm Brand of Fluconazole; Armstrong Brand of Fluconazole; 2-(2,4-Difluorophenyl)-1,3-bis(1H-1,2,4-triazol-1-yl)-2-propanol; Solacap; Canzol; Mack Brand of Fluconazole; AKOS000280854; Cryptal; Syscan; Spectrum_001654; DRG-0005; Fluc Hexal; Fluconazol; HMS2093M21; BSPBio_003504; Fungata; F8929_SIGMA; Pfizer Brand of Fluconazole; Spectrum3_001912; Fluconazol Isis; Oxifugol; KBio1_001030; 2-(2,4-Difluorophenyl)-1,3-di-1H-1,2,4-triazol-1-ylpropan-2-ol; Biozolene; LS-1858; MLS001306492; Neofomiral; MLS001304713; Flucobeta; AbZ Brand of Fluconazole; Fluconazole & hGCSF; FlucoLich; NCGC00095089-05; BIDD:GT0799; Pfleger Brand of Fluconazole; Hexal Brand of Fluconazole; Fluconazol Stada	86386-73-4	3365	192927	TTDS00359	Fungal Cytochrome P450 51	CYPL1;CYPLI;Cyt P450 14DM;Cytochrome P-450 lanosterol 14-alpha-demethylase;Cytochrome P450-dependent lanosterol 14-demethylase;Erg11p;Lanosterol 14 alpha-demethylase;Lanosterol 14-alpha demethylase;LDM;P450-14DM;P450L1;P450LI;Sterol 14-alpha demethylase;Sterol 14alpha-demethylase	Q96W81	N/A	N/A	inhibitor
DAP001101	Posaconazole	Spriafil; CID11520437; 171228-49-2; Posaconazole in combination with MGCD290; UNII-6TK1G07BHZ; HSDB 7421; DB01263; Posaconazole; Posaconazole SP; CHEMBL371939; CHEMBL1397; AC1L3W34; 4-[4-[4-[4-[[(3R,5R)-5-(2,4-difluorophenyl)-5-(1,2,4-triazol-1-ylmethyl)oxolan-3-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-2-[(2S,3S)-2-hydroxypentan-3-yl]-1,2,4-triazol-3-one; CID147912; CID468595; CHEBI:434337; Posaconazole [USAN:INN:BAN]; Noxafil (TN); AC1LAHLQ; Noxafil, Posaconazole; 3H-1,2,4-Triazol-3-one, 4-(4-(4-(4-((5-(2,4-difluorophenyl)tetrahydro-5-(1H-1,2,4-triazol-1-ylmethyl)-3-furanyl)methoxy)phenyl)-1-piperazinyl)phenyl)-2-(1-ethyl-2-hydroxypropyl)-2,4-dihydro-, (3R-(3alpha(1S*,2S*),5alpha))-; CID11542142; 4-[4-[4-[4-[[(5R)-5-(2,4-difluorophenyl)-5-(1,2,4-triazol-1-ylmethyl)oxolan-3-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-2-[(2S,3S)-2-hydroxypentan-3-yl]-1,2,4-triazol-3-one; D02555; Sch 56592; LS-187630; Noxafil; LS-186118; AC-1350; MolPort-006-666-426; X2N; CHEMBL371938; SCH-56592; D-threo-Pentitol, 2,5-anhydro-1,3,4-trideoxy-2-C-(2,4-difluorophenyl)-4-((4-(4-(4-(1-((1S,2S)-1-etyl-2-hydroxypropyl)-1,5-dihydro-5-oxo-4H-1,2,4-triazol-4-yl)phenyl)-1-piperazinyl)phenoxy)methyl)-1-(1H-1,2,4-triazol-1-yl)-; S1257_Selleck; 1-((1S,2S)-1-Ethyl-2-hydroxypropyl)-4-{4-[4-(4-{[(5S,3R)-5-(2,4-difluorophenyl)-5-(1,2,4-triazolylmethyl)oxolan-3-yl]methoxy}phenyl)piperazinyl]phenyl}-1,2,4-triazolin-5-one; AKOS005145917; LS-186988; Posaconazole (USAN/INN); 177571-33-4; SCH56592; CID10532764; 4-(p-(4-(p-(((3R,5R)-5-(2,4-Difluorophenyl)tetrahydro-5-(1H-1,2,4-triazol-1-ylmethyl)-3-furyl)methoxy)phenyl)-1-piperazinyl)phenyl)-1-((1S,2S)-1-ethyl-2-hydroxypropyl)-delta(sup 2)-1,2,4-triazolin-5-one	171228-49-2	147912	17396726	TTDS00359	Fungal Cytochrome P450 51	CYPL1;CYPLI;Cyt P450 14DM;Cytochrome P-450 lanosterol 14-alpha-demethylase;Cytochrome P450-dependent lanosterol 14-demethylase;Erg11p;Lanosterol 14 alpha-demethylase;Lanosterol 14-alpha demethylase;LDM;P450-14DM;P450L1;P450LI;Sterol 14-alpha demethylase;Sterol 14alpha-demethylase	Q96W81	N/A	N/A	inhibitor
DAP000629	Terconazole	AC1L1KA5; Prestwick_812; 85058-79-3; AB00513849; Tetrazol 3; HMS1569D11; Fungistat; 1-[4-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-4-propan-2-ylpiperazine; terconazole; CID50001; UNII-0KJ2VE664U; Prestwick3_000495; CID5404; Terazol Cream & Suppositories; Terazol; BPBio1_000429; 1-[4-[[(4S)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-4-propan-2-ylpiperazine; BIDD:GT0705; D00888; 1-(4-((2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl)methoxy)phenyl)-4-(1-methylethyl)piperazine; CAS-67915-31-5; Terazol 7  3; Terazol 3; CHEMBL1306; CID9936883; Zazole; Terconazole (USAN/INN); Terazol 7 & 3; NSC 331942; Piperazine, 1-(4-(((2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl)methoxy)phenyl)-4-(1-methylethyl)-, rel-; NCGC00179575-01; SMR001565413; SPBio_002310; Tercospor; R 42470; AC1L1895; Gyno-Terazol; AC1LA3NV; AR-1L5963; Terazol 3 (TN); Prestwick1_000495; MLS002153844; Prestwick2_000495; Terazol 7; Piperazine, 1-(4-((2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl)methoxy)phenyl)-4-(1-methylethyl)-, cis-; AC1Q3MYQ; NSC331942; Prestwick0_000495; Terconazolum; BSPBio_000389; C26H31Cl2N5O3; AR-1I2364; 1-[4-[[2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-4-propan-2-ylpiperazine; Triaconazole; C08080; nchembio.154-comp19; EINECS 267-751-6; Terconazolum [INN-Latin]; LS-176634; 1-[4-[[(2S,4R)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-4-propan-2-ylpiperazine; Tetrazol 7; 67915-31-5; DB00251; AC1L9B2M; Terconazol; NCGC00016912-01; Terconazole [USAN:INN:BAN]; MLS002701820; R-42470; BRD-K86204871-001-02-2; AC1Q3N0B; Terconazol [INN-Spanish]; CID480953; Piperazine, 1-[4-[[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-4-(1-methylethyl)-, rel-(2R,4S); CID441383; cis-1-(p-((2-(2,4-Dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl)methoxy)phenyl)-4-isopropylpiperazine; SMR001233206; R 42,470	67915-31-5	441383	7847952	TTDS00359	Fungal Cytochrome P450 51	CYPL1;CYPLI;Cyt P450 14DM;Cytochrome P-450 lanosterol 14-alpha-demethylase;Cytochrome P450-dependent lanosterol 14-demethylase;Erg11p;Lanosterol 14 alpha-demethylase;Lanosterol 14-alpha demethylase;LDM;P450-14DM;P450L1;P450LI;Sterol 14-alpha demethylase;Sterol 14alpha-demethylase	Q96W81	N/A	N/A	inhibitor
DAP001270	Sertaconazole	SZ; Prestwick3_001045; Sertaconazolum; Prestwick0_001045; SPBio_002905; 99592-39-9 (Nitrate); AC1L244H; CID65863; 99592-32-2; 1-(2-((7-Chlorobenzo(b)thien-3-yl)methoxy)-2-(2,4-dichlorophenyl)ethyl)-1H-imidazole; Sertaconazol; (+-)-1-(2,4-Dichloro-beta-((7-chlorobenzo(b)thien-3-yl)methoxy)phenethyl)imidazole; AB00514018; Sertaconazolum [Latin]; BRD-A95939040-008-03-3; ( inverted exclamation markA)-1-[2,4-dichloro-b-[(7-chlorobenzo[b]thien-3-yl)methoxy]phenethyl]imidazole; AC-6939; Sertaconazole; 7-Chloro-3-[1-(2,4-dichlorophenyl)-2-(1H-imidazol-1-yl)ethoxy-methyl]benzo[b]thiophene; Sertaconazole (INN); Prestwick1_001045; UNII-72W71I16EG; Prestwick2_001045; BSPBio_000970; NCGC00179356-01; 1-[2-[(7-chloro-1-benzothiophen-3-yl)methoxy]-2-(2,4-dichlorophenyl)ethyl]imidazole; 1H-Imidazole, 1-(2-((7-chlorobenzo(b)thien-3-yl)methoxy)-2-(2,4-dichlorophenyl)ethyl)-; 7-Cloro-3-(1-(2,4-diclorofenil)-2-(1H-imidazol-1-il)etoxi-metil)benzo(b)tiofeno [Spanish]; DB01153; Sertaconazol [Spanish]; HMS2089M16; AC1Q3MZP; BRN 5385663; LS-78267; 7-Cloro-3-(1-(2,4-diclorofenil)-2-(1H-imidazol-1-il)etoxi-metil)benzo(b)tiofeno; 7-Chloro-3-(1-(2,4-dichlorophenyl)-2-(1H-imidazol-1-yl)ethoxy-methyl)benzo(b)thiophene; C20H15Cl3N2OS; BPBio1_001068; FI-7045; D06883; Sertaconazole [INN]	99592-32-2	65863	207904	TTDS00359	Fungal Cytochrome P450 51	CYPL1;CYPLI;Cyt P450 14DM;Cytochrome P-450 lanosterol 14-alpha-demethylase;Cytochrome P450-dependent lanosterol 14-demethylase;Erg11p;Lanosterol 14 alpha-demethylase;Lanosterol 14-alpha demethylase;LDM;P450-14DM;P450L1;P450LI;Sterol 14-alpha demethylase;Sterol 14alpha-demethylase	Q96W81	N/A	N/A	inhibitor
DAP000631	Itraconazole	S2476_Selleck; Ambap84625-61-6; 2-butan-2-yl-4-[4-[4-[4-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one; AKOS000280875; MLS000863291; 2-butan-2-yl-4-[4-[4-[4-[[(2S,4R)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one; FT-0082511; (1)-cis-4-(4-(4-(4-((2-(2,4-Dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl)methoxy)phenyl)piperazin-1-yl)phenyl)-2,4-dihydro-2-sec-butyl-3H-1,2,4-triazol-3-one; CID9961741; Itraconazole & Nyotran; ITZ; SAM001246679; Itrizole; Sporal; 2-(butan-2-yl)-4-{4-[4-(4-{[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazin-1-yl]phenyl}-2,4-dihydro-3H-1,2,4-triazol-3-one; MolPort-000-883-864; CID55283; CID6917738; CID3793; Triasporn; AC1OCEL7; HMS2090M20; 3H-1,2,4-Triazol-3-one, 4-[4-[4-[4-[[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-1-piperazinyl]phenyl]-2,4-dihydro-2-(1-methylpropyl)-; BIDD:GT0796; AC1L1IRU; DB01167; 84604-65-9; Canadiol; 4-(4-{4-[4-({[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methyl}oxy)phenyl]piperazin-1-yl}phenyl)-2-(1-methylpropyl)-2,4-dihydro-3H-1,2,4-triazol-3-one; Sporanos; TL8005525; Prokanazol; Itraconazol [Spanish]; ITCZ; HMS2051K14; Itraconazolum; 3H-1,2,4-Triazol-3-one, 4-(4-(4-(4-((2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl)methoxy)phenyl)-1-piperazinyl)phenyl)-2,4-dihydro-2-(1-methylpropyl)-; Spherazole; AC1L1GQ5; Sporonox; CPD000058959; Itraconazole oral solution; Itraconazolum [Latin]; R-51211; 2-butan-2-yl-4-[4-[4-[4-[[2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one; MLS001148245; MLS000028582; (+-)-1-sec-Butyl-4-(p-(4-(p-(((2R*,4S*)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl)methoxy)phenyl)-1-piperazinyl)phenyl)-delta(sup 2)-1,2,4-triazolin-5-one; Itraconazol; C35H38Cl2N8O4; CHEBI:6076; R 51211; AC1Q6EZ3; itraconazole; Sporanox; I0732; Oriconazole; Itraconazole (JAN/USAN); Itraconazole & Nyotran(Liposomal Nystatin); LS-1843; MLS000759472; cis-Itraconazole; D00350; Hyphanox; Sempera; CHEMBL882; UNII-304NUG5GF4; 84625-61-6; Itrizole (TN); BRN 6042047; Intraconazole; NCGC00089812-03; MolPort-003-848-295; SMR000058959; CHEMBL22587; AC-542; I01-1043; Itraconazole [USAN:BAN:INN:JAN]; EINECS 283-347-2; Sporanox (TN); Oriconazole, R51211, Sporanox; 3H-1,2,4-Triazol-3-one, 4-[4-[4-[4-[[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-1-pipera-zinyl]phenyl]-2,4-dihydro-2-(1-methylpropyl); (+/-)-1-[( R *)- sec -butyl]-4-[ p -[4-[ p -[[(2 R *,4 S *)-2-(2,4-dichlorophenyl)-2-(1 H -1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-1-piperazinyl]phenyl]-(DELTA) 2 1,2,4-triazolin-5-one mixture with (+/-)-1-[( R *)- sec -butyl]-4-[ p -[4- [ p -[[(2 S *,4 R *)-2-(2,4-dichlorophenyl)-2-(1 H -1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-1-piperazinyl] phenyl]-(DELTA) 2 -1,2,4-triazolin-5-one; Itraconazole & Bovine Lactoferrin; Orungal	84625-61-6	55283	192757	TTDS00359	Fungal Cytochrome P450 51	CYPL1;CYPLI;Cyt P450 14DM;Cytochrome P-450 lanosterol 14-alpha-demethylase;Cytochrome P450-dependent lanosterol 14-demethylase;Erg11p;Lanosterol 14 alpha-demethylase;Lanosterol 14-alpha demethylase;LDM;P450-14DM;P450L1;P450LI;Sterol 14-alpha demethylase;Sterol 14alpha-demethylase	Q96W81	N/A	N/A	inhibitor
DCL001200	ISIS-EIF4E	N/A	N/A	N/A	N/A	TTDR01411	mRNA of eIF4E-BP2	N/A	Q13542	1979	ENSG00000148730	antisense
DAP000785	Vinblastine	Vinblastina (TN); (2ALPHA,2'BETA,3BETA,4ALPHA,5BETA)-VINCALEUKOBLASTINE; CID6710780; NSC 47842; AC1MXZJ2; KBio3_003033; Rozevin; SPBio_000680; UNII-5V9KLZ54CY; BRD-K01188359-065-02-5; BSPBio_001228; C07201; (2xi,3beta,4'beta,19xi)-vincaleukoblastine; BSPBio_003594; EINECS 212-734-0; MolPort-002-518-262; CID3823887; VLB; 29060-LE; CHEMBL607706; CHEMBL159; AC1L68D2; NDC 0002-1452-01; NCGC00022585-04; VR-8; CID241903; Vinblastin; Vinblastina; HMS2090K05; 1z2b; LS-187263; Neuro_000020; DB00570; D08675; NChemBio.2007.10-comp22; (3aR-(3aalpha,4beta,5beta,5abeta,9(3R*,5S*,7R*,9S*),10bR*,13aalpha))-methyl 4-(acetyloxy)-3a-ethyl-9-(5-ethyl-1,4,5,6,7,8,9,10-octahydro-5-hydroxy-9-(methoxycarbonyl)-2H-3,7-methanoazacycloundecino(5,4-b)indol-9-yl)-3a,4,5,5a,6,11,12,13a-octahydro-5-hydroxy-8-methoxy-6-methyl-1H-indolizino(8,1-cd)carbazole-5-carboxylate; MolPort-005-910-359; STOCK1N-38480; Vinblastina [DCIT]; Vinblastinum; CCRIS 9002; 1H-Indolizino(8,1-cd)carbazole-5-carboxylic acid, 4-(acetyloxy)-3a-ethyl-9-(5-ethyl-1,4,5,6,7,8,9,10-octahydro-5-hydroxy-9-(methoxycarbonyl)-2H-3,7-methanoazacycloundecino(5,4-b)indol-9-yl)-3a,4,5,5a,6,11,12,13a-octahydro-5-hydroxy-8-methoxy-6-methyl-, methyl ester, (3aR-(3aalpha,4beta,5beta,5abeta,9(3R*,5S*,7R*,9S*),10bR*,13aalpha))-; AC-20335; 865-21-4; NCI-C04842; NCGC00181127-01; LS-1859; CHEBI:27375; 143-67-9; Vincoblastine; Vincaleucoblastin; nchembio873-comp22; HSDB 3263; Vincaleukoblastine; Bio-0111; Spectrum2_000890; Vinblastine (INN); CHEBI:171516; CID13342; vinblastine; AC1L21JC; NCI60_004200; Vinblastine [INN:BAN]; Nincaluicolflastine; Vincaleucoblastine; Vinblastinum [INN-Latin]; BIDD:PXR0201; C46H58N4O9; Spectrum3_001994	865-21-4	13342	156698	TTDS00389	Tubulin beta-2 chain	Beta(II) isotype of Tubulin;Beta(II)-Tubulin;BetaII-Tubulin	P05217	N/A	N/A	inhibitor
DCL000622	RhuMAb Beta7	N/A	N/A	N/A	N/A	TTDC00031	Integrin beta-7	Gut homing receptor beta subunit;ITGB7	P26010	3695	ENSG00000139626	antibody
DCL000662	Vedolizmab	N/A	152854-19-8	444305	49740556	TTDC00031	Integrin beta-7	Gut homing receptor beta subunit;ITGB7	P26010	3695	ENSG00000139626	antagonist
DAP000800	Darbepoetin alfa	N/A	11096-26-7	N/A	46504480	TTDS00144	Erythropoietin Receptor	EPO-R;Full-length form	P19235	2057	ENSG00000187266	agonist
DAP000202	Epoetin alfa	N/A	113427-24-0	N/A	46508122	TTDS00144	Erythropoietin Receptor	EPO-R;Full-length form	P19235	2057	ENSG00000187266	agonist
DCL000319	Hematide	N/A	N/A	N/A	N/A	TTDS00144	Erythropoietin Receptor	EPO-R;Full-length form	P19235	2057	ENSG00000187266	agonist
DCL000733	Bupropion+naltrexone	N/A	31677-93-7	N/A	N/A	TTDS00522	Noradrenaline uptake	N/A	N/A	N/A	N/A	inhibitor
DCL000948	Radaxafine HCl	N/A	106083-71-0	65987	43122711	TTDS00522	Noradrenaline uptake	N/A	N/A	N/A	N/A	inhibitor
DCL000947	Radafaxine	Radafaxine; C496215; CPD-3483; hydroxybupropion	106083-71-0	9795056 	10549644	TTDS00522	Noradrenaline uptake	N/A	N/A	N/A	N/A	inhibitor
DAP001533	Trimipramine	5H-Dibenz(b,f)azepine-5-propanamine, 10,11-dihydro-N,N,beta-trimethyl-, (+)- (9CI); AB00053646; BPBio1_000739; Trimipramine (USAN/INN); 1-(3-Dimethylamino-2-methylpropyl)-4,5-dihydro-2,3:6,7-dibenzazepine; Trimipraminum; 10,11 Dihydro-N,N,beta-trimethyl-5H-dibenz(b,f)azepine-5-propanamine; 10633 RP; Surmontyl; 5H-Dibenz(b,f)azepine, 5-(3-(dimethylamino)-2-methylpropyl)-10,11-dihydro-, (-)-; Prestwick3_000806; 5-(3-(Dimethylamino)-2-methylpropyl)-10,11-dihydro-5H-dibenz(b,f)azepine; KBioGR_001118; Spectrum3_001151; UNII-6S082C9NDT; 5H-Dibenz(b,f)azepine, 10,11-dihydro-5-(3-(dimethylamino)-2-methylpropyl)-; (+)-Trimipramine; trimipramine; KBio2_001902; Prestwick2_000806; NCGC00016013-03; LS-60464; Spectrum5_001052; 5H-Dibenz(b,f)azepine, 5-(3-(dimethylamino)-2-methylpropyl)-; ( )-Trimipramine; 5-(gamma-Dimethylamino-beta-methylpropyl)-10,11-dihydro-5H-dibenzo(b,f)azepine; KBio3_002201; Trimipramina; 5-(gamma-dimethylamino-beta-methylpropyl)-10,11-dihydro-5H-dibenzo[b,f]azepine; 5-[3-(dimethylamino)-2-methylpropyl]-10,11-dihydro-5H-dibenz[b,f]azepine; Trimipramine [USAN:INN:BAN]; CHEMBL644; BSPBio_000671; 5H-Dibenz(b,f)azepine-5-propanamine, 10,11-dihydro-N,N,beta-trimethyl-; Trimeprimine; DivK1c_000093; InChI=1/C20H26N2/c1-16(14-21(2)3)15-22-19-10-6-4-8-17(19)12-13-18-9-5-7-11-20(18)22/h4-11,16H,12-15H2,1-3H; 5H-Dibenz(b,f)azepine-5-propanamine, 10,11-dihydro-N,N,beta-trimethyl-, (-)- (9CI); 5H-Dibenz(b,f)azepine, 5-(3-(dimethylamino)-2-methylpropyl)-10,11-dihydro-, (+)-; 5H-Dibenz(b,f)azepine-5-propanamine, 10,11-dihydro-N,N,beta-trimethyl-, (+)-; SPBio_002592; LS-60463; 5H-Dibenz(b,f)azepine, 5-(3-(dimethylamino)-2-methylpropyl)-10,11-dihydro-; (-)-Trimipramine; L000969; KBioSS_001902; Lopac0_001156; Trimeproprimine; 3564-75-8; 5H-Dibenz(b,f)azepine, 10,11-dihydro-5-(3-(dimethylamino)-2-methylpropyl)-, (-)-; 521-78-8 (maleate (1:1)); Prestwick0_000806; 3564-66-7; Sapilent; Trimeproprimin; Trimipramine, (-)-Isomer; LS-60465; 7162 RP; 5-20-08-00099 (Beilstein Handbook Reference); CHEBI:9738; Surmontil; Prestwick1_000806; BSPBio_002701; Trimipraminum [INN-Latin]; Spectrum_001422; Trimipramina [INN-Spanish]; BRD-A19195498-050-05-9; AC-15969; Spectrum2_001530; Spectrum4_000759; Stangyl; 3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N,2-trimethylpropan-1-amine; 3589-21-7 (mono-hydrochloride); 5H-Dibenz[b,f]azepine-5-propanamine, 10,11-dihydro-N,N,.beta.-trimethyl-; NINDS_000093; 2'-Metil-3'-dimetilamino-propil-5-iminodibenzile; Trimeprimina [Italian]; KBio2_004470; IL-6001; RP-7162; D00394; SPBio_001320; EINECS 212-008-3; 5H-Dibenz(b,f)azepine, 10,11-dihydro-5-(3-(dimethylamino)-2-methylpropyl)-, (+)-; 10,11-dihydro-N,N,beta-trimethyl-5H-dibenz[b,f]azepine-5-propanamine; BRN 1321466; Trimeprimina; 25332-13-2 (mesylate); CID5584; KBio2_007038; DB00726; IDI1_000093; MolPort-005-935-550; Oprea1_375679; 739-71-9; NCGC00162356-01; 3-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N,2-trimethylpropan-1-amine; FI 6120; 2'-Metil-3'-dimetilamino-propil-5-iminodibenzile [Italian]; KBio1_000093; AC1L1KO8; 10645 RP; IL 6001; 10,11-Dihydro-5-(3-dimethylamino-2-methylpropyl)-5H-dibenz(b,f)azepine; beta-Methylimipramine	739-71-9	4055	49698504	TTDS00522	Noradrenaline uptake	N/A	N/A	N/A	N/A	inhibitor
DCL000723	Bicifadine	N/A	71195-57-8	449171	12015676	TTDS00522	Noradrenaline uptake	N/A	N/A	N/A	N/A	inhibitor
DCL000679	AD-337	N/A	N/A	N/A	N/A	TTDS00522	Noradrenaline uptake	N/A	N/A	N/A	N/A	inhibitor
DCL001021	Tramadol ER	N/A	27203-92-5	33741	48416650	TTDS00522	Noradrenaline uptake	N/A	N/A	N/A	N/A	inhibitor
DPR000034	CYT-009-GhrQb	N/A	N/A	5884	46060463	TTDC00127	Growth hormone secretagogue receptor type 1	GH-releasing peptide receptor;Ghrelin receptor;GHRP;GHS-R;Growth hormone secretagogue receptor	Q92847	2693	ENSG00000121853	antagonist
DPR000041	EP-01492	N/A	N/A	N/A	N/A	TTDC00127	Growth hormone secretagogue receptor type 1	GH-releasing peptide receptor;Ghrelin receptor;GHRP;GHS-R;Growth hormone secretagogue receptor	Q92847	2693	ENSG00000121853	antagonist
DPR000187	TZP-301	N/A	N/A	N/A	N/A	TTDC00127	Growth hormone secretagogue receptor type 1	GH-releasing peptide receptor;Ghrelin receptor;GHRP;GHS-R;Growth hormone secretagogue receptor	Q92847	2693	ENSG00000121853	antagonist
DPR000167	AEZS-123	N/A	N/A	N/A	N/A	TTDC00127	Growth hormone secretagogue receptor type 1	GH-releasing peptide receptor;Ghrelin receptor;GHRP;GHS-R;Growth hormone secretagogue receptor	Q92847	2693	ENSG00000121853	antagonist
DCL000255	TZP-101	N/A	N/A	N/A	N/A	TTDC00127	Growth hormone secretagogue receptor type 1	GH-releasing peptide receptor;Ghrelin receptor;GHRP;GHS-R;Growth hormone secretagogue receptor	Q92847	2693	ENSG00000121853	agonist
DCL001007	SUN-11031	N/A	N/A	251951	46507751	TTDC00127	Growth hormone secretagogue receptor type 1	GH-releasing peptide receptor;Ghrelin receptor;GHRP;GHS-R;Growth hormone secretagogue receptor	Q92847	2693	ENSG00000121853	agonist
DCL000049	Anamorelin	N/A	N/A	N/A	N/A	TTDC00127	Growth hormone secretagogue receptor type 1	GH-releasing peptide receptor;Ghrelin receptor;GHRP;GHS-R;Growth hormone secretagogue receptor	Q92847	2693	ENSG00000121853	stimulator
DAP000470	Paclitaxel	BSPBio_001152; Pacligel; KBioSS_002517; T1912_SIGMA; cMAP_000068; NCI60_000601; EU-0101201; albumin-bound paclitaxel; C47H51NO14; BIDD:PXR0046; TA1; KBioGR_000492; HSDB 6839; KBioGR_002509; KBio2_007645; nchembio.215-comp9; Taxol.RTM. (Registered Trademark); KBio2_002509; NCGC00164367-01; 7-Epipaclitaxel; QW 8184; BMS-181339-01; MPI-5018; MolPort-001-742-627; HMS501G03; IDI1_002171; UPCMLD-DP108:002; T7402_SIGMA; MolPort-003-932-365; LS-31070; 33069-62-4; DHP-208; Vascular Wrap; LMPR0104390001; ABI 007; CHEMBL418410; Abraxis BioScience brand of albumin-bound paclitaxel; DB01229; KBio3_000903; Capxol; CHEMBL48; DHP-107; NSC358882; SMR000857385; Onxol, Taxol, Nov-Onxol, Paclitaxel; DTS-301; SPBio_000943; SDP-013; CPD-8718; 7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxete, benzenepropanoic acid deriv.; CHEBI:45863; Epitaxol; Plaxicel; Spectrum2_000872; KBio2_003060; Onxol; HMS1362J13; NCGC00024995-02; ABI007; NSC 125973; Paclical; KBio2_007152; BMS-181339; Prestwick2_000155; AC1L1IOG; KBio3_001834; HMS1990J13; 7-epi-Paclitaxel; Prestwick0_000155; Taxol A; MLS002695976; SDCCGMLS-0066823.P001; NCGC00024995-05; S1150_Selleck; AC-675; IDI1_000441; BPBio1_000320; Ebetaxel; CID36314; TaxAlbin; AB00513812; 157069-30-2; AC1L9AVF; Abraxane; NCGC00164367-02; KBio1_000441; Mitotax; KBio3_000904; HMS1922K08; SMR000394086; BSPBio_000290; Bio1_000851; KBio2_000492; MBT 0206; MolPort-003-665-783; P1632; Genexol; SPBio_002229; Bio1_001340; Paclitaxel (JAN/USP/INN); Nanotaxel; HMS2090D07; Bio1_000362; Bio-0076; TAXOL, 10-EPI,; Genexol-PM; Spectrum5_001491; CID6915727; 7,11-Methano-5H-cyclodeca[3,4]benz[1,2-b]oxete,benzenepropanoic acid deriv.; UPCMLD-DP108:001; Neuro_000060; NSC125973; KBio2_002016; BRD-A28746609-001-04-0; MLS000863266; CID441276; Onxal; NCGC00024995-06; CHEBI:103439; Xorane; MLS002154218; C07394; weekly paclitaxel; Prestwick3_000155; Intaxel; KBioGR_001893; CID4666; LipoPac; SMP1_000228; ACon1_002231; BRD-A23723433-001-01-2; KBio2_005628; ABI-007; MLS002172439; C466458; BRD-K62008436-001-03-1; Abraxane (TN); UNII-P88XT4IS4D; Prestwick1_000155; TAXOL (TN); I06-0014; NCGC00164367-03; MLS001077297; D00491; CCRIS 8143; Paxene; Anzatax; KBio2_004584; SPECTRUM1503908; HMS1792J13; Ambotz33069-62-4; Bio2_000896; Lopac0_001201; NINDS_000441; 12-benzoate, 9-ester with (2R,3S)-N-benzoyl-3-phenylisoserine; Paclitaxel (JAN/USP); Spectrum4_001197; OncoGel; Probes2_000350; S-8184 Paclitaxel Injectable Emulsion; Genetaxyl; Abraxane I.V. Suspension; BMS 181339-01; CID6713921; OAS-PAC-100; NSC-125973; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; TAXOL; CHEMBL100910; ANX-513; Genaxol; paclitaxel; KBio2_005077; HMS1568O12; NCGC00024995-04; NCGC00024995-07; nchembio.188-comp1; KBio3_002987; Paxceed; nchembio.2007.34-comp9; Nova-12005; BSPBio_002614; ST50306996; Paclitaxel (Taxol); KBioSS_002016; MEGxp0_001940; EmPAC; AC1L1VJI; NK 105; nchembio853-comp6; Yewtaxan; DivK1c_000441; Spectrum_001536; T 7402; T7191_SIGMA; DRG-0190; HMS2093K15; KBioSS_000492; Paxoral; 7-Epitaxol; Bio2_000416; Spectrum3_001057; NCGC00024995-03; 7-epi-Taxol; NP-010981	33069-62-4	36314	177831	TTDS00308	Tubulin beta	Beta-tubulin;Tubulin beta-1 chain	P07437	203068	ENSG00000196230; ENSG00000183311; ENSG00000235067; ENSG00000224156; ENSG00000229684; ENSG00000227739; ENSG00000232421; ENSG00000232575	binder
DAP000950	Mebendazole	Surfont; AKOS000539066; Anti-Worm; 5-Benzoyl-2-benzimidazolecarbamic acid, methyl ester; KBio2_006914; IDI1_000751; Carbamic acid, (5-benzoyl-1H-benzimidazol-2-yl)-, methyl ester; D008463; NCGC00016806-02; AB00052203; MEBENDAZOLE, 99%; KBioGR_000712; Mebendazol; Noverme; Spectrum3_001439; Oprea1_768530; Norgine Brand of Mebendazole; CHEMBL685; KBio2_004346; methyl N-(6-benzoyl-1H-1,3-benzodiazol-2-yl)carbamate; ZINC00121541; Carbamic acid, N-(5-benzoylbenzimidazol-2-yl)-, methyl ester; Vermox (TN); Esteve Brand of Mebendazole; Methyl 5-benzoyl benzimidazole-2-carbamate; Equivurm Plus; KBioSS_001778; Pripsen Mebendazole; Prestwick0_000217; DivK1c_000751; NSC 184849; CHEBI:6704; BSPBio_003178; Methyl N-(5-benzoyl-1H-benzimidazol-2-yl)carbamate; MolPort-000-765-625; HSDB 3232; Pfizer Brand of Mebendazole; BPBio1_000257; NCGC00021698-03; Bio-0803; Prestwick1_000217; Madicure; STK093862; Besantin; CPD000036734; Mebendazole(USAN); HMS1536H11; TL8002405; mebendazole; Abello Farmacia Brand of Mebendazole; Vermicidin; Oprea1_278237; Banworm; Prestwick_310; BRD-K77987382-001-01-7; 46404_FLUKA; methyl N-(6-benzoyl-1H-benzimidazol-2-yl)carbamate; Spectrum4_000416; UNII-81G6I5V05I; Ardeypharm Brand of Mebendazole; N-(Benzoyl-5, benzimidazolyl)-2, carbamate de methyle [French]; Vermicol; NSC184849; Vermin; Anti Worm; Ovitelmin; Degort's Brand of Mebendazole; Mebendazole [USAN:INN:BAN:JAN]; Bantenol; DB00643; BAS 00341140; HMS1568L15; N-2 (5-Benzoyl-benzimidazole) carbamate de methyle; Sufil; (5-Benzoyl-1H-benzimidazol-2-yl)-carbamic acid methyl ester; MBDZ; Streger Brand of Mebendazole; Boots Threadworm Treatment; 2-Benzimidazolecarbamic acid, 5-benzoyl-, methyl ester; 31431-39-7; HMS1921F03; NCGC00016806-01; Spectrum_001298; SAM002548959; Vermox; Mebendazolum; Mebendazole (JAN/USP); Spectrum5_001381; Methyl 5-benzoyl-2-benzimidazolecarbamate; EINECS 250-635-4; Prestwick3_000217; N-(Benzoyl-5, benzimidazolyl)-2, carbamate de methyle; SPECTRUM1501110; NINDS_000751; (5-Benzoyl-1H-benzimidazol-2-yl)carbamic acid methyl ester; Mebendan; N-2 (5-Benzoyl-benzimidazole) carbamate de methyle [French]; Elfar Brand of Mebendazole; Versid; AC1L1H98; HMS2092B15; Healthypharm Brand of Mebendazole; BRD-K77987382-001-06-6; Probes1_000013; Mebenvet; KBio3_002398; Methyl N-(5-benzoyl-2-benzimidazolyl)carbamate; M2523_FLUKA; Sqworm; 2-Benzimidazolecarbamic acid, 5-benzoyl-, methyl ester (8CI); SPBio_002154; R 17635; Prestwick2_000217; MLS000028491; AC-12064; HMS502F13; SMR000036734; Bio-0458; CBDivE_010559; LS-48951; NCGC00021698-06; Janssen Brand of Mebendazole; methyl [5-(phenylcarbonyl)-1H-benzimidazol-2-yl]carbamate; I06-2075; Carbamic acid, (5-benzoyl-1H-benzimidazol-2-yl)-, methyl ester (9CI); Mebutar; SPBio_001442; Spectrum2_001401; (5-Benzoyl-1H-benzoimidazol-2-yl)-carbamic acid methyl ester; 5-Benzoyl-2-benzimidazolecarbamic acid methyl ester; Diba Brand of Mebendazole; NCGC00021698-04; M2523_SIGMA; Taxandria Brand of Mebendazole; NCGC00021698-05; R17635; Wormkuur; Lomper; KBio1_000751; SSL Brand of Mebendazole; Leidapharm Brand of Mebendazole; KBio2_001778; Pantelmin; Tedec Meiji Brand of Mebendazole; Verpanyl; Mebendazole (JAN/USP/INN); TimTec1_000869; HMS2090B03; Vermirax; MolPort-001-889-615; 46404_RIEDEL; CID4030; R-17635; AC1Q44DR; Mebenoazole; Boots Brand of Mebendazole; Vermidil; BIDD:GT0087; CCRIS 4479; D00368; Mebex; Mebendazolum [INN-Latin]; Mebendazol [INN-Spanish]; Telmin; R 17,635; CAS-31431-39-7; Methyl 5-benzoyl-2-benzimidazolylcarbamate; BSPBio_000233; methyl (5-benzoyl-1H-benzimidazol-2-yl)carbamate; Probes2_000149	31431-39-7	4030	7847434	TTDS00308	Tubulin beta	Beta-tubulin;Tubulin beta-1 chain	P07437	203068	ENSG00000196230; ENSG00000183311; ENSG00000235067; ENSG00000224156; ENSG00000229684; ENSG00000227739; ENSG00000232421; ENSG00000232575	binder
DAP000951	Albendazole	Endoplus; AC-015; [5-(Propythio)-1H-benzimidazol-2-yl]carbamic acid methyl ester; AB00052377; Albendazole [USAN:INN:BAN:JAN]; albendazole; CHEBI:506787; methyl [(2Z)-5-(propylsulfanyl)-1,3-dihydro-2H-benzimidazol-2-ylidene]carbamate; CPD000036735; (5-Propylsulfanyl-1H-benzoimidazol-2-yl)-carbamic acid methyl ester; Albendoral; Albendazole Valdecasas Brand; S1640_Selleck; KBio2_007148; Methyl [5-(Propylthio)benzimidazol-2-yl]carbamate; NSC 220008; SmithKline Beecham Brand of Albendazole; SPBio_002253; Methyl-5-[propylthio]-2-benzimidazole carbamate; NSC220008; Albendazolum [INN-Latin]; SKF 62979; Albenza, Eskazole, Zentel, Andazol, Albendazole; NCGC00022896-07; KBioGR_000801; Oprea1_429292; Carbamic acid, [5-(propylthio)-1H-benzimidazol-2-yl]-, methyl ester; BAS 00439961; O-Methyl N-(5-(propylthio)-2-benzimidazolyl)carbamate; Albendazole Fustery Brand; InChI=1/C12H15N3O2S/c1-3-6-18-8-4-5-9-10(7-8)14-11(13-9)15-12(16)17-2/h4-5,7H,3,6H2,1-2H3,(H2,13,14,15,16); Bendapar; CID2082; Albendazole Monohydrochloride; CHEMBL1483; Albendazole Armstrong Brand; BSPBio_002548; A4673_SIGMA; HMS2093K13; (5-(Propylthio)-1H-benzimidazol-2-yl)carbamic acid methyl ester; MolPort-000-726-929; NCGC00022896-06; D00134; NINDS_000704; Armstrong Brand of Albendazole; Albenza; Disthelm; ((Propylthio)-5 1H-benzimidazolyl-2) carbamate de methyle; CARBAMIC ACID, (5-(PROPYLTHIO)-1H-BENZIMIDAZOL-2-YL)-, METHYL ESTER; STOCK2S-67946; TL8003543; A4673_FLUKA; I01-0380; Methyl 5-(propyl-thio)-2-benzimidazolecarbamate; BB_SC-1386; IDI1_000704; Albendazole Sanicoopa Brand; Noe Socopharm Brand of Albendazole; NCGC00022896-05; Digezanol; BSPBio_000034; Mediamix V Disthelm; SK&F-62979; Albendazolum; CAS-54965-21-8; Monohydrochloride, Albendazole; Pfizer Brand of Albendazole; EINECS 259-414-7; Hormona Brand of Albendazole; Methyl 5-(propylthio)-2-benzimidazolecarbamate; D015766; UNII-F4216019LN; HMS2090G19; NCGC00016876-02; STL046130; HMS1922K04; Smith Kline & French Brand of Albendazole; SK&F62979; CHEBI:16664; Albendazol; KBio1_000704; Liferpal Brand of Albendazole; Prestwick3_000247; methyl N-[6-(propylsulfanyl)-1H-1,3-benzodiazol-2-yl]carbamate; V Disthelm, Mediamix; Oprea1_585016; HMS502D06; AC1L1CVL; ZINC17146904; Prestwick0_000247; SKF-62979; HXHWSAZORRCQMX-UHFFFAOYSA-; HMS1568B16; ChemDiv1_000190; Noe-Socopharm Brand of Albendazole; Albendazole (JAN/USP/INN); KBioSS_002012; Diba Brand of Albendazole; BRD-K79131256-001-04-7; NCGC00016876-01; [5-(Propylthio)benzimidazol-2-yl]carbamic Acid Methyl Ester; Spectrum_001532; Fustery Brand of Albendazole; Albendazole Pfizer Brand; KBio2_004580; methyl [6-(propylsulfanyl)-1H-benzimidazol-2-yl]carbamate; SK&F 62979; Prestwick_675; LS-50618; Sanicoopa Brand of Albendazole; Valdecasas Brand of Albendazole; 5-(Propylthio)-2-carbomethoxyaminobenzimidazole; MolPort-000-760-571; Oprea1_640007; Eskazole; BIDD:GT0615; MLS000069722; SMR000036735; Prestwick1_000247; Proftril; AC1Q2YKD; methyl [5-(propylthio)-1H-benzimidazol-2-yl]carbamate; NCGC00022896-04; Prestwick2_000247; BPBio1_000038; Albendazole Diba Brand; MolPort-001-932-918; SPECTRUM1503903; Albendazole Hormona Brand; VU0239747-6; BIM-0051849.0001; Lurdex; Spectrum4_000201; Zentel; Gascop; Valbazen; Albendazol [INN-Spanish]; ChemDivAM_000003; Bilutac; ((Propylthio)-5 1H-benzimidazolyl-2) carbamate de methyle [French]; KBio2_002012; NCGC00022896-03; SAM002589939; STK387550; Albendazole Liferpal Brand; HSDB 7444; DB00518; Metiazol; AKOS000540882; DivK1c_000704; methyl N-(6-propylsulfanyl-1H-benzimidazol-2-yl)carbamate; Spectrum5_001567; Albendazole Noe-Socopharm Brand; Disthelm, Mediamix V; SKF62979; HMS587I14; methyl [5-(propylsulfanyl)-1H-benzimidazol-2-yl]carbamate; Albenza (TN); 54965-21-8; C01779; Zental	54965-21-8	2082	4909	TTDS00308	Tubulin beta	Beta-tubulin;Tubulin beta-1 chain	P07437	203068	ENSG00000196230; ENSG00000183311; ENSG00000235067; ENSG00000224156; ENSG00000229684; ENSG00000227739; ENSG00000232421; ENSG00000232575	binder
DCL000670	2-Methoxyestradiol	ESM; NSC-659853; PulmoLAR; C05302; 2-Hydroxyestradol 2-methyl ether; MolPort-003-927-295; CHEMBL299613; estra-1(10),2,4-triene-3,17-diol, 2-methoxy-, (17beta)-; Estra-1,3,5(10)-triene-3,17-diol, 2-methoxy-, (17beta)-; 2-Hydroxyestradiol 2-methyl ether; Lopac0_000739; Panzem NCD; ZINC03818826; M6383_SIGMA; Estra-1,3,5(10)-triene-3,17beta-diol, 2-methoxy-; 2,3,17beta-Trihydroxy-1,3,5(10)-estratriene 2-methyl ether; 362-07-2; Panzem; 2-Methoxyestra-1,3,5(10)-triene-3,17beta-diol; 2-Methoxyestradiol-17beta; 1,3,5(10)-Estratriene-2,3,17-triol 2-methyl ether; S1233_Selleck; NSC 659853; 2-ME2, 2-Methoxyestradiol; Estradiol, 2-methoxy-; M 6383; LS-64775; 2-MeOE2; AC1L25BI; CID66414; NCGC00094082-04; AC1Q7A32; I14-14338; (17beta)-2-Methoxyestra-1,3,5(10)-triene-3,17-diol; (8R,9S,13S,14S,17S)-2-methoxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol; MLS000028819; LMST02010035; 2ME2; EU-0100739; 3,17beta-Dihydroxy-2-methoxy-1,3,5(10)-estratriene; B3C40B85-1733-48FE-8418-A39011910D19; MLS001076279; 1,3,5(10)-ESTRATRIEN-2,3,17-BETA-TRIOL 2-METHYL ETHER; 2-Methoxyestradiol; SMP2_000045; (17beta)-2-methoxyestra-1(10),2,4-triene-3,17-diol; CHEBI:28955; SMR000058478	362-07-2	16760554	26759132	TTDS00308	Tubulin beta	Beta-tubulin;Tubulin beta-1 chain	P07437	203068	ENSG00000196230; ENSG00000183311; ENSG00000235067; ENSG00000224156; ENSG00000229684; ENSG00000227739; ENSG00000232421; ENSG00000232575	binder
DAP000949	Vindesine	Vindesin; Vindesine [USAN:INN:BAN]; Vindesine (USAN/INN); Vindesina; Vincaleukoblastine, 3-(aminocarbonyl)-O4-deacetyl-3-de(methoxycarbonyl)-; Vindesina [INN-Spanish]; MolPort-005-933-570; AC1L24KY; LS-162145; methyl (5S,7S,9S)-9-[(2beta,3beta,4beta,5alpha,12beta,19alpha)-3-carbamoyl-3,4-dihydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidin-15-yl]-5-ethyl-5-hydroxy-1,4,5,6,7,8,9,10-octahydro-2H-3,7-methanoazacycloundecino[5,4-b]indole-9-carboxylate; CHEMBL219146; DAVA; STOCK1N-75293; methyl (5S,7S,9S)-9-[(2b,3b,4b,5a,12b,19a)-3-carbamoyl-3,4-dihydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidin-15-yl]-5-ethyl-5-hydroxy-1,4,5,6,7,8,9,10-octahydro-2H-3,7-methanoazacycloundecino[5,4-b]indole-9-carboxylate; Vincaleukoblastine, 3-(aminocarbonyl)-O(sup 4)-deacetyl-3-de(methoxycarbonyl)-; UNII-RSA8KO39WH; CID40839; Vindesinum; Vindesinum [INN-Latin]; Vindesine [USAN:BAN:INN]; Lilly 112531; 3-Carbamoyl-4-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine; vindesine; D06304; EINECS 258-682-2; Desacetylvinblastine amide; Vincaleukoblastine, 23-amino-O(sup 4)-deacetyl-23-demethoxy-; 53643-48-4; 3-carbamoyl-O(4)-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine; HSDB 6961; NSC-245467; C43H55N5O7; HMS2090E15; 3-(aminocarbonyl)-O(4)-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine; DB00309; 3-(Aminocarbonyl)-O(sup 4)-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine; CHEBI:36373	59917-39-4	40839	181645	TTDS00308	Tubulin beta	Beta-tubulin;Tubulin beta-1 chain	P07437	203068	ENSG00000196230; ENSG00000183311; ENSG00000235067; ENSG00000224156; ENSG00000229684; ENSG00000227739; ENSG00000232421; ENSG00000232575	binder
DCL000333	Tasidotin hydrochloride	623174-20-9; BSF 223651; Tasidotin hydrochloride (USAN); Tasidotin hydrochloride; LU 223651; D06009; CID11479259; 848866-34-2; Tasidotin HCl; ILX 651	623174-20-9	11479259	47207667	TTDS00308	Tubulin beta	Beta-tubulin;Tubulin beta-1 chain	P07437	203068	ENSG00000196230; ENSG00000183311; ENSG00000235067; ENSG00000224156; ENSG00000229684; ENSG00000227739; ENSG00000232421; ENSG00000232575	binder
DAP000557	Vigabatrin	C6H11NO2; NCGC00024802-03; Vigabatrin (JAN/USAN/INN); .gamma.-Vinyl-.gamma.-aminobutyric acid; RMI-71890; Hoechst Brand of Vigabatrin; Lopac0_001277; CPP-109; KBio2_000848; BSPBio_003469; Vigabatrin [USAN:BAN:INN]; 74046-07-4; KBio3_002973; BPBio1_000925; gamma-Vinyl-gamma-Aminobutyric Acid; Yamanouchi Brand of Vigabatrin; Sabril; SpecPlus_000664; Vigabatrina [Spanish]; Vigabatrin Yamanouchi Brand; DB01080; Vigabatrine; C07500; gamma-Vinyl-GABA; D00535; NCGC00024802-06; Vigabatrinum [Latin]; Aventis Brand of Vigabatrin; MDL-71754; Vigabatrin Hoechst Brand; gamma Vinyl GABA; vigabatrin; CID5665; NCGC00024802-04; Vigabatrine [French]; M071754; KBio2_003416; MDL 71754; Sabril (TN); NCGC00024802-05; 4-aminohex-5-enoic acid; Prestwick2_000501; HMS1569F03; V8261_SIGMA; 5-Hexenoic acid, 4-amino-; ( inverted question mark)-gamma-Vinyl GABA; CHEMBL89598; (R,S)-4-Amino-5-hexenoic acid; Vigabatrina; 4-Aminohexenoic acid; AB00053309; 60643-86-9; RMI 71754; gamma-Vinyl GABA; RMI-71754; Vigabatrin Aventis Brand; Spectrum3_001825; NCGC00016087-08; BPBio1_000465; .gamma.-Vinyl-GABA; SPBio_002342; KBioSS_000848; gamma Vinyl gamma Aminobutyric Acid; MDL 71,754; Hexenoic acid, 4-amino; LS-75569; MolPort-003-666-796; Prestwick3_000501; GVG; 4-Amino-5-hexenoic acid; EU-0101277; SPECTRUM1502036; Sabrilex; Vigabatrin [USAN:INN:BAN]; Prestwick0_000501; DivK1c_006760; KBio1_001704; NCGC00024802-02; NCGC00016087-03; Spectrum_000368; D020888; Prestwick_837; 5-Hexenoic acid, 4-amino-, (+)-; Vigabatrinum; Acid, gamma-Vinyl-gamma-Aminobutyric; CHEBI:241484; (?)-gamma-Vinyl GABA; Biomol-NT_000247; HMS2094M21; Prestwick1_000501; BSPBio_000421; AC1L1KUZ; V 8261; KBio2_005984	60643-86-9	5665	183802	TTDS00024	4-aminobutyrate aminotransferase, mitochondrial	(S)-3-amino-2-methylpropionate transaminase;GABA aminotransferase;GABA transaminase;GABA-AT;GABA-T;Gamma-amino-N-butyrate transaminase;L-AIBAT	P80404	18	ENSG00000183044	inhibitor
DAP000556	Divalproex sodium	Depakote ER; Sodium hydrogen divalproate; Valproatum seminatricum; Sprinkle; 99-66-1 (Parent); CHEBI:4667; Sodium hydrogen bis(2-propylvalerate); Delepsine; S1703_Selleck; CID53519; Divalproate; Depakote (TN); pentanoic acid, 2-propyl-, sodium salt(2:1); D00304; Depakote Sprinkle; Valparin; Divalproex sodium (USP); Valcote; Depakote CP; Natrium hydrogen bis(2-propylvalerat); Valproate semisodique; Depakine chrono; AC1Q1VPW; Abbott-50711; Sodium divalproate; Sodium hydrogen bis(2-propylpentanoate); Valproate semisodium; Sodium hydrogen bis(2-propylvalerate), oligomer; Epival; Valproato semisodico; divalproex; Valdisoval; Divalproex sodium [USAN]; Semisodium Valproate; Valproic acid semisodium salt (2:1); Valproato semisodico [Spanish]; Valproate semisodique [French]; Divalproex sodium, Depakote, Epival; Abbott 50711; DIVALPROEX SODIUM; DB00510; Depakote; 76584-70-8; UNII-644VL95AO6; AC1Q1V4Q; sodium 2-propylpentanoate--2-propylpentanoic acid (1:1); Epilex; Pentanoic acid, 2-propyl-, sodium salt (2:1); Valproate semisodium (INN); LS-101863; I06-0339; sodium; 2-propylpentanoate; 2-propylpentanoic acid; Valproatum seminatricum [Latin]	76584-70-8	53519	7847370	TTDS00024	4-aminobutyrate aminotransferase, mitochondrial	(S)-3-amino-2-methylpropionate transaminase;GABA aminotransferase;GABA transaminase;GABA-AT;GABA-T;Gamma-amino-N-butyrate transaminase;L-AIBAT	P80404	18	ENSG00000183044	inhibitor
DAP000804	Pyridoxal Phosphate	MolPort-003-939-335; Pydoxal; SGCUT00188; Pyridoxal phosphate [JAN]; nchembio.266-comp20; Vitahexin-P; HI-Pyridoxin; PLP; Isonicotinaldehyde, 3-hydroxy-5-(hydroxymethyl)-2-methyl-, 5-(dihydrogen phosphate); pyridoxal phosphate; DB00114; 2-Methyl-3-hydroxy-4-formyl-5-hydroxymethylpyridine-5-calcium phosphate; Pyridoxal-5-monophosphate; Apolon B6; Pyridoxal 5-monophosphoric acid ester; 52064-48-9; Pal-P; 54-47-7; Pyridoxal 5'-phosphate monohydrate, vitamin B6; Hiadelon; Pyridoxal 5'-phosphate hydrate; 2-Methyl-3-hydroxy-4-formyl-5-hydroxymethylpyridine-5-calcium phosphate trihydrate; Apolon B(sub 6); 4-Formyl-5-hydroxy-6-methyl-pyridin-3-yl)methoxyphosphonic acid; bmse000111; Vitahexin P; to_000077; (4-formyl-5-hydroxy-6-methylpyridin-3-yl)methyl dihydrogen phosphate; Phosphopyridoxal coenzyme; Pyridoxaldehyde phosphate; pyridoxal-5P; (4-formyl-5-hydroxy-6-methyl-3-pyridinyl)methyl dihydrogen phosphate; Phosphoric acid mono-(4-formyl-5-hydroxy-6-methyl-pyridin-3-ylmethyl) ester; Coenzyme B6; NCGC00166300-01; pyridoxal  5-monophosphoric acid ester; Pyridoxal, 5-(dihydrogen phosphate); TL8005582; AC1Q2P2R; Piodel; 2-Methyl-3-hydroxy-4-formyl-5-pyridylmethylphosphoric acid; Pyridoxal monophosphate; pyridoxal-P; 3-Hydroxy-5-(hydroxymethyl)-2-methylisonicotinaldehyde 5-phosphate; Hairoxal; pyridoxal 5-phosphate; Codecarboxylase; Himitan; Pyromijin; Phosphoridoxal coenzyme; SRI 2392; Vitamin B6 phosphate; Pyridoxal, 5-(dihydrogen phosphate) (8CI); Hexermin P; 4-pyridinecarboxaldehyde, 3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]-; Vitazechs; Pyridoxal 5'-phosphate monohydrate - Vitamin B6; 52441-27-7; C00018; Pyridoxal 5'-(dihydrogen phosphate); P-5'-P; 4-Pyridinecarboxaldehyde, 3-hydroxy-2-methyl-5-((phosphonooxy)methyl)-; Pyrido; Pyridoxal P; 4-Pyridinecarboxaldehyde, 3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]- (9CI); NSC 82388; CID1051; Pyridoxal phosphate (6CI); Pyridoxal, 5-(dihydrogenphosphate); CHEMBL82202; Vitamin B6 phosphate (ester); Hexermin-P; nchembio.237-comp3; Pidopidon; EINECS 200-208-3; Phosphopyridoxal; SBB065295; AC1L1AM8; Pyridoxal-5'-phosphate; Sechvitan; nchembio861-comp1; Biosechs; 3-Hydroxy-2-methyl-5-((phosphonooxy)methyl)-4-pyridinecarboxaldehyde; Pyridoxal-5-Phosphate Hydrate; pyridoxal 5'-phosphate; 3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]-4-pyridinecarboxaldehyde; (4-Formyl-5-hydroxy-6-methyl(3-pyridyl))methyl dihydrogen phosphate; Sechvitan, Vitahexin P; NSC82388; Pyridoxyl phosphate; A26BDB6A-282A-4D13-A916-7B2B215B0FD6; Pyridoxal phosphate treated .beta.-lactoglobulin from bovine whey; PYRIDOXAL-5-PHOSPHATE; VITAMIN B6 COMPLEX; LS-134383; CHEBI:18405	54-47-7	1051	3320	TTDS00024	4-aminobutyrate aminotransferase, mitochondrial	(S)-3-amino-2-methylpropionate transaminase;GABA aminotransferase;GABA transaminase;GABA-AT;GABA-T;Gamma-amino-N-butyrate transaminase;L-AIBAT	P80404	18	ENSG00000183044	inhibitor
DAP000805	L-Alanine	Alanina [DCIT,Spanish]; Alanine [USAN:INN]; 25191-17-7; LS-15737; (S)-alpha-Aminopropionsaeure; CID5950; (C14)L-Alanine; nchembio.145-comp31; 2-Aminopropionic acid; AC-014; Propanoic acid, 2-amino-, (S)-; L-S-Aminopropionic acid; ALA; NCGC00024494-01; Poly-L-alanine; MolPort-003-925-460; alpha-Aminopropionic acid; 115967-49-2; (S)-2-Aminopropionic acid; F4F207FF-8FF8-4789-99A1-147AE0A36673; L-Alanine (JAN); Alanine, L- (7CI,8CI); L-Alanine, labeled with tritium; (L)-Alanine; (2S)-2-Aminopropanoic acid; L-Alanine, labeled with carbon-14; ALANINE, L-; NSC 206315; nchembio.255-comp3; L-2-Aminopropionsaeure; L-&alpha-alanine; AC1Q29HB; L-Alanine, N-coco alkyl derivs.; AB1002630; nchembio.237-comp9; InChI=1/C3H7NO2/c1-2(4)3(5)6/h2H,4H2,1H3,(H,5,6; Tocris-0205; (S)-(+)-Alanine; a-Alanine; L-2-Aminopropanoic acid; DB01786; CHEMBL279597; H-Ala-OH; (S)-()-Alanine; A7469_SIGMA; 130380-93-7; L-Alanine, homopolymer; Alanine (USP); A0179; bmse000028; L-alanine; alanina; alpha-Alanine; L-2-Aminopropionic acid; DB00160; L-Alanin; AC1Q29HA; L-alpha-alanine; 2-Aminopropanoic acid, L-; UNII-OF5P57N2ZX; L-alpha-Aminopropionic acid; L-a-Alanine; CHEBI:16977; nchem.554-comp3; L-(+)-Alanine; 6898-94-8; 05129_FLUKA; C00041; Poly-DL-alanine; 18875-37-1; HSDB 1801; Alaninum; I04-1136; (S)-2-Aminopropionsaeure; LPG; alanine; 170805-71-7; W381829_ALDRICH; AC1Q297C; (S)-2-Aminopropionic acid; L-|A-Aminopropionic acid; 759445-89-1; L-a-Aminopropionic acid; A7627_SIGMA; A4349_SIGMA; a-Aminopropionic acid; Propanoic acid, 2-amino-, (S); (S)-Alanine; 56-41-7; AC1L1LHC; L-Alanine (9CI); EINECS 200-273-8; polyalanine; 14C-L-Alanine; (S)-2-Aminopropanoic acid; nchembio816-comp4; AmbotzHAA1066; Alaninum [Latin]; 787635-21-6; AR-1J2938; D00012; Alanine (VAN)	56-41-7	5950	627087	TTDS00024	4-aminobutyrate aminotransferase, mitochondrial	(S)-3-amino-2-methylpropionate transaminase;GABA aminotransferase;GABA transaminase;GABA-AT;GABA-T;Gamma-amino-N-butyrate transaminase;L-AIBAT	P80404	18	ENSG00000183044	inhibitor
DAP000543	Pyruvic acid	1892-67-7; P76209_ALDRICH; BTS; 2-oxo-propionic acid; AB1002748; NCGC00165990-01; alpha-Oxopropionsaeure; AC1L1AMZ; CHEMBL1162144; NSC179; P0579; Pyruvic acid; CH3COCOOH; 2-Oxopropanoic acid; EINECS 204-824-3; .alpha.-Ketopropionic acid; |A-Ketopropionic acid; 2-Oxopropionic acid; AI3-11220; LS-2371; acide pyruvique; AC1Q1J9Y; B3CFF0AD-2F35-484C-B062-4AC88A1B2830; AR-1E4599; C00022; BRN 0506211; Pyruvic acid (8CI); BB_SC-7199; bmse000112; 2-oxo(1-14c)propanoic acid; LMFA01060077; NChemBio.2007.20-comp11; 4-03-00-01505 (Beilstein Handbook Reference); nchembio.237-comp20; NCIOpen2_000039; Pyruvic acid (natural); Propanoic acid, 2-oxo-; 2-Ketopropionic acid; Brenztraubensaeure; 2-Oxopropionsaeure; alpha-ketopropionic acid; a-Ketopropionic acid; 107360_ALDRICH; 2-Oxopropanoate; P-9250; nchembio867-comp8; CHEBI:32816; DB00119; 127-17-3; MolPort-001-779-763; W297003_ALDRICH; 2-Oxopropionic acid; InChI=1/C3H4O3/c1-2(4)3(5)6/h1H3,(H,5,6; alpha-keto propionic acid; CID1060; Pyroracemic acid; W297070_ALDRICH; AC1Q1JAT; nchembio.266-comp21; AKOS000118803; FEMA No. 2970; I04-0222; acetylformic acid; NSC 179; Propanoic acid, 2-oxo- (9CI); 2-Oxopropansaeure	127-17-3	1060	3324	TTDS00024	4-aminobutyrate aminotransferase, mitochondrial	(S)-3-amino-2-methylpropionate transaminase;GABA aminotransferase;GABA transaminase;GABA-AT;GABA-T;Gamma-amino-N-butyrate transaminase;L-AIBAT	P80404	18	ENSG00000183044	inhibitor
DAP001431	Tetracaine	4-14-00-01172 (Beilstein Handbook Reference); Tetracainum; AC-3480; Pontocaine; Diaethylaminoaethanol ester der p-butylaminobenzoesaeure; 4-[Butylamino]benzoic acid-2-[dimethylamino]ethyl ester; NCGC00016049-02; NINDS_000607; tetracaine; 2-dimethylaminoethyl 4-(butylamino)benzoate; Uromucaesthin; 136-47-0 (mono-hydrochloride); CAS-136-47-0; 2-(Dimethylamino)ethyl 4-(butylamino)benzoate; Prestwick0_000571; Tetracaina; SPBio_002601; Dicaine; Prestwick1_000571; KBio2_001512; NCGC00162367-01; Spectrum_001032; BRD-K45071273-003-05-8; Dicain; Spectrum2_001328; T7383_SIAL; KBio3_001444; KBio2_006648; NCGC00016049-04; Prestwick3_000571; BSPBio_001944; Mucaesthin; Tetracaina [INN-Spanish]; Spectrum5_001072; Spectrum4_000351; Prestwick2_000571; Laudocaine; D00551; Medihaler-Tetracaine; Dikain; Lopac0_001211; I01-1872; BSPBio_000382; KBioSS_001512; CHEBI:9468; SPBio_001455; NCGC00016049-01; C15H24N2O2; C07526; Fissucain; SBB058194; T3812_SIAL; 4-(Butylamino)benzoic acid 2-(dimethylamino)ethyl ester; BENZOIC ACID,4-BUTYLAMINO,2-DIMETHYLAMINOETHYL ESTER   PANTOCAIN BASE; Lopac-T-7508; InChI=1/C15H24N2O2/c1-4-5-10-16-14-8-6-13(7-9-14)15(18)19-12-11-17(2)3/h6-9,16H,4-5,10-12H2,1-3H; EINECS 202-316-6; Amethocaine; AC1L1KAQ; Benzoic acid, 4-(butylamino)-, 2-(dimethylamino)ethyl ester; Dimethylaminoethyl p-butyl-aminobenzoate; MolPort-001-783-476; 2-(Dimethylamino)ethyl p-(butylamino)benzoate; Contralgin; Tetrakain [Czech]; Tetrakain; LS-36312; DivK1c_000607; Meethobalm; Tetracaine (USP/INN); AB00053549; Anetain; Metraspray; Rexocaine; Medicaine; p-Butylaminobenzoyl-2-dimethylaminoethanol; UNII-0619F35CGV; Tetracainum [INN-Latin]; Tetracaine [USAN:INN]; CHEMBL698; T7383_SIGMA; BENZOIC ACID, p-(BUTYLAMINO)-, 2-(DIMETHYLAMINO)ETHYL ESTER; KBioGR_000781; CID5411; Niphanoid; 2-Dimethylaminoethylester kyseliny p-butylaminobenzoove; p-(Butylamino)benzoic acid, 2-(dimethylamino)ethyl ester; KBio2_004080; IDI1_000607; KBio1_000607; 2-Dimethylaminoethylester kyseliny p-butylaminobenzoove [Czech]; BPBio1_000422; Spectrum3_000562; Diaethylaminoaethanol ester der p-butylaminobenzoesaeure [German]; Amethocaine (TN); 94-24-6; Intercain; BRN 2216051	94-24-6	5411	9729	TTDS00157	Voltage-gated sodium channel subunit alpha Nav1.8	PN3;SNS;Transient tetrodotoxin-resistant Na+ current;TTX-R sodium channel;TTX-R/NaV1.8;Voltage-gated sodium channel NaV1.8	Q9Y5Y9	6336	ENSG00000185313	inhibitor
DCL000998	SPI-860	N/A	51012-32-9	5467	49698930	TTDS00157	Voltage-gated sodium channel subunit alpha Nav1.8	PN3;SNS;Transient tetrodotoxin-resistant Na+ current;TTX-R sodium channel;TTX-R/NaV1.8;Voltage-gated sodium channel NaV1.8	Q9Y5Y9	6336	ENSG00000185313	inhibitor
DCL000037	AM103	N/A	133454-47-4	71360	48404440	TTDC00062	5-lipoxygenase activating protein	FLAP;MK-886-binding protein	P20292	241	ENSG00000132965	inhibitor
DCL000104	DG031	CHEBI:244761; Benzeneacetic acid, alpha-cyclopentyl-4-(2-quinolinylmethoxy)-, (R)-; 128253-31-6; Bay X1005; Bay-x-1005; Veliflapon (USAN/INN); LS-172700; Bayx-1005; Bay X 1005; Bay-X1005; AC1L3X6M; CID123723; (2R)-2-cyclopentyl-2-[4-(quinolin-2-ylmethoxy)phenyl]acetic acid; Veliflapon; CHEMBL88712; 2-(4-(quinolin-2-yl-methoxy)phenyl)-2-cyclopentylacetic acid; CID9896918; D06664; C079315; C23H23NO3; DG-031	N/A	119032	39750278	TTDC00062	5-lipoxygenase activating protein	FLAP;MK-886-binding protein	P20292	241	ENSG00000132965	inhibitor
DCL000413	GSK2190915	N/A	83928-76-1	55191	47206241	TTDC00062	5-lipoxygenase activating protein	FLAP;MK-886-binding protein	P20292	241	ENSG00000132965	inhibitor
DCL000039	AM803	N/A	N/A	3692	47365323	TTDC00062	5-lipoxygenase activating protein	FLAP;MK-886-binding protein	P20292	241	ENSG00000132965	inhibitor
DCL000203	PTC299	N/A	72873-74-6	5228	48259039	TTDS00339	Vascular endothelial growth factor	Vascular endothelial cell growth factor;VEGF	N/A	N/A	N/A	inhibitor
DCL000736	Cand 5	N/A	N/A	N/A	N/A	TTDS00339	Vascular endothelial growth factor	Vascular endothelial cell growth factor;VEGF	N/A	N/A	N/A	inhibitor
DCL000523	Erlotinib+Bevacizumab	N/A	N/A	N/A	N/A	TTDS00339	Vascular endothelial growth factor	Vascular endothelial cell growth factor;VEGF	N/A	N/A	N/A	antibody
DCL000495	Bevacizumab+Erlotinib	N/A	N/A	N/A	N/A	TTDS00339	Vascular endothelial growth factor	Vascular endothelial cell growth factor;VEGF	N/A	N/A	N/A	inhibitor
DCL000497	Bevacizumab+Trastuzumab	N/A	434-13-9	9903	49698644	TTDS00339	Vascular endothelial growth factor	Vascular endothelial cell growth factor;VEGF	N/A	N/A	N/A	inhibitor
DCL001004	SU5416	SU 5416; NCGC00094381-02; CHEMBL276711; 3-((Z)-(3,5-Dimethylpyrrol-2-yl)methylene)-2-indolinone; HMS3229O13; 3-[(2,4-dimethylpyrrol-5-yl)methylidenyl]indolin-2-one; CID5329098; 204005-46-9; AC1NS627; SU5416; Semaxanib; 3-[(2,4-Dimethylpyrrol-5-yl)methylidene]-indolin-2-one; MLS001332520; 3-(1-(3,5-Dimethyl-1H-pyrrol-2-yl)meth-(Z)-ylidene)-2-oxo-2,3-dihydroindole; 1,3-Dihydro-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-2H-indol-2-one; 2H-Indol-2-one, 3-((3,5-dimethyl-1H-pyrrol-2-yl)methylene)-1,3-dihydro-, (3Z)-; Semaxinib; NSC696819; (3Z)-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-1H-indol-2-one; BRD-K63504947-001-05-5; UNII-71IA9S35AJ; Semaxnib; 3-(2,4-dimethylpyrrol-5-yl)methylidene-indolin-2-one; MLS001332519; SMR000568416; LS-83886; NCGC00094381-03; NSC-696819; S8442_SIGMA; InSolution&trade; VEGF Receptor 2 Kinase Inhibitor III; LS-193151; 1,3-Dihydro-3-[(3,5-dimethyl-1H-pyrrol-2-yl); Lopac0_001110; Semoxind; VEGF Receptor 2 Kinase Inhibitor III; 194413-58-6; C116890; nchembio778-comp2; 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one; MLS001074896; MolPort-003-959-606; NCGC00094381-01; SU-5416; Semaxanib (USAN/INN); NCGC00094381-04; methylene]-2H-indol-2-one; 2H-Indol-2-one, 3-[(3,5-dimethyl-2-pyrrolyl)methylene]-; (3Z)-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one; 2H-Indol-2-one, 3-((3,5-dimethyl-1H-pyrrol-2-yl)methylene)-1,3-dihydro-, (Z)-; S 8442; EU-0101110; TSU-16; HSCI1_000303; H-Indol-2-one, 3-((3,5-dimethyl-1H-pyrrol-2-yl)methylene)-1,3-dihydro-; D05819	204005-46-9	166553	26759729	TTDS00339	Vascular endothelial growth factor	Vascular endothelial cell growth factor;VEGF	N/A	N/A	N/A	inhibitor
DCL000496	Bevacizumab+Rituximab	N/A	7447-41-8	3028194	49746180	TTDS00339	Vascular endothelial growth factor	Vascular endothelial cell growth factor;VEGF	N/A	N/A	N/A	inhibitor
DCL001152	AT001/r84	N/A	N/A	N/A	N/A	TTDS00339	Vascular endothelial growth factor	Vascular endothelial cell growth factor;VEGF	N/A	N/A	N/A	antibody
DAP001259	Pegaptanib	N/A	222716-86-1	N/A	46504497	TTDS00339	Vascular endothelial growth factor	Vascular endothelial cell growth factor;VEGF	N/A	N/A	N/A	N/A
DCL000654	TAK-593	N/A	N/A	N/A	N/A	TTDS00339	Vascular endothelial growth factor	Vascular endothelial cell growth factor;VEGF	N/A	N/A	N/A	inhibitor
DCL000443	Avastin+/-Tarceva	N/A	481-39-0	3806	48504565	TTDS00339	Vascular endothelial growth factor	Vascular endothelial cell growth factor;VEGF	N/A	N/A	N/A	inhibitor
DCL001034	VEGF Trap	N/A	N/A	2092	49699344	TTDS00339	Vascular endothelial growth factor	Vascular endothelial cell growth factor;VEGF	N/A	N/A	N/A	inhibitor
DAP000393	Bevacizumab	Bevacizumab (genetical recombination) (JAN); Avastin (TN); Avastin; Bevacizumab; Bevacizumab (genetical recombination); D06409; 216974-75-3	216974-75-3	N/A	47208066	TTDS00339	Vascular endothelial growth factor	Vascular endothelial cell growth factor;VEGF	N/A	N/A	N/A	antibody
DAP000198	L-Proline	CHEBI:17203; Proline (VAN); 81710_SIGMA; bmse000047; CHEMBL54922; nchembio.186-comp54; DB02853; AC1Q71B7; Proline [USAN:INN]; 147-85-3; Carboxypyrrolidine; 81709_SIGMA; L-alpha-Pyrrolidinecarboxylic acid; 608998_ALDRICH; (-)-Proline; 2-Pyrrolidinecarboxylic acid, (S)-; C00148; FEMA Number 3319; L-Pyrrolidine-2-carboxylic acid; FEMA No. 3319; A01B5B63-CC3D-4796-A7B4-C2DE26A6FA93; (S)-Proline; P0481; 18875-45-1; nchembio816-comp9; TL80073505; AB1002323; NCGC00014017; (S)-2-Carboxypyrrolidine; CB 1707; 2-pyrrolidinecarboxylic acid; W331902_ALDRICH; EINECS 205-702-2; Proline (USP); (S)-Pyrrolidine-2-carboxylic acid; P8865_SIAL; LS-2381; AmbotzHAA1126; pro; (2S)-pyrrolidine-2-carboxylic acid; L-(2,3-3H)Proline; P0380_SIAL; L-proline; proline; AC1L3RTC; (-)-Proline (S)-2-Carboxypyrrolidine; H-Pro-OH; MolPort-001-757-108; PRO (IUPAC abbreviation); UNII-9DLQ4CIU6V; L-Prolin; Prolinum [Latin]; 4607-28-7; AI3-26710; Prolina [Spanish]; HSDB 1210; P5607_SIGMA; (L)-PROLINE; NCGC00097126-01; NSC-97923; 81709_FLUKA; P8865_SIGMA; (-)-2-Pyrrolidinecarboxylic acid; (S)-2-Pyrrolidinecarboxylic acid; AC-11190; 4305-67-3; 81710_FLUKA; (-)-(S)-Proline; L-Proline, labeled with carbon-14; L-Proline (JAN); CID145742; Proline, L-; D00035; NSC 46703; L-Proline-15N; 37159-97-0; DB00172; Prolinum; L-(-)-Proline; prolina	147-85-3	145742	3448	TTDS00323	Peptidyl-prolyl cis-trans isomerase A	Cyclophilin A;Cyclosporin A-binding protein;CyPA;PPIase;Rotamase	P62937	5478	ENSG00000196262	binder
DAP001193	Sulfanilamide	Sulfanilamide [INN:DCF]; KBio2_006105; Albexan; F 1162; Streptosil; Lusil; SAN; KBioSS_000969; KBio2_000969; BRN 2698014; Dipron; NCGC00016285-01; Tolder; Benzenesulfonamide, 4-(bis(2-bromoethyl)amino)- (9CI); Sulfanilamide, N(sup 4),N(sup 4)-bis(2-bromoethyl)-; Sanamid; Sulfana; AVC (TN); Spectrum4_000398; ZINC00002101; Prontalbin; 63-74-1; Therapol; F-1162; Sulfanilamide, N4,N4-bis(2-bromoethyl)-; 10103-15-8 (hydrochloride salt); AB1002011; Pysococcine; 1162 F; InChI=1/C6H8N2O2S/c7-5-1-3-6(4-2-5)11(8,9)10/h1-4H,7H2,(H2,8,9,10; 12765-80-9; Sulfanilamide Vaginal Cream; Prestwick0_000729; KBio2_003537; Septolix; Stramid; Sulfanilamida [INN-Spanish]; Streptopan; Sulfanidyl; BPBio1_000724; D08543; EINECS 200-563-4; S0119; 4-Aminophenylsulfonamide; IDI1_000528; Sulphonamide; Streptocom; Caswell No. 809A; Sulfanalone; 4-Aminobenzene-1-Sulfonamide; HMS2092E20; Streptocid; Streptocidum; p-Aminobenzenesulfamide; EPA Pesticide Chemical Code 077902; Septamide Album; Benzenesulfonamide, 4-amino-; LS-147746; Sulfanilimidic acid; Bactesid; AB00052138; 4-Sulfamoylaniline; Sulfanilamidum [INN-Latin]; Proseptine; NCGC00091144-01; SPECTRUM1500646; MolPort-000-871-476; Oprea1_273157; N4,N4-Bis(2-bromoethyl)sulfanilamide; Sulphanilamide Extra Pure; Copticide; NCGC00091144-03; BIDD:GT0170; Proseptol; 4-[bis(2-bromoethyl)amino]benzenesulfonamide; Lysococcine; Sulphanilamide Gr; Solfanilamide; HMS1570A20; NSC77647; 102489-34-9; BRN 0511852; CHEMBL21; Exoseptoplix; Antistrept; Sulfonylamide; Streptrocide; Sulfanilamide, N(sup4),N(sup4)-bis(2-bromoethyl)-; Ergaseptine; Strepamide; Sulfanilamide (INN); 6101-31-1 (hydrochloride); AKOS000119305; Bacteramid; CID70386; Streptocide; Sulfanil; Collomide; Infepan; Gombardol; p-Aminobenzenesulfonamide; LS-274; S1685_Selleck; KBioGR_000955; Septanilam; NINDS_000528; Aniline-p-sulfonic amide; Astrocid; SPBio_002597; Sulfamine; Albosal; Colsulanyde; Gerison; Spectrum_000489; NSC 7618; Prestwick3_000729; Prontosil White; 33626_SIAL; Streptocide White; CID5333; Streptamin; Orgaseptine; DB00259; Streptocid (TN); NCGC00091144-02; Pronzin Album; Strepsan; Estreptocida; BSPBio_000658; Benzenesulfonamide, 4-(bis(2-bromoethyl)amino)-; 4-(Bis(2-bromoethyl)amino)benzenesulfonamide; Erysipan; Sulfonamide P; 46874_FLUKA; Deseptyl; Astreptine; Stopton Album; PABS; STK298902; Rubiazol A; AC1Q51Y6; WLN: ZSWR DN2E2E; Sulfocidine; N(sup 4),N(sup 4)-Bis(2-bromoethyl)sulfanilamide; AC1L2DZ8; NSC7618; HMS501K10; Sulfonamide; C07458; C6H8N2O2S; HMS1921O07; AI3-00952; Solfanilamide [DCIT]; 4-Aminobenzenesulfonamide; p-Sulfamidoaniline; 1337-36-6; 1337-39-9; AC1L1K4E; Streptocide (VAN); Benzenesulfonamide, 4-[bis(2-bromoethyl)amino]-; p-Aminophenylsulfonamide; Sulfanilamide, N4,N4-bis(2-bromoethyl)- (8CI); Streptol; Sulfamidyl; Spectrum3_001406; p-Aminobenzenesulfonylamide; I06-0505; KBio3_002272; Prestwick_36; AVC; WLN: ZSWR DZ; KBio1_000528; Prestwick2_000729; aromatic/heteroaromatic sulfonamide 2; S9251_SIAL; Streptagol; CCRIS 764; Streptoclase; Spectrum5_001081; Ro13354; Prontosil Album; CAS-63-74-1; Streptozol; Streptozone; Sulfanilamidum; S0381; sulfanilamide; SMR000059035; BSPBio_003052; p-Sulfamoylaniline; AC-907/25014139; White streptocide; Proseptal; Prontosil I; DivK1c_000528; Sulfanilamide,; Strepton; p-Aminobenzensulfonamide; BENZENESULFONIC ACID,4-AMINO,AMIDE   SULFANILAMIDE; p-Anilinesulfonamide; Septoplex; NSC 77647; BB_SC-1483; 4-14-00-02658 (Beilstein Handbook Reference); 24706-25-0; Desseptyl; Sulphanilamide; Sulfocidin; Prestwick1_000729; UNII-21240MF57M; HSDB 223; MLS001074682; Ambeside; CHEBI:45373; NCIOpen2_008781; Prontylin; 955-79-3; I.C. 56; SPBio_000831; Fourneau 1162; AAS; 46874_RIEDEL; Sulfanilamida; Streptocid album; Septoplix; N(sup4),N(sup4)-Bis(2-bromoethyl)sulfanilamide; MLS002152940; 33626_RIEDEL; Septinal; Streptasol; Neococcyl; Streptamid; A-349; Spectrum2_000846; Benzenesulfonamide, p-amino-	63-74-1	5333	9661	TTDS00450	Mannose-6-phosphate isomerase	Phosphohexomutase;Phosphomannose isomerase;PMI	P34949	4351	ENSG00000178802	inhibitor
DAP001191	Sulfacetamide	N(sup 1)-Acetyl-4-aminophenylsulfonamide; NCGC00021857-05; Sulfair; Klaron; STK068185; KBio2_006600; N'-Acetylsulfanilamide; Sulfair-15; Solfacetamide [DCIT]; Ocusulf-10; Acetocid; KBio1_000227; Oclucid; AI3-26837; N-(4-Aminobenzenesulfonyl)acetamide; CCRIS 6273; WLN: ZR DSWMV1; Steramide; SAM002554931; FML-S; 127-56-0 (mono-hydrochloride salt, anhydrous); N-Sulfanilylacetamide; Isopto cetamide; 4-14-00-02662 (Beilstein Handbook Reference); AC-7630; IDI1_000227; N1-Acetylsulfanilamide; CHEMBL455; NSC63871; Caswell No. 808A; N-[(p-Aminophenyl)sulfonyl]acetamide; EINECS 205-640-6; BPBio1_000053; ARONIS022108; Sulphacetamide; N-Acetylsulfanilamide; Sulfacyl (VAN); KBio3_001993; NINDS_000227; Cetamide; DB00634; KBio2_004032; BB_SC-5547; SULSTER; Sulfacetamide sodium; Sodium sulamyd; NCGC00021857-04; AKOS000119729; CBChromo1_000180; KBioGR_001691; Sulphacetamidum; AC1L1K3B; Oprea1_810285; I14-13294; MolPort-000-900-614; Prestwick0_000014; Albamine; Bleph-10 liquifilm; OP-Sulfa 30; Sulfacetamide [USAN:INN]; Sulfanilazetamid; Sulamyd; Region; Sulfanilacetamide; NSC 63871; Sulfanilamide, N(sup 1)-acetyl-; NCGC00021857-03; N(sup 1)-Acetylsulfanilamide; Spectrum_000984; HMS1921A11; CHEBI:102525; Sulfacyl; N-[(4-Aminophenyl)sulfonyl]acetamide; Acetosulfamin; Sulfacetamide Monosodium Salt; Sulphasil; N(sup1)-Acetylsulfanilamide; Sulfacel-15; I-Sulfacet; N-Sulphanilylacetamide; SPBio_001415; KBioSS_001464; Sulfacetamidum; Sulfacetamida; EPA Pesticide Chemical Code 077904; CPD000058173; p-Aminobenzenesulfonoacetamide; Sulf-10; Sulfanilazetamid [German]; Steri-Units Sulfacetamide; N-(4-Aminophenylsulfonyl)acetamide; Ophthacet; Spectrum4_001146; D05947; Acetamide, N-[(4-aminophenyl)sulfonyl]-; N-(4-aminophenyl)sulfonylacetamide; N-Acetyl-4-aminobenzenesulfonamide; BRN 0981718; 144-80-9; A-500; Acetamide, N-((4-aminophenyl)sulfonyl)-; HMS500L09; N-((p-Aminophenyl)sulfonyl)acetamide; SMR000058173; Formosulfacetamide; Urosulfone; MLS001076499; Ak-Sulf; Urosulfon; CID5320; Sulfacet; S8627_SIGMA; HMS2092I13; SPBio_001968; Sulfacylum; sulfacetamide; Sodium sulfacetamide; BSPBio_000047; MLS000069710; SPECTRUM1500545; Prestwick1_000014; Acetamide, N-sulfanilyl-; Sulfair 15; Bleph-10; Sulfacetamide Sodium Usp; NCGC00018242-01; Spectrum5_001230; Sulfacetamide sodium anhydrous; UNII-4965G3J0F5; Albucid; Sulfacil; Solfacetamide; Oprea1_686524; Prestwick3_000014; KBio2_001464; Sebizon; 46770_RIEDEL; N -Acetylsulfanilamide; NCIOpen2_002838; N-((4-Aminophenyl)sulfonyl)acetamide; Ophthel-S; ZINC00057500; Spectrum2_001318; Isopto-Cetamide; Acetosulfamine; Sulfacetamide (USP/INN); Sulfacetamida [INN-Spanish]; p-Aminobenzenesulfonacetamide; DivK1c_000227; Sulphacetamide sodium; N-Acetylsulfanilamine; Sulten-10; 46770_FLUKA; CBDivE_013934; BSPBio_002773; Prestwick2_000014; Sultrin; Alesten; Spectrum3_001017; Sulf-15; LS-852; Sulfacetimide; Sulfacetamidum [INN-Latin]	144-80-9	5320	152109	TTDS00450	Mannose-6-phosphate isomerase	Phosphohexomutase;Phosphomannose isomerase;PMI	P34949	4351	ENSG00000178802	inhibitor
DAP001192	Sulfoxone	DB01145; Sodium sulfoxone; Aldapsone; Adesulfone sodium; Diamidin; KST-1A1474; AR-1A9274; Diason; CID5351; UNII-0G3C18OH4D; [sulfonylbis(4,1-phenyleneimino)]dimethanesulfinic acid; Aldesulfon; sulfoxone; Diazon; Sodium aldesulphone; [4-[4-(sulfinomethylamino)phenyl]sulfonylanilino]methanesulfinic acid; 14668-39-4; LS-187179; CHEMBL1570; Methanesulfinic acid, (sulfonylbis(4,1-phenyleneimino))bis-; Diasone sodium enterab; AC1Q6YP0; Novotrone; AC1L1K5Q	144-75-2	5351	152108	TTDS00450	Mannose-6-phosphate isomerase	Phosphohexomutase;Phosphomannose isomerase;PMI	P34949	4351	ENSG00000178802	inhibitor
DAP000004	Dasatinib	302962-49-8; LS-186641; MolPort-003-846-143; EC-000.2122; LS-187773; BCB03_000715; CHEBI:49375; 1N1; UNII-X78UG0A0RN; BMS-354825, Sprycel, BMS354825, Dasatinib; 2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)-N-(2-chloro-6-methylphenyl)thiazole-5-carboxamide; SPRYCEL (TN); nchembio.117-comp11; Sprycel; Dasatinib anhydrous; S1021_Selleck; NSC-732517; CHEMBL1421; LS-187028; N-(2-CHLORO-6-METHYLPHENYL)-2-({6-[4-(2-HYDROXYETHYL)PIPERAZIN-1-YL]-2-METHYLPYRIMIDIN-4-YL}AMINO)-1,3-THIAZOLE-5-CARBOXAMIDE; N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)thiazole-5-carboxamide; FT-0084503; Dasatinib (USAN); CID3062316; N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carboxamide; Kinome_3650; I14-1972; BMS354825; dasatinibum; 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-; AC1MI3ET; BMS 354825; N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide; AC1Q2P0C; D03658; Dasatinib, BMS 354825; EN002710; C488369; nchembio.162-comp4; 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-; (18F)-N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide; DB01254; N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide, monohydrate; Spyrcel; NCGC00181129-01; Dasatinib; BMS-354825; AmbotzLS-1203; nchembio.332-comp1; NSC732517; Dasatinib [USAN]	302962-49-8	3062316	10061134	TTDS00406	Proto-oncogene tyrosine-protein kinase Fyn	FYN;p59-Fyn;Protooncogene Syn;SLK	P06241	2534	ENSG00000010810	inhibitor
DCL001153	ATL1102	N/A	N/A	N/A	N/A	TTDR00217	mRNA of VLA-4	N/A	N/A	N/A	N/A	antisense
DCL000102	Darapladib	D03650; SB 480848; Darapladib (USAN); 356057-34-6; CHEBI:100154; CHEMBL204021; UNII-UI1U1MYH09; CID9939609; Darapladib	356057-34-6	9939609	17397748	TTDC00116	Platelet-activating factor acetylhydrolase	1-alkyl-2-acetylglycerophosphocholine esterase;2-acetyl-1-alkylglycerophosphocholine esterase;LDL-associated phospholipase A2;LDL-PLA(2);Lipoprotein-associated phospholipase A2;PAF 2-acylhydrolase;PAF acetylhydrolase	Q13093	7941	ENSG00000146070	inhibitor
DCL000022	GSK 659032	N/A	N/A	N/A	N/A	TTDC00116	Platelet-activating factor acetylhydrolase	1-alkyl-2-acetylglycerophosphocholine esterase;2-acetyl-1-alkylglycerophosphocholine esterase;LDL-associated phospholipase A2;LDL-PLA(2);Lipoprotein-associated phospholipase A2;PAF 2-acylhydrolase;PAF acetylhydrolase	Q13093	7941	ENSG00000146070	inhibitor
DCL000625	Rilapladib	CID9918381; Rilapladib; CID 9918381; 412950-08-4; D05728; SB 659032; Rilapladib (USAN); UNII-O14CWE893Z	194085-75-1	6918474	47207389	TTDC00116	Platelet-activating factor acetylhydrolase	1-alkyl-2-acetylglycerophosphocholine esterase;2-acetyl-1-alkylglycerophosphocholine esterase;LDL-associated phospholipase A2;LDL-PLA(2);Lipoprotein-associated phospholipase A2;PAF 2-acylhydrolase;PAF acetylhydrolase	Q13093	7941	ENSG00000146070	inhibitor
DAP000199	Tranexamic Acid	1ceb; BSPBio_002837; KBioSS_001871; Carxamin; cis-4-Aminomethylcyclohexane-1-carboxylic acid; Spiramin; STK503668; AB1003647; trans-4-(Aminomethyl)cyclohexane-carboxylic acid; trans-Amcha; Acidum tranexamicum; Acide tranexamique [INN-French]; Acidum tranexamicum [INN-Latin]; DV79; ALBB-006013; NCGC00094944-02; trans-p-(Aminomethyl)cyclohexanecarboxylic acid; KBio3_002337; Spectrum4_000046; IDI1_000655; NINDS_000655; Prestwick3_000171; CL-65336; AC-4687; Rikavarin (TN); HMS1568D03; BAY 3517; Anvitoff; KBio2_007007; Tranhexamic acid; AC1Q50F3; STOCK1N-16183; Trasamlon; Trans AMCHA; AC1Q546D; tranexamic acid; AR-1F6595; Transamin (TN); LT00159441; Hexapromin; 4-(Aminomethyl)cyclohexanecarboxylic acid; Cyclohexanecarboxylic acid, 4-(aminomethyl)-, trans-; Trans-1-(Aminomethyl)cyclohexane-4-carboxylic acid; Trans-4-(Aminomethyl)-1-cyclohexanecarboxylic acid;; MolPort-002-512-008; AMCA; Acido tranexamico; trans-Tranexamic acid; KABI 2161; 1197-18-8; Cyclohexanecarboxylic acid, 4-(aminomethyl)-, trans-; EINECS 214-818-2; Frenolyse; Tranexamic acid [USAN:INN:BAN:JAN]; MolPort-001-792-390; 857653_ALDRICH; Amikapron; trans-4-(Aminomethyl)-1-cyclohexanecarboxylic acid; 1197-17-7; Exacyl; CID5526; CHEBI:48669; D01136; trans-1-(Aminomethyl)cyclohexane-4-carboxylic acid; Cyklokapron (TN); LS-56612; KBio2_001871; DV-79; DivK1c_000655; Amstat; KBio2_004439; BSPBio_000061; NSC 291305; Transamin; Acido tranexamico [INN-Spanish]; Cyclocapron; Spectrum3_001189; SPECTRUM1502026; Prestwick2_000171; BRN 2207452; Ugurol; trans-4-(Aminomethyl)cyclohexanecarboxylic acid ester; RP 18,429; HMS502A17; AMH; CAS-1197-18-8; Tranex; 4-(aminomethyl)cyclohexane-1-carboxylic acid; NCGC00016569-01; Emorhalt; Cyklokapron; trans-4-(Aminomethyl)cyclohexane-1-carboxylic acid; CL 65336; Rikavarin; 4-(Aminomethyl)cyclohexanecarboxylic acid; DB00302; Spectrum5_001258; Tranexamic acid (JP15/USAN/INN); NSC291305; CHEMBL292500; Prestwick0_000171; BPBio1_000069; WLN: L6TJ AVQ D1Z -T; trans-1-Aminomethylcyclohexane-4-carboxylic acid; NCGC00016569-03; I04-0993; trans-4-(Aminomethyl)cyclohexanecarboxylic acid; Oprea1_786414; t-AMCHA; NCGC00094944-01; Tranexamic acid cis-form; Acide tranexamique; Trans-4-(Aminomethyl)cyclohexane-1-carboxylic acid; Trans-4-(Aminomethyl)cyclohexanecarboxylic acid; Trans-4-(Aminomethyl)cyclohexanecarboxylic acid ester; Trans-p-(Aminomethyl)cyclohexanecarboxylic; Spectrum_001391; Hexatron; AC1L1KJH; A0236; Rikavarin-S; Prestwick1_000171; Transamlon; LS-56611; Tamcha; 4-(Aminomethyl)-Cyclohexanecarboxylic Acid; HMS2092P03; Tranexamsaeure; cis-4-(Aminomethyl)cyclohexanecarboxylic acid; SPBio_000689; DV 79; cis-AMCHA; KBioGR_000511; AMCHA; trans-4-Aminomethylcyclohexane-1-carboxylic acid; CHEMBL877; NCGC00016569-02; Tranexan; 08455_FLUKA; UNII-6T84R30KC1; 3-14-00-00868 (Beilstein Handbook Reference); KBio1_000655; Mastop; tranexmic acid; Prestwick_476; AC1Q5U04; HMS1921F08; Cyclohexanecarboxylic acid, 4-(aminomethyl)-; Spectrum2_000655; AB00052260; SPBio_001982	1197-18-8	5526	582925	TTDS00392	Plasminogen	Plasmin;PLG	P00747	5340	ENSG00000122194	inhibitor
DAP001197	Anistreplase	N/A	81669-57-0	N/A	46504487	TTDS00392	Plasminogen	Plasmin;PLG	P00747	5340	ENSG00000122194	activator
DAP001195	Reteplase	D05721; Retevase (TN); Reteplase; Reteplase (USAN/INN); Retevase; 133652-38-7	133652-38-7	65820	47207382	TTDS00392	Plasminogen	Plasmin;PLG	P00747	5340	ENSG00000122194	activator
DAP000200	Aminocaproic Acid	3kiv; NCGC00015092-02; Epsilon S; epsilon Aminocaproic Acid; Acid, epsilon-Aminocaproic; Aminocaproic Acids; Caprocid; 177 J.D; Caproamin; Amicar, |A-amino caproic acid, |A-Ahx, 6-aminohexanoic acid, Aminocaproic acid; NSC400230; Aminohexanoic acid; KBioGR_000586; ACS; CBDivE_004370; Aminocaproic Acid In Plastic Container; CY 116; HEXANOIC ACID,6-AMINO; Hexanoic acid, 6-amino-; Aminocaproic acid; Eaca kabi; AC1Q54EY; Hexanoic acid, 6-amino-; Kyselina omega-aminokapronova; 6 Aminocaproic Acid; Aminocaproate; KBio2_005534; Capralense; Epsilcapramin; HMS1570P22; CY116; KBioSS_000398; CHEMBL1046; NSC-26154; Ipsilon; NSC 400230; Aminocaproic acid [USAN:BAN:INN]; STK246894; Lopac-A-7824; epsilon-Aminocaproic acid (JAN); .epsilon.-Aminocaproic acid; epsilon-Amino-n-hexanoic acid; NCGC00093587-02; .omega.-Aminohexanoic acid; SMR000059162; Prestwick1_000960; KBio2_002966; 6-Amino-n-hexanoic acid; LS-7191; 6 Aminohexanoic Acid; Spectrum4_000143; Prestwick3_000960; Prestwick0_000960; epsilon-Norleucine; Hemocaprol; UNII-U6F3787206; NCGC00015092-07; .epsilon.-Norleucine; EINECS 200-469-3; Lopac0_000082; Atsemin; KBio1_000551; NCGC00093587-04; Epsicaprom; AB00051911; EACA; SPECTRUM1500114; InChI=1/C6H13NO2/c7-5-3-1-2-4-6(8)9/h1-5,7H2,(H,8,9; acide aminocaproque; epsilon-Leucine; Kyselina omega-aminokapronova [Czech]; Acidum aminocaproicum [INN-Latin]; CHEBI:16586; AI3-14512; Capracid; NCGC00015092-01; 6-amino-n-caproate; Acepramin; MLS002695931; HMS501L13; DivK1c_000551; 87867-96-7; epsilcapramine; SPBio_003109; HMS2091I07; CAS-60-32-2; LMFA01100035; nchembio.104-comp21; epsilon-aminocaproate; 60-32-2; Aminocaproic acid (USP); DB00513; A0312; 6-Aminocaproic acid; EACA; Acide aminocaproique [INN-French]; .epsilon.-Leucine; Hemopar; WLN: Z5VQ; Amikar; Aminocaproic; Amicar (TN); aminocaproic acid; EACS; 177 J.D.; NINDS_000551; 1319-82-0; Acidum aminocaproicum [Latin]; .omega.-Aminocaproic acid; bmse000394; S1671_Selleck; amicar; NCGC00015092-03; NCGC00093587-03; BRN 0906872; Spectrum_000038; MolPort-001-779-881; AKOS000118734; .epsilon.-Aminohexanoic acid; nchembio.2007.30-comp14; HMS1920C07; Respramin; NSC212532; 6-aminohexanoic acid; BPBio1_001056; Spectrum2_000131; BIDD:GT0162; IDI1_000551; Acidum aminocaproicum; Hepin; Acid, 6-Aminohexanoic; A7824_SIGMA; Acido aminocaproico [INN-Spanish]; Caprolisin; CCRIS 7706; 6-Aminocaproic acid; NSC26154; Acido aminocaproico [DCIT,Spanish]; Acid, 6-Aminocaproic; 6-aminohexanoate; Afibrin; Epsikapron; Epsilon-Aminocapronsaeure; Epsicapron; AC-035; 6-amino-n-caproic acid; CID564; NSC 26154; SPBio_000202; Capranol; Aminocaproic acid (USP/INN); epsilon-Aminohexanoic acid; Acide aminocaproique [French]; Aminocaproic acid [USAN:INN:BAN]; Epsilon-aminocapronzuur; Epsamon; AC1L19IP; omega-Aminocaproic acid; CL-10304; CY-116; Acepramine; Hexanoic acid, amino-; 1cea; C6H13NO2; TL8003819; .epsilon. S; omega-Aminohexanoic acid; KBio2_000398; Capramol; S04-0132; BSPBio_000960; Spectrum5_000780; Aminokapron; D00160; JD 177; A 7824; D015119; EU-0100082; NCGC00093587-01; Prestwick2_000960; C02378; Acido aminocaproico; HSDB 3005; EPSILON-AMINOCAPROIC ACID; MLS001335991; epsilon-Ahx; epsilon-Amino-n-caproic acid; Caplamin; A2504_SIGMA; Acide aminocaproique; C3BDD377-8F43-4BEC-900A-D5850050BA82; 93208-38-9; CL 10304; 6-amino-hexanoic acid; DB04134	60-32-2	564	5420	TTDS00392	Plasminogen	Plasmin;PLG	P00747	5340	ENSG00000122194	inhibitor
DAP001198	Streptokinase	Streptococcal fibrinolysin; CID9815560; Streptochinasi [DCIT]; Streptokinasum [INN-Latin]; Estreptoquinasa; Streptochinasi; Kabikinase; Streptokinase; Awelysin; 9002-01-1; 4-cyclohexylpyrrolidine-2-carboxylic Acid; Streptase; Estreptoquinasa [INN-Spanish]; MolPort-005-934-537; I01-0884; Streptokinasum; EINECS 232-647-1; Kinase (enzyme-activating), strepto-; AC-13801	9002-01-1	N/A	49661779	TTDS00392	Plasminogen	Plasmin;PLG	P00747	5340	ENSG00000122194	activator
DAP000204	Tenecteplase	Tnkase (TN); Tenecteplase; 191588-94-0; D06070; Tenecteplase (USAN/INN); Tnkase	191588-94-0	N/A	47207728	TTDS00392	Plasminogen	Plasmin;PLG	P00747	5340	ENSG00000122194	activator
DAP001194	Urokinase	N/A	9039-53-6	N/A	46506299	TTDS00392	Plasminogen	Plasmin;PLG	P00747	5340	ENSG00000122194	activator
DAP000203	Alteplase	N/A	105857-23-6	2332	46507035	TTDS00392	Plasminogen	Plasmin;PLG	P00747	5340	ENSG00000122194	activator
DCL000206	PX-478	N/A	N/A	N/A	N/A	TTDC00101	Hypoxia-inducible factor 1 alpha	ARNT interacting protein;HIF-1;HIF1 alpha;HIF-1 alpha;HIF-1alpha;Hypoxia inducible factor 1;Hypoxia-inducible factor 1;Hypoxia-inducible transcription factor (HIF)-1;Member of PAS protein 1;MOP1;Transcription factor HIF-1	Q16665	3091	ENSG00000100644	inhibitor
DCL000127	HIF-1alpha	N/A	N/A	5328127	48179700	TTDC00101	Hypoxia-inducible factor 1 alpha	ARNT interacting protein;HIF-1;HIF1 alpha;HIF-1 alpha;HIF-1alpha;Hypoxia inducible factor 1;Hypoxia-inducible factor 1;Hypoxia-inducible transcription factor (HIF)-1;Member of PAS protein 1;MOP1;Transcription factor HIF-1	Q16665	3091	ENSG00000100644	inhibitor
DCL000097	CTS-21166	N/A	N/A	N/A	N/A	TTDC00092	Beta-secretase	Asp 2;ASP2;Aspartyl protease 2;BACE;BACE1;Beta-site AbetaPP-cleaving enzyme;Beta-site amyloid precursor protein cleaving enzyme;Beta-site amyloid precursor protein cleaving enzyme 1;Beta-site APP cleaving enzyme;Beta-site APP cleaving enzyme 1;Memapsin-2;Membrane-associated aspartic protease 2;Transmembrane aspartic protease	P56817	23621	ENSG00000186318	inhibitor
DCL000062	AZD-9684	N/A	20412-65-1	15548	49698825	TTDC00053	Carboxypeptidase B2	Carboxypeptidase U;CPU;pCPB;Plasma carboxypeptidase B;TAFI;Thrombin-activable fibrinolysis inhibitor	Q96IY4	1361	ENSG00000080618	inhibitor
DCL000267	ZK-thiazolidinone	N/A	165800-08-8	68740	47208036	TTDC00160	Serine/threonine-protein kinase PLK1	Mitotic serine-threonine kinase polo-like kinase 1;Plk1;PLK-1;Polo-like kinase 1;Serine-threonine protein kinase 13;STPK13	P53350	5347	ENSG00000166851	inhibitor
DCL000098	CYC-800	N/A	N/A	892	49663571	TTDC00160	Serine/threonine-protein kinase PLK1	Mitotic serine-threonine kinase polo-like kinase 1;Plk1;PLK-1;Polo-like kinase 1;Serine-threonine protein kinase 13;STPK13	P53350	5347	ENSG00000166851	inhibitor
DCL000148	LC-445	N/A	30868-30-5	5479525	47207319	TTDC00160	Serine/threonine-protein kinase PLK1	Mitotic serine-threonine kinase polo-like kinase 1;Plk1;PLK-1;Polo-like kinase 1;Serine-threonine protein kinase 13;STPK13	P53350	5347	ENSG00000166851	inhibitor
DCL000128	HMN-214	Acetamide, N-((4-methoxyphenyl)sulfonyl)-N-(2-((1E)-2-(1-oxido-4-pyridinyl)ethenyl)phenyl)-; CID9888590; Acetamide, N-((4-methoxyphenyl)sulfonyl)-N-(2-(2-(1-oxido-4-pyridinyl)ethenyl)phenyl)-, (E)-; (E)-4-(2-(2-(N-Acetyl-N-((p-methoxyphenyl)sulfonyl)amino)phenyl)ethenyl)pyridine 1-oxide; HMN-214; 173529-46-9; N-(4-methoxyphenyl)sulfonyl-N-[2-[(E)-2-(1-oxidopyridin-4-yl)ethenyl]phenyl]acetamide	173529-46-9	N/A	3818853	TTDC00160	Serine/threonine-protein kinase PLK1	Mitotic serine-threonine kinase polo-like kinase 1;Plk1;PLK-1;Polo-like kinase 1;Serine-threonine protein kinase 13;STPK13	P53350	5347	ENSG00000166851	inhibitor
DCL000180	NMS-1	N/A	N/A	N/A	N/A	TTDC00160	Serine/threonine-protein kinase PLK1	Mitotic serine-threonine kinase polo-like kinase 1;Plk1;PLK-1;Polo-like kinase 1;Serine-threonine protein kinase 13;STPK13	P53350	5347	ENSG00000166851	inhibitor
DCL000100	DAP-81	N/A	N/A	156391	49703461	TTDC00160	Serine/threonine-protein kinase PLK1	Mitotic serine-threonine kinase polo-like kinase 1;Plk1;PLK-1;Polo-like kinase 1;Serine-threonine protein kinase 13;STPK13	P53350	5347	ENSG00000166851	inhibitor
DCL000189	ON 019190.Na	N/A	N/A	131682	46519220	TTDC00160	Serine/threonine-protein kinase PLK1	Mitotic serine-threonine kinase polo-like kinase 1;Plk1;PLK-1;Polo-like kinase 1;Serine-threonine protein kinase 13;STPK13	P53350	5347	ENSG00000166851	inhibitor
DCL000067	BI 2536	R78; CID 11577250; CHEMBL513909; CID11364421; CHEBI:49868; S1109_Selleck; BI 2536; BI2536, BI 2536	N/A	N/A	N/A	TTDC00160	Serine/threonine-protein kinase PLK1	Mitotic serine-threonine kinase polo-like kinase 1;Plk1;PLK-1;Polo-like kinase 1;Serine-threonine protein kinase 13;STPK13	P53350	5347	ENSG00000166851	inhibitor
DCL000068	BI 6727	N/A	N/A	N/A	N/A	TTDC00160	Serine/threonine-protein kinase PLK1	Mitotic serine-threonine kinase polo-like kinase 1;Plk1;PLK-1;Polo-like kinase 1;Serine-threonine protein kinase 13;STPK13	P53350	5347	ENSG00000166851	inhibitor
DCL000378	GSK461364	N/A	N/A	N/A	N/A	TTDC00160	Serine/threonine-protein kinase PLK1	Mitotic serine-threonine kinase polo-like kinase 1;Plk1;PLK-1;Polo-like kinase 1;Serine-threonine protein kinase 13;STPK13	P53350	5347	ENSG00000166851	inhibitor
DCL000123	GSK461364	N/A	N/A	N/A	N/A	TTDC00160	Serine/threonine-protein kinase PLK1	Mitotic serine-threonine kinase polo-like kinase 1;Plk1;PLK-1;Polo-like kinase 1;Serine-threonine protein kinase 13;STPK13	P53350	5347	ENSG00000166851	inhibitor
DCL000971	S-777469	N/A	N/A	492405	42970923	TTDC00314	Cannabinoid receptor 2	Cannabinoid CB2 receptor;CB2;CB-2;CX5	P34972	1269	ENSG00000188822	agonist
DCL001051	AVI-4065	N/A	N/A	N/A	N/A	TTDC00275	HCV genome conserved portion (unspecified)	N/A	N/A	N/A	N/A	antisense
DCL001052	Merck drug	N/A	N/A	N/A	N/A	TTDC00275	HCV genome conserved portion (unspecified)	N/A	N/A	N/A	N/A	antisense
DAP000976	Cinalukast	Cinalukast (USAN/INN); Ro-24-5913; Butanoic acid, 4-((3-(2-(4-cyclobutyl-2-thiazolyl)ethenyl)phenyl)amino)-2,2-diethyl-4-oxo-, (E)-; Cinalukast [USAN:INN]; 4-[3-[(E)-2-(4-cyclobutyl-1,3-thiazol-2-yl)ethenyl]anilino]-2,2-diethyl-4-oxobutanoic acid; MolPort-003-666-874; CHEBI:126598; 3'-((E)-2-(4-Cyclobutyl-2-thiazolyl)vinyl)-2,2-diethylsuccinanilic acid; 4-({3-[(E)-2-(4-cyclobutyl-1,3-thiazol-2-yl)ethenyl]phenyl}amino)-2,2-diethyl-4-oxobutanoic acid; D02846; CID6436135; NCGC00092300-01; 128312-51-6; DB00587; L000942; BRD-K72816382-001-01-3; CHEMBL283754; (E)-4-[[3-(2-(4-Cyclobutyl-2-thiazolyl)ethenyl)phenyl]amino]-2,2-diethyl-4-oxobutanoic acid; AC1O5L5Y; C6239_SIGMA; Cinalukast; Ro 24-5913	128312-51-6	6436135	213582	TTDS00183	Cysteinyl leukotriene receptor 1	CysLTR1;Cysteinyl leukotriene D4 receptor;HG55;HMTMF81;Leukotriene D4-receptor;LTD4 receptor	Q9Y271	10800	ENSG00000173198	antagonist
DAP000091	Zafirlukast	cyclopentyl N-[3-[[2-methoxy-4-[(2-methylphenyl)sulfonylcarbamoyl]phenyl]methyl]-1-methylindol-5-yl]carbamate; ICI 204,219; CID5717; C07206; ICI 204219; L001011; MLS001424064; SAM001246577; STK646780; ZINC00896717; 107753-78-6; Accolate, Accoleit, Vanticon, Zafirlukast; NCGC00164547-01; Carbamic acid, (3-((2-methoxy-4-((((2-methylphenyl)sulfonyl)amino)carbonyl)phenyl)methyl)-1-methyl-1H-indol-5-yl)-, cyclopentyl ester; Accolate (TN); D00411; LS-50025; Novartis brand of zafirlukast; C062735; Zafirlukast [USAN:BAN:INN]; Aeronix; DB00549; Cyclopentyl 3-(2-methoxy-4-((o-tolylsulfonyl)carbamoyl)benzyl)-1-methylindole-5-carbamate; HMS2089J10; MLS000759421-02; Zeneca brand of zafirkulast; cyclopentyl [3-(2-methoxy-4-{[(2-methylphenyl)sulfonyl]carbamoyl}benzyl)-1-methyl-1H-indol-5-yl]carbamate; CHEMBL603; BIDD:GT0267; cyclopentyl 3-[2-methoxy-4-(2-methylphenylsulfonylcarbamoyl)benzyl]-1-methyl-1H-indol-5-ylcarbamate; AC1L1KZB; Bio-0152; 4-(5-cyclopentyloxy-carbonylamino-1-methyl-indol-3-ylmethyl)-3-methoxy-N-o-tolylsulfonylbenzamide; zafirlukast; MolPort-003-850-873; MLS000759421; 4-(5-cyclopentyloxycarbonylamino-1-methyl-1H-indol-3-ylmethyl)-3-methoxy-N-o-tolylsulfonylbenzamide; Accoleit; SMR000466316; Zafirlukast (JAN/USAN/INN); C31H33N3O6S; CHEBI:10100; 4-(5-cyclopentyloxycarbonylamino-2-methylindol-3-yl-methyl)-3-methoxy-N-O-tolylsulfonylbenzamide; Respix; cyclopentyl (1-methyl-3-{[2-(methyloxy)-4-({[(2-methylphenyl)sulfonyl]amino}carbonyl)phenyl]methyl}-1H-indol-5-yl)carbamate; Olmoran; CPD000466316; AstraZeneca brand of zafirlukast; I06-0398; UNII-XZ629S5L50; S1633_Selleck; Zafirst; ICI-204219; Accolate; Menarini brand of zafirlukast; HMS2051F12	107753-78-6	5717	196556	TTDS00183	Cysteinyl leukotriene receptor 1	CysLTR1;Cysteinyl leukotriene D4 receptor;HG55;HMTMF81;Leukotriene D4-receptor;LTD4 receptor	Q9Y271	10800	ENSG00000173198	antagonist
DAP000977	Pranlukast	CHEBI:126451; LS-194954; N-[4-oxo-2-(2H-tetrazol-5-yl)chromen-8-yl]-4-(4-phenylbutoxy)benzamide; L013134; Pranlukast (INN); AC1L1J6B; HMS2089H16; LS-194966; Azlaire; CHEMBL21333; D08408; Azlaire (TN); AC-696; CID4887	103177-37-3	115100	692058	TTDS00183	Cysteinyl leukotriene receptor 1	CysLTR1;Cysteinyl leukotriene D4 receptor;HG55;HMTMF81;Leukotriene D4-receptor;LTD4 receptor	Q9Y271	10800	ENSG00000173198	antagonist
DAP000309	Montelukast	CHEBI:50730; MK 0476; Brondilat (TN); C07482; CID5281040; Montair; Montelukast (INN); 2-[1-[[(1R)-1-[3-[(E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl]-3-[2-(2-hydroxypropan-2-yl)phenyl]propyl]sulfanylmethyl]cyclopropyl]acetic acid; (R-(E))-1-(((1-(3-(2-(7-Chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropaneacetic acid; HMS2089D07; {1-[({(1R)-1-{3-[(E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl}-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl}sulfanyl)methyl]cyclopropyl}acetic acid; C35H36ClNO3S; CHEMBL787; UNII-MHM278SD3E; Cyclopropaneacetic acid, 1-(((1-(3-(2-(7-chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)-, (R-(E))-; HSDB 7582; Apxi toxin; Brondilat; DB00471; Montelukast [INN:BAN]; MK-0476; D08229; Cyclopropaneacetic acid, 1-((((1R)-1-(3-((1E)-2-(7-chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)-; LS-173539; montelukast; AC1NQXXW; Singular; 151767-02-1 (sodium); 1-((((1R)-1-(3-((1E)-2-(7-Chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropaneacetic acid; BIDD:GT0394; sodium 1-(((1-(3-(2-(7-chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropylacetate; 158966-92-8	158966-92-8	5281040	9685	TTDS00183	Cysteinyl leukotriene receptor 1	CysLTR1;Cysteinyl leukotriene D4 receptor;HG55;HMTMF81;Leukotriene D4-receptor;LTD4 receptor	Q9Y271	10800	ENSG00000173198	antagonist
DCL000133	Implitapide	AC1NX6LL; (2S)-2-cyclopentyl-2-[3-[(2,4-dimethylpyrido[2,3-b]indol-9-yl)methyl]phenyl]-N-[(1R)-2-hydroxy-1-phenylethyl]acetamide; LS-193343; Implitapide [INN]; UNII-Q70OH404HR; Implitapide; CID5745206; 177469-96-4	N/A	5745206	12015050	TTDC00123	Microsomal triglyceride transfer protein, large subunit	N/A	P55157	4547	ENSG00000138823	inhibitor
DCL000072	BMS-201038	BMS 201038-01; 210823-48-6; AEGR-733; AEGR 733; CHEBI:382991; CHEMBL354541; CID9853053; AEGR733; 202833-31-6; BMS 201038; BMS 201238; 9H-Fluorene-9-carboxamide, N-(2,2,2-trifluoroethyl)-9-[4-[4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1-piperidinyl]butyl]-; 182431-12-5; BMS201038; BMS-201038; CID 9853053	118702-11-7	219018	30422397	TTDC00123	Microsomal triglyceride transfer protein, large subunit	N/A	P55157	4547	ENSG00000138823	inhibitor
DAP000892	Capreomycin	AC1MHD7F; (3S)-3,6-diamino-N-[[(2S,5S,8E,11S,15S)-15-amino-11-[(6R)-2-amino-1,4,5,6-tetrahydropyrimidin-6-yl]-8-[(carbamoylamino)methylidene]-2-(hydroxymethyl)-3,6,9,12,16-pentaoxo-1,4,7,10,13-pentazacyclohexadec-5-yl]methyl]hexanamide; (3S)-3,6-diamino-N-[[(2S,5S,8E,11S,15S)-15-amino-11-[(6R)-2-amino-1,4,5,6-tetrahydropyrimidin-6-yl]-8-[(carbamoylamino)methylidene]-2-methyl-3,6,9,12,16-pentaoxo-1,4,7,10,13-pentazacyclohexadec-5-yl]methyl]hexanamide; capreomycin; CID3000502; Caprocin (Disulfate); Capreomycin sulphate; DB00314; Capreomycin Sulfate Standard; Ogostal (Disulfate)	11003-38-6	3000502	4918	TTDS00221	70S prokaryotic ribosome	N/A	N/A	N/A	N/A	binder
DCL000938	PRX-08066	N/A	N/A	N/A	N/A	TTDS00104	5-hydroxytryptamine 2B receptor	5-HT 2B;5-HT-2B;Serotonin receptor;Serotonin receptor 2B	P41595	3357	ENSG00000135914	antagonist
DAP000475	Minaprine	AC1L1HMV; Spectrum4_000418; D05039; M3157_SIGMA; IDI1_000063; Minaprina [INN-Spanish]; BSPBio_002909; NCGC00016795-01; KBioSS_001814; Prestwick1_000066; BPBio1_000277; Minaprinum; Spectrum5_001593; BRD-K02867583-300-05-5; CB 30038; MolPort-003-958-699; CHEBI:51038; CHEMBL278819; Cantor; DB00805; CAS-25953-17-7; SPBio_001454; 4-Methyl-3-(2-morpholinoethylamino)-6-phenylpyridazin; AR-1G3866; 4-methyl-N-(2-morpholin-4-ylethyl)-6-phenylpyridazin-3-amine; 25905-77-5; KBio2_001814; KBioGR_000716; EINECS 247-329-8; AB00053599; KBio3_002409; KBio2_004382; Spectrum2_001407; Spectrum3_001445; SPBio_002172; Cantor (TN); DivK1c_000063; Prestwick0_000066; CID4199; NINDS_000063; Minaprina; Brantur; L001202; Minaprine dihydrochloride; Prestwick3_000066; N-(4-Methyl-6-phenyl-3-pyridazinyl)-4-morpholineethanamine; Minaprinum [INN-Latin]; 25953-17-7 (di-hydrochloride); KBio2_006950; Minaprine (USAN/INN); KBio1_000063; Spectrum_001334; M3157_FLUKA; BSPBio_000251; Prestwick2_000066; minaprine; Minaprine [USAN:BAN:INN]; 4-Morpholineethanamine, N-(4-methyl-6-phenyl-3-pyridazinyl)-; ZINC19796082; 4-(2-((4-Methyl-6-phenyl-3-pyridazinyl)amino)ethyl)morpholine; AC1Q4YHU; AGR 1240; LS-92883; 3-(morpholinoethyl)amino-4-methyl-6-phenylpyridazine; NCGC00016795-02	25905-77-5	4199	213627	TTDS00104	5-hydroxytryptamine 2B receptor	5-HT 2B;5-HT-2B;Serotonin receptor;Serotonin receptor 2B	P41595	3357	ENSG00000135914	antagonist
DAP000294	Triflupromazine	N,N-dimethyl-3-[2-(trifluoromethyl)phenothiazin-10-yl]propan-1-amine hydrochloride; NCI60_001029; NINDS_000808; Trifluopromazine hydrochloride; Vesprin; N,N-dimethyl-3-(2-(trifluoromethyl)-10H-phenothiazin-10-yl)-1-propanamine; Fluopromazine; Lopac-T-2896; Fluorofen; NCGC00016012-01; Spectrum_000095; C18H19F3N2S; Neoprin; KBio1_000808; AC1L1KMZ; PDSP1_001344; BPBio1_000227; 2-(Trifluoromethyl)promazine; EINECS 205-673-6; BSPBio_000205; 10-(3-(Dimethylamino)propyl)-2-(trifluoromethyl)phenothiazine; AB00053647; UNII-RO16TQF95Y; Lopac0_001146; BSPBio_003444; KBio2_000515; N,N-Dimethyl-2-(trifluoromethyl)-10H-phenothiazine-10-propanamine; Phenothiazine, 10-(3-(dimethylamino)propyl)-2-(trifluoromethyl)-; N,N-dimethyl-3-[2-(trifluoromethyl)-10H-phenothiazin-10-yl]propan-1-amine; Triflupromazina [INN-Spanish]; DB00508; nchembio873-comp69; PDSP2_001328; CHEBI:9711; NSC17473; Siquil; Triflupromazinum; AR-1K7464; Triflupromazinum [INN-Latin]; SPBio_002126; 146-54-3; NCGC00016012-09; Prestwick0_000053; DivK1c_000808; CHEMBL570; CID5568; HSDB 3407; Adazine; Nivoman; L001149; KBioSS_000515; 10-3-(Dimethylamino)propyl-2-(trifluoromethyl)phenothiazine; D00390; Triflupromazine [INN]; CAS-1098-60-8; Fluopromazine monohydrochloride; NCGC00024300-04; Spectrum5_001282; NCGC00016012-03; KBio2_003083; 2-Trifluoromethyl-10-(gamma-dimethylaminopropyl)phenothiazine; N,N-dimethyl-3-[2-(trifluoromethyl)phenothiazin-10-yl]propan-1-amine; Triflupromazina; Prestwick3_000053; KBioGR_001062; Psyquil; Vetame; KBio2_005651; Triflupromazine (USP/INN); NSC14959; triflupromazine; 10H-Phenothiazine-10-propanamine, N,N-dimethyl-2-(trifluoromethyl)-; Spectrum4_000741; LS-105500; NCGC00016012-02; Prestwick1_000053; Trifluopromazine; Prestwick2_000053; Vesprin (TN); NCI60_001426; IDI1_000808; AC1Q4JZU	146-54-3	5568	7847456	TTDS00104	5-hydroxytryptamine 2B receptor	5-HT 2B;5-HT-2B;Serotonin receptor;Serotonin receptor 2B	P41595	3357	ENSG00000135914	antagonist
DAP000284	Cosyntropin	D00284; 16960-16-0; Tetracosactide; Tetracosactide (INN); Cortrosyn (TN); COSYNTROPIN; Cosyntropin (USAN); Cortrosyn	16960-16-0	16129617	7847350	TTDS00286	Adrenocorticotropic hormone receptor	ACTH receptor;ACTH-R;Adrenocorticotropin receptor;MC2-R;Melanocortin-2 receptor	Q01718	4158	ENSG00000185231	antagonist
DPR000163	Batimastat	(2S,3R)-5-Methyl-3-(((alphaS)-alpha-(methylcarbamoyl)phenethyl)carbamoyl)-2-((2-thienylthio)methyl)hexanohydroxamic acid; CHEBI:40976; 2j83; C23H31N3O4S2; (2S,3R)-N-hydroxy-N'-[(2S)-1-(methylamino)-1-oxo-3-phenylpropan-2-yl]-3-(2-methylpropyl)-2-(thiophen-2-ylsulfanylmethyl)butanediamide; BB94; AC1NSFYO; 130370-60-4; C080985; BB-94; batimastat; CHEMBL279786; BB94 cpd; ISV-615; Batimastat (USAN/INN); MolPort-006-822-709; CHEBI:123429; 4-(N-HYDROXYAMINO)-2R-ISOBUTYL-2S-(2-THIENYLTHIOMETHYL)SUCCINYL-L-PHENYLALANINE-N-METHYLAMIDE; BB 94; UNII-BK349F52C9; BB-99; BB94, BB-94; (4-(N-hydroxyamino)-2-isobutyl-3-(thiophen-2-ylthiomethyl)succinyl)phenylalanine-N-methylamide; LS-45637; Butanediamide, N(sup 4)-hydroxy-N(sup 1)-(2-(methylamino)-2-oxo-1-(phenylmethyl)ethyl)-2-(2-methylpropyl)-3-((2-thienylthio)methyl)-, (2R-(1(S*),2R*,3S*))-; ISV-120; CID5362422; D03061; 1rm8; Batimastat [USAN:BAN:INN]; Butanediamide, N4-hydroxy-N1-(2-(methylamino)-2-oxo-1-(phenylmethyl)ethyl)-2-(2-methylpropyl)-3-((2-thienylthio)methyl)-, (2R-(1(S*),2R*,3S*))-; DSX; DB03880	N/A	N/A	N/A	TTDC00147	Interstitial collagenase	Fibroblast collagenase;Matrix metalloproteinase-1;MMP-1	P03956	4312	ENSG00000196611	inhibitor
DCL000014	BB-3644	N/A	143257-98-1	65997	43122719	TTDC00147	Interstitial collagenase	Fibroblast collagenase;Matrix metalloproteinase-1;MMP-1	P03956	4312	ENSG00000196611	inhibitor
DCL000004	Prinomastat	CHEMBL75094; D03797; MolPort-000-883-336; AG-3354; AC1LAD25; AG-3362; Prinomastat (USAN/INN); CHEBI:220195; 3-Thiomorpholinecarboxamide, N-hydroxy-2,2-dimethyl-4-[[4-(4-pyridinyloxy)phenyl]sulfonyl]-, (3S)-; CID466151; (3S)-N-hydroxy-2,2-dimethyl-4-(4-pyridin-4-yloxyphenyl)sulfonylthiomorpholine-3-carboxamide; AKOS000280753; Opc 51803	58-38-8	466151	17397885	TTDC00147	Interstitial collagenase	Fibroblast collagenase;Matrix metalloproteinase-1;MMP-1	P03956	4312	ENSG00000196611	inhibitor
DCL001039	XL784	N/A	N/A	N/A	N/A	TTDC00147	Interstitial collagenase	Fibroblast collagenase;Matrix metalloproteinase-1;MMP-1	P03956	4312	ENSG00000196611	inhibitor
DCL000003	BMS 275291	N-((2S)-2-Mercapto-1-oxo-4-(3,4,4-trimethyl-2,5-dioxo-1-imidazolidinyl)butyl)-L-leucyl-N,3-dimethyl-L-valinamide; L-Valinamide, N-((2S)-2-mercapto-1-oxo-4-(3,4,4-trimethyl-2,5-dioxo-1-imidazolidinyl)butyl)-L-leucyl-N,3-dimethyl-; BMS 275291; AC1L3WNB; (2S)-N-[(2S)-3,3-dimethyl-2-(methylamino)butanoyl]-4-methyl-2-[[(2S)-2-sulfanyl-4-(3,4,4-trimethyl-2,5-dioxoimidazolidin-1-yl)butanoyl]amino]pentanamide; UNII-1B47R6ZX4K; CID148203; D 2163	259188-38-0	148203	725892	TTDC00147	Interstitial collagenase	Fibroblast collagenase;Matrix metalloproteinase-1;MMP-1	P03956	4312	ENSG00000196611	inhibitor
DCL000005	Marimastat	15039-60-8; Butanediamide, N4-(2,2-dimethyl-1-((methylamino)carbonyl)propyl)-N1,2-dihydroxy-3-(2-methylpropyl)-, (2S-(N4(R*),2R*,3S*))-; D03795; (2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N',3-dihydroxy-2-(2-methylpropyl)butanediamide; Marimastat [USAN]; CHEBI:50662; BB-2516; Butanediamide, N4-((1S)-2,2-dimethyl-1-((methylamino)carbonyl)propyl)-N1,2-dihydroxy-3-(2-methylpropyl)-, (2S,3R)-; UNII-D5EQV23TDS; 154039-60-8; DB00786; CHEMBL279785; Butanediamide, N(sup 4)-(2,2-dimethyl-1-((methylamino)carbonyl)propyl)-N(sup 1),2-dihydroxy-3-(2-methylpropyl)-, (2S-(N(sup 4)(R*),2R*,3S*))-; (2S,3R)-N(4)-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N(1),2-dihydroxy-3-(2-methylpropyl)butanediamide; AC1L3O2N; C15H29N3O5; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoyl)propyl)carbamoyl)-2-hydroxy-5-methylhexanohydroxamic acid; CID119031; Marimastat; C100342; LS-45634; BB 2516; Marimastat (USAN/INN); (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoxy)propyl)carboyl)-2-hydroxy-5-methylhexanohydroxamic acid	154039-60-8	119031	46505547	TTDC00147	Interstitial collagenase	Fibroblast collagenase;Matrix metalloproteinase-1;MMP-1	P03956	4312	ENSG00000196611	inhibitor
DCL000201	PSN-101	N/A	210421-64-0	216235	46520589	TTDC00141	Hexokinase D	GCK;Glucokinase;Hexokinase type IV;HK IV;HK4	P35557	2645	ENSG00000106633	activator
DCL001154	AZD5658	N/A	N/A	N/A	N/A	TTDC00141	Hexokinase D	GCK;Glucokinase;Hexokinase type IV;HK IV;HK4	P35557	2645	ENSG00000106633	activator
DCL000475	AZD6370	N/A	N/A	N/A	N/A	TTDC00141	Hexokinase D	GCK;Glucokinase;Hexokinase type IV;HK IV;HK4	P35557	2645	ENSG00000106633	activator
DCL000457	AZD1656	N/A	N/A	N/A	N/A	TTDC00141	Hexokinase D	GCK;Glucokinase;Hexokinase type IV;HK IV;HK4	P35557	2645	ENSG00000106633	activator
DCL000614	R7201	N/A	N/A	N/A	N/A	TTDC00141	Hexokinase D	GCK;Glucokinase;Hexokinase type IV;HK IV;HK4	P35557	2645	ENSG00000106633	activator
DCL000153	Lonidamine	CCRIS 3516; NCGC00025244-01; Lonidamina; 57571-43-4; NCGC00015609-03; NCGC00015609-06; Doridamina (TN); Lopac-L-4900; AC-5626; 1-[(2,4-dichlorophenyl)methyl]indazole-3-carboxylic acid; Lonidamine [BAN:INN]; Dichlondazolic acid; L 4900; 1-(2,4-Dichlorobenzyl)-1H-indazole-3-carboxylic acid; MLS000028822; SBB063222; BRD-K78513633-001-03-3; NCGC00025244-03; Lonidamin; lonidamine; C016371; EU-0100718; 1-[(2,4-dichlorophenyl)methyl]-1H-indazole-3-carboxylic acid; Lopac0_000718; LS-7474; KN-228; Tocris-1646; NCGC00025244-02; AF-1890; Lonidamine (INN); CID39562; L4900_SIGMA; AC1L21YG; DICA; TH-070; 1-(2,4-Dichlorbenzyl)-indazole-3-carboxylic acid; 1H-Indazole-3-carboxylic acid, 1-(2,4-dichlorobenzyl)-; MolPort-003-957-796; EINECS 256-510-0; CHEBI:50138; Doridamina; D07257; Lonidaminum; 1-(2,4-dichlorobenzyl)indazole-3-carboxylic acid; SMR000058467; NCGC00015609-01; 50264-69-2; Lonidaminum [INN-Latin]; NSC741419; 1H-Indazole-3-carboxylic acid, 1-((2,4-dichlorophenyl)methyl)- (9CI); 1H-Indazole-3-carboxylic acid, 1-((2,4-dichlorophenyl)methyl)-; Diclondazolic acid; Lonidamina [INN-Spanish]; I01-0912; AF 1890; BRN 0894483	50264-69-2	39562	48413946	TTDC00141	Hexokinase D	GCK;Glucokinase;Hexokinase type IV;HK IV;HK4	P35557	2645	ENSG00000106633	inhibitor
DAP001250	Cinolazepam	1H-1,4-Benzodiazepine-1-propanenitrile, 2,3-dihydro-7-chloro-5-(2-fluorophenyl)-2-oxo-; C18H13ClFN3O2; OX-373; CID3033621; AC1MHW00; Gerodorm; D07328; 75696-02-5; AKOS005166889; AC1Q7ARL; UNII-68P0556B0U; Cinolazepamum; DB01594; Cinolazepam (INN); 7-chloro-5-(2-fluorophenyl)-2,3-dihydro-3-hydroxy-2-oxo-1H-1,4-benzodiazepine-1-propanenitrile; LS-34118; BRN 5359831; CHEBI:59514; 3-[7-chloro-5-(2-fluorophenyl)-3-hydroxy-2-oxo-3H-1,4-benzodiazepin-1-yl]propanenitrile; Cinolazepam; 3-[7-chloro-5-(2-fluorophenyl)-3-hydroxy-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-1-yl]propanenitrile; 1-(2-cyanoethyl)-7-chloro-3-hydroxy-5-(2'-fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one; 7-Chloro-5-(o-fluorophenyl)-2,3-dihydro-3-hydroxy-2-oxo-1H-1,4-benzodiazepine-1-propionitrile; Gerodorm (TN); Cinolazepam [INN]; Cinolazepamum [INN-Latin]; OX 373	75696-02-5	3033621	10047721	TTDS00454	Peripheral-type benzodiazepine receptor	Mitochondrial benzodiazepine receptor;PBR;Peripheral benzodiazepine receptor;PKBS;Translocator protein	P30536	706	ENSG00000100300	binder
DAP001252	Chlormezanone	NSC 169108; Miorilax; 2-(para-Chlorophenyl)tetrahydro-3-methyl-4H-1,3-thiazin-4-one, 1,1-dioxide; AKOS000121464; InChI=1/C11H12ClNO3S/c1-13-10(14)6-7-17(15,16)11(13)8-2-4-9(12)5-3-8/h2-5,11H,6-7H2,1H3; Muskel; Spectrum4_001237; Clorilax; Phenarol; Prestwick2_000336; Chlormezanone [BAN:INN:JAN]; AC1L1EB2; BRD-A20348246-001-05-9; Rilasol; NINDS_000886; DivK1c_000886; NCGC00024597-05; chlormezanone; 2-(4-chlorophenyl)-3-methyl-1,1-dioxo-1,3-thiazinan-4-one; (+-)-Chlormezanone; NCGC00024597-02; Mio-sed; Tanafol; Lopac0_000383; KBio2_003462; IDI1_000886; TRANCOPAL (TN); Chlormethazanone; KBio2_006030; HMS1569C13; Dichloromezanone; Chlormezanone (JAN/INN); Chlomedinon; EINECS 201-307-4; WIN 4692; KBio1_000886; KBio2_000894; WLN: T6VN DSWTJ B1 CR DG; HSDB 3300; (+-)-Fenarol; 4H-1,3-Thiazin-4-one, 2-(4-chlorophenyl)tetrahydro-3-methyl-1,1-dioxide; BSPBio_002728; 2-(4-Chlorophenyl)tetrahydro-3-methyl-4H,1,3-thiazin-4-one 1,1-Dioxide; 4H-1,3-Thiazin-4-one, 2-(p-chlorophenyl)tetrahydro-3-methyl-1,1-dioxide; MolPort-003-666-762; NCGC00024597-03; Banabin; Spectrum5_001364; dl-Chlormezanone; 2-(4-Chlorophenyl)-3-methyl-4-metathiazanone-1,1-dioxide; Chlormezanone [INN:BAN:JAN]; Alinam; Rilansyl; Suprotan; Spectrum3_001084; Muskel-Trancopal; Myolespen; Lobak; D00268; 4H-1,3-Thiazin-4-one, 2-(p-chlorophenyl)tetrahydro-3-methyl-, 1,1,-dioxide; HMS502M08; Chlormethazone; 2-(p-Chlorphenyl)-3-methyl-1,3-perhydrothiazin-4-on-1,1-dioxide; LS-150535; Dichloromethazanone; chlormezanona; Clormezanone; Chlormezanonum; 2-(p-Chlorophenyl)tetrahydro-3-methyl-4H-1,3-thiazin-4-one 1,1-dioxide; 2-(4-Chlorophenyl)tetrahydro-3-methyl-4H-1,3-thiazin-4-one 1,1-dioxide; BPBio1_001189; EU-0100383; Oprea1_275911; Clormetazanone; DB01178; 4H-1,3-Thiazin-4-one, 2-(p-chlorophenyl)tetrahydro-3-methyl-, 1,1-dioxide; C11H12ClNO3S; 2-(4-Chlorophenyl)-3-methyl-1,3-thiazinan-4-one 1,1-dioxide; KBio3_001948; I01-1903; Rilax; CHEBI:3619; Clormetazon; T5889171; SPBio_002292; 2-(4-Chlorphenyl)-3-methyl-4-metathiazanon-1,1-dioxid; Chlormezanon; Rillasol; KBioSS_000894; Supotran; Banabil-sintyal; S2021_Selleck; 80-77-3; 102818-65-5; Spectrum_000414; Rilaquil; Banabin-syntyal; NCGC00015191-08; Clormezanone [DCIT]; BSPBio_000371; AB00052410; Tranrilax; Prestwick3_000336; NSC169108; Chlormezanonum [INN-Latin]; SPECTRUM2300062; Prestwick0_000336; NCGC00015191-03; Biomol-NT_000277; C-192; UNII-GP568V9G19; Spectrum2_001807; BPBio1_000409; 4H-1,3-Thiazin-4-one, 2-(4-chlorophenyl)tetrahydro-3-methyl-, 1,1-dioxide; Prestwick1_000336; Clormezanona; Transanate; Rexan; SPBio_001793; 4H-1,3-Thiazin-4-one, tetrahydro-2-(p-chlorophenyl)-3-methyl-, 1,1-dioxide; Banabin-sintyal; Trancote; NCGC00024597-04; Rilassol; Bisina; CHEMBL1200714; Trancopal; Clormezanona [INN-Spanish]; KBioGR_001734; Prestwick_736; CID2717; WEQAYVWKMWHEJO-UHFFFAOYSA-	80-77-3	2717	9120	TTDS00454	Peripheral-type benzodiazepine receptor	Mitochondrial benzodiazepine receptor;PBR;Peripheral benzodiazepine receptor;PKBS;Translocator protein	P30536	706	ENSG00000100300	agonist
DAP001251	Adinazolam	U 41123; CHEMBL328250; Adinazolamum; 1-(8-chloro-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-1-yl)-N,N-dimethylmethanamine; 4H-(1,2,4)Triazolo(4,3-a)(1,4)benzodiazepine-1-methanamine, 8-chloro-N-N-dimethyl-6-phenyl-; U 41,123; 8-chloro-1-[(dimethylamino)methyl]-6-phenyl-4h-s-triazolo[4,3-a][1,4]benzodiazepine; Adinazolam [USAN:BAN:INN]; Adinazolam (USAN/INN); Deracyn; 37115-32-5; ADINAZOLAM; Adinazolam [USAN]; Adinazolamum [INN-Latin]; 8-Chloro-1-((dimethylamino)methyl)-6-phenyl-4H-s-triazolo(4,3-a)(1,4)benzodiazepine; UNII-KN08449444; AC1Q3S9N; D02770; U-41123; PDSP2_000520; DB00546; LS-174647; CHEBI:251412; C19H18ClN5; CID37632; PDSP1_000522; AC1L1Y4K	37115-32-5	37632	178987	TTDS00454	Peripheral-type benzodiazepine receptor	Mitochondrial benzodiazepine receptor;PBR;Peripheral benzodiazepine receptor;PKBS;Translocator protein	P30536	706	ENSG00000100300	agonist
DCL000794	Emapunil	N/A	226954-04-7	6433109	10549722	TTDS00454	Peripheral-type benzodiazepine receptor	Mitochondrial benzodiazepine receptor;PBR;Peripheral benzodiazepine receptor;PKBS;Translocator protein	P30536	706	ENSG00000100300	agonist
DCL000772	Dextofisopam	R-Tofisopam; AC1L4BXA; UNII-EZ15I5D6C1; Dextofisopam; D03737; Dextofisopam (USAN/INN); CID204105; 82059-50-5; (5R)-1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-5H-2,3-benzodiazepine	82059-50-5	4829	17397826	TTDS00454	Peripheral-type benzodiazepine receptor	Mitochondrial benzodiazepine receptor;PBR;Peripheral benzodiazepine receptor;PKBS;Translocator protein	P30536	706	ENSG00000100300	agonist
DCL000157	LY335979	CHEMBL80117; D06387; S1481_Selleck; LY 335979; Zosuquidar Trihydrochloride; Zosuquidar trihydrochloride, RS-33295-198, LY335979; RS-33295-198; (R)-4-((1aR,6R,10bS)-1,2-Difluoro-1,1a,6,10b-tetrahydrodibenzo(a,e)cyclopropa(c)cycloheptan-6-yl)-alpha-((5-quinoloyloxy)methyl)-1-piperazineethanol, trihydrochloride; AC1L8RC8; CID153997; Ly335979; Zosuquidar trihydrochloride (USAN); Zosuquidar HCl; 167465-36-3; LY-335979; AC1L4BI9; UNII-813AGY3126	167465-36-3	153997	47208044	TTDC00030	P-glycoprotein	ABCB4;ATP-binding cassette sub-family B member 4;MDR3;Multidrug resistance protein;P-gp;PGY3	P21439	5244	ENSG00000005471	inhibitor
DAP000818	Conjugated Estrogens	Conjugated estrogens; Oestrogen; Estrogens, steroidal; Progens; Estrogens, conjugated [USP]; Conjugated oestrogens [Steroidal oestrogens]; Equine Estrogens, Conjugated; Estrogens, conjugated synthetic A; CID5351489; C.E.S.; Presomen; Conjugated oestrogens; 438-67-5; Oestro-feminal; Estrogens, Conjugated; Conjugated Estrogenic Substances; Climarest; Conjugated estrogenic hormones; Estroplus; Estrogens conjugated; Steroidal estrogens; Estrone, hydrogen sulfate sodium salt; C12700000; Dagynil; Estrogens, conjugated-equine; Major Brand of Estrogens, Conjugated (USP); AC1NS0NL; Solvay Brand of Estrogens, Conjugated; Femavit; Par Estro; Trianon Brand of Estrogens, Conjugated; D004966; Estrogenic Hormones, Conjugated; Almirall Brand of Estrogens, Conjugated; Presomil; Carentil; Estrogens, conjugated (USP); NSC18313; Pasadena Brand of Estrogens, Conjugated (USP); Pharmacia Brand of Estrogens, Conjugated (USP); Estro-Feminal; Mack Brand of Estrogens, Conjugated (USP); Premarin; Wyeth Brand of Estrogens, Conjugated; HSDB 3076; Transannon; Estrogenic substances, conjugated; ASTA Medica Brand of Estrogens, Conjugated; Estra-1,3,5(10)-trien-17-one, 3-(sulfooxy)-, sodium salt; UNII-IU5QR144QX; HSD307600; Conjugated Equine Estrogens; Menotabs; sodium [(8R,9S,13S,14S)-13-methyl-17-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-yl] hydrogen sulfate; Congest; Oestrofeminal; Prelestrin; estrogens, conjugated USP; evex; Sodium estrone 3-monosulfate	438-67-5	9919	7847378	TTDS00250	Estrogen receptor beta	Beta-1;Erbeta;ER-beta;Oestrogen receptor beta	Q92731	2100	ENSG00000140009	antagonist
DPR000055	GW-3333	CHEBI:556718; CHEMBL514958; n2-[(2r,3s)-3-[formyl(hydroxy)amino]-4-methyl-2-(2-methylpropyl)pentanoyl]-n-pyridin-2-yl-l-isoleucinamide; GW3333; BIDD:PXR0031; AC1Q5NWC; CID216470; (2R,3S)-3-(Formyl-hydroxyamino)-2-(2-methyl-1-propyl)-4-methylpentanoic acid, ((1S,2S)-2-methyl-1-(2-pyridylcarbamoyl)-1-butyl)amide; (2R,3S)-3-[formyl(hydroxy)amino]-4-methyl-N-[(2S,3S)-3-methyl-1-oxo-1-(pyridin-2-ylamino)pentan-2-yl]-2-(2-methylpropyl)pentanamide; AC1L50QR; Gw 3333; AR-1K5100; GW-3333	212609-68-2	216470	789644	TTDR00847	ADAM 17	A disintegrin and metalloproteinase domain 17;CD156b antigen;Snake venom-like protease;TACE;TNF alpha converting enzyme;TNF-alpha convertase;TNF-alpha converting enzyme	P78536	6868	ENSG00000151694	inhibitor
DPR000038	DPC-333	N/A	N/A	N/A	N/A	TTDR00847	ADAM 17	A disintegrin and metalloproteinase domain 17;CD156b antigen;Snake venom-like protease;TACE;TNF alpha converting enzyme;TNF-alpha convertase;TNF-alpha converting enzyme	P78536	6868	ENSG00000151694	inhibitor
DAP000055	Ethambutol	D07925; CID470072; KBio2_006674; CID14052; AC1L9YT2; 1-butanol, 2,2'-(1,2-ethanediyldiimino)bis-; Ethambutol, (-)-isomer; MolPort-003-847-110; Servambutol (TN); CHEMBL43824; CL 40881 (dihydrochloride); CPD000046147; KBioGR_001209; AC1Q77PZ; Prestwick3_000028; KBio2_004106; 2,2'-(ethane-1,2-diyldiimino)dibutan-1-ol; (+)-N,N'-Bis(1-(hydroxymethyl)propyl)ethylenediamine; Ethambutol [INN:BAN]; (R)-2,2'-(1,2-Ethanediyldiimino)bis-1-butanol; Prestwick0_000028; (2S)-2-[2-(1-hydroxybutan-2-ylamino)ethylamino]butan-1-ol; 2-[2-(1-hydroxybutan-2-ylamino)ethylamino]butan-1-ol; Diambutol; AR-1C2065; Ethambutolum [INN-Latin]; BPBio1_000105; (2R)-2-[2-[[(2R)-1-hydroxybutan-2-yl]amino]ethylamino]butan-1-ol; IDI1_000561; D-Ethambutol; EMB; C06984; NINDS_000561; AC1LAKIP; Etambutol [INN-Spanish]; Tibutol; NSC653313; DivK1c_000561; Ethambutol (INN); AC1Q2SHV; (2S)-2-[2-[[(2S)-1-hydroxybutan-2-yl]amino]ethylamino]butan-1-ol; Ethambutolum; SPBio_001167; Spectrum3_000426; Spectrum4_000545; STOCK5S-98432; Etibi; AC1LAKIS; Aethambutolum; (+)-2,2'-(Ethylenediimino)di-1-butanol; D-2,2'-(Ethylenediimino)di-1-butanol; SAM002589988; SMR000046147; (+)-S,S-Ethambutol; STK711105; NCGC00178864-01; KBio2_001538; MolPort-002-507-956; KBio1_000561; KBio3_001232; AC1L1FKQ; (2S,7S)-2,7-diethyl-3,6-diazaoctane-1,8-diol; C10H24N2O2; AC1L230T; LS-187119; HSDB 3078; Ethambutol, racemic mixture; (2'S)-2,2'-[Ethane-1,2-diyldi(imino)]dibutan-1-ol; D-N,N'-Bis(1-hydroxymethylpropyl)ethylenediamine; AC1LABPH; D-2,2'-(Ethylenediimino)bis(1-butanol); BSPBio_000095; Prestwick1_000028; 1-Butanol, 2,2'-(1,2-ethanediyldiimino)bis-, (2S,2'S)-; KST-1A8084; Etambutolo; 75343-56-5; (2R)-2-[2-(1-hydroxybutan-2-ylamino)ethylamino]butan-1-ol; (2S)-2-[2-[[(2R)-1-hydroxybutan-2-yl]amino]ethylamino]butan-1-ol; CHEMBL44884; UNII-8G167061QZ; BSPBio_002012; SPBio_002016; MLS000082702; (S,S)-ethambutol; Myambutol (dihydrochloride); 2,2'-(1,2-Ethylenediimino)-di-1-butanol; d,N,N'-Bis(1-hydroxymethylpropyl)ethylenediamine; Ethambutol & Propolis; Servambutol; AR-1A7805; Etambutolo [DCIT]; KBioSS_001538; CID3279; (+)-ethambutol; LS-46537; (2S,2'S)-2,2'-(ethane-1,2-diyldiimino)dibutan-1-ol; (-)-(R,R)-2,2'-(1,2-Ethylenediimino)-di-1-butanol; (+)-(S,S)-2,2'-(1,2-Ethylenediimino)-di-1-butanol; 1-Butanol, 2,2'-(1,2-ethanediyldiimino)bis-, (R)-; 1070-11-7; Myambutol; Spectrum5_000702; Purderal; 1-Butanol, 2,2'-(1,2-ethanediyldiimino)bis-, [S-(R*,R*)]-; Prestwick2_000028; CID504259; CID465436; (S,R)-2,2'-(1,2-Ethylenediimino)-di-1-butanol; NCGC00016560-01; Miambutol; CAS-1070-11-7; Etambutol; Ethambutol, meso form; 74-55-5; DB00330; Spectrum_001058; 1-Butanol, 2,2'-(ethylenediimino)di-, (+)-; 1-Butanol, 2,2'-(1,2-ethanediyldiimino)bis-, (S-(R*,R*))-; AC1Q2C85; CHEBI:4877; Spectrum2_001014; 1-Butanol, 2,2'-(1,2-ethanediyldiimino)bis-, (R-(R*,R*))-; ethambutol; Ethambutol & EEP; EINECS 200-810-6; CID470071; NCGC00179661-01	74-55-5	3279	9198	TTDS00383	Probable arabinosyltransferase	N/A	N/A	N/A	N/A	inhibitor
DAP000496	Amiodarone	Amiodaronum [INN-Latin]; Alphapharm Brand of Amiodarone Hydrochloride; Bio1_000515; KBio2_005430; Leurquin Brand of Amiodarone Hydrochloride; Prestwick0_000409; (2-{4-[(2-butyl-1-benzofuran-3-yl)carbonyl]-2,6-diiodophenoxy}ethyl)diethylamine; STK529812; Cordarex; L-3428; Lopac0_000122; L3428; Amio-Aqueous IV; 2-Butyl-3-benzofuranyl p-[(2-diethylamino)ethoxy]-m,m-diiodophenyl ketone; Amiodaronum; NCGC00024242-06; Spectrum_000261; Spectrum2_001813; nchembio732-comp1; Aminodarone; 2-Butyl-3-benzofuranyl p-((2-diethylamino)ethoxy)-m,m-diiodophenyl ketone; Methanone, (2-butyl-3-benzofuranyl)[4-[2-(diethylamino)ethoxy]-3,5-diiodophenyl]-; UNII-N3RQ532IUT; 2-Butyl-3-benzofuranyl 4-(2-(diethylamino)ethoxy)-3,5-diiodophenyl ketone; Bio2_000294; BRN 1271711; 2-Butyl-3-(4'-beta-N-diethylaminoethoxy-3',5'-diiodobenzoyl)benzofuran; IDI1_000079; CHEBI:2663; Amiodarone Base; KBio2_003309; 2-Butyl-3-(3,5-diiodo-4-(beta-diethylaminoethoxy)benzoyl)benzofuran; NCGC00024242-05; Spectrum5_001533; SPBio_001825; Amiodarona [INN-Spanish]; Amiobeta; KBio2_000294; MolPort-003-703-670; Corbionax; Pacerone; on; KBio1_000079; STOCK1S-12240; Prestwick3_000409; Ketone, 2-butyl-3-benzofuranyl 4-(2-(diethylamino)ethoxy)-3,5-diiodophenyl; NCI60_041885; BIDD:PXR0146; 1951-25-3; KBio2_005877; BIDD:GT0425; D02910; Amjodaronum; AC1Q2VCU; Amidorone; DivK1c_000079; Cordarone Intravenous; KBioGR_000294; AC1L1D1R; CHEMBL633; Methanone, (2-butyl-3-benzofuranyl)(4-(2-(diethylamino)ethoxy)-3,5-diiodophenyl)-; QTL1_000008; BSPBio_001574; Ketone, 2-butyl-3-benzofuranyl 4-[2-(diethylamino)ethoxy]-3,5-diiodophenyl (7CI,8CI); IDI1_034044; NCGC00015096-03; Amiodarona; Berenguer Infale Brand of Amiodarone Hydrochloride; G Gam Brand of Amiodarone Hydrochloride; Armstrong Brand of Amiodarone Hydrochloride; 2-Butyl-3-[3,5-diiodo-4-(2-di; (2-butyl-1-benzofuran-3-yl)-[4-(2-diethylaminoethyloxy)-3,5-diiodophenyl]methanone; pms-Amiodarone; Kordaron; L001174; NINDS_000079; EINECS 217-772-1; Amiodarex; Sedacoron; Amiodarone (USAN/INN); Wyeth Brand of Amiodarone Hydrochloride; Prestwick2_000409; SKF 33134-A; NCGC00015096-10; Amiodarons; UNM000001215003; KBioSS_000294; Rytmarone; NCGC00024242-04; DB01118; KBio3_000587; Hexal Brand of Amiodarone Hydrochloride; Amiohexal; LS-87088; ASTA Medica Brand of Amiodarone Hydrochloride; NCGC00015096-02; (2-Butyl-3-benzofuranyl)(4-(2-(diethylamino)ethoxy)-3,5-diidophenyl)methanone; BSPBio_000338; Ancar; Pharma Investi Brand of Amiodarone Hydrochloride; 2-n-Butyl-3',5'-diiodo-4'-N-diethylaminoethoxy-3-benzoylbenzofuran; (2-butyl-1-benzofuran-3-yl){4-[2-(diethylamino)ethoxy]-3,5-diiodophenyl}methanone; BPBio1_000372; SKF 33134A; KBio2_000741; NCGC00024242-03; Lopac-A-8423; HMS2089C07; Aratac; KBio3_001800; Sedacorone; CAS-19774-82-4; AB00053422; HMS1989O16; CID2157; Betapharm Brand of Amiodarone Hydrochloride; Spectrum4_001190; Prestwick1_000409; 2-Butyl-3-(3,5-diiodo-4-(2-diethylaminoethoxy)benzoyl)benzofuran; amiodarone; Labaz; Tachydaron; Bio2_000774; D000638; KBio3_000588; (2-butylbenzofuran-3-yl)-[4-(2-diethylaminoethoxy)-3,5-diiodo-phenyl]-methanone; SPBio_002277; KBioGR_001859; Amiodarone [USAN:BAN:INN]; CBiol_001740; KBio2_002862; 5-18-02-00353 (Beilstein Handbook Reference); BSPBio_002580; Sanofi Winthrop Brand of Amiodarone Hydrochloride; nchembio.79-comp9; NCGC00015096-01; L 3428; C06823; Arycor; Bio1_001004; (2-butyl-1-benzofuran-3-yl)(4-{[2-(diethylamino)ethyl]oxy}-3,5-diiodophenyl)methanone; Bio1_000026; C25H29I2NO3; Cordarone; HMS1791O16; KBioSS_000741; Ortacrone; Spectrum3_001050; Braxan; ethylaminoethoxy)benzoyl]benzofuran	1951-25-3	2157	159329	TTDS00147	Potassium voltage-gated channel subfamily H member 2	Eag homolog;Eag related protein 1;Erg1;Ether-a-go-go related gene potassium channel 1;Ether-a-go-go related protein 1;H-ERG;HERG K+ channel;Voltage-gated potassium channel subunit Kv11.1	Q12809	3757	ENSG00000055118	blocker
DCL000837	HP-184	1H-Indol-1-amine, N-(3-fluoro-4-pyridinyl)-3-methyl-N-propyl-, monohydrochloride; 119229-64-0; N-(3-fluoropyridin-4-yl)-3-methyl-N-propylindol-1-amine; EN002124; HP-184; N-(3-Fluoro-4-pyridinyl)-3-methyl-N-propyl-1H-indol-1-amine; 119229-65-1; Nerispirdine; 1H-Indol-1-amine, N-(3-fluoro-4-pyridinyl)-3-methyl-N-propyl-; CID3081185; UNII-G7M7YWO6CG; Nerispirdine hydrochloride; AC1MIWGX; HP 184; N-(n-Propyl)-3-fluoro-4-pyridinyl-1H-3-methylindol-1-amine hydrochloride	119229-65-1	10302451	3882236	TTDS00147	Potassium voltage-gated channel subfamily H member 2	Eag homolog;Eag related protein 1;Erg1;Ether-a-go-go related gene potassium channel 1;Ether-a-go-go related protein 1;H-ERG;HERG K+ channel;Voltage-gated potassium channel subunit Kv11.1	Q12809	3757	ENSG00000055118	blocker
DAP000497	Propafenone	1-(2-(2-Hydroxy-3-(propylamino)propoxy)phenyl)-3-phenyl-1-propanone; CHEBI:127112; CHEMBL631; NINDS_000906; KBioGR_000817; BRD-A26334849-001-02-1; 107300-59-4; D08435; BRD-A26334849-003-05-0; LS-123071; BCBcMAP01_000079; SBB067234; Spectrum3_001905; 1-[2-[2-hydroxy-3-(propylamino)propoxy]phenyl]-3-phenylpropan-1-one; Spectrum2_001603; 54063-53-5; 1-Propanone, 1-[2-[2-hydroxy-3-(propylamino)propoxy]phenyl]-3-phenyl-; Lopac0_000919; Spectrum_001612; CPD001453705; 1-Propanone, 1-(2-(2-hydroxy-3-(propylamino)propoxy)phenyl)-3-phenyl-; KBio2_004660; Propafenon Hexal; S2500_Selleck; 1-[2-(2-Hydroxy-3-[propylamino]- propoxy)phenyl]-3-phenyl-1-propanone; HMS2089E09; Propafenon hexal (TN); Spectrum5_001271; AC1L1J9C; NCGC00089784-05; BSPBio_001465; Propafenona [INN-Spanish]; SAM002564228; NCGC00089784-02; Propafenone [INN:BAN]; 1-[2-(2-Hydroxy-3-(propylamino)propoxy)phenyl]-3-phenyl-1-propanone hydrochloride; AKOS000276940; Prestwick3_000499; BPBio1_000437; DB01182; Prestwick1_000499; BSPBio_000397; UNII-68IQX3T69U; KBioSS_002092; P4670_SIGMA; KBio2_007228; HMS1791J07; C07381; Propafenona; SPBio_001605; NCGC00089784-04; Spectrum4_000209; Propafenone (INN); Rythmol; EINECS 258-955-6; KBio2_002092; Propafenonum; 1-(2-(2-Hydroxy-3-propylaminopropoxy)phenyl)-3-phenylpropan-1-one; HMS1989J07; NCGC00015819-10; Propafenonum [INN-Latin]; BSPBio_003470; DivK1c_000906; IDI1_000906; NCGC00089784-03; CID4932; AB00053687; SPBio_002318; KBio3_002974; MolPort-000-881-283; Propafenone-HCl; Prestwick2_000499; propafenone; 34183-22-7 (hydrochloride); MolPort-002-545-323; KBio1_000906; Prestwick0_000499	54063-53-5	4932	181774	TTDS00147	Potassium voltage-gated channel subfamily H member 2	Eag homolog;Eag related protein 1;Erg1;Ether-a-go-go related gene potassium channel 1;Ether-a-go-go related protein 1;H-ERG;HERG K+ channel;Voltage-gated potassium channel subunit Kv11.1	Q12809	3757	ENSG00000055118	blocker
DAP000495	Dofetilide	Dofetilide; HMS2051N14; AC-385; MLS001424185; S1658_Selleck; MolPort-003-847-012; Dofetilidum; Dofetilida [INN-Spanish]; Dofetilide (JAN/USAN/INN); CPD000466333; Dofetilida; Dofetilide [USAN:BAN:INN]; Tikosyn, UK68798, Dofetilide; N-[4-[2-[2-[4-(methanesulfonamido)phenoxy]ethyl-methylamino]ethyl]phenyl]methanesulfonamide; UK 68798; beta-((p-Methanesulfonamidophenethyl)methylamino)methanesulfono-p-phenetidide; Methanesulfonamide, N-(4-(2-(methyl(2-(4-((methylsulfonyl)amino)phenoxy)ethyl)amino)ethyl)phenyl); AC1Q6VUS; UK 68,798; N-(4-{2-[methyl(2-{4-[(methylsulfonyl)amino]phenoxy}ethyl)amino]ethyl}phenyl)methanesulfonamide; 1-(4-methanesulfonamidophenoxy)-2-(N-(4-methanesulfonamidophenethyl)-N-methylamine)ethane; Dofetilidum [INN-Latin]; Methanesulfonamide, N-(4-(2-(methyl(2-(4-((methylsulfonyl)amino)phenoxy)ethyl)amino)ethyl)phenyl)-; Tikosyn; D00647; 115256-11-6; UK-68,798; CHEBI:4681; DB00204; Xelide; NCGC00164549-01; TL8000450; UNII-R4Z9X1N2ND; CID71329; SAM001246621; C063533; CHEMBL473; SMR000466333; Ambap115256-11-6; AC1L2FYH; I06-0340; LS-90151; 1-MSPMPE; MLS000759442; Tikosyn (TN); C19H27N3O5S2; C07751; HMS2089F03; UK-68798	115256-11-6	71329	213557	TTDS00147	Potassium voltage-gated channel subfamily H member 2	Eag homolog;Eag related protein 1;Erg1;Ether-a-go-go related gene potassium channel 1;Ether-a-go-go related protein 1;H-ERG;HERG K+ channel;Voltage-gated potassium channel subunit Kv11.1	Q12809	3757	ENSG00000055118	blocker
DAP001289	Alglucosidase alfa	N/A	420784-05-0	N/A	46504595	TTDS00481	Mannose-6-phosphate receptor	46 kDa mannose 6-phosphate receptor;CD Man-6-P receptor;CD-MPR;M6PR;MPR 46;MPR46;MPRD	P20645	4074	ENSG00000003056	binder
DAP001290	Galsulfase	D06565; 552858-79-4; Galsulfase; Galsulfase (genetical recombination); Aryplase; Galsulfase (USAN/INN); Aryplase (TN); Galsulfase (genetical recombination) (JAN)	552858-79-4	N/A	47208221	TTDS00481	Mannose-6-phosphate receptor	46 kDa mannose 6-phosphate receptor;CD Man-6-P receptor;CD-MPR;M6PR;MPR 46;MPR46;MPRD	P20645	4074	ENSG00000003056	binder
DAP000703	Zalcitabine	NCGC00090705-01; Ro 24-2027/000; Lopac0_000360; LS-1645; C9H13N3O3; ddC; NCGC00090705-10; C07207; SMR000058253; PC-SOD & ddC; HMS1548B19; 2',3'-DIDEOXYCYTIDINE; .beta.-D-2',3'-Dideoxycytidine & Granulocyte-macrophage colony-stimulating factor; Hivid, Dideoxycytidine, NSC 606170, Zalcitabine; D00412; NSC 606170; S1719_Selleck; ddC & GM-CSF; NCGC00090705-06; MLS001055363; 4-amino-1-[(2R,5S)-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one; AC1L2N6R; 2',3'-Dideoxycytidine & Nanoparticles (from human serum albumin or polyhexylcyanoacrylate); Zalcitabine (JAN/USP/INN); Interferon AD + ddC; DB00943; Sulfated polysaccharide-peptidoglycan DS-4152 & 2',3'-Dideoxycytidine; Hivid(TM); HSDB 7156; NCGC00179242-01; SRI-7707; DDC (DDC); ddC & NP (from PHCA or HSA); NCGC00090705-07; 3'-Azido-3'-deoxythymidine/2',3'-Dideoxycytidine; 16803P; CCRIS 692; Ro-24-2027/000; CID24066; ZINC00039906; UPCMLD-DP115:001; NSC606170; .beta.-D-2',3'-Dideoxycytidine; BPBio1_001378; D3581; HMS1571O15; MolPort-002-885-873; BSPBio_001253; Prestwick3_001037; zalcitabine; 1-(2,3-Dideoxy-beta-D-ribofuranosyl)cytosine; CPD000058253; 2',3'-Dideoxycytidine & Interferon.alpha.; ddC & IFN.alpha.; SAM001246779; Cytidine, 2',3'-dideoxy-; Hivid (TN); ddCyd; EU-0100360; ddC (Antiviral); Zalcitabine [USAN:INN:BAN]; NCGC00090705-03; UNII-6L3XT8CB3I; Lecithinized superoxide dismutase & .beta.-D-2',3'-Dideoxycytidine; Dideoxycytidine; 36775_FLUKA; DS-4152 & ddC; Cytidine, 2',3'-dideoxy- & Colony-stimulating factor; MLS000759540; MLS000069636; .beta.-D-DDC; ddC & sCD4; 7481-89-2; NCGC00090705-02; 5-25-14-00313 (Beilstein Handbook Reference); HIVID; Cytidine, 2',3'-dideoxy- & Interferon.alpha.; CHEBI:10101; HMS2051H18; SPBio_003104; D 5782; 4-amino-1-[(2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one; Zalcitibine; Prestwick1_001037; HMS2090C12; UPCMLD-DP115; 2',3'-Dideoxycytidine & sCD4(soluble recombinant protein); Prestwick0_001037; bmse000712; BRN 0654956; TimTec1_004969; MLS001424210; NCGC00090705-05; ddC & Interferon.alpha.; Prestwick2_001037; 2,3-dideoxycytidine; KS-1130; AC-824; CHEMBL853; NSC-606170; D5782_SIGMA	7481-89-2	24066	166590	TTDS00318	HIV reverse transcriptase	N/A	N/A	N/A	N/A	inhibitor
DAP000704	Abacavir	CHEMBL1380; (1S,4R)-4-[2-Amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol; 168146-84-7; {(1S-cis)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]cyclopent-2-en-1-yl}methanol; Bio-0001; [(1S,4R)-4-[2-amino-6-(cyclopropylamino)purin-9-yl]cyclopent-2-en-1-yl]methanol; D07057; NSC742406; abacavir; DB01048; ZINC02015928; AC1L9AXG; Ziagen (TM)(*Succinate salt*); (+/-)-Abacavir; C07624; Abacavir [INN]; CID441300; NCGC00164560-02; 136470-78-5; Abacavir (INN); (+/-)-4-[2-Amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol; Ziagen; 1592U89; CHEBI:421707; Trizivir; NCGC00164560-01	136470-78-5	65140	208126	TTDS00318	HIV reverse transcriptase	N/A	N/A	N/A	N/A	inhibitor
DAP000701	Zidovudine	CHEBI:127307; HMS2090G11; Azidothymidine; 3-Azido-3-deoxythymidine; HMS1921J20; BSPBio_000365; AZT & SST; HMS2092D06; AZT & rIFN.alpha.2; 3'-Azido-3'-deoxythymidine & Interleukin-2; Spectrum2_000927; AZT, Antiviral; Retrovir; CHEMBL129; 3'-Azido-3'deoxythymidine & Interferon .alpha.; Retrovir(TM); BRD-K72903603-001-04-6; Prestwick3_000333; Spectrum5_001101; AZT & HPA; DRG-0004; D015215; CHEBI:10110; C07210; NCGC00023945-08; Compound S; Zidovudine [USAN:INN:BAN:JAN]; CID35370; 3'-Azido-3'-deoxythymidine & Lithium & Interleukin-6; NINDS_000524; MLS000028548; NCGC00178237-02; Zidovudinum [Latin]; AZT & Li & GM-CSF; DS-4152 & AZT; Apo-Zidovudine; Interferon AD + 3'-azido-3'-deoxythymidine; 3'-Azidothymidine; BSPBio_003153; 3' Azido 3' deoxythymidine; LS-1159; BWA-509U; AZT & Colony-stimulating factor 2; HSDB 6515; AZT & Li & IL-6; Met-SDF-1.beta. & AZT; 3'-azido-3'-deoxythymidine, AZT; KBio3_002653; 3'-Deoxy-3'-azidothymidine; BWA509U; AZT & EPO; 399024-19-2; antiviral; AZT; 3'-Azido-2',3'-Dideoxythymidine; NCGC00023945-03; ZINC03779042; AZT & rsT4; AZT & Li & EPO; KBio1_000524; azidodeoxythymidine; SN-3-dipalmitoylglycerophospho-AZT (in a lipid vesicle); BW-A 509U; 1-(3-Azido-2,3-dideoxy-beta-D-ribofuranosyl)thymine; AZT Antiviral; IDI1_000524; 3'-Azido-3'-deoxythymidine & Interleukin-6; Zidovudina; NSC 602670; AZT & rsCD4 & rIFN.alpha.A; 3'-Azido-3'-deoxythymidine; AZT & NP (from PHCA or HSA); STK801891; Zidovudina [Spanish]; AZT & Interferon-.alpha.-2; KBioSS_001828; Liposomal AZT-SN-3; NCGC00178237-01; Aztec; CPD000058351; AZT & PM-19; Intron A & AZT; Zidovudine EP III; MLS002222249; AZT & GM-CSF; SAM002548971; KBio2_004396; CCRIS 105; AZT & IFN.alpha.; rIFN-beta seron & AZT; racemic-dipalmitoylglycerophospho-AZT (in a lipid vesicle); 3'-Azido-3'-deoxythymidine & Lithium & Interleukin-1; SPECTRUM1502109; AC1L1TKL; 3'-Azido-3'-deoxythymidine & Sho-Saiko-To; AC1Q2OEK; Antiviral AZT; AZT & Concanavalin A (ConA); PC-SOD+AZT; zidovudin; 3'-Azido-3'-deoxythymidine & Erythropoietin; NCGC00023945-04; Zidovudinum; Spectrum4_000332; DivK1c_000524; AZT & IL-1; 3' Azido 2',3' Dideoxythymidine; 3'-Azido-3'-deoxythymidine & Lymphoblastoid Interferon; Zidovudine (JAN/USP/INN); SPBio_000834; AZT & IL-6; AZT & sCD4; 3'-Azido-3'-deoxythymidine & Lithium & Erythropoietin; KBio2_006964; Spectrum_001348; Novo-Azt; AZT & Li & IL-1; ZIDOVUDINE [AZT]; Propolis & Thymidine, 3'-azido-3'-deoxy-; 3'-Azido-3'-deoxythymidine & Heteropolyoxotungstate PM-19; K7 [P Ti2 W10 O40]; KBioGR_000703; ZVD; Liposomal AZT-SN-1; MLS001055351; Propolis+AZT; Thymidine, 3'-azido-3'-deoxy-; AZT & Lymphoblastoid Interferon; BB_NC-1012; 3'-Azido-3'-deoxythymidine (AIDS); Cpd S; zidovudine; 3'-Azido-3'-deoxythymidine & Concanavalin A; A2169_SIGMA; 3&prime;-Azido-3&prime;-deoxythymidine; HMS501K06; Met-SDF-1.beta. & Zidovudine; SMR000058351; AZT & srCD4; AZT+PRO 140; AZT & IL-2; UNII-4B9XT59T7S; MLS002153202; AZT (Antiviral); Zidovudine+PRO 140; 3'-Azido-3'-deoxythymidine & Interleukin-1; Retrovir (TN); BW-A509U; BW A509U; BWA 509U; 30516-87-1; AZT TRANSPLACENTAL CARCINOGENESIS STUDY; BPBio1_000403; Spectrum3_001507; ZDV; DB00495; AZT & CD4(178)-PE 40; MLS001076358; SN-1-dipalmitoylglycerophospho-AZT (in a lipid vesicle); KBio2_001828; MolPort-002-507-286; Racemic Liposomal AZT; BW-A-509U; D00413; NCGC00023945-05	30516-87-1	35370	7847479	TTDS00318	HIV reverse transcriptase	N/A	N/A	N/A	N/A	inhibitor
DAP000702	Didanosine	ddI & GM-CSF; Lecithinized superoxide dismutase & Inosine, 2',3'-dideoxy-; 2',3'-Dideoxyinosine & sCD4(soluble recombinant protein); Listera ovata agglutinin & 2',3'-Dideoxyinosine; 9-((2R,5S)-5-Hydroxymethyl-tetrahydro-furan-2-yl)-1,9-dihydro-purin-6-one; Bio-0685; D3066; NCGC00159514-02; C06953; DDI and rIFN.alpha.2; NCGC00159514-03; Intron A & Videx; DDI; MLS002154216; SAM001246673; Dideoxyinosine (DDI); ddI & sCD4(rsCD4); BMY 40900; 2',3'-Dideoxyinosine & Interferon-.alpha.; CHEMBL1460; LOA & ddI; BRN 3619529; Didanosinum [INN-Latin]; MLS001055350; CID50599; Videx(TM); NSC 612049; didanosine; MolPort-002-507-371; MLS000759469; 2',3'-Dideoxyinosine & Granulocyte-macrophage colony-stimulating factor; DS-4152 & ddI; 2'3'-DIDEOXYINOSINE; Hypoxanthine ddN; Videx EC; ddIno; 2',3'-Dideoxyinosine (ddI); NSC612049; FT-0082664; CHEBI:490877; NCGC00164280-01; Didanosinum; NCGC00090691-01; 9-[(2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1,9-dihydro-6H-purin-6-one; 9-(2,3-Dideoxy-beta-D-ribofuranosyl)hypoxanthine; HMS2051J11; Didanosina; HMS2089N20; 2',3'-Dideoxyinosine (AIDS Initiative); DRG-0016; 2DI; PC-SOD+ddI; S1702_Selleck; Inosine, 2',3'-dideoxy- & Recombinant Interferon-.alpha.-2; D2I; Videx; NSC-612049; DB02392; 9-((2R,5S)-5-(hydroxymethyl)-tetrahydrofuran-2-yl)-1H-purin-6(9H)-one; D00296; 69655-05-6; 2',3'-dideoxyinosine, DDI, NSC 612049, Didanosine; MolPort-002-885-819; KS-1049; HSDB 6548; ddI & IFN-.alpha.; UNII-K3GDH6OH08; 9-(2,3-Dideoxy-beta-D-ribofuranosyl)-6-oxopurine; BMY-40900; 2',3'-Dideoxyinosine; ZINC13597823; DIDEOXYINOSINE; Didanosina [INN-Spanish]; Didanosine (JAN/USAN/INN); AC-12026; SMR000058576; 3'-Azido-3'-deoxythymidine + 2',3'-Dideoxyinosine; CCRIS 805; Videx EC(TM)(slow-release capsules); ddI + d4T combination; DB00900; Sulfated polysaccharide-peptidoglycan DS-4152 & 2',3'-Dideoxyinosine; MLS001424118; AC1L19ET; Didanosine and Interferon-.alpha.-2; CPD000058576; 9-[(2R,5R)-5-(HYDROXYMETHYL)TETRAHYDROFURAN-2-YL]-1,9-DIHYDRO-6H-PURIN-6-ONE; Videx (TN); 9-[(2R,5S)-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one; 2,3-dideoxyinosine	69655-05-6	50599	189028	TTDS00318	HIV reverse transcriptase	N/A	N/A	N/A	N/A	inhibitor
DAP000172	Stavudine	NCGC00023212-03; 2',3'-Didehydro-2',3'-dideoxythmidine; UNII-BO9LE4QFZF; SAM001246729; STK801888; 3'- Azido-3'-deoxythymidine & Granulocyte-macrophage colony-stimulating factor; CHEBI:207119; Estavudina [INN-Spanish]; C07312; HSDB 7338; 3'-Deoxy-2'-thymidinene; MolPort-002-507-283; Bristol-Myers Brand of Stavudine; NCGC00023212-07; 1-(2,3-Dideoxy-beta-D-glycero-2-pentenofuranosyl)thymine; CPD000058350; 2',3' Didehydro 3' deoxythymidine; BMY27857; d4T; BRN 0618327; 2',3'-DIDEHYDRO-3'-DEOXYTHYMIDINE (DDI); Zerut XR; 132425-31-1; NCGC00023212-08; 1-[(2R,5S)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-5-methylpyrimidine-2,4-dione; LS-1160; 2',3'-Anhydrothymidine; 1-[(2R,5S)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-5-methylpyrimidine-2,4(1H,3H)-dione; NCGC00023212-10; Bristol-Myers Squibb Brand of Stavudine; 3056-17-5; Zerit(TM); Zerit; D 4T (nucleoside); BMY 27857; Zerit (TN); Sanilvudine (JAN); NSC 163661; 2',3'-Didehydro-3'-deoxythymidine; D4T & GM-CSF; Stavudinum [INN-Latin]; MLS001055348; NSC163661; FT-0082665; AC1Q6BSH; AC1L2BQ9; Stavudine, Monosodium Salt; Stavudine (USAN/INN); sanilvudine; Thymine, 1-(2,3-dideoxy-beta-D-glycero-pent-2-enofuranosyl)- (7CI,8CI); ZINC00137884; BMY-27857; Zent; NCGC00023212-05; Stavudine [USAN:INN:BAN]; 3'-Deoxy-2',3'-didehydrothymidine; DB00649; D00445; Stavudinum; MLS000759504; 1-[5-(hydroxymethyl)-2,5-dihydro-2-furanyl]-5-methyl-2,4(1H,3H)-pyrimidinedione & Colony-stimulating factor 2; Thymidine, 2',3'-didehydro-3'-deoxy-; D018119; 2'-Thymidinene, 3'-deoxy-; D 1413; STV; CPD000673569; D 4T; MLS000028546; AC-5263; Estavudina; HMS2051O20; NCGC00023212-04; 1-(2,3-Dideoxy-beta-D-glycero-pent-2-enofuranosyl)thymine; D1413_SIGMA; CHEMBL991; Zerit Xr; D4TMBY-27857-3; Dideoxydidehydrothymidine; SMR000673569; Stavudine [USAN:BAN:INN]; EU-0100336; Lopac0_000336; ddeTyd; stavudine; SAM002589948; D3580; NCGC00023212-09; SMR000058350; ddeThd; Thymidine, 2',3'-didehydro-, 3'-deoxy-; CID18283; 2',3'-Anhydrothymidine; d4T; BB_NC-1008; MLS001077292; BIDD:GT0082; 2',3'-Didehydro-3'-deoxythimidine	3056-17-5	18283	9520	TTDS00318	HIV reverse transcriptase	N/A	N/A	N/A	N/A	inhibitor
DAP000700	Tenofovir	Phosphonic acid, [[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]- & Galanthus nivalis agglutinin (GNA); UNII-99YXE507IL; (R)-PMPA; Phosphonic acid, [[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]- & Hippeastrum hybrid agglutinin( HHA); Phosphonic acid, [[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]- (9CI); [(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethylphosphonic acid; Phosphonic acid, [[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]-; (R)-9-(2-Phosphonylmethoxypropyl)adenine; GNA & Tenofovir; 206184-49-8; Phosphonic acid, [[2-(6-amino-9H-purin-9; CHEMBL483; (R)-9-(2-Phosphonomethoxypropyl)adenine; GS 1275; GS 1278; Viread, Tenofovir; CHEBI:45809; TFV; KS-5021; NCGC00167535-01; S1401_Selleck; CID464205; HHA & Tenofovir; GS1278; PMPA; PMPA-(R); AC-760; D,L-Tenofovir; 147127-20-6; Apropovir; -yl)-1-methylethoxy]methyl]-, (R)-; Phosphonic acid, P-[[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]-; DB00300; Tenofovir; MolPort-003-850-411; AC1LA9BO; Tenefovir	147127-20-6	464205	699321	TTDS00318	HIV reverse transcriptase	N/A	N/A	N/A	N/A	inhibitor
DAP000056	Foscarnet	Foscarnet sodico [Spanish]; Spectrum3_001484; Foscarnetum natricum [Latin]; Spectrum2_000668; Foscarnet sodico; KBio2_001839; 4428-95-9 (Parent); Formic acid, phosphono-; Triapten; 34156-56-4; Foscarnetum natricum [INN-Latin]; Carboxyphosphonic acid; CHEMBL754; Foscarnet sodique [INN-French]; MSL & PFA; Phosphonoformic acid trisodium salt hexahydrate; KBioSS_001839; Foscarnet sodium (USAN/INN); AC1NB82R; KBio2_006975; 63585-09-1; Spectrum_001359; Phosphinecarboxylic acid, dihydroxy-, oxide, trisodium salt, hexahydrate; MolPort-003-895-968; HMS502N17; P6801_SIGMA; Foscarmet; 1nki; CHEBI:60269; dihydroxyphosphanecarboxylic acid oxide; Dihydroxyphosphinecarboxylic acid oxide and MSL, neutralizing monoclonal antibody; Dihydroxyphosphinecarboxylic acid oxide trisodium salt hexahydrate; foscarnet; Phosphonoformic acid; FOSCARNET SODIUM; LS-105953; AR-1L5079; AC1L1FVT; NChemBio.2007.9-comp7; 4428-95-9; Phosphinecarboxylic acid, dihydroxy-, oxide; Trisodium phosphonoformate hexahydrate; D02267; SPECTRUM1502019; Sodium phosphonoformate tribasic hexahydrate; Phosphonoformate; trisodium dioxidophosphinecarboxylate oxide; DRG-0017; Foscarnet sodium hydrate (JAN); Phosphonoformic acid, trisodium salt; Forscarnet sodium; Trisodium carboxyphosphate; PFA & rIFN.alpha.A; 63585-09-1 (tri-hydrochloride salt); A-29622; Spectrum4_000840; UNII-964YS0OOG1; CHEBI:141644; Foscarneto sodico [INN-Spanish]; LS-105952; Ambap63585-09-1; Foscarnet & IFN-.ALPHA.; Foscarnet sodique [French]; CID44561; AC-2085; CHEBI:127780; Dihydroxyphosphinecarboxylic acid oxide; KBio1_000915; Dihydroxyphosphinecarboxylic acid oxide trisodium salt; NCGC00094941-02; trisodium phosphonatoformate; CID169569; DB00529; BSPBio_003067; Trisodium phosphonoformte hexahydrate; UNII-364P9RVW4X; sodium dioxidophosphanecarboxylate oxide hydrate(3:1:6); IDI1_000915; SPBio_000735; EHB 776; AC1L5400; CID3415; LS-183979; Foscarnet sodium [USAN:INN:BAN]; Formic acid, phosphono-, trisodium salt, hexahydrate; Phosphinecarboxylic acid, dihydroxy-, oxide, trisodium salt; Phosphonoformic acid & IFN-.ALPHA.; Foscavir (TN); Foscavir; Phosphonoformic acid, trisodium salt, hexahydrate; A 29622; D00579; MolPort-003-665-560; Phgosphonocarboxylic acid; Foscarnet sodique; P6801_ALDRICH; CHEMBL666; 79510_FLUKA; Spectrum5_000932; DivK1c_000915; phosphonomethanoic acid; HMS1921D18; trisodium carboxyphosphate (anhydrous); Virudin; NCGC00094941-01; trisodium phosphonoformate (anhydrous); Trisodium phosphonoformate; KBio2_004407; trisodium phosphonatoformate hexahydrate; foscarnet sodium hexahydrate; NSC313410; Foscarneto sodico; AC1L2C37; LS-187793; EHB-776; trisodium dioxidophosphanecarboxylate oxide; HS-0008; Phosphonoformate(trisodium) & Recombinant Alpha-A Interferon; Foscarnetum natricum; HMS2092N15; Foscarnet sodium hydrate; LS-187063; NINDS_000915; AC1Q1UNV; KBio3_002567; Prestwick_1024; KBioGR_001419; C06456	63585-09-1	3415	595937	TTDS00318	HIV reverse transcriptase	N/A	N/A	N/A	N/A	inhibitor
DAP000138	Clotrimazole	Mycelex Troches; MLS001423972; Myclo Cream; Bayer Brand 1 of Clotrimazole; Lotrimin Af; I01-3474; HSDB 3266; D003022; D00282; NCGC00015251-01; NSC257473; Tibatin; Esparol; Mycelex-7 Combination Pack; Lotrimin (TN); KBio2_001823; 117829-71-7; Canesten 1-Day Therapy; Schering Brand of Clotrimazole; Cimitidine; CAS-23593-75-1; Clotrimazole Schering Brand; Spectrum_001343; Mycelex Solution; Clotrimaderm; Empecid; CPD-8926; Pedisafe; Lotrimax; clotrimazole; KBioGR_000850; SPBio_000176; C6019_SIGMA; 3ACDFDF8-38E3-4368-85D0-BDF8AE1E6591; Spectrum3_000359; Mycelex Twin Pack; Clotrimazole [USAN:INN:BAN:JAN]; BIDD:PXR0036; C06922; Canesten Cream; EINECS 245-764-8; NCGC00093761-03; Canestine; BSPBio_000114; Canesten Combi-Pak 3-Day Therapy; Rimazole; Lotrimin AF Lotion; Neo-Zol Cream; Gyne-Lotrimin 3; Mycelex G; CHEMBL104; Clotrimazol; LS-78271; NCGC00093761-04; Canesten Combi-Pak 1-Day Therapy; Lotrimin Cream; BIDD:GT0450; BAY-5097; Clotrimazolum; Lotrimin; Fem Care; Pan-Fungex; KBio3_001277; Spectrum5_000781; 33894_RIEDEL; Mono-baycuten; Gyne-Lotrimin Combination Pack; Kanesten; Bio-0442; Trivagizole 3; FB 5097; C 6019; Mycosporin; Gynix; Prestwick_120; B 5097; Bay-B 5097; 33894_FLUKA; Spectrum2_000128; Klotrimazole; Lotrimin AF Jock-Itch Cream; MLS000028502; Canesten 6-Day Therapy; Mycelex (TN); NCGC00093761-05; Lotrimin AF Cream; Prestwick0_000267; Mycofug; Prestwick1_000267; Mycelex-G; Prestwick3_000267; AC-279; Mycelex OTC; BSPBio_002057; Desamix F; Canesten 1-Day Cream Combi-Pak; Clotrimazole (JP15/USP/INN); Canifug; Mycelex: MycosporinRimazole; Mykosporin; Lotrimin Solution; Chlotrimazole; MLS000758243; HMS1920O21; QTL1_000024; C22H17ClN2; DivK1c_000665; DRG-0072; (Chlorotrityl)imidazole; NCIMech_000609; KBio2_006959; BAY b5097; Gyne lotrimin; CID2812; Myclo-Gyne; Canestene; NCGC00093761-01; FemCare; NSC 257473; Gyne-Lotrimin 3 Combination Pack; NCGC00015251-03; Cutistad; SPECTRUM1500200; DB00257; CHEBI:3764; SAM001247056; Bayer Brand 2 of Clotrimazole; Canesten Solution; Mycelax; clotrimeizol; HMS2051E11; Mycelex; NCGC00015251-09; Mycelex-7; nchembio790-comp30; Lopac0_000315; BPBio1_000126; STK700023; Clomatin; KBioSS_001823; Myclo Spray Solution; BAY b 5097; NCGC00015251-02; Canesten 3-Day Therapy; SPBio_002333; FB b 5097; NINDS_000665; SMR000058306; AB00051951; Spectrum4_000295; Gyne-Lotrimin; Nalbix; 23593-75-1; HMS2091G10; BAYb 5097; Mycelex Cream; EU-0100315; Clotrimazol [INN-Spanish]; 1-(o-Chlorotrityl)imidazole; Lopac-C-6019; Gino-Lotremine; Lotrimin Lotion; MolPort-002-557-756; Stiemazol; BRN 0622318; CCRIS 6245; Canesten; Prestwick2_000267; Myclo Solution; Clotrimazolum [INN-Latin]; KBio1_000665; HMS502B07; BAY 5097; KBio2_004391; NCGC00093761-02; UNII-G07GZ97H65; HMS1568F16; ZINC03807804; AC1L1EIW; Bay b 9057; Lotrimin AF Solution; NCGC00093761-06; CPD000058306; nchembio.65-comp9; S1606_Selleck; Trimysten; Monobaycuten; Mycelex 7; IDI1_000665	23593-75-1	2812	174033	TTDS00418	Cytochrome P450 3A4	Albendazole monooxygenase;Albendazole sulfoxidase;CYP3A3;CYP3A4;CYPIIIA3;CYPIIIA4;Cytochrome P450 3A3;HLp;NF-25;Nifedipine oxidase;P450-PCN1;Quinine 3-monooxygenase;Taurochenodeoxycholate 6-alpha-hydroxylase	P08684	1576	ENSG00000160868	inhibitor
DAP000733	Balsalazide	C17H15N3O6; (E)-5-((4-(((2-Carboxyethyl)amino)carbonyl)phenyl)azo)-2-hydroxybenzoic acid; Balsalazido [Spanish]; HMS2052K19; SAM001246804; MLS001424257; Balsalazido; Balsalazide [INN:BAN]; DB01014; AC1O3RJF; Balsalazida [Spanish]; Ambap80573-04-2; LS-36369; (E)-5-({p-[(2-carboxyethyl)carbamoyl]phenyl}azo)-2-salicylic acid; Balsalazide (INN); Benzoic acid, 5-((4-(((2-carboxyethyl)amino)carbonyl)phenyl)azo)-2-hydroxy-, (E)-; Balsalazidum [Latin]; SMR000469221; CPD000469221; BIDD:GT0772; UNII-P80AL8J7ZP; 3-(2-{4-[(2-carboxyethyl)carbamoyl]phenyl}hydrazinylidene)-6-oxocyclohexa-1,4-diene-1-carboxylic acid; (3Z)-3-[[4-(2-carboxyethylcarbamoyl)phenyl]hydrazinylidene]-6-oxocyclohexa-1,4-diene-1-carboxylic acid; 5-[(E)-{4-[(2-carboxyethyl)carbamoyl]phenyl}diazenyl]-2-hydroxybenzoic acid; 5-[4-(2-carboxy-ethylcarbamoyl)-phenylazo]-2-hydroxy-benzoic acid; 80573-04-2; Balsalazida; D07488; BALSALAZIDE; Colazal; CHEBI:267413; CID6335412; Balsalazide Disodium; Balsalazidum	80573-04-2	6335412	192139	TTDS00040	Prostaglandin G/H synthase 1	COX-1;Cyclooxygenase -1;Cyclooxygenase-1;PGH synthase 1;PGHS-1;PHS 1;Prostaglandin H2 synthase 1;Prostaglandin-endoperoxide synthase 1	P23219	5742	ENSG00000095303	inhibitor
DAP000730	Suprofen	(+-)-2-(p-(2-Thenoyl)phenyl)propionic acid; BPBio1_000783; Spectrum4_001027; R-25061; 52780-12-8; Suprocil; Spectrum3_000928; KBio3_001936; R 25061; Hydratropic acid, p-(2-thenoyl)-; MLS002154015; DB00870; AC-4551; Spectrum_001157; AC1L1K6E; AC1Q1LGM; KBio2_006773; CID5359; HMS501H18; SMR001233343; D00452; BSPBio_000711; 40828-46-4; alpha-Methyl-4-(2-thienylcarbonyl)benzeneacetic acid; D013496; EINECS 258-176-1; AKOS004909426; S1761_Selleck; SPECTRUM1501161; HMS2092J07; C07320; KBio1_000476; 2-(4-(2-Thienylcarbonyl)phenyl)propanoic acid; Benzeneacetic acid, .alpha.-methyl-4-(2-thienylcarbonyl)-; 2-(4-(2-Thenoyl)phenyl)propionsaeure; Suprofen [USAN:BAN:INN:JAN]; R-25,061; Suprofene [INN-French]; Benzeneacetic acid, .alpha.-methyl-4-(2-thienylcarbonyl)-; NCGC00094916-01; DivK1c_000476; 4-(2-Thenoyl)hydratropsaeure; KBioGR_001553; TN 762; NSC 303611; Profenal; Masterfen; 2-[4-(thiophene-2-carbonyl)phenyl]propanoic acid; KBio2_001637; Prestwick2_000816; 2-[4-(thiophen-2-ylcarbonyl)phenyl]propanoic acid; Benzeneacetic acid, alpha-methyl-4-(2-thienylcarbonyl)-, (R)-; Prestwick0_000816; SPBio_002632; KBioSS_001637; KBio2_004205; Suprofen (JAN/USP/INN); NCGC00094916-03; AB00052231; TYN-762P; BRD-A34006693-001-04-8; UNII-988GU2F9PE; TN-762; HMS1570D13; Prestwick3_000816; SPBio_001540; Benzeneacetic acid, alpha-methyl-4-(2-thienylcarbonyl)-; p-2-Thenoylhydratropic acid; HMS1921L19; suprofen; Suprofenum; Maldocil; Suprol; Sutoprofen; Profenal (TN); EINECS 258-175-6; LS-76363; IDI1_000476; Prestwick_131; CHEMBL956; NCGC00094916-02; Spectrum2_001430; (S)-2-(4-(Thien-2-ylcarbonyl)phenyl)butyric acid; (R)-(Thien-2-ylcarbonyl)propionic acid; EINECS 255-096-9; 52780-13-9; CHEBI:9362; MolPort-001-791-811; 77981-82-9; TN762; Sulproltin; NINDS_000476; Suprofene; Suprofenum [INN-Latin]; Prestwick1_000816; NSC303611; Spectrum5_001103; R25061; Srendam; (-)-alpha-Methyl-4-(2-thienylcarbonyl)benzeneacetic acid; LS-124867	40828-46-4	5359	179853	TTDS00040	Prostaglandin G/H synthase 1	COX-1;Cyclooxygenase -1;Cyclooxygenase-1;PGH synthase 1;PGHS-1;PHS 1;Prostaglandin H2 synthase 1;Prostaglandin-endoperoxide synthase 1	P23219	5742	ENSG00000095303	inhibitor
DAP000806	Gamma-Homolinolenic acid	8,11,14-Icosatrienoate; (Z,Z,Z)-8,11,14-Icosatrienoate; DGLA; Ro 12-1989; all-cis-8,11,14-icosatrienoic acid; eicosa-8Z,11Z,14Z-trienoic acid; (Z,Z,Z)-8,11,14-Icosatrienoic acid; Homo-gamma-linolensaeure; 20:3, n-6,9,12 all-cis; cis,cis,cis-8,11,14-Eicosatrienoic acid; 8c,11c,14c-Eicosatriensaeure; 1783-84-2; E4504_SIGMA; MolPort-003-933-184; Homo-gamma-linolenic acid; IDI1_033756; 8,11,14-eicosatrienoic acid, (8Z,11Z,14Z)-; cis-8,cis-11,cis-14-Eicosatrienoic acid; 20:3n-6; BRD-K20152659-001-02-0; CID5280581; AC1NQX97; 8,11,14-all-cis-Eicosatrienoic acid; all-cis-Eicosa-8,11,14-triensaeure; (8Z,11Z,14Z)-Icosatrienoic acid; Dihomo-gamma-linolenic acid; (Z,Z,Z)-8,11,14-Eicosatrienoate; NCGC00161350-01; (8Z,11Z,14Z)-icosa-8,11,14-trienoic acid; HMS1361A08; (8E,11E,14E)-8,11,14-Icosatrienoic acid; CHEMBL465183; cis-8,11,14-Eicosatrienoic Acid; DB00154; NCGC00161350-02; 8,11,14-Eicosatrienoic acid; 8,11,14-Eicosatrienoate; Star GLA (GNC); LMFA01030158; C 20:3 n-6; C03242; 8,11,14-Eicosatrienoic acid, (8Z,11Z,14Z)- (9CI); (Z,Z,Z)-8,11,14-Eicosatrienoic acid; NCGC00161350-03; 8c,11c,14c-eicosatrienoic acid; CHEBI:53486; BSPBio_001286; HMS1791A08; Bishomo-gamma-linolenic acid; gamma-Homolinolenic acid; dihomo-gamma-linolenic acid; 8, 11, 14-eicosatrienoic acid; Tona-lean 1000 CLA (Action Labs); BML3-B11; C20:3, n-6,9,12 all-cis; HMS1989A08; 8,11,14-Eicosatrienoic acid, (Z,Z,Z)- (8CI); all-cis-8,11,14-Eicosatrienoic acid	1783-84-2	5280581	8616330	TTDS00040	Prostaglandin G/H synthase 1	COX-1;Cyclooxygenase -1;Cyclooxygenase-1;PGH synthase 1;PGHS-1;PHS 1;Prostaglandin H2 synthase 1;Prostaglandin-endoperoxide synthase 1	P23219	5742	ENSG00000095303	inhibitor
DAP000734	Salsalate	Disalicylic acid; Salsalate; CHEMBL154111; KBioSS_002572; S0129; BRN 2590908; Benzoic acid, 2-hydroxy-, 2-carboxyphenyl ester; Sasapyrin; Disalicylic acid;; Disalyl; NSC-49171; Spectrum3_000173; 2-Carboxyphenyl salicylate; Disalicylsaeure; Spectrum4_000940; Disalcid (TN); Nobacid; 2-(2-hydroxybenzoyl)oxybenzoic acid; LS-37546; Salsalate (USP/INN); Salsalatum [INN-Latin]; AC1L1JQO; Salsalato; HMS2091A05; NSC 49171; Sal Ester Sal; SPBio_000845; 2-((2-Hydroxybenzoyl)oxy)benzoic acid; Benzoic acid, 2-hydroxy-, 2-carboxyphenyl ester; Salicylic acid, bimolecular ester; Salflex; Disalcid; DB01399; D00428; KBio2_002563; NSC49171; NCGC00096014-01; Spectrum_001998; AC-18298; Saloxium; sasapyrine; 2-Salicyloyloxybenzoic Acid; CID5161; Salicylic acid, bimolecular ester; AKOS003368478; Salsalato [INN-Spanish]; Spectrum2_000693; KBioGR_001500; Diplosal; AR-1L3959; Spectrum5_000670; Sasapyrine (JAN); Salicylsalicylic acid; BSPBio_001665; Salsalate [USAN:INN:BAN]; O-Salicyloylsalicylic Acid; Salicylic Acid Salicylate; 552-94-3; KBio2_007699; MolPort-003-666-101; o-Salicylsalicylic acid; SPECTRUM200331; Sasapyrinum; 2-{[(2-hydroxyphenyl)carbonyl]oxy}benzoic acid; AC1Q61P1; Salina; KBio2_005131; Salical; Diacesal; Salicyloylsalicylic acid; Salicylic acid, salicylate; ST083489; O-Salicylcylsalicylsaeure; KBio3_001165; Salysal; Sasapirin; UNII-V9MO595C9I; Salsalatum; EINECS 209-027-4; NCGC00096014-02	552-94-3	5161	7847494	TTDS00040	Prostaglandin G/H synthase 1	COX-1;Cyclooxygenase -1;Cyclooxygenase-1;PGH synthase 1;PGHS-1;PHS 1;Prostaglandin H2 synthase 1;Prostaglandin-endoperoxide synthase 1	P23219	5742	ENSG00000095303	inhibitor
DAP000731	Salicyclic acid	27301_SIAL; 247588_SIAL; BRN 0774890; BENZOIC ACID,2-HYDROXY   SALICYLIC ACID; phenol derivative, 7; salicylic acid; Hydrisalic Gel; STK258681; Alpha/Beta Hydroxy Acids (Glycolic Acid, Salicylic Acid); EPA Pesticide Chemical Code 076602; Psoriacid-S-stift; MLS000069653; SGCUT00012; LS-2169; Dr. Scholl's corn removers; DHS Sal Shampoo; CHEMBL424; 84210_SIAL; Ionil plus; 8052-31-1; Dr. Scholl's wart remover kit; NSC629474; Retarder W; Domerine; ortho Hydroxybenzoic Acid; 2-Hydroxybenzoic acid; NCGC00159447-04; Phenol-2-carboxylic acid; 84210_FLUKA; Acid, 2-Hydroxybenzoic; BIDD:ER0602; CID338; IDI1_000301; CMC_13852; AC1Q72IF; Sebulex; KBio2_006564; Acido salicilico; KBio1_000301; HSDB 672; Acid, Salicylic; S8519_SIGMA; Occlusal; DB00936; Acid, ortho-Hydroxybenzoic; salicylate; NSC180; I04-0192; Ionil; 105910_SIAL; Salicylic acid (TN); K 537; InChI=1/C7H6O3/c8-6-4-2-1-3-5(6)7(9)10/h1-4,8H,(H,9,10; Acidum salicylicum; S5922_SIGMA; EINECS 200-712-3; 69-72-7; UPCMLD-DP126:001; NSC 180; SMR000059163; ALPHA/BETA HYDROXY ACIDS (SALICYLIC ACID) (SEE ALPHA/BETA HYDROXY ACIDS); KBio2_003996; P&S Shampoo; Duofil wart remover; Duoplant; Saligel; Benzoic acid, 2-hydroxy- (9CI); AKOS000118979; Clear away wart remover; Oprea1_040343; Salicylic acid soap; Acido salicilico [Italian]; ATA fraction 10, ammonium salt; Spectrum_000948; KBio2_001428; SALICYLIC ACID (SEE ALSO ALPHA HYDROXY ACIDS); Duofilm; 2 Hydroxybenzoic Acid; Salonil; UNII-O414PZ4LPZ; UPCMLD-DP126; Kyselina 2-hydroxybenzoova [Czech]; AC1L190M; Salicylic acid [USAN:JAN]; Propa pH Peel-Off Acne Mask; Akurza Lotion; Acid, o-Hydroxybenzoic; Retarder SAX; Orthohydroxybenzoic acid; MolPort-001-769-476; Akurza Cream; W398500_ALDRICH; Compound w; WLN: QVR BQ; Kyselina salicylova [Czech]; NINDS_000301; o-hydroxybenzoic acid; to_000004; SAX; o-Carboxyphenol; Salicylic acid & Sulfur Soap; Ionil-Plus; CHEBI:16914; Acido o-idrossibenzoico [Italian]; SMP2_000145; Salicylic acid (6CI,8CI); Salicylic acid, tech.; D00097; AB1002436; H0206; Kyselina salicylova; 2-hydroxy(1-14c)benzoic acid; 105910_ALDRICH; Salicyclic acid; DivK1c_000301; SALICYLIC ACID, ACS; NCGC00159447-02; Rutranex; AR-1E2203; ortho-Hydroxybenzoic Acid; Verrugon; 7681-06-3; Dr. Scholl's callus removers; Caswell No. 731; Advanced pain relief callus removers; AI3-02407; o Hydroxybenzoic Acid; Mediplast pads; Salicylic acid-ring-UL-14C; bmse000252; CCRIS 6714; Stri-Dex; Salicylic acid (JP15/USP); S7401_SIGMA; Trans-Ver-Sal; Salex Cream; Sebucare; C00805; DuoPlant Gel; 2-Hydroxybenzoic acid; Salicylic acid; E9A559BE-383B-4F83-BC02-3031D03D558A; Kyselina 2-hydroxybenzoova; 2-Hydroxybenzenecarboxylic acid; AC1Q1HCK; D020156; Freezone; SBB052826; 2-Carboxyphenol; KBioSS_001428; Salex Lotion; Benzoic acid, 2-hydroxy-; Keralyt; Salicylic acid collodion; Salicylic acid, tech; Acido o-idrossibenzoico; Advanced pain relief corn removers	69-72-7	338	4063	TTDS00040	Prostaglandin G/H synthase 1	COX-1;Cyclooxygenase -1;Cyclooxygenase-1;PGH synthase 1;PGHS-1;PHS 1;Prostaglandin H2 synthase 1;Prostaglandin-endoperoxide synthase 1	P23219	5742	ENSG00000095303	inhibitor
DAP000729	Mesalazine	minosalicylic acid; A79809_ALDRICH; Schering Plough Brand of Mesalamine; SPD-476; MolPort-001-641-024; S1681_Selleck; KBio2_004993; Pentacol; 5 Aminosalicylic Acid; CAS-89-57-6; Mesalazinum; Falk Brand of Mesalamine; EINECS 201-919-1; BPBio1_001164; cMAP_000045; Prestwick3_001069; Antigen Brand of Mesalamine; A3613/0153179; Salofalk Granu-Stix; BB_NC-0015; 3-carboxy-4-hydroxyaniline; Provalis Brand of Mesalamine; Apriso; CID4075; Mezavant XL; Novo-5 ASA; Lialda; Ascolitin; 5-Aminosalicylic acid; Mesalamine Monosodium Salt; Mesalazinum [Latin]; SPBio_002969; Pentasa; Rowasa (TN); MLS000758287; Ipocol; AI3-15564; Norgine Brand of Mesalamine; Monosodium Salt, Mesalamine; HMS1571E20; SALICYLIC ACID, 5-AMINO-; WLN: ZR DQ CVQ; 5-AS; GlaxoSmithKline Brand of Mesalamine; Benzoic acid, 5-amino-2-hydroxy-; NCGC00090934-01; I06-0488; AKOS000118959; Pentasa (TN); A0317; Iialda (TN); Mesacol; ARONIS23914; AC1L1HCS; 5-aminosalicylic acid, Mesalazine, Asacol, Pentasa, Canasa, Mesalamine; Procter & Gamble Brand of Mesalamine; Mesasal; Schering-Plough Brand of Mesalamine; KBio3_002904; Axcan Brand of Mesalamine; NSC 38877; Fisalamine; AB00374979; Prestwick2_001069; 5-Aminosalicylate; Mesalazine (JAN/INN); BRN 2090421; AJG-501; 5 Aminosalicylate; InChI=1/C7H7NO3/c8-4-1-2-6(9)5(3-4)7(10)11/h1-3,9H,8H2,(H,10,11; DB00244; Hydrochloride, Mesalamine; SAM001247020; Z-206; sfRowasa; 09410_FLUKA; NSC38877; m-A; Novo 5 ASA; 35589-28-7 (mono-hydrochloride salt); Mesavance; 61513-32-4; Mesalazine MMX; HMS2051M21; Novo5 ASA; 5-Amino-2-hydroxybenzoic acid; 5-AS; Mesalamine; 5-ASA; Byk Brand of Mesalamine; MAX-002; Mesalamine Hydrochloride; Mesavancol; Allphar Brand of Mesalamine; Yamanouchi Brand of Mesalamine; SPD-480; UNII-4Q81I59GXC; Salofalk; Sanofi Synthelabo Brand of Mesalamine; p-Aminosalicylsaeure; m-Aminosalicylic acid; Mesalazina [Spanish]; Novopharm Brand of Mesalamine; Prestwick0_001069; BSPBio_001058; meta-Aminosalicylic Acid; Salicylic acid, 5-amino- (8CI); Asacolitin; AC1Q51L9; meta Aminosalicylic Acid; D00377; Mesalazina; Solvay Brand of Mesalamine; CCRIS 7334; D019804; 5-ASA; ||Asacolitin; Rowasa; KBio2_007561; Lixacol; Asacol (TN); m Aminosalicylic Acid; Oprea1_847633; Fivasa; HMS2090I09; Prestwick1_001069; 09409_FLUKA; mesalamine; 6291-36-7 (hydrochloride); Salozinal; AC-2764; SmithKline Brand of Mesalamine; Asalit; Ferring Brand of Mesalamine; MLS001424012; Mesalamine [USAN]; LS-1894; CHEMBL704; 4-14-00-02058 (Beilstein Handbook Reference); BIDD:GT0811; Claversal; Henning Berlin Brand of Mesalamine; Celltech Brand of Mesalamine; Mesalamine (USP); Asacol|; 5-Amino-2-hydroxybenzoic acid; Farmasa Brand of Mesalamine; SMR000145728; p-Aminosalicylsaeure [German]; HSDB 7512; KBio2_002425; MD-0901; Asacol HD; 2-Hydroxy-5-aminobenzoic acid; Canasa; 89-57-6; A6178_SIGMA; NCGC00090934-02; KBioSS_002431; STK301678; CPD000145728; Mesalazine; Asacol; 5-amino-2-hydroxy-benzoic acid; A3537_SIGMA; Mezavant; KBioGR_002425; Iialda; NCGC00016344-01; AB1001921; Merckle Brand of Mesalamine; Asacolon; CHEBI:6775	89-57-6	4075	7847443	TTDS00040	Prostaglandin G/H synthase 1	COX-1;Cyclooxygenase -1;Cyclooxygenase-1;PGH synthase 1;PGHS-1;PHS 1;Prostaglandin H2 synthase 1;Prostaglandin-endoperoxide synthase 1	P23219	5742	ENSG00000095303	inhibitor
DAP000732	Bromfenac	[2-amino-3-(4-bromobenzoyl)phenyl]acetic acid; DB00963; Xibrom; 91714-94-2; UNII-864P0921DW; [2-Amino-3-(4-bromo-benzoyl)-phenyl]-acetic acid; Duract; CHEMBL1077; 2-[2-amino-3-(4-bromobenzoyl)phenyl]acetic acid; Bromfenacum [Latin]; Bromfenacum; C15H12BrNO3; LS-178156; CID60726; BROMFENAC SODIUM; Bromfenac; Benzeneacetic acid, 2-amino-3-(4-bromobenzoyl)-; {2-amino-3-[(4-bromophenyl)carbonyl]phenyl}acetic acid; sodium 2-amino-3-(4-bromobenzoyl) phenylacetate sesquihydrate; AC1Q5DQ7; Ambap120638-55-3; Bromfenaco [Spanish]; AC1L1TSW; AHR-10282; CHEBI:240107; MolPort-000-883-091; Bromfenaco; Bromfenac [INN]; D07541; 2-Amino-3-(4-bromobenzoyl)benzeneacetic acid; Bromfenac (INN)	91714-94-2	60726	685533	TTDS00040	Prostaglandin G/H synthase 1	COX-1;Cyclooxygenase -1;Cyclooxygenase-1;PGH synthase 1;PGHS-1;PHS 1;Prostaglandin H2 synthase 1;Prostaglandin-endoperoxide synthase 1	P23219	5742	ENSG00000095303	inhibitor
DCL000234	SRT501	LS-2146; HMS1569F17; (E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol; KUC104385N; C059514; 1,3-Benzenediol, 5-(2-(4-hydroxyphenyl)ethenyl)-, (E)-; NCGC00024003-04; InChI=1/C14H12O3/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h1-9,15-17H/b2-1; trans-3,4&prime;,5-Trihydroxystilbene; to_000079; 1,3-Benzenediol, 5-(2-(4-hydroxyphenyl)ethenyl)-, (E)-; 3,5,4'-Trihydroxy-trans-stilbene; (E)-5-[2-(4-hydroxyphenyl)ethenyl]-1,3-benzendiol; CHEMBL165; HMS1990H15; FT-0082623; MLS001076538; ZINC00006787; SRT-501; MLS002222231; Prestwick2_000508; CPD-83; AC-727; SPECTRUM1502223; 31100-06-8; 3,5,4'-Trihydroxystilbene; (E)-resveratrol; BSPBio_001114; NSC 327430; CHEBI:45713; KSC-10-164; HMS2052I09; CU-01000001503-3; PREVENTION 8 (RESVERATROL); SDCCGMLS-0002998.P003; resveratrol; 5-((1E)-2-(4-Hydroxyphenyl)ethenyl)-1,3-benzenediol; 501-36-0; RM-1812; IDI1_002152; 3,4',5-Trihydroxy-trans-stilbene; trans-3,4',5-trihydroxystilbene; (E)-5-(p-Hydroxystyryl)resorcinol; TL8003323; CID445154; InChI=1/C14H12O3/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h1-9,15-17H/b2-1+; NCGC00024003-00; EU-0101111; HMS1362H15; AC1L9HIC; LUKBXSAWLPMMSZ-OWOJBTEDSA-; R 5010; BPBio1_000479; CHEBI:27881; C14H12O3; SAM001246888; 5-[(E)-2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol; 3,4',5-Trihydroxystilbene; STL; SGCUT00007; (E)-5-[2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; BRD-K80738081-001-10-4; BSPBio_003461; I06-0437; 3,4',5-trihydroxy-stilbene; resveratrol-3-sulfate; (E)-5-[2-(4-hydroxyphenyl)ethenyl]-1,3-benzendiol; NCGC00017352-07; R0071; SMR000058206; HSDB 7571; cis-resveratrol; RV; SRT 501; trans-1,2-(3,4',5-Trihydroxydiphenyl)ethylene; NCGC00017352-17; NCGC00024003-09; BSPBio_000435; MLS000069735; DB02709; NCGC00024003-07; NCGC00024003-11; Lopac0_001111; NCGC00024003-08; C03582; trans-resveratrol; 5-[(1E)-2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; BRD-K25591257-001-01-2; S1396_Selleck; NSC327430; NCGC00024003-10; nchembio.281-comp10; 34092_RIEDEL; R5010_SIGMA; MolPort-002-499-801; 3,4',5-Stilbenetriol; BRD-K80738081-001-06-2; Prestwick3_000508; NCGC00024003-06; nchembio.140-comp2; 34092_FLUKA; SRT501; MLS001055357; BB_NC-2570; LMPK13090005; Resvida; MLS002207121; HMS1921N04; Prestwick_619; CPD000058206; NCGC00024003-05; CCRIS 8952; 5-[2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; HMS1792H15; Resveratrol, E-; Spectrum5_000552; 5-[(E)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; 533C1DA0-4104-42B5-9D32-9265F40857E4	375823-41-9	N/A	17396767	TTDC00052	NAD-dependent deacetylase sirtuin-1	hSIR2;hSIRT1;SIR2L1;SIR2-like protein 1;SIRT1	Q96EB6	23411	ENSG00000096717	binder
DCL000372	GSK184072	N/A	N/A	6443207	43035735	TTDC00052	NAD-dependent deacetylase sirtuin-1	hSIR2;hSIRT1;SIR2L1;SIR2-like protein 1;SIRT1	Q96EB6	23411	ENSG00000096717	activator
DCL000414	GSK2245840	N/A	83928-66-9	55191	47206241	TTDC00052	NAD-dependent deacetylase sirtuin-1	hSIR2;hSIRT1;SIR2L1;SIR2-like protein 1;SIRT1	Q96EB6	23411	ENSG00000096717	activator
DAP001538	Fomivirsen sodium	Fomivirsen sodium; 160369-77-7; Vitravene Preservative Free; DRG-0234; DNA, d(P-thio)(G-C-G-T-T-T-G-C-T-C-T-T-C-T-T-C-T-T-G-C-G), eicosasodium salt; 144245-52-3; UNII-3Z6W3S36X5; Vitravene	N/A	N/A	N/A	TTDS00526	mRNA of IE2 region of cytomegalovirus	N/A	N/A	N/A	N/A	antisense
DCL001030	Ustekinumab	N/A	815610-63-0	N/A	85151085	TTDS00534	Interleukin-23	IL-23;Interleukin 23;P40 subunit of interleukin-23	Q9NPF7	51561	ENSG00000110944	antibody
DAP001277	Acetohydroxamic Acid	LS-13067; EINECS 208-913-8; A0051; sJX`HLdmMAH`; N-Acetylhydroxylamine; N-Acetyl hydroxyacetamide; Acethydroxamic acid; SMR000499570; NSC176136; WLN: QMV1; Spectrum3_000285; SPBio_000098; Spectrum5_000812; KBio3_001290; SPECTRUM1500103; Acetyl hydroxyamino; KBio2_002928; KBio1_000821; Lithostat (TN); I08-0057; AC1L1COH; MolPort-001-769-610; CCRIS 1730; cetohyroxamic acid; Acido acetohidroxamico; Acetohydroxamate; KBio2_000360; AC1Q1L7G; CHEBI:49029; Spectrum4_000138; UNII-4RZ82L2GY5; CHEBI:27777; HSDB 3585; ZINC04658603; 00507_FLUKA; Acethydroxamsaeure [German]; MLS001076662; Acethydroxamsaure; N-Hydroxyacetamide; Acidum acetohydroxamicum; BSPBio_001790; NSC 176136; AHA; Acetamide, N-hydroxy- (9CI); HMS2091G07; Methylhydroxamic acid; Prestwick_38; NINDS_000821; 546-88-3; Acetohydroxamic acid (USP/INN); D00220; Acetic acid, oxime; Acetamide, N-hydroxy-; KBioSS_000360; Hydroxylamine, N-acetyl-; Lithostat; HMS1920A07; CID1990; Acetohydroxamic acid [USAN:INN]; Acetylhydroxamic acid; N-hydroxyethanimidic acid; CHEMBL734; NSC5073; S14-0751; C06808; NCGC00094576-01; DB00551; AI3-62232; Acide acetohydroxamique; DivK1c_000821; 159034_ALDRICH; Acetohydroximic acid; Spectrum_000020; AKOS000172340; NCGC00094576-02; HMS502J03; Acethydroxamsaeure; HAE; N-hydroxyacetimidic acid; Acido acetohidroxamico [Spanish]; KBioGR_000556; IDI1_000821; KBio2_005496; Acide acetohydroxamique [French]; Spectrum2_000109; NCGC00094576-03; acetohydroxamic acid; Acidum acetohydroxamicum [Latin]	546-88-3	1990	9027	TTDS00479	Urease	Urea amidohydrolase;ureC	P18314	N/A	N/A	inhibitor
DCL000034	Almorexant	S2160_Selleck; Almorexant [INN]; (2R)-2-((1S)-6,7-dimethoxy-1-{2-(4-(trifluoromethyl)phenyl)ethyl}-3,4-dihydroisoquinolin-2(1H)-yl)-N-methyl-2-phenylacetamide; CHEMBL455136; ACT-078573; CHEBI:555140; 871224-64-5; Almorexant	871224-64-5	44148935	85149835	TTDC00153	Orexin receptor type 1	7-transmembrane G-protein coupled neuropeptide receptor;HFGAN72 receptor;Hypocretin receptor type 1;Orexin-1 receptor;Ox1r	O43613	3061	ENSG00000121764	antagonist
DCL000386	SB-649868	N/A	110-17-8	444972	49746076	TTDC00153	Orexin receptor type 1	7-transmembrane G-protein coupled neuropeptide receptor;HFGAN72 receptor;Hypocretin receptor type 1;Orexin-1 receptor;Ox1r	O43613	3061	ENSG00000121764	antagonist
DCL000909	Orexin-1 antagonist	N/A	266359-93-7	N/A	N/A	TTDC00153	Orexin receptor type 1	7-transmembrane G-protein coupled neuropeptide receptor;HFGAN72 receptor;Hypocretin receptor type 1;Orexin-1 receptor;Ox1r	O43613	3061	ENSG00000121764	antagonist
DCL000109	Enzastaurin	3-(1-methylindol-3-yl)-4-[1-[1-(pyridin-2-ylmethyl)piperidin-4-yl]indol-3-yl]pyrrole-2,5-dione; CHEMBL300138; UNII-UC96G28EQF; 1H-Pyrrole-2,5-dione, 3-(1-methyl-1H-indol-3-yl)-4-(1-(1-(2-pyridinylmethyl)-4-piperidinyl)-1H-indol-3-yl)-; 170364-57-5; LY317615; 3-(1-methyl-1H-indol-3-yl)-4-{1-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1H-indol-3-yl}-1H-pyrrole-2,5-dione; AC-5900; CID176167; AC1L41YQ; LY317615, Enzastaurin; LE-0014; S1055_Selleck; CHEBI:183217; Enzastaurin	170364-57-5	176167	3891570	TTDC00162	Glycogen synthase kinase-3 beta	GSK-3 beta	P49841	2932	ENSG00000082701	inhibitor
DCL000548	ISIS 113715	N/A	N/A	N/A	N/A	TTDC00191	mRNA of Protein-tyrosine phosphatase, non-receptor type 1	Protein tyrosine phosphatase 1B;Protein tyrosine phosphatase-1B;Protein-tyrosine phosphatase 1B;PTP1B;PTP-1B;Tyrosine phosphatase 1B	P18031	5770	ENSG00000196396	antisense
DCL001126	V85546	N/A	N/A	N/A	N/A	TTDC00157	Macrophage metalloelastase	HME;Macrophage elastase;Matrix metalloproteinase-12;ME;MMP-12	P39900	4321	N/A	inhibitor
DCL000454	AZD1236	N/A	N/A	N/A	N/A	TTDC00157	Macrophage metalloelastase	HME;Macrophage elastase;Matrix metalloproteinase-12;ME;MMP-12	P39900	4321	N/A	inhibitor
DCL000008	Neovastat	N/A	305838-77-1	N/A	3820640	TTDC00157	Macrophage metalloelastase	HME;Macrophage elastase;Matrix metalloproteinase-12;ME;MMP-12	P39900	4321	N/A	inhibitor
DCL001180	DPX-Survivac	N/A	N/A	N/A	N/A	TTDC00273	Baculoviral IAP repeat-containing protein 5	Apoptosis inhibitor 4;Apoptosis inhibitor survivin;Survivin	O15392	332	ENSG00000089685	N/A
DCL001082	Terameprocol	4-[(2S,3R)-4-(3,4-dimethoxyphenyl)-2,3-dimethylbutyl]-1,2-dimethoxybenzene; meso-Tetra-O-methylnordihydroguaiaretic acid; Butane, 1,4-bis(3,4-dimethoxyphenyl)-2,3-dimethyl-, meso-; AC1L9VRA; terameprocol; Terameprocol (INN/USAN); ZINC16953163; CHEMBL90983; CID476861; 24150-24-1; meso-1,4-Bis-(3,4-dimethoxyphenyl)-2,3-dimethylbutane; D09014; meso-Tetramethoxy-4,4'-(2,3-dimethyltetramethylene)dipyrocatechol; EM-1421	5701-82-6	476861 	N/A	TTDC00273	Baculoviral IAP repeat-containing protein 5	Apoptosis inhibitor 4;Apoptosis inhibitor survivin;Survivin	O15392	332	ENSG00000089685	inhibitor
DAP000517	Tocainide	MLS000759525; Tonocard; Tocainidum; D06172; EINECS 255-505-0; AB00514717; Alanyl-2,6-xylidide; BRN 2416564; NCGC00162129-03; Tocainidum [INN-Latin]; (-)-2-Amino-N-(2,6-dimethylphenyl)propanamide; 2-Amino-2',6'-propionoxylidide; Prestwick1_001027; Prestwick3_001027; Propanamide, 2-amino-N-(2,6-dimethylphenyl)-; C11H16N2O; 53984-26-2; NCGC00162129-02; SPBio_003074; MLS001423966; DB01056; Tocainida [INN-Spanish]; C07142; Prestwick0_001027; MolPort-005-935-577; 35891-93-1 (mono-hydrochloride); 41708-72-9; Astra W 36095; CHEMBL1762; UNII-27DXO59SAN; CID38945; CPD000466388; Propanamide, 2-amino-N-(2,6-dimethylphenyl)-, (-)-; Taquidil; BSPBio_001213; W-36095; BRD-A92670106-003-03-9; Tocainide (USAN/INN); CHEBI:9611; Tocainide [USAN:BAN:INN]; N-(2,6-dimethylphenyl)alaninamide; NCGC00162129-01; 2-Amino-N-(2,6-dimethylphenyl)propionamid; Tocainida; AC-16017; AC1Q5LWE; Prestwick2_001027; HMS2051G06; BPBio1_001335; 2',6'-Propionoxylidide, 2-amino-; SMR000466388; SAM001246759; Ambap41708-72-9; 2-AMINO-N-(2,6-DIMETHYLPHENYL)PROPANAMIDE; LS-125003; tocainide; AC1L20PS; 76213-25-7	41708-72-9	38945	9351	TTDS00402	Sodium channel protein type 5 subunit alpha	HH1;SCN5A;Sodium channel protein cardiac muscle subunit alpha;Sodium channel protein type V subunit alpha;Voltage-gated sodium channel subunit alpha Nav1.5	Q14524	6331	ENSG00000183873	blocker
DAP000510	Moricizine	Ethyl (10-(3-(4-morpholinyl)-1-oxopropyl)-10H-phenothiazin-2-yl)carbamate; EINECS 250-854-5; Moricizine (USAN); CID34633; AC1L1RZ3; Oprea1_701257; Moracizine; UNII-2GT1D0TMX1; EN-313; MLS001201823; BRD-K21548250-003-03-5; Moricizine [USAN]; AC1Q35C0; LS-50419; C22H25N3O4S; DB00680; MORICIZINE; Moracizine (INN); BIDD:GT0499; ethyl N-[10-(3-morpholin-4-ylpropanoyl)phenothiazin-2-yl]carbamate; ethyl [10-(3-morpholin-4-ylpropanoyl)-10H-phenothiazin-2-yl]carbamate; BAS 01947592; Moracizinum [INN-Latin]; STOCK1S-27850; Ethyl 10-(3-morpholinopropionyl)phenothiazine-2-carbamate; Oprea1_682904; MolPort-001-727-947; ethyl {10-[3-(morpholin-4-yl)propanoyl]-10H-phenothiazin-2-yl}carbamate; ethyl 10-(beta-N-morpholinylpropionyl)phenothiazine-2-carbamate; Moracizinum; NCGC00016809-01; Carbamic acid, (10-(3-(4-morpholinyl)-1-oxopropyl)-10H-phenothiazin-2-yl)-, ethyl ester; NCGC00074074-03; ZINC19340795; ethyl N-{10-[3-(morpholin-4-yl)propanoyl]-10H-phenothiazin-2-yl}carbamate; Moracizina; Phenothiazine-2-carbamic acid, 10-(3-morpholinopropionyl)-, ethyl ester; BPBio1_001104; G 214; Prestwick2_001051; TimTec1_000772; AB00514710; SPBio_002931; CHEMBL1075; STK370502; HMS1536D02; AKOS001487682; AC1Q35BY; 31883-05-3; CAS-31883-05-3; SMR000059585; CBDivE_008814; Prestwick3_001051; Moracizin; AC1Q65LI; C07743; Prestwick1_001051; Prestwick0_001051; CHEBI:6997; D05077; Moracizina [INN-Spanish]; BSPBio_001002	31883-05-3	34633	9945	TTDS00402	Sodium channel protein type 5 subunit alpha	HH1;SCN5A;Sodium channel protein cardiac muscle subunit alpha;Sodium channel protein type V subunit alpha;Voltage-gated sodium channel subunit alpha Nav1.5	Q14524	6331	ENSG00000183873	blocker
DAP000504	Disopyramide	Disopyramidum [INN-Latin]; Prestwick2_000266; BSPBio_001928; Rythmodan P (TN); Disopiramida; NCGC00093829-03; KBio2_004056; 2-Pyridineacetamide, .alpha.-[2-[bis(1-methylethyl)amino]ethyl]-.alpha.-phenyl-; 2-Pyridineacetamide, alpha-(2-(diisopropylamino)ethyl)-alpha-phenyl-; UNII-GFO928U8MQ; ST50411970; Ritmodan; 2-Pyridineacetamide, alpha-(2-(bis(1-methylethyl)amino)ethyl)-alpha-phenyl-; SPBio_002331; C06965; KBio2_006624; SC-7031; Disopiramida [INN-Spanish]; D7644_SIGMA; 4-[di(propan-2-yl)amino]-2-phenyl-2-pyridin-2-ylbutanamide; NCGC00015358-04; AC1L1F78; Prestwick_681; DivK1c_000489; AC-16018; NCGC00015358-08; LS-185086; Lopac0_000411; CHEMBL517; IDI1_000489; Prestwick3_000266; KBio1_000489; Isorythm; 54687-36-4 (mono-hydrochloride); EINECS 223-110-2; Disopyramide [USAN:BAN:INN:JAN]; Lispine; BRD-A29734509-001-03-8; NCGC00093829-01; xi-Disopyramide; D00303; Dicorantil; alpha-Diisopropylaminoethyl-alpha-phenylpyridine-2-acetamide; MolPort-003-846-985; 4-(diisopropylamino)-2-phenyl-2-pyridin-2-ylbutanamide; CHEBI:4657; H 3292; CID3114; Searle 703; KBio3_001148; HMS1568F14; SMR001307254; KBioSS_001488; Disopyramidum; D 7644; SPBio_001245; Rythmodan P; DB00280; 3737-09-5; Spectrum3_000404; NCGC00093829-02; BSPBio_000112; SC 7031; alpha-[2-[Bis(1-methylethyl)amino]ethyl]- alpha-phenyl-2-pyridine acetamide; Spectrum5_000943; Spectrum4_000524; KBioGR_001127; Rythmodan-La; MLS002222242; BPBio1_000124; NINDS_000489; Lopac0_000402; EU-0100402; Rythmodan; disopyramide; Prestwick1_000266; BRD-A29734509-011-02-9; KBio2_001488; Spectrum2_001033; Spectrum_001008; AB00053462; Disopyramide (JP15/USAN/INN); 22059-60-5 (phosphate (1:1)); NCGC00015358-09; alpha-(2-(Diisopropylamino)ethyl)-alpha-phenyl-2-pyridineacetamide; gamma-Diisopropylamino-alpha-phenyl-alpha-(2-pyridyl)butyramide; Disopyramide Free Base; Prestwick0_000266	3737-09-5	3114	162448	TTDS00402	Sodium channel protein type 5 subunit alpha	HH1;SCN5A;Sodium channel protein cardiac muscle subunit alpha;Sodium channel protein type V subunit alpha;Voltage-gated sodium channel subunit alpha Nav1.5	Q14524	6331	ENSG00000183873	blocker
DAP000514	Benzonatate	Polyethyleneglycol-p-n-butylaminobenzoate methyl ester; Benzoic acid, 4-(butylamino)-, 3,6,9,12,15,18,21,24,27-nonaoxaoctacos-1-yl ester (9CI); Tessalin; Prestwick3_000012; LS-36322; Benzonatate (USP/INN); DB00868; C30H53NO11; NCGC00016362-01; SMR001233469; Prestwick0_000012; Benzononatine; MLS002154171; UNII-5P4DHS6ENR; Tesalon; nonaethyleneglycol monomethyl ether p-n-butylaminobenzoate; Benzonatatum [INN-Latin]; Benzononantin; 104-31-4; MolPort-005-941-702; Benzoic acid, 4-(butylamino)-, 2,5,8,11,14,17,20,23,26-nonaoxaoctacos-28-yl ester; 3,6,9,12,15,18,21,24,27-Nonaoxaoctacos-1-yl 4-(butylamino)benzoate; AC1Q68HL; p-butylaminobenzoic acid omega-O-methylnonaethyleneglycol ester; 4-(butylamino)benzoic acid 3,6,9,12,15,18,21,24,27-nonaoxaoctacos-1-yl ester; Prestwick2_000012; 2,5,8,11,14,17,20,23,26-nonaoxaoctacosan-28-yl 4-(butylamino)benzoate; 2-[2-[2-[2-[2-[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl 4-butylaminobenzoate; Benzonatate [USAN:INN:BAN]; SPBio_001964; Exangit; Tessalon; 3,6,9,12,15,18,21,24,27-nonaoxaoctacosyl 4-butylaminobenzoate; p-(n)-Butylaminobenzoesaeure-(nonaaethylenglykol-monomethylaether)-ester [German]; Ventussin; EINECS 203-194-7; Tessalon-ciba; Benzoic acid, 4-(butylamino)-, 3,6,9,12,15,18,21,24,27-nonaoxaoctacos-1-yl ester; AR-1H9260; 2,5,8,11,14,17,20,23,26-Nonaoxaoctacosan-28-yl p-(butylamino)benzoate; BSPBio_000043; Tessalon Perles; HMS1568C05; Benzonatato [INN-Spanish]; CHEBI:3032; BPBio1_000049; Benzonatate; AC1L1PCL; KM65; CAS-104-31-4; Benzonatatum; Tessalon perles (TN); Ventussin-loz; Benzoic acid, p-(butylamino)-, 2-(2-(2-(2-(2-(2-(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethyl ester; p-(n)-Butylaminobenzoesaeure-(nonaaethylenglykol-monomethylaether)-ester; D00242; CID7699; NCGC00016362-02; AB00513795; 2-[2-[2-[2-[2-[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl 4-(butylamino)benzoate; Benzonatato; Prestwick1_000012	104-31-4	7699	9062	TTDS00402	Sodium channel protein type 5 subunit alpha	HH1;SCN5A;Sodium channel protein cardiac muscle subunit alpha;Sodium channel protein type V subunit alpha;Voltage-gated sodium channel subunit alpha Nav1.5	Q14524	6331	ENSG00000183873	blocker
DAP000505	Mexiletine	1-methyl-2-(2,6-xylyloxy)ethanamine; KBio2_004650; BSPBio_002254; KOE-1173; NCGC00015659-04; BSPBio_000022; SBB070242; KO-1173; BRN 2092205; 31828-71-4; CID4178; 5370-01-4 (hydrochloride); Spectrum5_001279; Lopac0_000784; 2-(2-Aminopropoxy)-1,3-DiMethyl-Benzene Hydrochloride; LS-68257; KBioSS_002082; C07220; Spectrum3_000727; KO1173; D08215; DB00379; EINECS 250-825-7; Mexiletina [INN-Spanish]; CHEBI:6916; Prestwick1_000241; CHEBI:115958; KBio1_000834; Mexityl; Prestwick0_000241; SPBio_002241; 1-Methyl-2-(2,6-xylyloxy)ethylamine; BRD-A64092382-003-04-3; Mexiletine HCL; UNII-1U511HHV4Z; I01-6374; NCGC00162253-02; 1-(2,6-Dimethylphenoxy)-2-propanamine; Prestwick3_000241; Mexiletine (INN); MolPort-001-790-944; NINDS_000834; (2RS)-1-(2,6-dimethylphenoxy)-2-aminopropane; Mexiletine; AC1L1HL7; 1-(2,6-dimethylphenoxy)propan-2-amine; 2-Propanamine, 1-(2,6-dimethylphenoxy)-; (+-)-1-(2,6-dimethylphenoxy)propan-2-amine; Mexiletine [INN:BAN]; KBio2_002082; NCGC00162253-01; KBio2_007218; Mexiletinum; Spectrum_001602; CHEMBL558; Mexiletinum [INN-Latin]; 1-(2',6'-Dimethylphenoxy)-2-aminopropane; KBioGR_001270; KBio3_001474; Mexilitine; Mexiletene; BPBio1_000026; AC1Q2BC5; IDI1_000834; 2-(2-aminopropoxy)-1,3-dimethylbenzene; ETHYLAMINE, 1-METHYL-2-(2,6-XYLYLOXY)-; Prestwick2_000241; Mexiletina; Spectrum4_000795; AC1Q2BC6; DivK1c_000834; AB00053683	31828-71-4	4178	9429	TTDS00402	Sodium channel protein type 5 subunit alpha	HH1;SCN5A;Sodium channel protein cardiac muscle subunit alpha;Sodium channel protein type V subunit alpha;Voltage-gated sodium channel subunit alpha Nav1.5	Q14524	6331	ENSG00000183873	blocker
DAP000512	Ethotoin	3-Ethyl-5-phenylimidazolidin-2,4-dione; BPBio1_000937; Prestwick3_000696; Accenon (TN); Accenon; Ethotoine [INN-French]; Ethotoinum; 2,4-Imidazolidinedione, 3-ethyl-5-phenyl-, (+-)-; AC1L1FLQ; D00708; Abbott brand of ethotoin; 86-35-1; C084606; Prestwick2_000696; 2,4-Imidazolidinedione, 3-ethyl-5-phenyl-; ethotoin; DB00754; Ethotoine; Etotoina [INN-Spanish]; Prestwick1_000696; AB00513897; 1-Ethyl-2,5-dioxo-4-phenylimidazolidine; CID3292; 3-Ethyl-5-phenyl-2,4-imidazolidinedione; Etotoina; UNII-46QG38NC4U; MLS002153961; SMR001233300; C07839; MolPort-003-666-682; LS-76194; Oprea1_374844; 3-ethyl-5-phenylimidazolidine-2,4-dione; CHEMBL1095; 5-24-08-00005 (Beilstein Handbook Reference); EINECS 201-665-1; Ethotoin (JAN/USP/INN); Peganone (TN); Hydantoin, 3-ethyl-5-phenyl-; Pegoanone; BSPBio_000851; Ethotoin [INN:BAN:JAN]; 3-Ethyl-5-phenylhydantoin; SPBio_002772; Prestwick0_000696; HMS1570K13; (+-)-3-Ethyl-5-phenylhydantoin; Ethotoinum [INN-Latin]; Peganone; CHEBI:4888; NCGC00179401-01; BRN 0188272; HSDB 3580	86-35-1	3292	10041	TTDS00402	Sodium channel protein type 5 subunit alpha	HH1;SCN5A;Sodium channel protein cardiac muscle subunit alpha;Sodium channel protein type V subunit alpha;Voltage-gated sodium channel subunit alpha Nav1.5	Q14524	6331	ENSG00000183873	blocker
DAP000507	Dibucaine	MLS000028425; MolPort-001-783-628; KBioSS_001408; Prestwick2_000076; 2-butoxy-N-(2-diethylaminoethyl)quinoline-4-carboxamide; QUINOLINE,2-BUTOXY,4-CARBOXY,(N-TRIETHYLAMINO) AMIDE   CINCHOCAIN; Cinchocainum; CHEBI:247956; NCGC00016338-03; ST51037211; Dibucaine (USP); BRD-K99121711-003-02-3; N-(2-(Diethylamino)ethyl)-2-butoxycinchoninamide; KBio2_001408; NSC 159055; Cinchocainum [INN-Latin]; Nupercainal (VAN); 2-Butoxy-quinoline-4-carboxylic acid (2-diethylamino-ethyl)-amide; Cinchocaine hydrochloride; 4-Quinolinecarboxamide, 2-butoxy-N-(2-(diethylamino)ethyl)-; SPBio_001121; Prestwick1_000076; Nupercaine; Nupercaine (TN); Nupercainal; Cincocainio [INN-Spanish]; Spectrum3_000384; BAS 00401270; BPBio1_000321; SMR000058391; N-[2-(Diethylamino)ethyl]-2-butoxycinchoninamide; Percamine; NINDS_000332; 85-79-0; KBio3_001387; 2-Butoxyquinoline-4-carboxylic acid diethylaminoethylamide; Cincainum; Dibucaine Base; 2-Butoxy-N-(.beta.-diethylaminoethyl)cinchoninamide; Spectrum_000928; D0513_SIAL; Cinchocaine (INN); 4-Quinolinecarboxamide, 2-butoxy-N-[2-(diethylamino)ethyl]-; C07879; alpha-Butyloxycinchoninic acid diethylethylenediamide; Cinchocaine; Prestwick_164; KBioGR_001049; Cincocaina [DCIT]; HSDB 3312; LS-53768; DivK1c_000332; 2-butoxy-N-[2-(diethylamino)ethyl]quinoline-4-carboxamide; Dibucain; dibucaine; 2-Butoxy-N-[2-(diethylamino)ethyl]cinchoninamide; InChI=1/C20H29N3O2/c1-4-7-14-25-19-15-17(16-10-8-9-11-18(16)22-19)20(24)21-12-13-23(5-2)6-3/h8-11,15H,4-7,12-14H2,1-3H3,(H,21,24; AC-2093; Cincocaina; Prestwick0_000076; I08-0059; AC1L1F05; BSPBio_000291; Dibucaine [USP]; BSPBio_002167; CHEMBL1086; 2-Butoxy-N-(2-(diethylamino)ethyl)cinchoninamide; Cincocainio; UNII-L6JW2TJG99; D00733; NSC159055; HMS1568O13; 2-N-Butoxy-N-(2-diethylaminoethyl)cinchoninamide; KBio2_006544; SPBio_002212; KBio1_000332; CID3025; Prestwick3_000076; Spectrum5_000865; Cinchocaine HCL; 2-butoxy-N-(alpha-diethylaminoethyl)cinchoninamide; Sovcaine; Dermacaine; C20H29N3O2; Dibucainum; alpha-Butyloxycinchonic acid-gamma-diethylethylenediamine; 4-22-00-02284 (Beilstein Handbook Reference); IDI1_000332; EINECS 201-632-1; Spectrum4_000505; 2-Butoxy-N-(beta-diethylaminoethyl)cinchoninamide; DB00527; BRD-K99121711-001-03-5; NCGC00016338-01; Cinchoninamide, 2-butoxy-N-[2-(diethylamino)ethyl]-; NCGC00016338-02; MLS001148085; .alpha.-Butyloxycinchoninic acid diethylethylenediamide; KBio2_003976; Cinchoninamide, 2-butoxy-N-(2-(diethylamino)ethyl)-; D0513_FLUKA; CAS-85-79-0; AB00053453; BRN 0275489; WLN: T66 BNJ CO4 EVM2N2&2; 2-Butoxy-N-[2-(diethylamino)ethyl]-4-quinolinecarboxamide; Spectrum2_001001	85-79-0	3025	10081	TTDS00402	Sodium channel protein type 5 subunit alpha	HH1;SCN5A;Sodium channel protein cardiac muscle subunit alpha;Sodium channel protein type V subunit alpha;Voltage-gated sodium channel subunit alpha Nav1.5	Q14524	6331	ENSG00000183873	blocker
DAP000519	Encainide	Encainida; Encainide (INN); BRN 0497572; no stereochem; (.+/-.)-4-Methoxy-N-[2-[2-(1-methyl-2-piperidinyl)ethyl]phenyl]benzamide; LS-174678; AC1L2J99; 66778-36-7; (+-)-4-Methoxy-N-(2-(2-(1-methyl-2-piperidinyl)ethyl)phenyl)benzamide; BENZAMIDE, 4-METHOXY-N-(2-(2-(1-METHYL-2-PIPERIDINYL)ETHYL)PHENYL)-, (+-)-; MJ-9067; 4-methoxy-2'-[2-(1-methyl-2-piperidyl)ethyl]benzanilide; C06978; C22H28N2O2; Encainidum [Latin]; Encainidum; MJ-9067-1; LS-27116; MJ 9067; Encainida [Spanish]; Encainide [INN:BAN]; 4-methoxy-N-[2-[2-(1-methylpiperidin-2-yl)ethyl]phenyl]benzamide; 5-22-09-00511 (Beilstein Handbook Reference); Encainide; UNII-SY3J0147NB; 37612-13-8; (+-)-2'-[2-(1-methyl-2-piperidyl)ethyl]-p-anisanilide; D07894; Encainide Hydrochloride, (+-)-Isomer; 4-methoxy-N-{2-[2-(1-methylpiperidin-2-yl)ethyl]phenyl}benzamide; CHEBI:4788; Enkaid; Encainide [French]; AC1Q5EI5; CID48041	66778-36-7	48033	9192	TTDS00402	Sodium channel protein type 5 subunit alpha	HH1;SCN5A;Sodium channel protein cardiac muscle subunit alpha;Sodium channel protein type V subunit alpha;Voltage-gated sodium channel subunit alpha Nav1.5	Q14524	6331	ENSG00000183873	blocker
DAP000509	Dyclonine	Dyclocainum; Dyclonin; Dyclonine [INN:BAN]; 1-(4-Butoxy-phenyl)-3-piperidin-1-yl-propan-1-one; 4-n-butoxy-beta-(1-piperidyl)propiophenone; NINDS_000632; DB00645; STK524544; Dycloninum [INN-Latin]; AC-12286; UNII-078A24Q30O; BRD-K72259270-003-05-8; Spectrum5_000951; dyclonine; BAS 00363810; Spectrum2_001013; 1-Propanone, 1-(4-butoxyphenyl)-3-(1-piperidinyl)- (9CI); CAS-536-43-6; NCGC00016498-02; CID3180; AKOS000505031; CHEBI:4724; AC1L1FCQ; Tanaclone; KBio2_001496; Diclonina [INN-Spanish]; Prestwick3_000264; NCGC00016498-01; 586-60-7; KBio1_000632; Dyclocaine; Spectrum_001016; 4'-Butoxy-3-piperidinopropiophenone; 1-(4-butoxyphenyl)-3-(piperidin-1-yl)propan-1-one; Spectrum3_000410; BSPBio_000108; PROPIOPHENONE, 4'-BUTOXY-3-PIPERIDINO-; Prestwick2_000264; Dyclothane; IDI1_000632; Spectrum4_000529; BRN 0224037; C07881; MolPort-001-926-955; Diclonina; SPBio_002327; 4-butoxy-beta-piperidinopropiophenone; KBio2_006632; KBio3_001160; KBioGR_001137; Diclonia; DivK1c_000632; SPBio_001165; AB00053467; KBioSS_001496; Prestwick1_000264; Dycloninum; STOCK1S-04530; 1-(4-Butoxyphenyl)-3-(1-piperidinyl)-1-propanone; LS-125084; KBio2_004064; Prestwick0_000264; D07881; 3-Piperidino-4'-butoxypropiophenone; BPBio1_000120; 1-(4-butoxyphenyl)-3-piperidin-1-ylpropan-1-one; 1-Propanone, 1-(4-butoxyphenyl)-3-(1-piperidinyl)-; BSPBio_001940; 2-(1-piperidyl)ethyl p-butoxyphenyl ketone; 536-43-6 (hydrochloride); Dyclonine (INN)	586-60-7	3180	10083	TTDS00402	Sodium channel protein type 5 subunit alpha	HH1;SCN5A;Sodium channel protein cardiac muscle subunit alpha;Sodium channel protein type V subunit alpha;Voltage-gated sodium channel subunit alpha Nav1.5	Q14524	6331	ENSG00000183873	blocker
DAP000506	Hexylcaine	LS-121960; 1-(cyclohexylamino)propan-2-yl benzoate; BRD-A97730597-003-03-2; BPBio1_000986; CID10770; AB00514688; DB00473; (2-Cyclohexylamino-1-methylethyl) benzoate; UNII-511IU0826Z; Hexilcaina; AC1L1VWQ; Osmocaine; 532-76-3 (hydrochloride); Hexylcainum [INN-Latin]; Hexylcainum; CHEBI:309162; HEXYLCAINE; 1-(Cyclohexylamino)-2-propanol benzoate (ester); Hexilcaina [INN-Spanish]; Prestwick0_000788; NCGC00179382-01; Prestwick1_000788; Hexylcaine [INN]; CHEMBL1197; C14172; AC1Q5Y9O; 532-77-4; Prestwick3_000788; 2-Propanol, 1-(cyclohexylamino)-, benzoate (ester); SPBio_002835; Prestwick2_000788; BSPBio_000896	532-77-4	10770	7846984	TTDS00402	Sodium channel protein type 5 subunit alpha	HH1;SCN5A;Sodium channel protein cardiac muscle subunit alpha;Sodium channel protein type V subunit alpha;Voltage-gated sodium channel subunit alpha Nav1.5	Q14524	6331	ENSG00000183873	blocker
DAP000515	Quinidine	804-63-7; 909767-48-2; NSC131458; 864908-93-0; CID5317112; Quin-Release; IBS-L0034250; Quniacridine; MLS001335913; 767303-40-2; Chinine; FT-0082277; LS-141252; 898813-59-7; quinidina; 898814-28-3; CID6453100; Cin-Quin; AC1OCD62; 882741-47-1; CHEBI:15854; AC1L9AHW; NSC5362; AC1NSZYU; CID667449; I14-3397; SPBio_002379; AC1MI1Q5; GNF-Pf-180; AC1OCD5W; AC1NSV58; CID9967055; CID5484450; NSC 5362; CID5748152; D08458; CID5953; AC1MBNAI; CHEMBL21578; chininum; BIDD:GT0144; AC1NX8JM; CID637552; CID6857801; 888714-03-2; CID25522; AC1LDI43; Conchinin; TNP00086; Coccinine; CID5320867; CID10448938; Quinicardine; AC1LDI46; Quinine Dab; Kinidin; Quindine; Quinimax; Epiquinidine; AC1NSZYR; 6183-68-2; CCRIS 5755; 6151-40-2; 12239-42-8; Quinidex; CID3000825; 840482-04-4; MLS001335914; (-)-Quinine; CID1065; CID6604605; 900789-95-9; 909263-47-4; C20H24N2O2; SMR000718748; NSC192949; Kinidin (TN); KBio2_001392; NCI-C56246; 56-54-2; AC1Q4EZ5; 898814-00-1; LS-194958; AC1OFCPL; TCMDC-131239; AC1NUNMO; AC1NSV55; CID441073; 128544-03-6; SPBio_001375; Lopac-Q-1250; SB01652; AC1O56R7; AC1L3RNZ; DB00468; 22620_FLUKA; KBio2_006528; SMP1_000254; AB00514657; NSC667852; NCI60_004320; AC1MHWS7; LT00645788; ST056282; L001278; AC1L9AHT; MLS001304041; quinidine; CID2728270; HMS1607A11; IDI1_000134; 845886-64-8; LS-4562; KBio3_001551; 890027-24-4; AC1L1R7Y; 500225-45-6; KBio2_003960; CID6916036; 899813-83-3; CID5320868; DB00908; CID3032576; Coco-Quinine; AR-1H2065; GNF-PF-5459; Pitayine; AC1L199L; CID6916033; 883881-01-4; 130-89-2; HSDB 225; SMR000857275; BIB1110; Quinine; 6151-39-9; AC1Q4EZ6; KBio1_000134; BB_NC-0697; CHEMBL576997; 22600_FLUKA; 549-56-4; HMS1304I22; CID667448; D08460; CID3036746; Chinidin; 572-59-8; 21480-31-9; KST-1A1085; AC1OAH7Z; NSC 192949; Chinin; 1407-83-6; AR-1A4833; 72646-90-3; 910878-25-0; CHEMBL170; HSDB 2501; CID94175; GNF-Pf-5423; 909882-78-6; Novoquinidin; 11010-73-4; beta-Quinine; Quinora; LS-221; NINDS_000134; Q3625_SIGMA; chinidinum; 906550-97-8; 6119-70-6; HMS1989J09; 875538-34-4; 911445-75-5; 130-95-0; CHEMBL601807; CID8549; AC1MHDEF; Lopac-Q-0875; AC1L1ANE; quinina; 900786-66-5; bmse000511; AC1LCUGN; Conchinine; 894767-09-0; C06526; 910880-97-6; CHEBI:111177; CPD000857275; CID441074; 6591-63-5; Auriquin; C06527; AC1Q58AF; CID5317111; Pitayin; Quiniduran; Conquinine; AC1O7GNZ; 22620_SIGMA; Aflukin; HMS2089E05; 50-54-4; 55980-20-6; 6912-57-8; RH01857; CID7048767; Chinidine; LS-187236; I14-3348; SAM002264644; AC1NUNML; AC1O7EE0; 918778-04-8; CHEMBL97; Quindan; CID5484444; AC1MHUCH; 910899-51-3; OR28880; CHEBI:28593; CCRIS 672; CID6602154; AC1L1LHL; Q0006; 857212-53-4; CID3034034	56-54-2	441074	8758	TTDS00402	Sodium channel protein type 5 subunit alpha	HH1;SCN5A;Sodium channel protein cardiac muscle subunit alpha;Sodium channel protein type V subunit alpha;Voltage-gated sodium channel subunit alpha Nav1.5	Q14524	6331	ENSG00000183873	blocker
DAP000520	Fosphenytoin	3-(hydroxymethyl)phenytoin disodium phosphate; AC1Q6NQH; HMPDP; 2,4-imidazolidinedione, 5,5-diphenyl-3-[(phosphonooxy)methyl]-; Fosfenitoina [INN-Spanish]; ACC-9653; Fosphenytoin [INN:BAN]; LS-187339; D07993; C07840; Fosphenytoinum; Fosphenytoin; 2,4-Imidazolidinedione, 5,5-diphenyl-3-((phosphonooxy)methyl)-; (2,5-dioxo-4,4-diphenylimidazolidin-1-yl)methyl dihydrogen phosphate; CID56339; Fosphenytoine [INN-French]; Fosphenytoin (INN); (3-Phosphoryloxymethyl)phenytoin; BIDD:GT0220; LS-178209; 93390-81-9; Fosphenytoinum [INN-Latin]; AC1L1KUO; DB01320; Fosphenytoine; UNII-B4SF212641; Fosfenitoina; 92134-98-0 (di-hydrochloride salt); Prodilantin; HSDB 7523; 3-(hydroxymethyl)phenytoin phosphate ester; 2,4-Imidazolidinedione, 5,5-diphenyl-3-((phosphonooxy)methyl)-, (SP-4-2)-	93390-81-9	56339	10042	TTDS00402	Sodium channel protein type 5 subunit alpha	HH1;SCN5A;Sodium channel protein cardiac muscle subunit alpha;Sodium channel protein type V subunit alpha;Voltage-gated sodium channel subunit alpha Nav1.5	Q14524	6331	ENSG00000183873	blocker
DAP000508	Mephenytoin	3-Methyl-5-ethyl-5-phenylhydantoin; KBio2_004542; Mephenytoine; MLS002154157; Hydantoin, 5-ethyl-3-methyl-5-phenyl-; 5-Ethyl-5-fenyl-3-methylhydantoin [Czech]; (+-)-5-Ethyl-3-methyl-5-phenylhydantoin; BRD-A83937277-001-03-0; Prestwick1_001108; MolPort-003-666-498; NCGC00165924-01; Insulton; Sedantoinal; EINECS 200-012-8; 5-ethyl-3-methyl-5-phenylimidazolidine-2,4-dione; 5 Ethyl 3 Methyl 5 Phenylhydantoin; Methyl hydantoin; Metydan; 5-Ethyl-3-methyl-5-phenylimidazolidin-2,4-dione; 2,4-Imidazolidinedione, 5-ethyl-3-methyl-5-phenyl-, (+-)-; Prestwick0_001108; NSC34652; BIM-0051837.0001; MEPHENYTOIN; 3-Methyl-5,5-ethylphenylhydantoin; Sacerno; HMS2089J22; Mesontoin; Oprea1_289074; KBioSS_001974; IDI1_000937; 3-Ethylnirvanol; 5-Ethyl-3-methyl-5-phenyl-2,4-imidazolidinedione; 2, 4-Imidazolidinedione, 5-ethyl-3-methyl-5-phenyl-; 3-Methyl-5, 5-ethylphenylhydantoin; 3-Methyl-5,5-phenylethylhydantoin; 3-Methyl-5-ethyl-5-phenylh; Fenantoin; CHEMBL861; WLN: T5MVNV EHJ C1 E2 ER; Triantoin; NIOSH/MU2276000; BRN 0017282; Epilan; NSC 34652; HMS1571M18; Phenetoin, Methyl; l-Mephenytoin; KBio2_001974; 5-Ethyl-3-methyl-5-phenyl-2,4-imidazolidinedione; 50-12-4; SMR001233457; AC-15964; Spectrum_001494; AB00052368; Mephenetoinum; HMS502O19; DB00532; KBio1_000937; NCGC00165924-02; Mephenytoine [INN-French]; Mephenytoinum; NINDS_000937; HSDB 3581; BSPBio_001216; Gerot-epilan; DivK1c_000937; Methyl Phenetoin; NSC-34652; 2,4-Imidazolidinedione, 5-ethyl-3-methyl-5-phenyl-; AC1L1HBP; A1073/0050334; Mesantoin; LS-76189; Mephenytoinum [INN-Latin]; Mephenytoin (USP/INN); BPBio1_001338; (-)-5-Ethyl-3-methyl-5-phenylhydantoin; Mefenitoina; Phenantoin; 3-Methyl-5,5-phenylethylhydantoin; Methoin; mephentoin; KBio2_007110; Methylphenetoin; Mesantoin (TN); KBioGR_001508; SPBio_003088; 5-Ethyl-3-methyl-5-phenylhydantoin; Mesdontoin; 5-Ethyl-3-methyl-5-phenyl-2,4(3H,5H)-imidazoledione; Prestwick2_001108; Sedantoin; (+-)-Mephenytoin; D00375; LS-76188; Spectrum4_001094; Sedantional; Mefenetoin; ydantoin; 5-Ethyl-3-methyl-5-phenyl-2,4(3H,5H)-imidazoledione; 5-Ethyl-3-methyl-5-phenylhydantoin; 5-Ethyl-3-methyl-5-phenylimidazolidin-2,4-dione; Hydantoin, 5-ethyl-3-methyl-5-phenyl-; Phenylethylmethylhydantoin; Epiazin; 5-Ethyl-5-fenyl-3-methylhydantoin; Mephenytoin [USAN:INN]; MU2276000; CID4060; l-3-Methyl-5-ethyl-5-phenylhydantoin; D008617; Prestwick3_001108; Mefenitoina [INN-Spanish]; Hydantoin, 5-ethyl-3-methyl-5-phenyl-, (-)-	50-12-4	4060	148526	TTDS00402	Sodium channel protein type 5 subunit alpha	HH1;SCN5A;Sodium channel protein cardiac muscle subunit alpha;Sodium channel protein type V subunit alpha;Voltage-gated sodium channel subunit alpha Nav1.5	Q14524	6331	ENSG00000183873	blocker
DAP000513	Proparacaine	Paracaine; EINECS 207-884-9; AC1L1J9I; BSPBio_000958; ST50819304; D08448; AB00444123; Proxymetacainum; Diocaine; Proxymetacainum [INN-Latin]; Proximetacaina [INN-Spanish]; beta-(Diethylamino)ethyl 4-n-propoxybenzoate; BPBio1_001054; BRN 2745891; Prossimetacaina; NCGC00016991-01; Proxymetacaine Hcl; Alcaine; DB00807; Proxymetacaine [INN:BAN]; AC-13440; 499-67-2; proparacaine; BRD-K79116891-003-03-7; C07383; Proxymetacaine (INN); LS-36008; Ocu-Caine; Ak-taine; NCGC00016991-02; Proximetacaina; CHEMBL1196; 5875-06-9 (mono-hydrochloride); Prossimetacaina [DCIT]; Prestwick0_000959; Prestwick1_000959; BENZOIC ACID, 3-AMINO-4-PROPOXY-, 2-(DIETHYLAMINO)ETHYL ESTER; Prestwick2_000959; Kainair; STK520616; UNII-B4OB0JHI1X; CHEBI:309007; 3-Amino-4-propoxybenzoic acid 2-(diethylamino)ethyl ester; SPBio_003107; CAS-1452000; Prestwick3_000959; MolPort-005-934-315; 2-(Diethylamino)ethyl 3-amino-4-propoxybenzoate; Ophthetic; Ophthaine; Proximetacainum; Proxymetacaine; Spectro-Caine; CID4935; 2-diethylaminoethyl 3-amino-4-propoxybenzoate	499-67-2	4935	9587	TTDS00402	Sodium channel protein type 5 subunit alpha	HH1;SCN5A;Sodium channel protein cardiac muscle subunit alpha;Sodium channel protein type V subunit alpha;Voltage-gated sodium channel subunit alpha Nav1.5	Q14524	6331	ENSG00000183873	blocker
DAP000518	Flecainide	Flecainida; LS-27388; SMP1_000074; Flecainide [INN:BAN]; CCRIS 313; Flecainide (INN); CHEBI:127588; AC-16019; BCBcMAP01_000189; AC1L1FQZ; KBioGR_000037; D07962; NCGC00025175-06; UNII-K94FTS1806; N-(2-Piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamide; 54143-55-4; Flecainida [INN-Spanish]; KBio2_005173; KBio2_000037; Prestwick3_000735; DB01195; Tambocor; HMS1791B19; Lopac0_000546; BSPBio_001317; 99495-87-1; 54143-56-5 (monoacetate); KBio2_002605; HMS2089E17; Bio1_000864; (+-)-Flecainide; Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-; Flecaine; IDI1_033787; R818; SPBio_002629; CID3356; BRD-A09472452-015-03-6; C17H20F6N2O3; KBioSS_000037; flecainide; Flecainidum; HMS1989B19; NCGC00025175-03; C07001; AB00513907; BPBio1_000760; Prestwick0_000735; CHEMBL652; Bio2_000037; KBio3_000073; MolPort-003-847-380; KBio3_000074; Prestwick1_000735; NSC719273; BSPBio_000690; Prestwick2_000735; Bio2_000517; N-(piperidin-2-ylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamide; BRD-A09472452-001-02-8; Bio1_000375; Bio1_001353; NCGC00025175-05; Flecainidum [INN-Latin]; N-(piperidin-2-ylmethyl)-2,5-bis[(2,2,2-trifluoroethyl)oxy]benzamide; NCGC00025175-04; TL80090300	54143-55-4	3356	181803	TTDS00402	Sodium channel protein type 5 subunit alpha	HH1;SCN5A;Sodium channel protein cardiac muscle subunit alpha;Sodium channel protein type V subunit alpha;Voltage-gated sodium channel subunit alpha Nav1.5	Q14524	6331	ENSG00000183873	blocker
DAP000511	Prilocaine	LS-2304; o-Propionotoluidide, 2-(propylamino)-; KBioSS_002129; Prestwick1_000199; Spectrum_001649; NSC 40027; MolPort-005-935-583; CID4906; BSPBio_000157; Prilocaine [USAN]; Prilocainum; C13H20N2O; Prilocaine (USP/INN); 2-(Propylamino)-o-propionotoluidide; D00553; Prestwick2_000199; DivK1c_000846; N-(2-methylphenyl)-N2-propylalaninamide; Citanest; IDI1_000846; Propitocaine (JAN); 2-Methyl-alpha-propylaminopropionanilide; KBio2_007265; KBio2_004697; N-[2-Methylphenyl]-2-[propylamino]propanamide; Spectrum2_001549; Prilocaina [INN-Spanish]; o-Methyl-2-propylaminopropionanilide; prilocaine; KBio3_001824; AC-2100; Propitocaine; AC1L1J7W; BSPBio_002604; EINECS 211-957-0; Ambap1786-81-8; Spectrum3_001052; S1619_Selleck; Propanamide, N-(2-methylphenyl)-2-(propylamino)-; BPBio1_000173; CHEMBL1194; N-(2-Methylphenyl)-2-(propylamino)propanamide; Propanamide, N-(2-methylphenyl)-2-(propylamino)- (9CI); DB00750; C07531; NCGC00162312-01; Prilocaina; BRN 2108498; NCGC00015860-03; HSDB 3386; KBio1_000846; Spectrum4_001192; I01-1860; Prestwick0_000199; o-Propionotuluidide, 2-propylamino-; L 67; Lopac0_001005; CHEBI:8404; 721-50-6; o-Methyl-alpha-propylaminopropionanilide; Astra 1515; Astra 1512; alpha-n-Propylamino-2-methylpropionanilide; AB00053665; NSC40027; SPBio_001398; BRD-A53952395-003-05-3; Prestwick3_000199; prilocaine base; o-Propionotoluidide, 2-propylamino-; UNII-046O35D44R; Prilocainum [INN-Latin]; KBio2_002129; 2-Methyl-.alpha.-propylaminopropionanilide; N-(2-methylphenyl)-N(2)-propylalaninamide; NINDS_000846; Spectrum5_001175; SPBio_002078; KBioGR_001883	721-50-6	4906	9734	TTDS00402	Sodium channel protein type 5 subunit alpha	HH1;SCN5A;Sodium channel protein cardiac muscle subunit alpha;Sodium channel protein type V subunit alpha;Voltage-gated sodium channel subunit alpha Nav1.5	Q14524	6331	ENSG00000183873	blocker
DAP000516	Procainamide	Procainamidum; BRD-K75089421-003-04-7; C13H21N3O; HMS1791J05; KBio2_006452; SMP1_000055; NCGC00024323-06; Spectrum_000836; NINDS_000931; AC1Q2ZC9; Bio1_001369; Lopac-P-9391; BSPBio_001463; BPBio1_000411; SPBio_001329; NCGC00015859-10; L001052; Prestwick0_000337; Benzamide, 4-amino-N-[2-(diethylamino)ethyl]-; KBio1_000931; NCGC00024323-03; KBioGR_000973; Novocaine amide; Prestwick3_000337; 4-14-00-01154 (Beilstein Handbook Reference); CHEMBL640; Novocainamid; Pronestyl-Sr; Novocainamide; BRD-K75089421-003-05-4; BRN 2214285; Procaine amide; CHEBI:8428; DivK1c_000931; C07401; STK367963; 614-39-1 (hydrochloride); Procainamide (INN); Benzamide, 4-amino-N-(2-(diethylamino)ethyl)- (9CI); IDI1_033933; IDI1_000931; Pronestyl; Prestwick1_000337; BSPBio_002229; Procanbid; NSC 27461; Novocamid; Procainamide [INN:BAN]; NCGC00015859-03; Benzamide, p-amino-N-(2-(diethylamino)ethyl)-; Bio2_000663; KBio3_001729; KBio3_000366; BIDD:GT0579; HSDB 3170; p-Aminobenzoic diethylaminoethylamide; Maybridge1_004389; Procapan; Procainamida; KBio2_005319; NCGC00024323-04; 4-amino-N-(2-diethylaminoethyl)benzamide; 51-06-9; KBioSS_000183; Lopac0_000995; KBio2_003884; ARONIS023727; 4-amino-N-(2-diethylaminoethyl)-benzamide; Biocoryl; Bio1_000880; NCGC00015859-02; CBDivE_003757; Bio1_000391; ST077772; Procan; Spectrum4_000487; D08421; EINECS 200-078-8; Spectrum5_000986; 2-Diethylaminoethylamid kyseliny p-aminobenzoove; 4-Amino-N-[2-(diethylamino)ethyl]benzamide; BRD-K75089421-001-02-5; 4-Amino-N-(2-(Diethylamino)Ethyl)Benzamide Sulfate; Procapan (free base); LS-25492; WLN: ZR DVM2N2&2; MolPort-001-783-481; DB01035; UNII-L39WTC366D; PROCAINAMIDE; KBio3_000365; AC1L1J8A; 2-Diethylaminoethylamid kyseliny p-aminobenzoove [Czech]; KBioGR_000183; HMS2089E13; CAS-614-39-1; NSC27461; NCGC00024323-05; AC1Q2ZCA; 4-Amino-N-(2-(diethylamino)ethyl)benzamide; NCGC00015859-01; Spectrum2_001295; SPBio_002294; Procamide; Bio2_000183; KBio2_002751; AKOS000271131; Benzamide, p-amino-N-[2-(diethylamino)ethyl]-; HMS553P13; CID4913; HMS1361J05; Prestwick2_000337; AC1Q2ZC8; Procainamidum [INN-Latin]; HMS1989J05; KBio2_000183; BSPBio_000373; Procainamida [INN-Spanish]; Benzamide, 4-amino-N-(2-(diethylamino)ethyl)-; KBioSS_001316; Spectrum3_000555; AB00053530; KBio2_001316; p-Amino-N-(2-diethylaminoethyl)benzamide	51-06-9	4913	9605	TTDS00402	Sodium channel protein type 5 subunit alpha	HH1;SCN5A;Sodium channel protein cardiac muscle subunit alpha;Sodium channel protein type V subunit alpha;Voltage-gated sodium channel subunit alpha Nav1.5	Q14524	6331	ENSG00000183873	blocker
DAP001432	Tetrodotoxin	T5651_SIGMA; HSDB 3543; TETRODOTOXIN; Spheroidine; 4-27-00-08206 (Beilstein Handbook Reference); BRN 0049176; BJT 1; 9014-39-5; Tetrodotoxine; CID20382; AC1L2G5D; LS-62012; CHEBI:9506; 2229-61-0; Octahydro-12-(hydroxymethyl)-2-imino-5,9:7,10adimethano-10aH-(1,3)dioxocino(6,5-d)pyrimidine-4,7,10,11,12-pentol; 12626-86-7; (1r,5r,6r,9r,11s,13s,14s)-3-amino-14-(hydroxymethyl)-8,10-dioxa-2,4-diazatetracyclo[7.3.1.17,11.01,6]tetradec-3-ene-5,9,12,13,14-pentol(non-preferred name); AC1Q6Z79; (1R,5R,6R,7R,9S,11R,12R,13S,14S)-14-(hydroxymethyl)-3-imino-8,10-dioxa-2,4-diazatetracyclo[7.3.1.1(7,11).0(1,6)]tetradecane-5,9,12,13,14-pentol; CID5460547; Maculotoxin; 4368-28-9; C11H17N3O8.H; CHEMBL507974; 5,9:7,10a-Dimethano-10aH-(1,3)dioxocino(6,5-d)pyrimidine-4,7,10,11,12-pentol, octahydro-12-(hydroxymethyl)-2-imino-, (4R,4aR,5R,7S,9S,10S,10aR,11S,12S)-; Tetradotoxin; CCRIS 9328; MolPort-003-959-757; 11026-09-8; EINECS 224-458-8; Babylonia japonica toxin 1; CID11174599; 11005-69-9; Octahydro-12-(hydroxymethyl)-2-imino-5,9:7,10a-dimethano-10aH-(1,3)dioxocino(6,5-d)pyrimidine-4,7,10,11,12-pentol; T8024_SIGMA; Fugu Toxin; 17289-88-2; Fugu poison; 5,9:7,10a-Dimethano-10aH-(1,3)dioxocino(6,5-d)pyrimidine-4,7,10,11,12-pentol, octahydro-12-(hydroxymethyl)-2-imino-; Tetrodoxin; (4R-(4alpha,4aalpha,5alpha,7alpha,9alpha,10alpha,10abeta,11S*,12S*))-Octahydro-12-(hydroxymethyl)-2-imino-5,9:7,10a-dimethano-10aH-(1,3)dioxocino(6,5-d) pyrimidine-4,7,10,11,12-pentol; 5,9:7,10a-Dimethano-10ah-(1,3)dioxocino(6,5-d)pyrimidine-4,7,10,11,12-pentol, octahydro-12-(hydroxymethyl)-2-imino-, (4R-(4alpha,4aalpha,5alpha,7alpha,9alpha,10alpha,10abeta,11S*,12S*))-; TTX; Tetrodontoxin; Tarichatoxin	4368-28-9	20382	13857	TTDS00402	Sodium channel protein type 5 subunit alpha	HH1;SCN5A;Sodium channel protein cardiac muscle subunit alpha;Sodium channel protein type V subunit alpha;Voltage-gated sodium channel subunit alpha Nav1.5	Q14524	6331	ENSG00000183873	blocker
DAP000503	Indecainide	UNII-3AZF20DM1T; AC1L1CGM; C20H24N2O; 74517-78-5; 9-(3-((1-methylethyl)amino)propyl)-9H-fluorene-9-carboxamide; 73681-12-6 (hydrochloride); CID52195; LY-135837; INDECAINIDE; DB00192; CCRIS 2655; LS-177129; Indecainidum; Indecainida; Indecainide [INN]; Indecainidum [Latin]; 9-(3-(Isopropylamino)propyl)-9-fluorenylcarboxamid; 9-[3-(propan-2-ylamino)propyl]fluorene-9-carboxamide; Ricainid; Indecainida [Spanish]; 9-(3-(Isopropylamino)propyl))fluorene-9-carboxamide; 9H-Fluorene-9-carboxamide, 9-(3-((1-methylethyl)amino)propyl)-; Ricainide	74517-78-5	52195	667965	TTDS00402	Sodium channel protein type 5 subunit alpha	HH1;SCN5A;Sodium channel protein cardiac muscle subunit alpha;Sodium channel protein type V subunit alpha;Voltage-gated sodium channel subunit alpha Nav1.5	Q14524	6331	ENSG00000183873	blocker
DCL000392	SB-756050	N/A	N/A	N/A	N/A	TTDS00272	Bile acid receptor	Farnesoid X receptor;Farnesoid X-activated receptor;Farnesol receptor HRR-1;Nuclear farnesoid X receptor;Retinoid X receptor-interacting protein 14;RXR-interacting protein 14	Q96RI1	9971	ENSG00000012504	agonist
DAP001389	Guggulsterone	95975-55-6; E-Guggulsteron; CHEMBL402063; Guggulsterone E; CHEMBL410683; CID6450278; (17Z)-Pregna-4,17(20)-diene-3,16-dione; (8R,9S,10R,13S,14S,17Z)-17-ethylidene-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15-decahydrocyclopenta[a]phenanthrene-3,16-dione; Cis-Guggulsterone; CID6439929; MolPort-003-941-496; ZINC19132424; 39025-23-5; G5168_SIGMA; CHEBI:519995; (17Z)-pregna-4,17-diene-3,16-dione; E-Guggulsterone; Guggulsterones Z; Pregna-4,17(20)-diene-3,16-dione, (17E)-; AC1O5SP4; (Z)-Guggulsterone; Pregna-4,17-diene-3,16-dione; Z-Guggulsterone; Guggulsterone; Spectrum5_002033; NCGC00091913-01; AC-6215; (17E)-pregna-4,17-diene-3,16-dione; Ambotz39025-23-5; 4,17(20)-cis-Pregnadiene-3,16-dione; 39025-24-6; (17E)-Pregna-4,17(20)-diene-3,16-dione; (8R,9S,10R,13S,14S,17E)-17-ethylidene-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15-decahydrocyclopenta[a]phenanthrene-3,16-dione; trans-Guggulsterone; AC1O51DD; NCGC00091910-01; Guggulsterones E	95975-55-6	6439929	724620	TTDS00272	Bile acid receptor	Farnesoid X receptor;Farnesoid X-activated receptor;Farnesol receptor HRR-1;Nuclear farnesoid X receptor;Retinoid X receptor-interacting protein 14;RXR-interacting protein 14	Q96RI1	9971	ENSG00000012504	antagonist
DAP001286	Interferon gamma-1b	N/A	82115-62-6	34475	46507194	TTDS00477	Interferon-gamma receptor	CD119;CDw119;IFN-gamma-R;IFNGR	P38484	3460	ENSG00000159128	binder
DCL001022	Traxoprodil	Traxoprodil; 1-Piperidineethanol, 4-hydroxy-alpha-(4-hydroxyphenyl)-beta-methyl-4-phenyl-, (alphaS,betaS)-; CID219101; 15571-11-6; ( )-CP 101606; LS-184042; 1-Piperidineethanol, 4-hydroxy-alpha-(4-hydroxyphenyl)-beta-methyl-4-phenyl-, (S-(R*,R*))-; AC1L5621; CP101606; CP-101606; AC1Q59EY; CHEMBL17350; CP 98113; CHEBI:119774; Traxoprodil [INN]; CP 101,606; AR-1B8535; CP 101606; 1-[(1s,2s)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]-4-phenylpiperidin-4-ol; KST-1B0691	189894-57-3	122129	791640	TTDC00299	Glutamate [NMDA] receptor subunit epsilon 2	Glutamate receptor NR2B subunit;HNR3;NMDA NR2B receptor;NMDA receptor NR2B;NMDA receptor subunit 2B;NMDAR2B;N-methyl D-aspartate receptor subtype 2B;N-methyl-D-aspartate receptor subunit 3;NR2B;NR3	Q13224	2904	ENSG00000150086	antagonist
DCL001104	Besonprodil	Besonprodil; PD 0196860; CID156328; 6-(2-(4-(4-Fluorobenzyl)-piperidin-1-yl)-ethanesulfinyl)-3H-benzoxazol-2-one; 253450-09-8; UNII-5K3N2D15WW; Co 200461; CHEMBL219631; Besonprodil (USAN); 2(3H)-Benzoxazolone, 6-((2-(4-((4-fluorophenyl)methyl)-1-piperidinyl)ethyl)sulfinyl); CI-1041; PD196860; CHEBI:469810; D03100; AC1L4FZ9; PD 196860; 6-[2-[4-[(4-fluorophenyl)methyl]piperidin-1-yl]ethylsulfinyl]-3H-1,3-benzoxazol-2-one	N/A	N/A	N/A	TTDC00299	Glutamate [NMDA] receptor subunit epsilon 2	Glutamate receptor NR2B subunit;HNR3;NMDA NR2B receptor;NMDA receptor NR2B;NMDA receptor subunit 2B;NMDAR2B;N-methyl D-aspartate receptor subtype 2B;N-methyl-D-aspartate receptor subunit 3;NR2B;NR3	Q13224	2904	ENSG00000150086	antagonist
DCL001109	EVT-101	N/A	N/A	N/A	N/A	TTDC00299	Glutamate [NMDA] receptor subunit epsilon 2	Glutamate receptor NR2B subunit;HNR3;NMDA NR2B receptor;NMDA receptor NR2B;NMDA receptor subunit 2B;NMDAR2B;N-methyl D-aspartate receptor subtype 2B;N-methyl-D-aspartate receptor subunit 3;NR2B;NR3	Q13224	2904	ENSG00000150086	antagonist
DCL000958	RGH-896	N/A	N/A	108045	44436950	TTDC00299	Glutamate [NMDA] receptor subunit epsilon 2	Glutamate receptor NR2B subunit;HNR3;NMDA NR2B receptor;NMDA receptor NR2B;NMDA receptor subunit 2B;NMDAR2B;N-methyl D-aspartate receptor subtype 2B;N-methyl-D-aspartate receptor subunit 3;NR2B;NR3	Q13224	2904	ENSG00000150086	antagonist
DCL000724	Bifeprunox	CID208951; D06566; CHEBI:467160; DU127090; DU 127090; Bifeprunox (USAN/INN); 350992-10-8; L001659; Bifeprunoxum [INN-Latin]; Bifeprunoxum; CHEMBL218166; Bifeprunox; 7-[4-[(3-phenylphenyl)methyl]piperazin-1-yl]-3H-1,3-benzoxazol-2-one; 7-(4-(Biphenyl-3-ylmethyl)piperazin-1-yl)benzoxazol-2(3H)-one; MolPort-005-943-082; Bifeprunox [INN]; AC1L4LOA; UNII-AP69E83Z79	350992-13-1	130021	47208222	TTDS00012	D(2) dopamine receptor	Dopamine D2 receptor;Dopamine receptor 2	P14416	1813	ENSG00000149295	agonist
DPR000002	(S)-amisulpride	N/A	71675-92-8	444254	49689717	TTDS00012	D(2) dopamine receptor	Dopamine D2 receptor;Dopamine receptor 2	P14416	1813	ENSG00000149295	antagonist
DCL000963	Risperidone Consta	N/A	106266-06-2	493326	38681195	TTDS00012	D(2) dopamine receptor	Dopamine D2 receptor;Dopamine receptor 2	P14416	1813	ENSG00000149295	antagonist
DAP000282	Bromocriptine	Prestwick0_000121; 2-Bromo-alpha-ergokryptin; (5'alpha)-2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)ergotaman-3',6',18-trione; Biomol-NT_000005; Ergocryptine, 2-bromo- (8CI); CHEBI:3181; CID31101; NCGC00024584-04; CB-154; (5'alpha)-2-bromo-12'-hydroxy-5'-(2-methylpropyl)-2'-(propan-2-yl)-3',6',18-trioxoergotaman; Ergotaman-3',6',18-trione, 2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-,(5'-alpha)-; (6aR,9R)-5-Bromo-N-((2R,5S,10aS,10bS)-10b-hydroxy-5-isobutyl-2-isopropyl-3,6-dioxooctahydro-2H-oxazolo[3,2-a]pyrrolo[2,1-c]pyrazin-2-yl)-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide; Apo-Bromocriptine; Bromocriptine [USAN:BAN:INN]; Bromocriptinum [INN-Latin]; 22260-51-1 (mesylate (salt)); NSC169774; AC1Q2716; Bromoergocriptine; Prestwick2_000121; Alti-Bromocriptine; NCI60_001365; Bromoergocryptine; DB01200; bromocriptine; C32H40BrN5O5; Bromocriptina; PDSP2_001500; C06856; Ergoset; CCRIS 3244; Bromocriptin; Ergotaman-3',6',18-trione, 2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'alpha-(2-methylpropyl)-; 2-Bromoergokryptine; MolPort-002-512-064; D03165; Bromocriptine methanesulfonate; Ergocryptine, 2-bromo-; Parlodel; 2-Bromo-alpha-ergokryptine; 2-Bromo-alpha-ergocryptine; Bromocriptine [BAN]; 2-Bromo-12'-hydroxy-2'-(1-methylethyl)-5'-alpha-(2-methylpropyl)ergotamin-3',6',18-trione; nchembio873-comp18; SPBio_002101; EINECS 247-128-5; AC-13601; Lopac0_000171; Bagren; LS-64540; Ergotaman-3',6',18-trione, 2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-, (5'alpha)-; BPBio1_001131; Bromocriptine (USAN/INN); AC1L1KXS; Bromocryptine; Bromocriptina [INN-Spanish]; BIDD:GT0464; Prestwick1_000121; (5'alpha)-2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-3',6',18-trioxoergotaman; Bromergocryptine; BRD-K14496212-001-01-1; (5'alpha)-2-bromo-12'-hydroxy-5'-isobutyl-2'-isopropyl-3',6',18-trioxoergotaman; Bromocryptin; UNII-3A64E3G5ZO; CHEMBL493; Bromocriptinum; 25614-03-3; Parlodel Snaptabs; 2-Bromoergocryptine Methanesulfonate	25614-03-3	31101	174998	TTDS00012	D(2) dopamine receptor	Dopamine D2 receptor;Dopamine receptor 2	P14416	1813	ENSG00000149295	agonist
DAP000312	Remoxipride	(-)-(S)-3-Bromo-N-((1-ethyl-2-pyrrolidinyl)methyl)-2,6-dimethoxybenzamide; A 33547; Remoxipride (USAN); AC1Q2696; 80125-14-0; AB00514647; Prestwick3_000971; NCGC00024870-02; BRD-K54094468-003-03-8; (-)-n-ethyl-2-(3-bromo-2,6-dimethoxybenzamidomethyl)pyrrolidine; NCGC00024870-01; (S)-3-Bromo-2,6-dimethoxy-N-((1-ethyl-2-pyrrolidinyl)methyl)benzamide; Remoxipridum; CAS-73220-03-8; BPBio1_001171; 73220-03-8 (mono-hydrochloride); BRD-K54094468-001-01-6; (-)-(S)-3-Brom-N-((1-ethyl-2-pyrrolidinyl)methyl)-2,6-dimethoxybenzamid; A-33547; Prestwick1_000971; SPBio_002912; Biomol-NT_000015; Remoxiprida; BPBio1_001103; Tocris-0916; Benzamide, 3-bromo-N-((1-ethyl-2-pyrrolidinyl)methyl)-2,6-dimethoxy-, (S)-; (S)-3-Bromo-N-((1-ethyl-2-pyrrolidinyl)methyl)-2,6-dimethoxybenzamide; LS-25856; Romoxipride; CHEMBL22242; DB00409; NCGC00016921-01; Prestwick0_000971; Remoxipride [USAN:BAN:INN]; Prestwick2_000971; BRN 4323708; 3-bromo-N-[[(2S)-1-ethylpyrrolidin-2-yl]methyl]-2,6-dimethoxybenzamide; Remoxipridum [INN-Latin]; BSPBio_001001; 117591-79-4 (mono-hydrochloride monohydrate); Benzamide, 3-bromo-2,6-dimethoxy-N-((1-ethyl-2-pyrrolidinyl)methyl)-, (S)-; D02682; FLA 731; FLA-731; HMS2089L19; CHEBI:127616; Remoxiprida [INN-Spanish]; UNII-0223RD59PE; Remoxipride; MolPort-003-666-824; NCGC00024870-03; CID54477; AC1L1H2R	80125-14-0	54477	192058	TTDS00012	D(2) dopamine receptor	Dopamine D2 receptor;Dopamine receptor 2	P14416	1813	ENSG00000149295	antagonist
DAP001368	Domperidone maleate	Prestwick-06G02; Bio-0028; (Z)-but-2-enedioic acid; 6-chloro-3-[1-[3-(2-oxo-3H-benzimidazol-1-yl)propyl]piperidin-4-yl]-1H-benzimidazol-2-one; 5-Chloro-1-(1-(3-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)propyl)piperidin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one maleate; Domperidone Maleate; AC1O7GNH; Domperidone (TN); D07868; 99497-03-7; CID6604595; EINECS 281-277-7; NCGC00017157-01; 57808-66-9 (Parent); 83898-65-1	99497-03-7	6443236	766054	TTDS00012	D(2) dopamine receptor	Dopamine D2 receptor;Dopamine receptor 2	P14416	1813	ENSG00000149295	antagonist
DCL001006	Sumanirole	4H-Imidazo(4,5,1-ij)quinolin-2(1H)-one, 5,6-Dihydro-5-(methylamino)-, (R)-; 2-Naphthalenesulfonic acid, compd with rel-(alphaS)-alpha-((1R)-1-(methylamino)ethyl)benzenemethanol (1:1); PNU-95666; Sumanirole; CID177343; 2-Naphthalenesulfonic acid, compd with (R*,S*)-alpha-(1-(methylamino)ethyl)benzenemethanol (1:1); 179386-43-7; AC1L42OU; PNU 95666; [2-[(1R)-1-(methylamino)ethyl]phenyl]methanol; naphthalene-2-sulfonic acid; UNII-3E93IV1U45; 179126-15-9; Benzenemethanol, alpha-((1R)-1-(methylamino)ethyl)-, (alphaS)-rel-,  2-naphthalenesulfonate (salt); U 95666E	179386-43-7	N/A	10549620	TTDS00012	D(2) dopamine receptor	Dopamine D2 receptor;Dopamine receptor 2	P14416	1813	ENSG00000149295	agonist
DPR000105	SDZ-HDC-912	PDSP1_000782; Sdz-208-912; 120478-65-1; n-[(8|A)-2-chloro-6-methylergolin-8-yl]-2,2-dimethylpropanamide; N-(2-Chloro-6-methylergoline-8-yl)-2,2-dimethylpropanamide; Sdz 208-912; PDSP2_000770; AC1Q3QBW; Sdz hdc 912; AC1L1ODH; CID58145	120478-65-1	58145	726566	TTDS00012	D(2) dopamine receptor	Dopamine D2 receptor;Dopamine receptor 2	P14416	1813	ENSG00000149295	binder
DAP000068	Ropinirole	Ropinirole (INN); 2H-Indol-2-one, 4-(2-(dipropylamino)ethyl)-1,3-dihydro-; Ropinirole [INN:BAN]; Lopac0_001101; SKF 101468; BRD-K15933101-003-01-2; 91374-21-9; NCGC00096064-01; SK&F-101,468; Ropinirolum [INN-Latin]; UNII-030PYR8953; 4-[2-(Dipropylamino)ethyl]-1,3-dihydro-2H-indol-2-one; 4-[2-(Dipropylamino)ethyl]indoline-2-one; Ropinirole; SKF 101468; BIDD:GT0826; Ropitor; CHEMBL589; NCGC00096064-02; MolPort-003-666-598; SPECTRUM1505178; Ropinirol [INN-Spanish]; Ropitor (TN); D08489; ropinirol; L000520; AC1L1JLL; NCGC00015893-01; ReQuip XL; CID5095; C07564; CHEBI:8888; AB1004799; TL8005859; LS-83890; Lopac-R-4152; Ropinirolum; 2H-Indol-2-one, 4-[2-(dipropylamino)ethyl]-1,3-dihydro-; DB00268; I06-0692; 4-[2-(dipropylamino)ethyl]-1,3-dihydro-2H-indol-2-one; HMS2093K04; SK&F 101468; ropinirole; ReQuip CR; 4-[2-(dipropylamino)ethyl]-1,3-dihydroindol-2-one; NCGC00015893-04; 91374-20-8 (hydrochloride)	91374-21-9	5095	7980537	TTDS00012	D(2) dopamine receptor	Dopamine D2 receptor;Dopamine receptor 2	P14416	1813	ENSG00000149295	agonist
DCL000873	Lurasidone hydrochloride	441351-20-8; SM 13496; Lurasidone hydrochloride; Lurasidone HCl; 367514-88-3; MK-3756; D04820; SMP-13496; N-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinylmethyl)-1-cyclohexylmethyl)-2,3-bicyclo(2.2.1)heptanedicarboximide; SM-13496; Lurasidone hydrochloride (USAN)	367514-87-2	213046	47206606	TTDS00012	D(2) dopamine receptor	Dopamine D2 receptor;Dopamine receptor 2	P14416	1813	ENSG00000149295	antagonist
DAP001364	Dapotum D	NSC169510; Flufenazine decanoate; AC1L1FTN; Decanoic acid, 2-(4-(3-(2-(trifluoromethyl)-10H-phenothiazin-10-yl)propyl)-1-piperazinyl)ethyl ester; CCRIS 3954; Fluphenazine depot; 5002-47-1; CHEMBL1200854; Decanoic acid, 2-[4-[3-[2-(trifluoromethyl)phenothiazin-10-yl]propyl]-1-piperazinyl]ethyl ester; Fluphenazine decanoate; AKOS003589045; Fluphenazine O-decanoate; EINECS 225-672-4; Fluphenaline decanoate; Moditen-depo; SQ 10,733; Dapotum D; WLN: T C666 BN ISJ EXFFF B3- AT6N DNTJ D2OV9; AC1Q4K03; Moditen depot; 2-(4-(3-(2-(Trifluoromethyl)phenothiazin-10-yl)propyl)-1-piperazinyl)ethyl decanoate; D00793; Fluphenazine decanoate (JAN/USP); Fluorophenazine decanoate; LS-59383; Prolixin decanoate (TN); MolPort-001-728-034; BRN 0599852; NSC 169510; UNII-FMU62K1L3C; C32H44F3N3O2S; CID3388; 2-[4-[3-[2-(trifluoromethyl)phenothiazin-10-yl]propyl]piperazin-1-yl]ethyl decanoate; Decanoic acid, 2-[4-[3-[2-(trifluoromethyl)-10H-phenothiazin-10-yl]propyl]-1-piperazinyl]ethyl ester; Modecate; AR-1J0863; 2-(4-{3-[2-(trifluoromethyl)-10H-phenothiazin-10-yl]propyl}piperazin-1-yl)ethyl decanoate; Decanoic acid, 2-(4-(3-(2-(trifluoromethyl)phenothiazin-10-yl)propyl)-1-piperazinyl)ethyl ester	5002-47-1	11191402	7847858	TTDS00012	D(2) dopamine receptor	Dopamine D2 receptor;Dopamine receptor 2	P14416	1813	ENSG00000149295	antagonist
DCL001041	Y-931	N/A	221058-55-5	N/A	N/A	TTDS00012	D(2) dopamine receptor	Dopamine D2 receptor;Dopamine receptor 2	P14416	1813	ENSG00000149295	binder
DPR000035	D1 agonist D2 antagonist	N/A	N/A	N/A	N/A	TTDS00012	D(2) dopamine receptor	Dopamine D2 receptor;Dopamine receptor 2	P14416	1813	ENSG00000149295	antagonist
DAP000026	Flupenthixol	L000972; 2709-56-0; 4-(3-(2-(Trifluoromethyl)thioxanthen-9-ylidene)propyl)-1-piperazineethanol; LS-112582; 2-Trifluoromethyl-9-(3-(4-(beta-hydroxyethyl)-1-piperazinyl)propylidene)thioxanthene; NCGC00162179-02; (Z)-4-(3-(2-(Trifluoromethyl)-9H-thioxanthen-9-ylidene)propyl)piperazine-1-ethanol; 1-Piperazineethanol, 4-(3-(2-(trifluoromethyl)-9H-thioxanthen-9-ylidene)propyl)- (9CI); EINECS 258-756-4; 53772-82-0; Biomol-NT_000021; D01044; BPBio1_000417; 1-Piperazineethanol, 4-[(3Z)-3-[2-(trifluoromethyl)-9H-thioxanthen-9-ylidene]propyl]-; 1-Piperazineethanol, 4-(3-(2-(trifluoromethyl)-9H-thioxanthen-9-ylidene)propyl)-; Depixol; cis(Z)Flupenthixol; 1-Piperazineethanol, 4-(3-(2-(trifluoromethyl)-9H-thioxanthen-9-ylidene)propyl)-, (Z)-; NCGC00162179-05; ALPHA-FLUPENTHIXOL; LS-112584; cis-Flupenthixol; cis-(Z)-Flupenthixol; Flupentixol; FLUPENTHIXOL; Lopac0_000528; NCGC00162179-01; 2-Trifluoromethyl-9-(3-(4-(2-hydroxyethyl)piperazin-1-yl)propylidene)thioxanthene; cis-Flupentixol; 1-Piperazineethanol, 4-[3-[2-(trifluoromethyl)-9H-thioxanthen-9-ylidene]propyl]-; Flupentixol (INN); CID5281881; (Z)-4-(3-(2-(Trifluoromethyl)-9H-thioxanthen-9-ylidene)propyl)-1-piperazineethanol; D005475; 4-(3-(2-(Trifluoromethyl)-9H-thioxanthen-9-ylidene)propyl)-1-piperazineethanol; C23H25F3N2OS; C11191; UNII-FA0UYH6QUO; LC 44; Depixol (TN); NCGC00162179-04; Prestwick3_000340; Siplaril; Fluxanxol; nchembio873-comp7; AC1NQZ8F; 1-Piperazineethanol, 4-(3-(2-(trifluoromethyl)thioxanthen-9-ylidene)propyl)-; Fluanxol; EINECS 220-304-9; NCGC00162179-03; Emergil; Flupentixol [INN:DCF]; BSPBio_000379; BPBio1_001183; BRD-K70487031-001-01-0; 2-[4-[(3Z)-3-[2-(Trifluoromethyl)thioxanthen-9-ylidene]propyl]piperazin-1-yl]ethanol; Flupentixolum [INN-Latin]; Siplarol; Prestwick2_000340; N 7009	2709-56-0	17012	13339	TTDS00012	D(2) dopamine receptor	Dopamine D2 receptor;Dopamine receptor 2	P14416	1813	ENSG00000149295	antagonist
DCL000966	Rotigotine patch	N/A	125572-93-2	3619466	49107774	TTDS00012	D(2) dopamine receptor	Dopamine D2 receptor;Dopamine receptor 2	P14416	1813	ENSG00000149295	agonist
DCL001002	SSR-181507	N/A	148262-19-5	177859	43529611	TTDS00012	D(2) dopamine receptor	Dopamine D2 receptor;Dopamine receptor 2	P14416	1813	ENSG00000149295	binder
DCL000703	Asenapine	EINECS 265-829-4; 1H-Dibenz[2,3:6,7]oxepino[4,5-c]pyrrole, 5-chloro-2,3,3a,12b-tetrahydro-2-met; trans-5-Chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-dibenz(2,3:6,7)oxepino(4,5-c)pyrrole; PDSP2_001584; hyl-, trans-; Org-5222; 1H-Dibenz[2,3:6,7]oxepino[4,5-c]pyrrole, 5-chloro-2,3,3a,12b-tetrahydro-2-methyl-, (3aR,12bR)-rel-; Org 5222; Asenapi; 65576-45-6; Asenapine; UNII-JKZ19V908O; AC1L4SHR; 1H-Dibenz(2,3:6,7)oxepino(4,5-c)pyrrole, 5-chloro-2,3,3a,12b-tetrahydro-2-methyl-, (3aR,12bR)-rel-; PDSP1_001600; 5-chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-dibenz(2,3-6,7)oxepino(4,5-c)pyrrole; 1H-Dibenz(2,3:6,7)oxepino(4,5-c)pyrrole, 5-chloro-2,3,3a,12b-tetrahydro-2-methyl-, trans-; CHEMBL504548; [13C,2H3]-Asenipine; Asenapine [INN:BAN]; CID163091; I14-8821; 1H-Dibenz[2,3:6,7]oxepino[4,5-c]pyrrole, 5-chloro-2,3,3a,12b-tetrahydro-2-methyl-, trans-; 135882-95-0	65576-45-6	3001386	34667915	TTDS00012	D(2) dopamine receptor	Dopamine D2 receptor;Dopamine receptor 2	P14416	1813	ENSG00000149295	antagonist
DCL000988	SLV-310	CID9888211; L001635; MolPort-005-933-329; CHEBI:317302; SLV-310; 2-[4-[4-(5-fluoro-1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-yl]butyl]isoindole-1,3-dione; CHEMBL131495	N/A	N/A	N/A	TTDS00012	D(2) dopamine receptor	Dopamine D2 receptor;Dopamine receptor 2	P14416	1813	ENSG00000149295	antagonist
DAP000310	Sulpiride	RV-12309; Almirall Brand of Sulpiride; Sulpiride (JP15/USAN/INN); Uriach Brand of Sulpiride; CHEMBL26; S-(-)-Sulpiride; Spyfarma Brand of Sulpiride; Sulpivert; Dolmatil; Eglonil; CID5355; Lebopride; Biomol-NT_000037; NCGC00015966-08; Bio-0717; Pontiride; EINECS 239-753-7; NCGC00024852-02; sulpiride; Oprea1_602476; Lisopiride; Aiglonyl; LS-20058; Darleton; Hoechst Brand of Sulpiride; Sanofi Synthelabo Brand of Sulpiride; Pyrkappl; KBio1_000278; ( inverted question mark)-Sulpiride; Areu Brand of Sulpiride; SMR000038923; LS-20059; Sulperide; BPBio1_001255; HMS1568K13; o-Anisamide, N-((1-ethyl-2-pyrrolidinyl)methyl)-5-sulfamoyl-; Hexal Brand of Sulpiride; Biomol-NT_000162; Synedil; BSPBio_000211; Arminol; Prestwick3_000056; Hennig Brand of Sulpiride; Valirem; Eusulpid; Sanofi-Synthelabo Brand of Sulpiride; EU-0001755; Mariastel; Magnetic resonance imaging sulpiride; 15676-16-1; BRD-A55272860-001-04-7; Sulpirida [INN-Spanish]; Fumouzer Brand of Sulpiride; IDI1_000278; Levosulpirida; S 8010; AC-12181; Mirbanil; DivK1c_000278; BPBio1_000233; Sulpyrid; Coolspan; MLS000069434; Dogmatyl (TN); 23672-07-3; nchembio873-comp17; Dolorgiet Brand of Sulpiride; (?)-Sulpiride; Sernevin; Desitin Brand of Sulpiride; NCGC00024852-04; Deponerton; C15H23N3O4S; NCGC00024852-05; Levopraid; Levosulpiridum [INN-Latin]; N-((1-Ethyl-2-pyrrolidinyl)methyl)-5-sulfamoyl-o-anisamide; Hormosan Brand of Sulpiride; Desisulpid; Neogama; Alimoral; Fidelan; Allphar Brand of Sulpiride; Guastil; SPBio_002132; Normum; Digton; Dogmatyl; Levosulpiride [INN]; I06-0054; Levosulpirida [INN-Spanish]; L000579; Championyl; vertigo-neogama; Meresa; Sulpiridum [INN-Latin]; Sulpitil; Sulpride; Norestran; Nufarol; Prestwick_431; Ekilid; Miradol; BPBio1_000463; Dresent; R.D. 1403; EU-0101050; S8010_SIGMA; Pharmacia Brand of Sulpiride; AC1L1K62; Levosulpiridum; (RS)-(+/-)-sulpiride; BRN 0494008; 5-22-08-00105 (Beilstein Handbook Reference); AKOS004912732; R. D. 1403; Erempharma Brand of Sulpiride; (+/-)-Sulpiride; vertigo neogama; Restful; Sulp; Krewel Brand of Sulpiride; Prestwick1_000056; Psicofarma Brand of Sulpiride; Psicocen; Sulpor; Lopac0_001050; STK368596; Calmoflorine; Tepavil; Sulpirida; Dobren; Levobren; Equilid; Omiryl; D01226; D013469; Rosemont Brand of Sulpiride; Sulpirid; NCGC00024852-03; Centrum Brand of Sulpiride; Stamonevrol; Vertigo Meresa; Sulpiride [USAN:INN:BAN:JAN]; Pyrikappl; Sulpiridum; Abilit; Isnamide; Prestwick0_000056; Suprium; MolPort-002-070-475; Dogmatil; Vertigo-Meresa; Enimon; Splotin; BRD-A55272860-001-03-9; RD 1403; NINDS_000278; Sursumid; Fardalan; Zemorcon; CCRIS 4248; Eglonyl; MLS001306443; NCGC00015966-04; HMS500N20; Prestwick2_000056; Omperan; Ozoderpin; Desmenat; Misulvan; Kylistro; DB00391	15676-16-1	5355	583043	TTDS00012	D(2) dopamine receptor	Dopamine D2 receptor;Dopamine receptor 2	P14416	1813	ENSG00000149295	antagonist
DCL000889	N-0923	C19H25NOS; Rotigotine CDS; CHEBI:358371; (6S)-6-[propyl(2-thiophen-2-ylethyl)amino]-5,6,7,8-tetrahydronaphthalen-1-ol; (-)-(S)-5,6,7,8-Tetrahydro-6-(propyl(2-(2-thienyl)ethyl)amino)-1-naphthol; L001423; AC1Q7ALS; 1-naphthalenol, 5,6,7,8-tetrahydro-6-(propyl (2-(2-thienyl)ethyl)amino-(6S)-; CHEBI:268876; SPM-962; AC-3547; 1-Naphthalenol, 5,6,7,8-tetrahydro-6-(propyl(2-(2-thienyl)ethyl)amino)-; SPM 962; CID57537; Neupro; 2-(N-n-Propyl-N-2-thienylethylamino)-5-hydroxytetralin; PDSP2_001830; AC1L1QQG; Rotigotine; 92206-54-7; LS-178435; 6-[propyl(2-thiophen-2-ylethyl)amino]-5,6,7,8-tetrahydronaphthalen-1-ol; (6S)-6-(Propyl(2-(2-thienyl)ethyl)amino)-5,6,7,8-tetrahydro-1-naphthalenol; N 0923; Rotigotine [USAN:INN]; 99755-59-6; DB05271; CHEMBL1303; D05768; UNII-87T4T8BO2E; N 0437; Neupro (TN); N 0437, (-)-isomer; 6-(Propyl(2-(2-thienyl)ethyl)amino)-5,6,7,8-tetrahydro-1-naphthalenol; CID59227; (-)-N-0437; NCGC00168748-01; N 0924; Rotigotine CDS Patch; N-0437; rotigotine transdermal patch; AC1L1N7C; Rotigotine (USAN/INN); SPM-937; CHEMBL104383; N-0924; N-0923; PDSP1_001847; MolPort-005-941-578; SPM-936	99755-59-6	59227	12014593	TTDS00012	D(2) dopamine receptor	Dopamine D2 receptor;Dopamine receptor 2	P14416	1813	ENSG00000149295	agonist
DAP001470	Dexamfetamine	dextroamphetamine; D-Amphetamine; (2S)-(+)-Amphetamine; (+/-)-beta-Phenylisopropylamine; DB01576; CID5826; (S)-alpha-Phenylethylamine; S(+)-Amphetamine; DEA No. 1100; Simpatedrin; Dexamfetamine (INN); (S)-alpha-Methylphenethylamine; Raphetamine; Fenylo-izopropylaminyl; Sympamin; (S)-1-Phenyl-2-propylamine; Rhinalator; Phenethylamine, alpha-methyl-, d-; Propisamine; Benzedrine; dextro-Amphetamine; (+)-alpha-Methylphenylethylamine; CHEMBL612; (S)-Amphetamine; Dexamfetamina [INN-Spanish]; LS-187774; EINECS 200-112-1; Dexamfetaminum; D-alpha-methylphenethylamine; Dexamfetamine; alpha-Methylphenethylamine, d-form; Sympamine; Benzeneethanamine, alpha-methyl-, (S)-; D-(+)-Amphetamine; Dexamphetaminum; (S)-(+)-Amphetamine; PDSP2_001495; Dexidrine; (2S)-1-phenylpropan-2-amine; Phenethylamine, alpha-methyl-, (+)-; dl-1-Phenyl-2-aminopropane; D03740; Dextroamphetamine resin complex; MolPort-004-285-839; Isoamycin; (S)-1-Phenyl-2-propanamine; D-(S)-Amphetamine; Dexamphetaminum [INN-Latin]; dl-Benzedrine; (S)-(+)-beta-Phenylisopropylamine; Dexedrine Spansule; dl-Amphetamine; Desamfetamina [DCIT]; Dexamfetamina; (+/-)-Desoxynorephedrine; Benzeneethanamine, alpha-methyl-, (alphaS)-; AC1L1L85; (+/-)-Benzedrine; Dephadren; beta-phenyl-isopropylamine; Psychedrine; NCGC00168247-01; (+)-Phenaminum; PDSP1_001511; D-AM; Benzeneethanamine, alpha-methyl-, (aS)- (9CI); HSDB 3055; BRN 2205872; Dexadrine; NSC 73713; Dexedrine; Amsustain; Dextroamphetamine [USAN]; D-2-Amino-1-phenylpropane; D-1-Phenyl-2-aminopropane; Dexacaps; Dexamphetamine; C07884; Sympatedrine; d-1-Phenyl-2-aminopropan [German]; Dextro-Amphetamine Sulfate; (alphaS)-alpha-methylbenzeneethanamine; 4-12-00-02587 (Beilstein Handbook Reference); Dextroamphetamine (USAN); Dexanfetamina [INN-Spanish]; Desamfetamina; CHEBI:4469; (+)-(S)-Amphetamine; Dexanfetamina; (S)-alpha-methylbenzeneethanamine; Weckamine; Dexamfetaminum [INN-Latin]; 51-64-9; (S)-1-Phenyl-2-aminopropane; (+)-Amphetamine; (+)-alpha-Methylphenethylamine; D-1-Phenyl-2-aminopropan; DB00182; Phenethylamine, alpha-methyl-, (+)- (8CI); LS-103617; UNII-TZ47U051FI	51-63-8	16077373	46506252	TTDS00012	D(2) dopamine receptor	Dopamine D2 receptor;Dopamine receptor 2	P14416	1813	ENSG00000149295	agonist
DCL000983	Sibenadet	N/A	154189-24-9	443590	36886849	TTDS00012	D(2) dopamine receptor	Dopamine D2 receptor;Dopamine receptor 2	P14416	1813	ENSG00000149295	agonist
DAP000846	Carphenazine	1-[10-[3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl]phenothiazin-2-yl]propan-1-one; Carfenazina [INN-Spanish]; Carfenazine; Carphenazin; Proketazin; 2622-30-2; AC1L2BCQ; AKOS003589058; Carfenazinum [INN-Latin]; MolPort-001-728-033; CID18104; DB01038; C24H31N3O2S; Carphenazine; 1-(10-(3-(4-(2-Hydroxyethyl)-1-piperazinyl)propyl)phenothiazin-2-yl)-1-propanone; 1-(10-{3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl}-10H-phenothiazin-2-yl)propan-1-one; NCGC00181121-01; 1-Propanone, 1-[10-[3-[4-(2-hydroxyethyl)-1-piperazinyl]propyl]-10H-phenothiazin-2-yl]-; UNII-CLY16Y8Z7E; Procethazine; Oprea1_747021; Carfenazine [INN:BAN]; EINECS 220-072-9; LS-174135	2622-30-2	18104	10516134	TTDS00012	D(2) dopamine receptor	Dopamine D2 receptor;Dopamine receptor 2	P14416	1813	ENSG00000149295	antagonist
DAP000979	Molindone	C16H24N2O2; C07230; Molindona; Molindona [INN-Spanish]; MolPort-005-940-887; 3-Ethyl-1,5,6,7-tetrahydro-2-methyl-5-(4-morpholinylmethyl)-4H-indol-4-one; AC1L2N2H; 3-Ethyl-6,7-dihydro-2-methyl-5-(morpholinomethyl)indol-4(5H)-one; Moban; Indol-4(5H)-one, 3-ethyl-6,7-dihydro-2-methyl-5-(morpholinomethyl)-; 4H-Indol-4-one, 3-ethyl-1,5,6,7-tetrahydro-2-methyl-5-(4-morpholinylmethyl)-; CHEBI:103799; 3-ethyl-2-methyl-5-(morpholin-4-ylmethyl)-4,5,6,7-tetrahydro-1H-indol-4-one; LS-83891; (+-)-Molindone; HSDB 3131; Prestwick1_001035; Molindonum [INN-Latin]; 15622-65-8 (mono-hydrochloride); AC-7052; Prestwick2_001035; I14-11948; NCGC00162218-01; BSPBio_001249; Oprea1_038890; D08226; 3-ethyl-2-methyl-5-(morpholin-4-ylmethyl)-1,5,6,7-tetrahydroindol-4-one; 3-ethyl-2-methyl-5-(morpholin-4-ylmethyl)-1,5,6,7-tetrahydro-4H-indol-4-one; NCGC00162218-02; BPBio1_001374; AC1Q2SRY; MOLINDONE; DB01618; CHEMBL460; BRD-A65280694-003-03-8; SPBio_003100; L001248; NCGC00162218-03; CID23897; Molindone [INN:BAN]; Molindone (INN); Molindone (MOL); Molindone Monohydrochloride; 7416-34-4; UNII-RT3Y3QMF8N; AB00514709; AC1Q6J6B; Molindonum; Prestwick0_001035; Prestwick3_001035; 65973-37-7	7416-34-4	23897	9439	TTDS00012	D(2) dopamine receptor	Dopamine D2 receptor;Dopamine receptor 2	P14416	1813	ENSG00000149295	binder
DCL000777	Dopamine antags	N/A	N/A	N/A	N/A	TTDS00012	D(2) dopamine receptor	Dopamine D2 receptor;Dopamine receptor 2	P14416	1813	ENSG00000149295	binder
DCL000836	HMR-2934	N/A	N/A	5330286	46394060	TTDS00012	D(2) dopamine receptor	Dopamine D2 receptor;Dopamine receptor 2	P14416	1813	ENSG00000149295	antagonist
DCL000817	GMC-283	N/A	183140-98-9	N/A	N/A	TTDS00012	D(2) dopamine receptor	Dopamine D2 receptor;Dopamine receptor 2	P14416	1813	ENSG00000149295	antagonist
DAP001496	Methamfetamine	N/A	537-46-2	10836	10318874	TTDS00012	D(2) dopamine receptor	Dopamine D2 receptor;Dopamine receptor 2	P14416	1813	ENSG00000149295	agonist
DAP000852	Dihydroergotoxine	NCGC00017400-06; Ergotaman-3',6',18-trione, 9,10-dihydro-12'-hydroxy-2'-methyl-5'-(phenylmethyl)-, (5'alpha,10alpha)-; Orstanorm; Dihidroergotamina; IDI1_000592; Ergont; (10alphaH)-5'alpha-benzyl-12'-hydroxy-2'-methyl-3',6',18-trioxo-9,10-dihydroergotaman; DET MS; DivK1c_000592; Diergo; SPBio_001235; CHEBI:4562; Ambotz511-12-6; DIHYDROERGOTOXINE; 9,10-dihydro-ergotamine; KBio2_006673; Diidroergotamina; CID10531; dihydroergotamine; BSPBio_002209; UNII-436O5HM03C; Dergotamine; Verladyn; 11032-41-0; 9,10-Dihydro-12'-hydroxy-2'-methyl-5'-(phenylmethyl)ergotoman-3',6',18-trione; D07837; NINDS_000592; KBio1_000592; KBio3_001429; LS-61979; Spectrum_001057; Ergot Alkaloids, Hydrogenated; Dihidroergotamina [INN-Spanish]; Migranal; CHEBI:658566; Dirgotarl; Spectrum4_000958; C07798; Spectrum2_001188; Dehydroergotamine; C33H37N5O5; Dihydroergotaminum [INN-Latin]; Seglor; Endophleban; Lopac0_000357; 5'-Benzyl-12'-hydroxy-2'-methyl-3',6',18-trioxo-9,10-dihydroergotaman; CID517557; AC1L1VEA; 511-12-6; Ikaran; BIDD:GT0120; CHEMBL1732; BRD-K72166146-066-02-1; Ergomimet; Angionorm; Morena; LS-64563; Co-Dergocrine; Spectrum3_000395; BRN 5720196; Ergoloid dihydroergotoxine; Ergoloid Mesylates (dihydroergotoxine); Agit; Dihydroergotoxin; AC1LAOVT; KBio2_004105; Ergotamine, 9,10-dihydro-; Dihydroergotamine methanesulfonate; KBio2_001537; DB00320; D.H.E.; KBioSS_001537; Ergotonin; DHE-45; 9,10-Dihydroergotamine; Neomigran; 6190-39-2 (mesylate); Dihydroergotaminum; Spectrum5_000905; KBioGR_001576; Dihydroergotamine (INN); Tonopres; (5'alpha)-12'-Hydroxy-2'-methyl-5'-(phenylmethyl)ergotoman-3',6',18-trione; Ergotamine, dihydro, methanesulfonate (salt); Dihydergot; Neomigran (TN); Diidroergotamina [DCIT]; (5'alpha)-5'-benzyl-12'-hydroxy-2'-methyl-3',6',18-trioxoergotaman; EINECS 208-123-3; Ergotoxine, dihydro-	11032-41-0	6420006	10321698	TTDS00012	D(2) dopamine receptor	Dopamine D2 receptor;Dopamine receptor 2	P14416	1813	ENSG00000149295	agonist
DAP000375	Fluphenazine	Lopac-F-4765; Moditen (Tabl or elixir); IDI1_000511; Moditen Hcl; KBio2_002386; D005476; Apo-Fluphenazine; AC1L1FSB; CID3372; L000257; NSC 62323; Spectrum4_000828; SR-01000003048-5; KBio2_003337; Spectrum3_001420; Prestwick2_000320; Elinol; Siqualine; Flufenazin; Spectrum2_001199; Fluphenazine hydrochloride; CAS-146-56-5; NCGC00015436-02; 4-[3-(2-Trifluoromethyl-10-phenothiazyl)-propyl]-1-piperazineethanol; KBioSS_002391; Prolixine; NCGC00024429-04; cMAP_000035; HSDB 3334; 1-Piperazineethanol, 4-(3-(2-(trifluoromethyl)-10H-phenothiazin-10-yl)propyl)- (9CI); Triflumethazine; Permitil Concentrate; 10-(3-(2-Hydroxyethyl)piperazinopropyl)-2-(trifluoromethyl)phenothiazine; FLUPHENAZINE; MolPort-001-727-938; 1-Piperazineethanol, 4-[3-[2-(trifluoromethyl)-10H-phenothiazin-10-yl]propyl]-; Dapotum; AB00053587; KBio3_002320; S94; BIDD:PXR0184; 2-(Trifluoromethyl)-10-(3-(1-(beta-hydroxyethyl)-4-pipe razinyl)propyl)phenothiazine; BRD-K55127134-300-05-4; Biomol-NT_000023; 2-(4-(3-[2-(Trifluoromethyl)-10H-phenothiazin-10-yl]propyl)-1-piperazinyl)ethanol; CHEBI:136842; Prolixin Concentrate; Phenothiazine, 10-(3-(4-(2-hydroxyethyl)-1-piperazinyl)propyl)-2-(trifluoromethyl)-; BRD-K55127134-001-01-7; KBioSS_000769; KBioGR_001375; 4-(3-(2-(trifluoromethyl)phenothiazin-10-yl)propyl)-1-Piperazineethanol; Siqualon; 1-Piperazineethanol, 4-(3-(2-(trifluoromethyl)phenothiazin-10-yl)propyl)-; NCGC00015436-03; Sevinol; Spectrum_000289; BPBio1_000352; Ftorphenazine; Lopac0_000555; nchembio873-comp68; SPBio_002539; Fluphenazinum [INN-Latin]; 2-(4-{3-[2-(trifluoromethyl)-10H-phenothiazin-10-yl]propyl}piperazin-1-yl)ethanol; Probes2_000295; KBio3_002865; NCGC00015436-01; ChemDiv1_024180; Fluphenazine [INN:BAN]; NCGC00015436-08; KBio2_007522; 10-(3'-(4"-(beta-Hydroxyethyl)-1"-piperazinyl)-propyl)-3-trifluoromethylphenothiazine; Fluphenazine (INN); D07977; 4-(3-(-Trifluoromethyl-10-phenothiazyl)-propyl)-1-piperazineethanol; 2-(Trifluoromethyl)-10-(3-(1-(beta-hydroxyethyl)-4-piperazinyl)propyl)phenothiazine; Probes1_000254; Flufenazina; NCGC00024429-03; DivK1c_000511; KBio2_005905; 69-23-8; C22H26F3N3OS; STK050763; 4-(3-(2-(Trifluoromethyl)-10H-phenothiazin-10-yl)propyl)-1-piperazineethanol; C07010; KBio1_000511; CHEBI:5123; Flufenazina [DCIT]; 2-[4-[3-[2-(trifluoromethyl)phenothiazin-10-yl]propyl]piperazin-1-yl]ethanol dihydrochloride; KBio2_004954; NINDS_000511; BPBio1_001187; DB00623; Bio-0775; Prestwick3_000320; BSPBio_000320; 47646-09-3; Spectrum5_001536; Prestwick1_000320; Fluphenazinum; HMS655L02; KBioGR_002386; Vespazine; Phthorphenazine; SQ 4918; Yespazine; Fluorfenazine; 1-(2-Hydroxyethyl)-4-(3-(trifluoromethyl-10-phenothiazinyl)propyl)-piperazine; Pacinol; NSC62323; 4-(3-(2-Trifluoromethyl-10-phenothiazyl)-propyl)-1-piperazineethanol; LS-112565; KBio2_000769; CHEMBL726; 2-[4-[3-[2-(trifluoromethyl)phenothiazin-10-yl]propyl]piperazin-1-yl]ethanol; Prestwick0_000320; Moditen (TN); BSPBio_003100; Hydrochloride, Fluphenazine; EINECS 200-702-9; 1-(2-Hydroxyethyl)-4-[3-(trifluoromethyl-10-phenothiazinyl)propyl]piperazine; Fluorphenazine; 1-Piperazineethanol, 4-(3-(2-(trifluoromethyl)-10H-phenothiazin-10-yl)propyl)-; AKOS001659031; 10-(3'-(4''-(beta-Hydroxyethyl)-1''-piperazinyl)-propyl)-3-trifluoromethylphenothiazine; Fluorophenazine; UNII-S79426A41Z; SPBio_001277; HMS2089C16	69-23-8	3372	149164	TTDS00012	D(2) dopamine receptor	Dopamine D2 receptor;Dopamine receptor 2	P14416	1813	ENSG00000149295	antagonist
DCL000981	SDZ-MAR-327	N/A	N/A	N/A	N/A	TTDS00012	D(2) dopamine receptor	Dopamine D2 receptor;Dopamine receptor 2	P14416	1813	ENSG00000149295	agonist
DAP000003	Risperidone	Jsp000573; BRD-K53857191-001-04-5; MLS000759429; Risperidona [Spanish]; Sequinan; Risperidone (RIS); Rispolin; 3-(2-[4-(6-fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl)-2-methyl-6,7,8,9-tetrahydro-pyrido[; BIDD:GT0262; R64,766; NCGC00015883-03; NCGC00094352-01; 4H-Pyrido(1,2-a)pyrimidin-4-one, 3-(2-(4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl)ethyl)-6,7,8,9-tetrahydro-2-methyl-; 4H-Pyrido(1,2-a)pyrimidin-4-one, 3-(2-(4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl)ethyl)-6 ,7,8,9-tetrahydro-2-methyl-; SMR000466323; 3-(2-[4-(6-fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl)-2-methyl-6,7,8,9-tetrahydropyrido[1,; Risperidal M-Tab; L000510; 4H-Pyrido[1,2-a]pyrimidin-4-one, 3-[2-[4-(6-fluoro-1,2-benz-isoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-; HMS1571M19; Risperidone, placebo; MLS001165758; 3-{2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidin-1-yl]ethyl}-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one; R-64-766; TL8000230; SAM001246595; AB00514010; CID5073; BRN 4891881; STK646402; R-64766; NCGC00015883-02; R64766; NCGC00094352-02; 3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido [1,2-a] pyrimidin-4-one; 3-[2-[-4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one; 3-[2-[4-(6-fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl]-2-methyl-6,7,8,9-tetrahydropyrido[1,; NCGC00179257-01; Risperin; CHEMBL85; Prestwick1_001029; R 64,766; CAS-106266-06-2; Rispolept; 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one; R-118; Risperdal (TN); CHEBI:8871; HMS2051H07; DB00734; UNII-L6UH7ZF8HC; 106266-06-2; HMS2089C22; CPD000466323; risperdone; NCGC00094352-03; Risperdal Consta; Lopac-R-118; Risperidone [USAN:BAN:INN]; HSDB 7580; 3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-6,7,8,9-tetrahydro-2-methyl-4H-pyrido(1,2-a)pyrimidin-4-one; SPBio_003078; AC-1306; Prestwick0_001029; Bio-0092; Risperidona; Risperidone (JAN/USAN/INN); Belivon; R 64 766, Risperdal, Risperidone; R 62 766; MLS001424081; MolPort-002-885-858; R 64766; Risperdal; 3-{2-[4-(6-Fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl}-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one; EU-0101074; Consta, Risperdal; Risperdal M-Tab; R-64,766; LS-134196; S1615_Selleck; 4H-Pyrido(1,2-a)pyrimidin-4-one, 6,7,8,9-tetrahydro-3-(2-(4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl)ethyl)-2-methyl-; 3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperi-dino]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]-pyrimidin-4-one; I01-1156; AC1L1JJU; Risperidal; Risperidonum [Latin]; risperidone; C23H27FN4O2; Risperidonum; 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one; D018967; KS-1106; NCGC00015883-01; D00426; 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one	106266-06-2	5073	7847492	TTDS00012	D(2) dopamine receptor	Dopamine D2 receptor;Dopamine receptor 2	P14416	1813	ENSG00000149295	antagonist
DCL000698	Aplindore fumarate	189681-71-8; Aplindore fumarate; Aplindore fumarate (USAN); D03214; AC1O5U60; (2S)-2-[(benzylamino)methyl]-2,3,7,9-tetrahydro-[1,4]dioxino[2,3-e]indol-8-one; (E)-but-2-enedioic acid; 8H-1,4-Dioxino(2,3-e)indol-8-one,2,3,7,9-tetrahydro-2-(((phenylmethyl)amino)methyl)-,2(S)-, (2E)-2-butenediotate (1:1); LS-193407; WAY-DAB-452; CID6440763; Aplindore; UNII-P13TV5A758	189681-71-8	444972	17397367	TTDS00012	D(2) dopamine receptor	Dopamine D2 receptor;Dopamine receptor 2	P14416	1813	ENSG00000149295	agonist
DCL000339	Nomifensine	CHEMBL273575; KBio1_000789; Nomifensine; Spectrum2_001548; KBio2_001379; KBioSS_001379; L001242; CID4528; NCGC00015727-06; SPBio_002035; Prestwick2_000108; Spectrum5_001004; (+-)-Nomifensin; 8-Amino-1,2,3,4-tetrahydro-2-methyl-4-phenylisoquinoline; KBio3_001785; nomifensin; 2-Methyl-4-phenyl-1,2,3,4-tetrahydro-8-isoquinolinamine 2-butenedioate; 8-Amino-1,2,3,4-tetrahydro-2-methyl-4-phenylisoquinoline maleate (1:1); 8-Isoquinolinamine, 1,2,3,4-tetrahydro-2-methyl-4-phenyl; SPBio_001396; LS-85340; D,L-nomifensine; 24526-64-5; Nomifensine Maleate (1:1); Prestwick1_000108; Spectrum3_000963; NINDS_000789; UNII-1LGS5JRP31; IDI1_000789; 2-methyl-4-phenyl-1,2,3,4-tetrahydroisoquinolin-8-amine; Nomifensine [INN:BAN]; Nomifenison; Nomifensina; AB00053664; BRD-A29644307-050-05-5; KBioGR_001438; R/S-nomifensine; Linamiphen; (+)-Nomifensine; LS-85807; BSPBio_000096; Nomiphensine; CHEBI:116225; 8-Amino-1,2,3,4-tetrahydro-2-methyl-4-phenylisochinolin; NCGC00089794-02; 2-methyl-4-phenyl-3,4-dihydro-1H-isoquinolin-8-amine; 32795-47-4 (maleate (1:1)); 2-Methyl-4-phenyl-1,2,3,4-tetrahydro-8-isoquinolinamine; (+-)-Nomifensine; Nomifensine maleate(USAN); Nomifensinum; AC1L1IDA; Isoquinoline, 1,2,3,4-tetrahydro-8-amino-2-methyl-4-phenyl-; Prestwick0_000108; BRN 6064059; 118184-50-2; Nomifensina [INN-Spanish]; KBio2_003947; 89664-20-0; CCRIS 9179; 8-Isoquinolinamine, 1,2,3,4-tetrahydro-2-methyl-4-phenyl-; (R)-1,2,3,4-Tetrahydro-2-methyl-4-phenyl-8-isoquinolinamine; -, (Z)-2-butenedioate (1:1); Spectrum4_001079; BPBio1_000106; 2-Methyl-4-phenyl-1,2,3,4-tetrahydro-isoquinolin-8-ylamine; 8-Isoquinolinamine, 1,2,3,4-tetrahydro-2-methyl-4-phenyl- (9CI); 8-ISOQUINOLINAMINE, 1,2,3,4-TETRAHYDRO-2-METHYL-4-PHENYL-, (R)-; DivK1c_000789; KBio2_006515; LS-85341; Lopac0_000875; DB04821; Prestwick3_000108; BRN 0484561; 8-ISOQUINOLINAMINE, 1,2,3,4-TETRAHYDRO-2-METHYL-4-PHENYL-, (+-)-; 89664-19-7; Spectrum_000899; (+-)-1,2,3,4-Tetrahydro-2-methyl-4-phenyl-8-isoquinolinamine; Nomifensinum [INN-Latin]; 8-Amino-2-methyl-4-phenyl-1,2,3,4-tetrahydroisoquinoline; (+)-Nomiphensine; BSPBio_002565	24526-64-5	4528	10444462	TTDS00012	D(2) dopamine receptor	Dopamine D2 receptor;Dopamine receptor 2	P14416	1813	ENSG00000149295	antagonist
DAP000252	Mesoridazine	10-[2-(1-Methyl-2-piperidyl)ethyl]-2-methylsulfinyl phenothiazine; BSPBio_000517; Lidanar; 10-[2(1-Methyl-2-piperidyl)ethyl]-2-(methylsulfinyl)phenothiazine; Mesoridazine [USAN:BAN:INN]; Mesoridazina [INN-Spanish]; Calodal; UNII-5XE4NWM740; Lidanil; NCGC00163157-02; Phenothiazine, 10-(2-(1-methyl-2-piperidyl)ethyl)-2-(methylsulfinyl)-; 10-[2-(1-methylpiperidin-2-yl)ethyl]-2-(methylsulfinyl)-10H-phenothiazine; 10-(2-(1-Methyl-2-piperidyl)ethyl)-2-methylsulfinyl phenothiazine; 10-(2(1-Methyl-2-piperidyl)ethyl)-2-(methylsulfinyl)-phenothiazine; 10H-Phenothiazine, 10-[2-(1-methyl-2-piperidinyl)ethyl]-2-(methylsulfinyl)-; LS-105603; Mesoridazinum; HSDB 3357; mesoridazine; Mesoridazina; THD-2-SO; CHEBI:248004; CID4078; CHEMBL1088; T-2-SO; Phenothiazine, 10-[2-(1-methyl-2-piperidyl)ethyl]-2-(methylsulfinyl)-; C07143; NCGC00163157-03; 10H-Phenothiazine, 10-(2-(1-methyl-2-piperidinyl)ethyl)-2-(methylsulfinyl)-; D02671; TPS 23; Thioridazien thiomethyl sulfoxide; Tps23; TPS-23; Mesoridazine (USAN/INN); Serentil Concentrate; NCI60_001547; BPBio1_001167; Thioridazine-2-sulfoxide; WLN: T C666 BN ISJ ESO&1 B2- BT6NTJ A; AB00513854; D008653; BPBio1_000569; CHEBI:6780; L000852; Thioridazine thiomethyl sulfoxide; Mesoridazinum [INN-Latin]; 5588-33-0; 10-(2-(1-Methyl-2-piperidinyl)ethyl)-2-(methylsulfinyl)-10H-phenothiazine; Serentil; NSC 186066; HMS2090H22; Biomol-NT_000013; NCGC00163157-01; AC1L1HD1; DB00933; Prestwick3_000529; Prestwick2_000529; Lidanar (TN); C21H26N2OS2; SPBio_002438; Prestwick1_000529; NC-123; BRD-A14395271-074-03-8; 10-(2(1-Methyl-2-piperidyl)ethyl)-2-(methylsulfinyl)phenothiazine; 10-[2-(1-methylpiperidin-2-yl)ethyl]-2-methylsulfinylphenothiazine; NSC186066; Thioridazine monosulfoxide analog; BRD-A14395271-001-01-5	5588-33-0	4078	9352	TTDS00012	D(2) dopamine receptor	Dopamine D2 receptor;Dopamine receptor 2	P14416	1813	ENSG00000149295	agonist
DAP000019	Pramipexole	(6S)-N6-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine; Pramipexole [USAN:INN]; SAM001247006; Spectrum_001838; 111GE001; HMS2051A21; LS-40722; SUD919CL2Y; Pramipexolum; 2-amino-4,5,6,7-tetrahydro-6-propylaminobenzothiazole; SpecPlus_000820; DivK1c_006916; KBioSS_002343; Mirapex; KBio2_007476; Pramipexole (USAN/INN); C10H17N3S; 2,6-Benzothiazolediamine, 4,5,6,7-tetrahydro-N(sup 6)-propyl-, (S)-; CPD000449298; MolPort-003-849-957; CHEBI:8356; (6S)-6-N-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine; BIDD:GT0250; CID119570; 2,6-Benzothiazolediamine, 4,5,6,7-tetrahydro-N6-propyl-, (S)-; KBio2_002340; MLS001423952; MLS000758250; Pramipexol; HMS2090C15; (-)-Pramipexole; 104632-26-0; KBio1_001860; NCGC00167441-01; U-98528E; 2-amino-6-propylaminotetrahydrobenzothiazole; Spectrum5_001453; SND-919; CHEMBL301265; (6S)-N(6)-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine; D05575; SBB070477; pramipexole; (S)-2-Amino-4,5,6,7-tetrahydro-6-(propylamino)benzothiazole; KBio2_004908; AC1L3P1T; SMR000449298	104632-26-0	59868	196318	TTDS00012	D(2) dopamine receptor	Dopamine D2 receptor;Dopamine receptor 2	P14416	1813	ENSG00000149295	agonist
DAP000530	Metoclopramide	Pms-Metoclopramide; Emetid; DivK1c_000069; Metoclopramida; CID4168; Prestwick1_000209; BPBio1_000217; Nu-Metoclopramide; Metoclol; Metoclopramida [INN-Spanish]; BSPBio_002027; Methochlopramide; Pramin; KBioSS_002118; AKOS000280832; Meclopran; L001078; CAS-7232-21-5; Duraclamid; NCGC00024440-03; Spectrum2_001720; Spectrum5_001449; Plasil; Mygdalon; Maxeran; Lopac-M-0763; CLOPRA-"YELLOW"; Maxolon; Spectrum4_000964; Neu-Sensamide; NCGC00024440-04; Reclomide; Elieten (TN); Spectrum3_000504; MolPort-000-883-854; 364-62-5; Apo-Metoclop; BSPBio_000197; HMS2089G16; (metaclopramide)4-Amino-5-chloro-N-(2-diethylamino-ethyl)-2-methoxy-benzamide; NCGC00015643-08; C14H22ClN3O2; AB00053498; Gastrosil; ST024773; KBio2_004686; SPBio_001740; 4-Amino-5-chloro-N-(2-(diethylamino)ethyl)-2-methoxybenzamide; NCGC00015643-01; n-Anisamide, 4-amino-5-chloro-N-(2-(diethylamino)ethyl)-; LS-20038; Imperan; 2-methoxy-4-amino-5-chloro-N,N-(dimethylaminoethyl)benzamide; 2576-84-3 (di-hydrochloride); DEL 1267; 1,5-Dimethyl-2-phenyl-1,2-dihydro-pyrazol-3-one; Gastromax; Prestwick0_000209; C07868; Metochlopramide; metoclopramide; Metoclopramide Monohydrochloride, Monohydrate; Metramid; Clopra-Yellow; Benzamide, 4-amino-5-chloro-N-(2-(diethylamino)ethyl)-2-methoxy-; 4-Amino-5-chloro-N-(2-(diethylamino)ethyl)-o-anisamide; 2-Methoxy-5-chloroprocainamide; o-Anisamide, 4-amino-5-chloro-N-(2-(diethylamino)ethyl)-; Plasil (pharmaceutical); NCI60_003185; IDI1_000069; 5-Chloro-2-methoxyprocainamide; BPBio1_001100; Paspertin; 4-Amino-5-chloro-N-(2-diethylamino-ethyl)-2-methoxy-benzamide(Metoclopramide); Octamide; UNII-L4YEB44I46; Primperan; Methoclopramide; Parmid; Gastro-Timelets; Metaclopramide; bmse000779; o-Anisamide, 4-amino-5-chloro-N-(2-(diethylamino)ethyl)- (8CI); KBio3_001527; o-Anisamide, 4-amino-5-chloro-N-[2-(diethylamino)ethyl]-; Gastrese; 4-Amino-5-chloro-N-(2-diethylamino-ethyl)-2-methoxy-benzamide (Mcp); Gastronerton; ARONIS24307; SPBio_002118; 54143-57-6 (mono-hydrochloride, mono-hydrate); Emitasol; BRD-K75641298-001-01-5; 4-Amino-5-chloro-2-methoxy-N-(beta-diethylaminoethyl)benzamide; Metoclopramide (JP15/INN); Gastrotablinen; BRD-K75641298-003-05-2; (metoclopramide)4-Amino-5-chloro-N-(2-diethylamino-ethyl)-2-methoxy-benzamide; KBioGR_001307; N-(Diethylaminoethyl)-2-methoxy-4-amino-5-chlorobenzamide; DB01233; AC1L1HKD; CHEMBL86; Clopromate; Reliveran; Metoclopramide Omega; Metoclopramidum [INN-Latin]; 4-amino-5-chloro-N-(2-diethylaminoethyl)-2-methoxybenzamide; Eucil; KBio2_007254; Gastrotem; Clopra; Peraprin; 4-amino-5-chloro-N-[2-(diethylamino)ethyl]-2-methoxybenzamide; 7232-21-5 (mono-hydrochloride); Metocobil; NCGC00015643-03; CHEBI:107736; Metaclopromide; 4-Amino-5-chloro-N-(2-diethylamino-ethyl)-2-methoxy-benzamide (metoclopramide); KBio2_002118; Terperan (TN); 4-Amino-5-chloro-N-(2-diethylamino-ethyl)-2-methoxy-benzamide; Emperal; Benzamide, 4-amino-5-chloro-N-[2-(diethylamino)ethyl]-2-methoxy-; Elieten; Metamide; Prestwick3_000209; 4 Amino-5-chloro-N-(2-(diethylamino)ethyl)-2-methoxybenzamide; Prestwick2_000209; Terperan; Lopac0_000762; Metoclopramidum; Pramidin; D00726; KBio1_000069; 2-Methoxy-4-amino-5-chloro-N,N-dimethylaminoethyl)benzamide; Moriperan; NINDS_000069; Biomol-NT_000082; Gastrobid; Spectrum_001638; Cerucal; Reglan; BRN 1884366; Pramiel; Benzamide, 4-amino-5-chloro-N-(2-(diethylamino)ethyl)-2-methoxy- (9CI); Metoclopramide [INN:BAN:JAN]; NCGC00015643-02; EINECS 206-662-9	364-62-5	4168	152911	TTDS00012	D(2) dopamine receptor	Dopamine D2 receptor;Dopamine receptor 2	P14416	1813	ENSG00000149295	antagonist
DAP000833	Chlorprothixene	Thioxanthene-.delta.(sup 9), .gamma.-propylamine, 2-chloro-N,N-dimethyl-; Clorprotisene; Traquilan; AKOS005065494; S1771_Selleck; Iaractan; PDSP1_001124; CID667466; L000872; NSC18720; alpha-Chlorprothixene; Spectrum4_000729; NSC56379; KBio3_002568; NCIStruc2_001491; Vetacalm; Chlorprothixene (JAN/USAN/INN); NCIStruc1_001079; CHEBI:3651; NCGC00096794-01; Chloroprothixene; CAS-6469-93-8; (.alpha.-2-Chloro-9-.omega.-dimethylamino-propylamine)thioxanthene; {3-[2-Chloro-thioxanthen-(9Z)-ylidene]-propyl}-dimethyl-amine; Tactaran; AC1LDI59; Prestwick0_000348; NCGC00013683; (3Z)-3-(2-chlorothioxanthen-9-ylidene)-N,N-dimethylpropan-1-amine; KBio2_001916; Ro 4-0403; NCGC00013683-02; (Z)-2-Chloro-9-(omega-dimethylaminopropylidene)thioxanthene; Chlorprothixene [USAN:INN:BAN:JAN]; Thioxanthene-delta(sup 9),gamma-propylamine, 2-chloro-N,N-dimethyl-, (Z)-; Truxal; N 714; CID2729; CHEMBL908; Truxaletten; KBio2_007052; N-714; Chlorprothixenum; MolPort-002-590-309; NSC 18720; I06-0499; Chlorprotixene; 113-59-7; WLN: T C666 BS IYJ FG IU3N1 & 1; Clorprotixeno; DB01239; IDI1_000143; SPBio_002336; 2-Chloro-N,N-dimethylthioxanthene-.delta.(sup 9), .gamma.-propylamine; Truxil; AKOS005065593; .alpha.-Chlorprothixene; Spectrum2_000857; Chlothixen; Prestwick1_000348; PDSP2_001108; UNII-9S7OD60EWP; SPBio_000873; 3-(2-chlorothioxanthen-9-ylidene)-N,N-dimethylpropan-1-amine; LS-153637; (3Z)-3-(2-chloro-9H-thioxanthen-9-ylidene)-N,N-dimethylpropan-1-amine; NCIOpen2_008709; SMR000431796; chlorprothixene; 3-(2-chloro-9H-thioxanthen-9-ylidene)-N,N-dimethyl-1-propanamine; Chlorprothixine; Thioxanthene-delta9,gamma-propylamine, 2-chloro-N,N-dimethyl-, (Z)-; Tardan; AC1LDI5C; Cloxan, Taractan, Truxal, Chlorprothixene; BPBio1_000457; Clorprotixeno [INN-Spanish]; STK545163; cis-2-Chloro-9-(3-dimethylaminopropylidene)thioxanthene; (3E)-3-(2-chloro-9H-thioxanthen-9-ylidene)-N,N-dimethylpropan-1-amine; D00790; NCIOpen2_008054; Chlorprotixen; Chlorprothixenum [INN-Latin]; AB00514666; C18H18ClNS; D002749; KBioSS_001916; 4695-61-8; Trictal; KBio1_000143; Thioxanthene-delta9,gamma-propylamine, 2-chloro-N,N-dimethyl-, (Z)- (8CI); cis-Chlorprothixene; C07953; 1-Propanamine, 3-(2-chloro-9H-thioxanthen-9-ylidene)-N,N-dimethyl-, (Z)-; Spectrum3_001564; Ro-4-0403; Thioxanthene-.DELTA.9,.gamma.-propylamine, 2-chloro-N,N-dimethyl-, (Z)-; BSPBio_003068; HSDB 2808; Chlorprotixine; 2-Chloro-9-[.omega.-(dimethylamino)propylidene]thioxanthene; (Z)-2-Chloro-N,N-dimethylthioxanthene-delta(sup 9,gamma)-propylamine; trans(E)-Chlorprothixen; 1-Propanamine, 3-(2-chloro-9H-thioxanthen-9-ylidene)-N,N-dimethyl-, (3Z)-; EINECS 204-032-8; 2-Chloro-9-[3-(dimethylamino)propylidene]thioxanthene; Paxyl; Taractan (TN); CHEBI:50931; Spectrum_001436; 3-(2-chloro-9H-thioxanthen-9-ylidene)-N,N-dimethylpropan-1-amine; Oprea1_572513; MLS000768404; Spectrum5_001050; (Z)-2-Chloro-N,N-dimethylthioxanthene-.DELTA.(sup9),(sup.gamma.)-propylamine; Tarasan; NINDS_000143; NCGC00166133-01; KBio2_004484; N 714C; Prestwick2_000348; Prestwick3_000348; CHEBI:50932; NSC56378; DivK1c_000143; NCI60_004376; Rentovet; CHEMBL90125; NSC-56378; CID667467; BSPBio_000415; KBioGR_000998; BRD-K59058766-003-04-5; Clorprotisene [DCIT]; Chlorprothixen; 1-Propanamine, 3-(2-chloro-9H-thioxanthen-9-ylidene)-N,N-dimethyl-, (3E)-; (3E)-3-(2-chlorothioxanthen-9-ylidene)-N,N-dimethylpropan-1-amine; NCI56378; NCIOpen2_008749; MK 184; Bio-0770; Taractan; AC1L1EC2; 2461-06-5	113-59-7	2729	10154	TTDS00012	D(2) dopamine receptor	Dopamine D2 receptor;Dopamine receptor 2	P14416	1813	ENSG00000149295	antagonist
DAP001503	PD-172760	N/A	111974-69-7	5002	48416505	TTDS00012	D(2) dopamine receptor	Dopamine D2 receptor;Dopamine receptor 2	P14416	1813	ENSG00000149295	antagonist
DAP000079	Ziprasidone	Ziprasidone mesylate trihydrate; ziprasidona; 5-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-6-chloro-1,3-dihydroindol-2-one; DB00246; I14-0766; UNII-6UKA5VEJ6X; CP-88,059-1; C21H21ClN4OS; Zipradon (TN); CP-88,059-01; 2H-Indol-2-one, 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-; ziprazidone; MolPort-003-850-885; ziprasidonum; CPD000466328; Geodon; SAM001246607; Zipradon; CP 88059-01; CP-88,059; CID60854; Ziprasidone [INN:BAN]; Ziprasidone hydrochloride; MLS000759435; CHEBI:10119; Ziprasidone; Ambap122883-93-6; AC1L1U27; C07568; 5-{2-[4-(1,2-benzisothiazol-3-yl)piperazin-1-yl]ethyl}-6-chloro-1,3-dihydro-2H-indol-2-one; CP 88059; 5-{2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl}-6-chloro-1,3-dihydro-2H-indol-2-one; BIDD:GT0042; CHEMBL708; CP-88059-1; TL8000889; 146939-27-7; 138982-67-9 (hydrochloride monohydrate); D08687; L000659; SMR000466328; Ziprasidone (INN); 6-chloro-5-[2-[4-(7-thia-8-azabicyclo[4.3.0]nona-1,3,5,8-tetraen-9-yl)piperazin-1-yl]ethyl]-1,3-dihydroindol-2-one; Zeldox; LS-83744	146939-27-7	60854	210748	TTDS00012	D(2) dopamine receptor	Dopamine D2 receptor;Dopamine receptor 2	P14416	1813	ENSG00000149295	agonist
DAP000001	Quetiapine	Quetiapine (INN); 111974-72-2; Norsic; Quetiapine hemifumarate; UNII-BGL0JSY5SI; SPECTRUM1505187; MolPort-002-506-329; HSDB 7557; quetiapina; 2-(2-(4-Dibenzo(b,f)(1,4)thiazepin-11-yl-1-piperazinyl)ethoxy)ethanol; CHEMBL716; HMS2093K06; Quetiapine fumarate; 2-{[2-(4-dibenzo[b,f][1,4]thiazepin-11-ylpiperazin-1-yl)ethyl]oxy}ethanol; BIDD:GT0279; ZD5077; Seroquel; C07397; Co-Quetiapine; Ethanol, 2-[2-(4-dibenzo[b,f][1,4]thiazepin-11-yl-1-piperazinyl)ethoxy]-; CHEBI:8707; I06-1980; Norsic (TN); C21H25N3O2S; NCGC00095911-03; URKOMYMAXPYINW-UHFFFAOYSA-; L001200; SMR000550491; LS-172170; 2-[2-(4-dibenzo[b,f][1,4]thiazepin-11-ylpiperazin-1-yl)ethoxy]ethanol; NCGC00095911-01; quetiapine; CID5002; 2-[2-(4-Dibenzo[b,f][1,4]thiazepin-11-yl-1-piperazinyl)ethoxy]ethanol; 2-[2-(4-benzo[b][1,4]benzothiazepin-6-ylpiperazin-1-yl)ethoxy]ethanol; MolPort-002-885-851; AKOS003588973; Quetiapine [INN:BAN]; DB01224; Seroquel (Fumarate); quetiapinum; InChI=1/C21H25N3O2S/c25-14-16-26-15-13-23-9-11-24(12-10-23)21-17-5-1-3-7-19(17)27-20-8-4-2-6-18(20)22-21/h1-8,25H,9-16H2; 111974-69-7; MLS001165710; ICI 204,636; NCGC00095911-04; AC1L1JE6; ZM 204,636; MLS001195658; ZINC19632628; Ethanol, 2-(2-(4-dibenzo(b,f)(1,4)thiazepin-11-yl-1-piperazinyl)ethoxy)-; D08456	111974-69-7	5002	9601	TTDS00012	D(2) dopamine receptor	Dopamine D2 receptor;Dopamine receptor 2	P14416	1813	ENSG00000149295	agonist
DCL000918	PD-158771	2-Pyrimidinamine, N-(4-(2-(4-phenyl-1-piperazinyl)ethyl)cyclohexyl)-, trans-; 189152-50-9; CHEMBL165679; CHEBI:374449; LS-134503; CID3075615; CHEBI:375533; trans-N-(4-(2-(4-Phenyl-1-piperazinyl)ethyl)cyclohexyl)-2-pyrimidinamine; PD 158771; L015054; N-[4-[2-(4-phenylpiperazin-1-yl)ethyl]cyclohexyl]pyrimidin-2-amine; AC1MIP35; CHEMBL164984	N/A	9841667	49684220	TTDS00012	D(2) dopamine receptor	Dopamine D2 receptor;Dopamine receptor 2	P14416	1813	ENSG00000149295	antagonist
DAP000845	Zuclopenthixol	BRD-K28761384-003-03-6; Prestwick3_000998; Zuclopenthixolum; PDSP1_001122; Clopenthixol (USAN); BPBio1_001205; D03556; Zuclopenthixol (INN); CHEBI:59115; LS-175496; Clopentixol; (Z)-4-(3-(2-Chlorothioxanthen-9-ylidene)propyl)-1-piperazineethanol; CID5311507; Clopixol; Clopenthixolum; Cisordinol; 2-[4-[(3Z)-3-(2-chlorothioxanthen-9-ylidene)propyl]piperazin-1-yl]ethanol; Zuclopentixol; NCGC00179306-01; D003006; alpha-Clopenthixol; BSPBio_001095; Acuphase; 2-{4-[(3Z)-3-(2-chloro-10H-dibenzo[b,e]thiopyran-10-ylidene)propyl]piperazin-1-yl}ethanol; 982-24-1; Clopentixol cis-(Z)-; 1-Piperazineethanol, 4-[(3Z)-3-(2-chloro-9H-thioxanthen-9-ylidene)propyl]-; AC1NSKQX; CHEBI:51364; Zuclopenthixol [BAN:INN]; DB01624; 2-{4-[3-(2-chloro-10H-dibenzo[b,e]thiopyran-10-ylidene)propyl]piperazin-1-yl}ethanol; PDSP2_001106; CLOPENTHIXOL; Prestwick2_000998; CHEMBL53904; 4-(3-(2-Chlorothioxanthen-9-ylidene)propyl)-1-piperazineethanol; 53772-83-1; Clopixol (TN); UNII-47ISU063SG; Zuclopentixol [Spanish]; C22H25ClN2OS; Zuclopenthixol; D02613; alpha Clopenthixol; AB00514719; EINECS 258-758-5; Zuclopenthixolum [Latin]	53772-83-1	5311507	11056550	TTDS00012	D(2) dopamine receptor	Dopamine D2 receptor;Dopamine receptor 2	P14416	1813	ENSG00000149295	antagonist
DCL000904	Ocaperidone	Ocaperidona; 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethylpyrido[1,2-a]pyrimidin-4-one; Ocaperidona [INN-Spanish]; PDSP2_000787; 8-[2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-1-piperidyl]ethyl]-2,9-dimethyl-6,10-diazabicyclo[4.4.0]deca-2,4,8,10-tetraen-7-one; AC1L2FZW; Ocaperidonum [INN-Latin]; Ocaperidone (USAN); UNII-26HUS7139V; PDSP1_000799; AC1Q6AQQ; AR-1E5960; Ocaperidone; CID71351; MolPort-005-932-424; 129029-23-8; D02675; 4H-Pyrido(1,2-a)pyrimidin-4-one, 3-(2-(4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl)ethyl)-2,9-dimethyl-; Ocaperidonum; 3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-2,9-dimethyl-4H-pyrido(1,2-a)pyrimidin-4-one; L001106	129029-23-8	71351	17396844	TTDS00012	D(2) dopamine receptor	Dopamine D2 receptor;Dopamine receptor 2	P14416	1813	ENSG00000149295	antagonist
DAP000373	Prochlorperazine	Prochlorpermazine; Prestwick3_000399; P77; Compazine (*Maleate*); 2-chloro-10-[3-(4-methylpiperazin-1-yl)propyl]phenothiazine; RP 6140; Proclorperazina; Bayer A 173; NCGC00023036-03; Proclorperazina [INN-Spanish]; Spectrum_000840; Prochlorperazinum [INN-Latin]; KBio2_002304; Compro; MolPort-001-611-821; NSC665801; KBio1_000413; Prochlorperazine (JAN/USP/INN); KBio2_006456; 2-Chloro-10-(3-(4-methyl-1-piperazinyl)propyl)phenothiazine; Prochlorperazine maleate; Vertigon; Temetid; BRD-K19352500-332-03-7; 58-38-8; LS-105399; NSC167375; CID4917; Novamin; Probes1_000265; Lopac0_001034; D00493; DivK1c_000413; NCGC00015856-02; 3-Chloro-10-(3-(4-methyl-1-piperazinyl)propyl)phenothiazine; Prochloroperazine; Eskatrol; KBioSS_001320; NCI60_022783; KBioGR_002304; N-(gamma-(4'-Methylpiperazinyl-1')propyl)-3-chlorophenothiazine; I06-1771; AC1L1J8I; Compazine; UNII-YHP6YLT61T; Prochlorperazine Edisylate Salt; 3-Chloro-10-(3-(1-methyl-4-piperazinyl)propyl)phenothiazine; Prestwick0_000399; Spectrum3_000881; 2-Chloro-10-(3-(4-methyl-1-piperazinyl)propyl)-10H-phenothiazine; Spectrum2_001297; KBioSS_002306; Kronocin; 10H-Phenothiazine, 2-chloro-10-(3-(4-methyl-1-piperazinyl)propyl)-; CAS-84-02-6; KBio3_002784; Probes2_000307; Emelent; CHEMBL728; L001030; NINDS_000413; Spectrum5_001339; Prochlorperazine mesilate; AB00053532; 84-02-6; 2-Chloro-10-[3-(4-methyl-1-piper- azinyl)propyl]-10H-pheno-thiazine dimaleate; SKF 4657; cMAP_000013; 2-chloro-10-[3-(4-methylpiperazin-1-yl)propyl]-10H-phenothiazine; SMR000058705; SPBio_001333; Chlorperazine; Meterazine; Chloro-3 (N-methylpiperazinyl-3 propyl)-10 phenothiazine; NCGC00015856-03; Lopac-P-9178; Chlormeprazine; Prochlorpemazine; EINECS 200-379-4; Prochlorperazine dimaleate; Prochlorperazine dihydrobromide; nchembio873-comp71; BRD-K19352500-070-02-5; Chloro-3 (N-methylpiperazinyl-3 propyl)-10 phenothiazine [French]; IDI1_000413; MLS000028600; HSDB 3171; Compro (TN); Phenothiazine, 2-chloro-10-(3-(4-methyl-1-piperazinyl)propyl)-; Prochlorperazin; KBio3_001762; Prochlorperazinum; 2-Chloro-10-(3-(1-methyl-4-piperazinyl)propyl)-phenothiazine; C20H24ClN3S; SPBio_002538; CHLOPERAZINE; DB00433; BSPBio_002394; KBio2_004872; KBio2_001320; prochlorperazine; Prestwick1_000399; KBio2_003888; NSC17478; Prestwick2_000399; BPBio1_000679; 6140 RP; Capazine; CHEBI:8435; Spectrum4_000972; Proclorperazine; Compazine Suppositories; NCGC00015856-01; Prochlorpromazine; KBioGR_001343; Procloperazine; Stemetil; Meterazin; NCGC00015856-07; KBio2_007440; 10H-Phenothiazine, 2-chloro-10-[3-(4-methyl-1-piperazinyl)propyl]-; BSPBio_000617; Prochlorperazine [USAN:INN:BAN:JAN]; Combid; AKOS003600762; Tementil; Nipodal; C07403	58-38-8	4917	7847559	TTDS00012	D(2) dopamine receptor	Dopamine D2 receptor;Dopamine receptor 2	P14416	1813	ENSG00000149295	antagonist
DAP000980	Fluspirilene	HMS1791D05; Bio-0707; McN-JR-6218; HMS1570F14; CID3396; Fluspirilene [USAN:INN:BAN]; EU-0100518; 1,3,8-Triazaspiro(4.5)decan-4-one, 8-(4,4-bis(p-fluorophenyl)butyl)-1-phenyl-; F100_SIGMA; AC1L1FUB; BSPBio_001343; Imap; NCGC00093913-02; NCGC00015424-08; Prestwick2_000906; Fluspirileno [INN-Spanish]; AB00513956; Prestwick0_000906; D02629; CHEMBL46516; DB04842; R6218; HMS1989D05; NCGC00093913-04; 8-[4,4-bis(4-fluorophenyl)butyl]-4-phenyl-2,4,8-triazaspiro[4.5]decan-1-one; C29H31F2N3O; NCGC00015424-02; NCGC00093913-01; Prestwick1_000906; 1-Phenyl-4-oxo-8-(4,4-bis(4-fluorophenyl)butyl)-1,3,8-triazaspiro(4,5)decane; BRN 0633853; Redeptin; BRD-K77947974-001-04-9; SMR000058304; MLS000069357; Lopac-F-100; 1841-19-6; 5-26-04-00097 (Beilstein Handbook Reference); Lopac0_000518; 8-(4,4-Bis(p-fluorophenyl)butyl)-1-phenyl-1,3,8-triazaspiro-(4.5)decan-4-one; 1,3,8-Triazaspiro(4.5)decan-4-one, 8-(4,4-bis(4-fluorophenyl)butyl)-1-phenyl-; NCGC00016595-01; Prestwick3_000906; 1,3,8-Triazaspiro[4.5]decan-4-one, 8-[4,4-bis(4-fluorophenyl)butyl]-1-phenyl-; Fluspirilene; SPBio_002951; R 6218; HMS2089C15; Spirodiflamine; Fluspirilenum; CAS-1841-19-6; L001195; NCGC00015424-01; Fluspirilen; NCGC00093913-03; NCGC00093913-05; MLS001333730; F-100; Fluspirilene (USAN/INN); 8-[4,4-bis (p-fluorophenyl)butyl]- 1-phenyl-1,3,8-triazino[4,5]decan-4-one; 8-[4,4-bis(4-fluorophenyl)butyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one; EINECS 217-418-6; Fluspirilenum [INN-Latin]; spiropiperidine analogue, 1; Oprea1_804941; 8-[4,4-bis(p-Fluorophenyl)butyl]-1-phenyl-1,3,8-triazino[4.5]decan-4-one; LS-154759; MolPort-002-540-769; Fluspirileno; BPBio1_000828; Imap (TN); BSPBio_000752	1841-19-6	3396	159093	TTDS00012	D(2) dopamine receptor	Dopamine D2 receptor;Dopamine receptor 2	P14416	1813	ENSG00000149295	antagonist
DAP000251	Cabergoline	HMS2090A09; 81409-90-7; C26H37N5O2; Ergoline-8-carboxamide, N-(3-(dimethylamino)propyl)-N-((ethylamino)carbonyl)-6-(2-propenyl)-, (8-beta)-; Ergoline-8beta-carboxamide, N-(3-(dimethylamino)propyl)-N-((ethylamino)carbonyl)-6-(2-propenyl)-; Cabergolina; AC-14150; cabergoline; BRN 6020775; Galastop; 1-ethyl-2-(3'-dimethylaminopropyl)-3-(6'-allylergoline-8'-beta-carbonyl)urea diphosphate; (8R)-6-allyl-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)ergoline-8-carboxamide; Cabaseril; Cabergolina [Spanish]; Cabaser; Dostinex (TN); UNII-LL60K9J05T; Cabergolinum [Latin]; MolPort-003-845-557; CHEMBL1201087; AC1Q5OQ0; 1-[(6-allylergoline-8beta-yl)carbonyl]-1-[3-(dimethylamino)propyl]-3-ethylurea; 85329-89-1 (diphosphate); C08187; FT-0081285; Sogilen; FCE-21336; Dostinex; D00987; (8beta)-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)-6-(prop-2-en-1-yl)ergoline-8-carboxamide; CID54746; Cabergoline (JAN/USAN/INN); (8beta)-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)-ergoline-8-carboxamide; BIDD:GT0775; 1-((6-Allylergolin-8beta-yl)carbonyl)-1-(3-(dimethylamino)propyl)-3-ethylurea; Cabaser (TN); Cabergolinum; (8beta)-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-prop-2-en-1-ylergoline-8-carboxamide; AC1L1HO0; DB00248; Cabergoline [USAN:BAN:INN]; BRD-K86882815-001-01-6; 1-ethyl-3-(3'-dimethylamionpropyl)-2-(6'-allylergoline-8'beta-carbonyl)urea; CHEBI:3286; LS-64370; CG-101	81409-90-7	54746	10387	TTDS00012	D(2) dopamine receptor	Dopamine D2 receptor;Dopamine receptor 2	P14416	1813	ENSG00000149295	agonist
DCL000668	(-)-3PPP, Maryland	N/A	N/A	N/A	N/A	TTDS00012	D(2) dopamine receptor	Dopamine D2 receptor;Dopamine receptor 2	P14416	1813	ENSG00000149295	agonist
DAP000844	Acetophenazine	Ketone, 10-(3-(4-(2-hydroxyethyl-1-piperazinyl)propyl)phenothiazin-2-yl methyl; L000816; Acetophenazina; Acetophenazinum [INN-Latin]; Acetophenazine [INN]; UNII-8620H6K4QH; Acetophenazina [INN-Spanish]; MolPort-001-728-032; AC1L2AG8; Ethanone, 1-(10-(3-(4-(2-hydroxyethyl)-1-piperazinyl)propyl)-10H-phenothiazin-2-yl)-; Acephenazinum; 2751-68-0; 1-[10-[3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl]phenothiazin-2-yl]ethanone; C23H29N3O2S; CHEMBL1085; CHEBI:2401; Tindal; AC1Q5GH3; Ethanone, 1-[10-[3-[4-(2-hydroxyethyl)-1-piperazinyl]propyl]-10H-phenothiazin-2-yl]-; 2-acetyl-10-[3-[4-(b-hydroxyethyl)piperazinyl]propyl]phenothiazine; ACETOPHENAZINE; AKOS003589050; Acetophenazinum; 1-(10-{3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl}-10H-phenothiazin-2-yl)ethanone; 10-(3-(4-(2-Hydroxyethyl)-1-piperazinyl)propyl)phenothiazin-2-yl methyl ketone; 5714-00-1 ((Z)-2-maleate [1:2]salt); LS-174186; CID17676; NCGC00181120-01	2751-68-0	441185	9026	TTDS00012	D(2) dopamine receptor	Dopamine D2 receptor;Dopamine receptor 2	P14416	1813	ENSG00000149295	antagonist
DAP000848	Amisulpride	Socian; Amisulpridum [INN-Latin]; Amisulprida [INN-Spanish]; Solian (TN); NCGC00092310-02; MLS001424039; 4-Amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-2-anisamid; MLS000758258; D07310; SAM001246639; NCGC00092310-04; CPD000449309; SAM001246966; A2729_SIGMA; MLS000759450; S1280_Selleck; 4-Amino-N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-(ethylsulfonyl)-2-methoxybenzamide; C17H27N3O4S; STK635172; HMS2051K10; Benzamide, 4-amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-2-methoxy-; Deniban; Amisulprida; SL-91.1077; Amisulpridum; LS-25532; Amisulpiride; Deniban (TN); DAN 2163; 4-amino-N-[(1-ethylpyrrolidin-2-yl)methyl]-5-(ethylsulfonyl)-2-methoxybenzamide; amisulpride; CID2159; L000106; SMR000449309; Bio-0114; CHEMBL243712; Solian, Amisulpride; Aminosultopride; MolPort-003-983-463; 4-Amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-o-anisamide; Solian; Amisulpride (INN); 71675-85-9; EINECS 275-831-7; NCGC00092310-01; AC-6820; 4-amino-N-[(1-ethylpyrrolidin-2-yl)methyl]-5-ethylsulfonyl-2-methoxybenzamide; I06-0334; Amisulpride [INN]; DB06288; DAN-2163; 4-Amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-2-methoxybenzamide; AC1L1D1X; BRD-A60197193-001-05-4	53583-79-2	2159	49681614	TTDS00012	D(2) dopamine receptor	Dopamine D2 receptor;Dopamine receptor 2	P14416	1813	ENSG00000149295	antagonist
DCL000911	Org-23366	N/A	187673-38-7	6324648	42973616	TTDS00012	D(2) dopamine receptor	Dopamine D2 receptor;Dopamine receptor 2	P14416	1813	ENSG00000149295	antagonist
DAP000316	Pimozide	LS-33236; KBio1_000386; KBio2_003493; Pimozide (JAN/USP/INN); McN-JR-6238; R6238; 2-Benzimidazolinone, 1-(1-(4,4-bis(p-fluorophenyl)butyl)-4-piperidyl)-; 1-(4,4-Bis(p-fluorophenyl)butyl)-4-(2-oxo-1-benzimidazolinyl)piperidine; Pimozida [INN-Spanish]; MLS001077311; DB01100; BSPBio_002941; HMS2089C11; 2062-78-4; BIDD:GT0435; NCGC00015802-02; KBioGR_000720; CAS-2062-78-4; KBio3_002441; R-6238; Orap forte; Primozida [INN-Spanish]; CHEMBL1423; EU-0100946; 1-(1-(4,4-Bis(p-fluorophenyl)butyl)-4-piperidyl)-2-benzimidazolinone; MolPort-001-736-597; P 1793; MLS000028410; SPBio_002495; AC1Q4NM9; HMS1989H21; NINDS_000386; HMS2092F09; Neoperidole; 3-[1-[4,4-bis(4-fluorophenyl)butyl]piperidin-4-yl]-1H-benzimidazol-2-one; NCGC00024888-07; 1-[1-[4,4-bis(4-Fluorophenyl)butyl]-4-piperidinyl]-1,3-dihydro-2H-benzimidazol-2-one; L000494; D00560; BRD-K01292756-001-06-0; KBio2_000925; CHEBI:8212; KBio2_006061; NCGC00024888-05; 1-[1-[4,4-Bis(p-fluorophenyl)butyl]-4-piperidyl]-2-benzimidazolinone; 1-{1-[4,4-bis(4-fluorophenyl)butyl]piperidin-4-yl}-2,3-dihydro-1H-1,3-benzodiazol-2-one; NCGC00024888-01; NCIMech_000356; CID16362; NCGC00024888-02; HMS1791H21; BSPBio_001439; Orap (TN); 2-Benzimidazolinone, 1-[1-[4,4-bis(p-fluorophenyl)butyl]-4-piperidyl]-; DivK1c_000386; UNII-1HIZ4DL86F; BSPBio_000276; 5-24-02-00367 (Beilstein Handbook Reference); KBioSS_000925; C07566; Pimozide [USAN:INN:BAN:JAN]; C28H29F2N3O; Prestwick3_000308; Antalon; AB00052215; NCGC00015802-15; NCGC00015802-04; MLS002702058; ASTA Medica Brand of Pimozide; Pimozidum [INN-Latin]; NCGC00024888-06; EINECS 218-171-7; AC1L27SR; Prestwick_395; NCGC00024888-04; Prestwick2_000308; BPBio1_000304; SPBio_001211; R 6238; Tocris-0937; 1-[4,4-Bis(p-fluorophenyl)butyl]-4-(2-oxo-1-benzimidazolinyl)piperidine; AC1Q4M09; HMS1568N18; Spectrum3_001451; BRN 0729089; NCGC00024888-03; Opiran; D010868; SMP1_000241; 1-{1-[4,4-bis(4-fluorophenyl)butyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one; P1793_SIGMA; Lopac0_000946; Pharmascience Brand of Pimozide; pimozide; Spectrum4_000420; WLN: T56 BMVNJ D- DT6NTJ A3YR DF&R DF; SMR000058385; Spectrum_000445; NCGC00022282-03; 1-[1-[4,4-Bis(4-fluorophenyl)butyl]-4-piperidinyl]-1,3-dihydro-2H- benzimidazol-2-one; 2H-Benzimidazol-2-one, 1-(1-(4,4-bis(4-fluorophenyl)butyl)-4-piperidinyl)-1,3-dihydro-; Prestwick0_000308; McN-JR 6238; 2H-Benzimidazol-2-one, 1-[1-[4,4-bis(4-fluorophenyl)butyl]-4-piperidinyl]-1,3-dihydro-; NSC170984; pimozida; Primozida; Pimozidum; BCBcMAP01_000043; CCRIS 9172; IDI1_000386; Janssen Brand of Pimozide; NCGC00016601-01; Spectrum5_001308; Spectrum2_001026; Orap; HMS1921H19; NSC 170984; HMS501D08; SPECTRUM1501134; Prestwick1_000308; Lopac-P-1793; NCGC00015802-01	2062-78-4	16362	9769	TTDS00012	D(2) dopamine receptor	Dopamine D2 receptor;Dopamine receptor 2	P14416	1813	ENSG00000149295	antagonist
DAP000374	Chlorpromazine	CHEMBL71; NCGC00024409-04; 10H-Phenothiazine-10-propanamine, 2-chloro-N,N-dimethyl-; BPBio1_000273; AKOS001490972; Fraction AB; KBio3_001231; Thorazine (TN); 2-chloro-10-[3-(dimethylamino)propyl]-; CAS-69-09-0; Z80; Oprea1_110255; SPBio_001111; JHICC02042; NCGC00015273-01; BAS 00010434; 2-Chloropromazine; 2601A; Spectrum_000142; NCGC00024409-06; Clorpromazina [Italian]; KBioSS_002314; Contomin; LS-105361; Prazilpromactil; 3-(2-chlorophenothiazin-10-yl)-N,N-dimethyl-propan-1-amine; SKF 2601A; 2-Chloro-10-[3-(dimethylamino)propyl]phenothiazine; Lopac0_000249; Chloro-3 (dimethylamino-3 propyl)-10 phenothiazine; Propaphen; Aminazine; Largactil Oral Drops; Proma; Bio1_001435; WLN: T C666 BN ISJ B3N1&1 EG; KBio2_003190; DB00477; Largactilothiazine; HMS1920M03; EINECS 200-045-8; Amplictil; BC 135; Chlorpromanyl (discontinued); DivK1c_000624; Plegomazin; QTL1_000021; NCGC00024409-05; Chlorpromazinum [INN-Latin]; SKF 2601-A; HMS501P06; Megaphen; Thorazine Suppositories; AC1L1EBT; D00270; MolPort-001-727-953; SPBio_002168; Novo-Chlorpromazine; Bio1_000457; BSPBio_000247; Prestwick0_000064; 2-chloro-10-(3-(dimethylamino)propyl)-phenothiazine; Fenactil; Amplicitil; N-(3-Dimethylaminopropyl)-3-chlorophenothiazine; Ampliactil; NCGC00024409-07; Thorazine Spansule; HL 5746; SPECTRUM1500184; Sanopron; Phenothiazine, 2-chloro-10-(3-(dimethylamino)propyl)-; 3-(2-Chloro-10H-phenothiazin-10-yl)-N,N-dimethyl-1-propanamine; Spectrum2_001156; Novomazina; Spectrum3_000346; 2-Cloro-10 (3-dimetilaminopropil)fenotiazina [Italian]; Propaphenin; Biomol-NT_000020; AB00051943; SR-01000000012-5; Largactil Liquid; 50-53-3; [3-(2-Chloro-phenothiazin-10-yl)-propyl]-dimethyl-amine; 4560 Rp hydrochloride; Clorpromazina [INN-Spanish]; Elmarin; Chlorpromazinum; Thorazine hydrochloride; SKF-2601; cMAP_000017; Prestwick2_000064; Largactil; Spectrum4_000283; KBioGR_002312; Chlorderazin; BPBio1_001181; Chlorpromazin; HSDB 3033; NSC17479; Chloropromazine; 2-Cloro-10 (3-dimetilaminopropil)fenotiazina; 34468-21-8; 4560 R.P; Chlordelazine; STK182870; Phenactyl; NCGC00015273-02; C06906; NSC 167745; Chlorpromazine (USP/INN); HMS2091E06; 3-(2-chloro-10H-phenothiazin-10-yl)-N,N-dimethylpropan-1-amine; Phenathyl; Chlor-PZ; Prozil; UNII-U42B7VYA4P; Cromedazine; CCRIS 3711; Chlorpromazine [USAN:INN:BAN]; Thorazine; Lopac-C-8138; NCGC00024409-08; chlorpromazine; Prestwick1_000064; HMS2089C12; CHEBI:3647; NSC167745; Bio1_000946; KBio2_002312; L000182; NCGC00015273-14; KBio2_005758; Phenothiazine hydrochloride; IDI1_000624; 2-Chloro-10-(3-(dimethylamino)propyl)phenothiazine; KBioGR_000806; Promazil; Spectrum5_000717; C17H19ClN2S; Chlorpromados; Chloro-3 (dimethylamino-3 propyl)-10 phenothiazine [French]; Fenaktyl; NINDS_000624; Psychozine; 2-chloro-N,N-dimethyl-10H-Phenothiazine-10-propanamine; Torazina; KBio1_000624; CID2726; Aminazin; KBio2_004880; STOCK1S-46588; Aminasine; 10-(3-Dimethylaminopropyl)-2-chlorophenothiazine; 3-(2-Chloro-10H-phenothiazin-10-yl)-N,N-dimethyl-1-propanamine; Chlor-Promanyl; KBio2_007448; BSPBio_002011; 3-(2-chlorophenothiazin-10-yl)-N,N-dimethylpropan-1-amine; Chlorpromazine Tannate; I14-6226; Largactyl; KBio2_000622; Esmind; Promactil; 4560 R.P.; Prestwick3_000064; KBioSS_000622; Phenothiazine, 2-chloro-10-[3-(dimethylamino)propyl]-; Plegomasine; Wintermin; Clorpromazina; NCGC00015273-03; 10H-Phenothiazine-10-propanamine, 2-chloro-N,N-dimethyl-, radical ion(1+); KBio3_002792	50-53-3	2726	148556	TTDS00012	D(2) dopamine receptor	Dopamine D2 receptor;Dopamine receptor 2	P14416	1813	ENSG00000149295	antagonist
DAP000069	Pergolide	Lopac0_000984; (8beta)-8-[(methylthio)methyl]-6-propylergoline; ST057534; Permax (TN); KBio2_002127; CHEBI:112494; CHEMBL531; NINDS_000442; SPBio_002099; KBio2_004695; LS-64479; KBio1_000442; BIDD:GT0177; NCGC00142538-03; C19H26N2S; KBioGR_001409; pergolide; Ergoline, 8-((methylthio)methyl)-6-propyl-, (8beta)-; IDI1_000442; (6aR,9R,10aR)-9-(Methylthiomethyl)-7-propyl-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinoline; MolPort-003-849-834; Permax; Pergolide [INN:BAN]; InChI=1/C19H26N2S/c1-3-7-21-11-13(12-22-2)8-16-15-5-4-6-17-19(15)14(10-20-17)9-18(16)21/h4-6,10,13,16,18,20H,3,7-9,11-12H2,1-2H3/t13-,16-,18-/m1/s; nchembio873-comp45; KBioSS_002127; Pergolida [INN-Spanish]; LY-127,809; AC1L2IT3; BPBio1_000254; 66104-22-1; Spectrum4_000835; HMS2089C18; D08339; NCGC00142538-02; BPBio1_001211; C07425; Prestwick2_000295; Pergolidum; DB01186; Pergolide (INN); (8beta)-8-[(methylsulfanyl)methyl]-6-propylergoline; BSPBio_000230; SPBio_002449; 66104-23-2 (mesylate); AC1Q7DT2; Prestwick1_000295; DivK1c_000442; Spectrum2_001970; CID47811; Prestwick0_000295; BRD-K60770992-066-05-2; KBio2_007263; BSPBio_003156; UNII-24MJ822NZ9; NCGC00142538-01; Prestwick3_000295; Spectrum3_001588; Pergolidum [INN-Latin]; BRD-K60770992-001-01-8; Pergolida; NCGC00017366-05; Spectrum_001647; Biomol-NT_000025; Spectrum5_001649; KBio3_002656	66104-22-1	47811	9629	TTDS00012	D(2) dopamine receptor	Dopamine D2 receptor;Dopamine receptor 2	P14416	1813	ENSG00000149295	agonist
DPR000003	1192U90	LS-25359; 2-Amino-N-(4-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)butyl)benzamide; 2-amino-N-[4-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]butyl]benzamide; 1192U90; PDSP1_001055; Benzamide, 2-amino-N-(4-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)butyl)-; 2-Amino-N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]butyl] benzamide; PDSP2_001039; 155289-31-9; CID127912; AC1L2SUW; L001475	155289-31-9	127912	704544	TTDS00012	D(2) dopamine receptor	Dopamine D2 receptor;Dopamine receptor 2	P14416	1813	ENSG00000149295	antagonist
DCL000917	PD-157695	N/A	N/A	3854666	49684195	TTDS00012	D(2) dopamine receptor	Dopamine D2 receptor;Dopamine receptor 2	P14416	1813	ENSG00000149295	antagonist
DAP000212	Dopamine	KBio1_000780; KBio3_002867; Dophamine; .Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride; 1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride; 3,4-Dihydroxyphenethylamine hydrochloride; 3-Hydroxytyramine hydrochloride; 4-(2-Aminoethyl)-1,; 3,4-Dihydroxyphenylethylamine; 3-Hydroxytyramine  Hydrobromide; NINDS_000780; 1,2-Benzenediol, 4-(2-aminoethyl)- (9CI); Dopamina [INN-Spanish]; IDI1_000780; KBio2_004956; 1,2-Benzenediol, 4-(2-aminoethyl)-; C03758; NSC169105; KBio2_004060; KBio2_005052; KBioSS_002491; Dopamin; Oxytyramine; KBio2_007524; 3-Hydroxytyramine; NCGC00015519-01; Biomol-NT_000001; 4-(2-Aminoethyl)benzene-1,2-diol; ; m-Hydroxytyramine hydrochloride; Dopamina; BSPBio_001932; KBioSS_002393; Lopac-H-8502; NCGC00096050-01; KW-3-060; UNII-VTD58H1Z2X; Medopa (TN); KBio3_001152; STK301601; KBio2_001492; 3-Hydroxtyramine; ASL 279; cMAP_000036; SPBio_001205; cMAP_000065; Hydroxytyramin; KBioGR_002388; Dopaminum [INN-Latin]; Lopac0_000586; .alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane; 3,4-dihydroxyphenethylamine; 4-(2-Aminoethyl)-1,2-bezenediol; Spectrum5_000945; KBio2_002484; Revimine; KBio2_007620; LDP; NCGC00096050-04; Dopamine (INN); nchembio.78-comp16; hydroxytyramine; NCGC00096050-02; BPBio1_001123; L-DOPAMINE; ST048774; DivK1c_000780; CHEBI:18243; CID681; Pyrocatechol, 4-(2-aminoethyl)-; (3H)-Dopamine; AC1Q54AX; IP 498; m-Hydroxytyramine-; a-(3,4-Dihydroxyphenyl)-b-aminoethane; BIDD:ER0506; MolPort-001-641-000; 2-benzenediol; 4-(2-Aminoethyl)pyrocatechol hydrochloride; Dopamine (USAN)(*hydrochloride*); Intropin [*hydrochloride*]; Pyrocatechol, 4-(2-aminoethyl)-; Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride; KBioSS_001492; KBio2_002388; nchembio705-8; nchembio.89-comp3; 4-(2-Aminoethyl)catechol; Pyrocatechol, 4-(2-aminoethyl)- (8CI); Spectrum_001012; EINECS 200-110-0; Spectrum4_000525; UPCMLD0ENAT5885989:001; CHEMBL59; KBio3_002962; NCGC00015519-08; NCGC00096050-05; SPECTRUM1505155; nchembio.107-comp4; 4-(2-Aminoethyl)pyrocatechol; D07870; AC1Q54AY; 4-(2-Aminoethyl)-1,2-benzenediol; NSC 173182; HSDB 3068; intropin; KBioGR_001129; Dopamine [INN:BAN]; DB00988; 4-(2-aminoethyl)-pyrocatechol; 1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium; alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane; Spectrum3_000406; nchembio.284-comp1; 2-(3,4-dihydroxyphenyl)ethylamine; 50444-17-2; nchembio801-comp8; dopamine; Dopaminum; Spectrum2_001023; AKOS003790978; NSC173182; nchembio.105-comp9; NCGC00096050-03; 62-31-7 (HYDROCHLORIDE); LS-159; Oprea1_088821; L000232; 153C5321-5FEE-4B0B-8925-F388F0EEEBD1; KBioGR_002484; AC1L19S5; 51-61-6; KBio2_006628	51-61-6	681	2667	TTDS00012	D(2) dopamine receptor	Dopamine D2 receptor;Dopamine receptor 2	P14416	1813	ENSG00000149295	agonist
DAP000100	Perphenazine	Spectrum2_001602; 2-Chloro-10-(3-(4-(2-hydroxyethyl)piperazin-1-yl)propyl)phenothiazine; Decentan; BPBio1_000188; 4-[3-(2-Chlorophenothiazin-10-yl)propyl]-1-piperazineethanol; MLS001146929; 2-[4-[3-(2-Chlorophenothiazin-10-yl)propyl]piperazin-1-yl]ethanol; STK019818; 2-Chloro-10-3-(1-(2-hydroxyethyl)-4-piperazinyl)propyl phenothiazine; C21H26ClN3OS; NCGC00015826-03; 1-Piperazineethanol, 4-(3-(2-chloro-10H-phenothiazin-10-yl)propyl)-; 2-Chloro-10-(3-(1-(2-hydroxyethyl)-4-piperazinyl)propyl)phenothiazine; SR-01000000137-4; D00503; 1',1-(2-Idrossietil)-4,3-(2-cloro-10-fenotiazil)propilpiperazina [Italian]; BIDD:GT0150; Prestwick2_000125; 4-[3-(2-Chloro-10H-phenothiazin-10-yl)propyl]-1-piperazineethanol; NCGC00024092-03; KBio2_002090; SPBio_001603; HMS2093M15; NCGC00015826-10; I06-1508; F-mon; DivK1c_000880; 4-(3-(2-Chlorophenothiazin-10-yl)propyl)-1-piperazineethanol; AI3-50151; Perphenan; HSDB 3379; CPD000058180; SMR000058180; C07427; 1-Piperazineethanol, 4-[3-(2-chloro-10H-phenothiazin-10-yl)propyl]-; KBio2_004658; 58-39-9; Perphenazine (JP15/USP/INN); D010546; SPBio_002109; CAS-58-39-9; Trilifan; Perphenazin; Perphenazinum; NCGC00015826-02; BAS 00139131; 2-{4-[3-(2-Chloro-phenothiazin-10-yl)-propyl]-piperazin-1-yl}-ethanol; Trifaron; AB00052390; AC-12196; Trilafon; Etaperazine; Ethaperazine; NCGC00015826-06; SCH-3940; 2-Chloro-10-[3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl]phenothiazine; CHEMBL567; EU-0072164; Spectrum4_000843; P 6402; Prestwick0_000125; NCGC00015826-01; AKOS000664046; KBioGR_001445; NCGC00024092-04; KBio1_000880; BSPBio_000170; Perfenazina [Italian]; NCGC00024092-05; Perfenazine; Prestwick3_000125; CHEBI:8028; Spectrum3_000758; NSC150866; L000919; Piperazineethanol, 4-(3-(2-chloro-10H-phenothiazin-10-yl)propyl)-; BSPBio_002376; NINDS_000880; 2-(4-[3-(2-Chloro-10H-phenothiazin-10-yl)propyl]-1-piperazinyl)ethanol; P6402_SIGMA; Triphenot; 1-(2-Hydroxyethyl)-4-(3-(2-chloro-10-phenothiazinyl)propyl)piperazine; UNII-FTA7XXY4EZ; Lopac0_000930; KBioSS_002090; 1-(2-Hydroxyethyl)-4-[3-(2-chloro-10-phenothiazinyl)propyl]piperazine; Prestwick_536; NSC 150866; IDI1_000880; .gamma.-[4-(.beta.-Hydroxyethyl)piperazin-1-yl]propyl-2-chlorophenothiazine; STOCK1S-21551; 1-Piperazineethanol, 4-(3-(2-chlorophenothiazin-10-yl)propyl)-; LS-112185; HMS1568I12; WLN: T C666 BN ISJ EG B3- AT6N DNTJ D2Q; Chlorpiprazine; Perphenazine [Trilafon]; Spectrum_001610; NCGC00024092-06; Sch 3940; Etaperazin; KBio3_001596; MolPort-001-727-942; SPECTRUM1503934; HMS1922M14; Fentazin; Lopac-P-6402; Perfenazina; Emesinal; SAM002264637; EU-0100930; MLS000069637; HMS502L22; Prestwick1_000125; EINECS 200-381-5; Perphenazine [INN:BAN:JAN]; Perphenazine maleate; 1',1-(2-Idrossietil)-4,3-(2-cloro-10-fenotiazil)propilpiperazina; perphenazine; 2-Chloro-10-3-[1-(2-hydroxyethyl)-4-piperazinyl]propyl phenothiazine; Chlorperphenazine; DB00850; Spectrum5_001493; Apo-Perphenazine; 1-Piperazineethanol, 4-[3-(2-chlorophenothiazin-10-yl)propyl]-; 2-{4-[3-(2-chloro-10H-phenothiazin-10-yl)propyl]piperazin-1-yl}ethanol; Tranquisan; 1-Piperazineethanol, 4-[3-(2-chlorophenothiazin-10-yl)propyl]-, trihydrochloride; Oprea1_603835; CID4748; BRD-K10995081-001-05-5; AC1L1IVB; Perphenazinum [INN-Latin]; nchembio873-comp26; Thilatazin; KBio2_007226; gamma-(4-(beta-Hydroxyethyl)piperazin-1-yl)propyl-2-chlorophenothiazine; PZC; Perfenazina [INN-Spanish]	58-39-9	4748	148869	TTDS00012	D(2) dopamine receptor	Dopamine D2 receptor;Dopamine receptor 2	P14416	1813	ENSG00000149295	antagonist
DAP001497	Nemonapride	75272-39-8; Emilace; N-(2RS,3RS)-(1-Benzyl-2-methyl-3-pyrrolidinyl)-5-chloro-2-methoxy-4-methylaminobenzamide; Benzamide, 5-chloro-2-methoxy-4-(methylamino)-N-((2R,3R)-2-methyl-1-(phenylmethyl)-3-pyrrolidinyl)-, rel-; D01468; PDSP1_001527; (+-)-cis-N-(1-Benzyl-2-methyl-3-pyrrolidinyl)-5-chloro-4-(methylamino)-o-anisamide; Benzamide, 5-chloro-2-methoxy-4-(methylamino)-N-(2-methyl-1-(phenylmethyl)-3-pyrrolidinyl)-,cis-(+-)-; UNII-Q88T5P3444; (+-)-cis-N-(1-Benzyl-2-methylpyrrolidin-3-yl)-5-chloro-2-methoxy-4-methylaminobenzamide; nemonapride, (cis)-isomer; N-[(2R,3R)-1-benzyl-2-methylpyrrolidin-3-yl]-5-chloro-2-methoxy-4-(methylamino)benzamide; Emilace (TN); PDSP2_001511; nemonapride; Nemonapride (JAN/INN); YM 09151-2; C12915; Emonapride; Benzamide, 5-chloro-2-methoxy-4-(methylamino)-N-(2-methyl-1-(phenylmethyl)-3-pyrrolidinyl)-, cis-(+-)-; LS-26124; CID156333; C21H26ClN3O2; 93664-94-9; YM-09151; AC1L4FZO; YM-09151-2	75272-39-8	156333	12013018	TTDS00012	D(2) dopamine receptor	Dopamine D2 receptor;Dopamine receptor 2	P14416	1813	ENSG00000149295	agonist
DCL001042	ZD-3638	N/A	152352-44-8	447043	49718186	TTDS00012	D(2) dopamine receptor	Dopamine D2 receptor;Dopamine receptor 2	P14416	1813	ENSG00000149295	binder
DCL000843	Iloperidone	L001176; Ethanone, 1-(4-(3-(4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl)propoxy)-3-methoxyphenyl)-; 4'-(3-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)propoxy)-3'-methoxyacetophenone; Iloperidone; D02666; AC1L2G0K; AKOS005146266; CID71360; Iloperidone (USAN/INN); PDSP2_000512; Zomaril; 133454-47-4; HP-873; AC1Q5GSB; I06-2110; Fiapta; LS-172870; FT-0084590; Iloperidone [USAN:INN]; PDSP1_000515; Fanapta, Zomaril, Iloperidone; MolPort-005-934-272; PDSP2_000513; C24H27FN2O4; ILO-522; AC-3482; 1-[4-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propoxy]-3-methoxyphenyl]ethanone; PDSP1_000514; S1483_Selleck; HP 873; CHEBI:113949; Fanapt; Fanapta; CHEMBL14376	133454-47-4	71360	17396835	TTDS00012	D(2) dopamine receptor	Dopamine D2 receptor;Dopamine receptor 2	P14416	1813	ENSG00000149295	antagonist
DAP000022	Olanzapine	MLS001165781; AKOS000282888; AC-665; HMS2089M04; Symbyax; Olansek; LY-170052; Midax; Zyprexa Intramuscular; InChI=1/C17H20N4S/c1-12-11-13-16(21-9-7-20(2)8-10-21)18-14-5-3-4-6-15(14)19-17(13)22-12/h3-6,11,19H,7-10H2,1-2H; Zyprexa Zydis; 10H-Thieno(2,3-b)(1,5)benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-; MolPort-002-885-845; Zalasta; DB00334; CID4585; CPD000466345; C17H20N4S; UNII-N7U69T4SZR; HMS2093I04; NCGC00096077-04; 2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno(2,3-b)(1,5)benzodiazepine; NCGC00096077-03; 2-methyl-4-(4-methyl-1-piperazinyl)-10 H -thieno[2,3- b ] [1,5]benzodiazepine; Zyprexa (TN); Olanzapine [USAN:INN]; Zydis; Lanzac; olanzapinum; MolPort-005-977-341; S2493_Selleck; MLS000759457; 132539-06-1; SPECTRUM1505024; SMR000466345; L000455; LY 170053; SAM001246652; olanzapine; LS-152313; Bio-0169; 10H-thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-; olanzapina; ALKS-7921; HMS2051H05; Olanzapine (OLA); Jsp001969; KS-1090; Olanzapine (JAN/USAN/INN); CHEBI:7735; C07322; MLS001195646; BIDD:PXR0138; D00454; 2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno[2,3-b][1,5]benzodiazepine; InChI=1/C17H20N4S/c1-12-11-13-16(21-9-7-20(2)8-10-21)18-14-5-3-4-6-15(14)19-17(13)22-12/h3-6,11,19H,7-10H2,1-2H3; I06-0784; MLS001424057; 2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine; C076029; NCGC00096077-01; LY-170053; STK634338; L005958; Lilly brand of olanzapine; Eli Lilly brand of olanzapine; 2-methyl-4-(4-methylpiperazin-1-yl)-5H-thieno[2,3-b][1,5]benzodiazepine; Zyprexa; MolPort-003-666-569; 2-methyl-4-(4-methylpiperazin-1-yl)-5H-thieno[3,2-c][1,5]benzodiazepine; BIDD:GT0332; AC1L1IHS; CHEMBL715; KVWDHTXUZHCGIO-UHFFFAOYSA-; Zyprexa Velotab; TL8000772	132539-06-1	4585	197059	TTDS00012	D(2) dopamine receptor	Dopamine D2 receptor;Dopamine receptor 2	P14416	1813	ENSG00000149295	agonist
DCL000991	SLV-319	Ibipinabant (USAN/INN); CHEBI:464871; 464213-10-3; CID 9826744; SLV-319; CHEBI:530253; CHEMBL412262; D09349; CID11179267; CID9826744; Ibipinabant; ZINC03964747; CHEMBL158784; LS-193349; CHEBI:363997; (+/-)-SLV319	362519-49-1	1132	49689491	TTDS00012	D(2) dopamine receptor	Dopamine D2 receptor;Dopamine receptor 2	P14416	1813	ENSG00000149295	antagonist
DAP000832	Sertindole	Lu-23-174; 1-(2-(4-(5-Chloro-1-(p-fluorophenyl)indol-3-yl)piperidino)ethyl)-2-imidazolidinone; S-1991; L001396; DB06144; UNII-GVV4Z879SP; SerLect; 1-(2-(4-(5-chloro-1-(4-fluorophenyl)-1H-indol-3-yl)-1-piperidinyl)ethyl)-2-imidazolidinone; CHEMBL12713; LS-79363; Sertindol; Sertindolum [INN-Latin]; 1-[2-[4-[5-Chloro-1-(p-fluorophenyl)indol-3-yl]piperidino]ethyl]-2-imidazolidinone; 1-[2-[4-[5-chloro-1-(4-fluorophenyl)-indol-3-yl]-1-piperidyl]ethyl]imidazolidin-2-one; CHEBI:9122; 1-(2-(4-(5-Chloro-1-(4-fluorophenyl)-1H-indole-3-yl)-1-piperidinyl)ethyl)-2-imidazolidinone; Sertindole (USAN/INN); 2-Imidazolidinone, 1-(2-(4-(5-chloro-1-(4-fluorophenyl)-1H-indol-3-yl)-1-piperidinyl)ethyl)-; 1-(2-{4-[5-chloro-1-(4-fluorophenyl)-1H-indol-3-yl]piperidin-1-yl}ethyl)imidazolidin-2-one; 2-Imidazolidinone, 1-(2-(4-(5-chloro-1-(4-fluorophenyl)-1H-indole-3-yl)-1-piperidinyl)ethyl)-; Serdolect; NCGC00181782-01; C07567; D00561; C066304; AC1L1SNB; AC1Q4NTT; SerLect (TN); SERTINDOLE; 106516-24-9; MolPort-005-933-379; Lu 23-174; PDSP2_001545; Sertindol [INN-Spanish]; PDSP1_001561; Sertindolum; C24H26ClFN4O; Sertindole [USAN:INN]; 1-[2-[4-[5-chloro-1-(4-fluorophenyl)indol-3-yl]piperidin-1-yl]ethyl]imidazolidin-2-one; sertindole hydrochloride; CID60149	106516-24-9	60149	7847627	TTDS00012	D(2) dopamine receptor	Dopamine D2 receptor;Dopamine receptor 2	P14416	1813	ENSG00000149295	antagonist
DAP000311	Loxapine	PDSP2_001042; Cloxazepine; 1977-10-2; 27833-64-3 (succinate); BSPBio_003479; Lopac0_000720; C18H18ClN3O; KBio2_003403; L001085; QTL1_000050; HF 3170; Oxilapine; HSDB 3111; BRN 0626753; Loxitane IM; 54810-23-0 (mono-hydrochloride); Loxapine (USAN/INN); Prestwick3_000132; SUM-3170; PDSP1_001058; SPBio_001814; Dibenzacepin; NCGC00021145-01; 2-Chloro-11-(4-methyl-1-piperazinyl)dibenz(b,f)(1,4)oxazepine; LW 3170; Dibenz[b,f][1,4]oxazepine, 2-chloro-11-(4-methyl-1-piperazinyl)-; Spectrum_000355; CHEMBL831; Loxapinum; Loxapinum [INN-Latin]; KBio2_005971; Spectrum2_001737; C07104; Loxapine [USAN:INN:BAN]; KBio3_002983; KBioSS_000835; Loxapine [USAN:BAN:INN]; CL-71,563; EINECS 217-835-3; CHEBI:50841; MolPort-002-885-838; NCGC00022279-04; Loxapina [INN-Spanish]; UNII-LER583670J; NCGC00022279-03; 2-Chloro-11-(4-methyl-1-piperazinyl)-dibenz(b,f)(1,4)oxazepine; KBio2_000835; BPBio1_000226; 8-chloro-6-(4-methylpiperazin-1-yl)benzo[b][1,4]benzoxazepine; HF3170; SUM 3170; CL-62362; Prestwick1_000132; SPBio_002143; Lossapina [DCIT]; SpecPlus_000823; Prestwick2_000132; S-805; CID3964; 2-chloro-11-(4-methylpiperazin-1-yl)dibenzo[b,f][1,4]oxazepine; Spectrum3_001830; NCGC00022279-05; Hydrofluoride 3170; Loxapinsuccinate; DivK1c_006919; LS-61562; 8-chloro-6-(4-methylpiperazin-1-yl)benzo[b][1,5]benzoxazepine; loxapine; AC1L1H3Z; AC1Q3ZWR; Lossapina; Dibenzoazepine; Spectrum5_001857; CL 62362; Loxapin; Dibenz(b,f)(1,4)oxazepine, 2-chloro-11-(4-methyl-1-piperazinyl)-; DB00408; BRD-K39915878-036-04-6; ZINC19796158; NCGC00021145-07; D02340; 2-Chloro-11-(4-methylpiperazino)dibenzo(b,f)(1,4)oxazepine; BRD-K39915878-036-05-3; KBio1_001863; Loxepine; S 805; Prestwick0_000132; BSPBio_000204; Loxapina	1977-10-2	3964	9315	TTDS00012	D(2) dopamine receptor	Dopamine D2 receptor;Dopamine receptor 2	P14416	1813	ENSG00000149295	antagonist
DAP000076	Aripiprazole	ALKS-9070; C094645; Abilitat; Abilify; S06-0010; Aripiprazole [USAN]; MolPort-003-844-657; STK625160; 7-[4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butoxy]-3,4-dihydrocarbostyril; SMR000466383; Abilify (TN); TL80090184; TL8000707; C12564; L001339; Asprito|; Bristol-Myers Squibb brand of aripiprazole; aripiprazol; 7-(4-(4-(2,3-Dichlorophenyl)-1-piperazinyl)butoxy)-3,4-dihydrocarbostyril; OPC-14597; MLS001424078; NCGC00159510-02; C23H27Cl2N3O2; HMS2093F22; 129722-12-9; 7-(4-(4-(2,3-Dichlorophenyl)-1-piperazinyl)butyloxy)-3,4-dihydro-2(1H)-quinolinone; Abilify Discmelt; CPD000466383; MolPort-002-885-808; ||OPC 14597; FT-0082572; MLS001165779; UNII-82VFR53I78; CID60795; 7-(4-(4-(2,3-Dichlorophenyl)-1-piperazinyl)butoxy)-3,4-dihydro-2(1H)-quinolinone; Discmelt; NCGC00159510-03; SAM001246750; 7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-3,4-dihydro-1H-quinolin-2-one; AC-1554; aripiprazolum; CHEMBL1112; AC1L1TXZ; MLS000759517; 2(1H)-Quinolinone, 7-[4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy]-3,4-dihydro-; HMS2089M20; Aripiprazole (JAN/USAN/INN); D01164; OPC 31; Arpizol; 2(1H)-Quinolinone, 7-(4-(4-(2,3-dichlorophenyl)-1-piperazinyl)butoxy)-3,4-dihydro-; Opc 14597; LS-142666; AC1Q3T38; Aripiprazole; CHEBI:31236; Otsuka brand of aripiprazole; BMS-337039; DB01238; Pripiprazole; Aripirazole; HMS2051I18; KS-1030; 7-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy}-3,4-dihydroquinolin-2(1H)-one; OPC-31; 24-29-3; HSDB 7320; Bio-0004; MLS001195621	129722-12-9	60795	582954	TTDS00012	D(2) dopamine receptor	Dopamine D2 receptor;Dopamine receptor 2	P14416	1813	ENSG00000149295	agonist
DCL000989	SLV-313	CID 9887537; CHEMBL221692; L001624; CID9887537; SLV-313	N/A	N/A	N/A	TTDS00012	D(2) dopamine receptor	Dopamine D2 receptor;Dopamine receptor 2	P14416	1813	ENSG00000149295	agonist
DCL000941	Quetiapine SR	N/A	111974-69-7	5002	48416505	TTDS00012	D(2) dopamine receptor	Dopamine D2 receptor;Dopamine receptor 2	P14416	1813	ENSG00000149295	antagonist
DAP001420	Quinagolide	Sulfamide, N,N-diethyl-N-(1,2,3,4,4a,5,10,10a-octahydro-6-hydroxy-1-propylbenzo(g)quinolin-3-yl)-, (3-alpha,4a-alpha,10a-beta)-(+-)-; Quinagolide; CID9908699; Quinagolide [BAN:INN]; AC1MJ64J; BRN 6074559; CV-205-502; CHEBI:157252; Quinagolida; C20H33N3O3S; CV205-502; 87056-78-8; 3-(diethylsulfamoylamino)-6-hydroxy-1-propyl-3,4,4a,5,10,10a-hexahydro-2H-benzo[g]quinoline; CID3086401; L003951; (+-)-N,N-Diethyl-N'-((3R*,4aR*,10aS*)-1,2,3,4,4a,5,10,10a-octahydro-6-hydroxy-1-propylbenzo(g)quinolin-3-yl)sulfamide; quinagolide, (3alpha,4aalpha,10abeta)-(+-)-isomer; N,N-diethyl-N'-(1,2,3,4,4a,5,10,10a-octahydro-6-hydroxy-1-propyl-3-benzo(g)quinolinyl)sulfamide, (3alpha,4aalpha,10abeta)-(+-)-isomer; (3S,4aS,10aR)-3-(diethylsulfamoylamino)-6-hydroxy-1-propyl-3,4,4a,5,10,10a-hexahydro-2H-benzo[g]quinoline; AC1L1JHQ; D07217; Quinagolide (INN/BAN); Quinagolida [INN-Spanish]; CV 205-502; CID55645; CHEMBL290962; UNII-80Q9QWN15M; Quinagolidum [INN-Latin]; LS-147705; Quinagolidum	97805-50-0	105105	682596	TTDS00012	D(2) dopamine receptor	Dopamine D2 receptor;Dopamine receptor 2	P14416	1813	ENSG00000149295	agonist
DCL000673	Abaperidone hydrochloride	7-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propoxy]-3-(hydroxymethyl)chromen-4-one hydrochloride; Abaperidone hydrochloride; CID6918450; AC1OCFG8; FI-8602.HCl	183849-43-6	3037308	12015267	TTDS00012	D(2) dopamine receptor	Dopamine D2 receptor;Dopamine receptor 2	P14416	1813	ENSG00000149295	antagonist
DCL000915	Pardoprunox	L001636; 7-(4-methylpiperazin-1-yl)-3H-1,3-benzoxazol-2-one; 269718-84-5; CID6918525; D09397; UNII-5R72CHP32S; 7-(4-methylpiperazin-1-yl)-3H-benzooxazol-2-one; Pardoprunox; Pardoprunox (USAN/INN); AC1OCFJE	269718-84-5	5166	49684196	TTDS00012	D(2) dopamine receptor	Dopamine D2 receptor;Dopamine receptor 2	P14416	1813	ENSG00000149295	agonist
DAP000313	Haloperidol	Dozic; H1512_SIGMA; H0912; Lealgin compositum; KBio2_001341; MolPort-000-883-311; Galoperidol; Tocris-0931; KBio3_001316; McN-JR-1625; Einalon S; HMS2091J09; NCGC00023875-04; KBioGR_000980; KBio2_006477; NCGC00023875-07; Peluces; NSC 615296; Aloperidolo [Italian]; NSC170973; BRN 0331267; EINECS 200-155-6; SPECTRUM1500325; CAS-52-86-8; Aloperidol; Linton; Sigaperidol; KBioSS_002395; Prestwick_250; BPBio1_000144; UNII-J6292F8L3D; NINDS_000654; Halopidol; CHEBI:5613; Haloperidol [USAN:INN:BAN:JAN]; HMS1568G12; Haloperidolum [INN-Latin]; Haloperidolum; 52-86-8; AKOS000280660; Spectrum3_000448; Spectrum4_000570; R-1625; DivK1c_000654; NCGC00023875-08; Bioperidolo; Novo-Peridol; BPBio1_001231; NSC615296; Oprea1_509923; BRD-K67783091-001-05-5; Uliolind; Serenase; IDI1_000654; I14-13404; KBioGR_002390; Prestwick1_000115; LS-48311; Sernel; Aloperidin; Peridol; Halosten; HMS2089M15; Biomol-NT_000035; KBio2_002390; NCGC00015500-02; Prestwick3_000115; D00136; Probes1_000255; Haldol; Lopac0_000583; NCGC00015500-06; Aloperidolo; AC1L1G7K; Halopoidol; 5-21-02-00377 (Beilstein Handbook Reference); BIDD:GT0128; AB00052008; AC1Q77Z0; HMS502A16; NSC 170973; Halidol; BRD-K67783091-001-04-8; Spectrum_000861; EU-0100583; SMR000058303; Lopac-H-1512; I14-14165; NCGC00015500-01; Haldol Solutab; Serenelfi; Pernox; DB00502; KBio3_002869; MLS000028450; CCRIS 1630; NCGC00023875-09; WLN: T6NTJ A3VR DF& DQ DR DG; Vesalium; Dozix; cMAP_000037; Apo-Haloperidol; AC-19691; MLS001146904; KBio2_007526; Spectrum5_000788; Ulcolind; Prestwick2_000115; Bio-0705; Keselan; CID3559; NCGC00023875-06; D006220; Sernas; LNEPOXFFQSENCJ-UHFFFAOYSA-; NCGC00015500-14; C21H23ClFNO2; Aloperidon; C01814; Halol; NCGC00023875-05; Haldol La; HMS1920D03; Probes2_000296; S1920_Selleck; HSDB 3093; Halopal; Serenace; Eukystol; H 1512; CHEMBL54; Brotopon; QTL1_000042; Spectrum2_001268; Pekuces; Haloperido; NCGC00023875-02; SPBio_002069; BSPBio_002096; BSPBio_000130; KBio1_000654; haloperidol; KBio2_004958; Pms Haloperidol; Prestwick0_000115; R 1625; Aldo; Fortunan; SPBio_001236; KBio2_003909; KBioSS_001341; Halojust; Haloperidol (JP15/USP); L000288; Aloperidolo [DCIT]; Haloperidol (JP15/USP/INN); Mixidol; NCGC00016234-01	52-86-8	3559	148665	TTDS00012	D(2) dopamine receptor	Dopamine D2 receptor;Dopamine receptor 2	P14416	1813	ENSG00000149295	antagonist
DAP001421	Quinagolide hydrochloride	Sulfamide, N,N-diethyl-N'-(1,2,3,4,4a,5,10,10a-octahydro-6-hydroxy-1-propylbenzo(g)quinolin-3-yl)-, monohydrochloride, (3-alpha,4a-alpha,10a-beta)-; 94424-50-7; CID3086400; Quinagolide HCl; Quinagolide hydrochloride (BAN); Norprolac; D08457; (3S,4aS,10aR)-3-(diethylsulfamoylamino)-6-hydroxy-1-propyl-3,4,4a,5,10,10a-hexahydro-2H-benzo[g]quinoline hydrochloride; AC1MJ64G; Quinagolide hydrochloride; Norprolac (TN); CV-205502; SDZ-205502	94424-50-7	3086400	3889208	TTDS00012	D(2) dopamine receptor	Dopamine D2 receptor;Dopamine receptor 2	P14416	1813	ENSG00000149295	agonist
DCL000727	Blonanserin	AD-5423; D01176; 132810-10-7; CHEBI:400585; 2-(4-ethylpiperazin-1-yl)-4-(4-fluorophenyl)-5,6,7,8,9,10-hexahydrocycloocta[b]pyridine; MolPort-005-942-422; I14-8575; 2-(4-Ethyl-1-piperazinyl)-4-(p-fluorophenyl)-5,6,7,8,9,10-hexahydrocycloocta(b)pyridine; CHEMBL178803; Cycloocta(b)pyridine, 2-(4-ethyl-1-piperazinyl)-4-(4-fluorophenyl)-5,6,7,8,9,10-hexahydro-; AC-1599; 2-(4-Ethyl-1-piperazinyl)-4-(4-fluorophenyl)-5,6,7,8,9,10-hexahydrocycloocta(b)pyridine; Blonanserin [INN]; PDSP2_000710; Cycloocta(b)pyridine, 2-(4-ethyl-1-piperazinyl)-4-(1-fluorophenyl)-5,6,7,8,9,10-hexahydro-; Lonasen; AD 5423; LS-57714; PDSP1_000720; Blonanserin (JAN/INN); CID125564; Blonanserin; AC1L2OS5; AKOS005145823; L001392	132810-10-7	125564	12014539	TTDS00012	D(2) dopamine receptor	Dopamine D2 receptor;Dopamine receptor 2	P14416	1813	ENSG00000149295	antagonist
DCL000859	Lamectacin	N/A	111974-69-7	5002	48416505	TTDS00012	D(2) dopamine receptor	Dopamine D2 receptor;Dopamine receptor 2	P14416	1813	ENSG00000149295	antagonist
DPR000103	S32504	N/A	220932-72-9	N/A	N/A	TTDS00012	D(2) dopamine receptor	Dopamine D2 receptor;Dopamine receptor 2	P14416	1813	ENSG00000149295	agonist
DAP000847	Paliperidone	Invega; 9-Hydroxyrisperidone; 4H-Pyrido(1,2-a)pyrimidin-4-one, 3-(2-(4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl)ethyl)-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-; 1,2-Benzisoxazole, 4H-pyrido[1,2-a]pyrimidin-4-one deriv.; Paliperidone [INN]; CID115237; 130049-84-2; R-76477; AC1L3GS8; droxyrisperidone; 147687-18-1; Paliperidone; 4H-Pyrido(1,2-a)pyrimidin-4-one, 3-(2-(4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl)ethyl)-6,7,8-tetrahydro-9-hydroxy-2-methyl-; I14-1945; CHEBI:568656; CHEMBL1621; 144598-75-4; NCGC00186014-01; RO-76477; 4H-Pyrido[1,2-a]pyrimidin-4-one, 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-; 130049-86-4; UNII-838F01T721; DB01267; L023985; 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one; FT-0080561; 4H-Pyrido(2,1-a)pyrimidin-4-one, 6,7,8,9-tetrahydro-3-(2-(4-(6-fluro-1,2-benzisoxazol-3-yl)-1-piperidinyl)ethyl)-9-hydroxy-2-methyl-; AC-1282; 9-Hy; RO76477; (9RS)-3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidin-1-yl))ethyl)-9-hydroxy-2-methyl-6,7,8,9-tetrahydro-4H-pyrido(1,2-a)pyrimidin-4-one; LS-134195; R 76477; RO 76477	144598-75-4	115237	14905143	TTDS00012	D(2) dopamine receptor	Dopamine D2 receptor;Dopamine receptor 2	P14416	1813	ENSG00000149295	antagonist
DAP000029	Clozapine	Clozapine (JAN/USP/INN); Bio1_000925; Clozapine [USAN:INN:BAN]; NCGC00022902-04; NCGC00015254-01; 8-Chloro-11-(4-methyl)-1-piperazinyl)-5H-dibenzo[b,e][1,4]diazepine; W-801; AC1L1EJE; KBio3_000619; Spectrum4_000898; clozapine; KBioGR_000310; Iprox; Clozaril (TN); 8-chloro-11-(4-methylpiperazin-1-yl)-5H-dibenzo[b,e][1,4]diazepine; Asaleptin; KBio2_002878; Lopac-C-6305; KBioSS_000310; clozapine(tautomer); KBio2_005446; Bio1_000436; C6305_SIGMA; Tocris-0444; HSDB 6478; InChI=1/C18H19ClN4/c1-22-8-10-23(11-9-22)18-14-4-2-3-5-15(14)20-16-7-6-13(19)12-17(16)21-18/h2-7,12,20H,8-11H2,1H3; CPD000058365; HMS1989P12; 5786-21-0; NCGC00022902-09; C06924; BRN 0764984; SPBio_002340; Spectrum_000139; UNII-J60AR2IKIC; Bio2_000310; C18H19ClN4; Spectrum2_000919; 8-Chloro-11-(4-methyl-piperazin-1-yl)-5H-dibenzo[b,e][1,4]diazepine; HF1854; DB00363; SAM002548976; QZUDBNBUXVUHMW-UHFFFAOYSA-; Clozapinum [INN-Latin]; Prestwick_693; CHEBI:3766; SPBio_000798; KBio2_000310; Bio1_001414; HF-1854; AC1Q3ZWP; D00283; Fazaclo; Lepotex; HMS501B05; Clorazil; AC-280; NCGC00022902-05; Leponex; CCRIS 9171; NCGC00015254-17; FT-0082373; Clozapina [INN-Spanish]; SPECTRUM1500685; CLOZARIL; I06-0047; KBio2_005735; 8-Chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo (b,e)(1,4)diazepine; KBio3_000620; NCGC00015254-02; HMS1569E21; KBio2_000599; NCGC00022902-02; NCGC00015254-03; CID2818; CAS-5786-21-0; NCGC00022902-07; DivK1c_000343; AKOS005064444; KBio2_003167; HMS2092I16; C 6305; MolPort-001-728-041; MLS001077282; MLS000028472; AC1Q3OPZ; HMS1791P12; KS-1166; Clozapinum; Fazaclo ODT; EINECS 227-313-7; NCGC00022902-13; NCGC00022902-06; Clozapina; 5H-Dibenzo(b,e)(1,4)diazepine, 8-chloro-11-(4-methyl-1-piperazinyl)-; D003024; NCGC00015254-07; Bio2_000790; LX 100-129; Clozapin; CHEMBL42; NCGC00022902-10; S2459_Selleck; NCGC00022902-11; L013417; 3-chloro-6-(4-methylpiperazin-1-yl)-5H-benzo[b][1,4]benzodiazepine; NCGC00022902-08; LS-60881; L000195; 8-Chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo(b,e)(1,4)diazepine; AR-1I2412; 8-Chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo[b,e][1,4]-diazepine; SMR000058365; EU-0100276; KBio3_002979; KBioSS_000599; KBioGR_001336; HMS1921C16; KBio1_000343; Prestwick1_000350; Prestwick0_000350; HMS1361P12; 5H-Dibenzo[b,e][1,4]diazepine, 8-chloro-11-(4-methyl-1-piperazinyl)-; NINDS_000343; Spectrum3_001828; LEX-123; HMS2089L13; BRD-K37289225-001-09-1	5786-21-0	2818	7847349	TTDS00012	D(2) dopamine receptor	Dopamine D2 receptor;Dopamine receptor 2	P14416	1813	ENSG00000149295	antagonist
DCL000056	AT-101	Isosorbide (JP15/USP/INN); 1,4:3,6-dianhydrohexitol; Sorbid; CHEMBL1200660; Bio-0643; 50974-60-2; NCGC00160508-01; 1,4:3,6-Dianhydro-D-sorbitol; Isosorbida [INN-Spanish]; EINECS 211-492-3; Vascardin dinitrate; BRN 0080510; 652-67-5; Glucitol, 1,4:3,6-dianhydro-, D-; Oprea1_439690; Ismotic (TN); 2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3,6-diol; AC1Q79SL; 42750-75-4; Isosorbide [USAN:INN:BAN:JAN]; TL8004635; 67803-92-3; STK801813; I0407; HSDB 3105; AC1L4190; Isobide; SMP1_000177; EINECS 248-906-7; AR-1B7417; NSC 40725; EINECS 211-374-1; BIDD:GT0695; Devicoran; 49871-92-3; Isosorbidum [INN-Latin]; D-Sorbitol, 1,4:3,6-dianhydro(furo[3,2-b]furan-3,6-diol, hexahydro-); 24332-71-6; MolPort-001-783-404; I14-6752; 1,4:3,6-Dianhydroglucitol; LS-71370; Isobide (TN); NSC40725; D00347; UNII-WXR179L51S; D-Glucitol, 1,4:3,6-dianhydro-; D-Sorbitol, {1,4:3,6-dianhydro(furo[3,2-b]furan-3,6-diol,} hexahydro-); LS-89261; Hydronol; Sorbitol, 1,4:3,6-dianhydro-; Isosorbidum; 1,4:3,6-Dianhydromannitol; 151380-60-8; A912284D-27E1-4FB0-91B8-86C8AB905297; 5-19-03-00201 (Beilstein Handbook Reference); 641-74-7; NSC270938; 152881-21-5; Hydronol (VAN); Isomannide; D-1,4:3,6-Dianhydroglucitol; isosorbide; 1,4:3,6-Dianhydro-D-glucitol; (3S,3aR,6R,6aR)-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3,6-diol; Ismotic; (+)-D-Isosorbide; AT-101; CID99937; AC1L1ZXO; Dianhydrosorbitol; D-Mannitol, 1,4:3,6-dianhydro-; KST-1B7297; CID12597; AT 101; ZINC18284778; Isosorbida; D-Glucitol, 1,4:3,6-dianhydro-; 28218-68-0; MolPort-000-812-960; Mannitol, 1,4:3,6-dianhydro-; NSC231906; Dianhydro-D-glucitol; 1,4:3,6-Dianhydrosorbitol; 1,4-Dianhydrosorbitol	652-67-5	12597	26683984	TTDC00168	Antiapoptotic protein BCL-XL	Bcl-XL	Q07817	598	ENSG00000171552	inhibitor
DCL000415	ABT-263	Navitoclax; ABT 263; 1000696-69-4; 923564-51-6; Benzamide, 4-(4-((2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohexen-1-yl)methyl)-1-piperazinyl)-N-((4-(((1R)-3-(4-morpholinyl)-1-((phenylthio)methyl)propyl)amino)-3-((trifluoromethyl)sulfonyl)phenyl)sulfonyl)-; CHEMBL443684; CHEBI:608147; ABT263, Navitoclax; I06-2050; S1001_Selleck; BRD-K82746043-001-03-7; BRD-K82746043-001-02-9; MolPort-006-391-499; 4-(4-{[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({4-({(1R)-3-morpholin-4-yl-1-[(phenylsulfanyl)methyl]propyl}amino)-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)benzamide; BRD-K82746043-001-01-1; ABT-263	119229-65-1	3081185	44854467	TTDC00168	Antiapoptotic protein BCL-XL	Bcl-XL	Q07817	598	ENSG00000171552	inhibitor
DAP000492	Pirenzepine	KBioGR_000794; Prestwick1_000129; NCGC00024297-05; MolPort-002-673-624; NCGC00015836-09; Spectrum2_001417; Gasteril; L-S 519; Pirenzepina; KBio3_002445; Prestwick2_000129; Spectrum3_001453; Pirenzepine (INN); Pirenzepinum; KBio2_004426; Lopac-P-7412; DB00670; Prestwick3_000129; 6H-Pyrido(2,3-b)(1,4)benzodiazepin-6-one, 5,11-dihydro-11-((4-methyl-1-piperazinyl)acetyl)-; KBio2_001858; NCGC00024297-04; LS-133128; AC1L1J3B; DivK1c_000127; Bio-0807; Prestwick0_000129; Pirenzepine [INN:BAN]; Ulcosan; Gastrozepin; NCGC00015836-01; D08389; Pirenzepinum [INN-Latin]; L000485; NCGC00015836-02; AB00053603; NCGC00024297-02; 28797-61-7; BSPBio_000178; CHEBI:8247; UNII-3G0285N20N; KBio2_006994; Pyrenzepine; SPBio_001494; KBio1_000127; IDI1_000127; EINECS 249-228-4; PDSP1_000965; NINDS_000127; BPBio1_000196; HMS2089K21; Spectrum4_000437; Pirenzepine Gastrozepin; 11-[(4-methylpiperazin-1-yl)acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one; Gastrotsepin; 11-((4-Methyl-1-piperazinyl)acetyl)-5,11-dihydro-6H-pyrido(2,3-b)(1,4)benzodiazepin-6-one; 6H-Pyrido[2,3-b][1,4]benzodiazepin-6-one, 5,11-dihydro-11-[(4-methyl-1-piperazinyl)acetyl]-; NCGC00015836-03; Tocris-1071; C07508; Pirenzepina [INN-Spanish]; CID4848; CHEMBL9967; Spectrum5_001344; 5,11-Dihydro-11-((4-methyl-1-piperazinyl)acetyl)-6H-pyrido(2,3-b)(1,4)benzodiazepin-6-one; 11-[2-(4-methylpiperazin-1-yl)acetyl]-5H-pyrido[2,3-b][1,4]benzodiazepin-6-one; PDSP2_000949; Pirenzepin; Lopac0_000962; BRN 0628987; BSPBio_002945; Spectrum_001378; KBioSS_001858; BRD-K89375097-300-05-4; C19H21N5O2; SPBio_002117; pirenzepine; CAS-29868-97-1	28797-61-7	4848	9711	TTDS00002	Muscarinic acetylcholine receptor M1	M1 receptor	P11229	1128	ENSG00000168539	antagonist
DAP001122	Trihexyphenidyl	Apo-Trihex; Spectrum_000632; Artane Sequels; C20H31NO; Spectrum4_000369; 1-Piperidinepropanol, alpha-cyclohexyl-alpha-phenyl-; CHEMBL1490; KBio2_001112; Triphenidyl; 144-11-6; Trihexifenidilo [INN-Spanish]; DivK1c_000372; Prestwick2_000701; AC1L1KNB; Trihexy; Trihexyphenidyle [INN-French]; Oprea1_853391; NCGC00016003-06; KBioSS_001112; 52-49-3 (hydrochloride); BPBio1_000971; BRN 0088959; KBio2_003680; Trihexylphenizyl; Prestwick1_000701; SPBio_002802; C07171; Prestwick3_000701; Spectrum3_001375; Spectrum5_001465; Trihexyphenidylum; SPBio_000757; Benzhexol; IDI1_000372; 1-Piperidinepropanol, .alpha.-cyclohexyl-.alpha.-phenyl-; D08638; Benzhexolum; 5-20-02-00231 (Beilstein Handbook Reference); BSPBio_002930; MolPort-001-783-510; DB00376; NINDS_000372; KBio3_002150; Trihexyphenidylum [INN-Latin]; Lopac0_001125; 1-cyclohexyl-1-phenyl-3-piperidin-1-ylpropan-1-ol; PMS Trihexyphenidyl; UNII-6RC5V8B7PO; BRD-A48180038-003-05-2; NCGC00089797-02; AB00053559; KBio1_000372; NSC12268; Trihexyphenidyl [INN:BAN]; CID5572; KBioGR_000837; KBio2_006248; LS-116010; Parkinane retard; NSC 12268; L000821; BSPBio_000881; Trihexane; Apo-trihex (TN); Trihexylphenidyl; trihexyphenidyl; EINECS 205-614-4; Trihexyphenidyl (INN); Trihexylphenidyle; Trihexyphenidyle; HSDB 3196; Prestwick0_000701; Spectrum2_000829; Trihexifenidilo; Sedrena (free base)	144-11-6	5572	9380	TTDS00002	Muscarinic acetylcholine receptor M1	M1 receptor	P11229	1128	ENSG00000168539	antagonist
DCL000279	Sabcomeline hydrochloride	Sabcomeline hydrochloride; 1-Azabicyclo(2.2.2)octane-3-acetonitrile, alpha-(methoxyimino)-, monohydrochloride, (R-(Z))-; 159912-58-0; CEB-2424; Memric; Sabcomeline HCl; BRL-55473; CID9577994; SB-202026A; SB 202026A	159912-58-0	9816017	47207440	TTDS00002	Muscarinic acetylcholine receptor M1	M1 receptor	P11229	1128	ENSG00000168539	agonist
DAP001123	Propantheline	Spectrum4_000973; (2-Hydroxyethyl)diisopropylmethylammonium bromide xanthene-9-carboxylate bromide; P 8891; Ercorax; SPBio_002674; Prestwick2_000827; BPBio1_000829; Kivatin; KBio3_001764; UNII-1306V2B0Q8; SAM002554922; L001263; AC1L1SQ1; Propantheline bromide (JP15/USP/INN); Ammonium, (2-hydroxyethyl)diisopropylmethyl-, xanthene-9-carboxylate (ester); propantheline; Pantas; C23H30NO3; Spectrum5_001076; 2-Hydroxyethyl]diisopropylmethyl- ammonium bromide xanthene-9-carboxylate; C07506; DivK1c_000802; NCGC00015854-02; Bromuro de proantelina [INN-Spanish]; Lopac-P-8891; PROPANTHELINE BROMIDE; KBio2_001350; Propanthelini bromidum; CHEMBL1240; Propantel; Prestwick_241; AC-13428; HSDB 3174; Corrigast; Prestwick0_000827; HMS1570F15; Ammonium, diisopropyl(2-hydroxyethyl)methyl-, bromide, xanthene-9-carboxylate; KBioGR_001345; TL8003337; NCGC00094306-03; HMS2092C19; BSPBio_002436; NCGC00021543-03; 298-50-0; NCI-C56257; KBio1_000802; KBio2_003918; Neometantyl; NCGC00094306-01; AB00053808; Pervagal; SPECTRUM1500511; HMS1920L18; NCGC00094306-02; MolPort-003-666-273; AC1L1J9G; Propanthelinium; KBio2_006486; IDI1_000802; CPD000058661; 2-Propanaminium, N-methyl-N-(1-methylethyl)-N-(2-((9H-xanthen-9-ylcarbonyl)oxy)ethyl)-, bromide (1:1); Propanthelini bromidum [INN-Latin]; Probanthine; KBioSS_001350; CAS-50-34-0; ZINC01530761; (2-Hydroxyethyl)diisopropylmethylammonium bromide xanthene-9-carboxylate; NCGC00094306-04; Prodixamon; SC-3171; Pro-Gastron; Ercotina; EU-0101014; Propantelina bromuro [DCIT]; CCRIS 6271; Bromuro de proantelina; BSPBio_000753; DB00782; LS-1304; CID4934; Propantelina bromuro; Xanthene-9-carboxylic acid, ester with (2-hydroxyethyl)diisopropylmethylammonium bromide; UNII-UX9Z118X9F; 2-Propanaminium, N-methyl-N-(1-methylethyl)-N-(2-((9H-xanthen-9-ylcarbonyl)oxy)ethyl)-, bromide; ST51052930; EINECS 200-030-6; Lopac0_001014; Propanthelinum; NINDS_000802; Ketaman; Propanthel; LS-174268; NCGC00016219-01; Propantheline bromide [USAN:INN:BAN:JAN]; MLS000028703; CID9279; Spectrum2_001300; methyl-di(propan-2-yl)-[2-(9H-xanthene-9-carbonyloxy)ethyl]azanium; NCGC00015854-01; Spectrum3_000882; NCGC00015854-07; Pantheline; D00481; Prestwick1_000827; Bromure de propantheline [INN-French]; Bromure de propantheline; SPBio_001339; 2-Propanaminium, N-methyl-N-(1-methylethyl)-N-(2-((9H-xanthen-9-ylcarbonyl)oxy)ethyl)-; Pro-Banthine (TN); Spectrum_000870; methyl-di(propan-2-yl)-[2-(9H-xanthene-9-carbonyloxy)ethyl]azanium bromide; Probantine; Prestwick3_000827; HMS502I04; N-methyl-N-(1-methylethyl)-N-{2-[(9H-xanthen-9-ylcarbonyl)oxy]ethyl}propan-2-aminium bromide; NCGC00094306-05; Pro-Banthine; Diisopropyl(2-hydroxyethyl)methylammonium bromide xanthene-9-carboxylate; SMR000058661; Neopepulsan; 50-34-0; MLS001333690; MLS001076547; EINECS 206-063-2	298-50-0	4934	9709	TTDS00002	Muscarinic acetylcholine receptor M1	M1 receptor	P11229	1128	ENSG00000168539	antagonist
DAP001116	Glycopyrrolate	Robinal; GLYCOPYRROLATE; NCGC00179456-01; AC1LAW54; Bromure de glycopyrronium [INN-French]; Bromuro de glicopirronio; Pyrrolidinium, 1,1-dimethyl-3-hydroxy-, bromide, alpha-cyclopentylmandelate; UNII-V92SO9WP2I; Bromure de glycopyrronium; Cuvposa; Pyrrolidinium, 3-hydroxy-1,1-dimethyl-, bromide, alpha-cyclopentylmandelate (8CI); Glycopyrronii bromidum; C19H28NO3; Glycopyrrolate bromide; 3-Hydroxy-1,1-dimethylpyrrolidinium bromide alpha-cyclopentylmandelate; Ritropirronium bromide; AR-1J1255; AC1Q1RGS; 1-Methyl-3-pyrrolidinyl .alpha.-phenylcyclopentaneglycolate methobromide; Ritropirronium bromide [INN]; CID521843; SPBio_002671; NSC 251252; Pyrrolidinium, 3-hydroxy-1,1-dimethyl-, bromide, .alpha.-cyclopentylmandelate; BSPBio_000732; ROBINUL FORTE; Bromuro de glicopirronio [INN-Spanish]; Glycopyrronium; Robinul (TN); Prestwick2_000746; glycopyrronium bromide; CHEMBL1201027; 53808-86-9; Robanul; Glycopyrroni bromidum; HMS2094A05; 3-Hydroxy-1,1-dimethylpyrrolidinium bromide .alpha.-cyclopentylmandelate; Gastrodyn; NSC 251251; Tarodyn; 3-(erythro-2-Cyclopentyl-2-hydroxy-2-phenylacetoxy)-1,1-dimethylpyrrolidiniumbromid; AC1L1G28; MolPort-002-885-831; Prestwick0_000746; (1,1-dimethylpyrrolidin-1-ium-3-yl) 2-cyclopentyl-2-hydroxy-2-phenylacetate; I14-3643; .beta.-1-Methyl-3-pyrrolidyl-.alpha.-cyclopentylmandelate methobromide; NSC251251; 596-51-0; CPD000469282; Pyrrolidinium, 3-[(cyclopentylhydroxyphenylacetyl)oxy]-1,1-dimethyl-, bromide; Tarodyl; NVA-237; NSC251252; Robinul; HMS1570E14; 1,1-Dimethyl-3-hydroxypyrrolidinium bromide .alpha.-cyclopentylmandelate; Copyrrolate; NSC 250836; 1-Methyl-3-pyrrolidyl alpha-phenylcyclopentaneglycolate methobromide; Asecryl; L001045; Glycopyrrolate [USAN]; Pyrrolidinium, 3-((cyclopentylhydroxyphenylacetyl)oxy)-1,1-dimethyl-, bromide; Bromure de ritropirronium; 3-Hydroxy-1,1-dimethylpyrrolidinium bromide-.alpha.-cyclopentylmandelate; AC1L1XX0; AC1Q60WT; Salt*); DB00986; Glycopyrrolate (USP); Prestwick1_000746; D00540; AHR 504; SMR000469282; CID3494; EINECS 209-887-0; MLS002222301; Glycopyrronium bromide (JAN/INN); NSC250836; Mandelic acid, .alpha.-cyclopentyl-, ester with 3-hydroxy-1,1-dimethylpyrrolidinium bromide; WLN: T5KTJ A1 A1 COVXQR&- AL5TJ &Q &E; .Beta.-1-Methyl-3-pyrrolidyl-.alpha.-cyclopentylmandelate methobromide; Pyrrolidinium, 3-hydroxy-1,1-dimethyl-, bromide, .alpha.-cyclopentylmandelate; CHEMBL1201335; LS-138344; SAM002589987; HMS2051P12; AC-15990; Prestwick3_000746; AB00513912; Bromure de ritropirronio; PT-001; (1,1-dimethylpyrrolidin-1-ium-3-yl) 2-cyclopentyl-2-hydroxy-2-phenylacetate bromide; Glycopyrronii bromidum [INN-Latin]; NVA 237; 1,1-Dimethyl-3-hydroxypyrrolidinium bromide alpha-cyclopentylmandelate; Pyrrolidinium, 3-hydroxy-1,1-dimethyl-, bromide, alpha-cyclopentylmandelate; Nodapton; AD-237; CID11693; AHR-504; SAM001246629; BPBio1_000806; MLS001424112; ST51054976	596-51-0	3494	794728	TTDS00002	Muscarinic acetylcholine receptor M1	M1 receptor	P11229	1128	ENSG00000168539	antagonist
DCL000402	GSK1034702	N/A	211110-63-3	9862248	45284526	TTDS00002	Muscarinic acetylcholine receptor M1	M1 receptor	P11229	1128	ENSG00000168539	agonist
DCL000957	Revatropate	[(3R)-1-azabicyclo[2.2.2]octan-3-yl] (2R)-2-(hydroxymethyl)-4-methylsulfinyl-2-phenylbutanoate; CID3035836; CID6918246; UK-112166; CID9690123; UNII-3W7L15V40W; AC1OCF7F; CID9554797; AC1MI026; UK-112,166; [(3R)-1-azabicyclo[2.2.2]octan-3-yl] (2S)-2-(hydroxymethyl)-4-methylsulfinyl-2-phenylbutanoate; Revatropate; Benzenacetic acid, alpha-(hydroxymethyl)-alpha-(2-(methylsulfinyl)ethyl)-, 1-azabicyclo(2.2.2)oct-3-yl ester, (3R-(3R*(S*(R*))))-; (3R-(3R*(S*(R*))))-1-Azabicyclo(2.2.2)oct-3-yl alpha-(hydroxymethyl)-alpha-(2-(methylsulfinyl)ethyl)benzenacetate; UK-112166-04; 149926-91-0	149926-91-0	9690123	12014788	TTDS00002	Muscarinic acetylcholine receptor M1	M1 receptor	P11229	1128	ENSG00000168539	antagonist
DCL000303	Talsaclidine fumarate	(E)-but-2-enedioic acid; 3-prop-2-ynoxy-1-azabicyclo[2.2.2]octane; 1-Azabicyclo(2.2.2)octane, 3-(2-propynyloxy)-, (R)-, (E)-2-butenedioate (1:1); CID6439491; D06000; Talsaclidine fumarate; 147025-54-5; AC1O5RRZ; 3-(2-Propynyloxy)-1-azabicyclo(2.2.2)octane 2-butenedioate; Talsaclidine fumarate (USAN); Wal 2014 FU	147025-54-5	6439491	47207658	TTDS00002	Muscarinic acetylcholine receptor M1	M1 receptor	P11229	1128	ENSG00000168539	agonist
DAP001125	Biperiden	1235-82-1 (hydrochloride); 5-Norbornene-2-methanol, alpha-phenyl-alpha-(2-piperidinoethyl)-; 1-Piperidinepropanol, alpha-bicyclo(2.2.1)hept-5-en-2-yl-alpha-phenyl-; Beperiden; alpha-5-Norbornen-2-yl-alpha-phenyl-1-piperidinepropanol; 1-PIPERIDINEPROPANOL, alpha-5-NORBORNEN-2-YL-alpha-PHENYL-; Biperidene hydrochloride; HMS2093N17; alpha-Bicyclo(2.2.1)hept-5-en-2-yl-alpha-phenyl-1-piperidinepropanol; 1-Bicycloheptenyl-1-phenyl-3-piperidino-propanol-1; D00779; Biperideno [INN-Spanish]; LS-116068; 514-65-8; Biperidenum; MolPort-003-666-707; HSDB 7639; Akineton (TN); PDSP2_000808; EINECS 208-184-6; Biperiden [USAN:INN:BAN:JAN]; AC1L1DJT; 1-Piperidinepropanol, .alpha.-bicyclo[2.2.1]hept-5-en-2-yl-.alpha.-phenyl-; UNII-0FRP6G56LD; Biperidine; Biperiden (JAN/USP/INN); 3-Piperidino-1-phenyl-1-bicycloheptenyl-1-propanol; Biperidene [INN-French]; 1-(Bicyclo(2.2.1)hept-5-en-2alpha-yl)-1-phenyl-3-piperidinopropanol; Biperideno; Prestwick1_000502; L001222; PDSP1_000821; alpha-bicyclo[2.2.1]hept-5-en-2-yl-alpha-phenyl-1-piperidinepropanol; KL 373; DB00810; Akineton; NCGC00182965-02; 3-Piperidino-1-phenyl-1-bicyclo(2.2.1)hepten-(5)-yl-propanol-(1); 3-Piperidino-1-phenyl-1-bicyclo(2.2.1)hepten-(5)-yl-propanol-(1) [German]; BRN 0290038; 1-(5-bicyclo[2.2.1]hept-2-enyl)-1-phenyl-3-piperidin-1-ylpropan-1-ol; Prestwick2_000502; CHEMBL1101; C07941; Prestwick0_000502; CID2381; CHEBI:3112; Biperidenum [INN-Latin]; alpha-(Bicyclo(2.2.1)hept-5-en-2-yl)-alpha-phenyl-1-piperidino propanol; Biperidene; 1-Piperidinepropanol, .alpha.-bicyclo[2.2.1]hept-5-en-2-yl-.alpha.-phenyl-, hydrochloride; SPBio_002344; NCIOpen2_009564; Biperiden [USAN:BAN:INN:JAN]; 5-20-02-00242 (Beilstein Handbook Reference); 1-(bicyclo[2.2.1]hept-5-en-2-yl)-1-phenyl-3-(piperidin-1-yl)propan-1-ol; biperiden	514-65-8	2381	153864	TTDS00002	Muscarinic acetylcholine receptor M1	M1 receptor	P11229	1128	ENSG00000168539	antagonist
DAP001120	Cycrimine	1-Phenyl-1-cyclopentyl-3-piperidino-1-propanol; 1-cyclopentyl-1-phenyl-3-piperidin-1-ylpropan-1-ol; (+-)-cycrimine; UNII-543567RFQQ; Pagitane; CHEBI:59692; alpha-Cyclopentyl-alpha-phenyl-1-Piperidinepropanol; DB00942; 1-Piperidinepropanol, .alpha.-cyclopentyl-.alpha.-phenyl-; 77-39-4; AC1L1ER2; AC1Q76Z6; LS-187213; Cycriminum; EINECS 201-024-6; 107661-05-2; cycrimine; AC1Q77DQ; 1-cyclopentyl-1-phenyl-3-(piperidin-1-yl)propan-1-ol; Cicrimina; AR-1K9623; Cicrimina [INN-Spanish]; L000920; CID2911; Cycriminum [INN-Latin]; 1-Piperidinepropanol, alpha-cyclopentyl-alpha-phenyl-	77-39-4	2911	10535560	TTDS00002	Muscarinic acetylcholine receptor M1	M1 receptor	P11229	1128	ENSG00000168539	binder
DCL000515	Darotropium + 642444	N/A	N/A	N/A	N/A	TTDS00002	Muscarinic acetylcholine receptor M1	M1 receptor	P11229	1128	ENSG00000168539	agonist
DAP001121	Benztropine	Benzatropine; Cogentinol; BSPBio_001912; Pms Benztropine; AC1L9B14; CHEMBL32104; 3alpha-(Diphenylmethoxy)-1alphaH,5alphaH-tropane; NCGC00162087-02; 8-Azabicyclo(3.2.1)octane, 3-(diphenylmethoxy)-8-methyl-, endo- (9CI); (5R)-3-benzhydryloxy-8-methyl-8-azabicyclo[3.2.1]octane; C06846; 1-alpha-H,5-alpha-H-Tropane, 3-alpha-(diphenylmethoxy)-; (3-endo)-3-[(diphenylmethyl)oxy]-8-methyl-8-azabicyclo[3.2.1]octane; AC1Q57W9; Cogentine; Benzatropinum; 92498-18-5; KBio3_001412; Benzhydryl 8-methyl-8-azabicyclo[3.2.1]oct-3-yl ether; Benzatropine mesilate; AR-1A1320; NCGC00159471-02; NK 02; L000767; 1alphaH,5alphaH-tropane, 3alpha-(diphenylmethoxy)-; KBioGR_000682; AC1Q3ZKJ; CHEBI:3048; Apo-Benztropine; CID441353; Spectrum_000078; STK931885; Benztropinum; Lopac0_000194; Benzatropina [INN-Spanish]; (1R,5R)-3-benzhydryloxy-8-methyl-8-azabicyclo[3.2.1]octane; Spectrum5_000884; 3alpha-benzhydryloxy-8-methyl-8-azabicyclo[3.2.1]octane; KBio2_005614; NCGC00162087-01; AR-1E7616; AC1L1NEG; 3endo-benzhydryloxytropane; KBioSS_000478; SPBio_000092; Spectrum3_000316; NCGC00162087-03; Spectrum4_000251; benztropine; CID2344; CID1201549; DivK1c_000523; KBio1_000523; IDI1_000523; Benzatropine [INN]; 8-Azabicyclo(3.2.1)octane, 3-(diphenylmethoxy)-8-methyl-, endo-; KBio2_003046; Benzatropina; DB00245; Spectrum2_000106; NCIOpen2_008292; NCI60_003960; Cobrentin; C21H25NO; CID6832; AC1Q57ZM; 86-13-5; 3-benzhydryloxy-8-methyl-8-azabicyclo[3.2.1]octane; HSDB 3014; Tropine benzohydryl ether; Benzatropinum [INN-Latin]; Akitan; KBio2_000478; (1r,5r)-3-(diphenylmethoxy)-8-methyl-8-azabicyclo[3.2.1]octane; 3alpha-(diphenylmethoxy)tropane; Benzatropine [INN:BAN]; AC1L1DGX; Benzatropine (INN); AC1Q3XL3; D07511; Oprea1_754774; NINDS_000523; 8-Azabicyclo[3.2.1]octane, 3-(diphenylmethoxy)-8-methyl-, endo-; MolPort-001-792-508; UNII-1NHL2J4X8K; 3-(diphenylmethoxy)-8-methyl-8-azabicyclo[3.2.1]octane; KST-1A8933; (3-endo)-3-(diphenylmethoxy)-8-methyl-8-azabicyclo[3.2.1]octane; LS-157780	86-13-5	6832	9064	TTDS00002	Muscarinic acetylcholine receptor M1	M1 receptor	P11229	1128	ENSG00000168539	antagonist
DAP001118	Dicyclomine	KBioGR_001057; LS-177325; L000680; Spectrum_000934; Dicycloverine [INN:BAN]; BRD-K68507560-003-05-5; Procyclomin; EINECS 201-009-4; Spectrum2_000590; GU8471000; BSPBio_002175; InChI=1/C19H35NO2/c1-3-20(4-2)15-16-22-18(21)19(13-9-6-10-14-19)17-11-7-5-8-12-17/h17H,3-16H2,1-2H3; 2-(diethylamino)ethyl 1-cyclohexylcyclohexane-1-carboxylate; Atumin; [1,1'-Bicyclohexyl]-1-carboxylic acid, 2-(diethylamino)ethyl ester; KBio2_003982; NCGC00015368-02; Dicymine; Wyovin; LS-56640; 104959-55-9; Diocyl hydrochloride; Dicycloverinum; KBio2_006550; Lopac0_000432; Dicycloverine; 67-92-5 (hydrochloride); D07820; .beta.-Diethylaminoethyl 1-cyclohexylcyclohexanecarboxylate hydrochloride; CHEMBL1123; DivK1c_000162; AC1L1F1K; BPBio1_000193; Prestwick2_000048; NSC404381; Kolantyl hydrochloride; Bicyclohexyl-1-carbonsaeure-2'diethylaminoethylester; [Bicyclohexyl]-1-carboxylic acid, 2-(diethylamino)ethyl ester hydrochloride; 2-diethylaminoethyl 1-cyclohexylcyclohexane-1-carboxylate hydrochloride; [Bicyclohexyl]-1-carboxylic acid, 2- (diethylamino)ethyl ester hydrochloride; MolPort-001-832-617; 2-(diethylamino)ethyl 1,1'-bi(cyclohexyl)-1-carboxylate; NCGC00015368-08; Spectrum5_000873; Sawamin; NCGC00015368-01; Di-syntramine; Dicyclomine Hcl; Spectrum3_000388; Diocyl; Formulex; KBioSS_001414; 2-diethylaminoethyl 1-cyclohexylcyclohexane-1-carboxylate; .beta.-Diethylaminoethyl-1-cyclohexylhexahydrobenzoate hydrochloride; CURUTKGFNZGFSE-UHFFFAOYSA-; C06951; 77-19-0; Dicycloverine (INN); Dicicloverina [INN-Spanish]; KBio3_001395; SPBio_002096; IDI1_000162; T472; CHEBI:265774; 1-Cyclohexylcyclohexanecarboxylic acid 2-(diethylamino)ethyl ester; Cyclohexanecarboxylic acid, 1-cyclohexyl-, 2-(diethylamino)ethyl ester; NINDS_000162; CAS-67-92-5; Bentylol hydrochloride; WLN: L6TJ A- AL6TJ AVO2N2&2 &GH; Spasmoban; Wyovin hydrochloride; Prestwick1_000048; Diethylaminocarbethoxybicyclohexyl hydrochloride; NCGC00016300-01; CHEBI:4514; HSDB 3058; (1,1'-Bicyclohexyl)-1-carboxylic acid, 2-(diethylamino)ethyl ester; Dicycloverin; BSPBio_000175; NCGC00024386-03; Dyspas; Oxityl-P; AC1Q2ZDW; Bentyl hydrochloride; KBio1_000162; Mamiesan; Dicicloverina; (Bicyclohexyl)-1-carboxylic acid, 2-(diethylamino)ethyl ester; dicyclomine; Dicycloverinum [INN-Latin]; Dicymine (TN); AB00053456; Prestwick0_000048; 856995-49-8; Merbentyl; Bentylol; SPBio_000440; Bentomine; Lopac-D-7909; Prestwick3_000048; DB00804; UNII-4KV4X8IF6V; CID3042; AC1Q2ZDX; Spectrum4_000509; J.L. 998; (BICYCLOHEXYL)-1-CARBOXYLIC ACID, 2-(DIETHYLAMINO)ETHYL ESTER, HYDROCHLORIDE; KBio2_001414; NIOSH/GU8471000; Dicycloverin hydrochloride; C19H35NO2	77-19-0	3042	9166	TTDS00002	Muscarinic acetylcholine receptor M1	M1 receptor	P11229	1128	ENSG00000168539	antagonist
DCL000514	Darotropium	N/A	189261-10-7	N/A	49661786	TTDS00002	Muscarinic acetylcholine receptor M1	M1 receptor	P11229	1128	ENSG00000168539	agonist
DAP001124	Oxyphenonium	oxyphenonium; Spastrex; 50-10-2 (bromide); UNII-D2G5508Y7I; EINECS 215-801-2; STOCK1S-44852; Methocidinum; Methacin; Methocidin [DCF:INN]; AC1L1L1W; 2-(2-cyclohexyl-2-hydroxy-2-phenylacetyl)oxyethyl-diethyl-methylazanium; MolPort-001-955-093; Atrenyl; Methocidine; Ethanaminium, 2-((cyclohexylhydroxyphenylacetyl)oxy)-N,N-diethyl-N-methyl-; 2-[2-cyclohexyl(hydroxy)phenylacetoxy]-n,n-diethyl-n-methylethanaminium; 2-((Cyclohexylhydroxyphenylacetyl)oxy)-N,N-diethyl-N-methylethanaminium; [2-(2-Cyclohexyl-2-hydroxy-2-phenyl-acetoxy)-ethyl]-diethyl-methyl-ammonium; Oxyphenonium Chloride; Metocidina; Hydroxymethylgramicidin; Oxiphenonum; Methocidine [INN-French]; Oxyphenonium Iodide; L000855; LS-173137; C21H34NO3; AKOS000510119; Metocidina [INN-Spanish]; CID5749; Methocidinum [INN-Latin]; BAS 01095672; Methocidin; 1407-05-2; Argicillin; AC1Q65RG; DB00219; AR-1D6728	50-10-2	5749	169280	TTDS00002	Muscarinic acetylcholine receptor M1	M1 receptor	P11229	1128	ENSG00000168539	antagonist
DAP001117	Clidinium	Spectrum2_000124; C07853; DivK1c_000698; BSPBio_000743; Prestwick0_000822; KBio2_000636; Benzilic acid, ester with 3-hydroxy-1-methylquinuclidinium; KBio1_000698; UNII-BO76JF850N; 7020-55-5; Prestwick3_000822; AC1L1EGK; MolPort-003-845-977; Prestwick1_000822; KBioGR_000842; AB00053797; SPBio_000168; Spectrum3_000354; (1-methyl-1-azoniabicyclo[2.2.2]octan-3-yl) 2-hydroxy-2,2-diphenylacetate; NINDS_000698; N-Methyl quinuclidinyl benzilate; 3-{[hydroxy(diphenyl)acetyl]oxy}-1-methyl-1-azoniabicyclo[2.2.2]octane; IDI1_000698; Spectrum4_000291; Prestwick2_000822; Spectrum5_001529; clidinium; CID2784; KBio2_003204; L001027; KBio3_001267; BPBio1_000819; DB00771; 1-Azoniabicyclo(2.2.2)octane, 3-((hydroxydiphenylacetyl)oxy)-1-methyl-; Spectrum_000156; CHEBI:3743; 3-hydroxy-1-methylquinuclidinium benzilate ester; BSPBio_002047; 3-Hydroxy-1-methylquinuclidinium benzilate (ester); 3485-62-9 (bromide); Quinuclidinium, 3-hydroxy-1-methyl-, benzilate (ester); CHEMBL620; SPBio_002664; KBio2_005772; KBioSS_000636	7020-55-5	2784	10055	TTDS00002	Muscarinic acetylcholine receptor M1	M1 receptor	P11229	1128	ENSG00000168539	antagonist
DCL000381	GSK573719	N/A	N/A	N/A	N/A	TTDS00002	Muscarinic acetylcholine receptor M1	M1 receptor	P11229	1128	ENSG00000168539	agonist
DCL000397	GSK961081	N/A	38398-32-2	6918305	47206230	TTDS00002	Muscarinic acetylcholine receptor M1	M1 receptor	P11229	1128	ENSG00000168539	agonist
DCL000268	Talsaclidine isomer	N/A	129508-81-2	71792	44924736	TTDS00002	Muscarinic acetylcholine receptor M1	M1 receptor	P11229	1128	ENSG00000168539	agonist
DAP001119	Ethopropazine	BSPBio_000799; NCGC00178860-03; 10-[2-(Diethylamino)-1-Propyl]phenothiazine; C19H24N2S; 10H-Phenothiazine-10-ethanamine, N,N-diethyl-.alpha.-methyl-; KBioGR_001215; Phenoprozine; Profenamina [INN-Spanish]; Parcidol; Athapropazine; Athopropazin; Spectrum4_000548; Spectrum3_000429; N,N-diethyl-1-phenothiazin-10-ylpropan-2-amine; CID3290; 522-00-9; Isothiazine; Fempropazine; Fenpropazina; Prestwick0_000840; Prodierazine; Profenamina; Spectrum_000815; PHENOTHIAZINE, 10-(2-(DIETHYLAMINO)PROPYL)-; CHEMBL1206; Parsotil; Aethopropropazin; nchembio.154-comp13; Profenamine (INN); NCIOpen2_008174; Parkin; Profenamina [Italian]; Prestwick3_000840; Rodipal; Prestwick2_000840; Profenaminum [INN-Latin]; Prestwick1_000840; BPBio1_000879; N,N-Diethyl-alpha-methyl-10H-phenothiazine-10-ethanamine; Prodictazin; IDI1_000061; Parsidol; Rocipel; Spectrum5_001592; D08426; AB00053474; ethopropazine; Phenopropazine; Etopropezina; Profenamine [INN:BAN]; KBio2_001295; EINECS 208-320-4; Parsidan; 10-[2-(Diethylamino)propyl]phenothiazine; SPBio_002720; DB00392; KBioSS_001295; Prophenamine; KBio3_001238; 10-[2-(Diethylamino)-2-methylethyl]phenothiazine; NINDS_000061; Isopthazine; Prophenaminum; BSPBio_002018; KBio1_000061; Rochipel; Lysivane; Isothazine; Ethapropazine; Parfezine; Pardidol; 2-Diethylamino-1-propyl-N-dibenzoparathiazine; DivK1c_000061; 10-(2-Diethylaminopropyl)phenothiazine; SKF 2538; SC 2538; CHEBI:313639; Parkisol; Spectrum2_000984; 10H-Phenothiazine-10-ethanamine, N,N-diethyl-alpha-methyl-; Ethopromazine; KBio2_003863; W 483; UNII-7WI4P02YN1; KBio2_006431; AC1L1FLK; N,N-Diethyl-1-(10H-phenothiazin-10-yl)-2-propanamine; L001334; SPBio_001047; Isotazin; LS-105451; Parsitan; Profenaminum; N,N-diethyl-1-(10H-phenothiazin-10-yl)propan-2-amine; Profenamine; RP 3356	1094-08-2	3290	153942	TTDS00002	Muscarinic acetylcholine receptor M1	M1 receptor	P11229	1128	ENSG00000168539	antagonist
DCL000328	Xanomeline tartrate	D06331; Memcor; 3-(4-(Hexyloxy)-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine L-(+)-tartrate (1:1); Xanomeline tartrate [USAN]; AC1Q5R2S; AR-1J3926; LY 246708 tartrate; CID71456; 152854-19-8; AC1L2G75; LS-131634; Pyridine, 3-(4-(hexyloxy0-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methyl-, (2R,3R)-2,3-dihydroxybutanedioate (1:1); Xanomeline tartrate (USAN); Xanomeline tartrate; Pyridine, 3-(4-(hexyloxy)-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methyl-, (R-(R*,R*))-2,3-dihydroxybutanedioate (1:1); (2R,3R)-2,3-dihydroxybutanedioic acid; 3-hexoxy-4-(1-methyl-3,6-dihydro-2H-pyridin-5-yl)-1,2,5-thiadiazole	152854-19-8	71456	47207988	TTDS00002	Muscarinic acetylcholine receptor M1	M1 receptor	P11229	1128	ENSG00000168539	agonist
DAP001206	Drospirenone	C035144; 1, 2-Dihydrospirorenone; C24H30O3; BRN 4765500; Drospirenone (JAN/USAN/INN); EINECS 266-679-2; ZINC03927200; ZK 30595; DB01395; Drospirenone; ZK30595; Angeliq, Drospirenone; 67392-87-4; Spiro(17H-dicyclopropa(6,7:15,16)cyclopenta(a)phenanthrene-17,2'(5'H)-furan)-3,5'(2H)-dione, 1,3',4',6,7,8,9,10,11,12,13,14,15,16,20,21-hexadecahydro-10,13-dimethyl-, (6R-(6alpha,7alpha,8beta,9alpha,10beta,13beta,14alpha,15alpha,16alpha,17beta; AC1L2AMM; Drospirenonum [INN-Latin]; Drospirenone [INN]; Drospirenonum; LS-146115; Drospirenona [INN-Spanish]; 6beta,7beta,15beta,16beta-dimethylene-3-oxo-17alpha-pregn-4-ene-21,17 carbolactone; 1,2-Dihydrospirorenone; Dihydrospirorenone; 6beta,7beta,15beta,16beta-dimethylen-3-oxo-17alpha-pregn-4-en-21,17-carbolacton; CHEBI:50838; UNII-N295J34A25; S1377_Selleck; 6beta,7beta;15beta,16beta-Dimethylene-3-oxo-17alpha-pregn-4-ene-21,17-carbolactone; (6R,7R,8R,9S,10R,13S,14S,15S,16S,17S)-1,3',4',6,6a,7,8,9,10,11,12,13,14,15,15a,16-Hexadecahydro-10,13-dimethylspiro-(17H-dicyclopropa(6,7:15,16)cyclopenta(a)phenanthrene-17,2'(5'H)-furan)-3,5'(2H)-dione; D03917; CID68873; SH-470; DRSP; Drospirenona; Dehydrospirorenone; Spiro(17H-dicyclopropa(6,7:15,16)cyclopenta(a)phenanthrene-17,2'(5'H)-furan)-3,5'(2H)-dione, 1,3',4',6,7,8,9,10,11,12,13,14,15,16,20,21-hexadecahydro-10,13-dimethyl-, (6R-(6alpha,7alpha,8beta,9alpha,10beta,13beta,14alpha,15alpha,16alpha,17beta))-; CCRIS 6523; 17-Hydroxy-6beta,7beta:15beta,16beta-dimethylene-3-oxo-17alpha-pregn-4-ene-21-carboxylic acid, gamma-lactone; 1,2-dihydro-spirorenone; CHEMBL1509; 6-beta,7-beta;15-beta,16-beta-Dimethylene-3-oxo-17-alpha-pregn-4-ene-21,17-carbolactone; ZK-30595; 3-oxo-6alpha,7alpha,15alpha,16alpha-tetrahydro-7'H,16'H-dicyclopropa[6,7;15,16]-17alpha-pregn-4-ene-21,17-carbolactone	67392-87-4	68873	12014580	TTDS00206	Mineralocorticoid receptor	Delta;Inner ear mineralocorticoid receptor;MR	P08235	4306	ENSG00000151623	binder
DAP001106	Desoxycorticosterone Pivalate	808-48-0; Corticosterone, deoxy-, pivalate (6CI,7CI); D03699; Pregn-4-ene-3,20-dione, 21-(2,2-dimethyl-1-oxopropoxy)-; Percorten (TN); DOCP; Percorten Pivalate; NCGC00160511-01; DTMA; Neodin-depositum; STOCK1N-55228; Desoxycorticosterone trimethylacetate; AKOS001581616; 4-08-00-02196 (Beilstein Handbook Reference); [2-(10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl)-2-oxoethyl] 2,2-dimethylpropanoate; Percorten; CHEMBL1200592; Cortexone M; Deoxycortone pivalate; CID13126; Deoxycortolone Pivalate; 11-Deoxycorticosterone, pivalate (8CI); Deoxycorticosterone pivalate; CID11876263; MolPort-002-527-902; NCGC00159355-02; CHEBI:50782; Deoxycorticosterone trimethylacetate; BRN 3174879; EINECS 212-366-0; DB01134; LS-118664; NSC 95278; Oprea1_314142; AC1L2133; Deoxycortone trimethylacetate; 3,20-dioxopregn-4-en-21-yl 2,2-dimethylpropanoate; 11-Deoxycorticosterone, pivalate; UNII-16665T4A2X; NSC95278; Desoxycortone pivalate; Desoxycorticosterone pivalate (USP); 21-(2,2-Dimethyl-1-oxopropoxy)pregn-4-ene-3,20-dione; Percorten M; ZINC04082455; MolPort-000-700-526; 11-Deoxycorticosterone pivalate; DESOXYCORTICOSTERONE PIVALATE	808-48-0	13126	156479	TTDS00206	Mineralocorticoid receptor	Delta;Inner ear mineralocorticoid receptor;MR	P08235	4306	ENSG00000151623	binder
DCL001257	XL550	N/A	N/A	N/A	N/A	TTDS00206	Mineralocorticoid receptor	Delta;Inner ear mineralocorticoid receptor;MR	P08235	4306	ENSG00000151623	antagonist
DAP001105	Fludrocortisone	Fludrocortisonum; 9 .alpha. FF; D005438; EINECS 204-833-2; 9 Fluorocortisol; Fluohydrocortisone; 9-alpha-Fluorocortisol; Florinef; (11beta)-9-Fluoro-11,17,21-trihydroxypregn-4-ene-3,20-dione; LMST02030103; LS-118690; Pregn-4-ene-3,20-dione, 9-fluoro-11,17,21-trihydroxy-, (11.beta.)-; Merck, Astonin; D07967; fludrocortisone; 9-alpha-Fluorohydrocortisone; 9alpha-Fluoro-17-hydroxycorticosterone; 9 Fluoro 17 Hydroxycortisone; Fluohydrisone; (8S,9R,10S,11S,13S,14S,17R)-9-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one; U 5963; Fludrocortisonum [INN-Latin]; Astonin H; 9 alpha Fluoro 17 Hydroxycorticosterone; 9 alpha Fluorohydrocortisone; 9 alpha Fludrohydrocortisone; Merck Brand of Fludrocortisone; 9.alpha.-Fluoro-17-hydroxycorticosterone; Cortisol, 9-fluoro-; Prestwick_648; CID31378; Alflorone; MolPort-005-943-437; Astonin-H (TN); ZK5; Astonin-H; CHEBI:50885; AC1L1LI8; AC1Q5HJH; F-COL; Fludrocortisona [INN-Spanish]; Fluorocortisol; Fludrocortisone (INN); Hydrocortisone-9alpha-fluoro; NCGC00181081-01; 9 alpha-Fluorocortisol; 9alpha-Fludrocortisone; WLN: L E5 B666 OV MUTJ A1 BF CQ E1 FV1Q FQ; 9.alpha.-Fluorohydrocortisone; 9 alpha-Fluorohydrocortisone; BRN 3014278; 127-31-1; 9-Fluoro-17-Hydroxycortisone; 9.alpha.-Fluorocortisol; Fludronef; Fludrone; 9-AF; UNII-U0476M545B; 9-Fluoro-11.beta.,17,21-trihydroxypregn-4-ene-3,20-dione; NSC 11318; 9-alpha-Fludrocortisone; 9 alpha-Fluoro-17-Hydroxycorticosterone; Corticosterone, 9-fluoro-17-hydroxy-; Fludrocortisona; 9 Fluorohydrocortisone; 9-Fluorocortisol; 9-AFH; Pregn-4-ene-3,20-dione, 9-fluoro-11beta,17,21-trihydroxy- (8CI); 9-Fluorohydrocortisone; 9-alpha-Fluoro-17-hydroxycorticosterone; Fludrocortone; 4-08-00-03427 (Beilstein Handbook Reference); 9alpha-Fluorocortisol; 9.alpha.-Fluoro-11.beta.,17.alpha.,21-trihydroxy-4-pregnene-3,20-dione; C21H29FO5; Astonin Merck; Pregn-4-ene-3,20-dione, 9-fluoro-11.beta.,17,21-trihydroxy-; DB02478; Pregn-4-ene-3,20-dione, 9-fluoro-11-beta,17,21-trihydroxy-; C07004; 9-Fluoro-11-beta,17,21-trihydroxypregn-4-ene-3,20-dione; Pregn-4-ene-3,20-dione, 9-fluoro-11beta,17,21-trihydroxy-; 9 alpha FF; Pregn-4-ene-3,20-dione, 9-fluoro-11,17,21-trihydroxy-, (11beta)-; Fludrocortisone [INN:BAN]; 9-Fluoro-11beta,17,21-trihydroxypregn-4-ene-3,20-dione; Fluodrocortisone; NSC11318; DB00687; 9alpha-Fluoro-11beta,17alpha,21-trihydroxy-4-pregnene-3,20-dione; HSDB 3332; ZINC04097304; 9alpha-Fluoro-hydrocortisone; Fluorocortisone; CHEMBL1201388; FCOL; Astonin; F-Cortef; 9 alpha-Fludrocortisone; StC 1400	127-31-1	31378	9217	TTDS00206	Mineralocorticoid receptor	Delta;Inner ear mineralocorticoid receptor;MR	P08235	4306	ENSG00000151623	agonist
DPR000162	YM-992	YM-35992; Lubazodone  hydrochloride; YM992; Morpholine, 2-(((7-fluoro-2,3-dihydro-1H-inden-4-yl)oxy)methyl)-, hydrochloride  (2S)-; (S)-2-(((7-fluoro-4-indanyl)oxy)methyl)morpholine hydrochloride; UNII-2KT2C544LR; Lubazodone HCl; D04788; Lubazodone hydrochloride; AC1L4IXB; Lubazodone  hydrochloride [USAN]; (2S)-2-[(7-fluoro-2,3-dihydro-1H-inden-4-yl)oxymethyl]morpholine hydrochloride; SM-50C; CID157918; 161178-10-5; Lubazodone hydrochloride (USAN)	N/A	N/A	N/A	TTDC00255	Sodium-dependent serotonin transporter	5HT transporter;5HTT;Solute carrier family 6 member 4	P31645	6532	ENSG00000108576	inhibitor
DCL001036	Vilazodone	Vilazodone; MolPort-005-933-319; L001518; CHEBI:412971; AC1OCFA2; 163521-12-8; CID6918314; 5-[4-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-yl]-1-benzofuran-2-carboxamide; Vilazodone [INN]; 5-[4-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-yl]benzofuran-2-carboxamide; CHEMBL439849	163521-12-8	9577221	3818317	TTDC00255	Sodium-dependent serotonin transporter	5HT transporter;5HTT;Solute carrier family 6 member 4	P31645	6532	ENSG00000108576	inhibitor
DPR000146	LY367265	MolPort-003-947-263; Lopac0_000648; NCGC00015600-04; LY-367,265; CHEBI:713416; NCGC00015600-02; AC1NDRET; MLS002172448; Lopac-L-2411; L 2411; CID4605800; L020228; EU-0100648; SMR001254083; CHEMBL1079460; NCGC00015600-01; NCGC00094014-01; NCGC00094014-02; L2411_SIGMA; 1-[2-[4-(6-fluoro-1H-indol-3-yl)-3,6-dihydro-1(2H)-pyridinyl]ethyl]-5,6-dihydro-1H,4H-[1,2,5]thiadiazolo[4.3.2-ij]quinoline-2,2-dioxide	N/A	N/A	N/A	TTDC00255	Sodium-dependent serotonin transporter	5HT transporter;5HTT;Solute carrier family 6 member 4	P31645	6532	ENSG00000108576	inhibitor
DCL000988	SLV-310	CID9888211; L001635; MolPort-005-933-329; CHEBI:317302; SLV-310; 2-[4-[4-(5-fluoro-1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-yl]butyl]isoindole-1,3-dione; CHEMBL131495	N/A	N/A	N/A	TTDC00255	Sodium-dependent serotonin transporter	5HT transporter;5HTT;Solute carrier family 6 member 4	P31645	6532	ENSG00000108576	blocker
DCL000849	IP-751	CT-3; LS-191444; CHEBI:40660; (6aR,10aR)-1-hydroxy-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene-9-carboxylic acid; IP-751; DMH-THC-11-OIC; 6H-Dibenzo(b,d)pyran-9-carboxylic acid, 3-(1,1-dimethylheptyl)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6-dimethyl-, (6aR,10aR); AJA; CID3083542; 137945-48-3; AC1MJ0SY; CPL-7075; CHEMBL456341; Ajulemic acid	137945-48-3	3083542	12015051	TTDS00131	Tumor necrosis factor	Cachectin;TNF;TNF alpha;TNF-a;TNFalpha;TNF-alpha;Tumor necrosis factor ligand superfamily member 2;Tumor necrosis factor receptor 1;Tumour necrosis factor;Tumour necrosis factor alpha	P01375	7124	ENSG00000204490; ENSG00000206439; ENSG00000228321; ENSG00000228849; ENSG00000230108; ENSG00000223952; ENSG00000232810	inhibitor
DCL000932	Pirfenidone	5-21-07-00197 (Beilstein Handbook Reference); Lopac0_000907; BRD-K96862998-001-03-1; I01-1466; BRN 1526549; Esbriet; Pirfenidonum [INN-Latin]; Pirfenidona; 5-methyl-1-phenylpyridin-2-one; S-7701; Lopac-P-2116; Bio1_001375; 5-Methyl-1-phenyl-2-(1H)-pyridone; 2(1H)-Pyridinone, 5-methyl-1-phenyl-; C093844; NCGC00015806-05; SMR000326900; AMR-69; 53179-13-8; 5-Methyl-1-phenyl-2(1H)-pyridone; LS-133834; 5-methyl-1-phenylpyridin-2(1H)-one; ZINC00001958; NCGC00024992-02; MLS000860042; PIRFENIDONE; Deskar; 5-Methyl-1-phenyl-1H-pyridin-2-one; CID40632; AC1L2454; NCGC00015806-03; Bio1_000886; EN000704; EU-0100907; FT-0082541; AC-6797; Pirfenidonum; Pirfenidone (JAN/USAN/INN); KS-5041; P 2116; Pirespa; Pirfenidone [USAN:INN]; AMR 69; NCGC00024992-01; Tocris-1093; Pirfenidona [INN-Spanish]; D01583; F-647; NCGC00024992-03; C12H11NO; Bio1_000397; P2116_SIGMA; Pirfenidone (Deskar); 2(1H)-Pyridone, 5-methyl-1-phenyl-; NCGC00015806-01	53179-13-8	40632	46500438	TTDS00131	Tumor necrosis factor	Cachectin;TNF;TNF alpha;TNF-a;TNFalpha;TNF-alpha;Tumor necrosis factor ligand superfamily member 2;Tumor necrosis factor receptor 1;Tumour necrosis factor;Tumour necrosis factor alpha	P01375	7124	ENSG00000204490; ENSG00000206439; ENSG00000228321; ENSG00000228849; ENSG00000230108; ENSG00000223952; ENSG00000232810	inhibitor
DAP001255	Lenalidomide	AC1L50II; CDC-5013; STK639603; IMiD3 cpd; NCGC00167491-01; LS-184040; 2,6-Piperidinedione, 3-(4-amino-1,3-dihydro-1-oxo-2H- isoindol-2-yl)-; DB00480; Revimid; 3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(4-Amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione; EC-000.2340; 346670-73-3; CID216326; Revlimid; IMID-5013; D04687; 191732-72-6; 2,6-Piperidinedione, 3-(4-amino-1,3-dihydro-1-oxo-2H-isoindol-2-yl)-; ENMD-0997; Thalidomide analog CC-5013; 3-(7-amino-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione; 443912-14-9; Revamid; 3-(7-Amino-3-oxo-1H-isoindol-2-yl)-piperidine-2,6-dione; Lenalidomide; S1029_Selleck; CC-5013; Celgene brand of lenalidomide; Lenalidomide [USAN]; Bio-0168; Lenalidomide (USAN/INN); CDC-501; AC-914; IMiD3; C467567; CC5013; CDC 501; AKOS005146276; Revlimid (Celgene); UNII-F0P408N6V4; ALBB-015321; MolPort-003-848-370; Revlimid (TN); NSC747972; CC 5013; CC-5013, Revlimid, Lenalidomide; CHEMBL848; I06-0831	191732-72-6	216326	789509	TTDS00131	Tumor necrosis factor	Cachectin;TNF;TNF alpha;TNF-a;TNFalpha;TNF-alpha;Tumor necrosis factor ligand superfamily member 2;Tumor necrosis factor receptor 1;Tumour necrosis factor;Tumour necrosis factor alpha	P01375	7124	ENSG00000204490; ENSG00000206439; ENSG00000228321; ENSG00000228849; ENSG00000230108; ENSG00000223952; ENSG00000232810	inhibitor
DAP000107	Infliximab	N/A	170277-31-3	N/A	46505602	TTDS00131	Tumor necrosis factor	Cachectin;TNF;TNF alpha;TNF-a;TNFalpha;TNF-alpha;Tumor necrosis factor ligand superfamily member 2;Tumor necrosis factor receptor 1;Tumour necrosis factor;Tumour necrosis factor alpha	P01375	7124	ENSG00000204490; ENSG00000206439; ENSG00000228321; ENSG00000228849; ENSG00000230108; ENSG00000223952; ENSG00000232810	antibody
DCL000745	Certolizumab	N/A	428863-50-7	N/A	17397581	TTDS00131	Tumor necrosis factor	Cachectin;TNF;TNF alpha;TNF-a;TNFalpha;TNF-alpha;Tumor necrosis factor ligand superfamily member 2;Tumor necrosis factor receptor 1;Tumour necrosis factor;Tumour necrosis factor alpha	P01375	7124	ENSG00000204490; ENSG00000206439; ENSG00000228321; ENSG00000228849; ENSG00000230108; ENSG00000223952; ENSG00000232810	inhibitor
DAP000865	Thalidomide	Talismol; Imidan (peyta); Imidene; Gastrinide; Prestwick_463; Sedalis sedi-lab; LS-140; N-Phthalimidoglutamic acid imide; D013792; Synovir; Thalidomide Pharmion; BPBio1_000159; AC1L1KBZ; KBio1_000051; Valgraine; HMS1792J17; KBio3_000911; Neurodyn; Distaval; KBio3_002802; N-Phthaloylglutamimide; Distaxal; BSPBio_000143; NINDS_000051; Pro-Bam M; UPCMLD-DP139:001; Sandormin; Thalidomidum; Shinnibrol; Neufatin; Prestwick2_000192; NSC527179; NCI60_023904; KBioGR_002322; HMS1568H05; Thalidomidum [INN-Latin]; Thaled; Prestwick1_000192; SPBio_000893; HMS2090O05; 3-Phthalimidoglutarimide; AC1Q6FJA; Pangul; Nibrol; Glutarimide, 2-phthalimido-; NCGC00024708-07; KBio2_002322; Asmaval; Kedavon; HMS2093G15; Slipro; Thalomide; Corronarobetin; N-Phthalyl-glutaminsaeure-imid [German]; N-Phthalyl-glutaminsaeure-imid; ( inverted question mark)-Thalidomide; Talidomide; DB01041; Psychotablets; NSC 527179; NSC91729; Enterosediv; Softenon; AI3-50606; T151_SIGMA; (?)-Thalidomide; alpha-Phthalimidoglutarimide; Ectiluran; AC-917; Kevadon; NCIOpen2_003188; HMS500C13; HMS1362J17; Telargean; T150_SIGMA; Talizer; Neosedyn; thalidomide; ST51039042; Neosydyn; Softenil; KBio3_000912; Predni-Sediv; Tensival; Nerosedyn; Thalomid (TM); Hippuzon; NCGC00015989-13; Calmorex; Thalomid (TN); NSC-66847; Bio1_001365; UNII-4Z8R6ORS6L; KBio2_000496; Distoval; Shin-naito S; Sedalis; EU-0101224; Neurosedyn; N-Phthalylglutamic acid imide; Sleepan; LS-109463; NCGC00024708-09; KBio2_005632; Talidomida [INN-Spanish]; .alpha.-N-Phthalylglutaramide; Thalidomine USP26; Prestwick3_000192; Neurosedin; Quietoplex; E-217; .alpha.-(N-Phthalimido)glutarimide; Thalidomide (+ and -); (+-)-Thalidomide; KBio2_007458; Neurosedym; K 17; Thalidomide (soluble form); Thalomid, Thalidomide; cMAP_000022; (+)-Thalidomide; KBio2_003064; SPBio_002064; NSC91730; THALIDOMIDE (AIDS INITIATIVE); CPD000058524; CHEMBL468; D00754; Theophilcholine; Psycholiquid; Glutanon; NCGC00015989-03; Pro-ban M; Pantosediv; Imida-lab; Thalin; EINECS 200-031-1; HSDB 3586; Spectrum5_001791; Thalinette; Spectrum3_001715; Celgene Brand of Thalidomide; MLS000069353; Asidon 3; 50-35-1; SMR000058524; KBioSS_002324; NSC66847; KBio3_002550; Talidomida; ENMD 0995; NCGC00024708-06; I06-0197; Sedin; Bio1_000876; NCGC00024708-04; Telagan; Lopac0_001224; Profarmil; Asmadion; Isomin; Bonbrrin; Spectrum4_001087; Thalidomide (JAN/USP/INN); Sedoval; Talimol; Noctosediv; WLN: T56 BVNVJ C- DT6VMVTJ -L; C13H10N2O4; Thaled (TN); CHEBI:105028; K-17; BRD-A93255169-001-06-9; Algosediv; HMS1990J17; Grippex; Yodomin; Talargan; NCGC00024708-03; Talidomide [DCIT]; Bio1_000387; Nevrodyn; NCGC00024708-02; alpha-(N-Phthalimido)glutarimide; SPECTRUM1503607; C07910; Thalidomide [USAN:INN:BAN]; Bio2_000418; (+/-)-THALIDOMIDE; Prestwick0_000192; Neaufatin; alpha-N-Phthalylglutaramide; Glupan; T144_SIGMA; 14088-68-7; WLN: T56 BVNVJ C- DT6VMVTJ; Thalidomide Celgene; Noxodyn; Polygripan; Contergan; Bonbrain; KBioGR_001474; IDI1_000051; KBioGR_000496; Bio2_000898; UPCMLD-DP139; IN1061; NCGC00024708-05; Valgis; Phthalimide, N-(2,6-dioxo-3-piperidyl)-; Poly-Giron; CID5426; Spectrum2_000707; HMS1922E12; BRN 0030233; CCRIS 8148; N-(2,6-Dioxo-3-piperidyl)phthalimide; S1193_Selleck; BSPBio_001156; Sedimide; 2,6-Dioxo-3-phthalimidopiperidine; .alpha.-Phthalimidoglutarimide; BSPBio_003330; 731-40-8; AB00052362; DivK1c_000051; KBio2_004890; Sedisperil; WLN: T56 BVNVJ C- DT6VMVTJ -D; KBioSS_000496; Calmore; Thalomid; IDI1_002173; MolPort-003-665-582; Quetimid; NCGC00024708-08; SAM002564245; Telargan	50-35-1	5426	10112	TTDS00131	Tumor necrosis factor	Cachectin;TNF;TNF alpha;TNF-a;TNFalpha;TNF-alpha;Tumor necrosis factor ligand superfamily member 2;Tumor necrosis factor receptor 1;Tumour necrosis factor;Tumour necrosis factor alpha	P01375	7124	ENSG00000204490; ENSG00000206439; ENSG00000228321; ENSG00000228849; ENSG00000230108; ENSG00000223952; ENSG00000232810	inhibitor
DAP000106	Etanercept	Etanercept (genetical recombination); Etanercept (USAN/INN); Etanercept (genetical recombination) (JAN); 185243-69-0; D00742; Enbrel (TN); Etanercept; Enbrel	185243-69-0	N/A	10099	TTDS00131	Tumor necrosis factor	Cachectin;TNF;TNF alpha;TNF-a;TNFalpha;TNF-alpha;Tumor necrosis factor ligand superfamily member 2;Tumor necrosis factor receptor 1;Tumour necrosis factor;Tumour necrosis factor alpha	P01375	7124	ENSG00000204490; ENSG00000206439; ENSG00000228321; ENSG00000228849; ENSG00000230108; ENSG00000223952; ENSG00000232810	antibody
DCL000047	AN0128	CID11704019; 872044-70-7; CHEMBL219629; 3-Hydroxypyridine-2-carbonyloxy-bis(3-chloro-4-methylphenyl)borane; AN0128; 2-Pyridinecarboxylic acid, 3-hydroxy-, anhydride with bis(3-chloro-4-methylphenyl)borinic acid; Bis(3-chloro-4-methyl-phenyl)boranyl 3-hydroxypyridine-2-carboxylate	872044-70-7	11704019	85151832	TTDS00131	Tumor necrosis factor	Cachectin;TNF;TNF alpha;TNF-a;TNFalpha;TNF-alpha;Tumor necrosis factor ligand superfamily member 2;Tumor necrosis factor receptor 1;Tumour necrosis factor;Tumour necrosis factor alpha	P01375	7124	ENSG00000204490; ENSG00000206439; ENSG00000228321; ENSG00000228849; ENSG00000230108; ENSG00000223952; ENSG00000232810	inhibitor
DCL000701	ART621	N/A	N/A	N/A	N/A	TTDS00131	Tumor necrosis factor	Cachectin;TNF;TNF alpha;TNF-a;TNFalpha;TNF-alpha;Tumor necrosis factor ligand superfamily member 2;Tumor necrosis factor receptor 1;Tumour necrosis factor;Tumour necrosis factor alpha	P01375	7124	ENSG00000204490; ENSG00000206439; ENSG00000228321; ENSG00000228849; ENSG00000230108; ENSG00000223952; ENSG00000232810	inhibitor
DCL000952	RDP-58	Allotrap 1258; UNII-5759XTJ706; RDP-58; AC1L55WS; Delmitide; D-Tyrosinamide, D-arginyl-D-norleucyl-D-norleucyl-D-norleucyl-D-arginyl-D-norleucyl-D-norleucyl-D-norleucylglycyl-; RSP-58; AR-1A2667; CID219021; AC1Q5JM9; 34374-11-3; (2R)-2-[[(2R)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-N-[(2R)-1-[[(2R)-1-[[(2R)-1-[[(2R)-1-[[(2R)-1-[[(2R)-1-[[2-[[(2R)-1-amino-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]hexanamide; KST-1A4007; Allotrap-1258; (2r)-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-5-guanidino-pentanoyl]amino]hexanoyl]amino]hexanoyl]amino]-n-[(1r)-1-[[(1r)-1-[[(1r)-1-[[(1r)-1-[[2-[[(1r)-2-amino-1-[(4-hydroxyphenyl)methyl]-2-oxo-ethyl]amino]-2-oxo-ethyl]carbamoyl]pentyl]carbamoyl]pentyl]carbamoyl]pentyl]carbamoyl]-4-guanidino-butyl]hexanamide; RDP 58	287096-87-1	219021	12015333	TTDS00131	Tumor necrosis factor	Cachectin;TNF;TNF alpha;TNF-a;TNFalpha;TNF-alpha;Tumor necrosis factor ligand superfamily member 2;Tumor necrosis factor receptor 1;Tumour necrosis factor;Tumour necrosis factor alpha	P01375	7124	ENSG00000204490; ENSG00000206439; ENSG00000228321; ENSG00000228849; ENSG00000230108; ENSG00000223952; ENSG00000232810	inhibitor
DCL001018	TgAAC-94	N/A	34661-75-1	5639	49699376	TTDS00131	Tumor necrosis factor	Cachectin;TNF;TNF alpha;TNF-a;TNFalpha;TNF-alpha;Tumor necrosis factor ligand superfamily member 2;Tumor necrosis factor receptor 1;Tumour necrosis factor;Tumour necrosis factor alpha	P01375	7124	ENSG00000204490; ENSG00000206439; ENSG00000228321; ENSG00000228849; ENSG00000230108; ENSG00000223952; ENSG00000232810	inhibitor
DAP000048	Pentoxifylline	BRD-K57569181-001-05-1; Rentylin; 2a3c; NCGC00015801-04; Lopac0_000936; UNII-SD6QCT3TSU; ZINC01530776; Spectrum2_001181; Torental; NCGC00015801-10; MLS000758298; Spectrum3_001820; HMS2051N06; IDI1_000729; EHT-0201; KBio3_002942; AB00052363; Hemovas; 1-(5-Oxohexyl)-3,7-dimethylxanthine; EINECS 229-374-5; Agapurin Retard; KBio2_007060; Pentoxifyllinum [INN-Latin]; Pentoxifyllinum; 1H-Purine-2,6-dione, 3,7-dihydro-3,7-dimethyl-1-(5-oxohexyl)-; SPECTRUM1503611; Px; BRN 0558929; EHT 0201; NCGC00067069-04; HMS502E11; KBio2_001924; BSPBio_000151; KBioGR_000893; Oxpentifylline; 3,7-dimethyl-1-(5-oxohexyl)purine-2,6-dione; Pentoxifilina; BB_SC-2111; D010431; CCRIS 6832; Pentoxyphyllin; Spectrum_001444; 3,7-Dimethyl-1-(5-oxohexyl)-3,7-dihydro-1H-purine-2,6-dione; SR-01000075641-4; 1,2,3,6-Tetrahydro-3,7-dimethyl-1-(5-oxohexyl)-2,6-purindion; Trental; Durapental; CAS-1677687; Pentoxiphyllium; NCGC00067069-03; Theobromine, 1-(5-oxohexyl)-; SPBio_001221; NINDS_000729; BSPBio_003439; Vasofirin; I06-1592; D00501; Pentoxifylline [USAN:INN:JAN]; IN1161; MLS000079026; SPBio_002072; AKOS000541484; NSC 637086; C07424; 5-26-14-00081 (Beilstein Handbook Reference); Pentoxyfylline; HMS2093G21; Pentoxiphyllin; Pentoxil (TN); Pentoxyphylline; NSC637086; NCGC00015801-02; AC1L1IUN; Pentoxifilina [INN-Spanish]; DivK1c_000729; Dimethyloxohexylxanthine; BL 191; BL191; CHEMBL628; Prestwick3_000196; 6493-05-6; NCGC00178062-02; BIDD:GT0174; SMR000035998; HMS1568H13; DB00806; BL-191; 1-(5-Oxohexyl)theobromine; Pentoxiphylline; PDSP2_000999; EU-0100936; 3,7-Dimethyl-1-(5-oxohexyl) xantine; P 1784; KBio1_000729; pentoxifylline; Trental (TN); Prestwick_608; Prestwick1_000196; 3,7-Dihydro-3,7-dimethyl-1-(5-oxohexyl)-1H-purine-2,6-dione; MLS001201764; KBioSS_001924; 3,7-Dimethyl-1-(5-oxohexyl)-1H,3H-purin-2,6-dione; Pentoxil; NCGC00015801-01; cis-9-Octadecenoyl coenzyme A; PENTOXYPHYLINE; BPBio1_000167; BAS 00897429; Vazofirin; LS-149385; EHT-201; C13H18N4O3; PNX; HMS1922E16; CID4740; 3,7-Dimethyl-1-(5-oxo-hexyl)-3,7-dihydro-purine-2,6-dione; EHT0201; Agapurin; Spectrum4_000227; NCGC00067069-02; SAM001247011; Spectrum5_001161; Azupentat; STK177321; CPD000035998; NCGC00178062-01; Ralofect; NCGC00067069-05; MolPort-001-823-263; Pentoxifylline (JAN/USP/INN); 3,7-Dimethyl-1-(5-oxohexyl)xanthine; Prestwick2_000196; Pentoxifyllin; KBio2_004492; Lopac-P-1784; 3,7-Dimethyl-1-(5-oxohexyl)xantine; PDSP1_001015; Ikomio; HMS2090H13; Prestwick0_000196	6493-05-6	4740	165572	TTDS00131	Tumor necrosis factor	Cachectin;TNF;TNF alpha;TNF-a;TNFalpha;TNF-alpha;Tumor necrosis factor ligand superfamily member 2;Tumor necrosis factor receptor 1;Tumour necrosis factor;Tumour necrosis factor alpha	P01375	7124	ENSG00000204490; ENSG00000206439; ENSG00000228321; ENSG00000228849; ENSG00000230108; ENSG00000223952; ENSG00000232810	antibody
DCL001012	Talactoferrin Alfa	Talactoferrin alfa (USAN/INN); Talactoferrin Alfa; D05991; 308240-58-6	308240-58-6	3036289	47574471	TTDS00131	Tumor necrosis factor	Cachectin;TNF;TNF alpha;TNF-a;TNFalpha;TNF-alpha;Tumor necrosis factor ligand superfamily member 2;Tumor necrosis factor receptor 1;Tumour necrosis factor;Tumour necrosis factor alpha	P01375	7124	ENSG00000204490; ENSG00000206439; ENSG00000228321; ENSG00000228849; ENSG00000230108; ENSG00000223952; ENSG00000232810	inhibitor
DPR000028	Celastrol	(2R,4aS,6aS,12bR,14aS,14bR)-10-hydroxy-2,4a,6a,9,12b,14a-hexamethyl-11-oxo-1,2,3,4,4a,5,6,6a,11,12b,13,14,14a,14b-tetradecahydropicene-2-carboxylic acid; KBio1_000718; KBio2_000815; 3-Hydroxy-24-nor-2-oxo-1(10),3,5,7-friedelatetraen-29-oic Acid; Celastrol, Celastrus scandens; Spectrum2_000150; KBio2_005951; Ambotz34157-83-0; nchembio.368-comp16; NSC70931; 34157-83-0; BSPBio_001905; KBioSS_000815; CHEBI:186102; NCI60_038570; KBio3_001405; KBioGR_002436; AC1L3V4O; Spectrum5_000805; D:A-Friedo-24-noroleana-1(10),3,5,7-tetraen-29-oic acid, 3-hydroxy-2-oxo-, (20alpha)-; SPECTRUM201664; Spectrum4_001966; Tripterin; NINDS_000718; CHEMBL301982; C050414; DivK1c_000718; NSC 70931; HMS1923A13; CID122724; NCGC00178913-01; SPBio_000260; (2R,4aS,6aR,6aS,14aS,14bR)-10-hydroxy-2,4a,6a,6a,9,14a-hexamethyl-11-oxo-1,3,4,5,6,13,14,14b-octahydropicene-2-carboxylic acid; KST-1A4115; AC-6031; 35327-72-1; C29H38O4; Spectrum_000335; AC1Q6P61; celastrol; IDI1_000718; Tripterine; MolPort-003-665-482; AR-1A3014; S1290_Selleck; KBio2_003383; LS-157465; Spectrum3_000233; 2-Picenecarboxylic acid, 1,2,3,4,4a,5,6,6a,11,12b,13,14,14a,14b-tetradecahydro-10-hydroxy-2,4a,6a,9,12b,14a-hexamethyl-11-oxo-	34157-83-0	122724	8138360	TTDS00131	Tumor necrosis factor	Cachectin;TNF;TNF alpha;TNF-a;TNFalpha;TNF-alpha;Tumor necrosis factor ligand superfamily member 2;Tumor necrosis factor receptor 1;Tumour necrosis factor;Tumour necrosis factor alpha	P01375	7124	ENSG00000204490; ENSG00000206439; ENSG00000228321; ENSG00000228849; ENSG00000230108; ENSG00000223952; ENSG00000232810	N/A
DCL000213	RDP58	N/A	287096-87-1	219021	57399829	TTDS00131	Tumor necrosis factor	Cachectin;TNF;TNF alpha;TNF-a;TNFalpha;TNF-alpha;Tumor necrosis factor ligand superfamily member 2;Tumor necrosis factor receptor 1;Tumour necrosis factor;Tumour necrosis factor alpha	P01375	7124	ENSG00000204490; ENSG00000206439; ENSG00000228321; ENSG00000228849; ENSG00000230108; ENSG00000223952; ENSG00000232810	inhibitor
DCL000818	Golimumab	D04358; 476181-74-5; Golimumab; Golimumab (USAN/INN)	476181-74-5	N/A	47206264	TTDS00131	Tumor necrosis factor	Cachectin;TNF;TNF alpha;TNF-a;TNFalpha;TNF-alpha;Tumor necrosis factor ligand superfamily member 2;Tumor necrosis factor receptor 1;Tumour necrosis factor;Tumour necrosis factor alpha	P01375	7124	ENSG00000204490; ENSG00000206439; ENSG00000228321; ENSG00000228849; ENSG00000230108; ENSG00000223952; ENSG00000232810	antibody
DCL000746	Certolizumab pegol	Certolizumab pegol (genetical recombination); Certolizumab pegol (USAN/INN); Certolizumab pegol; Certolizumab pegol (genetical recombination) (JAN); D03441; 428863-50-7	428863-50-7	N/A	17397581	TTDS00131	Tumor necrosis factor	Cachectin;TNF;TNF alpha;TNF-a;TNFalpha;TNF-alpha;Tumor necrosis factor ligand superfamily member 2;Tumor necrosis factor receptor 1;Tumour necrosis factor;Tumour necrosis factor alpha	P01375	7124	ENSG00000204490; ENSG00000206439; ENSG00000228321; ENSG00000228849; ENSG00000230108; ENSG00000223952; ENSG00000232810	antibody
DPR000050	Genz29155	N/A	374080-21-4	6918412	43529782	TTDS00131	Tumor necrosis factor	Cachectin;TNF;TNF alpha;TNF-a;TNFalpha;TNF-alpha;Tumor necrosis factor ligand superfamily member 2;Tumor necrosis factor receptor 1;Tumour necrosis factor;Tumour necrosis factor alpha	P01375	7124	ENSG00000204490; ENSG00000206439; ENSG00000228321; ENSG00000228849; ENSG00000230108; ENSG00000223952; ENSG00000232810	inhibitor
DAP000392	Adalimumab	331731-18-1; Humira; D02597; Humira (TN); Adalimumab (genetical recombination); Adalimumab; Adalimumab (USAN/INN); Adalimumab (genetical recombination) (JAN)	331731-18-1	16219006	47205810	TTDS00131	Tumor necrosis factor	Cachectin;TNF;TNF alpha;TNF-a;TNFalpha;TNF-alpha;Tumor necrosis factor ligand superfamily member 2;Tumor necrosis factor receptor 1;Tumour necrosis factor;Tumour necrosis factor alpha	P01375	7124	ENSG00000204490; ENSG00000206439; ENSG00000228321; ENSG00000228849; ENSG00000230108; ENSG00000223952; ENSG00000232810	antibody
DCL000095	CRx-191	N/A	N/A	N/A	N/A	TTDS00131	Tumor necrosis factor	Cachectin;TNF;TNF alpha;TNF-a;TNFalpha;TNF-alpha;Tumor necrosis factor ligand superfamily member 2;Tumor necrosis factor receptor 1;Tumour necrosis factor;Tumour necrosis factor alpha	P01375	7124	ENSG00000204490; ENSG00000206439; ENSG00000228321; ENSG00000228849; ENSG00000230108; ENSG00000223952; ENSG00000232810	inhibitor
DCL000510	CytoFab	N/A	81525-10-2	4413	47365353	TTDS00131	Tumor necrosis factor	Cachectin;TNF;TNF alpha;TNF-a;TNFalpha;TNF-alpha;Tumor necrosis factor ligand superfamily member 2;Tumor necrosis factor receptor 1;Tumour necrosis factor;Tumour necrosis factor alpha	P01375	7124	ENSG00000204490; ENSG00000206439; ENSG00000228321; ENSG00000228849; ENSG00000230108; ENSG00000223952; ENSG00000232810	antibody
DAP000381	Doxazosin	1-(4-Amino-6,7-dimethoxy-2-chinazolinyl)-4-(2,3-dihydro-1,4-benzodioxixin-2-ylcarbonyl)piperazin; Doxazosin [INN:BAN]; Prestwick0_000858; NCGC00018158-06; Lopac0_000474; HMS2090C20; 2-{4-[(2,3-dihydro-1,4-benzodioxin-2-yl)carbonyl]piperazin-1-yl}-6,7-dimethoxyquinazolin-4-amine; D07874; Doxazosine; Prestwick3_000858; Doxazosinum [Latin]; DB00590; AC-11062; Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-((2,3-dihydro-1,4-benzodioxin-2-yl)carbonyl)-; Cardura-4; UK 33274; BSPBio_000875; 1-(4-Amino-6,7-Dimethoxy-2-quinazolinyl)-4-(1,4-benzodioxan-2-ylcarbonyl)piperazin; SPBio_002796; MolPort-001-684-491; IDI1_003732; CPD000097306; I06-1346; LS-110228; AC1L1FAT; 74191-85-8; Cardura-2; AKOS001681453; HMS1383E01; SAM002589981; AC1Q470P; Prestwick1_000858; BRD-A13188892-066-03-3; L000738; 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-[4-(1,4-benzodioxan-2-yl)carpiperazin-1-yl)]-6,7-dimethoxyquinazoline mesylate; C23H25N5O5; Oprea1_259518; Cardura-1; BPBio1_000963; Doxazosina; Prestwick2_000858; doxazosin; UK-33274; Doxazosine [French]; Doxazosina [Spanish]; C06970; 2-[4-(2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl)piperazin-1-yl]-6,7-dimethoxyquinazolin-4-amine; Cardura XL (TN); Doxazosin (INN); Normothen; [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(2,3-dihydro-1,4-benzodioxin-3-yl)methanone; CID3157; AC1Q4EXN; 2-[4-(2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl)piperazin-1-yl]-6,7-bis(methyloxy)quinazolin-4-amine; Doxazosinum; CHEMBL707; UNII-NW1291F1W8; ChemDiv2_005017; 77883-43-3 (mesylate); D9815_SIGMA; NCGC00089775-02; CHEBI:4708	74191-85-8	3157	9184	TTDS00030	Alpha-1D adrenergic receptor	Alpha 1D-adrenoceptor;Alpha 1D-adrenoreceptor;Alpha adrenergic receptor 1a;Alpha-1A adrenergic receptor	P25100	146	ENSG00000171873	antagonist
DAP000371	Terazosin	terazosin; A 45975; SPBio_002701; Terazosine [INN-French]; C07127; Blavin; Terazosine; MLS001201836; Terazosina; 63590-64-7; Terazosin (INN); Lopac0_001138; 63074-08-8 (hydrochloride); CHEBI:9445; NCGC00025191-03; SAM002589982; Terazosin [INN:BAN]; STK567029; MLS001305722; Terazosabb (TN); BPBio1_000840; HMS2090P21; Hytrin; MLS000069703; Flumarc; 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-((tetrahydro-2-furanyl)carbonyl)piperazine; NCGC00016026-08; Terazosinum [INN-Latin]; Prestwick2_000751; LS-110234; STOCK4S-28262; [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl](tetrahydrofuran-2-yl)methanone; 70024-40-7 (mono-hydrochloride, dihydrate); BRD-A22256192-003-03-7; Terazosina [INN-Spanish]; Prestwick3_000751; AC-11120; D08569; Hytracin; CHEMBL611; AC1L1K9W; Terazosabb; CPD000058309; Abbott 45975; CID5401; 6,7-bis(methyloxy)-2-[4-(tetrahydrofuran-2-ylcarbonyl)piperazin-1-yl]quinazolin-4-amine; BSPBio_000762; 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(tetrahydro-2-furoyl)piperazine; Prestwick1_000751; A-45975; [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(oxolan-2-yl)methanone; Prestwick0_000751; DB01162; Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-((tetrahydro-2-furanyl)carbonyl)-; Trazosin HCl; Fosfomic; 6,7-dimethoxy-2-[4-(tetrahydrofuran-2-ylcarbonyl)piperazin-1-yl]quinazolin-4-amine; Vasomet; L000692; C19H25N5O4; SMR000058309; UNII-8L5014XET7; Terazosinum; MolPort-001-684-489	63590-64-7	5401	9337	TTDS00030	Alpha-1D adrenergic receptor	Alpha 1D-adrenoceptor;Alpha 1D-adrenoreceptor;Alpha adrenergic receptor 1a;Alpha-1A adrenergic receptor	P25100	146	ENSG00000171873	antagonist
DAP000370	Alfuzosin	SL 77499; LS-70106; MLS000759449; NCGC00095152-01; SL 77-499; 2-Furancarboxamide, N-(3-((4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino)propyl)tetrahydro-; AC1L1CWF; SAM001246638; Alfuzosine; KBioGR_001616; MolPort-003-666-623; Alfuzosina; Bio-0003; BSPBio_000323; Alfuzosina [Spanish]; UNII-90347YTW5F; Alfuzosine [French]; Prestwick3_000322; N-{3-[(4-amino-6,7-dimethoxyquinazolin-2-yl)(methyl)amino]propyl}tetrahydrofuran-2-carboxamide; BPBio1_000357; Alfuzosin (INN); CHEMBL709; 128707-53-9; CHEBI:51141; STK643675; Alfuzosinum [Latin]; Prestwick0_000322; NCGC00095152-05; SPBio_002244; BSPBio_002646; Alfusosine; Prestwick1_000322; DB00346; 86163-78-2; 81403-68-1 (hydrochloride); CPD000466340; NCGC00095152-03; Prestwick2_000322; KBio3_001866; MLS001424027; HMS2051I10; 81403-80-7; HMS1922P11; D07124; alphuzosine; CID2092; Alfuzosin [INN:BAN]; NCGC00095152-02; SMR000466340; L001317; SPECTRUM1505263; alfuzosin; Spectrum5_000817; HMS2093O06; BRD-A09056319-003-03-6; NCGC00095152-04; HSDB 7290; BRD-A09056319-001-02-2; AB00514667; Spectrum3_001063; N-(3-((4-Amino-6,7-dimethoxy-2-quinazolinyl)methylamino)propyl)tetrahydro-2-furancarboxamide; Spectrum2_000505; C19H27N5O4; SPBio_000429; N-[3-[(4-amino-6,7-dimethoxyquinazolin-2-yl)-methylamino]propyl]oxolane-2-carboxamide; Alfuzosinum; Spectrum4_001208; Xatral (TN)	81403-80-7	2092	682525	TTDS00030	Alpha-1D adrenergic receptor	Alpha 1D-adrenoceptor;Alpha 1D-adrenoreceptor;Alpha adrenergic receptor 1a;Alpha-1A adrenergic receptor	P25100	146	ENSG00000171873	antagonist
DAP001246	Gemcitabine	nchembio.90-comp2; 122111-03-9; GEO; DFdCyd; Gamcitabine; CCRIS 8984; Gemzar; CHEBI:175901; 4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one; nchembio.573-comp7; Gemcitabina; Gemcin; AC1L1TUQ; gemcitabine; Gemcitabina [INN-Spanish]; 2',2'-DiF-dC; CID60750; 2'-Deoxy-.beta.-D-2',2'-difluorocytidine; Gemtro; Gemcitabine stereoisomer; TL8005979; AB1004842; Cytidine, 2'-deoxy-2',2'-difluoro-2'-Deoxy-.beta.-D-2',2'-difluorocytidine; D02368; LY 188011; 4-Amino-1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one; Cytosine, 1-(2-deoxy-2,2-difluoro-beta-D-erythro-pentofuranosyl)-; LY188011; DB00441; LY-188011; Inno-D07001; CHEMBL888; Gemzar (hydrochloride); Gemcitabine (USAN/INN); 2',2'-Difluorodeoxycytidine; Gemcitabinum; 4-Amino-1-[3,3-difluoro-4-hydroxy-5-(hydroxymethyl) tetrahydrofuran-2-yl]-1H-pyrimidin-2-one; NSC 613327; UNII-B76N6SBZ8R; HMS2089P10; 2',2'-Difluoro-2'-deoxycytidine; 2',2'-Difluorodeoxycytidine; 2'-Deoxy-2',2'-difluorocytidine; DDFC; DFdC; DFdCyd; Folfugem; Gamcitabine; GemLip; Gemcel; Gemcitabine; LY 188011; NSC613327; Zefei; 95058-81-4; DDFC; C07650; LS-59139; ZINC18279854; Gemcitabinum [INN-Latin]; NChemBio.2007.10-comp25; 103882-84-4; 2'-Deoxy-2',2'-difluorocytidine; NCGC00168784-01; Gemcitabine HCl; 2(1H)-Pyrimidinone, 4-amino-1-(2-deoxy-2,2-difluoro-D-erythro-pentofuranosyl)-; HSDB 7567; dFdC	95058-81-4	60750	9852	TTDS00301	Thymidylate synthase	HrTS;Human recombinant thymidylate synthase;OK/SW-cl.29;TS;TSase	P13922	N/A	N/A	inhibitor
DAP000760	Trifluridine	MLS000028361; Viroptic, Trifluorothymidine, Trifluridine; MLS001148248; 2'-Deoxy-5-trifluoromethyluridine; CHEMBL1129; 2'-Deoxy-5-(trifluoromethyl)uridine; NSC 529182; C10H11F3N2O5; 1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-(trifluoromethyl)pyrimidine-2,4-dione; 2,4(1H,3H)-Pyrimidinedione, 1-(2-deoxy-beta-D-ribofuranosyl)-5-(trifluoromethyl)-; F3T; 5-Trifluoro-2'-deoxythymidine; Trifluridinum; TFDU; F3TDR; CID6256; NSC529182; Trifluoromethyldeoxyuridine; D00391; ZINC03842753; UNII-RMW9V5RW38; Thymidine, alpha,alpha,alpha-trifluoro-; Uridine, 2'-deoxy-5-(trifluoromethyl)-; CHEBI:269321; Viroptic; SMR000058583; BRN 0568095; S1778_Selleck; Trifluridine (USP/INN); T2511; T2255_SIGMA; Fluridine; Virophta; LS-153788; Trifluridine [USAN:INN]; AC1L1M4O; Trifluoridine; Trifluridina; CF3dUrd; CCRIS 2348; Uridine, 2'-deoxy-5-(trifluoromethyl)-; 5-(Trifluoromethyl)-2'-deoxyuridine; NSC75520; 5-(Trifluoromethyl)deoxyuridine; Trifluorothymine deoxyriboside; 5-Trifluoromethyl-2-deoxyuridine; Trifluridine; alpha,alpha,alpha-Trifluorothymidine; FT-0082240; 5-Trifluoromethyl-2'-deoxyuridine; HS-0007; Viroptic (TN); TRIFLUOROTHYMIDINE; 5-Trifluorothymidine; Trifluridina [INN-Spanish]; EINECS 200-722-8; 70-00-8; Trifluridinum [INN-Latin]; F3DThd; DB00432; NSC 75520	70-00-8	6256	7847457	TTDS00301	Thymidylate synthase	HrTS;Human recombinant thymidylate synthase;OK/SW-cl.29;TS;TSase	P13922	N/A	N/A	inhibitor
DAP000761	Capecitabine	Xabine; ZINC03806413; Ambap154361-50-9; Ro-09-1978/000; RG-340; Carbamic acid, (1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-, pentyl ester; Ro 09-1978; C15H22FN3O6; Xeloda, Captabin, Capecitabine; HSDB 7656; R340; 158798-73-3; capecitabinum; CID60953; S1156_Selleck; CHEMBL1773; CAPECITABINE; DB01101; pentyl N-[1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxopyrimidin-4-yl]carbamate; LS-59070; Capecitabine [USAN]; R-340; N(4)-Pentyloxycarbonyl-5'-deoxy-5-fluorocytidine; Xeloda; capecitabina; Capiibine; Capecitabine (JAN/USAN/INN); 5'-Deoxy-5-fluoro-N-((pentyloxy)carbonyl)cytidine; Ro 09-1978/000; (1-(5-Deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester; CHEBI:31348; Pentyl [1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate; 154361-50-9; AC1Q4KU8; C12650; C110904; Cytidine, 5'-deoxy-5-fluoro-N-((pentyloxy)carbonyl)-; 5'-deoxy-5-fluoro-N-[(pentyloxy)carbonyl]cytidine; FT-0082472; D01223; UNII-6804DJ8Z9U; Xeloda (TN); Caxeta; Capecitibine; AC1L1U83; Ro-09-1978; Pentyl 1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate; Capecitabin; MolPort-005-938-254	154361-50-9	60953	197173	TTDS00301	Thymidylate synthase	HrTS;Human recombinant thymidylate synthase;OK/SW-cl.29;TS;TSase	P13922	N/A	N/A	inhibitor
DAP000049	Pemetrexed	DB00642; 2-{4-[2-(2-AMINO-4-OXO-4,7-DIHYDRO-3H-PYRROLO[2,3-D]PYRIMIDIN-5-YL)-ETHYL]-BENZOYLAMINO}-PENTANEDIOIC ACID; AC1L98DY; 1juj; AC1Q5R1W; CHEMBL59843; Pemetrexed [INN:BAN]; I06-2128; I06-1253; NCGC00167517-01; LS-172988; UNII-04Q9AIZ7NO; CID60843; Alimta; LY 231514; 2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioic acid; nchembio.108-comp6; CHEBI:474008; CHEMBL225072; L-Glutamic acid, N-[4-[2-[2-amino-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl]ethyl]benzoyl]-; LY-231514; D07472; CID446556; (2S)-2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioic acid; HSDB 7316; NCI60_035021; CID394493; Pemetrexed; (2R)-2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioic acid; Alimta (TN); C20H21N5O6; n-{4-[2-(2-amino-4-oxo-4,7-dihydro-1h-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl}-d-glutamic acid; CHEBI:195145; L-Glutamic acid, N-(4-(2-(2-amino-4,7-dihydro-4-oxo-1H-pyrrolo(2,3-d)pyrimidin-5-yl)ethyl)benzoyl)-; LY231514; AC1L1U1D; AC1L9JT6; NSC698037; N-(4-(2-(2-Amino-3,4-dihydro-4-oxo-7H-pyrrolo(2,3-d)pyrimdin-5-yl)ethyl)benzoyl)glutamic acid; CHEBI:43746; LY 231,514; LY-231,514; LYA; 137281-23-3; LY-2315; Pemetrexed (INN)	150399-23-8	60843	197081	TTDS00301	Thymidylate synthase	HrTS;Human recombinant thymidylate synthase;OK/SW-cl.29;TS;TSase	P13922	N/A	N/A	inhibitor
DCL000337	Plevitrexed	(2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; UNII-L9P2881C3H; ZD 9331; 1H-Tetrazole-5-butanoic acid, alpha-((4-(((1,4-dihydro-2,7-dimethyl-4-oxo-6-quinazolinyl)methyl)-2-propynylamino)-2-fluorobenzoyl)amino)-, (S)-; (2S)-2-((4-(((2,7-Dimethyl-4-oxo-1,4-dihydroquinazolin-6-yl)methyl)(prop-2-ynyl)amino)-2-fluorobenzoyl)amino)-4-(1H-tetrazol-5-yl)butanoic acid; CHEMBL126648; 207-18-1; AC1Q6OHR; BGC9331; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; LS-184649; 153537-73-6; Plevitrexed [INN]; CHEBI:307492; 1H-Tetrazole-5-butanoic acid, alpha-((4-(((1,4-dihydro-2,7-dimethyl-4-oxo-6-quinazolinyl)methyl)-2-propynylamino)-2-fluorobenzoyl)amino)-, (alphaS)-; CID213022; ZD-9331; KST-1A2599; AR-1A3178; NCI60_034390; C094299; AC1L4U3V; ZD9331; NSC 696259; Plevitrexed	153537-73-6	213022	786875	TTDS00301	Thymidylate synthase	HrTS;Human recombinant thymidylate synthase;OK/SW-cl.29;TS;TSase	P13922	N/A	N/A	inhibitor
DCL000320	LY231514	DB00642; disodium (2S)-2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioate; Bio-0078; ST51053024; Tifolar; Pemetrexed [INN:BAN]; I06-1253; NCGC00167517-01; LS-172988; 150399-23-8; CID60843; Alimta; Pemetrexed disodium; LY231514 disodium; I06-1294; CHEBI:474008; CID446556; (2S)-2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioic acid; HSDB 7316; NCI60_035021; CID394493; Pemetrexed disodium [USAN]; (2R)-2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioic acid; C20H21N5O6; n-{4-[2-(2-amino-4-oxo-4,7-dihydro-1h-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl}-d-glutamic acid; CHEBI:195145; L-Glutamic acid, N-(4-(2-(2-amino-4,7-dihydro-4-oxo-1H-pyrrolo(2,3-d)pyrimidin-5-yl)ethyl)benzoyl)-; LY231514; Rolazar; AC1L9JT6; LY 231,514; D03828; C20H19N5O6.2Na; AC1OCF51; 2-{4-[2-(2-AMINO-4-OXO-4,7-DIHYDRO-3H-PYRROLO[2,3-D]PYRIMIDIN-5-YL)-ETHYL]-BENZOYLAMINO}-PENTANEDIOIC ACID; AC1L98DY; 1juj; AC1Q5R1W; disodium (2R)-2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioate; CHEMBL59843; I06-2128; LS-173384; UNII-04Q9AIZ7NO; CID6918197; LY 231514; 2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioic acid; nchembio.108-comp6; CHEMBL225072; L-Glutamic acid, N-[4-[2-[2-amino-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl]ethyl]benzoyl]-; LY-231514; D07472; CID125891; Disodium N-(p-(2-(2-amino-4,7-dihydro-4-oxo-1H-pyrrolo(2,3-d)pyrimidin-5-yl)ethyl)benzoyl)-L-glutamate; Pemetrexed; Alimta (TN); UNII-2PKU919BA9; Pemetrexed disodium (USAN); CHEMBL1200373; AC1L1U1D; NSC698037; N-(4-(2-(2-Amino-3,4-dihydro-4-oxo-7H-pyrrolo(2,3-d)pyrimdin-5-yl)ethyl)benzoyl)glutamic acid; CHEBI:43746; AC1L2PDW; LY-231,514; LYA; 137281-23-3; L-Glutamic acid, N-(4-(2-(2-amino-4,7-dihydro-4-oxo-1H-pyrrolo(2,3-d)pyrimidin-5-yl)ethyl)benzoyl)-, disodium salt; LY-2315; Pemetrexed (INN)	N/A	60843	46505640	TTDS00301	Thymidylate synthase	HrTS;Human recombinant thymidylate synthase;OK/SW-cl.29;TS;TSase	P13922	N/A	N/A	inhibitor
DAP001245	Floxuridine/5-fluorouracil	N/A	50-91-9	5790	148580	TTDS00301	Thymidylate synthase	HrTS;Human recombinant thymidylate synthase;OK/SW-cl.29;TS;TSase	P13922	N/A	N/A	inhibitor
DCL000289	Plevitrexed (R)-isomer	N/A	153537-74-7	213022	47158075	TTDS00301	Thymidylate synthase	HrTS;Human recombinant thymidylate synthase;OK/SW-cl.29;TS;TSase	P13922	N/A	N/A	inhibitor
DAP001339	(+)-Irinotecan	(1,4'-Bipiperidine)-1'-carboxylic acid, 4,11-diethyl-3,4,12-14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano(3',4':6,7)indolizino(1,2-b)quinolin-9-yl ester, (S)-; CHEBI:105985; CID60838; C33H38N4O6; (+)-Irinotecan; D08086; TL8006026; FT-0083650; HSDB 7607; BRD-K08547377-003-02-4; Irinotecanum; Irinotecan [INN:BAN]; AC1L1U0Z; Biotecan; Irinotecan (INN); NSC728073; BSPBio_002346; LS-44589; AC-7469; Irinotecan Hcl; IRINOTECAN, CPT-11; Camptosar; Irinotecanum [INN-Latin]; irinotecan; S1198_Selleck; 1u65; Camptosar, Campto, CPT-11, Irinotecan; Irinotecan hydrochloride; C16641; (4S)-4,11-DIETHYL-4-HYDROXY-3,14-DIOXO-3,4,12,14-TETRAHYDRO-1H-PYRANO[3',4':6,7]INDOLIZINO[1,2-B]QUINOLIN-9-YL 1,4'-BIPIPERIDINE-1'-CARBOXYLATE; NCI60_005051; UNII-7673326042; Biotecan (TN); IRINOTECAN HYDROCHLORIDE Trihydrate; CP0; (4S)-4,11-Diethyl-4-hydroxy-3,14-dioxo-4,12-dihydro-1H-pyrano[3,4-f]quinolino[2,3-a]indolizin-9-yl 4-piperidylpiperidinecarboxylate; Bio-0054; AC1Q6PGI; DB00762; CHEMBL481; 97682-44-5	100286-90-6	60838	217212	TTDS00301	Thymidylate synthase	HrTS;Human recombinant thymidylate synthase;OK/SW-cl.29;TS;TSase	P13922	N/A	N/A	inhibitor
DAP000759	Raltitrexed	Tomudex, TDX, ZD 1694, Raltitrexed; D 1694; N-(5-(((3,4-Dihydro-2-methyl-4-oxo-6-quinazolinyl)methyl)methylamino)-2-thenoyl)-L-glutamic acid; ZD-1694; AstraZeneca brand of raltitrexed; L-Glutamic acid, N-((5-(((1,4-dihydro-2-methyl-4-oxo-6-quinazolinyl)methyl)methylamino)-2-thienyl)carbonyl)-; 1i00; CPD000469217; SAM001246796; SA-Detection Disk Kit; Bio-0142; 2kce; C21H22N4O6S; Raltitrexed; CHEBI:474007; Raltitrexed (JAN/USAN/INN); 2tsr; CHEBI:41742; CID104758; NSC639186; ZD1694; D16; ZD 1694; SMR000469217; S1192_Selleck; Arkomedika brand of raltitrexed; MLS001424225; (2S)-2-[[5-[methyl-[(2-methyl-4-oxo-1H-quinazolin-6-yl)methyl]amino]thiophene-2-carbonyl]amino]pentanedioic acid; HMS2052I03; ICI D1694; D-1694; Tomudex; KS-5069; D1694; D01064; N-(5-(N-(3,4-Dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)-N-methylamino)-2-thenoyl)-L-glutamic acid; DB00293; Tomudex (TN); CHEMBL225071; LS-71840; C068874; AC-19671; ZD-16; 112887-68-0; ZN-D1694; ICI-D1694; NSC-639186; Zeneca brand of raltitrexed; (S)-2-[(1-{5-[Methyl-(2-methyl-4-oxo-3,4-dihydro-quinazolin-6-ylmethyl)-amino]-thiophen-2-yl}-methanoyl)-amino]-pentanedioic acid; ICI-D-1694; AC1L2XFZ; NCI60_013008; C11372	112887-68-0	104758	13546	TTDS00301	Thymidylate synthase	HrTS;Human recombinant thymidylate synthase;OK/SW-cl.29;TS;TSase	P13922	N/A	N/A	inhibitor
DAP001542	Flucytosine	MolPort-000-155-561; LS-59140; AKOS005063821; HMS2093J05; Flucystine; Ro-2-9915; MolPort-002-317-353; 5987P; UNII-D83282DT06; MLS000069463; MLS000759519; AKOS004912683; MolPort-001-774-493; 4-Amino-5-fluoropyrimidin-2(1H)-one; Flucytosine (JP15/USP/INN); C4H4FN3O; 4-Amino-5-fluoro-2-hyroxypyrimidine; HSDB 3082; Flucytosine [USAN:INN:BAN:JAN]; BSPBio_000868; I07-0006; 5-Fluorocytosine; Ancotil; Fluorcytosine; NCI60_000093; Ancotyl; AC-11748; Flucytosinum; 5-Fluorocytosine-6-3H; 4-Amino-5-fluoro-2(1H)-pyrimidinone; Flucitosina; Ancobon; Flucytosin; Flucitosina [DCIT]; Cytosine, 5-fluoro- (6CI,7CI,8CI); 6-amino-5-fluoro-1H-pyrimidin-2-one; Prestwick2_000934; Flucytosone; EINECS 217-968-7; GL663142 & 4-Amino-5-fluoropyrimidin-2(1H)-one; HMS2051M04; 4-Amino-5-fluoro-2-hydroxypyrimidine; D00323; 5-Fluorocystosine; 2022-85-7; Prestwick3_000934; 46850_FLUKA; F6770_SIGMA; 5-Flucytosine; Prestwick0_000934; CHEBI:5100; HMS1570L10; NSC 103805; 2(1H)-Pyrimidinone, 4-amino-5-fluoro-; SPBio_003037; MLS001076503; Flucytosinum [INN-Latin]; Cytosine, 5-fluoro-; WLN: T6MVNJ DZ EF; GL663142 & 5FC; 2-Hydroxy-4-amino-5-fluoropyrimidine; F7129_SIGMA; CPD000059047; CHEMBL1463; Prestwick1_000934; Fluorocytosine; Fluocytosine; BPBio1_000956; CAS-2022-85-7; SMR000059047; 5-Fluorocytosin; ZINC00896546; Ro 2-9915; 9074P; NCGC00016599-01; S1666_Selleck; 5-Flurocytosine; Ro 29915 E/265601; STK292386; F0321; AB00513969; Alcobon; CID3366; 6-Amino-2-oxo-5-fluoropyrimidine; 2(1H)-Pyrimidinone, 4-amino-5-fluoro-); LT00771985; flucytosine; SAM001246753; MolPort-003-990-777; AC1Q52OQ; 5-FC; DB01099; TL8001667; NSC103805; AC1L1FRT; Ancobon (TN); 5-fluoro cytosine	2022-85-7	3366	N/A	TTDS00301	Thymidylate synthase	HrTS;Human recombinant thymidylate synthase;OK/SW-cl.29;TS;TSase	P13922	N/A	N/A	inhibitor
DAP000829	Fluorouracil	NCGC00015442-03; Ftoruracil; Neocorp Brand of Fluorouracil; Fluoroplex (TN); 5-Fluor-2,4-pyrimidindiol [Czech]; Ulup; U-8953; STK297802; Roche Brand of Fluorouracil; SPBio_000291; ribosepharm Brand of Fluorouracil; 5-Fluoro-2,4(1H,3H)-pyrimidinedione; D005472; S1209_Selleck; AI3-25297; Fluorouracile; Effluderm; Fluroblastin; T5233394; 2,4-Dioxo-5-fluoropryimidine; Fluril; Cinco FU; MLS000069498; MolPort-000-156-102; 5-fluoropyrimidine-2,4(1H,3H)-dione; Efudix; Ferrer Brand of Fluorouracil; Dermatech Brand of Fluorouracil; D00584; Fluoro Uracile ICN; 5-Fluoropyrimidine-2,4-dione; Fluorouracilo [INN-Spanish]; 5-Ftouracyl; Kecimeton; NSC-19893; UNII-U3P01618RT; Haemato fu; Fluracil; BSPBio_002048; Fluorouracilum; NCI60_001652; Fluorouracile [DCIT]; Phthoruracil; Fluro Uracil; Teva Brand of Fluorouracil; C07649; 5-Fluor-2,4-pyrimidindiol; KBioSS_001321; NCGC00091349-05; 5-FU medac; Haemato Brand of Fluorouracil; biosyn Brand of Fluorouracil; CHEMBL185; HMS1920O18; 79108-01-3; NCGC00091349-08; Fluorouracilo Ferrer Far; NCGC00091349-01; 5-Fluoruracil [German]; AC-11201; Fluoruracil; 47576_FLUKA; TL8006093; nchembio.90-comp3; KBio2_003889; MolPort-005-861-486; EU-0100536; AKOS000119162; nchembio809-comp6; Fluorouracil Teva Brand; CHEBI:46345; NSC19893; Fluracilum; Fluoroblastin; Flurodex; NCGC00015442-01; Effluderm (free base); IDI1_000054; Riemser Brand of Fluorouracil; 4921-97-5; U 8953; NSC 19893; KBio3_001268; 5-FU; HMS2090I04; NCGC00015442-10; 5-HU Hexal; NCGC00091349-07; F8423_SIGMA; Fluorouracil Potassium Salt; KBioGR_001253; Fluorouracile Dakota; Arumel; Fluorouracilum [INN-Latin]; NCGC00091349-02; Queroplex; 5-Fluor-2,4-dihydroxypyrimidin [Czech]; FU; 1004-03-1; Dakota, Fluorouracile; Spectrum3_000434; 5-Fluor-2,4(1H,3H)-pyrimidindion; Ro 2-9757; Fluorouracil, 5-; Onkoworks Brand of Fluorouracil; AC1Q4N2X; Fluri; Phtoruracil; 5-Fluoracyl; 5-Fluoracil [German]; ZINC00897110; AC1L1FTE; ICN Brand of Fluorouracil; 5 FU Lederle; medac Brand of Fluorouracil; Allergan Brand of Fluorouracil; Fluorouracil Monopotassium Salt; MolPort-004-758-144; Ribofluor; CPD000038082; Fluoro-Uracile ICN; Efurix; 5-FU Lederle; NINDS_000054; Fluorouracilo; DB00544; 5 Fluorouracil biosyn; inhibits thymilidate synthetase; 5-Fluorouracil-biosyn; BB_NC-0576; 5-Fluoro-2,4-pyrimidinedione; I07-0022; 5 FU medac; tetratogen; 2,4(1H,3H)-Pyrimidinedione, 5-fluoro-; 5 Fluorouracil; Fluoro-uracilo; Carac; 51-21-8; KBio1_000054; FT-0082524; EINECS 200-085-6; Haemato-fu; 5-FU (TN); F0151; Efudex; Fluracedyl; Uracil, 5-fluoro-; Onkofluor; Spectrum4_000557; MolPort-003-990-447; MolPort-004-758-143; NCGC00091349-04; HMS500C16; UPCMLD-DP130:001; 2,4-Dioxo-5-fluoropyrimidine; MLS002415705; KBio2_006457; fluorouracil; Dermik Brand of Fluorouracil; Carac (TN); Fluorouracil-GRY; 5-Fluoruracil; Spectrum5_000718; Fluorouracil (JP15/USP/INN); 5-fluoro uracil; DivK1c_000054; 5FU; 5-Fluoropyrimidin-2,4-diol; 5-Fluor-2,4(1H,3H)-pyrimidindion [Czech]; HMS2091F19; WLN: T6MVMVJ EF; LS-153; Fluorouracil Monosodium Salt; Hexal Brand of Fluorouracil; CCRIS 2582; Spectrum_000841; AKOS003237897; Timazin; SAM002264615; SPECTRUM1500305; Ro-2-9757; SMR000038082; Fluorouracil GRY; 5-Fluor-2,4-dihydroxypyrimidin; UPCMLD-DP130; CID3385; Adrucil; Fluoro-uracile; Gry Brand of Fluorouracil; IN1335; Fluoroplex; Lopac0_000536; 5-Fluoracil; 5-Fluorouracil; Lopac-F-6627; KBio2_001321; HSDB 3228; URF; CPD0-1327; 1-fluoro-1h-pyrimidine-2,4-dione; 5-Faracil; 5 HU Hexal; Fluorouracil Mononitrate; 5-fluoro-1H-pyrimidine-2,4-dione; Dakota Brand of Fluorouracil; Adrucil (TN); F6627_SIGMA; F 6627; C4H3FN2O2; Neofluor; 1upf; Spectrum2_000076; 2,4-Dihydroxy-5-fluoropyrimidine; CSP Brand of Fluorouracil; Fluorouracil [USAN:INN:BAN:JAN]; NCGC00091349-03; Carzonal	51-21-8	3385	7847650	TTDS00301	Thymidylate synthase	HrTS;Human recombinant thymidylate synthase;OK/SW-cl.29;TS;TSase	P13922	N/A	N/A	inhibitor
DAP001244	Leucovorin/5-fluorouracil	N/A	1492-18-8	54575	148853	TTDS00301	Thymidylate synthase	HrTS;Human recombinant thymidylate synthase;OK/SW-cl.29;TS;TSase	P13922	N/A	N/A	inhibitor
DAP000967	Eculizumab	Alexion; Eculizumab; D03940; 219685-50-4; Eculizumab (genetical recombination) (JAN); Alexion (TN); Eculizumab (USAN/INN); Eculizumab (genetical recombination)	219685-50-4	5244802	47205928	TTDS00435	Complement C5	N/A	P01031	727	ENSG00000106804	antibody
DAP001221	Tretinoin	D00094; Retinoic acid, 9-cis-; Atralin; beta all trans Retinoic Acid; Retisol-A; Alitretinoin; Effederm; Nexret; HMS1361K22; Salt, Tretinoin Potassium; Acid A Vit (Belgium, Netherlands); Tretinoine; R 2625; 9-cis-RA; 187175-63-9; Renova (TN); Atra-IV; Vitamin A1 acid, all-trans-; AC1L9GWO; Isotretinoin Retinoic acid; WLN: L6UTJ A1 B1U1Y1 & U2U1Y1 & U1VQ C1 C1; beta-all-trans-Retinoic acid; NCGC00021808-04; Acid, trans-Retinoic; 13497-05-7 (hydrochloride salt); Acid, Vitamin A; BIDD:PXR0081; DB00982; all-trans-b-Retinoic acid; I14-2351; Stieva-A; Retacnyl; HMS2089D20; Aberela [Norway]; [3H]Retinoic acid; Airol; HSDB 7186; Tretinoinum [INN-Latin]; Tri-Luma; WLN: L6UTJ A1 B1U1Y1&U2U1Y1&U1VQ C1 C1; BPBio1_000082; .beta.-Retinoic acid; Tretinoin Sodium Salt; SR-01000000239-14; Effederm [France]; Vitinoin; HMS1791K22; Vesanoid (TN); EU-0101061; AC-6824; Vesnaroid; Zinc Salt, Tretinoin; HMS1921D14; AC1Q1J2J; beta-Ra; AKOS000280845; R2625_SIGMA; C00777; Panretin Gel; Tretinoinum; Cordes vas; beta-Retinoic acid; Retinoic acid, all-trans-; tretinoin liposome; SPECTRUM1502016; Retinoate; SR-01000000239; Tretinoino [INN-Spanish]; ATRA; Dermairol; trans-Retinoic acid; Vesanoid, Airol, Renova, Atralin, Retin-A, Avita,  Tretinoin; Retin-A Micro; 1n4h; Tretinoin Potassium Salt; Tretinoin (TN); Lsotretinoin; 302-79-4; Tretinoin (JAN/USP/INN); Avita (TN); PDT-002-002; MolPort-000-883-857; Acnavit; R0064; Cordes VAS [Germany]; Avita Gel; NCGC00021808-15; all-trans-Vitamin A1 acid; CHEBI:15367; bmse000562; BRN 2057223; 15-Apo-beta-caroten-15-oic acid; Aberela; RETINOIC ACID, ALL TRANS; all-trans-Vitamin A acid; nchembio.154-comp2; all-trans-Tretinoin; BSPBio_001500; Eudyna; Retin-A; CID444795; Vitamin A acid; Tretinoin [USAN:INN:BAN]; HMS2092N11; all-trans-beta-Retinoic acid; all trans-Retinoic acid; Sodium Salt, Tretinoin; ALRT 1057; Ro 1-5488; IDI1_033970; A-Vitaminsyre [Denmark]; UPCMLD-DP097; BML2-E05; Retinova; Spectrum5_001746; NSC122758; Tretinoina; DB00755; 56573-65-0; Tretinoin Zinc Salt; Tretinoino; Retinoic acid, all-trans- (8CI); Avitoin; Tretinoin 0.1% cream or placebo; Lopac0_001061; Acid, beta-all-trans-Retinoic; All Trans Retinoic Acid; NCGC00021808-07; b-Retinoic acid; NSC 122758; MLS002222211; Acid, all-trans-Retinoic; CCRIS 7098; NCGC00021808-14; A-Acido (Argentina); Tretinoin/All-Trans Retinoic Acid; Spectrum5_001933; AGN 100335; HMS1989K22; LMPR01090019; Tretin M; Solage; trans Retinoic Acid; Retinoic acid; Aknoten; Acnavit [Denmark]; HMS502N05; Vitamin a acid, trans-; Aknefug; CCRIS 3294; Retionic acid; Salt, Tretinoin Zinc; DB00523; Acide retinoique (French) (DSL); LS-1154; Avitoin [Norway]; LGD 100057; NCGC00021808-05; L000833; MLS000028588; Prestwick_424; NCGC00017280-06; Epi-aberel; Retinoic acid, cis-9,trans-13-; CPD000058245; 9(Z)-Retinoic acid; Tretinoina [INN-Spanish]; 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid; UNII-1UA8E65KDZ; NCGC00017280-17; all-(E)-Retinoic acid; all-trans-Retinoic acid; Aberel; Accutane Roche; HMS1568D16; SAM002264647; tretinoine (French) (EINECS); Potassium Salt, Tretinoin; 7005-78-9; A-Vitaminsyre; TRETINON; ST057075; Acid, Retinoic; Vitamin A acid, all-trans-; 5300-03-8; BAL4079; S1653_Selleck; D014212; NCGC00021808-06; AT-RA; tretinoin; 2,4,6,8-Nonatetranoic acid, 3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-; EINECS 206-129-0; Tretinoine [INN-French]; REA; Alltrans-retinoic acid; Stieva-a Forte; Prestwick3_000257; BIDD:GT0483; UNII-5688UTC01R; Retin A (TN); Vesanoid; All-trans Retinoic Acid; Tretinoin, all-trans-; Atragen; I04-0008; Betarretin; IDI1_000903; BSPBio_000074; Salt, Tretinoin Sodium; AGN 192013; HSDB 2169; Prestwick2_000257; NCGC00021808-09; CHEMBL38; NSC-122758; Panretyn; Renova; SMR000058245; Retin A; MLS001076515; MLS002207234	302-79-4	5538	7847162	TTDS00072	Retinoic acid receptor	N/A	N/A	N/A	N/A	binder
DAP001543	Vitamin A	AC1Q7BU9; Alphasterol; all-trans-Vitamin A1; 1406-67-3; NCGC00091784-01; M.V.C. 9+3; 95146_SIGMA; Apexol; Retinol solution; Apostavit; Retinol, all-trans-; Homagenets aorl; Vitamin A alcohol, all-trans-; 95146_FLUKA; Ophthalamin; AC1L9HU3; 68-26-8; Myvpack; Vi-a; Retinolum; Vitamin- A1; [11,12-3H]-Retinol; 2,4,6,8-Nonatetraen-1-ol, 3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-, (all-E)-; All-trans retinol; CCRIS 5444; Ro-a-vit; Spectrum5_001997; Epiteliol; Aquasynth; All Trans Retinol; NCGC00091784-02; AC-11701; A-Mulsal; SMP2_000102; D014801; Super A; Vitamin-?A alcohol; NSC122759; Vitamin A1, all-trans-; LS-1578; A-Sol; Homagenets Aoral; Vitamin A1 alcohol; retinol; Vitamin- A alcohol solution; R7632_SIGMA; 95144_SIGMA; Retrovitamin A; 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclchexen-1-yl)-2,4,6,8-nonatetraen-1-ol; .alpha.lin; Vogan-Neu; Alcovit A; Retinolo [DCIT]; Avita; 4-06-00-04133 (Beilstein Handbook Reference); 5979-23-7; Bentavit A; trans-retinol; Anatola A; UNII-81G40H8B0T; Prepalin; Aoral; Dofsol; Axerophthol; Vogan-nu; NCGC00091784-06; all-trans-Retinol; trans-Retinol acid (Vitamin A); Disatabs Tabs; Mvc Plus; Lard Factor; NCGC00091784-05; Vitamin-?A1; Vogan; CID445354; Vi-Dom-A; Vitpex; MolPort-001-785-962; Retinol, all trans-; all-trans-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol; NCGC00091784-03; Vitamin A alcohol; Wachstumsvitamin; CHEMBL986; NCGC00091784-04; Retinolum [INN-Latin]; Retin-11,12-t2-ol (9CI); Agoncal; Anti-infective vitamin; ALL-TRANS RETINOL (SEE ALSO RETINOID PROJECT 1); Alphalin; Avitol; Vi-Alpha; 17104-91-5; NSC 122759; 1341-18-0; AR-1L3057; Retinol-(cellular-retinol-binding-protein); Chocola A; Anatola; LMPR01090001; (2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraen-1-ol; Solu-A; 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol; Testavol; all-trans-Vitamin A; Atars; Cylasphere; Vitamin- A; BIDD:PXR0102; CHEBI:17336; Avibon; HMS2092L13; 95144_FLUKA; tROL; DB00162; C20H30O; Retinol [INN:BAN]; Axerol; Hi-A-Vita; Vitamin A1 alcohol, all trans; Vitamine A; 53637-36-8; all-trans-Vitamin A alcohol; LPK; ACON; Vitamin A (Feed); C17276; IDI1_000486; Biosterol; A-Vi-Pel; .alpha.sterol; UNII-G2SH0XKK91; Vio-A; Vitavel-A; 1rbp; 3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol, (all-E)-Isomer; A-Vitan; Antixerophthalmic vitamin; SPECTRUM1501203; ATAV; Vitamin A; SDCCGMLS-0066724.P001; EINECS 234-328-2; EINECS 200-683-7; Vitamin A alcohol (VAN); Vitamin A cryst; Hydrovit A; Oleovitamin A; Axerophtholum; (all-E)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol; beta-Retinol; 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonate-traen-1-ol; Vitamin-?A alcohol solution; Vitaminum A; 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexenyl)-2,4,6,8-nonatetraen-1-ol; HMS501I08; Vitamin A (USP); Vitamin- A alcohol; Afaxin; Vitamin A1 alcohol, all-trans-; Rovimix A 500; Vitavel A; Aquasol A Parenteral; 13123-33-6; BRN 0403040; Spectrum5_000993; SMR000112036; MLS001074751; Plivit A; Agiolan; M.V.I.-12; Retinolo; Del-VI-A; all-trans-Retinyl alcohol; Nio-A-Let; C00473; Thalasphere; ZINC03831417; Zinosan N; Vi-alpha; Vi-alpha; Vaflol; WLN: L6UTJ A1 B1U1Y1&U2U1Y1&U2Q C1 C1; Retinol, all-trans- (8CI); ST057232; 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol, (all-E)-; Alcohol 9,13-dimethyl-7-(1,1,5-trimethyl-6-cyclohexen-5-yl)-7,9,11,13-nonatetraen-15-ol; Vitamin-?A; Sehkraft A; Vafol; Testavol S; HMS1921B04; (2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraen-1-ol; D06543; Veroftal; alin; MLS001066379; HSDB 815; Dohyfral A; trans-Vitamin A alcohol; 11103-57-4; Vitamin A1; Vi-.alpha.; .beta.-Retinol; Antixerophthalmisches Vitamin	11103-57-4	445354	842011	TTDS00072	Retinoic acid receptor	N/A	N/A	N/A	N/A	binder
DAP000115	Adapalene	CHEMBL76401; AKOS005145841; CD-271; CD 271; Adapaleno; MolPort-003-986-211; NCGC00164617-01; MolPort-006-823-940; AC-1974; 6-(3-(1-Adamantyl)-4-methoxyphenyl)-2-naphthoic acid; TL8000241; CHEMBL1265; I06-0642; CHEBI:217732; ADAPALENE; AC1L1SOH; Differin, Adapalene; SMR000466349; CD271; SAM001246663; Differine; CID60164; CPD000466349; 106685-40-9; Adaferin; D01112; CHEBI:31174; 2-Naphthalenecarboxylic acid, 6-(4-methoxy-3-tricyclo(3.3.1.1(sup 3,7))dec-1-ylphenyl)-; C28H28O3; Differin (TN); MLS000759463; 6-(3-adamantan-1-yl-4-methoxyphenyl)naphthalene-2-carboxylic acid; KS-1196; 6-[3-(1-adamantyl)-4-methoxyphenyl]naphthalene-2-carboxylic acid; Adapaleno [INN-Spanish]; AC1Q5USH; Ambap106685-40-9; S1276_Selleck; Adapalene [USAN:BAN:INN]; Differin; Adapalene (JAN/USAN/INN); Adapalenum [INN-Latin]; LS-172017; DB00210; UNII-1L4806J2QF; BIDD:GT0264; Adapalenum; 6-[3-(adamantan-1-yl)-4-methoxyphenyl]-2-naphthoic acid	106685-40-9	60164	582899	TTDS00072	Retinoic acid receptor	N/A	N/A	N/A	N/A	binder
DAP000009	Isotretinoin	Prestwick_642; Spectrum5_001795; Ro-4-3780; Isotrex; Spectrum5_001937; CPD000471891; Ro-43780; 13 Cis-Retinoic Acid; Ro 4-3780; 13-cis RA; Accutane; BSPBio_003345; Isotretinoinum [INN-Latin]; Prestwick2_000256; RETINOIC ACID, 13-cis-; Isotretinoin Retinoic acid; HMS1361C13; HMS2092N07; NCGC00094358-05; Isotretinoine [INN-French]; Isotretinoin [USAN:INN:BAN]; BSPBio_000072; MLS001074662; R 3255; NCGC00094358-01; 13-RA; 4-09-00-02388 (Beilstein Handbook Reference); isotretinoino; HSDB 3929; 4759-48-2; NCGC00094358-08; NCGC00094358-04; BRD-K76723084-001-05-9; CHEBI:6067; CIP-Isotretinoin; BRN 1885770; Claravis; IDI1_033801; 13-cis-Retinoic acid; Isotretinoin; UNII-EH28UP18IF; HMS1791C13; HMS1568D14; AC1NQZZ4; (13cis)-retinoic acid; Isotretinoinum; Prestwick3_000256; SPECTRUM1502013; CCRIS 4286; Teriosal; (7E,9E,11E,13Z)-retinoic acid; (2Z,4E6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenoic acid; Roacutan; R3255_SIGMA; Isotretinoine; EINECS 225-296-0; Roaccutane; MolPort-003-666-394; LMPR01090021; BML2-E07; Retinoic acid, cis-; Lopac0_001081; Retinoic acid, (13cis)-; Accutane (TN); Sotret; Ro 43780; NCGC00094358-03; NCGC00094358-13; LS-143465; 13-cis-Vitamin A acid; 13-cis retinoic acid; SAM002548955; AC-15388; Ro 4 3780; 97950-17-9; HMS1989C13; HMS1921D08; Isotretinoin (USP); Ambap302-79-4; CID5282379; (2Z,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoic acid; Roaccutan; D00348; EU-0101081; Neovitamin A acid; SMR000471891; BSPBio_001331; Isotretinoin Zinc Salt, 13-cis-Isomer; 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)2-cis-4-trans-6-trans-8-trans-nonatetraenoic acid; Isotretinoino [INN-Spanish]; Isotane; Sotret (TN); CHEMBL547; Amnesteem; NCGC00094358-09; BPBio1_000080; NCGC00094358-06; 13 cis retinoic acid; NCGC00094358-07; NCGC00094358-02; Isotretinoin Zinc Salt, 13 cis Isomer; D015474	4759-48-2	5538	7847414	TTDS00072	Retinoic acid receptor	N/A	N/A	N/A	N/A	agonist
DAP000095	Anakinra	143090-92-0; Anakinra; D02934; Anakinra (USAN/INN); Kineret; Kineret (TN)	143090-92-0	N/A	46507944	TTDS00138	Interleukin 1 receptor	IL-1R	P14778	3554	ENSG00000115594	antagonist
DAP001296	Secretin	L-Histidyl-L-seryl-L-alpha-aspartylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-alpha-glutamyl-L-leucyl-L-seryl-L-arginyl-L-leucyl-L-arginyl-L-alpha-glutamylglycyl-L-alanyl-L-arginyl-L-leucyl-L-glutaminyl-L-arginyl-L-leucyl-L-leucyl-L-glutaminylglycyl-L-leucyl-L-valinamide; Hormone of the duodenal mucosa that activates pancreatic secretion and lowers the blood sugar level; Secrepan; Secretine; SECRETIN; SECREFLO; 1393-25-5; L-Histidyl-L-seryl-L-alpha-aspartylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-alpha-glutamyl-L-leucyl-L-seryl-L-arginyl-L-leucyl-L-arginyl-L-alpha-aspartyl-L-seryl-L-alanyl-L-arginyl-L-leucyl-L-glutaminyl-L-arginyl-L-leucyl-L-leucyl-L-glutaminylglycyl-L-leucyl-L-valinamide; Secretin (porcine); L-Valinamide, L-histidyl-L-seryl-L-.alpha.-aspartylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-.alpha.-glutamyl-L-leucyl-L-seryl-L-arginyl-L-leucyl-L-arginyl-L-.alpha.-glutamylglycyl-L-alanyl-L-arginyl-L-leucyl-L-glutaminyl-L-arginyl-L-leucyl-L-leucyl-L-glutaminylglycyl-L-leucyl-; Secretin (porcine), 15-L-glutamic acid-16-glycine-; Secretinum; 9002-77-1; SECRETIN-FERRING; Secretina [INN-Spanish]; 67307-60-2 (citrate (salt)); EINECS 215-733-3; Secretin-Kabi; UNII-A0426J905J; Secretin (pig), 15-L-glutamic acid-16-glycine-; Secretin [INN:BAN:DCF:JAN]; 108153-74-8; Secretolin; Secretina; Secretin (human); SecreFlow; LS-144747; Vitrum; Secretine [INN-French]; I06-1828; Human secretin; Secretinum [INN-Latin]; RG 1068; UNII-88C55N56UU	108153-74-8	N/A	46508060	TTDS00491	Secretin receptor	SCTR;SCT-R	P47872	6344	ENSG00000080293	binder
DCL001249	TTP435	N/A	N/A	N/A	N/A	TTDR00096	Agouti-related protein	Agouti related protein;Agouti-related peptide;AGRP	O00253	181	ENSG00000159723	inhibitor
DCL000927	PG-116800	PGE 530742; 4-Hexynoic acid, 2-(((4-((4-methoxybenzoyl)amino)phenyl)sulfonyl)amino)-6-(4-morpholinyl)-; PG 530742; PGE 7113313; 291533-11-4; 668998-02-5; PG-116800; PG 116800	N/A	N/A	N/A	TTDC00104	72 kDa type IV collagenase	72 kDa gelatinase;Gelatinase A;Matrix metalloproteinase 2;Matrix metalloproteinase-2;MMP-2;TBE-1	P08253	4313	ENSG00000087245	inhibitor
DCL000014	BB-3644	N/A	143257-98-1	65997	43122719	TTDC00104	72 kDa type IV collagenase	72 kDa gelatinase;Gelatinase A;Matrix metalloproteinase 2;Matrix metalloproteinase-2;MMP-2;TBE-1	P08253	4313	ENSG00000087245	inhibitor
DCL000008	Neovastat	N/A	305838-77-1	N/A	3820640	TTDC00104	72 kDa type IV collagenase	72 kDa gelatinase;Gelatinase A;Matrix metalloproteinase 2;Matrix metalloproteinase-2;MMP-2;TBE-1	P08253	4313	ENSG00000087245	inhibitor
DCL000005	Marimastat	15039-60-8; Butanediamide, N4-(2,2-dimethyl-1-((methylamino)carbonyl)propyl)-N1,2-dihydroxy-3-(2-methylpropyl)-, (2S-(N4(R*),2R*,3S*))-; D03795; (2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N',3-dihydroxy-2-(2-methylpropyl)butanediamide; Marimastat [USAN]; CHEBI:50662; BB-2516; Butanediamide, N4-((1S)-2,2-dimethyl-1-((methylamino)carbonyl)propyl)-N1,2-dihydroxy-3-(2-methylpropyl)-, (2S,3R)-; UNII-D5EQV23TDS; 154039-60-8; DB00786; CHEMBL279785; Butanediamide, N(sup 4)-(2,2-dimethyl-1-((methylamino)carbonyl)propyl)-N(sup 1),2-dihydroxy-3-(2-methylpropyl)-, (2S-(N(sup 4)(R*),2R*,3S*))-; (2S,3R)-N(4)-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N(1),2-dihydroxy-3-(2-methylpropyl)butanediamide; AC1L3O2N; C15H29N3O5; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoyl)propyl)carbamoyl)-2-hydroxy-5-methylhexanohydroxamic acid; CID119031; Marimastat; C100342; LS-45634; BB 2516; Marimastat (USAN/INN); (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoxy)propyl)carboyl)-2-hydroxy-5-methylhexanohydroxamic acid	154039-60-8	119031	46505547	TTDC00104	72 kDa type IV collagenase	72 kDa gelatinase;Gelatinase A;Matrix metalloproteinase 2;Matrix metalloproteinase-2;MMP-2;TBE-1	P08253	4313	ENSG00000087245	inhibitor
DPR000099	RO-26-2853	N/A	N/A	N/A	N/A	TTDC00104	72 kDa type IV collagenase	72 kDa gelatinase;Gelatinase A;Matrix metalloproteinase 2;Matrix metalloproteinase-2;MMP-2;TBE-1	P08253	4313	ENSG00000087245	inhibitor
DCL000004	Prinomastat	CHEMBL75094; D03797; MolPort-000-883-336; AG-3354; AC1LAD25; AG-3362; Prinomastat (USAN/INN); CHEBI:220195; 3-Thiomorpholinecarboxamide, N-hydroxy-2,2-dimethyl-4-[[4-(4-pyridinyloxy)phenyl]sulfonyl]-, (3S)-; CID466151; (3S)-N-hydroxy-2,2-dimethyl-4-(4-pyridin-4-yloxyphenyl)sulfonylthiomorpholine-3-carboxamide; AKOS000280753; Opc 51803	58-38-8	466151	17397885	TTDC00104	72 kDa type IV collagenase	72 kDa gelatinase;Gelatinase A;Matrix metalloproteinase 2;Matrix metalloproteinase-2;MMP-2;TBE-1	P08253	4313	ENSG00000087245	inhibitor
DPR000163	Batimastat	(2S,3R)-5-Methyl-3-(((alphaS)-alpha-(methylcarbamoyl)phenethyl)carbamoyl)-2-((2-thienylthio)methyl)hexanohydroxamic acid; CHEBI:40976; 2j83; C23H31N3O4S2; (2S,3R)-N-hydroxy-N'-[(2S)-1-(methylamino)-1-oxo-3-phenylpropan-2-yl]-3-(2-methylpropyl)-2-(thiophen-2-ylsulfanylmethyl)butanediamide; BB94; AC1NSFYO; 130370-60-4; C080985; BB-94; batimastat; CHEMBL279786; BB94 cpd; ISV-615; Batimastat (USAN/INN); MolPort-006-822-709; CHEBI:123429; 4-(N-HYDROXYAMINO)-2R-ISOBUTYL-2S-(2-THIENYLTHIOMETHYL)SUCCINYL-L-PHENYLALANINE-N-METHYLAMIDE; BB 94; UNII-BK349F52C9; BB-99; BB94, BB-94; (4-(N-hydroxyamino)-2-isobutyl-3-(thiophen-2-ylthiomethyl)succinyl)phenylalanine-N-methylamide; LS-45637; Butanediamide, N(sup 4)-hydroxy-N(sup 1)-(2-(methylamino)-2-oxo-1-(phenylmethyl)ethyl)-2-(2-methylpropyl)-3-((2-thienylthio)methyl)-, (2R-(1(S*),2R*,3S*))-; ISV-120; CID5362422; D03061; 1rm8; Batimastat [USAN:BAN:INN]; Butanediamide, N4-hydroxy-N1-(2-(methylamino)-2-oxo-1-(phenylmethyl)ethyl)-2-(2-methylpropyl)-3-((2-thienylthio)methyl)-, (2R-(1(S*),2R*,3S*))-; DSX; DB03880	N/A	N/A	N/A	TTDC00104	72 kDa type IV collagenase	72 kDa gelatinase;Gelatinase A;Matrix metalloproteinase 2;Matrix metalloproteinase-2;MMP-2;TBE-1	P08253	4313	ENSG00000087245	inhibitor
DPR000164	Metastat	CMT-3; Incyclinide; NSC-683551; Incyclinide (USAN); CID9820748; D04519; COL-3; Metastat (TN); Metastat	N/A	N/A	N/A	TTDC00104	72 kDa type IV collagenase	72 kDa gelatinase;Gelatinase A;Matrix metalloproteinase 2;Matrix metalloproteinase-2;MMP-2;TBE-1	P08253	4313	ENSG00000087245	inhibitor
DCL000243	Tanomastat	BAY-12-9566; CHEMBL261932; MolPort-003-850-390; D03802; (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid; CID6918336; AC1OCFB0; CHEBI:288694; Tanomastat; Tanomastat (USAN/INN); 179545-77-8	179545-77-8	6918336	17397890	TTDC00104	72 kDa type IV collagenase	72 kDa gelatinase;Gelatinase A;Matrix metalloproteinase 2;Matrix metalloproteinase-2;MMP-2;TBE-1	P08253	4313	ENSG00000087245	inhibitor
DCL000003	BMS 275291	N-((2S)-2-Mercapto-1-oxo-4-(3,4,4-trimethyl-2,5-dioxo-1-imidazolidinyl)butyl)-L-leucyl-N,3-dimethyl-L-valinamide; L-Valinamide, N-((2S)-2-mercapto-1-oxo-4-(3,4,4-trimethyl-2,5-dioxo-1-imidazolidinyl)butyl)-L-leucyl-N,3-dimethyl-; BMS 275291; AC1L3WNB; (2S)-N-[(2S)-3,3-dimethyl-2-(methylamino)butanoyl]-4-methyl-2-[[(2S)-2-sulfanyl-4-(3,4,4-trimethyl-2,5-dioxoimidazolidin-1-yl)butanoyl]amino]pentanamide; UNII-1B47R6ZX4K; CID148203; D 2163	259188-38-0	148203	725892	TTDC00104	72 kDa type IV collagenase	72 kDa gelatinase;Gelatinase A;Matrix metalloproteinase 2;Matrix metalloproteinase-2;MMP-2;TBE-1	P08253	4313	ENSG00000087245	inhibitor
DAP000013	Dipyridamole	HMS1568M06; Agilease; Spectrum5_000839; CPD000058382; UPCMLD-DP072:001; Dipyridamolum; EU-0100464; Pyrimido(5,4-d)pyrimidine, 2,6-bis(bis(2-hydroxyethyl)amino)-4,8-dipiperidino-; S1895_Selleck; Iv Persantine; HMS2089N15; D004176; AC1Q7CXU; Coronarine; KBio2_006620; BIM-0050449.0001; NCGC00015385-07; Miosen; NSC-515776; Natyl; LS-66732; AC1L1F6T; Dipyridamole (JP15/USP/INN); KBio2_004052; NSC 515776; Novo-Dipiradol; KBio2_001484; NCGC00023914-11; S1867_Selleck; IPRAD Brand of Dipyridamole; NCGC00015385-15; RA 8; Spectrum_001004; DB00975; Antistenocardin; 2,6-Bis(diethanolamino)-4,8-dipiperidinopyrimido[5,4-d]pyrimidine; Lopac0_000464; NCGC00023914-05; KBio3_001144; MLS001076306; Stenocardiol; NSC515776; Spectrum2_000972; IDI1_000696; Kurantil; NCGC00023914-04; CHEBI:4653; Dipyridamol; NCGC00023914-08; SMP2_000208; AC1Q7CXW; Coribon; 4-26-00-03840 (Beilstein Handbook Reference); ZINC00643046; HMS1989N16; Apo-Dipyridamole Fc; HMS502C18; Novopharm Brand of Dipyridamole; Dipiridamol [INN-Spanish]; Prestwick3_000142; UPCMLD-DP072; BRN 0068373; Pyrimido(5,4-d)pyrimidine, 2,6-bis[bis(2-hydroxyethyl)amino]-4,8-diperidino-; NCI60_005689; C24H40N8O4; 2,6-Bis(diethanolamino)-4,8-dipiperidinopyrimido[5,4-d]pyrimidine; Permole, Persantine, Dipyridan, Dipyridamole; Usaf Ge-12; SMR000058382; Peridamol; SPBio_002183; Apo-Dipyridamole; Dipyridamole [USAN:INN:BAN:JAN]; Tocris-0691; Cerebrovase; HMS1920I10; Cardoxil; BSPBio_001924; 2,6-Bis(diethanolamino)-4,8-dipiperidinopyrimido(5,4-d)pyrimidine; Prandiol 75; BSPBio_000244; AKOS000509426; Spectrum4_000522; KBio1_000696; Justpertin; NCGC00023914-09; Dipyridan; NCGC00015385-02; Stenocardil; Cleridium 150; 2-[[2-(bis(2-hydroxyethyl)amino)-4,8-di(piperidin-1-yl)pyrimido[6,5-e]pyrimidin-; Boehringer Ingelheim Brand of Dipyridamole; Prandiol; WLN: T66 BN DN GN INJ CCN HCN E- AT6NTJ B2Q F2Q& J- AT6NTJ B2Q F2Q; D9766_SIGMA; NCGC00023914-10; Apo-Dipyridamole Sc; NCGC00023914-07; MLS001333724; Prestwick2_000142; Permiltin; Stimolcardio; Berlin-Chemie Brand of Dipyridamole; HMS2091O18; Corosan; CAS-58-32-2; D 9766; Belmac Brand of Dipyridamole; MLS000028420; Apricor; NCGC00023914-02; Berlin Chemie Brand of Dipyridamole; Coridil; 58-32-2; Coroxin; RA-8; Dipyudamine; KBioSS_001484; SPECTRUM1500259; Dipyridamine; BAS 00818792; Persantine; Gulliostin; Cleridium; CID3108; NCGC00015385-03; Apotex Brand of Dipyridamole; Dipyridamolum [INN-Latin]; Curantil; NCGC00023914-06; BRD-K86301799-001-04-1; DivK1c_000696; Piroan; Chilcolan; 2,6-Bis(diethanolamine)-4,8-dipiperidinopyrimido[5,4-d]pyrimidine; Prestwick_145; IZEKFCXSFNUWAM-UHFFFAOYSA-; NCGC00015385-01; CHEMBL932; Dipiridamol; Lopac-D-9766; AC1Q7CXX; UNII-64ALC7F90C; D2274; SAM002264609; EINECS 200-374-7; Protangix; dipyridamole; Spectrum3_000402; Thymidine, 3'-azido-5-bromo-3'-deoxy-5,6-dihydro-6-methoxy-; HMS1791N16; Cardoxin; Dypyridamol; Bio-0173; Anginal; Prestwick1_000142; Persantin; AB00051974; MolPort-001-792-504; Ashbourne Brand of Dipyridamole; SPBio_001003; Cardioflux; D00302; Curantyl; AC-18100; Dipyramidole; KBioGR_001123; NINDS_000696; BPBio1_000270; Prestwick0_000142; BSPBio_001554; Persantine (TN)	58-32-2	3108	148864	TTDS00092	Adenosine deaminase	Adenosine aminohydrolase	P00813	100	ENSG00000196839	inhibitor
DAP000565	Cladribine	CHEBI:567361; Movectro; CPD000058553; Cladribine [USAN:INN:BAN]; BRN 0624220; cladribinum; SMR000058553; Leustat; DB00242; D01370; 4291-63-8; Chlorodeoxyadenosine; 2-chloro-deoxyadenosine; 2-chloro-6-amino-9-(2-deoxy-beta-D-erythro-pentofuranosyl)purine; cladribina; 2-Chloro-2'-deoxy-beta-adenosine; CHEMBL1619; 2 Chlorodeoxyadenosine; NSC 105014-F; Adenosine, 2-chloro-2'-deoxy; RWJ-26251; CldAdo; NCGC00164384-01; (2R,3S,5R)-5-(6-amino-2-chloropurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol; 2-Chlorodeoxyadenosine; MolPort-005-935-074; UNII-47M74X9YT5; NSC 105014; CID20279; Litak; Cladaribine; NSC-105014; AC-7591; FT-0080707; LS-15109; ADENOSINE, 2-CHLORO-2'-DEOXY-; CL9; MLS000759397; ZINC03798064; 24757-90-2; C10H12ClN5O3.C3H8; D017338; NCGC00022567-05; MLS001077345; RWJ-26251-000; AC1L2FXP; 2-Chloro-6-amino-9-(2-deoxy-beta-D-erythropentofuranosyl)purine; Cladribine; RWJ 26251; 2CdA; HSDB 7564; SAM001246526; 2-CdA; MLS000028377; Mylinax; MLS000028484; 2'-Deoxy-2-chloroadenosine; Cladarabine; MolPort-002-054-532; 2-Chloro-2'-deoxyadenosine; 2ClAdo; S1199_Selleck; HMS2052K13; Leustatin (TN); Leustatin; Leustatin, 2-chlorodeoxyadenosine, Cladribine; Cladribine (JAN/USAN/INN)	4291-63-8	20279	7848433	TTDS00092	Adenosine deaminase	Adenosine aminohydrolase	P00813	100	ENSG00000196839	inhibitor
DAP000567	Fludarabine	D07966; SQ Fludarabine; C10H12FN5O4; Fludarabinum; Fludarabina [Spanish]; NSC 118218; F-Ara-A; CCRIS 3382; AC1Q51CF; 9H-Purin-6-amine, 9-beta-D-arabinofuranosyl-2-fluoro-; FT-0082766; 9-beta-D-arabinofuranosyl-2-fluoro-9H-purin-6-amine; UNII-P2K93U8740; UNII-1X9VK9O1SC; FaraA; NSC 118218H; Fludara, Fludarabine; SAM002548956; (2R,3S,4S,5R)-2-(6-amino-2-fluoropurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol; MLS000028687; 2-Fluoro Ara-A; (2R,3S,4S,5R)-2-(6-amino-2-fluoro-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol; Fludarabina; Fluradosa (TN); CHEMBL1568; NSC-118218; CID657237; HSDB 6964; 21679-14-1; AC1LCW8I; Fludarabine; ZINC04216238; S1491_Selleck; EINECS 244-525-5; LS-15061; 9H-Purin-6-amine, 9-beta-D-arabinofuranosyl-2-fluoro- (9CI); Adenine, 9-beta-D-arabinofuranosyl-2-fluoro-; I14-4978; Fludarabine [INN]; 2-F-ara-A; Fludarabine (INN); Fludarabinum [Latin]; SMR000058874; CPD000058874; 9-beta-D-Arabinofuranosyl-2-fluoroadenine; Fluradosa; 2-Fluoro-9-beta-D-arabinofuranosyladenine	75607-67-9	30751	7848969	TTDS00092	Adenosine deaminase	Adenosine aminohydrolase	P00813	100	ENSG00000196839	inhibitor
DAP000566	Pentostatin	59979-24-7; PD-ADI; CHEMBL1580; CID439693; BIDD:GT0136; DB00552; CI-825; 2'-DCF; AC1L97UQ; Oncopent; Coforin; Nipent; Imidazo[4,5-d][1,3]diazepin-8-ol, 3-(2-deoxy-.beta.-D-erythro-pentofuranosyl)-3,4,7,8-tetrahydro-, (8R)-; Pentostatin (JAN/USAN/INN); (8R)-3-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7,8-dihydro-4H-imidazo[4,5-d][1,3]diazepin-8-ol; CO-Vidarabine; dCF; 2'-Dexoycoformycin; Vira A deaminase inhibitor; Nipent (TN); 53910-25-1; pentostatin; C02267; Covidarabine; Vidarbine; D00155; (8R)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol; PD-81565; 2'-Deoxycoformycin; Deoxycoformycin; Co-V; CL-67310465; (R)-3-(2-Deoxy-.beta.-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo(4,5-d)(1,3)diazepin-8-ol; CHEBI:41829	53910-25-1	40926	181721	TTDS00092	Adenosine deaminase	Adenosine aminohydrolase	P00813	100	ENSG00000196839	inhibitor
DAP000077	Zolmitriptan	CPD000449310; Spectrum2_000728; 4-[[3-(2-dimethylaminoethyl)-1H-indol-5-yl]methyl]oxazolidin-2-one; Zomig ZMT; 2-Oxazolidinone, 4-((3-(2-(dimethylamino)ethyl)-1H-indol-5-yl)methyl)-, (S)-; SPECTRUM1505281; MLS000758208; 311C90; Zomig Nasal Spray; CID60857; (S)-4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-2-oxazolidinone; Zomigon; Zomig; SAM001246841; Zomig-ZMT; (S)-4-((3-(2-(Dimethylamino)ethyl)-1H-indol-5-yl)methyl)-2-oxazolidinone; SAM001247064; SMR000449310; zolmitriptanum; Zolmitriptan [USAN]; Flezol; zolmitriptan; Zomig, Zomigon, AscoTopand, Zomigoro,  Zolmitriptan; SPBio_000656; S1649_Selleck; CHEBI:10124; BW-311C90; C07218; HMS2052K17; (4S)-4-[[3-(2-dimethylaminoethyl)-1H-indol-5-yl]methyl]-1,3-oxazolidin-2-one; LS-100559; (S)-4-[3-(2-Dimethylamino-ethyl)-1H-indol-5-ylmethyl]-oxazolidin-2-one; (4S)-4-({3-[2-(dimethylamino)ethyl]-1H-indol-5-yl}methyl)-1,3-oxazolidin-2-one; AC1L1U2E; HMS1922B04; CHEMBL1185; MLS001424172; zolmitriptane; 4-((3-(2-(Dimethylamino)ethyl)-1H-indol-5-yl)methyl)-2-oxazolidinone; 139264-17-8; HMS2093O14; BIDD:GT0040; AscoTop; KS-5072; Zolmitriptan RapidFilm; UNII-2FS66TH3YW; MolPort-003-666-626; (S)-4-((3-(2-(Dimethylamino)ethyl)indol-5-yl)methyl)-2-oxazolidinone; C16H21N3O2	139264-17-8	441240	7847481	TTDS00099	5-hydroxytryptamine 1B receptor	5-HT-1B;5-HT1B receptor;5-HT-1D-beta;S12;Serotonin 1D beta receptor;Serotonin receptor;Serotonin receptor 1B	P28222	3351	ENSG00000135312	agonist
DAP000063	Frovatriptan	UNII-H82Q2D5WA7; (6R)-6-(methylamino)-6,7,8,9-tetrahydro-5H-carbazole-3-carboxamide; SB 209509; Frovatriptan (INN); Allegro; Migard; HSDB 7363; 158747-02-5; CHEBI:350328; MolPort-005-932-844; Allergo filmtabletten (TN); Miguard; CHEMBL1279; Frova; BIDD:PXR0142; Rilamig; (R)-5,6,7,8-Tetrahydro-6-(methylamino)carbazole-3-carboxamide; Auradol; DB00998; AC1L2U95; CID77992; 1H-Carbazole-6-carboxamide, 2,3,4,9-tetrahydro-3-(methylamino)-, (R)-; LS-186996; Frovatriptan; (3R)-3-(methylamino)-2,3,4,9-tetrahydro-1H-carbazole-6-carboxamide; Allergo filmtabletten; D07997; Frovelan; LS-187764; SB-209509; 1H-Carbazole-6-carboxamide, 2,3,4,9-tetrahydro-3-(methylamino)-, (3R)-	158747-02-5	77992	655050	TTDS00099	5-hydroxytryptamine 1B receptor	5-HT-1B;5-HT1B receptor;5-HT-1D-beta;S12;Serotonin 1D beta receptor;Serotonin receptor;Serotonin receptor 1B	P28222	3351	ENSG00000135312	agonist
DAP000890	Naratriptan	Naramig; N-methyl-2-[3-(1-methyl-4-piperidyl)-1H-indol-5-yl]-ethanesulfonamide; L000432; D08255; naratriptan; 121679-13-8; UNII-QX3KXL1ZA2; Colatan; Amerge, Naramig,Naratriptan; CHEMBL1278; Naratriptan (INN); 1H-Indole-5-ethanesulfonamide, N-methyl-3-(1-methyl-4-piperidinyl)-; Naramig (TN); MolPort-005-932-823; BIDD:GT0312; CHEBI:7478; CID4440; C07792; S1488_Selleck; AC-5013; AC1L1I6A; InChI=1/C17H25N3O2S/c1-18-23(21,22)10-7-13-3-4-17-15(11-13)16(12-19-17)14-5-8-20(2)9-6-14/h3-4,11-12,14,18-19H,5-10H2,1-2H; N-methyl-2-(3-(1-methylpiperiden-4-yl)indole-5-yl)ethanesulfonamide; LS-83062; naratriptanum; N-methyl-2-[3-(1-methylpiperidin-4-yl)-1H-indol-5-yl]ethanesulfonamide; NCGC00181786-01; DB00952	121679-13-8	4440	9994	TTDS00099	5-hydroxytryptamine 1B receptor	5-HT-1B;5-HT1B receptor;5-HT-1D-beta;S12;Serotonin 1D beta receptor;Serotonin receptor;Serotonin receptor 1B	P28222	3351	ENSG00000135312	agonist
DAP000008	Eletriptan	(R)-3-[(1-Methyl-2-pyrrolidinyl)methyl]-5-[2-(phenylsulfonyl)ethyl]-1H-Indole; (R)-5-[2-(Benzenesulfonyl)ethyl]-3-[(N-methylpyrrolidin-2-yl)methyl]-1H-indole; Eletriptan; UK116044; 3-(((R)-1-Methyl-2-pyrrolidinyl)methyl)-5-(2-(phenylsulfonyl)ethyl)indole; UK 116044; Eletriptan (INN); UK-116044-04; AC1L2U98; D07887; UK-116044; 5-[2-(benzenesulfonyl)ethyl]-3-[[(2R)-1-methylpyrrolidin-2-yl]methyl]-1H-indole; UNII-22QOO9B8KI; AB1004885; DB00216; CHEMBL1510; CID77993; AC-3397; eletriptanum; Eletriptan; CHEBI:50922; AKOS005145842; 1H-Indole, 3-(((2R)-1-methyl-2-pyrrolidinyl)methyl)-5-(2-(phenylsulfonyl)ethyl)ethyl)-; 3-{[(2R)-1-methylpyrrolidin-2-yl]methyl}-5-[2-(phenylsulfonyl)ethyl]-1H-indole; Eletriptan [INN:BAN]; NCGC00181130-01; LS-186998; MolPort-005-940-717; LS-187637; 143322-58-1; Relpax	143322-58-1	77993	655051	TTDS00099	5-hydroxytryptamine 1B receptor	5-HT-1B;5-HT1B receptor;5-HT-1D-beta;S12;Serotonin 1D beta receptor;Serotonin receptor;Serotonin receptor 1B	P28222	3351	ENSG00000135312	agonist
DCL000806	Fluphenazine Decanoate	NSC169510; Flufenazine decanoate; AC1L1FTN; Decanoic acid, 2-(4-(3-(2-(trifluoromethyl)-10H-phenothiazin-10-yl)propyl)-1-piperazinyl)ethyl ester; CCRIS 3954; Fluphenazine depot; 5002-47-1; CHEMBL1200854; Decanoic acid, 2-[4-[3-[2-(trifluoromethyl)phenothiazin-10-yl]propyl]-1-piperazinyl]ethyl ester; Fluphenazine decanoate; AKOS003589045; Fluphenazine O-decanoate; EINECS 225-672-4; Fluphenaline decanoate; Moditen-depo; SQ 10,733; Dapotum D; WLN: T C666 BN ISJ EXFFF B3- AT6N DNTJ D2OV9; AC1Q4K03; Moditen depot; 2-(4-(3-(2-(Trifluoromethyl)phenothiazin-10-yl)propyl)-1-piperazinyl)ethyl decanoate; D00793; Fluphenazine decanoate (JAN/USP); Fluorophenazine decanoate; LS-59383; Prolixin decanoate (TN); MolPort-001-728-034; BRN 0599852; NSC 169510; UNII-FMU62K1L3C; C32H44F3N3O2S; CID3388; 2-[4-[3-[2-(trifluoromethyl)phenothiazin-10-yl]propyl]piperazin-1-yl]ethyl decanoate; Decanoic acid, 2-[4-[3-[2-(trifluoromethyl)-10H-phenothiazin-10-yl]propyl]-1-piperazinyl]ethyl ester; Modecate; AR-1J0863; 2-(4-{3-[2-(trifluoromethyl)-10H-phenothiazin-10-yl]propyl}piperazin-1-yl)ethyl decanoate; Decanoic acid, 2-(4-(3-(2-(trifluoromethyl)phenothiazin-10-yl)propyl)-1-piperazinyl)ethyl ester	5002-47-1	490519	46506645	TTDS00099	5-hydroxytryptamine 1B receptor	5-HT-1B;5-HT1B receptor;5-HT-1D-beta;S12;Serotonin 1D beta receptor;Serotonin receptor;Serotonin receptor 1B	P28222	3351	ENSG00000135312	antagonist
DCL000793	Elzasonan hydrochloride	AC1O5TUJ; Elzasonan hydrochloride; D03983; UNII-X38F62RR8L; (2E)-4-(3,4-dichlorophenyl)-2-[[2-(4-methylpiperazin-1-yl)phenyl]methylidene]thiomorpholin-3-one hydrochloride; 220322-05-4; CID6440591; Elzasonan HCl; AC1O6SNF; (2Z)-4-(3,4-dichlorophenyl)-2-[[2-(4-methylpiperazin-1-yl)phenyl]methylidene]thiomorpholin-3-one hydrochloride; Elzasonan hydrochloride (USAN); CP 448187-01; CID6506051	220322-05-4	6473739	47205966	TTDS00099	5-hydroxytryptamine 1B receptor	5-HT-1B;5-HT1B receptor;5-HT-1D-beta;S12;Serotonin 1D beta receptor;Serotonin receptor;Serotonin receptor 1B	P28222	3351	ENSG00000135312	antagonist
DAP000218	Almotriptan	Spectrum5_001554; I06-0492; KBio2_004976; Spectrum2_000498; Spectrum3_001006; Spectrum4_001134; Almotriptan (USAN); Spectrum_001884; CID123606; N,N-dimethyl-2-[5-(pyrrolidin-1-ylsulfonylmethyl)-1H-indol-3-yl]ethanamine; N,N-dimethyl-2-{5-[(pyrrolidin-1-ylsulfonyl)methyl]-1H-indol-3-yl}ethanamine; KBio2_007544; NCGC00095135-01; KBio3_001951; CHEBI:520985; Axert; AC1L3WYP; NCGC00095135-02; D02824; Almotriptan; 1-(((3-(2-(Dimethylamino)ethyl)indol-5-yl)methyl)sulfonyl)pyrrolidine; DB00918; MolPort-003-666-604; Almotriptan [USAN:INN:BAN]; Almogran; LS-173461; PNU-180638; BIDD:GT0048; HMS1922L13; SPECTRUM1505204; CHEMBL1505; KBioSS_002414; BRD-K67601717-001-02-0; 154323-57-6; KBioGR_001647; UNII-1O4XL5SN61; BSPBio_002731; C17H27N3O2S; Pyrrolidine, 1-(((3-(2-(dimethylamino)ethyl)-1H-indol-5-yl)methyl)sulfonyl)-; SPBio_000395; NCGC00095135-03; LAS-31416; KBio2_002408; L000846	181183-52-8	123606	700325	TTDS00099	5-hydroxytryptamine 1B receptor	5-HT-1B;5-HT1B receptor;5-HT-1D-beta;S12;Serotonin 1D beta receptor;Serotonin receptor;Serotonin receptor 1B	P28222	3351	ENSG00000135312	agonist
DAP001405	Morantel tartrate	MLS001148663; CID6433951; MORANTEL TARTRATE SALT; AC1O4WH4; 46473_FLUKA; LS-135579; MolPort-003-933-855; SMR000058831; C12H16N2S.C4H6O6; Pyrimidine, 1,4,5,6-tetrahydro-1-methyl-2-(2-(3-methyl-2-thienyl)ethenyl)-, (E)-,(R-(R*,R*))-2,3-dihydroxybutanedioate (1:1); 2,3-dihydroxybutanedioic acid; 1-methyl-2-[(E)-2-(3-methylthiophen-2-yl)ethenyl]-5,6-dihydro-4H-pyrimidine; D05076; Prestwick2_000061; (E)-1,4,5,6-Tetrahydro-1-methyl-2-(2-(3-methyl-2-thienyl)vinyl)pyrimidine tartrate (1:1); Prestwick_508; EINECS 247-481-5; Prestwick3_000061; Pyrimidine, 1,4,5,6-tetrahydro-1-methyl-2-(2-(3-methyl-2-thienyl)vinyl)-, (E)-, tartrate (1:1); CP 12009-18; BSPBio_000241; MLS000069820; Pyrimidine, 1,4,5,6-tetrahydro-1-methyl-2-(2-(3-methyl-2-thienyl)ethenyl)-, (E)-, (R-(R*,R*))-2,3-dihydroxybutanedioate (1:1); Pyrimidine, 1,4,5,6-tetrahydro-1-methyl-2-(2-(3-methyl-2-thienyl)vinyl)-, (E)-,tartrate (1:1); (2R,3R)-2,3-dihydroxybutanedioic acid; 1-methyl-2-[(E)-2-(3-methylthiophen-2-yl)ethenyl]-5,6-dihydro-4H-pyrimidine; Morantel tartrate [USAN]; AC1O5H2F; UNII-5WF7E9QC3F; Banminth II; Paratect; MORANTEL TARTRATE; Morantel tartrate hydrate; HMS1568M03; BPBio1_000267; 46473_RIEDEL; AI3-29747; 26155-31-7; CID6419965; Morantel tartrate (USP)	26155-31-7	6419965	175192	TTDS00307	Fumarate reductase flavoprotein subunit	FRDA;Fumarate reductase	P00363	N/A	N/A	inhibitor
DAP001413	Oxantel pamoate	68813-55-8; Telopar; Telopar (TN); Oxantel pamoate (USAN); AC1NQY08; EINECS 272-332-6; Phenol, 3-(2-(1,4,5,6-tetrahydro-1-methyl-2-pyrimidinyl)ethenyl), (E)-, 4,4'-methylenebis(3-hydroxy-2-naphthalenecarboxylate) (1:1) (salt); CP-14445; D00806; Oxantel embonate; CID5281086; 4,4'-Methylenebis(3-hydroxy-2-naphthoic) acid, compound with (E)-3-(2-(1,4,5,6-tetrahydro-1-methylpyrimidin-2-yl)vinyl)phenol (1:1); CP-14445-16; HMS2093L04	68813-55-8	5281086	188746	TTDS00307	Fumarate reductase flavoprotein subunit	FRDA;Fumarate reductase	P00363	N/A	N/A	inhibitor
DAP000664	Thiabendazole	Prestwick_813; Tiabendazolum [INN-Latin]; Thiabenzole; ZINC00073711; 123242-33-1; Polival; CAS-148-79-8; 8028-27-1; Thiabendazole [BSI:ISO]; NSC 525040; Drawipas; LS-864; Equizole; Testo; HMS500D14; Storite; 8027-10-9; G 491; Tibimix 20; NCGC00016410-01; Minzolum; BSPBio_000507; BRN 0611403; SPBio_001481; HMS1569J09; Tiabendazol [INN-Spanish, French]; C10H7N3S; Mertec; 2-(4-Thiazolyl)-1H-benzimidazole; NCI60_004280; NCGC00021671-07; MolPort-001-002-054; Mintezol; E-Z-Ex; Mintesol; Thiabendazole [USAN:BAN]; Prestwick0_000524; Eprofil; 45684_RIEDEL; SAM002564239; Equizole A; Thiabenzazole; Tecto B; Prestwick2_000524; Metasol TK-100; CHEBI:45979; Tecto; NCGC00021671-06; Tecto rph; MK 360; Mycozol; EINECS 205-725-8; CPD000058170; SPBio_002428; WLN: T56 BM DNJ C-ET5N CSJ; AC1L1KCB; Mertect 340f; Ormogal; Caswell No. 849A; STK394289; DB08630; Cropasal; Thiabendole; NCGC00016410-02; KBio2_002967; Tecto 60; BIDD:ER0372; Thiprazole; 2-(1,3-Thiazol-4-yl)benzimidazole; Thibenzole; Omnizole; 1H-Benzimidazole, 2-(4-thiazolyl)-; KBioSS_000399; T8904_SIGMA; MLS000053094; 98002-42-7; Syntol M100; Hokustar HP; MLS-0002984.P004; IDI1_000072; KBioGR_000787; Spectrum4_000354; NSC 90507; Helmindrax octelmin; 8018-04-0; Pitrizet; HSDB 2027; NCGC00021671-05; Thiaben; Tresaderm; Metasol TK 100; MK-360; Mintezol (TN); Tiabendazol; Captan T; SPECTRUM1500570; TL8001064; 94977-06-7; TBZ 60W; TBZ-6; Spectrum5_001009; 2-(4-Thiazolyl)benzimidazole; NSC90507; EPA Pesticide Chemical Code 060101; Spectrum3_001407; PS1057_SUPELCO; Tecto 40F; NCIOpen2_005709; CCRIS 4510; D00372; 2-(1,3-Thiazol-4-yl)-1H-benzimidazole; NCI60_042006; KBio2_000399; NCGC00021671-09; Metasol tk 10; CID5430; Thibenzole 200; Sistesan; Tecto 10P; Tebuzate; Prestwick1_000524; Tiabenda; 4-(1H-benzimidazol-2-yl)-1,3-thiazole; Bovizole; Biogard; Equivet TZ; Benzimidazole, 2-(4-thiazolyl)-; Prestwick3_000524; Tubazole; Mertect 160; Tbdz; TBZ 6; 2-(1,3-thiazol-4-yl)-1H-1,3-benzodiazole; Bio-0781; BRD-K77695569-001-05-2; S1739_Selleck; Thiabendazol; D013827; 2-Thiazol-4-yl-1H-benzoimidazole; Chemviron TK 100; Spectrum2_001331; Thibenzol; 2-Thiazole-4-ylbenzimidazole; APL-luster; DB00730; Mintezole; Thiabendazole (USP); Mertect; NSC525040; 1yvm; 2-[4-Thiazoly]benzimidazole; Hymush; SMR000058170; Thibenzole att; SDCCGMLS-0002984.P003; UNII-N1Q45E87DT; Tiabendazole (JAN/INN); Bioguard; KBio3_002274; NCGC00021671-04; 145316-67-2; 2-(Thiazol-4-yl)benzimidazole; Tiabendazolum; A0920/0043056; 4-(2-Benzimidazolyl)thiazole; Lombristop; KBio2_005535; Top Form Wormer; HMS2092M07; DivK1c_000072; MLS000069718; NCGC00021671-08; AI3-50598; Nemapan; BSPBio_003054; 2-(4'-Thiazolyl)benzimidazole; thiabendazole; 45684_FLUKA; BPBio1_000559; Mintezol, Equizole, Thiabendazole; Thibendole; Mertect lsp; BAS 00600238; Nemacin; T5535_SIGMA; Sanaizol 100; AB00052107; Tiabendazole; RPH; NINDS_000072; HMS1921E05; AC1Q4W1V; 148-79-8; Spectrum_000039; RTU Flowable Fungicide; Tobaz; I06-0809; Thiabendazolum; KBio1_000072; AKOS000120940; Triasox; CHEMBL625	148-79-8	5430	7847438	TTDS00307	Fumarate reductase flavoprotein subunit	FRDA;Fumarate reductase	P00363	N/A	N/A	inhibitor
DCL000996	Sotrastaurin acetate	N/A	908351-31-5	448087	46392991	TTDC00178	Protein kinase C, theta type	NPKC-theta;Protein kinase C theta	Q04759	5588	ENSG00000065675	inhibitor
DCL000400	GSK1014802	N/A	153436-22-7	6450546	47206237	TTDS00155	Sodium channel	N/A	N/A	N/A	N/A	blocker
DCL000739	Carisbamate	1,2-Ethanediol, 1-(2-chlorophenyl)-, 2-carbamate, (1S)-; 1,2-Ethanediol, 1-(2-chlorophenyl)-, 2-carbamate, (S)-; AC1OCFHA; D06573; RWJ 333369; JNJ 10234094; S-2-O-Carbamoyl-1-o-chlorophenyl-ethanol; RWJ-333369; CID6918474; Carisbamate; 194085-75-1; Comfyde; JNJ-10234094; YKP-509; YKP 509; UNII-P7725I9V3Z; [(2S)-2-(2-chlorophenyl)-2-hydroxyethyl] carbamate; Carisbamate (USAN)	194085-75-1	6918474	47208229	TTDS00155	Sodium channel	N/A	N/A	N/A	N/A	blocker
DAP001233	Levobupivacaine	(S)-1-Butyl-2',6'-pipecoloxylidide; CAS-18010-40-7; MolPort-004-959-713; Levobupivacaine; NCGC00159482-02; (2S)-1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide; AC1L3NQM; DB01002; D08116; C18H28N2O; (-)-bupivacaine; 27262-47-1; Levobupivacaine [INN:BAN]; NCGC00016733-01; LS-187025; L-(-)-bupivacaine; LS-109843; L(-)-Bupivacaine; CHEBI:6149; 2',6'-Pipecoloxylidide, 1-butyl-, L-(-)-; Novabupi; Novabupi (TN); Levobupivacaine (INN); L-(-)-1-Butyl-2',6'-pipecoloxylidide; (S)-bupivacaine; C07887; LS-187789; CID92253; 27262-48-2; BIDD:GT0471	27262-47-1	92253	10089	TTDS00155	Sodium channel	N/A	N/A	N/A	N/A	blocker
DAP000130	Phenytoin	Epasmir 5; Sylantoic; Epilantin; Labopal; Phanantin; Lopac0_000378; Convul; Diphenylan; Di-Lan (VAN); Neos-Hidantoina; Bio-0370; D 4007; Di-Hydan; ZINC18140189; Epdantoin Simple; CHEMBL16; Dantinal; AKOS003245432; Elepsindon; Diphedan; Om hidantoina simple; AC1Q6G55; DivK1c_000507; Epelin; Di-Phetine; HMS2089E11; Difetoin; IFLab1_000214; Hidantina vitoria; Iphenylhydantoin; NCGC00091492-01; Idantoin; Hidantal; Dintoin; Fenytoine; Novantoina; Phenytoinum; BIDD:PXR0090; Didan TDC 250; Comital; Sanepil; Eptal; Diphenylhydantoine [French]; MLS001074087; 125-59-7; DPH (VAN); Epihydan; Dihycon; KBio2_001585; NINDS_000507; taco sal; Phenytex; DILANTIN-30; NCGC00091492-05; Phanatine; Epinat; MLS002454401; 5,5-Diphenylhydantoin (phenytoin); MolPort-004-876-351; Hidan; phenytoin (PHN); Aleviatin; Fenytoin Dak; NCGC00093810-01; 2,4-Imidazolidinedione, 5,5-diphenyl- (9CI); Hydantal; I14-6452; KBio2_004153; Spectrum4_000984; AC-376; Sodantoin; Dantoinal; component of Mebroin; Citrulliamon; Dantoinal klinos; Hidantilo; epasmir ''5''; AI3-52498; LS-34; Fenitoina [INN-Spanish]; Hydantin; Om-Hydantoine; Auranile; KBio1_000507; Sodanthon; Ekko; KBio3_001780; D00512; Novophenytoin; Solantoin; Phentoin; 5,5-Diphenyl-imidazolidine-2,4-dione; Dillantin; Oprea1_373280; Epilan D; Diphenylhydantoin (VAN); phenytoin; Dilantin (TN); 5,5-Dwufenylohydantoina; Diphentoin; Epanutin; Toin unicelles; 57-41-0; Fenitoin; Oxylan; Thilophenyl; MolPort-001-785-683; Phenhydan; STK058029; KBioSS_001585; Ritmenal; NCI-C55765; DB00252; fenidantoin ''s''; Eptoin; Phenhydanin; Dilabid; AC1Q6G56; KBio2_006721; Dilantin-125; Ekko capsules; AKOS000416887; Hidantina; NCGC00015342-04; Citrullamon; Phenytoinum [INN-Latin]; NCGC00091492-02; SPBio_001281; elepsi ndon; 5,5-Diphenylimidazolidin-2,4-dione; Saceril; HMS1694O05; Phenytoin [USAN:INN:BAN:JAN]; SMR000059026; Difenilhidantoina; Fenidantoin "s"; Phenitoin; NCGC00093810-02; Hindatal; Spectrum2_001281; Idantoil; Diphenylhydantoine; CCRIS 515; MolPort-002-365-712; NCGC00015342-02; Sinergina; Phenatine; Ditoinate; CL12003; Hidantina senosian; IDI1_000507; Diphenylhydatanoin; Dilantin; BSPBio_001437; Fenitoina; BRD-K55930204-001-02-7; MLS000069789; Didan-tdc-250; STK182871; Sodium Diphenylhydantoinate; Dihydan toin; Enkelfel; EINECS 200-328-6; Zentronal; Fentoin; 2-hydroxy-5,5-diphenyl-3,5-dihydro-4H-imidazol-4-one; Phenytoine [INN-French]; Di-Lan; C07443; Minetoin; PHENYTOIN (5,5-DIPHENYLHYDANTOIN); CHEBI:8107; Diphedal; Fenylepsin; Epifenyl; Causoin; InChI=1/C15H12N2O2/c18-13-15(17-14(19)16-13,11-7-3-1-4-8-11)12-9-5-2-6-10-12/h1-10H,(H2,16,17,18,19; D0894; Kessodanten; 5,5-Diphenyl-2,4-imidazolidinedione; ictalis simp le; Neosidantoina; fen toin; Hidantomin; Lepsin; NSC 8722; Epasmir "5"; Dilantin acid; TOIN; NSC8722; Difenin; Diphenylhydantoin; Phentytoin; Solantyl; EU-0100378; Lopac-D-4007; Diphentyn; NCGC00091492-03; Tacosal; Diphantoin; Spectrum5_001369; HMS1989H19; PHENYTEK; Epised; Fenidantoin s; 5,5-DIPHENYLHYDANTOIN; Hydantol; Dihydantoin; Phenytoine; BAS 00281572; Sodanton; IDI1_008433; KBioGR_001387; Zentropil; Ictalis simple; Dantoine; Danten; Hydantoin, 5,5-diphenyl-; NCGC00015342-01; 5,5-Dwufenylohydantoina [Polish]; Difhydan; D4007_SIGMA; BIDD:GT0625; Lepitoin; WLN: T5MVMV EHJ ER& ER; phenat ine; Epilan-D; Lopac0_000329; HMS1791H19; Hydantoin, 5,5-diphenyl- (8CI); UNII-6158TKW0C5; CID1775; Dintoina; AC1L1C7L; Phenytoin-Gerot; Solantin; 5,5-diphenylimidazolidine-2,4-dione; Antisacer; Silantin; Hydantoinal; PHENYTOIN SODIUM, EXTENDED; 5,5-Diphenylhydantoin (IUPAC); Diphenat; ZINC02510358; Comitoina; Phenytoin (JP15/USP/INN); 2,4-Imidazolidinedione, 5,5-diphenyl-; HMS1412J16; Diphenine; Spectrum_001105; Fenantoin Mn Pharma; NCGC00091492-04; NCGC00021139-01; Phenytoin AWD; Gerot-epilan-D; Lehydan; Diphenin; Spectrum3_000890; Denyl; Epdantoine simple; 630-93-3; Extended Phenytoin Sodium; Epamin; Phenatoine; Dilantine; Difenilhidantoina [Spanish]	57-41-0	1775	148821	TTDS00155	Sodium channel	N/A	N/A	N/A	N/A	blocker
DCL000867	Licarbazepine	(-)-10,11-Dihydro-10-hydroxy-5H-dibenz(b,f)azepine-5-carboxamide; LS-60364; Licarbazepine; 10-Hydroxycarbamazepine; C07493; 10-Hydroxycarbazepine; 5H-Dibenz(b,f)azepine-5-carboxamide, 10,11-dihydro-10-hydroxy-; GP-47779; 10-HYDROXY-CARBAMAZEPINE; CHEMBL1067; AC1L3FTT; C039775; 10,11-Dihydro-10-hydroxycarbamazepine; CID114709; 10-OH-Carbazepine; 10,11-Dihydro-10-hydroxy-5H-dibenz(b,f)azepine-5-carboxamide; GP 47779; 10-Hydroxy-10,11-dihydrocarbamazepine; MolPort-003-846-741; 5-hydroxy-5,6-dihydrobenzo[b][1]benzazepine-11-carboxamide; UNII-XFX1A5KJ3V; AR-1C0020; 29331-92-8; 10-Hydroxy-10,11-dihydro-5H-dibenz(b,f)azepine-5-carboxamide; AC1Q5JEU; 5H-Dibenz[b,f]azepine-5-carboxamide, 10,11-dihydro-10-hydroxy-	29331-92-8	5485198	43650382	TTDS00155	Sodium channel	N/A	N/A	N/A	N/A	blocker
DAP000129	Carbamazepine	Spectrum5_000936; Carbatrol extended-release; Carbamazepine (JP15/USP/INN); BSPBio_001929; SPECTRUM1500159; WLN: T C676 BNJ BVZ; SAM002264603; D00252; NSC169864; C 4024; AC1L1DXT; Timonil; BRN 1246090; NCGC00015234-01; MolPort-000-710-574; Prestwick3_000052; Stazepine; Carbamazepina [INN-Spanish]; 2-azatricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3(8),4,6,9,12,14-heptaene-2-carboxamide; Carbelan; DivK1c_003750; NCGC00023877-04; G-32883; Neurotol; NCGC00023877-08; Tegretol-Xr; AC1Q4ZSU; AC-10560; Calepsin; Carbamezepine; HMS1920I17; Spectrum3_000325; 5-Carbamoyl-5H-dibenzo(b,f)azepine; 5-Carbamyldibenzo(b,f)azepine; HMS1568K05; HMS2090M07; Amizepin; nchem.859-comp7; Lopac-C-4024; Prestwick1_000052; ChemDiv1_018966; Telesmin; Spectrum4_000262; Trimonil; Biston; Taro-Carbamazepine Cr; 5H-Dibenz(b,f)azepine-5-carboxamide; NCGC00023877-05; Neurotop retard; Sirtal; Carbamazepine [USAN:INN:BAN:JAN]; STK177357; KBioGR_000724; AKOS003235644; 5-Carbamoyl-5H-dibenz[b,f]azepine; HMS501D10; KBioSS_000516; Spectrum2_000125; NINDS_000388; Prestwick_104; Geigy 32883; NSC 169864; HMS2091O19; CBChromo1_000350; EINECS 206-062-7; BSPBio_000203; Carbamazepinum [INN-Latin]; NCGC00015234-07; LS-60362; KBio1_000388; 5-Carbamoyldibenzo(b,f)azepine; BPBio1_000225; Lexin; carbamazepine (Tegretol); Teril; S1693_Selleck; Oprea1_790775; Carbatrol; benzo[b][1]benzazepine-11-carboxamide; NCGC00023877-03; Prestwick2_000052; G 32883; C06868; UNII-33CM23913M; MLS001055475; Stazepin; Novo-Carbamaz; 85756-57-6 (di-hydrate); BIM-0050280.0001; SPBio_000170; 5-Carbamyl-5H-dibenzo(b,f)azepine; Bio-0751; KBio2_000516; Carbamazepen; CDS1_002710; 5H-Dibenzo[b,f]azepine-5-carboxamide; SPD-417; NCGC00023877-06; MLS001074172; HMS640O02; CARBAMAZEPINE, U.S.P.; Atretol; Nu-Carbamazepine; BIDD:GT0479; CHEBI:3387; Tegretol Cr; CID2554; Equetro; Epitol; KBio2_005652; Carbamazepinum; NCGC00023877-07; C8981_SIAL; MLS000069652; Carbazepin; 5-Carbamoyl-5H-dibenz(b,f)azepine; EU-0100292; Tegretol Chewtabs; Prestwick0_000052; Epitol, Equetro, Tegretol, Biston, Calepsin, Carbamazepine; Karbamazepin; Finlepsin; I06-0863; Carbamazepan; carbamazepine; KBio3_001149; SMR000058201; Tegretol (TN); Carbazepine; Tegretol; 298-46-4; BRD-K71799949-001-06-7; DivK1c_000388; Carbamazepin; AC1Q4ZSV; Apo-Carbamazepine; Equetro (TN); SMR001227191; 5H-Dibenz[b,f]azepine-5- carboxamide; CAS-298-46-4; Taro-Carbamazepine; NCGC00015234-13; NCGC00015234-03; HSDB 3019; NCGC00015234-02; ZINC00004785; DB00564; CHEMBL108; IDI1_000388; Spectrum_000096; Tegretal; Carbamazepina; Bipotrol; SPBio_002124; C4024_SIGMA; KBio2_003084; 5H-Dibenz[b,f]azepine-5-carboxamide; C4024_SIAL; Lopac0_000292; Amizepine; CPD001227191	298-46-4	2554	7847318	TTDS00155	Sodium channel	N/A	N/A	N/A	N/A	blocker
DAP001234	Benzocaine	NCGC00094598-01; Aethylium paraminobenzoicum; 4-14-00-01129 (Beilstein Handbook Reference); Spectrum4_000249; Ethyl 4-aminobenzoate hydrochloride; SPBio_002844; 4-Aminobenzoic acid ethyl ester; Outgro; MLS001331704; NSC 41531; Benzoic acid, amino-, ethyl ester; Methanesulfonate, Benzocaine; AE-562/40377256; Prestwick2_000712; Ethyl p-aminophenylcarboxylate; Spectrum2_000117; Solarcaine; A0271; Ethyl 4-aminobenzoate; C07527; Solu H; ZINC12358719; D00552; CID2337; benzocaine; KBio3_001408; Ethyl aminobenzoate (VAN); Ethyl PABA; Prestwick0_000712; ethylaminobenzoate-4; LS-35847; p-(Ethoxycarbonyl)aniline; Topcaine; 23239-88-5 (hydrochloride); Benzocaine Hydrobromide; AR-1H9065; Ethoform; Benzocaine Methanesulfonate; AC1Q341A; Bensokain; Acetate, Benzocaine; HMS1920G09; Parathesine; Otocain; AB00051923; MLS002153970; BRN 0638434; p-Carbethoxyaniline; Anesthesine; KBio2_000474; Hurricaine; Ethyl aminobenzoate (JP15); NCGC00016352-01; MolPort-000-871-526; 94-09-7 (Parent); UNII-U3RSY48JW5; Americaine; 1333-08-0; HMS1570O05; Anaesthan-syngala; NINDS_000932; Parathesin (TN); Anaesthesinum; Benzocaine Acetate; STK043620; IDI1_000932; BSPBio_000923; KBio1_000932; Norcaine; Identhesin; Ethyl aminobenzoate; BPBio1_001017; Caswell No. 430A; Aethoform; Ethylester kyseliny p-aminobenzoove; Benzocaina; NSC 122792; 112909_ALDRICH; Benzoic acid, p-amino-, ethyl ester; KBioSS_000474; Prestwick3_000712; p-Ethoxycarboxylic aniline; Ora-jel; Oprea1_827402; AC1Q64JE; AI3-02081; Hydrobromide, Benzocaine; Formate, Benzocaine; Anestezin [Russian]; Prestwick_991; Benzocainum; Keloform; Benzocaine Formate; EPA Pesticide Chemical Code 097001; Parathesin; nchembio.182-comp4; 4-amino-benzoic acid ethyl ester; 112909_SIAL; SMR000059025; Norcainum; Benzocaine Hydrochloride; HSDB 7225; WLN: ZR DVO2; Anesthesin; BSPBio_001908; p-Aminobenzoic acid, ethyl ester; p-Aminobenzoic ethyl ester; Anesthone; Ethyl p-aminobenzoate; KBioGR_000658; Chloraseptic; Orthesin; 4 Aminobenzoic Acid Ethyl Ester; CHEMBL278172; DivK1c_000932; Benzoic acid, 4-amino-, ethyl ester; I05-0204; Oprea1_750694; h-4-abz-oet; AKOS000119763; Benzocaine [INN:BAN]; Ethylester kyseliny p-aminobenzoove [Czech]; 94-09-7; CHEBI:116735; NSC4688; Benzocaina [INN-Spanish]; Amben ethyl ester; 71123-91-6; 23239-88-5; Dermoplast; Ethylis aminobenzoas; Anestezin; Ethoforme; Spectrum5_000860; SPBio_000134; Baby Anbesol; D001566; DB01086; AC1L1DGC; 4-Aminobenzoic acid, ethyl ester; 06952_FLUKA; HMS502O14; HMS2091M11; NSC41531; BRD-K75466013-001-05-2; Benzocainum [INN-Latin]; Spectrum_000074; KBio2_003042; NCGC00094598-02; Hydrochloride, Benzocaine; CAS-94-09-7; Benzocaine (USP/INN); 4-(Ethoxycarbonyl)aniline; EINECS 202-303-5; BB_SC-0019; Benzoic acid, 4-amino-, ethyl ester, hydrochloride; Spectrum3_000314; ETHYL-P-AMINOBENZOATE; p-Aminobenzoic acid ethyl ester; E1501_SIGMA; Prestwick1_000712; SPECTRUM1500139; Anaesthesin; Anaesthin; Norcain; KBio2_005610; 4-Carbethoxyaniline	94-09-7	2337	9730	TTDS00155	Sodium channel	N/A	N/A	N/A	N/A	blocker
DCL000791	Eslicarbazepine acetate	ZINC00007295; CHEBI:239940; CHEMBL87992; NCGC00165752-02; [(5S)-11-carbamoyl-5,6-dihydrobenzo[b][1]benzazepin-5-yl] acetate; Erelib; 10-Acetoxy-10,11-dihydro-5H-dibenz(b,f)azepine-5-carboxamide; Zebinix; BIA-2-093; NCGC00165752-01; 5H-Dibenz9b,f)azepine-5-carboxamide, 10-(acetyloxy)-10,11-dihydro-, (10S)-; Exalief; B5435_SIGMA; CID179344; 236395-14-5; Pazzul; MolPort-005-942-413; AC1L452K; SEP-0002093; S-(-)-10-Acetoxy-10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide; Eslicarbazepine acetate; Stedesa; BIA 2-093; AKOS005145781	75970-99-9	123618	47207679	TTDS00155	Sodium channel	N/A	N/A	N/A	N/A	blocker
DAP001231	Oxybuprocaine	NCGC00016667-01; Oxibuprokain; 4-Amino-3-butoxybenzoic acid 2-(diethylamino)ethyl ester; diethylaminoethyl-4-amino-3-butoxybenzoate; 4-Amino-3-butoxybenzoic acid 2-diethylaminoethyl ester; Benzoic acid, 4-amino-3-butoxy-, 2-(diethylamino)ethyl ester (7CI,8CI,9CI); 99-43-4; Monofree oxybuprocaine; Prestwick2_000057; Prestwick1_000057; BRD-K04185004-003-03-6; MLS001332643; 3-Butoxy-4-aminobenzoic acid 2-(diethylamino)ethyl ester; Oxybuprocainum [INN-Latin]; Benoxinate; Prestwick3_000057; 4-Amino-3-butoxy-benzoic acid 2-diethylamino-ethyl ester; Novesinol; butoxyprocaine; 3-Butoxy-4-aminobenzoic acid 2-diethylaminoethyl ester; AC1L1ILS; BPBio1_000235; Oxybuprocainum; S 749; oxybuprocaine hydrochloride; Benoxinate hydrochloride; Oxybuprocaine; NCGC00016667-02; BENZOIC ACID, 4-AMINO-3-BUTOXY-, 2-(DIETHYLAMINO)ETHYL ESTER; Oxibuprocainum; Oxybuprocaine (INN); Novescine; SPBio_002134; 2-Diethylaminoethyl 4-amino-3-butoxybenzoate; 4-Amino-3-n-butoxy-benzoesaeure-diaethylaminoaethylester; 4-Amino-3-n-butoxy-benzoesaeure-diaethylaminoaethylester [German]; Oxybucaine; CHEBI:309594; Oxybuprocaine HCL; CAS-5987-82-6; CID4633; LS-35639; SBB065174; 13718-13-3 (hydrochloride); MLS001332644; Conjucain; DB00892; Oxibuprocaina; UNII-AXQ0JYM303; Butoxyaminobenzoyldiethylaminoethanol; Prestwick0_000057; STK520615; CHEMBL1200; 2-(diethylamino)ethyl 4-amino-3-n-butoxybenzoate; D08319; 5987-82-6 (mono-hydrochloride); Oxybuprocaine [INN:BAN]; Prescaina; SMR000857098; Oxyriprocaine; 4-Amino-3-butoxy-2-(diethylamino)ethyl ester benzoic acid; BRN 2288926; Oxibuprocaina [INN-Spanish]; 2-(Diethylamino)ethyl 4-amino-3-butoxybenzoate; I01-7205; Monofree oxybuprocaine (TN); Benoxil; BSPBio_000213; Dorsacain	99-43-4	4633	150504	TTDS00155	Sodium channel	N/A	N/A	N/A	N/A	blocker
DAP001235	Permethrin	47956_SUPELCO; NRDC 146; Ambush; 3-phenoxybenzyl 3-(2,2-dichloroethenyl)-2,2-dimethylcyclopropanecarboxylate; 52645-53-1; 45893_RIEDEL; LS-58640; Permethrine,c&t; Elimite Cream; 45614_RIEDEL; CID40326; AC1Q3FFG; CHEBI:34911; ST50975270; NCGC00159390-09; 52341-32-9; FMC 35171; 52341-33-0; PS758_SUPELCO; NCGC00159390-00; trans-(+-)-Permethrin; (+-)-cis-Fmc 33297; 45614_FLUKA; Permethrin (isomers) solution; NCGC00159390-06; (+)-CIS-PERMETHRIN; MLS001332525; 1RS-trans-Permethrin; C21H20Cl2O3; TL8003462; Permethrin (isomers); Nix Cream Rinse; Cyclopropanecarboxylic acid, 3-(2,2-dichloroethenyl)-2,2-dimethyl-, (3-phenoxyphenyl)methyl ester, cis-(+-)-; SMR000778043; [3-(phenyloxy)phenyl]methyl 3-(2,2-dichloroethenyl)-2,2-dimethylcyclopropanecarboxylate; Permethrin; BRN 4153590; 3-Phenoxybenzyle (1RS)-cis, trans-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropane carboxylate; AC1L23IC; NCGC00159390-07; (+-)-cis-Permethrin; (3-Phenoxyphenyl)methyl (+-)-cis,trans-3-(2,2-dichloroethenyl)-2,2-dimethylcyclopropanecarboxylate; NCGC00159390-04; Transpermethrin; NRDC 148; MolPort-003-933-021; DB04930; Cyclopropanecarboxylic acid, 3-(2,2-dichlorovinyl)-2,2-dimethyl-, (3-phenoxyphenyl)methyl ester, (1R-cis)-; CHEMBL1525; Cyclopropanecarboxylic acid, 3-(2,2-dichloroethenyl)-2,2-dimethyl-, (3-phenoxyphenyl)methyl ester, trans-(+-)-; Transpermethrin [ISO]; 442748_SUPELCO; NCGC00159390-08; LS-58636; Cyclopropanecarboxylic acid, 3-(2,2-dichlorovinyl)-2,2-dimethyl-, (3-phenoxyphenyl)methyl ester, (1R-trans)-; (+)-trans-Permethrin; NCGC00159390-05; Acticin Cream; AI3-29296; 1RS,cis-Permethrin; MLS001332526; PerFoam; (+-)-trans-Permethrin; (3-phenoxyphenyl)methyl 3-(2,2-dichloroethenyl)-2,2-dimethylcyclopropane-1-carboxylate; NCGC00159390-02; 45893_FLUKA	52645-53-1	40326	10438901	TTDS00155	Sodium channel	N/A	N/A	N/A	N/A	blocker
DAP001229	Bupivacaine	Sensorcaine-MPF Spinal; BPBio1_000298; Bupivacaine Carbonate; Prestwick0_000305; DUR-843; Marcaine HCL; DB00297; AKOS001637202; Win 11318; Bucaine; Marcaine; 38396-39-3; 1-Butyl-N-(2,6-dimethylphenyl)-2-piperidinecarboxamide; NCGC00178579-02; ( inverted exclamation markA)-bupivacaine; AH 250; EINECS 218-553-3; KBio2_007140; Marcaine Spinal; NSC119660; 2180-92-9; SMR000058218; BRD-A01636364-003-05-2; Bio-0886; Bupivacaina; NCGC00178579-01; DepoBupivacaine; Bupivacaine HCL; AC1L1DRE; Sensorcaine; MolPort-004-955-820; KBio2_002004; Bupivacainum [INN-Latin]; 1-Butyl-2',6'-pipecoloxylidide; HMS2090F12; Spectrum3_000974; MLS001361336; IDI1_000758; LS-2222; C18H28N2O; UNII-Y8335394RO; bupivacaine; LS-109841; 2-Piperidinecarboxamide, 1-butyl-N-(2,6-dimethylphenyl)-; 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide; Sensorcaine-MPF; Win 11318 HCl; NINDS_000758; Anekain; Carbostesin; Bupivacaina [INN-Spanish]; DivK1c_000758; Bupivacaine HCL KIT; 15233-43-9; Prestwick3_000305; AC-2096; Bucaine (TN); SPBio_001558; AB00053674; CHEBI:3215; AC1Q5LX4; KBio2_004572; 2',6'-Pipecoloxylidide, 1-butyl-; (1)-1-Butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide; D07552; Bloqueina; Bupivacaine [INN:BAN]; SPBio_002489; Spectrum4_001098; DL-Bupivacaine; Prestwick2_000305; Prestwick1_000305; CID2474; KST-1A4609; EINECS 253-911-2; Spectrum5_001483; KBioSS_002004; BSPBio_002607; cBupivacaine; Transdur-Bupivacaine; Bupivacaine (INN); CHEMBL1098; Marcaina; C07529; L000695; Bupivacaine Monohydrochloride, Monohydrate; KBio3_001827; Spectrum_001524; Spectrum2_001589; KBioGR_001516; Bupivan; AR-1A0242; 2-Piperidinecarboxamide, 1-butyl-N-(2,6-dimethylphenyl)-, (+-)-; (+-)-Bupivacaine; BSPBio_000270; dl-1-Butyl-2',6'-pipecoloxylidide; KBio1_000758; Bupivacainum	2180-92-9	2474	9732	TTDS00155	Sodium channel	N/A	N/A	N/A	N/A	blocker
DCL000949	Ralfinamide	C475054; Ralfinamide; NW-1029; (2S)-2-[[4-[(2-fluorophenyl)methoxy]phenyl]methylamino]propanamide; CID5745207; 133865-88-0; Ralfinamide [INN]; Ralfinamida [INN-Spanish]; UNII-3LPF0S0GVV; (2S)-2-(4-(2-Fluorobenzyloxy)benzylamino)propanamide; AC1NX6LN; NW 1029; Ralfinamida	133865-88-0	5745207	3846305	TTDS00155	Sodium channel	N/A	N/A	N/A	N/A	blocker
DAP001230	Ropivacaine	2-Piperidinecarboxamide, N-(2,6-dimethylphenyl)-1-propyl-, monohydrochloride, (S)-; LS-113954; AC1L41QM; ropivacaine monohydrochloride,; 98717-15-8; Ropivacaine monohydrochloride; NCGC00164597-01; CID175804; SAM001246524; CID175805; I14-176; C07532; Naropin (TN); ST51051452; CPD000469137; BIDD:GT0203; Ropivacaine hydrochloride; C17H26N2O.HCl; MolPort-003-983-292; AC1L41QN; MLS001401363; Ropivacaine; Naropin; SMR000469137; CHEMBL1077896; 2-Piperidinecarboxamide, N-(2,6-dimethylphenyl)-1-propyl-, hydrochloride (1:1), (2S)-; (2S)-N-(2,6-dimethylphenyl)-1-propylpiperidine-2-carboxamide; ROPIVACAINE HCl; (2S)-N-(2,6-dimethylphenyl)-1-propylpiperidine-2-carboxamide hydrochloride; D08490; 84057-95-4; 2-Piperidinecarboxamide, N-(2,6-dimethylphenyl)-1-propyl-, (2S)-; CHEBI:8890; ropivacaine monohydrochloride,  (S)-isomer	84057-95-4	71273	213495	TTDS00155	Sodium channel	N/A	N/A	N/A	N/A	blocker
DAP001516	Rufinamide	1-(2,6-Difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide; ZINC00007782; 106308-44-5; E-2080; S1256_Selleck; UNII-WFW942PR79; SMR000857122; Rufinamide; MLS001332513; Banzel, Rufinamide; NCGC00165883-03; SYN-111; AKOS005145897; CHEMBL1201754; NCGC00165883-02; Rufinamide (USAN/INN); CGP-33101; I06-1425; Cgp 33101; MLS001332514; Xilep; AC1L2V8C; SBB070637; 1H-1,2,3-Triazole-4-carboxamide, 1-((2,6-difluorophenyl)methyl)-; Inovelon; RUF-331; 1-[(2,6-difluorophenyl)methyl]triazole-4-carboxamide; Banzel; MolPort-005-942-441; 1-[(2,6-difluorophenyl)methyl]-1H-1,2,3-Triazole-4-carboxamide; NCGC00165883-01; CID129228; 1H-1,2,3-Triazole-4-carboxamide, 1-[(2,6-difluorophenyl)methyl]-; D05775; R8404_SIGMA; AC-1429	106308-44-5	129228	47207436	TTDS00155	Sodium channel	N/A	N/A	N/A	N/A	blocker
DAP001232	Mepivacaine	Mepivacaina [INN-Spanish]; Scandicaine; 22801-44-1; DB00961; Mepivacainum [INN-Latin]; BSPBio_003297; KBio2_001960; mepivacaine; LS-109849; S-Ropivacaine Mesylate; BRD-A03216249-003-02-9; N-Methyl-2-pipecolic acid, 2,6-dimethylanilide; DivK1c_006970; Spectrum4_000596; UNII-B6E06QE59J; Spectrum3_001629; Mepivacaine [INN:BAN]; C07528; 1-METHYL-2',6'-PIPECOLOXYLIDIDE; (+-)-1-Methyl-2',6'-pipecoloxylidide; D(-)-Mepivacaine; Mepivicaine; Mepivacainum; LS-109848; Carboplyin Dental; BRN 0211230; KBio3_002517; Arestocaine HCL; 5-22-01-00223 (Beilstein Handbook Reference); N-Methyl-2-pipecolic acid, 2,6-xylidide; N-(2,6-Dimethylphenyl)-1-methylpiperidine-2-carboxamide; MolPort-005-935-383; KBio2_004528; SPBio_001811; 1722-62-9 (mono-hydrochloride); KBioGR_001092; KBioSS_001960; Spectrum_001480; SpecPlus_000874; Mepivacaina; AC-15503; I01-1864; D-mepivacaine; 2',6'-Pipecoloxylidide, 1-methyl-; Spectrum5_001354; 2-Piperidinecarboxamide, N-(2,6-dimethylphenyl)-1-methyl-; Scandicain; EINECS 202-543-0; KBio1_001914; Carboplyin Dental (TN); Scandicane; Carbocaine; AC1L1HBV; CID4062; CHEBI:6759; 2',6'-Pipecoloxylidide, 1-methyl-, D-(-)-; CHEMBL1087; DL-Mepivacaine; D08181; 34811-66-0; N-(2,6-Dimethylphenyl)-1-methyl-2-piperidinecarboxamide; N-Methylhexahydro-2-picolinic acid, 2,6-dimethylanilide; Polocaine-Mpf; Spectrum2_001656; KBio2_007096; Isocaine HCL; Mepivacaine (INN); 96-88-8; NCGC00089774-02	96-88-8	4062	9731	TTDS00155	Sodium channel	N/A	N/A	N/A	N/A	blocker
DCL000929	Phenylbutyrate	Spectrum4_000092; 4-phenylbutyrate; Spectrum5_001003; CID20354; CPD000059104; AC1L2G3A; Spectrum2_001798; BRD-K67102207-236-01-0; I01-3326; DB02000; SAM002264634; NSC 295; .gamma.-Phenylbutyric acid; KBio1_001854; GAMMA-PHENYL-BUTYRIC ACID; FT-0082934; ZINC02037928; BSPBio_002484; AC-3254; Benzenebutanoic acid; AI3-12065; SPBio_001755; gamma-Phenylbutyric acid; TL8001458; AI3-11761; AC1Q5W0X; Phenylbutyrate; Butyric acid, 4-phenyl- (8CI); 4-PHENYLBUTYRIC ACID; NSC295; 2ay7; 4-phenylbutans; Butanoic acid, phenyl ester; Benzenebutyric acid; NCGC00018113-01; Butyric acid, 4-phenyl-; LS-173716; SpecPlus_000814; bmse000701; Spectrum3_000782; EINECS 217-341-8; CID4775; 4-Phenylbutanoic acid; DivK1c_006910; 4346-18-3; KBio2_001811; AKOS002952627; P0643; 1821-12-1; KBioGR_000384; OBKXEAXTFZPCHS-UHFFFAOYSA-; EINECS 224-405-9; InChI=1/C10H12O2/c11-10(12)8-4-7-9-5-2-1-3-6-9/h1-3,5-6H,4,7-8H2,(H,11,12); 2-methyl-1-phenyl-propan-2-amine; AKOS000154540; MLS000069408; AC1L1IXE; KBio2_006947; P21005_ALDRICH; MolPort-000-871-587; Spectrum_001331; MLS001076482; SBB008452; NCI60_002455; 4-PHENYL-BUTANOIC ACID; CHEBI:41500; phenyl butanoate; LS-46421; HDInhib_000004; 1716-12-7 (hydrochloride); NCI60_020145; AC1Q75DT; .omega.-Phenylbutanoic acid; phenyl butyrate; BRD-K67102207-001-02-6; AR-1G4411; AB1001924; CHEMBL1469; KBioSS_001811; SMR000059104; Butyric acid, phenyl ester; omega-Phenylbutanoic acid; AC1Q75DU; 1-Phenylbutyric acid; KBio2_004379; FR-2080; KBio3_001704	90315-82-5	2733848	12051860	TTDS00155	Sodium channel	N/A	N/A	N/A	N/A	blocker
DAP000012	Disulfiram	Nocceler; DB00822; NCGC00094423-07; Antivitium; C01692; Akrochem TETD; B0479; UNII-TR3MLJ1UAI; Ethyl tuads; Prestwick1_000097; NCGC00094423-06; CCRIS 582; SAM001247028; AI3-27340; NSC25953; Accel TET; Tetraethylthiuram; TTD; Antaethyl; Disulfram; UPCMLD-DP090; Gababentin; Esperal; Disulphuram; Refusal; Ekagom TETDS; SPBio_001191; STL069539; Abstinil; Stopaethyl; Tenutex; Ancazide ET; NCGC00094423-01; CHEBI:4659; 86720_ALDRICH; Disulfirame [DCIT]; Aversan; HMS1568C16; Antetan; Anticol; Alcophobin; BPBio1_000060; Abstenisil; UPCMLD-DP090:001; CHEMBL964; Spectrum_001010; T 1132; AKOS000120201; Anteyl; Noxal; AC1Q2YXI; Antadix; Antabus; Ethyldithiurame; Esperal [France]; Ethyl Tuex; Abstensil; ENT 27,340; TETD; KBioSS_001490; Noxal (VAN); EINECS 202-607-8; 97-77-8; 86720_FLUKA; Alk-aubs; Tetidis; Sanceler TET-G; THIOCID; Antiethanol; CID3117; Ethyl Thiurad; Espenal; Antethyl; Spectrum2_001176; Contralin; Averzan; SMR000059171; KBio2_006626; HMS1920I16; ARONIS24121; Contrapot; NCGC00094423-02; KBioGR_000895; Antaetil; Disulfan; Nocbin; Lopac-T-1132; tet raethylthiuram; WLN: 2N2 & YUS & S 2; Cronetal; Disulfiramo; LS-2031; Teturamin; KBio2_001490; Anthethyl; Nocceler TET; Anti-ethyl; Eta bus; TTS x; TATD; Dicupral; Ethyldithiourame; Prestwick0_000097; Antikol; Abstinyl; Thiuram E; Stopethyl; Tetraetil; Etyl Tuex; Ethyl Tuads Rodform; CAS-97-77-8; Antietanol; Tenurid; Perkait TETD; S1680_Selleck; Prestwick_182; Tillram; Perkacit TETD; Antabuse (TN); Thireranide; Ekaland TETD; Thiuranide; SBB058706; MLS001076475; C10H20N2S4; Disulfiramum; NCGC00094423-03; Usaf B-33; BSPBio_001930; Tuads, ethyl; Nocceler TET-G; T1132_SIGMA; 155-01-1; Tiuram; HMS2051M17; Disulfuram; Disetil; Disulfirm; Sanceler TET; Antetil; Disulfirame; NCGC00016000-02; Antietil; Spectrum5_001590; MolPort-001-792-519; Teturam; CPD000059171; 11078-22-1; MLS000758264; MLS000069818; NCGC00016000-03; Soxinol TET; NCGC00016000-09; Prestwick3_000097; D004221; Stopety; HMS2090C18; Antiaethan; Ethyl Thiudad; Exhoran; SPECTRUM1500262; Tetradine; NCI-C02959; Spectrum4_000228; Stopetyl; Antalcol; NSC 190940; Antabuse; Antab use; NSC 25953; D00131; Ro-sulfiram; Krotenal; KBio3_001150; Spectrum3_000405; KBio2_004058; disulfiram; Antivitium (Spain); Lopac0_001164; Antaethan; Ethyl Thiram; HMS2091O22; NCGC00094423-05; Tetradin; Etabus; S00294; Hoca; Robac TET; NSC-25953; Antaenyl; Ekagom TEDS; Prestwick2_000097; Ephorran; Bonibal; ZINC01529266; AC1L1F7H; Dupon 4472; Accel TET-R; EU-0101164; nchembio.559-comp2; SPBio_001993; TTS; Ekagom DTET; Exhorran; HSDB 3317; Ro-Sulfram-500 (USA); AB00051976; NCGC00016000-01; BSPBio_000054	97-77-8	3117	4833	TTDS00053	Aldehyde dehydrogenase	N/A	N/A	N/A	N/A	inhibitor
DCL001243	SPC4955	N/A	N/A	N/A	N/A	TTDC00331	Apolipoprotein B-100	Apo B-100	P04114	338	ENSG00000084674	inhibitor
DAP000856	Ethynodiol Diacetate	Prestwick0_000908; 17-alpha-Ethynyl-3,17-dihydroxy-4-estrene diacetate; Prestwick1_000908; Ethynodiol diacetate (JAN/USP); E7263_SIGMA; SC 11800; BSPBio_000756; AB00513958; 3beta,17beta-Diacetoxy-17alpha-ethynyl-4-estrene; SMR000058858; Ethynodiol diacetate [Progestins]; 3beta,17beta-Diacetoxy-19-nor-17alpha-pregn-4-en-20-yne; Ethyndiol Diacetate; 17-alpha-Ethynylestr-4-ene-3-beta,17-beta-diol acetate; Metrodiol; 297-76-7; Etynodiol Acetate; SPBio_002955; Cervicundin; LMST02030124; (3-beta,17-alpha)-19-Norpregn-4-en-20-yne-3,17-diol diacetate; [(3S,8R,9S,10R,13S,14S,17R)-17-acetyloxy-17-ethynyl-13-methyl-2,3,6,7,8,9,10,11,12,14,15,16-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl] acetate; Luteonorm; C12724; Ethinodiol diacetate; 19-Nor-17-alpha-pregn-4-en-20-yne-3-beta,17-diol diacetate; 17alpha-Ethynyl-4-estrene-3beta,17beta-diol diacetate; Prestwick3_000908; 17-alpha-Ethynyl-4-estrene-3-beta,17-beta-diol diacetate; 3beta, 17beta-Diacetoxy-17alpha-ethynyl-4-oestrene; 17-alpha-Ethynyl-19-norandrost-4-ene-3-beta,17-beta-diol diacetate; 19-Norpregn-4-en-20-yne-3,17-diol, diacetate, (3beta,17alpha)-; LS-7392; Ethynodiol diacetate [USAN]; SC-11800; 19-Nor-17-alpha-pregn-4-en-20-yne-3-beta,17-diol, diacetate; CID9270; 17alpha-Ethynylestr-4-ene-3beta,17beta-diol acetate; BPBio1_000832; MLS000028661; DB00823; 3-beta, 17-beta-Diacetoxy-17-alpha-ethynyl-4-oestrene; HMS1570F18; (3 beta, 17 alpha)-19-Norpregn-4-en-20-yne-3,17 diol Diacetate; 17alpha-Ethynyl-3,17-dihydroxy-4-estrene diacetate; NCGC00166138-02; (3beta,17beta)-17-ethynylestr-4-ene-3,17-diyl diacetate; MolPort-003-941-317; Continuin; D01294; UNII-62H10A1236; Femulen; 8080 C. B.; ZINC03876023; NCGC00166138-01; CHEBI:31580; Ovulen 50; Luto-metrodiol; ETHYNODIOL DIACETATE; CHEMBL1200624; 17alpha-ethynylestr-4-ene-3beta,17beta-diyl diacetate; Metrodiol diacetate; 8080 C. B; EINECS 206-044-9; CCRIS 305; AC1L1SPA; 19-Nor-17alpha-pregn-4-en-20-yne-3beta,17-diol diacetate; 3-beta,17-beta-Diacetoxy-19-nor-17-alpha-pregn-4-en-20-yne; Etynodiol di(acetate); 17alpha-Ethynyl-19-norandrost-4-ene-3beta,17-beta-diol diacetate; Prestwick2_000908	297-76-7	9270	583113	TTDS00245	Progesterone receptor	PR	P06401	5241	ENSG00000082175	binder
DAP001208	Norgestrel	Microgyn; Monovar; NorLevo; alpha-Norgestrel; Norgestrelum; 13-Ethyl-17-alpha-ethynyl-17-beta-hydroxy-4-gonen-3-one; Norgestrel [USAN:INN:BAN:JAN]; HMS2051M08; DB00367; SAM001246694; Monofeme 28; Trinordiol 28; 6533-00-2; SH 70850; BAY86-5028; Triphasil 28; Wy 3707; N2260_FLUKA; Norplant System in Plastic Container; Ovrette (TN); Microlut; Norgestrel-(-)-D; HSDB 3595; Neogynon 21; 18,19-Dinor-4-pregnen-20-yn-3-one; BIDD:PXR0194; Rigevidon 21+7; component of Lo/ovral; C08149; 13-Ethyl-17alpha-ethynylgon-4-en-17beta-ol-3-one; Minivlar 30; Norplant (TN); Microgest ED; SH 850; AC1Q6OEV; 13-BETA-ETHYL-17-ALPHA-ETHYNYL-17-BETA-HYDROXYGON-4-EN-3-ONE; LS-62084; D00950; 72-HOURS; HMS2090O06; Levonorgestrel [USAN:INN:BAN]; Levora-28; Wy-3707; LD norgestrel [French]; UNII-5W7SIA7YZW; SMR000059117; 18-Methylnorethisterone; Norplant II; Ovral-Lo; Preven; CHEMBL1389; EINECS 212-349-8; 4222-79-1; Mirena (TN); CPD000059117; 13-Ethyl-17-alpha-ethynylgon-4-en-17-beta-ol-3-one; Follistrel; Levonorgestrelum; Ovrette; 17alpha-Ethynyl-18-homo-19-nor-testosterone; Capronor; 17alpha-Ethynyl-17-hydroxy-18-methylestr-4-en-3-one; Ovoplex 30-150; Trigoa; Levlen; Ld norgestrel; Prestwick0_000773; Ovranette; D00954; 17alpha-Ethynyl-13-ethyl-19-nortestosterone; E-Gen-C; Prestwick3_000773; NCGC00159349-02; Levonova; Levonelle, D-Norgestrel, Levonova, Levonorgestrel; MolPort-002-510-453; Mirena; Triquilar ED; Microlution; 13-Ehyl-17alpha-ethynyl-17-hydroxygon-4-en-3-one; SMR000653526; Microluton; 19-Nortestosterone, 17-ethynyl-18-methyl-; 121714-72-5; Norgestrel (JP15/USP/INN); 13beta-Ethyl-17alpha-ethynyl-17beta-hydroxygon-4-en-3-one; ZINC03814395; Microval; 18-Methyl-17-alpha-ethynyl-19-nortestosterone; SPBio_002785; 17alpha-Ethynyl-13beta-ethyl-3-oxo-4-estren-17beta-ol; NCGC00159349-03; Triciclor; Levora-21; MLS000069491; NSC744007; Trivora; Postinor-2; norgestrel; AC1L211U; BRN 2391114; Bio-0595; D(&#8722;)-Norgestrel; HMS1570K08; BAY 86-5028; Levonorgestrelum [INN-Latin]; Norgeston; CID13109; Neogest; Tetragynon; LMST02030119; Jadelle; CCRIS 6525; Levonorgestrel implants; 797-63-7; MLS001074069; HSDB 6483; EINECS 229-433-5; UNII-3J8Q1747Z2; C08153; Norplant 2; BPBio1_000932; MLS000759484; D-Norgestrel; 17alpha-Ethynyl-18-homo-19-nortestosterone; FH 122-A; Levlen ED; Levonelle; Norplant-2; Microgynon 28; Prestwick2_000773; LS-62083; LO/Ovral; Levonorgestrel; CHEBI:44593; dl-13-beta-Ethyl-17-alpha-ethynyl-19-nortestosterone; 17-Ethynyl-18-methyl-19-nortestosterone; Norgestrelum [INN-Latin]; dl-Norgestrel; 17alpha-ethynyl-17beta-hydroxy-18a-homoestr-4-en-3-one; CCRIS 9033; Microgynon 21; (-)-Norgestrel; Logynon ED; 17-alpha-Ethynyl-13-ethyl-19-nortestosterone; Trifeme 28; DB00506; BSPBio_000846; Nordet; Prestwick_109; D-(-)-Norgestrel; Levonorgestrel (JAN/USP/INN); 797-62-6; Microgynon CD; SOH-075; Microgynon 30 ED; Wy-5104; Methylnorethindrone; BRD-K35189033-001-03-0; Plan B; d(-)-Norgestrel; Trinordiol 21; Nordette 28; Norgestrel [Progestins]; Stediril 30; Triphasil 21; Postinor; CHEBI:6443; S1727_Selleck; 13-beta-Ethyl-17alpha-ethynyl-17beta-hydroxygon-4-en-3-one; NORPLANT; Nordette 21; Tri-Levlen 21; Norgestrel [USAN:BAN:INN:JAN]; N2260_SIGMA; Triagynon; Prestwick1_000773	6533-00-2	13109	7848017	TTDS00245	Progesterone receptor	PR	P06401	5241	ENSG00000082175	agonist
DAP001554	Ulipristal	N/A	N/A	N/A	N/A	TTDS00245	Progesterone receptor	PR	P06401	5241	ENSG00000082175	modulator
DAP001211	Medroxyprogesterone	AC1L1VM7; 17alpha-Hydroxy-6alpha-methyl-4-pregnene-3,20-dione; (6S,8R,9S,10R,13S,14S,17R)-17-acetyl-17-hydroxy-6,10,13-trimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one; HMS2052A13; Pregn-4-ene-3,20-dione, 17-hydroxy-6-alpha-methyl-; Farlutal inyectable (TN); CBP-1011; SAM001246906; Medroxiprogesteronum; 520-85-4; LS-118713; 46411_FLUKA; Medroxyprogesterone [INN:BAN]; Pregn-4-ene-3,20-dione, 17-hydroxy-6-methyl-, (6.alpha.)-; Medroprogesterone Acetate; 17 alpha-Hydroxy-6 alpha-Methylprogesterone; 6-alpha-Methyl-17-alpha-hydroxyprogesterone; NSC 27408; CHEMBL1390; Pregn-4-ene-3,20-dione, 17-hydroxy-6-methyl-, (6-alpha)- (9CI); MolPort-005-934-866; Strakan Brand of Medroxyprogesterone; Farlutal inyectable; 17-Hydroxy-6alpha-methyl-pregn-4-ene-3,20-dione; 17-Hydroxy-6alpha-methylprogesterone; 17alpha-Hydroxy-6alpha-methylprogesterone; 6alpha-Methyl-17alpha-hydroxyprogesterone; 6alpha-Methyl-4-pregnen-17alpha-ol-3,20-dione; Medroxyprogesteron; UNII-HSU1C9YRES; NCGC00023064-04; 6alpha-Methyl-4-pregnen-17alpha-ol-3,20-dione; LMST02030176; Medroxyprogesteronum; 17-Hydroxy-6.alpha.-methylprogesterone; Medroxiprogesterona; DB00603; Medrossiprogesterone; Medroxyprogesteron; Pregn-4-ene-3,20-dione, 17-hydroxy-6.alpha.-methyl-; MLS000069571; CHEBI:6715; medroxyprogesterone; Asconale; Lunelle; 46411_RIEDEL; Hydroxymethylprogesterone; Sodelut G; BRN 2510965; NSC27408; 17alpha-Hydroxy-6alpha-methylprogesterone; 6alpha-Methyl-17alpha-hydroxyprogesterone; CID10631; U 8840; 4-08-00-02211 (Beilstein Handbook Reference); Methylhydroxyprogesterone; ZINC05763835; 17-Hydroxy-6alpha-methyl-pregn-4-ene-3,20-dione; Pregn-4-ene-3,20-dione, 17-hydroxy-6-methyl-, (6alpha)-; Medroxyprogesteron acetate; MPA Gyn 5; Colirest; HSDB 3114; 6alpha-Methyl-5-pregnen-17alpha-ol-3,20-dione; ST082267; Medroxiprogesterona [INN-Spanish]; Medroxyprogesteronum [INN-Latin]; Pregn-4-ene-3,20-dione, 17-hydroxy-6-methyl-, (6-alpha)-; Medrossiprogesterone [DCIT]; CPD000058769; (6alpha)-17-hydroxy-6-methylpregn-4-ene-3,20-dione; 17 alpha Hydroxy 6 alpha Methylprogesterone; 6-Dihydromegestrol; g-Farlutal; Hematrol; 17.alpha.-Hydroxy-6.alpha.-methylprogesterone; D008525; EINECS 208-298-6; Pregn-4-ene-3,20-dione, 17-hydroxy-6-methyl-, (6alpha)- (9CI); 6.alpha.-Methyl-17.alpha.-hydroxyprogesterone; C07119; SMR000058769; D08166; 17-Hydroxy-6alpha-methylprogesterone; M6013_SIGMA; MLS001076098; AC-14528; Adgyn Medro; Medroxyprogesterone (INN); Medroxyprogesterone Strakan Brand; Novo-Medrone	520-85-4	10631	9330	TTDS00245	Progesterone receptor	PR	P06401	5241	ENSG00000082175	agonist
DAP001207	Levonorgestrel	Microgyn; Monovar; NorLevo; alpha-Norgestrel; Norgestrelum; 13-Ethyl-17-alpha-ethynyl-17-beta-hydroxy-4-gonen-3-one; Norgestrel [USAN:INN:BAN:JAN]; HMS2051M08; DB00367; SAM001246694; Monofeme 28; Trinordiol 28; 6533-00-2; SH 70850; BAY86-5028; Triphasil 28; Wy 3707; N2260_FLUKA; Norplant System in Plastic Container; Ovrette (TN); Microlut; Norgestrel-(-)-D; HSDB 3595; Neogynon 21; 18,19-Dinor-4-pregnen-20-yn-3-one; BIDD:PXR0194; Rigevidon 21+7; component of Lo/ovral; C08149; 13-Ethyl-17alpha-ethynylgon-4-en-17beta-ol-3-one; Minivlar 30; Norplant (TN); Microgest ED; SH 850; AC1Q6OEV; 13-BETA-ETHYL-17-ALPHA-ETHYNYL-17-BETA-HYDROXYGON-4-EN-3-ONE; LS-62084; D00950; 72-HOURS; HMS2090O06; Levonorgestrel [USAN:INN:BAN]; Levora-28; Wy-3707; LD norgestrel [French]; UNII-5W7SIA7YZW; SMR000059117; 18-Methylnorethisterone; Norplant II; Ovral-Lo; Preven; CHEMBL1389; EINECS 212-349-8; 4222-79-1; Mirena (TN); CPD000059117; 13-Ethyl-17-alpha-ethynylgon-4-en-17-beta-ol-3-one; Follistrel; Levonorgestrelum; Ovrette; 17alpha-Ethynyl-18-homo-19-nor-testosterone; Capronor; 17alpha-Ethynyl-17-hydroxy-18-methylestr-4-en-3-one; Ovoplex 30-150; Trigoa; Levlen; Ld norgestrel; Prestwick0_000773; Ovranette; D00954; 17alpha-Ethynyl-13-ethyl-19-nortestosterone; E-Gen-C; Prestwick3_000773; NCGC00159349-02; Levonova; Levonelle, D-Norgestrel, Levonova, Levonorgestrel; MolPort-002-510-453; Mirena; Triquilar ED; Microlution; 13-Ehyl-17alpha-ethynyl-17-hydroxygon-4-en-3-one; SMR000653526; Microluton; 19-Nortestosterone, 17-ethynyl-18-methyl-; 121714-72-5; Norgestrel (JP15/USP/INN); 13beta-Ethyl-17alpha-ethynyl-17beta-hydroxygon-4-en-3-one; ZINC03814395; Microval; 18-Methyl-17-alpha-ethynyl-19-nortestosterone; SPBio_002785; 17alpha-Ethynyl-13beta-ethyl-3-oxo-4-estren-17beta-ol; NCGC00159349-03; Triciclor; Levora-21; MLS000069491; NSC744007; Trivora; Postinor-2; norgestrel; AC1L211U; BRN 2391114; Bio-0595; D(&#8722;)-Norgestrel; HMS1570K08; BAY 86-5028; Levonorgestrelum [INN-Latin]; Norgeston; CID13109; Neogest; Tetragynon; LMST02030119; Jadelle; CCRIS 6525; Levonorgestrel implants; 797-63-7; MLS001074069; HSDB 6483; EINECS 229-433-5; UNII-3J8Q1747Z2; C08153; Norplant 2; BPBio1_000932; MLS000759484; D-Norgestrel; 17alpha-Ethynyl-18-homo-19-nortestosterone; FH 122-A; Levlen ED; Levonelle; Norplant-2; Microgynon 28; Prestwick2_000773; LS-62083; LO/Ovral; Levonorgestrel; CHEBI:44593; dl-13-beta-Ethyl-17-alpha-ethynyl-19-nortestosterone; 17-Ethynyl-18-methyl-19-nortestosterone; Norgestrelum [INN-Latin]; dl-Norgestrel; 17alpha-ethynyl-17beta-hydroxy-18a-homoestr-4-en-3-one; CCRIS 9033; Microgynon 21; (-)-Norgestrel; Logynon ED; 17-alpha-Ethynyl-13-ethyl-19-nortestosterone; Trifeme 28; DB00506; BSPBio_000846; Nordet; Prestwick_109; D-(-)-Norgestrel; Levonorgestrel (JAN/USP/INN); 797-62-6; Microgynon CD; SOH-075; Microgynon 30 ED; Wy-5104; Methylnorethindrone; BRD-K35189033-001-03-0; Plan B; d(-)-Norgestrel; Trinordiol 21; Nordette 28; Norgestrel [Progestins]; Stediril 30; Triphasil 21; Postinor; CHEBI:6443; S1727_Selleck; 13-beta-Ethyl-17alpha-ethynyl-17beta-hydroxygon-4-en-3-one; NORPLANT; Nordette 21; Tri-Levlen 21; Norgestrel [USAN:BAN:INN:JAN]; N2260_SIGMA; Triagynon; Prestwick1_000773	17489-40-6	13109	10349	TTDS00245	Progesterone receptor	PR	P06401	5241	ENSG00000082175	binder
DAP000090	Mifepristone	HMS2052L05; Mifepristone Danco Brand; Exelgyn Brand of Mifepristone; CI-1073; (8S,11R,13S,14S,17S)-11-(4-dimethylaminophenyl)-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one; M 8046; Pictovir (TM); FT-0082666; SMR000058481; RU-38486; Spectrum5_002045; mifepristone; BPBio1_000262; TL8005515; CID55245; HSCI1_000369; DB00834; (11beta,17beta)-11-(4-(Dimethylamino)phenyl)-17-hydroxy-17-(1-propynyl)-estra-4,9-dien-3-one; M8046_SIGMA; CHEBI:50692; HSDB 6841; Mifepristone (USAN/INN); 11beta-(4-(Dimethylamino)phenyl)-17beta-hydroxy-17-(1-propynyl)estra-4,9-dien-3-on; Mifepristone [USAN:INN:BAN]; UNII-320T6RNW1F; (11beta,17beta)-11-(4-(Dimethylamino)-phenyl)-17-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one; Estra-4,9-dien-3-one, 11-(4-(dimethylamino)phenyl)-17-hydroxy-17-(1-propynyl)-, (11-beta,17-beta)-; MLS001074115; SPBio_002457; Mifepristone Exelgyn Brand; ZK98296; HMS2090L22; Mifepriston; RU 486; S1611_Selleck; MolPort-003-849-222; C-1073; Contragest Brand of Mifepristone; Prestwick1_000299; NCGC00025179-05; Mifeprex; (11beta,17beta)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-prop-1-yn-1-ylestra-4,9-dien-3-one; ZK-98296; RU-486; Prestwick0_000299; 83203-42-3; HMS1568L20; Ambap84371-65-3; RU 486-6; SAM001246881; RU-486, MIFEPRISTONE; 11-(4-DIMETHYLAMINO-PHENYL)-17-HYDROXY-13-METHYL-17-PROP-1-YNYL-1,2,6,7,8,11,12,13,14,15,16,17-DODEC AHYDRO-CYCLOPENTA[A]PHENANTHREN-3-ONE; 11beta-(4-Dimethyl-?amino)-?phenyl-17beta-hydroxy-17-(1-propynyl)-?estra-4,9-dien-3-one; Mifepristonum [Latin]; RU38486; Danco Brand of Mifepristone; ZK 98296; D015735; Prestwick3_000299; EU-0100801; Mifepristone Contragest Brand; Mifeprex (TN); AC1L1IOO; Mifepristonum; D00585; Lopac0_000801; R38486; Mifegyne; BSPBio_000238; 11beta-(p-(Dimethylamino)phenyl)-17beta-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one; NCGC00025179-08; 11beta-(4-(Dimethylamino)phenyl)-17-hydroxy-21-methyl-19-nor-17alpha-pregna-4,9-dien-20-m-3-on; VGX-410C; R-38486; C29H35NO2; BRD-K37270826-001-04-5; BRN 5779404; VGX-410; 11beta-(4-(N,N-Dimethylamino)phenyl)-17alpha-(prop-1-ynyl)-delta4,9-estradiene-17beta-ol-3-one; 122742-25-0; RU-486, RU-38486, Mifegyne, Mifeprex, Mifepristone; RU 38486; (11beta,17beta)-11-(4-(Dimethylamino)phenyl)-17-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one; Pictovir; ZINC03831128; 84371-65-3; CHEMBL157; Prestwick_570; R 38486; NCGC00179632-01; LS-64723; C07652; Mifepristona; Estra-4,9-dien-3-one, 11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(1-propynyl)-, (11b,17b)-; BIDD:PXR0123; MLS000069785; VX-410; Prestwick2_000299; 17-beta-Hydroxy-11-beta-(4-dimethylaminophenyl-1)-17-alpha-(prop-1-ynyl)oestra-4,9-dien-3-one; Corlux; CPD000058481; RU486; Estra-4,9-dien-3-one, 11-(4-(dimethylamino)phenyl)-17-hydroxy-17-(1-propynyl)-, (11beta,17beta)-; Mifepristona [Spanish]	84371-65-3	55245	7847651	TTDS00245	Progesterone receptor	PR	P06401	5241	ENSG00000082175	antagonist
DCL000705	Asoprisnil	CHEMBL267431; J867; 11beta-(4-((E)-(Hydroxyimino)methyl)phenyl)-17beta-methoxy-17-(methoxymethyl)estra-4,9-dien-3-one; CID9577221; Asoprisnil; Asoprisnil (USAN/INN); 199396-76-4; Benzaldehyde, 4-((11beta,17beta)-17-methoxy-17-(methoxymethyl)-3-oxoestra-4,9-dien-11-yl)-, 1-oxime, (C(E))-; D02996; J-867	199396-76-4	9577221	17397152	TTDS00245	Progesterone receptor	PR	P06401	5241	ENSG00000082175	modulator
DAP001210	Norgestimate	ORF 10131; Norgestimatum [INN-Latin]; CHEBI:50815; (17alpha)-17-(Acetyloxy)-13-ethyl-18,19-dinorpregn-4-en-20-yn-3-one 3-oxime; (3E)-17alpha-ethynyl-3-(hydroxyimino)-18a-homoestr-4-en-17beta-yl acetate; C017576; UNII-C291HFX4DY; (17-alpha)-17-(Acetyloxy)-13-ethyl-18,19-dinorpregn-4-en-20-yn-3-one 3-oxime; NORGESTIMATE; CID6540478; 35189-28-7; NCGC00181353-01; D 138; D05209; d-13beta-Ethyl-17alpha-ethynyl-17beta-acetoxygon-4-en-3-one oxime; AC1O712U; ORF-10131; RWJ 10131; d-13-beta-Ethyl-17-alpha-ethynyl-17-beta-acetoxygon-4-en-3-one oxime; Dexnorgestrel acetime; Norgestimato [INN-Spanish]; Norgestimatum; 18,19-Dinor-17-pregn-4-en-20-yn-3-one, 17-(acetyloxy)-13-ethyl-, oxime, (17alpha)- (+)-; AC-655; Norgestimate (USP/INN); DB00957; [(3E,8R,9S,10R,13S,14S,17R)-13-ethyl-17-ethynyl-3-hydroxyimino-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-yl] acetate; norgestrel oxime acetate; LS-62080; Norgestimato; Ortho-Prefest; (+)-13-Ethyl-17-hydroxy-18,19-dinor-17alpha-pregn-4-en-20-yn-3-one oxime acetate (ester); Norgestimate [USAN:INN:BAN]; I14-9729; CHEMBL1200934; 18,19-Dinorpregn-4-en-20-yn-3-one, 17-(acetyloxy)-13-ethyl-, 3-oxime, (17-alpha)-; RWJ-10131; ZINC03938695; 18,19-Dinor-17-pregn-4-en-20-yn-3-one, 17-(acetyloxy)-13-ethyl-, oxime, (17alpha)-(+)-	35189-28-7	6540478	178495	TTDS00245	Progesterone receptor	PR	P06401	5241	ENSG00000082175	agonist
DAP001205	Dydrogesterone	Dydrogesteronum; Dydrogesteronum [INN-Latin]; MLS002153947; Dydrogesterona; Retrone; D004394; Gestatron; HSDB 3321; delta(sup 6)-Retroprogesterone; Prestwick3_000671; ZINC03875998; 9-.beta.,10.alpha.-Pregna-4,6-diene-3,20-dione; 6-Dehydro-retro-progesterone; (8S,9R,10S,13S,14S,17S)-17-acetyl-10,13-dimethyl-1,2,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-one; Prodel; Prestwick0_000671; Hydrogesterone; Dydrogesterona [INN-Spanish]; Duphaston; 152-62-5; Pregna-4,6-diene-3,20-dione, (9-beta,10-alpha)-; BSPBio_000761; NCGC00179445-01; 9-beta,10alpha-Pregna-4,6-diene-3,20-dione; NSC92336; I06-1088; BPBio1_000839; Didrogesterone [DCIT]; 9beta,10alpha-Pregna-4,6-diene-3,20-dione; D01217; Retro-6-dehydroprogesterone; UNII-90I02KLE8K; Dufaston; MolPort-005-940-416; BRD-K68620903-001-03-1; CHEBI:31527; 6-Dehydro-9beta,10alpha-progesterone; CID9051; .DELTA.6-Retroprogesterone; Isopregnenone; 10alpha-Isopregnenone; Duphaston (TN); AC1L1S7M; Dydrogesterone (JP15/USP/INN); Retroprogesterone, 6-dehydro-; didrogesterona; delta(6)-Retroprogesterone; (9-beta,10-alpha)-Pregna-4,6-diene-3,20-dione; Hydrogestrone; Pregna-4,6-diene-3,20-dione, (9.beta.,10.alpha.)-; 6-Dehydro-9.beta.,10.alpha.-progesterone; CHEMBL1200853; Pregna-4,6-diene-3,20-dione, (9beta,10alpha)-; Didrogesterone; SPBio_002682; Solvay Brand of Dydrogesterone; Prestwick2_000671; 6-Dehydroretroprogesterone; Duvaron; DB00378; AB00513884; Diphaston; 9.beta.,10.alpha.-Pregna-4,6-diene-3,20-dione; (9beta,10alpha)-pregna-4,6-diene-3,20-dione; 6-Dehydro-9 beta-10 alpha-progesterone; NSC 92336; 9beta,10alpha-Pregna-4,6-diene-3,20-dione (8CI); Gynorest (TN); 9-beta,10-alpha-Pregna-4,6-diene-3,20-dione; Pregna-4,6-diene-3,20-dione, (9-beta,10-alpha)- (9CI); Dydrogesterone [USAN:INN:BAN:JAN]; 6 Dehydro 9 beta 10 alpha progesterone; Prestwick1_000671; Terolut; Dehydrogesterone; LS-118418; HMS1570G03; Gynorest; dydrogesterone; SMR001233286; CCRIS 9069; EINECS 205-806-8	152-62-5	9051	7848280	TTDS00245	Progesterone receptor	PR	P06401	5241	ENSG00000082175	agonist
DAP001209	Desogestrel	LMST02030104; CHEBI:4453; UNII-81K9V7M3A3; Desogestrelum [INN-Latin]; CID40973; EINECS 258-929-4; C07629; (8S,9S,10R,13S,14S,17R)-13-ethyl-17-ethynyl-11-methylidene-1,2,3,6,7,8,9,10,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-ol; C22H30O; 18,19-Dinorpregn-4-en-20-yn-17-ol, 13-ethyl-11-methylene-, (17-alpha)-; MolPort-003-846-424; 13-Ethyl-11-methylene-18,19-dinor-17 alpha-pregn-4-en-20-yn-17-ol; D017135; alpha-pregn-4-en-20-yn-17-ol, 13-Ethyl-11-methylene-18,19-dinor-17; AC-308; 17alpha-ethynyl-11-methylidene-18a-homo-estr-4-en-17beta-ol; AC1Q282A; 13 Ethyl 11 methylene 18,19 dinor 17 alpha pregn 4 en 20 yn 17 ol; Desogestrelum; Desogestrel [USAN:BAN:INN]; AC1L24T4; 54024-22-5; Organon Brand of Desogestrel; Org-2969; HSDB 3593; Org2969; ORG 2969; D02367; DB00304; NCGC00167449-01; CHEMBL1533; Desogestrel (USAN/INN); desogen; 18,19-Dinorpregn-4-en-20-yn-17-ol, 13-ethyl-11-methylene-, (17alpha)-; ZINC04097416; (17alpha)-13-Ethyl-11-methylene-18,19-dinorpregn-4-en-20-yn-17-ol; DESOGESTREL; 13-Ethyl-11-methylene-18,19-dinor-17alpha-pregn-4-en-20-yn-17-ol; LS-62079; Cerazette	54024-22-5	40973	181763	TTDS00245	Progesterone receptor	PR	P06401	5241	ENSG00000082175	modulator
DAP000855	Etonogestrel	Etonogestrel (USAN/INN); 54048-10-1; NCGC00168777-01; CHEBI:50777; MolPort-003-847-336; CID6917715; ETONOGESTREL; 3-Oxodesogestrel; AC1OCEK1; (8S,9S,10R,13S,14S,17R)-13-ethyl-17-ethynyl-17-hydroxy-11-methylidene-2,6,7,8,9,10,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one; etonogestrelum; ZINC11680067; 17alpha-ethynyl-17beta-hydroxy-11-methylidene-18a-homo-estr-4-en-3-one; CHEMBL1531; 3-Ketodesogestrel; Implanon; Implanon (TN); D04104; Org-3236	54048-10-1	40976	181766	TTDS00245	Progesterone receptor	PR	P06401	5241	ENSG00000082175	binder
DAP000861	Megestrol	Chronopil; CID19090; HSDB 3233; 17-Hydroxy-6-methylpregna-4,6-diene-3,20-dione; Pregna-4,6-diene-3,20-dione, 17-hydroxy-6-methyl-; UNII-EA6LD1M70M; Megestrol (INN); C07120; Megestrolum [INN-Latin]; DB00351; Megestrolo [DCIT]; 3562-63-8; Chronopil (TN); EINECS 222-628-6; Megestrolo; D08167; AC1L2DG3; Megestrol [INN:BAN]; D008535; (8R,9S,10R,13S,14S,17R)-17-acetyl-17-hydroxy-6,10,13-trimethyl-2,8,9,11,12,14,15,16-octahydro-1H-cyclopenta[a]phenanthren-3-one; LS-118488; megestrol	3562-63-8	19090	9331	TTDS00245	Progesterone receptor	PR	P06401	5241	ENSG00000082175	binder
DAP001212	Norethindrone	norethindrone; HMS501L15; N.E.E; 17-Ethynyl-17-hydroxyestr-4-en-3-one; Norethindirone; Noriday; BSPBio_000066; Noretisterona; BRD-A39415247-001-02-1; Micronor; Triella; EINECS 200-681-6; Utovlan; Norethin 1/35 E; Norpregneninolone; Minovlar; Normapause; Norethin; 17alpha-Ethynyl-4-estren-17-ol-3-one; Nodiol; ARONIS24281; MLS001163874; Norfor; Norlutin; Synphase; 46525_RIEDEL; LMST02030097; Microneth; STOCK1N-04274; Gestest; Noraethisteronum; Synphasic 28; Norethisteron; Jenest; Ortho-Novum 1 35; HSDB 3370; Norethindrone (USP); SC 4640; Prestwick_646; SMR000499579; Micronor (TN); N.E.E.; CPD000499579; SMR000718762; C05028; Oprea1_606355; 19-Nor-17alpha-ethynyltestosterone; Ovysmen 0.5 35; Orlest; Norethisterone [Progestins]; Gencept; Nor-Q.D; Ethynylmortestosterone; Primolut-N; Ciclovulan; CID5702093; CID4536; HMS2090D21; 19-Norethisterone; 4-Estren-17alpha-ethynyl-17beta-ol-3-one; STK730956; Nelova; Norgestin; 17-Ethinyl-19-nortestosterone; Nora-BE; Noretisterona [INN-Spanish]; Conceplan; SPBio_001052; Noriday 28; D00182; Brevicon; KBio2_001491; 19-Norethindrone; 19-Nor-17alpa-ethynyltestosterone; MolPort-003-861-444; KBio2_006627; BB_NC-0600; Brevinor 28; Spectrum3_000521; AC1Q6OG5; Norethynodron; Prestwick3_000253; BPBio1_000074; KBio2_004059; Norethynodrone; Brevinor; N0449; 17-alpha-Ethynyl-19-nortestosterone; AC1O5EOU; Estrinor; 17-ethynyl-17beta-hydroxyestr-4-en-3-one; Micronovum; Ortho 1 35; Norluten; HMS1920B10; AR-1C1071; AI3-26422; Anovule; BRD-K92073408-001-03-3; Prestwick2_000253; Nor-Q.D.; Norcept; Ortho-Novum 7 7 7; BRN 1915671; 19-Norethinyltestosterone; 17.alpha.-Ethynyl-4-estren-17-ol-3-one; Noretisterone; Proluteasi; Errin; HMS2091J10; Conludag; Ethinyl-19-nortestosterone; Ethynylnortestosterone; Norethindrone [USAN]; Ortho 7 7 7; UNII-T18F433X4S; Genora; WLN: L E5 B666 OV MUTJ E FQ F1UU1 -A&F; Demulen; Noresthisterone; Norethisteronum; Ortho-Novum 1 50; Norpregneninotone; Norethyndron; AC1L1M2R; 17.alpha.-Ethinyl-19-nortestosterone; Norethadrone; Brevinor 21; BSPBio_002101; KBio1_000553; 17alpha-Ethynyl-19-nortestosterone; NSC9564; Norcept-E; CCRIS 484; Conludaf; MLS001304093; 19-Nortestosterone, 17-ethynyl-; N4128_SIGMA; Mini-pill; Utovlar; MolPort-002-507-131; Norethisteronum [INN-Latin]; A3564/0151191; CHEBI:7627; Loestrin; Norcolute; Norcolut; Spectrum2_001066; Primolut-N (TN); Norluton; NCGC00178820-01; 19-Nor-17-ethinyl testosterone; Norethin 1/50 M; 17alpha-Ethinyl-19-nortestosterone; IDI1_000553; MolPort-002-509-542; Spectrum4_000079; Trinovum 21; AKOS004119895; 19-Nor-17-ethinyltestosterone; component of Noriday; Activella; Noretisterone [DCIT]; SPBio_002285; Spectrum_001011; 17.alpha.-Ethynyl-19-nortestosterone; Camila; DB00717; AC1L1IDS; 19-Nor-17.alpha.-ethynyltestosterone; Menzol; AC1NWAOX; 19-Nor-ethinyl--4,5-testosterone; NSC-9564; Anovulatorio; 17-alpha-Ethynyl-4-estren-17-ol-3-one; MolPort-002-728-977; Jenest-28; Nor-QD; 46525_FLUKA; SPECTRUM1500437; 19-Nor-17-alpha-ethynyltestosterone; Primolut N; CID6432649; Prestwick1_000253; MLS001076679; Noralutin; Camila (TN); ST094767; Mini-Pe; AC-11100; CID6230; Brevinor-1 28; Norethisterone; CHEMBL1162; SAM002564223; ZINC03814419; Spectrum5_001198; 19-Nor-ethindrone; Norethisterone (JP15); Tri-Norinyl; Ovysmen 1 35; KBio3_001601; Norethindrone Norethisterone; Prestwick0_000253; KBioGR_000637; Milli; Micronett; DivK1c_000553; I06-0104; 68-22-4; KBioSS_001491; Brevinor-1 21; NCGC00179669-01; HMS1568D08; Norpregneninlone; Anhydrohydroxynorprogesterone; LS-97425; Ethinylnortestosterone; NINDS_000553	68-22-4	6230	7847250	TTDS00245	Progesterone receptor	PR	P06401	5241	ENSG00000082175	agonist
DCL000520	DwLIP-GCGRrx	N/A	4533-39-5	20628	29290208	TTDS00439	Glucagon receptor	N/A	P47871	2642	ENSG00000215644	binder
DAP001037	Glucagon recombinant	N/A	9007-92-5	N/A	4670	TTDS00439	Glucagon receptor	N/A	P47871	2642	ENSG00000215644	binder
DPR000189	ZP2929	N/A	N/A	N/A	N/A	TTDS00439	Glucagon receptor	N/A	P47871	2642	ENSG00000215644	agonist
DCL000263	XL647	N/A	168626-94-6	5712	49684198	TTDC00045	Ephrin type-B receptor 4	Tyrosine-protein kinase receptor HTK;Tyrosine-protein kinase TYRO11	P54760	2050	ENSG00000196411	inhibitor
DCL001065	AEG35156	N/A	928841-57-0	N/A	85150306	TTDC00280	mRNA of Inhibitor of apoptosis protein	Baculoviral IAP repeat-containing protein 4;HILP;IAP-like protein;Inhibitor of apoptosis protein 3;XIAP;X-linked IAP;X-linked inhibitor of apoptosis;X-linked inhibitor of apoptosis protein	P98170	331	ENSG00000101966	N/A
DPR000172	AT008	N/A	N/A	N/A	N/A	TTDC00226	C-C chemokine receptor type 4	CC chemokine receptor 4;C-C CKR-4;CC-CKR-4;CCR4;CCR-4;K5-5	P51679	1233	ENSG00000183813	antibody
DCL000427	AMG 761	N/A	N/A	N/A	N/A	TTDC00226	C-C chemokine receptor type 4	CC chemokine receptor 4;C-C CKR-4;CC-CKR-4;CCR4;CCR-4;K5-5	P51679	1233	ENSG00000183813	antibody
DAP000830	Monobenzone	Dermochinona; 4-(Benzyl-Oxy)Phenol; C006429; AI3-14325; NCGC00016360-02; 4-(Benzyloxyl)phenol; Monobenzone; ZINC00001748; AKOS000119555; Monobenzyl ether hydroquinone; Benoquin (TN); BSPBio_000784; UNII-9L2KA76MG5; AC1Q579O; CAS-103-16-2; C14244; NCGC00016360-01; CHEMBL1388; Novo-depigman; 4-phenylmethoxyphenol; AR-1H6680; Hydroquinone monobenzyl ether; Monobenzone; PBP; Monobenzonum [INN-Latin]; Prestwick3_000912; TL806329; Phenol, p-(benzyloxy)-; MolPort-000-519-128; CHEBI:34380; EINECS 203-083-3; BPBio1_000864; Phenol, 4-(phenylmethoxy)-; 158348_ALDRICH; B1104; SBB038524; DB00600; Alba; AB00513959; WLN: QR DO1R; Prestwick0_000912; 4-06-00-05728 (Beilstein Handbook Reference); P-BENZYLOXYPHENOL; Agerite alba; AC1L1P7V; Leucodinine; Pigmex; Hydrochinon monobenzylether; Hydroquinone monobenzyl ether; Monobenzona [INN-Spanish]; Jsp000332; Hydroquinone benzyl ether; Alba-Dome; 4-(Benzyloxy)phenol; Benzyl hydroquinone; Prestwick1_000912; HSDB 4019; P-(BENZYLOXY)PHENOL; SPBio_002973; AC-2492; I01-1484; Monobenzona; 4-(Phenylmethoxy)phenol; LS-7440; D05072; Monobenzonum; HYDROQUINONE MONOBENZYL ETHER, N F; NSC 2132; Benoquin; Monobenzone (USP/INN); S1652_Selleck; HMS1570H06; AB1001901; Monobenzyl Ether of Hydroquinone; Benzoquin; Benoquin, Monobenzone; 4-benzyloxy phenol; Monobenzyl hydroquinone; Benzyl p-hydroxyphenyl ether; Carmifal; Depigman; Hydrochinon monobenzylether [Czech]; Oprea1_698781; BRN 1958305; ICN brand of monobenzone; 4-phenylmethoxy-phenol; HMS1580P12; 103-16-2; Prestwick2_000912; BIDD:ER0003; Agerite; NSC2132; 4-Benzyloxyphenol; NSC33918; Monobenzone [INN]; CID7638; AC1Q78XV; Superlite; Monobenzon; p-Hydroxyphenyl benzyl ether; Superlite (antioxidant)	103-16-2	7638	7847054	TTDS00373	Tyrosine oxidase	LB24-AB;Monophenol monooxygenase;SK29-AB;Tumor rejection antigen AB;Tyrosinase	P14679	7299	ENSG00000077498	inhibitor
DAP001485	Isoxyl	Amixyl; AC1MHDQA; CARBANILIDE, 4,4'-BIS(ISOPENTYLOXY)THIO-; Tiocarlide (INN); Thiocarlide; Tiocarlid; N,N'-Bis(4-(3-methylbutoxy)phenyl)thiourea; Thiourea, N,N'-bis(4-(3-methylbutoxy)phenyl)-; Tiocarlidum [INN-Latin]; 1,3-bis[4-(3-methylbutoxy)phenyl]thiourea; LS-51568; BRN 2546347; 910-86-1; Tiocarlida [INN-Spanish]; ZINC04217571; CID3001386; EINECS 213-006-5; Tiocarlida; Tiocarlidum; 4-13-00-01187 (Beilstein Handbook Reference); C23H32N2O2S; Isoxyl; NSC742400; D07246; 4,4'-Diisoamyloxythiocarbanilide; BRN2546347; CHEMBL214920; Thiourea, N,N'-bis(4-(3-methylbutoxy)phenyl)- (9CI); Tiocarlide; 4,4'-Bis(isopentyloxy)thiocarbanilide; Thiourea, N,N'-bis[4-(3-methylbutoxy)phenyl]-; Tiocarlide [INN:DCF]; Disoxyl	910-86-1	3001386	618324	TTDS00516	Acyl-CoA desaturase	9 stearoyl-desaturase;Delta(9)-desaturase;Delta-9-stearoyl desaturase;Des A3;DesA3;Fatty acid desaturase;Membrane-bound 9 desaturase;SCD;Stearoyl-CoA desaturase;Stearoyl-coenzyme A (Delta9) desaturase	Q6MWZ3	N/A	N/A	binder
DAP000952	Chlorzoxazone	KBio2_005764; 2-Hydroxy-5-chlorobenzoxazole; KBio3_001239; Parafon Forte DSC; SAM002554888; 5-Chlorobenzoxazolone; HMS1920O07; Lopac-C-4397; Remofleks; Prestwick_62; Prestwick1_000163; chlorzoxazone; 5-Chloro-2-hydroxybenzoxazole; CHEBI:415123; SPBio_001077; BSPBio_000025; Chlorzoxazone [INN:BAN:JAN]; Chlorzoxazon; AB00051947; 5-Chlorbenzoxazolin-2-on; Spectrum4_000287; KBio2_000628; Prestwick2_000163; Chloroxazone; D00771; Chlorzoxazonum [INN-Latin]; KBioGR_000814; 95-25-0; component of Parafon Forte; C 4397; 5-chloro-3H-1,3-benzoxazol-2-one; Spectrum5_000745; Chlorsoxazone; NCGC00093714-02; CLW; 5-chloro-1,3-benzoxazol-2-ol; EINECS 202-403-9; Myoflexin; LS-42267; 5-Chloro-2-benzoxazolol; 5-Chlorobenzoksazolon-2; Lopac0_000253; AI3-63119; SMR000058269; AKOS000404381; BPBio1_000029; DB00356; C2237; Escoflex; SPECTRUM1500188; Paraflex; NSC26189; HMS1568B07; InChI=1/C7H4ClNO2/c8-4-1-2-6-5(3-4)9-7(10)11-6/h1-3H,(H,9,10; C4397_SIGMA; HMS2091E14; Klorzoxazon; chlorzoxazona; Neoflex; 5-chlorobenzoxazolin-2-one; McNeil Brand of Chlorzoxazone; NINDS_000895; Relaxazone; AB1004047; CPD000058269; 5-Chloro-2(3H)-benzoxazolone; 5-Chloro-2-hydroxybenzoxazole; 5-Chlorobenzoxazol-2-one; UNII-H0DE420U8G; 2-BENZOXAZOLINONE, 5-CHLORO-; CID2733; MLS000069380; I14-4579; C7H4ClNO2; AC1L1ECE; KBio2_003196; CAS-95-25-0; BRD-K98174813-001-05-7; D002753; Nyoflex; CHEMBL1371; 5-Chlorobenzoxazolidone; Chlorzoxazonum; EZE-DS; 5-Chlorobenzoksazolinon-2; CHEBI:3655; Parafon Forte; Clorzoxazona [INN-Spanish]; DivK1c_000895; 5-Chlorobenzoksazolinon-2 [Polish]; STK071582; IDI1_000895; WLN: T56 BMVOJ HG; Spectrum2_001149; Chlorzoxane; SPBio_001946; Pathorysin; KBioSS_000628; MolPort-001-759-947; 5-Chloro-3(H)-2-benzoxazolone; KBio1_000895; NCGC00093714-04; BSPBio_002019; Biomioran; Prestwick0_000163; 2(3H)-Benzoxazolone, 5-chloro-; NCGC00093714-01; NCGC00015238-03; 5-Chloro-2-benzoxazolone; Remular; Spectrum_000148; Strifon Forte Dsc; AC1Q3KM0; 5-Chlorobenzoksazolon-2 [Polish]; C07931; Chlorzoxazone (JAN/USP/INN); AC1Q3KM1; HMS502M17; NCGC00093714-03; NCGC00015238-01; 5-Chloro-2-benzoxazolinone; Parafon; NSC 26189; Ortho Brand of Chlorzoxazone; Remular-S; 5-Chloro-2(3H)-benzoxazolone; AC-12192; Solaxin; Prestwick3_000163; Mioran; 5-Chloro-1,3-benzoxazol-2(3H)-one; NCGC00015238-09; Myoflexine; EU-0100253; Clorzoxazona; Paraflex (TN); Usaf ma-10; 32850-84-3; NCGC00015238-02; SBB003864; Spectrum3_000350; Miotran	95-25-0	2733	7847836	TTDS00145	Calcium-activated potassium channel	Ca(2+)-activated potassium channel IKCa1;Ca-activated K channel;Gardos channel;HSK4;IK channel KCNN4;IK1;IKCa1;IKCa1 Ca 2+ -activated K + channel;Intermediate conductance calcium-activated potassium channel protein 4;KCa4;KCNN4;Putative Gardos channel;SK4	Q12791	3778	ENSG00000156113	activator
DCL000445	AVE0118	N/A	N/A	N/A	N/A	TTDS00145	Calcium-activated potassium channel	Ca(2+)-activated potassium channel IKCa1;Ca-activated K channel;Gardos channel;HSK4;IK channel KCNN4;IK1;IKCa1;IKCa1 Ca 2+ -activated K + channel;Intermediate conductance calcium-activated potassium channel protein 4;KCa4;KCNN4;Putative Gardos channel;SK4	Q12791	3778	ENSG00000156113	blocker
DAP000953	Halofantrine	Halfan (TN); AC1L1XMK; 36167-63-2; MolPort-005-940-418; 69756-53-2; UNII-Q2OS4303HZ; NCGC00179250-01; (1)-Halofantrine; C26H30Cl2F3NO.HCl; WR 171669; EINECS 252-895-4; Halofantrine Hydrochloride [USAN]; 3-(dibutylamino)-1-[1,3-dichloro-6-(trifluoromethyl)phenanthren-9-yl]propan-1-ol hydrochloride; I14-2822; 9-Phenanthrenemethanol, 1,3-dichloro-alpha-(2-(dibutylamino)ethyl)-6-(trifluoromethyl)-, hydrochloride; SMR001233418; 1,3-Dichloro-alpha-(2-(dibutylamino)ethyl)-6-(trifluoromethyl)phenanthren-1-methanol hydrochloride; HALOFANTRINE HYDROCHLORIDE; CHEMBL1107; DB01218; 1-(1,3-Dichloro-6-trifluoromethyl-9-phenanthryl)-3-(di-n-butylamino)propanol hydrochloride; Prestwick3_001031; LS-187198; Prestwick0_001031; Halfan; 1,3-Dichloro-alpha-(2-(dibutylamino)ethyl)-6-(trifluoromethyl)-9-phenanthrenemethanol hydrochloride; 1,3-Dichloro-6-trifluoromethyl-9-(3-(dibutylamino)-1-hydroxypropyl)phenanthrene HCl; D02485; MLS002154111; SPBio_003092; WR-171,669; CHEMBL1200901; CHEBI:252728; 106927-11-1; MolPort-005-942-171; 1-(1,3-dichloro-6-trifluoromethyl-9-phenanthryl)-3-di(n-butyl)aminopropanol HCl; Halofantrine; WR 171,699; FT-0082696; 3-(Dibutylamino)-1-(1,3-dichloro-6-(trifluoromethyl)phenanthren-9-yl)propan-1-ol hydrochloride; (+-)-Halofantrine hydrochloride; Halofantrino [Spanish]; Prestwick1_001031; AC1L1XMN; BPBio1_001366; AB00514703; UNII-H77DL0Y630; 3-(dibutylamino)-1-[1,3-dichloro-6-(trifluoromethyl)phenanthren-9-yl]propan-1-ol; Halofantrino; Halofantrine HCl; AC-481; CID37392; WR-171699; Prestwick2_001031; NCI60_002593; 1,3-Dichloro-.alpha.-[2-(dibutylamino)ethyl]-6-(trifluoromethyl)-9-phenanthrene-methanol; 9-(3-(dibutylamino)-1-hydroxypropyl)-1,3-dichloro-6-(trifluoromethyl)phenanthrene hydrochloride; 1,3-Dichloro-.alpha.-[2-(dibutylamino)ethyl]-6- (trifluoromethyl)-9-phenathrenemethanol; 9-Phenanthrenemethanol, 1,3-dichloro-.alpha.-[2-(dibutylamino)ethyl]-6-(trifluoromethyl)-(1); WR-171669; AC1Q4K45; Halofantrine hydrochloride (USAN); HMS1571O03; CID37393; 9-Phenanthrenemethanol, 1,3-dichloro-alpha-(2-(dibutylamino)ethyl)-6-(trifluoromethyl)-,hydrochloride; Halofantrine [USAN]; 66051-63-6; SK&F-102866; dl-WR 171669; LS-102675; BSPBio_001241	69756-53-2	37393	603092	TTDS00145	Calcium-activated potassium channel	Ca(2+)-activated potassium channel IKCa1;Ca-activated K channel;Gardos channel;HSK4;IK channel KCNN4;IK1;IKCa1;IKCa1 Ca 2+ -activated K + channel;Intermediate conductance calcium-activated potassium channel protein 4;KCa4;KCNN4;Putative Gardos channel;SK4	Q12791	3778	ENSG00000156113	blocker
DAP001355	Charybdotoxin	ChTX; CTX Toxin; Toxin, Quinquestriatus; Toxin, CTX; Charybdotoxin (reduced); 115422-61-2; 95751-30-7; Quinquestriatus Toxin; D018999; CHARYBDOTOXIN	95751-30-7	N/A	3800523	TTDS00145	Calcium-activated potassium channel	Ca(2+)-activated potassium channel IKCa1;Ca-activated K channel;Gardos channel;HSK4;IK channel KCNN4;IK1;IKCa1;IKCa1 Ca 2+ -activated K + channel;Intermediate conductance calcium-activated potassium channel protein 4;KCa4;KCNN4;Putative Gardos channel;SK4	Q12791	3778	ENSG00000156113	blocker
DAP000491	Quinine	InChI=1/C20H24N2O2/c1-3-13-12-22-9-7-14(13)10-19(22)20(23)16-6-8-21-18-5-4-15(24-2)11-17(16)18/h3-6,8,11,13-14,19-20,23H,1,7,9-10,12H2,2H; Cinchonan-9-ol, 6'-methoxy-, (8alpha,9R)-; 804-63-7; 909767-48-2; (S)-(5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl)-(6-methoxyquinolin-4-yl)methanol; NSC131458; 864908-93-0; NCGC00159499-02; IBS-L0034250; Quniacridine; .alpha.-(6-Methoxy-4-quinoyl)-5-vinyl-2-quinclidinemethanol; 6-Methoxycinchonine; 767303-40-2; Chinine; LS-141252; 898813-59-7; 898814-28-3; Cin-Quin; (R)-(6-methoxyquinolin-4-yl)((2S,4S,8R)-8-vinylquinuclidin-2-yl)methanol; 6'-Methoxycinchonan-9-ol; nchembio.87-comp19; CHEBI:15854; HMS1791J11; NSC5362; (8S,9R)-Quinine; Chinin [German]; I14-3397; AC1MI1Q5; (3|A,8|A,9r)-6'-methoxycinchonan-9-ol; Kinder Quinina (TN); MolPort-002-507-196; QUININE MONO HCL; NSC 5362; Quinine sulphate; chininum; CID637552; NCGC00142453-01; NCGC00162322-02; 888714-03-2; Conchinin; Quinine Dab; Quinimax; 6183-68-2; CCRIS 5755; NCGC00166281-01; WLN: T66 BNJ HO1 EYQ-DT66 A B CNTJ A1U1; 12239-42-8; Kinder Quinina; Quinidex; (8S,9R)-6'-Methoxycinchonan-9-ol; 840482-04-4; (-)-Quinine; CID1065; 900789-95-9; 909263-47-4; nchembio.215-comp5; C20H24N2O2; SMR000718748; NSC192949; Quinsan (*2:1 Sulfate salt*), dihydrate; 56-54-2; MolPort-000-146-082; AC1Q4EZ5; LS-194958; Quinoline alkaloid; (R)-[(2S,4S,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol; (R)-[(2S,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol; NCGC00162322-01; CID441073; 128544-03-6; Quine (*2:1 Sulfate salt*, dihydrate); Cinchonan-9-ol, 6'-methoxy-, (9S)-; EINECS 205-003-2; quinine sulfate; nchem.180-comp1a; SB01652; (R)-(-)-quinine; nchem.1039-compI; NCGC00015871-03; DB00468; 22620_FLUKA; MolPort-001-766-747; Quinine, polymers; (1R)-(6-Methoxyquinolin-4-yl)((1S,4S,5R)-5-vinylquinuclidin-2-yl)methanol; NSC667852; NCI60_004320; LT00645788; AC1MHWS7; ST056282; L001278; (+)-Quinidine; AC1L9AHT; MLS001304041; Quinine [BAN]; quinidine; HMS1607A11; (S)-[(2R,4R,5S)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol; LS-4562; 890027-24-4; AC1L1R7Y; Quinine, tannate; Quinamm (*2:1 Sulfate salt*), dihydrate; (5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl)-(6-methoxyquinolin-4-yl)methanol; 899813-83-3; Coco-Quinine; AR-1H2065; (R)-[(2S,4R,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol; Quinine anhydrous; Q0028; 130-89-2; 145904_ALDRICH; 2-Quinuclidinemethanol, alpha-(6-methoxy-4-quinolyl)-5-vinyl-; nchembio.368-comp9; Quinine; 2-Quinuclidinemethanol, .alpha.-(6-methoxy-4-quinolyl)-5-vinyl-; BB_NC-0697; Cinchonan-9-ol, 6'-methoxy-; 6'-Methoxycinchonidine; 549-56-4; D08460; CID3036746; NCGC00159499-03; (R)-(-)-Quinine, 6-methoxycinchonidine; 21480-31-9; KST-1A1085; NSC 192949; Chinin; 1407-83-6; AR-1A4833; 72646-90-3; 910878-25-0; CHEMBL170; HSDB 2501; 909882-78-6; Quinora; beta-Quinine; Cinchonan-9-ol, 6'-methoxy-, (8.alpha.,9R)-; (9R)-6'-methoxy-8alpha-cinchonan-9-ol; Cinchonan-9-ol, 6'-methoxy-, (8.alpha.,9R)-, sulfate; Quinine bisulfate; 906550-97-8; 6119-70-6; 875538-34-4; 911445-75-5; 130-95-0; (8.alpha.,9R)-6'-Methoxycinchonan-9-ol; CID8549; AC1L1ANE; quinina; Biquinate (*Bisulfate heptathydrate*); 900786-66-5; AC1LCUGN; 6'-Methoxycinchonine; 894767-09-0; C06526; 910880-97-6; CHEBI:111177; (8-alpha,9R)-6'-Methoxycinchonan-9-ol; Quinine, Anhydrous; AC1Q58AF; Dentojel (*Bisulfate heptathydrate*); Conquinine; 22620_SIGMA; MolPort-003-901-021; Aflukin; HMS2089E05; 55980-20-6; Lopac0_001029; Quinine (BAN); 6912-57-8; Cinchonan-9-ol, 6'-methoxy-, (8-alpha,9R)-; I14-3348; 918778-04-8; CHEMBL97; Quindan; NCGC00163142-03; (R)-(6-Methoxy-quinolin-4-yl)-((2S,5S)-5-vinyl-1-aza-bicyclo[2.2.2]oct-2-yl)-methanol; UNII-A7V27PHC7A; EINECS 215-805-4; 857212-53-4; Quinineanhydrous; CID3034034	130-95-0	8549	151706	TTDS00145	Calcium-activated potassium channel	Ca(2+)-activated potassium channel IKCa1;Ca-activated K channel;Gardos channel;HSK4;IK channel KCNN4;IK1;IKCa1;IKCa1 Ca 2+ -activated K + channel;Intermediate conductance calcium-activated potassium channel protein 4;KCa4;KCNN4;Putative Gardos channel;SK4	Q12791	3778	ENSG00000156113	blocker
DCL000276	ICA-17043	AR-1D1152; Benzeneacetamide, 4-fluoro-alpha-(4-fluorophenyl)-alpha-phenyl-; UNII-TS6G201A6Q; I14-1293; 2,2-bis(4-fluorophenyl)-2-phenylacetamide; ICA 17043; AC1Q4NLN; CID216327; Bis(4-fluorophenyl)phenylacetamide; AC1L50IL; ICA-17043; Senicapoc; Senicapoc (USAN); CHEMBL405821; 4-Fluoro-alpha-(4-fluorophenyl)-alpha-phenylbenzeneacetamide; LS-191067; D06640	289656-45-7	216327	12015469	TTDS00145	Calcium-activated potassium channel	Ca(2+)-activated potassium channel IKCa1;Ca-activated K channel;Gardos channel;HSK4;IK channel KCNN4;IK1;IKCa1;IKCa1 Ca 2+ -activated K + channel;Intermediate conductance calcium-activated potassium channel protein 4;KCa4;KCNN4;Putative Gardos channel;SK4	Q12791	3778	ENSG00000156113	blocker
DCL001056	ISIS 14803	N/A	N/A	N/A	N/A	TTDC00270	HCV internal ribosome entry site (IRES)	N/A	N/A	N/A	N/A	antisense
DCL000554	Losmapimod	N/A	133718-29-3	9571043	44709239	TTDC00201	Mitogen-activated protein kinase 14	CRK1;CSAID binding protein;CSBP;Cytokine suppressive anti-inflammatory drug binding protein;MAP kinase MXI2;MAP kinase p38;MAP kinase p38alpha;MAX-interacting protein 2;Mitogen-activated protein kinase p38;Mitogen-activated protein kinase p38 alpha;P38 mitogen activated protein kinase;P38 Mitogen-activated protein kinase alpha;SAPK2A	Q16539	1432	ENSG00000112062	inhibitor
DCL000517	Dilmapimod	N/A	285983-48-4	N/A	N/A	TTDC00201	Mitogen-activated protein kinase 14	CRK1;CSAID binding protein;CSBP;Cytokine suppressive anti-inflammatory drug binding protein;MAP kinase MXI2;MAP kinase p38;MAP kinase p38alpha;MAX-interacting protein 2;Mitogen-activated protein kinase p38;Mitogen-activated protein kinase p38 alpha;P38 mitogen activated protein kinase;P38 Mitogen-activated protein kinase alpha;SAPK2A	Q16539	1432	ENSG00000112062	inhibitor
DCL000531	GSK610677	N/A	N/A	5282440	49699399	TTDC00201	Mitogen-activated protein kinase 14	CRK1;CSAID binding protein;CSBP;Cytokine suppressive anti-inflammatory drug binding protein;MAP kinase MXI2;MAP kinase p38;MAP kinase p38alpha;MAX-interacting protein 2;Mitogen-activated protein kinase p38;Mitogen-activated protein kinase p38 alpha;P38 mitogen activated protein kinase;P38 Mitogen-activated protein kinase alpha;SAPK2A	Q16539	1432	ENSG00000112062	inhibitor
DAP001384	Fosmidomycin	Fosmidomycine; AC1L19JA; Fosmidomycina [INN-Spanish]; FR-31564; 3-[FORMYL(HYDROXY)AMINO]PROPYLPHOSPHONIC ACID; CHEMBL203125; Fosmidomycinum; 3-(N-Formyl-N-hydroxyamino)-propylphosphonic acid; CID572; (3-(N-Hydroxyformamido)propyl)phosphonic acid; 66508-37-0 (mono-hydrochloride salt); UNII-5829E3D9I9; (3-(Formylhydroxyamino)propyl)phosphonic acid, monosodium salt; 66508-37-0; FOM; nchembio.221-comp22; Fosmidomycine [INN-French]; NChemBio.2007.9-comp4; 66508-53-0; CHEBI:443725; 3-(Formyl-hydroxy-amino)propylphosphonic acid; Fosmidomycina; 3-(N-hydroxyformamido)propylphosphonic acid; {3-[formyl(hydroxy)amino]propyl}phosphonic acid; DB02948; fosmidomycin; Fosmidomycinum [INN-Latin]	66508-53-0	572	635741	TTDS00236	1-deoxy-D-xylulose-5-phosphate reductoisomerase	1-deoxyxylulose-5-phosphate reductoisomerase;2-C-Methyl-d-erythritol 4-phosphate synthase;DOXP reductoisomerase;DXP reductoisomerase;DXR;IspC	N/A	N/A	N/A	binder
DCL000425	AMG 386	N/A	N/A	5360545	49746451	TTDC00210	Angiopoietin-2	ANG-2	O15123	285	ENSG00000091879	inhibitor
DCL001175	CVX-060	N/A	N/A	N/A	N/A	TTDC00210	Angiopoietin-2	ANG-2	O15123	285	ENSG00000091879	antibody
DCL001208	MEDI3617	N/A	N/A	N/A	N/A	TTDC00210	Angiopoietin-2	ANG-2	O15123	285	ENSG00000091879	antibody
DCL000628	Rituxan Immunology	N/A	N/A	23644059	46504923	TTDS00268	B-lymphocyte antigen CD20	B-lymphocyte surface antigen B1;Bp35;CD20;Leu-16	P11836	931	ENSG00000156738	antibody
DCL000627	Rituxan Hemotalogy/oncology	N/A	N/A	N/A	N/A	TTDS00268	B-lymphocyte antigen CD20	B-lymphocyte surface antigen B1;Bp35;CD20;Leu-16	P11836	931	ENSG00000156738	antibody
DAP000384	Tositumomab	N/A	192391-48-3	N/A	46506662	TTDS00268	B-lymphocyte antigen CD20	B-lymphocyte surface antigen B1;Bp35;CD20;Leu-16	P11836	931	ENSG00000156738	antibody
DCL000581	Ocrelizumab	Ocrelizumab (USAN); 637334-45-3; D05218; Ocrelizumab; Ocrelizumab (genetical recombination) (JAN); Ocrelizumab (genetical recombination)	637334-45-3	N/A	47206937	TTDS00268	B-lymphocyte antigen CD20	B-lymphocyte surface antigen B1;Bp35;CD20;Leu-16	P11836	931	ENSG00000156738	antibody
DAP000383	Ibritumomab	N/A	174722-31-7	N/A	46506112	TTDS00268	B-lymphocyte antigen CD20	B-lymphocyte surface antigen B1;Bp35;CD20;Leu-16	P11836	931	ENSG00000156738	antibody
DCL000613	R7159	N/A	68367-52-2	337359	48416546	TTDS00268	B-lymphocyte antigen CD20	B-lymphocyte surface antigen B1;Bp35;CD20;Leu-16	P11836	931	ENSG00000156738	antibody
DCL000496	Bevacizumab+Rituximab	N/A	7447-41-8	3028194	49746180	TTDS00268	B-lymphocyte antigen CD20	B-lymphocyte surface antigen B1;Bp35;CD20;Leu-16	P11836	931	ENSG00000156738	antibody
DAP000382	Rituximab	N/A	174722-31-7	10201696	46505820	TTDS00268	B-lymphocyte antigen CD20	B-lymphocyte surface antigen B1;Bp35;CD20;Leu-16	P11836	931	ENSG00000156738	antibody
DCL000534	Iboctadekin & rituximab	N/A	26305-03-3	5478883	49699079	TTDS00268	B-lymphocyte antigen CD20	B-lymphocyte surface antigen B1;Bp35;CD20;Leu-16	P11836	931	ENSG00000156738	antibody
DCL000529	GA101	N/A	N/A	N/A	N/A	TTDS00268	B-lymphocyte antigen CD20	B-lymphocyte surface antigen B1;Bp35;CD20;Leu-16	P11836	931	ENSG00000156738	antibody
DCL000582	Ofatumumab	N/A	N/A	6918251	43529634	TTDS00268	B-lymphocyte antigen CD20	B-lymphocyte surface antigen B1;Bp35;CD20;Leu-16	P11836	931	ENSG00000156738	antibody
DPR000014	Apafant	WEB2086; PDSP1_000669; 4-(3-(4-(o-Chlorophenyl)-9-methyl-6H-thieno(3,2-f)-s-triazolo(4,3-a)(1,4)diazepin-2-yl)propionyl)morpholine; AC1Q3P7E; MolPort-003-844-652; LS-92643; NCGC00092377-01; 3-(4-(2-chlorophenyl)-9-methyl-6H-thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepine-2-yl)-1-(4-morpholinyl)-1-propanone; triazolodiazepine; L001111; Oprea1_587188; Morpholine, 4-((4-(2-chlorophenyl)-9-methyl-6H-thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepin-2-yl)-1-oxopropyl)-; AC1L246K; Apafantum [INN-Latin]; Apafanto [INN-Spanish]; CHEBI:124420; UNII-J613NI05SV; C052518; 105219-56-5; PDSP2_000659; Web 2086; BRN 4302553; Apafantum; Apafant; BRD-K28115081-001-01-9; DE-081; C22H22ClN5O2S; ZINC00608180; CHEMBL280164; WEB-2086; Apafanto; WEB 2086BS; 4-[3-[4-(2-chlorophenyl)-9-methyl-6h-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-2-yl]-1-oxopropyl]morpholine; CID65889; Apafant [USAN:INN]	105219-56-5	65889	12013921	TTDR01165	Platelet-activating factor receptor	PAF-R	P25105	5724	ENSG00000169403	antagonist
DCL000029	ABT-869	ABT 869; ABT869, Linifanib, AL-39324, RG3635; N-(4-(3-Amino-1H-indazol-4-yl)phenyl)-N1-(2-fluoro-5-methylphenyl)urea; CHEMBL223360; Urea, N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl)-; CID11485656; Linifanib; EC-000.2119; S1003_Selleck; 796967-16-3; N-(4-(3-Amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl)urea; RG-3635; Kinome_532; AL-39324; ABT-869	796967-16-4	11485656	49689152	TTDC00263	Macrophage colony-stimulating factor 1	CSF-1;Lanimostim;MCSF;M-CSF;Processed macrophage colony-stimulating factor 1	P09603	1435	ENSG00000184371	inhibitor
DCL000353	Axitinib	ST51054130; ZINC03816287; Benzamide, N-methyl-2-((3-((1E)-2-(2-pyridinyl)ethenyl)-1H-indazo)-6-yl)thio)-; 319460-85-0; AC1O51X3; I14-1971; N-methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-indazol-6-yl)sulfanyl)benzamide; N-methyl-2-[[3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]sulfanyl]benzamide; AG 013736; C503983; Axitinib; MolPort-006-392-413; AC-1539; AG013736; UNII-C9LVQ0YUXG; S1005_Selleck; AG-013736, Axitinib; AG-013736; EC-000.2322; CID6450551; Benzamide, N-methyl-2-[[3-[(1E)-2-(2-pyridinyl)ethenyl]-1H-indazol-6-yl]thio]-; AG-13736; 790713-39-2	319460-85-0	6450551	3889615	TTDC00263	Macrophage colony-stimulating factor 1	CSF-1;Lanimostim;MCSF;M-CSF;Processed macrophage colony-stimulating factor 1	P09603	1435	ENSG00000184371	inhibitor
DCL000373	GSK221149	N/A	N/A	N/A	N/A	TTDS00264	Oxytocin receptor	OT-R;OXTR	P30559	5021	ENSG00000180914	antagonist
DAP000269	Carbetocin	I06-1830; (2S)-N-[(2S)-1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]-1-[(3R,6S,9S,12S,15S)-6-(2-amino-2-oxoethyl)-9-(3-amino-3-oxopropyl)-12-[(2S)-butan-2-yl]-15-[(4-hydroxyphenyl)methyl]-16-methyl-5,8,11,14,17-pentaoxo-1-thia-4,7,10,13,16-pentazacycloicosane-3-carbonyl]pyrrolidine-2-carboxamide; KST-1B3849; 1-Carbaoxytocin, 1-butanoic acid-2-(O-methyl-L-tyrosine)-; 3888-84-4; AR-1B9521; EINECS 253-312-6; AC-3444; Carbetocinum [INN-Latin]; CID71715; Carbetocino [INN-Spanish]; 1-Buttersaeure-2-(3-(4-methoxyphenyl)-L-alanin)oxytocin; 1-Carboxytocin, 1-butanoic acid-2-(O-methyl-L-tyrosine)-; 1-{[(3r,6s,9s,12s,15s)-6-(2-amino-2-oxoethyl)-9-(3-amino-3-oxopropyl)-12-[(2s)-butan-2-yl]-15-(4-hydroxybenzyl)-16-methyl-5,8,11,14,17-pentaoxo-1-thia-4,7,10,13,16-pentaazacycloicosan-3-yl]carbonyl}-l-prolyl-l-leucylglycinamide; AC1L2GOJ; DB01282; Carbetocin	37025-55-1	71715	213985	TTDS00264	Oxytocin receptor	OT-R;OXTR	P30559	5021	ENSG00000180914	agonist
DAP001156	Oxytocin	Syntocinon (TN); NCGC00167132-01; BCBcMAP01_000094; O4375_SIGMA; Oxitocina; Oxytocin (JP15/USP/INN); OXT; L-Cysteinyl-L-tyrosyl-L-isoleucyl-L-glutaminyl-L-asparaginyl-L-cysteinyl-L-prolyl-L-leucylglycinamide cyclic(1-6)-disulfide; Pitocin; 50-56-6; Ocytocin; Syntocinon; C00746; CID439302; O3251_SIGMA; CHEMBL395429; CHEBI:7872; Oxytocin (TN); (2S)-1-[(4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-[(2S)-butan-2-yl]-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-N-[(2S)-1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]pyrrolidine-2-carboxamide; 1-({(4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-16-(4-hydroxybenzyl)-13-[(1S)-1-methylpropyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-4-yl}carbonyl)-L-prolyl-L-leucylglycinamide; TI-001; OXYTOCIN; alpha-Hypophamine; CHEBI:492195; MolPort-003-938-941; HS-2021; AC1L9735; Oxytocine; D00089; Pitocin (TN); Oxytocinum; Oxytocic hormone; nchembio.184-comp2	50-56-6	439302	4008	TTDS00264	Oxytocin receptor	OT-R;OXTR	P30559	5021	ENSG00000180914	agonist
DAP001561	Ipilimumab	MDX-010; MDX-101; BMS-734016	N/A	N/A	N/A	TTDC00259	Cytotoxic T-lymphocyte protein 4	CD152;CTLA-4;Cytotoxic T-lymphocyte-associated antigen 4	P16410	1493	ENSG00000163599	antibody
DCL000506	CP-675206	N/A	N/A	N/A	N/A	TTDC00259	Cytotoxic T-lymphocyte protein 4	CD152;CTLA-4;Cytotoxic T-lymphocyte-associated antigen 4	P16410	1493	ENSG00000163599	antibody
DCL000518	Dulanermin	N/A	N/A	N/A	N/A	TTDC00266	Tumor necrosis factor receptor superfamily member 10B	CD262;Death receptor 5;TNF-related apoptosis-inducing ligand receptor 2;TRAIL receptor 2;TRAIL-R2	O14763	8795	ENSG00000120889	agonist
DCL000621	RhApo2L/TRAIL	N/A	N/A	N/A	N/A	TTDC00266	Tumor necrosis factor receptor superfamily member 10B	CD262;Death receptor 5;TNF-related apoptosis-inducing ligand receptor 2;TRAIL receptor 2;TRAIL-R2	O14763	8795	ENSG00000120889	agonist
DCL000504	Conatumumab	N/A	896731-82-1	N/A	N/A	TTDC00266	Tumor necrosis factor receptor superfamily member 10B	CD262;Death receptor 5;TNF-related apoptosis-inducing ligand receptor 2;TRAIL receptor 2;TRAIL-R2	O14763	8795	ENSG00000120889	agonist
DCL000439	Apomab	N/A	N/A	N/A	N/A	TTDC00266	Tumor necrosis factor receptor superfamily member 10B	CD262;Death receptor 5;TNF-related apoptosis-inducing ligand receptor 2;TRAIL receptor 2;TRAIL-R2	O14763	8795	ENSG00000120889	agonist
DAP000851	Gemifloxacin	BSPBio_002308; NCGC00178711-01; 210353-52-9; SB-265805; Gemifloxacin; CHEMBL430; BRD-A40787240-066-02-0; SB 265805; CID9571107; 7-(3-Aminomethyl-4-methoxyimino-pyrrolidine-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-(1,8)-naphthyridine-3-carboxylic acid; LS-187779; Factiv; LB-20304; 204519-64-2; 210353-53-0; Factive; 7-(3-Aminomethyl)-4-methoxyimino-pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid; 210353-55-2; Gemifloxacin mesilate; 214346-11-9; LB 20304a; CHEBI:101853; 210353-56-3; 175463-14-6; 1,8-Naphthyridine-3-carboxylic acid, 7-(3-(aminomethyl)-4-(methoxyimino)-1-pyrrolidinyl)-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-; Gemifloxacin [INN]; Gemifloxacin (INN); 7-[3-(aminomethyl)-4-(methoxyimino)pyrrolidin-1-yl]-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid; 1,8-Naphthyridine-3-carboxylic acid, 7-[(4Z)-3-(aminomethyl)-4-(methoxyimino)-1-pyrrolidinyl]-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-; D08012; LS-186992; Factiv (TN); LB 20304	175463-14-6	5464436	610685	TTDS00084	Topoisomerase IV subunit A	DNA topoisomerase IV	P72525	N/A	N/A	inhibitor
DAP001005	Grepafloxacin	AC1L2I4Z; 126292-40-8; LS-141560; 146863-02-7; (+/-)-3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-5-methyl-7-(3-methyl-1-piperazinyl)-4-oxo-; CCRIS 7284; CID72474; 1-Cyclopropyl-6-fluoro-1,4-dihydro-5-methyl-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; DB00365; 119914-60-2; Grepafloxacin [INN]; (+-)-1-Cyclopropyl-6-fluoro-1,4-dihydro-5-methyl-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; CHEBI:117136; Raxar; 3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-5-methyl-7-(3-methyl-1-piperazinyl)-4-oxo-; NCGC00167527-01; 3-Quinolinecarboxylic acid, 1,4-dihydro-1-cyclopropyl-6-fluoro-5-methyl-7-(3-methyl-1-piperazinyl)-4-oxo-; C11368; UNII-L1M1U2HC31; CHEMBL583; Grepafloxacin; Grepafloxacin (unspecified); 1-cyclopropyl-6-fluoro-5-methyl-7-(3-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid; 161967-81-3	119914-60-2	72474	13542	TTDS00084	Topoisomerase IV subunit A	DNA topoisomerase IV	P72525	N/A	N/A	inhibitor
DAP000190	Ciprofloxacin	UNII-5E8K9I0O4U; C17H18FN3O3; CCRIS 5241; DivK1c_000095; BAY q 3939; Cipro I.V.; SPBio_002065; Ciprofloxacino; BRD-K04804440-311-02-3; ARONIS020379; ciprofloxacin; Bay-09867; Cifloxin; Ciprofloxacin hydrochloride; Ciflox; BSPBio_003344; MLS001336035; 1-Cyclopropyl-6-fluoro-1,4-dihydro-7-(1-piperazinyl)-4-oxo-3-quinoline carboxylic acid; Fimoflox; Ciprodar; CPFX; Ciprofloxacino [INN-Spanish]; Prestwick1_000113; BAY-Q-3939; Cipro (TN); Proksi 500; HMS2093I03; KBio3_002846; Proflox; Spectrum_000162; 17850_FLUKA; Ciprofloxacine; BIDD:GT0205; Cixan; Cycin; Ciprecu; Prestwick0_000113; Spectrum3_001872; Bi-Cipro; D00186; Alcon Cilox; IDI1_000095; 3-Quinolinecarboxylic acid,1,4-dihydro-1-cyclopropyl-6-fluoro-4-oxo-7-(1-piperazinyl); KBioGR_001567; Velomonit; AC-7613; 1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid; Quinolid; SMP1_000125; Ipiflox; NCGC00095058-02; KBio2_003210; Cipromycin; Ciprofloxacinum [INN-Latin]; Ciprofloxacin monohydrochloride; 1-cyclopropyl-6-fluoro-7-hexahydro-1-pyrazinyl-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid; Ciplus; AC1L1EEW; 33434_RIEDEL; 1-CYCLOPROPYL-6-FLUORO-4-OXO-7-PIPERAZIN-1-YL-1,4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID; CAS-93107-08-5; CID2764; CIPRO IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER; Ciprobay; Ciprobay Uro; 1-Cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydro-quinoline-3-carboxylic acid; Sophixin Ofteno; 3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-; Baflox; KBio1_000095; Cipro IV; Ciprolin; 1-Cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperzinyl)-3-quinolinecarboxylic acid HCl H2O; CHEBI:100241; Superocin; HMS1922E18; Septicide; 33434_FLUKA; Ciproxan; SPBio_001474; Ciprofloxacin (JAN/USP/INN); KBio2_005778; 1-Cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid; BAS 06989041; Ciproxina; BRN 3568352; Ciprofloxacin [USAN:INN:BAN]; AKOS000269653; Corsacin; Ciprolon; Cipro XR; HSDB 6987; Rancif; 3-Quinolinecarboxylic acid, 1,4-dihydro-1-cyclopropyl-6-fluoro-4-oxo-7-(1-piperazinyl)-; Ciprocinol; Cilab; Ciprofloxacine [INN-French]; Spectrum2_001567; 1-cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid; Ciprofloxacin Hydrchloride; Proksi 250; Cyprobay; Ciproquinol; Spectrum5_001089; Liposomal-ciprofloxacin; Prestwick2_000113; NINDS_000095; Ciprowin; Proflaxin; NCGC00095058-01; CRL-1605 & Ciprofloxacin; HMS2090O07; BSPBio_000126; Eni; 85721-33-1; Probiox; Bay o 9867 (*Hydrochloride*); KBio2_000642; NCGC00178128-01; MolPort-000-819-654; STK021082; Baycip; Quintor; CPF; CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER; Ciproxine; Spitacin; BPBio1_000140; Oprea1_313572; SPECTRUM1503614; Cipro; Ciproxin; BAYQ3939; CHEMBL8; Loxan; Cipro (*Hydrochloride*); Bio-0540; Bacquinor; Prestwick3_000113; Flociprin; Unex; Ciprofloxacina; Cipro XL; SMR000471901; LS-141563; Ciprofloxacin HCl; NSC620634; Bernoflox; Zumaflox; Bay o 9867; Citopcin; Ciprofloxacinum; DB00537; Spectrum4_000874; Ciprogis; Roxytal; nchembio820-comp1; Ciprofloxacin dihydrochloride; Italnik; 1-Cyclopropyl-6-fluoro-4-oxo-7-(1-piperazinyl)-1,4-dihydro-3-quinolinecarboxylic acid; C05349; NCGC00016959-01; CBMicro_048498; Ciloxan (*Hydrochloride*); HMS500E17; Oprea1_008239; Ciprinol; Ciriax; Ciproflox; KBioSS_000642	85721-33-1	2764	192835	TTDS00084	Topoisomerase IV subunit A	DNA topoisomerase IV	P72525	N/A	N/A	inhibitor
DAP001176	Amdinocillin	70178-27-7; UNII-V10579P3QZ; D02888; 32887-01-7; Mecilinamo [INN-Spanish]; Mecillinam; LS-149883; InChI=1/C15H23N3O3S/c1-15(2)11(14(20)21)18-12(19)10(13(18)22-15)16-9-17-7-5-3-4-6-8-17/h9-11,13H,3-8H2,1-2H3,(H,20,21)/b16-9+/t10-,11+,13?/m1/s; FL 1060; Coactin (TN); HMS2051E14; Amdinocillin [USAN]; Mecillinamum; 6-((Hexahydro-1H-azepin-1-yl)methyleneamino)penicillanic acid; 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-(((hexahydro-1H-azepin-1-yl)methylene)amino)-3,3-dimethyl-7-oxo-, (+)-; Ambap32887-01-7; SMR000466361; CHEMBL258646; CPD000466361; Mecilinamo; 73937-07-2; AC1L1VGC; Ro-10-9070; MLS001424041; Mecillinamum [INN-Latin]; 51556-89-9; CHEMBL530; Selexidin; MLS000759478; (2S,5R,6R)-6-{[(1E)-azepan-1-ylmethylidene]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; Amdinocillin Mecillinam; Mecillinam (INN); Amdinocillin (USAN); Ro 10-9070; C15H23N3O3S; Penicillin HX; SAM001246687; (2S,5R,6R)-6-(((Hexahydro-1H-azepin-1-yl)methylene)amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid; 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-(((hexahydro-1H-azepin-1-yl)methylene)amino)-3,3-dimethyl-7-oxo-, (2S-(2alpha,5alpha,6beta))-; rel-(2R,6S)-6-{[(1E)-azepan-1-ylmethylene]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; DB01163; Coactin; 4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[(1E)-(hexahydro-1H-azepin-1-yl)methylene]amino]-3,3-dimethyl-7-oxo-, (2S,6R)-; FL-1060; (2S,5R,6R)-6-[(azepan-1-ylmethylidene)amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; Ro 109070; Hexacillin; CID36273; EINECS 251-277-1; 6beta-[(azepan-1-ylmethylidene)amino]-2,2-dimethylpenam-3alpha-carboxylic acid; 79580-20-4; (2S,5R,6R)-6-(azepan-1-ylmethylideneamino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; AMDINOCILLIN	32887-01-7	36273	10823391	TTDS00211	Penicillin binding protein 2	PBP-2	P0A3M5	N/A	N/A	inhibitor
DAP000459	Imipenem	64221-86-9; Tienamycin; CHEBI:471744; DB01598; CID104838; CHEMBL373477; AR-1A6479; KST-1A7214; Prestwick_844; imipenem; Imipenem anhydrous; Prestwick0_000519; HMS1569H19; N-Formimidoylthienamycin; Imipemide; BPBio1_000525; Prestwick3_000519; Ambap64221-86-9; D04515; BIDD:GT0686; NCGC00167958-03; CPD-9231; (5R,6S)-6-[(1R)-1-hydroxyethyl]-3-({2-[(iminomethyl)amino]ethyl}thio)-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; 1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 6-[(1R)-1-hydroxyethyl]-3-[[2-[(iminomethyl)amino]ethyl]thio]-7-oxo-, (5R,6S)-; [5R-[5.alpha.,6.alpha.(R*)]]-6-(1-Hydroxyethyl)-3-[[2- [(iminomethyl)amino]ethyl]thio]-7-oxo-1-azabicyclo[3.2.0]hept-2- ene-2-carboxylic acid monohydrate; (5R,6S)-3-[2-(aminomethylideneamino)ethylsulfanyl]-6-[(1R)-1-hydroxyethyl]-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; HMS2090A15; Imipenem (INN); (5R,6S)-3-(2-Formimidoylamino-ethylsulfanyl)-6-((R)-1-hydroxy-ethyl)-7-oxo-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylic acid; CHEMBL148; NCGC00167958-01; Prestwick2_000519; 6623-14-9; Imipenem, N-Formimidoyl thienamycin; 74431-23-5; NCGC00167958-02; SPBio_002398; Prestwick1_000519; AC1L2XLB; AC-528; NSC717864; (5R,6S)-6-((R)-1-Hydroxyethyl)-3-(2-(iminomethylamino)ethylthio)-7-oxo-1-azabicyclo(3.2.0)hept-2-ene-2-carbonsaeure; BSPBio_000477; C06665; CHEBI:143934	74431-23-5	104838	10321787	TTDS00211	Penicillin binding protein 2	PBP-2	P0A3M5	N/A	N/A	binder
DAP001361	Clorgyline	Prestwick2_000344; 17780-72-2; BRD-K73251053-003-03-2; C13H15Cl2NO; UNII-LYJ16FZU9Q; CLORGYLINE; CPD-7656; CAS-17780-75-5; N-[3-(2,4-DICHLOROPHENOXY)PROPYL]-N-METHYL-N-PROP-2-YNYLAMINE; Clorgilina; M & B 9302; MolPort-002-052-034; N-(3-(2,4-Dichlorophenoxy)propyl)-N-methyl-2-propynylamine; Clorgiline [INN]; CID4380; Lopac-M-3778; BRN 1976758; D03248; Prestwick3_000344; Clorgiline (INN); BPBio1_000449; 2-Propynylamine, N-(3-(2,4-dichlorophenoxy)propyl)-N-methyl-; Clorgilina [INN-Spanish]; Clorgiline; C11685; 2-Propyn-1-amine, N-(3-(2,4-dichlorophenoxy)propyl)-N-methyl-; Clorgilinum [INN-Latin]; D003010; M and B 9302; DB04017; Clorgilinum; Lopac0_000746; NCGC00015669-04; 2-Propyn-1-amine, N-(3-(2,4-dichlorophenoxy)propyl)-N-methyl- (9CI); NCGC00162235-01; SPBio_002328; CHEMBL8706; NCGC00015669-02; Clorgilin; BSPBio_000407; LS-125796; n-methyl-n-propargyl-3-(2,4-dichlorophenoxy)propylamine; L001342; 3-(2,4-dichlorophenoxy)-N-methyl-N-prop-2-ynylpropan-1-amine; NCGC00015669-01; Chlorgyline; AC1L1I1A; Prestwick0_000344; Prestwick1_000344	17780-72-2	4380	13850	TTDS00289	Amine oxidase [flavin-containing] A	MAO-A;Monoamine oxidase;Monoamine oxidase A	P21397	4128	ENSG00000189221	inhibitor
DCL000751	CHF-3381	N/A	202914-18-9	5351154	44716690	TTDS00289	Amine oxidase [flavin-containing] A	MAO-A;Monoamine oxidase;Monoamine oxidase A	P21397	4128	ENSG00000189221	inhibitor
DAP000577	Isocarboxazid	CCRIS 9178; 1-Benzyl-2-(5-methyl-3-isoxazolyl-carbonyl)hydrazine; CAS-59-63-2; Marplan (TN); Isocarboxazide [INN-French]; MLS002154005; Isocarboxazida; D007520; 5-methyl-N'-(phenylmethyl)isoxazole-3-carbohydrazide; HMS1570O12; NSC169893; 59-63-2; Maraplan; NCGC00016267-02; 5-Methyl-3-isoxazolecarboxylic acid 2-benzylhydrazide; CID3759; Isocarboxazid [INN:BAN]; MLS003106729; EINECS 200-438-4; Prestwick1_000795; LS-86607; Isocarboxazidum; BRD-K93332168-001-03-2; SPBio_002869; AC1L1GNE; Isocarboxazidum [INN-Latin]; Prestwick3_000795; Marplan; NCGC00016267-01; 1-Benzyl-2-(5-methyl-3-isoxazolylcarbonyl)hydrazine; 3-Isoxazolecarboxylic acid, 5-methyl-, 2-(phenylmethyl)hydrazide; D02580; BRN 0201295; Benazide; N'-Benzyl N-methyl-5-isoxazolecarboxylhydrazide-3; AB00513923; CHEMBL1201168; Isocarboxazid (INN); isocarboxazid; BMIH; Isocarbonazid; Ro 5-0831; N'-benzyl-5-methyl-1,2-oxazole-3-carbohydrazide; UNII-34237V843T; Prestwick2_000795; Enerzer; DB01247; BPBio1_001024; Isocarbossazide [DCIT]; BSPBio_000930; NSC 169893; WLN: T5NOJ C1 EVMM1R; Isocarboxazide; Isocarbossazide; 4-27-00-03999 (Beilstein Handbook Reference); ZINC00001587; 3-Isoxazolecarboxylic acid, 5-methyl-, 2-benzylhydrazide; MolPort-003-848-234; Ro 5-0831/1; Isocarboxyzid; SMR001233334; Isocarboxazida [INN-Spanish]; Prestwick0_000795; Marplon	59-63-2	3759	148916	TTDS00289	Amine oxidase [flavin-containing] A	MAO-A;Monoamine oxidase;Monoamine oxidase A	P21397	4128	ENSG00000189221	inhibitor
DAP000081	Tranylcypromine	AC1L9B1D; DivK1c_000588; AC1O7GD6; BRD-A43974575-065-02-8; Cyclopropanamine, 2-phenyl-, (1R,2S)-rel-; NINDS_000588; STOCK1S-62620; D08625; Spectrum2_000960; Spectrum5_001451; Cyclopropanamine, 2-phenyl-, trans-(.+/-.)-; UNII-3E3V44J4Z9; SMR000039637; CBChromo1_000132; AC1Q1HO9; Tranilcipromina; CID19493; SKF Trans-385; CHEMBL1179; 95-62-5; Sulfate, Tranylcypromine; GJZ; Lopac0_001013; tranylcypromine; Cyclopropylamine, 2-phenyl-, (1S-trans)-; AC1L2E8J; AC1Q53BI; Prestwick2_000173; KBioSS_002078; dl-Tranylcypromine; Goldshield Brand of Tranylcypromine Sulfate; CHEMBL257990; trans-DL-2-Phenylcyclopropylamine; CHEBI:588391; 3-12-00-02797 (Beilstein Handbook Reference); Spectrum4_000361; LS-58823; AC1Q4UBQ; PDSP2_001079; CID6971118; BRD-K88809146-003-02-1; Prestwick0_000173; Lopac-P-8511; KBio2_007214; D014191; NCGC00162316-01; BSPBio_002898; Allphar Brand of Tranylcypromine Sulfate; KBio2_002078; SKF 385; MolPort-001-791-393; KBio2_003895; Cyclopropylamine, trans-2-phenyl-; GlaxoSmithKline Brand of Tranylcypromine Sulfate; LS-187134; KBio2_001327; Tranylcyprominum [INN-Latin]; (-)-Tranylcypromine; CID26070; AC-15970; MLS001306494; AC1ODZ9B; Tranilcipromina [INN-Spanish]; CHEBI:293460; PDSP1_001096; trans 2 Phenylcyclopropylamine; Cyclopropanamine, 2-phenyl-, (1R-trans)- (9CI); KBio3_002118; CID6604304; Link Brand of Tranylcypromine Sulfate; Jatrosom; (1R)-2-phenylcyclopropan-1-amine; AC1NWAQS; NCGC00178400-01; Tranylcypromine [INN:BAN]; Spectrum4_001219; CID441233; Cyclopropanamine, 2-phenyl-, trans-; EINECS 205-841-9; (1R,2R)-2-phenylcyclopropan-1-amine; BSPBio_002656; (+)-Tranylcypromine; LS-58824; Cyclopropylamine, 2-phenyl-, trans-(.+-.)-; BRN 2802413; CHEMBL467794; Parnate; Cyclopropylamine, 2-phenyl-, trans-(-)-; PDSP1_001095; 2-Phenyl-1-aminocyclopropane, trans-; 2-phenylcyclopropan-1-amine; NCGC00015848-01; Transamine; Tranylcypromine (INN); MolPort-002-551-002; Parnitene; AC1L1KJT; AC1L9ASR; NSC 80664; NCGC00016598-01; Spectrum5_001829; Cyclopropanamine, 2-phenyl-, trans-(.+-.)-; C9H11N; DB00752; (1S,2S)-2-phenylcyclopropan-1-amine; CHEBI:527107; (2S)-2-phenylcyclopropan-1-amine; CID5530; AC1L1ACF; Cyclopropanamine, 2-phenyl-, (1R-trans)-; Cyclopropylamine, 2-phenyl-, trans-(.+/-.)-; SPBio_000960; NCGC00178400-02; Tranylcyprominum; CID441360; IDI1_000588; KBioGR_001658; trans-2-Phenylcyclopropylamine; AC1Q1HO4; KBio2_006463; Cyclopropanamine, 2-phenyl-, trans-(+)-; Prestwick1_000173; CID5702124; (+)-trans-2-Phenylcyclopropylamine; HSDB 3404; Cyclopropylamine, 2-phenyl-, trans-(+-)-; 155-09-9; 3721-26-4; esparma Brand of Tranylcypromine Sulfate; CHEMBL313833; CCRIS 3344; CHEBI:231607; MolPort-001-783-425; NCGC00015848-03; KBio2_004646; l-Tranylcypromine; Racemic Tranylcypromine; Cyclopropanamine, 2-phenyl-, trans-(+-)-; 2-Phenylcyclopropanamine; CAS-1986-47-6; Spectrum3_001068; trans-(-)-2-Phenylcyclopropanamine; CYCLOPROPYLAMINE, 2-PHENYL-, trans-; KBio3_001876; (1R,2S)-2-phenylcyclopropanamine; KBioSS_001327; Spectrum_001598; d-Tranylcypromine; HMS2089B04; (+)-(R)-Tranylcypromine; KBio1_000588; Spectrum3_001369; NCGC00179670-01; (1S,2R)-2-phenylcyclopropan-1-amine; NSC80664; Spectrum_000847; AR-1E4939; PDSP2_001080; KBioGR_000821; 1tnl; (1S)-2-phenylcyclopropan-1-amine; C07155; (1R,2S)-2-phenylcyclopropan-1-amine; BRN 3195803; SmithKline Brand of Tranylcypromine Sulfate; SPBio_001986; LS-58822; 3721-28-6	155-09-9	441233	9364	TTDS00289	Amine oxidase [flavin-containing] A	MAO-A;Monoamine oxidase;Monoamine oxidase A	P21397	4128	ENSG00000189221	inhibitor
DAP000576	Moclobemide	ratiopharm Brand of Moclobemide; Nu Pharm Brand of Moclobemide; Moclobemide 1A Brand; 4-Chlor-N-(2-morpholinoethyl)benzamid; Chem mart Brand of Moclobemide; Moclobemid-Puren; AC1Q3IOZ; Merck dura Brand of Moclobemide; Terry White Chemists Moclobemide; Novo-Moclobemide; AKOS003270184; 4-chloro-N-(2-morpholin-4-ylethyl)benzamide; Stada, Moclobemid; Moclobemide Stadapharm Brand; Hoffmann-La Roche Brand of Moclobemide; Moclaime; Oprea1_256739; Rimoc; Aurorix (TN); BRN 0530974; Moclobamide; 4-Chloro-N-(2-morpholin-4-yl-ethyl)-benzamide; Moclobeta; BAS 03214735; betapharm Brand of Moclobemide; Kendrick Brand of Moclobemide; Pharmascience Brand of Moclobemide; Moclobemida; Ro 11-1163/000; moclobemide; von ct, Moclobemid; CHEMBL86304; ct Arzneimittel Brand of Moclobemide; Moclobemide Healthsense Brand; Moclobemide Azupharma Brand; NuMoclobemide; Moclobemide [USAN:INN:BAN]; STK222240; Moclobemid von ct; BC Brand of Moclobemide; Ro 11 1163; Moclobemide ct-Arzneimittel Brand; SMR000012114; Moclamide; Moclobemide Temmler Brand; Moclobemide (USAN/INN); esparma Brand of Moclobemide; C13H17ClN2O2; CPD000012114; NovoMoclobemide; AC-12467; Apo-Moclobemide; BIM-0048213.P001; 4-chloro-N-[2-(morpholin-4-yl)ethyl]benzamide; Moclobemid-ratiopharm; MLS000070549; Moclobemide Roche Brand; Ro 11-1163; HSDB 7180; HMS2051A16; Nu Moclobemide; Moclobemide BC Brand; Moclonorm; Apotex Brand of Moclobemide; Moclobemid 1A Pharma; Roche Brand of Moclobemide; Moclobemide betapharm Brand; NCGC00027930-03; Alphapharm Brand of Moclobemide; Temmler Brand of Moclobemide; D020912; Moclobemid Puren; Moclobemide, GenRX; ct-Arzneimittel Brand of Moclobemide; Feraken; Moclobemide, Chem mart; Hoffmann La Roche Brand of Moclobemide; p-Chloro-N-(2-morpholinoethyl)benzamide; Aurorex; Oprea1_270122; Moclobemide Faulding Brand; PMS-Moclobemide; Moclobemide Alpharma Brand; Moclobemide Hexal Brand; Terry White Chemists Brand of Moclobemide; Faulding Brand of Moclobemide; Manerix; D02561; Moclamine; GenRX Moclobemide; Nu-Pharm Brand of Moclobemide; Aurorix; BENZAMIDE, 4-CHLORO-N-(2-(4-MORPHOLINYL)ETHYL)-; Moclobemid-1A Pharma; Moclobemide Alphapharm Brand; Moclobemide ratiopharm Brand; Apo Moclobemide; Azupharma Brand of Moclobemide; SAM001246614; Moclobemid1A Pharma; Ro-11-1163; NCGC00027930-04; Moclobemid Stada; Arima; 4-Chloro-N-(2-(4-morpholinyl)ethyl)benzamide; PMS Moclobemide; Moclobemida [INN-Spanish]; Moclobemide Bull Brand; DBL Moclobemide; Healthsense Brand of Moclobemide; Novo Moclobemide; Moclobemide Nu-Pharm Brand; Moclobemid; Stadapharm Brand of Moclobemide; Hexal Brand of Moclobemide; CBMicro_048319; ZINC19606670; GNF-PF-695; Nu-Moclobemide; Alpharma Brand of Moclobemide; Moclobemidum; AZU, Moclobemid; MolPort-001-503-124; Moclobemide Kendrick Brand; Moclix; NCGC00027930-05; Moclobemid ratiopharm; CID4235; 1A Brand of Moclobemide; 71320-77-9; DB01171; Moclobemide, Healthsense; Deprenorm; MLS000759438; Moclobemide Pharmascience Brand; Moclodura; Moclobemide esparma Brand; Moclobemid AZU; Chem mart Moclobemide; Bull Brand of Moclobemide; Healthsense Moclobemide; Moclobemidum [INN-Latin]; Moclobemide Novopharm Brand; Moclobemide [USAN:BAN:INN]; Novopharm Brand of Moclobemide; ST50016353; MLS001240195; AC1L1HPM; Moclobemide Apotex Brand; Moclobemide, DBL; LS-26161	71320-77-9	4235	189524	TTDS00289	Amine oxidase [flavin-containing] A	MAO-A;Monoamine oxidase;Monoamine oxidase A	P21397	4128	ENSG00000189221	inhibitor
DCL000239	T487	2-(2,4-diethyloctoxy)-N-[2-(2,4-diethyloctoxy)ethyl]-N-methyl-ethanamine; T487; 2-(2,4-diethyloctoxy)-N-[2-(2,4-diethyloctoxy)ethyl]-N-methylethanamine; AC1MVK5U; MolPort-001-839-620; CID3684533	N/A	16220015	47499808	TTDC00125	C-X-C chemokine receptor type 3	CD183 antigen;Chemokine receptor CXCR3;Chemokine receptor CXCR3/interferon-inducible protein-10;CKR-L2;CXC-R3;CXCR-3;CXCR3/IP-10;Interferon-inducible protein 10 receptor	P49682	2833	ENSG00000186810	antagonist
DCL000575	MLN0415	N/A	N/A	N/A	N/A	TTDC00222	Inhibitor of nuclear factor kappa-B kinase	I kappa B kinase;IkBK;IKK	Q14164	9641	ENSG00000143466	inhibitor
DPR000181	ISIS-STAT3	N/A	N/A	N/A	N/A	TTDR01387	mRNA of STAT3	N/A	P40763	6774	ENSG00000168610	antisense
DAP000808	L-Tyrosine	UNII-42HK56048U; bmse000051; (S)-2-Amino-3-(p-hydroxyphenyl)propionic acid; 2-Amino-3-(p-hydroxyphenyl)propionic acid; Tyrosine (USP/INN); (S)-2-Amino-3-(4-hydroxyphenyl)propionic acid; alpha-Amino-p-hydroxyhydrocinnamic acid, (-)-; Tyrosine, L- (8CI); D00022; Melanin synthesized from Tyr substrate catalyzed by tyrosinase for 6 hrs, oxidized with hydrogen peroxide; L-Tyrosin; NCGC00159350-03; L-tyrosine; Melanin synthesized from Tyr substrate catalyzed by tyrosinase for 6 hrs; CHEMBL925; T4321_SIGMA; L-Phenylalanine-4-hydroxy-; Melanin synthesized from Tyr substrate catalyzed by tyrosinase, sulfonated using sulfur trioxide/DMF complex for 1.5-7 hours; 2csm; BB_NC-1194; Tyrosinum [Latin]; tyrosine; L-Phenylalanine, 4-hydroxy-; AC1L1LPI; Tyrosine Power; (S)-Tyrosine; 25619-78-7; DB03839; EINECS 200-460-4; AC1Q4U7L; Tyrosinum; Tyrosine [USAN:INN]; Free-Form L-Tyrosine; DD69927C-C6A8-4BC6-8E9A-0AB423B176E7; 55520-40-6; (S)-alpha-Amino-4-hydroxybenzenepropanoic acid; 4ts1; L-Tyrosine hydrochloride; Rxosine; T3754_SIAL; AC1Q4U7M; Tyrosine (VAN); C00082; AB1002647; T0550; p-Tyrosine; L-Tyrosine, monomer; FEMA No. 3736; H-Tyr-OH; CID6057; tyr; MolPort-001-792-016; T4321_SIAL; 3-(4-Hydroxyphenyl)-L-alanine; TYR NH3+ COOH; 60-18-4; (S)-3-(p-Hydroxyphenyl)alanine; NSC 82624; (2S)-2-amino-3-(4-hydroxyphenyl)propanoic acid; L-p-Tyrosine; nchembio.121-comp7; AC-11295; DB00135; nchembio.186-comp84; nchembio.284-comp7; 4-Hydroxy-L-phenylalanine; (-)-alpha-Amino-p-hydroxyhydrocinnamic acid; Propanoic acid, 2-amino-3-(4-hydroxyphenyl)-(S)-; Benzenepropanoic acid, alpha-amino-4-hydroxy-, (S)-; nchembio.105-comp1; CHEBI:17895; 3-(p-Hydroxyphenyl)alanine; W373605_ALDRICH; 93829_SIGMA; L-Tyrosine, homopolymer; Tyrosine, L-; alpha-Amino-beta-(4-hydroxyphenyl)propionic acid; L-Tyrosine (JAN); L-2-Amino-3-p-hydroxyphenylpropanoic acid; beta-(p-Hydroxyphenyl)alanine; 2-Amino-3-(4-hydroxyphenyl)propanoic acid, (S)-; DTY; (S)-2-Amino-3-(4-hydroxyphenyl)propionic acid; 3-(4-Hydroxyphenyl)-L-alanine; AI3-09055; tirosina; HSDB 2003; Melanin synthesized from Tyr substrate catalyzed by tyrosinase for 6 hrs, oxidized with hydrogen peroxide, <3 kd fraction; AR-1J3457; Melanin synthesized from Tyr substrate catalyzed by tyrosinase, brominated with N-bromosuccinimide; L-(-)-Tyrosine; Tirosina [Spanish]; 2-Amino-3-(4-hydroxyphenyl)propanoic acid-(S)-; Propanoic acid, 2-amino-3-(4-hydroxyphenyl)-, (S)-; alpha-Amino-4-hydroxybenzenepropanoic acid, (S)-; 1991-85-1; 140-43-2; L-Tyrosine (9CI); 93829_FLUKA; LS-2336; 46209-14-7; nchembio816-comp11; T8566_SIGMA; NCGC00159350-02	60-18-4	6057	8144790	TTDS00365	Tyrosine 3-monooxygenase	TH;Tyrosine 3-hydroxylase	P07101	7054	ENSG00000180176	binder
DAP000538	Tetrahydrobiopterin	5,6,7,8-tetrahydro-L-erythrobiopterin; 6R-L-erythro-5,6,7,8-tetrahydrobiopterin; CHEBI:15372; 5,6,7,8-tetrahydrobiopterin; 6R-BH4; 4(1H)-Pteridinone, 5,6,7,8-tetrahydro-2-amino-6-(1,2-dihydroxypropyl)-; AC1Q6ING; ZINC13585233; 6R-5,6,7,8-Tetrahydrobiopterin; SMP1_000285; tetra-hydro-biopterin; 5,6,7,8-tetra-H-biopterin; ZINC04475363; 6R-L-5,6,7,8-Tetrahydrobiopterin; MolPort-004-964-609; Sapropterina; Dapropterin; BPH4; Kuvan; 5-26-18-00418 (Beilstein Handbook Reference); Sapropterinum; ZINC00057518; C9H15N5O3; 5,6,7,8-Tetrahydro-2-amino-6-(1,2-dihydroxypropyl)-4(1H)-pteridinone; L-erythro-2-Amino-6-(1,2-dihydroxypropyl)-5,6,7,8-tetrahydro-4(3H)-pteridinon; tetra-H-biopterin; CID1125; LS-126327; 69081654-1FB6-4B89-B9B9-823C9887EE36; C00272; tetrahydrobiopterin; (6R)-2-amino-6-[(1R,2S)-1,2-dihydroxypropyl]-5,6,7,8-tetrahydropteridin-4(1H)-one; (6R)-L-erythro-tetrahydrobiopterin; CID44257; 5,6,7,8 Tetrahydrobiopterin; AC1L1AS5; 2-Amino-6-(1,2-dihydroxypropyl)-5,6,7,8-tetrahydoro-4(1H)-pteridinone; 7-tetrahydrobiopterin; D08505; Sapropterina [INN-Spanish]; 5,6,7,8-erythro-tetrahydrobiopterin; R-THBP; Sapropterinum [INN-Latin]; Sapropterin; Sapropterin [INN]; 27070-47-9; (-)-(6R)-2-Amino-6-((1R,2S)-1,2-dihydroxypropyl)-5,6,7,8-tetrahydro-4(3H)-pteridinone; phenylalanine hydroxylase cofactor; 62989-33-7; AC1L2BG0; BH4; AC1Q6INE; 2-amino-6-(1,2-dihydroxypropyl)-5,6,7,8-tetrahydro-1H-pteridin-4-one; BRN 0544742; THB; Phenoptin; (6R)-2-amino-6-[(1R,2S)-1,2-dihydroxypropyl]-5,6,7,8-tetrahydro-1H-pteridin-4-one; UNII-EGX657432I; CHEMBL1201774; 2-amino-6-(1,2-dihydroxypropyl)-5,6,7,8-tetrahydropteridin-4(3H)-one; (6R)-2-amino-6-[(1R,2S)-1,2-dihydroxypropyl]-5,6,7,8-tetrahydropteridin-4(3H)-one; AR-1H3940; Sapropterin (INN); (6R,1'R,2'S)-5,6,7,8 TETRAHYDROBIOPTERIN; Biopterin, 5,6,7,8-tetrahydro-; DB00360; BCBcMAP01_000204; 17528-72-2; tetrahydro-6-biopterin; 5,6,7,8-tetrahydrodictyopterin; (1R,2S)-(2-Amino-3,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)-1,2-propandiol; CID9816201; CHEBI:59560	17528-72-2	1125	3570	TTDS00365	Tyrosine 3-monooxygenase	TH;Tyrosine 3-hydroxylase	P07101	7054	ENSG00000180176	cofactor
DAP000807	L-Phenylalanine	CHEMBL301523; 3617-44-5; alpha-Amino-beta-phenylpropionic acid, L-; DB02556; L-Alanine, 3-(p-[bis(2-chloroethyl)amino]phenyl)-N-formyl-; NCIStruc1_000204; Alanine, 3-(p-(bis(2-chloroethyl)amino)phenyl)-N-formyl-, (-)-; (S)-2-Amino-3-phenylpropionic acid; N-Formyl-L-p-sarcolysin; endophenyl; 67675-33-6; 5297-02-9; nchembio.186-comp89; LS-15879; Phenylalanine, L-; (S)-2-Amino-3-phenylpropanoic acid; L-PHENYLALININE; 1f2p; N-Formyl-L-sarcolysin; L-Phenylalanine (JP15); NCGC00095047-04; W358509_ALDRICH; P2126_SIAL; CHEBI:17295; (L)-Phenylalanine; CID37278; 3-Phenylalanine; 3-[4-[bis(2-chloroethyl)amino]phenyl]-2-formamidopropanoic acid; NCGC00095047-01; Alanine, phenyl-, L-; Hydrocinnamic acid, alpha-amino-; AC1L1LVU; NSC 37024; NCGC00095047-03; nchembio.255-comp2; phe; MolPort-001-757-101; L-Alanine, phenyl-; LS-1515; Benzenepropanoic acid, alpha-amino-, (S)-; nchembio.185-comp8; NSC37024; Phenylalanine (VAN); D00021; L-PHENYL ALANINE (SEE ALSO 22839-47-0, ASPARTAME; 303-47-9 OCHRATOXINA; 673-06-3 D-PHENYL); (S)-(-)-Phenylalanine; L-phenylalanine; 801204-11-5; Alanine, 3-phenyl-; L-Alanine, 3-phenyl-; 10549-09-4; (2S)-2-amino-3-phenylpropanoic acid; EINECS 200-568-1; NSC-9959; NCGC00013103; CB 3208; P8740_SIGMA; nchembio816-comp8; 1F9436B3-8B0D-4AC6-A004-4249B0BDA436; 78019_SIGMA; bmse000045; DB00120; CID6140; N-Formylmelphalan; 32526-17-3; phenylalanine; AmbotzHAA1121; alpha-Aminohydrocinnamic acid, L-; H-Phe-OH; Alanine, 3-[p-[bis(2-chloroethyl)amino]phenyl]-N-formyl-, L-; beta-Phenylalnine, (-)-; (S)-Phenylalanine; 2-Amino-3-phenylpropionic acid, L-; AC1L1XF0; AB1003608; NCIStruc2_000248; 35849-41-3; P8740_SIAL; P5482_SIGMA; C00079; beta-Phenyl-L-alanine; L-Phenylalanine, 4-[bis(2-chloroethyl)amino]-N-formyl-; ALANINE, 3-(p-(BIS(2-CHLOROETHYL)AMINO)PHENYL)-N-FORMYL-, L-; CCRIS 4254; L-3-(p-(Bis(2-chloroethyl)amino)phenyl)-N-formylalanine; Phenylalaninum; L-Phenylalanine,; Antibiotic FN 1636; P0134; (S)-alpha-Amino-beta-phenylpropionic acid; L-Phenylalanine, 4-(bis(2-chloroethyl)amino)-N-formyl- (9CI); Phenylalanine [USAN:INN:JAN]; alpha-Aminohydrocinnamic acid; Phenylalaninum [Latin]; NCI9959; HSDB 1825; fenilalanina; 1usi; NSC 79477; NCGC00095047-02; L-Antibiotic FN 1636; 3-Phenyl-L-alanine; (S)-alpha-Aminohydrocinnamic acid; FEMA No. 3585; beta-Phenylalanine; 78019_FLUKA; L-Alanine, 3-(p-(bis(2-chloroethyl)amino)phenyl)-N-formyl-; (S)-alpha-Amino-benzenepropanoic acid; Fenilalanina [Spanish]; 63-91-2; Phenylalanine (USP/INN); UNII-47E5O17Y3R	63-91-2	6140	3379	TTDS00365	Tyrosine 3-monooxygenase	TH;Tyrosine 3-hydroxylase	P07101	7054	ENSG00000180176	binder
DAP000471	Metyrosine	H 9/88; (-)-alpha-Methyl-L-tyrosine; ST075173; ( -)-alpha-Methyl-DL-tyrosine; (R,S)-2-Amino-3-(4-hydroxyphenyl)-2-methylpropionsaeure; alpha-Methyltyrosine; AC1Q2B51; AC1L201X; Metirosinum [INN-Latin]; CID441350; Tyrosine, alpha-methyl-; Spectrum3_001846; AI3-62542; SPECTRUM2300312; CHEMBL1200862; DL-2-Methyl-3-(4-hydroxyphenyl)alanine; 69577_FLUKA; BSPBio_003232; CID12650; EINECS 211-599-5; UNII-X88TTO174Z; LS-158317; SAM001246859; Metirosine (INN); a-methyl-L-p-tyrosine; NCGC00015701-02; SMR000059140; Metirosinum; DL-alpha-Methyl-p-tyrosine; UNII-DOQ0J0TPF7; M 8131; MolPort-001-792-045; Metirosine; alpha-Methyltyrosine, (+,-)-Isomer; NCGC00094144-05; MK 781; 658-48-0; Metyrosine [USAN]; EINECS 210-635-7; DB00765; L 588357-0; 4-Hydroxy-alpha-methylphenylalanine; MK-781; AC1Q29EO; DL-Tyrosine, alpha-methyl-; Racemetirosinum; CPD000059140; AmbotzHAA5370; L-2-Methyl-3-(4-hydroxy-?phenyl)alanine; alpha-Methyltyrosine, (D,L)-Isomer; Tyrosine, .alpha.-methyl-; alpha-Methylparatyrosine, DL-; M-5185; Lopac0_000001; C07921; alpha-Methyl-dl-tyrosine; Metyrosine (USP); NCGC00094144-01; EU-0100001; L-alpha-Methyl-p-tyrosine; AmbotzHAA5490; Lopac-120693; NCGC00015701-03; Demser; C10H13NO3; Alpha-Methyl-L-P-Tyrosine; NCGC00094144-04; STK272180; EINECS 211-523-0; Metirosina; D00762; Demser (TN); Racemetirosina [INN-Spanish]; Metyrosine, DL-; AC1L9B0V; AC1L1F85; CID3125; LS-176577; Lopac0_000811; Racemetirosina; SAM001246895; NCGC00095904-01; Racemetirosine; (2R)-2-amino-3-(4-hydroxyphenyl)-2-methylpropanoic acid; L-Tyrosine, .alpha.-methyl-; AKOS003391424; L-Tyrosine, alpha-methyl-, (-)-; 672-87-7; METYROSINE; MLS000028638; .alpha.-Methyl-p-tyrosine; L-AMPT; Racemetirosine [INN]; NCGC00015701-01; DL-alpha-Methyltyrosine; 120693_ALDRICH; (+-)-alpha-Methyl-DL-tyrosine; M8131_SIGMA; alpha-Methyl-para-tyrosine; 620-30-4; CPD000466921; Racemetirosinum [INN-Latin]; (S)-alpha-Methyltyrosine; NCGC00015701-05; L-588357-0; BRN 2938704; NCGC00093528-02; NCGC00094144-03; (-)-(S)-2-Amino-3-(4-hydroxyphenyl)-2-methylpropionsaeure; alpha-Methyl-p-tyrosine; alpha-Methyltyrosine, (L)-Isomer; alpha-Methyl-L-tyrosine; 4-14-00-02453 (Beilstein Handbook Reference); Metirosina [INN-Spanish]; KBio3_002732; 2-amino-3-(4-hydroxyphenyl)-2-methylpropanoic acid; EU-0100811; alpha-MPT; NCGC00093528-01; Lopac-M-8131; MolPort-001-792-900; (2S)-2-amino-3-(4-hydroxyphenyl)-2-methylpropanoic acid; Methyltyrosine; NCGC00094144-06	672-87-7	441350	10123	TTDS00365	Tyrosine 3-monooxygenase	TH;Tyrosine 3-hydroxylase	P07101	7054	ENSG00000180176	binder
DCL001150	ASG-22ME	N/A	N/A	N/A	N/A	TTDC00343	Nectin-4	Poliovirus receptor-related protein 4;Ig superfamily receptor LNIR	Q96NY8	81607	ENSG00000143217	antibody
DAP000306	Nimodipine	3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-,2-methoxyethyl 1-methylethyl ester; C07267; Modus; Admon; Nimodipino Bayvit; Bio-0178; KBio1_001756; NCGC00024675-06; HMS1922E04; MLS000863294; Spectrum_001880; 66085-59-4; Esteve Brand of Nimodipine; N149_SIGMA; Hexal Brand of Nimodipine; 3,5-pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl), 2-methoxyethyl 1-methylethyl ester; MolPort-001-840-190; HMS1361F19; Bio1_001096; Brainal; MLS002172461; 1,4-Dihydro-2,6-dimethyl-4-(3&prime;-nitrophenyl)-3,5-pyridinedicarboxylic acid 2-methoxyethyl-1-methylethyl Ester; 4-[4-(4-chlorophenyl)-4-hydroxy-1-piperidyl]-N,N-dimethyl-2,2-diphenyl-butanamide; Bio2_000117; Periplum, Nimotop, BRN 0459792, DRG-0139; CPD000058300; 2-Methoxyethyl-1-methylethyl ester; KBio2_000117; Nimodipinum [INN-Latin]; Bio2_000597; Nimodipine [USAN:BAN:INN]; KBio2_002685; HMS2089H13; Bio1_000118; DRG-0139; Nimodipine (USAN/INN); EINECS 266-127-0; CHEBI:465248; 3-O-(2-methoxyethyl) 5-O-propan-2-yl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; KBio2_007539; 3,5-pyridinecarboxylic acid 2-methoxyethyl 1-methylethyl ester; NCGC00024675-08; EU-0100891; KBioSS_002408; NCGC00024675-02; Nimotop(TM); AC1Q4G7S; BPBio1_000876; 1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 2-methoxyethyl 1-methylethyl ester; KBio3_001632; HMS2093G11; BSPBio_002412; MLS001076550; Nimodipin-ISIS; BRD-A58048407-001-06-3; KBio2_005253; IDI1_033867; SAM001246890; SPBio_001464; Prestwick2_000918; CBiol_001832; HMS1989F19; Prestwick1_000918; Nimodipin ISIS; MLS002154061; KBioGR_001262; Lopac0_000891; NCGC00024675-07; KBioGR_000117; Nimodipino; UNII-57WA9QZ5WH; CID4497; Bayer Brand of Nimodipine; STK642934; KBio2_004971; C21H26N2O7; EG-1961; SPECTRUM1503600; N-149; CHEMBL40792; Vita Brand of Nimodipine; BSPBio_001397; D009553; Nimodipino [INN-Spanish]; FT-0082761; 2-methoxyethyl propan-2-yl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; NCGC00024675-03; KBio2_002403; DB00393; SMR000058300; Alpharma Brand of Nimodipine; Isopropyl 2-methoxyethyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate; Bio1_000607; 1-methylethyl 2-(methyloxy)ethyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; NimodipinISIS; Remontal; CHEMBL1428; AC1L1IAS; NCGC00015714-12; NimoGel; AC-11694; CHEBI:160965; NIMOTOP (TN); NCGC00015714-04; Andromaco Brand of Nimodipine; Kenesil; nimodipine; Periplum; KBio3_000234; KBioSS_000117; Spectrum2_001562; SPBio_002985; BAY e 9736; nchembio.476-comp9; Nimotop,  Nimodipine; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-methoxyethyl 1-methylethyl ester; NCGC00024675-09; 3-(2-methoxyethyl) 5-propan-2-yl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; Nimodipin Hexal; HMS2052M05; AB00513963; LS-131292; NCGC00024675-05; Nimodipinum; BSPBio_000796; BRN 0459792; NCGC00024675-04; Spectrum5_001687; HMS1570H18; Prestwick0_000918; 1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-; HMS1791F19; Calnit; 1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid; I06-0230; MLS000069381; Spectrum4_000791; Cantabria Brand of Nimodipine; nchembio.79-comp6; Spectrum3_000766; Bay-E 9736; S1747_Selleck; D00438; Almirall Brand of Nimodipine; Nimotop; Bayvit Brand of Nimodipine; Bay-e-9736; Elan Brand of Nimodipine; DivK1c_006812; KBio3_000233; Prestwick3_000918; SpecPlus_000716	66085-59-4	4497	187034	TTDS00163	Calcium channel	N/A	N/A	N/A	N/A	blocker
DAP000595	Nisoldipine	HMS2089K20; nisoldipine; SMR000466370; CHEMBL1726; Nisocor; D015737; Isobutyl 1,4-dihydro-5-methoxycarbonyl-2,6-dimethyl-4-(2-nitrophenyl)-3-pyridincarboxylat; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-, methyl 2-methylpropyl ester; Sular; MLS000759498; STK631543; NCGC00164633-01; BRN 0454188; CHEMBL441428; Nisoldipino; Nisoldipine (JAN/USAN/INN); 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-, methyl 2-methylpropyl ester, (+-)-; HMS2093F15; Baymycard; D00618; EINECS 264-407-7; HMS2051O18; Nisoldipino [INN-Spanish]; C20H24N2O6; methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; SAM001246719; AC1L1IAY; MLS001424102; MolPort-003-666-664; Bay-k-5552; CPD000466370; BIDD:GT0684; Zadipina; 3-O-methyl 5-O-(2-methylpropyl) 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; Nisoldipinum; UNII-4I8HAB65SZ; Bio-0177; CID4499; AC-987; Nisoldipinum [INN-Latin]; 63675-72-9; Syscor; FT-0082489; Bay k 5552; CHEBI:161014; Sular (TN); C07699; MLS002153943; LS-131295; Nisoldipin; DB00401; (+-)-Isobutyl methyl 1,4-dihydro-2,6-dimethyl-4-(o-nitrophenyl)-3,5-pyridinedicarboxylate; Nisoldipine [USAN:BAN:INN:JAN]	63675-72-9	4499	184770	TTDS00163	Calcium channel	N/A	N/A	N/A	N/A	blocker
DAP000487	Felodipine	Plendil (TN); Hoechst Brand of Felodipine; ratiopharm Brand of Felodipine; C18H19Cl2NO4; Lexxel; SPBio_002555; Munobal Retard; Felodipin ratiopharm; UNII-OL961R6O2C; HMS1569O18; HMS2089J05; H 154-82; 86189-69-7; 1A Brand of Felodipine; Fensel; felodipin von ct; Prestwick1_000478; Plandil; H 154 82; H 154/82; Felodur ER; Munobal; 3,5-pyridinedicarboxylic acid, 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-,ethyl methyl ester, (+-)-; betapharm Brand of Felodipine; Hydac; Felo-Puren; MLS000069629; MLS001077361; 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid ethyl methyl ester; ct-Arzneimittel Brand of Felodipine; MolPort-002-801-136; Felodipin AbZ; Logimax; AstraZeneca Brand of Felodipine; Felodipin AZU; Lopac0_000508; Felo Biochemie; Heumann, Felodipin; Felodipine [USAN:BAN:INN]; 3-ethyl 5-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate; D00319; CID3333; LS-131202; Flodil; AC1Q32PZ; Felodur; Stadapharm Brand of Felodipine; DB01023; CGH-869; 72509-76-3; ethyl methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate; Astra Brand of Felodipine; 5-O-ethyl 3-O-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate; (+-)-Ethyl methyl 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate; Prestwick2_000478; 3,5-Pyridinedicarboxylic acid, 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-, ethyl methyl ester; Aliud Brand of Felodipine; Agon; AC-2124; CHEMBL22571; Prestwick3_000478; Plendil ER; Felodipin dura; 4-(2,3-dichloro-phenyl)-2,6-dimethyl-1,4-dihydro-pyridine-3,5-dicarboxylic acid 3-ethyl ester 5-methyl ester; Promed Brand of Felodipine; Felocor; BIDD:GT0733; Plendil Retard; Alpharma Brand of Felodipine; felodipine; TheraPharm Brand of Felodipine; Hexal Brand of Felodipine; Felodipin 1A Pharma; AbZ Brand of Felodipine; MLS002153832; Plendil, Renedil, Feloday, Felodipine; MLS001333735; Felodipin Heumann; Felodipina; Modip; Preslow; Plendil Depottab; (+/-) ethyl methyl 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate; Prestwick0_000478; NCGC00093906-02; F9677_SIGMA; dl-Felodipine; BRN 4331472; Penedil; AGON SR; H-154/82; Felodipinum [INN-Latin]; F 9677; Felodipin AL; AE-641/11429675; Felodipinum; 3,5-Pyridinedicarboxylic acid, 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-, ethyl methyl ester, (+-)-; BPBio1_000678; Felobeta; Plendil; BSPBio_000616; Felodipina [INN-Spanish]; EU-0100508; SMR000058204; Aventis Brand of Felodipine; Alphapharm Brand of Felodipine; NCGC00093906-01; I14-9560; CHEBI:585948; Perfudal; Felogamma; BRD-A30815329-001-03-0; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-4-(2,3-dichlorophenyl)-2,6-dimethyl-, ethyl methyl ester; 3-Ethyl 5-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydro-3,5-pyridinedicarboxylate; AC1L1FP2; S1885_Selleck; CPD001496951; Heumann Brand of Felodipine; MLS002153409; Splendil; Felodipine (JAN/USP/INN); CHEMBL1480; 4-(2,3-Dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinecarboxylic acid ethyl methyl ester; Prestwick_797; Felodipin Stada; Felodipin-ratiopharm; SAM002589971; Pharmaceutica Astra Brand of Felodipine; D015736; Felogard; Worwag Brand of Felodipine; BC Brand of Felodipine; H 15482; NCGC00015455-08; CHEBI:127617; Merck dura Brand of Felodipine; Azupharma Brand of Felodipine; NCGC00015455-03; Prevex; Pharmacia Spain Brand of Felodipine; Felo Puren; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-4-(2,3-dichlorophenyl)-2,6-dimethyl-,ethyl methyl ester; Renedil; Felodipine [USAN:INN:BAN]; Feloday; ct Arzneimittel Brand of Felodipine	72509-76-3	3333	189780	TTDS00163	Calcium channel	N/A	N/A	N/A	N/A	blocker
DAP000486	Nicardipine	IDI1_033859; L000715; AC1L1I8Y; methyl 2-[methyl(phenylmethyl)amino]ethyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; NCGC00015747-06; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-,2-(benzylmethylamino)ethyl methyl ester; DB00622; NCGC00162262-04; Ambap55985-32-5; 5-O-[2-[benzyl(methyl)amino]ethyl] 3-O-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; BRN 0504321; NCGC00162262-02; EINECS 259-932-3; C07264; HMS1989F11; Nicardipinum [INN-Latin]; Bio2_000589; Y-93; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-(benzylmethylamino)ethyl methyl ester; HMS2089C09; KBioSS_000109; KBioSS_001852; Spectrum_001372; MolPort-002-484-049; LS-131263; Bio2_000109; KBioGR_000744; Spectrum5_001320; CHEMBL1484; Bio1_000088; KBio2_006988; HMS1791F11; Prestwick2_000383; Spectrum4_000422; BSPBio_001389; Lopac0_000809; BSPBio_000565; KBio2_004420; DivK1c_000540; Prestwick1_000383; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl 2-(methyl(phenylmethyl)amino)ethyl ester; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl 2-[methyl(phenylmethyl)amino]ethyl ester; CID4474; BIDD:GT0621; BRD-A26711594-001-02-7; Oprea1_436998; Nicardipine (INN); SPBio_002486; Spectrum2_001415; KBio2_000109; KBio2_001852; BSPBio_002943; IDI1_000540; Nicardipino; Nicardipine LA; CBiol_001802; Bio1_000577; Nicardipine [INN:BAN]; nicardipine; NCGC00162262-03; NCGC00162262-01; KBio1_000540; C26H29N3O6; 55985-32-5; BPBio1_000623; Bio1_001066; NINDS_000540; KBioGR_000109; KBio2_005245; Prestwick0_000383; KBio3_002443; D08270; Prestwick3_000383; 2-(Benzylmethylamino)ethyl methyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)pyridine-3,5-dicarboxylate; CHEBI:507549; KBio3_000218; AB00514658; KBio3_000217; KBio2_002677; Cardene IV; AC-19947; Nicardipinum; Cardene (TN); BRD-A26711594-003-05-6; Spectrum3_001452; AKOS001637090; Nicardipino [INN-Spanish]; SPBio_001490; UNII-CZ5312222S	55985-32-5	4474	182381	TTDS00163	Calcium channel	N/A	N/A	N/A	N/A	blocker
DCL000879	MEM-1003	N/A	518048-05-0	11598201	49632214	TTDS00163	Calcium channel	N/A	N/A	N/A	N/A	blocker
DCL000588	Ozarelix	N/A	N/A	N/A	N/A	TTDS00253	Gonadotropin-releasing hormone	GnRH;Gonadoliberin;Leutinizing-hormone-releasing hormone;LHRH;LH-RH;Luliberin	N/A	N/A	N/A	inhibitor
DAP000094	Abarelix	UNII-W486SJ5824; Abarelix; N-Acetyl-3-(2-naphthyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridyl)-D-alanyl-L-seryl-N-methyl-L-tyrosyl-D-asparginyl-L-leucyl-N6-isopropyl-L-lysyl-L-prolyl-D-alaninamide; Abarelix (USAN/INN); D-Alaninamide, N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-N-methyl-L-tyrosyl-D-asparaginyl-L-leucyl-N6-(1-methylethyl)-L-lysyl-L-prolyl- 10; Abarelix-Depot-M; PPI-149; LS-181947; 183552-38-7; R-3827; Abarelix [USAN]; Plenaxis depot; PPI 149; CHEBI:337298; Plenaxis; Plenaxis (TN); R 3827; N-Acetyl-3-(2-naphthyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridyl)-D-alanyl-L-seryl-N-methyl-L-tyrosyl-D-asparaginyl-L-leucyl-N(sup 6)-isopropyl-L-lysyl-L-prolyl-D-alaninamide; N-acetyl-3-(2-naphthyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(pyridin-3-yl)-D-alanyl-L-seryl-N-methyl-L-tyrosyl-D-asparginyl-L-leucyl-N(6)-isopropyl-L-lysyl-L-prolyl-D-alaninamide; CHEMBL1252; D02738	183552-38-7	16131215	12015126	TTDS00253	Gonadotropin-releasing hormone	GnRH;Gonadoliberin;Leutinizing-hormone-releasing hormone;LHRH;LH-RH;Luliberin	N/A	N/A	N/A	inhibitor
DCL001177	Debio 025	N/A	N/A	N/A	N/A	TTDR00122	Cyclophilin	Cyclosporin A-binding protein;Peptidyl-prolyl cis-trans isomerase;Peptidylprolyl isomerase;PPIase;Rotamase	N/A	N/A	N/A	inhibitor
DPR000185	SCY-641	N/A	N/A	N/A	N/A	TTDR00122	Cyclophilin	Cyclosporin A-binding protein;Peptidyl-prolyl cis-trans isomerase;Peptidylprolyl isomerase;PPIase;Rotamase	N/A	N/A	N/A	inhibitor
DCL001238	SCY-635	N/A	N/A	N/A	N/A	TTDR00122	Cyclophilin	Cyclosporin A-binding protein;Peptidyl-prolyl cis-trans isomerase;Peptidylprolyl isomerase;PPIase;Rotamase	N/A	N/A	N/A	inhibitor
DAP001226	Iodipamide	Bilignostum; Transbilix; EINECS 210-105-5; CHEBI:43294; NCGC00016523-02; I0639_SIGMA; Prestwick3_000939; 3,3'-[(1,6-DIOXOHEXANE-1,6-DIYL)DIIMINO]BIS(2,4,6-TRIIODOBENZOIC ACID); AC1Q5M0A; MLS001066414; 3,3'-(Adipoyldiimino)bis(2,4,6-triiodobenzoic acid); Cholografin; UNII-TKQ858A3VW; 4-14-00-01122 (Beilstein Handbook Reference); BRD-K67261995-001-03-4; 3-[5-[(3-CARBOXY-2,4,6-TRIIODO-PHENYL)CARBAMOYL]PENTANOYLAMINO]-2,4,6-TRIIODO-BENZOIC ACID; 3,3'-Adipoyldiiminobis(2,4,6-triiodobenzoic Acid); D01774; Adipiodona; Iodipamide [USAN]; DB04711; Adipiodone; MolPort-001-783-518; SPBio_003047; Adipiodone (JAN/INN); CHEMBL1165268; BPBio1_000966; Prestwick1_000939; SBB058156; AC1L1GLQ; BRN 2230896; Benzoic acid, 3,3'-(adipoyldiimino)bis(2,4,6-triiodo-; Iodipamide (USP); CAS-606-17-7; IDB; LS-35555; 606-17-7; Bilignost; 3,3'(Adipoyldiimino)bis(2,4,6-triiodobenzoic acid); Adipiodonum [INN-Latin]; CID3739; Prestwick0_000939; Iodipamic acid; N,N''-Adipoyl-bis(3-amino-2,4,6-triiodbenzoesaeure); NCGC00016523-01; I0639_FLUKA; Cholospect; I0299; Prestwick2_000939; Benzoic acid, 3,3'-((1,6-dioxo-1,6-hexanediyl)diimino)bis(2,4,6-triiodo-; IODIPAMIDE; 3-[[6-(3-carboxy-2,4,6-triiodoanilino)-6-oxohexanoyl]amino]-2,4,6-triiodobenzoic acid; Adipiodona [INN-Spanish]; Adipiodonum; AR-1E8468; HMS1570L20; Adipiodon; BSPBio_000878; AB00513970; SMR000471884; Biligrafin	606-17-7	3739	7888314	TTDS00336	Serum albumin	N/A	P02768	213	ENSG00000163631	binder
DAP001228	Bismuth	265462_ALDRICH; 452386_ALDRICH; AC1O4PN8; bismuth;; 24267-48-9; 264008_ALDRICH; MolPort-003-925-759; BISMUTH, 99.999%; BISMUTH, 99.95%; LTBB002773; 95375_FLUKA; CHEBI:33301; bismuto; AC1NSDYX; Bismut; Wismut; HSDB 2078; 17034_FLUKA; CID5359367; Bismuth, elemental; Bismuth(III) nitrate solution; AR-1I0647; 7440-69-9; 83Bi; BISMUTH; 556130_ALDRICH; 265470_ALDRICH; Bismuth-209; C15471; Bismuth standard for ICP; LS-44708; EINECS 231-177-4; Bismuth standard for AAS; 95372_ALDRICH; 25243-76-9; 95372_FLUKA	7440-69-9	16682734	10072	TTDS00336	Serum albumin	N/A	P02768	213	ENSG00000163631	binder
DAP001372	Ebselen	NCGC00024072-03; 1,2-Benzisoselenazol-3(2H)-one, 2-phenyl-; Ebselenum [Latin]; NCGC00178610-01; E 3520; SPBio_001301; MLS001148646; Ebseleno; KBio2_002630; C13H9NOSe; Prestwick3_000740; NCGC00015412-13; CAS-60940-34-3; KBio2_005198; HMS502P13; NINDS_000951; HMS1570C22; NCGC00015412-03; PZ51; BCBcMAP01_000149; PZ 51; NCGC00024072-04; CID3194; ebselen; AC-1124; 2-Phenyl-1,2-benzisoselenazolin-3-one; Spectrum4_000445; RP 60931; CPD000058445; EU-0100541; AC1L1FDW; UNII-40X2P7DPGH; Prestwick0_000740; NCGC00015412-01; Bio2_000542; CHEBI:175507; 2-Phenyl-1,2-benzisoselenazol-3(2H)-one; KBioGR_000062; HMS2052N09; Spectrum3_000799; Lopac0_000541; HMS1989D04; Ebselene; SAM001247071; BSPBio_001342; Harmokisane; BSPBio_002538; Spectrum5_001713; AB00053217; QTL1_000035; HMS1361D04; nchembio.109-comp1; BPBio1_000770; Ebseleno [Spanish]; IDI1_000951; DivK1c_000951; BRD-K29359156-001-06-1; Prestwick2_000740; SMR000058445; Prestwick_1057; DR 3305; I09-1611; Prestwick1_000740; BSPBio_000700; Ebselen [INN]; PZ-51; CHEMBL51085; NSC 639762; CCRIS 3714; Ebselenum; NCGC00015412-06; HMS1791D04; 2-phenyl-1,2-benzoisoselenazol-3(2H)-one; SPI-3005; LS-33527; MLS000028488; KBio3_000124; Bio2_000062; NCGC00024072-05; MLS-0003066.0001; Ebselene [French]; Spectrum2_001441; NCGC00178610-03; 60940-34-3; KBio2_000062; SPI-1005; KBioGR_000830; KBio3_000123; E3520_SIGMA; SPBio_002639; NSC639762; DR-3305; NCGC00178610-02; C042986; KBio3_001758; NCGC00015412-02; KBio1_000951; KBioSS_000062; Lopac-E-3520; IDI1_033812; 2-phenyl-1,2-benzoselenazol-3-one	60940-34-3	3194	10321966	TTDS00336	Serum albumin	N/A	P02768	213	ENSG00000163631	binder
DAP001227	Sodium lauryl sulfate	CP 75424; nchembio.109-comp2; Duponol WAQE; SDS; Finasol osr2; 71736_SIGMA; Incronol SLS; MolPort-003-925-454; Orvus WA Paste; SBB060993; LS-190429; 191490-40-1; Sulfetal L 95; 71736_FLUKA; tvm 474; Steinapol NLS 90; HSDB 1315; Cycloryl 585N; Natriumlaurylsulfat; Conco Sulfate WAG; CID9028; Conco Sulfate WAS; 111726-87-5; AC1N7L82; Perlandrol L; Richonol A; 151-21-3; Sterling WAQ-CH; Berol 452; avirol 118; CID4329331; CHEBI:8984; Stepanol WA-100; Melanol CL 30; Lauyl sodium sulfate; texapon DL; Ultra sulfate sl-1; Lanette Wax-S; Carsonol SLS; NSC 402488; Gardinol; 51222-39-0; Carsonol SLS Special; Hexamol SLS; Conco sulfate WN; S0588; AI3-00356; Detergent 66; Duponal WAQE; Sipon WD; Duponol; Maprofix 563; Duponol methyl; Stepanol WA Paste; Emal 10; Stepanol WA; 71725_SIGMA; Empicol LS 30; Neutrazyme; SDS Running Buffer; Carsonol SLS Paste B; 64441-33-4; CHEBI:23872; Sipex sd; Maprofix WAC-LA; Stepanol ME; Tarapon K 12; 129203-37-8; Duponol WAQ; SLS; CPD-8876; Maprobix NEU; Sulfopon wa 1; I09-0526; Stepanol me dry; Duponol QC; Stepanol methyl; CHEMBL23393; D01045; 237743-45-2; Sipon PD; Montopol La Paste; NCGC00091020-03; DODECYL SULFATE; CID3423265; Emersal 6400; Sipon LS 100; Duponol waqa; 71717_SIGMA; L3771_SIGMA; Maprofix LK; Swascol 3L; Duponol WAQM; Aquarex ME; Perlankrol L; Standapol WAQ; 71729_FLUKA; Stepanol ME Dry AW; 152155-52-7; L6026_SIAL; Stepanol wac; D0996; Rewopol NLS 30; 172826-72-1; C11166; Avirol 118 conc; Empicol LPZ; Duponol WA dry; NCGC00091020-02; EINECS 205-788-1; Perklankrol ESD 60; Melanol CL; Sintapon L; Cycloryl 31; Maprofix NEU; Sipex OP; Avirol 101; Irium; Monagen Y 100; 145269-44-9; 952092-90-9; NALS; Solsol needles; syntapon; 1335-72-4; 12738-53-3; Monogen Y 100; Duponol qx; Stepanol waq; Standapol 112 conc; dupanal; Akyposal SDS; 62862_RIEDEL; Sinnopon LS 95; NCI-C50191; IPC-SDS; Duponol C; WAQE; Aquarex methyl; Laurylsiran sodny; Duponal; Richonol C; AC1MQ93Y; Sipex SP; Dupanol WAQ; 71717_FLUKA; Product no. 161; Stepanol T 28; EMAL O; Product no. 75; L4390_SIGMA; Nikkol SLS; Cycloryl 21; 58640-35-0; 71729_SIGMA; Maprofix WAC; I0352; Conco Sulfate WAN; Sulfotex wa; Trepenol WA; Duponol WA; 61711-39-5; Odoripon Al 95; 71725_FLUKA; 12765-21-8; 05030_FLUKA; Sipex sb; 121481-64-9; Caswell No. 779; UNII-368GB5141J; Sterling wa paste; Standapol wa-ac; Dreft; Duponol Me; Jordanol SL-300; MP SILICA RP 18; LS-880; standapol 112; S-4600; 74433-77-5; L4522_SIGMA; Anticerumen; Sipex UB; Cycloryl 580; Conco sulfate WA; Finasol osr(sub 2); Richonol af; NCGC00091020-01; 8048-56-4; Quolac EX-UB; 62862_SIAL; 57176-54-2; Sinnopon LS 100; Sipon LSB; 156108-01-9; Empicol LX 28; Sodium Laurylsulfate; 303179-49-9; Sipon LS; Emulsifier no. 104; L5750_SIAL; 71726_FLUKA; 436143_SIAL; CCRIS 6272; L4509_SIAL; 8012-56-4; 1334-67-4; Standapol was 100	151-21-3	9028	13348	TTDS00336	Serum albumin	N/A	P02768	213	ENSG00000163631	binder
DAP001225	Gadobenate Dimeglumine	LS-71353; CID197281; Gadolinate(2-), (4-carboxy-5,8,11-tris(carboxymethyl)-1-phenyl-2-oxa-5,8,11-triazatridecan-13-oato(5-)-N5,N8,N11,O4,O5,O8,O11,O13)-, dihydrogen, comp. with 1-deoxy-1-(methylamino)-D-glucitol (1:2); B-19036/7; Gadobenic acid; 113662-23-0 (Parent); HSDB 7546; 2-[2-[2-[bis(2-oxido-2-oxoethyl)amino]ethyl-(2-oxido-2-oxoethyl)amino]ethyl-(2-oxido-2-oxoethyl)amino]-3-phenylmethoxypropanoate; gadolinium(3+); hydron; (2R,3R,4R,5S)-6-(methylamino)hexane-1,2,3,4,5-pentol; 127000-20-8; CHEMBL1200571; E-7155; Gadobenate Dimeglumine [USAN]; AC1OCF5F; AC1L536T; Gadobenate dimeglumine (USAN); B 1903617; Gd-Bopta/dimeg; Multihance; UNII-3Q6PPC19PO; D04283; Meglumine gadobenate (JAN); CID6918204; Multihance Multipack; 2-[carboxymethyl-[2-[2-[carboxymethyl-(2-oxido-2-oxoethyl)amino]ethyl-(2-oxido-2-oxoethyl)amino]ethyl]amino]-3-phenylmethoxypropanoate; gadolinium(3+); (2R,3R,4R,5S)-6-(methylamino)hexane-1,2,3,4,5-pentol; Gadobenate dimeglumine; Gadobenic acid dimeglumine salt; Meglumine gadobenate; Multihance (TN); Dihydrogen ((+-)-4-carboxy-5,8,11-tris(carboxymethyl)-1-phenyl-2-oxa-5,8,11-triazatridecan-13-oato(5-))gadolinate(2-), compound with 1-deoxy-1-(methylamino)-D-glucitol (1:2); DB00743; D-Glucitol, 1-deoxy-1-(methylamino)-, (4-carboxy-5,8,11-tris(carboxymethyl)-1-phenyl-2-oxa-5,8,11-triazatridecan-13-oato(5-)-N(sup 5),N(sup 8),N(sup 11),O(sup 4),O(sup 5),O(sup 8), O(sup 11),O(sup 13)-gadolinate(2-) (2:1); Gd-BOPTA; Gadolinate(2-), (4-carboxy-5,8,11-tris(carboxymethyl)-1-phenyl-2-oxa-5,8,11-triazatridecan-13-oato(5-)-N(sup 5),N(sup 8),N(sup 11),O(sup 4),O(sup 5),O(sup 8),O(sup 11),O(sup 13))-, dihydrogen, comp. with 1-deoxy-1-(methylamino)-D-glucitol (1:2)	113662-23-0	6918204	3733331	TTDS00336	Serum albumin	N/A	P02768	213	ENSG00000163631	binder
DAP001050	Hexachlorophene	Hilo Cat Flea Powder; Hexosan; 2,2'-Methylenebis(3,4,6-trichlorophenol); Hexachlorophenum; KBio2_006483; Esaclorofene; Fesia-sin; M0219; Spectrum4_000573; UN2875; Scrubteam Surgical Spongebrush; TRICHLOROPHENE; NSC49115; Cotofilm; Hexafen; HMS2091J13; Staphene O; Nabac; NCGC00091195-02; Armohex; Exofene; NCGC00091195-01; Hexachlorophene, Pharma; Hexaphene-LV; Acigena; B & b Flea Kontroller for Dogs Only; Fascol; DB00756; Solu-Heks; NSC9887; Surofene; NCGC00091195-03; Bis(3,5,6-trichloro-2-hydroxyphenyl)-methane; Phenol, 2,2'-methylenebis(3,4,6-trichloro)-; HSDB 224; B 32; B32; Nabac 25 ec; 2,2'-Dihydroxy-3,5,6,3',5',6'-hexachlorodiphenylmethane; E-Z Scrub; AT-7; STK377478; Gamophen; Turgex; 3,3',5,5',6,6'-Hexachloro-2,2'-dihydroxydiphenylmethane; AC1L1GAE; Hexachlorophene [INN]; ZINC01530968; MLS001148404; Bis(3,5,6-trichloro-2-hydroxyphenyl)methane; Methane, bis(2,3,5-trichloro-6-hydroxyphenyl); KBio3_001320; Enditch Pet Shampoo; Hexachlorophen; BRN 2064407; Bis-2,3,5-trichloro-6-hydroxyfenylmethan [Czech]; Methylenebis(3,4,6-trichlorophenol); B 32 (VAN); HMS1920D07; Spectrum2_001105; Spectrum5_000792; Septi-Soft; BRD-K99792991-001-02-6; KBioSS_001347; Caswell No. 566; Bis(2-hydroxy-3,5,6-trichlorophenyl)methane; SMR000058356; Hexachlorophene (USP/INN); Gamophene; Blockade Anti Bacterial Finish; Trisophen; 45526_FLUKA; H4625_ALDRICH; BIDD:GT0722; Bis(2,3,5-tric hloro-6-hydroxyphenyl)methane; GERMA-MEDICA "MG"; Steraskin; Spectrum_000867; AT 7; NSC 49115; Bis(2,3,5-trichloro-6-hydroxyphenyl)methane; Phenol, 2,2'-methylenebis[3,4,6-trichloro-; MLS000028433; Hexa-Germ; Hexabalm; KBio1_000630; At-17; Phenol, 2,2'-methylenebis(3,4,6-trichloro-; C13H6Cl6O2; UNII-IWW5FV6NK2; 3,4,6-trichloro-2-[(2,3,5-trichloro-6-hydroxyphenyl)methyl]phenol; Hexachlorophane; Pedigree Dog Shampoo Bar; Ritosept; EINECS 200-733-8; KUC106447N; H4625_SIGMA; EPA Pesticide Chemical Code 044901; Methane, bis(2,3,5-trichloro-6-hydroxyphenyl)-; SBB058855; CHEMBL496; D006582; IDI1_000630; Esaclorofene [DCIT]; KBio2_003915; Bilevon; CCRIS 331; 139411-96-4; Fostril; 2,2'-Methylene bis(3,4,6-trichlorophenol); G-II; HMS501P12; AI3-02372; MLS-0072923.0001; Septofen; Almederm; Hexachlorophene [UN2875] [Poison]; SPBio_001210; Pre-Op; G-Eleven; BIDD:ER0608; PRE-OP II; Hilo Flea Powder; WLN: QR BG DG EG F1R BQ CG EG FG; Germa-Medica; BSPBio_002100; Phisohex (TN); D00859; Hexachlorophenum [INN-Latin]; 2,2'-Methylenebis[3,4,6-trichlorophenol]; SAM002554903; MLS002152906; Hexascrub; Bis-2,3,5-trichloro-6-hydroxyfenylmethan; Dermadex; H3P; Brevity Blue Liquid Bacteriostatic Scouring Cream; Hexachlorofen [Czech]; G-11; 70-30-4; Surgi-Cin; Steral; LS-1597; 2,2'-methanediylbis(3,4,6-trichlorophenol); 45526_RIEDEL; 8054-98-6; Septisol; Distodin; Surgi-Cen; hexachlorophene; C08039; KBio2_001347; RCRA waste no. U132; Rcra waste number U132; NINDS_000630; NCGC00091195-04; CID3598; KSC-19-051; Bis-2,3,5-trichlor-6-hydroxyfenylmethan; Hexaclorofeno; Bivelon; Eleven; Phiso-Scrub; Tersaseptic; Hexide; CPD000058356; NCI-C02653; Soy-dome; DivK1c_000630; NCGC00091195-05; Compound G-11; 2,2',3,3',5,5'-Hexachloro-6,6'-dihydroxydiphenylmethane; Thera-Groom Pet Shampoo for Dogs for Veterinary Use Only; Fo stril; MolPort-001-785-865; Fomac; Neosept V; pHisoHex; En-Viron D Concentrated Phenolic Disinfectant; Isobac; Spectrum3_000450; SPECTRUM1500328; KBioGR_001006; 2,2 -Methylene-bis-[3,4,6-trichlorophenol]; Hexaclorofeno [INN-Spanish]; Brevity Blue Liquid Sanitizing Scouring Cream; Hexachlorofen; Phisodan; Hexophene; Ster-zac	70-30-4	3598	149191	TTDS00058	Glutamate dehydrogenase	N/A	Q9NGT0	N/A	N/A	inhibitor
DAP000165	Chloroquine	(+)-Chloroquine; Chingamin; Artrichin; CQ; Trochin; KBio2_003160; Nivaquine B; KBioGR_000778; Heliopar; (R)-(-)-Chloroquine; IDI1_000404; Chloroquinum [INN-Latin]; Nivachine; Bemasulph; Reumachlor; Roquine; 58175-87-4; Sanoquin; CCRIS 3439; Chloroquine, D-; Ipsen 225; BRN 0482809; Elestol; LS-141726; EINECS 200-191-2; NSC 187208; Chloroquine (USP/INN); UNII-886U3H6UFF; Gontochin phosphate; BSPBio_000595; Chloroquine Bis-Phosphoric Acid; nchembio.215-comp4; Prestwick0_000548; Amokin; Ronaquine; Chloroquine [USAN:INN:BAN]; NSC187208; Clorochina [DCIT]; Quinercyl; NSC14050; NCGC00015256-04; CHEMBL76; AC1L1EB8; Malaquin; Aralen; ( -)-Chloroquine; 7-Chloro-4-[[4-(diethylamino)-1-methylbutyl]amino]quinoline; Silbesan; Klorokin; Solprina; Resochen; Spectrum2_000127; Chloroquinum; KBio1_000404; Spectrum3_000341; Spectrum4_000279; Chloroquine phosphate; Bemaphate; Bemaco; Bipiquin; Benaquin; Prestwick2_000548; Khingamin; DivK1c_000404; WLN: T66 BNJ EMY1&3N2&2 IG; Chloroquinium; NINDS_000404; 58175-86-3; Spectrum_000132; Chemochin; N4-(7-chloroquinolin-4-yl)-N1,N1-diethylpentane-1,4-diamine; Cocartrit; Gontochin; Cloroquina [INN-Spanish]; nchembio.368-comp8; Chloroquina; Chlorochinum; HMS2090O03; N4-(7-Chloro-4-quinolinyl)-N1,N1-diethyl-1,4-pentanediamine; ST 21; Arechine; Siragan; KBio3_001221; MolMap_000009; Arechin; WIN 244; (-)-Chloroquine; Arolen; SMP2_000034; Chloroin; KBioSS_000592; BPBio1_000655; Lapaquin; SN 6718; AC1Q2ZA7; Delagil; Malaquin (*Diphosphate*); Miniquine; Cloroquina; Chloraquine; BSPBio_002001; DB00608; Resoquine; Cidanchin; 50-63-5; Malaren; Sopaquin; HSDB 3029; nchembio.87-comp17; CID2719; MolPort-001-783-623; Rivoquine; AB00053436; Prestwick1_000548; SPBio_000174; CU-01000012392-2; Ro 01-6014/N2; Capquin; Imagon; 3545-67-3; 7-Chloro-4-((4-(diethylamino)-1-methylbutyl)amino)quinoline; Neochin; Resoquina; Mesylith; 3377 RP opalate; Malarex; Arthrochin; Dichinalex; Tanakan; Avloclor; Tanakene; Tresochin; Chlorochin; Reumaquin; NCGC00162120-01; 56598-66-4; Quinoscan; ST 21 (pharmaceutical); Aralen HCl; C18H26ClN3; Avlochlor; Quingamine; Lopac0_000296; KBio2_000592; C07625; Pfizerquine; AC1Q2ZA8; Resochin; Quinilon; Spectrum5_000707; BRD-A91699651-065-01-1; RP 3377; Quinagamin; Clorochina; RP-3377; Chloroquine (VAN); Chlorquin; Quinagamine; Chloroquin; KBio2_005728; Quinachlor; Prestwick3_000548; SPBio_002516; NCI60_000894; {4-[(7-chloroquinolin-4-yl)amino]pentyl}diethylamine; 54-05-7; SN-7618; D02366; W 7618; Iroquine; CHEBI:3638; Chlorochine; Arequin; Quinoline, 7-chloro-4-(4-diethylamino-1-methyl-butylamino)-; chloroquine	54-05-7	2719	9827	TTDS00058	Glutamate dehydrogenase	N/A	Q9NGT0	N/A	N/A	inhibitor
DCL000681	AdPEDR	N/A	N/A	123683	42698957	TTDC00252	Pigment epithelium-derived factor	EPC-1;PEDF;Serpin-F1	P36955	5176	ENSG00000132386	inhibitor
DAP000141	Ergotamine	Lingraine; AC1L1TTJ; (5'|A)-5'-benzyl-12'-hydroxy-2'-methyl-3',6',18-trioxoergotaman 2,3-dihydroxybutanedioate(2:1); 379-79-3; AC1L1QJJ; CID8223; Ergotaman-3',6',18-trione, 12'-hydroxy-2'-methyl-5'-(phenylmethyl)-, (5'alpha)-; Femergin; Ergotamine, tartrate (2:1) (salt) (8CI); Secupan; KST-1A0172; Secagyn; Ergotamine bitartrate; ETIN; Ergotamine hemitartrate; Gynergen; HSDB 4076; Gotamine tartrate; Ergoton-A; Ergotamine, tartrate (2:1); 113-15-5 (Parent); ERGOTAMINE; Ergate; ERGOTAMINE (SEE ALSO: ERGOTAMINE TARTRATE (CAS 379-79-3)); Ergotartrate; Neo-ergotin; Ergotamine (INN); Ergomar; EINECS 204-023-9; Cornutamine; Avetol; Ambotz113-15-5; Ergotaman-3',6',18-trione, 12'-hydroxy-2'-methyl-5'-(phenylmethyl)-, (5'-alpha)- (9CI); Ergostat; Ergotamina [INN-Spanish]; Cornutamin; LS-564; NSC 95090; 12'-Hydroxy-2'-methyl-5'alpha-(phenylmethyl)ergotaman-3',6',18-trione; EINECS 206-835-9; DB00696; Rigetamin; CID11722266; UNII-PR834Q503T; Ergotamin; D07906; Wigrettes; 113-15-5; Ergotamine tartrate (VAN); CHEBI:4826; ergotamine tartrate; AR-1A6598; BRN 0078890; Ergotaman-3',6',18-trione, 12'-hydroxy-2'-methyl-5'-(phenylmethyl)-, (5'-alpha)-; Ergotaman-3',6',18-trione, 12'-hydroxy-2'-methyl-5'-(phenylmethyl)-, (5alpha)-, (2R,3R)-2,3-dihydroxybutanedioate (2:1); Temigran; Ergotamine [INN:BAN]; HMS2089H22; Lingran; CID9787; Migretamine; Exmigra; Ergotamine tartrate, Avetol, Cornutamin, Ergam, Ergotartrate; 379-79-3 (2:1 tartrate salt); Ergonsvine; NSC 41869; Ergotaman-3',6',18-trione, 12'-hydroxy-2'-methyl-5'-(phenylmethyl)-, (5'alpha)-, (2R,3R)-2,3-dihydroxybutanedioate (2:1) (salt); Medihaler ergotamine; CHEMBL442; Ergam; C33H35N5O5; Ergotaminum [INN-Latin]; CCRIS 487	113-15-5	8223	151355	TTDS00027	Alpha-1 adrenergic receptor	Alpha1-adrenoceptor	N/A	N/A	N/A	agonist
DAP000899	Phenylpropanolamine	Fugoa; KBio2_006719; Dura-Vent; LS-97285; WLN: ZY1&YQR -L; SpecPlus_000934; SPBio_000051; Prestwick0_000324; Cathine [INN]; LS-97461; Spectrum2_000016; Spectrum4_000983; BSPBio_000327; Conex; LS-97462; Dexatrim; Propadrine; C9H13NO; KBioGR_001385; Myminic; (1R,2S)-Norephedrine; 700-65-2; Cathinum; NSC9920; PDSP2_001338; AC1L1IYB; Fansia; BIDD:GT0376; CHEBI:327494; WLN: ZY1&YQR; DEA No. 1230; LS-176795; Rhindecon; Guaipax; d-Norpseudoephedrine; Spectrum5_001156; NSC 17704; NSC 9920; C16719; l-Nor-psi-ephedrine; l-Norephedrine; 134-60-1; Prestwick1_000324; 36393-57-4; LS-97284; Spectrum5_000330; Rhymed; (+)-Norephedrine; L-(-)-Norephedrine; Norephedrine; Cathine; (-)-Norephedrine; Minusine; Prestwick2_000324; Propagest; UNII-33RU150WUN; AB00375975; 492-39-7; D08368; NSC120735; KBioGR_001950; KBio1_000795; Gentab; BPBio1_000361; CID4786; Ami-Tex; dl-Norephedrine; 74530_FLUKA; 282553_ALDRICH; PDSP1_001354; AC1L4QZI; Cathinum [INN-Latin]; NCGC00178157-02; AC1L1UWH; AR-1J0988; 6891-23-2; Vanex; Despec; 37577-07-4; Spectrum2_000516; KBio2_004151; Partuss; .psi.-Norephedrine; UNII-E1L4ZW2F8O; NSC17704; Acutrim; KBio3_002512; (-)-Norephedrin; AC1L1C6K; KBio1_001974; 16960-27-3; SPBio_002248; TAVIST-D; Katine; PDSP1_001349; Spectrum_001103; BRN 3196918; KBio2_001583; USAF CS-6; Phenylpropanolaminum; PDSP1_001348; Mydriatin; Spectrum4_001685; AR-1J0987; KBio3_001778; Phenyldrine; phenylpropanolamine; Prestwick3_000324; C02343; L-(-)-Norephedrine; 1926-74-5; MolPort-001-794-194; NCGC00178157-01; Spectrum3_001706; ULR; L001077; Fugoa Depot; HMS2090P12; CHEMBL136560; 37577-28-9; CID26934; 27818-48-0; KBioSS_001583; PDSP2_001333; (+-)-Norephedrine; BRN 2802895; I01-8924; Nolex; C07911; (+/-)-Norephedrin; SPECTRUM2300253; (+-)-Norephedrin; DivK1c_007030; HSDB 6485; IDI1_000795; Mucron; EINECS 238-900-2; EINECS 207-755-7; MolPort-001-769-340; EINECS 253-014-6; Phenylfenesin; Snaplets; Codimal; AB1001936; BSPBio_003292; d-Nor-psi-ephedrine; 317500_ALDRICH; DB00397; Super Odrinex; SPBio_000471; EINECS 207-754-1; PDSP2_001332; 36393-56-3; MolPort-001-794-233; Phenoxine; Exponcit; D-(+)-Norephedrine; I01-8913; NINDS_000795; MolPort-001-788-006; Norpseudoephedrine; CID162265; 492-41-1; l-Nor-psi-ephedrin; Fansia (TN); psi-Norephedrine; Contuss; Fenilpropanolamina; Phenylpropanolamina; CID10297; (.+-.)-Norephedrine; 14838-15-4; AC1Q59PM; DivK1c_000795; NOREPHEDRINE, (-)-; 48115-38-4; Pseudonorephedrine; EINECS 211-850-9; Cathina; Spectrum3_000889	14838-15-4	26934	10113	TTDS00027	Alpha-1 adrenergic receptor	Alpha1-adrenoceptor	N/A	N/A	N/A	agonist
DAP000135	Carvedilol	Kredex; STK621453; CPD000449280; C24H26N2O4; 2-Propanol, 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-; 72956-09-3; TL8005080; Carvedilolum; NCGC00167832-01; MLS001424092; Spectrum5_001436; KBioGR_001252; CHEMBL723; Carvedilolum [Latin]; Coreg; Bio-0014; 1-(9H-carbazol-4-yloxy)-3-[(2-{[2-(methyloxy)phenyl]oxy}ethyl)amino]propan-2-ol; DB01136; SAM001246736; (+-)-1-Carbazol-4-yloxy)-3-((2-(o-methoxyphenoxy)ethyl)amino)-2-propanol; KBio2_002145; 1-(9H-Carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-2-propanol; carvedilol, (+-)-isomer; SMR000449280; Dilatrend; L001243; Spectrum3_001182; BM-14190; Carvedilol (JAN/USAN/INN); D00255; KBio3_002323; DQ-2466; carvedilol; Spectrum_001665; I06-0064; Coropress; CHEBI:3441; UNII-0K47UL67F2; Eucardic; NCGC00167832-03; LS-121875; SPBio_001885; EG-P042; NCGC00167832-02; I06-1477; MolPort-003-666-814; 2-Propanol, 1-(9H-carbazol-4-yloxy)-3-((2-(2-methoxyphenoxy)ethyl)amino)-, (+-)-; SK&F-105517; Artist; 2-Propanol, 1-(9H-carbazol-4-yloxy)-3-((2-(2-methoxyphenoxy)ethyl)amino)-; HMS2093E12; BM 14190; BM-14.190; DQ 2466; Querto; 1-(9H-carbazol-4-yloxy)-3-[2-(2-methoxyphenoxy)ethylamino]propan-2-ol; MLS000759508; AC1L1E0B; Spectrum2_001673; SAM001247021; HMS2089B09; carvedilol, 14C-labeled; Coropres; 1-(9H-Carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-2-propanol; BM-14190; HMS2051N03; 1-(9H-carbazol-4-yloxy)-3-{[2-(2-methoxyphenoxy)ethyl]amino}propan-2-ol; KBio2_007281; Carvedilol [USAN:INN:BAN:JAN]; AC-1641; Coreg CR; KBio2_004713; HSDB 7044; MLS000758299; carvedilol, (R)-isomer; GlaxoSmithKline brand of carvedilol; SKF 105517; Atlana Pharma brand of carvedilol; carvedilol, (S)-isomer; BM-14-190; Artist (TN); C043211; Coreg (TN); AB1004830; BRD-A10977446-045-01-1; C06875; (+/-)-1-(Carbazol-4-yloxy)-3-[[2-(o-methoxyphenoxy)ethyl]amino]-2-propanol; Spectrum4_000636; CID2585; BRD-A10977446-001-04-8; 107741-96-8; KBioSS_002145; C2260; (+-)-1-(Carbazol-4-yloxy)-3-((2-(o-methoxyphenoxy)ethyl)amino)-2-propanol; Lakeside brand of carvedilol; Dibloc; Roche brand of carvedilol	72956-09-3	2585	189887	TTDS00027	Alpha-1 adrenergic receptor	Alpha1-adrenoceptor	N/A	N/A	N/A	antagonist
DAP000229	Midodrine	C12H18N2O4; CHEMBL1200461; BRD-A79981887-003-05-7; 3092-17-9; Metligene; Midodrina [INN-Spanish]; Midodrinum; 1-(2',5'-Dimethoxyphenyl)-2-glycinamidoethanol hydrochloride; (RS)-N'-(beta-Hydroxy-2,5-dimethoxy-phenethyl)glycinamid; 2-Amino-N-(2-(2,5-dimethoxyphenyl)-2-hyyroxyethyl)acetamide monohydrochloride; D01307; UNII-6YE7PBM15H; Hipertan; Amatine; SMR000058833; 2-amino-N-[2-(2,5-dimethoxyphenyl)-2-hydroxyethyl]acetamide hydrochloride; SPBio_002062; MLS001332568; St. Peter 224; Spectrum5_000962; SPBio_001390; NINDS_000955; SBB066174; Pro-Amatine (TN); DivK1c_000955; Midodrine hydrochloride [USAN:JAN]; CHEBI:31847; C12H18N2O4.HCl; BSPBio_000141; KBioSS_002121; N-[2-(2,5-dimethoxyphenyl)-2-hydroxyethyl]glycinamide; KBio1_000955; St 1085; MLS002154233; A-4020 Linz; LS-8052; NCGC00178238-02; Midodrine HCL; KBioGR_000763; KBio3_002650; EINECS 256-148-3; ProAmatine; (+-)-1-(2',5'-Dimethoxyphenyl)-2-glycinamidoethanol hydrochloride; I06-0865; AC1L2BU9; (+-)-2-Amino-N-(beta-hydroxy-2,5-dimethoxyphenethyl)acetamide monohydrochloride; Spectrum_001641; Prestwick1_000191; DB00211; Spectrum2_001545; Midodrine hydrochloride [USAN]; 42794-76-3 (Parent); MIDODRINE HYDROCHLORIDE; Gutron; DL-N1-(beta-Hydroxy-2,5-dimethoxyphenethyl)glycinamid; LS-8042; 2-Amino-N-(2,5-dimethoxy-beta-hydroxyphenethylacetamide; Alphamine; KBio2_002121; SPECTRUM1503257; Acetamide, 2-amino-N-(beta-hydroxy-2,5-dimethoxyphenethyl)-, monohydrochloride, (+-)-; D08220; 42794-76-3; Acetamide, 2-amino-N-(2-(2,5-dimethoxyphenyl)-2-hydroxyethyl)-; Pro-Amatine; CHEBI:6933; Midodrine (INN); ( -)-Midodrin hydrochloride; HMS1568H03; M8277_SIGMA; Acetamide, 2-amino-N-(2-(2,5-dimethoxyphenyl)-2-hydroxyethyl)-, monohydrochloride, (+-)-; CID18340; CPD000058833; 43218-56-0; 97476-58-9; BPBio1_000157; Midodrine Monohydrochloride; KBio2_004689; BSPBio_003150; Spectrum4_000192; Prestwick2_000191; UNII-59JV96YTXV; HMS1922O03; M8277_FLUKA; MolPort-003-849-221; Midodrine [BAN:INN]; ST-1085; 2-amino-N-[2-(2,5-dimethoxyphenyl)-2-hydroxyethyl]acetamide; Acetamide, 2-amino-N-(beta-hydroxy-2,5-dimethoxyphenethyl)-, hydrochloride; (+-)-Midodrine hydrochloride; ( -)-Midodrine hydrochloride; NCGC00095311-01; LS-174957; N-{2-[2,5-bis(methyloxy)phenyl]-2-hydroxyethyl}glycinamide; ()-1-(2,5-Dimethoxyphenyl)-2-glycinamidoethanol; MLS001332567; 2-Amino-N-(2-(2,5-dimethoxyphenyl)-2-hydroxyethyl)acetamide monohydrochloride; A 4020 Linz; Midodrinum [INN-Latin]; Midamine; Midodrina; 3092-17-9 (mono-hydrochloride); midodrine; TL8002369; 1-(2',5'-Dimethoxyphenyl)-2-glycinamidoethanol; Prestwick0_000191; CID4195; EINECS 255-945-3; C07890; AC1L1HMJ; MolPort-003-666-473; Acetamide, 2-amino-N-(2-(2,5-dimethoxyphenyl)-2-hydroxyethyl)-, monohydrochloride; NCGC00178238-01; [+/-]-1-[2,5-Dimethoxyphenyl]-2-glycinamidoethanol; TS 701; Midodrin; Prestwick3_000191; 2-Amino-N-(2,5-dimethoxy-beta-hydroxyphenethyl)acetamid; Midodrine [INN:BAN]; SAM002564219; IDI1_000955; KBio2_007257; 2-Amino-N-(2,5-dimethoxy-beta-hydroxyphenethyl)acetamide; (+/-)-1-(2,5-Dimethoxyphenyl)-2-glycinamidoethanol; Prestwick_625; Midodrine hydrochloride (JAN/USAN); Spectrum3_001585; AB00053715	133163-28-7	4195	10092	TTDS00027	Alpha-1 adrenergic receptor	Alpha1-adrenoceptor	N/A	N/A	N/A	agonist
DAP000086	Tamsulosin	Tamsulosina [INN-Spanish]; 5-[2-[2-(2-ethoxyphenoxy)ethylamino]propyl]-2-methoxy-benzenesulfonamide; Harnal; 5-[(2R)-2-{[2-(2-ethoxyphenoxy)ethyl]amino}propyl]-2-methoxybenzenesulfonamide; CHEBI:9398; Benzenesulfonamide, 5-(2-((2-(2-ethoxyphenoxy)ethyl)amino)propyl)-2-methoxy-, (R)-; CHEMBL836; FT-0082894; Tamsulosine [INN-French]; Tamsulon; BIDD:GT0261; Tamsolusin; C07124; HMS2090P15; Flomax (TN); Flowmax; TAMSULOSIN; 5-{(2R)-2-[(2-{[2-(ethyloxy)phenyl]oxy}ethyl)amino]propyl}-2-(methyloxy)benzenesulfonamide; LS-31578; Tamsulosine; 106133-20-4; MolPort-003-850-388; 5-(2-((2-(2-ethoxyphenoxy)ethyl)amino)propyl)-2-methoxybenzenesulfonamide; 5-[(2R)-2-[2-(2-ethoxyphenoxy)ethylamino]propyl]-2-methoxybenzenesulfonamide; UNII-G3P28OML5I; Tamsulosinum [INN-Latin]; Tamsulosinum; Tamsulon (TN); Tamsulosin [INN:BAN]; STK626950; DB00706; Flomax; D08560; NCGC00167442-01; Tamsulosin (INN); (R)-5-(2-((2-(2-Ethoxyphenoxy)ethyl)amino)propyl)-2-methoxybenzenesulfonamide; Tamsulosina; CID129211; AC1L2V76; C20H28N2O5S	106133-20-4	129211	668003	TTDS00027	Alpha-1 adrenergic receptor	Alpha1-adrenoceptor	N/A	N/A	N/A	antagonist
DAP000038	Labetalol	Sch-19927; TL8002725; Prestwick0_000277; LS-26936; BRD-A07440155-003-05-6; CHEMBL429; KBioSS_002087; AC-18747; 3-Carboxamido-4-hydroxy-alpha-((1-methyl-3-phenylpropylamino)methyl)benzyl alcohol; CID3869; Albetol; AC1L1GW8; Labetalol [INN:BAN]; 2-Hydroxy-5-(1-hydroxy-2-((1-methyl-3-phenylpropyl)amino)ethyl)benzamide; Spectrum5_001010; BSPBio_000154; Prestwick2_000277; AB00053659; Labetolol; MolPort-003-898-140; IDI1_000474; SBB067266; SPBio_000905; SPBio_002373; Labetalol (INN); AH 5158; EINECS 253-258-3; DivK1c_000474; NINDS_000474; Spectrum_001607; Prestwick3_000277; 36894-69-6; KBio2_007223; Labetalolum [INN-Latin]; AH-5158; KBio2_004655; labetalol; DB00598; 2-hydroxy-5-[1-hydroxy-2-(4-phenylbutan-2-ylamino)ethyl]benzamide; Lopac0_000687; CHEBI:6343; KBio2_002087; HSDB 6537; Ibidomide; BPBio1_000170; Spectrum4_000184; BSPBio_003142; D08106; C07063; NORMOZIDE; UNII-R5H8897N95; Spectrum2_000863; 5-(1-Hydroxy-2-(1-methyl-3-phenylpropylamino)ethyl)salicylamide; Benzamide, 2-hydroxy-5-[1-hydroxy-2-[(1-methyl-3-phenylpropyl)amino]ethyl]-; Spectrum3_001581; NCGC00089800-02; 2-hydroxy-5-{1-hydroxy-2-[(1-methyl-3-phenylpropyl)amino]ethyl}benzamide; L001344; Labetalolum; Benzamide, 2-hydroxy-5-(1-hydroxy-2-((1-methyl-3-phenylpropyl)amino)ethyl)-; KBio3_002642; KBio1_000474; KBioGR_000727; NCGC00015595-06; Prestwick1_000277	36894-69-6	3869	9275	TTDS00027	Alpha-1 adrenergic receptor	Alpha1-adrenoceptor	N/A	N/A	N/A	antagonist
DAP000300	Prazosin	Prazosina; BCBcMAP01_000227; HMS2089G09; Prestwick0_000947; IDI1_002113; Quinazoline, 4-amino-6,7-dimethoxy-2-(4-(2-furoyl)piperazin-1-yl)-; 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)piperazine; Spectrum5_001365; 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl) piperazine; Prazosina [INN-Spanish]; BSPBio_001036; [4-(4-amino-6,7-dimethoxy-quinazolin-2-yl)piperazin-1-yl]-(2-furyl)methanone; Minipress (TN); NCI60_002417; TNP00312; STK301545; KBioSS_000376; CAS-19237-84-4; 1-(3-Amino-6,7-dimethoxy-2- quinazolinyl)-4-(2-furanyl-carbonyl)piperazine hydrochloride; DB00457; C07368; 2-[4-(2-furoyl)piperazin-1-yl]-6,7-dimethoxyquinazolin-4-amine; Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furoyl)-; L000666; Justac; KBioGR_000376; KBio2_002944; BPBio1_001006; 19216-56-9; NCGC00024324-08; Spectrum4_000483; NCGC00016740-01; HMS1990D17; Furazosin; Spectrum_000822; Bio1_000365; NCGC00016740-14; SPBio_001297; Oprea1_314778; NINDS_000375; KBio3_000731; KBioGR_000965; Prazosinum; Prestwick2_000947; KBio2_003870; Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)- (9CI); C19H21N5O4; CHEMBL2; 4-(4-Amino-6,7-dimethoxyquinazolin-2-yl)piperazinyl 2-furyl ketone; BRD-K49111258-001-02-8; KBio2_000376; Prazosine [INN-French]; NCGC00024324-02; IDI1_000375; NCGC00024324-04; AB00053528; [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(furan-2-yl)methanone; prazosin; Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)-; KBio2_005512; BSPBio_002221; Bio1_001343; HMS1362D17; Lentopres; CHEBI:8364; BRD-K49111258-003-05-7; KBio3_000732; SMP1_000063; D08411; Prazosine; BSPBio_000914; HSDB 3298; NCGC00024324-07; NCGC00024324-05; Prazosinum [INN-Latin]; BRN 0768345; TL8001573; CID4893; NCGC00016740-02; NCGC00024324-09; Bio2_000358; AC1L1J6T; [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl](furan-2-yl)methanone; SPBio_003073; 2-(4-(2-Furoyl)piperazin-1-yl)-4-amino-6,7-dimethoxyquinazoline; AKOS000310009; KBio1_000375; CP-12299; EINECS 242-885-8; Tocris-0623; HMS1792D17; KBioSS_001302; [3H]-Prazosin; MolPort-000-891-036; Prazosin [INN:BAN]; NCGC00024324-06; Prazosin (INN); Prestwick3_000947; 5-25-13-00365 (Beilstein Handbook Reference); Spectrum2_001289; LS-140002; Prazosin HCl; Prazocin; Bio1_000854; ZINC00601304; NCGC00016740-03; KBio2_001302; Spectrum3_000551; Bio2_000838; DivK1c_000375; ST075549; Prestwick1_000947; UNII-XM03YJ541D; Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furoyl)- (8CI); KBio3_001721; KBio2_006438	19216-56-9	4893	9572	TTDS00027	Alpha-1 adrenergic receptor	Alpha1-adrenoceptor	N/A	N/A	N/A	antagonist
DCL000369	Bosutinib	xy]-3-quinolinecarbonitrile; K00615a; SKI606; 3-Quinolinecarbonitrile, 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-; 380843-75-4; SKI-606; CHEBI:39112; 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile; AC-2413; ST51054132; C471992; 3-Quinolinecarbonitrile, 4-((2,4-dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methyl-1-piperazinyl)propoxy)-; Bosutinib (USAN); UNII-5018V4AEZ0; I14-1974; PF-5208763; Bosutinib; EC-000.2261; CHEMBL288441; 4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile; CID5328940; 4-((2,4-dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile; SKI 606; AC1NS5P1; D03252; 4-((2,4-dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methyl-1-piperazinyl)propoxy)-3-quinolinecarbonitrile; 4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propo; 380443-75-4	N/A	5328940	26746630	TTDS00350	Proto-oncogene tyrosine-protein kinase ABL1	C-ABL;P150	P42684	27	ENSG00000143322	inhibitor
DAP000474	Adenosine triphosphate	Triphosphaden; 1vjd; nchembio.2007.22-comp5; nchembio.265-comp8; NCGC00163309-01; 34369-07-8; 1y8p; nchembio.94-comp18; 56-65-5; Ado-5'-P-P-P; 1gz3; ZINC12402865; CHEBI:30616; 1r0x; 1vjc; nchembio.135-comp2; Adenylpyrophosphoric acid; AC1L1LHX; 9H-Purin-6-amine, 9-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-.beta.-D-ribofuranosyl]-; 9-beta-D-Arabinofuranosyladenine 5'-triphosphate; Cardenosine; CID5957; Adenosine 5'-(tetrahydrogen triphosphate); Adetol; Glucobasin; Atriphos; EINECS 200-283-2; adenosine-triphosphate; Triphosadenine; Bio1_001384; [[[(2R,3S,4R,5R)-5-(6-Aminopurin-9-yl)-3,4-dihydroxy-oxolan-2-yl]methoxy-hydroxy-phosphoryl]oxy-hydroxy-phosphoryl]oxyphosphonic acid; CHEBI:15422; 3b2q; nchembio.208-comp1; adenosine-5'-triphosphate; CID5461108; Bio1_000406; adenosine 5'-triphosphate(4-); Ara-ATP; nchembio856-comp13; 71800-44-7; 1r10; [[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate; Myotriphos; Bio1_000895; 1xsc; nchembio.266-comp10; Adenosine, 5'-(tetrahydrogen triphosphate); Atipi; 1t44; CHEMBL14249; Triphosphoric acid adenosine ester; -beta-D-ribofuranosyl]-; 51569-41-6; Adenosine 5'-triphosphate; 1gz4; 2hmw; Adenosine triphosphate; 3d2e; 1m83; ATP (nucleotide); Adenosinetriphosphate; Triphosaden; 1mau; Triphosadenine (DCF); 2j9l; Adenosintriphosphorsaeure; bmse000006; nchembio.143-comp2; AC1NUU71; Fosfobion; D08646; 2fgh; Phosphobion; 1yid; 84412-18-0; 16488-07-6; 2e5y; A9788C43-4BC5-46E2-8560-41C5FA7D3AA3; DB00171; ATP; 896506-78-8; 2p0x; NChemBio.2007.9-comp27; MolPort-002-533-479; 9H-purin-6-amine, 9-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]; 1b38; ZINC04261765; [[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-oxidophosphoryl]oxy-oxidophosphoryl] phosphate; Striadyne; adenylpyrophosphate; 2cbz; 1kxp; nchembio.199-comp4; Triadenyl; H4atp; Adenosine 5'-triphosphoric acid; 10168-83-9; Adephos; ZINC18456332; 5'-Atp; ZINC12402864; LS-15176; Adynol; 5-(6-Aminopurin-9-yl)-3,4-dihydroxy-oxolan-2-ylmethoxy-hydroxy-phosphoryloxy-hydroxy-phosphoryl oxyphosphonic acid; 2hmu; 1maw; 2vt3; 1b39; 2p09	56-65-5	5957	3304	TTDS00350	Proto-oncogene tyrosine-protein kinase ABL1	C-ABL;P150	P42684	27	ENSG00000143322	inhibitor
DAP000179	Imatinib	AC-524; 4-[(4-methylpiperazin-1-yl)methyl]-N-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)benzamide; Cgp 57148; 152459-95-5; CHEMBL941; sti-571; I01-1232; nchembio.282-comp6; alpha-(4-Methyl-1-piperazinyl)-3'-((4-(3-pyridyl)-2-pyrimidinyl)amino)-p-tolu-p-toluidide; Imatinib (INN); Glamox; 4-(4-METHYL-PIPERAZIN-1-YLMETHYL)-N-[4-METHYL-3-(4-PYRIDIN-3-YL-PYRIMIDIN-2-YLAMINO)-PHENYL]-BENZAMIDE; Imatinib free base; BRD-K92723993-066-02-9; NCGC00159456-02; CID5291; MolPort-000-883-342; CCRIS 9076; benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-; Imatinib; BIDD:GT0047; N-(3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)-4-methylphenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; AKOS000280662; STK617705; CGP 57148B; nchembio.117-comp23; Benzamide, 4-((4-methyl)-1-piperazinyl)methyl)-N-(4-methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)phenyl)-; AC1L1K0Z; Imatinib [INN:BAN]; EN002706; nchembio.162-comp5; 4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide; LS-182208; DB00619; STI; FT-0083542; 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide methanesulfonate; Kinome_3724; NSC743414; 112GI019; NCGC00159456-04; 4-[(4-methylpiperazin-1-yl)methyl]-N-{4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl}benzamide; 1iep; CHEBI:45783; Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI); nchembio.83-comp14; D08066; Imatinib Methansulfonate; HMS2089D03; 1xbb; UNII-BKJ8M8G5HI; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-phenyl]benzamide; DB03261; NCGC00159456-03; LS-187106; Glamox (TN); STI571; STI 571	152459-95-5	5291	841977	TTDS00350	Proto-oncogene tyrosine-protein kinase ABL1	C-ABL;P150	P42684	27	ENSG00000143322	inhibitor
DAP000004	Dasatinib	302962-49-8; LS-186641; MolPort-003-846-143; EC-000.2122; LS-187773; BCB03_000715; CHEBI:49375; 1N1; UNII-X78UG0A0RN; BMS-354825, Sprycel, BMS354825, Dasatinib; 2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)-N-(2-chloro-6-methylphenyl)thiazole-5-carboxamide; SPRYCEL (TN); nchembio.117-comp11; Sprycel; Dasatinib anhydrous; S1021_Selleck; NSC-732517; CHEMBL1421; LS-187028; N-(2-CHLORO-6-METHYLPHENYL)-2-({6-[4-(2-HYDROXYETHYL)PIPERAZIN-1-YL]-2-METHYLPYRIMIDIN-4-YL}AMINO)-1,3-THIAZOLE-5-CARBOXAMIDE; N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)thiazole-5-carboxamide; FT-0084503; Dasatinib (USAN); CID3062316; N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carboxamide; Kinome_3650; I14-1972; BMS354825; dasatinibum; 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-; AC1MI3ET; BMS 354825; N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide; AC1Q2P0C; D03658; Dasatinib, BMS 354825; EN002710; C488369; nchembio.162-comp4; 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-; (18F)-N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide; DB01254; N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide, monohydrate; Spyrcel; NCGC00181129-01; Dasatinib; BMS-354825; AmbotzLS-1203; nchembio.332-comp1; NSC732517; Dasatinib [USAN]	302962-49-8	3062316	10061134	TTDS00350	Proto-oncogene tyrosine-protein kinase ABL1	C-ABL;P150	P42684	27	ENSG00000143322	inhibitor
DCL000368	AZD0530	4-Quinazolinamine, N-(5-chloro-1,3-benzodioxol-4-yl)-7-(2-(4-methyl-1-piperazinyl)ethoxy)-5-((tetrahydro-2H-pyran-4-yl)oxy)-; 4-(6-Chloro-2,3-methylenedioxyanilino)-7-(2-(4-methylpiperazin-1-yl)ethoxy)-5-tetrahydropyran-4-yloxyquinazoline; AZD0530; N-(5-Chloro-1,3-benzodioxol-4-yl)-7-(2-(4-methylpiperazin-1-yl)ethoxy)-5-(tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine; ST51054135; I14-1980; CHEMBL217092; CID10302451; 379231-04-6; AC-5249; nchembio866-comp19; LS-193231; Saracatinib; AZD-0530; Saracatinib, AZD-0530, AZD0530; 2h8h; AKOS005145757; H8H; S1006_Selleck; CHEBI:47458	N/A	10302451	46512739	TTDS00350	Proto-oncogene tyrosine-protein kinase ABL1	C-ABL;P150	P42684	27	ENSG00000143322	inhibitor
DCL000360	Nilotinib	4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazo; Benzamide, 4-methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-(4-(3-pyridinyl)-2-pyrimidinyl)amino)-; AKOS005063561; Nilotinib; 641571-10-0; 4-Methyl-N-[3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl]-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]benzamide; C498826; CHEBI:52172; CID644241; S1033_Selleck; 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide; NSC747599; 4-Methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide; NIL; CHEMBL255863; nilotinibum; Benzamide, 4-methyl-N-((3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-(4-(3-pyridinyl)-2-pyrimidinyl)amino)-; Benzamide, 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]- (9CI); 4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide; AMN 107; Nilotinib (INN/USAN); AMN-107; 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl]benzamide; AC-647; l-1-yl)-3-(trifluoromethyl)phenyl]benzamide; DB04868; Nilotinib, AMN107, Tasigna; I01-1225; D08953; 4-Methyl-3-(4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-[5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl]benzamide; AMN107; TL8004531; AC1LD8U3; Tasigna; EN002707; EC-000.2344; Tasigna (Novartis); MolPort-003-987-089; benzamide, 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-; Tasigna, AMN-107, Nilotinib; UNII-F41401512X	N/A	N/A	N/A	TTDS00350	Proto-oncogene tyrosine-protein kinase ABL1	C-ABL;P150	P42684	27	ENSG00000143322	inhibitor
DCL000253	TTP889	N/A	N/A	6481192	43070165	TTDC00078	Coagulation factor IX	Christmas factor;Factor IX;Plasma thromboplastin component;PTC	P00740	2158	ENSG00000101981	inhibitor
DCL000212	RB-006	N/A	N/A	N/A	N/A	TTDC00078	Coagulation factor IX	Christmas factor;Factor IX;Plasma thromboplastin component;PTC	P00740	2158	ENSG00000101981	inhibitor
DCL000013	R1295	N/A	N/A	11520239	49684227	TTDS00445	Integrin alpha-4	CD49d;Integrin alpha 4 beta 1;Integrin alpha-IV;Very late antigen 4;VLA-4	P13612	3676	ENSG00000115232	antagonist
DAP001094	Natalizumab	Natalizumab (INN); Natalizumab; Tysabri; D06886; 189261-10-7; Tysabri (TN)	189261-10-7	N/A	49661786	TTDS00445	Integrin alpha-4	CD49d;Integrin alpha 4 beta 1;Integrin alpha-IV;Very late antigen 4;VLA-4	P13612	3676	ENSG00000115232	antibody
DCL000743	CDP323	N/A	N/A	N/A	N/A	TTDS00445	Integrin alpha-4	CD49d;Integrin alpha 4 beta 1;Integrin alpha-IV;Very late antigen 4;VLA-4	P13612	3676	ENSG00000115232	antagonist
DPR000001	GSK683699	N/A	N/A	119	48585079	TTDS00445	Integrin alpha-4	CD49d;Integrin alpha 4 beta 1;Integrin alpha-IV;Very late antigen 4;VLA-4	P13612	3676	ENSG00000115232	binder
DCL000978	SB-683699	SB 683699; (1,1'-Biphenyl)-4-propanoic acid, alpha-((2,6-difluorobenzoyl)amino)-4'-(ethoxymethyl)-2',6'-dimethoxy-, (alphaS)-; 2-[(2,6-difluorobenzoyl)amino]-3-[4-[4-(ethoxymethyl)-2,6-dimethoxy-phenyl]phenyl]propanoic Acid; (1,1'-Biphenyl)-4-propanoic acid, alpha-((2,6-difluorobenzoyl)amino)-4'-(ethoxymethyl)- 2',6'-dimethoxy-, (alphaS)-; 402567-16-2; UNII-OJY3SK9H5F; Firategrast (USAN); CID9935681; Firategrast; D06590; SB-683699	387867-13-2	3038522	48426754	TTDS00445	Integrin alpha-4	CD49d;Integrin alpha 4 beta 1;Integrin alpha-IV;Very late antigen 4;VLA-4	P13612	3676	ENSG00000115232	antagonist
DCL000662	Vedolizmab	N/A	152854-19-8	444305	49740556	TTDS00445	Integrin alpha-4	CD49d;Integrin alpha 4 beta 1;Integrin alpha-IV;Very late antigen 4;VLA-4	P13612	3676	ENSG00000115232	antagonist
DCL000528	Firategrast	SB 683699; (1,1'-Biphenyl)-4-propanoic acid, alpha-((2,6-difluorobenzoyl)amino)-4'-(ethoxymethyl)-2',6'-dimethoxy-, (alphaS)-; 2-[(2,6-difluorobenzoyl)amino]-3-[4-[4-(ethoxymethyl)-2,6-dimethoxy-phenyl]phenyl]propanoic Acid; (1,1'-Biphenyl)-4-propanoic acid, alpha-((2,6-difluorobenzoyl)amino)-4'-(ethoxymethyl)- 2',6'-dimethoxy-, (alphaS)-; 402567-16-2; UNII-OJY3SK9H5F; Firategrast (USAN); CID9935681; Firategrast; D06590; SB-683699	402567-16-2	5310933	47208241	TTDS00445	Integrin alpha-4	CD49d;Integrin alpha 4 beta 1;Integrin alpha-IV;Very late antigen 4;VLA-4	P13612	3676	ENSG00000115232	antagonist
DCL000441	ATL/TV1102	N/A	N/A	N/A	N/A	TTDS00445	Integrin alpha-4	CD49d;Integrin alpha 4 beta 1;Integrin alpha-IV;Very late antigen 4;VLA-4	P13612	3676	ENSG00000115232	binder
DCL000716	Belatacept	Belatacept (USAN/INN); D03222; 706808-37-9; Belatacept	706808-37-9	7099	17397375	TTDC00208	T-cell-specific surface glycoprotein CD28	CD28-S2;TP44	P10747	940	ENSG00000178562	inhibitor
DAP000163	Ethchlorvynol	Ethchlorvinol; DEA No. 2540; Placidyl (TN); LS-102223; Ethclorvynol; Aethyl-chlorvynol; Ethchlorvinyl; Ethchlorvynol (JAN/USP/INN); Serenesil; HSDB 3079; A 71; Roeridorm; AR-1I7766; 3-(beta-Chlorovinyl)-1-pentyn-3-ol; 5-Chloro-3-ethylpent-1-yn-4-en-3-ol; beta-Chlorvinyl ethyl ethynyl carbinol; Ethchlorovynol; AC1NQXZT; Etchlorvinolo; Placidil; Serenil; Alvinol; Etclorvinol; D00704; Serensil; Ethyl beta-chlorovinyl ethynyl carbinol; Ethychlorvynol; 113-18-8; beta-Chlorovinyl ethyl ethynyl carbinol; CHEMBL591; 1-Chloro-3-ethyl-1-penten-4-yn-3-ol; Ethochlorvynol; MolPort-004-285-854; 1-Penten-4-yn-3-ol, 1-chloro-3-ethyl-; Normosan; DB00189; CHEBI:4882; Ethchlorvynolum; NSC 30372; Ethchlorvynolum [INN-Latin]; UNII-6EIM3851UZ; C7H9ClO; Placidyl; C07833; Nromoson; ethchlorvynol; Normoson; Arvynol; CID5281077; BRN 1702245; 1-chloro-3-ethylpent-1-en-4-yn-3-ol; Ethchlorvynol [USAN:INN:BAN]; AC1Q3HC3; (E)-1-chloro-3-ethylpent-1-en-4-yn-3-ol; Etclorvinol [INN-Spanish]; AI3-23721; 1-Chloro-3-ethylpent-1-4-yn-3-ol; Normonson; Nostel; Serensiloline	113-18-8	3281	10035	TTDS00410	Gamma-aminobutyric acid receptor subunit beta-2	GABA(A) receptor subunit beta-2;GABRB2	P47870	2561	ENSG00000145864	antagonist
DAP001006	Rifaximin	CHEMBL1617; Rifaximina [Spanish]; Rifamycin L 105SV; AC-19112; Rifacol; Rifamycin L 105; Rifaximine; Fatroximin; LS-64147; alpha-0817185; LS-178059; 80621-81-4; 2,7-(Epoxypentadeca(1,11,13)trienimino)benzofuro(4,5-e)pyrido(1,2-a)benzimidazole-1,15(2H)-dione, 25-(acetyloxy)-5,6,21,23-tetrahydroxy-27-methoxy-2,4,11,16,20,22,24,26-octamethyl-, (2S-(2R*,16Z,18E,20R*,21R*,22S*,23S*,24S*,25R*,26S*,27R*,28E))-; L 105SV; L 105; Xifaxan; 88747-56-2; DB01220; Ritacol; Normix; Rifaximin [USAN:INN]; Rifaximinum; BRN 3584528; S1790_Selleck; Bio-0556; SMR000466324; Rifaximin; Xifaxan, Rifacol, Fatroximin, Rifaximin; Rifaxin; Flonorm; L 105 (Ansamacrolide antibiotic); Rifamixin; (2S,16Z,18E,20S,21S,22R,23R,24R,25S,26S,27S,28E)-5,6,21,23,25 Pentahydroxy-27-methoxy-2,4,11,16,20,22,24,26-octamethyl-2,7-(epoxypentadeca(1,11,13)trienimino)benzofuro(4,5-e)pyrido(1,2-a)benzimidazole-1,15(2H)-dione, 25-acetate; Rifaxidin; C43H51N3O11; Xifaxsan; Rifaximinum [Latin]; Rifaximine [French]; UNII-L36O5T016N; Lumenax; 4-deoxy-4'-methylpyrido(1',2'-1,2)imidazo(5,4C)rifamycin; Xifaxsan (TN); Lormyx; MLS000759430; 4-Deoxy-4'-methylpyrido(1',2'-1,2)imidazo(5,4-c)rifamycin SV; Rifaximina; Spiraxin; RedActiv; D02554; Rifaximin (USAN/INN)	80621-81-4	6436173	214371	TTDS00226	Plastid RNA polymerase beta-subunit	DNA-directed RNA polymerase beta chain;RNA polymerase beta subunit;RNAP beta subunit;RpoB;Transcriptase beta chain	P21421	N/A	N/A	inhibitor
DAP000717	Ezetimibe	SMR000466334; 1-(4-fluorophenyl)-3(R)-[3-(4-fluorophenyl)-3(S)-hydroxypropyl]-4(S)-(4-hydroxyphenyl)-2-azetidinone; CPD000466334; AC1L442L; MSD brand of ezetimibe; (3R,4S)-1-(p-Fluorophenyl)-3-((3S)-3-(p-fluorophenyl)-3-hydroxypropyl)-4-(p-hydroxyphenyl)-2-azetidinone; AC-1057; (-)-Sch 58235; MolPort-005-938-627; MLS000759443; MK-0653; CHEMBL1138; Essex brand of ezetimibe; Zetia , Ezetrol,  Ezetimibe; STOCK6S-73750; DB00973; 163222-33-1; Zient; Ezetimibe [USAN:INN]; MLS001424125; Merck brand of ezetimibe; Zetia (TN); Ezetimibe (JAN/USAN/INN); Ezetrol; LS-181801; SAM001246623; STK640490; 1-(4-fluorophenyl)-3(R)-[3-(4-fluorophenyl)-3(S)-(4-hydroxyphenyl)-2-azetidione; Zetia; (3R,4S)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)azetidin-2-one; CHEBI:49040; 2-Azetidinone, 1-(4-fluorophenyl)-3-(3-(4-fluorophenyl)-3-hydroxypropyl)-4-(4-hydroxyphenyl)-, (3R-(3alpha(S*),4beta))-; 2-Azetidinone, 1-(4-fluorophenyl)-3-((3S)-3-(4-fluorophenyl)-3-hydroxypropyl)-4-(4-hydroxyphenyl)-, (3R,4S)-; Schering-Plough brand of ezetimibe; Ezetimibe; Sch 58235; HMS2051K16; 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-, (3R,4S)-; SCH58235; Ezedoc; S1655_Selleck; (1-(4-fluorophenyl)-(3R)-(3-(4-fluorophenyl)-(3S)-hydroxypropyl)-(4S)-(4-hydroxyphenyl)-2-azetidinone); C108606; ezetimib; CID150311; SCH-58235; D01966; UNII-EOR26LQQ24; ZINC03810860	163222-33-1	150311	727861	TTDS00328	Niemann-Pick C1-like protein 1	Niemann-Pick C1 Like 1;NPC1L1	Q9UHC9	29881	ENSG00000015520	inhibitor
DCL000969	RTI-336	CHEBI:177830; RTI-336; CHEMBL432878	N/A	N/A	N/A	TTDS00017	Sodium-dependent dopamine transporter	DA transporter;DAT;Dopamine transporter	Q01959	6531	ENSG00000142319	blocker
DCL001032	Vanoxerine	CAS-67469-78-7; NCGC00015300-02; Prestwick3_000386; AR-1B9770; BPBio1_001141; 1-[2-[bis(4-Fluorophenyl)methoxy]ethyl]-4-[3-phenylpropyl]piperazine dihydrochloride; LS-187205; 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine; AKOS003588978; BRD-K32501161-300-03-9; 1-{2-[bis(4-fluorophenyl)methoxy]ethyl}-4-(3-phenylpropyl)piperazine dihydrochloride; NCGC00024581-01; LS-107633; GBR-12909; Vanoxeamine; KBio1_001940; MolPort-003-983-576; GBR 12909 dihydrochloride; NCI60_038175; Piperazine, 1-(2-(bis(4-fluorophenyl)methoxy)ethyl)-4-(3-phenylpropyl)-, dihydrochloride; HMS1569M13; NCGC00015300-01; D052_SIGMA; Lopac0_000446; AC1Q3AML; 1-(2 (Bis(4-fluorophenyl)methoxy)ethyl)-4-(3-phenylpropyl)piperazine di-hcl; NCGC00024581-03; AC1L2XPW; 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine dihydrochloride; CID104920; Gbr 12909; S2171_Selleck; Vanoxerine; Vanoxerina [INN-Spanish]; Prestwick0_000386; AB00053750; BRD-K32501161-001-01-7; 67469-69-6; NCGC00024581-02; Prestwick1_000386; NCGC00093862-01; SpecPlus_000900; UNII-90X28IKH43; CID3455; DivK1c_006996; AC1L1FZ5; Prestwick2_000386; Vanoxerine [INN]; CHEMBL543876; Tocris-0421; GBR-12909 dihydrochloride; BSPBio_000571; Lopac-D-052; D-052; 1-(2-(Bis(p-fluorophenyl)methoxy)ethyl)-4-(3-phenylpropyl)piperazine; Vanoxerinum; MolPort-002-506-333; Vanoxerinum [INN-Latin]; SPBio_002492; EU-0100446; 1-(2-bis-[4-FLUOROPHENYL]-METHOXYETHYL)-4-(3-PHENYL-2-PROPYL)PIPERAZINE; NCGC00015300-07; I-893; CHEMBL281594; Vanoxerina; Prestwick_664; I 893; Biomol-NT_000010; BPBio1_000629; 1-(2-[bis(4-Fluorophenyl)methoxy]ethyl)-4-(3-phenylpropyl)piperazine dihydrochloride; 67469-78-7	67469-78-7	38003	46504818	TTDS00017	Sodium-dependent dopamine transporter	DA transporter;DAT;Dopamine transporter	Q01959	6531	ENSG00000142319	blocker
DAP000024	Methylphenidate	Meridil; Metadate CD; Ritalin LA; C07196; DEA No. 1724; Ritalin-SR; Daytrana (TN); Methylin; Methyl phenidyl acetate; Centredin; EINECS 204-028-6; MolPort-001-779-620; Methylfenidan; Methylphenidate [INN:BAN]; Metilfenidato; alpha-Phenyl-2-piperidineacetic acid methyl ester; Plimasine; 4311/B Ciba; Methyl alpha-phenyl-alpha-2-piperidinylacetate; Methylin ER; Metilfenidato [Italian]; nchembio.2007.55-comp28; Ritalin SR; Phenidylate; Centedein; alpha-Phenyl-alpha-(2-piperidyl)acetic acid methyl ester; methyl phenyl(piperidin-2-yl)acetate; 2-Piperidineacetic acid, alpha-phenyl-, methyl ester; DB00422; .alpha.-Phenyl-2-piperidineacetic acid methyl ester; CHEBI:6887; CHEMBL796; C 4311; Methylphenidate (USAN/INN); Metadate; 2-Piperidineacetic acid, .alpha.-phenyl-, methyl ester; D04999; Methylphenidatum [INN-Latin]; Methyl alpha-phenyl-alpha-(2-piperidyl)acetate; Calocain; AC1L1HJM; methyl 2-phenyl-2-piperidin-2-ylacetate; DB06701; 113-45-1; Metadate ER; Centedrin; Tsentedrin; HSDB 3126; Methylphenidatum; Daytrana; 298-59-9 (hydrochloride); Methyl phenidate; Metilfenidato [INN-Spanish]; LS-565; Methyl (2-phenyl-2-(2-piperidyl)acetate); Methylphenidan; Methyl phenidylacetate; Methylofenidan; PMS-Methylphenidate; METHYLPHENIDATE (SEE ALSO: METHYLPHENIDATE HYDROCHLORIDE, CAS 298-59-9, NTPNO 10266-R); CID4158; Ritaline; L001307; MethyPatch; Riphenidate; Methylphen; methylphenidate; UNII-207ZZ9QZ49; NCI-C56280; Concerta; d-methylphenidate HCl; Ritcher works; Ritalin	113-45-1	4158	7854358	TTDS00017	Sodium-dependent dopamine transporter	DA transporter;DAT;Dopamine transporter	Q01959	6531	ENSG00000142319	blocker
DAP000568	Fomepizole	BRN 0105204; SBB004402; CHEMBL1308; 4-Methylpyrazol; D00707; Antizol; AC1Q2OKA; AC1L1FV5; ZINC00897288; NCGC00015646-01; NCGC00015646-03; NCGC00162231-01; 222569_ALDRICH; 4-methylpyrazole monohydrochloride; M0774; Paladin brand of fomepizole; fomepizole; Fomepizole [USAN:INN]; Fomepizol [INN-Spanish]; PYRAZOLE, 4-METHYL-; C4H6N2; MLS002153469; Fomepizol; C07837; CHEBI:5141; 1H-Pyrazole, 4-methyl-; TL8005172; AC1Q2OK9; DB01213; CID3406; STK256626; AKOS000265586; Fomepizolum [INN-Latin]; Antizol (TN); LS-128524; C010238; SMR000326764; Orphan brand of fomepizole; 7554-65-6; 4-Methyl-1H-pyrazole; EINECS 231-445-0; I11-0350; S14-0570; SMR000059088; Lopac-M-1387; 5-23-05-00031 (Beilstein Handbook Reference); 4-Methylpyrazole; AC-4833; UNII-83LCM6L2BY; Fomepizole (USAN/INN); MLS001335923; Lopac0_000723; CPD0-1652; Fomepizolum	7554-65-6	3406	10039	TTDS00060	Alcohol dehydrogenase	Aldehyde reductase;Aldo-keto reductase family 1 member A1	P14550	10327	ENSG00000117448	inhibitor
DPR000117	UCL-2000 and butabindide	N/A	185213-03-0	N/A	N/A	TTDC00082	Cholecystokinin type A receptor	CCK-A receptor;CCK-AR	P32238	886	ENSG00000163394	agonist
DCL000814	GI-181771	N/A	N/A	N/A	N/A	TTDC00082	Cholecystokinin type A receptor	CCK-A receptor;CCK-AR	P32238	886	ENSG00000163394	agonist
DCL000119	GI 181771	N/A	N/A	N/A	N/A	TTDC00082	Cholecystokinin type A receptor	CCK-A receptor;CCK-AR	P32238	886	ENSG00000163394	agonist
DPR000091	PD-170292	PD-170292; CHEMBL14153; CHEBI:112961	N/A	10479502	49684247	TTDC00082	Cholecystokinin type A receptor	CCK-A receptor;CCK-AR	P32238	886	ENSG00000163394	agonist
DCL000103	Dexloxiglumide	(4R)-4-[(3,4-dichlorobenzoyl)amino]-5-[3-methoxypropyl(pentyl)amino]-5-oxopentanoic acid; 119817-90-2; AC1L24A8; Dexloxiglumida [INN-Spanish]; Dexloxiglumidum [INN-Latin]; Dexloxiglumide; CHEMBL550781; CID65937; Dexloxiglumidum; CR-2017; AKOS000279054; Dexloxiglumida; AC1Q3MXI; C103490; n2-(3,4-dichlorobenzoyl)-n1-(3-methoxypropyl)-n1-pentyl-d-a-glutamine	119817-90-2	65937	12014679	TTDC00082	Cholecystokinin type A receptor	CCK-A receptor;CCK-AR	P32238	886	ENSG00000163394	antagonist
DPR000005	A-71378	Desamino-tyr(SO3H)-nle-gly-trp-nle-(N-methyl)asp-phe-NH2; CHEMBL269016; AC1OCF35; A71378; CHEBI:262879; A 71378; CID6918156; (3S)-4-[[(2R)-1-[2-[[(2S)-2-[[1H-indol-3-ylmethyl-[2-[[(2S)-2-[3-(4-sulfooxyphenyl)propanoylamino]hexanoyl]amino]acetyl]carbamoyl]amino]hexanoyl]carbamoyl]phenyl]propan-2-yl]amino]-3-(methylamino)-4-oxobutanoic acid; A-71378; L-Phenylalaninamide, N-(1-oxo-3-(4-(sulfooxy)phenyl)propyl)-L-norleucylglycyl-L-tryptophyl-L-norleucyl-N-methyl-L-alpha-aspartyl-; 127902-33-4; AC1NUR8P; (3S)-4-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-[[(2S)-2-[[(2S)-3-(1H-indol-3-yl)-2-[[2-[[(2S)-2-[3-(4-sulfooxyphenyl)propanoylamino]hexanoyl]amino]acetyl]amino]propanoyl]amino]hexanoyl]-methylamino]-4-oxobutanoic acid; CID5489450	127902-33-4	6918156	12014495	TTDC00082	Cholecystokinin type A receptor	CCK-A receptor;CCK-AR	P32238	886	ENSG00000163394	agonist
DPR000006	A-74498	N/A	N/A	N/A	N/A	TTDC00082	Cholecystokinin type A receptor	CCK-A receptor;CCK-AR	P32238	886	ENSG00000163394	agonist
DCL000244	Tarazepide	D02710; CID10343641; Tarazepide (INN); Tarazepide; 141374-81-4	141374-81-4	65993	17396877	TTDC00082	Cholecystokinin type A receptor	CCK-A receptor;CCK-AR	P32238	886	ENSG00000163394	antagonist
DCL000149	Lintitript	UNII-3YFV00531K; PDSP2_000932; SR-27897B; AC1L3TXG; PDSP1_000946; CHEMBL249973; C20H14ClN3O3S; SR 27897B; 1-((2-(4-(2-Chlorophenyl)thiazol-2-yl)aminocarbonyl)indolyl)acetic acid; LS-172957; NCGC00167729-01; 136381-85-6; SR-27897; SR 27897; 2-((4-(o-Chlorophenyl)-2-thiazolyl)carbamoyl)indole-1-acetic acid; SR27897; CID122077; 1H-Indole-1-acetic acid, 2-(((4-(2-chlorophenyl)-2-thiazolyl)amino)carbonyl)-; 2-[2-[[4-(2-chlorophenyl)-1,3-thiazol-2-yl]carbamoyl]indol-1-yl]acetic acid; L000575; BRD-K35629949-001-01-2; Lintitript	136381-85-6	122077	698591	TTDC00082	Cholecystokinin type A receptor	CCK-A receptor;CCK-AR	P32238	886	ENSG00000163394	antagonist
DPR000015	AR-R-1589	N/A	N/A	N/A	N/A	TTDC00082	Cholecystokinin type A receptor	CCK-A receptor;CCK-AR	P32238	886	ENSG00000163394	agonist
DPR000051	GG-8573	N/A	N/A	N/A	N/A	TTDC00082	Cholecystokinin type A receptor	CCK-A receptor;CCK-AR	P32238	886	ENSG00000163394	agonist
DPR000046	FPL-14294	4-(Sulfoxy)phenylacetyl-methionyl-glycyl-trptophyl-methionyl-aspartyl-methylphenylalaninehydrazide; L-Phenylalaninamide, N-((4-(sulfooxy)phenyl)acetyl)-L-methionylglycyl-L-tryptophyl-L-methionyl-L-alpha-aspartyl-nalpha-methyl-; 154132-95-3; Hpa(SO3H)-met-gly-trp-met-asp-mephe-NH2NH3; (3S)-3-[[(2S)-2-[[(2S)-3-(1H-indol-3-yl)-2-[[2-[[(2S)-4-methylsulfanyl-2-[[2-(4-sulfooxyphenyl)acetyl]amino]butanoyl]amino]acetyl]amino]propanoyl]amino]-4-methylsulfanylbutanoyl]amino]-4-[[(2S)-2-(methylamino)-3-phenylpropanoyl]amino]-4-oxobutanoic acid; AC1L31X9; CID132969; Fpl-14294; 4-(Sulfoxy)-phenylacetyl(mephe6)cck-6; Fpl 14294	154132-95-3	132969	709278	TTDC00082	Cholecystokinin type A receptor	CCK-A receptor;CCK-AR	P32238	886	ENSG00000163394	agonist
DCL000478	AZD6918	N/A	N/A	N/A	N/A	TTDC00318	High affinity nerve growth factor receptor	NGF-trk receptor type A;NTRK1;P140-TrkA;TRK1 transforming tyrosine kinase protein;Trk-A	P04629	4914	ENSG00000198400	inhibitor
DAP001395	Lestaurtinib	156256-78-9; Lestaurtinib; CEP 701; ZINC03781738; CEP-701; KT-5555; NCGC00168772-01; Lestaurtinib (USAN/INN); 111358-88-4; UNII-DO989GC5D1; CHEBI:697145; CHEMBL603469; A 1544750; KT 5555; 9,12-Epoxy-1H-diindolo(1,2,3-fg:3',2',1'-kl)pyrrolo(3,4-i)(1,6)benzodiazocin-1-one, 2,3,9,10,11,12-hexahydro-10-hydroxy-10-(hydroxymethyl)-9-methyl-, (9S-(9alpha,10beta,12alpha))-; 9,12-Epoxy-1H-diindolo(1,2,3-fg:3',2',1'-kl)pyrrolo(3,4-i)(1,6)benzodiazocin-1-one, 2,3,9,10,11,12-hexahydro-10-hydroxy-10-(hydroxymethyl)-9-methyl-, (9S,10S,12R)-; SP 924; D04696; SPM-924; KT5555; AC-5243; MolPort-003-848-372	111358-88-4	126565	703268	TTDC00318	High affinity nerve growth factor receptor	NGF-trk receptor type A;NTRK1;P140-TrkA;TRK1 transforming tyrosine kinase protein;Trk-A	P04629	4914	ENSG00000198400	inhibitor
DAP000876	Menthol	(1r,2s,5r)-(-)-menthol; M0321; D008610; Menthol, trans-1,3,trans-1,4-; NSC 62788; rac-Menthol; LS-57201; Menthol, (1alpha,2beta,5alpha)-Isomer; dl-Menthol; Menthol, trans-1,3,cis-1,4-; Menthol, cis-1,3,trans-1,4-; Hexahydrothymol; NCGC00159382-02; d-Menthol; BRN 3194263; 89-78-1; 6C6A4A8C-A054-468C-A1F0-F29E39838CF2; Menthol, (.+/-.)-; (+/-)-Menthol; LS-89531; NCI-C50000; CCRIS 9231; MolPort-001-793-392; nchembio862-comp1; Racementol [INN-Spanish]; MENTHOL; NSC62788; Levomentholum; D-p-Menthan-3-ol; HMS1922G13; NCGC00164247-01; l-Menthol (natural); l-Menthol; Levomenthol; Levomenthol [INN:BAN]; NSC2603; UNII-L7T10EIP3A; (-)-menthol; HMS2092L14; SPECTRUM1503134; 20747-49-3; CHEBI:545611; BRN 1902288; KBio3_002562; CHEBI:15409; 15785_SIAL; AI3-08161; 551376_FLUKA; MolPort-000-849-729; Menthol racemique [French]; (1S,2R,5R)-(+)-Isomenthol; Menthol (USP); Headache crystals; MENTHOL, (+)-neo-; (+)-p-Menthan-3-ol; EINECS 201-939-0; AC1L1B2E; MLS002207256; W266523_ALDRICH; (+-)-(1R*,3R*,4S*)-Menthol; (1S,2R,5S)-Menthol; l-(-)-Menthol; D04849; 588733_ALDRICH; Racementhol [INN:BAN]; Neoisomenthol; ()-Menthol; KBio2_005921; LS-89533; Spectrum2_000855; l-Menthol (TN); EINECS 218-690-9; AC1Q1NQ2; cis-1,3-trans-1,4-(+-)-menthol; Tra-kill tracheal mite killer; Racementholum; p-Menthan-3-ol; 63975-60-0; Racemic menthol; d,l-Menthol; 5-Methyl-2-(1-methylethyl)cyclohexanol; (R)-(-)-Menthol; (1R,2S,5R)-Menthol; UNII-BZ1R15MTK7; Levomentholum [INN-Latin]; 5-methyl-2-propan-2-ylcyclohexan-1-ol; 5-methyl-2-(propan-2-yl)cyclohexanol; Menthol, (1S,3S,4R)-(+)-; 2-Isopropyl-5-methylcyclohexanol; Menthacamphor; I14-7371; (+)-Neo-menthol; UNII-YS08XHA860; Menthol solution; dl-Menthol (JP15); --MENTHOL; AC1L28FR; CCRIS 3728; LMPR0102090001; Menthol, (1R,3R,4S)-(-)-; 15356-60-2; EPA Pesticide Chemical Code 051601; NINDS_000820; NSC 2603; NOOLISFMXDJSKH-KXUCPTDWSA-; I06-1216; SDCCGMLS-0066659.P001; DivK1c_000820; LS-2353; Cyclohexanol, 2-isopropyl-5-methyl-; D00064; BB_NC-0057; dl-3-p-Menthanol; 551376_ALDRICH; 4-Isopropyl-1-methylcyclohexan-3-ol; BSPBio_003062; 19863P; Spectrum3_001561; (-)-Menthyl alcohol; CHEMBL470670; 15785_RIEDEL; CID1254; Robitussin Cough Drops; Menthol racemique; (&#8722;)-Menthol; ZINC01482164; NCGC00164247-02; EINECS 216-074-4; EINECS 207-724-8; Racementhol; Fisherman's friend lozenges (TN); Menthomenthol; Fisherman's friend lozenges; EINECS 239-387-8; Menthol, cis-1,3,cis-1,4-; C10H20O; HSDB 5662; 613290_ALDRICH; CCRIS 4666; (1S, 2S, 5R)-(+)-Neomenthol; LS-886; WLN: L6TJ AY1&1 DQ D1 -L; AR-1J3337; AC1Q2QQM; Menthol natural, brazilian; Menthol, dl-; Menthol natural; NOOLISFMXDJSKH-KXUCPTDWBX; AKOS000119740; d-Neomenthol; Spectrum5_001060; cis-1 ,3-trans-1,4-(+-)-menthol; (1R)-(-)-Menthol; Menthol, l-; DB00825; U.S.P. Menthol; M2772_SIAL; 63660_FLUKA; 491-02-1; Racementol; 63670_ALDRICH; HMS502I22; 98167-53-4; C00400; (+-)-Menthol; 613290_FLUKA; 15356-70-4; KBio1_000820; SPBio_000869; (L)-MENTHOL; KBioSS_000785; (1S,2R,5S)-(+)-Menthol; RACEMIC MENTHOL U.S.P.; Menthyl alcohol; WLN: L6TJ AY1&1 BQ D1; Peppermint camphor; CHEMBL256087; CCRIS 375; HSDB 593; (1R,3R,4S)-(-)-MENTHOL; EINECS 239-388-3; Menthol racemic; Spectrum_000305; 1490-04-6; IDI1_000820; (-)-p-Menthan-3-ol; W266507_ALDRICH; 2216-51-5; AI3-52408; NCGC00159382-03; (+/-)-p-Menthan-3-ol; KBio2_000785; Racementholum [INN-Latin]; D-(-)-Menthol; l-Menthol (JP15); Menthol (VAN); 3-p-Menthol; SMR001306785; KBio2_003353; (-)-trans-p-Menthan-cis-ol; STK802468; W266590_ALDRICH; 5-Methyl-2-(1-methylethyl)-cyclohexanol; M0545; 63670_FLUKA; FEMA No. 2665; D04918; (-)-(1R,3R,4S)-Menthol; CID16666; Caswell No. 540	2216-51-5	16666	3690	TTDS00465	Transient receptor potential cation channel subfamily A member 1	ANKTM1;Ankyrin-like with transmembrane domains protein 1;Transformation-sensitive protein p120;TRPA1	O75762	8989	ENSG00000104321	activator
DPR000188	XL475	N/A	N/A	N/A	N/A	TTDR01440	TGR5	G-protein coupled bile acid receptor 1;G-protein coupled receptor GPCR19;hGPCR19;Membrane-type receptor for bile acids;M-BAR;hBG37;BG37;GPBAR1	Q8TDU6	151306	ENSG00000179921	agonist
DAP000260	Pentagastrin	Pentagastrin (JAN/USAN/INN); AC1L9FJD; Peptavlon; CID444007; (3S)-4-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-[[(2S)-2-[[(2S)-3-(1H-indol-3-yl)-2-[3-(2-methylpropoxycarbonylamino)propanoylamino]propanoyl]amino]-4-methylsulfanylbutanoyl]amino]-4-oxobutanoic acid; DB00183; Peptavlon (TN); D01631	5534-95-2	444007	7848694	TTDS00043	Gastrin/cholecystokinin type B receptor	CCK-B receptor;CCK-BR	P32239	887	ENSG00000110148	agonist
DAP000961	Ceruletide	CCRIS 3063; LS-48549; Cerulein; 17650-98-5; Ceruletide; UNII-888Y08971B; CHEBI:59219; D03442; Caerulein; 5-Oxo-L-prolyl-L-glutaminyl-L-alpha-aspartyl-O-sulfo-L-tyrosyl-L-threonylglycyl-L-tryptophyl-L-methionyl-L-alpha-aspartyl-L-phenylalaninamide; Ceruletide [USAN:INN:BAN]; 5-Oxo-L-prolyl-L-glutaminyl-L-aspartyl-L-tyrosyl-L-threonylglycyl-L-tryptophyl-L-methionyl-L-aspartylphenyl-L-alaninamide 4-(hydrogen sulfate) (ester); Ceruletidum [INN-Latin]; Ceruletida [INN-Spanish]; 5-oxo-L-prolyl-L-glutaminyl-L-a-aspartyl-O-sulfo-L-tyrosyl-L-threonylglycyl-L-tryptophyl-L-methionyl-L-a-aspartyl-L-phenylalaninamide; Ceruletidum; Ceruletide (USAN/INN); Ceruletida	17650-98-5	168399	745880	TTDS00043	Gastrin/cholecystokinin type B receptor	CCK-B receptor;CCK-BR	P32239	887	ENSG00000110148	agonist
DPR000091	PD-170292	PD-170292; CHEMBL14153; CHEBI:112961	N/A	10479502	49684247	TTDS00043	Gastrin/cholecystokinin type B receptor	CCK-B receptor;CCK-BR	P32239	887	ENSG00000110148	agonist
DPR000051	GG-8573	N/A	N/A	N/A	N/A	TTDS00043	Gastrin/cholecystokinin type B receptor	CCK-B receptor;CCK-BR	P32239	887	ENSG00000110148	antagonist
DCL001237	S-555739	N/A	N/A	N/A	N/A	TTDR00802	Prostaglandin D2 receptor	PGD receptor;Prostanoid DP receptor	Q13258	5729	ENSG00000168229	antagonist
DPR000067	Laropiprant+niacin	N/A	571170-77-9	N/A	N/A	TTDR00802	Prostaglandin D2 receptor	PGD receptor;Prostanoid DP receptor	Q13258	5729	ENSG00000168229	antagonist
DCL001059	iCo-007	N/A	N/A	N/A	N/A	TTDC00310	mRNA of RAF proto-oncogene serine/threonine-protein kinase	CRaf;C-RAF;Raf kinase;Raf-1	P04049	5894	ENSG00000132155	antisense
DAP000206	Phenformin	Phenforminum; Fenormin; MolPort-001-792-517; KBio2_002392; AC1Q4YZM; Retardo; 4-12-00-02472 (Beilstein Handbook Reference); Phenformine [INN-French]; LS-569; Prestwick0_000179; N'-beta-Fenetilformamidiniliminourea [Italian]; C07673; CHEMBL170988; AC1L1QL7; NCGC00016543-01; Phenformine; KBio2_007528; D08351; BRD-K11399644-003-03-0; Fenformina [INN-Spanish]; 1-(diaminomethylidene)-2-phenethylguanidine; Fenformina; Phenformin (BAN); Fenformin; BRN 1977317; Prestwick1_000179; Pedg; SPBio_001998; STK635703; N'-beta-Fenetilformamidiniliminourea; DB Comb; BSPBio_000077; Fenfoduron; Dibiraf; Feguanide; Dipar; Phenformix; N-Phenethylbiguanide hydrochloride; UNII-DD5K7529CE; Cronoformin; Phenformine HCl; PHENFORMIN; DB00914; NCGC00016543-02; CCRIS 500; Phenethyldiguanide; N'-beta-Phenethylformamidinylliminourea; Glukopostin; Prestwick3_000179; beta-Phenethylbiguanide; Lentobetic; Meltrol-50; PHENFORMIN (SEE ALSO PHENFORMIN HYDROCHLORIDE 834-28-6); Debeone; Normoglucina; DBI; HSDB 3154; beta-PEBG; Dibotin; Phenformin [INN:BAN]; Azucaps; KBioSS_002397; EINECS 204-057-4; KBio3_002871; beta-Phenethybiguanide; Phenoformine hydrochloride; I14-13372; CID8249; Glyphen; Biguanide, 1-phenethyl-; W 32; 1-Phenethylbiguanide; DBI monohydrochloride; cMAP_000038; Debinyl; N-(2-Phenylethyl)imidodicarbonimidic diamide; Db-retard; Diabis; KBioGR_002392; Imidodicarbonimidic diamide, N-(2-phenylethyl)-; ZINC14768667; Phenylethylbiguanide; Dibein; BPBio1_000085; KBio2_004960; Phenforminum [INN-Latin]; D Bretard; NCI-C01741; 114-86-3; CHEBI:382509; Meltrol; CAS-834-28-6; Insoral; Prestwick2_000179	114-86-3	8249	151385	TTDS00209	AMP-activated protein kinase	5'AMP-activated protein kinase;AMPK	N/A	N/A	N/A	activator
DCL000084	CGX-1160	N/A	N/A	6321351	47885128	TTDC00144	Neurotensin receptor type 1	High-affinity levocabastine-insensitive neurotensin receptor;NTR subtype 1;NTR1;NT-R1;NT-R-1;NTRH	P30989	4923	ENSG00000101188	agonist
DCL000163	Meclinertant	SR48692; Meclinertant; PDSP2_000637; 2-((1-(7-Chloro-4-quinolinyl)-5-(2,6-dimethoxyphenyl)pyrazol-3-yl)carbonylamino)tricyclo(3.3.1.1.(3.7))decan-2-carboxylic acid; CID119192; SR-48692; 2-(((1-(7-Chloroquinolin-4-yl)-5-(2,6-dimethoxyphenyl)-1H-pyrazol-3-yl)carbonyl)amino)tricyclo(3.3.1.1(sup 3,7) )decane-2-carboxylic acid; 2-[[1-(7-chloroquinolin-4-yl)-5-(2,6-dimethoxyphenyl)pyrazole-3-carbonyl]amino]adamantane-2-carboxylic acid; 146362-70-1; L001448; CHEBI:557258; AC1L3OCW; SR 48692; LS-184738; Reminertant; CHEMBL506981; PDSP1_000642; Tricyclo(3.3.1.13,7)decane-2-carboxylic acid, 2-(((1-(7-chloro-4-quinolinyl)-5-(2,6-dimethoxyphenyl)-1H-pyrazol-3-yl)carbonyl)amino)-	N/A	119192	12014763	TTDC00144	Neurotensin receptor type 1	High-affinity levocabastine-insensitive neurotensin receptor;NTR subtype 1;NTR1;NT-R1;NT-R-1;NTRH	P30989	4923	ENSG00000101188	antagonist
DAP000276	Bexarotene	4-[1-(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalen-2-yl)ethenyl]benzoic acid; CHEBI:50859; Targret; 153559-49-0; LG100069; LGD-1069; LG 1069; p-(1-(5,6,7,8-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthyl)vinyl)benzoic acid; BIDD:PXR0021; HMS2089L14; Targretin (TN); SBB067189; LS-38306; 3-methyl-TTNEB; CID82146; Bexarotene; AC1L32UG; 4-(1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethenyl)benzoic acid; Benzoic acid, 4-(1-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)ethenyl)-; LG-100069; 4-[1-3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthaleneyl)vinyl]benzene carboxylic acid; Targretyn; HSDB 7453; CHEMBL1023; bexaroteno; Ligand brand of bexarotene; Targrexin; LGD1069; Bexarotene [USAN]; bexarotenum; 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)vinyl]benzoic acid; 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)ethenyl]benzoic acid; Targretin; Bexarotene (USAN/INN); DB00307; LG1069; I14-1941; MolPort-003-845-030; Elan brand of bexarotene; LG69 compound; Targretin-gel; NCGC00181016-01; 4-(1-(5,6,7,8-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)ethenyl)benzoic acid; UNII-A61RXM4375; 9RA; LGD 1069; C095105; D03106	153559-49-0	82146	659076	TTDS00354	Retinoid X receptor	RXR	N/A	N/A	N/A	agonist
DAP001543	Vitamin A	AC1Q7BU9; Alphasterol; all-trans-Vitamin A1; 1406-67-3; NCGC00091784-01; M.V.C. 9+3; 95146_SIGMA; Apexol; Retinol solution; Apostavit; Retinol, all-trans-; Homagenets aorl; Vitamin A alcohol, all-trans-; 95146_FLUKA; Ophthalamin; AC1L9HU3; 68-26-8; Myvpack; Vi-a; Retinolum; Vitamin- A1; [11,12-3H]-Retinol; 2,4,6,8-Nonatetraen-1-ol, 3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-, (all-E)-; All-trans retinol; CCRIS 5444; Ro-a-vit; Spectrum5_001997; Epiteliol; Aquasynth; All Trans Retinol; NCGC00091784-02; AC-11701; A-Mulsal; SMP2_000102; D014801; Super A; Vitamin-?A alcohol; NSC122759; Vitamin A1, all-trans-; LS-1578; A-Sol; Homagenets Aoral; Vitamin A1 alcohol; retinol; Vitamin- A alcohol solution; R7632_SIGMA; 95144_SIGMA; Retrovitamin A; 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclchexen-1-yl)-2,4,6,8-nonatetraen-1-ol; .alpha.lin; Vogan-Neu; Alcovit A; Retinolo [DCIT]; Avita; 4-06-00-04133 (Beilstein Handbook Reference); 5979-23-7; Bentavit A; trans-retinol; Anatola A; UNII-81G40H8B0T; Prepalin; Aoral; Dofsol; Axerophthol; Vogan-nu; NCGC00091784-06; all-trans-Retinol; trans-Retinol acid (Vitamin A); Disatabs Tabs; Mvc Plus; Lard Factor; NCGC00091784-05; Vitamin-?A1; Vogan; CID445354; Vi-Dom-A; Vitpex; MolPort-001-785-962; Retinol, all trans-; all-trans-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol; NCGC00091784-03; Vitamin A alcohol; Wachstumsvitamin; CHEMBL986; NCGC00091784-04; Retinolum [INN-Latin]; Retin-11,12-t2-ol (9CI); Agoncal; Anti-infective vitamin; ALL-TRANS RETINOL (SEE ALSO RETINOID PROJECT 1); Alphalin; Avitol; Vi-Alpha; 17104-91-5; NSC 122759; 1341-18-0; AR-1L3057; Retinol-(cellular-retinol-binding-protein); Chocola A; Anatola; LMPR01090001; (2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraen-1-ol; Solu-A; 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol; Testavol; all-trans-Vitamin A; Atars; Cylasphere; Vitamin- A; BIDD:PXR0102; CHEBI:17336; Avibon; HMS2092L13; 95144_FLUKA; tROL; DB00162; C20H30O; Retinol [INN:BAN]; Axerol; Hi-A-Vita; Vitamin A1 alcohol, all trans; Vitamine A; 53637-36-8; all-trans-Vitamin A alcohol; LPK; ACON; Vitamin A (Feed); C17276; IDI1_000486; Biosterol; A-Vi-Pel; .alpha.sterol; UNII-G2SH0XKK91; Vio-A; Vitavel-A; 1rbp; 3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol, (all-E)-Isomer; A-Vitan; Antixerophthalmic vitamin; SPECTRUM1501203; ATAV; Vitamin A; SDCCGMLS-0066724.P001; EINECS 234-328-2; EINECS 200-683-7; Vitamin A alcohol (VAN); Vitamin A cryst; Hydrovit A; Oleovitamin A; Axerophtholum; (all-E)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol; beta-Retinol; 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonate-traen-1-ol; Vitamin-?A alcohol solution; Vitaminum A; 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexenyl)-2,4,6,8-nonatetraen-1-ol; HMS501I08; Vitamin A (USP); Vitamin- A alcohol; Afaxin; Vitamin A1 alcohol, all-trans-; Rovimix A 500; Vitavel A; Aquasol A Parenteral; 13123-33-6; BRN 0403040; Spectrum5_000993; SMR000112036; MLS001074751; Plivit A; Agiolan; M.V.I.-12; Retinolo; Del-VI-A; all-trans-Retinyl alcohol; Nio-A-Let; C00473; Thalasphere; ZINC03831417; Zinosan N; Vi-alpha; Vi-alpha; Vaflol; WLN: L6UTJ A1 B1U1Y1&U2U1Y1&U2Q C1 C1; Retinol, all-trans- (8CI); ST057232; 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol, (all-E)-; Alcohol 9,13-dimethyl-7-(1,1,5-trimethyl-6-cyclohexen-5-yl)-7,9,11,13-nonatetraen-15-ol; Vitamin-?A; Sehkraft A; Vafol; Testavol S; HMS1921B04; (2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraen-1-ol; D06543; Veroftal; alin; MLS001066379; HSDB 815; Dohyfral A; trans-Vitamin A alcohol; 11103-57-4; Vitamin A1; Vi-.alpha.; .beta.-Retinol; Antixerophthalmisches Vitamin	11103-57-4	445354	842011	TTDS00354	Retinoid X receptor	RXR	N/A	N/A	N/A	binder
DCL000602	R1450	N/A	N/A	N/A	N/A	TTDC00180	Amyloid beta A4 protein	ABPP;Alzheimer's disease amyloid protein;Amyloid beta precursor protein;Amyloid precursor protein;APP;APPI;Beta-amyloid peptide;Cerebral vascular amyloid peptide;CVAP;Gamma-Secretase;PN-II;PreA4;Protease nexin-II;Vascular beta-amyloid	P05067	351	ENSG00000142192	antibody
DCL000428	Anti-Abeta	N/A	N/A	N/A	N/A	TTDC00180	Amyloid beta A4 protein	ABPP;Alzheimer's disease amyloid protein;Amyloid beta precursor protein;Amyloid precursor protein;APP;APPI;Beta-amyloid peptide;Cerebral vascular amyloid peptide;CVAP;Gamma-Secretase;PN-II;PreA4;Protease nexin-II;Vascular beta-amyloid	P05067	351	ENSG00000142192	antibody
DPR000011	AG-021541	N/A	N/A	N/A	N/A	TTDR01272	Hepatitis C Virus RNA-dependent RNA Polymerase	N/A	N/A	N/A	N/A	inhibitor
DPR000007	A-837093	1(lambda) 6-benzo[1,2,4]thiadiazin-3-yl)-4-methyl-4-(3-methyl-butyl)-3-oxo-; (S)-2-(7-Methanesulfonylamino-1,1-dioxo-1,4-dihydro-; 3,4-dihydro-naphthalen-1-olate; CHEMBL469738; (R)-2-(7-Methanesulfonylamino-1,1-dioxo-1,4-dihydro-; A-837093	N/A	N/A	N/A	TTDR01272	Hepatitis C Virus RNA-dependent RNA Polymerase	N/A	N/A	N/A	N/A	inhibitor
DAP000874	Mannitol	Mannit; D00062; 63559_SIGMA; M9647_SIAL; Mannazucker; Osmitrol 10% In Water; Maniton-S; Mannidex; Isotol; 87-78-5; Osmitrol 20% In Water; Mannitol 20% In Plastic Container; Mannite; HSDB 714; Mannitol 20%; 15719_ALDRICH; M0044; D-(-)-Mannitol; MANNITOL 25%; Osmitrol; AI3-19511; AC1Q28E5; UNII-3OWL53L36A; Resectisol In Plastic Container; (2R,3R,4R,5R)-hexane-1,2,3,4,5,6-hexol; 85085-15-0; Osmitrol 5% In Water; NSC 407017; 63560_FLUKA; 123897-58-5; manita; SORBITOL-MANNITOL IN PLASTIC CONTAINER; M1902_SIGMA; Osmofundin; Diosmol; 15719_RIEDEL; MANNITOL 15% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.45%; AC-12776; Osmosal; AB1002081; Invenex; OSMITROL 20% IN WATER IN PLASTIC CONTAINER; OSMITROL 5% IN WATER IN PLASTIC CONTAINER; Osmitrol (TN); (L)-Mannitol; Osmitrol 15% In Water; ZINC02041302; Mannitol 5% In Plastic Container; MANNITOL 5% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.12%; CHEMBL689; NCGC00164246-01; Cordycepic acid; Mannitol 15%; 33440_SIGMA; AR-1J3861; Mannitol, D-; Mannitol [USAN]; D-mannitol; Mannitol 15% In Plastic Container; LS-89250; 63565_SIGMA; bmse000099; OSMITROL 15% IN WATER IN PLASTIC CONTAINER; CID6251; M8429_SIAL; Mannistol; Mannitol 5%; MLS001335977; M9546_SIAL; 133-43-7; Hexahydroxyhexane; Ambap69-65-8; D008353; Resectisol; Mannidex 16700; SMR000857324; Marine Crystal; DL-Mannitol; Mannitol (USP); Mannogem 2080; 36413-61-3; D-Mannitol (JP15); MolPort-003-927-039; M4125_SIAL; BRN 1721898; EINECS 201-770-2; TL806434; NCI-C50362; MTL; OSMITROL 10% IN WATER IN PLASTIC CONTAINER; MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER; 33440_RIEDEL; Mannigen; Mannitol (VAN); mannitol; CHEBI:16899; ED1D1E61-FEFB-430A-AFDC-D1F4A957FC3D; D-mannite; C00392; LS-1588; 69-65-8; EINECS 200-711-8; CCRIS 369; C6H14O6; 75398-80-0; 4-01-00-02841 (Beilstein Handbook Reference); 5149-40-6; 63559_FLUKA; MLS001335978; Mannitol 10% In Plastic Container; AC1L1M49; Mannitol 10%; Manna sugar; SDM No. 35; 63565_FLUKA; Sorbitol-Mannitol; NSC 9256; cpd without stereochemical designation	69-65-8	453	3682	TTDS00505	Mannitol 2-dehydrogenase 	M2DH;MDH	Q4WQY4	N/A	N/A	activator
DAP001310	Mefloquine	AC1L1HAJ; NCGC00161831-02; WR-142,490; Spectrum4_001066; SPBio_001591; Mefloquina [INN-Spanish]; SPBio_002111; Racemic mefloquine; mefloquine; DivK1c_000790; Prestwick3_000126; Prestwick1_000126; CHEMBL411329; SPECTRUM1503070; Mefloquinum; DB00358; [2,8-bis(trifluoromethyl)quinolin-4-yl]-piperidin-2-ylmethanol; WR-177,602; (+)-threo-4-Quinolinemethanol, .alpha.-2-piperidinyl-2,8-bis(trifluoromethyl)-, (11S, 2'S)-; (R)-[2,8-bis(trifluoromethyl)quinolin-4-yl]-[(2S)-piperidin-2-yl]methanol; AC1L9UO6; nchembio.215-comp3; Ro-21-5998-001; NSC157387; 51742-87-1; BRD-A89585551-003-03-4; Erthro-.alpha.-[2-piperidyl]-2,8-bis[trifluoromethyl]-4-quinolinemethanol; Prestwick0_000126; (DL-erythro-alpha-2-Piperidyl-2,8-bis(trifluoromethyl)-4-quinolinemethanol; CID40692; RTI1172-1-1; BIDD:PXR0166; CHEBI:151162; (+)-(11R,2'S)-erythro-Mefloquine; (+/-)-threo-4-Quinolinemethanol, .alpha.-2-piperidinyl-2,8-bis(trifluoromethyl)-; BPBio1_000190; NCGC00016864-01; C17H16F6N2O; 68682-27-9; AB00052310; 4-Quinolinemethanol, alpha-(2R)-2-piperidinyl-2,8-bis(trifluoromethyl)-, (alphaS)-; Ro 21-5998; C07633; AC1MHD7O; (+)-Threo-Mefloquine; (-)-Threo-Mefloquine; RTI1173-1-1; HSDB 6853; NINDS_000790; HMS502H12; MolPort-003-981-155; RTI1174-1-1; CHEBI:403542; CHEMBL416956; NCGC00161831-01; MQ; Lariam (Hydrochloride); AC1MHD7J; 53230-10-7; (+)-Mefloquine; AC1Q4K1I; HMS1922C09; KBioGR_001392; Mefloquine (USAN/INN); 4-Quinolinemethanol, alpha-(2S)-2-piperidinyl-2,8-bis(trifluoromethyl)-, (alphaR)-; RTI1169-1-1; 4-Quinolinemethanol, .alpha.-(2R)-2-piperidinyl-2,8-bis(trifluoromethyl)-, (.alpha.S)-; CID456309; Mefloquinone; RTI1189-1-1; 4-Quinolinemethanol, .alpha.-(2S)-2-piperidinyl-2,8-bis(trifluoromethyl)-, (.alpha.R)-; (+)-erythro-4-Quinolinemethanol, .alpha.-2-piperidinyl-2,8-bis(trifluoromethyl)-; 49752-90-1; 4-Quinolinemethanol, alpha-(2R)-2-piperidinyl-2,8-bis(trifluoromethyl)-, (alphaS)-rel-; BIDD:GT0596; Mephloquine; NCGC00094994-02; 51744-84-4; LS-187797; CID3000506; nchembio.87-comp20; Spectrum5_001122; RO 13-7225; RO 13-7224; CID3000516; (S)-[2,8-bis(trifluoromethyl)quinolin-4-yl]-[(2R)-piperidin-2-yl]methanol; IDI1_000790; (R)-[2,8-bis(trifluoromethyl)quinolin-4-yl]-[(2R)-piperidin-2-yl]methanol; Lariam; Mefloquinum [INN-Latin]; NCGC00094994-01; KBio2_006928; EINECS 256-468-3; Mefloquin; Spectrum2_001516; 51688-68-7; (S)-[2,8-bis(trifluoromethyl)quinolin-4-yl][(2R)-piperidin-2-yl]methanol; KBio1_000790; RTI1188-1-1; 51744-85-5; (S)-[2,8-bis(trifluoromethyl)quinolin-4-yl]-[(2S)-piperidin-2-yl]methanol; CAS-51773-92-3; (-)-threo-4-Quinolinemethanol, .alpha.-2-piperidinyl-2,8-bis(trifluoromethyl)-, (11R, 2'R)-; 4-Quinolinemethanol, .alpha.-2-piperidinyl-2,8-bis(trifluoromethyl)-, (R*,S*)-(.+/-.)-; (+/-)-erythro-4-Quinolinemethanol, .alpha.-2-piperidinyl-2,8-bis(trifluoromethyl)-; 4-Quinolinemethanol, alpha-2-piperidinyl-2,8-bis(trifluoromethyl)-, (R*,S*)-(+/-)-; SPB-80406; AR-1G4597; WR 142490; WR-142490; CHEMBL411685; KBio3_002046; KBioSS_001792; AC1L249S; NCGC00094994-04; Spectrum3_000953; alpha-2-Piperidyl-2,8-bis(trifluoromethyl)quinoline-4-methanol; CHEMBL411686; D04895; alpha-2-Piperidinyl-2,8-bis(trifluoromethyl)-4-quinolinemethanol; KBio2_001792; (-)-(11S,2'R)-erythro-Mefloquine; Mefloquine [USAN:INN:BAN]; (-)-Mefloquine; UNII-TML814419R; Prestwick2_000126; Ro 21-5998 (Hydrochloride); Mefloquina; 4-Quinolinemethanol, alpha-2-piperidinyl-2,8-bis(trifluoromethyl)-, (R*,S*)-(+-)-; 4-quinolinemethanol, a-2-piperidinyl-2,8-bis(trifluoromethyl)-; KBio2_004360; CID4046; LS-142023; NCGC00094994-03; 4-Quinolinemethanol, alpha-2-piperidinyl-2,8-bis(trifluoromethyl)-; BSPBio_000172; Spectrum_001312; Ro 215998	53230-10-7	4046	9835	TTDS00460	Food vacuoles	N/A	N/A	N/A	N/A	binder
DCL000291	T-705	AC1Q2G5G; 2-Pyrazinecarboxamide, 6-fluoro-3-hydroxy-; CHEMBL221722; Favipiravir; Favipiravir (JAN/INN); 259793-96-9; T-705; AIDS121660; 5-fluoro-2-oxo-1H-pyrazine-3-carboxamide; MolPort-004-768-381; 3-bromo-5-hydroxy-4-methyl-2,6-dinitro-benzoic Acid; CID492405; CID4424075; 3-bromo-5-hydroxy-4-methyl-2,6-dinitrobenzoic acid; T705; UNII-EW5GL2X7E0; D09537; MolPort-001-801-281; AKOS005166863; AC1NAB6K; AC1LAOUM	N/A	492405	652965	TTDC00001	RNA-dependent RNA polymerase	NIb;NI-b;Nonstructural protein 5b;NS5B;Nuclear inclusion protein B;P66;P70;RdRp;RNA-directed RNA polymerase;Virus-encoded nonstructural protein 5B	P87764	N/A	N/A	inhibitor
DCL000277	LG100268	LG-100268; EN002167; C095104; 6-(1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopropyl)nicotinic acid; CID3922; CHEBI:43621; DB01941; 3-Pyridinecarboxylic acid, 6-(1-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)cyclopropyl)-; LG2; BIDD:PXR0022; C15640; 6-[1-(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalen-2-yl)cyclopropyl]pyridine-3-carboxylic acid; LG 100268; CHEBI:161111; lg100268; AC1Q2QPU; AC1L1H0H; CHEMBL288436; 6-[1-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-nicotinic acid; AmbkkkkK580; AR-1H0639; LS-131046; 153559-76-3; 6-[1-(3,5,5,8,8-PENTAMETHYL-5,6,7,8-TETRAHYDRONAPHTHALEN-2-YL)CYCLOPROPYL]PYRIDINE-3-CARBOXYLIC ACID	153559-76-3	3922	46505129	TTDS00073	Retinoic acid receptor alpha	RAR alpha;RAR-alpha	P10276	5914	ENSG00000131759	agonist
DAP000275	Alitretinoin	D00094; Ro 1-5488; LGD-1057; Atralin; IDI1_033970; CHEBI:50648; LG-100057; Retisol-A; UPCMLD-DP097; BML2-E05; Alitretinoin; Retinova; Effederm; Spectrum5_001746; NSC122758; STOCK1N-38565; Tretinoina; DB00755; Nexret; 9C-RA; HMS1361K22; 56573-65-0; Tretinoin Zinc Salt; Tretinoine; Tretinoino; R 2625; 9-cis-RA; Avitoin; 187175-63-9; NCGC00161590-06; HMS1361K17; Renova (TN); Atra-IV; Lopac0_001061; AC1L9GWO; IDI1_033965; NCGC00021808-07; NCGC00021808-04; LMPR01090022; Acid, trans-Retinoic; (9cis)-retinoic acid; D02815; b-Retinoic acid; STK801887; AGN-192013; NSC 122758; 9-CIS-RETINOIC ACID; Acid, Vitamin A; MLS002222211; BIDD:PXR0081; CCRIS 7098; DB00982; NCGC00021808-14; A-Acido (Argentina); LGD 1057; BAL-4079; NSC-659772; Spectrum5_001933; AGN 100335; HMS1989K22; LMPR01090019; Tretin M; Solage; I14-2351; Panretin; trans Retinoic Acid; Stieva-A; Retinoic acid; Retacnyl; Aknoten; Alitretinoin [USAN]; HMS2089D20; Acnavit [Denmark]; Panrexin; HMS502N05; Aberela [Norway]; [3H]Retinoic acid; Airol; HSDB 7186; Tri-Luma; Aknefug; BPBio1_000082; CCRIS 3294; Retionic acid; Salt, Tretinoin Zinc; DB00523; LS-1154; .beta.-Retinoic acid; CID449171; Avitoin [Norway]; LGD 100057; NCGC00021808-05; L000833; NCGC00161590-05; MLS000028588; Prestwick_424; NCGC00017280-06; Epi-aberel; SR-01000000239-14; Effederm [France]; alitretinoina; HMS1791K17; Vitinoin; CPD000058245; 9(Z)-Retinoic acid; HMS1791K22; AC1L9MT9; UNII-1UA8E65KDZ; NCGC00017280-17; Aberel; CHEMBL705; Vesanoid (TN); Accutane Roche; EU-0101061; 9-cis Retinoic Acid; HMS1568D16; AC-6824; SAM002264647; Vesnaroid; NCGC00161590-01; 7005-78-9; MolPort-002-507-281; Zinc Salt, Tretinoin; HMS1921D14; A-Vitaminsyre; AC1Q1J2J; UPCMLD-DP097:002; TRETINON; beta-Ra; AKOS000280845; ST057075; R2625_SIGMA; nchembio861-comp8; Acid, Retinoic; C00777; Panretin Gel; ALRT-1057; Tretinoinum; Cordes vas; beta-Retinoic acid; tretinoin liposome; SPECTRUM1502016; 5300-03-8; BAL4079; S1653_Selleck; D014212; nchembio.106-comp3; Retinoate; SR-01000000239; SR-05000013784; ATRA; Dermairol; NCGC00021808-06; alitretinoine; trans-Retinoic acid; NSC 659772; AT-RA; tretinoin; EINECS 206-129-0; Toctino; Retin-A Micro; BSPBio_001495; REA; 1n4h; Spectrum5_001935; 9-cis RA; Stieva-a Forte; 9-CRA; SR-05000013784-1; Prestwick3_000257; Tretinoin (TN); BIDD:GT0483; Panretin (TN); Lsotretinoin; 302-79-4; UNII-5688UTC01R; Retin A (TN); NCGC00161590-04; Avita (TN); Vesanoid; 9 Cis Retinoic Acid; NCGC00161590-03; Atragen; PDT-002-002; I04-0008; MolPort-000-883-857; Acnavit; R0064; Cordes VAS [Germany]; Avita Gel; NCGC00021808-15; BB_NC-1005; BML2-E06; NSC659772; CHEBI:15367; Betarretin; NCGC00161590-07; bmse000562; IDI1_000903; BSPBio_000074; BRN 2057223; AGN 192013; Aberela; 9CRA; 9-cis-Tretinoin; nchembio.154-comp2; all-trans-Tretinoin; BSPBio_001500; LS-1328; Eudyna; HSDB 2169; Prestwick2_000257; Retin-A; Alitretinoin (USAN); CID444795; Vitamin A acid; NCGC00021808-09; CHEMBL38; Ro-04-4079; C15493; NCGC00161590-02; NSC-122758; Panretyn; Renova; HMS1989K17; HMS2092N11; R4643_SIGMA; alitretinoinum; SMR000058245; Retin A; ALRT 1057; MLS001076515; UPCMLD-DP097:001; MLS002207234	5300-03-8	444795	164122	TTDS00073	Retinoic acid receptor alpha	RAR alpha;RAR-alpha	P10276	5914	ENSG00000131759	agonist
DAP000461	Tamibarotene	Amnolake; Amnoid (TN); Amnoid; DB04942; N-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl)-2-naphthyl)terephthalamic acid; 4-[(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)carbamoyl]benzoic acid; FT-0080835; AM-80; UNII-08V52GZ3H9; AC1L33F5; N-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)terephthalamic acid; Amnoleuk; Tamibarotene (JAN/INN); NSC 608000; TM-411; AC-7049; Am80; Tamibaro; NSC-608000; retinobenzoic acid; NSC608000; TOS-80; Benzoic acid, 4-(((5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)amino)carbonyl)-; NCGC00181111-01; 4-(((5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)amino)carbonyl)benzoic acid; Terephthalic acid mono-5,5,8,8-tetramethyl- 5,6,7, 8-tetrahydro-2-naphthylamide; 121GE003; 94497-51-5; C12864; Z-208; Tamibarotene; 2cbr; 4-[(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)carbamoyl]benzoic acid; C061133; 4-((5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)carbamoyl)benzoic acid; CHEMBL25202; NCI60_004716; CHEBI:32181; LS-38350; I14-1960; Terephthalic acid mono-5,5,8,8-tetramethyl- 5,6,7,8-tetrahydro-2-naphthylamide; Am 80; D01418; CID108143	94497-51-5	108143	10234613	TTDS00073	Retinoic acid receptor alpha	RAR alpha;RAR-alpha	P10276	5914	ENSG00000131759	binder
DCL000205	PX-12	AC1Q7EBH; PX 12; 2-((1-Methylpropyl)dithio)-1H-imidazole; PX-12; 1H-Imidazole, 2-((1-methylpropyl)dithio)-; 2-(butan-2-yldisulfanyl)-1H-imidazole; AC1L5624; 2-(sec-butyldisulfanyl)-1h-imidazole; AR-1C9880; CHEMBL406050; Iv 2 Compound; CID219104	141400-58-0	219104	791642	TTDC00075	Thioredoxin	ADF;ATL-derived factor;SASP;Surface associated sulphydryl protein	P10599	7295	ENSG00000136810	inhibitor
DCL000309	Glucobay	(2R,3R,4R,5S,6R)-5-[(2R,3R,4R,5S,6R)-5-[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl]amino]oxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,4-triol; CID444254; 1ukt; 4,6-dideoxy-4-{[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl]amino}-alpha-D-glucopyranosyl-(1->4)-alpha-D-glucopyranosyl-(1->4)-D-glucopyranose; SPECTRUM1505172; Bay g 5421; CID41774; D-Glucose, O-4,6-dideoxy-4-(((1S-(1-alpha,4-alpha,5-beta,6-alpha))-4,5,6-trihydroxy-3-(hydroxymethyl)-2-cyclohexen-1-yl)amino)-alpha-D-glucopyranosyl-(1-4)-O-alpha-D-glucopyranosyl-(1-4)-; ACR; CHEBI:2376; ACI-(1-4)GLD-(1-4)GLC-(1-4)GLB; HMC-(1-4)AGL-(1-4)GLC-(1-4)GLC; Bay-g-5421; AC1L9G0J; CHEMBL394434; Prandase; NCGC00160515-01; Acarbosum; S1271_Selleck; 56180-94-0; HMS2093I22; Acarbosa; O-4,6-Dideoxy-4-(((1S-(1alpha,4alpha,5beta,6alpha))-4,5,6-trihydroxy-3-(hydroxymethyl)-2-cyclohexen-1-yl)amino)-alpha-D-glucopyranosyl-(1-4)-O-alpha-D-glucopyranosyl-(1-4)-D-glucose; Glucobay; DB00284; C06802; C25H43NO18; UNII-T58MSI464G; Acarbosum [INN-Latin]; CID441184; Glucor; D-glucose, O-4,6-dideoxy-4-(((1S-(1 alpha,4 alpha,5 beta,6 alpha))-4,5,6-trihydroxy-3-(hydroxymethyl)-2-cyclohexen-1-yl)amino)-alpha-D-glucopyranosyl-(1-4)-O-alpha-D-glucopyr anosyl-(1-4)-; O-4,6-Dideoxy-4-(((1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-2-cyclohexen-1-yl)amino)-alpha-D-glucopyranosyl-(1->4)-O-alpha-D-glucopyranosyl-(1->4)-D-glucose; MLS000759506; acarbose; AC1L26GM; SAM001246733; Acarbose (JAN/USAN/INN); Beta-Acarbose; AC1L9APL; CHEMBL1566; QPS; CPD000466376; Acarbose [USAN:BAN:INN:JAN]; LS-71702; Prandase, Precose, Glucobay, Bay-g 5421, Acarbose; CHEBI:506767; SMR000466376; (3R,4R,5S,6R)-5-[(2R,3R,4R,5S,6R)-5-[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl]amino]oxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,4-triol; HMS2051F03; MolPort-002-507-369; Acarbosa [INN-Spanish]; 1agm; MLS001424056; BB_NC-1311; Precose; D00216; 4,6-dideoxy-4-{[(1S,4S,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl]amino}-alpha-D-glucopyranosyl-(1->4)-alpha-D-glucopyranosyl-(1->4)-D-glucose; D-Glucose, O-4,6-dideoxy-4-(((1S-(1alpha,4alpha,5beta,6alpha))-4,5,6-trihydroxy-3-(hydroxymethyl)-2-cyclohexen-1-yl)amino)-alpha-D-glucopyranosyl-(1-4)-O-alpha-D-glucopyranosyl-(1-4)-; STK801930; D-Glucose, O-4,6-dideoxy-4-(((1S-(1alpha,4alpha,5beta,6alpha))-4,5,6-trihydroxy-3-(hydroxymethyl)-2-cyclohexen-1-yl)amino)-alpha-D-glucopyranosyl-(1->4)-O-alpha-D-glucopyranosyl-(1->4)-; BAY-g 5421; Precose (TN); EINECS 260-030-7; (2R,3R,4R,5S,6R)-5-[(2R,3R,4R,5S,6R)-5-[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4S,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl]amino]oxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,4-triol; O-4,6-Dideoxy-4-(((1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-2-cyclohexen-1-yl)amino)-alpha-D-glucopyranosyl-(1-4)-O-alpha-D-glucopyranosyl-(1-4)-D-glucose	N/A	441184	12012879	TTDC00023	Lysosomal alpha-glucosidase	Acid maltase;Aglucosidase alfa	P10253	2548	ENSG00000171298	inhibitor
DCL000082	Celgosivir	MDL-28574; MX-3253; VIR-222; 6-O-Butanoylcastanospermine; BuCast; AC1L1TTH; Butanoic acid, (1S,6S,7S,8R,8aR)-octahydro-1,7,8-trihydroxy-6-indolizinyl ester; Celgosivir; MBI-3253; CID60734; MDL 28,574A; Butanoic acid, octahydro-1,7,8-trihydroxy-6-indolizinyl ester, (1S-(1alpha,6beta,7alpha,8beta,8abeta))-; [(1S,6S,7S,8R,8aR)-1,7,8-trihydroxy-1,2,3,5,6,7,8,8a-octahydroindolizin-6-yl] butanoate; MDL 28,574; B-CAST; MDL 28574; UNII-895VG117HN; 121104-96-9; AC1Q5X0B; MolPort-005-943-127; (1S,6S,7S,8R,8aR)-Octahydro-1,7,8-trihydroxy-6-indolizinyl butyrate	N/A	60734	12014437	TTDC00023	Lysosomal alpha-glucosidase	Acid maltase;Aglucosidase alfa	P10253	2548	ENSG00000171298	inhibitor
DAP000828	Potassium Chloride	K. tab; Potassium chloride (JP15/USP); KCL (TN); Super K; Kalium Durules; 11118_FLUKA; K-Contin; KM potassium chloride; Klorvess; Kelp salt; Kaliumchlorid; Kaysiel; potassium chloride; K-SR; Kalitabs; Durules; Acronitol; 449989_ALDRICH; Potassium Chloride BP; MolPort-003-933-039; Emplets potassium chloride; Micro-K Extentcaps; Kalium-Durettes; K-Care; Neobakasal; Kalipor; Kay-Cee-L; Miopotasio; 60130_SIAL; Potassium Cl; K-Tab; Selora; Potassium standard concentrate 10.00 g K; Chlorvescent; 451029_ALDRICH; Apo-K; K-Lease; 05257_FLUKA; Lento-Kalium; Potassium chloride 20meq in plastic container; 126415-35-8; HSDB 1252; Kay-EM; Leo K; Monopotassium chloride; Super K (salt); 60130_FLUKA; Ultra K Chlor; Leo-K; Ultra-K-Chlor; 60137_FLUKA; EINECS 231-211-8; 05433_FLUKA; K-Lyte Cl; K+8; CHEMBL1200731; 34070_RIEDEL; Kayciel; Potassium Chloride in Plastic Container; 59217-68-4; CID4873; K-10; P5405_SIGMA; KCL Retard; Steropotassium; 60131_FLUKA; Potassium muriate; Potasol; 12636_SIAL; Trona muriate of potash; D011189; Kaleorid; Kaon-Cl TABS; Chloropotassuril; Kaliglutol; Klor-Con M15; Addi-K; Kayback; LS-1643; P9333_SIAL; Chloride of potash; Chlorid draselny; Trona potassium chloride; Natural sylvite; Rekawan Retard; POTASSIUM CHLORIDE, U.S.P.; Diffu-K; UNII-660YQ98I10; Potavescent; Klor-Con M20; Kalium S.R.; Kaliolite; 60138_FLUKA; Kay Ciel; Kadalex; Keylyte; Kalium-duriles; KSR; Kaon-ci; Potassium chloride (K3Cl3); Kaon-Cl (TN); Kaon Cl-10; P4504_SIAL; 60142_FLUKA; K-dur (TN); Tripotassium trichloride; Potassium monochloride; Celeka; K-lyte/C1; Potassium chloride standard; Infalyte; ISA (ionic strength adjustment solution: 1 M KCl); Klor-con (TN); Kalium Retard; 60136_FLUKA; Kaon-Cl 10; Kolyum; K-Lor; Chloropotassuril diffu-K; MolPort-003-925-259; Repone-K; IN2900; EPA Pesticide Chemical Code 013904; Caswell No. 686; P9541_SIGMA; KCl-retard Zyma; 58221_FLUKA; Potassium Chloride 10meq in Plastic Container; 34262_FLUKA; Kalinor-Retard P; CHEBI:32588; Kaon Cl; K-Predne-Dome; DB00761; Kalcorid; Kalium SR; 60128_SIGMA; WLN: KA G; Kalinorm Depottab; Span-K; Duffi-K; Kalitrans Retard; Potassium chloride (KCl); POTASSIUM CHLORIDE, ACS; P8041_SIGMA; Klotrix (TN); Kaleorod; Chlorid draselny [Czech]; Kalium S.R; Ten-K; D02060; 02682_FLUKA; Kalium Duriles; Kaon Ultra; Durules-K; KCL; Hydrochloric acid potassium salt (1:1); Klor-Lyte; Potasion; Durekal; K-Dur; P9327_SIAL; NSC77368; Sylvite; K Tab; Kloren; K-Sol; Micro-K 10; 60142_SIGMA; Conductance standard solution; Plus Kalium Retard; Micro-Kalium Retard; Clor-K-Zaf; Kalium-R; Slow-K tablets; 60133_SIAL; Potassium thallium chloride (KTlCl); Micro-K LS; 409316_ALDRICH; Kalipoz; Lento-K; 31248_SIAL; K+10; Kato; 60128_FLUKA; 34262_RIEDEL; Potassium chloride solution; 03375_FLUKA; 204099_ALDRICH; Kaliduron; Rekawan; Potassium chloride 30meq in plastic container; Potassium chloride 40meq in plastic container; Repone K; 60134_FLUKA; Rum-K; Kalilente; P3911_SIAL; 79103-76-7; CCRIS 1962; Kalinorm; 60121_FLUKA; Enpott; Potassium chloride [JAN]; Pfiklor; Conductivity Standard Solution, 1413 -?S/cm; [KCl]; Cena-K; Kaskay; K-Grad; Peter-kal; 319309_SIAL; Nu-K; Sando-K; Klotrix; Kaon-Cl; 60133_FLUKA; Conductivity Standard Solution, 500 -?S/cm; Muriate of potash; Dipotassium dichloride; 7447-40-7; Potassium atomic spectroscopy standard concentrate 1.00 g K; K-Norm; Kaochlor; Enseal; Klor-Con; Kay-Ciel; Slow-K; Sal digestnum sylvii; NSC 77368; Chloride, Potassium; Klor-Con M10; 61794_FLUKA; 12636_RIEDEL; 12599-00-7; 31248_RIEDEL; AC1L1J5E; K-Lyte/Cl; CID24015; Micro-K	7447-40-7	24015	7849122	TTDS00116	Solute carrier family 12 member 1	Bumetanide-sensitive sodium-(potassium)-chloride cotransporter 2;Bumetanide-sensitive sodium-(potassium)Solute carrier family 12 member 1-chloride cotransporter 2;Kidney-specific Na-K-Cl symporter;Na+/K+/2CL- co-transporter;NKCC2;Solute carrier family 12 member	Q13621	6557	ENSG00000074803	binder
DAP000521	Chlorthalidone	Oxodolin; SMR000058635; AC1Q558X; Chlorthalidone [USAN:INN:BAN]; LS-31408; Benzenesulfonamide, 2-chloro-5-(2,3-dihydro-1-hydroxy-3-oxo-1H-isoindol-1-yl)-; 3-Hydroxy-3-(4-chloro-3-sulfamylphenyl)phthalimidine; UNII-Q0MQD1073Q; AC-11367; 3-(4'-Chloro-3'-sulfamoylphenyl)-3-hydroxyphthalimidine; Prestwick_759; Oksodolin (oxodolin); AB00051946; AC1L1ECB; KBioGR_001574; Chlorothalidone; Benzenesulfonamide, 2-chloro-5-(1-hydroxy-3-oxo-1-isoindolinyl)-; MolPort-002-736-049; C14H11ClN2O4S; Clortalidone; CHEMBL1055; KBio2_005762; BSPBio_002017; NCGC00094616-03; Prestwick2_000351; Racemic chlorthalidone; Oradil; chlorthalidone; 1-Keto-3-(3'-sulfamyl-4'-chlorophenyl)-3-hydroxyisoindoline; MLS000069531; Chlortalidonum [INN-Latin]; Famolin; Urolin; NSC69200; 1-Oxo-3-(3-sulfamyl-4-chlorophenyl)-3-hydroxyisoindoline; Chlortalidone; Prestwick3_000351; HMS2091E12; Natriuran; HMS1569G03; SPBio_002362; NCGC00094616-02; G 33182; Renon; 2-chloro-5-(1-hydroxy-3-oxo-2H-isoindol-1-yl)benzenesulfonamide; Hydro-Long; 2-Chloro-5-(1-hydroxy-3-oxo-1-isoindolinyl)benzenesulfonamide; Isoren; 77-36-1; NSC 69200; CPD000058635; Clortalidone [DCIT]; ST088141; NCGC00094616-01; Spectrum5_000743; Chlorthalidone (USP); NINDS_000731; I06-0208; Hygroton (TN); D002752; Chlorthalidon; (+-)-Chlorthalidone; HMS502E13; C2775_SIGMA; CID2732; SPECTRUM1500187; BRN 0312295; Spectrum4_000957; SAM002589983; CHEBI:3654; KBio2_003194; STK686335; Prestwick0_000351; Phthalamodine; Chlortalidone (JAN/INN); Chlorphthalidolone; Prestwick1_000351; Thalitone; KBio3_001237; KBio2_000626; Spectrum_000146; BRD-A26384407-001-05-3; Chlortalidonum; 5-22-07-00602 (Beilstein Handbook Reference); C2775_FLUKA; HMS1920M09; DB00310; D00272; DivK1c_000731; BSPBio_000441; SPBio_000058; KBio1_000731; Igroton; HSDB 3035; EINECS 201-022-5; A3836/0162845; Zambesil; NCGC00094616-04; Chlorphthalidone; Saluretin; Hygroton; Spectrum2_000099; IDI1_000731; Higroton; Thalitone (TN); KBioSS_000626; Clortalidona; 2-Chloro-5-(1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl)benzenesulfonamide; 2-chloro-5-(2,3-dihydro-1-hydroxy-3-oxo-1H-isoindol-1-yl)benzenesulfonamide; Clortalidona [INN-Spanish]; (+-)-Hygroton; Spectrum3_000349; Oxodoline; Phthalamudine; BPBio1_000487; G-33182	77-36-1	2732	149435	TTDS00116	Solute carrier family 12 member 1	Bumetanide-sensitive sodium-(potassium)-chloride cotransporter 2;Bumetanide-sensitive sodium-(potassium)Solute carrier family 12 member 1-chloride cotransporter 2;Kidney-specific Na-K-Cl symporter;Na+/K+/2CL- co-transporter;NKCC2;Solute carrier family 12 member	Q13621	6557	ENSG00000074803	blocker
DAP000043	Furosemide	UNII-7LXU5N7ZO5; Oedemex; HMS2091H05; Odemase; KBio2_006716; Radonna; UPCMLD-DP022; Errolon; Lasix Retard; fulvamide; Urosemide; LB-502; HMS501M17; SMR000058202; Furosemide Monosodium Salt; Aquasin; Furfan; MolPort-001-641-065; Furosemide "mita"; 41733-55-5 (mono-hydrochloride salt); Farsix; Fusid; Franyl; Furosedon; BSPBio_002054; Edenol; Furosemide Monohydrochloride; Fuluvamine; Promedes; less Diur; Kofuzon; KBio1_000575; Frumide; Fursol; AC1Q557O; MLS001306403; Selectofur; HMS2090K06; Urex; Desal; SMP1_000129; Lazix; Marsemide; Fu sid; Laxur; BRD-K78010432-001-05-8; Furodrix; Salix; NINDS_000575; Polysquall A; SPBio_001129; WLN: T5OJ B1MR CG FVQ DSZW; CCRIS 1951; SPBio_002322; Furovite; Diuzol; STK177334; Dirine; Prestwick2_000341; Diumide-K; Trofurit; Katlex; Mirfat; Uridon; NCGC00090893-05; Synephron; Uremide; Furanturil; Fuluvamide; Golan; Sal diureticum; MLS001066374; Frusemin; Discoid; Furetic; Furosemide [USAN:INN:JAN]; NCGC00090893-03; CID3440; Furesis; Arasemide; D005665; Salinex; Beronald; EINECS 200-203-6; Salurid; Aisemide; Furomide M.D; Novosemide; Hoe-058A; CHEBI:47426; Lasix, Frusemide,  Furosemide; Uresix; Furanthryl; NCGC00090893-02; Moilarorin; Radisemide; Frusenex; Yidoli; F4381_SIGMA; Jenafusid; Bio-0044; Puresis; 2-Furfurylamino-4-chloro-5-sulfamoylbenzoic acid; furosemide; Radouna; Furmid; BPBio1_000443; Furix; FUN; Luscek; Protargen; Transit; Prestwick3_000341; Liside; Spectrum4_000560; Vesix; Furex; Macasirool; Frusema; AC-11067; Hissuflux; Prefemin; Furosemidum; KBioGR_001259; CPD000058202; Furorese; BSPBio_000401; FUROSEMIDE USP; TL8003563; Apo-Frusemide; Impugan; Furosix; Profemin; KBioSS_001580; Furosemidu [Polish]; AC1L1FXW; CAS-54-31-9; S1603_Selleck; Uritol; Hydro; 54-31-9; Logirene; UPCMLD-DP022:001; Edemid; F0182; Disemide; 5-18-09-00555 (Beilstein Handbook Reference); Frusetic; Prestwick0_000341; Chlor-N-(2-furylmethyl)-5-sulfamylanthranilsaeure; Endural; Prestwick_752; D00331; AKOS000266625; Anthranilic acid, 4-chloro-N-furfuryl-5-sulfamoyl-; Salurex; Hydroled; 4-chloro-2-(furan-2-ylmethylamino)-5-sulfamoylbenzoic acid; Lowpston; Frusedan; Frumex; C12H11ClN2O5S; Myrosemide; Desdemin; DB07799; Furosemidum [INN-Latin]; LB 502; Furantral; Retep; Hydrex; DB00695; Oprea1_667724; Furosemidu; Disal; Seguril; HSDB 3086; 4-Chloro-N-(2-furylmethyl)-5-sulfamoylanthranilic acid; DivK1c_000575; Lasix (TN); Lasix; Frusid; Diusil; Bioretic; Eutensin; Lasilix; ARONIS24304; Diural; Hydro-rapid; LS-204; Fulsix; Zafimida; IDI1_000575; Spectrum5_000744; Furosemix; Prestwick1_000341; Furosemida; Fursemida; Eliur; Mita; Kutrix; Spirofur; Rosemide; Furobeta; Diurin; Fursemid; Urex-M; Rosis; Cetasix; SAM002264614; Spectrum2_001005; KBio2_001580; Lasex; Urian; Diurapid; Furomen; Fluidrol; Dryptal; Sigasalur; Furosemide (JP15/USP/INN); Lasemid; I04-0179; Nelsix; Aldalix; BIDD:GT0139; Furodiurol; Promide; Anfuramaide; Aldic; Furosan; Neo-renal; Durafurid; AB00052001; Odemex; Fluss; Furosemid; Furosifar; Furomide M.D.; Apo-Furosemide; furosemide ''mita''; Furoter; Furo-puren; Salix (brand of furosemide); Chlor-N-(2-furylmethyl)-5-sulfamylanthranilsaeure [German]; Furanthril; Furantril; Aluzine; NCI-C55936; NSC 269420; 4-Chloro-N-furfuryl-5-sulfamoylanthranilic acid; HMS1569E03; NSC269420; KBio2_004148; Frusemid; 4-Chloro-5-sulfamoyl-N-furfuryl-anthranilic acid; Diurolasa; NCGC00090893-01; Rusyde; Furocot; KBio3_001274; Furosemida [INN-Spanish]; Lowpstron; Aquarid; HMS1920B03; Dranex; Diusemide; BRN 0840915; Kolkin; Furo-Basan; NCGC00090893-06; Furomex; Furoside; Furose; Spectrum3_000437; NCGC00016241-01; CHEMBL35; Lasix Special; Spectrum_001100; Lasiletten; Fursemide; 4-chloro-2-[(furan-2-ylmethyl)amino]-5-sulfamoylbenzoic acid; Frusemide; SPECTRUM1500310; Depix; Nadis	54-31-9	3440	148711	TTDS00116	Solute carrier family 12 member 1	Bumetanide-sensitive sodium-(potassium)-chloride cotransporter 2;Bumetanide-sensitive sodium-(potassium)Solute carrier family 12 member 1-chloride cotransporter 2;Kidney-specific Na-K-Cl symporter;Na+/K+/2CL- co-transporter;NKCC2;Solute carrier family 12 member	Q13621	6557	ENSG00000074803	blocker
DAP000035	Trichlormethiazide	KBio3_002146; Trichlormethiazidum; BPBio1_000825; Naquasone; Isestran; Spectrum_000520; Jones Brand of Trichloromethiazide; trichloromethiazide, 6; Flurese; BSPBio_000749; D014237; KBio1_000366; LS-40435; 6-Chloro-3-(dichloromethyl)3,4-dihydro-7-sulfamyl-1,2,4-benzothiadiazine-1,1-dioxide; Prestwick0_000825; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3-(dichloromethyl)-3,4-dihydro-, 1,1-dioxide; HMS2092O19; 6-Chloro-3-[dichloromethyl]-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide-1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3-(dichloromethyl)-3,4-dihydro-,1,1-dioxide; Spectrum3_001373; MLS000028705; DivK1c_000366; Triclormetiazide; KBio2_006136; Prestwick_1020; NSC 61560; Kubacron; AR-1H7280; CID5560; EINECS 205-118-8; Trichlormetazid; HMS1570F11; 3-Dichloromethyl-6-chloro-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide; Naqua (TN); C07767; T1318; Diurese; 3-(Dichloromethyl)-6-chloro-7-sulfamoyl-3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide; Trichlorex; Triclormetiazide [DCIT]; 3-(Dichloromethyl)-6-chloro-7-sulfamoyl-3,4-dihydro-1,2,4-benzothiadiazine-1,1-dioxide; Schering Brand of Trichlormethiazide; Carvacron; Trichlormethiazide [INN:JAN]; Aquazide; Trichlormethiazidum [INN-Latin]; Metahydrin; Metatensin; Nakva; SPBio_000916; Triclormetiazida; 6-Chloro-3-dichloromethyl-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-Dioxide; NINDS_000366; HMS1921G13; UNII-Q58C92TUN0; Anistadin; Triflumen; KBioGR_000833; MLS001076545; BSPBio_002926; HMS501C08; Fluitran; Prestwick3_000825; AC1L1KMB; BRD-A28940325-001-05-9; IDI1_000366; Eurinol; Triclormetiazide [Italian]; Spectrum2_000948; Trichloromethiadiazide; 133-67-5; SPECTRUM1500590; Trichlormethiazid; Esmarin; Diuroral; Diurazida; SMR000058712; Trichlormethiazide (JP15/USP/INN); NSC61560; HMS2090G08; Tolcasone; 6-Chloro-3-(dichloromethyl)-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; Trichlordiuride; 6-Chloro-3-dichloromethyl-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine1,1-dioxide; Aponorin; NCGC00089756-02; NCGC00089756-03; Intromene; WLN: T66 BSWM EM DHJ DYGG HG ISZW; 6-Chloro-3-(dichloromethyl)-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide1,1-dioxide; Flutra; Diu-Hydrin; KBio2_003568; Trichlormas; CHEMBL1054; Ciba 7057-Su; HSDB 3406; Salurin (wadel); 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3-(dichloromethyl)-3,4-dihydro-, 1,1-dioxide, (+-)-; T1016_SIGMA; Flurese (VAN); SPBio_002670; Triclordiuride; Achletin; Naqua; Chlopolidine; trichlormethiazide; Schebitran; Triclormetiazida [INN-Spanish]; D00658; Prestwick1_000825; 3-Dichloromethylhydrochlorothiazide; Tachionin; KBio2_001000; Spectrum5_001074; MolPort-003-666-298; Trichlormethiazide W/ Reserpine; Trichloromethiazide; Gangesol; (+-)-6-Chloro-3-(dichloromethyl)-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 3-Dichloromethyl-6-chloro-7-sulfamoyl-3,4-dihydro-1,2,4-benzothiadiazine-1,1-dioxide; AB00052117; Hydrotrichlorothiazide; Prestwick2_000825; 6-Chloro-3-(dichloromethyl)3,4-dihydro-7-sulfamoyl-1,2,4-benzothiadiazine-1,1-dioxide; KBioSS_001000; NCIOpen2_007750; DB01021; Cretonin; American Urologicals Brand of Trichloromethiazide; ST51015129; Spectrum4_000367; 3-Dichloromethyl-6-chloro-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine1,1-dioxide; AC1Q6TQ0; BRN 0629145	133-67-5	5560	9969	TTDS00116	Solute carrier family 12 member 1	Bumetanide-sensitive sodium-(potassium)-chloride cotransporter 2;Bumetanide-sensitive sodium-(potassium)Solute carrier family 12 member 1-chloride cotransporter 2;Kidney-specific Na-K-Cl symporter;Na+/K+/2CL- co-transporter;NKCC2;Solute carrier family 12 member	Q13621	6557	ENSG00000074803	blocker
DAP000748	Ethacrynic acid	Spectrum2_000097; Ethacrynic acid (USP); CHEBI:4876; 2-[2,3-dichloro-4-(2-methylidenebutanoyl)phenoxy]acetic acid; SMR000058600; Etacrynic acid (JP15/INN); NCGC00022601-04; NSC 624008; C13H12Cl2O4; (2,3-Dichloro-4-(2-methylenebutyryl)phenoxy)acetic acid; KBio3_001230; CCRIS 4638; BRD-K63630713-001-05-0; Acidum etacrynicum [INN-Latin]; Acido etacrinico [INN-Spanish]; bmse000134; BSPBio_000078; 2,3-Dichloro-4-(2-methylenebutyryl)phenoxy acetic acid; Ethacryinic Acid; ethacrynate; Acido etacrinico; Prestwick_671; Ethacrinique (acide); Etacrinic acid; Kyselina ethakrynova [Czech]; NSC 85791; 2,3-Dichloro-4-(2-methylenebutyl)phenoxyacetic acid; NCGC00016260-02; Etacrynic Acid; NCGC00022601-05; SPBio_000054; BPBio1_000086; Acidum etacrynicum; Hidromedin; Spectrum4_000544; Kyselina 4-(2-(1-butenyl)karbonyl)-2,3-dichlorfenoxyoctova [Czech]; NCI60_041898; Methylenebutyrylphenoxyacetic acid; MolPort-003-666-185; [2,3-Dichloro-4-(2-methylene-1-oxobutyl)phenoxy]acetic acid; NSC624008; Kyselina 4-(2-(1-butenyl)karbonyl)-2,3-dichlorfenoxyoctova; HMS1568D20; Crinuryl; MLS000069535; MK 595; BRN 1915060; [4-(2-Methylenebutyryl)-2,3-dichlorophenoxy]acetic acid; Acide etacrynique [INN-French]; CHEMBL456; Edecril; Reomax; Kyselina ethakrynova; KBio2_006429; SPBio_002297; Prestwick2_000259; Spectrum3_000425; (2,3-Dichloro-4-[2-methylenebutyryl]phenoxy)acetic acid; Edecrina; SPECTRUM1500287; Prestwick1_000259; 58-54-8; Acide etacrynique; [2,3-Dichloro-4-(2-methylenebutyryl)phenoxy]acetic acid; CAS-58-54-8; DB00903; AC1L1FKN; 2,3-Dichloro-4(2-methylene- butyryl)phenoxy] acetic acid; 6500-81-8 (hydrochloride salt); 2gss; Acetic acid, (2,3-dichloro-4-(2-methylene-1-oxobutyl)phenoxy)-; (2,3-Dichloro-4-(2-methylene-1-oxobutyl)phenoxy)acetic acid; KBio2_001293; MK-595; Prestwick3_000259; Ethacrynic Acid, Sodium Salt; Prestwick0_000259; Etakrinic acid; E4754_FLUKA; HMS2089N17; EINECS 200-384-1; Otacril; Hydromedin; Spectrum_000813; AB00051988; WLN: QV1OR BG CG DVY2&U1; SBB064161; CID3278; Acetic acid, (2,3-dichloro-4-(2-methylenebutyryl)phenoxy)-; NCGC00022601-03; BSPBio_002010; Acetic acid, [2,3-dichloro-4-(2-methylene-1-oxobutyl)phenoxy]-; KBioGR_001207; MLS002701928; Acetic acid, [2,3-dichloro-4-(2-methylenebutyryl)phenoxy]-; NSC85791; KBio2_003861; Mingit; E0526; LS-240; HMS502M22; E4754_SIGMA; ETHACRYNIC ACID; HMS1920M16; 2,3-Dichloro-4-(2-methylenebutyryl)phenoxyacetic acid; (4-(2-Methylenebutyryl)-2,3-dichlorophenoxy)acetic acid; Methylenebutyryl phenoxyacetic acid; AKOS003404732; KBio1_000900; Ethacrinic acid; KBioSS_001293; Spectrum5_000680; SAM002264611; [2,3-dichloro-4-(2-methylenebutanoyl)phenoxy]acetic acid; HSDB 2136; Uregit; Ethacrynic acid [USAN:BAN]; CPD000058600; IDI1_000900; DivK1c_000900; Endecril; [2,3-dichloro-4-(2-methylidenebutanoyl)phenoxy]acetic acid; D00313; UNII-M5DP350VZV; NINDS_000900; Edecrin; 1gsf; HMS2091D17; Taladren; NCGC00016260-01	58-54-8	3278	9197	TTDS00116	Solute carrier family 12 member 1	Bumetanide-sensitive sodium-(potassium)-chloride cotransporter 2;Bumetanide-sensitive sodium-(potassium)Solute carrier family 12 member 1-chloride cotransporter 2;Kidney-specific Na-K-Cl symporter;Na+/K+/2CL- co-transporter;NKCC2;Solute carrier family 12 member	Q13621	6557	ENSG00000074803	blocker
DAP000747	Hydroflumethiazide	2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3,4-dihydro-6-(trifluoromethyl)-, 1,1-dioxide; KBio2_006521; CID3647; MLS000028516; Diurometon; Di-adenil; Spectrum_000905; 7-Sulfamyl-6-trifluoromethyl-3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide; C07763; EINECS 205-173-8; Rodiuran; Metforylthiazidin; Enjit; Hidroalogen; Hidroflumetiazida; Hydrenox; Hydroflumethiazidum [INN-Latin]; SPBio_001139; SPBio_001966; Elodrine; AC1L1GEH; AC1Q4JYO; Metflorylthiazidine; H8760_SIGMA; CPD000058284; Olmagran; SPECTRUM1500341; Prestwick1_000013; HFZ; 7-Sulfamoyl-6-trifluoromethyl-3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide; Saluron (TN); UNII-501CFL162R; H8760_FLUKA; 4-27-00-08035 (Beilstein Handbook Reference); KBio2_001385; MolPort-001-771-232; 6-(Trifluoromethyl)-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 2H-1,2, 4-Benzothiadiazine-7-sulfonamide, 3, 4-dihydro-6-(trifluoromethyl)-, 1,1-dioxide; 3, 4-Dihydro-6-trifluorom; Saluron; LS-40451; Vergonil; Prestwick3_000013; 6-Trifluoromethyl-3,4-dihydro-7-sulfamoyl-2H-1,2,4-benzothiadiazine 1,1-dioxide; Idroflumetiazide [DCIT]; Rontyl; IDI1_000512; 3,4-Dihydro-6-(trifluoromethyl)-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; WLN: T66 BSWM EM DHJ HXFFF ISZW; Hydol; NSC 44627; ethyl-2H-1,2, 4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 3, 4-Dihydro-6-trifluoromethyl-7-sulfamoylbenzo-1,2,4-thiadiazine 1, 1-dioxide; 3,4-Dihydro-7-sulfamoyl-6-trifluoromethyl-2H-1,2, 4-benzothi; 6-Trifluoromethyl-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine-1,1-dioxide; 7-Sulfamyl-6-trifluoromethyl-3,4-dihydro-1,2,4-benzothiadiazine 1, 1-dioxide; Prestwick0_000013; HMS1568C07; Spectrum2_001010; SR-01000003094-2; Glomerulin; KBioSS_001385; KBio2_003953; DivK1c_000512; CHEMBL1763; SAM002703134; NCGC00016401-01; HMS501J14; Hydroflumethizide; NINDS_000512; 6-Trifluoromethyl-7-sulfamoyl-3,4-dihydro-1,2,4-benzothiadiazine-1,1-dioxide; Hydroflumethiazide [INN:BAN:JAN]; NCGC00016401-02; Robezon; 3,4-Dihydro-7-sulfamoyl-6-trifluoromethyl-2H-1,2,4-benzothiadiazine 1,1-dioxide; Elodrin; Methforylthiazidine; HSDB 3340; Metforylthiadiazin; HMS1920F05; 1,1-dioxo-6-(trifluoromethyl)-3,4-dihydro-2H-1; Hydroflumethiazidum; adiazine 1,1-dioxide; 6-Trifluoromethyl-3, 4-dihydro-7-sulfamoyl-2H-1,2,4-benzothiadiazine 1,1-dioxide; 6-Trifluoromethyl-7-sulfamoyl-3,4-dihydro-1,2, 4-benzothiadiazine-1,1-dioxide; 7-Sulfamoyl-6-tri; D00654; 3,4-Dihydro-6-trifluoromethyl-7-sulfamoylbenzo-1,2,4-thiadiazine 1,1-dioxide; KBioGR_000359; Spectrum5_000832; ZINC00897225; KBio1_000512; Bristurin; Idroflumetiazide; C8H8F3N3O4S2; CAS-135-09-1; 3,4-Dihydro-6-trifluoromethyl-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 3,4-Dihydro-7-sulfamyl-6-trifluoromethyl-2H-1,2,4-benzothiadiazine 1,1-dioxide; Hydroflumethiazide (JAN/USP/INN); 135-09-1; nchembio747-comp19; MLS001148090; Rivosil; KBio3_001360; BSPBio_002140; Di-ademil; Prestwick2_000013; NaClex; AR-1J2060; BRN 0342692; Hidroflumetiazida [INN-Spanish]; fluoromethyl-3, 4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide; SB01887; NCGC00023353-04; Dihydroflumethiazide; Trifluoromethylhydrazide; BPBio1_000051; hydroflumethiazide; Prestwick_268; Trifluoromethylhydrothiazide; Flutizide; BSPBio_000045; SMR000058284; NSC44627; Hidroflumetiazid; Spectrum3_000460; component of Salutensin; NCGC00023353-03; Leodrine; Spandiuril; Hydroflumethazide; Finuret; Diucardin; Naciex (glaxo); Bristab; 6-(Trifluoromethyl)-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; BRD-K36862742-001-05-8; AB00052016; DB00774; HMS2091L13; Sisuril; Spectrum4_000010; Dihydroflumethazide; Diuredemina	135-09-1	3647	9965	TTDS00116	Solute carrier family 12 member 1	Bumetanide-sensitive sodium-(potassium)-chloride cotransporter 2;Bumetanide-sensitive sodium-(potassium)Solute carrier family 12 member 1-chloride cotransporter 2;Kidney-specific Na-K-Cl symporter;Na+/K+/2CL- co-transporter;NKCC2;Solute carrier family 12 member	Q13621	6557	ENSG00000074803	blocker
DAP000361	Bumetanide	Bumetanide Leo Brand; KBio2_002796; IDI1_033978; AB00052253; NCGC00015149-03; Prestwick1_000276; Lunetoron; HMS2092N03; NCGC00022072-07; Lopac0_000162; KBio3_002561; Atlantis Brand of Bumetanide; KBioSS_000228; BPBio1_000168; 3-(Aminosulfonyl)-5-(butylamino)-4-phenoxybenzoic acid; Bio1_000910; Bumetanidum; NCGC00015149-12; S1287_Selleck; NCGC00022072-03; 3-(aminosulfonyl)-5-(butylamino)-4-(phenyloxy)benzoic acid; Leo Brand of Bumetanide; Drenural; HMS1361L10; BSPBio_000152; Prestwick2_000276; SMP1_000049; B 3023; I06-2277; Spectrum5_001212; D00247; Spectrum4_000030; Fordiuran; Bumetanide Roche Brand; Ro-10-6338; Bio1_000421; KBio2_005364; CPD000058418; Prestwick_679; SPECTRUM1502004; Bumetanide (JP15/USP); NCGC00022072-04; LS-36330; Bumetanide Farmacusi Brand; 28395-03-1; HMS1568H14; Bumetanide Atlantis Brand; Fontego; Senosiain Brand of Bumetanide; Bumex, Bumetanide; NCGC00015149-06; DivK1c_000034; KBio2_004365; Bumex (TN); KBio1_000034; SPBio_000980; KBioGR_000228; SMR000058418; Spectrum_001317; Cambiex; EINECS 249-004-6; KBio3_000456; KBioGR_000439; NCGC00022072-05; Grossmann Brand of Bumetanide; Bumetanide (JP15/USP/INN); Bumetanide Grossmann Brand; ST51014910; MLS000028457; Aquazone; Bio2_000708; Lixil-Leo; KBio3_000455; BRN 2185351; 3-butylamino-4-(phenoxy)-5-sulfamoylbenzoic acid; KBio2_000228; DB00887; KBio2_006933; Bumetanide [USAN:BAN:INN:JAN]; SPBio_002371; IDI1_000034; BSPBio_003061; Segurex; Bumetanide Senosiain Brand; Lixil; BSPBio_001508; Butinat; UNII-0Y2S3XUQ5H; KBioSS_001797; AC-15228; AstraZeneca Brand of Bumetanide; HMS1791L10; PF 1593; NINDS_000034; Spectrum2_001050; Benzoic acid, 3-(aminosulfonyl)-5-(butylamino)-4-phenoxy-; Prestwick3_000276; Prestwick0_000276; CID2471; SAM002564195; Spectrum3_001481; AC1L1DR5; 3-(Butylamino)-4-phenoxy-5-sulfamoylbenzoic acid; HMS1921B20; Bumethanide; Bumetanida [INN-Spanish]; Bumetanida; CHEBI:3213; Bumetanidum [INN-Latin]; CHEMBL1072; MLS001148265; Bumedyl; HMS500B16; HMS2089P13; Bio1_001399; EU-0100162; C17H20N2O5S; NCGC00022072-08; PF-1593; Diurama; KBio2_001797; D002034; BRD-K38197229-001-06-7; Ro 10-6338; CAS-28395-03-1; Lopac-B-3023; Burine; Burinex; NCGC00022072-06; Bio2_000228; B3023_SIGMA; MolPort-003-666-390; Farmacusi Brand of Bumetanide; Yurinex; bumetanide; Miccil; PF1593; Bumetanide AstraZeneca Brand; HMS1989L10; NCGC00015149-01; BENZOIC ACID, 3-(BUTYLAMINO)-4-PHENOXY-5-SULFAMOYL-; Roche Brand of Bumetanide; Bumex; NCGC00015149-02	28395-03-1	2471	175984	TTDS00116	Solute carrier family 12 member 1	Bumetanide-sensitive sodium-(potassium)-chloride cotransporter 2;Bumetanide-sensitive sodium-(potassium)Solute carrier family 12 member 1-chloride cotransporter 2;Kidney-specific Na-K-Cl symporter;Na+/K+/2CL- co-transporter;NKCC2;Solute carrier family 12 member	Q13621	6557	ENSG00000074803	blocker
DAP000745	Torasemide	AC1L26H7; 3-pyridinesulfonamide,N-(((1-methylethyl)amino)carbonyl)-4-((3-methylphenyl)amino)-; MLS001424121; CAS-56211-40-6; Luprac; MLS001195611; PW-2132; KBio2_002256; Prestwick2_001030; Torasemide N; SPBio_003080; N-(((1-Methylethyl)amino)carbonyl)-4-((3-methylphenyl)amino)-3-pyridinesulfonamide; Spectrum5_001699; Luprac (TN); BRN 0498515; MolPort-002-885-870; JDL 464; AC1Q6UVM; KBioGR_000820; 3-Pyridinesulfonamide, N-(((1-methylethyl)amino)carbonyl)-4-((3-methylphenyl)amino)-; Torocard; Torsemide [USAN]; 1-isopropyl-3-[(4- m -toluidino-3-pyridyl) sulfonyl]urea; Ambap56211-40-6; KBio3_003008; BIDD:GT0623; Unat; C16H20N4O3S; Spectrum4_000290; Demadex, Torsemide; NCGC00095141-01; TL8003646; Dilutol; Spectrum3_001832; AC 4464; 1-isopropyl-3-((4-(3-methylphenylamino)pyridine)-3-sulfonyl)urea; Sutril; CID41781; BM 02015; MolPort-003-666-610; ZINC00005823; 1-Isopropyl-3-((4-m-toluidino-3-pyridyl)sulfonyl)urea; AC-4464; HMS1922N05; KS-1123; 1-[4-(3-methylanilino)pyridin-3-yl]sulfonyl-3-propan-2-ylurea; AB00514011; Torasemidum; JDL-464; GJ-1090; C026116; Toradiur; 56211-40-6; NCGC00016879-01; LS-131973; BPBio1_001341; SMR000466313; Torasemide; NCGC00095141-03; Prestwick0_001030; N-{[(1-methylethyl)amino]carbonyl}-4-[(3-methylphenyl)amino]pyridine-3-sulfonamide; Torasemida; Spectrum_001776; Prestwick1_001030; SAM001246567; BSPBio_003503; Torasemida [INN-Spanish]; Torsemide (USP); Torem; TORSEMIDE; UNII-W31X2H97FB; BSPBio_001219; Presoril; HMS2051L21; Torasemidum [INN-Latin]; Prestwick3_001030; NCGC00095141-02; Demadex (TN); I06-0056; AC-18762; SPBio_001063; BM-02015; DB00214; N-(Isopropylcarbamoyl)-4-(m-tolylamino)pyridine-3-sulfonamide; CHEMBL1148; CCRIS 6736; KBio2_004824; S1698_Selleck; BRD-K30480208-001-05-2; Spectrum2_001142; KBio2_007392; Torasemide (JAN/INN); Torrem; SPECTRUM1505211; KBioSS_002257; Demadex; D00382; MLS000759418; HMS1571M21; CPD000466313; MLS001165687	56211-40-6	41781	182449	TTDS00116	Solute carrier family 12 member 1	Bumetanide-sensitive sodium-(potassium)-chloride cotransporter 2;Bumetanide-sensitive sodium-(potassium)Solute carrier family 12 member 1-chloride cotransporter 2;Kidney-specific Na-K-Cl symporter;Na+/K+/2CL- co-transporter;NKCC2;Solute carrier family 12 member	Q13621	6557	ENSG00000074803	blocker
DAP000188	Bendroflumethiazide	BL H368; DB00436; Bendroflumethazide; Poliuron; CID2315; Bendrofluazide; Aprinox; (+-)-3-Benzyl-3,4-dihydro-6-(trifluoromethyl)-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; DivK1c_000274; Bendroflumethiazide (JAN/USP/INN); Benuron; Salures; Spectrum_001386; Livesan; KBio1_000274; Naigaril; 3-Benzyl-3,4-dihydro-6-(trifluoromethyl)-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; Thiazidico; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3,4-dihydro-3-(phenylmethyl)-6-(trifluoromethyl)-, 1,1-dioxide; CPD000058802; Bristuron; SPECTRUM1503104; Bendroflumetiazide; KBioGR_001188; Bendroflumetiazida [INN-Spanish]; Centyl; CHEBI:3013; KBio2_007002; BRD-A80017228-001-05-9; Benzy-rodiuran; SPBio_002827; IDI1_000274; Naturetin; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3-benzyl-3,4-dihydro-6-(trifluoromethyl)-,1,1-dioxide; Prestwick3_000784; ST51014919; +--3-benzyl-3,4-dihydro-6-(trifluoromethyl)-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; NINDS_000274; SPBio_001308; bendrofumethiazide; Prestwick0_000784; C07758; C15H14F3N3O4S2; Urlea; Naturetin (TN); Plusuril; Be 724-A; BSPBio_000888; Rautrax N; Bentride; Benzydroflumethiazide; Spectrum2_001524; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3,4-dihydro-3-(phenylmethyl)-6-(trifluoromethyl)-, 1,1-dioxide, (+-)-; 4-27-00-08041 (Beilstein Handbook Reference); 3-Benzyl-6-trifluoromethyl-7-sulfamoyl-3,4-dihydro-1,2,4-benzothiadiazine, 1,1-dioxide; Orsile; Naturine; Niagaril; Benzhydroflumethiazide; UNM000000601501; Relan beta; Spectrum5_001016; NCGC00089729-03; Neo-rontyl; Spectrum3_001558; EINECS 200-800-1; Berkozide; B5775_FLUKA; FT 8; Naturetin-2.5; HMS1570M10; NATURETIN-5; Benzylrodiuran; Sodiuretic; MLS000028558; 6-trifluoromethyl-3-benzyl-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide; 3,4-Dihydro-3-(phenylmethyl)-6-(trifluoromethyl)-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; BSPBio_003036; HMS1922E15; AC1L1DEI; Spectrum4_000774; Corzide; MolPort-003-666-443; Nateretin; 3-(phenylmethyl)-6-(trifluoromethyl)-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; Bendroflumethiazide [USP]; BPBio1_000978; Sinesalin; Pluryle; CHEMBL1684; LS-40431; Bendroflumetiazida; Rauzide; BRN 0373316; KBio2_001866; Pluryl; Neo-naclex; Bendroflumethiazidum; 96782-79-5; EU-0009291; HSDB 3293; HMS500N16; 3-Benzyl-6-trifluoromethyl-7-sulfamoyl-3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide; B5775_SIGMA; AB00052315; NATURETIN-10; KBio2_004434; Bendroflumetiazide [DCIT]; HMS2092J16; FT 81; BHFT; Nikion; Bendroflumethiazidum [INN-Latin]; 3-Benzyl-6-(trifluoromethyl)-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3-benzyl-3,4-dihydro-6-(trifluoromethyl)-, 1,1-dioxide; UNII-5Q52X6ICJI; Prestwick2_000784; KBioSS_001866; nchembio747-comp20; BENDROFLUMETHIAZIDE; SAM002264598; 73-48-3; KBio3_002536; SMR000058802; Salural; Intolex; D00650; MLS001076062; Prestwick1_000784; Prestwick_992; Bristuric; Flumersil; NCGC00089729-02; Flumesil; 6-Trifluoromethyl-3-benzyl-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine, 1,1-dioxide; Benzylhydroflumethiazide; Repicin	73-48-3	2315	9960	TTDS00116	Solute carrier family 12 member 1	Bumetanide-sensitive sodium-(potassium)-chloride cotransporter 2;Bumetanide-sensitive sodium-(potassium)Solute carrier family 12 member 1-chloride cotransporter 2;Kidney-specific Na-K-Cl symporter;Na+/K+/2CL- co-transporter;NKCC2;Solute carrier family 12 member	Q13621	6557	ENSG00000074803	blocker
DAP000746	Methyclothiazide	NSC 110431; CI-625; Enduron (TN); Methyclothiazide (JAN/USP/INN); Enduronum; Meticlotiazida; WLN: T66 BSWN EM DHJ C1 D1G HG ISZW; SBB070984; EINECS 205-172-2; NSC110431; AC1Q6TPS; SMR001550236; 6-Chloro-3-(chloromethyl)-3,4-dihydro-2-methyl-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; NSC-110431; Naturon; DB00232; LS-40433; CID4121; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3-(chloromethyl)-3,4-dihydro-,1,1-dioxide; D00656; Aquaresen; Methychlothiazide; Methylcyclothiazide; Meticlotiazida [INN-Spanish]; NCGC00167446-01; AR-1J4220; (+-)-6-Chloro-3-(chloromethyl)-3,4-dihydro-2-methyl-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; BRN 0765361; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3-(chloromethyl)-3,4-dihydro-2-methyl-, 1,1-dioxide, (+-)-; methyclothiazide; MLS002704228; 6-Chloro-3-(chloromethyl)-2-methyl-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; e; 6-Chloro-3-(chloromethyl)-3,4-dihydro-2-methyl-2H-1,2, 4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 135-07-9; 6-chloro-3-(chloromethyl)-2-methyl-1,1-dioxo-3,4-dihydro-1; Methyclothiazidum [INN-Latin]; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3-(chloromethyl)-3,4-dihydro-2-methyl-, 1,1-dioxide; 6-Chloro-3-chloromethyl-2-methyl-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide; 6-Chloro-3-(chloromethyl)-2-methyl-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3-(chloromethyl)-3,4-dihydro-2-methyl-, 1,1-dioxid; Methyclothiazide [USAN:INN:BAN:JAN]; Ciba 7272-Su; Enduron; Naturon (VAN); Methycyclothiazide; AC1L1HGJ; Methyclothiazid; Methylchlorothiazide; UNII-L3H46UAC61; Meticlotiazide; Meticlotiazide [DCIT]; HSDB 3363; Aquatensen; CHEMBL1577; C07765; Methyclothiazidum; Duretic; C9H11Cl2N3O4S2; METHYLCLOTHIAZIDE; I06-1878	135-07-9	4121	9967	TTDS00116	Solute carrier family 12 member 1	Bumetanide-sensitive sodium-(potassium)-chloride cotransporter 2;Bumetanide-sensitive sodium-(potassium)Solute carrier family 12 member 1-chloride cotransporter 2;Kidney-specific Na-K-Cl symporter;Na+/K+/2CL- co-transporter;NKCC2;Solute carrier family 12 member	Q13621	6557	ENSG00000074803	blocker
DCL000081	CD-NP	N/A	N/A	N/A	N/A	TTDC00029	Atrial natriuretic peptide receptor B	ANP-B;ANPRB;Atrial natriuretic peptide B-type receptor;GC-B;Guanylate cyclase B;NPR-B	P20594	4882	ENSG00000159899	activator
DCL001203	ISIS-SOD1	N/A	N/A	N/A	N/A	TTDC00325	mRNA of copper zinc superoxide dismutase 1	mRNA of Superoxide dismutase [Cu-Zn];mRNA of Superoxide dismutase 1	P00441	6647	ENSG00000142168	antisense
DCL001099	LY293558	Decahydro-6-(2-(1H-tetrazol-5-yl)ethyl)-3-isoquinolinecarboxylic acid; UNII-GA36S2O9C2; CID127894; CHEBI:114665; LY293558; (3S,4aR,6R,8aR)-6-[2-(2H-tetrazol-5-yl)ethyl]-1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline-3-carboxylic acid; Ted-isoquinoline-3-cooh; Tezampanel, anhydrous; 3-Isoquinolinecarboxylic acid, decahydro-6-(2-(1H-tetrazol-5-yl)ethyl)-, (3S-(3alpha,4aalpha,6beta,8aalpha))-; LY 293558; 3-Isoquinolinecarboxylic acid, decahydro-6-(2-(1H-tetrazol-5-yl)ethyl)-, (3S,4aR,6R,8aR)-; LS-85440; 6-(2-(1H-Tetrazol-5-yl)ethyl)-1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline-3-carboxylic acid; AC1L2STK; 150131-78-5; 154652-83-2; CHEMBL14935	N/A	N/A	N/A	TTDS00122	Glutamate receptor, ionotropic kainate 1	EAA3;Excitatory amino acid receptor 3;GluR5;GluR-5;GluR5 kainate receptor;Glutamate receptor 5	P39086	2897	ENSG00000171189	antagonist
DAP000137	Topiramate	2,3:4,5-Bis-O-(1-methylethylidene)-36-D-fructo-pyranose sulfamate; beta.-D-Fructopyranose, 2,3:4,5-bis-O-(1-methylethylidene)-, 1-sulfamate; Topamax, Topiramate; DB00273; MLS000759431; C12H21NO8S; CPD000466325; Topiramic acid; Tipiramato [Spanish]; CBChromo1_000352; Epitoma; T0575_SIGMA; CHEMBL220492; BIDD:PXR0127; Epitomax; 2,3-4,5-bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate; Topiramate (JAN/USAN/INN); NCGC00178714-01; TL8006021; BRN 5988957; SMR000466325; KW-6485; HMS2093D20; MolPort-002-885-869; KS-1122; 2,3:4,5-Bis-O-(1-methylethylidene) .beta.-D-fructopyranose sulfamate; Janssen brand of topiramate; Topamax; 2,3:4,5-Di- O -isopropylidene-(beta)-D-fructopyranose sulfamate; MolPort-001-615-062; C07502; LS-69764; Topiramate / Placebo; Topiramate (TPM); 97240-79-4; Topiramatum [INN-Latin]; Cilag brand of topiramate; McN 4853; Tipiramato; Ortho brand of topiramate; Topamax (TN); UNII-0H73WJJ391; RWJ-17021; Tipiramate; Topiramato [INN-Spanish]; Topiramate [USAN:BAN:INN]; HMS1922H06; 2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate; AKOS000424547; SAM001246601; Spectrum2_001128; RWJ 17021; D00537; 2,3:4,5-Di-O-isopropylidene-beta-D-fructopyranose sulfamate; topiramate tablet; Topamax Sprinkle; C052342; Topiramatum; S1438_Selleck; Topina; CID5284627; .beta.-D-Fructopyranose, 2,3:4,5-bis-O-(1-methylethylidene)-, sulfamate (9CI); 5H-Bis[1,3]dioxolo[4,5-b:4',5'-d]pyran, .beta.; BIDD:GT0854; Topimax; MLS001424070; topiramate; -D-fructopyranose deriv.; CHEBI:129573; McN-4853; Topamac; STOCK1N-71037; HMS2051L09; SPBio_000995; USL-255; beta-D-Fructopyranose, 2,3:4,5-bis-O-(1-methylethylidene)-, sulfamate; Topiramato; Topomax; BSPBio_002306; RWJ-17021-000; [(3aS,5aR,8aR,8bS)-2,2,7,7-tetramethyltetrahydro-3aH-bis[1,3]dioxolo[4,5-b:4',5'-d]pyran-3a-yl]methyl sulfamate; topiramatum [Latin]; TOR; Tipiramate [French]; LS-187392; HSDB 7531; SPECTRUM1505801	97240-79-4	5284627	194321	TTDS00122	Glutamate receptor, ionotropic kainate 1	EAA3;Excitatory amino acid receptor 3;GluR5;GluR-5;GluR5 kainate receptor;Glutamate receptor 5	P39086	2897	ENSG00000171189	antagonist
DPR000033	Cruentaren	N/A	N/A	N/A	N/A	TTDS00427	Vacuolar ATP synthase catalytic subunit A	ATP6A1;ATP6V1A;ATP6V1A1;Vacuolar ATPase isoform VA68;Vacuolar proton pump subunit alpha;V-ATPase 69 kDa subunit;V-ATPase subunit A;VPP2	P38606	523	ENSG00000114573	inhibitor
DAP001103	Lutropin alfa	Luveris; Lutropin alfa; Luveris (TN); 152923-57-4; D04824; Lutropin alfa (USAN/INN)	152923-57-4	N/A	47206610	TTDS00254	Lutropin-choriogonadotropic hormone receptor	LH/CG-R;LHR;LHRH receptor;LSH-R;Luteinizing hormone receptor;Luteinizing hormone-releasing hormone receptor	P22888	3973	ENSG00000138039	binder
DCL000009	XL418	N/A	N/A	N/A	N/A	TTDC00145	Ribosomal protein S6 kinase	P70-S6K;S6K	P23443	6198	ENSG00000108443	inhibitor
DCL000748	Cethromycin	CHEMBL365528; CID447451; (1R,2R,4R,6R,7R,8R,10R,13R,14S)-7-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-13-ethyl-2,4,6,8,10,14-hexamethyl-6-[(E)-3-quinolin-3-ylprop-2-enoxy]-12,15-dioxa-17-azabicyclo[12.3.0]heptadecane-3,9,11,16-tetrone; CHEMBL133924; ABT-773; C12020; 205110-48-1; (1S,2R,5R,7R,8R,9R,11R,13R,14R)-2-Ethyl-1,5,7,9,11,13-Hexamethyl-9-[3-(3-quinolyl)-2(E)-propenyloxy]-8-[3,4,6-trideoxy-3-(dimethylamino)-beta-D-glucopyranosyloxy]-3,17-dioxa-15-azabicyclo[12.3.0]hepta; 2H-Oxacyclotetradecino(4,3-d)oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyloctahydro-3a,7,9,11,13,15-hexamethyl-11-((3-(3-quinolinyl)-2-propenyl)oxy)-10-((3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl)oxy)-, (3aS,4R,7R,9R,10R,11R,13R,15R,15aR)-; Abbott-195773; ABT 773; LS-187642; Cethromycin [USAN]; A-195773; AC1NQZEX; AC1L9KVM; D02391; Cethromycin; (3aS,4R,7R,9R,10R,11R,13R,15R,15aR)-4-Ethyl-3a,7,9,11,13,15 hexamethyl-11-((3-(quinolin-3-yl)prop-2-enyl)oxy)-10-((3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl)oxy)octahydro-2H-oxacyclotetradecino(4,3-d)oxazole-2,6,8,14(1H,7H,9H)-tetrone; CID5282045; (1R,2R,4R,6S,7R,8R,10R,13R,14S)-7-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-13-ethyl-2,4,6,8,10,14-hexamethyl-6-[(E)-3-quinolin-3-ylprop-2-enoxy]-12,15-dioxa-17-azabicyclo[12.3.0]heptadecane-3,9,11,16-tetrone; LS-187007; Restanza; Cethromycin (USAN/INN); CHEBI:40317; (3aS,4R,7R,9R,10R,11R,13R,15R,15aR)-4-Ethyl-3a,7,9,11,13,15-hexamethyl-11-((3-(quinolin-3-yl)prop-2-enyl)oxy)-10-((3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl)oxy)octahydro-2H-oxacyclotetradecino(4,3-d)oxazole-2,6,8,14(1H,7H,9H)-tetrone; A-195773.0	205110-48-1	447451	12015222	TTDS00217	23S rRNA	Plastid 23S rRNA;RrnL	N/A	N/A	N/A	inhibitor
DAP000398	Linezolid	ZINC02008866; linezolid; Linezolid [USAN:INN]; U 100766; D00947; NDA 21-131 Zyvox for injection (linezolid injection); 165800-03-3; Zyvoxid; BIDD:GT0404; AC-16128; NDA 21-130 Zyvox (linezolid tablets); FT-0080803; DB00601; ZLD; Zyvoxa; CID441401; Linezolid & VRC3375; Linezolid (JAN/USAN/INN); N-[[(5S)-3-(3-fluoro-4-morpholin-4-ylphenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide; MolPort-003-986-503; MLS001424075; N-({5S)-3-[3-Fluoro-4-(4-morpholinyl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide, N-[[(S)-3-(3-Fluoro-4-morpholinophenyl)-2-oxo-5-oxazolidinyl]methyl]acetamide; Acetamide, N-(((5S)-3-(3-fluoro-4-(4-morpholinyl)phenyl)-2-oxo-5-oxazolidinyl)methyl)-; 111GE017; CHEMBL126; PNU-100766, U-100766, Zyvoxid, Zyvoxam, Linezolid; HSDB 7478; LS-173594; N-((3-(3-fluoro-4-morpholinylphenyl)-2-oxo-5-oxazolidinyl)methyl)acetamide; PNU-100766; NDA 21-132 Zyvox oral suspension (linzolid oral suspension); DB08769; CPD000466335; SMR000466335; (S)-N-[[3-(3-fluoro-4-morpholinylphenyl)-2-oxo-5-oxazolidinyl]methyl]acetamide; U-100766; MLS000759444; Zyvox; CHEBI:126280; C16H20FN3O4; PNU 100766; HMS2051F08; Zyvoxam; Acetamide, N-[[(5S)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-; N-(((S)-3-(3-Fluoro-4-morpholinophenyl)-2-oxo-5-oxazolidinyl)methyl)acetamide; S1408_Selleck; SAM001246624; C08146; AC1L9B3M; Zyvox (TN); HMS2089K06; TL8001272; Acetamide, N-((3-(3-fluoro-4-(4-morpholinyl)phenyl)-2-oxo-5-oxazolidinyl)methyl)-, (S)-; Linezlid	165800-03-3	441401	10346	TTDS00217	23S rRNA	Plastid 23S rRNA;RrnL	N/A	N/A	N/A	binder
DAP001492	Macrolides	N/A	1401-69-0	5280440	7849535	TTDS00217	23S rRNA	Plastid 23S rRNA;RrnL	N/A	N/A	N/A	binder
DCL000280	Evernimicin	C12050; Everninomycins; AC1MJ6D1; CID11083799; CID10820405; CID3086535; [(2R,3R,4R,6S)-6-[(2'R,3'S,3aR,4R,4'R,6S,7S,7aR)-6-[(2S,3R,4S,5S,6R)-2-[(2R,4S,6S)-6-[(3aR,3'aS,4R,6'S,7R,7'R,7aS,7'aS)-7-(2,4-dihydroxy-6-methylbenzoyl)oxy-7'-hydroxyspiro[3a,6,7,7a-tetrahydro-[1,3]dioxolo[4,5-c]pyran-4,2'-4,6,7,7a-tetrahydro-3aH-[1,3]dioxolo[4,5-c]pyran]-6'-yl]oxy-4-hydroxy-5-methoxy-2-(methoxymethyl)oxan-3-yl]oxy-3-hydroxy-5-methoxy-6-methyloxan-4-yl]oxy-4',7-dihydroxy-2',4,7a-trimethylspiro[3a,4,6,7-tetrahydro-[1,3]dioxolo[4,5-c]pyran-2,6'-oxane]-3'-yl]oxy-4-[(2R,4S,5R,6S)-5-methoxy-4,6-dimethyl-4-nitrooxan-2-yl]oxy-2-methyloxan-3-yl] 3,5-dichloro-4-hydroxy-2-methoxy-6-methylbenzoate; CID9812692; Evernimicin [USAN:INN]; CID10820404; CID9898724; [(2R,3R,4R,6S)-6-[(2R,2'R,3'S,3aR,4R,4'R,6S,7S,7aR)-6-[(2S,3R,4R,5S,6R)-2-[(2R,3S,4S,5S,6S)-6-[(3aR,3'aS,4R,6'S,7R,7'R,7aS,7'aS)-7-(2,4-dihydroxy-6-methylbenzoyl)oxy-7'-hydroxyspiro[3a,6,7,7a-tetrahydro-[1,3]dioxolo[4,5-c]pyran-4,2'-4,6,7,7a-tetrahydro-3aH-[1,3]dioxolo[4,5-c]pyran]-6'-yl]oxy-4-hydroxy-5-methoxy-2-(methoxymethyl)oxan-3-yl]oxy-3-hydroxy-5-methoxy-6-methyloxan-4-yl]oxy-4',7-dihydroxy-2',4,7a-trimethylspiro[3a,4,6,7-tetrahydro-[1,3]dioxolo[4,5-c]pyran-2,6'-oxane]-3'-yl]oxy-4-[(2S,4S,5R,6S)-5-methoxy-4,6-dimethyl-4-nitrooxan-2-yl]oxy-2-methyloxan-3-yl] 3,5-dichloro-4-hydroxy-2-methoxy-6-methylbenzoate; CID9812693; Ziracin; CID9963992; [(2R,3R,4R,6S)-6-[(2R,2'R,3'S,3aR,4R,4'R,6S,7S,7aR)-6-[(2S,3R,4R,5S,6R)-2-[(2R,3S,4S,5S,6S)-6-[(3aR,3'aS,4S,6'S,7R,7'R,7aS,7'aS)-7-(2,4-dihydroxy-6-methylbenzoyl)oxy-7'-hydroxyspiro[3a,6,7,7a-tetrahydro-[1,3]dioxolo[4,5-c]pyran-4,2'-4,6,7,7a-tetrahydro-3aH-[1,3]dioxolo[4,5-c]pyran]-6'-yl]oxy-4-hydroxy-5-methoxy-2-(methoxymethyl)oxan-3-yl]oxy-3-hydroxy-5-methoxy-6-methyloxan-4-yl]oxy-4',7-dihydroxy-2',4,7a-trimethylspiro[3a,4,6,7-tetrahydro-[1,3]dioxolo[4,5-c]pyran-2,6'-oxane]-3'-yl]oxy-4-[(2S,4S,5R,6S)-5-methoxy-4,6-dimethyl-4-nitrooxan-2-yl]oxy-2-methyloxan-3-yl] 3,5-dichloro-4-hydroxy-2-methoxy-6-methylbenzoate; AC1OCETK; Antibiotic 13-384-1; CID443597; Evernimicin; CID9963993; Sch-27899; Everninomycin; Everninomicin; 53024-98-9; AC1L9EW5; CID9877278; CID6917933; CHEMBL263367	109545-84-8	3086535	47206067	TTDS00217	23S rRNA	Plastid 23S rRNA;RrnL	N/A	N/A	N/A	binder
DCL000237	Stannsoporfin	C055421; D05922; Stanate (TN); Stanate; SNMPP; Stannsoporfin; Tin mesoporphyrin; Stannsoporfin (USAN/INN); 106344-20-1; Sn Mesoporphyrin	106344-20-1	23725028	47207580	TTDC00134	Heme oxygenase 1	Heme Oxygenase-1;HO-1	P09601	3162	ENSG00000100292	inhibitor
DAP001107	Rasagiline	(R)-N-2-Propynyl-1-indanamine; RAS; 1-Indanamine, N-2-propynyl-, (R)-; (1R)-N-(prop-2-yn-1-yl)-2,3-dihydro-1H-inden-1-amine; Azilect (TN); Rasagiline (INN); MolPort-003-850-132; NCGC00168774-01; rasagiline; CHEMBL887; LS-186771; CID3052776; CHEBI:45357; UNII-003N66TS6T; D08469; 1H-Inden-1-amine, 2,3-dihydro-N-2-propynyl-, (1R); AC-723; ZINC19875504; AC1MHJZT; DB01367; Rasagiline [INN]; 136236-51-6; (1R)-N-prop-2-ynyl-2,3-dihydro-1H-inden-1-amine; LS-187776	136236-51-6	3052776	10056118	TTDS00341	Amine oxidase [flavin-containing] B	MAO-B;Monoamine oxidase;Monoamine oxidase B	P27338	4129	ENSG00000069535	inhibitor
DAP000578	Phenelzine	cMAP_000003; Phenylethyl hydrazine-HCl; DivK1c_000062; Phenethylhydrazine; UNII-O408N561GF; 2-Phenylethylhydrazine; W 1544-A; BPBio1_000043; Prestwick1_000170; Fenelzyna [Polish]; CHEBI:248018; Spectrum4_000475; HYDRAZINE, PHENETHYL-; 4-15-00-01269 (Beilstein Handbook Reference); KBioSS_002266; W1544; CHEMBL1089; KBioSS_001331; KBioGR_002265; Prestwick3_000170; Phenelzine (BAN); KBio2_001331; NCGC00162301-01; 1-Hydrazino-2-phenylethane; KBio2_007401; EINECS 200-117-9; CID3675; IDI1_000062; BSPBio_000039; AC1L1GGN; Phenelzine; 2-Phenethylhydrazine; Prestwick2_000170; Spectrum3_000677; AKOS000131105; Lopac0_000971; Spectrum_000851; CBChromo1_000176; KBioGR_000950; NINDS_000062; BRN 0742354; KBio2_004833; KBio3_001593; Phenelzinum [INN-Latin]; Spectrum2_001009; LS-76934; Fenelzyna; SPBio_001960; MolPort-003-991-749; C07430; Lopac-P-6777; Fenelzyne [Polish]; NCGC00015830-02; Hydrazine, (2-phenylethyl)-; Phenylethylhydrazine; CAS-156-51-4; beta-Phenylethylhydrazine; Phenelzinum; KBio2_002265; KBio1_000062; Spectrum5_000990; KBio2_006467; CPD001496977; Phenelezine; BRD-K87024524-065-05-2; NCGC00015830-04; Fenelzina; SPBio_001137; KBio3_002745; NCGC00015830-01; KBio2_003899; Phenelzine [INN:BAN]; AB00053520; Fenelzina [INN-Spanish]; 51-71-8; BSPBio_002373; D08349; Prestwick0_000170; SAM002589985; DB00780; MLS000758253; Fenelzyne	51-71-8	3675	9634	TTDS00341	Amine oxidase [flavin-containing] B	MAO-B;Monoamine oxidase;Monoamine oxidase B	P27338	4129	ENSG00000069535	inhibitor
DAP000579	Selegiline	Jumex; Gen-Selegiline; Selegiline, (R)-Isomer; Selegilina; Selegilinum; CID26757; l-E 250; Eldepryl; Nu-Selegiline; (-)-Deprenil; LS-30156; MolPort-000-883-771; N-methyl-N-[(2R)-1-phenylpropan-2-yl]prop-2-yn-1-amine; L-Deprenalin; BSPBio_001589; (2R)-N-methyl-1-phenyl-N-prop-2-ynylpropan-2-amine; selegiline; Apo-Selegiline; HMS1989P11; Deprenyl; 14611-51-9; NCGC00024994-04; (R)-(-)-N,alpha-Dimethyl-N-2-propinylphenethylamine; NCGC00024994-01; Selegiline (USAN/INN); STK640578; DB01037; 2079-54-1 (deprenyl.hydrochloride); Sd Deprenyl; (-)-(N)-Methyl-N-((1R)-1-methyl-2-phenylethyl)prop-2-yn-1-amine; Yumex; Carbex; Selegilina [INN-Spanish]; BRD-K86434416-001-02-7; ZINC19632633; Benzeneethanamine, N,alpha-dimethyl-N-2-propynyl-, (R)-; Prestwick0_000552; Zelapar; Selegiline Transdermal System (STS) patch; Selegyline; Emsam; BRD-K86434416-003-03-1; Humex; NCGC00024994-03; D03731; AKOS000281115; Selegeline Hcl; Selegiline [INN:BAN]; Novo-Selegiline; Benzeneethanamine, N,alpha-methyl-N-2-propynyl-, (alphaR)-; SPBio_002544; (R)-(-)-N-Methyl-N-(1-phenyl-2-propyl)-2-propinylamin; Prestwick1_000552; C13H17N; Prestwick3_000552; Prestwick2_000552; 14611-52-0 (hydrochloride); Tocris-1095; C07245; Selegilinum [INN-Latin]; HMS1791P11; UNII-2K1V7GP655; HMS2089D09; CHEBI:9086; BPBio1_000687; L-Deprenyl; Emsam (TN); CHEMBL972; BSPBio_000623; N-methyl-N-[(1R)-1-methyl-2-phenylethyl]prop-2-yn-1-amine; AC1L1BTZ; Anipryl; NCGC00024994-02; AC1Q2860	14611-51-9	26757	9454	TTDS00341	Amine oxidase [flavin-containing] B	MAO-B;Monoamine oxidase;Monoamine oxidase B	P27338	4129	ENSG00000069535	inhibitor
DAP000081	Tranylcypromine	AC1L9B1D; DivK1c_000588; AC1O7GD6; BRD-A43974575-065-02-8; Cyclopropanamine, 2-phenyl-, (1R,2S)-rel-; NINDS_000588; STOCK1S-62620; D08625; Spectrum2_000960; Spectrum5_001451; Cyclopropanamine, 2-phenyl-, trans-(.+/-.)-; UNII-3E3V44J4Z9; SMR000039637; CBChromo1_000132; AC1Q1HO9; Tranilcipromina; CID19493; SKF Trans-385; CHEMBL1179; 95-62-5; Sulfate, Tranylcypromine; GJZ; Lopac0_001013; tranylcypromine; Cyclopropylamine, 2-phenyl-, (1S-trans)-; AC1L2E8J; AC1Q53BI; Prestwick2_000173; KBioSS_002078; dl-Tranylcypromine; Goldshield Brand of Tranylcypromine Sulfate; CHEMBL257990; trans-DL-2-Phenylcyclopropylamine; CHEBI:588391; 3-12-00-02797 (Beilstein Handbook Reference); Spectrum4_000361; LS-58823; AC1Q4UBQ; PDSP2_001079; CID6971118; BRD-K88809146-003-02-1; Prestwick0_000173; Lopac-P-8511; KBio2_007214; D014191; NCGC00162316-01; BSPBio_002898; Allphar Brand of Tranylcypromine Sulfate; KBio2_002078; SKF 385; MolPort-001-791-393; KBio2_003895; Cyclopropylamine, trans-2-phenyl-; GlaxoSmithKline Brand of Tranylcypromine Sulfate; LS-187134; KBio2_001327; Tranylcyprominum [INN-Latin]; (-)-Tranylcypromine; CID26070; AC-15970; MLS001306494; AC1ODZ9B; Tranilcipromina [INN-Spanish]; CHEBI:293460; PDSP1_001096; trans 2 Phenylcyclopropylamine; Cyclopropanamine, 2-phenyl-, (1R-trans)- (9CI); KBio3_002118; CID6604304; Link Brand of Tranylcypromine Sulfate; Jatrosom; (1R)-2-phenylcyclopropan-1-amine; AC1NWAQS; NCGC00178400-01; Tranylcypromine [INN:BAN]; Spectrum4_001219; CID441233; Cyclopropanamine, 2-phenyl-, trans-; EINECS 205-841-9; (1R,2R)-2-phenylcyclopropan-1-amine; BSPBio_002656; (+)-Tranylcypromine; LS-58824; Cyclopropylamine, 2-phenyl-, trans-(.+-.)-; BRN 2802413; CHEMBL467794; Parnate; Cyclopropylamine, 2-phenyl-, trans-(-)-; PDSP1_001095; 2-Phenyl-1-aminocyclopropane, trans-; 2-phenylcyclopropan-1-amine; NCGC00015848-01; Transamine; Tranylcypromine (INN); MolPort-002-551-002; Parnitene; AC1L1KJT; AC1L9ASR; NSC 80664; NCGC00016598-01; Spectrum5_001829; Cyclopropanamine, 2-phenyl-, trans-(.+-.)-; C9H11N; DB00752; (1S,2S)-2-phenylcyclopropan-1-amine; CHEBI:527107; (2S)-2-phenylcyclopropan-1-amine; CID5530; AC1L1ACF; Cyclopropanamine, 2-phenyl-, (1R-trans)-; Cyclopropylamine, 2-phenyl-, trans-(.+/-.)-; SPBio_000960; NCGC00178400-02; Tranylcyprominum; CID441360; IDI1_000588; KBioGR_001658; trans-2-Phenylcyclopropylamine; AC1Q1HO4; KBio2_006463; Cyclopropanamine, 2-phenyl-, trans-(+)-; Prestwick1_000173; CID5702124; (+)-trans-2-Phenylcyclopropylamine; HSDB 3404; Cyclopropylamine, 2-phenyl-, trans-(+-)-; 155-09-9; 3721-26-4; esparma Brand of Tranylcypromine Sulfate; CHEMBL313833; CCRIS 3344; CHEBI:231607; MolPort-001-783-425; NCGC00015848-03; KBio2_004646; l-Tranylcypromine; Racemic Tranylcypromine; Cyclopropanamine, 2-phenyl-, trans-(+-)-; 2-Phenylcyclopropanamine; CAS-1986-47-6; Spectrum3_001068; trans-(-)-2-Phenylcyclopropanamine; CYCLOPROPYLAMINE, 2-PHENYL-, trans-; KBio3_001876; (1R,2S)-2-phenylcyclopropanamine; KBioSS_001327; Spectrum_001598; d-Tranylcypromine; HMS2089B04; (+)-(R)-Tranylcypromine; KBio1_000588; Spectrum3_001369; NCGC00179670-01; (1S,2R)-2-phenylcyclopropan-1-amine; NSC80664; Spectrum_000847; AR-1E4939; PDSP2_001080; KBioGR_000821; 1tnl; (1S)-2-phenylcyclopropan-1-amine; C07155; (1R,2S)-2-phenylcyclopropan-1-amine; BRN 3195803; SmithKline Brand of Tranylcypromine Sulfate; SPBio_001986; LS-58822; 3721-28-6	155-09-9	441233	9364	TTDS00341	Amine oxidase [flavin-containing] B	MAO-B;Monoamine oxidase;Monoamine oxidase B	P27338	4129	ENSG00000069535	inhibitor
DCL000972	Safinamide	(2S)-2-[[4-[(3-Fluorophenyl)methoxy]phenyl]methylamino]propanamide; N2-{4-[(3-fluorobenzyl)oxy]benzyl}-L-alaninamide; Safinamide; (2R)-2-[[4-[(3-fluorophenyl)methoxy]phenyl]methylamino]propanamide; CID131682; 133865-89-1; AC1L2ZLK; CID5487407; MolPort-005-942-375; (S)-2-(((4-((3-Fluorophenyl)methoxy)phenyl)methyl)amino)propanamide; Fce 26743; AC1NUPG0; Fce-26743; CHEBI:235095; UNII-90ENL74SIG; 2-(4-(3-Fluorobenzyloxy)benzylamino)propionamide; M6252; Propanamide, 2-(((4-((3-fluorophenyl)methoxy)phenyl)methyl)amino)-, (S)-; CHEMBL82327; CHEMBL396778	133865-89-1	127317	46519220	TTDS00341	Amine oxidase [flavin-containing] B	MAO-B;Monoamine oxidase;Monoamine oxidase B	P27338	4129	ENSG00000069535	inhibitor
DPR000092	PF9601N	N/A	N/A	N/A	N/A	TTDS00341	Amine oxidase [flavin-containing] B	MAO-B;Monoamine oxidase;Monoamine oxidase B	P27338	4129	ENSG00000069535	inhibitor
DAP000580	Pargyline	Pargylinum; UNII-9MV14S8G3E; D08453; NCGC00024240-03; Pargylinum [INN-Latin]; Spectrum2_001039; KBio2_003689; CBChromo1_000308; Prestwick0_000183; AC1Q3X8K; NCGC00015841-01; Benzyl-methyl-2-propinylamin; NCGC00015841-03; CCRIS 6740; IDI1_000053; N-methyl-N-(phenylmethyl)prop-2-yn-1-amine; AC1Q3X8L; KBio2_006257; MO 911; SPBio_001257; pargyline; Paragyline; NINDS_000053; 555-57-7; CHEMBL673; N-Methyl-N-2-propynylbenzylamine; Spectrum5_001030; KBioSS_001121; Pargylin; BENZYLAMINE, N-METHYL-N-2-PROPYNYL-; Pargylamine; C11H13N; Benzenemethanamine, N-methyl-N-2-propynyl-; NCGC00015841-07; Prestwick3_000183; Prestwick1_000183; -amine; N-Methyl-N-(2-propynyl)benzylamine-; Methylbenzylpropynylamine; EINECS 209-101-6; 2-12-00-00548 (Beilstein Handbook Reference); CHEBI:128477; 2-Propynylamine, N-benzyl-N-methyl-; Benzenemethanamine, N-methyl-N-2-propynyl-; Benzylamine, N-methyl-N-2-propynyl-; Benzylmethylpropynylamine; Methylbenzylpropynylamine; N-Benzyl-N-methyl-2-propyn-1; ST079278; CID4688; N-Benzyl-N-methyl-2-propyn-1-amine; Benzylmethylpropargylamine; Pargilina; Lopac0_001022; N-benzyl-N-methylprop-2-yn-1-amine; Spectrum3_000540; BRD-K83597974-003-05-7; SPBio_002026; DivK1c_000053; AB00053516; Spectrum4_000469; BSPBio_000105; BPBio1_000117; KBioGR_000918; KBio1_000053; Spectrum_000641; LS-43403; NCGC00015841-02; N-Methyl-N-benzylpropynylamine; Pargyline [INN:BAN]; N-Methyl-N-propargylbenzylamine; KBio3_001659; Lopac-P-8013; N-Benzyl-N-methyl-2-propynylamine; InChI=1/C11H13N/c1-3-9-12(2)10-11-7-5-4-6-8-11/h1,4-8H,9-10H2,2H3; BSPBio_002159; M74253_ALDRICH; Supirdyl; nchembio.307-comp18; DB01626; MolPort-001-792-188; NSC43798; A 19120; Pargyline (INN); CAS-306-07-0; Pargilina [INN-Spanish]; Eutron; DPWPWRLQFGFJFI-UHFFFAOYSA-; Eudatin; AI3-62058; BRN 1938132; AC1L1IQA; Prestwick2_000183; Benzyl-methyl-2-propinylamin [Czech]; C07414; KBio2_001121	555-57-7	4688	9618	TTDS00341	Amine oxidase [flavin-containing] B	MAO-B;Monoamine oxidase;Monoamine oxidase B	P27338	4129	ENSG00000069535	inhibitor
DCL000751	CHF-3381	N/A	202914-18-9	5351154	44716690	TTDS00341	Amine oxidase [flavin-containing] B	MAO-B;Monoamine oxidase;Monoamine oxidase B	P27338	4129	ENSG00000069535	inhibitor
DAP001299	Satumomab Pendetide	N/A	138955-26-7	6211	46505873	TTDS00458	TAG-72 antigen	N/A	N/A	N/A	N/A	binder
DCL000824	GSK372475	N/A	N/A	N/A	N/A	TTDS00016	Dopamine reuptake	Dopamine re-uptake	N/A	N/A	N/A	inhibitor
DCL000779	DOV 21947	N/A	N/A	N/A	N/A	TTDS00016	Dopamine reuptake	Dopamine re-uptake	N/A	N/A	N/A	inhibitor
DCL000733	Bupropion+naltrexone	N/A	31677-93-7	N/A	N/A	TTDS00016	Dopamine reuptake	Dopamine re-uptake	N/A	N/A	N/A	inhibitor
DCL000781	DOV-21947	N/A	N/A	N/A	N/A	TTDS00016	Dopamine reuptake	Dopamine re-uptake	N/A	N/A	N/A	inhibitor
DAP000860	Phenmetrazine	A 66; 2-Fenyl-3-methylmorfolin [Czech]; AC1L1IWB; 134-49-6; dl-2-Phenyl-3-methyltetrahydro-1,4-oxazine; 2-Phenyl-3-methylmorpholine; EINECS 205-143-4; LS-93169; Psychamine A 66; 3-Methyl-2-phenylmorpholine; 1707-14-8 (hydrochloride); AC-16023; Dexphenmetrazine; phenmetrazine; Fenmetrazin; DB00830; Phenmetrazinum [INN-Latin]; Preludin hydrochloride; MolPort-001-783-678; Fenmetrazina [INN-Spanish]; DEA No. 1631; NCGC00164535-01; Oxazimedrine; 2-Fenyl-3-methylmorfolin; Fenmetrazina; AKOS003662804; Phenmetrazin; Probese-P; BRN 0140490; CID4762; Defenmetrazin; Cafilon; Morpholine, 3-methyl-2-phenyl-; Phenmetrazinum; ST081100; UNII-XA501VL3VR; 21288-73-3; 154-40-5; C07432; Phenmetraline; 3-Methyl-2-phenyltetrahydro-2H-1,4-oxazine; Phenmetrazine [INN:BAN]; HSDB 3156	134-49-6	4762	9636	TTDS00016	Dopamine reuptake	Dopamine re-uptake	N/A	N/A	N/A	inhibitor
DCL000340	Amineptine	S 1694; 30272-08-3 (hydrochloride); HEPTANOIC ACID, 7-((10,11-DIHYDRO-5H-DIBENZO(a,d)CYCLOHEPTEN-5-YL)AMINO)-; Amineptinum; Amineptine (INN); Amineptino [INN-Spanish]; EU 1694; BRN 2170218; AC1Q5WBU; 57574-09-1; 7-((10,11-Dihydro-5H-dibenzo(a,d)cyclohepten-5-yl)amino)heptanoic acid; Amineptine; UNII-27T1I13L6G; D07335; Survector (TN); 7-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylamino)heptanoic acid; AC1L1SHI; Amineptino; CHEBI:32499; LS-74382; Amineptine [INN]; Amineptin; Amineptinum [INN-Latin]; MolPort-004-285-838; CHEMBL418995; 10,11-dihydrodibenzo(a,d)cyclohept-5-enyl-7-aminoheptanoic acid; EINECS 260-818-0; CID34870	57574-09-1	34869	176540	TTDS00016	Dopamine reuptake	Dopamine re-uptake	N/A	N/A	N/A	inhibitor
DCL000321	Brasofensine	CID9554198; Brasofensine [INN]; 171655-91-7; UNII-1YP2S94RVH; Brasofensine	171655-91-7	9554198	3846334	TTDS00016	Dopamine reuptake	Dopamine re-uptake	N/A	N/A	N/A	inhibitor
DCL000900	NS 2359	N/A	843660-54-8	N/A	N/A	TTDS00016	Dopamine reuptake	Dopamine re-uptake	N/A	N/A	N/A	inhibitor
DCL000948	Radaxafine HCl	N/A	106083-71-0	65987	43122711	TTDS00016	Dopamine reuptake	Dopamine re-uptake	N/A	N/A	N/A	inhibitor
DCL000947	Radafaxine	Radafaxine; C496215; CPD-3483; hydroxybupropion	106083-71-0	9795056 	10549644	TTDS00016	Dopamine reuptake	Dopamine re-uptake	N/A	N/A	N/A	inhibitor
DAP000834	Cocaine	53-21-4 (hydrochloride); Snort; Allococaine; Cecil; Jam; (-)-Cocaine base; Charlie; methyl (1S,4R,5R)-3-benzoyloxy-8-methyl-8-azabicyclo[3.2.1]octane-4-carboxylate; Blow [Street Name]; SMR001338843; Depsococaine; MolPort-002-535-520; DB00907; Happy powder; Toke; Bernies; Cocktail; D00110; Gold dust [Street Name]; White girl or lady; Coca; Bernice; DEA No. 9041; Methyl 3beta-hydroxy-1alphaH,5alphaH-tropane-2beta-carboxylate benzoate (ester); Cocaine, l-; Blast; Trails; Eritroxilina; Sleighride; Sweet Stuff; Neurocaine; Delcaine; Flake [Street Name]; Lady [Street Name]; Ecgonine methyl ester benzoate; Carrie; Blow; CID11779748; Moonrocks; Burese; KBio1_000975; Kokayeen; Kokain; methyl 3-benzoyloxy-8-methyl-8-azabicyclo[3.2.1]octane-4-carboxylate; Florida Snow; Happy trails; Bernice [Street Name]; Cola; AC1L3U2D; 2-beta-Tropanecarboxylic acid, 3-beta-hydroxy-, methyl ester, benzoate (ester); Flake; C8912_SIGMA; AC1L1EK2; Cocaine [BAN]; STOCK1N-68258; d-Pseudococaine; Erytroxylin; (R)-Cocaine; CHEBI:27958; C01416; Ecgonine, methyl ester, benzoate (ester); (1R,2R,3S,5S)-2-Methoxycarbonyltropan-3-yl benzoate; Blizzard; Snow (birds); C" Carrie; 610089_FLUKA; AC-16037; Caviar; G-Rock; Badrock; 50-36-2; Prime Time; HSDB 6469; 1-Cocaine; cocainum; Dextrocaine; UNII-I5Y540LHVR; 2-beta-Carbomethoxy-3-beta-benzoxytropane; Flex; Rock [Street Name]; l-Cocain; Goofball; 2beta-Carbomethoxy-3beta-benzoxytropane; Isococain; Kokan; Benzoylethylecgonine; CID446220; Snow; Cocaine (TN); MLS002320697; DivK1c_000975; COC; methyl (3S,4R)-3-benzoyloxy-8-methyl-8-azabicyclo[3.2.1]octane-4-carboxylate; cocaine; Cholly; Methyl 3-(benzoyloxy)-8-methyl-8-azabicyclo[3.2.1]octane-2-carboxylate; Girl; Cocain; Crack cocaine; Heaven; L000836; 3beta-Hydroxy-2beta-tropanecarboxylic acid methyl ester benzoate (ester); Bouncing Powder; NCGC00159467-02; Gold dust; AC1L9JBL; Pseudococaine; Leaf; Star dust; Allopseudococaine; Cocaina; Toot; Rock; 1i7z; Cocaine (USP); Nose candy; CID5760; Dama blanca; NINDS_000975; nchembio.284-comp4; Foo Foo; L-Cocaine; 610089_ALDRICH; (1R,2R,3S,5S)-2-(methoxycarbonyl)tropan-3-yl benzoate; Chicken Scratch; Corine; Happy dust [Street Name]; Ecgonine methyl ester benzoate solution; Methyl Benzoylecgonine; MolPort-003-937-722; beta-Cocain; Crack; Isococaine; Pseudoallococaine; CPD-9776; Yeyo; Hell; Candy; Coke; AC1L1L2T; Cocaine solution; Happy dust; Cocaine free base; Star-spangled powder; Girl [Street Name]; Kibbles n' Bits; (-)-Cocaine; Benzoylmethylecgonine; IDI1_000975; Cocaine-M; 1q72; Bazooka; LS-157759; CID2826; 3-Tropanylbenzoate-2-carboxylic acid methyl ester; Pimp's drug; Toot [Street Name]; EINECS 200-032-7; Freeze; Cecil [Street Name]; Cabello; Lady; AC-20208; Green gold	50-36-2	5760	148543	TTDS00016	Dopamine reuptake	Dopamine re-uptake	N/A	N/A	N/A	inhibitor
DCL000780	DOV-216303	N/A	N/A	N/A	N/A	TTDS00016	Dopamine reuptake	Dopamine re-uptake	N/A	N/A	N/A	inhibitor
DAP000358	Misoprostol	CCRIS 6859; CHEMBL606; HSDB 3573; methyl (11alpha,13E)-11,16-dihydroxy-16-methyl-9-oxoprost-13-en-1-oate; Ambap103601-27-0; CID5282381; Misoprostolum [INN-Latin]; Cytotec; SMR000058558; DB00929; Misoprostol (JAN/USAN/INN); NCGC00162445-01; misoprostol; SMP1_000193; M6807_SIGMA; Misopess; XP-16J; methyl 7-[(1R,2R,3R)-3-hydroxy-2-[(E)-4-hydroxy-4-methyloct-1-enyl]-5-oxocyclopentyl]heptanoate; (+/-)-15-Deoxy-(16RS)-16-hydroxy-16-methylprostaglandin E1 methyl ester; SC 29333; Misotol; GyMiso; Misoprostolum; Prost-13-en-1-oic acid, 11,16-dihydroxy-16-methyl-9-oxo-, methyl ester, (11alpha,13E)-(+-)-; BRN 4155643; (11-alpha,13E)-(+-)-11,16-Dihydroxy-16-methyl-9-oxoprost-13-en-1-oic acid methyl ester; 62015-39-8; Methyl (+-)-11-alpha,16-dihydroxy-16-methyl-9-oxoprost-13-en-1-oate; D00419; MolPort-003-666-830; Isprelor; 59122-46-2; AC1NQZZA; SC-29333; I14-11712; MLS000028863; Cytotec (TN); UNII-0E43V0BB57; Prost-13-en-1-oic acid, 11,16-dihydroxy-16-methyl-9-oxo-, methyl ester, (11alpha,13E)-; HMS2090L10; NCGC00162445-02	59122-46-2	5282381	183429	TTDS00170	Prostacyclin receptor	IP prostanoid receptor;PGI receptor;Prostaglandin I2 receptor;Prostanoid IP receptor	P43119	5739	ENSG00000160013	antagonist
DAP001213	Epoprostenol	PGX; AC1NR00P; AC1L3FZB; Epoprostenolum [INN-Latin]; BRD-K64054020-001-02-7; KBioSS_000216; 61849-14-7; prostaglandin I2; 5-[(3aR,4R,5R,6aS)-5-hydroxy-4-[(3S)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid; TRY 200; CHEBI:15552; (5E)-5-[(3aR,4R,5R,6aS)-5-hydroxy-4-[(E,3R)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid; C01312; epoprostenol; (5Z,13E,15S)-6,9alpha-epoxy-11alpha,15-dihydroxyprosta-5,13-dienoic acid; Bio2_000216; Epoprostanol; Epoprostenolum; 6,9-alpha-Epoxy-11-alpha,15(S)-dihydroxyprosta-5(Z),13(E)-dien-1-oic acid; U 53,217; KBioGR_000216; CHEMBL1139; KBio2_005352; Prosta-5,13-dien-1-oic acid, 6,9-epoxy-11,15-dihydroxy-, (5Z,9-alpha,11-alpha,13E,15S)-; (5Z,13E)-(15S)-6,9alpha-Epoxy-11alpha,15-dihydroxyprosta-5,13-dienoate; AR-1I7150; AC1NQX0K; (5Z)-5-[(3aR,4R,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid; Bio2_000696; KBio2_002784; Try-200; PDSP2_001704; NCGC00161285-02; NCGC00161285-03; KBio2_000216; (Z)-(3aR,4R,5R,6aS)-Hexahydro-5-hydroxy-4-((E)-(3S)-3-hydroxy-1-octenyl)-2H-cyclopenta(b)furan-delta(sup 2,delta)-valeric acid; CID5282411; Prostacyclins; Prostaglandin I(2); CID6450541; DB01240; Epoprostenol (TN); CID11969614; CID114805; PG-I2; 5-[5-hydroxy-4-(3-hydroxyoct-1-enyl)-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid; KBio3_000432; BRN 1690090; U-53217; AC1L18LX; prostacyclin; 5-[(3aR,4R,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid; 35121-78-9; 136626-78-3; Prostacycline; CHEMBL307845; NCGC00161285-01; CID159; Vasocyclin; LMFA03010087; BSPBio_001496; CID9864371; KBio3_000431; D00106; CID6434194; LS-125828; CID5280427; BIDD:GT0514; AC1O51WG; Epoprostenol [USAN:INN]; IDI1_033966; Prostaglandin I; 63859-31-4; PGI(sub 2); KB-IV-24; PDSP1_001721; Prosta-5,13-dien-1-oic acid, 6,9-epoxy-11,15-dihydroxy-, (5Z,9alpha,11alpha,13E,15S)-; Flolan; SMP2_000227; HMS1989K18; UNII-DCR9Z582X0; Prostaglandins X; Epoprostenol (USAN/INN); AC1O5HI7; HMS1791K18; Prostaglandin X; 63748-50-5; (5Z,9alpha,11alpha,13E,15S)-6,9-epoxy-11,15-dihydroxyprosta-5,13-dien-1-oic acid; (5Z,9alpha,11alpha,13E,15S)-11,15-dihydroxy-6,9-epoxyprosta-5,13-dien-1-oic acid; (5Z)-5-[(4R,5R)-5-hydroxy-4-[(E,3S)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid; PGI2; CID9975312; Prostacyclin I2	35121-78-9	5280427	7847174	TTDS00170	Prostacyclin receptor	IP prostanoid receptor;PGI receptor;Prostaglandin I2 receptor;Prostanoid IP receptor	P43119	5739	ENSG00000160013	agonist
DAP001214	Treprostinil	treprostinilo; L001079; AC1OCF2J; CID9800580; UT-15; Treprostinil (USAN/INN); ({(1R,2R,3aS,9aS)-2-hydroxy-1-[(3S)-3-hydroxyoctyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]naphthalen-5-yl}oxy)acetic acid; 81846-19-7; 289480-64-4 (Sodium salt); U 62840; UNII-RUM6K67ESG; Remodulin (TN); Treprostinil [USAN:INN]; 2-[[(1R,2R,3aS,9aS)-2-hydroxy-1-[(3S)-3-hydroxyoctyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[g]naphthalen-5-yl]oxy]acetic acid; AC1L1HPX; ((1R,2R,3aS,9aS)-2-hydroxy-1-((3S)-3-hydroxyoctyl)-2,3,3a,4,9,9a-hexahydro-1H-cylopent(b)naphthalen-5-yl)oxy)acetate; CID6918140; 15AU81; Acetic acid, ((2,3,3a,4,9,9a-hexahydro-2-hydroxy-1-(3-hydroxyoctyl)-1H-benz(f)inden-5-yl)oxy)-, (1R-(1alpha(S*),2beta,3aalpha,9aalpha))-; 2-[[(1S,2S,3aR,9aR)-2-hydroxy-1-[(3R)-3-hydroxyoctyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[g]naphthalen-5-yl]oxy]acetic acid; treprostinilum; CID11246284; CID54786; CHEBI:50861; U-62,840; LRX 15; LS-187014; Acetic acid, (((1R,2R,3aS,9aS)-2,3,3a,4,9,9a-hexahydro-2-hydroxy-1-((3S)-3-hydroxyoctyl)-1H-benz(f)inden-5-yl)oxy)-; Treprostinil; LS-177654; Viveta; 15 AU81; Uniprost; DB00374; D06213; Treprostinil sodium; LS-187645	81846-19-7	54786	192299	TTDS00170	Prostacyclin receptor	IP prostanoid receptor;PGI receptor;Prostaglandin I2 receptor;Prostanoid IP receptor	P43119	5739	ENSG00000160013	agonist
DAP000826	Dinoprost Tromethamine	Prosta-5,13-dien-1-oic acid, (5Z,9-alpha,11-alpha,13E,15S)-9,11,15-trihydroxy-,compd. with trimethylolaminomethane; PGF2-alpha tromethamine salt; Prostaglandin F(sub 2a) tromethamine; Prosta-5,13-dien-1-oic acid, 9,11,15-trihydroxy-, (5Z,9alpha,11alpha,13E,15S)-, compd. with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1); D01352; prostaglandin F2alpha tromethamine; Dinoprost tromethamine [USAN:JAN]; Ensaprost; LS-125841; PROSTAGLANDIN F2ALPHA TRIS SALT; 5-Heptenoic acid, 7-(3,5-dihydroxy-2-(3-hydroxy-1-octenyl)cyclopentyl)-, tham; EINECS 254-002-3; SMR000058792; Prostaglandin F2-alpha tromethamine; 38562-01-5; AC1NR011; Prostaglandin F-2alpha tromethamine salt; MLS000028821; Dinolytic; C20H34O5.C4H11NO3; Pronalgon F; P5069_SIGMA; Protaglandin F2-alpha-tham salt; Prostin F2 alpha; CHEMBL1200896; Zinoprost; 38473-38-0; P0424_SIGMA; Lutalyse; Enzaprost F compd. with trisamine; THAM PGF2-alpha; Tromethamine prostaglandin F2-alpha; MolPort-003-939-186; U-14,583E; Prostaglandin F2alpha tham; Dinoprost, trometamol salt; PGF2-alpha tham; 1,3-Propanediol, 2-amino-2-(hydroxymethyl)-, (5Z,9alpha,11alpha,13E,15S)-9,11,15-trihydroxyprosta-5,13-dien-1-oate (salt); U 14585; Prostaglandin F2a tromethamine; Prostaglandin F2-alpha THAM; dinoprost tromethamine; Panacelan F tromethamine salt; 51553-13-0; 36300-07-9; 2-amino-2-(hydroxymethyl)propane-1,3-diol; (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]cyclopentyl]hept-5-enoic acid; Dinoprost tromethamine (JAN/USP); PGF2-alpha tromethamine; Prostamate; PGF2alpha THAM; Prostalmon F; DB01160; UNII-CT6BBQ5A68; (E,Z)-(1R,2R,3R,5S)-7-(3,5-Dihydroxy-2-((3S)-(3-hydroxy-1-octenyl))cyclopentyl)-5-heptenoic acid compound with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1); Prostaglandin F2-alpha THAM salt; PGF2alpha tromethamine; CID5282415; PGF2alpha-Tris; Prostin F2 alpha (TN); PGF2-alpha tris salt; 7-(3,5-Dihydroxy-2-(3-hydroxy-1-octenyl)cyclopentyl)-5-heptenoic acid, tromethamine salt; (5Z,9alpha,11alpha,13E,15S)-9,11,15-Trihydroxyprosta-5,13-dienoic acid tris salt; U-14583E; NSC 196515; Lutalyse (Veterinary); Prosta-5,13-dien-1-oic acid, (5Z,9-alpha,11-alpha,13E,15S)-9,11,15-trihydroxy-, compd. with trimethylolaminomethane	38562-01-5	5282415	213676	TTDS00170	Prostacyclin receptor	IP prostanoid receptor;PGI receptor;Prostaglandin I2 receptor;Prostanoid IP receptor	P43119	5739	ENSG00000160013	antagonist
DCL000875	LymphoStat B	LymphoStat-B; LymphoStat-B (TN); Belimumab (USAN); D03068; 356547-88-1; Belimumab	356547-88-1	5957	3820832	TTDC00196	Tumor necrosis factor ligand superfamily member 13B	B cell-activating factor;B lymphocyte stimulator;BAFF;BLyS;Dendritic cell-derived TNF-like molecule;TALL-1;TNF-and APOL-related leukocyte expressed ligand 1;UNQ401/PRO738	Q9Y275	10673	ENSG00000102524	inhibitor
DCL000729	BR3-Fc	N/A	N/A	N/A	N/A	TTDC00196	Tumor necrosis factor ligand superfamily member 13B	B cell-activating factor;B lymphocyte stimulator;BAFF;BLyS;Dendritic cell-derived TNF-like molecule;TALL-1;TNF-and APOL-related leukocyte expressed ligand 1;UNQ401/PRO738	Q9Y275	10673	ENSG00000102524	inhibitor
DCL000692	AMG 623	N/A	N/A	N/A	N/A	TTDC00196	Tumor necrosis factor ligand superfamily member 13B	B cell-activating factor;B lymphocyte stimulator;BAFF;BLyS;Dendritic cell-derived TNF-like molecule;TALL-1;TNF-and APOL-related leukocyte expressed ligand 1;UNQ401/PRO738	Q9Y275	10673	ENSG00000102524	inhibitor
DCL000706	Atacicept	N/A	845264-92-8	N/A	N/A	TTDC00196	Tumor necrosis factor ligand superfamily member 13B	B cell-activating factor;B lymphocyte stimulator;BAFF;BLyS;Dendritic cell-derived TNF-like molecule;TALL-1;TNF-and APOL-related leukocyte expressed ligand 1;UNQ401/PRO738	Q9Y275	10673	ENSG00000102524	inhibitor
DCL000493	Belimumab	LymphoStat-B; LymphoStat-B (TN); Belimumab (USAN); D03068; 356547-88-1; Belimumab	356547-88-1	10451420	17397223	TTDC00196	Tumor necrosis factor ligand superfamily member 13B	B cell-activating factor;B lymphocyte stimulator;BAFF;BLyS;Dendritic cell-derived TNF-like molecule;TALL-1;TNF-and APOL-related leukocyte expressed ligand 1;UNQ401/PRO738	Q9Y275	10673	ENSG00000102524	antibody
DCL000287	ATL-146e	N/A	N/A	5311340	49684216	TTDS00187	Adenosine A2a receptor	A(2A) adenosine receptor;A2a Adenosine receptor;Adenosine receptor A2a	P29274	135	ENSG00000128271	agonist
DCL001009	T-62	N/A	40312-34-3	N/A	N/A	TTDS00187	Adenosine A2a receptor	A(2A) adenosine receptor;A2a Adenosine receptor;Adenosine receptor A2a	P29274	135	ENSG00000128271	antagonist
DCL000887	MRE-0094	N/A	N/A	N/A	N/A	TTDS00187	Adenosine A2a receptor	A(2A) adenosine receptor;A2a Adenosine receptor;Adenosine receptor A2a	P29274	135	ENSG00000128271	agonist
DCL000979	SCH 420814	Preladenant; L021041; CID 10117987; SCH-420814; CHEBI:510123; CHEMBL240624; UNII-950O97NUPO; Sch 420814; 377727-87-2; CID10117987; 7H-Pyrazolo(4,3-e)(1,2,4)triazolo(1,5-c)pyrimidin-5-amine, 2-(2-furanyl)-7-(2-(4-(4-(2-methoxyethoxy)phenyl)-1-piperazinyl)ethyl)-	623174-20-9	9895066	47207667	TTDS00187	Adenosine A2a receptor	A(2A) adenosine receptor;A2a Adenosine receptor;Adenosine receptor A2a	P29274	135	ENSG00000128271	antagonist
DCL000856	KW-3902	MK-7418; 8-(3-Noradamantyl)-1,3-dipropylxanthine; AC1Q6LCF; 8-(Hexahydro-2,5-methanopentalen-3a(1H)-yl)-3,7-dihydro-1,3-dipropyl-1H-purine-2,6-dione; KW 3902; Rolofylline (USAN); CID64627; 8-(hexahydro-2,5-methanopentalen-3a(1h)-yl)-1,3-dipropyl-3,7-dihydro-1h-purine-2,6-dione; 1H-Purine-2,6-dione, 8-(hexahydro-2,5-methanopentalen-3a(1H)-yl)-3,7-dihydro-1,3-dipropyl-; 1,3-Dipropyl-8-(3-noradamantyl)xanthine; Rolofylline; CHEBI:176666; AC1L21M5; HMR-4902; D08989; 136199-02-5; 8-(Noradamantan-3-yl)-1,3-dipropylxanthine; KW-3902; LS-126967; CHEMBL52333; L001406; 1,3-Dnax	136199-02-5	64627	12014585	TTDS00187	Adenosine A2a receptor	A(2A) adenosine receptor;A2a Adenosine receptor;Adenosine receptor A2a	P29274	135	ENSG00000128271	antagonist
DPR000009	Adenosine A(2A) receptor antagonist	N/A	N/A	N/A	N/A	TTDS00187	Adenosine A2a receptor	A(2A) adenosine receptor;A2a Adenosine receptor;Adenosine receptor A2a	P29274	135	ENSG00000128271	antagonist
DAP000099	Caffeine	MLS001056714; Stim; NCGC00090699-03; Caffine; Quick Pep; Theophylline, 7-methyl; nchembio774-comp2; 3,7-dihydro-1,3,7-trimethyl-1H-purine; Cafecon; Passauer Brand of Caffeine; Caffeine (USP); AC-12774; BSPBio_001921; Coffeine; DivK1c_000730; NCGC00168808-02; Coffein; Caffedrine Caplets; KBio1_000730; NCGC00015208-02; Caffeine Pure; Bio1_001451; Seid Brand of Caffeine; Theobromine, 1-methyl-; CHEMBL113; C1778_SIAL; Nodaca; Methylxanthine theophylline; SMR000326667; KBio2_001781; CCRIS 1314; nchembio.243-comp7; NINDS_000730; LS-237; Caffeine (natural); Vivarin; NCGC00090699-06; Caffeine solution; DB00201; No-Doz; Republic Drug Brand of Caffeine; Bio-0579; Pierre Fabre Brand of Caffeine; Lopac0_000228; C2042; Refresh'n; 1,3,7-Trimethyl-2,6-dioxopurine; NCGC00015208-14; C6035_SIGMA; Spectrum3_000321; MolPort-000-730-850; Natural Caffeinum; Anhydrous caffeine (TN); 1-methyltheobromine; Caffeine, synthetic; CFF; NCIOpen2_008255; Quick-Pep; C8960_SIAL; DHC Plus; Bio1_000473; Spectrum4_001782; Diurex; caffeine; BIDD:PXR0172; 1l5q; Tri-Aqua; CHEBI:27732; P-A-C Analgesic Tablets; D00528; Methyltheobromine; Coffeinum; A.S.A. and Codeine Compound; 27602_FLUKA; Caffeine [BAN:JAN]; KBio2_004349; 1gfz; Mateina; Coffeinum Purrum; Durvitan; caffenium; PDSP2_001000; EINECS 200-362-1; Thompson Brand 1 of Caffeine; Caffein; Coffeinum N; Probes2_000128; Spectrum_001301; HSDB 36; 07E4FB58-FD79-4175-8E3D-05BF96954522; Midol Maximum Strength; 2a3b; KBioSS_001781; UNII-3G6A5W338E; PDSP2_001219; 71701-02-5; AI3-20154; Propoxyphene Compound-65; Anacin Maximum Strength; Anhydrous caffeine (JP15); BIM-0050216.0001; 95789-13-2; NCGC00090699-04; C7731_SIAL; KBio3_001141; 1l7x; Eldiatric C; component of Cafergot; NCGC00090699-08; Pep-Back; CU-01000012617-3; HMS2091O11; FEMA No. 2224; 7-Methyltheophylline; NCGC00090699-07; Xanthine, 1,3,7-trimethyl; Organex; BIDD:ER0554; cafeine; Compound 65; No Doz; KBioGR_002325; Cafamil; NSC 5036; Hycomine; Theobromine Me; SPECTRUM1500155; NCGC00090699-01; Dasin; Lopac-C-0750; Cafeina; Caffeina [Italian]; Merck dura Brand of Caffeine; Alert-pep; SPBio_001222; NCGC00090699-05; SDCCGMLS-0064595.P002; Thompson Brand 2 of Caffeine; SDCCGMLS-0064595.P001; Thein; IDI1_000730; Coffein [German]; MLS001066409; teina; Enerjets; Koffein; AC1Q3Z23; Caffeine, Monohydrate; TNP00310; Bristol-Myers Squibb Brand of Caffeine; 58-08-2; NCI-C02733; Probes1_000150; Wake-Up; HMS1920I09; D002110; BRD-K02404261-001-03-5; Keep Alert; PDSP1_001016; AKOS000121334; Spectrum5_000423; Propoxyphene Compound 65; Kofein [Czech]; C6035_FLUKA; ACon1_000085; NCGC00015208-04; BRD-K02404261-001-02-7; EU-0100228; MLS001055341; Dexitac; Hycomine Compound; Spectrum2_001261; 1,3,7-Trimethylpurine-2,6-dione; Nodoz Maximum Strength Caplets; Ultra Pep-Back; BRN 0017705; SK 65 Compound; Caffeine, anhydrous; HMS502E12; bmse000206; Cafipel; NCGC00168808-01; SK-65 Compound; Phensal; Miudol; Methyltheobromide; 75035_FLUKA; Tirend; 5-26-13-00558 (Beilstein); Percoffedrinol N; Theine; AC1L1DV2; Monomethyl derivative of Theophylline; Koffein [German]; nchembio.63-comp5; Bio1_000962; ZINC00001084; L000155; C07481; Theophylline Me; BIDD:GT0632; Guaranine; C0750_SIAL; KBio2_006917; MolMap_000054; Kofein; W222402_ALDRICH; CID2519; NCGC00015208-01; I14-4386; Ercatab; Dexitac Stay Alert Stimulant; WLN: T56 BN DN FNVNVJ B1 F1 H1; Caffeina; NCGC00090699-09; MEGxp0_001350; 1-3-7-TRIMETHYLXANTHINE; Caffedrine; STK177283; Berlin-Chemie Brand of Caffeine; GlaxoSmithKline Brand of Caffeine; Anhydrous caffeine; NCGC00090699-02; Percutafeine; Nix Nap; PDSP1_001235; NSC5036; C 0750; 1,3,7-Trimethylxanthine; DHCplus	58-08-2	2519	148854	TTDS00187	Adenosine A2a receptor	A(2A) adenosine receptor;A2a Adenosine receptor;Adenosine receptor A2a	P29274	135	ENSG00000128271	antagonist
DCL000312	KW-6002	155270-99-8; LS-126708; Istradefylline [USAN:INN]; 8-(2-(3,4-dimethoxyphenyl)ethenyl)-1,3-diethyl-3,7-dihydro-7-methyl-1H-purine-2,6-dione; UNII-2GZ0LIK7T4; CHEMBL431770; (E)-8-(3,4-Dimethoxystyryl)-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione; Istradefylline (JAN/USAN/INN); (E)-8-(3,4-Dimethoxystyryl)-1,3-diethyl-7-methylxanthine; 8-[(E)-2-(3,4-dimethoxyphenyl)ethenyl]-1,3-diethyl-7-methylpurine-2,6-dione; 1H-Purine-2,6-dione, 8-((1E)-2-(3,4-dimethoxyphenyl)ethenyl)-1,3-diethyl-3,7-dihydro-7-methyl-; AC1NSJVH; 8-((1E)-2-(3,4-Dimethoxyphenyl)ethenyl)-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione; CHEBI:222252; KW-6002; L001483; 1H-Purine-2,6-dione, 3,7-dihydro-1,3-diethyl-8-(2-(3,4-dimethoxyphenyl)ethenyl)-7-methyl-, (E)-; D04641; C111599; Istradefylline; CID5311037; KW 6002	155270-99-8	5311037	12014869	TTDS00187	Adenosine A2a receptor	A(2A) adenosine receptor;A2a Adenosine receptor;Adenosine receptor A2a	P29274	135	ENSG00000128271	antagonist
DCL000771	Dexefaroxan	Dexefaroxan; 2-Imidazoline, 2-(2-ethyl-2,3-dihydro-2-benzofuranyl)-, ( )-(R)-; NCGC00015410-01; KST-1A1946; AR-1A0132; Lopac-E-3263; CID208820; UNII-F751MO69EV; AC1Q4UEV; AC1L4LF7; (+)-(r)-2-(2-ethyl-2,3-dihydro-2-benzofuranyl)-2-imidazoline; NCGC00024793-01; Tocris-0792; 2-[(2R)-2-ethyl-3H-1-benzofuran-2-yl]-4,5-dihydro-1H-imidazole; Dexefaroxan [INN]; 16950-79-1	143249-88-1	208820	783638	TTDS00187	Adenosine A2a receptor	A(2A) adenosine receptor;A2a Adenosine receptor;Adenosine receptor A2a	P29274	135	ENSG00000128271	agonist
DCL000725	BIIB014	V2006	N/A	N/A	N/A	TTDS00187	Adenosine A2a receptor	A(2A) adenosine receptor;A2a Adenosine receptor;Adenosine receptor A2a	P29274	135	ENSG00000128271	antagonist
DCL000832	GW-493838	N/A	N/A	N/A	N/A	TTDS00187	Adenosine A2a receptor	A(2A) adenosine receptor;A2a Adenosine receptor;Adenosine receptor A2a	P29274	135	ENSG00000128271	agonist
DCL000722	BG-9928	AC1L50QI; CHEMBL414157; Bicyclo(2.2.2)octane-1-propanoic acid, 4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)-; 4-(2,3,6,7-Tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)bicyclo(2.2.2)octane-1-propanoic acid; CID216466; BG-9928; CHEBI:461768; BG9928; AR-1H9820; AC1Q5VXX; 3-[4-(2,6-dioxo-1,3-dipropyl-7H-purin-8-yl)-1-bicyclo[2.2.2]octanyl]propanoic acid; Bg 9928; CHEBI:461763; CHEMBL386974; LS-193368; L001665; bicyclo[2.2.2]octane-1-propanoic acid, 4-(2,3,6,9-tetrahydro-2,6-dioxo-1,3-dipropyl-1h-purin-8-yl)-	340021-17-2	216466	789640	TTDS00187	Adenosine A2a receptor	A(2A) adenosine receptor;A2a Adenosine receptor;Adenosine receptor A2a	P29274	135	ENSG00000128271	antagonist
DAP000424	Metyrapone	CHEMBL934; Novartis Brand of Metyrapone; AC1Q1LHX; SPBio_002947; CID4174; CPD-7023; CHEBI:44241; Metyrapon; SAM002297829; ZINC00001728; 37245-80-0; HMS1570F10; D00410; LS-123097; Metyrapone Alliance Brand; NCGC00161837-01; NSC25265; C14H14N2O; D008797; Metroprione; Metopiron; 2-Methyl-1,2-di-3-pyridinyl-1-propanone; 1-Propanone, 2-methyl-1,2-di-3-pyridyl-; Metirapona; Prestwick3_000904; 1-Propanone, 1,2-di-3-pyridyl-2-methyl-; 2-Methyl-1,2-bis(3-pyridyl)-1-propanone; Prestwick1_000904; BIDD:PXR0082; 4885, SU; Metopirone; Metopyrone; BRD-K46862739-001-03-6; Methapyrapone; NSC 25265; Metirapona [INN-Spanish]; Metyrapone [USAN:INN:BAN:JAN]; 856525_ALDRICH; metyrapone; Su 4885; MLS001066377; MLS001335881; HSDB 2500; 2-methyl-1,2-dipyridin-3-yl-propan-1-one; C07205; ST51006925; Methopirapone; Metyraponum; Metapirone; Methopyrone; Mepyrapone; EU-0009322; EINECS 200-206-2; SMR000059134; 1-Propanone, 2-methyl-1,2-di-3-pyridinyl-; AB00513955; Metyrapone Novartis Brand; Su-4885; Methopyrapone; Prestwick2_000904; BPBio1_000824; Metapyron; HMS2094I07; 54-36-4; METOPIRONE (TN); MolPort-001-794-644; 2-Methyl-1,2-di-3-pyridyl-1-propanone; MYT; BSPBio_000748; CAS-54-36-4; MLS001335882; DB01011; Metyrapone (JP15/USP/INN); Methbipyranone; 2-methyl-1,2-dipyridin-3-ylpropan-1-one; 1,2-Di-3-pyridyl-2-methyl-1-propanone; NCGC00016242-01; Methopyrinine; AC1L1HKV; UNII-ZS9KD92H6V; Metyraponum [INN-Latin]; Alliance Brand of Metyrapone; Prestwick0_000904; CPD000059134	54-36-4	4174	9414	TTDS00420	Cytochrome P450 11B1, mitochondrial	CYP11B1;CYPXIB1;P450C11;P-450c11;S11BH;Steroid 11-beta-hydroxylase	P15538	1584	ENSG00000160882	inhibitor
DCL000870	Lixivaptan	D04752; L001508; CID172997; AC1L59LM; N-[3-chloro-4-(6,11-dihydropyrrolo[2,1-c][1,4]benzodiazepine-5-carbonyl)phenyl]-5-fluoro-2-methylbenzamide; CHEMBL49429; Lixivaptan; UNII-8F5X4B082E; VPA-985; Lixivaptan (USAN/INN); VPA985; 168079-32-1; Lixivaptan [USAN:INN]; CHEBI:173070	168079-32-1	172997	47206571	TTDS00111	Vasopressin V2 receptor	Antidiuretic hormone receptor;AVPR V2;Renal-type arginine vasopressin receptor	P30518	554	ENSG00000126895	antagonist
DAP001530	Tolvaptan	OPC 41061; PDSP2_001721; CHEBI:327437; CHEMBL344159; CID216237; Samsca; AC1L50C9; UNII-21G72T1950; C116664; benzazepine derivative, 32; 150683-30-0; 7-Chloro-5-hydroxy-1-(2-methyl-4-(2-methylbenzoylamino)benzoyl)2,3,4,5-tetrahydro-1H-1-benzazepine; OPC-41061; PDSP1_001738; Tolvaptan; ( -)-4'-((7-Chloro-2,3,4,5-tetrahydro-5-hydroxy-1H-1-benzazepin-1-yl)carbonyl)-o-tolu-m-toluidide; L001628; N-[4-(7-chloro-5-hydroxy-2,3,4,5-tetrahydro-1-benzazepine-1-carbonyl)-3-methylphenyl]-2-methylbenzamide	150683-30-0	216237	12015154	TTDS00111	Vasopressin V2 receptor	Antidiuretic hormone receptor;AVPR V2;Renal-type arginine vasopressin receptor	P30518	554	ENSG00000126895	antagonist
DAP000098	Conivaptan	4'-((4,5-dihydro-2-methylimidazo(4,5-d)(1)benzazepin-6(1H)-yl)carbonyl)-2-biphenylcarboxanilide; Conivaptan; L001531; N-{4-[(2-methyl-4,5-dihydroimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl}biphenyl-2-carboxamide; MolPort-005-940-873; UNII-0NJ98Y462X; AC1L45SX; YM 087; ZINC12503187; PDSP2_001718; L001073; N-[4-(2-methyl-4,5-dihydro-3H-imidazo[4,5-d][1]benzazepine-6-carbonyl)phenyl]-2-phenylbenzamide; Conivaptan [INN]; D07748; PDSP1_001735; Conivaptan (INN); (1,1'-Biphenyl)-2-carboxamide, N-(4-(4,5-dihydro-2-methylimidazo(4,5-d)(1)benzazepin-6(1H)-yl)carbonyl)phenyl)-; CID151171; LS-187117; 210101-16-9; I14-8805; YM-087; CHEMBL1755; YM087; DB00872; CHEBI:681850	210101-16-9	151171	728713	TTDS00111	Vasopressin V2 receptor	Antidiuretic hormone receptor;AVPR V2;Renal-type arginine vasopressin receptor	P30518	554	ENSG00000126895	antagonist
DCL000974	Satavaptan	SR-121463A; CID9810773; SR-121463; 308145-17-7; Benzamide, N-(1,1-dimethylethyl)-4-((cis-5'-ethoxy-4-(2-(4-morpholinyl)ethoxy)-2'-oxospiro(cyclohexane-1,3'-(3H)indol)-1'(2'H)-yl)sulfonyl)-3-methoxy-, phosphate (1:1); Aquilda; SR-121463B; SR-121463F; Satavaptan	185913-78-4	7029	24714757	TTDS00111	Vasopressin V2 receptor	Antidiuretic hormone receptor;AVPR V2;Renal-type arginine vasopressin receptor	P30518	554	ENSG00000126895	antagonist
DAP000074	Desmopressin	D00291; 1-Deamino-8-D-arginine vasopressin; EINECS 240-726-7; Desamino-8-D-arginine vasopressin, l-; 1-Desamino-8-D-arginine vasopressin; LS-187262; 16679-58-6; Desmopressin Monoacetate, Trihydrate; 1-Desamino-8-arginine Vasopressin; UNII-ENR1LLB0FP; DESMOPRESSIN; Deamino-8-D-arginine, l-, vasopressin; LS-173612; DDAVP; N-[1-[(2-amino-2-oxoethyl)amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]-1-[7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide; CHEMBL264448; 62288-83-9 (monoacetate); Deamino Arginine Vasopressin; Desmopressinum; Desmopresina [INN-Spanish]; 1-{[7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-(4-hydroxybenzyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-4-yl]carbonyl}prolyl-n5-(diaminomethylidene)ornithylglycinamide; C4H10.CH2O; Desmopressine [INN-French]; Desmopresina; Desmopressine; Desmopressin [INN:BAN]; AC1L1EDS; Adiuretin SD; L001026; Vasopressin, 1-(3-mercaptopropanoic acid)-8-D-arginine-; Adiuretin; AC1Q5JBY; Desmopressinum [INN-Latin]; 6917-99-3; Desmopressin (INN); Vasopressin, Deamino Arginine; 62357-86-2 (monoacetate trihydrate); C06944; Minirin; CID27991	16679-58-6	27991	170515	TTDS00111	Vasopressin V2 receptor	Antidiuretic hormone receptor;AVPR V2;Renal-type arginine vasopressin receptor	P30518	554	ENSG00000126895	stimulator
DAP000018	Vasopressin	Vasopressini injectio [INN-Latin]; D014667; Vasopressina; Inyectable de vasopresina; Parke-Davis Brand of Vasopressin (USP); EINECS 234-236-2; Vasopressine; CID11979316; Vasopressin; Monarch Brand of Vasopressin; Vasopressini injectio; Vasopressinum; American Regent Brand of Vasopressin; HSDB 3412; beta Hypophamine; Solute injectable de vasopressine [INN-French]; Leiormone; Tonephin; Vasopressin (JP15/USP); Vasopressin injection; American Pharmaceutical Brand of Vasopressin; Antidiuretic Hormones; Vasopressina [DCIT]; Pituitrin; Solute injectable de vasopressine; ADH (hormone); Antidiuretic hormone; Vasopressin Monarch Brand; Vasopressins; beta-Hypophamine; Pitressin (TN); LS-161408; Pitressin; Vasopressin (USP); D00101; Inyectable de vasopresina [INN-Spanish]; 11000-17-2	11000-17-2	24774	167533	TTDS00111	Vasopressin V2 receptor	Antidiuretic hormone receptor;AVPR V2;Renal-type arginine vasopressin receptor	P30518	554	ENSG00000126895	agonist
DAP000279	Ibutilide	(E)-but-2-enedioic acid; N-[4-[4-[ethyl(heptyl)amino]-1-hydroxybutyl]phenyl]methanesulfonamide; 2C20H36N2O3S.C4H4O4; Ibutilide [INN:BAN]; LS-90124; (+-)-4'-(4-(Ethylheptylamino)-1-hydroxybutyl)methanesulfoanilide (E)-2-butenedioate (2:1); 122647-32-9; U82208E; C20H36N2O3S; Ibutilide [BAN:INN]; LS-172765; DB00308; LS-90123; Methanesulfonamide, N-(4-(4-(ethylheptylamino)-1-hydroxybutyl)phenyl)-, (E)-2-butenedioate (2:1) (salt); Butilide fumarate; Ibutilidum; Corvert (TN); I06-1701; n-(4-{4-[ethyl(heptyl)amino]-1-hydroxybutyl}phenyl)methanesulfonamide; Ibutilida; D08060; 122647-32-9 (Fumarate); Methanesulfonamide, N-(4-(4-(ethylheptylamino)-1-hydroxybutyl)phenyl)-, (+-)-,(E)-2-butenedioate (2:1) (salt); IBUTILIDE FUMARATE; AC1NQXZ2; AC1L1TUW; D00648; 122647-31-8 (Parent); Corvert; C07753; CID60753; U-82208E; U82209E; U 70226E; N-(4-(4-(ethylheptylamino)-1-hydroxybutyl)phenyl)methanesulfonamide; UNII-2436VX1U9B; Ibutilide Fumarate [USAN]; NCGC00181771-01; U-82209E; ibutilide, (+-)-isomer; Methanesulfonamide, N-(4-(4-(ethylheptylamino)-1-hydroxybutyl)phenyl)-, (+-)-, (E)-2-butenedioate (2:1) (salt); UNII-9L5X4M5L6I; MolPort-005-932-621; CID6437366; CHEMBL533; Ibutilida [INN-Spanish]; Ibutilide; CID5281065; AC1Q6VUF; (+-)-4'-(4-(Ethylheptylamino)-1-hydroxybutyl)methanesulfonanilide fumarate (2:1) (salt); AC1O5NJM; Ibutilidum [INN-Latin]; U-70226E; 130350-52-6; Ibutilide (INN); ibutilide, fumarate salt (2:1), (+-)-isomer; CHEMBL1200564; Ibutilide fumarate (USAN); (+-)-N-(4-(4-(Ethylheptylamino)-1-hydroxybutyl)phenyl)methanesulfonamide (E)-butenedioate; N-[4-[4-[ethyl(heptyl)amino]-1-hydroxybutyl]phenyl]methanesulfonamide; CHEBI:112608; 122647-31-8	122647-32-9	60753	731244	TTDS00414	Voltage-dependent L-type calcium channel subunit alpha-1C	CACH2;CACN2;CACNA1C;CACNL1A1;Calcium channel, L type, alpha-1 polypeptide, isoform 1, cardiac muscle;CCHL1A1;Voltage-gated calcium channel subunit alpha Cav1.2	Q13936	775	ENSG00000151067	activator
DCL000694	AMG-714	N/A	N/A	N/A	N/A	TTDC00251	Interleukin-15	IL-15	P40933	3600	ENSG00000164136	antibody
DPR000013	AMG 714	N/A	N/A	N/A	N/A	TTDC00251	Interleukin-15	IL-15	P40933	3600	ENSG00000164136	inhibitor
DCL001259	ZGN-433	N/A	N/A	N/A	N/A	TTDR00721	Methionine aminopeptidase 2	(MetAP)-2;Initiation factor 2 associated 67 kDa glycoprotein;MetAP 2;P67;P67eIF2;Peptidase M 2	Q8SR45	N/A	N/A	inhibitor
DCL000140	KAI-1455	N/A	57-53-4	4064	48425274	TTDC00066	Protein kinase C, epsilon type	NPKC-epsilon;PKC epsilon;Protein Kinase C epsilon	Q02156	5581	ENSG00000171132	activator
DAP000185	Aprotinin	Trasylol; APROTININ; Riker 52G; RPDFCLEPPYTGPCKARIIRYFYNAKAGLCQTFVYGGCRAKRNNFKSAEDCMRTCGGA; RP-9921; 9087-70-1; RPDFCLEPPYTGPCKARIIRYFYNAKAGLCQTFVYGGCRAKRNNFKSAEDCMRTCGGA; Aprotinin; Zymofren; Trazinin; Bayer A 128; Iniprol	9087-70-1	16130295	617567	TTDS00282	Trypsin	Trypsinogen	N/A	N/A	N/A	inhibitor
DCL000019	Dermolastin	N/A	N/A	N/A	N/A	TTDS00282	Trypsin	Trypsinogen	N/A	N/A	N/A	inhibitor
DCL000019	Dermolastin	N/A	N/A	N/A	N/A	TTDC00028	Tissue kallikrein	Glandular kallikrein;hGK;Kallikrein;KLK	P20151	3817	ENSG00000167751	inhibitor
DAP000757	Auranofin	CID6918453; AURANOFIN; NSC321521; SK&F 39162; Gold, (1-thio-.beta.-D-glucopyranosato)(triethylphosphine)-, 2,3,4,6-tetraacetate; Ridauran; SK&F-39162; Ridaura; 34031-32-8; Gold, (2,3,4,6-tetra-O-acetyl-1-thio-.beta.-D-glucopyranosato-S)(triethylphosphine)-; (1-Thio-.beta.-D-glucopyranosato)(triethylphosphine)gold 2,3,4,6-tetraacetate	34031-32-8	6333901	574276	TTDS00276	Thioredoxin reductase, cytoplasmic	Cytosolic thioredoxin reductase;Thioredoxin reductase;TR;TR1;TrxR	Q8J0U0	N/A	N/A	inhibitor
DAP001352	Biricodar	2-Piperidinecarboxylic acid, 1-(oxo(3,4,5-trimethoxyphenyl)acetyl)-, 4-(3-pyridinyl)-1-(3-(3-pyridinyl)propyl)butyl ester, (S)-; CHEMBL350775; 159997-94-1; AC1MI37E; 1,7-dipyridin-3-ylheptan-4-yl (2S)-1-[2-oxo-2-(3,4,5-trimethoxyphenyl)acetyl]piperidine-2-carboxylate; Incel; Biricodar; CHEBI:355753; Vx 710; CID3037617; UNII-3KG76X4KJK; Biricodar [INN]	174254-13-8	3037617	17397283	TTDS00288	Multidrug resistance-associated protein 1	Mrp1;Multidrug resistance protein 1	P33527	4363	ENSG00000103222	modulator
DCL000306	Benzbromarone	Benzbromaron-ratiopharm; Uricovac; Heumann Brand of Benzbromarone; BPBio1_000549; SAM001246877; Benzbromarone Heumann Brand; (3,5-Dibromo-4-hydroxyphenyl)(2-ethyl-1-benzofuran-3-yl)methanone; AC-6162; ratiopharm Brand of Benzbromarone; KETONE, 3,5-DIBROMO-4-HYDROXYPHENYL 2-ETHYL-3-BENZOFURANYL; Benzbromaronum [INN-Latin]; AL, Benzbromaron; Benzbromaron AL; Aliud Brand of Benzbromarone; HMS1569I21; Exurate; Benzbromarone Sanfer Brand; Benzbromaronratiopharm; CPD000058310; 3-(3,5-Dibromo-4-hydroxybenzoyl)-2-ethylbenzofuran; 3-[3,5-DIBROMO-4-HYDROXYBENZOYL]-2-ETHYLBENZOFURAN; MolPort-002-622-240; Oprea1_140235; Prestwick1_000370; NCGC00013895-02; Normurat; B5774_FLUKA; L 2214-Labaz; ZINC00608205; LS-87131; NCGC00013895; Benzbromarone (JP15/USAN/INN); Acifugan; Prestwick_709; MLS001074105; 3562-84-3; CHEMBL388590; CID2333; UNM000001228903; Narcaricin; Hipurik; 3,5-Dibromo-4-hydroxyphenyl-2-ethyl-3-benzofuranyl ketone; Prestwick2_000370; 2-Ethyl-3-(3,5-dibrom-4-hydroxybenzoyl)benzofuran; SMR000058310; SPBio_002420; Minuric; Benzbromaron ratiopharm; NCIStruc1_001498; BRD-K11717138-001-03-0; HMS2093J04; Uroleap (TN); L2214-Labaz; Benzofuran, 3-(3,5-dibromo-4-hydroxybenzoyl)-2-ethyl-; Benzobromarona [INN-Spanish]; Desuric; L-2214; (3,5-Dibromo-4-hydroxyphenyl)(2-ethyl-1-benzofuran-3-yl)methanone; 3, 5-Dibromo-4-hydroxyphenyl-2-ethyl-3-benzofuranyl ketone; Ketone, 3,5-dibromo-4-hydroxyphenyl 2-ethyl-3-benzofuranyl; Methanone, (3; Urinorm; MLS000028522; CAS-3562-84-3; Prestwick0_000370; CHEBI:3023; UNII-4POG0RL69O; Besuric; AC1L1DG0; L2214; FT-0083530; SBB057006; BRN 0273668; HMS2052K05; NSC-85433; benzbromarone; Methanone, (3,5-dibromo-4-hydroxyphenyl)(2-ethyl-3-benzofuranyl)-; L 2214; MLS000737128; NSC85433; Uroleap; Benzobromarona; Prestwick3_000370; MLS001424143; I06-1261; (3,5-dibromo-4-hydroxyphenyl)-(2-ethyl-1-benzofuran-3-yl)methanone; , 5-dibromo-4-hydroxyphenyl)(2-ethyl-3-benzofuranyl)-; Azubromaron; MJ 10061; NCIStruc2_001681; EINECS 222-630-7; Benzbromarone Aliud Brand; B5774_SIGMA; Benzbromaron; NCGC00013895-03; D001553; (2-Ethyl-3-benzofuranyl)-(3,5-dibrom-4-hydroxyphenyl)keton; Benzbromaronum; Harolan; C17H12Br2O3; NCI60_041884; D01056; NSC 85433; Benzbromarone [USAN:INN:BAN]; Benzbromarone ratiopharm Brand; Sanfer Brand of Benzbromarone; Sanofi Winthrop Brand of Benzbromarone; NCI85433; NCGC00022066-04; BSPBio_000499	3562-84-3	2333	48415612	TTDS00288	Multidrug resistance-associated protein 1	Mrp1;Multidrug resistance protein 1	P33527	4363	ENSG00000103222	stimulator
DAP000794	Sulfinpyrazone	KBioSS_001502; IDI1_000090; USAF GE-13; 4-(2-Benzenesulfinylethyl)-1,2-diphenylpyrazolidine-3,5-dione; Sulfinpirazona; HMS2092K11; 1,2-Diphenyl-3,5-dioxo-4-(2'-phenyl-sulfinyl-aethyl)-pyrazolidin; SMR000058991; MolPort-003-666-286; Anturen; EINECS 200-357-4; ()-Sulfinpyrazone; UNII-V6OFU47K3W; Prestwick_455; sulfinpyrazone (SPZ); Nu-Sulfinpyrazone; DivK1c_000090; S9509_FLUKA; AB00052103; 1,2-Diphenyl-4-(2'-phenylsulfinethyl)-3,5-pyrazolidinedione; Anturane; Anturano; G 28,315; G 28315; Spectrum5_000984; NSC75925; KBio1_000090; 1,2-diphenyl-4-[2-(phenylsulfinyl)ethyl]pyrazolidine-3,5-dione; DB01138; D013442; Novartis Brand of Sulfinpyrazone; 3,5-Pyrazolidinedione, 1,2-diphenyl-4-(2-(phenylsulfinyl)ethyl)-; Prestwick1_000290; BSPBio_000200; Diphenylpyrazone; 4-(Phenylsulfoxyethyl)-1,2-diphenyl-3,5-pyrazolidinedione; KBio2_006638; Sulfinpirazona [INN-Spanish]; AC-13602; Prestwick0_000290; AC1L1K4Z; BIDD:PXR0096; Sulfoxyphenylpyrazolidin; NCGC00016255-01; CHEMBL832; SBB058184; SPBio_001447; 1,2-Diphenyl-4-(phenylsulfinylethyl)-3,5-pyrazolidinedione; CPD000058991; NCGC00023932-04; Apotex Brand of Sulfinpyrazone; Nu-Pharm Brand of Sulfinpyrazone; BRD-A36217750-001-05-6; CAS-57-96-5; 3,5-Pyrazolidinedione, 1,2-diphenyl-4-[2-(phenylsulfinyl)ethyl]-; Spectrum4_000845; SPECTRUM1500554; NCGC00018267-01; HSDB 3396; Sulfinpyrazone (JP15/USP/INN); Novopyrazone; 1,2-Diphenyl-3,5-dioxo-4-(2-phenylsulfinylethyl)pyrazolidine; NINDS_000090; KBio3_001540; Sulfinpyrazon; Apo-Sulfinpyrazone; (+/-)-SULFINPYRAZONE; HMS1921C09; Enturan; Spectrum2_001324; MLS000028565; 4-[2-(benzenesulfinyl)ethyl]-1,2-diphenylpyrazolidine-3,5-dione; 1,2-Diphenyl-4-[2-(phenylsulfinyl)ethyl-3,5-pyrazolidinedione; BPBio1_000220; C23H20N2O3S; Spectrum3_000590; Anturane (TN); Spectrum_001022; Sulfinpyrazone [USAN:INN:JAN]; 1,2-Diphenyl-3,5-dioxo- 4- (2-phenylsulfinylethyl) pyrazolidine; sulfinpyrazone; KBioGR_001449; S9509_SIGMA; KBio2_004070; SPBio_002419; Nu Sulfinpyrazone; Sulfinpyrazine; Prestwick3_000290; BSPBio_002040; 1,2-Diphenyl-3,5-dioxo-4-(2'-phenyl-sulfinyl-aethyl)-pyrazolidin [German]; D00449; 1,2-Diphenyl-4-(2-(phenylsulfinyl)ethyl)-3,5-pyrazolidinedione; Sulfoxyphenylpyrazolidine; Anturidin; BRN 0713597; HMS500E12; CID5342; 57-96-5; Sulfinpyrazonum; MLS001074941; Anturanil; CHEBI:9342; WLN: T5VNNV EHJ BR& CR& E2SO&R; KBio2_001502; Prestwick2_000290; C07317; LS-128688; Enturen; Anturan; NSC 75925; Sulfinpyrazonum [INN-Latin]; Nu Pharm Brand of Sulfinpyrazone; SAM002554932; NCGC00023932-03; HMS1568J22; Sulphinpyrazone; Apo Sulfinpyrazone	57-96-5	5342	9525	TTDS00288	Multidrug resistance-associated protein 1	Mrp1;Multidrug resistance protein 1	P33527	4363	ENSG00000103222	modulator
DCL000021	PRLX 93936	N/A	N/A	N/A	N/A	TTDC00038	Voltage-dependent anion-selective channel protein 2	hVDAC2;Outer mitochondrial membrane protein porin 2;VDAC-2	P45880	7417	ENSG00000165637	activator
DCL000611	R7112	N/A	N/A	N/A	N/A	TTDC00206	Ubiquitin-protein ligase E3 Mdm2	Double minute 2 protein;Hdm2;MDM2;MDM2 protein;Oncoprotein Mdm2;P53-binding protein Mdm2	Q00987	4193	ENSG00000135679	inhibitor
DAP001512	Rifampicin	Riforal; NCGC00016699-01; KBio3_003018; HMS2089F12; CHEBI:455936; Rimactan; Rifamycin AMP; Ramp; 8-(((4-Methyl-1-piperazinyl)imino)methyl)rifamycin SV; 3-(((4-Methyl-1-piperazinyl)imino)-methyl)rifamycin; Rifadine; Reserpine & Rifampicin; Dione 21-acetate; Rifadin Iv; Spectrum3_001837; 3-(((4-Methyl-1-piperazinyl)imino)methyl)rifamycin SV; KBio2_003487; NSC-113926; HSDB 3181; STK080143; Rifadin I.V; S1764_Selleck; Rifadin, Rimactane, Rifampicin, Rifampin; CCRIS 551; NCGC00022678-04; Rifomycin SV, 8-(N-(4-methyl-1-piperazinyl)formidoyl)-; SAM002264646; 1-b]furan-21-yl acetate; Rimactazid; AZT + Rifampin; SMR000058322; KBio2_000919; CHEBI:28077; HMS1569J11; Rifoldin; NSC113926; Rifampicine; Rimactizid; MLS000028552; Rifampicin & Propolis; Rifampicina [INN-Spanish]; Sinerdol; LS-7689; MLS001148237; Rifampicinum [INN-Latin]; Rifinah; R3501_SIAL; CID5702112; DB01045; 62534-43-4; RFP; CHEMBL180; CID6842115; Famcin; KBioSS_000919; Ba 41166; MolPort-003-666-281; MolPort-000-767-051; L-5103 Lepetit; 8-[[(4-Methylpiperazinyl)imino]methyl]rifamycin sv; Rofact; Rifaprodin; 3-([(4-Methyl-1-piperazinyl)imino]methyl)rifamycin SV; Piperine & Rifampicin; 3-[(4-Methyl-1-piperazinyl)iminomethyl]rifamycin SV; NCGC00022678-05; KBio1_000550; Rifampicin [INN:BAN:JAN]; C43H58N4O12; yl]-, (2S,12Z,14E,16S,17S,18R,19R,20R,21S,22R,23S,24E)-; CID5381226; NCGC00018178-01; Rifcin; Rifamicin AMP; CID6912767; Rifampicine [French]; Eremfat; CID5458213; 3-(4-Methylpiperazinyliminomethyl)rifamycin SV; Rifamycin, 3-[[(4-methyl-1-piperazinyl)imino]methyl]-; Rifobac; Archidyn; Tubocin; Arficin; Rifomycin sv, 8-[N-(4-Methyl-1-piperazinyl)formidoyl]-; 8-(4-Methylpiperazinyliminomethyl) rifamycin SV; DivK1c_000550; Rf; CAS-13292-46-1; L-5103; NINDS_000550; Rifampicin; NCGC00160500-01; Doloresum; SMR000653525; Rimycin; CID5388984; BIDD:PXR0014; MLS001333745; Rifa; R-Cin; NCGC00022678-03; R7382_SIGMA; Rifampicina; Rifadin; SPECTRUM1500529; Rifampicin SV; Rifam; BSPBio_000509; Rifampin [USAN]; Rifoldine; HMS1920P08; Spectrum5_002018; Rifadin (TN); Rifamor; NSC 113926; UNII-VJT6J7R4TR; D00211; Dipicin; Abrifam; 3-[[(4-Methyl-1-piperazinyl)imino]-methyl]rifamycin; Rimactin; MolPort-006-395-891; 3-(4-Methylpiperazinyliminomethyl)-rifamycin SV; CID6708473; 13292-46-1; HMS2092G09; BPBio1_000561; Rifamycin, 3-(((4-methyl-1-piperazinyl)imino)methyl)-; Bio-0621; Rfamipicin; CID6604339; KBioGR_001780; Rifagen; SPBio_002430; WLN: V1 WQ A&1 E&1 E1UN- AT6N DNTJ D1; 83907_SIGMA; Rifaldin; 8CI); Arzide; BA-41166E; CPD001906767; HMS501L12; Spectrum_000439; C06688; KBio2_006055; 46713_FLUKA; R3501_SIGMA; Rifaldazin; 8-[[(4-Methyl-1-piperazinyl)imino]methyl]rifamycin sv; RMP; Rifampicin & EEP; Benemicin; TNP00313; DRG-0109; Spectrum4_001250; Prestwick1_000525; NCGC00017365-01; R0079; NCI60_000309; Benemycin; Rimazid; Prestwick3_000525; Rifamsolin; 8-[[(4-Methyl-1-piperazinyl)imino[methyl]rifamycin; R/AMP; Rimactane; Rimactane (TN); 83907_FLUKA; EINECS 236-312-0; Rifampicinum; 46713_RIEDEL; rifampin; Ba 41166/E; Prestwick_833; Rifadin I.V.; Fenampicin; Rifampin (USP); R5777_SIGMA; nchembio884-comp4; CID6913622; Prestwick0_000525; Rifampicin (JP15/INN); Rifaldazine; Prestwick2_000525; MolPort-002-513-586	13292-46-1	5458213	48425599	TTDS00227	RNA polymerase	N/A	N/A	N/A	N/A	binder
DAP000197	Rifampin	Riforal; Rifa; R-Cin; HMS2089F12; R7382_SIGMA; NCGC00022678-03; Rifampicina; Rimactan; Rifamycin AMP; Rifadin; Ramp; 8-(((4-Methyl-1-piperazinyl)imino)methyl)rifamycin SV; SPECTRUM1500529; Rifampicin SV; 3-(((4-Methyl-1-piperazinyl)imino)-methyl)rifamycin; Rifam; Rifadine; Reserpine & Rifampicin; BSPBio_000509; Dione 21-acetate; Rifampin [USAN]; Rifoldine; HMS1920P08; 3-(((4-Methyl-1-piperazinyl)imino)methyl)rifamycin SV; Spectrum5_002018; Rifadin (TN); Rifamor; NSC 113926; NSC-113926; HSDB 3181; STK080143; Rifadin I.V; S1764_Selleck; UNII-VJT6J7R4TR; Rifadin, Rimactane, Rifampicin, Rifampin; CCRIS 551; NCGC00022678-04; D00211; Rifomycin SV, 8-(N-(4-methyl-1-piperazinyl)formidoyl)-; SAM002264646; 1-b]furan-21-yl acetate; Rimactazid; Dipicin; AZT + Rifampin; 3-[[(4-Methyl-1-piperazinyl)imino]-methyl]rifamycin; Abrifam; MolPort-006-395-891; 3-(4-Methylpiperazinyliminomethyl)-rifamycin SV; 13292-46-1; HMS2092G09; CHEBI:28077; HMS1569J11; Rifoldin; NSC113926; Rifampicine; BPBio1_000561; Rifamycin, 3-(((4-methyl-1-piperazinyl)imino)methyl)-; Bio-0621; Rimactizid; Rifagen; WLN: V1 WQ A&1 E&1 E1UN- AT6N DNTJ D1; Rifampicin & Propolis; Rifampicina [INN-Spanish]; 83907_SIGMA; Sinerdol; LS-7689; Rifaldin; MLS001148237; 8CI); Rifampicinum [INN-Latin]; Rifinah; R3501_SIAL; CID5702112; Arzide; 62534-43-4; BA-41166E; CPD001906767; RFP; CHEMBL180; Famcin; HMS501L12; C06688; Ba 41166; MolPort-003-666-281; 46713_FLUKA; R3501_SIGMA; MolPort-000-767-051; L-5103 Lepetit; 8-[[(4-Methylpiperazinyl)imino]methyl]rifamycin sv; Rifaldazin; Rifaprodin; 3-([(4-Methyl-1-piperazinyl)imino]methyl)rifamycin SV; 8-[[(4-Methyl-1-piperazinyl)imino]methyl]rifamycin sv; Piperine & Rifampicin; RMP; Rifampicin & EEP; 3-[(4-Methyl-1-piperazinyl)iminomethyl]rifamycin SV; NCGC00022678-05; Benemicin; Rifampicin [INN:BAN:JAN]; DRG-0109; C43H58N4O12; yl]-, (2S,12Z,14E,16S,17S,18R,19R,20R,21S,22R,23S,24E)-; CID5381226; R0079; Rifcin; Rifamicin AMP; Benemycin; Rifampicine [French]; Rimazid; Eremfat; CID5458213; Prestwick3_000525; Rifamsolin; 8-[[(4-Methyl-1-piperazinyl)imino[methyl]rifamycin; 3-(4-Methylpiperazinyliminomethyl)rifamycin SV; R/AMP; Rifamycin, 3-[[(4-methyl-1-piperazinyl)imino]methyl]-; Rifobac; Archidyn; Rimactane; Tubocin; Rimactane (TN); Arficin; 83907_FLUKA; EINECS 236-312-0; Rifampicinum; Rifomycin sv, 8-[N-(4-Methyl-1-piperazinyl)formidoyl]-; 46713_RIEDEL; 8-(4-Methylpiperazinyliminomethyl) rifamycin SV; rifampin; Ba 41166/E; Prestwick_833; Rifadin I.V.; Rf; Fenampicin; L-5103; Rifampin (USP); R5777_SIGMA; Rifampicin; NCGC00160500-01; CID6913622; Rifampicin (JP15/INN); Rifaldazine; Doloresum; Prestwick2_000525; SMR000653525; MolPort-002-513-586; Rimycin	13292-46-1	5381226	168608	TTDS00227	RNA polymerase	N/A	N/A	N/A	N/A	inhibitor
DCL000498	BIBW 2992	Tovok; Afatinib; FT-0083487; CID 10184653; 915958-11-1; CID10184653; Tovok, BIBW2992; 2-Butenamide, N-(4-((3-chloro-4-fluorophenyl)amino)-7-(((3S)-tetrahydro-3-furanyl)oxy)-6-quinazolinyl)-4-(dimethylamino)-; S1011_Selleck; BIBW-2992; 439081-18-2; CHEBI:61390; CHEMBL1173655; BIBW 2992; Tomtovok; (2E)-N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[(3S)-tetrahydrofuran-3-yloxy]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide; CHEBI:750126	N/A	N/A	N/A	TTDS00249	Receptor protein-tyrosine kinase erbB-2	C-erbB-2;C-erbB-2 oncoprotein;Epidermal growth factor receptor 2;Erb2;ERBB2;HER-2;HER2 (erbB2/neu);HER2/neu;MLN 19;NEU proto-oncogene;P185erbB2;Tyrosine kinase receptor ErbB2;Tyrosine kinase-type cell surface receptor HER2	P04626	2064	ENSG00000141736	inhibitor
DCL000345	CP-724714	CP 724714; FT-0083520; CHEMBL483321; CP-724714; AKOS005146427; 2-Methoxy-N-(3-(4-((3-methyl-4-((6-methyl-3-pyridinyl)oxy)phenyl)amino)-6-quinazolinyl)-2-propenyl)acetamide; 2-Methoxy-N-[(2E)-3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propen-1-yl]acetamide; CID9874913; CP724,714,  CP-724,714; CID 9874913; 845680-17-3; S1167_Selleck; CP-724,714	N/A	9874913	74684963	TTDS00249	Receptor protein-tyrosine kinase erbB-2	C-erbB-2;C-erbB-2 oncoprotein;Epidermal growth factor receptor 2;Erb2;ERBB2;HER-2;HER2 (erbB2/neu);HER2/neu;MLN 19;NEU proto-oncogene;P185erbB2;Tyrosine kinase receptor ErbB2;Tyrosine kinase-type cell surface receptor HER2	P04626	2064	ENSG00000141736	inhibitor
DCL000263	XL647	N/A	168626-94-6	5712	49684198	TTDS00249	Receptor protein-tyrosine kinase erbB-2	C-erbB-2;C-erbB-2 oncoprotein;Epidermal growth factor receptor 2;Erb2;ERBB2;HER-2;HER2 (erbB2/neu);HER2/neu;MLN 19;NEU proto-oncogene;P185erbB2;Tyrosine kinase receptor ErbB2;Tyrosine kinase-type cell surface receptor HER2	P04626	2064	ENSG00000141736	inhibitor
DCL001231	S-222611	N/A	N/A	N/A	N/A	TTDS00249	Receptor protein-tyrosine kinase erbB-2	C-erbB-2;C-erbB-2 oncoprotein;Epidermal growth factor receptor 2;Erb2;ERBB2;HER-2;HER2 (erbB2/neu);HER2/neu;MLN 19;NEU proto-oncogene;P185erbB2;Tyrosine kinase receptor ErbB2;Tyrosine kinase-type cell surface receptor HER2	P04626	2064	ENSG00000141736	inhibitor
DCL000660	Trastuzumab-DM1	N/A	163521-12-8	N/A	3818317	TTDS00249	Receptor protein-tyrosine kinase erbB-2	C-erbB-2;C-erbB-2 oncoprotein;Epidermal growth factor receptor 2;Erb2;ERBB2;HER-2;HER2 (erbB2/neu);HER2/neu;MLN 19;NEU proto-oncogene;P185erbB2;Tyrosine kinase receptor ErbB2;Tyrosine kinase-type cell surface receptor HER2	P04626	2064	ENSG00000141736	antibody
DCL000497	Bevacizumab+Trastuzumab	N/A	434-13-9	9903	49698644	TTDS00249	Receptor protein-tyrosine kinase erbB-2	C-erbB-2;C-erbB-2 oncoprotein;Epidermal growth factor receptor 2;Erb2;ERBB2;HER-2;HER2 (erbB2/neu);HER2/neu;MLN 19;NEU proto-oncogene;P185erbB2;Tyrosine kinase receptor ErbB2;Tyrosine kinase-type cell surface receptor HER2	P04626	2064	ENSG00000141736	antibody
DAP000391	Trastuzumab	Trastuzumab (genetical recombination) (JAN); Herceptin (TN); Trastuzumab; 180288-69-1; Herceptin; D03257; Trastuzumab (INN); Trastuzumab (genetical recombination)	180288-69-1	N/A	736684	TTDS00249	Receptor protein-tyrosine kinase erbB-2	C-erbB-2;C-erbB-2 oncoprotein;Epidermal growth factor receptor 2;Erb2;ERBB2;HER-2;HER2 (erbB2/neu);HER2/neu;MLN 19;NEU proto-oncogene;P185erbB2;Tyrosine kinase receptor ErbB2;Tyrosine kinase-type cell surface receptor HER2	P04626	2064	ENSG00000141736	antibody
DCL000649	TAK-285	N/A	N/A	N/A	N/A	TTDS00249	Receptor protein-tyrosine kinase erbB-2	C-erbB-2;C-erbB-2 oncoprotein;Epidermal growth factor receptor 2;Erb2;ERBB2;HER-2;HER2 (erbB2/neu);HER2/neu;MLN 19;NEU proto-oncogene;P185erbB2;Tyrosine kinase receptor ErbB2;Tyrosine kinase-type cell surface receptor HER2	P04626	2064	ENSG00000141736	inhibitor
DCL000346	HKI-272	N/A	698387-09-6	9915743	76593408	TTDS00249	Receptor protein-tyrosine kinase erbB-2	C-erbB-2;C-erbB-2 oncoprotein;Epidermal growth factor receptor 2;Erb2;ERBB2;HER-2;HER2 (erbB2/neu);HER2/neu;MLN 19;NEU proto-oncogene;P185erbB2;Tyrosine kinase receptor ErbB2;Tyrosine kinase-type cell surface receptor HER2	P04626	2064	ENSG00000141736	inhibitor
DCL000086	CI-1033	S1019_Selleck; N-(4-((3-Chloro-4-fluorophenyl)amino)-7-(3-(morpholin-4-yl)propoxy)quinazolin-6-yl)prop-2-enamide; Canertinib HCl; N-[4-(3-chloro-4-fluoroanilino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]prop-2-enamide dihydrochloride; 2-Propenamide, N-(4-((3-chloro-4-fluorophenyl) amino)-7-(3-(4-morpholinyl) propoxy)-6-quinazolinyl)-, dihydrochloride; CI-1033; UNII-C78W1K5ASF; D03350; AC1L4G5R; I14-8433; 2-Propenamide, N-(4-((3-chloro-4-fluorophenyl)amino)-7-(3-(4-morpholinyl)propoxy)-6-quinazolinyl)-, dihydrochloride; EC-000.2258; 267243-28-7; CI1033; PD-0183805; 289499-45-2; CHEMBL545315; PD 183805; CHEMBL31965; CID156413; CHEBI:61399; N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(morpholin-4-yl)propoxy]quinazolin-6-yl}prop-2-enamide; LS-185636; Canertinib dihydrochloride; N-[4-(3-Chloro-4-fluorophenylamino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]acrylamide dihydrochloride; N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl]-2-propenamide dihydrochloride; Canertinib, PD-183805, CI1033, PD183805; AKOS005145818; Canertinib dihydrochloride [USAN]; Canertinib; CID156414; AC-2414; I06-1255; CI 1033; N-[4-(3-chloro-4-fluoroanilino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]prop-2-enamide; Canertinib dihydrochloride (USAN); AB1004832; Canertinib dihydrochloride; PD-183805; AC1L4G5O; UNII-ICJ93X8X90; N-(4-(3-chloro-4-fluorophenyl)amino)-7-(3-morpholin-4-yl)propoxy)quinazolin-6-yl)prop-2-enamide dihydrochloride	289499-45-2	156414	12015296	TTDS00249	Receptor protein-tyrosine kinase erbB-2	C-erbB-2;C-erbB-2 oncoprotein;Epidermal growth factor receptor 2;Erb2;ERBB2;HER-2;HER2 (erbB2/neu);HER2/neu;MLN 19;NEU proto-oncogene;P185erbB2;Tyrosine kinase receptor ErbB2;Tyrosine kinase-type cell surface receptor HER2	P04626	2064	ENSG00000141736	inhibitor
DAP001451	Tyverb/Tykerb	N/A	198821-22-6	11557040	12015501	TTDS00249	Receptor protein-tyrosine kinase erbB-2	C-erbB-2;C-erbB-2 oncoprotein;Epidermal growth factor receptor 2;Erb2;ERBB2;HER-2;HER2 (erbB2/neu);HER2/neu;MLN 19;NEU proto-oncogene;P185erbB2;Tyrosine kinase receptor ErbB2;Tyrosine kinase-type cell surface receptor HER2	P04626	2064	ENSG00000141736	inhibitor
DCL000486	AZD8931	N/A	N/A	N/A	N/A	TTDS00249	Receptor protein-tyrosine kinase erbB-2	C-erbB-2;C-erbB-2 oncoprotein;Epidermal growth factor receptor 2;Erb2;ERBB2;HER-2;HER2 (erbB2/neu);HER2/neu;MLN 19;NEU proto-oncogene;P185erbB2;Tyrosine kinase receptor ErbB2;Tyrosine kinase-type cell surface receptor HER2	P04626	2064	ENSG00000141736	inhibitor
DCL000343	BMS-599626	N/A	N/A	N/A	N/A	TTDS00249	Receptor protein-tyrosine kinase erbB-2	C-erbB-2;C-erbB-2 oncoprotein;Epidermal growth factor receptor 2;Erb2;ERBB2;HER-2;HER2 (erbB2/neu);HER2/neu;MLN 19;NEU proto-oncogene;P185erbB2;Tyrosine kinase receptor ErbB2;Tyrosine kinase-type cell surface receptor HER2	P04626	2064	ENSG00000141736	inhibitor
DAP000853	Lapatinib	FMM; I01-1247; LS-187029; Tycerb; AC1L4LL4; TL80090051; CHEMBL554; EN002712; 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-; DB02584; GW 572016; Lapatinib (INN); Lapatinib [INN]; CHEBI:49603; Lapatinib tosilate hydrate; Lapatinib Ditosylate; AKOS005145766; AC-1314; 4-[[3-Chloro-4-(3-fluorobenzyloxy)phenyl]amino]-6-[5-[[(2-methanesulfonylethyl)amino]methyl]furan-2-yl]quinazoline; GSK572016; GW 572016; GW 572016X; Lapatinib; N-(3-Chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-((2-methylsulfonylethylamino)methyl)-2-furyl)quinazolin-4-amine; NCGC00167507-01; HMS2089H10; N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine; 388082-78-8; N-(3-Chloro-4-{[(3-fluorophenyl)methyl]oxy}phenyl)-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furanyl]-4-quinazolinamine; CID208908; LS-187771; Kinome_3685; Lapatinib, Tykerb, GW572016; 231277-92-2; D08108; nchembio866-comp20; AB1004631; 4-Quinazolinamine, N-(3-chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl)-; Lapatinib; GW 572016X; Kinome_3684; NSC745750; DB01259; UNII-0VUA21238F; GW572016; GSK 572016; 1xkk; N-{3-CHLORO-4-[(3-FLUOROBENZYL)OXY]PHENYL}-6-[5-({[2-(METHYLSULFONYL)ETHYL]AMINO}METHYL)-2-FURYL]-4-QUINAZOLINAMINE	388082-78-8	208908	14911387	TTDS00249	Receptor protein-tyrosine kinase erbB-2	C-erbB-2;C-erbB-2 oncoprotein;Epidermal growth factor receptor 2;Erb2;ERBB2;HER-2;HER2 (erbB2/neu);HER2/neu;MLN 19;NEU proto-oncogene;P185erbB2;Tyrosine kinase receptor ErbB2;Tyrosine kinase-type cell surface receptor HER2	P04626	2064	ENSG00000141736	inhibitor
DCL000347	TAK165	Mubritinib (USAN/INN); I14-8814; UNII-V734AZP9BR; 1H-1,2,3-triazole, 1-(4-(4-((2-((1E)-2-(4-(trifluoromethyl)phenyl)ethenyl)-4-oxazolyl)methoxy)phenyl)butyl)-; AC1O61A3; Mubritinib; D04025; TAK 165; CID6444692; 4-[[4-[4-(triazol-1-yl)butyl]phenoxy]methyl]-2-[(E)-2-[4-(trifluoromethyl)phenyl]ethenyl]-1,3-oxazole; AC-5248; 366017-09-6	366017-09-6	6444692	50490680	TTDS00249	Receptor protein-tyrosine kinase erbB-2	C-erbB-2;C-erbB-2 oncoprotein;Epidermal growth factor receptor 2;Erb2;ERBB2;HER-2;HER2 (erbB2/neu);HER2/neu;MLN 19;NEU proto-oncogene;P185erbB2;Tyrosine kinase receptor ErbB2;Tyrosine kinase-type cell surface receptor HER2	P04626	2064	ENSG00000141736	inhibitor
DCL000589	Pazopanib + Tyverb/Tykerb	N/A	N/A	443391	36886718	TTDS00249	Receptor protein-tyrosine kinase erbB-2	C-erbB-2;C-erbB-2 oncoprotein;Epidermal growth factor receptor 2;Erb2;ERBB2;HER-2;HER2 (erbB2/neu);HER2/neu;MLN 19;NEU proto-oncogene;P185erbB2;Tyrosine kinase receptor ErbB2;Tyrosine kinase-type cell surface receptor HER2	P04626	2064	ENSG00000141736	inhibitor
DCL000592	Pertuzumab	380610-27-5; Pertuzumab (USAN/INN); D05446; Pertuzumab (genetical recombination) (JAN); Pertuzumab (genetical recombination); Pertuzumab	145040-37-5	2540	47207115	TTDS00249	Receptor protein-tyrosine kinase erbB-2	C-erbB-2;C-erbB-2 oncoprotein;Epidermal growth factor receptor 2;Erb2;ERBB2;HER-2;HER2 (erbB2/neu);HER2/neu;MLN 19;NEU proto-oncogene;P185erbB2;Tyrosine kinase receptor ErbB2;Tyrosine kinase-type cell surface receptor HER2	P04626	2064	ENSG00000141736	inhibitor
DCL000344	Tykerb	CID11557040; CHEMBL1201179; Lapatinib ditosylate (USAN); GW-572016F; GW-572016; Lapatinib tosilate hydrate (JAN); Lapatinib tosilate hydrate; Lapatinib Ditosylate; LAPATINIB DITOSYLATE MONOHYDRATE; Tykerb (TN); Tykerb; Tyverb; D04024; GW-2016; 388082-78-8	388082-78-8	208908	783738	TTDS00249	Receptor protein-tyrosine kinase erbB-2	C-erbB-2;C-erbB-2 oncoprotein;Epidermal growth factor receptor 2;Erb2;ERBB2;HER-2;HER2 (erbB2/neu);HER2/neu;MLN 19;NEU proto-oncogene;P185erbB2;Tyrosine kinase receptor ErbB2;Tyrosine kinase-type cell surface receptor HER2	P04626	2064	ENSG00000141736	inhibitor
DAP001392	Inamrinone	LS-44658; HMS1570O22; NINDS_000136; CHEMBL12856; Amrinone; CID3698; Amrinonum [INN-Latin]; 5-Amino-(3,4'-bipyridin)-6(1H)-one; A4056_SIGMA; 60719-84-8; NCGC00095984-01; AC-12186; 5-amino-3,4'-bipyridin-6(1H)-one; Spectrum_001350; Wincoram; STK590307; Spectrum2_001980; 5-Amino(3,4'-bipyridin)-6(1H)-one; AC1L1GIK; Spectrum5_000999; MolPort-002-652-742; SPBio_002139; 3-Amino-5-(4-pyridinyl)-2(1H)-pyridinone; CAS-60719-84-8; KBio2_001830; Prestwick0_000800; Cordemcura; DivK1c_000136; AWD 08-250; EINECS 262-390-0; Amrinonum; Bio-0795; IDI1_000136; NCGC00164379-01; Inocor; I06-0688; 5-25-15-00181 (Beilstein Handbook Reference); ZINC08673078; Amrinone (JAN/INN); Prestwick3_000800; Prestwick_44; BRD-K45924332-001-04-4; C10H9N3O; 5-Amino-(3,4'-bipyridine)-6(1H)-one; NCGC00016896-01; Cartonic; UNII-JUT23379TN; CCRIS 3794; Amcoral (TN); DB01427; KBioGR_001398; KBio2_006966; Spectrum4_001069; KBio2_004398; BPBio1_001034; MLS001074083; Inamrinone (USP); 3-amino-5-pyridin-4-yl-1H-pyridin-2-one; MLS000069829; BRN 0744819; KBio1_000136; Spectrum3_000956; BSPBio_000940; SPBio_002879; Prestwick2_000800; WIN 40680; [3,4'-Bipyridin]-6(1H)-one, 5-amino-; Amcoral; Amrinona [INN-Spanish]; Inamrinone lactate; (3,4'-BIPYRIDIN)-6(1H)-ONE, 5-AMINO-; KBio3_002052; Amrinona; Inamrinone [USAN:BAN:INN]; HMS500G18; Amrinon; Prestwick1_000800; SMR000058850; KBioSS_001830; Win-40680; D00231; SPECTRUM1503084; inamrinone	60719-84-8	3698	7847298	TTDS00201	CAMP-phosphodiesterase	3',5'-cyclic-nucleotide phosphodiesterase;Cyclic Amp phosphodiesterase	N/A	N/A	N/A	inhibitor
DAP000792	Raloxifene	Raloxifeno [Spanish]; LY 139481; Methanone, [6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]-; Raloxifene Hcl; KBioSS_002364; LY-139481; BSPBio_000903; 84449-90-1; [6-hydroxy-2-(4-hydroxyphenyl)-1-benzothien-3-yl]{4-[(2-piperidin-1-ylethyl)oxy]phenyl}methanone; Keoxifene; KBio2_002361; RAL; CCRIS 7129; SPBio_002824; SMP2_000095; Raloxifene [INN:BAN]; HMS2089F06; CHEBI:8772; Raloxifenum; NSC747974; NCGC00015889-02; cMAP_000032; Eviden (TN); C28H27NO4S; DB00481; UNII-YX9162EO3I; C07228; Raloxifeno; raloxifene; BPBio1_000995; VU0155042-3; Prestwick2_000862; LS-177821; BIDD:ER0216; (6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl)(4-(2-(piperidin-1-yl)ethoxy)phenyl)methanone; Lopac-R-1402; KBio3_002840; NCGC00092353-02; BIDD:GT0795; Raxeto; Raxeto (TN); MolPort-003-850-106; CHEBI:45355; CID5035; [6-hydroxy-2-(4-hydroxyphenyl)-1-benzothien-3-yl][4-(2-piperidin-1-ylethoxy)phenyl]methanone; Methanone, (6-hydroxy-2-(4-hydroxyphenyl)benzo(b)thien-3-yl)(4-(2-(1-piperidinyl)ethoxy)phenyl)-; Raloxifene (INN); NCGC00015889-01; KBioGR_002361; D08465; Prestwick1_000862; HSDB 7460; [6-hydroxy-2-(4-hydroxyphenyl)-1-benzothiophen-3-yl]-[4-(2-piperidin-1-ylethoxy)phenyl]methanone; 82640-04-8 (hydrochloride); CHEMBL81; [6-Hydroxy-2-(4-hydroxy-phenyl)-benzo[b]thiophen-3-yl]-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone; Raloxifenum [Latin]; Lopac0_001051; nchembio.76-comp4; Prestwick3_000862; NCGC00015889-07; [2-(4-Hydroxyphenyl)-6-hydroxybenzo[b]thien-3-yl][4-(2-(1-piperidinyl)ethoxy)phenyl]methanone; KBio2_007497; CAS-82640-04-8; nchembio.140-comp6; KBio2_004929; (2-(4-Hydroxyphenyl)-6-hydroxybenzo(b)thien-3-yl)(4-(2-(1-piperidinyl)ethoxy)phenyl)methanone; AC1L1JGT; Eviden; Prestwick0_000862	84449-90-1	5035	148636	TTDS00242	Estrogen receptor	ER;ERalpha;ER-alpha;Estradiol receptor;Estrogen receptor alpha;Oestrogen receptor;Oestrogen receptor alpha	Q13262	N/A	N/A	modulator
DAP001017	Danazol	SMR000058321; SPBio_002029; 17alpha-Pregna-2,4-dien-20-yno(2,3-d)isoxazol-17-ol; (1R,3aS,3bR,10aR,10bS,12aS)-1-ethynyl-10a,12a-dimethyl-2,3,3a,3b,4,5,10,10a,10b,11,12,12a-dodecahydro-1H-cyclopenta[7,8]phenanthro[3,2-d]isoxazol-1-ol; CPD000058321; BRD-K48970916-001-03-0; ratiopharm Brand of Danazol; Danocrine (TN); Danogen; Sanofi Winthrop Brand of Danazol; WIN 17757; HMS2090A22; AC1L1FAD; LS-118524; AC-6836; NCGC00179665-01; 17-alpha-Pregna-2,4-dien-20-yno(2,3-d)isoxazol-17-ol; Danatrol; Danazant; EINECS 241-270-1; BSPBio_000090; Sanofi Synthelabo Brand of Danazol; Danazolum [INN-Latin]; WIN 17,757; AC1Q29FD; Winobanin; 20-yno[2,3-d]isoxazol-17-ol,} (17.alpha.)-; Prestwick3_000105; [1,2]oxazolo[4',5':2,3]-17alpha-pregn-4-en-20-yn-17-ol; Cyclomen; (1S,2R,13R,14S,17R,18S)-17-ethynyl-2,18-dimethyl-7-oxa-6-azapentacyclo[11.7.0.0^{2,10}.0^{4,8}.0^{14,18}]icosa-4(8),5,9-trien-17-ol; Chronogyn; Danol; D00289; Win 17, 757; Alphapharm Brand of Danazol; CID28417; UNII-N29QWW3BUO; BPBio1_000100; Danazol [USAN:BAN:INN:JAN]; CCRIS 6747; MolPort-002-513-504; Prestwick0_000105; anatrol; Danokrin; danazol; Pregna-2,4-dien-20-yno(2,3-d)isoxazol-17-ol,(17alpha)-; Prestwick2_000105; CHEBI:4315; STOCK1N-23495; Danocrine; NCGC00164400-01; D003613; NSC270916; 1-Ethynyl-10a,12a-dimethyl-2,3,3a,3b,4,5,10,10a,10b,11,12,12a-dodecahydro-1H-cyclopenta[7,8]phenanthro[3,2-d]isoxazol-1-ol; 17.Alpha.-Pregna-2, {4-dien-20-yno[2,3-d]isoxazol-17-ol}; Pregna-2, {4-dien-; Danoval; Panacrine; MLS001066617; Kendrick Brand of Danazol; Pregna-2,4-dien-20-yno(2,3-d)isoxazol-17-ol, (17alpha)-; MLS001306473; 17230-88-5; Ladogal; Danazol-ratiopharm; 17-alpha-Pregn-4-en-20-yno(2,3-d)isoxazol-17-ol; DB01406; Sanofi Brand of Danazol; NSC 270916; Antigen Brand of Danazol; Danazol (JAN/USP/INN); CHEMBL1479; Prestwick1_000105; Danazolum; WIN-17757; 17-alpha-2,4-Pregnadien-20-yno(2,3-d)isoxazol-17-ol; SAM002564203; ZINC03881958; Danazole; Prestwick_150; Danzol; HMS1568E12; AC1Q282K; Norciden	17230-88-5	28417	170876	TTDS00242	Estrogen receptor	ER;ERalpha;ER-alpha;Estradiol receptor;Estrogen receptor alpha;Oestrogen receptor;Oestrogen receptor alpha	Q13262	N/A	N/A	antagonist
DAP000793	Toremifene	Ethanamine, 2-(4-((1Z)-4-chloro-1,2-diphenyl-1-butenyl)phenoxy)-N,N-dimethyl-; BIDD:ER0222; 2-({4-[(1Z)-4-chloro-1,2-diphenylbut-1-en-1-yl]phenyl}oxy)-N,N-dimethylethanamine; NCGC00160530-01; CHEMBL1655; C08166; D08620; 98644-21-4; BIDD:GT0211; CHEBI:9635; GTx-006; STK626445; (Z)-2-(4-(4-Chloro-1,2-diphenyl-1-butenyl)phenoxy)-N,N-dimethylethanamine; Z-Toremifene; 89778-27-8 (citrate (1:1)); Toremifene Citrate (1:1); GTx 006; {2-[4-(4-Chloro-1,2-diphenyl-but-1-enyl)-phenoxy]-ethyl}-dimethyl-amine; CCRIS 8745; Farestone; 2-{4-[(1Z)-4-chloro-1,2-diphenylbut-1-en-1-yl]phenoxy}-N,N-dimethylethanamine; toremifene; Ethanamine, 2-(4-(4-chloro-1,2-diphenyl-1-butenyl)phenoxy)-N,N-dimethyl-, (Z)-; CID3005573; GTX-006 (Acapodene); Toremifeno; 2-(p-[(Z)-4-chloro-1,2-diphenyl-1-butenyl]-phenoxy)-N,N-dimethyl-ethylamine citrate(1:1); Toremifeno [Spanish]; AC-1751; Estrimex; STOCK6S-27411; DB00539; FC-1157a; HMS2090B22; Toremifenum; 2-[4-[(Z)-4-chloro-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine; UNII-7NFE54O27T; AC1MHJ33; 89778-26-7; 2-(para-((Z)-4-Chloro-1,2-diphenyl-1-butenyl)phenoxy)-N,N-dimethylethylamine (IUPAC); LS-7729; Toremifenum [Latin]; MolPort-002-508-208; BIDD:PXR0202; Acapodene; Toremifene Base; Toremifene [INN:BAN]; Toremifene (INN)	89778-26-7	3005573	193362	TTDS00242	Estrogen receptor	ER;ERalpha;ER-alpha;Estradiol receptor;Estrogen receptor alpha;Oestrogen receptor;Oestrogen receptor alpha	Q13262	N/A	N/A	modulator
DCL001219	Ospemifene	N/A	N/A	N/A	N/A	TTDS00242	Estrogen receptor	ER;ERalpha;ER-alpha;Estradiol receptor;Estrogen receptor alpha;Oestrogen receptor;Oestrogen receptor alpha	Q13262	N/A	N/A	modulator
DAP001016	Quinestrol	Eston; CHEBI:8716; E7887_SIGMA; MLS000069756; SMR000058815; 3-(Cyclopentyloxy)-19-nor-17-alpha-pregna-1,3,5(10)-trien-20-yn-17-ol; QUINESTROL; 3-(Cyclopentyloxy)-19-nor-17alpha-pregna-1,3,5(10)-trien-20-yn-17-ol; Estrovis 4000; LMST02010037; CHEMBL1201165; 3-Cyclopentyloxy-17alpha-ethynylestra-1,3,5(10)-trien-17beta-ol; Quinestrolum; NCGC00166146-01; 152-43-2; Qui-Lea; CID9046; MLS001077287; EECPE; W-3566; Quinestrolo [DCIT]; 19-Norpregna-1,3,5(10)-trien-20-yn-17-ol, 3-(cyclopentyloxy)-, (17alpha)-; Estradiol-17-beta 3-cyclopentyl ether; ZINC03875993; 17ALPHA-ETHYLNYL-1,3,5[10]ESTRATRIENE-3,17BETA-DIOL 3-CYCLOPENTYL ETHER; LS-97370; Quinestrolo; Quilea; Quinestrolum [INN-Latin]; Plestrovis; C07619; 17alpha-Ethynyl-1,3,5(10)-estratriene-3,17beta-diol 3-cyclopentyl ether; 17alpha-Ethynylestradiol 3-cyclopentyl ether; EINECS 205-803-1; MolPort-003-941-325; 19-Nor-17-alpha-pregna-1,3,5(10)-trien-20-yn-17-ol, 3-(cyclopentyloxy)-; DB04575; Quinestrol [USAN:INN:BAN]; C25H32O2; AC1L1S77; W 3566; Estrovister; D00576; UNII-JR0N7XD5GZ; Estrovis (TN); Estrovis; Ethinyl Estradiol 3-Cyclopentyl Ether; (8R,9S,13S,14S,17R)-3-cyclopentyloxy-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-ol; 3-(cyclopentyloxy)-17beta-ethynylestra-1,3,5(10)-trien-17-ol; 17-alpha-Ethinylestradiol 3-cyclopentyl ether; Quinestrol (USAN/INN)	152-43-2	9046	7847642	TTDS00242	Estrogen receptor	ER;ERalpha;ER-alpha;Estradiol receptor;Estrogen receptor alpha;Oestrogen receptor;Oestrogen receptor alpha	Q13262	N/A	N/A	modulator
DAP001014	Mestranol	ZINC03815424; 3-Methoxy-17-alpha-ethynylestradiol; EE(sub3)ME; NSC84032; Menophase; 17-alpha-Ethinyl estradiol 3-methyl ether; 17-Ethynyl-3-methoxy-1,3,5(10)-oestratien-17-beta-ol; Ethinylestradiol 3-methyl ether; Prestwick1_000846; MolPort-002-507-152; 43085-54-7; 17-alpha-Ethinyl oestradiol 3-methyl ether; Ethinyloestradiol 3-methyl ether; SPBio_002752; 8027 C. B.; Ovastol; Prestwick_966; 3-Methoxy-17-ethynyloestradiol-17-beta; 8027 C. B; 17-alpha-Ethynyloestradiol methyl ether; HMS2051J22; Ethinyl Estradiol 3 Methyl Ether; LS-7485; 17-Ethynylestradiol 3-methyl ether; SMR000059128; Norquen; 3-O-Methylethynylestradiol; EINECS 200-777-8; 53445-46-8; AC-13293; EPA Pesticide Chemical Code 115401; component of Norquen; Estra-1,3,5(10)-trien-17beta-ol, 17-ethynyl-3-methoxy-; Prestwick2_000846; 17alpha-Ethinyl estradiol 3-methyl ether; Prestwick3_000846; 3-Methoxyethynylestradiol; Alpha.-19-Norpregna-1,3,5(10)-trien-20-yn-17-ol, 3-meth; C07618; 17alpha-Ethynyloestradiol 3-methyl ether; 17alpha-Ethinylestradiol 3-methyl ether; Caswell No. 547A; Devocin; Inostral (steroid); 17-ethynyl-3-methoxyoestra-1(10),2,4-trien-17beta-ol; BIDD:ER0199; Ethinyl Estradiol 3-Methyl Ether; 3-Methoxyethynyloestradiol; NSC 84032; delta-MVE; Prestwick0_000846; CID6291; 17-Ethynyl-3-methoxyestra-1,3,5(10)-trien-17-ol; 3-Methoxy-17alpha-ethynylestradiol; BSPBio_000831; Ethynylestradiol 3-methyl ether; SC 4725; MLS001077321; CCRIS 377; BPBio1_000915; 3-Methoxy-17-alpha-ethynyloestradiol; S2125_Selleck; CPD000059128; NCGC00093347-02; 72-33-3; 3-Methoxy-17-alpha-ethinyloestradiol; 17-ethynyl-3-methoxyestra-1(10),2,4-trien-17beta-ol; component of Ortho-Novum; Compound 33355; 3-Methoxy-17alpha-ethynyl-1,3,5(10)-estratrien-17beta-ol; 3-Methoxy-17alpha-ethynyloestradiol; AI3-51798; 17-Ethynyl-3-methoxyestra-1,3,5(10)-trien-17-ol; 17.; CHEMBL1201151; D008656; NCGC00179410-01; 17alpha-19-Norpregna-1,3,5(10)-trien-20-yn-17-ol, 3-methoxy-; 3-Methoxy-17-alpha-ethynyl-1,3,5(10)-estratrien-17-beta-ol; 3-Methoxy-17alpha-ethinylestradiol; D00575; 17-alpha-Ethynyl-3-methoxy-1,3,5(10)-estratrien-17-beta-ol; HSDB 3588; 3-Methoxy-17-alpha-ethynyl-1,3,5(10)-oestratrien-17-beta-ol; 17-Ethynyloestradiol 3-methyl ether; Mestranolo; 3-Methylethynyloestradiol; BRN 2625905; Ethynylestradiol methyl ether; AC1L1M7F; UNII-B2V233XGE7; component of Norinyl; EE3ME; .delta.-MVE; 17alpha-Ethinyl oestradiol 3-methyl ether; mestranol; DB01357; BB_NC-0628; Mestranol [USAN:INN:BAN:JAN]; 17alpha-Ethynylestradiol 3-methyl ether; 855871_ALDRICH; CHEBI:6784; Mestranolo [DCIT]; 3-Methoxy-17-alpha-ethinylestradiol; MLS000028595; HMS1570J13; 3-Methoxy-19-norpregna-1,3,5(10)-trien-20-yn-17beta-ol; Mestranol (JP15/USP/INN); 17alpha-Ethynylestradiol methyl ether; Ethynyloestradiol 3-methyl ether; 3-Methoxy-17alpha-ethinyloestradiol; Mestranol [Steroidal oestrogens]; 3-Methoxy-17-alpha-19-norpregna-1,3,5(10)-trien-20-yn-17-ol; (17beta)-17-ethynyl-3-(methyloxy)estra-1,3,5(10)-trien-17-ol; 3-Methoxy-19-nor-17alpha-pregna-1,3,5(10)-trien-20-yn-17-ol; 17beta-Estradiol, 17-ethynyl-, 3-(methyl ether); 3-Methoxy-19-nor-17-alpha-pregna-1,3,5(10)-trien-20-yn-17-ol; 3-Methylethynylestradiol; Mestranolum; 3-Methoxy-17alpha-ethynyl-1,3,5(10)-oestratrien-17beta-ol; SAM001246866; BRD-K31920458-001-03-8; component of Ovulen; Mestranolum [INN-Latin]	72-33-3	6291	10321875	TTDS00242	Estrogen receptor	ER;ERalpha;ER-alpha;Estradiol receptor;Estrogen receptor alpha;Oestrogen receptor;Oestrogen receptor alpha	Q13262	N/A	N/A	agonist
DAP000854	Estradiol	IDI1_002118; KBio2_007405; Bio-E-Gel; Prestwick3_000441; BIDD:PXR0065; 3,17-beta-Oestradiol; estradiol; HMS1990E07; Progynon DH; HSDB 3589; Dihydroxyestrin; CID5757; Sandrena 1; Estrasorb; nchembio794-comp6; KBio3_000769; 17.beta.-Oestradiol; Macrodiol; KBio2_005541; Oestradiol-17.beta.; E 8875; MolPort-001-794-632; D-Estradiol; 3,17.beta.-Estradiol; 17-beta; Estraderm TTS 100; Ginosedol; component of Menrium; 17-E; D00105; [2,4,6,7-3H]-E2; NSC-9895; Femtran; Estrogel; Sandrena Gel; Polyestradiol; KBio2_002973; Estrofem Forte; [3H]-estradiol; Femanest; Oestrogynal; Macrol; Evamist; SMR000059126; cis-Oestradiol; Bio1_000403; KBio2_004837; Estradiolum; 73459-61-7; Oesclim; Estring; SL-1100; NCGC00091544-07; Gynoestryl; Divigel (TN); 17-beta-estradiol; Tradelia; CHEBI:16469; B-Estradiol; Sisare Gel; S-21400; BPBio1_000532; Femestral; Aerodiol; Profoliol; EINECS 200-023-8; VIVELLE-DOT; Menest; NCGC00091544-05; Lopac0_000503; Climaderm; Microdiol; NCGC00091544-09; SAM001247032; Bardiol; Estradiol-17-beta; 17beta oestradiol; Estring (TN); Evorel; bmse000642; Femogen; Estraderm TTS 50; CPD-352; Dihydroxyoestrin; cMAP_000005; D-3,17beta-Estradiol; Ovociclina; Femtrace; Vagifem; 2d06; Nordicol; Prestwick0_000441; Oestergon; progynon; Estroclim; Estrifam; Aquadiol; Zesteen; Perlatanol; Esclim; 17.beta.-Estradiol; KBioGR_000405; NCGC00091544-04; Climara Forte; Bio1_000892; E0025; HMS2090E18; Dimenformon; BSPBio_001065; Estraderm; SMP1_000121; Oestradiol-17-beta; Oestradiol R; SPBio_002421; BSPBio_000482; Gelestra; Estrodiolum; estradiol-17beta; Destradiol; Ovocylin; Follicyclin; Systen; Dihydromenformon; Estraldine; NCGC00091544-08; Zerella; Dermestril; cis-Estradiol; NCGC00091544-02; CMC_11154; E(sub 2); Estrace; KBio2_002269; Estradiolo [DCIT]; Climara; MLS000758312; NCGC00091544-12; S1709_Selleck; AC1L1L2K; Theelin, dihydro-; Dihydrotheelin; Gynodiol; KBio2_000405; Estraderm (TN); LMST02010001; HMS2051C17; HMS1792E07; GynPolar; Encore; nchembio775-comp2; Estradiolo; MLS000069494; 873662-39-6; Fempatch; Alora; Oestrogel; Altrad; Estraderm TTS; KBioSS_002270; Zesteem; nchembio.76-comp2; SK-Estrogens; 1jgl; Femestrol; NCGC00179321-02; E2758_SIGMA; 17beta-Oestradiol; Climara (TN); Oestradiol-17beta; Vivelle (TN); 50-28-2; nchembio860-comp1; Compudose 365; Estradot; MLS001076331; Diogynets; C18H24O2; Progynon-DH; Corpagen; E8875_SIGMA; HMS1569I04; Estradiol-17.beta.; Zumenon; nchembio.168-comp3; Estrofem 2; Estreva; Spectrum5_002055; .beta.-Estradiol; 17-.BETA.-Estradiol; EU-0100503; D-Oestradiol; Trial SAT; KBioGR_002269; KBioSS_000405; Innofem; NCGC00179321-01; 17 beta-Estradiol; E2257_SIGMA; Prestwick2_000441; 3,17-beta-Estradiol; CPD000059126; Estrovite; Syndiol; Estrace (TN); Trocosone; Vivelle; Diogyn; UNII-4TI98Z838E; Estrapak 50; Ovocyclin; NSC9895; Compudose 200; CHEMBL135; Estradiol, .beta.-; Epiestriol 50; Bio2_000363; Estroclim 50; KBio3_002749; Elestrin; .beta.-Oestradiol; KBio3_000770; NCGC00091544-06; E 2; Ovasterol; Ovocycline; LS-137; Gynestrel; Bio-0812; Ginedisc; HMS1362E07; C00951; Oestradiol; 1qkt; Lamdiol; Bio1_001381; .alpha.-Estradiol; Innofem (TN); Extrasorb; Vagifem (TN); Oestroglandol; NCGC00091544-01; Estradiolum [INN]; Ovastevol; Beta-estradiol; 17beta-Estradiol; 17b-Oestradiol; Profoliol B; Ovahormon; Estrogel (TN); 17E; E1024_SIGMA; E1132_SIGMA; Oestradiolum; BIDD:ER0125; Prestwick1_000441; Oestradiol Berco; Primofol; [3H]]estradiol; Compudose; Bio2_000843; 3,17beta-Estradiol; Estradiol-3,17beta; DB00783; Menorest; 17beta-Estradiol; Estring vaginal ring; .alpha.-Oestradiol; Estradiol [USAN:INN]; Dihydroxyesterin; AC-10460; Divigel; 17-beta-OH-estradiol; Estradiol-17 beta; Gynergon; NCGC00091544-00; Estrasorb (TN); Prestwick_207; Estraderm MX; CCRIS 280; Dihydrofolliculin; 1qku; beta-Estradiol	50-28-2	5757	148536	TTDS00242	Estrogen receptor	ER;ERalpha;ER-alpha;Estradiol receptor;Estrogen receptor alpha;Oestrogen receptor;Oestrogen receptor alpha	Q13262	N/A	N/A	agonist
DAP001019	Estriol	1,3,5(10)-Estratriene-3,16.alpha., 17.beta.-triol; Tridestrin; DB04573; 1,3,5(10)-Estratriene-3,16-alpha,17beta-triol; D00185; Ovestrion; BRN 2508172; Orgastyptin; ZINC03815418; estriol; Orestin; HSDB 3590; Prestwick2_001096; Oestriol; CID5756; Oestriolum; Theelol; Overstin; A 13610; BPBio1_001290; 16-alpha,17-beta-Oestriol; 16.alpha.,17.beta.-Estriol; 16.alpha.-Hydroxyoestradiol; 46565_RIEDEL; BSPBio_001172; Hormomed; Prestwick3_001096; E0218; 3,16-alpha,17-beta-Trihydroxy-delta-1,3,5-oestratriene; Synapause; MLS000069812; 16.alpha.-Hydroxy-17.beta.-estradiol; Destriol; E1253_SIGMA; SMR000059210; Thulol; BRD-K17016787-001-03-5; Deuslon A; Estriol [USAN:JAN]; 16,17-Epiestriol; 16-Hydroxyestradiol; Oestra-1,3,5(10)-triene-3,16.alpha.,17.beta.-triol; 3,16.alpha.,17.beta.-Estriol; Estriolo [Italian]; 16-Epiestriol; Holin; 50-27-1; Estratriol; Estriel (TN); SMP1_000122; 3,16alpha,17beta-Trihydroxy-delta-1,3,5-oestratriene; Triodurin; Klimoral; SPBio_003056; Stiptanon; E1149_SIGMA; Deuslon-A; S2466_Selleck; 16-alpha-Hydroxyestradiol; CCRIS 284; Trihydroxyoestrin; NSC 12169; CHEMBL193482; Estriol (JP15/USP); Estra-1,3,5(10)-triene-3,16,17-triol, (16alpha,17beta)-; Estra-1,3,5(10)-trien-3,16.alpha.,17.beta.-triol; Estra-1,3,5(10)-trien-3,16alpha,17beta-triol; 3,16-alpha,17-beta-Trihydroxyoestra-1,3,5(10)-triene; 16.alpha.-Estriol; Oestra-1,3,5(10)-triene-3,16-alpha,17-beta-triol; HMS1571K14; 6EC6F23B-A991-4606-8BC7-146D915DAB31; Ortho-Gynest; Estriolo; Estra-1,3,5(10)-triene-3,16,17-triol; nchembio.76-comp38; Hormonin; Gynaesan; 16.alpha.-Hydroxyestradiol; Ovestin; Folicular hormone; Hemostyptanon; 3,16-alpha,17-beta-Trihydroxy-delta-1,3,5-estratriene; 4-06-00-07550 (Beilstein Handbook Reference); Triovex; 3,16.alpha.,17.beta.-Trihydroxyestra-1,3,5(10)-triene; Estra-1,3,5(10)-triene-3,16,17-triol, (16.alpha.,17.beta.)-; 16-alpha-Hydroxyoestradiol; CHEBI:27974; 3,16-alpha,17-beta-Trihydroxyestra-1,3,5(10)-triene; BIDD:ER0124; 16alpha-Hydroxyoestradiol; 3,16.alpha.,17.beta.-Trihydroxy-.delta.-1,3,5-oestratriene; Follicular hormone hydrate; 16alpha,17beta-Estriol; LMST02010003; 3,16alpha,17beta-Trihydroxy-1,3,5(10)-estratriene; Oestra-1,3,5(10)-triene-3,16.alpha., 17.beta.-triol; Trihydroxyestrin; WLN: L E5 B666TTT&J E1 FQ GQ OQ; 16alpha-Hydroxyestradiol; 1,3,5-Estratriene-3.beta.,16-.alpha.,17-.beta.-triol; C05141; Prestwick1_001096; (16.alpha.,17.beta.)-Oestra-1,3,5(10)-triene-3,16,17-triol; 16-alpha,17-beta-Estriol; C18H24O3; 16alpha-Hydroxy-17beta-estradiol; 3,16-alpha,17-beta-Estriol; AB00514045; Oestra-1,3,5(10)-triene-3,16alpha,17beta-triol; 1,3,5-Estratriene-3beta,16alpha,17beta-triol; 1,3,5-Oestratriene-3beta,16alpha,17beta-triol; OE3; estra-1(10),2,4-triene-3,16,17-triol, (16alpha,17beta)-; Estra-1,3,5(10)-triene-3,16.alpha., 17.beta.-triol; 3,16alpha,17beta-Estriol; 1,3,5-Oestratriene-3-.beta.,16.alpha.,17.beta.-triol; Estra-1,3,5(10)-triene-3,16alpha,17beta-triol; Oestratriol; NCGC00179277-01; 3,16.alpha.,17.beta.-Trihydroxy-.delta.-1,3,5-estratriene; 1,3,5(10)-Estratriene-3,16.alpha.,17.beta.-triol; Aacifemine; HMS2090E20; EINECS 200-022-2; Estra-1,3,5(10)-trien-3,16.alpha., 17.beta.-triol; Oestriol [Steroidal oestrogens]; 3,16.alpha.,17.beta.-Trihydroxy-1,3,5(10)-estratriene; (16.alpha.,17.beta.)-Estra-1,3,5(10)-triene-3,16,17-triol; NSC12169; Estriol, unconjugated; 46565_FLUKA; NSC-12169; (16alpha,17beta)-Estra-1,3,5(10)-triene-3,16,17-triol; 3,16-alpha,17-beta-Oestriol; LS-64877; Prestwick0_001096; 16alpha,17beta-Oestriol; Estriel; 1,3,5(10)-ESTRATRIENE-3,16,17-TRIOL; 1,3,5(10)-Estratriene-3,16alpha,17beta-Triol; 3,16alpha,17beta-trihydroxy-Delta(1,3,5)-estratriene; 16.alpha.,17.beta.-Oestriol; ESL; (16alpha,17beta)-Oestra-1,3,5(10)-triene-3,16,17-triol; AC1L1L2H; Estra-1,3,5(10)-triene-3,16.alpha.,17.beta.-triol	50-27-1	5756	14897919	TTDS00242	Estrogen receptor	ER;ERalpha;ER-alpha;Estradiol receptor;Estrogen receptor alpha;Oestrogen receptor;Oestrogen receptor alpha	Q13262	N/A	N/A	agonist
DAP001012	Chlorotrianisene	HMS1570G16; Spectrum4_000954; MolPort-001-783-515; Merbentul; Chlorestrolo; Clorotrianisene; Chlorotrianisene [INN:BAN]; SMR000058658; CID11289; Prestwick2_000757; NSC10108; HSDB 3302; Metace; Spectrum2_000704; BSPBio_002005; Chlorotrianisene [BAN:INN]; 1,1',1''-(2-chloroethene-1,1,2-triyl)tris[4-(methyloxy)benzene]; KBio2_000596; Benzene, 1,1',1'-(1-chloro-1-ethenyl-2-ylidene)tris(4-methoxy)-; AC-12512; Tris(p-methoxyphenyl)chloroethylene; Clorotrianiseno [INN-Spanish]; Clorotrianiseno; Clorotrisin; Triagen; Khlortrianizen; D00269; chlorotrianisene; Chlortrianizen; WLN: 1OR DYGUYR DO1&R DO1; Spectrum5_000711; Benzene, 1,1',1''-(1-chloro-1-ethenyl-2-ylidene)tris[4-methoxy-; CHEBI:3641; KBio2_005732; AC1L1X1E; Prestwick1_000757; CAS-569-57-3; 4-06-00-07650 (Beilstein Handbook Reference); SPBio_002713; Anisene; Chlorotrianisene (INN); SPBio_000887; Spectrum_000136; NSC-10108; Chlorotrianisene [Nonsteroidal oestrogens]; Tace (pharmaceutical); Clorotrianisene [DCIT]; Spectrum3_000343; 1,1',1''-(1-Chloro-1-ethenyl-2-ylidene)-tris(4-methoxybenzene); TACE (TN); TACE; Chlorotrianisine; SPECTRUM1500181; Chloortrianisestrol; Chlorotrianisenum; NCGC00091333-03; Prestwick3_000757; KBioGR_001568; MLS002415722; KBio2_003164; Chlorotrisin; NCGC00016511-01; Benzene, 1,1',1''-(1-chloro-1-ethenyl-2-ylidene)tris(4-methoxy)-; NCGC00091333-02; Chlorotris(p-methoxyphenyl)ethylene; Chlortrianisestrol; C23H21ClO3; 1-[1-chloro-2,2-bis(4-methoxyphenyl)ethenyl]-4-methoxybenzene; Rianil; Benzene, 1,1',1''-(1-chloro-1-ethenyl-2-ylidene)tris(4-methoxy-; C7128_SIGMA; KBio3_001225; chlorotrianisestrol; Tace-fn; Tri-p-anisylchloroethylene; Prestwick0_000757; HMS2091C20; Clorestrolo; Hormonisene; Prestwick_22; MLS000028625; CCRIS 4769; BRN 1891845; NCGC00091333-01; LS-226; ZINC01530598; AC1Q3FDW; BSPBio_000774; Chlorotrianisenum [INN-Latin]; Chlortrianisenum; Chlortrianisen; AB00051941; Chlortrianisene; Chlorotrianizen; UNII-6V5034L121; MolPort-005-933-845; Chlortrianisoestrolum; DB00269; KBioSS_000596; Ethylene, chlorotris(p-methoxyphenyl)-; HMS1920K17; CHEMBL1200761; Trianisestrol; EINECS 209-318-6; 569-57-3; BPBio1_000852; 1,1',1''-(2-chloroethene-1,1,2-triyl)tris(4-methoxybenzene)	569-57-3	11289	9121	TTDS00242	Estrogen receptor	ER;ERalpha;ER-alpha;Estradiol receptor;Estrogen receptor alpha;Oestrogen receptor;Oestrogen receptor alpha	Q13262	N/A	N/A	binder
DPR000042	Estrogen and selective estrogen receptor modulators	N/A	N/A	N/A	N/A	TTDS00242	Estrogen receptor	ER;ERalpha;ER-alpha;Estradiol receptor;Estrogen receptor alpha;Oestrogen receptor;Oestrogen receptor alpha	Q13262	N/A	N/A	modulator
DAP001445	Lasofoxifene	C3D; (5R,6S)-6-phenyl-5-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol; Lasofoxifene; CP 336156; CP-336,156; 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-(4-(2-(1-pyrrolidinyl)ethoxy)phenyl)-, (5R-cis)-; LS-192130; CID216416; MolPort-006-394-766; cis-1R-(4'-pyrrolidinoethoxyphenyl)-2S-phenyl-6-hydroxy-1,2,3,4-tetrahydronaphthalene, tartrate salt; CHEBI:41282; UNII-337G83N988; AC1L50OI; CHEMBL328190; Lasofoxifene [INN]; 180916-16-9; Oporia; 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-(4-(2-(1-pyrrolidinyl)ethoxy)phenyl)-, (5R,6S)-	180916-16-9	216416	49688680	TTDS00242	Estrogen receptor	ER;ERalpha;ER-alpha;Estradiol receptor;Estrogen receptor alpha;Oestrogen receptor;Oestrogen receptor alpha	Q13262	N/A	N/A	modulator
DAP001013	Clomifene	UNII-3JU1DU3652; 2-[4-[(E)-2-chloro-1,2-diphenylethenyl]phenoxy]-N,N-diethylethanamine; clomiphene; Clomifene (INN); Ethanamine, 2-[4-(2-chloro-1,2-diphenylethenyl)phenoxy]-N,N-diethyl-; Clomifert; cis-2-(p-(2-Chloro-1,2-diphenylvinyl)phenoxy)triethylamine; trans-2-(p-(2-Chloro-1,2-diphenylvinyl)phenoxy)triethylamine; Clomifen; AC1LU7KN; Clostilbegit; 2-{4-[(E)-2-chloro-1,2-diphenylethenyl]phenoxy}-N,N-diethylethanamine; cis-2-(4-(2-Chloro-1,2-diphenylethenyl)phenoxy)-N,N-diethylethanamine; CHEBI:373794; Zuclomiphene [USAN]; BPBio1_000675; RMI 16,289; 1-(p-(beta-Diethylaminoethoxy)-phenyl)-1,2-diphenylchloroethylene; Zuclomifeno; SMR000718756; ICI 46476; Ethanamine, 2-(4-(2-chloro-1,2-diphenylethenyl)phenoxy)-N,N-diethyl-; Chlomaphene; 50-41-9 (citrate (1:1)); En-Clomiphene; Prestwick2_000397; (Z)-isomer; Enclomiphene [USAN]; CHEBI:192984; Zuclomiphene (USAN); NCGC00179503-01; Zuclomifene; cis-Clomifene; Enclomiphen; Transclomiphene; D08910; NCGC00164385-02; ISOMER B; LS-157235; 15690-57-0; CID1548953; 2-[4-[(Z)-2-chloro-1,2-diphenylethenyl]phenoxy]-N,N-diethylethanamine; (E)-2-(p-(2-Chloro-1,2-diphenylvinyl)phenoxy)triethylamine; BRD-K29950728-048-02-6; Transclomifenum; MLS001304092; Prestwick3_000397; Ethanamine, 2-(4-(2-chloro-1,2-diphenylethenyl)phenoxy)-N,N-diethyl-, (E)-; STK525981; Clomifeno; Zuclomiphene; BRD-K04218075-048-03-4; HMS2090O17; Enclomifeno [INN-Spanish]; Clomifenum; 911-45-5; Clomiphene B; Androxal; UNII-1HRS458QU2; BIDD:ER0223; Cisclomifenum; Enclomiphene (USAN); 2-(p-(beta-Chloro-alpha-phenylstyryl)phenoxy)-triethylamine; 2-({4-[(Z)-2-chloro-1,2-diphenylethenyl]phenyl}oxy)-N,N-diethylethanamine; RMI-16289; D07726; (Z)-2-(p-(2-Chloro-1,2-diphenylvinyl)phenoxy)triethylamine; CHEBI:3752; trans-2-(4-(2-Chloro-1,2-diphenylethenyl)phenoxy)-N,N-diethylethanamine; HSDB 3039; 2-(p-(beta-chloro-alpha-phenylstyryl)phenoxy)triethylamine; trans-Clomiphene; Triethylamine, 2-(p-(2-chloro-1,2-diphenylvinyl)phenoxy)-, (Z)-; AC1LU7KR; Enclomifene; Clomifene [INN:BAN]; Bio-0712; 2-[4-(2-chloro-1,2-diphenylethenyl)phenoxy]-N,N-diethylethanamine; Zuclomifenum [INN-Latin]; C06917; Cisclomiphene; CHEMBL954; RMI-16312; LS-157234; Clomifene (TN); Zuclomifenum; Spectrum5_000757; QTL1_000019; IDI1_000462; D09037; DB00882; MolPort-002-508-010; Klostilbegit; EINECS 213-008-6; trans-Clomifene; 15690-55-8; Triethylamine, 2-(p-(2-chloro-1,2-diphenylvinyl)phenoxy)-; Enclomifenum [INN-Latin]; CHEMBL167779; BSPBio_002053; Clomifenum [INN-Latin]; Clomifeno [INN-Spanish]; cis-Clomiphene; BIDD:GT0216; Chloramifene; Enclomifeno; 2-(p-(2-Chloro-1,2-diphenylvinyl)phenoxy)triethylamine; Triethylamine, 2-(p-(2-chloro-1,2-diphenylvinyl)phenoxy)-, (E)-; LS-157236; Enclomifenum; Zuclomifeno [INN-Spanish]; Enclomiphene; UNII-R6D2UI4FLS; Ethanamine, 2-(4-(2-chloro-1,2-diphenylethenyl)phenoxy)-N,N-diethyl-, (Z)-; Clomifene; 2-(4-(2-Chloro-1,2-diphenylethenyl)phenoxy)-N,N-diethylethanamine; CID1548955; BSPBio_000613	911-45-5	1548955	156834	TTDS00242	Estrogen receptor	ER;ERalpha;ER-alpha;Estradiol receptor;Estrogen receptor alpha;Oestrogen receptor;Oestrogen receptor alpha	Q13262	N/A	N/A	modulator
DAP000319	Fulvestrant	7alpha-[9[(4,4,5,5,5-Pentafluropentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene-3, 17 beta diol; (7alpha,17beta)-7-{9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl}estra-1,3,5(10)-triene-3,17-diol; CHEMBL1358; Fulvestrant (JAN/USAN/INN); Ici 182780; ICI 182,780; S1191_Selleck; I06-1109; ZM-182780; AC1L2XEN; NCGC00164789-02; BIDD:ER0348; NSC719276; nchembio.76-comp5; Faslodex(ICI 182,780); LS-64781; Faslodex, ICI 182780, Fulvestrant; HMS2090N22; 7-(9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl)estra-1,3,5(10)-triene-3,17-diol; ZD 182780; AC-4693; (7R,8R,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol; DB00947; ICI-182780; HSDB 7658; CCRIS 8741; Fulvestrant [USAN]; UNII-22X328QOC4; C32H47F5O3S; ZD-182780; 129453-61-8; AstraZeneca brand of fulvestrant; 7alpha-(9-((4,4,5,5,5,-Pentafluoropentyl)sulfinyl)nonyl)estra-1,3,5(10)-triene-3,17beta-diol; CHEBI:404798; C070081; D01161; ZM 182780; 7alpha-(9-((4,4,5,5,5-Pentafluoropentyl)sulfinyl)nonyl)estra-1,3,5(10)-triene-3,17beta-diol; BIDD:PXR0136; CID104741; nchembio.168-comp5; Faslodex; Fulvestrant; ICI 182,789; ZD-9238; (7R,8S,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl) nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol; (7R,13S,17S)-13-methyl-7-(9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol; Estra-1,3,5(10)-triene-3,17-diol, 7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-, (7alpha,17beta)-; Faslodex (TN); nchembio775-comp4	129453-61-8	104741	582951	TTDS00242	Estrogen receptor	ER;ERalpha;ER-alpha;Estradiol receptor;Estrogen receptor alpha;Oestrogen receptor;Oestrogen receptor alpha	Q13262	N/A	N/A	antagonist
DAP000033	Mitotane	Chloditan; 1,1-Dichloro-2,2-bis(2,4'-dichlorophenyl)ethane; KBio2_007641; NCI-C04933; 49015_SUPELCO; Mitotan; o,p-Tde; 2-(o-Chlorophenyl)-2-(p-chlorophenyl)-1,1-dichloroethane; NCGC00015226-09; 2,2-Bis(2-chlorophenyl-4-chlorophenyl)-1,1-dichloroethane; UNII-78E4J5IB5J; NCGC00091374-02; Lopac0_000251; CID4211; Mitotanum [INN-Latin]; ST51016017; AI3-07575; NCGC00091374-01; Spectrum2_000916; 2,4'-Ddd; 2-(2-Chlorophenyl)-2-(4-chlorophenyl)-1,1-dichloroethane; 53-19-0; NCGC00091374-05; Benzene, 1-chloro-2-[2,2-dichloro-1-(4-chlorophenyl)ethyl]-; HMS502D05; MLS001335900; Ethane, 1,1-dichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)- (8CI); KBioGR_001237; NCGC00015226-03; MLS002152914; mitotane; ortho,para DDD; Ethane, 2-(o-chlorophenyl)-2-(p-chlorophenyl)-1,1-dichloro-; DB00648; 25925_SIGMA; HMS1923K19; 1-Chloro-2-(2,2-dichloro-1-(4-chlorophenyl)ethyl)benzene; C14H10Cl4; C 3010; NCGC00091374-06; 1-Chloro-2-[2,2-dichloro-1-(4-chlorophenyl)ethyl]benzene; SPBio_000792; Mitotane (JAN/USP/INN); KBioSS_002513; MLS002153233; CB 313; Mytotan; WLN: GYGYR BG&R DG; Chlodithane; NINDS_000703; 1-(2-Chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane; SMR000326696; AC1L1HNV; 1,1-Dichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)ethane; (+-)-1,1-Dichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)ethane; Lysodren; Khlodithan; HMS2091E07; 35485_RIEDEL; Benzene, 1-chloro-2-(2,2-dichloro-1-(4-chlorophenyl)ethyl)-, (+-)-; Lysodren (TN); D008939; BRN 2056007; CHEMBL1670; CB-313; o,p'-DDD; D00420; NCGC00091374-04; NCI60_003688; EU-0100251; DivK1c_000703; KBio2_005073; Chlodithan; BSPBio_002517; HSDB 3240; PS694_SUPELCO; NSC38721; o,p-DDD; IDI1_000703; Mitotanum; 35485_FLUKA; o,p'-Dichlorodiphenyldichloroethane; Mitotano; EINECS 200-166-6; Spectrum_001959; AC1Q3H13; Bristol Myers Squibb Brand of Mitotane; 2,4'-Dichlorodiphenyldichloroethane; Mitotane [USAN:INN:JAN]; Mitotano [INN-Spanish]; Spectrum4_000709; 1,1-Dichloro-2-(p-chlorophenyl)-2-(o-chlorophenyl)ethane; Prestwick_75; CB313; MolPort-001-779-578; Khloditan; NCGC00091374-03; (2,4'-Dichlorodiphenyl)dichloroethane; CCRIS 4397; Spectrum3_000869; Benzene, 1-chloro-2-(2,2-dichloro-1-(4-chlorophenyl)ethyl)-; (o,p)-DDD; NSC-38721; 2,4'-Dichlorophenyldichlorethane; MLS001335899; ortho,para-DDD; KBio3_002017; o,p'-TDE; LS-185; Bristol-Myers Squibb Brand of Mitotane; KBio1_000703; KBio2_002505; Spectrum5_002060; SPECTRUM330082; Ethane, 1,1-dichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)-; 25925_FLUKA; DDD, o,p'-; NSC 38721	53-19-0	4211	148675	TTDS00242	Estrogen receptor	ER;ERalpha;ER-alpha;Estradiol receptor;Estrogen receptor alpha;Oestrogen receptor;Oestrogen receptor alpha	Q13262	N/A	N/A	binder
DAP001015	Dienestrol	AR-1F8019; IDI1_000771; CHEBI:4518; alpha-Dienestrol; CCRIS 9121; Dienestrolo [DCIT]; DB00890; UNII-RRW32X4U1F; SPECTRUM1500241; MLS001077274; Oestrodiene; (E,E)-Dienestrol; LS-104381; Oestrasid; 84-17-3; AC1LDI60; 22090-87-5; 4-[(2E,4E)-4-(4-hydroxyphenyl)hexa-2,4-dien-3-yl]phenol; NSC 59809; Dienoestrol bp; Dienol; Dienoestrol [Nonsteroidal oestrogens]; 4,4'-(Diethylideneethylene)diphenol; Follormon; NCGC00022210-04; C08090; Oestroral; Estroral; Teserene; DV (TN); 3,4-Bis(4-hydroxyphenyl)-2,4-hexadiene; Dienoestrol; p,p'-(Diethylideneethylene)diphenol; Willnestrol; AC1Q7B18; 3,4-Bis(p-hydroxyphenyl)-2,4-hexadiene; Retalon; MLS000069528; Phenol, 4,4'-(diethylideneethylene)di-; DV; Dienestrolum [INN-Latin]; para-Dien; Isodienestrol; Estraguard; Estragard; Estrodienol; Dienestrolum; EINECS 201-519-7; Di(para-oxyphenyl)-2,4-hexadiene; SMR000058597; Dienestrol (USP/INN); BPBio1_001030; Oestrodienol; HMS1570O18; D0449; 46190_RIEDEL; Synestrol; Phenol, 4,4'-(1,2-diethylidene-1,2-ethanediyl)bis-; AC-13162; Agaldog; 4,4'-Dihydroxy-gamma,delta-diphenyl-beta,delta-hexadiene; 4,4'-Hydroxy-gamma,delta-diphenyl-beta,delta-hexadiene; BSPBio_000936; Phenol, 4,4'-(1,2-diethylidene-1,2-ethanediyl)bis-, (E,E)-; 2,4-Hexadiene, 3,4-bis(4-hydroxyphenyl)-; Dehydrostilboestrol; Dienesterol; 46190_FLUKA; 4,4'-(1,2-Diethylidene-1,2-ethanediyl)bisphenol; MolPort-003-666-162; 4,4'-hexa-2,4-diene-3,4-diyldiphenol; S1858_Selleck; Gynefollin; Dienestrolo; BSPBio_002177; HMS2091M14; Prestwick2_000798; Restrol; D3253_SIGMA; Spectrum5_000875; Prestwick_52; CHEMBL1018; ZINC00001283; MLS002207222; Dinovex; Prestwick3_000798; Dienestrol (E,E); BRD-K95309561-001-05-6; HMS1920G04; MLS002222156; Sexadien; Phenol, 4,4'-(1,2-diethylidene-1,2-ethanediyl)bis-, (E,E)- (9CI); Dehydrostilbestrol; D00898; Phenol, 4,4'-((1E,2E)-1,2-diethylidene-1,2-ethanediyl)bis-; CID667476; HSDB 3313; 3,4-Bis(para-hydroxyphenyl)-2,4-hexadiene; Dienestrol, (E,E)-Isomer; 4,4'-(2E,4E)-hexa-2,4-diene-3,4-diyldiphenol; Dinestrol; Hormofemin; NCGC00022210-03; nchembio.78-comp10; Restrol, Dienestrol; Di(p-oxyphenyl)-2,4-hexadiene; Cycladiene; HMS502G13; NCGC00178779-01; dienestrol; Follidiene; 13029-44-2; NCGC00178779-02; Oestrovis; Phenol, 4,4'-(diethylideneethylene)di-, trans-, (E,E)-; para,para'-(Diethylideneethylene)diphenol	84-17-3	3049	10290	TTDS00242	Estrogen receptor	ER;ERalpha;ER-alpha;Estradiol receptor;Estrogen receptor alpha;Oestrogen receptor;Oestrogen receptor alpha	Q13262	N/A	N/A	agonist
DAP001018	Ethinyl Estradiol	Amenoron; Eticylol; AC-2169; Primogyn; NSC10973; Estradiol, Ethinyl; Eticyclol; HMS2051I19; EE; Palonyl; CHEMBL691; ETHINYLESTRADIOL; 17 alpha-Ethinylestradiol; Amenorone; to_000048; Ethinylestradiol (JP15/INN); Estradiol, Ethynyl; NCGC00091533-01; Neo-Estrone; 17.alpha.-Ethinylestradiol; Etinestrol; Ertonyl; Dyloform; Schering Brand of Ethinyl Estradiol; ethinyl estradiol; Progynon M; Prosexol; SGCUT00127; Anovlar; Estigyn; 17-Ethinyl-3,17-oestradiol; Ethinyl Oestradiol Effik; NCI60_000234; Ethinyloestradiol; EO; Feminone; Certostat; BIDD:ER0162; Ethinyloestradiol [Steroidal oestrogens]; SMR000058319; Ethinyl Estradiol [USP]; Jenapharm, Ethinylestradiol; Effik Brand of Ethinyl Estradiol; Spanestrin; Esteed; Nogest-S; E4876_SIGMA; Ylestrol; 17 alpha-Ethynylestradiol; Ethynyl estradiol; HSDB 3587; Progynon C; Menolyn; Eston-E; 46263_FLUKA; Orestralyn; LMST02010036; BRN 2419975; Chee-O-Gen; 17alpha-Ethynyloestradiol; Ethinylestradiol [INN:BAN:JAN]; 17.alpha.-Ethinyl-17.beta.-estradiol; Ortho-Cyclen; Ginestrene; 17alpha-Ethynylestradiol; 17alpha-Ethinylestradiol; 17-Ethynylestradiol; Eticyclin; Primogyn C; Etistradiol; 17-Ethynyloestradiol; 17.beta.-Estradiol, 17-ethynyl-; 17.alpha.-Ethynylestradiol; Diprol; Ethy 11; CID5991; Estoral (Orion); CCRIS 286; D004997; Dicromil; MLS000758274; Hemihydrate, Ethinyl Estradiol; Linoral; DB00977; S1625_Selleck; OVULEN-21; 77538-56-8; D00554; component of Demulen; Ethinyl-oestranol; Etinilestradiol; Etinilestradiol [INN-Spanish]; EINECS 200-342-2; Etinilestradiolo [DCIT]; NSC-10973; Ethynylestradiol; Etinilestradiolo; Aethinyloestradiolum; Ethynylestradiol, Ethinyl Estradiol; 17.alpha.-Ethynylestradiol-l7.beta.; 17-alpha-Ethynylestradiol-17-beta; Ethinylestradiol Jenapharm; Diogyn-E; Follicoral; EE2; component of Oracon; Estopherol; 17.alpha.-Ethynyloestradiol-17.beta.; Estoral (VAN); Orestrayln; Jenapharm Brand of Ethinyl Estradiol; AC1L1LK6; NCGC00091533-04; 17 alpha-ethinyestradiol; Etinoestryl; Novestrol; 17alpha-Ethinylestradiol-17beta; Primogyn M; Estoral; LS-231; EE(sub 2); UNII-423D2T571U; 17.alpha.-Ethynyloestradiol; Ethinyl-Oestradiol Effik; 17-alpha-Ethynylestradiol; Ethynyloestradiol; Etinestryl; Aethinyoestradiol [German]; Inestra; 17-alpha-Ethinyl-17-beta-estradiol; CHEBI:4903; Ethinyl estradiol (USP); MLS000028479; CPD000058319; NCGC00091533-05; 17alpha-Ethinyl estradiol; Ethinyl Estradiol Hemihydrate; 17-Ethinyl-3,17-estradiol; 17alpha-Ethynyloestradiol-17beta; 17beta-Estradiol, 17-ethynyl-; Organon Brand of Ethinyl Estradiol; Cyclosa; Ethinoral; 17.alpha.-Ethynyl-17.beta.-oestradiol; Ethidol; Ethinylestradiolum [INN-Latin]; OVULEN-28; Kolpolyn; C07534; Estinyl (TN); 406932-93-2; Etivex; Perovex; Diogyn E; Oradiol; Aethinyoestradiol; Microfollin; component of Ortrel; Lynoral; 57-63-6; AI3-52941; 17a-Ethynylestradiol; Estinyl; Diognat-E; Ethinyl E2; 46263_RIEDEL; Microfollin Forte; PUBERTAL ETHINYL ESTRADIOL STUDY; WLN: L E5 B666TTT&J E1 FQ F1UU1 OQ; MolPort-001-794-636; Bio-0610; Ethinylestriol; 17-alpha-ethynyl estradiol; Ethinylestradiolum; 17-Ethinylestradiol; Estorals; 17-alpha-Ethynyl-17-beta-oestradiol; Ethinyl Estradiol, (8 alpha)-Isomer; Estradiol, 17-ethynyl-; Estoral [Orion]; SAM001247008; Chee-O-Genf; 17 alpha-Ethynyloestradiol	57-63-6	5991	148835	TTDS00242	Estrogen receptor	ER;ERalpha;ER-alpha;Estradiol receptor;Estrogen receptor alpha;Oestrogen receptor;Oestrogen receptor alpha	Q13262	N/A	N/A	agonist
DAP001011	Diethylstilbestrol	Dietilstilbestrolo [DCIT]; NCGC00090749-06; neo-Oestranol 1; Sibol; 46207_FLUKA; Stilbetin; New-Estranol 1; C07620; Oestromon; Diaethylstilboestrolum; Synthofolin; cis-Diethylstilbesterol; Stilboestrol; D00577; UNII-731DCA35BT; Dawe's destrol; Sintestrol; Stilkap; Bio-0854; MLS000028447; Tampovagan; Dietilstilbestrolo; ZINC00001290; Synestrin; EINECS 200-278-5; Prestwick3_000756; CCRIS 240; LS-146816; Stilbestrone; strobene; RCRA waste no. U089; Stilbestrol (TN); BIDD:ER0159; Estrosyn; diethylstilbestrol; Co Pharma Brand of Diethylstilbestrol; TRANSGENIC MODEL EVALUATION (DES); Dietilestilbestrol; CHEBI:41922; 218944_ALDRICH; Makarol; Palestrol; Menostilbeen; Tampovagan stilboestrol; DB00255; ST IL; Apstil; C18H20O2; TRANS-DIETHYSTILBESTEROL; HMS2091M18; E-Diethylstilbestrol; Prestwick2_000756; STIL; HMS1920G08; 8049-42-1; Serral; Cyren; BPBio1_000850; Oestromensil; Oestrol vetag; Grafestrol; ARONIS23859; Oestromensyl; Stibilium; Prestwick_1070; Domestrol; DiBestrol "2" Premix; Oestromienin; STK366318; Microest; 8053-00-7; trans-Diethylstilbestrol; Neo-Oestranol I; 4,4'-(3E)-hex-3-ene-3,4-diyldiphenol; Stilbestrol; anti gestil; Dibestrol; MLS002222298; Stilbene Estrogen; 4,4'-Stilbenediol, 2,2'-diethyl-; Vagestrol; Gynopharm; NCGC00090749-04; Diethylstilbestrol [USAN:INN]; Stilbol; Rumestrol 1; HSDB 3060; LS-220; Di-Estryl; 56-53-1; .alpha.,.alpha.'-Diethylstilbenediol; Hi-Bestrol; Dietilestilbestrol [Spanish]; Bufon; MolPort-001-785-868; BSPBio_000772; AKOS005111142; IDI1_000519; Dietilestilbestrol [INN-Spanish]; Acnestrol; Percutatrine oestrogenique iscovesco; I14-11699; AC1L9M2H; SPECTRUM1500244; Stilbestrol, diethyl-; nchembio.76-comp3; DES (synthetic estrogen); Agostilben; cis-Diethylstilbestrol; neo-oe stranol 1; 3,4-bis(4-hydroxyphenyl)hex-3-ene; Climaterine; Dibestrol '2' premix; Distilbene; 3-Hexene,3,4-bis(p-hydroxyphenyl)-; CID448537; Estrobene; Desma; 46207_RIEDEL; Iscovesco; NCGC00090749-05; D0526; BSPBio_002201; OeKolp; (E)-Diethylstilbestrol; Stilbofollin; NCGC00090749-02; Diastyl; Rcra waste number U089; MG 137; Diethylstilbestrol, (Z)-Isomer; oestrolmensil; trans-Diethylstilbesterol; Comestrol estrobene; Sedestran; nchembio.168-comp6; Stil-Rol; diethylstilbestrol (DES); APS Brand of Diethylstilbestrol; NSC-3070; cis-Des; (E)-3,4-Bis(4-hydroxyphenyl)-3-hexene; RGLYKWWBQGJZGM-ISLYRVAYSA-; 8028-09-9; HMS2090C14; Sexocretin; NCGC00090749-03; Antigestil; alpha,alpha'-Diethyl-4,4'-stilbenediol; Oestromenin; DES; AC1Q2C9S; DiBestrol 2 Premix; Estril; Stilboestroform; Co-Pharma Brand of Diethylstilbestrol; Stilbofolin; Gerda Brand of Diethylstilbestrol; Diethylstilbesterol; Diethylstilbestrol (USP/INN); Estromenin; Rumestrol 2; Stilbestroform; NSC3070; 8030-34-0; Comestrol; Dicorvin; Synthoestrin; nchembio.140-comp1; Idroestril; Micrest; Estilbin MCO; trans-Diethylstilboesterol; D4628_SIGMA; Stilphostrol; Estrogen, Stilbene; Dyestrol; hibestrol; Diethylstilbestrol BP; Estrogenine; 8026-45-7; Synthestrin; Bio-des; Diethylstilboesterol; 4,4'-Dihydroxydiethylstilbene; Syntofolin; Fonatol; Estilbin ''MCO''; (E)-4,4'-(hex-3-ene-3,4-diyl)diphenol; Pabestrol; 3,4'(4,4'-Dihydroxyphenyl)hex-3-ene; HMS1570G14; 63528-82-5 (di-hydrochloride salt); S1859_Selleck; 3,4-Bis(p-hydroxyphenyl)-3-hexene; SMR000058263; Destrol; Diethylstilbestrolum [INN-Latin]; NCGC00090749-01; 22610-99-7; Tylosterone; 4,4'-hex-3-ene-3,4-diyldiphenol; Stilboefral; Diethylstilbestrol, Disodium Salt; WLN: QR DY2&UY2&R DQ; Oestrogenine; Cyren A; Spectrum5_000799; D004054; Protectona; CHEMBL411; Milestrol; MLS002174252; alpha,alpha'-Diethylstilbenediol; HMS501J21; BRN 2056095; Diethylstilbestrolum	56-53-1	3054	9822	TTDS00242	Estrogen receptor	ER;ERalpha;ER-alpha;Estradiol receptor;Estrogen receptor alpha;Oestrogen receptor;Oestrogen receptor alpha	Q13262	N/A	N/A	agonist
DAP000108	Tamoxifen	HMS1792J11; C07108; Nourytam; Tamone; ,citrate; (Z)-2-(para-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylamine (IUPAC); Tamoxifeno [INN-Spanish]; BPBio1_000278; trans-2-[4-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine; Novo-Tamoxifen; NCGC00024928-03; Diemon; Ethylamine, N,N-dimethyl-2-(p-(1,2-diphenyl-1-butenyl)phenoxy)-, (Z)-; BSPBio_001150; 1ya4; Tamoxifen [INN:BAN]; Tamoxifen and its salts; UNII-094ZI81Y45; BRD-K93754473-001-02-9; CHEBI:41774; D08559; Prestwick3_000146; nchembio.76-comp1; 1-p-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene; cMAP_000044; L024126; Retaxim; (Z)-1-(p-Dimethylaminoethoxyphenyl)-1,2-diphenyl-1-butene; Oncomox; HSDB 6782; Lopac0_001203; Spectrum5_001417; BIDD:PXR0003; BRD-K93754473-048-05-3; 1-para-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene; ST50511785; Ethanamine, 2-(4-(1,2-diphenyl-1-butenyl)phenoxy)-N,N-dimethyl-, (Z)-; 2-[4-[(Z)-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine; LS-393; Spectrum5_002043; NCGC00024928-07; NSC727681; Gen-Tamoxifen; Crisafeno; Citofen; Tamoxifen (INN); MolPort-003-850-384; Prestwick2_000146; (Z)-2-(4-(1,2-diphenylbut-1-enyl)phenoxy)-N,N-dimethylethanamine; NCGC00024928-01; BSPBio_001982; CCRIS 3275; IDI1_002170; Tomaxithen; Tamoxifen (TN); TAMOXIFEN (TAMOXIFEN CITRATE (54965-24-1)); SMR000059172; QTL1_000079; Pms-Tamoxifen; Tamoxifenum; BSPBio_000252; DB00675; nchembio732-comp3; C26H29NO; HMS1362J11; MLS001332536; Tamoxifenum [INN-Latin]; NCGC00024928-05; Tamoxifene [INN-French]; ICI 47699; NCGC00024928-09; tamoxifen; trans-Tamoxifen; CID2733526; EINECS 234-118-0; Tamoxifene; AC1MBZ3R; Tamoxifeno; HMS1990J11; Tamoxifen (Z); ICI-47699; TRANS FORM OF TAMOXIFEN; Tocris-0999; 54965-24-1 (citrate); Tamizam; BIDD:GT0009; Novaldex; Valodex; Istubol; MLS001332535; CHEMBL83; NCGC00024928-08; Tamoxen; T5648_SIGMA; 2-{4-[(1Z)-1,2-diphenylbut-1-en-1-yl]phenoxy}-N,N-dimethylethanamine; (Z)-2-(4-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylethanamine; IDI1_000258; (Z)-2-[p-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine; 1-p-.beta.-Dimethylamino-ethoxyphenyl-trans-1,2-diphenylbut-1-ene; BIDD:ER0008; 10540-29-1; NCGC00024928-12; nchembio.140-comp7; Tamoplex (TN); (Z)-2-[4-(1,2)-DIPHENYL-1-BUTENYL)-PHENOXY]-N,N-DIMETHYLETHANAMINE; Ethanamine, 2-(4-((1Z)-1,2-diphenyl-1-butenyl)phenoxy)-N,N-dimethyl-; NCGC00024928-04; HMS2090N08; UPCMLD-DP027; Nolvadex-D; ICI-46,474	10540-29-1	2733526	9319	TTDS00242	Estrogen receptor	ER;ERalpha;ER-alpha;Estradiol receptor;Estrogen receptor alpha;Oestrogen receptor;Oestrogen receptor alpha	Q13262	N/A	N/A	antagonist
DAP001020	Estrone	Aquacrine; BRN 1915077; Estronum; Estrone, (8 alpha)-Isomer; 3-Hydroxy-oestra-1,3,5(10)-trien-17-one; HMS2090E22; Ketohydroxy-Estratriene; AC1L1LBE; Estrona [Spanish]; Unden (pharmaceutical) (VAN); NCGC00179433-01; 3-Hydroxy-1,3,5(10)-estratrien-17-one; Crinovaryl; Estrone [USAN:INN]; LS-64884; Folisan; WynestronPencap M; NATURAL ESTROGENIC SUBSTANCE-ESTRONE; SGCUT00128; Estra-1,3,5(10)-trien-17-one, 3-hydroxy-; Thynestron; estrol; Endofolliculina; Oestrone, Estrone; Estrugenone; 1,3,5(10)-Estratrien-3-ol-17-one; OESTRONE; ACon1_000122; C00468; DB00655; Estrona; 3-Hydroxy-17-keto-estra-1,3,5-triene; Estrone-A; (13S)-3-hydroxy-13-methyl-7,8,9,11,12,13,15,16-octahydro-6H-cyclopenta[a]phenanthren-17(14H)-one; ACon0_000083; Unden; EU-0100513; Hormofollin; Estrone (TN); STK801833; Oestroform; Menformon A; to_000049; NCGC00023643-04; 3-hydroxy-estra-1,3,5(10)-trien-17-one; folliculin; CCRIS 285; E1274_SIGMA; SPBio_002977; Esterone; Estrone (JAN/USP/INN); Theelin; delta-1,3,5-oestratrien-3-beta-ol-17-one; MLS001077340; Crystogen; E 9750; Estrona [INN-Spanish]; Oestrin; Femestrone inj.; 46573_FLUKA; MolPort-001-742-529; Ovifollin; estrone; NCGC00023643-03; CHEBI:17263; 3-Hydroxyestra-1,3,5(10)-trien-17-one; Ketodestrin; Unden (pharmaceutical); Estrogenic Substance; NCGC00023643-06; Estrone (E1); Bio-0668; SMP1_000123; Femidyn; (8R,9S,13S,14S)-3-hydroxy-13-methyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-one; MLS000028475; Hormovarine; MEGxm0_000444; HMS1570H10; 3-08-00-01171 (Beilstein Handbook Reference); Folipex; Estrone, (+-)-Isomer; Estrone, (9 beta)-Isomer; 86C77018-146D-4603-ACEA-CA0D8C4F1E2C; NSC 9699; Unigen; 3-Hydroxy-17-keto-oestra-1,3,5-triene; Oestronum; Thelykinin; [2,4,6,7-3H]-E1; NCGC00023643-10; Femestrone injection; Solliculin; Prestwick3_000914; Disynformon; E9750_SIGMA; Destrone; E(sub 1); Mestronaq; Vortech Brand of Estrone; D00067; NCGC00023643-05; E0026; follicular hormone; HSDB 3324; Folliculine benzoate; BRD-K81839095-001-04-6; Lopac0_000513; Menagen; Follestrol; delta-1,3,5-Oestratrien-3beta-ol-17-one; AC-1395; D004970; Prestwick0_000914; estrovarin; AB00382990; Prestwick2_000914; Ketohydroxyoestrin; 46573_RIEDEL; Kestrone; Prestwick1_000914; Estronum [INN-Latin]; Oestroperos; Folliculine; 37242-41-4; Wynestron; Cristallovar; Follestrine; 3-Hydroxyestra-1,3,5(10)-triene-17-one; EINECS 200-164-5; Estron; bmse000549; Glandubolin; Menformon; SMR000058338; NCGC00179433-03; Spectrum5_002047; BSPBio_000788; BPBio1_000868; Penncap M; Ketohydroxyestrin; Fem-O-Gen; CHEMBL1405; Perlatan; Ovex (tablets); Hiestrone; UNII-2DI9HA706A; Thelestrin; Estrusol; MLS002695951; Kolpon; Oestrone [Steroidal oestrogens]; delta-1,3,5-Estratrien-3beta-ol-17-one; Wehgen; S1665_Selleck; CID5870; Hyrex Brand of Estrone; NCGC00179433-02; Fermidyn; Hormestrin; nchembio.76-comp37; LMST02010004; delta-1,3,5-estratrien-3-beta-ol-17-one; Tokokin; Folikrin; Hauck Brand of Estrone; Estrin; Ketophydroxyestrin; Follicunodis; 1,3,5(10)-Oestratrien-3-ol-17-one; 53-16-7; CMC_13458; BIDD:ER0145; estra-1(10),2,4-trien-17-one, 3-hydroxy-	53-16-7	5870	148674	TTDS00242	Estrogen receptor	ER;ERalpha;ER-alpha;Estradiol receptor;Estrogen receptor alpha;Oestrogen receptor;Oestrogen receptor alpha	Q13262	N/A	N/A	agonist
DCL001063	Affinitak	N/A	N/A	N/A	N/A	TTDC00287	mRNA of PKC-alpha	N/A	N/A	N/A	N/A	antisense
DPR000020	BIBO-3304	N/A	191868-14-1	N/A	N/A	TTDC00040	Neuropeptide Y receptor type 2	NPY2R;NPY2-R;NPY-Y2 receptor;Y2 receptor	P49146	4887	ENSG00000185149	antagonist
DCL000940	PYY3-36	N/A	N/A	N/A	N/A	TTDC00040	Neuropeptide Y receptor type 2	NPY2R;NPY2-R;NPY-Y2 receptor;Y2 receptor	P49146	4887	ENSG00000185149	agonist
DPR000024	BMS-192548	N/A	152923-57-4	N/A	47206610	TTDC00040	Neuropeptide Y receptor type 2	NPY2R;NPY2-R;NPY-Y2 receptor;Y2 receptor	P49146	4887	ENSG00000185149	antagonist
DPR000008	AC-162352	N/A	123583-37-9	N/A	3811137	TTDC00040	Neuropeptide Y receptor type 2	NPY2R;NPY2-R;NPY-Y2 receptor;Y2 receptor	P49146	4887	ENSG00000185149	agonist
DCL000250	TM30338	N/A	N/A	N/A	N/A	TTDC00040	Neuropeptide Y receptor type 2	NPY2R;NPY2-R;NPY-Y2 receptor;Y2 receptor	P49146	4887	ENSG00000185149	agonist
DCL000638	SAR407899	N/A	N/A	N/A	N/A	TTDC00202	Rho-associated protein kinase 1	Let-502 kinase;P160 ROCK-1;P160(rock);P160ROCK;Rho kinase;Rho-associated kinase;Rho-associated protein kinase;Rho-associated, coiled-coil containing protein kinase;Rho-associated, coiled-coil containing protein kinase 1;ROCK;Rok	Q13464	6093	ENSG00000067900	inhibitor
DCL000959	Rho-kinase inhibitor	H-1152P; (S)-(+)-2-Methyl-1-[(4-methyl-5-isoquinolinyl)sulfonyl]homopiperazine, 2HCl; H-1152; Rho Kinase Inhibitor; InSolution&trade; Rho Kinase Inhibitor	N/A	N/A	N/A	TTDC00202	Rho-associated protein kinase 1	Let-502 kinase;P160 ROCK-1;P160(rock);P160ROCK;Rho kinase;Rho-associated kinase;Rho-associated protein kinase;Rho-associated, coiled-coil containing protein kinase;Rho-associated, coiled-coil containing protein kinase 1;ROCK;Rok	Q13464	6093	ENSG00000067900	inhibitor
DCL000747	Cethrin	N/A	N/A	16760630	26759430	TTDC00202	Rho-associated protein kinase 1	Let-502 kinase;P160 ROCK-1;P160(rock);P160ROCK;Rho kinase;Rho-associated kinase;Rho-associated protein kinase;Rho-associated, coiled-coil containing protein kinase;Rho-associated, coiled-coil containing protein kinase 1;ROCK;Rok	Q13464	6093	ENSG00000067900	inhibitor
DCL001017	TG101348	N/A	936091-26-8	N/A	N/A	TTDC00187	Tyrosine-protein kinase JAK2	JAK-2;Janus kinase 2	O60674	3717	ENSG00000096968	inhibitor
DCL000542	INCB18424	INC-424; INCB-018424; Ruxolitinib phosphate; INCB-18424	N/A	23644203	46506179	TTDC00187	Tyrosine-protein kinase JAK2	JAK-2;Janus kinase 2	O60674	3717	ENSG00000096968	inhibitor
DCL001038	XL019	N/A	N/A	N/A	N/A	TTDC00187	Tyrosine-protein kinase JAK2	JAK-2;Janus kinase 2	O60674	3717	ENSG00000096968	inhibitor
DCL000844	INCB018424	INC-424; INCB-018424; Ruxolitinib phosphate; INCB-18424	N/A	N/A	N/A	TTDC00187	Tyrosine-protein kinase JAK2	JAK-2;Janus kinase 2	O60674	3717	ENSG00000096968	inhibitor
DCL000852	ITF2357	Carbamic acid, N-(4-((hydroxyamino)carbonyl)phenyl)-, (6-((diethylamino)methyl)-2-naphthalenyl)methyl ester, hydrochloride (1:1); ITF2357; EC-000.2471; 383198-22-9; 199657-29-9; Givinostat	N/A	N/A	N/A	TTDC00187	Tyrosine-protein kinase JAK2	JAK-2;Janus kinase 2	O60674	3717	ENSG00000096968	inhibitor
DCL000545	INCB28050	N/A	152811-62-6	177336	47954535	TTDC00187	Tyrosine-protein kinase JAK2	JAK-2;Janus kinase 2	O60674	3717	ENSG00000096968	inhibitor
DAP001133	Diphenidol	Difenidolum [INN-Latin]; AKOS001675735; Difenidol; 1-Piperidinebutanol, alpha,alpha-diphenyl-; Benzhydrol, alpha-(3-piperidinopropyl)-; alpha,alpha-Diphenyl-1-piperidinebutanol; BRD-K01663662-003-03-8; NCGC00016624-01; 1,1-diphenyl-4-piperidin-1-ylbutan-1-ol hydrochloride; DIPHENIDOL; CHEBI:4638; Diphenidol (USAN/INN); AC1L1F2N; Prestwick2_000252; D03858; 1,1-diphenyl-4-piperidin-1-ylbutan-1-ol; Diphenidol [USAN:BAN]; AC-4261; I06-1541; Difenidolo [DCIT]; Difenidol HCl; CID3055; Prestwick3_000252; 3254-89-5 (hydrochloride); UNII-NQO8R319LY; SBB066245; SKF 478; LS-114371; AR-1I3639; SK-478; 972-02-1; Nometic; Difenidolo; AC1Q76Y5; InChI=1/C21H27NO/c23-21(19-11-4-1-5-12-19,20-13-6-2-7-14-20)15-10-18-22-16-8-3-9-17-22/h1-2,4-7,11-14,23H,3,8-10,15-18H2; Prestwick0_000252; Diphenyl(3-(1-piperidyl)propyl)carbinol; Prestwick1_000252; OGAKLTJNUQRZJU-UHFFFAOYSA-; HSDB 3316; DB01231; SK&F-478; 1-Piperidinebutanol, .alpha.,.alpha.-diphenyl-; Difenidolum; Vontrol; BSPBio_000064; EINECS 213-540-9; BRN 0265884; BPBio1_000072; SPBio_002283; NCGC00016624-02; CHEMBL936; Avomol; CAS-3254-89-5; defenidol; C06961	972-02-1	3055	9175	TTDS00005	Muscarinic acetylcholine receptor M4	M4 receptor	P08173	1132	ENSG00000180720	antagonist
DAP000345	Tropicamide	Tropicamida [INN-Spanish]; SMP1_000304; Epitromina; Ro 1-7683; SPBio_002196; 1508-75-4; NINDS_000448; STK934612; Tropicamide Ocumed Brand; N-ethyl-3-hydroxy-2-phenyl-N-(pyridin-4-ylmethyl)propanamide; Lopac0_001223; n-ethyl-n-(g-picolyl)tropamide; AR-1K6980; MLS001306442; Minims tropicamide; HMS1568N17; KBio3_001509; HMS1921I09; NCGC00016065-03; Stulln Brand 2 of Tropicamide; AB00052120; Tropicamide Rivex Brand; NCGC00024866-03; Mydriacyl (TN); NCGC00024866-04; Tropicacyl; IDI1_000448; N-Ethyl-2-phenyl-N-(4-pyridylmethyl)hydracrylamide; N-Ethyl-N-(4-pyridylmethyl)tropamid; Tropicamide Alcon Brand; DB00809; Prestwick2_000228; Tropicamide [USAN:INN:BANJAN]; T9778_SIGMA; Akorn Brand of Tropicamide; Tropicamidum; EU-0101223; SMR000058523; LS-28545; (+-)-N-Ethyl-2-phenyl-N-(4-pyridylmethyl)hydracrylamide; 5-22-09-00359 (Beilstein Handbook Reference); Tropicamide Novartis Brand; Spectrum2_000936; BPBio1_000303; Prestwick1_000228; BRN 0285563; Tropicamide, (S)-Isomer; Mydriaticum; Spectro-Cyl; Cahill May Roberts Brand of Tropicamide; Bio-0810; KBio2_001064; Opticyl; Alcon Brand of Tropicamide; Tropikamid; Mydriacyl; Spectrum_000584; Tropicamide, (R)-Isomer; Ocumed Brand of Tropicamide; D014331; Spectrum5_001585; Chauvin Brand of Tropicamide; Rivex Brand of Tropicamide; Tropicamide Monohydrochloride, (S)-Isomer; HMS501G10; BSPBio_000275; Prestwick3_000228; N-Ethyl-N-(4-pyridylmethyl)tropamide; MLS002154240; Hydracrylamide, N-ethyl-2-phenyl-N-(4-pyridylmethyl)-; Benzeneacetamide, N-ethyl-.alpha.-(hydroxymethyl)-N-(4-pyridinylmethyl)-; Tropicamide Chauvin Brand; Tropicamide Monofree; AC1Q5IFA; Medical Ophthalmics Brand of Tropicamide; EINECS 216-140-2; Mydriafair; Benzeneacetamide, N-ethyl-alpha-(hydroxymethyl)-N-(4-pyridinylmethyl)-; Bournonville Brand of Tropicamide; Tropicamidum [INN-Latin]; NCGC00016065-08; KBio2_006200; Stulln Brand 1 of Tropicamide; Tropicamide Monohydrochloride, (R)-Isomer; KBio2_003632; Prestwick_487; NCGC00024866-05; Tropicamide (JP15/USP/INN); Tropicamida; MolPort-000-159-321; Ocu-Tropic; Tropicamide Minims; Mydrum; Paremyd; Tropimil; Tropicamide Faure; Prestwick0_000228; D00397; N-Ethyl-2-phenyl-N-4-[-pyridyl-methyl]hydracrylamide; AC1L1KOZ; Tropicamide, (+-)-Isomer; CHEMBL1200604; HMS2089M05; KBioSS_001064; UNII-N0A3Z5XTC6; I-Picamide; SPBio_000872; Pharmafair Brand of Tropicamide; OcuTropic; AC-816; T 9778; NCGC00024866-02; Ocu Tropic; CPD000058523; I06-0811; N-Ethyl-alpha-(hydroxymethyl)-N-(4-pyridinylmethyl)benzeneacetamide; KBio1_000448; CID5593; tropicamide; Novartis Brand of Tropicamide; Mydral; Spectrum3_000655; DivK1c_000448; HMS2092A18; NCGC00024866-06; KBioGR_000873; SAM002564235; Tropicamide Pharmafair Brand; Spectrum4_000377; Benzeneacetamide, N-ethyl-alpha-(hydroxymethyl)-N-(4-pyridinylmethyl)-, (+-)-; Triaminic DM; Visumidriatic; SPECTRUM1500599; Ocusoft Brand of Tropicamide; BRD-A79672927-001-05-8; Bistropamide; L001262; TL8001101; Colircusi Tropicamida; BSPBio_002289	1508-75-4	5593	7847463	TTDS00005	Muscarinic acetylcholine receptor M4	M4 receptor	P08173	1132	ENSG00000180720	antagonist
DCL000215	Resiquimod	C099445; CHEMBL383322; AC1L4M46; S-28463; 1-[4-amino-2-(ethoxymethyl)imidazo[4,5-c]quinolin-1-yl]-2-methylpropan-2-ol; 4-amino-2-ethoxymethyl-alpha,alpha-dimethyl-1H-imidazo(4,5-c)quinoline-1-ethanol; CHEBI:36706; 1-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-2-methylpropan-2-ol; 4-amino-2-(ethoxymethyl)-a,a-dimethyl-1h-imidazo[4,5-c]quinoline-1-ethanol; 144875-48-9; 1H-Imidazo(4,5-c)quinoline-1-ethanol, 4-amino-2-(ethoxymethyl)-alpha,alpha-dimethyl-; Resiquimod; 171742-32-8; CID159603; R848; UNII-V3DMU7PVXF; Resiquimod [INN]; AC1Q4YO8; R 848; VML-600; AR-1G0546; MolPort-006-822-593; R-848; AR-1G0547; 1-(4-Amino-2-ethoxymethyl-imidazo[4,5-c]quinolin-1-yl)-2-methyl-propan-2-ol; C402365; S 28463; R848 compound	144875-48-9	159603	17425420	TTDC00056	Toll-like receptor 8	CD288 antigen;TLR8	Q9NR97	51311	ENSG00000101916	agonist
DCL000020	CPG 52364	N/A	453562-69-1	11667893	47214228	TTDC00056	Toll-like receptor 8	CD288 antigen;TLR8	Q9NR97	51311	ENSG00000101916	antagonist
DCL000173	MSX-122	N/A	129791-92-0	6540558	45991762	TTDC00121	C-X-C chemokine receptor type 4	CD184 antigen;Chemokine receptor CXCR4;CXCR4;CXC-R4;CXCR-4;FB22;Fusin;HM89;LCR1;LESTR;Leukocyte-derived seven transmembrane domain receptor;NPYRL;SDF-1 receptor;Stromal cell-derived factor 1 receptor	P61073	7852	ENSG00000121966	antagonist
DCL000041	AMD-3100	C28H54N8.8HCl; Bicyclam; LS-173476; 1,4,8,11-Tetraazacyclotetradecane, 1,1'-(1,4-phenylenebis(methylene))bis-; 1,1'-[1,4-Phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane] & Galanthus nivalis agglutinin (GNA); JM 2987; LS-187299; MolPort-003-940-217; HHA & AMD-3100; Plerixafor (INN/USAN); CHEMBL18442; NCGC00165722-01; SID-791; 1,1'-[1,4-Phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane] & Hippeastrum hybrid agglutinin( HHA); Sid 791; AC1Q3AB8; 155148-31-5; Amd 3100; 110078-46-1; JM-2987; JLK-169; L000104; AMD3100; SDZ SID 791; Plerixafor; AMD-3100; JM3100; D08971; 1,1'-[1,4-Phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane]; 1,1'-(1,4-Phenylenebis(methylene))bis-1,4,8,11-tetraazacyclotetradecane octahydrochloride; SDZ-SID-791; DB06809; 1,4,8,11-Tetraazacyclotetradecane, 1,1'-(1,4-phenylenebis(methylene))bis-, octahydrochloride; AC1L22ET; 1,1'-[1,4-Phenylenebis(methylene)]bis-1,4,8,11-tetraazacyclotetradecane octahydrochloride; JM-3100; Mozobil (TN); Mozobil; I14-9461; 1-[[4-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)phenyl]methyl]-1,4,8,11-tetrazacyclotetradecane octahydrochloride; CID65014; 1-[[4-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)phenyl]methyl]-1,4,8,11-tetrazacyclotetradecane; GNA & AMD-3100; 1,1'-{1,4-phenylenebis(methylene)}-bis{1,4,8,11-tetraaza-cyclotetradecane}; CHEBI:120346; CID65015; bicyclam JM-2987; JM 3100; Plerixafor hydrochloride; UNII-S915P5499N; AC1L22EQ; 1,1'-(1,4-Phenylenebis-(methylene))-bis-1,4,8,11-tetraazacyclotetradecane octahydrochloride dihydrate; SID791	N/A	65015	26683765	TTDC00121	C-X-C chemokine receptor type 4	CD184 antigen;Chemokine receptor CXCR4;CXCR4;CXC-R4;CXCR-4;FB22;Fusin;HM89;LCR1;LESTR;Leukocyte-derived seven transmembrane domain receptor;NPYRL;SDF-1 receptor;Stromal cell-derived factor 1 receptor	P61073	7852	ENSG00000121966	antagonist
DCL000040	AMD-070	690656-53-2; N'-(1H-Benzo[d]imidazol-2-ylmethyl)-N'-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine Trihydrobromide Dihydrate; AMD 070; AMD-070; AMD11070; AMD070; CID10126019; S14-0353; CHEMBL1088913; ST51054666; N-(1H-benzoimidazol-2-ylmethyl)-N-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine	N/A	N/A	N/A	TTDC00121	C-X-C chemokine receptor type 4	CD184 antigen;Chemokine receptor CXCR4;CXCR4;CXC-R4;CXCR-4;FB22;Fusin;HM89;LCR1;LESTR;Leukocyte-derived seven transmembrane domain receptor;NPYRL;SDF-1 receptor;Stromal cell-derived factor 1 receptor	P61073	7852	ENSG00000121966	antagonist
DCL000922	Plerixafor	1,4,8,11-Tetraazacyclotetradecane, 1,1'-(1,4-phenylenebis(methylene))bis-; 1,1'-[1,4-Phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane] & Galanthus nivalis agglutinin (GNA); JM 2987; LS-187299; HHA & AMD-3100; Plerixafor (INN/USAN); CHEMBL18442; NCGC00165722-01; 1,1'-[1,4-Phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane] & Hippeastrum hybrid agglutinin( HHA); 155148-31-5; Amd 3100; 110078-46-1; L000104; AMD3100; SDZ SID 791; Plerixafor; AMD-3100; JM3100; D08971; 1,1'-[1,4-Phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane]; DB06809; AC1L22ET; JM-3100; Mozobil (TN); Mozobil; I14-9461; 1-[[4-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)phenyl]methyl]-1,4,8,11-tetrazacyclotetradecane; GNA & AMD-3100; 1,1'-{1,4-phenylenebis(methylene)}-bis{1,4,8,11-tetraaza-cyclotetradecane}; CHEBI:120346; CID65015; bicyclam JM-2987; JM 3100; UNII-S915P5499N; SID791	155148-31-5	5311429	48317616	TTDC00121	C-X-C chemokine receptor type 4	CD184 antigen;Chemokine receptor CXCR4;CXCR4;CXC-R4;CXCR-4;FB22;Fusin;HM89;LCR1;LESTR;Leukocyte-derived seven transmembrane domain receptor;NPYRL;SDF-1 receptor;Stromal cell-derived factor 1 receptor	P61073	7852	ENSG00000121966	antagonist
DPR000144	KRH-2731	N/A	N/A	N/A	N/A	TTDC00121	C-X-C chemokine receptor type 4	CD184 antigen;Chemokine receptor CXCR4;CXCR4;CXC-R4;CXCR-4;FB22;Fusin;HM89;LCR1;LESTR;Leukocyte-derived seven transmembrane domain receptor;NPYRL;SDF-1 receptor;Stromal cell-derived factor 1 receptor	P61073	7852	ENSG00000121966	binder
DAP000179	Imatinib	AC-524; 4-[(4-methylpiperazin-1-yl)methyl]-N-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)benzamide; Cgp 57148; 152459-95-5; CHEMBL941; sti-571; I01-1232; nchembio.282-comp6; alpha-(4-Methyl-1-piperazinyl)-3'-((4-(3-pyridyl)-2-pyrimidinyl)amino)-p-tolu-p-toluidide; Imatinib (INN); Glamox; 4-(4-METHYL-PIPERAZIN-1-YLMETHYL)-N-[4-METHYL-3-(4-PYRIDIN-3-YL-PYRIMIDIN-2-YLAMINO)-PHENYL]-BENZAMIDE; Imatinib free base; BRD-K92723993-066-02-9; NCGC00159456-02; CID5291; MolPort-000-883-342; CCRIS 9076; benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-; Imatinib; BIDD:GT0047; N-(3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)-4-methylphenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; AKOS000280662; STK617705; CGP 57148B; nchembio.117-comp23; Benzamide, 4-((4-methyl)-1-piperazinyl)methyl)-N-(4-methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)phenyl)-; AC1L1K0Z; Imatinib [INN:BAN]; EN002706; nchembio.162-comp5; 4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide; LS-182208; DB00619; STI; FT-0083542; 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide methanesulfonate; Kinome_3724; NSC743414; 112GI019; NCGC00159456-04; 4-[(4-methylpiperazin-1-yl)methyl]-N-{4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl}benzamide; 1iep; CHEBI:45783; Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI); nchembio.83-comp14; D08066; Imatinib Methansulfonate; HMS2089D03; 1xbb; UNII-BKJ8M8G5HI; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-phenyl]benzamide; DB03261; NCGC00159456-03; LS-187106; Glamox (TN); STI571; STI 571	152459-95-5	5291	841977	TTDS00261	Platelet-derived growth factor receptor	PDGF-R;PDGFR kinase;Platelet-derived growth factor receptor tyrosine kinase	N/A	N/A	N/A	inhibitor
DCL000356	BAY-57-9352	2-Pyridinecarboxamide, 4-(((4-((4-chlorophenyl)amino)furo(2,3-d)pyridazin-7-yl)oxy)methyl)-N-methyl-; Bay 57-9352; UNII-18P7197Q7J; 332012-40-5; CID 9808844; CID9808844; Telatinib	332012-40-5 	9808844	75059184	TTDS00261	Platelet-derived growth factor receptor	PDGF-R;PDGFR kinase;Platelet-derived growth factor receptor tyrosine kinase	N/A	N/A	N/A	inhibitor
DCL000353	Axitinib	ST51054130; ZINC03816287; Benzamide, N-methyl-2-((3-((1E)-2-(2-pyridinyl)ethenyl)-1H-indazo)-6-yl)thio)-; 319460-85-0; AC1O51X3; I14-1971; N-methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-indazol-6-yl)sulfanyl)benzamide; N-methyl-2-[[3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]sulfanyl]benzamide; AG 013736; C503983; Axitinib; MolPort-006-392-413; AC-1539; AG013736; UNII-C9LVQ0YUXG; S1005_Selleck; AG-013736, Axitinib; AG-013736; EC-000.2322; CID6450551; Benzamide, N-methyl-2-[[3-[(1E)-2-(2-pyridinyl)ethenyl]-1H-indazol-6-yl]thio]-; AG-13736; 790713-39-2	319460-85-0	6450551	3889615	TTDS00261	Platelet-derived growth factor receptor	PDGF-R;PDGFR kinase;Platelet-derived growth factor receptor tyrosine kinase	N/A	N/A	N/A	inhibitor
DAP000005	Sunitinib	PDGF TK antagonist; 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-; AC1NS62J; SU 11248; 5-(5-FLUORO-2-OXO-1,2-DIHYDRO-INDOL-3-YLIDENEMETHYL)-2,4-DIMETHYL-1H-PYRROLE-3-CARBOXYLIC ACID (2-DIETHYLAMINO-ETHYL)-AMIDE; NSC736511; SU-11248J; 326914-13-0; NSC750690; K00588a; Su-011248; Sunitinib; SU-12662; KS-5022; CHEMBL535; UNII-V99T50803M; Sunitanib; 557795-19-4; N-(2-diethylaminoethyl)-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; NCGC00164631-01; SU11248; 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)- (5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-; LS-187023; DB01268; I01-1229; CID5329102; SU-11248; CHEBI:38940; sunitinibum; DB07417; LS-187648; N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; FT-0083556; Sutent; D08552; Sunitinib (free base); Sunitinib (INN); EN002687; 1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-	557795-19-4	5329102	14830382	TTDS00261	Platelet-derived growth factor receptor	PDGF-R;PDGFR kinase;Platelet-derived growth factor receptor tyrosine kinase	N/A	N/A	N/A	inhibitor
DCL000578	Motesanib	453562-69-1; UNII-U1JK633AYI; ZINC18710082; CID11667893; AMG706; AKOS005146333; N-(3,3-dimethyl-2,3-dihydro-1H-indol-6-yl)-2-[(pyridin-4-ylmethyl)amino]pyridine-3-carboxamide; N-(2,3-dihydro-3,3-dimethyl-1H-indol-6-yl)-2-((4-pyridinylmethyl)amino)-3-pyridinecarboxamide; D06678; Motesanib; CHEMBL572881; AMG-706; AMG 706; CHEBI:51098	453562-69-1	11667893	47208329	TTDS00261	Platelet-derived growth factor receptor	PDGF-R;PDGFR kinase;Platelet-derived growth factor receptor tyrosine kinase	N/A	N/A	N/A	inhibitor
DCL000646	Sunitinib malate	SU010398; N-(2-diethylaminoethyl)-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; (2S)-2-hydroxybutanedioic acid; PNU-290940AD; SU011248; SU-010398; PHA-290940AD; AKOS005145765; FT-0083555; Sunitinib malate [USAN]; Sutent, SU-11248; D06402; SU-011248 L-malate salt; Sunitinib malate; N-(2-(Diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (2S)-hydroxybutanedioate; ST51053712; Sutent (TN); AC1O5CMQ; CHEMBL1567; 341031-54-7; LS-186078; 1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-,     (2S)-hydroxybutanedioate (1:1); CHEBI:550864; MolPort-003-986-763; 1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1); SU011248 L-malate salt; TL8002546; Sunitinib malate (JAN/USAN); UNII-LVX8N1UT73; CID6456015; Butanedioic acid, hydroxy-, (2S)-, compd. with N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (1:1); SU-11248 L-malate salt; SU 011248; S1042_Selleck	557795-19-4	5329102	14830382	TTDS00261	Platelet-derived growth factor receptor	PDGF-R;PDGFR kinase;Platelet-derived growth factor receptor tyrosine kinase	N/A	N/A	N/A	inhibitor
DAP001550	Pazopanib HCl	N/A	N/A	N/A	N/A	TTDS00261	Platelet-derived growth factor receptor	PDGF-R;PDGFR kinase;Platelet-derived growth factor receptor tyrosine kinase	N/A	N/A	N/A	inhibitor
DCL000248	TKI258	CID 9977819; 4-Amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one; S1018_Selleck; CID9886808; EC-000.2257; 405169-16-6; CID9977819; UNII-I35H55G906; Chir 258; 804551-71-1; AKOS005146311; TKI-258; CHEMBL522892; CHEBI:594834; TKI-258, Dovitinib, CHIR258, TKI258; CHIR-258	804551-71-1	9886808	46147922	TTDS00261	Platelet-derived growth factor receptor	PDGF-R;PDGFR kinase;Platelet-derived growth factor receptor tyrosine kinase	N/A	N/A	N/A	inhibitor
DAP001466	CT-102	N/A	N/A	N/A	N/A	TTDS00261	Platelet-derived growth factor receptor	PDGF-R;PDGFR kinase;Platelet-derived growth factor receptor tyrosine kinase	N/A	N/A	N/A	activator
DCL000359	CP-868596	N/A	32205-91-7	5360621	47808597	TTDS00261	Platelet-derived growth factor receptor	PDGF-R;PDGFR kinase;Platelet-derived growth factor receptor tyrosine kinase	N/A	N/A	N/A	inhibitor
DAP000028	Becaplermin	Becaplermin (USAN/INN); 165101-51-9; D03065; Regranex (TN); Regranex; Becaplermin	165101-51-9	N/A	17397220	TTDS00261	Platelet-derived growth factor receptor	PDGF-R;PDGFR kinase;Platelet-derived growth factor receptor tyrosine kinase	N/A	N/A	N/A	inhibitor
DCL000579	Motesanib diphosphate	S1032_Selleck; Motesanib diphosphate; Motesanib diphosphate [USAN]; D08947; 857876-30-3; Motesanib diphosphate (USAN); UNII-T6Q3060U91; AMG-706. Motesanib Diphosphate; EC-000.2343	850649-62-6	11450633	22395889	TTDS00261	Platelet-derived growth factor receptor	PDGF-R;PDGFR kinase;Platelet-derived growth factor receptor tyrosine kinase	N/A	N/A	N/A	inhibitor
DCL000342	SU-6668	N/A	N/A	5329099	12015385	TTDS00261	Platelet-derived growth factor receptor	PDGF-R;PDGFR kinase;Platelet-derived growth factor receptor tyrosine kinase	N/A	N/A	N/A	inhibitor
DCL000351	Pazopanib	Pazopanib; CID10113978; GW-786034; I09-0358; 790713-33-6; 5-[[4-[(2,3-Dimethyl-2H-indazol-6-yl)(methyl)amino]pyrimidin-2-yl]amino]-2-methylbenzenesulfonami; GW786034; 444731-52-6; 5-[[4-[(2,3-dimethylindazol-6-yl)-methyl-amino]pyrimidin-2-yl]amino]-2-methyl-benzenesulfonamide; AKOS005145819; UNII-7RN5DR86CK; ST51053493; CHEMBL477772; MolPort-006-827-156; Votrient; GW 786034; Kinome_3790; Benzenesulfonamide, 5-((4-((2,3-dimethyl-2H-indazol-6-yl)methylamino)-2-pyrimidinyl)amino)-2-methyl-; Pazopanib [INN]; Benzenesulfonamide, 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-	444731-52-6	11525740	22395868	TTDS00261	Platelet-derived growth factor receptor	PDGF-R;PDGFR kinase;Platelet-derived growth factor receptor tyrosine kinase	N/A	N/A	N/A	inhibitor
DCL000171	MP470	N/A	850879-09-3	N/A	85151253	TTDS00261	Platelet-derived growth factor receptor	PDGF-R;PDGFR kinase;Platelet-derived growth factor receptor tyrosine kinase	N/A	N/A	N/A	inhibitor
DCL000360	Nilotinib	4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazo; Benzamide, 4-methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-(4-(3-pyridinyl)-2-pyrimidinyl)amino)-; AKOS005063561; Nilotinib; 641571-10-0; 4-Methyl-N-[3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl]-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]benzamide; C498826; CHEBI:52172; CID644241; S1033_Selleck; 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide; NSC747599; 4-Methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide; NIL; CHEMBL255863; nilotinibum; Benzamide, 4-methyl-N-((3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-(4-(3-pyridinyl)-2-pyrimidinyl)amino)-; Benzamide, 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]- (9CI); 4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide; AMN 107; Nilotinib (INN/USAN); AMN-107; 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl]benzamide; AC-647; l-1-yl)-3-(trifluoromethyl)phenyl]benzamide; DB04868; Nilotinib, AMN107, Tasigna; I01-1225; D08953; 4-Methyl-3-(4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-[5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl]benzamide; AMN107; TL8004531; AC1LD8U3; Tasigna; EN002707; EC-000.2344; Tasigna (Novartis); MolPort-003-987-089; benzamide, 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-; Tasigna, AMN-107, Nilotinib; UNII-F41401512X	N/A	N/A	N/A	TTDS00261	Platelet-derived growth factor receptor	PDGF-R;PDGFR kinase;Platelet-derived growth factor receptor tyrosine kinase	N/A	N/A	N/A	inhibitor
DCL000964	Roflumilast	3-(CYCLOPROPYLMETHOXY)-N-(3,5-DICHLOROPYRIDIN-4-YL)-4-(DIFLUOROMETHOXY)BENZAMIDE; ZINC00592419; 1xoq; AKOS005146309; 1xmu; S2131_Selleck; CHEMBL193240; 3-Cyclopropylmethoxy-N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)benzamide; APTA-2217; C424423; Benzamide, 3-(cyclopropylmethoxy)-N-(3,5-dichloro-4-pyridinyl)-4-(difluoromethoxy)-; Roflumilast; Roflumilast (JAN/USAN/INN); D05744; DAXAS; BY217; Roflumilast [USAN]; BY-217; CHEBI:47657; B9302-107; 3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-di-chloropyrid-4-yl)benzamide; UNII-0P6C6ZOP5U; AC1L9MU7; ROF; CID449193; LS-26272; BYK20869; 162401-32-3	162401-32-3	449193	47207405	TTDC00170	Phosphodiesterase isozyme 4	PDE4;Phosphodiesterase 4	Q86V67	N/A	N/A	inhibitor
DCL000906	ONO-6126	N/A	N/A	100594	44430699	TTDC00170	Phosphodiesterase isozyme 4	PDE4;Phosphodiesterase 4	Q86V67	N/A	N/A	inhibitor
DCL000699	Apremilast	CC-10004; Apremilast; D08860; CID11561674; Apremilast (USAN); CHEMBL514800; CHEBI:558773; N-[2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methylsulfonyl-ethyl]-1,3-dioxo-isoindol-4-yl]acetamide	608141-41-9	11561674	50086920	TTDC00170	Phosphodiesterase isozyme 4	PDE4;Phosphodiesterase 4	Q86V67	N/A	N/A	inhibitor
DCL000833	GW842470X	N/A	N/A	N/A	N/A	TTDC00170	Phosphodiesterase isozyme 4	PDE4;Phosphodiesterase 4	Q86V67	N/A	N/A	inhibitor
DCL000839	IC-485	N/A	N/A	23724886	17397915	TTDC00170	Phosphodiesterase isozyme 4	PDE4;Phosphodiesterase 4	Q86V67	N/A	N/A	inhibitor
DCL000752	Cilomilast	Cilomilast; DB03849; 1xom; 153259-65-5; PDSP2_001271; CHEMBL511115; S1455_Selleck; Cilomilast (JAN/USAN/INN); D01704; Cilomilast [USAN:INN]; Ariflo; LS-56637; AC1L45SU; cis-4-Cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)cyclohexanecarboxylic acid; SB207499; CIO; CID151170; Ariflo (TN); C433247; Ariflo, SB-207499,Cilomilast; cis-4-Cyano-4-(3-(cyclopentyloxy)-4-methoxyphenyl)cyclohexanecarboxylic acid; NCGC00167520-01; 1xlx; CHEBI:221895; cis-4-(3-(Cyclopentyloxy)-4-methoxyphenyl)-4-cyanocyclohexane-1-carboxylic acid; SB 207499; CIS-4-CYANO-4-[3-(CYCLOPENTYLOXY)-4-METHOXYPHENYL]CYCLOHEXANECARBOXYLIC ACID; PDSP1_001287; Cyclohexanecarboxylic acid, 4-cyano-4-(3-(cyclopentyloxy)-4-methoxyphenyl)-, cis-; 4-cyano-4-(3-cyclopentoxy-4-methoxy-phenyl)-cyclohexane-1- carboxylic acid; MolPort-005-940-870; MolPort-005-943-371; SB-207499; 4-cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)cyclohexane-1-carboxylic acid	153259-65-5	151170	46515098	TTDC00170	Phosphodiesterase isozyme 4	PDE4;Phosphodiesterase 4	Q86V67	N/A	N/A	inhibitor
DCL000700	Arofylline	ZINC13658656; AR-1E6861; Arofyllin; UNII-87L38AY71R; AC1L4YAX; SMR000459612; CID166553; D02985; Arofylline; 3-(4-chlorophenyl)-1-propyl-3,7-dihydro-1H-purine-2,6-dione; MLS000860828; KM09088; MolPort-002-908-644; Arofylline (USAN/INN); AC1Q3SIW; 3-(4-chlorophenyl)-1-propyl-7H-purine-2,6-dione	136145-07-8	5311006	17397141	TTDC00170	Phosphodiesterase isozyme 4	PDE4;Phosphodiesterase 4	Q86V67	N/A	N/A	inhibitor
DCL000077	CC-10004	666854-78-0; CC-10004; UNII-UP7QBP99PN; CC 10004; Apremilast; D08860; CID11561674; Apremilast (USAN); CHEMBL514800; CHEBI:558773; N-[2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methylsulfonyl-ethyl]-1,3-dioxo-isoindol-4-yl]acetamide	N/A	N/A	N/A	TTDC00170	Phosphodiesterase isozyme 4	PDE4;Phosphodiesterase 4	Q86V67	N/A	N/A	inhibitor
DCL000245	Telcagepant	MK0974; N-(6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl)-4-(2-oxo-2,3-dihydro-1H-imidazo(4,5-b)pyridin-1-yl)piperidine-1-carboxamide; CID11319053; MK-0974; CHEMBL236593; Telcagepant; MK 0974; CID 11169048; Telcagepant (USAN); N7R; D09391; 781649-09-0; C525458; CHEBI:502280	474877-20-8	N/A	3820998	TTDC00093	Calcitonin gene-related peptide type 1 receptor	Calcitonin gene-related peptide 1 receptor;Calcitonin receptor-like receptor;CGRP receptor 1;CGRP type 1 receptor	Q16602	10203	ENSG00000064989	antagonist
DPR000081	NPY antagonist	N/A	262418-00-8	N/A	N/A	TTDC00089	Neuropeptide Y receptor type 5	Neuropeptide Y (NPY) Y(5) receptor;Neuropeptide Y receptor Y5;NPY5-R;NPYY5;NPY-Y5 receptor;Y5 receptor	Q15761	4889	ENSG00000164129	antagonist
DCL000083	CGP71683A	CHEBI:119320; L000175; CHEMBL17645; AC1NSM13; CHEMBL195380; CHEBI:424351; CID5312114; NCGC00165960-01; CGP71683A; CGP-71683A; N-[[4-[[(4-aminoquinazolin-2-yl)amino]methyl]cyclohexyl]methyl]naphthalene-1-sulfonamide; NCGC00159542-01	N/A	5312114	7978910	TTDC00089	Neuropeptide Y receptor type 5	Neuropeptide Y (NPY) Y(5) receptor;Neuropeptide Y receptor Y5;NPY5-R;NPYY5;NPY-Y5 receptor;Y5 receptor	Q15761	4889	ENSG00000164129	antagonist
DPR000082	NPY5RA-972	N/A	N/A	N/A	N/A	TTDC00089	Neuropeptide Y receptor type 5	Neuropeptide Y (NPY) Y(5) receptor;Neuropeptide Y receptor Y5;NPY5-R;NPYY5;NPY-Y5 receptor;Y5 receptor	Q15761	4889	ENSG00000164129	antagonist
DPR000047	FR-79620	CID10421577; 3-(5-methyl-2-phenyl-1H-imidazol-4-yl)pyridine; CHEBI:101543; FR-79620; CHEMBL6893	N/A	N/A	N/A	TTDC00089	Neuropeptide Y receptor type 5	Neuropeptide Y (NPY) Y(5) receptor;Neuropeptide Y receptor Y5;NPY5-R;NPYY5;NPY-Y5 receptor;Y5 receptor	Q15761	4889	ENSG00000164129	antagonist
DPR000056	GW-594884A	N/A	N/A	N/A	N/A	TTDC00089	Neuropeptide Y receptor type 5	Neuropeptide Y (NPY) Y(5) receptor;Neuropeptide Y receptor Y5;NPY5-R;NPYY5;NPY-Y5 receptor;Y5 receptor	Q15761	4889	ENSG00000164129	antagonist
DCL001232	S-234462	N/A	N/A	N/A	N/A	TTDC00089	Neuropeptide Y receptor type 5	Neuropeptide Y (NPY) Y(5) receptor;Neuropeptide Y receptor Y5;NPY5-R;NPYY5;NPY-Y5 receptor;Y5 receptor	Q15761	4889	ENSG00000164129	antagonist
DCL001251	Velneperit	N/A	N/A	N/A	N/A	TTDC00089	Neuropeptide Y receptor type 5	Neuropeptide Y (NPY) Y(5) receptor;Neuropeptide Y receptor Y5;NPY5-R;NPYY5;NPY-Y5 receptor;Y5 receptor	Q15761	4889	ENSG00000164129	antagonist
DCL000711	Axovan-3	N/A	N/A	N/A	N/A	TTDC00089	Neuropeptide Y receptor type 5	Neuropeptide Y (NPY) Y(5) receptor;Neuropeptide Y receptor Y5;NPY5-R;NPYY5;NPY-Y5 receptor;Y5 receptor	Q15761	4889	ENSG00000164129	antagonist
DCL001181	EXC 001	N/A	N/A	N/A	N/A	TTDC00335	mRNA of connective tissue growth factor	mRNA of CCN family member 2;mRNA of Hypertrophic chondrocyte-specific protein 24;mRNA of Insulin-like growth factor-binding protein 8;mRNA of IBP-8;mRNA of IGF-binding protein 8;mRNA of IGFBP-8;mRNA of CTGF;mRNA of CCN2	P29279	1490	ENSG00000118523	antisense
DCL000055	AS1409	N/A	N/A	3779	48436603	TTDC00012	Fibronectin	CIG;Cold-insoluble globulin;FN;FN1;Ugl-Y1;Ugl-Y2;Ugl-Y3	P02751	2335	ENSG00000115414	binder
DPR000075	MGluRIII agonist and mGlu5 antagonist	N/A	287096-87-1	219021	45277720	TTDC00126	Metabotropic glutamate receptor 3	Group III metabotropic glutamate receptor;mGLUR3	Q14832	2913	ENSG00000198822	agonist
DCL000159	LY404039	LY-404039; S6001_Selleck; CHEBI:466096; CID9834591; 635318-11-5; 4-amino-2-thiabicyclo(3.1.0)hexane-4,6-dicarboxylic acid; CHEMBL375611; LY 404039; (1R,2S,5R,6R)-2-amino-4,4-dioxo-4$l^{6}-thiabicyclo[3.1.0]hexane-2,6-dicarboxylic Acid; LY404039	635318-11-5	9834591	85149777	TTDC00126	Metabotropic glutamate receptor 3	Group III metabotropic glutamate receptor;mGLUR3	Q14832	2913	ENSG00000198822	agonist
DCL001112	LY-544344	N/A	N/A	N/A	N/A	TTDC00126	Metabotropic glutamate receptor 3	Group III metabotropic glutamate receptor;mGLUR3	Q14832	2913	ENSG00000198822	agonist
DCL000158	LY354740	CID213056; (1S,2S,5R,6S)-2-Aminobicyclo(3.1.0)hexane-2,6-dicarboxylic  acid  monohydrate; LS-43724; MolPort-004-797-148; I14-10174; AC1L4GL9; 2-Aminobicyclo(3.1.0)hexane-2,6-dicarboxylic acid; 176199-48-7; LY-354740; LY354740; UNII-ONU5A67T2S; LS-43725; Eglumegad; MolPort-004-797-150; C8H11NO4; LS-173689; AR-1A1554; (1S,2S,5R,6S)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid; 4-aminobicyclo[3.1.0]hexane-4,6-dicarboxylic acid; (1R,4S,5S,6S)-4-aminobicyclo[3.1.0]hexane-4,6-dicarboxylic acid; AC1Q4UAB; Eglumegad [INN]; Bicyclo(3.1.0)hexane-2,6-dicarboxylic acid, 2-amino-,  monohydrate,(1S,2S,5R,6S)-; LY-354740 monohydrate; LY-314582; CHEBI:104480; 177317-28-1; Eglumegad (USAN); LY314582; AC1L3G0W; AC1L4U61; (1R,4S,5S,6S)-4-aminobicyclo[3.1.0]hexane-4,6-dicarboxylic acid hydrate; Eglumetad (INN/USAN); LY 314582; L000367; LY-366563; LY 354740; Eglumegad [USAN]; CID156665; Eglumetad hydrate; D08908; CID114827; PDSP1_000258; 209216-09-1; Eglumegad hydrate; LY 366563; LY366563; D03966; Bicyclo(3.1.0)hexane-2,6-dicarboxylic acid, 2-amino-; PDSP2_000257; (1S,2S,5R,6S)-2-Aminobicyclo(3.1.0)hexane-2,6-dicarboxylic acid; CHEMBL8759; KST-1A2632; Eglumetad	176199-48-7	213056	7979829	TTDC00126	Metabotropic glutamate receptor 3	Group III metabotropic glutamate receptor;mGLUR3	Q14832	2913	ENSG00000198822	agonist
DPR000025	BMS-433771	1-cyclopropyl-3-[[1-(4-hydroxybutyl)benzimidazol-2-yl]methyl]imidazo[4,5-c]pyridin-2-one; AC1O55AR; BMS-433771; CHEMBL243876; CID6478034; 1-cyclopropyl-3-[[1-(3-hydroxypropyl)benzimidazol-2-yl]methyl]imidazo[4,5-c]pyridin-2-one; AC1L9T3I; AIDS161903; CHEMBL243875; CID500516; Bms 433771	380603-10-1	6478034	26683794	TTDS00314	4-hydroxyphenylpyruvate dioxygenase	4HPPD;F Alloantigen;F protein;HPD;HPPDase	P49429	N/A	N/A	inhibitor
DAP000774	Nitisinone	FE-0200; nitisinonum; SC 0735; 104206-65-7; Nitisinone [INN]; Orfadin (TN); Orfadin; 2-[2-nitro-4-(trifluoromethyl)benzoyl]cyclohexane-1,3-dione; nitisinona; 2-(Alpha,alpha,alpha-trifluoro-2-nitro-p-tuluoyl)-1,3-cyclohexanedione; 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione; 2-(2-Nitro-4-trifluoromethylbenzoyl)cyclohexane-1,3-dione; UNII-K5BN214699; CHEBI:50378; Nitisinone [USAN:INN]; Nitisone; 2-{[2-nitro-4-(trifluoromethyl)phenyl]carbonyl}cyclohexane-1,3-dione; Nitisinone (NTBC); Nitisinone (JAN/USAN/INN); CHEMBL1337; C14H10F3NO5; Nitisinone; BIDD:PXR0129; D05177; 1,3-Cyclohexanedione, 2-(2-nitro-4-(trifluoromethyl)benzoyl)-; AC1L3GZK; LS-56815; CID115355; DB00348	104206-65-7	115355	692349	TTDS00314	4-hydroxyphenylpyruvate dioxygenase	4HPPD;F Alloantigen;F protein;HPD;HPPDase	P49429	N/A	N/A	inhibitor
DCL000678	ACV-1	N/A	740980-24-9	N/A	N/A	TTDC00242	Neuronal acetylcholine receptor subunit alpha-10	NACHR alpha 10;Nicotinic acetylcholine receptor subunit alpha 10	Q9GZZ6	57053	ENSG00000129749	antagonist
DAP000795	Meclizine	Ru-Vert-M; Antivert; KBioGR_000473; 1-(p-Chlorobenzhydryl)-4-(m-methylbenzyl)diethylenediamine; Itinerol; KBio1_000407; KBioSS_001371; Antivert/50; 1-(p-Chlorobenzhydryl)-4-(m-methylbenzyl)piperazine; 1-[(4-chlorophenyl)(phenyl)methyl]-4-[(3-methylphenyl)methyl]piperazine; KBio3_001449; NINDS_000407; UNII-3L5TQ84570; BSPBio_000534; IDI1_000407; KBio2_003939; EINECS 209-323-3; Postafene; Sea-Legs; NSC169189; Piperazine, 1-[(4-chlorophenyl)phenylmethyl]-4-[(3-methylphenyl)methyl]-; Spectrum_000891; DB00737; (+-)-Meclizine; Piperazine, 1-((4-chlorophenyl)phenylmethyl)-4-((3-methylphenyl)methyl)-; HSDB 3113; Parachloramine; D08163; 1-(p-Chloro-alpha-phenylbenzyl)-4-(m-methylbenzyl)piperazine; meclizine; 1-[(4-chlorophenyl)-phenylmethyl]-4-[(3-methylphenyl)methyl]piperazine; Suprimal; Nevidoxine (TN); Prestwick3_000457; AB00053493; Piperazine, 1-(p-chloro-alpha-phenylbenzyl)-4-(m-methylbenzyl)-; 1-(p-Chloro-.alpha.-phenylbenzyl)-4-(m-methylbenzyl)piperazine; SPBio_002473; C07116; Histamethizine; Marex; Spectrum2_000110; Histametizyne; Dramamine II; Diadril; Meclizine Hcl; UCB 5062; KBio2_006507; Antivert/25; Neo-suprimel; U. C. B. 5062; Meclicot; Meclozina [INN-Spanish]; WLN: T6N DNTJ AYR&R DG& D1R C1; Nevidoxine; Histametizyn; Travelon; Ancolon; Spectrum4_000037; Prestwick2_000457; 36236-67-6 (hydrochloride); 1-p-Chlorobenzhydryl-4-m-methylbenzylpiperazine; Sabari; DivK1c_000407; SPBio_000100; BPBio1_000588; Bonadettes; Siguran; Navicalm; Vomissels; Monamine; CID4034; Calmonal; LS-111206; BSPBio_001949; BRN 0332002; Ravelon; NSC 169189; AC1L1H9K; Prestwick1_000457; L001136; Ancolan; Vomisseis; U.C.B. 5062; 1-((4-Chlorophenyl)phenylmethyl)-4-((3-methylphenyl)methyl)piperazine; 569-65-3; CHEMBL1623; C25H27ClN2; Neo-suprimal; UCB 5052; Neo-istafene; Meclozinum [INN-Latin]; Peremesin; AC1Q2IO5; Meclozina; Subari; Veritab; Meclozinum; Histamethine; Chiclida; UCB 170; Medivert; Meclizine [INN:BAN]; MolPort-002-069-043; Bonine; KBio2_001371; Piperazine, 1-(p-chloro-.alpha.-phenylbenzyl)-4-(m-methylbenzyl)-; Histametizine; Spectrum5_000919; 1104-22-9 (di-hydrochloride); Meclozine; Spectrum3_000485; Prestwick0_000457; Meclozine (BAN); BRD-A50311610-300-05-4	569-65-3	4034	9327	TTDS00351	Orphan nuclear receptor NR1I3	CAR;Constitutive androstane receptor;NR1I3;Nuclear receptor CAR;Orphan nuclear receptor CAR;Orphan nuclear receptor MB67	Q14994	9970	ENSG00000143257	modulator
DAP001301	Muromonab	N/A	140608-64-6	N/A	46507837	TTDS00473	T-cell surface glycoprotein CD3 epsilon chain	CD3e;T3E;T-cell surface antigen T3/Leu-4 epsilon chain	P07766	916	ENSG00000198851	binder
DCL001026	TRX4	N/A	881191-44-2	N/A	N/A	TTDS00473	T-cell surface glycoprotein CD3 epsilon chain	CD3e;T3E;T-cell surface antigen T3/Leu-4 epsilon chain	P07766	916	ENSG00000198851	antibody
DCL000587	Otelixizumab	N/A	123774-72-1	N/A	47207464	TTDS00473	T-cell surface glycoprotein CD3 epsilon chain	CD3e;T3E;T-cell surface antigen T3/Leu-4 epsilon chain	P07766	916	ENSG00000198851	antibody
DAP000266	Zaleplon	ZINC00006300; Sonata; 3'-(3-Cyanopyrazolo(1,5-a)pyrimidin-7-yl)-N-ethylacetanilide; CL 284846; CHEMBL1521; ZAL-846; D00530; AZ-007; HMS2052J11; CL284,846; zaleplon; LS-8737; Acetamide, N-(3-(3-cyanopyrazolo(1,5-a)pyrimidin-7-yl)phenyl)-N-ethyl-; TL8001114; BIDD:GT0046; 3'-(3-Cyanopyrazolo(1,5-alpha)pyrimidin-7-yl)-N-ethylacetanilide; N-[3-(3-cyanopyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-N-ethylacetamide; LS-173402; SAM001246641; MLS000759451; Sonata (TN); LJC 10846; CL 284,846; Zerene; DEA No. 2781; C17H15N5O; CHEBI:10102; AC1L1KZH; L-846; 151319-34-5; UNII-S62U433RMH; Bio-0542; SKP-1041; CID5719; AKOS000280863; N-(3-(3-Cyanopyrazolo(1,5-a)pyrimidin-7-yl)phenyl)-N-ethylacetamide; I06-0419; LJC-10846; AC-2082; DB00962; SMR000238180; CPD000238180; C07484; CL-284846; Zaleplon (JAN/USAN/INN); Zaleplon [USAN:INN]; ZAL 846; NCGC00160525-01; L 846; Acetamide, N-(3-(3-cyanopyrazolo(1,5-alpha)pyrimidin-7-yl)phenyl)-N-ethyl-; MolPort-000-883-860; L846; Zalaplon; Staccato-zaleplon	151319-34-5	5719	9687	TTDS00293	Omega 1 Benzodiazepine receptor	Omega-1 receptor situated on the alpha subunit of the GABA-A receptor complex	N/A	N/A	N/A	agonist
DAP001484	Indiplon	MolPort-005-941-775; N-methyl-N-[3-[3-(thiophene-2-carbonyl)pyrazolo[1,5-a]pyrimidin-7-yl]phenyl]acetamide; UNII-8BT63DA42E; Acetamide, N-methyl-N-(3-(3-(2-thienylcarbonyl)pyrazolo(1,5-a)pyrimidin-7-yl)phenyl)-; AC1O52E3; NBI-34060; CID6450813; NBI 34060; Indiplon; D02640; 325715-02-4; CHEMBL262075; ZINC00538650; Indiplon (USAN/INN); AC-2358	325715-02-4	6450813	17396810	TTDS00293	Omega 1 Benzodiazepine receptor	Omega-1 receptor situated on the alpha subunit of the GABA-A receptor complex	N/A	N/A	N/A	agonist
DCL000805	Flibanserin	1-(2-(4-alpha,alpha,alpha-Trifluoro-m-tolyl)-1-piperazinyl)ethyl)-2-benzimidazolinone; PDSP1_001329; 3-[2-[4-[4-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]-1H-benzimidazol-2-one; UNII-37JK4STR6Z; 1,3-Dihydro-1-(2-(4-(3-(trifluoromethyl)phenyl)-1-piperazinyl)ethyl)-2H-benzimidazol-2-one; 1-(2-(4-(alpha,alpha,alpha-Trifluoro-m-tolyl)-1-piperazinyl)ethyl)-2-benzimidazolinone; MolPort-006-666-415; CID127941; Flibanserin [USAN]; Bimt-17; ST51054021; AC1L2SWZ; C20H21F3N4O; PDSP2_001313; 1-(2-(4-(3-Trifluoromethylphenyl)piperazin-1-yl)ethyl)benzimidazol(1H)-2-one; AC-1628; Flibanserin; LS-173616; Bimt 17	167933-07-5	159594	17396748	TTDS00103	5-hydroxytryptamine 2A receptor	5-HT-2;5-HT-2A;5-HT2A receptor;5-hydroxytryptamine receptor 2A;Serotonin receptor;Serotonin receptor 2A	P28223	3356	ENSG00000102468	agonist
DPR000043	Fananserin	Fananserin (USAN/INN); CHEBI:231689; BRD-K08998509-001-01-6; Fananserin [USAN:INN]; 2H-Naphth(1,8-cd)isothiazole, 2-(3-(4-(4-fluorophenyl)-1-piperazinyl)propyl)-, 1,1-dioxide; 127625-29-0; UNII-38QJ762ET6; Fananserin; 2-(3-(4-(4-fluorophenyl)-1-piperazinyl)propyl)-2H-naphth(1,8-cd)isothiazole 1,1-dioxide; L003900; CID60785; C23H24FN3O2S; RP-62203; AC1L1TX5; LS-172687; D02656; RP 62203; 2-(3-(4-(p-Fluorophenyl)-1-piperazinyl)propyl)-2H-naphth(1,8-cd)isothiazole 1,1-dioxide; NCGC00167808-01	127625-29-0	123905	47205811	TTDS00103	5-hydroxytryptamine 2A receptor	5-HT-2;5-HT-2A;5-HT2A receptor;5-hydroxytryptamine receptor 2A;Serotonin receptor;Serotonin receptor 2A	P28223	3356	ENSG00000102468	antagonist
DCL000963	Risperidone Consta	N/A	106266-06-2	493326	38681195	TTDS00103	5-hydroxytryptamine 2A receptor	5-HT-2;5-HT-2A;5-HT2A receptor;5-hydroxytryptamine receptor 2A;Serotonin receptor;Serotonin receptor 2A	P28223	3356	ENSG00000102468	antagonist
DCL000904	Ocaperidone	Ocaperidona; 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethylpyrido[1,2-a]pyrimidin-4-one; Ocaperidona [INN-Spanish]; PDSP2_000787; 8-[2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-1-piperidyl]ethyl]-2,9-dimethyl-6,10-diazabicyclo[4.4.0]deca-2,4,8,10-tetraen-7-one; AC1L2FZW; Ocaperidonum [INN-Latin]; Ocaperidone (USAN); UNII-26HUS7139V; PDSP1_000799; AC1Q6AQQ; AR-1E5960; Ocaperidone; CID71351; MolPort-005-932-424; 129029-23-8; D02675; 4H-Pyrido(1,2-a)pyrimidin-4-one, 3-(2-(4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl)ethyl)-2,9-dimethyl-; Ocaperidonum; 3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-2,9-dimethyl-4H-pyrido(1,2-a)pyrimidin-4-one; L001106	129029-23-8	71351	17396844	TTDS00103	5-hydroxytryptamine 2A receptor	5-HT-2;5-HT-2A;5-HT2A receptor;5-hydroxytryptamine receptor 2A;Serotonin receptor;Serotonin receptor 2A	P28223	3356	ENSG00000102468	antagonist
DCL000673	Abaperidone hydrochloride	7-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propoxy]-3-(hydroxymethyl)chromen-4-one hydrochloride; Abaperidone hydrochloride; CID6918450; AC1OCFG8; FI-8602.HCl	183849-43-6	3037308	12015267	TTDS00103	5-hydroxytryptamine 2A receptor	5-HT-2;5-HT-2A;5-HT2A receptor;5-hydroxytryptamine receptor 2A;Serotonin receptor;Serotonin receptor 2A	P28223	3356	ENSG00000102468	antagonist
DCL000817	GMC-283	N/A	183140-98-9	N/A	N/A	TTDS00103	5-hydroxytryptamine 2A receptor	5-HT-2;5-HT-2A;5-HT2A receptor;5-hydroxytryptamine receptor 2A;Serotonin receptor;Serotonin receptor 2A	P28223	3356	ENSG00000102468	antagonist
DPR000162	YM-992	YM-35992; Lubazodone  hydrochloride; YM992; Morpholine, 2-(((7-fluoro-2,3-dihydro-1H-inden-4-yl)oxy)methyl)-, hydrochloride  (2S)-; (S)-2-(((7-fluoro-4-indanyl)oxy)methyl)morpholine hydrochloride; UNII-2KT2C544LR; Lubazodone HCl; D04788; Lubazodone hydrochloride; AC1L4IXB; Lubazodone  hydrochloride [USAN]; (2S)-2-[(7-fluoro-2,3-dihydro-1H-inden-4-yl)oxymethyl]morpholine hydrochloride; SM-50C; CID157918; 161178-10-5; Lubazodone hydrochloride (USAN)	N/A	N/A	N/A	TTDS00103	5-hydroxytryptamine 2A receptor	5-HT-2;5-HT-2A;5-HT2A receptor;5-hydroxytryptamine receptor 2A;Serotonin receptor;Serotonin receptor 2A	P28223	3356	ENSG00000102468	inhibitor
DCL000911	Org-23366	N/A	187673-38-7	6324648	42973616	TTDS00103	5-hydroxytryptamine 2A receptor	5-HT-2;5-HT-2A;5-HT2A receptor;5-hydroxytryptamine receptor 2A;Serotonin receptor;Serotonin receptor 2A	P28223	3356	ENSG00000102468	antagonist
DCL000727	Blonanserin	AD-5423; D01176; 132810-10-7; CHEBI:400585; 2-(4-ethylpiperazin-1-yl)-4-(4-fluorophenyl)-5,6,7,8,9,10-hexahydrocycloocta[b]pyridine; MolPort-005-942-422; I14-8575; 2-(4-Ethyl-1-piperazinyl)-4-(p-fluorophenyl)-5,6,7,8,9,10-hexahydrocycloocta(b)pyridine; CHEMBL178803; Cycloocta(b)pyridine, 2-(4-ethyl-1-piperazinyl)-4-(4-fluorophenyl)-5,6,7,8,9,10-hexahydro-; AC-1599; 2-(4-Ethyl-1-piperazinyl)-4-(4-fluorophenyl)-5,6,7,8,9,10-hexahydrocycloocta(b)pyridine; Blonanserin [INN]; PDSP2_000710; Cycloocta(b)pyridine, 2-(4-ethyl-1-piperazinyl)-4-(1-fluorophenyl)-5,6,7,8,9,10-hexahydro-; Lonasen; AD 5423; LS-57714; PDSP1_000720; Blonanserin (JAN/INN); CID125564; Blonanserin; AC1L2OS5; AKOS005145823; L001392	132810-10-7	125564	12014539	TTDS00103	5-hydroxytryptamine 2A receptor	5-HT-2;5-HT-2A;5-HT2A receptor;5-hydroxytryptamine receptor 2A;Serotonin receptor;Serotonin receptor 2A	P28223	3356	ENSG00000102468	antagonist
DPR000146	LY367265	MolPort-003-947-263; Lopac0_000648; NCGC00015600-04; LY-367,265; CHEBI:713416; NCGC00015600-02; AC1NDRET; MLS002172448; Lopac-L-2411; L 2411; CID4605800; L020228; EU-0100648; SMR001254083; CHEMBL1079460; NCGC00015600-01; NCGC00094014-01; NCGC00094014-02; L2411_SIGMA; 1-[2-[4-(6-fluoro-1H-indol-3-yl)-3,6-dihydro-1(2H)-pyridinyl]ethyl]-5,6-dihydro-1H,4H-[1,2,5]thiadiazolo[4.3.2-ij]quinoline-2,2-dioxide	N/A	N/A	N/A	TTDS00103	5-hydroxytryptamine 2A receptor	5-HT-2;5-HT-2A;5-HT2A receptor;5-hydroxytryptamine receptor 2A;Serotonin receptor;Serotonin receptor 2A	P28223	3356	ENSG00000102468	inhibitor
DCL000873	Lurasidone hydrochloride	441351-20-8; SM 13496; Lurasidone hydrochloride; Lurasidone HCl; 367514-88-3; MK-3756; D04820; SMP-13496; N-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinylmethyl)-1-cyclohexylmethyl)-2,3-bicyclo(2.2.1)heptanedicarboximide; SM-13496; Lurasidone hydrochloride (USAN)	367514-87-2	213046	47206606	TTDS00103	5-hydroxytryptamine 2A receptor	5-HT-2;5-HT-2A;5-HT2A receptor;5-hydroxytryptamine receptor 2A;Serotonin receptor;Serotonin receptor 2A	P28223	3356	ENSG00000102468	antagonist
DCL000930	Pimavanserin	CID10071196; I14-1981; Pimavanserin; 1-[(4-fluorophenyl)methyl]-1-(1-methyl-4-piperidyl)-3-[[4-(2-methylpropoxy)phenyl]methyl]urea; ST51054136; AC-5273	706779-91-1	16058810	47207478	TTDS00103	5-hydroxytryptamine 2A receptor	5-HT-2;5-HT-2A;5-HT2A receptor;5-hydroxytryptamine receptor 2A;Serotonin receptor;Serotonin receptor 2A	P28223	3356	ENSG00000102468	antagonist
DPR000003	1192U90	LS-25359; 2-Amino-N-(4-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)butyl)benzamide; 2-amino-N-[4-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]butyl]benzamide; 1192U90; PDSP1_001055; Benzamide, 2-amino-N-(4-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)butyl)-; 2-Amino-N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]butyl] benzamide; PDSP2_001039; 155289-31-9; CID127912; AC1L2SUW; L001475	155289-31-9	127912	704544	TTDS00103	5-hydroxytryptamine 2A receptor	5-HT-2;5-HT-2A;5-HT2A receptor;5-hydroxytryptamine receptor 2A;Serotonin receptor;Serotonin receptor 2A	P28223	3356	ENSG00000102468	antagonist
DAP001427	Sarpogrelate	Sarpogrelate [INN]; 4-{[1-(dimethylamino)-3-{2-[2-(3-methoxyphenyl)ethyl]phenoxy}propan-2-yl]oxy}-4-oxobutanoic acid; Sarpogrelate (INN); D08508; 125926-17-2; UNII-19P708E787; butanedioic acid, mono[2-(dimethylamino)-1-[[2-[2-(3-methoxyphenyl)ethyl]phenoxy]methyl]ethyl] ester; CID5160; AR-1I1045; AC1L1JQL; AC1Q5VS0; L000858; CHEMBL52939; STK631325; CHEBI:180532; 4-[1-(dimethylamino)-3-[2-[2-(3-methoxyphenyl)ethyl]phenoxy]propan-2-yl]oxy-4-oxobutanoic acid; LS-187118; NCGC00167489-01; 135309-80-7	125926-17-2	5160	3862730	TTDS00103	5-hydroxytryptamine 2A receptor	5-HT-2;5-HT-2A;5-HT2A receptor;5-hydroxytryptamine receptor 2A;Serotonin receptor;Serotonin receptor 2A	P28223	3356	ENSG00000102468	antagonist
DCL001019	TGBA01AD	N/A	3083-77-0	1177	48334698	TTDS00103	5-hydroxytryptamine 2A receptor	5-HT-2;5-HT-2A;5-HT2A receptor;5-hydroxytryptamine receptor 2A;Serotonin receptor;Serotonin receptor 2A	P28223	3356	ENSG00000102468	agonist
DCL000680	Adatanserin	WY 50324; N-[2-(4-pyrimidin-2-ylpiperazin-1-yl)ethyl]adamantane-1-carboxamide; Adatanserin [INN]; Tricyclo(3.3.1.1(3,7))decane-1-carboxamide, N-(2-(4-(2-pyrimidinyl)-1-piperazinyl)ethyl)-; CID130918; UNII-W5U6WQM26H; L001372; AC1L2Y9D; Adatanserin; 144966-96-1 (Monohydrochloride); 127266-56-2	127266-56-2	107778	707386	TTDS00103	5-hydroxytryptamine 2A receptor	5-HT-2;5-HT-2A;5-HT2A receptor;5-hydroxytryptamine receptor 2A;Serotonin receptor;Serotonin receptor 2A	P28223	3356	ENSG00000102468	antagonist
DCL000703	Asenapine	EINECS 265-829-4; 1H-Dibenz[2,3:6,7]oxepino[4,5-c]pyrrole, 5-chloro-2,3,3a,12b-tetrahydro-2-met; trans-5-Chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-dibenz(2,3:6,7)oxepino(4,5-c)pyrrole; PDSP2_001584; hyl-, trans-; Org-5222; 1H-Dibenz[2,3:6,7]oxepino[4,5-c]pyrrole, 5-chloro-2,3,3a,12b-tetrahydro-2-methyl-, (3aR,12bR)-rel-; Org 5222; Asenapi; 65576-45-6; Asenapine; UNII-JKZ19V908O; AC1L4SHR; 1H-Dibenz(2,3:6,7)oxepino(4,5-c)pyrrole, 5-chloro-2,3,3a,12b-tetrahydro-2-methyl-, (3aR,12bR)-rel-; PDSP1_001600; 5-chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-dibenz(2,3-6,7)oxepino(4,5-c)pyrrole; 1H-Dibenz(2,3:6,7)oxepino(4,5-c)pyrrole, 5-chloro-2,3,3a,12b-tetrahydro-2-methyl-, trans-; CHEMBL504548; [13C,2H3]-Asenipine; Asenapine [INN:BAN]; CID163091; I14-8821; 1H-Dibenz[2,3:6,7]oxepino[4,5-c]pyrrole, 5-chloro-2,3,3a,12b-tetrahydro-2-methyl-, trans-; 135882-95-0	65576-45-6	3001386	34667915	TTDS00103	5-hydroxytryptamine 2A receptor	5-HT-2;5-HT-2A;5-HT2A receptor;5-hydroxytryptamine receptor 2A;Serotonin receptor;Serotonin receptor 2A	P28223	3356	ENSG00000102468	antagonist
DCL000843	Iloperidone	L001176; Ethanone, 1-(4-(3-(4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl)propoxy)-3-methoxyphenyl)-; 4'-(3-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)propoxy)-3'-methoxyacetophenone; Iloperidone; D02666; AC1L2G0K; AKOS005146266; CID71360; Iloperidone (USAN/INN); PDSP2_000512; Zomaril; 133454-47-4; HP-873; AC1Q5GSB; I06-2110; Fiapta; LS-172870; FT-0084590; Iloperidone [USAN:INN]; PDSP1_000515; Fanapta, Zomaril, Iloperidone; MolPort-005-934-272; PDSP2_000513; C24H27FN2O4; ILO-522; AC-3482; 1-[4-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propoxy]-3-methoxyphenyl]ethanone; PDSP1_000514; S1483_Selleck; HP 873; CHEBI:113949; Fanapt; Fanapta; CHEMBL14376	133454-47-4	71360	17396835	TTDS00103	5-hydroxytryptamine 2A receptor	5-HT-2;5-HT-2A;5-HT2A receptor;5-hydroxytryptamine receptor 2A;Serotonin receptor;Serotonin receptor 2A	P28223	3356	ENSG00000102468	antagonist
DCL000999	SR46349B	(E)-but-2-enedioic acid; 4-[(E)-3-(2-dimethylaminoethyloxyamino)-3-(2-fluorophenyl)prop-2-enylidene]cyclohexa-2,5-dien-1-one; 4-((3Z)-3-(2-Dimethylaminoethyl)oxyimino-3-(2-fluorophenyl)propen-1-yl)phenol hemifumarate; 2-Propen-1-one, 1-(2-fluorophenyl)-3-(4-hydroxyphenyl)-, O-(2-(dimethylamino)ethyl)oxime, (Z,E)-, (E)-2-butenedioate (2:1) (salt); SR 46349B; CID6438382; SR-46349B; Eplivanserin fumarate; AC1O5PLB; 130580-02-8; LS-184149; SR 46349	36951-72-1	4234	49742601	TTDS00103	5-hydroxytryptamine 2A receptor	5-HT-2;5-HT-2A;5-HT2A receptor;5-hydroxytryptamine receptor 2A;Serotonin receptor;Serotonin receptor 2A	P28223	3356	ENSG00000102468	binder
DCL001042	ZD-3638	N/A	152352-44-8	447043	49718186	TTDS00103	5-hydroxytryptamine 2A receptor	5-HT-2;5-HT-2A;5-HT2A receptor;5-hydroxytryptamine receptor 2A;Serotonin receptor;Serotonin receptor 2A	P28223	3356	ENSG00000102468	binder
DCL000678	ACV-1	N/A	740980-24-9	N/A	N/A	TTDC00239	Neuronal acetylcholine receptor subunit alpha-9	NACHR alpha 9;Nicotinic acetylcholine receptor subunit alpha 9	Q9UGM1	55584	ENSG00000174343	antagonist
DCL001067	ALN-RSV01	N/A	N/A	N/A	N/A	TTDC00279	mRNA of respiratory syncytial virus nucleocapsid protein	N structural protein;NC	P15130	N/A	N/A	N/A
DAP000164	Tiagabine	tiagabine; (3R)-1-[4,4-bis(3-methylthiophen-2-yl)but-3-enyl]piperidine-3-carboxylic acid; NO-328; CID60648; Tiagabinum; 3-Piperidinecarboxylic acid, 1-(4,4-bis(3-methyl-2-thienyl)-3-butenyl)-, (R)-; NCGC00164626-01; AC-7048; N-(4,4-di(3-methylthien-2-yl)but-3-enyl)nipecotic acid; AC1L1TNE; Tiagabina; LS-114651; D08588; (3R)-1-[4,4-bis(3-methyl-2-thienyl)but-3-en-1-yl]piperidine-3-carboxylic acid; A-70569-1; CHEMBL1027; Tiagabina [INN-Spanish]; C20H25NO2S2; HSDB 7527; Gabitril (TN); NO-329; UNII-Z80I64HMNP; Tiagabine (INN); BIDD:GT0018; Tiagabine [INN]; ABBOTT-70569-1; (-)-(R)-1-(4,4-Bis(3-methyl-2-thienyl)-3-butenyl)nipecotic acid; Gabitril; CHEBI:222170; Tiagabinum [INN-Latin]; NO 329; Tiagabine [INN:BAN]; AC1Q5R43; 115103-54-3; DB00906; C07503	115103-54-3	60648	196924	TTDS00023	Gamma-aminobutyric acid uptake	GABA uptake	N/A	N/A	N/A	inhibitor
DAP001437	Vinpocetine	Prestwick0_000268; NCGC00021727-07; Eburnamenine-14-carboxylic acid, ethyl ester, (3-alpha,16-alpha)-; KBioGR_001430; ZINC19796031; Eburnamenine-14-carboxylic acid, ethyl ester, (3alpha,16alpha)-; (+)-Apovincaminic acid ethyl ester; SPBio_002335; NCGC00021727-06; TCV-3B; I06-1883; CHEBI:210947; Prestwick_963; KBio1_001367; 42971-09-5; NCGC00018204-05; BPBio1_000128; DivK1c_006423; Spectrum5_000966; Vinpocetinum; NCGC00021727-05; HMS1568F18; RGH 4405; LS-63711; Spectrum2_001529; KBioSS_001880; V 6383; cis-Apovincaminic acid ethyl ester; D01371; Ceractin; NCGC00021727-04; NCGC00018204-10; 1H-Indolo[3,2,1-de]pyrido[3,2,1-ij][1,5]naphthyridine, eburnamenine-14-carboxylic acid deriv.; V6383_SIGMA; BRD-K53318339-001-05-8; (+)-cis-Apovincaminic acid ethyl ester; CID443955; Vinpocetine (JAN/USAN/INN); SMR000058241; AY 27255; Spectrum_001400; BSPBio_000116; AC1L9FGV; Spectrum4_001075; HMS2092L06; KBio2_007016; EINECS 256-028-0; ST056350; Apovincaminate d'ethyle [French]; Vinpocetine [USAN:INN:JAN]; HMS2090J22; SPBio_001318; Spectrum3_000961; Vinpocetine-ethyl apovincaminate; Eburnamenine-14-carboxylic acid ethyl ester; AY 27,255; Ethyl (+)-apovincaminate; EU-0101257; BSPBio_002561; KBio2_004448; 3-alpha,16-alpha-Apovincaminic acid ethyl ester; Prestwick3_000268; Prestwick1_000268; KBio3_001781; Cavinton; TCV 3B; C22H26N2O2; ethyl apovincaminate, (3alpha,16alpha)-isomer; NCGC00168782-01; SPECTRUM1503115; Ultra-Vinca; MLS000069635; KBio2_001880; Bravinton; Eburnamenine-14-carboxylic acid ethyl ester;; Ethyl (+)-cis-apovincaminate; HMS1922G05; Vinpocetinum [INN-Latin]; Ethyl apovincamin-22-oate; ethyl (3alpha,16alpha)-eburnamenine-14-carboxylate; (3alpha, 16alpha)-Eburnamenine-14-carboxylic acid ethyl ester; MLS001076294; Prestwick2_000268; Apovincaminate d'ethyle; CHEMBL71752; Lopac0_001257; vinpocetine; Apovincaminic acid ethyl ester; SpecPlus_000327; MolPort-003-666-450; BRN 0900803; RGH-4405; 115986-87-3	42971-09-5	443955	7848434	TTDS00167	Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1	61 kDa Cam-PDE;Cam-PDE 1;Cam-PDE 1A;HCam-1;PDE-I	Q14123	5137	ENSG00000154678	inhibitor
DCL000086	CI-1033	S1019_Selleck; N-(4-((3-Chloro-4-fluorophenyl)amino)-7-(3-(morpholin-4-yl)propoxy)quinazolin-6-yl)prop-2-enamide; Canertinib HCl; N-[4-(3-chloro-4-fluoroanilino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]prop-2-enamide dihydrochloride; 2-Propenamide, N-(4-((3-chloro-4-fluorophenyl) amino)-7-(3-(4-morpholinyl) propoxy)-6-quinazolinyl)-, dihydrochloride; CI-1033; UNII-C78W1K5ASF; D03350; AC1L4G5R; I14-8433; 2-Propenamide, N-(4-((3-chloro-4-fluorophenyl)amino)-7-(3-(4-morpholinyl)propoxy)-6-quinazolinyl)-, dihydrochloride; EC-000.2258; 267243-28-7; CI1033; PD-0183805; 289499-45-2; CHEMBL545315; PD 183805; CHEMBL31965; CID156413; CHEBI:61399; N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(morpholin-4-yl)propoxy]quinazolin-6-yl}prop-2-enamide; LS-185636; Canertinib dihydrochloride; N-[4-(3-Chloro-4-fluorophenylamino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]acrylamide dihydrochloride; N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl]-2-propenamide dihydrochloride; Canertinib, PD-183805, CI1033, PD183805; AKOS005145818; Canertinib dihydrochloride [USAN]; Canertinib; CID156414; AC-2414; I06-1255; CI 1033; N-[4-(3-chloro-4-fluoroanilino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]prop-2-enamide; Canertinib dihydrochloride (USAN); AB1004832; Canertinib dihydrochloride; PD-183805; AC1L4G5O; UNII-ICJ93X8X90; N-(4-(3-chloro-4-fluorophenyl)amino)-7-(3-morpholin-4-yl)propoxy)quinazolin-6-yl)prop-2-enamide dihydrochloride	289499-45-2	156414	12015296	TTDC00114	Receptor protein-tyrosine kinase erbB-4	ERBB4;P180erbB4;Tyrosine kinase-type cell surface receptor HER4	Q15303	2066	ENSG00000178568	inhibitor
DAP001522	Sodium oxybate	Sodium gammahydroxybutyrate; 4-Hydroxybutyrate sodium; 4-Hydroxybutyric acid monosodium salt; C4H7O3.Na; OR28769; Xyrem; HMS2091E15; Sodium Oxybate [USAN]; Anetamin; 4-Hydroxybutyric acid sodium salt; gamma-Hydroxy sodium butyrate; WY 3478; D05866; Sodium oxybate (USAN); LS-48077; Gamma OH; GHB; gamma-Hydroxybutyrate sodium salt; Sodium Oxybutyrate; Hydroxybutyric acid monosodium salt; gamma-Hydroxybutyric acid sodium salt; Butanoic acid, 4-hydroxy-, monosodium salt; EINECS 207-953-3; 4-Hydroxybuttersaeure natriumsalz; UNII-7G33012534; EB 27; ARONIS24196; Sodium gamma-hydroxybutyrate; CID10412; Butyric acid, 4-hydroxy-, monosodium salt; 502-85-2; BUTYRIC ACID, 4-HYDROXY-, SODIUM SALT; Oxybate sodium; CHEMBL1200682; Sodium oxybate; Butanoic acid, 4-hydroxy-, sodium salt (1:1); Sodium-4-hydroxybutyrate; WY-3478; Butanoic acid, 4-hydroxy-, sodium salt; H-4040; Somsanit; gamma-Hydroxybutyrate sodium; Sodium 4-hydroxybutyrate; Butyric acid, 4-hydroxy-, monosodium salt (8CI); Xyrem (TN); H3635_SIGMA; MolPort-006-717-541; MolPort-001-766-711; gamma-Hydroxybutyric acid, sodium salt; Natrium 4-hydroxybutyrat; NSC 84223	502-85-2	5360545	47207527	TTDS00512	Gamma-hydroxybutyrate receptor	GPR172A;PAR1;PERV-A receptor 1;Protein GPR172A	Q9HAB3	79581	N/A	agonist
DAP001311	Gamma Hydroxybutyric Acid	PDSP2_000340; utyric acid monosodium salt; Sodium .gamma.-hydroxybutyrate; 4 HB; 4-Hydroxybutyrate sodium; Xyrem; Hydroxybutyric acid-; .gamma.-Hydroxybutyric acid decomposition product; Anetamin; 4-hydroxy-butyric acid; WY 3478; PDSP1_000342; gamma-Hydroxybutyric acid; Gamma OH; GHB; BRN 1720582; 4-Hydroxybutanoic acid; .Gamma.-Hydroxy sodium butyrate; .Gamma.-Hydroxybutyrate sodium; .Gamma.-Hydroxybutyric acid monosodium salt; .Gamma.-Hydroxybutyric acid, sodium salt; 4-Hydroxybutyric acid monosodium salt; 4-Hydroxy; AA3E2AF0-AB7A-4A1E-A391-199C049D7162; AC1L1V58; EB 27; SHB; Butanoic acid, 4-hydroxy-; CHEMBL1342; 4-Hydroxyalkanoic acid; 52352-27-9; 502-85-2; .gamma.-OH; HSDB 6927; 4-Hydroxybutyric acid; NSC84223; Sodium .gamma.-oxybutyrate; UNII-30IW36W5B2; Oxybate sodium; CHEBI:30830; Sodium Oxybate (4-hydroxybutanoic acid); 4-03-00-00774 (Beilstein Handbook Reference); Gamma Hydroxybutyric Acid; Somsanit; 4-Hydroxyacid; LMFA01050006; C00989; Butyric acid, 4-hydroxy-; LS-46312; .Gamma.-Hydroxy butyrate; C4H8O3; gamma-Hydroxybutanoic acid; 4-Hydroxycarboxylic acid; C01991; 591-81-1; CID10413; butyric acid sodium salt; Butanoic acid, 4-hydroxy-, monosodium salt; Butanoic acid, 4-hydroxy-, sodium salt; Butyric acid, 4-hydroxy-, monosodium salt; Butyric acid, 4-hydroxy-, sodium salt; Hydroxyb; 4-OHB; Gam-OH; Oxybate; 4-Hydroxybuttersaeure; 3-carboxypropoxy acid; oxy-n-butyric acid	591-81-1	3037032	8144929	TTDS00512	Gamma-hydroxybutyrate receptor	GPR172A;PAR1;PERV-A receptor 1;Protein GPR172A	Q9HAB3	79581	N/A	agonist
DCL000021	PRLX 93936	N/A	N/A	N/A	N/A	TTDC00061	Voltage-dependent anion-selective channel protein 3	hVDAC3;Outer mitochondrial membrane protein porin 3;VDAC3;VDAC-3	Q9Y277	7419	ENSG00000078668	activator
DAP001265	Trimethadione	Abbott Brand of Trimethadione; Trimethdione; Trimetadione [DCIT]; SPBio_002390; D00392; Petilep; Trimethadione [INN:JAN]; Tridilona; BPBio1_000517; Tioxanona; Tridione (TN); InChI=1/C6H9NO3/c1-6(2)4(8)7(3)5(9)10-6/h1-3H3; CHEBI:131804; Epidione; T0781_SIGMA; NSC 15799; C6H9NO3; 3,5,5-Trimethyl-1,3-oxazolidine-2,4-dione; Convexina; Pitmal; Tridone; AC1L1KNK; Minoaleuiatin; Trioxanona; NSC15799; NCGC00016383-01; Prestwick1_000515; 3,5,5-TRIMETHYL-OXAZOLIDINE-2,4-DIONE; CHEMBL695; Trimethinum; Trimetin; Trimethin; Prestwick2_000515; ZINC01530710; EINECS 204-845-8; Trimedal; Absentol; IRYJRGCIQBGHIV-UHFFFAOYSA-; Epidone; Convenixa; 3,5,5-Trojmetylooksazolidyno-2,4-dion [Polish]; Triozanona; UNII-R7GV3H6FQ4; Prestwick_815; trimethadione; Epixal; AC1Q3XZF; D014293; Trimethadion; Absetil; BRN 0121627; SMR000499583; Prestwick0_000515; Trimethadione (JP15/INN); Edion; Trimedone; HMS1569H11; Mino-Aleviatin; Tromedone; Petidon; T0781_FLUKA; Trimetadione; Neo-Absentol; CID5576; Prestwick3_000515; CAS-127-48-0; Tredione; Minoaleviatin; Trimetadiona; 3,5,5-Trimethyl-2,4-oxazolidinedione; WLN: T5OVNV EHJ C1 E1 E1; HMS2093D10; 3,5,5,-Trimethyloxazolidine-2,4-dione; Trimethadionum [INN-Latin]; MolPort-001-846-840; BSPBio_000469; A 2297; Troxidone; 127-48-0; Trimethadionum; 3,5,5-Trojmetylooksazolidyno-2,4-dion; Tridion; Trioksal; Tridione; NCGC00016383-02; LS-7736; MLS001076685; Etydion; Ptimal; Trilidona; 3,3,5-Trimethyl-2,4-diketooxazolidine; 2,4-OXAZOLIDINEDIONE, 3,5,5-TRIMETHYL-; Trimetadiona [INN-Spanish]; Petimalin; DB00347; Tricione; Petidion; NSC169503	127-48-0	5576	7847458	TTDS00161	Voltage-dependent T-type calcium channel alpha-1G subunit	Cav;Cav3.1c;NBR13;Voltage-dependent T-type calcium channel;Voltage-gated calcium channel alpha subunit Cav3.1	Q9P0X4	8911	ENSG00000100346	blocker
DCL000530	Gabapentin enacarbil	Cyclohexaneacetic acid, 1-((((1-(2-methyl-1-oxopropoxy)ethoxy)carbonyl)amino)methyl)-; XP-13512; GSK-1838262; Solzira; UNII-75OCL1SPBQ; Gabapentin enacarbil; XP 13512; D09539; XP13512; 478296-72-9; XP-053; 791632-57-0; ASP-8825; CID9883933; Horizant; Gabapentin enacarbil (JAN/USAN/INN)	N/A	9883933	22395865	TTDS00161	Voltage-dependent T-type calcium channel alpha-1G subunit	Cav;Cav3.1c;NBR13;Voltage-dependent T-type calcium channel;Voltage-gated calcium channel alpha subunit Cav3.1	Q9P0X4	8911	ENSG00000100346	modulator
DAP001266	Paramethadione	5-Ethyl-3,5-dimethyl-1,3-oxazolidine-2,4-dione; Parametadione [DCIT]; Paramethadione (INN); 2,4-Oxazolidinedione, 5-ethyl-3,5-dimethyl-; D00495; Paradione (TN); MolPort-003-666-699; Parametadione; BRN 0127715; Paramethadione [INN:BAN]; LS-100334; Parametadiona [INN-Spanish]; EINECS 204-098-8; Isoethadione; Paramethadione [BAN:INN]; AC1L1QNH; A 348; Paradione; CID8280; 4-27-00-03255 (Beilstein Handbook Reference); DB00617; HSDB 3245; C07411; PARAMETHADIONE; Paramethadionum [INN-Latin]; C7H11NO3; 115-67-3; Paramethadionum; UNII-Z615FRW64N; Parametadiona; 5-Ethyl-3,5-dimethyl-2,4-oxazolidinedione; 3,5-Dimethyl-5-ethyloxazolidine-2,4-dione; CHEMBL1100	115-67-3	8280	9615	TTDS00161	Voltage-dependent T-type calcium channel alpha-1G subunit	Cav;Cav3.1c;NBR13;Voltage-dependent T-type calcium channel;Voltage-gated calcium channel alpha subunit Cav3.1	Q9P0X4	8911	ENSG00000100346	blocker
DCL000590	PD-200390	N/A	148047-03-4	188931	33510541	TTDS00161	Voltage-dependent T-type calcium channel alpha-1G subunit	Cav;Cav3.1c;NBR13;Voltage-dependent T-type calcium channel;Voltage-gated calcium channel alpha subunit Cav3.1	Q9P0X4	8911	ENSG00000100346	modulator
DAP000526	Ethosuximide	Piknolepsin; Parke Davis Brand of Ethosuximide; Pemal; Emeside; 3-Ethyl-3-methyl-2,5-pyrrolidinedione; NSC 64013; Ethosuximidum [INN-Latin]; gamma-Methyl-gamma-ethyl-succinimide; Spectrum3_000944; CI-366; Faes Brand of Ethosuximide; E7138_SIGMA; KBio3_002008; NCGC00093923-04; 2,5-Pyrrolidinedione, 3-ethyl-3-methyl-, (+-)-; Ethosuxide; CN-10,395; HSDB 1119; Faes, Etosuximida; EU-0100532; KBio2_004433; E 7138; Zarondan-Saft; Ethosuccimid; Pyknole.psi.num; D00539; SPBio_001465; Zarontin; Zarondan; Ronton; Ethosuximide [USAN:INN:BAN:JAN]; 2,5-Pyrrolidinedione, 3-ethyl-3-methyl-; CID3291; EINECS 201-048-7; Ethosuccimide; Thilopemal; Etosuccimide; NCGC00015418-02; Simatin; Wernigerode Brand of Ethosuximide; alpha-Methyl-alpha-ethylsuccinimide; MolPort-003-666-417; Suxilep; IDI1_000218; 2-Methyl-2-ethylsuccinimide; E0746; Ethosuximide (JP15/USP/INN); Suxin; KBio2_007001; Thetamid; Petinimid; AC1L1FLN; KBioGR_001342; BPBio1_000033; Aethosuximide; Zarontin (TN); CHEBI:4887; Suximal; Spectrum_001385; KBioSS_001865; Pfizer Brand of Ethosuximide; Aethosuccimidum; Desitin Brand of Ethosuximide; NCGC00093923-03; 3-Methyl-3-ethylpyrrolidine-2,5-dione; 3-Ethyl-3-methylpyrroline-2,5-dione; Capitus; Ethylmethylsuccimide; Suksilep; LS-147585; Prestwick1_000165; KBio1_000218; CHEMBL696; Prestwick3_000165; Ethymal; C.I. 366; Succimal; Pentinimid; KBio2_001865; .alpha.-Ethyl-.alpha.-methylsuccinimide; ST51037248; Suxinutin; Warner Lambert Brand of Ethosuximide; Etosuximida Faes; Asamid; Ethosuccinimide; Etomal; Aethosuximide [German]; Petnidan; HMS2092D20; Etosuximida; Cl 366; HMS1921L14; D005013; .gamma.-Methyl-.gamma.-ethylsuccinimide; Epileo Petit MAL; Piknole.psi.n; Spectrum2_001483; Lopac0_000532; BSPBio_000029; NINDS_000218; gamma-ethyl-gamma-methyl-succinimide; ethosuximide; UNII-5SEH9X1D1D; H-490; NCGC00093923-02; Pemalin; Succimitin; CI 366; Fortbenton Brand of Ethosuximide; Etosuximide; WLN: T5VMVTJ D2 D1; Atysmal; Succinimide, 2-ethyl-2-methyl-; H 940; Etosuximid; NCGC00093923-01; PM-671; AC1Q2SOO; SPECTRUM1502196; LAB Brand of Ethosuximide; Jenapharm Brand of Ethosuximide; Etosuccimide [DCIT]; 3-Ethyl-3-methylpyrrolidine-2,5-dione; 3-Ethyl-3-methyl-2,5-pyrrolidinedione; .Alpha.-Ethyl-.alpha.-methylsuccinimide; .Gamma.-Methyl-.gamma.-ethylsuccinimide; 2, 5-Pyrrolidinedione, 3-ethyl-3-methyl-; 3-Ethyl-3-methyl-2, 5-pyrrolidinedion; Zaraondan; NCIOpen2_000014; Simatin(E); 2-Ethyl-2-methylsuccinimide; Zarodan; (+-)-2-Ethyl-2-methylsuccinimide; Etosuximida [INN-Spanish]; NCGC00015418-06; PM 671; C07505; e; 3-Ethyl-3-methylpyrroline-2,5-dione; Succinimide, 2-ethyl-2-methyl-; CHEBI:131811; CN-10395; SPBio_001950; Ethosuximidum; Katwijk Brand of Ethosuximide; NSC64013; 77-67-8; 3-Methyl-3-ethylsuccinimide; Pyknolepsinum; Prestwick0_000165; Peptinimid; HMS1568B11; Zartalin; N-Ethyl methylsuccinimide; Prestwick2_000165; BRD-A99633051-001-04-7; Mesentol; DivK1c_000218; 5-21-09-00595 (Beilstein Handbook Reference); Spectrum5_001073; Prestwick_611; DB00593; United Drug Brand of Ethosuximide; AB00052288; 3-Ethyl-3-methylsuccinimide; Spectrum4_001051; Warner-Lambert Brand of Ethosuximide; alpha-Ethyl-alpha-methylsuccinimide; HMS500K20; BRN 0117054	77-67-8	3291	7847605	TTDS00161	Voltage-dependent T-type calcium channel alpha-1G subunit	Cav;Cav3.1c;NBR13;Voltage-dependent T-type calcium channel;Voltage-gated calcium channel alpha subunit Cav3.1	Q9P0X4	8911	ENSG00000100346	blocker
DAP001253	Methsuximide	N-Methyl-alpha-methyl-alpha-phenylsuccinimide; Mesuximidum [INN-Latin]; 1,3-Dimethyl-3-phenyl-pyrrolidin-2,5-dione; DB05246; UNII-0G76K8X6C0; alpha-Methylphensuximide; 2,5-Pyrrolidinedione,1,3-dimethyl-3-phenyl-, (+-)-; 2,5-Pyrrolidinedione,1,3-dimethyl-3-phenyl-; (+-)-N,2-Dimethyl-2-phenylsuccinimide; 1,3-Dimethyl-3-phenylsuccinimide; Mesuximidum; BRN 0168315; alpha-Methyl-alpha-phenyl N-methyl succinimide; MolPort-003-666-689; 1,3-dimethyl-3-phenylpyrrolidine-2,5-dione; PM 396; LS-147580; AC1Q3XU0; 1,3-Dimethyl-3-phenyl-2,5-pyrrolidinedione; CID6476; AC1L1MM3; Metosuccimmide; Methsuximid; Mesuximide (INN); Metosuccimmide [DCIT]; C12H13NO2; AC-15963; mesuximid; METHSUXIMIDE; Mesuximide; HSDB 3124; Mesuximida [INN-Spanish]; Methsuximide [BAN]; Celontin; (RS)-1,3-Dimethyl-3-phenyl-2,5-pyrrolidindion; Celontin (TN); 5-21-11-00209 (Beilstein Handbook Reference); Mesuximida; 77-41-8; Methsuximide (USP); Petinutin; D00404; CHEMBL697; 2,5-Pyrrolidinedione, 1,3-dimethyl-3-phenyl-; EINECS 201-026-7; Succinimide, N,2-dimethyl-2-phenyl-; 1,3-Dimethyl-3-phenyl-2,5-dioxopyrrolidine; Metsuccimide; N,2-Dimethyl-2-phenylsuccinimide	77-41-8	6476	10394084	TTDS00161	Voltage-dependent T-type calcium channel alpha-1G subunit	Cav;Cav3.1c;NBR13;Voltage-dependent T-type calcium channel;Voltage-gated calcium channel alpha subunit Cav3.1	Q9P0X4	8911	ENSG00000100346	blocker
DAP001264	Pregabalin	C8H17NO2; TL8001062; UNII-55JG375S6M; (S)-3-(Aminomethyl)-5-methylhexanoic acid; (R-)-3-isobutyl GABA; S1731_Selleck; SBB062901; (3S)-3-(aminomethyl)-5-methylhexanoic acid; TOS-BB-0910; 148553-50-8; 121GE001; HSDB 7530; C080245; CI 1008; (S+)-3-isobutyl GABA; CID5486971; Pregabalin [USAN]; Hexanoic acid, 3-(aminomethyl)-5-methyl-, (3S)-; AC1NUP03; CHEBI:236161; CI-1008; AKOS005145504; MolPort-000-861-733; Pregablin; DB00230; Lyrica (TN); CHEMBL1059; LS-75191; AC-1158; Pregabalin (JAN/USAN/INN); FT-0080911; Pregabalin; Hexanoic acid, 3-(aminomethyl)-5-methyl-, (S)-; 3-isobutyl GABA; PD 144723; Lyrica; D02716; PD-144723	148553-50-8	5486971	702621	TTDS00161	Voltage-dependent T-type calcium channel alpha-1G subunit	Cav;Cav3.1c;NBR13;Voltage-dependent T-type calcium channel;Voltage-gated calcium channel alpha subunit Cav3.1	Q9P0X4	8911	ENSG00000100346	modulator
DAP000040	Verapamil	HMS1791L15; 2-(3,4-Dimethoxyphenyl)-5-((2-(3,4-dimethoxyphenyl)ethyl)(methyl)amino)-2-isopropylpentanenitrile, (+/-)-; 5-[(3,4-Dimethoxyphenethyl)methylamino]-2-(3,4-dimethoxyphenyl)-2-isopropylvaleronitrile; NCI60_020143; Spectrum2_001740; nchembio.79-comp5; Isoptimo; nchembio.368-comp2; 2-(3,4-dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethyl-methylamino]-2-propan-2-ylpentanenitrile; LS-174; Verapamilum; Verapamilo; Cordilox; (+/-)-VERAPAMIL; Benzeneacetonitrile, alpha-(3-((2-(3,4-dimethoxyphenyl)ethyl)methylamino) propyl)-3,4-dimethoxy-alpha-(1-methylethyl)-; 52-53-9; KBio3_000465; KBio2_002801; 2-(3,4-Dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethyl-methyl-amino]-2-(1-methylethyl) pentanenitrile; Valeronitrile, 5-((3,4-dimethoxyphenethyl)methylamino)-2-(3,4-dimethoxyphenyl)-2-isopropyl-; Verapamil [USAN:INN:BAN]; C27H38N2O4; CP-16533-1; NINDS_000399; D02356; KBio2_000233; Dilacoran; KBioGR_000233; NCGC00024710-04; Benzeneacetonitrile, .alpha.-[3-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]propyl]-3,4-dimethoxy-.alpha.-(1-methylethyl)-; CHEBI:9948; Verapamil (USAN/INN); BRD-A09533288-003-05-6; Veracim; KBio2_007479; CID2520; NSC272366; Verapamilum [INN-Latin]; Isoptin; Prestwick3_000141; KBioSS_000233; Iproveratril; L001330; HMS2089H17; Bio1_001403; Bio2_000713; alpha-(3-((2-(3,4-Dimethoxyphenyl)ethyl)-methylamino)propyl)-3,4-dimethoxy-alpha-(1-methylethyl)benzeneacetonitrile; DivK1c_000399; KBio2_002343; AB00053495; Verapamil [USAN:BAN:INN]; Prestwick1_000141; Veraptin; alpha-((N-Methyl-N-homoveratryl)-gamma-aminopropyl)-3,4-dimethoxyphenylacetonitrile; 5-((3,4-Dimethoxyphenethyl)methylamino)-2-(3,4-dimethoxyphenyl)-2-isopropylvaleronitrile; Bio-0754; NCGC00024710-07; Benzeneacetonitrile, alpha-(3-((2-(3,4-dimethoxyphenyl)ethyl)methylamino)propyl)-3,4-dimethoxy-alpha-(1-methylethyl)-, (+-)-; CCRIS 6749; BPBio1_000268; Isotopin; KBio2_005369; Calcan; I06-0063; NCGC00016083-14; Calan; UNII-CJ0O37KU29; Verexamil; MolPort-000-721-258; KBioGR_001372; CHEMBL6966; NCGC00024710-05; BRD-A09533288-001-02-7; SPBio_001820; SPBio_002181; HMS1989L15; D-365; EINECS 200-145-1; Prestwick2_000141; DB00661; Verapamilo [INN-Spanish]; 56949-77-0; KBioGR_002343; 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile; cMAP_000023; Benzeneacetonitrile, alpha-(3-((2-(3,4-dimethoxyphenyl)ethyl)methylamino)propyl)-3,4-dimethoxy-alpha-(1-methylethyl)-; STK538085; KBio2_004911; FT-0080127; (1)-3-(3,4-Dimethoxyphenyl)-6-((5,6-dimethoxyphenethyl)methylamino)hexane-3-carbonitrile; NCGC00024710-08; BSPBio_001513; Prestwick0_000141; IDI1_033983; KBioSS_002346; Spectrum5_001786; KBio1_000399; C07188; EINECS 260-462-6; Spectrum4_000906; Vasolan; KBio3_002823; IDI1_000399; AC-16016; AC1L1DV5; BSPBio_002358; Lopac0_001237; (+-)-Verapamil; KBio3_000466; Drosteakard; NCGC00024710-09; NCGC00024710-06; Arpamyl; Dexverapamil; alpha-Isopropyl-alpha-((N-methyl-N-homoveratryl)-gamma-aminopropyl)-3,4-dimethoxyphenylacetonitrile; BSPBio_000242; Bio1_000914; VERAPAMIL; Bio2_000233; Bio1_000425	52-53-9	2520	7849415	TTDS00161	Voltage-dependent T-type calcium channel alpha-1G subunit	Cav;Cav3.1c;NBR13;Voltage-dependent T-type calcium channel;Voltage-gated calcium channel alpha subunit Cav3.1	Q9P0X4	8911	ENSG00000100346	blocker
DCL000341	Mibefradil	CHEBI:172035; AC1L1TOE; CID60663; DB01388; (1S,2S)-2-(2-{[3-(1H-benzimidazol-2-yl)propyl](methyl)amino}ethyl)-6-fluoro-1-(1-methylethyl)-1,2,3,4-tetrahydronaphthalen-2-yl (methyloxy)acetate; C29H38FN3O3; CHEMBL45816; C07222; 2-(2-((3-(1H-Benzimidazol-2-yl)propyl)methylamino)ethyl)-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl methoxyacetate (1S-cis)-; BRD-K09549677-300-01-8; Acetic acid, methoxy-, 2-(2-((3-(1H-benzimidazol-2-yl)propyl)methylamino)ethyl)-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester, (1S-cis)-; AC1Q4NDV; [(1S,2S)-2-[2-[3-(1H-benzimidazol-2-yl)propyl-methylamino]ethyl]-6-fluoro-1-propan-2-yl-3,4-dihydro-1H-naphthalen-2-yl] 2-methoxyacetate; NCGC00161420-01; NCGC00161420-03; Lopac-M-5441; Mibefradil; (1S-cis)-2-(2-((3-(1H-Benzimidazol-2-yl)propyl)methylamino)ethyl)-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl methoxyacetate; NCGC00015683-01; 116644-53-2; 116666-63-8 (dihydrochloride); Mibefradil (INN); Lopac0_000748; LS-172325; NCGC00161420-04; Mibefradil [INN:BAN]; (1s,2s)-2-[2-[[3-(2-benzimidazolyl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-isopropyl-2-naphthyl methoxyacetate; D08217	116644-53-2	60663	9431	TTDS00161	Voltage-dependent T-type calcium channel alpha-1G subunit	Cav;Cav3.1c;NBR13;Voltage-dependent T-type calcium channel;Voltage-gated calcium channel alpha subunit Cav3.1	Q9P0X4	8911	ENSG00000100346	blocker
DPR000169	ALN-PCS	N/A	N/A	N/A	N/A	TTDR01439	mRNA of proprotein convertase subtilisin/kexin type 9	mRNA of Neural apoptosis-regulated convertase 1;mRNA of NARC-1;mRNA of Proprotein convertase 9;mRNA of PC9;mRNA of Subtilisin/kexin-like protease PC9;mRNA of PCSK9	Q8NBP7	255738	ENSG00000169174	N/A
DPR000173	BMS-PCSK9	N/A	N/A	N/A	N/A	TTDR01439	mRNA of proprotein convertase subtilisin/kexin type 9	mRNA of Neural apoptosis-regulated convertase 1;mRNA of NARC-1;mRNA of Proprotein convertase 9;mRNA of PC9;mRNA of Subtilisin/kexin-like protease PC9;mRNA of PCSK9	Q8NBP7	255738	ENSG00000169174	antisense
DCL000404	GSK1144814	N/A	N/A	897403	1144814	TTDC00117	Nigral tachykinin NK(3) receptor	Neurokinin B receptor;Neurokinin-3 receptor;Neuromedin K receptor;NK-3 receptor;NK-3R;NKR;Tachykinin receptor 3	P29371	6870	ENSG00000169836	antagonist
DCL000221	SB222200	Tocris-1393; 3-methyl-2-phenyl-N-[(1S)-1-phenylpropyl]quinoline-4-carboxamide; NCGC00025140-01; Lopac0_000100; CID6604009; CHEMBL10284; SB 222200; 174635-69-9; 4-Quinolinecarboxamide, 3-methyl-2-phenyl-N-(1-phenylpropyl)-, (S)-; S 5192; MLS000862200; C109112; N-(alpha-ethylbenzyl)-3-methyl-2-phenylquinoline-4-carboxamide; AC1O7G71; NCGC00025140-03; NCGC00025140-04; S5192_SIGMA; CHEBI:107077; (S)-3-Methyl-2-phenyl-N-(1-phenylpropyl)-4-quinolinecarboxamide; Lopac-S-5192; NCGC00015956-01; 4-Quinolinecarboxamide, 3-methyl-2-phenyl-N-((1S)-1-phenylpropyl)-; EU-0100100; SMR000326963; SB-222200; MLS001056793; NCGC00025140-02	174635-69-9	N/A	N/A	TTDC00117	Nigral tachykinin NK(3) receptor	Neurokinin B receptor;Neurokinin-3 receptor;Neuromedin K receptor;NK-3 receptor;NK-3R;NKR;Tachykinin receptor 3	P29371	6870	ENSG00000169836	antagonist
DCL000241	Talnetant	174636-32-9; AC1L325X; PDSP1_001725; L001526; SB-223412; PDSP2_001708; UNII-CZ3T9T146K; LS-185659; Talnetant; CHEBI:106596; N-((S)-alpha-Ethylbenzyl)-3-hydroxy-2-phenylcinchoninamide; SB 223412; CID133090; CHEMBL275544; N-(alpha-Ethylbenzyl)-3-hydroxy-2-phenylquinoline-4-carboxamide; 4-Quinolinecarboxamide, 3-hydroxy-2-phenyl-N-(1-phenylpropyl)-, (S)-; 4-Quinolinecaeboxamide, 3-hydroxy-2-phenyl-N-((1S)-1-phenylpropyl)-; Talnetant [INN]; 3-hydroxy-2-phenyl-N-(1-phenylpropyl)quinoline-4-carboxamide	174636-32-9	133090	709393	TTDC00117	Nigral tachykinin NK(3) receptor	Neurokinin B receptor;Neurokinin-3 receptor;Neuromedin K receptor;NK-3 receptor;NK-3R;NKR;Tachykinin receptor 3	P29371	6870	ENSG00000169836	antagonist
DCL000191	Osanetant	N-(1-(3-((R)-1-Benzoyl-3-(3,4-dichlorophenyl)-3-piperidyl)propyl)-4-phenyl-4-piperidyl)-N-methylacetamide; PDSP2_001479; SR-142801; Osanetant [INN]; CHEMBL346178; Acetamide, N-(1-(3-(1-benzoyl-3-(3,4-dichlorophenyl)-3-piperidinyl)propyl)-4-phenyl-4-piperidinyl)-N-methyl-, (R)-; SR-142806; CHEBI:354086; LS-187093; N-(1-(3-((3R)-1-benzoyl-3-(3,4-dichlorophenyl)-3-piperidinyl)propyl)-4-phenyl-4-piperidinyl)-N-methylacetamide; n-(1-{3-[(3r)-1-benzoyl-3-(3,4-dichlorophenyl)piperidin-3-yl]propyl}-4-phenylpiperidin-4-yl)-n-methylacetamide; SB-236984; LS-185126; I06-1312; AC1Q3O5K; PDSP1_001495; CID219077; N-[1-[3-[(3R)-1-benzoyl-3-(3,4-dichlorophenyl)piperidin-3-yl]propyl]-4-phenylpiperidin-4-yl]-N-methylacetamide; AR-1J7075; SR-14280; AC1L560J; Osanetant	160492-56-8	219077	791618	TTDC00117	Nigral tachykinin NK(3) receptor	Neurokinin B receptor;Neurokinin-3 receptor;Neuromedin K receptor;NK-3 receptor;NK-3R;NKR;Tachykinin receptor 3	P29371	6870	ENSG00000169836	antagonist
DCL000759	CS-003	N/A	N/A	N/A	N/A	TTDC00117	Nigral tachykinin NK(3) receptor	Neurokinin B receptor;Neurokinin-3 receptor;Neuromedin K receptor;NK-3 receptor;NK-3R;NKR;Tachykinin receptor 3	P29371	6870	ENSG00000169836	antagonist
DCL000335	Agomelatine	S-20098; N-(2-(7-Methoxynaphth-1-yl)ethyl)acetamide; S 20098; AGO-178; ZINC00005608; C15H17NO2; D02578; Valdoxan; 138112-76-2; AGO178; N-(2-(7-methoxy-1-naphthyl)ethyl)acetamide; Thymanax; CID82148; AC-3395; S1243_Selleck; N-[2-(7-methoxynaphthalen-1-yl)ethyl]acetamide; Valdoxan (TN); AKOS005145681; L000528; PDSP2_001767; PDSP1_001784; C084711; S20098; PDSP2_001289; AGO 178; Agomelatine [INN]; UNII-137R1N49AD; N-(2-(7-Methoxy-1-naphthalenyl)ethyl)acetamide; CHEBI:108209; AC1L32UM; PDSP1_001305; I14-1072; CHEMBL10878; Valdoxan, Melitor, Thymanax, Agomelatine; Agomelatine (INN); LS-9830; Agomelatine; Acetamide, N-(2-(7-methoxy-1-naphthalenyl)ethyl)-	138112-76-2	82148	17396749	TTDS00393	Melatonin receptor type 1A	N/A	P48039	4543	ENSG00000168412	agonist
DCL000324	LY-156735	Acetamide, N-(2-(6-chloro-5-methoxy-1H-indol-3-yl)propyl)-, (R)-; CID219018; AC1L55WJ; LY 156735; MolPort-005-943-156; 1551-16-2; n-[(2r)-2-(6-chloro-5-methoxy-1h-indol-3-yl)propyl]acetamide; ZINC00021620; AR-1K2942; LY-156735; Acetamide, N-((2R)-2-(6-chloro-5-methoxy-1H-indol-3-yl)propyl)-	118702-11-7	219018	791553	TTDS00393	Melatonin receptor type 1A	N/A	P48039	4543	ENSG00000168412	agonist
DCL000329	VEC-162	N/A	135354-02-8	128919	49658806	TTDS00393	Melatonin receptor type 1A	N/A	P48039	4543	ENSG00000168412	agonist
DAP000429	Melatonin	NCGC00090727-02; CCRIS 3472; KBio3_002226; WLN: T56 BMJ D2MV1 GO1; A4039/0172195; NCGC00090727-03; NCGC00090727-06; KBio1_000353; HSCI1_000400; N-[2-(5-Methoxy-1H-indol-3-yl)-ethyl]-acetamide; HSDB 7509; 5-22-12-00042 (Beilstein Handbook Reference); BIDD:ER0618; Melovine; Prestwick2_000458; PREVENTION 1 (MELATONIN) (PREVENTION 1); MolPort-000-737-883; D008550; NCGC00090727-07; EINECS 200-797-7; MLS001240204; AC1Q4F1X; Revital Melatonin; PREVENTION 2 (MELATONIN); Melatonin; NCGC00015680-13; D08170; ML1; AKOS000276269; HMS501B15; N-[2-(5-methoxyindol-3-yl)ethyl]acetamide; DivK1c_000353; SMR000326666; Circadin; KBioSS_000665; Acetamide, N-(2-(5-methoxy-1H-indol-3-yl)ethyl)-; PREVENTION 3 (MELATONIN); Nature'S Harmony; Spectrum2_001344; NINDS_000353; M1105; AB00053279; BRD-K97530723-001-07-6; MLS000859594; KBio2_003233; NMR/14327425; Melatonex; SPBio_002475; SDCCGMLS-0065812.P002; Night Rest; CHEBI:16796; KBioGR_000591; N-(2-(5-Methoxyindol-3-yl)ethyl)acetamide; EU-0100787; Melapure; AC1Q4F1W; Mela-T; CHEMBL45; NCGC00015680-01; BAS 01281092; NSC 113928; N-acetyl-5-methoxy-tryptamine; NCGC00090727-04; HMS1921E04; HMS1569K18; Acetamide, N-[2-(5-methoxy-1H-indol-3-yl)ethyl]- (9CI); PREVENTION 5 (MELATONIN); SPECTRUM1500690; BRN 0205542; Prestwick_312; Melatonina; C01598; I10-0345; DB08189; 0E2B08C1-B325-45B1-8939-6F9081EFDFA4; SPBio_001527; NSC56423; NCGC00015680-06; KBio2_000665; Acetamide, N-(2-(5-methoxyindol-3-yl)ethyl)-; M5250_SIGMA; PREVENTION 4 (MELATONIN); M-1200; Melatol; CID896; Posidorm; HMS1380B22; Bio-0635; Sleep Right; MLS001055382; Spectrum4_000066; L001261; Prestwick0_000458; S1204_Selleck; NCI60_004378; M-1250; ChemDiv2_003916; Oprea1_104553; NCGC00090727-09; NCGC00015680-02; DB01065; SMP2_000309; Acetamide, N-[2-(5-methoxyindol-3-yl)ethyl]- (6CI,8CI); CAS-73-31-4; LS-1623; IDI1_002631; Melatonina (TN); KBio2_005801; Prestwick1_000458; Acetamide, N-[2-(5-methoxyindol-3-yl)ethyl]-; N-Acetyl-5-methoxytryptamine; Rx Balance; Acetamide, N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-; STK386880; BPBio1_000590; MT6; Melatonine; Vivitas; N-(2-(5-Methoxy-1H-indol-3-yl)ethyl)acetamide; NCGC00090727-05; Lopac0_000787; BSPBio_003006; Prestwick3_000458; IDI1_000353; Spectrum5_001745; NCGC00090727-01; NCGC00015680-03; I05-0076; Spectrum_000185; Oprea1_814234; ZINC00057060; HMS2089F09; Acetamide, N-(2-(5-methoxy-1H-indol-3-yl)ethyl)- (9CI); Spectrum3_001393; BSPBio_000536; 73-31-4; N-[2-(5-Methoxy-1H-indol-3-yl)ethyl]acetamide; NCGC00090727-08; UNII-JL5DK93RCL; 4-ACETAMIDO-4'-ISOTHIO-CYANATOSTILBENE-2,2'-DISULFONIC ACID; Pineal Hormone; IN1244; Melatonex, Melatonin; AC1L1A9Q; SDCCGMLS-0065812.P001; NSC113928; M 5250; 5-Methoxy-N-acetyltryptamine; Lopac-M-5250; TNP00300; Acetamide, {N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-}; Acetamide, {N-[2-(5-methoxyindol-3-yl)ethyl]-}; N-(2-(5-Methoxy-1H-indol-3-yl)ethyl)acetamide	73-31-4	896	149246	TTDS00393	Melatonin receptor type 1A	N/A	P48039	4543	ENSG00000168412	binder
DAP000070	Ramelteon	LS-187367; I06-1429; Ramelteon (JAN/USAN/INN); Ramelteon; DB00980; Ramelteon [USAN]; D02689; CHEMBL1218; (-)-N-(2-(((8S)-1,6,7,8-Tetrahydro-2H-indeno(5,4-b)furan-8-yl)ethyl)propanamide; CID208902; (S)-N-(2-(1,6,7,8-tetrahydro-2H-indeno-(5,4)furan-8-yl)ethyl)propionamide; Rozerem, TAK-375, Ramelteon; S1259_Selleck; UNII-901AS54I69; AC-5275; C495910; AC1Q5OQL; AR-1K4568; HMS1922H18; n-{2-[(8s)-1,6,7,8-tetrahydro-2h-indeno[5,4-b]fur-8-yl]ethyl}propanamid; 196597-26-9; LS-186569; TAK-375; CHEBI:321962; BRD-K28761891-001-01-0; AC1L4LKM; SPECTRUM1505817; Propanamide, N-(2-((8S)-1,6,7,8-tetrahydro-2H-indeno(5,4-b)furan-8-yl)ethyl)-; Rozerem; HMS2093F12; BSPBio_002318; MolPort-003-666-751; ZINC03960338; Rozerem (TN); N-[2-[(8S)-2,6,7,8-tetrahydro-1H-cyclopenta[e][1]benzofuran-8-yl]ethyl]propanamide	196597-26-9	208902	783731	TTDS00393	Melatonin receptor type 1A	N/A	P48039	4543	ENSG00000168412	agonist
DCL000860	Laquinamod	N/A	248282-07-7	N/A	N/A	TTDC00225	Macrophage inflammatory protein-2-alpha	CXCL2;Gro-beta;Growth regulated protein beta;Macrophage inflammatory protein 2;MIP2-alpha	P19875	2920	ENSG00000081041	modulator
DAP001219	Aliskiren	Rasilez; D03208; CID5493444; Aliskiren (USAN/INN); Benzeneoctanamide, .delta.-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-.gamma.-hydroxy-4-methoxy-3-(3-methoxypropoxy)-.alpha.,.zeta.-bis(1-methylethyl)-, (.alpha.S,.gamma.S,.delta.S,.zeta.S)-; Rasilez (TN); SPP 100; C41; CHEMBL1639; |(2S,4S,5S,7S)-N-(2-Carbamoyl-2-methylpropyl)-5-amino-4-hydroxy-2,7-diisopropyl-8-[4-methoxy-3-(3-methoxypropoxy)phenyl]octanamide; Aliskiren; AC1NUU28; DB01258; (2S,4S,5S,7S)-5-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-8-methyl-2-(propan-2-yl)nonanamide; (2S,4S,5S,7S)-5-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-7-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-8-methyl-2-propan-2-ylnonanamide; 173334-57-1; CHEBI:601027; octanamide, .delta.-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-.gamma.-hydroxy-4-methoxy-3-(3-methoxypropoxy)-.alpha.,.zeta.-bis(1-methylethyl)-, [.alpha.S-(.alpha.R*,.gamma.R*,.delta.R*,.zeta.R*)]-||	173334-57-1	5493444	17397362	TTDS00451	Renin, renal	Angiotensinogenase;Renin	P00797	5972	ENSG00000143839	inhibitor
DAP001220	Remikiren	(S)-alpha-((S)-alpha-((t-butylsulfonyl)methyl)hydrocinnamamido)-N-((1S,2R,3S)-1-(cyclohexylmethyl)-3-cyclopropyl-2,3-dihydroxypropyl)imidazole-4-propionamide; CHEMBL31601; LS-172931; (2R)-2-benzyl-3-tert-butylsulfonyl-N-[(2S)-1-[[(2R,3S,4R)-1-cyclohexyl-4-cyclopropyl-3,4-dihydroxybutan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]propanamide; 135669-48-6; CCRIS 6519; Remikiren; 1H-Imidazole-4-propanamide, N-(1-(cyclohexylmethyl)-3-cyclopropyl-2,3-dihydroxypropyl)-alpha-((2-(((1,1-dimethylethyl)sulfonyl)methyl)-1-oxo-3-phenylpropyl)amino)-, (1S-(1R*(R*(R*)),2S*,3R*))-; AC1NUWCS; AC1O44IV; LS-78865; C33H50N4O6S; CHEBI:142751; CID5462340; Remikiren [INN]; Remikiren (INN); CID5230731; D09038; UNII-LC7FBL96A4; 126222-34-2; (2S)-2-benzyl-3-tert-butylsulfonyl-N-[(2S)-1-[[(2S,3R,4S)-1-cyclohexyl-4-cyclopropyl-3,4-dihydroxybutan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]propanamide; DB00212; Ro-42-5892; AC1NQY7T; CID6324659; REM; C07465; (alphaS)-alpha-((alphaS)-alpha-((tert-Butylsulfonyl)methyl)hydrocinnamamido)-N-((1S,2R,3S)-1-(cyclohexylmethyl)-3-cyclopropyl-2,3-dihydroxypropyl)imidazole-4-propionamide; 2-benzyl-3-tert-butylsulfonyl-N-[1-[(1-cyclohexyl-4-cyclopropyl-3,4-dihydroxybutan-2-yl)amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]propanamide; Ro 42-5892	126222-34-2	5462340	9668	TTDS00451	Renin, renal	Angiotensinogenase;Renin	P00797	5972	ENSG00000143839	inhibitor
DCL001213	Miravirsen	N/A	N/A	N/A	N/A	TTDC00324	MicroRNA miR-122	N/A	N/A	N/A	N/A	inhibitor
DAP000564	Clodronate	Acidum clodronicum [INN-Latin]; Disodium, Clodronate; (Dichloro-phosphono-methyl)-phosphonic acid; Acid, Dichloromethanediphosphonic; HSCI1_000244; Bonefos; Acido clodronico; Clodronic Acid; Phosphonic acid, (dichloromethylene)di- (8CI); [dichloro(phosphono)methyl]phosphonic acid; Dichloromethylene Biphosphonate; Sodium, Clodronate; HMS2089N14; DB00720; Acide clodronique; dichloromethylene-1,1-bisphosphonic acid; Phosphonic acid, (dichloromethylene)di-; (Lip-C); CID25419; (dichloromethanediyl)bis(phosphonic acid); AC1L1936; UNII-0813BZ6866; (Dichloromethylene)diphosphonic acid; EINECS 234-212-1; D03545; Lopac0_000398; Dichloromethylenebisphosphonate; LS-106549; Acide clodronique [INN-French]; Dichlormethylen-bis(phosphonsaeure); Dichloromethanediphosphonic acid; Clodronsaeure; D004002; Biphosphonate, Dichloromethylene; Dichloromethylidene diphosphonate; Dichloromethanediphosphonate; 10596-23-3; Acido clodronico [INN-Spanish]; Clodronic acid (USAN/INN); Liposomes containing clodronic acid; (Dichloromethylene)bisphosphonic acid; CHEBI:110423; Acidum clodronicum; Clodronic acid [USAN:BAN:INN]; Dichloromethylene Diphosphonate; Methanedichlorodiphosphonate; dichloromethylene-1,1-diphosphonic acid; Clodronate; Methanedichlorodiphosphonic acid; Acid, Clodronic; Diphosphonate, Dichloromethane; CHEMBL12318; Phosphonic acid, (dichloromethylene)bis-; BRN 1876367; Diphosphonate, Dichloromethylene	10596-23-3	25419	168153	TTDS00405	Adenine nucleotide translocator 1	ADP,ATP carrier protein 1;ADP,ATP carrier protein, heart/skeletal muscle isoform T1;ADP/ATP translocase 1;ANT 1;ANT1;SLC25A4;Solute carrier family 25 member 4	P12235	291	ENSG00000151729	inhibitor
DAP001143	Trimethaphan	1,3-dibenzyl-2-oxodecahydrothieno[1',2':1,2]thieno[3,4-d]imidazol-5-ium; TRIMETHAPHAN; Thieno(1',2':1,2)thieno(3,4-d)imidazol-5-ium, decahydro-2-oxo-1,3-bis(phenylmethyl)- (VAN); PDSP1_000122; PDSP2_000122; Thieno(1',2':1,2)thieno(3,4-d)imidazol-5-ium, decahydro-2-oxo-1,3-bis(phenylmethyl)-; Trimetaphanum; LS-187792; CID23576; D014294; Trimetaphan; 7187-66-8; DB01116; AC1L2MN5; Thimethaphan; AC1Q6LI1; CHEBI:9728; LS-187055; C07174	7187-66-8	23576	166148	TTDS00141	Neuronal acetylcholine receptor protein, alpha-4 chain	Alpha-4 nAChR;Nicotinic acetylcholine receptor alpha4	P43681	1137	ENSG00000101204	antagonist
DCL000551	Ispronicline	RJR-1734; 482299-54-7; CID9881145; 4-Penten-2-amine, N-methyl-5-(5-(1-methylethoxy)-3-pyridinyl)-, (2S,4E)-; CHEMBL188462; (E)-N-methyl-5-(5-propan-2-yloxypyridin-3-yl)pent-4-en-2-amine; D08935; CID9824145; Ispronicline (INN/USAN); 252870-53-4; TC 01734; AZD-3480; UNII-3E05NBH9V5; RJR 1734; Ispronicline; CHEBI:416483	482299-54-7	N/A	10549742	TTDS00141	Neuronal acetylcholine receptor protein, alpha-4 chain	Alpha-4 nAChR;Nicotinic acetylcholine receptor alpha4	P43681	1137	ENSG00000101204	agonist
DAP000265	Varenicline	CHEMBL1396; 7,8,9,10-Tetrahydro-6,10-methano-6H-pyrazino(2,3-h)(3)benzazepine; 249296-44-4; Varenicline (INN); AKOS005145561; 7,8,9,10-tetrahydro-6h-6,10-methanoazepino[4,5-g]quinoxaline; HSDB 7591; CID170361; LS-187375; AR-1H2911; Varenicline; I14-1963; AC1Q4W6H; D08669; CP 526555; AC1L55H0; UNII-W6HS99O8ZO; 6,10-Methano-6H-pyrazino(2,3-h)(3)benzazepine, 7,8,9,10-tetrahydro-; CHEBI:430452	249296-44-4	5310966	16411442	TTDS00141	Neuronal acetylcholine receptor protein, alpha-4 chain	Alpha-4 nAChR;Nicotinic acetylcholine receptor alpha4	P43681	1137	ENSG00000101204	agonist
DCL000658	TC-5619	TC-5619	N/A	16727410	26683811	TTDS00141	Neuronal acetylcholine receptor protein, alpha-4 chain	Alpha-4 nAChR;Nicotinic acetylcholine receptor alpha4	P43681	1137	ENSG00000101204	agonist
DCL001044	ABT-894	N/A	799279-80-4	5487301	48329128	TTDS00141	Neuronal acetylcholine receptor protein, alpha-4 chain	Alpha-4 nAChR;Nicotinic acetylcholine receptor alpha4	P43681	1137	ENSG00000101204	agonist
DCL000456	AZD1446	N/A	N/A	N/A	N/A	TTDS00141	Neuronal acetylcholine receptor protein, alpha-4 chain	Alpha-4 nAChR;Nicotinic acetylcholine receptor alpha4	P43681	1137	ENSG00000101204	agonist
DAP001144	Pentolinium	pentolineum; AC1Q28R1; CHEMBL1271; Pentolinium; AC1L1L9T; 1-methyl-1-[5-(1-methylpyrrolidin-1-ium-1-yl)pentyl]pyrrolidin-1-ium; 34801-12-2; AR-1B4870; Pentolonum; 144-44-5; LS-173200; ZINC02041380; CID5850; KST-1B3415; UNII-ULL76WPU5X; DB01090; Pentolonium; Pyrrolidinium, 1,1'-(1,5-pentanediyl)bis(1-methyl-; 1,1'-pentane-1,5-diylbis(1-methylpyrrolidinium); CHEBI:347401; AB00053826	52-62-0	5850	741991	TTDS00141	Neuronal acetylcholine receptor protein, alpha-4 chain	Alpha-4 nAChR;Nicotinic acetylcholine receptor alpha4	P43681	1137	ENSG00000101204	antagonist
DCL001221	PF-04620110	N/A	N/A	N/A	N/A	TTDS00466	Diglyceride acyltransferase	ACAT-related gene product 1;AGRP1;DGAT;DGAT1;Diacylglycerol O-acyltransferase 1	O75907	8694	ENSG00000185000; ENSG00000261698	inhibitor
DAP001306	Hesperetin	Spectrum2_001793; Spectrum4_001935; C013015; IDI1_001039; KBio1_001039; KBio2_005797; Hesperin; BIDD:ER0512; Spectrum3_001104; Flavanone, 3',5,7-trihydroxy-4'-methoxy- (VAN); Spectrum5_000683; KBioGR_002311; 4H-1-Benzopyran-4-one, 2,3-dihydro-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-, (S)-; H4125_FLUKA; MLS002154205; NSC 57654; HMS503O19; KBio2_000661; Flavanone, 3',5,7-trihydroxy-4'-methoxy- (VAN) (8CI); NSC-57654; TNP00238; MolPort-003-665-801; BCBcMAP01_000087; BPBio1_000186; BSPBio_000168; Prestwick_908; Prestwick3_000124; BRD-K30553453-001-05-8; HMS1568I10; KBio3_002028; ZINC00039092; Hesperitin; SMR001233491; SPECTRUM310012; NCGC00016482-01; KBio2_003229; S2308_Selleck; NCGC00142415-01; hesperetin; 3',5,7-Trihydroxy-4'-methoxyflavanone; (-)-hesperetin; BSPBio_002808; Cyanidanon 4'-methyl ether 1626; 520-33-2; LMPK12140003; CAS-520-33-2; Oprea1_828704; C01709; NCGC00016482-02; NCGC00142415-02; CHEMBL399121; SMP1_000148; YSO2; DivK1c_001039; 4H-1-Benzopyran-4-one, 2,3-dihydro-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-, (S)- (9CI); EINECS 208-290-2; AC1Q6KIN; NINDS_001039; (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-2,3-dihydro-4H-chromen-4-one; (S)-2,3-Dihydro-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-4-benzopyrone; CHEBI:28230; Prestwick2_000124; DB01094; H4125_SIGMA; Prestwick1_000124; LS-185786; H0721; (S)-2,3-dihydro-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-4H-1-benzopyran-4-one; SPBio_001745; (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-2,3-dihydrochromen-4-one; Prestwick0_000124; 3',5,7-Trihydroxy-4-methoxyflavanone; ST055624; SDCCGMLS-0066605.P001; SPBio_002107; Spectrum_000181; AC1L2HRS; 5,7,3'-Trihydroxy-4'-methoxyflavanone; KBioSS_000661; CID72281	520-33-2	72281	4847	TTDS00466	Diglyceride acyltransferase	ACAT-related gene product 1;AGRP1;DGAT;DGAT1;Diacylglycerol O-acyltransferase 1	O75907	8694	ENSG00000185000; ENSG00000261698	inhibitor
DCL001155	AZD7687	N/A	N/A	N/A	N/A	TTDS00466	Diglyceride acyltransferase	ACAT-related gene product 1;AGRP1;DGAT;DGAT1;Diacylglycerol O-acyltransferase 1	O75907	8694	ENSG00000185000; ENSG00000261698	inhibitor
DAP000217	Felypressin	AC1Q5JBT; Felipressina; L-Cysteinyl-L-phenylalanyl-L-phenylalanyl-L-glutaminyl-L-asparaginyl-L-cysteinyl-L-prolyl-L-lysylglycinamide cyclic (1-6)disulfide; Octopressin; L-Cysteinyl-L-phenylalanyl-L-phenylalanyl-L-glutaminyl-L-asparaginyl-L-cysteinyl-L-prolyl-L-lysylglycinamide cyclic (1->6)disulfide; AR-1B9586; Phenylalanine Lysine Vasopressin; KST-1B5883; 1-{[19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13,16-dibenzyl-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-4-yl]carbonyl}prolyllysylglycinamide; Vasopressin, Phenylalanyl-Lysyl; LS-175689; CID5956; N-[6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13,16-dibenzyl-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide; Felypressinum [INN-Latin]; Felypressine; 2-(L-Phenylalanine)-8-L-lysinevasopressin; Felypressinum; Felypressin [USAN:INN:BAN]; PLV-2; Felipressina [DCIT]; 58249-87-9; Vasopressin, 2-L-phenylalanine-8-L-lysine-; EINECS 200-282-7; Felypressine [INN-French]; FELYPRESSIN; L001276; Octapressin; UNII-17N2918V6G; Felipresina; Felipresina [INN-Spanish]; AC1L1LHU; Phelypressin	56-59-7	5956	148784	TTDS00109	Vasopressin V1a receptor	Antidiuretic hormone receptor 1a;AVPR V1a;V1a vasopressin receptor;V1aR;Vascular/hepatic-type arginine vasopressin receptor	P37288	552	ENSG00000166148	agonist
DPR000080	NOX-F37	N/A	N/A	N/A	N/A	TTDS00109	Vasopressin V1a receptor	Antidiuretic hormone receptor 1a;AVPR V1a;V1a vasopressin receptor;V1aR;Vascular/hepatic-type arginine vasopressin receptor	P37288	552	ENSG00000166148	antagonist
DAP000098	Conivaptan	4'-((4,5-dihydro-2-methylimidazo(4,5-d)(1)benzazepin-6(1H)-yl)carbonyl)-2-biphenylcarboxanilide; Conivaptan; L001531; N-{4-[(2-methyl-4,5-dihydroimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl}biphenyl-2-carboxamide; MolPort-005-940-873; UNII-0NJ98Y462X; AC1L45SX; YM 087; ZINC12503187; PDSP2_001718; L001073; N-[4-(2-methyl-4,5-dihydro-3H-imidazo[4,5-d][1]benzazepine-6-carbonyl)phenyl]-2-phenylbenzamide; Conivaptan [INN]; D07748; PDSP1_001735; Conivaptan (INN); (1,1'-Biphenyl)-2-carboxamide, N-(4-(4,5-dihydro-2-methylimidazo(4,5-d)(1)benzazepin-6(1H)-yl)carbonyl)phenyl)-; CID151171; LS-187117; 210101-16-9; I14-8805; YM-087; CHEMBL1755; YM087; DB00872; CHEBI:681850	210101-16-9	151171	728713	TTDS00109	Vasopressin V1a receptor	Antidiuretic hormone receptor 1a;AVPR V1a;V1a vasopressin receptor;V1aR;Vascular/hepatic-type arginine vasopressin receptor	P37288	552	ENSG00000166148	antagonist
DAP000058	Terlipressin	HS-2028; Terlipressine [INN-French]; (2s)-1-{[(4r,7s,10s,13s,16s,19r)-19-{[({[(aminoacetyl)amino]acetyl}amino)acetyl]amino}-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-(4-hydroxybenzyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-4-yl]carbonyl}-n-{(2s)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl}pyrrolidine-2-carboxamide(non-preferred name); EINECS 238-680-8; Terlipressinum [INN-Latin]; Terlipressina [INN-Spanish]; AC1Q5JB2; UNII-7Z5X49W53P; Terlipressine; Terlipressin [BAN:INN]; DB02638; Terlipressina; Terlipressin; AC1L2HDP; 14636-12-5; N-(N-(N-Glycylglycyl)glycyl)-8-L-lysinevasopressin; glypressin; (2S)-1-[(4R,7S,10S,13S,16S,19R)-19-[[2-[[2-[(2-aminoacetyl)amino]acetyl]amino]acetyl]amino]-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-N-[(2S)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]pyrrolidine-2-carboxamide; LS-161411; CID72081; Lucassin; Terlipressinum	14636-12-5	72081	29211741	TTDS00109	Vasopressin V1a receptor	Antidiuretic hormone receptor 1a;AVPR V1a;V1a vasopressin receptor;V1aR;Vascular/hepatic-type arginine vasopressin receptor	P37288	552	ENSG00000166148	stimulator
DCL000259	VX-680	VX-680; MK 0457; Cyclopropanecarboxylic acid N-(4-((4-(4-methylpiperazin-1-yl)-6-(5-methyl-2H-pyrazol-3-ylamino)pyrimidin-2-yl)sulfanyl)phenyl)amide; Cyclopropanecarboxylic Acid {4-[4-(4-Methyl-Piperazin-1-Yl)-6-(5-Methyl-2h-Pyrazol-3-Ylamino)-Pyrimidin-2-Ylsulfanyl]-Phenyl}-Amide; VX6; Tozasertib (USAN); AC1NUV5F; VX-68; Cyclopropanecarboxamide, N-(4-((4-(4-methyl-1-piperazinyl)-6-((5-methyl-1H-pyrazol-3-yl)amino)-2-pyrimidinyl)thio)phenyl)-; MLS001065920; CID5494449; CHEMBL572878; L-001281814; Kinome_3803; S1048_Selleck; Tozasertib; ST51054127; Cyclopropane carboxylic acid{4-[4-(4-methyl-piperazin-1-yl)-6-(5-methyl-2H-pyrazol-3-ylamino)-pyrimidin-2-ylsulphanyl]-phenyl}-amide; 2f4j; MK-0457, Tozasertib, VX680, VX-680; NSC745967; EC-000.2365; MK-045; SMR000486395; D08279; VX 680; 639089-54-6; MK-0457; I14-1964; N-[4-[4-(4-methylpiperazin-1-yl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl]sulfanylphenyl]cyclopropanecarboxamide; N-(4-(4-(3-methyl-1H-pyrazol-5-ylamino)-6-(4-methylpiperazin-1-yl)pyrimidin-2-ylthio)phenyl)cyclopropanecarboxamide	N/A	5494449	46513935	TTDC00006	Aurora kinase A	Aurora/IPL1-related kinase 1;Aurora-A;Aurora-related kinase 1;Breast tumor-amplified kinase;hARK1;Serine/threonine kinase 15;Serine/threonine-protein kinase 6	O14965	6790	ENSG00000087586	inhibitor
DCL000169	MLN8054	CHEMBL259084; CID 11712649; MLN8054; ZZL; Kinome_1204; S1100_Selleck; CID11712649; EC-000.2342; MLN-8054	869363-13-3	N/A	N/A	TTDC00006	Aurora kinase A	Aurora/IPL1-related kinase 1;Aurora-A;Aurora-related kinase 1;Breast tumor-amplified kinase;hARK1;Serine/threonine kinase 15;Serine/threonine-protein kinase 6	O14965	6790	ENSG00000087586	inhibitor
DCL000210	R763	N/A	N/A	N/A	N/A	TTDC00006	Aurora kinase A	Aurora/IPL1-related kinase 1;Aurora-A;Aurora-related kinase 1;Breast tumor-amplified kinase;hARK1;Serine/threonine kinase 15;Serine/threonine-protein kinase 6	O14965	6790	ENSG00000087586	inhibitor
DCL000006	SNS-314	SN-314; SNS-314; DB07361; CHEMBL518051; Kinome_3712; AK2	76721-89-6	3132	49700751	TTDC00006	Aurora kinase A	Aurora/IPL1-related kinase 1;Aurora-A;Aurora-related kinase 1;Breast tumor-amplified kinase;hARK1;Serine/threonine kinase 15;Serine/threonine-protein kinase 6	O14965	6790	ENSG00000087586	inhibitor
DCL000059	AT9283	N/A	N/A	N/A	N/A	TTDC00006	Aurora kinase A	Aurora/IPL1-related kinase 1;Aurora-A;Aurora-related kinase 1;Breast tumor-amplified kinase;hARK1;Serine/threonine kinase 15;Serine/threonine-protein kinase 6	O14965	6790	ENSG00000087586	inhibitor
DCL001071	ENMD-2076	N/A	N/A	N/A	N/A	TTDC00006	Aurora kinase A	Aurora/IPL1-related kinase 1;Aurora-A;Aurora-related kinase 1;Breast tumor-amplified kinase;hARK1;Serine/threonine kinase 15;Serine/threonine-protein kinase 6	O14965	6790	ENSG00000087586	inhibitor
DCL001076	PF-03814735	N/A	N/A	N/A	N/A	TTDC00006	Aurora kinase A	Aurora/IPL1-related kinase 1;Aurora-A;Aurora-related kinase 1;Breast tumor-amplified kinase;hARK1;Serine/threonine kinase 15;Serine/threonine-protein kinase 6	O14965	6790	ENSG00000087586	inhibitor
DCL001083	VX-689	N/A	N/A	N/A	N/A	TTDC00006	Aurora kinase A	Aurora/IPL1-related kinase 1;Aurora-A;Aurora-related kinase 1;Breast tumor-amplified kinase;hARK1;Serine/threonine kinase 15;Serine/threonine-protein kinase 6	O14965	6790	ENSG00000087586	inhibitor
DCL001068	AT-9283	CID 11496629; AT-9283; pyrazole-benzimidazole urea analogue, 16; CHEMBL495727; CID11496629	N/A	N/A	N/A	TTDC00006	Aurora kinase A	Aurora/IPL1-related kinase 1;Aurora-A;Aurora-related kinase 1;Breast tumor-amplified kinase;hARK1;Serine/threonine kinase 15;Serine/threonine-protein kinase 6	O14965	6790	ENSG00000087586	inhibitor
DCL000010	CYC116	N/A	N/A	N/A	N/A	TTDC00006	Aurora kinase A	Aurora/IPL1-related kinase 1;Aurora-A;Aurora-related kinase 1;Breast tumor-amplified kinase;hARK1;Serine/threonine kinase 15;Serine/threonine-protein kinase 6	O14965	6790	ENSG00000087586	inhibitor
DCL001070	CYC-116	CHEBI:620120; CHEMBL482967; CID6420138; CYC-116, CYC116; Kinome_636; S1171_Selleck; AC1O4WKE; CYC-116; 4-methyl-5-[2-(4-morpholin-4-ylanilino)pyrimidin-4-yl]-1,3-thiazol-2-amine; 2c5t	N/A	N/A	N/A	TTDC00006	Aurora kinase A	Aurora/IPL1-related kinase 1;Aurora-A;Aurora-related kinase 1;Breast tumor-amplified kinase;hARK1;Serine/threonine kinase 15;Serine/threonine-protein kinase 6	O14965	6790	ENSG00000087586	inhibitor
DCL001078	PHA-739358	5-Amido-pyrrolopyrazole 9d; CID11442891; UNII-M3X659D0FY; S1107_Selleck; Danusertib, PHA-739358; CID 11994441; CHEMBL402548; PHA-739358; I06-2258; PHA 739358; Danusertib; (R)-N-(5-(2-methoxy-2-phenylacetyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)-4-(4-methylpiperazin-1-yl)benzamide; Benzamide, 4-(4-methyl-1-piperazinyl)-N-(1,4,5,6-tetrahydro-5-((2R)-     methoxyphenylacetyl)pyrrolo(3,4-c)pyrazol-3-yl)-; 2j50; EC-000.2352; EN003071; 827318-97-8	N/A	N/A	N/A	TTDC00006	Aurora kinase A	Aurora/IPL1-related kinase 1;Aurora-A;Aurora-related kinase 1;Breast tumor-amplified kinase;hARK1;Serine/threonine kinase 15;Serine/threonine-protein kinase 6	O14965	6790	ENSG00000087586	inhibitor
DCL000342	SU-6668	N/A	N/A	5329099	12015385	TTDC00006	Aurora kinase A	Aurora/IPL1-related kinase 1;Aurora-A;Aurora-related kinase 1;Breast tumor-amplified kinase;hARK1;Serine/threonine kinase 15;Serine/threonine-protein kinase 6	O14965	6790	ENSG00000087586	inhibitor
DCL000170	MLN8237	N/A	N/A	N/A	N/A	TTDC00006	Aurora kinase A	Aurora/IPL1-related kinase 1;Aurora-A;Aurora-related kinase 1;Breast tumor-amplified kinase;hARK1;Serine/threonine kinase 15;Serine/threonine-protein kinase 6	O14965	6790	ENSG00000087586	inhibitor
DCL000452	AZD1152	N/A	722544-51-6	N/A	N/A	TTDC00006	Aurora kinase A	Aurora/IPL1-related kinase 1;Aurora-A;Aurora-related kinase 1;Breast tumor-amplified kinase;hARK1;Serine/threonine kinase 15;Serine/threonine-protein kinase 6	O14965	6790	ENSG00000087586	inhibitor
DCL000572	MK-5108	N/A	N/A	9939559	48095971	TTDC00006	Aurora kinase A	Aurora/IPL1-related kinase 1;Aurora-A;Aurora-related kinase 1;Breast tumor-amplified kinase;hARK1;Serine/threonine kinase 15;Serine/threonine-protein kinase 6	O14965	6790	ENSG00000087586	inhibitor
DCL001046	OGX-427	N/A	N/A	N/A	N/A	TTDC00269	mRNA of Heat shock 27 kDa protein	28 kDa heat shock protein;Estrogen-regulated 24 kDa protein;Heat shock protein 27;HSP 27;HspB1;SRP27;Stress-responsive protein 27	P04792	3315	ENSG00000106211	antisense
DCL000435	Anti-NRP1	N/A	N/A	N/A	N/A	TTDC00183	Neuropilin-1	Membrane-bound;Platelet-derived endothelial cell growth factor receptor;Vascular endothelial cell growth factor 165 receptor	O14786	8829	ENSG00000099250	inhibitor
DAP000153	Sulfasalazine	ratio-Sulfasalazine; SBB058178; Accucol; Benzoic acid, 2-hydroxy-5-((4-((2-pyridinylamino)sulfonyl)phenyl)azo)-; BSPBio_000479; KBio2_007450; sulfasalazine; SI-88; Salazopiridazin; Asulfidine; Salazosulfapyridinum; Salazopyrin  en-tabs; AC1NSE0P; Azopyrin; S.A.S. 500; MLS000759399; 5-((p-(2-Pyridylsulfamoyl)phenyl)azo)salicylic acid; Henning Berlin Brand of Sulfasalazine; HMS502K22; AC1Q72VB; LS-46; Salazosulfapyridine; 5-(para-(2-pyridylsulfamoyl)phenylazo)salicylic acid; AC-20497; Spectrum_000998; Sulfasalazin; Azulfidine (TN); nchembio.212-comp9; Pms-Sulfasalazine E.C.; NCGC00090903-04; 599-79-1; NCGC00016518-01; Salazopyrin EN-Tabs; Sanofi Synthelabo Brand of Sulfasalazine; DB00795; BIDD:GT0161; C07316; S.A.S.-500; CHEBI:9334; Salazosulfapyridinum [INN-Latin]; Sulcolon; HMS2090P13; EINECS 209-974-3; NSC667219; Ratiopharm Brand of Sulfasalazine; CHEBI:489907; Pleon; SPECTRUM1500552; SMR000059146; Salazosulfapyridin; PMS-Sulfasalazine; BPBio1_000527; Azosulfidin; BSPBio_002888; Prestwick_848; KBio2_004046; BRD-K10670311-001-06-4; Sulfasalazine (USP/INN); DB08518; D012460; 2-hydroxy-5-(4-[(pyridin-2-ylamino)sulfonyl]phenyl}diazenyl)benzoic acid; CID5353980; Salisulf; Prestwick3_000520; HMS1921C05; Sulfasalazin medac; AKOS002311709; Prestwick1_000520; Salicylic acid, 5-((p-(2-pyridylsulfamoyl)phenyl)azo)-; medac Brand of Sulfasalazine; DivK1c_000860; MLS001424109; Salazo-sulfapyridinum; Sulphasalazine; Azopyrine; KBio3_002794; Prestwick0_000520; Ulcol; UNII-3XC8GUZ6CB; MolPort-001-792-507; SASP; Azulfidine; Colo Pleon; Spectrum4_000347; Spectrum2_001216; KBio2_001478; ST50767935; Sulfasalazin Heyl; Sulfasalazinum [INN-Latin]; Pfizer Brand of Sulfasalazine; 4-(Pyridyl-2-amidosulfonyl)-3'-carboxy-4'-hydroxyazobenzene; Azulfidine EN-tabs; NCGC00090903-05; Ashbourne Brand of Sulfasalazine; CHEBI:45504; Salazosulfapiridina [INN-Spanish]; FNA Brand of Sulfasalazine; Sulfasalazina [INN-Spanish]; 2-HYDROXY-(5-([4-(2-PYRIDINYLAMINO)SULFONYL]PHENYL)AZO)BENZOIC ACID; KBio2_004882; HMS2092K07; Azulfadine; Azlufidine EN-Tabs; I06-0676; Sulfasalazinum; CID5384001; NSC203730; Salazosulfapiridina; 2-hydroxy-5-{[4-(pyridin-2-ylsulfamoyl)phenyl]diazenyl}benzoic acid; KBioGR_002314; SMP2_000059; ratio Sulfasalazine; Spectrum5_001443; 5-[p-(2-Pyridylsulfamoyl)phenylazo]salicylic acid; Ucine; EN, Azulfidine; Sulfazalazine; Salicylic acid, 5-[[p-(2-pyridylsulfamoyl)phenyl]azo]-; Reupirin; NSC 667219; MolPort-003-986-992; Prestwick2_000520; Spectrum3_001364; Sulphasalazine, N-; NINDS_000860; Azulfidine EN; Benzoic acid, 2-Hydroxy-5-[[4-[(2-pyridinylamino)sulfonyl]phenyl]azo]-; 2-hydroxy-5-[(E)-{4-[(pyridin-2-ylamino)sulfonyl]phenyl}diazenyl]benzoic acid; 5-22-08-00433 (Beilstein Handbook Reference); Sulfasalazina; NCGC00090903-01; SPBio_002400; AC1NTMDP; 5-[p-(2-Pyridylsulfamyl)phenylazo]salicylic acid; CHEMBL421; KBio1_000860; Sulfasalazin-Heyl; KBio2_006614; Sulfasalazine Pfizer Brand; 5-(p-(2-Pyridinylsulfamoyl)Phenylazo)Salicylic Acid; IDI1_000860; KBioSS_002316; KBioGR_000753; CPD000059146; S0580; KBio2_002314; SPBio_001032; NCGC00090903-03; Pyralin EN; CAS-599-79-1; BRN 0356241; Salazosulfapyridine (JP15); cMAP_000018; Alphapharm Brand of Sulfasalazine; CHEMBL242373; C18H14N4O5S; w-t Sasp oral; 13gs; Heyl Brand of Sulfasalazine; Salicylazosulfapyridine; SAM001246530; WLN: T6NJ BSWMR DNUNR DQ CVQ; KBio3_002108; TL8003811; Benzosulfa; Salazopyridin; 5-[4-(2-Pyridylsulfamoyl)phenylazo]salicylic Acid; 2-Hydroxy-5-((4-((2-pyridinylamino)sulfonyl)phenyl)azo)benzoic acid; 5-(p-(2-Pyridylsulfamyl)phenylazo)salicylic acid; S.A.S. Enteric-500; D00448; Colo-Pleon; KBioSS_001478; HMS1569H21; Alti-Sulfasalazine; Salazopyrin; Sas-500; SSZ; AC1NS4RK; NCGC00090903-02; Sulfasalazine FNA; NSC 203730; 5-[4-(2-Pyridylsulfamoyl)-phenylazo]-salicylic acid; CID5359476; Sulfasalazine [USAN:INN]; HMS2051J21; CCRIS 4713; HSDB 3395; 5-(4-(2-Pyridylsulfamoyl)phenylazo)-2-hydroxybenzoic acid	599-79-1	5353980	9524	TTDS00528	5-aminoimidazole-4-carboxamidoribonucleotide (AICAR) transformylase	N/A	N/A	N/A	N/A	inhibitor
DAP000473	Abciximab	N/A	143653-53-6	N/A	46505910	TTDS00077	Glycoprotein IIb/IIIa receptor	Alpha(IIb)beta(3) integrin receptor;Fibrinogen receptor;Glycoprotein GP IIb/IIIa;Glycoprotein IIb/IIIa;Gp IIb/IIIa;GpIIb/IIIa receptor;GPIIb-IIIa receptor;Integrin alpha IIb beta 3;Integrin alphaIIbbeta3;Integrin IIb beta3;Integrin IIbbeta3;Platelet glycoprotein IIb/IIIa fibrinogen receptor complex;Platelet GPIIb/IIIa receptor;Platelet GPIIb-IIIa;Platelet integrin IIbbeta3	N/A	N/A	N/A	antagonist
DAP000696	Tirofiban	151065-53-1; CHEBI:9605; Tirofiban (INN); Aggrastat; Tirofiban [INN:BAN]; D08607; Agrastat (TN); CHEMBL916; (2S)-2-(butylsulfonylamino)-3-[4-(4-piperidin-4-ylbutoxy)phenyl]propanoic acid; C07965; Tirofiban [BAN:INN]; L-700462; N-(butylsulfonyl)-O-(4-piperidin-4-ylbutyl)-L-tyrosine; 142373-60-2 (hydrochloride); LS-173214; tirofibanum; L-700,462; UNII-GGX234SI5H; HSDB 7323; C22H36N2O5S; N-(Butylsulfonyl)-O-(4-(4-piperidyl)butyl)-L-tyrosine; BIDD:GT0363; tirofiban; DB00775; AC1L1U7O; n-(butylsulfonyl)-o-[4-(piperidin-4-yl)butyl]-l-tyrosine; 144494-65-5; MK-383; AC1Q6VFB; CHEBI:40602; CID60947; L-Tyrosine, N-(butylsulfonyl)-O-(4-(4-piperidinyl)butyl)-; Agrastat; AGG; N-(BUTYLSULFONYL)-O-[4-(4-PIPERIDINYL)BUTYL]-L-TYROSINE	144494-65-5	60947	654151	TTDS00077	Glycoprotein IIb/IIIa receptor	Alpha(IIb)beta(3) integrin receptor;Fibrinogen receptor;Glycoprotein GP IIb/IIIa;Glycoprotein IIb/IIIa;Gp IIb/IIIa;GpIIb/IIIa receptor;GPIIb-IIIa receptor;Integrin alpha IIb beta 3;Integrin alphaIIbbeta3;Integrin IIb beta3;Integrin IIbbeta3;Platelet glycoprotein IIb/IIIa fibrinogen receptor complex;Platelet GPIIb/IIIa receptor;Platelet GPIIb-IIIa;Platelet integrin IIbbeta3	N/A	N/A	N/A	antagonist
DAP000285	Eptifibatide	I06-0351; 2-[(3S,6S,12S,20R,23S)-20-carbamoyl-12-[4-(diaminomethylideneamino)butyl]-3-(1H-indol-3-ylmethyl)-2,5,8,11,14,22-hexaoxo-17,18-dithia-1,4,7,10,13,21-hexazabicyclo[21.3.0]hexacosan-6-yl]acetic acid; Integrilin; nchembio829-comp11; BIDD:GT0422; HS-2011; 148031-34-9; N(6)-amidino-N(2)-(3-mercaptopropionyl)-L-lysylglycyl-L-alpha-aspartyl-L-tryptophyl-L-prolyl-L-cysteinamide, cyclic(1-6)-disulfide; FT-0082227; CID448812; UNII-NA8320J834; 2-[20-carbamoyl-12-[4-(diaminomethylideneamino)butyl]-3-(1H-indol-3-ylmethyl)-2,5,8,11,14,22-hexaoxo-17,18-dithia-1,4,7,10,13,21-hexazabicyclo[21.3.0]hexacosan-6-yl]acetic acid; C68-22; L-Cysteinamide,N6-(aminoiminomethyl)-N2-(3-mercapto-1-oxopropyl)-L-lysylglycyl-L-alpha-aspartyl-L-tryptophy-L-propyl-,cyclic (1-6)-disulfide; NCGC00167505-01; LS-173318; AC1L3WYY; L-Cysteinamide, N6-(aminoiminomethyl)-N2-(3-mercapto-1-oxopropyl)-L-lysylglycyl-L-alpha-aspartyl-L-tryptophy-L-prolyl-, cyclic (1-6)-disulfide; AC1L9MDI; Intrifiban; Sch-60936; CHEMBL1174; CID123610; 157630-07-4; N(sup 6)-Amidino-N(sup 2)-(3-mercaptopropionyl)-L-lysylglycyl-L-alpha-aspartyl-L-tryptophyl-L-prolyl-L-cysteinamide, cyclic(1-6)-disulfide; C35H49N11O9S2; 188627-80-7; LS-182837; S(1),S(6)-cyclo[N(6)-carbamimidoyl-N(2)-(3-sulfanylpropanoyl)-L-lysylglycyl-L-alpha-aspartyl-L-tryptophyl-L-prolyl-L-cysteinamide]; [(3R,11S,17S,20S,25aS)-11-(4-carbamimidamidobutyl)-3-carbamoyl-20-(1H-indol-3-ylmethyl)-1,9,12,15,18,21-hexaoxodocosahydro-7H-pyrrolo[2,1-g][1,2,5,8,11,14,17,20]dithiahexaazacyclotricosin-17-yl]acetic acid; SB-1; Eptifibatide; Integrelin; CHEBI:291902	188627-80-7	123610	700331	TTDS00077	Glycoprotein IIb/IIIa receptor	Alpha(IIb)beta(3) integrin receptor;Fibrinogen receptor;Glycoprotein GP IIb/IIIa;Glycoprotein IIb/IIIa;Gp IIb/IIIa;GpIIb/IIIa receptor;GPIIb-IIIa receptor;Integrin alpha IIb beta 3;Integrin alphaIIbbeta3;Integrin IIb beta3;Integrin IIbbeta3;Platelet glycoprotein IIb/IIIa fibrinogen receptor complex;Platelet GPIIb/IIIa receptor;Platelet GPIIb-IIIa;Platelet integrin IIbbeta3	N/A	N/A	N/A	antagonist
DAP000210	Gemfibrozil	Lopid R; Fetinor; Sigma Brand of Gemfibrozil; Gemfibrozilum [INN-Latin]; BRN 1881200; Bexal Brand of Gemfibrozil; SPBio_002148; AC-4225; Micolip; HMS2090K14; Gemfibrozilo [INN-Spanish]; Nu-Gemfibrozil; Lanaterom; D015248; TAD Brand of Gemfibrozil; BSPBio_000227; gemfibrozil; Normolip; Hipolixan; Cantabria Brand of Gemfibrozil; 2,2-Dimethyl-5-(2,5-xylyloxy)valeriansaeure; Prestwick0_000214; KBio2_003873; Brozil; 5-(2,5-Dimethyl-Phenoxy)-2,2-Dimethyl-Pentanoic Acid; BRD-K11129031-001-05-1; WL-Gemfibrozil; Decrelip; Pfizer Brand of Gemfibrozil; Synbrozil; Prestwick2_000214; Bolutol; 5-[(2,5-dimethylphenyl)oxy]-2,2-dimethylpentanoic acid; CI719; Innogen; Gen-Fibro; BPBio1_000251; Lifibron; Quimifar Brand of Gemfibrozil; Gemfibromax; D00334; Fibratol; EINECS 247-280-2; Gen Gemfibrozil; Gemfibrozilo Bayvit; 2,2-Dimethyl-5-(2,5-xylyloxy)valeric acid; Warner-Lambert Brand of Gemfibrozil; Spectrum5_001991; Gen-Gemfibrozil; G9518_SIGMA; Fibrocit; Bayvit Brand of Gemfibrozil; SR-01000000056-6; Gemfibrozilo Bexal; AC1L1FZT; Genlip; Gozid; Gemfibrozilo; Gemfibrozil (JAN/USP/INN); KBio3_001280; Clearol; KBioGR_000964; Reducel; Lipozid; SR-01000000056; GenGemfibrozil; NCGC00016794-01; Lipizyl; Trialmin; Spectrum5_000750; Nu-Pharm Brand of Gemfibrozil; Nu Gemfibrozil; CI-719; Novopharm Brand of Gemfibrozil; Ipsen Brand of Gemfibrozil; UNII-Q8X02027X3; GEMFIBROZIL (SEE ALSO PEROXISOME PROJECT (GEMFIBROZIL)); STK618740; NCGC00022722-04; Renabrazin; Parke Davis Brand of Gemfibrozil; Apo-Gemfibrozil; Novo-Gemfibrozil; 1A Brand of Gemfibrozil; Healthsense Gemfibrozil; Spectrum_000825; Chem mart Gemfibrozil; Innogem; BB_SC-4837; Terry White Chemists Brand of Gemfibrozil; LS-1085; Bull Brand of Gemfibrozil; IDI1_000138; CPD000058393; Lipazil; Jezil; Prestwick_637; Lipigem; Menarini Brand of Gemfibrozil; Healthsense Brand of Gemfibrozil; Hidil; DivK1c_000138; Ipolipid; Gemfi 1A Pharma; Pilder; MLS001055364; I01-1855; AC1Q2JC7; nchembio790-comp22; ApoGemfibrozil; SPBio_001174; Spectrum2_001097; Cholespid; Gemfibril; Polyxit; Alphapharm Brand of Gemfibrozil; NCGC00016794-02; KBioSS_001305; Farmasierra Brand of Gemfibrozil; S1729_Selleck; TL8002081; PMS-Gemfibrozil; Sinelip; NCGC00022722-05; Progemzal; Low-Lip; CHEMBL457; Prestwick3_000214; Gemd; United Drug Brand of Gemfibrozil; Ausgem; Genpharm Brand of Gemfibrozil; NINDS_000138; Gevilon Uno; Spectrum4_000562; Tentroc; Lipira; 2,2-Dimethyl-5-(2,5-dimethylphenoxy)pentanoic acid; HMS1568L09; Taborcil; Lipur; Apo Gemfibrozil; SBPA Gemfibrozil; AB00052003; SPECTRUM1500313; Pharmascience Brand of Gemfibrozil; AKOS001606691; NCGC00022722-06; Chem mart Brand of Gemfibrozil; Litarek; DBL Gemfibrozil; Biochemie Brand of Gemfibrozil; CID3463; SAM002564211; Elmogan; Gemlipid; CAS-25812-30-0; Apotex Brand of Gemfibrozil; Nu Pharm Brand of Gemfibrozil; GenRX Gemfibrozil; MLS000028421; SMR000058393; NCGC00022722-03; NuGemfibrozil; Gemfibrozil [USAN:BAN:INN]; Novo Gemfibrozil; Regulip; Terry White Chemists Gemfibrozil; Valeric acid, 2,2-dimethyl-5-(2,5-xylyloxy)-; Gemfibrozil, GenRX; PMS Gemfibrozil; Pentanoic acid, 5-(2,5-dimethylphenoxy)-2,2-dimethyl-; HMS1920B07; 2,2-Dimethyl-5-(2,5-dimethylphenoxy)valeriansaeure; BSPBio_002060; Lipox Gemfi; CHEBI:5296; Spectrum3_000440; 5-(2,5-Dimethylphenoxy)-2,2-dimethylpentanoic acid; MolPort-001-794-413; GFZ; Bayvit, Gemfibrozilo; Lopid; Douglas Brand of Gemfibrozil; PEROXISOME PROJECT (GEMFIBROZIL) (SEE ALSO GEMFIBROZIL); Gemnpid; CCRIS 318; TEVA-A; Gemfibrozil, SBPA; 25812-30-0; KBio2_006441; Faulding Brand of Gemfibrozil; Gemcor, Lopid, Jezil, Gen-Fibro, Gemfibrozil; KBio1_000138; NCGC00022722-07; Warner Lambert Brand of Gemfibrozil; Gemfibrozilum; Gem-S; HMS2091H11; Hexal Brand of Gemfibrozil; Gemfibrozilo Ur; Ferrer Brand of Gemfibrozil; HMS500G20; Gemfibrozil, Healthsense; Prestwick1_000214; Gemfibrosil; KBio2_001305; DB01241; Lopid (TN); CI 719; Gemhexal; ARONIS24091	25812-30-0	3463	175056	TTDS00066	Lipoprotein lipase	LPL	P06858	4023	ENSG00000175445	activator
DAP000262	Clofibrate	ELPI; Normet; BIDD:GT0172; NCGC00093755-06; KBio3_000594; DB00636; KBioGR_000885; HMS2093G07; Ethyl alpha-p-chlorophenoxyisobutyrate; Recolip; CBiol_001860; Regelan N; C12H15ClO3; EINECS 211-277-4; Lipomid; KBio2_002215; Atrovis; HMS1791O19; er; NCGC00093755-04; Skerolip; NCI60_041748; Clofibratum [INN-Latin]; Sklerepmexe; Atromid-S,  Clofibrate; MolPort-000-145-477; Angiokapsul; Regardin; Novofibrate; WLN: GR DOX1&1&VO2; AY-61123; EU-0100306; BML2-F02; Clofar; ICI 28257; HMS2089P03; HSDB 3038; NSC 79389; ICI-28257; Deliva; Amotril S; NCGC00093755-05; Lipavlon; BIDD:PXR0178; Azionyl; NCGC00093755-03; Spectrum2_001209; Clofibrate [USAN:INN:BAN:JAN]; KBio1_000926; Ethyl alpha-(4-chlorophenoxy)isobutyrate; Delipid; Atheromide; UNII-HPN91K7FU3; Ethyl 2-(4-chlorophenoxy)isobutyrate; Spectrum_001735; Clofibric Acid, Ethyl Ester; BSPBio_001577; KBio2_000297; KBio2_004783; Yoclo; HMS502J04; CHEMBL565; Oxan 600; Apolan; Ateculon; SMR000058279; Cartagyl; Antilipid; Bio1_000146; Clobrat; Clobren-5F; Ethyl-alpha-p-chlorophenoxy-isobutyrate; D002994; AC1L1EHK; Citiflus; KBio3_000593; Atromida; Antilipide; Xyduril; Athranid-wirkstoff; C06916; Bio1_000635; DivK1c_000926; ZINC00056648; Chlorophenoxyisobutyrate, Ethyl; BRN 1913459; SPBio_000998; Clofinit; CPIB; Bioscleran; Robigram; Klofibrat; Sklero-tablinene; Sklero-Tablinen; clofibrate; Lipamid; Clofipront; Lopac-C-6643; Liposid; Anparton; HMS1989O19; Cinnarizin; DivK1c_000822; Bresit; KBio2_002865; NCGC00015257-09; Miskleron; Spectrum5_001133; KBioSS_002215; HMS1361O19; MLS001336012; IDI1_000822; Arterosol; Liponorm; IDI1_000926; TL8004467; Athebrate; Persantinat; Sklero; Ethyl 2-(p-chlorophenoxy)isobutyrate; Ethyl chlorophenoxyisobutyrate; KBioGR_000297; Lobetrin; Ethyl para-chlorophenoxyisobutyrate; Lipidsenker; KBio2_007351; Lipide 500; Spectrum4_000223; CCRIS 177; KBioSS_000297; KBio2_005433; Gerastop; Misclerone; Arterioflexin; Clofibram; Liprinal; Claripex; NINDS_000926; Neo-Atromid; CHEBI:3750; Amotril; Hyclorate; Chlorfenisate; S1820_Selleck; NINDS_000822; 637-07-0; Miscleron; NSC79389; Negalip; Lipofacton; Ateriosan; Vincamin compositum; Clofibate; Liporil; Ethyl clofibrate; EPIB; Dura clofibrat; Normolipol; LS-7282; BCBcMAP01_000104; Liprin; Levatrom; ATROMID-S (TN); UPCMLD-DP019:001; NCGC00093755-08; MLS001336011; NCGC00093755-01; Artevil; Chlorphenisate; KBio1_000822; Lipavil; Ethyl p-chlorophenoxyisobutyrate; Normat; neo-Atomid; Regelan; Atromid; Sklero-tabuls; Serotinex; Fibralem; Athromidin; Scrobin; C 6643; Liporeduct; Sklerolip; NCGC00015257-01; MLS002153494; UPCMLD-DP019; Clofibrato [Spanish]; Bio1_001124; Clobren-SF; NCGC00015257-02; NCGC00093755-07; Skleromex; NCIOpen2_004739; Atheropront; clofibrate (CLOF); ST50319977; Clofibrat; I01-1842; Ethyl alpha-(p-chlorophenoxy)isobutyrate; Normalip; Bio2_000297; Serofinex; Clofibratum; nchembio790-comp25; Klofiran; Claripex CPIB; NSC-79389; Atromid S; Bio2_000777; HMS502O08; Atromidin; IDI1_034047; D00279; 19 more names available; Cloberat; Skleromexe; Lopac0_000306; AC1Q3200; AY 61123; Clofibrate (JP15/USP/INN); Atrolen; Clofibrato; Atromid-S; Ticlobran; Clofibrato [INN-Spanish]; CID2796; C6643_SIGMA	637-07-0	2796	9133	TTDS00066	Lipoprotein lipase	LPL	P06858	4023	ENSG00000175445	activator
DPR000177	ISIS-FGFR4	N/A	N/A	N/A	N/A	TTDR01438	mRNA of FGFR4	mRNA of Fibroblast growth factor receptor 4;mRNA of FGFR-4;mRNA of CD334	P22455	2264	ENSG00000160867	antisense
DCL001125	CB1954/EP-0152R, NQO2 prodrug therapy	N/A	N/A	N/A	N/A	TTDC00138	NRH dehydrogenase [quinone] 2	NAD(P)H qui oxidoreductase 2;NQO2;NRH:qui oxidoreductase 2;NRH:quinone oxidoreductase 2;QR2;Qui reductase 2;Quinone oxidoreductase 2;Quinone reductase 2	Q6LFA2	N/A	N/A	inhibitor
DCL000198	Prolarix	N/A	N/A	N/A	N/A	TTDC00138	NRH dehydrogenase [quinone] 2	NAD(P)H qui oxidoreductase 2;NQO2;NRH:qui oxidoreductase 2;NRH:quinone oxidoreductase 2;QR2;Qui reductase 2;Quinone oxidoreductase 2;Quinone reductase 2	Q6LFA2	N/A	N/A	activator
DAP000198	L-Proline	CHEBI:17203; Proline (VAN); 81710_SIGMA; bmse000047; CHEMBL54922; nchembio.186-comp54; DB02853; AC1Q71B7; Proline [USAN:INN]; 147-85-3; Carboxypyrrolidine; 81709_SIGMA; L-alpha-Pyrrolidinecarboxylic acid; 608998_ALDRICH; (-)-Proline; 2-Pyrrolidinecarboxylic acid, (S)-; C00148; FEMA Number 3319; L-Pyrrolidine-2-carboxylic acid; FEMA No. 3319; A01B5B63-CC3D-4796-A7B4-C2DE26A6FA93; (S)-Proline; P0481; 18875-45-1; nchembio816-comp9; TL80073505; AB1002323; NCGC00014017; (S)-2-Carboxypyrrolidine; CB 1707; 2-pyrrolidinecarboxylic acid; W331902_ALDRICH; EINECS 205-702-2; Proline (USP); (S)-Pyrrolidine-2-carboxylic acid; P8865_SIAL; LS-2381; AmbotzHAA1126; pro; (2S)-pyrrolidine-2-carboxylic acid; L-(2,3-3H)Proline; P0380_SIAL; L-proline; proline; AC1L3RTC; (-)-Proline (S)-2-Carboxypyrrolidine; H-Pro-OH; MolPort-001-757-108; PRO (IUPAC abbreviation); UNII-9DLQ4CIU6V; L-Prolin; Prolinum [Latin]; 4607-28-7; AI3-26710; Prolina [Spanish]; HSDB 1210; P5607_SIGMA; (L)-PROLINE; NCGC00097126-01; NSC-97923; 81709_FLUKA; P8865_SIGMA; (-)-2-Pyrrolidinecarboxylic acid; (S)-2-Pyrrolidinecarboxylic acid; AC-11190; 4305-67-3; 81710_FLUKA; (-)-(S)-Proline; L-Proline, labeled with carbon-14; L-Proline (JAN); CID145742; Proline, L-; D00035; NSC 46703; L-Proline-15N; 37159-97-0; DB00172; Prolinum; L-(-)-Proline; prolina	147-85-3	145742	3448	TTDS00417	Peptidyl-prolyl cis-trans isomerase B	Cyclophilin B;CYPB;CYP-S1;PPIase;PPIB;Rotamase;S-cyclophilin;SCYLP	P23284	5479	ENSG00000166794	binder
DAP000718	Hydrocortisone	Meusicort; Protocort; Scalpicin Capilar; BPBio1_000544; Hytone (TN); Hydrocortisone alcohol; Preparation H Hydrocortisone Cream; DB07886; Systral Hydrocort; H-Cort; Nutracort; Vytone; Anusol HC (TN); Incortin-H; Hi-cor; component of Lubricort; Hydrocortisone-Water Soluble; Prestwick3_000447; Hydrocortisone solution; Cort-Dome; Prestwick1_000447; Hytone; SMR000653523; C21H30O5; Tarcortin; Genacort (lotion); Komed HC; VoSol HC; 17alpha-Hydroxycorticosterone; LS-7439; Dihydrocostisone; MLS001148103; SAM002264617; Mildison; Genacort; Hydracort; Cortifan; HMS1569I16; EINECS 200-020-1; Lubricort; NCGC00022848-06; Glycort; Scheroson F; Hydrocortisone [INN:BAN:JAN]; Cortef; 11beta-Hydroxycortisone; HC #4; AKOS001582651; Dermocortal; Drotic; Dermacort; Aeroseb HC; COR-OTICIN; MolPort-001-794-637; Prestwick_265; 8056-08-4; Acticort; Esiderm H; Algicirtis; AI3-25006; Cortiment; component of Otalgine; DB00741; Milliderm; Hycortole; NCGC00022848-12; Transderma H; 11-beta-Hydroxycortisone; Hydrocortisone base; Hidalone; Reichstein's substance M; H4001_SIGMA; Otocort; Colocort; NCGC00022848-07; Hydrocortisone free alcohol; Cortisol alcohol; Basan-Corti; Chronocort; Cortanal; SMR000059022; [3H]cortisol; Cleiton; H0396_SIGMA; Cortolotion; Stie-cort; Maintasone; Stiefcorcil; Remederm HC; Acticort (TN); Idrocortisone; SPBio_002433; Heb Cort; Foille Insetti; Domolene-HC; Medicort; Synacort; Cortoxide; Hycortol; 17-Hydroxycorticosterone; Hydro-Adreson; Balneol-hc; Anti-inflammatory hormone; Prestwick0_000447; Proctozone HC; DuoCort; Ef corlin; MLS000069609; C00735; EU-0100594; Epicort; Flexicort; Idrocortisone [DCIT]; Anucort-HC; D00088; Cremesone; Ala-Scalp; NSC10483; S1696_Selleck; ACETASOL HC; Hydrocortone; ORLEX HC; AC1L1L2B; Dermil; Ficortril; Epiderm H; Aquanil HC; Dioderm; Heb-Cort; MLS002222189; Ala-Cort; Optef; NCGC00022848-09; Derm-Aid; ACETIC ACID W/ HYDROCORTISONE; Permicort; HC; Hytone lotion; Compound F (kendall); Prevex HC; Rectasol-HC; HYDROCORTISONE AND ACETIC ACID; BRD-K93568044-001-03-1; 80562-38-5; Penecort; Alacort; 11beta-Hydrocortisone; Anflam; Lacticare-HC; Hydro-Colisona; component of Neo-Cort-Dome; NSC-10483; hydrocortisone; H6909_SIGMA; Hydrocortal; Prepcort; UPCMLD-DP133; Amberin; Eldecort; Anusol HC; Lopac0_000594; CCRIS 5854; Gyno-Cortisone; Cortesal; Texacort; Scalp-Cort; Hydroxycortisone; Neosporin-H Ear; Efcorbin; Cortifair; NCI60_000118; Aquacort; Lacticare HC; CID5754; UPCMLD-DP133:001; Hydrocortisone (JP15/USP/INN); Eldercort; Incortin-hydrogen; Cortisporin; Nogenic HC; Cremicort-H; Hytisone; BSPBio_000494; Beta-hc; 2v95; Efcortelan; CHEMBL389621; Prestwick2_000447; 11-beta-Hydrocortisone; Nystaform-HC; Barseb HC; SMP1_000156; Traumaide; Efcortelin; Polcort H; Cyclodextrin-encapsulated hydrocortisone; Cortisporin Otico; Signef; HYDROCORTISONE IN ABSORBASE; Sigmacort; Proctocort; AC-12902; 11beta,17,21-Trihydroxyprogesterone; Hydrocortisyl; Kyypakkaus; Dome-cort; HSDB 3339; Cetacort; Bio-0648; Cortisolonum; NSC 10483; Hidro-Colisona; Uniderm; LMST02030001; Neo-Cortef; 8063-42-1; H0888_SIGMA; Epicortisol; Rectoid; Sanatison; Timocort; Hydrocortisonum [INN-Latin]; CaldeCORT Spray; Dermolate; Cortisol,  Hydrocortisone; Alphaderm; UNII-WI4X0X7BPJ; CHEBI:17650; Kendall's compound F; Cortril; Lactisona; Cortef (TN); B48448A1-24BA-47CA-8D9E-43E5BC949386; HC (HYDROCORTISONE); Hidrocortisona [INN-Spanish]; Dermaspray; Corticreme; H0135_SIGMA; Schericur; Hydroskin; Hycort; HMS2090M04; H 4001; Hydro-RX; Otosone-F; Pediotic Suspension; Hydrocorticosterone; Cobadex; Compound F; Hydrasson; MLS002207135; Cutisol; 50-23-7; Delacort; Anucort; Cortonema; CPD000653523; Corhydron; Clear aid; Fiocortril; Texacort lotion 25; Colocort (TN); Cortisol; Evacort; H3160_SIGMA; HC #1; Cortispray; Zenoxone; Aeroseb-HC; Cortenema	50-23-7	5754	3998	TTDS00337	Nitric oxide synthase, inducible	Hepatocyte NOS;HEP-NOS;Inducible nitric oxide synthase;Inducible NOS;INOS;NOS, type II	P35228	4843	ENSG00000007171	inhibitor
DCL000993	SLV-323	N/A	N/A	N/A	N/A	TTDS00194	Substance-P receptor	Neurokinin 1 receptor;NK-1 receptor;NK-1R;SPR;Substance P receptor;Tachykinin 1 receptor;Tachykinin neurokinin 1 receptor;Tachykinin receptor 1	P25103	6869	ENSG00000115353	modulator
DCL000800	Ezlopitant	CHEMBL515966; AC1Q573W; CID6426143; 147116-64-1; CHEBI:589439; AR-1A3447; D04122; Ezlopitant (USAN/INN); 2-benzhydryl-N-[(2-methoxy-5-propan-2-ylphenyl)methyl]-1-azabicyclo[2.2.2]octan-3-amine; AC1L4NQ6; (2S,3S)-2-benzhydryl-N-[(2-methoxy-5-propan-2-ylphenyl)methyl]-1-azabicyclo[2.2.2]octan-3-amine; KST-1A2038; L001573; AC1O519L; CID188927; Ezlopitant; (2s,3s)-2-(diphenylmethyl)-n-(5-isopropyl-2-methoxybenzyl)quinuclidin-3-amine	147116-64-1	23724902	47206070	TTDS00194	Substance-P receptor	Neurokinin 1 receptor;NK-1 receptor;NK-1R;SPR;Substance P receptor;Tachykinin 1 receptor;Tachykinin neurokinin 1 receptor;Tachykinin receptor 1	P25103	6869	ENSG00000115353	antagonist
DCL000666	Zunrisa/Rezonic	N/A	N/A	26757	49698549	TTDS00194	Substance-P receptor	Neurokinin 1 receptor;NK-1 receptor;NK-1R;SPR;Substance P receptor;Tachykinin 1 receptor;Tachykinin neurokinin 1 receptor;Tachykinin receptor 1	P25103	6869	ENSG00000115353	antagonist
DCL000667	GSK 679769	N/A	N/A	N/A	N/A	TTDS00194	Substance-P receptor	Neurokinin 1 receptor;NK-1 receptor;NK-1R;SPR;Substance P receptor;Tachykinin 1 receptor;Tachykinin neurokinin 1 receptor;Tachykinin receptor 1	P25103	6869	ENSG00000115353	antagonist
DCL000464	AZD2624	N/A	N/A	N/A	N/A	TTDS00194	Substance-P receptor	Neurokinin 1 receptor;NK-1 receptor;NK-1R;SPR;Substance P receptor;Tachykinin 1 receptor;Tachykinin neurokinin 1 receptor;Tachykinin receptor 1	P25103	6869	ENSG00000115353	antagonist
DCL000585	Orvepitant	N/A	N/A	N/A	N/A	TTDS00194	Substance-P receptor	Neurokinin 1 receptor;NK-1 receptor;NK-1R;SPR;Substance P receptor;Tachykinin 1 receptor;Tachykinin neurokinin 1 receptor;Tachykinin receptor 1	P25103	6869	ENSG00000115353	antagonist
DCL000776	DNK-333	DNK333; Benzamide, N-((1R,2E)-1-((3,4-dichlorophenyl)methyl)-4-(((3R)-hexahydro-2-oxo-1H-azepin-3-yl)amino)-4-oxo-2-butenyl)-N-methyl-3,5-bis(trifluoromethyl)-; N-((R,R)-(E)-1-(3,4-Dichlorobenzyl)-3-(2-oxoazepan-3-yl)carbamoyl)allyl-N-methyl-3,5-bis(trifluoromethyl)benzamide; 398507-81-8; DNK 333	203932-02-9	N/A	N/A	TTDS00194	Substance-P receptor	Neurokinin 1 receptor;NK-1 receptor;NK-1R;SPR;Substance P receptor;Tachykinin 1 receptor;Tachykinin neurokinin 1 receptor;Tachykinin receptor 1	P25103	6869	ENSG00000115353	antagonist
DCL000377	GSK424887	N/A	N/A	107810	44436760	TTDS00194	Substance-P receptor	Neurokinin 1 receptor;NK-1 receptor;NK-1R;SPR;Substance P receptor;Tachykinin 1 receptor;Tachykinin neurokinin 1 receptor;Tachykinin receptor 1	P25103	6869	ENSG00000115353	antagonist
DCL000404	GSK1144814	N/A	N/A	897403	1144814	TTDS00194	Substance-P receptor	Neurokinin 1 receptor;NK-1 receptor;NK-1R;SPR;Substance P receptor;Tachykinin 1 receptor;Tachykinin neurokinin 1 receptor;Tachykinin receptor 1	P25103	6869	ENSG00000115353	antagonist
DAP000362	Aprepitant	170729-80-3; Aprepitant (JAN/USAN/INN); MK-869; CHEMBL135613; 3H-1,2,4-Triazol-3-one, 5-((2-(1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(4-fluorophenyl)-4-morpholinyl)methyl)-1,2-dihydro-, (2R-(2alpha(R*),3alpha))-; Emend (TN); 5-{[(2R,3S)-2-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy}-3-(4-fluorophenyl)morpholin-4-yl]methyl}-2,4-dihydro-3H-1,2,4-triazol-3-one; 3-(((2R,3S)-3-(p-Fluorophenyl)-2-(((alphaR)-alpha-methyl-3,5-bis(trifluoromethyl)benzyl)oxy)morpholino)methyl)-delta(sup 2)-1,2,4-triazolin-5-one; 3-(((2R,3S)-3-(p-Fluorophenyl)-2-(((alphaR)-alpha-methyl-3,5-bis(trifluoromethyl)benzyl)oxy)morpholino)methyl)-Delta(2)-1,2,4-triazolin-5-one; 221350-96-5; MK 869; I06-1151; LS-156477; 3H-1,2,4-Triazol-3-one, 5-(((2R,3S)-2-((1R)-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(4-fluorophenyl)-4-morpholinyl)methyl)-1,2-dihydro-; L-754030; Aprepitant [USAN]; Aprepitant; CHEMBL1471; CID11214788; MK-0869; CID151165; CID6918365; CID9936947; MK 0869; Emend; NCGC00181785-01; D02968; ONO-7436; AC1OCFCG; AC1L45SL; MolPort-006-392-367; CHEBI:499361; L 754030; HMS2090N12; CID9936948; MK-869, L-754030, Emend, Aprepitant; 5-[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)morpholin-4-yl]methyl]-1,2-dihydro-1,2,4-triazol-3-one; DB00673; CHEBI:323967; S1189_Selleck; CID11318675; CHEMBL249465; UNII-1NF15YR6UY; 5-[[(2S,3R)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)morpholin-4-yl]methyl]-1,2-dihydro-1,2,4-triazol-3-one	170729-80-3	151165	728707	TTDS00194	Substance-P receptor	Neurokinin 1 receptor;NK-1 receptor;NK-1R;SPR;Substance P receptor;Tachykinin 1 receptor;Tachykinin neurokinin 1 receptor;Tachykinin receptor 1	P25103	6869	ENSG00000115353	antagonist
DCL000763	DA-5018	MolPort-005-943-140; CHEBI:261605; Capsavanil; LS-182242; 147497-64-1; AC1L42NL; 2-[4-(2-aminoethoxy)-3-methoxyphenyl]-N-[3-(3,4-dimethylphenyl)propyl]acetamide; 2-[4-(2-aminoethoxy)-3-methoxyphenyl]-N-[3-(3,4-dimethylphenyl)propyl]acetamide hydrochloride; CID177287; Da 5018; KR-25018; CID177286; Davasaicin; 174661-97-3; DA-5018; CHEMBL328628; Benzeneacetamide, 4-(2-aminoethoxy)-N-(3-(3,4-dimethylphenyl)propyl)-3-methoxy-, monohydrochloride; AC1L42NK	147497-64-1	177287	12015097	TTDS00194	Substance-P receptor	Neurokinin 1 receptor;NK-1 receptor;NK-1R;SPR;Substance P receptor;Tachykinin 1 receptor;Tachykinin neurokinin 1 receptor;Tachykinin receptor 1	P25103	6869	ENSG00000115353	antagonist
DCL001035	Vestipitant	N/A	334476-46-9	N/A	10549791	TTDS00194	Substance-P receptor	Neurokinin 1 receptor;NK-1 receptor;NK-1R;SPR;Substance P receptor;Tachykinin 1 receptor;Tachykinin neurokinin 1 receptor;Tachykinin receptor 1	P25103	6869	ENSG00000115353	antagonist
DCL001011	TAK-637	CHEBI:313748; TAK-637; CID9894349; CID 9894349; CHEBI:313113; CHEMBL339486	217185-75-6	1122655	26759232	TTDS00194	Substance-P receptor	Neurokinin 1 receptor;NK-1 receptor;NK-1R;SPR;Substance P receptor;Tachykinin 1 receptor;Tachykinin neurokinin 1 receptor;Tachykinin receptor 1	P25103	6869	ENSG00000115353	antagonist
DCL000943	R 673	2-(4-Nitro-phenyl)-benzooxazole; NCI60_036569; Oprea1_641073; Benzoxazole, 2-(4-nitrophenyl)-; BAS 00119028; AC-20987; 2-{4-nitrophenyl}-1,3-benzoxazole; R 673; CID70047; Benzoxazole, 2-(p-nitrophenyl)- (8CI); Benzoxazole, 2-(p-nitrophenyl)-; 2-(4-nitrophenyl)-1,3-benzoxazole; ZINC00289566; MolPort-001-631-632; AC1L2D8N; NSC702048; AR-1H9379; LS-42211; Oprea1_482358; AE-641/30106022; AC1Q21EW; AKOS000635168; 2-(4-Nitrophenyl)benzoxazole	840-58-4	70047	212231	TTDS00194	Substance-P receptor	Neurokinin 1 receptor;NK-1 receptor;NK-1R;SPR;Substance P receptor;Tachykinin 1 receptor;Tachykinin neurokinin 1 receptor;Tachykinin receptor 1	P25103	6869	ENSG00000115353	antagonist
DCL000759	CS-003	N/A	N/A	N/A	N/A	TTDS00194	Substance-P receptor	Neurokinin 1 receptor;NK-1 receptor;NK-1R;SPR;Substance P receptor;Tachykinin 1 receptor;Tachykinin neurokinin 1 receptor;Tachykinin receptor 1	P25103	6869	ENSG00000115353	antagonist
DCL000990	SLV-317	N/A	N/A	1349907	49698640	TTDS00194	Substance-P receptor	Neurokinin 1 receptor;NK-1 receptor;NK-1R;SPR;Substance P receptor;Tachykinin 1 receptor;Tachykinin neurokinin 1 receptor;Tachykinin receptor 1	P25103	6869	ENSG00000115353	antagonist
DCL000857	L-759274	N/A	737803-81-5	N/A	3821055	TTDS00194	Substance-P receptor	Neurokinin 1 receptor;NK-1 receptor;NK-1R;SPR;Substance P receptor;Tachykinin 1 receptor;Tachykinin neurokinin 1 receptor;Tachykinin receptor 1	P25103	6869	ENSG00000115353	antagonist
DCL000741	Casopitant	UNII-3B03KPM27L; Rezonic; GW679769; 1-Piperidinecarboxamide, 4-(4-acetyl-1-piperazinyl)-N-((1R)-1-(3,5-bis(trifluoromethyl)phenyl)ethyl)-2-(4-fluoro-2-methylphenyl)-N-methyl-, (2R,4S)-; Casopitant; 414910-27-3; GW 679769; CID 9917021; Zunrisa; CID9917021	414910-30-8	23725089	47208230	TTDS00194	Substance-P receptor	Neurokinin 1 receptor;NK-1 receptor;NK-1R;SPR;Substance P receptor;Tachykinin 1 receptor;Tachykinin neurokinin 1 receptor;Tachykinin receptor 1	P25103	6869	ENSG00000115353	antagonist
DCL001166	BMS-908662	N/A	N/A	N/A	N/A	TTDS00346	B-Raf proto-oncogene serine/threonine-protein kinase	BRAF;B-Raf;B-raf protein;BRAF serine/threonine kinase;BRAF(V599E);P94;V-Raf murine sarcoma viral oncogene homolog B1	P15056	673	ENSG00000157764	inhibitor
DCL000615	R7204	N/A	N/A	8515	48807484	TTDS00346	B-Raf proto-oncogene serine/threonine-protein kinase	BRAF;B-Raf;B-raf protein;BRAF serine/threonine kinase;BRAF(V599E);P94;V-Raf murine sarcoma viral oncogene homolog B1	P15056	673	ENSG00000157764	inhibitor
DCL001191	GSK2118436	N/A	N/A	N/A	N/A	TTDS00346	B-Raf proto-oncogene serine/threonine-protein kinase	BRAF;B-Raf;B-raf protein;BRAF serine/threonine kinase;BRAF(V599E);P94;V-Raf murine sarcoma viral oncogene homolog B1	P15056	673	ENSG00000157764	inhibitor
DAP000006	Sorafenib	BAY-54-9085; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide; BAY-43-0006; Sorafenib [INN]; NCGC00167488-01; CID216239; D08524; CHEBI:50924; 4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]AMINO}CARBONYL)AMINO]PHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE; Kinome_766; Bio-0100; sorafenibum; BAY 439006; Sorafenib; AC-1674; BAY 54-9085 (tosylate salt); LS-187788; DB00398; ZINC01493878; 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-; LS-186067; MolPort-003-850-270; Nexavar; DB07438; BAY-43-9006; 4-(4-{3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; NSC-724772; K00597a; AB1004622; BRD-K23984367-001-01-8; STK627350; N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea; I06-0856; 4(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; BAY 43-9006 (free base); CHEBI:47228; N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcar bamoyl)-4-pyridyloxy)phenyl)urea; nchembio.117-comp17; CHEMBL1336; N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea; 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide; 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide; BAX; EN002709; AC1L50CF; Sorafenib (INN); 4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide; 2-Pyridinecarboxamide, 4-(4-((((4-chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-; NSC747971; LS-187021; 4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate; UNII-9ZOQ3TZI87; BAY 43-9006; BAY43-9006; 284461-73-0; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide	284461-73-0	216239	789424	TTDS00346	B-Raf proto-oncogene serine/threonine-protein kinase	BRAF;B-Raf;B-raf protein;BRAF serine/threonine kinase;BRAF(V599E);P94;V-Raf murine sarcoma viral oncogene homolog B1	P15056	673	ENSG00000157764	inhibitor
DCL001079	R547	LS-193675; ZINC13983251; R547; DB08094; R-547; CHEMBL384304; [4-amino-2-[(1-methylsulfonylpiperidin-4-yl)amino]pyrimidin-5-yl]-(2,3-difluoro-6-methoxyphenyl)methanone; 2fvd; LIA; CID6918852; AC1OCFYV	N/A	N/A	N/A	TTDC00166	Cell division control protein 2 homolog	CDK1;Cyclin-dependent kinase 1;P34 protein kinase	Q6LFL1	N/A	N/A	inhibitor
DCL001080	R-roscovitine	2a4l; AR-1A2673; LS-182554; AC-2416; CYC202; 3ddq; Seliciclib; CYC202, Seliciclib, R-roscovitine, Roscovitine; M02443; 1-Butanol, 2-((9-(1-methylethyl)-6-((phenylmethyl)amino)-9H-purin-2-yl)amino)-, (R)-; CBiol_002016; 1-Butanol, 2-((9-(1-methylethyl)-6-((phenylmethyl)amino)-9H-purin-2- yl)amino)-, (2R)-; HMS1362F19; IDI1_002134; BiomolKI2_000054; S1153_Selleck; HMS1990F19; NSC-701554; AC1L4NH4; R7772_SIGMA; MolPort-003-959-463; CYC 202; 186692-46-6; CYC-202; AR-1A2674; 1-Butanol, 2-((9-(1-methylethyl)-6-((phenylmethyl)amino)-9H-purin-2-yl)amino)-, (2R)-; 6-(Benzylamino)-2(R)-[[1-(hydroxymethyl)propyl]amino]-9-isopropylpurine; Bio1_000302; KBioGR_000418; Bio1_000791; BRD-K07691486-001-03-1; Rosco; AKOS005146319; (2R)-2-[[6-(benzylamino)-9-propan-2-ylpurin-2-yl]amino]butan-1-ol; RRC; CID160355; HMS3229N13; 1-Butanol, 2-((9-(1-methylethyl)-6-((phenylmethyl)amino)-9H-purin-2- yl)amino)-, (R)-; KST-1A2714; NCGC00094374-04; 1-Butanol, 2-[[9-(1-methylethyl)-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-, (2R)-; SMP1_000266; HMS1792F19; BMK1-E12; KBioSS_000418; NCGC00094374-01; NSC701554; BCBcMAP01_000013; BRD-K07691486-001-05-6; KBio2_000418; KST-1A2715; ZINC01649340; CHEMBL14762; R-Roscovitine; NCGC00094374-02; Lopac0_001102; 2-(R)-[[9-(1-Methylethyl)-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-1-butanol; 2-(R)-(1-Ethyl-2-hydroxyethylamino)-6-benzylamino-9-isopropylpurine; KBio3_000795; BiomolKI_000048; roscovitine; (R)-roscovitine; NCI60_036420; Bio1_001280; InSolution&trade; Roscovitine; KBio2_002986; BSPBio_001078; KBio2_005554; Ambotz186692-46-6; NSC 701554; NCGC00094374-03; 2-[[9-(1-Methylethyl)-6-[(phenylmethyl)amino]- 9H-purin-2-yl]amino]-(R)-1-butanol; HSCI1_000092; (2r)-2-{[6-(benzylamino)-9-isopropyl-9h-purin-2-yl]amino}-1-butanol; AC1Q4VI5; Bio2_000379; Bio2_000859; KBio3_000796	186692-46-6	160355 	737846	TTDC00166	Cell division control protein 2 homolog	CDK1;Cyclin-dependent kinase 1;P34 protein kinase	Q6LFL1	N/A	N/A	inhibitor
DCL001082	Terameprocol	4-[(2S,3R)-4-(3,4-dimethoxyphenyl)-2,3-dimethylbutyl]-1,2-dimethoxybenzene; meso-Tetra-O-methylnordihydroguaiaretic acid; Butane, 1,4-bis(3,4-dimethoxyphenyl)-2,3-dimethyl-, meso-; AC1L9VRA; terameprocol; Terameprocol (INN/USAN); ZINC16953163; CHEMBL90983; CID476861; 24150-24-1; meso-1,4-Bis-(3,4-dimethoxyphenyl)-2,3-dimethylbutane; D09014; meso-Tetramethoxy-4,4'-(2,3-dimethyltetramethylene)dipyrocatechol; EM-1421	5701-82-6	476861 	N/A	TTDC00166	Cell division control protein 2 homolog	CDK1;Cyclin-dependent kinase 1;P34 protein kinase	Q6LFL1	N/A	N/A	inhibitor
DCL001074	P276-00	N/A	N/A	N/A	N/A	TTDC00166	Cell division control protein 2 homolog	CDK1;Cyclin-dependent kinase 1;P34 protein kinase	Q6LFL1	N/A	N/A	inhibitor
DCL000366	Ro 31-7453	AC1NS2UU; CID5327686; Bisindolylmaleimide deriv. 44; Ro-31-7453; 3-(1-methylindol-3-yl)-4-(1-methyl-6-nitroindol-3-yl)pyrrole-2,5-dione; MKC-1; CHEMBL52885	443912-18-3	N/A	3820971	TTDC00166	Cell division control protein 2 homolog	CDK1;Cyclin-dependent kinase 1;P34 protein kinase	Q6LFL1	N/A	N/A	inhibitor
DCL001084	ZK 304709	N/A	N/A	N/A	N/A	TTDC00166	Cell division control protein 2 homolog	CDK1;Cyclin-dependent kinase 1;P34 protein kinase	Q6LFL1	N/A	N/A	inhibitor
DCL001081	SCH 727965	Dinaciclib; SCH-727965	N/A	N/A	N/A	TTDC00166	Cell division control protein 2 homolog	CDK1;Cyclin-dependent kinase 1;P34 protein kinase	Q6LFL1	N/A	N/A	inhibitor
DPR000124	AG-024322	N-[[5-[(3E)-3-(4,6-difluorobenzimidazol-2-ylidene)-1,2-dihydroindazol-5-yl]-4-methylpyridin-3-yl]methyl]ethanamine; AG-24322; AG-024322; AC1OCFY2; CID6918834	N/A	N/A	N/A	TTDC00166	Cell division control protein 2 homolog	CDK1;Cyclin-dependent kinase 1;P34 protein kinase	Q6LFL1	N/A	N/A	inhibitor
DAP000592	Carbidopa	SMR000058235; Benzenepropanoic acid, alpha-hydrazino-3,4-dihydroxy-alpha-methyl-, (S)-; S1891_Selleck; CHEBI:39585; Carbidopa (anhydrous); Benzenepropanoic acid, alpha-hydrazino-3,4-dihydroxy-alpha-methyl-, monohydrate, (S); S-(-)-alpha-Hydrazino-3,4-dihydroxy-2-methylbenzenepropanoic acid; MLS000069628; (S)-carbidopa hydrate; NCGC00024596-05; (alphaS)-alpha-hydrazino-3,4-dihydroxy-alpha-methylbenzenepropanoic acid; L-alpha-Methyldopahydrazine; Lodosyn; N-Aminomethyldopa; HMS2089B12; NCGC00024596-03; L-alpha-Methyl-beta-(3,4-dihydroxyphenyl)-alpha-hydrazinopropionic acid; MLS002207014; CHEMBL1201236; 31823-41-3; NCGC00024596-01; Carbidopa Monohydrate; CPD-11550; Carbidopa, (S)-Isomer; Carbidopum [INN-Latin]; Atamet; Carbidopa-1-wasser; MolPort-003-940-629; HYDROCINNAMIC ACID, alpha-HYDRAZINO-3,4-DIHYDROXY-alpha-METHYL-, L-; Carbidopa [USAN:INN:BAN]; 27925-91-3; UNII-MNX7R8C5VO; (S)-carbidopa; CHEMBL1200748; CID38101; Lopac0_000382; 38821-49-7; L-alpha-Methyl-alpha-hydrazino-beta-(3,4-dihydroxyphenylpropionic acid; (2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid hydrate; Benzenepropanoic acid, alpha-hydrazino-3,4-dihydroxy-alpha-methyl-, monohydrate, (S)-; L-alpha-(3,4-dihydroxybenzyl)-alpha-hydrazinopropionic acid monohydrate; Carbidopa hydrate; EU-0100382; C1335_SIGMA; S(-)-CARBIDOPA; Methyldopahydrazine; CID34359; AC1L1Z32; MK 486; Lodosyn, Carbidopa; BB_SC-5095; MK-486; (-)-L-alpha-Hydrazino-3,4-dihydroxy-alpha-methylhydrocinnamic acid monohydrate; LS-77199; SMP1_000057; KINSON, 3-(3,4-DIHYDROXY-PHENYL)-2-HYDRAZINO-2-METHYL-PROPIONIC ACID; ST055523; CHEBI:3395; (S)-(-)-carbidopa; S-(-)-Carbidopa; S(-)-alpha-Hydrazino-3,4-dihydroxy-alpha-methylhydrocinnamic acid monohydrate; C-DOPA; (2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid--water (1/1); (-)-L-alpha-Hydrazino-3,4-dihydroxy-alpha-methylhydrocinnamic acid; DB00190; alpha-Hydrazino-alpha-methyl-beta-(3,4-dihydroxyphenyl)propionic acid; L-3-(3,4-Dihydroxyphenyl)-2-methyl-2-hydrazinopropionic acid; (2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid monohydrate; (2S)-3-(3,4-dihydroxyphenyl)-2-hydrazino-2-methylpropanoic acid; Carbidopa, Entacapone, & Levodopa; (S)-alpha--Hydrazino-3,4-dihydroxy-alpha--methyl-benzenepropanoic acid monohydrate; Carbidopum; AC1L1RFR; carbidopum monohydricum; carbidopa; 28860-95-9; Hadrazino-alpha-methyldopa; NCGC00024596-06; (2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid; UNII-KR87B45RGH; AC-1676; Carbidopa anhydrous; MolPort-005-934-181; Stalevo; C126_SIGMA; AC1Q5QGW; Lodosin; C-126; Hydrocinnamic acid, (-)-L-alpha-hydrazino-3,4-dihydroxy-alpha-methyl-, monohydrate; (alphaS)-alpha-hydrazino-3,4-dihydroxy-alpha-methylbenzenepropanoic acid monohydrate; CCRIS 5093; (S)-(-)-carbidopa hydrate; alpha-Methyldopahydrazine; MK-485; EINECS 249-271-9; Tocris-0455	28860-95-9	34359	176096	TTDS00361	Aromatic-L-amino-acid decarboxylase	AADC;DDC;DOPA decarboxylase	P20711	1644	ENSG00000132437	inhibitor
DAP000869	Vitamin B6	Piridoxina [INN-Spanish]; HMS2093L07; AC-907/25014218; CHEMBL1364; AIDS006784; Pydox; EINECS 232-503-8; Piridossina; LS-2332; 5-Hydroxy-6-methyl-3,4-pyridinedimethanol; AC-12024; CPD0-1221; P6280_SIGMA; AC1L1LMI; pyridoxine; Benadon; MolPort-002-137-856; Rodex (R); Pyridoxine, hydrochloride; 5-Hydroxy-6-methyl-3,4-pyridinedicarbinol hydrochloride; PYRIDOXINE HYDROCHLORIDE, U.S.P.; Vitaped; Oprea1_061614; 65-23-6 (Parent); Prestwick1_000623; SPBio_002805; 58-56-0 (hydrochloride); AR-1J1632; AR-1A6363; 4,5-Bis(hydroxymethyl)-2-methylpyridin-3-ol hydrochloride; KST-1A8556; 3,4-Pyridinedimethanol, 5-hydroxy-6-methyl-; 2B3E07D2-E4CC-4CC5-B085-6070BA01F9F0; Pyridoxine chloride; MolPort-005-933-330; AC1Q2G66; Pyridoxolum; Vitamin V6 (TN); NSC36225 (HCL); 3-Hydroxy-4,5-dimethylol-.alpha.-picoline hydrochloride; 5-Hydroxy-6-methyl-3,4-pyridinedimethanol hydrochloride; I02-1897; AC1L1AMH; Tex Six T.R.; STOCK1N-08684; Pyridoxin hydrochloride; CHEMBL1200756; CHEBI:30961; TimTec1_000657; Hexabetalin; Hexermine; AC1L2XK2; CID1054; bmse000288; Pyridoxine [INN:BAN]; NSC36225; Pyridoxinum; Prestwick0_000623; Hydoxin; AC-14512; 58-56-0; Aderoxine; D025101; 4,5-bis(hydroxymethyl)-2-methyl-3-pyridinol hydrochloride; UNII-KV2JZ1BI6Z; Pyridoxine hydrogen chloride; BPBio1_000646; SMR000674613; Cernevit-12; 2-Methyl-3-hydroxy-4,5-di(hydroxymethyl)pyridine; Hexabione hydrochloride; Pyridoxin; 58-56-0 (HCL); 3-Hydroxy-4,5-dihydroxymethyl-2-methylpyridine hydrochloride; Gravidox; Pyridoxine (INN); BSPBio_000586; Pyridoxol, hydrochloride; 47862_SUPELCO; Pyridoxinum hydrochloricum; Hexa-Betalin (R); D02179; 2-Methyl-3-hydroxy-4,5-dihydroxymethyl-pyridin [German]; P4722_SIAL; component of Alestrol; C8H11NO3; Prestwick3_000623; CID104817; 2-Methyl-4,5-bis(hydroxymethyl)-3-hydroxypyridine; NCGC00016261-01; MLS001074329; 65-23-6; AC1Q3F63; Hexa-betalin (TN); 2-Methyl-3-hydroxy-4,5-bis(hydroxymethyl)pyridine; HSDB 1212; WLN: T6NJ B1 CQ D1Q E1Q &GH; 85078-23-5; Pyridoxinium chloride; P9755_SIAL; Nestrex; PN HCl; MLS002153915; 4,5-Bis(hydroxymethyl)-2-methyl-3-pyridinol; Pyridoxine monohydrochloride; SMP2_000230; CAS-58-56-0; 8059-24-3; BIDD:PXR0180; NSC 36225; Pyridoxine hydrochloride [USAN:JAN]; Paxadon; Pyridoxine hydrochloride (JP15/USP); 3-hydroxy-4,5-bis(hydroxymethyl)-2-methylpyridine; Alestrol; Pyridoxol hydrochloride; LS-187072; NCGC00180946-01; NCGC00164317-01; 4-Deoxypyridoxine 5'-phosphate; c1302; Hexobion; vitamin B6; Bonasanit; AI3-19016; Spondylonal; 4,5-bis(hydroxymethyl)-2-methylpyridine-3-ol; Vitamin B 6; Pyridoxine Hydrochloride (B6); CID6019; Aderomine hydrochloride; C00314; 2-Picoline-4,5-dimethanol, 3-hydroxy-; D08454; CHEBI:16709; Pyridoxinum hydrochloricum (Hungarian); Pyridox; Pyridoxinum [INN-Latin]; Adermine hydrochloride; Adermine; ZINC00049154; 3-Hydroxy-4,5-dimethylol-alpha-picoline; Piridoxina; BB_NC-0050; Adermin hydrochloride; CBDivE_015627; ZINC21983293; Hexa-Betalin; Campoviton 6; EINECS 200-386-2; 2-methyl-3-hydroxy-4,5-bis(hydroxy-methyl) pyridine; Rodex TD; Hexermin; Piridossina [DCIT]; I02-2297; HMS1569N08; Hexavibex; 3,4-Pyridinedimethanol, 5-hydroxy-6-methyl-, hydrochloride; Pyridipca; CCRIS 1903; Pyridoxol; Beesix; Aderoxin; 3-Hydroxy-4,5-dimethylol-alpha-picoline hydrochloride; Vitamin V6; (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate; 2-methyl-4,5-dimethylol-pyridin-3-ol; Vitamin B6-hydrochloride; UNII-68Y4CF58BV; P8666_SIGMA; DB00165; nchembio.93-comp1; Vitamin-?B6; PN; STK177324; MolPort-002-319-991; Pyridoxine HCl; Godabion; 2-methyl-3-hydroxy-4,5-dihydroxymethylpyridine; Prestwick_925; P5669_SIGMA; LS-134393; Rodex; Becilan; P0561; 4,5-bis(hydroxymethyl)-2-methylpyridin-3-ol; AC1Q22HP; PYRIDOXINE HYDROCHLORIDE; Pyridoxine-HCl Microencapsulated; AIDS-006784; 12001-78-4; 2-Methyl-3-hydroxy-4,5-dihydroxymethyl-pyridin; EINECS 200-603-0; Vitamin-?B6 hydrochloride; Prestwick2_000623; 5-Hydroxy-6-methyl-3,4-pyridinedimethanol, hydrochloride	65-23-6	1054	3123	TTDS00361	Aromatic-L-amino-acid decarboxylase	AADC;DDC;DOPA decarboxylase	P20711	1644	ENSG00000132437	cofactor
DAP001328	Daptomycin	103060-53-3; D01080; MolPort-003-846-138; C12013; DAPTOMYCIN; Dapcin; N-decanoyl-L-tryptophyl-L-asparaginyl-N-[(3S,6S,9R,15S,18R,21S,24S,30S,31R)-3-[2-(2-aminophenyl)-2-oxoethyl]-24-(3-aminopropyl)-15,21-bis(carboxymethyl)-6-[(2R)-1-carboxypropan-2-yl]-9-(hydroxymethyl)-18,31-dimethyl-2,5,8,11,14,17,20,23,26,29-decaoxo-1-oxa-4,7,10,13,16,19,22,25,28-nonaazacyclohentriacontan-30-yl]-L-alpha-asparagine; MK-3009; N-decanoyl-L-tryptophyl-D-asparaginyl-L-aspartyl-L-threonylglycyl-L-ornithyl-L-aspartyl-D-alanyl-L-aspartylglycyl-D-seryl-threo-3-methyl-L-glutamyl-3-anthraniloyl-L-alanine epsilon(1)-lactone; Daptomicina [Spanish]; CHEMBL508162; Daptomycine [French]; N-decanoyl-L-tryptophyl-L-asparaginyl-N-[(3S,6S,9R,15S,18R,21S,24S,30S,31R)-3-[2-(2-aminophenyl)-2-oxoethyl]-24-(3-aminopropyl)-15,21-bis(carboxymethyl)-6-[(2R)-1-carboxypropan-2-yl]-9-(hydroxymethyl)-18,31-dimethyl-2,5,8,11,14,17,20,23,26,29-decaoxo-1-ox; N-decanoyl-L-tryptophyl-D-asparaginyl-L-aspartyl-L-threonylglycyl-L-ornithyl-L-aspartyl-D-alanyl-L-aspartylglycyl-D-seryl-threo-3-methyl-L-glutamyl-3-anthraniloyl-L-alanine 1.13-3.4-lactone; UNII-NWQ5N31VKK; Daptomycine; AKOS005146218; Daptomycinum; N-Decanoyl-L-tryptophyl-L-asparaginyl-L-aspartyl-L-threonylglycyl-L-ornithyl-L-aspartyl-D-alanyl-L-aspartylglycyl-D-seryl-threo-3-methyl-L-glutamyl-3-anthraniloyl-L-alanine epsilon1-lactone; Daptomycin [USAN:INN:BAN]; Cubicin (TN); CHEBI:600103; Deptomycin; Daptomycin (JAN/USAN/INN); nchembio.184-comp5; N-decanoyl-L-tryptophyl-D-asparaginyl-N-[(3S,6S,9R,15S,18R,21S,24S,30S,31R)-3-[2-(2-aminophenyl)-2-oxoethyl]-24-(3-aminopropyl)-15,21-bis(carboxymethyl)-6-[(2R)-1-carboxypropan-2-yl]-9-(hydroxymethyl)-18,31-dimethyl-2,5,8,11,14,17,20,23,26,29-decaoxo-1-oxa-4,7,10,13,16,19,22,25,28-nonaazacyclohentriacontan-30-yl]-L-alpha-asparagine; Daptomycinum [Latin]; Cidecin; C72H101N17O26; LY146032; LS-171846; Cubicin; Daptomicina; LY-146032	103060-53-3	16129629	14171	TTDS00462	Bacterial outer membrane	N/A	N/A	N/A	N/A	binder
DAP001326	Chlorhexidine	BSPBio_000246; Merfen-incolore; Periogard; Chlorhexidine gluconate; Sterido; AB1003159; BRN 2826432; Chlorhexidinum [INN-Latin]; Spectrum_000237; NSC526936; Chlorhexidine [INN:BAN]; KBio1_000761; DivK1c_000761; 4-12-00-01201 (Beilstein Handbook Reference); I06-0621; NCGC00091025-01; N',N'''''-hexane-1,6-diylbis[N-(4-chlorophenyl)(imidodicarbonimidic diamide)]; Clorhexidina; 348031_ALDRICH; KBioSS_000717; BPBio1_000272; BSPBio_001977; AB00053427; Sebidin A; LS-43917; 1,1'-Hexamethylenebis[5-(4-chlorophenyl)biguanide; Hexadol; NINDS_000761; HMS1568M08; N,N''''-hexane-1,6-diylbis[N'-(4-chlorophenyl)(imidodicarbonimidic diamide)]; 1,1'-Hexamethylenebis(5-(p-chlorophenyl)biguanide); Savloclens; 55-56-1; Chlorhexidin [Czech]; KBio2_000717; KBio3_001197; 24798_FLUKA; C22H30Cl2N10; 2,4,11,13-Tetraazatetradecanediimidamide, N,N'-bis(4-chlorophenyl)-3,12-diimino-; Cloresidina; Clorhexidina [INN-Spanish]; Oro-Clense; IDI1_000761; N,N'-Bis(4-chlorophenyl)-3,12-diimino-2,4,11,13-tetraazatetradecanediimidamide; 282227_ALDRICH; D07668; Hibiclens; Peridex; QTL1_000020; KBioGR_000774; Soretol; Prestwick1_000143; Prestwick3_000143; Spectrum2_000135; Chlorhexidinum; Fimeil; CHEBI:3614; DB00878; CHEMBL790; MK-412A; MolPort-002-541-741; Nolvasan; 1,1 inverted exclamation marka-Hexamethylenebis[5-(4-chlorophenyl)biguanide]; Savlon babycare; MLS002154209; NCGC00091025-02; 1,6-Di(N-p-chlorophenyldiguanido)hexane; Cloresidina [DCIT]; MLS001332387; Hibispray; Chlorhexidin; KBio2_005853; 1,1'-Hexamethylene bis(5-(p-chlorophenyl)biguanide); I14-0050; Dentisept [veterinary] (TN); Merfen-incolore (TN); Spectrum3_000339; CID9552079; CCRIS 9230; 1,6-Bis(5-(p-chlorophenyl)biguandino)hexane; STOCK1S-18831; Prestwick0_000143; 1,6-Bis(p-chlorophenyldiguanido)hexane; Decanoylacetaldehyde Sodium Sulfide; AVAGARD; Hibistat; 1,6-Di(4'-chlorophenyldiguanido)hexane; UNII-R4KO0DY52L; SPBio_000210; Spectrum5_001322; C06902; chlorhexidine; Prestwick2_000143; Nolvasan (*Diacetate*); Spectrum4_000277; EINECS 200-238-7; Chlorhexidine (INN); Dentisept [veterinary]; Biguanide, 1,1'-hexamethylenebis(5-(p-chlorophenyl)-; Sterilon; Sodium Houttuyfonamide; 2,4,11,13-Tetraazatetradecanediimidamide, N,N''-bis(4-chlorophenyl)-3,12-diimino-; KBio2_003285; HSDB 7196; Prestwick_53; Novalsan; Tubulicid; Superspray; Rotersept; NCGC00016246-01; Lisium (*Dihydrochloride*); N,N'-Bis(4-chlorophenyl)-3,12-diimino-2,4,11,13-tetraazatetradeca- nediimidamide; SPBio_002185; MLS001332388; CAS-55-56-1; SMR000857146; Chlorhexidine Base; STK089248	55-56-1	9552079	9119	TTDS00462	Bacterial outer membrane	N/A	N/A	N/A	N/A	N/A
DAP001323	Polymyxin B Sulfate	NCGC00094763-01; Polymxin B sulfate; Terramycin Ophthalmic; polymyxin b; Polimixina B; Polymyxine B [INN-French]; I06-1086; UNII-19371312D4; UNII-J2VZ07J96K; EINECS 215-774-7; Polymixin B sulfate; AC1NWAPL; LS-118122; HMS2092A07; S1395_Selleck; HMS1920J04; EINECS 215-768-4; Polymyxin B sulfate; Polymyxinum B [INN-Latin]; Polymyxinum B; N-[4-amino-1-[[1-[[4-amino-1-oxo-1-[[6,9,18-tris(2-aminoethyl)-15-benzyl-3-(1-hydroxyethyl)-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methyloctanamide; sulfuric acid; MolPort-003-665-543; 1405-20-5; SPECTRUM1500492; Polymyxin B, sulfate; Polymyxin B Sulfate [USAN:JAN]; 4-amino-N-[1-[[4-amino-1-oxo-1-[[6,9,18-tris(2-aminoethyl)-15-benzyl-3-(2-hydroxyethyl)-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-4-hydroxy-1-oxobutan-2-yl]-2-formamidobutanamide; sulfuric acid; NCGC00094763-02; CHEMBL1200626; AC1MJ145; Polymyxine B; CID3083708; Aerosporin; CID5702105; Polimixina B [INN-Spanish]; 1404-26-8; HMS502E14; Aerosporin, PMB, Poly-RX, Polymyxin B sulphate	1405-20-5	5702105	8149488	TTDS00462	Bacterial outer membrane	N/A	N/A	N/A	N/A	binder
DAP001463	Cefozopran	128007-70-5; LS-172220; CZOP; Cefozopran; ST51053161; D01052; CID9571080; 113359-04-9; Cefozopran (INN); Imidazo(1,2-b)pyridazinium, 1-((7-(((5-amino-1,2,4-thiadiazol-3-yl)(methoxyimino)acetyl)amino)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-, inner salt, (6R-(6alpha,7beta(Z)))-; ZINC22008130; (-)-1-(((6R,7R)-7-(2-(5-Amino-1,2,4-thiadiazol-3-yl)glyoxylamido)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-1H-imidazo(1,2-b)pyridazin-4-ium hydroxide inner salt, 7(sup 2)-(Z)-(O-methyloxime); Imidazo(1,2-b)pyridazinium, 1-((6R,7R)-7-(((2Z)-(5-amino-1,2,4-thiadiazol-3-yl)(methoxyimino)acetyl)amino)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-, inner salt; C11203; Cefozopran [INN]; 123572-82-7; I06-1627; SCE 2787; CCRIS 6737; C19H17N9O5S2; UNII-1LG87K28LW; 133790-04-2; 125882-76-0	113359-04-9	5491955	7848115	TTDS00462	Bacterial outer membrane	N/A	N/A	N/A	N/A	inhibitor
DAP001327	Gramicidin D	Gramicidins; C11218; CHEBI:5530; Gramicidin J; C60H92N12O10; LS-73105; CID73357; Gramicidinum S [INN-Latin]; LS-73094; Gramicidin [INN:BAN]; nchembio.145-comp39; Gramicin S-A; 1,10-anhydro(L-leucyl-D-phenylalanyl-L-prolyl-L-valyl-L-ornithyl-L-leucyl-D-phenylalanyl-L-prolyl-L-valyl-L-ornithine); 1393-88-0; Gramoderm; Gramicidin D; EINECS 215-738-0; Gramicidina S; Gramicidin S; CHEMBL373496; Gramicidina D; BRN 0605227; Gramacidine S; 60976-67-2; Gramicidinum [INN-Latin]; Gramicidin P; EINECS 215-790-4; Gramicidina S [INN-Spanish]; 113-73-5; Gramacidine S [INN-French]; Gramicidina [INN-Spanish]; Gramicin S 1; Gramicidin S [INN]; Gramicidin K; Neosporin Ophthalmic Solution; Gramicidine [INN-French]; Gramicidin A(1); Gramicidin C; AC1L2JPY; AC1Q1OAM; Cyclo(L-valyl-L-ornithyl-L-leucyl-D-phenylalanyl-L-prolyl-L-valyl-L-ornithyl-L-leucyl-D-phenylalanyl-L-prolyl); Gramicidin Dubos; Gramicidinum S	1405-97-6	16130140	597752	TTDS00462	Bacterial outer membrane	N/A	N/A	N/A	N/A	binder
DCL001008	SUN13834	N/A	161715-24-8	5567	48416662	TTDS00462	Bacterial outer membrane	N/A	N/A	N/A	N/A	inhibitor
DAP001321	Silver sulfadiazine	CID452254; AC-3535; NSC 625324; AC1L9Q6O; Par Brand 1 of Silver Sulfadiazine; AC1O8LAG; Smith & Nephew Brand of Silver Sulfadiazine; Sulfadiazine silverSilvadene; SMR000059233; Monarch Brand of Silver Sulfadiazine; 4-Amino-N-(2-pyrimidinyl)benzenesulfonamide silver salt; Sulfadiazine, silver (USP); Silvederma; 481181_ALDRICH; Sulfadiazine silver salt; silver 4-amino-N-pyrimidin-2-ylbenzenesulfonamide; D012837; AC1NUR63; Major Brand of Silver Sulfadiazine; Sulfadiazine silver (JP15); Silvadene (TN); MolPort-003-934-423; Sulfadiazine, Silver [USAN]; Par Brand 3 of Silver Sulfadiazine; Dermazine; Silver(I) sulfadiazine; TL8001845; Sulfargen; I06-0145; Aldo Brand of Silver Sulfadiazine; silver sulfadiazine; medphano Brand of Silver Sulfadiazine; UNII-W46JY43EJR; Sherwood Brand of Silver Sulfadiazine; AKOS005111099; ARONIS23842; CHEMBL1200766; AC1L9ATF; Rhone-Poulenc Rorer Brand of Silver Sulfadiazine; SSD (1% Silver Sulfadiazine Cream USP); S0595; CID31011; Thermazene; silver sulfadiazinate; Sulfafdiazine, Silver; LS-147839; CID5459124; Dermazin; N1-2-Pyrimidinylsulfanilamide monosilver(1+) salt; Sicazine; D00433; AC1L1KQS; AKOS005111434; STL069502; 22199-08-2; Flammazine; AC-19319; Silver,(4-amino-N-2-pyrimidinylbenzenesulfonamidato-NN,O1)-; Silver, [4-amino-N-(2-pyrimidinyl-.kappa.N1) benzenesulfonamidato-.kappa.O]-; CID11947738; Geben; Silvadene; Rhone Poulenc Rorer Brand of Silver Sulfadiazine; Sulfanilamide, N(sup 1)-2-pyrimidinyl-, monosilver(1+) salt; Par Brand 2 of Silver Sulfadiazine; EINECS 244-834-5; Sulfadiazin, silbersalz; (4-Amino-N-pyrimidin-2-ylbenzenesulphonamidato-NN,O1)silver; CHEBI:9142; Brandiazin; CID441244; SSD; silver (4-aminophenyl)sulfonyl-pyrimidin-2-ylazanide; MolPort-003-986-619; Sildaflo; Silbertone; MolPort-006-395-987; 4-amino-N-pyrimidin-2-ylbenzenesulfonamide; silver; SULFADIAZINE SILVER; Silver Sulfafdiazine; Sulfadiazin silber; MLS000069662; Silver, (4-amino-N-2-pyrimidinylbenzenesulfonamidato-NN,O1)-; Sulfanilamide,N1-2-pyrimidinyl-, monosilver(1+) salt; Sulfadiazine, silver; Flamazine; C10H9N4O2S.Ag; silver(1+) [(4-aminophenyl)sulfonyl](pyrimidin-2-yl)azanide; DB05245; Pharmascience Brand of Silver Sulfadiazine; SSD AF; NSC625324; Zenith Brand of Silver Sulfadiazine; Silver sulphadiazine; N(sup 1)-2-Pyrimidinylsulfanilamide monosilver(1+) salt; I06-145; Benzenesulfonamide, 4-amino-N-2-pyrimidinyl-, monosilver(1+) salt; Benzenesulfonamide,4-amino-N-2-pyrimidinyl-, silver complex; Solvay Brand of Silver Sulfadiazine; Abbott Brand of Silver Sulfadiazine	22199-08-2	441244	10298772	TTDS00462	Bacterial outer membrane	N/A	N/A	N/A	N/A	binder
DCL000778	Doripenem	CHEMBL491571; Doripenem; FT-0081127; CID73303; NCGC00167510-01; S 4661; 1-Azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 3-((5-(((aminosulfonyl)amino)methyl)-3-pyrrolidinyl)thio)-6-(1-hydroxyethyl)-4-methyl-7-oxo-, (4R-(3(3S*,5S*),4alpha,5beta,6beta(R*)))-; 148016-81-3; S-4661; (4R,5S,6S)-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-3-[(3S,5S)-5-[(sulfamoylamino)methyl]pyrrolidin-3-yl]sulfanyl-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; I14-8431; Doribax; D03895; AC1L2JMJ; UNII-BHV525JOBH; 1-Azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 3-(((3S,5S)-5-(((aminosulfonyl)amino)methyl)-3-pyrrolidinyl)thio)-6-((1R)-1-hydroxyethyl)-4-methyl-7-oxo-, (4R,5S,6S)-; Doripenem (USAN/INN)	148016-81-3	73303	17397979	TTDS00462	Bacterial outer membrane	N/A	N/A	N/A	N/A	inhibitor
DAP001324	Colistin	Colistin sulfate, nonsterile; AC1NSJWT; 1066-17-7; CID5311054; Polymyxin E; Polymyxin E. Sulfate; N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18S,21S)-6,9,18-tris(2-aminoethyl)-3-[(1R)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-5-methylheptanamide; Colistin sulphate; colistin; DB00803	1264-72-8	5311054	7978985	TTDS00462	Bacterial outer membrane	N/A	N/A	N/A	N/A	binder
DAP001477	Faropenem	AC1L246Z; CHEBI:51257; FPM; 106560-14-9; CHEMBL556262; TL8000237; I06-0479; MolPort-003-986-210; Fropenem; (5R,6S)-6-[(1R)-1-hydroxyethyl]-7-oxo-3-[(2R)-oxolan-2-yl]-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; faropenem; (+)-(5R,6S)-6-((1R)-1-Hydroxyethyl)-7-oxo-3-((2R)-tetrahydro-2-furyl)-4-thia-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid; CID65894; UNII-F52Y83BGH3; (5R,6S)-6-[(1R)-1-hydroxyethyl]-7-oxo-3-[(2R)-tetrahydrofuran-2-yl]-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; 6alpha-[(1R)-1-hydroxyethyl]-2-[(2R)-tetrahydrofuran-2-yl]-2,3-didehydropenam-3-carboxylic acid	141702-36-5	65894	3814630	TTDS00462	Bacterial outer membrane	N/A	N/A	N/A	N/A	inhibitor
DAP001329	Colistimethate	Colistin methanesulfonate sodium salt; Colistrimethate sodium; AC1L50DO; 37196-55-7; Colistimethate; Colistin sodium methanesulfonate from bacillus colistinus; Colistinemethanesulfonate sodique; 11048-71-8; DB01111; Coly-mycin injectable; 2680-63-9; Sodium colistin methanesulfonate; 11033-40-2; CID216258; LS-54708; Colymycin M; UNII-XW0E5YS77G; EINECS 232-516-9; 12768-67-1; Sodium colistinemethanesulfonate; 12705-41-8 (Parent); Colimycin M; 12676-33-4; Coly-Mycin M Parenteral; Colistinmethanesulfonic acid, sodium salt; 155704-91-9; Colistin sodium methanesulfonate; 21362-08-3; Colistimethate sodium; Colistimethate sodium [USAN:INN]; Colistimethale Sodium; Colimicina; 1867-68-1; Colimyscine; Colistin sulfomethate sodium; pentasodium [2-[17-(1-hydroxyethyl)-22-[[2-[[3-hydroxy-2-[[2-(6-methyloctanoylamino)-4-(sulfonatomethylamino)butanoyl]amino]butanoyl]amino]-4-(sulfonatomethylamino)butanoyl]amino]-5,8-bis(2-methylpropyl)-3,6,9,12,15,18,23-heptaoxo-11,14-bis[2-(sulfonatomethylamino)ethyl]-1,4,7,10,13,16,19-heptazacyclotricos-2-yl]ethylamino]methanesulfonate; 8068-37-9; Pentasodium colistinmethanesulfonate; Coly-Mycin M; Colistin Sulfomethate; Sodium colistimethate; W 1929; 8068-28-8	8068-28-8	216258	789446	TTDS00462	Bacterial outer membrane	N/A	N/A	N/A	N/A	binder
DAP001330	Vancomycin	nchembio.350-comp1; 64685-75-2 (sulfate); Vancomycin (USP); MolPort-001-794-649; Vancomicina; CHEMBL262777; Vancomycin [USAN:INN:BAN]; Vancocin (TN); Vancomycinum; AC1L24VU; D00212; CHEBI:28001; Prestwick1_000497; C66H75Cl2N9O24; Vancocin; Prestwick2_000497; LMPK14000004; CID441141; Lopac0_001267; AC1L9AMI; SPBio_002314; CID6917992; VANCOMYCIN; AC1Q29OH; C06689; Vancomycine [INN-French]; Vancocin HCL; 1404-90-6; Prestwick0_000497; LS-161387; Vancomycine; CID6426898; CID14969; HSDB 3262; DB00512; VAN; NCGC00162383-02; Vancomycinum [INN-Latin]; UNII-6Q205EH1VU; EINECS 215-772-6; CID5311496; 1404-93-9 (hydrochloride); Vancomicina [INN-Spanish]; BIDD:GT0353	1404-90-6	441141	8914	TTDS00462	Bacterial outer membrane	N/A	N/A	N/A	N/A	binder
DCL000912	Oritavancin	171099-57-3; (3S,6R,7R,22R,23S,26S,36R,38aR)-22-(3-Amino-2,3,6-trideoxy-3-C-methyl-alpha-L-mannopyranosyloxy)-3-(carbamoylmethyl)-10,19-dichloro-44-[2-O-[3-(4'-chlorobiphenyl-4-ylmethylamino)-2,3,6-trideoxy-3-C-me; (4''R)-22-O-(3-Amino-2,3,6-trideoxy-3-C-methyl-alpha-L-arabinohexopyranosyl)-N3''-(p-(p-chlorophenyl)benzyl)vancomycin; (4''R)-22-O-(3-Amino-2,3,6-trideoxy-3-C-methyl-alpha-L-arabino-hexopyranosyl)-N3''-(4'-chloro[1,1'-biphenyl]-4-ylmethyl)vancomycin; C12034; Nuvocid; Oritavancin; Oritavancin [INN]; LY333328; Chlorobiphenyl-chloroeremomycin	171099-57-3	16129632	12014991	TTDS00462	Bacterial outer membrane	N/A	N/A	N/A	N/A	inhibitor
DAP001325	Candicidin	CANDICIDIN; CID6474902; AC1O6FKD; (23E,25E,27E,29E,31E,33E,35E)-22-(4-amino-3,5-dihydroxy-6-methyloxan-2-yl)oxy-10,12,14,18,20-pentahydroxy-37-methyl-2,4,8,16-tetraoxo-1-oxacyclooctatriaconta-23,25,27,29,31,33,35-heptaene-19-carboxylic acid	1403-17-4	11953885	8915	TTDS00462	Bacterial outer membrane	N/A	N/A	N/A	N/A	binder
DCL000422	Alvocidib	UNII-45AD6X575G; S1230_Selleck; 2-(2-CHLORO-PHENYL)-5,7-DIHYDROXY-8-(3-HYDROXY-1-METHYL-PIPERIDIN-4-YL)-4H-BENZOPYRAN-4-ONE; Alvocidib; FLAVO; 131740-09-5; DB03496; HMR-1275, Alvocidib, L868275, Flavopiridol; Flavopiridol; 4H-1-Benzopyran-4-one, 2-(2-chlorophenyl)-5,7-dihydroxy-8-((3R,4S)-3-hydroxy-1-methyl-4-piperidinyl)-, rel-(-)-; 1e1y; CHEMBL428690; L 868275; CHEMBL8817; AC1NRALK; CID5287969; 4H-1-Benzopyran-4-one, 2-(2-chlorophenyl)-2,3-dihydro-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methyl-4-piperidinyl]-; L-868275; 1c8k; 358739-39-6; 4H-1-Benzopyran-4-one, 2-(2-chlorophenyl)-5,7-dihydroxy-8-(3-hydroxy-1-methyl-4-piperidinyl)-, cis-(-)-; 146426-40-6; Alvocidib [INN]; L86-8275; NSC649890; (-)cis-5,7-Dihydroxy-2-(2-chlorophenyl)-8-(4-(3-hydroxy-1-methyl)piperidinyl)-4H-1-benzopyran-4-one; 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]chromen-4-one; LS-173272; C21H20ClNO5; HMR-1275; Flavopiridol hydrochloride	131740-09-5	5287969	17397037	TTDC00212	Cyclin-dependent kinase	Cell division protein kinase;Cyclin-dependent protein kinase	N/A	N/A	N/A	inhibitor
DCL000066	BF-Derm1	N/A	168079-32-1	172997	47206571	TTDC00027	Histidine decarboxylase	HDC	P19113	3067	ENSG00000140287	inhibitor
DAP001313	Iron	Fe-40; CHEBI:18248; C00023; IRMM524B_FLUKA; 356808_ALDRICH; Atomiron 5M; MolPort-003-925-001; Diseases (animal), iron overload; PZh-1M3; 190454-13-8; Atomel 95; 266213_ALDRICH; 39344-71-3; 161135-39-3; ATW 432; LOHA; 209309_ALDRICH; 195161-83-2; Copy Powder CS 105-175; Atomel 28; PZh3M; 266256_ALDRICH; Atomiron 44MR; Siderol; AC1L2N38; NC 100; DSP 1000; C3518_SIGMA; HS (iron); Diseases, iron overload; Ferrum; DSP 128B; ATW 230; Iron(III) nitrate solution; Ancor B; D007501; PZh-2; 443783-52-6; FT 3 (element); PZh2M1; FE; Iron(1+) ion; 73135-38-3; 209309_SIAL; PZh3; 129048-51-7; 02583_FLUKA; Hoeganaes EH; Vitedyn-Slo; 14067-02-8; PZh2M2; 7439-89-6; 8011-79-8; 255637_ALDRICH; PZh1M1; HQ (metal); DSP 135; DB01592; Atomel 500M; PZhO; CCRIS 1580; F 60 (metal); CID23925; Hoeganaes ATW 230; PZh2M; UNII-E1UOL152H7; Iron monocation; Yieronia; EFV 250; 26Fe; 356832_ALDRICH; 267953_ALDRICH; EINECS 231-096-4; IRMM524A_FLUKA; Ed-In-Sol; Ferrovac E; DSP 138; Hemocyte; 44890_FLUKA; PZh4M; Eisen; ferrous iron; 44890_ALDRICH; Iron, ion (Fe1+) (8CI,9CI); SUY-B 2; Ferro-Caps; Iron, elemental; Feronate; Iron ion(1+); 12310_RIEDEL; EF 250; Ferro-Time; Atomiron AFP 5; EFV 250/400; HS 4849; Ferrousal; Iron(1+); Armco iron; 338141_ALDRICH; 3ZhP; Iron (Fe1+); Iron standard for AAS; 12310_ALDRICH; IRON; GS 6; EFV 200/300; Atomiron AFP 25; 267945_ALDRICH; Iron (Fe); LS-3196; Ancor en 80/150; HSDB 604; 675141-17-0; 413054_ALDRICH; Remko; Iron, ion (Fe1+); hierro; Iron ion (Fe+); Ferretts; 70884-35-4; C3518_SIAL; Fe1+; 8053-60-9; 356824_ALDRICH; DSP 135C; EF 1000; Carbonyl iron; Atomel 300M200; 199281-22-6; HF 2 (element); HL (iron)	7439-89-6	23925	3325	TTDS00498	Hemoglobin	Beta-globin;HBB;Hemoglobin beta chain;LVV-hemorphin-7	P69905	3039; 3040	ENSG00000188536; ENSG00000206172	activator
DAP001312	Iron Dextran	37318-94-8; 9044-58-0; Norferan; Sulfuric acid iron salt (1:1); Hawthron Brand of Iron-Dextran Complex; Eisendextran; Hematran; Fero Gradumet; IRON DEXTRAN; Sulfuric acid, iron salt; Infed; Ferdex 100; Prolongal; Myofer 100; Dextran-Iron Complex; CCRIS 347; Imfergen; 9009-88-5; D007505; GlaxoSmithKline Brand of Iron-Dextran Complex; Iron-dextran complex; Sulfuric acid, iron salt (1:?); UNII-95HR524N2M; Icar; Sulphuric acid, iron salt; Dextran iron complex; Ursoferran; AC1LAX7G; Iron hydrogenated dextran; B 75; Ferroglukin 75; Proferdex; Hauck Brand of Iron-Dextran Complex; Polyfer; Imferon; 8050-93-9; 11129-47-8; EINECS 233-336-3; 9004-66-4; Iro-Jex; American Regent Brand of Iron-Dextran Complex; Dexferrum; Iron dextran injection; 10124-49-9; Imperon; Imposil; iron; sulfuric acid; WLN: FE S-O4; Ferroglucin; HSDB 5102; Vortech Brand of Iron-Dextran Complex; Sanofi Brand of Iron-Dextran Complex; Eisendextran [German]; CID105075; 53858-58-5; NSC57631; A 100; AC1L2XZQ; 9061-47-6; Chinofer; RCRA waste number U139; Ferridextran; 37349-14-7; 50643-00-0; Sulfuric acid iron(2+) salt (1:1); AR-1J0769; Ironorm injection; NSC146177; Ferric dextran; Dextrofer; Fenate; Dextrofer 75; Ferrodextran; Goldline Brand of Iron-Dextran Complex; Watson Brand of Iron-Dextran Complex; A 100 (Pharmaceutical); Fe-Dextran; Iron dextran complex	9004-66-4	N/A	7849202	TTDS00498	Hemoglobin	Beta-globin;HBB;Hemoglobin beta chain;LVV-hemorphin-7	P69905	3039; 3040	ENSG00000188536; ENSG00000206172	activator
DAP000954	Aprindine	UNII-5Y48085P9Q; NCGC00186042-01; Aprindina; 33237-74-0; AC1L1D6R; 37640-71-4; N'-(2,3-dihydro-1H-inden-2-yl)-N,N-diethyl-N'-phenylpropane-1,3-diamine; N-(2,3-Dihydro-1H-inden-2-yl)-N',N'-diethyl-N-phenyl-1,3-propanediamine; CID2218; LS-119829; Aprinidine; CHEMBL1213033; Aprindine (USAN/INN); Aprindinum; Aprindine [USAN:BAN:INN]; 1,3-Propanediamine, N-(2,3-dihydro-1H-inden-2-yl)-N',N'-diethyl-N-phenyl-; N-(2,3-dihydro-1H-inden-2-yl)-N',N'-diethyl-N-phenylpropane-1,3-diamine; NSC284614; APRINDINE; Aprindinum [INN-Latin]; Aprindin; N,N-Diethyl-N'-2-indanyl-N'-phenyl-1,3-propanediamine monohydrochloride; Fibocil; Aprindina [INN-Spanish]; D02969; C22H30N2; AC 1802; DB01429; Compound 83846; N,N-Diethyl-N'-2-indanyl-N'-phenyl-1,3-propanediamine; N-(3-(Diethylamino)propyl)-N-phenyl-2-indanamine	37640-71-4	2218	7853763	TTDS00432	Calmodulin	N/A	P02593	N/A	N/A	inhibitor
DAP000034	Trifluoperazine	CHEBI:101325; STOCK1S-51401; NCI17474; HSDB 3195; TFP; Trifluoromethyl-10-(3'-(1-methyl-4-piperazinyl)propyl)phenothiazine; KBio2_001148; PDSP2_001284; Modalina; Bio1_000458; Prestwick0_000313; BRD-K89732114-001-03-4; AC1Q3ZYE; BSPBio_000306; Trifluperazine; Spectrum3_001374; Calmazine; 10-(3-(4-Methyl-1-piperazinyl)propyl)-2-(trifluoromethyl)phenothiazine; HMS1792L11; Apo-trifluoperazine (TN); NCGC00024251-06; Trifluoperazina [Italian]; HMS1362L11; STK182873; NCIStruc1_001127; NCIStruc2_001093; Biomol-NT_000060; KBio1_000843; NCGC00024251-07; Prestwick2_000313; Spectrum4_000368; Lopac0_001232; NCI60_001427; KBio2_003098; NSC46061; Trifluoperazine HCl; Tripfluoperazine Hydrochloride; KBio3_000960; CID5566; NSC 46061; Novo-Trifluzine; cMAP_000048; Trifluoperazine (INN); MLS002702821; NSC 17474; NCGC00013226-04; CHEBI:45951; Triftazine; Stelazine Concentrate; BSPBio_001190; Stelazine (*Dihydrochloride*); HMS1990L11; 10-[3-(4-Methyl-1-piperazinyl)propyl]-2-(trifluoromethyl)-10H-phenothiazine; Spectrum5_001553; 10-(gamma-(N'-Methylpiperazino)propyl)-2-trifluoromethylphenothiazine; KBioGR_002431; NCGC00013226-03; nchembio873-comp70; Trifluroperizine; KBioGR_000530; BIDD:PXR0132; IDI1_002190; KBio2_005666; D08636; RP 7623; MolPort-001-727-956; Fluoperazine; KBio2_006284; DivK1c_000843; AKOS001487920; 10-[3-(4-METHYL-PIPERAZIN-1-YL)-PROPYL]-2-TRIFLUOROMETHYL-10H-PHENOTHIAZINE; NCGC00024251-04; KBio3_002148; Trifluoperazinum [INN-Latin]; 10H-Phenothiazine, 10-(3-(4-methyl-1-piperazinyl)propyl)-2-(trifluoromethyl)-; C21H24F3N3S; L001075; 2-Trifluoromethyl-10-(3'-(1-methyl-4-piperazinyl)propyl)phenothiazine; CCRIS 6994; 10-[3-(4-methylpiperazin-1-yl)propyl]-2-(trifluoromethyl)phenothiazine dihydrochloride; BRD-K89732114-300-05-5; Bio1_000947; KBio2_000530; Apo-Trifluoperazine; Triperazine; Bio2_000435; Bio2_000915; IDI1_000843; QTL1_000085; BPBio1_001345; Triflurin; SPBio_000755; 117-89-5; 10H-Phenothiazine, 10-[3-(4-methyl-1-piperazinyl)propyl]-2-(trifluoromethyl)-; CHEMBL422; NSC-17474; SR-01000003020-6; PMS Trifluoperazine; DB08616; KBioSS_000530; KBio2_004999; KBio3_002910; CAS-440-17-5; Stellazine; Trifluoperazine [INN:BAN]; SMR001566649; BRD-K89732114-001-02-6; Trifluoperazin; KBio2_007567; AC1L1KMT; Flurazine; KBioGR_000835; AB00053558; 10-[3-(4-methylpiperazin-1-yl)propyl]-2-(trifluoromethyl)-10H-phenothiazine; Trifluoroperazine; KBio3_000959; NCGC00013226; NSC17474; Trifluoperazina [INN-Spanish]; SPBio_002525; NCGC00024251-03; HMS2089J11; Trifluoperazina; Spectrum2_000828; 10-(3-(4-methyl-1-piperazinyl)propyl)-2-(trifluoromethyl)-10H-phenothiazine; Trifluoromethylperazine; NINDS_000843; Prestwick1_000313; UNII-214IZI85K3; Trifluoperazinum; 10-[3-(4-methylpiperazin-1-yl)propyl]-2-(trifluoromethyl)phenothiazine; Trifluoroperazine dihydrochloride; Prestwick3_000313; LS-105595; Triphtazin; NCGC00013226-02; C07168; Lopac-T-8516; NCGC00013226-12; trifluoperazine; Eskazine; PDSP1_001300; KBioSS_002437; Spectrum_000668; NCI60_004087; KBio2_002431; Triphthasine; NCGC00024251-05; Phenothiazine, 10-(3-(4-methyl-1-piperazinyl)propyl)-2-(trifluoromethyl)-; KBio2_003716; Triphtazine; BSPBio_002928; Triftazin; Stelazine; Trifluoperazine dihydrochloride; EINECS 204-219-4; KBioSS_001148; Bio1_001436; BPBio1_000338; 10-(3-(4-methyl-1-piperazinyl)propyl)-2-(trifluoromethyl)-phenothiazine; DB00831; SKF 5019	117-89-5	5566	9377	TTDS00432	Calmodulin	N/A	P02593	N/A	N/A	inhibitor
DCL001139	ALN-VSP	N/A	N/A	N/A	N/A	TTDC00339	mRNA of kinesin spindle protein	mRNA of Kinesin-like protein KIF11;mRNA of Kinesin-like protein 1;mRNA of Kinesin-like spindle protein HKSP;mRNA of Kinesin-related motor protein Eg5;mRNA of Thyroid receptor-interacting protein 5;mRNA of TR-interacting protein 5;mRNA of TRIP-5;mRNA of KIF11	P52732	3832	ENSG00000138160	N/A
DCL000236	STA-9090	N/A	131094-16-1	N/A	17397511	TTDC00018	Heat shock protein HSP 90	HSP 86;HSP90A;HSP90AA1;HSPC1;HSPCA;Renal carcinoma antigen NY-REN-38	P07900	3320	ENSG00000080824	inhibitor
DCL000035	Alvespimycin hydrochloride	17-DMAG; S1142_Selleck; 17DMAG; Alvespimycin hydrochloride; 17-N,N-Dimethylaminoethylamino-17-demethoxy-geldanamycin, HCl; 17-Desmethoxy-17-N,N-dimethylaminoethylamino-geldanamycin, HCl; 17DMAG, Alvespimycin, KOS-1022, NSC 707545, 17-DMAG; 467214-21-7; CID9852573; D06554; Alvespimycin hydrochloride (USAN); NSC 707545	467214-21-7	9852573	47208210	TTDC00018	Heat shock protein HSP 90	HSP 86;HSP90A;HSP90AA1;HSPC1;HSPCA;Renal carcinoma antigen NY-REN-38	P07900	3320	ENSG00000080824	inhibitor
DCL000057	AT13387	CID11955716; AT-13387; CHEMBL1214827; CID 11955716	482299-54-7	N/A	10549742	TTDC00018	Heat shock protein HSP 90	HSP 86;HSP90A;HSP90AA1;HSPC1;HSPCA;Renal carcinoma antigen NY-REN-38	P07900	3320	ENSG00000080824	inhibitor
DCL000089	CNF1010	N/A	N/A	N/A	N/A	TTDC00018	Heat shock protein HSP 90	HSP 86;HSP90A;HSP90AA1;HSPC1;HSPCA;Renal carcinoma antigen NY-REN-38	P07900	3320	ENSG00000080824	inhibitor
DCL000242	Tanespimycin	HMS1989H16; BSPBio_001434; 17-AG; CP-127374; NSC-330507D; MolPort-003-983-836; AC1O6S9N; Tanespimycin (USAN); NSC-704057; Tanespimycin; D06650; NCGC00163424-01; [(3R,5S,6R,7S,8E,10S,11S,12Z,14E)-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-21-(prop-2-enylamino)-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; IDI1_033904; NSC-330507; 75747-14-7; NCGC00163424-02; [(3S,5S,6R,7S,8E,10R,11S,12E,14E)-6-Hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-21-(prop-2-enylamino)-17-azabicyclo[16.3.1]docosa-8,12,14,18,21-pentaen-10-yl] carbamate; 17-Allylaminogeldanamycin; CHEMBL109480; 17-(Allylamino)-17-demethoxygeldanamycin; A00281; CNF-101; 17AAG, Tanespimycin, Geldanamycin, NSC330507, 17-(Allylamino)-17-demethoxygeldanamycin, CP 127374; NChemBio.2007.10-comp2; CID6505803; S1141_Selleck; HMS1361H16; HMS1791H16; 17-AAG	75747-14-7	6505803	47208301	TTDC00018	Heat shock protein HSP 90	HSP 86;HSP90A;HSP90AA1;HSPC1;HSPCA;Renal carcinoma antigen NY-REN-38	P07900	3320	ENSG00000080824	inhibitor
DCL000231	SNX-5422	N/A	N/A	3448	49698969	TTDC00018	Heat shock protein HSP 90	HSP 86;HSP90A;HSP90AA1;HSPC1;HSPCA;Renal carcinoma antigen NY-REN-38	P07900	3320	ENSG00000080824	inhibitor
DCL000137	IPI-504	UNII-928Q33Q049; 857402-63-2; 17-Allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride; IPI 504; IPI-504; 17-allyl-aminogeldanamycin	857402-63-2	44148156	85149781	TTDC00018	Heat shock protein HSP 90	HSP 86;HSP90A;HSP90AA1;HSPC1;HSPCA;Renal carcinoma antigen NY-REN-38	P07900	3320	ENSG00000080824	inhibitor
DAP000590	Docetaxel	TXL; ZDZOTLJHXYCWBA-VCVYQWHSSA-; DB01248; C11231; ANX-514; docetaxel; nchembio.2007.34-comp7; Taxotere (TN); MolPort-003-847-005; (2alpha,5beta,7beta,10beta,13alpha)-4-(acetyloxy)-13-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7,10-trihydroxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate; N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol; docetaxel 114977-28-5; Docetaxel (INN); N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel; InChI=1/C43H53NO14/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,5; (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl (aR,bS)-b-[[(1,1-dimethylethoxy)carbonyl]amino]-a-hydroxybenzenepropanoate; RP-56976; nchembio853-comp8; XRP-6976L; CHEMBL92; 114977-28-5; EmDOC; AC-383; 01885_FLUKA; nchembio.573-comp11; 4-(acetyloxy)-13alpha-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate; nchembio.188-comp8; HMS2089K08; NSC-628503; Taxotere(R); N-debenzoyl-N-Boc-10-deacetyl taxol; AC1L3WHJ; SDP-014; CID148124; Docetaxel, Trihydrate; Taxotere; CHEBI:4672; D07866; Docetaxel anhydrous	114977-28-5	148124	13410	TTDS00271	Tubulin	N/A	N/A	N/A	N/A	inhibitor
DCL000798	Epothilon	N/A	1520044-54-7	N/A	53787971	TTDS00271	Tubulin	N/A	N/A	N/A	N/A	N/A
DCL001167	BNC105	N/A	N/A	N/A	N/A	TTDS00271	Tubulin	N/A	N/A	N/A	N/A	inhibitor
DCL000552	Larotaxel	CID6918260; CID 9832607; Larotaxel; XRP9881; XRP 9881; PNU 100940; Benzenepropanoic acid, beta-(((1,1-dimethylethoxy)carbonyl)amino)-alpha-hydroxy-, (1S,2S,4S,7R,8aR,9aS,10aR,12aS,12bR)-7,12a-bis(acetyloxy)-1-(benzoyloxy)-1,3,4,7,8,9,9a,10,10a,12,12a,12b-dodecahydro-2-hydroxy-5,13,13-trimethyl-8-oxo-2,6-methano-2H-cyclodeca(3,4)cyclopropa(4,5)benz(1,2-b)oxet-4-yl ester, (alphaR,betaS)-; 156294-36-9	156294-36-9	6918260	85150270	TTDS00271	Tubulin	N/A	N/A	N/A	N/A	inhibitor
DAP001562	Ixabepilone	BMS-247550; azaepothilone B	N/A	N/A	N/A	TTDS00271	Tubulin	N/A	N/A	N/A	N/A	N/A
DAP001557	Eribulin	N/A	N/A	N/A	N/A	TTDS00271	Tubulin	N/A	N/A	N/A	N/A	inhibitor
DAP000765	Vinorelbine	C'-Norvincaleukoblastine, 3',4'-didehydro-4'-deoxy-; MolPort-006-823-869; CHEMBL607994; methyl (2beta,3beta,4beta,5alpha,12beta,19alpha)-4-acetoxy-15-[(6R,8S)-4-ethyl-8-(methoxycarbonyl)-1,3,6,7,8,9-hexahydro-2,6-methanoazecino[4,3-b]indol-8-yl]-3-hydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidine-3-carboxylate; CHEBI:480999; UNII-Q6C979R91Y; I06-0084; CID6426842; Aspidospermidine-3-carboxylic acid, 4-(acetyloxy)-6,7-didehydro-15-((2R,6R,8S)-4-ethyl-1,3,6,7,8,9-hexahydro-8-(methoxycarbonyl)-2,6-methano-2H-azecino(4,3-b)indol-8-yl)-3-hydroxy-16-methoxy-1-methyl-, methyl ester, (2beta,3beta,4beta,5alpha,12R,19alpha)-; DB00361; Vinorelbina [Spanish]; KW 2307 base; Eunades; 71486-22-1; Aspidospermidine-3-carboxylic acid, 4-(acetyloxy)-6,7-didehydro-15-((2R,6R,8S)-4-ethyl-1,3,6,7,8,9-hexahydro-8-(methoxycarbonyl)-2,6-methano-2H-azecino(4,3-b)indol-8-yl)-3-hydroxy-16-methoxy-1-methyl-, methyl ester, (2beta,3beta,4beta,5alpha,12beta,19alpha)-; CID5672; AC1L1KVK; C45H54N4O8; AC1L75Q4; BIDD:PXR0186; ANX-530; NCGC00165966-02; Ambap71486-22-1; CID60780; I06-0085; Vinorelbinum; Navelbine base; Nor-5'-anhydrovinblastine; Vinorelbine ditartrate; vinorelbine; NVB; Vinorelbine Ditartarate; Vinorelbin; KW-2307; Vinorelbine [INN:BAN]; AC1L1TWQ; HSDB 7665; Vinorelbine (INN); methyl (2b,3b,4b,5a,12b,19a)-4-(acetyloxy)-15-[(6R,8S)-4-ethyl-8-(methoxycarbonyl)-1,3,6,7,8,9-hexahydro-2,6-methanoazecino[4,3-b]indol-8-yl]-3-hydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidine-3-carboxylate; Vinorelbina; CID5311497; Navelbine (TN); Exelbine; MolPort-006-822-661; Vinorelbine tartrate; KW 2307; HMS2090E13; LS-97533; SDP-012; Navelbine; D08680; CID355119; Vinorelbinum [Latin]	71486-22-1	60780	668899	TTDS00271	Tubulin	N/A	N/A	N/A	N/A	inhibitor
DAP001254	Colchicine	NCGC00169157-03; NCI60_041659; HMS1569I07; NSC 757; NCGC00025125-11; nchembio853-comp2; Kolkicin; Colchicin; Acetamide, N-((7S)-5,6,7,9-tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo(a)heptalen-7-yl)-; NCGC00025125-01; Acetamide, N-(5,6,7,9-tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo[.alpha.]heptalen-7-yl)-; C22H25NO6; BSPBio_002083; S2284_Selleck; 7alphaH-Colchicine; N-(5,6,7,9-Tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo[.alpha.]heptalen-7-yl)-acetamide; NCGC00169157-02; Spectrum_000842; N-((7S)-5,6,7,9-tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo(a)heptalen-7-yl)- acetamide; UPCMLD-DP065; N-(5,6,7,9-Tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo(a)heptalen-7-yl)acetamide; N-[(7S)-1,2,3,10-tetramethoxy-9-oxo-6,7-dihydro-5H-benzo[a]heptalen-7-yl]acetamide; Prestwick_695; NCGC00025125-02; 64-86-8; 5843-86-7; Acetamide, N-(5,6,7,9-tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo(a)heptalen-7-yl)-, (S)-; AC1L1LXO; MPC-004; CPD-9785; KBio3_001303; AKOS001582887; N-[(7S)-5,6,7,9-tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo[a]heptalen-7-yl]acetamide; C3915_SIGMA; Spectrum2_000075; BRD-K00259736-001-06-5; CHEMBL107; BB_NC-0737; colchicine; UNII-SML2Y3J35T; HMS1920A08; C 9754; SPBio_002406; NINDS_000753; EU-0100310; NChemBio.2007.10-comp20; Spectrum4_000298; IDI1_000753; NSC757; N-[(7S)-1,2,3,10-tetramethoxy-9-oxo-5,6,7,9-tetrahydrobenzo[a]heptalen-7-yl]acetamide; AI3-31149; ACon1_000353; KBio2_006458; Lopac0_000310; CCRIS 691; Spectrum3_000362; Colcin; Acetamide, N-(5,6,7,9-tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo[a]heptalen-7-yl)-, (S)-; MLS001304089; Colchineos; Condylon; MolPort-001-742-594; SMR000058323; Colchicina; 7.alpha.H-Colchicine; spindle poison; NCGC00025125-03; Prestwick1_000363; Colchicine, Colchicum autumnale; DivK1c_000753; Acetamide, N-(5,6,7,9-tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo(alpha)heptalen-7-yl)-; Prestwick0_000363; Tocris-1364; CHEBI:27882; Colchicine (TN); NCGC00025125-05; BPBio1_000535; Colchicine [JAN]; LS-279; KBio1_000753; MLS001055448; Benzo(a)heptalen-9(5H)-one; KBio2_003890; Prestwick2_000363; Acetamide, N-(5,6,7,9-tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo(.alpha.)heptalen-7-yl)-; BSPBio_000485; NCGC00025125-04; KBio2_001322; MLS002153786; 30512-31-3; C9754_SIGMA; CID6167; SPECTRUM1500205; Prestwick3_000363; KBioSS_001322; KBioGR_000856; Colchicinum; Colchicin [German]; Colchicine, (+-)-Isomer; NCGC00025125-06; EINECS 200-598-5; MEGxp0_001879; D003078; Colchicine, (R)-Isomer; Colcrys; (S)-N-(5,6,7,9-Tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo[a]heptalen-7-yl)acetamide; Colchicina [Italian]; Colchysat; WLN: L B677 MV&T&J CO1 DO1 EO1 JMV1 NO1; HMS2091G16; SPBio_000289; Colchisol; Colsaloid; HMS502F15; SDCCGMLS-0066633.P001; C07592; N-Acetyl trimethylcolchicinic acid methylether; UPCMLD-DP065:001; Benzo(a)heptalen-9(5H)-one, 7-acetamido-6,7-dihydro-1,2,3,10-tetramethoxy-; LOC; Colchicine (JP15/USP); DB08117; NCGC00025125-07; binds to tubulin; inhibits microtubular assembly; ZINC00621853; NCGC00169157-01; HSDB 3044; Spectrum5_000787; MLS001055448-02; 7-alpha-H-Colchicine; Goutnil; Colstat; Benzo[a]heptalen-9(5H)-one, 7-acetamido-6,7-dihydro-1,2,3,10-tetramethoxy-; DB01394; D00570	64-86-8	6167	7847636	TTDS00271	Tubulin	N/A	N/A	N/A	N/A	binder
DAP000114	Vincristine	LS-228; Indole alkaloid; Vincasar; LCR; Z-D-Val-Lys(Z)-OH; Vinkristin; VIN; Lilly 37231 (1:1 sulfate salt); 22-Oxovincaleukoblastine; CID5978; Vincaleukoblastine, 22-oxo-; Vincaleukoblastine, 22-oxo- 22-Oxovincaleukoblastine; vincristine; Vincristinum [INN-Latin]; Vincristine (INN); UNII-5J49Q6B70F; 28379-27-3; C46H56N4O10; Onco TCS; AC1L1LJC; Vincasar (1:1 sulfate salt); Vincristina [DCIT]; Vincristinum; Vincristina; Vincrstine; CHEBI:28445; Tecnocris (TN); NCGC00163700-01; Tecnocris; HSDB 3199; Leurocristine; EINECS 200-318-1; D08679; CCRIS 5763; VCR; NCI-C04864; Vincrex (1:1 sulfate salt); Liposomal Vincristine; DB00541; Vincrystine; HMS2090E19; Oncovine; Oncovin (1:1 sulfate salt); NCI60_026703; C07204; NSC-67574; 57-22-7; Marqibo; Vincristine [INN:BAN]	57-22-7	5978	148816	TTDS00271	Tubulin	N/A	N/A	N/A	N/A	binder
DCL001197	Indibulin	N/A	N/A	N/A	N/A	TTDS00271	Tubulin	N/A	N/A	N/A	N/A	N/A
DCL000787	E 7974	N/A	N/A	N/A	N/A	TTDS00271	Tubulin	N/A	N/A	N/A	N/A	inhibitor
DCL000502	Cabazitaxel	CID 9897396; CABAZITAXEL; CHEMBL1201748; CID9854073; Taxoid XRP6258; DB06772; Jevtana	890654-44-1	N/A	85151112	TTDS00271	Tubulin	N/A	N/A	N/A	N/A	inhibitor
DCL000069	Bimosiamose	TBC-1269; Bimosiamose; CHEBI:787792; 187269-40-5; UNII-97B5KCW80W; CID 9811353; (1,1'-Biphenyl)-3-acetic acid, 3',3'''-(1,6-hexanediyl)bis(6'-(alpha-D-mannopyranosyloxy)-; CID9811353; TBC 1269; CHEMBL1215923	187269-40-5	N/A	10549630	TTDC00098	E-selectin	CD62E;CD62E antigen;ELAM-1;Endothelial leukocyte adhesion molecule 1;LECAM2;Leukocyte-endothelial cell adhesion molecule 2	P16581	6401	ENSG00000007908	inhibitor
DAP001394	Ketanserin	CHEMBL51; AC1L1GSK; Spectrum2_001713; HMS2094I03; I06-0365; LS-140148; EINECS 277-680-2; Taseron; 2,4(1H,3H)-Quinazolinedione, 3-(2-(4-(4-fluorobenzoyl)-1-piperidinyl)ethyl)-; NCGC00024865-03; R-41,468; AC-2024; CHEBI:6123; R-41468; NCGC00021146-01; 3-(2-{4-[(4-fluorophenyl)carbonyl]piperidin-1-yl}ethyl)quinazoline-2,4(1H,3H)-dione; NCGC00021146-07; Ketanserine; Ketanserinum [INN-Latin]; NCGC00024865-05; Ketanserina [INN-Spanish]; NCGC00024865-02; Perketal; D02363; BRD-K49671696-347-02-8; 3-[2-[4-(4-fluorobenzoyl)piperidin-1-yl]ethyl]-1H-quinazoline-2,4-dione; Serefrex; Ketanserinum; ST51051219; PDSP2_000634; Ketanserin (USAN/INN); C22H22FN3O3; BRD-K49671696-001-02-1; Ketaserin; 3-(2-(4-(p-Fluorobenzoyl)piperidino)ethyl)-2,4-(1H,3H)-quinazolinedione; 74050-98-9; Tocris-0908; C07464; PDSP1_000639; SPECTRUM1505346; Ketanserin; 3-[2-[4-(4-fluorobenzoyl)-1-piperidyl]ethyl]-1H-quinazoline-2,4-dione; CID3822; 3-(2-(4-(4-Fluorobenzoyl)piperidinol)ethyl)-2,4(1H,3H)-quinazolinedione; NCGC00024865-04; Biomol-NT_000096; (+)-3-[2-[4-(4-Fluorobenzoyl)-1-piperidinyl]ethyl]-2,4(1H,3H)-quinazolinedione; HMS1923O11; Ketanserina; NCGC00024865-01; Ketanserin [USAN:BAN:INN]; SPBio_001726; BPBio1_001356; R 41,468; HMS2090H18; [3H]-Ketanserin; Ketanserine [INN-French]; Sufrexal; L000764; 3-{2-[4-(4-fluorobenzoyl)piperidin-1-yl]ethyl}quinazoline-2,4(1H,3H)-dione	74050-98-9	3822	9667	TTDS00102	5-hydroxytryptamine 2 receptor	5-HT2 receptor;5-HTB2;Serotonin receptor 2	N/A	N/A	N/A	antagonist
DCL000806	Fluphenazine Decanoate	NSC169510; Flufenazine decanoate; AC1L1FTN; Decanoic acid, 2-(4-(3-(2-(trifluoromethyl)-10H-phenothiazin-10-yl)propyl)-1-piperazinyl)ethyl ester; CCRIS 3954; Fluphenazine depot; 5002-47-1; CHEMBL1200854; Decanoic acid, 2-[4-[3-[2-(trifluoromethyl)phenothiazin-10-yl]propyl]-1-piperazinyl]ethyl ester; Fluphenazine decanoate; AKOS003589045; Fluphenazine O-decanoate; EINECS 225-672-4; Fluphenaline decanoate; Moditen-depo; SQ 10,733; Dapotum D; WLN: T C666 BN ISJ EXFFF B3- AT6N DNTJ D2OV9; AC1Q4K03; Moditen depot; 2-(4-(3-(2-(Trifluoromethyl)phenothiazin-10-yl)propyl)-1-piperazinyl)ethyl decanoate; D00793; Fluphenazine decanoate (JAN/USP); Fluorophenazine decanoate; LS-59383; Prolixin decanoate (TN); MolPort-001-728-034; BRN 0599852; NSC 169510; UNII-FMU62K1L3C; C32H44F3N3O2S; CID3388; 2-[4-[3-[2-(trifluoromethyl)phenothiazin-10-yl]propyl]piperazin-1-yl]ethyl decanoate; Decanoic acid, 2-[4-[3-[2-(trifluoromethyl)-10H-phenothiazin-10-yl]propyl]-1-piperazinyl]ethyl ester; Modecate; AR-1J0863; 2-(4-{3-[2-(trifluoromethyl)-10H-phenothiazin-10-yl]propyl}piperazin-1-yl)ethyl decanoate; Decanoic acid, 2-(4-(3-(2-(trifluoromethyl)phenothiazin-10-yl)propyl)-1-piperazinyl)ethyl ester	5002-47-1	490519	46506645	TTDS00102	5-hydroxytryptamine 2 receptor	5-HT2 receptor;5-HTB2;Serotonin receptor 2	N/A	N/A	N/A	antagonist
DCL000282	E2101	N/A	N/A	N/A	N/A	TTDS00102	5-hydroxytryptamine 2 receptor	5-HT2 receptor;5-HTB2;Serotonin receptor 2	N/A	N/A	N/A	antagonist
DAP000293	Mianserin	NCGC00015656-09; NINDS_000844; KBioSS_002303; DB06148; KBioGR_001820; Spectrum4_001260; PDSP1_001532; Mianserine; mianserin; Mianserin (INN); 24219-97-4; Dibenzo(c,f)pyrazino(1,2-a)azepine, 1,2,3,4,10,14b-hexahydro-2-methyl-; Prestwick3_000099; Oprea1_703627; Mianserina [INN-Spanish]; Lopac0_000744; Spectrum_001810; Tolvon; BSPBio_000058; SPBio_000986; BRD-A19661776-001-01-5; Mianserine [INN-French]; 21535-47-7 (mono-hydrochloride); Prestwick2_000099; Mianserina; CHEBI:51137; 2-Methyl-1,2,3,4,10,14b-hexahydrodibenzo[c,f]pyrazino[1,2-a]azepine; Spectrum5_001772; PDSP2_001516; SPBio_001997; Norval; Tolvan; Mianserinum; BRN 0755346; Spectrum3_001836; EINECS 246-088-6; CHEMBL6437; KBio3_003016; Tolvon (TN); Mianseryna [Polish]; Mianseryna; AC1L1HLP; CID4184; D08216; Prestwick1_000099; NCGC00024926-04; LS-61197; BSPBio_003511; 1,2,3,4,10,14b-Hexahydro-2-methyldibenzo(c,f)pyrazino(1,2-a)azepine; DivK1c_000844; C18H20N2; KBio2_007437; Mianserin [INN:BAN]; BPBio1_000331; Biomol-NT_000135; L000736; Mianserin Monohydrochloride; HSDB 7182; Dibenzo[c,f]pyrazino[1,2-a]azepine, 1,2,3,4,10,14b-hexahydro-2-methyl-; IDI1_000844; HMS2089A04; KBio2_004869; MolPort-003-849-215; AC-631; KBio2_002301; Spectrum2_001203; Mianserinum [INN-Latin]; NCGC00024926-03; BRD-A19661776-003-05-2; KBio1_000844; BPBio1_000064; Prestwick0_000099	24219-97-4	4184	14848151	TTDS00102	5-hydroxytryptamine 2 receptor	5-HT2 receptor;5-HTB2;Serotonin receptor 2	N/A	N/A	N/A	antagonist
DAP000891	Cyclobenzaprine	Cyclobenzaprinum [INN-Latin]; NCGC00013841-02; NSC169900; BSPBio_000490; KBioSS_002015; 9715 R.P.; LS-60766; BIDD:PXR0152; NCGC00013841; Spectrum4_000162; N,N-Dimethyl-3-(dibenzo(a,d)cycloheptene-4-ylidene)propylamine; Spectrum2_001534; 1-Propanamine, 3-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-N,N-dimethyl-; BRD-K42348709-003-05-7; CAS-6202-23-9; NSC78206; KBioGR_000643; C06931; 1-Propanamine, 3-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-N,N-dimethyl- (9CI); EINECS 206-145-8; SPBio_001348; Ciclobenzaprina [INN-Spanish]; Proheptatriene; Ro 4-1577; 303-53-7; Flexeril hydrochloride; D07758; Spectrum_001535; nchembio747-comp21; KBio2_002015; Oprea1_534683; Spectrum3_001566; KBio2_004583; 5H-DIBENZO(a,d)CYCLOHEPTENE-delta(sup 5),gamma-PROPYLAMINE, N,N-DIMETHYL-; 3-(5H-dibenzo[a,d][7]annulen-5-ylidene)-N,N-dimethylpropan-1-amine; Cyclobenzaprine [INN]; Fexmid; NCI60_041725; 6202-23-9 (hydrochloride); cyclobenzaprine; KBio2_007151; 5H-Dibenzo(a,d)cycloheptene-.delta.5,.gamma.-propylamine, N,N-dimethyl-; Prestwick1_000445; KBio1_000047; BIDD:GT0485; BSPBio_003072; DivK1c_000047; Lisseril; CID2895; Lopac0_000303; Prestwick3_000445; NSC173379; NCI78206; CHEMBL669; NCIStruc2_001486; BPBio1_000540; 5-(3-Dimetilaminopropiliden)-5H-dibenzo-(a,d)-ciclopentene; KBio3_002572; 5-(3-Dimetilaminopropiliden)-5H-dibenzo-(a,d)-ciclopentene [Italian]; MK-130 HCl; AC1L1EPQ; IDI1_000047; UNII-69O5WQQ5TI; Proeptatriene [Italian]; 3-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-N,N-dimethylpropan-1-amine; NCGC00162122-01; L001021; C20H21N; 3-(5H-Dibenzo[a,d]cyclohepten-5-ylidene)-N,N-dimethyl-1-propanamine; Proeptatriene; Ciclobenzaprina; 1-Propanamine, 3-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-N,N-dimethyl-; Spectrum5_001259; MK 130; NCGC00013841-03; NSC-78206; QTL1_000027; Prestwick0_000445; Prestwick2_000445; NCGC00096951-01; Flexeril; NCIStruc1_001572; N,N-Dimethyl-5H-dibenzo(a,d)cycloheptene-delta(sup 5),gamma-propylamine; SPBio_002429; Cyclobenzaprine (INN); DB00924; 10,11-Dehydroamitriptyline; Cyclobenz; AB00514668; N,N-dimethyl-5H-dibenzo(a,d)cycloheptene-Delta(5,gamma)-propylamine; 9715 R.P; NINDS_000047; CHEBI:3996; Proheptatrien; 5H-Dibenzo(a,d)cycloheptene-.delta.(sup 5),.gamma.-propylamine, N,N-dimethyl-; Lopac-C-4542; NCGC00013841-06; Cyclobenzaprinum; Yurelax	303-53-7	2895	9148	TTDS00102	5-hydroxytryptamine 2 receptor	5-HT2 receptor;5-HTB2;Serotonin receptor 2	N/A	N/A	N/A	antagonist
DCL000154	LR3001	N/A	N/A	N/A	N/A	TTDC00022	mRNA of Myb proto-oncogene protein	C-myb;MYB	P10242	4602	ENSG00000118513	antisense
DAP000396	Teriparatide	52232-67-4; Forteo; Teriparatide (genetical recombination); Teriparatide (genetical recombination) (JAN); Teriparatide (USAN/INN); Forteo (TN); D06078; TERIPARATIDE	52232-67-4	16133850	47207736	TTDS00258	Parathyroid hormone/parathyroid hormone-related peptide receptor	Parathyroid hormone-related peptide (PTHRP);PTH/PTHr receptor;PTH/PTHrP type I receptor	Q03431	5745	ENSG00000160801	binder
DCL001083	VX-689	N/A	N/A	N/A	N/A	TTDC00139	Serine/threonine protein kinase 12	AIM-1;Aurora- and Ipl1-like midbody-associated protein 1;Aurora/IPL1-related kinase 2;Aurora-2;Aurora-2 kinase;Aurora-B;Aurora-related kinase 2;STK-1	Q96GD4	9212	ENSG00000178999	inhibitor
DCL000259	VX-680	VX-680; MK 0457; Cyclopropanecarboxylic acid N-(4-((4-(4-methylpiperazin-1-yl)-6-(5-methyl-2H-pyrazol-3-ylamino)pyrimidin-2-yl)sulfanyl)phenyl)amide; Cyclopropanecarboxylic Acid {4-[4-(4-Methyl-Piperazin-1-Yl)-6-(5-Methyl-2h-Pyrazol-3-Ylamino)-Pyrimidin-2-Ylsulfanyl]-Phenyl}-Amide; VX6; Tozasertib (USAN); AC1NUV5F; VX-68; Cyclopropanecarboxamide, N-(4-((4-(4-methyl-1-piperazinyl)-6-((5-methyl-1H-pyrazol-3-yl)amino)-2-pyrimidinyl)thio)phenyl)-; MLS001065920; CID5494449; CHEMBL572878; L-001281814; Kinome_3803; S1048_Selleck; Tozasertib; ST51054127; Cyclopropane carboxylic acid{4-[4-(4-methyl-piperazin-1-yl)-6-(5-methyl-2H-pyrazol-3-ylamino)-pyrimidin-2-ylsulphanyl]-phenyl}-amide; 2f4j; MK-0457, Tozasertib, VX680, VX-680; NSC745967; EC-000.2365; MK-045; SMR000486395; D08279; VX 680; 639089-54-6; MK-0457; I14-1964; N-[4-[4-(4-methylpiperazin-1-yl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl]sulfanylphenyl]cyclopropanecarboxamide; N-(4-(4-(3-methyl-1H-pyrazol-5-ylamino)-6-(4-methylpiperazin-1-yl)pyrimidin-2-ylthio)phenyl)cyclopropanecarboxamide	N/A	5494449	46513935	TTDC00139	Serine/threonine protein kinase 12	AIM-1;Aurora- and Ipl1-like midbody-associated protein 1;Aurora/IPL1-related kinase 2;Aurora-2;Aurora-2 kinase;Aurora-B;Aurora-related kinase 2;STK-1	Q96GD4	9212	ENSG00000178999	inhibitor
DCL001068	AT-9283	CID 11496629; AT-9283; pyrazole-benzimidazole urea analogue, 16; CHEMBL495727; CID11496629	N/A	N/A	N/A	TTDC00139	Serine/threonine protein kinase 12	AIM-1;Aurora- and Ipl1-like midbody-associated protein 1;Aurora/IPL1-related kinase 2;Aurora-2;Aurora-2 kinase;Aurora-B;Aurora-related kinase 2;STK-1	Q96GD4	9212	ENSG00000178999	inhibitor
DCL001070	CYC-116	CHEBI:620120; CHEMBL482967; CID6420138; CYC-116, CYC116; Kinome_636; S1171_Selleck; AC1O4WKE; CYC-116; 4-methyl-5-[2-(4-morpholin-4-ylanilino)pyrimidin-4-yl]-1,3-thiazol-2-amine; 2c5t	N/A	N/A	N/A	TTDC00139	Serine/threonine protein kinase 12	AIM-1;Aurora- and Ipl1-like midbody-associated protein 1;Aurora/IPL1-related kinase 2;Aurora-2;Aurora-2 kinase;Aurora-B;Aurora-related kinase 2;STK-1	Q96GD4	9212	ENSG00000178999	inhibitor
DCL000010	CYC116	N/A	N/A	N/A	N/A	TTDC00139	Serine/threonine protein kinase 12	AIM-1;Aurora- and Ipl1-like midbody-associated protein 1;Aurora/IPL1-related kinase 2;Aurora-2;Aurora-2 kinase;Aurora-B;Aurora-related kinase 2;STK-1	Q96GD4	9212	ENSG00000178999	inhibitor
DCL000210	R763	N/A	N/A	N/A	N/A	TTDC00139	Serine/threonine protein kinase 12	AIM-1;Aurora- and Ipl1-like midbody-associated protein 1;Aurora/IPL1-related kinase 2;Aurora-2;Aurora-2 kinase;Aurora-B;Aurora-related kinase 2;STK-1	Q96GD4	9212	ENSG00000178999	inhibitor
DCL000006	SNS-314	SN-314; SNS-314; DB07361; CHEMBL518051; Kinome_3712; AK2	76721-89-6	3132	49700751	TTDC00139	Serine/threonine protein kinase 12	AIM-1;Aurora- and Ipl1-like midbody-associated protein 1;Aurora/IPL1-related kinase 2;Aurora-2;Aurora-2 kinase;Aurora-B;Aurora-related kinase 2;STK-1	Q96GD4	9212	ENSG00000178999	inhibitor
DCL001078	PHA-739358	5-Amido-pyrrolopyrazole 9d; CID11442891; UNII-M3X659D0FY; S1107_Selleck; Danusertib, PHA-739358; CID 11994441; CHEMBL402548; PHA-739358; I06-2258; PHA 739358; Danusertib; (R)-N-(5-(2-methoxy-2-phenylacetyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)-4-(4-methylpiperazin-1-yl)benzamide; Benzamide, 4-(4-methyl-1-piperazinyl)-N-(1,4,5,6-tetrahydro-5-((2R)-     methoxyphenylacetyl)pyrrolo(3,4-c)pyrazol-3-yl)-; 2j50; EC-000.2352; EN003071; 827318-97-8	N/A	N/A	N/A	TTDC00139	Serine/threonine protein kinase 12	AIM-1;Aurora- and Ipl1-like midbody-associated protein 1;Aurora/IPL1-related kinase 2;Aurora-2;Aurora-2 kinase;Aurora-B;Aurora-related kinase 2;STK-1	Q96GD4	9212	ENSG00000178999	inhibitor
DCL000342	SU-6668	N/A	N/A	5329099	12015385	TTDC00139	Serine/threonine protein kinase 12	AIM-1;Aurora- and Ipl1-like midbody-associated protein 1;Aurora/IPL1-related kinase 2;Aurora-2;Aurora-2 kinase;Aurora-B;Aurora-related kinase 2;STK-1	Q96GD4	9212	ENSG00000178999	inhibitor
DCL000657	TAK-901	N/A	83913-06-8	3036289	47574471	TTDC00139	Serine/threonine protein kinase 12	AIM-1;Aurora- and Ipl1-like midbody-associated protein 1;Aurora/IPL1-related kinase 2;Aurora-2;Aurora-2 kinase;Aurora-B;Aurora-related kinase 2;STK-1	Q96GD4	9212	ENSG00000178999	inhibitor
DCL000059	AT9283	N/A	N/A	N/A	N/A	TTDC00139	Serine/threonine protein kinase 12	AIM-1;Aurora- and Ipl1-like midbody-associated protein 1;Aurora/IPL1-related kinase 2;Aurora-2;Aurora-2 kinase;Aurora-B;Aurora-related kinase 2;STK-1	Q96GD4	9212	ENSG00000178999	inhibitor
DCL001076	PF-03814735	N/A	N/A	N/A	N/A	TTDC00139	Serine/threonine protein kinase 12	AIM-1;Aurora- and Ipl1-like midbody-associated protein 1;Aurora/IPL1-related kinase 2;Aurora-2;Aurora-2 kinase;Aurora-B;Aurora-related kinase 2;STK-1	Q96GD4	9212	ENSG00000178999	inhibitor
DCL000452	AZD1152	N/A	722544-51-6	N/A	N/A	TTDC00139	Serine/threonine protein kinase 12	AIM-1;Aurora- and Ipl1-like midbody-associated protein 1;Aurora/IPL1-related kinase 2;Aurora-2;Aurora-2 kinase;Aurora-B;Aurora-related kinase 2;STK-1	Q96GD4	9212	ENSG00000178999	inhibitor
DCL000572	MK-5108	N/A	N/A	9939559	48095971	TTDC00139	Serine/threonine protein kinase 12	AIM-1;Aurora- and Ipl1-like midbody-associated protein 1;Aurora/IPL1-related kinase 2;Aurora-2;Aurora-2 kinase;Aurora-B;Aurora-related kinase 2;STK-1	Q96GD4	9212	ENSG00000178999	inhibitor
DCL001072	GSK1070916	CHEBI:722556; AKOS005145558; CHEMBL1090479; GSK-1070916	N/A	N/A	N/A	TTDC00139	Serine/threonine protein kinase 12	AIM-1;Aurora- and Ipl1-like midbody-associated protein 1;Aurora/IPL1-related kinase 2;Aurora-2;Aurora-2 kinase;Aurora-B;Aurora-related kinase 2;STK-1	Q96GD4	9212	ENSG00000178999	inhibitor
DCL000162	MBX-8025	N/A	N/A	N/A	N/A	TTDC00069	Peroxisome proliferator activated receptor delta	NUC1;NUCI;Nuclear hormone receptor 1;Peroxisome proliferator activated receptor beta/delta;Peroxisome proliferator-activated receptor beta;PPAR-beta;PPARdelta;PPAR-delta	Q03181	5467	ENSG00000112033	agonist
DCL000897	Netoglitazone	Netoglitazone (USAN/INN); CID204109; Netoglitazone; Netoglitazone [USAN]; D05150; UNII-QOV2JZ647A; 5-[[6-[(2-fluorophenyl)methoxy]naphthalen-2-yl]methyl]-1,3-thiazolidine-2,4-dione; RWJ-241947; CHEMBL93747; MolPort-005-942-719; MCC 555; AC1L4BXM; 5-({6-[(2-fluorobenzyl)oxy]naphthalen-2-yl}methyl)-1,3-thiazolidine-2,4-dione; C115174; Isaglitazone; 161600-01-7; 2,4-Thiazolidinedione, 5-((6-((2-fluorophenyl)methoxy)-2-naphthalenyl)methyl)-; 5-((6-((2-fluorophenyl)methoxy)-2-naphthalenyl)methyl)-2,4-thiazolidinedione; MCC-555	161599-99-1	204109	47206874	TTDC00069	Peroxisome proliferator activated receptor delta	NUC1;NUCI;Nuclear hormone receptor 1;Peroxisome proliferator activated receptor beta/delta;Peroxisome proliferator-activated receptor beta;PPAR-beta;PPARdelta;PPAR-delta	Q03181	5467	ENSG00000112033	agonist
DCL000143	KD3010	N/A	N/A	N/A	N/A	TTDC00069	Peroxisome proliferator activated receptor delta	NUC1;NUCI;Nuclear hormone receptor 1;Peroxisome proliferator activated receptor beta/delta;Peroxisome proliferator-activated receptor beta;PPAR-beta;PPARdelta;PPAR-delta	Q03181	5467	ENSG00000112033	agonist
DPR000064	KD-3020	N/A	N/A	N/A	N/A	TTDC00069	Peroxisome proliferator activated receptor delta	NUC1;NUCI;Nuclear hormone receptor 1;Peroxisome proliferator activated receptor beta/delta;Peroxisome proliferator-activated receptor beta;PPAR-beta;PPARdelta;PPAR-delta	Q03181	5467	ENSG00000112033	agonist
DCL000827	GSK-677954	N/A	884324-15-6	N/A	N/A	TTDC00069	Peroxisome proliferator activated receptor delta	NUC1;NUCI;Nuclear hormone receptor 1;Peroxisome proliferator activated receptor beta/delta;Peroxisome proliferator-activated receptor beta;PPAR-beta;PPARdelta;PPAR-delta	Q03181	5467	ENSG00000112033	agonist
DAP000253	Hydrocodone	Dihydrocodeinone; Hydrocodone (INN); 4-27-00-03580 (Beilstein Handbook Reference); NSC19044; Morphinan-6-one, 4,5alpha-epoxy-3-methoxy-17-methyl- (8CI); 3-methoxy-17-methyl-4,5alpha-epoxymorphinan-6-one; MolPort-002-527-170; 34195-34-1 (tartrate (1:1), hydrate (2:5)); 125-29-1; NSC 19044; CHEMBL1457; WLN: T B6566 B6/CO 4ABBC R BX FV HO PN GHT&&TTJ JO1 P1; 9007-52-7; Hydrocodeinonebitartrate; DICO; (5alpha)-17-methyl-3-(methyloxy)-4,5-epoxymorphinan-6-one; Hydrocone; Codeinone, dihydro-; 50678-79-0; Morphinan-6-one, 4,5-epoxy-3-methoxy-17-methyl-, (5alpha)- (9CI); Codinovo; LS-92156; Hydroconum; Dicodid; C08024; UNII-6YKS4Y3WQ7; hidrocodona; DEA No. 9193; Morphinan-6-one, 4,5alpha-epoxy-3-methoxy-17-methyl-; EINECS 204-733-9; BRN 0094193; (-)-Dihydrocodeinone; Hydrocodone [INN:BAN]; DB00956; 6-Oxo-3-methoxy-N-methyl-4,5-epoxymorphinan; Morphinan-6-one, 4,5-epoxy-3-methoxy-17-methyl-, (5alpha)-; HYDROCODONE; CHEBI:5779; NCGC00159317-02; D08045; Hydrocon; Hydrocodon; CID5284569; Multacodin; NCGC00159317-03; Hydrocodonum; Idrocodone [DCIT]; Bekadid; 4aH-8,9c-Iminoethanophenanthro[4,5-bcd]furan-5-(6H)-one, 7,7a,8,9-tetrahydro-3-methoxy-12-methyl-; 4,5-alpha-Epoxy-3-methoxy-17-methylmorphinan-6-one; STOCK1N-54181; Hidrocodona [INN-Spanish]; 1037-91-8; Hydrocodonum [INN-Latin]; 4,5alpha-Epoxy-3-methoxy-17-methylmorphinan-6-one; HSDB 3097; 4,5.alpha.-Epoxy-3-methoxy-17-methylmorphinan-6-one; Morphinan-6-one, 4,5-alpha-epoxy-3-methoxy-17-methyl-; Idrocodone	125-29-1	5284569	173376	TTDS00128	Delta-type opioid receptor	Delta opioid receptor;DOR-1	P41143	4985	ENSG00000116329	agonist
DAP000213	Codeine	C1653_FLUKA; Actacode; Morphine monomethyl ether; Morphine-3-methyl ether; Morphinan-6-ol, 7,8-didehydro-4,5-epoxy-3-methoxy-17-methyl-, (5alpha,6alpha)-; Isocodeine; CODEINE (SEE ALSO: CODEINE PHOSPHATE (CAS 52-28-8)); Robitussin AC; Codeine [BAN]; 3-methoxy-17-methyl-7,8-didehydro-4,5alpha-epoxymorphinan-6alpha-ol; Morphinan-6-ol, 7,8-didehydro-4,5-epoxy-3-methoxy-17-methyl-, (5-alpha,6-alpha)- (9CI); C5901_FLUKA; AC-11114; 7,8-didehydro-4,5-epoxy-3-methoxy-17-methyl-(5alpha, 6alpha)-morphinan 6-ol; Ardinex; N-Methylmorphine; 7,8-Didehydro-4,5-epoxy-3-methoxy-17-methylmorphinan-6-ol; Codein; Morphine-3-methyl ester; codeine; AC1Q4DTD; CODEINE BASE; Morphinan-6-alpha-ol, 7,8-didehydro-4,5-alpha-epoxy-3-methoxy-17-methyl-; STOCK1N-42851; (6alpha,13alpha)-3-methoxy-17-methyl-7,8-didehydro-4,5-epoxymorphinan-6-ol; 3-o-methylmorphine monohydrate; CCRIS 7555; Morphinan-6alpha-ol, 7,8-didehydro-4,5alpha-epoxy-3-methoxy-17-methyl- (8CI); Norcodine, N-methyl; morphine monomethy l ether; C06174; Calcidrine; Codeine anhydrous; Codicept; codeina; LS-1695; Morphinan-6-ol, 7,8-didehydro-4,5-epoxy-3-methoxy-17-methyl-, (5-alpha,6-alpha)-; Methylmorphine; MolPort-002-506-913; 7,8-didehydro-4,5-ep oxy-3-methoxy-17-methylmorphinan-6-ol; CHEMBL485; metilmorfina; Novahistine DH; O3-Methylmorphine; 7,8-didehydro-4,5-alpha-epoxy-3-methoxy-17-methylmorphinan-6-alpha-ol; Codeine (anhydrous); O(3)-methylmorphine; N-methylnorcodeine; 41444-62-6 (PO4); C1653_SIGMA; N-methyl norcodine; Codalgin Forte Codate; (5alpha,6alpha)-17-methyl-3-(methyloxy)-7,8-didehydro-4,5-epoxymorphinan-6-ol; nchembio.317-comp2; codeinum; DB00318; Morphine 3-methyl ether; C5901_SIGMA; CID5284371; CHEBI:16714; l-Codeine; 76-57-3; Coducept; Morphinan-6alpha-ol, 7,8-didehydro-4,5alpha-epoxy-3-methoxy-17-methyl-; HSDB 3043; (-)-Codeine; Norcodeine, N-methyl; EINECS 200-969-1; Morphinan-6-ol, 7,8-didehydro-4,5-epoxy-3-methoxy-17-methyl-, (5alpha,6alpha)- (9CI); 7,8-didehydro-4,5alpha-epoxy-3-methoxy-17-methylmorphinan-6alpha-ol; Codeine solution	76-57-3	5284371	149398	TTDS00128	Delta-type opioid receptor	Delta opioid receptor;DOR-1	P41143	4985	ENSG00000116329	agonist
DPR000021	BIO-306	N/A	N/A	3960	49699208	TTDS00128	Delta-type opioid receptor	Delta opioid receptor;DOR-1	P41143	4985	ENSG00000116329	agonist
DAP000425	Loperamide	1-Piperidinebutanamide, 4-(4-chlorophenyl)-4-hydroxy-N,N-dimethyl-alpha,alpha-diphenyl-; BRD-K61250553-001-02-9; Loperamida [INN-Spanish]; Prestwick0_000144; 4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-N,N-dimethyl-2,2-diphenylbutanamide; Lopac0_000708; Loperamida; KBio2_005237; Prestwick1_000144; Bio1_000082; Spectrum2_001738; loperamide; BSPBio_001381; KBio2_000101; Kaopectate II; Loperamide [INN:BAN]; AC1L1H38; NCGC00015608-01; Tocris-0840; HMS2089C13; 4-(4-Chlorophenyl)-N,N-dimethyl-.alpha.,.alpha.-diphenyl-4-hydroxy-1-piperidinebutanamide; NINDS_000215; 2-methoxyethyl1-methylethyl2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; KBio2_000854; Rho-Loperamide; Prestwick2_000144; KBioSS_000854; R-18553; KBio2_002669; DivK1c_000215; Loperamidum; Loperacap; Pepto Diarrhea Control; 1-Piperidinebutanamide, 4-(4-chlorophenyl)-4-hydroxy-N,N-dimethyl-.alpha.,.alpha.-diphenyl-; 5-21-02-00379 (Beilstein Handbook Reference); PMS-Loperamide; Spectrum3_001015; Oprea1_109220; KBio2_005990; AB00053697; NCGC00024818-03; BSPBio_002769; BSPBio_000248; NCGC00016828-01; Loperamide Monohydrochloride; KBioGR_000101; Lopac-L-4762; LS-114352; BRD-K61250553-003-05-8; NCGC00024818-05; Ioperamide; KBio2_003422; NCGC00024818-04; SPBio_002187; UNII-6X9OC3H4II; CHEMBL841; KBio1_000215; Bio1_000571; C29H33ClN2O2; Loperamide (INN); NCGC00024818-02; KBio3_000201; Bio1_001060; CBiol_001796; C07080; HMS1791F03; Nu-Loperamide; BRN 1558273; Prestwick3_000144; 34552-83-5 (mono-hydrochloride); nchembio.79-comp7; 4-(4-Chlorophenyl)-N,N-dimethyl-alpha,alpha-diphenyl-4-hydroxy-1-piperidinebutanamide; Imodium A-D Caplets; L000709; D08144; SPBio_001816; NCGC00024818-01; Apo-Loperamide; BAS 01889668; Spectrum5_001374; HMS1989F03; KBioGR_001685; BPBio1_000274; IDI1_000215; CID3955; Diamide (TN); Diarr-Eze; EINECS 258-416-5; Bio2_000101; AKOS000573892; CHEBI:162259; DB00836; MolPort-001-969-016; Bio2_000581; Spectrum4_001143; 53179-11-6; ST095179; KBioSS_000101; NCGC00015608-08; KBio3_000202; Maalox Anti-Diarrheal; CHEBI:6532; KBio3_001989; CAS-34552-83-5; nchembio.559-comp8; Loperamidum [INN-Latin]; IDI1_033851; Spectrum_000374	53179-11-6	3955	9291	TTDS00128	Delta-type opioid receptor	Delta opioid receptor;DOR-1	P41143	4985	ENSG00000116329	binder
DAP000380	Nalbuphine	D08246; Prestwick0_000118; BPBio1_000150; HMS2089I04; Nalbufina; BSPBio_000136; (5alpha,6alpha)-17-(cyclobutylmethyl)-4,5-epoxymorphinan-3,6,14-triol; Nalbuphinum; Intapan (TN); SPBio_002075; Prestwick2_000118; 20594-83-6; nalbuphine; Prestwick3_000118; Prestwick1_000118; CHEMBL895; 17-cyclobutylmethyl-4,5alpha-epoxymorphinan-3,6alpha,14-triol; CHEBI:7454; C07251; CID5311304; BRD-K66404838-003-03-8; BIDD:GT0060; Nalbuphine (INN); Intapan	20594-83-6	5360630	9460	TTDS00128	Delta-type opioid receptor	Delta opioid receptor;DOR-1	P41143	4985	ENSG00000116329	antagonist
DAP000283	Oxycodone	Hydroxycodeinon; Morphinan-6-one, 4,5alpha-epoxy-14-hydroxy-3-methoxy-17-methyl- (8CI); C08018; 4,5-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one; OxyIR; Endine (Australia); Dinarkon; Supendol [Canada]; LS-92148; 14-hydroxy-3-methoxy-17-methyl-4,5alpha-epoxymorphinan-6-one; Remoxy; (-)-14-Hydroxydihydrocodeinone; HSDB 3142; Dihydro-14-hydroxycodeinone; D05312; Oxycodeinon; BRN 0043446; Oxycodone hydrochloride; Oxicon; 124-90-3 (hydrochloride); Pancodone retard (United Kingdom); WLN: T B6566 B6/CO 4ABBC R BX FV HO PN GHT&&TTJ CQ JO1 P1; Oxanest; Oxicodona; Percobarb; Oxycontin; Oxycodone (USAN/INN); Supendol; (5alpha)-14-hydroxy-17-methyl-3-(methyloxy)-4,5-epoxymorphinan-6-one; 76-42-6; Oxycodone [USAN:INN:BAN]; Oxyfast; Morphinan-6-one, 4,5-epoxy-14-hydroxy-3-methoxy-17-methyl-, (5alpha)-; 14-Hydroxydihydrocodeinone; Ossicodone [DCIT]; MolPort-004-285-989; Codeinone, dihydrohydroxy-; Oxycone; UNII-CD35PMG570; Dihydrohydroxycodeinone; CHEBI:7852; Endone; DB00497; Oxiconum; Diphydrone; oxycodone; Oxicone; AC1Q4DTG; PTI-821; EINECS 200-960-2; Ossicodone; Dihydrohydroxycondeinone; CHEMBL656; Dihydroxycodeinone; Supeudol; Oxycodon; Oxycodonum; 4,5alpha-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one; CID5284603; Combunox; Eubine [France]; Oxycodonum [INN-Latin]; Theocodin; Roxicodone; Codeinone, 7,8-dihydro-14-hydroxy-; Oxynorm; Eubine; 25333-72-6 (Terephthalate); 4,5.alpha.-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one; Tekodin (free base); Oxicodona [INN-Spanish]; Dihydrone; Pancodine; 4aH-8,9c-Iminoethanophenanthro[4,5-bcd]furan-5(6H)-one, 7,7a,8,9-tetrahydro-7a-hydroxy-3-methoxy-12-methyl-; NSC19043; Morphinan-6-one, 4,5alpha-epoxy-14-hydroxy-3-methoxy-17-methyl-; DEA No. 9143; (-)-Oxycodone; Oxycodone Hcl; Percolone; Eucodal; AC-16043; Oxycodone Concentrate; Oxycodeinone; NSC 19043; Roxicet; Eucodalum; Percodan; Codeinone, dihydro-14-hydroxy-; Morphinan-6-one, 4,5-alpha-epoxy-14-hydroxy-3-methoxy-17-methyl-	76-42-6	5284603	149393	TTDS00128	Delta-type opioid receptor	Delta opioid receptor;DOR-1	P41143	4985	ENSG00000116329	agonist
DAP000214	Butorphanol	17-(CYCLOBUTYLMETHYL)MORPHINAN-3,14-DIOL; C06863; Butorfanol; LS-91729; Butorphanol (USAN/INN); Moradol; UNII-QV897JC36D; (-)-N-cyclobutylmethyl-3,14-dihydroxymorphinan; EINECS 255-808-8; CHEMBL33986; BC-2627; levo-BC-2627; D03197; Butorphanol [USAN:BAN:INN]; Beforal; (-)-17-(Cyclobutylmethyl)morphinan-3,14-diol; l-BC 2627; Butorphanolum; 42408-82-2; BIDD:GT0549; CID5361092; Butorfanol [INN-Spanish]; Butorphanolum [INN-Latin]; Butorphanol tartrate; butorphanol; C21H29NO2; DEA No. 9720; CHEBI:3242; Morphinan-3,14-diol, 17-(cyclobutylmethyl)-; Stadol; (-)-butorphanol	58786-99-5	5361092	7853849	TTDS00128	Delta-type opioid receptor	Delta opioid receptor;DOR-1	P41143	4985	ENSG00000116329	agonist
DAP000379	Naltrexone	SPBio_002071; BRD-K88172511-310-03-8; 17-(Cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxmorphinan-6-one, (5.alpha.)-; Prestwick3_000116; Vivitrol (TN); Celupan; Prestwick2_000116; MolPort-004-920-221; MLS002153483; Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-alpha-epoxy-3,14-dihydroxy-; HMS2089O11; CCRIS 3506; N-Cyclopropylmethylnoroxymorphone; Prestwick0_000116; Naltrexona [INN-Spanish]; Depade; LS-92094; 3,14-dihydroxy-17-(cyclopropylmethyl)-4,5alpha-epoxymorphinan-6-one; naltrexone; Naltrexona; CID5360515; Naltrexonum [INN-Latin]; Naltrexone (USAN/INN); 16676-29-2; EN-1639A; naltrexone (ReVia); PDSP2_000847; 16590-41-3; Prestwick1_000116; EINECS 240-649-9; DB00704; BSPBio_000132; CHEMBL142; BIDD:GT0405; 17-(Cyclopropylmethyl)-4,5alpha-epoxy-3,14-dihydroxymorphinan-6-one; C07253; SMP1_000206; Naltrexone [USAN:BAN:INN]; Vivitrol; MorViva; Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-, (5alpha)-; Vivitrex; CHEBI:7465; Naltrexonum; HSDB 6750; UNII-5S6W795CQM; BRN 3596648; Naltrexone [USAN:INN:BAN]; 17-(Cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinan-6-one; PTI-555; BPBio1_000146; HS-0002; N-Cyclopropylmethyl-14-hydroxydihydromorphinone; D05113; UM-792; CHEBI:121459	16590-41-3	5360515	9462	TTDS00128	Delta-type opioid receptor	Delta opioid receptor;DOR-1	P41143	4985	ENSG00000116329	antagonist
DCL000775	Divers drug	N/A	N/A	N/A	N/A	TTDS00128	Delta-type opioid receptor	Delta opioid receptor;DOR-1	P41143	4985	ENSG00000116329	agonist
DAP000472	Hydromorphone	EINECS 207-383-5; Idromorfone; CID5284570; DB00327; WLN: T B6566 B6/CO 4ABBC R BX FV HO PN GHT&&TTJ JQ P1; Dilaudid-hp; Hydromorphonum [INN-Latin]; (5alpha)-3-hydroxy-17-methyl-4,5-epoxymorphinan-6-one; D08047; Morphinan-6-one, 4,5alpha-epoxy-3-hydroxy-17-methyl- (8CI); Hidromorfona; LS-92152; 4,5-Epoxy-3-hydroxy-17-methylmorphinan-6-one; Dimorphone; (-)-(5R)-4,5-Epoxy-3-hydroxy-9alpha-methylmorphinan-6-one; UNII-Q812464R06; 41376-02-7; Idromorfone [DCIT]; 6-Deoxy-7,8-dihydro-6-oxomorphine; hydromorphone; C07042; Hydromorphone HCL; 466-99-9; Hydromorfona [Spanish]; LS-187185; 4,5alpha-Epoxy-3-hydroxy-17-methyl-6-morphinanone; Dihydromorfinon [Czech]; NSC19046; Morphinone, dihydro-; 7,8-Dihydromorphinone; DEA No. 9150; Hydromorphon; Dihydromorphinone; (-)-Hydromorphone; Dihydromorfinon; 3-hydroxy-17-methyl-4,5alpha-epoxymorphinan-6-one; CHEBI:5790; Morphinan-6-one, 4,5-epoxy-3-hydroxy-17-methyl-, (5alpha)-; NSC 19046; Laudicon; HSDB 3341; MolPort-004-285-951; Dilaudid Oros; Morphinan-6-one, 4,5-alpha-epoxy-3-hydroxy-17-methyl-; Dilaudid; Morphinan-6-one, 4,5alpha-epoxy-3-hydroxy-17-methyl-; 18145-12-5; DiMo; Hidromorfona [INN-Spanish]; Laudacon; Novolaudon; Hydromorphonum; Hydromorphone [INN:BAN]; CHEMBL398707; Hydromorphone (INN); Hydromorfona	466-99-9	5284570	9254	TTDS00128	Delta-type opioid receptor	Delta opioid receptor;DOR-1	P41143	4985	ENSG00000116329	binder
DPR000059	Icofungipen	MolPort-004-778-493; BAY 10-8888; Icofungipen [INN]; CID216240; UNII-I20202Q8M8; 56564-73-9; KST-1A6081; AC1L50CI; PLD-118; BAY-10-8888; PLD118; (1R,2S)-2-Amino-4-methylenecyclopentane-1-carboxylic acid; Icofungipen; C471265; 198022-65-0; (1R,2S)-2-amino-4-methylidenecyclopentane-1-carboxylic acid; PLD 118; CHEMBL343803; (1r,2s)-2-amino-4-methylidenecyclopentanecarboxylic acid; AR-1A1157; AC1Q5QVF; Cyclopentanecarboxylic acid, 2-amino-4-methylene-, (1R,2S)-; Cyclopentanecarboxylic acid, 2-amino-4-methylene-, (1R-cis)-	526194-96-7	216240	12015244	TTDS00223	Isoleucyl-tRNA synthetase (bacterial)	IleRS;IRS;Isoleucine--tRNA ligase	Q99UR8	N/A	N/A	binder
DAP000711	Mupirocin	CHEBI:135271; CPD000471888; Mupirocine [French]; Mupirocinum; Mupirocin, 14C-Labeled; Nonanoic acid, 9-((3-methyl-1-oxo-4-(tetrahydro-3,4-dihydroxy-5-((3-(2-hydroxy-1-methylpropyl)oxiranyl)methyl)-2H-pyran-2-yl)-2-butenyl)oxy)-, (2S-(2alpha(E),3beta,4beta,5alpha(2R*,3R*(1R*,2R*))))-; LS-177887; Pseudomonic acid; SAM002589979; CID446596; BRL 4910A; Bactroban; M7694_SIGMA; 9-[(E)-4-[(2S,3R,4R,5S)-3,4-dihydroxy-5-[[(2S,3S)-3-[(2S,3S)-3-hydroxybutan-2-yl]oxiran-2-yl]methyl]oxan-2-yl]-3-methylbut-2-enoyl]oxynonanoic acid; Bactroban Nasal; MRC; MolPort-003-666-882; Mupirocin; BRL-4910A; Bactoderm; Pseudomonic acid A; Centany; DB00410; UNII-D0GX863OA5; CHEMBL719; Mupirocin (USP/INN); SMR000471888; Bactroban (TN); NCGC00164554-03; MLS001074711; BIDD:GT0320; Mupirocina; Centany (TN); C11758; 8-Carboxyoctyl (E)-4-(2S,3R,4R,5S)-5-((2S,3S,4S,5S)-2,3-epoxy-5-hydroxy-4-methylhexyl)-3,4-dihydroxytetrahydro-2H-pyran-2-yl)-3-methylcrotonat; C26H44O9; Mupirocina [Spanish]; AC1L9JV4; 12650-69-0; Mupirocine; Mupirocinum [Latin]; 1jzs; Plasimine; 5,9-Anhydro-2,3,4,8-tetradeoxy-8-[[3-(2-hydroxy-1-methylpropyl)oxiranyl]methyl]-3-methyl-[2E,8[2S,3S(1S,2S); D01076	12650-69-0	446596	7848139	TTDS00223	Isoleucyl-tRNA synthetase (bacterial)	IleRS;IRS;Isoleucine--tRNA ligase	Q99UR8	N/A	N/A	inhibitor
DCL001172	Clemizole	N/A	N/A	N/A	N/A	TTDC00321	HCV NS4B protein	N/A	N/A	N/A	N/A	inhibitor
DCL000970	Ruboxistaurin	169939-94-0; 1uu3; LS-187626; LY-333531; LS-186984; CID153999; CHEMBL91829; 9H,18H-5,21:12,17-Dimethenodibenzo(e,k)pyrrolo(3,4-h)(1,4,13)oxadiazacyclohexadecine-18,20(19H)-dione, 9-((dimethylamino)methyl)-6,7,10,11-tetrahydro-, (9S)-; Ruboxistaurin; LY-333,531; (9S)-9-((Dimethylamino)methyl)-6,7,10,11-tetrahydro-9H,19H-5,21:12,17-dimethenodibenzo(e,k)pyrrolo(3,4-h)(1,4,13)oxadiazacyclohexadecene-18,20-dione; AC1L4BIF; K00587a; LY333531; 13-((Dimethylamino)methyl)-10,11,14,15-tetrahydro-4,9:16,21-dimetheno-1H,13H-dibenzo(e,k)pyrrolo(3,4-h)(1,4,13)oxadiazacyclohexadecene-1,3(2H)-dione; LY 333531; Ruboxistaurin [INN]; LY4; UNII-721809WQCP	202260-21-7	153999	731401	TTDC00163	Protein kinase C, beta type	PKC-B;PKC-beta;Protein Kinase C beta	P05771	5579	ENSG00000166501	inhibitor
DCL000996	Sotrastaurin acetate	N/A	908351-31-5	448087	46392991	TTDC00163	Protein kinase C, beta type	PKC-B;PKC-beta;Protein Kinase C beta	P05771	5579	ENSG00000166501	inhibitor
DCL000109	Enzastaurin	3-(1-methylindol-3-yl)-4-[1-[1-(pyridin-2-ylmethyl)piperidin-4-yl]indol-3-yl]pyrrole-2,5-dione; CHEMBL300138; UNII-UC96G28EQF; 1H-Pyrrole-2,5-dione, 3-(1-methyl-1H-indol-3-yl)-4-(1-(1-(2-pyridinylmethyl)-4-piperidinyl)-1H-indol-3-yl)-; 170364-57-5; LY317615; 3-(1-methyl-1H-indol-3-yl)-4-{1-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1H-indol-3-yl}-1H-pyrrole-2,5-dione; AC-5900; CID176167; AC1L41YQ; LY317615, Enzastaurin; LE-0014; S1055_Selleck; CHEBI:183217; Enzastaurin	170364-57-5	176167	3891570	TTDC00163	Protein kinase C, beta type	PKC-B;PKC-beta;Protein Kinase C beta	P05771	5579	ENSG00000166501	inhibitor
DCL001044	ABT-894	N/A	799279-80-4	5487301	48329128	TTDC00301	Neuronal acetylcholine receptor protein, beta-2 chain	Beta-2 nAChR;Nicotinic acetylcholine receptor beta 2-subunit protein;Nicotinic acetylcholine receptor beta2	P17787	1141	ENSG00000160716	agonist
DAP000340	Ranitidine	Raniben; AC1Q1WQX; Zantadin; Melfax; Mauran; Duractin; 1,1-Ethenediamine, N-[2-[[[5-[(dimethylamino)methyl]-2-furanyl]methyl]thio]ethyl]-N'-methyl-2-nitro-, (E)-; N (2-(((5-((Dimethylamino)methyl)-2-furanyl)methyl)thio)ethyl)-N'-methyl-2-nitro-1,1-ethenediamine; (E)-1-N'-[2-[[5-(dimethylaminomethyl)furan-2-yl]methylsulfanyl]ethyl]-1-N-methyl-2-nitroethene-1,1-diamine; Rantacid; Axoban; ZANTAC; Rantidine HCL; SPECTRUM1501151; Sostril; Tocris-1967; Istomar; Verlost; NCGC00094913-03; Ulcex; ranitidine; Spectrum5_001189; 1,1-Ethenediamine, N-[2-[[[5-[(dimethylamino)methyl]-2-furanyl]methyl]thio]ethyl]-N'-methyl-2-nitro-; Taural; Ranitidine [USAN:BAN:INN]; Ulceranin; UNII-884KT10YB7; Vizerul; Microtid; NCGC00018108-01; Kuracid; Raniter; 66357-35-5; AC1MHDJB; Ranitidinum; Lopac0_001073; RND; HMS1921L07; Noctone; Raniplex; Terposen; Lopac-R-101; Raticina; IDI1_000440; Weidos; Acidex; Achedos; NCGC00015876-02; CHEMBL512; HSDB 3925; Ranitidine (USAN/INN); Rani-nerton; Ranitidine (TN); KST-1B7387; AC-12712; Ranitidine HCL; NCGC00094913-04; Randin; Zantic; C13H22N4O3S; Ranitidina; Atural; CID3001055; Ranifur; Raniogas; Ranin; 1,1-Ethenediamine, N-(2-(((5-((dimethylamino)methyl)-2-furanyl)methyl)thio)ethyl)-N'-methyl-2-nitro-; HMS2092H15; Gastrial; Ranitin; LS-67645; Ranidine; Ezopta; Ranitidinum [INN-Latin]; Biotidin; NCGC00024387-02; Ranibloc; NCGC00015876-01; Radinat; Rani-Q; Ranitiget; Rantidine; Ranitidina [INN-Spanish]; MolPort-003-666-370; Fendibina; Weichilin; NCGC00094913-01; ST050299; EINECS 266-332-5; CHEBI:8776; Ratic; NCGC00094913-05; D00422; Zantab; Ranitidin; Prestwick2_000201; I09-0405; Gastrolav; Ultidine; Ptinolin; Gastrosedol; DB00863; HMS501F22; Curan; CAS-66357-59-3; Urantac; Gastridina; Nu-Ranit; Ul-Pep; 66357-59-3 (hydrochloride); L000504; NCGC00094913-02; Vesyca; Ranisen; N-(2-((5-((Dimethylamino)methyl)furfuryl)thio)ethyl)-N'-methyl-2-nitro-1,1-ethenediamine; AR-1B4779; Sampep; 68109-63-7; Raniberl; Xanidine; Quicran; BIDD:GT0179; Alquen; (E)-N-{2-[({5-[(dimethylamino)methyl]-2-furyl}methyl)sulfanyl]ethyl}-N'-methyl-2-nitroethene-1,1-diamine; Logast; (E)-N-{2-[({5-[(dimethylamino)methyl]furan-2-yl}methyl)sulfanyl]ethyl}-N'-methyl-2-nitroethene-1,1-diamine; NCGC00015876-08; Quantor; STK619092; Coralen	66357-35-5	3001055	187111	TTDS00087	Histamine H2 receptor	Gastric receptor I;H2R;Histamine receptor 2	P25021	3274	ENSG00000113749	antagonist
DAP001081	Betazole	2-(3-Pyrazolyl)ethylamine; L000831; AC1L1PG3; AB00514680; 3-(beta-aminoethyl)pyrazole; BSPBio_000165; MolPort-001-787-387; Betazolum; Prestwick1_000043; UNII-1C065P542O; BETAZOLE; Lilly 96791; Betazolo; BPBio1_000183; CHEBI:59170; Betazole [INN]; NCGC00016995-01; CID7741; 2-(1H-pyrazol-5-yl)ethanamine; SPBio_002086; Prestwick3_000043; Betazolum [INN-Latin]; AR-1H9721; DB00272; AC1Q4WVG; Betazolo [DCIT]; Betazol [INN-Spanish]; Ametazole; NCGC00016995-02; EINECS 203-278-3; 2-(1H-Pyrazol-3-yl)ethanamine; Prestwick0_000043; Betazol; 3-(2-Aminoethyl)pyrazole; Prestwick-01E04; Prestwick2_000043; 138-92-1 (di-hydrochloride); LS-171948; 1H-Pyrazole-3-ethanamine	105-20-4	7741	10503079	TTDS00087	Histamine H2 receptor	Gastric receptor I;H2R;Histamine receptor 2	P25021	3274	ENSG00000113749	antagonist
DAP000341	Famotidine	(1Z)-N'-(aminosulfonyl)-3-[({2-[(diaminomethylidene)amino]-1,3-thiazol-4-yl}methyl)thio]propanimidamide; HMS2089I12; 76824-35-6; Novo-Famotidine; (1Z)-3-[({2-[(diaminomethylidene)amino]-1,3-thiazol-4-yl}methyl)sulfanyl]-N'-sulfamoylpropanimidamide; Famotidinum [Latin]; Dipsin; MLS001423994; Tamin; MolPort-003-941-395; Nulcerin; Famodine; CHEMBL902; Famopsin; Fagastine; Famosan; Huberdina; HMS2051A07; Rogasti; NCGC00015446-06; F 6889; Lopac-F-6889; Peptifam; FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER; Famox; YM-11170; Nu-Famotidine; Fanosin; Pepzan; YM 11170; Gastro; Blocacid; Digervin; NCGC00018276-02; Dinul; Notidin; Weimok; Gaster; Lecedil; Sigafam; N'-(Aminosulfonyl)-3-([2-(diaminomethyleneamino)-4-thiazolyl]methylthio)propanamidine; Ulfagel; Lopac0_000497; Apogastine; Farmotex; Mylanta AR; Cepal; CHEBI:4975; AC1Q50E1; AC-11713; Confobos; Ulfinol; Cuantin; Pepcid AC Gelcaps; Invigan; F0530; Ulcatif; Fanobel; MLS000758205; Famoxal; Famodin; Yamarin; L013386; 3-[({2-[(diaminomethylidene)amino]-1,3-thiazol-4-yl}methyl)sulfanyl]-N-sulfamoylpropanimidamide; Pepcidine; Purifam; Famotep; NCGC00015446-01; Quamatel; Ulceprax; Fudone; Peptidin; Antodine; BSPBio_000088; Propanimidamide, 3-[[[2-[aminoiminomethyl)amino]-4-thiazoyl]methyl]thio]-N-(aminosulfonyl); Duovel; MK 208; Brolin; AC1NWASH; C8H15N7O2S3; Dispronil; Gastrofam; Apo-Famotidine; SMR000058961; BIDD:GT0759; Whitidin; Propanimidamide, 3-(((2-((aminoiminomethyl)amino)-4-thiazolyl)methyl)thio)-N-(aminosulfonyl)-; Gastridan; HS-0054; Vagostal; HSDB 3572; Pepcidin; Ingastri; Motiax; NCGC00093899-02; F6889_SIGMA; AC1Q50E0; NCGC00018276-01; XUFQPHANEAPEMJ-UHFFFAOYSA-; Famulcer; Panalba; famotidine; SAM001247033; Sedanium-R; PEPCID; MK-208; Cronol; Ulfamid; Quamtel; Gastrion; CPD000058961; PDSP2_000396; Mensoma; FAMOTIDINE PRESERVATIVE FREE; Prestwick3_000104; Fibonel; Pepcid AC; PEPCID PRESERVATIVE FREE IN PLASTIC CONTAINER; Propanimidamide, N'-(aminosulfonyl)-3-(((2-((diaminomethylene)amino)-4-thiazolyl)methyl)thio)-; Famotin; Rubacina; HMS1568E10; Tipodex; MLS000028583; Pepdif; Bio-0739; Ganor; L003830; 3-[[2-(diaminomethylideneamino)-1,3-thiazol-4-yl]methylsulfanyl]-N'-sulfamoylpro; Famo; Pepdul; L 643341; Neocidine; Pepdine; STK527689; Pepcid RPD; InChI=1/C8H15N7O2S3/c9-6(15-20(12,16)17)1-2-18-3-5-4-19-8(13-5)14-7(10)11/h4H,1-3H2,(H2,9,15)(H2,12,16,17)(H4,10,11,13,14); Gastridin; Famonit; NCGC00093899-01; Gastrosidin; Fluxid; Nulceran; Ulfam; Famocid; Tairal; Pepfamin; Famotidine [USAN:BAN:INN:JAN]; LS-121117; Famos; Dispromil; YM-1170; NCGC00093899-03; Famotidina [Spanish]; Famodil; Supertidine; Logos; Pepcidac; Pepcidina; Muclox; 3-(2-Guanidinothiazol-4-ylmethylthio)-N1-sulfamoylpropionamide; Renapepsa; Famtac; (1-Amino-3-(((2-((diaminomethylene)amino)-4-thiazolyl)methyl)thio)propylidene)sulfamide; PDSP1_000398; Gastrodomina; Nevofam; Ulgarine; Durater; Amfamox; Bestidine; TL8005267; Dibrit 40; Topcid; Fadyn; DB00927; Restadin; PEPCID COMPLETE; Ferotine; PEPCID PRESERVATIVE FREE; Fanox; Hacip; Prestwick2_000104; Fadin; Famovane; Midefam; Famotal; Gastropen; EU-0100497; NCGC00015446-02; H2 Bloc; 3-[[2-(diaminomethylideneamino)-1,3-thiazol-4-yl]methylsulfanyl]-N'-sulfamoylpropanimidamide; Ulcofam; Famogard; CAS-76824-35-6; CID5702160; BPBio1_000098; Fadine; Pepcidin Rapitab; NCGC00015446-03; MolPort-002-557-620; Evatin; Famodar; Famowal; Peptan; Mosul; Prestwick_212	76824-35-6	3325	191368	TTDS00087	Histamine H2 receptor	Gastric receptor I;H2R;Histamine receptor 2	P25021	3274	ENSG00000113749	antagonist
DAP000339	Nizatidine	(E)-N-{2-[({2-[(dimethylamino)methyl]-1,3-thiazol-4-yl}methyl)thio]ethyl}-N'-methyl-2-nitroethene-1,1-diamine; Ulxid; LY 139037; Panaxid; Nizatidina [Spanish]; SAM001246752; Nizax; Prestwick2_000921; UNII-P41PML4GHR; nizatidine; (E)-1-N'-[2-[[2-(dimethylaminomethyl)-1,3-thiazol-4-yl]methylsulfanyl]ethyl]-1-N-methyl-2-nitroethene-1,1-diamine; LS-67650; CPD000466384; Cronizat; 1,1-ethenediamine, n-[2-[[[2-[(dimethylamino)methyl]-4-thiazolyl]methyl]thio]ethyl]-n'-methyl-2-nitro-; MolPort-003-849-605; DB00585; L000761; BIDD:GT0761; 76963-41-2; AR-1B4780; Nizatidine [USAN:BAN:INN:JAN]; N-(2-(((2-((Dimethylamino)methyl)-4-thiazolyl)methyl)thio)ethyl)-N'-methyl-2-nitro-1,1-ethenediamine; KST-1B8734; CID3033637; Zanizal; Antizid; Tazac; Calmaxid; SMR000466384; Acinon; (E)-N-[2-[[2-(dimethylaminomethyl)-1,3-thiazol-4-yl]methylsulfanyl]ethyl]-N'-methyl-2-nitroethene-1,1-diamine; Zinga; Gastrax; Naxidine; Nizatidina; AC1Q40UA; Axid Ar; LY-139037; MLS001076680; C12H21N5O2S2; N-(4-(6-Methylamino-7-nitro-2-thia-5-aza-6-hepten-1-yl)-2-thiazolylmethyl)-N,N-dimethylamin; Splendil ER; 81336-20-1; I14-0503; Ambap76963-41-2; CAS-76963-41-2; Nizaxid; AC1Q1WQW; ZE-101; 1,1-Ethenediamine, N-(2-(((2-((dimethylamino)methyl)-4-thiazolyl)methyl)thio)ethyl)-N'-methyl-2-nitro-; NCGC00016934-01; C07270; HMS2094A15; Galitidin; ZL-101; HMS2051K04; D00440; HSDB 3574; 1,1-Ethenediamine, N-(2-(((2-((dimethylamino)methyl)-4-thiazoly)methyl)thio)ethyl)-N'-methyl-2-nitro-; Axid (TN); Niatidine; BRN 4846056; Acinon (TN); Ulcosol; CHEMBL653; Nizatidinum [Latin]; Distaxid; Nizatidinum; AC1MHW19; Axid; AC-5272; MLS000759518; Nizatidine (JAN/USP/INN)	76963-41-2	3033637	191384	TTDS00087	Histamine H2 receptor	Gastric receptor I;H2R;Histamine receptor 2	P25021	3274	ENSG00000113749	antagonist
DAP000338	Cimetidine	HMS1921C14; Cimetidine [USAN:INN:BAN:JAN]; Ulcomedina; Bio-0395; SPECTRUM1500684; NSC335308; N-Cyano-N'-Methyl-N''-(2-(((5-Methyl-1H-Imidazol-4-YL)Methyl)Thio)Ethyl) Guanidine; UPCMLD-DP029:001; KBio3_002198; Tocris-0902; MLS000069791; Guanidine, N-cyano-N'-methyl-N''-[2-[[(5-methyl-1H-imidazol-4-yl)methyl]thio]ethyl]-; DRG-0150; HSDB 3917; Guanidine, N-cyano-N'-methyl-N''-[2-[[5-methyl-1H-imidazol-4-yl)methyl]thio]ethyl]-; AC-12795; 1-cyano-2-methyl-3-[2-[(5-methyl-1H-imidazol-4-yl)methylsulfanyl]ethyl]guanidine; 2-cyano-1-methyl-3-(2-{[(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl}ethyl)guanidine; SKF-92334; Tagamet; Ulcestop; IDI1_000166; NINDS_000166; SAM002554892; Spectrum4_000812; BSPBio_000091; HMS2092I14; N-Cyano-N'-methyl-N''-(2-(((5-methyl-1 H-imidazol-4-yl) methyl)thio)ethyl)guanidine; SKF-92334; Sigmetadine; Tagamet; I14-0371; NCGC00015240-03; L003827; EINECS 257-232-2; CHEBI:3699; C10H16N6S; Tratul; NCGC00024859-02; N-cyano-N'-methyl-N''-(2-([(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl)ethyl)guanidine; Lopac0_000293; Biomet400; Evicer; FPF 1002; UPCMLD-DP029; Cimetidinum; BRD-K34157611-001-04-6; Tametin; DivK1c_000166; Acibilin; Guanidine, N''-cyano-N-methyl-N'-[2-[[(5-methyl-1H-imidazol-4-yl)methyl]thio]ethyl]-; MolPort-001-838-193; 51481-61-9; Altramet; LS-7278; NCGC00024859-05; Brumetidina; CID2756; N''-cyano-N-methyl-N'-(2-(((5-methyl-1H-imidazol-4-yl)methyl)thio)-ethyl)guanidine; Gastromet; MLS001148596; Gastrobitan; Tagamet, SKF-92334, Tratul, Tametin, Dyspamet, Acinil, Cimetidine; NCGC00015240-01; Magicul; AC1L1EE8; Spectrum5_001541; Guanidine, N''-cyano-N-methyl-N'-(2-(((5-methyl-1H-imidazol-4-yl)methyl)thio)ethyl)-; Histodil; Tagamet (TN); Tagamet Hb 200; Metracin; HMS2089O03; AC1Q3XK6; Ambap2984-61-4; NCGC00091439-03; SMR000038895; Lopac-C-4522; C 4522; Ulcimet; KBioSS_000975; TL8003410; cimetidine; Venopex; Spectrum3_001389; ZINC18207290; Valmagen; SK&F-92334; CHEMBL30; NCGC00024859-01; C4522_SIGMA; Cimetadine; Ulcedin; MolPort-003-895-998; SKF 92334; Acinil; 2984-61-4; Prestwick_65; Cimetidinum [INN-Latin]; KBio2_000975; NCGC00091439-02; S1845_Selleck; 2-Cyano-1-methyl-3-(2-(((5-methylimidazol-4-yl)methyl)thio)ethyl)guanidine; Ulcofalk; Edalene; MLS002153265; KBio2_006111; NCGC00024859-04; Cimetidine Hcl; BPBio1_000101; CCRIS 3247; nchembio732-comp5; MolPort-002-542-886; STK528249; 1-Cyano-2-methyl-3-[2-[[(5-methylimidazol-4-yl)methyl]thio]ethyl]guanidine; BRD-K18618618-001-01-6; CHEBI:101620; Prestwick3_000026; KBio1_000166; Cimetidina [INN-Spanish]; Ulcomet; Cimetag; Tagamet Hb; KBio2_003543; Cimal; CIMETIDINE A/AB; NCGC00091439-01; Spectrum2_000782; Cimetidine (JP15/USP/INN); HMS500I08; 1-Cyano-2-methyl-3-(2-(((5-methyl-4-imidazolyl)methyl)thio)ethyl)guanidine; L013434; CPD001370748; NCI60_002936; N-Cyano-N'-methyl-N''-(2-(((5-methyl-1H-imidazol-4-yl)methyl)thio)ethyl)guanidine; Ci metum; SBB057794; MLS002154178; LS-73446; 2-cyano-1-methyl-3-(2-{[(5-methyl-1H-imidazol-4-yl)methyl]thio}ethyl)guanidine; Spectrum_000495; L000186; NCGC00091439-04; ZINC18115268; Dyspamet; D00295; N-cyano-N'-methyl-N''-(2-{[(5-methyl-1H-imidazol-4-yl)methyl]thio}ethyl)guanidine; Cimetum; NCGC00024859-03; EU-0100293; Guanidine, N-cyano-N'-methyl-N''-(2-(((5-methyl-1H-imidazol-4-yl)methyl)thio) ethyl)-; Ulhys; 2-Cyano-1-methyl-3-[2-(5-methyl-1H-imidazol-4-yl-methylthio)ethyl]guanidine; N''-Cyano-N-methyl-N'-[2-[(5-methyl-1H-imidazol-4-yl)methylthio]ethyl]guanidine; N''-cyano-N-methyl-N'-(2-{[(5-methyl-1H-imidazol-4-yl)methyl]thio}ethyl)guanidine; LS-73445; BSPBio_002978; Cimetidina; Eureceptor; Guanidine, N-cyano-N'-methyl-N''-(2-(((5-methyl-1H-imidazol-4-yl)methyl)thio)ethyl)-; Peptol; KBioGR_001323; NCGC00185989-01; Ulcedine; N-Cyano-N'-methyl-[2-[[[5-methyl-1H-imidazol-4-yl]methyl]thio]ethyl]guanidine; DB00501; SPBio_000884	51481-61-9	2756	180968	TTDS00087	Histamine H2 receptor	Gastric receptor I;H2R;Histamine receptor 2	P25021	3274	ENSG00000113749	antagonist
DCL000141	KAI-9803	N/A	1818-68-4	4971	49743212	TTDC00077	Protein kinase C, delta type	NPKC-delta;Protein Kinase C delta	Q05655	5580	ENSG00000163932	inhibitor
DPR000128	LY525327	N/A	N/A	N/A	N/A	TTDC00100	Metabotropic glutamate receptor 5	5b;Glutamate receptor mGLU5;mGluR5	P41594	2915	ENSG00000168959	antagonist
DCL000463	AZD2516	N/A	N/A	N/A	N/A	TTDC00100	Metabotropic glutamate receptor 5	5b;Glutamate receptor mGLU5;mGluR5	P41594	2915	ENSG00000168959	antagonist
DPR000075	MGluRIII agonist and mGlu5 antagonist	N/A	287096-87-1	219021	45277720	TTDC00100	Metabotropic glutamate receptor 5	5b;Glutamate receptor mGLU5;mGluR5	P41594	2915	ENSG00000168959	antagonist
DCL000031	ADX10059	N/A	N/A	N/A	N/A	TTDC00100	Metabotropic glutamate receptor 5	5b;Glutamate receptor mGLU5;mGluR5	P41594	2915	ENSG00000168959	modulator
DCL000032	ADX-48621	N/A	N/A	N/A	N/A	TTDC00100	Metabotropic glutamate receptor 5	5b;Glutamate receptor mGLU5;mGluR5	P41594	2915	ENSG00000168959	modulator
DPR000148	McN3377	ZINC00001436; N-(3-Chlorophenyl)-N'-(4,5-dihydro-1-methyl-4-oxo-1H-imidazole-2-yl)urea; McN-3377; Fenobamum; KST-1B8127; 1-(3-chlorophenyl)-3-(3-methyl-5-oxo-4H-imidazol-2-yl)urea; Fenobamum [INN-Latin]; NCGC00092384-01; KST-1B8126; AC1Q6I6E; NPL-2009; AC1L4S0S; CHEBI:508410; CHEMBL239800; MolPort-002-494-450; BRD-K41160163-001-01-9; F0430_SIGMA; Fenobam; 1-(3-chlorophenyl)-3-[(2e)-1-methyl-4-oxoimidazolidin-2-ylidene]urea; 7255-99-4; AR-1B1412; AR-1B1411; N-(3-Chlorophenyl)-N'-(4,5-dihydro-1-methyl-4-oxo-1H-imidazol-2-yl)urea; UNII-078RCY7I27; L001092; 57653-26-6; 7256-23-7; LS-193274; NCGC00092384-02; CID162834; Urea, N-(3-chlorophenyl)-N'-(4,5-dihydro-1-methyl-4-oxo-1H-imidazol-2-yl)-	N/A	N/A	N/A	TTDC00100	Metabotropic glutamate receptor 5	5b;Glutamate receptor mGLU5;mGluR5	P41594	2915	ENSG00000168959	modulator
DPR000127	LY467711	N/A	N/A	N/A	N/A	TTDC00100	Metabotropic glutamate receptor 5	5b;Glutamate receptor mGLU5;mGluR5	P41594	2915	ENSG00000168959	antagonist
DCL000461	AZD2066	N/A	N/A	N/A	N/A	TTDC00100	Metabotropic glutamate receptor 5	5b;Glutamate receptor mGLU5;mGluR5	P41594	2915	ENSG00000168959	antagonist
DCL000019	Dermolastin	N/A	N/A	N/A	N/A	TTDC00019	Cathepsin G	CG;CTSG	P08311	1511	ENSG00000100448	inhibitor
DAP001393	Isovanillin	5-Formylguaiacol; AKOS000120260; iso-Vanillin; Isovanilline; H0263; Oxy-3 methoxy-4 benzaldehyde; ISOVANILLIN; 59940_FLUKA; 3-hydroxy-4-anisaldehyde; CID12127; 59940_ALDRICH; TL8004050; WLN: VHR CQ DO1; p-Anisaldehyde, 3-hydroxy- (8CI); CPD-8489; 4-Methoxy-3-hydroxybenzaldehyde; NCIOpen2_001085; 3-Hydroxyanisaldehyde; Isovanillin; Benzaldehyde, 3-hydroxy-4-methoxy-; CHEMBL275563; BB_NC-2245; 3-Hydroxyanisaldehyde; BRN 1073021; InChI=1/C8H8O3/c1-11-8-3-2-6(5-9)4-7(8)10/h2-5,10H,1H; LS-25072; ZINC00164617; I01-0153; 4-08-00-01764 (Beilstein Handbook Reference); AB1002458; p-Anisaldehyde, 3-hydroxy-; SMR000156287; 3-Hydroxy-4-methoxybenzaldehyde; 3-Hydroxy-p-anisaldehyde; 621-59-0; MolPort-000-146-016; AC1Q469E; 143685_ALDRICH; 59927_FLUKA; NSC82996; AC1L1YWO; MLS000574853; AC-541; STK400134; I0519; isovanilin; EINECS 210-694-9; CHEBI:113170; NSC 82996; Oxy-3 methoxy-4 benzaldehyde [French]	621-59-0	12127	592256	TTDS00078	Aldehyde oxidase	N/A	Q06278	316	ENSG00000138356	inhibitor
DAP000544	Menadione	KBio2_001708; UNII-723JX6CXY5; K-Thrombyl; SMR000653532; Juva-K; AI3-14700; QTL1_000056; HMS1921P06; K-Vitan; 2-Methyl-1,4-naftochinon [Czech]; BB_NC-2319; AC1L1HBA; MolPort-001-766-699; KBio2_004276; KBio3_003005; 2-Methyl-1,4-naphthoquinone; 3-Methyl-1,4-naphthoquinone; Kativ-G; Prestwick0_000459; Kipca; Kappaxan (VAN); Koaxin; Menaphthone; Prokayvit; Menaquinone 0; Menaphthon; M5625_SIGMA; SPECTRUM1502254; Bio1_000471; C05377; Prestwick2_000459; 03AAE1E9-B215-45AF-976C-91E61894A467; HMS1569K20; Mitenon; NCGC00094978-02; KBio2_005095; SpecPlus_000191; CPD-3766; Kolklot; Menadion; ZINC00001677; Spectrum_001228; LS-95654; DB00170; Vicasol; 72060-21-0; 2-Methyl-1,4-naphthochinon; cMAP_000077; HSDB 3354; Menadione [USAN:BAN]; Memodol; SMR000059102; KBio2_006844; 2-Methyl-1,4-naphthochinon [German]; menadione; Vitamin K0; Spectrum2_001194; 2-methyl-1,4-naphthoquinone, 5; EINECS 200-372-6; CHEBI:28869; BPBio1_000592; D02335; Menadionum; S1949_Selleck; KBioGR_002527; BSPBio_000538; 1,4-Naphthalenedione, 2-methyl-, radical ion(1-); Methyl-1,4-naphthoquinone; NCI60_003945; KBio2_007663; Kayquinone; WLN: L66 BV EVJ C1; NSC4170; Bio1_000960; HMS500D22; KBioSS_002535; MLS001148443; 2-Methyl-1,4-naphthalenedione; Methylnaphthoquinone; ARONIS24154; Vitamin-?K3; I14-2821; VK3; Kaergona; 2-Methyl-1,4-naftochinon; CAS-58-27-5; 2-methylnaphthalene-1,4-dione; M0373; 47775_SUPELCO; LS-95653; 58-27-5; Kipca-Oil Soluble; AC1Q2HB3; Aquinone; Spectrum5_001764; Kipca, oil soluble; Kaykot; Mitenone; KBio2_002527; KBio1_001231; InChI=1/C11H8O2/c1-7-6-10(12)8-4-2-3-5-9(8)11(7)13/h2-6H,1H; CCRIS 6672; NSC 4170; Vitamin K3 : 2-Methyl-1,4-naphthoquinone; Panosine; CID4055; Klottone; 34524-96-4; Prestwick_313; KBioSS_001708; KBio1_000080; KBioGR_000984; Karcon; NCGC00016258-01; Vitamin K3; Menadione semiquinone; Hemodal; Kanone; MLS000069420; C11H8O2; CHEMBL590; Kappaxin (TN); NCIMech_000105; HMS2092F12; nchembio.109-comp5; Methyl-1,4-naphthalenedione; Kayklot; Kareon; DivK1c_000080; Spectrum4_000722; AKOS004910447; Usaf ek-5185; Prestwick1_000459; Prestwick3_000459; Menadione (K3); 2-Methylnaphthoquinone; DivK1c_006287; IDI1_000080; Synkay; NCGC00094978-01; Bio1_001449; BIDD:ER0556; Kappaxin; SPBio_001267; Vitamin K 3; 1,4-Naphthoquinone, 2-methyl-; Aquakay; NAPHTHOQUINONE, METHYL-; SPBio_002477; M9429_SIGMA; Vitamin K2(0); Menadione (USP); 1,4-Naphthalenedione, 2-methyl-; Menaphtone; Thyloquinone; NINDS_000080	58-27-5	4055	7751	TTDS00078	Aldehyde oxidase	N/A	Q06278	316	ENSG00000138356	inhibitor
DCL000688	Alfa-interferon	N/A	142192-09-4	N/A	3814724	TTDS00492	Interferon-alpha/beta receptor	IFN-alpha-REC;IFN-R;Interferon alpha/beta receptor;Type I interferon receptor	P48551	3455	ENSG00000159110	stimulator
DAP001284	Interferon alfacon-1	Infergen (TN); Advaferon; Interferon alfacon-1 (genetical recombination); Advaferon (TN); Interferon alfacon-1 (USAN/INN); D02744; Interferon alfacon-1; Interferon alfacon-1 (genetical recombination) (JAN); Infergen; 118390-30-0	118390-30-0	9554198	47205817	TTDS00492	Interferon-alpha/beta receptor	IFN-alpha-REC;IFN-R;Interferon alpha/beta receptor;Type I interferon receptor	P48551	3455	ENSG00000159110	binder
DAP001281	Interferon alfa-n3	D04553; Interferon alfa-n3; Alferon N (TN); Interferon alfa-n3 (USAN); Alferon N	N/A	N/A	47206398	TTDS00492	Interferon-alpha/beta receptor	IFN-alpha-REC;IFN-R;Interferon alpha/beta receptor;Type I interferon receptor	P48551	3455	ENSG00000159110	binder
DCL000623	RhuMAb IFN alpha	N/A	N/A	N/A	N/A	TTDS00492	Interferon-alpha/beta receptor	IFN-alpha-REC;IFN-R;Interferon alpha/beta receptor;Type I interferon receptor	P48551	3455	ENSG00000159110	antibody
DAP001285	Interferon Alfa-2b, Recombinant	N/A	99210-65-8	N/A	47205818	TTDS00492	Interferon-alpha/beta receptor	IFN-alpha-REC;IFN-R;Interferon alpha/beta receptor;Type I interferon receptor	P48551	3455	ENSG00000159110	binder
DCL000432	Anti-IFN alfa	N/A	N/A	N/A	N/A	TTDS00492	Interferon-alpha/beta receptor	IFN-alpha-REC;IFN-R;Interferon alpha/beta receptor;Type I interferon receptor	P48551	3455	ENSG00000159110	antagonist
DAP001278	Peginterferon alfa-2a	Peginterferon alfa-2a (genetical recombination) (JAN); Peginterferon alfa-2a (USAN/INN); 198153-51-4; Pegasys (TN); D02747; Pegasys; Peginterferon alfa-2a (genetical recombination); Peginterferon alfa-2a	198153-51-4	5360545	47205819	TTDS00492	Interferon-alpha/beta receptor	IFN-alpha-REC;IFN-R;Interferon alpha/beta receptor;Type I interferon receptor	P48551	3455	ENSG00000159110	binder
DAP001282	Interferon beta-1a	145258-61-3; Avonex; D04554; Avonex (TN); Interferon beta-1a (genetical recombination) (JAN); Interferon beta-1a (genetical recombination); Interferon beta-1a (USAN); Interferon beta-1a	145258-61-3	6438354	47206399	TTDS00492	Interferon-alpha/beta receptor	IFN-alpha-REC;IFN-R;Interferon alpha/beta receptor;Type I interferon receptor	P48551	3455	ENSG00000159110	binder
DAP001279	Peginterferon alfa-2b	Pegintron (TN); Peginterferon alfa-2b (generical recombination) (JAN); 215647-85-1; Peginterferon alfa-2b; PegIntron; Peginterferon alfa-2b (INN); D02748; Peginterferon alfa-2b (generical recombination)	99210-65-8	N/A	47205820	TTDS00492	Interferon-alpha/beta receptor	IFN-alpha-REC;IFN-R;Interferon alpha/beta receptor;Type I interferon receptor	P48551	3455	ENSG00000159110	binder
DAP001280	Interferon alfa-n1	Interferon alfa-n1; 308067-63-2; D04552; alfa-Interferon; Interferon alfa-n1 (USAN); Well-feron (TN); Well-feron	74899-72-2	119029	47206397	TTDS00492	Interferon-alpha/beta receptor	IFN-alpha-REC;IFN-R;Interferon alpha/beta receptor;Type I interferon receptor	P48551	3455	ENSG00000159110	binder
DAP001283	Interferon beta-1b	N/A	145155-23-3	N/A	10103	TTDS00492	Interferon-alpha/beta receptor	IFN-alpha-REC;IFN-R;Interferon alpha/beta receptor;Type I interferon receptor	P48551	3455	ENSG00000159110	binder
DCL000640	Sifalimumab	N/A	162635-04-3	23724530	47207726	TTDS00492	Interferon-alpha/beta receptor	IFN-alpha-REC;IFN-R;Interferon alpha/beta receptor;Type I interferon receptor	P48551	3455	ENSG00000159110	antibody
DAP000575	Triamterene	6-PHENYL-2,4,7-TRIAMINO PTERIDINE; 396-01-0; CPD000059118; SPBio_000876; Triamterine; KBio2_003556; 6-phenylpteridine-2,4,7-triamine; Triamterene (JP15/USP/INN); Renezide; EU-0101196; SK-8542; Isobar; HMS501F15; Triamterena [INN-Spanish]; Triamteren; HSDB 3405; 6-Phenyl-2,4,7-triaminopteridine; BIDD:GT0534; Fluss 40; CCRIS 5872; 2,4,7-Triamino-6-fenilpteridina; Noridil; 2,4,7-Pteridinetriamine, 6-phenyl-; ARONIS23836; Diurene; Diren; NSC77625; NCGC00016016-01; EINECS 206-904-3; SPBio_002048; AI3-60017; Dinazide; TRIAMTERENE USP; Triamthiazid; SK&F-8542; SPECTRUM1500589; Jatropur; UNII-WS821Z52LQ; Urocaudal; Pteridine deriv. 11; NSC 639359; Turfa; Dyrenium; Prestwick_480; NCGC00016016-07; NCGC00016016-03; Jenateren; AKOS003790819; NCGC00023458-07; Pterophene; Dyren; Dytac; Trispan; Triteren; pter ophene; HMS1568G09; Triamteril complex; AB00052116; I06-1678; Triamterena; D014223; C12H11N7; Dytenzide; Nephral; AC1Q52QZ; BRN 0266723; NCGC00023458-03; Prestwick2_000034; Triurene; 2,4,7-Triamino-6-fenilpteridina [Italian]; Goldshield Brand of Triamterene; Ademin(e); KBio1_000433; Triamterenum; Triamizide; Spectrum5_001034; BPBio1_000141; NCI-C56042; KBio3_002144; Jorba Brand of Triamterene; Anjal; LS-1250; Spectrum3_001372; SK&F 8542; WLN: T66 BN DN GN JNJ CZ EZ HR& IZ; Ademine; Hypertorr; SMR000059118; Prestwick3_000034; Oprea1_825704; NCI C56042; Bio-0612; Noridyl; SALI-PUREN; Triampur; NCGC00023458-06; Pteridine, 2,4,7-triamino-6-phenyl-; D00386; Wellspring Brand of Triamterene; KBio2_000988; Triamteril; CAS-396-01-0; triamterene; HMS2092O17; DivK1c_000433; Teridin; Lopac-T-4143; ZINC00120286; Prestwick1_000034; Spectrum2_000938; Diarol; Thiazid Wolff; Trizid; AC-14066; Uretren; Ademin; Reviten; nchembio.215-comp12; STK300348; NCGC00023458-05; Pterofen; T4143_SIGMA; Hidiurese; MLS000069431; Diucelpin; CID5546; Esiteren; NCGC00016016-02; Triamterenum [INN-Latin]; NCGC00023458-04; NCGC00016016-12; Spectrum_000508; CHEMBL585; Kalspare; Taturil; Tricilone; DB00384; Tri-Span; SAM002554937; Amteren; IDI1_000433; Apo-triazide; Triamterene [USAN:INN:BAN:JAN]; Lopac0_001196; SmithKline Beecham Brand of Triamterene; MolPort-001-641-070; BSPBio_000127; NSC 77625; 5-26-17-00447 (Beilstein Handbook Reference); KBio2_006124; NSC639359; NCIOpen2_004741; Masuharmin; NINDS_000433; Diuteren; Dazid; AC1L1KL5; T 4143; Spectrum4_000366; Teriam; Hydrene; KBioGR_000831; BRD-K92049597-001-05-9; SMP1_000147; Prestwick0_000034; BSPBio_002924; Diutensat; SKF 8542; KBioSS_000988; 6-Phenyl-2,4,7-pteridinetriamine; Dyrenium (TN); 2,4,7-Triamino-6-phenylpteridine; Ditak; Dyberzide; Jsp006872	396-01-0	5546	153028	TTDS00158	Amiloride-sensitive sodium channel alpha-subunit	Alpha ENaC;Alpha NaCH;Epithelial Na+ channel alpha subunit;Nonvoltage-gated sodium channel 1 alpha subunit;SCNEA	P37088	6337	ENSG00000111319	blocker
DAP000187	Amiloride	BPBio1_000015; Pyrazinecarboxamide, 3,5-diamino-N-(aminoiminomethyl)-6-chloro-, monohydrochloride; EINECS 220-024-7; KBioSS_000394; NCGC00024443-06; MLS001060798; BRD-K97181089-003-02-3; IDI1_034042; Tocris-0890; Amiloride (INN); NCGC00024443-02; AC-13631; Lopac0_000111; Amiloridum [INN-Latin]; DB00594; BIDD:GT0466; Prestwick1_000007; NCGC00024443-07; BSPBio_001572; SPBio_001934; KBio2_005530; HMS1989O14; BSPBio_001826; Guanamprazine; LS-1094; KBioSS_000292; NCGC00024443-09; 3,5-diamino-N-[amino(imino)methyl]-6-chloropyrazine-2-carboxamide; NCGC00015089-12; HMS1791O14; ST079279; KBio2_000394; BCBcMAP01_000101; KBioGR_000544; ZINC04340269; NCGC00024443-05; CHEBI:2639; NCGC00015089-01; Amiloride [INN:BAN]; Spectrum4_000132; HMS2089H05; SMR000449325; N-Amidino-3,5-diamino-6-chloropyrazinecarboxamide; C06821; SMR000486264; Lopac-A-7410; KBio1_000182; KBio3_000583; Bio2_000772; Amilorida [INN-Spanish]; KBio3_001326; 3,5-diamino-N-carbamimidoyl-6-chloropyrazine-2-carboxamide; D07447; CCRIS 6545; 2016-88-8 (anhydrous hydrochloride); N-Amidino-3,5-diamino-6-chlorpyrazincarboxamid; Amipramizide; BSPBio_000013; MolPort-005-934-472; Amilorida; C6H8ClN7O; MK-870 (Hydrochloride dihydrate); Pyrazinecarboxamide, 3,5-diamino-N-(aminoiminomethyl)-6-chloro-; Prestwick3_000007; AB00053415; Bio1_001337; Amikal (Hydrochloride dihydrate); KBio2_005428; Amiprazidine; AMILORIDE (SEE ALSO: AMILORIDE HCL (2016-88-8)); Amiloridum; DivK1c_000182; Amipramizid; CHEMBL945; Midamor (Hydrochloride dihydrate); Bio1_000359; 2609-46-3; BRD-K97181089-310-03-0; Prestwick2_000007; Prestwick0_000007; UNII-7DZO8EB0Z3; Spectrum3_000293; IDI1_000182; Spectrum2_000118; AMILORIDE; KBio2_002962; 3,5-Diamino-N-(aminoiminomethyl)-6-chloropyrazinecarboxamide; CPD-10324; Guanamprazin; AC1Q3POC; Spectrum5_000776; MolPort-005-937-651; KBio3_000584; MLS000758249; KBio2_000292; 3,5-diamino-6-chloro-N-(diaminomethylidene)pyrazine-2-carboxamide; Amiloride HCL; Amiloride hydrochloride hydrate; Amyloride; Bio2_000292; Amiclaran (TN); AC1L27IZ; Midamor; Spectrum_000034; 17440-83-4 (hydrochloride); 1f5l; KBio2_002860; NCGC00015089-02; Amiclaran; NINDS_000182; KBioGR_000292; SPBio_000136; Bio1_000848; Amipramidin; CID16231	2016-88-8	16231	9039	TTDS00158	Amiloride-sensitive sodium channel alpha-subunit	Alpha ENaC;Alpha NaCH;Epithelial Na+ channel alpha subunit;Nonvoltage-gated sodium channel 1 alpha subunit;SCNEA	P37088	6337	ENSG00000111319	blocker
DAP000751	Polythiazide	6-chloro-2-methyl-1,1-dioxo-3-(2,2,2-trifluoroethylsulfanylmethyl)-3,4-dihydro-1; AR-1L3046; D00657; LS-1223; AC1L1J55; CID4870; 6-Chloro-3,4-dihydro-2-methyl-3-(((2,2,2-trifluoroethyl)thio)methyl)-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; Renese; C11H13ClF3N3O4S3; NSC108161; NSC 108161; 6-chloro-2-methyl-3-{[(2,2,2-trifluoroethyl)thio]methyl}-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; Polythiazidum [INN-Latin]; 6-Chloro-3,4-dihydro-2-methyl-3-[[(2,2,2-trifluoroethyl)thio]methyl]-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; CHEMBL1587; Polythiazide (JAN/USAN/INN); Renese (TN); Politiazida [INN-Spanish]; Nephril; HSDB 850; CCRIS 6094; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3,4-dihydro-2-methyl-3-[[(2,2,2-trifluoroethyl)thio]methyl]-, 1,1-dioxide; WLN: T66 BSWN EM DHJ C1 D1S1XFFF HG ISZW; Polythiazide [USAN:INN:BAN:JAN]; C07766; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3,4-dihydro-2-methyl-3-(((2,2,2-trifluoroethyl)thio)methyl)-, 1,1-dioxide (8CI, 9CI); 6-Chloro-3,4-dihydro-2-methyl-7-sulphamoyl-3-(2,2,2-trifluoroethylthiomethyl)-2H-benzo-1,2,4-thiadiazine 1,1-dioxide; AC1Q6TPT; 346-18-9; Polythiazidum; BRN 0770371; polythiazide; Politiazida; P-2525; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3,4-dihydro-2-methyl-3-(((2,2,2-trifluoroethyl)thio)methyl)-, 1,1-dioxide; Drenusil; EINECS 206-468-4; 2-Methyl-3-(beta,beta,beta-trifluoroethylthiomethyl)-6-chloro-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide; UNII-36780APV5N; DB01324; P 2525	346-18-9	4870	10475848	TTDS00117	Solute carrier family 12 member 3	Na-Cl symporter;SLC12A3;Thiazide-sensitive Na-Cl cotransporter;Thiazide-sensitive sodium-chloride cotransporter	P55017	6559	ENSG00000070915	blocker
DAP000750	Hydrochlorothiazide	DB00999; Pantemon; H1274; Hydro-Aquil; NCGC00021906-08; NCGC00015508-07; Ro-hydrazide; Aquazide-H; LS-243; NCGC00021906-07; Aquarills; Tandiur; D006852; Neo-codema; Lopac-H-4759; DivK1c_000289; Aquarius; AB00052012; NCI60_004317; Hydrozide; Hydro-chlor; Hydro Par; Dichlotiazid; Cidrex; Thiuretic; Esidrix; Carozide; Dihydrochlorurit; Spironazide; KBio2_003925; Chlorizide; Apo-Hydro; adiazine-1,1-dioxide; 6-Chloro-7-sulfamoyl-3, 4-dihy; Spectrum_000877; BAS 00371709; Sectrazide; Medozide; Chlorzide; Mictrin; Idrotiazide; Dihydrochlorurite; Dichlothiazide; Urozide; Neoflumen; HydroDIURIL; Hidroclorotiazida [INN-Spanish]; NCGC00015508-03; Condiuren; Hydrochlorothiazid; Aldectazide 50/50; HMS500O11; Mikorten; SAM002554901; Novodiurex; NCGC00021906-04; Drenol; Aldazida; Oprea1_357174; dro-2H-1,2,4-benzothiadiazine 1,1-dioxide; Component of Butizide Prestabs; panurin dichloride; BSPBio_000017; KBioSS_001357; NINDS_000289; UNII-0J48LPH2TH; WLN: T66 BSWM EM DHJ HG ISZW; Disalunil; Spectrum3_000456; component of Cyclex; Mazide 25 mg; BIDD:GT0153; Acesistem; Ambap58-93-5; Hydropres; NCGC00021906-06; Prestwick0_000009; Raunova Plus; Idroclorotiazide [DCIT]; Hydro-Diuril; Thiaretic; Dichlotride; Hydrochlorthiazide; component of Dyazide; Hydrochlorat; Inderide 80/25; Hidrosaluretil; Apresazide; NSC53477; CID3639; I09-0531; Hydro-D; Dihydrochlorothiazid; Dihydroxychlorothiazidum; AF-614/30832002; Vetidrex; Hidroclorotiazida; Idroclorotiazide; Natrinax; Hidrochlortiazid; Lotensin HCT; EU-0100614; Selozide; Chlothia; Hydrozide Injection, Veterinary; Neo-Flumen; KBioGR_000351; SPBio_001259; Didral; 125727-50-6; Acuretic; Indroclor; ARONIS24316; Diclotride; 3,4-Dihydrochlorothiazide; KBio1_000289; Megadiuril; HCT; AC1L1GDT; 58-93-5; Maybridge Compound 10; Dichlorosal; Hydrochlorothiazide Intensol; AC-11072; Nefrix; Microzide (TN); D00340; Hidro-Niagrin; Dihydrochlorothiazidum; Fluvin; SMR000035778; NCGC00015508-01; 8049-49-8; Diu-melusin; Prestwick3_000009; CAS-58-93-5; Chlorosulthiadil; Oretic; Bio-0714; BRN 0625101; SPECTRUM1500335; Timolide; Neo-Minzil; NCGC00021906-05; Briazide; NCGC00015508-02; component of Aldoril; Diaqua; Esidrex; Hypothiazide; H 4759; Hydrex-semi; Hydrochlorothiazide (JP15/USP/INN); BPBio1_000019; AKOS000121373; Direma; Spectrum2_001040; Unazid; Diurogen; component of Aldactazide; Su 5879; Microzide; Thlaretic; Hydrosaluric; NSC 53477; Diu 25 Vigt; Prestwick2_000009; KBio2_001357; Saldiuril; Hydril; Hydrochlorothiazidum [INN-Latin]; Dihydrochlorothiazide; HMS1568A19; Hydrocot; Ivaugan; diclot ride; Hydrochlorothiazide [INN:BAN:JAN]; CCRIS 2082; Hydrochlorthiazidum; Prestwick_263; FT-0082750; AC1Q55FM; H4759_SIAL; component of Caplaril; Esoidrina; Hydrodiuretic; Concor Plus; Hydrothide; Spectrum5_000824; Hydro-T; CHEMBL435; Aquazide H; 3,4-Dihydro-6-chloro-7-sulfamyl-1,2, 4-benzothi; KBio3_001352; Dicyclotride; Hypothiazid; Caplaril; C7H8ClN3O4S2; S1708_Selleck; Esidrix (TN); HCZ; HMS553N04; IDI1_000289; Hidril; Clorana; Panurin; Acuilix; HMS1920D19; Hydrochlorot; NCI-C55925; Manuril; Bremil; Hyclosid; STK315354; Maschitt; Vaseretic; HCT-Isis; KBio2_006493; Newtolide; Roxane; Lopac0_000614; Prestwick1_000009; Aldactazide 25/25; CPD000035778; Nefrol; Disothiazid; HMS2091L05; HSDB 3096; SPBio_001938; Hidroronol; Moduretic; Servithiazid; Jen-Diril; BRD-K13078532-001-05-2; Urodiazin; HCTZ; NCGC00021906-03; Spectrum4_000006; Hydro-Saluric; Dihydran; Dichlorotride; NCGC00015508-12; MolPort-000-144-465; Aldoril; component of Butizide Prestabs; ZINC00896569; MLS000069619; Hytrid; Maybridge1_004336; Modurcen; EINECS 200-403-3; Chlorsulfonamidodihydrobenzothiadiazine dioxide; BSPBio_002132; Hidrotiazida; H2910_SIAL; hydrochlorothiazide; component of Esimil; Dixidrasi; Catiazida; Hydrochlorothiazidum	58-93-5	3639	7847406	TTDS00117	Solute carrier family 12 member 3	Na-Cl symporter;SLC12A3;Thiazide-sensitive Na-Cl cotransporter;Thiazide-sensitive sodium-chloride cotransporter	P55017	6559	ENSG00000070915	blocker
DAP000188	Bendroflumethiazide	BL H368; DB00436; Bendroflumethazide; Poliuron; CID2315; Bendrofluazide; Aprinox; (+-)-3-Benzyl-3,4-dihydro-6-(trifluoromethyl)-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; DivK1c_000274; Bendroflumethiazide (JAN/USP/INN); Benuron; Salures; Spectrum_001386; Livesan; KBio1_000274; Naigaril; 3-Benzyl-3,4-dihydro-6-(trifluoromethyl)-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; Thiazidico; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3,4-dihydro-3-(phenylmethyl)-6-(trifluoromethyl)-, 1,1-dioxide; CPD000058802; Bristuron; SPECTRUM1503104; Bendroflumetiazide; KBioGR_001188; Bendroflumetiazida [INN-Spanish]; Centyl; CHEBI:3013; KBio2_007002; BRD-A80017228-001-05-9; Benzy-rodiuran; SPBio_002827; IDI1_000274; Naturetin; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3-benzyl-3,4-dihydro-6-(trifluoromethyl)-,1,1-dioxide; Prestwick3_000784; ST51014919; +--3-benzyl-3,4-dihydro-6-(trifluoromethyl)-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; NINDS_000274; SPBio_001308; bendrofumethiazide; Prestwick0_000784; C07758; C15H14F3N3O4S2; Urlea; Naturetin (TN); Plusuril; Be 724-A; BSPBio_000888; Rautrax N; Bentride; Benzydroflumethiazide; Spectrum2_001524; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3,4-dihydro-3-(phenylmethyl)-6-(trifluoromethyl)-, 1,1-dioxide, (+-)-; 4-27-00-08041 (Beilstein Handbook Reference); 3-Benzyl-6-trifluoromethyl-7-sulfamoyl-3,4-dihydro-1,2,4-benzothiadiazine, 1,1-dioxide; Orsile; Naturine; Niagaril; Benzhydroflumethiazide; UNM000000601501; Relan beta; Spectrum5_001016; NCGC00089729-03; Neo-rontyl; Spectrum3_001558; EINECS 200-800-1; Berkozide; B5775_FLUKA; FT 8; Naturetin-2.5; HMS1570M10; NATURETIN-5; Benzylrodiuran; Sodiuretic; MLS000028558; 6-trifluoromethyl-3-benzyl-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide; 3,4-Dihydro-3-(phenylmethyl)-6-(trifluoromethyl)-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; BSPBio_003036; HMS1922E15; AC1L1DEI; Spectrum4_000774; Corzide; MolPort-003-666-443; Nateretin; 3-(phenylmethyl)-6-(trifluoromethyl)-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; Bendroflumethiazide [USP]; BPBio1_000978; Sinesalin; Pluryle; CHEMBL1684; LS-40431; Bendroflumetiazida; Rauzide; BRN 0373316; KBio2_001866; Pluryl; Neo-naclex; Bendroflumethiazidum; 96782-79-5; EU-0009291; HSDB 3293; HMS500N16; 3-Benzyl-6-trifluoromethyl-7-sulfamoyl-3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide; B5775_SIGMA; AB00052315; NATURETIN-10; KBio2_004434; Bendroflumetiazide [DCIT]; HMS2092J16; FT 81; BHFT; Nikion; Bendroflumethiazidum [INN-Latin]; 3-Benzyl-6-(trifluoromethyl)-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3-benzyl-3,4-dihydro-6-(trifluoromethyl)-, 1,1-dioxide; UNII-5Q52X6ICJI; Prestwick2_000784; KBioSS_001866; nchembio747-comp20; BENDROFLUMETHIAZIDE; SAM002264598; 73-48-3; KBio3_002536; SMR000058802; Salural; Intolex; D00650; MLS001076062; Prestwick1_000784; Prestwick_992; Bristuric; Flumersil; NCGC00089729-02; Flumesil; 6-Trifluoromethyl-3-benzyl-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine, 1,1-dioxide; Benzylhydroflumethiazide; Repicin	73-48-3	2315	9960	TTDS00117	Solute carrier family 12 member 3	Na-Cl symporter;SLC12A3;Thiazide-sensitive Na-Cl cotransporter;Thiazide-sensitive sodium-chloride cotransporter	P55017	6559	ENSG00000070915	blocker
DAP000749	Metolazone	SPECTRUM2300325; Spectrum4_000229; Metolazone (JAN/USP/INN); Spectrum_000456; BPBio1_000138; NCGC00093985-05; SPBio_001842; IDI1_000275; Zaroxolyn; SPBio_002063; Prestwick_333; 7-Chloro-1,2,3,4-tetrahydro-2-methyl-4-oxo-3-o-tolyl-6-quinazolinesulfonamide; Diulo; 17560-51-9; CID4170; Metalozone; Prestwick3_000112; 7-Chloro-1,2,3,4-tetrahydro-2-methyl-3-(2-methylphenyl)-4-oxo-6-quinazolinesulfonamide; MLS002153316; HMS1922L16; Oldren; LS-140226; 6-Quinazolinesulfonamide, 7-chloro-1,2,3,4-tetrahydro-2-methyl-4-oxo-3-o-tolyl-; BSPBio_000124; NCGC00093985-04; Metolazona [INN-Spanish]; Metolazona; Mykrox; NCGC00093985-02; Mykrox, Zaroxolyn, Diulo, Metolazone; 6-Quinazolinesulfonamide, 1,2,3,4-tetrahydro-7-chloro-2-methyl-4-oxo-3-o-tolyl-; UNII-TZ7V40X7VX; HMS2093P14; NCGC00093985-08; Prestwick2_000112; KBio1_000275; 7-chloro-2-methyl-3-(2-methylphenyl)-4-oxo-1,2-dihydroquinazoline-6-sulfonamide; D00431; NCGC00093985-01; BRD-A61793559-001-05-7; KBio2_006072; metolazone; AC1L1HKJ; 2-Methyl-3-o-tolyl-6-sulfamyl-7-chloro-1,2,3,4-tetrahydro-4-quinazolinone; DB00524; Spectrum5_001237; HMS500N17; 5-25-09-00212 (Beilstein Handbook Reference); Metalazone; KBio2_000936; M1195_SIGMA; HMS1568G06; EINECS 241-539-3; DivK1c_000275; AB00052055; 6-Quinazolinesulfonamide, 7-chloro-1,2,3,4-tetrahydro-2-methyl-3-(2-methylphenyl)-4-oxo-; SR-720-22; Spectrum2_001741; BSPBio_002422; Xuret; Zaroxolyn (TN); Metolazonum [INN-Latin]; Prestwick1_000112; S1610_Selleck; KBioSS_000936; KBioGR_000897; SMR001230730; Prestwick0_000112; Metolazone [USAN:BAN:INN:JAN]; HSDB 3367; NCGC00093985-03; MolPort-003-666-780; Microx; SR 720-22; Metolazonum; CHEMBL878; BRN 0965506; MLS002154200; NINDS_000275; NCGC00093985-06; Metenix; KBio2_003504	17560-51-9	4170	7847497	TTDS00117	Solute carrier family 12 member 3	Na-Cl symporter;SLC12A3;Thiazide-sensitive Na-Cl cotransporter;Thiazide-sensitive sodium-chloride cotransporter	P55017	6559	ENSG00000070915	blocker
DPR000072	MCP-1	N/A	N/A	N/A	623363	TTDR00451	C-C motif chemokine 2	CCL2;HC11;MCAF;MCP1;MCP-1;Monocyte Chemoattractant Protein 1;Monocyte chemoattractant protein-1;Monocyte chemotactic and activating factor;Monocyte chemotactic protein 1;Monocyte secretory protein JE;SCYA2;Small-inducible cytokine A2	P13500	6347	ENSG00000108691	inhibitor
DPR000102	RS-504393	N/A	300816-15-3	N/A	N/A	TTDR00451	C-C motif chemokine 2	CCL2;HC11;MCAF;MCP1;MCP-1;Monocyte Chemoattractant Protein 1;Monocyte chemoattractant protein-1;Monocyte chemotactic and activating factor;Monocyte chemotactic protein 1;Monocyte secretory protein JE;SCYA2;Small-inducible cytokine A2	P13500	6347	ENSG00000108691	inhibitor
DAP001539	Zoledronic acid	UNII-70HZ18PH24; CGP 42446A; C088658; Zometa, Zomera, Aclasta and Reclast, Zoledronic Acid; S00092; AKOS005145739; Aclasta; (1-Hydroxy-2-imidazol-1-ylethylidene)diphosphonic acid; Novartis brand of zoledronic acid; D08689; CGP 42'446; Bisphosphonate 3; Zometa; Zoledronic acid (INN); Zoledronic acid; (1-hydroxy-2-(1H-imidazol-1-yl)ethylidene)bisphosphonic acid; CGP-42446; CHEMBL924; LS-181815; CGP-42'446; AC1L2ACJ; AC1Q6RN3; Phosphonic acid,[1-hydroxy-2-(1H-imidazol-1-yl)ethylidene]bis-; 2-(imidazol-1-yl)-1-hydroxyethylidene-1,1-bisphosphonic acid; Zometa Concentrate; ZOL; (1-hydroxy-2-imidazol-1-yl-1-phosphonoethyl)phosphonic acid; Reclast; I06-0710; HMS2089O09; CID68740; 2-(imidazol-1-yl)-1-hydroxyethane-1,1-diphosphonic acid; Zoledronate; [1-hydroxy-2-(1H-imidazol-1-yl)ethane-1,1-diyl]bis(phosphonic acid); MolPort-002-885-874; Zometa (TN); MolPort-003-850-890; BIDD:GT0292; NSC721517; KS-1132; Reclast (TN); (1-hydroxy-2-imidazol-1-yl-phosphonoethyl)phosphonic acid monohydrate; CGP 42446; Bio-0112; DB00399; BIDD:PXR0134; NCGC00159521-02; CHEBI:46557; S1314_Selleck; 118072-93-8; Phosphonic acid, (1-hydroxy-2-(1H-imidazol-1-yl)ethylidene)bis-; Zometa (Novartis); NCGC00159521-03; FT-0082657; AC-1092; Zoledronic acid [USAN:INN]	N/A	68740	11528905	TTDS00372	Farnesyl pyrophosphate synthetase	Farnesyl diphosphate synthase;Farnesyl diphosphate synthetase;Farnesyl pyrophosphate synthase;FPP synthase;FPP synthetase;FPPS;FPS	Q86C09	N/A	N/A	inhibitor
DAP001416	Pamidronate disodium	1-hydroxy-3-aminopropane-1,1-diphosphonic acid; UNII-OYY3447OMC; CGP-23339AE; Phosphonic acid, (3-amino-1-hydroxypropylidene)bis-; Disodium dihydrogen (3-amino-1-hydroxypropylidene)bisphosphonate; Aredia; HMS2090C13; ChemDiv1_025240; amino-1-hydroxypropane-1,1-diphosphonate; Acide pamidronique [INN-French]; Pamidronate disodium [USAN:JAN]; LS-106422; Aminohydroxypropylidene diphosphonate disodium salt; 40391-99-9 (Parent); Ribodroat; DB00282; AC1L1IP4; BIDD:GT0538; KS-1092; aminopropanehydroxydiphosphonate; AHPrBP; Acido pamidronico; AKOS003599275; 109552-15-0; LS-106427; 40391-99-9; (3-amino-1-hydroxypropylidene)-1,1-biphosphonate; CHEMBL834; C019248; I14-2407; (3-Amino-1-hydroxypropylidene)diphosphonic acid disodium salt; EINECS 260-647-1; CID60342; Amidronate; AC1O3LQE; D07281; disodium (3-amino-1-hydroxypropane-1,1-diyl)bis[hydrogen (phosphonate)]; 3-Amino-1-hydroxypropane-1,1-diphosphonic acid disodium salt; (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate; amidronate disodium salt; NCGC00159433-02; Ribodroat (TN); MolPort-002-131-054; sodium(3-amino-1-hydroxypropane-1,1-diyl)bis[hydrogen(phosphonate)] hydrate(2:1:5); C3H9NO7P2.2Na.5H2O; 3-amino-1-hydroxy-propane-1,1-bisphosphonate (sodium salt); UNII-8742T8ZQZA; 57248-88-1; CGP 23339AE; Disodium 3-amino-1-hydroxypropane-1,1-diphosphonate; Pamidronate sodium; 57248-88-1 (di-hydrochloride salt); Aredia (TN); disodium [3-amino-1-hydroxy-1-[hydroxy(oxido)phosphoryl]propyl]-hydroxyphosphinate pentahydrate; I14-2259; Bisphosphonate 6; CGP 23339A; AC1Q1USE; CID6331770; Disodium pamidronate; C07395; Phosphonic acid, (3-amino-1-hydroxypropylidene)bis-, disodium salt; aminohydroxypropylidene diphosphonate; Disodium dihydrogen (3-amino-1-hydroxypropylidene)diphosphonate, pentahydrate; Pamidronic acid (INN); NSC720699; CID73351; Acido pamidronico [INN-Spanish]; Disodium-3-amino-1-hydroxypropylidene-1,1-diphosphonate pentahydrate; (3-AMINO-1-HYDROXY-1-PHOSPHONO-PROPYL)PHOSPHONIC ACID; Acide pamidronique; IG-7913; Acidum pamidronicum [INN-Latin]; pamidronate monosodium; LS-174826; CID4674; Disodium (3-amino-1-hydroxypropylidene)bisphosphonate pentahydrate; Pamidronate disodium pentahydrate; AC1Q1USD; Aminomux; S1311_Selleck; MolPort-001-759-086; Phosphonic acid, (3-amino-1-hydroxypropylidene)bis-, disodium salt, pentahydrate; Pamidronic acid [INN:BAN]; Pamidronate disodium hydrate (JAN); HMS658L06; PAMIDRONIC ACID; AC1L2JPJ; pamidronate calcium; Disodium pamidronate pentahydrate; Aredia, Pamidronate Disodium; AC1L1T1Z; PAMIDRONATE DISODIUM; C3H9NO7P2.2Na; NSC722600; disodium(3-amino-1-hydroxypropane-1,1-diyl)bis[hydrogen(phosphonate)]; pamidronate; (3-Amino-1-hydroxypropylidene)bisphosphonic acid; AC1L1IP1; EINECS 254-905-2; STOCK1N-12562; CHEMBL676; 3-Amino-1-hydroxypropylidene-1,1-diphosphonate; CGP 23339 A; (3-amino-1-hydroxy-1-phosphonopropyl)phosphonic acid; sodium; Novartis brand of pamidronate disodium salt; Pamidronate disodium hydrate; (3-Amino-1-hydroxypropylidene)diphosphonic acid; Pamidronate disodium (USAN); disodium [3-amino-1-hydroxy-1-[hydroxy(oxido)phosphoryl]propyl]-hydroxyphosphinate; (3-amino-1-hydroxy-1-phosphonopropyl)phosphonic acid; pamindronate disodium; Acidum pamidronicum; D3921; (3-amino-1-hydroxypropane-1,1-diyl)bis(phosphonic acid); NCGC00159433-03; HSCI1_000312; Pamidronic acid disodium salt; C3H11NO7P2; CGP-23339A; D00941	109552-15-0	16078998	196672	TTDS00372	Farnesyl pyrophosphate synthetase	Farnesyl diphosphate synthase;Farnesyl diphosphate synthetase;Farnesyl pyrophosphate synthase;FPP synthase;FPP synthetase;FPPS;FPS	Q86C09	N/A	N/A	inhibitor
DAP001022	Ibandronate	R484; I14-0821; BM 210955; Bisphosphonate 2; IBANDRONATE SODIUM; RPR-102289A; MolPort-003-848-124; 1-hydroxy-3-(methylpentylamino)propylidenebisphosphonate; Boniva; (1-hydroxy-3-(methylpentylamino)propylidene)bisphosphonate; Bonviva; DB00710; Ibandronate; 114084-78-5; BM-210955; Ibandronic acid (INN); Ibandronic Acid; D08056; Bondronat; [1-hydroxy-3-[methyl(pentyl)amino]-1-phosphonopropyl]phosphonic acid; Phosphonic acid, [1-hydroxy-3-(methylpentylamino)propylidene]bis-; HMS2090A13; AC1Q6RN2; CHEBI:41060; CHEMBL997; LS-183991; C073007; Roche brand of ibandronic acid, sodium salt, monohydrate; Acid ibandronico; Bondronat (TN); (1-Hydroxy-3-(methylpentylamino)propylidene)diphosphonic acid; BM-21.0955; LS-187361; [1-HYDROXY-3-(METHYL-PENTYL-AMINO)-1-PHOSPHONO-PROPYL]-PHOSPHONIC ACID; Phosphonic acid, P,P'-[1-hydroxy-3-(methylpentylamino)propylidene]bis-; AC1L1U21; RPR 102289A; ibandronic acid, sodium salt, monohydrate; CID60852; UNII-UMD7G2653W; AC-521; BM 21.0955; BFQ; DB04635; Phosphonic acid, (1-hydroxy-3-(methylpentylamino)propylidene)bis-; Ibandronic acid [INN:BAN]	114084-78-5	60852	214304	TTDS00372	Farnesyl pyrophosphate synthetase	Farnesyl diphosphate synthase;Farnesyl diphosphate synthetase;Farnesyl pyrophosphate synthase;FPP synthase;FPP synthetase;FPPS;FPS	Q86C09	N/A	N/A	inhibitor
DAP000182	Alendronate	(4-Amino-1-hydroxybutylidene)bisphosphonic acid; ST50036159; 4-Amino-1-hydroxybutane-1,1-diphosphonic Acid; Alendronic acid [INN:BAN]; MK 217; Oprea1_422906; 4-Amino-1-hydroxybutylidene-1,1-bis(phosphonic acid); Acide alendronique; SPECTRUM1505166; 4-Amino-1-hydroxybutylidene-1,1-bisphosphonate; alendronate; NCGC00096054-04; Acido alendronico; Arendal; (4-amino-1-hydroxybutane-1,1-diyl)bis(phosphonic acid); C07752; Acido alendronico [INN-Spanish]; (4-Amino-1-hydroxybutylidene)diphosphonic acid; MolPort-000-421-410; UNII-X1J18R4W8P; (4-amino-1-hydroxy-1-phosphonobutyl)phosphonic acid; D07119; 4-Amino-1-hydroxybutane-1,1-diphosphonate; Alendronic acid (INN); Acide alendronique [INN-French]; NCGC00096054-01; CHEBI:2567; Fosamax; 121268-17-5 (mono-hydrochloride salt, trihydrate); BIDD:GT0180; Phosphonic acid, (4-amino-1-hydroxybutylidene)bis-; Acidum alendronicum; Phosphonic acid, (4-amino-1-hydroxybutylidene)bis; Acidum alendronicum [INN-Latin]; ALENDRONATE SODIUM; ALENDRONIC ACID; AKOS001015793; LS-106421; AC1L1CW3; HSCI1_000337; 1yhm; DB00630; 66376-36-1; bisphosphonate, 65; CID2088; MK-217; NCGC00096054-03; CHEMBL870	66376-36-1	2088	9954	TTDS00372	Farnesyl pyrophosphate synthetase	Farnesyl diphosphate synthase;Farnesyl diphosphate synthetase;Farnesyl pyrophosphate synthase;FPP synthase;FPP synthetase;FPPS;FPS	Q86C09	N/A	N/A	inhibitor
DAP001023	Zoledronate	UNII-70HZ18PH24; CGP 42446A; C088658; Zometa, Zomera, Aclasta and Reclast, Zoledronic Acid; S00092; AKOS005145739; Aclasta; (1-Hydroxy-2-imidazol-1-ylethylidene)diphosphonic acid; Novartis brand of zoledronic acid; D08689; CGP 42'446; Bisphosphonate 3; Zometa; Zoledronic acid (INN); Zoledronic acid; (1-hydroxy-2-(1H-imidazol-1-yl)ethylidene)bisphosphonic acid; CGP-42446; CHEMBL924; LS-181815; CGP-42'446; AC1L2ACJ; AC1Q6RN3; Phosphonic acid,[1-hydroxy-2-(1H-imidazol-1-yl)ethylidene]bis-; 2-(imidazol-1-yl)-1-hydroxyethylidene-1,1-bisphosphonic acid; Zometa Concentrate; ZOL; (1-hydroxy-2-imidazol-1-yl-1-phosphonoethyl)phosphonic acid; Reclast; I06-0710; HMS2089O09; CID68740; 2-(imidazol-1-yl)-1-hydroxyethane-1,1-diphosphonic acid; Zoledronate; [1-hydroxy-2-(1H-imidazol-1-yl)ethane-1,1-diyl]bis(phosphonic acid); MolPort-002-885-874; Zometa (TN); MolPort-003-850-890; BIDD:GT0292; NSC721517; KS-1132; Reclast (TN); (1-hydroxy-2-imidazol-1-yl-phosphonoethyl)phosphonic acid monohydrate; CGP 42446; Bio-0112; DB00399; BIDD:PXR0134; NCGC00159521-02; CHEBI:46557; S1314_Selleck; 118072-93-8; Phosphonic acid, (1-hydroxy-2-(1H-imidazol-1-yl)ethylidene)bis-; Zometa (Novartis); NCGC00159521-03; FT-0082657; AC-1092; Zoledronic acid [USAN:INN]	118072-93-8	68740	536160	TTDS00372	Farnesyl pyrophosphate synthetase	Farnesyl diphosphate synthase;Farnesyl diphosphate synthetase;Farnesyl pyrophosphate synthase;FPP synthase;FPP synthetase;FPPS;FPS	Q86C09	N/A	N/A	inhibitor
DAP001021	Pamidronate	1-hydroxy-3-aminopropane-1,1-diphosphonic acid; UNII-OYY3447OMC; Phosphonic acid, (3-amino-1-hydroxypropylidene)bis-; Aredia; HMS2090C13; ChemDiv1_025240; amino-1-hydroxypropane-1,1-diphosphonate; Acide pamidronique [INN-French]; Ribodroat; DB00282; AC1L1IP4; BIDD:GT0538; aminopropanehydroxydiphosphonate; AHPrBP; Acido pamidronico; AKOS003599275; 40391-99-9; (3-amino-1-hydroxypropylidene)-1,1-biphosphonate; CHEMBL834; C019248; I14-2407; Amidronate; D07281; (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate; NCGC00159433-02; Ribodroat (TN); MolPort-002-131-054; 57248-88-1; 57248-88-1 (di-hydrochloride salt); Bisphosphonate 6; C07395; aminohydroxypropylidene diphosphonate; Pamidronic acid (INN); Acido pamidronico [INN-Spanish]; (3-AMINO-1-HYDROXY-1-PHOSPHONO-PROPYL)PHOSPHONIC ACID; Acide pamidronique; Acidum pamidronicum [INN-Latin]; pamidronate monosodium; LS-174826; CID4674; Aminomux; Pamidronic acid [INN:BAN]; HMS658L06; PAMIDRONIC ACID; pamidronate calcium; PAMIDRONATE DISODIUM; pamidronate; (3-Amino-1-hydroxypropylidene)bisphosphonic acid; EINECS 254-905-2; STOCK1N-12562; 3-Amino-1-hydroxypropylidene-1,1-diphosphonate; Novartis brand of pamidronate disodium salt; (3-Amino-1-hydroxypropylidene)diphosphonic acid; (3-amino-1-hydroxy-1-phosphonopropyl)phosphonic acid; Acidum pamidronicum; (3-amino-1-hydroxypropane-1,1-diyl)bis(phosphonic acid); NCGC00159433-03; HSCI1_000312; C3H11NO7P2	40391-99-9	4674	9599	TTDS00372	Farnesyl pyrophosphate synthetase	Farnesyl diphosphate synthase;Farnesyl diphosphate synthetase;Farnesyl pyrophosphate synthase;FPP synthase;FPP synthetase;FPPS;FPS	Q86C09	N/A	N/A	inhibitor
DAP000658	Risedronate	MolPort-005-934-614; NE 58019; 115436-72-1; Acido risedronico; Risedronate; 1-HYDROXY-2-(3-PYRIDINYL)ETHYLIDENE BIS-PHOSPHONIC ACID; Ridron; Acido risedronico [INN-Spanish]; HSDB 7326; 105462-24-6; 115436-72-1 (mono-hydrochloride salt); Acide risedronique; UNII-KM2Z91756Z; Benet; BIDD:GT0010; Risedronic acid [INN:BAN]; (1-hydroxy-2-pyridin-3-ylethane-1,1-diyl)bis(phosphonic acid); DB02782; Risedronic acid (INN); Ridron (TN); C08233; (1-Hydroxy-2-(3-pyridyl)ethylidene)diphosphonic acid; LS-171967; (1-hydroxy-1-phosphono-2-pyridin-3-ylethyl)phosphonic acid; Acidum risedronicum; CHEMBL923; Risedronic acid; Acidum risedronicum [INN-Latin]; I04-0049; C7H11NO7P2; HMS2090C21; Phosphonic acid, (1-hydroxy-2-(3-pyridinyl)ethylidene)bis-; RIS; Acide risedronique [INN-French]; D08484; AC1L1JX6; DB00884; AC-1295; CID5245; Bisphosphonate 1	105462-24-6	5245	634947	TTDS00372	Farnesyl pyrophosphate synthetase	Farnesyl diphosphate synthase;Farnesyl diphosphate synthetase;Farnesyl pyrophosphate synthase;FPP synthase;FPP synthetase;FPPS;FPS	Q86C09	N/A	N/A	inhibitor
DAP000539	Griseofulvin	griseofulvin; SpecPlus_000336; G2664_SIAL; Fulcin; KBio2_006432; UNII-32HRV3E3D5; SPECTRUM200046; (+)-Griseofulvin; Fulvicin-P/G; Murfulvin; BSPBio_000271; C06686; Griseofulvin-forte; C17H17ClO6; IDI1_000154; CHEBI:27779; BRN 0095226; Grisactin Ultra; Fulvicin U F; Gresfeed; Griseofulvin and Alpha-IFN; curling fact or; Likunden; KBio1_000154; GRISEOFULVIN, ULTRAMICROCRYSTALLINE; NCGC00091120-04; Bio-0245; EPA Pesticide Chemical Code 471400; Grifulvin V; FULVICIN P/G 165; CPD000718755; Fulvican grisactin; Sporostatin; KBio3_001121; BIDD:GT0024; NCGC00091120-07; Griseofulvin [USAN:INN:BAN:JAN]; Griseomix; NCGC00091120-01; Prestwick3_000226; NCGC00091120-06; AC1Q496M; HSDB 1722; DB00400; CHEMBL562; FulvicinUF; Griseofulvinum; Griseofulvin forte; MLS002152905; Grisofulvin; LS-702; ACon1_001843; Caswell No. 471B; SDCCGMLS-0066450.P001; Grisefuline; Prestwick_247; CID441140; MEGxm0_000184; Spectrum3_000161; DivK1c_000154; Fulvicin-U-F; Fulvinil; Spectrum_000816; DivK1c_006432; Fulvicin-U/F; Spirofulvin; interacts with polymerized microtubules and associated proteins; Griseostatin; Grysio; Xuanjing; Griseofulvina [INN-Spanish]; Sporostatin xan; Gris PEG; Grisovin FP; Curling factor; Grisactin; Fulvidex (Veterinary); Griscofulvin; HMS1923E09; USAF SC-2; Likuden; Fulvicin Bolus (Veterinary); Fulcine; MLS001304062; MLS002154239; 46309_RIEDEL; Fungivin; GrisPEG; Grifulin; Gris-PEG; NSC 34533; ULTRAGRIS-330; Fulvina; NCGC00091120-03; Griseofulvine; BRD-K08273968-001-05-9; Griseofulvina; Lamoryl; Griseofulvinum [INN-Latin]; Grizeofulvin; Neo-Fulcin; Fulvicin P/G; HMS2091A03; 5-18-05-00150 (Beilstein Handbook Reference); SPBio_000225; Fulvicin-U/F (Veterinary); Grifulvin; AC1L9AMF; Fulvicin U/F; Greosin; KBio1_001376; EINECS 204-767-4; GRISEOFULVIN, MICROCRYSTALLINE; Spectrum4_000927; FULVICIN P/G 330; NCGC00091120-05; Biogrisin-FP; SMR000718755; Grisovin; MolPort-001-739-410; G4753_SIGMA; Delmofulvina; Grisetin; Griseofulvine [INN-French]; ACon0_000953; HMS500H16; NCGC00091120-02; CCRIS 320; Fulvicin; Spectrum2_000213; Fulvistatin; KBio2_003864; Poncyl; 7-Chloro-4,6,2'-trimethoxy-6'-methylgris-2'-en-3,4'-dione; BSPBio_001621; Amudane; Spectrum5_000648; AI3-51015; D006118; Guservin; ULTRAGRIS-165; 46309_FLUKA; 126-07-8; Grise ostatin; Griseo; KBioGR_001454; NP-002466; KBio2_001296; Gricin; BPBio1_000299; LMPK13060001; BIM-0051396.0001; V, Grifulvin; KBioSS_001296; ZINC00622123; FT-0082593; NINDS_000154; SAM002589940	126-07-8	441140	8911	TTDS00300	Human keratin	N/A	Q16195	N/A	N/A	inducer
DAP000986	Procarbazine	D08423; BRN 0958270; NCIOpen2_004074; HMS2090J09; EINECS 211-582-2; NCGC00016438-01; NSC-77213; Procarbazina [INN-Spanish]; NCI60_041703; Procarbazine [INN:BAN]; BSPBio_001244; p-(N'-Methylhydrazinomethyl)-N-isopropylbenzamide; Ro 4-6467/1; Prestwick3_001112; UNII-35S93Y190K; Ro 4-6467; MolPort-005-940-370; procarbazine; CB 400-497; Benzamide, N-(1-methylethyl)-4-((2-methylhydrazino)methyl)-; 671-16-9; BIDD:GT0183; Natulan; Procarbazine Monohydrochloride; N-(1-Methylethyl)-4-[(2-methylhydrazino)methyl]benzamide; p-Toluamide, N-isopropyl-alpha-(2-methylhydrazino)-; HSDB 3250; LS-7671; CAS-366-70-1; C07402; N-Isopropyl-p-(2-methylhydrazinomethyl)-benzamide; CID4915; Procarbazine (INN); DB01168; Procarbazinum [INN-Latin]; Procarbazin [German]; Procarbazina; Natulanar; Prestwick1_001112; MIH; 366-70-1 (mono-hydrochloride); MBH; PCX; Ambap671-16-9; Procarbazinum; C12H19N3O; N-(1-Methylethyl)-4-((2-methylhydrazino)methyl)benzamide; AC1L1J8E; AC-4547; I01-8931; N-Isopropyl-4-[(2-methylhydrazino)methyl]benzamide; CHEMBL1321; Ibenzmethyzin; Procarbazin; 1-Methyl-2-(p-(isopropylcarbamoyl)benzyl)hydrazine; p-(2-Methylhydrazinomethyl)-N-isopropylbenzamide; Prestwick2_001112; 4-((2-Methylhydrazino)methyl)-N-isopropylbenzamide; Ibenzmethyzine; Prestwick0_001112; 2-(p-Isopropylcarbamoylbenzyl)-1-methylhydrazine; SPBio_003112; BPBio1_001369; N-Isopropyl-alpha-(2-methylhydrazino)-p-toluamide; Benzamide, N-(1-methylethyl)-4-((2-methylhydrazino)methyl)- (9CI); p-Toluamide, N-isopropyl-.alpha.-(2-methylhydrazino)-; N-4-Isopropylcarbamoylbenzyl-N'-methylhydrazine; Benzamide, N-(1-methylethyl)-4-[(2-methylhydrazino)methyl]-; 4-[(2-methylhydrazinyl)methyl]-N-propan-2-ylbenzamide; NCGC00016438-02; SRI-10847; CCRIS 2389	671-16-9	4915	9606	TTDS00213	DNA	N/A	N/A	N/A	N/A	N/A
DAP000537	Ifosfamide	Ifosfamidum [INN-Latin]; Ifosphamide; BPBio1_000865; Iphosphamid; 2H-1,3,2-Oxazaphosphorin-2-amine, N,3-bis( 2-chloroethyl)tetrahydro-, 2-oxide; (R,S)-N,3-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide; NPFAPI-04; WLN: T6NPOTJ AM2G BO B2G; C07047; BSPBio_000785; 2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide; Ifosfamida [INN-Spanish]; 3,} 2-oxazaphosphorine oxide; {3-(2-Chloroethyl)-2-[(2-; Ifsofamide; LS-99799; EINECS 223-237-3; AB00513932; 3-(2-Chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide; HMS2090M12; MLS002154021; 3778-73-2; N,N-Bis(beta-chloroethyl)-amino-N',O-propylene-phosphoric acid ester diamide; CID3690; CCRIS 352; UNII-UM20QQM95Y; 2,3-N,N(sup 1)-Bis(2-chloroethyl)diamido-1,3,2-oxazaphosphoridinoxyd; Ifosfamidum; IFEX (TN); 3-(2-Chloroethyl)-2-((2-chloroethyl)amino)perhydro-2H-1,3,2-oxazaphosphorine oxide; Z-4942; Ifex; (+-)-Ifosfamid; NSC 109724; Cyfos; (+-)-Tetrahydro-N,3-bis(2-chloroethyl)-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide; (+-)-Ifosphamide; Ifosfamide (JAN/USP/INN); CAS-3778-73-2; 2,3-(N,N(sup 1)-Bis(2-chloroethyl)diamido)-1,3,2-oxazaphosphoridinoxyd; Iphosphamid(e); Prestwick1_000833; Mitoxana, Ifex, Ifosfamide; Iso-Endoxan; LS-102; isosfamide; NSC109724; Prestwick0_000833; 36341-88-5; 3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,3,2-oxazaphosphorineoxide; BRN 0611835; HMS1570H07; AC1L1GHW; 3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2- oxide; SPBio_002706; 2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide (8CI); NCI-C01638; NSC 109,724; Holoxan; I-Phosphamide; Ambap3778-73-2; Mitoxana; CHEMBL1024; Z 4942; 1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-, 2-oxide; N-(2-Chloraethyl)-N'-(2-chloraethyl)-N',O-propylen-phosphorsaureester-diamid; ifosfamide; 3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,3,2-oxazaphosphorine oxide; I06-0494; NSC-109,724; Prestwick3_000833; STL058690; Prestwick2_000833; (D,L)-Ifosfamide; MJF-9325; HSDB 7023; D007069; NSC109,724; ASTA Z 4942; D00343; DB01181; MJF 9325; Ifosfamid; S1302_Selleck; Isophosphamide; Isofosfamide; NCGC00179435-01; Ifosfamide [USAN:INN:BAN:JAN]; Naxamide; N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylen ephosphoric acid diamide; N-(2-Chloraethyl)-N'-(2-chloraethyl)-N',O-propylen-phosphorsaureester-diamid [German]; N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylenephosphoric acid diamide; AC-2113; 3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide; N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylene phosphoric acid ester diamide; Isoendoxan; 2H-1,3,2-Oxazaphosphorin-2-amine, N,3-bis(2-chloroethyl)tetrahydro-, 2-oxide; 2,3-N,N(sup 1)-Bis(2-chloroethyl)diamido-1,3,2-oxazaphosphoridinoxy-; N-(2-Chloroethyl)-N-(3-(2-chloroethyl)-2-oxido-1,3,2-oxazaphosphinan-2-yl)amine; N,3-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide; {3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,; Holoxan 1000; Ifosfamide Sterile; HMS2093N07; 2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-, 2-oxide; (R,S)-Ifosphamide; Iso Endoxan; Z4942; N,3-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide; Ifosfamida; SMR001233348; 1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide; NCI60_000233; N,3-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide; Iphosphamide; 84711-20-6; NSC-109724; N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylenephosphoric acid ester diamide; NCGC00016639-01; A 4942; CHEBI:5864; 2H-1,3,2-Oxazaphosphorin-2-amine, tetrahydro-N,3-bis(2-chloroethyl)-, 2-oxide, (+-)-; MolPort-003-666-704	3778-73-2	3690	162510	TTDS00213	DNA	N/A	N/A	N/A	N/A	N/A
DAP000194	Thioguanine	MLS001333131; 5580-03-0; Spectrum3_000577; GlaxoSmithKline Brand of Tioguanine; 2-Aminopurine-6(1H)-thione; Wellcome Brand of Thioguanine; Spectrum2_000695; Guanine, thio- (VAN); KBioGR_001452; SBB067147; T0212; A4660_SIGMA; Tioguaninum; cMAP_000061; C07648; 2-Amino-6-mercaptopurine; S1774_Selleck; SPECTRUM1500573; NSC-752; 6-TG; AKOS003389499; BSPBio_001994; CHEBI:136864; MolPort-001-813-204; 2-Amino-6-purinethiol; D08603; THG; 2-Amino 6MP; Glaxo Wellcome Brand of Thioguanine; I14-1541; UNII-WIX31ZPX66; BW 5071; CID2723601; TG; D013866; 2-Amino-1,7-dihydro-6H-purin-6-thion [Czech]; EINECS 205-827-2; 6-Mercaptoguanine; Tioguanine; KBio3_001494; Thioguanine Hemihydrate; Wellcome U3B; FT-0083572; 6-Thioguanine, Thioguanine; KBioGR_002476; KBio2_002476; DX4; Purine-6(1H)-thione, 2-amino-; purine antimetabolite: antimetabolite: inhibits nucleic acid replication; C5H7N5S; HSDB 2504; Lanvis (TN); DivK1c_000428; ZINC18085533; KBio2_003283; Tioguanina Wellcome; Thioguanin-GSK; KBio3_002954; 2-Amino-6-MP; NSC 752; SMR000857244; ThioguaninGSK; 2-Amino-9H-purine-6-thiol; Spectrum_000235; Tioguanina [INN-Spanish]; 2-amino-3,7-dihydropurine-6-thione; KBioSS_002483; IDI1_000428; MolPort-000-929-106; Glaxo Wellcome Brand of Tioguanine; Lanvis; Thioguanine [USAN:BAN]; Purine-6-thiol, 2-amino-; NCI60_041643; Thioguanine Monosodium Salt; ST50298831; CHEMBL727; NCIOpen2_004153; SPBio_000849; thioguanine; KBio2_005851; AI3-26078; Thioguanin GSK; Tioguanine GlaxoSmithKline Brand; Tioguanine (INN); 2-Aminopurin-6-thiol; NSC752; HMS1921E09; UNII-FTK8U1GZNX; 2-Amino-1,7-dihydro-6H-purin-6-thion; 2-Aminopurin-6-thiol [Czech]; Guanine, thio-; A4882_SIGMA; GlaxoSmithKline Brand of Thioguanine; 154-42-7; KBio2_005044; MolPort-003-984-174; HMS2092M11; 6-Thioguanine (6-TG); Thioguanine Tabloid; SMP2_000326; NCGC00094792-03; 2-Thioguanine; AC1MC379; 2-Aminopurine-6-thiol; KBioSS_000715; CCRIS 8997; NINDS_000428; 6 Thioguanine; 2-Amino-6-merkaptopurin; KBio2_007612; HMS501F10; LS-888; Tioguanina; Tioguaninum [INN-Latin]; 2-Amino-1,7-dihydro-6H-purine-6-thione; 6-Mercapto-2-aminopurine; KBio2_000715; 6H-Purine-6-thione, 2-amino-1,7-dihydro-; MLS001333132; Spectrum4_000926; AC-11125; Spectrum5_001455; WLN: T56 BNM FYM INJ FUS HZ; KBio1_000428; 2 Amino 6 Purinethiol; 6-Thioguanine; Tioguanin; NCGC00094792-01; NCGC00094792-02; Tabloid; DB00352; LT00455187; 2-Amino-6-merkaptopurin [Czech]	154-42-7	2723601	152248	TTDS00213	DNA	N/A	N/A	N/A	N/A	N/A
DAP001402	Mitomycin C	D00208; BSPBio_001267; KBio2_005743; KBio3_001073; CBiol_001927; Mutamycin; CHEBI:27504; BRD-K59670716-001-02-6; Mitomycine [INN-French]; Mitomycinum C; Mytozytrex; Bio1_001191; Ametycin; KBio2_000607; M4287_SIGMA; C06681; CHEMBL105; 50-07-7; Mitamycin; NSC 26980; C15H18N4O5; HMS1362O09; LS-136; Mitomycin C (JP15); Mitomycine; KBioSS_000607; UNII-50SG953SK6; 74349-48-7; Mitomycin C from Streptomyces caespitosus; NSC-26980; AC1L1L1Q; Ametycine; Mitomycin [USAN:INN:BAN]; CID5746; mitomycin C; EINECS 200-008-6; M0440_SIGMA; Mitomycin; Mitomycyna C; Mitomicina [INN-Spanish]; Muamycin; HMS1792O09; Mitomycinum; Mitomycinum [INN-Latin]; Bio1_000213; Bio1_000702; Mit-C; CCRIS 414; KBio2_003175; Muamycin (TN); Ambotz50-07-7; MLS001332654; Mitomycin (USP/INN); DB00305; 1404-00-8; M0503_SIGMA; Mitomycin C, Streptomyces caespitosus, Carrier-Free; 7481-68-7; Mitomycin-C; SMP1_000307; Mito-C; Mitozytrex; Mytomycin; HMS1990O09; 7-Amino-9alpha-methoxymitosane; MMC; Mitomycins; Mitocin C; NCI-C04706; Mitomycyna C [Polish]; HMS2089F16; SMR000058401; Mitomycin (TN); Mitomicina; MolPort-003-938-644; Mitocin-C; NCGC00163468-02; RCRA waste number U010; AI3-26199; Bio2_000464; HSDB 3239; Mitomycin C, Streptomyces caespitosus; nchembio.559-comp7; RCRA waste no. U010; Bio2_000944; IDI1_002219; LS-173087; KBio3_001074; KBioGR_000607; 144085-53-0	50-07-7	5746	8906	TTDS00213	DNA	N/A	N/A	N/A	N/A	N/A
DAP000982	Adenine	AC1L18OI; WLN: T56 BM DN FN HNJ IZ; nchembio.2007.56-comp15; 1H-Purine, 6-amino; CCRIS 2556; 9H-Purine, 1,6-dihydro-6-imino-; KBio1_001575; DB00173; Spectrum3_000616; NCGC00094856-02; 2p8n; cMAP_000085; 6-Amino-3H-purine; Adenine-8-14C; BSPBio_002152; MolPort-004-758-264; 3,6-Dihydro-6-iminopurine; NCI60_000998; MolPort-001-785-186; 1jys; 1H-Purin-6-amine (9CI); KBio3_003040; 42911-33-1; D000225; 6-Amino-1H-purine; HMS2092K20; 6-Aminopurine; 1nli; 1,6-Dihydro-6-Imnopurine; NSC 14666; EINECS 200-796-1; Purine, 6-amino-; KBio2_001586; 6379C0E0-C1BB-4087-96C5-1DE281B8EA4C; Spectrum2_000583; NCGC00094856-03; Vitamin B 4; D00034; 1H-Purin-6-amine; I07-0071; MolPort-004-758-265; purine, 6; Adenine [JAN]; KBioSS_002571; 5426-35-7; AC1Q52Y5; MolPort-004-759-679; SPBio_000426; TL806440; KBioSS_001586; 2pqj; 66224-65-5; AC-2028; ADE; A8626_SIGMA; MolPort-004-758-262; Oprea1_057274; 4, Vitamin B; 6-Aminopurine; Vitamin B4; MolPort-004-758-653; Adenine (8CI); AD2; Spectrum5_000542; B 4, Vitamin; A2786_SIGMA; Leucon (TN); InChI=1/C5H5N5/c6-4-3-5(9-1-7-3)10-2-8-4/h1-2H,(H3,6,7,8,9,10; DivK1c_006631; KBio2_005130; 6-Amino-9H-purine; C00147; Pedatisectine B; 520-75-2; KBioGR_002447; SpecPlus_000535; I14-7794; TL8005091; A5665_SIGMA; I06-0527; NSC14666; MolPort-004-758-263; KBio2_002562; 9H-Purin-6-amine; AI3-50679; NCGC00094856-01; KBio2_007698; 1,6-Dihydro-6-iminopurine; A0149; KBio2_006722; CID190; 22051-90-7; FT-0082877; MolPort-001-785-762; Adeninimine; 42911-34-2; KBio3_001652; CHEMBL226345; STOCK1N-48520; ZINC00000882; nchembio.186-comp107; ANE; 1wei; bmse000060; STK387542; AB1004094; ALBB-005925; 7H-Purin-6-amine; Leuco-4; Spectrum4_001891; USAF CB-18; Spectrum_001106; AKOS000118903; Vitamin-?B4; Vitamin B4; MLS001066342; AC1Q52XT; SMR000471871; Adenine (JAN/USP); HMS1921I14; A2426_SIGMA; SPECTRUM1500807; adenine; Adenin; KBioGR_002562; adenine-ring; KBio2_004154; CHEBI:16708; LS-15058; 6-Amino-7H-purine; 2'-DEOXY-ADENOSINE-3'-5'-DIPHOSPHATE; 1H-Purine, 6-amino-; SDCCGMLS-0066584.P001; 73-24-5	73-24-5	190	3447	TTDS00213	DNA	N/A	N/A	N/A	N/A	binder
DAP000536	Dactinomycin	UNII-1CC1JFE158; MolPort-001-739-741; FT-0080366; C06770; Actactinomycin A IV; dactinomyein d; UPCMLD-DP055:002; AC1L9W52; Actinomycin I(sub 1); CHEBI:123721; Meractinomycin; UPCMLD-DP055:001; Actinomycindioic D acid, dilactone; actinomyein-theo-val-pro-sar-meval; Dactinomicina [INN-Spanish]; Dilactone actin omycindioic D acid; 01815_FLUKA; Actinomycin X 1; Actinomycin I (sub1); Dilactone actinomycindioic D acid; Bio1_000342; Actinomycin-?IV; Actinomycin C (sub1); MEGxm0_000350; PXZ-THR-DVA-PRO-SAR-MVA-THR-DVA-PRO-SAR-MVA; DVA-DPR-SAR-MVA-(c1)DTH-PXZ-(c11)DTH-DVA-DPR-SAR-MVA; LMPK14000005; Dactinomicina; Cosmegen; Dactinomycin D; Actinomycin IV; A4262_SIGMA; COSMEGEN (TN); Dactinomycin [USAN:BAN]; AC1L1CQX; GNF-PF-1977; CPD000469227; NCGC00090796-01; NSC191297; CHEMBL1554; Lyovac cosmegen; NSC-3053; o)-(1-oxo-1,2-ethanediyl)]bis(N-methyl)L-valine; HSDB 3220; EINECS 200-063-6; NCI-C04682; SMR000469227; ACon0_000471; DACTINOMYCIN; 50-76-0; Actinomycin I; Dactinomycinum [INN-Latin]; MolPort-003-925-177; NSC3053; Oncostatin K; ACTINOMYCIN D  AMP; Actinomycin I1; Acto-D; Bio1_000831; Actinomycin D (JP15); (- )-actinomycin d; C62H86N12O16; NCGC00025059-02; Chounghwamycin B; NSC 3053; C1; Actinomycin-(threo-val-pro-sar-meval); HBF 386 meractinomycin; SAM001246846; HBF 386; l-3-oxo-; WLN: 16- AN FVN IVN LVO PVM SVTJ G1 J1 KY1&1 N1 RY1&1; UPCMLD-DP055; actinomycin cl; CBiol_002056; Bio1_001320; actinomycin D; 4,6-dimethyl-3-oxo-3H-phenoxazine-1,9-dicarboxamide; NCGC00161622-01; HMS2052O17; Neuro_000003; Actinomycin A IV; AD (VAN); DB00970; Actinomycin Aiv; Actinomycin 11 cosmegen; NP-005932; Dactinomycine; ACon1_001004; Actinomycin-[threo-val-pro-sar-meval]; BRD-A42383464-001-02-2; BCBcMAP01_000155; CHEBI:27666; Actinomycin 7; NCGC00169767-01; AI3-26374; A1410_SIGMA; Antibiotic from Streptomyces parvullus; CID457193; Dactinomycine [INN-French]; D Actinomycin; NCI60_030539; actinomycin x i; CID2019; Actinomycin C(sub1); Actinomycin C1; (-)-actinomycin d; LS-142; CHEMBL427947; SMP1_000005; Dactinomycinum; X 97; NCGC00161622-02; A9415_SIGMA; 1H-Pyrrolo(2,1-1)-(1,4,7,10,13)oxatetraazacyclohexadecine; MLS001424196; Actinomycin D deriv. of 3H-phenoxaocardazine; ACT D; Actinomycin D, sodium deoxyribonucleic acid complex; Actinomycin X1; -pentone; ACTINOMYCIN-D; Actinomycin I(sub1); Dilactone actinomycin D acid; D00214; CCRIS 9; Dactinomycin (USP)	50-76-0	2019	8990	TTDS00213	DNA	N/A	N/A	N/A	N/A	N/A
DCL001027	TV-4710	N/A	N/A	488029	38677141	TTDS00213	DNA	N/A	N/A	N/A	N/A	inhibitor
DAP000990	Uracil mustard	5-(Di-2-chloroethyl)aminouracil; U-8344; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4(1H,3H)-dione; 5-[Bis(2-chloroethyl)amino]uracil; Uracil nitrogen mustard; NCGC00160575-01; 66-75-1; RCRA waste no. U237; HSDB 3261; 5-N,N-Bis(2-chloroethyl)aminouracil; CID6194; Uracillost; Uramustina; AI3-50439; Uramustinum; NSC34462; 2,6-Dihydroxy-5-bis[2-chloroethyl]aminopyrimidine; Uracilmostaza; 5-[bis(2-chloroethyl)amino]-1H-pyrimidine-2,4-dione; Uracil, 5-[bis(2-chloroethyl)amino]-; Uracil mustard [USAN]; NCI-C04820; C11686; MolPort-001-832-800; Uracil mustard (USAN); AC1L1LZU; 2,6-Dihydroxy-5-bis(2-chloroethyl)aminopyrimidine; URACIL  MUSTARD  (500 MG)  (FOR  U.S.  SALE ONLY); C8H11Cl2N3O2; ENT 50439; Uracil lost; UNII-W7KQ46GJ8U; Uracil lost [German]; NSC 34462; 5-(Bis(2-chloroethyl)amino)uracil; Uramustin; Uracil mustard (TN); LS-285; Desmethyldopan; 5-(Bis(2-chlorethyl)amino)-2,4(1H,3H)pyrimidinedione; SK-19849; Uramustine (INN); RCRA waste number U237; 2,4(1H,3H)-Pyrimidinedione, 5-(bis(2-chloroethyl)amino)-; Uramustine; 5-[Bis(2-chlorethyl)amino]-2,4(1H,3H)pyrimidinedione; CHEMBL1488; Nordopan; Uramustina [INN-Spanish]; WLN: T6MVMVJ EN2G2G; 2,4(1H,3H)-Pyrimidinedione, 5-[bis(2-chloroethyl)amino]-; NCI60_003061; Demethyldopan; 5-[Di(beta-chloroethyl)amino]uracil; CB-4835; 5-(Bis(2-chloroethyl)amino)-2,4(1H,3H)pyrimidinedione; CCRIS 618; U 8344; FT-0080363; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4-diol; AC1Q79A4; Uramustinum [INN-Latin]; CHEBI:9884; URACIL MUSTARD; Uracil, 5-(bis(2-chloroethyl)amino)-; 5-[Di(.beta.-chloroethyl)amino]uracil; NSC-34462; Chlorethaminacil; 5-[Di(2-chloroethyl)amino]uracil; 5-Aminouracil mustard; DB00791; 5-(Bis(2-chloroethyl)amino)-2,4-(1H,3H)pyrimidinedione; 5-[bis(2-chloroethyl)amino]-2,4(1H,3H)-pyrimidinedione; D06265; 5-(Di-(beta-chloroethyl)amino)uracil; EINECS 200-631-3; Aminouracil mustard	66-75-1	6194	13851	TTDS00213	DNA	N/A	N/A	N/A	N/A	modulator
DAP000984	Streptozocin	MolPort-003-665-493; AB00513906; KBio2_006576; Estreptozocina; Prestwick3_000732; Streptozocinium [Latin]; 2-deoxy-2-{[methyl(nitroso)carbamoyl]amino}-alpha-D-glucopyranose; Streptozocinium; Spectrum3_001087; S1312_Selleck; D-Glucose, 2-deoxy-2-(((methylnitrosoamino)carbonyl)amino)- (9CI); CID29327; STRZ; NCGC00178500-01; streptozocin; HMS501K13; HMS1921A07; ZINC03977737; BPBio1_000754; N-D-Glucosyl-(2)-N'-nitrosomethylurea; S0130_SIAL; NCGC00178500-02; Zanosar; STREPTOZOTOCIN; 1-methyl-1-nitroso-3-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]urea; SMP1_000282; KBio1_000531; BCBcMAP01_000142; Streptozocine [INN-French]; Spectrum5_001047; KBio2_001440; 2-Deoxy-2[[(methylnitrosoamino)-carbonyl]amino]-D-glucopyranose; Streptozocine; C07313; Spectrum_000960; Spectrum4_001244; HMS2092I09; BSPBio_002734; KBioGR_001768; 2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose; CHEBI:9288; DB00428; 2-Deoxy-2-(((methylnitrosoamino)carbonyl)amino)-D-glucopyranose; binds to DNA; SPBio_000243; IDI1_000531; streptozosin; S0130_SIGMA; Ambap18883-66-4; Streptozocinum [INN-Latin]; Streptozocin, Zanosar, STZ,Streptozotocin; KBio3_001954; KBioSS_001440; CHEMBL1603; Streptozocin (USAN/INN); D05932; Spectrum2_000062; N-D-Glucosyl-(2)-N'-nitrosomethylharnstoff; Streptozocinum; alkylating agent; KBio2_004008; BSPBio_000684; NINDS_000531; UNII-5W494URQ81; SPECTRUM1500543; 18883-66-4; AC1L1H7V; Zanosar (TN); DivK1c_000531; N-(Methylnitrosocarbamoyl)-alpha-D-glucosamine	18883-66-4	29327	171661	TTDS00213	DNA	N/A	N/A	N/A	N/A	N/A
DAP000850	Hydroxystilbamidine Isethionate	Ethanesulfonic acid, 2-hydroxy-, compd. with 4-(2-(4-(aminoiminomethyl)phenyl)ethenyl)-3-hydroxybenzenecarboximidamide (2:1); 533-22-2; 2-Hydroxyethanesulphonic acid, compound with 4-(2-(4-amidinophenyl)vinyl)-3-hydroxybenzenecarboxamidine (2:1); LS-175439; Benzenecarboximidamide, 4-(2-(4-(aminoiminomethyl)phenyl)ethenyl)-3-hydroxy-, bis(2-hydroxyethanesulfonate) (salt); UNII-0163PVD2QZ; AC1NSE04; 2-Hydroxystilbamidine diisethionate; Hydroxystilbamidine diisethionate; (4E)-4-[2-[4-(diaminomethylidene)cyclohexa-2,5-dien-1-ylidene]ethylidene]-3-oxocyclohexa-1,5-diene-1-carboximidamide; 2-hydroxyethanesulfonic acid; 2-Hydroxy-4,4'-stilbenedicarboxamidine diisethionate; 2-Hydroxy-4,4'-diamidinostilbene di(beta-hydroxyethanesulfonate); C16H16N4O.2C2H6O4S; NSC 259242; Ethanesulfonic acid, 2-hydroxy-, compd. with 2-hydroxy-4,4'-stilbenedicarboxamidine (2:1); 2-Hydroxy-4,4'-stilbenedicarboxamidine bis(2-hydroxyethanesulfonate) (salt); Hydroxystilbamide; 2-Hydroxy-4,4'-diguanylstilbene diisethionate; 2-Hydroxystilbamidine isethionate; hydroxystilbamidine isethionate; EINECS 208-557-3; Ethanesulfonic acid, 2-hydroxy-, compd. with 2-hydroxy-4,4'-stilbenedicarboxamidine (2:1) (8CI); CID5359440	533-22-2	16051924	24438506	TTDS00213	DNA	N/A	N/A	N/A	N/A	binder
DAP000535	Carboplatin	C2043; DivK1c_000892; Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2); 70903-55-8; anedicarboxylato(2-)-O,O']-,} (SP-4-2)-; S1215_Selleck; C 2538; cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II); Carboplatine [French]; MolPort-003-845-609; cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II); Lopac0_000230; HMS2090M05; UNII-BG3F62OND5; MolPort-003-665-501; CCRIS 3404; NSC201345; azanide; cyclobutane-1,1-dicarboxylic acid; platinum(2+); cis-Diammine(cyclobutanedicarboxylato)platinum II; NINDS_000892; Paraplatin, Carboplatin; CHEBI:31355; Carbopaltin; CHEMBL288376; NSC 241240; Platinum, diammine(1,1-cyclobutanedicarboxylato(2-))-, (SP-4-2)-; nchembio.573-comp10; cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II); CID426756; NSC241240; Carboplatin [USAN:INN:BAN:JAN]; KBio2_004577; NCGC00093695-01; cis -Diammine[1,1-cyclobutane-dicarboxylato] platinum; NSC 201345; EINECS 255-446-0; (SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum; Paraplatin (TN); CID10339178; D01363; Spectrum2_000898; HMS2092B22; NCGC00015223-01; Cbdca; Paraplatin-AQ; NCGC00094961-02; Carboplatinum; KBio2_007145; Ercar; LS-117689; DB00958; Spectrum3_001503; SPBio_000716; Carboplatino; Platinum(II), (1,1-cyclobutanedicarboxylato)diammine-, cis-; AC1L8I6U; IUPAC: Azane; Cyclobutane-1,1-dicarboxylate; Platinum(+2) Cation; CID6603770; Platinum, diammine[1,1-cyclobutanedicarboxylato(2-)-O,O']-, (SP-4-2)-; CID5352133; CID2567; CID498142; boxylato)diammine-, cis-; Platinum, diamine(1, 1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2)-; Platinum, diammine[1,1-cyclobutanedicarboxylato(2-)-O,O']-, (SP-4-2)-; Platinum, {diammine[1,1-cyclobut; HSDB 6957; cis-Diammine(1,1-cyclobutanedicarboxylato)platinum; nchembio873-comp3; Diammine(1,1-cyclobutanedicarboxylato)platinum (II); SPECTRUM1502106; HMS502M14; AC-1457; Diammine-1,1-cyclobutane dicarboxylate platinum II; CID38904; nchembio773-comp2; diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum; IDI1_000892; Carboplatino [Spanish]; Ambap41575-94-4; 1,1-Cyclobutanedicarboxylate diammine platinum(II); NCGC00162099-02; Paraplatin; C6H10N2O4Pt; 41575-94-4; CID6398587; BSPBio_003145; I14-2390; Carboplatin (USAN); 1,1-Cyclobutanedicarboxylate diammine platinum (II); NCGC00167800-01; CHEMBL1351; KBio1_000892; NCGC00094961-01; Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum; Platinum, diamine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2)-; NCGC00094961-03; Spectrum4_000337; Spectrum_001529; 1,1-Cyclobutanedicarboxylate diammine platinum(II); Cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II); Cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II); Platinum(II), (1, 1-cyclobutanedicar; JM-8; EU-0100230; Carboplatinum [Latin]; Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2)-; Carboplatin (JAN/USP/INN); KBio2_002009; C2538_SIGMA; KBioGR_000713; NCGC00178242-01; HMS1921J16; NSC-241240; KBio3_002645; Lopac-C-2538; NCGC00162099-01; carboplatin; Carboplatine; Platinum, diammine(1,1-cyclobutanedi(carboxylato-kappaO)(2-))-, (SP-4-2)-; Spectrum5_001094; cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II); KBioSS_002009; JM 8; InChI=1/C6H8O4.2H2N.Pt/c7-4(8)6(5(9)10)2-1-3-6;;;/h1-3H2,(H,7,8)(H,9,10);2*1H2;/q;2*-1;+4/p-; cis-Diammine(1,1-cyclobutanedicarboxylato) platinum	41575-94-4	498142	794720	TTDS00213	DNA	N/A	N/A	N/A	N/A	N/A
DAP001401	Mitomycin A	CID19972; Azirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione, 8-[[(aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b-hexahydro-6,8a-dimethoxy-5-methyl-, [1aR-(1a.alpha.,8.beta.,8a.alpha.,8b.alpha.)]-; KST-1A4681; CID4209; Azirino(2',3':3,4)pyrrolo(1,2-a)indole-4,7-dione, 8-(((aminocarbonyl)oxy)methyl)-1,1a,2,8,8a,8b-hexahydro-6,8a-dimethoxy-5-methyl-, (1aR-(1aalpha,8beta,8aalpha,8balpha))-; [(1ar,8r,8as,8br)-6,8a-dimethoxy-5-methyl-4,7-dioxo-1,1a,2,4,7,8,8a,8b-octahydroazireno[2',3':3,4]pyrrolo[1,2-a]indol-8-yl]methyl carbamate; AR-1A7962; Azirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione, 1,1a,2,8,8a,8b-hexahydro-8-(hydroxymethyl)-6,8a-dimethoxy-5-methyl-, carbamate; AC1L5NSO; CID253278; AC1L2F9E; LS-23440; NSC 75986; MolPort-003-849-237; Azirino(2',3':3,4)pyrrolo(1,2-a)indole-4,7-dione, 1,1a,2,8,8a,8b-hexahydro-8-(hydroxymethyl)-6,8a-dimethoxy-5-methyl-, carbamate (ester); HSDB 3418; 4055-39-4; WLN: T D3 B556 BN EM JV MVTTT&J GO1 H1OVZ KO1 L1; NSC75986; AC1L1HNP; CHEMBL298359; Mitomycin A; Azirino(2',3':3,4)pyrrolo(1,2-a)indole-4,7-dione, 8-(((aminocarbonyl)oxy)methyl)-1,1a,2,8,8a,8b-hexahydro-6,8a-dimethoxy-5-methyl-, (1aR-(1aalpha,8beta,8aalpha,8balpha))- (9CI)	4055-40-7	19973	162828	TTDS00213	DNA	N/A	N/A	N/A	N/A	N/A
DAP000998	Nitrofurantoin	Fua Med; 1-[(5-Nitrofurfurylidene)amino]hydantoin; EINECS 200-646-5; BSPBio_002073; fua-med; Furaloid; Furadoine; Furobactina; Nitrofurantoina; ND-7248; BIDD:GT0181; Trantoin; ZINC07997568; Usaf ea-2; Novofuran; Macrobid; AKOS001678301; Furodantin; 67-20-9; N-(5-nitro-2-furfurylidene)-1-aminohyda ntoin; N-(5-Nitrofurfurylidene)-1-aminohydantoin; I07-0015; Furabid; Berkfurin; Cyantin; furophen; Chemiofuran; 2,4-Imidazolidenedione, 1-(((5-nitro-2-furanyl)methylene)amino)-; C8H6N4O5; Furachel; UNII-927AH8112L; Fur-ren; Furadonine; NSC 44150; 1-(((5-nitro-2-furanyl)methylene)amino)-2,4-imidazolidinedione; 1-[(5-:nitrofurfurylidene)amino]hydantoin; HMS1920P21; NCGC00091505-03; Furadantin Retard; Furadantin (TN); Uro-Selz; Macrodantin; SPECTRUM1500433; Nitrofurantoin (JAN/USP/INN); NITROFURANTION; D00439; NSC 2107; Macrofurin; Gerofuran; AC1O7GAU; Bio-0352; Furadantine; Urolisa; Nitrofurantoin [USAN:INN:BAN:JAN]; CID6604200; Furadantine mc; 1-{[(1E)-(5-nitro-2-furyl)methylene]amino}imidazolidine-2,4-dione; Urodin; NCI-C55196; urodil; Urizept; Siraliden; Prestwick3_000168; 1-[[(5-Nitro-2-furanyl)methylene]amino]-2,4-imidazolidinedione; Furadantina MC; NCGC00091505-01; Nitoin; Nierofu; Orafuran; Cistofuran; 1-(5-Nitro-2-furfurylideneamino)hydantoin; Furadantoin; Urantoin; Nitrex; Furophen T; IDI1_000224; Prestwick_358; 2,4-Imidazolidinedione, 1-[[(5-nitro-2-furanyl)methylene]amino]-; Berkfuran; NITROFURANTOIN, MACROCRYSTALLINE; Furalan; Furedan; 1-((5-Nitrofurfurylidene)amino)hydantoin; Uro-Tablinen; ND-3320; NSC44150; Ro-Antoin; MolPort-001-018-217; 2,4-Imidazolidinedione, 1-(((5-nitro-2-furanyl)methylene)amino)-; HMS1568B17; Nitrofurantoine; Phenurin; Zoofurin; HMS500L06; CHEMBL572; BPBio1_000039; N-(5-Nitro-2-furfurylideno)-1-aminohydantoina; BSPBio_000035; Nitrofur-C; 54-87-5 (hydrochloride salt); AB00513815; N-Toin; Dantafur; N-(5-Nitro-2-furfurylidene)-1-aminohydantoin; Furatoin; 5-Nitrofurantoin; Macrofuran; Nifuretten; Nitrofurantoine [INN-French]; BRD-K76927775-001-05-0; NSC2107; Prestwick2_000168; Furadontin; Furadonin; Welfurin; PiyEloseptyl; NITROFURANTOIN MACROCRYSTALLINE; HMS2091H16; Spectrum5_001367; uro-tablineu; Furina; 17140-81-7 (mono-hydrate); Nitrofurantoina [DCIT]; Uerineks; Alfuran; Parfuran; 1-{[(1E)-(5-nitrofuran-2-yl)methylidene]amino}imidazolidine-2,4-dione; Ituran; Macrodantina; Cystit; NCGC00091505-04; nitrofurantoin; 1-(5-Nitro-2-furfurylidenamino)hydantoin; 1-[(E)-(5-nitrofuran-2-yl)methylideneamino]imidazolidine-2,4-dione; Macpac; Urolong; AI3-26388; Nifurantin; Furantoin; Furadantin; Nitrofurantoinum [INN-Latin]; Ceduran; CCRIS 1192; Hydantoin, 1-((5-nitrofurfurylidene)amino)-; N-(5-Nitro-2-furfurylideno)-1-aminohydantoina [Polish]; LS-1560; NCGC00091505-05; Urofurin; Furadoninum; Urofuran; Benkfuran; Furadantine-MC; Nitrofuradantin; HSDB 3135; Nitrofurantoinum	67-20-9	5353830	149113	TTDS00213	DNA	N/A	N/A	N/A	N/A	N/A
DAP000987	Temozolomide	Temozolamide; CHEBI:153686; SMR000466338; 8-Carbamoyl-3-methylimidazo(5,1-d)-1,2,3,5-tetrazin-4(3H)-one; Temozolomidum [Latin]; LS-80558; TMZ-Bioshuttle; AC1L1K9B; 3-Methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetraazine-8-carboxamide; {Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide,} 3, 4-dihydro-3-methyl-4-oxo-; M&B-39831; CPD000466338; ZINC01482184; CHEMBL810; NCI60_003316; Sch-52365; 85622-93-1; HMS2090B08; NSC-362856; NSC362856; Temozolomide [INN:BAN]; C047246; temozolomide; CCRG-81045; Bio-0147; MB 39831; 3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide; M&B 39831; NSC 362856; NCGC00167429-02; 3,4-Dihydro-3-methyl-4-oxoimidazo(5,1-d)-as-tetrazine-8-carboxamide; Schering brand of temozolomide; Temozolomidum; D06067; CCRIS 8996; Temodal; I14-1943; MLS002701861; 3-methyl-4-oxoimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide; M-39831; DB00853; Temodal (TN); Schering-Plough brand of temozolomide; UNII-YF1K15M17Y; TL8005593; Imidazo(5,1-d)(1,2,3,5)tetrazine-8-carboxamide, 3,4-dihydro-3-methyl-4-oxo-; Essex brand of temozolomide; 3,4-Dihydro-3-methyl-4-oxoimidazo(5,1-d)-1,2,3,5-tetrazine-8-carboxamide; Sch 52365; Methazolastone; C6H6N6O2; M  B 39831; Temozolomide (JAN/USAN/INN); I06-0149; Temozolodida; HMS2051O12; Temozolodida [Spanish]; Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3,4-dihydro-3-methyl-4-oxo-; 3-Methyl-4-oxo-3,4-dihydroimidazo(5,1-d)(1,2,3,5)tetrazine-8-carboxamide; AC-758; SAM001246636; MLS001424028; STK623541; Temodar; BRN 5547136; CID5394; CCRG 81045; NCGC00167429-01; M & B 39831; MLS000759447; BIDD:GT0204	85622-93-1	5394	655054	TTDS00213	DNA	N/A	N/A	N/A	N/A	N/A
DAP000041	Carmustine	STK624770; Bio-0118; SMR000058426; Carmustin; Bi CNU; HMS2092J22; Gliadel, BCNU, NSC-409962, Becenun, Carmustine; 1,3-Bis(.beta.-chloroethyl)-1-nitrosourea; Bis(chloroethyl)nitrosourea; Bis(2-chloroethyl)nitrosourea; Bischloroethylnitrosourea; 154-93-8; Bischlorethylnitrosourea; DB00262; NCGC00093665-04; BCNU; FT-0083563; NCI-C04773; I14-11976; 1,3-Bis(2-chloroethyl)nitrosourea; NCGC00093665-01; AC1L1DZQ; Spectrum_000265; NINDS_000835; Gliadel; Nitrumon; ZINC03830387; Lopac0_000188; BCNU [Chloroethyl nitrosoureas]; Spectrum4_000888; SRI 1720; FDA 0345; NCGC00015204-02; Spectrum5_000920; NSC409962; 1,3-Bis(2-chloroethyl)-1-nitrosourea; KBio2_003313; Bischlorethylnitrosurea; CCRIS 810; Carmustina; AC-10563; D002330; IDI1_000835; CHEMBL513; NCI60_003931; NSC 409962; AI3-52216; Carmustinum [INN-Latin]; Bischloroethyl nitrosourea [Chloroethyl nitrosoureas]; NSC-409962; KBio2_000745; Gliadel Wafer; CHEBI:3423; C 0400; Carmustinum; MolPort-003-665-505; KBio1_000835; S1521_Selleck; carmustine; Becenum; Lopac-C-0400; DivK1c_000835; C5H11Cl2N3O2; WLN: ONN2GVM2G; Bischloroethyl nitrosourea; HMS502J17; Carmubris; 1,3-BIS(CHLOROETHYL)-1-NITROSOUREA; UNII-U68WG3173Y; NCGC00093665-03; carmustine in ethanol; CID2578; Urea, 1,3-bis(2-chloroethyl)-1-nitroso-; EU-0100188; BRN 2049744; C0400_SIGMA; 1,3-Bis(beta-chloroethyl)-1-nitrosourea; NCGC00093665-02; EINECS 205-838-2; BiCNU; MLS001333962; KBioSS_000745; Bis-N,N'-(chloroethyl)nitrosourea; KBioGR_001296; Carmustine [USAN:INN:BAN]; BCNU; 1,3-Bis(2-chloroethyl)-1-nitrosourea; Prestwick_997; D00254; NCGC00015204-06; SK 27702; Bis(2-chloroethyl)1-nitrosourea; Becenun; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Carmustine (USAN/INN); LS-890; FIVB; KBio2_005881; NCGC00015204-01; Carmustina [INN-Spanish]; DTI 015; BiCNU (TN); Urea, N,N'-bis(2-chloroethyl)-N-nitroso-	154-93-8	2578	152253	TTDS00213	DNA	N/A	N/A	N/A	N/A	N/A
DAP001458	Balofloxacin	CHEMBL1210954; I06-2288; CID65958; ST51053894; Baloxin; UNII-Q022B63JPM; (+-)-1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-(methylamino)piperidino)-4-oxo-3-quinoline arboxylic acid; AC1L24BT; LS-141556; Q 35; 1-cyclopropyl-6-fluoro-8-methoxy-7-[3-(methylamino)piperidin-1-yl]-4-oxoquinoline-3-carboxylic acid; FT-0082371; (+-)-1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-(methylamino)piperidino)-4-oxo-3-quinolinecarboxylic acid; AC1Q4N6B; Balofloxacin [INN]; TL8000675; Balofloxacin; 127294-70-6; NCGC00167532-01; 3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-(methylamino)-1-piperidinyl)-4-oxo-; I14-0602	127294-70-6	5282515	854151	TTDS00213	DNA	N/A	N/A	N/A	N/A	inhibitor
DAP000849	Clofarabine	DB00631; 2-Chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-9H-purin-6-amine; clofarabinum; CID119182; Clolar (TN); 3S211048; Clofarabine; Bio-0121; 2-Chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine; D03546; C1-F-Ara-A; LS-126466; Clofarabine (USAN/INN); CHEBI:681569; 9H-Purin-6-amine, 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-; 2-Cl-2'-F-araA; 123318-82-1; S1218_Selleck; Clofarex; HMS2090A07; Clolar; FT-0082882; AC-274; AC1L3OC8; CFB; CAFdA; MolPort-005-941-711; Clolar, Evoltra,  Clofarabine; Cl-F-Ara-A; ZINC03798247; Evoltra; DB07554; CHEMBL1750; Clofarabine [USAN]; 2-chloro-9-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)adenine; UNII-762RDY0Y2H; 2-Chloro-9-(2-deoxy-2-fluoro-b-D-arabinofuranosyl)-9H-purin-6-amine; AKOS005063562; clofarabina; (2R,3R,4S,5R)-5-(6-amino-2-chloropurin-9-yl)-4-fluoro-2-(hydroxymethyl)oxolan-3-ol	123318-82-1	119182	695844	TTDS00213	DNA	N/A	N/A	N/A	N/A	binder
DAP000147	Mercaptopurine	6H-Purine-6-thione, 1,7-dihydro-; AKOS000275858; NCI-C04886; 7-Mercapto-1,3,4,6-tetrazaindene; MP; Wellcome Brand of 6-Mercaptopurine; Leukerin, 99% - Carc; LS-141; HMS2091B20; WLN: T56 BM DN FN HNJ ISH; 9H-Purin-6-yl hydrosulfide; 6-MP; AG-670/31547064; Ismipur; U-4748; KBio1_000493; KBio2_003969; FT-0083571; 5818-33-7; CCRIS 2761; UNII-PKK6MUZ20G; S1305_Selleck; GlaxoSmithKline Brand of 6-Mercaptopurine; AC-11464; 6 Mercaptopurine Monohydrate; Spectrum2_000060; 1,9-dihydro-6H-purine-6-thione; NCIMech_000025; KBio3_001481; PM6; Leupu rin; GlaxoSmithKline Brand of 6 Mercaptopurine; 50-44-2; SPECTRUM1500387; NCGC00094717-03; M0063; 6-Merkaptopurin [Czech]; 3,7-dihydropurine-6-thione; mercaptopurine; 6-Merkaptopurin; Leukerin; C01756; 3H-Purine-6-thiol; Merkaptopuryna [Polish]; C5H4N4S; Purinethol; KBio2_004931; Mercaptopurin; CHEBI:50667; C02380; Spectrum4_000857; 63810_FLUKA; CID667490; DivK1c_000493; 6-Thiopurine; 6H-Purine-6-thione, 1,7-dihydro-; 7-Mercapto-1,3,4,6-tetrazaindene; Glaxo Wellcome Brand of 6 Mercaptopurine; 9H-Purine-6(1H)-thione; Purinethol (TN); CHEBI:2208; 6-MERCAPTOPURINE MONOHYDRATE; cMAP_000033; NSC755; KBio3_002842; KBio2_007499; HMS501I15; MLS001304020; MolPort-001-815-626; KBioGR_001493; 1,7-Dihydro-6H-purine-6-thione; Mercaptopurin [German]; Puri Nethol; 6-Thiohypoxanthine; 6-Mercaptopurine; Purinethiol; 6 Thiohypoxanthine; Leupurin; 5818-60-0; SPBio_000219; Mercaptopurine (VAN); DB01033; Spectrum_000921; D04931; Mercaptopurina Wellcome; 6-Thioxopurine; Mercapurin; Glaxo Wellcome Brand of 6-Mercaptopurine; MolPort-001-783-696; D015122; Purine-6-thiol; Purinethol, 6-mercaptopurine, 6-MP, Mercaptopurine; Purine-6(1H)-thione; Wellcome Brand of 6 Mercaptopurine; CHEMBL1425; Mercaptopurina [INN-Spanish]; KBioSS_001401; BB_SC-0064; Mercaptopurinum [INN-Latin]; Mercaleukim; MLS001304953; NINDS_000493; STK727062; NSC 755; EINECS 200-037-4; KBioSS_002366; 39454-94-9; 6 MP; BW 57 323H; 1H-Purine, 6-mercapto-; 6 Mercaptopurine; Purine, 6-mercapto-; CPD000544948; KBio2_001401; Puri-Nethol; 6-Purinethiol; AC1LDI73; NCI60_041653; F3329-0452; Hypoxanthine, thio-; Mercaptopurinum; NCGC00094717-01; KBio2_002363; MolPort-003-846-751; AKOS000170222; 6-Mercaptopurin; purine antimetabolite: inhibits nucleic acid replication; Mercaptopurine, 6-; NCGC00094717-02; Mern; IDI1_000493; HSDB 3235; I14-1716; 7H-purine-6-thiol; MLS001066623; SMR000544948; Spectrum5_000950; 5759-99-9; Mercaleukin; Thiopurine; Merkaptopuryna; Ambap50-44-2; 6112-76-1; Mercaptopurina; 6 Thiopurine; SAM002589937; NSC-755; KBio2_006537; 6112-76-1 (monohydrate); Mercaptopurine (INN); BSPBio_001981; Mercaptopurine anhydrous; Mercaptopurine (anhydrous); Purimethol; HMS1920L07; Spectrum3_000491; KBioGR_002363	50-44-2	667490	5422	TTDS00213	DNA	N/A	N/A	N/A	N/A	N/A
DAP000985	Nelarabine	Nelzarabine (USAN); NCGC00181098-01; NSC-686673; GW-506U; AC1L6N9B; 34793-34-5; 506U78; C11H15N5O5; ArranonG; 506U; CID151121; Arranon, Nelarabine; NSC 686673; (2R,3S,4S,5R)-2-(2-amino-6-methoxypurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol; NSC 66381; CHEMBL406852; Nelarabine [USAN]; NSC686673; 121032-29-9; S1213_Selleck; AC1L3W6K; LS-172477; 9-beta-D-Arabinofuranosyl-6-methoxy-9H-purin-2-amine; U78; 7803-88-5; (2R,3R,4S,5R)-2-(2-amino-6-methoxypurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol; Nelarabine (JAN/USAN); 2-(2-amino-6-methoxypurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol; Nelarabine; 2-Amino-6-methoxypurine arabinoside; ZINC03823492; AC1L45PO; Nelzarabine [USAN]; Atriance; O-Methoxydeoxyguanosine; BRN 0703603; 2-Amino-9-beta-D-arabinofuranosyl-6-methoxy-9H-purine; Nelzarabine; DB01280; Arranon; Arranon (TN); 9H-Purin-2-amine, 9beta-D-arabinofuranosyl-6-methyl-; CID96312; Nelarabine (INN); CID248862; D05134; AC-3548; 6'-O-Methylguanosine; 9beta-D-Arabinofuranosyl-6-methoxy-9H-purin-2-amine; Guanosine, O-methyl-; 9h-purin-2-amine, 6-methoxy-9-|A-d-ribofuranosyl-; GW 506U78; NSC66381; GW506U78; I14-8429; O-Methylguanosine; 2-(2-Amino-6-methoxy-purin-9-yl)-5-hydroxymethyl-tetrahydro-furan-3,4-diol; UNII-60158CV180; NSC132361; CHEMBL1201112; LS-73962; AC1Q4XYR; AR-1H5711; GW-506U78; AC1Q4F8K; AC1MHTJS; CID3011155; Arranon (GlaxoSmithKline); D06488; (3S,4S,5R)-2-(2-amino-6-methoxypurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol	121032-29-9	3011155	14922755	TTDS00213	DNA	N/A	N/A	N/A	N/A	binder
DAP000787	Chlorambucil	NSC 3088; NCGC00023250-09; KBio2_005694; KBio2_000558; Glaxo Wellcome Brand of Chlorambucil; EU-0100227; C 0253; Ecloril; CHEBI:28830; CCRIS 126; Chloorambucol; Phenylbuttersaeure-lost [German]; Chlocambucil; Spectrum3_000336; NSC-3088; Elcorin; BRD-K29458283-001-05-9; CPD000058372; KBio1_000688; Spectrum_000118; NCI60_002639; NCGC00023250-03; NINDS_000688; BSPBio_001971; Chlorambucil [INN:BAN]; LS-1158; Clorambucilo [INN-Spanish]; SPBio_000249; LEUKERAN (TN); Prestwick0_001079; BRN 0999011; Lympholysin; WLN: QV3R DN2G2G; Chlorambucilum [INN-Latin]; Leuk ersan; KBio2_003126; AC1Q75DO; Chlorambucilum; chlorambucil; Chlorbutine; Leukoran; DB00291; HMS1571G20; NCGC00023250-08; NCI-C03485; Chlorbutinum; SAM002564202; Chlorobutine; Phenylbuttersaeure-lost; UNII-18D0SL7309; MLS001076130; GlaxoSmithKline Brand of Chlorambucil; Spectrum2_000065; NCGC00015199-07; NSC3088; KBioSS_000558; Prestwick3_001079; MolPort-000-152-694; Amboclorin; 23125_FLUKA; Clorambucilo; Leukeran; HMS1920M15; FT-0083565; CB1348; MLS000028443; EINECS 206-162-0; Linfolysin; Elcoril; Spectrum5_000677; BSPBio_001098; KBioGR_000766; Ambochlorin; NCGC00023250-07; NCGC00023250-00; Prestwick1_001079; CID2708; DivK1c_000688; 305-03-3; Linfolizin; SMR000058372; CAS-305-03-3; Chlorambucil (USP/INN); NCGC00023250-06; Clorambucile [DCIT]; AB00051938; SPBio_002999; Spectrum4_000273; HMS2091A22; Chloraminophene; Phenylbutyric acid nitrogen mustard; Leukersan; AI3-26083; NCGC00015199-03; Lopac-C-0253; D00266; CB 1348; Chloroambucil; Chlorbutin; Wellcome Brand of Chlorambucil; SPECTRUM1500171; Clorambucile; KBio3_001191; Lopac0_000227; AC1L1EAB; ST50410766; Chloraminophen; NCGC00015199-02; HSDB 3026; NCGC00023250-04; NCGC00015199-14; Cb l348; C0253_SIGMA; RCRA waste no. U035; Chlorobutin; NCGC00023250-10; TL8002353; HMS2090M19; Rcra waste number U035; BPBio1_001208; CHEMBL515; D002699; Prestwick2_001079; NCGC00023250-05; CB-1348; Leukeran tablets; NCGC00015199-01; IDI1_000688; HMS502C10; C14H19Cl2NO2	305-03-3	2708	152571	TTDS00213	DNA	N/A	N/A	N/A	N/A	N/A
DCL000521	Elsamitrucin	C33H35NO13; Benzo[g][2]benzopyrano[5,4,3-cde][2]benzopyran-5,12-dione, 10-[[2-O-(2-amino-2,6-dideoxy-3-O-methylhexopyranosyl)-6-deoxy-3-C-methylhexopyranosyl]oxy]-6-hydroxy-1-methyl-; NSC369327; CID5362259; BBM-2478A; Elsamitrucina; BMS-181171; E-87/025; Elsamitrucinum [INN-Latin]; SPI 28090; ELSAMITRUCIN; Elsamitrucinum; Elsamicin; UNII-ZTV0FOB6NU; Antibiotic BBM 2478A; BMY 28090; BBM 2478A; Elsamitrucine [INN-French]; Elsamitrucina [INN-Spanish]; NSC-369327; BRN 5214813; Elsamitrucine; Benzo(h)(1)benzopyrano(5,4,3-cde)(1)benzopyran-5,12-dione, 10-((2-O-(2-amino-2,6-dideoxy-3-O-methyl-alpha-D-galactopyranosyl)-6-deoxy-3-C-methyl-beta-D-galactopyranosyl)oxy)-6-hydroxy-1-methyl-; Elsamitrucin [USAN:INN]; Chartreusin analog; 97068-30-9; Elsamicin A; Benzo[h][1]benzopyrano[5,4,3-cde][1]benzopyran-5,12-dione, 10-[[2-O-(2-amino-2,6-dideoxy-3-O-methyl-.alpha.-D- galactopyranosyl)-6-deoxy-3-C-methyl-.beta.-D- galactopyranosyl]oxy]-6-hydroxy-1-methyl-; BU-2478A; LS-33663; CID5384876; 10-O-Elsaminosylelsarosylchartarin; NCI60_003404; BMY-28090; 2-Amino-2,6-dideoxy-3-O-methyl-D-galactose	22260-51-1	31101	47205961	TTDS00213	DNA	N/A	N/A	N/A	N/A	N/A
DCL000816	Glufosfamide	D 19575; 132682-98-5; CID123628; beta-D-Glucopyranose 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate; glc-IPM; HSDB 7024; UNII-1W5N8SZD9A; Glucosylifostamide mustard; beta-D-Glucopyranose, 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate); D-19575; Glucosyl-ifosfamide mustard; AC1L3X04; (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol; LS-71462; Glufosfamide; MolPort-005-942-376	132682-98-5	123628	12014754	TTDS00213	DNA	N/A	N/A	N/A	N/A	inhibitor
DAP000989	Altretamine	NINDS_000772; Rhone-Poulenc Rorer Brand of Altretamine; HTM; UNII-Q8BIH59O7H; EINECS 211-428-4; AC-12006; Altretamine Chiesi Brand; Hexalen (TN); HMS1922C05; Spectrum2_000907; Hexalen; NCGC00015100-01; Spectrum_001308; ENT 50852; CHEBI:24564; NCGC00021216-04; Spectrum3_000951; Altretamine Bellon Brand; KBio2_004356; Prestwick1_000946; D02841; NCI60_000871; HMS2092H16; CID2123; CPD000058181; WLN: T6N CN ENJ BN1&1 DN1&1 FN1&1; NCGC00015100-03; 1,3,5-Triazine-2,4,6-triamine, N,N,N',N',N',N'-hexamethyl-; s-Triazine, 2,4,6-tris(dimethylamino)-; KBio1_000772; Altretamine (USP/INN); MLS001076123; 645-05-6; Altretamina; SMR000058181; HXM; MolPort-002-111-210; Lopac0_000083; Hexinawas; Prestwick2_000946; NSC 13875; DB00488; Rhone Poulenc Rorer Brand of Altretamine; NSC13875; InChI=1/C9H18N6/c1-13(2)7-10-8(14(3)4)12-9(11-7)15(5)6/h1-6H; 2,4,6-Tris(dimethylamino)-1,3,5-triazine; SPECTRUM1503065; HMS1383L15; SPBio_000754; KBioSS_001788; Spectrum4_001064; Lopac-A-8723; NC 195; HMM; no)-s-triazine; s-Triazine, 2,4,6-tris(dimethylamino)-; 1,3,5-Triazine-2,4,6-triamine, N,N,N',N',N'',N''-hexamethyl-; A 8723; CHEMBL1455; ChemDiv2_005185; S1278_Selleck; N~2~,N~2~,N~4~,N~4~,N~6~,N~6~-Hexamethyl-1,3,5-triazine-2,4,6-triamine; 1,3,5-Triazine-2,4,6-triamine, N,N,N',N',N'', N''-hexamethyl-; 2,4, 6-Tris(dimethylamino)-1,3,5-triazine; 2,4,6-Tris(dimethylami; NCGC00021216-03; BSPBio_000912; KBioGR_001388; IDI1_000772; 2,4,6-Tris(dimethylamino)-s-triazine; SAM002564241; Hemel; NCGC00015100-02; HMS502G14; Hexalen, Altretamine; NCGC00021216-07; CAS-654-05-6; KBio2_001788; C9H18N6; AB00052308; Chiesi Brand of Altretamine; HMS1570N14; A0567/0026158; HSDB 7559; MLS000069621; Spectrum5_001092; KBio3_002042; KBio2_006924; altretamine; BRD-K67043667-001-04-1; SPBio_003071; STK749184; NCGC00021216-05; NCGC00015100-11; AKOS001729401; Wassermann Brand of Altretamine; ST086739; DivK1c_000772; Bellon Brand of Altretamine; HEXAMETHYLMELAMINE; NCGC00015100-06; IDI1_003900; ZINC00000905; KB-913; HMS2090G17; N,N,N',N',N'',N''-hexamethyl-1,3,5-triazine-2,4,6-triamine; D006585; 549835_ALDRICH; I06-0604; 2-N,2-N,4-N,4-N,6-N,6-N-hexamethyl-1,3,5-triazine-2,4,6-triamine; Hexastat; EU-0100083; Prestwick3_000946; AI3-50852; AC1L1CYX; NSC-13875; NCI-C50259; LS-1549; Altretamina [INN-Spanish]; Prestwick0_000946; Altretaminum; NCGC00021216-06; A8723_SIGMA; Altretamine [USAN:INN:BAN]; BPBio1_001004; MGI Pharma Brand of Altretamine; Altretamine Wassermann Brand; Melamine, hexamethyl-; BRN 0195058; Altretaminum [INN-Latin]; CCRIS 5492; FT-0083576	645-05-6	2123	155900	TTDS00213	DNA	N/A	N/A	N/A	N/A	N/A
DAP000531	Bleomycin	CCRIS 2754; HSDB 3208; C55H86N17O21S3; EINECS 234-356-5; 1400-95-9; AC1L9UFF; 3-[[2-[2-[2-[[(2S,3R)-2-[[(2S,3S,4R)-4-[[(2S,3R)-2-[[6-amino-2-[(1S)-3-amino-1-[[(2S)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2R,3S,4S,5S,6S)-3-[(2R,3S,4S,5R,6R)-4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-(1H-imidazol-5-yl)propanoyl]amino]-3-hydroxy-2-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]ethyl]-1,3-thiazol-4-yl]-1,3-thiazole-4-carbonyl]amino]propyl-dimethylsulfanium; Blenoxane; CHEMBL403664; CID456190; Bleomycine; BLM; Bleomycinum [INN-Latin]; 3-[[2-[2-[2-[[(2S,3R)-2-[[(2S,3S,4R)-4-[[(2S,3R)-2-[[6-amino-2-[(1S)-3-amino-1-[[(2S)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[3-[4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-(1H-imidazol-5-yl)propanoyl]amino]-3-hydroxy-2-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]ethyl]-1,3-thiazol-4-yl]-1,3-thiazole-4-carbonyl]amino]propyl-dimethylsulfanium; STOCK1N-74760; CID5360373; Bleomycine [INN-French]; LMPK14000006; NSC 125066; 9041-93-4 (sulfate (salt)); Bleomycin B(2); CHEBI:3139; 37208-04-1; Zhengguangmycin A2 [Chinese]; Bleomycinum; Bleomicin; DB00290; Bleocin; 37293-16-6; 37353-43-8; LS-524; C55H85N17O21S3; LS-44860; 9041-93-4; NDC 0015-3010; bleomycin a2; Bleo; Pingyangmyvin A2; (betaR)-N(alpha)-{[6-amino-2-((1S)-3-amino-1-{[(2S)-2,3-diamino-3-oxopropyl]amino}-3-oxopropyl)-5-methylpyrimidin-4-yl]carbonyl}-beta-{2-O-[3-O-(aminocarbonyl)-alpha-D-mannopyranosyl]-alpha-L-gulopyranosyloxy}-N-[(1R,2S,3S)-5-({(1S,2R)-1-[({2-[4-({[3-(dimethylsulfonio)propyl]amino}carbonyl)-2,4'-bi-1,3-thiazol-2'-yl]ethyl}amino)carbonyl]-2-hydroxypropyl}amino)-3-hydroxy-4-methyl-5-oxopentan-2-yl]-L-histidinamide; Bleomicina [INN-Spanish]; AC1NSEJD; Bleogin; Bleomycin A(2); bleomycin; Bleomycins; Bleomycinamide, N1-(3-(dimethylsulfonio)propyl)-; Bleomicina; Bleomycin sulfate; C06854; UNII-40S1VHN69B; N(1)-[3-(dimethylsulfonio)propyl]bleomycinamide; 11056-06-7; Bleomycin A2 & Bleomycin B2.; UNII-13M89UEA7W; N1-(3-(Dimethylsulfonio)propyl)bleomycinamide; AC1NUTOQ; 11116-31-7; 3-[[2-[2-[2-[[(2S,3R)-2-[[(2S,3S,4R)-4-[[(2S)-2-[[6-amino-2-[(1S)-3-amino-1-[[(2S)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2R,3S,4S,5S,6S)-3-[(2R,3S,4S,5R,6R)-4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-(1H-imidazol-5-yl)propanoyl]amino]-3-hydroxy-2-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]ethyl]-1,3-thiazol-4-yl]-1,3-thiazole-4-carbonyl]amino]propyl-dimethylsulfanium; Zhengguangmycin A2; CID5460769	11056-06-7	5360373	9072	TTDS00213	DNA	N/A	N/A	N/A	N/A	N/A
DAP000215	Cisplatin	Platinoxan; CHEBI:35852; nchembio773-comp1; Platidiam; cis-Diamminedichloroplatinum; EU-0100918; cis-Dichlorodiammineplatinum(II); Plastin; Lederplatin; (SP-4-2)-diamminedichloridoplatinum; CPD0-1392; (SP-4-1)-diamminedichloridoplatinum; Cismaplat; Platamine; Abiplatin; Briplatin; cis-diamminedichloridoplatinum(II); cis-[PtCl2(NH3)2]; (SP-4-1)-diamminedichloroplatinum; Cisplatyl; Citoplationo; cis-DDP; trans-diamminedichloridoplatinum(II); Peyrone's chloride; Randa; (SP-4-2)-diamminedichloroplatinum; Biocisplatinum; Cisplatine; Peyrone's salt; CID441203; Cisplatino; DB00515; Neoplatin; Cisplatinum	15663-27-1	441203	7847341	TTDS00213	DNA	N/A	N/A	N/A	N/A	N/A
DAP000996	Methoxsalen	O-methylxanthotoxol; 8-Methoxy; 9-methoxyfuro[3,2-g]chromen-7-one; 5-Benzofuranacrylic acid, 6-hydroxy-7-methoxy-, .delta.-lactone; Xanthotoxine; NCGC00178871-02; Methoxsalen [BAN:JAN]; DivK1c_000763; ICN Brand 3 of Methoxsalen; New-Meladinin; Dermatech Brand of Methoxsalen; 9-(methyloxy)-7H-furo[3,2-g]chromen-7-one; Methoxsalen plus ultraviolet radiation; 8 Methoxypsoralen; Meladinine; Oxoralen; Methoxalen; 8-methoxyfuranocoumarins; Methoxsalen Dermatech Brand; BRD-K63430059-001-06-5; CHEBI:18358; NCGC00178871-01; Methoxsalen (JP15/USP); BPBio1_000680; NCGC00060938-05; Oxsoralen lotion; NINDS_000763; SDCCGMLS-0042377.P002; A1783/0075596; 8-Methoxy-4',5':6,7-furocoumarin; BSPBio_001997; KBio2_006639; MEGxp0_000095; Ultramop; 8-methoxyfurocoumarins; Methoxsalen, 8-; CPD000071170; 9-Methoxyfuro(3,2-g)chromen-7-one; I06-0695; 8-MOP; OXSORALEN (TN); 8-Methoxy(furano-3'.2':6.7-coumarin); 8-Methoxypsoralene; Methoxsalen Delta Brand; 9-Methoxypsoralen; 7H-Furo[3,2-g][1]benzopyran-7-one, 9-methoxy-; Delta Brand of Methoxsalen; Methoxsalen Sanofi-Synthelabo Brand; Uvadex; ACon1_000174; Zanthotoxin; NCGC00060938-04; Deltasoralen; 7H-Furo(3,2-G)(1)benzopyran-7-one, 9-methoxy-; Meloxine; KBioGR_000543; CHEBI:52028; SPECTRUM1500400; Oxsoralen; Methoxsalen with ultra-violet A theraphy; NCGC00060938-03; Spectrum_001023; Mex America Brand of Methoxsalen; 9-Methoxy-7H-furo(3,2-g)benzopyran-7-one; BRN 0196453; SPBio_001004; Methoxaten; Methoxa-Dome; Ammoidin; CCRIS 2083; Ammodin; MolPort-000-696-480; CPD-13042; NCI-C55903; Mex-America Brand of Methoxsalen; 8MOP; D008730; C01864; Dermox; NCGC00178871-03; Psoralen-mop; 8-Methoxy-4',5',6,7-furocoumarin; SAM002548974; NCGC00060938-02; Methoxsalen Mex-America Brand; EINECS 206-066-9; 8-MP; 5-19-06-00015 (Beilstein Handbook Reference); Galderma Brand of Methoxsalen; ZINC02548959; Meladinina; Psoralon-MOP; 7-Furocoumarin; Proralone-mop; Spectrum2_001052; XANTHOTOXIN; S1952_Selleck; Oxsoralen Ultra; 8-METHOXYPSORALEN + UVA (SEE ALSO C55903); 8MO; 8-Methoxy-[furano-3'.2':6.7-coumarin]; DB Brand of Methoxsalen; Geroxalen; BRD-K63430059-001-03-2; HSDB 2505; Sanofi-Synthelabo Brand of Methoxsalen; 8-Methoxypsoralen; Oprea1_166319; KBio3_001497; 12692-94-3; X0009; KBio2_001503; KBio2_004071; NCGC00060938-06; MLS002303011; Ultra Mop; 8-Methoxyfuranocoumarin; 9-Methoxyfuro[3,2-g][1]benzopyran-7-one; 9-Methoxy-7H-furo[3,2-g]chromen-7-one; 6-Hydroxy-7-methoxy-5-benzofuranacrylic acid delta-lactone; Methoxy-8-psoralen; NSC45923; KBioSS_001503; an 8-methoxyfurocoumarin; Methoxsalen Canderm Brand; Prestwick_661; D00139; Oxsoralen-ultra; ICN Brand 1 of Methoxsalen; NCI60_004085; HMS502G05; HMS1920N05; ICN Brand 2 of Methoxsalen; CHEMBL416; M3501_SIAL; Puvamet; Prestwick0_000479; SPBio_002557; 9-Methoxy-7H-furo(3,2-g)(1)benzopyran-7-one; STOCK1N-03091; HMS2091D20; 9-Methoxy-7H-furo[3,2-g][1]benzopyran-7-one; Oxsoralen Ul tra; Puvalen; 8-Methoxy-(furano-3'.2':6.7-coumarin); Prestwick3_000479; Methoxsalen Chinoin Brand; Boehringer Ingelheim Brand of Methoxsalen; Jsp005650; Meladinin (VAN); M3501_FLUKA; NCGC00016418-01; Chinoin Brand of Methoxsalen; BSPBio_000618; Ultramop Lotion; methoxsalen; AC-4259; Meladinin; Oxypsoralen; CID4114; WLN: T C566 DO LVOJ BO1; Spectrum3_000499; Meladoxen; MLS000062633; Prestwick1_000479; FT-0082222; Sanofi Synthelabo Brand of Methoxsalen; Methoxa Dome; DB00553; 8-Methoxy-2',3',6,7-furocoumarin; 8 MOP; STK735539; KBio1_000763; Spectrum4_000052; 298-81-7; HMS1569O20; AKOS000277012; Spectrum5_001891; LS-68; SMR000071170; Canderm Brand of Methoxsalen; UNII-U4VJ29L7BQ; CAS-298-81-7; 5-Benzofuranacrylic acid, 6-hydroxy-7-methoxy-, delta-lactone; AC1L1HFY; Prestwick2_000479; NSC 45923; 8-Methoxypsoralen with ultraviolet A therapy; 9-metho xy-7H-furo(3,2-g)benzopyran-7-one; IDI1_000763	298-81-7	4114	152480	TTDS00213	DNA	N/A	N/A	N/A	N/A	binder
DAP000991	Lomustine	(Cloro-2-etil)-1-cicloesil-3-nitrosourea; NCI60_041743; NSC79037; DB01206; CeeNU (TN); D00363; Bristol Myers Squibb Brand of Lomustine; SRI 2200; S1840_Selleck; lomustine; medac Brand of Lomustine; Cyclohexyl chloroethyl nitrosourea; Lomustine [USAN:BAN:INN]; 1-Nitrosourea, 1-(2-chloroethyl)-3-cyclohexyl-; D008130; CCNU [Chloroethyl nitrosoureas]; Lomustine (USAN/INN); Chloroethylcyclohexylnitrosourea; 1-(2-Chloroethyl)-3-cyclohexylnitrosourea; EINECS 235-859-2; CCNU; WLN: L6TJ AMVNNO&2G; 13010-47-4; I06-0087; CINU; ICIG 1109; 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea; CCRIS 860; 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea [Chloroethyl nitrosoureas]; CeeNU; Lomustine medac Brand; CeeNU, CCNU, Lomustine; NSC 79037; Urea, N-(2-chloroethyl)-N'-cyclohexyl-N-nitroso-; (Chloro-2-ethyl)-1-cyclohexyl-3-nitrosourea; Lomustinum [INN-Latin]; CID3950; OR5087; Rhone Poulenc Rorer Brand of Lomustine; (Cloro-2-etil)-1-cicloesil-3-nitrosourea [Italian]; N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosourea; FT-0083566; NCIMech_000220; Lomustina [INN-Spanish]; NCI-C04740; Urea, 1-(2-chloroethyl)-3-cyclohexyl-1-nitroso-; MolPort-001-768-818; NPFAPI-06; HSDB 6519; CHEMBL514; NSC-79037; Rhone-Poulenc Rorer Brand of Lomustine; LS-728; C9H16ClN3O2; NCGC00167466-01; BRN 2125058; Lomustinum; Belustine; RB 1509; Bristol-Myers Squibb Brand of Lomustine; AC1L1H2T; Urea, 1-(2-chloroethyl)-3-cyclohexyl)-1-nitroso-; HMS2090A17; AI3-52779; AC-10564; Cecenu; UNII-7BRF0Z81KG; Lomustina; ZINC03831006	13010-47-4	3950	168381	TTDS00213	DNA	N/A	N/A	N/A	N/A	inhibitor
DAP000062	Oxaliplatin	D01790; CHEMBL1201055; Eloxatin (TN); CID9887054; Oxaliplatin (JAN/USAN/INN)	61825-94-3	9887054	184140	TTDS00213	DNA	N/A	N/A	N/A	N/A	N/A
DAP000995	Proflavine	AE-562/12222295; Proflavin; 3,6 -Diaminoacridine sulfate; ZINC03775644; 3,6-ACRIDINEDIAMINE; NCGC00166245-01; C13H11N3; C11181; Proflavina [INN-Spanish]; Proflavina; PRL; InChI=1/C13H11N3/c14-10-3-1-8-5-9-2-4-11(15)7-13(9)16-12(8)6-10/h1-7H,14-15H2; Profoliol-B; BRN 0166050; Progarmed; AC1Q52GA; EINECS 202-172-4; Isoflav base; 1811-28-5; 3,6-Diamino-acridinium; Acridine, 3,6-diamino-; AC1L1O07; 3,6-Diaminoacridine; Proflavinum; STK380650; 5-22-11-00322 (Beilstein Handbook Reference); WDVSHHCDHLJJJR-UHFFFAOYSA-; NCIMech_000209; Proflavine [INN]; 1qvu; 2,8-Diaminoacridine; 1qvt; 952-23-8; NCI60_032077; NCI60_004767; CID7099; 3,7-Diamino-5-azaanthracene; CHEBI:8452; Profura; 1bcu; AI3-52128; 92-62-6; DB01123; CHEMBL55400; 3,6-Acridinediamine hydrochloride; 2,8-Diaminoacridinium; LS-14311; Proflavine; AC1Q52G9; Proflavine Hemi-Sulfate; 3,6-Diaminoacridinium; Proflavine hemisulfate; UNII-CY3RNB3K4T; Proflavinum [INN-Latin]; MolPort-001-790-988; 2,8-Diaminoacridine (European); HSDB 7071; CHEBI:45272; NCI60_004643; PF; acridine-3,6-diamine; CCRIS 1244	92-62-6	7099	13362	TTDS00213	DNA	N/A	N/A	N/A	N/A	binder
DAP000994	Mitomycin	D00208; BSPBio_001267; KBio2_005743; KBio3_001073; CBiol_001927; Mutamycin; CHEBI:27504; BRD-K59670716-001-02-6; Mitomycine [INN-French]; Mitomycinum C; Mytozytrex; Bio1_001191; Ametycin; KBio2_000607; M4287_SIGMA; C06681; CHEMBL105; 50-07-7; Mitamycin; NSC 26980; C15H18N4O5; HMS1362O09; LS-136; Mitomycin C (JP15); Mitomycine; KBioSS_000607; UNII-50SG953SK6; 74349-48-7; Mitomycin C from Streptomyces caespitosus; NSC-26980; AC1L1L1Q; Ametycine; Mitomycin [USAN:INN:BAN]; CID5746; mitomycin C; EINECS 200-008-6; M0440_SIGMA; Mitomycin; Mitomycyna C; Mitomicina [INN-Spanish]; Muamycin; HMS1792O09; Mitomycinum; Mitomycinum [INN-Latin]; Bio1_000213; Bio1_000702; Mit-C; CCRIS 414; KBio2_003175; Muamycin (TN); Ambotz50-07-7; MLS001332654; Mitomycin (USP/INN); DB00305; 1404-00-8; M0503_SIGMA; Mitomycin C, Streptomyces caespitosus, Carrier-Free; 7481-68-7; Mitomycin-C; SMP1_000307; Mito-C; Mitozytrex; Mytomycin; HMS1990O09; 7-Amino-9alpha-methoxymitosane; MMC; Mitomycins; Mitocin C; NCI-C04706; Mitomycyna C [Polish]; HMS2089F16; SMR000058401; Mitomycin (TN); Mitomicina; MolPort-003-938-644; Mitocin-C; NCGC00163468-02; RCRA waste number U010; AI3-26199; Bio2_000464; HSDB 3239; Mitomycin C, Streptomyces caespitosus; nchembio.559-comp7; RCRA waste no. U010; Bio2_000944; IDI1_002219; LS-173087; KBio3_001074; KBioGR_000607; 144085-53-0	50-07-7	5746	148522	TTDS00213	DNA	N/A	N/A	N/A	N/A	binder
DPR000062	Indol-3-carbinol	N/A	700-06-1	161721	46236516	TTDS00213	DNA	N/A	N/A	N/A	N/A	binder
DAP000791	Melphalan	CB-3025; Melfalan; p-N-di(chloroethyl)aminophenylala nine; p-N-Di(chloroethyl)aminophenylalanine; NINDS_000653; Spectrum3_000684; NCI-C04853; ALKERAN (TN); EINECS 205-726-3; NSC 8806; Prestwick_1006; L-PAM; RCRA waste no. U150; L-Sarkolysin; Melphalan (JP15/USP/INN); LS-15868; NSC241286; CHEMBL852; L-Phenylalanine mustard; phenylalanine nitrogen mu stard; Spectrum_000397; p-L-sarcolysine; HMS2090B09; Rcra waste number U150; LS-865; HMS2091B16; NSC-8806; At-290; NCGC00090757-01; NSC 241286; Alkeran; Melphalanum [INN-Latin]; 3025 C.B.; L-Sarcolysine; Melfalano; BRN 2816456; AC1LA2OE; SK-15673; SMP2_000174; CHEBI:165415; 4-[Bis(2-chloroethyl)amino]-L-phenylalanine; BSPBio_002407; NCGC00090757-02; Alanine Nitrogen Mustard; Alanine, 3-(p-(bis(2-chloroethyl)amino)phenyl)-; 4-[Bis-(2-chloroethyl)amino]-L-phenylalanine; Spectrum4_000882; Alanine, 3-(p-(bis(2-chloroethyl)amino)phenyl)-, L-; 3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine; C13H18Cl2N2O2; (2s)-2-amino-3-(4-[bis(2-chloroethyl)amino]phenyl)propanoic acid; MLS001333666; NCGC00090757-03; L-3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine; KBio3_001627; Phenylalanine mustard; HSDB 3234; Melfalano [INN-Spanish]; p-N-Bis(2-chloroethyl)amino-L-phenylalanine; Melphalan [USAN:INN:BAN:JAN]; HMS502A15; Alanine, 3-[p-[bis(2-chloroethyl)amino]phenyl]-, L-; SPECTRUM1500382; CHEBI:28876; M2011_SIGMA; TL8001065; (2S)-2-amino-3-[4-[bis(2-chloroethyl)amino]phenyl]propanoic acid; AY3360000; Levopholan; 3025 c.b; UNII-Q41OR9510P; L-Phenylalanine, 4-(bis(2-chloroethyl)amino)-; 4-14-00-01689 (Beilstein Handbook Reference); KBio2_003445; 3-p-(Di(2-chloroethyl)amino)-phenyl-L-alanine; Spectrum2_000074; CB 3025; melphalan; SMR000058720; L-3-(para-(Bis(2-chloroethyl)amino)phenyl)alanine; NSC8806; Melphalanum; KBio2_000877; TRANSGENIC MODEL EVALUATION (MELPHALAN); p-Di-(2-chloroethyl)amino-L-phenylalanine; KBio1_000653; SPBio_000287; 3-(p-(Bis(2-chloroethyl)amino)phenyl)-L-alanine; p-Bis(beta-chloroethyl)aminophenylalanine; KBioSS_000877; KBio2_006013; BIDD:GT0044; p-L-Sarcolysin; TRANSGENIC LEP (MELPHALAN) (SEE ALSO MELPHALAN); Phenylalanine nitrogen mustard; MLS002153368; CCRIS 374; 148-82-3; D00369; p-N,N-bis(2-chloroethyl)amino-L-phenylalanine; MELPHALAN (SEE ALSO TRANSGENIC MODEL EVALUATION (MELPHALAN)); 3223-07-2; BRD-K87827419-001-02-8; NIOSH/AY3360000; Levofolan; Levofalan; AmbotzHAA1563; KBioGR_001284; 4-(Bis(2-chloroethyl)amino)-L-phenylalanine; IDI1_000653; Spectrum5_001601; DivK1c_000653; CID460612; MolPort-003-665-535; L-Sarcolysin	148-82-3	4053	7847435	TTDS00213	DNA	N/A	N/A	N/A	N/A	N/A
DAP000993	Furazolidone	3-(5-Nitrofurfurylideneamino)-2-oxazolidinone; STK388219; 3-{[(E)-(5-nitrofuran-2-yl)methylidene]amino}-1,3-oxazolidin-2-one; D00830; LS-100676; 3-[(5-Nitrofurylidene)amino]-2-oxazolidone; F-8900; 3-(5'-Nitrofurfuralamino)-2-oxazolidone; BPBio1_000743; IDI1_000085; Furoxone; Furox; CHEBI:5195; 3-[(5-Nitrofurfurylidene)amino]-2-oxazolidinone; 46297_RIEDEL; Topazone; Furazolidone (USP/INN); Nitrofurazolidone; Furazolidon; EINECS 200-653-3; N-(5-Nitro-2-furfurylidene)-3-amino-2-oxazolidone; BSPBio_000675; 2-Oxazolidinone, 3-((5-nitrofurfurylidene)amino)-; Furoxone (TN); 3-[(E)-(5-nitrofuran-2-yl)methylideneamino]-1,3-oxazolidin-2-one; Roptazol; Medaron; NCGC00095304-01; Diafuron; Furazolidine; furazolidone; Bio-0354; BIDD:GT0182; Neftin; HMS1920O22; BRD-K11756522-001-03-2; D005664; Furazolidona [INN-Spanish]; N-(5-Nitro-2-furfurylidene)-3-aminooxazolidine-2-one; Furoxane; NCGC00095304-02; I05-0078; Sclaventerol; 3-{[(5-nitro-2-furyl)methylene]amino}-1,3-oxazolidin-2-one; Puradin; Trifurox; F9505_SIGMA; Prestwick3_000808; Giardil; Furaxone; AB00443658; Furazolidonum; Nicolen; Corizium; Furazolum; Furoxone Liquid; Furazolidona; Bifuron; Furox Aerosol Powder (Veterinary); Ortazol; Furoxon; Prestwick2_000808; NCGC00095304-03; 2-Furanmethanimine, 5-nitro-N-(2-oxo-3-oxazolidinyl)-; 8023-25-4; HSDB 7036; Tricoron; Nifurazolidonum; 3-[[(5-Nitro-2-furanyl)methylene]amino]-2-oxazolidinone; 46297_FLUKA; MolPort-000-836-892; 3-[(5-Nitrofurfurylidene)amino]-2-oxazolidone; 5-Nitro-N-(2-oxo-3-oxazolidinyl)-2-furanmethanimine; C07999; Furazol; 2-Oxazolidinone, 3-((5-nitrofurfurylidine)amino)-; CCRIS 1540; DB00614; NCGC00095304-04; AC-11695; Furazolidone [INN:BAN]; 3-((5-Nitrofurfurylidene)amino)-2-oxazolidinone; 8027-73-4; Furazon; SPECTRUM1500309; Coryzium; AKOS001678302; NSC6469; Giarlam; Furidon; Trichofuron; NSC 6469; Furozolidine; Furall; 2-Oxazolidinone, 3-(((5-nitro-2-furanyl)methylene)amino)-; 3-((5-Nitrofurylidene)amino)-2-oxazolidone; Nitrofuroxon; Furazolidonum [INN-Latin]; 3-(((5-Nitro-2-furanyl)methylene)amino)-2-oxazolidinone; Furovag; Enterotoxon; Usaf ea-1; BSPBio_002052; 3-((5-Nitrofurfurylidene)amino)-2-oxazolidone; BRD-K10647544-001-02-0; AI3-50103; Tricofuron; UNII-5J9CPU3RE0; Fiurox aerosol powder; 67-45-8; Furoxal; Nifuran; CHEMBL1103; Furaxon; Optazol; 2-Oxazolidinone, 3-[[(5-nitro-2-furanyl)methylene]amino]-; Spectrum5_000742; AC1NT43A; CID5323714; InChI=1/C8H7N3O5/c12-8-10(3-4-15-8)9-5-6-1-2-7(16-6)11(13)14/h1-2,5H,3-4H2/b9-5; Viofuragyn; HMS500E07; Nitrofurazolidonum; Tikofuran; NF 180 custom mix ten; NF-180; HMS2091H03; Furoxone Swine Mix; Nifurazolidone; 3-{[(5-Nitro-2-furanyl)methylene]amino}-2-oxazolidinone; Nifulidone	67-45-8	3435	10200	TTDS00213	DNA	N/A	N/A	N/A	N/A	binder
DAP000533	Dacarbazine	D00288; HMS2091I20; 4(5)-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide; Dacarbazinum; 5-(3,3-dimethyltriaz-1-en-1-yl)-1H-imidazole-4-carboxamide; DTIC, DTIC-Dome, Dacarbazine; 5-[3,3-Dimethyl-1-triazenyl]imidazole-4-carboxamide; 5-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide; Dacarbazine [USAN:INN:BAN:JAN]; KBioGR_000896; HMS2090A20; NSC45388; ICDT; 5-(Dimethyltriazeno)imidazole-4-carboximide; NINDS_000326; 1H-imidazole-4-carboxamide, 5-(3,3-dimethyl-1-triazenyl)-; IDI1_000326; 1H-Imidazole-4-carboxamide, 5- (3,4-dimethyl-1-triazenyl)-; 4342-03-4; EINECS 224-396-1; MLS001332543; NCGC00016986-01; C6H10N6O; DTICDome; KBio2_001364; KBio2_006500; CHEMBL476; NIOSH/HE1150000; Dtic-Dome (TN); BRD-K35520305-001-07-8; 5-(3,3-Dimethyl-1-triazenyl)-1H-imidazole-4-carboxamide; MolPort-003-846-120; NCI-C04717; Carboxamide, Dimethyl Imidazole; CID5351166; Imidazole-4(or 5)-carboxamide, 5(or 4)-(3,3-dimethyl-1-triazeno)-; DTIC-Dome; CID5353562; AC1NS4BN; 5-(3,3-Dimethyltriazeno)-imidazole-4-carbamide; CCRIS 190; Spectrum4_000308; SPECTRUM1500218; DivK1c_000326; AC1NS01W; HSDB 3219; Dacarbazino; Dimethyl Imidazole Carboxamide; KBio1_000326; Dacarbazinum [INN-Latin]; 5(or 4)-(dimethyltriazeno)imidazole-4(or 5)-carboxamide; 37626-23-6; DTIE; (5E)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide; NSC 45388; Prestwick1_000574; BPBio1_000428; HMS501A08; 5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide; BSPBio_002091; NCGC00091861-03; HMS1569D10; Spectrum5_000823; 5-(Dimethyltriazeno)-4-imidazolecarboxamide; DTIC Dome; HE1150000; 5-(3,3-Dimethyltri azeno)imidazole-4-carboxamide; Prestwick0_000574; ST51014976; 4-[3,3-dimethyltriaz-1-en-1-yl]-1H-imidazole-5-carboxamide; 4-[(1E)-3,3-Dimethyltriaz-1-en-1-yl]-1H-imidazole-5-carboxamide; BSPBio_000388; (5Z)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide; D2390_SIGMA; CAS-891986; 5-(3,3-Dimethyl-1-triazenyl)imidazole-4-carboxamide; Di-methyl-triazenoimidazolecarboxamide; Imidazole Carboxamide, Dimethyl; Prestwick2_000574; 4-(3,3-Dimethyltriazeno)imidazole-5-carboxamide; KBioSS_001364; Biocarbazine R; 5(or 4)-(dimethyltriazeno)imidazol e-4(or 5)-carboxamide; SMP2_000251; Dimethyl Triazeno Imidazole Carboxamide; WLN: T5M CNJ DVZ ENUNN1&1; AC1NQXVV; Prestwick_904; SMR000857131; dacarbazine; Deticene; LS-119; KBio3_001311; D003606; ICDMT; 4(5)-(3,3-Dimethyl-1-triazeno)imidazole-5(4)-carboxamide; Prestwick3_000574; 4-(3,3-Dimethyl-1-triazeno)imidazole-5-carboxamide; Imidazole carboxamide; SPBio_001075; I06-2280; Biocarbazin; DB00851; Imidazole-4-carboxamide, 5-(3,3-dimethyl-1-triazeno)-; 4-(or 5)-(3,3-Dimethyl-1-triazeno)imidazole-5(or 4)-carboxamide; Spectrum2_001148; MolPort-006-709-420; NCGC00091861-02; Carboxamide, 5-(3,3-dimethyl-1-triazeno)imidazole-4-; NCGC00091861-04; (Dimethyltriazeno)imidazolecarboxamide; KBio2_003932; NPFAPI-05; 4-(5)-(3,3-Dimethyl-1-triazeno)imidazole-5(4)-carboxamide; Dimethyltriazenoimidazolecarboxamide; MolPort-003-666-153; D3634; 4-(Dimethyltriazeno)imidazole-5-carboxamide; DTIC; CID5281007; Biocarbazine; Imidazole-4-carboxamide, 5-(3,3-dimethyl-1-triazenyl)-; NCIMech_000261; Dacarbazino [INN-Spanish]; SPBio_002607; CHEBI:4305; AI3-52825; 4-(Dimethyltriazeno)imidazole-5-c arboxamide; NCI60_004053; NSC-45388; MLS001332544; Spectrum_000884; Spectrum3_000366; Decarbazine; 94361-71-4; UNII-7GR28W0FJI; 5-(Dimethyltriazeno)imidazole-4-carboxamide; NCGC00091861-01; Di-me-triazenoimidazolecarboxamide; S1221_Selleck; I14-1659; Dacarbazine (JAN/USP/INN); Dacatic; 5-(3,3-Dimethyltriazeno)imidazole-4-carboxamide; 4-(or 5)-(3,3-Dimethyl-1-triazeno)imidazole-5(or  4)-carboxamide	4342-03-4	5351166	163170	TTDS00213	DNA	N/A	N/A	N/A	N/A	N/A
DCL000674	Abetimus sodium	169147-32-4; D03204; Abetimus sodium (USAN); Abetimus sodium	169147-32-4	N/A	17397358	TTDS00213	DNA	N/A	N/A	N/A	N/A	inhibitor
DAP000988	Pipobroman	KBioSS_002207; Pipobroman [USAN:INN]; MolPort-003-665-507; HMS1922C10; Spectrum2_000912; A 1803; Spectrum5_001135; Spectrum3_001047; Amedel; AI3-50113; WLN: T6N DNTJ AV2E DV2E; 3-bromo-1-[4-(3-bromopropanoyl)piperazin-1-yl]propan-1-one; CHEMBL1585; pipobroman; Vercyte; 1,4-Bis(3-bromopropanoyl)piperazine; 1, 4-Bis(3-bromopropionyl)piperazine; N,N'-Bis(3-bromopropionyl)piperazine; Piperazine, 1,4-bis(3-bromo-1-oxopropyl)-; Piperazine, 1,4-bis(3-bromopropionyl)-; Piperazine, 1,4-bis(3-bromopropionyl)-; 54-91-1; IDI1_000799; HMS502H21; Pipobromanum [INN-Latin]; SPBio_000784; BSPBio_002574; NCI60_002008; HMS2093E11; KBio2_002207; C10H16Br2N2O2; NINDS_000799; CCRIS 2753; N,N'-Bis(3-bromopropionyl)piperazine; Pipobroman (JAN/USAN/INN); N,N-Bis-(3-bromopropionyl)-piperazine; KBio2_007343; KBio2_004775; HSDB 3249; NSC-25154; VERCYTE (TN); NCGC00095048-03; CID4842; NCGC00095048-04; UNII-6Q99RDT97R; DivK1c_000799; 1,4-Bis(3-bromopropionyl)piperazine; LS-110402; NSC25154; A-8103; DB00236; C07362; KBio1_000799; AC1L1J2T; D00467; NSC 25154; KBio3_001794; Spectrum_001727; NCGC00095048-02; SPECTRUM1503393; NCGC00095048-01; Pipobromanum; BRN 0749866; Piperazine, 1,4-bis(3-bromo-1-oxopropyl)-; 1,4-Bis(3-bromopropanoyl)piperazine	54-91-1	4842	148729	TTDS00213	DNA	N/A	N/A	N/A	N/A	binder
DAP000532	Cyclophosphamide	EINECS 200-015-4; Cyclophosphamide (anhydrous); KBio2_001338; Spectrum2_001146; LS-99787; KBio2_003906; Spectrum_000858; Semdoxan; AC1L1EQQ; Ciclofosfamida; CB-4564; Revimmune; STK177249; NCGC00091741-02; 50-18-0; UNII-6UXW23996M; Cyclostin; Spectrum3_000370; Lopac0_000238; HMS2090A12; BSPBio_002099; Cyclophosphamides; (-)-Cyclophosphamide; Senduxan; SK 20501; Cyclophosphamide (INN); B 518; NSC26271; Mitoxan; Spectrum4_000304; WLN: T6MPOTJ BO BN2G2G; Cytoxan (TN); CHEMBL88; Endoxanal; NCGC00015209-06; Endoxana; CHEMBL32520; Cyclophosphamide (TN); Neosar; Cyclophosphane; HSDB 3047; Endoxan-Asta; Zyklophosphamid; Cyklofosfamid [Czech]; Cyclophosphamid; RCRA waste no. U058; NCGC00015209-01; Enduxan; CCRIS 188; (RS)-Cyclophosphamide; Ciclophosphamide; 6055-19-2 (monohydrate); ASTA; CHEBI:4027; 4-Hydroxy-cyclophosphan-mamophosphatide; Cyclophosphamidum; N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide; Lyophilized Cytoxan; NCI60_002097; C 0768; KBio3_001319; Lopac-C-0768; SPBio_001071; ASTA B518; DivK1c_000246; C07888; LS-1302; Endoxan R; B-518; Occupation, cyclophosphamide exposure; NSC273033; bis(2-Chloroethyl)phosphamide cyclic propanolamide ester; Sendoxan; cyclophosphamide; Cytophosphan; KBio1_000246; NCGC00091741-03; Cyclophosphan; Procytox; Cytophosphane; S1217_Selleck; bis(2-Chloroethyl)phosphami de cyclic propanolamide; Clafen; Cyclophosphanum; 60007-95-6; NSC 26271; NCI-C04900; MolPort-001-783-420; Zyklophosphamid [German]; Endoxane; Cytoxan Lyoph; CB 4564; D07760; EU-0100238; Cyclophosphamide (anhydrous form); D,L-Cyclophosphamide; DB00531; Cytoxan; Cyclophosphoramide; KBioSS_001338; NCGC00015209-03; NINDS_000246; 1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine; Cyklofosfamid; Rcra waste number U058; Cyclophosphamide anhydrous; Ciclophosphamide [INN]; CID2907; 75526-90-8; Cyclophosphamide Sterile; NSC-26271; Claphene; C7H15Cl2N2O2P; Cyclophosphamidum [INN-Latin]; Spectrum5_000795; (+-)-Cyclophosphamide; Asta B 518; STOCK2S-91217; Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester; CY; IDI1_000246; KBio2_006474; Ciclofosfamida [INN-Spanish]; Cyclophosphamide, (+-)-Isomer; NSC273034; Genoxal; Cycloblastin; 1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin; AI3-26198; CMSMOCZEIVJLDB-UHFFFAOYSA-; BRN 0011744; Endoxan; KBioGR_000888	6055-19-2	2907	148529	TTDS00213	DNA	N/A	N/A	N/A	N/A	N/A
DAP001465	Ciprofloxacin XR	N/A	86393-32-0	2764	7849275	TTDS00213	DNA	N/A	N/A	N/A	N/A	inhibitor
DAP000997	Idoxuridine	1-(4-Hydroxy-5-hydroxymethyltetrahydrofuran-2-yl)-5-iodo-1H-pyrimidine-2,4-dione; Idu Oculos; KST-1B5615; HERPLEX (TN); Iducher; 5-IUDR; Prestwick1_000018; Prestwick2_000018; 1-[(2R,4S,5S)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione; CHEMBL55681; Dendrid (TN); HMS1568C17; I0258; ZINC17779640; I7125_SIAL; CID6093284; AC1L32PJ; 1-[(2S,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione; 5-(125-I)-Iodo-2-deoxyuridine; ZINC13547843; CID5905; 2'-Deoxy-5-iodouridine; Uracil, 5-iodo-1-(2-deoxy-beta-D-ribofuranosyl)-; 1-[(2R,4R,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione; 4-24-00-01235 (Beilstein Handbook Reference); Idoxene; CID6419973; Uridine, 5-iodo-2'-deoxy-; Herplex liquifilm; 5-Iododeoxyuridine; SMR001330614; AC1LAD5A; EU-0051633; CID6604188; I01-1120; Antizona; Idoxuridine (JP15/USP/INN); URIDINE, 2'-DEOXY-5-IODO-; Prestwick0_000018; Herpe-Gel; 5-I-2'-dUrd; CHEBI:100594; NSC39661; Idoxuridin; 5IdU; SPBio_001976; IDU; Spectanefran; HMS664F22; Ophthalmadine; Idoxuridinum [INN-Latin]; 1beta-D-2'-Deoxyribofuranosyl-5-iodouracil; Allergan 201; Herpid; Oftan-IDU; 1-[4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione; EINECS 200-207-8; 1-[(2R,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione; NSC-39661; Idossuridina [DCIT]; Uridine, 2'-deoxy-5-(iodo-125I)-; MolPort-001-828-315; IdUrd; Iduoculos; Iodoxuridine; AI3-50861; C9H11IN2O5; SMP2_000072; 5-Iodo-2'-deoxyuridine; 2'-deoxy-5-(125i)iodouridine; Iododeoxyuridine; ZINC05223557; CID10021274; NCGC00016243-01; MolPort-002-700-148; ID2; Virudox; AB00674532-01; idoxuridine; CID3687; Stoxil; DB00249; Herpidu; Dendrid; Kerecid; SMR001233472; SKF 14287; AC1Q77TF; AC1LAEAG; ZINC03834173; CID1272916; MolPort-001-792-514; DB03778; Prestwick3_000018; UNII-LGP81V5245; Uracil, 5-iodo-1-(2-deoxy-.beta.-D-ribofuranosyl)-; AC1LOX7N; 2'-Deoxy-5-(iodo-125I)uridine; 1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione; BSPBio_000055; AC1O4WH8; 5-Iodouracil deoxyriboside; Idexur; 1-(2-deoxypentofuranosyl)-4-hydroxy-5-iodopyrimidin-2(1H)-one; Idoxuridinum; AC1Q4P64; ZINC00537850; 1-[(2S,4S,5S)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione; CHEMBL268690; Iododeoxyridine; Iduridin; Herpes-Gel; AC1Q1GNE; Herpesil; F1531-0025; LT00440811; MolPort-004-954-137; 1-[(2R,4R,5S)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione; 54-42-2; AR-1E1094; 60110-67-0; CHEBI:147675; CID512326; HMS2090M10; CHEMBL240359; Emanil; 1.beta.-D-2'-Deoxyribofuranosyl-5-iodouracil; Allergan 211; ChemDiv1_027236; AKOS003631534; A1555/0067734; CID511644; Oprea1_780054; STK673655; BPBio1_000061; nchembio.90-comp8; MLS002702846; Idoxuridine [USAN:INN:BAN:JAN]; SK&F 14287; AR-1E1122; AC1L45MB; 1336-77-2; AC1L1GHN; CID179629; Synmiol; 56061-30-4; Heratil; LS-160825; AC1L1LE0; Idoxuridina [INN-Spanish]; (+)-5-Iodo-2'-deoxyuridine; CID107764; CHEMBL408518; Herplex; ST041015; 1-(2-deoxypentofuranosyl)-5-iodopyrimidine-2,4(1h,3h)-dione; CID9884756; Idoxuridina; NCI60_003716; XQFRJNBWHJMXHO-UHFFFAOYSA-; MLS002154175; Allergan-211; Idulea; Idossuridina; AC1O1BNO; AC1O7GAI; CCRIS 2827; AR-1B0767; D00342; Iododeoxyuridine-125I; Joddeoxiuridin; 5-Iododesoxyuridine; HSDB 7479; CHEMBL788; AC1MHON1; 5IUDR; CID3008588; 53745-34-9; IDUR; ZINC02562618; SK&F-14287; NSC 39661; ZINC03586101; AC1Q7CC1; TL8003566; BRN 0030397; Kerecide; IUDR; CAS-54-42-2; Iduviran; NCGC00179673-01; 1-[(2S,4R,5S)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione; I7125_SIGMA; Prestwick_523; 1-(2-Deoxy-beta-D-ribofuranosyl)-5-iodouracil; 1-beta-D-2'-Deoxyribofuranosyl-5-iodouracil; WLN: T6NVMVJ EI A- ET5OTJ B1Q CQ	54-42-2	5905	7847408	TTDS00213	DNA	N/A	N/A	N/A	N/A	binder
DAP000981	Dornase Alfa	N/A	9003-98-9	N/A	46507792	TTDS00213	DNA	N/A	N/A	N/A	N/A	N/A
DAP000788	Daunorubicin	23942-76-9; BRN 1445583; Daunoblastin; Daunorubicin (liposomal); 28020-80-6; (+)-Daunomycin; (7S,9R)-9-Acetyl-7-[(2S,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; DaunoXome; 20830-81-3; daunorubicin; NChemBio.2007.10-comp14; 11006-54-5; Cerubidine; LS-997; LS-187381; HSDB 5095; 11048-29-6; RP 13057; CID30323; Daunamycin; NCGC00024246-05; BPBio1_000389; Daunomycin; EINECS 244-069-7; 5,12-Naphthacenedione, 8-acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S-cis)-; Dauno-Rubidomycine; DAUNORUBICIN HCL; NSC 83142; Daunorubicinum [INN-Latin]; Antibiotics from Streptomyces coeruleorubidus; CHEBI:41977; FI 6339; Anthracyline; (8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-.alpha.-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro--6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione; Daunorubicine; Cerubidin; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside; Daunorubicinum; RCRA waste no. U059; NCGC00025173-01; NSC-82151; MolPort-002-533-961; HMS2089H04; Rubomycin; HMS2091K06; 27576-81-4; AC1L1JCP; NCI-C04693; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; NCGC00024246-06; VS-103; DaunoXome (TN); AC1Q29OI; DB00694; CCRIS 914; Rubidomycin; Daunorubicin (INN); 5,12-Naphthacenedione, 8-acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S,10S)-; FI6339; BRD-K43389675-003-02-7; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; CHEMBL178; Prestwick3_000487; (8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione; UNII-ZS7284E0ZP; 149541-57-1; Leukaemomycin C; AI3-52942; AB00514669; Daunorrubicina; nchembio723-comp2; Tocris-1467; C01907; 1407-15-4; LMPK13050002; DM1; Daunoblastine; Acetyladriamycin; Rubomycin C; Daunarubicinum; Daunorubicin [INN:BAN]; Daunorubicin, Hydrochloride; D07776; BSPBio_000353	20830-81-3	30323	172470	TTDS00213	DNA	N/A	N/A	N/A	N/A	N/A
DAP000216	Primaquine	SN 13272; DivK1c_000806; D08420; Prestwick0_000476; BSPBio_002223; N4-(6-Methoxy-8-quinolinyl)-1,4-pentanediamine; 8-[(4-Amino-1-methylbutyl)amino]-6-methoxyquinoline; KBioSS_001310; CHEBI:8405; 4-N-(6-methoxyquinolin-8-yl)pentane-1,4-diamine; AC1Q4F0C; (-)-N4-(6-Methoxy-8-quinolinyl)-1,4-pentanediamine; IDI1_000806; (-)-Primaquine; 8-(4-Amino-1-methylbutylamino)-6-methoxyquinoline; Quinoline, 8-[(4-amino-1-methylbutyl)amino]-6-methoxy-; Oprea1_546209; Quinoline, 8-(4-amino-1-methylbutylamino)-6-methoxy-; EINECS 201-987-2; UNII-MVR3634GX1; SPBio_002551; KBio2_003878; ethylbutylamino)-6-methoxyquinoline; CCRIS 4109; Neo-Quipenyl; 8-((4-Amino-1-methylbutyl)amino)-6-methoxyquinoline; SPBio_000674; N(4)-(6-methoxyquinolin-8-yl)pentane-1,4-diamine; 1,4-Pentanediamine, N4-(6-methoxy-8-quinolinyl)-; Spectrum4_000484; KBio1_000806; S. N. 13272; AC1L1J80; (+/-)-Primaquine; MolPort-001-794-628; WR 2975; SN 13,272; 6-Methoxy-8-[4-amino-1-methylbutylamino]quinoline; NCI60_001035; dl-Primaquine; Primachina [DCIT]; KBio2_001310; LS-141312; 90-34-6; TG1-296; Prestwick1_000476; Primaquine (INN); 4-22-00-05817 (Beilstein Handbook Reference); NCGC00178754-02; Primaquin; STOCK5S-90838; 63-45-6 (1:2 PO4); 8-(4-Amino-1-m; AB00053529; Spectrum2_000887; Kanaprim; HSDB 6516; CID4908; 1,4-Pentanediamine, N4-(6-methoxy-8-quinolinyl)- (9CI); NSC 27296; 6-Methoxy-8-(4-amino-1-methylbutylamino)quinoline; NINDS_000806; BSPBio_000612; Spectrum_000830; 1,4-Pentanediamine, N(4)-(6-methoxy-8-quinolinyl)-; Spectrum5_001363; Primaquinum; PQ; HMS2090J17; BPBio1_000674; Primaquina [INN-Spanish]; Primaquina; Prestwick3_000476; 6-Methoxy-8-[(4-amino-1-methylbutyl)amino]quinoline; CHEMBL506; I08-0048; KBio3_001723; BRN 0019337; Quinoline, 8-[(4-amino-1-methylbutyl)amino]-6-methoxy- (6CI,8CI); Primachin; DB01087; NCI60_005887; Primachina; KBioGR_000967; (+)-Primaquine; NCGC00178754-01; 63-45-6; ()-Primaquine; Primaquine Bis-Phosphoric Acid; AC1Q4F4Q; Spectrum3_000552; (+)-N4-(6-Methoxy-8-quinolinyl)-1,4-pentanediamine; Quinoline, 8-(4-amino-1-methylbutylamino)-6-methoxy; N-(5-aminopentan-2-yl)-6-methoxyquinolin-8-amine; WLN: T66 BNJ HO1 JMY1&3Z; Primaquinum [INN-Latin]; 8-[(4-Amino-1-methylbutyl)amino]-6-methoxyquinoline; TG1-297; Prestwick2_000476; SMP1_000263; NSC27296; PRIMAQUINE; Kanaprim (TN); N~4~-[6-(methyloxy)quinolin-8-yl]pentane-1,4-diamine; KBio2_006446; Primachinum; C07627; Primaquine [INN:BAN]	90-34-6	4908	9829	TTDS00213	DNA	N/A	N/A	N/A	N/A	N/A
DAP000790	Mechlorethamine	Mechloroethamine; Mustargen; Bis(2-chloroethyl)methylamine; Mitoxine (*Hydrochloride*); CID4033; T-1024; IDI1_000759; Caryolysin; Spectrum5_001702; Embechine; Chlormethine (INN); DB00888; LS-7559; beta,beta'-Dichlorodiethyl-N-methylamine; N-Lost; Mebichloramine; Dichloren; UNII-50D9XSG0VR; N-Methyl-2,2'-dichlorodiethylamine; Chloramine (the nitrogen mustard); Bis(beta-chloroethyl) methylamine; ENT-25294; HN2; Spectrum4_000924; Nitrogen mustard; Stickstofflost (*Hydrochloride*); 2-Chloro-N-(2-chloroethyl)-N-methylethanamine; N-Methyl-lost; KBio2_001369; NCGC00091835-05; HSDB 5083; CHEBI:28925; 2-Chloro-N-(2-chloroethyl)-N-methylethanamine; N,N-Bis(2-chloroethyl)-N-methylamine; .Beta.,.beta.'-Dichlorodiethyl-N-methylamine; 1, 5-Dichloro-3-methyl-3-azapentane hydrochloride; 2,2'-Dichloro-N-me; 51-75-2; CCRIS 447; KBioGR_001448; thyldiethylamine; Embichin; TL 146; C07115; 126-85-2 (N-oxide); Mechlorethanamine; Chlormethine [INN:BAN]; DivK1c_000759; Caryolysine; KBioSS_001369; Chlorethazine; N,N-Bis(2-chloroethyl)methylamine; Methylbis(beta-chloroethyl)amine; HN-2; 2,2'-Dichlorodiethyl-methylamine; N-Methyl-bis-chloraethylamin; Methylbis(2-chloroethyl)amine; BRN 0605323; Clormetina [INN-Spanish]; N-Methyl-bis(beta-chloroethyl)amine; Mecloretamina [Italian]; KBio3_001447; IBS-L0033631; NCGC00091835-02; N-Methyl lost; Diethylamine, 2,2'-dichloro-N-methyl-; CHEMBL427; N-Methyl-bis-chloraethylamin [German]; NCI60_041682; Mustine; NCGC00091835-04; Nitrogranulogen; Spectrum2_000448; Chlormethine; Carolysine; Spectrum3_000484; 302-70-5 (N-oxide, hydrochloride); T 1024; BSPBio_001947; Di(2-chloroethyl)methylamine; Methyldi(2-chloroethyl)amine; 55-86-7 (HYDROCHLORIDE); SPBio_000496; Me chloroethamine; Clormetina; MolPort-001-785-592; Cloramin; HMS1920J15; NSC762; Ethanamine, 2-chloro-N-(2-chloroethyl)-N-methyl-; SPECTRUM1500375; Nitrogen mustard (HN-2); HMS2091B04; I14-8708; C5H11Cl2N; KBio2_006505; Spectrum_000889; N-Methyl-bis(2-chloroethyl)amine; Dichlor amine; KBio1_000759; EINECS 200-120-5; D07671; N,N-Di(chloroethyl)methylamine; MBA; Nitol (*Hydrochloride*); KBio2_003937; AC1L1H9H; Mutagen; N-Methyl-lost [German]; Stickstofflost (ebewe); Mecloretamina; Mustine note; Antimit; Chlormethinum [INN-Latin]; HMS502F21; 2,2'-Dichloro-N-methyldiethylamine; mechlorethamine; NCGC00091835-03; Bis(beta-chloroethyl)methylamine; NINDS_000759	51-75-2	4033	9326	TTDS00213	DNA	N/A	N/A	N/A	N/A	N/A
DAP000534	Metronidazole	Tricowas B; SAM001247010; Apo-Metronidazole; M1547_SIGMA; Tricho-gynaedron; D00409; Trichomonacid 'pharmachim'; Vandazole; Danizol; SPBio_000666; KBio1_000007; Bio-0694; Rathimed; 2-(2-methyl-5-nitroimidazol-1-yl)ethanol; WLN: T5N CNJ A2Q B1 ENW; Metronidazolum; AB00052046; Clont; Zadstat; Flagemona; Trichomol; Noritate; Metro Gel; ZERO/004064; NCGC00022059-05; Metrolyl; Elyzol; CHEBI:6909; Metronidazolo [DCIT]; MetroLotion; MLS000028590; Fossyol; 46461_RIEDEL; Methronidazole; 2-Methyl-5-nitroimidazole-1-ethanol; Trikacide; Meronidal; BSPBio_000002; 443-48-1; Trichocide; HMS1568A04; Deflamon-wirkstoff; RP 8823; Metronidazole (JP15/USP/INN); Flagesol; Metro Cream; CHEMBL137; NSC-50364; BPBio1_000004; FLAGYL I.V. RTU IN PLASTIC CONTAINER; Metronidazole [USAN:INN:BAN:JAN]; CB-01-14 MMX; HMS1920N19; WLN: T6NTJ DQ ANU1- ET5N CNJ A1 BNW; Methyl-5-nitroimidazole-1-ethanol; Acromona; Flagyl I.V.; LS-1264; Orvagil; M3761_SIGMA; BRN 0611683; Trimeks; Metric 21; I14-0667; KBio2_004083; Tricocet; Flagyl Er; METRO I.V; 1-Hydroxyethyl-2-methyl-5-nitroimidazole; CONT; KBioGR_000559; Protostat; NINDS_000007; Takimetol; MolPort-002-502-101; CID4173; BAS 02983617; SBB041018; Klont; Metronidazole in Plastic Container; Eumin; Metrogyl; Bexon; NIDA; neo-Tric; SPBio_001941; Trichex; Anagiardil; Vertisal; CHEBI:39845; metronidazole; Metronidazole Phosphoester; M9036_SIGMA; Metrolag; Spectrum2_000883; Novonidazol; Metrodzhil; HMS2090B19; IDR-90105; Spectrum4_000060; MetroGel; IDI1_000007; Metro I.V.; NSC 50364; Vagilen; NSC 69587; 2-Methyl-5-nitro-1-imidazoleethanol; RP-8823; SMR000058175; AC1Q2P2Z; Spectrum5_001289; Spectrum_001035; UNII-140QMO216E; Flagyl I.V. RTU; Flagyl (TN); Gineflavir; MetroCream; Zidoval; Satric; Caswell No. 579AA; Klion; WLN: T5N CNJA2Q B1 ENW; Trivazol; KBio3_001531; Nidagel; MetroGel-Vaginal; Florazole; Prestwick3_000081; Flagyl; Flagyl 375; AC1L1HKS; NCGC00016446-02; Maybridge1_001999; 99616-64-5; Sanatrichom; Metro I.V. In Plastic Container; Metronidazol [INN-Spanish]; Metrozine; Metronidazole Monohydrochloride; MLS000758286; Spectrum3_000506; NCGC00016446-01; SC 10295; AKOS000269646; Metronidaz; Prestwick0_000081; BSPBio_002031; HMS2091F14; DB00916; Trikamon; Metric; Trichopal; Metryl; BIDD:GT0107; Tricom; Bayer 5360; MolPort-000-141-892; Noritate (TN); Prestwick1_000081; ZINC00113442; CAS-443-48-1; Metronidazolum [INN-Latin]; Ginefla vir; NCGC00022059-04; Metrotop; EPA Pesticide Chemical Code 120401; EINECS 207-136-1; SMP1_000189; Atrivyl; METRONIDAZOLE USP; CCRIS 410; Mexibol; Deflamon; Mexibol 'silanes'; Nalox; Monagyl; M3761_FLUKA; 46461_FLUKA; APMN; NSC69587; ARONIS24285; Flegyl; Trikozol; BCBcMAP01_000184; NCIOpen2_000337; BAY-5360; STK177359; NSC50364; CPD000058175; Imidazole-1-ethanol, 2-methyl-5-nitro-; S1907_Selleck; Monasin; Metrogel-vaginal (TN); Entizol; Rosased; Wagitran; Tricho cordes; HMS547C19; HMS2051G07; SPECTRUM1500412; Trikojol; AC-10556; KBio2_006651; Vagimid; KBio2_001515; Metronidazol; HSDB 3129; Metromidol; Trichazol; BRD-K52020312-001-05-2; giniflavir; HMS500A09; Prestwick2_000081; KBioSS_001515; 69198-10-3 (mono-hydrochloride); DivK1c_000007; Trichopol; Arilin; Giatricol; Metronidazolo; M0924; Efloran; Flagil; Prestwick_334; NCGC00022059-03	443-48-1	4173	7847475	TTDS00213	DNA	N/A	N/A	N/A	N/A	N/A
DAP000789	Clofazimine	2-Phenazinamine, 3,5-dihydro-N,5-bis(4-chlorophenyl)-3-[(1-methylethyl)imino]-; CHEMBL1083384; N,5-bis(4-chlorophenyl)-3-(propan-2-ylimino)-3,5-dihydrophenazin-2-amine; MLS001424318; Prestwick3_000376; EINECS 217-980-2; SPBio_002452; N,5-Bis(4-chlorophenyl)-3,5-dihydro-3-[(1-methylethyl)imino]-2-phenazinamine; G-30320; CID2794; B 663 (Pharmaceutical); clofazimine; NCGC00016600-02; ST51014966; Lampren; Clofazimine [USAN:INN:BAN]; AC1L1EHE; SAM001246878; N,5-Bis(4-chlorophenyl)-3,5-dihydro-3-(isopropylimino)phenazin-2-amine; B. 663; CHEBI:3749; Prestwick_685; DB00845; NSC141046; N,5-Bis(4-chlorophenyl)-3,5-dihydro-3-(1-methylethyl)imino)-2-phenazinamine; BIDD:PXR0147; B 663 (VAN); C06915; NSC 141046; Prestwick1_000376; 4-25-00-03033 (Beilstein Handbook Reference); SMR000058704; 2-Phenazinamine, N,5-bis(4-chlorophenyl)-3,5-dihydro-3-((1-methylethyl)imino)-; 2-Phenazinamine, N,5-bis(4-chlorophenyl)-3,5-dihydro-3-[(1-methylethyl)imino]-; Lamprene (TN); 2030-63-9; CFZ; Liposome-encapsulated clofazimine; BSPBio_000531; BRN 0060420; I06-1891; MLS000028617; Chlofazimine; Phenazine, 2,10-dihydro-3-(p-chloroanilino)-10-(p-chlorophenyl)-2-(isopropylimino)-; NCGC00179529-01; CAS-2030-63-9; B 663, pharmaceutical; 3-(p-Chloranilino)-10-(p-chlorphenyl)-2,10-dihydro-2-(isopropylimino)-phenazin; Clofaziminum; 2-Phenazinamine, 3,5-dihydro-N,5-bis(4-chlorophenyl)-3-((1-methylethyl)imino)-; HMS2093J10; 3-(p-Chloroanilino)-10-(p-chlorophenyl)-2,10-dihydro-2-(isopropylimino)phenazine; CPD000058704; D00278; HMS2052B05; N,5-bis(4-chlorophenyl)-3-propan-2-yliminophenazin-2-amine; B663; 3-(p-Chloranilino)-10-(p-chlorphenyl)-2,10-dihydro-2-(isopropylimino)-phenazin [German]; 3-(p-Chloranilino)-10-(p-chlorophenyl)-2,10-dihydro-2-(isopropylimino)-phenazine; Prestwick2_000376; (3Z)-N,5-bis(4-chlorophenyl)-3-[(1-methylethyl)imino]-3,5-dihydrophenazin-2-amine; CHEBI:730395; Phenazine, 3-(p-chloroanilino)-10-(p-chlorophenyl)-2,10-dihydro-2-(isopropylimino)-; NSC-141046; BPBio1_000585; Clofaziminum [INN-Latin]; B-663; CHEMBL1292; B 663; G-30,320; Lamprene; Prestwick0_000376; Clofazimine (JAN/USP/INN); C8895_SIGMA; Clofazimina; 3-(p-Chloranilino)-10-(p-chlorophenyl)-2,10-dihydro-2-(isopropylimino)phenazine; HMS1569K13; SMP2_000339; C27H22Cl2N4; UNII-D959AE5USF; NCGC00016600-01; G 30320; LS-103014; Clofazimina [INN-Spanish]	2030-63-9	2794	159498	TTDS00213	DNA	N/A	N/A	N/A	N/A	N/A
DAP000983	Busulfan	HMS1920I07; HMS502K09; GT 41; Mablin; COVZYZSDYWQREU-UHFFFAOYSA-; BRN 1791786; NCGC00090905-06; 4-methylsulfonyloxybutyl methanesulfonate; 1,4-Dimethanesulphonyloxybutane; 1,4-Butanediyl dimethanesulfonate; Ambap55-98-1; X 149; Milecitan; Mielevcin; 1, 4-Dimethanesulfonoxybutane; KBio2_003080; Spectrum4_000259; KBio2_000512; AC1L1DRQ; MYLERAN (TN); NSC750; Busulfano; butane-1,4-diyl dimethanesulfonate; 1,4-Dimethylsulfonoxybutane; Busulfan (JP15/USP/INN); Mylerlan; 1,4-Butanediol, dimethanesulphonate; C6H14O6S2; Busulfan Orphan Brand; MLS001076666; Mielucin; Methanesulfonic acid, tetram ethylene ester; NCGC00090905-05; BUSULFAN (1,4-BUTANEDIOL, DIMETHANESULFONATE); KBio3_001420; EINECS 200-250-2; SPECTRUM1500152; KBio1_000847; Spectrum2_000067; DB01008; Leucosulfan; Tetramethylenester kyseliny methansulfonove [Czech]; FT-0083567; Mielosan; SMR000058613; 1,4-Dimethanesulfonoxybutane; D00248; Prestwick_989; 2041 C. B; WLN: WS1&O4OSW1; AC-198; Busulfan Wellcome Brand; Tetramethylene bis[methanesulfonate]; 1,4-Dimethylsulfonyloxybutane; NINDS_000847; CID2478; Busulfan Wellcome; Buzulfan; D002066; Busulfanum [INN-Latin]; CHEBI:28901; DivK1c_000847; 2041 C. B.; NCGC00090905-03; B2635_SIGMA; Mitostan; 1,4-Dimethanesulfonyloxybutane; B2635_FLUKA; GT 2041; InChI=1/C6H14O6S2/c1-13(7,8)11-5-3-4-6-12-14(2,9)10/h3-6H2,1-2H3; HMS2091O09; Busulfan [INN:JAN]; KBioSS_000512; AC1Q4GRQ; 4-((Methylsulfonyl)oxy)butyl methanesulfonate; 1, {4-Bis[methanesulfonoxy]butane}; 1,4-Bis(methanesulfonyloxy)butane; 1,4-Butanediol dimethylsulfonate; 1,4-Dimethanesulfonyloxybutane; Methanesulfonic; 1,4-Butanediol, dimethanesulfonate; Glaxo Wellcome Brand of Busulfan; Tetramethylene dimethane sulfonate; acid, tetramethylene ester; Tetramethylene {bis[methanesulfonate]}; Tetramethylene dimethane sulfonate; G.T. 41; 1,4-Dimethane sulfonyl oxybutane; Sulfabutin; Tetramethylene bis(methanesulfonate); NCI-C01592; Spectrum_000092; NSC 750; C.B. 2041; 1,4-Butanediol dimethylsulfonate; AKOS003614975; Butanedioldimethanesulfonate; 1,4-Dimethanesulfonoxylbutane; Wellcome, Busulfan; alkylating agent: crosslinks guanine residues; AN 33501; 1, 4-Dimethylsulfonoxybutane; Mitosan; 1,4-Di(methylsulfonoxy)butane; busulfan; Spectrum3_000320; KBioGR_000698; Wellcome Brand of Busulfan; CHEMBL820; UNII-G1LN9045DK; CB 2041; NCGC00090905-01; Mileran; Myelosan; Misulban; Myeloleukon; B1022; S1692_Selleck; Tetramethylenester kyseliny methansulfonove; Glyzophrol; Myeleukon; 1,4-BUTANEDIOL DIMETHANESULFONATE; ST50825921; NSC-750sulphabutin; Sulfabutin (VAN); Methanesulfonic acid, tetramethylene ester; BSPBio_001920; 1,4-Bis(methanesulfonyloxy)butane; NCGC00090905-04; Busulphan; Sulphabutin; MolPort-001-783-406; CCRIS 418; Myelosanum; Mylecytan; Spectrum5_000928; GlaxoSmithKline Brand of Busulfan; 1,4-Bis(methanesulfonoxy)butane; NCI60_041640; 55-98-1; IDI1_000847; 1,4-Butanediol dimethanesulphonate; 1,4-Bis[methanesulfonoxy]butane; NCIMech_000192; 1,4-Butanedi yl dimethanesulfonate; SPBio_000253; NSC-750; I09-1371; Busulfano [INN-Spanish]; AI3-25012; KBio2_005648; Busulfex; 2041 C.B.; SAM002554887; Citosulfan; Myleran; HSDB 7605; Busulfan GlaxoSmithKline Brand; 2041 C.B; CPD000058613; Busulphane; Myleran, Busulfex, Busulfan; LS-1358; Busulfanum; NCGC00090905-07; Orphan Brand of Busulfan; NCGC00090905-02; n-Butane-1,3-di(methylsulfonate); 1,4-Dimesyloxybutane; Myleran tablets	55-98-1	2478	148760	TTDS00213	DNA	N/A	N/A	N/A	N/A	N/A
DAP000992	Oxamniquine	UK 4271; 1,2,3,4-Tetrahydro-2-((isopropylamino)methyl)-7-nitro-6-quinolinemethanol; CID4612; 1,2,3,4-Tetrahydro-2-(((1-methylethyl)amino)methyl)-7-nitro-6-quinolinemethanol; (2-{[(1-methylethyl)amino]methyl}-7-nitro-1,2,3,4-tetrahydroquinolin-6-yl)methanol; Vansil; Mansil (TN); C07341; MLS000756891; CCRIS 4113; 1,2,3,4-Tetrahydro-2-[(isopropylamino)methyl]-7-nitro-6-quinolinemethanol; 6-Quinolinemethanol, 1,2,3,4-tetrahydro-2-((isopropylamino)methyl)-7-nitro-; BRN 0485597; Mansil; NSC352888; Vansil (TN); 2-((Isopropylamino)methyl)-7-nitro-1,2,3,4-tetrahydro-6-quinolinemethanol; 21738-42-1; Oxamniquine [USAN:BAN:INN]; Oxamniquinum [INN-Latin]; Prestwick2_001026; Oxaminiquine; Oxamniquine (USAN/INN); SMR000528982; 6-Quinolinemethanol, 1,2,3,4-tetrahydro-2-[[(1-methylethyl)amino]methyl]-7-nitro-; DB01096; HSDB 6510; 6-Hydroxymethyl-2-isopropylaminomethyl-7-nitro-1,2,3,4-tetrahydroquinoline; 2-(Isopropylaminomethyl)-7-nitro-1,2,3,4-tetrahydroquinoline-6-methanol; [7-nitro-2-[(propan-2-ylamino)methyl]-1,2,3,4-tetrahydroquinolin-6-yl]methanol; Oxamniquina; SPBio_003072; NSC 352888; HMS1571M13; UK 4261; Oxamniquina [INN-Spanish]; {2-[(Isopropylamino)methyl]-7-nitro-1,2,3,4-tetrahydroquinolin-6-yl}methanol; 5-22-11-00475 (Beilstein Handbook Reference); D00460; UNII-0O977R722D; EINECS 244-556-4; LS-142025; AC1L1IK1; 6-Quinolinemethanol, 1,2,3,4-tetrahydro-2-[(isopropylamino)methyl]-7-nitro-; UK-4271; CHEMBL847; Prestwick0_001026; oxamniquine; Oxamniquinum; Prestwick1_001026; C14H21N3O3; 6-Quinolinemethanol, 1,2,3,4-tetrahydro-2-(((1-methylethyl)amino)methyl)-7-nitro-	21738-42-1	4612	9548	TTDS00213	DNA	N/A	N/A	N/A	N/A	binder
DPR000122	Huntingtin gene antisense	N/A	N/A	N/A	N/A	TTDR01268	mRNA of Huntingtin protein	N/A	N/A	N/A	N/A	antisense
DPR000168	ALN-HTT	N/A	N/A	N/A	N/A	TTDR01268	mRNA of Huntingtin protein	N/A	N/A	N/A	N/A	N/A
DCL000012	JSM 6427	N/A	N/A	N/A	N/A	TTDC00148	Integrin beta-1	Beta(1) integrin;CD29 antigen;Fibronectin receptor beta subunit;Integrin VLA-4 beta subunit	P05556	3688	ENSG00000150093	antagonist
DCL000209	R411	UNII-XN95730F0N; 86924-16-5; Polycyanine; 828271-96-1; R-411; Ro 27-2441; Valategrast hydrochloride; L-Phenylalanine, N-(2-chloro-6-methylbenzoyl)-4-((2,6-dichlorobenzoyl)amino)-, 2-(diethylamino)ethyl ester, monohydrochloride; Valategrast HCl; Poly B 411; R 411	N/A	5360545	49746451	TTDC00148	Integrin beta-1	Beta(1) integrin;CD29 antigen;Fibronectin receptor beta subunit;Integrin VLA-4 beta subunit	P05556	3688	ENSG00000150093	antagonist
DAP000959	Papaverine	Dynovas; Isoquinoline, 6,7-dimethoxy-1-veratryl-(8Cl); Papaverine [BAN]; Papaverinium chloride; Papaverina; Papaverine monohydrochloride; Cardoverina; BSPBio_000426; Papaverine Hcl; NSC136630; Isoquinoline, 6,7-dimethoxy-1-veratryl- (8CI); LS-85584; 6,7-Dimethoxy-1-(3,4-dimethoxybenzyl)isoquinoline; Paveron; CHEMBL19224; Spectrum3_000537; Ro-Papav; Papacon; Papaverine chlorohydrate; RS 47; AB00053515; 1-[(3,4-Dimethoxyphenyl)methyl]6,7-dimethoxyisoquinoline; 4-[(6,7-Dimethoxyisoquinolyl)methyl]-1,2-dimethoxybenzene; Paptial T.R.; Papaverine (BAN); BRD-K15567136-001-01-1; Panergon; KBioSS_000471; Cerebid; Vaso-Pav; BSPBio_002153; NCGC00015810-01; papaverine; 58-74-2; Qua bid; EV1; 1-(3,4-Dimethoxybenzyl)-6,7-dimethoxyisoquinoline; Dilaves; Isoquinoline, 6,7-dimethoxy-1-veratryl-; PAP H; Papanerin-hcl; Paverolan; KBio2_003039; KBio3_001653; Genabid; Prestwick2_000583; Papaverina [Italian]; Ceraspan; KBioGR_000914; TNP00305; Pavatest; nchembio.317-comp11; Papalease; SPBio_002645; Drapavel; Pavagen; NCGC00024428-04; MolPort-000-881-409; Isoquinoline, 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-; Pamelon; Robaxapap; Pavarine; Vasal; EINECS 200-397-2; Papaverin; Forpavin; InChI=1/C20H21NO4/c1-22-17-6-5-13(10-18(17)23-2)9-16-15-12-20(25-4)19(24-3)11-14(15)7-8-21-16/h5-8,10-12H,9H2,1-4H; BPBio1_000470; Spectrum2_000978; Pavacen; Spectrum_000071; Pavatym; NINDS_000321; IDI1_000321; NCGC00024428-03; Spectrum4_000467; ACon1_002094; Papital T.R.; 1-(3,4-Dimethoxy-benzyl)-6,7-dimethoxy-isoquinoline; Papanerin; Durapav; 6,7-Dimethoxy-1-veratrylisoquinoline; Cardiospan; KBio2_005607; 61-25-6 (hydrochloride); SPBio_001015; Oprea1_810508; AKOS000277460; DB01113; Pavacels; Prestwick3_000583; BRD-K15567136-003-06-6; STOCK1N-09376; DivK1c_000321; Pavatine; Prestwick1_000583; NCGC00015810-04; DB07725; STK039035; Papanerine; Alapav; MEGxp0_001880; WLN: T66 CNJ B1R CO1 DO1& HO1 IO1; Mesotina (TN); S-M-R; 1-((3,4-Dimethoxyphenyl)methyl)-6,7-dimethoxyisoquinoline; NCGC00015810-09; Isoquinoline, 1-((3,4-dimethoxyphenyl)methyl)-6,7-dimethoxy-; D07425; Mesotina; Papaversan; NSC35443; Pavabid; UNII-DAA13NKG2Q; Pavnell; Pavabid Hp; Delapav; Cerespan; Lopac-P-3510; NCI60_003183; Oprea1_387689; 5-21-06-00182 (Beilstein Handbook Reference); NCGC00015810-02; KBio2_000471; SDCCGMLS-0003037.P003; 1-{[3,4-bis(methyloxy)phenyl]methyl}-6,7-bis(methyloxy)isoquinoline; Pavacap; AC1L1IPM; AC1Q4CFN; KBio1_000321; CID4680; Pavacot; ZINC00056555; CAS-61-25-6; Myobid; Chlorhydrate de papaverine; Pameion; NSC 136630; Prestwick0_000583; Spectrum5_001188; Papavarine chlorhydrate; 61-25-6; 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxyisoquinoline; NCGC00015810-03; Dispamil; Lopac0_000957; ACon1_000238; BAS 00674058; C06533; BRN 0312930	61-25-6	4680	8763	TTDS00296	CGMP-specific 3',5'-cyclic phosphodiesterase	CGB-PDE;CGMP-binding cGMP-specific phosphodiesterase;Phosphodiesterase 5	O76074	8654	ENSG00000138735	inhibitor
DCL000661	UK-369003	N/A	N/A	N/A	N/A	TTDS00296	CGMP-specific 3',5'-cyclic phosphodiesterase	CGB-PDE;CGMP-binding cGMP-specific phosphodiesterase;Phosphodiesterase 5	O76074	8654	ENSG00000138735	inhibitor
DAP000615	Tadalafil	GF-196960; HSDB 7303; SAM001246586; MLS001424132; CHEMBL779; 1xoz; Cialis (TN); Pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione, 6-(1,3- benzodioxol-5-yl)-2,3,6,7,12,12a-hexahydro-2-methyl-, (6R,12aR)-; S1512_Selleck; Cialis, GF 196960, IC 351, ICOS 351, Tadalafil; LS-187770; Lilly brand of tadalafil; MolPort-002-885-864; IC-351; Pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione, 6-(1,3-benzodioxol-5-yl)-2,3,6,7,12,12a-hexahydro-2-methyl-, (6R,12aR)-; Tadalafil; MLS000759426; Tadalafil [USAN]; KS-1117; Tadanafil; (6R,12aR)-2,3,6,7,12,12a-Hexahydro-2-methyl-6-(3,4-(methylenedioxy)phenyl) pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione; Tadalafil (JAN/USAN/INN); Pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione, 6-(1,3-benzodioxol-5-yl)-2,3,6,7,12,12a-hexahydro-2-methyl-, (6R-trans)-; ADCIRCA; MLS001195644; D02008; Cialis; GF 196960; Acdirca; 171596-29-5; DB00820; AC1L380B; C429886; FT-0080116; LS-186558; IC 351; HMS2051N17; ICOS 351; (6R-trans)-6-(1,3-Benzodioxol-5-yl)-2,3,6,7,12,12a-hexahydro-2-methyl-pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione; CPD000466321; UNII-742SXX0ICT; SMR000466321; CHEBI:41488; LS-187015; MLS001165782; Ic351; CID110635; (6R,12aR)-2,3,6,7,12,12a-Hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione; ZINC03993855	171596-29-5	110635	687903	TTDS00296	CGMP-specific 3',5'-cyclic phosphodiesterase	CGB-PDE;CGMP-binding cGMP-specific phosphodiesterase;Phosphodiesterase 5	O76074	8654	ENSG00000138735	inhibitor
DAP000960	Udenafil	3-(1-methyl-7-oxo-3-propyl-4H-pyrazolo[4,3-d]pyrimidin-5-yl)-N-[2-(1-methylpyrrolidin-2-yl)ethyl]-4-propoxybenzenesulfonamide; DA 8159; Udenafil; Zydena; 5-(2-Propyloxy-5-(1-methyl-2-pyrollidinylethylamidosulfonyl)phenyl)-1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo(4,3-d)pyrimidine-7-one; Benzenesulfonamide, 3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo(4,3-d)pyrimidin-5-yl)-N-(2-(1-methyl-2-pyrrolidinyl)ethyl)-4-propoxy-; DA-8159; I14-12963; AC1OCFJA; DB06267; CID6918523	268203-93-6	6918523	12015432	TTDS00296	CGMP-specific 3',5'-cyclic phosphodiesterase	CGB-PDE;CGMP-binding cGMP-specific phosphodiesterase;Phosphodiesterase 5	O76074	8654	ENSG00000138735	inhibitor
DAP000414	Vardenafil	HMS2089K04; 2-[2-ethoxy-5-(4-ethylpiperazin-1-yl)sulfonylphenyl]-5-methyl-7-propyl-1H-imidazo[5,1-f][1,2,4]triazin-4-one; DB00862; Levitra (TN); BRD-K13926615-003-01-7; CID110634; VARDENAFIL, LEVITRA; MolPort-005-975-775; BAY38-9456; STOCK6S-20068; S2515_Selleck; BAY 38-9456; VDN; 2-(2-Ethoxy-5-(4-ethylpiperazin-1-yl-1-sulfonyl)phenyl)-5-methyl-7-propyl-3H-imidazo(5,1-f)(1,2,4)triazin-4-one; LS-111467; UNII-UCE6F4125H; Piperazine, 1-((3-(1,4-dihydro-5-methyl-4-oxo-7-propylimidazo(5,1-f)(1,2,4)triazin-2-yl)-4-ethoxyphenyl)sulfonyl)-4-ethyl-; Vardenafil (INN); HSDB 7304; AC1L3808; CHEMBL1520; 1-((3-(3,4-Dihydro-5-methyl-4-oxo-7-propylimidazo(5,1-f)-as-triazin-2-yl)-4-ethoxyphenyl)sulfonyl)-4-ethylpiperazine; NCGC00167533-01; BSPBio_002392; 2-{2-ethoxy-5-[(4-ethylpiperazin-1-yl)sulfonyl]phenyl}-5-methyl-7-propylimidazo[5,1-f][1,2,4]triazin-4-ol; STK642629; 2-{2-ETHOXY-5-[(4-ETHYLPIPERAZIN-1-YL)SULFONYL]PHENYL}-5-METHYL-7-PROPYLIMIDAZO[5,1-F][1,2,4]TRIAZIN-4(1H)-ONE; 224785-90-4; Vardenafil; D08668; MolPort-002-672-272	224785-90-4	110634	687902	TTDS00296	CGMP-specific 3',5'-cyclic phosphodiesterase	CGB-PDE;CGMP-binding cGMP-specific phosphodiesterase;Phosphodiesterase 5	O76074	8654	ENSG00000138735	binder
DAP000614	Sildenafil	KBio2_002035; KBioGR_001052; C22H30N6O4S; 5-[2-ethoxy-5-(4-methylpiperazin-1-yl)sulfonylphenyl]-1-methyl-3-propyl-4H-pyrazolo[4,3-d]pyrimidin-7-one; 5-{2-ethoxy-5-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}-1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one; Ambap139755-83-2; 171599-83-0 (citrate); I06-0023; VIA; 2h42; SMR000752512; Spectrum2_001648; Piperazine, 1-((3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo(4,3-d)pyrimidin-5-yl)-4-ethoxyphenyl)sulfonyl)-4-methyl-; Aphrodil (TN); 5-[2-Ethoxy-5-(4-methyl-piperazine-1-sulfonyl)-phenyl]-1-methyl-3-propyl-1,6-dihydro-pyrazolo[4,3-d]pyrimidin-7-one (Sildenafil or Viagra); Sildenafil (INN); HMS2089M12; KBio1_001838; UK-92,480-10; LS-111655; BAS 04213629; Sildenafil [INN:BAN]; DB00203; D08514; 1udt; AC-938; BIDD:GT0352; HMS1922B19; sildenafil; HMS2093O17; NCGC00095099-01; 5-(2-ethoxy-5-(4-methylpiperazin-1-ylsulfonyl)phenyl)-1-methyl-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-7(6H)-one; SpecPlus_000798; KBioSS_002035; Aphrodil; Spectrum5_001508; 5-{2-(ethyloxy)-5-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}-1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one; NCGC00095099-02; MolPort-001-995-394; UK-92480; 139755-83-2; 1-((3-(4,7-Dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo(4,3-d)pyrimidin-5-yl)-4-ethoxyphenyl)sulfonyl)-4-methylpiperazine; HMS1684K08; MLS001240224; CHEBI:9139; KBio2_004603; HSDB 7305; 1xos; DivK1c_006894; MolPort-002-885-861; Spectrum_001555; UNII-3M7OB98Y7H; MLS001304737; KBio2_007171; Spectrum3_001892; BSPBio_003424; SPECTRUM1504099; Jsp002373; 1-((3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo(4,3-d)pyrimidin-5-yl)-4-ethoxyphenyl)sulfonyl)-4-methylpiperazine citrate; AC1L1JUI; CID5212; SPBio_001775; BRD-K79759585-001-02-1; NCGC00159496-02; Spectrum4_000586; KBio3_002927; 5-[2-Ethoxy-5-(4-methyl-piperazine-1-sulfonyl)-phenyl]-1-methyl-3-propyl-1,6-dihydro-pyrazolo[4,3-d]pyrimidin-7-one(Sildenafil); CHEMBL192; C07259	139755-83-2	5212	205034	TTDS00296	CGMP-specific 3',5'-cyclic phosphodiesterase	CGB-PDE;CGMP-binding cGMP-specific phosphodiesterase;Phosphodiesterase 5	O76074	8654	ENSG00000138735	inhibitor
DAP000739	Hydroxyurea	Idrossicarbamide; NCGC00093974-02; Carbamyl hydroxamate; 55291_FLUKA; Hydurea; NCGC00093974-05; Idrossicarbamide [DCIT]; 127-07-1; Hydroxylamine, N-(aminocarbonyl)-; NHY; MolMap_000029; SK 22591; SQ-1089; Bio1_001429; KBio3_001384; Oncocarbide; NCIMech_000139; NINDS_000556; 4-03-00-00170 (Beilstein Handbook Reference); Hydreia; NCI-C04831; DRG-0253; N-Carbamoylhydroxylamine; Hidrix; Droxia (TN); N-Hydroxymocovina; CCRIS 958; nchembio749-comp3; Hydroxyharnstoff; hydroxyaminomethanamide; KBio2_006525; Hydroxyharnstoff [German]; Hydroxyurea [USAN:BAN]; H0310; HU; S-phase/G-1 interface inhibitor; Hydroxycarbamidum; Hydroxycarbamide; Spectrum_000909; NCGC00093974-03; FT-0083575; urea, N-hydroxy-; MLS001332382; Lopac0_000596; NCI C04831; E0723DBA-5AF3-49D1-B5F6-59420AB87AC9; Hydroxycarbamid; CID3657; KBioGR_000383; KBio2_001389; Biosupressin; Bio1_000451; Oxyurea; H 8627; Spectrum3_000462; Onco-carbide; SMR000059149; nchembio.90-comp4; Hydroxyurea(d4); N-Hydroxymocovina [Czech]; Droxia; Spectrum4_000012; KBio1_000556; SPECTRUM1500344; carbamide oxide; Spectrum5_000836; SPBio_000247; hydroxyurea; Hydroxylamine, N-carbamoyl-; NCGC00093974-04; Mylocel; Hydroxycarbamine; AC1Q4ZXK; nchembio.573-comp3; HMS501L18; D006918; HMS1920F09; Carbamohydroximic acid; CHEMBL467; H8627_SIGMA; Hydroxyurea (D4); BSPBio_002164; EINECS 204-821-7; Carrbamoyl Oxime; 1-HYDROXYUREA; NSC32065; BB_SC-7256; Hydroxicarbamidum; Urea, hydroxy-; BRN 1741548; Hidroxicarbamida [INN-Spanish]; NSC 32065; NCGC00015520-07; NCGC00015520-01; HSDB 6887; Carbamohydroxyamic acid; Carbamohydroxamic acid; Hidroxicarbamida; DivK1c_000556; Hydroxycarbamide (JAN/INN); HYDREA (TN); NCGC00093974-01; MLS002153389; Spectrum2_000064; WLN: ZVMQ; D00341; H20210; Hydrea (TM); KBio2_003957; tetratogen: inhibits ribonucleoside diphosphate reductase; UNII-X6Q56QN5QC; Litalir; Bio1_000940; Lopac-H-8627; DB01005; Carbamoyl oxime; Hydroxylurea; KBioSS_001389; HMS2091L17; Hydroxyurea (USP); NCGC00015520-02; EU-0100596; MolPort-000-003-971; Hydroxycarbamidum [INN-Latin]; N-(Aminocarbonyl) Hydroxyamine; Hydura; Siklos; LS-709; SQ 1089; HYDROXY-UREA; C07044; CHEBI:44423; NCI60_002773; TL8000673; Hydrea; MLS001332381; S1896_Selleck; AI3-51139; IDI1_000556; N-Hydroxyurea; I05-0250; Droxia (TM); Litaler; Hydrea, Biosupressin, Cytodrox, Hydroxyurea; AC1L1GF8; N-HYDROXY UREA	127-07-1	3657	90752	TTDS00246	Ribonucleoside-diphosphate reductase	Ribonucleoside diphosphate reductase;Ribonucleotide reductase	P08543	N/A	N/A	inhibitor
DAP000849	Clofarabine	DB00631; 2-Chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-9H-purin-6-amine; clofarabinum; CID119182; Clolar (TN); 3S211048; Clofarabine; Bio-0121; 2-Chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine; D03546; C1-F-Ara-A; LS-126466; Clofarabine (USAN/INN); CHEBI:681569; 9H-Purin-6-amine, 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-; 2-Cl-2'-F-araA; 123318-82-1; S1218_Selleck; Clofarex; HMS2090A07; Clolar; FT-0082882; AC-274; AC1L3OC8; CFB; CAFdA; MolPort-005-941-711; Clolar, Evoltra,  Clofarabine; Cl-F-Ara-A; ZINC03798247; Evoltra; DB07554; CHEMBL1750; Clofarabine [USAN]; 2-chloro-9-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)adenine; UNII-762RDY0Y2H; 2-Chloro-9-(2-deoxy-2-fluoro-b-D-arabinofuranosyl)-9H-purin-6-amine; AKOS005063562; clofarabina; (2R,3R,4S,5R)-5-(6-amino-2-chloropurin-9-yl)-4-fluoro-2-(hydroxymethyl)oxolan-3-ol	123318-82-1	119182	695844	TTDS00246	Ribonucleoside-diphosphate reductase	Ribonucleoside diphosphate reductase;Ribonucleotide reductase	P08543	N/A	N/A	inhibitor
DAP000728	Hydralazine	Hydralazine [INN:BAN]; EC-000.1838; Spectrum3_000455; Prestwick0_000169; HLZ; Spectrum5_000822; RPTUSVTUFVMDQK-UHFFFAOYSA-; Spectrum2_000969; 1(2H)-Phthalazinone hydrazone; Hidral (TN); WLN: T66 CNNJ BMZ; DB01275; C-5968; ST50512087; KBio3_001350; Aprezolin; Idralazina; phthalazin-1-ylhydrazine; MolPort-000-876-738; KBioGR_000349; D08044; C8H8N4; CHEMBL276832; Prestwick1_000169; C 5968; 1(2H)-Phthalazinone, hydrazone; IDI1_000117; NCGC00015501-02; Hidralazina [Spanish]; Hydrazone 1(2H)-phthalazinone; KBio2_006491; Hydralazinum; KBio1_000117; BRN 0132615; NCIOpen2_001484; NSC126699; 6-Hydralazine; SPBio_000977; Lopac-H-1753; NCGC00162199-01; (2H)-Phthalazinone hydrazone; NSC 126699; BSPBio_002130; 86-54-4; AC1Q4UY1; CAS-304-20-1; ZINC12360535; NCGC00015501-05; 5-25-17-00412 (Beilstein Handbook Reference); Ciba 5968; BRD-K82103381-003-03-7; EINECS 201-680-3; C-5068; InChI=1/C8H8N4/c9-11-8-7-4-2-1-3-6(7)5-10-12-8/h1-5H,9H2,(H,11,12); SPBio_001958; Praparat 5968; C07040; CHEBI:5775; 1-Hydrazinophthalazine; [2H-Phthalazin-(1Z)-Ylidene]-Hydrazine Hydrochloride; Hidralazina [INN-Spanish]; Hydralazin; UNII-26NAK24LS8; (1Z)-1(2H)-Phthalazinone hydrazone; CCRIS 5385; Spectrum_000875; LS-109171; 304-20-1 (mono-hydrochloride); CID3637; MolPort-001-794-088; Hidral; Hipoftalin; NCGC00015501-01; Spectrum4_000005; Idralazina [DCIT]; Idralazina [Italian]; Apresoline; Phthalazine, 1-hydrazino-; KBio2_003923; Lopac0_000593; Hydrallazin; Hydrazinophthalazine; KBioSS_001355; NINDS_000117; hydralazine; Oprea1_207681; AKOS000122609; BA 5968; Hydralazinum [INN-Latin]; KBio2_001355; Hypophthalin; Apressin (pharmaceutical); Apresolin; Hydralazine (INN); Hidralazina; Prestwick2_000169; Hidralazin; Hydrallazine; Apressoline; Oprea1_416878; AC1L1GDN; DivK1c_000117; 1-Phthalazinylhydrazine; Apressin	86-54-4	3637	9252	TTDS00179	Prolyl 4-hydroxylase alpha subunit	4-PH alpha;Procollagen-proline,2-oxoglutarate-4-dioxygenase alpha;Prolyl hydroxylase	N/A	N/A	N/A	inhibitor
DCL000954	Renzapride	4-amino-N-[(4S,5S)-1-azabicyclo[3.3.1]nonan-4-yl]-5-chloro-2-methoxybenzamide; Benzamide, 4-amino-N-1-azabicyclo(3.3.1)non-4-yl-5-chloro-2-methoxy-, endo-; CID3086547; (( -)-endo)-4-Amino-5-chloro-2-methoxy-N-(1-azabicyclo(3.3.1)non-4-yl)benzamide; AC1MJ6DN; 109828-31-1; 112727-80-7; Renzapridum [INN-Latin]; Renzaprida; 125636-29-5; LS-186857; Renzaprida [INN-Spanish]; Renzapridum; Renzapride; 4-Amino-N-1-azabicyclo(3.3.1)non-4-yl-5-chloro-2-methoxybenzamide endo-; Renzapride [INN]; LS-187513	112727-80-7	3035241	47208053	TTDS00107	5-hydroxytryptamine 4 receptor	5-HT4;5-HT-4;5-HT4 receptor;Serotonin receptor;Serotonin receptor 4	Q13639	3360	ENSG00000164270	agonist
DCL000939	Pumosetrag	Pumosetrag; DDP-733; N-((3R)-1-Azabicyclo(2.2.2)oct-3-yl)-7-oxo-4,7-dihydrothieno(3,2-b)pyridine-6-carboxamide; Thieno(3,2-b)pyridine-6-carboxamide, N-1-azabicyclo(2.2.2)oct-3-yl-4,7-dihydro-7-oxo-, (R)-; N-[(3R)-1-azabicyclo[2.2.2]octan-3-yl]-7-oxo-4H-thieno[3,2-b]pyridine-6-carboxamide; CID154104; MKC-733; N-(1-azabicyclo[2.2.2]oct-8-yl)-2-oxo-9-thia-5-azabicyclo[4.3.0]nona-3,7,10-triene-3-carboxamide; 153062-94-3; AC1L4BPC	194093-42-0	N/A	3817323	TTDS00107	5-hydroxytryptamine 4 receptor	5-HT4;5-HT-4;5-HT4 receptor;Serotonin receptor;Serotonin receptor 4	Q13639	3360	ENSG00000164270	agonist
DAP000222	Cisapride	Benzamide, 4-amino-5-chloro-N-(1-(3-(4-fluorophenoxy)propyl)-3-methoxy-4-piperidinyl)-2-methoxy-, cis-; 86718-68-5; Cisawal; Kinestase; R-51619; Rapulid; Benzamide, 4-amino-5-chloro-N-(1-(3-(4-fluorophenoxy)propyl)-3-methoxy -4-piperidinyl)-2-methoxy-, cis-; CID2769; HMS1569E22; Kaudalit; T 1341; R 51619; Risamol; L000938; UNII-UVL329170W; cisapride; Prestwick0_000430; Vomiprid; (+-)-Cisapride; Cisaprida [Spanish]; I01-0115; Cisapridum [Latin]; STL058624; MolPort-003-666-853; Pridesia; Unamol; Propulsid; EINECS 279-689-7; C06910; Cisaprida [INN-Spanish]; Prepulsid; Syspride; Vomipride; Propulsin; Cisapron; Dispep; Acenalin; C23H29ClFN3O4.H2O; Alimix Forte; SPBio_002359; Unipride; Prestwick2_000430; NCGC00168465-01; 4-amino-5-chloro-N-[1-{3-[(4-fluorophenyl)oxy]propyl}-3-(methyloxy)piperidin-4-yl]-2-(methyloxy)benzamide; AC-1912; Benzamide, 4-amino-5-chloro-N-(1-(3-(4-fluorophenoxy)propyl)-3-methoxy-4-piperidinyl)-2-methoxy-, monohydrate, cis-; Risamal; Enteropride; Cisaprida; 4-amino-5-chloro-N-[1-[3-(4-fluorophenoxy)propyl]-3-methoxypiperidin-4-yl]-2-methoxybenzamide; Prestwick1_000430; AC1L1EFB; LS-25437; DB00604; Cipride; Propulsid Quicksolv; Alipride; Alimix; D00274; HSDB 3571; 4-amino-5-chloro-N-{1-[3-(4-fluorophenoxy)propyl]-3-methoxypiperidin-4-yl}-2-methoxybenzamide; Pulsid; Cisapridum; Colinorm; 81098-60-4; Acpulsif; Cisapride [USAN:BAN:INN:JAN]; Guptro; Cisapride (USAN/INN); Cisapridum [INN-Latin]; Prestwick_786; Esorid; cis-4-Amino-5-chloro-N-(1-(3-(p-fluorophenoxy)propyl)-3-methoxy-4-piperidyl)-o-anisamide; Presid; Benzamide, 4-amino-5-chloro-N-[1-[3-(4-fluorophenoxy)propyl]-3-methoxy-4-piperidinyl]-2-methoxy-, cis-	81098-60-4	2769	192212	TTDS00107	5-hydroxytryptamine 4 receptor	5-HT4;5-HT-4;5-HT4 receptor;Serotonin receptor;Serotonin receptor 4	Q13639	3360	ENSG00000164270	agonist
DAP001526	Tegaserod	BSPBio_002344; HMS1922J08; Tegaserod (USAN/INN); CID5362436; NCGC00095192-01; CHEBI:222247; CHEMBL76370; KBio2_007632; Spectrum4_000730; SPBio_001180; 1-[[(Z)-(5-methoxyindol-3-ylidene)methyl]amino]-2-pentylguanidine; Spectrum_001950; KBio2_002496; Spectrum3_001855; Spectrum2_001100; AC1NSFYX; KBio2_005064; nchembio.559-comp5; MolPort-005-934-409; SPECTRUM1505823; MolPort-002-885-865; NCGC00095192-03; KBioSS_002504; BSPBio_003270; NCGC00095192-04; AC-4564; KBio3_002771; Spectrum5_001691; KBioGR_001000; D06056; NCGC00095192-02	189188-57-6	122724	47207714	TTDS00107	5-hydroxytryptamine 4 receptor	5-HT4;5-HT-4;5-HT4 receptor;Serotonin receptor;Serotonin receptor 4	Q13639	3360	ENSG00000164270	agonist
DCL000806	Fluphenazine Decanoate	NSC169510; Flufenazine decanoate; AC1L1FTN; Decanoic acid, 2-(4-(3-(2-(trifluoromethyl)-10H-phenothiazin-10-yl)propyl)-1-piperazinyl)ethyl ester; CCRIS 3954; Fluphenazine depot; 5002-47-1; CHEMBL1200854; Decanoic acid, 2-[4-[3-[2-(trifluoromethyl)phenothiazin-10-yl]propyl]-1-piperazinyl]ethyl ester; Fluphenazine decanoate; AKOS003589045; Fluphenazine O-decanoate; EINECS 225-672-4; Fluphenaline decanoate; Moditen-depo; SQ 10,733; Dapotum D; WLN: T C666 BN ISJ EXFFF B3- AT6N DNTJ D2OV9; AC1Q4K03; Moditen depot; 2-(4-(3-(2-(Trifluoromethyl)phenothiazin-10-yl)propyl)-1-piperazinyl)ethyl decanoate; D00793; Fluphenazine decanoate (JAN/USP); Fluorophenazine decanoate; LS-59383; Prolixin decanoate (TN); MolPort-001-728-034; BRN 0599852; NSC 169510; UNII-FMU62K1L3C; C32H44F3N3O2S; CID3388; 2-[4-[3-[2-(trifluoromethyl)phenothiazin-10-yl]propyl]piperazin-1-yl]ethyl decanoate; Decanoic acid, 2-[4-[3-[2-(trifluoromethyl)-10H-phenothiazin-10-yl]propyl]-1-piperazinyl]ethyl ester; Modecate; AR-1J0863; 2-(4-{3-[2-(trifluoromethyl)-10H-phenothiazin-10-yl]propyl}piperazin-1-yl)ethyl decanoate; Decanoic acid, 2-(4-(3-(2-(trifluoromethyl)phenothiazin-10-yl)propyl)-1-piperazinyl)ethyl ester	5002-47-1	490519	46506645	TTDS00107	5-hydroxytryptamine 4 receptor	5-HT4;5-HT-4;5-HT4 receptor;Serotonin receptor;Serotonin receptor 4	Q13639	3360	ENSG00000164270	antagonist
DCL000672	5-HT4/D2 antagonists	N/A	N/A	N/A	N/A	TTDS00107	5-hydroxytryptamine 4 receptor	5-HT4;5-HT-4;5-HT4 receptor;Serotonin receptor;Serotonin receptor 4	Q13639	3360	ENSG00000164270	antagonist
DAP000588	Quinapril	(3S)-2-(N-{(1S)-1-[(ethyloxy)carbonyl]-3-phenylpropyl}-L-alanyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid; DivK1c_000710; quinapril; KBio2_002077; KBio2_004645; Spectrum_001597; Quinapril [INN:BAN]; NINDS_000710; 3-Isoquinolinecarboxylic acid, 2-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)-1,2,3,4-tetrahydro-, (3S-(2(R*(R*)),3R*))-; 85441-61-8; KBio3_002522; DB00881; AC1Q63IE; IDI1_000710; Quinaprilum; C07398; KBioGR_000994; Quinapril (USP/INN); CHEBI:8713; QUINAPRIL HCL; BSPBio_003022; Spectrum3_001551; Spectrum5_001075; BIDD:GT0797; (3S)-2-{(2S)-2-[(1S)-1-ethoxycarbonyl-3-phenylpropylamino]propanoyl}-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid; C25H30N2O5; SPBio_000749; HMS2090L05; (3S)-2-{N-((S)-1-Ethoxycarbonyl-3-phenylpropyl)-L-alanyl}-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid; UNII-RJ84Y44811; Spectrum2_000825; BRD-K72222507-003-03-6; HMS502D12; Spectrum4_000727; Quinaprilum [Latin]; NCGC00167962-01; MolPort-003-987-265; CHEMBL1592; CID54892; (3S)-2-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-3,4-dihydro-1H-isoquinoline-3-carboxylic acid; KBio1_000710; [3S-[2[R*(R*)],3R*]]-2-[2-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-3-Isoquinolinecarboxylic acid ; Ectren; Koretic; Quinapril; NCGC00167962-02; D03752; KBioSS_002077; AB1004863; AC1L1HXL; LS-177872; TL8005458; KBio2_007213	85441-61-8	54892	9602	TTDS00181	Angiotensin-converting enzyme	ACE;CD143 antigen;Dipeptidyl carboxypeptidase I;Kininase II	P22966	N/A	N/A	inhibitor
DAP000583	Trandolapril	Mavik (TN); (2S,3aR,7aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carboxylic acid; Odric; Trandolaprilum; Trandolapril [INN:BAN]; RU 44570; CHEMBL1519; 87679-37-6; CID5484727; FT-0082544; Udrik; trandolapril; 1H-Indole-2-carboxylic acid, 1-((2S)-2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydro-, (2S,3aR,7aS)-; UNII-1T0N3G9CRC; (2S,3aR,7aS)-1-((S)-N-((S)-1-Carboxy-3-phenylpropyl)alanyl)hexahydro-2-indolinecarboxylic acid, 1-ethyl ester; D00383; Trandolapril (JAN/INN); RU44570; NCGC00182079-03; (2S,3aR,7aS)-1-(N-((1S)-1-((Ethyloxy)carbonyl)-3-phenylpropyl)-L-alanyl)octahydro-1H-indole-2-carboxylic Acid; Trandolaprilum [Latin]; 1H-Indole-2-carboxylic acid, octahydro-1-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)-, (2S-(1(R*(R*)),2-alpha,3a-alpha,7a-beta))-; Odrik; DB00519; RU-44570; I06-1849; Preran; LS-82763; Gopten; Mavik; BIDD:GT0804; 1-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydro-1H-indol-2-carboxylic acid; CCRIS 6594; C24H34N2O5; AC1NUNSR	87679-37-6	5484727	7847449	TTDS00181	Angiotensin-converting enzyme	ACE;CD143 antigen;Dipeptidyl carboxypeptidase I;Kininase II	P22966	N/A	N/A	inhibitor
DAP000911	Spirapril	1,4-Dithia-7-azaspiro(4.4)nonane-8-carboxylic acid, 7-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)-, (8S-(7(R*(R*)),8R*))-; CHEMBL431; LS-63095; AC1NSKNL; CID5311447; C22H30N2O5S2; Renormax; DB01348; Spirapril [INN:BAN]; (2S)-3-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-6,9-dithia-3-azaspiro[4.4]nonane-2-carboxylic acid; Spiraprilum [Latin]; Spirapril; CHEBI:101967; Sch-33844; Spirapril (INN); BRN 4277924; TI-211-950; 83647-97-6; 1,4-Dithia-7-azaspiro(4,4)nonane-8-carboxylic acid, 7-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)-, (8S-(7(R*(R*)),8R*))-; Espirapril [Spanish]; Setrilan; Not established; D08529; Sandopril	83647-97-6	5311447	12013873	TTDS00181	Angiotensin-converting enzyme	ACE;CD143 antigen;Dipeptidyl carboxypeptidase I;Kininase II	P22966	N/A	N/A	inhibitor
DCL000188	Omapatrilat	CID656629; (4S,7S,10aS)-5-oxo-4-[[(2S)-3-phenyl-2-sulfanylpropanoyl]amino]-2,3,4,7,8,9,10,10a-octahydropyrido[2,1-b][1,3]thiazepine-7-carboxylic acid; 167305-00-2; Omapatrilat (JAN/USAN/INN); AC1LCVB7; BMS-186716; Omapatrilat; CHEBI:159756; D01970; CHEMBL289556	167305-00-2	656629	12014939	TTDS00181	Angiotensin-converting enzyme	ACE;CD143 antigen;Dipeptidyl carboxypeptidase I;Kininase II	P22966	N/A	N/A	inhibitor
DAP000585	Enalapril	CHEBI:116847; KBio1_000408; IDI1_000408; Spectrum2_001455; Vasotec; KBio2_006923; Spectrum5_001107; Enalapril (INN); CAS-76095-16-4; BIDD:GT0751; CID5388962; enalapril; NCGC00016932-01; SPBio_001349; BPBio1_000340; DivK1c_000408; KBio3_002535; 75847-73-3; NCGC00021569-05; Spectrum_001307; (2S)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]pyrrolidine-2-carboxylic acid; CHEBI:4784; Prestwick3_000314; BSPBio_000308; CHEMBL578; N-[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]-L-alanyl-L-proline; KBioGR_000355; NCGC00021569-04; HMS2090E08; AC1NTUS5; Enalapril (TN); BSPBio_003035; Spectrum3_001478; D07892; LS-190651; KBioSS_001787; KBio2_001787; MolPort-002-885-877; NCGC00021569-06; Spectrum4_000008; N-{(1S)-1-[(ethyloxy)carbonyl]-3-phenylpropyl}-L-alanyl-L-proline; C06977; KBio2_004355; NINDS_000408	75847-73-3	5362032	191211	TTDS00181	Angiotensin-converting enzyme	ACE;CD143 antigen;Dipeptidyl carboxypeptidase I;Kininase II	P22966	N/A	N/A	inhibitor
DCL000160	M-100240	142695-08-7; AC1L33RX; MDL-100240; Mdl 100240; (4S,7S,12bR)-7-[[(2S)-2-acetylsulfanyl-3-phenylpropanoyl]amino]-6-oxo-2,3,4,7,8,12b-hexahydro-1H-pyrido[2,1-a][2]benzazepine-4-carboxylic acid; Mdl 100,142; M-100240; Pyrido(2,1-a)(2)benzazepine-4-carboxylic acid, 7-((2-(acetylthio)-1-oxo-3-phenylpropyl)amino)-1,2,3,4,6,7,8,12b-octahydro-6-oxo-, (4S-(4alph,7alpha(R*),12bbeta))-; CID133985; Mdl 100,240	177172-49-5	158797	47207678	TTDS00181	Angiotensin-converting enzyme	ACE;CD143 antigen;Dipeptidyl carboxypeptidase I;Kininase II	P22966	N/A	N/A	N/A
DAP000586	Moexipril	103775-10-6; Moexiprilum; BIDD:GT0007; Moexiprilum [INN-Latin]; Moexipril [INN:BAN]; AC1L3LQP; LS-194436; AC1Q63ID; MOEXIPRIL; (3S)-2-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-6,7-dimethoxy-3,4-dihydro-1H-isoquinoline-3-carboxylic acid; BRD-K34441861-003-01-3; (3S)-2-(N-{(1S)-1-[(ethyloxy)carbonyl]-3-phenylpropyl}-L-alanyl)-6,7-bis(methyloxy)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid; Uniretic; C07704; Moexipril (INN); DB00691; CHEMBL1165; 109715-88-0; CHEBI:288707; AR-1J6805; CID91270; D08225	103775-10-6	91270	9906	TTDS00181	Angiotensin-converting enzyme	ACE;CD143 antigen;Dipeptidyl carboxypeptidase I;Kininase II	P22966	N/A	N/A	inhibitor
DAP000909	Deserpidine	ORETICYL 50; Deserpidic acid, methyl ester, 3,4,5-trimethoxybenzoate; methyl (3beta,16beta,17alpha,18beta,20alpha)-17-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]yohimban-16-carboxylate; Deserpidinum; Recanescin; Deserpidin; CHEMBL1200515; A-11025; Deserpidina; Recanescine; Halmonyl; Benz[g]indolo[2,3-a]quinolizine-1-carboxylic acid, 1,2,3,4,4a,5,7,8,-13,13b,14,14a-dodecahydro-3-hydroxy-2-methoxy-, methyl ester, 3,4,5-trimethoxybenzoate; C06541; 3-beta,20-alpha-Yohimban-16-beta-carboxylic acid, 18-beta-hydroxy-17-alpha-methoxy-, methyl ester, 3,4,5-trimethoxybenzoate (ester); Deserpidine (INN); Methyl 18beta-hydroxy-17alpha-methoxy-3beta,20alpha-yohimban-16beta-carboxylate, 3,4,5-trimethoxybenzoate (ester); Tranquinil; EINECS 205-004-8; LS-7299; BRN 0101820; (3beta,16beta,17alpha,18beta,20alpha)-17-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]yohimban-16-carboxylic acid methyl ester; Deserpidinum [INN-Latin]; Lilly 22641; Desmethoxyreserpine; Methyl 17alpha-methoxy-18beta-((3,4,5-trimethoxybenzoyl)oxy)-3beta,20alpha-yohimban-16beta-carboxylate; CHEBI:27478; 3-beta,20-alpha-Yohimban-16-beta-carboxylic acid, 18-beta-hydroxy-17-alpha-methoxy-,methyl ester, 3,4,5-trimethoxybenzoate (ester); MD-0232; CID8550; D08194; Halmonyl (TN); AC1Q5YIY; Canescine; Raunormine; NCGC00168786-01; I06-1877; NSC72138; 11-Demethoxyreserpine; 11-Desmethoxyreserpine; UNII-9016E3VB47; Desepridine; Deserpidina [INN-Spanish]; Deserpidine [INN:BAN]; NCGC00168786-02; 17.alpha.-Methoxy-18.beta.-[(3,4,5-trimethoxybenzoyl)oxy]-3.beta.,20.alpha.-yohimban-16.beta.-carboxylic acid methyl ester; Methyl 17alpha-methoxy-18beta-(3,4,5-trimethoxybenzoyloxy)-3beta,20alpha-yohimban-16beta-carboxylat; DB01089; methyl (3beta,16beta,17alpha,18beta,20alpha)-17-(methyloxy)-18-({[3,4,5-tris(methyloxy)phenyl]carbonyl}oxy)yohimban-16-carboxylate; Yohimban-16-carboxylic acid, 17-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-, methyl ester, (3b,16b,17a,18b,20a)-; C32H38N2O8; Raunormin; DESERPIDINE; Reserpidine; AR-1I3653; Deresperine; Canescin; Harmonyl; 131-01-1; 4-25-00-01282 (Beilstein Handbook Reference); NSC 72138; AC1L1R81; 959244-16-7	131-01-1	8550	8771	TTDS00181	Angiotensin-converting enzyme	ACE;CD143 antigen;Dipeptidyl carboxypeptidase I;Kininase II	P22966	N/A	N/A	inhibitor
DAP000912	Cilazapril	(1S,9S)-9-(((S)-1-Carboxy-3-phenylpropyl)amino)octahydro-10-oxo-6H-pyridazino(1,2-a)(1,2)diazepine-1-carboxylic acid 9-ethyl ester monohydrate; MolPort-003-986-212; Cilazaprilum [Latin]; Inibace; 6H-Pyridazino(1,2-a)(1,2)diazepine-1-carboxylic acid, octahydro-9-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-10-oxo-, hydrate, (1S-(1-alpha,9-alpha(R*)))-; D07699; Cilazapril (anhydrous); 92077-78-6; CID56330; MolPort-005-943-746; C22H31N3O5; 88768-40-5; Dynorm; Cilazapril anhydrous; LS-129694; D01069; Inhibace (TN); (4S,7S)-7-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]-6-oxo-1,2,3,4,7,8,9,10-octahydropyridazino[1,2-a]diazepine-4-carboxylic acid hydrate; Ro-31-2848; Ro 31-2848 monohydrate; Ro 31-2848; AC-269; Cilazapril hydrate; AC1L1KU0; AC1L1KTX; 6H-Pyridazino(1,2-a)(1,2)diazepine-1-carboxylic acid, 9-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)octahydro-10-oxo-, monohydrate, (1S-(1alpha,9alpha(R*)))-; (4S,7S)-7-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]-6-oxo-1,2,3,4,7,8,9,10-octahydropyridazino[1,2-a]diazepine-4-carboxylic acid; Cilazapril [USAN:INN:BAN:JAN]; UNII-8Q9454114Q; Cilazapril (USAN); 92077-78-6 (Parent); 88768-40-5 (anhydrous); Ro 34-2848; Cilazapril hydrate (JAN); LS-178061; CHEMBL515606; Justor; Cilazaprilum; Inhibace; I06-1280; DB01340; cilazapril; CILAZAPRIL MONOHYDRATE; TL8000244; Cilazapril (INN); Ro-312848; AC1Q63IB; Cilazil; UNII-19KW7PI29F; Cilazapril, Anhydrous; CID56329; Vascace; 6H-Pyridazino(1,2-a)(1,2)diazepine-1-carboxylic acid, 9-(((1S)-1-(ethoxycarbonyl)-3-phenylpropyl)amino)octahydro-10-oxo-, (1S,9S)-; 6H-Pyridazino(1,2-a)(1,2)diazepine-1-carboxylic acid, 9-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)octahydro-10-oxo-, (1S-(1alpha,9alpha(R*)))-; I06-1285	92077-78-6	56329	193657	TTDS00181	Angiotensin-converting enzyme	ACE;CD143 antigen;Dipeptidyl carboxypeptidase I;Kininase II	P22966	N/A	N/A	inhibitor
DAP000810	Perindopril	CHEBI:8024; KBio2_007630; SMR001233453; 82834-16-0 (Parent); LS-178402; Coversum; Perindopril (USAN/INN); Spectrum5_001689; BRD-K92731339-227-02-3; Coverex; (2S,3aS,7aS)-1-[(2S)-2-{[(2S)-1-ethoxy-1-oxopentan-2-yl]amino}propanoyl]octahydro-1H-indole-2-carboxylic acid; C07706; Spectrum3_001683; KBio2_005062; McN-A-2833; D03753; (2S,3aS,7aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxopentan-2-yl]amino]propanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carboxylic acid; AC1L32S9; SPBio_001216; BIDD:GT0786; KBio2_002494; C19H32N2O5; (2S)-2-[(1S)-1-Carbethoxybutylamino]-1-oxopropyl-(2S,3aS,7aS)-perhydroindole-2-carboxylic acid; Spectrum4_000775; Coversyl; Spectrum_001948; ethyl N-{(2S)-1-[(2S,3aS,7aS)-2-carboxyoctahydro-1H-indol-1-yl]-1-oxopropan-2-yl}-L-norvalinate; PERINDOPRIL; KBio3_002426; SED-9490; MLS002154153; 1H-Indole-2-carboxylic acid, 1-((2S)-2-(((1S)-1-(ethoxycarbonyl)butyl)amino)-1-oxopropyl)octahydro-, (2S,3aS,7aS)-; CID107807; Prestarium; S-9490; DW-7950; BSPBio_003206; Coverene Cor; DB00790; 82834-16-0; MolPort-005-935-307; Spectrum2_001108; ACEON; KBioSS_002502; CHEMBL1581; cpd with unspecified MF; 99149-83-4; KBioGR_001190	107133-36-8	107807	7854486	TTDS00181	Angiotensin-converting enzyme	ACE;CD143 antigen;Dipeptidyl carboxypeptidase I;Kininase II	P22966	N/A	N/A	inhibitor
DCL000132	Ilepatril	N/A	N/A	1641	48259452	TTDS00181	Angiotensin-converting enzyme	ACE;CD143 antigen;Dipeptidyl carboxypeptidase I;Kininase II	P22966	N/A	N/A	inhibitor
DAP000587	Lisinopril	Tensopril; L0220; Lisoril; MK-521; KBioSS_000977; N2-((S)-1-Carboxy-3-phenylpropyl)-L-lysyl-L-proline; LPR; CHEMBL1237; MolPort-002-507-428; Novatec; Zestril; Lipril; Prinil; ICI-209K; MLS001306481; Prestwick3_000301; Spectrum2_001456; CCRIS 3568; Lisinopril anhydrous; Zestril (TN); TL8005499; KBio1_001037; Lisipril; KBio2_006113; Spectrum5_000995; Spectrum3_000941; Longes; Sinopril; KBio2_003545; L-Proline, 1-(N2-(1-carboxy-3-phenylpropyl)-L-lysyl)-; Cipral; BIDD:GT0755; 76547-98-3; KBio2_000977; [N2-[(S)-1-CARBOXY-3-PHENYLPROPYL]-L-LYSYL-L-PROLINE; BSPBio_000262; SPBio_002481; Lysinopril; MK 521; CID5362119; Prinivil; Acercomp; BB_NC-1454; L-Proline, N2-((1S)-1-carboxy-3-phenylpropyl)-L-lysyl-; Linvas; (S)-1-(N(2)-(1-carboxy-3-phenylpropyl)-L-lysyl)-L-proline; HMS2090O14; D08131; Acerbon; BRN 4276619; Doneka; NCGC00179623-01; KBioGR_001599; Prestwick2_000301; DB00722; IDI1_001037; Loril; Presiten; Carace; Lisinopril (anhydrous); 83915-83-7 (Parent); Inhibril; SPBio_001351; Lispril; Spectrum4_001040; Tensyn; Tersif; HMS1921B14; Spectrum_000497; Sinopryl; Linopril; Lisinoprilum [Latin]; Lisinopril (INN); AC1NSFPF; DivK1c_001037; Inopril; Cipril; SMR000544473; LS-118899; BRD-K67966701-335-03-5; Vivatec; BPBio1_000290; Lisinal; Lisinoprilum; CHEBI:43755; Noperten; SPECTRUM1501217; Prestwick0_000301; lisinopril; Coric; MLS001306436; EINECS 278-488-1; 1-[Nalpha-[(S)-1-Carboxy-3-phenylpropyl]-L-lysyl]-L-proline; I06-1895; NINDS_001037; C21H31N3O5; N2-[(1S)-1-carboxy-3-phenylpropyl]-L-lysyl-L-proline; MK 522; (2S)-1-[(2S)-6-amino-2-[[(2S)-1-hydroxy-1-oxo-4-phenylbutan-2-yl]amino]hexanoyl]pyrrolidine-2-carboxylic acid; HMS2092L21; (S)-1-(N2-(1-Carboxy-3-phenylpropyl)-L-lysyl)-L-proline; HMS503O15; KBio3_002002; 77726-95-5; Prestwick1_000301; N(2)-[(1S)-1-carboxy-3-phenylpropyl]-L-lysyl-L-proline; Alapril; N-(1(S)-Carboxy-3-phenylpropyl)-L-lysyl-L-proline; 1-(N2-(1-Carboxy-3-phenylpropyl)-L-lysyl)-L-proline; L-Proline, N2-[(1S)-1-carboxy-3-phenylpropyl]-L-lysyl-; L-Proline, 1-(N(sup 2)-(1-carboxy-3-phenylpropyl)-L-lysyl)-, (S)-; (S)-1-(N(sup 2)-(1-Carboxy-3-phenylpropyl)-L-lysyl)-L-proline	83915-83-7	5362119	205105	TTDS00181	Angiotensin-converting enzyme	ACE;CD143 antigen;Dipeptidyl carboxypeptidase I;Kininase II	P22966	N/A	N/A	inhibitor
DAP000584	Benazepril	Spectrum2_000482; [(3S)-3-({(1S)-1-[(ethyloxy)carbonyl]-3-phenylpropyl}amino)-2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl]acetic acid; C06843; Benazepril (INN); NCGC00165740-02; [(3S)-3-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}-2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl]acetic acid; KBioSS_002464; UNII-UDM7Q7QWP8; Benazepril Sandoz; Forteekor [veterinary] (TN); Benazeprilum; benazepril; Spectrum4_000286; Benazepril Sandoz (TN); 1H-1-Benzazepine-1-acetic acid, 3-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-2,3,4,5-tetrahydro-2-oxo-, (S-(R*,R*))-; STK627447; benzazepril; KBio2_005025; Benazepril [INN:BAN]; SPBio_000343; D07499; KBio3_002707; CHEMBL838; BSPBio_003487; 86541-75-5; Spectrum3_001674; BRD-K49807096-003-02-3; CHEBI:3011; CGS-14824-A; DB00542; Spectrum5_001546; KBio2_007593; KBio2_002457; LS-27973; NCGC00165740-01; CID5362124; BIDD:GT0800; Benazeprilum [Latin]; AC1NSFPL; benazapril; 2-[(3S)-3-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]-2-oxo-4,5-dihydro-3H-1-benzazepin-1-yl]acetic acid; Spectrum_001922; Forteekor [veterinary]; [(3S)-3-{[(1S)-1-(ethoxycarbonyl)-3-phenylpropyl]amino}-2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl]acetic acid; KBioGR_000812	86541-75-5	5362124	205187	TTDS00181	Angiotensin-converting enzyme	ACE;CD143 antigen;Dipeptidyl carboxypeptidase I;Kininase II	P22966	N/A	N/A	inhibitor
DAP000589	Captopril	1-[(2S)-2-methyl-3-sulfanylpropanoyl]-L-proline; HMS500K10; BPBio1_000063; 3-Mercapto-2-methylpropionyl-proline; MLS000069484; 1-(3-Mercapto-2-methyl-1-oxopropyl)-L-proline; HSDB 6527; SQ-14225; captopril; L-Proline, 1-(3-mercapto-2-methyl-1-oxopropyl)-, (S)-; Apopril (TN); IDI1_000208; KBioSS_001168; BSPBio_000057; D00251; Spectrum3_001388; C4042_SIGMA; (S)-1-(3-Mercapto-2-methyl-1-oxo-propyl)-L-proline; NCGC00023654-09; SQ-14534; NCGC00023654-07; KBio2_001168; Asisten; Aceplus; (2S)-1-(3-Mercapto-2-methylpropionyl)-L-proline; 1-(D-3-Mercapto-2-methyl-1-oxopropyl)-L-proline (S,S); CHEBI:3380; 1j37; Capoten; C9H15NO3S; (S)-1-(3-Mercapto-2-methyl-1-oxopropyl)-L-proline; SMP1_000056; Acepress; KBioGR_001321; NCGC00023654-06; KBio1_000208; AC-12047; Prestwick3_000019; Lopril; SPBio_001022; CID44093; Garranil; Captopryl; CPD0-2067; BIM-0050290.0001; X8Z; Tensobon; SQ 14,225; Tensiomin; D-3-Mercapto-2-methylpropionylproline; EU-0100302; MLS001076488; KBio3_002196; Cesplon; FT-0082749; BB_NC-2104; Captoprilum [INN-Latin]; 1-((2S)-3-Mercapto-2-methylpropionyl)-L-proline; Capoten (TN); BSPBio_002976; DivK1c_000208; D-3-Mercapto-2-methylpropanoyl-L-proline; Acediur; 1-Pyrrolidinecarboxylic acid, 1-(D-3-mercapto-2-methyl-1-propionyl)-, L-(S,S)-; KBio2_006304; SQ 14225; Isopresol; MCO; KBio2_003736; Captopril (JP15/USP/INN); C 4042; Lopirin [Switzerland]; UNII-9G64RSX1XD; Hypertil; NCGC00023654-10; SPECTRUM1500682; NCGC00023654-04; CHEMBL1560; UPCMLD-DP003; Alopresin; NCGC00023654-05; SAM002564201; Apopril; Acepril; L-Captopril; BRD-K54529596-001-04-0; AC1Q5R48; Tensoprel; N-[(S)-3-Mercapto-2-methylpropionyl]-L-proline; Captopril [USAN:INN:BAN:JAN]; HMS1921C12; HMS2092I12; L-Proline, 1-((2S)-3-mercapto-2-methyl-1-oxopropyl)-; Hipertil; (2S)-1-[(2S)-2-methyl-3-sulfanylpropanoyl]pyrrolidine-2-carboxylic acid; DB01197; Tenosbon; C8856_SIAL; SQ-14,534; C4042_SIAL; MolPort-001-794-639; NCGC00015235-02; NCGC00023654-03; Lopac0_000302; SQ-14,225; STK802012; AC1Q29GZ; Captril; Dilabar; ST079562; NCGC00023654-08; Captoprilum; Prestwick_103; [2S]-1-[3-Mercapto-2-methylpropionyl]-L-proline; Lopirin; Spectrum_000688; Captoril; Spectrum2_001211; LS-137465; Garranil (discontinued); EINECS 263-607-1; 62571-86-2; UPCMLD-DP003:001; Spectrum4_000811; CPD000059061; AC1L2B4L; CHEMBL82; SMR000059061; Spectrum5_001587; D-2-Methyl-3-mercaptopropanoyl-L-proline; HMS2089P19; SA 333; NCGC00015235-01; Lopac-C-4042; NINDS_000208; Captolane	62571-86-2	44093	7847317	TTDS00181	Angiotensin-converting enzyme	ACE;CD143 antigen;Dipeptidyl carboxypeptidase I;Kininase II	P22966	N/A	N/A	inhibitor
DCL000024	GSK 796406	N/A	N/A	1234	48258991	TTDS00181	Angiotensin-converting enzyme	ACE;CD143 antigen;Dipeptidyl carboxypeptidase I;Kininase II	P22966	N/A	N/A	inhibitor
DAP000910	Rescinnamine	CCRIS 4711; Normorescina; NSC15628; ACon1_002115; Cinnaloid; O-(3,4,5-Trimethoxy-trans-cinnamoyl) methyl reserpate; Apolon; Apoterin S; Rescinpal; Raurescin; Reserpinin; Tsuruselpi S; Cinnasil; Rescin; Trimethoxy cinnamoyl reserpate de methyl; Rescinnamine [BAN:INN:JAN]; Cinatabs; Rescinamina [INN-Spanish]; BRD-K52930707-001-04-8; Recinnamine; Resealoid; Trimethoxycinnamoyl methyl reserpate; Rescinnamina; 3,4,5-Trimethoxycinnamic acid, methyl reserpate; C06540; NSC 15628; 3,4,5-Trimethylcinnamic acid, ester with methyl reserpate; BRN 0075328; Reserpinene; Methyl reserpate 3,4,5-trimethoxycinnamic acid ester; UNII-Q6W1F7DJ2D; Anapral; MEGxp0_001952; Resipal; Reserpinine (C35 alkaloid); Rescidan; Prestwick_558; Cinamine; Reserpic acid methyl ester 3,4,5-trimethoxycinnamate; Reserpinine; Tenamine; Reskinnamin; Rescisan; Cartric; Rescinnamina [DCIT]; Raurescine; Rescinnamin; BPBio1_000392; BRD-K52930707-001-02-2; Paresinan; Rozex; Rescamin; Prestwick3_000568; 3,4,5-Trimethylcinnamoyl methyl reserpate; Raupyrol; 4-25-00-01323 (Beilstein Handbook Reference); Tuareg; C35H42N2O9; D00198; Rescinnaminum; MLS002153878; Rescinnamine (JAN/INN); Methyl 18-O-(3,4,5-trimethoxycinnamoyl)reserpate; LS-1060; Prestwick2_000568; SMR001233232; Scinnamina; Resepinine (C35 alkaloid); 3,4,5-Trimethoxycinnamoyl methyl reserpate; HMS1569B18; Rescitens; rescinnamine; Methyl trimethoxycinnamoylreserpate; Moderil; Rescinnamine (VAN); Anaprel; Reserpinine (VAN); CHEMBL1668; MolPort-001-742-634; CID5280954; Rescaloid; EINECS 246-471-8; 84-34-4; BSPBio_000356; CHEBI:28572; Trimethoxy cinnamoyl reserpate de methyl [French]; Tsuruselpi S (TN); HSDB 2176; Rescinnaminum [INN-Latin]; Recitensina; NP-011016; AI3-52763; 24815-24-5; DB01180; Rescinamina; Apoterin	24815-24-5	32681	8770	TTDS00181	Angiotensin-converting enzyme	ACE;CD143 antigen;Dipeptidyl carboxypeptidase I;Kininase II	P22966	N/A	N/A	inhibitor
DAP000581	Ramipril	87333-19-5; CHEBI:8774; (2S-(1(R*(R*)),2alpha,3abeta,6abeta))-1-(2-((1-(Ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydrocyclopenta(b)pyrrole-2-carboxylic acid.; Pramace; MLS001423965; KBio2_005072; Cardace; UNII-L35JN3I7SJ; SPECTRUM1505214; BIDD:GT0803; AC1NSFPR; KBioSS_002512; Altace (TN); KBio3_002849; S1793_Selleck; AC-1347; Hoechst Brand of Ramipril; (2S,3aS,6aS)-1-((S)-N-((S)-1-Carboxy-3-phenylpropyl)alanyl)octahydrocyclopenta(b)pyrrole-2-carboxylic acid, 1-ethyl ester; HOE 498; Delix; Ramiprilum; D00421; MolPort-001-736-571; (2S,3aS,6aS)-1-[(2S)-2-{[(1S)-1-ethoxycarbonyl-3-phenylpropyl]amino}propanoyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid; STK801937; Monarch Brand of Ramipril; Almirall Brand of Ramipril; SAM001246757; Astra Brand of Ramipril; Hypren; Zabien; SAM002699899; Aventis Brand of Ramipril; DB00178; Hytren; CHEMBL1168; Carasel; HMS2051E04; R0404_SIGMA; MLS001216547; (2S,3aS,6aS)-1-[(2S)-2-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}propanoyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid (non-preferred name); (2s,3as,6as)-1-[(s)-2-((s)-1-ethoxycarbonyl-3-phenyl-propylamino)-propionyl]-octahydro-cyclopenta[b]; NCGC00178127-01; Spectrum3_001794; N-(1S-carboethoxy-3-phenylpropyl)-S-alanyl-cis,endo-2-azabicyclo[3.3.0]octane-3S-carboxylic Acid; D017257; Triatec; Spectrum_001958; (2 S ,3 aS ,6 aS )-1[( S )-N-[( S )-1-Carboxy-3-phenylpropyl] alanyl] octahydrocyclopenta [ b ]pyrrole-2-carboxylic acid, 1-ethyl ester; [2s,3as,6as]-1-[(2s)-2-[[(1s)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydrocyclopen; C23H32N2O5; HMS2093M10; HMS2090L11; AstraZeneca Brand of Ramipril; (2s,3as,6as)-1-((s)-2-((s)-1-ethoxy-1-oxo-4-phenylbutan-2-ylamino)propanoyl)-octahydrocyclopenta[b]p; HOE498; Tritace; Aventis Pharma Brand of Ramipril; (2S,3aS,6aS)-1-((S)-2-((S)-1-ethoxy-1-oxo-4-phenylbutan-2-ylamino)propanoyl) octahydrocyclopenta[b]pyrrole-2-carboxylic acid; (2S,3aS,6aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-3,3a,4,5,6,6a-hexahydro-2H-cyclopenta[b]pyrrole-2-carboxylic acid; Altace; Lostapres; Ramipril [USAN:INN:BAN]; KBio2_002504; KBioGR_001858; SMR000466386; CHEBI:289203; Vesdil; Hoe-498; Pramace (discontinued); Spectrum4_001269; Cyclopenta(b)pyrrole-2-carboxylic acid, 1-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydro-, (2S-(1(R*(R*)),2alpha,3abeta,6abeta))-; MLS000759523; Acovil; Spectrum5_001721; LS-58199; (2s,3as,6as)-1((s)-n-((s)-1-carboxy-3-phenylpropyl)alanyl)octahydrocyclopenta(b)pyrrole-2-carboxylic; [2S,3aS,6aS]-1-[(2S)-2-[[(1S)-1-(Ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid; Ramipril (USP/INN); Bio-0651; 126613-39-6; Cyclopenta(b)pyrrole-2-carboxylic acid, 1-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydro-, (2S(1(R*(R*)),2alpha,3abeta,6abeta))-; Quark; (2S,3aS,6aS)-1-((S)-N-((S)-1-Ethoxycarbonyl-3-phenylpropyl)alanyl)octahydrocyclopenta(b)pyrrol-2-carbonsaeure; Ramace; CID5362129; Promed Brand of Ramipril; Ramiprilum [Latin]; KBio2_007640; CPD000466386; Naprix; ramipril; BSPBio_003347; Ramipro, Tritace, Altace, Prilace, Ramipril	87333-19-5	5362129	193088	TTDS00181	Angiotensin-converting enzyme	ACE;CD143 antigen;Dipeptidyl carboxypeptidase I;Kininase II	P22966	N/A	N/A	inhibitor
DAP000582	Fosinopril	DB00492; CID9601226; (4S)-4-cyclohexyl-1-({[2-methyl-1-(propanoyloxy)propoxy](4-phenylbutyl)phosphoryl}acetyl)-L-proline; (2S,4S)-4-cyclohexyl-1-[2-[(2-methyl-1-propanoyloxypropoxy)-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid; SQ-28,555; D07992; Staril; FOSINOPRIL SODIUM; CID10461195; 4-cyclohexyl-1-[2-[(2-methyl-1-propanoyloxypropoxy)-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid; KBioGR_001544; LS-118919; 98048-97-6; L-proline,4-cyclohexyl-1-(((2-methyl-1-Z(1-oxopropoxy)propoxy)(4-phenylbutyl)phosphinyl)acetyl)-(1(S*(R*)),2alpha,4beta)-; C07016; (2S,4S)-4-cyclohexyl-1-{2-[(2-methyl-1-propionyloxy-propoxy)-(4-phenyl-butyl)-phosphinoyl]-acetyl}-pyrrolidine-2-carboxylic acid; IDI1_000908; Spectrum4_001102; KBio1_000908; AC1L1FW8; fosinopril; (2S,4S)-4-cyclohexyl-1-[2-[[(1S)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid; Monopril (TN); HMS2089P08; DivK1c_000908; AC-13899; Acecor; CID6708482; CID9872634; LS-187220; L-Proline, 4-cyclohexyl-1-(((2-methyl-1-(1-oxopropoxy)propoxy)(4-phenylbutyl)phosphinyl)acetyl)-, (1(S*(R*)),2alpha,4beta)-; Fosinopril [INN:BAN]; SQ-28555; AC1O8F9P; C30H46NO7P; (4S)-4-cyclohexyl-1-{[{[2-methyl-1-(propanoyloxy)propyl]oxy}(4-phenylbutyl)phosphoryl]acetyl}-L-proline; Monopril; NINDS_000908; CID55891; Fosinopril (INN); AC1L1K09; UNII-R43D2573WO; CID3420; L-Proline, 4-cyclohexyl-1-(((2-methyl-1-(1-oxopropoxy)propoxy)(4-phenylbutyl)phosphinyl)acetyl)-, (2alpha,4beta)-; MolPort-005-934-570; Fosenopril; Fosinopril, (1(S*(R*)),2 alpha,4 beta)-Isomer; BIDD:GT0229	98048-97-6	55891	194429	TTDS00181	Angiotensin-converting enzyme	ACE;CD143 antigen;Dipeptidyl carboxypeptidase I;Kininase II	P22966	N/A	N/A	inhibitor
DAP001374	Enalaprilat	(2S)-1-[(2S)-2-[[(2S)-1-hydroxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]pyrrolidine-2-carboxylic acid; LS-187219; SMR000466359; HMS2051H16; CHEMBL1200697; CHEMBL577; Enalprilate hydrate; Enalaprilate; Enalaprilic acid; CID6917719; Enalapril acid; Enalapril diacid; CID5462501; 1-(N-((S)-1-Carboxy-3-phenylpropyl)-L-alanyl)-L-proline dihydrate; D03769; Enalaprilat; LS-118903; HMS2089P04; CPD000466359; S1657_Selleck; Vasotec I.V.; 1-((2S)-2-{[(1S)-1-CARBOXY-3-PHENYLPROPYL]AMINO}PROPANOYL)-L-PROLINE; MLS001424138; 76420-72-9; EAL; Enalaprilat (USP); MolPort-005-943-792; SAM001246684; CHEBI:59877; BIDD:GT0752; N-[(1S)-1-carboxy-3-phenylpropyl]-L-alanyl-L-proline--water (1/2); AC1OCEK7; Enalaprilat anhydrous; MK-422; NCGC00164593-01; CHEBI:116759; C18H24N2O5.2H2O; SBB065733; ENALAPRILAT INHIBITOR; CHEBI:42302; N-[(1S)-1-carboxy-3-phenylpropyl]-L-alanyl-L-proline; MLS000759476; Enalaprilatum; AC1NUWEA; (2S)-1-[(2S)-2-[[(2S)-1-hydroxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]pyrrolidine-2-carboxylic acid dihydrate; CHEBI:4786; C11720; enalprilat hydrate	76420-72-9	6917719	17397858	TTDS00181	Angiotensin-converting enzyme	ACE;CD143 antigen;Dipeptidyl carboxypeptidase I;Kininase II	P22966	N/A	N/A	inhibitor
DCL000894	Nepadutant	Nepadutant; Cyclo(N-(2-acetamido-2-deoxy-beta-D-glucopyranosyl)-L-asparaginyl-L-alpha-aspartyl-L-tryptophyl-L-phenylalanyl-L-2,3-diaminopropionyl-L-leucyl),cyclic(2-5)-peptide; LS-55819; MEN 11420; MEN-11,420; cyclo(Asn(2-deoxy-2-AcNH-beta-D-Glc)-Asp-Trp-Phe-Dap-Leu)cyclo(2beta,5beta); C107754; (2S)-2-[[(3S,6S,9S,12S)-12-[[(2S)-4-[[(2R,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]amino]-2-amino-4-oxobutanoyl]amino]-6-benzyl-9-(1H-indol-3-ylmethyl)-5,8,11,14-tetraoxo-1,4,7,10-tetrazacyclotetradecane-3-carbonyl]amino]-4-methylpentanoic acid; Cyclo(N-(2-acetamido-2-deoxy-beta-D-glucopyranosyl)-L-asparginyl-L-alpha-aspartyl-L-tryptophyl-L-phenylalanyl-L-2,3-diaminopropionyl-L-leucyl), cyclic(2-5)-peptide; AC1MJ6M2; 183747-35-5; Nepadutant [INN]; CID3086682	183747-35-5	3086682	3889604	TTDC00090	Substance-K receptor	Neurokinin A receptor;NK-2 receptor;NK-2R;SKR;Tachykinin neurokinin 2 receptor;Tachykinin receptor 2	P21452	6865	ENSG00000075073	antagonist
DCL000220	Saredutant	CHEMBL308148; SR 48968C; SR-48965; LS-25204; SR48968C; SR 48965; SR-489686; SR-48968; AC1L2XTE; CHEBI:215369; N-((S)-beta-(2-(4-Acetamido-4-phenylpiperidino)ethyl)-3,4-dichlorophenethyl)-N-methylbenzamide; PDSP2_000650; SR48968; SR 48968; N-[(2S)-4-(4-acetamido-4-phenylpiperidin-1-yl)-2-(3,4-dichlorophenyl)butyl]-N-methylbenzamide; Benzamide, N-(4-(4-(acetylamino)-4-phenyl-1-piperidinyl)-2-(3,4-dichlorophenyl)butyl)-N-methyl-, (S)-; Benzamide, N-((2S)-4-(4-(acetylamino)-4-phenyl-1-piperidinyl)-2-(3,4-dichlorophenyl)butyl)-N-methyl-; PDSP1_000659; CID104974; (S)-N-Methyl-N(4-(4-acetylamino-4-phenylpiperidino)-2-(3,4-dichlorophenyl)butyl)benzamide; SR-48968C; C073839; 142001-63-6; Saredutant	N/A	104974	12014694	TTDC00090	Substance-K receptor	Neurokinin A receptor;NK-2 receptor;NK-2R;SKR;Tachykinin neurokinin 2 receptor;Tachykinin receptor 2	P21452	6865	ENSG00000075073	antagonist
DCL000776	DNK-333	DNK333; Benzamide, N-((1R,2E)-1-((3,4-dichlorophenyl)methyl)-4-(((3R)-hexahydro-2-oxo-1H-azepin-3-yl)amino)-4-oxo-2-butenyl)-N-methyl-3,5-bis(trifluoromethyl)-; N-((R,R)-(E)-1-(3,4-Dichlorobenzyl)-3-(2-oxoazepan-3-yl)carbamoyl)allyl-N-methyl-3,5-bis(trifluoromethyl)benzamide; 398507-81-8; DNK 333	203932-02-9	N/A	N/A	TTDC00090	Substance-K receptor	Neurokinin A receptor;NK-2 receptor;NK-2R;SKR;Tachykinin neurokinin 2 receptor;Tachykinin receptor 2	P21452	6865	ENSG00000075073	antagonist
DPR000107	SLV-332	N/A	910-86-1	3001386	34667915	TTDC00090	Substance-K receptor	Neurokinin A receptor;NK-2 receptor;NK-2R;SKR;Tachykinin neurokinin 2 receptor;Tachykinin receptor 2	P21452	6865	ENSG00000075073	antagonist
DCL000759	CS-003	N/A	N/A	N/A	N/A	TTDC00090	Substance-K receptor	Neurokinin A receptor;NK-2 receptor;NK-2R;SKR;Tachykinin neurokinin 2 receptor;Tachykinin receptor 2	P21452	6865	ENSG00000075073	antagonist
DCL000232	SR 144190	C110304; 3-(1-(2-(4-benzoyl-2-(3,4-difluorophenyl)morpholin-2-yl)ethyl)-4-phenylpiperidin-4-yl)-1-dimethylurea; CID9810217; L015346; CID 9810217; SR-144190; SR 144190	146369-65-5	644210	43765917	TTDC00090	Substance-K receptor	Neurokinin A receptor;NK-2 receptor;NK-2R;SKR;Tachykinin neurokinin 2 receptor;Tachykinin receptor 2	P21452	6865	ENSG00000075073	antagonist
DCL000130	ICA-105665	N/A	N/A	N/A	N/A	TTDC00128	Potassium voltage-gated channel subfamily KQT member 3	K+ channel KCNQ3;KQT-like 3;Potassium channel alpha subunit KvLQT3;Potassium channel KQT-like 3;Voltage-gated potassium channel subunit Kv7.3	O43525	3786	ENSG00000184156	activator
DAP000716	Mivacurium	Mivacurii chloridum; bis[3-[(1R)-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propyl] (E)-oct-4-enedioate dichloride; Mivacurium; 133814-19-4; MIVACURIUM CHLORIDE; Mivacurium chloride (USAN/INN); (R)-1,2,3,4-Tetrahydro-2-(3-hydroxypropyl)-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxybenzyl)isoquinolinium chloride, (E)-4-octenedioate (2:1); Mivacurii chloridum [Latin]; Mivacron; Chlorure de mivacurium [French]; Cloruro de mivacurio [Spanish]; MIVACRON IN DEXTROSE 5% IN PLASTIC CONTAINER; C58H80N2O14; BW B109OU dichloride; AC1NQXZZ; NCGC00167469-01; LS-172022; 106861-44-3; C07550; CID5281042; Mivacron (TN); CHEMBL984; D00763; BWB109OU; BW-B109OU; BW-B1090U; Cloruro de mivacurio; bis[3-[(1R)-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propyl] (E)-oct-4-enedioate; DB01226; Mivacurium chloride [USAN:INN:BAN]; Chlorure de mivacurium; Isoquinolinium, 2,2'-((1,8-dioxo-4-octene-1,8-diyl)bis(oxy-3,1-propanediyl))bis(1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-((3,4,5-trimethoxyphenyl)methyl)-, dichloride, (R-(R*,R*-(E)))-; Isoquinolinium, 2,2'-((1,8-dioxo-4-octene-1,8-diyl)bis(oxy-3,1-propanediyl))bis(1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-((3,4,5-trimethoxyphenyl)methyl)-, (1R-(1R*(E(1'R*))))-; 106791-40-6; AC1NQXXZ; CID5281080	106791-40-6	5281042	9753	TTDS00400	Neuronal acetylcholine receptor subunit alpha-2	CHRNA2	Q15822	1135	ENSG00000120903	antagonist
DAP000824	Metocurine Iodide	Dimethylchondrocurarine iodide; C40H48N2O6; METOCURINE IODIDE; Methyl-curarin [German]; Metocurini Iodidum; NSC 36388; (+)-O,O'-Dimethylchondrocurarine diiodide; 13H-4,6:21,24-Dietheno-8,12-metheno-1H-pyrido(3',2':14,15)(1,11)dioxacycloeicosino(2,3,4-ij)isoquinolinium, 2,3,13a,14,15,16,25,25a-octahydro-9,18,19,29-tetramethoxy-1,1,14,14-tetramethyl-, diiodide, (13aR,25aS)-; Dimetiltubocurarinio, ioduro de; Metokurinjodid; Tubocurarine, O,O'-dimethyl-, diiodide; Metocurine iodide [USAN]; (+)-O,O'-Dimethylchondrocurarine Di-iodide; 7601-55-0; Metubine iodide; LS-158180; 6,6',7',12'-Tetramethoxy-2,2,2',2'-tetramethyltubocuraranium diiodide; UNII-O0U0E87X7F; Dimethyltubocurarine Iodide; Metubine; Metokuriinijodidi; D00761; AC1L2NB6; DB00416; Methyl-curarin; 2,2,2',2'-tetramethyl-6,6',7',12'-tetrakis(methyloxy)tubocuraran-2,2'-diium diiodide; 13H-4,6:21,24-Dietheno-8,12-metheno-1H-pyrido(3',2':14,15)(1,11)dioxacycloeicosino(2,3,4-ij)isoquinolinium, 2,3,13a,14,15,16,25,25a-octahydro-9,18,19,29-tetramethoxy-1,1,14,14-tetramethyl-, diiodide, (13aR-(13aR*,25aS*))-; Metubine iodide (TN); Tubocuraranium, 6,6',7',12'-tetramethoxy-2,2,2',2'-tetramethyl-, diiodide; Dimethylether of d-tubocurarine iodide; metocurine diiodide; Dimethyl tubocurarine iodide; Metocurine iodide (USAN); EINECS 231-510-3; Mutubine Iodide; 5152-30-7 (Parent); CID24244; CHEMBL1739; AC1Q1T8M; O,O'-Dimethylchondrocurarine diiodide; Trimethyltubocurarine Iodide	7601-55-0	24244	166758	TTDS00400	Neuronal acetylcholine receptor subunit alpha-2	CHRNA2	Q15822	1135	ENSG00000120903	antagonist
DAP000354	Vecuronium	CHEBI:9939; HMS2090D22; (2|A,3|A,5|A,16|A,17|A)-3,17-diacetoxy-16-(1-methylpiperidinium-1-yl)-2-(piperidin-1-yl)androstane; [(2S,3S,5S,8R,9S,10S,13S,14S,16S,17R)-17-acetyloxy-10,13-dimethyl-16-(1-methylpiperidin-1-ium-1-yl)-2-piperidin-1-yl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl] acetate; DB01339; AC1Q5X7S; AC1L22EF; (2beta,3alpha,5alpha,16beta,17beta)-3,17-diacetoxy-16-(1-methylpiperidinium-1-yl)-2-(piperidin-1-yl)androstane; Vecuronium; Piperidinium, 1-((2beta,3alpha,5alpha,16beta,17beta)-3,17-bis(acetyloxy)-2-(1-piperidinyl)androstan-16-yl)-1-methyl-; 86029-43-8; CID39765; C07553; NCGC00167467-01	50700-72-6	39764	12013268	TTDS00400	Neuronal acetylcholine receptor subunit alpha-2	CHRNA2	Q15822	1135	ENSG00000120903	antagonist
DAP000349	Rocuronium	143558-00-3; C07556; CID441290; (2beta,3alpha,5alpha,16beta,17beta)-17-acetoxy-16-(1-allylpyrrolidinium-1-yl)-3-hydroxy-2-(morpholin-4-yl)androstane; BIDD:GT0360; DB00728; NCGC00167433-01; HMS2090E03; AC1L9AWM; Rocuronium; CHEBI:8884; [(2S,3S,5S,8R,9S,10S,13S,14S,16S,17R)-3-hydroxy-10,13-dimethyl-2-morpholin-4-yl-16-(1-prop-2-enylpyrrolidin-1-ium-1-yl)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl] acetate	119302-91-9	441290	7980535	TTDS00400	Neuronal acetylcholine receptor subunit alpha-2	CHRNA2	Q15822	1135	ENSG00000120903	antagonist
DAP000350	Doxacurium chloride	Doxacurii chloridum [Latin]; Chlorure de doxacurium [French]; Cloruro de doxacurio [Spanish]; BW A938U dichloride; AC1NSJYE; CID5311077; 1-O-[3-[(1R)-6,7,8-trimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propyl] 4-O-[3-[(1S)-6,7,8-trimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propyl] butanedioate; BW-A-938U; Doxacurium chloride [USAN:INN:BAN]; AC1NSJYB; Isoquinolinium, 2,2'-((1,4-dioxo-1,4-butanediyl)bis(oxy-3,1-propanediyl))bis(1,2,3,4-tetrahydro-6,7,8-trimethoxy-2-methyl-1-((3,4,5-trimethoxyphenyl)methyl)-, dichloride, (1alpha,2beta(1'S*,2'R*))-, mixture with (+-)-(1alpha,2beta(1'R*,2'S*))-2,2'-((1,4-dioxo-1,4-butanediyl)bis(oxy-3,1-propanediyl))bis(1,2,3,4-tetrahydro-6,7,8-trimethoxy-2-methyl-1-((3,4,5-trimethoxyphenyl)met; (1R,2S;1S,2R)-1,2,3,4-Tetrahydro-2-(3-hydroxypropyl)-6,7,8-trimethoxy-2-methyl-1-(3,4,5-trimethoxybenzyl)isoquinolinium chloride, succinate (2:1), mixture with (+-)-(1R*,2S*;1R*,2S*)-1,2,3,4-tetrahydro-2-(3-hydroxypropyl)-6,7,8-trimethoxy-2-methyl-1-(3,4,5-trimethoxybenzyl)isoquinolinium chloride, succinate (2:1); BW A938U; Isoquinolinium, 2,2'-((1,4-dioxo-1,4-butanediyl)bis(oxy-3,1-propanediyl))bis(1,2,3,4-tetrahydro-6,7,8-trimethoxy-2-methyl-1-((3,4,5-trimethoxyphenyl)methyl)-, dichloride, (1alpha,2beta(1'S*,2'R*))-, mixture with (+-)-(1alpha,2beta(1'R*,2'S*))-2,2'-((1,4-dioxo-1,4-butanediyl)bis(oxy-3,1-propanediyl))bis(1,2,3,4-tetrahydro-6,7,8-trimethoxy-2-methyl-1-((3,4,5-trimethoxyphenyl)methyl)isoquinolinium) dichloride; CHEMBL1200753; LS-172021; C56H78N2O16; DOXACURIUM CHLORIDE; BW-A938U; BW-A 938U; CID5311076; 1-O-[3-[(1R)-6,7,8-trimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propyl] 4-O-[3-[(1S)-6,7,8-trimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propyl] butanedioate dichloride	106819-53-8	60168	196533	TTDS00400	Neuronal acetylcholine receptor subunit alpha-2	CHRNA2	Q15822	1135	ENSG00000120903	antagonist
DAP000348	Levallorphan	Levalorfano [INN-Spanish]; CID5359371; Levallofano; DB00504; Levalorfano; Levallofano [DCIT]; AC1L1GZN; HSDB 2148; Levo-3-hydroxy-N-allyl morphinan; Morphinan-3-ol, 17-allyl-; 17-Allylmorphinan-3-ol; Morphinan-3-ol, 17-allyl-, (-)-; CID3912; Morphinan-3-ol, 17-(2-propenyl)-; (-)-3-Hydroxy-N-allylmorphinan; N-Allyl-3-hydroxymorphinan; Levallorphanum; CHEMBL608539; EINECS 205-799-1; 152-02-3; C07069; 17-prop-2-en-1-ylmorphinan-3-ol; Morphinan, 17-allyl-3-hydroxy-; Levallorphane; Naloxiphan; UNII-353613BU4U; Levallorphane [INN-French]; Levallorphan [INN:BAN]; levallorphan; L001162; Ro-1-7700; LS-91860; Levallorphanum [INN-Latin]; L-N-Allyl-3-hydroxymorphinan	152-02-3	5359371	152219	TTDS00400	Neuronal acetylcholine receptor subunit alpha-2	CHRNA2	Q15822	1135	ENSG00000120903	antagonist
DAP000353	Pipecuronium	UNII-1N3O74HM92; Arduan; 68399-58-6; CID50192; LS-176664; PIPECURONIUM; Piperazinium, 4,4'-((2beta,3alpha,5alpha,16beta,17beta)-3,17-bis(acetyloxy)androstane-2,16-diyl)bis(1,1-dimethyl-; Pipecurium; Piperazinium, 4,4'-((2beta,3alpha,5alpha,16beta,17beta)-3,17-bis(acetyloxy)androstane-2,16-diyl)bis(1,1-dimethyl); C07554; 52212-02-9 (dibromide); AC1L18MB; C35H62N4O4; DB01338; [(2S,3S,5S,8R,9S,10S,13S,14S,16S,17R)-17-acetyloxy-2,16-bis(4,4-dimethylpiperazin-4-ium-1-yl)-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl] acetate; 68399-57-5 (dibromide, dihydrate)	68399-58-6	50192	14764962	TTDS00400	Neuronal acetylcholine receptor subunit alpha-2	CHRNA2	Q15822	1135	ENSG00000120903	antagonist
DAP000351	Tubocurarine	(+)-Tubocurarine chloride; LS-158183; 1406-69-5; Curarin-haf; 303-11-7; D-Tubocurarine chloride; Tubocurarine, chloride, hydrochloride, (+)- (8CI); KBio2_007654; Chlorure de tubocurarine; Tubocurarin; d-Tubocurarine dichloride; 57-94-3; Tubocurarini chloridum; Cloruro de tubocurarina; CHEBI:543040; C07547; Tubocurarina cloruro; KBio3_001990; 2,2',2'-trimethyl-6,6'-bis(methyloxy)tubocuraran-2,2'-diium-7',12'-diol dichloride; Spectrum3_001095; Intocostrine T; 31498-75-6; d-Tubocurarine hydrochloride; (+) Tubocurarine; Tubadil; Tubocurarini chloridum [INN-Latin]; D08655; d-Paracurarine chloride; 7',12'-Dihydroxy-6,6'-dimethoxy-2,2',2'-trimethyltubocuraranium; Tubocurarine chloride (TN); PDSP1_001485; Tubarine; PDSP2_001469; SpecPlus_000475; Spectrum_001966; LS-187260; Chlorure de tubocurarine [INN-French]; 30519-12-1; 13H-4,6:21,24-Dietheno-8,12-metheno-1H-pyrido(3',2':14,15)(1,11)dioxacycloeicosino(2,3,4-ij)isoquinolinium, 2,3,13a,14,15,16,25,25a-octahydro-9,19-dihydroxy-18,29-dimethoxy-1,14,14-trimethyl-, chloride, hydrochloride, (13aR,25aS)-; tubocurarine; 548-18-5; Tubocurarine hydrochloride; AC1L1LKX; Tubocurarine chloride (INN); EINECS 200-356-9; 7',12'-dihydroxy-6,6'-dimethoxy-2,2',2'-trimethyltubocuraran-2'-ium; CHEBI:9774; KBioGR_002264; KBio2_005086; HMS2089C06; NCGC00163242-01; Tubocurarine chloride; 64780-74-1; (+)-Tubocurarine chloride hydrochloride; CID6000; Delacurarine; 57-95-4; KBio2_002518; 1370-17-8; Tubocuraranium, 7',12'-dihydroxy-6,6'-dimethoxy-2,2',2'-trimethyl-, chloride, hydrochloride; NCGC00178480-01; d-Tubocurarine; DivK1c_006571; Dextrotubocurarine chloride; Tubocurarine, chloride, hydrochloride, (+)-; Tubocurarina cloruro [DCIT]; Tubocurarine chloride (anhydrous); 13H-4,6:21,24-Dietheno-8,12-metheno-1H-pyrido(3',2':14,15)(1,11)dioxacycloeicosino(2,3,4-ij)isoquinolinium, 2,3,13a,14,15,16,25,25a-octahydro-9,19-dihydroxy-18,29-dimethoxy-1,14,14-trimethyl-, chloride, hydrochloride, (13aR-(13aR*,25aS*))-; Cloruro de tubocurarina [INN-Spanish]; BSPBio_002770; DB01199; Tubocurarine, dichloride, (+)-; Isoquinoline alkaloid; Spectrum5_000685; KBio1_001515; d-(+)-Tubocurarine chloride; Spectrum2_001335; SDCCGMLS-0066631.P001; Tubocurarinum; SPBio_001489; Tubaine; KBioSS_002526; d-7',12'-Dihydroxy-6,6'-dimethoxy-2,2',2'-trimethyltubocuraranium chloride; CID64645; Amelizol; Jexin; AC1L21N8; Spectrum4_001922; Tubaine (TN); 3671-75-8; 29132-50-1	6989-98-6	6000	148848	TTDS00400	Neuronal acetylcholine receptor subunit alpha-2	CHRNA2	Q15822	1135	ENSG00000120903	antagonist
DAP000378	Decamethonium	NSC27268; 541-22-0 (dibromide); Prestwick2_000968; Decamethonum; NCGC00015323-03; C 10 (VAN) (*dibromide salt*); 1420-40-2 (diiodide); (DM)Br2; HMS2089A18; CHEBI:41934; Lopac-D-1260; 541-22-0; CHEMBL1190; InChI=1/C16H38N2/c1-17(2,3)15-13-11-9-7-8-10-12-14-16-18(4,5)6/h7-16H2,1-6H3/q+; BSPBio_000975; LS-17289; NCGC00015323-01; Prestwick1_000968; NCGC00022291-03; BRN 1774794; DB01245; 1,10-Decanediaminium, N,N,N,N',N',N'-hexamethyl-, dibromide; bmse000719; 3198-38-7 (dichloride); Prestwick3_000968; N,N,N,N',N',N'-hexamethyldecane-1,10-diaminium; CAS-541-22-0; NCGC00015323-02; AB00382965; 1,10-Decanediaminium, N,N,N,N',N',N'-hexamethyl-; Syncurine (*dibromide salt*); Ammonium, decamethylenebis(trimethyl-; CID2968; Syncurine; trimethyl-[10-(trimethylazaniumyl)decyl]azanium; NCGC00015323-08; AR-1K0685; AC1Q28RH; AIDS351484; SPBio_002896; decamethonium; Prestwick0_000968; C16H38N2; C11733; Lopac0_000385; DECAMETHONIUM ION; AIDS-351484; ZINC01532339; NCGC00163237-01; L001318; BPBio1_001073; UNII-C1CG1S3T2W; 1,10-Decanediaminium, N,N,N,N',N',N'-hexamethyl- (9CI); AC1L1EVK; decamethylenebis(trimethylammonium)bromide; HSDB 3221; 156-74-1	156-74-1	2968	13898	TTDS00400	Neuronal acetylcholine receptor subunit alpha-2	CHRNA2	Q15822	1135	ENSG00000120903	antagonist
DAP000352	Metocurine	CID21233; C07919; 7601-55-0 (diiodide); 13H-4,6:21,24-Dietheno-8,12-metheno-1H-pyrido(3',2':14,15)(1,11)dioxacycloeicosino(2,3,4-ij)isoquinolinium, 2,3,13a,14,15,16,25,25a-octahydro-9,18,19,29-tetramethoxy-1,1,14,14-tetramethyl-, (13aR,25aS)-; CHEMBL1259; UNII-V0M92G2U26; Tubocurarine, O,O'-dimethyl-, (+)-; Tubocurarine dimethyl ether iodide; Tubocuraranium, 6,6',7',12'-tetramethoxy-2,2,2',2'-tetramethyl- (9CI); DB01336; 33335-58-9 (dichloride); Chondrocurarine, O,O'-dimethyl-; O,O'-Dimethyltubocurarine; CHEBI:339465; Tubocuraranium, 6,6',7',12'-tetramethoxy-2,2,2',2'-tetramethyl-; LS-158185; Chondrocurarine, O,O'-dimethyl- (8CI); AC1L2HW8; METOCURINE; N,N',O,O-Tetramethyl-(+)-tubocurine; BRN 3583380	5152-30-7	21233	10121	TTDS00400	Neuronal acetylcholine receptor subunit alpha-2	CHRNA2	Q15822	1135	ENSG00000120903	antagonist
DAP000347	Carbachol	.gamma.-Carbamoyl choline chloride; Carbacholinum; Karbamoylcholin chlorid [Czech]; Lentin; Karbachol; TL 457; 2-((Aminocarbonyl)oxy)-N,N,N-trimethylethanaminium chloride; Ethanaminium, 2-((aminocarbonyl)oxy)-N,N,N-trimethyl-, chloride (1:1); Carbacolina; Carbachol [INN:BAN:JAN]; NCGC00093705-04; SBB057998; Carbamoylcholine-hydrochloride; (carbachol)(2-Carbamoyloxy-ethyl)-trimethyl-ammonium; gamma-Carbamoyl choline chloride; Choline chloride, carbamoyl-; carbachol; Carcholin; AC1LAVH8; NCGC00093705-01; Isopto Carbachol; Karbamoylcholin chlorid; (2-Carbamoyloxy-ethyl)-trimethyl-ammonium(Carbachol); Carbacholum chloratum; MolPort-003-666-136; MLS002153502; SMR000058584; Carbocholin; HMS1570P21; Carbastat; C 4382; HSDB 6373; Carbacholum [INN-Latin]; Coletyl; Ethanaminium, 2-((aminocarbonyl)oxy)-N,N,N-trimethyl-, chloride; Carbamylcholine chloride; UNII-8Y164V895Y; Mistura C; Choline chlorine carbamate; AC1L1L8K; Vasoperif; Carbacholinium chloratum; Ethanaminium, 2-(aminocarbonyl)oxy-N,N,N-trimethyl-, chloride; 2-((Aminocarbonyl)oxy)-N,N,N-trimethylethanaminum chloride; Carbacol; Carbacol [INN-Spanish]; NCGC00093705-03; Choline chloride, carbamate; Carbach; SPECTRUM1500158; HMS502E07; C-1770; WLN: ZVO2K1&1&1 &Q &G; Choline chloride carbamate; Choline, chloride carbamate(ester); 2-[(aminocarbonyl)oxy]-N,N,N-trimethylethanaminium chloride; Carbamoylcholine chloride; D00524; EU-0100243; Lentine [French]; Carbacholini chloridum; CARBACHOL CHLORIDE; Prestwick_1036; Carbaminoylcholine chloride; EINECS 200-127-3; Carbacolo; Carbocholine; Ethanaminium, 2-[(aminocarbonyl)oxy]-N,N,N-trimethyl-, chloride; Doryl (VAN); CB; CID5831; HMS2091O17; CHEMBL14; Carbamiotin; Lentine; C4382_SIGMA; Karbachol [Czech]; NCGC00093705-02; (2-Hydroxyethyl)trimethyl ammonium chloride carbamate; Carbacholine chloride; (2-Hydroxyethyl)trimethylammonium chloride carbamate; Carbachol hydrochloride; Rilentol; Carbachol (JAN/USP/INN); Choline, chloride, carbamate, hydrochloride; Doryl (pharmaceutical); Choline, chloride, carbamate; Carbaminocholine chloride; (2-Carbamoyloxyethyl)trimethylammonium chloride; Carbacholine; NSC32865; Carbochol; 2-(carbamoyloxy)-N,N,N-trimethylethanaminium chloride; 2-carbamoyloxyethyl(trimethyl)azanium chloride; Carbamic acid, ester with choline chloride; Carbamoylcholine; Carbacholin; P. V. Carbachol; Miostat; Choline carbamate chloride; Miostat (TN); LS-53194; Carbacolo [DCIT]; Jestryl; C6H15N2O2.Cl; Carbacholum; HMS1920I15; Moryl; NCGC00093705-05; NSC 32865; CHEBI:3385; (2-Carbamoyloxy-ethyl)-trimethyl-ammonium; C0596; Carbyl; 51-83-2; Doryl	51-83-2	2551	7978854	TTDS00400	Neuronal acetylcholine receptor subunit alpha-2	CHRNA2	Q15822	1135	ENSG00000120903	antagonist
DCL000264	XL765	N/A	210101-16-9	151171	47583799	TTDS00265	Serine/threonine-protein kinase mTOR	FK506-binding protein 12-rapamycin complex-associated protein 1;FKBP12-rapamycin complex-associated protein;FKBP-rapamycin associated protein;FRAP;FRAP1;Mammalian target of rapamycin;mTOR;Rapamycin target protein;RAPT1;Target of rapamycin;TOR kinase	P42345	2475	ENSG00000198793	inhibitor
DCL000767	Deforolimus	Deforolimus (USAN); AP-23573; D08900; AP 23573; Deforolimus; S1022_Selleck; Ridaforolimus; MK 8669; CID10191580; MK-8669; CID11520894; 42-(Dimethylphosphinate)rapamycin; 572924-54-0; AP23573, MK-8669, Ridaforolimus, Deforolimus	572924-54-0	11520894	49684238	TTDS00265	Serine/threonine-protein kinase mTOR	FK506-binding protein 12-rapamycin complex-associated protein 1;FKBP12-rapamycin complex-associated protein;FKBP-rapamycin associated protein;FRAP;FRAP1;Mammalian target of rapamycin;mTOR;Rapamycin target protein;RAPT1;Target of rapamycin;TOR kinase	P42345	2475	ENSG00000198793	inhibitor
DCL001094	AP23573	Deforolimus (USAN); AP-23573; D08900; AP 23573; Deforolimus; S1022_Selleck; Ridaforolimus; MK 8669; MK-8669; 42-(Dimethylphosphinate)rapamycin; 572924-54-0; AP23573, MK-8669, Ridaforolimus, Deforolimus	N/A	N/A	N/A	TTDS00265	Serine/threonine-protein kinase mTOR	FK506-binding protein 12-rapamycin complex-associated protein 1;FKBP12-rapamycin complex-associated protein;FKBP-rapamycin associated protein;FRAP;FRAP1;Mammalian target of rapamycin;mTOR;Rapamycin target protein;RAPT1;Target of rapamycin;TOR kinase	P42345	2475	ENSG00000198793	inhibitor
DAP001223	Everolimus	DB01590; Certican; 159351-69-6; UNII-9HW64Q8G6G; NCGC00167512-01; Zortress; NVP-RAD-001; CERTICAN(R); RAD-001C; Rapamycin, 42-O-(2-hydroxyethyl)-; (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-{(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone; MolPort-003-925-588; (1R,9S,12S,15R,16E,23S,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriacont; CHEMBL1201755; RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus; (1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone; (1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone; LS-143292; D02714; RAD-001; (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34as)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethy; Everolimus (JAN/USAN/INN); (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone; 42-O-(2-Hydroxyethyl)rapamycin; RAD001; MolPort-003-847-342; 07741_FLUKA; S1120_Selleck; SDZ-RAD; Everolimus; 40-O-(2-hydroxyethyl)-rapamycin; Afinitor; Everolimus [USAN]; RAD 001	159351-69-6	6442177	12014881	TTDS00265	Serine/threonine-protein kinase mTOR	FK506-binding protein 12-rapamycin complex-associated protein 1;FKBP12-rapamycin complex-associated protein;FKBP-rapamycin associated protein;FRAP;FRAP1;Mammalian target of rapamycin;mTOR;Rapamycin target protein;RAPT1;Target of rapamycin;TOR kinase	P42345	2475	ENSG00000198793	inhibitor
DCL001198	INK128	N/A	N/A	N/A	N/A	TTDS00265	Serine/threonine-protein kinase mTOR	FK506-binding protein 12-rapamycin complex-associated protein 1;FKBP12-rapamycin complex-associated protein;FKBP-rapamycin associated protein;FRAP;FRAP1;Mammalian target of rapamycin;mTOR;Rapamycin target protein;RAPT1;Target of rapamycin;TOR kinase	P42345	2475	ENSG00000198793	inhibitor
DAP001222	Temsirolimus	DB06287; WAY-130,779; Torisel; CCI-779; MolPort-003-850-408; Cci 779; 42-(3-Hydroxy-2-(hydroxymethyl)-2-methylpropanoate)rapamycin; Torisel (TN); Temsirolimus; D06068; Temsirolimus [USAN]; WAY-CCI 779; NCGC00167518-01; Rapamycin 42-[3-hydroxy-2(hydroxymethyl)-2-methylpropanoate]; Temserolimus; CHEMBL1201182; Temsirolimus (JAN/USAN/INN); 42-[3-Hydroxy-2-(hydroxymethyl)-2-methylpropanoate]rapamycin; NSC683864; Torisel, CCI-779, Temsirolimus; NSC-683864; S1044_Selleck; 343261-52-9; LS-186555; (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone 4'-(2,2-bis(hydroxymethyl)propionate); Rapamycin, 42-(3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate); LS-187004; LS-187783; C15182; 162635-04-3; (1R,2R,4S)-4-{(2R)-2-[(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-1,5,11,28,29-pentaoxo-1,4,5,6,9,10,11,12,13,14,21,22,23,24,25,26,27,28,29,31,32,33,34,34a-tetracosahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontin-3-yl]propyl}-2-methoxycyclohexyl 3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate; Rapamycin 42-(2,2-bis(hydroxymethyl)propionate)	162635-04-3	6918289	47207726	TTDS00265	Serine/threonine-protein kinase mTOR	FK506-binding protein 12-rapamycin complex-associated protein 1;FKBP12-rapamycin complex-associated protein;FKBP-rapamycin associated protein;FRAP;FRAP1;Mammalian target of rapamycin;mTOR;Rapamycin target protein;RAPT1;Target of rapamycin;TOR kinase	P42345	2475	ENSG00000198793	inhibitor
DCL001086	BGT226	N/A	N/A	N/A	N/A	TTDS00265	Serine/threonine-protein kinase mTOR	FK506-binding protein 12-rapamycin complex-associated protein 1;FKBP12-rapamycin complex-associated protein;FKBP-rapamycin associated protein;FRAP;FRAP1;Mammalian target of rapamycin;mTOR;Rapamycin target protein;RAPT1;Target of rapamycin;TOR kinase	P42345	2475	ENSG00000198793	inhibitor
DCL000624	Ridaforolimus	AP-23573; AP 23573; Deforolimus; S1022_Selleck; Ridaforolimus; MK 8669; MK-8669; 572924-54-0; AP23573, MK-8669, Ridaforolimus, Deforolimus	572924-54-0	N/A	N/A	TTDS00265	Serine/threonine-protein kinase mTOR	FK506-binding protein 12-rapamycin complex-associated protein 1;FKBP12-rapamycin complex-associated protein;FKBP-rapamycin associated protein;FRAP;FRAP1;Mammalian target of rapamycin;mTOR;Rapamycin target protein;RAPT1;Target of rapamycin;TOR kinase	P42345	2475	ENSG00000198793	inhibitor
DAP000663	Sirolimus	CID5924240; Perceiva; heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy; 3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone; nchembio883-comp3; SILA 9268A; DivK1c_006936; KBioGR_000410; Rapamycin Immunosuppressant Drug; AY-22989; UNM-0000358684; MLS000028373; (6H,31H)-pentone, 4,9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-; Sirolimus [USAN:BAN:INN]; (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-; NCI60_001851; Sirolimus, Rapamune,Rapamycin; CID5497196; CID5374464; DB00877; Bio2_000855; KBio1_001880; nchembio.79-comp1; Bio2_000375; CID6610346; CID9854379; D00753; Rapamune; CID10795871; Bio1_000782; KBio3_000780; Rapamycin (TN); 1pbk; SMR000058564; C07909; (3-(4-hydroxy-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-; CID6711160; CID9854380; MolMap_000043; KBio2_002978; Sirolimus (USAN/INN); WY-090217; SpecPlus_000840; CID5358081; CHEMBL413; LS-143290; CCRIS 9024; Rapamune (TN); NSC 226080; CID9962928; DE-109; R0395_SIAL; CHEBI:100923; Sirolimus (RAPAMUNE); 1fkb; Sirolimus; MS-R001; CBiol_002007; CID6610270; nchembio762-comp1; BiomolKI2_000084; KBio2_000410; HSDB 7284; CID5284616; 53123-88-9; AC1L9ZMV; NCIMech_000355; CID9833581; 9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-9,27-dihydroxy-3-; rapamycin; Bio1_000293; CID11959112; CID5040; KBio2_005546; CID5460439; CID10213190; NCGC00021305-05; 19E,21R*,23R*,26S*,27S*,34aR*))-; 23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29; CID313006; 23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine; FT-0082351; RPM; 23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine; RAP; QTL1_000069; Ambotz53123-88-9; Rapamycin C-7, analog 4; (-)-Rapamycin; SIIA 9268A; UNII-W36ZG6FT64; R0395_SIGMA; C51H79NO13; BIDD:PXR0165; S1039_Selleck; nchembio.100-comp4; CID9962926; Bio1_001271; RAPA; KBioSS_000410; nchembio.2007.42-comp2; LMPK06000003; CHEBI:9168; CID6436030; SMP1_000255; Rapamycin from Streptomyces hygroscopicus; AC1L1JH9; AC-722; A422989, NSC226080; AY 22989; HMS2089A21; CID11949238; NSC226080; CID478951; Rapammune; Antibiotic AY 22989; LCP-Siro; MolPort-003-959-433; Wy 090217; AC1L7MJ9; KBio3_000779; CID6713081	53123-88-9	6436030	207443	TTDS00265	Serine/threonine-protein kinase mTOR	FK506-binding protein 12-rapamycin complex-associated protein 1;FKBP12-rapamycin complex-associated protein;FKBP-rapamycin associated protein;FRAP;FRAP1;Mammalian target of rapamycin;mTOR;Rapamycin target protein;RAPT1;Target of rapamycin;TOR kinase	P42345	2475	ENSG00000198793	inhibitor
DCL001085	BEZ235	BEZ235; NVP-BEZ235, BEZ235; CID11977753; EC-000.2325; BEZ-235; 2-(4-(2,3-dihydro-3-methyl-2-oxo-8-(quinolin-3-yl)imidazo[4,5-c]quinolin-1-yl)phenyl)-2-methylpropanenitrile; Kinome_2911; ZINC24760115; S14-0511; CID 11977753; NVP-BEZ-235; S1009_Selleck; nchembio.117-comp24; ST51056474; MolPort-005-737-784	N/A	N/A	N/A	TTDS00265	Serine/threonine-protein kinase mTOR	FK506-binding protein 12-rapamycin complex-associated protein 1;FKBP12-rapamycin complex-associated protein;FKBP-rapamycin associated protein;FRAP;FRAP1;Mammalian target of rapamycin;mTOR;Rapamycin target protein;RAPT1;Target of rapamycin;TOR kinase	P42345	2475	ENSG00000198793	inhibitor
DCL001095	OSI-027	N/A	N/A	N/A	N/A	TTDS00265	Serine/threonine-protein kinase mTOR	FK506-binding protein 12-rapamycin complex-associated protein 1;FKBP12-rapamycin complex-associated protein;FKBP-rapamycin associated protein;FRAP;FRAP1;Mammalian target of rapamycin;mTOR;Rapamycin target protein;RAPT1;Target of rapamycin;TOR kinase	P42345	2475	ENSG00000198793	inhibitor
DCL001189	GDC-0980	N/A	N/A	N/A	N/A	TTDS00265	Serine/threonine-protein kinase mTOR	FK506-binding protein 12-rapamycin complex-associated protein 1;FKBP12-rapamycin complex-associated protein;FKBP-rapamycin associated protein;FRAP;FRAP1;Mammalian target of rapamycin;mTOR;Rapamycin target protein;RAPT1;Target of rapamycin;TOR kinase	P42345	2475	ENSG00000198793	inhibitor
DCL000481	AZD8055	N/A	N/A	219078	46531903	TTDS00265	Serine/threonine-protein kinase mTOR	FK506-binding protein 12-rapamycin complex-associated protein 1;FKBP12-rapamycin complex-associated protein;FKBP-rapamycin associated protein;FRAP;FRAP1;Mammalian target of rapamycin;mTOR;Rapamycin target protein;RAPT1;Target of rapamycin;TOR kinase	P42345	2475	ENSG00000198793	inhibitor
DCL000107	E2012	N/A	N/A	N/A	N/A	TTDC00051	Gamma-secretase	APH;Aph-1beta;Presenilin-stabilization factor-like;PSFL	Q8WW43	83464	ENSG00000138613	modulator
DCL000114	Fibrostat	N/A	N/A	N/A	N/A	TTDC00120	Protein-glutamine gamma-glutamyltransferase	TG(C);TG(C)Protein-glutamine gamma-glutamyltransferase;TGase C;TGase-H;TGC;Tissue transglutaminase;Tranglutaminase 2;Transglutaminase 2;TTg	P21980	7052	ENSG00000198959	inhibitor
DCL000871	LJP-1082	N/A	73332-88-4	3037609	36105454	TTDC00264	Beta-2-glycoprotein 1	Activated protein C-binding protein;Anticardiolipin cofactor;APC inhibitor;Apo-H;Apolipoprotein H;B2GPI;Beta(2)GPI;Beta-2-glycoprotein I	P02749	350	ENSG00000091583	inhibitor
DCL000558	MEDI-528	N/A	N/A	N/A	N/A	TTDC00186	Interleukin-9	IL-9;P40 cytokine;T-cell growth factor P40	P15248	3578	ENSG00000145839	inhibitor
DCL000676	ABT-874	N/A	339308-60-0	N/A	3820778	TTDC00033	Interleukin-12	CLMF p35;Cytotoxic lymphocyte maturation factor 35 kDa subunit;IL-12;NK cell stimulatory factor;NKSF	P29459	3592	ENSG00000168811	antibody
DCL001030	Ustekinumab	N/A	815610-63-0	N/A	85151085	TTDC00033	Interleukin-12	CLMF p35;Cytotoxic lymphocyte maturation factor 35 kDa subunit;IL-12;NK cell stimulatory factor;NKSF	P29459	3592	ENSG00000168811	antibody
DCL000235	STA-5326	STA5326; STA 5326; STA-5326; Apilimod; CID10173277; N-[(3-methylphenyl)methylideneamino]-6-morpholin-4-yl-2-(2-pyridin-2-ylethoxy)pyrimidin-4-amine; 541550-19-0	870087-36-8	11527330	47208212	TTDC00033	Interleukin-12	CLMF p35;Cytotoxic lymphocyte maturation factor 35 kDa subunit;IL-12;NK cell stimulatory factor;NKSF	P29459	3592	ENSG00000168811	inhibitor
DAP000820	Histamine Phosphate	Histamine phosphate (USP); 4-(2-Aminoethyl)imidazole bis(dihydrogen phosphate); EINECS 200-118-4; 4-2(2-Aminoethyl)Imidazole-Di-Acid Phosphate; UNII-QWB37T4WZZ; Histamine diphosphate; 74-56-6; Histamine biphosphate; Histamine phosphate [USP]; Histamine dihydrogen phosphate; 2-Imidazol-4-ylethylamine orthophosphoric acid (1:2); Histamine phosphate (1:2); D04445; AC1L23E4; Histamine phosphate (TN); Histamine acid phosphate; 1H-Imidazole-4-ethanamine, phosphate (1:2); LS-78569; H0147; CID65513; Histamine positive; 51-74-1; 4-(2-Aminoethyl)imidazole di-acid phosphate; 53623-99-7; DB00667	51-74-1	65513	207516	TTDS00085	Histamine receptor	N/A	N/A	N/A	N/A	agonist
DAP000096	Cetrorelix	Ac-D-Nal(2)-D-Phe(pCl)-D-Pal(3)-Ser-Tyr-D-Cit-Leu-Arg-Pro-D-Ala-NH2; N-acetyl-3-(2-naphthyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridyl)-D-alanyl-L-seryl-L-tyrosyl-N5-carbomoyl-D-ornithyl-L-leucyl-L-prolyl-D-alaninamide; 120287-85-6; CHEMBL1200490; D07665; Cetrotide (TN); HS-2008; Cetrorelix (INN); N-acetyl-3-(naphthalen-2-yl)-D-alanyl-4-chloro-D-phenylalanyl-3-(pyridin-3-yl)-D-alanyl-L-seryl-L-tyrosyl-N(5)-carbamoyl-D-ornithyl-L-leucyl-L-arginyl-L-prolyl-D-alaninamide; Cetrorelixum; Cetrorelix; CHEBI:59224	120287-85-6	16129715	7848748	TTDS00273	Gonadotropin-releasing hormone receptor	GnRH receptor;GnRH-R;Gonadotrophin releasing hormone receptor;Hypothalamic gonadotropin-releasing hormone receptor	P30968	2798	ENSG00000109163	antagonist
DAP001446	Leuprorelin acetate	acetic acid; N-[1-[[1-[[1-[[1-[[1-[[1-[[5-(diaminomethylideneamino)-1-[2-(ethylcarbamoyl)pyrrolidin-1-yl]-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide; Leuprorelin acetate (JAN); CID441410; NSC746847; 5-oxoPro-His-Trp-Ser-Tyr-D-Leu-Leu-Arg-ProNHC2H5 dihydrate; D00989; Lupron (TN); Leuprolide acetate; AC1L9B44	N/A	657181	12013727	TTDS00273	Gonadotropin-releasing hormone receptor	GnRH receptor;GnRH-R;Gonadotrophin releasing hormone receptor;Hypothalamic gonadotropin-releasing hormone receptor	P30968	2798	ENSG00000109163	agonist
DAP001386	Ganirelix	D08010; Orgalutran (TN); 123246-29-7; Ganirelix; 124904-93-4; Ganirelixum [INN-Latin]; RS-26306; Orgalutran; LS-187280; D-Alaninamide, N-acetyl-3-(1-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-L-tyrosyl-N6-(bis(ethylamino)methylene)-D-lysyl-L-leucyl-N6-(bis(ethylamino)methylene)-L-lysyl-L-prolyl-; Ganirelix acetate; Ganirelixum; CHEBI:336376; UNII-IX503L9WN0; LS-181948; Ganirelix (INN); CHEMBL1251; Ganirelix [INN:BAN]	123246-29-7	25081094	700328	TTDS00273	Gonadotropin-releasing hormone receptor	GnRH receptor;GnRH-R;Gonadotrophin releasing hormone receptor;Hypothalamic gonadotropin-releasing hormone receptor	P30968	2798	ENSG00000109163	antagonist
DAP001052	Gonadorelin	L000690; Synthetic LH-FSH-RH; Hypocrine; Lutrepulse KIT; Gonadorelin [INN:BAN]; Fertagyl (TN); Human LH-RH; Synthetic Gn-RH; Gonadotropin-releasing hormone; FSH-Releasing Hormone; Gonadorelina; Luteinizing hormone-releasing hormone; LH-Releasing factor (pig); Follicle-stimulating hormone-releasing factor (pig); Gonadotropin-releasing hormone I; Factrel; Synthetic LH-releasing hormone; Luteinizing hormone-releasing factor (human); LH-Releasing hormone (porcine); Synthetic LH-releasing factor; LUTEINIZING HORMONE; C55H75N17O13; Lutamin; CID36523; Glycinamide, 5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosylglycyl-L-leucyl-L-arginyl-L-prolyl-; HOE 471; Fertagyl; Lutal; Luforan; p-Glu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2; 9061-55-6; pyroGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2; Synthetic LH-RH/FSH-RH; DB00644; EINECS 251-553-1; Gonadorelinum; LH-RH (swine); UNII-9O7312W37G; Porcine LH-releasing factor; AY-24031; Dirigestran Spofa; Porchine LH-RH; Synthetic LRF; LH-FSH Releasing Hormone; Gonadotropin-releasing factor; LHFSHRH; Luteinizing hormone-releasing hormone (swin); Gonadorelina [INN-Spanish]; Synthetic LH-FSH releasing hormone; Lutrefact; Luteinizing hormone-releasing factor (pig); LHRH; Gonadotropin, luteinizing hormone-releasing hormone, synthetic; Gonadorelinum [INN-Latin]; Ovine LH-RH; Ovine gonadotropin-releasing hormone; LH-RH; Synthetic gonadotropin-releasing hormone; Luliberin; 9034-40-6; 71339-77-0; I06-0360; Synthetic decapeptide FSH/LH-RH; Mammalian LH-RH; 51952-41-1 (Hydrochloride); LHFSH Releasing Hormone; Gonadotropin releasing hormone; N-[1-[[1-[[1-[[1-[[2-[[1-[[1-[2-[(2-amino-2-oxoethyl)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide; Synthetic LH-RF; D08027; AC1L1VXF; Luteinizing hormone-releasing factor (rat); Synthetic LH-releasing hormone/FSH-releasing hormone; Synthetic gonadotropic hormone-releasing hormone; C07607; 71447-49-9; Gn-RH; 9042-18-6; Luteinizing hormone-releasing factor (sheep); GnRH-I; Relisorm l; LS-174422; Synthetic gonadoliberin; Relisorm; Synthetic LH-RH; Luteinizing hormone-releasing factor (swine); Kryptocur; Gonadoliberin I; Relefact; 33515-09-2; 52699-48-6 (Acetate); LFRH; GONADORELIN; Dirigestran; 38569-05-0; Gonadorelin (INN); LH-Releasing hormone; 9066-58-4; 6918-09-8; Mammalian GnRH; Mammalian gonadotropin-releasing hormone	6918-09-8	36523	9809	TTDS00273	Gonadotropin-releasing hormone receptor	GnRH receptor;GnRH-R;Gonadotrophin releasing hormone receptor;Hypothalamic gonadotropin-releasing hormone receptor	P30968	2798	ENSG00000109163	agonist
DCL000650	TAK-385	N/A	N/A	N/A	N/A	TTDS00273	Gonadotropin-releasing hormone receptor	GnRH receptor;GnRH-R;Gonadotrophin releasing hormone receptor;Hypothalamic gonadotropin-releasing hormone receptor	P30968	2798	ENSG00000109163	antagonist
DAP001051	Nafarelin	DB00666; I06-0375; Luteinizing hormone-releasing factor (pig), 6-(3-(2-naphthalenyl)-D-alanine)-; L004233; Nafareline; Nafarelin (INN); AC1Q1P5R; NAFARELIN; Synarel; Nafareline [French]; C07613; LS-88237; Nafarelinum [Latin]; Nafarelinum; HS-2018; Nafarelina; RS-94991-298; BIDD:GT0760; LHRH, Ala(2-naphthyl)(6)-; MolPort-006-823-890; NAFARELIN ACETATE; 6-(3-(2-Naphthalenyl)-D-alanine)luteinizing hormone-releasing factor (pig); 76932-60-0 (monoacetate (salt)); C15H17NO; Nafarelin Acetate, Hydrate; D08241; UNII-1X0094V6JV; 86220-42-0 (acetate (salt), hydrate); 6918-10-1; Nafarelin [INN:BAN]; 76932-56-4; Nafarelina [Spanish]	76932-56-4	16129618	9815	TTDS00273	Gonadotropin-releasing hormone receptor	GnRH receptor;GnRH-R;Gonadotrophin releasing hormone receptor;Hypothalamic gonadotropin-releasing hormone receptor	P30968	2798	ENSG00000109163	agonist
DAP000061	Phenobarbital	5-Ethyl-5-phenyl-pyrimidine-2,4,6-trione; Chinoin; Euneryl; DivK1c_000987; Fenemal; Austrominal; Sedonal (sedative); 50-06-6; Valprin 50-PB; Nirvonal; Luramin; D00506; HSDB 3157; 5-ethyl-5-phenyl-1,3-diazinane-2,4,6-trione; Pharmetten; Seda-Tablinen; I06-0652; Helional; component of Primatene P; Haplopan; Dormina; Parkotal; Aephenal; Somnosan; Noptil; Stental Extentabs; Lephebar; CCRIS 502; Phenobarb; AC1L1IWE; Phenyral; Luminal; Talpheno; Tridezibarbitur; component of Tedral; Luminal (TN); 57-30-7 (mono-hydrochloride salt); Calminal; Phenonyl; Sedofen; Starilettae; Bialminal; IDI1_000987; Barbivis; Phenylethylmalonylurea; Levsin PB Drops and Tablets; Lixophen; Episedal; Chardonna-2; Thenobarbital; Nova-Pheno; Solfoton talpheno; component of Slowten; Phenylethyl barbituric acid; Phenyletten; Haplos; DB01174; component of Valpin 50-PB; Somnoletten; Stental; LS-135; Hysteps; Somnolens; Triphenatol; Sedicat; Aphenylbarbit; Phenemal; CHEMBL40; Ensodorm; seda-tabl inen; Solu-Barb; Epilol; Cratecil; Fenylettae; NSC9848; Fenobarbitale [DCIT]; Fenobarbital [INN-Spanish]; Phenobarbituric acid; Sedabar; Barbilehae (barbilettae); Phenomet; Starifen; Hypnogen; C07434; Barbophen; Linasen; Promptonal; Elixir of phenobarbital; 46755-67-3; Solfoton; Phen-Bar; SK-Phenobarbital; MolPort-001-783-066; barbilehae; Pamine PB; Ensobarb; Sedonal; Bartol; phenobarbital (PB); Lumesyn; Phenobarbitalum [INN]; EINECS 200-007-0; Cabronal; Lumofridetten; theominal; UNII-YQE403BP4D; Doscalun; Antrocol; barbellon; Eskabarb; Nunol; Barbonal; Hennoletten; 5-Ethyl-5-phenyl-2,4,6(1H,3H,5H)-pyrimidinetrione; Teoloxin; Lumen; Agrypnal; Hypno-Tablinetten; AI3-02726; Phenobarbitone; 5-Ethyl-5-phenylbarbituric acid; Cardenal; Aphenyletten; Fenobarbital; Versomnal; Donphen; d ezibarbitur; Zadoletten; le phebar; Phenylethylbarbitursaeure; Barbiphenyl; HMS503E15; Dormiral; Phenylethylbarbituric acid; NINDS_000987; Theoloxin; phenobarbital; Neurobarb; Dormital; Sevenal; Sombutol; MolPort-003-959-166; barbellen; NCGC00159493-03; Duneryl; Sedophen; Sedonettes; Phenylaethylbarbitursaeure; 5-Ethyl-5-phenyl-2,4,6-pyrimidinetrione; Fenobarbitale; Coronaletta; CID4763; Liquital; Gardenal; Hypnoltol; Epidorm; 11097-06-6; Hypnaletten; Triabarb; Damoral; 5-ethyl-5-phenylpyrimidine-2,4,6(1H,3H,5H)-trione; Phenobal; Phenobarbitol; PUBERTAL PHENOBARBITAL STUDY; Phenobarbitalum; Gustase-Plus; Oprea1_384816; Luphenil; Lubrokal; Phenobarbyl; 5-Ethyl-5-phenyl-2,4,6-(1H,3H,5H)pyrimidinetrione; Acido 5-fenil-5-etilbarbiturico; Barbiphen; Acido 5-fenil-5-etilbarbiturico [Italian]; NSC128143; Barbita; phenylral; component of Hecadrol; Lepinaletten; Phenobarbital (JP15/USP/INN); Leonal; KBio1_000987; Adonal; Phenemalum; Amylofene; NSC 128143; Spasepilin; Phazyme-PB; P1636_SIGMA; SMR000058986; Bardorm; Lepinal; 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-5-phenyl-; Phenyl-ethyl-barbituric acid; Lefebar; Dezibarbitur; Calmetten; Phenolurio; Zadonal; Teolaxin; CHEBI:8069; Phenobarbitonum; Glysoletten; Somonal; Barbituric acid, 5-ethyl-5-phenyl-; component of Bronkotabs; Sedlyn; Arco-Lase Plus; Barbinal; Fenbital; Lumesettes; Phenaemal; Phenobarbital, Monosodium Salt; Gardepanyl; aephe nal; BIDD:PXR0061; WLN: T6VMVMV FHJ F2 FR; component of Antrocol; Henotal; MLS001240232; Barbipenyl; Phenobarbital [USAN:INN:JAN]; Hypnolone; Hypnette; BAS 00226811; AKOS000605404; Phenylethylbarbiturate; Epanal; PHOB; barbapil; NCGC00159493-02; DEA No. 2285; Phenobarbitalum [INN-Latin]; Codibarbita; Molinal; Lubergal; Fenosed; stental exte ntabs; Etilfen; Barbipil; Barbenyl; Blu-phen; Phenoluric; Phenoturic; Polcominal; InChI=1/C12H12N2O3/c1-2-12(8-6-4-3-5-7-8)9(15)13-11(17)14-10(12)16/h3-7H,2H2,1H3,(H2,13,14,15,16,17; Sedizorin; 5-Phenyl-5-ethylbarbituric acid; Epsylone; fen osed	50-06-6	4763	7847572	TTDS00018	Gamma-aminobutyric acid receptor	GABA receptor	N/A	N/A	N/A	antagonist
DCL000788	E-2007	Perampanel; 2-(2-oxo-1-phenyl-5-pyridin-2-yl-pyridin-3-yl)benzonitrile; E 2007; D08964; 3-(2-Cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one; Perampanel (USAN); CHEMBL1214124; E-2007; UNII-H821664NPK; 380917-97-5; CID9924495	380917-97-5	9924495	85150212	TTDS00018	Gamma-aminobutyric acid receptor	GABA receptor	N/A	N/A	N/A	agonist
DAP000259	Clonazepam	Kenoket; EINECS 216-596-2; Iktorivil; Oprea1_168772; LS-34260; DivK1c_000973; KBio1_000973; HMS2093H22; 2-H-1,4-Benzodiazepin-2-one, 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-; 106955-87-7; Lktorivil; D002998; 5-(o-chlorophenyl)-7-nitro-1,3-dihydro-2H-1,4-benzodiazepin-2-one; 5-24-04-00351 (Beilstein Handbook Reference); 2H-1,4-Benzodiazepin-2-one, 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-; CHEMBL452; AC-15733; 7-Nitro-5-(2-chlorophenyl)-3H-1,4-benzodiazepin-2(1H)-one; LS-34156; 1622-61-3; Ro-5-4023; 1,3-Dihydro-5-(o-chlorophenyl)-7-nitro-3H-1,4-benzodiazepin-2-one; NSC179913; Clonopin; HSDB 3265; Klonopin; 5-(2-Chlorophenyl)-7-nitro-3H-1,4-benzodiazepin-2(1H)-one; Rivoril; Clonazepam [USAN:INN:BAN:JAN]; UNII-5PE9FDE8GB; Chlonazepam; Cloazepam; DB01068; C15H10ClN3O3; Lonazep; C1277_SIGMA; Clonazepamum; 2H-1,4-Benzodiazepin-2-one, 5-(2-chlorophenyl)-1,3-dihydro-7-nitro-; 5-(2-chlorophenyl)-7-nitro-1,3-dihydro-1,4-benzodiazepin-2-one; RO4023; 5-(o-Chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one; Clonazepam (JP15/USP/INN); AC1L1EI2; MolPort-001-729-088; 5-(o-Chlorophenyl)-7-nitro-1H-1,4-benzodiazepin-2(3H)-one; Rivatril; Ro 54023; 5-(2-Chloro-phenyl)-7-nitro-1,3-dihydro-benzo[e][1,4]diazepin-2-one; BRN 0759557; 5-(2-Chlorophenyl)-7-nitro-1,3-dihydro-2H-1,4-benzodiazepin-2-one; Ro 5-4023; BAS 00308658; Clonex; Ro 4023; CID2802; Solfidin; Rivotril; CHEBI:3756; Ro 4-8180; Alti-Clonazepam; Paxam; DF2374250; DEA No. 2737; I14-1364; IDI1_000973; 1,3-Dihydro-7-nitro-5-(2-chlorophenyl)-2H-1,4.benzodiazepin-2-one; WLN: T67 GMV JN IHJ CNW KR BG; Antilepsin; Landsen; Melzap; 3H-1,4-Benzodiazepin-2-one, 1,3-dihydro-5-(o-chlorophenyl)-7-nitro-; NIOSH/DF2374250; ZINC03813003; HMS503C07; 5-(2-Chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one; Jsp003251; Klonopin (TN); Ravotril; NINDS_000973; BIDD:PXR0144; D00280; Ro 5-4023/B-7; Klonopin Rapidly Disintegrating; Antelepsin; NSC 179913; Clonazepamum [INN-Latin]; clonazepam	1622-61-3	2802	158706	TTDS00018	Gamma-aminobutyric acid receptor	GABA receptor	N/A	N/A	N/A	agonist
DCL000772	Dextofisopam	R-Tofisopam; AC1L4BXA; UNII-EZ15I5D6C1; Dextofisopam; D03737; Dextofisopam (USAN/INN); CID204105; 82059-50-5; (5R)-1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-5H-2,3-benzodiazepine	82059-50-5	4829	17397826	TTDS00018	Gamma-aminobutyric acid receptor	GABA receptor	N/A	N/A	N/A	agonist
DPR000023	BL-1020	955400-87-0; BL 1020; Perphenazine 4-aminobutyrate; Butanoic acid, 4-amino-, 2-(4-(3-(2-chloro-10H-phenothiazin-10-yl)propyl)-1-piperazinyl)ethyl ester; BL-1020; 751477-01-7	1027512-25-9	213046	47362895	TTDS00018	Gamma-aminobutyric acid receptor	GABA receptor	N/A	N/A	N/A	agonist
DCL000928	Phentermine+topiramate	N/A	122-09-8	N/A	N/A	TTDS00018	Gamma-aminobutyric acid receptor	GABA receptor	N/A	N/A	N/A	modulator
DAP000666	Piperazine	NCIOpen2_005575; D00807; NCIOpen2_001151; NCIOpen2_005182; NCIOpen2_005200; PZE; 1,4-Diethylenediamine; 1,4-Diazacyclohexane; Diethylenediamine; LTBB000432; Anthalazine; EINECS 203-808-3; 1951-97-9 (unspecified phosphate); P45907_SIAL; NCIOpen2_004982; NCIOpen2_004862; UN2579; Piperazin [German]; ARONIS23910; Worm-A-Ton; Spectrum_001113; Pyrazine, hexahy; 110-85-0; P0447; Wurmirazin; NCIOpen2_004952; NCIOpen2_005108; 80621_FLUKA; BIDD:GT0273; NCIOpen2_004914; IDI1_000038; NCIOpen2_004904; NCIOpen2_004874; Spectrum5_001817; Hexahydropyrazine; NCIOpen2_001231; NCIOpen2_005980; CCRIS 5950; NCIOpen2_001033; 8017-90-1; KBio2_006729; HMS2092A03; Vermex; Dispermine; NCIOpen2_004834; 16832-43-2 (unspecified hydrate); Pyrazine, hexahydro-; NCIOpen2_000984; Lumbrical; CHEBI:28568; NCIOpen2_005145; nchembio814-comp12; NINDS_000038; DivK1c_000038; NCIOpen2_001073; C07973; HSDB 1093; KBio2_001593; NCIOpen2_000988; InChI=1/C4H10N2/c1-2-6-4-3-5-1/h5-6H,1-4H; Piperazine anhydrous; NCIOpen2_004830; Pipersol; 5-23-01-00030 (Beilstein Handbook Reference); Piperazine, anhydrous; Jsp000824; Eraverm; KBioSS_001593; NSC 474; Piperazin [Germany]; 14538-56-8 (phosphate[1:1]); P0446; NCIOpen2_004954; AR-1L1009; 854880-15-2; NCIOpen2_005072; AC1Q1IA7; NCGC00094762-02; Piperazine [UN2579]  [Corrosive]; Piperazine [USAN]; BRN 0102555; DB00592; Pyrazine hexahydride; KBio2_004161; NCIOpen2_005034; Piperazine Hexa-Hydrate; 142-63-2 (hexahydrate); 1,4-Diazacyclohexane; UNII-1RTM4PAL0V; NCIOpen2_004994; KBio1_000038; Asca-Trol No. 3; 8057-14-5 (unspecified salt); NCIOpen2_001269; NCIOpen2_001111; Worm-away; NCIOpen2_001262; HMS500B20; Vermizine (TN); Eraverm (VAN); PIPERAZINE (HEXAHYDRATE); CID4837; NCIOpen2_005102; Piperazine [UN2579] [Corrosive]; 8027-81-4; MolPort-000-872-010; AKOS000269028; dro-; piperazinium oleate; LS-517; NCIOpen2_005187; SPECTRUM1500490; NCIOpen2_005062; NCIOpen2_001031; 1,4-Piperazine; Uvilon; NCIOpen2_001024; AC1Q1IA9; piperazine; AC1L1J2E; NCGC00094762-01; NCIOpen2_004942; Upixon; 7542-23-6 (mono-hydrochloride); Piperazine Dihydrochloride Dihydrochloride Hydrate; NCIOpen2_005022; 6094-40-2 (unspecified hydrochloride); AB1003720; I14-11172; Hexahydro-1,4-diazine; NCIOpen2_001071; HMS1920H20; 3597-26-0 (unspecified sulfate); NCIOpen2_004910; WLN: T6M DMTJ; 142-64-3 (di-hydrochloride); Piperazidine; NCIOpen2_005032; AC1Q1IA8; CHEMBL1412; Diethylenediamine; Antiren; NCIOpen2_005185; Diethyleneimine; Vermizine; NCIOpen2_004992; NCIOpen2_009422; Piperazin; Piperazine (USP); NSC474; 14007-05-7 (unspecified hydrobromide); 861800-35-3	110-85-0	4837	7847872	TTDS00018	Gamma-aminobutyric acid receptor	GABA receptor	N/A	N/A	N/A	antagonist
DCL000811	Ganaxolone	CID11537287; GANAXOLONE; Pregnan-20-one, 3-hydroxy-3-methyl-, (3alpha,5alpha)-; AC1OCF9O; 38398-32-2; Ganaxolone (USAN/INN); D04300; NCGC00165802-02; CID6918305; CHEBI:370090; NCGC00165802-03; CCD 1042; CID38022; UNII-98WI44OHIQ; 3alpha-Hydroxy-3-methyl-5alpha-pregnan-20-one; CHEMBL161915; G7795_SIGMA; 1-[(3R,5S,10S,13S,17S)-3-hydroxy-3,10,13-trimethyl-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]ethanone; 1-[(3R,5S,8R,9S,10S,13S,14S,17S)-3-hydroxy-3,10,13-trimethyl-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]ethanone; 3alpha-Hydroxy-3beta-methyl-5alpha-pregnan-20-one; LS-118581; CCD-1042; (3alpha,5alpha)-3-Hydroxy-3-methylpregnan-20-one; C22H36O2; Ganaxolone [USAN]; AC1L1YWW	38398-32-2	21157	47206230	TTDS00018	Gamma-aminobutyric acid receptor	GABA receptor	N/A	N/A	N/A	modulator
DCL000929	Phenylbutyrate	Spectrum4_000092; 4-phenylbutyrate; Spectrum5_001003; CID20354; CPD000059104; AC1L2G3A; Spectrum2_001798; BRD-K67102207-236-01-0; I01-3326; DB02000; SAM002264634; NSC 295; .gamma.-Phenylbutyric acid; KBio1_001854; GAMMA-PHENYL-BUTYRIC ACID; FT-0082934; ZINC02037928; BSPBio_002484; AC-3254; Benzenebutanoic acid; AI3-12065; SPBio_001755; gamma-Phenylbutyric acid; TL8001458; AI3-11761; AC1Q5W0X; Phenylbutyrate; Butyric acid, 4-phenyl- (8CI); 4-PHENYLBUTYRIC ACID; NSC295; 2ay7; 4-phenylbutans; Butanoic acid, phenyl ester; Benzenebutyric acid; NCGC00018113-01; Butyric acid, 4-phenyl-; LS-173716; SpecPlus_000814; bmse000701; Spectrum3_000782; EINECS 217-341-8; CID4775; 4-Phenylbutanoic acid; DivK1c_006910; 4346-18-3; KBio2_001811; AKOS002952627; P0643; 1821-12-1; KBioGR_000384; OBKXEAXTFZPCHS-UHFFFAOYSA-; EINECS 224-405-9; InChI=1/C10H12O2/c11-10(12)8-4-7-9-5-2-1-3-6-9/h1-3,5-6H,4,7-8H2,(H,11,12); 2-methyl-1-phenyl-propan-2-amine; AKOS000154540; MLS000069408; AC1L1IXE; KBio2_006947; P21005_ALDRICH; MolPort-000-871-587; Spectrum_001331; MLS001076482; SBB008452; NCI60_002455; 4-PHENYL-BUTANOIC ACID; CHEBI:41500; phenyl butanoate; LS-46421; HDInhib_000004; 1716-12-7 (hydrochloride); NCI60_020145; AC1Q75DT; .omega.-Phenylbutanoic acid; phenyl butyrate; BRD-K67102207-001-02-6; AR-1G4411; AB1001924; CHEMBL1469; KBioSS_001811; SMR000059104; Butyric acid, phenyl ester; omega-Phenylbutanoic acid; AC1Q75DU; 1-Phenylbutyric acid; KBio2_004379; FR-2080; KBio3_001704	90315-82-5	2733848	12051860	TTDS00018	Gamma-aminobutyric acid receptor	GABA receptor	N/A	N/A	N/A	agonist
DCL000240	T-5224	T5224; CID9647566; AKOS003047196; MolPort-001-803-184	N/A	N/A	N/A	TTDC00119	Transcription factor AP-1	Activator protein 1;Activator protein-1;AP1;AP-1 transcription factor;C-jun proto-oncogene;P39;Proto-oncogene c-jun;V-jun avian sarcoma virus 17 oncogene homolog	P05412	3725	ENSG00000177606	inhibitor
DCL001151	ASG-5ME	N/A	N/A	N/A	N/A	TTDC00340	Choline transporter-like protein 4	Solute carrier family 44 member 4;SLC44A4	Q53GD3	80736	ENSG00000204385; ENSG00000206378; ENSG00000229077; ENSG00000235336; ENSG00000228263; ENSG00000232180; ENSG00000231479	antibody
DAP001344	Aldosterone	Aldocortin; Aldosteronum [INN-Latin]; SR-01000838883-2; 11beta,21-Dihydroxypregn-4-ene-3,18,20-trione; 11beta,21-dihydroxy-3,20-dioxopregn-4-en-18-al; CHEMBL273453; LS-118602; Pregn-4-en-18-al, 11,21-dihydroxy-3,20-dioxo-, (11beta)-; (11BETA)-11,21-DIHYDROXY-3,20-DIOXOPREGN-4-EN-18-AL; Aldosterona; 152-04-5; EINECS 200-139-9; Aldosterone, (11 beta,17 alpha)-Isomer; d-Aldosterone; 11beta,21-dihydroxy-3,20-dioxo-pregn-4-ene-18-al; NCGC00164236-01; MLS001333163; 18-Formyl-11beta,21-dihydroxy-4-pregnene-3,20-dione; Reichstein X; NSC 73856; CHEBI:27584; 11beta,21-Dihydroxy-3,20-dioxo-4-pregnen-18-al; UNII-4964P6T9RB; Pregn-4-en-18-al, 11,21-dihydroxy-3,20-dioxo-, (11-beta)-; Electrocortin; AC1L1L95; 10328-70-8; NSC73856; A9477_SIGMA; (8S,9S,10R,11S,13R,14S,17S)-11-hydroxy-17-(2-hydroxyacetyl)-10-methyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthrene-13-carbaldehyde; DB04630; Aldocortene; Aldocorten; LMST02030026; BRN 3224996; ZINC03833824; Aldosteronum; 52-39-1; ALDOSTERONE; 18-Oxocorticosterone; 11beta,21-Dihydroxy-3,20-dioxo-4-pregnen-18-al, 18,11-halbacetal; (+)-Aldosterone; BIDD:ER0511; 11beta,21-Dihydroxy-3,20-diketopregn-4-ene-18-al; Aldosterone [INN:BAN:DCF]; SR-01000838883; 18-Aldocorticosterone; Elektrocortin; MLS001333164; CID5839; Aldosterone, (+-)-Isomer; 11beta,21-Dihydroxy-3,20-diketo-4-pregnen-18-al; 4-08-00-03491 (Beilstein Handbook Reference); 11.beta.,21-Dihydroxypregn-4-ene-3,18,20-trione; C01780; SMR000857170; D000450; Aldosterona [INN-Spanish]	52-39-1	5839	148643	TTDS00153	Na-K-2Cl cotransporter	Basolateral Na-K-Cl symporter;Bumetanide-sensitive sodium-(potassium)-chloride cotransporter 1;Na + K + -2Cl - cotransporter;NKCC1	P55011	6558	ENSG00000064651	blocker
DAP000831	Valproic Acid	nchembio.79-comp4; Deproic; Myproic Acid; MLS001076682; Acide valproique [INN-French]; Vupral; KBio2_007413; G2M-777; I04-0211; Novo-Valproic; Acido valproico; Acido valproico [INN-Spanish]; NCGC00091149-01; Valproic acid USP; Di-n-propylacetic acid; Ergenyl; Med Valproic; CID3121; KBioGR_002277; Kyselina 2-propylvalerova [Czech]; MolPort-001-791-895; 2-Propylvaleric acid; Valproate; DB00313; SAM002564230; HSDB 3582; SBB065764; VPA; Acidum valproicum; KBio3_002757; KBio2_003569; Valproinsaeure; Mylproin; Valproic acid USP24; Avugane; Valproic acid (USP); KBio2_002277; 2-n-Propyl-n-valeric acid; Di-n-propylessigsaure [German]; Di-n-propylessigsaure; Valproic acid [USAN:INN:BAN]; NCGC00091149-04; 2 PP (base); MLS001335928; Nu-Valproic; P0823; Propylvaleric acid; Valproic Acid, Sodium Salt (2:1); MLS002415770; BIDD:GT0858; AC1Q2ULA; NINDS_000273; n-Dipropylacetic acid; KBio1_000273; KBioSS_001001; KBioSS_002278; CPD000499581; Convulsofin; Dipropylacetic acid; AI3-10500; Valeric acid, 2-propyl-; Spectrum3_001733; EINECS 202-777-3; KBio2_001001; PMS-Valproic Acid; 4-Heptanecarboxylic acid; Dipropyl Acetate; Di-n-propylessigsaeure; nchembio815-comp21; CHEMBL109; Depakin chrono; 76584-70-8 (hydrochloride salt (2:1)); SPBio_000912; Abbott 44090; Depakin; Pentanoic acid, 2-propyl-; Penta-Valproic; Spectrum_000521; Savicol; KBioGR_000871; NSC93819; 99-66-1; MLS001335927; WLN: QVY3 & 3; P6273_SIGMA; SMR000499581; InChI=1/C8H16O2/c1-3-5-7(6-4-2)8(9)10/h7H,3-6H2,1-2H3,(H,9,10); Alti-Valproic; Convulex; UNII-614OI1Z5WI; Depakine chrono; HMS2089J06; NCGC00091149-02; KBio2_004845; VALPROIC ACID; DivK1c_000273; LS-2068; C07185; NCGC00091149-03; Dom-Valproic; Depakene; D00399; KBio3_002626; Semisodium Valproate; Depakote (TM); Acide valproique; Acidum valproicum [INN-Latin]; Spectrum2_000946; Stavzor; NSC 93819; Depakene (TN); Dipropylacetate; n-DPA; 2-Propylpentanoic acid; Depakine; Kyselina 2-propylvalerova; BRN 1750447; Acetic acid, dipropyl-; AC1L1F7T; Spectrum4_000376; Baceca; LS-161170; NIJJYAXOARWZEE-UHFFFAOYSA-; CHEBI:39867; KBio2_006137	99-66-1	3121	7854737	TTDC00297	Histone deacetylase	HD;HDAC	N/A	N/A	N/A	inhibitor
DCL001054	VRX496	MLS001195634; DB00220; AC-20032; NFV; 3-Isoquinolinecarboxamide, N-(1,1-dimethylethyl)decahydro-2-[2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-(phenylthio)butyl]-, [3S-[2(2S*,3S*),3.alpha.,4a.beta.,8a.beta.]]-; N-(1,1-Dimethylethyl)decahydro-2-(2-hydroxy-3-((3-hydroxy-2-methylbenzoyl)amino)-4-(phenylthio)butyl)-3-isoquinolinecarboxamide (3S-(2(2S*,3S*),3alpha,4abeta,8abeta))-; nelfinavir; 3-Isoquinolinecarboxamide, N-(1,1-dimethylethyl)decahydro-2- [(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-(phenylthio)butyl]-, (3S,4aS,8aS)-; C07257; Met-Stromal Cell-derived Factor-1.beta. (Human) & Nelfinavir; 1UN; AC1L20J6; 2-[2-HYDROXY-3-(3-HYDROXY-2-METHYL-BENZOYLAMINO)-4-PHENYL SULFANYL-BUTYL]-DECAHYDRO-ISOQUINOLINE-3-CARBOXYLIC ACID TERT-BUTYLAMIDE; D08259; Nelfinavir (INN); BIDD:GT0395; Viracept (TM)(*Mesylate salt*); NELFINAVIR MESYLATE AG1343; AKOS000280862; NSC722664; 1ohr; AG1343 (*Mesylate salt*); 3-Isoquinolinecarboxamide, N-(1,1-dimethyl ethyl)decahydro-2-[(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-(phenylthio)butyl]-, (3S,4aS,8aS)-; MLS001304729; AG1343; NCGC00090782-03; 3-Isoquinolinecarboxamide, N-(1,1-dimethylethyl)decahydro-2-(2-hydroxy-3-((3-hydroxy-2-methylbenzoyl)amino)-4-(phenylthio)butyl)-, (3S-(2-(2S*,3S*),3-alpha,4a-beta,8a-beta))-; Nelfinavir [BAN:INN]; 3-Isoquinolinecarboxamide, N-(1,1-dimethylethyl)decahydro-2-((2R,3R)-2-hydroxy-3-((3-hydroxy-2-methylbenzoyl)amino)-4-(phenylthio)butyl)-, (3S,4aS,8aS)-; CID64143; C32H45N3O4S; (3S-(2(2S*,3S*),3alpha,4abeta,8abeta))-N-(1,1-Dimethylethyl)decahydro-2-(2-hydroxy-3-((3-hydroxy-2-methylbenzoyl)amino)-4-(phenylthio)butyl)-3-isoquinolinecarboxamide; VRX496; MolPort-000-883-833; NLF; Nelfinavir [INN:BAN]; MolPort-002-885-844; 159989-64-7; NSC747167; (3S,4aS,8aS)-N-tert-butyl-2-[(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-phenylsulfanylbutyl]-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinoline-3-carboxamide; BIDD:PXR0143; 159989-65-8 (monomethane sulfonate (salt)); SMR000596515; Nelfinavir Monomethane Sulfonate; Met-SDF-1.beta. & Nelfinavir; LS-85417; Viracept (TN); AG1346; CHEMBL584; UNII-HO3OGH5D7I; NCGC00090782-04	N/A	N/A	N/A	TTDC00283	mRNA of HIV-1 envelope protein	N/A	N/A	N/A	N/A	antisense
DCL000828	GSK-681323	N/A	N/A	N/A	N/A	TTDC00044	MAP kinase p38	ERK5;ERK6;ERK-6;Extracellular signal-regulated kinase 6;MAP kinase p38 gamma;MAPK12;Mitogen-activated protein kinase 12;Mitogen-activated protein kinase p38 gamma;SAPK3;Stress-activated protein kinase 3	P53778	6300	ENSG00000188130	inhibitor
DCL000944	R1503	N/A	209783-80-2	4261	49738862	TTDC00044	MAP kinase p38	ERK5;ERK6;ERK-6;Extracellular signal-regulated kinase 6;MAP kinase p38 gamma;MAPK12;Mitogen-activated protein kinase 12;Mitogen-activated protein kinase p38 gamma;SAPK3;Stress-activated protein kinase 3	P53778	6300	ENSG00000188130	inhibitor
DCL000260	VX-702	VX-702; Kinome_3176; EC-000.2363; S6005_Selleck; 6-[carbamoyl-(2,6-difluorophenyl)amino]-2-(2,4-difluorophenyl)pyridine-3-carboxamide; ST51054128; CHEMBL1090090; I14-1965; CHEBI:719385; CID10341154	479543-46-9	N/A	85154293	TTDC00044	MAP kinase p38	ERK5;ERK6;ERK-6;Extracellular signal-regulated kinase 6;MAP kinase p38 gamma;MAPK12;Mitogen-activated protein kinase 12;Mitogen-activated protein kinase p38 gamma;SAPK3;Stress-activated protein kinase 3	P53778	6300	ENSG00000188130	inhibitor
DCL000226	SCIO-469	N/A	750646-72-1	N/A	3821056	TTDC00044	MAP kinase p38	ERK5;ERK6;ERK-6;Extracellular signal-regulated kinase 6;MAP kinase p38 gamma;MAPK12;Mitogen-activated protein kinase 12;Mitogen-activated protein kinase p38 gamma;SAPK3;Stress-activated protein kinase 3	P53778	6300	ENSG00000188130	inhibitor
DCL000071	BIRB 796	1-(5-TERT-BUTYL-2-P-TOLYL-2H-PYRAZOL-3-YL)-3-[4-(2-MORPHOLIN-4-YL-ETHOXY)-NAPHTHALEN-1-YL]-UREA; 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3(4-(2-morpholin-4-yl-ethoxy)naph- thalen-1-yl)urea; CID156422; Doramapimod (USAN/INN); 285983-48-4; 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3(4-(2-morpholin-4-yl-ethoxy)naphthalen-1-yl)urea; UNII-HO1A8B3YVV; D03736; 1kv2; C452139; Doramapimod, BIRB 796; AC1L4G66; Doramapimod; Urea, N-(3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl)-N'-(4-(2-(4-morpholinyl)ethoxy)-1-naphthalenyl)-; 1-(3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl)-3-(4-(2-(morpholin-4-yl)ethoxy)naphthalen-1-yl)urea; CHEMBL103667; 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]urea; nchembio.162-comp7; DB03044; BIRB-796; TL80090041; BIRB796; 1-(3-tert-butyl-1-p-tolyl-1H-pyrazol-5-yl)-3-(4-(2-morpholinoethoxy)naphthalen-1-yl)urea; B96; BIRB 796; Kinome_2137; S1574_Selleck	285983-48-4	156422	733829	TTDC00044	MAP kinase p38	ERK5;ERK6;ERK-6;Extracellular signal-regulated kinase 6;MAP kinase p38 gamma;MAPK12;Mitogen-activated protein kinase 12;Mitogen-activated protein kinase p38 gamma;SAPK3;Stress-activated protein kinase 3	P53778	6300	ENSG00000188130	inhibitor
DCL000261	VX-745	SBB062898; 5-(2,6-Dichlorophenyl)-2-((2,4-difluorophenyl)thio)-6H-pyrimido(1,6-b)pyridazin-6-one; ZINC13493055; 209410-46-8; 6H-Pyrimido[1,6-b]pyridazin-6-one,5-(2,6-dichlorophenyl)-2-[(2,4-difluorophenyl)thio]-; 5-(2,6-dichlorophenyl)-2-(2,4-difluorophenyl)sulfanylpyrimido[1,6-b]pyridazin-6-one; 6H-Pyrimido[1,6-b]pyridazin-6-one, 5-(2,6-dichlorophenyl)-2-[(2,4-difluorophenyl)thio]-; VX-745; VX745, VX-745; Jsp004294; AC-707; Kinome_3767; DB07138; CHEMBL119385; CID3038525; MolPort-005-942-914; 6H-Pyrimido(1,6-b)pyridazin-6-one, 5-(2,6-dichlorophenyl)-2-((2,4-difluorophenyl)thio)-; I01-3410; S1458_Selleck; AC1MI50I	N/A	3038525	46515551	TTDC00044	MAP kinase p38	ERK5;ERK6;ERK-6;Extracellular signal-regulated kinase 6;MAP kinase p38 gamma;MAPK12;Mitogen-activated protein kinase 12;Mitogen-activated protein kinase p38 gamma;SAPK3;Stress-activated protein kinase 3	P53778	6300	ENSG00000188130	inhibitor
DCL000054	ARRY-797	N/A	N/A	N/A	N/A	TTDC00044	MAP kinase p38	ERK5;ERK6;ERK-6;Extracellular signal-regulated kinase 6;MAP kinase p38 gamma;MAPK12;Mitogen-activated protein kinase 12;Mitogen-activated protein kinase p38 gamma;SAPK3;Stress-activated protein kinase 3	P53778	6300	ENSG00000188130	inhibitor
DCL000142	KC706	N/A	N/A	N/A	N/A	TTDC00044	MAP kinase p38	ERK5;ERK6;ERK-6;Extracellular signal-regulated kinase 6;MAP kinase p38 gamma;MAPK12;Mitogen-activated protein kinase 12;Mitogen-activated protein kinase p38 gamma;SAPK3;Stress-activated protein kinase 3	P53778	6300	ENSG00000188130	inhibitor
DPR000108	SMP-534	N/A	N/A	445629	48169378	TTDC00044	MAP kinase p38	ERK5;ERK6;ERK-6;Extracellular signal-regulated kinase 6;MAP kinase p38 gamma;MAPK12;Mitogen-activated protein kinase 12;Mitogen-activated protein kinase p38 gamma;SAPK3;Stress-activated protein kinase 3	P53778	6300	ENSG00000188130	inhibitor
DCL000023	SB681323	N/A	N/A	N/A	N/A	TTDC00044	MAP kinase p38	ERK5;ERK6;ERK-6;Extracellular signal-regulated kinase 6;MAP kinase p38 gamma;MAPK12;Mitogen-activated protein kinase 12;Mitogen-activated protein kinase p38 gamma;SAPK3;Stress-activated protein kinase 3	P53778	6300	ENSG00000188130	inhibitor
DCL000161	MB07803	N/A	N/A	N/A	N/A	TTDC00152	Fructose-1,6-bisphosphatase	D-fructose-1,6-bisphosphate 1-phosphohydrolase;FBP1;FBPase;Fructose 1,6-bisphosphatase	P09467	2203	ENSG00000165140	inhibitor
DAP000782	Azathioprine	Spectrum_000064; Prestwick_41; A 4638; STOCK1S-27186; AI-981/34845012; A2593_SIAL; AB00443544; EU-0100027; BRD-K60324116-001-01-5; azatiopr in; 6-(Methyl-p-nitro-5-imidazolyl)thiopurine; WLN: T56 BM DN FN HNJ IS- ET5N CNJ A1 DNW; 6-(3-Methyl-5-nitro-3H-imidazol-4-ylsulfanyl)-7H-purine; NCGC00090836-06; KBio2_002427; SMR000427366; Imurek; HMS501N08; Ccucol; EINECS 207-175-4; MolPort-003-665-485; IDI1_000586; 6-(1-Methyl-4-nitroimidazol-5-ylthio)purin; SDCCGMLS-0065415.P001; CBDivE_013132; MolPort-000-745-914; KBio2_000464; Azasan; AB00443544-03; NCGC00094593-01; 6-[(1-methyl-4-nitro-1H-imidazol-5-yl)sulfanyl]-7H-purine; 6-(1-Methyl-p-nitro-5-imidazolyl)thiopurine; SPECTRUM1500133; FT-0083532; Azamun [Czech]; NSC 39084; NCGC00090836-03; 6-(1'-Methyl-4'-nitro-5'-imidazolyl)mercaptopurine; 6-({4-nitro-1-methyl-1H-imidazol-5-yl}sulfanyl)-7H-purine; CCRIS 62; NCGC00015060-12; BW 57322; AI3-50290; NINDS_000586; Purine, 6-((1-methyl-4-nitroimidazol-5-yl)thio)-; Spectrum3_000308; DB00993; KBio1_000586; KBio2_004995; Prestwick3_000094; CHEBI:2948; B. W. 57-322; 6-[(1-Methyl-4-nitroimidazol-5-yl)thio]purine; Azatioprina [INN-Spanish]; CHEMBL1542; MLS001049307; NSC-39084; Azamun; 6-(1-Methyl-p-nitro-5-imidazolyl)-thiopurine; DivK1c_000586; BW-57-322; STOCK1S-20293; NSC39084; C06837; Prestwick1_000094; A4638_SIAL; azathioprine; HMS1920E17; LS-123; KBio3_001376; NCGC00090836-05; ZINC04258316; A4638_SIGMA; 6-(1'-Methyl-4'-nitro-5'-imidazolyl)-mercaptopurine; Spectrum2_000068; 6-[(1-Methyl-4-nitroimidazol-5-yl)- thio] purine; HSDB 7084; Spectrum4_000243; ChemDiv1_002659; 6-(Methyl-p-nitro-5-imidazolyl)-thiopurine; Lopac0_000027; Prestwick0_000094; Imuran; Imurel; Muran; NCGC00015060-01; Azathioprinum; Azathioprinum [INN-Latin]; AC1Q3Z1F; [Methyl(nitroimidazolyl)mercaptopurine]; Prestwick2_000094; HMS1568C10; BSPBio_000048; CAS-446-86-6; KBioGR_002427; BRD-K32821942-001-05-6; KBio2_007563; 6-((1-Methyl-4-nitro-1H-imidazol-5-yl)thio)-1H-purine; AC1L1DAL; Immuran; 55774-33-9 (hydrochloride salt); S1721_Selleck; Azothioprine; SPBio_000255; Azathioprine sodium; HMS2091K19; KBioSS_002433; 6-(1-Methyl-4-nitroimidazol-5-ylthio)purin [Czech]; Purine, 6-[(1-methyl-4-nitroimidazol-5-yl)thio]-; 1H-Purine, 6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-; NCGC00094593-03; AC-4230; BPBio1_000054; Azatioprina; 6-1'-Methyl,4'-nitro,5'-imidazolyl mercaptopurine; KBioGR_000646; 6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-1H-Purine; Azathioprin; BW 57-322; 6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-7H-purine; UNII-MRK240IY2L; 1H-Purine, 6-((1-methyl-4-nitro-1H-imidazol-5-yl)thio)-; Thiopurine 6-(1-methyl-4-nitroimidazol-5-yl); MolPort-000-764-262; 6-(1-Methyl-4-nitroimidazol-5-yl)thiopurine; KBio2_005600; 446-86-6; NCGC00094593-02; NCGC00090836-02; KBio3_002906; NCGC00015060-04; BSPBio_001876; KBioSS_000464; Azasan (TN); CID2265; NCGC00015060-02; STK831906; Azathioprine (JP15/USP/INN); Azathiopurine; C9H7N7O2S; NCGC00090836-04; Oprea1_375441; cMAP_000046; D00238; SPBio_001987; 6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-9H-purine; Purine, 6-(1-methyl-4-nitro-5-imidazolylthio)-; Lopac-A-4638; Methylnitroimidazolylmercaptopurine; Oprea1_533384; Spectrum5_000848; Azanin; Oprea1_633462; 9H-Purine, 6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-; 1H-Purine, 6-((1-methyl-4-nitro-1H-imidazol-5-yl)thio)-; HMS594I19; NCGC00090836-01; Cytostatics; Azasan, Imuran, Azamun, BW-57-322, NSC-39084,  Azathioprine; 6-(3-methyl-5-nitroimidazol-4-yl)sulfanyl-7H-purine; 6-((1-Methyl-4-nitroimidazol-5-yl)thio)purine; KBio2_003032; Azathioprine [USAN:INN:BAN:JAN]; SAM002589938; NCI-C03474; CPD000427366; Imuran (TN); Azatioprin	446-86-6	2265	9055	TTDS00401	Inosine-5'-monophosphate dehydrogenase 1	IMP dehydrogenase 1;IMPD 1;IMPD1;IMPDH1;IMPDH-I	P20839	3614	ENSG00000106348	inhibitor
DCL000179	NM-702	NM-702; NM 702; 4-bromo-6-[3-(4-chlorophenyl)propoxy]-5-(pyridin-3-ylmethylamino)-2H-pyridazin-3-one Hydrochloride; MolPort-005-942-721; CID9848253; Parogrelil hydrochloride; 4-bromo-6-(3-(4-chlorophenyl)propoxy)-5-(3-pyridylmethylamino)-3(2H)-pyridazinone hydrochloride; NM702; 878796-94-2	878796-94-2	9848253	85151730	TTDC00315	Phosphodiesterase	N/A	Q08497	N/A	N/A	inhibitor
DAP001316	L-Tryptophan	CID6305; alpha-Amino-beta-(3-indolyl)-propionic acid; 1beta-3-Indolylalanine; Tryptophane [French]; (S)-(-)-Tryptopha n; alpha-amino-beta-(3-indolyl)-pr opionic acid; (S)-Tryptophan 1H-Indole-3-alanine, (S)-; (S)-(-)-2-Amino-3-(3-indolyl)propionic Acid; TRP NH3+ COOH; (S)-Tryptophan; MT1; T4196_SIGMA; tryptophan; T0254_SIAL; L-(-)-Tryptophan; trp; UNII-8DUH1N11BX; 2-Amino-3-indolylpropanoic acid; DB00150; 93659_SIGMA; NCGC00094437-03; T0541; 73-22-3; NSC 13119; Ardeytropin; EU-0101183; Indoe-3-propionic acid, alpha-amino-; Tryptophan (VAN); (-)-Tryptophan; (S)-a-Amino-1H-indole-3-propanoic acid; nchembio.212-comp12; Tryptophan [USAN:INN]; Optimax; l-b-3-Indolylalanine; AC1Q4U80; NChemBio.2007.20-comp7; Lopac-T-0254; 1H-Indole-3-alanine; T 0254; 151A3008-4CFE-40C9-AC0B-467EF0CB50EA; (S)-a-Amino-b-indolepropionic acid; Tryptophane; Propionic acid, 2-amino-3-indol-3-yl; Tryptophan (USP/INN); 1H-Indole-3-alanine, (S)-; T4196_SIAL; SMR000326686; Alanine, 3-indol-3-yl; bmse000050; LTR; 1-beta-3-Indolylalanine; L-beta-3-Indolylalanine; D00020; alpha'-Amino-3-indolepropionic acid; L-tryptophan; (S)-2-Amino-3-(1H-indol-3-yl)propanoic acid; Tryptophanum; AC-17050; (S)-alpha-Amino-1H-indole-3-propanoic acid; (S)-2-Amino-3-(3-indolyl)propionic acid; nchembio.107-comp2; L-Tryptophan (JP15); WV; L-(-)-Tryptophane; L-Tryptophane; Tryptophanum [Latin]; L-TRYPTOPHAN SIGMA GRADE; NCI-C01729; h-Trp-oh; 2-amino-3-indol-3-ylpropionic acid; 3-Indol-3-ylalanine; Tryptophan (H-3); Lyphan; IDI1_000457; CCRIS 617; EINECS 200-795-6; (S)-alpha-amino-beta-(3-indolyl)-propionic acid; L-alpha-amino-3-indolepropionic acid; NINDS_000457; tryptacin; L-Trp; EH 121; nchembio.186-comp94; Pacitron; 6912-86-3; (2S)-2-amino-3-(1H-indol-3-yl)propanoic acid; Propionic acid, 2-amino-3-indol-3-yl-; L-Alanine, 3-(1H-indol-3-yl)-; LS-1622; (S)-alpha-Aminoindole-3-propionic acid; Indole-3-propionic acid, alpha-amino-; 2-Amino-3-(lH-indol-3-yl)-propanoic acid; HMS501G19; Alti-Tryptophan; AI3-18478; DB03225; (L)-TRYPTOPHAN; BB_NC-1911; C00078; NCGC00015994-01; HSDB 4142; Triptofano [Spanish]; T8941_SIGMA; Sedanoct; NCGC00094437-01; LS-185087; 1H-Indole-3-propanoic acid, alpha-amino-, (S)-; DivK1c_000457; (S)-a-Aminoindole-3-propionic acid; Tryptan; MLS001056750; Kalma; AC1L1M8F; 80206-30-0; trofan; triptofano; 1qaw; L-Ttp; TRP-01; Indole-3-alanine; MolPort-001-794-499; CHEMBL54976; (S)-alpha-Amino-beta-indolepropionic acid; L-alpha-Aminoindole-3-propionic acid; 2a4m; l-a-Aminoindole-3-propionic acid; NCGC00094437-02; Tryptophan, L- (8CI); Alanine, 3-indol-3-yl-; CHEBI:16828; Tryptophan, L-; 1H-Indole-3-alanine (VAN); S(-)-1-alpha-Aminoindole-3-propionic acid; (S)-(-)-Tryptophan; KBio1_000457; Lopac0_001183; 93659_FLUKA; L-Tryptofan; L-Tryptophan (9CI); alpha-Amino-3-indolepropionic acid, L-	73-22-3	6305	8144649	TTDS00476	Indoleamine 2,3-dioxygenase	 INDO;IDO;Indoleamine-pyrrole 2,3-dioxygenase	P14902	3620	ENSG00000131203	binder
DCL000544	INCB24360	N/A	N/A	N/A	N/A	TTDS00476	Indoleamine 2,3-dioxygenase	 INDO;IDO;Indoleamine-pyrrole 2,3-dioxygenase	P14902	3620	ENSG00000131203	inhibitor
DCL001218	OPI-1002	N/A	N/A	N/A	N/A	TTDR01174	mRNA of Tumour protein p53	N/A	N/A	N/A	N/A	N/A
DAP000823	Homatropine Methylbromide	Omatropina metilbromuro; Esopin; Homatropine methyl bromide; N-Methylhomatropinium Bromide; AC1Q1RH8; (8,8-dimethyl-8-azoniabicyclo[3.2.1]octan-3-yl) 2-hydroxy-2-phenylacetate bromide; Npvatropine; CHEBI:50373; Malcotran; Sed-Tems; Camatropine; Metilbromuro de homatropina [INN-Spanish]; 3-alpha-Hydroxy-8-methyl-1-alpha-H,5-alpha-H-tropanium bromide mandelate; Novatrin; 8-Methylhomatropinium bromide; UNII-68JRS2HC1C; Omatropina metilbromuro [DCIT]; Sethyl; Novatropine; DB00725; AC1NWAN9; 8-Azoniabicyclo(3.2.1)octane, 3-((hydroxyphenylacetyl)oxy)-8,8-dimethyl-, bromide, endo-; HMS500G13; Homatropine methobromide; D02070; Methylhomatropinum bromatum; 8-Azoniabicyclo(3.2.1)octane, 3-((2-hydroxy-2-phenylacetyl)oxy)-8,8-dimethyl-, bromide (1:1), (3-endo)-; Metilbromuro de homatropina; AC1L1MZP; ST50993907; Mesopin; 58725-74-9; Homatropini methylbromidum; NCGC00094694-02; Methylhomatropine bromide; NSC34399; MolPort-003-666-201; 3-{[hydroxy(phenyl)acetyl]oxy}-8,8-dimethyl-8-azoniabicyclo[3.2.1]octane bromide; Homapin-10; Homapin; Methylbromure d'homatropine; Tropinium methobromide mandelate; HOMATROPINIUM, 8-METHYL-, BROMIDE; 3alpha-Hydroxy-8-methyl-1alphaH,5alphaH-tropanium bromide mandelate; Methyl Bromide Homatropine; EINECS 201-284-0; AR-1F1361; Homatropine DL- methylbromide; CID5702066; Equipin; [(5S)-8,8-dimethyl-8-azoniabicyclo[3.2.1]octan-3-yl] 2-hydroxy-2-phenylacetate bromide; Equipin (TN); I06-2047; HMS1920D15; Homapin-5; Homatropini methylbromidum [INN-Latin]; Homatropine methylbromide (USP); 55198-66-8; H0448; CID6646; CHEMBL1200851; NSC 34399; DL-Methylbromide; Homatropine methylbromide [INN:BAN]; C16H21NO3.CH3Br; SPECTRUM1500333; NCGC00094694-01; 3-[2-hydroxy(phenyl)acetoxy]-8,8-dimethyl-8-azoniabicyclo[3.2.1]octane bromide; Homatromide; DL-Homatropine methyl bromide; Hycodan, probilagol; 8-Azoniabicyclo(3.2.1)octane, 3-((hydroxyphenylacetyl)oxy)-8,8-dimethyl-, bromide, (3-endo)-; Arkitropin; Novatrine; homatropine methylbromide; Methylhomatropine; 80-49-9; Humulon lead salt; LS-75887; Methylbromure d'homatropine [INN-French]; HMS2091J21	80-49-9	6646	149623	TTDS00006	Muscarinic acetylcholine receptor M5	M5 receptor	P08912	1133	ENSG00000184984	antagonist
DAP000430	Promazine	10H-Phenothiazine-10-propanamine, N,N-dimethyl-, monohydrochloride; NSC31447; RP 3276; Propazinum; Neo-Hibernex; NCGC00015829-02; SPBio_000797; WLN: T C666 BN ISJ BY2&N1&1; Oprea1_813117; NCGC00015829-03; 10H-Phenothiazine-10-propanamine, N,N-dimethyl- (9CI); Promazin; BSPBio_002775; Spectrum3_001018; BSPBio_000845; Berophen; Prestwick3_000693; Combelen [veterinary] (TN); UNII-O9M39HTM5W; KBio2_001346; Combelen [veterinary]; NINDS_000419; Promazina [Italian]; NSC 31447; NCGC00024337-04; Romtiazin; Prazin; N-Dimethylamino-1-methylethyl thiodiphenylamine; DB00420; Tomil; NCGC00015829-01; DivK1c_000419; Ampazine; Lopac0_000961; Prazine; WY 1094; 3276 R. P; Spectrum_000866; Prestwick1_000693; A 145; Wy-1094; Promazina; Promazinum [INN-Latin]; Esparin; Prestwick2_000693; 10H-Phenothiazine-10-propanamine, N,N-dimethyl-; Verophen; AB00053534; LS-105489; CID4926; WLN: T C666 BN ISJ B3N1&1; KBioSS_001346; Phenothiazine, 10-[3-(dimethylamino)propyl]-; Prestwick0_000693; Promazina [INN-Spanish]; Promwill; EINECS 200-382-0; D08430; promazine; Lopac-P-6656; KBioGR_001695; L000671; KBio2_003914; Liranol; Spectrum5_001116; Phenothiazine, 10-(3-(dimethylamino)propyl)-; 3276 R. P.; Dimethyl(3-phenothiazin-10-ylpropyl)amine; 10H-Phenothiazine-10-propanamine, N,N-dimethyl-; Protactyl; Spectrum4_001148; BPBio1_000931; Sinophenin; C07379; 58-40-2; Promazinum; N,N-dimethyl-3-(10H-phenothiazin-10-yl)propan-1-amine; KBio2_006482; IDI1_000419; Promazine (INN); Promazine [INN:BAN]; SPBio_002766; N-(3-Dimethylaminopropyl)phenothiazine; MolPort-001-783-681; 10-[3-(Dimethylamino)propyl]phenothiazine; KBio1_000419; 10-(3-(Dimethylamino)propyl)phenothiazine; HSDB 3172; AC1L1J90; CAS-53-60-1; KBio3_001995; N,N-dimethyl-3-phenothiazin-10-ylpropan-1-amine; CHEBI:8459; CHEMBL564; NCGC00015829-09; Spectrum2_000839	58-40-2	4926	9583	TTDS00006	Muscarinic acetylcholine receptor M5	M5 receptor	P08912	1133	ENSG00000184984	binder
DAP000377	Atropine	(+/-)-Atropine; b eta-(Hydroxymethyl)benzeneacetic acid 8-methyl-8-azabicyclo[3.2.1]oct-3-yl ester; DL-Tropanyl 2-hydroxy-1-phenylpropionate; Atropine Care; Troyl tropate; ST057178; Atropen; CHEBI:15884; Atropen (TN); FT-0082634; Tropic acid, 3-alpha-tropanyl ester; 1alphaH,5alphaH-Tropan-3beta-ol; BRD-A27290375-001-01-8; CID174174; tropan-3alpha-yl 3-hydroxy-2-phenylpropanoate; MEGxp0_001878; [(1S,5R)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl] 3-hydroxy-2-phenyl-propanoate; A0132_SIGMA; HSDB 2199; D00113; ST057655; T0534; dl-Hyoscyamine; MLS000069795; Ocu-Tropine; Atropine Sulfate S.O.P.; Minims; tropan-3alpha-ol; AI3-60219; hyoscyamine; 8-Methyl-8-azabicyclo[3.2.1]octan-3-yl 3-hydroxy-2-phenylpropionate; Atropair; Protamine & Atropine; d1-hyoscyamine; Atropina [Italian]; ATROPINE; C17H23NO3; NCGC00016370-01; atropinium(1+); nchembio.307-comp21; 1-alpha-H,5-alpha-H-Tropan-3-alpha-ol (+-)-tropate (ester) (8CI); 8-Methyl-8-azabicyclo[3.2.1]oct-3-yl tropate; SMR000058248; (3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl tropate; SAM002554885; (+-)-hyoscyamine; 51-55-8; [(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate; (+/-)-Hyoscyamine; Urised; LS-7203; Bellergal-S; NCGC00142514-01; Atropin; Neo-Diophen; Cytospaz; Isopto Atropine; beta-Phenyl-gamma-oxypropionsaure-tropyl-ester [German]; endo-8-methyl-8-azabicyclo[3.2.1]octan-3-ol; Atropine (USP); NCGC00142514-03; atropinium cation; A2468_SIGMA; (+-)-atropine; CAS-120-29-6; Belladenal; AKOS005137976; tropan-3beta-ol; MolPort-001-742-593; CHEBI:15742; Atropina; AC1L5AX3; beta-Phenyl-gamma-oxypropionsaeure-tropyl-ester [German]; 120-29-6; Atropine [BAN]; Atropt; DB00572; endo-(+/-)-alpha-(Hydroxymethyl)benzeneacetic acid 8-methyl-8-azabicyclo[3.2.1]oct-3-yl ester; Tropic acid, ester with tropine; DB04026; Isopto-atropine; bmse000649; Atropinol; HMS2089A16; MLS002695888; 8-Methyl-8-azabicyclo[3.2.1]oct-3-yl 3-hydroxy-2-phenylpropanoate; Benzeneacetic acid, alpha-(hydroxymethyl)-, (3-endo)-8-methyl-8-azabicyclo(3.2.1)oct-3-yl ester; 1alphaH,5alphaH-Tropan-3alpha-ol (+-)-tropate (ester); (3-exo)-8-methyl-8-azabicyclo[3.2.1]octan-3-ol; CHEMBL1235490; CHEBI:537621; MolPort-003-986-158; dl-Tropyltropate; NP-010662; Benzeneacetic acid, alpha-(hydroxymethyl)-8-methyl-8-azabicyclo(3.2.1)oct-3-yl ester, endo-(+-)-; 2-Phenylhydracrylic acid 3-alpha-tropanyl ester; Benzeneacetic acid, alpha-(hydroxymethyl)-, 8-methyl-8-azabicyclo(3.2.1)oct-3-yl ester, endo-(+-)-; Minims Atropine; C01479; Benzeneacetic acid, alpha-(hydroxymethyl)-, 8-methyl-8-azabicyclo(3.2.1)oct-3-yl ester, endo-(+/-)-; CHEBI:57858; Tropanol; Eyesules; CHEBI:16684; a-Tropine; Hyoscyamine sulfate; (3-endo)-8-methyl-8-azabicyclo[3.2.1]octan-3-ol; Ambap120-29-6; Atropin [German]; 1-alpha-H,5-alpha-H-Tropan-3-alpha-ol (+-)-tropate (ester); OR22908; Tropine (+/-)-tropate; CCRIS 3080; Benzeneacetic acid, alpha-(hydroxymethyl)- 8-methyl-8-azabicyclo(3.2.1)oct-3-yl ester endo-(+-)-; Tropine tropate; Benzeneacetic acid, alpha-(hydroxymethyl)-8-methyl-8-azabicyclo(3,2,1)oct-3-yl ester, endo-(+-)-; Benzeneacetic acid, alpha-(hydroxymethyl)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl ester endo-(+-)-; CPD001906768; (3-endo,8-syn)-3-[(3-hydroxy-2-phenylpropanoyl)oxy]-8-methyl-8-azoniabicyclo[3.2.1]octane; 1alphaH,5alphaH-Tropan-3alpha-ol; (3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl 3-hydroxy-2-phenylpropanoate; Anaspaz; Atrosulf; Tropine, tropate (ester); AC1Q3XL2; Atropin-flexiolen; DL-Tropyl tropate; I-Tropine; ACon1_000046; EINECS 200-104-8; TL8000018; (3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl (2S)-3-hydroxy-2-phenylpropanoate; (+,-)-Tropyl tropate; MLS001148094	51-55-8	174174	4651	TTDS00006	Muscarinic acetylcholine receptor M5	M5 receptor	P08912	1133	ENSG00000184984	antagonist
DAP000346	Metixene	Methixart; Piperidine, 1-methyl-3-(thioxanthen-9-ylmethyl)-; 1-methyl-3-(thioxanthen-9-ylmethyl)- piperidine hydrochloride; METHIXENE; Trest; metixene hydrochloride; Methyloxan; 115511-20-1; Tremarit; Metisene [DCIT]; Methixen [German]; Metixene (INN); C20H23NS; Raunana; 1553-34-0; Prestwick3_000491; 7081-40-5 (hydrochloride monohydrate); Metixene; Metixeno; Methixen; CID4167; Tremaril hydrochloride; LS-115790; 4969-02-2; Prestwick0_000491; BRD-A33711280-311-02-0; 1553-34-0 (HYDROCHLORIDE); Metixenum; Tremonil (*hydrochloride*); 1-Methyl-3-(thioxanthen-9-ylmethyl) piperidine; Metixene (*hydrochloride*); 60 SJ 1977 (*hydrochloride*); Prestwick2_000491; Tremaril; Prestwick1_000491; 60 SJ 1977; AC1L1HKA; Metixeno [INN-Spanish]; NCIOpen2_008789; CHEBI:51024; I06-0457; AR-1C4472; Methixene hydrochloride; Atosil; Methixene (*hydrochloride*); DB00340; Tremonil; BPBio1_000421; Metisene; 1-Methyl-3-(9H-thioxanthen-9-ylmethyl)piperidine; 4-27-00-01421 (Beilstein Handbook Reference); Contalyl; SPBio_002302; EINECS 225-610-6; L001125; 115511-21-2; UNII-32VY6L26ZW; NSC78194; Piperidine, 1-methyl-3-(9H-thioxanthen-9-ylmethyl)-; D08209; BSPBio_000381; BRN 0267181; Tremoquil; 1-Methyl-3-(9H-thioxanthen-9-yl-methyl)piperidine; 1-Methyl-3-(thioxanthen-9-ylmethyl)-1-piperidine; 1-Pipecoline, 3-(thioxanthen-9-yl)methyl-; 9-(1'-Methylpiperidine-3'-methyl)thioxanthene; Metixene [INN:BAN]; Metixenum [INN-Latin]; Dalpan; AC1Q7G3S	4969-02-2	4167	551137	TTDS00006	Muscarinic acetylcholine receptor M5	M5 receptor	P08912	1133	ENSG00000184984	antagonist
DCL001158	BI 207127	N/A	N/A	N/A	N/A	TTDC00198	HCV polymerase	N/A	Q68929	N/A	N/A	inhibitor
DCL000539	IDX375	N/A	N/A	N/A	N/A	TTDC00198	HCV polymerase	N/A	Q68929	N/A	N/A	inhibitor
DCL001225	PSI-938	N/A	N/A	N/A	N/A	TTDC00198	HCV polymerase	N/A	Q68929	N/A	N/A	inhibitor
DCL001131	ABT-333	N/A	N/A	N/A	N/A	TTDC00198	HCV polymerase	N/A	Q68929	N/A	N/A	inhibitor
DCL001193	IDX-189	N/A	N/A	N/A	N/A	TTDC00198	HCV polymerase	N/A	Q68929	N/A	N/A	inhibitor
DCL001185	Filibuvir	N/A	N/A	N/A	N/A	TTDC00198	HCV polymerase	N/A	Q68929	N/A	N/A	inhibitor
DCL000835	HCV-796	79Z; D08951; CHEMBL1092581; DB07238; 691852-58-1; CID 11561383; UNII-EYK815W3Z8; HCV-796; Nesbuvir; CID11561383; Nesbuvir (USAN)	N/A	11561383	24716663	TTDC00198	HCV polymerase	N/A	Q68929	N/A	N/A	inhibitor
DCL001215	MK-3281	N/A	N/A	N/A	N/A	TTDC00198	HCV polymerase	N/A	Q68929	N/A	N/A	inhibitor
DCL001255	VX-759	N/A	N/A	N/A	N/A	TTDC00198	HCV polymerase	N/A	Q68929	N/A	N/A	inhibitor
DCL001229	RG7128	N/A	N/A	N/A	N/A	TTDC00198	HCV polymerase	N/A	Q68929	N/A	N/A	inhibitor
DCL000612	R7128	R-4048; CHEMBL562967; RG-7128; RO-5024048; R-7128	N/A	N/A	N/A	TTDC00198	HCV polymerase	N/A	Q68929	N/A	N/A	inhibitor
DCL001130	ABT-072	N/A	N/A	N/A	N/A	TTDC00198	HCV polymerase	N/A	Q68929	N/A	N/A	inhibitor
DCL001162	BMS 791325	N/A	N/A	N/A	N/A	TTDC00198	HCV polymerase	N/A	Q68929	N/A	N/A	inhibitor
DCL001040	XTL-2125	N/A	N/A	N/A	N/A	TTDC00198	HCV polymerase	N/A	Q68929	N/A	N/A	inhibitor
DCL001248	TMC649128	N/A	N/A	N/A	N/A	TTDC00198	HCV polymerase	N/A	Q68929	N/A	N/A	inhibitor
DCL001245	Tegobuvir	N/A	N/A	N/A	N/A	TTDC00198	HCV polymerase	N/A	Q68929	N/A	N/A	inhibitor
DCL001256	VX-916	N/A	N/A	N/A	N/A	TTDC00198	HCV polymerase	N/A	Q68929	N/A	N/A	inhibitor
DCL001224	PSI-7977	N/A	N/A	N/A	N/A	TTDC00198	HCV polymerase	N/A	Q68929	N/A	N/A	inhibitor
DCL001240	Setrobuvir	N/A	N/A	N/A	N/A	TTDC00198	HCV polymerase	N/A	Q68929	N/A	N/A	inhibitor
DCL001253	VX-222	N/A	N/A	N/A	N/A	TTDC00198	HCV polymerase	N/A	Q68929	N/A	N/A	inhibitor
DAP000764	Pentamidine	WLN: MUYZR DO5OR DYZUM; pentamidine; C19H24N4O2; MolPort-001-792-506; CID4735; CHEMBL55; Pentam 300 (as isethionate); AB00053572; Prestwick3_000553; EINECS 202-841-0; MB-800; Pentamidine [INN:BAN:DCF]; PENTAMIDINE ISETHIONATE; Benzenecarboximidamide, 4,4'-(1,5-pentanediylbis(oxy))bis- (9CI); 4, 4'-Diamidinodiphenoxypentane; Pentam 300; Pentamidina [DCIT]; KBio3_001252; Pentamidine (INN); CHEBI:45081; Prestwick1_000553; SPBio_000290; RP-2512; nchembio873-comp32; PENTAM; HMS2089J14; AC-12459; NSC9921; 4-10-00-00447 (Beilstein Handbook Reference); Pentam 300 (*Isethionate); HSDB 7474; Pentamidinum [INN-Latin]; Benzenecarboximidamide, 4,4'-[1,5-pentanediylbis(oxy)]bis-; 4,4'-(Pentamethylenedioxy)dibenzamide; p,p'-(Pentamethylene-dioxy)bis-benzamidine; Benzenecarboximidamide, 4,4'-(1,5-pentanediylbis(oxy))bis-; 4,4'-(1,5-Pentanediylbis(oxy))bis-benzenecarboximidamide; C07420; RP 2512 (*Isethionate); 100-33-4; NSC 9921; Pentamidine mesylate; Pneumopent; 6823-79-6; p,p'-(Pentamethylenedioxy)bis[benzamidine]; 1,3-BIS(4-AMIDINOPHENOXY)PENTANE; Spectrum5_001808; Pentacarinat; Lomidine; CCRIS 3825; Spectrum3_000276; 4,4'-Diamidinodiphenoxypentane; Spectrum2_000155; Prestwick2_000553; LS-27566; AC1Q4YYD; p,p'-(Pentamethylenedioxy)dibenzamidine; AC1L1IU8; Pentamidina; Pentamidinum; MB 800; UNII-673LC5J4LQ; BSPBio_000625; NCGC00179034-02; NCI60_042221; 4-[5-(4-Carbamimidoylphenoxy)pentoxy]benzenecarboximidamide; Benzenecarboximidamide, 4,4'-[1,5-pentanediylbis(oxy)]bis-; D08333; Pentamidine isetionate; NSC620107; KBioGR_000879; Nebupent (as isethionate); Nebupent; Pentamidin; 4,4'-Diamidino-.alpha.,.omega.-diphenoxypentane; Pentacarinat (as isethionate); SPBio_002546; Pentacarinat (*Isethionate); Spectrum4_000380; Nebupent (*Isethionate); DB00738; 4,4'-(Pentamethylenedioxy)dibenzamidine; BSPBio_001752; BRN 3159790; PNT; Pentamide; NCGC00179034-01; BPBio1_000689; Lomidine (TN); Pentamidine Isethionate 2-Hydroxy-Ethanesulfonic Acid; Benzamidine, 4,4'-(pentamethylenedioxy)di-; 4,4'-[pentane-1,5-diylbis(oxy)]dibenzenecarboximidamide	100-33-4	4735	150570	TTDS00130	Tryptase	N/A	N/A	N/A	N/A	inhibitor
DCL000599	PF-4523655	N/A	N/A	5186	44371650	TTDC00241	mRNA of HIF-1 responsive protein RTP801	DNA-damage-inducible transcript 4 protein;Protein regulated in development and DNA damage response 1;REDD-1	Q9NX09	54541	ENSG00000168209	N/A
DAP001031	Suramin	Germanin; Belganyl; 1,3,5-naphthalenetrisulfonic acid, 8,8'-[carbonylbis[imino-3,1-phenylenecarbonylimino(4-methyl-3,1-phenylene)carbonylimino]]bis-; 1,3,5-Naphthylenetrisulfonic acid, 8,8'-(ureylenebis(m-phenylenecarbonylimino(4-methyl-m-phenylene)carbonylimino))di-; Lopac0_001182; L000585; C07974; Naganol 6 Na; WLN: L66J BSWQ DSWQ GSWQ JMVR D1 CMVR CMVMR CVMR B1 EVM-JL66J BSWQ DSWQ GSWQ &-NA-6; EINECS 205-658-4; Farma 939; KBio2_004965; 8,8'-[carbonylbis[imino-3,1-phenylenecarbonylimino(4-methyl-3,1-phenylene)carbonylimino]]bisnaphthalene-1,3,5-trisulphonic acid; 3-14-00-02267 (Beilstein Handbook Reference); LS-95867; Spectrum4_001247; SpecPlus_000662; 1,3,5-Naphthalenetrisulfonic acid, 8,8'-(carbonylbis(imino-3,1-phenylenecarbonylimino(4-methyl-3,1-phenylene)carbonylimino))bis-; DB04786; KBioSS_002402; Antrypol; SGCTO-001; Farma; Naganol; KBio1_001702; CID5361; NSC34936; SVR; 8-[[4-methyl-3-[[3-[[3-[[2-methyl-5-[(4,6,8-trisulfonaphthalen-1-yl)carbamoyl]phenyl]carbamoyl]phenyl]carbamoylamino]benzoyl]amino]benzoyl]amino]naphthalene-1,3,5-trisulfonic acid; Suramine; NSC 34936; Suramine sodium; sym-bis(m-aminobenzoyl-m-amino-p-methylbenzoyl-1-napthylamino-4,6,8-trisulfonate) carbamide; m,m'-Ureylen-bis-(8-(m-(benzamido)-p-toluamido)naphthalin-1,3,5-trisulfonsaeure); Spectrum3_000724; 1,3,5-Naphthalenetrisulfonic acid, 8,8'-[ureylenebis[m-phenylenecarbonylimino(4-methyl-m-phenylene)carbonylimino]]di-, hexasodium salt; KBio2_002397; 8,8'-[CARBONYLBIS[IMINO-3,1-PHENYLENECARBONYLIMINO(4-METHYL-3,1-PHENYLENE)CARBONYLIMINO]]BIS-1,3,5-NAPHTHALENETRISULFONIC; suramin; 8,8'-[Carbonylbis[imino-3,1-phenylenecarbonylimino(4-methyl-3,1-phenylene)carbonyl-imino]]bis-1,3,5-napthalenetrisulfonic acid; AC1L1K6K; Fourneau; 8,8'-[Ureylenebis[m-phenylenecarbonylimino(4-methyl-m-phenylene)carbonylimino]]di-1,3,5-naphthalenetrisulfonic acid; Moranyl; DivK1c_006758; 145-63-1; C51H40N6O23S6; KBioGR_001774; BSPBio_002248; 1,3,5-Naphthalenetrisulfonic acid, 8,8'-[ureylenebis[m-phenylenecarbonylimino(4-methyl-m-phenylene)carbonylimino]]di- (8CI); Naganil; Naganine; Naganin; NCGC00163318-01; Naphuride; BRN 3230873; 8,8'-(Carbonylbis(imino-3,1-phenylenecarbonylimino(4-methyl-3,1-phenylene)carbonylimino))bisnaphthalene-1,3,5-trisulphonic acid; Spectrum_001877; Harnstoff, symmetischer der 3-aminobenzoyl-3-amino-4-methylbenzoyl-1-naphthylamin-4,6,8-trisulfonsaeure; CHEMBL265502; Carbanilide, 3,3'-bis((5-((4,6,8-trisulfo-1-naphthyl)carbamoyl)-o-tolyl)carbamoyl)-; 129-46-4 (hexa-hydrochloride salt); KBio3_001468; KBio2_007533; SURAMIN SODIUM; 1,3,5-Naphthalenetrisulfonic acid, 8,8'-[carbonylbis[imino-3,1-phenylenecarbonylimino(4-methyl-3,1-phenylene)carbonylimino]]bis-, hexasodium salt; 1,3,5-Naphthalenetrisulfonic acid, 8,8'-[carbonylbis[imino-3,1-phenylenecarbonylimino(4-methyl-3,1-phenylene)carbonylimino]]bis- (9CI); CHEBI:45906; 8,8'-[Carbonylbis[imino-3,1-phenylenecarbonylimino(4-methyl-3,1-phenylene)carbonyl-imino]]bis-1,3,5-naphthalenetrisulfonic acid; Sodium suramin	145-63-1	5361	7890636	TTDS00438	Follicle stimulating hormone receptor	Follitropin receptor;FSH-R	P23945	2492	ENSG00000170820	antagonist
DAP001028	Follitropin beta	N/A	9002-68-0	N/A	46508818	TTDS00438	Follicle stimulating hormone receptor	Follitropin receptor;FSH-R	P23945	2492	ENSG00000170820	binder
DAP001030	Choriogonadotropin alfa	N/A	177073-44-8	N/A	46506863	TTDS00438	Follicle stimulating hormone receptor	Follitropin receptor;FSH-R	P23945	2492	ENSG00000170820	binder
DAP001027	Menotropins	Menotropins (USP); Human Menopausal Gonadotrophin (JP15); MENOTROPINS; D02692; Humegon (TN); 61489-71-2; Human Menopausal Gonadotrophin; Humegon	61489-71-2	5360545	47205812	TTDS00438	Follicle stimulating hormone receptor	Follitropin receptor;FSH-R	P23945	2492	ENSG00000170820	binder
DAP001029	Urofollitropin	97048-13-0; 1-[19-amino-7-(2-amino-2-oxoethyl)-13-butan-2-yl-10-(1-hydroxyethyl)-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-N-[1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]pyrrolidine-2-carboxamide; Metrodin; Urofollitrophin; 27115-19-1; 26995-91-5; Fertinorm HP; CID62819; 1,2-Dithia-5,8,11,14,17-penaazacycloeicosane, cyclic peptide deriv.; Oxytocin, 4-L-threonine-; 4-(L-Threonine)oxytocin; (4-Threonine)oxytocin; Fertinex; Urofollitropin; AC1L1XUA; Bravelle	146479-72-3	62819	204910	TTDS00438	Follicle stimulating hormone receptor	Follitropin receptor;FSH-R	P23945	2492	ENSG00000170820	binder
DAP001060	Erythrityl Tetranitrate	Erythritol, tetranitrate (8CI); Cardilate; Tetranitrato de eritritilo; Tetranitrol; NSC106566; Cardiloid; Tetranitrate d'eritrityle [INN-French]; Erythrol tetranitrate; ERYTHRITYL TETRANITRATE; AC1L2MW9; meso-Erythritol tetranitrate; Eritrityli tetranitras; Erythritetranitrat; Erythrityl tetranitrate [USAN]; Tetranitrate d'eritrityle; EINECS 230-734-9; Tetranitrate d'erithrityle; Cardivell; Eritritile tetranitrato [DCIT]; Nitroerythrol; 1,2,3,4-Butanetetrol, tetranitrate, (R*,S*)-; CID23723; Nitroerythrite; 1,3,4-trinitrooxybutan-2-yl nitrate; DB01613; Eritritile tetranitrato; Tetranitrin; Eritrityli tetranitras [INN-Latin]; Erythritol tetranitrate; 7297-25-8; LS-177011; Tetranitrato de eritritilo [INN-Spanish]; Eritrityl tetranitrate; NSC 106566; Erythritol, tetranitrate; 1,2,3,4-Butanetetralyl tetranitrate; Cardiwell; CHEMBL453636; ETN; Nitroerythrit; C4H6N4O12	7297-25-8	23723	10507903	TTDS00443	Guanylate cyclase	Guanylyl Cyclase	N/A	N/A	N/A	stimulator
DAP001059	Nitroglycerin	Trinitrin; CHEBI:28787; 9010-02-0; Nitrong Retard; HMS2094M15; CCRIS 4089; Nitrol Ointment; Transderm-nitro (TN); Nitro-Gesanit Retard; Nitrogliceryna; Glycerin trinitrate; Nitrine-TDC; Percutol; Nitro Mack Retard; Niong Retard; Vasoglyn; Coro-Nitro; Ratiopharm; CHEMBL730; GTN; nitroglycerin; Trinitron; Blasting oil; NitroQuick; Nitroglycerol; Nitro-Dur 5; Trinitroglycerin; Nitro-lent; Nitropen; Nitropront; Minitro; Suscard; Aldonitrin; Nitrek; Nitrong parenteral; Nitromint; Nitrangin; Glyceryl; Transderm-nitro; Soup; MQX-503; Turicard; C07455; Aquo-Trimitrosan; Gepan Nitroglicerin; Vasolator; Nysconitrine; Nit-Ret; Klavikordal; NITRO IV; Nitrodisc; 105469-31-6; Temponitrin; EINECS 200-240-8; Nitro-M-Bid; NitroDur; UN3064; Nitroretard; Transderm-Nitro TTS; Deponit TTS 5; Cordipatch; UN1204; Triniplas; Nitro-Bid; Willong; Nitro Bid; D00515; Nitora; NitrocapT.D.; Nitroperlinit; Glycerol trinitrate; Nitrocard; Nitroderm TTS; Nitrocontin; Lentonitrina; NitroQuik; Nitrospan; BIDD:GT0142; Glyceryl nitrate; Nitrogard; Nitro Rorer; UN0144; Nitronal Aqueous; Percutol Oint; LS-7741; Mionitrat; Nitroletten; Nitrorex; D005996; Nitromex; Gilustenon; Trinitrate, Glyceryl; Neos nitro OPT; Niglycon; Nitroprol; Nitroplast; Nitrocerin; Nitrostat; Buccard; 8013-23-8; Angiplex; Nitro-Pflaster; Natispray; Anglix; UNII-G59M7S0WS3; Glonoin; Nitradisc; Transiderm-nitro; Tridil sublin; Angiolingual; Nitrong; Nitriderm; Nitro Dur; Transderm-N TTS; Nitroglyn; RCRA waste no. P081; Gilucor nitro; Trinitroglycerol; Trinitrol; Nitradisc Pad; SK-878; Nitro-bid (TN); Nitrobukal; Sustak; Nitro-Mack Retard; Trinitrin Tablets; Nitrolingual; Nitroclyn; Trinitrolong; Glyceroltrinitraat; Nitromist (TN); C3H5N3O9; Lenitral; Nitropatch; NitroBid; Nitro-Time; Nitro-dur; NK-843; HSDB 30; NitroCor; DB00727; Nitrolingual Spray; Minitram; UN0143; Top-Nitro; Angorin; Niong; Nitroderm TTS-5; Susadrin; Blasting gelatin; Glycerylnitrat; Nitrocine; AC1L1IBV; Nitroglycerin (NG); Herwicard; Nitroject; NG; Nitrozell retard; Diafusor; Sustac; Deponit 5; Nitroderm; Deponit TTS 10; Nitrocot; Nitrobaat; c0061; Nitradisc TTS; Angibid; Nitrocontin Continus; Nitrorectal; Nitromint Aerosol; Tridil; Trinitrosan; Nitrocine 5; Nitro Dur TTS; Niglin; Minitran; Glycerintrinitrate; Minitran (TN); Transderm Nitro; SK-106N; Vascana; Cardinit; Myovin; Cardiodisco; Nitromint Retard; Nitrocap; Corditrine; Nitrogard-SR; CPD-143; Vernies; Adesitrin; Glytrin; Deponit-5; Nitroprontan; Perglottal; Colenitral; NTG; Myoglycerin; Myocon; Nitro-Dur 10; Chitamite; Nitroglin; Percutol Oint.; Nitromack Retard; Rectogesic; 80066-48-4; Nitromel; Nitrong-SR; Sustonit; Nitroglicerina; Nitropercuten; 55-63-0; Dauxona; Trinipatch; Nitrostabilin; Anogesic; Trinitrina Erba; Cellegesic; Nitrolowe; Perlinganit; Buccal; 100292-13-5; Nitro Retard; Trinalgon; Herzer; Nitroderm TTS Ext; SK-866; IMX-150; Mi-Trates; Nitro-Span; Glycerine trinitrate; Nitrodyl TTS; Nitrodyl; Angonist; Perganit; NitrocapT.D; Plastranit; MED-2002; Spirit of glonoin; BRN 1802063; GTN-Pohl; Dynamite; Nitroglycerine; Discotrine; Nitroglycerin-ACC; SDM No. 17; Nitronet; Cardabid; Cardamist; Nitrolin; Nitro-Par; Nitriderm TTS; CID4510; Nirmin; Polnitrin; Millisrol; Epinitril; NitroMist; Glyceryl trinitrate; TNG; UN3319; Nitrolan; Nitroard; Nitrovis; Deponit; Nitro-dur (TN); Nitrobid Oint	55-63-0	4510	7847581	TTDS00443	Guanylate cyclase	Guanylyl Cyclase	N/A	N/A	N/A	stimulator
DAP001057	Isosorbide Dinitrate	MLS001333562; KBio2_000643; NSC80038; Vasorbate; NCGC00178830-01; Diniket; Dignionitrat; Spectrum4_000025; Flindix; Sorbislo; Dinitrato de isosorbida [INN-Spanish]; ISD; UN2907; EureCor; 59812_ALDRICH; Spectrum3_000600; AC-12153; Nitrosorbon; HSDB 3417; Glucitol, 1,4:3,6-dianhydro-, dinitrate, D-; Isorbid; LS-71376; Emoper; D007548; 87-33-2; ZINC18089317; Spectrum2_001069; Sorbitrate; Dinitrosorbide; Sorbidnitrate; Prestwick1_000714; Isoket retard 40; CCRIS 1910; Isoket Retard120; Isosorbidi dinitras; Dinitrate d'isosorbide; SPECTRUM1500358; Myorexon; D00516; TYB 3215; AC1L1NIG; SST-101; Isochron; KBio3_001580; Cedocard; Sorbide; Carvanil; KBioGR_000429; KBio1_000436; IDI1_000436; Iso-Bid; Isostat; Isosorbide dinitrato [DCIT]; Iso Bid; Xanyl; BSPBio_002080; Titradose; Prestwick2_000714; KBio2_005779; Corovliss; Sorbide T.D.; Rigedal; DB00883; Dianhydrosorbitol 2,5-dinitrate; CHEBI:6061; Frandol; Cornilat; MLS001333561; IBD 20; Isosorbide dinitrate (JP15/USP/INN); Sorbide, dinitrate; Cardonit 40; Sorquat; Isordil (TN); 1,4:3,6-Dianhydro-D-glucitol dinitrate; Resoidan; CID6883; 1,4:3,6-dianhydro-2,5-di-O-nitro-D-glucitol; D-Glucitol, 1,4:3,6-dianhydro-, dinitrate; NINDS_000436; ISOSORBIDE DINITRATE; Sorbonit; Isomak R; Astridine; Dinitrato de isosorbida; SDM No. 40; Laserdil; C6H8N2O8; UNII-IA7306519N; Cardis; D-; Spectrum_000163; 6659-58-1; HMS1920H15; 1,4:3,6-Dianhydrosorbitol 2,5-dinitrate; D-Isosorbide dinitrate-Lactose mixture; Iso-Mack; HMS2091P05; Dinitroisosorbide; Isosorbide dinitrate mixture with not <60% lactose, mannose, starch or calcium hydrogen phosphate [UN2907] [Flammable solid]; Tinidil; SPBio_001058; Isoket Retard 120; Sorbangil; Sorate-10; Isordil; Claodical; D-Glucitol, 1,4:3,6-dianhydro-, 2,5-dinitrate; Lomilan; Disorlon; Isosorbide dinitrate mixture with not <60% lactose, mannose, starch or calcium hydrogen phosphate [UN2907]  [Flammable solid]; Corosorbide; Korodil; Difutrat; DivK1c_000436; Isordil Tembids; Dilatrate SR; NCGC00178830-02; Cardio 10; KBio2_003211; Dinitrate d'isosorbide [INN-French]; C07456; Cedocard Retard; Isoket; Maycor; Prestwick3_000714; Isosorbide 2,5-dinitrate; 54650-95-2; Dilatrate-SR; MolPort-003-666-213; Nosim; ISDN; SDM No. 50; BSPBio_000927; SPBio_002848; HMS501F18; Sorbide nitrate; Isosorbide dinitrate [USAN:INN:BAN:JAN]; Nitrosorbide; SMR000857256; Coronex; Spectrum5_001057; IsoBid; NSC 80038; Sorate-5; BPBio1_001021; Dinitrate, Isosorbide; Dilatrate; Isotrate; Isosorbide dinitrato; D-Isosorbide dinitrate; BiDil; Langoran; Sorbidinitrate; 1,4:3, 6-Dianhydro-D-glucitol dinitrate; 1,4:3,6-Dianhydrosorbitol 2, 5-dinitrate; D-Glucitol, 1,4:3,6-dianhydro-, dinitrate; Dianhydrosorbitol 2,5-dinitrate; Glucitol, 1,4:3, 6-dianhydro-, dinitrate,; Dilatrate-sr (TN); Vasodilat; KBioSS_000643; Angidil; Sorbidi nitras; Sorbidilat; Isodinit; HMS1570O09; Isoket Retard-120; Iso-Puren; Carvasin; [(3S,3aS,6R,6aS)-3-nitrooxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl] nitrate; Harrical; Rifloc Retard; Isosorbidi nitras; Prestwick0_000714; Nitrosorbid; Vascardin; AB00513900; 59812_FLUKA; Isosorbidi dinitras [INN-Latin]; Sorquad; EINECS 201-740-9; Prestwick_81	87-33-2	6883	7979661	TTDS00443	Guanylate cyclase	Guanylyl Cyclase	N/A	N/A	N/A	stimulator
DAP001056	Nitric Oxide	HSDB 1246; Nitric oxide trimer; D009569; UNII-31C4KY9ESH; Nitric Oxide, Endothelium Derived; Nitric oxide 10% by volume or more; Vasodilator, Endogenous Nitrate; monoxido de nitrogeno; NO(.); oxyde azotique; OHM 11771; DB00435; D00074; nitrogen monoxide; RCRA waste no. P076; CID945; 295566_ALDRICH; CCRIS 4319; UN 1660; AC1Q6QZ0; 14332-28-6; INOmax; LS-7547; Stickstoff(II)-oxid; AC1L3QHF; Nitric oxide, compressed [UN1660]  [Poison gas]; monoxyde d'azote; AR-1K7463; 90452-29-2; Oxyde nitrique [French]; 53851-19-7; 10102-43-9; Endothelium-Derived Nitric Oxide; [NO]; Bioxyde d'azote [French]; LS-192158; Nitric oxide, compressed [UN1660] [Poison gas]; oxidonitrogen(.); nitrosyl; Nitric Oxide, Endothelium-Derived; oxido nitrico; UN1660; 51005-20-0; Nitrosyl hydride; 51005-21-1; Nitroxyl; MolPort-003-929-452; AC1L1ADQ; Nitrate Vasodilator, Endogenous; Bioxyde d'azote; CHEMBL1200689; C00533; nitric oxide; Mononitrogen monoxide; Oxide, Nitric; Stickstoffmonoxid; Nitric oxide (JAN); nitrogen monooxide; Nitrosyl radical; Monoxide, Nitrogen; CHEMBL1234765; Endogenous Nitrate Vasodilator; oxido de nitrogeno(II); HNO; (.)NO; Monoxide, Mononitrogen; Nitrosyl hydride ((NO)H); Stickmonoxyd [German]; oxoazanyl; Nitrogen oxide (NO); INOmax (TN); (NO)(.); EINECS 233-271-0; NITRIC-OXIDE; Nitroxide radical; CID145068; Stickmonoxyd	10102-43-9	145068	3815	TTDS00443	Guanylate cyclase	Guanylyl Cyclase	N/A	N/A	N/A	stimulator
DAP001058	Isosorbide Mononitrate	CID27661; ARONIS24085; Conpin; Pentacard 20; Imdur Durules; Nitex; Isomonat; Fem-Mono; Conpin Retardkaps; ISMN AL; CCRIS 1911; Mono-Sanorania; [(3S,3aR,6R,6aS)-3-hydroxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl] nitrate; Imodur; MolPort-003-848-286; UN3251; CHEBI:6062; NCGC00167981-01; BM 22.145; ISMN Stada; IS 5-MN; ISMN AbZ; Turimonit; Isosorbide mononitrate [USAN:BAN:INN:JAN]; Etimonis; ISMN Lannacher; BRN 5851319; 1,4:3,6-dianhydro-5-O-nitro-D-glucitol; Monomax; C030397; Monolong 60; Monit 20; Monosorb XL 60; Isomon; I0403; Ismo (TN); ISOSORBIDE MONONITRATE; AC1L1DOS; Isosorbidi mononitras [Latin]; Pertil; Isosobide-5-mononitrate [UN3251] [Flammable solid]; Multitab; ISMN; Ismox; Percorina; ISMN Apogepha; Monosordil; Monoket; Plodin; Glucitol, 1,4:3,6-dianhydro-, 5-nitrate, D-; 1,4:3,6-Dianhydro-D-glucitol 5-nitrate; Monocord; Titarane; 16051-77-7; AKOS005110986; Medocor; Mononitrato de isosorbida [Spanish]; Isosorbide mononitrate (JAN/USP/INN); Isopen-20; Imazin; Mononitrato de isosorbida; ISMN Hexal; Mono Mack; Olicard 40; monocinque; C6H9NO6; Monocord 20; Imdur; ISMO; Elantan; BM 22-145; HMS2093K07; Mononitrate d'isosorbide; Monosorb; Monoket Retard; Olicardin; Monosorbitrate; Monis; Monisid; IHD; Mononit; Mononit Retard 50; Imdur (TN); Monit; Monizid; Vasdilat; Sorbimon; Isosorbide mononitrate [USAN:INN:BAN:JAN]; Corangin SR; Isosorbide-5-mononitrate; ISMN Basics; Isomonit; 5-Ismn; Mononitrate d'isosorbide [French]; vasotrate; Edistol; ZINC01849548; DB01020; Ismexin; Olicard-retard; Duride; Imdur 60; Isosobide-5-mononitrate [UN3251]  [Flammable solid]; Mono Corax; 5-ISMN Durules; EINECS 240-197-2; AC1Q21WK; Monolong; Monicor; MonoSigma; Mono Mac 50D; Promocard; Olicard; IS 5MN; Monodur Durules; C07714; Monotrate; Monoclair; Elantan Retard; Sigacora; Ismo-20; Mono-Mack; AHR-4698; LS-71381; D-Glucitol, 1,4:3,6-dianhydro-, 5-nitrate; Uniket; CHEMBL1311; Orasorbil; Monocord 40; Monopront; BM-22-145; Mono Corax Retard; Monocedocard; D00630; Corangin; ISMN Heumann; Elantan Long; UNII-LX1OH63030; Epicordin; Monolong 40; Isosorbide 5-nitrate; I14-3287; ISMN Atid; Monocord 50 SR; Isosorbide 5-mononitrate; Mononit 40; Iturol; AHR 4698; Nitramin; Mononit 20; Isosorbidi mononitras; Monoket OD; Imtrate; isosorbide-5-nitrate	16051-77-7	27661	9916	TTDS00443	Guanylate cyclase	Guanylyl Cyclase	N/A	N/A	N/A	stimulator
DCL000804	Fingolimod	AC1L332W; nchembio804-comp4; 2-Amino-2-(4-octylphenethyl)propane-1,3-diol; MolPort-003-847-513; CHEMBL314854; CID107970; LS-187221; nchembio.547-comp4; UNII-3QN8BYN5QF; Fingolimod; CHEBI:244940	162359-55-9	107970	10549599	TTDC00258	Sphingosine 1-phosphate receptor 1	Endothelial differentiation G-protein coupled receptor 1;S1P receptor 1;S1P receptor Edg-1;S1P1;Sphingosine 1-phosphate receptor Edg-1	P21453	1901	ENSG00000170989	modulator
DCL000808	FTY720	FTY720; Fingolimod hydrochloride; LS-120139; 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol hydrochloride; AC1L332T; S5002_Selleck; Gilenia; 1,3-Propanediol, 2-amino-2-(2-(4-octylphenyl)ethyl)-, hydrochloride; CID107969; Fingolimod hydrochloride (JAN/USAN); 2-Amino-2-(2-(4-octylphenyl)ethyl)-1,3-propanediol hydrochloride; Fty 720; 2-Amino-2-(2-(4-octylphenyl)ethyl)propane-1,3-diol, HCl; CHEMBL544665; AC-1929; MolPort-006-666-484; D04187; AKOS005145784; ST51051590; Gilenya; EC-000.2314; 162359-56-0; IN1328; I01-1261; 2-Amino-2-[2-(4-octyl-phenyl)-ethyl]-propane -1,3-diol hydrochloride; FTY-720A; Fingolimod HCl; C19H33NO2.HCl; Fingolimod hydrochloride [USAN]; UNII-G926EC510T; Fty-720	162359-56-0	107970	26758737	TTDC00258	Sphingosine 1-phosphate receptor 1	Endothelial differentiation G-protein coupled receptor 1;S1P receptor 1;S1P receptor Edg-1;S1P1;Sphingosine 1-phosphate receptor Edg-1	P21453	1901	ENSG00000170989	modulator
DCL000605	R3477	N/A	N/A	N/A	N/A	TTDC00258	Sphingosine 1-phosphate receptor 1	Endothelial differentiation G-protein coupled receptor 1;S1P receptor 1;S1P receptor Edg-1;S1P1;Sphingosine 1-phosphate receptor Edg-1	P21453	1901	ENSG00000170989	agonist
DCL001127	Gilenia	FTY720; Fingolimod hydrochloride; LS-120139; 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol hydrochloride; AC1L332T; S5002_Selleck; Gilenia; 1,3-Propanediol, 2-amino-2-(2-(4-octylphenyl)ethyl)-, hydrochloride; CID107969; Fingolimod hydrochloride (JAN/USAN); 2-Amino-2-(2-(4-octylphenyl)ethyl)-1,3-propanediol hydrochloride; Fty 720; 2-Amino-2-(2-(4-octylphenyl)ethyl)propane-1,3-diol, HCl; CHEMBL544665; AC-1929; MolPort-006-666-484; D04187; AKOS005145784; ST51051590; Gilenya; EC-000.2314; 162359-56-0; IN1328; I01-1261; 2-Amino-2-[2-(4-octyl-phenyl)-ethyl]-propane -1,3-diol hydrochloride; FTY-720A; Fingolimod HCl; C19H33NO2.HCl; Fingolimod hydrochloride [USAN]; UNII-G926EC510T; Fty-720	N/A	N/A	N/A	TTDC00258	Sphingosine 1-phosphate receptor 1	Endothelial differentiation G-protein coupled receptor 1;S1P receptor 1;S1P receptor Edg-1;S1P1;Sphingosine 1-phosphate receptor Edg-1	P21453	1901	ENSG00000170989	inhibitor
DPR000073	Melanotetan II	N/A	121062-08-6	6323491	49703995	TTDR00375	Melanocortin-3 receptor	MC3-R	P41968	4159	ENSG00000124089	agonist
DCL000580	Nerispirdine	1H-Indol-1-amine, N-(3-fluoro-4-pyridinyl)-3-methyl-N-propyl-, monohydrochloride; 119229-64-0; N-(3-fluoropyridin-4-yl)-3-methyl-N-propylindol-1-amine; EN002124; HP-184; N-(3-Fluoro-4-pyridinyl)-3-methyl-N-propyl-1H-indol-1-amine; 119229-65-1; Nerispirdine; 1H-Indol-1-amine, N-(3-fluoro-4-pyridinyl)-3-methyl-N-propyl-; CID3081185; UNII-G7M7YWO6CG; Nerispirdine hydrochloride; AC1MIWGX; HP 184; N-(n-Propyl)-3-fluoro-4-pyridinyl-1H-3-methylindol-1-amine hydrochloride	162401-32-3	449193	47207405	TTDS00148	Potassium voltage-gated channel subfamily KQT member 1	IKs producing slow voltage-gated potassium channel alpha subunit KvLQT1;KCNQ1 channel;KQT-like 1;Kv7.1;Voltage-gated potassium channel subunit Kv7.1	P51787	3784	ENSG00000053918	blocker
DAP000498	Indapamide	Ipamix; HMS2090M16; MolPort-003-666-209; BSPBio_002174; BPBio1_000263; I0730; Natrilix; Prestwick3_000220; Spectrum3_000467; Spectrum4_000017; Natrix (TN); Metindamide; NLozol, Arifon, Fludex, Noranat, Veroxil, Tertensif, Indapamide; Tandix; NCGC00089727-02; Apo-Indapamide; Nu-Indapamide; LS-26138; CID3702; NCGC00089727-03; Indapamide (JAN/USP); Indapamida; I01-0369; 4-Chloro-N-(2-methyl-1-indolinyl)-3-sulfamoylbenzamide; Tertensif; Novo-Indapamide; HMS1920F19; KBio2_001397; S1730_Selleck; Lozol; UNII-F089I0511L; 1-(4-Chloro-3-sulfamoylbenzamido)-2-methylindoline; Indamol; Spectrum5_000866; 3-(Aminosulfonyl)-4-chloro-N-(2,3-dihydro-2-methyl-1H-indol-1-yl)benzamide; Lozide; KBio1_000508; Benzamide, 3-(aminosulfonyl)-4-chloro-N-(2,3-dihydro-2-methyl-1H-indol-1-yl)-; AC1L1GIW; I1887_SIGMA; AB00052021; IDI1_000508; KBioSS_001397; BSPBio_000239; Indapamide [USAN:INN:BAN:JAN]; Veroxil; NINDS_000508; Indapamidum [INN-Latin]; SMR000058829; EINECS 248-012-7; 5-20-06-00348 (Beilstein Handbook Reference); HMS501J10; Fludex; KBio2_003965; SE-1520; Indapamide (USP); SE 1520; KBioGR_000393; Arifon; Indaflex; HMS2091N07; KBio2_006533; Spectrum_000917; I1887_FLUKA; Benzamide, 3-(aminosulfonyl)-4-chloro-N-(2,3-dihydro-2-methyl-1H-indol-l-yl)-; MLS002222229; CHEMBL406; MLS001148152; N-[4-Chloro-3-sulfamoylbenzamido]-2- methylindoline; 49564-58-1; SPBio_001019; indapamide; Lozol (TN); Spectrum2_000980; BRD-A95869247-001-04-6; Benzamide, 3-(aminosulfonyl)-4-chloro-N-(2,3-dihydro-2-methyl-1H-indol-1-yl)- (9CI); Damide; AC-2073; 26807-65-8; Bajaten; S-1520; MLS000028554; SPECTRUM1500349; RHC 2555; TL8002131; BRN 1604026; SAM002564214; Cormil; ST51015024; USV 2555; DivK1c_000508; D00345; BENZAMIDE, 4-CHLORO-N-(2-METHYL-1-INDOLINYL)-3-SULFAMOYL-; Pressurai; Natrix; DB00808; N-(4-Chloro-3-sulfamoylbenzamido)-2-methylindoline; CPD000058829; 4-chloro-N-(2-methyl-2,3-dihydroindol-1-yl)-3-sulfamoylbenzamide; Indapamidum; KBio3_001394; Noranat; Idapamide; Indapamida [INN-Spanish]	26807-65-8	3702	7847411	TTDS00148	Potassium voltage-gated channel subfamily KQT member 1	IKs producing slow voltage-gated potassium channel alpha subunit KvLQT1;KCNQ1 channel;KQT-like 1;Kv7.1;Voltage-gated potassium channel subunit Kv7.1	P51787	3784	ENSG00000053918	blocker
DAP000662	Propofol	Disoprofol; MLS002454360; MLS001335999; propofol; 2,6-DIISOPROPYLPHENOL; SPBio_003031; C07523; NCGC00091538-04; Aquafol; Fresofol; BRN 1866484; DB00818; Propofol IDD-D; 2,6-Diisopropylphenol; Phenol, 2, 6-bis(1-methylethyl)-; NSC5105; Propofolum [Latin]; NCGC00091538-02; Rovi Brand of Propofol; Lopac-D126608; Propofol Fresenius; Diisopropylphenol; Ivofol; UNII-YI7VU623SF; NCGC00015389-02; D126608_ALDRICH; Prestwick0_000931; InChI=1/C12H18O/c1-8(2)10-6-5-7-11(9(3)4)12(10)13/h5-9,13H,1-4H; 4-06-00-03435 (Beilstein Handbook Reference); Diprivan Injectable emulsion; MolPort-001-794-517; S01-0189; Diprivan (TN); NCGC00091538-03; Zeneca Brand of Propofol; HMS2094E17; Ampofol; Abbott Brand of Propofol; 2,6-di(propan-2-yl)phenol; SPECTRUM1505022; C12H18O; CPD000059151; CPD-11437; HSDB 7123; NCGC00091538-01; CHEMBL526; BSPBio_000862; 2,6-Diisopropyl phenol; EU-0100437; AM-149; HMS2089O21; Propofol MCT; Fresenius Kabi Brand of Propofol; Prestwick3_000931; LS-996; 2,6-Bis(1-methylethyl)phenol; ICI 35,868; CID4943; Fresenius Brand of Propofol; Alpha Brand of Propofol; 2,6-Bis(Isopropyl)-phenol; MLS001066348; AC-2038; Propofol (JAN/USAN/INN); Recofol; SMR000059151; BPBio1_000950; NCGC00091538-06; D0617; Parnell Brand of Propofol; BPBio1_000969; 2,6 Diisopropylphenol; NCGC00015389-01; Phenol, 2,6-diisopropyl-; Disoprivan; D00549; Curamed Brand of Propofol; HMS1570L04; Diprivan; BIDD:GT0436; CCRIS 9000; NCGC00015389-09; 2, 6-Diisopropylphenol; Phenol, 2,6-bis(1-methylethyl)-; Juste Brand of Propofol; ICI35,868; PFL; AC1Q1OUI; Propofol [USAN:INN:BAN]; 28449-97-0; Dipravan; ST50405911; Jsp004266; BRD-K82255054-001-03-5; Biomol-NT_000248; ICI-35,868; ZINC00968303; Braun Brand of Propofol; ICI-35868; ICI 35868; NSC 5105; AI3-26295; Propofol Rovi; ICI35868; Rapinovet; EINECS 218-206-6; ZD-0859; ghl.PD_Mitscher_leg0.558; Propofol(2,6-Diisopropylphenol); Propofol-Lipuro; CHEBI:44915; CAS-2078-54-8; Propofolum; 2078-54-8; DDS-04F; D015742; nchembio.552-comp7; NCGC00091538-05; AB00513968; Propofol Abbott; Astra Brand of Propofol; SAM002264610; D126608; 2,6-bis(1-methylethyl)-phenol; AC1L1J9Y; Pisa Brand of Propofol; W505102_ALDRICH; 50356-15-5; Prestwick2_000931; AstraZeneca Brand of Propofol; Lopac0_000437; Schering Brand of Propofol; Prestwick1_000931; NCGC00015389-04	2078-54-8	4943	9726	TTDS00177	Fatty-acid amide hydrolase	Anandamide amidase;Anandamide amidohydrolase;Anandamide synthase;Arachidonylethanolamide synthase;FAAH;Fatty acid amide hydrolase;Oleamide hydrolase	O00519	2166	ENSG00000117480	inhibitor
DAP000661	Thiopental	Penthiobarbital; 5-24-09-00172 (Beilstein Handbook Reference); DB00599; Thionembutal; Intraval; T1022_FLUKA; ()Thiopental solution; Trapanal; (+/-)Thiopental solution; AC1Q2UJN; Barbituric acid, 5-ethyl-5-(1-methylbutyl)-2-thio-; NINDS_000993; Thiopentobarbitone; 4,6,(1H,5H)-Pyrimidinedione, 5-ethyldihydro-5-(1-methylbutyl)-2-thioxo- (9CI); T1022_SIGMA; Spectrum_001786; AC1MHDBY; KBioSS_002273; Thiomebumal; CHEBI:102166; Thiopentobarbital; Thiopental [BAN]; C11H18N2O2S; Tiopentale; (+/-)-THIOPENTAL; CID3000715; BRN 0209361; KBio1_000993; 5-ethyl-2-mercapto-5-(1-methylbutyl)pyrimidine-4,6(1H,5H)-dione; SPBio_002215; Tiopentale [Italian]; Spectrum3_001781; Thiopentone; KBioGR_001010; Spectrum5_001692; 59709-53-4; (+-)-Thiopental; I14-14129; BRD-A72603112-236-02-4; UNII-JI8Z5M7NA3; C07521; 2-Thio-5-ethyl-5-sec-pentylbarbituric acid; 5-ethyl-5-pentan-2-yl-2-sulfanylidene-1,3-diazinane-4,6-dione; T1019_SIGMA; 5-ethyl-5-(1-methylbutyl)-2-thioxodihydropyrimidine-4,6(1H,5H)-dione; 5-Ethyl-5-(1-methylbutyl)-2-thiobarbituric acid; 5-Ethyl-5-(1-methyl-butyl)-2-thioxo-dihydro-pyrimidine-4,6-dione; CHEMBL441; 4,6(1H,5H)-Pyrimidinedione, 5-ethyldihydro-5-(1-methylbutyl)-2-thioxo-; AC-16029; 5-Ethyl-5-(1-methylbutyl)-2-thiobarbituric acid; NCGC00159524-01; KBio2_002272; 4,6,(1H,5H)-Pyrimidinedione, 5-ethyldihydro-5-(1-methylbutyl)-2-thioxo-; KBio2_007408; BSPBio_003301; Spectrum2_001998; Pentothiobarbital; KBio2_004840; DivK1c_000993; IDI1_000993; thiopental; 76-75-5; LS-24395; EINECS 200-984-3; Thiopentobarbituric acid; Thiothal; Spectrum4_000575; KBio3_002803	76-75-5	3000715	9724	TTDS00177	Fatty-acid amide hydrolase	Anandamide amidase;Anandamide amidohydrolase;Anandamide synthase;Arachidonylethanolamide synthase;FAAH;Fatty acid amide hydrolase;Oleamide hydrolase	O00519	2166	ENSG00000117480	inhibitor
DCL000643	SSR411298	N/A	N/A	N/A	N/A	TTDS00177	Fatty-acid amide hydrolase	Anandamide amidase;Anandamide amidohydrolase;Anandamide synthase;Arachidonylethanolamide synthase;FAAH;Fatty acid amide hydrolase;Oleamide hydrolase	O00519	2166	ENSG00000117480	inhibitor
DCL000284	RPR 200765A	N/A	218160-20-4	N/A	N/A	TTDS00041	Prostaglandin G/H synthase 2	COX-2;Cyclooxygenase 2;Cyclooxygenase -2;Cyclooxygenase-2;Heme-protein prostaglandin G/H synthase;PGH synthase 2;PGHS-2;PHS II;Prostaglandin H2 synthase 2;Prostaglandin-endoperoxide synthase 2	P35354	5743	ENSG00000073756	inhibitor
DAP000181	Piroxicam	Prestwick_573; HMS1920H22; Akten; D00127; Riacen; Pyroxycam; CHEBI:8249; AC-12216; Roxiden; Artroxicam; BRN 0627692; HMS2092A05; Erazon; AC1Q3XLJ; 4-Hydroxy-2-methyl-N-2-pyridyl-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide; Felden; CHEMBL527; Feldene Fast; Roxicam; Geldene; (4-Hydroxy-2-methyl-1,1-dioxobenzo[e]1,2-thiazin-3-yl)-N-(2-pyridyl)carboxamide; 3-[hydroxy(pyridin-2-ylamino)methylidene]-2-methyl-3,4-dihydro-2H-1; CP 16171; Piroxicamum [INN-Latin]; Piroflex; BAS 04381594; LS-7663; 36322-90-4; piroxicam; Bio-0759; Caliment; CCRIS 3719; HMS1792D11; Apo-Piroxicam; CHF 1251; HMS1990D11; Flogobene; EINECS 252-974-3; 4-hydroxy-2-methyl-N-(pyridin-2-yl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide; Reudene; STK177288; BAXO; Piroftal; AK1015; Larapam; UNII-13T4O6VMAM; D010894; Pirkam; Zunden; 4-Hydroxy-2-methyl-N-(2-pyridyl)-2H-1,2-benzothiazin-3-caboxyamid-1,1-dioxid; NSC666076; CP-16171; CP16171; EU-0100900; C01608; 4-hydroxy-2-methyl-N-pyridin-2-yl-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide; S1713_Selleck; DB00554; HMS1362D11; Piroxicam [USAN:BAN:INN:JAN]; Feldene Gel; Solocalm; Piroxicam (JP15/USP/INN); Bruxicam; P0847_SIAL; 4-Hydroxy-2-methyl-3-(pyrid-2-yl-carbamoyl)-2H-1,2-benzothiazine 1,1-dioxide; AC1NQX1P; Feldene, Roxam, Piroxicam; Improntal; P 5654; HMS1568L03; Pipoxicam; 4-Hydroxy-2-methyl-N-(2-pyridyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide; C15H13N3O4S; MolPort-001-888-120; 4-Hydroxy-2-methyl-N-(2-pyridyl)-2H-1,2-benzothiazin-3-caboxyamid-1,1-dioxid [German]; Feldene (TN); Feldene; (3E)-3-[hydroxy-(pyridin-2-ylamino)methylidene]-2-methyl-1,1-dioxo-1; piroxicam usp; CID5280452; NSC 666076; SPECTRUM1500491; Sasulen; HMS501C11; 2H-1,2-Benzothiazine-3-carboxamide, 4-hydroxy-2-methyl-N-2-pyridinyl-, 1,1-dioxide; AKOS000714958; Piroxicamum	36322-90-4	5280452	4761	TTDS00041	Prostaglandin G/H synthase 2	COX-2;Cyclooxygenase 2;Cyclooxygenase -2;Cyclooxygenase-2;Heme-protein prostaglandin G/H synthase;PGH synthase 2;PGHS-2;PHS II;Prostaglandin H2 synthase 2;Prostaglandin-endoperoxide synthase 2	P35354	5743	ENSG00000073756	inhibitor
DAP000779	Mefenamic acid	to_000071; Namphen; BSPBio_000207; M1782; Pinewood Brand of Mefenamic Acid; STK666691; Vialidon; SAM002554908; Parkemed; Ponmel; First Horizon Brand of Mefenamic Acid; Methenamic acid; Tanston; Apo-Mefenamic; AGN-1255; Mefac; 2-[(2,3-dimethylphenyl)amino]benzoic acid; Mycasaal; NCGC00022393-03; Contraflam; Benzoic acid, 2-((2,3-dimethylphenyl)amino)-; Pharmascience Brand of Mefenamic Acid; 2-(2,3-Xylidino)benzoic Acid; Ac. mefenamico; CID4044; Prestwick0_000054; EINECS 200-513-1; DB00784; PMS Mefenamic Acid; Prestwick3_000054; Mefacit; KBioSS_000654; NuMefenamic; Mefedolo; Pinalgesic; Ponalar; CI-473; Prestwick_506; Bafhameritin-M; MolPort-001-839-968; Acido mefenamico [INN-Spanish]; APS Brand of Mefenamic Acid; 2-(2,3-dimethylphenylamino)benzoic acid; CHEBI:129989; Acid, Mefenaminic; Ponstan; F0850-6853; Ponalgic; CAS-61-68-7; Anthranilic acid, N-2,3-xylyl-; Bonabol; NINDS_000298; BSPBio_002724; Acid, Mefenamic; Mephenamic acid; Spectrum2_001941; Prestwick2_000054; HMS1568K09; C02168; Ashbourne Brand of Mefenamic Acid; DivK1c_000298; Warner-Lambert Brand of Mefenamic Acid; Rolan; Nu-Mefenamic; CPD000058188; Mefanamic acid; Mefenamic acid [USAN:INN:BAN:JAN]; Nu Mefenamic; MLS000069709; A1077/0050549; SGCUT00005; HMS2090B07; Apo Mefenamic; N-(2,3-Dimethylphenyl)anthranilic acid; Anthranilic acid, N-(2,3-xylyl)-; Nu-Pharm Brand of Mefenamic Acid; Acido mefenamico; LS-20589; 2-(2,3-Dimethylanilino)benzoic acid; Pontal; AKOS001025551; NCGC00022393-04; N-2,3-Xylylanthranilic acid; IDI1_000298; Mephenaminic acid; Nu Pharm Brand of Mefenamic Acid; 2-((2,3-Dimethylphenyl)amino)benzoic acid; AC1Q2NNQ; 61-68-7; ID8; WLN: QVR BMR B1 C1; Bafameritin-M; Pfizer Brand of Mefenamic Acid; HMS1921D13; in-M; HSDB 3115; Ponstel (TN); BRD-K92778217-001-06-1; 2-Diphenylaminecarboxylic acid, 2',3'-dimethyl-; INF 3355; Chemidex Brand of Mefenamic Acid; BRN 2216243; Ponstan forte; Mefenaminsaeure; Mefenacid; Ac. mefenamico [Italian]; Acidum mefenamicum [INN-Latin]; Mefenamate; SPECTRUM1501103; KBio1_000298; KBio2_005790; I14-3644; Ponstyl; Godecke Brand of Mefenamic Acid; SMR000058188; INF-3355; KBio2_000654; Warner Lambert Brand of Mefenamic Acid; Lysalgo; CN 35355; KBio2_003222; UNII-367589PJ2C; CI 473; NCGC00016278-02; KBioGR_001730; Farmasierra Brand of Mefenamic Acid; PMS-Mefenamic Acid; Apotex Brand of Mefenamic Acid; NSC94437; Acide mefenamique [French]; D00151; M4267_SIGMA; InChI=1/C15H15NO2/c1-10-6-5-9-13(11(10)2)16-14-8-4-3-7-12(14)15(17)18/h3-9,16H,1-2H3,(H,17,18; AC1L1HAE; Forte, Ponstan; Spectrum3_001082; AC-11160; N-(2,3-Xylyl)anthranilic acid; Rowa Brand of Mefenamic Acid; Oprea1_193889; Tamany Bonsan; Clonmel Brand of Mefenamic Acid; Acide mefenamique [INN-French]; Mefenamic acid (JP15/USP/INN); NCGC00016278-01; Mefenaminic Acid; SPBio_002128; Parke Davis Brand of Mefenamic Acid; NCGC00022393-05; D008528; Acide mefenamique; MLS001074162; ApoMefenamic; Ponstil; Elan Brand of Mefenamic Acid; Prestwick1_000054; mefenamic acid; NSC 94437; SMP2_000141; UNM000001233403; N-(2,3-Xylyl)-2-aminobenzoic acid; Ponsyl; Antigen Brand of Mefenamic Acid; CHEMBL686; HL 1; Coslan; CL 473; BPBio1_000229; HMS500O20; Mefenaminsaeure [German]; Benzoic acid, 2-[(2,3-dimethylphenyl)amino]-; CN-35355; SPBio_002001; Acidum mefenamicum; AB00052200; HMS2092B17; Spectrum5_001341; Ponstel; Spectrum4_001235; Benzoic acid, 2-(2,3-dimethylphenyl)amino-; KBio3_001944; Dysman; Spectrum_000174; Mefic	61-68-7	4044	148984	TTDS00041	Prostaglandin G/H synthase 2	COX-2;Cyclooxygenase 2;Cyclooxygenase -2;Cyclooxygenase-2;Heme-protein prostaglandin G/H synthase;PGH synthase 2;PGHS-2;PHS II;Prostaglandin H2 synthase 2;Prostaglandin-endoperoxide synthase 2	P35354	5743	ENSG00000073756	inhibitor
DAP000972	Niflumic Acid	2-(alpha,alpha,alpha-Trifluoro-m-toluidino)nicotinic acid; HMS1791F15; Nifluminic acid; HMS500N19; NCGC00023636-07; Spectrum4_000043; 2-(3-Trifluoromethyl-phenylamino)-nicotinic acid; AB00052255; Prestwick0_000255; KBioGR_000113; Acid, Niflumic; SMR000058199; KBio2_002681; 3-Pyridinecarboxylic acid, 2-((3-(trifluoromethyl)phenyl)amino)-; SC 1332; Prestwick3_000255; KBio2_000113; LS-96639; C13H9F3N2O2; HMS1921D12; Niflugel (TN); Spectrum3_001485; Niflumic acid (INN); 5-22-13-00598 (Beilstein Handbook Reference); 2-(3-[Trifluoromethyl]anilino)nicotinic acid; Spectrum5_001216; 2-[(3-Trifluoromethylphenyl)amino]nicotinic Acid; IDI1_000277; AB1004097; 39690A; CHEMBL63323; CCRIS 5740; N 0630; Aza-2 dimethyl-2',3' (tetrazolyl-5)-6 diphenylamino [French]; BSPBio_000070; BRD-K98763141-001-06-8; BRD-K98763141-001-04-3; Forenol; Niflumic acid [INN:DCF]; Acide niflumique [French]; NCGC00023636-08; UPSA Conseil Brand of Niflumic Acid; BRN 0489360; 2-(3-(Trifluoromethyl)-phenyl)aminonicotinic acid; Lopac0_000845; 2-(3-Trifluoromethylanilino)nicotinic Acid; Acidum niflumicum; AC1L1IA4; HMS2090D19; D08275; Donalgin; KBio2_005249; NCGC00015724-06; 2-[3-(Trifluoromethyl)anilino]nicotinic acid; KBio3_000226; DivK1c_000277; NCGC00015724-03; Acido niflumico; Lopac-N-0630; Niflumate; Acide niflumique; 2-{[3-(TRIFLUOROMETHYL)PHENYL]AMINO}NICOTINIC ACID; Aza-2 dimethyl-2',3' (tetrazolyl-5)-6 diphenylamino; SPBio_000928; Acido niflumico [Italian]; AKOS000519590; HMS1568D12; SPECTRUM1502015; EINECS 224-516-2; Niflam; NCGC00023636-03; 2-[(3-TRIFLUOROMETHYL)PHENYL]AMINO-3-PYRIDINE-CARBOXYLIC ACID; UPSA Brand 1 of Niflumic Acid; niflumic acid; CAS-4394-00-7; Spectrum_001353; NFL; NCGC00023636-04; BSPBio_003069; Bio2_000593; Niflugel; Landruma; UPSA Brand 2 of Niflumic Acid; 2-{[3-(trifluoromethyl)phenyl]amino}pyridine-3-carboxylic acid; CID4488; 3-Pyridinecarboxylic acid, 2-[[3-(trifluoromethyl)phenyl]amino]-; Actol; KBio3_002569; KBioGR_000505; KBio3_000225; Nicotinic acid, 2-(alpha,alpha,alpha-trifluoro-m-toluidino)-; BAS 00821161; 1td7; KBio2_004401; Bio1_000603; CBiol_001828; Flunir; Acidum niflumicum [INN-Latin]; S00109; 2-(3-(Trifluoromethyl)anilino)nicotinic acid; HMS1989F15; NCGC00023636-09; Bio1_001092; Upsamedica Brand of Niflumic Acid; Prestwick1_000255; MLS001076327; NINDS_000277; UNII-4U5MP5IUD8; IDI1_033863; NCGC00015724-01; MolPort-000-140-647; 2-[3-(trifluoromethyl)anilino]pyridine-3-carboxylic acid; NCGC00023636-05; HMS1361F15; NCGC00015724-13; N0630_SIGMA; Niflactol; KBio2_001833; Spectrum2_000794; EU-0100845; BPBio1_000078; Bio2_000113; STK803109; 2-[alpha,alpha,alpha-trifluoro-m-toluidino]-nicotinic acid; KBioSS_001833; DB04552; BSPBio_001393; NCGC00015724-02; C13698; SPBio_002289; Acide niflumique [INN-French]; NCGC00023636-06; KBio2_006969; AC-2652; UP 83; 2-[3-(Trifluoromethyl)anilino]nicotinic acid; 2-(|A,|A,|A-Trifluoro-m-toluidino)nicotinic acid; Prestwick2_000255; Nifluril; Acido niflumico [INN-Spanish]; KBio1_000277; 4394-00-7; 2-[(3-Trifluoromethyl)phenyl]amino]-3-pyridinecarboxylic Acid; KBioSS_000113; MLS000069713; D009544; Bio1_000114; Prestwick_890	4394-00-7	4488	7889362	TTDS00041	Prostaglandin G/H synthase 2	COX-2;Cyclooxygenase 2;Cyclooxygenase -2;Cyclooxygenase-2;Heme-protein prostaglandin G/H synthase;PGH synthase 2;PGHS-2;PHS II;Prostaglandin H2 synthase 2;Prostaglandin-endoperoxide synthase 2	P35354	5743	ENSG00000073756	inhibitor
DAP000737	Celecoxib	KBioGR_000723; NCGC00091455-01; SMR000550473; Celebrex (TN); CHEMBL118; Onsenal; KBio2_002351; LS-31667; Celecoxib [Old RN]; KBio2_000912; CPD000550473; CHEBI:41423; CID2662; AI-525; MLS001195656; Solexa; C07589; KBio3_003037; benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-; Celebra; SC-58635; YM177; Medicoxib; S1261_Selleck; Celecoxib (SC-58635); HMS502M15; Celecoxi; 184007-95-2; 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1Hpyrazol-1-yl] benzenesulfonamide; SC 58635; SAM002589995; Spectrum5_001324; Celecox; Spectrum_000432; HSDB 7038; Spectrum4_000182; YM 177; KBio3_002830; KBioSS_000912; KBio1_000893; 4-(5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide; FT-0080064; BSPBio_003596; AC1L1E6K; Celecoxib [USAN]; NINDS_000893; Benzenesulfonamide, 4-(5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)-; DB00482; Celocoxib; SPBio_001512; SC58635; KBio2_004919; HMS2089L18; ZINC02570895; Spectrum2_001576; cMAP_000027; BRD-K02637541-001-02-4; KBio2_003480; Xilebao; NCGC00091455-04; AC-4228; CCRIS 8679; UNM-0000305813; Pfizer brand of celecoxib; NCI60_041049; KBio2_006048; D00567; I01-1033; 4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide; NCGC00091455-03; TL8001323; DivK1c_000893; Spectrum3_001996; C17H14F3N3O2S; 4-[5-(4-METHYLPHENYL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOL-1-YL]BENZENESULFONAMIDE; KBioGR_002351; Benzenesulfonamide,4-(5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl); 169590-42-5; Celebrex; YM-177; BIDD:GT0408; NSC719627; CEL; MLS001304708; TPI-336; KBioSS_002354; 1oq5; Celecoxib (JAN/USAN/INN); Celebrex, Celebra, Celecoxib; SC-58553, SC-58635; Eurocox; IDI1_000893; p-(5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide; HMS2093I07; C105934; SPECTRUM1503678; KBio2_007487; MolPort-002-885-815; MLS001165684; NCGC00091455-02; celecoxib; CEP-33222; HMS1922G14	169590-42-5	2662	205043	TTDS00041	Prostaglandin G/H synthase 2	COX-2;Cyclooxygenase 2;Cyclooxygenase -2;Cyclooxygenase-2;Heme-protein prostaglandin G/H synthase;PGH synthase 2;PGHS-2;PHS II;Prostaglandin H2 synthase 2;Prostaglandin-endoperoxide synthase 2	P35354	5743	ENSG00000073756	inhibitor
DAP000735	Nabumetone	BRL-14777; Relafen; NCGC00095063-02; HMS2090D13; SPECTRUM1503650; N6142_SIGMA; Consolan; Relif; Apotex Brand of Nabumetone; Mayoly-Spindler Brand of Nabumetone; Flambate; AC1Q4F4K; BIDD:GT0104; KBioGR_000687; CPD000058835; Rhoxal-nabumetone; nchembio.128-comp30; SmithKline Beecham Brand of Nabumetone; Nabumetone (JAN/USP/INN); CCRIS 8108; Prestwick3_000909; IDI1_000850; KBio2_001966; NCGC00095063-01; DivK1c_000850; HMS1922G10; BRL 14777; KBioSS_001966; MolPort-001-793-710; KBio2_007102; nabumetone; Nabucox; AC1L1I3P; SPBio_002097; Prodac; AC-19025; Prestwick0_000909; Prestwick2_000909; CAS-42924-53-8; Nabumetonum; BPBio1_000834; Gen-Nabumetone; Relifex; MLS000069541; NCGC00016853-01; Nabumetona; SAM002564225; AB00052392; Relifen; HMS1570F20; D00425; BRN 2103472; 42924-53-8; Apo-Nabumetone; Spectrum_001486; SMR000058835; Ambap42924-53-8; Arthraxan; BSPBio_000758; Uriach Brand of Nabumetone; 4-(6-Methoxy-2-naphthalenyl)-2-butanone; Nabumetonum [INN-Latin]; HMS2093I05; KBio2_004534; MLS001076325; KBio1_000850; CID4409; 4-(6-methoxynaphthalen-2-yl)butan-2-one; HMS502K12; Dolsinal; CHEMBL1070; C035605; LS-46825; Nabuser; UNII-LW0TIW155Z; Genpharm Brand of Nabumetone; Nabumetone [USAN:BAN:INN:JAN]; Mebutan; N6142_FLUKA; SmithKline Brand of Nabumetone; Arthaxan; Prestwick1_000909; Unimetone; nabumeton; Spectrum2_001969; Spectrum5_001286; DB00461; Spectrum4_000174; BRD-K65146499-001-04-8; Listran; Balmox; Wassermann Brand of Nabumetone; GlaxoSmithKline Brand of Nabumetone; 4-(6-Methoxy-2-naphthyl)-2-butanone; SPBio_002957; Relafen (TN); Rhoxalpharma Brand of Nabumetone; ZINC00020221; 2-Butanone, 4-(6-methoxy-2-naphthalenyl)-; NINDS_000850	42924-53-8	4409	7847491	TTDS00041	Prostaglandin G/H synthase 2	COX-2;Cyclooxygenase 2;Cyclooxygenase -2;Cyclooxygenase-2;Heme-protein prostaglandin G/H synthase;PGH synthase 2;PGHS-2;PHS II;Prostaglandin H2 synthase 2;Prostaglandin-endoperoxide synthase 2	P35354	5743	ENSG00000073756	inhibitor
DPR000079	Nimesulide	HMS502C15; EINECS 257-431-4; N-[4-Nitro-2-phenoxyphenyl]-methanesulfonamide; MLS001148268; Guaxan; Nimesulidum [INN-Latin]; SMR000058484; SBB066407; NCGC00015725-01; EU-0100855; C012655; HMS1922K17; CHEMBL56367; Therabel Brand of Nimesulide; Aldoron; HMS1792G05; Flogovital; Nimedex; NCGC00021842-03; Lopac0_000855; Nimesulide [BAN:INN]; SPBio_001382; BSPBio_003112; KBio3_000826; Alcala Brand of Nimesulide; KBio2_000443; MLS000069680; Sulidene; R-805; Nexen; AC-4524; BCBcMAP01_000034; KBio2_007193; KBio3_000825; D01049; NCGC00015725-12; Prestwick2_000194; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CID4495; N1016_SIGMA; Nisulid; Helsinn Brand of Nimesulide; Mesulid; NCGC00021842-07; BPBio1_000163; Ergha Brand of Nimesulide; NCGC00021842-05; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Bio2_000382; Prestwick3_000194; NCGC00021842-04; Aulin; 4'-Nitro-2'-phenoxymethanesulfonanilide; Bio2_000862; BSPBio_001103; BRD-K76775527-001-06-2; BRN 2421175; Eskaflam; Nimesulide (JAN/INN); SmithKline Beecham Brand of Nimesulide; N 1016; Nise Gel; 4'-Nitro-2'-phenoxymethansulfonanilid; Maver Brand of Nimesulide; KBioSS_002057; AB00052332; Spectrum2_001541; Orthobid; HMS1990G05; CCRIS 8225; LS-90290; MolPort-003-849-391; Spectrum_001577; Prestwick_618; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)- (9CI); Nimed; NCGC00015725-02; NIM-03; KBio1_000693; Nimesulidum; Nimesulida [INN-Spanish]; KBio2_005579; Alter Brand of Nimesulide; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; C13H12N2O5S; Redaflam; Prestwick0_000194; IDI1_002137; Nimesil; NCGC00015725-03; HMS1568H09; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; NCGC00021842-06; NCGC00015725-06; KBioGR_000443; lizepat; Lopac-N-1016; IDI1_000693; R 805; CHEBI:44445; HMS2089B14; NIM; STL018679; DivK1c_000693; 4-Nitro-2-phenoxy-methanesulfonanilide; Nimesulida; SPBio_002068; KBioSS_000443; NINDS_000693; Prestwick1_000194; Spectrum3_001576; Spectrum5_000964; KBio2_003011; NCGC00021842-08; SPECTRUM1503231; 51803-78-2; Lakeside Brand of Nimesulide; KBio2_002057; Antifloxil; DB04743; BSPBio_000147; nchembio.147-comp1; nimesulide; KBioGR_000695; HMS1362G05; AC1L1IAM; Spectrum4_000178; KBio2_004625; KBio3_002612; CAS-51803-78-2	51803-78-2	4495	26697157	TTDS00041	Prostaglandin G/H synthase 2	COX-2;Cyclooxygenase 2;Cyclooxygenase -2;Cyclooxygenase-2;Heme-protein prostaglandin G/H synthase;PGH synthase 2;PGHS-2;PHS II;Prostaglandin H2 synthase 2;Prostaglandin-endoperoxide synthase 2	P35354	5743	ENSG00000073756	inhibitor
DAP000970	Lumiracoxib	LS-187647; STOCK6S-73581; CHEMBL404108; Benzeneacetic acid, 2-((2-chloro-6-fluorophenyl)amino)-5-methyl-; LS-187022; CHEBI:524824; COX 189; 2-((2-Chloro-6-fluorophenyl)amino)-5-methylbenzeneacetic acid; COX189; 2-((2-Chloro-6-fluorophenyl)amino)-5-methylphenyl)acetic acid; DB01283; NCGC00181795-01; 2-(2-((2-chloro-6-fluoro-phenyl)amino)-5-methyl-phenyl)acetic acid; Joicela; Lumiracoxib (USAN/INN); D03714; AC-1738; Lumiracoxib [USAN:INN]; Prexige (Novartis); UNII-V91T9204HU; LS-185762; C473384; COX-189; 2-[2-(2-chloro-6-fluoroanilino)-5-methylphenyl]acetic acid; CID151166; Prexige; Lumiracoxib; Novartis brand of lumiracoxib; MolPort-003-824-911; AC1L45SO; I06-0368; 220991-20-8	220991-20-8	151166	17397805	TTDS00041	Prostaglandin G/H synthase 2	COX-2;Cyclooxygenase 2;Cyclooxygenase -2;Cyclooxygenase-2;Heme-protein prostaglandin G/H synthase;PGH synthase 2;PGHS-2;PHS II;Prostaglandin H2 synthase 2;Prostaglandin-endoperoxide synthase 2	P35354	5743	ENSG00000073756	inhibitor
DAP000971	Meloxicam	D00969; (3E)-3-[hydroxy-[(5-methyl-1,3-thiazol-2-yl)amino]methylidene]-2-methyl-1,1-dioxo-1; CCRIS 9139; Mobic (TN); Masflex; LS-40538; Bio-0826; DB00814; Gen-meloxicam; Movicox; Movatec; Novo-meloxicam; 4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide; Abbott brand of meloxicam; Uticox; Meloxivet; AKOS000279442; SPECTRUM1504150; Squibb brand of meloxicam; C08169; AC1Q3XZW; UHAC-62XX; 133687-22-6; Meloxicam [USAN:BAN:INN]; FT-0082769; STK620505; HMS2089B18; Mobicox; 4-hydroxy-2-mehtyl-N-(5-mehtyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide; 2H-1,2-Benzothiazine-3-carboxamide, 4-hydroxy-2-methyl-N-(5-methylthiazolyl)-, 1,1-dioxide; 4-hydroxy-2-methyl-N-(5-methyl-1,3-thiazol-2-yl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide; Mobic, Metacam, Parocin, Meloxicam; I06-0490; S1734_Selleck; M1959; C065757; Boehringer Ingelheim brand of meloxicam; Ratio-meloxicam; Dom-meloxicam; Mobec; 4-Hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide; Movalis; Parocin; Meloxicam (JAN/USAN/INN); CHEMBL599; PMS-meloxicam; Europharma brand of meloxicam; TL8005001; Almirall brand of meloxicam; Co Meloxicam; 71125-38-7; Metacam; Meloxicamum; CID5281106; PHL-meloxicam; AC1NQY12; Meloxicamum [Latin]; UNII-VG2QF83CGL; HMS1922D19; Tenaron; Apo-meloxicam; reumoxicam; UH-AC 62XX; MolPort-002-885-839; AC-1325; Promeco brand of meloxicam; C14H13N3O4S2; Mobic; miloxicam; meloxicam; 4-Hydroxy-2-methyl-N-(5-methyl-2-thiazoyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide	71125-38-7	5281106	10369	TTDS00041	Prostaglandin G/H synthase 2	COX-2;Cyclooxygenase 2;Cyclooxygenase -2;Cyclooxygenase-2;Heme-protein prostaglandin G/H synthase;PGH synthase 2;PGHS-2;PHS II;Prostaglandin H2 synthase 2;Prostaglandin-endoperoxide synthase 2	P35354	5743	ENSG00000073756	inhibitor
DAP000780	Ibuprofen	Napacetin; HSDB 3099; Ibu-Tab; Novogent; SMR000058184; Anco; IB-100; Proartinal; Syntofene; Zafen; AC1L1GGE; Antalfene; Haltran; Salivia; Nagifen-D; Ibular; Novadol; Panafen; CPD000058184; Oralfene; Ibudolor; Kesan; KBio2_001329; Ergix; Bloom; TL8001184; Fibraflex; Dentigoa; HMS1920F15; Manypren; Rafen; Algofen; Seclodin; BRN 2049713; Perofen; IDI1_000887; Act-3; RD 13621; Sugafen; MLS000069733; I01-7039; Antagil; Nobafon; Rhinadvil; Ibumetin; Tonal; Dignoflex; Dolofin; Drin; IP-82; Librofem; Balkaprofen; Salprofen; SPBio_000178; Moment; D00126; Rebugen; Gynofug; Nobfelon; Noalgil; 58560-75-1; Togal N; Ibuprofene; Cunil; Dura-Ibu; Liptan; Ibu-Tab 200; Dolormin; Tabalon 400; Nerofen; Proflex; Trendar; Tofen; Ibubeta; Inflam; Anflagen; Dolocyl; Antarene; Sednafen; D007052; Noritis; NSC 256857; Brufen; 15687-27-1; PediaProfen; Femidol; I 4883; STK177358; Ibuhexal; Lidifen; Grefen; Ibu-Attritin; U-18,573; Ak+C2278tren; Andran; Amelior; C13H18O2; Cap-Profen; Neo-Helvagit; Ibusal; Ibugel; Seklodin; Dibufen; Ranofen; Dolmaral; Medipren; Deep Relief; NCI60_002065; Bukrefen; HMS2091N03; CCRIS 3223; I0415; Dansida; Ibol; Solpaflex; Isodol; Combiflam; Ibugen; Solufen; Seskafen; Brufen 400; Dolofen; Emflam; CHEBI:5855; Paduden; Femadon; Lamidon; Anafen; Ibumed; Mensoton; Opturem; I7905_SIAL; Dolgirid; Ostarin; UCB 79171; Gelufene; Lopane; Codral; Buracaps; Ibutid; HMS502M09; Fendol; Adran; Eputex; Fenbid; Nurofen; Nuprin; Ibulav; Rufen; Inabrin; Sadefen; Cobo; Narfen; Kratalgin; Upfen; Motrin (TN); DB01050; IP 82; Nobfen; Ibu-slo; Easifon; Zofen; Artofen; Ibulagic; Brofen; Doltibil; Novogent N; U-18573; SAM002264619; Dolofort; ARONIS23835; Duafen; Artril; Motrin; Ibren; Novo-Profen; Ibudol; IP82; Neo-Mindol; AC-11312; Dolofen-F; Ibuflamar; 139466-08-3; Gofen; Fenspan; Suprafen; Antiflam; Novoprofen; Ibucasen; BB_SC-1358; Advil; Daiprophen; Tatanal; Mynosedin; Optifen; Citalgan; Tempil; Burana; Suspren; Pedia-Profen; Buburone; Ibuprofenum; Doloren; Pantrop; Ibulgan; C01588; Ebufac; Motrin IB; Ibu; Amibufen; Dolven; Tab-Profen; Midol; KBio2_006465; Ibufug; Ozonol; Tabalon; Bufeno; Emflam-200; Ibumerck; Ibuprin; Siyafen; R.D. 13621; ibuprofen; Rupan; KBio1_000887; Faspic; Alaxan; Dolgit; Nuprilan; HMS2089P05; Ibubest; Brufanic; AC1Q1P85; Actiprofen; Nobgen; Ibuprofeno; U 18573; Midol 200; Dolomax; Lebrufen; Femafen; Duobrus; I4883_SIGMA; Apsifen; Femapirin; Inoven; Apsifen-F; AC1Q1P84; NINDS_000887; Exneural; Ibuprophen; Rofen; Junifen; ACHES-N-PAIN; Cesra; Relcofen; Betaprofen; Ibuprocin; Ibuprohm; Bruflam; Ifen; Malafene; Urem; Ibuleve; Quadrax; Dolo-Dolgit; Am-Fam 400; Donjust B; Ipren; KBio2_003897; Provon; EU-0100691; Dolibu; Esprenit; CID3672; Advil (TN); Butylenin; Amersol; Dorival; Dalsy; Paxofen; DOLO PUREN; Neobrufen; Brufort; LS-7454; Norton; Bufigen; MLS001146965; Jenaprofen; Ibupirac; Ostofen; Ibugesic; Melfen; VUFB 9649; Artril 300; Irfen; NSC256857; Carol; Rufin; Dologel; Unipron; Ibufen; Uprofen; Dysdolen; Profen; Epobron; Stelar; Roidenin; KBio3_001390; Bupron; BIDD:GT0050; Ibu-slow; Bluton; Adex 200; CHEMBL521	15687-27-1	3672	170047	TTDS00041	Prostaglandin G/H synthase 2	COX-2;Cyclooxygenase 2;Cyclooxygenase -2;Cyclooxygenase-2;Heme-protein prostaglandin G/H synthase;PGH synthase 2;PGHS-2;PHS II;Prostaglandin H2 synthase 2;Prostaglandin-endoperoxide synthase 2	P35354	5743	ENSG00000073756	inhibitor
DCL000830	GW-406381	GW406381; GW 406381; 478702-57-7; 8-(4-ethoxyphenyl)-7-(4-methylsulfonylphenyl)-1,2,9-triazabicyclo[4.3.0]nona-2,4,6,8-tetraene; Pyrazolo(1,5-b)pyridazine, 2-(4-ethoxyphenyl)-3-(4-(methylsulfonyl)phenyl)-; 221148-46-5; CID9832687; CHEBI:410199; CHEMBL364804	478702-57-7	N/A	N/A	TTDS00041	Prostaglandin G/H synthase 2	COX-2;Cyclooxygenase 2;Cyclooxygenase -2;Cyclooxygenase-2;Heme-protein prostaglandin G/H synthase;PGH synthase 2;PGHS-2;PHS II;Prostaglandin H2 synthase 2;Prostaglandin-endoperoxide synthase 2	P35354	5743	ENSG00000073756	inhibitor
DAP000975	Carprofen	33975_RIEDEL; Carprofenum [INN-Latin]; 2-(6-Chloro-9H-carbazol-2-yl)propanoic acid; (.+-.)-6-Chloro-.alpha.-methylcarbazole-2-acetic acid; 9H-Carbazole-2-acetic acid, 6-chloro-.alpha.-methyl-, (-)-; 9H-Carbazole-2-acetic acid, 6-chloro-.al; SMR000718633; Carprofeno [INN-Spanish]; Ridamyl; ( -)-6-Chlor-alpha-methyl-2-carbazolessigsaeure; UNII-FFL0D546HO; I06-0673; 6-Chloro-alpha-methyl-9H-carbazole-2-acetic acid; Carprofeno; MolPort-002-070-322; 2-(6-Chloro-9H-carbazol-2-yl)propanoic acid; 53716-49-7; C 5720; Rimadyl (TN); 9H-Carbazole-2-acetic acid, 6-chloro-.alpha.-methyl-, (-)-; Ro-20-5720; Ro-20-5720/000; CCRIS 3507; STK711093; NSC 297935; AC1L1DZZ; 9H-CARBAZOLE-2-ACETIC ACID, 6-CHLORO-alpha-METHYL-; EINECS 258-712-4; (+-)-6-Chloro-alpha-methylcarbazole-2-acetic acid; Ro 205720; HMS1921D04; (+/-)-2-(3-chloro-9H-carbazol-7-yl)propanoic acid; C-5720; Ro 20-5720; LS-51674; CHEBI:364453; LS-51673; NSC297935; Spectrum4_001038; D03410; CID2581; C15H12ClNO2; SPECTRUM1502006; Spectrum3_000939; Rimadyl; MLS001306441; BB_SC-2794; Carprofen (USAN/INN); Carprofen [USAN:INN:BAN]; carprofen; Ro 20-5720/000; Carprofenum; CHEMBL1316; Spectrum2_001236; pha.-methyl-, (.+-.)-; 5-22-03-00391 (Beilstein Handbook Reference); (+-)-isomer of carprofen; Spectrum5_001802; MLS001201778; (.+-.)-6-Chloro-.alpha.-methylcarbazole-2-acetic acid; KBioGR_001595; Imadyl; AC-1266; NCGC00094937-02; 6-Chloro-alpha-methylcarbazole-2-acetic acid; 9H-CARBAZOLE-2-ACETIC ACID, 6-CHLORO-alpha-METHYL-, (+-)-; 6-Chlor-alpha-methyl-carbazol-2-essigsaeure; BRN 0487098; 6-Chlor-alpha-methyl-carbazol-2-essigsaeure [German]; 52263-47-5; 33975_FLUKA; Carprofeno [Spanish]; Carprofene [INN-French]; Carprofene; NCGC00094937-01; 2-(6-Chloro-9H-carbazol-2-yl)-propionic acid; 9H-Carbazole-2-acetic acid, 6-chloro-.alpha.-methyl-, (.+-.)-; SPBio_001112; HMS2092B16; KBio3_001978; DB00821	53716-49-7	2581	181659	TTDS00041	Prostaglandin G/H synthase 2	COX-2;Cyclooxygenase 2;Cyclooxygenase -2;Cyclooxygenase-2;Heme-protein prostaglandin G/H synthase;PGH synthase 2;PGHS-2;PHS II;Prostaglandin H2 synthase 2;Prostaglandin-endoperoxide synthase 2	P35354	5743	ENSG00000073756	inhibitor
DAP000778	Etodolac	1,8-Diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indole-1-acetic acid; E 0516; 1,3,4,9-Tetrahydro-1,8-diethylpyrano(3,4-b)indole-1-acetic acid; Edolan; KBioGR_000680; MLS000028474; Spectrum4_000410; SPECTRUM1501005; CID3308; 1,8-Diethyl-1,3,4,9-tetrahydropyrano(3,4-b)indole-1-acetic acid; BPBio1_000333; Etodolac, (+-)-Isomer; D00315; Etodolac, Monosodium Salt, (S)-Isomer; Lodine SR; Prestwick1_000231; 41340-25-4; NSC 282126; Etodolac, Monosodium Salt, (+-) Isomer; Osteluc; AC1L1FN2; Etodolic acid; Prestwick_209; SPBio_002222; HMS2092O20; NCGC00015399-04; LS-7393; E0516_SIGMA; SPBio_001374; D017308; CCRIS 3923; DivK1c_000147; HMS500H09; AC-4231; etodolac; Hypen; Spectrum_001244; Prestwick2_000231; Etodolac (JP15/USP/INN); AB00052194; Prestwick0_000231; MLS001077315; BSPBio_000301; NINDS_000147; Etodolac [USAN:INN:BAN]; KBio2_001724; SBB067257; AY24236; KBioSS_001724; 2-(1,8-diethyl-4,9-dihydro-3H-pyrano[3,4-b]indol-1-yl)acetic acid; Ramodar; NCGC00089769-05; (+-)-1,8-Diethyl-1,3,4,9-tetrahydropyrano(3,4-b)indole-1-acetic acid; IDI1_000147; Acid, Etodolic; CHEBI:4909; Lodine; CPD000058443; NCGC00089769-04; Pyrano[3,4-b]indole-1-acetic acid, 1,8-diethyl-1,3,4,9-tetrahydro-; (1,8-Diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl)acetic acid; (1,8-Diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl)acetic acid; 1,8-Diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indole-1-acetic acid; Pyrano[3,4-b]indole-1-acetic acid, 1,8-diethyl-1,3,4,9-tetrahydro-; AY 24,236; RAK-591; AY24,236; Etodolacetodolic acid; Lodine XL; AY-24236; AY 24236; Etodolaco; Prestwick3_000231; Pyrano(3,4-b)indole-1-acetic acid, 1,8-diethyl-1,3,4,9-tetrahydro-(+-)-; Etodolacum [INN-Latin]; CHEMBL622; Etodolac [USAN:BAN:INN]; BRD-A74667430-001-05-3; Ultradol; Lodine (TN); Spectrum2_001387; KBio2_004292; Lopac0_000479; Spectrum3_001429; KBio1_000147; Etodolaco [INN-Spanish]; NCGC00089769-07; NCGC00089769-03; MolPort-001-759-084; [1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl]acetic acid; HMS1921B09; NCGC00015399-11; KBio2_006860; KBio3_002358; SMR000058443; DB00749; 110781-63-0 (mono-hydrochloride salt); SAM002589968; AY-24,236; Etodolacum; NCGC00089769-06; NSC282126; Etodolac, Monosodium Salt; NCGC00089769-02; 1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-ylacetic acid; Spectrum5_001347; HMS1568P03; CHEBI:126431; EU-0100479; UNII-2M36281008; Pyrano(3,4-b)indole-1-acetic acid, 1,3,4,9-tetrahydro-1,8-diethyl-; Pyrano(3,4-b)indole-1-acetic acid, 1,8-diethyl-1,3,4,9-tetrahydro-; BSPBio_003138	41340-25-4	3308	179980	TTDS00041	Prostaglandin G/H synthase 2	COX-2;Cyclooxygenase 2;Cyclooxygenase -2;Cyclooxygenase-2;Heme-protein prostaglandin G/H synthase;PGH synthase 2;PGHS-2;PHS II;Prostaglandin H2 synthase 2;Prostaglandin-endoperoxide synthase 2	P35354	5743	ENSG00000073756	inhibitor
DAP000968	Naproxen	UNII-57Y76R9ATQ; UPCMLD-DP001; (S)-()-6-Methoxy-alpha-methyl-2-naphthaleneacetic acid; KBio3_001567; Soproxen; Naproxi 250; Prestwick2_000791; 65126_FLUKA; SPECTRUM1500425; KBioGR_000597; Novonaprox; ARONIS24306; (S)-(+)-Naproxen; Naxopren; (S)-2-(6-Methoxy-2-naphthyl)propionic acid; NCGC00016759-01; Napflam; Prestwick0_000791; Naproxene [INN-French]; d-2-(6'-Methoxy-2'-naphthyl)-propionsaeure [German]; 2-Naphthaleneacetic acid, 6-methoxy-.alpha.-methyl-, (.alpha.S)-; (S)-6-Methoxy-.alpha.-methyl-2-naphthaleneacetic acid; NCGC00161591-01; Lopac0_000792; SPBio_002861; Spectrum_000977; Velsay; HMS500M04; UPCMLD-DP001:001; Fuxen; BIDD:GT0062; Prestwick1_000791; Patxen; Danaprox; SPBio_000966; d-2-(6-Methoxy-2-naphthyl)propionic acid; Sinton; TL8003659; (S)-(+)-2-(6-Methoxy-2-naphthyl)propionic acid; FT-0082415; Congex; Duk; Naprelan; Narocin; BRD-K59197931-236-09-6; Nalyxan; NINDS_000242; Equiproxen; Naposin; Aleve; Apronax; Propionic acid, 2-(6-methoxy-2-naphthyl)-, (+)-; (S)-()-2-(6-Methoxy-2-naphthyl)propionic acid; Rahsen; Napratec; HMS2091H12; Clinosyn; Tohexen; CMWTZPSULFXXJA-VIFPVBQESA-; Leniartil; CAS-22204-53-1; (2S)-2-(6-methoxynaphthalen-2-yl)propanoic acid; Napmel; 22204-53-1; (+)-Naproxen; Proxen LE; Nafasol; Bonyl; Apo-Naproxen; Laraflex; Pronaxen; Noflam; Napren E; Genoxen; Arthrisil; Sinartrin; Spectrum5_001327; Naproxene; Naprius; (+)-6-Methoxy-alpha-methyl-2-naphthaleneacetic acid; Lefaine; Floginax; Naprosyn LLE Forte; Axer; DivK1c_000242; Flexen; BSPBio_002067; Apo-Napro-NA; 284785_ALDRICH; CHEBI:7476; 2-Naphthaleneacetic acid, 6-methoxy-alpha-methyl-, (+)-; Equiproxen (Veterinary); Spectrum4_000069; (+)-2-(Methoxy-2-naphthyl)-propionsaeure; Sutony; MolPort-000-145-960; AC1Q4ET9; SR-01000075977-3; HMS1920P13; Calosen; Narma; d-2-(6'-Methoxy-2'-naphthyl)-propionsaeure; Nycopren; Napxen; 2-Naphthaleneacetic acid, 6-methoxy-alpha-methyl-, (+)- (8CI); Saritilron; Atiflan; KBio2_006593; InChI=1/C14H14O3/c1-9(14(15)16)10-3-4-12-8-13(17-2)6-5-11(12)7-10/h3-9H,1-2H3,(H,15,16)/t9-/m0/s1; (+)-2-(Methoxy-2-naphthyl)-propionic acid; Naxyn 500; Prexan; Reuxen; Naproxi 500; Naxyn; Naxen F; DB08298; (+)-2-(6-Methoxy-2-naphthyl)propionic acid; Vinsen; Headlon; 46482_RIEDEL; KBio1_000242; Artroxen; Naprosin; KBioSS_001457; (+)-2-(Methoxy-2-naphthyl)-propionsaeure [German]; AC1Q4F4H; Flanax Forte; AC-1363; (S)-(+)-6-Methoxy-alpha-methyl-2-naphthaleneacetic acid; BRD-K59197931-001-02-9; N8280_SIAL; Spectrum3_000514; Spectrum2_001043; Traumox; Naprontag; Napren; d-Naproxen; NAPROXEN; (S)-2-(6-Methoxy-2-naphthyl)propanoic acid; Acusprain; CHEMBL154; (+)NAPROXEN; Priaxen; Sutolin; EINECS 244-838-7; HMS2089N21; LS-124738; Methoxypropiocin; Naprosyn LLE; Flexipen; Roxen; Anaprox; NPS; KBio2_004025; M1021; CID156391; CCRIS 5265; Bipronyl; Prafena; Prestwick_349; Naproxenum [INN-Latin]; (S)-6-Methoxy-alpha-methyl-2-naphthaleneacetic acid; Rheumaflex; Naproxen [USAN:BAN:INN:JAN]; AC1Q4F4I; (+)-(S)-6-Methoxy-alpha-methyl-2-naphthaleneacetic acid; Veradol; RS-3540; Naproxeno; (S)-Naproxen; Naxyn 250; Naprosyne; Xenar; Artagen; U-Ritis; RS 3540; IDI1_000242; Naxen; (+)-(S)-Naproxen; HSDB 3369; Dysmenalgit N; Anexopen; Naproxeno [INN-Spanish]; Artrixen; AC1L4G3X; Anax; Daprox; 2-Naphthaleneacetic acid, 6-methoxy-alpha-methyl-, (S)-; KBio2_001457; NCGC00021127-01; STOCK1N-50633; 46482_FLUKA; Proxen LLE; Ec-Naprosyn; CG 3117; Naproxenum	22204-53-1	1302	4682	TTDS00041	Prostaglandin G/H synthase 2	COX-2;Cyclooxygenase 2;Cyclooxygenase -2;Cyclooxygenase-2;Heme-protein prostaglandin G/H synthase;PGH synthase 2;PGHS-2;PHS II;Prostaglandin H2 synthase 2;Prostaglandin-endoperoxide synthase 2	P35354	5743	ENSG00000073756	inhibitor
DAP000973	Tiaprofenic acid	EINECS 251-329-3; 5-Benzoyl-alpha-methyl-2-thiopheneacetic acid; BSPBio_000391; Prestwick2_000496; AC1L1KEZ; Dom-tiaprofenic; Acido tiaprofenico [INN-Spanish]; Prestwick0_000496; alpha-methyl-5-benzoyl-2-thienylacetic acid; LS-152878; Prestwick_814; 5-benzoyl-alpha-methylthiophene-2-acetic acid; 2-(5-benzoylthiophen-2-yl)propanoic acid; Acide tiaprofenique; Surgam SR; 2-Thiopheneacetic acid, 5-benzoyl-alpha-methyl-; CID5468; 5-18-08-00405 (Beilstein Handbook Reference); tiaprofenic acid; HMS1569D13; MLS002153845; D01325; 33005-95-7; Acide tiaprofenique [INN-French]; BRN 1380662; DB01600; Tiaprofenic-300 - Tab; Prestwick3_000496; Prestwick1_000496; Acido tiaprofenico; 2-[5-(phenylcarbonyl)-2-thienyl]propanoic acid; FC 3001; CHEMBL365795; SMR001233207; 2-(5-Benzyl-2-thienyl)propionsaeure; Tiaprofensaeure; BRD-A72988804-001-03-8; Apo-Tiaprofenic Tablets; CHEBI:32221; Tiaprofenic acid (JAN/INN); Surgam (TN); Tiaprofenic-200 - Tab; Tiaprofenic acid [INN:BAN:DCF:JAN]; Acidum tiaprofenicum; Surgam; Acidum tiaprofenicum [INN-Latin]; RU 15060; 2-Thiopheneacetic acid, 5-benzoyl-.alpha.-methyl-; BPBio1_000431; SPBio_002312	33005-95-7	5468	10321760	TTDS00041	Prostaglandin G/H synthase 2	COX-2;Cyclooxygenase 2;Cyclooxygenase -2;Cyclooxygenase-2;Heme-protein prostaglandin G/H synthase;PGH synthase 2;PGHS-2;PHS II;Prostaglandin H2 synthase 2;Prostaglandin-endoperoxide synthase 2	P35354	5743	ENSG00000073756	inhibitor
DAP000974	Phenylbutazone	KBio2_004127; Alqoverin; Artrizone; Fenibutazona; SPECTRUM1500482; Scanbutazone; Ipsoflame; MolPort-001-783-564; Novophenyl; AZOLID (TN); Butaphen; Fenylbutazon; Buvetzone; Bute, Butazolidin, Butatron, Phenylbutazone; Butylpyrin; Buzon; esteve; Fenibutal; DivK1c_000331; Robizone; component of Azolid-A; Zolidinum; HMS2091P08; Butartril; B.T.Z; Diozol; CHEBI:48574; G 13871; Rectofasa; NCGC00015846-01; Bunetzone; Phenyl-Mobuzon; 3,5-Dioxo-1,2-diphenyl-4-n-butyl-pyrazolidin; NCGC00023855-05; fe nilbutine; Butartrina; Phenyzone; Lopac-P-8386; art rizin; Tetnor; Fenartil; 4-Butyl-1,2-diphenyl-3,5-pyrazolidinedione; Butadiona; NCI-C55414; HMS1920H06; Chembutazone; Butone; Intrabutazone; 1,2-Diphenyl-4-butyl-3,5-dioxopyrazolidine; NCGC00015846-06; Fenibutasan; Lopac0_000993; 1,2-Diphenyl-2,3-dioxo-4-N-butylpyrazoline; KBioSS_001559; Antadol; Reumuzol; D010653; EINECS 200-029-0; Butagesic; NCGC00023855-04; R-3-ZON; D00510; 1,2-Diphenyl-3,5-dioxo-4-butylpyrazolidine; Malgesic; Azolid; CCRIS 2374; Rubatone; CHEMBL101; Reumune; C07440; P8386_SIGMA; 3,5-dioxo-4-butyl-1-diphenyl-pyrazolidine; Usaf ge-15; Fenibutol; HSDB 3159; Alka Butazolidin; Lingel; Phen-Buta-Vet; 50-33-9; Intrazone; NSC25134; Schemergen; Butaluy; Schemergin; WLN: T5VNNV EHJ BR& CR& E4; 4297-92-1; Azobutyl; Fenilbutina; Reumazol; Reumasyl; 'Esteve'; Febuzina; Robizon-V; Oprea1_416494; Fenilbutazone; DB08343; Butatron; 4-Butyl-1,2 -diphenyl-3,5-dioxo pyrazolidine; Butacote; KBioGR_000954; MLS001148412; Azdid; Alindor; Buta phen; Benzone; Spectrum4_000477; B.t.z.; NCGC00015846-12; Pyrabutol; Mephabutazon; 4-n-Butyl-1,2-diphenyl-3,5-pyrazolidinedione; VAC-10; MLS000069424; Tencodyne; UNII-GN5P7K3T8S; SMR000059073; Reumazin; Uzone; Bio-0693; KBio3_001589; NCGC00023855-07; MLS002152929; Butapyrazole; Bute; butyl pyrin; Apo-Phenylbutazone; Butalgina; P1686; Todalgil; Fenilbutazona [INN-Spanish]; butadione; Phenbutazol; P 8386; Artizin; Phenylbutazon; Ticinil; Butidiona; Flexazone; Phenopyrine; Zolaphen; Reudo; Bizolin; Spectrum5_001335; Mepha-Butazon; S1654_Selleck; 3,5-Dioxo-1,2-diphenyl-4-N-butylpyrazolidine; Phebuzin; Spectrum_001079; Butazolidine; Ia-But; Fenilbutazone [DCIT]; Tevcodyne; IDI1_000331; Fenotone; AC-683; Phenylbutazonum [INN-Latin]; Busone; STK388348; Phebuzine; Elmedal; SR-01000000004-4; Ecobutazone; KBio2_006695; Intalbut; NINDS_000331; NCGC00023855-06; SPBio_001283; 3,5-Pyrazolidinedione, 4-butyl-1,2-diphenyl-; AC1L1IXW; Robizone-V; Bizolin 200; Digibutina; Butapirazol; 1,2-diphenyl-3,5-dioxo-4-n-butylpyrazoline; Butazina; Fenilidina; 4-Butyl-1,2-diphenylpyrazolidine-3,5-dione; Butazolidin; Arthrizon; Butadion; Equi bute; HMS2090H17; 4-Butyl-1,2-diphenyl-3,5-dioxo pyrazolidine; Shigrodin; BSPBio_002369; Reudox; Phenylbutazone [USAN:INN:BAN:JAN]; UNM000001255503; LS-71; Pyrazolidin; Therazone; Kadol; nchembio.128-comp31; Anerval; Praecirheumin; Butacompren; Tazone; Butarecbon; Diphenylbutazone; Butoz; Alkabutazona; 4-Butyl-1,2-diphenyl-3,5-dioxopyrazolidine; Neo-zoline; NCGC00023855-03; Merizone; Phenbutazone; Phenylbutazon [German]; AC1Q2VLE; KBio1_000331; NSC 25134; CID4781; 3,5-Dioxe-4 buty-1, diphenyl-pyrazolidine; Fenilbutazona; Fenilbutazon; Nadozone; Phenyl butazone; Phenyzene; HMS501A13; Equipalazone; Phenylbutaz; AKOS001592731; NCI-C56531; NCGC00015846-02; Reupolar; Anpuzone; 4-BUTYL-1,2-DIPHENYL-PYRAZOLIDINE-3,5-DIONE; Artropan; NCGC00181112-01; Wescozone; Butiwas-Simple; BRN 0290080; phenylbutazone; DB00812; DA-192; A 7514; Diphebuzol; G 13,871; Spectrum2_001282; NCGC00023855-08; Artrizin; Butadionum; Equiphen; I01-0883; Fenilbutine; Butazona; Phenylbutazonum; Butalidon; EU-0100993; Phenylbutazone (JP15/USP/INN); Betazed; Cotylbutazone; Butapirazole; Spectrum3_000675; Nadazone; P1Z; KBio2_001559; Anuspiramin; Pirarreumol "B"; Eributazone; Exrheudon N; Diossidone; Mephabutazone; 1,2-Diphenyl-4-butyl-3,5-pyrazolidinedione; Pirarreumol B	50-33-9	4781	9644	TTDS00041	Prostaglandin G/H synthase 2	COX-2;Cyclooxygenase 2;Cyclooxygenase -2;Cyclooxygenase-2;Heme-protein prostaglandin G/H synthase;PGH synthase 2;PGHS-2;PHS II;Prostaglandin H2 synthase 2;Prostaglandin-endoperoxide synthase 2	P35354	5743	ENSG00000073756	inhibitor
DAP000623	Ketoprofen	NCGC00094043-02; Orugesic; L'Acide (benzoyl-3-phenyl)-2-propionique; Oprea1_117113; Ketoprofenum [INN-Latin]; Prestwick1_000219; Oscorel; InChI=1/C16H14O3/c1-11(16(18)19)13-8-5-9-14(10-13)15(17)12-6-3-2-4-7-12/h2-11H,1H3,(H,18,19); SMR000040181; D00132; MolPort-001-684-346; CPD000040181; (+-)-m-Benzoylhydratropic acid; RU 4733; NINDS_000598; 22071-15-4; AC1Q1LGA; Orudis KT; Spectrum5_001254; 19583 RP; NCGC00094043-03; Prestwick_617; Lertus; Oruvail; IDI1_000598; Benzoylhydratropic Acid; RP19583; K2012_SIAL; Alrheumum; NCGC00015578-02; AC-1486; KBio2_001789; Acide (benzoyl-3-phenyl)-2-propionique; CID3825; SPECTRUM1501215; K1751_SIGMA; NCGC00094043-01; 22161-86-0; Ketoprofen (JP15/USP/INN); 2-(m-Benzoylphenyl)propionic acid; Ketoprofeno; DivK1c_000598; m-Benzoylhydratropic acid; HMS2089B16; 34016_RIEDEL; MLS001306444; Ketoprofenum; SPBio_002158; Dexal; 19,583 RP; 2-(3-Benzoylphenyl)propanoic acid; RP-19583; K1751_SIAL; Hydratropic acid, m-benzoyl-, (+-)-; 3-Benzoylhydratropic acid; S1645_Selleck; BPBio1_000261; Lopac0_000686; KBio2_004357; NCGC00094043-04; 2-(3-Benzoylphenyl)propionic acid; Alrheumun; Profenid; BIM-0050664.0001; I01-3439; Fastum; Capisten; Toprek; Toprec; CHEMBL571; 172964-50-0; RP, 19,583; KBioGR_000435; KBio3_002537; (+-)-3-Benzoyl-alpha-methylbenzeneacetic acid; HMS1568L19; AC1L1GST; Ketoprofen [USAN:INN:BAN:JAN]; LS-7470; SPBio_000952; racemic-Ketoprofen; Ketoprofene; RP 19583; Orudis; HMS2092L19; MLS001201752; Prestwick0_000219; Orudis, Oruvail, Ketoflam, Orudis KT, Ketoprofen; Kefenid; 2-[3-Benzoylphenyl]propionic acid; KBio1_000598; Ketoprophene; Iso-K; HMS501N20; Prestwick3_000219; Epatec; EINECS 244-759-8; KBio2_006925; Ketoprofen (+-); 3-BENZOYL-ALPHA-METHYLBENZENEACETIC ACID; Benzeneacetic acid, 3-benzoyl-.alpha.-methyl-; 154907-35-4; CHEBI:6128; Meprofen; Ketoprofene [INN-French]; DB01009; 2-[3-(phenylcarbonyl)phenyl]propanoic acid; CCRIS 4508; EU-0100686; 2-[3-(benzoyl)phenyl]propanoic acid; BRD-A97739905-001-05-9; UNII-90Y4QC304K; AB00052249; Benzeneacetic acid, 3-benzoyl-alpha-methyl-; Aneol; Benzeneacetic acid, 3-benzoyl-alpha-methyl-, (+-)-; Spectrum4_000028; Propionic acid, 2-(3-benzoylphenyl)-; D007660; Ketopron; 34016_FLUKA; DKYWVDODHFEZIM-UHFFFAOYSA-; Alrheumat; MLS000079024; BSPBio_003037; BIDD:GT0443; Spectrum_001309; K0038; Orudis (TN); Spectrum3_001479; K 1751; LS-28621; ketoprofen; NCGC00015578-07; FT-0082352; Bio-0742; MLS000028446; UNM-0000306100; Spectrum2_000956; C01716; Actron; Ketoprofeno [INN-Spanish]; HMS1921B12; Menamin; SAM002264620; KBioSS_001789; Acide (benzoyl-3-phenyl)-2-propionique [French]; BSPBio_000237; Prestwick2_000219	22071-15-4	3825	4853	TTDS00041	Prostaglandin G/H synthase 2	COX-2;Cyclooxygenase 2;Cyclooxygenase -2;Cyclooxygenase-2;Heme-protein prostaglandin G/H synthase;PGH synthase 2;PGHS-2;PHS II;Prostaglandin H2 synthase 2;Prostaglandin-endoperoxide synthase 2	P35354	5743	ENSG00000073756	inhibitor
DAP000777	Tolmetin	AC1L1KI1; CID5509; 1-Methyl-5-(4-methylbenzoyl)-pyrrole-2-acetic acid; SPBio_002792; KBio2_006551; 5-22-06-00392 (Beilstein Handbook Reference); 1-Methyl-5-(4-methylbenzoyl)-1H-pyrrole-2-acetic acid; KBioSS_001415; Tolmetina [DCIT]; NINDS_000213; Spectrum3_000603; KBio1_000213; Spectrum_000935; Tolectin; Spectrum2_001205; Oprea1_869397; 1H-Pyrrole-2-acetic acid, 1-methyl-5-(4-methylbenzoyl)-; KBio3_001606; SPBio_000990; Spectrum5_001194; Prestwick0_000856; IDI1_000213; Tolmetino [INN-Spanish]; Prestwick2_000856; Pyrrole-2-acetic acid, 1-methyl-5-p-toluoyl-; KBioGR_000797; HMS2090D06; BIDD:GT0468; 5-(p-Toluoyl)-1-methylpyrrole-2-acetic acid; HSDB 3403; 35711-34-3 (anhydrous sodium salt); CHEMBL1020; MCN 2559; Tolmetino; DivK1c_000213; BRN 0485305; BRD-K82562631-236-02-0; C07149; BPBio1_000959; Tolmetin [USAN:BAN:INN]; Tolmetina; Tolmetin (USAN/INN); 64490-92-2 (sodium dihydrate salt); Tolmetine; DB00500; 26171-23-3; BRD-K82562631-325-03-9; Acido 1-metil-5-(p-tolnil)-pirrol-2-acetico; TL8006558; Tolmetinum [INN-Latin]; tolmetin; 1-Methyl-5-p-toluoylpyrrole-2-acetic acid; D02355; KBio2_003983; 2-[1-methyl-5-(4-methylbenzoyl)pyrrol-2-yl]acetic acid; MolPort-003-987-733; McN-2559; CHEBI:218617; LS-136618; BSPBio_002106; Tolmetine [INN-French]; Prestwick3_000856; EINECS 247-497-2; Prestwick1_000856; Spectrum4_000359; Tolmetinum; BSPBio_000871; UNII-D8K2JPN18B; Acido 1-metil-5-(p-tolnil)-pirrol-2-acetico [Spanish]; Tolmetin Sodium, Dihydrate; KBio2_001415	26171-23-3	5509	7849414	TTDS00041	Prostaglandin G/H synthase 2	COX-2;Cyclooxygenase 2;Cyclooxygenase -2;Cyclooxygenase-2;Heme-protein prostaglandin G/H synthase;PGH synthase 2;PGHS-2;PHS II;Prostaglandin H2 synthase 2;Prostaglandin-endoperoxide synthase 2	P35354	5743	ENSG00000073756	inhibitor
DAP001338	Rofecoxib	NCGC00095118-01; Merck Frosst brand of rofecoxib; KBioGR_002345; MK 996; Merck brand of rofecoxib; MK 966; MolPort-006-817-786; C07590; MK 0966; Spectrum4_000631; BSPBio_002705; KBio1_001709; Vioxx (trademark); Spectrum_000119; SPBio_000492; 4-(4-(Methylsulfonyl)phenyl)-3-phenyl-2(5H)-furanone; HMS2093E04; AKOS000280931; Merck Sharp & Dhome brand of rofecoxib; 186912-82-3; Cahill May Roberts brand of rofecoxib; cMAP_000024; KBioGR_001242; SpecPlus_000669; 4-(4-methylsulfonylphenyl)-3-phenyl-5H-furan-2-one; STK635144; SMR000466331; DivK1c_006765; Spectrum2_000446; KBio2_005695; CPD000466331; Bio-0094; HMS2089H20; MLS001165770; AC-13144; 4-[4-(methylsulfonyl)phenyl]-3-phenyl-2(5H)-furanone; KBio2_000559; MolPort-000-883-878; CID5090; 4-(p-(Methylsulfonyl)phenyl)-3-phenyl-2(5H)-furanone; CHEMBL122; KBioSS_000559; CCRIS 8967; Vioxx; KBio2_007481; CHEBI:8887; 3-Phenyl-4-(4-(methylsulfonyl)phenyl))-2(5H)-furanone; KS-1107; KBio2_002345; 3-phenyl-4-[4-(methylsulfonyl)phenyl]-2(5H)-furanone; DB00533; LS-70511; KBio2_004913; NSC720256; KBio2_003127; 2(5H)-Furanone, 4-[4-(methyl-sulfonyl)phenyl]-3-phenyl-; HMS1922H11; KBio3_002205; Jsp003237; HMS2051G16; C17H14O4S; 3-(4-methylsulfonylphenyl)-4-phenyl-2H-furan-5-one; Vioxx (TN); 2(5H)-Furanone, 4-(4-(methylsulfonyl)phenyl)-3-phenyl-; NCGC00095118-04; Rofecoxib (JAN/USAN/INN); FT-0081390; ZINC00007455; refecoxib; KBio3_002825; MK0966; NCI60_041175; Vioxx Dolor; MLS001195623; D00568; Ceoxx; KBioSS_002348; MSD brand of rofecoxib; 4-[4-(methylsulfonyl)phenyl]-3-phenylfuran-2(5H)-one; UNII-0QTW8Z7MCR; L000912; MLS000759440; 162011-90-7; Spectrum5_001598; HSDB 7262; SPECTRUM1504235; MK-0966; Spectrum3_001153; SAM001246617; NCGC00095118-02; MK-966; MLS001424113; NCGC00095118-03; I01-1042; BIDD:GT0399; rofecoxib; BRD-K21733600-001-02-6; AC1L1JL6; C116926; MK 0996	162011-90-7	5090	207247	TTDS00041	Prostaglandin G/H synthase 2	COX-2;Cyclooxygenase 2;Cyclooxygenase -2;Cyclooxygenase-2;Heme-protein prostaglandin G/H synthase;PGH synthase 2;PGHS-2;PHS II;Prostaglandin H2 synthase 2;Prostaglandin-endoperoxide synthase 2	P35354	5743	ENSG00000073756	inhibitor
DAP000738	Etoricoxib	Etoricoxib; MK-663; Algix; HMS2090A05; CID123619; L001141; DB01628; 202409-33-4; 5-chloro-6'-methyl-3-[4-(methylsulfonyl)phenyl]-2,3'-bipyridine; L791456; L-791456; Merck Sharp & Dohme brand of etoricoxib; MK-0663; Etoricoxib [USAN:INN:BAN]; 2,3'-Bipyridine, 5-chloro-6'-methyl-3-(4-(methylsulfonyl)phenyl)-; MolPort-003-847-339; UNII-WRX4NFY03R; D03710; CHEMBL416146; 5CH; ZINC00579472; C11718; 5-chloro-2-(6-methylpyridin-3-yl)-3-(4-methylsulfonylphenyl)pyridine; Etoricoxibe; Tauxib; C422649; Nucoxia; MK 663; AC1L3WZM; NCGC00164578-01; CHEBI:6339; CHEBI:106706; MK 0663; DB07166; FT-0082494; 5-Chloro-6'-methyl-3-(p-(methylsulfonyl)phenyl)-2,3'-bipyridine; LS-181802; Arcoxia; Etoricoxib (USAN/INN)	202409-33-4	123619	13883	TTDS00041	Prostaglandin G/H synthase 2	COX-2;Cyclooxygenase 2;Cyclooxygenase -2;Cyclooxygenase-2;Heme-protein prostaglandin G/H synthase;PGH synthase 2;PGHS-2;PHS II;Prostaglandin H2 synthase 2;Prostaglandin-endoperoxide synthase 2	P35354	5743	ENSG00000073756	inhibitor
DCL000905	ONO-2506	UNII-F2628ZD0FO; Cereact; ONO-2506; Acidum arundicum [INN-Latin]; MK-0724; Acido arundico [INN-Spanish]; CID208925; Proglia; AC1L4LMD; 185517-21-9; AC1Q5RZ6; D06296; Acide arundique; AR-1A2718; ONO-2506PO; Acide arundique [INN-French]; 186692-44-4; Arocyte; CID9815462; Arundic acid [INN]; KST-1A2706; Arundic acid (JAN/INN); Ono2506; Arundic acid; Acidum arundicum; 21447-39-2; AR-1E5222; (2R)-2-Propyloctanoic acid; Acido arzndico; AC1LB7DT; AC1Q5QIF; 2-Propyloctanoic acid; CID552716	185517-21-9	208925	12015175	TTDS00041	Prostaglandin G/H synthase 2	COX-2;Cyclooxygenase 2;Cyclooxygenase -2;Cyclooxygenase-2;Heme-protein prostaglandin G/H synthase;PGH synthase 2;PGHS-2;PHS II;Prostaglandin H2 synthase 2;Prostaglandin-endoperoxide synthase 2	P35354	5743	ENSG00000073756	inhibitor
DAP000152	Diflunisal	Apotex Brand of Diflunisal; 3-BIPHENYLCARBOXYLIC ACID, 2',4'-DIFLUORO-4-HYDROXY-; Spectrum3_000392; Reuflos; Nu-Diflunisal; NCGC00016765-02; Diflunisalum; Novopharm Brand of Diflunisal; Dolobid; Frosst SA Brand of Diflunisal; Adomal; SMR000058723; KBio2_001442; CHEBI:39669; CID3059; Merck Sharp & Dohme Brand of Diflunisal; SPECTRUM1500245; [1,1'-Biphenyl]-3-carboxylic acid, 2',4'-difluoro-4-hydroxy-; DivK1c_000938; 2',4'-Difluoro-4-hydroxy-(1,1'-biphenyl)-3-carboxylic acid; Diflunisal Novopharm Brand; SPBio_002058; 5-(2,4-DIFLUOROPHENYL)-2-HYDROXY-BENZOIC ACID; Prestwick3_000039; Prestwick_168; 2',4'-difluoro-4-hydroxybiphenyl-3-carboxylic acid; NCGC00022783-04; 2-(Hydroxy)-5-(2,4-difluorophenyl)benzoic acid; MK-647; KBioGR_001085; Novo-Diflunisal; Diflunisalum [INN-Latin]; Nu Pharm Brand of Diflunisal; Nu-Pharm Brand of Diflunisal; Diflunisal [USAN:INN:BAN:JAN]; 5-(2,4-difluorophenyl)-2-hydroxybenzoic acid; 5-(2,4-Difluorophenyl)salicylic acid; D3281_SIGMA; CHEMBL898; Dolocid; C01691; AC1L1F2Z; I01-3451; Spectrum4_000513; BSPBio_000137; HMS502O20; UNII-7C546U4DEN; NCGC00022783-03; Spectrum5_000901; Diflunisal (JAN/USP/INN); BIDD:GT0063; KBio2_004010; IDI1_000938; DB00861; EINECS 245-034-9; Flovacil; MK647; CPD000058723; 22494-42-4; Prestwick2_000039; MLS000028678; Spectrum_000962; Dolobil; BSPBio_002203; SBB058143; KBioSS_001442; D004061; HMS1920G10; C13H8F2O3; Dolobid (TN); AB00051969; Merck Brand of Diflunisal; DB06895; Dolisal; SPBio_001163; Algobid; 2',4'-Difluoro-4-hydroxy-3-biphenylcarboxylic acid; HMS1568G19; MK 647; Citidol; HMS2090C16; Prestwick0_000039; BPBio1_000151; KBio2_006578; Dolobis; D00130; Difludol; KBio1_000938; Fluniget; MolPort-001-727-460; Apo-Diflunisal; Unisal; KBio3_001423; MLS001146895; NINDS_000938; 1FL; NCGC00016765-01; diflunisal; 5-[2,4-Difluorophenyl]salicylic acid; Cahill May Roberts Brand of Diflunisal; Fluodonil; HMS2091M20; Spectrum2_001012; Flustar; SAM002554896; Prestwick1_000039; (1,1'-Biphenyl)-3-carboxylic acid, 2',4'-difluoro-4-hydroxy-; LS-44258; Noaldol; BRN 2654431; CAS-22494-42-4; BRD-K22031190-001-05-3; D3281_FLUKA	22494-42-4	3059	4832	TTDS00041	Prostaglandin G/H synthase 2	COX-2;Cyclooxygenase 2;Cyclooxygenase -2;Cyclooxygenase-2;Heme-protein prostaglandin G/H synthase;PGH synthase 2;PGHS-2;PHS II;Prostaglandin H2 synthase 2;Prostaglandin-endoperoxide synthase 2	P35354	5743	ENSG00000073756	inhibitor
DCL000826	GSK-644784	N/A	197502-82-2	456199	39289321	TTDS00041	Prostaglandin G/H synthase 2	COX-2;Cyclooxygenase 2;Cyclooxygenase -2;Cyclooxygenase-2;Heme-protein prostaglandin G/H synthase;PGH synthase 2;PGHS-2;PHS II;Prostaglandin H2 synthase 2;Prostaglandin-endoperoxide synthase 2	P35354	5743	ENSG00000073756	inhibitor
DAP001541	Valdecoxib	Spectrum3_001001; KBio2_002227; InChI=1/C16H14N2O3S/c1-11-15(12-7-9-14(10-8-12)22(17,19)20)16(18-21-11)13-5-3-2-4-6-13/h2-10H,1H3,(H2,17,19,20; NCGC00095129-02; Pfizer brand of valdecoxib; 4-(5-methyl-3-phenyl-isoxazol-4-yl)benzenesulfonamide; Spectrum2_000508; COX; KBio2_007363; NCGC00095129-01; Benzenesulfonamide, 4-(5-methyl-3-phenyl-4-isoxazolyl)-; Valdecoxib (USAN/INN); KBio3_001941; SPECTRUM1504302; Benzenesulfonamide, 4-(5-methyl-3-phenyl-4-isoxazolyl)- (9CI); Valdecoxib; HMS1922J21; UNM-0000305814; AC-120; SC-65872; MLS001424105; ZINC00006694; 4-(Methyl-3-phenyl-isoxazol-4-yl)-benzenesulfonamide; KBio2_004795; CPD000466327; NCGC00095129-03; BRD-K12994359-001-02-8; SC 65872; UNII-2919279Q3W; HMS2051P07; 4-(5-methyl-3-phenylisoxazol-4-yl)benzenesulfonamide; HSDB 7302; YM-974; C406224; ND-0214; Valdyn; 4-(5-Methyl-3-phenyl-4-isoxazolyl)benzenesulfonamide; D02709; CHEBI:41662; 181695-72-7; MLS000759433; SAM001246603; BSPBio_002721; 4-(5-methyl-3-phenyl-1,2-oxazol-4-yl)benzenesulfonamide; Spectrum5_001476; MLS001165699; MLS001195631; DB07576; Spectrum4_001129; p-(5-Methyl-3-phenyl-4-isoxazolyl)benzenesulfonamide; Valdecoxib [USAN]; DB00580; KBioGR_001617; CHEMBL865; Bextra; CID119607; 2aw1; MolPort-000-883-874; 4-(5-methyl-3-phenyl-4-isoxazolyl) benzenesulfonamide; KBioSS_002227; SPBio_000435; SMR000466327; Spectrum_001747; AKOS000280920; Kudeq; C16H14N2O3S; LS-173713; AC1L3P42	181695-72-7	119607	53789038	TTDS00041	Prostaglandin G/H synthase 2	COX-2;Cyclooxygenase 2;Cyclooxygenase -2;Cyclooxygenase-2;Heme-protein prostaglandin G/H synthase;PGH synthase 2;PGHS-2;PHS II;Prostaglandin H2 synthase 2;Prostaglandin-endoperoxide synthase 2	P35354	5743	ENSG00000073756	inhibitor
DAP000736	Tenoxicam	HMS2090P19; KBio1_000252; NCGC00016889-01; 3-[hydroxy-(pyridin-2-ylamino)methylidene]-2-methyl-1,1-dioxothieno[2,3-e]thiazin-4-one; SMR000058865; Tenoxicamum [INN-Latin]; CID5312154; C032801; AKOS000282084; Solvay brand of tenoxicam; Bio-0104; MLS001074071; CCRIS 5264; BCBcMAP01_000251; CID5282194; CID5397; S2512_Selleck; Tilcotil; Spectrum_001430; HMS2092L20; KBio2_004478; Spectrum2_001080; HMS1569J15; AC-4526; (3Z)-3-[hydroxy-(pyridin-2-ylamino)methylidene]-2-methyl-1,1-dioxothieno[2,3-e]thiazin-4-one; Liman; KBio2_007046; DivK1c_000252; Ro 12-0068; KBioSS_001910; BRN 0572193; STK637103; Prestwick2_000527; Ro-120068; HMS500M14; Spectrum5_001615; Ambap59804-37-4; Tilcotil (TN); D01767; NCGC00095260-01; Tenoxicam [USAN:BAN:INN:JAN]; LS-152556; Roche brand of tenoxicam; Prestwick1_000527; Prestwick_849; Novag brand of tenoxicam; Prestwick3_000527; Spectrum3_001563; Mobiflex; Apotex brand of tenoxicam; SMP1_000040; KBioGR_001022; Novo-Tenoxicam; 4-Hydroxy-2-methyl-N-2-pyridinyl-2H-thieno(2,3-e)-1,2-thiazine-3-carboxamide 1,1-dioxide; 4-HYDROXY-2-METHYL-N-2-PYRIDINYL-2H-THIENO[2,3-E]-1,2-THIAZINE-3-CARBOXAMIDE 1,1-DIOXIDE; MLS000069830; Spectrum4_000731; Ro 12-0068/000; SPBio_001100; UNII-Z1R9N0A399; SPBio_002434; (3E)-3-[hydroxy-(pyridin-2-ylamino)methylidene]-2-methyl-1,1-dioxothieno[2,3-e]thiazin-4-one; BSPBio_000513; tenoxicam; CHEMBL487234; T0909_SIGMA; IDI1_000252; 59804-37-4; CAS-59804-37-4; BSPBio_003066; 4-hydroxy-2-methyl-N-(pyridin-2-yl)-2H-thieno[2,3-e][1,2]thiazine-3-carboxamide 1,1-dioxide; BPBio1_000565; KBio3_002566; 2H-Thieno(2,3-e)-1,2-thiazine-3-carboxamide, 4-hydroxy-2-methyl-N-2-pyridinyl-, 1,1-dioxide; Artriunic; HMS1923I15; AC1NQZN7; NINDS_000252; MolPort-000-884-690; DB00469; Novopharm brand of tenoxicam; 4-Hydroxy-2-methyl-N-2-pyridyl-2H-thieno(2,3-e)-1,2-thiazine-3-carboxamide 1,1-dioxide; SPECTRUM1503142; AC1NSM4C; Tenoxicam (JAN/USAN/INN); AC1L1K9K; Prestwick0_000527; KBio2_001910; Tenoxicamum; I02-0320; BIDD:GT0650; NCGC00095260-02; Reutenox; Apo-Tenoxicam; Ro-12-0068	59804-37-4	5312154	183540	TTDS00041	Prostaglandin G/H synthase 2	COX-2;Cyclooxygenase 2;Cyclooxygenase -2;Cyclooxygenase-2;Heme-protein prostaglandin G/H synthase;PGH synthase 2;PGHS-2;PHS II;Prostaglandin H2 synthase 2;Prostaglandin-endoperoxide synthase 2	P35354	5743	ENSG00000073756	inhibitor
DCL000186	OGX-011	N/A	809298-11-1	N/A	10550006	TTDC00142	mRNA of Clusterin	Apo-J;Apolipoprotein J;CLI;Complement cytolysis inhibitor;Complement-associated protein SP-40,40;NA1/NA2;Testosterone-repressed prostate message 2;TRPM-2	P10909	1191	ENSG00000120885	antisense
DAP000874	Mannitol	Mannit; D00062; 63559_SIGMA; M9647_SIAL; Mannazucker; Osmitrol 10% In Water; Maniton-S; Mannidex; Isotol; 87-78-5; Osmitrol 20% In Water; Mannitol 20% In Plastic Container; Mannite; HSDB 714; Mannitol 20%; 15719_ALDRICH; M0044; D-(-)-Mannitol; MANNITOL 25%; Osmitrol; AI3-19511; AC1Q28E5; UNII-3OWL53L36A; Resectisol In Plastic Container; (2R,3R,4R,5R)-hexane-1,2,3,4,5,6-hexol; 85085-15-0; Osmitrol 5% In Water; NSC 407017; 63560_FLUKA; 123897-58-5; manita; SORBITOL-MANNITOL IN PLASTIC CONTAINER; M1902_SIGMA; Osmofundin; Diosmol; 15719_RIEDEL; MANNITOL 15% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.45%; AC-12776; Osmosal; AB1002081; Invenex; OSMITROL 20% IN WATER IN PLASTIC CONTAINER; OSMITROL 5% IN WATER IN PLASTIC CONTAINER; Osmitrol (TN); (L)-Mannitol; Osmitrol 15% In Water; ZINC02041302; Mannitol 5% In Plastic Container; MANNITOL 5% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.12%; CHEMBL689; NCGC00164246-01; Cordycepic acid; Mannitol 15%; 33440_SIGMA; AR-1J3861; Mannitol, D-; Mannitol [USAN]; D-mannitol; Mannitol 15% In Plastic Container; LS-89250; 63565_SIGMA; bmse000099; OSMITROL 15% IN WATER IN PLASTIC CONTAINER; CID6251; M8429_SIAL; Mannistol; Mannitol 5%; MLS001335977; M9546_SIAL; 133-43-7; Hexahydroxyhexane; Ambap69-65-8; D008353; Resectisol; Mannidex 16700; SMR000857324; Marine Crystal; DL-Mannitol; Mannitol (USP); Mannogem 2080; 36413-61-3; D-Mannitol (JP15); MolPort-003-927-039; M4125_SIAL; BRN 1721898; EINECS 201-770-2; TL806434; NCI-C50362; MTL; OSMITROL 10% IN WATER IN PLASTIC CONTAINER; MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER; 33440_RIEDEL; Mannigen; Mannitol (VAN); mannitol; CHEBI:16899; ED1D1E61-FEFB-430A-AFDC-D1F4A957FC3D; D-mannite; C00392; LS-1588; 69-65-8; EINECS 200-711-8; CCRIS 369; C6H14O6; 75398-80-0; 4-01-00-02841 (Beilstein Handbook Reference); 5149-40-6; 63559_FLUKA; MLS001335978; Mannitol 10% In Plastic Container; AC1L1M49; Mannitol 10%; Manna sugar; SDM No. 35; 63565_FLUKA; Sorbitol-Mannitol; NSC 9256; cpd without stereochemical designation	69-65-8	453	3682	TTDS00506	Mannitol-1-phosphate 5-dehydrogenase	M1PDH;MPD;mpdA;MPDH	Q4X1A4	N/A	N/A	activator
DCL001201	ISIS-FXI	N/A	N/A	N/A	N/A	TTDC00330	mRNA of Factor XI	mRNA of Coagulation factor XI;mRNA of FXI;mRNA of Plasma thromboplastin antecedent;mRNA of PTA	P03951	2160	ENSG00000088926	antisense
DAP001468	D-cycloserine	C3H6N2O2; BSPBio_002121; NSC 154851; MolPort-000-858-643; D-cycloserine; 3-Isoxazolidinone, 4-amino-, d-; Serine, cyclo-; Wasserina; alpha-Cycloserine; 30020_FLUKA; KBio2_001340; 3-Isoxazolidinone, 4-amino-, (R); R-4-Amino-3-isoxazolidinone; D-4-amino-3-isoxazolidinone; UNII-95IK5KI84Z; Closina; Spectrum5_000797; DRG-0195; SAM001247014; 3-Isoxazolidinone, 4-amino-, (+)- (8CI); (+)-4-Amino-3-isoxazolidinone; (R)-(+)-4-Amino-3-isoxazolidinone; NCGC00093713-01; Lopac-C-3909; Seromycin (TN); NCGC00016306-05; 68-41-7; Cyclo-D-serine; Cyclorin; C7670_SIGMA; HSDB 3218; K-300; KBio1_000098; SPBio_003029; Oxamycin; 3-Isoxazolidinone, 4-amino-, (R)-; BIDD:GT0707; CAS-68-41-7; LMPK14000007; cycloserine; (R)-Cycloserine; BRN 0080798; MLS001423962; KBioSS_001340; Cycloserinum; Lopac-C-1159; D-4-Amino-3-isossazolidone; NCGC00016306-01; EINECS 200-688-4; C3909_SIGMA; Lopac-C-7005; AI3-50153; C-9390; D-4-amino-3-isoxazolidone; SC-49088; CID6234; AC1L1M33; Oxamicina; Spectrum4_000305; NINDS_000098; 3-Isoxazolidinone, 4-amino-, (+)-; Miroseryn; HMS500E20; AC1Q4UA7; Novoserin; IDI1_000098; Spectrum3_000371; EU-0100252; Prestwick0_001089; KBio2_003908; orientomycin; Miroserina; (R)-3-Isoxazolidinone, 4-amino-; 3-Isoxazolidinone, 4-amino-, (4R)- (9CI); (4R)-4-Amino-3-isoxazolidinone; Tebemicina; SPECTRUM1500215; 3-Isoxazolidinone, 4-amino-, D; Cycloserine [INN:BAN:JAN]; NCGC00093713-02; SAM002264599; Spectrum_000860; DB03123; (4R)-4-amino-1,2-oxazolidin-3-one; Lopac0_000252; NCGC00015213-01; SMR000058313; Cicloserina [Italian]; C 3909; SPBio_000008; HMS2091I14; Prestwick1_001089; 4AX; (R)-4-Amino-3-isoxazolidone; HMS2051C15; 4-27-00-05549 (Beilstein Handbook Reference); E-733-A; MLS000758215; PA 94; HMS1920C06; D-amino-3-isoxazolidinone; AC-4721; (R)-(+)-Cycloserine; CPD-2482; Prestwick2_001089; KBio2_006476; PA-94; CHEBI:40009; 1pb9; RO-1-9213; NCGC00016306-02; CAS-339-72-0; (4R)-4-aminoisoxazolidin-3-one; CPD000058313; Cicloserina; BB_NC-1631; S1998_Selleck; I-1431; FA6C7F8B-D080-4EA3-978F-1ECFB5A29D09; NCGC00015213-02; Spectrum2_000084; Tisomycin; BPBio1_001252; D-(+)-Cycloserine; (R)-4-AMINO-ISOXAZOLIDIN-3-ONE; AB00443920; Oxamicina [Italian]; C6880_SIGMA; Micoserina; CHEMBL771; D-CS; Prestwick3_001089; C-9400; D00877; KBio3_001341; Cycloserinum [INN-Latin]; Closerin; R-(+)-Cycloserine; Cycloserine (JP15/USP/INN); LS-86757; KBioGR_000890; Cicloserina [INN-Spanish]; R(+)-4-Amino-3-isoxazolidinone; HMS1571I20; SMP1_000167; NCGC00016306-03; NCGC00015213-03; Farmiserina; BSPBio_001138; (R)-4-Amino-3-isoxazolidinone; (+)-Cycloserine; D-4-Amino-3-isossazolidone [Italian]; Seromycin; C08057; 30020_SIGMA; DivK1c_000098	68-41-7	449215	29203181	TTDS00135	NMDA receptor	N/A	N/A	N/A	N/A	agonist
DPR000010	ADX-2 series	N/A	N/A	363272	44857772	TTDS00135	NMDA receptor	N/A	N/A	N/A	N/A	antagonist
DAP001499	Nitrous oxide	Oxido nitroso [Spanish]; nitrogenium oxydulatum; 850203-00-8; gaz hilarant; Hyponitrous acid anhydride; Nitrous oxide [JAN]; D009609; Nitrous oxide (TN); Stickdioxyd; N2O; 295590_ALDRICH; 130835-71-1; 147527-07-9; CHEMBL1234579; Distickstoffmonoxid; Diazyne 1-oxide; Stickstoff(I)-oxid; 00583_FLUKA; 10024-97-2; UN1070; Nitrogen oxide (N2O); protoxyde d'azote; Nitrous oxide, refrigerated liquid [UN2201] [Nonflammable gas]; Nitrous oxide [UN1070]  [Nonflammable gas]; Nitrous oxide [Anaesthetics, volatile]; Dinitrogen oxide; Nitrous oxide, refrigerated liquid [UN2201]  [Nonflammable gas]; CHEBI:17045; Factitious air; 794457-85-5; oxidodinitrogen(N--N); LS-7622; UN2201; Nitrous oxide [UN1070] [Nonflammable gas]; Protoxyde d'azote [French]; nitrous oxide; Nitrous oxide, compressed; Nitrous oxide, refrigerated liquid; Laughing gas; 175876-44-5; FEMA No. 2779; D00102; Lachgas; Dinitrogen monoxide; AC1L1ADZ; HSDB 504; Oxido nitroso; Nitrogen hypoxide; 847968-13-2; C00887; Nitrous oxide (JP15/USP); oxyde nitreux; 126386-65-0; CCRIS 1225; NITROUS-OXIDE; 129451-49-6; Gas, Laughing; EINECS 233-032-0; CID948; Stickdioxyd [German]; Oxide, Nitrous	10024-97-2	948	48414241	TTDS00135	NMDA receptor	N/A	N/A	N/A	N/A	antagonist
DAP000015	L-Glutamic Acid	D-Glutamiensuur; PDSP2_001523; Glutamic Acid [USAN:INN]; 1ii5; Glutamic acid, (S)-; L-2-Aminoglutaric acid; 26717-13-5; AC1Q4U8C; 2-Aminoglutaric acid; L-Glutaminic acid; Gulutamine (USP); glu; 27322E29-9696-49C1-B541-86BEF72DE2F3; MolPort-001-770-254; 1-Aminopropane-1,3-dicarboxylic acid; Glutamic acid, L-, peptides; Biomol-NT_000170; AC1Q4U8B; Glutamidex; L-Glutamic acid, homopolymer; (S)-(+)-Glutamic acid; Glutaminic acid (VAN); NCGC00024502-01; FEMA No. 3285; Acido glutamico; G5667_SIGMA; alpha-aminoglutaric acid; L-glu; (S)-2-Aminopentanedioic acid; Glu; 2-Aminopentanedioic acid, (S)-; Glutamate, L-; 09581_FLUKA; CHEMBL575060; alpha-L-Glutamic acid polymer; E 620; 24595-14-0 (unspecified potassium salt); 7558-63-6 (mono-ammonium salt); AC1Q28OF; 49449_SIGMA; 138-16-9; PDSP1_000128; Glutaton; L-Glutamic acid, homopolymer (9CI); nchembio816-comp2; PDSP1_001539; H-Glu-OH; a-Aminoglutaric acid; G8415_SIGMA; AB1002631; L-Glutaminsaeure; Glutamic acid (H-3); nchembio.198-comp6; AI3-18472; (2S)-2-Aminopentanedioic acid; Lopac0_000529; Glutamicol; (S)-2-Aminopentanedioic acid; nchembio.186-comp9; nchembio.266-comp23; nchembio.2007.55-comp22; L-glutamate; Acide glutamique; PDSP2_000127; Aciglut; EINECS 200-293-7; Poly(alpha-L-glutamic acid); glut; CCRIS 7314; POLYGLUTAMIC ACID; Glutamic acid (VAN); Glusate; alpha-Glutamic acid; Glutamic acid, L-; EPA Pesticide Chemical Code 374350; 10549-13-0; Pentanedioic acid, 2-amino-, (S)-; GLUTAMIC ACID; 25513-46-6; Acidum glutamicum [INN-Latin]; AC1L1OVN; DB00142; 2-aminopentanedioic acid; 19473-49-5 (mono-potassium salt); L-Glutamic acid (JAN); C00025; Acidum glutamicum; AC-11294; 24938-00-9; a-Glutamic acid; CID33032; BPBio1_001132; 55695-80-2 (mono-lithium salt); 138-15-8 (unspecified hydrochloride); 6899-05-4; HSCI1_000269; NCGC00024502-03; alpha-Aminoglutaric acid (VAN); DB02517; 49449_FLUKA; UNII-3KX376GY7L; Acido glutamico [INN-Spanish]; Glutaminol; W328502_ALDRICH; NSC 143503; glutacid; Acide glutamique [INN-French]; LS-2330; Acidum glutaminicum; Sodium Glutamate (L-glutamic Acid); LS-71885; L-(+)-glutamic acid; G0059; nchembio.586-comp22; 16690-92-9 (di-hydrochloride salt); Tocris-0218; CHEBI:16015; glutaminic acid; D00007; glutamate; L-glutamic acid; L-Glutamic acid (9CI); 84960-48-5; G1251_SIGMA; Glutamic Acid (L-glutamic acid); L-a-Aminoglutaric acid; L-alpha-Aminoglutaric acid; 56-86-0; NCGC00024502-04; NCGC00024502-02; FT-0085107; 1ftj; Poly-L-glutamate; 1xff; Glutamic acid polymer; 19238-49-4 (unspecified calcium salt); L-Glutamic acid hydrochloride; Gulutamine; (S)-Glutamic acid; Glutamic acid, L- (7CI,8CI); AmbotzHAA1087	56-86-0	33032	3327	TTDS00135	NMDA receptor	N/A	N/A	N/A	N/A	antagonist
DAP000493	Memantine	Memantine [INN]; Biomol-NT_000209; HSDB 7327; Spectrum_000607; Memantine [INN:BAN]; BPBio1_001270; STK520682; Oprea1_480562; CHEBI:152523; Prestwick2_000978; EU-0053634; 1,3-Dimethyl-5-adamantanamine; CBMicro_020348; KBioSS_001087; BPBio1_001117; 41100-52-1 (Hydrochloride); Memantinum [INN-Latin]; AB00053600; 3,5-dimethyladamantan-1-amine; Spectrum5_001355; 3,5-Dimethyladamantan-1-ylamine; 19982-08-2; 3,5-Dimethyl-1-adamantylamine; Memantine (INN); ST057652; D08174; Prestwick0_000978; Memantina [INN-Spanish]; 51052-62-1; AKOS000113995; BSPBio_001015; KBioGR_001543; Spectrum2_001408; MolPort-002-041-858; KBio2_006223; LS-157051; Prestwick1_000978; Spectrum4_001022; BBL000737; Prestwick3_000978; AC1L1HB7; 1-Amino-3,5-dimethyladamantane; DivK1c_000068; IDI1_000068; NINDS_000068; DB01043; UNII-W8O17SJF3T; Memantinum; KBio2_003655; KBio2_001087; 3,5-dimethyltricyclo[3.3.1.1~3,7~]decan-1-amine; KBio1_000068; Tricyclo(3.3.1.1(3,7))decan-1-amine, 3,5-dimethyl-; NCGC00015705-05; KBio3_001926; Exiba; HMS500D10; Memantine HCL; SPBio_002926; NCGC00024782-03; Spectrum3_000923; Lopac0_000861; CID4054; ZERO/006024; 3,5-Dimethyl-1-adamantanamine; memantine; Memantina; Memantin; CHEMBL807; NCGC00024782-02; Ebixa; 3,5-Dimethyltricyclo(3.3.1.1(3,7))decan-1-amine; C13736; Exiba (TN); SPBio_001456	19982-08-2	4054	586325	TTDS00135	NMDA receptor	N/A	N/A	N/A	N/A	antagonist
DCL000790	EAA-090	CHEBI:230411; 144912-63-0; D05447; CHEMBL79810; Perzinfotel; EAA-090; 2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-6-yl)ethylphosphonic acid; WAY-126090; UNII-FX5AUU7Z8T; AC1OCF6Z; LS-192334; EAA 090; CHEMBL452461; CID6918236; Perzinfotel (USAN/INN); Way 126090	144912-63-0	6918236	12014746	TTDS00135	NMDA receptor	N/A	N/A	N/A	N/A	antagonist
DAP001147	Benzphetamine	CID2341; Benzeneethanamine, N,alpha-dimethyl-N-(phenylmethyl)-; (alphaS)-N,alpha-dimethylphenethylamine; DB00865; Benzfetamina [Spanish]; d-Benzphetamine; MolPort-002-051-901; benzaphetamine; N-benzyl-N-methyl-1-phenylpropan-2-amine; BRN 3203999; Benzeneethanamine, N,alpha-dimethyl-N-(phenylmethyl)-, (S)-; Benzfetaminum; DEA No. 1228; CID5311017; Benzfetamine; Benzfetaminum [Latin]; N-Benzylmethamphetamin; N,alpha-Dimethyl-N-(phenylmethyl)-benzeneethanamine; Benzeneethanamine, N,alpha-dimethyl-N-(phenylmethyl)-, (+)- (9CI); AC1NSJU8; (S)-benzphetamine; Benzfetamina [INN-Spanish]; L000849; N-Benzyl-N-methyl-1-phenyl-2-propanamine; AC1L1DGO; Phenethylamine, N-benzyl-N,.alpha.-dimethyl-, (+)-; N-methyl-1-phenyl-N-(phenylmethyl)propan-2-amine; LS-103107; (2S)-N-benzyl-N-methyl-1-phenylpropan-2-amine; Phenethylamine, N-benzyl-N,alpha-dimethyl-, (+)-; (+)-N,alpha-dimethyl-N-(phenylmethyl)-benzeneethanamine; CPD-10530; C17H21N; C07538; (S)-(+)-N-benzyl-N,alpha-dimethylphenethylamine; LS-187200; HSDB 3294; Benzfetamine [INN:BAN]; Benzofetamina [INN-Spanish]; Benzfetamina; Benzeneethanamine, N,alpha-dimethyl-N-(phenylmethyl)-, (+)-; Benzfetamine (INN); 156-08-1; (S)-(+)-benzphetamine; Benzphetaminum; D07514; N,alpha-Dimethyl-N-(phenylmethyl)benzeneethanamine; Benzphetaminum [INN-Latin]; benzphetamine; (+)-N-benzyl-N,alpha-dimethylphenethylamine; U 0441; CHEBI:3044; D-N-Methyl-N-benzyl-beta-phenylisopropylamine; Benzfetamina [DCIT]; Benzylamphetamine; Benzeneethanamine, N,.alpha.-dimethyl-N-(phenylmethyl)-, (+)-; (+)-benzphetamine; Benzfetaminum [INN-Latin]; UNII-0M3S43XK27; Benzofetamina; (R,S)-N-Benzyl-alpha,N-dimethylphenethylamin; 101-47-3; N-Benzyl-N,alpha-dimethylphenethylamine	156-08-1	2341	152260	TTDS00135	NMDA receptor	N/A	N/A	N/A	N/A	antagonist
DCL000755	CNS-5161	AC1L4UT0; CNS5161; CHEMBL41306; MolPort-005-942-556; Guanidine, N'-(2-chloro-5-(methylthio)phenyl)-N-methyl-N-(3-(methylthio)phenyl)-; 2-(2-chloro-5-methylsulfanylphenyl)-1-methyl-1-(3-methylsulfanylphenyl)guanidine; AR-1D6726; CID192711; 2-[2-chloro-5-(methylsulfanyl)phenyl]-1-methyl-1-[3-(methylsulfanyl)phenyl]guanidine; CNS-5161; AC1Q3RIA; CHEBI:160106	160754-76-7	148197	770071	TTDS00135	NMDA receptor	N/A	N/A	N/A	N/A	antagonist
DCL000751	CHF-3381	N/A	202914-18-9	5351154	44716690	TTDS00135	NMDA receptor	N/A	N/A	N/A	N/A	antagonist
DCL000876	Magnesium	37426_RIEDEL; magnesio; 14147-08-1; LTBB002624; 63043_FLUKA; 465666_SIAL; 63040_ALDRICH; EINECS 231-104-6; AC1NUW87; 37506_FLUKA; AQUANAL-plus magnesium (Mg) 100-1500 mg/L; Magnesium or magnesium alloys with >50% magnesium in pellets, turnings or ribbons [UN1869] [Flammable solid]; 499579_ALDRICH; 253987_SIAL; UN1418; Magnesio [Italian]; 63035_FLUKA; 12Mg; 7439-95-4; CID5462224; 67208-78-0; LS-88579; Magnesium or magnesium alloys with >50% magnesium in pellets, turnings or ribbons [UN1869]  [Flammable solid]; 683043_ALDRICH; Magnesium powdered; 63035_ALDRICH; UN2950; 299405_ALDRICH; CHEBI:25107; 37426_FLUKA; 63045_FLUKA; Magnesium granules, coated particle size not <149 microns [UN2950] [Dangerous when wet]; MAGNESIUM NITRATE, ACS; 465992_ALDRICH; 13112_RIEDEL; 63045_ALDRICH; Magnesium hydride [UN2010]  [Dangerous when wet]; AQUANAL(R)-plus magnesium (Mg) 100-1500 mg/L; 37466_FLUKA; Magnesium, powder or magnesium alloys, powder [UN1418]  [Dangerous when wet, Spontaneously combustible]; 200905_SIAL; MolPort-003-926-255; Magnesium modifier; D008274; Magnesium granules, coated particle size not <149 microns [UN2950]  [Dangerous when wet]; Magnesium Matrix Modifier; Magnesium sheet; 37466_RIEDEL; Magnesium nitrate - nitric acid solution; Magnesium preparation; 13103_RIEDEL; 298688-48-9; 266302_SIAL; Rieke's active magnesium; 13112_ALDRICH; 13103_ALDRICH; 403148_ALDRICH; Magnesium, powder or magnesium alloys, powder [UN1418] [Dangerous when wet, Spontaneously combustible]; HSDB 654; MAGNESIUM; 474754_ALDRICH; 37506_RIEDEL; UN2010; 254118_ALDRICH; AB1002296; 199281-20-4; 60616-74-2; MAGNESIUM, ATOMIZED POWDER,18 MICRON; 254126_SIAL; UN1869; 63040_FLUKA	7439-95-4	5311022	46508750	TTDS00135	NMDA receptor	N/A	N/A	N/A	N/A	antagonist
DAP000858	Orphenadrine	EINECS 201-509-2; Mialgin (TN); Orfenadrina; 2-(Phenyl-o-tolylmethoxy)ethyldimethylamine; 83-98-7; Methyldiphenylhydramine; CHEBI:177779; DivK1c_000853; Orphenadrin; CID4601; KBio2_006661; 4682-36-4 (citrate); KBio2_001525; Lysantin; N,N-Dimethyl-2-(o-methyl-alpha-phenylbenzyl)oxy)ethylamine; Spectrum3_000531; KBioGR_000880; Orphenate; N,N-dimethyl-2-[(2-methylphenyl)-phenylmethoxy]ethanamine; Myolin; CBDivE_006102; Orphenadrine (INN); Prestwick0_000239; KBio3_001641; SPBio_001255; Ethanamine, N,N-dimethyl-2-[(2-methylphenyl)phenylmethoxy]-; NINDS_000853; Spectrum4_000460; DB01173; orphenadrine; 2-Methyldiphenhydramine; Phenyl-o-tolylmethyl dimethyaminoethyl ether; C07935; 341-69-5 (hydrochloride); NCGC00089814-03; LS-68148; Spectrum5_001036; BPBio1_000349; BRN 1885151; CHEMBL900; Orfenadrina [INN-Spanish]; AC1L1IJ4; BSPBio_002141; Norflex Orphenadrine Citrate; Biorphen; Lopac0_000884; N,N-Dimethyl-2-[(o-methyl-alpha-phenylbenzyl)oxy]ethylamine; beta-Dimethylaminoethyl 2-methylbenzhydryl ether; WS 2434; Mefenamine; Ethylamine, N,N-dimethyl-2-((o-methyl-alpha-phenylbenzyl)oxy)-; beta-Dimethylaminoethyl-2-methylbenzhydryl ether; Orphenadine; Orphenadrinum; Ethanamine, N,N-dimethyl-2-((2-methylphenyl)phenylmethoxy)-; MolPort-002-052-046; ORP; Orfro; ST50406606; Antiflex; KBio1_000853; AB00053510; Orphenadrine [INN:BAN]; Prestwick1_000239; NCGC00015771-09; Spectrum_001045; Mephenamine; CHEBI:7789; HSDB 3139; Mio-Rel; N,N-dimethyl-2-{[(2-methylphenyl)(phenyl)methyl]oxy}ethanamine; Brocasipal; Orphenadrinum [INN-Latin]; Orphenedrine; 4-06-00-04727 (Beilstein Handbook Reference); SPBio_002238; L001253; Sodium Mefenamine; N,N-dimethyl-2-(alpha-2-tolylbenzoyloxy)ethylamine; Prestwick2_000239; Spectrum2_001038; Orphenadinum; Oprea1_476547; o-Monomethyldiphenhydramine; BRD-A53576514-003-03-1; UNII-AL805O9OG9; o-Methyldiphenhydramine; Disipal; KBioSS_001525; BSPBio_000317; Brocadisipal; Prestwick3_000239; KBio2_004093; NCGC00089814-02; IDI1_000853; N,N-Dimethyl-2-(alpha-2-tolylbenzoyloxy)ethylamin; Myotrol; D08305; N,N-Dimethyl-2-[(2-methylphenyl)(phenyl)methoxy]ethanamine	83-98-7	4601	10137	TTDS00135	NMDA receptor	N/A	N/A	N/A	N/A	antagonist
DCL000773	Dextromethorphan+quinidine	N/A	6700-34-1	5360696	10321646	TTDS00135	NMDA receptor	N/A	N/A	N/A	N/A	antagonist
DCL000784	D-serine	D-Ser; S4250_SIGMA; nchem.554-comp9; NSC77689; NCGC00094363-05; S0033; AC1Q5R15; D-serine; AR-1I7048; BPBio1_001226; DD977692-169B-4266-88C3-E07F0B21A5BF; D-2-Amino-3-hydroxypropionic Acid; AmbotzHAA1051; CHEMBL285123; NCGC00094363-03; H-D-Ser-OH; NCGC00094363-04; S-2590; S 4250; (2R)-2-amino-3-hydroxypropanoic acid; EU-0101088; (R)-2-Amino-3-hydroxypropionic acid; EINECS 206-229-4; AI3-18476; serine d-; NCGC00094363-02; NCGC00094363-01; CHEBI:16523; (R)-2-amino-3-hydroxypropanoic acid; Lopac0_001088; MolPort-000-158-483; d-(+)-serine; D-Serin; AC1Q4UB3; nchembio.145-comp14; SERINE (L); LS-144974; 1pb8; 62595-04-4; Jsp005844; NSC 77689; R(-)-2-Amino-3-hydroxypropionic acid; AC1L2FHY; C00740; DSN; AC-19235; CID71077; Biomol-NT_000197; 312-84-5; UNII-1K77H2Z9B1; Serine D-form; serine; InChI=1/C3H7NO3/c4-2(1-5)3(6)7/h2,5H,1,4H2,(H,6,7	N/A	N/A	8146362	TTDS00135	NMDA receptor	N/A	N/A	N/A	N/A	modulator
DAP000093	Felbamate	MLS000758238; BIDD:GT0463; EINECS 247-001-4; C07501; BRN 3345236; CHEMBL1094; Schering brand of felbamate; Lopac0_000524; Felbatol; 4-06-00-05993 (Beilstein Handbook Reference); Tocris-0869; NCGC00023092-06; SBB070639; Felbamate [USAN:INN]; AC1L1FOW; ZINC01530803; BRD-K99107520-001-01-9; MolPort-003-666-873; Felbamatum [Latin]; MLS001077299; C047360; CHEBI:4995; CID3331; NCGC00023092-02; BPBio1_001258; Felbamyl; ADD-03055; Lopac-F-0778; Wallace brand 2 of felbamate; Felbamatum; felbamate; Felbatol (TN); HSDB 7525; W-554; (3-carbamoyloxy-2-phenylpropyl) carbamate; UNII-X72RBB02N8; NCGC00015429-06; 1,3-Propanediol, 2-phenyl-, dicarbamate; SMR000449307; carbamic acid 2-phenyltrimethylene ester; Felbamato; Biomol-NT_000203; F 0778; I06-0353; F0778_SIGMA; NCGC00015429-02; EU-0100524; DB00949; NCGC00015429-01; Schering-Plough brand of felbamate; Felbamate (USAN/INN); 2-Phenylpropane-1,3-diyl dicarbamate; SMR000058448; NCGC00015429-09; C11H14N2O4; HMS2093P19; NCGC00023092-04; 2-Phenyl-1,3-propanediol dicarbamate; Carbamic acid, 2-phenyltrimethylene ester; S1330_Selleck; 25451-15-4; Taloxa; (3-carbamoyloxy-2-phenyl-propyl) carbamate; D00536; W 554; LS-120706; Essex brand of felbamate; Felbamato [Spanish]; NCGC00023092-05; Wallace brand 1 of felbamate; MLS000028465; Prestwick0_000919	25451-15-4	3331	7847602	TTDS00135	NMDA receptor	N/A	N/A	N/A	N/A	antagonist
DPR000126	Remacemide	PR1032-646; CHEMBL25843; 2-amino-N-(1-methyl-1,2-diphenylethyl)acetamide; Remacemida; (+-)-2-Amino-N-(1-methyl-1,2-diphenylethyl)acetamide; PR 934-423; LS-8058; FPL 12924AA; REMACEMIDE; C067553; LS-8059; FPL 12924; FPL 14144; 118754-12-4; FPL 14145; Remacemida [INN-Spanish]; Acetamide, 2-amino-N-(1-methyl-1,2-diphenylethyl)-, (+)-; BRD-A36074203-003-03-5; 128298-28-2; CID60511; PR-934-423; FPL-12944AA; Acetamide, 2-amino-N-(1-methyl-1,2-diphenylethyl)-, (-)-; Remacemidum; AC1L1TE2; PR 1032-644; remacemide monohydrochloride, (+-)-isomer; MolPort-002-546-231; Remacemide [INN]; (-)-2-Amino-N-(1-methyl-1,2-diphenylethyl)acetamide; Acetamide, 2-amino-N-(1-methyl-1,2-diphenylethyl)-, (+-)-; (+)-2-Amino-N-(1-methyl-1,2-diphenylethyl)acetamide; 118754-14-6; C17H20N2O; Remacemidum [INN-Latin]; 2-amino-N-(1,2-diphenylpropan-2-yl)acetamide; LS-8057	N/A	N/A	N/A	TTDS00135	NMDA receptor	N/A	N/A	N/A	N/A	agonist
DAP000201	Magnesium Sulfate	13143_RIEDEL; 208094_SIAL; Sulfuric acid magnesium salt (1:1); Magnesium sulfate solution; Magnesium Sulphate Hydrate; Magnesium(II) sulfate; M2643_SIGMA; Sal Angalis; Magnesium Sulfate, Heptahydrate; Sal anglicum; 63139_FLUKA; CCRIS 8411; UNII-DE08037SAB; AC1LAX36; EPA Pesticide Chemical Code 050503; MgSO4; CHEBI:32599; magnesium(2+) ion sulfate; EINECS 231-298-2; SDA 15-062-07; Heptahydrate Magnesium Sulfate; 10034-99-8 (heptahydrate); 38146_FLUKA; 139939-75-6; MolPort-003-925-000; Sulfuric acid, mono-C10-16-alkyl esters, magnesium salts; EINECS 242-691-3; C10-C16 Alkyl alcohol sulfuric acid magnesium salt; M8150_SIGMA; AI3-02029; EINECS 268-365-0; 18939-43-0; Sal De sedlitz; Magnesium hydrogensulphate; Magnesiumsulfat; 38146_RIEDEL; Sulfuric acid, magnesium salt; 63136_SIAL; Caswell No. 534; 7487-88-9; 13143_SIAL; Sal catharticum; Magnesium sulfate hexahydrate; Sulfate, Magnesium; Magnesium sulfate anhydrous; Hair salt; CID24083; M3409_SIGMA; 34276_RIEDEL; Sulfuric acid magnesium salt (VAN); 68081-97-0; AC1Q1U66; D008278; 63139_SIAL; Sulfuric acid, magnesium salt (1:1); NSC 146179; (C10-C16) Alkylalcohol sulfuric acid, magnesium salt; CPD0-2390; Sal seidlitense; Magnesium sulfate (1:1); Magnesium sulphate; Kieserite [as monohydrate]; 10028-26-9; Sal amarum; MAGNESIUM SULFATE; EINECS 233-073-4; HSDB 664; DB00653; Salts of england; LS-88605; UNII-ML30MJ2U7I; Sel d'angleterre; 63126_FLUKA; Magnesium sulfate dried; Bitter salt; 203726_ALDRICH; 63136_FLUKA; OT-S (drying agent); 00627_FLUKA; Magnesium sulfate in dextrose 5% in plastic container; Sulfuric acid, C10-16 alkyl ester, magnesium salt; Magnesium Sulfate In Plastic Container; M7506_SIAL; Tomix OT; OT-S; Magnesium bisulfate; AC1L2N76; Sulfuric acid magnesium salt; Epsom salt; 34276_FLUKA	7487-88-9	24083	7979848	TTDS00135	NMDA receptor	N/A	N/A	N/A	N/A	antagonist
DAP001146	Amphetamine	CID3007; 1-Phenylpropan-2-amin; (S)-.alpha.-Phenylethylamine; 1-Phenyl-2-aminopropane; 3-Phenyl-2-propylamine; Levoamphetamine; Phenethylamine, alpha-methyl-, (+-)-; beta-Phenylisopropylamin [German]; Isoamyne; S(+)-Amphetamine; Allodene; DEA No. 1100; AMPHETAMINE; (+-)-alpha-Methylphenylethylamine; (+-)-alpha-Methylbenzeneethanamine; 300-62-9; levo-Amphetamine; (+-)-alpha-Methylphenethylamine; Fenylo-izopropylaminyl; DL-Amphetamine solution; Simpatina; Benzedrine; Phenethylamine, alpha-methyl-; AC1Q5065; HSDB 3287; LS-1428; beta-Phenylisopropylamine; Oktedrin; Amfetamine (INN); Adderall; Profamina; Anorexide; 60-13-9 (sulfate (2:1)); DivK1c_000991; (+)-.alpha.-Methylphenethylamine; Amfetamina [INN-Spanish]; IDI1_000991; Ortedrine; alpha-Methylphenylethylamine; racemic-Desoxynor-ephedrine; KBio1_000991; Phenedrine; (S)-(+)-.beta.-Phenylisopropylamine; 1-Phenyl-2-amino-propan [German]; Benzebar; ALPHA-METHYL-BENZENEETHANAMIDE (SEE ALSO DL-AMPHETAMINE SULFATE); C07514; 610240_ALDRICH; Isomyn; CHEBI:2679; 610240_FLUKA; NSC27159; L-Amphetamine; .alpha.-Methylphenethylamine, d-form; UNII-CK833KGX7E; Benzeneethanamine, alpha-methyl-, (+-)-; NSC 27159; (+-)-Benzedrine; beta-Aminopropylbenzene; Amfetamin (TN); Anorexine; LS-1148; AMPHETAMINE, (D); Norephedrane; nchembio.284-comp5; Phenamine; WLN: ZY1&1R -D; Benzeneethanamine, .alpha.-methyl-, (.+/-.)-; .alpha.-Methylbenzeneethanamine; 1-Methyl-2-phenylethylamine; Actedron; Percomon; Protioamphetamine; AR-1H6584; Amfetamine; CHEMBL405; .beta.-Phenylisopropylamine; nchembio.2007.55-comp27; .alpha.-Methylphenylethylamine; Phenethylamine, D-.alpha.-methyl-; Fenopromin; Desoxynorephedrine; NINDS_000991; Anfetamina; Phenethylamine, .alpha.-methyl-, (+)-; .beta.-Aminopropylbenzene; Amfetamine [INN:BAN]; Benzeneethanamine, alpha-methyl-; WLN: ZY1&1R; d-.alpha.-Methylphenethylamine; Benzeneethanamine, .alpha.-methyl-; beta-Aminopropylbenzene (VAN); alpha-Methylbenzeneethaneamine; HMS503G03; Amfetamina [Italian]; component of Amodex; Dexedrine; Amsustain; .alpha.-Methylphenethylamine; L000864; Amfetamin; Phenethylamine, .alpha.-methyl-, (.+/-.)-; Amphetamin; 1-Phenyl-2-aminopropane (VAN); 1-Phenyl-2-amino-propan; Fenylo-izopropylaminyl [Polish]; amfetaminum; 17108-96-2; dl-alpha-Methylphenethylamine; Amfetamina; NSC73713; Amfetaminum [INN-Latin]; Amphetamine resin complex; AC1L1EYQ; 96332-84-2; Benzeneethanamine, .alpha.-methyl-, (S)-; Phenethylamine, .alpha.-methyl-; Finam; Elastonon; Amphetamine, its salts, optical isomers, and salts of its optical isomers; .beta.-Phenylisopropylamin; AMPHETAMINE (SEE ALSO: D-AMPHETAMINE (51-64-9) & AMPHETAMINE SULFATE (60-13-9)); component of Biphetamine; EINECS 206-096-2; alpha-Methylphenethylamine; (+)-.alpha.-Methylphenylethylamine; Phenethylamine, .alpha.-methyl-, d-; Phenethylamine, alpha-methyl, (+-)-; Novydrine; 60-15-1; D07445; AI3-02438; Mecodrin; Anfetamina [Spanish]; C9H13N; Amphetamine Sulfate (2:1); MolPort-001-783-432; Adipan; NSC170999; Mydrial; Benzolone; beta-Phenylisopropylamin; Desoxynorephedrin; 1-Phenyl-2-propylamine; EINECS 200-458-3; Oprea1_447423; 1-phenylpropan-2-amine; Thyramine; 2-Amino-1-phenylpropane; 1-Phenyl-2-propanamine	300-62-9	5826	148619	TTDS00135	NMDA receptor	N/A	N/A	N/A	N/A	antagonist
DCL000477	AZD6765	N/A	N/A	N/A	N/A	TTDS00135	NMDA receptor	N/A	N/A	N/A	N/A	antagonist
DCL000770	Dexanabinol	PRS 211007-000; 7-Hydroxy-delta-6-tetrahydrocannabinoldimethylheptyl; 5'(1,1-Dimethylheptyl)-7-hydroxyhexahydrocannabinol; 1,1-Dimethylheptyl-11-hydroxytetrahydrocannabinol; LS-186902; CHEBI:321361; MolPort-005-940-875; Sinnabidiol; 1,1-Dimethylheptyl-7-hydroxy-delta(6)-tetrahydrocannabinol; CHEMBL334533; AC1L32QF; HU-211; ZINC03799010; 11-Hydroxy-delta(8)-tetrahydrocannabinol-dimethylheptyl; 11-OH-delta(8)-Thc-dmh; LS-187556; PDSP2_000937; (6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol; CID107778; HU 211; 11-Hydroxymethyl-delta(8)-tetrahydrocannabinol-dimethylheptyl; 112924-45-5; 6H-Dibenzo(b,d)pyran-9-methanol, 3-(1,1-dimethylheptyl)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6-dimethyl-, (6aS-trans)-; 11-Hydroxy-delta-8-dmh-thc; Dexanabinol	112924-45-5	107778	685052	TTDS00135	NMDA receptor	N/A	N/A	N/A	N/A	antagonist
DCL000696	Amitriptyline+ketamine	N/A	50-48-6	6450813	49708490	TTDS00135	NMDA receptor	N/A	N/A	N/A	N/A	antagonist
DCL000895	Neramexane	1,3,3,5,5-Pentamethylcyclohexanamine; Cyclohexanamine, 1,3,3,5,5-pentamethyl-; AC1O5FL0; 219810-59-0; Neramexane; Mrz 2579; CID6433106; 1,3,3,5,5-pentamethylcyclohexan-1-amine; Neramexane [INN]; MRZ 2-579; UNII-856DX0KJ84	219810-59-0	6433106	10549697	TTDS00135	NMDA receptor	N/A	N/A	N/A	N/A	antagonist
DAP001148	Ketamine	cyclohexanone, 2-(2-chlorophenyl)-2-(methylamino)-; CHEBI:138833; Ketamine Base; MolPort-001-838-070; NCGC00159480-02; Ketoject; ketamine; DEA No. 7285; C13H16ClNO; Cyclohexanone, 2-(2-chlorophenyl)-2-(methylamino)-, (.+/-.)-; dl-Ketamine; (+/-)-2-(o-Chlorophenyl)-2-(methylamino)cyclohexanone; Ketaminum [INN-Latin]; Ketalar base; Cyclohexanone, 2-(2-chlorophenyl)-2-(methylamino)- (9CI); Special K [street name]; Cyclohexanone, 2-(o-chlorophenyl)-2-(methylamino)-, (.+-.)-; Calypsol; KBio1_000217; NINDS_000217; Cyclohexanone, 2-(2-chlorophenyl)-2-(methylamino)-, (.+-.)-; C07525; KETAMINE HCL; LS-57301; 2-(Methylamino)-2-(2-chlorophenyl)cyclohexanone; NSC70151; MLS001331674; 2-(2-chlorophenyl)-2-(methylamino)cyclohexan-1-one; AC1L1GSH; AC1Q40UR; Cetamina; 79499-51-7; Ketaminum; Ketaject; 100477-72-3; Tekam; 2-(o-Chlorophenyl)-2-(methylamino)-cyclohexanone; Ketolar; CHEBI:6121; Tekam (TN); (+/-)-2-(2-Chlorophenyl)-2-(methylamino)cyclohexanone; AKOS001053247; Cyclohexanone, 2-(2-chlorophenyl)-2-(methylamino)-, (+-)- (9CI); CLSTA 20; 33643-45-7; CI-581; D08098; CHEMBL742; CID3821; CI 581 base; Special K; (+-)-Ketamine; 6740-88-1; BRN 2216965; Ketanest; Ketamine [INN:BAN]; Ketamine (INN); Ketalar; SMR000238141; Cyclohexanone, 2-(o-chlorophenyl)-2-(methylamino)-, (+-)-; DB01221; NSC 70151; EINECS 229-804-1; Cyclohexanone, 2-(o-chlorophenyl)-2-(methylamino)-, (+/-)- (8CI); (+/-)-Ketamine; DivK1c_000217; IDI1_000217; Cyclohexanone, 2-(2-chlorophenyl)-2-(methylamino)-, (+-)-; 2-(o-Chlorophenyl)-2-(methylamino)cyclohexanone; Cyclohexanone, 2-(2-chlorophenyl)-2-(methylamino)-, (+/-)-; Green; Cyclohexanone, 2-(o-chlorophenyl)-2-(methylamino)-; 2-(2-Chlorophenyl)-2-(methylamino)cyclohexanone; UNII-690G0D6V8H; NCGC00159480-03; Cetamina [INN-Spanish]; T385	6740-88-1	3821	9728	TTDS00135	NMDA receptor	N/A	N/A	N/A	N/A	antagonist
DCL000850	Ipamorelin	N/A	170851-70-4	3038469	3846293	TTDS00446	Growth hormone-releasing hormone receptor	GHRH receptor;GRF receptor;GRFR	Q02643	2692	ENSG00000106128	antagonist
DAP001556	Tesamorelin	N/A	N/A	N/A	N/A	TTDS00446	Growth hormone-releasing hormone receptor	GHRH receptor;GRF receptor;GRFR	Q02643	2692	ENSG00000106128	binder
DAP001055	Sermorelin	Sermoreline; Sermorelin [INN:BAN]; UNII-89243S03TE; Sermorelinum; C08192; D08509; GROWTH HORMONE RELEASING FACTOR, Fragment 1-29 Amide; Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn- Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln- Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln- Asp-Ile-Met-Ser-Arg-NH2; Sermorelin (INN); Sermorelina; Geref (TN); 86168-78-7; 114466-38-5 (acetate); Sermoreline [French]; Sermorelinum [Latin]; Sermorelina [Spanish]; SERMORELIN; Somatoliberin (human pancreatic islet), 29-L-argininamide-30-de-L-glutamine-31-de-L-glutamine-32-deglycine-33-de-L-glutamic acid-34-de-L-serine-35-de-L-asparagine-36-de-L-glutamine-37-de-L-glutamic acid-38-de-L-arginine-39-deglycine-40-de-L-alanine-41-de-L-arginine-42-de-L-alanine-43-de-L-argininyl-44-de-L-leucinamide; L000266	86168-78-7	16129620	10391	TTDS00446	Growth hormone-releasing hormone receptor	GHRH receptor;GRF receptor;GRFR	Q02643	2692	ENSG00000106128	binder
DCL000118	GHRH analog	N/A	N/A	N/A	N/A	TTDS00446	Growth hormone-releasing hormone receptor	GHRH receptor;GRF receptor;GRFR	Q02643	2692	ENSG00000106128	agonist
DPR000093	PT-15	N/A	N/A	5360545	49746451	TTDC00072	Melanocortin-4 receptor	MC4-R	P32245	4160	ENSG00000166603	agonist
DPR000029	CHIR-01020	N/A	83387-25-1	5361918	49684206	TTDC00072	Melanocortin-4 receptor	MC4-R	P32245	4160	ENSG00000166603	agonist
DCL000074	Bremelanotide	Bremelanotide (USAN/INN); D06569	189691-06-3	23725087	47208225	TTDC00072	Melanocortin-4 receptor	MC4-R	P32245	4160	ENSG00000166603	agonist
DPR000100	Ro-27-3225	N/A	N/A	N/A	N/A	TTDC00072	Melanocortin-4 receptor	MC4-R	P32245	4160	ENSG00000166603	agonist
DPR000061	IDDBCP-150101	N/A	N/A	N/A	N/A	TTDC00072	Melanocortin-4 receptor	MC4-R	P32245	4160	ENSG00000166603	agonist
DPR000184	RM-493	N/A	N/A	N/A	N/A	TTDC00072	Melanocortin-4 receptor	MC4-R	P32245	4160	ENSG00000166603	agonist
DPR000073	Melanotetan II	N/A	121062-08-6	6323491	49703995	TTDC00072	Melanocortin-4 receptor	MC4-R	P32245	4160	ENSG00000166603	agonist
DPR000070	MC-4 agonist	N/A	N/A	N/A	N/A	TTDC00072	Melanocortin-4 receptor	MC4-R	P32245	4160	ENSG00000166603	agonist
DAP000604	Cyclothiazide	Ciclotiazide; UNII-P71U09G5BW; CHEBI:192458; C 9847; C12685; 6-Chloro-3,4-dihydro-3-(5-norbornen-2-yl)-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; BPBio1_001320; Anhydron; EU-0100321; 2259-96-3; 6-Chloro-3,4-dihydro-3-(2-norbornen-5-yl)-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3-bicyclo[2.2.1]hept-5-en-2-yl-6-chloro-3,4-dihydro-, 1,1-dioxide; Spectrum5_001639; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3,4-dihydro-6-chloro-3-(5-norbornen-2-yl)-,1,1-dioxide; 3-Bicyclo[2.2.1]hept-5-en-2-yl-6-chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; CID2910; Fluidil; D01256; Ciclotiazida; C9847_SIGMA; C14H16ClN3O4S2; Cyclothiazidum [INN-Latin]; 6-Chloro-3-(2-norbornen-5-yl)-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide; Cyclothiazidum; Doburil; Cyclothiazide (JAN/USAN/INN); MDi 193; Lilly 35,483; DivK1c_000904; DB00606; 6-Chloro-3,4-dihydro-3-(2-norbornen-5-yl)-2H-1,2-4-benzothiadiazine-7-sulfonamide 1,1-dioxide; Spectrum4_000050; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3,4-dihydro-3-(5-norbornen-2-yl)-, 1,1-dioxide; HMS2093A19; KBioGR_000519; 3-(bicyclo[2.2.1]hept-5-en-2-yl)-6-chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; NCGC00015288-04; NINDS_000904; cyclothiazide; 6-Chloro-3,4-dihydro-3-(norbornen-2-yl)-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; MLS001077326; 6-chloro-3,4-dihydro-3-(norbornen-2-yl)-2H-1,2,4- benzothiadiazine-7-sulfonamide 1,1-dioxide; SMR000653479; AC1L1EQZ; HSDB 3310; Lopac0_000321; Renazide; NCGC00024745-02; MolPort-003-666-800; Aquirel; AC1Q6TQ1; 6-Chloro-3,4-dihydro-3-(2-norbornen-5-yl)-7-sulfamoyl-1,2,4-benzothiadiazine 1,1-dioxide; EINECS 218-859-7; BRN 0722843; Biomol-NT_000224; Anhydron (TN); NCGC00024745-03; AR-1E7381; KBio1_000904; Valmiran; 3-Bicyclo(2.2.1)hept-5-en-2-yl-6-chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; HMS502N06; NCGC00024745-04; Ciclotiazide [DCIT]; CHEMBL61593; Ciclotiazida [INN-Spanish]; Cyclothiazide [USAN:INN:BAN]; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3,4-dihydro-6-chloro-3-(5-norbornen-2-yl)-, 1,1-dioxide; IDI1_000904; CHEBI:31448; LS-40445; BRD-A38675539-001-01-0; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3-bicyclo(2.2.1)hept-5-en-2-yl-6-chloro-3,4-dihydro-, 1,1-dioxide; NCGC00015288-07	2259-96-3	2910	583075	TTDS00306	Carbonic anhydrase II	CA-II;Carbonate dehydratase II;Carbonic anhydrase C	P00918	760	ENSG00000104267	inhibitor
DAP000606	Ethinamate	WLN: L6TJ AOVZ A1UU1; Valaminetten; Valmid (TN); Etinamato; Valaminettae; E3258_FLUKA; Carbamic acid, 1-ethynylcyclohexyl ester; 1-Ethinylcyclohexyl carbonate; BRN 1946056; DEA No. 2545; (1-ethynylcyclohexyl) carbamate; USAF EL-42; CHEBI:4884; NSC30282; Etinamate; Aethinyl-cyclohexyl-carbamat [German]; ethinamate; Carbamate de l'ethinylcyclohexanol [French]; Ethinimate; valamid; 1-Ethynylcyclohexyl carbamate; UNII-IAN371PP48; Aethinyl-cyclohexyl-carbamat; NSC524623; AC1L1FL5; Cyclohexanol, 1-ethynyl-, carbamate; 1-Ethynylcyclohexanol carbamate; ZINC00001385; Etinamato [INN-Spanish]; Ethinamat; E3258_SIGMA; Ethinamatum; HSDB 3325; EINECS 204-789-4; NSC11538; Valmid; D00703; NSC31618; 126-52-3; Ethynylcyclohexyl carbamate; LS-57167; Valamin; Ethinamatum [INN-Latin]; Ethinamate (JAN/INN); CHEMBL1576; Cyclohexanol, 1-ethynyl-, 1-carbamate; NSC 11538; C07832; Ethinamate [INN:BAN:JAN]; 1-Ethinylcyclohexyl carbamate; Valmidate; Volamin; 1-ethynylcyclohexylcarbamate; Carbamate de L'ethinylcyclohexanol; Valaminetta; DB01031; CID3284; MolPort-003-941-264	126-52-3	3284	10034	TTDS00306	Carbonic anhydrase II	CA-II;Carbonate dehydratase II;Carbonic anhydrase C	P00918	760	ENSG00000104267	inhibitor
DAP000605	Chlorothiazide	NCGC00091042-03; Minzil; Diuril, Chlotride, Chlorothiazide; NINDS_000675; CAS-58-94-6; Diuresal; CCRIS 5999; 6-chloro-4H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; Lopac-C-4911; Urinex; Prestwick0_000251; SPECTRUM1500180; HMS2091C18; CID2720; NCGC00015242-05; BRD-K88682005-001-05-9; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-, 1,1-dioxide; BIDD:GT0635; SPBio_002281; Chlorurit; KBioGR_000780; Chlorothiazid; KBio2_005730; S1641_Selleck; CHEMBL842; Diurite; Chlotride; C7H6ClN3O4S2; C 4911; Salunil; KBioSS_000594; Chlrosal; LS-244; CPD000058429; Diuril; NSC 25693; C07461; Prestwick2_000251; Spectrum4_000280; Aldoclor; NCGC00091042-02; Diutrid; C2259; Prestwick3_000251; HSDB 3030; Saluretil; Flumen; WLN: T66 BSWM ENJ HG ISZW; Diuril Boluses; Spectrum5_001446; Chloriazid; SAM002554891; IDI1_000675; Spectrum3_000342; 6-Chloro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-7-sulfamoyl-2H-1,2,4-benzothiadiazine 1,1-dioxide; Clorotiazida; AC-18732; Diurilix; Spectrum_000134; HMS1568D04; Yadalan; NCGC00015242-01; Thiazide; C4911_SIGMA; I06-2278; SMR000058429; Alurene; Neo-Dema; Chlorothiazide (JAN/USP/INN); Clotride; 6-Chloro-7-sulfamoyl-2H-1,2,4-benzothiadiazine 1,1-dioxide; Chlorthiazidum; Chlorthiazid; NSC25693; HMS502B17; Lopac0_000254; NCGC00015242-09; EU-0100254; Chlortiazid; Clorotiazide [DCIT]; KBio2_003162; Chlorthiazide; Prestwick_56; Warduzide; Prestwick1_000251; Clorotiazida [INN-Spanish]; EINECS 200-404-9; MolPort-003-845-912; component of Aldoclor; Clorotiazide; NCGC00091042-05; Chlorothiazidum; Chlorothiazide [USAN:INN:BAN]; NCGC00015242-02; chlorotiazida; Diupres; DivK1c_000675; UNII-77W477J15H; AC1L1EBB; SPBio_000288; Diuril (TN); Chlorothiazidum [INN-Latin]; BPBio1_000070; D00519; MLS000028398; BSPBio_000062; CHEBI:3640; NCGC00091042-01; Chlorosal; Salisan; Diuril Boluses, Veterinary; BSPBio_002003; MolPort-003-666-143; KBio1_000675; D002740; 6-Chloro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; Spectrum2_000154; Sk-chlorothiazide; KBio2_000594; chlorothiazide; NCGC00015242-03; Saluric; NCGC00091042-04; 58-94-6; KBio3_001223; HMS1920K15; DB00880	58-94-6	2720	9664	TTDS00306	Carbonic anhydrase II	CA-II;Carbonate dehydratase II;Carbonic anhydrase C	P00918	760	ENSG00000104267	inhibitor
DAP000775	Dorzolamide	AB00514687; BRD-K48617017-003-03-1; dorzolamide; 120279-96-1; (4S,6S)-4-(ethylamino)-6-methyl-7,7-dioxo-5,6-dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide; SPBio_003116; BIDD:GT0306; (4S-TRANS)-4-(ETHYLAMINO)-5,6-DIHYDRO-6-METHYL-4H-THIENO(2,3-B)THIOPYRAN-2-SULFONAMIDE-7,7-DIOXIDE; Prestwick2_001116; Trusopt (TN); Prestwick3_001116; Trusopt; MolPort-005-941-739; HMS2089O06; 1cil; (4S,6S)-4-(ethylamino)-6-methyl-5,6-dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide 7,7-dioxide; C06969; Prestwick1_001116; Dorzolamide (DZA); AC1NR4NP; Prestwick0_001116; DB04507; BPBio1_001377; CID5284549; (4S,trans)-4-(ethylamino)-6-methyl-5,6-dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide 7,7-dioxide; BSPBio_001252; STK645522; Dorzolamide (INN); CHEBI:4702; (4S,6S)-4-Ethylamino-6-methyl-7,7-dioxo-4,5,6,7-tetrahydro-7lambda*6*-thieno[2,3-b]thiopyran-2-sulfonic acid amide; CHEMBL218490; D07871	120279-96-1	3154	9183	TTDS00306	Carbonic anhydrase II	CA-II;Carbonate dehydratase II;Carbonic anhydrase C	P00918	760	ENSG00000104267	inhibitor
DAP000603	Benzthiazide	Pro-aqua; C07759; 6-chloro-3-{[(phenylmethyl)thio]methyl}-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; Urazide; Pfizer 1393; S-Aqua; Proaqua; Benzthazide; HSDB 3296; Diucen; Fovane; Spectrum4_000250; Rid-ema; NCGC00094599-01; Aquapres; Exna (TN); AC1L1DGU; Hy-drine; NCGC00016347-01; Diucene; Exna; CID2343; SPECTRUM1500141; Prestwick0_000824; Benztiazide; CHEBI:3047; Benzothiazide; Benztiazide [DCIT]; Spectrum5_000882; Regulon; KBio1_000491; Prestwick3_000824; P 1393; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3-(((phenylmethyl)thio)methyl)-, 1,1-dioxide; 91-33-8; 3-((Benzylthio)methyl)-6-chloro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; Lemazide; HMS1570F09; NINDS_000491; Aquatag; 6-Chloro-3-(((phenylmethyl)thio)methyl)-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3-[[(phenylmethyl)thio]methyl]-, 1,1-dioxide; EINECS 202-061-0; benzthiazide; KBioSS_000476; SPBio_001061; BSPBio_001910; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3-((benzylthio)methyl)-6-chloro-, 1,1-dioxide; 3-((Benzylthio)methyl)-6-chloro-2H-1,2,4-benzothiadiazine-7-sulfonamide1,1-dioxide; KBio2_005612; NCGC00016347-02; B7149_SIGMA; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3-((benzylthio)menthyl)-6-chloro-, 1,1-dioxide; DB00562; Spectrum3_000315; IDI1_000491; C15H14ClN3O4S3; 3-[(Benzylsulfanyl)methyl]-6-chloro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 3-((Benzylthio)methyl)-6-chloro-7-sulfamoyl-2H-benzo-1,2,4-thiadiazine-1,1-dioxide; LS-40432; D00651; KBio2_000476; Spectrum2_001141; Aquasec; SMR000058805; 3-(benzylsulfanylmethyl)-6-chloro-1,1-dioxo-4H-1; Prestwick_993; Prestwick2_000824; 3-Benzylthiomethyl-6-chloro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; HyDrine; 6-Chloro-7-sulfamoyl-3-benzylthiomethyl-2H-1,2,4-benzothiadiazine 1,1-dioxide; CHEMBL1201039; KBio3_001410; CAS-91-33-8; Exosalt; AR-1H9302; DivK1c_000491; SPBio_002668; MolPort-003-666-130; Dihydrex; KBio2_003044; Urese; B7149_ALDRICH; HMS2091M13; Edemex; 3-Benzylthiomethyl-6-chloro-7-sulfamoyl-1,2,4-benzothiadiazine 1,1-dioxide; UNII-1TD8J48L61; Fouane; 3-((Benzylthio)methyl)-6-chloro-7-sulfamoyl-2H-benzo-1,2,4-thiadiazine 1,1-dioxide; Benzthiazide (JAN/INN); ST51014925; Benzotiazida [INN-Spanish]; NCGC00094599-02; Benzthiazidum [INN-Latin]; Spectrum_000076; BSPBio_000747; HMS501I13; HMS1920G11; Benzthiazidum; MLS000069562; Prestwick1_000824; BRD-K21450440-001-05-4; 6-chloro-1,1-dioxo-3-(phenylmethylsulfanylmethyl)-4H-benzo[e][1,2,4]thiadiazine-7-sulfonamide; BPBio1_000823; Benzthiazide [USAN:INN:BAN]; Aqua-Scrip; MolPort-003-940-508; KBioGR_000660; Benzotiazida; Freeuril; AC1Q6TPO	91-33-8	2343	9961	TTDS00306	Carbonic anhydrase II	CA-II;Carbonate dehydratase II;Carbonic anhydrase C	P00918	760	ENSG00000104267	inhibitor
DAP000205	Metformin	BRD-K79602928-003-04-1; Fluamine; N,N-Dimethyldiguanide; KBioGR_002310; ZINC12859773; Metforminum; SPBio_001928; KBioSS_002312; NCGC00016564-01; Imidodicarbonimidic diamide-, N,N-dimethyl-; N,N-Dimethylbiguanide; T5895664; Metformine [INN-French]; AKOS000121065; Nu-Metformin; Metformin [USAN:INN:BAN]; S2483_Selleck; DMGG; EINECS 211-517-8; Prestwick2_000004; Dimethyldiguanide; BIDD:GT0697; LS-43899; Metformine; Islotin; MolPort-004-288-389; Diabetosan; metformin; STK011633; CID4091; LA-6023; 1,1-Dimethylbiguanide; KBio2_007446; 3-(diaminomethylidene)-1,1-dimethylguanidine; cMAP_000016; Siofor; Glumetza; Metformin (USAN/INN); Prestwick1_000004; NNDG; NCGC00016564-02; Gliguanid; C4H11N5; BPBio1_000009; Flumamine; AC1L1HE4; Melbin; Imidodicarbonimidic diamide, N,N-dimethyl-; N,N-dimethylimidodicarbonimidic diamide; KBio2_002310; BSPBio_000007; HMS2089D19; NCGC00016564-03; CHEMBL1431; Glycon; 657-24-9; Gen-Metformin; Metformina; Prestwick3_000004; D04966; HSCI1_000295; Metiguanide; N1,N1-Dimethylbiguanide; Haurymelin; KBio3_002790; MolPort-002-929-560; KBio2_004878; BIGUANIDE, 1,1-DIMETHYL-; Glifage; UNII-9100L32L2N; Dimethylbiguanide; 1,1-Dimethyl biguanide; Metformina [Spanish]; Dimethylbiguanidine; Diabex; CAS-1115-70-4; MolPort-005-767-418; CCRIS 9321; Dimethylguanylguanidine; BSPBio_002314; Metforminum [INN-Latin]; Prestwick0_000004; C07151; CHEBI:6801; DB00331; Metformina [DCIT]	657-24-9	4091	9360	TTDS00357	Acetyl-CoA carboxylase 2	ACC2;ACCbeta;ACC-beta;Acetyl CoA carboxylase beta;Acetyl-Coenzyme A carboxylase beta	O00763	32	ENSG00000076555	activator
DCL000946	R-788	945745-48-2; 2H-Pyrido(3,2-b)-1,4-oxazin-3(4H)-one, 6-((5-fluoro-2-((3,4,5-trimethoxyphenyl)amino)-4-pyrimidinyl)amino)-2,2-dimethyl-4-((phosphonooxy)methyl)-; R 788	N/A	N/A	N/A	TTDC00156	Tyrosine-protein kinase SYK	Spleen tyrosine kinase	P43405	6850	ENSG00000165025	inhibitor
DCL000208	R343	N/A	150770-63-1	16129690	40663486	TTDC00156	Tyrosine-protein kinase SYK	Spleen tyrosine kinase	P43405	6850	ENSG00000165025	inhibitor
DCL000211	R788	N/A	8025-81-8	N/A	47207566	TTDC00156	Tyrosine-protein kinase SYK	Spleen tyrosine kinase	P43405	6850	ENSG00000165025	inhibitor
DAP000113	Filgrastim	N/A	143011-72-7	5282515	46505833	TTDS00411	Macrophage colony-stimulating factor receptor	CD115;c-fms;CSF1R;CSF-1-R;FMS;Fms proto-oncogene	Q99062	1441	ENSG00000119535	binder
DAP000395	Pegfilgrastim	Neulasta (TN); 208265-92-3; D06889; Pegfilgrastim (INN); Neulasta; Pegfilgrastim	208265-92-3	N/A	49661789	TTDS00411	Macrophage colony-stimulating factor receptor	CD115;c-fms;CSF1R;CSF-1-R;FMS;Fms proto-oncogene	Q99062	1441	ENSG00000119535	binder
DCL000271	Arbidol	1-methyl-2-((phenylthio)methyl)-3-carbethoxy-4-((dimethylamino)methyl)-5-hydroxy-6-bromindole hydrochloride; SMR000413980; MC-101; 131707-25-0; CID131410; 1H-Indole-3-carboxylic acid, 6-bromo-4-((dimethylamino)methyl)-5-hydroxy-1-methyl-2-((phenylthio)methyl)-, ethyl ester, monohydrochloride, hydrate; A1957/0082320; MolPort-002-322-540; ethyl 6-bromo-4-[(dimethylamino)methyl]-5-hydroxy-1-methyl-2-[(phenylsulfanyl)methyl]-1H-indole-3-carboxylate; AC1L2Z4R; AC1L2Z4U; TL80090957; 1H-Indole-3-carboxylic acid, 6-bromo-4-((dimethylamino)methyl)-5-hydroxy-1-methyl-2-((phenylthio)methyl)-, ethyl ester, moonohydrochloride; LS-82546; 1H-Indole-3-carboxylic acid, 6-bromo-4-((dimethylamino)methyl)-5-hydroxy-1-methyl-2-((phenylthio)methyl)-, ethyl ester; MolPort-000-271-936; arbidole; 6-Bromo-4-dimethylaminomethyl-5-hydroxy-1-methyl-2-phenylsulfanylmethyl-1H-indole-3-carboxylic  acid ethyl ester; Oprea1_482224; AC1Q25HS; CHEMBL1214598; CID 131410; Arbidol; STK021887; STOCK1S-19879; ethyl 6-bromo-4-(dimethylaminomethyl)-5-hydroxy-1-methyl-2-(phenylsulfanylmethyl)indole-3-carboxylate; AKOS001485435; AC-1622; 6-Bromo-5-hydroxy-4-methylaminomethyl-1-methyl-2-benzenesulfenylmethylindole-3-ethyl carboxylate; AR-1I9514; Oprea1_384852; ChemDiv1_000732; CID131411; ethyl 6-bromo-4-(dimethylaminomethyl)-5-hydroxy-1-methyl-2-(phenylsulfanylmethyl)indole-3-carboxylate hydrate hydrochloride; MLS000777586; HMS589B06; C22H25BrN2O3S.HCl.H2O; 131707-23-8; AKOS005064143	N/A	131411	24715633	TTDC00002	Hemagglutinin	HA;Hemagglutinin HA1 chain;Hemagglutinin HA2 chain	P03437	N/A	N/A	inhibitor
DCL000087	Cilansetron	Cilansetron (USAN/INN); 120635-74-7; DU-123265; D03495; CID6918107; Cilansetron; Calmactin; KC-9946	120635-74-7	6918107	17397631	TTDC00009	5-hydroxy-tryptamine 3B receptor	5-HT3B;5-HT-3B;5-hydroxytryptamine receptor 3B;HTR3B;Serotonin receptor 3B	O95264	9177	ENSG00000149305	antagonist
DAP001142	Prothionamide	MLS001201789; EINECS 238-093-7; MolPort-000-159-776; Protionamide (INN); HMS2090J11; RP 9778; 2-Propyl-thioisonicotinamide; KBio3_002911; NCGC00095164-02; I06-0623; STK366469; AC1LDFXW; AC-4518; UNII-76YOO33643; LS-84822; NCGC00095164-03; Trevintix (TN); MLS000042521; HMS1922D06; 1321 TH; Protionamidum; Spectrum3_001964; SPECTRUM1505316; Isonicotinamide, 2-propylthio-; ZINC03874803; Protionamide [INN:DCF]; SPBio_000057; Spectrum2_000019; 2-Propylthioisonicotinamide; Protionizina; Prothionamide (JP15); TH-1321; 5-22-02-00376 (Beilstein Handbook Reference); 14222-60-7; 2-Propylisonicotinylthioamide; BSPBio_003564; Prothionamidum; BRN 0118164; Tebeform; 9778 R.P.; 9778 R.P; SMR000047660; Protionamidum [INN-Latin]; Tuberex; Peteha; Protionamida; 4-Pyridinecarbothioamide, 2-propyl-; TH 1321; C9H12N2S; BB_SC-2027; Ektebin; 2-propylpyridine-4-carbothioamide; CID666418; Protionamid; 2-Propyl-4-thiocarbamoylpyridine; 2-Propyl-4-pyridinecarbothioamide; NCGC00095164-01; Protionamida [INN-Spanish]; D01195; 4-Pyridinecarbothioamide, 2-propyl- (9CI); prothionamide; Trevintix; Protionamide	14222-60-7	666418	50600489	TTDS00384	Enoyl-[acyl-carrier-protein] reductase [NADH]	InhA;NADH-dependent enoyl-ACP reductase	P46533	N/A	N/A	inhibitor
DAP000011	Isoniazid	Isoniton; Cortinazine; Spectrum2_000107; Zidafimia; isoco tin; Isonizide; In-73; Raumanon; Tyvid; Isobicina; KBio2_006469; Continazine; Mybasan; Hyozid; Tibemid; Hydra; CCRIS 351; TB-Razide; KBio3_001424; NCGC00022648-05; Isoniazid & Propolis; HMS2089I16; Niadrin; Rimiphone; KBio2_001333; Ebidene; Nitadon; Dinacrin; isozid e; I3377_SIGMA; Unicocyde; INHd20; AC1L1GNZ; AC1Q54UQ; Rimitsid; Sauterazid; Chemiazid; KBio2_003901; CAS-54-85-3; TB-Phlogin; Prestwick0_000161; 41466-07-3; HIA; Isoniazid SA; Zonazide; Inh-Burgthal; FSR-3; Prestwick_578; Antituberkulosum; Hidrulta; Nicozide; Isocidene; NSC 9659; LANIZID; Evalon; Tibiazide; MLS001055327; Dow-Isoniazid; Nyscozid; Spectrum4_000022; Pyrizidin; Tibusan; Isoniazid & EEP; Isonizida; Isotebe; BSPBio_000021; Tibizide; AKOS000119062; Isonico; Anidrasona; nchembio884-comp3; BPBio1_000025; Isonikazid; TB-Vis; Tibinide; AZT + Isoniazid; nidra zid; Hid rasonil; Atcotibine; Isonicotinhydrazid; Neoxin; Neoteben; Phthisen; Preparation 6424; WLN: T6NJ DVMZ; Eutizon; FSR 3; I0138; tubercid; SPECTRUM1500355; Nikozid; C07054; Defonin; Nicizina; Percin; Isonerit; Tekazin; Hidrun; NINDS_000070; Tebecid; HMS500D12; KBioGR_000423; 7640-37-1; Vederon; Isohydrazide; Niteban; NSC9659; Tebilon; Tubizid; rimif on; AC1Q54UP; Hydrazid; Isotinyl; DB00951; Armazide; Isoniazida; Tibison; 5015 RP; Nicotisan; Fetefu; BP 5015; Laniazid; RP 5015; STK086288; Tubazide; BPBio1_001322; Nicazide; Sauterzid; Isoniazide; Isonicotan; Niconyl; Prestwick3_000161; Rimicid; D00346; Ismazide; Isonirit; Isokin; Isonex; Cemidon; HMS1920H09; Isonicotinohydrazide; KBio1_000070; NCGC00016244-01; Isolyn; Isonide; Pyridicin; I.A.I.; Abdizide; Cotinizin; Tisin; NCGC00022648-04; Robiselin; Tisiodrazida; HSDB 1647; Isotamine; Tubecotubercid; AI3-23936; Andrazide; Laniozid; 37271-10-6; Prestwick1_000161; Isoniacid; D007538; Retozide; Pyreazid; Cotinazin; Hydrazide; AB00052025; HMS1568B03; Tibazide; CHEBI:6030; I.A.I; Prestwick2_000161; BB_SC-6246; Armacide; Teebaconin; Isozyd; Spectrum5_000876; Ido-tebin; UNII-V83O1VOZ8L; tebemid; MLS000069444; SPBio_000094; Idrazil; EINECS 200-214-6; Isocotin; C6H7N3O; Tubilysin; Nidaton; SAM002554904; Dibutin; Vazadrine; Diforin; ZINC00001590; Razide; RY-EF-Tb; Tebenic; Chemidon; Isocid; LS-205; NCGC00016244-02; Isonidrin; bacillen; Ertuban; Pycazide; 5015 R.P.; Nicotibine; Usaf cb-2; INH; Nicotibina; Isozide; RU-EF-Tb; Roxifen; Azuren; Oprea1_396155; Nitebannsc 9659; CID3767; NCGC00022648-03; Inah; Cedin (Aerosol); Pelazid; Nicetal; CHEMBL64; Rimifon; 5015 R.P; Ditubin; CPD000059082; Stanozide; Tubazid; Laniazid (TN); SMR000059082; Fimalene; I14-9731; Zinadon; Iscotin; Tubeco; Tubicon; Hidranizil; Nevin; Sanohidrazina; Eralon; Spectrum_000853; Tebexin; Nidrazid; Cedin; Isoniazidum; Isidrina; 54-85-3; Hycozid; Hidrasonil; Isonilex; Isonicotil; Neo-Tizide; L 1945; bp 5 015; BSPBio_002204; Tubomel; isoniazid; Pyricidin; FRS-3; Armazid; SPBio_001942; GINK; Isonin; Hyzyd; Tuberian; Isonicazide; Biomol-NT_000288; 62229-51-0; HMS2091N19; Isonindon; Neumandin; Bacillin; IDI1_000070; Tebos; I3377_FLUKA; Tizide; Isotebezid; Unicozyde; S1937_Selleck; MolPort-000-141-557; Spectrum3_000472; NCGC00022648-06; Tibivis; Inizid; Robisellin; DivK1c_000070; Niplen; BIDD:GT0140; Antimicina; Isonicid; Nydrazid; RP-5015; Isozid; KBioSS_001333	54-85-3	3767	9266	TTDS00384	Enoyl-[acyl-carrier-protein] reductase [NADH]	InhA;NADH-dependent enoyl-ACP reductase	P46533	N/A	N/A	inhibitor
DAP001141	Ethionamide	1314-Th; NCGC00091074-02; Tuberoid; Prestwick1_000526; Isonicotinamide, 2-ethylthio-; SPBio_002432; HMS1920M22; alpha-Ethylisothionicotinamide; 2-Ethylisothionicotinamide; Prestwick3_000526; 2-Ethylthioisonicotinamide; WLN: T6NJ B2 DYZUS; SAM002554899; Prestwick2_000526; DivK1c_000145; Spectrum3_000428; 1314 TN; Nisotin; NCGC00016497-01; Tiomid; D00591; SMR001370750; BPBio1_000563; E0695; SPBio_001087; Aethionamidum; CPD001370750; NCGC00091074-03; Fatoliamid; Tuberoson; 2-ethylisonicotinic acid thiomide; 2-ethyl-4-aminothiocarbonylpyridine; Trecator SC; Aetiva; Amidazine; Etionamida; NCI-C01694; 536-33-4; Etionamide [DCIT]; Trecator-SC; .alpha.-Ethyl-thioisonicotinamide; 2-Ethylisonicotinothioamide; Etiocidan; 3-Ethylisothionicotinamide; Trekator; 2-Ethylisonicotinic thioamide; C8H10N2S; Isothin; 2-e thylisothionicotinamide; Rigenicid; Iridozin; 2-ETHYL-4-PYRIDINECARBOTHIOAMIDE; Ethina (VAN); .alpha.-Ethylisonicotinoylthioamide; Isotiamida; C07665; HMS2091F03; Ethyonomide; HSDB 7473; Tubenamide; Thianide; .alpha.-Ethylthioisonicotinamide; 1314 TH; S1777_Selleck; Etionamid; alpha-Ethylisonicotinoylthioamide; MolPort-000-159-777; Ethylisothiamide; CID2761171; MLS002454402; CAS-536-33-4; SPECTRUM1500292; Trescatyl; HMS1569J13; Thiomid; Etionizine; Atina; Etionamida [INN-Spanish]; 2-Ethyl-thioisonicotinamide; Etionizin; NCGC00091074-01; alpha-Ethylthioisonicotinamide; AC1MC4CB; Nicotion; BSPBio_002016; Ethionamidum; .alpha.-Ethylisothionicotinamide; Ethionamid prothionamid; Prestwick_842; Tubermin; KBio3_001236; NSC255115; Trecator; 2-Ethylisonicotinic acid thioamide; AB00051990; .alpha.-Ethylisonicotinic acid thioamide; Thioamide; Ethionamide (JP15/USP/INN); Etionid; MLS001074114; UNII-OAY8ORS3CQ; E6005_SIGMA; Ethimide; 2-Ethyl-4-thiocarbamoylpyridine; Iridocin Bayer; SMR000058716; Bayer5312; Tianid; Spectrum5_000979; SBB055548; Isonicotinimidic acid, 2-ethylthio-; alpha-ethylt hioisonicotinamide; DB00609; D005000; NSC 255115; CHEMBL1441; alpha-Ethylisonicotinic acid thioamide; TH 1314; Spectrum_001082; Bayer 5312; Amidazin; KBioSS_001562; CHEBI:4885; NINDS_000145; 2-ethylthioisonicotinamide, Trecator SC, Amidazine, Ethionamide; Wyeth Brand of Ethionamide; 1314TH; IDI1_000145; Trecator-SC (TN); Iridocin; KBioGR_001213; 2-Ethylisonicotinoylthioamide; Ethionamidum [INN-Latin]; Etionamide; BRD-K33710385-001-05-4; Sertinon; ethionamide; HMS500H07; Thianid; Aetina; NCGC00091074-04; Prestwick0_000526; AEOCXXJPGCBFJA-UHFFFAOYSA-; MLS000069764; Ethionamide [USAN:INN:BAN:JAN]; BSPBio_000511; Ethatyl; KBio2_004130; AC-13715; BRN 0116474; Thioniden; KBio2_006698; 4-Pyridinecarbothioamide, 2-ethyl-; KBio1_000145; ZINC03872520; Itiocide; InChI=1/C8H10N2S/c1-2-7-5-6(8(9)11)3-4-10-7/h3-5H,2H2,1H3,(H2,9,11); Trescazide; Teberus; LS-199; 2-ethylpyridine-4-carbothioamide; Etioniamid; Nizotin; Spectrum2_000994; Ethioniamide; Spectrum4_000547; 2-Ethyl-4-thioamidylpyridine; Ethina; KBio2_001562; F.I. 58-30; :ethionamide; Etimid; EINECS 208-628-9; Ethinamide; Etionizina; 5-22-02-00360 (Beilstein Handbook Reference); CCRIS 287; Tio-Mid	536-33-4	2761171	9867	TTDS00384	Enoyl-[acyl-carrier-protein] reductase [NADH]	InhA;NADH-dependent enoyl-ACP reductase	P46533	N/A	N/A	inhibitor
DPR000089	PCSK9 inhibitor	N/A	N/A	N/A	N/A	TTDR01164	Proprotein convertase subtilisin/kexin type 9	NARC-1;Neural apoptosis-regulated convertase 1;Proprotein convertase PC9;Subtilisin/kexin-like protease PC9	Q8NBP7	255738	ENSG00000169174	inhibitor
DPR000012	ALN-PCS01	N/A	N/A	N/A	N/A	TTDR01164	Proprotein convertase subtilisin/kexin type 9	NARC-1;Neural apoptosis-regulated convertase 1;Proprotein convertase PC9;Subtilisin/kexin-like protease PC9	Q8NBP7	255738	ENSG00000169174	inhibitor
DCL001244	SPC5001	N/A	N/A	N/A	N/A	TTDR01164	Proprotein convertase subtilisin/kexin type 9	NARC-1;Neural apoptosis-regulated convertase 1;Proprotein convertase PC9;Subtilisin/kexin-like protease PC9	Q8NBP7	255738	ENSG00000169174	inhibitor
DCL000689	Alphagen	N/A	140850-73-3	6438340	47206350	TTDS00285	Alpha-1-antitrypsin	Alpha-1 protease inhibitor;Alpha-1-antiproteinase;Alpha1-proteinase;PRO0684/PRO2209	P01009	5265	ENSG00000197249	modulator
DAP001560	Alpha1-proteinase inhibitor	N/A	N/A	N/A	N/A	TTDS00285	Alpha-1-antitrypsin	Alpha-1 protease inhibitor;Alpha-1-antiproteinase;Alpha1-proteinase;PRO0684/PRO2209	P01009	5265	ENSG00000197249	inhibitor
DAP001439	Zemaira	N/A	9041-92-3	N/A	57288482	TTDS00285	Alpha-1-antitrypsin	Alpha-1 protease inhibitor;Alpha-1-antiproteinase;Alpha1-proteinase;PRO0684/PRO2209	P01009	5265	ENSG00000197249	inhibitor
DAP001247	Propylthiouracil	thyreos tat ii; Propylthiouracilum [INN-Latin]; PROPYL THIOURACIL; KBioSS_001356; NCGC00022715-03; BRD-K48168960-001-04-4; 51-52-5; 2-Thio-6-propyl-1,3-pyrimidin-4-one; 46698_RIEDEL; Propiltiouracile [DCIT]; NCGC00016229-02; HMS1766D22; 6-N-Propylthiouracil; 6-propyl-2-sulfanylidene-2,3-dihydropyrimidin-4(1H)-one; NINDS_000268; Propiltiouracilo [INN-Spanish]; BRD-K48168960-001-05-1; 6-Propil-tiouracile; Propycil; KBio2_006492; Propylthiorit; Propyl-Thyracil; PTU (thyreostatic); 6-Propil-tiouracile [Italian]; 2-Mercapto-6-propylpyrimidin-4-ol; HMS2092E03; LS-158; HC210060; Propylthiouracil (JP15/USP/INN); NCGC00090881-01; Propilthiouracil; Spectrum2_001302; WLN: T6MYMVJ BUS F3; Spectrum_000876; BSPBio_000387; 6-Propyl-2-thio-2,4(1H,3H)pyrimidinedione; Prothiucil; 6-Propyl-2-thiouracil; HMS500N10; MLS000028494; EINECS 200-103-2; Propiltiouracilo; MolPort-000-664-275; DivK1c_000268; KBio2_003924; MLS002303010; HMS1569D09; Prothycil; AKOS000120319; 6-propyl-2-thiopyrimidine-2,4(1H,3H)-dione; 2,3-Dihydro-6-propyl-2-thioxo-4(1H)-pyrimidinone; Prestwick3_000494; NCGC00183321-01; NCGC00090881-02; 6 Propyl 2 Thiouracil; HMS1920L22; thyreostat propyl-thyracil; AKOS001053246; Spectrum5_001815; Propylthiouracile; CID657298; D00562; NSC70461; NCGC00016229-01; ZINC18213075; D011441; CHEMBL1518; IDI1_000268; MolPort-000-145-889; 6-(n-Propyl)-2-thiouracil; 6-Propyl-2-thio-2,4(1H,3H)-pyrimidinedione; Uracil, 6-propyl-2-thio-; 2-Mercapto-6-propyl-4-pyrimidone; BPBio1_000427; T0517-6237; Propylthiouracil [INN:BAN:JAN]; 2-Thio-4-oxo-6-propyl-1,3-pyrimidine; CPD000058275; NCGC00090881-03; S1988_Selleck; DB00550; C7H10N2OS; F3097-4245; Propylthiouracilum; 2-Mercapto-6-propylpyrimid-4-one; I03-0144; 46698_FLUKA; 4-Hydroxy-2-mercapto-6-propylpyrimidine; KBioGR_001003; Propylthiouracile [INN-French]; AI3-25477; SAM002554926; propylthiouracil; NSC6498; 4-Propyl-2-thiouracil; Thyreostat II; Propacil; SPBio_002308; CAS-51-52-5; NSC 6498; Propythiouracil; SBB003855; AC-10795; MolPort-004-414-251; Prestwick0_000494; Propyl-Thiorit; Protiural; 6-Prop yl-2-thiouracil; Propyl-Thiorist; SPECTRUM1500515; C07569; ptu(thyreostatic); UNII-721M9407IY; CHEBI:8502; 6-propyl-2-sulfanylidene-1H-pyrimidin-4-one; Prestwick1_000494; CPD-11429; KBio3_002622; InChI=1/C7H10N2OS/c1-2-3-5-4-6(10)9-7(11)8-5/h4H,2-3H2,1H3,(H2,8,9,10,11; 500-50-5; 6-n-PROPYL-2-MERCAPTO-4-HYDROXYPYRIMIDINE; 2-Mercapto-4-hydroxy-6-n-propylpyrimidine; 6-Propylthiouracil; KBio2_001356; Prestwick2_000494; Spectrum3_001731; 6-Thio-4-propyluracil; Prestwick_810; Propiltiouracile; P3755_SIGMA; P0533; 6-propyl-2-thioxo-2,3-dihydropyrimidin-4(1H)-one; Propylthiouracil (TN); SMR000058275; Prothyran; KBio1_000268; 4(1H)-Pyrimidinone, 2,3-dihydro-6-propyl-2-thioxo-; NCGC00178089-01; 6-propyl-2 thiouracil; AC1LCWBA; SPBio_001363; 6-N-Propyl-2-thiouracil; Prothiurone; CCRIS 544; HSDB 3390; Spectrum4_000492; NCGC00178089-02; Thiuragyl; BSPBio_003402; ZINC04640636; Procasil	51-52-5	657298	9772	TTDS00426	Type I iodothyronine deiodinase	5DI;DIO1;DIOI;ITDI1;TXDI1;Type 1 DI;Type-I 5'-deiodinase	P49895	1733	ENSG00000211452	inhibitor
DPR000170	ANAVEX 1007	N/A	N/A	N/A	N/A	TTDR01435	Sigma 2-type opioid receptor	N/A	N/A	N/A	N/A	agonist
DCL000131	Icatibant	WIN 65365; AC1Q5QRX; 130308-48-4; HOE 140; (2S)-2-[[(3aS,7aS)-1-[2-[(2S)-2-[[(2S)-2-[[2-[[(4R)-1-[1-[2-[[(2R)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]-4-hydroxypyrrolidine-2-carbonyl]amino]acetyl]amino]-3-thiophen-2-ylpropanoyl]amino]-3-hydroxypropanoyl]-3,4-dihydro-1H-isoquinoline-3-carbonyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoic acid; JE049; AC1L2G0Q; L-Arginine, D-arginyl-L-arginyl-L-prolyl-trans-4-hydroxy-L-prolylglycyl-3-(2-thienyl)-L-alanyl-L-seryl-D-1,2,3,4-tetrahydro-3-isoquinolinecarbonyl-L-(2alpha,3abeta,7abeta)-octahydro-1H-indole-2-carbonyl-; DB06196; 13996-86-6; Firazyr; Icatibant; LS-172762; Hoe-140; HOE140; AR-1A3141; C59H89N19O13S; L-Arginine, D-arginyl-L-arginyl-L-prolyl-trans-4-hydroxy-L-prolylglycyl-3-(2-thienyl)-L-alanyl-L-seryl-L-1,2,3,4-tetrahydro-3-isoquinolinecarbonyl-L-(2alpha,3abeta,7abeta)-octahydro-1H-indole-2-carbonyl-; CHEMBL411169; WIN-65365; 138614-30-9 (acetate); CHEBI:163731; Icatibant [INN]; CID71364; KST-1A1301; 153322-84-0; (2s)-2-({[(3as,7as)-1-({2-[(2s)-2-{[(2s)-2-({[({(4r)-1-[(1-{2-({(2r)-2-amino-5-[(diaminomethylidene)amino]pentanoyl}amino)-5-[(diaminomethylidene)amino]pentanoyl}pyrrolidin-2-yl)carbonyl]-4-hydroxypyrrolidin-2-yl}carbonyl)amino]acetyl}amino)-3-(thiophen-2-yl)propanoyl]amino}-3-hydroxypropanoyl]-1,2,3,4-tetrahydroisoquinolin-3-yl}carbonyl)octahydro-1h-indol-2-yl]carbonyl}amino)-5-[(diaminomethylidene)amino]pentanoic acid(non-preferred name); D-Arg(Hyp(3)-Thi(5)-D-Tic(7)-Oic(8))BK	138614-30-9	71364	213595	TTDC00111	B2 bradykinin receptor	B2R;BK B(2) receptor;BK-2 receptor;Bradykinin B2 receptor	P30411	624	ENSG00000168398	antagonist
DCL000050	Anatibant	UNII-CLO4JRD21F; (2S)-N-(3-(4-Carbamimidoylbenzamido)propyl)-1-(2,4-dichloro-3-((2,4-dimethyl-8-quinolyloxy)methyl)phenylsulfonyl)pyrrolidine-2-carboxamide; Anatibant; 209733-45-9; MolPort-005-943-155; CID9831652; Anatibant [INN]	209733-45-9	3025957	3820043	TTDC00111	B2 bradykinin receptor	B2R;BK B(2) receptor;BK-2 receptor;Bradykinin B2 receptor	P30411	624	ENSG00000168398	antagonist
DCL000146	Labradimil	L024094; Lobradimil; AC1OCF8R; 139183-63-4; N2-((S)-2-(L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolylglycyl-3-(2-thienyl)-L-alanyl-L-seryl-L-prolinamido)-3-(p-methoxyphenyl)propyl)-L-arginine; DRG-0182; Cereport; 2-[[2-[[1-[2-[[2-[[2-[[1-[1-[2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]-4-hydroxypyrrolidine-2-carbonyl]amino]acetyl]amino]-3-thiophen-2-ylpropanoyl]amino]-3-hydroxypropanoyl]pyrrolidine-2-carbonyl]amino]-3-(4-methoxyphenyl)propyl]amino]-5-(diaminomethylideneamino)pentanoic acid; (2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[2-[[(2S,4R)-1-[(2S)-1-[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]-4-hydroxypyrrolidine-2-carbonyl]amino]acetyl]amino]-3-thiophen-2-ylpropanoyl]amino]-3-hydroxypropanoyl]pyrrolidine-2-carbonyl]amino]-3-(4-methoxyphenyl)propyl]amino]-5-(diaminomethylideneamino)pentanoic acid; L-Prolinamide, L-arginyl-L-prolyl-trans-4-hydroxy-L-prolyl-3-(2-thienyl)-L-alanylglycyl-L-seryl-N-(2-((4-((aminoiminomethyl)amino)-1-carboxybutyl)amino)-1-((4-methoxyphenyl)methyl)ethyl)-, (S-(R*,R*))-; NSC724318; CID64145; RMP-7; AC1L20JC; (S-(R*,R*))-L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolyl-3-(2-thienyl)-L-alanylglycyl-L-seryl-N-(2-((4-((aminoiminomethyl)amino)-1-carboxybutyl)amino)-1-((4-methoxyphenyl)methyl)ethyl)-L-prolinamide; L-Arginine, L-arginyl-L-prolyl-(4R)-4-hydroxy-L-prolyl-3-(2-thienyl)-L-alanylglycyl-L-seryl-L-prolyl-O-methyl-L-tyrosyl-psi(CH2-NH)-; Receptor mediated permeabilizer; RMP 7; 173220-35-4; Bradykinin, 3-(trans-4-hydroxy-L-proline)-5-(3-(2-thienyl)-L-alanine)-8-de-L-phenylalanine-9-(N2-(2-amino-3-(4-methoxyphenyl)propyl)-L-arginine)-, (S)-; Labradimil; CID6918284	N/A	64145	12014925	TTDC00111	B2 bradykinin receptor	B2R;BK B(2) receptor;BK-2 receptor;Bradykinin B2 receptor	P30411	624	ENSG00000168398	agonist
DCL000251	TM30339	N/A	N/A	N/A	N/A	TTDC00043	Neuropeptide Y receptor type 4	NPY4R;NPY4-R;Pancreatic polypeptide receptor 1;PP1;PPYR1	P50391	5540	ENSG00000204174; ENSG00000263039	agonist
DCL000250	TM30338	N/A	N/A	N/A	N/A	TTDC00043	Neuropeptide Y receptor type 4	NPY4R;NPY4-R;Pancreatic polypeptide receptor 1;PP1;PPYR1	P50391	5540	ENSG00000204174; ENSG00000263039	agonist
DCL000266	Zarnestra	(R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; AC1Q3OVC; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, (+)-; R115777; JAN; UNII-MAT637500A; D03720; 1x81; 192185-72-1; AR-1H0636; AR-1H0635; LS-187640; CCRIS 9329; Zarnestra, IND 58359, R115777, Tipifarnib; Tipifarnib; CHEMBL289228; Tipifarnib (USAN/INN); 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H )-quinolinone; S1453_Selleck; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE; CID159324; NSC-702818; AC1L4LN0; LS-184411; R-115777; Tipifarnib [USAN]; (R)-( )-R115777; Zarnestra; R 115777; LS-187005; R-11577	192185-72-1	159324	12015141	TTDC00065	Farnesyltransferase	CAAX farnesyltransferase;CAAX farnesyltransferase alpha subunit;FTase;FTase-alpha;GGTase-I-alpha;Protein farnesyltransferase alpha subunit;RAS proteins prenyltransferase;RAS proteins prenyltransferase alpha;Type I protein geranyl-geranyltransferase alpha subunit	Q8IHP6	N/A	N/A	inhibitor
DCL000152	Lonafarnib	1-Piperidinecarboxamide, 4-(2-(4-((11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo(5,6)cyclohepta(1,2-b)pyridin-11-yl)-1-piperidinyl)-2-oxoethyl)-; D04768; ( )4-(2-(4-(8-Chloro-3,10-dibromo-6,11-dihydro-5H-benzo(5,6)cyclohepta(1,2-b)pyridin-11-yl)-1-piperidinyl)-2-oxoethyl)-1-piperidinecarboxamide; Lonafarnib (USAN/INN); SCH-066336; Sch-66336; CHEMBL298734; Sarasar; Lonafarnib [USAN]; 1o5m; AC1L3WMQ; 1-Piperidinecarboxamide, 4(2-(4-(11R-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo(5,6)cyclohepta(1,2-b)pyridine-11-yl)-1-piperidinyl)-2-oxoethyl)-; NSC719467; Sch 66336; CID148195; (+)4-(2-(4-(8-chloro-3,10-dibromo-6,11-dihydro-5H-benzo(5,6)cyclohepta(1,2-b)pyridin-11-yl)-1-piperidinyl)-2-oxoethyl)-1-piperidinecarboxamide; AKOS005145760; (+)-4[2-[4-(8-Chloro-3,10-dibromo-6,11-dihydro-5H-benzo[5,6] cyclohepta[1,2-b]-pyridin-11(R)-yl-1-piperidinyl]-2-oxo-ethyl]-1-piperidinecarboxamide; Sch66336; C115354; LS-184039; Lonafarnib; 1-Piperidinecarboxamide, 4-(2-(4-((11R-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo(5,6)cyclohepta(1,2-b)pyridin-11-yl)-1-piperidinyl)-2-oxoethyl)-; UNII-IOW153004F; (+)-4-(2-(4-(11R)-3,10-Dibromo-8-chloro-6,11-dihydro-5H-benzo(5,6)cyclohepta(1,2-b)pyridin-11-yl)-piperidin-1-yl))-2-oxoethyl)-piperidine-1-carboxamide; 4-{2-[4-(3,10-DIBROMO-8-CHLORO-6,11-DIHYDRO-5H-BENZO[5,6]CYCLOHEPTA[1,2-B]PYRIDIN-11-YL)PIPERIDIN-1-YL]-2-OXOETHYL}PIPERIDINE-1-CARBOXAMIDE; 4-(2-(4-(8-Chloro-3,10-dibromo-6,11-dihydro-5H-benzo-(5,6)-cyclohepta(1,2-b)-pyridin-11(R)-yl)-1-piperidinyl)-2-oxo-ethyl)-1-piperidinecarboxamide; 193275-84-2	193275-84-2	148195	47206583	TTDC00065	Farnesyltransferase	CAAX farnesyltransferase;CAAX farnesyltransferase alpha subunit;FTase;FTase-alpha;GGTase-I-alpha;Protein farnesyltransferase alpha subunit;RAS proteins prenyltransferase;RAS proteins prenyltransferase alpha;Type I protein geranyl-geranyltransferase alpha subunit	Q8IHP6	N/A	N/A	inhibitor
DCL000091	CP-609,754	N/A	N/A	N/A	N/A	TTDC00065	Farnesyltransferase	CAAX farnesyltransferase;CAAX farnesyltransferase alpha subunit;FTase;FTase-alpha;GGTase-I-alpha;Protein farnesyltransferase alpha subunit;RAS proteins prenyltransferase;RAS proteins prenyltransferase alpha;Type I protein geranyl-geranyltransferase alpha subunit	Q8IHP6	N/A	N/A	inhibitor
DCL000061	AZD3409	N/A	102565-09-3	5487115	39472990	TTDC00065	Farnesyltransferase	CAAX farnesyltransferase;CAAX farnesyltransferase alpha subunit;FTase;FTase-alpha;GGTase-I-alpha;Protein farnesyltransferase alpha subunit;RAS proteins prenyltransferase;RAS proteins prenyltransferase alpha;Type I protein geranyl-geranyltransferase alpha subunit	Q8IHP6	N/A	N/A	inhibitor
DCL000073	BMS214662	ZINC03925649; 195987-41-8; MolPort-005-943-117; CID448545; (R)-1-((1H-imidazol-5-yl)methyl)-3-benzyl-4-(thiophen-2-ylsulfonyl)-2,3,4,5-tetrahydro-1H-benzo[e][1,4]diazepine-7-carbonitrile; AC1L9M2P; BMS-214662; (3R)-3-benzyl-1-(1H-imidazol-5-ylmethyl)-4-thiophen-2-ylsulfonyl-3,5-dihydro-2H-1,4-benzodiazepine-7-carbonitrile; nchembio.149-comp5; BMV; CHEBI:374775; BMS 214662; CHEMBL351706; 7-cyano-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine; 3-BENZYL-1-(1H-IMIDAZOL-4-YLMETHYL)-4-(THIEN-2-YLSULFONYL)-2,3,4,5-TETRAHYDRO-1H-1,4-BENZODIAZEPINE-7-CARBONITRILE	N/A	N/A	N/A	TTDC00065	Farnesyltransferase	CAAX farnesyltransferase;CAAX farnesyltransferase alpha subunit;FTase;FTase-alpha;GGTase-I-alpha;Protein farnesyltransferase alpha subunit;RAS proteins prenyltransferase;RAS proteins prenyltransferase alpha;Type I protein geranyl-geranyltransferase alpha subunit	Q8IHP6	N/A	N/A	inhibitor
DPR000074	MGluR2 agonist	N/A	N/A	N/A	N/A	TTDR00321	Metabotropic glutamate receptor 2	Glutamate receptor mGLU2;Group II metabotropic glutamate receptor;mGLUR2	Q14416	2912	ENSG00000164082	agonist
DCL001112	LY-544344	N/A	N/A	N/A	N/A	TTDR00321	Metabotropic glutamate receptor 2	Glutamate receptor mGLU2;Group II metabotropic glutamate receptor;mGLUR2	Q14416	2912	ENSG00000164082	agonist
DCL000423	AMG 108	N/A	209799-67-7	444499	49689710	TTDC00234	Interleukin-1 receptor, type II	Antigen CDw121b;IL-1R-2;IL-1R-beta;Interleukin 1 receptor type II	P27930	7850	ENSG00000115590	antagonist
DCL000868	Linaclotide	Linaclotide (USAN); D09355; 851199-59-2; UNII-N0TXR0XR5X; Linaclotide	851199-59-2	65351	48505939	TTDC00171	Guanylyl cyclase C	GCC;GC-C;HSTAR;Intestinal guanylate cyclase;STA receptor	P25092	2984	ENSG00000070019	activator
DCL000125	Guanilib	N/A	339177-26-3	N/A	47207035	TTDC00171	Guanylyl cyclase C	GCC;GC-C;HSTAR;Intestinal guanylate cyclase;STA receptor	P25092	2984	ENSG00000070019	activator
DCL000878	MD-1100	Linaclotide acetate (USAN); MM-416775; MD-1100; Linaclotide acetate; UNII-NSF067KU1M; D06612; 851199-60-5	N/A	N/A	N/A	TTDC00171	Guanylyl cyclase C	GCC;GC-C;HSTAR;Intestinal guanylate cyclase;STA receptor	P25092	2984	ENSG00000070019	activator
DAP000160	Levofloxacin	(3S)-9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid; Cravit Ophthalmic; SMR000466387; Ofloxacin S-(-)-form; LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER; RWJ-25213; LEVOFLOXACIN; Spectrum3_000995; R-Ofloxacin; DR3355; CCRIS 4073; HR-355; Volequin; (R)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid; DR-3355: L-isomer of ofloxacin; KBioGR_001605; SAM001246758; HMS1922J07; Oftaquix; Leroxacin; MolPort-002-885-835; LS-133260; Spectrum4_001123; Nofaxin; Spectrum_001719; (&#8722;)-Ofloxacin; MLS001165709; Cravit (TN); KBio3_001909; Floxacin; LFX; Levofloxacin tablet, suspension or intravenous; NCGC00178529-01; KBio2_007335; AC-7593; (-)-(S)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid; Aeroquin; C18H20FN3O4.H2O; 100986-85-4; (-)-Ofloxacin; C07660; Levox; KBio2_004767; Levoxacin; 28266_FLUKA; Levofloxacine; Floxel; CHEMBL33; 100986-86-5; MLS001423977; Levofloxacinum; KBioSS_002199; DR-3355; Mosardal; Spectrum5_001438; Levofloxacino [INN-Spanish]; C18H20FN3O4; (-)-(S)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyridol[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid hemihydrate; L0193; Levofloxacin [USAN:INN:JAN]; KBio2_002199; HMS2090O10; (-)-(S)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7Hpyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid hemihydrate; 28266_SIGMA; Levofloxacine [INN-French]; Iquix; Reskuin; BRD-K09471561-001-06-7; Levokacin; Lesacin; (R)-isomer; 7H-Pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid, 2,3-dihydro-9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-, (S)-; CID149096; 7H-Pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid, 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-, (3S)-; CPD000466387; 7H-Pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid, 2,3-dihydro-9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-, hemihydrate, (S)-; LS-171761; AC1L3YF8; Spectrum2_001676; HMS2051G04; (S)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid; Cravit; (S)-(-)-Ofloxacin; Levaquin; S1940_Selleck; SPBio_001891; Levofloxacinum [INN-Latin]; HMS2093E18; (S)-Ofloxacin; LVX; Levofloxacin (INN); MP-376; DR 3354; HR 355; BSPBio_002689; Quixin; MLS000759524; SPECTRUM1504260; Elequine; D08120; S-(-)-Ofloxacin; d-Levofloxacin; Ambap100986-85-4; DB01137; Tavanic; RWJ 25213-097; L-Ofloxacin; Levofloxacino; CCRIS 4074	100986-85-4	149096	195031	TTDS00080	DNA topoisomerase II	DNA gyrase;Topo II;Topoisomerase II;Type II topoisomerase enzyme	Q02880	7155	ENSG00000077097	inhibitor
DAP000057	Mitoxantrone	9,10-Anthracenedione, 1,4-dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]-; KBio3_002660; Mitoxanthrone; Misostol (TN); KBioGR_001531; 9,10-Anthracenedione, 1,4-dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl] amino]-; 70711-41-0 (acetate); SPBio_000756; BSPBio_000569; Dihydroxyanthraquinone; Spectrum4_000866; Mitoxantrone [INN]; 70945-62-9; Mitoxantrona; 9,10-Anthracenedione, 1,4-dihydroxy-5,8-bis((2-((2-hydroxyethyl)amino)ethyl)amino)-; 70476-82-3; NSC-279836; NSC-301739; Spectrum_001655; 1,4-Dihydroxy-5,8-bis[2-(2-hydroxyethylamino)ethylamino]anthracene-9,10-dione; BRD-K21680192-300-05-2; S2485_Selleck; 1,4-Bis(2-(2-hydroxyethylamino)ethyl)amino)-5,8-dihydroxyanthraquinone; MLS002703044; 70476-82-3 (hydrochloride); NCGC00015693-02; UNII-BZ114NVM5P; Mitoxantron; 1,4-Dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]-9,10-anthracenedione; DivK1c_000516; Lopac-M-6545; Mitoxantronum [INN-Latin]; Mitoxantrone (free base); 1,4-DIHYDROXY-5,8-BIS({2-[(2-HYDROXYETHYL)AMINO]ETHYL}AMINO)-9,10-ANTHRACENEDIONE; LS-20638; CAS-70476-82-3; ANTHRAQUINONE, 5,8-BIS((2-((2-HYDROXYETHYL)AMINO)ETHYL)AMINO)-1,4-DIHYDROXY-; Prestwick0_000385; C11195; Spectrum5_001205; NSC301739; Misostol; BIDD:PXR0181; KBio2_007271; SR-01000076001; VU0244399-2; SPBio_002490; DHAQ; MITOXANTRONE, Mitoxantrone Hydrochloride, Mitoxantrone dihydrochloride, MITOXANTHRONE HYDROCHLORIDE; NINDS_000516; CCRIS 7604; KBio1_000516; KBioSS_002135; NSC299195; NSC-299195; 70711-41-0; BPBio1_000627; NCI60_002276; IDI1_000516; HMS2090D05; SMR001549953; 1,4-Dihydroxy-5,8-bis(5-hydroxy-3-azapentylamino)anthrachinon; NSC-287836; Prestwick3_000385; CHEMBL58; AB00053716; NCGC00162251-01; AN-584/42007670; Spectrum2_000908; Mitozantrone; AC1L1HNY; MITOXANTRONE, 1,4-DIHYDROXY-5,8-BIS({2-[(2-HYDROXYETHYL)AMINO]ETHYL}AMINO)ANTHRA-9,10-QUINONE; DHAQ HCl; Prestwick2_000385; DHAD; Liposome Encapsulated Mitoxantrone (LEM); Mitoxantrona [INN-Spanish]; 1,4-Dihydroxy-5,8-bis(2-((2-hydroxyethyl)amino)ethylamino)-9,10-anthracenedione; Mitoxantrone (INN); NSC 279836; KBio2_002135; Lopac0_000779; DB01204; SR-01000076001-7; 2fum; 1,4-dihydroxy-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)anthra-9,10-quinone; D08224; 1,4-dihydroxy-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)anthracene-9,10-dione; Mitozantrone hydrochloride; BRN 2795126; NCI60_002535; NCGC00015693-04; CID4212; NSC279836; Prestwick1_000385; 9,10-Anthracenedione, 1,4-dihydroxy-5,8-bis((2-((2-hydroxyethyl)amino)ethyl)amino)- (9CI); MIX; MolPort-003-849-239; 65271-80-9; 5,8-Bis((2-((2-hydroxyethyl)amino)ethyl)amino)-1,4-dihydroxyanthraquinone; KBio2_004703; Novantrone(R) (mitoxantrone for injection concentrate); CHEBI:50729; 137635-96-2; STK631833; Spectrum3_001590; DHAQ (*Diacetate salt*); mitoxantrone; NChemBio.2007.10-comp17; SMP2_000179; Mitoxantrone 2HCl; Neuro_000153; BRD-K21680192-300-07-8; NSC-301739D; BSPBio_003160; NCGC00015693-01; C22H28N4O6; Mitoxantronum	65271-80-9	4212	13376	TTDS00080	DNA topoisomerase II	DNA gyrase;Topo II;Topoisomerase II;Type II topoisomerase enzyme	Q02880	7155	ENSG00000077097	inhibitor
DAP000786	Etoposide	SMR000112002; Prestwick2_000396; 4'-O-Demethyl-1-O-(4,6-O-ethylidene-beta-D-glucopyranosyl)epipodophyllotoxin; Etoposide (VP16); Bio1_000489; SPBio_002532; MolPort-004-955-161; C01576; nchembio.573-comp8; CID284997; Demethyl Epipodophyllotoxin Ethylidine Glucoside; EINECS 251-509-1; Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-.beta.-D-glucopyranoside); CID6610299; Eposin, Vepesid, VP-16, Toposar, Etoposide; Demethyl-epiodophyllotoxin ethylidene glucoside; Vepeside; UNII-6PLQ3CP4P3; Ambap33419-42-0; Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-beta-D-glucopyranoside); 4'-Demethylepipodophyllotoxin ethylidene-.beta.-D-glucoside; NK 171; CPD000112002; Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside (8CI); NChemBio.2007.10-comp19; 121471-01-0; HMS2052N05; 136598-18-0; Etoposido; VP-16-213; AC1L1FN8; CID3310; NSC141540; 4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside); AC1NR4OG; CHEBI:588795; D00125; 35317-32-9; VP 16-213; 4-Demethylepipodophyllotoxin-.beta.-D-ethylideneglucoside; NSC-141540; etoposide; CID36462; 4'-Demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside); CID11758093; trans-Etoposide; VP-16; MolPort-004-905-001; Bio1_000978; Prestwick3_000396; nchembio873-comp2; AC1L1VT3; Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside; Etoposidum; 4-Demethylepipodophyllotoxin beta-D-ethylideneglucoside; Demethylepipodophyllotoxin-beta-D-ethylideneglucoside; Eposin; AB00438905; ZINC03938684; MLS000049957; MLS002207239; Zuyeyidal; VP 16213; Etoposide (JP15/USP/INN); MLS001074951; Bio1_001467; NSC 141540; Etoposidum [INN-Latin]; Eposide; Etoposido [INN-Spanish]; CHEMBL44657; DEMETHY-EPIPODOPHYLLOTOXIN,ETHYLIDENE GLUCOSIDE,; DB00773; AC1L6246; HSDB 6517; MLS002222184; CHEBI:4911; Prestwick_211; Epipodophyllotoxin-beta-D-ethyliden-glucoside, 4'-demethyl-; Toposar; I06-0248; LS-1214; VePesid; NCGC00025056-02; SAM001246880; AC1O4WGG; ZINC03830818; BRD-K37798499-001-02-5; AC1Q47JJ; AC1O7M1N; Lastet; CID5284558; Epipodophyllotoxin VP-16213; MLS002153463; VP 16 (pharmaceutical); VePESID (TN); KBioSS_002410; 33419-42-0; HMS1569O13; Etosid; S1225_Selleck; E0675; HMS2089F14; Prestwick0_000396; Etoposide [USAN:INN:BAN:JAN]; Prestwick1_000396; Etopophos (phosphate salt); CID6419930; MolPort-003-983-431; Etopol; 76576-58-4; BPBio1_000673; Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-.beta.-D-glucopyranoside; CCRIS 2392; VP 16; 4'-Demethyl-epipodophyllotoxin 9-[4,6-O-(R)-ethylidene-beta-D-glucopyranoside; ST056353; 201594-04-9; 51854-34-3; MLS001424283; Vepesid J; E1383_SIGMA; ETOP; BSPBio_000611; (-)-Etoposide	33419-42-0	36462	177966	TTDS00080	DNA topoisomerase II	DNA gyrase;Topo II;Topoisomerase II;Type II topoisomerase enzyme	Q02880	7155	ENSG00000077097	inhibitor
DAP000050	Idarubicin	5,12-Naphthacenedione, 7,8,9,10-tetrahydro-9-acetyl-7-((3-amino-2,3,6-trideoxy-.alpha.-L-lyxo-hexopyranosyl)oxy)-6,9,11-trihydroxy-, (7S-cis)-; 4-DMD; Lopac0_000600; NCGC00093976-02; DMDR; Idarubicine [INN-French]; 57852-57-0 (HYDROCHLORIDE); SMR000466355; NCGC00093976-01; 4-Demethoxydaunomycin; Idamycin; CID42890; 4-Demethoxydaunorubicin; KBioSS_002388; 4-Desmethoxydaunorubicin; IMI-30; DB01177; 57852-57-0; CHEBI:42068; I1656_SIGMA; UNII-ZRP63D75JW; Zavedos (TN); Idarubicina; Idarubicinum; IDARUBICIN; Zavedos; idarubicin hydrochloride; EU-0100600; I06-1097; Idarubicin Hcl; LS-94015; 5,12-Naphthacenedione, 9-acetyl-7-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,9,11-trihydroxy-, (7S-cis)-; MLS000759470; NCGC00093976-04; Daunomycin, 4-demethoxy-; NSC-256439; 5,12-Naphthacenedione, 7,8,9,10-tetrahydro-9-acetyl-7-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-6,9,11-trihydroxy-, (7S-cis)-; Idarubicinum [INN-Latin]; BRD-K69650333-001-01-1; Idarubicine; Idarubicina [INN-Spanish]; AC1Q6JJ4; NSC256439; (1s,3s)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-|A-l-lyxo-hexopyranoside; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione; D08062; IMI 30; (1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; AC1L28SA; (7S-cis)-9-Acetyl-7-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione; CCRIS 5083; CHEMBL1117; Idarubicin [INN:BAN]; DM5; C26H27NO9; Idarubicin (INN); I 1656; 58957-92-9; HMS2089D05; NCGC00093976-03; Idarubicin Hcl Pfs	58957-92-9	42890	183368	TTDS00080	DNA topoisomerase II	DNA gyrase;Topo II;Topoisomerase II;Type II topoisomerase enzyme	Q02880	7155	ENSG00000077097	inhibitor
DAP000929	Rosoxacin	Rosoxacin (USAN/INN); D02305; Rosoxacino [INN-Spanish]; 1-ethyl-4-oxo-7-pyridin-4-ylquinoline-3-carboxylic acid; Eradacil; Rosoxacine [INN-French]; AC1Q6BFC; AR-1C3002; Win-35123; Rosoxacinum [INN-Latin]; Roxadyl (TN); CHEMBL291157; Roxadyl; NSC 146617; 1-Ethyl-1,4-dihydro-4-oxo-7-(4-pyridinyl)-3-quinolinecarboxylic acid; Eradacin; Rosoxacin [USAN:INN]; UNII-3Y1OT3J4NW; PD 107522; Oprea1_128096; EINECS 254-758-4; CID287180; 3-Quinolinecarboxylic acid, 1-ethyl-1,4-dihydro-4-oxo-7-(4-pyridinyl)-; 1-ethyl-4-oxo-7-(pyridin-4-yl)-1,4-dihydroquinoline-3-carboxylic acid; Acrosoxacin; C17H14N2O3; Rosoxacino; ROSOXACIN; 1-Ethyl-1,4-dihydro-4-oxo-7-(4-pyridyl)-3-quinolinecarboxylic acid; AC1L66T4; 40034-42-2; WIN 35213; Win 35,213; Rosoxacine; NSC146617; DB00817; LS-174814; Winuron; Eracine; Rosoxacinum	40034-42-2	287180	429531	TTDS00080	DNA topoisomerase II	DNA gyrase;Topo II;Topoisomerase II;Type II topoisomerase enzyme	Q02880	7155	ENSG00000077097	inhibitor
DAP000649	Dexrazoxane	ICRF-187; (S)-(+)-1,2-Bis(3,5-dioxopiperazin-1-yl)propane; CHEMBL1200778; Dextrorazoxane; I14-10061; D03730; 2,6-Piperazinedione, 4,4'-propylenedi-, (+)-; Dexrazoxano; ADR 529; (+)-1,2-Bis(3,5-dioxopiperazin-1-yl)propane; CHEBI:50224; S1222_Selleck; 2,6-Piperazinedione, 4,4'-(1-methyl-1,2-ethanediyl)bis-, hydrochloride, (S)-; ICRF 187; 2,6-Piperazinedione, 4,4'-(1-methyl-1,2-ethanediyl)bis-, (+)- (9CI); 4,4'-(2S)-propane-1,2-diyldipiperazine-2,6-dione; DB00380; Dexrazoxane; Dexrazoxane HCl; Dexrazoxane (TN); Dexrazoxane hydrochloride; Totect (TN); Razoxane, (S)-Isomer; AC1L2G28; Soluble ICRF (L-isosomer); Totect, ICRF-187, Zinecard, Cardioxane, Dexrazoxane Hydrochloride; BRN 5759131; Dexrazoxanum [INN-Latin]; dyzoxane; Desrazoxane; CHEBI:50223; NSC 169780; D07807; 2,6-Piperazinedione,4,4'-(1-methyl-1,2-ethanediyl)bis-, (S)-; NSC169780; 4-[(2S)-2-(3,5-dioxopiperazin-1-yl)propyl]piperazine-2,6-dione; Cardioxane; Zinecard (TN); 4-[(2S)-2-(3,5-dioxopiperazin-1-yl)propyl]piperazine-2,6-dione hydrochloride; C11H16N4O4; (+)-(S)-4,4'-Propylenedi-2,6-piperazinedione; Dexrazoxane [USAN:BAN:INN]; UNII-048L81261F; 2,6-Piperazinedione, 4,4'-(1-methyl-1,2-ethanediyl)bis-, (S)-; HSDB 7319; Dexrazoxanum; 2,6-Piperazinedione,4,4'-[(1S)-1-methyl-1,2-ethanediyl]bis-; DB02444; CID71384; Eucardion; CID6918223; CHEMBL1738; Totect; BIDD:GT0068; (+)-1,2-Bis(3,5-dioxo-1-piperazinyl)propane; UNII-5346058Q7S; 2,6-Piperazinedione, 4,4'-(1-methyl-1,2-ethanediyl)bis-, (+)-; ICRF 187 hydrochloride; Dexrazoxane (USAN/INN); LS-111911; AC1OCF6D; I06-1989; TopoTect; AC1Q6LVI; Savene; 24584-09-6; Dexrazoxano [INN-Spanish]; Zinecard; NCI60_001367; 149003-01-0	24584-09-6	71384	213617	TTDS00080	DNA topoisomerase II	DNA gyrase;Topo II;Topoisomerase II;Type II topoisomerase enzyme	Q02880	7155	ENSG00000077097	inhibitor
DAP001002	Novobiocin	Stilbiocina; Spectrum2_000977; Novobiocine; Novo-R; KBio2_007538; C05080; ACon1_001693; 1aj6; ACon0_000808; KBio3_001615; Novobiocina [INN-Spanish]; DB01051; Albamycin; novobiocin; U 6391; (3r,4s,5r,6r)-5-hydroxy-6-[(2-hydroxy-3-{[4-hydroxy-3-(3-methylbut-2-en-1-yl)benzoyl]amino}-8-methyl-4-oxo-4h-chromen-7-yl)oxy]-3-methoxy-2,2-dimethyltetrahydro-2h-pyran-4-yl carbamate(non-preferred name); AR-1A4403; KBioSS_002407; AI3-50148; SPBio_001013; (3R,4S,5R,6R)-5-hydroxy-6-{[4-hydroxy-3-({[4-hydroxy-3-(3-methylbut-2-en-1-yl)phenyl]carbonyl}amino)-8-methyl-2-oxo-2H-chromen-7-yl]oxy}-3-methoxy-2,2-dimethyltetrahydro-2H-pyran-4-yl carbamate; Streptonivicin; nchembio.2007.28-comp33; Spectrum3_000528; SMR000718617; Novobiocinum; HSDB 7443; Novobiocinum [INN-Latin]; 4309-70-0 (calcium salt); 303-81-1; Crystallinic acid; KBio1_000260; AC1L1SUS; CID9346; MEGxm0_000273; 1476-53-5; BRD-K85307935-236-02-0; [(3R,4S,5R,6R)-5-hydroxy-6-[2-hydroxy-3-[[4-hydroxy-3-(3-methylbut-2-enyl)benzoyl]amino]-8-methyl-4-oxochromen-7-yl]oxy-3-methoxy-2,2-dimethyloxan-4-yl] carbamate; KBio2_006617; Cathomycin; KBio2_004970; C31H36N2O11; KBioSS_001481; Spectrum5_001274; Antibiotic PA-93; CHEMBL36506; Robiocina; LS-25404; Spectrum_001001; N-[7-[[3-O-(Aminocarbonyl)-6-deoxy-5-C-methyl-4-O-methyl-.beta.-L-lyxo-hexopyranosyl]oxy]-4-hydroxy-8-methyl-2-oxo-2H-1-benzopyran-3-yl]-4-hydroxy-3-(3-methyl-2-butenyl); Novobiocin sodium salt; 4676-58-8; IDI1_000260; AC1Q6NLU; Novobiocina; cMAP_000043; Spectrum4_000457; NOV; MolPort-000-771-685; KBio2_004049; KBioGR_002402; DivK1c_000260; Cardelmycin; KBio3_002881; 7-(Carbamoyltetrahydro-3-hydroxy-5-methoxy-6,6-dimethylpyran-2-yloxy)-4-hydroxy-3-(4-hydroxy-3-(3-methylbut-2-enyl)benzamide)-8-methyl-2H-chromen-2-one; 1476-53-5 (mono-hydrochloride salt); BSPBio_002115; Coumarin, 7-(4-(carbamoyloxy)tetrahydro-3-hydroxy-5-methoxy-6,6-dimethylpyran-2-yloxy)-4-hydroxy-3-(4-hydroxy-3-(4-hydroxy-3-(3-methyl-2-butenyl)benzamido)-8-methyl-; KBio2_001481; PA 93; Spheromycin; Sirbiocina; EINECS 206-146-3; Albamix; NINDS_000260; Streptonivicin (*Sodium salt*); Novobiocine [INN-French]; UNII-17EC19951N; KST-1A4924; 7-(3-(O-Carbamoyl)-4-(O-methyl)-5,5-dimethyl-alpha-L-lyxopyranosyloxy)-4-hydroxy-3-(4-hydroxy-3-(3-methyl-2-butenyl)benzamidol)-8-methylcumarin; Benzamide, N-(7-((3-O-(aminocarbonyl)-6-deoxy-5-C-methyl-4-O-methyl-beta-L-lyxo-hexopyranosyl)oxy)-4-hydroxy-8-methyl-2-oxo-2H-1-benzopyran-3-yl)-4-hydroxy-3-(3-methyl-2-butenyl)-; KBio2_002402; KBioGR_000874; STOCK1N-34236; Inamycin; Novobiocin [INN:BAN]; MLS001032086; CHEBI:148697; Cathocin	303-81-1	9346	7526	TTDS00080	DNA topoisomerase II	DNA gyrase;Topo II;Topoisomerase II;Type II topoisomerase enzyme	Q02880	7155	ENSG00000077097	inhibitor
DAP000999	Cinoxacin	ST044511; Azolinic Acid; NCGC00023754-04; EINECS 249-133-8; DB00827; Compound 64716; HMS500P20; Cinoxacine; NCGC00023754-03; UNII-LMK22VUH23; AC1L1EEQ; NSC304467; Oprea1_131085; Cinobactin; NCGC00023754-06; Lopac-C-8645; Prestwick3_000780; 1-Ethyl-6,7-methylenedioxy-4(1H)-oxocinnoline-3-carboxylic acid; Uronorm; KBio3_001263; KBio2_000632; Cinoxacine [INN-French]; NCGC00023754-05; C8645_SIGMA; (1,3)Dioxolo(4,5-g)cinnoline-3-carboxylic acid, 1-ethyl-1,4-dihydro-4-oxo-; MolPort-001-794-447; (1,3)Dioxolo(4,5-g)cinnoline-3-carboxylic acid, 1,4-dihydro-1-ethyl-4-oxo-; 1-Ethyl-1,4-dihydro-4-oxo(1,3)dioxolo(4,5-g)cinnoline-3-carboxylic acid; KBio1_000318; KBioSS_000632; cinoxacin; Cinoxacin [USAN:BAN:INN:JAN]; BRD-K14704277-001-05-1; Lopac0_000309; Lilly 64716; D00872; Spectrum_000152; BSPBio_000860; Cinoxacinum; LS-62687; Cinobac; SPECTRUM1500190; EU-0100309; NCGC00015277-04; SPBio_000360; Spectrum2_000570; SPBio_002799; BPBio1_000946; NSC 304467; NCGC00015277-01; Prestwick0_000780; NINDS_000318; AC1Q317Y; BRN 1084304; KBio2_003200; 1-Ethyl-1,4-dihydro-4-oxo[1,3]dioxolo[4,5-g]cinnoline-3-carboxylic acid; Prestwick1_000780; C08052; Spectrum5_000749; CCRIS 8206; NCGC00023754-07; CHEBI:3716; 1-Ethyl-4-oxo-1,4-dihydro[1,3]dioxolo[4,5-g]cinnoline-3-carboxylic acid; NCGC00015277-14; 28657-80-9; KBio2_005768; Clinoxacin; TNP00246; NCGC00015277-02; Prestwick2_000780; C12H10N2O5; Spectrum3_000352; BSPBio_002043; NCGC00015277-03; MLS001148076; SMR000058232; CHEMBL1208; HMS2091E18; [1,3]Dioxolo[4,5-g]cinnoline-3-carboxylic acid, 1-ethyl-1,4-dihydro-4-oxo-; DivK1c_000318; 1-ethyl-4-oxo-[1,3]dioxolo[4,5-g]cinnoline-3-carboxylic acid; C 8645; CAS-28657-80-9; Spectrum4_000289; IDI1_000318; Cinoxacinum [INN-Latin]; Prestwick_239; Cinoxacino [INN-Spanish]; KBioGR_000818; NCGC00015277-07; MLS000069630; Cinoxacin (JAN/USP/INN); CID2762; Cinoxacino; HMS1920O11; Cinx; HMS1570K22; Cinobac (TN)	28657-80-9	2762	10252	TTDS00080	DNA topoisomerase II	DNA gyrase;Topo II;Topoisomerase II;Type II topoisomerase enzyme	Q02880	7155	ENSG00000077097	inhibitor
DCL000290	TOP-53	(5R,5aR,8aR,9S)-9-[2-[2-dimethylaminoethyl(methyl)amino]ethyl]-5-(4-hydroxy-3,5-dimethoxyphenyl)-5a,8,8a,9-tetrahydro-5H-[2]benzofuro[6,5-f][1,3]benzodioxol-6-one dihydrochloride; CID6918225; TOP-53; AC1OCF6H; Top 53	147238-98-0	6918225	12014725	TTDS00080	DNA topoisomerase II	DNA gyrase;Topo II;Topoisomerase II;Type II topoisomerase enzyme	Q02880	7155	ENSG00000077097	inhibitor
DCL000535	Iboctadekin + Doxil	N/A	N/A	N/A	N/A	TTDS00080	DNA topoisomerase II	DNA gyrase;Topo II;Topoisomerase II;Type II topoisomerase enzyme	Q02880	7155	ENSG00000077097	inhibitor
DAP000650	Valrubicin	CHEMBL20225; 136816-53-0; [2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-4-[5-hydroxy-6-methyl-4-[(2,2,2-trifluoroacetyl)amino]oxan-2-yl]oxy-7-methoxy-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]ethyl] pentanoate; Valstar Preservative Free; N-Trifluoroacetyladriamycin 14-valerate; NSC-246131; HSDB 7288; Pentanoic acid, 2-((2S,4S)-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetylamino)-, alpha-L-lysohexopyranoxyl)oxy)-2-naphthacenyl)-2-oxoethyl ester; I06-1096; Valrubicin (USP/INN); NSC246131; Pentanoic acid, 2-[1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-[[2,3,6-trideoxy-3-[(trifluoroacetyl)amino]-.alpha.-L-lyxo-hexopyranosyl]oxy]-2-naphthacenyl]-2-oxoethyl ester, (2S-cis)-; 56124-62-0; Valstar (TN); UNII-2C6NUM6878; AC1L26EA; C34H36F3NO13; LS-15286; Valrubicin [USAN]; Trifluoroacetyladriamycin-14-valerate; CID41744; (2S-cis)-Pentanoic acid, 2-(1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetyl)amino)-alpha-L-lyxo-hexopyranosyl)oxy)-2-naphth acenyl)-2-oxoethyl ester; (2S-cis)-2-(1,2,3,4,6,11-Hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetyl)amino)-alpha-L-lyxo-hexopyranosyl)oxy)-2-naphthacenyl)-2-oxoethyl pentanoate; AD 32; (8S,10S)-8-Glycoloyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-10-((2,3,6-trideoxy-3-(2,2,2-trifluoroacetamido)-alpha-L-lyxo-hexopyranosyl)oxy)-5,12-naphthacenedione 8(sup 2)-valerate; NCI60_001970; Antibiotic AD 32; Valstar; N-Trifluoroacetyladriamycin-14-valerate; Valrubicin; Adriamycin, trifluoroacetyl-, 14-valerate; N-Trifluoroacetyldoxorubicin 14-valerate; DB00385; D02697; NSC 246131	56124-62-0	41744	182424	TTDS00080	DNA topoisomerase II	DNA gyrase;Topo II;Topoisomerase II;Type II topoisomerase enzyme	Q02880	7155	ENSG00000077097	inhibitor
DAP000654	Norfloxacin	KBio1_000084; D00210; SPECTRUM1500440; HMS1920B16; Norfloxacin [USAN:BAN:INN:JAN]; Oprea1_375152; STK177250; Norfloxacin Merck Brand; AM 715; KBio2_006633; MLS000069650; 1-ethyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydroquinoline-3-carboxylic acid; NCGC00016916-02; BIDD:GT0725; Barazan; ARONIS24170; HMS2091J16; Prestwick0_000221; Spectrum_001017; Prestwick_633; SPBio_002182; HMS2090F03; Prestwick3_000221; D009643; AM-715; CHEMBL9; 1-Ethyl-6-fluor-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-chinolincarbonsaeure; S1509_Selleck; MK-366; 1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-[1-piperazinyl]-3-quinoline- carboxylic acid; Chibroxin; 1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid; Spectrum4_000453; HMS1568N03; 70458-96-7; C16H18FN3O3; 3-Quinolinecarboxylic acid, 1,4-dihydro-1-ethyl-6-fluoro-4-oxo-7-(1-piperazinyl)-; KBioGR_000866; Sebercim; NCGC00016916-01; KBio3_001607; NCGC00021725-04; AM-0715; AM 0715; SPBio_001173; nchembio820-comp2; Prestwick1_000221; LS-141592; BPBio1_000289; CAS-70458-96-7; Norfloxacino; BSPBio_002107; KBio2_004065; SMR000058200; 68077-27-0; UNII-N0F8P22L1P; Lexinor; MK 0366; Merck Brand of Norfloxacin; Norfloxacinum [INN-Latin]; DivK1c_000084; DB01059; BRN 0567897; NCGC00021725-03; KBioSS_001497; BCBcMAP01_000218; Prestwick2_000221; BB_SC-0063; Noroxin (TN); norfloxacin; Spectrum2_001017; BSPBio_000261; Noroxin; Chibroxin, MK-366, Baccidal, Sebercim, Zoroxin, Norfloxacin; Norflo; Norfloxacinum; MK 366; 3-Quinolinecarboxylic acid, 1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-; Norfloxacin (JP15/USP/INN); AC1L1IE1; I14-0947; CCRIS 6302; AKOS000417391; MolPort-001-738-625; 1,4-Dihydro-1-ethyl-6-fluoro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid; EINECS 274-614-4; Norfloxacino [INN-Spanish]; NFLX; Norfloxacine [INN-French]; BRD-K11196887-001-05-5; MK0366; C06687; CHEBI:100246; MK366; KBio2_001497; Spectrum3_000524; NINDS_000084; Norfloxacine; 1-ethyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid; Fulgram; SMP1_000216; Baccidal; Spectrum5_001154; HMS500E06; CID4539; 1-ethyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid; AM0715; IDI1_000084; MK-0366; AC-6855	70458-96-7	4539	8912	TTDS00080	DNA topoisomerase II	DNA gyrase;Topo II;Topoisomerase II;Type II topoisomerase enzyme	Q02880	7155	ENSG00000077097	inhibitor
DAP001000	Enoxacin	NINDS_000420; LS-95946; E3764_SIGMA; Bactidan; Spectrum2_001731; 74011-58-8; Enoxin; Faulding Brand of Enoxacin; NCGC00178309-02; 1,8-Naphthyridine-3-carboxylic acid, 1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-; Flumark; AT-2266; IDI1_000420; PD-107779; BPBio1_000491; HMS1569G07; C15H17FN4O3; Pierre Fabre Brand of Enoxacin Sesquihydrate; KBio2_007155; KBioGR_000651; 1-Ethyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid; CL23362; PD 107779; Enoxacine [French]; HMS2090E10; Enoram; NSC 627409; BRN 3628995; E3764_FLUKA; BIDD:GT0191; BSPBio_003080; AC1L1FGQ; CI 919; Spectrum3_001570; SPECTRUM1503215; CAS-74011-58-8; CI-919; NCGC00178309-01; Enoxacin Sesquihydrate; enoxacin; Prestwick2_000353; NSC629661; KBio3_002580; BCBcMAP01_000009; BRD-K78113049-001-05-5; CHEBI:157175; I06-0290; Enoxacino [Spanish]; 1-ethyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,8-naphthyridine-3-carboxylic acid; AT 2266; NCGC00016927-01; CHEMBL826; Sesquihydrate, Enoxacin; CCRIS 5242; C06979; Prestwick1_000353; HMS2092N20; NCI60_009618; 1-ethyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid; Prestwick0_000353; 1-ethyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid; Comprecin; SPBio_001802; Almitil; CID3229; Enoxor; NCGC00023864-04; KBioSS_002019; Enoxacin [USAN:BAN:INN:JAN]; E0762; SPBio_002366; D00310; BSPBio_000445; DivK1c_000420; HMS1922I17; Penetrex (TN); KBio2_004587; 1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7- [1-piperazinyl]-1,8-naphthyridine-3-carboxylic acid; HMS501E22; NSC 629661; UNII-325OGW249P; Enoxacin (USAN/INN); KBio2_002019; D015365; Spectrum4_000166; Enoxacinum; NCGC00023864-03; AT2266; CI919; KBio1_000420; DB00467; SMR000058233; 1,8-Naphthyridine-3-carboxylic acid, 6-fluoro-1,4-dihydro- 4-oxo-7-piperazinyl; Rhone-Poulenc Rorer Brand of Enoxacin Sesquihydrate; Prestwick_708; Enoxacino; Spectrum_001539; NCGC00016927-02; 1,8-Naphthyridine-3-carboxylic acid, 1,4-dihydro-1-ethyl-6-fluoro-4-oxo-7-(1-piperazinyl)-; Oprea1_147866; Enoxacinum [Latin]; 1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-1,8-naphthyridine-3-carboxylic acid; SMP1_000113; Spectrum5_001044; PD107779; MLS000069645; Penetrex; Enoxacine; TL8005116; Prestwick3_000353; Rhone Poulenc Rorer Brand of Enoxacin Sesquihydrate	74011-58-8	3229	9193	TTDS00080	DNA topoisomerase II	DNA gyrase;Topo II;Topoisomerase II;Type II topoisomerase enzyme	Q02880	7155	ENSG00000077097	inhibitor
DAP000928	Fleroxacin	LS-141577; Ro-23-6240/000; Fleroxacin [USAN:BAN:INN:JAN]; UNII-N804LDH51K; SMR000466302; S2469_Selleck; fleroxacin; F0646; 33930_FLUKA; Fleroxacinum [Latin]; 79660-72-3; Fleroxacin (JAN/USAN/INN); NCGC00167558-01; 6,8-Difluoro-1-(2-fluoroethyl)1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; AC1Q3ZU5; Fleroxicin; Megalone; AC1Q4N64; FLRX; 6,8-Difluoro-1-(2-fluoroethyl)-1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; Fleroxacine; SAM001246535; AR-1H0470; Megalosin; Fleroxacinum; Fleroxacino; MLS000759401; C17H18F3N3O3; Megalocin; Ro 23-6240/000; Fleroxacine [French]; CCRIS 3972; CPD000466302; Fleroxacino [Spanish]; CID3357; C13179; AM-833; Megalocin (TN); Ro 23-6240; HMS2090I08; Quinodis; SBB070988; CHEMBL6273; AC1L1FR2; 3-Quinolinecarboxylic acid, 6,8-difluoro-1-(2-fluoroethyl)-1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo-; 6,8-difluoro-1-(2-fluoroethyl)-7-(4-methyl-1-piperazinyl)-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid; AM 833; Ro-236240; BRN 4300996; Megalone (TN); D01716; 33930_RIEDEL; 6,8-difluoro-1-(2-fluoroethyl)-7-(4-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid; 6,8-Difluoro-1-(2-fluoroethyl)-1,4-dihydro-7-(4-methylpiperazino)-4-oxo-3-quinolinecarboxylic acid; 3-Quinolinecarboxylic acid, 1,4-dihydro-6,8-difluoro-1-(2-fluoroethyl)-7-(4-methyl-1-piperazinyl)-4-oxo-	79660-72-3	N/A	46506357	TTDS00080	DNA topoisomerase II	DNA gyrase;Topo II;Topoisomerase II;Type II topoisomerase enzyme	Q02880	7155	ENSG00000077097	inhibitor
DAP001387	Gatifloxacin	Kinome_3137; MLS000040259; (+-)-1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; Gatifloxacin; SAM002589955; PD-135432; 1-cyclopropyl-6-fluoro-8-methoxy-7-(3-methylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; MLS000759493; Spectrum3_000999; BMS-206584; AM 1155; Gatiflo; 1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; Gatifloxacin (TN); 160738-57-8; AM-1155; S1340_Sellekc; KBio3_001917; D08011; Spectrum2_000487; NCGC00095126-02; 1-cyclopropyl-6-fluoro-8-methoxy-7-(3-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid; S1340_Selleck; Zymer (TN); TL8001438; BMS-206584-01; PD135432; CPD000043336; KBio2_005010; AC1L1K82; Tequin in dextrose 5% in plastic container; FT-0082686; Zymar; Spectrum4_001127; KBioSS_002448; GTFX; HMS2093G06; Gatispan; Gatilox; AC-1944; AKOS004119932; SPBio_000353; Gatifloxacin (INN); CID5379; LS-184402; Gatiquin; CHEBI:5280; BRD-A74980173-001-02-8; Zymaxid; KBio2_007578; 180200-66-2; Tequin; SMR000043336; 112811-59-3; 3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-; AM-1155 (*Sesquihydrate*); Zymer; CG-5501; Gatifloxacin & Gamma Interferon; I06-2286; KBioGR_001613; Gatifloxacin [USAN:INN]; 1-Cyclopropyl-1,4-dihydro-6-fluoro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; MolPort-001-738-626; Spectrum_001909; NCGC00178525-01; HMS2090K10; I06-2287; C07661; KBio2_002442; BSPBio_002697; Spectrum5_001468; HMS1922J15; NCGC00095126-01; CHEMBL31; CG 5501; PD 135432; STK801620; SAM001246715; Gatiflo,Tequin and Zymar,  Gatifloxacin; BMS 206584-01; BB_SC-1123; DB01044; SPECTRUM1504272; Gaity; Bonoq	112811-59-3	5379	9863	TTDS00080	DNA topoisomerase II	DNA gyrase;Topo II;Topoisomerase II;Type II topoisomerase enzyme	Q02880	7155	ENSG00000077097	inhibitor
DAP000193	Epirubicin	Epirubicine; Epirubicin; Pidorubicina [INN-Spanish]; 5,12-Naphthacenedione, 10-((3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S-cis)-; SMR000466308; AC1Q6JIV; Epirubicin (INN); Ellence; 4'-Epiadriamycin; 4'-Epi-DXR; Epiadriamycin; 56390-09-1 (hydrochloride); 56420-45-2; IMI 28; Epirubicina [INN-Spanish]; 5,12-Naphthacenedione, 10-((3-amino-2,3,6-trideoxy-beta-L-arabino-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S-cis)-; Ridorubicin; Epirubicinum [INN-Latin]; Triferric doxorubicin; Pidorubicinum [INN-Latin]; Pidorubicine [INN-French]; NChemBio.2007.10-comp15; Farmorubicin (TN); Pidorubicinum; (1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside; Epidoxorubicin; 4'-epi-DX; (7S,9S)-7-[(2R,4S,5R,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; CID41867; CCRIS 2261; 57918-25-9; CHEMBL417; AC1L26NP; 10-((3-amino-2,3,6-trideoxy-beta-L-arabino-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-(8S-cis)-5,12-naphthacenedione; 4'-epi-Doxorubicin; NSC256942; UNII-3Z8479ZZ5X; Epirubicinum [Latin]; WP 697; MLS000759412; NSC 256942; (1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside; C11230; 4'-epidoxorubicin; LS-93992; Epirubicin [INN:BAN]; Epirubicina; Epirubicine [French]; 56390-09-1; 4-Epidoxorubicin; Pidorubicine; Pidorubicin; HSDB 6962; Epirubicinum; Epirubicina [Spanish]; Epirubicine [INN-French]; CHEBI:47898; Pharmorubicin Pfs; (7S,9R)-7-[(2S,4S,5R,6S)-4-Amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; NSC-256942; C27H29NO11; Pidorubicina; LS-187190; DB00445; BRN 1445813; Epi-DX; D07901	56420-45-2	41867	182518	TTDS00080	DNA topoisomerase II	DNA gyrase;Topo II;Topoisomerase II;Type II topoisomerase enzyme	Q02880	7155	ENSG00000077097	inhibitor
DAP000192	Doxorubicin	Adriamycin semiquinone; Doxorubicine [INN-French]; LMPK13050001; Adriamycin RDF (hydrochloride salt); EINECS 245-495-6; Aerosolized Doxorubicin; Adriacin (hydrochloride salt); Prestwick3_000438; Prestwick0_000438; 14-Hydroxydaunorubicine; Probes2_000129; CHEMBL179; MLS000759533; Hydroxydaunomycin hydrochloride (hydrochloride salt); Doxorubicin-hLL1; D03899; ThermoDox; Doxorubicin citrate; 23257-17-2; Doxorubicin-P4/D10 conjugate; 111266-55-8; 25316-40-9 (hydrochloride); NChemBio.2007.10-comp13; 24385-08-8; Prestwick1_000438; Adriblastina (TN); ADM; adriablatina (hydrochloride salt); LS-165655; NDC 38242-874; CHEBI:28748; CCRIS 739; Doxorubicina [INN-Spanish]; Triferric doxorubicin; DOX-SL; FI 106; DB00997; BSPBio_001031; Probes1_000151; Myocet; SPBio_002395; TLC D-99; Prestwick2_000438; LS-1029; Doxorubicin hydrochloride (hydrochloride salt); Adriablastin; CID31703; Doxorubicin-P4/D10; NCI-C01514; RDF Rubex; Doxorubicin-hLL1 conjugate; adriablastine (hydrochloride salt); Doxorubicin (USAN/INN); Doxorubicinum [INN-Latin]; NSC 123127; Adriblastin; Adriblas tina; 25311-50-6; Doxil; 25316-40-9; AC1L1M5T; Farmablastina (hydrochloride salt); 29042-30-6; Adriamycin PFS (hydrochloride salt); Doxorubicin [USAN:INN:BAN]; adr iablatina (hydrochloride salt); C01661; Adriblastina (hydrochloride salt); JT9100000; DM2; Doxorubicine; Rubex (hydrochloride salt); Adriamycin RDF; BSPBio_000456; BPBio1_000502; Hydroxydaunomycin hydrochlor ide (hydrochloride salt); Doxorubicin Hydrochloride; AC1Q29OJ; Doxorubicina; Resmycin; Conjugate of doxorubicin with humanized monoclonal antibody LL1 against CD74; nchembio809-comp5; 14-Hydroxydaunomycin; Adriamycin; 23214-92-8; HSDB 3070; Rubex; UNII-80168379AG; NIOSH/JT9100000; Adriblastina; doxorubicin; Conjugate of doxorubicin with monoclonal antibody P4/D10 against GP120; adriblatina (hydrochloride salt); Adriamycin PFS; C27H29NO11; SMP1_000106; ADR; Hydroxydaunorubicin hydrochloride (hydrochloride salt); adiblastine (hydrochloride salt); BRD-K92093830-003-04-3; Doxorubicinum; HMS2089H06	23214-92-8	31703	173764	TTDS00080	DNA topoisomerase II	DNA gyrase;Topo II;Topoisomerase II;Type II topoisomerase enzyme	Q02880	7155	ENSG00000077097	inhibitor
DAP000652	Trovafloxacin	AKOS000277872; CHEMBL190562; 7-[(1R,5S)-6-amino-3-azabicyclo[3.1.0]hexan-3-yl]-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid; AC1L1Y44; CP99219; CHEMBL428; 1,8-Naphthyridine-3-carboxylic acid, 7-(6-amino-3-azabicyclo[3.1.0]hex-3-yl)-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-, (1alpha,5alpha,6alpha)-; CP 99,219; DB00685; 7-[(1r,5s)-6-amino-3-azabicyclo[3.1.0]hex-3-yl]-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid; CP-99,219; C080163; Trovafloxacin; Fluorinated quinolone; C07664; 147059-72-1; 7-[(1R,5S,6s)-6-amino-3-azabicyclo[3.1.0]hex-3-yl]-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid; TVFX; Trovafloxacin [INN]; C20H15F3N4O3; Trovan (oral); 146836-84-2; Trovafloxacin (INN); LS-95890; CID62959; D08654; 7-((1R,5S)-6-Amino-3-aza-bicyclo[3.1.0]hex-3-yl)-1-(2,4-difluoro-phenyl)-6-fluoro-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid; UNII-9F388J00UK; (1alpha,5alpha,6alpha)-7-(6-Amino-3-azabicyclo[3.1.0]hex-3-yl)-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid; Trovan; CP-99219; 1,8-Naphthyridine-3-carboxylic acid, 1,4-dihydro-7-(6-amino-3-azabicyclo(3.1.0)hex-3-yl)-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-, (1-alpha,5-alpha,6-alpha)-; CP 99219; AC1Q4NG5	147059-72-1	62959	9866	TTDS00080	DNA topoisomerase II	DNA gyrase;Topo II;Topoisomerase II;Type II topoisomerase enzyme	Q02880	7155	ENSG00000077097	inhibitor
DAP001001	Pefloxacin	SMR000273037; Oprea1_546341; BRD-K55034111-066-02-3; 3-Quinolinecarboxylic acid, 1-ethyl-6-fluoro-1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo-; 1-ethyl-6-fluoro-7-(4-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid; Pefloxacinum [INN-Latin]; Pefloxacine; Pefloxacin [INN-French]; Pefloxacin; Pefloxacin (USAN/INN); C17H20FN3O3; AC1Q5RD0; STOCK1S-14007; EINECS 274-611-8; Spectrum3_001971; CHEMBL267648; AKOS000280245; 1-ethyl-6-fluoro-7-(4-methyl-1-piperazinyl)-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid; 1-ethyl-6-fluoro-7-(4-methylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(4-methyl-1-piperazinyl)-3-quinolinecarboxylic acid; Pefloxacin methanesulfonate; PERFLOXACIN; BRN 0567618; PFLX; MolPort-000-883-203; 70458-95-6 (MESYLATE); D02306; AM-725; MLS000713556; CHEBI:50199; LS-141589; Pefloxacinum; Peflacine; 2589 R.B; 1-Ethyl-6-fluoro-1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; 1-Ethyl-6-fluoro-1,4-dihydro-7-(4-methyl-1- piperazinyl)-4-oxo-3-quinolinecarboxylic acid; SPBio_000127; DB00487; Oprea1_063677; HMS1613E05; STK169677; MolPort-002-885-848; Abactal; KBio3_002945; Spectrum2_000034; Pefloxacino; BAS 00463355; 1589 RB; Labocton; 3-Quinolinecarboxylic acid, 1,4-dihydro-1-ethyl-6-fluoro-7-(4-methyl-1-piperazinyl)-4-oxo-; Pefloxacino [INN-Spanish]; 3-Quinolinecarboxylic acid, 1-ethyl-6-fluoro-1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo; CCRIS 8210; HMS2090H09; EU 5306; BSPBio_003571; 70458-92-3; EU-5306; 1584RB; Silver Pefloxacin; Pefloxacin [USAN:BAN:INN]; AC1L1AEA; UNII-2H52Z9F2Q5; CID51081	70458-92-3	51081	189349	TTDS00080	DNA topoisomerase II	DNA gyrase;Topo II;Topoisomerase II;Type II topoisomerase enzyme	Q02880	7155	ENSG00000077097	inhibitor
DAP001509	Quinolones	N/A	835903-13-4	3036108	36104347	TTDS00080	DNA topoisomerase II	DNA gyrase;Topo II;Topoisomerase II;Type II topoisomerase enzyme	Q02880	7155	ENSG00000077097	inhibitor
DAP001003	Lucanthone	CBC 900139; LUCANTHONE HYDROCHLORIDE; 1-[[2-(Diethylamino)ethyl]amino]-4-methylthioxanthone; 1-((2-(Diethylamino)ethyl)amino)-4-methylthioxanthen-9-one; CHEMBL279014; CCRIS 1106; Lucanthon; Miracol; AI3-16160; CID10180; Thioxanthen-9-one, 1-((2-(diethylamino)ethyl)amino)-4-methyl-; Miracil D; 1-{[2-(Diethylamino)ethyl]amino}-4-methyl-9H-thioxanthen-9-one; 479-50-5; EINECS 207-532-4; Tixantone; Lucantona; 9H-Thioxanthen-9-one, 1-((2-(diethylamino)ethyl)amino)-4-methyl- (9CI); 9H-Thioxanthen-9-one, 1-((2-(diethylamino)ethyl)amino)-4-methyl-; 1-(2-diethylaminoethylamino)-4-methylthioxanthen-9-one; Nilodin; Lucanthone [INN:BAN]; CHEBI:51052; Lucanthonum; Scapuren; 5-18-11-00503 (Beilstein Handbook Reference); Lucantona [INN-Spanish]; LS-153695; Lucanthonum [INN-Latin]; 548-57-2; NCIMech_000830; NCI60_000988; DB04967; BRN 0312369; LUCANTHONE; C11715; Lucanthone monohydrochloride; DR-15771; AC1L1UNW; BW 57223	479-50-5	10180	11405383	TTDS00080	DNA topoisomerase II	DNA gyrase;Topo II;Topoisomerase II;Type II topoisomerase enzyme	Q02880	7155	ENSG00000077097	inhibitor
DAP000851	Gemifloxacin	BSPBio_002308; NCGC00178711-01; 210353-52-9; SB-265805; Gemifloxacin; CHEMBL430; BRD-A40787240-066-02-0; SB 265805; CID9571107; 7-(3-Aminomethyl-4-methoxyimino-pyrrolidine-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-(1,8)-naphthyridine-3-carboxylic acid; LS-187779; Factiv; LB-20304; 204519-64-2; 210353-53-0; Factive; 7-(3-Aminomethyl)-4-methoxyimino-pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid; 210353-55-2; Gemifloxacin mesilate; 214346-11-9; LB 20304a; CHEBI:101853; 210353-56-3; 175463-14-6; 1,8-Naphthyridine-3-carboxylic acid, 7-(3-(aminomethyl)-4-(methoxyimino)-1-pyrrolidinyl)-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-; Gemifloxacin [INN]; Gemifloxacin (INN); 7-[3-(aminomethyl)-4-(methoxyimino)pyrrolidin-1-yl]-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid; 1,8-Naphthyridine-3-carboxylic acid, 7-[(4Z)-3-(aminomethyl)-4-(methoxyimino)-1-pyrrolidinyl]-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-; D08012; LS-186992; Factiv (TN); LB 20304	175463-14-6	5464436	610685	TTDS00080	DNA topoisomerase II	DNA gyrase;Topo II;Topoisomerase II;Type II topoisomerase enzyme	Q02880	7155	ENSG00000077097	inhibitor
DAP001348	Dhaq diacetate	1,4-Dihydroxy-5,8-bis(2-((2-hydroxyethyl)amino)ethylamino)-9,10-anthracenedione diacetate; 65271-80-9 (Parent); 5,8-Bis((2-((2-hydroxyethyl)amino)ethyl)amino)-1,4-dihydroxy-9,10-anthracenedione diacetate; Dhaq diacetate; 70711-41-0; 2-[[5,8-dihydroxy-4-[2-(2-hydroxyethylazaniumyl)ethylamino]-9,10-dioxoanthracen-1-yl]amino]ethyl-(2-hydroxyethyl)azanium diacetate; Anthraquinone, 5,8-bis((2-((2-hydroxyethyl)amino)ethyl)amino)-1,4-dihydroxy-, 1,4-diacetate (salt); AC1L1AJM; 5,8-Bis((2-((2-hydroxyethyl)amino)ethyl)amino)-1,4-dihydroxyanthraquinone 1,4-diaceate; LS-20639; CID51151; NSC 299195; Mitoxantrone diacetate	70711-41-0	51151	189409	TTDS00080	DNA topoisomerase II	DNA gyrase;Topo II;Topoisomerase II;Type II topoisomerase enzyme	Q02880	7155	ENSG00000077097	inhibitor
DCL000334	Garenoxacin	UNII-V72H9867WB; 1-cyclopropyl-8-(difluoromethoxy)-7-[(1R)-1-methyl-2,3-dihydro-1H-isoindol-5-yl]-4-oxoquinoline-3-carboxylic acid; 223652-82-2 (MESYLATE SALT); T 3811; T-3811; 194804-75-6; CHEMBL215303; AC1L3XUP; BMS-284756 (*Mesylate salt*); Garenoxacin; T-3811MEa; BMS 284756 (*Mesylate salt*); CID124093; NCGC00181770-01; 1-Cyclopropyl-8-(difluoromethoxy)-7-[(1R)-(1-methyl-2,3-dihydro-1H-5-isoindolyl)-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid; 223652-82-2	91421-42-0	124093	700864	TTDS00080	DNA topoisomerase II	DNA gyrase;Topo II;Topoisomerase II;Type II topoisomerase enzyme	Q02880	7155	ENSG00000077097	inhibitor
DAP001360	ciprofloxacin	UNII-5E8K9I0O4U; CCRIS 5241; DivK1c_000095; Cipro I.V.; Ciprofloxacino; Cifloxin; 1-Cyclopropyl-6-fluoro-1,4-dihydro-7-(1-piperazinyl)-4-oxo-3-quinoline carboxylic acid; Fimoflox; Ciprodar; CPFX; Ciprofloxacino [INN-Spanish]; Prestwick1_000113; Cipro (TN); Proksi 500; Spectrum_000162; 17850_FLUKA; Cycin; Ciprecu; Spectrum3_001872; D00186; 3-Quinolinecarboxylic acid,1,4-dihydro-1-cyclopropyl-6-fluoro-4-oxo-7-(1-piperazinyl); AC-7613; 1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid; Quinolid; SMP1_000125; KBio2_003210; Cipromycin; Ciprofloxacinum [INN-Latin]; Ciprofloxacin monohydrochloride; 1-cyclopropyl-6-fluoro-7-hexahydro-1-pyrazinyl-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid; 33434_RIEDEL; 1-CYCLOPROPYL-6-FLUORO-4-OXO-7-PIPERAZIN-1-YL-1,4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID; CIPRO IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER; Ciprobay; 1-Cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydro-quinoline-3-carboxylic acid; 3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-; Baflox; Cipro IV; 1-Cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperzinyl)-3-quinolinecarboxylic acid HCl H2O; CHEBI:100241; 33434_FLUKA; Ciproxan; Ciproxina; BRN 3568352; AKOS000269653; Corsacin; Cipro XR; Rancif; Ciprocinol; 1-cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid; Ciprofloxacin Hydrchloride; Proksi 250; Cyprobay; Ciproquinol; Spectrum5_001089; Liposomal-ciprofloxacin; Prestwick2_000113; Proflaxin; NCGC00095058-01; Probiox; KBio2_000642; NCGC00178128-01; Quintor; CPF; CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER; Oprea1_313572; Bacquinor; Prestwick3_000113; Flociprin; Cipro XL; Ciprofloxacin HCl; NSC620634; Bernoflox; Zumaflox; Bay o 9867; Ciprofloxacinum; Roxytal; Ciprofloxacin dihydrochloride; NCGC00016959-01; Ciloxan (*Hydrochloride*); HMS500E17; Ciprinol; C17H18FN3O3; BAY q 3939; SPBio_002065; BRD-K04804440-311-02-3; ARONIS020379; ciprofloxacin; Bay-09867; Ciprofloxacin hydrochloride; Ciflox; BSPBio_003344; MLS001336035; BAY-Q-3939; HMS2093I03; KBio3_002846; Proflox; Ciprofloxacine; BIDD:GT0205; Cixan; Prestwick0_000113; Bi-Cipro; Alcon Cilox; IDI1_000095; KBioGR_001567; Velomonit; Ipiflox; NCGC00095058-02; Ciplus; AC1L1EEW; CAS-93107-08-5; CID2764; Ciprobay Uro; Sophixin Ofteno; KBio1_000095; Ciprolin; Superocin; HMS1922E18; Septicide; SPBio_001474; Ciprofloxacin (JAN/USP/INN); KBio2_005778; 1-Cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid; BAS 06989041; Ciprofloxacin [USAN:INN:BAN]; Ciprolon; HSDB 6987; 3-Quinolinecarboxylic acid, 1,4-dihydro-1-cyclopropyl-6-fluoro-4-oxo-7-(1-piperazinyl)-; Cilab; Ciprofloxacine [INN-French]; Spectrum2_001567; NINDS_000095; Ciprowin; CRL-1605 & Ciprofloxacin; HMS2090O07; BSPBio_000126; Eni; 85721-33-1; Bay o 9867 (*Hydrochloride*); MolPort-000-819-654; STK021082; Baycip; Ciproxine; Spitacin; BPBio1_000140; SPECTRUM1503614; Cipro; Ciproxin; BAYQ3939; CHEMBL8; Loxan; Cipro (*Hydrochloride*); Bio-0540; Unex; Ciprofloxacina; SMR000471901; LS-141563; Citopcin; DB00537; Spectrum4_000874; Ciprogis; nchembio820-comp1; Italnik; 1-Cyclopropyl-6-fluoro-4-oxo-7-(1-piperazinyl)-1,4-dihydro-3-quinolinecarboxylic acid; C05349; CBMicro_048498; Oprea1_008239; Ciriax; Ciproflox; KBioSS_000642	85721-33-1	2764	192835	TTDS00080	DNA topoisomerase II	DNA gyrase;Topo II;Topoisomerase II;Type II topoisomerase enzyme	Q02880	7155	ENSG00000077097	inhibitor
DAP000161	Sparfloxacin	Zagam (TN); PD131501; 3-Quinolinecarboxylic acid, 1,4-dihydro-5-amino-1-cyclopropyl-6,8-difluoro-7-(3,5-dimethyl-1-piperazinyl)-4-oxo-, cis-; PD 1315-1; 5-Amino-1-cyclohexyl-7-(cis-3,5-dimethylpiperazino)-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid; C19H22F2N4O3; Sparfloxacin [USAN:BAN:INN:JAN]; CI 978; 3-Quinolinecarboxylic acid, 5-amino-1-cyclopropyl-7-((3R,5S)-3,5-dimethyl-1-piperazinyl)-6,8-difluoro-1,4-dihydro-4-oxo-, rel-; D00590; MolPort-002-507-759; Sparfloxacinum [INN-Latin]; 5-Amino-1-cyclopropyl-7-(cis-3,5-dimethyl-1-piperazinyl)-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid; SPFX; 33967_FLUKA; Esparfloxacino; 3-Quinolinecarboxylic acid, 5-amino-1-cyclopropyl-7-(3,5-dimethyl-1-piperazinyl)-6,8-difluoro-1,4-dihydro-4-oxo-, cis-; 110871-86-8; sparfloxacin, cis-isomer; Sparfloxacin (JAN/USAN/INN); (cis)-5-amino-1-cyclopropyl-7-(3,5-dimethyl-1-piperazinyl)-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid; PD-131501; 111542-93-9; CHEBI:9212; DB01208; 5-amino-1-cyclopropyl-7-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-6,8-difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; Spara; HMS2090N19; STK802067; Liposome-encapsulated sparfloxacin; Sparfloxacinum; 56968_FLUKA; BB_SC-1127; BRN 3658018; Esparfloxacino [INN-Spanish]; Zagam; AT-4140; 33967_RIEDEL; SMR000466312; AT 4140; AC1Q29E9; CPD000466312; Sparfloxacine [INN-French]; CI-978; 5-Amino-1-cyclopropyl-7-(cis-3,5-dimethyl)-6,8- difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid & RU 40555; Sparfloxacin & RU 40555; CP-103826; CHEMBL850; AC1L1TB5; PD 131501; MLS000759417; C07662; 56968_SIGMA; AC-11574; Sparfloxacine; I06-1320; CP 103826; sparfloxacin; NCGC00166294-01; UNII-Q90AGA787L; 5-amino-1-cyclopropyl-7-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-6,8-difluoro-4-oxoquinoline-3-carboxylic acid; RP-64206; DRG-0143; LS-141521; CID60464; SAM001246566; 5-Amino-1-cyclopropyl-7-(cis-3,5-dimethyl-1-piperazinyl)- 6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid; cis-5-Amino-1-cyclopropyl-7-(3,5-dimethyl-1-piperazinyl)-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid	110871-86-8	60464	9864	TTDS00080	DNA topoisomerase II	DNA gyrase;Topo II;Topoisomerase II;Type II topoisomerase enzyme	Q02880	7155	ENSG00000077097	inhibitor
DAP001479	Fluoroquinolone	N/A	147059-72-1	47318	48414254	TTDS00080	DNA topoisomerase II	DNA gyrase;Topo II;Topoisomerase II;Type II topoisomerase enzyme	Q02880	7155	ENSG00000077097	inhibitor
DCL000995	SNS-595	vosaroxin; CID 9952884; AG 7352; SPC-595; CHEMBL68117; SNS 595; CID9952884; 175414-77-4; Voreloxin (USAN); D08024; Voreloxin; SNS-595; 1,4-Dihydro-7-(3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid; AG-7352; SPC 595; 1,8-Naphthyridine-3-carboxylic acid, 1,4-dihydro-7-(3-methoxy-4-(methylamino)-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-, (3S-trans)-; ( )-AG-7352	175414-77-4	16129638	47207769	TTDS00080	DNA topoisomerase II	DNA gyrase;Topo II;Topoisomerase II;Type II topoisomerase enzyme	Q02880	7155	ENSG00000077097	inhibitor
DAP000159	Gatifloxacin	CHEBI:5280; Kinome_3137; MLS000040259; BRD-A74980173-001-02-8; (+-)-1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; Gatifloxacin; SAM002589955; PD-135432; Zymaxid; KBio2_007578; 180200-66-2; 1-cyclopropyl-6-fluoro-8-methoxy-7-(3-methylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; MLS000759493; Tequin; SMR000043336; Spectrum3_000999; 112811-59-3; BMS-206584; AM 1155; 3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-; Gatiflo; 1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; AM-1155 (*Sesquihydrate*); Zymer; CG-5501; Gatifloxacin & Gamma Interferon; Gatifloxacin (TN); 160738-57-8; I06-2286; AM-1155; S1340_Sellekc; KBio3_001917; D08011; Spectrum2_000487; KBioGR_001613; NCGC00095126-02; 1-cyclopropyl-6-fluoro-8-methoxy-7-(3-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid; S1340_Selleck; Gatifloxacin [USAN:INN]; 1-Cyclopropyl-1,4-dihydro-6-fluoro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; MolPort-001-738-626; Spectrum_001909; NCGC00178525-01; Zymer (TN); TL8001438; HMS2090K10; BMS-206584-01; I06-2287; PD135432; CPD000043336; C07661; KBio2_002442; KBio2_005010; BSPBio_002697; AC1L1K82; Tequin in dextrose 5% in plastic container; FT-0082686; Zymar; Spectrum4_001127; KBioSS_002448; GTFX; Spectrum5_001468; HMS2093G06; HMS1922J15; NCGC00095126-01; Gatispan; CHEMBL31; CG 5501; PD 135432; Gatilox; STK801620; SAM001246715; AC-1944; Gatiflo,Tequin and Zymar,  Gatifloxacin; BMS 206584-01; AKOS004119932; BB_SC-1123; DB01044; SPBio_000353; SPECTRUM1504272; Gaity; Gatifloxacin (INN); Bonoq; CID5379; LS-184402; Gatiquin	112811-59-3	5379	9863	TTDS00080	DNA topoisomerase II	DNA gyrase;Topo II;Topoisomerase II;Type II topoisomerase enzyme	Q02880	7155	ENSG00000077097	inhibitor
DCL000332	Salvicine	N/A	N/A	63952	49707200	TTDS00080	DNA topoisomerase II	DNA gyrase;Topo II;Topoisomerase II;Type II topoisomerase enzyme	Q02880	7155	ENSG00000077097	inhibitor
DAP000651	Teniposide	4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-2-thenylidene-beta-D-glucopyranoside); Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-2-thenylidene-beta-D-glucopyranoside); Vumon; MolPort-003-666-525; BRD-A35588707-001-02-2; CID6708778; CID107642; Spectrum_001549; CID275784; I06-2040; KST-1A3576; KBio2_007165; HMS2093O15; D02698; 29767-20-2; KBio3_002939; Vumon (TN); KBioGR_001050; LS-63999; DB00444; CID5284623; 55256-09-2; AC1L32H7; Teniposide [USAN:BAN:INN]; Teniposidum; AC1L1K9H; FT-0080118; Ambap29767-20-2; VM 26; KBio1_001832; NCI60_000540; Teniposido [INN-Spanish]; Spectrum5_001111; KBio2_004597; Epipodophyllotoxin-beta-D-thenylidene-glucoside, 4'-demethyl-; BSPBio_003436; CID5396; MLS000766234; AC1L5IF3; Spectrum2_001647; Vumon, VM-26, Vehem, NSC 122819, Teniposide; Teniposido; 4'-Demethyl-epipodophyllotoxin-beta-D-thenylidene-glucoside; KBioSS_002029; Vehem; Neuro_000056; teniposide; EINECS 249-831-2; AR-1A6252; 4'-Demethylepipodophyllotoxin-beta-D-thenylidine glucoside; C32H32O13S; CID34698; Veham-Sandoz; Vee M-26; S1787_Selleck; Spectrum3_001898; 35317-44-3; CHEMBL278534; AC1L9QDK; PTG; NSC 122819; Spectrum4_000585; Demethyl Epipodophyllotoxin Thenylidine Glucoside; KST-1A5976; VM-26; HMS1922B15; SPBio_001773; AR-1A6526; DivK1c_006888; Teniposidum [INN-Latin]; HSDB 6546; Teniposide (USAN/INN); 31514-29-1; MolPort-005-940-276; CCRIS 2058; NSC 12819; SpecPlus_000792; SPECTRUM1504094; C11153; 4'-Demethylepipodophyllotoxin 9-(4,6-O-2-thenylidene-beta-D-glucopyranoside); AC1NR4S8; 4'-Demethylepipodophyllotoxin thenylidene glucoside; CID452548; AC1L1S3X; AC1O8FOE; 4-Demethylepipodophyllotoxin-.beta.-D-thenylideneglucoside; KBio2_002029; UNII-957E6438QA; 23362-13-2; NSC122819; AC-759; MolPort-006-822-656; 4'-Dimethyl-9-(4,6-O-2-thenyid)-epipodophyllotoxin; 299-36-5; NSC-122819; SMR000528847	29767-20-2	34698	176397	TTDS00080	DNA topoisomerase II	DNA gyrase;Topo II;Topoisomerase II;Type II topoisomerase enzyme	Q02880	7155	ENSG00000077097	inhibitor
DAP000158	Moxifloxacin	DB00218; CHEMBL32; 186826-86-8; MXF; LS-141510; (1'S,6'S)-1-Cyclopropyl-7-(2,8-diazabicyclo[4.3.0]non-8-yl)-6-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; CID152946; 151096-09-2; AC1L49EP; moxifloxacin; I06-1961; Avelox I.V.; UNII-U188XYD42P; BAY 12-8039 (*Hydrochloride*); Actira (*Hydrochloride*); CCRIS 8690; Moxifloxacin [INN:BAN]; 3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-((4aS,7aS)-octahydro-6H-pyrrolo(3,4-b)pyridin-6-yl)-4-oxo-; MFX; Avelox (*Hydrochloride*); Vigamox; 192927-63-2; Avelox; 7-[(4aS,7aS)-1,2,3,4,4a,5,7,7a-octahydropyrrolo[3,4-b]pyridin-6-yl]-1-cyclopropyl-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid; 1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-((4aS,7aS)-octahydro-6H-pyrrolo(3,4-b)pyridin-6-yl)-4-oxo-3-quinolinecarboxylic acid; MXFX	354812-41-2	152946	730447	TTDS00080	DNA topoisomerase II	DNA gyrase;Topo II;Topoisomerase II;Type II topoisomerase enzyme	Q02880	7155	ENSG00000077097	inhibitor
DAP000817	Nalidixic Acid	Uriclar; Acide nalidixique; LS-72; BSPBio_000113; Unaserus; nalidixic acid; Narigix; UNII-3B91HWA56M; SPBio_002034; SMR000058264; Nevigramon; Acido nalidixico; Nalidixinic acid; 1-Ethyl-7-methyl-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid; Sicmylon; AKOS000120074; Jicsron; 1-Aethyl-7-methyl-1,8-naphthyridin-4-on-3-karbonsaeure [German]; NINDS_000058; Poleon; KBio3_001109; CCRIS 2365; Eucistin; NCGC00021730-04; KBio2_006534; Urisal; naladixic acid; SPECTRUM1500756; NCGC00021730-03; CPD000058264; Oprea1_010545; N-1200; KBio2_001398; Nalidixate; Nalidixan; NegGram; Dixinal; SAM002554914; 1-Ethyl-1,4-dihydro-7-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid; HMS1921G10; KBio1_000058; Nalix; Nalidixic acid USP27; NCGC00021730-05; Acido nalidixico [INN-Spanish]; BIDD:GT0529; Acide 1-etil-7-metil-1,8-naftiridin-4-one-3-carbossilico [Italian]; Acide nalidixique [INN-French]; BSPBio_001889; KBioSS_001398; 1-Ethyl-7-methyl-1,4-dihydro-1,8-naphthyridin-4-one-3-carboxylic acid; SR-01000003086-4; Nalidixane; Specifin; D00183; Cybis; Wintron; Wintomylon; 5-25-07-00384 (Beilstein Handbook Reference); 1,4-Dihydro-1-ethyl-7-methyl-1,8-naphthyridin-4-one-3-carboxylic acid; 1-Ethyl-1,4-dihydro-7-methyl-4-oxo-1,8-naphthyridine-3-carboxilic acid; WIN 18,320; Acide 1-etil-7-metil-1,8-naftiridin-4-one-3-carbossilico; Nalidixic acid [USAN:INN:BAN:JAN]; Uropan; 3-Carboxy-1-ethyl-7-methyl-1,8-naphthyridin-4-one; Dixiben; Nalidixic acid (JP15/USP/INN); Nogram; NCGC00021730-06; Nalitucsan; NCIOpen2_004342; Spectrum2_001360; 3-Carboxy-1-ethyl-7-methyl-1,8-naphthidin-4-one; HMS2092K04; BB_NC-2103; Acide nalidixique [French]; AC1Q310A; wil 18,320; Acido nalidissico; BRN 0750515; Nalurin; Lopac0_000837; Nicelate; STK735579; N5035_SIAL; BRD-K47886988-323-03-0; NCGC00018181-01; CHEMBL5; 3374-05-8 (hydrochloride salt, anhydrous); Acid, Nalidixic; Uroneg; Prestwick2_000187; VU0239598-6; CID4421; Negram; Nalidic acid; 389-08-2; 1-Ethyl-7-methyl-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid; UPCMLD-DP129:001; MLS001148578; 1-Aethyl-7-methyl-1,8-naphthyridin-4-on-3-karbonsaeure; Betaxina; Sodium Nalidixic Acid, Monohydrate; NegGram (TN); Uralgin; D009268; BPBio1_000125; Naxuril; Spectrum_000918; NCGC00021730-07; Specifen; WLN: T66 BN EV JNJ B2 DVQ I1; NCI-C56199; Naldixic acid; Acidum nalidixicum [INN-Latin]; MolPort-001-769-233; S2328_Selleck; HMS561K17; NSC82174; Prestwick3_000187; MLS002303041; 1,8-Naphthyridine-3-carboxylic acid, 1-ethyl-1,4-dihydro-7-methyl-4-oxo-; Acido nalidissico [DCIT]; Acide nalidixico; N0490; N8878_SIAL; 1,4-Dihydro-1-ethyl-7-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid; EINECS 206-864-7; Spectrum3_000075; DivK1c_000058; HMS500C20; AC1L1I4P; MLS000028504; Acidum nalidixicum; Kusnarin; Acide nalidixico [Italian]; WIN 183203; UPCMLD-DP129; Nalidixic; Prestwick1_000187; Uronidix; Sodium Nalidixic Acid, Anhydrous; NALIDIXATE SODIUM; Maybridge1_007101; DB00779; NCI60_041807; CHEBI:100147; Innoxalon; Prestwick0_000187; Urodixin; KBioGR_001333; C05079; HSDB 3241; InChI=1/C12H12N2O3/c1-3-14-6-9(12(16)17)10(15)8-5-4-7(2)13-11(8)14/h4-6H,3H2,1-2H3,(H,16,17; Uriben; Nalidixin; 1-ethyl-7-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid; NSC-82174; Sodium, Nalidixate; Uroman; WIN-18320; Spectrum5_001540; Spectrum4_000817; SPBio_001579; KBio2_003966; 1-ethyl-7-methyl-1,4-dihydro-1,8-naphthyridin-4-one-3-ca rboxylic acid; ZERO/002632; IDI1_000058; Nalidicron	389-08-2	4421	7525	TTDS00080	DNA topoisomerase II	DNA gyrase;Topo II;Topoisomerase II;Type II topoisomerase enzyme	Q02880	7155	ENSG00000077097	inhibitor
DAP000655	Ofloxacin	Floxin (TN); BPBio1_000345; Prestwick3_000237; 33703_FLUKA; Oflocee; SPBio_001387; Floxstat; Inoflox; Praxin; 83380-47-6; HMS1921H12; KBio2_006802; 85344-55-4; KBio1_000721; Exocine; Ofloxacine; MLS000028749; ORF 18489; DEXTROFLOXACINE; Otonil; O-Flox; PT 01; Tabrin; Loxinter; Ofloxacin, (S)-Isomer; ( -)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)(1,4)benzoxazin-6-carbonsaeure; MolPort-000-873-068; ORF-28489; SAM002264629; Medofloxine; NCGC00094219-05; NCGC00178284-02; Onexacin; DL-8280, HOE-280, Exocin, Flobacin, Floxin, Floxil, Monoflocet, Ofloxacin; Ofloxacino; Quotavil; Lopac0_000904; Oxaldin; SPBio_002234; S1463_Selleck; Sinflo; KBio3_002617; Ofloxacina; HMS2090F07; DivK1c_000721; HMS502E03; Hoe-280; Visiren; Rilox; STK256723; NCGC00178284-01; NCGC00094219-02; MLS001074203; Quinolon; 7H-Pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid, 2,3-dihydro-9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-, (+-)-; (+/-)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7- -oxo-7H-pyrido(1,2,3-de)- -1,4-benzoxazine-6-carboxylic acid; Oflodura; Novecin; Fugacin; OFX; Ru-43280; Operan; EU-0100904; Ofloxacin Otic; Ofus; C07321; KBio2_004234; 82419-36-1; Ofloxacine [French]; Marfloxacin; KBio2_001666; UNII-A4P49JAZ9H; Orocin; (+-)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid; Prestwick2_000237; Floxil; AKOS001033517; NCGC00094219-04; Obide; DL-8280; Kinoxacin; Prestwick0_000237; Oflodal; Qinolon; D00453; Liflox; FLOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER; Zanocin; CHEBI:7731; Uro Tarivid; BRD-A24228527-001-05-9; Ofloxacinum [Latin]; SPECTRUM1502044; 7H-Pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid, 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-, (+-)-; Oflin; Flotavid; Oflocet; BSPBio_000313; Effexin; HOE 280; C18H20FN3O4; XED; ofloxacin; MolPort-000-422-241; AC-7616; Ofloxacine; DL-8280; HOE-280; 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid; IDI1_000721; Ofcin; Oflox; O 8757; NCGC00094219-03; CID4583; Mergexin; O8757_SIGMA; WP-0405; (+/-)-Floxin; Viotisone; AB00513820; Pharflox; CCRIS 5233; NCGC00015772-10; Floxin otic; 118120-51-7 (hydrochloride); Danoflox; (+/-)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperaz inyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid; Ofloxin; I06-0112; Oflocin; Spectrum_001186; Taravid; Prestwick1_000237; FLOXIN IN DEXTROSE 5%; Qipro; SMR000058192; Floxal; Flobacin; KBioSS_001666; KBioGR_000667; Oprea1_242882; DL 8280; Spectrum4_000324; Flodemex; Nufafloqo; DB01165; HMS1568P15; Exocin; I06-0380; (+/-)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid; Floxin; 33703_RIEDEL; Spectrum5_001063; 7H-Pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid, 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-; NSC727071; NCGC00015772-02; Ofloxacina [DCIT]; AC1L1IHM; Puiritol; Oflodex; Flovid; LS-133259; Telbit; OFLX; HMS2092B10; Ofloxacin (JP15/USP/INN); NCGC00094219-06; BSPBio_003117; Spectrum2_001464; Ofloxacin [USAN:BAN:INN:JAN]; Ofloxacino [Spanish]; Bactocin; BB_SC-1252; Ocuflox; CPD000058192; Kinflocin; Tructum; Tariflox; Spectrum3_001499; BRN 3657947; Occidal; NCGC00094219-01; Ofloxacinum; Tarivid; CHEMBL4; NINDS_000721	82419-36-1	4583	192373	TTDS00080	DNA topoisomerase II	DNA gyrase;Topo II;Topoisomerase II;Type II topoisomerase enzyme	Q02880	7155	ENSG00000077097	inhibitor
DAP000046	Amsacrine	NSC249992; CI 880; Methanesulfonamide, N-[4-(9-acridinylamino)-3-methoxyphenyl]-; Lamasine; Amekrin; UNII-00DPD30SOY; D02321; Amsacrine [USAN:BAN:INN]; N-[4-(Acridin-9-ylamino)-3-(methyloxy)phenyl]methanesulfonamide; N-[4-(acridin-9-ylmethyl)-3-methoxyphenyl]methanesulfonamide; AB1004823; AC1L1D3L; Methanesulfonanilide, 4'-(9-acridinylamino)-3'-methoxy-; Amsacrine (USAN/INN); BRN 0500176; NCIMech_000607; Methanesulfonamide, N-(4-(9-acridinylamino)-3-methoxyphenyl)-; SN 21429; 4'-(9-Acridinylamino)methanesulfon-m-anisidide; NSC-141549; NSC-156303; C01553; m-AMSA; 4'-(9-Acridinylamino)-3'-methoxymethanesulfonanilide; mAMSA; nchembio.100-comp16; Neuro_000118; NSC 249992; SN-11841; meta-AMSA; amsacrine; Lopac-A-9809; AMSA, M-; Amsine; Amsidine; N-[4-(acridin-9-ylamino)-3-(methyloxy)phenyl]methanesulfonamide; N-[4-(9-Acridinylamino)-3-methoxyphenyl]methanesulfonamide; NSC-249992; 4'-(9-Acridinylamino)methanesulfon-meta-anisidide; SN11841; LS-1319; CI-880; meta-Amsacrine; nAMSA; DB00276; C21H19N3O3S; Methanesulfon-m-anisidide, 4'-(9-acridinylamino)-; CID2179; AMSA P-D; EINECS 257-094-3; Amsidyl; Amsacrinum [INN-Latin]; Lopac0_000154; N-(4-(Acridin-9-ylamino)-3-methoxyphenyl)methanesulfonamide; CHEBI:2687; NCGC00162077-01; CCRIS 1027; N-(4-(9-Acridinylamino)-3-methoxyphenyl)methanesulfonamide; WLN: T C666 BNJ IMR BO1 DMSW1; 5-22-11-00030 (Beilstein Handbook Reference); N-[4-(acridin-9-ylamino)-3-methoxyphenyl]methanesulfonamide; CHEMBL43; NCI60_001995; NSC 156303; NCGC00015113-03; Amsacrina [INN-Spanish]; Amecrin; Acridinyl Anisidide; nchem.981-comp12; NCI-249992; 4'-(9-Acridinylamino)methanesulphon-m-anisidide; Amsidyl (TN); HSDB 7087; NCGC00015113-01; Acridinylanisidide; 51264-14-3; Amsacrinum; Amsacrina; N-[4-(9-Acridinylamino)-3-methoxy-phenyl]methanesulfonamide; I14-9555; Cain's Acridine	51264-14-3	2179	4711	TTDS00080	DNA topoisomerase II	DNA gyrase;Topo II;Topoisomerase II;Type II topoisomerase enzyme	Q02880	7155	ENSG00000077097	inhibitor
DAP001342	Aclarubicin	MolPort-004-845-383; AC1L27WP; LS-93909; NSC 208734; KBio2_003515; CID152688; Aclarubicin (USAN/INN); KBio2_006083; AC1L48VL; Aclacin; CID154943; SMP1_000003; Antibiotic MA 144A1; Aclarubicino [INN-Spanish]; BCBcMAP01_000191; CID6712061; MolPort-003-665-565; MolPort-003-983-841; 64520-15-6; NSC240619; 10-epi-Aclacinomycin A; NINDS_000678; acene-1-carboxylate; QTL1_000003; CID451415; 72711-48-9; 79617-46-2; KBio1_000678; NCIMech_000395; Spectrum_000467; HMS502B20; C42H53NO15; AC1L4DB3; CHEMBL45414; CHEBI:170281; DivK1c_000678; .alpha.-L-lyxo-hexopyranosyl]-oxy]-1-naphthacenecarboxalic acid methyl ester; Aclarubicino; Neuro_000108; AC1O8MK9; NSC-208734; Antibiotic MA144-A1; KBioGR_001156; Spectrum2_001934; AC1L9PMJ; Spectrum4_000768; Aclarubicin [USAN:BAN:INN]; STK177207; MA 144G1; IDI1_000678; LS-93950; MA 144-A1; D02756; LS-93943; A8959_SIGMA; NSC208734; Aclarubicine [INN-French]; Aclarubicine; AC1L1CQ0; Antibiotic MA 144G1; Spectrum5_001041; KBioSS_000947; NCI60_001746; CCRIS 2262; 57576-44-0; NCI60_018879; AC1O8OA8; aclarubicin; CID6713097; Aclacur; Jaclacin; UNII-74KXF8I502; SPBio_001967; AC1L7CAE; EINECS 260-824-3; CID42474; KBio2_000947; Aclacinomycin A; CID2008; HMS2089B13; 77448-81-8; CID308141; Aclucinomycin A; MA-144A1; NSC-208,734; Antibiotic MA 144A; CHEMBL502620; Aclarubicinum; Aclarubicinum [INN-Latin]	57576-44-0	451415	17396914	TTDS00080	DNA topoisomerase II	DNA gyrase;Topo II;Topoisomerase II;Type II topoisomerase enzyme	Q02880	7155	ENSG00000077097	inhibitor
DCL000396	GSK945237	N/A	N/A	N/A	N/A	TTDS00080	DNA topoisomerase II	DNA gyrase;Topo II;Topoisomerase II;Type II topoisomerase enzyme	Q02880	7155	ENSG00000077097	inhibitor
DAP000653	Lomefloxacin	DB00978; TL8006033; UNII-9VC7S3ZXXB; SC-47111 (hydrochloride); SC 47111A; CHEMBL561; BSPBio_003107; BSPBio_000315; Lomefloxacinum [Latin]; SPBio_000851; 98079-52-8 (HYDROCHLORIDE); BRD-A75850590-003-05-6; 98079-51-7; 3-Quinolinecarboxylic acid, 1,4-dihydro-6,8-difluoro-1-ethyl-7-(3-methyl-1-piperazinyl)-4-oxo-; Prestwick2_000238; CID3948; Lomefloxacin (USAN); L2906_SIGMA; ST072201; BRN 4210041; NY-198 (hydrochloride); DM 10 (bactericide); Prestwick0_000238; 1,4-Dihydro-6,8-difluoro-1-ethyl-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; SC-4711; (+-)-1-Ethyl-6,8-difluoro-1,4-dihydro-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; KBio3_002607; lomefloxacin; SC-47111B (mesylate); NCGC00178293-02; Prestwick1_000238; Maxaquin (hydrochloride); KBio2_007047; Lomefloxacino [Spanish]; KBio2_004479; BPBio1_000347; SMP1_000287; D02318; CCRIS 6305; C17H19F2N3O3; DivK1c_000365; LS-141570; KBio2_001911; SC-47111A; 1-ethyl-6,8-difluoro-7-(3-methylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 3-Quinolinecarboxylic acid, 1-ethyl-6,8-difluoro-1,4-dihydro-7-(3-methyl-1-piperazinyl)-4-oxo-, monohydrochloride; Lopac0_000678; NCGC00178293-01; Spectrum3_001494; C07078; DM-10; Prestwick3_000238; 1-ethyl-6,8-difluoro-7-(3-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid; KBioSS_001911; NCGC00162221-01; 3-Quinolinecarboxylic acid, 1-ethyl-6,8-difluoro-1,4-dihydro-7-(3-methyl-1-piperazinyl)-4-oxo- (+/-); SC 4711; CHEBI:116278; Lomefloxacine; 1-Ethyl-6,8-difluoro-1,4-dihydro-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; Spectrum5_001246; Lomefloxacin [USAN:BAN:INN]; Lomefloxacino; IDI1_000365; Spectrum2_000696; AC1L1H2N; (+-)-1-Ethyl-6,8-difluoro-1,4-dihydro-7-(3-methyl-1-piperazinyl)-4-; NCGC00015603-05; SPBio_002236; NINDS_000365; HMS2090O16; KBio1_000365; Spectrum4_000158; Lomefloxacine [French]; UNII-L6BR2WJD8V; KBioGR_000636; 3-Quinolinecarboxylic acid, 1-ethyl-6,8-difluoro-1,4-dihydro-7-(3-methyl-1-piperazinyl)-4-oxo-, (+-)-; Lomefloxacinum; Spectrum_001431; LFLX	98079-51-7	3948	9289	TTDS00080	DNA topoisomerase II	DNA gyrase;Topo II;Topoisomerase II;Type II topoisomerase enzyme	Q02880	7155	ENSG00000077097	inhibitor
DAP000190	Ciprofloxacin	UNII-5E8K9I0O4U; C17H18FN3O3; CCRIS 5241; DivK1c_000095; BAY q 3939; Cipro I.V.; SPBio_002065; Ciprofloxacino; BRD-K04804440-311-02-3; ARONIS020379; ciprofloxacin; Bay-09867; Cifloxin; Ciprofloxacin hydrochloride; Ciflox; BSPBio_003344; MLS001336035; 1-Cyclopropyl-6-fluoro-1,4-dihydro-7-(1-piperazinyl)-4-oxo-3-quinoline carboxylic acid; Fimoflox; Ciprodar; CPFX; Ciprofloxacino [INN-Spanish]; Prestwick1_000113; BAY-Q-3939; Cipro (TN); Proksi 500; HMS2093I03; KBio3_002846; Proflox; Spectrum_000162; 17850_FLUKA; Ciprofloxacine; BIDD:GT0205; Cixan; Cycin; Ciprecu; Prestwick0_000113; Spectrum3_001872; Bi-Cipro; D00186; Alcon Cilox; IDI1_000095; 3-Quinolinecarboxylic acid,1,4-dihydro-1-cyclopropyl-6-fluoro-4-oxo-7-(1-piperazinyl); KBioGR_001567; Velomonit; AC-7613; 1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid; Quinolid; SMP1_000125; Ipiflox; NCGC00095058-02; KBio2_003210; Cipromycin; Ciprofloxacinum [INN-Latin]; Ciprofloxacin monohydrochloride; 1-cyclopropyl-6-fluoro-7-hexahydro-1-pyrazinyl-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid; Ciplus; AC1L1EEW; 33434_RIEDEL; 1-CYCLOPROPYL-6-FLUORO-4-OXO-7-PIPERAZIN-1-YL-1,4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID; CAS-93107-08-5; CID2764; CIPRO IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER; Ciprobay; Ciprobay Uro; 1-Cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydro-quinoline-3-carboxylic acid; Sophixin Ofteno; 3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-; Baflox; KBio1_000095; Cipro IV; Ciprolin; 1-Cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperzinyl)-3-quinolinecarboxylic acid HCl H2O; CHEBI:100241; Superocin; HMS1922E18; Septicide; 33434_FLUKA; Ciproxan; SPBio_001474; Ciprofloxacin (JAN/USP/INN); KBio2_005778; 1-Cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid; BAS 06989041; Ciproxina; BRN 3568352; Ciprofloxacin [USAN:INN:BAN]; AKOS000269653; Corsacin; Ciprolon; Cipro XR; HSDB 6987; Rancif; 3-Quinolinecarboxylic acid, 1,4-dihydro-1-cyclopropyl-6-fluoro-4-oxo-7-(1-piperazinyl)-; Ciprocinol; Cilab; Ciprofloxacine [INN-French]; Spectrum2_001567; 1-cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid; Ciprofloxacin Hydrchloride; Proksi 250; Cyprobay; Ciproquinol; Spectrum5_001089; Liposomal-ciprofloxacin; Prestwick2_000113; NINDS_000095; Ciprowin; Proflaxin; NCGC00095058-01; CRL-1605 & Ciprofloxacin; HMS2090O07; BSPBio_000126; Eni; 85721-33-1; Probiox; Bay o 9867 (*Hydrochloride*); KBio2_000642; NCGC00178128-01; MolPort-000-819-654; STK021082; Baycip; Quintor; CPF; CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER; Ciproxine; Spitacin; BPBio1_000140; Oprea1_313572; SPECTRUM1503614; Cipro; Ciproxin; BAYQ3939; CHEMBL8; Loxan; Cipro (*Hydrochloride*); Bio-0540; Bacquinor; Prestwick3_000113; Flociprin; Unex; Ciprofloxacina; Cipro XL; SMR000471901; LS-141563; Ciprofloxacin HCl; NSC620634; Bernoflox; Zumaflox; Bay o 9867; Citopcin; Ciprofloxacinum; DB00537; Spectrum4_000874; Ciprogis; Roxytal; nchembio820-comp1; Ciprofloxacin dihydrochloride; Italnik; 1-Cyclopropyl-6-fluoro-4-oxo-7-(1-piperazinyl)-1,4-dihydro-3-quinolinecarboxylic acid; C05349; NCGC00016959-01; CBMicro_048498; Ciloxan (*Hydrochloride*); HMS500E17; Oprea1_008239; Ciprinol; Ciriax; Ciproflox; KBioSS_000642	85721-33-1	2764	192835	TTDS00080	DNA topoisomerase II	DNA gyrase;Topo II;Topoisomerase II;Type II topoisomerase enzyme	Q02880	7155	ENSG00000077097	inhibitor
DAP001500	Novobiocine	Stilbiocina; Spectrum2_000977; Novobiocine; Novo-R; KBio2_007538; C05080; ACon1_001693; 1aj6; ACon0_000808; KBio3_001615; Novobiocina [INN-Spanish]; DB01051; Albamycin; novobiocin; U 6391; (3r,4s,5r,6r)-5-hydroxy-6-[(2-hydroxy-3-{[4-hydroxy-3-(3-methylbut-2-en-1-yl)benzoyl]amino}-8-methyl-4-oxo-4h-chromen-7-yl)oxy]-3-methoxy-2,2-dimethyltetrahydro-2h-pyran-4-yl carbamate(non-preferred name); AR-1A4403; KBioSS_002407; AI3-50148; SPBio_001013; (3R,4S,5R,6R)-5-hydroxy-6-{[4-hydroxy-3-({[4-hydroxy-3-(3-methylbut-2-en-1-yl)phenyl]carbonyl}amino)-8-methyl-2-oxo-2H-chromen-7-yl]oxy}-3-methoxy-2,2-dimethyltetrahydro-2H-pyran-4-yl carbamate; Streptonivicin; nchembio.2007.28-comp33; Spectrum3_000528; SMR000718617; Novobiocinum; HSDB 7443; Novobiocinum [INN-Latin]; 4309-70-0 (calcium salt); 303-81-1; Crystallinic acid; KBio1_000260; AC1L1SUS; CID9346; MEGxm0_000273; 1476-53-5; BRD-K85307935-236-02-0; [(3R,4S,5R,6R)-5-hydroxy-6-[2-hydroxy-3-[[4-hydroxy-3-(3-methylbut-2-enyl)benzoyl]amino]-8-methyl-4-oxochromen-7-yl]oxy-3-methoxy-2,2-dimethyloxan-4-yl] carbamate; KBio2_006617; Cathomycin; KBio2_004970; C31H36N2O11; KBioSS_001481; Spectrum5_001274; Antibiotic PA-93; CHEMBL36506; Robiocina; LS-25404; Spectrum_001001; N-[7-[[3-O-(Aminocarbonyl)-6-deoxy-5-C-methyl-4-O-methyl-.beta.-L-lyxo-hexopyranosyl]oxy]-4-hydroxy-8-methyl-2-oxo-2H-1-benzopyran-3-yl]-4-hydroxy-3-(3-methyl-2-butenyl); Novobiocin sodium salt; 4676-58-8; IDI1_000260; AC1Q6NLU; Novobiocina; cMAP_000043; Spectrum4_000457; NOV; MolPort-000-771-685; KBio2_004049; KBioGR_002402; DivK1c_000260; Cardelmycin; KBio3_002881; 7-(Carbamoyltetrahydro-3-hydroxy-5-methoxy-6,6-dimethylpyran-2-yloxy)-4-hydroxy-3-(4-hydroxy-3-(3-methylbut-2-enyl)benzamide)-8-methyl-2H-chromen-2-one; 1476-53-5 (mono-hydrochloride salt); BSPBio_002115; Coumarin, 7-(4-(carbamoyloxy)tetrahydro-3-hydroxy-5-methoxy-6,6-dimethylpyran-2-yloxy)-4-hydroxy-3-(4-hydroxy-3-(4-hydroxy-3-(3-methyl-2-butenyl)benzamido)-8-methyl-; KBio2_001481; PA 93; Spheromycin; Sirbiocina; EINECS 206-146-3; Albamix; NINDS_000260; Streptonivicin (*Sodium salt*); Novobiocine [INN-French]; UNII-17EC19951N; KST-1A4924; 7-(3-(O-Carbamoyl)-4-(O-methyl)-5,5-dimethyl-alpha-L-lyxopyranosyloxy)-4-hydroxy-3-(4-hydroxy-3-(3-methyl-2-butenyl)benzamidol)-8-methylcumarin; Benzamide, N-(7-((3-O-(aminocarbonyl)-6-deoxy-5-C-methyl-4-O-methyl-beta-L-lyxo-hexopyranosyl)oxy)-4-hydroxy-8-methyl-2-oxo-2H-1-benzopyran-3-yl)-4-hydroxy-3-(3-methyl-2-butenyl)-; KBio2_002402; KBioGR_000874; STOCK1N-34236; Inamycin; Novobiocin [INN:BAN]; MLS001032086; CHEBI:148697; Cathocin	4309-70-0	5460341	163120	TTDS00080	DNA topoisomerase II	DNA gyrase;Topo II;Topoisomerase II;Type II topoisomerase enzyme	Q02880	7155	ENSG00000077097	binder
DCL000018	CAP-232	CID6918265; TLN-232; AC1OCF7X; CAP-232; (4R,7S,10R,13S,16R)-7-(4-aminobutyl)-N-[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]-16-[[(2R)-2-amino-3-phenylpropanoyl]amino]-13-[(4-hydroxyphenyl)methyl]-10-(1H-indol-3-ylmethyl)-6,9,12,15-tetraoxo-1,2-dithia-5,8,11,14-tetrazacycloheptadecane-4-carboxamide; CHEMBL539934	N/A	6918265	12014851	TTDC00034	Somatostatin receptor type 4	SS4R;SSTR4	P31391	6754	ENSG00000132671	agonist
DAP001546	Vitamin B3	N/A	N/A	N/A	N/A	TTDC00317	Nicotinic acid receptor	GPR109A;G-protein coupled receptor 109A;G-protein coupled receptor HM74A;HM74A;Niacin receptor 1;NIACR1	Q8TDS4	338442	ENSG00000182782	agonist
DCL000543	INCB19602	N/A	N/A	N/A	N/A	TTDC00317	Nicotinic acid receptor	GPR109A;G-protein coupled receptor 109A;G-protein coupled receptor HM74A;HM74A;Niacin receptor 1;NIACR1	Q8TDS4	338442	ENSG00000182782	agonist
DCL000376	GSK256073	N/A	N/A	N/A	N/A	TTDC00317	Nicotinic acid receptor	GPR109A;G-protein coupled receptor 109A;G-protein coupled receptor HM74A;HM74A;Niacin receptor 1;NIACR1	Q8TDS4	338442	ENSG00000182782	agonist
DCL001066	AGN211745	N/A	N/A	N/A	N/A	TTDC00288	mRNA of Vascular endothelial growth factor receptor	N/A	N/A	N/A	N/A	N/A
DCL000436	Anti-oxLDL	N/A	137945-48-3	3083542	36413917	TTDC00219	Tumor necrosis factor receptor superfamily member 4	ACT35 antigen;CD134 antigen;Cell surface receptor OX40;OX40 antigen;OX40L receptor;TAX-transcriptionally activated glycoprotein 1 receptor	P43489	7293	ENSG00000186827	antagonist
DCL000608	R4930	N/A	1069-66-5	5360545	49746451	TTDC00219	Tumor necrosis factor receptor superfamily member 4	ACT35 antigen;CD134 antigen;Cell surface receptor OX40;OX40 antigen;OX40L receptor;TAX-transcriptionally activated glycoprotein 1 receptor	P43489	7293	ENSG00000186827	antagonist
DCL000532	HuMAb OX40L	N/A	198153-51-4	N/A	47205819	TTDC00219	Tumor necrosis factor receptor superfamily member 4	ACT35 antigen;CD134 antigen;Cell surface receptor OX40;OX40 antigen;OX40L receptor;TAX-transcriptionally activated glycoprotein 1 receptor	P43489	7293	ENSG00000186827	antagonist
DAP000607	Tolcapone	CHEBI:367825; UNII-CIF6334OLY; 3,4-dihydroxy-5'-methyl-5-nitrobenzophenone; (3,4-Dihydroxy-5-nitrophenyl)(4-methylphenyl)methanone; Ro-40-7592; FT-0082597; Tasmar (TN); Ro 40-7592; InChI=1/C14H11NO5/c1-8-2-4-9(5-3-8)13(17)10-6-11(15(19)20)14(18)12(16)7-10/h2-7,16,18H,1H; 3,4-Dihydroxy-4'-methyl-5-nitrobenzophenone; Tolcapone (JAN/USAN/INN); AC-791; Tolcapone; AC1NFJIT; Methanone,(3,4-dihydroxy-5-nitrophenyl)(4-methylphenyl); BIDD:GT0032; 134308-13-7; MolPort-003-850-570; HMS2089K14; I14-13303; Tasmar; CID4659569; (3,4-dihydroxy-5-nitrophenyl)-(4-methylphenyl)methanone; C07949; CPD-7664; Roche brand of tolcapone; CHEMBL1324; D00786; Methanone, (3,4-dihydroxy-5-nitrophenyl)(4-methylphenyl)-; Tolcapone [USAN:INN]; CCRIS 7904; NCGC00181767-01; DB00323; C14H11NO5; LS-91226; C066340	134308-13-7	4659569	10150	TTDS00362	Catechol-O-methyl-transferase	Catechol-O-methyltransferase;COMT;MB-COMT;S-COMT	P21964	1312	ENSG00000093010	inhibitor
DCL000795	Entacapone+levodopa+carbidopa	N/A	130929-57-6 + 59-92-7	N/A	10550026	TTDS00362	Catechol-O-methyl-transferase	Catechol-O-methyltransferase;COMT;MB-COMT;S-COMT	P21964	1312	ENSG00000093010	inhibitor
DAP000608	Entacapone	D00781; C07943; ENTACAPONE; Novartis brand of entacapone; CHEMBL953; Comtan; HMS2089O16; (E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethylprop-2-enamide; COM-998; Entacapone (JAN/USAN/INN); CID5281081; Entacaponum [INN-Latin]; CHEBI:4798; DB00494; Orion brand of entacapone; OR 611; MolPort-003-847-054; AC-393; Comtess; 2-Propenamide, 2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethyl-, (2E)-; Comtan (TN); Entacaponum; LS-123327; OR-611; NCGC00164555-01; LS-172316; BIDD:GT0026; (E)-2-Cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethyl-2-propenamide; (E)-2-cyano-3-(3,4-dihydroxy-5-nitro-phenyl)-N,N-diethyl-prop-2-enamide; C14H15N3O5; 116314-67-1; Entacapone [USAN:INN]; AC1NQY02; Entacapona; UNII-4975G9NM6T; 2-Cyano-N,N-diethyl-3-(3,4-dihydroxy-5-nitrophenyl)propenamide; 2-Propenamide, 2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethyl-; N,N-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl) acrylamide; KB475572; 130929-57-6; (E)-alpha-Cyano-N,N-diethyl-3,4-dihydroxy-5-nitrocinnamamide; Entacapona [INN-Spanish]; (2E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethylprop-2-enamide; C071192	130929-57-6	5281081	197051	TTDS00362	Catechol-O-methyl-transferase	Catechol-O-methyltransferase;COMT;MB-COMT;S-COMT	P21964	1312	ENSG00000093010	inhibitor
DCL000327	Taranabant	N-((1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl)-2-methyl-2-((5-(trifluoromethyl)pyridin-2-yl)oxy)propanamide; CID 10152529; Taranabant [USAN]; MK0364; Taranabant (INN/USAN); C521311; Propanamide, N-((1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl)-2-methyl-2-((5-(trifluoromethyl)-2-pyridinyl)oxy)-; LS-193766; CHEBI:464983; Taranabant; UNII-X9U622S114; MK 0364; l]-2-methyl-2-[(5-(trifluoromethyl)pyridin-2-yl)oxy]propanamide; MK-0364; AKOS005145560; MK 0364; N-[(1S,2S)-3-(4-Chlorophenyl)-2-(3-cyanophenyl)-1-methylpropy; N-(3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl)-2-methyl-2-((5-(trifluoromethyl)pyridin-2-yl)oxy)propanamide; Propanamide, N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[[5-(trifluoromethyl)-2-pyridinyl]oxy]-; CHEMBL220360; N-[(1S,2S)-3-(4-Chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[[5-(trifluoromethyl)pyridin-2-yl]oxy]propanamide; MK-0634; CID11226090; 701977-09-5; D09009	701977-09-5	11226090	42305700	TTDS00334	Cannabinoid receptor 1	CANN6;Cannabinoid CB1 receptor;CB1;CB-R	P21554	1268	ENSG00000118432	antagonist
DCL000991	SLV-319	Ibipinabant (USAN/INN); CHEBI:464871; 464213-10-3; CID 9826744; SLV-319; CHEBI:530253; CHEMBL412262; D09349; CID11179267; CID9826744; Ibipinabant; ZINC03964747; CHEMBL158784; LS-193349; CHEBI:363997; (+/-)-SLV319	362519-49-1	1132	49689491	TTDS00334	Cannabinoid receptor 1	CANN6;Cannabinoid CB1 receptor;CB1;CB-R	P21554	1268	ENSG00000118432	antagonist
DCL001015	Tebipenem	CID9800194; Tebipenem [INN]; Tebipenem; 161715-24-8; CID 9800194; CHEMBL576981; UNII-95AK1A52I8	158681-13-1	N/A	3818219	TTDS00334	Cannabinoid receptor 1	CANN6;Cannabinoid CB1 receptor;CB1;CB-R	P21554	1268	ENSG00000118432	antagonist
DCL000962	Rimonbant	168273-06-1; Rimonabant (JAN/USAN/INN); D05731; Rimonabant; Acomplia; Acomplia (TN)	158681-13-1	104850	10587968	TTDS00334	Cannabinoid receptor 1	CANN6;Cannabinoid CB1 receptor;CB1;CB-R	P21554	1268	ENSG00000118432	antagonist
DCL000448	AVE1625	N/A	358970-97-5	N/A	N/A	TTDS00334	Cannabinoid receptor 1	CANN6;Cannabinoid CB1 receptor;CB1;CB-R	P21554	1268	ENSG00000118432	antagonist
DPR000037	Dianicline+rimonabant	N/A	292634-27-6	8378	49703385	TTDS00334	Cannabinoid receptor 1	CANN6;Cannabinoid CB1 receptor;CB1;CB-R	P21554	1268	ENSG00000118432	agonist
DCL000462	AZD2207	N/A	N/A	6398473	46507669	TTDS00334	Cannabinoid receptor 1	CANN6;Cannabinoid CB1 receptor;CB1;CB-R	P21554	1268	ENSG00000118432	antagonist
DCL000742	CBD cannabis derivative	N/A	74912-19-9	173616	750962	TTDS00334	Cannabinoid receptor 1	CANN6;Cannabinoid CB1 receptor;CB1;CB-R	P21554	1268	ENSG00000118432	antagonist
DCL001260	ZY01	N/A	N/A	N/A	N/A	TTDS00334	Cannabinoid receptor 1	CANN6;Cannabinoid CB1 receptor;CB1;CB-R	P21554	1268	ENSG00000118432	antagonist
DCL000855	KDS-2000	N/A	N/A	N/A	N/A	TTDS00334	Cannabinoid receptor 1	CANN6;Cannabinoid CB1 receptor;CB1;CB-R	P21554	1268	ENSG00000118432	agonist
DCL000459	AZD1940	N/A	N/A	64627	44929537	TTDS00334	Cannabinoid receptor 1	CANN6;Cannabinoid CB1 receptor;CB1;CB-R	P21554	1268	ENSG00000118432	agonist
DPR000182	JD-5037	N/A	N/A	N/A	N/A	TTDS00334	Cannabinoid receptor 1	CANN6;Cannabinoid CB1 receptor;CB1;CB-R	P21554	1268	ENSG00000118432	agonist
DPR000027	CB1 antagonist	N/A	168273-06-1	4037	49698868	TTDS00334	Cannabinoid receptor 1	CANN6;Cannabinoid CB1 receptor;CB1;CB-R	P21554	1268	ENSG00000118432	antagonist
DAP000207	Marinol	1-trans-.delta.(sup9)-tetrahydrocannabinol; (-)-trans-delta9-Tetrahydrocannabinol; T4764_SIGMA; PDSP2_000714; L-trans-.delta.9-Tetrahydrocannabinol; T4764_FLUKA; 9-delta-Tetrahydrocannabinol; Cannabinol, tetrahydro- (6CI); nchembio.552-comp1; delta(sup 9)-Tetrahydrocannabinol; 6465-30-1; (-)-trans-Delta1-Tetrahydrocannabinol; Cannabis resin; (-)-trans-.DELTA.9-Tetrahydrocannabinol; delta1-Tetrahydrocannabinol; nchembio.86-comp3; QCD 84924; NSC 134454; 14C-.DELTA.1-Tetrahydrocannabinol; trans-.DELTA.9-Tetrahydrocannabinol; DRG-0138; QCD-84924; .DELTA.9-THC; CCRIS 4726; trans-delta9-Tetrahydrocannabinol; Omegaven; delta9-Tetrahydrocannabinol (VAN); Fats and Glyceridic oils, fish, n-3 fatty acid-high; LS-975; Cannabinol, 1-trans-delta(sup 9)-tetrahydro-; ZINC01530625; (-)-3,4-trans-Delta1-Tetrahydrocannabinol; delta-9-tetrahydrocannabinol; delta(sup 1)-Thc; (-)-.DELTA.9-THC; delta9-THC; trans-delta-9-Tetrahydrocannabinol; MolPort-003-959-698; (L)-.delta.1-Tetrahydrocannabinol; (-)-.DELTA.1-Tetrahydrocannabinol; 308064-99-5; delta(9)-THC; EPA 28; 1-trans-delta9-Tetrahydrocannabinol; Cannabinol, Delta1-tetrahydro- (7CI); delta(1)-Tetrahydrocannabinol; Abbott 40566; delta(sup 9)-Thc; CHEBI:104496; (-)-delta9-(trans)-Tetrahydrocannabinol; Cannabinol, .DELTA.1-tetrahydro-; Sonergx; L-.delta.1-trans-Tetrahydrocannabinol; 1972-08-3; CAT-310; Marinol (TN); (-)-delta1-Tetrahydrocannabinol; Marinol; L-trans-delta9-Tetrahydrocannabinol; D00306; EPA-PLUS; Tetranabinex; 5957-27-7; Dronabinolum; delta(sup 1)-Tetrahydrocannabinol; SP 104; delta(1)-THC; Deltanyne; 9-tetrahydrocannabinol; 14146-43-1; (-)-delta9-Tetrahydrocannabinol; Dronabinolum [Latin]; (-)-delta9-trans-Tetrahydrocannabinol; Fish oils, n-3 fatty acid-high; THC-delta-9; Delta9-Tetrahydrocannabinol solution; (-)-delta(sup 1)-3,4-trans-Tetrahydrocannabinol; THC; delta9-Tetrahydrocannabinol; nchembio.129-comp1; delta9-trans-Tetrahydrocannabinol; 1-trans-delta(sup9)-tetrahydrocannabinol; trans-tetrahydrocannabinol; AC1L277U; Ganja; Dronabinol (USP/INN); (l)-delta1-Tetrahydrocannabinol; .DELTA.1-Tetrahydrocannabinol; delta1-Tetrahydrocannabinol (VAN); 9-ene-Tetrahydrocannabinol; Drona binol; Dronabinol; UNII-7J8897W37S; Cannabinol, 1-trans-.delta.(sup9)-tetrahydro-; 1-trans-D9-Tetrahydrocannabinol; AC1Q2VRZ; MaxEPA; .DELTA.1-THC; T2386_SIGMA; Hashish; Dronabinol [USAN:INN]; BIDD:GT0427; Cannabinol, delta1-tetrahydro-; Tetrahydrocannabinols (-)-delta1-3,4-trans-form; delta(9)-Tetrahydrocannabinol; L-delta1-trans-Tetrahydrocannabinol; CHEMBL465; L-delta(sup 1)-tetrahydrocannabinol; Marincap; delta1-THC; (-)-.DELTA.9-Tetrahydrocannabinol; (-)-.delta.(sup9)-trans-Tetrahydrocannabinol; .delta.-9-THC; TETRAHYDROCANNABINOL; DEA No. 7370; Namisol; NSC134454; Tetrahydrocannabinol delta9; Relivar; DB00470; Fish oils, omega-3 fatty acid-high; 1-trans-delta-9-Tetrahydrocannabinol; C06972; DEA No. 7369; delta-9-THC; .DELTA.9-trans-Tetrahydrocannabinol; L-.delta.1-Tetrahydrocannabinol; Compassia; CID16078; (l)-delta(sup 1)-Tetrahydrocannabinol; (-)-.DELTA.9-trans-Tetrahydrocannabinol; 26108-45-2; Pro-Mega; HSDB 6471; .delta.(sup9)-THC; delta-THC; 1363-19-5; omega-3-Fatty acid; 6H-Dibenzo; Promega; delta(9)-Tetrahydrocannibinol; 1-trans-delta(sup 9)-Tetrahydrocannabinol; (-)-trans-Delta9-THC; 14146-29-3	1972-08-3	16078	386512	TTDS00334	Cannabinoid receptor 1	CANN6;Cannabinoid CB1 receptor;CB1;CB-R	P21554	1268	ENSG00000118432	agonist
DCL000458	AZD1704	N/A	N/A	N/A	N/A	TTDS00334	Cannabinoid receptor 1	CANN6;Cannabinoid CB1 receptor;CB1;CB-R	P21554	1268	ENSG00000118432	antagonist
DCL001246	TM38837	N/A	N/A	N/A	N/A	TTDS00334	Cannabinoid receptor 1	CANN6;Cannabinoid CB1 receptor;CB1;CB-R	P21554	1268	ENSG00000118432	antagonist
DCL000453	AZD1175	N/A	N/A	N/A	N/A	TTDS00334	Cannabinoid receptor 1	CANN6;Cannabinoid CB1 receptor;CB1;CB-R	P21554	1268	ENSG00000118432	antagonist
DAP000307	Rimonabant	AC-163720; 5-(4-Chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-1-piperidinyl-1H-pyrazole-3-carboxamide; MolPort-003-850-185; SR-141716; Acomplia (TN); AC-731; 1H-Pyrazole-3-carboxamide, 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-1-piperidinyl-; L000572; DB06155; AC1L2XM5; I06-0381; Acomplia; SR141,716A; Rimonabant (JAN/USAN/INN); Slimona; D05731; SR141716; SR 141716; 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide; 5-(p-Chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-piperidinopyrazole-3-carboxamide; LS-128155; CHEMBL111; Rimonabant; nchembio.552-comp16; SR141716A; Rimoslim; C14319; nchembio.129-comp21; SR-141716A; NCGC00164572-01; ZINC01540228; A 281; UNII-RML78EN3XE; [3H]SR141716A; Rimonabant [USAN:INN]; CID104850; Riobant; 168273-06-1; 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-piperidin-1-ylpyrazole-3-carboxamide; STK642500	158681-13-1	104850	47207392	TTDS00334	Cannabinoid receptor 1	CANN6;Cannabinoid CB1 receptor;CB1;CB-R	P21554	1268	ENSG00000118432	antagonist
DCL000508	CP-945598	Otenabant hydrochloride (USAN); CP 945598; otenabant; CHEMBL562668; D09363; 1-[8-(2-chlorophenyl)-9-(4-chlorophenyl)purin-6-yl]-4-ethylamino-piperidine-4-carboxamide; CP-945,598; Otenabant (USAN/INN); 919516-56-6; 686347-12-6; 1-(8-(2-Chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl)-4-(ethylamino)piperidine-4-carboxamide monohydrochloride; D09362; Otenabant hydrochloride; CP-945598; CID10052040; 686344-29-6	677010-34-3	N/A	47208272	TTDS00334	Cannabinoid receptor 1	CANN6;Cannabinoid CB1 receptor;CB1;CB-R	P21554	1268	ENSG00000118432	antagonist
DCL000122	GRN163L	N/A	868169-64-6	N/A	85154791	TTDC00055	Telomerase protein component 1	p240;p80 telomerase homolog;Telomerase protein 1;Telomerase-associated protein 1	Q99973	7011	ENSG00000129566	inhibitor
DAP001307	Estramustine	Ro-22-2296/000; NSC89201; AC1L60XG; Estramustine (USAN/INN); C11228; Estra-1,3,5(10)-triene-3,17-diol, 3-[bis(2-chloroethyl)carbamate], (17.beta.)-; Estradiol 3-[bis(2-chloroethyl)carbamate]; CID259331; Estramustina; LMST02010038; BIDD:GT0482; Estra-1,3,5(10)-triene-3,17-diol (17.beta.)-, 3-[bis(2-chloroethyl)carbamate]; [(8R,9S,13S,14S,17S)-17-hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-yl] N,N-bis(2-chloroethyl)carbamate; NCGC00164581-01; CHEMBL1575; (17beta)-17-hydroxyestra-1(10),2,4-trien-3-yl bis(2-chloroethyl)carbamate; estramustine; NCI60_041982; 17.beta.-Estradiol 3-[bis(2-chloroethyl)carbamate]; Estramustinum; CHEBI:4868; D04066; Ambap2998-57-4; 2998-57-4	2998-57-4	18140	161211	TTDS00459	Estramustine binding protein	N/A	N/A	N/A	N/A	binder
DCL000007	SNS-032	CID3025986; S1145_Selleck; BMS-387032; Kinome_3820; AC-5242; I09-1579; CID6918586; LS-186036; BMS-387032, SNS-032; N-(5-(((5-(1,1-Dimethylethyl)-2-oxazolyl)methyl)thio)-2-thiazolyl)-4-piperidinecarboxamide; SNS-032; N-[5-[(5-tert-butyl-1,3-oxazol-2-yl)methylsulfanyl]-1,3-thiazol-2-yl]piperidine-4-carboxamide; (2R,3R)-2,3-dihydroxybutanedioic acid; MolPort-005-942-660; 345627-80-7; N-[5-[(5-tert-butyl-1,3-oxazol-2-yl)methylsulfanyl]-1,3-thiazol-2-yl]piperidine-4-carboxamide; AC1OCFM7; AC1MHGD4; CHEMBL296468; N-[5-[[[5-(1,1-Dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4-piperidinecarboxamide L-tartaric acid salt (2:1); 4-Piperidinecarboxamide, N-(5-(((5-(1,1-dimethylethyl)-2-oxazolyl)methyl)thio)-2-thiazolyl)-; BMS-387072	N/A	6918586	12015560	TTDC00094	Cell division protein kinase 7	39 kDa protein kinase;CAK;CAK1;CDK7;CDK-activating kinase;Cyclin-dependent kinase 7;P39 Mo15;STK1;TFIIH basal transcription factor complex kinase subunit	P50613	1022	ENSG00000134058	inhibitor
DCL001084	ZK 304709	N/A	N/A	N/A	N/A	TTDC00094	Cell division protein kinase 7	39 kDa protein kinase;CAK;CAK1;CDK7;CDK-activating kinase;Cyclin-dependent kinase 7;P39 Mo15;STK1;TFIIH basal transcription factor complex kinase subunit	P50613	1022	ENSG00000134058	inhibitor
DCL001079	R547	LS-193675; ZINC13983251; R547; DB08094; R-547; CHEMBL384304; [4-amino-2-[(1-methylsulfonylpiperidin-4-yl)amino]pyrimidin-5-yl]-(2,3-difluoro-6-methoxyphenyl)methanone; 2fvd; LIA; CID6918852; AC1OCFYV	N/A	N/A	N/A	TTDC00094	Cell division protein kinase 7	39 kDa protein kinase;CAK;CAK1;CDK7;CDK-activating kinase;Cyclin-dependent kinase 7;P39 Mo15;STK1;TFIIH basal transcription factor complex kinase subunit	P50613	1022	ENSG00000134058	inhibitor
DCL001080	R-roscovitine	2a4l; AR-1A2673; LS-182554; AC-2416; CYC202; 3ddq; Seliciclib; CYC202, Seliciclib, R-roscovitine, Roscovitine; M02443; 1-Butanol, 2-((9-(1-methylethyl)-6-((phenylmethyl)amino)-9H-purin-2-yl)amino)-, (R)-; CBiol_002016; 1-Butanol, 2-((9-(1-methylethyl)-6-((phenylmethyl)amino)-9H-purin-2- yl)amino)-, (2R)-; HMS1362F19; IDI1_002134; BiomolKI2_000054; S1153_Selleck; HMS1990F19; NSC-701554; AC1L4NH4; R7772_SIGMA; MolPort-003-959-463; CYC 202; 186692-46-6; CYC-202; AR-1A2674; 1-Butanol, 2-((9-(1-methylethyl)-6-((phenylmethyl)amino)-9H-purin-2-yl)amino)-, (2R)-; 6-(Benzylamino)-2(R)-[[1-(hydroxymethyl)propyl]amino]-9-isopropylpurine; Bio1_000302; KBioGR_000418; Bio1_000791; BRD-K07691486-001-03-1; Rosco; AKOS005146319; (2R)-2-[[6-(benzylamino)-9-propan-2-ylpurin-2-yl]amino]butan-1-ol; RRC; CID160355; HMS3229N13; 1-Butanol, 2-((9-(1-methylethyl)-6-((phenylmethyl)amino)-9H-purin-2- yl)amino)-, (R)-; KST-1A2714; NCGC00094374-04; 1-Butanol, 2-[[9-(1-methylethyl)-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-, (2R)-; SMP1_000266; HMS1792F19; BMK1-E12; KBioSS_000418; NCGC00094374-01; NSC701554; BCBcMAP01_000013; BRD-K07691486-001-05-6; KBio2_000418; KST-1A2715; ZINC01649340; CHEMBL14762; R-Roscovitine; NCGC00094374-02; Lopac0_001102; 2-(R)-[[9-(1-Methylethyl)-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-1-butanol; 2-(R)-(1-Ethyl-2-hydroxyethylamino)-6-benzylamino-9-isopropylpurine; KBio3_000795; BiomolKI_000048; roscovitine; (R)-roscovitine; NCI60_036420; Bio1_001280; InSolution&trade; Roscovitine; KBio2_002986; BSPBio_001078; KBio2_005554; Ambotz186692-46-6; NSC 701554; NCGC00094374-03; 2-[[9-(1-Methylethyl)-6-[(phenylmethyl)amino]- 9H-purin-2-yl]amino]-(R)-1-butanol; HSCI1_000092; (2r)-2-{[6-(benzylamino)-9-isopropyl-9h-purin-2-yl]amino}-1-butanol; AC1Q4VI5; Bio2_000379; Bio2_000859; KBio3_000796	186692-46-6	160355 	737846	TTDC00094	Cell division protein kinase 7	39 kDa protein kinase;CAK;CAK1;CDK7;CDK-activating kinase;Cyclin-dependent kinase 7;P39 Mo15;STK1;TFIIH basal transcription factor complex kinase subunit	P50613	1022	ENSG00000134058	inhibitor
DAP000872	N-Acetyl-D-glucosamine	MLS001333154; MolPort-003-666-324; DivK1c_000352; CHEBI:27425; N-acetyl-alpha-D-glucosaminides; 2-Acetylamino-2-deoxy-D-glucose; NDG; CID899; C00140; N-acetylglucosamine; n-acetyl-b-d-glucosamine; KBio2_001479; JFD00446; 2-acetamido-2-deoxyhexopyranose; CHEBI:28009; D-Glucose, 2-acetamido-2-deoxy-; 134-61-2; 2-ACETAMIDO-2-DEOXY-D-ALLOSE; 173382-53-1; MolPort-003-871-954; N-Acetyl-alpha-D-glucosamine; CID439174; AC1Q5JMS; N-Acetylchondrosamine; SR-01000634877-1; N-[(2R,3R,4S,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide; N-Acetyl-D-Allosamine; pharmaceutical aid; Aflexa; Glucosamine Complex; acetylglucosamine; MLS001333128; hydrolyzed chitin; AC1L335S; NCGC00178341-01; C03878; MolPort-001-769-950; Crab Shell Chitin; 20880-45-9; 7512-17-6; N-Acetyl-D-glucosamine-Agarose; KBio2_004047; ZINC03860151; 10036-64-3; N-Acetylhexosamine; KBioGR_001817; AC1Q5JMQ; CHEBI:44280; CID82313; CHEMBL1234611; CHEMBL447878; 2-Acetamido-2-deoxyglucose; UNII-T13TI5GH3D; DB00141; KBio3_002240; AC1L2N8G; AC-11093; MLS001333153; SPBio_001565; KBio1_000352; Spectrum_000999; Spectrum2_001353; N-Acetyl-D-hexosamine; hexopyranose, 2-(acetylamino)-2-deoxy-; 6-Acetamido-6-deoxy-acpha-D-glucopyranose; SPECTRUM1500715; A0092; 2-acetamido-2-deoxy-D-glucopyranose; 2-(Acetylamino)-2-deoxyhexopyranose; CHEBI:506227; 2-Acetamido-D-glucose; HMS501B14; ZINC05883957; IDI1_000352; 6-Acetamido-6-deoxy-.alpha.-D-glucopyranose; N-acetyl-D-glucosamine; nchembio.520-comp1; Glucosamine, N-acetyl; STOCK1N-72555; N-Acetyl-D-galactosamine; MolPort-002-903-801; KBioSS_001479; bmse000231; EINECS 231-368-2; N-acetyl-D-mannosamine; AI3-51898; AR-1K5743; EINECS 233-115-1; nchembio.2007.41-comp2; AC1L96TK; N-[(2R,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide; 14215-68-0; N-Acetyl-beta-D-glucosamine; LS-183152; 948887-87-4; AC-19960; AC1L1A9Z; CID445246; N-Acetylgalactosamine; 7132-76-5; KBio2_006615; A2278_SIGMA; GlcNAc; CID24139; Spectrum4_001179; N-[2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide; HMS1921E22; AC1L9HNX; NSC 400525; 1rdn; Natures Blend Glucosamine; AR-1J1882; 1398-61-4; Maxi GS; BSPBio_003020; MolPort-000-146-208; AC1Q5M0I; N-Acetylchitosamine; MLS001333127; D-Glucose, 2-(acetylamino)-2-deoxy-; Spectrum3_001400; CPD-12541; CHEBI:44278; 2-(ACETYLAMINO)-2-DEOXY-A-D-GLUCOPYRANOSE; ZINC03983907; SMR000857252; NSC 524344; 2-acetamido-2-deoxy-beta-D-glucopyranose; NAcGlc; N-[(3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide; 2-Acetamido-2-deoxy-D-glucose; L001205; A8176_SIGMA; .alpha.-D-Galactopyranose, 2-(acetylamino)-2-deoxy-; nchembio.151-comp5; GS-500; 98632-70-3; C02711; SMR000857242; N-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide; nchembio.96-comp2; CHEMBL1234669; NINDS_000352; SB01966	7512-17-6	439174	3440	TTDS00495	Alpha-N-acetylglucosaminidase	Alpha-N-acetylglucosaminidase 77 kDa form;Alpha-N-acetylglucosaminidase 82 kDa form;N-acetyl-alpha-glucosaminidase;NAG;NAGLU;UFHSD1	P54802	4669	ENSG00000108784	activator
DAP000727	Rabeprazole	Eraloc (TN); LY307640; SAM001246619; BIDD:GT0019; rabeprazole; SMR000469174; Rebeprazole sodium; D08463; Eraloc; 2-[[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methylsulfinyl]-1H-benzimidazole; dexrabeprazole; CHEBI:8768; C063129; 2-({[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methyl}sulfinyl)-1H-benzimidazole; CL23619; 1H-Benzimidazole, 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]methyl]sulfinyl]-; DB01129; CID5029; HSDB 7321; CPD000469174; MolPort-005-935-061; I06-0755; AC1L1JGC; LS-172365; 117976-89-3; Rabeprazole [INN:BAN]; C07864; Rabeprazole (INN); UNII-32828355LL; CHEMBL1219; MLS001401446; 1H-Benzimidazole, 2-(((4-(3-methoxypropoxy)-3-methyl-2-pyridinyl)methyl)sulfinyl)-; HMS2052P03; C18H21N3O3S; 2-((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methylsulfinyl)-1H-benzimidazole; 2-(((4-(3-Methoxypropoxy)-3-methyl-2-pyridinyl)methyl)sulfinyl)-1H-benzimidazole; Rabeprazole [BAN:INN]	117976-89-3	5029	10066	TTDS00044	Potassium-transporting ATPase alpha chain 1	Gastric H(+)/K(+)-ATPase;Gastric H+/K+ ATPase alpha subunit;Proton pump	P20648	495	ENSG00000105675	inhibitor
DCL000524	Esomeprazole magnesium	H 199/18; Omeprazole magnesium; LS-181810; 5-methoxy-1H-1,3-benzimidazol-2-yl (4-methoxy-3,5-dimethyl-2-pyridinyl)methyl sulfoxide; AC1NSJYQ; 302841-07-2; AC1L2XMA; Perprazole; Nexium; D05259; D01984; D-961H; Esomeprazole magnesium; 161973-10-0; magnesium 5-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]benzimidazol-1-ide trihydrate; 320416-93-1; AC1L2XM7; Magnesium, bis(5-methoxy-2-(((4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)sulfinyl)-1H-benzimidazolato)-, (T-4-(S),(S))-; CID130565; H-199/18; Magnesium, bis(5-methoxy-2-((S)-((4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)sulfinyl-kappaO)-1H-benzimidazolato-kappaN1)-, (T-4)-; MolPort-005-940-841; 5-Methoxy-2-((S)-((4-methoxy-3,5-dimethyl-2-pyridyl)methyl)sulfinyl)benzimidazole, magnesium salt (2:1), trihydrate; AC-402; magnesium 5-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]benzimidazol-1-ide; KS-1054; CID130564; 95382-33-5; SMR000550477; MLS001165732; I06-1976; Nexium, Esomeprazole magnesium; N Bis (1H-Benzimidazole,5-methoxy-2-[(S)-[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)sulfinyl]-); UNII-R6DXU4WAY9; Magnesium, bis(5-methoxy-2-((S)-((4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)sulfinyl-kappaO)-1H-benzimidazolato-kappaN1)-, trihydrate, (T-4)-; Esomeprazole magnesium hydrate; Prilosec OTC; CID9568613; H199/18; Esomeprazole magnesium trihydrate; (S)-Omeprazole magnesium; Esomeprazole magnesium (USAN); 202742-32-3; ST51053319; (-)-Omeprazole magnesium; 371759-50-1; 217087-09-7; Nexium (TN); Esomeprazole magnesium hydrate (JAN); 376628-34-1; 1H-Benzimidazole, 5-methoxy-2-((S)-((4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)sulfinyl)-, magnesium salt, trihydrate; 372519-57-8; MolPort-002-885-822; Prilosec OTC (TN); S1743_Selleck	N/A	9568614	12015282	TTDS00044	Potassium-transporting ATPase alpha chain 1	Gastric H(+)/K(+)-ATPase;Gastric H+/K+ ATPase alpha subunit;Proton pump	P20648	495	ENSG00000105675	inhibitor
DAP000725	Lansoprazole	AB00052388; ABT-006; Ulpax; NCGC00015615-03; Prezal; Lansoprazolum; NINDS_000920; Spectrum2_000444; 1H-Benzimidazole, 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-; SMR000058469; Lanproton; Lederle Brand of Lansoprazole; TAP Brand of Lansoprazole; 2-(((3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl)methyl)sulfinyl)-1H-benzimidazole; Lanzol-30; MLS001074170; Promeco Brand of Lansoprazole; Promeco; Blason; NCGC00023826-04; HMS2093M07; SAM001246544; SPECTRUM1503926; Prevacid, Prevacid NapraPAC, Prevacid SoluTab, Lansoprazole; Biuret Reagent Solution; Lansoprazolum [INN-Latin]; STK621169; Prosogan; A-65006; Lanzopral; Limpidex; L8533_SIGMA; Prestwick0_001072; Aprazol; Ketian; NCGC00015615-06; NCGC00023826-05; TAK 390MR; BIDD:GT0006; LS-33080; Lanston; lansoprazole; L 8533; MolPort-003-666-508; BRD-A49172652-001-05-7; Opiren; Pro Ulco; Bio-0824; SPBio_002992; Lanzul; KBio2_002060; Prevacid (TN); AG-1749; Prevacid I.V.; NCGC00023826-03; Spectrum5_001521; 2-({[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methyl}sulfinyl)-1H-benzimidazole; Lanzor; Dakar; HMS1922M04; CPD000058469; Lansoprazole [USAN:BAN:INN]; C058687; Prevacid Iv; AC1L1GX8; Suprecid; Ogastro; TAK-390MR; HMS1571G06; Lanzo; BPBio1_001194; Almirall Brand of Lansoprazole; Mesactol; Lanz; DB00448; Takepron; I06-0018; 2-(((3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl)methyl)sulfinyl)benzimidazole; AG 1749; Hormona Brand of Lansoprazole; IDI1_000920; Ilsatec; TAK390MR; Prevacid; CHEBI:6375; Lansox; Abbot Brand of Lansoprazole; KBio3_001330; Lansopep; MLS-0003247.0001; KBioGR_001491; Lancid; 2-(((3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl)methyl)sulfinyl)-1H-benzimidazole; Zoprol; Spectrum4_000856; lanzoprazole; D00355; Prevacid SoluTab; PrevOnco; CHEMBL480; Vinas Brand of Lansoprazole; C16H14F3N3O2S; Amarin; Salvar Brand of Lansoprazole; CAS-103577-45-3; Prestwick1_001072; Wyeth Brand of Lansoprazole; Lansoprazole (JAN/USP/INN); Spectrum_001580; Tecnobio Brand of Lansoprazole; Prestwick3_001072; NCGC00023826-07; Lopac-L-8533; KBioSS_002060; Prevacid I.V; 1H-Benzimidazole, 2-(((3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl)methyl)sulfinyl)-; Compraz; Lasoprol; UNII-0K5C5T2QPG; KBio2_007196; CID3883; Lansoprazol [INN-Spanish]; Bamalite; Lopac0_000709; FT-0082011; Lansoprazol; NCGC00015615-11; TL8000155; Prestwick2_001072; DivK1c_000920; HSDB 7204; NCGC00015615-02; 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl] methyl] sulfinyl] benzimidazole; HMS2052F05; 2-[[[3-methyl-4-(2,2,2-trifluroethoxy)-2-pyridyl]methyl]sulfinyl]benzimidazole; HMS502N22; 2-[({3-methyl-4-[(2,2,2-trifluoroethyl)oxy]pyridin-2-yl}methyl)sulfinyl]-1H-benzimidazole; KBio2_004628; MLS000759405; MLS000069705; Biuret Gr; MolPort-006-394-760; Hoechst Brand of Lansoprazole; Ogast; BSPBio_001084; Lanzol; Promp; SPBio_000488; BRN 4333393; NCGC00023826-06; Spectrum3_000295; Agopton; KBio1_000920; A 65006; Takeda Brand of Lansoprazole; Zoton; BSPBio_001830; Monolitum; 103577-45-3; 2-[[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methylsulfinyl]-1H-benzimidazole; lansoprazole sulphone; CG-4801; NCGC00015615-01; EU-0100709; S1354_Selleck	103577-45-3	3883	196229	TTDS00044	Potassium-transporting ATPase alpha chain 1	Gastric H(+)/K(+)-ATPase;Gastric H+/K+ ATPase alpha subunit;Proton pump	P20648	495	ENSG00000105675	inhibitor
DAP000724	Pantoprazole	Pantoprozole; 102625-70-7; SKF-96022; Pantoprazol [INN-Spanish]; UNII-D8TST4O562; Protium; Pantoprazol; 6-(difluoromethoxy)-2-[(3,4-dimethoxypyridin-2-yl)methylsulfinyl]-1H-benzimidazole; D05353; MolPort-003-666-752; SBB070993; DB00213; Pantoprazolum; I06-0068; Pantoprazole [USAN:BAN:INN]; HSDB 7292; HMS1922H20; MolPort-005-933-577; Somac; 5-(Difluoromethoxy)-2-(((3,4-dimethoxy-2-pyridyl)methyl)sulfinyl)benzimidazole; C11806; 1H-Benzimidazole, 6-(difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]-; Protonix; 1H-Benzimidazole, 5-(difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]-; AC1L1IPJ; Astropan; NCGC00095188-01; CHEBI:519598; Pantor; C16H15F2N3O4S; Protonix IV; CHEMBL1502; BIDD:GT0003; pantoprazole; Pantoprazole Na; 5-(difluoromethoxy)-2-{[(3,4-dimethoxypyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole; SK-96022; HMS2093F14; SPECTRUM1505818; Pantoprazole Sodium; SK&F-96022; BSPBio_002320; Pantoprazole (USAN/INN); NCGC00095188-02; HMS2090H03; TL8000127; CID4679; AC-679; BY 1023; CHEBI:7915; Pantoprazolum [INN-Latin]; 1H-Benzimidazole, 5-(difluoromethoxy)-2-(((3,4-dimethoxy-2-pyridinyl)methyl)sulfinyl)-; LS-32883; Pantozol; BY-1023; SK&F 96022; BRD-A22380646-001-01-5; NCGC00095188-03	102625-70-7	4679	213529	TTDS00044	Potassium-transporting ATPase alpha chain 1	Gastric H(+)/K(+)-ATPase;Gastric H+/K+ ATPase alpha subunit;Proton pump	P20648	495	ENSG00000105675	inhibitor
DAP001443	Dexlansoprazole	ZINC00599734; CID9578005; dexlansoprazole; 138530-94-6; T 168390; Kapidex; TAK 390; D08903; MolPort-002-885-834; CHEMBL1201863; Dexlansoprazole (INN/USAN); KS-1075; UNII-UYE4T5I70X	103577-45-3	9578005	755741 	TTDS00044	Potassium-transporting ATPase alpha chain 1	Gastric H(+)/K(+)-ATPase;Gastric H+/K+ ATPase alpha subunit;Proton pump	P20648	495	ENSG00000105675	inhibitor
DAP000726	Esomeprazole	O0359; Inhibitron; Esomeprazole; CHEBI:50275; SMR000058847; Gibancer; omeprazole; Ortanol; Omeprazole magnesium; CID4594; CID9579578; Elgam; Exter; I06-0705; Prestwick2_000493; 193469-77-1; LS-7629; Omeprazole delayed-release; HMS2090E16; InChI=1/C17H19N3O3S/c1-10-8-18-15(11(2)16(10)23-4)9-24(21)17-19-13-6-5-12(22-3)7-14(13)20-17/h5-8H,9H2,1-4H3,(H,19,20; Emeproton; Zepral; OMEP; Prazolit; AGI-010; Omepradex; Proclor; Prestwick1_000493; O104_SIGMA; 1H-benzimidazole, 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1-methyl-; CID9568614; Omeprazone; C07324; H 168-68; NCGC00021522-03; 131959-78-9; AC1L1IIJ; UNII-KG60484QX9; Osiren; Omizac; Procelac; Omeprazolum; BPBio1_000425; BIDD:GT0189; Losec, Omesec, Prilosec, Zegerid, Omeprazole; 1H-Benzimidazole, 5-methoxy-2-((S)-((4-methoxy-3,5-dimethyl-2- pyridinyl)methyl)sulfinyl)-; Ulcometion; Omepral; CHEMBL1503; Dizprazol; 6-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]-1H-benzimidazole; 5-methoxy-2-{(S)-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole; Inhipump; Ulsen; Prilosec; Prysma; BIDD:GT0020; UNII-N3PA6559FT; Omezol; 5-Methoxy-2[(4-methoxy-3,5-dimethyl-2-pyridyl)methylsulfinyl]-1H-benzimidazole; Paprazol; Nilsec; Bio-0888; Ceprandal; Nexium; Zefxon; Peptilcer; Prilosec OTC; HMS2052G17; Omez; Inexium paranova (TN); 2-({[3,5-dimethyl-4-(methyloxy)pyridin-2-yl]methyl}sulfinyl)-5-(methyloxy)-1H-benzimidazole; (-)-Omeprazole; Omeprazon; AKOS005066653; CHEBI:519601; MLS000069373; Tedec Ulceral; Miracid; (S)-(-)-Omeprazole; (S)-Omeprazole; Omegast; Pepticus; Lomac; HMS1569D07; DB00736; Omeprol; UPCMLD-DP075:001; Ozoken; MolPort-003-849-702; Axagon; AC-401; ZINC04693574; HMS2090F11; Maybridge4_002645; Miol; Esomeprazole [INN:BAN]; Omebeta; H168/68; Secrepina; Esomeprazole (INN); Olit; BRD-A55962179-001-04-9; CAS-73590-58-6; NCGC00021522-04; UPCMLD-DP075; Mepral; Esomperazole; H 168/68; LS-185188; 6-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole; SAN-15; Mopral; Omeprazol; CCRIS 7099; Gastroloc; 326602-80-6; TL8005099; Omapren; Omed; MolPort-005-943-880; IDI1_032523; Morecon; Omeprazole [USAN:INN:BAN:JAN]; Losec; Omid; Ocid; D07917; Prestwick0_000493; Nopramin; SPBio_002306; BSPBio_000385; MolPort-003-666-741; Esopral; S1389_Selleck; Lucen; 1H-benzimidazole, 6-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-; 5-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole; Omesek; Belmazol; MLS001076112; CPD000058847; NCGC00021522-05; Gastrimut; NCGC00016925-01; Nuclosina; Inexium paranova; esomeprazol; Parizac; H-168/68; ZINC04693575; Antra MUPS; 73590-58-6; DB00338; Lensor; Zimor; Gasec; Ramezol; Danlox; Desec; 5-Methoxy-2-((S)-((4-methoxy-3,5-dimethyl-2-pyridyl)methyl)sulfinyl)benzimidazole; 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole; 172964-80-6; Epirazole; Prestwick3_000493; Ulcsep; 119141-89-8; Audazol; Ulzol; Indurgan; Prazidec; MolPort-003-807-515; Antra; 5-Methoxy-2-(((4-methoxy-3,5-dimethyl-2-pyridyl)methyl)sulfinyl)benzimidazole; HSDB 3575; HMS1528I05; Prestwick_808; Demeprazol; ( -)-Omeprazole; Pepticum; Omebeta 20; Omezolan; Ulceral; Result; Prazentol; esomeprazolum; Nexium IV; Olexin; Omisec; DM-3458; Regulacid; SAM001246900; OMZ; Ultop; MLS001424148; Logastric; Zegerid; Omeprazolum [INN-Latin]; Omeprazole (JAN/USP/INN); Ulcesep; 2-(((3,5-Dimethyl-4-methoxy-2-pyridyl)methyl)sulfinyl)-5-methoxy-1H-benzimidazole; Omeprazol [INN-Spanish]; Dudencer; NCGC00016925-02; STK623746; Nexiam; 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1-methyl-1H-benzimidazole; Erbolin; Sanamidol; CHEBI:7772; 1H-Benzimidazole, 5-methoxy-2-(((4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)sulfinyl)-; Ulcozol; 119141-88-7; Victrix; Prilosec (TN); Emilok; AULCER; Ompanyt; D00455; Zoltum	161796-78-7	4594	3865629	TTDS00044	Potassium-transporting ATPase alpha chain 1	Gastric H(+)/K(+)-ATPase;Gastric H+/K+ ATPase alpha subunit;Proton pump	P20648	495	ENSG00000105675	inhibitor
DAP000180	Omeprazole	O0359; Inhibitron; Esomeprazole; SMR000058847; Gibancer; omeprazole; Ortanol; Omeprazole magnesium; CID4594; Elgam; Exter; I06-0705; Prestwick2_000493; LS-7629; Omeprazole delayed-release; HMS2090E16; Emeproton; Zepral; OMEP; Prazolit; AGI-010; Omepradex; Proclor; Prestwick1_000493; O104_SIGMA; Omeprazone; C07324; H 168-68; NCGC00021522-03; 131959-78-9; AC1L1IIJ; UNII-KG60484QX9; Osiren; Omizac; Procelac; Omeprazolum; BPBio1_000425; BIDD:GT0189; Losec, Omesec, Prilosec, Zegerid, Omeprazole; Ulcometion; Omepral; CHEMBL1503; Dizprazol; 6-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]-1H-benzimidazole; Inhipump; Ulsen; Prilosec; Prysma; Omezol; 5-Methoxy-2[(4-methoxy-3,5-dimethyl-2-pyridyl)methylsulfinyl]-1H-benzimidazole; Paprazol; Nilsec; Bio-0888; Ceprandal; Nexium; Zefxon; Peptilcer; Prilosec OTC; HMS2052G17; Omez; 2-({[3,5-dimethyl-4-(methyloxy)pyridin-2-yl]methyl}sulfinyl)-5-(methyloxy)-1H-benzimidazole; Omeprazon; AKOS005066653; CHEBI:519601; MLS000069373; Tedec Ulceral; Miracid; Omegast; Pepticus; Lomac; HMS1569D07; DB00736; Omeprol; UPCMLD-DP075:001; Ozoken; MolPort-003-849-702; Axagon; AC-401; HMS2090F11; Maybridge4_002645; Miol; Omebeta; H168/68; Secrepina; Olit; BRD-A55962179-001-04-9; CAS-73590-58-6; NCGC00021522-04; UPCMLD-DP075; Mepral; Esomperazole; H 168/68; SAN-15; Mopral; Omeprazol; CCRIS 7099; Gastroloc; TL8005099; Omapren; Omed; IDI1_032523; Morecon; Omeprazole [USAN:INN:BAN:JAN]; Losec; Omid; Ocid; Prestwick0_000493; Nopramin; SPBio_002306; BSPBio_000385; MolPort-003-666-741; Esopral; S1389_Selleck; Lucen; 5-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole; Omesek; Belmazol; MLS001076112; CPD000058847; NCGC00021522-05; Gastrimut; NCGC00016925-01; Nuclosina; esomeprazol; Parizac; H-168/68; Antra MUPS; 73590-58-6; DB00338; Lensor; Zimor; Gasec; Ramezol; Danlox; Desec; 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole; 172964-80-6; Epirazole; Prestwick3_000493; Ulcsep; 119141-89-8; Audazol; Ulzol; Indurgan; Prazidec; MolPort-003-807-515; Antra; 5-Methoxy-2-(((4-methoxy-3,5-dimethyl-2-pyridyl)methyl)sulfinyl)benzimidazole; HSDB 3575; HMS1528I05; Prestwick_808; Demeprazol; ( -)-Omeprazole; Pepticum; Omebeta 20; Omezolan; Ulceral; Result; Prazentol; Nexium IV; Olexin; Omisec; DM-3458; Regulacid; SAM001246900; OMZ; Ultop; MLS001424148; Logastric; Zegerid; Omeprazolum [INN-Latin]; Omeprazole (JAN/USP/INN); Ulcesep; 2-(((3,5-Dimethyl-4-methoxy-2-pyridyl)methyl)sulfinyl)-5-methoxy-1H-benzimidazole; Omeprazol [INN-Spanish]; Dudencer; NCGC00016925-02; STK623746; Erbolin; Sanamidol; CHEBI:7772; 1H-Benzimidazole, 5-methoxy-2-(((4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)sulfinyl)-; Ulcozol; Victrix; Prilosec (TN); Emilok; AULCER; Ompanyt; D00455; Zoltum	73590-58-6	4594	189970	TTDS00044	Potassium-transporting ATPase alpha chain 1	Gastric H(+)/K(+)-ATPase;Gastric H+/K+ ATPase alpha subunit;Proton pump	P20648	495	ENSG00000105675	inhibitor
DCL000525	Esomeprazole magnesium+Aspirin	N/A	N/A	N/A	N/A	TTDS00044	Potassium-transporting ATPase alpha chain 1	Gastric H(+)/K(+)-ATPase;Gastric H+/K+ ATPase alpha subunit;Proton pump	P20648	495	ENSG00000105675	inhibitor
DAP000355	Doxacurium	AC1L1SOW; Doxacurii chloridum [Latin]; Chlorure de doxacurium [French]; D00760; AC1L1SOT; Cloruro de doxacurio [Spanish]; Doxacurii chloridum; L000825; DB01135; Chlorure de doxacurium; UNII-M78TVM3G5Z; Nuromax (TN); C07549; Cloruro de doxacurio; 106819-53-8; doxacurium chloride(no stereochemistry); DB01334; Nuromax; CID60168; Doxacurium; AC1Q1RPW; CID60169; AC1Q66PG; bis[3-[6,7,8-trimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propyl] butanedioate dichloride; Doxacurium chloride (USAN/INN); bis[3-[6,7,8-trimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propyl] butanedioate	106819-53-8	60168	16874762	TTDS00349	Nicotinic acetylcholine receptor alpha subunit	N/A	N/A	N/A	N/A	antagonist
DCL000017	XL844	N/A	N/A	N/A	N/A	TTDC00010	Serine/threonine-protein kinase Chk2	Cds1;CHEK2;CHK2;RAD53	O96017	11200	ENSG00000183765	inhibitor
DCL000726	BIM23A760	N/A	N/A	N/A	N/A	TTDS00394	Somatostatin receptor type 2	Somatostatin receptor 2;SRIF-1;SS2R;Sst(2)	P30874	6752	ENSG00000180616	antagonist
DAP000397	Octreotide	D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-L-cysteinyl-L-threoninol cyclic (2-7)-disulfide; CHEBI:427278; zacycloicosane-4-carboxamide acetate; L-Cysteinamide, D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L- threonyl-N-(2-hydroxy-1-(hydroxymethyl)propyl)-, cyclic (2->7)-disulfide, (R-(R*; D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L-cysteinamide cyclic (2-7)-disulfide; CID383414; 10-(4-aminobutyl)-19-[(2-amino-3-phenylpropanoyl)amino]-16-benzyl-N-(1,3-dihydroxybutan-2-yl)-7-(1-hydroxyethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide; AC1L8LCD; C5H12O2.C4H10; Sandoz 201-995; SMS-201-995; Octreotidum [Latin]; L000453; AC1L9M4X; CID448601; Octreotida; L-Cysteinamide, D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-(2-hydroxy-1-(hydroxymethyl)propyl)-, cyclic (2-7)-disulfide, (R-(R*,R*))-; Sandostatine; NCI60_025753; Octreotide-LAR; Octreotidum; D00442; CID54374; 79517-01-4 (acetate salt); LS-187135; 83150-76-9; Octreotide (USAN/INN); Octreotide [USAN:INN:BAN]; 10-(4-aminobutyl)-19-[(2-amino-3-phenylpropanoyl)amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-(1-hydroxyethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide; CHEMBL1680; LS-177735; HMS2090C09; nchembio.184-comp3; 10-(4-Aminobutyl)-19-((2-amino-3-phenylpropanoyl)amino)-16-benzyl-7-(1-hydroxyethyl)-N-(2-hydroxy-1-(hydroxymethyl)propyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaa; Octreotide; SMS 201-995; SM 201-995; Longastatin; NCGC00181796-01; D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L-cysteinamide cyclic (2->7)-disulfide; DRG-0115; AC1L1GVU; CHEBI:611465; Octreotide Acetate Salt; HS-2020; Octreotida [Spanish]; (4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-19-[[(2R)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-[(1R)-1-hydroxyethyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide; C07306; UNII-RWM8CCW8GP; SAN 201-995	83150-76-9	383414	7847508	TTDS00394	Somatostatin receptor type 2	Somatostatin receptor 2;SRIF-1;SS2R;Sst(2)	P30874	6752	ENSG00000180616	binder
DAP001488	Lanreotide Autogel	N/A	108736-35-2	71349	213580	TTDS00394	Somatostatin receptor type 2	Somatostatin receptor 2;SRIF-1;SS2R;Sst(2)	P30874	6752	ENSG00000180616	binder
DCL000193	Pasireotide	N/A	396091-73-9	N/A	10549826	TTDS00394	Somatostatin receptor type 2	Somatostatin receptor 2;SRIF-1;SS2R;Sst(2)	P30874	6752	ENSG00000180616	agonist
DCL000105	DG041	CHEMBL565591; CHEBI:683423; CID 11296282; D-000151746; DTSI; CID11296282; DG-041	N/A	N/A	N/A	TTDC00037	Prostaglandin E2 receptor EP3 subtype	PGE receptor, EP3 subtype;PGE2-R;Prostanoid EP3 receptor	P43115	5733	ENSG00000050628	antagonist
DAP000070	Ramelteon	LS-187367; I06-1429; Ramelteon (JAN/USAN/INN); Ramelteon; DB00980; Ramelteon [USAN]; D02689; CHEMBL1218; (-)-N-(2-(((8S)-1,6,7,8-Tetrahydro-2H-indeno(5,4-b)furan-8-yl)ethyl)propanamide; CID208902; (S)-N-(2-(1,6,7,8-tetrahydro-2H-indeno-(5,4)furan-8-yl)ethyl)propionamide; Rozerem, TAK-375, Ramelteon; S1259_Selleck; UNII-901AS54I69; AC-5275; C495910; AC1Q5OQL; AR-1K4568; HMS1922H18; n-{2-[(8s)-1,6,7,8-tetrahydro-2h-indeno[5,4-b]fur-8-yl]ethyl}propanamid; 196597-26-9; LS-186569; TAK-375; CHEBI:321962; BRD-K28761891-001-01-0; AC1L4LKM; SPECTRUM1505817; Propanamide, N-(2-((8S)-1,6,7,8-tetrahydro-2H-indeno(5,4-b)furan-8-yl)ethyl)-; Rozerem; HMS2093F12; BSPBio_002318; MolPort-003-666-751; ZINC03960338; Rozerem (TN); N-[2-[(8S)-2,6,7,8-tetrahydro-1H-cyclopenta[e][1]benzofuran-8-yl]ethyl]propanamide	196597-26-9	208902	783731	TTDS00422	Melatonin receptor type 1B	Mel1b melatonin receptor;Mel-1B-R;MTNR1B	P49286	4544	ENSG00000134640	agonist
DAP000208	Lubiprostone	Amitiza; MolPort-006-666-405; Prostan-1-oic acid, 16,16-difluoro-11-hydroxy-9,15-dioxo-, (11alpha)-; (-)-7-((2R,4aR,5R,7aR)-2-(1,1-Difluoropentyl)-2-hydroxy-6-oxooctahydrocyclopenta (b)pyran-5-yl)heptanoic acid; Lubiprostone; Prostan-1-oic acid, 11,15-epoxy-16,16-difluoro-15-hydroxy-9-oxo-, (11alpha,15R)-; S1675_Selleck; UNII-7662KG2R6K; SPI 0211; Amitiza, RU-0211, SPI-0211, Lubiprostone; LS-186535; C506401; LS-187360; 7-((1R,4R,6R,9R)-4-(1,1-difluoropentyl)-4-hydroxy-8-oxo-5-oxabicyclo(4.3.0)non-9-yl)heptanoic acid; 7-[(2R,4aR,5R,7aR)-2-(1,1-difluoropentyl)-2-hydroxy-6-oxo-3,4,4a,5,7,7a-hexahydrocyclopenta[b]pyran-5-yl]heptanoic acid; SPI0211; I06-2319; RU-0211; (-)-7-((2R,4aR,5R,7aR)-2-(1,1-Difluoropentyl)-2-hydroxy-6-oxooctahydrocyclopenta(b)pyran-5-yl)heptanoic acid; SPI-0211; 136790-76-6; AC-1863; RU 0211; AC1L4IXH; CHEMBL1201134; 333963-40-9; RU0211; Lubiprostone [USAN]; CID157920	136790-76-6	656719	586296	TTDS00287	Chloride channel protein 2	ClC-2;ClC-2 chloride channel;ClC-2 Cl- channel	P51788	1181	ENSG00000114859	activator
DCL000431	Anti-EGFL7	N/A	N/A	N/A	N/A	TTDC00238	EGF-like domain-containing protein 7	Multiple EGF-like domain protein 7;Multiple epidermal growth factor-like domain protein 7;NOTCH4-like protein;Vascular endothelial statin;VE-statin;ZNEU1	Q9UHF1	51162	ENSG00000172889	antibody
DCL000538	IDX136	N/A	N/A	N/A	N/A	TTDS00315	DNA polymerase (HSV)	DNA polymerase;Herpes simplex virus-specified DNA polymerase	P04293	N/A	N/A	inhibitor
DCL000308	Lobucavir	[1R-1.alpha.,2.beta.,3.alpha.]-2-Amino-9-[2,3-bis(hydroxymethyl)cyclobutyl]- 6H-purin-6-one; (R)-9-[2,3-Bis(hydroxymethyl)-1-cyclobutyl]guanine; A-69992; 6H-Purin-6-one, 2-amino-9-(2,3-bis(hydroxymethyl)cyclobutyl)-1,9-dihydro-, (1alpha,2beta,3alpha)-(+-)-; 127759-89-1; 6H-Purin-6-one, 2-amino-9-(2,3-bis(hydroxymethyl)cyclobutyl)-1,9-dihydro, (1R-(1alpha,2beta,3alpha)); SQ-34514; Lobucavir [USAN:INN]; 126062-18-8; D04757; Bms 180194; (+-)Cyclobut-G; Cyclobut-G; 2-amino-9-[(1r,2r,3s)-2,3-bis(hydroxymethyl)cyclobutyl]-1,9-dihydro-6h-purin-6-one; (+/-)-Cyclobut-G; (+/-)-Lobucavir; 6H-Purin-6-one, 2-amino-9-(2,3-bis(hydroxymethyl)cyclobutyl)-1,9-dihydro-, (1R-(1alpha,2beta,3alpha))-; 6H-Purin-6-one, 2-amino-9-((1R,2R,3S)-2,3-bis(hydroxymethyl)cyclobutyl)-1,9-dihydro-, rel-; C11H15N5O3; 9-((1R,2R,3S)-2,3-Bis(hydroxymethyl)cyclobutyl)guanine; 9-[1.beta.-2.alpha.-3.beta.]-2,3-Bis(hydroxymethyl)-1-cyclobutyl]guanine; DRG-0235; SQ 33054; Lobucavir (USAN/INN); UNII-8U5PYQ1R2E; 2-Amino-9-(2,3-bis(hydroxymethyl)cyclobutyl)-1,9-dihydro-6H-purin-6-one; (+)-Cyclobut G; LS-172690; 9-(2,3-Bis-(hydroxymethyl)-1-cyclobutyl)guanine; (+)Cyclobut-G; CCRIS 9309; C-Oxt-G; C-Oxetanocin-G; 126373-87-3; 2-amino-9-[(1R,2R,3S)-2,3-bis(hydroxymethyl)cyclobutyl]-3H-purin-6-one; SQ 34,514; AC1Q6I9Z; Cygalovir; 6H-Purin-6-one, 2-amino-9-((1R,2R,3S)-2,3-bis(hydroxymethyl)cyclobutyl)-1,9-dihydro-; AC1L1TX8; BMS-180194; LOBUCAVIR; (+/-)-9-[2,3-Bis(hydroxymethyl)-1-cyclobutyl]guanine; (R)-BHCG; (+/-)-BHCG; SQ-33,054; Carbocyclic oxetanocin G; CID60786	127759-89-1	60786	47206573	TTDS00315	DNA polymerase (HSV)	DNA polymerase;Herpes simplex virus-specified DNA polymerase	P04293	N/A	N/A	inhibitor
DAP000488	Penciclovir	MB2488; 97845-62-0 (mono-hydrochloride salt); CHEMBL1540; BRL 39123; D05407; FT-0080010; I14-2420; IN1162; MLS000759422; CCRIS 9213; Penciclovir [USAN:INN:BAN]; SBB067261; Penciclovir & Human interferon-.beta.; HMS2090H11; SAM001246580; CPD000466317; NCGC00164630-01; 9-[2-hydroxy-1-(hydroxymethyl)-ethoxymethyl]guanine; 39809-25-1; C07417; 2-amino-9-[4-hydroxy-3-(hydroxymethyl)butyl]-1,9-dihydro-6H-purin-6-one; SMR000466317; 9-(4-Hydroxy-3-(hydroxymethyl)butyl)guanine; 6H-Purin-6-one, 2-amino-1,9-dihydro-9-(4-hydroxy-3-(hydroxymethyl)butyl)- & Human interferon-beta; DB00299; Penciclovirum; Pencyclovir; UNII-359HUE8FJC; penciclovir; MLS001424110; BRL-39123; 9-(4-hydroxy-3-hydroxymethylbut-1-yl)-guanine; Denavir (TN); Denavir; 2-amino-9-[4-hydroxy-3-(hydroxymethyl)butyl]-3,9-dihydropurin-6-one; 6H-Purin-6-one, 2-amino-1,9-dihydro-9-(4-hydroxy-3-(hydroxymethyl)butyl)- & Human interferon-.gamma.; 6H-Purin-6-one, 2-amino-1,9-dihydro-9-(4-hydroxy-3-(hydroxymethyl)butyl)-; DB01730; C10H15N5O3; Penciclovirum [INN-Latin]; CHEBI:530597; CID4725; 9-[4-hydroxy-3-(hydroxymethyl)but-1-yl]guanine; Penciclovir & Human interferon-.gamma.; LS-127198; CHEBI:44870; 9-(4-HYDROXY-3-(HYDROXYMETHYL)BUT-1-YL)GUANINE; CHEBI:7956; Adenovir; 9-(4-hydroxy-3-hydroxymethylbut-1-yl)guanine; 6H-Purin-6-one, 2-amino-1,9-dihydro-9-(4-hydroxy-3-(hydroxymethyl)butyl)- & Human interferon-.alpha.; Vectavir; HMS2051D06; 2-Amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)butyl]-6H-purin-6-one; ZINC00001899; 2-amino-9-[4-hydroxy-3-(hydroxymethyl)butyl]-3H-purin-6-one; AC-11104; PE2; Penciclovir & Human interferon-.alpha.; Penciclovir (USAN/INN); AC1L1ITE	39809-25-1	4725	213685	TTDS00315	DNA polymerase (HSV)	DNA polymerase;Herpes simplex virus-specified DNA polymerase	P04293	N/A	N/A	inhibitor
DCL000288	Cilnidipine	3-O-(2-methoxyethyl) 5-O-[(E)-3-phenylprop-2-enyl] 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; 132203-70-4; Siscard; C1493_SIGMA; AC-270; C27H28N2O7; STK623341; Bio-0164; NCGC00162150-01; FRC-8653; CHEBI:31399; FRC 8653; I06-0491; BRD-A07875874-001-01-6; HMS2089J07; Cilnidipine [INN]; Cilnidipine (JAN/INN); CID5282138; Cinaldipine; CHEBI:438069; CHEMBL452076; Cinalong; Atelec; AC1NQZJB; cilnidipine; 2-methoxyethyl (2E)-3-phenylprop-2-en-1-yl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; LS-131293; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-methoxyethyl 3-phenyl-2-propenyl ester, (E)-(+-)-; Atelec (TN); D01173; 1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 2-methoxyethyl (2E)-3-phenyl-2-propenyl ester; NCGC00162150-02; NCGC00162150-03; MolPort-003-845-950; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-,2-methoxyethyl 3-phenyl-2-propenyl ester, (E)-(+-)-; (+-)-(E)-Cinnamyl 2-methoxyethyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate; S1293_Selleck	N/A	5282138	24892414	TTDS00529	Voltage-dependent N-type calcium channel	BIII;Brain calcium channel III;Calcium channel, L type, alpha-1 polypeptide isoform 5;N-type Ca2+ channel;Voltage-dependent N-type calcium channel alpha-1B subunit;Voltage-gated calcium channel alpha subunit Cav2.2	Q00975	774	ENSG00000148408	blocker
DCL000949	Ralfinamide	C475054; Ralfinamide; NW-1029; (2S)-2-[[4-[(2-fluorophenyl)methoxy]phenyl]methylamino]propanamide; CID5745207; 133865-88-0; Ralfinamide [INN]; Ralfinamida [INN-Spanish]; UNII-3LPF0S0GVV; (2S)-2-(4-(2-Fluorobenzyloxy)benzylamino)propanamide; AC1NX6LN; NW 1029; Ralfinamida	133865-88-0	5745207	3846305	TTDS00529	Voltage-dependent N-type calcium channel	BIII;Brain calcium channel III;Calcium channel, L type, alpha-1 polypeptide isoform 5;N-type Ca2+ channel;Voltage-dependent N-type calcium channel alpha-1B subunit;Voltage-gated calcium channel alpha subunit Cav2.2	Q00975	774	ENSG00000148408	blocker
DAP001540	Ziconotide	L-Cysteinyl-L-lysylglycyl-L-lysylglycyl-L-alanyl-L-lysyl-L-cysteinyl-L-seryl-L-arginyl-L-leucyl-L-methionyl-L-tyrosyl-L-alpha-aspartyl-L-cysteinyl-L-cysteinyl-L-threonylglycyl-L-seryl-L-cysteinyl-L-arginyl-L-serylglycyl-L-lysyl-L-cysteinamide cyclic (1-16),(8-20),(15-25)-tris(disulfide); Prialt; omega-Conotoxin mviia, conus magus; omega-Conopeptide MVIIA (Conus); omega-Conotoxin M VIIA (reduced), cyclic (1-16),(8-20),(15-25)-tris(disulfide); 148979-96-8; 148979-97-9; LS-172052; omega-Conotoxin M VIIA; SNX-111; UNII-7I64C51O16; DRG-0250; 150770-63-1; C8H6; 107452-89-1; HSDB 7609; I06-1841; NCGC00181313-01; omega-conotoxin MVIIA; Ziconotide [USAN]; Ziconotide; SNX 111	107452-89-1	447451	47208020	TTDS00529	Voltage-dependent N-type calcium channel	BIII;Brain calcium channel III;Calcium channel, L type, alpha-1 polypeptide isoform 5;N-type Ca2+ channel;Voltage-dependent N-type calcium channel alpha-1B subunit;Voltage-gated calcium channel alpha subunit Cav2.2	Q00975	774	ENSG00000148408	blocker
DCL000150	L-NAME	KBio2_000561; NCGC00024717-05; KBio3_001002; 50903-99-6; KBio2_005697; N-Nitro-L-arginine methylester; NG-NITROARGININE METHYL ESTER; IDI1_002196; N(5)-(Imino(nitroamino)methyl)-L-ornithine methyl ester; BSPBio_001221; NCGC00024717-02; nchembio821-comp14; Bio1_001420; Tocris-0665; KBio2_003129; KBio3_001001; CHEBI:103098; N(G)-Nitro-L-arginine methyl ester; Bio1_000931; N-.omega.-Nitro-O-arginine methyl ester; N(G)-Nitroarginine methyl ester; CHEMBL7890; Bio2_000441; N-Nitroarginine methyl ester; NCGC00024717-04; HMS1792M03; 126265-24-5; N(sup G)-Nitro-L-arginine methyl ester; N-omega-Nitro-O-arginine methyl ester; C04337; Methyl (2S)-2-amino-5-[(amino-nitramido-methylidene)amino]pentanoate; NCGC00024717-06; NCGC00024717-01; KBioGR_000561; HMS1362M03; HMS1990M03; AmbotzHAA5810; nchembio.92-comp7; Bio1_000442; L-NAME; Ngamma-Nitro-L-arginine methyl ester; KBioSS_000561; CID39836; HSCI1_000257; methyl N5-(N'-nitrocarbamimidoyl)-L-ornithinate; AC1L22K6; methyl (2S)-2-amino-5-[[amino(nitramido)methylidene]amino]pentanoate; NCGC00024717-07; L-Ornithine, N(5)-(imino(nitroamino)methyl)-, methyl ester; Lopac0_000848; Bio2_000921; NCGC00024717-03	50903-99-6	39836	799994	TTDC00097	Nitric-oxide synthase, endothelial	CNOS;Constitutive NOS;EC-NOS;Endothelial nitric oxide synthase;Endothelial NOS;ENOS;NOS, type III;NOSIII	P29474	4846	ENSG00000164867	inhibitor
DCL000151	L-NMMA	targinina; KBio3_002876; NCGC00024780-04; M 7033; KBio3_002795; AC1L362E; N5-(Methylamidino)-L-ornithine acetate salt; N(G)-Methyl-L-arginine acetate; EU-0100750; L-Ornithine, N5-(imino(methylamino)methyl)-, monoacetate; MLS002172472; (2S)-2-amino-5-[(N'-methylcarbamimidoyl)amino]pentanoic acid; AR-1K5638; C03884; N(5)-(methylamidino)-L-ornithine; AR-1G6894; Tocris-0771; L-NMMA; Ngamma-Monomethyl-L-arginine; nchembio.2007.33-comp8; NCGC00024780-01; NG-Monomethyl-L-arginine acetate; n5-(n-methylcarbamimidoyl)-l-ornithine acetate(1:1); NG-Me-L-Arg, AcOH; N(5)-(N-methylcarbamimidoyl)-L-ornithine; Nomega-Methyl-L-arginine acetate salt; NG-Monomethyl-L-arginine, Monoacetate Salt; CID135242; M7033_SIGMA; 17035-90-4; AC1Q5SZL; (2S)-2-amino-5-{[imino(methylamino)methyl]amino}pentanoic acid; CHEBI:525372; AC1Q5QMC; CID132862; CHEMBL256147; N-omega-monomethyl-L-arginine; nchembio794-comp11; acetic acid; (2S)-2-amino-5-[(N'-methylcarbamimidoyl)amino]pentanoic acid; NG-Methyl-L-arginine acetate salt; NG-monomethyl-L-argine; nchembio.92-comp5; M1365; tilargininum; CHEBI:28229; BSPBio_003557; CPD000449329; MLS000758278; SAM001247049; N5-(Imino(methylamino)methyl)-L-ornithine monoacetate; SMR000449329; Lopac0_000750; Tilarginine acetate [USAN]; HMS2051M15; Nomega-Monomethyl-L-arginine Acetate; NCGC00024780-02; L-Monomethylarginine; MolPort-003-849-265; Nomega-Methyl-L-arginine Acetate; MLS001401412; NCGC00178003-01; AC1L31PO; acide (2S)-2-amino-5-(3-methylguanidino)pentanoique; Spectrum3_001937; N(5)-[imino(methylamino)methyl]-L-ornithine; L-Ornithine, N5-[imino(methylamino)methyl]-[CAS]; BSPBio_003537; 546C88; ANO 1020; targininum; tilarginina; N(5)-(metilamidino)-L-ornitina; 53308-83-1; NCGC00015698-01; Tilarginine Acetate; Spectrum3_001957; N5-(N-methylcarbamimidoyl)-L-ornithine; N-Monomethyl-L-arginine; Nomega-Me-L-Arg; (2S)-2-amino-5-(N'-methylcarbamimidamido)pentanoic acid; NG-Monomethyl-L-arginine acetate salt; Targinine; NCGC00024780-03; Lopac-M-7033	N/A	4366	49693484	TTDC00097	Nitric-oxide synthase, endothelial	CNOS;Constitutive NOS;EC-NOS;Endothelial nitric oxide synthase;Endothelial NOS;ENOS;NOS, type III;NOSIII	P29474	4846	ENSG00000164867	inhibitor
DCL000030	ACCLAIM	Oprea1_475947; Ethyl-2-((4-(6-chloro-2-benzoxazolyloxy))-phenoxy)propionate; (+/-)-2-(4-((6-Chloro-2-benzoxazolyl)oxy)phenoxy)propanoic acid ethyl ester; Fenoxaprop ethyl; PUMA; 87714-45-2; EINECS 266-362-9; Ethyl (+-)-2-(4-(6-chloro-2-benzoxazolyloxy)phenoxy)propanoate; LS-121247; AC1L2J1X; Depon; Caswell No. 431C; Oprea1_660788; FENOXAPROP-ETHYL; Propanoic acid, 2-(4-((6-chloro-2-benzoxazolyl)oxy)phenoxy)-, ethyl ester; Propanoic acid, 2-(4-((6-chloro-2-benzoxazolyl)oxy)phenoxy)-, ethyl ester, (+-)-; CID47938; MolPort-005-940-863; C11024; Excel; Ethyl 2-(4-[(6-chloro-1,3-benzoxazol-2-yl)oxy]phenoxy)propanoate; 66441-23-4; NCGC00168307-02; Whip; Fenoxaprop ethyl ester [ANSI]; BRN 1166633; Ethyl (D+)-2-(4-(6-chlor-2-benzoxazolyloxy)phenoxy)propanoate; Ethyl (D+)-2-(4-(6-chlor-2-benzoxazolyloxy)phenoxy)propanoate [French]; ethyl 2-[4-[(6-chloro-1,3-benzoxazol-2-yl)oxy]phenoxy]propanoate; HSDB 6848; Propanoic acid, 2-(4-((6-chloro-2-benzoxazolyl)oxy)phenoxy)-, ethyl ester, (.+/-.)-; Acclaim; 2-(4-((6-Chloro-2-benzoxazolylen)oxy)phenoxy)propanoic acid, ethyl ester; ethyl 2-{4-[(6-chloro-1,3-benzoxazol-2-yl)oxy]phenoxy}propanoate; EPA Pesticide Chemical Code 128701; Furore; Ethyl 2-(4-((6-chlorobenzoxazol-2-yl)oxy)phenoxy)propionate; HOE 33171; Tiller Herbicide; NCGC00168307-01; I06-1528; CHEMBL37932; 82110-72-3; Fenoxaprop ethyl ester; HOE-A 25-01	66441-23-4	47938	48425883	TTDC00097	Nitric-oxide synthase, endothelial	CNOS;Constitutive NOS;EC-NOS;Endothelial nitric oxide synthase;Endothelial NOS;ENOS;NOS, type III;NOSIII	P29474	4846	ENSG00000164867	stimulator
DCL001134	ACE-041	N/A	N/A	N/A	N/A	TTDC00338	Activin receptor-like kinase-1	Serine/threonine-protein kinase receptor R3;SKR3;Activin receptor-like kinase 1;ALK-1;TGF-B superfamily receptor type I;TSR-I;ACVRL1;ACVRLK1	P37023	94	ENSG00000139567	inhibitor
DCL000684	AGN-199981	N/A	N/A	N/A	N/A	TTDC00293	Alpha-2B adrenergic receptor	Alpha-2B adrenoceptor;Alpha-2B adrenoreceptor;Subtype C2	P18089	151	ENSG00000222040	agonist
DAP000280	Brimonidine	NCGC00023468-04; 5-brom-n-(4,5-dihydro-1h-imidazol-2-yl)chinoxalin-6-amin; ZINC21303210; U104_SIGMA; MLS001076349; AC-162; UK 14,304-18; Brimonidine [INN:BAN]; MLS000069370; CID2435; UK 14308; NCGC00023468-07; L000615; NCGC00016069-01; AR-1G7332; SAM002548958; 5-Bromo-6-(2-imidazolin-2-ylamino)quinoxaline; Tocris-0425; Lopac0_001216; UK 14304; U-104; Bromoxidine; NCGC00023468-05; 59803-98-4; 70359-46-5 (tartrate[1:1]); 5-bromo-6-(imidazolidinylideneamino)quinoxaline; 6-Quinoxalinamine, 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)- (9CI); PDSP1_000640; 5-Bromo-N-(2-imidazolin-2-yl)-6-quinoxalinamine; 6-Quinoxalinamine, 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)-; 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine; Brimonidine (INN); AC1Q26LW; nchembio705-7; FT-0082636; NCGC00016069-02; C11H10BrN5; 5-bromo-6-(imidazolin-2-ylamino)quinoxaline; UK 14304-18; UNII-E6GNX3HHTE; brimonidina; NCGC00016069-06; CPD000058355; AGN 190342; LK 14304-18; CHEMBL844; NCGC00023468-02; D07540; brimonidinum; Lopac-U-104; CHEBI:3175; BRN 0751629; T6531398; UK 14,304; BIDD:GT0649; NSC318825; DB00484; MolPort-003-959-841; 5-Bromo-N-(4,5-dihydro-1H-imidazol-2-yl)-6-quinoxalinamine; NCGC00016069-11; AGN-190342; AC1L1DO5; C07886; UK-14,304-18; PDSP2_000635; NCGC00023468-06; LS-142950; SMR000058355; AC1Q24IC; UK-14304; brimonidine; EU-0101216; UK-14,308	59803-98-4	2435	213378	TTDS00032	Alpha-2A adrenergic receptor	Alpha-2A adrenoceptor;Alpha-2A adrenoreceptor;Alpha-2AAR subtype C10	P08913	150	ENSG00000150594	agonist
DAP001362	Connexyn	N-(Aminoiminomethyl)-2,6-dichlorobenzeneacetamide hydrochloride; D00606; N-(Aminoiminomethyl)-2,6-dichlorophenylacetamide monohydrochloride; SMR000058453; CID71401; BS-100-141; Benzeneacetamide, N-(aminoiminomethyl)-2,6-dichloro-, hydrochloride (1:1); HMS1569C19; Intuniv; EU-0100519; LON 798; N-(diaminomethylidene)-2-(2,6-dichlorophenyl)acetamide hydrochloride; UNII-PML56A160O; GUANFACINE HCL; AC1Q3P39; MLS000069745; N-Amidino-2-(2,6-dichlorophenyl)acetamide monohydrochloride; Tenex; n-carbamimidoyl-2-(2,6-dichlorphenyl)acetamidhydrochlorid; guanfacine hydrochloride; Connexyn; C9H9Cl2N3O.HCl; CHEMBL1200494; G 1043; Benzeneacetamide, N-(aminoiminomethyl)-2,6-dichloro-, monohydrochloride; 29110-47-2 (Parent); 29110-48-3; Prestwick_740; Estulic; EINECS 249-443-3; MLS002222252; LS-28474; SPD-503; Guanfacine hydrochloride [USAN:JAN]; Guanfacine hydrochloride (JAN/USP); N-(aminoiminomethyl)-2,6-dichloro-benzeneacetamide hydrochloride; MolPort-003-666-686; NCGC00180965-01; N-Amidino-2-(2,6-dichlorophenyl)acetamide hydrochloride; NCGC00093914-01; BS 100-141; MLS001077329; AR-1K6511; Tenex (TN); AC1L2G3E	29110-47-2	71401	12013435	TTDS00032	Alpha-2A adrenergic receptor	Alpha-2A adrenoceptor;Alpha-2A adrenoreceptor;Alpha-2AAR subtype C10	P08913	150	ENSG00000150594	agonist
DAP000437	Cephalexin	Cephalexin 1-wasser; Ceporexin; Ibrexin; Cepol; Cefalexgobens; NCGC00159522-03; Prestwick3_000358; Cephanasten; Keforal; Domucef; Maksipor; CHEBI:3534; Ceporex; Ades[prex; Syncl; Tepaxin; Oriphex; BRD-K90733503-002-03-6; Pectril; Cefalexina; 23325-78-2; KS-1134; Prestwick2_000358; Cefalessina; Medolexin; Cefalexine; Bactopenor; Celexin; Ortisporina; Beliam; Ospexin; Cephacillin; Mamlexin; LS-174191; Alsporin; Cefalessina [DCIT]; 17692-47-6; cephalexin; Cefalexinum; Sepexin; Cephaxin; Palitrex; Cefalexina [INN-Spanish]; Syncle; Cepexin; ZINC03830500; Voxxim; Madlexin; D00263; Sencephalin; Lenocef; Kefalospes; Karilexina; 7-(D-alpha-Aminophenylacetamido)desacetoxycephalosporanic acid; AC1O6OSE; Cephalexin monohydrate; Lonflex; Keftab (TN); Cusisporina-Cefalox; Noveol; Prestwick0_000358; NCGC00159522-02; Roceph Distab; Henina Oral; EINECS 239-773-6; Factagard; Cephalexine; Servispor; Uphalexin; Neokef; Cephalobene; Biocef; Nufex; Aristosporin; SMR000338536; Cefadal; Servicef; Azabort; Rogevil; AC1L1Y1M; Ambal; D00906; S 6437; Cefacet; Cefibacter; Ceporexine; C16H17N3O4S; Cophalexin; Sartosona; Prestwick_750; Rilexine; Lopilexin; Prindex; Viosporine; CHEMBL1200544; Sinthecillin; Cephin; Larixin; Sanaxin; Cefadin; Cefalexine [INN-French]; Losporal; 7-(D-2-Amino-2-phenylacetamido)-3-methyl-delta (sup 3)-cephem-4- carboxylic acid; 7-(D-2-Amino-2-phenylacetamido)-3-methyl-delta3-cephem-4-carboxylic acid; Tokiolexin; Theratrex; UNII-5SFF1W6677; Ibilex; Adcadina; cefalexin monohydrate; CID6560168; CPD-9227; Erocetin; Cephalexin (USP); Panixine Disperdose; 38932-40-0 (mono-hydrochloride salt); Prestwick1_000358; 105879-42-3 (mono-hydrochloride, mono-hydrate); Cephalexin [USAN:BAN]; Durantel DS; Mamalexin; MLS000759527; Pyassan; Oracef; 105879-42-3 (mono-hydrochloride,mono-hydrate); Cefadina; Cefalexin generics; Ceporex Forte; Lilly 66873; Cefovit; 15686-71-2; CID27447; Ceflax; SQ 20248; Roceph; Felexin; Kekrinal; Zozarine; Inphalex; Zabytrex; Kidolex; Cefaloto; Cefa-iskia; Cefalexina Northia; Ed A-Ceph; Cepastar; CPD000338536; Cephalex von ct; Oroxin; Sporicef; Cefalekey; Cefalexin; 23325-78-2 (mono-hydrate); UNII-OBN7UDS42Y; Novolexin; Cefalin; Cefalexina Richet; Cefax; C06895; Kefolan; Doriman; 14101-75-8; Keflex (TN); SAM001246761; Cefalexinum [INN-Latin]; Ceffanex; CID62921; Neolexina; Ceforal; MolPort-002-507-304; 15686-71-2 (Parent); L-Keflex; BB_NC-1052; Alexin; ZINC01530596; Winlex; Synecl; Sialexin; Cefaseptin; Cephalexinum; Cefaleksin; Alcephin; LS-149963; LS-173992; DB00567; Panixine disperdose (TN); Keftab; Keflex; Lafarine; Keflet; Cephalexin, (6R-(6alpha,7beta))-Isomer; Cefalexin Scand Pharm; CEX; Loisine; Durantel; Sporidex; BSPBio_000455; CHEBI:3535; Ceporexin-E; CHEMBL1727; Cephalexin 1-hydrate; AC1L1D8M; Cephalexin hydrate; Cephalexin (anhydrous); cefalexin.H2O; Sintolexyn; 66905-57-5 (di-hydrate); Lexibiotico; C08099; Cefalexin Sodium; Check; SPBio_002376; BRN 0965503; HMS1569G17; cephalexin.H2O; Medoxine; HMS2051A04; cefalexin hydrate; HSDB 3022; Carnosporin; AKOS004119846; MolPort-006-823-789; Fexin; Cefablan; BPBio1_000501; Cefalival; Efemida; Cefalexin (JP15)	15686-71-2	27447	625390	TTDS00210	Penicillin binding protein	N/A	N/A	N/A	N/A	binder
DAP001165	Penicillin V	C08126; Meropenin; KBio2_001487; Fenacilin; Berromycin, Penicillin; Penicillin, Phenoxymethyl; Calcipen; Beromycin; BRN 0096259; Stabicillin; 1098-87-9 (mono-hydrochloride salt); CHEBI:27446; NINDS_000779; NCGC00159342-02; Phenoxymethylpenicillinic acid potassium salt; UNII-Z61I075U2W; phenoxymethylpenicillinic acid; 2,2-dimethyl-6beta-[(phenoxyacetyl)amino]penam-3alpha-carboxylic acid; Penapar-Vk; Rocilin; Spectrum3_000543; Penicillin-Vk; Vebecillin; Fenospen; Bio-0630; D05411; 3,3-Dimethyl-7-oxo-6-((phenyloxyacetyl)amino)-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid; Phenoxymethylpenicilline [INN-French]; phenoxomethylpenicillin; V-Cyline; CID6869; V-Cillin (TN); Apocillin; AR-1H6492; Spectrum5_001409; BRD-K43966364-237-02-2; Vegacillin; 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-6-((phenoxyacetyl)amino)-, (2S,5R,6R)-; (2S,5R,6R)-3,3-Dimethyl-7-oxo-6-(2-phenoxyacetamido)-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid; Phenoxymethylpenicillinum [INN-Latin]; phenoxymethylpenicillanyl; Acipen V; Fenoxypen; 3,3-dimethyl-6beta-[(phenoxyacetyl)amino]penam-2alpha-carboxylic acid (PIN); KBioSS_001487; DB08415; 4-27-00-05884 (Beilstein Handbook Reference); IDI1_000779; Beromycin, Penicillin; AB00514745; DivK1c_000779; V-Cillin; CCRIS 752; Penicillanic acid, 6-phenoxyacetamido-; Apopen; phenoxomethylpenicillanyl; V-Cil; KBio1_000779; Robicillin; Oratren; 87-08-1; KBioGR_000944; V-Tablopen; penicillin v; Beepen-VK; Phenoxymethyl penicillin; Fenossimetilpenicillina; Compocillin V; Ospen; PVA; KBio2_004055; 6-Phenoxyacetamidopenicillanic acid; Pen-vee; Spectrum_001007; Phenoxymethylpenicillin (INN); (2S,5R,6R)-3,3-dimethyl-7-oxo-6-[(2-phenoxyacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-6-(2-phenoxyacetamido)-; C16H18N2O5S; Phenoxymethylpenicillinum; Eskacillin V; Phenopenicillin; Pen-Oral; acipen-v; Oracillin; Spectrum2_000495; LS-1861; MolPort-002-515-462; AC1L1NHG; Phenoxymethylpenicilline; KBio3_001685; KBio2_006623; V-Cillin K; Penicillin V (USP); AC1Q5QX3; PV; CHEBI:53706; Pen-V; V-Cylina; BSPBio_002185; PNV; Phenoxymethylenepenicillinic acid; Phenoxymethylpenicillin; 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-6-((phenoxyacetyl)amino)-, (2S-(2alpha,5alpha,6beta))-; SMR000539431; Spectrum4_000472; Fenoxymethylpenicillin; DB00417; Distaquaine V; SPBio_000389; Betapen-VK; HSDB 6314; Penicillin V [USAN]; 132-98-9 (mono-potassium salt); P-Mega-Tablinen; Fenossimetilpenicillina [DCIT]; Fenoximetilpenicilina [INN-Spanish]; 2,2-dimethyl-6beta-[(phenoxyacetyl)amino]penam-3alpha-carbonyl; 147-48-8 (mono-hydrochloride salt); CHEMBL615; EINECS 201-722-0; (2S,5R,6R)-3,3-DIMETHYL-7-OXO-6-(2-PHENOXYACETAMIDO)-4-THIA-1- AZABICYCLO(3.2.0)HEPTANE-2-CARBOXYLIC ACID; Penicillin phenoxymethyl; MLS001304105; Phenocillin; Phenomycilline; (2S,5R,6R)-3,3-dimethyl-7-oxo-6-{[(phenyloxy)acetyl]amino}-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; Fenoximetilpenicilina; Crystapen V; (2S,5R,6R)-3,3-Dimethyl-7-oxo-6-[(phenoxyacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 132-98-9; Phenoximethylpenicillinum; Eskacillian V	87-08-1	6869	10326	TTDS00210	Penicillin binding protein	N/A	N/A	N/A	N/A	binder
DAP000438	Carbenicillin	Carboxybenzylpenicillin; alpha-Carboxybenzylpenicillin solution; DB00578; 4697-36-3; 6-(alpha-Carboxyphenylacetamido)penicillanic acid; IDI1_000735; Carbenicillin (INN); Carbenicillinum; AC1L2H29; Carbenicillin [INN:BAN]; Spectrum4_000263; NINDS_000735; N-(2-Carboxy-3,3-dimethyl-7-oxo-4-thia-azabicyclo(3.2.0)hept-6-yl)-2-phenylmalonamic acid; Carbenicilline; Carbenicillina [DCIT]; Malonamic acid, N-(2-carboxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)hept-6-yl)-2-phenyl-; KBio1_000735; KBio2_000518; N-(2-carboxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)hept-6-yl)-2-phenylmalonamic acid; Carbenicillinum [INN-Latin]; HSDB 3020; Pyopen; C17H18N2O6S; EINECS 225-171-0; DivK1c_000735; alpha-Phenyl(carboxymethylpenicillin); LS-88731; AC1Q5QWI; CBPC; Carbenicilina [INN-Spanish]; (2S,5R,6R)-6-[(3-hydroxy-3-oxo-2-phenylpropanoyl)amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; Spectrum3_000326; Carbenicilline [INN-French]; Carbenicillina; Spectrum5_000900; Carboxybenzylpenicillin acid; NSC111071; KBio2_003086; alpha-Carboxybenzylpencillin; Carbenicilina; 4800-94-6 (di-hydrochloride salt); Spectrum_000098; 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[(carboxyphenylacetyl)amino]-3,3-dimethyl-7-oxo-, (2S,5R,6R)-; KBioSS_000518; D07614; C06869; KBioGR_000726; KBio3_001151; CID20824; Carboxybenzyl Penicillin; BSPBio_001931; UNII-G42ZU72N5G; 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-((carboxyphenylacetyl)amino)-3,3-dimethyl-7-oxo-, (2S-(2alpha,5alpha,6beta))-; (2S,5R,6R)-6-{[carboxy(phenyl)acetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; carbenicillin; Spectrum2_000120; 6beta-(2-carboxy-2-phenylacetamido)-2,2-dimethylpenam-3alpha-carboxylic acid; SPBio_000140; CHEBI:3393; CHEMBL1214; KBio2_005654; C1613_SIGMA	4697-36-3	20824	9086	TTDS00210	Penicillin binding protein	N/A	N/A	N/A	N/A	binder
DAP000449	Cefazolin	Cefazoline [INN-French]; Lopac0_000274; NSC291561; Cephazolin; KBioGR_000734; KBio3_001159; CHEBI:474053; Prestwick2_000736; (6R, 7R)-3-[[(5-Methyl-1,3,4-thiadiazol-2- yl)thio]methyl]-8-oxo-7-[[1H-tetrazol-1- yl)acetyl]amino]-5-thia-1-azabicyclo[4.2.0]oct-2- ene-2-carboxylic acid; Prestwick3_000736; Spectrum5_000665; (6R,7R)-3-{[(5-methyl-1,3,4-thiadiazol-2-yl)thio]methyl}-8-oxo-7-[(1H-tetrazol-1-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; Cefazolin (USP); C14H14N8O4S3; 7-(1-(1H-)-Tetrazolylacetamido)-3-(2-(5-methyl-1,3,4-thiadiazolyl)thiomethyl)delta3-cephem-4-carboxylic acid; Spectrum_000106; CEZ; MLS001032060; UNII-IHS69L0Y4T; AC1Q6LOT; Cefazolina; SPBio_002631; EINECS 247-362-8; BRN 4169371; AC1L1P98; Prestwick0_000736; NINDS_000014; Prestwick1_000736; Cefazolina [INN-Spanish]; SMR000387025; Cephazoline; cefazolin; Bio-0576; (6R-trans)-3-(((5-Methyl-1,3,4-thiadiazol-2-yl)thio)methyl)-8-oxo-7-(((1H-tetrazol-1-yl)acetyl)-amino)-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; BSPBio_000692; Cephazolin Sodium; Cefamezine; IDI1_000014; SPBio_001039; Cefamezin; NCGC00159465-02; Elzogram; 27164-46-1; C06880; 25953-19-9; KBio1_000014; MolPort-002-507-461; MLS001049010; BPBio1_000762; Spectrum4_000267; Spectrum2_001140; CID33255; Cefazolin [USAN:INN]; BSPBio_001939; KBio2_000546; CHEMBL1435; DivK1c_000014; cefazolin(usp); Cefazolinum; KBio2_003114; Cefazolinum [INN-Latin]; Cefazoline; AC-16010; Cephazolidin; Spectrum3_000330; KBioSS_000546; 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-(((5-methyl-1,3,4-thiadiazol-2-yl)thio)methyl)-8-oxo-7-(((1H-tetrazol-1-yl)acetyl)amino)-, (6R-trans)-; 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-(((5-methyl-1,3,4-thiadiazol-2-yl)thio)methyl)-8-oxo-7-((1H-tetrazol-1-ylacetyl)amino)-, (6R-trans)-; HSDB 3213; 3-{[(5-methyl-1,3,4-thiadiazol-2-yl)sulfanyl]methyl}-7beta-[(1H-tetrazol-1-ylacetyl)amino]-3,4-didehydrocepham-4-carboxylic acid; LS-150084; (6R,7R)-3-[(5-methyl-1,3,4-thiadiazol-2-yl)sulfanylmethyl]-8-oxo-7-[[2-(tetrazol-1-yl)acetyl]amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-(((5-methyl-1,3,4-thiadiazol-2-yl)thio)methyl)-8-oxo-7-(2-(1H-tetrazol-1-yl)acetamido)-; D02299; KBio2_005682; (6R,7R)-3-{[(5-methyl-1,3,4-thiadiazol-2-yl)sulfanyl]methyl}-8-oxo-7-[(1H-tetrazol-1-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; Cephamezine; (6R,7R)-3-(((5-Methyl-1,3,4-thiadiazol-2-yl)thio)methyl)-8-oxo-7-(2-(1H-tetrazol-1-yl)acetamido)-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid	25953-19-9	656510	9097	TTDS00210	Penicillin binding protein	N/A	N/A	N/A	N/A	binder
DAP000434	Loracarbef	LY-163892; (6R,7S)-7-[[(2R)-2-amino-2-phenylacetyl]amino]-3-chloro-8-oxo-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; KT-3777; 7beta-[(2R)-2-ammonio-2-phenylacetyl]nitrilo-3-chloro-3,4-didehydrocepham-4-carboxylate; CHEBI:47544; Lorafem; CID5284585; CID5284584; 7beta-[(2R)-2-amino-2-phenylacetyl]nitrilo-3-chloro-3,4-didehydrocepham-4-carboxylic acid; Loracarbef hydrate; Loracarbefum; (6R,7S)-7-{[(2R)-2-ammonio-2-phenylacetyl]amino}-3-chloro-8-oxo-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; (6R,7S)-7-[[(2R)-2-amino-2-phenylacetyl]amino]-3-chloro-8-oxo-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid hydrate; CHEBI:281056; Lorabid; (6R,7S)-7-{[(2R)-2-amino-2-phenylacetyl]amino}-3-chloro-8-oxo-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid hydrate; CHEBI:214480; 7beta-[(2R)-2-amino-2-phenylacetyl]nitrilo-3-chloro-3,4-didehydrocepham-4-carboxylate; (6R,7S)-7-{[(2R)-2-amino-2-phenylacetyl]amino}-3-chloro-8-oxo-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; CHEMBL1200610; BIDD:GT0753; I06-1267; AC1NR4Q1; loracarbef; AC1NR4Q4; (6R,7S)-7-{[(2R)-2-amino-2-phenylacetyl]amino}-3-chloro-8-oxo-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; CHEMBL1013; 76470-66-1	76470-66-1	3956	191326	TTDS00210	Penicillin binding protein	N/A	N/A	N/A	N/A	binder
DAP001175	Ceforanide	Ceforanide (USP/INN); Ceforanido [INN-Spanish]; Precef; 60925-61-3; BPBio1_000638; (6R,7R)-7-(2-(alpha-Amino-o-tolyl)acetamido)-3-(((1-(carboxymethyl)-1H-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; Ceforanido; BRD-K37848908-001-03-1; BL-S 786; Radacef; bl s786; Precef (TN); Prestwick3_000470; 7-(o-(Aminomethyl)phenylacetamido)-3-(((1-(carboxymethyl)-1H-tetrazol-5-yl)thio)methyl)-3-cephem-4-carboxylic acid; DB00923; Prestwick1_000470; Ceforanide [USAN:INN:BAN]; (6R,7R)-7-({[2-(aminomethyl)phenyl]acetyl}amino)-3-({[1-(carboxymethyl)-1H-tetrazol-5-yl]sulfanyl}methyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; Prestwick2_000470; C06884; 7-[O-(aminomethyl)phenylacetamido]-3-[[[1-(carboxymethyl)-1H-tetrazol-5-yl]thio]methyl]-3-cephem-4-carboxylic acid; Ceforanidum [INN-Latin]; (6R-trans)-7-(((2-(Aminomethyl)phenyl)acetyl)amino)-3-(((1-(carboxymethyl)-1H-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; CHEBI:3495; AC1L2A0U; AB00513845; D00259; LS-176135; CID43507; (6R,7R)-7-[[2-[2-(aminomethyl)phenyl]acetyl]amino]-3-[[1-(carboxymethyl)tetrazol-5-yl]sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; C20H21N7O6S2; Prestwick0_000470; BSPBio_000580; (6R,7R)-7-({[2-(aminomethyl)phenyl]acetyl}amino)-3-({[1-(carboxymethyl)-1H-tetrazol-5-yl]thio}methyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; UNII-8M1YF8951V; AC1Q6LON; 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2-(aminomethyl)phenyl)acetyl)amino)-3-(((1-(carboxymethyl)-1H-tetrazol-5-yl)thio)methyl)-8-oxo-, (6R-trans)-; SPBio_002519; HMS1569M22; 7beta-[2-(aminomethyl)phenyl]acetamido-3-{[1-(carboxymethyl)-1H-tetrazol-5-yl]sulfanyl}methyl-3,4-didehydrocepham-4-carboxylic acid; Ceforanidum; CHEMBL1201046; CEFORANIDE; BL-S786	60925-61-3	43507	9101	TTDS00210	Penicillin binding protein	N/A	N/A	N/A	N/A	binder
DAP001164	Piperacillin	CCRIS 7362; CID43672; Prestwick0_000755; piperacillin; (2S,5R,6R)-6-{[(2R)-2-{[(4-ethyl-2,3-dioxopiperazin-1-yl)carbonyl]amino}-2-phenylacetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; SPBio_002709; BSPBio_000770; CHEMBL702; Peracin (TN); 4-ethyl-2,3-dioxopiperazine carbonyl ampicillin; Pipril; Pipercillin; Piperacillin Monosodium Salt; Pipracil; BPBio1_000848; Peperacillin; Piperacillin (INN); BRD-K86873305-236-03-0; T-1220; Pipracil, Piper; PIPERACILLIN SODIUM; Cl-227193; 61477-96-1; CHEBI:8232; (2S,5R,6R)-6-[[(2R)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[(2R)-[[(4-ethyl-2,3-dioxo-1-piperazinyl)carbonyl]amino]phenylacetyl]amino]-3,3-dimethyl-7-oxo-, (2S,5R,6R)-; EINECS 262-811-8; Peracin; 59703-84-3 (mono-hydrochloride salt); (2S-(2alpha,5alpha,6beta(S*)))-6-(((((4-Ethyl-2,3-dioxopiperazin-1-yl)carbonyl)amino)phenylacetyl)amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid; 59703-84-3; Prestwick1_000755; Piperacillin anhydrous; Prestwick3_000755; 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-(((((4-ethyl-2,3-dioxo-1-piperazinyl)carbonyl)amino)phenylacetyl)amino)-3,3-dimethyl-7-oxo-, (2S-(2alpha,5alpha,6beta(S*)))-; Prestwick2_000755; D08380; C14034; AC1L2ACR; 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 3,3-dimethyl-6-(((((4-ethyl-2,3-dioxo-1-piperazinyl)carbonyl)amino)phenylacetyl)amino)-7-oxo-, (2S-(2-alpha,5-alpha,6-beta(S*)))-; 6-(D-(-)-alpha-(4-Ethyl-2,3-dioxo-1-piperazinecarboxamido)phenylacetamido)penicillanic acid; Piperacillin (anhydrous); UNII-9I628532GX; LS-149794; PIPC; C23H27N5O7S; 6beta-{(2R)-2-[(4-ethyl-2,3-dioxopiperazin-1-yl)carboxamido]-2-phenylacetamido}-2,2-dimethylpenam-3alpha-carboxylic acid; BIDD:GT0167; AC1Q5QXJ; HMS2090H19	66258-76-2	43672	184033	TTDS00210	Penicillin binding protein	N/A	N/A	N/A	N/A	binder
DAP001167	Hetacillin	Hetacillin [USAN:INN:BAN]; (2S,5R,6R)-6-(2,2-dimethyl-5-oxo-4-phenylimidazolidin-1-yl)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; KBioSS_001345; DB00739; AC1L2A4V; C19H23N3O4S; NINDS_000003; 6beta-[(4R)-2,2-dimethyl-5-oxo-4-phenylimidazolidin-1-yl]-2,2-dimethylpenam-3alpha-carboxylic acid; AC1Q5V35; 6-(2,2-Dimethyl-5-oxo-4-phenyl-1-imidazolidinyl)penicillansaeure; CID68633; Hetacilline; 6-(2,2-Dimethyl-5-oxo-4-phenyl-1-imidazolidinyl)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid; hetacillin; CID10500546; BRL-804; C11729; HETACILLIN POTASSIUM; Spectrum4_000572; Hetacilina; KBio2_003913; Spectrum_000865; Hetacillinum; Hetacillinum [INN-Latin]; AC1L4VWW; KBio2_006481; Hetacillin (USAN/INN); AR-1G9691; 6beta-[(4R)-2,2-dimethyl-5-oxo-4-phenylimidazolidin-1-yl]penicillanic acid; (2S,5R,6R)-6-[(4R)-2,2-dimethyl-5-oxo-4-phenylimidazolidin-1-yl]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; DivK1c_000003; LS-187244; CHEBI:5683; CHEMBL1201116; Versapen (TN); Versapen; CID3596; CID443387; UNII-TN4JSC48CV; CID193260; BSPBio_002098; 6-(2,2-dimethyl-5-oxo-4-phenylimidazolidin-1-yl)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; KBio3_001318; 3511-16-8; Spectrum2_001116; AC1L1GA8; AC1L9EKH; BRL 804; EINECS 222-512-5; (2S,%R,6R)-6-(2,2-Dimethyl-5-oxo-4-phenyl-1-imidazolidinyl)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptan-2-carbonsaeure; Etacillina [DCIT]; Phenazacillin; Hetacilline [INN-French]; Spectrum3_000449; KBio2_001345; KBioGR_001004; BL-P 804; IDI1_000003; 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-(2,2-dimethyl-5-oxo-4-phenyl-1-imidazolidinyl)-3,3-dimethyl-7-oxo-, (2S-(2alpha,5alpha,6beta(S*)))-; (2S,5R)-6-[(4R)-2,2-dimethyl-5-oxo-4-phenylimidazolidin-1-yl]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; LS-174509; D01074; Hetacilina [INN-Spanish]; N,N'-Isopropylidene-A-amino-benzyl penicillin; Spectrum5_000790; SPBio_001252; KBio1_000003; Etacillina	3511-16-8	443387	13894	TTDS00210	Penicillin binding protein	N/A	N/A	N/A	N/A	binder
DAP000457	Cefpodoxime	D07650; TL8005407; (6R,7R)-7-({(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(methyloxy)imino]acetyl}amino)-3-[(methyloxy)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; CHEMBL1672; Cefpodoximum [Latin]; Epoxim; 80210-62-4; UNII-7R4F94TVGY; Cefpodoximum; Cefpodoxim acid; (6R,7R)-7-[[(2E)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-(methoxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; RU 51807; AC1O426G; C15H17N5O6S2; Cefpodoxima [Spanish]; LS-177540; 7-{[(2-amino-1,3-thiazol-4-yl)(methoxyimino)acetyl]amino}-3-(methoxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; Cefpodoxima; CHEBI:606443; (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-(methoxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; C08114; AC1O3S8J; 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[(2E)-2-(2-amino-4-thiazolyl)-2-(methoxyimino)-1-oxoethyl]amino]-3-(methoxymethyl)-8-oxo-; Cefpodoxime [INN:BAN]; CID6335986; AC1Q6LP9; DB01416; CID9570848; CPDX; Epoxim (TN); CEFPODOXIME; Cefpodoxime (INN); MolPort-003-845-691; 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2-amino-4-thiazolyl)(methoxyimino)acetyl)amino)-3-(methoxymethyl)-8-oxo-, (6R-(6alpha,7beta(Z)))-; BIDD:GT0771	82619-04-3	6335986	14832042	TTDS00210	Penicillin binding protein	N/A	N/A	N/A	N/A	binder
DAP001162	Bacampicillin	6-((R)-2-Amino-2-phenylacetamido)penicillansaeure-(1-(ethoxycarbonyloxy)ethylester; 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-((aminophenylacetyl)amino)-3,3-dimethyl-7-oxo-, 1-((ethoxycarbonyl)oxy)ethyl ester, (2S-(2alpha,5alpha,6beta(S*)))-; CID441397; BRD-A41698174-003-03-9; AC1L22L9; 1-ethoxycarbonyloxyethyl (2S,5R,6R)-6-[[(2R)-2-amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate; 1-ethoxycarbonyloxyethyl (2S,5R)-6-[[(2R)-2-amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate; bacampicillinum; LS-175201; BPBio1_000410; Prestwick1_000416; UNII-8GM2J22278; 50972-17-3; SPBio_002311; Prestwick3_000416; AC1L9B3D; CID39849; 1-[(ethoxycarbonyl)oxy]ethyl 6beta-[(2R)-2-amino-2-phenylacetamido]-2,2-dimethylpenam-3alpha-carboxylate; 1-[(ethoxycarbonyl)oxy]ethyl (2S,5R,6R)-6-{[(2R)-2-amino-2-phenylacetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate; Bacampicillin (INN); bacampicillin; CHEMBL1583; BSPBio_000372; 1-ethoxycarbonyloxyethyl (2S,5R,6R)-6-[[(2S)-2-amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate; Bacampicilina [INN-Spanish]; Bacampicilline [INN-French]; Penglobe; D07487; AC1NSJTW; CID5311013; Bacampicillinum [INN-Latin]; Penglobe (TN); CHEBI:2968; DB01602; Prestwick2_000416; Bacampicillin hydrochloride; Prestwick0_000416; C08122; NCGC00179582-01; Bacampicillin [INN:BAN]; 1-Ethoxycarbonyloxyethyl (2S,5R,6R)-6((R)-(2-amino-2-phenylacetamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptan-2-carboxylat; (2S,5R,6R)-6((R)-(2-Amino-2-phenylacetamido))-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid ester with ethyl 1-hydroxyethylcarbonate; 1'-Ethoxycarbonyloxyethyl-(6-D-alpha-aminophenylacetamido)penicillanate; Bacampicilina; Bacampicilline; C21H27N3O7S; 37661-08-8 (mono-hydrochloride)	50972-17-3	441397	10298823	TTDS00210	Penicillin binding protein	N/A	N/A	N/A	N/A	binder
DAP000453	Ceftizoxime	C06890; Ceftizoxime (INN); 7beta-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-2,3-didehydropenam-2-carboxylic acid; 68401-81-0; LS-150023; (6R,7R)-7-(2-(2-Amino-4-thiazolyl)glyoxyamido)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-carbonsaeure-7-(Z)-(O-methyloxim); 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2-amino-4-thiazolyl)(methoxyimino)acetyl)amino)-8-oxo-, (6R-(6alpha,7beta(Z)))-; 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2-amino-4-thiazolyl)(methoxyimino)acetyl)amino)-8-oxo-, (6R-(6-alpha,7-beta(Z)))-; syn-7-(2-(2-Amino-4-thiazolyl)-2-methoxyiminoacetamido)-3-cephem-4-carboxylic acid; ceftizoxime; Eposerin; Ceftizoxima; UNII-C43C467DPE; FR-13749; 68401-82-1; DB01332; Ceftizoximum; CHEMBL528; SKF-88373; (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-(2-(2-Amino-4-thiazolyl)-2Z-(methoxyimino)acetamido)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-2-carbonsaeure; C13H13N5O5S2; D07658; Ceftizoxima [INN-Spanish]; AC1O6SWV; SK&F 88373-2; CID6533629; Ceftizoximum [INN-Latin]; Ceftix; FK749; (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; Ceftizoxime Monosodium Salt; CHEBI:553473; FR-13479; FR 13749; Ceftizoxime [INN:BAN]; (6R,7R)-7-({(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(methyloxy)imino]acetyl}amino)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; FK-749; 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2-amino-4- thiazolyl)(methoxyimino)acetyl)amino)-8-oxo-, (6R-(6-alpha,7-beta(Z)))-; 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[(2Z)-(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-8-oxo-, (6R,7R)-; 68401-82-1 (mono hydrochloride salt)	68401-81-0	6533629	11641637	TTDS00210	Penicillin binding protein	N/A	N/A	N/A	N/A	binder
DAP001173	Cefonicid	Cefonicido; CID4630261; Cefonicidum; CID43592; MolPort-006-391-990; DB01328; 6beta-[(2R)-2-hydroxy-2-phenylacetamido]-3-({[1-(sulfomethyl)-1H-tetrazol-5-yl]sulfanyl}methyl)ceph-3-em-4-carboxylic acid; 7-[(2-hydroxy-2-phenylacetyl)amino]-8-oxo-3-[[1-(sulfomethyl)tetrazol-5-yl]sulfanylmethyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; CHEBI:3491; Cefonicido [INN-Spanish]; CID43594; Sodium Cefonicid; (6R,7R)-7-{[(2R)-2-hydroxy-2-phenylacetyl]amino}-8-oxo-3-({[1-(sulfomethyl)-1H-tetrazol-5-yl]sulfanyl}methyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; LS-187318; AC1L2A76; 61270-58-4; 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((hydroxyphenylacetyl)amino)-8-oxo-3-(((1-(sulfomethyl)-1H-tetrazol-5-yl)thio)methyl)-, (6R-(6alpha,7beta(R*)))-; BRN 1066181; SK&F-75073; UNII-6532B86WFG; (7R)-7-(2-Hydroxy-2-phenylacetylamino)-6-oxo-3-{[1-(sulfomethyl)(1,2,3,4-tetraazol-5-ylthio)]methyl}-2H,7H,7aH-azetidino[2,1-b]1,3-thiazine-4-carboxylic acid; D07644; (6R,7R)-7-[(2-hydroxy-2-phenylacetyl)amino]-8-oxo-3-[[1-(sulfomethyl)tetrazol-5-yl]sulfanylmethyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 61270-78-8 (di-hydrochloride salt); BIDD:GT0667; C06882; CHEMBL1601; AC1NDR63; CID11006063; AC1L2A7C; Cefonicidum [INN-Latin]; Cefonicid Monosodium Salt; C18H18N6O8S3; Cefonicid [INN:BAN]; Monocef (TN); (6R,7R)-7-[[(2R)-2-hydroxy-2-phenylacetyl]amino]-8-oxo-3-[[1-(sulfomethyl)tetrazol-5-yl]sulfanylmethyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; SKF-75073-2; (6R,7R)-7-{[(2R)-2-hydroxy-2-phenylacetyl]amino}-8-oxo-3-({[1-(sulfomethyl)-1H-tetrazol-5-yl]thio}methyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; AC1Q6LOE; CID11307798; CEFONICID; Cefonicid (INN); Monocef; 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((hydroxyphenylacetyl)amino)-8-oxo-3-(((1-sulfomethyl)-1H-tetrazol-5-yl)thio)methyl)-, (6R-(6-alpha,7-beta(R*)))-; Praticef; LS-150074	61270-58-4	43592	183965	TTDS00210	Penicillin binding protein	N/A	N/A	N/A	N/A	binder
DAP000455	Cefepime	Cefepimum; Cefepime [USAN:INN]; 88040-23-7; Axepim; Maxipime; CFPM; cefepime; BMY-28142; Cepimex; LS-178033; HMS2089M18; Cefepime (USAN/INN); D02376; CHEBI:478164; (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-[(1-methylpyrrolidinium-1-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; CHEMBL186; AC1NUIFH; CID5479537; Maxcef; ZINC03871924; 7beta-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido]-3-[(1-methylpyrrolidinium-1-yl)methyl]-3,4-didehydrocepham-4-carboxylate; Cefepimum [Latin]; C08111; 1-(((6R,7R)-7-(2-(2-Amino-4-thiazolyl)glyoxylamido)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-1-methylpyrrolidinium hydroxide, inner salt, 7(sup 2)-(Z)-(O-methyloxime); Cefepima [Spanish]; Cepimax; DB01413; UNII-807PW4VQE3; C19H24N6O5S2; Cefepima; (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(1-methylpyrrolidin-1-ium-1-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; BMY 28142; Pyrrolidinium, 1-((7-(((2-amino-4-thiazolyl)(methoxyimino)acetyl)amino)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-1-methyl-, hydroxide, inner salt, (6R-(6alpha,7beta(Z)))-	88040-23-7	5479537	7849435	TTDS00210	Penicillin binding protein	N/A	N/A	N/A	N/A	binder
DAP001170	Meticillin	Penicillin, Dimethoxyphenyl; IDI1_000100; (2S,5R,6R)-6-{[(2,6-dimethoxyphenyl)carbonyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 6beta-(2,6-dimethoxybenzamido)-2,2-dimethylpenam-3alpha-carboxylic acid; Meticillin; KBio2_001473; BRL 1241; CHEMBL575; Penicillin, (2,6-dimethoxyphenyl)-; KBio2_006609; Spectrum_000993; AC1L1LRX; C07177; Meticillinum; KBio2_004041; Spectrum2_001965; 6beta-(2,6-dimethoxybenzamido)penicillanic acid; DivK1c_000100; Spectrum4_000878; 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-(2,6-dimethoxybenzamido)-3,3-dimethyl-7-oxo-; Meticillin [INN]; CHEBI:6827; LS-149790; 6-(2,6-Dimethoxybenzamido)penicillanic acid; 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-(2,6-dimethoxybenzamido)-3,3,-dimethyl-7-oxo-; Meticilina [INN-Spanish]; Spectrum5_001600; 6-(2,3-Dimethoxybenzamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid; CID6087; Meticilina; Spectrum3_000494; Methicillin [BAN]; Meticilline; Meticillinum [INN-Latin]; Methycillin; Meticilline [INN-French]; Metacillin; HSDB 3121; 7246-14-2 (mono-hydrochloride salt, monohydrate); (2S,5R,6R)-6-[(2,6-dimethoxybenzoyl)amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2,6-Dimethoxyphenyl)penicillin; BSPBio_001987; SPBio_002089; DB01603; 61-32-5; 132-92-3 (mono-hydrochloride salt, hydrate); Methicillinum; C17H20N2O6S; Staphcillin; KBioSS_001473; UNII-Q91FH1328A; NINDS_000100; Meticillina; 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-((2,6-dimethoxybenzoyl)amino)-3,3-dimethyl-7-oxo-, (2S-(2alpha,5alpha,6beta))-; Meticillina [DCIT]; KBio3_001487; KBio1_000100; Methicillin Monohydrate, Monosodium Salt; Dimocillin; KBioGR_001575; methicillin; MII; EINECS 200-505-8; BRD-K34388247-236-02-5	61-32-5	6087	11335275	TTDS00210	Penicillin binding protein	N/A	N/A	N/A	N/A	binder
DAP001172	Cefacetrile	Cefacetrile; Celospor; 7-(2-Cyanacetamido)-3-(hydroxymethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-2-carboxylat acetat (ester); Cefacetrilum; Cefacetrilo [INN-Spanish]; (6R,7R)-3-[(acetyloxy)methyl]-7-[(cyanoacetyl)amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; AC1L3MBP; Vetrimast [veterinary]; CID91562; Vetrimast [veterinary] (TN); EINECS 233-508-8; Cefacetrilum [INN-Latin]; (6R,7R)-3-(acetyloxymethyl)-7-[(2-cyanoacetyl)amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; D07629; 10206-21-0; C13H13N3O6S; LS-171802; 7-Cyanacetylamino-cephalosporansaeure; Cefacetrile (INN); DB01414; Cephacetrile; (6R,7R)-3-Acetoxymethyl-7-(2-cyanacetamido)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-2-carbonsaeure; 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-((acetyloxy)methyl)-7-((cyanoacetyl)amino)-8-oxo-, monosodium salt, (6R-trans)-; C-36278-Ba; Cefacetrilo; UNII-FDM21QQ344; Cefacetril	10206-21-0	91562	10224877	TTDS00210	Penicillin binding protein	N/A	N/A	N/A	N/A	binder
DAP001174	Pivmecillinam	2,2-dimethylpropanoyloxymethyl (2S,5R,6R)-6-(azepan-1-ylmethylideneamino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate; Hydroxymethyl (2S,5R,6R)-6-(((hexahydro-1H-azepin-1-yl)methylene)amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylate pivalate (ester); 337376-15-5; Amdinocillin pivoxil (USAN); C21H33N3O5S; Amdinocillin pivoxil [USAN]; PMPC; SPBio_002933; Pivmecilinamo; Prestwick3_001053; Prestwick0_001053; Prestwick1_001053; Pivmecilinamo [INN-Spanish]; NCGC00016813-01; AC1L1VG9; LS-174396; Coactabs (TN); DB01605; CAS-32887-03-9; Pivamdinocillin; Prestwick2_001053; Ro 10-9071; [(2,2-dimethylpropanoyl)oxy]methyl (2S,5R,6R)-6-[(azepan-1-ylmethylidene)amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate; 32886-97-8; NCGC00179344-01; BRD-K67100011-003-03-0; CID115163; AC1L3GMZ; Pivmecillinam; Pivmecillinamum [INN-Latin]; 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-(((hexahydro-1H-azepin-1-yl)methylene)amino)-3,3-dimethyl-7-oxo-, (2,2-dimethyl-1-oxopropoxy)methyl ester, (2S-(2alpha,5alpha,6beta))-; CHEBI:51210; [(2,2-dimethylpropanoyl)oxy]methyl(2s,5r,6r)-6-{[(e)-azepan-1-ylmethylidene]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate; EINECS 251-276-6; Coactabs; AC1Q68K2; BSPBio_001006; Pivmecillinamum; [(2,2-dimethylpropanoyl)oxy]methyl 6beta-[(azepan-1-ylmethylidene)amino]-2,2-dimethylpenam-3alpha-carboxylate; Amdinocillin Pivoxil; AR-1A8050; CID36272; UNII-1WAM1OQ30B; D02889; KST-1A3932; Pivmecillinam (INN); amdinocillin, pivaloyloxymethyl ester; 2,2-dimethylpropanoyloxymethyl (5R,6R)-6-(azepan-1-ylmethylideneamino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate; AB00514713; BPBio1_001108; Mecillinam Pivaloyl Ester; Selexid	32886-97-8	36272	177795	TTDS00210	Penicillin binding protein	N/A	N/A	N/A	N/A	binder
DAP001171	Pivampicillin	Pivaloylampicillin; D08396; Pivampicillinum [INN-Latin]; Pondocillin; CHEBI:8255; 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-((aminophenylacetyl)amino)-3,3-dimethyl-7-oxo-, (2,2-dimethyl-1-oxopropoxy)methyl ester, (2S-(2alpha,5alpha,6beta(S*)))-; Pivampicillinum; Pivaloyloxymethyl ampicillinate; Pivampicillin (INN); 2,2-dimethylpropanoyloxymethyl (2S,5R,6R)-6-[[(2R)-2-amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate; Prestwick3_001009; MK 191; Pivampicilina; HMS1571I19; Prestwick0_001009; 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-(2-amino-2-phenylacetamido)-3,3-dimethyl-7-oxo-, hydroxymethyl ester, pivalate (ester), D-(-)-; AB00513999; Pivampicilline; DB01604; 33817-20-8; Prestwick1_001009; CID33478; Pivampicilline [INN-French]; Ampicillin pivaloyloxymethyl ester; EINECS 251-688-6; Ampicillin Pivaloyl Ester; AC1L1PP5; Pivampicilina [INN-Spanish]; BSPBio_001137; Pivampicillin Monohydrochloride; [(2,2-dimethylpropanoyl)oxy]methyl 6beta-[(2R)-2-amino-2-phenylacetamido]-2,2-dimethylpenam-3alpha-carboxylate; SPBio_003018; Pondocillin (TN); 26309-95-5 (mono-hydrochloride); NCGC00179290-01; Pivampicillin; BPBio1_001251; C22H29N3O6S; Prestwick2_001009; LS-149724; Pivampicillin [INN:BAN]	33817-20-8	33478	11467037	TTDS00210	Penicillin binding protein	N/A	N/A	N/A	N/A	binder
DAP000443	Amoxicillin	Amoxicillin (anhydrous); Delacillin; Moxatag; DisperMox; Amoxicilline [INN-French]; Vetramox; Ro 10-8756; CHEBI:2676; DB01060; Utimox; HSDB 3204; MolPort-005-933-687; Amopenixin; Trimox; Lamoxy; Bristamox; Amoxi-Mast; 6-(D-(-)-p-Hydroxy-alpha-aminobenzyl)penicillin; Unicillin; 81030-75-3; AMPC; Moxacin; Amoxicilline [INN]; 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[amino (4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-, [2S-[2.alpha.,5.alpha.,6.beta.(S*)]]-; C06827; MLS002222248; Metifarma capsules; 33911-69-2; 4-Thia-1-azobicyclo(3.2.0)heptane-2-carboxylic acid, 6-((amino(4-hydroxyphenyl)acetyl)amino)-3,3-dimethyl-7-oxo-, (2S-(2alpha,5alpha,6beta(S)))-; Clamoxyl; Pamoxicillin; Biomox; 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-(2-amino-2-(p-hydroxyphenyl)acetamido)-3,3-dimethyl-7-oxo-, D- (8CI); 6beta-[(2R)-2-amino-2-(4-hydroxyphenyl)acetamido]-2,2-dimethylpenam-3alpha-carboxylic acid; Amoxibiotic; 26787-78-0; AC-12263; Prestwick_713; Amoxicilline; Actimoxi; BLP 1410; Amoxicillin anhydrous; BSPBio_000453; Amoxycillin; BRD-K55044200-001-03-9; MLS000028632; Metafarma capsules; Ambap26787-78-0; SPBio_002374; Cemoxin; alpha-Amino-p-hydroxybenzylpenicillin; Prestwick1_000357; HMS1569G15; Amoxicilina; 61336-70-7 (TRIHYDRATE); SMR000058707; Robamox; Amoxicillinum [INN-Latin]; 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-(2-amino-2-(p-hydroxyphenyl)acetamido)-3,3-dimethyl-7-oxo-, D-; Wymox; Prestwick2_000357; Amoxivet; Prestwick3_000357; Amolin; EINECS 248-003-8; 71447-36-4; 6beta-[(2R)-2-amino-2-(4-hydroxyphenyl)acetamido]-2,2-dimethylpenam-3alpha-carbonyl; Amoxicillin (INN); 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-((amino(4-hydroxyphenyl)acetyl)amino)-3,3-dimethyl-7-oxo-; Apo-Amoxi; (2S,5R,6R)-6-[[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; CHEBI:53712; Amoxi; Larotid; (2S,5R,6R)-6-{[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; CHEMBL1082; Amopen; Amoxicillinum; Prestwick0_000357; D-(-)-alpha-Amino-p-hydroxybenzylpenicillin; Polymox; Ospamox; AX; NSC277174; Amoxil; Anemolin; amoxicillanyl; 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-(((2R)-amino(4-hydroxyphenyl)acetyl)amino)-3,3-dimethyl-7-oxo-, (2S,5R,6R)-; CPD000058707; D-2-Amino-2-(4-hydroxyphenyl)acetamidopenicillanic acid; Amoclen; LS-149721; Amoxicillin (TN); Aspenil; 34642-77-8 (mono-hydrochloride salt); Amoxycillin Trihydrate; Ibiamox; Amoxiden; Efpenix; SAM002264592; BRL-2333; D-Amoxicillin; Hydroxyampicillin; Sumox; AMOXICILLIN CRYSTALLINE; Histocillin; Sawamox PM; Piramox; BPBio1_000499; NCGC00179554-01; NSC 277174; Amoxicilina [INN-Spanish]; amoxicillin; AMOXICILLIN PEDIATRIC; 6-(p-Hydroxy-alpha-aminophenylacetamido)penicillanic acid; Amoxicaps; 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-((amino(4-hydroxyphenyl)acetyl)amino)-3,3-dimethyl-7-oxo-, (2S-(2alpha,5alpha,6beta(S*)))-; 6-(D-(-)-alpha-Amino-p-hydroxyphenylacetamido)penicillanic acid; CID33613; Tolodina; MolPort-003-981-182; AC1L1PY2; Moxal; p-Hydroxyampicillin; BL-P 1410; Hiconcil; Imacillin; Flemoxin; (-)-6-(2-Amino-2-(P-hydroxyphenyl)acetamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo-(3.2.0)heptane-2-carboxylic acid; D07452	26787-78-0	33613	175459	TTDS00210	Penicillin binding protein	N/A	N/A	N/A	N/A	binder
DAP000448	Cefamandole	(6R,7R)-7-{[(2R)-2-hydroxy-2-phenylacetyl]amino}-3-{[(1-methyl-1H-tetrazol-5-yl)thio]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 30034-03-8; DB01326; (6R,7R)-7-{[(2R)-2-hydroxy-2-phenylacetyl]amino}-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; Prestwick3_000747; Prestwick2_000747; Prestwick1_000747; AC-1294; D02344; CHEBI:3480; (6R,7R)-7-[[(2R)-2-hydroxy-2-phenylacetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; CHEMBL1146; 34444-01-4; Cefamandole (USAN/INN); (6R,7R)-7-(R)-Mandelamido-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-carboxylic acid; BRD-K27130738-236-03-4; CID456255; cefamandole; Prestwick0_000747; 7beta-[(2R)-2-hydroxy-2-phenylacetamido]-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}ceph-3-em-4-carboxylic acid; 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[(2R)-2-hydroxy-2-phenylacetyl]amino]-3-[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-8-oxo-, 6R,7R)-; MolPort-005-933-283; BPBio1_000808; Cefadole; SPBio_002673; AC1L9UKI; CPD0-2066; C06879; Cefamandolum; BSPBio_000734	34444-01-4	456255	10302112	TTDS00210	Penicillin binding protein	N/A	N/A	N/A	N/A	binder
DAP001159	Cyclacillin	4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-(((1-aminocyclohexyl)carbonyl)amino)-3,3-dimethyl-7-oxo-, (2S-(2alpha,5alpha,6beta))-; Cyclapen-W (TN); NCGC00016629-01; Prestwick2_001120; C12766; BPBio1_001385; HMS1571O22; ciclacillin; Syngacillin; NCI60_041965; AC1L2D99; D01334; Ultracillin; Prestwick0_001120; Ciclacilina; Vipicil; Ciclacillinum; BSPBio_001260; Noblicil; Vastcillin (TN); Ciclacilline; Ciclacilline [INN-French]; Bastcillin; 6-(1-Aminocyclohexanecarboxamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid; LS-55797; SPBio_003120; AC 98; UNII-72ZJ154X86; EINECS 222-470-8; 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[(1-aminocyclohexyl)carbonyl]amino]-3,3-dimethyl-7-oxo-, [2S-(2.alpha.,5.alpha.,6.beta.)]-; C-12104; NCGC00179238-01; WY 4508; Ciclacillum; 6beta-(1-aminocyclohexanecarboxamido)-2,2-dimethylpenam-3alpha-carboxylic acid; CHEMBL1200356; Wyvital; Ciclacillin (JP15/INN); Citosarin; Aminocyclohexyl penicillin; 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-(1-aminocyclohexanecarboxamido)-3,3-dimethyl-7-oxo- (8CI); Wy-4508; 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-(1-aminocyclohexanecarboxamido)-3,3-dimethyl-7-oxo-; Peamezin; BRD-K89046952-001-03-4; Cyclacillin [USAN]; (2S,5R,6R)-6-{[(1-aminocyclohexyl)carbonyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; Orfilina; WY4508; CID19003; NSC 88789; CYCLACILLIN; 3485-14-1; AB00514059; 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-(1-aminocyclohexanecarboxamido)-3,3-dimethyl-7-oxo-; AC-PC; Cyclapen; Ciclacilina [INN-Spanish]; 6-(1-Aminocyclohexanecarboxamido)penicillanic acid; Calthor; Aminocyclohexylpenicillin; Vastcillin; 6-(1-Aminocyclohexanecarboxamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; DB01000; Cyclacillin (USAN); Penicillin, (aminocyclohexyl)-; 6-(1-Aminocyclohexylcarboxamido)penicillanic acid; (2S,5R,6R)-6-[(1-aminocyclohexanecarbonyl)amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; CHEBI:31444; CAS-3485-14-1; WLN: T45 ANV ESTJ F1 F1 GVQ CMV- AL6TJ AZ; Ciclacillinum [INN-Latin]; Prestwick3_001120; (1-Aminocyclohexyl)penicillin; BRN 0938663; Cyclapen-W; NSC88789; Prestwick1_001120	3485-14-1	19003	583155	TTDS00210	Penicillin binding protein	N/A	N/A	N/A	N/A	binder
DAP000451	Cefotetan	Prestwick1_000473; BPBio1_000668; ICI-156834; Cefotetanum; MolPort-005-935-573; CHEBI:3499; cefotetan; (6R,7S)-7-({[4-(2-amino-1-carboxy-2-oxoethylidene)-1,3-dithietan-2-yl]carbonyl}amino)-7-methoxy-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; C06886; I06-1743; 69712-56-7; D00260; CID53025; SMR001233197; AB00513847; AC-2141; (6R,7S)-7-(4-(carbamoylcarboxymethylene)-1,3-dithiethane-2-carboxamido)-7-methoxy-3-(((1-methyl-1H-tetrazol-5- yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2- carboxylic acid; (6R,7S)-7-[[4-(1-amino-3-hydroxy-1,3-dioxopropan-2-ylidene)-1,3-dithietane-2-carbonyl]amino]-7-methoxy-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; Prestwick3_000473; BSPBio_000606; Prestwick0_000473; CHEMBL474579; AC1L1E33; SPBio_002545; NCGC00179507-01; HMS1569O08; 7beta-({[4-(2-amino-1-carboxy-2-oxoethylidene)-1,3-dithietan-2-yl]carbonyl}amino)-7alpha-methoxy-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-3,4-didehydrocepham-4-carboxylic acid; Cefotetan (JP15/USP/INN); MLS002153829; Prestwick2_000473	69712-56-7	50614	11011827	TTDS00210	Penicillin binding protein	N/A	N/A	N/A	N/A	binder
DAP001157	Cefpiramide	7beta-[(2R)-2-{[(4-hydroxy-6-methylpyridin-3-yl)carbonyl]amino}-2-(4-hydroxyphenyl)acetamido]-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-3,4-didehydrocepham-4-carboxylic acid; 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((((4-hydroxy-6-methyl-3-pyridinyl)carbonyl)amino)(4-hydroxyphenyl)acetyl)amino)-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-, (6R-(6alpha,7beta(R*)))-; WY 44635; CID636405; Cefpiramido [INN-Spanish]; 70797-11-4; cefpiramide; (6R,7R)-7-{[(2R)-2-{[(4-hydroxy-6-methylpyridin-3-yl)carbonyl]amino}-2-(4-hydroxyphenyl)acetyl]amino}-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; CHEBI:59213; CID53130; KST-1A9138; NCGC00167444-01; Cefpiramido; Cefpiramide (USP/INN); AC1LCS6B; UNII-P936YA152N; AC1L1E4W; 95984-77-3; AC1L1EAF; (6r)-7-{[(2r)-2-(4-hydroxyphenyl)-2-{[(6-methyl-4-oxo-1,4-dihydropyridin-3-yl)carbonyl]amino}acetyl]amino}-3-{[(1-methyl-1h-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; LS-187253; (6R,7R)-7-[[(2R)-2-(4-hydroxyphenyl)-2-[(6-methyl-4-oxo-1H-pyridine-3-carbonyl)amino]acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; D03428; (6R,7R)-7-((R)-2-(4-Hydroxy-6-methylnicotinamido)-2-(p-hydroxyphe- nyl)acetamido)-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-- 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; AR-1A6903; Cefpiramidum [INN-Latin]; AC1L32I1; (6R,7R)-7-[[2-(4-hydroxyphenyl)-2-[(6-methyl-4-oxo-1H-pyridine-3-carbonyl)amino]acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; Cefpiramidum; CID2642; 74849-93-7 (hydrochloride salt); CID107654; WY 44,635; (6R)-7-[[(2R)-2-(4-hydroxyphenyl)-2-[(6-methyl-4-oxo-1H-pyridine-3-carbonyl)amino]acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; DB00430; 7-[[2-(4-hydroxyphenyl)-2-[(6-methyl-4-oxo-1H-pyridine-3-carbonyl)amino]acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; Cefpiramide [USAN:INN]	70797-11-4	107654	684895	TTDS00210	Penicillin binding protein	N/A	N/A	N/A	N/A	binder
DAP001161	Cloxacillin	6-(3-(o-Chlorophenyl)-5-methyl-4-isoxazolecarboxamido)penicillanic acid; AC1L1LSU; Tegopen; Syntarpen; DivK1c_000736; KBioGR_000852; BPBio1_000123; CHEBI:49566; 61-72-3; 6-(((3-(2-Chlorophenyl)-5-methyl-4-isoxazolyl)carbonyl)amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid; BSPBio_002059; BRL-1621 (sodium monohydrate); Methocillin S; CID6098; Cloxacillin sodium; Methylchlorphenylisoxazoryl-penicillin; Cloxacilina [INN-Spanish]; MCIPC; KBio2_006961; HSDB 3042; Clossacillina [DCIT]; Spectrum3_000360; Orbenin (TN); (2S,5R,6R)-6-({[3-(2-chlorophenyl)-5-methylisoxazol-4-yl]carbonyl}amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; [3-(O-CHLOROPHENYL)-5-METHYL-4-ISOXAZOLYL]PENICILLIN; CHEMBL891; C19H18ClN3O5S; SPBio_002032; Tegopen (sodium monohydrate); KBio2_004393; EINECS 200-514-7; D07733; Orbenin; Spectrum5_000783; Cloxacillinum [INN-Latin]; Clossacillina; Chloroxacillin; Spectrum4_000296; Spectrum2_001143; Cloxacillinum; 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-(3-(O-chlorophenyl)-5-methyl-4-isoxazolecarboxamido)-3,3-dimethyl-7-oxo-; Cloxacillin (INN); Prestwick1_000186; BRL 1621; Cloxapen (sodium monohydrate); Cloxacilina; LS-149769; BSPBio_000111; KBio2_001825; 8056-79-9; Nu-Cloxi; KBioSS_001825; UNII-O6X5QGC2VB; (3-(o-Chlorophenyl)-5-methyl-4-isoxazolyl)penicillin; NINDS_000736; 50763-55-8; 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-(3-(o-chlorophenyl)-S-methyl-4-isoxazolecarboxamido)-3,3-dimethyl-7-oxo-; DB01147; cloxacillin; Cloxacilline; Prestwick3_000186; Cloxacillin [INN:BAN]; C06923; BRD-K01244426-236-05-5; Novo-Cloxin; Prestwick2_000186; IDI1_000736; SPBio_001065; 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[3-(2-chlorophenyl)-5-methyl-4-isoxazolyl]carbonyl]amino]-3,3-dimethyl-7-oxo-, (2S,5R,6R)-; 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-(((3-(2-chlorophenyl)-5-methyl-4-isoxazolyl)carbonyl)amino)-3,3-dimethyl-7-oxo-, (2S-(2alpha,5alpha,6beta))-; KBio3_001279; KBio1_000736; Prestwick0_000186; P-25 (sodium monohydrate); Cloxacilline [INN-French]; Spectrum_001345; (2S,5R,6R)-6-[[3-(2-chlorophenyl)-5-methyl-1,2-oxazole-4-carbonyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid	61-72-3	6098	9140	TTDS00210	Penicillin binding protein	N/A	N/A	N/A	N/A	binder
DAP000436	Cefdinir	DB00535; CID6915944; CI-983; HMS2093K20; FK-482; PD-134393; BIDD:GT0827; (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(hydroxyimino)acetyl]amino}-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; HMS1922L19; Cefzon (TN); Cefdirnir; 91832-40-5; Omnicef, FK-482, BMY-28488, PD 134393, CI-983, Cefdinir; FK 482; SPECTRUM1505208; cefdinir; Omnicef; Cefdinirum; 7beta-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(hydroxyimino)acetamido]-3-ethenyl-3,4-didehydrocepham-4-carboxylic acid; S1605_Selleck; AC1OCD3C; 7-(2 (2-aminothiazol-4-yl)-2-hydroxyiminoacetamido)-3-vinyl-3-cephem-4-carboxylic acid; BMY 28488; 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2-amino-4-thiazolyl) (hydroxyimino)acetyl)amino)-3-ethenyl-8-oxo-, (6R-(6alpha,7beta(Z)))-; 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2-amino-4-thiazolyl)(hydroxyiminoacetyl)amino)-3-ethenyl-8-oxo-, (6R-(6-alpha,7-beta(Z)))-; UNII-CI0FAO63WC; (-)-(6R,7R)-7-(2-(2-Amino-4-thiazolyl)glyoxylamido)-8-oxo-3-vinyl-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7(sup 2)-(Z)-oxime; KS-1038; BSPBio_002735; CHEMBL927; (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-hydroxyiminoacetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; PD 134393; FR-80482; C14H13N5O5S2; Cefzon; Cefdinirum [INN-Latin]; MolPort-002-885-812; Omnicef (TN); Cefdinir (JP15/USAN/INN); C08110; CFDN; Cefdinir [USAN:INN]; CHEBI:3485; D00917; CI 983; NCGC00178499-01; Spectrum5_001560; LS-149988; Cefdinyl	91832-40-5	6915944	7847980	TTDS00210	Penicillin binding protein	N/A	N/A	N/A	N/A	binder
DAP000444	Cefditoren	104145-95-1; CID9571074; Cefditoren [USAN:INN]; C19H18N6O5S3; UNII-81QS09V3YW; LS-171904; 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((2-amino-4-thiazolyl)(methoxyimino)acetyl)amino-3-(2-(4-methyl-5-thiazolyl)ethenyl)-8-oxo-, (6R-(3(Z),6alpha,7beta(Z)))-; Cefditoren; (+)-(6R,7R)-7-(2-(2-Amino-4-thiazolyl)glyoxylamido)-3-((Z)-2-(4-methyl-5-thiazolyl)vinyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7(sup 2)-(Z)-(O-methyloxime); (6R-(3(Z),6alpha,7beta(Z)))-7-((2-Amino-4-thiazolyl)(methoxyimino)acetyl)amino-3-(2-(4-methyl-5-thiazolyl)ethenyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid	117467-28-4	9571074	213535	TTDS00210	Penicillin binding protein	N/A	N/A	N/A	N/A	binder
DAP001168	Penicillin G	Benzylpenicilline; SPECTRUM1500465; NINDS_000316; Phenylacetyl-6-aminopenicillanic acid; CHEBI:7963; Penicillinic acid, benzyl-; KBio1_000316; Benzopenicillin; CID5904; Penicillin G potassium salt; ST51052951; BSPBio_002183; MLS001076462; D02336; 2,2-dimethyl-6beta-(phenylacetamido)penam-3alpha-carboxylic acid; Benzylpenicillin; 2,2-dimethyl-6beta-(phenylacetamido)penam-3alpha-carboxylate; PENK_SIAL; Prestwick2_001078; Sodium penicillin; Compocillin G; BRD-K55191674-237-02-7; CID640429; BPBio1_001206; Bencilpenicilina [Spanish]; nchembio.252-comp1; AC1L1LDX; MLS001032123; Pharmacillin; ZINC03871701; LS-195224; Gelacillin; (Phenylmethyl)penicillinic acid; Benzyl-6-aminopenicillinic acid; Prestwick1_001078; Penicillinic acid, (phenylmethyl)-; CHEBI:18208; Penicillin G potassium (USP); Spectrum3_000542; AC1LD0NQ; (Phenylmethyl)penicillin; PENK_SIGMA; Abbocillin; SPBio_000475; 46609_FLUKA; P1772; Benzylpenicillin potassium (JP15); I06-1083; Benzylpenicillinum [Latin]; Benzylpenicillinum; Penicillin; 46609_RIEDEL; Benzylpenicillin [INN:BAN]; Crysticillin 300 A.S.; CHEMBL1223; Benzylpenicillin G; Spectrum_000933; potassium 2,2-dimethyl-6beta-(phenylacetamido)penam-3alpha-carboxylate; HMS500P18; Benzyl penicillin; BSPBio_001096; Galofak; HMS1920F12; P7794_SIGMA; benzylpenicilline potassique; Cillora; BRN 0044740; 6-(2-Phenylacetamido)penicillanic acid; Pfizerpen (TN); KBioGR_000942; IDI1_000316; AC-14408; CHEMBL29; KBio2_003981; Ursopen; P8721_SIAL; NCGC00159348-02; AB00384263; NChemBio.2007.21-comp4; 113-98-4 (mono-potassium salt); Bio-0602; Liquacillin; Benzylpenicillinic acid; Prestwick3_001078; EINECS 200-506-3; Bencilpenicilina; C16H18N2O4S; MLS001173382; AC1Q2CBJ; penicillin g; Benzylpenicilline [French]; Phenylacetamidopenicillanic acid; Bicillin; (5R,6R)-Benzylpenicillin; Spectrum5_001108; KBioSS_001413; 4-27-00-05861 (Beilstein Handbook Reference); Pfizerpen; HSDB 3166; 61-33-6; Prestwick0_001078; nchembio.177-comp1; DB01053; CID443084; MolPort-003-666-255; Pradupen; Dropcillin; Megacillin; Free penicillin G; Cilloral; UNII-Q42T66VG0C; MLS000766897; PENICILLIN-G; Spectrum2_000518; SMR000538912; NCGC00021679-03; CHEBI:51354; SPBio_002998; LS-149836; C05551; D01053; Sodium benzylpenicillin; Penicillin G potassium; Benzylpenicillin potassium salt; MolPort-002-511-679; PNN; KBio2_006549; KBio2_001413; Cosmopen; Cilopen; Spectrum4_000471; HMS2091N12; Penicillin potassium G, crystalline; Penicillin-G potassium; Pencillin G; KBio3_001683; Ayercillin; MLS000069426; Penicillin, (phenylmethyl)-; SMR000059004; Free penicillin II; 69-57-8 (mono-hydrochloride salt); Specilline G; NCGC00021679-04; Benzylpenicillin (INN); NSC 193396; BRD-K55191674-236-03-7; Benzylpenicillin potassium; Free benzylpenicillin; DivK1c_000316; AR-1K9813; Bicillin (*Benzathine Salt, Tetrahydrate*)	61-33-6	5904	7885	TTDS00210	Penicillin binding protein	N/A	N/A	N/A	N/A	binder
DAP000432	Ampicillin	Novo-ampicillin; BRL 1341; Divercillin; Ultrabion; Ampi-bol; Penbritin; Supen; Pfizerpen-A; AB-PC Sol; Amplisom; Britacil; Ampicillin anhydrate; Principen '500'; Doktacillin; NCGC00023282-05; D-Ampicillin; Ampicillina; Amipenix S; DivK1c_000466; Totacillin (sodium); Spectrum3_000301; CHEBI:53713; Ampifarm; MolPort-001-794-635; Ampicillin Anhydrous; Anhydrous ampicillin (JP15); BA 7305; A9393_SIGMA; C06574; Ampipenin, nt3; Ampichel; Ampicil; Adobacillin; 1h8s; Olin Kid; Pen A; Duphacillin; Totacillin-N; Ampicillin [USAN:INN:BAN:JAN]; Principen; 6beta-[(2R)-2-amino-2-phenylacetamido]-2,2-dimethylpenam-3alpha-carboxylic acid; Norobrittin; Rosampline; Amblosin; Polycillin; anhydrous ampicillin; Pfizerpen A; Orbicilina; Principen '250'; Ampicillin (USP/INN); Ampivet; OMNIPEN (AMPICILLIN); Ampikel; Ampen; Pensyn; NCGC00023282-06; Ukapen; Ampicillin Base; MLS000028405; Racenacillin; 7177-48-2 (TRIHYDRATE); 37234-64-3; HMS2090I11; AB-PC; Ampicillinum [INN-Latin]; Penicline; CHEBI:28971; KBio2_005566; Binotal; 69-52-3 (mono-hydrochloride salt); Ampicillina [DCIT]; 98520-55-9; Ampicillin [USAN:BAN:INN:JAN]; SPBio_002067; 50584-05-9; Polycillin-N; Semicillin; HI 63; D-(-)-6-(alpha-Aminophenylacetamido)penicillanic acid; Ampicilina [INN-Spanish]; Vampen; Pentrex; SQ 17382; Servicillin; Ampi-Tab; Ampicilline; Tolomol; Trifacilina; Austrapen; Totalciclina; Penicillin, (aminophenylmethyl)-; Morepen; Ponecil; CHEMBL174; Amfipen; Wypicil; Ampicillinum; Guicitrine; EINECS 200-709-7; Lifeampil; Bayer 5427; Ampy-Penyl; KBio3_001362; 6beta-[(2R)-2-amino-2-phenylacetamido]-2,2-dimethylpenam-3alpha-carbonyl; Viccillin S; ABPC; Sumipanto; 800-79-3; HSDB 3009; AY 6108; Totapen; Ampicin; Cimex; D-Cillin; Copharcilin; Ampicilina; Polyflex (Veterinary); Ampipenin; BRL-1341; Pen A Oral; ampicillin; Nuvapen; SMR000058352; KBio2_000430; Penbritin syrup; Spectrum2_000769; KBio1_000466; Penbritin paediatric; Ultrabron; LS-1586; Pen Ampil; AC1L1M46; AY-6108; KBioSS_000430; Aminobenzylpenicillin; P 50; Spectrum5_000814; Ampicillin A; Totacillin; 6-(D(-)-alpha-Aminophenylacetamido)penicillanic acid; Prestwick1_000114; KS-R1; CID6249; Prestwick3_000114; D-(-)-Ampicillin; Ampivax; Ampicillin acid; Amplin; UNII-7C782967RD; BPBio1_000142; SPBio_000818; DB00415; Synpenin; Principen '125'; Alpen; Omnipen; Spectrum4_000149; Delcillin; Prestwick0_000114; IDI1_000466; Acillin; Pentrexyl; Texcillin; MLS001074168; Roscillin; Amcill; Spectrum_000050; P-50; LS-169948; Ampiscel; BIDD:GT0184; Guicitrina; Semicillin R; BSPBio_000128; Ampimed; Bonapicillin; 69-53-4; Amplital; 47355-94-2; Prestwick2_000114; KBio2_002998; Penicillin, Aminobenzyl; Ampisyn; Ro-Ampen; D00204; AMPICILLIN (SEE ALSO AMPICILLIN TRIHYDRATE 7177-48-2); 8056-87-9; Ampicilline [INN-French]; Deripen; Omnipen-N; SBB063111; AY  6108; Princillin; Amplacilina; Omnipen (TN); KBioGR_000598; QIDamp; NSC 528986; Penbristol; Grampenil; 33604-21-6; Viccillin; D-(-)-alpha-Aminopenicillin; Penbrock; NSC-528986; BSPBio_001862; Campicillin; NINDS_000466; WY-5103; NSC528986; Ampi-Co; Tokiocillin; Pentrexl; SMP1_000211; Penimic; AC-14075; ampicillanyl; Amplipenyl; D-(-)-alpha-Aminobenzylpenicillin; SK-Ampicillin; Penbritin-S; Amfipen V; 96707-69-6	69-53-4	6249	149171	TTDS00210	Penicillin binding protein	N/A	N/A	N/A	N/A	binder
DAP000435	Dicloxacillin	KBioGR_001053; (2S,5R,6R)-6-[[3-(2,6-dichlorophenyl)-5-methyl-1,2-oxazole-4-carbonyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; Diclossacillina; KBioSS_001412; Dycill; BRD-K05673000-323-02-8; DivK1c_000658; Dichloroxacillin; LS-174329; UNII-COF19H7WBK; Dicloxacillinum; Dicloxacilline; Dicloxaciclin; Dicloxacillin sodium; KBio3_001391; 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-(((3-(2,6-dichlorophenyl)-5-methyl-4-isoxazolyl)carbonyl)amino)-3,3-dimethyl-7-oxo-, (2S-(2alpha,5alpha,6beta))-; KBio2_003980; CHEMBL893; Maclicine; 3116-76-5; dicloxacillin; KBio2_001412; Pathocil; BSPBio_002171; 6beta-{[3-(2,6-dichlorophenyl)-5-methyl-1,2-oxazol-4-yl]carboxamido}-2,2-dimethylpenam-3alpha-carboxylic acid; NINDS_000658; 6-(3-(2,6-Dichlorophenyl)-5-methyl-4-isoxazolecarboxamido)penicillanic acid; BSPBio_000500; Spectrum2_000981; Dicloxacillin, Monosodium Salt, Mono-Hydrate; IDI1_000658; KBio2_006548; 343-55-5 (mono-hydrochloride salt, anhydrous); AC1L2BXC; 6-(3-(2,6-Dichlorophenyl)-5-methyl-4-isoxazolecarboxamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid; Prestwick2_000450; Dicloxacillin (USAN/INN); D02348; SPBio_002439; AC1Q5QXP; SPBio_001041; Spectrum3_000386; Dynapen; Spectrum5_000869; R-13423; Spectrum_000932; Dicloxacycline; Dicloxacilline [INN-French]; Prestwick0_000450; DB00485; Dicloxacilina [INN-Spanish]; CID18381; Spectrum4_000507; CHEBI:4511; Prestwick1_000450; (2S,5R,6R)-6-({[3-(2,6-dichlorophenyl)-5-methyl-1,2-oxazol-4-yl]carbonyl}amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; C06950; 13412-64-1 (mono-hydrochloride salt, mono-hydrate); EINECS 221-488-3; Prestwick3_000450; KBio1_000658; Methyldichlorophenylisoxazolylpenicillin; C19H17Cl2N3O5S; Diclossacillina [DCIT]; Dicloxacilina; Dicloxacillin [USAN:INN:BAN]; HSDB 3222; BRL 1702; BPBio1_000550; (2S,5R,6R)-6-({[3-(2,6-dichlorophenyl)-5-methylisoxazol-4-yl]carbonyl}amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 3-(2,6-Dichlorophenyl)-5-methyl-4-isoxazolylpenicillin; Dicloxacilin; Dicloxacillinum [INN-Latin]	3116-76-5	18381	9165	TTDS00210	Penicillin binding protein	N/A	N/A	N/A	N/A	binder
DAP000445	Cefuroxime	Sodium (6R,7R)-7-(2-(2-furyl)glyoxylamido)-3-(hydroxymethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylate, 7(sup 2)-(Z)-(O-methyloxime), carbamate (ester); 55268-75-2; Froxal [inj.]; Cetroxil [inj.]; D00915; cefuroximesodium; Cefuroxim Norcox [inj.]; BSPBio_000939; C4417_FLUKA; Prestwick3_000720; Cefuroxim; Cefuroxime (TN); Cefuroxime sodium [USAN:BAN:JAN]; BRN 5783190; (6R,7R)-3-(carbamoyloxymethyl)-7-[[(2Z)-2-(furan-2-yl)-2-methoxyiminoacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; MolPort-002-885-814; EINECS 260-073-1; Zinacef; LS-2226; UNII-R8A7M9MY61; Sodium cefuroxime; CXM; Cefuroxim Lilly; AC1Q41FS; Zinacef Danmark; Cefuroxim Norcox; cefuroxime na; ZINACEF IN PLASTIC CONTAINER; LS-149936; Cefuroxima Richet; AC1NUIFB; EINECS 259-560-1; Cefofix; Biofuroksym; Cefuroxim AJ; Cefuroxime sodium salt; BIDD:GT0619; Lifurox; Cefuroximine; 3-[(carbamoyloxy)methyl]-7beta-[(2Z)-2-(furan-2-yl)-2-(methoxyimino)acetamido]-3,4-didehydrocepham-4-carboxylic acid; Cefuroxime for Injection and Dextrose for Injection in Duplex Container; Cefuroxime sodium (JP15/USP); Cetroxil; UNII-O1R9FJ93ED; Sharox [inj.]; Curoxim; CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER; Spectrazolr; CHEBI:3515; CHEMBL1436; Froxal; Cefuroximum; Cefuroxim Hexal; C08108; Furoxil; KS-1040; Medoxim; Cefuril; Cefuroxime [USAN:INN:BAN]; cefuroxime; Cefumax; Kesint; Cefuroxime (USAN/INN); C16H16N4O8S; Cefurex; D00262; Cefuroximo [INN-Spanish]; Cefuroxim curasan; Curocef; CPD0-2069; Cefuroxima Fabra; Cefuroxim MN; C16H15N4O8S.Na; (6R,7R)-3-[(carbamoyloxy)methyl]-7-{[(2Z)-2-furan-2-yl-2-(methoxyimino)acetyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; CEFUROXIME SODIUM; 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-(((aminocarbonyl)oxy)methyl)-7-((2-furanyl(methoxyimino)acetyl)amino)-8-oxo-, (6R-(6alpha,7beta(Z)))-; C4417_SIGMA; BRD-K02733959-236-02-8; Anaptivan; Sharox; Ketocef; AC-4539; CID5479529; 56238-63-2; KEFUROX IN PLASTIC CONTAINER; Cefuroximo; Biociclin; Cephuroxime; 153012-39-6; AC-15028; Curoxime; Bioxima; C06894; 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-(((aminocarbonyl)oxy)methyl)-7-((2-furanyl(methyoxyimino)acetyl)amino)-8-oxo-, (6R-(6-alpha,7-beta(Z)))-; (6R,7R)-7-(2-(2-Furyl)glyoxylamido)-3-(hydroxymethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid 7(sup 2)-(Z)-(O-methyloxime) carbamate (ester); CID6523269; Zinacef (TN); Sodium (6R-(6alpha,7beta(Z)))-3-(((aminocarbonyl)oxy)methyl)-7-(2-furyl(methoxyimino)acetamido)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylate; Ultroxim; (6R,7R)-3-[(carbamoyloxy)methyl]-7-[(2Z)-2-(furan-2-yl)-2-(methoxyimino)acetamido]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-(((aminocarbonyl)oxy)methyl)-7-((2-furanyl(methoxyimino)acetyl)amino)-8-oxo-, monosodium salt (6R-(6alpha,7beta(Z)))-; Cefuroxim Genericsn; BPBio1_001033; Zinnat [inj.]; MolPort-005-938-003; Cefuroxim Fresenius; Cefuroximum [INN-Latin]; Colifossim; Curoxima	55268-75-2	5361202	182117	TTDS00210	Penicillin binding protein	N/A	N/A	N/A	N/A	binder
DAP001158	Cephaloglycin	D01949; Cefaloglicina [INN-Spanish]; C13440; CEG; (6R,7R)-3-(acetyloxymethyl)-7-[[(2R)-2-amino-2-phenylacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; CHEBI:34613; Cephaloglycin anhdyous; LS-149962; AC1L2DJO; 7-(2-D-alpha-Aminophenylacetamido)cephalosporanic acid; 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(2-amino-2-phenylacetamido)-3-(hydroxymethyl)-8-oxo-, acetate (ester), D-; C18H19N3O6S; Cephaloglycin (anhydrous); Cefaloglycine; 7-(D-2-Amino-2-phenylacetamido)-3-acetoxymethyl-delta(sup 3)-cephem-4-carboxylic acid; CHEMBL1200971; CEPHALOGLYCIN; Cefaloglycin; EINECS 222-696-7; Cefaloglycine [INN-French]; MolPort-004-964-699; Cefaloglycin (JAN); UNII-HD2D469W6U; Cefaloglicina; Lilly 39435; 3-((Acetyloxy)methyl)-7-((aminophenylacetyl)amino)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; 3577-01-3; Cephaoglycin acid; 3-acetoxymethyl-7beta-[(2R)-2-amino-2-phenylacetamido]-3,4-didehydrocepham-4-carboxylic acid; CID19150; DB00689; Cephaloglycin anhydrous; 7-(D-alpha-Aminophenyl-acetamido)cephalosporanic acid; 7-(2-Amino-2-phenylacetamido)-3-(hydroxymethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)octane-2-carboxylic acid, acetate inner salt; Cefaloglycinum [INN-Latin]; Kafocin; Cephaloglycine; HSDB 3214; 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-((acetyloxy)methyl)-7-((aminophenylacetyl)amino)-8-oxo-, (6R-(6alpha,7beta(R*)))-; 7-(D-2-Amino-2-phenylacetamido)-3-acetoxymethyl-delta(sup3)-cephem-4-carboxylic acid; Kefglycin; AC1Q6LOC; Cefaloglycinum; (6R,7R)-3-(acetoxymethyl)-7-{[(2R)-2-amino-2-phenylacetyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-[(acetyloxy)methyl]-7-{[(2R)-2-amino-2-phenylacetyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; D-Cephaloglycine; D-(-)-Cephaloglycin; 7-(2-Amino-2-phenylacetamido)-3-(hydroxymethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid acetate (ester)	3577-01-3	19150	586181	TTDS00210	Penicillin binding protein	N/A	N/A	N/A	N/A	binder
DAP000431	Ertapenem	Ertapenem [INN]; 1-Azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 3-((5-(((3-carboxyphenyl)amino)carbonyl)-3-pyrrolidinyl)thio)-6-(1-hydroxyethyl)-4-methyl-7-oxo-, (4R-(3(3S*,5S*),4alpha,5beta,6beta(R*)))-; CHEMBL1359; D07908; Ertapenem; LS-187017; (4R,5S,6S)-3-({(3S,5S)-5-[(3-carboxyphenyl)carbamoyl]pyrrolidin-3-yl}sulfanyl)-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; LS-187767; DB00303; 1-Azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 3-(((3S,5S)-5-(((3-carboxyphenyl)amino)carbonyl)-3-pyrrolidinyl)thio)-6-((1R)-1-hydroxyethyl-4-methyl-7-oxo-, (4R,5S,6S)-; AC-6814; Invanz (TN); (4R,5S,6S)-3-((3S,5S)-5-((3-carboxyphenyl)carbamoyl)pyrrolidin-3-ylthio)-6-((R)-1-hydroxyethyl)-4-methyl-7-oxo-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylic acid; UNII-G32F6EID2H; MolPort-005-935-353; (4R,5S,6S)-3-[(3S,5S)-5-[(3-carboxyphenyl)carbamoyl]pyrrolidin-3-yl]sulfanyl-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; 153832-46-3; CID150610; CHEBI:404903; AC1L44OL; (1R,5S,6S,8R,2'S,4'S)-2-(2-(3-carboxyphenylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylic acid; I06-0484; Ertapenem (INN)	153832-46-3	150610	728127	TTDS00210	Penicillin binding protein	N/A	N/A	N/A	N/A	binder
DAP000439	Cefixime	MLS002222332; FR-17027; (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(carboxymethyloxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; Denvar; Necopen; D00258; AB00513842; BSPBio_000564; CHEBI:472657; AC-4350; Cefixime (JP15/USP/INN); LS-187248; CID5362065; CEFIXIME; 7beta-{(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(carboxymethoxy)imino]acetamido}-3-ethenyl-3,4-didehydrocepham-4-carboxylic acid; (6r,7r)-7-[-2-(2-amino-thiazol-4-yl)-2-carboxymethoxyimino-acetylamino]-8-oxo-3-vinyl-5-thia-1-aza-b; C06881; BRD-K71059170-001-02-5; Prestwick3_000462; 79350-37-1; Cefixima; Tricef; CHEBI:530642; (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-{[(carboxymethyl)oxy]imino}acetyl]amino}-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; MolPort-003-845-687; BPBio1_000622; CL-284635; SMR001307271; CFIX; (6R,7R)-7-({(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(carboxymethoxy)imino]acetyl}amino)-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; FK-027; Cefiximum; AC1NSFNI; NCGC00179521-01; Suprax (TN); CHEMBL1541	79350-37-1	54362	9098	TTDS00210	Penicillin binding protein	N/A	N/A	N/A	N/A	binder
DAP000442	Cefaclor	5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((aminophenylacetyl)amino)-3-chloro-8-oxo-, monohydrate, (6R-(6-alpha,7-beta(R*)))-; Spectrum2_001189; 7-(2-Amino-2-phenyl-acetylamino)-3-chloro-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid; Panacef; UNII-69K7K19H4L; 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((aminophenylacetyl)amino)-3-chloro-8-oxo-, monohydrate, (6R-(6alpha,7beta(R*)))-; MolPort-003-845-678; BRD-K20338176-002-03-5; Ceclor (TN); C6895_SIGMA; Distaclor; HMS1569B11; KBio1_001987; (6R,7R)-7-((R)-2-Amino-2-phenylacetamido)-3-chloro-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid monohydrate; HMS2052C11; Ceclor; CHEMBL1201018; MolPort-003-666-328; Cefaclor anhydrous; NCGC00022612-07; SpecPlus_000947; CPD000058250; 53994-73-3; Cefaclor [USAN:INN:BAN:JAN]; 3-Chloro-7-D-(2-phenylglycinamido)-3-cephem-4-carboxylic acid monohydrate; S-6472; AC1L1ABM; (6R,7R)-7-[[(2R)-2-amino-2-phenylacetyl]amino]-3-chloro-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid hydrate; Cefaclor (USP); Cefaclorum; SMR000058250; C06877; Lilly 99638 hydrate; L-Kefral; cefaclor; Muco Panoral; SAM001246884; Cefaclor hydrate; D00256; Alenfral (TN); (6R,7R)-7-{[(2R)-2-amino-2-phenylacetyl]amino}-3-chloro-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[(2R)-2-amino-2-phenylacetyl]amino]-3-chloro-8-oxo-, (6R,7R)-; Kefolor Suspension; Prestwick2_000485; Cefaclor-1-wasser; 3-Chloro-7-D-(2-phenylglycinamido)-3-cephem-4-carboxylic acid; Spectrum5_001727; CHEBI:3478; Prestwick_783; Prestwick0_001102; BPBio1_001326; NCGC00022612-04; KBio2_006686; Alenfral; DivK1c_007043; (6R,7R)-7-[[(2R)-2-amino-2-phenylacetyl]amino]-3-chloro-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; Spectrum_001070; MLS000069617; MLS001424193; SPBio_001237; S1499_Selleck; Prestwick2_001102; KBioGR_000386; BPBio1_000385; Prestwick3_000485; NCGC00022612-05; HMS1921G22; AB00052174; Ceclor, Distaclor, Keflor, Raniclor,  Cefaclor; CID51039; 7beta-{[(2R)-2-amino-2-phenylacetyl]amino}-3-chloro-3,4-didehydrocepham-4-carboxylic acid; Cefaclor (JP15); Prestwick0_000485; ST057228; KBio3_002777; Spectrum3_001858; SPECTRUM1500771; Kefolor; CCL; SPBio_002270; Dystaclor MR; D02352; Prestwick1_001102; AC1Q6LO5; HMS1571M06; Alfacet; BSPBio_003276; KBio2_004118; CID51038; NCGC00022612-06; KBio2_001550; Spectrum4_000093; Cefaclor monohydrate; C15H14ClN3O4S; Prestwick3_001102; Alfatil Kapseln; Panoral; BSPBio_001204; AC1L1ABP; Prestwick1_000485; 70356-03-5; BSPBio_000349; LS-149967; SPBio_003082; KBioSS_001550; Compound 99638; Alfatil; HMS2092K08	53994-73-3	40958	181752	TTDS00210	Penicillin binding protein	N/A	N/A	N/A	N/A	binder
DAP000458	Ticarcillin	alpha-carboxy-3-thienylmethylpenicillin; D08593; Prestwick2_001067; Ticarcilline; AC1Q5QWE; Ticarcillin (INN); DB01607; Ticillin [veterinary]; (2S,5R,6R)-6-{[(2R)-2-carboxy-2-(3-thienyl)acetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; CHEMBL1449; TICARCILLIN; AC1L1WMX; (2S,5R,6R)-6-[[(2R)-3-hydroxy-3-oxo-2-thiophen-3-ylpropanoyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 17778_FLUKA; 34787-01-4; EINECS 252-213-5; Ticarcilline [INN-French]; Prestwick1_001067; LS-174491; (2S,5R,6R)-6-{[(2R)-2-carboxy-2-thiophen-3-ylacetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 6beta-{[(2R)-2-carboxy-2-thiophen-3-ylacetyl]amino}-2,2-dimethylpenam-3alpha-carboxylic acid; Ticarcillinum [INN-Latin]; 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-((carboxy-3-thienylacetyl)amino)-3,3-dimethyl-7-oxo-, (2S-(2alpha,5alpha,6beta(S*)))-; C07139; Prestwick0_001067; MolPort-003-927-225; Ticillin [veterinary] (TN); Ticarcilina; SPBio_002967; BRL-2288; C15H16N2O6S2; a-carboxy-3-thienylmethylpenicillin; CHEBI:9587; UNII-F93UJX4SWT; CID36921; Ticarcillin Supplement; TIPC; Ticarcillinum; Ticarcillin [INN:BAN]; Ticarcilina [INN-Spanish]	34787-01-4	36921	9348	TTDS00210	Penicillin binding protein	N/A	N/A	N/A	N/A	binder
DAP001166	Nafcillin	nafcillin; Nafcilline; C07250; (2-ethoxy-1-naphthalenyl)penicillin; Prestwick0_000843; CID8982; UNII-4CNZ27M7RV; Nafcillin [INN:BAN]; Unipen; HSDB 3133; Nafcilin-1; 6-[(2-Ethoxy-naphthalene-1-carbonyl)-amino]-3,3-dimethyl-7-oxo-4-thia-1-aza-bicyclo[3.2.0]heptane-2-carboxylic acid anion; 985-16-0; Naphcillin; 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[(2-ethoxy-1-naphthalenyl)carbonyl]amino]-3,3-dimethyl-7-oxo-, (2S,5R,6R)-; Nafcillin & VRC3375; Penicillin, (2-ethoxy-1-naphthalenyl)-; CHEMBL1443; Nafcilina [INN-Spanish]; (2-Ethoxy-1-naphthyl)penicillin; BRD-K18574842-323-03-3; BRN 0862393; SPBio_002746; 985-16-0 (mono-hydrochloride salt, anhydrous); Naphthamidopenicillin; Nafcilina; (2S,5R,6R)-6-{[(2-ethoxynaphthalen-1-yl)carbonyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; Nallpen; CHEBI:7447; Prestwick3_000843; Penicillin, (2-ethoxy-1-naphthyl)-; BPBio1_000909; DB00607; EINECS 205-690-9; Prestwick1_000843; Nafcillin, Monosodium Salt, Anhydrous; Nafcilline [INN-French]; Nafcillinum; C21H22N2O5S; BSPBio_000825; 147-52-4; (2S,5R,6R)-6-[(2-ethoxynaphthalene-1-carbonyl)amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 6-(2-ethoxy-1-naphthamido)penicillanic acid; LS-149872; D08242; Nafcillinum [INN-Latin]; NAFCILLIN SODIUM; 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-(((2-ethoxy-1-naphthalenyl)carbonyl)amino)-3,3-dimethyl-7-oxo-, (2S-(2alpha,5alpha,6beta))-; Nallpen In Plastic Container; 6beta-(2-ethoxynaphthalene-1-carboxamido)-2,2-dimethylpenam-3alpha-carboxylic acid; 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-(2-ethoxy-1-naphthamido)-3,3-dimethyl-7-oxo-; (2S,5R,6R)-6-({[2-(ethyloxy)naphthalen-1-yl]carbonyl}amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; Nafcillin (INN); Prestwick2_000843; Nafcillin sodium for injection; AC1L1S2D	985-16-0	8982	9459	TTDS00210	Penicillin binding protein	N/A	N/A	N/A	N/A	binder
DAP000452	Cefoxitin	C06887; Spectrum2_000676; Spectrum_001399; C08106; MLS002222151; CPD-9233; CHEBI:209807; Spectrum3_001491; Prestwick_12; NCGC00093351-03; MolPort-003-666-398; SPECTRUM1502031; CEFOXITIN SODIUM; (6R,7S)-3-(carbamoyloxymethyl)-7-methoxy-8-oxo-7-[(2-thiophen-2-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; DivK1c_000576; cefoxitin; MLS000028557; 35607-66-0; KBio2_004447; CHEMBL996; Prestwick3_000832; Spectrum 001399; CHEMBL1200530; CHEBI:53655; HMS1921F14; Spectrum5_001145; Prestwick1_000832; AC1L9SPP; BIDD:GT0505; SMR000058809; KBioGR_000626; SPBio_000771; NCGC00093351-02; KBio2_001879; Cefoxitin sodium (JAN/USP); Cefoxitin (USAN/INN); DB01331; IDI1_000576; D02345; Spectrum4_000153; (6R,7S)-3-[(carbamoyloxy)methyl]-7-methoxy-8-oxo-7-[(2-thienylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; 3-[(carbamoyloxy)methyl]-7alpha-methoxy-7beta-[(thiophen-2-yl)acetamido]-3,4-didehydrocepham-4-carboxylic acid; Cefoxitin sodium salt; CID441392; BPBio1_000863; CID441199; Mefoxin; Prestwick0_000832; AC-1303; AC1L9AQF; 3-[(carbamoyloxy)methyl]-7alpha-methoxy-7beta-[(2-thienylacetyl)amino]-3,4-didehydrocepham-4-carboxylate; (6R,7S)-3-(carbamoyloxymethyl)-7-methoxy-8-oxo-7-[(2-thiophen-2-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; D00913; BSPBio_003101; KBio3_002601; Mefoxitin; 33564-30-6; MLS001076334; SPBio_002704; KBio1_000576; NINDS_000576; HMS2092P11; SAM002564251; (6R,7S)-3-{[(aminocarbonyl)oxy]methyl}-7-(methyloxy)-8-oxo-7-[(2-thienylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; HMS1570H05; AB00513931; ZINC03830449; KBioSS_001879; Prestwick2_000832; Mefoxin (TN); CPD000058809; HMS501M18; BSPBio_000783; KBio2_007015	35607-66-0	441199	10298759	TTDS00210	Penicillin binding protein	N/A	N/A	N/A	N/A	binder
DAP000440	Oxacillin	Oxacilina; MPi-PC; Oxacillin [INN:BAN]; DB00713; (2S,5R,6R)-3,3-dimethyl-6-[(5-methyl-3-phenyl-1,2-oxazole-4-carbonyl)amino]-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 7240-38-2 (monosodium salt, monohydrate); 5-Methyl-3-phenyl-4-isoxazolyl-penicillin; Oxacillinum [INN-Latin]; 66-79-5; (5-methyl-3-phenyl-4-isoxazolyl)penicillin; 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-6-(((5-methyl-3-phenyl-4-isoxazolyl)carbonyl)amino)-7-oxo-, (2S-(2.alpha.,5.alpha.,6.beta.))-; 2,2-dimethyl-6beta-(5-methyl-3-phenyl-1,2-oxazole-4-carboxamido)penam-3alpha-carboxylic acid; Prostaphlin; Oxacillin, Monosodium Salt, Anhydrous; LS-149809; Prostaphlyn; (2S,5R,6R)-3,3-dimethyl-6-{[(5-methyl-3-phenylisoxazol-4-yl)carbonyl]amino}-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; OXACILLIN SODIUM; Ossacillina; Penicillin, (5-methyl-3-phenyl-4-isoxazolyl)-; 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-6-[[(5-methyl-3-phenyl-4-isoxazolyl)carbonyl]amino]-7-oxo-, (2S,5R,6R)-; D08307; 1173-88-2; C07334; UNII-UH95VD7V76; 1173-88-2 (anhydrous monosodium salt); CID6196; Penicillin, Methylphenylisoxazolyl; Oxacillinum; Bactocill; CHEBI:7809; EINECS 200-635-5; C19H19N3O5S; Oxazocilline; Oxacillin (INN); oxacillin; Oxacilline; Oxacilina [INN-Spanish]; Oxazocillin; 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 3,3-dimethyl-6-(((5-methyl-3-phenyl-4-isoxazolyl)carbonyl)amino)-7-oxo-, (2S-(2alpha,5alpha,6beta))-; 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 3,3-dimethyl-6-(5-methyl-3-phenyl-4-isoxazolecarboxamide)-7-oxo-; 6beta-(5-methyl-3-phenylisoxazol-4-yl)penicillanic acid; Ossacillina [DCIT]; MPI-penicillin; AC1L1M00; Oxacilina (TN); Oxacilline [INN-French]; CHEMBL819; Sodium oxacillin	66-79-5	6196	9541	TTDS00210	Penicillin binding protein	N/A	N/A	N/A	N/A	binder
DAP000447	Cefprozil	Brisoral; LS-149959; CID5281006; D07651; Cefzil (TN); CHEBI:3506; Cefzil; Cefprozilo [INN-Spanish]; 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((amino(4-hydroxyphenyl)acetyl)amino)-8-oxo-3-(1-propenyl)-, (6R-(6alpha,7beta(R*)))-; Cefprozil (TN); NCGC00159513-02; cefprozil; Cefprozilum [INN-Latin]; MolPort-002-885-813; Cefprozilum; BMY 28100; Cefprozilo; AC1NQXVS; Cefprozil (INN); 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2R)-amino(4-hydroxyphenyl)acetyl)amino)-8-oxo-3-(1-propenyl)-, (6R,7R)-; Cefprozil anhydrous; Serozil; C06888; CHEMBL276568; 92665-29-7; (6R,7R)-7-{[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino}-8-oxo-3-(prop-1-en-1-yl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; UNII-1M698F4H4E; DB01150; I06-1766; Arzimol; (6R,7R)-7-[[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-8-oxo-3-[(E)-prop-1-enyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; Cronocef; BIDD:GT0833; Procef	92665-29-7	5281006	205164	TTDS00210	Penicillin binding protein	N/A	N/A	N/A	N/A	binder
DAP000441	Meropenem	(6S)-2-{[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]sulfanyl}-6-[(1R)-1-hydroxyethyl]-1beta-methyl-2,3-didehydro-1-carbapenam-3-carboxylic acid; BPBio1_001334; AB1004614; MERONEM; AB00514051; 96036-03-2; SM-7338; Prestwick3_001106; (1R,5S,6S)-2-[(3S,5S)-5-(dimethylaminocarbonyl)pyrrolidin-3-ylthio]-6-[(R)-1-hydroxyethyl]-1-methylcarbapen-2-em-3-carboxylic acid trihydrate; Meronem (TN); Prestwick2_001106; (2S,3R,4R)-2-[(1S,2R)-1-carboxy-2-hydroxypropyl]-4-{[(3S,5R)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]sulfanyl}-3-methyl-3,4-dihydro-2H-pyrrole-5-carboxylic acid; (4R,5S,6S)-3-[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]sulfanyl-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; SPBio_003086; Merrem I.V. (TN); Meronem;Meropen;Meropenem;Merrem; MLS001401437; MEPM; Prestwick0_001106; ICI-194660; CPD000469184; CID441130; (4R,5S,6S)-3-{[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]thio}-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; HMS1571M14; meropenem; SMR000469184; HMS2051G08; D08185; Meropenem anhydrous; Merrem; AC1L9ALL; Ambap119478-56-7; Prestwick1_001106; NCGC00179259-01; CHEMBL127; (5S,6S)-3-((3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-ylthio)-6-((S)-1-hydroxyethyl)-4-methyl-7-oxo-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylic acid; CHEBI:43968; MolPort-006-709-417; BIDD:GT0851; Meropen; HMS2090C05; BSPBio_001212; Meropenem (INN); SAM001246650	119478-56-7	64778	206724	TTDS00210	Penicillin binding protein	N/A	N/A	N/A	N/A	binder
DAP001163	Flucloxacillin	4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[3-(2-chloro-6-fluorophenyl)-5-methyl-4-isoxazolyl]carbonyl]amino]-3,3-dimethyl-7-oxo-, (2S,6R)-; NCI60_002254; AC1Q5QXQ; LS-175377; Flucloxacillinum; flucloxacillin sodium; InChI=1/C19H17ClFN3O5S/c1-7-10(12(23-29-7)11-8(20)5-4-6-9(11)21)15(25)22-13-16(26)24-14(18(27)28)19(2,3)30-17(13)24/h4-6,13-14,17H,1-3H3,(H,22,25)(H,27,28)/t13-,14+,17?/m1/s; MFIPC; AC1L2I2K; C11748; D04196; 3-(2-Chloro-6-fluorophenyl)-5-methyl-4-isoxazolylpenicillin; 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-(((3-(2-chloro-6-fluorophenyl)-5-methyl-4-isoxazolyl)carbonyl)amino)-3,3-dimethyl-7-oxo-, (2S(2alpha,5alpha,6beta)); (2S,5R,6R)-6-[[3-(2-chloro-6-fluorophenyl)-5-methyl-1,2-oxazole-4-carbonyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; CHEBI:5098; EINECS 226-051-0; rel-(2R,6S)-6-({[3-(2-chloro-6-fluorophenyl)-5-methylisoxazol-4-yl]carbonyl}amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylato; Flucloxacillin-Sodium; CHEMBL222645; D005436; C19H17ClFN3O5S; Flucloxacillinum [INN-Latin]; (2S,5R,6R)-6-({[3-(2-chloro-6-fluorophenyl)-5-methylisoxazol-4-yl]carbonyl}amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; Fluclox; 5250-39-5; Floxacillin (USAN); Flucloxacillin (INN); Floxacillin [USAN]; FLOXACILLIN; CID21319; 6beta-[3-(2-chloro-6-fluorophenyl)-5-methyl-1,2-oxazole-4-carboxamido]-2,2-dimethylpenam-3alpha-carboxylic acid; Flucloxacilline; Flucloxacilline [INN-French]; BRL 2039; (2S,5R,6R)-6-({[3-(2-chloro-6-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]carbonyl}amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; UNII-43B2M34G2V; Fluorochloroxacillin; flucloxacilina; Flucloxacillin; Floxapen; 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-(((3-(2-chloro-6-fluorophenyl)-5-methyl-4-isoxazolyl)carbonyl)amino)-3,3-dimethyl-7-oxo-, (2S-(2alpha,5alpha,6beta))-; DB00301; Floxapen (TN); Flucloxacilina [INN-Spanish]	5250-39-5	21319	13913	TTDS00210	Penicillin binding protein	N/A	N/A	N/A	N/A	binder
DAP000433	Ceftazidime	Ceftazidime (INN); CEFTAZIDIME (ARGININE FORMULATION); ceftazidime; UNII-9M416Z9QNR; I06-1102; Ceptaz (TN); (6R,7R)-7-[[(2E)-2-(2-amino-1,3-thiazol-4-yl)-2-(1-hydroxy-2-methyl-1-oxopropan-2-yl)oxyiminoacetyl]amino]-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; Ceftazidime pentahydrate; CHEMBL201; DB00438; Ceftazidime anhydrous; ceftazidimum; Ceftazidimum [INN-Latin]; (6R,7R)-7-[[2-(2-amino-1,3-thiazol-4-yl)-2-(1-hydroxy-2-methyl-1-oxopropan-2-yl)oxyiminoacetyl]amino]-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(1-hydroxy-2-methyl-1-oxopropan-2-yl)oxyiminoacetyl]amino]-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; SN 401; AB00513848; C2225; AC1L1E5K; 7-[[2-(2-amino-1,3-thiazol-4-yl)-2-(1-hydroxy-2-methyl-1-oxopropan-2-yl)oxyiminoacetyl]amino]-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; Pyridinium, 1-((7-(((2-amino-4-thiazolyl)((1-carboxy-1-methylethoxy)imino)acetyl)amino)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-, hydroxide, inner salt,(6R-(6-alpha,7-beta-(Z)))-; AC1NUK7U; 72558-82-8; BRN 4344904; Pyridinium, 1-((7-(((2-amino-4-thiazolyl)((1-carboxy-1-methylethoxy)imino)acetyl)amino)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-, hydroxide, inner salt, (6R-(6-alpha,7-beta-(Z)))-; C06889; (6R,7R)-7-({(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(1-carboxy-1-methylethoxy)imino]acetyl}amino)-8-oxo-3-(pyridinium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; AC1L3MNA; ceftazidima; Fortaz (TN); Fortaz; Ceftazidima [INN-Spanish]; CID5484131; CID2650; Ceptaz; CHEBI:3508; D07654; LS-132194; AC1NUN9Q; Ceftazidime (TN); (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-{[(2-carboxypropan-2-yl)oxy]imino}acetyl]amino}-8-oxo-3-(pyridinium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; Ceftazidime Sodium In Plastic Container; Fortaz In Plastic Container; 7beta-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-{[(2-carboxypropan-2-yl)oxy]imino}acetyl]amino}-3-(pyridinium-1-ylmethyl)-3,4-didehydrocepham-4-carboxylate; CID5481173; HMS2090M13; EINECS 276-715-9; C22H22N6O7S2; BIDD:GT0734	78439-06-2	5481173	9106	TTDS00210	Penicillin binding protein	N/A	N/A	N/A	N/A	binder
DAP000454	Cefradine	Cephradin; SKF D 39304; 58456-86-3 (dihydrate); Sefril; C06897; Cefradine; Cefradina; AC1Q6LOA; Cephradine (USP); DB01333; D00264; 7-(D-2-Amino-2-(1,4-cyclohexadienyl)acetamide)desacetoxycephalosporanicacid; DivK1c_000739; CHEBI:3547; LS-149955; Cephradine (anhydrous); VELOSEF '500'; Velosef; AC-1409; SK-D-39304; 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((amino-1,4-cyclohexadien-1-ylacetyl)amino)-3-methyl-8-oxo-, (6R-(6alpha,7beta(R*)))-; Cefradine (JAN/INN); 7beta-[(2R)-2-(cyclohexa-1,4-dienyl)-2-phenylacetamido]-3-methyl-3,4-didehydrocepham-4-carboxylic acid; SK&F D-39304; cephradine; C8395_SIGMA; BRN 6075388; SQ 11436; 38821-53-3; HSDB 3216; (6R,7R)-7-((R)-2-Amino-2-(1,4-cyclohexadien-1-yl)acetamido)-3-methyl-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; SQ-11436; Anspor; SQ-22022; KBio1_000739; Cefradinum; 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((amino-1,4-cyclohexadien-1-ylacetyl)amino)-3-methyl-8-oxo-, (6R-(6-alpha,7-beta(R*)))-; CHEMBL1604; EINECS 254-137-8; Eskacef; AC1L1Z38; HMS502E21; Velosef (TN); UNII-9YA6SX5S4D; 7-(D-2-Amino-2-(1,4-cyclohexadien-1-yl)acetamido)-3-methyl-8-oxo-5-thia-1-azabicyclo(4.2.0)-oct-2-ene-2-caboxylic acid; (6R,7R)-7-{[(2R)-2-amino-2-cyclohexa-1,4-dien-1-ylacetyl]amino}-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(2R)-2-amino-2-cyclohexa-1,4-dien-1-ylacetyl]amino]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; CPD0-2068; CID38103; VELOSEF '250'; NINDS_000739; Cefradin; Cefradinum [INN-Latin]; VELOSEF '125'; MolPort-003-940-846; IDI1_000739; Cefradina [INN-Spanish]; Cephradine [USAN:BAN]; CEPHRADINE SODIUM; Anspor (TN)	38821-53-3	38103	11335914	TTDS00210	Penicillin binding protein	N/A	N/A	N/A	N/A	binder
DAP001169	Azlocillin	3,3-dimethyl-7-oxo-6-{[{[(2-oxoimidazolidin-1-yl)carbonyl]amino}(phenyl)acetyl]amino}-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; Azlocilline; (2S,5R,6R)-3,3-dimethyl-7-oxo-6-[[2-[(2-oxoimidazolidine-1-carbonyl)amino]-2-phenylacetyl]amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; Spectrum5_001251; ST070946; 3,3-dimethyl-7-oxo-6-[[2-[(2-oxoimidazolidine-1-carbonyl)amino]-2-phenylacetyl]amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; Spectrum_001382; (2S,5R,6R)-3,3-dimethyl-7-oxo-6-[[(2R)-2-[(2-oxoimidazolidine-1-carbonyl)amino]-2-phenylacetyl]amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; CHEMBL417013; Bayer Brand of Azlocillin; (2S,5R,6R)-3,3-dimethyl-7-oxo-6-{[(2R)-2-{[(2-oxoimidazolidin-1-yl)carbonyl]amino}-2-phenylacetyl]amino}-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; Spectrum3_000983; SPBio_002662; Securopen; (5R,6R)-3,3-dimethyl-7-oxo-6-[[(2R)-2-[(2-oxoimidazolidine-1-carbonyl)amino]-2-phenylacetyl]amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2R,5R,6S)-3,3-dimethyl-7-oxo-6-[[(2R)-2-[(2-oxoimidazolidine-1-carbonyl)amino]-2-phenylacetyl]amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2r,5s,6s)-3,3-dimethyl-7-oxo-6-{[(2r)-2-{[(2-oxoimidazolidin-1-yl)carbonyl]amino}-2-phenylacetyl]amino}-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; CID5284519; Azlocillinum; Azlocillin [USAN:BAN:INN]; Azlocillin Sodium (Sterile); AC1L1DB3; C20H23N5O6S; 6-((R)-2-(2-Oxoimidazolidin-1-carboxamido)-2-phenylacetamido)penicillansaeure; BSPBio_000741; SPBio_001304; I06-1570; CHEMBL1537; STOCK1N-31653; CID657279; AKOS000715136; AC1L1Y3Z; BPBio1_000817; azlocillin; AC1NR4M1; BAS 00444356; D02339; CID6398677; (2S,5R,6R)-3,3-Dimethyl-7-oxo-6-((R)-2-(2-oxo-1-imidazolidinecarboxamido)-2-phenylacetamido)-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid; AC1O6OS2; NINDS_000016; KBioGR_001558; (2S,5S,6R)-3,3-dimethyl-7-oxo-6-[[(2R)-2-[(2-oxoimidazolidine-1-carbonyl)amino]-2-phenylacetyl]amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; AC1L1Y3W; CID1548938; Prestwick1_000821; EINECS 253-348-2; Azlocillinum [INN-Latin]; Prestwick0_000821; C06839; KBio2_004430; LS-149817; 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-6-(((((2-oxo-1-imidazolidinyl)carbonyl)amino)phenylacetyl)amino)-, (2S-(2alpha,5alpha,6beta(S*)))-; KBio1_000016; (2R,5S,6S)-3,3-dimethyl-7-oxo-6-[[(2R)-2-[(2-oxoimidazolidine-1-carbonyl)amino]-2-phenylacetyl]amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-6-[[[[((R)-2-oxo-1-imidazolidinyl)carbonyl]amino]phenylacetyl]amino]-, (2S,5R,6R)-; Bay-e 6905; CID6560164; 2,2-dimethyl-6beta-[(2R)-2-{[(2-oxoimidazolidin-1-yl)carbonyl]amino}-2-phenylacetamido]penam-3alpha-carboxylic acid; Azlocilline [INN-French]; Prestwick2_000821; Azlocilina [INN-Spanish]; AC1LU7JT; KBio3_001865; BRD-K60663764-236-02-1; 37091-66-0; MolPort-002-515-775; AC1Q5R6T; CID6479523; Prestwick3_000821; (2S,5R,6R)-3,3-dimethyl-7-oxo-6-{[(2S)-2-{[(2-oxoimidazolidin-1-yl)carbonyl]amino}-2-phenylacetyl]amino}-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; AC1LCWAC; UNII-HUM6H389W0; MLS001163992; BSPBio_002645; (6R)-3,3-dimethyl-7-oxo-6-[[2-[(2-oxoimidazolidine-1-carbonyl)amino]-2-phenylacetyl]amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; CID37624; KBio2_006998; Azlocillin (USAN/INN); DivK1c_000016; AC1O4QNM; IDI1_000016; CID37625; MolPort-001-933-252; Spectrum4_001109; CHEBI:2956; SMR000539430; STK177243; Azlocilina; (2S,5R,6R)-3,3-dimethyl-7-oxo-6-[[(2S)-2-[(2-oxoimidazolidine-1-carbonyl)amino]-2-phenylacetyl]amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; DB01061; KBio2_001862; Spectrum2_001522; CID2271; KBioSS_001862; AC1O580A	37091-66-0	37625	9057	TTDS00210	Penicillin binding protein	N/A	N/A	N/A	N/A	binder
DAP000450	Cefoperazone	I06-1099; C25H27N9O8S2; CHEMBL507674; SPBio_002254; BSPBio_000333; Cefoperazono; D07645; 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((((4-ethyl-2,3-dioxo-1-piperazinyl)carbonyl)amino)(4-hydroxyphenyl)acetyl)amino)-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-, (6R-(6-alpha,7-beta(R*)))-; (6R,7S)-7-[[(2S)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-(4-hydroxyphenyl)acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; KBioSS_001919; BRN 0603333; (6R,7R)-7-[[2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-(4-hydroxyphenyl)acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; CID44187; LS-187731; Cefoperazon; CP 52640; (6S,7R)-7-[[(2S)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-(4-hydroxyphenyl)acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 72448-63-6; Cefoperazonum [INN-Latin]; BPBio1_000367; UNII-7U75I1278D; AC1L2BAX; Cefoperazonum; AC1OFCHJ; AC1L2BAU; IDI1_000128; EINECS 263-749-4; AC1OFCHP; CID6604594; HMS2090M09; Cefoperazone [INN:BAN]; Prestwick3_000327; NCGC00179599-01; AC-12103; Spectrum2_001764; KBio2_007055; AC1L1E3W; Spectrum4_000322; AC1O7GNF; CID44185; KBio3_001552; DB01329; 7beta-{[{[(4-ethyl-2,3-dioxopiperazin-1-yl)carbonyl]amino}(4-hydroxyphenyl)acetyl]amino}-3-[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl-3,4-didehydrocepham-4-carboxylic acid; KBio1_000128; Spectrum_001439; Cefoperazone sodium salt; Prestwick0_000327; 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((((4-ethyl-2,3-dioxo-1-piperazinyl)carbonyl)amino)(4-hydroxyphenyl)acetyl)amino)-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-, (6R-(6alpha,7beta(R*)))-; BSPBio_002332; CID7048628; DivK1c_000128; 62893-19-0; Peracef [veterinary]; CID2630; Cefoperazone (INN); BRD-K02292852-335-03-1; (6R,7R)-7-((R)-2-(4-Ethyl-2,3-dioxo-1-piperazinylcarboxamido)-2-(4-hydroxyphenyl)acetamido)-3-((1-methyl-1H-tetrazol-5-yl)thiomethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-2-carbonsaeure; (6R,7R)-7-[[(2S)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-(4-hydroxyphenyl)acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; CHEBI:3493; Cefobid; BIDD:GT0677; ChemDiv1_024737; Spectrum5_001140; KBio2_001919; Prestwick1_000327; (6R,7R)-7-{[(2R)-2-{[(4-ethyl-2,3-dioxopiperazin-1-yl)carbonyl]amino}-2-(4-hydroxyphenyl)acetyl]amino}-3-{[(1-methyl-1H-tetrazol-5-yl)thio]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; cefoperazone; SPBio_001627; (6R,7S)-7-[[(2R)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-(4-hydroxyphenyl)acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(2R)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-(4-hydroxyphenyl)acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; KBio2_004487; [6R-[6.alpha.,7.beta.(R*)]]-7-[[[[(4-Ethyl-2,3-dioxo-1-piperazinyl)carbonyl]amino](4-hydroxyphenyl)acetyl]amino]-3-[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-8-oxo-5-thia-1-azabicyclo[4. 2.0]oct-2-; C06883; CID7048630; CID7048632; LS-150056; 62893-20-3 (hydrochloride salt); (6R,7R)-7-{[{[(4-ethyl-2,3-dioxopiperazin-1-yl)carbonyl]amino}(4-hydroxyphenyl)acetyl]amino}-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; Spectrum3_000746; KBioGR_000663; 7-[[2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-(4-hydroxyphenyl)acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; Cefoperazono [INN-Spanish]; Prestwick2_000327; NINDS_000128; Peracef [veterinary] (TN); Cefobid (TN); MolPort-005-933-617; AC1OFCHV	62893-19-0	44185	184435	TTDS00210	Penicillin binding protein	N/A	N/A	N/A	N/A	binder
DAP001160	Cephapirin	Prestwick1_000851; Cefapirinum [INN-Latin]; Spectrum2_000103; BSPBio_001965; 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 3-[(acetyloxy)methyl]-8-oxo-7-[[(4-pyridinylthio)acetyl]amino]-, (6R,7R)-; CHEBI:554446; 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-((acetyloxy)methyl)-8-oxo-7-(((4-pyridinylthio)acetyl)amino)-, (6R-trans)-; Cefa -ak; Cefapirine [INN-French]; C06896; D07636; Cephapirine; Spectrum4_000270; Cephalosporanic acid, 7-(2-(4-pyridylthio)acetamido)-; CEPHAPIRIN SODIUM; Cefapirin [INN:BAN]; AC1Q6LOX; KBioSS_000552; Cefa; 3-(Hydroxymethyl)-8-oxo-7-(2-(4-pyridylthio)acetamidol-5-thia-1-azabicyclo(4.2.0)oct-2-en-2carbonsaeure acetat; CEPR; KBio2_005688; SPBio_000086; KBio1_000042; (6R,7R)-3-[(acetyloxy)methyl]-8-oxo-7-{[(pyridin-4-ylthio)acetyl]amino}-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; EINECS 244-466-5; Spectrum_000112; KBioGR_000740; 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-(hydroxymethyl)-8-oxo-7-(2-(4-pyridylthio)acetamido)-, acetate (ester); (6R,7R)-3-(acetyloxymethyl)-8-oxo-7-[(2-pyridin-4-ylsulfanylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; AC1L1K3J; Cefapirina [INN-Spanish]; Cefapirine; IDI1_000042; Spectrum3_000333; Spectrum5_000671; 24356-60-3 (mono-hydrochloride salt); BRN 1095157; Prestwick2_000851; DivK1c_000042; 21593-23-7; LS-150067; NSC179171; Cefadyl; Metricure (TN); C17H17N3O6S2; DB01139; Cefapirin; ANTIBIOTIC BL-P1322; HSDB 3215; KBio2_003120; Cefaprin; 7-(2-(4-Pyridylthio)acetamido)cephalosporanic acid; Cephapirin Monosodium Salt; Metricure; SPBio_002782; Cefapirina; Prestwick0_000851; NINDS_000042; KBio3_001185; BL-P 1322; UNII-89B59H32VN; cephapirin; (6R,7R)-3-(Acetoxymethyl)-8-oxo-7-(2-(4-pyridylthio)acetamido)-5-thia-1-azabicyclo(4.2.0)oct-2-en-2-carbonsaeure; Lopac0_000279; Cefapirinum; KBio2_000552; CHEMBL1599; (6R,7R)-3-acetoxymethyl-7-[(pyridin-4-ylsulfanyl)acetamido]-3,4-didehydrocepham-4-carboxylic acid; Cefaprin sodium; Cefapirin (BAN); CID30699	21593-23-7	30699	9113	TTDS00210	Penicillin binding protein	N/A	N/A	N/A	N/A	binder
DAP000456	Ceftibuten	KBioGR_001649; CHEBI:3510; CID6375005; HMS2093K18; Ceftibuteno [INN-Spanish]; HMS1922L17; SPECTRUM1505207; 7beta-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-4-carboxybut-2-enoyl]amino}-3,4-didehydrocepham-4-carboxylic acid; Spectrum2_001684; AC1L44AE; 97519-40-9; 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((2-(2-amino-4-thiazolyl)-4-carboxy-1-oxo-2-butenyl)amino)-8-oxo-, (6R-(6alpha,7beta(Z)))-; 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((2-(2-amino-4-thiazolyl)-4-carboxy-1-oxo-2-butenyl)amino)-8-oxo-, (6R-(6-alpha,7-beta(Z)))-; D00922; (+)-(6R,7R)-7-((Z)-2-(2-Amino-4-thiazolyl)-4-carboxycrotonamido)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; CID5282242; DB01415; Ceftibutenum; AC1L1E5W; LS-187379; AKOS005146205; Spectrum5_001558; cis-ceftibuten; Cephalosporin 7432-S; C15H14N4O6S2; KBioSS_002287; (6R,7R)-7-[[2-(2-amino-1,3-thiazol-4-yl)-5-hydroxy-5-oxopent-2-enoyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; SPBio_001608; UNII-IW71N46B4Y; 7-[[2-(2-amino-1,3-thiazol-4-yl)-5-hydroxy-5-oxopent-2-enoyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; C08117; AC1NQY0W; cis-Ceftibutin; ceftibuten; BSPBio_002733; Ceftibuten [USAN:INN:BAN]; BIDD:GT0855; S 7432; NCGC00095137-01; Spectrum_001794; AC1NQZPP; KBio2_002285; Ceftem; Sch-39720; Sch 39720; AC1O4QO4; CID178967; AC1O44MA; KBio2_004853; NCGC00178501-01; CID2654; 7-[[(Z)-2-(2-amino-1,3-thiazol-4-yl)-5-hydroxy-5-oxopent-2-enoyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7432-S; Spectrum3_001007; KBio2_007421; MolPort-003-666-607; Ceftibuten (USAN/INN); (6R,7R)-7-[[(E)-2-(2-amino-1,3-thiazol-4-yl)-5-hydroxy-5-oxopent-2-enoyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; Keimax; Antibiotic 7432S; 7-[[(E)-2-(2-amino-1,3-thiazol-4-yl)-5-hydroxy-5-oxopent-2-enoyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; Ceftibuteno; Ceprifran; NCGC00095137-02; CID6398762; Ceftibutenum [INN-Latin]; Ceftibutene; 97519-39-6; Cephem; KBio3_001953; Spectrum4_001135; Cedax; Isocef; CHEMBL1605; (6R,7R)-7-[[(Z)-2-(2-amino-1,3-thiazol-4-yl)-5-hydroxy-5-oxopent-2-enoyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-4-carboxybut-2-enoyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; Ceftibutene [INN-French]; trans-Ceftibuten; LS-149976; CID5281102; CETB	97519-39-6	5282241	10317	TTDS00210	Penicillin binding protein	N/A	N/A	N/A	N/A	binder
DAP000446	Cefadroxil	HMS1569G10; Cefadroxil anhydrous; Cefadroxilo [INN-Spanish]; DivK1c_000409; CHEBI:3479; 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2R)-amino(4-hydroxyphenyl)acetyl)amino)-3-methyl-8-oxo-, (6R,7R)-; KBio2_000544; AB00513838; Prestwick3_000434; 50370-12-2; KBio2_003112; C06878; (6R,7R)-7-{[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino}-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; Prestwick0_000434; Prestwick2_000434; HMS501E11; KBio1_000409; CDX; SMR001306770; Sumacef; SPBio_002387; BPBio1_000494; KBio2_005680; EINECS 256-555-6; Sumacef (TN); BL-S 578; UNII-Q525PA8JJB; (6R,7R)-7-[[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7beta-{[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino}-3,4-didehydrocepham-4-carboxylic acid; CPD0-2070; Cefadroxilum [INN-Latin]; S-578; cefadroxil; Spectrum5_000663; NCGC00179556-01; AC1L2J3O; KBioGR_000732; BB_NC-1256; MJF-11567-3; C7020_FLUKA; Spectrum_000104; CHEMBL1644; 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((amino(4-hydroxyphenyl)acetyl)amino)-3-methyl-8-oxo-, (6R-(6-alpha,7-beta(R*)))-; D-Cefadroxil; SPBio_000014; Cefadroxilo; D00257; S 578; BSPBio_000448; KBioSS_000544; IDI1_000409; Prestwick1_000434; Cefadroxilum; (6R,7R)-7-((R)-2-Amino-2-(p-hydroxyphenyl)acetamido)-3-methyl-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; BL-S578; CID47965; Spectrum2_000087; Cephadroxil; NINDS_000409; MLS002207219; Cefadroxil (JP15); STK801939; C7020_SIGMA; Spectrum4_000266; MolPort-002-507-346	66592-87-8	2610	180636	TTDS00210	Penicillin binding protein	N/A	N/A	N/A	N/A	binder
DCL001234	S-297995	N/A	N/A	N/A	N/A	TTDS00125	Opioid receptor	N/A	N/A	N/A	N/A	antagonist
DAP000017	Dextropropoxyphene	Dextropropoxifeno; (D)-PROPOXYPHENE; 469-62-5; SK 65; HSDB 3175; [(2S,3R)-4-(dimethylamino)-3-methyl-1,2-diphenylbutan-2-yl] propanoate; alpha-D-4-Dimethylamino-3-methyl-1,2-diphenyl-2-butanol-propionat; AC1L1UHN; UNII-S2F83W92TK; EINECS 207-420-5; (S)-alpha-(2-(Dimethylamino)-1-methylethyl)-alpha-phenylbenzeneethanol propanoate; alpha-(+)-4-Dimethylamino-1,2-diphenyl-3-methyl-2-butanol propionate ester; CHEMBL1213351; Benzeneethanol, alpha-(2-(dimethylamino)-1-methylethyl)-alpha-phenyl-, propanoate (ester), (S-(R*,S*))-; DEA No. 9273; Dextropropoxyphene; Femadol; Dextropropoxyphenum [INN-Latin]; (+)-1,2-Diphenyl-2-propionoxy-3-methyl-4-dimethylaminobutane; Dextroproxifeno; (1S,2R)-1-benzyl-3-(dimethylamino)-2-methyl-1-phenylpropyl propanoate; Proxagesic; CID10100; Dextropropoxifeno [INN-Spanish]; 2-Butanol, 4-(dimethylamino)-3-methyl-1,2-diphenyl-, propionate (ester), (2S,3R)-; Antalvic; LS-46517; Benzeneethanol, alpha-((1R)-2-(dimethylamino)-1-methylethyl)-alpha-phenyl-, propanoate (ester), (alphaS)-; alpha-(+)-4-Dimethylamino-1,2-diphenyl-3-methyl-2-propionoxybutane; alpha-4-Dimethylamino-1,2-diphenyl-3-methyl-2-butanol propionate; 2-Butanol, 4-(dimethylamino)-3-methyl-1,2-diphenyl-, propionate, (+)-; 21086-94-2; CHEBI:51173; (+)-4-Dimethylamino-1,2-diphenyl-3-methyl-2-propionyloxybutane; Algafan; 3818-94-8; Destropropossifene; Propoxyphene, (+)-; C22H29NO2; alpha-D-4-Dimethylamino-3-methyl-1,2-diphenyl-2-butanol-propionat [German]; Dextropropoxyphenum; propoxyphene; Destropropossifene [DCIT]; Dextroproxifeno [Spanish]; 4-Dimethylamino-3-methyl-1,2-diphenyl-2-propoxybutane; Dextropropoxyphene [INN:BAN]; Dextropropoxyphen; d-Propoxyphene; Proxyphen; Levopropoxyphene; alpha-D-4-Dimethylamino-3-methyl-1,2-diphenyl-2-butanol propionate; Bulk dextropropoxyphene (non-dosage forms)	469-62-5	15330	9610	TTDS00125	Opioid receptor	N/A	N/A	N/A	N/A	agonist
DCL000733	Bupropion+naltrexone	N/A	31677-93-7	N/A	N/A	TTDS00125	Opioid receptor	N/A	N/A	N/A	N/A	antagonist
DCL000908	Oravescent fentanyl	N/A	990-73-8	5360545	49746451	TTDS00125	Opioid receptor	N/A	N/A	N/A	N/A	agonist
DAP000268	Levorphanol	1,3,4,9,10,10a-Hexahydro-11-methyl-2H-10,4a-iminoethanophenanthren-6-ol, l-; Dromoran; 17-Methylmorphinan-3-ol; Racemorphane; levorphanol; Racemic dromoran; Aromarone; Racemorphanum [INN-Latin]; 1,3,4,9,10,10a-Hexahydro-11-methyl-2H-10,4a-iminoethanophenanthren-6-ol, dl-mixture; LS-91821; N-Methyl-3-hydroxymorphinan; Levodroman; MolPort-001-783-640; ( -)-N-Methylmorphinan-3-ol; Levorfanolo [DCIT]; Levorfanol; Antalgin; Morphinan-3-ol, 17-methyl-; dl-3-Hydroxy-N-methylmorphinan; Morphinan-3-ol, 17-methyl-, (-)-; Methorfinan; 1,3,4,9,10,10a-Hexahydro-6-hydroxy-2H-10,4a-(iminoethano)-11-methylphenanthrene; (-)-3-Hydroxy-N-methylmorphinan; CHEBI:119572; Cetarin; DEA No. 9733; NU 2206; (+)-3-Hydroxy-17-methylmorphinan; D08123; Morphinan, 3-hydroxy-17-methyl-; Methorphinan; LS-92022; Racemorfano [INN-Spanish]; C17H23NO; Morphinan-3-ol, 17-methyl-, (+-)-; Orphan; DEXTRORPHAN; 2H-10, 4a-Iminoethanophenanthren-6-ol, 1,3,4,9,10,10a-hexahydro-11-methyl-, dl-; 297-90-5; 2H-10,4a-Iminoethanophenanthren-6-ol, 1,3,4,9,10,10a-hexahydro-11-methyl-; Levorphanolum [INN-Latin]; Levorfanol [INN-Spanish]; 3-Hydroxy-N-methylmorphinan; EINECS 206-048-0; (+-)-3-Hydroxy-N-methylmorphinan; Methorfinan [Czech]; Racemorphane [INN-French]; (-)-N-Methylmorphinan-3-ol; EINECS 201-002-6; Levorphan; UC205_SIGMA; Racemorphan; Morphinan, 3-hydroxy-N-methyl-, (+-)-; CID5359272; Racemorfano; UNII-27618J1N2X; Ro 1-5431; Racemorphanum; HSDB 3349; Racemethorphanum; Levorfanolo; Racemorphan [INN:BAN]; 2H-10,4a-Iminoethanophenanthren-6-ol, 1,3,4,9,10,10a-hexahydro-11-methyl-, l-; L-Dromoran; Levorphanol (INN); (+-)-17-Methylmorphinan-3-ol; C08014; 77-07-6; 125-74-6; DEA No. 9220; Levorphanolum	77-07-6	5359272	10214	TTDS00125	Opioid receptor	N/A	N/A	N/A	N/A	agonist
DAP000140	Tramadol	AKOS005066335; Tramadolum; C07153; STOCK4S-19075; Amanda; Tramadol [INN:BAN]; Tramadol; CHEMBL1066; (+)-trans-Tramadol free ba; NCGC00159343-02; (1R,2R)-2-Dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexanol; Ultram; MLS000333190; MolPort-002-507-778; BIDD:GT0075; Tramadol (INN); Amanda (TN); (1R,2R)-2-[(dimethylamino)methyl]-1-[3-(methyloxy)phenyl]cyclohexanol; Tradonal odis; (+)-(R,R)-trans-Tramadol; AC1Q59O2; LS-57116; HMS2090D10; (1R,2R)-2-(dimethylaminomethyl)-1-(3-methoxyphenyl)cyclohexan-1-ol; Cyclohexanol, 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)-, (1R,2R)-; EINECS 248-319-6; DB00193; Ralivia flashtab; LS-57115; Tramal; D08623; Ralivia ER; Cyclohexanol, 2-((dimethylamino)methyl)-1-(m-methoxyphenyl)-; Cyclohexanol, 2-((dimethylamino)-1-(3-methoxyphenyl)-, cis-(+-)-; Cyclohexanol, 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)-, (1R-cis)-; Cyclohexanol, 2-((dimethylamino)methyl)-1-(3-methoxyphenyl)-, cis-(+-)-; UNII-39J1LGJ30J; Tramadol HCl BP/EP; Tridural; CID33741; AC1L1Q6E; Tramadolum [INN-Latin]; Tramodol Hcl; Jsp005295; 27203-92-5; SMR000436547	27203-92-5	33741	175579	TTDS00125	Opioid receptor	N/A	N/A	N/A	N/A	agonist
DAP001407	Nalmefene	Nalmefeno; (5alpha)-17-(Cyclopropylmethyl)-4,5-epoxy-6-methylenemorphinan-3,14-diol; UNII-TOV02TDP9I; MLS000069366; nalmefene; NIH-10365; Cessal; D05111; Nalmetreno; Morphinan-3,14-diol, 17-(cyclopropylmethyl)-4,5-epoxy-6-methylene-, (5alpha)-; Nalmetreno [INN-Spanish]; Nalmefeno [INN-Spanish]; MolPort-003-959-014; Nalmetrenum [INN-Latin]; Alcofene; Nalmefene [USAN:BAN:INN]; NCGC00021666-03; ORF-11676; CID5284594; 58895-64-0 (hydrochloride); LS-91713; Soberal; C08027; Nalmefene (USAN/INN); Nalmefenum [INN-Latin]; ORF 11676; Arthene; Cervene; Revex; 6-Desoxy-6-methylenenaltrexone; (5alpha)-17-(Cyclopropylmethyl)-4,5-epoxy-6-methylenemorphinon-3,14-diol; 55096-26-9; SMR000058884; HSDB 6761; Incystene; JF 1; N5770_SIGMA; Nalmefenum; 9a-(Cyclopropylmethyl)-4,5alpha-epoxy-6-methylen-3,14-morphinandiol; CHEBI:200696; PDSP2_001543; Nalmetrene; CHEMBL982; 17-(Cyclopropylmethyl)-4,5alpha-epoxy-6-methylenemorphinan-3,14-diol; Nalmetrenum; (5alpha)-17-(cyclopropylmethyl)-6-methylidene-4,5-epoxymorphinan-3,14-diol; JF-1	55096-26-9	5284594	10227	TTDS00125	Opioid receptor	N/A	N/A	N/A	N/A	antagonist
DAP000071	Morphine	DB00295; 4,5alpha-Epoxy-17-methyl-7-morphinen-3,6alpha-diol; MSIR; SDZ202-250; 47106-99-0; Infumorph; nchembio.64-comp1; 57-27-2; MORPHINE, (5A,6A)-7,8-DIDEHYDRO-4,5-EPOXY-17-METHYLMORPHINIAN-3,6-DIOL, MORPHIUM, MORPHIA, DOLCONTIN, DUROMORPH, MORPHINA, NEPENTHE; EINECS 200-320-2; Morphinan-3,6-alpha-diol, 7,8-didehydro-4,5-alpha-epoxy-17-methyl-; Morphine Extra-Forte; Duromorph; Oramorph SR; MolPort-003-849-273; Ms Emma; morphine; CHEMBL70; M-Eslon; Duramorph PF; MS/L; Morphin [German]; Hard stuff; Roxanol 100; (5alpha,6alpha)-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol; Dulcontin; 64-31-3; Astramorph PF; Roxanol; Morphine H.P; Morphin; Morphine Forte; M.O.S; Morphitec; Morphina [Italian]; Dolcontin; 85201-37-2; CCRIS 5762; Avinza; RMS Uniserts; UNII-76I7G6D29C; Morphium; Morfina; Unkie; Hocus; Morfina [Italian]; l-Morphine; 64-31-3 (sulfate (2:1) (salt) anhydrous); Morphina; nchembio.317-comp1; MS/S; Meconium; 6211-15-0 (sulfate (2:1) (salt) pentahydrate); LS-91748; 9H-9,9c-Iminoethanophenanthro(4,5-bcd)furan-3,5-diol, 4alpha,5,7alpha,8-tetrahydro-12-methyl-; Moscontin; 7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol; RMS; (5alpha,6alpha)-17-methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol; (-)(5.alpha.,6.alpha.)-7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol; 8053-16-5; (-)-Morphine; Rescudose; OMS Concentrate; C01516; Statex SR; Cube juice; Roxanol UD; CID5288826; SDZ 202-250; Ospalivina; 9H-9,9c-Iminoethanophenanthro(4,5-bcd)furan-3,5-diol, 4a,5,7a,8-tetrahydro-12-methyl-; 7,8-Didehydro-4,5-epoxy-17-methyl-morphinan-3,6-diol; Morphinism; Kadian; (7R,7AS,12BS)-3-METHYL-2,3,4,4A,7,7A-HEXAHYDRO-1H-4,12-METHANO[1]BENZOFURO[3,2-E]ISOQUINOLINE-7,9-DIOL; Dreamer; MORPHINE SULFATE; DEA No. 9300; 4-methyl-(13R,14S)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol; Nepenthe; Morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl- (5alpha,6alpha)-; Epimorph; Morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl-, (5alpha,6alpha)-; Morphia; BIDD:GT0147; HSDB 2134; (5alpha,6alpha)-7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol; Morpho; 17-methyl-7,8-didehydro-4,5alpha-epoxymorphinan-3,6alpha-diol; Morphine [BAN]; MS Contin; CHEBI:17303; Statex Drops; (5R,6S,9R,13S,14R)-4,5-Epoxy-N-methyl-7-morphinen-3,6-diol; NSC11441; D-(-)-Morphine; Morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl- (5..alpha.,6.alpha.)-; MOI; DepoDur; Morphinum; (-)Morphine sulfate	57-27-2	5288826	148818	TTDS00125	Opioid receptor	N/A	N/A	N/A	N/A	agonist
DAP000267	Methadone	Amidon; Racemic methadone; CHEMBL651; Heptadone; 3-Hetpanone, 6-(dimethylamino)-4,4-diphenyl-, (R)- (9CI); d-6-(Dimethylamino)-4,4-diphenyl-3-heptanone; Levometadona; Hoechst 10820; LS-74486; 3-HEPTANONE, 6-(DIMETHYLAMINO)-4,4-DIPHENYL-, (+-)-; d-Methadone; AC1Q2RLW; (R)-6-(Dimethylamino)-4,4-diphenyl-3-heptanone; Methadone M; 6-Dimethylamino-4,4-diphenyl-3-heptanone; 6-dimethylamino-4,4-di(phenyl)heptan-3-one; Methadon; BRN 3213669; K 174; NINDS_000963; (+-)-Methadone; l-Methadone; Diaminon; Phenadone; Dolophine HCL; 3-Hetpanone, 6-(dimethylamino)-4,4-diphenyl-, (R)-; 6-(dimethylamino)-4,4-diphenylheptan-3-one; BRN 3213667; Dextromethadone; D08195; LS-74487; Dolophin; Heptanon; LS-74485; Methadonum; Heptadone (*Hydrochloride*); (6R)-Methadone; 297-88-1; Ketalgin; Methadone [INN:BAN]; AC1L1HEG; Dolophine (*Hydrochloride*); Adanon; AN 148; HSDB 3119; Tussol; Biscuits; S-(+)-Methadone; L-(+)-Methadone; IDI1_000963; (+/-)-Tussal; Sedo-Rapide; DEA No. 9250; (+/-)-Methadone; DB00333; Levometadona [INN-Spanish]; CHEBI:6807; 6-(Dimethylamino)-4,4-diphenyl-3-heptanone dl-mixture; UNII-UC6VBE7V1Z; Methadone HCL Intensol; KBio1_000963; dl-Methadone; Heptanon (pharmaceutical); Levomethadonum; L-Polamidon; (-)-Methadone; Dollies; l-Polamivet; (R)-6-(Dimethylamino)-4,4-diphenyl-3-hetpanone; MolPort-001-785-650; Polamivet; Metadona [Spanish]; Methadona [Spanish]; A 4624; 3-14-00-00278 (Beilstein Handbook Reference); 3-Heptanone, 6-(dimethylamino)-4,4-diphenyl-; Althose; Methaquaione; Hoescht 10820 (*Hydrochloride*); Levothyl; Amidone; Methadonum [INN-Latin]; 1095-90-5 (hydrochloride); Westadone; Levomethadone [INN]; CID4095; Metadona; AC-16055; (-)-(R)-6-(Dimethylamino)-4,4-diphenyl-3-heptanone; 5653-80-5; Algovetin; L000874; DivK1c_000963; AN-148 (*Hydrochloride*); Levomethadonum [INN-Latin]; 76-99-3; 3-HEPTANONE, 6-(DIMETHYLAMINO)-4,4-DIPHENYL-, (S)-; Dolly; methadone; EINECS 200-996-9; Phenadone (*Hydrochloride*); Dolophine; (S)-6-(Dimethylamino)-4,4-diphenyl-3-heptanone; Methadonum [Latin]; L-6-(Dimethylamino)-4,4-diphenyl-3-heptanone; Metasedin; Metadone; Polamidone; Metadona [INN-Spanish]; 6S-Methadone; 3-14-00-00279 (Beilstein Handbook Reference); (+)-Methadone; 3-HEPTANONE, 6-(DIMETHYLAMINO)-4,4-DIPHENYL-, L-; C07163; Fenadone (*Hydrochloride*); Methadona; Metadone [DCIT]; BRN 3213668; Methadone (BAN); Heptanon (*Hydrochloride*)	76-99-3	4095	149416	TTDS00125	Opioid receptor	N/A	N/A	N/A	N/A	agonist
DAP000357	Sufentanil	MolPort-004-286-008; C08022; DB00708; 56030-54-7; N-[4-(methoxymethyl)-1-(2-thiophen-2-ylethyl)piperidin-4-yl]-N-phenylpropanamide; CHEMBL658; LS-175693; Sufentanilum; SUFENTANIL; CID41693; Sulfentanil; UNII-AFE2YW0IIZ; C22H30N2O2S; Oprea1_246787; D05938; CHEBI:127638; Propanamide, N-[4-(methoxymethyl)-1-[2-(2-thienyl)ethyl]-4-piperidinyl]-N-phenyl-; PDSP1_001741; Sufentanil (USAN/INN); CHEBI:9316; N-{4-(methoxymethyl)-1-[2-(2-thienyl)ethyl]piperidin-4-yl}-N-phenylpropanamide; L000580; R-30730; 60561-17-3 (citrate); Chronogesic; AC1L26AJ; R 30730; Oprea1_120838; Sulfentanyl; AC1Q5I7B; Propanamide, N-(4-(methoxymethyl)-1-(2-(2-thienyl)ethyl)-4-piperidinyl)-N-phenyl-; N-(4-(Methoxymethyl)-1-(2-(2-thienyl)ethyl)-4-piperidyl)propionanilide; PDSP2_001724; N-(4-(Methoxymethyl)-1-(2-(2-thienyl)ethyl)-4-piperidinyl)-N-phenylpropanamide; Sufentanilum [INN-Latin]; Sufentanil [USAN:BAN:INN]; HSDB 6760; Sufentanyl; N-{4-[(methyloxy)methyl]-1-[2-(2-thienyl)ethyl]piperidin-4-yl}-N-phenylpropanamide	56030-54-7	41693	10222	TTDS00125	Opioid receptor	N/A	N/A	N/A	N/A	antagonist
DAP000356	Pentazocine	Pentazocina [DCIT]; Pentazocin; EINECS 244-593-6; Fortalin; CHEMBL583086; EINECS 259-735-2; Pentazocina; KST-1B5746; NSC107430; 17146-95-1 (lactate); 39188-58-4; CID4736; 57165-12-5; Sosegon; Talacen; 1,2,3,4,5,6-Hexahydro-6,11-dimethyl-3-(3-methylbut-2-enyl)-2,6-methano-3-benzazocin-8-ol; Talwan; CID66387; CID11000612; C19H27NO; Algopent (free base); CHEBI:116117; Soseton; Pentagin; AR-1B5050; CID9669; 3-(3-Methyl-2-butenyl)-1,2,3,4,5,6-hexahydro-6,11-dimethyl-2,6-methano-3-benzazocin-8-ol; L001017; (2R,6R,11R)-6,11-dimethyl-3-(3-methylbut-2-en-1-yl)-1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-8-ol; Lexir; 1,2,3,4,5,6-Hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-2,6-methano-3-benzazocin-8-ol; L-pentazocine; Pentazocine, Pentazocin, Sosegon, WIN 20228; 2-(3,3-Dimethylallyl)-2',2'-hydroxy-5,9-dimethyl-6,7-benzomorphan; pentazocine; NSC 107430; 2-Dimethylallyl-5,9-dimethyl-2'-hydroxybenzomorphan; Pentazocaine; AC1L1IUB; II-C-2; 2,6-Methano-3-benzazocin-8-ol, 1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-, (2alpha,6alpha,11R*)-; 2,6-Methano-3-benzazocin-8-ol, 1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-; Pentazocine (JP15/USP/INN); D00498; CHEBI:196159; 21820-34-8; AC1L9AVL; PDSP2_000663; DEA No. 9709; AC1L259C; PDSP1_000673; LS-187180; NIH 7958; CHEMBL100116; MolPort-006-395-642; WIN 20228; (2R*,6R*,11R*)-1,2,3,4,5,6-Hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-2,6-methano-3-benzazocin-8-ol; EINECS 206-634-6; LS-90597; 2,6-Methano-3-benzazocin-8-ol, 1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-, (2alpha, 6alpha,11R*)-; Liticon; LS-89500; CHEBI:265474; (2alpha,6alpha,11R*)-(1)-1,2,3,4,5,6-Hexahydro-6,11-dimethyl-3-(3-methylbut-2-enyl)-2,6-methano-3-benzazocin-8-ol; KF-1820; 64024-15-3 (hydrochloride); CHEBI:671145; C07421; Fortalgesic; Fortral (TN); Pentazocinum; 2-(3,3-Dimethylallyl)cyclazocine; CHEMBL560; Pentazocine [USAN:INN:BAN:JAN]; AC1Q7AHR; CID441278; PDSP2_001111; AC1L1TJY; NSC-107430; 359-83-1; Sosigon; DB00652; Pentazocinum [INN-Latin]; 2,6-Methano-3-benzazocin-8-ol, 1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-, (2.alpha.,6.alpha.,11R*)-; Fortral; UNII-RP4A60D26L; HSDB 3150; 2'-Hydroxy-5,9-dimethyl-2-(3,3-dimethylallyl)-6,7-benzomorphan	359-83-1	441278	9625	TTDS00125	Opioid receptor	N/A	N/A	N/A	N/A	antagonist
DCL000805	Flibanserin	1-(2-(4-alpha,alpha,alpha-Trifluoro-m-tolyl)-1-piperazinyl)ethyl)-2-benzimidazolinone; PDSP1_001329; 3-[2-[4-[4-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]-1H-benzimidazol-2-one; UNII-37JK4STR6Z; 1,3-Dihydro-1-(2-(4-(3-(trifluoromethyl)phenyl)-1-piperazinyl)ethyl)-2H-benzimidazol-2-one; 1-(2-(4-(alpha,alpha,alpha-Trifluoro-m-tolyl)-1-piperazinyl)ethyl)-2-benzimidazolinone; MolPort-006-666-415; CID127941; Flibanserin [USAN]; Bimt-17; ST51054021; AC1L2SWZ; C20H21F3N4O; PDSP2_001313; 1-(2-(4-(3-Trifluoromethylphenyl)piperazin-1-yl)ethyl)benzimidazol(1H)-2-one; AC-1628; Flibanserin; LS-173616; Bimt 17	167933-07-5	159594	17396748	TTDS00098	5-hydroxytryptamine 1A receptor	5-HT1A;5-HT-1A;5-HT1A receptor;5-hydroxytryptamine receptor 1A;G-21;Serotonin receptor;Serotonin receptor 1A	P08908	3350	ENSG00000178394	agonist
DCL000724	Bifeprunox	CID208951; D06566; CHEBI:467160; DU127090; DU 127090; Bifeprunox (USAN/INN); 350992-10-8; L001659; Bifeprunoxum [INN-Latin]; Bifeprunoxum; CHEMBL218166; Bifeprunox; 7-[4-[(3-phenylphenyl)methyl]piperazin-1-yl]-3H-1,3-benzoxazol-2-one; 7-(4-(Biphenyl-3-ylmethyl)piperazin-1-yl)benzoxazol-2(3H)-one; MolPort-005-943-082; Bifeprunox [INN]; AC1L4LOA; UNII-AP69E83Z79	350992-13-1	130021	47208222	TTDS00098	5-hydroxytryptamine 1A receptor	5-HT1A;5-HT-1A;5-HT1A receptor;5-hydroxytryptamine receptor 1A;G-21;Serotonin receptor;Serotonin receptor 1A	P08908	3350	ENSG00000178394	agonist
DCL000991	SLV-319	Ibipinabant (USAN/INN); CHEBI:464871; 464213-10-3; CID 9826744; SLV-319; CHEBI:530253; CHEMBL412262; D09349; CID11179267; CID9826744; Ibipinabant; ZINC03964747; CHEMBL158784; LS-193349; CHEBI:363997; (+/-)-SLV319	362519-49-1	1132	49689491	TTDS00098	5-hydroxytryptamine 1A receptor	5-HT1A;5-HT-1A;5-HT1A receptor;5-hydroxytryptamine receptor 1A;G-21;Serotonin receptor;Serotonin receptor 1A	P08908	3350	ENSG00000178394	antagonist
DCL000918	PD-158771	2-Pyrimidinamine, N-(4-(2-(4-phenyl-1-piperazinyl)ethyl)cyclohexyl)-, trans-; 189152-50-9; CHEMBL165679; CHEBI:374449; LS-134503; CID3075615; CHEBI:375533; trans-N-(4-(2-(4-Phenyl-1-piperazinyl)ethyl)cyclohexyl)-2-pyrimidinamine; PD 158771; L015054; N-[4-[2-(4-phenylpiperazin-1-yl)ethyl]cyclohexyl]pyrimidin-2-amine; AC1MIP35; CHEMBL164984	N/A	9841667	49684220	TTDS00098	5-hydroxytryptamine 1A receptor	5-HT1A;5-HT-1A;5-HT1A receptor;5-hydroxytryptamine receptor 1A;G-21;Serotonin receptor;Serotonin receptor 1A	P08908	3350	ENSG00000178394	antagonist
DCL000732	BTS-79018	N/A	170353-17-0	N/A	N/A	TTDS00098	5-hydroxytryptamine 1A receptor	5-HT1A;5-HT-1A;5-HT1A receptor;5-hydroxytryptamine receptor 1A;G-21;Serotonin receptor;Serotonin receptor 1A	P08908	3350	ENSG00000178394	binder
DCL000989	SLV-313	CID 9887537; CHEMBL221692; L001624; CID9887537; SLV-313	N/A	N/A	N/A	TTDS00098	5-hydroxytryptamine 1A receptor	5-HT1A;5-HT-1A;5-HT1A receptor;5-hydroxytryptamine receptor 1A;G-21;Serotonin receptor;Serotonin receptor 1A	P08908	3350	ENSG00000178394	agonist
DCL000673	Abaperidone hydrochloride	7-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propoxy]-3-(hydroxymethyl)chromen-4-one hydrochloride; Abaperidone hydrochloride; CID6918450; AC1OCFG8; FI-8602.HCl	183849-43-6	3037308	12015267	TTDS00098	5-hydroxytryptamine 1A receptor	5-HT1A;5-HT-1A;5-HT1A receptor;5-hydroxytryptamine receptor 1A;G-21;Serotonin receptor;Serotonin receptor 1A	P08908	3350	ENSG00000178394	antagonist
DCL000663	Xaliproden	NCGC00167574-02; 1,2,3,6-tetrahydro-1-(2-(2-naphthalenyl)ethyl)-4-(3-(trifluoromethyl)phenyl)-pyridine; D06327; PDSP2_000054; NCGC00167574-01; AC1L2UOT; CHEBI:48520; 1-(2-naphthalen-2-ylethyl)-4-[3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-pyridine; L001401; Xaliproden (USAN); Xaliproden; PDSP1_000054; 135354-02-8; 1,2,3,6-tetrahydro-1-(2-(2-naphthyl)ethyl)-4-(alpha,alpha,alpha-trifluoro-m-tolyl)pyridine; BRD-K88358234-003-01-4; CID128919; 1-[2-(2-naphthyl)ethyl]-4-[3-(trifluoromethyl)phenyl]-1,2,3,6-tetrahydropyridine; 1-(2-(2-Naphthyl)ethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine; Pyridine, 1,2,3,6-tetrahydro-1-(2-(2-naphthalenyl)ethyl)-4-(3-(trifluoromethyl)phenyl)-	428863-50-7	128919	47207984	TTDS00098	5-hydroxytryptamine 1A receptor	5-HT1A;5-HT-1A;5-HT1A receptor;5-hydroxytryptamine receptor 1A;G-21;Serotonin receptor;Serotonin receptor 1A	P08908	3350	ENSG00000178394	antagonist
DCL001036	Vilazodone	Vilazodone; MolPort-005-933-319; L001518; CHEBI:412971; AC1OCFA2; 163521-12-8; CID6918314; 5-[4-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-yl]-1-benzofuran-2-carboxamide; Vilazodone [INN]; 5-[4-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-yl]benzofuran-2-carboxamide; CHEMBL439849	163521-12-8	9577221	3818317	TTDS00098	5-hydroxytryptamine 1A receptor	5-HT1A;5-HT-1A;5-HT1A receptor;5-hydroxytryptamine receptor 1A;G-21;Serotonin receptor;Serotonin receptor 1A	P08908	3350	ENSG00000178394	antagonist
DCL000973	Sarizotan	AC1MHW5N; 1-(3,4-dihydro-2H-chromen-2-yl)-N-[[5-(4-fluorophenyl)pyridin-3-yl]methyl]methanamine; CID3058747; L001578; UNII-467LU0UCUW; Sarizotan; N-((3,4-Dihydro-2H-1-benzopyran-2-yl)methyl)-5-(4-fluorophenyl)-3-pyridinemethanamine; EMD 128130; 177975-08-5; (-)-3-((((R)-2-Chromanylmethyl)amino)methyl)-5-(p-fluorophenyl)pyridine; Sarizotan [INN]; LS-192590	177976-12-4	3058747	3862729	TTDS00098	5-hydroxytryptamine 1A receptor	5-HT1A;5-HT-1A;5-HT1A receptor;5-hydroxytryptamine receptor 1A;G-21;Serotonin receptor;Serotonin receptor 1A	P08908	3350	ENSG00000178394	agonist
DCL000981	SDZ-MAR-327	N/A	N/A	N/A	N/A	TTDS00098	5-hydroxytryptamine 1A receptor	5-HT1A;5-HT-1A;5-HT1A receptor;5-hydroxytryptamine receptor 1A;G-21;Serotonin receptor;Serotonin receptor 1A	P08908	3350	ENSG00000178394	agonist
DAP000031	Buspirone	NCGC00024905-01; AC1L1DRN; Bespar; SPBio_002418; BRD-K93461745-003-03-7; HMS2090K19; LS-22723; Ansiced; KBio2_002236; IDI1_000921; CHEMBL49; 8-Azaspiro(4,5)decane-7,9-dione, 8-(4-(4-(2-pyrimidinyl)piperizinyl)butyl)-; CHEBI:3223; Gen-Buspirone (TN); C13H21NO2.C9H14N4; N-(4-(4-(2-pyrimidinyl)-1-piperazinyl)butyl)-1-cyclopentanediacetamide; AKOS002313325; Tocris-0962; KBio2_007372; Buspirone (INN); KBioSS_002236; KBio1_000921; CAS-33386-08-2; CID2477; Biomol-NT_000108; Prestwick1_000369; STOCK1S-11244; Prestwick0_000369; Axoren; Anxiron; 8-{4-[4-(pyrimidin-2-yl)piperazin-1-yl]butyl}-8-azaspiro[4.5]decane-7,9-dione; 8-Azaspiro[4.5]decane-7,9-dione, 8-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-; 8-Azaspiro(4.5)decane-7,9-dione, 8-(4-(4-(2-pyrimidinyl)-1-piperazinyl)butyl)-; Buspirone-MDTS; MolPort-002-539-709; MJ-9022-1; AB00053432; Buspisal; Gen-Buspirone; C06861; EINECS 253-072-2; NCGC00015162-01; Buspironum [INN-Latin]; KBio2_004804; BSPBio_000497; Lopac0_000223; UNII-TK65WKS8HL; Buspirona; D07593; DB00490; BAS 00928841; NINDS_000921; BPBio1_000547; Buspironum; 36505-84-7; BPBio1_001403; NCGC00024905-03; NCGC00015162-06; Buspirone [INN:BAN]; STK086268; L001110; 8-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]-8-azaspiro[4.5]decane-7,9-dione; Spectrum_001756; NCGC00016820-01; BRN 0964904; buspirone; DivK1c_000921; Buspirona [INN-Spanish]; Prestwick3_000369; Prestwick2_000369; Ansial; BIDD:GT0519; BRD-K93461745-001-01-5; Lopac-B-7148; 8-(4-(4-(2-Pyrimidinyl)-1-piperizinyl)butyl)-8-azaspiro(4,5)decane-7,9-dione; NCGC00024905-02; 8-[4-(4-Pyrimidin-2-yl-piperazin-1-yl)-butyl]-8-aza-spiro[4.5]decane-7,9-dione	36505-84-7	2477	9079	TTDS00098	5-hydroxytryptamine 1A receptor	5-HT1A;5-HT-1A;5-HT1A receptor;5-hydroxytryptamine receptor 1A;G-21;Serotonin receptor;Serotonin receptor 1A	P08908	3350	ENSG00000178394	agonist
DCL000907	OPC-14523	N/A	145969-30-8	66644	48501062	TTDS00098	5-hydroxytryptamine 1A receptor	5-HT1A;5-HT-1A;5-HT1A receptor;5-hydroxytryptamine receptor 1A;G-21;Serotonin receptor;Serotonin receptor 1A	P08908	3350	ENSG00000178394	agonist
DCL000937	PRX-00023	N/A	740873-06-7	11430856	N/A	TTDS00098	5-hydroxytryptamine 1A receptor	5-HT1A;5-HT-1A;5-HT1A receptor;5-hydroxytryptamine receptor 1A;G-21;Serotonin receptor;Serotonin receptor 1A	P08908	3350	ENSG00000178394	agonist
DCL000813	Gepirone ER	CHEMBL284092; 3,3-dimethyl-1-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]glutarimide; CHEBI:150290; Gepironum [Latin]; UNII-JW5Y7B8Z18; 83928-66-9 (mono-hydrochloride); MJ-13805; 83928-76-1; Gepironum; Gepirona; Gepirone ER; 2,6-Piperidinedione, 4,4-dimethyl-1-(4-(4-(2-pyrimidinyl)-1-piperazinyl)butyl)-; L001135; Gepirone [INN]; MJ 13805-1; Gepirona [Spanish]; 4,4-dimethyl-1-(4-(4-(2-pyrimidinyl)-1-piperazinyl)butyl)-2,6-piperidinedione; Gepirone; MJ 13805; LS-177790; AC1L1IK6; BMY 13805; MolPort-005-942-415; 4,4-dimethyl-1-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]piperidine-2,6-dione; AC1Q6F8Q; BMY-13805; CID55191	83928-76-1	55191	12012960	TTDS00098	5-hydroxytryptamine 1A receptor	5-HT1A;5-HT-1A;5-HT1A receptor;5-hydroxytryptamine receptor 1A;G-21;Serotonin receptor;Serotonin receptor 1A	P08908	3350	ENSG00000178394	agonist
DCL000371	GSK163090	N/A	N/A	3372	49698907	TTDS00098	5-hydroxytryptamine 1A receptor	5-HT1A;5-HT-1A;5-HT1A receptor;5-hydroxytryptamine receptor 1A;G-21;Serotonin receptor;Serotonin receptor 1A	P08908	3350	ENSG00000178394	antagonist
DPR000003	1192U90	LS-25359; 2-Amino-N-(4-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)butyl)benzamide; 2-amino-N-[4-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]butyl]benzamide; 1192U90; PDSP1_001055; Benzamide, 2-amino-N-(4-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)butyl)-; 2-Amino-N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]butyl] benzamide; PDSP2_001039; 155289-31-9; CID127912; AC1L2SUW; L001475	155289-31-9	127912	704544	TTDS00098	5-hydroxytryptamine 1A receptor	5-HT1A;5-HT-1A;5-HT1A receptor;5-hydroxytryptamine receptor 1A;G-21;Serotonin receptor;Serotonin receptor 1A	P08908	3350	ENSG00000178394	agonist
DAP001450	Treximet	Sumatriptan succinate and naproxen sodium; Naproxen sodium mixture with sumatriptan succinate; Sumatriptan succinate mixture with naproxen sodium; Trexima; 811794-26-0; Naproxen mixture with sumatriptan; Sumatriptan mixture with naproxen; CID11342822; CID 11342822; Naproxen / sumatriptan; Treximet	154189-24-9	183812	47207493	TTDS00098	5-hydroxytryptamine 1A receptor	5-HT1A;5-HT-1A;5-HT1A receptor;5-hydroxytryptamine receptor 1A;G-21;Serotonin receptor;Serotonin receptor 1A	P08908	3350	ENSG00000178394	antagonist
DCL001019	TGBA01AD	N/A	3083-77-0	1177	48334698	TTDS00098	5-hydroxytryptamine 1A receptor	5-HT1A;5-HT-1A;5-HT1A receptor;5-hydroxytryptamine receptor 1A;G-21;Serotonin receptor;Serotonin receptor 1A	P08908	3350	ENSG00000178394	agonist
DCL001002	SSR-181507	N/A	148262-19-5	177859	43529611	TTDS00098	5-hydroxytryptamine 1A receptor	5-HT1A;5-HT-1A;5-HT1A receptor;5-hydroxytryptamine receptor 1A;G-21;Serotonin receptor;Serotonin receptor 1A	P08908	3350	ENSG00000178394	binder
DCL000680	Adatanserin	WY 50324; N-[2-(4-pyrimidin-2-ylpiperazin-1-yl)ethyl]adamantane-1-carboxamide; Adatanserin [INN]; Tricyclo(3.3.1.1(3,7))decane-1-carboxamide, N-(2-(4-(2-pyrimidinyl)-1-piperazinyl)ethyl)-; CID130918; UNII-W5U6WQM26H; L001372; AC1L2Y9D; Adatanserin; 144966-96-1 (Monohydrochloride); 127266-56-2	127266-56-2	107778	707386	TTDS00098	5-hydroxytryptamine 1A receptor	5-HT1A;5-HT-1A;5-HT1A receptor;5-hydroxytryptamine receptor 1A;G-21;Serotonin receptor;Serotonin receptor 1A	P08908	3350	ENSG00000178394	agonist
DCL000885	MN-305	MolPort-005-943-180; AC1L55Z0; MCI-242; MN-305; 3-(1,3-benzodioxol-5-yloxy)-N-[[(3S)-2,3-dihydro-1,4-benzodioxin-3-yl]methyl]propan-1-amine hydrochloride; 137275-80-0; 1,4-Benzodioxin-2-methanamine, 2,3-dihydro-N-(3-(1,3-benzodioxol-5-yloxy)propyl)-, hydrochloride, (S)-; MKC-242; Mkc 242; Osemozotan hydrochloride; 5-(3-((2S)-(1,4-Benzodioxan-2-ylmethyl)amino)propoxy)-1,3-benzodioxol hydrochloride; CID198746; LS-34575	N/A	198747	12014645	TTDS00098	5-hydroxytryptamine 1A receptor	5-HT1A;5-HT-1A;5-HT1A receptor;5-hydroxytryptamine receptor 1A;G-21;Serotonin receptor;Serotonin receptor 1A	P08908	3350	ENSG00000178394	agonist
DAP001303	Arcitumomab	154361-48-5; D02977; Cea-Scan (TN); Arcitumomab (USAN/INN); Arcitumomab; CEA-Scan	154361-48-5	9837243	47205822	TTDS00487	Carcinoembryonic antigen	Carcinoembryonic antigen CGM1;CD66d;CEACAM3;CGM1	P40198	1084	ENSG00000170956	antibody
DAP000773	Allopurinol	Allopur; Xanturic; nchembio.92-comp3; Allopurinolum; UNII-63CZ7GJN5I; SMR000059083; HMS2091G15; D000493; Allohexal; CCRIS 626; Adenock; Atisuril; KBioSS_000386; STK711106; NCGC00015094-01; Caplenal; Rimapurinol; Uriprim; Purinol; Dabrosin; Dura Al; MolPort-004-758-159; IDI1_000685; Bio-0799; KBio2_002954; NSC 1390; Ketanrift; Remid; NCIOpen2_001825; Hamarin; Aloprim; 184856-42-6; CPD000059083; BW-56-158; Spectrum3_000289; EU-0100102; NCGC00091134-03; Dabroson; Xanturat; Lopurin; NCGC00015094-03; Bloxanth; Bleminol; Sigapurol; NSC101655; S1630_Selleck; Uribenz; Ledopur; Prestwick_511; Pureduct; Suspendol; Epidropal; Riball; 39464-14-7; Lopac-A-8003; Cosuric; CID2094; Quimica, Pan; Allohexan; Milurite; AC-019; Uripurinol; SPBio_000056; AC1Q6FWV; C5H4N4O; BW 56-158; Allozym; Allopurin; NSC 101655; MLS000069453; Jsp005881; B. W. 56-158; Uritas; MLS001148183; Foligan; BSPBio_001798; allopurinol; Lysuron; CHEMBL1467; CPD-9024; A0907; Apo-Allopurinol; Nektrohan; AC1Q6GP7; KBioGR_000550; Cellidrin; Spectrum_000026; HMS1920A15; 4-HPP; Alopurinol; Geapur; Apulonga; NCGC00091134-02; Allural; HPP; Lopac0_000102; Alloprin; NCGC00094580-01; 315-30-0; Gotax; STK378584; Alositol; NINDS_000685; CHEBI:495607; NSC1390; Aluline; BIM-0061756.0001; MolPort-000-141-383; A8003_SIGMA; I03-0052; Epuric; Spectrum4_000135; Ailural; KBio1_000685; BB_SC-5394; Progout; Spectrum2_000098; MolPort-004-758-167; Ketobun-A; Zygout; Uricemil; A 8003; Ailurial; MolPort-004-758-643; Allpargin; Urobenyl; Monarch; KBio2_005522; Anzief; SAM002554884; AKOS000267490; Jenapurinol; Miniplanor; Urbol; Gichtex; KBio2_000386; AL-100; Hexanuret; NCGC00094580-02; DB00437; Milurit; Urtias 100; Anoprolin; SPECTRUM1500108; Embarin; Zyloprim; Uridocid; Apurin; nchembio732-comp4; Xanthomax; Allo-Puren; CHEBI:40279; DivK1c_000685; AKOS000269759; HSDB 3004; Zyloric; NSC-1390; 22767-92-6; LS-1180; MolPort-000-870-337; Spectrum5_000768; Allorin; HMS502C07; EN000932; Novopurol; Takanarumin; MolPort-004-758-166; BW 56158; EINECS 206-250-9; Tipuric; Allopurinol(I); Urtias; KBio3_001298; Capurate; Pan Quimica; Urosin; AC1L1CWL; Roucol; Apurol; Aloral; Urolit; NCGC00015094-06; NCGC00091134-01	315-30-0	2094	152626	TTDS00056	Xanthine dehydrogenase/oxidase	Xanthine oxidase	P47989	7498	ENSG00000158125	inhibitor
DAP001444	Febuxostat	CHEBI:747206; LS-173202; AC1L33UC; S1547; 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methyl-1,3-thiazole-5-carboxylic acid; CHEMBL1164729; 2-(3-Cyano-4-(2-methylpropoxy)phenyl)-4-methylthiazole-5-carboxylic acid; CID134018; 111GE013; MolPort-005-940-740; AC-425; 2-(3-Cyano-4-isobutoxyphenyl)-4-methyl-5-thiazolecarboxylic acid; Febuxostat; TEI; Febuxostat (JAN/USAN/INN); Tei-6720; CHEBI:45943; C16H16N2O3S; D01206; Tei 6720; UNII-101V0R1N2E; DB03786; TMX 67; 5-Thiazolecarboxylic acid, 2-(3-cyano-4-(2-methylpropoxy)phenyl)-4-methyl-; 144060-53-7; Uloric; 2-(3-CYANO-4-ISOBUTOXY-PHENYL)-4-METHYL-5-THIAZOLE-CARBOXYLIC ACID; Febuxostat [USAN]; TMX-67, Adenuric, Uloric, Febuxostat; FT-0081351; S1547_Selleck; 5-Thiazolecarboxylic acid, 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methyl-; TMX-67; Adenuric	N/A	134018	12014717	TTDS00056	Xanthine dehydrogenase/oxidase	Xanthine oxidase	P47989	7498	ENSG00000158125	inhibitor
DCL000863	Leptin	N/A	496775-62-3	9846180	7979748	TTDS00056	Xanthine dehydrogenase/oxidase	Xanthine oxidase	P47989	7498	ENSG00000158125	inhibitor
DCL000567	MK-0752	N/A	N/A	N/A	N/A	TTDC00233	Gamma secretase	N/A	N/A	N/A	N/A	inhibitor
DCL000607	R4733	N/A	502-85-2	5360545	49746451	TTDC00233	Gamma secretase	N/A	N/A	N/A	N/A	inhibitor
DAP000873	Ursodeoxycholic acid	Acido ursodeossicolico; U-9000; MolPort-005-932-884; 7beta-Hydroxylithocholic acid; MLS001066373; UDCS; Antigall; 3 alpha,7 beta-Dihydroxy-5 beta-cholan-24-oic Acid; Ursodiol [USAN]; 5-beta-Cholan-24-oic acid, 3-alpha,7-beta-dihydroxy-; ursodeoxycholate; Ursodeoxycholic acid (JP15/INN); Ursodiol (USP); Cholan-24-oic acid, 3,7-dihydroxy-, (3-alpha,5-beta,7-beta)- (9CI); URSODEOXYCHOLIC ACID; Lyeton; C07880; Acide ursodesoxycholique [INN-French]; NCI60_028904; CHEMBL73390; LS-53033; (3alpha,5beta,7beta)-3,7-dihydroxycholan-24-oic acid; 3alpha,7beta-Dihydroxy-5beta-cholan-24-oic acid; Cholit-ursan; Urso (TN); U0030; (4R)-4-[(3R,5S,7S,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid; ursodiol; chenodeoxycholic acid; BRN 3219888; 3-alpha,7-beta-Dioxycholanic acid; CHEBI:9907; Ursacol; Cholan-24-oic acid, 3,7-dihydroxy-, (3alpha,5beta,7beta)-; HMS1570P18; Solutrat; 3,7-Dihydroxycholan-24-oic acid; AB00513977; UrSO; Ursochol; Ursofalk; Urso 250; CID31401; Actigall; Ursobilin; Prestwick3_000958; 7-beta-Hydroxylithocholic acid; BB_NC-2372; 3alpha,7beta-Dihydroxy-5beta-cholanic acid; S1643_Selleck; NSC 657950; 3-alpha,7-beta-Dihydroxy-5-beta-cholanoic acid; 128-13-2; UDCA; EINECS 204-879-3; Dom-ursodiol c; UNII-724L30Y2QR; Urosiol; MolPort-001-794-630; CPD000058403; D00734; SMP2_000012; Ursolvan; 17-beta-(1-Methyl-3-carboxypropyl)etiocholane-3-alpha,7-beta-diol; AC-18919; Ursodamor; Delursan; SMR000058403; SPBio_003105; Urso Forte; ISO-URSODEOXYCHOLIC ACID; 80225-86-1; CPD-10534; Ursocholic acid, deoxy-; Ursosan; MLS000028461; Prestwick0_000958; Acido ursodeoxicolico; NSC 683769; 5beta-Cholan-24-oic acid-3alpha,7beta-diol; BSPBio_000956; C24H40O4; PMS-ursodiol c; Sodium Ursodeoxycholate; Cholan-24-oic acid, 3,7-dihydroxy-, (3-alpha,5-beta,7-beta)-; Acide ursodesoxycholique; CID11516715; Arsacol; PHL-ursodiol c; 4-10-00-01604 (Beilstein Handbook Reference); Acidum ursodeoxycholicum; Destolit; Acido ursodeoxicolico [INN-Spanish]; DB01586; Litursol; AC-2081; Ursacholic Acid; Actigall (TN); LMST04010033; Deoxyursocholic Acid; Urso DS; NCGC00179363-01; U5127_SIGMA; BPBio1_001052; Ursodesoxycholic acid; Acido ursodeossicolico [Italian]; CHEMBL1551; Prestwick2_000958; Deursil; Prestwick1_000958; Peptarom; Acidum ursodeoxycholicum [INN-Latin]; 5beta-Cholanic Acid-3alpha,7beta-diol; Ursodeoxy cholic acid; (3alpha,5beta,7beta,8xi)-3,7-dihydroxycholan-24-oic acid; 50809-41-1; Ursodexycholic Acid; SAM002264653; CCRIS 5502; IU5; AC1L1LJH; 3-alpha,7-beta-Dihydroxycholanic acid; Ursodeoxycholic acid, UDCA, Ursosan, Ursofalk, Urso Forte, Udiliv, Ursodiol	128-13-2	31401	7847799	TTDS00513	Sodium-dependent vitamin C transporter 2	hSVCT2;KIAA0238;Na(+)/L-ascorbic acid transporter 2;NBTL1;Nucleobase transporter-like 1 protein;SLC23A1;SLC23A2;Solute carrier family 23 member 2;SVCT2;Yolk sac permease-like molecule 2;YSPL2	Q9UGH3	9962	ENSG00000089057	activator
DCL000652	TAK-448	N/A	N/A	N/A	N/A	TTDC00231	G-protein coupled receptor 54	GPR54;KiSS-1 receptor GPR54	Q969F8	84634	ENSG00000116014	agonist
DCL000655	TAK-683	N/A	119477-85-9	6449854	43041026	TTDC00231	G-protein coupled receptor 54	GPR54;KiSS-1 receptor GPR54	Q969F8	84634	ENSG00000116014	agonist
DAP001551	Dalfampridine	N/A	N/A	N/A	N/A	TTDS00150	ATP-sensitive K+ channel	Cardiac inward rectifier;CIR;GIRK4;Heart KATP channel;Inward rectifier K+ channel Kir3.4;KATP channel;KATP-1;Potassium channel, inwardly rectifying, subfamily J, member 5	P48544	3762	ENSG00000120457	blocker
DAP000037	Glibenclamide	Debtan; Glibenclamid Heumann; Gliban; CHEBI:5441; Euglucon 5; Praeciglucon; EU-0100499; STK362992; NCGC00023447-07; Glucobene; Glyburide [USAN]; KBio2_000730; Glybenzcyclamide; Libanil; HMS1568P14; Diabiphage; Euclamin; Norglicem 5; Neogluconin; Glibenclamid Basics; Urea, 1-(p-(2-(5-chloro-2-methoxybenzamido)ethyl)benzenesulfonyl)-3-cyclohexyl-; Glicem; Glycomin; BSPBio_001351; CPD000058229; Adiab; N-(4-(2-(5-Chloro-2-methoxybenzamido)ethyl)phenylsulfonyl)-N'-cyclohexylurea; Apo-Glibenclamide; Miglucan; Novo-Glyburide; U-26452; CAS-10238-21-8; Melix; UNII-SX6K58TVWC; SPBio_002531; Pira; KBio2_005207; Glimel; HMS2093P04; Abbenclamide; Glycolande; HMS1989D13; Nadib; Glibenclamida; Gen-Glybe; Bio1_000565; Glibenclamid AL; Semi-Euglucon; Betanase; NCGC00016689-01; Gluben; Betanese 5; Glibetic; MLS001077262; Daonil; Euglucon N; Lopac0_000499; Glibenclamid Genericon; Gliben; Bio1_001054; 1-(p-(2-(5-Chloro-2-methoxybenzamido)ethyl)benzenesulfonyl)-3-cyclohexylurea; Cytagon; BSPBio_000312; Glibenclamid-Ratiopharm; 10238-21-8; Glibenclamide; Spectrum4_001199; Bio-0156; Diabeta (TN); HB420; BPBio1_000344; Prestwick2_000316; ZINC00537805; I06-0716; Prestwick1_000316; SR-01000000196-5; KBio3_000141; Lederglib; Sugril; AC1L1G1Q; AC1Q44V7; SPECTRUM2300229; NCGC00015467-16; N-p-[2-(5-Chloro-2-methoxybenzamido)ethyl]benzenesulfonyl-N'-cyclohexylurea; Glibadone; D00336; DivK1c_000481; Dibelet; Calabren; Orabetic; glyburide; Semi-daonil; CHEMBL472; Glybenclamide; Azuglucon; HB 420; NCGC00015467-06; AB00051949; NCGC00023447-10; Tocris-0911; Glyburide (micronized); NCGC00023447-04; BSPBio_003053; KBioGR_000071; NCGC00023447-08; UR 606; BRD-K36927236-001-06-0; Glyben; BRN 2230085; Glucoremed; KBio1_000481; HMS2089L06; BIDD:GT0239; HMS501I03; G 0639; Gilemal; Glimidstata; D005905; Gluco-Tablimen; Micronized glyburide; Glibenil; Glimide; Glucomid; Lopac-G-0639; Humedia; SMR000058229; Glibenclamid-Cophar; 1-((p-(2-(5-Chloro-o-anisamido)ethyl)phenyl)sulfonyl)-3-cyclohexylurea; C23H28ClN3O5S; KBioSS_000730; SAM002564212; Glucoven; CID3488; NCGC00023447-11; SPBio_001831; UPCMLD-DP006:001; LS-159295; N-p-[2-(5-Chloro-2-methoxybenzamido)-ethyl]benzene-sulfonyl-N -cyclohexylurea; Benclamin; Glibesyn; Micronase; Glynase; Prestwick_569; Euglykon; DB01016; G0639_SIAL; Glibenclamidum [INN-Latin]; Glibenclamidum; Glibenbeta; Glibens; C07022; Micronase (TN); Glidiabet; Hemi-Daonil; Probes1_000431; Bio2_000551; KBio2_000071; Glibet; Semi-Gliben-Puren N; IDI1_033821; Med-Glionil; G2539_SIAL; Glisulin; KBio3_002273; KBio3_000142; NCGC00015467-02; Gewaglucon; HB-419; Spectrum2_001816; NCGC00023447-05; HMS1922L08; Diabeta; Euglucan; HB 419; Hexaglucon; GBN 5; HMS1361D13; NCGC00023447-09; KBioGR_001897; KBio2_002639; Glucohexal; U 26452; NCGC00023447-06; Glibenclamid Fabra; Glucolon; Probes2_000378; NINDS_000481; MLS000069721; NCGC00023447-02; AKOS001487495; Tiabet; NCGC00015467-01; Glitisol; HMS1791D13; Renabetic; HB-420; Glyburide (USP); 5-chloro-N-[2-[4-(cyclohexylcarbamoylsulfamoyl)phenyl]ethyl]-2-methoxybenzamide; S1716_Selleck; Euglucon; KBio2_005866; Spectrum_000250; Lisaglucon; Maninil; UPCMLD-DP006; HB419; Gliben-Puren N; PresTab; Glibenclamida [INN-Spanish]; Oprea1_764617; Prodiabet; IDI1_000481; EINECS 233-570-6; KBioSS_000071; Bio1_000076; Glibenclamide (JP15/INN); Normoglucon; Suraben; Yuglucon; CBiol_001790; Urea, 1-((p-(2-(chloro-o-anisamido)ethyl)phenyl)sulfonyl)-3-cyclohexyl-; MolPort-000-784-850; Duraglucon; Bio2_000071; Bastiverit; Prestwick0_000316; Glibenclamid Riker M; Dia-basan; Glubate; Gliboral; Spectrum5_001631; NCGC00023447-12; Glibenclamid Riker M.; G0639_SIGMA; Prestwick3_000316; Spectrum3_001327; KBio2_003298; Glamide; Glibil; Glynase (TN); 5-Chloro-N-[4-(cyclohexylureidosulfonyl)phenethyl]-2-methoxybenzamide	10238-21-8	3488	167865	TTDS00150	ATP-sensitive K+ channel	Cardiac inward rectifier;CIR;GIRK4;Heart KATP channel;Inward rectifier K+ channel Kir3.4;KATP channel;KATP-1;Potassium channel, inwardly rectifying, subfamily J, member 5	P48544	3762	ENSG00000120457	blocker
DCL001047	MBI 1121	N/A	N/A	N/A	N/A	TTDC00277	mRNA of E1 region of human papillomavirus	N/A	N/A	N/A	N/A	antisense
DPR000030	Chitin synthase inhibitor	N/A	N/A	N/A	N/A	TTDR01166	Chitin synthase 1	Chitin-UDP acetyl-glucosaminyl transferase 1	P08004	N/A	N/A	inhibitor
DAP001435	Triclosan	SBB058565; Ether, 2'-hydroxy-2,4,4'-trichlorodiphenyl; MLS001335937; HMS2093L17; Ster Zac Bath Concentrate; UNII-4NM5039Y5X; Aquasept; D014260; AC1L1KMN; Microshield T; CPD0-1227; Oxy Skin Wash; MLS001074876; Irgasan DP300; SAM002554907; 72779_SIGMA; Triclosanum; SMR000471847; Phenyl ether, 2'-hydroxy-2,4,4'-trichloro-; CH-3565; HSDB 7194; 112099-35-1; 2,4,4'-Trichloro-2'-hydroxy diphenyl ether; 88032-08-0; SSL Brand of Triclosan; 72779_FLUKA; TL8002539; TCL; Stri-Dex Cleansing Bar; EINECS 222-182-2; CPD000471847; D06226; Dermtek Brand of Triclosan; Caswell No. 186A; Cloxifenol; Cloxifenolum; Triclosan (USP/INN); Trans Canaderm Brand of Triclosan; 2,4,4'-Trichloro-2'-hydroxydiphenyl ether; NCGC00159417-04; CH 3565; Lexol 300; S00100; BRN 2057142; C12059; 261921-78-2; NCGC00159417-02; Clearasil Daily Face Wash; MLS001066347; 5-CHLORO-2-(2,4-DICHLOROPHENOXY)PHENOL; DB08604; DP-300; CID5564; MolPort-003-666-702; Procter & Gamble Brand of Triclosan; CCRIS 9253; EPA Pesticide Chemical Code 054901; Sapoderm; Triclosanum [INN-Latin]; 5-Chloro-2-(2,4-dichloro-phenoxy)-phenol; Manusept; Triclosan Pharmachem Brand; 164325-69-3; Irgasan DP 300; 524190_ALDRICH; Trisan; LS-67854; Triclosan; Irgasan; GlaxoSmithKline Brand of Triclosan; CHEMBL849; Ster-Zac Bath Concentrate; CHEBI:164200; Reckitt Brand of Triclosan; IN1424; Stri-Dex Face Wash; MLS001335938; I01-2897; AC-10667; Pharmachem Brand of Triclosan; 2-Hydroxy-2',4,4'-trichlorodiphenyl Ether; Triclosan [USAN:BAN:INN]; NCGC00159417-03; Johnson & Johnson Brand of Triclosan; 3380-34-5; triclosan; Stri-Dex cleansing bar (TN); C12H7Cl3O2; Triclosan Reckitt Brand; Cliniclean; Irgasan; SterZac Bath Concentrate; Phenol, 5-chloro-2-(2,4-dichlorophenoxy)-	3380-34-5	5564	14214	TTDS00235	Enoyl-ACP reductase	Enoyl-ACP reductase FabI;Enoyl-acyl carrier protein reductase;Enoyl-acyl carrier reductase;Enoyl-acyl-carrier protein reductase;FABI;NADH-dependent enoyl-ACP reductase	Q9BH77	N/A	N/A	binder
DCL000412	GSK1614235	N/A	N/A	N/A	N/A	TTDC00260	Sodium/glucose cotransporter 1	High affinity sodium-glucose cotransporter;Na(+)/glucose cotransporter 1;Solute carrier family 5 member 1	P13866	6523	ENSG00000100170	blocker
DAP000476	Thioridazine	Mellaril (*Hydrochloride*); KBio1_000066; Melleril; Ridazine; Spectrum_001066; Thioridazin; Tioridazina [INN-Spanish]; Spectrum4_000356; Melleril (liquid); 50-52-2; cMAP_000015; DivK1c_000066; BPBio1_000325; Prestwick0_000078; 57129-06-3; Mallorol; Lopac0_001252; Mellerette; KBio2_002308; BPBio1_001175; NCGC00089809-03; Thioridazine, prolongatum; 10H-Phenothiazine, 10-[2-(1-methyl-2-piperidinyl)ethyl]-2-(methylthio)-; D00373; Sonapax; Prestwick1_000078; Thioridazine Hcl Intensol; 10-[2-(1-methylpiperidin-2-yl)ethyl]-2-(methylthio)-10H-phenothiazine; Stalleril; SPBio_002216; SPBio_001483; KBio2_004876; AC1L1KDN; NINDS_000066; Thioxidazine; KBioSS_001546; TP-21; 10H-Phenothiazine, 10-(2-(1-methyl-2-piperidinyl)ethyl)-2-(methylthio)-; Orsanil; Melleryl; CHEBI:9566; Mellarit; L001321; Spectrum5_001062; 10-(2-(1-Methyl-2-piperidyl)ethyl)-2-(methylthio)phenothiazine; BSPBio_002030; Thioridazine Hcl; KBio3_002788; Thoridazine hydrochloride; KBio2_006682; Meleril; Thioridazinum [INN-Latin]; CHEMBL479; HMS2090J04; UNII-N3D6TG58NI; KBio2_004114; NCGC00089809-02; Tioridazina; Phenothiazine, 10-[2-(1-methyl-2-piperidyl)ethyl]-2-(methylthio)-; Mellaril-S (TN); Prestwick2_000078; Metlaril; 3-Methylmercapto-N-(2'-(N-methyl-2-piperidyl)ethyl)phenothiazine; KBio3_001530; Mellaril; thioridazine; Tioridazin; Thioridazine (USP/INN); Thioridazine prolongatum; DB00679; KBioSS_002310; EINECS 200-044-2; Phenothiazine, 10-((1-methyl-2-piperidyl)ethyl)-2-(methylthio)-; Malloryl; 2-Methylmercapto-10-(2-(N-methyl-2-piperidyl)ethyl)phenothiazine; Melleretten; C21H26N2S2; dl-Thioridazine; HSDB 3189; LS-105605; Mellerets; IDI1_000066; KBio2_007444; Novoridazine; (+-)-Thioridazine; 10-[2-(1-methylpiperidin-2-yl)ethyl]-2-(methylsulfanyl)-10H-phenothiazine; BSPBio_000295; 10-[2-(1-methyl-2-piperidyl)ethyl]-2-methylsulfanyl-phenothiazine; Thioridazine [USAN:INN:BAN]; Thioridazinum; CID5452; 10-[2-(1-methylpiperidin-2-yl)ethyl]-2-methylsulfanylphenothiazine; Spectrum3_000585; AI3-51923; AB00053553; Prestwick3_000078; Aldazine; Biomol-NT_000017; Mellaril-S; KBioGR_000791; Spectrum2_001332; KBioGR_002308; KBio2_001546; NCGC00016059-10	50-52-2	5452	148555	TTDS00026	Alpha adrenergic receptor	Alpha-adrenoceptor	N/A	N/A	N/A	antagonist
DAP001408	Naphazoline	KBio2_004023; Opcon; KBioSS_001455; Nafazolin; 4,5-Dihydro-2-(1-naphthylmethyl)imidazole; NINDS_000456; Spectrum4_000068; 2-(alpha-Naphthylmethyl)-imidazoline; BSPBio_000171; SPBio_002092; Prestwick2_000046; Nafazolina; BRD-K77641333-003-05-7; CAS-550-99-2; AC1L1I5Y; alpha-Naphthylmethyl imidazoline; 1H-Imidazole, 4,5-dihydro-2-(1-naphthalenylmethyl)-; HMS1394P03; 835-31-4; Spectrum5_001424; L000878; KBio2_001455; DB06711; LS-79666; Naphthizine; CHEBI:142468; CHEMBL761; D08253; Naphazoline (INN); 2-(1-Naphthylmethyl)-4,5-dihydro-1H-imidazole; BRN 0151864; Naphazoline Monohydrochloride; Prestwick1_000046; 2-(Naphthyl-(1')-methyl)imidazolin [German]; Antan; NCGC00016506-02; Spectrum_000975; Enamine_000333; STK300042; AKOS000295230; Nafazoline; KBio3_001565; SPBio_001008; KBioGR_000595; Spectrum3_000513; DivK1c_000456; BPBio1_000189; 2-(Naphthyl-(1')-methyl)imidazolin; 2-(1-Naphthylmethyl)-2-imidazoline; 2-(naphthalen-1-ylmethyl)-4,5-dihydro-1H-imidazole; IDI1_000456; Ciba 2020/R; Naphazolinum [INN-Latin]; CID4436; MolPort-001-641-043; Prestwick3_000046; 2-Imidazoline, 2-(1-naphthylmethyl)-; STOCK1S-50748; Nafazolin (TN); Naphazolinum [Latin]; Naphazoline [INN:BAN]; EINECS 212-641-5; naphazoline; 5-23-08-00293 (Beilstein Handbook Reference); AK-968/41090774; 550-99-2 (mono-hydrochloride); UNII-H231GF11BV; Nafazolina [DCIT]; Prestwick0_000046; Spectrum2_001054; NCGC00016506-01; Nafazoline [Spanish]; KBio1_000456; BSPBio_002065; Clearine; NCGC00024349-03; HMS2090D15; Naphazolinum; KBio2_006591; C14H14N2	835-31-4	4436	156624	TTDS00026	Alpha adrenergic receptor	Alpha-adrenoceptor	N/A	N/A	N/A	agonist
DAP000477	Tolazoline	CAS-59-97-2; Spectrum_000731; 2-Benzyl-2-imidazoline; DivK1c_000328; Priscol; 2-(phenylmethyl)-4,5-dihydro-1H-imidazole; L000960; NCGC00016271-02; Artonil; Priscoline; SPBio_000988; DB00797; Vasimid; CID5504; 2-IMIDAZOLINE, 2-BENZYL-; KBio1_000328; Tolazolin; Olitensol; Tolazolinum [INN-Latin]; Benzylimidazoline; KBio2_006347; KBioGR_000793; 59-97-2 (mono-hydrochloride); NCGC00016271-01; BSPBio_002068; Spectrum4_000357; 293490_ALDRICH; NSC35110; Benzolin; Imidaline; Tolazoline [INN:BAN]; KBio3_001568; MolPort-002-626-489; Tolazine [veterinary] (TN); Divascol; NSC 35110; D08614; Tolazine [veterinary]; Ciba 3259; 2-BENZYL-4,5-IMIDAZOLINE HCl; tolazoline; 2-Benzyl-4,5-imidazoline; Spectrum5_001788; NINDS_000328; WLN: T5M CN BUTJ B1R; Phenylmethylimidazoline; BRN 0128757; Kasimid; KBio2_003779; 59-97-2; IDI1_000328; 59-98-3; Prestwick1_000060; Spectrum3_000594; Imidalin; Spectrum2_001204; Benzolin (VAN); AKOS000357643; 1H-Imidazole, 4,5-dihydro-2-(phenylmethyl)-; Peripherine; Tolazoline Monohydrochloride; UNII-CHH9H12AQ3; Prestwick2_000060; 4,5-Dihydro-2-(phenylmethyl)-1H-imidazole; Pridazole; Tolazolina; C07147; Tolazolinum; NCGC00016271-03; SPBio_002140; 1H-Imidazole, 4,5-dihydro-2-(phenylmethyl)-; 2-Benzyl-2-imidazoline; Prestwick0_000060; Benzidazol; Tolazolina [INN-Spanish]; 2-Benzyl-4,5-dihydro-1H-imidazole; Benzolin (vasodilator) (VAN); STOCK4S-93327; 5-23-06-00488 (Beilstein Handbook Reference); KBio2_001211; BPBio1_000241; Benzalolin; AC1L1KHM; KBioSS_001211; Vasodil; Benzolin (vasodilator); EINECS 200-448-9; 1H-Imidazole, 4,5-dihydro-2-(phenylmethyl)- (9CI); BSPBio_000219; C10H12N2; Tolazoline (INN); BRD-K46211610-003-05-1; Benzazoline; Lambril; Dilatol ASI; CHEBI:28502; LS-79571; Prestwick3_000060; Vasodilatan; 2-Benzylimidazoline; CHEMBL770; Prefaxil	59-98-3	5504	9356	TTDS00026	Alpha adrenergic receptor	Alpha-adrenoceptor	N/A	N/A	N/A	antagonist
DAP000225	Metaraminol	m-Hydroxypropadrine; 1-(m-Hydroxyphenyl)-2-amino-1-propanol; 3-[(1R,2S)-2-amino-1-hydroxypropyl]phenol; m-Hydroxyphenylpropanolamine; 1-alpha-(1-Aminoethyl)-m-hydroxybenzyl alcohol; Hydroxynorephedrine; AC1L1LE3; m-Hydroxy-alpha-(1-aminoethyl)-benzyl alcohol; 2-Amino-1-(m-hydroxyphenyl)-1-propanol; DB00610; m-Hydroxynorephedrine; Benzenemethanol, alpha-(1-aminoethyl)-3-hydroxy-, (R-(R*,S*))- ( 9CI); C07146; UNII-818U2PZ2EH; Pressonex; metaraminol; NCGC00178024-01; Isophenylephrine; Metaraminolum [Latin]; Benzyl alcohol, alpha-(1-aminoethyl)-m-hydroxy-, (-)-; D08192; Metaraminol [INN:BAN]; CID5906; LS-42645; CHEBI:6794; HSDB 2716; Pressorol; Metaraminolum [INN-Latin]; 1-Metaraminol; m-Hydroxy norephedrine; Metaradrin; alpha-(m-Hydroxyphenyl)-beta-aminopropanol; (-)-Erythro-metaraminol; Benzenemethanol, alpha-(1-aminoethyl)-3-hydroxy-, (R-(R*,S*))-; 54-49-9; Metaraminolum; Araminol; L-Metaraminol; alpha-(1-Aminoethyl)-m-hydroxybenzyl alcohol; 3-Hydroxyphenylisopropanolamine; meta-Hydroxynorephedrine; Metaraminol (INN); CCRIS 8465; alpha-(1-Aminoethyl)-3-hydroxybenzenemethanol; 33402-03-8 (bitartrate (1:1) (salt)); Icoral B; NCGC00178024-02; Metaradrine	54-49-9	5906	9355	TTDS00026	Alpha adrenergic receptor	Alpha-adrenoceptor	N/A	N/A	N/A	agonist
DAP000228	Ephedrine	Ephoxamin; psi-Ephedrine, (+)-; MLS000069657; I01-8925; l-Pseudoephedrine; Fedrin; LS-63962; Sudafed; Pseudo 60's; AR-1I7143; l-Ephedrine; Spectrum_001020; CID9457; KBio1_000461; PDSP2_001330; LS-43083; C02765; KBioGR_001763; NCGC00162174-01; (-)-threo-Ephedrine; L(-)-Ephedrine; I-Sedrin; L-(+)-Ephedrine; Spectrum2_001303; AC-20231; KBio2_004068; Spectrum4_000497; Mandrin; Ephedrine dl-; DivK1c_000181; (+)-Pseudoephedrine; NSC165609; Acunaso (TN); AC1Q3XJM; NINDS_000461; PDSP1_001106; (1R,2R)-Ephedrine; CHEBI:15407; MolPort-001-769-085; Spectrum_000878; CHEBI:51209; 50906-05-3; AC1L1JGK; MolPort-001-684-478; (1S,2R)-Ephedrine; Ephedrotal; Ephedrital; C01575; 134910_ALDRICH; Ephedsol; AR-1A0126; Ephedrin; PDSP2_001327; d-Isoephedrine; 1-Sedrin; Ephedremal; Psi-ephedrin; SPBio_001377; EINECS 206-292-8; 299-42-3; STK367993; Lopac0_000501; CID9294; Spectrum5_001106; EPHEDRINE, (+)-; Ephedrine, (-)-; NCI-C55652; d-Pseudoephedrine; CHEMBL1590; AC1O8JUO; HSDB 3177; d-psi-Ephedrine; Jsp005664; CPDD 0049; KBio2_003926; AC1L1NUA; WLN: QYR&Y1&M1; DivK1c_000461; 321-98-2; NCGC00178180-01; LS-63961; AC1Q59F5; EINECS 206-293-3; (-)-psi-Ephedrine; Efidac/24; PDSP2_001090; I01-3584; SMR000059174; NINDS_000181; PSEUDOEPHEDRINE; Spectrum3_000414; KBio2_001358; KBioSS_001358; Zephrol; Oprea1_287330; Acunaso; AC1Q3XJN; WLN: QYR & Y1 & M1; 38732-95-5; 50-98-6; Biophedrin; 287644_ALDRICH; Nasol; LS-125921; Pseudo-12; (-)-Ephedrine; DivK1c_000451; KBio3_001188; BSPBio_001968; Pseudoephedrinum; MolPort-001-684-479; Spectrum3_000563; Afrinol; BIDD:GT0817; 304-87-0; EINECS 206-080-5; AC1Q3XJE; Robidrine; Spectrum2_000137; Spectrum2_001309; AC1Q7701; 4607-45-8; Ephedrine (USP); KBioGR_001013; PDSP1_001345; AC-20292; Eciphin; KBio3_002762; Maxenal; Besan; Ephedrine [USAN:BAN]; Sanedrine; CHEMBL357080; Decofed; NCGC00015408-01; Ephendronal; Pseudoefedrina; NCGC00178889-01; Spectrum5_000879; CID11972440; NINDS_000451; BRN 4231286; Cenafed; 321-97-1; AC1L1Y3M; UNII-03VRY66076; 287636_ALDRICH; KBio1_000451; L-(-)-Ephedrine; CHEMBL211456; (-)-Pseudoephedrine; Ephedrol; racephedrine; d-Ephedrine; 37577-31-4; EPHEDRINE, (+-)-; 6912-63-6; ( )-Pseudoephedrine; PDSP1_001347; Isoephedrine; BRN 3197916; IDI1_000451; NSC170951; KST-1A9168; trans-Ephedrine; AC1L1T31; (+)-Ephedrin; PDSP2_001329; BSPBio_001946; LS-63963; Lexofedrin; Sudafed Decongestant; 30987-59-8; KBio2_006636; LS-63964; 7009-81-6; KBioSS_001500; MolPort-001-684-477; CID62946; Spectrum4_001162; STOCK1N-42675; (+)-threo-Ephedrine; LS-125922; PDSP2_000167; KBio3_001446; AI3-02761; Manadrin; 45261_FLUKA; CID8650; KBio2_006494; Vencipon; EINECS 202-017-0; 968-63-8; UNII-GN83C131XS; KBio1_000181; SPBio_001365; Ephedrine, (.+/-.)-; Ephedrosan; C10H15NO; Lopac-E-3250; AKOS000268842; NCGC00015408-02; Benylin Decongestant; PDSP1_001346; Efedrin; Pseudoephedrine (D); --EPHEDRINE; CID6710657; BSPBio_003261; PDSP1_000168; CPD-9954; Myfedrine; L000968; Kratedyn; NSC 165609; Eltor 120; Ephedral; I01-8928; Ephedrine, L-(-)-; Drixoral N.D.; EINECS 202-018-6; Pseudo; NSC8971; (+)-Ephedrine; DB01364; Ephedrine l-form; HSDB 3072; Spectrum3_001771; IDI1_000461; DB00852; KBio2_001500; D08449; ST023802; Ephedrine (TN); PDSP1_001343; Ephedrine; 53214-57-6; Pedia Care; UNII-7CUC9DDI9F; D00124; (+)-psi-Ephedrine; (L)-EPHEDRINE; Neodurasina; Neodurasina (TN); AC1L1SR1; IDI1_000181; PDSP2_001331; Genaphed; 1-EPHEDRINE; NCI60_002955; 90-82-4; Ambap299-42-3; 649031_ALDRICH; NSC 170951; (+-)-Ephedrine; 321-96-0; AC1L1RFA; CID5032; SPBio_000214; Psi-ephedrine; CID7028; Spectrum5_000650; NSC 8971; L(+)-psi-Ephedrine; MolPort-001-684-474	299-42-3	9294	10517637	TTDS00026	Alpha adrenergic receptor	Alpha-adrenoceptor	N/A	N/A	N/A	agonist
DAP000412	Droperidol	CHEBI:4717; Dridol; luorophenyl)-4-oxobutyl]-1,2,3,6-tetrahydro-4-pyridyl]-2-benzimidazolinone; 1-1-[3-(p-Fluorobenzoyl)propyl]-1,2,3,6-tetrahydro-4-pyridyl-2-benzimidazolinone; 2-Benzimidazolinone, 1-[1-[3-(p-fluorobenz; McN-JR 4749; Spectrum4_000407; CCRIS 9070; NCGC00094884-02; 2H-Benzimidazol-2-one, 1-[1-[4-(4-fluorophenyl)-4-oxobutyl]-1,2,3,6-tetrahydro-4-pyridinyl]-1,3-dihydro-; SPBio_002380; component of Innovar; Sintodril; Droperidolum [INN-Latin]; Innovan; Droleptan (TN); Thalamonal; NCGC00094884-01; Ina.psi.ne; LS-33253; 5-24-02-00388 (Beilstein Handbook Reference); Inapsin; IDI1_000103; Spectrum_001220; Droperidolo [DCIT]; Spectrum3_001426; 3-[1-[4-(4-fluorophenyl)-4-oxobutyl]-3,6-dihydro-2H-pyridin-4-yl]-1H-benzimidazol-2-one; HMS1569G21; Spectrum2_001386; Inappin; BRN 0579168; droperidol; Prestwick3_000360; Halkan; SPBio_001372; NCGC00016504-01; HS-0065; Droperidol [USAN:INN:BAN:JAN]; Inapsine; INAPSINE (TN); EINECS 208-957-8; HMS500F05; 1-[1-[3-(p-Fluorobenzoyl)propyl]-1,2,3,6-tetrahydro-4-pyridyl]-2-benzimidazolinone; 1-[1-[4-(p-Fluorophenyl)-4-oxobutyl]-1,2,3,6-tetrahydro-4-pyridyl]-2-benzimidazolinone; HMS2051L06; KBio2_004268; 2H-Benzimidazol-2-one, 1-(1-(4-(4-fluorophenyl)-4-oxobutyl)-1,2,3,6-tetrahydro-4-pyridinyl)-1,3-dihydro-; WLN: T56 BMVNJ D3- DT6N CUTJ A3VR DF; Ina.psi.n; Droleptan; Inoval; NSC 169874; SPECTRUM1501002; NSC169874; NCGC00016504-02; CHEBI:252751; Innovar-vet; L001006; MLS000028671; Inopsin; D1414_SIGMA; Prestwick_705; KBio1_000103; Sintosian; 548-73-2; Dehydrobenzperidol; R4749; CHEMBL1108; ZINC19796080; MLS001148120; DHBP; MLS002153445; BPBio1_000505; HMS1921B03; KBio2_006836; 1-1-[3-(p-Fluorobenzoyl)propyl]-1,2,3,6-tetrahydro-4-pyridyl-2-benzimidazolinone; UNII-O9U0F09D5X; Vetkalm; 1-(1-(4-(p-Fluorophenyl)-4-oxobutyl)-1,2,3,6-tetrahydro-4-pyridyl)-2-benzimidazolinone; Prestwick2_000360; Ino.psi.n; Properidol; Taylor Brand of Droperidol; KBioSS_001700; 1-{1-[4-(4-fluorophenyl)-4-oxobutyl]-1,2,3,6-tetrahydropyridin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one; SAM001247013; 1-(1-(3-(p-Fluorobenzoyl)propyl)-1,2,3,6-tetrahydro-4-pyridyl)-2-benzimidazolinone; BSPBio_000459; DivK1c_000103; Deidrobenzperidolo; Leptofen; Droperidol (JP15/USP/INN); 1-(1-(4-(4-Fluorophenyl)-4-oxobutyl)-1,2,3,6-tetrahydro-4-pyridinyl)-1,3-dihydro-2H-benzimidazol-2-one; 1-[1-[3-(p-Fluorobenzoyl)propyl]-1,2,3,6-tetrahydro-4-pyridyl]-2-benzimidazolinone; 1-[1-[4-(p-F; Prestwick0_000360; 2-Benzimidazolinone, 1-(1-(3-(p-fluorobenzoyl)propyl)-1,2,3,6-tetrahydro-4-pyridyl)-; Droperidolo; 2-Benzimidazolinone, 1-[1-[3-(p-fluorobenzoyl)propyl]-1,2,3,6-tetrahydro-4-pyridyl]-; BSPBio_003132; R 4749; R-4749; D004329; Spectrum5_001305; Janssen Brand of Droperidol; Droperidolum; DB00450; NINDS_000103; I14-2728; Thalamanol; MLS000758203; KBioGR_000674; KBio3_002352; CPD000058855; SMR000058855; D00308; McN-JR-4749; HMS2092O16; AC-3537; KBio2_001700; Prestwick1_000360; CAS-548-73-2; Dehydrobenzoperidol; Dehidrobenzperidol; C22H22FN3O2; oyl)propyl]-1,2,3,6-tetrahydro-4-pyridyl]-; 2H-Benzimidazol-2-one, 1-[1-[4-(4-fluorophenyl)-4-oxobutyl]-1,2,3,6-tetrahydro-4-pyridinyl]-1,3-dihydro-; AC1L1FBQ; Leptanal; HSDB 3320; Dihidrobenzperidol; Kern Brand of Droperidol; CID3168; BRD-K97158071-001-05-8	548-73-2	3168	9188	TTDS00026	Alpha adrenergic receptor	Alpha-adrenoceptor	N/A	N/A	N/A	binder
DAP000195	Pseudoephedrine	psi-Ephedrine, (+)-; Sudafed; Pseudo 60's; Triaminic AM Decongestant Formula; C02765; Pseudoephedrine, (+)-; KBioGR_001763; Spectrum2_001303; Sudafed Decongestant Extra Strength; (+)-Pseudoephedrine; Acunaso (TN); BRD-K84175871-003-02-2; Spectrum_000878; CHEBI:51209; Pseudoephedrine (INN); Pseudoephedrine d-form; Pseudoephedrine Ephedrine; (+)-(1S,2S)-Pseudoephedrine; d-Isoephedrine; Psi-ephedrin; d-Pseudoephedrine; CHEMBL1590; HSDB 3177; d-psi-Ephedrine; KBio2_003926; AC1L1NUA; NCGC00178180-01; Efidac/24; PSEUDOEPHEDRINE; KBio2_001358; KBioSS_001358; (1S,2S)-Pseudoephedrine, polymer-bound; Acunaso; Dimetapp Decongestant Pediatric Drops; Pseudo-12; DivK1c_000451; Sudafed Decongestant 12 Hour; Pseudoephedrinum; Afrinol; (1S,2S)-(+)-Pseudoephedrine; BIDD:GT0817; 304-87-0; Robidrine; Benzenemethanol, alpha-((1S)-1-(methylamino)ethyl)-, (alpha-S)-; Pseudoephedrine [INN:BAN]; AC-20292; KBio3_002762; Maxenal; Besan; Pseudoephedrinum [INN-Latin]; Balminil Decongestant Syrup; Decofed; NCGC00015408-01; Pseudoefedrina; alpha-(1-(Methylamino)ethyl)benzyl alcohol; NINDS_000451; Cenafed; 287636_ALDRICH; KBio1_000451; 37577-31-4; ( )-Pseudoephedrine; Efidac 24 Pseudoephedrine Hcl; PDSP1_001347; Isoephedrine; IDI1_000451; Benzenemethanol, alpha-((1S)-1-(methylamino)ethyl)-, (alpha-S)- (9CI); trans-Ephedrine; Sudafed Decongestant; 30987-59-8; Benzenemethanol, alpha-(1-(methylamino)ethyl)-, (S-(R*,R*))-; Spectrum4_001162; STOCK1N-42675; (+)-threo-Ephedrine; LS-125922; d-psi-2-Methylamino-1-phenyl-1-propanol; KBio2_006494; SPBio_001365; C10H15NO; Benzenemethanol, alpha-((1S)-1-(methylamino)ethyl)-, (alphaS)-; Lopac-E-3250; Benylin Decongestant; L-(+)-Pseudoephedrine; Pseudoephedrine (D); BSPBio_003261; CPD-9954; Myfedrine; Eltor 120; (1S,2S)-2-Methylamino-1-phenyl-1-propanol; I01-8928; Drixoral N.D.; EINECS 202-018-6; Pseudo; Pseudoephedrine, L-(+)-; Spectrum3_001771; DB00852; D08449; Ephedrine; Pedia Care; UNII-7CUC9DDI9F; (+)-psi-Ephedrine; Neodurasina; Neodurasina (TN); Dimetapp Decongestant; Drixoral Nasal Decongestant; Triaminic Infant Oral Decongestant Drops; Pseudoefedrina [INN-Spanish]; Genaphed; (1S,2S)-Pseudoephedrine; NCI60_002955; 90-82-4; 649031_ALDRICH; Psi-ephedrine; CID7028; (1S,2S)-2-(methylamino)-1-phenylpropan-1-ol; Spectrum5_000650; L(+)-psi-Ephedrine; MolPort-001-684-474	90-82-4	7028	150051	TTDS00026	Alpha adrenergic receptor	Alpha-adrenoceptor	N/A	N/A	N/A	stimulator
DAP000224	Phenylephrine	Relief Eye Drops for Red Eyes; phenylephrine; AI3-02402; L-Phenylephedrine; Isophrin; I-Phrine; CHEBI:8093; AC1Q40UF; Alcon Efrin; Phenylephrine (INN); Benzyl alcohol, m-hydroxy-alpha-((methylamino)methyl)-, (-)-; NCGC00024257-06; m-Synephrine; Isophrim; m-Methylaminoethanolphenol; NCGC00015825-01; KBio3_001640; Mesatonum; (R)-3-Hydroxy-alpha-((methylamino)methyl)benzenemethanol; PDSP2_001092; Ak-nefrin; UNII-1WS297W6MV; Neosynephrine; Mezaton; Spersaphrine; Phenylephrinum [INN-Latin]; Mesatone; Isopto Frin; l-alpha-Hydroxy-beta-methylamino-3-hydroxy-L-ethylbenzene; Cyclomydril; SPBio_001280; Spectrum2_001280; Prefrin Liquifilm; 59-42-7; Spectrum4_000967; Neofrin; Phenylephrine Minims (TN); Phenylephrine, l-; NCGC00015825-02; 61-76-7 (hydrochloride); CCRIS 8464; Metsatonum; m-Sympatol; KBio1_000597; NCGC00024257-03; D08365; Metaoxedrin; Phenylephrinum; MolPort-001-792-191; NINDS_000597; Nostril Spray Pump; Ocu-Phrin Sterile Eye Drops; P0395; Phenoptic; PDSP1_001108; (-)-m-Hydroxy-alpha-(methylaminomethyl)benzyl alcohol; Nostril Spray Pump Mild; Alconefrin Nasal Drops 25; Spectrum3_000770; Minims Phenylephrine; Metasynephrine; Mydfrin; Ocugestrin; 3-[(1R)-1-hydroxy-2-(methylamino)ethyl]phenol; Alconefrin Nasal Drops 12; Ah-Chew; Visadron; Alconefrin Nasal Spray 25; Benzenemethanol, 3-hydroxy-alpha-((methylamino)methyl)-, (R)- (9CI); L-Phenylephrine; (R)-2-Hydroxy-2-(3-hydroxyphenyl)-N-methylethylamine; Duration; AC1L1LO9; BSPBio_002420; Spectrum5_001411; Dionephrine; m-Sympathol; KBioGR_001313; Metaoxedrine; HSDB 3383; Lopac0_000920; EINECS 200-424-8; Doktors; l-1-(m-Hydroxyphenyl)-2-methylaminoethanol; Tannins, compds. with (R)-3-hydroxy-alpha-((methylamino)methyl)benzenemethanol; l-m-Hydroxy-alpha-((methylamino)methyl)benzyl alcohol; Phenylephrine [INN:BAN]; DB00388; BIDD:GT0157; Metasympatol; Fenilefrina; Mesaton; Fenilefrina [INN-Spanish]; Benzenemethanol, 3-hydroxy-alpha-((methylamino)methyl)-, (R)-; R(-)-Phenylephrine; CHEMBL1215; m-Oxedrine; LS-43027; Neo-Synephrine; KBioSS_001581; Ak-dilate; l-(3-Hydroxyphenyl)-N-methylethanolamine; Dilatair; KBio2_006717; Metaoxedrinum; Phenylephrine Minims; C07441; Nostril; Neo-Synephrine Nasal Jelly; EINECS 215-810-1; Spectrum_001101; CID6041; IDI1_000597; DivK1c_000597; Neo-Synephrine Nasal Drops; Lopac-P-6126; KBio2_004149; KBio2_001581; NCGC00024257-05; Neo-Synephrine Nasal Spray; 1416-03-1; Alconefrin Nasal Drops 50	59-42-7	6041	9645	TTDS00026	Alpha adrenergic receptor	Alpha-adrenoceptor	N/A	N/A	N/A	agonist
DAP000059	Guanadrel Sulfate	HSDB 6536; Hylorel (TN); U 28,288D; CID68552; (1,4-Dioxaspiro(4.5)dec-2-ylmethyl)guanidine sulfate (2:1); Guanadrel sulfate (USP); 2C10H19N3O2.H2O4S; LS-173930; Hyloride; 40580-59-4 (Parent); CL-1388R; 22195-34-2; Guanadrel sulfate; CL 1388R; 2-(1,4-dioxaspiro[4.5]decan-3-ylmethyl)guanidine; sulfuric acid; Guanadrel sulfate [USAN]; HMS1570I16; U 28288D; guanadrel sulfate (2:1); Guanidine (1,4-dioxaspiro(4.5)dec-2-ylmethyl)-, sulfate (2:1); Hylorel; AC1L29ZD; UNII-MT147RMO91; D00607; U-28288D	22195-34-2	38521	179728	TTDS00026	Alpha adrenergic receptor	Alpha-adrenoceptor	N/A	N/A	N/A	antagonist
DAP000299	Phentolamine	Phentolaminum [INN-Latin]; MLS001201741; Prestwick2_000230; KBioGR_001338; 2-(N-(m-Hydroxyphenyl)-p-toluidinomethyl)imidazoline; Regitipe; AC1Q2KIW; BRD-K90333595-001-02-8; BSPBio_001435; Prestwick1_000230; D08362; BRN 0272944; 3-[N-(4,5-dihydro-1H-imidazol-2-ylmethyl)-4-methylanilino]phenol; 3-[(4,5-dihydro-1H-imidazol-2-ylmethyl)(4-methylphenyl)amino]phenol; NCGC00016311-01; UNII-Z468598HBV; AKOS004119917; Phentolamine (INN); DB00692; 5-25-09-00365 (Beilstein Handbook Reference); IDI1_000807; NCGC00021804-10; MLS000040874; 73-05-2 (mono-hydrochloride); SMR000058051; Phentalamine; C 7337; 2-((N-(m-Hydroxyphenyl)-p-toluidino)methyl)-2-imidazoline; Regitin; Regitine; HMS1989H17; DivK1c_000807; C17H19N3O; Rogitine; Spectrum5_001704; BSPBio_000279; HSDB 3382; C 7337 Ciba; Phentolamine mesylate [USAN]; Spectrum4_000899; Phenol, 3-[[(4,5-dihydro-1H-imidazol-2-yl)methyl](4-methylphenyl)amino]-; Spectrum3_000788; 2-Imidazoline, 2-((N-(m-hydroxyphenyl)-p-toluidino)methyl)-; KBio1_000807; Phentolamine methanesulfonate; BPBio1_000307; nchembio705-6; Spectrum_000077; KBio2_003045; CID5775; NCGC00021804-08; CAS-73-05-2; 65-28-1 (mesylate (salt)); HMS2089E03; Phentolamine, methyl sulfonate; NCGC00016311-15; Prestwick0_000230; L001116; NCGC00016311-03; Fentolamina; LS-104396; Phenol, m-(N-(2-imidazolin-2-ylmethyl)-p-toluidino)-; Phenotolamine; AC1L1L3Z; HMS1791H17; KBio2_000477; STK802099; KBioSS_000477; BSPBio_002496; CHEMBL597; NCGC00021804-06; Phentolaminum; SPBio_002200; 2-(m-Hydroxy-N-p-tolylanilinomethyl)-2-imidazoline; CHEBI:120131; KBio2_005613; NCGC00021804-09; Phentolamine [INN:BAN]; BRD-K90333595-003-04-0; phentolamine; KBio3_001716; SMP1_000236; NINDS_000807; Phenol, 3-(((4,5-dihydro-1H-imidazol-2-yl)methyl)(4-methylphenyl)amino)-; Dibasin; STOCK4S-00358; EINECS 200-053-1; 50-60-2; Prestwick3_000230; MolPort-001-783-569; NCGC00016311-02; NCGC00021804-07; Lopac0_000982; Regityn; BCBcMAP01_000014; Fentolamina [INN-Spanish]; Fentolamin; 2-(N'-p-Tolyl-N'-m-hydroxyphenylaminomethyl)-2-imidazoline	50-60-2	5775	148562	TTDS00026	Alpha adrenergic receptor	Alpha-adrenoceptor	N/A	N/A	N/A	antagonist
DAP000078	Dihydroergotamine	NCGC00017400-06; CHEMBL1732; Ergotaman-3',6',18-trione, 9,10-dihydro-12'-hydroxy-2'-methyl-5'-(phenylmethyl)-, (5'alpha,10alpha)-; BRD-K72166146-066-02-1; Ergomimet; Orstanorm; Angionorm; Dihidroergotamina; IDI1_000592; Morena; Ergont; LS-64563; (10alphaH)-5'alpha-benzyl-12'-hydroxy-2'-methyl-3',6',18-trioxo-9,10-dihydroergotaman; Co-Dergocrine; Spectrum3_000395; BRN 5720196; Ergoloid dihydroergotoxine; DET MS; Ergoloid Mesylates (dihydroergotoxine); DivK1c_000592; Diergo; SPBio_001235; CHEBI:4562; Agit; Dihydroergotoxin; Ambotz511-12-6; DIHYDROERGOTOXINE; 9,10-dihydro-ergotamine; KBio2_006673; Diidroergotamina; KBio2_004105; CID10531; dihydroergotamine; Ergotamine, 9,10-dihydro-; BSPBio_002209; Dihydroergotamine methanesulfonate; KBio2_001537; UNII-436O5HM03C; Dergotamine; DB00320; Verladyn; D.H.E.; 9,10-Dihydro-12'-hydroxy-2'-methyl-5'-(phenylmethyl)ergotoman-3',6',18-trione; KBioSS_001537; D07837; NINDS_000592; KBio1_000592; KBio3_001429; Ergotonin; LS-61979; Spectrum_001057; Ergot Alkaloids, Hydrogenated; Dihidroergotamina [INN-Spanish]; DHE-45; 9,10-Dihydroergotamine; Neomigran; 6190-39-2 (mesylate); Migranal; Dihydroergotaminum; Spectrum5_000905; CHEBI:658566; KBioGR_001576; Dihydroergotamine (INN); Tonopres; (5'alpha)-12'-Hydroxy-2'-methyl-5'-(phenylmethyl)ergotoman-3',6',18-trione; Dirgotarl; Spectrum4_000958; Dihydergot; Neomigran (TN); Diidroergotamina [DCIT]; C07798; Spectrum2_001188; (5'alpha)-5'-benzyl-12'-hydroxy-2'-methyl-3',6',18-trioxoergotaman; Dehydroergotamine; EINECS 208-123-3; C33H37N5O5; Dihydroergotaminum [INN-Latin]; Seglor; Endophleban; Ergotoxine, dihydro-; Lopac0_000357; 5'-Benzyl-12'-hydroxy-2'-methyl-3',6',18-trioxo-9,10-dihydroergotaman; AC1L1VEA; 511-12-6; Ikaran; BIDD:GT0120	6190-39-2	10531	153817	TTDS00026	Alpha adrenergic receptor	Alpha-adrenoceptor	N/A	N/A	N/A	agonist
DAP000227	Ergonovine	Ergometrin; Ergometrine; Ergometrine (INN); C19H23N3O2; Secometrin; 9,10-Didehydro-N-(alpha-(hydroxymethyl)ethyl)-6-methylergoline-8-beta-carboxamide; C07543; DB01253; N-[(2S)-1-hydroxypropan-2-yl]-6-methyl-9,10-didehydroergoline-8beta-carboxamide; 78207-83-7; 11002-48-5; UNII-WH41D8433D; Ergotrate Maleate; 60-79-7; MolPort-004-955-259; Secacornin; [8beta(S)]-9,10-didehydro-N-(2-hydroxy-1-methylethyl)-6-methylergoline-8-carboxamide; Margonovine; ST057158; CHEMBL119443; Ergotocine; Ergobasine; Lysergamide, N-((S)-2-hydroxy-1-methylethyl)-; Ergoline-8-beta-carboxamide, 9,10-didehydro-N-((S)-2-hydroxy-1-methylethyl)-6-methyl-; Basergin; HSDB 4075; AC1L9FE0; Lysergic acid propanolamide; ERGONOVINE; SMP1_000118; Ergometrinum [INN-Latin]; Ergoline-8-carboxamide, 9,10-didehydro-N-(2-hydroxy-1-methylethyl)-6-methyl-, (8beta(S))-; N-(2-Hydroxy-1-methylethyl)-D(+)-lysergamide; Neofemergen; D-Lysergic acid 1-hydroxymethylethylamide; Ergotrate; CID443884; EINECS 200-485-0; Ergometrine [INN:BAN]; CHEBI:4822; Ergoklinine; L-Lysergic-L(beta-hydroxyisopropylamide); D07905; Ergometrinum; N-(1-(Hydroxymethyl)ethyl)-D-lysergamide; D-Lysergic acid-L-propanolamide; Ergobasin; 9,10-Didehydro-N-(2-hydroxy-1-methylethyl)-6-methylergoline-8beta(S)-carboxamide; Ergostetrine; Ergometrina [INN-Spanish]; Ergometrina; LS-64359; N-(alpha-(Hydroxymethyl)ethyl)-D-lysergamide	60-79-7	443884	148957	TTDS00026	Alpha adrenergic receptor	Alpha-adrenoceptor	N/A	N/A	N/A	agonist
DAP000897	Bevantolol	CI-775; BRN 2769444; 1-((2-(3,4-dimethoxyphenyl)ethyl)amino)- 3-(3-methylphenoxy)-2-propanol; Bevantololum [INN-Latin]; Bevantolol; CHEMBL314010; UNII-34ZXW6ZV21; 1-(3,4-dimethoxyphenethylamino)-3-m-tolyloxy-propan-2-ol; 1-(3,4-Dimethoxyphenethylamino)-3-(m-tolyloxy)-2-propanol; CI 775; 1-{[2-(3,4-dimethoxyphenyl)ethyl]amino}-3-(3-methylphenoxy)propan-2-ol; LS-122167; 2-Propanol, 1-((2-(3,4-dimethoxyphenyl)ethyl)amino)-3-(3-methylphenoxy)-; 1-((2-(3,4-Dimethoxyphenyl)ethyl)amino)-3-(3-methylphenoxy)-2-propanol; Bevantolol [INN:BAN]; L013370; 59170-23-9; DB01295; AC1L1DJ8; (+-)-bevantolol; C20H27NO4; NSC132348; 1-[2-(3,4-dimethoxyphenyl)ethylamino]-3-(3-methylphenoxy)propan-2-ol; CHEBI:238698; CID2372; Bevantololum; MolPort-005-942-286; 42864-78-8 (hydrochloride); 1-[2-(3,4-Dimethoxy-phenyl)-ethylamino]-3-m-tolyloxy-propan-2-ol	59170-23-9	2372	14952538	TTDS00026	Alpha adrenergic receptor	Alpha-adrenoceptor	N/A	N/A	N/A	antagonist
DAP000478	Phenoxybenzamine	Bensylyt; Benzylyt; Lopac0_000235; DB00925; phenoxybenzamine; D08358; Bio2_000479; BSPBio_000908; BPBio1_001000; Benzenemethanamine, N-(2-chloroethyl)-N-(1-methyl-2-phenoxyethyl)-; HSDB 4005; BSPBio_002356; NCGC00089748-07; IDI1_002234; KBioSS_000618; Dibenylene; Prestwick1_000944; Dibenylin; Bio2_000959; 688A; EINECS 200-446-8; BRN 2129697; Fenossibenzamina [DCIT]; KBio3_001096; NINDS_000800; AB00053702; 4-12-00-02204 (Beilstein Handbook Reference); Benzylamine, N-(2-chloroethyl)-N-(1-methyl-2-phenoxyethyl)-; SPBio_003067; KBio1_000800; KBio3_001095; 2-(N-Benzyl-2-chloroethylamino)-1-phenoxypropane; AC-13214; KBio2_003426; HMS1990P19; A 688; KBio2_003186; Dibenzyran; Phenoxybenzaminum; POB HCl; HMS1792P19; NCGC00089748-04; Prestwick3_000944; KBioSS_000858; Phenoxybenzamine [INN:BAN]; CID4768; IDI1_000800; AC1L1IWT; N-(2-chloroethyl)-N-(phenylmethyl)-1-(phenyloxy)propan-2-amine; 63-92-3 (hydrochloride); BSPBio_001278; Prestwick0_000944; Fenoxibenzamina; KBio2_005994; Phenoxybenzaminum [INN-Latin]; CHEMBL753; MolPort-001-785-595; UNII-0TTZ664R7Z; LS-43286; SPBio_001829; Spectrum_000378; Spectrum5_001370; HMS1362P19; Bensylyte; Spectrum2_001815; KBioGR_001158; 102737-84-8; KBioGR_000618; Dibenzylene; Phenoxybenzamine Hcl; HMS2089J09; Fenossibenzamina; NCGC00089748-03; NCGC00089748-05; Fenoxibenzamina [INN-Spanish]; NSC 37448; Dibenzylin; N-(2-Chloroethyl)-N-(1-methyl-2-phenoxyethyl)benzylamine; C07435; CHEBI:141434; Prestwick2_000944; Benzyl(2-chloroethyl)-(1-methyl-2-phenoxyethyl)amine; N-(2-Chloroethyl)-N-(1-methyl-2-phenoxyethyl)benzenemethanamine; KBio2_000618; Spectrum4_000769; CCRIS 505; Bensylyt NEN; KBio2_005754; DivK1c_000800; N-benzyl-N-(2-chloroethyl)-1-phenoxypropan-2-amine; Dibenyline; 59-96-1; L001197; Phenoxybenzamine (INN); N-Phenoxyisopropyl-N-benzyl-beta-chloroethylamine; KBio2_000858; NCGC00015121-11; Dibenziran	59-96-1	4768	9639	TTDS00026	Alpha adrenergic receptor	Alpha-adrenoceptor	N/A	N/A	N/A	antagonist
DAP000226	Methyldopa	Sembrina; (2S)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid; EINECS 209-089-2; Medopa; Methyldopa (INN); L(-)-beta-(3,4-Dihydroxyphenyl)-alpha-methylalanine; Prestwick2_000326; Novomedopa; KBio3_001521; HMS1920N09; alpha-Methyl dopa; Baypresol; AC1Q29EL; AC-11671; Medopal; Medomet; EU-0100853; Aldometil; MK-351; Methyldopa; alpha-Methyl-beta-(3,4-dihydroxyphenyl)-L-alanine; 3-(3,4-DIHYDROXYPHENYL)-2-METHYL-L-ALANINE; KBio2_006553; NCGC00024667-03; CHEMBL459; Dopatec; Dopegyt; Hyperpax; MolPort-001-792-485; S1642_Selleck; IDI1_000142; LS-216; MK-351; Alpha medopa; SPECTRUM1500403; KBioGR_000547; Methyl-L-dopa; L-alpha-Methyl-3,4-dihydroxyphenylalanine; HMS500H04; HMS1569A13; NCGC00024667-02; Prestwick0_000326; (S)-(-)-alpha-Methyldopa; 1339-75-9; l-3-(3,4-Dihydroxyphenyl)-2-methylalanine; Nu-Medopa; 133161-54-3; Methyldopa (L,-); BSPBio_002021; NCGC00024667-08; Alanine, 3-(3,4-dihydroxyphenyl)-2-methyl-, L-(-)-; Spectrum4_000054; KBio1_000142; alpha-Methyldopa; Spectrum5_001295; NCGC00024667-06; NSC 169916; Grospisk; NINDS_000142; HMS2091F04; METHYL DOPA (SEE ALSO METHYL DOPA SESQUIHYDRATE); Nr.C 2294; Dopamethyperpax; Presinol; L-alpha-Methyl DOPA; Methyldopa (anhydrous); CCRIS 4671; KBio2_001417; Dopegit; 555-30-6; Lopac0_000853; HSDB 218; Sedometil; Spectrum2_001068; Prestwick_732; SPBio_001056; NSC169916; KBioSS_001417; SPBio_002252; HMS2090B11; Methoplain; levo-3-(3,4-Dihydroxyphenyl)-2-methylalanine; alpha-Methyl-L-3,4-dihydroxyphenylalanine; Methyldopum; Aldomet; NCI-C55721; L-(alpha-Md); Aldoril D50; L-2-Amino-2-methyl-3-(3,4-dihydroxyphenyl)propionic acid; MLS000028644; Becanta; Spectrum3_000501; Medopren; DivK1c_000142; L-Methyl Dopa; AMD; 779-08-8; DB00968; CID38853; Hypolag; L-Tyrosine, 3-hydroxy-alpha-methyl-; Alphamethyldopa; NCGC00024667-05; C07194; Methyldopum [INN-Latin]; LT00847269; AC1L20K1; BIDD:GT0620; alpha-Methyldopa (VAN); L-(-)-3-(3,4-Dihydroxyphenyl)-2-methylalanine; 3-Hydroxy-alpha-methyl-L-tyrosine; Presolisin; D08205; Prestwick1_000326; l-alpha-Methyldopa; UNII-56LH93261Y; 3-Hydroxy-.alpha.-methyl-L-tyrosine; Dopamet; Aldomet (TN); alpha-Methyldihydroxyphenylalanine; 4290-08-8; L-Methyldopa; Methyldopa anhydrous; (-)-3-(3,4-Dihydroxyphenyl)-2-Methyl-L-Alanine Sesqui-Hydrate; Mk. b51; Methyl dopa; AC1Q29EM; L-(-)-alpha-Methyl-beta-(3,4-dihydroxyphenyl)alanine; Prestwick3_000326; Metildopa [INN-Spanish]; Dopergit; methyldopa; Aldomin; NCGC00024667-01; Tocris-0584; Aldoril D30; Bayer 1440 L; Metildopa; Apo-Methyldopa; KBio2_003985; BPBio1_000365; MK 351; Aldoril, Dopamet, Dopegyt, Methyldopa; BSPBio_000331; Spectrum_000937; CHEBI:61058; SMR000059170	555-30-6	38853	9403	TTDS00026	Alpha adrenergic receptor	Alpha-adrenoceptor	N/A	N/A	N/A	agonist
DAP000298	Dapiprazole	Dapiprazole [INN]; DB00298; 3-{2-[4-(2-methylphenyl)piperazin-1-yl]ethyl}-5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyridine; CHEBI:51066; Dapiprazole; UNII-DS9UJN1I0X; Dapiprazol; Dapirazol; Dapirazolum; Rev-Eyes; 3-(2-(4-(2-methylphenyl)-1-piperazinyl)ethyl)-5,6,7,8,-tetrahydro-1,2,4-triazolo(4,3-a)pyridine hydrochloride; Dapirazolum [INN-Latin]; Reversil; Dapiprazole (INN); Dapiprazol [German]; Remydrial; Glamidolo; dapiprazolum; CID3033538; 3-[2-[4-(2-methylphenyl)piperazin-1-yl]ethyl]-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyridine; 72822-12-9; 1,2,4-Triazolo(4,3-a)pyridine, 5,6,7,8-tetrahydro-3-(2-(4-(2-methylphenyl)-1-piperazinyl)ethyl)-; C19H27N5; LS-156734; AC1MHVUH; D07775; s-Triazolo(4,3-a)pyridine, 5,6,7,8-tetrahydro-3-(2-(4-(o-tolyl)-1-piperazinyl)ethyl)-,hydrochloride; Dapirazol [INN-Spanish]; L000681; 5,6,7,8-Tetrahydro-3-(2-(4-(o-tolyl)-1-piperazinyl)ethyl)-s-triazolo(4,3-a)pyridine	72822-12-9	3033538	189873	TTDS00026	Alpha adrenergic receptor	Alpha-adrenoceptor	N/A	N/A	N/A	antagonist
DAP000898	Mephentermine	Wyfentermina; Wyamine; EINECS 202-901-6; BRN 1363850; Mephenterdrinum; Mefentermin; 2-Methyl-2-methylamino-1-phenylpropane; Mephetedrine; Spectrum4_000188; Mephentermine [INN:BAN]; CAS-1212-72-2; KBio2_002091; Mefentermina; SPBio_000608; Vialin; HSDB 2172; Benzeneethanamine, N,.alpha.,.alpha.-trimethyl-; Spectrum3_001220; BSPBio_002640; KBioGR_000735; N-Methyl-omega-phenyl-tert-butylamine; NCGC00016570-03; WY-585; Mefenterdrin; N-Methyl-omega-phenyl-t-butylamine; N-Methylphentermine; N,2-dimethyl-1-phenylpropan-2-amine; KBio2_007227; NINDS_000229; 2-Methylamino-2-methyl-1-phenylpropane; KBio3_002140; SPBio_002591; LS-103737; Spectrum_001611; DivK1c_000229; AC1L1GGT; Prestwick0_000726; Prestwick3_000726; Spectrum2_000474; Mephenterminum [INN-Latin]; Prestwick1_000726; NCGC00016570-01; 100-92-5; C07889; Benzeneethanamine, N,alpha,alpha-trimethyl-; omega-Phenyl-tert-butyl-methylamine; Mephine; KBio1_000229; Mephentermine (INN); Mephenterminum; BSPBio_000652; ST075547; MEPHENTERMINE; Mefentermina [INN-Spanish]; AB00053662; Mephenterdrine; NCGC00016570-02; DB01365; 1212-72-2 (sulfate (2:1)); KBio2_004659; Prestwick2_000726; KBioSS_002091; Mephentermine Sulfate (2:1); N,alpha,alpha-Trimethylphenethylamine; Spectrum5_001008; Phenethylamine, N,alpha,alpha-trimethyl-; BPBio1_000718; Phenethylamine, N,.alpha.,.alpha.-trimethyl-; UNII-TEZ91L71V4; CID3677; D08180; N,alpha,alpha-Trimethylbenzeneethanamine; IDI1_000229	100-92-5	3677	10091	TTDS00026	Alpha adrenergic receptor	Alpha-adrenoceptor	N/A	N/A	N/A	agonist
DCL000854	KB-6806	N/A	N/A	3052762	45292272	TTDS00106	5-hydroxytryptamine 3 receptor	5-HT-3;5-HT3 receptor;5-HT3R;5-hydroxytryptamine receptor 3;5-hydroxytryptamine receptor type 3;Serotonin-gated ion channel receptor	P46098	3359	ENSG00000166736	antagonist
DAP000295	Granisetron	CHEMBL519643; C07023; BRL-43694; 1-methyl-N-[(3-endo)-9-methyl-9-azabicyclo[3.3.1]non-3-yl]-1H-indazole-3-carboxamide; CID5284566; 109889-09-0; BIDD:GT0272; AC1NR4P1; granisetron; HMS2089P14; 1-methyl-N-[(1S,5R)-9-methyl-9-azabicyclo[3.3.1]nonan-3-yl]indazole-3-carboxamide; Granisetron (USAN/INN); D04370; MolPort-005-943-366	109889-09-0	3510	9235	TTDS00106	5-hydroxytryptamine 3 receptor	5-HT-3;5-HT3 receptor;5-HT3R;5-hydroxytryptamine receptor 3;5-hydroxytryptamine receptor type 3;Serotonin-gated ion channel receptor	P46098	3359	ENSG00000166736	antagonist
DAP000221	Ondansetron	Prestwick3_001058; STOCK4S-10990; BSPBio_001016; BPBio1_001118; BRN 3622981; DB00904; ZOFRAN IN PLASTIC CONTAINER; Zofran; DESMETHYLONDANSETRON; C07325; MolPort-001-944-253; BRD-A19736161-003-03-0; I06-0687; C18H19N3O; CPD001307702; L000456; CID4595; CBDivE_008994; Prestwick1_001058; 9-Methyl-3-(2-methyl-imidazol-1-ylmethyl)-1,2,3,9-tetrahydro-carbazol-4-one; GR38032F; AB00373674; Sandoz ondansetron; Zophren; ondansetron; Ondansetron (JAN/USP/INN); (RS)-1,2,3,9-Tetrahydro-9-methyl-3-(2-methylimidazol-1-ylmethyl)carbazol-4-one; Ratio-ondansetron; D00456; Ondansetron, (+,-)-Isomer; GR 38032; 99614-02-5; LS-51878; BAS 00717177; HMS2090H16; LS-172305; GR-38032F; 103639-04-9 (mono-hydrochloride dihydrate); Apo-ondansetron; SPBio_002938; SAM002589958; SN-307; Zofran ODT (TN); AKOS000599484; 1,2,3,9-Tetrahydro-9-methyl-3-((2-methyl-1H-imidazol-1-yl)methyl)-4H-carbazol-4-one; TimTec1_001750; CHEMBL46; ondansetron (Zofran); Zudan; NCI60_022780; 9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1H-carbazol-4-one; 108303-49-7; PHL-ondansetron; 4H-Carbazol-4-one, 1,2,3,9-tetrahydro-9-methyl-3-((2-methyl-1H-imidazol-1-yl)methyl)-; Ondansetron [USAN:INN:BAN]; Oprea1_852372; Zofran ODT; Prestwick2_001058; 9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-1,2,3,9-tetrahydro-4H-carbazol-4-one; 116002-70-1; UNII-4AF302ESOS; AC1L1IIM; PMS-ondansetron; Novo-ondansetron; GR 38032X; I06-1329; BRD-A19736161-001-01-8; Oprea1_435466; STK370548; 99614-01-4 (mono-hydrochloride); TL8006071; Prestwick0_001058	99614-02-5	4595	194568	TTDS00106	5-hydroxytryptamine 3 receptor	5-HT-3;5-HT3 receptor;5-HT3R;5-hydroxytryptamine receptor 3;5-hydroxytryptamine receptor type 3;Serotonin-gated ion channel receptor	P46098	3359	ENSG00000166736	agonist
DCL000864	Lerisetron	AC1Q4Y93; CID65997; Lerisetron; 1-benzyl-2-piperazin-1-ylbenzimidazole; UNII-Q36R82SXRG; CHEBI:188791; CHEMBL56900; AC1L24E5; 143257-98-1; lerisetron[inn]	143257-98-1	65997	208055	TTDS00106	5-hydroxytryptamine 3 receptor	5-HT-3;5-HT3 receptor;5-HT3R;5-hydroxytryptamine receptor 3;5-hydroxytryptamine receptor type 3;Serotonin-gated ion channel receptor	P46098	3359	ENSG00000166736	antagonist
DCL000824	GSK372475	N/A	N/A	N/A	N/A	TTDS00172	Serotonin re-uptake	Serotonin reuptake	N/A	N/A	N/A	inhibitor
DAP000864	Amitriptyline	Oprea1_479304; NCGC00024433-04; PDSP2_001548; 5-(gamma-Dimethylaminopropylidine)-5H-dibenzo(a,d)(1,4)cycloheptadiene; Amitriptylin; Laroxil; 3-(10,11-dihydro-5H-dibenzo[a,d][7]annulen-5-ylidene)-N,N-dimethylpropan-1-amine; NCGC00015095-02; CAS-549-18-8; Amitriptyline [INN:BAN]; Sylvemid; BRN 2217885; CID2160; Amitriptylin [German]; Triptilin; L001041; 5-(3-Dimethylaminopropylidene)-5H-dibenzo[a,d]-10,11-dihydrocycloheptene; Flavyl; DB00321; KBio2_002261; LS-60747; NCGC00015095-03; AKOS000512694; Amitriptilina [INN-Spanish]; Lopac0_000112; N 750; Adepress; Amitriprolidine; 5-(gamma-Dimethylaminopropylidene)-5H-dibenzo[a,d]10,11-dihydrocycloheptene; Prestwick1_000074; Amitriptylinum [INN-Latin]; Amitryptyline; Sarotex; AB00514631; BSPBio_000287; PDSP1_001564; STK525215; NINDS_000766; EINECS 200-041-6; KBio2_005560; STOCK1S-56825; KBio3_001336; Laroxyl; Spectrum4_000146; Amitriptylinum; Prestwick2_000074; Lopac-A-8404; 3-(10,11-Dihydro-5H-dibenzo(a,d)cyclohepten-5-yliden)-N,N-dimethylpropylamin; 5-(3-Dimethylaminopropylidene)-10,11-dihydro-5H-dibenzo(a,d)cycloheptatriene; Amitriptyline (INN); CHEBI:2666; NCGC00015095-01; BPBio1_000317; Elavil; Lantron; SPBio_002208; D07448; Triptisol; 30227-34-0 (maleate (1:1)); UNII-1806D8D52K; NSC169910; KBioSS_000424; MolPort-001-662-651; 17086-03-2 (pamoate (2:1)); KBioGR_000592; Elanil; Amytriptiline; Damilan; TP0; IDI1_000766; Spectrum_000044; Tryptanol; 5-(gamma-Dimethylaminopropylidene)-5H-dibenzo(a,d)(1,4)cycloheptadiene; Damilen; Laroxyl (TN); Spectrum3_000298; Amitryptiline; 5-(3'-Dimethylaminopropylidene)-dibenzo-[a,d][1,4]-cycloheptadiene; KBio2_002992; 5-(gamma-Dimethylaminopropylidene)-5H-Dibenzo[a,d][1,4]cycloheptadiene; 10,11-dihydro-5-(gamma-dimethylaminopropylidene)-5H-dibenzo[a,d]cycloheptene; KBioSS_002262; KBio1_000766; CHEMBL629; amitriptyline; AC1L1D20; CCRIS 9174; DivK1c_000766; 10,11-Dihydro-5-(gamma-dimethylaminopropylidene)-5H-dibenzo(a,d)cycloheptene; C06824; Amitriptilina; Amytriptylin; BIDD:GT0115; Spectrum5_000806; KBio2_004829; Amitriptilina [Italian]; 50-48-6; Amitril; KBioGR_002261; MK 230; 5-(3-dimethylaminopropylidene)dibenzo[a,d][1,4]-cycloheptadiene; Spectrum2_000101; Seroten; [3-(10,11-Dihydro-dibenzo[a,d]cyclohepten-5-ylidene)-propyl]-dimethyl-amine; Prestwick0_000074; SPBio_000082; BAS 00269727; Triptanol; BSPBio_001836; KBio3_002741; 10,11-Dihydro-N,N-dimethyl-5H-dibenzo(a,d)heptalene-delta(5),gamma-propylamine; 5-(3'-Dimethylaminopropylidene)-dibenzo-(a,d)(1,4)-cycloheptadiene; Redomex; Damitriptyline; KBio2_007397; Adepril; Ro 4-1575; Proheptadiene; KBio2_000424; BRD-K53737926-003-05-4; 5-(gamma-Dimethylaminopropylidene)-10,11-dihydro-5H-dibenzo(a,d)cycloheptene; 549-18-8 (hydrochloride); cMAP_000001; 5-(3-Dimethylaminopropylidene)-10,11-dihydro-5H-dibenzo(a,d)cycloheptene; Prestwick3_000074; NCGC00015095-10	50-48-6	2160	9042	TTDS00172	Serotonin re-uptake	Serotonin reuptake	N/A	N/A	N/A	inhibitor
DAP000741	Escitalopram	BSPBio_002644; KBio3_001864; (1S)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile; NCGC00178555-01; Escitalopram [INN]; NCGC00025160-01; BIDD:PXR0135; DB01175; KBioGR_001644; Spectrum2_000551; KBio2_007017; CHEBI:36791; KBio2_004449; Esertia; 5-Isobenzofurancarbonitrile, 1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydro-, (1S)-; Escitalopram (INN); D07913; Esertia (TN); NCGC00015267-02; Spectrum3_001062; SPBio_000621; Spectrum5_001693; CHEMBL1508; 128196-01-0; KBioSS_001881; Tocris-1427; CID146570; KBio2_001881; BRD-K70301876-034-02-0; (S)-Citalopram; AC1L3TGW; Spectrum4_001212; HMS2089O08; NCGC00015267-01; Spectrum_001401; Lopac-C-7861; LS-183517; UNII-4O4S742ANY; Escitalopram; (1S)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3H-2-benzofuran-5-carbonitrile; (+)-(S)-1-(3-(Dimethylamino)propyl)-1-(p-fluorophenyl)-5-phthalancarbonitrile; S(+)-Citalopram	128196-01-0	146570	724297	TTDS00172	Serotonin re-uptake	Serotonin reuptake	N/A	N/A	N/A	inhibitor
DAP001341	(S)-Duloxetine	PDSP2_001369; PDSP2_000953; 116539-59-4; (S)-N-Methyl-gamma-(1-naphthalenyloxy)-2-thiophenepropanamine; (3S)-N-methyl-3-(1-naphthyloxy)-3-(2-thienyl)propan-1-amine; LS-172322; SAM001247059; Cymbalta; CHEBI:36795; AC-15704; PDSP1_001385; NCGC00164559-01; MolPort-003-847-038; CID60835; HSDB 7368; 2-Thiophenepropanamine, N-methyl-gamma-(1-naphthalenyloxy)-, (S)-; Yentreve (TN); Duloxetine [INN:BAN]; HMS2051I05; MLS001423946; (3S)-N-methyl-3-naphthalen-1-yloxy-3-thiophen-2-ylpropan-1-amine; CHEMBL1175; (S)-Duloxetine; MLS000758267; CPD000449282; (3S)-N-methyl-3-(naphthalen-1-yloxy)-3-(2-thienyl)propan-1-amine; C18H19NOS; Yentreve; AC1L1U0Q; Duloxetine (INN); AC1Q57H7; UNII-O5TNM5N07U; duloxetine; LY 248686; 2-Thiophenepropanamine, N-methyl-gamma-(1-naphthalenyloxy)-, (gammaS)-; D07880; DB00476; PDSP1_000969; SMR000449282; duloxetine, (+)-isomer	116539-58-3	60835	50064210	TTDS00172	Serotonin re-uptake	Serotonin reuptake	N/A	N/A	N/A	inhibitor
DAP000463	Paroxetine	KBio1_001828; 110429-35-1; C07415; KBio2_002232; NCGC00025355-07; Spectrum_001752; Paroxetine (TN); KBio2_007368; (-)-trans-4-(4-Fluorophenyl)-3-(3,4-methylenedioxyphenoxymethyl)piperidine; HMS2090H05; D02362; (-)-trans-4-(p-fluorophenyl)-3-[[3,4-(methylenedioxy)phenoxy]methyl]-piperidine; MolPort-003-849-791; CHEBI:7936; Paxil; 61869-08-7; PaxPar; Casbol; piperidine, 3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-, (3S,4R)-; 78246-49-8 (hydrochloride); Piperidine, 3-((1,3-benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)-, (3S,4R)-; (-)-Paroxetine; Paroxetina; BRD-K37991163-003-02-7; AC1Q4LV6; (-)-(3S,4R)-4-(p-Fluorophenyl)-3-((3,4-methylenedioxy)phenoxy)methyl)piperidine; Paroxetine [USAN:INN:BAN]; 3-(Benzo[1,3]Dioxol-5-Yl-Oxymethyl)-4-(4-Fluoro-Phenyl)-Piperidine Hydrochloride; TL8003967; I14-7752; LS-114249; Motivan; Piperidine, 3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-, (3S-trans)-; [3H]Paroxetine; AC1L2AKL; BPBio1_000949; BSPBio_000861; NCGC00025355-03; Aropax; Paroxetinum [INN-Latin]; AB00514724; NCGC00025355-08; BRL-29060; DB00715; Seroxat CR; FG 7051; (-)-(3S,4R)-4-(p-Fluorophenyl)-3-((3,4-(methylenedioxy)phenoxy)methyl)piperidine; NNC-20-7051; Paxetil; DivK1c_006884; AC1Q1H18; Paroxetinum; (3S-trans)-3-[(1,3-Benzodioxol-5-yl-oxy)methyl]-4-(4-fluorophenyl)piperidine; BRL 29060; NCGC00025355-02; Frosinor; NCGC00025355-06; KBioSS_002232; FG-7051; Paroxetine (USP/INN); 64006-44-6 (maleate); (3S-trans)-3-((1,3-benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)piperidine; CID43815; KBio2_004800; Spectrum5_001665; NCGC00025355-04; (3S,4R)-3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine; Piperidine, 3-((1,3-benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)-, (3S-trans)-; (3S,4R)-3-(1,3-benzodioxol-5-yloxymethyl)-4-(4-fluorophenyl)piperidine; Seroxat; CHEMBL490; Pexeva; Paxil CR; Paroxetine Hcl; UNII-41VRH5220H; FT-0085087; Paroxetina [INN-Spanish]; 63952-24-9; paroxetine; Prestwick3_000851; BIDD:GT0673; SpecPlus_000788; C19H20FNO3; NCGC00025355-05	61869-08-7	43815	9619	TTDS00172	Serotonin re-uptake	Serotonin reuptake	N/A	N/A	N/A	inhibitor
DCL000723	Bicifadine	N/A	71195-57-8	449171	12015676	TTDS00172	Serotonin re-uptake	Serotonin reuptake	N/A	N/A	N/A	inhibitor
DAP001547	Milnacipran HCl	N/A	N/A	N/A	N/A	TTDS00172	Serotonin re-uptake	Serotonin reuptake	N/A	N/A	N/A	inhibitor
DAP000740	Fluvoxamine	Fluvoxaminum [INN-Latin]; fluvoxamine; AC1NT50J; 61718-82-9 (maleate); AB00514702; LS-101999; 2-[(E)-[5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene]amino]oxyethanamine; Dumyrox; Maveral; AC1Q4JNU; CHEBI:5138; 54739-18-3; Prestwick2_000995; NCGC00021870-04; C15H21F3N2O2; Fluvoxaminum; BRD-K53517854-050-03-2; CHEMBL814; Faverin; AC-1679; D07984; CID5324346; Fluvoxamina; BIDD:GT0609; MolPort-005-943-374; Dumirox; BPBio1_001199; Floxyfral; Fluvoxamine (INN); Prestwick3_000995; C07571; 2-[({5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene}amino)oxy]ethanamine; BSPBio_001089; NCGC00021870-05; (1E)-5-methoxy-1-[4-(trifluoromethyl)phenyl]pentan-1-one O-(2-aminoethyl)oxime; 1-Pentanone, 5-methoxy-1-(4-(trifluoromethyl)phenyl)-, O-(2-aminoethyl)oxime, (E)-; Fluvoxamine [INN:BAN]; I01-8382; fluvoxamine-CR; DB00176; UNII-O4L1XPO44W; NCGC00018193-07; AR-1D5360; Lopac0_000495; Fluvoxamina [INN-Spanish]	54739-18-3	3404	9774	TTDS00172	Serotonin re-uptake	Serotonin reuptake	N/A	N/A	N/A	inhibitor
DAP000104	Trazodone	Trittico (TN); KBio2_001904; Desyrel Dividose; KBio3_002540; 19794-93-5; CHEMBL621; Lopac-T-6154; Trazodonum; DB00656; Trazodona [INN-Spanish]; LS-156735; Trazodona; NCGC00016035-09; 1,2,4-Triazolo[4,3-a]pyridin-3(2H)-one, 2-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-; Desyrel(trazodone hcl salt); CAS-25332-39-2; Lopac0_001159; Prestwick2_000292; 2-{3-[4-(3-chlorophenyl)piperazin-1-yl]propyl}[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one; EINECS 243-317-1; Trazodonum [Latin]; Oprea1_185901; Prestwick1_000292; CID5533; Trazodonum [INN-Latin]; Trazodone [INN:BAN]; BSPBio_000224; NINDS_000196; L000771; nchembio873-comp51; UNII-YBK48BXK30; Trazalon; trazodone (Desyrel); NCGC00016035-01; IDI1_000196; MLS000758230; Trazolan; BRD-K70778732-003-05-1; 1,2,4-Triazolo(4,3-a)pyridin-3(2H)-one, 2-(3-(4-(3-chlorophenyl)-1-piperazinyl)propyl)-; Trazodon; Trazodone Hcl; AC-6778; 2-(3-[4-(3-Chlorophenyl)-1-piperazinyl]propyl)[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one; KBioGR_001110; Spectrum4_000755; KBio2_007040; Spectrum2_000854; NCGC00024405-03; BPBio1_000248; Spectrum5_000974; AC1L1KK2; Desirel; Prestwick3_000292; Trazodil; Trazodone (INN); Sideril; 8-[3-[4-(3-Chlorophenyl)piperazin-1-yl]propyl]-1,7,8-triazabicyclo[4.3.0]nona-2,4,6-trien-9-one hydrochloride; Trittico; I06-1977; Tradozone; BSPBio_003040; Beneficat; Trazodona [Spanish]; s-Triazolo(4,3-a)pyridin-3(2H)-one, 2-(3-(4-(m-chlorophenyl)-1-piperazinyl)propyl)-; C07156; SPBio_002443; NCGC00016035-03; BRN 0628010; KBio1_000196; CHEBI:9654; 2-[3-[4-(3-chlorophenyl)piperazin-1-yl]propyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one; C19H22ClN5O; SPBio_000867; D08626; Trialodine; Trazonil; Spectrum3_001560; trazodone; Spectrum_001424; NCGC00016035-02; KBio2_004472; MolPort-003-850-601; DivK1c_000196; Prestwick0_000292; KBioSS_001904	19794-93-5	5533	172043	TTDS00172	Serotonin re-uptake	Serotonin reuptake	N/A	N/A	N/A	inhibitor
DAP001436	Ultracet	N/A	147630-09-9	44153587	85150200	TTDS00172	Serotonin re-uptake	Serotonin reuptake	N/A	N/A	N/A	inhibitor
DAP000862	Diethylpropion	AC1L1NUD; Reginon; Silutin; MolPort-001-783-471; 4-14-00-00144 (Beilstein Handbook Reference); 2-(Diethylamino)propiophenone; Diethylcathinone; Obesitex; 2-(Diethylamino)-1-phenyl-1-propanone; 2-(diethylamino)-1-phenylpropan-1-one; Cegramine; Prefamone; Regenon; Tepanil; CHEBI:4530; Amfepramone (INN); C13H19NO; EINECS 202-019-1; Amfepramone HCL; Amfepramonum; Modulor; 1-Phenyl-2-diethylamino-1-propanone; Diethylpropione; 2-Diethylaminopropiophenone; UNII-Q94YYU22B8; Amfepramone; Anfamon; Amphepramon; Diethylpropion HCL; Tylinal; alpha-Diethylaminopropiophenone; Amfepramonum [INN-Latin]; C06954; Adiposon; Derfon; Parabolin; 90-84-6; DIETHYLPROPION; Keramik; Frekentine; Amfepramon; Anfepramona [INN-Spanish]; Amfepramone hydrochloride; DEA No. 1610; Magrene; Diethylpropion (BAN); Keramin; Amphepramone; AC-13099; Amphepramonum hydrochloride; Diethylpropione hydrochloride; DB00937; CID7029; Propiophenone, 2-diethylamino-; alpha-Benzoyltriethylamine; Dobesin; Fenyl-(1-diethylaminoethyl)keton; Phepranon; BRN 2804400; Propiophenone, 2-(diethylamino)-; D07444; LS-125137; HSDB 3059; Danylen; Nopropiophenone; Anfepramona; UR 1423; (+-)-diethylpropion; Neobes; 1-Propanone, 2-(diethylamino)-1-phenyl-; Anorex; Tenuate hydrochloride; Fenyl-(1-diethylaminoethyl)keton [Czech]; Amfepramone [INN]	134-80-5	7029	9169	TTDS00172	Serotonin re-uptake	Serotonin reuptake	N/A	N/A	N/A	inhibitor
DCL000769	Desvenlafaxine SR	N/A	93413-62-8	125017	701788	TTDS00172	Serotonin re-uptake	Serotonin reuptake	N/A	N/A	N/A	inhibitor
DCL000968	R-sibutramine metabolite	N/A	N/A	N/A	N/A	TTDS00172	Serotonin re-uptake	Serotonin reuptake	N/A	N/A	N/A	inhibitor
DCL001021	Tramadol ER	N/A	27203-92-5	33741	48416650	TTDS00172	Serotonin re-uptake	Serotonin reuptake	N/A	N/A	N/A	inhibitor
DAP001528	Tianeptine	30123-17-2 (mono-hydrochloride salt); ST51053933; Stablon (TN); Tianeptine; Tianeptinum; Tianeptine [INN]; AC1L2AMD; 72797-41-2; AC-2091; 66981-73-5; MolPort-003-850-549; (1)-7-((3-Chloro-6,11-dihydro-6-methyldibenzo(c,f)(1,2)thiazepin-11-yl)amino)heptanoic acid S,S-dioxide; EINECS 276-851-9; AC1Q3MR6; Tianeptine (INN); 7-[(3-chloro-6-methyl-5,5-dioxido-6,11-dihydrodibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid; Tianeptina; D02575; I14-0750; 7-[(3-chloro-6-methyl-5,5-dioxo-11H-benzo[c][2,1]benzothiazepin-11-yl)amino]heptanoic acid; TL8004726; CID68870; Tianeptine Acid	26638-66-4	3075702	17396746	TTDS00172	Serotonin re-uptake	Serotonin reuptake	N/A	N/A	N/A	inhibitor
DCL000779	DOV 21947	N/A	N/A	N/A	N/A	TTDS00172	Serotonin re-uptake	Serotonin reuptake	N/A	N/A	N/A	inhibitor
DCL000781	DOV-21947	N/A	N/A	N/A	N/A	TTDS00172	Serotonin re-uptake	Serotonin reuptake	N/A	N/A	N/A	inhibitor
DAP000186	Fluoxetine	AKOS003663021; Prestwick1_000511; Floxetine; Fontex; Fluoxetine (USAN/INN); Prestwick2_000511; Fluoxetine (TN); LS-31040; BRD-A31159102-001-01-9; L000931; Eufor; TL8003595; N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine; Lopac0_000558; HMS2090H14; (+) or (-)-N-Methyl-3-phenyl-3-((alpha,alpha,alpha-trifluoro-p-tolyl)oxy)propylamine; Methyl({3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl})amine; AC1L1FTH; SpecPlus_000723; Prestwick3_000511; (+-)-N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine; NCGC00024879-03; CID3386; CHEMBL41; dl-3-(p-Trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine; KBio3_002595; (+) or (-)-N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine; (+/-)-N-Methyl-3-p-(p-trifluoromethylphenoxy)-3-phenylpropylamine; KBio2_007295; Fluoxetinum [INN-Latin]; Portal; Benzenepropanamine, N-methyl-.gamma.-[4-(trifluoromethyl)phenoxy]-; Spectrum2_001658; Methyl-[3-phenyl-3-(4-trifluoromethyl-phenoxy)-propyl]-amine; Prozac Weekly; 59333-67-4 (hydrochloride); AB00053774; Fluoxetina; BSPBio_003375; Fluoxetine [USAN:INN:BAN]; Benzenepropanamine, N-methyl-.gamma.-[4-(trifluoromethyl)phenoxy]-, (.+/-.)-; Fluoxetina [Spanish]; SPBio_001815; Lilly-110140; KBio1_001763; fluoxetine (Prozac); Fluoxetine Hcl; D00326; Biomol-NT_000152; 3-(p-Trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine; KBioSS_002159; Fluoxetinum; nchembio.534-comp2; DB00472; MolPort-001-683-482; KBio2_002159; (+-)-N-Methyl-3-phenyl-3-((alpha,alpha,alpha-trifluoro-p-tolyl)oxy)propylamine; Spectrum3_001648; Benzenepropamine, N-methyl-gamma-(4-(trifluoromethyl)phenoxy)-, (+-)-; benzenepropanamine, N-methyl-gamma-[4-(trifluoromethyl)phenoxy]-; N-Methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine; BSPBio_000461; BRD-A31159102-003-05-6; Benzenepropanamine, N-methyl-gamma-(4-(trifluoromethyl)phenoxy)-, (+-)-; (+/-)-N-Methyl-3-phenyl-3-[(alpha,alpha,alpha-trifluoro-p-tolyl)oxy]propylamine; C17H18F3NO; BPBio1_000354; Animex-On; CHEBI:5118; Reneuron; STK734483; AC-14564; NCGC00024879-04; DivK1c_006819; NSC283480; (+/-)-N-Methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine; Spectrum_001679; (+/-)-N-Methyl-gamma-[4-(trifluoromethyl)phenoxy]benzenepropanamine; Fluval; UNII-01K63SUP8D; Spectrum5_001518; N-methyl-3-phenyl-3-{[4-(trifluoromethyl)phenyl]oxy}propan-1-amine; 54910-89-3; (+/-)-Fluoxetine; KBioGR_001166; NCGC00015428-10; 52341-67-0; 57226-07-0; Pulvules; N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine; Benzenepropanamine, N-methyl-gamma-[4-(trifluoromethyl)phenoxy]-, (+/-)-; KBio2_004727; SPBio_002382; Prestwick0_000511; Spectrum4_000613; Fluoxetin; fluoxetine; (+/-)-N-Methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propylamine]; BPBio1_000509; Reconcile; Fluoxetina [INN-Spanish]; Bio-0787	54910-89-3	3386	181999	TTDS00172	Serotonin re-uptake	Serotonin reuptake	N/A	N/A	N/A	inhibitor
DAP001224	Dexfenfluramine	Ponderax (TN); MolPort-001-794-054; 2-Ethylamino-1-(3-trifluoromethylphenyl)propane; DEA No. 1670; CHEMBL248702; Pesos; (+/-)-Fenfluramine hydrochloride; Adipomin; CID66265; AC-16024; LS-103506; DB00574; Dextrofenfluramine; PDSP2_000685; fenfluramine; NCGC00159473-03; Phenethylamine, N-ethyl-alpha-methyl-m-(trifluoromethyl)-, (+-)-; 3-(Trifluoromethyl)-N-ethyl-alpha-methylphenethylamine; Fenfluramine, (+-)-Isomer; Prestwick_868; Benzeneethanamine, N-ethyl-alpha-methyl-3-(trifluoromethyl)-, (+-)- (9CI); Obedrex; 1-(meta-Trifluoromethyl-phenyl)-2 ethylaminopropane; Phenethylamine, N-ethyl-.alpha.-methyl-m-(trifluoromethyl)-; LS-103505; Dexfenfluramina [Spanish]; DivK1c_000980; Adifax; PDSP2_001403; S 768; (+-)-Fenfluramine; NINDS_000980; NCGC00159473-04; AC1Q4JS0; Dexfenfluraminum; 458-24-2; HSDB 7356; CID3337; LS-103507; EINECS 207-276-3; N-Ethyl-alpha-methyl-3-trifluoromethylphenethylamine; Dexfenfluraminum [Latin]; 404-82-0 (hydrochloride); 1-(m-trifluoromethyl-phenyl)-2-ethylaminopropane; N-Ethyl-alpha-methyl-3-(trifluoromethyl)benzeneethanamine; L000742; UNII-2DS058H2CF; d-Fenfluramine; (S)-Fenfluramine; Fenfluraminum; PDSP1_001419; HSDB 3080; NCGC00159473-02; PDSP1_000695; (S)-N-ethyl-1-[3-(trifluoromethyl)phenyl]propan-2-amine; (2S)-N-ethyl-1-[3-(trifluoromethyl)phenyl]propan-2-amine; DEXFENFLURAN; AC1Q31F0; IDI1_000980; Ponderex; Fenfluramina [DCIT]; Rotondin; N-ethyl-1-[3-(trifluoromethyl)phenyl]propan-2-amine; (+)-Fenfluramine; Phenethylamine, N-ethyl-alpha-methyl-m-(trifluoromethyl)-; Fenfluramina; Fenfluramine (INN); d-N-Ethyl-alpha-methyl-m-trifluoromethylphenethylamine; Phenethylamine, N-ethyl-alpha-methyl-m-(trifluoromethyl)-, (S)-; C12H16F3N; Benzeneethanamine, N-ethyl-alpha-methyl-3-(trifluoromethyl)-; DB01191; 5220-89-3; Isomeride; Benzeneethanamine, N-ethyl-alpha-methyl-3-(trifluoromethyl)-, (S)-; Dexfenfluramine (INN); D07805; BRN 4783711; N-Ethyl-alpha-methyl-m-(trifluoromethyl)phenethylamine; D07945; AC1L1FPE; Levofenfluramine [INN]; Dexafenfluramine; Fenfluramine [INN:BAN]; Ponderax PA; Acino; Benzeneethanamine, N-ethyl-.alpha.-methyl-3-(trifluoromethyl)-; CHEBI:439329; AC1Q31EZ; ()-Fenfluramine hydrochloride; MolPort-004-964-519; Benzeneethanamine, N-ethyl-alpha-methyl-3-(trifluoromethyl)-, (+-)-; Dexfenfluramina; Benzeneethanamine, N-ethyl-alpha-methyl-3-(trifluoromethyl)- (9CI); Benzeneethanamine, N-ethyl-alpha-methyl-3-(trifluoromethyl)-, (S)- (9CI); Fenfluraminum [INN-Latin]; Dexfenfluramine [INN:BAN]; Dexfenfluramine; 3239-44-9; AC1L24ZO; KBio1_000980; C06996; CHEBI:5000; CHEMBL87493	3239-44-9	3337	161613	TTDS00172	Serotonin re-uptake	Serotonin reuptake	N/A	N/A	N/A	inhibitor
DAP001428	Seroxat	110429-35-1; C07415; KBio2_002232; NCGC00025355-07; HMS2090H05; D02362; MolPort-003-849-791; CHEBI:7936; 61869-08-7; Piperidine, 3-((1,3-benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)-, (3S,4R)-; Paroxetina; BRD-K37991163-003-02-7; AC1Q4LV6; 3-(Benzo[1,3]Dioxol-5-Yl-Oxymethyl)-4-(4-Fluoro-Phenyl)-Piperidine Hydrochloride; TL8003967; I14-7752; LS-114249; Piperidine, 3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-, (3S-trans)-; [3H]Paroxetine; BSPBio_000861; Aropax; AB00514724; Seroxat CR; (-)-(3S,4R)-4-(p-Fluorophenyl)-3-((3,4-(methylenedioxy)phenoxy)methyl)piperidine; NNC-20-7051; Paxetil; DivK1c_006884; AC1Q1H18; Paroxetinum; BRL 29060; NCGC00025355-02; Frosinor; Paroxetine (USP/INN); (3S-trans)-3-((1,3-benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)piperidine; CID43815; KBio2_004800; (3S,4R)-3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine; Piperidine, 3-((1,3-benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)-, (3S-trans)-; (3S,4R)-3-(1,3-benzodioxol-5-yloxymethyl)-4-(4-fluorophenyl)piperidine; Seroxat; CHEMBL490; Paxil CR; Paroxetina [INN-Spanish]; 63952-24-9; BIDD:GT0673; KBio1_001828; Spectrum_001752; Paroxetine (TN); KBio2_007368; (-)-trans-4-(4-Fluorophenyl)-3-(3,4-methylenedioxyphenoxymethyl)piperidine; (-)-trans-4-(p-fluorophenyl)-3-[[3,4-(methylenedioxy)phenoxy]methyl]-piperidine; Paxil; PaxPar; Casbol; piperidine, 3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-, (3S,4R)-; 78246-49-8 (hydrochloride); (-)-Paroxetine; (-)-(3S,4R)-4-(p-Fluorophenyl)-3-((3,4-methylenedioxy)phenoxy)methyl)piperidine; Paroxetine [USAN:INN:BAN]; Motivan; AC1L2AKL; BPBio1_000949; NCGC00025355-03; Paroxetinum [INN-Latin]; NCGC00025355-08; BRL-29060; DB00715; FG 7051; (3S-trans)-3-[(1,3-Benzodioxol-5-yl-oxy)methyl]-4-(4-fluorophenyl)piperidine; NCGC00025355-06; KBioSS_002232; FG-7051; 64006-44-6 (maleate); Spectrum5_001665; NCGC00025355-04; Pexeva; Paroxetine Hcl; UNII-41VRH5220H; FT-0085087; paroxetine; Prestwick3_000851; SpecPlus_000788; C19H20FNO3; NCGC00025355-05	61869-08-7	43815	841246	TTDS00172	Serotonin re-uptake	Serotonin reuptake	N/A	N/A	N/A	inhibitor
DAP000118	Citalopram	CPD000465669; 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile; Citalopram [Celexa]; Citadur; Pramcit; CHEMBL549; Ciazil; Cipram; NCGC00025160-02; D07704; Lu-10-171; Temperax; Oropram; [3H]Citalopram; Citopam; NCGC00015267-07; UNII-0DHU5B8D6V; HMS2090O09; BPBio1_000929; Cytalopram; Lopac0_000258; I01-0382; CHEBI:3723; Citalopram (USP/INN); Nitalapram; SAM002589960; L001223; Akarin; HMS2093A14; Citalopram [INN:BAN]; 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3H-2-benzofuran-5-carbonitrile; AC1L1EFH; Celexa; 1-(3-(Dimethylamino)propyl)-1-(p-fluorophenyl)-5-phthalancarbonitrile; 5-Isobenzofurancarbonitrile, 1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydro-; Citadur (TN); Lu 10-171; AC-12214; Zetalo; STL058639; LS-84327; ST069372; 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-; AE-641/00603021; Vodelax; MolPort-003-666-794; 59729-33-8; WSEQXVZVJXJVFP-UHFFFAOYSA-; Dalsan; Citalec; Cilift; 1,3-dihydro[3,4]benzofuran-5-carbonitrile; C20H21FN2O; Citabax; EINECS 261-891-1; DB00215; Celapram; C07572; InChI=1/C20H21FN2O/c1-23(2)11-3-10-20(17-5-7-18(21)8-6-17)19-9-4-15(13-22)12-16(19)14-24-20/h4-9,12H,3,10-11,14H2,1-2H3; AB00513896; Citalopramum; BRD-A47598013-004-02-0; Talohexal; Seropram; Celius; 5-Isobenzofurancarbonitrile, 1,3-dihydro-1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-; CID2771; Prestwick3_000692; Zentius; Talam; Ciprapine; Citalopramum [INN-Latin]; Humorup; Recital; BSPBio_000843; 1,3-Dihydro-1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-5-isobenzofurancarbonitrile; citalopram	59729-33-8	2771	183529	TTDS00172	Serotonin re-uptake	Serotonin reuptake	N/A	N/A	N/A	inhibitor
DAP000176	Sibutramine	Butramin (TN); Spectrum4_001137; Spectrum_001961; MolPort-002-507-758; HMS2090N17; AKOS004119970; KBio2_005076; TL8000239; 106650-56-0; UNII-WV5EC51866; Sibutraminum [Latin]; Spectrum3_001009; Spectrum2_001686; N-1-(1-(4-chlorophenyl)cyclobutyl)-3-methylbutyl-N,N-dimethylamine HCl; SAM001247105; KBioSS_002516; Sibutraminum; NCGC00092357-02; CPD000238156; KBio2_002508; AC-15773; LS-172014; AC1L1JUC; Meridia; CID5210; I05-0006; Spectrum5_001440; SPBio_001612; CHEMBL1419; DEA No. 1675; 84485-00-7 (hydrochloride); Butramin; SMR000238156; Sibutramine (INN); MLS001401362; Reductil; FT-0082832; HMS2052P05; Sibutramine [INN:BAN]; 1-[1-(4-chlorophenyl)cyclobutyl]-N,N,3-trimethylbutan-1-amine; STK802066; D08513; Cyclobutanemethanamine, 1-(4-chlorophenyl)-N,N-dimethyl-alpha-(2-methylpropyl)-; sibutramine; Sibutramina [Spanish]; MLS001066619; Medaria; Sibutramina; STOCK4S-20116; C17H26ClN; KBio2_007644; KBio3_001957; DB01105; C07247; BSPBio_002737; KBioGR_001653; BTS-54524	106650-56-0	5210	206707	TTDS00172	Serotonin re-uptake	Serotonin reuptake	N/A	N/A	N/A	inhibitor
DCL000907	OPC-14523	N/A	145969-30-8	66644	48501062	TTDS00172	Serotonin re-uptake	Serotonin reuptake	N/A	N/A	N/A	inhibitor
DAP000052	Bupropion	Bupropion Hcl; 34841-36-6 (hydrochloride); BSPBio_000038; AC1L198Y; KBioGR_001168; KBio2_004711; CPD000472526; (+-)-1-(3-chlorophenyl)-2-((1,1-dimethylethyl)amino)-1-propanone; Bupropion (Old RN); BRD-A05186015-003-05-7; UNII-01ZG3TPX31; SMR000472526; Elont; .alpha.-(tert-Butylamino)-m-chloropropiophenone; MolPort-003-845-432; (+-)-Bupropion; KBio1_001994; SAM001246699; L000725; ( -)-2-(tert-Butylamino)-3'-chlorpropiophenon; Amfebutamone; MLS001424015; Amfebutamona; BPBio1_000042; alpha-(tert-butylamino)-m-chloropropiophenone; BSPBio_002247; DB01156; 34911-55-2; 2-(Tert-Butylamino)-3'-chloropropiophenone; 1-Propanone, 1-(3-chlorophenyl)-2-[(1, 1-dimethylethyl)amino]-; Propiophenone, 2-(tert-butylamino)-3'-chloro-; KBio2_007279; Prestwick0_000249; Spectrum_001663; KBioSS_002143; D07591; Lopac0_000166; AMFEBUTAMONE HCl; Bupropion hydrocloride; CHEBI:3219; AC-197; Bupropion (USAN); Bupropion (INN); Amfebutamonum [INN-Latin]; Spectrum2_001659; Bupropion SR; NCGC00015122-06; Jsp006301; LS-122817; KBio3_001467; 1-Propanone, 1-(3-chlorophenyl)-2-((1,1-dimethylethyl)amino)-; Spectrum4_000614; BRN 2101062; TL8002604; Spectrum3_000644; Amfebutamona [INN-Spanish]; NCI60_002714; 2-(tert-butylamino)-1-(3-chlorophenyl)propan-1-one; Prestwick3_000249; 1-Propanone, 1-(3-chlorophenyl)-2-((1,1-dimethylethyl)amino)-, (+-)-; AB00053756; HMS2051G10; Amfebutamon; Bupropion [INN:BAN]; Prestwick1_000249; Spectrum5_001406; C06860; Prestwick2_000249; SPBio_001817; bupropion; CHEMBL894; CID444; KBio2_002143; 1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]-; amfebutamonum; SPBio_002257; 1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]-, ()-; DivK1c_007050; HMS2089G14; ( -)-2-(tert-Butylamino)-3'-chloropropiophenone; 34841-39-9; SpecPlus_000954; NCGC00089751-02; NSC315851; 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]propan-1-one	34841-39-9	444	178415	TTDS00172	Serotonin re-uptake	Serotonin reuptake	N/A	N/A	N/A	inhibitor
DCL000900	NS 2359	N/A	843660-54-8	N/A	N/A	TTDS00172	Serotonin re-uptake	Serotonin reuptake	N/A	N/A	N/A	inhibitor
DCL001023	Trazodone CR	N/A	19794-93-5	5533	172043	TTDS00172	Serotonin re-uptake	Serotonin reuptake	N/A	N/A	N/A	inhibitor
DCL001019	TGBA01AD	N/A	3083-77-0	1177	48334698	TTDS00172	Serotonin re-uptake	Serotonin reuptake	N/A	N/A	N/A	inhibitor
DAP000494	Duloxetine	PDSP2_001369; PDSP2_000953; (3S)-N-methyl-3-naphthalen-1-yloxy-3-thiophen-2-ylpropan-1-amine; CHEMBL1175; (S)-Duloxetine; 116539-59-4; (S)-N-Methyl-gamma-(1-naphthalenyloxy)-2-thiophenepropanamine; MLS000758267; (3S)-N-methyl-3-(1-naphthyloxy)-3-(2-thienyl)propan-1-amine; LS-172322; SAM001247059; Cymbalta; CHEBI:36795; CPD000449282; (3S)-N-methyl-3-(naphthalen-1-yloxy)-3-(2-thienyl)propan-1-amine; AC-15704; C18H19NOS; PDSP1_001385; Yentreve; NCGC00164559-01; MolPort-003-847-038; AC1L1U0Q; CID60835; HSDB 7368; 2-Thiophenepropanamine, N-methyl-gamma-(1-naphthalenyloxy)-, (S)-; Duloxetine (INN); Yentreve (TN); AC1Q57H7; Duloxetine [INN:BAN]; UNII-O5TNM5N07U; duloxetine; LY 248686; 2-Thiophenepropanamine, N-methyl-gamma-(1-naphthalenyloxy)-, (gammaS)-; D07880; DB00476; PDSP1_000969; HMS2051I05; MLS001423946; SMR000449282; duloxetine, (+)-isomer	136434-34-9	60835	704934	TTDS00172	Serotonin re-uptake	Serotonin reuptake	N/A	N/A	N/A	inhibitor
DAP001533	Trimipramine	5H-Dibenz(b,f)azepine-5-propanamine, 10,11-dihydro-N,N,beta-trimethyl-, (+)- (9CI); AB00053646; BPBio1_000739; Trimipramine (USAN/INN); 1-(3-Dimethylamino-2-methylpropyl)-4,5-dihydro-2,3:6,7-dibenzazepine; Trimipraminum; 10,11 Dihydro-N,N,beta-trimethyl-5H-dibenz(b,f)azepine-5-propanamine; 10633 RP; Surmontyl; 5H-Dibenz(b,f)azepine, 5-(3-(dimethylamino)-2-methylpropyl)-10,11-dihydro-, (-)-; Prestwick3_000806; 5-(3-(Dimethylamino)-2-methylpropyl)-10,11-dihydro-5H-dibenz(b,f)azepine; KBioGR_001118; Spectrum3_001151; UNII-6S082C9NDT; 5H-Dibenz(b,f)azepine, 10,11-dihydro-5-(3-(dimethylamino)-2-methylpropyl)-; (+)-Trimipramine; trimipramine; KBio2_001902; Prestwick2_000806; NCGC00016013-03; LS-60464; Spectrum5_001052; 5H-Dibenz(b,f)azepine, 5-(3-(dimethylamino)-2-methylpropyl)-; ( )-Trimipramine; 5-(gamma-Dimethylamino-beta-methylpropyl)-10,11-dihydro-5H-dibenzo(b,f)azepine; KBio3_002201; Trimipramina; 5-(gamma-dimethylamino-beta-methylpropyl)-10,11-dihydro-5H-dibenzo[b,f]azepine; 5-[3-(dimethylamino)-2-methylpropyl]-10,11-dihydro-5H-dibenz[b,f]azepine; Trimipramine [USAN:INN:BAN]; CHEMBL644; BSPBio_000671; 5H-Dibenz(b,f)azepine-5-propanamine, 10,11-dihydro-N,N,beta-trimethyl-; Trimeprimine; DivK1c_000093; InChI=1/C20H26N2/c1-16(14-21(2)3)15-22-19-10-6-4-8-17(19)12-13-18-9-5-7-11-20(18)22/h4-11,16H,12-15H2,1-3H; 5H-Dibenz(b,f)azepine-5-propanamine, 10,11-dihydro-N,N,beta-trimethyl-, (-)- (9CI); 5H-Dibenz(b,f)azepine, 5-(3-(dimethylamino)-2-methylpropyl)-10,11-dihydro-, (+)-; 5H-Dibenz(b,f)azepine-5-propanamine, 10,11-dihydro-N,N,beta-trimethyl-, (+)-; SPBio_002592; LS-60463; 5H-Dibenz(b,f)azepine, 5-(3-(dimethylamino)-2-methylpropyl)-10,11-dihydro-; (-)-Trimipramine; L000969; KBioSS_001902; Lopac0_001156; Trimeproprimine; 3564-75-8; 5H-Dibenz(b,f)azepine, 10,11-dihydro-5-(3-(dimethylamino)-2-methylpropyl)-, (-)-; 521-78-8 (maleate (1:1)); Prestwick0_000806; 3564-66-7; Sapilent; Trimeproprimin; Trimipramine, (-)-Isomer; LS-60465; 7162 RP; 5-20-08-00099 (Beilstein Handbook Reference); CHEBI:9738; Surmontil; Prestwick1_000806; BSPBio_002701; Trimipraminum [INN-Latin]; Spectrum_001422; Trimipramina [INN-Spanish]; BRD-A19195498-050-05-9; AC-15969; Spectrum2_001530; Spectrum4_000759; Stangyl; 3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N,2-trimethylpropan-1-amine; 3589-21-7 (mono-hydrochloride); 5H-Dibenz[b,f]azepine-5-propanamine, 10,11-dihydro-N,N,.beta.-trimethyl-; NINDS_000093; 2'-Metil-3'-dimetilamino-propil-5-iminodibenzile; Trimeprimina [Italian]; KBio2_004470; IL-6001; RP-7162; D00394; SPBio_001320; EINECS 212-008-3; 5H-Dibenz(b,f)azepine, 10,11-dihydro-5-(3-(dimethylamino)-2-methylpropyl)-, (+)-; 10,11-dihydro-N,N,beta-trimethyl-5H-dibenz[b,f]azepine-5-propanamine; BRN 1321466; Trimeprimina; 25332-13-2 (mesylate); CID5584; KBio2_007038; DB00726; IDI1_000093; MolPort-005-935-550; Oprea1_375679; 739-71-9; NCGC00162356-01; 3-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N,2-trimethylpropan-1-amine; FI 6120; 2'-Metil-3'-dimetilamino-propil-5-iminodibenzile [Italian]; KBio1_000093; AC1L1KO8; 10645 RP; IL 6001; 10,11-Dihydro-5-(3-dimethylamino-2-methylpropyl)-5H-dibenz(b,f)azepine; beta-Methylimipramine	739-71-9	4055	49698504	TTDS00172	Serotonin re-uptake	Serotonin reuptake	N/A	N/A	N/A	inhibitor
DAP000742	Clomipramine	Hydiphen; IDI1_000797; BIDD:PXR0151; AKOS001487687; Lopac0_000307; NCGC00015264-03; Clomipramina [INN-Spanish]; LS-60386; 3-(3-Chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethyl-1-propanamine; Spectrum3_001707; Tocris-0457; NCGC00024355-05; Prestwick1_000269; Monochlorimipramine; 5H-Dibenz[b,f]azepine-5-propanamine, 3-chloro-10,11-dihydro-N,N-dimethyl-; KBioGR_000759; SPBio_001778; Clomipraminum; KBio2_003492; CHEBI:47780; BRN 1323477; 3-Chloro-5-[3-(dimethylamino)propyl]-10,11-dihydro-5H-dibenz[b,f]azepine; KBioSS_000924; NSC169865; STOCK2S-26559; NCGC00024355-04; Clomipramine (INN); DivK1c_000797; 3-Chloro-5-(3-(dimethylamino)propyl)-10,11-dihydro-5H-dibenz(b,f)azepine; BSPBio_000118; NINDS_000797; 17321-77-6 (mono-hydrochloride); 5H-Dibenz(b,f)azepine-5-propanamine, 3-chloro-10,11-dihydro-N,N-dimethyl-; KBio1_000797; Spectrum4_000350; 3-(2-chloro-5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N-dimethylpropan-1-amine; 5H-Dibenz(b,f)azepine, 3-chloro-5-(3-(dimethylamino)propyl)-10,11-dihydro- (8CI); D07727; C14H12ClN.C6H15N; UNII-NUV44L116D; Spectrum_000444; WLN: T C676 BN & T & J B3N1 & 1 EG; Prestwick2_000269; L000890; 5H-Dibenz(b,f)azepine, 10,11-dihydro-3-chloro-5-(3-(dimethylamino)propyl)-; NCGC00015264-09; 3-Chloroimipramine; NSC 169865; PDSP2_000240; Spectrum2_001729; Prestwick3_000269; Clomicalm; KBio3_002514; Lopac-C-7291; 83162-38-3; Clomipraminum [INN-Latin]; CHEBI:100996; NCGC00015264-01; BRD-K52989797-003-05-8; KBio2_000924; NCGC00024355-02; PDSP1_000241; Anafranil base; clomipramine; CHEMBL415; DB01242; Clomipramine [INN:BAN]; Anafranil (TN); 5H-Dibenz(b,f)azepine, 3-chloro-5-(3-(dimethylamino)propyl)-10,11-dihydro-; NCGC00015264-02; Clomipramina; 303-49-1; G 34586; 5-20-08-00103 (Beilstein Handbook Reference); EINECS 206-144-2; KBio2_006060; SPBio_002337; STK534842; 3-chloro-10,11-dihydro-N,N-dimethyl-5H-Dibenz(b,f)azepine-5-propanamine; 3-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethylpropan-1-amine; AB00053695; 5H-Dibenz[b,f]azepine, 3-chloro-5-[3-(dimethylamino)propyl]-10,11-dihydro-; Prestwick0_000269; CAS-17321-77-6; Biomol-NT_000151; Oprea1_312582; BRD-K52989797-001-01-1; Chlomipramine; BSPBio_003294; CID2801; AC1L1EHZ; DB07600; Spectrum5_001235; BPBio1_000130; 5H-Dibenz[b,f]azepine, 10,11-dihydro-3-chloro-5-[3-(dimethylamino)propyl]-; 10,11-dihydro-3-chloro-5-(3-(dimethylamino)propyl)-5H-dibenz(b,f)azepine; C06918; BPBio1_000661; MolPort-002-051-949; Anafranil (free base); Chlorimipramine	303-49-1	2801	152550	TTDS00172	Serotonin re-uptake	Serotonin reuptake	N/A	N/A	N/A	inhibitor
DAP000054	Venlafaxine	SPBio_000583; AC1L1KU8; Venlafaxine ER; Cyclohexanol, 1-(2-(dimethylamino)-1-(4-methoxyphenyl)ethyl)-, (+-)-; Efectin (TN); LS-57095; STK621394; KBio3_001877; Venlafaxinum; UNII-GRZ5RCB1QG; SpecPlus_000842; KBioSS_002151; Spectrum_001671; D08670; KBioGR_001590; NCGC00095109-03; HMS2090F04; VenlafaxineXR; 1-{2-(dimethylamino)-1-[4-(methyloxy)phenyl]ethyl}cyclohexanol; Efectin; Elafax; Venlafaxina; NCGC00095109-04; CHEMBL637; DivK1c_006938; HMS1922F05; Venlafaxine [INN:BAN]; Spectrum2_000542; Venlafaxine [BAN:INN]; BRD-A51714012-003-01-1; 1-[2-(Dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexanol; venlafaxine (Effexor); Venlafaxina [INN-Spanish]; Spectrum3_000989; 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexan-1-ol; CID5656; Wy 45030; 93413-69-5; NCGC00095109-02; MolPort-003-666-534; HMS2093A12; KBio2_002151; N,N-dimethyl-2-(1-hydroxycyclohexyl)-2-(4-methoxyphenyl)ethylamine; 1-[2-dimethylamino-1-(4-methoxyphenyl)ethyl]cyclohexan-1-ol; 1-[(1R)-2-(Dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexanol; DB00285; BRD-A51714012-001-02-3; Spectrum4_001115; BSPBio_002657; Venlafaxine (INN); 99300-78-4 (hydrochloride); NCGC00095109-01; KBio2_004719; C07187; AB1004809; KBio1_001882; CHEBI:9943; Spectrum5_001516; KBio2_007287; venlafaxine; Venlafaxinum [INN-Latin]; AC-1547; SPECTRUM1504171	93413-69-5	5656	193901	TTDS00172	Serotonin re-uptake	Serotonin reuptake	N/A	N/A	N/A	inhibitor
DCL000780	DOV-216303	N/A	N/A	N/A	N/A	TTDS00172	Serotonin re-uptake	Serotonin reuptake	N/A	N/A	N/A	inhibitor
DAP001452	Amfepramone	AC1L1NUD; Reginon; Silutin; MolPort-001-783-471; 4-14-00-00144 (Beilstein Handbook Reference); 2-(Diethylamino)propiophenone; Diethylcathinone; Obesitex; 2-(Diethylamino)-1-phenyl-1-propanone; 2-(diethylamino)-1-phenylpropan-1-one; Cegramine; Prefamone; Regenon; Tepanil; CHEBI:4530; Amfepramone (INN); C13H19NO; EINECS 202-019-1; Amfepramone HCL; Amfepramonum; Modulor; 1-Phenyl-2-diethylamino-1-propanone; Diethylpropione; 2-Diethylaminopropiophenone; UNII-Q94YYU22B8; Amfepramone; Anfamon; Amphepramon; Diethylpropion HCL; Tylinal; alpha-Diethylaminopropiophenone; Amfepramonum [INN-Latin]; C06954; Adiposon; Derfon; Parabolin; 90-84-6; DIETHYLPROPION; Keramik; Frekentine; Amfepramon; Anfepramona [INN-Spanish]; Amfepramone hydrochloride; DEA No. 1610; Magrene; Diethylpropion (BAN); Keramin; Amphepramone; AC-13099; Amphepramonum hydrochloride; Diethylpropione hydrochloride; DB00937; CID7029; Propiophenone, 2-diethylamino-; alpha-Benzoyltriethylamine; Dobesin; Fenyl-(1-diethylaminoethyl)keton; Phepranon; BRN 2804400; Propiophenone, 2-(diethylamino)-; D07444; LS-125137; HSDB 3059; Danylen; Nopropiophenone; Anfepramona; UR 1423; (+-)-diethylpropion; Neobes; 1-Propanone, 2-(diethylamino)-1-phenyl-; Anorex; Tenuate hydrochloride; Fenyl-(1-diethylaminoethyl)keton [Czech]; Amfepramone [INN]	90-84-6	7029	150052	TTDS00172	Serotonin re-uptake	Serotonin reuptake	N/A	N/A	N/A	inhibitor
DAP000051	Sertraline	Prestwick3_001014; HSDB 7037; DB01104; UNII-QUC7NX6WMB; AC1Q3XJU; AC-15639; Sertralina [Spanish]; sertraline; AB1004870; AC1Q3O5N; C17H17Cl2N; BSPBio_002698; (1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalen-1-amine; BRN 5753709; D02360; C07246; Cp 51974; 79617-96-2; NCGC00092386-06; 1-Naphthalenamine,1,2,3,4-tetrahydro-4-(3,4-dichlorophenyl)-N-methyl-, (1S-cis)-; NCGC00092386-07; LS-94179; (1S-cis)-1,2,3,4-Tetrahydro-4-(3,4-dichlorophenyl)-N-methyl-1-naphthalenamine; 1-Naphthalenamine, 1,2,3,4-tetrahydro-4-(3,4-dichlorophenyl)-N-methyl-, (1S-cis)-; NCGC00092386-03; Apo-Sertraline; BIDD:GT0768; AB00514002; KBioGR_001724; 79559-97-0 (Hydrochloride); CHEBI:9123; FT-0081122; SRE; DB08567; SMR000596516; Sertralina; BIDD:PXR0193; KBio3_001918; SPBio_000385; Sertraline (INN); BRD-K82036761-003-02-1; Sertraline [INN:BAN]; MolPort-002-885-860; NCGC00092386-04; Spectrum4_001232; sertraline (Zoloft); BSPBio_001167; CID68617; BPBio1_001285; 1-Naphthalenamine, 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-, (1S,4S)-; Sertralinum; MLS002222308; (1S-cis)-4-(3,4-Dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine; (+)-Sertraline; CP 51974; Sertraline; Spectrum2_000493; AC1L2A41; Spectrum3_001079; MLS001195647; CHEMBL809; NCGC00092386-09; NCGC00092386-05; Sertralinum [Latin]; Sertraline [Zoloft]; Lustral; NCGC00092386-08	79617-96-2	68617	210738	TTDS00172	Serotonin re-uptake	Serotonin reuptake	N/A	N/A	N/A	inhibitor
DAP000834	Cocaine	53-21-4 (hydrochloride); Snort; Allococaine; Cecil; Jam; (-)-Cocaine base; Charlie; methyl (1S,4R,5R)-3-benzoyloxy-8-methyl-8-azabicyclo[3.2.1]octane-4-carboxylate; Blow [Street Name]; SMR001338843; Depsococaine; MolPort-002-535-520; DB00907; Happy powder; Toke; Bernies; Cocktail; D00110; Gold dust [Street Name]; White girl or lady; Coca; Bernice; DEA No. 9041; Methyl 3beta-hydroxy-1alphaH,5alphaH-tropane-2beta-carboxylate benzoate (ester); Cocaine, l-; Blast; Trails; Eritroxilina; Sleighride; Sweet Stuff; Neurocaine; Delcaine; Flake [Street Name]; Lady [Street Name]; Ecgonine methyl ester benzoate; Carrie; Blow; CID11779748; Moonrocks; Burese; KBio1_000975; Kokayeen; Kokain; methyl 3-benzoyloxy-8-methyl-8-azabicyclo[3.2.1]octane-4-carboxylate; Florida Snow; Happy trails; Bernice [Street Name]; Cola; AC1L3U2D; 2-beta-Tropanecarboxylic acid, 3-beta-hydroxy-, methyl ester, benzoate (ester); Flake; C8912_SIGMA; AC1L1EK2; Cocaine [BAN]; STOCK1N-68258; d-Pseudococaine; Erytroxylin; (R)-Cocaine; CHEBI:27958; C01416; Ecgonine, methyl ester, benzoate (ester); (1R,2R,3S,5S)-2-Methoxycarbonyltropan-3-yl benzoate; Blizzard; Snow (birds); C" Carrie; 610089_FLUKA; AC-16037; Caviar; G-Rock; Badrock; 50-36-2; Prime Time; HSDB 6469; 1-Cocaine; cocainum; Dextrocaine; UNII-I5Y540LHVR; 2-beta-Carbomethoxy-3-beta-benzoxytropane; Flex; Rock [Street Name]; l-Cocain; Goofball; 2beta-Carbomethoxy-3beta-benzoxytropane; Isococain; Kokan; Benzoylethylecgonine; CID446220; Snow; Cocaine (TN); MLS002320697; DivK1c_000975; COC; methyl (3S,4R)-3-benzoyloxy-8-methyl-8-azabicyclo[3.2.1]octane-4-carboxylate; cocaine; Cholly; Methyl 3-(benzoyloxy)-8-methyl-8-azabicyclo[3.2.1]octane-2-carboxylate; Girl; Cocain; Crack cocaine; Heaven; L000836; 3beta-Hydroxy-2beta-tropanecarboxylic acid methyl ester benzoate (ester); Bouncing Powder; NCGC00159467-02; Gold dust; AC1L9JBL; Pseudococaine; Leaf; Star dust; Allopseudococaine; Cocaina; Toot; Rock; 1i7z; Cocaine (USP); Nose candy; CID5760; Dama blanca; NINDS_000975; nchembio.284-comp4; Foo Foo; L-Cocaine; 610089_ALDRICH; (1R,2R,3S,5S)-2-(methoxycarbonyl)tropan-3-yl benzoate; Chicken Scratch; Corine; Happy dust [Street Name]; Ecgonine methyl ester benzoate solution; Methyl Benzoylecgonine; MolPort-003-937-722; beta-Cocain; Crack; Isococaine; Pseudoallococaine; CPD-9776; Yeyo; Hell; Candy; Coke; AC1L1L2T; Cocaine solution; Happy dust; Cocaine free base; Star-spangled powder; Girl [Street Name]; Kibbles n' Bits; (-)-Cocaine; Benzoylmethylecgonine; IDI1_000975; Cocaine-M; 1q72; Bazooka; LS-157759; CID2826; 3-Tropanylbenzoate-2-carboxylic acid methyl ester; Pimp's drug; Toot [Street Name]; EINECS 200-032-7; Freeze; Cecil [Street Name]; Cabello; Lady; AC-20208; Green gold	50-36-2	5760	148543	TTDS00172	Serotonin re-uptake	Serotonin reuptake	N/A	N/A	N/A	inhibitor
DAP000290	Calcidiol	VDY; MolPort-003-927-271; HMS1791G13; 3-{2-[1-(5-HYDROXY-1,5-DIMETHYL-HEXYL)-7A-METHYL-OCTAHYDRO-INDEN-4-YLIDENE]-ETHYLIDENE}-4-METHYLENE-CYCLOHEXANOL; 19356-17-3; Calderol; DB00146; H4014_SIGMA; HMS1361G13; Delakmin; Calcifediol; ZINC04474414; (1R,3Z)-3-[(2E)-2-[(1R,7aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol; (5Z,7E)-9,10-Seco-5,7,10(19)-cholestatrien-3beta,25-diol; 9,10-Secocholesta-5,7,10(19)-triene-1,25-diol, (3.beta,.5Z,7E)-; BML2-E02; 5,6-trans-25-Hydroxycholescalciferol; B91135EC-8937-4D8B-A533-CCD82F33C1B0; 25-Hydroxycholecalciferol (Calcifediol); Calcifidiol; Cholecalciferol, 25-hydroxy-; Calcifediol anhydrous; 25-(OH)Vitamin D3; 9,10-Secocholesta-5,7,10(19)-triene-3beta,25-diol; 25631-40-7; S1469_Selleck; 5,6-cis-25-Hydroxyvitamin D3; EINECS 242-990-9; Calcifediolum; 25-Hydroxycholescalciferol; (1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol; Calcifediolum [INN-Latin]; 17938_SIGMA; 9,10-Secocholesta-5,7,10(19)-triene-3,25-diol, (3beta,5Z,7E)-; IDI1_033881; Calcidiol; 25-Hydroxycholecalciferol; 25-hydroxyvitamin D3; 25-Hydroxyvitamin D3 monohydrate; U-32070E; NCGC00161326-04; 25-Hydroxyvitamin D; CID5283731; CID6433735; 5,6-trans-9,10-Seco-5,7,10(19)-cholestatrien-3beta,25-diol; CHEMBL1040; AC1O5GOQ; (3S,5Z,7E)-9,10-secocholesta-5,7,10-triene-3,25-diol; (3beta,5Z,7E)-9,10-secocholesta-5,7,10(19)-triene-3,25-diol; C01561; LMST03020246; CHEMBL1222; AC1NR2WF; UNII-T0WXW8F54E; 17938_FLUKA; CHEBI:17933; HMS2089L21; Spectrum5_001931; (3S,5Z,7E)-9,10-secocholesta-5,7,10(19)-triene-3,25-diol; HMS1989G13; Ro 8-8892; (5Z,7E)-(3S)-9,10-secocholesta-5,7,10(19)-triene-3,25-diol; NCGC00161326-01; 25(OH)D3; BSPBio_001411	19356-17-3	6433735	171856	TTDS00251	Vitamin D receptor	1,25-dihydroxyvitamin D3 receptor;Nuclear vitamin D receptor;VDR;Vitamin D(3) receptor;Vitamin D3 receptor	P11473	7421	ENSG00000111424	antagonist
DAP000292	Calcipotriol	SAM001246670; NCGC00167465-01; calcipotriene; LMST03020106; MC-903; ZINC03921872; CID5288783; HMS2089J08; CHEMBL1200666; SMR000466353; BMS-181161; CPD000466353; (1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5S)-5-cyclopropyl-5-hydroxypent-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol; MolPort-003-845-563; Dovonex; CHEBI:50749; 1-ALPHA,24S-(OH)2-22-ENE-26,27-DEHYDROVITAMIN D3; (1S,5Z,7Z,17ALPHA,22E)-24-CYCLOPROPYL-9,10-SECOCHOLA-5,7,10,22-TETRAENE-1,3,24-TRIOL; MLS000759467; HMS2051N11; Divonex; Calcipotriol; AC1NRC3V; MLS001424130	112965-21-6	5282134	7848188	TTDS00251	Vitamin D receptor	1,25-dihydroxyvitamin D3 receptor;Nuclear vitamin D receptor;VDR;Vitamin D(3) receptor;Vitamin D3 receptor	P11473	7421	ENSG00000111424	antagonist
DAP000365	Dihydrotachysterol	Dht(sub 2); (3E)-3-[(2E)-2-[1-[(E)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylcyclohexan-1-ol; dihydrotachysterol; C06957; 9,10-Secoergosta-5,7,22-trien-3-ol, (3.beta.,5E,7E,10.alpha.,22E)-; LS-148512; MolPort-003-941-198; AC1NQXW4; Dygratyl; D9257_SIGMA; EINECS 200-672-7; Dihydrotachysterol(sub 2); NCGC00166147-01; CHEBI:4591; Dihidrotaquisterol; Dichystrolum; Diidrotachisterolo [DCIT]; ST075187; Parterol; Dihydrotachysterolum [INN-Latin]; Anti-tetany substance 10; CID5702045; HSDB 3314; IDI1_000869; CID5353584; 67-96-9; NCGC00166147-02; 9,10-Secoergosta-5,7,22-trien-3beta-ol; HMS502L11; Dihydrotachysterolum; Tachysterol2, dihydro-; Antitanil; 9,10-Secoergosta-5,7,22-trien-3-ol, (3beta,5E,7E,10alpha,22E)-; (3Z)-3-[(2E)-2-[1-[(E)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylcyclohexan-1-ol; Dihydral; Tachyrol; D9257_FLUKA; Calcamine; Dht Intensol; (3S,5E,7E,10S,22E)-9,10-secoergosta-5,7,22-trien-3-ol; C28H46O; AC1NSJXZ; CID5281010; Diidrotachisterolo; (1S,3E,4S)-3-[(2E)-2-[(3aS,7aR)-1-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylcyclohexan-1-ol; Tachysterol, dihydro-; DB01070; (1S,3E,4S)-3-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylcyclohexan-1-ol; AC1NWALO; Dihidrotaquisterol [INN-Spanish]; DHT2; CID5311071; Hytakerol; Dihydrotachysterol [INN:BAN:JAN]; Tachystin; AT 10; AC1NS4C8; LMST03010056; A.T. 10	67-96-9	5281010	149136	TTDS00251	Vitamin D receptor	1,25-dihydroxyvitamin D3 receptor;Nuclear vitamin D receptor;VDR;Vitamin D(3) receptor;Vitamin D3 receptor	P11473	7421	ENSG00000111424	antagonist
DAP001273	Cholecalciferol	Vigorsan; NCGC00159331-02; MolPort-003-666-021; AB1002422; KBio2_004211; (5Z,7E)-(3S)-9,10-secocholesta-5,7,10(19)-trien-3-ol; D3-Vigantol; C9756_SIGMA; Oleovitamin D3; Spectrum4_001201; KBio2_001643; Bio-0845; Colecalciferol; 1406-16-2; NSC375571; LS-825; CC; CID7251172; 9,10-Seco(5Z,7E)-5,7,10(19)-cholestatrien-3-ol; AC1OIEWB; KBio3_001628; KBio2_006779; CID11463269; EINECS 215-797-2; CHEMBL1042; 25(OH)D; Colecalciferolo; Arachitol; Micro-dee; 9,10-Secocholesta-5,7,10(19)-trien-3-ol, (3beta,5Z,7E)-; AC1OF2GL; Cholecalciferol [USAN:BAN:JAN]; I05-0041; 9,10-Secocholestr-5,7,10(19)-trien-3-ol,3-.beta.,5Z,7E-; HMS2092M12; Prestwick0_000429; Calciol; CID10340013; Cholecalciferol (D3); KBioSS_001643; NCGC00178668-01; LMST03020220; AC1O5EOF; CID7067440; Cholecalciferolum; Colecalciferolum; AC1LU7IZ; Spectrum3_000764; ()-Vitamin D3; 9,10-Secocholesta-5,7,10(19)-trien-3-beta-ol; Colecalciferolo [DCIT]; CID10045875; VITAMIN D3 POWDER; Prestwick2_000429; CID6221; UNII-1C6V77QF41; LMST03020221; 8050-67-7; Ebivit; C1357_SIAL; NEO Dohyfral D3; NCGC00017328-01; CID1548921; HMS1569E20; 89193_FLUKA; Vitinc Dan-Dee-3; CID10000117; DB00169; CHEBI:283119; CID7067439; BSPBio_002408; CID11014566; Prestwick1_000429; BSPBio_000418; NSC-375571; (3beta,5Z,7E)-9,10-secocholesta-5,7,10(19)-trien-3-ol; AC1O7GQ3; SpecPlus_000180; AC1NR2UU; 9,10-Secocholestra-5,7,10(19)-trien-3-ol, (3beta,5Z,7E)-; Ricketon; Spectrum_001163; AC1O7GAV; CID10883523; 7-Dehydrocholestrol, activated; Provitina; NSC 375571; LT00244775; (+)-Vitamin D3; 7-Dehydrocholesterol activated; Activated 7-dehydrocholesterol; AC1OIEW5; CID11058152; CCRIS 6286; UPCMLD-DP152:001; NCGC00016301-01; CID6992015; Activated 7-dehydrocholesterol; Colecalciferol (INN); Vitamin D3 emulsifiable; ZINC04492878; CID2735; CID5280795; CID6992016; AC1OF2GI; SPBio_002357; Spectrum2_001369; 57651-82-8; KBioGR_001602; Cholecalciferol, D3; ZINC04474460; Colecalcipherol; EINECS 200-673-2; cholecalciferol; CID6604201; SMP1_000068; LMST03020001; CID5353527; CID5283710; NCGC00159331-04; Delta-D (TN); MolPort-001-740-051; SPBio_001298; NCGC00179565-01; MolPort-001-785-972; vitamin d-3; CID11025493; Rampage; SR-05000001559; ZINC04492874; ZINC04492876; TNP00266; Delta-D; BPBio1_000460; CID10894379; (+)-Vitamin D3; MolPort-004-946-964; NCGC00179565-02; Trivitan; C9774_SIAL; ACon1_001997; C05443; CID5283711; CHEBI:28940; bmse000507; VITAMIN_D3; Delsterol; (3S,5Z,7E)-9,10-secocholesta-5,7,10(19)-trien-3-ol; Vitamin D3; LMST03020219; 47763_SUPELCO; LS-1570; KBio1_001220; VITAMIN D; NCGC00142511-01; AC1L1M23; Provitamine; ST057172; CID9821465; ZINC04492875; D3-Vicotrat; AC1NSHJX; 9,10-Secocholesta-5(Z),7(E),10(19)-trien-3(.beta.)-ol; Colecalciferolum [INN-Latin]; AC-11697; CID6604662; CHEMBL432780; 7-Dehydrocholesterol activated; Prestwick_63; 67-97-0; CID5283712; AC1L1ECK; D00188; Duphafral D3 1000; CID7251174; SR-05000001559-3; Irradiated 7-dehydrocholesterol; Deparal; C27H44O; CID6708595; AC1NR2UO; (5Z,7E)-(3S)-9,10-seco-5,7,10(19)-cholestatrien-3-ol; EPA Pesticide Chemical Code 202901; 8024-19-9; NCGC00091072-01; CID6432644; DivK1c_006276; 9,10-Seco(5Z,7E)-5,7,10(19)-cholestatrien-3beta-ol; CCRIS 5813; AC1NS4AJ; CID6713938; CID5363362; Prestwick3_000429; FeraCol; AC1NR2UR; MEGxm0_000458; 7-Dehydrocholesterol, Activated; CAS-67-97-0; UPCMLD-DP152; Vi-de-3-hydrosol; AC1O8PWJ; AC1NQXLN; HSDB 820; Cholecalciferol (JP15/USP); AC1O8FEU; 7-Dehydrocholesterol, irradiated	67-97-0	6221	7805	TTDS00251	Vitamin D receptor	1,25-dihydroxyvitamin D3 receptor;Nuclear vitamin D receptor;VDR;Vitamin D(3) receptor;Vitamin D3 receptor	P11473	7421	ENSG00000111424	binder
DAP000291	Ergocalciferol	31316-19-5; I05-0022; Irradiated ergosta-5,7,22-trien-3-beta-ol; 95220_FLUKA; CID6536972; Crystallina; 47768_SUPELCO; Oleovitamin D, Synthetic; component of Geltabs Vitamin D; Vitamina D2; Ergocalciferol: Vitamin D; Detalup; Ergocalciferolum; VITAMIN_D2; Irradiated ergosta-5,7,22-trien-3.beta.-ol; Ergocalciferolo [DCIT]; BSPBio_000380; 'Ergosterol irradiated'; BPBio1_000418; CID5702050; (3S,5Z,7E,14xi,17alpha,22E)-9,10-secoergosta-5,7,10,22-tetraen-3-ol; Dee-Roual; Ergosterol irradiated; HSDB 819; AC1NSSVD; MEGxm0_000466; MLS001332467; SMR000857106; ergocalciferol; Mykostin; Calciferol (TN); AC1O5EDK; (3-beta,5Z,7E,22E)-9,10-Secoergosta-5,7,10,(19),22-tetraen-3-ol; Sorex C.R.; Calciferol; AC1NWAM3; Davitamon D; ST057150; MolPort-001-740-057; Vio-D; CID3249; LMST03010014; (3beta,5Z,7E,22E)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol; Vitamin-?D2; MolPort-003-666-178; Radiostol; ACon1_002187; Ergocalciferol (D2); Novovitamin-D; AC-1355; STOCK1N-53397; De-rat concentrate; Calciferolum; Fortodyl; MolPort-006-822-629; HMS1920K20; 9,10,Secoergosta-5,7,10(19),22-tetraen 3.beta.-ol; CALCIFEROL IN A GELATIN MATRIX; CID11003810; AC1NS9GI; Condacaps; LMST03010001; 9,10-Secoergosta-5,7,10(19),22-tetraen-3-ol, (3.beta.,5Z,7E,22E)-; Prestwick3_000420; Drisdol; (5Z,7E,22E)-(3S)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol; NSC62792; MLS001332468; Radstein; Ergocalciferol (JP15/USP); SPECTRUM1500276; EINECS 200-014-9; WLN: L56 FYTJ A1 BY1&1U1Y1&Y1&1 FU2U- BL6YYTJ AU1 DQ; Oleovitamin D; Dee-Osterol; CID5353610; HMS2091B19; VITAMIN D2 WATER DISPERSABLE U.S.P.; Shock-ferol sterogyl; Uvesterol-D; Buco-D; DB00153; CID5315257; Viostdrol; MolPort-002-526-645; Dee-Ronal; CHEBI:28934; Ergosterol activated; D-Tracetten; BSPBio_001974; Geltabs; AC1O6WAM; AC1NS4DE; Deratol; Vigantol; bmse000510; Ergocalciferol [INN:BAN:JAN]; Dee-Ron; Drisdol (TN); 8017-28-5; Calciferon 2; Rodinec; Hi-Deratol; Mulsiferol; Vitavel-D; Viosterol in Oil; Ostelin; 7489-18-1; IDI1_000805; 50-14-6; CID5280793; E5750_SIGMA; AC1NQXLH; D00187; Ergosterol, irradiated; Infron; Crtron; Vitamin- D2; Sorex C.R; 9,10-Secoergosta-5,7,10(19),22-tetraen-3-ol, (3beta,5Z,7E,22E)-; Metadee; Shock-ferol; Davitin; UNII-VS041H42XC; CALCIFEROL, U.S.P.; NCGC00179579-01; AC1L1FIE; Sterogyl; CHEMBL1536; Diactol; Synthetic Vitamin D; Radsterin; ZINC04629876; Haliver; D-Arthin; CID6432478; LS-3228; Oleovitamin D2; Ertron; Condocaps; Condol; 9,10-Secoergosta-5,7,10(19),22-tetraen-3-beta-ol; Divit urto; Hyperkil; Ergocalciferolo; (3S,5Z,7E,22E)-9,10-secoergosta-5,7,10,22-tetraen-3-ol; Irradiated ergosterol; Mina D2; 95220_SIGMA; ZINC04474571; 7E677DC1-E1C4-4FC5-8F4A-BCE1857F7E87; Daral; Ergorone; Deltalin; Spectrum5_000666; Geltabs Vitamin D; Prestwick_554; 9,10-Seco(5Z,7E,22E)-5,7,10(19),22-ergostatetraen-3-ol; NCGC00142497-01; Calciferol (vitamin D2); Ercalciol; NSC 62792; Viosterol; Decaps; C28H44O; HMS502I07; (+)-Vitamin D2; CID5356615; (3S,5Z,7E,22E)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol; Ergocalciferolum [INN-Latin]; NCGC00179579-02; MolPort-001-793-930; C05441; VITAMIN D2; Rodine C; Ergocalciferols; (5Z,7E,22E)-(3S)-9,10-seco-5,7,10(19),22-ergostatetraen-3-ol; vitamin d-2	50-14-6	5280793	7803	TTDS00251	Vitamin D receptor	1,25-dihydroxyvitamin D3 receptor;Nuclear vitamin D receptor;VDR;Vitamin D(3) receptor;Vitamin D3 receptor	P11473	7421	ENSG00000111424	antagonist
DAP000211	Paricalcitol	LMST04030163; DB00910; AC1NQY0Z; 131918-61-1; Zemplar; Zemplar (TN); CHEMBL1200622; C084656; UNII-6702D36OG5; 19-Nor-1alpha,25-dihydroxyvitamin D2; HSDB 7360; Abbott brand of paricalcitol; Paricalcitol [USAN]; CID5281104; 19-Nor-1-alpha,25-dihydroxyvitamin D2; CHEBI:7931; Compound-49510; (7E,22E)-19-Nor-9,10-secoergosta-5,7,22-triene-1alpha,3beta,25-triol; (1alpha.3beta,7E,22E)-19-Nor-9,10-secoergosta-5,7,22-triene-1,3,25-triol; D00930; ABT-358; 19-Nor-1,25-(OH)2D2; LS-172812; 19-Nor-1alpha,25-dihydroxyvitamin D2; Paricalcitol; Paricalcitol (USAN/INN); AKOS005145562; 19-Nor-9,10-secoergosta-5,7,22-triene-1,3,25-triol, (1alpha,3beta,7E,22E)-; BIDD:GT0330; Paricalcitol, 19-nor-(OH)2-vitD2, paracalcin; 19-Nor-9,10-secoergosta-5,7,22-triene-1,3,25-triol,(1alpha,3beta,7E,22E); (1R,3R)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5S)-6-hydroxy-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol; (1R,3R,7E)-17beta-[(2R,3E,5S)-6-hydroxy-5,6-dimethylhept-3-en-2-yl]-9,10-secoestra-5,7-diene-1,3-diol; AC-1198; C08127; Ab 122358; Paricalcitol; Compound 49510; Paracalcin	131918-61-1	5281104	10327	TTDS00251	Vitamin D receptor	1,25-dihydroxyvitamin D3 receptor;Nuclear vitamin D receptor;VDR;Vitamin D(3) receptor;Vitamin D3 receptor	P11473	7421	ENSG00000111424	agonist
DAP000289	Calcitriol	1,25(OH2)D3; Calcijex; HMS1989A09; CHEBI:17823; BML2-E03; BCBcMAP01_000160; SMR000466393; Calcitriol [USAN:INN:BAN:JAN]; 1,25-(OH)2D3; 1alpha,25-Dihydroxyvitamin D3; Silkis; D00129; 9,10-Secocholesta-5,7,10(19)-triene-1,3,25-triol, (1.alpha.,3.beta,.5Z,7E)-; S1466_Selleck; (1R,3S)-5-{2-[(1R,3aS,7aR)-1-((R)-5-Hydroxy-1,5-dimethyl-hexyl)-7a-methyl-octahydro-inden-4-ylidene]-ethylidene}-4-methylene-cyclohexane-1,3-diol; IDI1_033757; (1alpha,3beta,5Z,7E)-9,10-secocholesta-5,7,10(19)-triene-1,3,25-triol; Ro 215535; 1 alpha,25-Dihydroxyvitamin D3; (5Z,7E)-9,10-Secocholesta-5,7,10(19)-triene-1-alpha,3-beta,25-triol; Vectical; CID5280453; 1,25-dihydroxy-20-epi-Vitamin D3; 1alpha,25-Dihydroxyvitamin D; 1-alpha,25-Dihydroxycholecalciferol; 20-epi-1alpha,25-dihydroxycholecaliferol; Topitriol; HMS2089N03; U 49562; NCGC00161327-01; MolPort-002-045-698; Asentar; EINECS 250-963-8; Vitamin D3, 1alpha, 25-Dihydroxy-; 1alpha,25(OH)2D3; 1,25D3; HMS1361A09; Ro 21-5535; SAM001246772; Decostriol; (1S,3R,5Z,7E)-9,10-secocholesta-5,7,10(19)-triene-1,3,25-triol; HSDB 3482; 1,25-Dihydroxyvitamin D3; BSPBio_001287; 1,25(OH)2-20epi-D3; 1-alpha,-1,25-Dihydroxyvitamin D3; Rocaltrol; Cholecalciferol, 1-alpha,25-dihydroxy-; C01673; 1,25 (OH)2 D3; (5Z,7E)-9,10-Secocholesta-5,7,10(19)-triene-1alpha,3beta,25-triol; Calcitriol (JAN/USAN/INN); (5Z,7E)-(1S,3R)-9,10-secocholesta-5,7,10(19)-triene-1,3,25-triol; 1-alpha,25-Dihydroxyvitamin D3; calcitriol; 1,25-DIHYDROXYCHOLECALCIFEROL; 9,10-seco(5Z,7E)-5,7,10(19)-cholestatriene-1alpha, 3beta, 25-triol; Ambap32222-06-3; Rocaltrol (TN); 1,25(OH)2D3 & CD4; D1530_SIGMA; 1,25-DHCC; Dihydroxyvitamin D3; 17936_SIGMA; ZINC03924790; HMS2051F06; Spectrum5_002061; MC-1288; 1.Alpha.,25-Dihydroxy-26,27-hexadeuterovitamin D3; CCRIS 5522; 1-alpha-25-dihydroxyvitamin D3; Soltriol; Calcijex, Silkis, Rocaltrol, Topitriol, Cholecalciferol,Calcitriol; CPD000466393; HMS1791A09; 1,25-Dihydroxycholecaliferol; 1alpha,25(OH)2-D3; (1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol; LS-53093; 17936_FLUKA; 1,25-(OH)2-D3; AC1NQX1S; LMST03020258; Calcitriolum [INN-Latin]; Ro-21-5535; (1S,3R,5Z,7E)-9,10-secocholesta-5,7,10-triene-1,3,25-triol; MLS001424122; CHEMBL846; MC1288; 9,10-Secocholesta-5,7,10(19)-triene-1,3,25-triol, (1.alpha.,3.beta,.5Z,7E)- & CD4; 1db1; 9,10-Seco(5Z,7E)-5,7,10(19)-cholestatriene-1alpha,3beta,25-triol; Calcitriolum; 1alpha,25-Dihydroxycholecalciferol; 9,10-Secocholesta-5,7,10(19)-triene-1,3,25-triol, (1alpha,3beta,5Z,7E)-; MLS000759536; vit D; NCGC00161327-04; 1,25-dihydroxy vitamin D3; DN 101; CD-2027; AC-1859; 32222-06-3; DN-101	32222-06-3	134070	4817	TTDS00251	Vitamin D receptor	1,25-dihydroxyvitamin D3 receptor;Nuclear vitamin D receptor;VDR;Vitamin D(3) receptor;Vitamin D3 receptor	P11473	7421	ENSG00000111424	antagonist
DCL000782	Doxercalciferol	1-alpha-Hydroxyvitamin D2; D01009; Doxcercalciferol; ZINC04641374; C08211; AKOS005146517; TSA 840; 1alpha-Hydroxyergocalciferol; LMST03010028; Doxercalciferol; Hectorol; BCI-101; (5Z,7E,22E)-9,10-Secoergosta-5,7,10(19),22-tetraene-1alpha,3beta-diol; CHEMBL1200810; Vitamin D2, 1alpha-Hydroxy-; HSCI1_000341; 1-Hydroxyergocalciferol; BRN 4716774; CID5281107; LS-144720; AC1NQY15; Hectorol (TN); (1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol; 1alpha-OH-D2; 9,10-Secoergosta-5,7,10(19),22-tetraene-1,3-diol,(1-alpha,3-beta,5Z,7E,22E); 9,10-Secoergosta-5,7,10(19),22-tetraene-1,3-diol, (1-alpha,3-beta,5Z,7E,22E)-; Doxercalciferol [INN]; 54573-75-0; Doxercalciferol (INN)	54573-75-0	158540	49703688	TTDS00251	Vitamin D receptor	1,25-dihydroxyvitamin D3 receptor;Nuclear vitamin D receptor;VDR;Vitamin D(3) receptor;Vitamin D3 receptor	P11473	7421	ENSG00000111424	antagonist
DAP000385	Alemtuzumab	N/A	216503-57-0	N/A	533268	TTDS00096	CAMPATH-1 antigen	Cambridge pathology 1 antigen;CD52;CD52 antigen;CDW52;Epididymal secretory protein E5	P31358	1043	ENSG00000169442	antibody
DCL001239	SelG1	N/A	N/A	N/A	N/A	TTDC00197	P-selectin	CD62P;GMP-140;Granule membrane protein 140;LECAM3;Leukocyte-endothelial cell adhesion molecule 3;PADGEM	P16109	6403	ENSG00000174175	antibody
DCL000967	RPSGL-Ig	N/A	N/A	N/A	N/A	TTDC00197	P-selectin	CD62P;GMP-140;Granule membrane protein 140;LECAM3;Leukocyte-endothelial cell adhesion molecule 3;PADGEM	P16109	6403	ENSG00000174175	inhibitor
DCL000108	Ecallantide	N/A	460738-38-9	N/A	47205919	TTDC00013	Plasma kallikrein	Fletcher factor;Kininogenin;KLK3;KLKB1;Plasma kallikrein heavy chain;Plasma kallikrein light chain;Plasma prekallikrein	P03952	3818	ENSG00000164344	inhibitor
DCL000293	Xanthine	CHEBI:17712; AKOS000498219; 3,9-dihydro-1H-purine-2,6-dione; 28522-58-9; X0004; 9H-Purine-2,6-(1H,3H)-dione; Pseudoxanthine; Xanthine (VAN) (8CI); 33669-67-9; ARONIS008606; Purine-2,6-diol; C00385; 1H-Purine-2,6-diol; AC-11706; X7375_SIGMA; MolPort-003-984-175; X-0950; Xanthin; AR-1L8237; 2,6(1,3)-Purinedion; AC1L1AWZ; CHEBI:48517; XAN; LS-162511; 9H-Purine-2,6(1H,3H)-dione; LRFVTYWOQMYALW-UHFFFAOYSA-; STL064827; Xanthic oxide; MolPort-001-608-721; 69-89-6; MolPort-002-132-115; ZINC13517187; NSC14664; 2,6-dioxopurine; 51953-26-5; 16819-86-6; 3,9-Dihydro-purine-2,6-dione; I07-0041; NSC 14664; BB_SC-9416; Xanthine (VAN); 1H-Purine-2,6-dione, 3,7-dihydro-; X4002_SIGMA; 92AB342E-6550-4B2B-AD76-E75AC1C2EB45; bmse000127; 6050-36-8; NCGC00164338-01; MolMap_000070; 9H-Purine-2,6-diol; nchembio.2007.33-comp41; Isoxanthine; Purine-2,6-(1H,3H)-dione; AI3-52268; CCRIS 994; Oprea1_474175; InChI=1/C5H4N4O2/c10-4-2-3(7-1-6-2)8-5(11)9-4/h1H,(H3,6,7,8,9,10,11); AB00171825-02; nchembio.92-comp4; xanthine; CID1188; Purine-2,6(1H,3H)-dione; HMS1659G11; 2,6-Dioxo-1,2,3,6-tetrahydropurine; Purine-2(3H),6(1H)-dione; 1H-Purine-2,6-dione, 3,9-dihydro-; 2-Oxohypoxanthine; DB02134; CHEMBL1424; AC1Q2AP8; F3034-0083; EPA Pesticide Chemical Code 116900; 42911-15-9; SDCCGMLS-0065805.P001; 3,7-Dihydro-1H-purine-2,6-dione; 3,7-dihydropurine-2,6-dione; ZINC04261793; 2,6-Dihydroxypurine; EINECS 200-718-6; USAF CB-17; X0626_SIGMA	69-89-6	1188	3675	TTDS00188	Adenosine A2b receptor	A2b Adenosine receptor;Adenosine receptor A2b	P29275	136	ENSG00000170425	antagonist
DAP001375	Enprofylline paradox	N/A	41078-02-8	1676	179921	TTDS00188	Adenosine A2b receptor	A2b Adenosine receptor;Adenosine receptor A2b	P29275	136	ENSG00000170425	antagonist
DCL000620	Resatorvid	N/A	N/A	21310426	49689352	TTDC00209	Toll-like receptor 4	HToll;TLR-4	O00206	7099	ENSG00000136869	antagonist
DCL000735	Canakinumab	N/A	914613-48-2	N/A	85150696	TTDS00447	Interleukin-1 beta	Catabolin;IL-1 beta;IL-1beta	P01584	3553	ENSG00000125538	antibody
DCL000838	Ibudilast	EU-0100599; I 0157; NCGC00025261-03; 1-Propanone, 2-methyl-1-(2-(1-methylethyl)pyrazolo(1,5-a)pyridin-3-yl)-; 2-Isopropyl-3-isobutyrylpyrazolo(1,5-a)pyridine; Bio-0127; Ibudilast (JAN/INN); Eyevinal; 1-(2-Isopropylpyrazolo(1,5-a)pyridin-3-yl)-2-methyl-1-propanone; CID3671; Ke Tas; CHEBI:123745; C038366; 2-methyl-1-(2-propan-2-ylpyrazolo[1,5-a]pyridin-3-yl)propan-1-one; I0157_SIGMA; NCGC00025261-02; AV-411; I0740; KC-404; NCGC00025261-01; KC 404; SMR000326961; Ibudilastum; Tocris-1694; 2-Methyl-1-[2-(1-methylethyl)pyrazolo[1,5-a]pyridin-3-yl] 1-propanone; DB05266; Ketas (TN); MN-166; 50847-11-5; NCGC00015542-06; Ibudilast [INN:JAN]; Lopac-I-0157; I06-0361; AC-1044; AV 411; Ibudilastum [Latin]; BRN 0656579; CHEMBL19449; ZINC00004234; ibudilast; D01385; Pyrazolo(1,5-a)pyridine, 3-isobutyryl-2-isopropyl-; NCGC00015542-03; 3-Isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine; BRD-K16444452-001-03-4; LS-129153; Lopac0_000599; UNII-M0TTH61XC5; 3-Isobutyryl-2-isopropylpyrazolo(1,5-a)pyridine; AC1L1GGB; L003042; Ketas; MolPort-003-848-127; 5-24-03-00396 (Beilstein Handbook Reference); HMS2089B21; NCGC00015542-01; MLS000862198	50847-11-5	3671	46500478	TTDS00447	Interleukin-1 beta	Catabolin;IL-1 beta;IL-1beta	P01584	3553	ENSG00000125538	inhibitor
DAP001097	Glucosamine	InChI=1/C6H13NO5/c7-3-5(10)4(9)2(1-8)12-6(3)11/h2-6,8-11H,1,7H2/t2-,3-,4-,5-,6-/m1/s1; KBio2_001311; Glucosaminum [INN-Latin]; 90-77-7; KBio2_006447; 4-04-00-02017 (Beilstein Handbook Reference); nchembio.2007.41-comp7; AC1L96WB; D04334; 6490-70-6; KBioSS_001311; EINECS 222-311-2; LS-71671; AC1L2D1C; D-glucosamine; 2-Amino-2-deoxy-D-glucose; HMS500N03; CID18897; 2-Amino-2-deoxy-beta-D-glucopyranose; D-Glucose, 2-amino-2-deoxy-; MSWZFWKMSRAUBD-QZABAPFNSA-; chitosamine; DivK1c_000261; 911653-84-4; Glucosamine (USAN/INN); DB01296; CHEBI:47977; 880765-44-6; MolPort-003-944-937; nchembio.412-comp5; Glucosamina [INN-Spanish]; Glucosamina; 2-amino-2-deoxyglucose; GCS; SPBio_000477; Glucosamine [USAN:INN]; AC1L9B8P; Viartril-S; BSPBio_002086; NINDS_000261; C08349; KBio3_001306; CID441477; (2S,5R)-3-amino-6-(hydroxymethyl)oxane-2,4,5-triol; AC1Q4UBH; KBio2_003879; (3R,4R,5S,6R)-3-amino-6-(hydroxymethyl)oxane-2,4,5-triol; KBio1_000261; BRN 1724602; Glucosaminum; Glucose, 2-amino-2-deoxy-; 2B4D44B2-D5AC-4DA4-9BE6-A4AE9574E4A6; IDI1_000261; CPD0-1193; 58267-75-7; 3416-24-8; (2R,3R,4R,5S,6R)-3-amino-6-(hydroxymethyl)oxane-2,4,5-triol; partially N-deacetylated poly-beta-1,6-N-acetyl-D-glucosamine; NCGC00178826-01; HSDB 7469; 2351-15-7; bmse000247; CHEMBL234432; C00329; nchembio.189-comp4; 28905-10-4; Spectrum5_000756; 2-amino-2-deoxy-D-glucopyranose; Spectrum2_000519; KBioGR_000970; 14257-69-3; CID439213; Spectrum_000831; 58-87-7; beta-D-Glucosamine; Spectrum3_000443; glucosamine; STK801823; CHEBI:28393; D-Glucose, 2-deoxy-2-Amino-; NCGC00164421-01; Spectrum4_000565; MolPort-002-507-091	3416-24-8	439213	48416057	TTDS00447	Interleukin-1 beta	Catabolin;IL-1 beta;IL-1beta	P01584	3553	ENSG00000125538	inhibitor
DPR000028	Celastrol	(2R,4aS,6aS,12bR,14aS,14bR)-10-hydroxy-2,4a,6a,9,12b,14a-hexamethyl-11-oxo-1,2,3,4,4a,5,6,6a,11,12b,13,14,14a,14b-tetradecahydropicene-2-carboxylic acid; KBio1_000718; KBio2_000815; 3-Hydroxy-24-nor-2-oxo-1(10),3,5,7-friedelatetraen-29-oic Acid; Celastrol, Celastrus scandens; Spectrum2_000150; KBio2_005951; Ambotz34157-83-0; nchembio.368-comp16; NSC70931; 34157-83-0; BSPBio_001905; KBioSS_000815; CHEBI:186102; NCI60_038570; KBio3_001405; KBioGR_002436; AC1L3V4O; Spectrum5_000805; D:A-Friedo-24-noroleana-1(10),3,5,7-tetraen-29-oic acid, 3-hydroxy-2-oxo-, (20alpha)-; SPECTRUM201664; Spectrum4_001966; Tripterin; NINDS_000718; CHEMBL301982; C050414; DivK1c_000718; NSC 70931; HMS1923A13; CID122724; NCGC00178913-01; SPBio_000260; (2R,4aS,6aR,6aS,14aS,14bR)-10-hydroxy-2,4a,6a,6a,9,14a-hexamethyl-11-oxo-1,3,4,5,6,13,14,14b-octahydropicene-2-carboxylic acid; KST-1A4115; AC-6031; 35327-72-1; C29H38O4; Spectrum_000335; AC1Q6P61; celastrol; IDI1_000718; Tripterine; MolPort-003-665-482; AR-1A3014; S1290_Selleck; KBio2_003383; LS-157465; Spectrum3_000233; 2-Picenecarboxylic acid, 1,2,3,4,4a,5,6,6a,11,12b,13,14,14a,14b-tetradecahydro-10-hydroxy-2,4a,6a,9,12b,14a-hexamethyl-11-oxo-	34157-83-0	122724	8138360	TTDS00447	Interleukin-1 beta	Catabolin;IL-1 beta;IL-1beta	P01584	3553	ENSG00000125538	N/A
DAP001096	Gallium nitrate	N/A	13494-90-1	61635	15490402	TTDS00447	Interleukin-1 beta	Catabolin;IL-1 beta;IL-1beta	P01584	3553	ENSG00000125538	inhibitor
DCL001165	BMS-833923	N/A	N/A	N/A	N/A	TTDC00344	Smoothened	Smoothened homolog;SMO;Protein Gx	Q99835	6608	ENSG00000128602	inhibitor
DAP000599	Methazolamide	AB00490015; LS-10006; NCGC00018188-01; HSDB 3269; Spectrum2_001543; Methazolamidum; Prestwick1_000802; M4156_SIGMA; Acetamide, N-(5-(aminosulfonyl)-3-methyl-1,3,4-thiadiazol-2(3H)-ylidene)-; IDI1_000582; BSPBio_003508; AC1L1HEV; EINECS 209-066-7; MolPort-001-791-152; D008704; Methazolamidum [INN-Latin]; HMS501N04; N-(3-methyl-5-sulfamoyl-2,3-dihydro-1,3,4-thiadiazol-2-ylidene)acetamide; methazolamide; Methazolamide (MZA); N-(4-Methyl-2-sulfamoyl-delta(sup 2)-1,3,4-thiadiazolin-5-ylidene)acetamide; HMS1922M19; HMS2093A05; MLS000028532; 5-Acetylimino-4-methyl-delta(sup 2)-1,3,4-thiadiazoline-2-sulfonamide; Metazolamide; BPBio1_000731; BSPBio_000663; N-Methylacetazolamide; N-(4-Methyl-2-sulfamoyl-Delta2-1,3,4-thiadiazolin-5-ylidene) acetamide; KBio3_003013; DivK1c_000582; Neptazaneat; AC1Q40D9; Prestwick3_000802; SPBio_001386; N-(3-methyl-5-sulfamoyl-1,3,4-thiadiazol-2-ylidene)acetamide; Prestwick_1007; Acetamide, N-[5-(aminosulfonyl)-3-methyl-1,3,4-thiadiazol-2(3H)-ylidene]-; SAM002589943; BRN 0232387; Naptazane; CPD001496938; M4156_FLUKA; HMS1570B05; C5H8N4O3S2; KBio1_000582; KBioGR_000739; UNII-W733B0S9SD; N-[(2E)-5-(aminosulfonyl)-3-methyl-1,3,4-thiadiazol-2(3H)-ylidene]acetamide; Spectrum_001615; Metazolamida; NCGC00178022-02; BRD-K71053238-001-04-4; SMR000058287; BRD-K71053238-001-03-6; KBio2_004663; NCGC00022950-03; NCGC00016508-01; Prestwick2_000802; CAS-554-57-4; N Methylacetazolamide; CID4100; Metazolamide [DCIT]; ZINC12503151; CHEMBL19; D00655; SPBio_002584; Methazolamide (JAN/USP/INN); DB00703; KBioSS_002095; Oprea1_161738; AC1Q40D8; Metazolamida [INN-Spanish]; KBio2_007231; NINDS_000582; I09-1225; SPECTRUM1503252; Neptazane; 2-Acetylimino-3-methyl-delta(sup 4)-1,3,4-thiadiazoline-5-sulfonamide; Neptazane (TN); C07764; Prestwick0_000802; Methenamide; 4-27-00-08221 (Beilstein Handbook Reference); NCGC00178022-01; ST081366; Methazolamide [INN:BAN:JAN]; CHEBI:101124; KBio2_002095; Acetamide, N-(4-methyl-2-sulfamoyl-delta(sup 2)-1,3,4-thiadiazolin-5-ylidene)-; Spectrum4_000190; NCGC00022950-04; 554-57-4; Spectrum5_001006; MLS001146905; Spectrum3_001914	554-57-4	4100	9966	TTDS00304	Carbonic anhydrase	N/A	N/A	N/A	N/A	inhibitor
DAP000955	Quinethazone	ZINC00000686; Quinethazon; Quinetazona [INN-Spanish]; BPBio1_001078; Quinethazone [INN:BAN:JAN]; Quinethazone (JAN/INN); 6-Quinazolinesulfonamide, 1,2,3,4-tetrahydro-7-chloro-2-ethyl-4-oxo-; CID6307; Chinetazone [DCIT]; Chinethazone; Hydromox (TN); SMR001233433; AB00514022; Quinetazona; MLS002154126; DB01325; 6-Quinazolinesulfonamide, 7-chloro-2-ethyl-1,2,3,4-tetrahydro-4-oxo-; Quinethazonum [INN-Latin]; CCRIS 6098; BSPBio_000980; HSDB 3392; BRN 0818554; Quinethazone (aquamox); Chinetazone; Prestwick3_001050; 5-25-09-00214 (Beilstein Handbook Reference); 7-Chloro-2-ethyl-1,2,3,4-tetrahydro-4-oxo-6-quinazolinesulfonamide; Chinethazonum; Idrokin; AC1L1M8L; 7-Chloro-2-ethyl-6-sulfamoyl-1,2,3,4-tetrahydro-4-quinazolinone; Prestwick0_001050; MolPort-002-070-273; CHEMBL1532; Quinethazonum; UNII-455E0S048W; LS-1624; 7-chloro-2-ethyl-4-oxo-1,2,3,4-tetrahydroquinazoline-6-sulfonamide; Prestwick1_001050; 7-chloro-2-ethyl-4-oxo-2,3-dihydro-1H-quinazoline-6-sulfonamide; BRD-A59303141-001-03-9; HMS1571A22; 73-49-4; QUINETHAZONE; Hydromox; D00461; 2-Ethyl-7-chloro-1,2,3,4-tetrahydro-4-oxochinazolin-6-sulfonamid; CL 36010; Aquamox; Prestwick2_001050; C10H12ClN3O3S; 7-Chloro-2-ethyl-1,2,3,4-tetrahydro-4-oxo-6-sulfamoylquinazoline; EINECS 200-801-7; C07342; SPBio_002910	73-49-4	6307	7847527	TTDS00304	Carbonic anhydrase	N/A	N/A	N/A	N/A	inhibitor
DAP000601	Dichlorphenamide	Dichlorphenamid; SBB058142; Diclofenamida [INN-Spanish]; Prestwick3_000809; Dichlorophenamide (DCP); Daranide; CHEMBL17; Prestwick0_000809; Oratrol; EINECS 204-440-6; AC1L1F18; UNII-VVJ6673MHY; BSPBio_000677; DB07948; MLS002154010; ZINC00896918; Diclofenamida; Merck Brand of Dichlorphenamide; NCGC00016371-02; Glajust; Diclofenamide; DB01144; Dichlorphenamide (USP); Diclofenamidum [INN-Latin]; BPBio1_000745; Glaumid; LS-30043; Antidrasi; 120-97-8; Llorens Brand of Dichlorphenamide; HMS1570B19; Daranide (TN); Dichlorophenamide; 3,4-Dichloro-5-sulfamylbenzenesulfonamide; Diclofenamidum; I7A; CHEBI:101085; Barastonin; BRN 2703329; NCGC00016371-01; CB 8000; 1,3-Disulfamoyl-4,5-dichlorobenzene; SMR001233338; C07459; BRD-K71499074-001-03-8; 4,5-Dichloro-benzene-1,3-disulfonic acid diamide; Prestwick2_000809; m-Benzenedisulfonamide, 4,5-dichloro-; Diclofenamid; 1,3-Benzenedisulfonamide, 4,5-dichloro-; 4,5-Dichloro-m-benzenedisulfonamide; S2177_Selleck; Diclofenamide (JP15/INN); Glaucol; D004005; Prestwick_1071; FT-0084528; 4,5-Dichloro-1,3-disulfamoylbenzene; 1,3-Disulfamyl-4,5-dichlorobenzene; CAS-120-97-8; 4,5-Dichloro-1,3-benzenedisulfonamide; dichlorphenamide; Dasanide; Dichlorphenamide [BAN]; 2pou; Glauconide; 4,5-dichlorobenzene-1,3-disulfonamide; Glafco; HSDB 3267; MolPort-004-285-635; Dichlofenamide; D00518; CID3038; C6H6Cl2N2O4S2; Prestwick1_000809; SPBio_002598	120-97-8	3038	9662	TTDS00304	Carbonic anhydrase	N/A	N/A	N/A	N/A	inhibitor
DAP000600	Acetazolamide	Diutazol; Prestwick2_000003; Apo-Acetazolamide; DivK1c_000017; Acetazolamide Wassermann Brand; SBB056640; Acetazolamide Sodium, (Sterile); Glauconox; Jumer Brand of Acetazolamide; Acetazolamide [INN:BAN:JAN]; BAS 01585728; SPBio_000004; Grin Brand of Acetazolamide; KBioGR_000558; Diuramide; 1ydd; BZKPWHYZMXOIDC-UHFFFAOYSA-; D00218; Acetazolamide Apotex Brand; I09-0425; NCGC00015074-06; Donmox; Storzolamide; Llorens Brand of Acetazolamide; Glaumox; AkZol; AB00051906; BSPBio_000005; KBio3_001288; SPECTRUM1500102; Atenezol; Apo Acetazolamide; Acetadiazol; EINECS 200-440-5; Huma Zolamide; NCGC00015074-02; 5661-25-6; NCGC00023455-05; Didoc; 4-Diamox; Carbonic anhydrase inhibitor 6063; Acetazolamidum [INN-Latin]; Glupax; AKOS000715163; Phonurit; Acetazolamine; NCGC00023455-06; Acetazolamida; Acetazolamide Chiesi Brand; 3czv; Huma-Zolamide; HMS2091G05; Carbonic Anhydrase Inhibitor No. 6063; Diacarb; Acetazolamida [INN-Spanish]; C06805; Acetazolamidum; Cidamex; KBio1_000017; 59-66-5; MLS000028435; MLS001148438; Wassermann Brand of Acetazolamide; Eumicton; Prestwick1_000003; AI3-52458; Acetazolam; SK-acetazolamide; Diuriwas; CID1986; CHEBI:27690; Spectrum2_000082; Prestwick3_000003; BSPBio_001788; AC1L1CO5; Storz Brand of Acetazolamide Preparation; A6011_SIAL; 2h4n; NCGC00015074-01; Duiramid; Spectrum4_000139; Fonurit; Ciba Vision Brand of Acetazolamide; Nephramide; Nephramid; WLN: T5NN DSJ CSZW EMV1; Lopac-A-6011; HSDB 3002; NSC145177; KBio2_005494; Acetazolamid; Diuramid; HumaZolamide; Acetazolamide, Monosodium Salt; UNII-O3FX965V0I; LS-10227; HMS500A19; Defiltran; IDI1_000017; 1ydb; Dioptic Brand of Acetazolamide; EU-0100039; Diamox (TN); AC-12779; Spectrum_000018; CCRIS 5811; Natrionex; NCGC00023455-03; Vetamox; ICN Brand of Acetazolamide; Lopac0_000039; Wyeth Brand of Acetazolamide Preparation; Novopharm Brand of Acetazolamide; Chiesi Brand of Acetazolamide; NSC 145177; Orion Brand of Acetazolamide; DB00819; Acetazolamide (JP15/USP/INN); Prestwick0_000003; KBio2_002926; Medphano Brand of Acetazolamide; CPD0-1626; Acetazolamide ICN Brand; Diamox; Diluran; CAS-59-66-5; Monosodium Salt Acetazolamide; SPBio_001926; Spectrum5_000738; NINDS_000017; A 6011; D000086; Ak Zol; Dazamide; MolPort-001-783-578; Edemox; CPD000058394; Acetazolamide Llorens Brand; Acetamidothiadiazolesulfonamide; Glaupax; Acetazolamide Medphano Brand; NCGC00023455-07; Apotex Brand of Acetazolamide; Diureticum-holzinger; Acetazolamide Jumer Brand; BIDD:GT0643; Diakarb; KBio2_000358; Diamox Sequels; 1424-27-7 (mono-hydrochloride salt); Acetazolamide Orion Brand; Acetozalamide; NCGC00023455-04; NCGC00015074-03; 1zsb; Ak-Zol; ApoAcetazolamide; CHEMBL20; KBioSS_000358; NCGC00015074-11; Acetazolamide Novopharm Brand; Acetazolamide (AAZ); Acetazoleamide; HMS1920A05; Spectrum3_000284; SMR000058394; A6011_SIGMA; 1yda; Dehydratin; Prestwick_4; Acetazolamide Grin Brand; SAM002554883; Acetamox; C4H6N4O3S2; Acetazolamide Dioptic Brand; BPBio1_000007; HMS1568A07; 8017-69-4; acetazolamide	59-66-5	1986	9024	TTDS00304	Carbonic anhydrase	N/A	N/A	N/A	N/A	inhibitor
DCL000928	Phentermine+topiramate	N/A	122-09-8	N/A	N/A	TTDS00304	Carbonic anhydrase	N/A	N/A	N/A	N/A	inhibitor
DAP000598	Ethoxzolamide	Cardrase; 2-Benzothiazolesulfonamide, 6-ethoxy-; 3caj; HMS2094M03; NSC10679; Ethoxzolamide (EZA); 6-Ethoxy-2-benzothiazolesulfonamide; nchem.365-comp2; 6-Ethoxy-benzothiazole-2-sulfonic acid amide; Glaucotensil; CHEMBL18; MolPort-003-666-681; CID3295; NSC 10679; AI3-50805; InChI=1/C9H10N2O3S2/c1-2-14-6-3-4-7-8(5-6)15-9(11-7)16(10,12)13/h3-5H,2H2,1H3,(H2,10,12,13; 6-Ethoxyzolamide; ethoxzolamide; nchembio.157-comp4; 6-Ethoxy-1,3-benzothiazole-2-sulfonamide; BRN 0212240; 6-(ethyloxy)-1,3-benzothiazole-2-sulfonamide; Diuretic C; D005016; C9H10N2O3S2; HSDB 3268; Ethoxyzolamide; D02441; U-4191; NCGC00018249-01; 333328_ALDRICH; ST086115; EINECS 207-199-5; 6-Ethoxybenzothiazole-2-sulfonamide; 452-35-7; ZINC00056721; Redupresin; DB00311; SMR000059148; CHEBI:101096; AC1L1FLZ; UNII-Z52H4811WX; NCGC00022533-04; MLS000028637; WLN: T56 BN DSJ CSZW GO2; Ethoxazolamide; 6-Ethoxybenzothiazole-2-sulphonamide; Cardrase (TN); HMS2093J03; MLS001077357; Mingoral; 4-27-00-04404 (Beilstein Handbook Reference); Ethamide; EZL; Etoxzolamide; LS-40823; 6-Ethoxybenzo[d]thiazole-2-sulfonamide; DB07727	452-35-7	3295	7849499	TTDS00304	Carbonic anhydrase	N/A	N/A	N/A	N/A	inhibitor
DAP000602	Brinzolamide	Birnzolamide; AC1L2AKA; 3znc; AL-4862; BSPBio_000489; BRD-K74913225-001-03-3; C111827; BPBio1_000539; Prestwick2_000365; Brinzolamide; (4R)-4-(ethylamino)-2-(3-methoxypropyl)-1,1-dioxo-3,4-dihydrothieno[3,2-e]thiazine-6-sulfonamide; (R)-4-(ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-2H-thieno(3,2-e)-1,2-thiazine-6-sulfonamide; Prestwick0_000365; CHEBI:3176; 138890-62-7; AB00513824; UNII-9451Z89515; AC-5277; MLS002153787; D00652; Allphar brand of brinzolamide; MolPort-005-940-291; FT-0082471; Prestwick1_000365; C07760; Azopt; HMS1569I11; AL 4862; 2H-Thieno(3,2-e)-1,2-thiazine-6-sulfonamide,4-(ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-,1,1-dioxide,R; AKOS005145708; (4R)-4-(ethylamino)-2-(3-methoxypropyl)-3,4-dihydro-2H-thieno[3,2-e][1,2]thiazine-6-sulfonamide 1,1-dioxide; Azopt (TN); I09-0605; C12H21N3O5S3; SPBio_002410; Alcon brand of brinzolamide; 2H-Thieno(3,2-e)-1,2-thiazine-6-sulfonamide, 4-(ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-, 1,1-dioxide, (R)-; (R)-4-(Ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-2H-thieno(3,2-e)-1,2-thiazine-6-sulfonamide 1,1-dioxide; SMR001233169; BZ1; CID68844; AC1Q6UVB; Brinzolamide [USAN]; BIDD:GT0039; (+)-4-ETHYLAMINO-3,4-DIHYDRO-2-(METHOXY)PROPYL-2H-THIENO[3,2-E]-1,2-THIAZINE-6-SULFONAMIDE-1,1-DIOXIDE; Brinzolamide (BRZ); Prestwick3_000365; AL04862; DB01194; CHEMBL220491; Brinzolamide (JAN/USP/INN); LS-173036	138890-62-7	68844	210988	TTDS00304	Carbonic anhydrase	N/A	N/A	N/A	N/A	inhibitor
DAP000956	Diazoxide	HMS1989B09; MLS000028459; CAS-364-98-7; Bio2_000507; Prestwick1_000087; ZINC03872277; Diazoxide (JAN/USP/INN); D003981; D00294; UNII-O5CB12L4FN; NCGC00024907-07; CID3019; MolPort-003-941-186; KBioGR_000027; KBio3_000053; NSC 64198; BSPBio_001307; nchembio.150-comp49; DB01119; NCGC00015380-05; SPECTRUM2300206; Spectrum4_001248; HMS2093N12; KBioSS_000027; Sch 6783; NCGC00024907-01; CPD000058392; EU-0100404; NSC76130; NSC-64198; HMS1361B09; 7-Cloro-3-metil-2H-1,2,4-benzotiodiazina-1,1-diossido; 7-Chloro-3-methyl-2H-1,2,4-benzothiadiazine 1,1-dioxide; NCGC00024907-08; D 9035; IDI1_033777; Hyperstat; Mutabase; CBiol_001750; Diazoxido; Bio1_000525; Eudemine; CHEBI:4495; Prestwick_163; Diazoxidum [INN-Latin]; VU0239714-6; Diazoxide [USAN:INN:BAN]; 2H-1,2,4-Benzothiadiazine, 7-chloro-3-methyl-, 1,1-dioxide; SRG-95213; Prestwick2_000087; Prestwick0_000087; Diazossido [Italian]; NCGC00015380-03; 364-98-7; SPBio_001953; KBio2_000027; Aroglycem; Proglicem; BRD-K73109821-001-05-2; NCGC00015380-02; Bio1_000036; nchembio.476-comp10; Bio2_000027; NCGC00015380-12; 7-Cloro-3-metil-2H-1,2,4-benzotiodiazina-1,1-diossido [Italian]; Hyperstat (TN); Diazossido; HMS2089L04; SRG 95213; Spectrum3_000735; NCGC00024907-03; HMS1568A16; LS-40410; BPBio1_000016; Diazoxidum; C8H7ClN2O2S; Sch-6783; NSC 76130; NSC64198; MolPort-003-666-772; NCGC00015380-01; SMR000058392; I06-2041; Lopac0_000404; HMS2051P20; CHEMBL181; D9035_SIGMA; KBio2_005163; 2H-1,2, 4-Benzothiadiazine, 7-chloro-3-methyl-, 1,1-dioxide; 7-Chloro-3-methyl-1lambda~4~,2,4-benzothiadiazin-1-ol 1-oxide; 7-Chloro-3-methyl-2H-1,2,4-benzothiadiazine 1,1-dioxide; NCGC00024907-02; Bio1_001014; MLS001076071; Diazossido [DCIT]; 7-chloro-3-methyl-4H-1; NCGC00024907-04; Diazoxido [INN-Spanish]; KBioGR_001776; BSPBio_002290; C06949; KBio2_002595; EINECS 206-668-1; Tocris-0964; NCGC00024907-05; diazoxide; Proglycem; AC1L1EZN; KBio3_001510; HMS1922L22; Dizoxide; NCGC00024907-06; SAM001246872; Lopac-D-9035; HMS1791B09; Hypertonalum; KBio3_000054; BSPBio_000014; Prestwick3_000087	364-98-7	3019	9164	TTDS00304	Carbonic anhydrase	N/A	N/A	N/A	N/A	inhibitor
DAP001319	Adenosine monophosphate	Formycin 5'-phosphate hydrate; AMP (nucleotide); a-5mp; 67583-85-1; 162756-82-3; 2gmk; Muskeladenosin-phosphorsaeure; adenylate; 1H-Pyrazolo(4,3-d)pyrimidine, 7-amino-3-beta-D-ribofuranosyl-, 5'-(dihydrogen phosphate)-, hydrate; 8-Aminoadenosine 5'-monophosphate; Adenovite; Prestwick2_000356; Adenine polynucleotides; Adenosine 5'-(dihydrogen phosphate); Lycedan; Adenosine-5-phosphate; MolPort-003-987-006; BRN 0054612; NCGC00163319-01; DB00131; NCGC00163319-02; D02769; adenosine-monophosphate; Formycin A 5'-monophosphate hydrate; A5MP; 53624-78-5; Phosaden; nchembio.266-comp19; Adenosine phosphate [USAN:INN:BAN]; (S)-1-C-(7-Amino-1H-pyrazolo(4,3-d)pyrimidin-3-yl)-1,4-anhydro-D-ribitol, 5-(dihydrogen phosphate); MolPort-004-946-768; HSDB 3281; Adenosine-5'-monophosphate; Formycin 5'-monophosphate hydrate; Prestwick3_000356; CID15938965; Phosphentaside; Polyadenylic acids; ZINC03860156; 47287-97-8; NSC 20264; My-B-Den; Adenosine monophosphate; Fosfato de adenosina [INN-Spanish]; AMP; 61-19-8; Adenosine-5-monophosphate(2-); PAdo; ASMP; LS-15192; POLY A; adenosine 5'-phosphate; Adenyl; Phosphate d'adenosine [INN-French]; Muscle adenylic acid; bmse000005; Phosphate d'adenosine; Adenosine phosphate (USAN/INN); Adenylic acid (VAN); Prestwick0_000356; 1z6s; CHEMBL752; Adenyl (TN); 7gpb; C00020; CHEBI:456215; 9H-Purin-6-amine, 9-(5-O-phosphono-.beta.-D-ribofuranosyl)-; Adenosine-5'-monophosphate; 2vfk; 9H-purin-6-amine, 9-(5-O-phosphono-beta-D-ribofuranosyl)-; Adenosine phosphate [USAN:BAN:INN]; 34051-12-2; nchembio867-comp5; Adenosine-5'-monophosphoric acid; 2gsu; 5'-adenosine monophosphate; A0158; Fosfato de adenosina; Phosphaden; Adenosine-5-monophosphoric acid; Vitamin B8; Myoston; BPBio1_000497; 47286-65-7; 5'-Adenylic acid, 8-amino-; 5'-Adenylic acid, homopolymer; AMP dianion; AR-1H6048; Adenosine 5'-monophosphoric acid; Adenosine, mono(dihydrogen phosphate) (ester); BSPBio_000451; Adenosini phosphas [INN-Latin]; Cardiomone; Adenosine 5'-phosphoric acid; 24937-83-5; 5'-adenylic acid; 3dhv; 5'-AMP; 5'-Thio-5'-adenylic acid; Monophosphadenine; 5'-Deoxy-5'-thioadenosine 5'-monophosphate; Adenosini phosphas; 1pyg; 7-Amino-3-beta-D-ribofuranosyl-1H-pyrazolo(4,3-d)pyrimidine 5'-(dihydrogen phosphate) hydrate; adenosine-5'P; NSC-20264; AMP (VAN); 7A8E6D15-9136-44C1-88C9-E1A224638E56; Formycin 5'-phosphate; Prestwick1_000356; Adenosine Monophosphate (Amp); Adenosine-5-monophosphate dianion; Ergadenylic acid; 1ua4; SPBio_002372; CID6083; 2qrk; 4-26-00-03615 (Beilstein Handbook Reference); Ado5'P; AC1Q1ID5; CHEBI:16027; 8gpb; LS-129209; EINECS 200-500-0; adenosine phosphate; Muskeladenylsaeure; AC1L1LRL; 55036-25-4; [(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate; adenosine-phosphate; GAMMA-ARSONO-BETA, GAMMA-METHYLENEADENOSINE-5'-DIPHOSPHATE; 13270-66-1; STOCK1N-70887; adenosine 5'-monophosphate; 697214-87-2; TL8003885; 5'-Adenylic acid, 5'-thio-; ADENOSINE-5'-PHOSPHATE; 2q8m; adenylic acid; 5'-O-phosphonoadenosine; 5'-O-phosphonatoadenosine	61-19-8	6083	3322	TTDS00500	Adenylate cyclase type 1	ADCY1;Adenylate cyclase type I;Adenylyl cyclase 1;ATP pyrophosphate-lyase 1;Ca(2+)/calmodulin-activated adenylyl cyclase	Q08828	107	ENSG00000164742	binder
DCL000273	Lonapalene	Lonapalenum; CHEBI:153018; Lonapaleno [Spanish]; CHEMBL36648; Lonapalene (USAN); RS-43179; CID56237; Lonapalenum [Latin]; LONAPALENE; RS 43179; D04770; 6-Chloro-2,3-dimethoxy-1,4-naphthalenediol diacetate; AC1L1KN9; Lonapaleno; (4-acetyloxy-6-chloro-2,3-dimethoxynaphthalen-1-yl) acetate; 91431-42-4	91431-42-4	56237	47206584	TTDS00112	Arachidonate 5-lipoxygenase	5-lipoxygenase;5-LO;5-LOX	P09917	240	ENSG00000012779	inhibitor
DCL000754	CJ-13610	C496810; CJ-13,610; CJ 13610	179420-35-0	3600	47216887	TTDS00112	Arachidonate 5-lipoxygenase	5-lipoxygenase;5-LO;5-LOX	P09917	240	ENSG00000012779	inhibitor
DAP000591	Zileuton	AKOS000280127; C063449; CPD000466377; 1-[1-(1-benzothien-2-yl)ethyl]-1-hydroxyurea; 1-[1-(1-benzothiophen-2-yl)ethyl]-1-hydroxyurea; DB00744; Abbot 64077; Bio-0924; Zileuton [USAN:INN:BAN]; C11H12N2O2S; Zyflo; ABBOTT-64077; 111406-87-2; FT-0082368; Zileutonum; Urea, N-(1-benzo(b)thien-2-ylethyl)-N-hydroxy-, (+-)-; Ziluton; S1443_Selleck; ABT-077; AC-13198; A 64077; CHEBI:10112; 154003-29-9; SMR000466377; ZYFLO, Zileuton; MLS001424079; Zyflo CR; D00414; NCGC00159453-02; MolPort-003-850-877; N-[1-(benzo[b]thiophen-2-yl)ethyl]-N-hydroxyurea; (+-)-1-(1-Benzo[b]thien-2-ylethyl)-1-hydroxyurea; Prestwick0_001090; HMS2093H06; Zyflo Filmtab; SAM001246738; UNII-V1L22WVE2S; Zileuton (USP/INN); MLS000759510; ZILEUTON; 133305-01-8; CTI-02; CHEMBL93; AC1L1TCB; HMS2051M20; Urea, N-(1-benzo(b)thien-2-ylethyl)-N-hydroxy-; (+-)-1-(1-Benzo(b)thien-2-ylethyl)-1-hydroxyurea; Abbott brand of zileuton; LS-158908; A-64077; Abbott 64077; CID60490; Zileutonum [INN-Latin]; HMS2089J12; N-(1-Benzo(b)thien-2-ylethyl)-N-hydroxyurea; (+/-)-1-(1-Benzo[b]thien-2-ylethyl)-1-hydroxyurea; MolPort-000-883-253; Leutrol; Zyflo (TN)	111406-87-2	60490	196786	TTDS00112	Arachidonate 5-lipoxygenase	5-lipoxygenase;5-LO;5-LOX	P09917	240	ENSG00000012779	inhibitor
DCL000865	Leukotriene antagonist	N/A	158966-92-8	4992	49698888	TTDS00112	Arachidonate 5-lipoxygenase	5-lipoxygenase;5-LO;5-LOX	P09917	240	ENSG00000012779	inhibitor
DAP000913	Masoprocol	741285-10-9; meso-NDGA; NCGC00094201-01; NDGA; C18H22O4; EU-0100877; 4-[(2S,3R)-4-(3,4-dihydroxyphenyl)-2,3-dimethylbutyl]benzene-1,2-diol; AC1Q7ACC; AC1L2G35; 27686-84-6; DB00179; (R*,S*)-4,4'-(2,3-Dimethylbutane-1,4-diyl)bispyrocatechol; 334707-72-1; 1,2-Benzenediol, 4,4'-(2,3-dimethyl-1,4-butanediyl)bis-, (R*,S*)-; meso-4,4'-(2,3-Dimethyltetramethylene)dipyrocatechol; 1,2-Benzenediol, 4,4'-((2R,3S)-2,3-dimethyl-1,4-butanediyl)bis-, rel-; EINECS 248-606-6; D04862; CHX-100; 1,2-Benzenediol, 4,4'-(2,3-dimethyl-1,4-butanediyl)bis-, (R*,S*)-; Masoprocol (USAN/INN); NCGC00094201-04; ZINC00012342; CID71398; Nordihydroguaiaretic acid (meso-form); ZINC12359927; Actinex (TN); Lopac0_000877; Lopac-N-5023; C10719; 500-38-9; BIDD:ER0127; Masoprocolum [INN-Latin]; NCGC00015741-03; NCGC00094201-02; TNP00263; Actinex; UNII-7BO8G1BYQU; CHX 100; NCGC00015741-02; Masoprocolum; meso-Nordihydroguaiaretic acid; meso-4,4'-(2,3-Dimethyltetramethylene)dipyrocatechol; Nordihydroguaiaretic acid from Larrea divaricata (creosote bush); LS-174190; Masoprocol; CHEMBL313972; Masoprocol [USAN:INN]; N 5023; NCGC00015741-01	500-38-9	71398	12902	TTDS00112	Arachidonate 5-lipoxygenase	5-lipoxygenase;5-LO;5-LOX	P09917	240	ENSG00000012779	inhibitor
DAP000914	Diethylcarbamazine	Prestwick2_000284; Spectrum3_000390; DivK1c_000548; 1642-54-2 (citrate (1:1)); Prestwick3_000284; Dietilcarbamazina; Bitirazine; Carbamazine; KBioGR_001081; Camin; Ethodryl; CHEMBL684; Decacide; N,N-Diethyl-4-methyl-1-piperazinecarboxamide; NCGC00178778-01; Diethylcarbamazine (INN); NCGC00178778-02; Spatonin; 4-23-00-00225 (Beilstein Handbook Reference); 8028-18-0; AI3-19612; NINDS_000548; KBio2_003986; 90-89-1; 1-Diethylcarbamyl-4-methylpiperazine; 1-Piperazinecarboxamide, N,N-diethyl-4-methyl-; 5348-97-0; KBio2_001418; N,N-diethyl-4-methylpiperazine-1-carboxamide; Caracide; Diethyl carbamazine; Dietilcarbamazina [INN-Spanish]; KBio2_006554; LS-110688; 12672-34-3; IDI1_000548; Ditrazine Base; Cypip; Carbilazine; UNII-V867Q8X3ZD; NSC1364; Diethylcarbamazinum; 84L; Spectrum_000938; BSPBio_000188; CID3052; AKOS003268016; AB00053457; FR-1031; Caricide; Diaethylcarbamazinum; DB00711; 1-Piperazinecarboxamide, N,N-diethyl-4-methyl-; BPBio1_000208; MolPort-001-788-448; D07825; C07968; AC1L1F2E; Spectrum4_000511; Camin (TN); Diethylcarbamazinum [INN-Latin]; Prestwick1_000284; EINECS 202-023-3; Luxuran; Notezine; Prestwick0_000284; BRD-K45542189-048-05-6; SPBio_001203; SPBio_002407; BSPBio_002179; Diethylcarbamazine [INN:BAN]; KBio1_000548; KBioSS_001418; 5348-97-0 (mono-hydrochloride); BRN 0143029; diethylcarbamazine; Spectrum5_000877; KBio3_001399; Spectrum2_001022	90-89-1	3052	10169	TTDS00112	Arachidonate 5-lipoxygenase	5-lipoxygenase;5-LO;5-LOX	P09917	240	ENSG00000012779	inhibitor
DCL000315	ABT-761	1-[(2R)-4-[5-[(4-fluorophenyl)methyl]thiophen-2-yl]but-3-yn-2-yl]-1-hydroxyurea; Atreleuton (USAN/INN); 154355-76-7; A-85761; AC1MJ6LB; CHEBI:193440; ABT-761; UNII-U301T88E1M; CID3086671; Atreleuton; ABT 761; D03010; CHEMBL59356; Atreleuton [USAN]	N/A	3086671	7980075	TTDS00112	Arachidonate 5-lipoxygenase	5-lipoxygenase;5-LO;5-LOX	P09917	240	ENSG00000012779	inhibitor
DCL000269	Linazolast	[4-[(1E,3E)-5-[2-(4-benzhydryloxypiperidin-1-yl)ethylamino]-5-oxopenta-1,3-dienyl]-2-methoxyphenyl] ethyl carbonate; 110501-66-1; Linetastine; CID6439232; Carbonic acid, 4-(5-((2-(4-(diphenylmethoxy)-1-piperidinyl)ethyl)amino)-5-oxo-1,3-pentadienyl)-2-methoxyphenyl ethyl ester; Tmk688; CCRIS 6902; UNII-7U248Z56LA; AC1O5R98; Linazolast; YM-257; CHEMBL314338; TMK-688; Tmk 688; CHEBI:236100; Linetastine [INN]; 159776-68-8	110501-66-1	6439232	12014083	TTDS00112	Arachidonate 5-lipoxygenase	5-lipoxygenase;5-LO;5-LOX	P09917	240	ENSG00000012779	inhibitor
DCL000307	MK-591	CHEMBL16596; C078266; Quiflapon [INN]; 2CS; 1H-Indole-2-propanoic acid, 1-((4-chlorophenyl)methyl)-3-((1,1-dimethylethyl)thio)-alpha,alpha-dimethyl-5-(2-quinolinylmethoxy)-; L-686,708; LS-187285; Quiflapon; LS-172970; MK 0591; 3-(tert-butylthio)-1-(p-chlorobenzyl)-a,a-dimethyl-5-(2-quinolylmethoxy)indole-2-propionic acid; 136668-42-3; 3-(1-(4-chlorobenzyl-3-(t-butylthio)-5-(quinolin-2-ylmethoxy)indol-2-yl))-2,2-dimethyl propanoic acid; MK 591; AC1L1U63; C34H34ClN2O3S.Na; MK-0591; MK-591; CHEBI:117620; CID60923; AC1Q5RPF; L-686708; 3-(tert-Butylthio)-1-(p-chlorobenzyl)-alpha,alpha-dimethyl-5-(2-quinolylmethoxy)indole-2-propionic acid; L 686708; 3-[3-tert-butylsulfanyl-1-[(4-chlorophenyl)methyl]-5-(quinolin-2-ylmethoxy)indol-2-yl]-2,2-dimethylpropanoic acid	136668-42-3	60923	47207332	TTDS00112	Arachidonate 5-lipoxygenase	5-lipoxygenase;5-LO;5-LOX	P09917	240	ENSG00000012779	inhibitor
DCL000301	Linetastine	[4-[(1E,3E)-5-[2-(4-benzhydryloxypiperidin-1-yl)ethylamino]-5-oxopenta-1,3-dienyl]-2-methoxyphenyl] ethyl carbonate; 110501-66-1; Linetastine; CID6439232; Carbonic acid, 4-(5-((2-(4-(diphenylmethoxy)-1-piperidinyl)ethyl)amino)-5-oxo-1,3-pentadienyl)-2-methoxyphenyl ethyl ester; Tmk688; CCRIS 6902; UNII-7U248Z56LA; AC1O5R98; Linazolast; YM-257; CHEMBL314338; TMK-688; Tmk 688; CHEBI:236100; Linetastine [INN]; 159776-68-8	159776-68-8	6439232	12014083	TTDS00112	Arachidonate 5-lipoxygenase	5-lipoxygenase;5-LO;5-LOX	P09917	240	ENSG00000012779	inhibitor
DCL000302	Licofelone	BRN 6823674; 2,3-Dihydro-6-(4-chlorophenyl)-2,2-dimethyl-7-phenyl-1H-pyrrolizine-5-acetic acid; ML 3000; AC1L320X; (2,2-dimethyl-6-(4-chlorophenyl)-7-phenyl-2,3-dihydro-1H-pyrrolizine-5-yl)acetic acid; ML-3000; 1H-Pyrrolizine-5-acetic acid, 2,3-dihydro-6-(4-chlorophenyl)-2,2-dimethyl-7-phenyl-; C23H22ClNO2; Licofelone [INN]; 2,2-Dimethyl-6-(4-chlorophenyl-7-phenyl-2,3-dihydro-1H-pyrrolizine-5-yl)acetic acid; CHEBI:47532; UNII-P5T6BYS22Y; [6-(4-CHLOROPHENYL)-2,2-DIMETHYL-7-PHENYL-2,3-DIHYDRO-1H-PYRROLIZIN-5-YL]ACETIC ACID; 2-[2-(4-chlorophenyl)-6,6-dimethyl-1-phenyl-5,7-dihydropyrrolizin-3-yl]acetic acid; LS-139092; Licofelone; 6-(4-Chlorophenyl)-2,3-dihydro-2,2-dimethyl-7-phenyl-1H-pyrrolizine-5-acetic acid; 156897-06-2; CID133021; (6-(4-Chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl)acetic acid; C088092; CHEMBL300982; LCF; CHEBI:186324	156897-06-2	133021	12014886	TTDS00112	Arachidonate 5-lipoxygenase	5-lipoxygenase;5-LO;5-LOX	P09917	240	ENSG00000012779	inhibitor
DAP001546	Vitamin B3	N/A	N/A	N/A	N/A	TTDS00531	Diacylglycerol O-acyltransferase 2	Diglyceride acyltransferase 2;DGAT2	Q96PD7	84649	ENSG00000062282	inhibitor
DCL001149	ARI-3037MO	N/A	N/A	N/A	N/A	TTDS00531	Diacylglycerol O-acyltransferase 2	Diglyceride acyltransferase 2;DGAT2	Q96PD7	84649	ENSG00000062282	inhibitor
DCL000518	Dulanermin	N/A	N/A	N/A	N/A	TTDC00267	Tumor necrosis factor receptor superfamily member 10A	CD261;Death receptor 4;TNF-related apoptosis-inducing ligand receptor 1;TRAIL receptor 1;TRAIL-R1	O00220	8797	ENSG00000104689	agonist
DCL000621	RhApo2L/TRAIL	N/A	N/A	N/A	N/A	TTDC00267	Tumor necrosis factor receptor superfamily member 10A	CD261;Death receptor 4;TNF-related apoptosis-inducing ligand receptor 1;TRAIL receptor 1;TRAIL-R1	O00220	8797	ENSG00000104689	agonist
DAP000462	Tazarotene	AC1L1K88; Zorac; 118292-40-3; Avage (TN); ethyl 6-[(4,4-dimethyl-3,4-dihydro-2H-thiochromen-6-yl)ethynyl]nicotinate; S1569_Selleck; tazaroteno; Avage; Tazorac, Avage, Zora, Tazarotene; Tazoral; I14-1992; Suretin; 3-Pyridinecarboxylic acid, 6-((3,4-dihydro-4,4-dimethyl-2H-1-benzothiopyran-6-yl)ethynyl)-,ethyl ester; Tazarotene [USAN:INN]; ZINC01542199; ethyl 6-[2-(4,4-dimethyl-2,3-dihydrothiochromen-6-yl)ethynyl]pyridine-3-carboxylate; BIDD:GT0293; D01132; S1684_Selleck; MolPort-005-932-693; 3-Pyridinecarboxylic acid, 6-((3,4-dihydro-4,4-dimethyl-2H-1-benzothiopyran-6-yl)ethynyl)-, ethyl ester; AC-755; tazarotenum; NCGC00167525-01; Tazarotene (JAN/USAN/INN); C21H21NO2S; C086827; DB00799; CID5381; CHEMBL1657; C12531; ethyl 6-(2-(4,4-dimethylthiochroman-6-yl)ethynyl)nicotinate; LS-130838; AGN 190168; Ethyl 6-((4,4-dimethylthiochroman-6-yl)ethynyl)nicotinate; CHEBI:32184; Tazorac; tazarotene; UNII-81BDR9Y8PS; AGN-190168	118292-40-3	5381	582921	TTDS00075	Retinoic acid receptor gamma	N/A	P13631	5916	ENSG00000172819	binder
DCL000129	HspE7 (TLR3 agonist adjuvant)	N/A	N/A	N/A	532014	TTDC00007	Toll-like receptor 3	CD283;TLR3	O15455	7098	ENSG00000164342	agonist
DCL000197	PI-88	PI-88; CHEBI:703983; CHEMBL603733	223576-45-2	N/A	3819350	TTDC00060	Heparanase	Endo-glucoronidase;HEP;Heparanase 50 kDa subunit;Heparanase 8 kDa subunit;Heparanase-1;HPA;Hpa1;HPR1;HPSE;HPSE1;HSE1	Q9Y251	10855	ENSG00000173083	inhibitor
DCL000535	Iboctadekin + Doxil	N/A	N/A	N/A	N/A	TTDC00221	Interleukin-18	IFN-gamma-inducing factor;IL-1 gamma;IL-18;Interferon-gamma inducing factor;Interleukin-1 gamma	Q14116	3606	ENSG00000150782	modulator
DCL000534	Iboctadekin & rituximab	N/A	26305-03-3	5478883	49699079	TTDC00221	Interleukin-18	IFN-gamma-inducing factor;IL-1 gamma;IL-18;Interferon-gamma inducing factor;Interleukin-1 gamma	Q14116	3606	ENSG00000150782	modulator
DCL000842	IL-18BP	N/A	N/A	N/A	N/A	TTDC00221	Interleukin-18	IFN-gamma-inducing factor;IL-1 gamma;IL-18;Interferon-gamma inducing factor;Interleukin-1 gamma	Q14116	3606	ENSG00000150782	binder
DCL000179	NM-702	NM-702; NM 702; 4-bromo-6-[3-(4-chlorophenyl)propoxy]-5-(pyridin-3-ylmethylamino)-2H-pyridazin-3-one Hydrochloride; MolPort-005-942-721; CID9848253; Parogrelil hydrochloride; 4-bromo-6-(3-(4-chlorophenyl)propoxy)-5-(3-pyridylmethylamino)-3(2H)-pyridazinone hydrochloride; NM702; 878796-94-2	878796-94-2	9848253	85151730	TTDC00086	Thromboxane-A synthase	Thromboxane A2 synthase;TS;TXA synthase;TXS	P24557	6916	ENSG00000059377	inhibitor
DCL000181	NV-52	N/A	N/A	N/A	N/A	TTDC00086	Thromboxane-A synthase	Thromboxane A2 synthase;TS;TXA synthase;TXS	P24557	6916	ENSG00000059377	inhibitor
DCL000238	STX 64	(6-oxo-8,9,10,11-tetrahydro-7H-cyclohepta[c]chromen-3-yl) sulfamate; CHEBI:40248; CID5287541; CHEMBL286738; 1ttm; STX-64; BN-83495; DB02292; AC1NR9VI; 6-OXO-8,9,10,11-TETRAHYDRO-7H-CYCLOHEPTA[C][1]BENZOPYRAN-3-O-SULFAMATE; 667-Coumate	N/A	N/A	N/A	TTDC00149	Steryl-sulfatase	Arylsulfatase C;ASC;Estrone sulfatase;Steroid sulfatase;Steryl-sulfate sulfohydrolase;STS	P08842	412	ENSG00000101846	inhibitor
DCL001145	Anti-HER3/EGFR DAF	N/A	N/A	N/A	N/A	TTDR01265	Receptor protein-tyrosine kinase erbB-3	C-erbB3;C-erbB-3 protein;Tyrosine kinase-type cell surface receptor HER3	P21860	2065	ENSG00000065361	antibody
DAP000610	Amrinone	C10H9N3O; LS-44658; HMS1570O22; 5-Amino-(3,4'-bipyridine)-6(1H)-one; NINDS_000136; CHEMBL12856; NCGC00016896-01; Amrinone; Cartonic; CID3698; Amrinonum [INN-Latin]; UNII-JUT23379TN; 5-Amino-(3,4'-bipyridin)-6(1H)-one; CCRIS 3794; Amcoral (TN); A4056_SIGMA; DB01427; KBioGR_001398; KBio2_006966; Spectrum4_001069; KBio2_004398; 60719-84-8; BPBio1_001034; MLS001074083; NCGC00095984-01; AC-12186; Inamrinone (USP); 3-amino-5-pyridin-4-yl-1H-pyridin-2-one; 5-amino-3,4'-bipyridin-6(1H)-one; MLS000069829; Spectrum_001350; BRN 0744819; Wincoram; KBio1_000136; STK590307; Spectrum3_000956; Spectrum2_001980; 5-Amino(3,4'-bipyridin)-6(1H)-one; BSPBio_000940; AC1L1GIK; Spectrum5_000999; SPBio_002879; MolPort-002-652-742; Prestwick2_000800; SPBio_002139; WIN 40680; [3,4'-Bipyridin]-6(1H)-one, 5-amino-; 3-Amino-5-(4-pyridinyl)-2(1H)-pyridinone; CAS-60719-84-8; KBio2_001830; Prestwick0_000800; Amcoral; Cordemcura; DivK1c_000136; Amrinona [INN-Spanish]; AWD 08-250; Inamrinone lactate; (3,4'-BIPYRIDIN)-6(1H)-ONE, 5-AMINO-; EINECS 262-390-0; Amrinonum; KBio3_002052; Amrinona; Bio-0795; Inamrinone [USAN:BAN:INN]; HMS500G18; IDI1_000136; Amrinon; Prestwick1_000800; NCGC00164379-01; Inocor; SMR000058850; KBioSS_001830; I06-0688; 5-25-15-00181 (Beilstein Handbook Reference); ZINC08673078; Amrinone (JAN/INN); Prestwick3_000800; Win-40680; D00231; Prestwick_44; SPECTRUM1503084; BRD-K45924332-001-04-4; inamrinone	60719-84-8	3698	12013242	TTDS00200	CGMP-inhibited 3',5'-cyclic phosphodiesterase	CAMP phosphodiesterase III;CGI-PDE;Cyclic AMP phosphodiesterase III;Cyclic GMP inhibited phosphodiesterase;PDE3;Phosphodiesterase 3;Phosphodiesterase III	N/A	N/A	N/A	inhibitor
DAP000868	Oxtriphylline	Cholini theophyllinas [INN-Latin]; Theophyllinate de choline; Theophylline cholinate; 1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl-, ion(1-), 2-hydroxy-N,N,N-trimethylethanaminium; Theophylline, compd. with choline; Theophylline salt of choline; Zy 15061; OXTRIPHYLLINE; 13930-27-3; AC1L2GKJ; Cholini theophyllinas; Oxtriphylline pediatric; (2-Hydroxyethyl)trimethylammonium compound with theophylline; Colina teofillinato [DCIT]; 56553-57-2; Teofilinato de colina [INN-Spanish]; Choline, compd. with theophylline (1:1); 146-71-4; Filoral; Sabidal; Cholinophyllin; 1,3-dimethyl-7H-purine-2,6-dione; 2-hydroxyethyl(trimethyl)azanium; CID20585; Choline, hydroxide, compd. with theophylline (1:1); Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with 3,7-dihydro-1,3-dimethylpurine-2,6-dione; Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with 3,7-dihydro-1,3-dimethyl-1H-purine-2,6-dione (1:1); UNII-3K045XR58X; Theophyllinate de choline [INN-French]; Choline salt with theophylline (1:1); Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with 3,7-dihydro-1,3-dimethyl-1H-purine-2,6-dione; Colina teofillinato; LS-53330; Cholinophylline; EINECS 224-798-7; LS-185028; Soliphylline; Teofilinato de colina; Teofilcolina; Choledyl SA 400; Choline theophylline salt; Theoxylline; Choledyl; Oxtriphylline [USAN]; Oxtrimethylline; Teokolin; Cholegyl	4499-40-5	656652	7849079	TTDS00200	CGMP-inhibited 3',5'-cyclic phosphodiesterase	CAMP phosphodiesterase III;CGI-PDE;Cyclic AMP phosphodiesterase III;Cyclic GMP inhibited phosphodiesterase;PDE3;Phosphodiesterase 3;Phosphodiesterase III	N/A	N/A	N/A	inhibitor
DAP000611	Enoximone	Enoximonum; Lopac0_000410; AC1Q4GY8; Perfan; Enoximone [USAN:BAN:INN]; Lopac-E-1279; MLS001335964; RMI-17043; ZINC09225358; NCGC00015400-04; SMR000857318; EU-0100410; E 1279; Perfan (TN); MLS002172494; NCGC00015400-02; ENOXIMONE; 2H-Imidazol-2-one, 1,3-dihydro-4-methyl-5-(4-(methylthio)benzoyl)-; MLS001335963; AC-3396; CID53708; NCGC00093835-02; NCGC00015400-01; E1279_SIGMA; DB04880; Enoximona [Spanish]; 4-methyl-5-(4-methylsulfanylbenzoyl)-1,3-dihydroimidazol-2-one; AKOS005145769; Enoximone (USAN/INN); MDL-17,043; MDL 17,043; AC1L1FGC; 1,3-Dihydro-4-methyl-5-[4-methylthiobenzoyl]-2H-imidazol-2-one; CHEMBL249856; NCGC00093835-01; D04004; LS-78854; Enoximonum [Latin]; MDL-17043; Fenoximone; CHEBI:521520; 1,3-Dihydro-4-methyl-5-(4-methylthiobenzoyl)-2H-imidazol-2-one; 4-Methyl-5-(p-(methylthio)benzoyl)-4-imidazolin-2-one; 77671-31-9; Enoximona; Perfane	77671-31-9	53708	11111134	TTDS00200	CGMP-inhibited 3',5'-cyclic phosphodiesterase	CAMP phosphodiesterase III;CGI-PDE;Cyclic AMP phosphodiesterase III;Cyclic GMP inhibited phosphodiesterase;PDE3;Phosphodiesterase 3;Phosphodiesterase III	N/A	N/A	N/A	inhibitor
DCL000996	Sotrastaurin acetate	N/A	908351-31-5	448087	46392991	TTDC00182	Protein kinase C, alpha type	PKC-A;PKCalpha;PKC-alpha;Protein Kinase C alpha	P17252	5578	ENSG00000154229	inhibitor
DCL000853	K-832	N/A	N/A	N/A	N/A	TTDC00300	Interleukin-1	IL-1	N/A	N/A	N/A	inhibitor
DCL000961	Rilonacept	Rilonacept; 501081-76-1; Rilonacept (USAN/INN); D06635	501081-76-1	104924	47208286	TTDC00300	Interleukin-1	IL-1	N/A	N/A	N/A	binder
DCL000693	AMG108	N/A	N/A	N/A	N/A	TTDC00300	Interleukin-1	IL-1	N/A	N/A	N/A	antibody
DAP000387	Omalizumab	Omalizumab (genetical recombination) (JAN); 242138-07-4; Omalizumab (genetical recombination); Xolair (TN); Omalizumab (USAN/INN); D05251; Xolair; Omalizumab	242138-07-4	N/A	47206967	TTDS00132	Immunoglobulin E	IgE	N/A	N/A	N/A	antibody
DCL000015	Curaxin CBLC102	N/A	N/A	6427053	43021080	TTDC00118	Cellular tumor antigen p53	Antigen NY-CO-13;P53;Phosphoprotein p53;Tumor suppressor p53	P04637	7157	ENSG00000141510	activator
DCL000193	Pasireotide	N/A	396091-73-9	N/A	10549826	TTDC00254	Somatostatin receptor type 3	SS3R;SSR-28	P32745	6753	ENSG00000183473	agonist
DCL000764	DA-7101	N/A	N/A	N/A	N/A	TTDS00228	Beta-lactamase	Cephalosporinase	P00811	N/A	N/A	inhibitor
DAP000948	Clavulanate	D07711; (Z)-(2R,5R)-3-(2-Hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo(3.2.0)heptane-2-carboxylic acid; BRL-14151; BRN 0787059; acidum clavulanicum; Clavulanate; AC1NQXUM; (2R,3Z,5R)-3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; Clavulansaeure; CLAVULANIC ACID; UNII-23521W1S24; Clavulanic acid [BAN:INN]; 61177-45-5 (mono-potassium-salt); EINECS 261-069-2; DB00766; Clavulinic Acid; 57943-81-4 (mono-hydrochloride-salt); CHEBI:48947; 58001-44-8; Clavulansaeure [INN]; Clavulanic acid (INN); (Z)-(2R,5R)-3-(2-Hydroxyethyliden)-7-oxo-4-oxa-1-azabicyclo(3.2.0)heptan-2-carbonsaeure; Sodium Clavulanate; Antibiotic MM 14151; Clavulox (TN); Acido clavulanico [INN-Spanish]; 4-Oxa-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 3-(2-hydroxyethylidene)-7-oxo-,(2R-(2-alpha,3Z,5-alpha))-; J01; Acide clavulanique; Clavulox; 3008-B; C8H9NO5; Acidum clavulanicum [INN-Latin]; MM-14151; Acide clavulanique [INN-French]; BSPBio_002430; CID5280980; C06662; 4-Oxa-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 3-(2-hydroxyethylidene)-7-oxo-, (2R-(2-alpha,3Z,5-alpha))-; Acido clavulanico; LS-98544; 4-Oxa-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 3-(2-hydroxyethylidene)-7-oxo-, (2R-(2alpha,3Z,5alpha)); CHEMBL777; MM 14151	58001-44-8	5280980	8887	TTDS00228	Beta-lactamase	Cephalosporinase	P00811	N/A	N/A	inhibitor
DAP000926	Tazobactam	DB01606; CID123630; 89786-04-9; D00660; TAZ; CHEBI:100207; (2S,3S,5R)-3-methyl-7-oxo-3-(1H-1,2,3-triazol-1-ylmethyl)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid 4,4-dioxide; MolPort-002-500-123; CHEMBL404; 89785-84-2; BIDD:GT0212; C07771; Tazobactam; YTR830H; YTR-830H; CL298741; 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3-methyl-7-oxo-3-(1H-1,2,3-triazol-1-ylmethyl)-, 4,4-dioxide, (2S,3S,5R)-; AC1L3X07; AC-7620; (2S,3S,5R)-3-methyl-4,4,7-trioxo-3-(triazol-1-ylmethyl)-4; Tazobactam (JAN/USAN/INN); CL-298741	89786-04-9	123630	10240806	TTDS00228	Beta-lactamase	Cephalosporinase	P00811	N/A	N/A	inhibitor
DAP000390	Gemtuzumab ozogamicin	N/A	220578-59-6	N/A	46505767	TTDS00091	Myeloid cell surface antigen CD33	CD33;Gp67;Siglec-3	P20138	945	ENSG00000105383	antibody
DAP000151	Drotrecogin alfa	Drotrecogin alfa (activated); Drotrecogin alfa; Xigris (TN); Xigris; 98530-76-8; Drotrecogin alfa (activated) (USAN); D03918	60202-16-6	121850	47205907	TTDS00205	Coagulation Factor VIIIa	Factor VIIIa	P00451	2157	ENSG00000185010	inhibitor
DCL000042	Amelubant	Amelubant [INN]; LS-49968; BIIL 284; Ethyl ((4-((3-((4-(1-(4-hydroxyphenyl)-1-methylethyl)phenoxy)methyl)benzyl)oxy)phenyl)(imino)methyl)carbamate; 346735-24-8; UNII-E0018IF0K4; Amelubant; CID9604655; BIIL 283 BS; Carbamic acid, ((4-((3-((4-(1-(4-hydroxyphenyl)-1-methylethyl)phenoxy)methyl)phenyl)methoxy)phenyl)iminomethyl)-, ethyl ester	346735-24-8	9604655	10560398	TTDC00129	Leukotriene B4 receptor 1	Chemoattractant receptor-like 1;Leukotriene B(4) receptor BLT1;LTB4-R;LTB4-R 1;P2Y purinoceptor 7;P2Y7	Q15722	1241	ENSG00000213903	antagonist
DCL000070	Biomed 101	N/A	N/A	N/A	N/A	TTDC00129	Leukotriene B4 receptor 1	Chemoattractant receptor-like 1;Leukotriene B(4) receptor BLT1;LTB4-R;LTB4-R 1;P2Y purinoceptor 7;P2Y7	Q15722	1241	ENSG00000213903	binder
DCL000155	LTB 019	N/A	N/A	N/A	N/A	TTDC00129	Leukotriene B4 receptor 1	Chemoattractant receptor-like 1;Leukotriene B(4) receptor BLT1;LTB4-R;LTB4-R 1;P2Y purinoceptor 7;P2Y7	Q15722	1241	ENSG00000213903	antagonist
DCL000874	LY-293111	AC1L4328; CHEMBL329123; CHEMBL96023; CID177941; CID177940; 2-[3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]-2-propylphenoxy]benzoic acid; LY293111; Etalocib (USAN); PDSP1_001237; D04074; PDSP2_001221; 161172-51-6; CHEBI:243957; Etalocib sodium; LY-293111 Sodium; LY-293111Na; VML-295; Etalocib; LY-193111; LY 293111; L001468; CHEBI:260370; 152608-41-8; VML295; LY-293111; LS-37416; UNII-THY6RIW44R	161172-51-6	177941	47206030	TTDC00129	Leukotriene B4 receptor 1	Chemoattractant receptor-like 1;Leukotriene B(4) receptor BLT1;LTB4-R;LTB4-R 1;P2Y purinoceptor 7;P2Y7	Q15722	1241	ENSG00000213903	antagonist
DCL000156	LY293111	N/A	161172-51-6	23663993	10549597	TTDC00129	Leukotriene B4 receptor 1	Chemoattractant receptor-like 1;Leukotriene B(4) receptor BLT1;LTB4-R;LTB4-R 1;P2Y purinoceptor 7;P2Y7	Q15722	1241	ENSG00000213903	antagonist
DAP001508	Pyronaridine	4-((7-Chloro-2-methoxybenzo(b)-1,5-naphthyridin-10-yl)amino)-2,6-bis(1-pyrrolidinylmethyl)phenol; MolPort-002-507-948; CHEMBL35228; Pyronaridine; C29H32ClN5O2; 74847-35-1; AC1NUNYW; LS-177158; CID5485198; pyronaridine phosphate salt; Phenol, 4-[(7-chloro-2-methoxybenzo[b]-1,5-naphthyridin-10-yl)amino]-2,6-bis(1-pyrrolidinylmethyl)-; STOCK5S-98760; Phenol, 4-((7-chloro-2-methoxybenzo(b)-1,5-naphthyridin-10-yl)amino)-2,6-bis(1-pyrrolidinylmethyl)-; 2-Methoxy-7-chloro-10-(3',5'-bis(pyrrolin-1-ylmethyl)-4'-hydroxyphenylamino)benzo(b)-1,5-naphthyridine; 4-[(7-chloro-2-methoxybenzo[b][1,5]naphthyridin-10-yl)amino]-2,6-bis(pyrrolidin-1-ylmethyl)phenol; Malaridine; STK597795; Benzonaphthyridine 7351; 4-[(7-chloro-2-methoxy-1,5-dihydrobenzo[b][1,5]naphthyridin-10-yl)imino]-2,6-bis(pyrrolidin-1-ylmethyl)cyclohexa-2,5-dien-1-one	74847-35-1	5485198	685042	TTDS00517	Sarcoplasmic/endoplasmic reticulum calcium ATPase	ATP4;Ca(2+)-ATPase;Ca2+-ATPase;Calcium pump;Calcium-transporting ATPase;SERCA;SERCA pump;SR Ca(2+)-ATPase	N/A	N/A	N/A	inhibitor
DAP001504	Piperaquine	LS-142194; I06-1673; 83764-65-2; Quinoline, 4,4'-(1,3-propanediyldi-4,1-piperazinediyl)bis(7-chloro- (9CI); Quinoline, 4,4'-(1,3-propanediyldi-4,1-piperazinediyl)bis(7-chloro-; AC1L3UA1; ST51053186; 1,3-bis(1-(7-chloro-4'-quinolyl)-4'-piperazinyl)propane; AC1Q3T7B; 5-23-03-00072 (Beilstein Handbook Reference); CHEMBL303933; 1,3-bis(4-(7'-chloro-4'-quinoline)-1-piperazine); 7-chloro-4-[4-[3-[4-(7-chloroquinolin-4-yl)piperazin-1-yl]propyl]piperazin-1-yl]quinoline; FT-0082661; Piperaquinoline; CID122262; Quinoline, 4,4'-(trimethylenedi-4,1-piperazinediyl)bis(7-chloro-; Quinoline, 4,4'-(1,3-propanediyldi-4,1-piperazinediyl)bis(7-chloro-); piperaquine; BRN 0905079; Quinoline, 4,4'-(1,3-propanediyldi-4,1-piperazinediyl)bis[7-chloro-; C29H32Cl2N6; 4,4'-(propane-1,3-diyldipiperazine-4,1-diyl)bis(7-chloroquinoline); 4085-31-8; AR-1F7471	4085-31-8	5079497	38703728	TTDS00517	Sarcoplasmic/endoplasmic reticulum calcium ATPase	ATP4;Ca(2+)-ATPase;Ca2+-ATPase;Calcium pump;Calcium-transporting ATPase;SERCA;SERCA pump;SR Ca(2+)-ATPase	N/A	N/A	N/A	inhibitor
DAP001502	OZ277	OZ-277; CHEMBL404431; CHEMBL578577; CID 10475633; CID10475633; 664338-39-0; CHEMBL221773	N/A	5163	47736664	TTDS00517	Sarcoplasmic/endoplasmic reticulum calcium ATPase	ATP4;Ca(2+)-ATPase;Ca2+-ATPase;Calcium pump;Calcium-transporting ATPase;SERCA;SERCA pump;SR Ca(2+)-ATPase	N/A	N/A	N/A	inhibitor
DAP001456	Artesunate	D02482; Artesunato [INN-Spanish]; Arsumax (TN); AC1L2XWW; Dihydroartemisinine-12-alpha-succinate; 252637-87-9; Artesunate (superseded RN); Artesunate (USAN); Butanedioic acid,  mono((3R,5aS,6R,8aS,9R,10S,12R,12aR)-decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano(4,3-j)-1,2-benzodioxepin-10-yl) ester; Plasmotrim; CID6917864; LS-187735; Artesunic acid; Butanedioic acid, mono(decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano(4,3-j)-1,2-benzodioxepin-10-yl) ester; Ambap88495-63-0; CID65664; CID156252; (3R,5aS,6R,8aS,9R,10S,12R,12aR)-Decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano(4,3-j)-1,2-benzodioxepin-10-ol, hydrogen succinate; HSDB 7458; 83507-69-1; NSC712571; HMS2051I14; CPD000466336; 112346-66-4; Artesunatum [INN-Latin]; Nuartez; 4-Oxo-4-(((3R,5aS,6R,8aS,9R,10S,12R,12aR)-3,6,9-trimethyldecahydro-3,12-epoxypyrano(4,3-j)-1,2-benzodioxepin-10-yl  hydrogen  butanedioate; MLS000759445; Dihydroqinghasu hemsuccinate; 182824-33-5; MolPort-006-392-384; MLS001424053; BB_NC-1045; CID11520210; CHEMBL258608; WR 256283; 4-oxo-4-{[(5aS,6R,8aS,9R,10S,12R,12aR)-3,6,9-trimethyldecahydro-3,12-epoxy[1,2]dioxepino[4,3-i]isochromen-10-yl]oxy}butanoic acid; AKOS004119951; 88495-63-0; S2265_Selleck; STK801911; CHEMBL218601; AC1L23PW; FT-0082543; 91487-94-4; UNII-60W3249T9M; Artesunato; HMS2090L16; WR-256283; Dihydroqinghaosusuccinate; 4-oxo-4-{[(3r,5as,6r,8as,9r,10r,12r,12ar)-3,6,9-trimethyldecahydro-3,12-epoxy[1,2]dioxepino[4,3-i]isochromen-10-yl]oxy}butanoic acid; Artesunatum; Quinghaosu reduced succinate ester; AC1Q5VRV; SM 804; CID105031; Arsumax; NCI60_039350; Arinate; C19H28O8; CID9821433; Artesunate; Qinghaozhi; CID5464098; CID11988384; SAM001246628; LS-177760; Artsuna; Succinyl dihydroartemisinin; AC1L4FU0; I06-0204; SMR000466336; Plasmotrin; MolPort-001-732-325	88495-63-0	6917864	17396661	TTDS00517	Sarcoplasmic/endoplasmic reticulum calcium ATPase	ATP4;Ca(2+)-ATPase;Ca2+-ATPase;Calcium pump;Calcium-transporting ATPase;SERCA;SERCA pump;SR Ca(2+)-ATPase	N/A	N/A	N/A	inhibitor
DAP001471	Dihydroartemisinin	CID456410; Ambotz71939-50-9; (3R,5aS,6R,8aS,9R,12R,12aR)-3,6,9-trimethyldecahydro-3,12-epoxypyrano[4,3-j][1,2]benzodioxepin-10-ol; [3R-(3.alpha.,5a.beta.,6.beta.,8a.beta.,9.alpha.,10.alpha.,12.beta.,12aR*)]-Decahydro-10-hydroxy-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4.3-j]-1,2-benzodioxepin; 81496-81-3; 1,5,9-trimethyl-(1R,4S,5R,8S,9R,10S,12R,13R)-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-ol(Dihydroartemisinin); 71939-50-9; Dihydroartemisinin; JAV-110; VM3352; CHEMBL25164; D07362; CHEBI:207229; AC1L9UV6; CID6918483; 3,12-Epoxy-12H-pyrano(4,3-j)-1,2-benzodioxepin-10-ol, decahydro-3,6,9-trimethyl-, (3R-(3alpha,5abeta,6beta,8abeta,9alpha,10alpha,12beta,12aR*))-; Dihydroquinghaosu; AC-2067; Dihydroartemisinine; Artenimol; 3,12-Epoxy-12H-pyrano(4,3-j)-1,2-benzodioxepin-10-ol, decahydro-3,6,9-trimethyl-, (3R,5aS,6R,8aS,9R,10S,12R,12aR)-; Artenimol (INN); Dihydroqinghaosu; Cotecxin; GNF-PF-5634; D3793; Dihydroquinghoasu; LS-64240; AC1L32PY; CID107770	71939-50-9	6918483	12015359	TTDS00517	Sarcoplasmic/endoplasmic reticulum calcium ATPase	ATP4;Ca(2+)-ATPase;Ca2+-ATPase;Calcium pump;Calcium-transporting ATPase;SERCA;SERCA pump;SR Ca(2+)-ATPase	N/A	N/A	N/A	inhibitor
DAP001455	Artemisinin SP	N/A	N/A	3765	47885261	TTDS00517	Sarcoplasmic/endoplasmic reticulum calcium ATPase	ATP4;Ca(2+)-ATPase;Ca2+-ATPase;Calcium pump;Calcium-transporting ATPase;SERCA;SERCA pump;SR Ca(2+)-ATPase	N/A	N/A	N/A	inhibitor
DAP001454	Artemisinin	KBio2_006967; KBioSS_001831; A0854/0040033; CHEMBL77; AKOS004119830; (#43;)-Artemisinin; NCGC00161634-03; HMS1569D17; Ambap63968-64-9; Qing Hau SU; 3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin-10(3H)-one, octahydro-3,6,9-trimethyl-; Spectrum4_000721; (3R,5aS,6R,8aS,9R,12S,12aR)-Octahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano(4,3-j)-1,2-benzodioxepin-10(3H)-one; 63968-64-9; ST056292; DivK1c_000656; CID641602; AC1L9Q59; AC1LD383; MLS001304036; TL8004521; NCGC00161634-02; Artemisinine [French]; CID9838675; HMS1607A03; (+)-Arteannuin; SPBio_001583; MLS001097650; LMPR0103190003; C09538; Prestwick1_000498; Spectrum_001351; KBioGR_000982; MolPort-002-493-751; MolPort-002-692-529; NSC 369397; KBio2_004399; SMR000578089; Prestwick2_000498; AC1L2AIV; AC1Q6O1J; 2AB44F63-5D0F-424A-AA3F-24062F9C1CED; NSC369397; CID5458876; Quing Hau Sau; Spectrum2_001512; AR-1E9905; BSPBio_000395; Artemisininum [Latin]; 1,5,9-trimethyl-(1R,4S,5R,9R,12S,13R)-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-one; Artemisinina; AC1Q6O6P; BPBio1_000435; HMS502A18; ZINC08143788; CHEMBL345083; CID452191; C15H22O5; Artesin; LS-64242; IDI1_000656; MLS002153846; BRN 4194670; Arteannuin; Qinghaosu; 3,6,9-trimethyloctahydro-3,12-epoxy[1,2]dioxepino[4,3-i]isochromen-10(3H)-one; Spectrum3_001549; Qinghaosu [Chinese]; CID2240; 3,12-Epoxy-12H-pyranol(4,3-j)-1,2-benzodioxepin-10(3H)-one, octahydro-3,6,9-trimethyl-, (3-alpha,5a-beta,6-beta,8a-beta,9-alpha,12-beta,12aR*)-(+)-; AC1L1D8I; GNF-PF-5671; KBio1_000656; (+)-Artemisinin; Prestwick0_000498; Artemisinin [INN]; 3,12-Epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin-10(3H)-one, octahydro-3,6,9-trimethyl-, (3R,5aS,6R,8aS,9R,12S,12aR)-; artemisinin; BB_NC-0820; SPECTRUM1503042; CPD-7561; InChI=1/C15H22O5/c1-8-4-5-11-9(2)12(16)17-13-15(11)10(8)6-7-14(3,18-13)19-20-15/h8-11,13H,4-7H2,1-3H; NINDS_000656; Qing Hau Sau; UPCMLD-DP074:001; (5aS,6R,8aS,9R,12S,12aR)-3,6,9-trimethyloctahydro-3,12-epoxy[1,2]dioxepino[4,3-i]isochromen-10(3H)-one; Qinghosu; SPBio_002316; nchembio806-comp6; Coartem, Artemisinin; Qing Hau Sau [Chinese]; SMR000554414; Spectrum5_001098; MLS001195096; SDCCGMLS-0066721.P001; CHEBI:223316; Huanghuahaosu; I06-0006; nchembio.215-comp2; 91487-93-3; HMS2090I17; CHEBI:106677; CID68827; Artemisininum; Artemisia annua L., extract; S1282_Selleck; NCGC00161634-01; quinghaosu; 361593_ALDRICH; Artemisinina [Spanish]; FT-0082854; UNII-9RMU91N5K2; KBio3_002498; NCGC00142461-01; nchembio875-comp2; Artemisine; Prestwick3_000498; HMS1923O03; D02481; UPCMLD-DP074; (3R,5aS,6R,8aS,9R,12S,12aR)-3,6,9-trimethyloctahydro-3,12-epoxypyrano[4,3-j][1,2]benzodioxepin-10(3H)-one; nchembio.87-comp18; Octahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano(4,3-j)-1,2-benzodioxepin-10(3H)-one; Prestwick_818; Artemisinin (INN); AKOS001483011; AC-2064; BSPBio_002998; GNF-Pf-5341; NCGC00160207-01; 361593_SIGMA; KBio2_001831; Artemisinine	63968-64-9	148184	49720288	TTDS00517	Sarcoplasmic/endoplasmic reticulum calcium ATPase	ATP4;Ca(2+)-ATPase;Ca2+-ATPase;Calcium pump;Calcium-transporting ATPase;SERCA;SERCA pump;SR Ca(2+)-ATPase	N/A	N/A	N/A	inhibitor
DCL000637	SAR351034	N/A	N/A	N/A	N/A	TTDS00340	Peroxisome proliferator activated receptor alpha	Peroxisome proliferater-activated receptor alpha;PPARalpha;PPAR-alpha	Q07869	5465	ENSG00000186951	agonist
DCL000419	Aleglitazar	CID10274777; UNII-41T4OAG59U; CHEBI:620672; Aleglitazar (USAN); D08845; 475479-34-6; Aleglitazar; RO7; CHEMBL519504; 2-methoxy-3-[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]benzothiophen-7-yl]propanoic Acid; DB08483	475479-34-6	N/A	N/A	TTDS00340	Peroxisome proliferator activated receptor alpha	Peroxisome proliferater-activated receptor alpha;PPARalpha;PPAR-alpha	Q07869	5465	ENSG00000186951	agonist
DAP001182	Bezafibrate	BRN 4267656; BSPBio_000535; Hennig Brand of Bezafibrate; AB1004588; 2-[4-(2-[4-Chlorobenzamido]ethyl)- phenoxy]-2-methylpropanoic acid; B3346; KBio3_000068; Betapharm Brand of Bezafibrate; Lakeside Brand of Bezafibrate; Bezafibrate Bayer Brand; Beza-Puren; Reducterol; Bezacur; DB01393; DB08380; BM15.075; Regadrin B; Spectrum5_001079; NCGC00016850-02; Bezafibrate Isis Brand; PB, Bezafibrat; Propionic acid, 2-(4-(2-((4-chlorobenzoyl)amino)ethyl)phenoxy)-2-methyl-; BezaLande; NCGC00023317-07; Eulitop; Bezafibrate Synthelabo Brand; KBio1_000092; KBio2_005170; Difaterol; Bezafibrate Azupharma Brand; BF-759; HMS2092B12; HMS500E14; durabezur; Beza Puren; Cedur; BM-15075; B7273_SIGMA; Bezafibrato [Spanish]; AB00052265; NCGC00023317-05; Bezafibrate Teva Brand; MLS001148205; LS-124535; TAD Brand of Bezafibrate; Spectrum4_000325; AC1L20XS; KBio2_000034; Azufibrat; Azupharma Brand of Bezafibrate; Prestwick3_000378; Synthelabo Brand of Bezafibrate; Bezafibrat PB; Spectrum5_001967; C19H20ClNO4; Befibrat; Berlin-Chemie Brand of Bezafibrate; Isis Brand of Bezafibrate; Solibay; Propanoic acid, 2-(4-(2-((4-chlorobenzoyl)amino)ethyl)phenoxy)-2-methyl-; KBio2_002602; 2-(4-{2-[(4-chlorobenzoyl)amino]ethyl}phenoxy)-2-methylpropanoic acid; Bezabeta; Bayer Brand of Bezafibrate; 2-(p-(2-(p-Chlorobenzamido)ethyl)phenoxy)-2-methylpropionic acid; Bezafibrate (JP15/USAN/INN); Bezafibrate Elfar Brand; Prestwick1_000378; Bezafibrate Hennig Brand; DivK1c_000092; Prestwick_724; 41859-67-0; KBioGR_000669; Befizal; HMS1569K17; Berlin Chemie Brand of Bezafibrate; NCGC00016850-01; Bezafisal; SMR000058298; Bezatol; BSPBio_003119; Bezamerck; Prestwick0_000378; KBio3_000067; KBio2_007059; D001629; KBioSS_000034; Bezafibrato; CID39042; MLS000028533; Bezalip; Bezafibrate Roche Brand; Bezafibrate Lakeside Brand; Bezafibrate TAD Brand; HMS1361B16; EINECS 255-567-9; Prestwick2_000378; Cryopharma Brand of Bezafibrate; Bio2_000034; Merckle Brand of Bezafibrate; SPBio_002456; Spectrum_001443; BRD-K46018455-001-06-0; AKOS005107743; Bezafibrate Betapharm Brand; NINDS_000092; BM-15.075; a-[4-(4-chlorobenzoylaminoethyl)phenoxy]isobutyric acid; KBio2_004491; AC1Q5E4V; Boehringer Mannheim Brand of Bezafibrate; HMS1989B16; Bio2_000514; Bezalip Retard; Beza Lande; LO 44; Bezatol SR; Hexal Brand of Bezafibrate; KBio2_001923; Elfar Brand of Bezafibrate; AC-6817; Teva Brand of Bezafibrate; CAS-41859-67-0; Roche Brand of Bezafibrate; BezaPuren; BM 15075; Bezafibrate Merckle Brand; ST51014927; 2-[4-[2-(4-Chlorobenzamido)ethyl]phenoxy]isobutyric Acid; Spectrum3_001500; bezafibrate; HMS1791B16; NCGC00023317-08; MolPort-001-738-424; I06-1311; KBioSS_001923; Beza-Lande; Bezafibrate Hexal Brand; KBio3_002619; HMS1921H16; Lipox; Bezafibrate Cryopharma Brand; Bezafibrat; KBioGR_000034; Bezatol SR (TN); NCGC00023317-04; NCGC00016850-11; BPBio1_000589; HMS2089F04; CHEMBL264374; CHEBI:47612; Bezafibrate [USAN:BAN:INN:JAN]; IDI1_033784; BM 15.075; D01366; Bezafibratum; CCRIS 9085; 2-[4-[2-(4-Chlorobenzamido)ethyl]phenoxy]-2-methylpropanoic acid; Bezafibrato [INN-Spanish]; Bezafibrate Berlin-Chemie Brand; Spectrum2_000922; SPBio_000824; Sklerofibrat; 2-[4-[2-[(4-chlorobenzoyl)amino]ethyl]phenoxy]-2-methylpropanoic acid; NCGC00023317-03; NCGC00023317-06; SPECTRUM1502046; Bezafibratum [INN-Latin]; BSPBio_001314; IDI1_000092	41859-67-0	39042	10321679	TTDS00340	Peroxisome proliferator activated receptor alpha	Peroxisome proliferater-activated receptor alpha;PPARalpha;PPAR-alpha	Q07869	5465	ENSG00000186951	agonist
DCL000897	Netoglitazone	Netoglitazone (USAN/INN); CID204109; Netoglitazone; Netoglitazone [USAN]; D05150; UNII-QOV2JZ647A; 5-[[6-[(2-fluorophenyl)methoxy]naphthalen-2-yl]methyl]-1,3-thiazolidine-2,4-dione; RWJ-241947; CHEMBL93747; MolPort-005-942-719; MCC 555; AC1L4BXM; 5-({6-[(2-fluorobenzyl)oxy]naphthalen-2-yl}methyl)-1,3-thiazolidine-2,4-dione; C115174; Isaglitazone; 161600-01-7; 2,4-Thiazolidinedione, 5-((6-((2-fluorophenyl)methoxy)-2-naphthalenyl)methyl)-; 5-((6-((2-fluorophenyl)methoxy)-2-naphthalenyl)methyl)-2,4-thiazolidinedione; MCC-555	161599-99-1	204109	47206874	TTDS00340	Peroxisome proliferator activated receptor alpha	Peroxisome proliferater-activated receptor alpha;PPARalpha;PPAR-alpha	Q07869	5465	ENSG00000186951	agonist
DCL000827	GSK-677954	N/A	884324-15-6	N/A	N/A	TTDS00340	Peroxisome proliferator activated receptor alpha	Peroxisome proliferater-activated receptor alpha;PPARalpha;PPAR-alpha	Q07869	5465	ENSG00000186951	agonist
DCL000447	AVE0897	N/A	N/A	N/A	N/A	TTDS00340	Peroxisome proliferator activated receptor alpha	Peroxisome proliferater-activated receptor alpha;PPARalpha;PPAR-alpha	Q07869	5465	ENSG00000186951	agonist
DAP000270	Fenofibrate	Elasterate; BRD-K50388907-001-05-6; isopropyl 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoate; Lipidil-Ter; IDI1_000557; AB00052196; Nu Fenofibrate; ratiopharm Brand of Procetofen; Spectrum5_001479; Lipofen; CCRIS 7282; Spectrum_001250; AKOS005107777; FNF; Lipofene; Novartis Brand of Procetofen; GRS-027; C07586; UNII-U202363UOS; NCGC00021475-03; Gen Fenofibrate; HMS1568H12; Schering Plough Brand of Procetofen; Elasterin; D00565; Bouchara Brand of Procetofen; Lofibra; EU-0100486; Triglide (TN); Spectrum4_000413; Fenofibrat Heumann; Lopac-F-6020; GNR-Pharma Brand of Procetofen; Liposit; Reliant Brand of Procetofen; MTW-Fenofibrat; Aliud Brand of Procetofen; Anto Brand of Procetofen; Secalip; Azupharma Brand of Procetofen; Fenofibrat AZU; Prestwick0_000275; betapharm Brand of Procetofen; Antara Micronized Procetofen; KBio2_006866; nchembio790-comp24; Lipsin; Fenofibrat AL; Abbott Brand of Procetofen; Lipidil Micro; LCP-FenoChol; C20H21ClO4; MLS001148191; HMS501L19; Tricor; NCGC00021475-07; Gen-Fenofibrate; Fenofibrate [INN:BAN]; Fenofibrato; EINECS 256-376-3; KBio1_000557; durafenat; AC1L1FPK; Antara (micronized); Fenomax; Micronized Procetofen, Antara; NINDS_000557; CHEMBL672; Fulcro; BSPBio_000150; Lipantil (TN); CID3339; Supralip; BSPBio_003162; Novopharm Brand of Procetofen; PMS-Fenofibrate Micro; Prestwick1_000275; Fenofibrate MSD; NCGC00021475-04; MTW Fenofibrat; HMS1921B17; Phenofibrate; HMS2092B05; CPD000058299; Merck dura Brand of Procetofen; Lipanthyl; KBioSS_001730; Apotex Brand of Procetofen; Lichtenstein Brand of Procetofen; S1794_Selleck; Fenofibratum; Fenofibrate IDD-P; D011345; Pharmascience Brand of Procetofen; F6020_SIGMA; Procetofen; NSC 281319; Lipidil Supra; Fenofibrat FPh; MolPort-002-887-051; Isopropyl 2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropionate; Schering-Plough Brand of Procetofen; Fenofanton; Fenofibrat-ratiopharm; SAM002264613; Heumann, Fenofibrat; Apo Feno Micro; Fenofibratum [INN-Latin]; FENOFIBRATE (MICRONIZED); Protolipan; Antara; NCGC00021475-08; Fenobrate; Q-Pharm Brand of Procetofen; Fenofibrato [INN-Spanish]; NCGC00015437-03; Knoll Brand of Procetofen; LF 178; TL8003296; Heumann Brand of Procetofen; CHEBI:5001; NCGC00015437-01; AZU, Fenofibrat; Isopropyl 2-(p-(p-chlorobenzoyl)phenoxy)-2-methylpropionate; KBio3_002382; Genpharm Brand of Procetofen; Procetofene; Prestwick_217; LCP-Feno; Nu-Pharm Brand of Procetofen; Lipirex; Fenogal; Prestwick3_000275; I06-0048; Hexal, Fenofibrat; Lipofen (TN); CAS-49562-28-9; Ankebin; 49562-28-9; BPBio1_000166; MTW Brand of Procetofen; Hexal Brand of Procetofen; Triglide; LF-178; ct Arzneimittel Brand of Procetofen; PMS Fenofibrate Micro; Fournier Brand of Procetofen; TRICOR (MICRONIZED); fenofibrate; ZINC00584092; LF178; Fenofibrate Debat; Fenotard; BRN 2062462; Nu Pharm Brand of Procetofen; Pharmavit; Gate Brand of Procetofen; Lipantil; Luxacor; DivK1c_000557; Fenoglide; Finofibrate; KBio2_004298; Antara (TN); fenofibrat von ct; Lopac0_000486; DB01039; ST085313; LS-121256; Lipoclar; NCGC00021475-06; Lipidil Ter; SMR000058299; Apo Fenofibrate; Sedufen; F 6020; AbZ Brand of Procetofen; MLS000028515; NCGC00015437-02; BIDD:GT0574; Lipidex; Q Pharm Brand of Procetofen; Procetofen, Antara Micronized; Apo-Fenofibrate; Fenobeta; Fenofibrat AbZ; Novo-Fenofibrate; Controlip; Nu-Fenofibrate; Lipifen; NCGC00015437-12; Proctofene; NSC281319; SPBio_002369; Fenofibrat ratiopharm; AC-4227; KBio2_001730; Fenofibrate (JAN/INN); Apo-Feno-Micro; Spectrum2_001390; Debat, Fenofibrate; United Drug Brand of Procetofen; Fenofibrat Stada; Fenofibrat Hexal; CIP-Fenofibrate; Lipidil; HMS2090G20; Stadapharm Brand of Procetofen; KBioGR_000706; NCGC00015437-06; Procetofen Reliant Brand; SPECTRUM1501010; Liparison; Nolipax; SPBio_001380; Stada, Fenofibrat; ct-Arzneimittel Brand of Procetofen; Tricor (TN); Prestwick2_000275; NCGC00021475-05; Spectrum3_001431; Novo Fenofibrate; GNR Pharma Brand of Procetofen	49562-28-9	3339	180502	TTDS00340	Peroxisome proliferator activated receptor alpha	Peroxisome proliferater-activated receptor alpha;PPARalpha;PPAR-alpha	Q07869	5465	ENSG00000186951	agonist
DAP001359	Ciprofibrate	C13H14Cl2O3; MolPort-003-666-795; BPBio1_001202; I14-0695; STK624758; WIN 35833; BRN 1984981; AC-1018; Ciprofibrate; C0330_SIGMA; SMR000857190; NCGC00164447-01; Prestwick3_001076; Ciprofibrate [USAN:BAN:INN]; CCRIS 173; BRD-A49358627-001-03-9; D03521; 52214-84-3; BB_SC-4841; Ciprofibrato [INN-Spanish]; Lopac0_000168; Ciprofibratum; 2-{4-[2,2-dichlorocyclopropyl]phenoxy}-2-methylpropanoic acid; HMS1571G14; 2-(p-(2,2-Dichlorocyclopropyl)phenoxy)-2-methylpropionic acid; Ciprofibrate (USAN/INN); Ciprofibratum [INN-Latin]; Prestwick1_001076; 2-[4-(2,2-Dichlorocyclopropyl)phenoxy]-2-methylpropanoic acid; 2-{[4-(2,2-dichlorocyclopropyl)phenyl]oxy}-2-methylpropanoic acid; SPBio_002996; Oroxadin; NCGC00093652-01; nchembio790-comp23; Sanofi Winthrop brand of ciprofibrate; LS-7279; Win 35,833; Modalim; MLS002154143; Prestwick0_001076; Win-35833; Propanoic acid, 2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methyl-; AB00514032; CID2763; 2-(4-(2,2-Dichlorocyclopropyl)phenoxy)2-methylpropanoic acid; NCGC00015202-04; NCGC00093652-02; Ciprol; Sanofi Synthelabo brand of ciprofibrate; Hiperlipen; BSPBio_001092; Ciprofibrato; C019304; Hyperlipen; C 0330; CHEBI:50867; Propionic acid, 2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methyl-; CHEMBL557555; EINECS 257-744-6; Lipanor; Prestwick2_001076; 2-[p-(2,2-Dichlorocyclopropyl)phenoxy]-2-methylpropanoic acid; AC1L1EET; NCGC00015202-02; EU-0100168	52214-84-3	2763	17397655	TTDS00340	Peroxisome proliferator activated receptor alpha	Peroxisome proliferater-activated receptor alpha;PPARalpha;PPAR-alpha	Q07869	5465	ENSG00000186951	agonist
DAP001440	AD-4833	5-(4-(2-(5-ethyl-2-pyridyl)ethoxy)benzyl)-2,4-thiazolidinedione; Pioglitazone [BAN:INN]; 2,4-Thiazolidinedione, 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]- (9CI); HS-0047; Pioglitazona; KBioSS_002103; HMS2089H14; 5-[[4-[2-(5-Ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-2,4-thiazolidinedione; Spectrum3_001002; 5-[[4-[2-[(5-ethyl-2-pyridyl)]ethoxy]phenyl]methyl]thiazolidine- 2,4-dione; Duetact; Spectrum5_001480; I06-0089; CID4829; 111025-46-8; 5-[4-[2-(5-Ethyl-2-pyridyl)ethoxy]benzyl]thiazolidine-2,4-dione; (+/-)-5-[p-[2-(ethyl-2-pyridyl)ethoxy]benzyl]-2,4-thiazolidinedione; UNII-X4OV71U42S; 2,4-Thiazolidinedione, 5-((4-(2-(5-ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-; NCGC00163128-02; (+/-)-5-[[4-[2-(5-Ethyl-2-pyridinyl)-ethoxy]phenyl]methyl]-2,4-thiazolidinedione; 2,4-Thiazolidinedione, 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-, (+/-)-; AD-4833; Zactos; Actos; (+-)-5-((4-(2-(5-ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione; KBioGR_001619; CHEBI:8228; CHEMBL595; Spectrum_001623; MolPort-002-508-211; pioglitazone (INN); DB01132; KBio3_001943; KBio2_007239; Pioglitazonum; AC-1021; 198077-89-3; Spectrum2_001679; 2,4-thiazolidinedione, 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-; D08378; 5-[[4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl]methyl]thiazolidine-2,4-dione; U 72107A; U 72107; Spectrum4_001130; NCGC00163128-01; 5-[[4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione; KBio2_004671; LS-151327; HSDB 7322; Pioglitazona [INN-Spanish]; SPBio_001897; Actost; U-72107; KBio2_002103; 5-{4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl}-1,3-thiazolidine-2,4-dione; Actos (TN); 2,4-Thiazolidinedione, 5-((4-(2-(5-ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-, (+-)-; Pioglitazone [INN:BAN]; BSPBio_002723; C07675; AB1004597; 5-((4-(2-(5-Ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione; BRD-A48430263-003-02-4; Glustin; C19H20N2O3S; 105355-27-9; nchembio790-comp10; U72,107A; Pioglitazone; Spectrum5_002067; Pioglitazonum [INN-Latin]; AC1L1J1Q; AD 4833	N/A	4829	22395182	TTDS00340	Peroxisome proliferator activated receptor alpha	Peroxisome proliferater-activated receptor alpha;PPARalpha;PPAR-alpha	Q07869	5465	ENSG00000186951	N/A
DCL000090	COR100140	N/A	N/A	6918365	45276209	TTDC00103	Macrophage migration inhibitory factor	GIF;Glycosylation-inhibiting factor;MIF;Phenylpyruvate tautomerase	P14174	4282	ENSG00000240972	inhibitor
DPR000106	Sirna-027	N/A	52232-67-4	N/A	47207736	TTDC00334	mRNA of VEGFR1	mRNA of Vascular endothelial growth factor receptor 1;mRNA of VEGFR-1;mRNA of Fms-like tyrosine kinase 1;mRNA of FLT-1;mRNA of Tyrosine-protein kinase FRT;mRNA of Tyrosine-protein kinase receptor FLT;mRNA of Vascular permeability factor receptor;mRNA of FLT1	P17948	2321	ENSG00000102755	N/A
DCL000426	AMG 479	N/A	N/A	N/A	N/A	TTDS00269	Insulin-like growth factor I receptor	CD221 antigen;IGF-1 receptor;IGF-1R;IGF-IR;Type 1 insulin-like growth factor receptor	P08069	3480	ENSG00000140443	inhibitor
DCL000566	MK-0646	N/A	112727-80-7	3035241	47208053	TTDS00269	Insulin-like growth factor I receptor	CD221 antigen;IGF-1 receptor;IGF-1R;IGF-IR;Type 1 insulin-like growth factor receptor	P08069	3480	ENSG00000140443	inhibitor
DCL000527	Figitumumab	N/A	N/A	6917781	43529205	TTDS00269	Insulin-like growth factor I receptor	CD221 antigen;IGF-1 receptor;IGF-1R;IGF-IR;Type 1 insulin-like growth factor receptor	P08069	3480	ENSG00000140443	inhibitor
DCL000364	AEW-541	N/A	N/A	N/A	N/A	TTDS00269	Insulin-like growth factor I receptor	CD221 antigen;IGF-1 receptor;IGF-1R;IGF-IR;Type 1 insulin-like growth factor receptor	P08069	3480	ENSG00000140443	inhibitor
DCL000603	R1507	N/A	N/A	N/A	N/A	TTDS00269	Insulin-like growth factor I receptor	CD221 antigen;IGF-1 receptor;IGF-1R;IGF-IR;Type 1 insulin-like growth factor receptor	P08069	3480	ENSG00000140443	inhibitor
DAP000287	Mecasermin	N/A	68562-41-4	N/A	46504889	TTDS00269	Insulin-like growth factor I receptor	CD221 antigen;IGF-1 receptor;IGF-1R;IGF-IR;Type 1 insulin-like growth factor receptor	P08069	3480	ENSG00000140443	inhibitor
DAP001429	Sulindac sulfide	AC1L3MF1; CID5352624; (Z)-5-Fluoro-2-methyl-1-[p-(methylthio)benzylidene]indene-3-acetic acid; 1H-Indene-3-acetic acid, 5-fluoro-2-methyl-1-(4-(methylthio)phenyl)methylene-, (Z)-; C20H17FO2S; EINECS 250-892-2; MolPort-003-850-356; AC1O0B8G; 2-[6-fluoro-2-methyl-3-[(4-methylsulfanylphenyl)methylidene]inden-1-yl]acetic acid; CID6034911; AC-20512; (Z)-Sulindac sulfide; S3131_SIGMA; Sulindac sulfide; AC1NS2PY; CHEMBL18797; 5-Fluoro-2-methyl-1-((4-(methylthio)phenyl)methylene)-1H-indene-3-acetic acid; EINECS 256-403-9; 49627-27-2; 1H-Indene-3-acetic acid, 5-fluoro-2-methyl-1-((4-(methylthio)phenyl)methylene)-, (Z)-; 2-[(3E)-6-fluoro-2-methyl-3-[(4-methylsulfanylphenyl)methylidene]inden-1-yl]acetic acid; 2-[(3Z)-6-fluoro-2-methyl-3-[(4-methylsulfanylphenyl)methylidene]inden-1-yl]acetic acid; CID10569396; 5-Fluoro-2-methyl-1-(p-methylthiobenzylidene)-3-indenyl acetic acid; 3309-71-5; KST-1B3169; CID91605; {5-fluoro-2-methyl-1-[4-(methylsulfanyl)benzylidene]-1h-inden-3-yl}acetic acid; CHEMBL1408; AR-1A9608; PC7345; NCGC00161601-01; (Z)-5-Fluoro-2-methyl-1-((4-(methylthio)phenyl)methylene)-1H-indene-3-acetic acid; 32004-67-4; 1H-Indene-3-acetic acid, 5-fluoro-2-methyl-1-(p-(methylthio)benzylidene)-; UPCMLD-DP020; UPCMLD-DP020:001; 1H-Indene-3-acetic acid, 5-fluoro-2-methyl-1-((4-(methylthio)phenyl)methylene)-; UNM-0000306137; CHEBI:121650; AC1Q4OEI; 5-fluoro-2-methyl-1-(4-methylthiobenzylidene)inden-3-ylacetic acid; LS-174363	32004-67-4	5352624	668392	TTDS00039	Cyclooxygenase	Cyclooxygenase (COX1 and COX2);PHS;Prostaglandin H2 synthase;Prostaglandin synthase	N/A	N/A	N/A	inhibitor
DAP000619	Fenoprofen	NCGC00094887-02; SPBio_002707; 53746-45-5 (calcium salt, dihydrate); Fenoprofen calcium; Benzeneacetic acid, .alpha.-methyl-3-phenoxy-, (.+/-.)-; Spectrum2_001391; CHEMBL1297; AC1Q5RW1; 2-(3-Phenoxyphenyl)propanoic acid; HMS1921B19; HMS2090G18; HMS502K10; C06997; Spectrum4_001009; KBio1_000848; Lilly 53838; EINECS 250-850-3; 34597-40-5 (calcium salt, anhydrous); D02350; BRN 2118687; SPECTRUM1501011; Fenoprofene [INN-French]; KBio2_006868; Feneprofen calcium salt dihydrate; NINDS_000848; Prestwick0_000754; Spectrum3_000910; KBio3_001860; AB00052197; NCGC00094887-01; (+-)-2-(3-Phenoxyphenyl)propionic acid; HSDB 3328; UNII-RA33EAC7KY; KBio2_001732; Fenoprofeno; Feprona; DB00573; Hydratropic acid, m-phenoxy-, (+-)-; alpha-Methyl-3-phenoxybenzeneacetic acid; 29679-58-1; HMS2092B07; Nalgesic; Fenoprofen calcium hydrate; Spectrum_001252; EINECS 249-770-1; SPBio_001402; BPBio1_000846; Prestwick3_000754; Benzeneacetic acid, alpha-methyl-3-phenoxy-, (+-)-; 31879-05-7; Fenoprofen (USAN/INN); 95907-05-4; KBio2_004300; 2-(m-phenoxyphenyl)propionic acid; CID3342; (+-)-m-Phenoxyhydratropic acid; CHEBI:5004; Fenoprofenum [INN-Latin]; AR-1J0752; BSPBio_000768; KBioSS_001732; MolPort-003-666-345; Prestwick2_000754; DivK1c_000848; 2-[3-(phenyloxy)phenyl]propanoic acid; Nalfon; Fenoprofene; LS-76362; alpha-(m-phenoxyphenyl)propionic acid; 2-(3-Phenoxyphenyl)propionic acid; Spectrum5_001311; Fenoprofen Dihydrate, Calcium Salt; KBioGR_001477; Fenoprofen [USAN:BAN:INN]; Fenoprofenum; fenoprofen; Fenoprofeno [INN-Spanish]; AC1L1FPT; Prestwick1_000754; IDI1_000848	34597-40-5	3342	7854132	TTDS00039	Cyclooxygenase	Cyclooxygenase (COX1 and COX2);PHS;Prostaglandin H2 synthase;Prostaglandin synthase	N/A	N/A	N/A	inhibitor
DAP000843	Aspirin	Acisal; NCGC00015067-04; Pharmacin; CCRIS 3243; Spectrum3_001295; Acetosal; A 5376; component of Synirin; D00109; XAXA; Acetylsal; Decaten; Spectrum2_001899; NCGC00090977-05; AIN; CID2244; Aloxiprimum; Benaspir; SMR000059138; 1oxr; ASA; KBioSS_001725; Acimetten; Aspirdrops; Neuronika; Rhodine; Rheumin tabletten; 11126-37-7; AC1Q1LA0; Solprin acid; Tasprin; Aspirin (JP15/USP); Lopac-A-5376; MolPort-000-871-622; DivK1c_000555; I14-7505; D001241; NCGC00090977-04; Measurin; Acetosalic acid; SPECTRUM1500130; Ecolen; Acetisal; Acetylsalicylsaure; Kapsazal; Bayer Aspirin 8 Hour; KBio2_001725; Easprin (TN); Cemirit; Pirseal; CHEBI:15365; Aspro Clear; ACETYLSALICYLIC ACID; Bay-e-4465; PL-2200; Salacetin; 26914-13-6; Aspirina 03; Bialpirinia; A6810_SIGMA; Spectrum_001245; Enterosarein; Adiro; Extren; Triple-sal; Micristin; AC 5230; Entrophen; Globoid; Aspro; AC1L1D8U; Aspalon; Ecotrin; Colfarit; NCGC00090977-03; Solfrin; Acetylsalicylsaeure; AKOS000118884; KBioSS_002272; Aspirine; MLS001055329; Asprin; UNM-0000306102; Levius; KBio2_004839; A.S.A. empirin; Idragin; Acetysalicylic acid; Ronal; Rhonal; Aceticyl; Spectrum4_000099; Polopiryna; WLN: QVR BOV1; Solupsan; Bi-prin; NSC27223; Entericin; 11126-35-5; IDI1_000555; KBio3_002149; KBio1_000555; Duramax; HMS2090G03; Spira-Dine; NSC406186; NCGC00090977-01; Ascoden-30; 2349-94-2; UNII R16CO5Y76E; Acetilum acidulatum; S-211; Supac; NINDS_000555; Endydol; KBio2_002271; cMAP_000006; Acetylsalycilic acid; Aspirin [BAN:JAN]; BRN 0779271; Globentyl; Spectrum5_000740; EINECS 200-064-1; component of Midol; HSDB 652; Acetosalin; ECM; Azetylsalizylsaeure; UNII=R16CO5Y76E; SPBio_001838; aspirin; MLS001066332; Helicon; HMS2091K13; Magnecyl; Saletin; Bialpirina; Acetysal; Aspec; A.S.A.; KBio2_007407; Claradin; Solprin; Temperal; NCGC00090977-02; Novid; UNII-R16CO5Y76E; Acetilsalicilico; R16CO5Y76E [UNII]; Dolean pH 8; A.S.A; Asacard; EU-0100038; NCGC00015067-01; Easprin; Bayer Plus; Aspirin; 50-78-2; Bufferin; Contrheuma retard; Empirin with Codeine; KBioGR_002271; Nu-seals aspirin; A3160_SIGMA; 98201-60-6; 8-hour Bayer; Istopirin; Asteric; nchem.859-comp6; Enterosarine; Empirin; ASA; Aspirin; MLS001336045; Bayer; AB1003266; MLS001336046; BIDD:GT0118; Asagran; Dispril; St. Joseph; Cardioaspirin; LS-143; NCGC00090977-07; NSC 27223; SP 189; Aspir-Mox; Salcetogen; Acylpyrin; Acetonyl; ZORprin; CHEMBL25; Polopirin; Premaspin; A5376_SIGMA; Solpyron; DB00945; Acetylsalicylate; Clariprin; Rheumintabletten; Medisyl; Enterophen; Acetoxybenzoic acid; HMS501L17; Persistin; KBio2_006861; NCGC00090977-06; C01405; Delgesic; A2093_SIGMA; Aspergum; Acetophen; KBio2_004293; Acesal; Lopac0_000038; Acetylin; Endosprin; Bayer Buffered; ST075414; Yasta; Asatard; NCGC00015067-09; Nu-seals; AI3-02956; KBioGR_000398; HMS1920E13; Acenterine; KBio3_002751; NCI60_002222	50-78-2	2244	4594	TTDS00039	Cyclooxygenase	Cyclooxygenase (COX1 and COX2);PHS;Prostaglandin H2 synthase;Prostaglandin synthase	N/A	N/A	N/A	inhibitor
DAP000621	Flurbiprofen	KBio3_001270; 2-(3-fluoro-4-phenylphenyl)propanoic acid; Spectrum4_000558; KBio2_004144; DB00712; SPBio_001209; FLURBIPROFEN SODIUM; KBio1_000804; Prestwick2_000917; CID3394; HMS2091F21; Yakuban; Adofeed; Zepolas; BTS-18322; NCGC00025287-03; InChI=1/C15H13FO2/c1-10(15(17)18)12-7-8-13(14(16)9-12)11-5-3-2-4-6-11/h2-10H,1H3,(H,17,18); Spectrum5_000720; CHEMBL563; 2-(2-fluoro-[1,1'-biphenyl-4-yl])propanoic acid; KBioGR_001255; Anmetarin; 51543-38-5; AKOS004119934; F8514_SIGMA; Prestwick3_000917; Novo-Flurprofen; BSPBio_002050; STK802101; U-27182; CHEBI:5130; Ansaid (TN); Flurbiprofene [INN-French]; AC-12003; Spectrum_001096; Apo-Flurbiprofen; KBio2_006712; D00330; AB00051999; Ocufen; [+/-]-2-Fluoro-alpha-methyl-4-biphenylacetic acid; Anside; Prestwick1_000917; Fluriproben; Flugalin; NCI60_030812; IDI1_000804; Spectrum3_000435; Froben; UNII-5GRO578KLP; BRD-A86044036-001-05-9; SAM002564209; KBioSS_001576; BTS 18322; S-Flurbiprofen; [1,1'-Biphenyl]-4-acetic acid, 2-fluoro-.alpha.-methyl-; HMS2090I06; MLS000028441; 2-(2-Fluorobiphenyl-4-yl)propionic Acid; Flurbiprofen [USAN:INN:BAN:JAN]; BIM-0051387.0001; Flurbiprofeno; CCRIS 3708; Prestwick0_000917; C15H13FO2; MLS000040873; KBio2_001576; HMS1920O20; MolPort-000-812-253; Flubiprofen; Flurbiprofenum; Spectrum2_001025; SYTBZMRGLBWNTM-UHFFFAOYSA-; HMS1570H16; NSC685699; NCGC00025287-04; Stayban; EINECS 257-262-6; Flurbiprofene; (1,1'-Biphenyl)-4-acetic acid, 2-fluoro-alpha-methyl-; EINECS 225-827-6; L-790,330; Antadys; U 27182; Froben Sr; Nu-Flurbiprofen; Ansaid; BSPBio_000794; FLP; BPBio1_000874; F0371; (+-)-2-(2-Fluoro-4-biphenylyl)propionic acid; 2-Fluoro-alpha-methyl-(1,1'-biphenyl)-4-acetic acid; 4-Biphenylacetic acid, 2-fluoro-alpha-methyl-; HMS502I06; (1)-2-Fluoro-alpha-methyl(1,1'-biphenyl)-4-acetic acid; HMS2051A05; MKS-11; BB_SC-1257; 5104-49-4; FP 70; Flurofen; SAM001246961; 2-Fluoro-alpha-methyl-4-biphenylacetic acid; 2-(2-fluorobiphenyl-4-yl)propanoic acid; U 27,182; Ocuflur; NSC685700; AC1Q1LGF; (+/-)-2-Fluoro-alpha-methyl[1,1&prime;-biphenyl]-4-acetic Acid; MLS000758198; (+-)-2-Fluoro-alpha-methyl-4-biphenylacetic acid; DivK1c_000804; Flurbiprofenum [INN-Latin]; 3-Fluoro-4-phenylhydratropic acid; MLS001401361; IN1332; (1,1'-Biphenyl)-4-acetic acid, 2-fluoro-alpha-methyl-, (+-)-; SPECTRUM1500308; Flurbiprofeno [INN-Spanish]; Cebutid; CPD000042823; NINDS_000804; AC1L1FU5; (+/-)-2-Fluoro-alpha-methyl-4-biphenylacetic acid; flurbiprofen; SMR000042823; Adfeed; Flurbiprofen (JP15/USP/INN); [1,1'-Biphenyl]-4-acetic acid, 2-fluoro-.alpha.-methyl-, (R)-; LS-44091; SPBio_002983; MLS001201729	5104-49-4	3394	163961	TTDS00039	Cyclooxygenase	Cyclooxygenase (COX1 and COX2);PHS;Prostaglandin H2 synthase;Prostaglandin synthase	N/A	N/A	N/A	inhibitor
DAP000622	Oxaprozin	Prestwick1_001060; Prestwick0_001060; AKOS000206807; Rhoxal-oxaprozin; KBio3_001916; DB00991; C008729; NSC 310839; Xopane; AC1L1IK7; NCGC00094249-02; Oxaprozina; HMS2093O08; Spectrum3_001078; Deflam; Lopac0_000944; NCI60_002681; 3-(4,5-Diphenyl-1,3-oxazol-2-yl)propanoic acid; I14-8703; Oxaprozina [INN-Spanish]; C18H15NO3; AC1Q759K; BIDD:GT0438; Oxaprozin (JP15/USAN/INN); Alvo; SAM001246770; NCGC00094249-01; WY-21743; NCGC00014711-02; SR-01000076053-3; SMR000058286; Voir; HMS1571C22; NCGC00014711-11; 3-(4,5-Diphenyl-1,3-oxazol-2-yl)propanoic acid; .Beta.-(4,5-Diphenyloxazol-2-yl)propionic acid; 2-Oxazolepropanoic acid, 4,5-diphenyl-; 2-Oxazolepropionic acid, 4,5-diphenyl-; 3-(4, 5-Diphenyl-2-oxazo; Prestwick2_001060; O9637_SIGMA; Oxaprozinum [INN-Latin]; NCIStruc1_000799; Danoprox; Actirin; BSPBio_002696; NCGC00094249-05; Maybridge1_008800; MLS001424072; AC-11349; 4,5-Diphenyl-2-oxazolepropionic acid; LS-100216; HMS566H22; Prestwick3_001060; Rhoxalpharma brand of oxaprozin; NCGC00014711-04; WY-21,743; UNII-MHJ80W9LRB; CHEMBL1071; beta-(4,5-Diphenyloxazol-2-yl)propionic acid; Pfizer brand of oxaprozin; NSC-310839; EU-0100944; Oxaprozinum; Daypro (TN); NCGC00094249-03; lyl)propenoic acid; 4, 5-Diphenyl-2-oxazolepropionic acid; NSC310839; TRB brand of oxaprozin; MLS000759535; NCGC00094249-06; 4,5-Diphenyl-2-oxazolepropanoic acid; BRN 1083168; Spectrum2_001696; Oxaprozine [INN-French]; NCGC00014711; CID4614; AB00514024; Lopac-O-9637; NCIStruc2_000787; BPBio1_001122; 21256-18-8; Oprea1_509470; CAS-21256-18-8; Dayrun; O 9637; 3-(4,5-Diphenyl-2-oxazolyl)propenoic acid; CSC brand of oxaprozin; Apo-Oxaprozin; CPD000058286; Daypro; CHEBI:239225; WY 21743; BIDD:PXR0149; HMS2051L15; 2-Oxazolepropanoic acid, 4,5-diphenyl-; SBB053166; SPBio_001652; Spectrum4_001231; KBioGR_001722; HSDB 7586; Oxaprozin [USAN:BAN:INN:JAN]; NCGC00094249-07; BSPBio_001020; NCGC00094249-04; BRD-K25394294-001-05-7; oxaprozin; 2-OXAZOLEPROPIONIC ACID, 4,5-DIPHENYL-; C07356; AC1Q759J; MolPort-000-146-829; Oxaprozine; EINECS 244-296-1; NCI310839; D00463; SPBio_002940; .beta.-(4,5-Diphenyloxazol-2-yl)propionic acid; HMS1922P17; NCGC00014711-03; Apotex brand of oxaprozin; SPECTRUM1505267	21256-18-8	4614	172661	TTDS00039	Cyclooxygenase	Cyclooxygenase (COX1 and COX2);PHS;Prostaglandin H2 synthase;Prostaglandin synthase	N/A	N/A	N/A	inhibitor
DAP000618	Ketorolac	CHEMBL469; D020910; Ketorolac (INN); Toradol (TN); Ketorolaco; 5-(phenylcarbonyl)-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid; LS-139094; BRD-A40639672-234-05-7; Macril; Ketorolac [INN:BAN]; AC1L1GSW; (.+/-.)-2,3-Dihydro-5-benzoyl-1H-pyrrolizine-1-carboxylic acid; RS-37619; D08104; (+-)-isomer; AC-545; UNII-YZI5105V0L; CID3826; RS 37619; I14-2832; (+-)-Ketorolac; NCGC00185990-01; 1H-Pyrrolizine-1-carboxylic acid, 2,3-dihydro-5-benzoyl-, (+-)-; STL018674; C07062; 74103-06-3; 5-Benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid; SBB067312; 1H-Pyrrolizine-1-carboxylic acid, 5-benzoyl-2,3-dihydro; AB00053682; ketorolac; Ketoralac; Ketorolacum; Ketorolaco [Spanish]; 1H-Pyrrolizine-1-carboxylic acid, 5-benzoyl-2,3-dihydro-; DB00465; Ketorolacum [Latin]; CHEBI:105080; MolPort-005-933-093; 5-Benzoyl-1,2-dihydro-3H-pyrrolo(1,2a)pyrrole-1-carboxylic acid; 1H-Pyrrolizine-1-carboxylic acid, 2,3-dihydro-5-benzoyl-, (.+/-.)-; (+-)-5-Benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid; 66635-83-4	66635-83-4	3826	9274	TTDS00039	Cyclooxygenase	Cyclooxygenase (COX1 and COX2);PHS;Prostaglandin H2 synthase;Prostaglandin synthase	N/A	N/A	N/A	inhibitor
DAP000776	Acetaminophen	Panadol; Banesin; Anhiba; Nealgyl; Treuphadol; Pyrinazine; Calpol; Percocet-5; Seskamol; Nodolex; Abensanil; Neopap; Prontina; Tylex; Babikan; Parador; Vips; Cetadol; Pulmofen; Oltyl; Febrectal; Scentalgyl; Inalgex; Panale ve; Parakapton; Aferadol; Panofen; Cosutone; Febricet; Lonarid; Aminofen; Paraspen; Duaneo; Ildamol; Homoolan; Fever All; Termalgine; Bacetamol; Sanicopyrine; Termofren; Setakop; Veralgina; Capital; Suppap; Infadrops; Arfen; Paracetamole; Predimol; Neodolito; Pyrigesic; NeoCitran; Amadil; Titralgan; Febrectol; Lekadol; Febrinol; Tabalgin; Stopain; Febrilix; Asplin; Apamide; Atralidon; Alpiny; Rounox; Dypap; Phenipirin; Geluprane; Dirox; Snaplets-FR; Rubophen; Paracemol; Febranine; Predualito; Panacete; Acetavance; Paralink; Panadeine Co; Dolcor; Neotrend; Algomol; Dolefin; Disprol; Parasin; Mexalen; Daygrip; Genapap; Aspac; Neodol; Dolorfug; Minafen; Schmerzex; Acephen; Dorocoff; Gelocatil; Termacet; Parake; Dristancito; Kataprin; Codapane; Napafen; Actamin; Finiweh; Anuphen; Codabrol; Algotropyl; Desfebre; Viruflu; Apitrelal; Lemgrip; Scanol; Tazamol; Fluparmol; Momentum; Lonarid Mono; Piramin; Vermidon; Jin Gang; Paramol; Tempanal; Setamol; Tylenol; Dolegrippin; Polmofen; Dularin; Acetagesic; Paracetamol; Eneril; Panodil; Neuridon; Tussapap; Sunetheton; Maxadol; Panasorbe; Supadol mono; Biocetamol; Calapol; Tapanol; Causalon; Exdol; Duorol; Sifenol; Conacetol; Toximer P; Paradrops; Doliprane; Pedric; Lemsip; Acamol; A-Per; Helon N; Anacin-3; Liquagesic; Captin; Utragin; Labamol; Phendon; Abenol; Supofen; Pamol; Nina; Valadol; Acetofen; Plicet; Acenol; Panado-Co; Codisal; Asomal; Magnidol; Tocris-1706; Excipain; Cadafen; Grippostad; Stanback; Tempra; Tylol; Dymadon Co; Calmanticold; Ty lenol; Paroma; Paracetol; Pyromed; Dolko; Farmadol; Analter; Paracetamolo; Treupel mon; Apadon; Abrolet; Sinaspril; Malex N; Cefalex; Acetamol; Arthralgen; Hedex; Durapan; Anelix; Pinex; Gynospasmine; Ortensan; Fepanil; Finimal; Oxycocet; Anaflon; Darocet; Dimindol; Paralyoc; Parcetol; Panasorb; Parelan; Influbene N; NSC3991; KBio1_000660; Zolben; Valgesic; Enelfa; Pacimol; Zatinol; Actimol; L024125; Oraphen-PD; APAP; Paracodol; Perfalgan; Gattaphen T; Parogal; Valorin; Korum; Lyteca Syrup; Vivimed; Panamax; Actifed Plus; Liqiprine; Asetam; Puernol; Deminofen; Paracin; Algina; Dresan; Paracetanol; Noral; Acetaminofen; Acetaco; Nobedon; Eu-Med; NilnOcen; Paracenol; Prompt; Salzone; Geralgine-P; Remedol; CHEBI:46195; Sinedol; Tralgon; Algesidal; Pyregesic-C; Papa-Deine; Parmol; Paracet; Darvocet; Dolprone; Painex; Spalt N; Pantalgin; Aceta Elixir; Pacemo; NEBS; Pediapirin; Tiffy; Paedol; Naprinol; Semolacin; Fendon; Fanalgic; Upsanol; Minoset; Dolgesic; Dafalgan; Ecosetol; Setol; Curpol; Para-Suppo; Medocodene; D oliprane; Gripin Bebe; Alvedon; Robigesic; Curadon; Codicet; Pasolind; Panaleve; Codalgin; Servigesic; Malidens; SPBio_002836; Acertol; Paralief; Lestemp; Dolorstop; Panex; Cuponol; Tymol; Tricoton; Febrolin; Doloreduct; Clixodyne; Democyl; Andox; Antidol; Paranox; Injectapap; Cofamol; Afebrin; Paldesic; Pediatrix; Bayer Select; Supramol-M; Codoliprane; Tylenol (TN); Duracetamol; Febrex; Fensum; Empracet; Paralen; Tylex CD; Elixodyne; Lupocet; Dolofugin; Afebryl; Reliv; Abrol; Pe-Tam; Paramolan; Ofirmev; Parasedol; Neo-Fepramol; Paceco; Sedalito; Dymadon; Sanicet; Paracod; Anacin 3; Acetalgin; Rupemol; AC1Q1KYK; Dhamol; Demogripal; Alpinyl; Phogoglandin; Panets; Prodol; Pacet; Tapar; NCX 701; Calonal; Fevor; Febro-Gesic; Pasolind N; Termalgin; Rivalgyl; Paedialgon; Tachiprina; Oralgan; Sinmol; Pacemol; Anapap; Panadeine; Temlo; TYL; Lyteca; Verpol; Panadiene; Febrin; AC1Q1KYJ; Accu-Tap; Volpan; Custodial; Treupel N; Redutemp; Malgis; Bickie-mol; Parapan; Miralgin; Multin; Datril; Atasol; Janupap; Pirinasol; Fortalidon P; Febridol; CCRIS 3; Apacet; Genebs; RubieMol; Benmyo; Dolotec	103-90-2	1983	7847284	TTDS00039	Cyclooxygenase	Cyclooxygenase (COX1 and COX2);PHS;Prostaglandin H2 synthase;Prostaglandin synthase	N/A	N/A	N/A	inhibitor
DCL000892	NCX-4016	nitroaspirin; nitric oxide-releasing aspirin; 2-Acetoxybenzoic acid 3-(nitrooxymethyl)phenyl ester; C102148; m-NO-aspirin; 175033-36-0; AC1L3O2Q; Benzoic acid, 2-(acetyloxy)-, 2-((nitrooxy)methyl)phenyl ester; ZINC00022315; [3-(nitrooxymethyl)phenyl] 2-acetyloxybenzoate; m-NO-ASA; MolPort-003-849-606; LS-35540; Ncx-4016; C16H13NO7; CHEMBL374385; NO-ASA; 2-((Nitrooxy)methyl)phenyl 2-(acetyloxy)benzoate; 3-(Nitroxymethyl)phenyl 2-acetoxybenzoate; 2-Acetoxybenzoate-2-(1-nitroxymethyl)phenyl ester; CID119032; Benzoic acid, 2-(acetyloxy)-, 3-((nitrooxy)methyl)phenyl ester; 3-((Nitrooxy)methyl)phenyl 2-(acetyloxy)benzoate; 190442-10-5; LS-35539; 2-Acetoxybenzoic acid 3-nitrooxymethylphenyl ester; Ncx 4016	175033-36-0	5283344	12015129	TTDS00039	Cyclooxygenase	Cyclooxygenase (COX1 and COX2);PHS;Prostaglandin H2 synthase;Prostaglandin synthase	N/A	N/A	N/A	inhibitor
DAP001506	Pravigard	N/A	98201-60-6	2244	148573	TTDS00039	Cyclooxygenase	Cyclooxygenase (COX1 and COX2);PHS;Prostaglandin H2 synthase;Prostaglandin synthase	N/A	N/A	N/A	inhibitor
DAP001457	Asasantin	N/A	87653-67-6	3108	713654	TTDS00039	Cyclooxygenase	Cyclooxygenase (COX1 and COX2);PHS;Prostaglandin H2 synthase;Prostaglandin synthase	N/A	N/A	N/A	inhibitor
DCL000717	Benzydamine	3-[(1-benzyl-1H-indazol-3-yl)oxy]-N,N-dimethylpropan-1-amine; 1-Propanamine, N,N-dimethyl-3-[[1-(phenylmethyl)-1H-indazol-3-yl]oxy]-; 132-69-4 (mono-hydrochloride); MolPort-001-684-202; CHEBI:109913; NCGC00016397-02; BPBio1_000258; Apo-Benzydamine (TN); C19H23N3O; Benzydaminum [INN-Latin]; 3-(1-benzylindazol-3-yl)oxy-N,N-dimethylpropan-1-amine; HMS2090P22; CID12555; EINECS 211-388-8; AC-15604; Benzidamina; Bencidamina [INN-Spanish]; 1-Benzyl-3-(3-(dimethylamino)propoxy)-1H-indazole; Benzindamine; Apo-Benzydamine; Bencidamina; BENZYDAMINE; C 1523; Prestwick3_000297; 1H-Indazole, 1-benzyl-3-(3-(dimethylamino)propoxy)-; LS-81420; 1-Propanamine, N,N-dimethyl-3-((1-(phenylmethyl)-1H-indazol-3-yl)oxy)-; AC1L1ZUF; TL8004545; Benzydamine (INN); D07516; {3-[(1-benzyl-1H-indazol-3-yl)oxy]propyl}dimethylamine; STK711092; BSPBio_000234; Prestwick2_000297; Benzydaminum; Benzidamine; BRD-K28542495-003-03-6; Benzydamine Monohydrochoride; CHEMBL12610; AC1Q4XUF; CAS-132-69-4; 642-72-8; Benzydamine [INN:BAN]; 5-23-11-00248 (Beilstein Handbook Reference); NCGC00016397-01; Prestwick0_000297; Benzidamina [DCIT]; STOCK6S-01108; BRN 0896536; AC1Q3WS9; Prestwick1_000297; SPBio_002453	100-46-9	7504	48415031	TTDS00039	Cyclooxygenase	Cyclooxygenase (COX1 and COX2);PHS;Prostaglandin H2 synthase;Prostaglandin synthase	N/A	N/A	N/A	inhibitor
DAP000620	Diclofenac	Oprea1_011155; diclofenac; BRN 2146636; SBB068617; Spectrum5_000867; CHEMBL139; Benfofen; D30801; Duravolten; Apo-Diclo; Assaren; BSPBio_002169; KBioGR_001051; 2-[2-(2,6-dichloroanilino)phenyl]acetic acid; Effekton; Solaraze T; Spectrum_000930; Prestwick3_000594; AC1L1F0T; DivK1c_000272; KBio2_006546; Novapirina; DIF; Diclac; Diclofenamic acid; dichlofenac; 15307-81-0 (mono-potassium salt); Lopac0_000441; Dicloreuma; SPBio_002687; 15307-86-5; SR-38; Voltaren Rapide; Diclofenacum; Voltaren; I14-7739; HMS2090C10; Acetic acid, [o-(2,6-dichloroanilino)phenyl]- (8CI); Diclord; BRD-K08252256-236-05-6; EINECS 239-348-5; KBio2_007442; henyl)-o-aminophenylacetic acid; Prestwick2_000594; Diclomelan; SPBio_001081; Rhumalgan; BPBio1_000516; 2b17; BSPBio_000468; GP-45,840; ACETIC ACID, (o-(2,6-DICHLOROANILINO)PHENYL)-; Voltaren-XR; Prestwick0_000594; Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]-; Voltaren ophthalmic; Voltarol; Dyloject; IDI1_000402; Nu-Diclo; KBio1_000272; 2-(2,6-Dichlorophenylamino)phenylacetic acid; Benzeneacetic acid, 2-((2,6-dichlorophenyl)amino)- (9CI); Spectrum3_000385; NINDS_000402; cMAP_000014; CID3033; Dolobasan; KBio2_003978; 2-(2,6-Dichloroanilino)phenylacetic Acid; CHEBI:47381; KBio1_000402; UNM000001216103; (2,6-Dichlorophenyl)amino]benzeneacetic acid; D07816; Benzeneacetic acid, 2-((2,6-dichlorophenyl)amino)-; Transfenac; 2-[2-(2,6-Dichlorophenylamino)phenyl]acetic acid; Dichlofenac; HSDB 7234; AKOS001579542; Ecofenac; ProSorb-D; Voltaren Ophtha; Diclofenaco; STK984493; Spectrum2_000991; Dicloreum; Diclobenin; D3748; Voldal; HMS501E04; Dichlofenal; Diclo-Phlogont; Primofenac; MolPort-000-003-072; Xenid; UNII-144O8QL0L1; Diclofenaco [INN-Spanish]; {2-[(2,6-dichlorophenyl)amino]phenyl}acetic acid; N-(2,6-Dichlorop; Diclofenac (INN); Diclofenac [INN:BAN]; BIDD:GT0380; KBioSS_001410; Voltaflan; [o-(2,6-Dichloroanilino)phenyl]acetic acid; Diclofenac acid; NCGC00021125-01; KBio2_002306; C01690; KBio2_004874; Novo-Difenac SR; Novo-Difenac; Prestwick1_000594; NINDS_000272; KBio2_001410; ISV-205; 2-((2,6-Dichlorophenyl)amino)benzeneacetic acid; KBioSS_002308; Solaraze; IDI1_000272; DivK1c_000402; Spectrum4_000506; LS-11575; Pennsaid; Dicrofenac; KBio3_002786; Solaraze (TN); Diclo-Puren; 2-[(2,6-Dichlorophenyl)amino]benzeneacetic acid; Diclophenac; Voltaren SR; KBioGR_002306; DB00586; KBio3_001389; Orthofen; Diclonate P; Diclofenacum [INN-Latin]; 2-[2,6-DICHLOROPHENYL)AMINO]BENZENEACETIC ACID	15307-86-5	3033	4831	TTDS00039	Cyclooxygenase	Cyclooxygenase (COX1 and COX2);PHS;Prostaglandin H2 synthase;Prostaglandin synthase	N/A	N/A	N/A	inhibitor
DAP000617	Indomethacin	Indometacine [INN-French]; NCGC00015562-19; Indometicina; CCRIS 3502; NINDS_000271; Lausit; KBio2_000489; KBio1_000271; AB00052022; HMS1990I11; KBioGR_000395; Indometacina; USAN; Indo-rectolmin; UNII-XXE1CET956; I 7378; Prestwick2_000272; Indomee; MLS000069402; LS-187; Lopac0_000692; I8280_SIGMA; Indometacina [INN-Spanish]; LS-82147; Infrocin; Indomethacin [USAN:BAN]; DivK1c_000271; CPD-10545; Indo-tablinen; HSDB 3101; IN1454; Indmethacine; Indomethazine; IMN; 503560-73-4; Chrono-indicid; NCGC00015562-03; C01926; KBioSS_001399; BSPBio_001149; Inflazon; Imbrilon; Liometacen; BSPBio_000144; Confortid; NCGC00024135-09; Lopac-I-7378; NCGC00024135-02; NCI-C56144; Elmetacin; KBioGR_000489; HMS1920F21; SMR000058195; Indocin I.V.; 7681-54-1 (hydrochloride salt); CHEMBL6; Indocid Pda; Indocin Sr; Indomod; Indomecol; NCGC00024135-05; CHEBI:49662; Sadoreum; Dolcidium; Indocid Sr; Prestwick3_000272; Spectrum3_000468; Spectrum_000919; Spectrum4_000018; BIM-0050670.0001; Bio-0704; UPCMLD-DP023:001; Indoptic; KBio2_005625; Spectrum2_000970; 1z9h; HMS500N13; I0655; UPCMLD-DP023; Indomethacin, Indochron E-R, Indocin-SR, Indocid, Indocin, Indomethacin; Indomethacine; Dolcidium PL; SPBio_000979; Novomethacin; Indometacinum [INN-Latin]; NCGC00024135-06; Indocin; BSPBio_002176; Indo-Lemmon; AC-532; Indocin I.V; HMS1362I11; Oprea1_686105; Indocin (TN); Metartril; Indoxen; HMS1568H06; L000959; Indo-phlogont; Rheumacin LA; Indocid; IDI1_000271; Indameth; Prestwick1_000272; Bonidon Gel; Novo-Methacin; Mezolin; Indo-Spray; Metacen; CID3715; CAS-53-86-1; Chrono-indocid; HMS2089N19; KBio2_003057; KBio3_001396; Artrivia; D00141; NCGC00015562-08; BRD-K57222227-001-06-1; KBio2_003967; EINECS 200-186-5; Miametan; KBioSS_000489; EU-0100692; Methazine; NCGC00015562-02; Indomethine; Bonidon; KBio3_000897; Prestwick_597; DB00328; I7378_SIGMA; KBio2_001399; nchembio.147-comp11; Artracin; Aconip; AC1L1GJQ; Inteban sp; NCGC00024135-11; 74252-25-8 (hydrochloride salt, tri-hydrate); Indometacinum; Apo-Indomethacin; 53-86-1; Mikametan; NCGC00024135-07; Tocris-1708; CGIGDMFJXJATDK-UHFFFAOYSA-; Indocid (pharmaceutical); NCGC00024135-04; 37242-43-6; Hicin; Bio2_000885; Flexin continus; Indolar SR; S00108; Chibro-amuno; Arthrexin; MolMap_000032; Indomo; Vonum; Indometacin (JP15/INN); S1723_Selleck; Rhemacin LA; Catlep; HMS2091N09; Durametacin; indometacin; indomethacin; Idomethine; Aconip (TN); MolPort-000-917-894; Indacin; KBio3_000898; MLS001074194; IDI1_002160; SPECTRUM1500350; Indomet 140; Indorektal; Bio2_000405; BPBio1_000160; Metindol; Bonidin; Indomed; Artrinovo; Indomethacin & MAP-30; Prestwick0_000272; HMS1792I11; Indomethacin (USP); Indometacyna [Polish]; NCGC00015562-01; Spectrum5_000868; BIDD:GT0132; BRN 0497341; NCI60_041708; SPBio_002363; Indomethancin; Indomethacinum; Indometacyna; Indoptol; AKOS000592893; 91853-74-6; Amuno; Tannex; Indomethegan; MLS000758212; NCGC00024135-08; Reumacide; Indometacine; Indometicina [Spanish]; Inacid; Dolovin; Mobilan; SMR000449290; DESMETHYL INDOMETHACIN; KBio2_006535	53-86-1	3715	148696	TTDS00039	Cyclooxygenase	Cyclooxygenase (COX1 and COX2);PHS;Prostaglandin H2 synthase;Prostaglandin synthase	N/A	N/A	N/A	inhibitor
DAP000969	Icosapent	cis-5,8,11,14,17-Eicosapentaenoic acid; BRD-K47192521-001-02-1; NCGC00161344-01; HMS1989C10; BSPBio_001328; 5,8,11,14,17-Icosapentaenoic acid; 25377-48-4; Icosapent; CHEMBL460026; E0441; Icosapento; Eicosapentaenoic acid; 5Z,8Z,11Z,14Z,17Z-Eicosapentaenoic acid; 5,8,11,14,17-Eicosapentaenoic acid, (5Z,8Z,11Z,14Z,17Z)- (9CI); 10417-94-4; CID446284; (5Z,8Z,11Z,14Z,17Z)-Eicosapentaenoate; cis-Delta(5,8,11,14,17)-eicosapentaenoic acid; cis, cis, cis, cis, cis-eicosa-5,8,11,14,17-pentaenoic acid; DB00159; 5,8,11,14,17-Eicosapentaenoic acid (6CI); 7F8BF016-B146-4F72-A52E-B9298BA3A9AB; (5Z,8Z,11Z,14Z,17Z)-5,8,11,14,17-eicosapentaenoic acid; (5Z,8Z,11Z,14Z,17Z)-Icosapentaenoic acid; CHEBI:28364; EICOSAPENTAENOIC ACID (20:5 n-3); 5,8,11,14,17-Eicosapentaenoic acid, (all-Z)- (8CI); E2011_SIGMA; 5,8,11,14,17-Eicosapentaenoic acid, (all-Z)-; C20:5 omega-3; (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoic acid; (5Z,8Z,11Z,14Z,17Z)-Eicosapentaenoic acid; 44864_FLUKA; 5,8,11,14,17-Eicosapentaenoic acid, (5Z,8Z,11Z,14Z,17Z)-; HMS1361C10; CCRIS 3279; L001256; (Z,Z,Z,Z,Z)-5,8,11,14,17-eicosapentaenoic acid; C06428; LMFA01030759; NCGC00161344-02; Icosapento [INN-Spanish]; Timnodonic acid; (all-Z)-delta5,8,11,14,17-Eicosapentaenoic acid; NCGC00161344-04; HMS1791C10; E7006_SIGMA; Icosapentaenoic acid; EPA; (all-Z)-5,8,11,14,17-Eicosapentaenoic acid; Icosapentum; D08061; all cis-5,8,11,14,17-Icosapentaenoic Acid; all cis-5,8,11,14,17-Eicosapentaenoic Acid; (all-cis)-5,8,11,14,17-Eicosapentaenoic acid; cis-5,8,11,14,17-EPA; BML3-B01; 5,8,11,14,17-EICOSAPENTAENOIC ACID; 3gwx; MolPort-003-933-180; NCGC00161344-03; IDI1_033798; 1553-41-9; Eicosapentaenoic acid, 5,8,11,14,17-(Z,Z,Z,Z,Z)-; AC1L9JFR; Icosapentum [INN-Latin]; all-cis-icosa-5,8,11,14,17-pentaenoic acid	10417-94-4	446284	11533194	TTDS00039	Cyclooxygenase	Cyclooxygenase (COX1 and COX2);PHS;Prostaglandin H2 synthase;Prostaglandin synthase	N/A	N/A	N/A	binder
DAP000815	Meclofenamic acid	INF-4668; I04-0402; 2-(2,6-dichloro-3-methylanilino)benzoic acid; 2-[(2,6-dichloro-3-methylphenyl)amino]benzoic acid; Meclophenamic acid; 644-62-2; BSPBio_001951; Acidum meclofenamicum [INN-Latin]; Anthranilic acid, N-(2,6-dichloro-m-tolyl)-; KBioSS_001373; BRD-K50398167-236-02-9; CI-583; NSC95309; CCRIS 5532; CID4037; Spectrum5_000942; Lopac0_000727; SBB065798; N-(3-Methyl-2,6-dichlorophenyl)anthranilic acid; KBio2_001373; KBio3_001451; KBioGR_000475; BRD-K50398167-323-03-3; Acidum meclofenamicum; Meclofenamic acid [USAN:INN:BAN]; EINECS 211-419-5; Prestwick0_000206; KBio2_003941; SPBio_000970; Acido meclofenamico [INN-Spanish]; Prestwick1_000206; NCGC00021132-01; Meclofenamic acid (USAN/INN); Spectrum2_001045; meclofenamic acid; Meclomen; Acido meclofenamico; KBio1_000504; benzoic acid, 2-[(2,6-dichloro-3-methylphenyl)amino]-; NINDS_000504; N-(2,6-Dichloro-m-tolyl)anthranilic acid; C07117; LS-20487; DB00939; IDI1_000504; INF 4668; Prestwick2_000206; KBio2_006509; Prestwick3_000206; N-(2,6-Dichloro-3-methylphenyl)anthranilic acid; AC1L1H9T; CL 583; InChI=1/C14H11Cl2NO2/c1-8-6-7-10(15)13(12(8)16)17-11-5-3-2-4-9(11)14(18)19/h2-7,17H,1H3,(H,18,19; Spectrum3_000486; meclofenamate; Arquel; Benzoic acid, 2-((2,6-dichloro-3-methylphenyl)amino)-; Acide meclofenamique; Acide meclofenamique [INN-French]; BPBio1_000211; CHEMBL509; D02341; BSPBio_000191; UNM000001246303; Spectrum4_000038; UNII-48I5LU4ZWD; DivK1c_000504; AR-1J3913; Spectrum_000893; 2-(2,6-Dichloro-3-methylphenyl)aminobenzoic acid; AC1Q3R48; 2-((2,6-Dichloro-3-methylphenyl)amino)benzoic acid; SPBio_002112; BRN 2221428; NSC 95309; Meclomen (free acid)	644-62-2	4037	7849400	TTDS00039	Cyclooxygenase	Cyclooxygenase (COX1 and COX2);PHS;Prostaglandin H2 synthase;Prostaglandin synthase	N/A	N/A	N/A	inhibitor
DAP000705	Nelfinavir	MLS001195634; DB00220; NSC722664; AC-20032; 1ohr; AG1343 (*Mesylate salt*); 3-Isoquinolinecarboxamide, N-(1,1-dimethyl ethyl)decahydro-2-[(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-(phenylthio)butyl]-, (3S,4aS,8aS)-; NFV; MLS001304729; AG1343; 3-Isoquinolinecarboxamide, N-(1,1-dimethylethyl)decahydro-2-[2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-(phenylthio)butyl]-, [3S-[2(2S*,3S*),3.alpha.,4a.beta.,8a.beta.]]-; NCGC00090782-03; 3-Isoquinolinecarboxamide, N-(1,1-dimethylethyl)decahydro-2-(2-hydroxy-3-((3-hydroxy-2-methylbenzoyl)amino)-4-(phenylthio)butyl)-, (3S-(2-(2S*,3S*),3-alpha,4a-beta,8a-beta))-; N-(1,1-Dimethylethyl)decahydro-2-(2-hydroxy-3-((3-hydroxy-2-methylbenzoyl)amino)-4-(phenylthio)butyl)-3-isoquinolinecarboxamide (3S-(2(2S*,3S*),3alpha,4abeta,8abeta))-; nelfinavir; Nelfinavir [BAN:INN]; 3-Isoquinolinecarboxamide, N-(1,1-dimethylethyl)decahydro-2-((2R,3R)-2-hydroxy-3-((3-hydroxy-2-methylbenzoyl)amino)-4-(phenylthio)butyl)-, (3S,4aS,8aS)-; CID64143; 3-Isoquinolinecarboxamide, N-(1,1-dimethylethyl)decahydro-2- [(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-(phenylthio)butyl]-, (3S,4aS,8aS)-; C32H45N3O4S; (3S-(2(2S*,3S*),3alpha,4abeta,8abeta))-N-(1,1-Dimethylethyl)decahydro-2-(2-hydroxy-3-((3-hydroxy-2-methylbenzoyl)amino)-4-(phenylthio)butyl)-3-isoquinolinecarboxamide; VRX496; C07257; Met-Stromal Cell-derived Factor-1.beta. (Human) & Nelfinavir; MolPort-000-883-833; NLF; Nelfinavir [INN:BAN]; MolPort-002-885-844; 1UN; 159989-64-7; NSC747167; (3S,4aS,8aS)-N-tert-butyl-2-[(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-phenylsulfanylbutyl]-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinoline-3-carboxamide; AC1L20J6; BIDD:PXR0143; 159989-65-8 (monomethane sulfonate (salt)); 2-[2-HYDROXY-3-(3-HYDROXY-2-METHYL-BENZOYLAMINO)-4-PHENYL SULFANYL-BUTYL]-DECAHYDRO-ISOQUINOLINE-3-CARBOXYLIC ACID TERT-BUTYLAMIDE; D08259; SMR000596515; Nelfinavir (INN); Nelfinavir Monomethane Sulfonate; BIDD:GT0395; Viracept (TM)(*Mesylate salt*); Met-SDF-1.beta. & Nelfinavir; NELFINAVIR MESYLATE AG1343; LS-85417; AKOS000280862; Viracept (TN); AG1346; CHEMBL584; UNII-HO3OGH5D7I; NCGC00090782-04	159989-64-7	64143	206971	TTDS00319	HIV-1 protease	HIV-1 peptidase;HIV-1 Retropepsin;Retropepsin	O90777	N/A	N/A	inhibitor
DAP000708	Lopinavir	DB01601; 1(2H)-Pyrimidineacetamide, N-[(1S,3S,4S)-4-[[(2,6-dimethylphenoxy)acetyl]amino]-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl]tetrahydro-.alpha.-(1-methylethyl)-2-oxo-, (aS)-; MolPort-003-848-410; 1(2H)-Pyrimidineacetamide, N-((1S,3S,4S)-4-(((2,6-dimethylphenoxy)acetyl)amino)-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl)tetrahyrdo-alpha-1-methylethyl)-2-oxo-, (alphaS)-; C12871; NCGC00164576-02; ABT 378; 1(2H)-pyrimidineacetamide,N-((1S,3S,4S)-4-(((2,6-dimethylphenoxy)acetyl)amino)-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl)tetrahydro-alpha-1-methylethyl)-2-oxo-,(alphaS)-; NCGC00164576-01; LPV; CHEBI:40456; RS-346; 2q5k; N-(4-(((2,6-dimethylphenoxy)acetyl)amino)-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl)tetrahydro-alpha-(1-methylethyl)-2-oxo-1(2H)-pydrimidineacetamide; Lopinavir [USAN:INN:BAN]; ABT 157378; A-157378.0; CHEMBL729; ABT-378, LOPINAVIR; Koletra; LS-173766; (1S-(1R*(R*),3R*,4R*))-N-(4-(((2,6-Dimethylphenoxy)acetyl)amino)-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl)tetrahydro-alpha-(1-methylethyl)-2-oxo-1(2H)-pyrimidineacetamide; ABT-378; 1mui; D01425; AB1; AC1L3OPJ; S1380_Selleck; Lopinavir; (alphaS)-Tetrahydro-N-((alphaS)-alpha-((2S,3S)-2-hydroxy-4-phenyl-3-(2-(2,6-xylyloxy)acetamido)butyl)phenethyl)-alpha-isopropyl-2-oxo-1(2H)-pyrimidineacetamide; 1(2H)-pyrimidineacetamide, N-[(1S,3S,4S)-4-[[2-(2,6-dimethylphenoxy)acetyl]amino]-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl]tetrahydro-alpha-(1-methylethyl)-2-oxo-, (alphaS)-; Lopinavir (JAN/USAN/INN); C37H48N4O5; CID92727; A 157378; 2rkf; (2S)-N-[(2S,4S,5S)-5-[[2-(2,6-dimethylphenoxy)acetyl]amino]-4-hydroxy-1,6-diphenylhexan-2-yl]-3-methyl-2-(2-oxo-1,3-diazinan-1-yl)butanamide; Aluviran; 192725-17-0; 1(2H)-Pyrimidineacetamide, N-[(1S,3S,4S)-4-[[(2,6-dimethylphenoxy)acetyl]amino]-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl]tetrahydro-alpha-(1-methylethyl)-2-oxo-, (alphaS)- (9CI); 1(2H)-Pyrimidineacetamide, N-[4-[[(2,6-dimethylphenoxy)acetyl]amino]-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl]tetrahydro-alpha-(1-methylethyl)-2-oxo-, [1S-[1R*(R*),3R*,4R*]]-; AIDS032937; A-157378-0; UNII-2494G1JF75; 2rkg; N-{1-BENZYL-4-[2-(2,6-DIMETHYL-PHENOXY)-ACETYLAMINO]-3-HYDROXY-5-PHENYL-PENTYL}-3-METHYL-2-(2-OXO-TETRAHYDRO-PYRIMIDIN-1-YL)-BUTYRAMIDE; 2o4s; A 157378.0	192725-17-0	92727	10225535	TTDS00319	HIV-1 protease	HIV-1 peptidase;HIV-1 Retropepsin;Retropepsin	O90777	N/A	N/A	inhibitor
DAP000706	Atazanavir	BMS 232632; HMS2089P22; 2,5,6,10,13-Pentaazatetradecanedioic acid, 3,12-bis(1,1-dimethylethyl)-8-hydroxy-4,11-dioxo-9-(phenylmethyl)-6-((4-(2-pyridinyl)phenyl)methyl)-, dimethyl ester, (3S,8S,9S,12S)-; Reyataz, BMS-232632, Atazanavir; Reyataz; CHEMBL1163; LS-183909; atazanavirum; methyl N-[(2S)-1-[2-[(2S,3S)-2-hydroxy-3-[[(2S)-2-(methoxycarbonylamino)-3,3-dimethylbutanoyl]amino]-4-phenylbutyl]-2-[(4-pyridin-2-ylphenyl)methyl]hydrazinyl]-3,3-dimethyl-1-oxobutan-2-yl]carbamate; CGP-73547; dimethyl (3S,8S,9S,12S)-9-benzyl-3,12-di-tert-butyl-8-hydroxy-4,11-dioxo-6-[4-(2-pyridyl)benzyl]-2,5,6,10,13-pentaazatetradecanedioate; (2S)-N-(3-{[(2S)-2-(Methoxycarbonylamino)-3,3-dimethylbutanoylamino][(4-(2-pyridyl)phenyl)methyl]amino}(1S,2S)-2-hydroxy-1-benzylpropyl)-2-(methoxycarbonylamino)-3,3-dimethylbutanamide; UNII-QZU4H47A3S; HSDB 7339; DB01072; 2,5,6,10,13-Pentaazatetradecanedioic acid, 3,12-bis(1,1-dimethylethyl)-8-hydroxy-4,11-dioxo-9-(phenylmethyl)-6-[[4-(2-pyridinyl)phenyl]methyl]-, 1,14-dimethyl ester, (3S,8S,9S,12S)-; Reyataz(TM) (*1:1 sulfate*); DR7; Atazanavir; S1457_Selleck; CID148192; 2aqu; METHYL [(1S,4S,5S,10S)-4-BENZYL-1,10-DI-TERT-BUTYL-5-HYDROXY-2,9,12-TRIOXO-7-(4-PYRIDIN-2-YLBENZYL)-13-OXA-3,7,8,11-TETRAAZATETRADEC-1-YL]CARBAMATE; ATZ; CGP 73547; ATV; D07471; (3S,8S,9S,12S)-3,12-BIS(1,1-DIMETHYLETHYL)-8-HYDROXY-4,11-DIOXO-9-(PHENYLMETHYL)-6-[[4-(2-PYRIDINYL)PHENYL]METHYL]-2,5,6,10,13-PENTAAZATETRADECANEDIOIC ACID DIMETHYL ESTER; 2,5,6,10,13-Pentaazatetradecanedioic acid, 3,12-bis(1,1-dimethylethyl)-8-hydroxy-4,11-dioxo-9-(phenylmethyl)-6-((4-(2-pyridinyl)phenyl)methyl)-, dimethyl ester, (3S-(3R*,8R*,9R*,12R*))-; 198904-31-3; Reyataz (TN); Atazanavir (INN); AC1L3WMH; Atazanavir [INN:BAN]; BMS-232632; MolPort-003-986-575; LS-187373; TL8001639; Latazanavir; CHEBI:37924; Zrivada	198904-31-3	148192	725881	TTDS00319	HIV-1 protease	HIV-1 peptidase;HIV-1 Retropepsin;Retropepsin	O90777	N/A	N/A	inhibitor
DAP001085	Tipranavir	Aptivus (TN); PNU-140690E; CID65027; 174484-41-4; DB00932; 2o4l; Aptivus(TM); 2o4p; Aptivus; TPV; UNII-ZZT404XD09; 2-Pyridinesulfonamide, N-[3-[(1R)-1-[(6R)-5,6-dihydro-4-hydroxy-2-oxo-6-(2-phenylethyl)-6-propyl-2H-pyran-3-yl]propyl]phenyl]-5-(trifluoromethyl)-; N-[3-[(1R)-1-[(2R)-6-hydroxy-4-oxo-2-phenethyl-2-propyl-3H-pyran-5-yl]propyl]phenyl]-5-(trifluoromethyl)pyridine-2-sulfonamide; PNU-140690; Aptivus (Boehringer Ingelheim); 2o4n; Tipranavir; AC1L22FH; N-(3-{(1R)-1-[(6R)-4-HYDROXY-2-OXO-6-PHENETHYL-6-PROPYL-5,6-DIHYDRO-2H-PYRAN-3-YL]PROPYL}PHENYL)-5-(TRIFLUOROMETHYL)-2-PYRIDINESULFONAMIDE; 2-Pyridinesulfonamide, N-(3-((1R)-1-((6R)-5,6-dihydro-4-hydroxy-2-oxo-6-(2-phenylethyl)-6-propyl-2H-pyran-3-yl)propyl)phenyl)-5-(trifluoromethyl)-; MolPort-003-850-561; AC1Q4JPW; PNU 140690; 2-Pyridinesulfonamide, N-(3-(1-(5,6-dihydro-4-hydroxy-2-oxo-6-(2-phenylethyl)-6-propyl-2H-pyran-3-yl)propyl)phenyl)-5-(trifluoromethyl)-, (R-(R*,R*))-; U-140690; CHEMBL222559; D08605; U 140690; Tipranavir (INN); 1d4y	174484-41-4	65027	206974	TTDS00319	HIV-1 protease	HIV-1 peptidase;HIV-1 Retropepsin;Retropepsin	O90777	N/A	N/A	inhibitor
DAP001086	Darunavir	618109-00-5; CHEMBL1323; (3R,3aS,6aR)-Hexahydrofuro(2,3-b)furan-3-yl N-((1S,2R)-1-benzyl-2-hydroxy-3-(N1-isobutylsulfanilamido)propyl)carbamate; Darunavirum [INN-Latin]; TMC 114; D03656; 206361-99-1; TMC114; (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl N-((1S,2R)-1-benzyl-2-hydroxy-3-(N(1)-isobutylsulfanilamido)propyl)carbamate; 2f80; AIDS073035; Prezista(TM); Carbamic acid, [(1S,2R)-3-[[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester; {(1S,2R)-3-[(4-Amino-benzenesulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxy-propyl}-carbamic acid (3R,3aS,6aR)-(hexahydro-furo[2,3-b]furan-3-yl) ester; LS-191295; UIC-96017; UIC 94017; DB01264; CHEBI:367163; Darunavir (USAN/INN); LS-187026; LS-187772; 2hs1; Darunavir [USAN]; TMC-114; 3d20; (3R,3aS,6aR)-tetrahydro-2H-furo[2,3-b]furan-3-yl (2S,3R)-4-(4-amino-N-neopentylphenylsulfonamido)-3-hydroxy-1-phenylbutan-2-ylcarbamate; 2f8g; [(S)-3-[(4-Amino-benzenesulfonyl)-isobutyl-amino]-2-hydroxy-1-((R)-phenylmethyl)-propyl]-carbamic acid (3R,3aS,6aR)-(hexahydro-furo[2,3-b]furan-3-yl) ester; 2ien; N-((1S,2R)-3-(((4-Aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-benzylpropyl)((1S,2R,5R)-4,6-dioxabicyclo(3.3.0)oct-2-yloxy)carboxamide; UIC-94017; 2idw; 3cyw; [(3aS,4R,6aR)-2,3,3a,4,5,6a-hexahydrofuro[2,3-b]furan-4-yl] N-[(2S,3R)-4-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-3-hydroxy-1-phenylbutan-2-yl]carbamate; 3bvb; 2f81; 3d1z; (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl [(2S,3R)-4-{[(4-aminophenyl)sulfonyl](2-methylpropyl)amino}-3-hydroxy-1-phenylbutan-2-yl]carbamate; UNII-YO603Y8113; Prezista; MolPort-003-846-141; Darunavirum; 2hs2; CID213039; (3R,3AS,6AR)-HEXAHYDROFURO[2,3-B]FURAN-3-YL(1S,2R)-3-[[(4-AMINOPHENYL)SULFONYL](ISOBUTYL)AMINO]-1-BENZYL-2-HYDROXYPROPYLCARBAMATE; (3-((4-aminobenzenesulfonyl)isobutylamino)-1-benzyl-2-hydroxypropyl)carbamic acid hexahydrofuro(2,3-b)furan-3-yl ester; (3R,3aS,6aR)-tetrahydro-2H-furo[2,3-b]furan-3-yl (2S,3R)-4-(4-amino-N-isobutylphenylsulfonamido)-3-hydroxy-1-phenylbutan-2-ylcarbamate; Darunavir; AC1L4U4V	206361-99-1	213039	17397753	TTDS00319	HIV-1 protease	HIV-1 peptidase;HIV-1 Retropepsin;Retropepsin	O90777	N/A	N/A	inhibitor
DAP000707	Fosamprenavir	AC1L2ZCO; (3-(((4-Aminophenyl)sulfonyl)(2-methylpropyl)amino)-1-(phenylmethyl)-2-(phosphonooxy)propyl)carbamic acid C-(tetrahydro-3-furanyl) ester; Telzir; LS-187787; CID131536; MolPort-005-943-058; Carbamic acid, ((1S,2R)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-1-(phenylmethyl)-2-(phosphonooxy)propyl)-, C-((3S)-tetrahydro-3-furanyl) ester; Amprenavir phosphate; GW433908G (*Calcium Salt*); 226700-79-4; DB01319; GW 433908; ((3S)Oxolan-3-yloxy)-N-((1S,2R)-3-{[(4-aminophenyl)sulfonyl](2-methylpropyl)amino}-1-benzyl-2-(phosphonooxy)propyl)carboxamide; LS-187013; Fosamprenavir [INN]; GW433908; GW433908A (*Sodium Salt*); CHEMBL1664; [(3S)-oxolan-3-yl] N-[(2S,3R)-4-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-1-phenyl-3-phosphonooxybutan-2-yl]carbamate; D02497; Telzir(TM); VX-175; Fosamprenavir; VX 175; Lexiva (TM); Fosamprenavir (INN); HSDB 7340	226700-79-4	131536	10242897	TTDS00319	HIV-1 protease	HIV-1 peptidase;HIV-1 Retropepsin;Retropepsin	O90777	N/A	N/A	inhibitor
DCL000164	Medusa IL-2	N/A	N/A	N/A	N/A	TTDC00026	Interleukin-2 receptor subunit beta	CD122;High affinity IL-2 receptor subunit beta;IL-2 receptor;IL2RB;P70-75;p75	P14784	3560	ENSG00000100385	agonist
DAP000918	Nateglinide	(2R)-3-phenyl-2-[(4-propan-2-ylcyclohexanecarbonyl)amino]propanoic acid; Novartis brand of nateglinide; MolPort-003-849-337; MolPort-003-986-201; AC1Q5SES; AY-4166; CPD000466372; IPCCPA; YM-026; nate-glinide; CID5311309; BIDD:GT0257; NCGC00095121-02; HMS2051G20; 105816-04-4; n-{[4-(propan-2-yl)cyclohexyl]carbonyl}phenylalanine; CHEMBL783; HMS2089A10; A-4166; N-{[trans-4-(propan-2-yl)cyclohexyl]carbonyl}-D-phenylalanine; SMR000466372; AC1L1I6J; DJN-608; AC1NSKEK; S2489_Selleck; CHEMBL286559; NCGC00095121-01; DJN 608; N-((4-isopropylcyclohexyl)carbonyl)phenylalanine; senaglinide; Bio-0067; 3-phenyl-2-[(4-propan-2-ylcyclohexanecarbonyl)amino]propanoic acid; nateglinide; TL8000218; Starlix; Trazec; SDZ-DJN-608; MLS000759500; D-phenylalanine, N-((trans-4-(1-methylethyl)cyclohexyl)carbonyl)-; C060142; Nateglinide [INN]; AC-1690; SAM001246721; MLS001424043; Fastic; CID4443; nateglinide, (cis,D-Phe)-isomer; AR-1K4414; Starsis; nateglinide, (D-Phe)-isomer; MolPort-005-933-780; SBB066156; STK647123; I06-0674	105816-04-4	60026	196417	TTDS00431	ATP-sensitive inward rectifier potassium channel 10	ATP dependent K+ channel;ATP-dependent inwardly rectifying potassium channel Kir4.1;ATP-sensitive potassium channel;Inward rectifier K+ channel Kir1.2;Potassium channel, inwardly rectifying, subfamily J, member 10	P78508	3766	ENSG00000177807	blocker
DAP000924	Gliquidone	Prestwick0_000991; CHEMBL383634; ARDF 26 SE; 1-cyclohexyl-3-[4-[2-(7-methoxy-4,4-dimethyl-1,3-dioxoisoquinolin-2-yl)ethyl]phenyl]sulfonylurea; 1-Cyclohexyl-3-(p-beta-(4,4-dimethyl-2-methoxy-1,3-(2H,4H)-isoquinolinedione-2-yl)phenethyl)sulfonylurea; Bio-0157; BSPBio_001081; NCGC00179315-01; D02430; TL8002523; BPBio1_001191; AKOS001037880; Glurenorm (TN); Gliquidona [INN-Spanish]; ARDF 26; CAS-33342-05-1; Prestwick2_000991; Glurenorm; BRD-K80396088-001-03-9; DB01251; AC-18847; LS-31460; glycvidon; AB00513989; MLS000881123; AC1L3MFD; N-[(cyclohexylamino)carbonyl]-4-{2-[4,4-dimethyl-7-(methyloxy)-1,3-dioxo-3,4-dihydroisoquinolin-2(1H)-yl]ethyl}benzenesulfonamide; Gliquidone [BAN:INN]; AR-DF 26; Gliquidona; SPBio_002972; glikvidon; EINECS 251-463-2; HMS1571G03; Prestwick3_000991; Gliquidonum [INN-Latin]; MLS000881174; Oprea1_069443; CID91610; C27H33N3O6S; LS-159650; G0332; ZINC01482077; 1-cyclohexyl-3-(p-beta-(4,4- dimethyl-2-methoxy-1,3-(2H,4H)-isoquinolinedione- 2-yl)phenethyl)sulfonylurea; BRN 1559726; UNII-C7C2QDD75P; MolPort-001-727-724; MLS002154087; 1-Cyclohexyl-3-((p-(2-(3,4-dihydro-7-methoxy-4,4-dimethyl-1,3-dioxo-2(1H)-isoquinolyl)ethyl)phenyl)sulfonyl)urea; I06-0185; Beglynora; 33342-05-1; Beglynor; SMR000685793; Benzenesulfonamide, N-((cyclohexylamino)carbonyl)-4-(2-(3,4-dihydro-7-methoxy-4,4-dimethyl-1,3-dioxo-2(1H)-isoquinolinyl)ethyl)-; Prestwick1_000991; Gliquidone (INN); Gliquidonum; 62783-47-5 (mono-hydrochloride salt); Gliquidone; NCGC00016819-01	33342-05-1	91610	10224909	TTDS00431	ATP-sensitive inward rectifier potassium channel 10	ATP dependent K+ channel;ATP-dependent inwardly rectifying potassium channel Kir4.1;ATP-sensitive potassium channel;Inward rectifier K+ channel Kir1.2;Potassium channel, inwardly rectifying, subfamily J, member 10	P78508	3766	ENSG00000177807	binder
DAP000921	Glycodiazine	5-25-12-00549 (Beilstein Handbook Reference); Glycodiazin [German]; BRN 0552655; C13H15N3O4S; N-[5-(2-methoxyethoxy)pyrimidin-2-yl]benzenesulfonamide; N-(5-(2-Methoxyethoxy)-2-pyrimidinyl)benzenesulfonamide; Benzenesulfonamide, N-[5-(2-methoxyethoxy)-2-pyrimidinyl]-; N-(5-(2-Methoxyethoxy)-2-pyrimidinyl)benzenesulphonamide; EINECS 206-426-5; 2-Benzolsulfonamido-5-beta-methoxy-aethoxy-pyrimidine; CID9565; UNII-4C5I4BQZ8F; Glymidinum; Benzenesulfonamide, N-(5-(2-methoxyethoxy)-2-pyrimidinyl)-; Glycodiazine; GLYMIDINE; Glycodiazin; N-(5-{[2-(methyloxy)ethyl]oxy}pyrimidin-2-yl)benzenesulfonamide; 5-beta-(Methoxyethoxy)-2-(phenylsulfonylamido)pyrimidine; DB01382; 339-44-6; 2-Benzolsulfonamido-5-.beta.-methoxy-aethoxy-pyrimidine; Glidiazine; 2-Benzolsulfonamido-5-beta-methoxy-aethoxy-pyrimidine [German]; AC1L1TBP; LS-31627	339-44-6	9565	152778	TTDS00431	ATP-sensitive inward rectifier potassium channel 10	ATP dependent K+ channel;ATP-dependent inwardly rectifying potassium channel Kir4.1;ATP-sensitive potassium channel;Inward rectifier K+ channel Kir1.2;Potassium channel, inwardly rectifying, subfamily J, member 10	P78508	3766	ENSG00000177807	binder
DAP000923	Chlorpropamide	Catanil; Prestwick2_000323; KBio2_003192; NCGC00015216-07; C 1290; Apo-Chlorpropamide; NCGC00021451-04; HMS1569A07; 1-[p-Chlorobenzenesulfonyl]-3-propylurea; KBioSS_002274; Clorpropamide [DCIT]; N-Propyl-N'-p-chlorphenylsulfonylcarbamide; N-Propyl-N'-(p-chlorobenzenesulfonyl)urea; Clorpropamid; Benzenesulfonamide, 4-chloro-N-[(propylamino)carbonyl]-; N-(p-Chlorobenzenesulfonyl)-N'-propylurea; Diabechlor; n-Propyl-N'-p-chlorophenylsulfonylcarbamide; Spectrum4_000284; Urea, 1-[(p-chlorophenyl)sulfonyl]-3-propyl-; D002747; BPBio1_000359; Prestwick1_000323; SPBio_002246; N-(4-Chlorophenylsulfonyl)-N'-propylurea; 1-(p-Chlorophenylsulfonyl)-3-propylurea; C10H13ClN2O3S; U-9818; BRD-K97746869-001-05-6; CHLORPROPAMIDE USP; Spectrum5_000719; MolPort-001-779-601; HMS2091E08; Stabinol; 1-((p-Chlorophenyl)sulfonyl)-3-propylurea; Spectrum2_000089; BRN 2218363; Prestwick_684; CHEMBL498; KBio2_007409; Insulase; Clorpropamida [INN-Spanish]; Urea, 1-((p-chlorophenyl)sulfonyl)-3-propyl-; 1-(p-Chlorobenzenesulfonyl)-3-propylurea; SMR000058364; Dynalase; BSPBio_000325; 1-Propyl-3-(p-chlorobenzenesulfonyl)urea; 94-20-2; Prodiaben; Apotex Brand of Chlorpropamide; Melitase; 1-p-Chlorophenyl-3-(propylsulfonyl)urea; Diabeneza; Chlorpropamidum; Farmasierra Brand of Chlorpropamide; Chloropropamide; 1-(4-Chlorophenylsulfonyl)-3-propylurea; Spectrum_000144; NSC 626720; chlorpropamide; U-3818; Prestwick0_000323; Lopac0_000229; WLN: GR DSWMVM3; Clorpropamida; Millinese; AC1L1EBW; NSC44634; NCGC00021451-07; Lopac-C-1290; MLS000028395; KBio1_000513; Diabexan; N3-Butyl-N1-p-chlorobenzenesulfonylure a; EINECS 202-314-5; NCGC00015216-03; 1-(4-chlorophenyl)sulfonyl-3-propylurea; Chlorpropamidum [INN-Latin]; DivK1c_000513; dia benese; C1220; 4-Chloro-N-((propylamino)carbonyl)benzenesulfonamide; Chlorpropamide (JP15/USP/INN); HSDB 2051; KBio2_000624; NCGC00015216-02; Bioglumin; AKOS001482739; Mellinese; D00271; CID2727; Chlorpropamide Bp/ Usp; 1-(p-Chlorobenzensulfonyl)-3-propylurea; Benzenesulfonamide, 4-chloro-N-((propylamino)carbonyl)-; Urea, 1-((p-chlorophenyl)sulfonyl)-3-propyl-; P 607; KBio2_004841; Prestwick3_000323; Pfizer Brand of Chlorpropamide; Diabinese (TN); KBio2_005760; Chloronase; NCGC00021451-08; Asucrol; ZINC01530599; n-propyl-N'-p-chlorophenylsu lfonylcarbamide; KBio2_002273; 1-(para-Chlorophenylsulfonyl)-3-propylurea; Clorpropamide [Italian]; Chlorpropamid; NCGC00021451-05; HMS501J15; CCRIS 155; Diabenese; LS-1959; NINDS_000513; Diabinese; KBioGR_002273; HMS1920M05; Chlorpropamide [INN:BAN:JAN]; Meldian; SAM002554890; Oradian; 4-chloro-N-[(propylamino)carbonyl]benzenesulfonamide; 4-Chloro-4-((propylamino)carbonyl)benzenesulfonamide; Chlorodiabina; KBioSS_000624; CAS-94-20-2; KBio3_002753; 4-chloro-N-(propylcarbamoyl)benzenesulfonamide; Benzenesulfonamide, 4-chloro-N-((propylamino)carbonyl)-; AB00051944; EU-0100229; N3-Butyl-N1-p-chlorobenzenesulfonylurea; CHEBI:3650; Diamel Ex; KBio3_001233; DB00672; Spectrum3_000347; Glisema; Clorpropamide; Adiaben; C1290_SIGMA; KBioGR_000808; NCGC00015216-01; Diabet-Pages; SPECTRUM1500185; AC1Q2Y2Z; NCGC00021451-03; Insogen; NSC 44634; MLS001148665; NSC626720; IDI1_000513; Novo-Propamide; Byk Gulden Brand of Chlorpropamide; Urea, 1-((p-chloropenyl)sulfonyl)-3-propyl-; NCGC00021451-06; Diabetoral; STK857458; NCGC00015216-12; BSPBio_002013; Diabenal; UNII-WTM2C3IL2X; Glucamide; Chlorporpamide; C1290_FLUKA; NCI-C01752; cMAP_000007; SPBio_000018; 1-[(4-chlorobenzene)sulfonyl]-3-propylurea; Bio-0154; Diabaril; CPD000058364	94-20-2	2727	150222	TTDS00431	ATP-sensitive inward rectifier potassium channel 10	ATP dependent K+ channel;ATP-dependent inwardly rectifying potassium channel Kir4.1;ATP-sensitive potassium channel;Inward rectifier K+ channel Kir1.2;Potassium channel, inwardly rectifying, subfamily J, member 10	P78508	3766	ENSG00000177807	blocker
DAP000919	Tolazamide	NSC70762; Prestwick_865; Tolazolamide; Prestwick3_000554; SR-01000003105-4; Bio2_000705; Lopac-T-2408; 1-(((((4-Methylphenyl)sulfonyl)amino)carbonyl)amino)azepane; 1-(Hexahydro-1-azepinyl)-3-p-tolylsulfonylurea; 1-(Hexahydro-1H-azepin-1-yl)-3-(p-tolylsulfonyl)urea; 4-(p-Tolylsulfonyl)-1,1-hexamethylene; IDI1_033975; BCBcMAP01_000061; 1-(Hexahydro-1H-azepin-1-yl)-3-(p-toluenesulfonyl)urea; Benzenesulfonamide, N-[[(hexahydro-1H-azepin-1-yl)amino]carbonyl]-4-methyl-; NCGC00023701-05; D00379; NCGC00023701-10; KBio2_006885; HMS1921P19; HMS1569P09; KBioGR_000939; CPD000058290; 59866P; HMS1361L07; SPBio_002548; Norglycin; CCRIS 591; tolazamide; BRD-K32164935-001-06-8; HMS500K14; Bio1_001182; Bio1_000204; Diabewas; Tolanase; NCGC00016009-02; Urea, 1-(hexahydroazepin-1-yl)-3-p-tolylsulfonyl-; KBioSS_001749; 1-(azepan-1-yl)-3-(4-methylphenyl)sulfonylurea; NINDS_000212; U-17835; NCGC00016009-03; CBiol_001918; NCGC00016009-14; Tolamide; KBio2_001749; KBio3_000450; BRN 1323565; ZINC00057512; Spectrum2_001449; NCGC00023701-03; Tolazamidum [INN-Latin]; Tolazamida [INN-Spanish]; 1156-19-0; NSC-70762; Benzenesulfonamide, N-(((hexahydro-1H-azepin-1-yl)-amino)carbonyl)-4-methyl-; Bio1_000693; 4-(p-Tolylsulfonyl)-1,1-hexamethylenesemicarbazide; DivK1c_000212; KBio3_002525; SAM002564236; Tolinase (TN); NCIOpen2_008361; 5-20-04-00062 (Beilstein Handbook Reference); Spectrum_001269; Urea, 1-(hexahydro-1H-azepin-1-yl)-3-(p-tolylsulfonyl)-; HMS2089L10; Prestwick2_000554; IDI1_000212; LS-578; BSPBio_003025; KBio2_000225; N-(((Hexahydro-1H-azepin-1-yl)-amino)carbonyl)-4-methylbenzenesulfonamide; 3-azepan-1-yl-1-(4-methylphenyl)sulfonyl-urea; EU-0101195; CAS-1156-19-0; Benzenesulfonamide, N-(((hexahydro-1H-azepin-1-yl)amino)carbonyl)-4-methyl-; Oprea1_061180; SPECTRUM1501201; Spectrum5_001204; CID5503; SPBio_001317; HSDB 3192; Prestwick1_000554; NCGC00016009-06; SMR000058290; KBio2_005361; NCGC00023701-08; KBio1_000212; N-(((hexahydro-1H-azepin-1-yl)amino)carbonyl)-4-methylbenzenesulfonamide; Spectrum3_001473; AC1L1KHJ; BSPBio_000627; NSC 70762; KBioGR_000225; KBio3_000449; Tolazamide [USAN:INN:BAN:JAN]; NCGC00016009-01; KBio2_004317; NCGC00023701-06; HMS1989L07; Tolazamide (JP15/USP/INN); AI3-50826; MolPort-001-826-273; N-(p-Toluenesulfonyl)-N'-hexamethyleniminourea; HMS1791L07; EINECS 214-588-3; AB00052247; Lopac0_001195; 1-(Hexahydro-1H-azepin-1-yl)-3-(p-tolylsulfonyl)urea; KBioSS_000225; NCGC00023701-09; 1-(Hexahydro-1-azepinyl)-3-p-tolylsulfonylurea; Spectrum4_000240; WLN: T7NTJ AMVMSWR D1; BPBio1_000691; NCGC00023701-07; UNII-9LT1BRO48Q; Bio2_000225; MLS001076161; Tolazamidum; rea, 1-(hexahydroazepin-1-yl)-3-p-tolylsulfonyl-; semicarbazide; Benzenesulfonamide, {N-[[(hexahydro-1H-azepin-1-yl)amino]carbonyl]-4-methyl-}; N-(p-Toluenesulfonyl)-N'-hexamethyleniminourea; Urea, 1-(hexahydro-1H-azepin-1-yl)-3-(p-tolylsulfonyl)-; U; nchembio.79-comp25; KBio2_002793; MLS000028534; D014042; Pharmacia Brand of Tolazamide; Prestwick0_000554; U 17835; NCI-C03327; NCGC00023701-04; HMS2092L09; DB00839; C14H21N3O3S; BSPBio_001505; T 2408; Tolazamida; CHEMBL817; T2408_SIGMA; Tolinase; N-[(azepan-1-ylamino)carbonyl]-4-methylbenzenesulfonamide	1156-19-0	5503	7847445	TTDS00431	ATP-sensitive inward rectifier potassium channel 10	ATP dependent K+ channel;ATP-dependent inwardly rectifying potassium channel Kir4.1;ATP-sensitive potassium channel;Inward rectifier K+ channel Kir1.2;Potassium channel, inwardly rectifying, subfamily J, member 10	P78508	3766	ENSG00000177807	blocker
DAP000143	Minoxidil	NCGC00179672-01; 38304-91-5; Bio2_000585; EU-0100786; Prestwick_521; SMR000326812; KBio1_000160; 2,4-Pyrimidinediamine, 6-(1-piperidinyl)-, 3-oxide; Minossidile [Italian]; SAM002589949; DivK1c_000160; SGCUT00112; MLS000028566; MINOXIDIL (FOR WOMEN); Spectrum4_000063; KBio2_002673; Spectrum3_000509; Rogaine for Men; Rogaine for Women; Bio2_000105; AC1L1HN1; Theroxidil; SPECTRUM1500415; nchembio.79-comp10; CHEMBL609587; Minoximen; LS-135040; Riup (TN); Spectrum_000969; NCGC00024666-01; MINOXIDIL (FOR MEN); CPD000058963; KBioGR_000585; S1383_Selleck; BRN 0886240; NCGC00024666-05; HMS2091F20; NCGC00018278-01; ZINC00001735; NCGC00015673-04; Rogaine Extra Strength for Men; Loniten; Pyrimidine, 2,4-diamino-6-piperidino-, 3-oxide; SPBio_001006; SPBio_001980; CHEBI:49774; Rogaine; KBio3_000210; to_000070; Minoxidil (USP/INN); Bio1_001062; MolPort-003-666-236; 2,4-Diamino-6-piperidino-pyrimidine-3-oxide; KBio2_004017; 5-25-12-00317 (Beilstein Handbook Reference); AB00513797; BPBio1_000065; NCGC00015673-02; C9H15N5.H2O; HMS1920P03; Pfizer Brand of Minoxidil; Normoxidil; Prestwick3_000020; Prestwick0_000020; Alostil; Spectrum5_001299; Minoxigaine; CAS-38304-91-5; HMS1989F07; Prexidil; 2,4-Diamino-6-piperidinopyrimidine 3-oxide; 2,6-Diamino-4-piperidinopyrimidin-1-oxid; Gen-Minoxidil; NCGC00024666-02; minoxidil; KBio2_005241; Spectrum2_001053; 2,4-Diamino-6-piperidinilpirimidina-3-ossido; 2,4-Diamino-6-piperidinilpirimidina-3-ossido [Italian]; Bio1_000573; Men's Rogaine; Tocris-0583; KBio3_000209; 6-[1-Piperidinyl]pyrimidine-2,4-diamine 3 oxide; 2,4-Diamino-6-piperidinopyrimidine 3-N-oxide; D00418; NCGC00024666-06; SMR000058963; Minoxidil Pfizer Brand; DB00350; CHEMBL802; HMS1361F07; 6-(1-Piperidinyl)-2,4-pyrimidinediamine 3-oxide; NCGC00015673-01; MLS001077294; Lopac0_000786; BSPBio_002037; Neoxidil; KBio3_001537; KBio2_000105; Tricoxidil; Bio1_000084; Minoxidil [USAN:BAN:INN]; HMS2089L08; EINECS 253-874-2; 6-Piperidino-2,4-diaminopyrimidine 3-oxide; SBB056986; KBioGR_000105; NCGC00015673-11; Alopexil; Regaine; M1389; 16317-69-4; NCGC00024666-07; BCBcMAP01_000193; CPD-7668; ROGAINE EXTRA STRENGTH (FOR MEN); TM-160; NCGC00024666-03; HMS1791F07; 3-hydroxy-2-imino-6-piperidin-1-ylpyrimidin-4-amine; Pierminox; CHEBI:6942; Mens Rogaine Foam; MINOXIDIL EXTRA STRENGTH (FOR MEN); Men s Rogaine Foam; AC-5271; NCGC00024666-08; U-10858; MLS000859953; ROGAINE (FOR WOMEN); RiUP; KBioSS_001449; Prestwick1_000020; D008914; BRD-K14888893-001-02-3; NINDS_000160; BSPBio_000059; BSPBio_001385; HMS500H22; HMS1568C21; DB08225; HSDB 6538; Jsp006715; Rogaine, Regaine, Avacor and Mintop, Minoxidil; KBio2_001449; Minoxidilum [INN-Latin]; M 4145; NCGC00024666-04; IDI1_033855; Minossidile; U-10,858; KBioSS_000105; Prestwick2_000020; Trocoxidil; CID4201; Lopac-M-4145; Apo-Gain; MINOXIDIL EXTRA STRENGTH FOR MEN; KBio2_006585; 6-Amino-1,2-dihydro-1-hydroxy-2-imino-4-piperidinopyrimidine; IDI1_000160; 2,3-Dihydro-3-hydroxy-2-imino-6-(1-piperidinyl)-4-pyrimidinamine; BRD-K06902185-001-05-2; MolPort-005-932-694; Minoxidilum; CBiol_001798; Rogaine (TN); Lonolox; SMP1_000192; ROGAINE (FOR MEN); Ambap38304-91-5; 6-(piperidin-1-yl)pyrimidine-2,4-diamine 3-oxide; 3-hydroxy-2-imino-6-(1-piperidyl)pyrimidin-4-amine; Minodyl; Loniten (TN); U 10858	38304-91-5	4201	7847484	TTDS00431	ATP-sensitive inward rectifier potassium channel 10	ATP dependent K+ channel;ATP-dependent inwardly rectifying potassium channel Kir4.1;ATP-sensitive potassium channel;Inward rectifier K+ channel Kir1.2;Potassium channel, inwardly rectifying, subfamily J, member 10	P78508	3766	ENSG00000177807	N/A
DAP000920	Glipizide	Glipizidum; Pfizer Brand 1 of Glipizide; N-[2-[4-(cyclohexylcarbamoylsulfamoyl)phenyl]ethyl]-5-methylpyrazine-2-carboxamide; Glucotrol XL; NCGC00023748-06; CHEMBL1073; SMR000058455; Bio2_000549; NCGC00016802-01; S1715_Selelck; HMS1361D11; BPBio1_000224; Glypidizine; KBioGR_000069; Metaglip; G-117; G117_SIGMA; Glibenese Brand of Glipizide; Glipizida; EINECS 249-427-6; Semiglynase; LS-159679; Lopac0_000621; KBio3_000138; Kenfarma Brand of Glipizide; Glidiazinamide; CID3478; NCGC00015462-05; Minidiab; KS-1068; Glipizide Extended-Release Tablets; KBioSS_000069; Bio-0161; 29094-61-9; D00335; nchembio.128-comp32; KBio2_005205; Glucotrol (TN); Glibenese; Glide; 1-Cyclohexyl-3-((p-(2-(5-methylpyrazinecarboxamido)ethyl)phenyl)sulfonyl)urea; NCGC00015462-02; Alphapharm Brand of Glipizide; Bio1_000563; CPD000058455; Bio2_000069; Lopac-G-117; BIDD:GT0476; Prestwick_242; Pyrazinecarboxamide, N-[2-[4-[[[(cyclohexylamino)carbonyl]amino]sulfonyl]phenyl]ethyl]-5-methyl-; Glipizidum [INN-Latin]; NCGC00023748-07; CP 28720; NCGC00023748-03; BRN 0903495; BSPBio_001349; AC1Q2OG0; Pfizer Brand 2 of Glipizide; Glupitel; Mindiab; Glipizide [USAN:BAN:INN]; STK631952; CBiol_001788; I06-1985; IDI1_033819; D005913; SPBio_002141; Glipizide (USP/INN); 172964-66-8; Pyrazinecarboxamide, N-(2-(4-((((cyclohexylamino)carbonyl)amino)sulfonyl)phenyl)ethyl)-5-methyl-; NCGC00015462-11; Lilly Brand of Glipizide; NCGC00015462-01; Glucotrol XL, Glucotrol, Glipizide; 29094-66-4; 1-Cyclohexyl-3-{4-[2-(5-methylpyrazine-2-carboxamido)ethyl]phenylsulfonyl}urea; BSPBio_000202; DB01067; HMS1791D11; K-4024; Dipazide; HMS2089C21; CP-28720; MolPort-003-666-685; K4024; Glipizide Kenfarma Brand; AC-15789; MLS001148176; 30553_FLUKA; Glipizida [INN-Spanish]; Melizide; NCGC00023748-05; Digrin; Ozidia; Napizide; Glyde; N-(2-{4-[(cyclohexylcarbamoyl)sulfamoyl]phenyl}ethyl)-5-methylpyrazine-2-carboxamide; KBio2_002637; I06-0186; Glupizide; TK 1320; Prestwick1_000131; HMS2093J09; SAM002564210; Prestwick3_000131; UNII-X7WDT95N5C; CP 28,720; Lacer Brand of Glipizide; Glydiazinamide; Glidiab; Bio1_000074; Glucozide; Gluco-Rite; C21H27N5O4S; N-(4-(beta-(5-Methylpyrazine-2-carboxamido)ethyl)benzenesulphonyl)-N'-cyclohexylurea; Glucotrol; AC1L1G0Z; glipizide; EU-0100621; Minidab; K 4024; KBio2_000069; BRD-K12219985-001-04-8; Prestwick0_000131; NCGC00023748-04; Glipid; HMS1989D11; Samarium(III) ionophore I; MolPort-002-885-830; CAS-29094-61-9; Minodiab; CHEBI:239286; Glucolip; Glican; TL8006447; S1715_Selleck; Glibetin; N-[2-(4-{[(cyclohexylcarbamoyl)amino]sulfonyl}phenyl)ethyl]-5-methylpyrazine-2-carboxamide; ZINC00537795; Urea, 1-cyclohexyl-3-((p-(2-(5-methylpyrazinecarboxamido)ethyl)phenyl)sulfonyl)-; Prestwick2_000131; MLS000069386; Sucrazide; Bio1_001052; Aldiab; 38777-27-4; KBio3_000137; HMS1568K04	29094-61-9	3478	7847401	TTDS00431	ATP-sensitive inward rectifier potassium channel 10	ATP dependent K+ channel;ATP-dependent inwardly rectifying potassium channel Kir4.1;ATP-sensitive potassium channel;Inward rectifier K+ channel Kir1.2;Potassium channel, inwardly rectifying, subfamily J, member 10	P78508	3766	ENSG00000177807	blocker
DAP000922	Acetohexamide	CCRIS 4; Prestwick2_000055; Acetohexamida [INN-Spanish]; 1-(4-acetylphenyl)sulfonyl-3-cyclohexylurea; EU-0100088; SPBio_002130; BPBio1_000231; Lopac0_000088; D000092; C06806; CAS-968-81-0; Acetohexamidum; 8054-32-8; Metaglucina; NCGC00091230-02; Acetohexamide Salvat Brand; Minoral; Dymelor; HSDB 3280; 4-Acetyl-N-[(cyclohexylamino)- carbonyl]benzenesulfonamide; HMS2093H21; Acetohexamide [USAN:INN:BAN:JAN]; Lopac-A-178; NCGC00091230-01; Acetohexamida; U-14812; Dimelin; Ordimel; Acetohexamid; CID1989; Acetohexamide Lilly Brand; 968-81-0; DB00414; NCI-C03247; Salvat Brand of Acetohexamide; ord imel; N-(p-Acetylphenylsulfonyl)-N'-cyclohexylurea; NCGC00015014-01; dimelin (antidiabetic); Prestwick_3; BSPBio_000209; NCGC00015014-03; NCGC00091230-03; Urea, 1-((p-acetylphenyl)sulfonyl)-3-cyclohexyl-; A178_SIGMA; Acetohexamide (JP15/USP/INN); 3-cyclohexyl-1-(p-acetylphenylsulfonyl)urea; MolPort-003-666-680; NCGC00091230-04; Prestwick0_000055; MLS002154186; Prestwick1_000055; NCGC00016555-01; Benzenesulfonamide, 4-acetyl-N-[(cyclohexylamino)carbonyl]-; D00219; Hypoglicil; Lilly Brand of Acetohexamide; CHEBI:28052; Gamadiabet; A-178; UNII-QGC8W08I6I; 4-Acetyl-N-[(cyclohexylamino)carbonyl]benzenesulfonamide; C15H20N2O4S; LS-2019; AC1L1COE; Dymelor (TN); Prestwick3_000055; 4-acetyl-N-((cyclohexylamino)carbonyl)benzenesulf onamide; Benzenesulfonamide, 4-acetyl-N-((cyclohexylamino)carbonyl)-; 1-((p-Acetylphenyl)sulfonyl)-3-cyclohexylurea; BRN 2225115; HMS1568K11; U 14812; BRD-K52960356-001-03-1; EINECS 213-530-4; N-(p-Acetylbenzenesulfonyl)-N'-cyclohexylurea; Dimelor; Tsiklamid; A178_FLUKA; 1-(p-Acetylbenzenesulfonyl)-3-cyclohexylurea; 4-Acetyl-N-((cyclohexylamino)carbonyl)benzenesulfonamide; Acetohexamidum [INN-Latin]; acetohexamide; SMR001233477; NCGC00015014-07; CHEMBL1589	968-81-0	1989	9025	TTDS00431	ATP-sensitive inward rectifier potassium channel 10	ATP dependent K+ channel;ATP-dependent inwardly rectifying potassium channel Kir4.1;ATP-sensitive potassium channel;Inward rectifier K+ channel Kir1.2;Potassium channel, inwardly rectifying, subfamily J, member 10	P78508	3766	ENSG00000177807	binder
DAP000925	Glisoxepide	Pro-Diaban; LS-86560; Bay B 4231; MolPort-001-836-874; BRN 0592109; 25046-79-1; UNII-H7SC0I332I; N-{2-[4-({[(azepan-1-ylamino)carbonyl]amino}sulfonyl)phenyl]ethyl}-5-methylisoxazole-3-carboxamide; 1-(Hexahydro-1H-azepin-1-yl)-3-((p-(2-(5-methyl-3-isoxazolecarboxamido)ethyl)phenyl)sulfonyl)urea; Glisoxepide; N-[2-[4-(azepan-1-ylcarbamoylsulfamoyl)phenyl]ethyl]-5-methyl-1,2-oxazole-3-carboxamide; AC1L1OEO; Glisoxepida [INN-Spanish]; Glisoxepide [INN:BAN:DCF]; Glisoxepida; BS 4231; NCGC00159475-02; EINECS 246-579-5; Glisoxepida [Spanish]; C20H27N5O5S; Glisepin; FBB 4231; Glisoxepid; Glisoxepidum; RP 22410; D07118; Glisoxepide (INN); DB01289; Glisoxepidum [INN-Latin]; CID32778; 3-Isoxazolecarboxamide, N-(2-(4-(((((hexahydro-1H-azepin-1-yl)amino)carbonyl)amino)sulfonyl)phenyl)ethyl)-5-methyl-	25046-79-1	32778	15478163	TTDS00431	ATP-sensitive inward rectifier potassium channel 10	ATP dependent K+ channel;ATP-dependent inwardly rectifying potassium channel Kir4.1;ATP-sensitive potassium channel;Inward rectifier K+ channel Kir1.2;Potassium channel, inwardly rectifying, subfamily J, member 10	P78508	3766	ENSG00000177807	blocker
DAP000917	Mitiglinide	2H-Isoindole-2-butanoic acid, octahydro-gamma-oxo-alpha-(phenylmethyl)-, calcium salt, (2(S)-cis)-; S21403; 2C19H24NO3.Ca; TL8001004; AC1NUHLY; (2S)-4-[(3aR,7aS)-1,3,3a,4,5,6,7,7a-octahydroisoindol-2-yl]-2-benzyl-4-oxobutanoic acid; AC1L3TLA; CID121891; AC-632; LS-173249; KAD 1229; Mitiglinide; CHEMBL471498; calcium (2S)-4-[(3aS,7aR)-1,3,3a,4,5,6,7,7a-octahydroisoindol-2-yl]-2-benzyl-4-oxobutanoate; Calcium 2-benzyl-3-(cis-hexahydro-2-isoindolinylcarbonyl)propionate dihydrate; CID5478927; Kad-1229; 145525-41-3; Mitiglinide calcium; C13326; MolPort-003-986-436; 2-Benzyl-3-(hexahydro-2-isoindolinylcarbonyl)propionate; Mitiglinide calcium hydrate	145375-43-5	3047758	10053765	TTDS00431	ATP-sensitive inward rectifier potassium channel 10	ATP dependent K+ channel;ATP-dependent inwardly rectifying potassium channel Kir4.1;ATP-sensitive potassium channel;Inward rectifier K+ channel Kir1.2;Potassium channel, inwardly rectifying, subfamily J, member 10	P78508	3766	ENSG00000177807	blocker
DPR000163	Batimastat	(2S,3R)-5-Methyl-3-(((alphaS)-alpha-(methylcarbamoyl)phenethyl)carbamoyl)-2-((2-thienylthio)methyl)hexanohydroxamic acid; CHEBI:40976; 2j83; C23H31N3O4S2; (2S,3R)-N-hydroxy-N'-[(2S)-1-(methylamino)-1-oxo-3-phenylpropan-2-yl]-3-(2-methylpropyl)-2-(thiophen-2-ylsulfanylmethyl)butanediamide; BB94; AC1NSFYO; 130370-60-4; C080985; BB-94; batimastat; CHEMBL279786; BB94 cpd; ISV-615; Batimastat (USAN/INN); MolPort-006-822-709; CHEBI:123429; 4-(N-HYDROXYAMINO)-2R-ISOBUTYL-2S-(2-THIENYLTHIOMETHYL)SUCCINYL-L-PHENYLALANINE-N-METHYLAMIDE; BB 94; UNII-BK349F52C9; BB-99; BB94, BB-94; (4-(N-hydroxyamino)-2-isobutyl-3-(thiophen-2-ylthiomethyl)succinyl)phenylalanine-N-methylamide; LS-45637; Butanediamide, N(sup 4)-hydroxy-N(sup 1)-(2-(methylamino)-2-oxo-1-(phenylmethyl)ethyl)-2-(2-methylpropyl)-3-((2-thienylthio)methyl)-, (2R-(1(S*),2R*,3S*))-; ISV-120; CID5362422; D03061; 1rm8; Batimastat [USAN:BAN:INN]; Butanediamide, N4-hydroxy-N1-(2-(methylamino)-2-oxo-1-(phenylmethyl)ethyl)-2-(2-methylpropyl)-3-((2-thienylthio)methyl)-, (2R-(1(S*),2R*,3S*))-; DSX; DB03880	N/A	N/A	N/A	TTDR00029	Matrilysin	Matrin;Matrix metalloproteinase-7;MMP-7;Pump-1 protease;Uterine metalloproteinase	P09237	4316	ENSG00000137673	inhibitor
DCL000014	BB-3644	N/A	143257-98-1	65997	43122719	TTDR00029	Matrilysin	Matrin;Matrix metalloproteinase-7;MMP-7;Pump-1 protease;Uterine metalloproteinase	P09237	4316	ENSG00000137673	inhibitor
DCL000004	Prinomastat	CHEMBL75094; D03797; MolPort-000-883-336; AG-3354; AC1LAD25; AG-3362; Prinomastat (USAN/INN); CHEBI:220195; 3-Thiomorpholinecarboxamide, N-hydroxy-2,2-dimethyl-4-[[4-(4-pyridinyloxy)phenyl]sulfonyl]-, (3S)-; CID466151; (3S)-N-hydroxy-2,2-dimethyl-4-(4-pyridin-4-yloxyphenyl)sulfonylthiomorpholine-3-carboxamide; AKOS000280753; Opc 51803	58-38-8	466151	17397885	TTDR00029	Matrilysin	Matrin;Matrix metalloproteinase-7;MMP-7;Pump-1 protease;Uterine metalloproteinase	P09237	4316	ENSG00000137673	inhibitor
DCL000003	BMS 275291	N-((2S)-2-Mercapto-1-oxo-4-(3,4,4-trimethyl-2,5-dioxo-1-imidazolidinyl)butyl)-L-leucyl-N,3-dimethyl-L-valinamide; L-Valinamide, N-((2S)-2-mercapto-1-oxo-4-(3,4,4-trimethyl-2,5-dioxo-1-imidazolidinyl)butyl)-L-leucyl-N,3-dimethyl-; BMS 275291; AC1L3WNB; (2S)-N-[(2S)-3,3-dimethyl-2-(methylamino)butanoyl]-4-methyl-2-[[(2S)-2-sulfanyl-4-(3,4,4-trimethyl-2,5-dioxoimidazolidin-1-yl)butanoyl]amino]pentanamide; UNII-1B47R6ZX4K; CID148203; D 2163	259188-38-0	148203	725892	TTDR00029	Matrilysin	Matrin;Matrix metalloproteinase-7;MMP-7;Pump-1 protease;Uterine metalloproteinase	P09237	4316	ENSG00000137673	inhibitor
DCL000005	Marimastat	15039-60-8; Butanediamide, N4-(2,2-dimethyl-1-((methylamino)carbonyl)propyl)-N1,2-dihydroxy-3-(2-methylpropyl)-, (2S-(N4(R*),2R*,3S*))-; D03795; (2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N',3-dihydroxy-2-(2-methylpropyl)butanediamide; Marimastat [USAN]; CHEBI:50662; BB-2516; Butanediamide, N4-((1S)-2,2-dimethyl-1-((methylamino)carbonyl)propyl)-N1,2-dihydroxy-3-(2-methylpropyl)-, (2S,3R)-; UNII-D5EQV23TDS; 154039-60-8; DB00786; CHEMBL279785; Butanediamide, N(sup 4)-(2,2-dimethyl-1-((methylamino)carbonyl)propyl)-N(sup 1),2-dihydroxy-3-(2-methylpropyl)-, (2S-(N(sup 4)(R*),2R*,3S*))-; (2S,3R)-N(4)-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N(1),2-dihydroxy-3-(2-methylpropyl)butanediamide; AC1L3O2N; C15H29N3O5; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoyl)propyl)carbamoyl)-2-hydroxy-5-methylhexanohydroxamic acid; CID119031; Marimastat; C100342; LS-45634; BB 2516; Marimastat (USAN/INN); (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoxy)propyl)carboyl)-2-hydroxy-5-methylhexanohydroxamic acid	154039-60-8	119031	46505547	TTDR00029	Matrilysin	Matrin;Matrix metalloproteinase-7;MMP-7;Pump-1 protease;Uterine metalloproteinase	P09237	4316	ENSG00000137673	inhibitor
DPR000098	RMG-40083	N/A	N/A	N/A	N/A	TTDS00520	Neuronal acetylcholine receptor protein, alpha-7 chain	Alpha(7) nicotinic receptor;Alpha7 nAChR;Alpha-7 nAChR;Alpha7 nicotinic receptor;Nicotinic acetylcholine receptor alpha7;Nicotinic acetylcholine receptor subunit alpha 7	P36544	1139	ENSG00000175344	antagonist
DCL000880	MEM-3454	N/A	116649-85-5	123879	40875157	TTDS00520	Neuronal acetylcholine receptor protein, alpha-7 chain	Alpha(7) nicotinic receptor;Alpha7 nAChR;Alpha-7 nAChR;Alpha7 nicotinic receptor;Nicotinic acetylcholine receptor alpha7;Nicotinic acetylcholine receptor subunit alpha 7	P36544	1139	ENSG00000175344	antagonist
DCL000606	R3487	N/A	N/A	5360545	49746451	TTDS00520	Neuronal acetylcholine receptor protein, alpha-7 chain	Alpha(7) nicotinic receptor;Alpha7 nAChR;Alpha-7 nAChR;Alpha7 nicotinic receptor;Nicotinic acetylcholine receptor alpha7;Nicotinic acetylcholine receptor subunit alpha 7	P36544	1139	ENSG00000175344	agonist
DCL001014	TC-1698	N/A	700834-58-8	N/A	N/A	TTDS00520	Neuronal acetylcholine receptor protein, alpha-7 chain	Alpha(7) nicotinic receptor;Alpha7 nAChR;Alpha-7 nAChR;Alpha7 nicotinic receptor;Nicotinic acetylcholine receptor alpha7;Nicotinic acetylcholine receptor subunit alpha 7	P36544	1139	ENSG00000175344	binder
DAP001525	TC-5280	N/A	146939-27-7	60854	48416712	TTDS00520	Neuronal acetylcholine receptor protein, alpha-7 chain	Alpha(7) nicotinic receptor;Alpha7 nAChR;Alpha-7 nAChR;Alpha7 nicotinic receptor;Nicotinic acetylcholine receptor alpha7;Nicotinic acetylcholine receptor subunit alpha 7	P36544	1139	ENSG00000175344	binder
DCL000935	PNU-282987	N-((3R)-1-Azabicyclo(2.2.2)oct-3-yl)-4-chlorobenzamide hydrochloride; PNU-282987; CID11243536; C498513; CHEMBL554984	123464-89-1	9795278	26683795	TTDS00520	Neuronal acetylcholine receptor protein, alpha-7 chain	Alpha(7) nicotinic receptor;Alpha7 nAChR;Alpha-7 nAChR;Alpha7 nicotinic receptor;Nicotinic acetylcholine receptor alpha7;Nicotinic acetylcholine receptor subunit alpha 7	P36544	1139	ENSG00000175344	antagonist
DCL000609	R4996	N/A	N/A	N/A	N/A	TTDS00520	Neuronal acetylcholine receptor protein, alpha-7 chain	Alpha(7) nicotinic receptor;Alpha7 nAChR;Alpha-7 nAChR;Alpha7 nicotinic receptor;Nicotinic acetylcholine receptor alpha7;Nicotinic acetylcholine receptor subunit alpha 7	P36544	1139	ENSG00000175344	agonist
DAP001318	Bortezomib	CID387447; LDP-341; MolPort-003-845-298; Boronic acid, [(1(R)-3-methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]-; N-[(1R)-1-(DIHYDROXYBORYL)-3-METHYLBUTYL]-N-(PYRAZIN-2-YLCARBONYL)-L-PHENYLALANINAMIDE; NCI60_029010; PROSCRIPT BORONIC ACID; CHEBI:287372; D03150; CHEBI:41143; CHEMBL325041; Bortezomib (JAN/USAN/INN); Boronic acid, [1-[[1-oxo-3-phenyl-2-[(2-pyrazinylcarbonyl) amino]propyl]amino]-3-methylbutyl]-, L-(S)-; N-[(1R)-1-(dihydroxyboranyl)-3-methylbutyl]-Nalpha-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide; DPBA; PS-341; Bortezomib; LPD-341; 179324-69-7; SBB071337; [(1R)-3-methyl-1-[[(2S)-3-phenyl-2-(pyrazine-2-carbonylamino)propanoyl]amino]butyl]boronic acid; DB07475; I14-3268; Velcade (TN); LPD 341; NSC681239; S1013_Selleck; NSC-681239; Pyz-Phe-boroLeu; Velcade, MG-341, PS-341, Bortezomib; FT-0082488; AC1L8TUW	179324-69-7	93860	670916	TTDS00461	26S proteasome	N/A	N/A	N/A	N/A	inhibitor
DCL000884	MLN3897	N/A	N/A	N/A	N/A	TTDC00215	C-C chemokine receptor type 1	C-C CKR-1;CC-CKR-1;CCR1;CCR-1;Chemokine receptor CCR1;HM145;LD78 receptor;Macrophage inflammatory protein-1 alpha receptor;MIP-1alpha-R;RANTES-R	P32246	1230	ENSG00000163823	antagonist
DCL000469	AZD4818	N/A	N/A	445642	36888288	TTDC00215	C-C chemokine receptor type 1	C-C CKR-1;CC-CKR-1;CCR1;CCR-1;Chemokine receptor CCR1;HM145;LD78 receptor;Macrophage inflammatory protein-1 alpha receptor;MIP-1alpha-R;RANTES-R	P32246	1230	ENSG00000163823	antagonist
DCL000708	AVE1701	N/A	N/A	N/A	N/A	TTDC00215	C-C chemokine receptor type 1	C-C CKR-1;CC-CKR-1;CCR1;CCR-1;Chemokine receptor CCR1;HM145;LD78 receptor;Macrophage inflammatory protein-1 alpha receptor;MIP-1alpha-R;RANTES-R	P32246	1230	ENSG00000163823	antagonist
DCL000576	MLN4924	N/A	N/A	N/A	N/A	TTDC00245	NEDD8-activating enzyme E1 catalytic subunit	NEDD8-activating enzyme E1C;Ubiquitin-activating enzyme 3;Ubiquitin-activating enzyme E1C;Ubiquitin-like modifier-activating enzyme 3	Q8TBC4	9039	ENSG00000144744	inhibitor
DPR000117	UCL-2000 and butabindide	N/A	185213-03-0	N/A	N/A	TTDR01033	Tripeptidyl-peptidase II	CCK-inactivating peptidase tripeptidyl peptidase;TPP II;TPP-II;Tripeptidyl aminopeptidase	P29144	7174	ENSG00000134900	inhibitor
DCL001220	PF-03882845	N/A	N/A	N/A	N/A	TTDS00196	Aldosterone receptor	N/A	N/A	N/A	N/A	antagonist
DAP000085	Eplerenone	Eplerenone (JAN/USAN/INN); CHEMBL1095097; Selara; MolPort-003-986-216; C12512; D01115; 107724-20-9; CGP-30083; AC1L9FDC; TL8000270; CHEBI:726453; Inspra; Inspra, Epoxymexrenone, CGP30083, SC-66110,Eplerenone; NCGC00159559-02; Inspra (TN); SC-66110; NCGC00159559-01; AC-4213; CID443872; Epoxymexrenone; S1707_Selleck; ZINC03985982; 7alpha-methoxycarbonyl-3-oxo-9,11alpha-epoxy-17alpha-pregn-4-ene-21,17-carbolactone; CHEBI:31547; Eplerenone	107724-20-9	150310	727860	TTDS00196	Aldosterone receptor	N/A	N/A	N/A	N/A	antagonist
DAP000297	Spironolactone	Prestwick0_000128; 7alpha-(acetylsulfanyl)-3-oxo-17alpha-pregn-4-ene-21,17-carbolactone; Alter Brand of Spironolactone; SMR000471892; NSC150399; Alphapharm Brand of Spironolactone; spironolactone; Deverol; Cardel Brand of Spironolactone; Flumach; Supra-puren; Spiroctan; Dexo Brand of Spironolactone; CHEBI:9241; BIDD:PXR0071; Sagisal; LT00772287; Urusonin; MLS002153245; CID5833; Mayoly-Spindler Brand of Spironolactone; Spironolattone [DCIT]; SC9420; Spiridon; BRD-K90027355-001-03-4; MLS001333253; Jenapharm Brand of Spironolactone; CHEBI:428201; 4-18-00-01601 (Beilstein Handbook Reference); UNII-27O7W4T232; Hormosan Brand of Spironolactone; Suracton; Almatol; Aldactone (TN); Osyrol; Spironolactone (JP15/USP/INN); EINECS 200-133-6; Merck dura Brand of Spironolactone; D013148; Sprioderm; Spironolactone A; Spiractin; Spirobeta; Prestwick2_000128; spiro von ct; Generosan Brand of Spironolactone; Frumikal; Veroshpiron; HMS1568I18; BRN 0057767; spironolattone; Espironolactona [INN-Spanish]; Spirolone; ZINC03861599; Spiro L.U.T.; D00443; Alderon; 496916-40-6; Aldopur; Worwag Brand of Spironolactone; BPBio1_000194; Spirogamma; Spirolang; Verospirone Opianin; 7-alpha-Acetylthio-3-oxo-17-alpha-pregn-4-ene-21,17-beta-carbolactone; SC-9420; Laractone; Spiroderm; Spironone; ct Arzneimittel Brand of Spironolactone; NCGC00164397-01; Xenalon; Lacdene; Spironolactonum; MLS001333254; Practon; SPBio_002115; Lacalmin; Novo-Spiroton; Dira; HSDB 3184; Uractone; Spironolactone [INN:BAN:JAN]; AC-4214; S0260; ct-Arzneimittel Brand of Spironolactone; WLN: L E5 B666 FX OV MUTJ A1 E1 KSV1 F-& CT5VOXTJ; Spiroctanie; Ashbourne Brand of Spironolactone; Nefurofan; Prestwick3_000128; Spiresis; Spironolactonum [INN-Latin]; Abbolactone; C07310; Spirone; Novo Spiroton; Spirono Isis; Searle Brand of Spironolactone; CHEMBL1393; Spirono-Isis; SC 9420; C24H32O4S; SNL; NSC 150399; Spiro-Tablinen; Pfizer Brand of Spironolactone; Roche Brand of Spironolactone; Sincomen; von ct, spiro; S3378_SIGMA; Alpharma Brand of Spironolactone; I06-1970; Aldace; betapharm Brand of Spironolactone; AC1L1L8Q; Duraspiron; Spirolactone; DB00421; Altex; HMS2090N21; Spiretic; Spirolakton; AB00513806; CPD000471892; NCGC00164397-02; Spironolactone [BAN:INN:JAN]; BSPBio_000176; Novopharm Brand of Spironolactone; Jenaspiron; Aldactide; Azupharma Brand of Spironolactone; Verospiron; SAM002264648; Spiro[17H-cyclopenta[a]phenauthrene-17,2'-(3'H)-furan]; Diatensec; 52-01-7; LS-118614; Espironolactona Alter; Acelat; Espironolactona Mundogen; Aldactone A; Prestwick1_000128; 4-Pregnen-21-oic acid-17alpha-ol-3-one-7alpha-thiol gamma-lactone 7-acetate; Aquareduct; NovoSpiroton; Spirospare; Melarcon; Spironocompren; MLS001074672; Spiro(17H-cyclopenta(a)phenauthrene-17,2'-(3'H)-furan); Espironolactona; Aldactone; Pharmafrid Brand of Spironolactone; Mundogen Brand of Spironolactone; CHEBI:45692; Verospirone; Euteberol; MLS002207058; Aldactazide	52-01-7	5833	9518	TTDS00196	Aldosterone receptor	N/A	N/A	N/A	N/A	antagonist
DAP000481	Metoprolol	AstraZeneca Brand of Seloken; Dutoprol; Meijoprolol; 1-[(1-methylethyl)amino]-3-({4-[2-(methyloxy)ethyl]phenyl}oxy)propan-2-ol; Tartrate, Metoprolol; L000669; AstraZeneca Brand of Metaoprolol Tartrate; LOPRESSIDONE; Metoprololum; Spesikor; Preblok; Leiras Brand of Metoprolol Succinate or Metoprolol Tartrate; I06-0125; H 93 26; H 9326; 1-(Isopropylamino)-3-(4-(2-methoxyethyl)phenoxy)propan-2-ol; Jsp006606; Lopressor; CGP 2175; (RS)-Metoprolol; 37350-58-6; EINECS 253-483-7; NCGC00021148-03; 1-(Isopropylamino)-3-(p-(2-methoxyethyl)phenoxy)-2-propanol; MolPort-005-938-039; 2-Propanol, 1-[4-(2-methoxyethyl)phenoxy]-3-[(1-methylethyl)amino]-, (.+/-.)-; 1-[4-(2-methoxyethyl)phenoxy]-3-(propan-2-ylamino)propan-2-ol; Toprol; Betalok; Selo-Zok; 1-[4-(2-methoxyethyl)phenoxy]-3-propan-2-ylamino-propan-2-ol; BRD-A03623303-045-02-0; Betaloc; Betaloc-Astra; Lopresoretic; NCGC00021148-04; Seloken AstraZeneca Brand; Metohexal; CHEMBL13; Beloc-Duriles; Beatrolol; Metoprololum [INN-Latin]; Metoprolol succinate; Beloc Duriles; D008790; AB00053499; dl-Metoprolol; 2-Propanol, 1-(4-(2-methoxyethyl)phenoxy)-3-((1-methylethyl)amino)-, (+-)-; AC1L1HKM; Presolol; LS-122450; AC-19022; CGP-2175; BetalocAstra; D02358; HSDB 6531; H 93-26; CHEBI:6904; I01-7125; CID4171; BelocDuriles; C07202; 2-Propanol, 1-(4-(2-methoxyethyl)phenoxy)-3-((1-methylethyl)amino)-; Betaloc Astra; EINECS 257-166-4; 51384-51-1; CGP2175; Novartis Brand of Metprolol Tartrate; 54163-88-1; UNII-GEB06NHM23; Metoprolol (USAN/INN); Spesicor; HMS2090B15; Seroken; Seloken; TOPROL-XL; CCRIS 4198; Metoprolol [USAN:INN:BAN]; Lopresor; Metroprolol; 1-(isopropylamino)-3-[4-(2-methoxyethyl)phenoxy]propan-2-ol; 3-[4-(2-methoxyethyl)phenoxy]-1-(propan-2-ylamino)propan-2-ol; NCGC00021148-02; DB00264; metoprolol	37350-58-6	4171	205122	TTDS00036	Beta-1 adrenergic receptor	Beta-1 adrenoceptor;Beta-1 adrenoreceptor	P08588	153	ENSG00000043591	antagonist
DAP000245	Dobutamine	Dobutamine Tartrate (1:1), (S-(R*,R*))-Isomer; Lopac0_000365; 34368-04-2; Lilly 81929; rac-dobutamine; racemic-Dobutamine; HMS2089K05; D03879; 1,2-Benzenediol, 4-[2-[[3-(4-hydroxyphenyl)-1-methylpropyl]amino]ethyl]-, (.+/-.)-; SPBio_002364; BRD-A78322124-003-03-3; UNII-3S12J47372; 4-(2-{[4-(4-hydroxyphenyl)butan-2-yl]amino}ethyl)benzene-1,2-diol; CHEBI:4670; Dobutamine Hcl in Dextrose 5%; Dobutaminum; EINECS 277-982-4; 52663-81-7 (hydrochloride); Dobutamina; 4-(2-{[3-(4-hydroxyphenyl)-1-methylpropyl]amino}ethyl)benzene-1,2-diol; Prestwick1_000352; 34368-04-2 (Parent); dobutamine; Prestwick0_000352; Dobutaminum [INN-Latin]; LS-174467; dobutamine(usp); 4-[2-[4-(4-hydroxyphenyl)butan-2-ylamino]ethyl]benzene-1,2-diol; Prestwick2_000352; LY 81929; L001157; DB00841; 3,4-dihydroxy-N-[3-(4-hydroxyphenyl)-1-methylpropyl]-beta-phenylethylamine; C06967; AC1Q7AD1; (+-)-4-(2-((3-(p-Hydroxyphenyl)-1-methylpropyl)amino)ethyl)pyrocatechol; Dobutamine hydrobromide; BSPBio_000443; Prestwick3_000352; DL-dobutamine; 1,2-Benzenediol, 4-(2-((3-(4-hydroxyphenyl)-1-methylpropyl)amino)ethyl)-, (+-)-; Dobutamina [INN-Spanish]; UNII-0WR771DJXV; Dobutamine [USAN:BAN:INN]; NCGC00024629-03; NCGC00024629-02; NCGC00015321-05; AC1L1WFF; Dobutamine Hcl; Dobutamine [USAN]; 74753-15-4 (hydrobromide); 74753-15-4; CHEMBL926; CID36811; BPBio1_000489; Dobutamine (USP/INN)	34368-04-2	36811	9181	TTDS00036	Beta-1 adrenergic receptor	Beta-1 adrenoceptor;Beta-1 adrenoreceptor	P08588	153	ENSG00000043591	agonist
DAP001396	Levobetaxolol	(2s)-1-{4-[2-(cyclopropylmethoxy)ethyl]phenoxy}-3-(isopropylamino)propan-2-ol; AC1L1TO2; 2-Propanol, 1-(4-(2-(cyclopropylmethoxy)ethyl)phenoxy)-3-((1-methylethyl)amino)-, (2S)-; (S)-Betaxolol; CHEBI:59254; AC1Q58SH; UNII-75O9XHA4TU; Levobetaxolol; Levobetaxolol [INN]; (2S)-1-{4-[2-(cyclopropylmethoxy)ethyl]phenoxy}-3-(propan-2-ylamino)propan-2-ol; (S)-(-)-Betaxolol; STK636241; (2S)-1-[4-[2-(cyclopropylmethoxy)ethyl]phenoxy]-3-(propan-2-ylamino)propan-2-ol; 93221-48-8; C18H29NO3; (S)-1-(isopropylamino)-3-[p-(cyclopropylmethoxyethyl)phenoxy]-2-propanol; LS-178203; CID60657; (-)-Betaxolol	116209-55-3	60657	728134	TTDS00036	Beta-1 adrenergic receptor	Beta-1 adrenoceptor;Beta-1 adrenoreceptor	P08588	153	ENSG00000043591	antagonist
DAP000485	Oxprenolol	oxprenolol; 1-(propan-2-ylamino)-3-(2-prop-2-enoxyphenoxy)propan-2-ol; 1-[(1-Methylethyl)amino]-3-[2-(2-propenyloxy)phenoxy]-2-propanol; Slow-Pren (*hydrochloride*); (1)-1-(o-(Allyloxy)phenoxy)-3-(isopropylamino)propan-2-ol; Coretal; BRD-A43671941-003-03-6; dl-Alprenolol; DB01580; 1-((1-Methylethyl)amino)-3-(2-(2-propenyloxy)phenoxy)-2-propanol; 1-(Isopropylamino)-2-hydroxy-3-(o-(allyloxy)phenoxy)propane; Trasacor (*hydrochloride*); Trasacor; L013416; Laracor; Osprenololo; Trasicor; Oxprenolol (TN); (+-)-Oxprenolol; Slow-pren; Slow Trasicor; Osprenololo [DCIT]; Prestwick3_001057; AC1L1ILM; 2-Propanol, 1-(2-allyloxyphenoxy)-3-(isopropylamino)-; SPBio_002937; CID4631; AB00514712; Trasicor (*hydrochloride*); BPBio1_001116; LS-121642; UNII-519MXN9YZR; BSPBio_001014; Prestwick1_001057; 2-Propanol, 1-((1-methylethyl)amino)-3-(2-(2-propenyloxy)phenoxy)-; EINECS 229-257-9; Oxprenolol Ba 39089 (*hydrochloride*); 22972-96-9; Koretal; Oxprenolol [INN:BAN]; CHEMBL546; Trasicor 80; 71186-75-9; dl-Oxprenolol; 22972-98-1; (+)-1-(o-(Allyloxy)phenoxy)-3-(isopropylamino)propan-2-ol; C15H23NO3; Laracor (*hydrochloride*); Tevacor; Oxprenolol, dl-; 6452-71-7; EINECS 245-359-6; CCRIS 4201; EINECS 245-357-5; Oxprenololum [INN-Latin]; 1-[2-(Allyloxy)phenoxy]-3-(isopropylamino)-2-propanol; Oxprenolol (INN); 6452-73-9 (HYDROCHLORIDE); Coretal (*hydrochloride*); Prestwick0_001057; Oxprenololum; 1-(o-(Allyloxy)phenoxy)-3-(isopropylamino)-2-propanol; CHEBI:113756; 2-Propanol, 1-[(1-methylethyl)amino]-3-[2-(2-propenyloxy)phenoxy]-; Prestwick2_001057; D08318; 2-Propanol, 1-[(1-methylethyl)amino]-3-[2-(2-propenyloxy)phenoxy]-, (+/-)	6452-71-7	4631	10354504	TTDS00036	Beta-1 adrenergic receptor	Beta-1 adrenoceptor;Beta-1 adrenoreceptor	P08588	153	ENSG00000043591	antagonist
DAP000482	Atenolol	Teno-basan; Jenatenol; NCGC00024566-07; KBio2_004412; D00235; I01-3572; Atenol Gador; CCRIS 4196; Tenolol; EINECS 249-451-7; Atenol-Mepha; BENZENEACETAMIDE, 4-(2-HYDROXY-3-((1-METHYLETHYL)AMINO)PROPOXY)-, (+-)-; Betatop Ge; Atenol Cophar; KBio3_002415; Prenolol; NCGC00015007-07; Benzeneacetamide, 4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)-; Alinor; MLS000069622; Atenol Atid; Corotenol; NCGC00024566-03; Atenol Fecofar; ( inverted question mark)-Atenolol; Benzeneacetamide, 4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]-; Cardaxen; Juvental; Atenol ct; Vascoten; Atenol Stada; KBioGR_000790; AC1Q1QBX; Atcardil; Loten; AC1L1D99; Hypoten; Vericordin; Atenomel; L000116; HMS2090I19; UNII-50VV3VW0TI; 60966-51-0; Hipres; Cuxanorm; Tenoprin; Wesipin; Atenol-Wolff; Duraatenolol; LS-28557; IDI1_000057; AC-11142; Tenoblock; Atenololum; Spectrum4_000435; Tenidon; Atenol NM Pharma; NCGC00015007-13; Apo-Atenolol; Evitocor; Anselol; SAM002564193; Lopac0_000121; HMS2092D19; Atenolol (JP15/USP/INN); Atenol Trom; 1-p-Carbamoylmethylphenoxy-3-isopropylamino-2-propanol; Noten; ICI66082; Serten; MLS001304038; D001262; Atenil; Tenormin (TN); Premorine; (+/-)-4-[2-Hydroxy-3-[(1-methylethyl)amino]propoxy]benzeneacetamide; ICI 66082; DivK1c_000057; Normalol; Myocord; Blocotenol; Acetamide,2-(p-(2-hydroxy-3-(isopropylamino)propoxy)phenyl); Acetamide, 2-(p-(2-hydroxy-3-(isopropylamino)propoxy)phenyl)-; Ormidol; CPD000036768; SPBio_001482; Servitenol; Aircrit; Atecard; BSPBio_002915; Atenol acis; 4-[2'-Hydroxy-3'-(isopropylamino)propoxy]phenylacetamide; 2-[4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]acetamide; Tenormine [French]; METKIMKYRPQLGS-UHFFFAOYSA-; Atenololum [INN-Latin]; A 7655; Atenblock; Atenol Nordic; Felo-Bits; Prinorm; Atenol AL; Tenormine; Stermin; Lotenal; 2-(4-{2-hydroxy-3-[(propan-2-yl)amino]propoxy}phenyl)acetamide; Atenol Genericon; Xaten; DB00335; (+-)-4-(2-Hydroxy-3-isopropylaminopropoxy)phenylacetamide; 2-(p-(2-Hydroxy-3-(isopropylamino)propoxy)phenyl)acetamide; Oraday; Uniloc; HMS1569L13; Spectrum5_001509; Atendol; MolPort-001-792-717; 4-(2-Hydroxy-3-((1-methylethyl)amino)propoxy)benzeneacetamide; STK528649; LS-9707; Atenol-ratiopharm; Tredol; 2-{4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl}acetamide; ARONIS23884; Neatenol; Prenormine; NCGC00024566-05; BIM-0050109.0001; Atenol PB; EU-0100121; duratenol; ICI-66082; EINECS 262-544-7; 4-[2 -Hydroxy-3 -(isopropylamino)-propoxy]phenylacetamide; (+-)-Atenolol; Betablok; NCGC00024566-04; Atenol Heumann; AKOS005111050; 2-[4-(2-Hydroxy-3-isopropylaminopropoxy)phenyl]acetamide; Atenol; Tensotin; Spectrum_001364; Atenol von ct; CHEMBL24; Atenol Quesada; Spectrum3_001448; 29122-68-7; Farnormin; Plenacor; InChI=1/C14H22N2O3/c1-10(2)16-8-12(17)9-19-13-5-3-11(4-6-13)7-14(15)18/h3-6,10,12,16-17H,7-9H2,1-2H3,(H2,15,18); HMS1921H09; Ibinolo; A7655_SIGMA; Cardiopress; Panapres; Antipressan; Atenol GNR; Spectrum2_001411; Tensimin; KBio2_006980; Atenet; KBioSS_001844; 2-[4-({2-hydroxy-3-[(1-methylethyl)amino]propyl}oxy)phenyl]acetamide; HSDB 6526; (1)-2-(4-(2-Hydroxy-3-(isopropylamino)propoxy)phenyl)acetamide; Betacard; Betasyn; (?)-Atenolol; BRN 2739235; Tenormin; Atehexal; MLS001066372; KBio2_001844; Seles beta; Selobloc; Atenol Tika; MLS001074163; Aterol; Atenolin; benzeneacetamide, 4-[2'-hydroxy-3;-[(1-methylethyl)amino]propoxy]-; Blokium; NCGC00024566-06; Atenol 1A pharma; Tenobloc; BRD-A20239487-001-02-5; KBio1_000057; Normiten; NINDS_000057; 2-(4-(2-Hydroxy-3-isopropylaminopropoxy)phenyl)acetamid; Atenolol [USAN:INN:BAN:JAN]; CHEBI:2904; atenolol; CID2249; SPECTRUM1501127; SMR000036768; Unibloc; Ateni; Scheinpharm Atenol; ICI 66,082; Altol; Atereal; Oprea1_448775; BB_SC-1519; Internolol; Atenol MSD; Lo-ten; HMS500C19	29122-68-7	2249	176216	TTDS00036	Beta-1 adrenergic receptor	Beta-1 adrenoceptor;Beta-1 adrenoreceptor	P08588	153	ENSG00000043591	antagonist
DAP000304	Esmolol	methyl 3-[4-({2-hydroxy-3-[(1-methylethyl)amino]propyl}oxy)phenyl]propanoate; HMS2090P06; AC1Q5ZXA; (+-)-methyl p-(2-hydroxy-3-(isopropylamino)propoxy)hydrocinnamate; Esmolol [INN:BAN]; CID59768; 81161-17-3 (Hydrochloride); CHEMBL768; D07916; DB00187; Benzenepropanoic acid, 4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)-, methyl ester; 103598-03-4; CHEBI:4856; AC-12058; LS-31121; C06980; methyl p-(2-hydroxy-3-(isopropylamino)propoxy)hydrocinnamate; LS-185019; ESMOLOL; 84057-94-3; methyl 3-{4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl}propanoate; methyl p-[2-hydroxy-3-(isopropylamino)propoxy]hydrocinnamate; ASL 8052-001; methyl 3-[4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]propanoate; AC1L1RWQ; Methyl 4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)benzenepropanoate; 81147-92-4; MolPort-005-933-593; L001332; Esmolol (INN); (+-)-Esmolol; BRN 5287174; UNII-MDY902UXSR	103598-03-4	59768	9194	TTDS00036	Beta-1 adrenergic receptor	Beta-1 adrenoceptor;Beta-1 adrenoreceptor	P08588	153	ENSG00000043591	antagonist
DAP000942	Nebivolol	PDSP2_000243; Nebivololum [Latin]; 1-(6-fluoro-3,4-dihydro-2H-chromen-2-yl)-2-[[2-(6-fluoro-3,4-dihydro-2H-chromen-2-yl)-2-hydroxyethyl]amino]ethanol; 2,2'-iminobis[1-(6-fluoro-3,4-dihydro-2H-chromen-2-yl)ethanol]; CID71301; UNII-030Y90569U; 104365-59-5; 118457-14-0; Nebivololum; alpha,alpha'-(Iminobis(methylene))bis(6-fluoro-3,4-dihydro-2H-1-benzopyran-2-methanol); R65,824; Nebipill; alpha,alpha'-(Iminodimethylene)bis(6-fluoro-2-chromanmethanol); Nubeta; AC1Q4OMF; Nebivolol; Bystolic; Lobivon; Nebivolol (USAN/INN); R-67555; Nebilong; PI-21858; C22H25F2NO4; D05127; Nebivolol [USAN:INN:BAN]; MolPort-003-849-343; Nebilet; 2H-1-Benzopyran-2-methanol, alpha,alpha'-(iminobis(methylene))bis(6-fluoro-3,4-dihydro-; PDSP1_000244; LS-178404; L001284; CHEMBL434394; AC1L2FX8; 99200-09-6; R 67555; AC-1611; alpha,alpha'-(iminobis(methylene))bis(6-fluoro-3,4-dihydro)-2H-1-benzopyran-2-methanol; I06-0378; DB04861; Nebicard-5	99200-09-6	71301	14757350	TTDS00036	Beta-1 adrenergic receptor	Beta-1 adrenoceptor;Beta-1 adrenoreceptor	P08588	153	ENSG00000043591	antagonist
DAP000941	Alprenolol	CHEMBL266195; NCGC00089741-03; AR-1L8247; NINDS_000015; 1-(o-Allylphenoxy)-3-(isopropylamino)-2-propanol; CHEBI:51211; Yobir; BPBio1_000044; NCGC00089741-02; Alprenololum [INN-Latin]; KBioGR_001652; UNII-877K5MQ27W; DB00866; 1-(o-Allylphenoxy)-3-isopropylamino)-2-propanol; Spectrum3_001066; BRD-A00993607-003-05-5; H-56-28; SPBio_001827; Alprenolol [INN:BAN]; D07156; KBioSS_000648; Spectrum4_001216; KBio2_005784; CID2119; Spectrum2_001814; MolPort-003-717-938; Alprenololum; Oprea1_368995; 13655-52-2; 1-[2-(propen-2-ylphenoxy)]-3-(isopropylamino)propan-2-ol; Prestwick2_000250; BSPBio_000040; Spectrum5_001414; 2-Propanol, 1-(o-allylphenoxy)-3-(isopropylamino)-; KBio2_003216; 2-Propanol, 1-[(1-methylethyl)amino]-3-[2-(2-propenyl)phenoxy]-; IDI1_000015; KBio3_001872; KBio1_000015; NCGC00089741-04; AC1Q57NL; nchembio801-comp5; AB00053431; L000961; NCGC00015099-08; Alpheprol; Spectrum_000168; Prestwick0_000250; alprenolol; LS-121647; Alprenolol (INN); DivK1c_000015; BSPBio_002652; 1-(2-Allylphenoxy)-3-isopropylamino-2-propanol; Prestwick3_000250; KBio2_000648; Lopac0_000152; EINECS 237-140-9; 2-Propanol, 1-((1-methylethyl)amino)-3-(2-(2-propenyl)phenoxy)-; 1-(propan-2-ylamino)-3-(2-prop-2-enylphenoxy)propan-2-ol; SPBio_002259; Prestwick1_000250; Alfeprol; Alfeprol [Russian]; AC1L1CYO; HMS2089G06	13655-52-2	2119	168916	TTDS00036	Beta-1 adrenergic receptor	Beta-1 adrenoceptor;Beta-1 adrenoreceptor	P08588	153	ENSG00000043591	antagonist
DAP000372	Sotalol	NCGC00024899-03; Prestwick1_000966; NCGC00015919-05; Sotalol (INN); CCRIS 4204; Methanesulfonamide, N-(4-(1-hydroxy-2-((1-methylethyl)amino)ethyl)phenyl)- (9CI); CID5253; CHEMBL471; AC1L1JXU; Sotalolum [INN-Latin]; Methanesulfonamide, N-(4-(1-hydroxy-2-((1-methylethyl)amino)ethyl)phenyl)-, (+-)-; Prestwick2_000966; BSPBio_000971; LS-90249; Prestwick0_000966; 3930-20-9; Prestwick3_000966; Sotalolum; C07309; HMS2089K09; D08525; Methanesulfonanilide, 4'-(1-hydroxy-2-(isopropylamino)ethyl)-; 27948-47-6; Darob mite (TN); .beta.-Cardone; Sotalol [INN:BAN]; Darob mite; N-[4-[1-hydroxy-2-(propan-2-ylamino)ethyl]phenyl]methanesulfonamide; AB00514715; MolPort-002-042-381; 4'-(1-Hydroxy-2-(isopropylamino)ethyl)methane sulfonanilide; BPBio1_001069; L013427; C12H20N2O3S; N-{4-[1-hydroxy-2-(propan-2-ylamino)ethyl]phenyl}methanesulfonamide; UNII-A6D97U294I; Sotalol Monohydrochloride; Methanesulfonamide, N-(4-(1-hydroxy-2-((1-methylethyl)amino)ethyl)phenyl)-; sotalol; N-(4-{1-hydroxy-2-[(1-methylethyl)amino]ethyl}phenyl)methanesulfonamide; AC-19021; 959-24-0 (mono-hydrochloride); SBB066409; NCGC00024899-02; DB00489; BRD-A33168282-003-03-2; MJ-1999; Lopac0_001055; beta-Cardone; d,l-Sotalol; 4'-(1-Hydroxy-2-isopropylaminoethyl)methanesulfonanilid; SPBio_002892	3930-20-9	5253	9517	TTDS00036	Beta-1 adrenergic receptor	Beta-1 adrenoceptor;Beta-1 adrenoreceptor	P08588	153	ENSG00000043591	antagonist
DAP000483	Bisoprolol	Emconcor; Euradal; CID2405; BPBio1_000373; Bisoprolol hemifumarate; Isoten; Prestwick3_000330; 2-Propanol, 1-(4-((2-(1-methylethoxy)ethoxy)methyl)phenoxy)-3-((1-methylethyl)amino)-; Bisoprololum [Latin]; 66722-44-9; CHEMBL645; L000133; Concor; AC-18540; Monocor; EMD-33-512; Bisoprolol (USAN/INN); Soloc; Prestwick2_000330; ARONIS24082; 1-(propan-2-ylamino)-3-[4-(2-propan-2-yloxyethoxymethyl)phenoxy]propan-2-ol; SBB065120; UNII-Y41JS2NL6U; NCGC00024868-04; 1-[(1-methylethyl)amino]-3-({4-[({2-[(1-methylethyl)oxy]ethyl}oxy)methyl]phenyl}oxy)propan-2-ol; Bisoprolol [USAN:BAN:INN]; 1-{4-[(2-isopropoxyethoxy)methyl]phenoxy}-3-(isopropylamino)propan-2-ol; Zebeta; AKOS005110983; SPBio_002260; BSPBio_000339; C06852; EMD-33512; Bisoprolol fumerate; DB00612; D02342; Prestwick0_000330; Prestwick1_000330; C18H31NO4; Soprol; BISOPROLOL; I01-7040; Emcor; LS-122509; MolPort-005-937-320; AC1L1DLQ; NCGC00024868-02; (+-)-1-((alpha-(2-Isopropoxyethoxy)-p-tolyl)oxy)-3-(isopropylamino)-2-propanol; NCGC00024868-03; CHEBI:3127; AB00514681; Cardicor; 2-Propanol, 1-(4-((2-(1-methylethoxy)ethoxy)methyl)phenoxy)-3-((1-methylethyl)amino)-, (+-)-; 2-Propanol, 1-[4-[[2-(1-methylethoxy)ethoxy]methyl]phenoxy]-3-[(1-methylethyl)amino]-, (.+/-.)-; Detensiel; Bisoprololum; NCGC00024868-05; (RS)-1-(4-(2-Isopropoxyethoxymethyl)phenoxy)-3-(isopropylamino)-2-propanol; Bisocor; CL-297939	66722-44-9	2405	187179	TTDS00036	Beta-1 adrenergic receptor	Beta-1 adrenoceptor;Beta-1 adrenoreceptor	P08588	153	ENSG00000043591	antagonist
DAP000940	Practolol	KBio2_007070; (+-)-Practolol; SPBio_001504; Spectrum2_001572; BRD-A41304429-001-04-9; MolPort-000-182-968; LS-10763; practolol; NCGC00024810-02; 6673-35-4; Teranol; ICI-50172; Spectrum5_001123; Praktololu [Polish]; MLS002153779; HMS1569C05; Spectrum_001454; Eralzdin Practolol; AC1L1J62; KBioGR_001497; HMS502N03; Prestwick0_000332; Prestwick3_000332; NCGC00024810-03; NINDS_000901; N-{4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl}acetamide; EINECS 229-712-1; CID4883; Practololo [DCIT]; N-[4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]acetamide; N-{4-[2-hydroxy-3-(isopropylamino)propoxy]phenyl}acetamide; KBio2_004502; BSPBio_000363; ICI 50172; AB00052459; Practololum [INN-Latin]; Acetamide, N-[4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]phenyl]-; Eraldin; Prestwick2_000332; CHEMBL6995; DivK1c_000901; Prestwick1_000332; KBio2_001934; Acetamide, N-(4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)phenyl)-; IDI1_000901; SMR001233163; Spectrum4_000859; AKOS002685374; HMS2089I09; BPBio1_000401; Praktololu; Oprea1_095524; 4'-(2-Hydroxy-3-(isopropylamino)propoxy)acetanilide; KBioSS_001934; CCRIS 1089; F1288-0015; 1-(4-Acetamidophenoxy)-3-isopropylamino-2-propanol; Acetanilide, 4'-(2-hydroxy-3-(isopropylamino)propoxy)-; Practololum; KBio1_000901; Practolol [USAN:BAN:INN]; Dalzic; UNII-SUG9176GRW; N-[4-({2-hydroxy-3-[(1-methylethyl)amino]propyl}oxy)phenyl]acetamide; SPBio_002284; CHEBI:258351; AC1Q1QBZ; L000491; N-(4-(2-Hydroxy-3-((1-methylethyl)amino)propoxy)phenyl)acetamide; Prestwick_742; AY 21011; Practololo	6673-35-4	443371	10299290	TTDS00036	Beta-1 adrenergic receptor	Beta-1 adrenoceptor;Beta-1 adrenoreceptor	P08588	153	ENSG00000043591	antagonist
DAP000484	Acebutolol	(+-)-Acebutolol; Acetobutolol [INN-Spanish]; C06803; 3'-Acetyl-4'-(2-hydroxy-3-(isopropylamino)propoxy)butyranilide; M&B-17803 A; KBio1_000612; 37517-30-9; Prestwick0_000069; BPBio1_000283; CID1978; Prestwick2_000069; N-[3-acetyl-4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]butanamide; Sectral; (+-)-3'-Acetyl-4'-(2-hydroxy-3-(isopropylamino)propoxy)butyranilide; BSPBio_001986; N-(3-Acetyl-4-[2-hydroxy-3-(isopropylamino)propoxy]phenyl)butanamide; CHEMBL642; M & B 17803A; Butanamide, N-(3-acetyl-4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)phenyl)-, (+-)-; BSPBio_000257; BRN 2162244; UNII-67P356D8GH; Butanamide, N-(3-acetyl-4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)phenyl)-,monohydrochloride,( -)-; Acebutolol (USAN/INN); Acebutololo; BRD-A29260609-003-05-4; Acebrutololum [INN-Latin]; Acebutolol [USAN:INN:BAN]; Prent; MolPort-003-844-375; KBio2_006107; SPBio_002178; KBio3_001486; L000998; 3'-(Acetyl-4'-(2-hydroxy-3-(isopropylamino)propoxy)butyranilide; Acebutololum; CCRIS 9214; DivK1c_000612; KBioSS_000971; (+-)-N-(3-Acetyl-4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)phenyl)butanamide; N-{3-acetyl-4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl}butanamide; LS-45389; Prestwick3_000069; SPBio_001499; 34381-68-5 (hydrochloride); KBio2_003539; AC1L1CNH; EINECS 253-539-0; Butanamide, N-[3-acetyl-4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]phenyl]-, (.+/-.)-; acebutolol; Spectrum4_000802; Neptal; RP 21823; 1-(2-Acetyl-4-n-butyramidophenoxy)-2-hydroxy-3-isopropylaminopropane; 3'-Acetyl-4'-(2-hydroxy-3-isopropylaminopropoxy)butyranilid; NINDS_000612; Spectrum_000491; N-[3-acetyl-4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]phenyl]butanamide; CHEBI:2379; IDI1_000612; Acebrutololum; C18H28N2O4; KBio2_000971; DB01193; Spectrum5_001399; Spectrum2_001340; AB00053574; 28197-63-9; D02338; Acebutololum [INN-Latin]; Acebutolol HCL; Spectrum3_000573; dl-Acebutolol; 5'-Butyramido-2'-(2-hydroxy-3-isopropylaminopropoxy)acetophenone; Prestwick1_000069; Acetobutolol; KBioGR_001283	37517-30-9	1978	9022	TTDS00036	Beta-1 adrenergic receptor	Beta-1 adrenoceptor;Beta-1 adrenoreceptor	P08588	153	ENSG00000043591	antagonist
DAP000305	Betaxolol	Prestwick1_000382; AC1L1DIZ; SPBio_002484; Lopac0_000193; CHEBI:3082; BSPBio_000563; CHEMBL423; DB00195; Betazolol; Prestwick3_000382; ALO-1401-02; D07526; Kerlone; L000125; Betaxolol (TN); (.+/-.)-1-[p-[2-(Cyclopropylmethoxy)ethyl]phenoxy]-3-(isopropylamino)-2-propanol; 1-(isopropylamino)-3-[p-(cyclopropylmethoxyethyl)phenoxy]-2-propanol; SL 75212; CID2369; UNII-O0ZR1R6RZ2; 1-[(4-{2-[(cyclopropylmethyl)oxy]ethyl}phenyl)oxy]-3-[(1-methylethyl)amino]propan-2-ol; Prestwick0_000382; Betaxolol HCL; Prestwick2_000382; C06849; HMS2089I07; AC-1115; NCGC00024863-04; Betaxolol (INN); MolPort-003-845-027; 63659-18-7; LS-122005; 2-Propanol, 1-(4-(2-(cyclopropylmethoxy)ethyl)phenoxy)-3-((1-methylethyl)amino)-; C18H29NO3; 1-[4-[2-(cyclopropylmethoxy)ethyl]phenoxy]-3-(propan-2-ylamino)propan-2-ol; betaxolol; NCGC00024863-03; Betaxololum; 1-{4-[2-(cyclopropylmethoxy)ethyl]phenoxy}-3-(propan-2-ylamino)propan-2-ol; NCGC00015159-08; KERLEDEX; Betaxololum [INN-Latin]; Betaxolol [INN:BAN]; 1-(4-(2-(Cyclopropylmethoxy)ethyl)phenoxy)-3-((1-methylethyl)amino)-2-propanol; BRD-A02759312-003-03-9; BPBio1_000621; SL-75212; 63659-19-8 (hydrochloride)	63659-18-7	2369	9067	TTDS00036	Beta-1 adrenergic receptor	Beta-1 adrenoceptor;Beta-1 adrenoreceptor	P08588	153	ENSG00000043591	antagonist
DPR000186	SGN-19A	N/A	N/A	N/A	N/A	TTDC00135	B-lymphocyte antigen CD19	B-lymphocyte surface antigen B4;CD19;Differentiation antigen CD19;Leu-12	P15391	930	ENSG00000177455	antibody
DCL001209	MEDI-551	N/A	N/A	N/A	N/A	TTDC00135	B-lymphocyte antigen CD19	B-lymphocyte surface antigen B4;CD19;Differentiation antigen CD19;Leu-12	P15391	930	ENSG00000177455	antibody
DCL000219	SAR3419	N/A	N/A	N/A	N/A	TTDC00135	B-lymphocyte antigen CD19	B-lymphocyte surface antigen B4;CD19;Differentiation antigen CD19;Leu-12	P15391	930	ENSG00000177455	antibody
DAP001247	Propylthiouracil	thyreos tat ii; Propylthiouracilum [INN-Latin]; PROPYL THIOURACIL; KBioSS_001356; NCGC00022715-03; BRD-K48168960-001-04-4; 51-52-5; 2-Thio-6-propyl-1,3-pyrimidin-4-one; 46698_RIEDEL; Propiltiouracile [DCIT]; NCGC00016229-02; HMS1766D22; 6-N-Propylthiouracil; 6-propyl-2-sulfanylidene-2,3-dihydropyrimidin-4(1H)-one; NINDS_000268; Propiltiouracilo [INN-Spanish]; BRD-K48168960-001-05-1; 6-Propil-tiouracile; Propycil; KBio2_006492; Propylthiorit; Propyl-Thyracil; PTU (thyreostatic); 6-Propil-tiouracile [Italian]; 2-Mercapto-6-propylpyrimidin-4-ol; HMS2092E03; LS-158; HC210060; Propylthiouracil (JP15/USP/INN); NCGC00090881-01; Propilthiouracil; Spectrum2_001302; WLN: T6MYMVJ BUS F3; Spectrum_000876; BSPBio_000387; 6-Propyl-2-thio-2,4(1H,3H)pyrimidinedione; Prothiucil; 6-Propyl-2-thiouracil; HMS500N10; MLS000028494; EINECS 200-103-2; Propiltiouracilo; MolPort-000-664-275; DivK1c_000268; KBio2_003924; MLS002303010; HMS1569D09; Prothycil; AKOS000120319; 6-propyl-2-thiopyrimidine-2,4(1H,3H)-dione; 2,3-Dihydro-6-propyl-2-thioxo-4(1H)-pyrimidinone; Prestwick3_000494; NCGC00183321-01; NCGC00090881-02; 6 Propyl 2 Thiouracil; HMS1920L22; thyreostat propyl-thyracil; AKOS001053246; Spectrum5_001815; Propylthiouracile; CID657298; D00562; NSC70461; NCGC00016229-01; ZINC18213075; D011441; CHEMBL1518; IDI1_000268; MolPort-000-145-889; 6-(n-Propyl)-2-thiouracil; 6-Propyl-2-thio-2,4(1H,3H)-pyrimidinedione; Uracil, 6-propyl-2-thio-; 2-Mercapto-6-propyl-4-pyrimidone; BPBio1_000427; T0517-6237; Propylthiouracil [INN:BAN:JAN]; 2-Thio-4-oxo-6-propyl-1,3-pyrimidine; CPD000058275; NCGC00090881-03; S1988_Selleck; DB00550; C7H10N2OS; F3097-4245; Propylthiouracilum; 2-Mercapto-6-propylpyrimid-4-one; I03-0144; 46698_FLUKA; 4-Hydroxy-2-mercapto-6-propylpyrimidine; KBioGR_001003; Propylthiouracile [INN-French]; AI3-25477; SAM002554926; propylthiouracil; NSC6498; 4-Propyl-2-thiouracil; Thyreostat II; Propacil; SPBio_002308; CAS-51-52-5; NSC 6498; Propythiouracil; SBB003855; AC-10795; MolPort-004-414-251; Prestwick0_000494; Propyl-Thiorit; Protiural; 6-Prop yl-2-thiouracil; Propyl-Thiorist; SPECTRUM1500515; C07569; ptu(thyreostatic); UNII-721M9407IY; CHEBI:8502; 6-propyl-2-sulfanylidene-1H-pyrimidin-4-one; Prestwick1_000494; CPD-11429; KBio3_002622; InChI=1/C7H10N2OS/c1-2-3-5-4-6(10)9-7(11)8-5/h4H,2-3H2,1H3,(H2,8,9,10,11; 500-50-5; 6-n-PROPYL-2-MERCAPTO-4-HYDROXYPYRIMIDINE; 2-Mercapto-4-hydroxy-6-n-propylpyrimidine; 6-Propylthiouracil; KBio2_001356; Prestwick2_000494; Spectrum3_001731; 6-Thio-4-propyluracil; Prestwick_810; Propiltiouracile; P3755_SIGMA; P0533; 6-propyl-2-thioxo-2,3-dihydropyrimidin-4(1H)-one; Propylthiouracil (TN); SMR000058275; Prothyran; KBio1_000268; 4(1H)-Pyrimidinone, 2,3-dihydro-6-propyl-2-thioxo-; NCGC00178089-01; 6-propyl-2 thiouracil; AC1LCWBA; SPBio_001363; 6-N-Propyl-2-thiouracil; Prothiurone; CCRIS 544; HSDB 3390; Spectrum4_000492; NCGC00178089-02; Thiuragyl; BSPBio_003402; ZINC04640636; Procasil	51-52-5	657298	9772	TTDS00380	Thyroid peroxidase	Thyroperoxidase;TPO	P07202	7173	ENSG00000115705	inhibitor
DAP000762	Carbimazole	CHEBI:617099; 3-Methyl-2-thioxo-4-imidazoline-1-carboxylic acid ethyl ester; Carbimazol henning (TN); NCGC00016760-01; NCGC00177988-02; Neo-Thyreostat; Carbotiroid; Carbethoxymethimazole; Thyrostat; Prestwick_788; 4-24-00-00064 (Beilstein Handbook Reference); D07616; Athyromazole; Mertiran; Prestwick0_000439; 1H-Imidazole-1-carboxylic acid, 2,3-dihydro-3-methyl-2-thioxo-, ethyl ester; AC1L1KVD; Carbimazol [INN-Spanish, French]; BSPBio_000458; Carbimazol; AC-10285; Spectrum2_001251; KBio3_002918; CID31072; Prestwick3_000439; Carbimazole (INN); AKOS001647527; DB00389; Carbinazole; Spectrum3_001968; I06-0843; Carbimazole [INN:BAN:DCF]; CHEMBL508102; HMS1569G20; Carbimazole; Carbimazol spofa; SPECTRUM1505323; SBB058031; BSPBio_003568; Carbimazolum [INN-Latin]; ethyl 3-methyl-2-sulfanylideneimidazole-1-carboxylate; CAS-22232-54-8; Basolest; Neo-Mercazole; NCGC00095167-02; Ethyl 3-methyl-2-thioimidazoline-1-carboxylate; 1-Ethoxycarbonyl-3-methyl-2-thioimidazol; EINECS 244-854-4; TYRAZOL; C07615; AC1Q7F0E; Prestwick1_000439; Carbimazolum; Atirozidina; Neo-Tireol; 1-Ethoxycarbonyl-3-methyl-2-thioxo-4-imidazoline; 1H-Imidazole-1-carboxylic acid, 2,3-dihydro-3-methyl-2-thioxo, ethyl ester; NCGC00177988-01; HMS1922D12; Neomercazole; NCGC00095167-01; 4-Imidazoline-1-carboxylic acid, 3-methyl-2-thioxo-, ethyl ester; ZINC00001091; BRN 0144339; BPBio1_000504; Carbimazol henning; BRD-K87156652-001-05-1; CG1; MolPort-003-666-636; cg 1; SPBio_002397; Prestwick2_000439; 22232-54-8; Ethyl 3-methyl-2-thioxo-2,3-dihydro-1H-imidazole-1-carboxylate; LS-79591; SPBio_001182	22232-54-8	31072	9817	TTDS00380	Thyroid peroxidase	Thyroperoxidase;TPO	P07202	7173	ENSG00000115705	inhibitor
DAP000763	Methimazole	1,3-Dihydro-1-Methyl-2H-Imidazol-2-Thione; Thiamazol Henning; Mercasolyl; EINECS 200-482-4; Eli Lilly Brand of Methimazole; 1-Methyl-2-Imidazolethione; Philopharm Brand of Methimazole; Thycapsol; 46429_RIEDEL; Strumazol; Thiamazolum [INN-Latin]; HMS2094C05; Tirodril; M8506_FLUKA; Imidazole-2-thiol, 1-methyl-; Tapazole; 63760_FLUKA; MLS000028413; 301507_ALDRICH; IDI1_000188; Thyrozol; Henning Berlin Brand of Methimazole; CAS-60-56-0; 2-Mercaptomethylimidazole; KBio3_001489; Sanofi Synthelabo Brand of Methimazole; BPBio1_000982; 2-Mercapto-1-methylimidazole; Thiamazol [INN-French]; Prestwick0_000786; AC1LQFQZ; I09-0350; 60-56-0; DivK1c_000188; Thimazol; Merkazolil; Basolan; Thimazole; 1-Methyl-imidazole-2-thiol; NCGC00016273-01; Thymidazol; Methiamazole; 1,3-Dihydro-1-methyl-2H-imidazole-2-thione; Tapuzole; 3-methyl-1H-imidazole-2-thione; C4H6N2S; Methizol; Thiamazol Hexal; 1-METHYL-1,3-DIHYDRO-2H-IMIDAZOLE-2-THIONE; BB_SC-1357; Spectrum4_000048; KBio1_000188; Metizol; M8506_SIGMA; 1-Methylimidazole-2-thiol; methimazole; Temmler Brand of Methimazole; S1609_Selleck; Prestwick3_000786; CHEMBL1515; Spectrum5_000954; LS-7490; Frentirox; 46429_FLUKA; CID1349907; Usaf el-30; Methamazole; Methimazol; Prestwick1_000786; SAM002548951; Methimazolum; AKOS000269708; HSDB 3361; Henning, Thiamazol; MolPort-000-563-838; SMR000058376; MMZ; Mercazolyl; Thycapzol; Spectrum3_000495; Metazolo; AKOS000119427; UNII-554Z48XN5E; Imidazole-2-thiol,1-methyl-; Metisol; Hexal Brand of Methimazole; Spectrum_000995; STK802184; Mestinon, Regonol, Pyridostigmine Bromide; KBioGR_000515; Hexal, Thiamazol; Mercazol; Merkastan; HMS2091D12; BSPBio_001989; HMS500J10; Metothyrin; Thiamazole (JP15/INN); ZINC01187543; NCGC00016273-02; Tiamazolo [DCIT]; Strumazole; SPBio_001266; WLN: T5N CNJ A BSH; KBio2_006611; 85916-84-3; CPD000058376; AC-785; D008713; Bio-0823; Methimazole (USP); 1-Methyl-1,3-dihydroimidazole-2-thione; 1-Methyl-2-imidazolethiol; Methylmercaptoimidazole; 2H-Imidazole-2-thione, 1,3-dihydro-1-methyl-; Metothyrine; N-Methyl-2-mercaptoimidazole; Metimazol; NINDS_000188; Mercaptazole; Thacapzol; BIDD:GT0163; Mercazolylum; 1-Methylimidazole-2(3H)-thione; Methymazol; NCGC00094721-02; HMS1920L17; Thiamazolum; MolPort-002-508-019; 1-Methyl-1H-imidazole-2-thiol; 1 Methyl 2 mercaptoimidazole; Jones Brand of Methimazole; thiamazole; DB00763; KBio2_001475; Tapazole (TN); Prestwick2_000786; Thymidazole; 1-Methyl-2-mercaptoimidazole; Estedi Brand of Methimazole; M0868; Tiamazolo; SPECTRUM1500396; HMS2090B17; 1-Metylo 2 merkaptoimidazolem [Polish]; Tiamazol; AI3-60285; Metotirin; Spectrum2_001273; NSC 38608; Favistan; NSC38608; 1-Metylo 2 merkaptoimidazolem; Merck Brand of Methimazole; NCGC00178875-01; BSPBio_000892; Imidazole, 1-methyl-2-mercapto-; NCGC00094721-01; KBioSS_001475; SPBio_002831; Mercazole; HMS1570M14; Danantizol; STK300018; 4-Imidazoline-2-thione, 1-methyl-; CPD-11282; KBio2_004043; D00401; CHEBI:50673; Thiamazol; Tiamazol [INN-Spanish]; Prestwick_1010; Methimazole [USAN:BAN]; Nourypharma Brand of Methimazole; AC1Q3Z01	60-56-0	1349907	7847467	TTDS00380	Thyroid peroxidase	Thyroperoxidase;TPO	P07202	7173	ENSG00000115705	inhibitor
DCL001211	MEDI-575	N/A	N/A	N/A	N/A	TTDC00311	Alpha platelet-derived growth factor receptor	CD140a antigen;PDGF-R-alpha;Platelet-derived growth factor receptor alpha	P16234	5156	ENSG00000134853	antibody
DCL000654	TAK-593	N/A	N/A	N/A	N/A	TTDC00311	Alpha platelet-derived growth factor receptor	CD140a antigen;PDGF-R-alpha;Platelet-derived growth factor receptor alpha	P16234	5156	ENSG00000134853	inhibitor
DAP000002	Theophylline	Theonite; Duraphyllin; Slo Phyllin; Theopek; BIDD:ER0557; Prestwick2_000820; Uni-Dur; Dimethylxanthine; Constant-T; Lopac0_000014; DB00277; SPBio_002640; Theophyl-SR; Theo-Sav; Theodur Dry Syrup; Prestwick3_000820; aminophylline; Spectrum5_001232; CPD-12479; Bronchoparat; Prestwick2_000873; Prestwick1_000873; CID2153; Theo-Nite; KBio2_006654; Theospan; MolPort-001-737-342; 1,3 Dimethylxanthine; NCGC00018117-01; KBio3_001583; AKOS000120961; Slo-bid; Afonilum Retard; Spectrum4_000353; Talotren; Theolix; Lanophyllin; 1H-purine-2,6-dione; Elixicon; Uniphyl; MLS002153487; HSDB 3399; Bronchoretard; Elixophyllin (TN); KBio2_004086; BIDD:GT0151; SMR000058537; Theacitin; Teocen 200; Aerolate SR; Theo-24; SAM002554935; Teofyllamin; Pseudotheophylline; MolPort-001-002-058; Theoclear L.A.-130; Physpan; Nuelin S.A.; MLS000069390; SloPhyllin; Theo-dur; Theo-Dur-Sprinkle; Pulmo-Timelets; C07130; BCBcMAP01_000071; NCGC00022112-11; Optiphyllin; Teofilina [Polish]; Doraphyllin; BPBio1_000791; Quibron T/SR; AC-20328; Quibron-t (TN); CCRIS 4729; Theobid Duracap; Pro-vent; Nuelin S.A; Asmalix; Elixophyllin; NCI60_001736; NCGC00022112-03; 46157-00-0; Uniphyl (TN); Theodur; Prestwick3_000873; Quibron T-SR; 58-55-9; Theodur G; CPD000058537; Somophyllin-t; Theolair; Teofilina; Theochron; ct, theo von; Nuelin SA; Uniphyllin; CHEMBL190; SomophyllinT; Egifilin; NSC2066; BPBio1_001041; Theodrip; Theotard; Theophyllin; Spectrum2_000842; Constant T; Theodel; SPBio_002866; Theona P; Unifyl; Etheophyl; Uniphyllin continus; NCGC00022112-07; Austyn; Euphylong; 56645-32-0; Solosin; Elixomin; Nuelin; HMS2089A06; 1,3-Dimethylxanthine; PDSP1_001234; S1621_Selleck; Xanthium; Prestwick0_000873; NCGC00022112-08; Theo24; T0179; Spectrum_001038; Theolair (TN); Theo-11; HMS500K05; Bronkodyl SR; GS 2591A; nchembio.273-comp2; Choledyl SA; Synophylate; Afonilm; Theoclear-80; Somophyllin T; Uniphylline; Teonova; Theophyl; Quibron TSR; T1633_SIGMA; Bronkotabs; D013806; theo von ct; PDSP2_001218; Theolair-SR; NINDS_000203; Somophyllin CRT; Respid; AI3-50216; SMP1_000291; Asmax; Bronchodid Duracap; CHEBI:28177; LS-241; Accurbron; Aerolate III; Tefamin; Quibron T SR; Telbans Dry Syrup; Theostat 80; Quibron T; HMS2092M05; Elixex; Quibron-T; Theocontin; Xantivent; Theoclear 80; Theobid; T9031_SIGMA; ConstantT; IDI1_000203; KBioSS_001518; KBio1_000203; Theovent; Afonilum; Theodur G (TN); KBio2_001518; AB00052106; Prestwick1_000820; Theoclear-200; Theo-DS; UPCMLD-DP123; Theo-Organidin; Tesona; Theo 24; ZINC18043251; Chronophyllin; Mudrane; Unilong; Theophyl-225; Theophyline; D00371; LaBID; T7770_SIGMA; EINECS 200-385-7; C7H8N4O2; Theofol; 2a3a; BSPBio_002363; NCGC00022112-09; Aerolate; Sustaire; KBioGR_000785; Armophylline; Maphylline; Cetraphylline; T4924_SIGMA; NCGC00022112-04; Theograd; NCGC00022112-10; Quibron-T/SR; Quibron; Theocin; Telb-DS; UPCMLD-DP123:001; Spophyllin retard; Aquaphyllin; Respbid; NCGC00022112-05; Somophyllin-CRT; Theophylline-[8-3H; Aerobin; Somophyllin-DF; Hylate; Teosona; Theostat; Theoclear LA; PDSP2_001002; SPECTRUM1500568; Liquophylline; Theophylline (JP15); Theoclair-SR; PDSP1_001018; 75448-53-2; Elixophylline; Theokin; Theolixir; Acet-theocin; L000595; Parkophyllin; von ct, theo; BSPBio_000945; Theobid Jr.; Bilordyl; T-Phyl; Theophylline-SR; BSPBio_000719; Elixophyllin SR; ST024762; Prestwick0_000820; Respicur; Duraphyl; Theo-24 (TN); Theoplus; HMS1921E03; Theal tablets; AC1L1D1F; Elixophyllin(e); SPBio_000823; THEOBID JR; LASMA; Pulmidur; MLS002152943; Theoclear; Diffumal; Spectrum3_000672; STK397040; NSC 2066; Medaphyllin; Theo Dur; Slo-phyllin; Teolair; Labophylline; X 115; theophylline; Bronkodyl; NCGC00018117-16; DivK1c_000203; UNII-0I55128JYK; 111079-49-3	58-55-9	2153	7847437	TTDS00185	Adenosine receptor	N/A	N/A	N/A	N/A	antagonist
DCL001075	PD-0332991	EC-000.2350; 6-ACETYL-8-CYCLOPENTYL-5-METHYL-2-[(5-PIPERAZIN-1-YLPYRIDIN-2-YL)AMINO]PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE; PD-332991; CHEMBL189963; S1116_Selleck; CID5330286; Pyrido(2,3-d)pyrimidin-7(8H)-one, 6-acetyl-8-cyclopentyl-5-methyl-2-((5-(1-piperazinyl)-2-pyridinyl)amino)-; LQQ; 6-acetyl-8-cyclopentyl-5-methyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one; 2euf; Kinome_3823; 6-Acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-ylpyridin-2-ylamino)-8H-pyrido(2,3-d)pyrimidin-7-one; PD0332991; 571190-30-2; PD 332991, PD 0332991, PD0332991; AC1NS8RV; Kinome_3824; PD-0332991; PD 0332991	N/A	N/A	N/A	TTDC00169	Cell division protein kinase 6	CDK6;Cyclin-dependent kinase 6;Serine/threonine protein kinase PLSTIRE;Serine/threonine-protein kinase PLSTIRE	Q00534	1021	ENSG00000105810	inhibitor
DCL000077	Capridine-beta	666854-78-0; CC-10004; UNII-UP7QBP99PN; CC 10004; Apremilast; D08860; CID11561674; Apremilast (USAN); CHEMBL514800; CHEBI:558773; N-[2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methylsulfonyl-ethyl]-1,3-dioxo-isoindol-4-yl]acetamide	N/A	N/A	N/A	TTDC00169	Cell division protein kinase 6	CDK6;Cyclin-dependent kinase 6;Serine/threonine protein kinase PLSTIRE;Serine/threonine-protein kinase PLSTIRE	Q00534	1021	ENSG00000105810	inhibitor
DAP001314	Benzylpenicilloyl Polylysine	AC1L3OEE; CHEMBL1201779; 2-(2-((5-Carboxypentyl)amino)-2-oxo-1-((phenylacetyl)amino)ethyl)-5,5-dimethyl-4-thiazolidinecarboxylic acid; CID119212; 2642-55-9; benzylpenicilloyl G polylysine; Penicilloyl-polylysine; Benzylpenicilloyl; AR-1H9694; 2-[2-[(6-hydroxy-6-oxohexyl)amino]-2-oxo-1-[(2-phenylacetyl)amino]ethyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid; benzylpenicilloyl-polylysine; DB00895; 4-Thiazolidinecarboxylic acid, 2-(2-((5-carboxypentyl)amino)-2-oxo-1-((phenylacetyl)amino)ethyl)-5,5-dimethyl-; Benzylpenicilloyl G; Benzylpenicilloyl polylysine; AC1Q5KWZ; CHEBI:59297; LS-187378	2642-55-9	119212	695873	TTDS00484	High affinity immunoglobulin epsilon receptor	Fc-epsilon RI-gamma;FCER1G;FceRI gamma;IgE Fc receptor subunit gamma	P30273	2207	ENSG00000158869	binder
DAP001293	Nitazoxanide	Salicylamide, N-(5-nitro-2-thiazolyl)-, acetate (ester); Nitazoxanid; SMR000466367; N-(5-Nitro-2-thiazolyl)salicylamide acetate (ester); Colufase; Daxon, Dexidex, Kidonax, Pacovanton, Paramix, Nitax, Zox, Nitazoxanide; Nitazoxanida; o-(N-(5-Nitrothiazol-2-yl)carbamoyl)phenyl acetate; LS-144176; NSC 697855; Taenitaz; NSC697855; Daxon; Alinia; 2-Acetyloxy-N-[(5-nitro-2-thiazolyl)]benzamide; Nitazoxanida [INN-Spanish]; NCGC00090774-01; Alinia (TN); Nitazoxanidum; STK395664; NITAZOXANIDE; MolPort-002-042-244; azt+ nitazoxanide; CHEMBL1401; Benzamide, 2-(acetyloxy)-N-(5-nitro-2-thiazolyl)-; Cryptaz; FT-0082459; I14-6011; Tizoxanide glucuronide; [2-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl] acetate; AC1Q5NVY; CID41684; C12H9N3O5S; SAM001246708; Nitazoxanide [USAN:INN]; D02486; ZINC03956788; EINECS 259-931-8; Nitazoxanide (USAN/INN); CPD000466367; Oprea1_263587; AC1L26A1; DB00507; 2-(Acetolyloxy)-N-(5-nitro-2-thiazolyl)benzamide; BRN 1225475; 2-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl acetate; UNII-SOA12P041N; Phavic-1; (2-((5-Nitro-2-thiazolyl)carbamoyl)phenyl)acetat; AZT + Nitazoxanide; 55981-09-4; NCI60_034935; AC-1302; SBB068315; HMS2051L04; N-(5-Nitrothiazol-2-yl)salicylamide acetate ester; MLS000759492; Nitazoxanidum [INN-Latin]; MLS001424074; S1627_Selleck; NCIMech_000843; Heliton; 2-Acetyloxy-N-[(5-nitro-2-thiazolyl)]benzamide; Salicylamide, N-(5-nitro-2-thiazolyl)- acetate (ester)	55981-09-4	41684	182380	TTDS00455	Parasitic pyruvate:ferredoxin oxidoreductase	N/A	N/A	N/A	N/A	inhibitor
DCL000936	Pramlintide	L-Tyrosinamide, L-lysyl-L-cysteinyl-L-asparaginyl-L-threonyl-L-alanyl-L-threonyl-L-cysteinyl-L-alanyl-L-threonyl-L-glutaminyl-L-arginyl-L-leucyl-L-alanyl-L-asparaginyl-L-phenylalanyl-L-leucyl-L-valyl-L-histidyl-L-seryl-L-seryl-L-asparaginyl-L-asparaginyl-L-phenylalanylglycyl-L-prolyl-L-isoleucyl-L-leucyl-L-prolyl-L-prolyl-L-threonyl-L-asparaginyl-L-valylglycyl-L-seryl-L-asparaginyl-L-threonyl-, cyclic (2-7)-disulfide; AC0137; AC 0137; 187887-46-3; Pramlintide acetate; Pramlintide; Amylin (human) , 25-L-proline-28-L-proline-29-L-proline-; Pramlintide [USAN]; UNII-726I6TE06G; UNII-D3FM8FA78T; Triproamylin; 196078-30-5; 151126-32-8; LS-181996; LS-188084; Symlin; Pramlintide acetate hydrate; Pramlintide acetate [USAN]	151126-32-8	N/A	47207257	TTDS00440	Glucagon-like peptide 1 receptor	GLP-1 receptor;GLP-1R;GLP-1-R	P43220	2740	ENSG00000112164	agonist
DPR000189	ZP2929	N/A	N/A	N/A	N/A	TTDS00440	Glucagon-like peptide 1 receptor	GLP-1 receptor;GLP-1R;GLP-1-R	P43220	2740	ENSG00000112164	agonist
DCL000829	GTP-010	N/A	188039-54-5	N/A	47205815	TTDS00440	Glucagon-like peptide 1 receptor	GLP-1 receptor;GLP-1R;GLP-1-R	P43220	2740	ENSG00000112164	agonist
DCL001261	ZYOG1	N/A	N/A	N/A	N/A	TTDS00440	Glucagon-like peptide 1 receptor	GLP-1 receptor;GLP-1R;GLP-1-R	P43220	2740	ENSG00000112164	agonist
DCL000869	Liraglutide	NN2211; NN 2211; Liraglutida [INN-Spanish]; victoza; NN-2211; N26-(Hexadecanoyl-gamma-glutamyle)-(34-arginine)GLP-1-(7-37)-peptide; 204656-20-2; Liraglutidum; Liraglutide [USAN:INN]; UNII-839I73S42A; Liraglutidum [INN-Latin]; C439759; N26-(Hexadecanoyl-gamma-glutamyle)-(34-arginine)glucagon-like-peptide-1-(7-37)-peptide; Liraglutida; Liraglutide; Glycine, L-histidyl-L-alanyl-L-alpha-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-alpha-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-alpha-glutamylglycyl-L-glutaminyl-L-alanyl-L-alanyl-N6-(N-(1-oxohexadecyl)-L-gamma-glutamyl)-L-lysyl-L-alpha-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-arginylglycyl-L-arginyl-	204656-20-2	N/A	47208061	TTDS00440	Glucagon-like peptide 1 receptor	GLP-1 receptor;GLP-1R;GLP-1-R	P43220	2740	ENSG00000112164	agonist
DAP001038	Exenatide	UNII-9P1872D4OL; 335149-21-8; LY2148568; L-Serinamide, L-histidylglycyl-L-alpha-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-alpha-aspartyl-L-leucyl-L-seryl-L-lysyl-L-glutaminyl-L-methionyl-L-alpha-glutamyl-L-alpha-glutamyl-L-alpha-glutamyl-L-alanyl-L-valyl-L-arginyl-L-leucyl-L-phenylalanyl-L-isoleucyl-L-alpha-glutamyl-L-tryptophyl-L-leucyl-L-lysyl-L-asparaginylglycylglycyl-L-prolyl-L-seryl-L-serylglycyl-L-alanyl-L-prolyl-L-prolyl-L-prolyl-; Exenatide Synthetic; Exendin-4; AC 2993A; Exenatide; Extendin-4; 141732-76-5; Exendin 4; 286014-72-0; C074031; AC 2993 LAR; Exendin 4 (Heloderma suspectum); 141758-74-9; Byetta; CHEMBL414357; Ex4 peptide; CHEBI:490990; Exendin 3 (Heloderma horridum), 2-glycine-3-L-glutamic acid-; AC 2993	141758-74-9	15991534	47206069	TTDS00440	Glucagon-like peptide 1 receptor	GLP-1 receptor;GLP-1R;GLP-1-R	P43220	2740	ENSG00000112164	binder
DCL001210	MEDI-573	N/A	N/A	N/A	N/A	TTDR01003	Insulin-like growth factor IA	IGF-1;IGF-IA;Insulin-like growth factor-1;Somatomedin C	P01343	N/A	N/A	antibody
DCL001144	Anti-FGFR3	N/A	N/A	N/A	N/A	TTDC00131	Fibroblast growth factor receptor 3	FGFR3;FGFR-3	P22607	2261	ENSG00000068078	antibody
DCL000361	AEE-788	CID10297043; CHEMBL587723; AEE-788, NVP-AEE 788, AEE788; GNF-Pf-5343; CHEBI:40629; 497839-62-0; 1H-Pyrrolo(2,3-d)pyrimidin-4-amine, 6-(4-((4-ethyl-1-piperazinyl)methyl)phenyl)-N-((1R)-1-phenylethyl)-; CID 11578515; CID11578515; S1486_Selleck; AEE788; AEE; AEE 788	N/A	10297043	56464542	TTDC00131	Fibroblast growth factor receptor 3	FGFR3;FGFR-3	P22607	2261	ENSG00000068078	inhibitor
DCL000358	BMS-582664	CHEMBL270995; Brivanib alaninate (INN/USAN); BMS-582664, Brivanib alaninate; CID 11154925; BMS-582664; 649735-63-7; S1138_Selleck; D08878; L-Alanine, (1R)-2-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-5-methylpyrrolo(2,1-f)(1,2,4)triazin-6-yl)oxy)-1-methylethyl ester; UNII-U2Y5OFN795; BMS582664; BMS 582664; Brivanib alaninate; CID11154925	124495-31-4	130197	29308853	TTDC00131	Fibroblast growth factor receptor 3	FGFR3;FGFR-3	P22607	2261	ENSG00000068078	inhibitor
DCL000248	TKI258	CID 9977819; 4-Amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one; S1018_Selleck; CID9886808; EC-000.2257; 405169-16-6; CID9977819; UNII-I35H55G906; Chir 258; 804551-71-1; AKOS005146311; TKI-258; CHEMBL522892; CHEBI:594834; TKI-258, Dovitinib, CHIR258, TKI258; CHIR-258	804551-71-1	9886808	46147922	TTDC00131	Fibroblast growth factor receptor 3	FGFR3;FGFR-3	P22607	2261	ENSG00000068078	inhibitor
DCL000918	PD-158771	2-Pyrimidinamine, N-(4-(2-(4-phenyl-1-piperazinyl)ethyl)cyclohexyl)-, trans-; 189152-50-9; CHEMBL165679; CHEBI:374449; LS-134503; CID3075615; CHEBI:375533; trans-N-(4-(2-(4-Phenyl-1-piperazinyl)ethyl)cyclohexyl)-2-pyrimidinamine; PD 158771; L015054; N-[4-[2-(4-phenylpiperazin-1-yl)ethyl]cyclohexyl]pyrimidin-2-amine; AC1MIP35; CHEMBL164984	N/A	9841667	49684220	TTDS00013	D(3) dopamine receptor	Dopamine receptor 3	P35462	1814	ENSG00000151577	antagonist
DCL000976	SB-277011	215803-78-4; CHEMBL85606; SB-277011; CHEBI:237398; SB 277011; 4-Quinolinecarboxamide, N-(trans-4-(2-(6-cyano-3,4-dihydro-2(1H)-isoquinolinyl)ethyl)cyclohexyl)-; CID5311096; SB 277011A; SB 277011-A; PDSP1_000723; LS-192656; N-[4-[2-(6-cyano-3,4-dihydro-1H-isoquinolin-2-yl)ethyl]cyclohexyl]quinoline-4-carboxamide; PDSP2_000713; AC1NSJZE; L000710	304853-42-7	4369524	47207661	TTDS00013	D(3) dopamine receptor	Dopamine receptor 3	P35462	1814	ENSG00000151577	antagonist
DCL000916	PD-157533	N/A	N/A	N/A	N/A	TTDS00013	D(3) dopamine receptor	Dopamine receptor 3	P35462	1814	ENSG00000151577	antagonist
DCL000732	BTS-79018	N/A	170353-17-0	N/A	N/A	TTDS00013	D(3) dopamine receptor	Dopamine receptor 3	P35462	1814	ENSG00000151577	binder
DCL000934	PNU-177864	N/A	192231-16-6	444972	49746076	TTDS00013	D(3) dopamine receptor	Dopamine receptor 3	P35462	1814	ENSG00000151577	antagonist
DCL000709	AVE-5997EF	N/A	N/A	N/A	N/A	TTDS00013	D(3) dopamine receptor	Dopamine receptor 3	P35462	1814	ENSG00000151577	antagonist
DCL000925	Pfizer 10	N/A	N/A	N/A	N/A	TTDS00013	D(3) dopamine receptor	Dopamine receptor 3	P35462	1814	ENSG00000151577	agonist
DCL000384	GSK618334	N/A	162359-56-0	107970	47206133	TTDS00013	D(3) dopamine receptor	Dopamine receptor 3	P35462	1814	ENSG00000151577	antagonist
DCL000973	Sarizotan	AC1MHW5N; 1-(3,4-dihydro-2H-chromen-2-yl)-N-[[5-(4-fluorophenyl)pyridin-3-yl]methyl]methanamine; CID3058747; L001578; UNII-467LU0UCUW; Sarizotan; N-((3,4-Dihydro-2H-1-benzopyran-2-yl)methyl)-5-(4-fluorophenyl)-3-pyridinemethanamine; EMD 128130; 177975-08-5; (-)-3-((((R)-2-Chromanylmethyl)amino)methyl)-5-(p-fluorophenyl)pyridine; Sarizotan [INN]; LS-192590	177976-12-4	3058747	3862729	TTDS00013	D(3) dopamine receptor	Dopamine receptor 3	P35462	1814	ENSG00000151577	agonist
DAP000068	Ropinirole	Ropinirole (INN); 2H-Indol-2-one, 4-(2-(dipropylamino)ethyl)-1,3-dihydro-; Ropinirole [INN:BAN]; Lopac0_001101; SKF 101468; BRD-K15933101-003-01-2; 91374-21-9; NCGC00096064-01; SK&F-101,468; Ropinirolum [INN-Latin]; UNII-030PYR8953; 4-[2-(Dipropylamino)ethyl]-1,3-dihydro-2H-indol-2-one; 4-[2-(Dipropylamino)ethyl]indoline-2-one; Ropinirole; SKF 101468; BIDD:GT0826; Ropitor; CHEMBL589; NCGC00096064-02; MolPort-003-666-598; SPECTRUM1505178; Ropinirol [INN-Spanish]; Ropitor (TN); D08489; ropinirol; L000520; AC1L1JLL; NCGC00015893-01; ReQuip XL; CID5095; C07564; CHEBI:8888; AB1004799; TL8005859; LS-83890; Lopac-R-4152; Ropinirolum; 2H-Indol-2-one, 4-[2-(dipropylamino)ethyl]-1,3-dihydro-; DB00268; I06-0692; 4-[2-(dipropylamino)ethyl]-1,3-dihydro-2H-indol-2-one; HMS2093K04; SK&F 101468; ropinirole; ReQuip CR; 4-[2-(dipropylamino)ethyl]-1,3-dihydroindol-2-one; NCGC00015893-04; 91374-20-8 (hydrochloride)	91374-21-9	5095	7980537	TTDS00013	D(3) dopamine receptor	Dopamine receptor 3	P35462	1814	ENSG00000151577	agonist
DCL000383	GSK598809	N/A	N/A	N/A	N/A	TTDS00013	D(3) dopamine receptor	Dopamine receptor 3	P35462	1814	ENSG00000151577	antagonist
DCL000728	BP4.879a	N/A	N/A	5311254	47586782	TTDS00013	D(3) dopamine receptor	Dopamine receptor 3	P35462	1814	ENSG00000151577	antagonist
DCL001028	U-99194A	PNU-99194A; AC1L3OD5; 5,6-Dimethoxy-N,N-dipropyl-2,3-dihydro-1H-inden-2-amine hydrochloride; AR-1G6208; CHEMBL543760; AC1Q3DK0; 1H-Indan-2-amine, 2,3-dihydro-5,6-dimethoxy-N,N-dipropyl-, hydrochloride; U 99194; Pnu 99194A; C086335; u-99194a; U 99194A; LS-183373; CID119195; 5,6-Dimethoxy-2-(dipropylamino)indan hydrochloride; 5,6-dimethoxy-2-(di-n-propylamino)indan; (5,6-dimethoxyindan-2-yl)dipropylamine; LS-173451; 5,6-Dimethoxy-N,N-dipropyl-2,3-dihydro-1H-indan-2-amine; U-99194; 1H-Inden-2-amine, 2,3-dihydro-5,6-dimethoxy-N,N-dipropyl-, hydrochloride; 153570-58-2; 5,6-dimethoxy-n,n-dipropyl-2,3-dihydro-1h-inden-2-amine hydrochloride(1:1)	83598-46-3	27991	695854	TTDS00013	D(3) dopamine receptor	Dopamine receptor 3	P35462	1814	ENSG00000151577	binder
DAP000019	Pramipexole	(6S)-N6-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine; Pramipexole [USAN:INN]; SAM001247006; Spectrum_001838; 111GE001; HMS2051A21; LS-40722; SUD919CL2Y; Pramipexolum; 2-amino-4,5,6,7-tetrahydro-6-propylaminobenzothiazole; SpecPlus_000820; DivK1c_006916; KBioSS_002343; Mirapex; KBio2_007476; Pramipexole (USAN/INN); C10H17N3S; 2,6-Benzothiazolediamine, 4,5,6,7-tetrahydro-N(sup 6)-propyl-, (S)-; CPD000449298; MolPort-003-849-957; CHEBI:8356; (6S)-6-N-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine; BIDD:GT0250; CID119570; 2,6-Benzothiazolediamine, 4,5,6,7-tetrahydro-N6-propyl-, (S)-; KBio2_002340; MLS001423952; MLS000758250; Pramipexol; HMS2090C15; (-)-Pramipexole; 104632-26-0; KBio1_001860; NCGC00167441-01; U-98528E; 2-amino-6-propylaminotetrahydrobenzothiazole; Spectrum5_001453; SND-919; CHEMBL301265; (6S)-N(6)-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine; D05575; SBB070477; pramipexole; (S)-2-Amino-4,5,6,7-tetrahydro-6-(propylamino)benzothiazole; KBio2_004908; AC1L3P1T; SMR000449298	104632-26-0	59868	196318	TTDS00013	D(3) dopamine receptor	Dopamine receptor 3	P35462	1814	ENSG00000151577	agonist
DPR000095	RGH-1756	N/A	207277-37-0	5275	49699088	TTDS00013	D(3) dopamine receptor	Dopamine receptor 3	P35462	1814	ENSG00000151577	antagonist
DCL000917	PD-157695	N/A	N/A	3854666	49684195	TTDS00013	D(3) dopamine receptor	Dopamine receptor 3	P35462	1814	ENSG00000151577	antagonist
DCL000595	PF-217830	PF-00217830; CID11697676; 7-[4-(4-naphthalen-1-ylpiperazin-1-yl)butoxy]-3,4-dihydro-1H-1,8-naphthyridin-2-one; PF-217830	193275-84-2	148195	49704087	TTDS00013	D(3) dopamine receptor	Dopamine receptor 3	P35462	1814	ENSG00000151577	antagonist
DPR000103	S32504	N/A	220932-72-9	N/A	N/A	TTDS00013	D(3) dopamine receptor	Dopamine receptor 3	P35462	1814	ENSG00000151577	agonist
DCL001049	HGTV43	N/A	N/A	N/A	N/A	TTDC00274	mRNA of HIV Tar and Tat/Rev	N/A	N/A	N/A	N/A	antisense
DCL000006	SNS-314	SN-314; SNS-314; DB07361; CHEMBL518051; Kinome_3712; AK2	76721-89-6	3132	49700751	TTDC00059	Serine/threonine-protein kinase 13	Aurora/Ipl1/Eg2 protein 2;Aurora/Ipl1-related kinase 3;Aurora-C	Q9UQB9	6795	ENSG00000105146	inhibitor
DCL001072	GSK1070916	CHEBI:722556; AKOS005145558; CHEMBL1090479; GSK-1070916	N/A	N/A	N/A	TTDC00059	Serine/threonine-protein kinase 13	Aurora/Ipl1/Eg2 protein 2;Aurora/Ipl1-related kinase 3;Aurora-C	Q9UQB9	6795	ENSG00000105146	inhibitor
DCL000420	Alicaforsen	Intercellular adhesion molecule-1 antisense oligodeoxynucleotide; 185229-68-9; DNA, d((R)-P-thio)(G-C-C-A-A-G-C-T-G-G-C-A-T-C-C-G-T-C-A); Deoxyribonucleic acid, d((R)-P-thio)(G-C-C-C-A-A-G-C-T-G-G-C-A-T-C-C-G-T-C-A); ISIS 2302; LS-63362; ISIS-2302; Alicaforsen; Alicaforsen [INN]	185229-68-9	16197724	733439	TTDC00192	mRNA of Intercellular adhesion molecule-1	CD54 antigen;ICAM-1;Major group rhinovirus receptor	P05362	3383	ENSG00000090339	antisense
DCL001252	Vidofludimus	N/A	N/A	N/A	N/A	TTDC00214	Interleukin-17	CTLA-8;Cytotoxic T lymphocyte-associated antigen 8;IL-17;IL-17A	Q16552	3605	ENSG00000112115	inhibitor
DCL000685	AIN457	N/A	N/A	N/A	N/A	TTDC00214	Interleukin-17	CTLA-8;Cytotoxic T lymphocyte-associated antigen 8;IL-17;IL-17A	Q16552	3605	ENSG00000112115	inhibitor
DCL001055	Antisense TAR and RevM10	N/A	N/A	N/A	N/A	TTDC00284	mRNA of HIV reverse transcriptase	N/A	N/A	N/A	N/A	antisense
DAP001333	Arsenic trioxide	UN 1561; HSDB 419; UN1561; CHEMBL405991; AC1L24QX; arsenic(3+); oxygen(2-); Acide arsenieux [French]; EINECS 215-481-4; Arsenic blanc [French]; Arsenic trioxide [UN1561]  [Poison]; Rcra waste number P012; Arsenious trioxide; AI3-01163; D02106; EPA Pesticide Chemical Code 007001; Anhydride arsenieux [French]; Arsentrioxide; Arsenic trioxide [JAN]; Caswell No. 059; naonobin; CCRIS 5455; Oxyde Arsenieux [ISO-French]; Arseni trioxydum; Arsenious Acid Anhydride; UNII-S7V92P67HO; Arsenic trioxide (JP15/USAN); Arsenous oxide [ISO]; Trixenox; Arsenic(III) trioxide; Trisenox (TN); C006632; MolPort-006-823-587; Arsenic oxide (As2O3); 28380-38-3; RCRA waste no. P012; CID14888; Oxyde Arsenieux; Arsenox; Trisenox; Arsenigen saure [German]; LS-761	1327-53-3	518740	10506726	TTDS00464	Malignant cancer cells	N/A	N/A	N/A	N/A	inhibitor
DCL001228	RG3039	N/A	N/A	N/A	N/A	TTDC00341	Scavenger decapping enzyme DcpS	Scavenger mRNA-decapping enzyme DcpS;DCS-1;Hint-related 7meGMP-directed hydrolase;Histidine triad protein member 5;HINT-5;DCPS	Q96C86	28960	ENSG00000110063	inhibitor
DCL000138	Isofagomine tartrate	NN-42-1007; Plicera; HGT-3410; Isofagomine tartrate; Afegostat tartrate; AT-2101	71142-71-7	3036757	36104859	TTDC00014	Glucosylceramidase	Acid beta-glucosidase;Alglucerase;Beta-glucocerebrosidase;D-glucosyl-N-acylsphingosine glucohydrolase;Imiglucerase	P04062	2629	ENSG00000177628	inhibitor
DCL000516	Denosumab	Denosumab (USAN); Denosumab (genetical recombination); Denosumab; 615258-40-7; D03684; Denosumab (genetical recombination) (JAN)	615258-40-7	N/A	17397780	TTDC00224	Tumor necrosis factor ligand superfamily member 11	ODF;OPGL;Osteoclast differentiation factor;Osteoprotegerin ligand;RANKL;Receptor activator of nuclear factor kappa B ligand;TNF-related activation-induced cytokine;TRANCE	O14788	8600	ENSG00000120659	antibody
DCL000094	CRF-1 antagonist	N/A	N/A	N/A	N/A	TTDC00073	Corticotropin releasing factor receptor 1	Corticotropin-releasing hormone receptor 1;Corticotropin-releasing hormone type 1 receptor;CRF receptor;CRF1;CRF-1 receptor;CRF-R;CRF-R1;CRH-R 1	P34998	1394	ENSG00000120088	antagonist
DCL000757	CP-316,311	CID9818802; CHEMBL270738; CP-316311	N/A	9818802	74515667	TTDC00073	Corticotropin releasing factor receptor 1	Corticotropin-releasing hormone receptor 1;Corticotropin-releasing hormone type 1 receptor;CRF receptor;CRF1;CRF-1 receptor;CRF-R;CRF-R1;CRH-R 1	P34998	1394	ENSG00000120088	antagonist
DCL000382	GSK586529	N/A	N/A	N/A	N/A	TTDC00073	Corticotropin releasing factor receptor 1	Corticotropin-releasing hormone receptor 1;Corticotropin-releasing hormone type 1 receptor;CRF receptor;CRF1;CRF-1 receptor;CRF-R;CRF-R1;CRH-R 1	P34998	1394	ENSG00000120088	antagonist
DCL000175	NBI-37582	N/A	N/A	5486700	44823278	TTDC00073	Corticotropin releasing factor receptor 1	Corticotropin-releasing hormone receptor 1;Corticotropin-releasing hormone type 1 receptor;CRF receptor;CRF1;CRF-1 receptor;CRF-R;CRF-R1;CRH-R 1	P34998	1394	ENSG00000120088	antagonist
DCL000834	GW876008	CHEMBL514270; CID 11223423; GW-876008; CID11223423	N/A	N/A	N/A	TTDC00073	Corticotropin releasing factor receptor 1	Corticotropin-releasing hormone receptor 1;Corticotropin-releasing hormone type 1 receptor;CRF receptor;CRF1;CRF-1 receptor;CRF-R;CRF-R1;CRH-R 1	P34998	1394	ENSG00000120088	antagonist
DCL000174	NBI-34041	N/A	N/A	5486700	44823278	TTDC00073	Corticotropin releasing factor receptor 1	Corticotropin-releasing hormone receptor 1;Corticotropin-releasing hormone type 1 receptor;CRF receptor;CRF1;CRF-1 receptor;CRF-R;CRF-R1;CRH-R 1	P34998	1394	ENSG00000120088	antagonist
DCL000642	SSR125543	PDSP1_000883; C14129; CHEMBL291657; AC1NQZWP; 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine; PDSP2_000869; CID5282340; CHEBI:202752; SSR 125543; 752253-39-7	N/A	216237	47657166	TTDC00073	Corticotropin releasing factor receptor 1	Corticotropin-releasing hormone receptor 1;Corticotropin-releasing hormone type 1 receptor;CRF receptor;CRF1;CRF-1 receptor;CRF-R;CRF-R1;CRH-R 1	P34998	1394	ENSG00000120088	antagonist
DCL000923	Pexacerfont	N/A	459856-18-9	9884366	85150145	TTDC00073	Corticotropin releasing factor receptor 1	Corticotropin-releasing hormone receptor 1;Corticotropin-releasing hormone type 1 receptor;CRF receptor;CRF1;CRF-1 receptor;CRF-R;CRF-R1;CRH-R 1	P34998	1394	ENSG00000120088	antagonist
DCL000380	GSK561679	N/A	N/A	N/A	N/A	TTDC00073	Corticotropin releasing factor receptor 1	Corticotropin-releasing hormone receptor 1;Corticotropin-releasing hormone type 1 receptor;CRF receptor;CRF1;CRF-1 receptor;CRF-R;CRF-R1;CRH-R 1	P34998	1394	ENSG00000120088	antagonist
DAP001287	Oprelvekin	Oprelvekin; Oprelvekin (genetical recombination); Neumega (TN); Oprelvekin (genetical recombination) (JAN); 145941-26-0; D05266; Oprelvekin (USAN/INN); Neumega	145941-26-0	N/A	47206975	TTDS00501	Interleukin-11 receptor alpha chain	IL11RA;IL-11RA;IL-11R-alpha	Q14626	3590	ENSG00000137070	binder
DCL000117	Forodesine	4H-Pyrrolo(3,2-d)pyrimidin-4-one, 7-((2S,3S,4R,5R)-3,4-dihydroxy-5-(hydroxymethyl)-2-pyrrolidinyl)-1,5-dihydro-; 1g2o; Forodesine (USAN/INN); 1-(9-deazahypoxanthin-9-yl)-1,4-dideoxy-1,4-iminoribitol; CHEBI:43362; Immucillin-H; 7-[(2S,3S,4R,5R)-3,4-dihydroxy-5-(hydroxymethyl)pyrrolidin-2-yl]-1,5-dihydro-4H-pyrrolo[3,2-d]pyrimidin-4-one; 2-(Acetylamino)-3-methoxy-N-(phenylmethyl)-, (2R)-; 1b8o; Fodosine (TN); CID444499; CHEMBL218291; 7-[(2S,3S,4R,5R)-3,4-dihydroxy-5-(hydroxymethyl)pyrrolidin-2-yl]-1,5-dihydropyrrolo[3,2-d]pyrimidin-4-one; Immucillin H; 1,4-dideoxy-4-aza-1-(s)-(9-deazahypoxanthin-9-yl)-d-ribitol; Fodosine; 2ff2; (1S)-1,4-dideoxy-4-imino-(9-deazahypoxanthin-9-yl)-D-ribitol; Forodesine; IMH; CHEBI:460237; AC1L9GFJ; 2ff1; D06596; 1nw4; (2R,3R,4S,5S)-2-(hydroxymethyl)-5-(4-hydroxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl)pyrrolidine-3,4-diol; UNII-426X066ELK; 209799-67-7	209799-67-7	444499	47208247	TTDC00091	Purine nucleoside phosphorylase	Inosine phosphorylase;PNP;Purine-nucleoside phosphorylase	Q9BMI9	N/A	N/A	inhibitor
DCL000064	BCX-34	PELDESINE; DB07442; AC1L1TZE; BCX-34; 4H-Pyrrolo(3,2-d)pyrimidin-4-one, 1,5-dihydro-2-amino-7-(3-pyridinylmethyl)-; BC3; 2-Amino-3,5-dihydro-7-(3-pyridylmethyl)-4H-pyrrolo(3,2-d)pyrimidin-4-one; CHEMBL311300; CID60817; LS-139612; AC1Q6I9H; 133432-71-0; Peldesine (USAN); 2-amino-7-(pyridin-3-ylmethyl)-1,5-dihydropyrrolo[3,2-d]pyrimidin-4-one; DB02568; Peldesine [USAN]; CHEBI:228309; D05396; 2-amino-7-(pyridin-3-ylmethyl)-5h-pyrrolo[3,2-d]pyrimidin-4-ol; 9-(3-Pyridylmethyl)-7H-9-deazaguanine; 2-Amino-7-(Pyridin-3-Ylmethyl)-3,5-Dihydro-4h-Pyrrolo[3,2-D]pyrimidin-4-One; 4H-Pyrrolo(3,2-d)pyrimidin-4-one, 2-amino-3,5-dihydro-7-(3-pyridinylmethyl)-; BCX 34	133432-71-0	60817	12014771	TTDC00091	Purine nucleoside phosphorylase	Inosine phosphorylase;PNP;Purine-nucleoside phosphorylase	Q9BMI9	N/A	N/A	inhibitor
DCL000065	BCX-4208	N/A	N/A	657181	47213858	TTDC00091	Purine nucleoside phosphorylase	Inosine phosphorylase;PNP;Purine-nucleoside phosphorylase	Q9BMI9	N/A	N/A	inhibitor
DCL000258	Varespladib	D08107; 2-(1-benzyl-2-ethyl-3-oxamoylindol-4-yl)oxyacetic acid; Varespladib [INN]; LY315920; AC1L4F10; CID155815; CHEBI:348537; CHEMBL148674; Varespladib; EC-000.2361; 172733-42-5 (Sodium salt); 172732-68-2; MolPort-005-933-324; FT-0083800; S1110_Selleck; Varespladib (USAN/INN); LY-315920, LY-333013, Varespladib; Acetic acid, ((3-(aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl)oxy)-,; Varepladib [INN]	172733-42-5	155815	733210	TTDC00025	Phospholipase A2, membrane associated	GIIC sPLA2;Group IIA phospholipase A2;Non-pancreatic secretory phospholipase A2;NPS-PLA2;Phosphatidylcholine 2-acylhydrolase;PLA2B;PLA2G2A;PLA2L;RASF-A	P14555	5320	ENSG00000188257	inhibitor
DCL000391	SB-742457	607742-69-8; CID11256720; SB 742457; GSK-742457; CHEBI:730553; 3-(benzenesulfonyl)-8-piperazin-1-yl-quinoline; SB-742457; GSK 742457; CHEMBL1083390	N/A	3446	49738855	TTDC00185	5-hydroxytryptamine 6 receptor	5-HT-6;5-HT6 receptor;Serotonin receptor;Serotonin receptor 6	P50406	3362	ENSG00000158748	antagonist
DPR000159	TP-023	N/A	N/A	N/A	N/A	TTDS00019	Gamma-aminobutyric acid A receptor	GABA(A) receptor;GABA-A receptor	N/A	N/A	N/A	modulator
DAP001385	Gaboxadol	DivK1c_000211; LU 2030; LS-86797; MK-0928; Spectrum_001484; KBio2_004532; Prestwick0_000972; CID3448; Spectrum5_001907; THIP; CHEMBL312443; UNII-K1M5RVL18S; AB00053777; Prestwick1_000972; NINDS_000211; C015542; NCGC00024801-03; LU-2-030; Gaboxadolum; SPBio_001560; Isoxazolo(5,4-c)pyridin-3(2H)-one, 4,5,6,7-tetrahydro-; KBio3_001476; Biomol-NT_000235; Lopac-T-101; Lu-02-030; Prestwick3_000972; BSPBio_001003; Prestwick-13B03; KBio2_007100; Gaboxadolum [Latin]; KBioGR_000683; D04282; NCGC00015982-06; Lopac0_001233; 4,5,6,7-Tetrahydroisoxazole(5,4-c)pyridin-3-ol; CHEBI:232234; BPBio1_001105; KBio2_001964; KBio1_000211; Spectrum3_000728; Prestwick2_000972; gaboxadol; NCGC00024801-01; 4,5,6,7-Tetrahydroisoxazolo(5,4-c)pyridin-3-ol; IDI1_000211; 4,5,6,7-tetrahydro-[1,2]oxazolo[5,4-c]pyridin-3-one; AC1L1FYK; Gaboxadol [USAN:INN]; 64603-91-4; Tocris-0807; NCGC00015982-01; C13693; BSPBio_002256; Spectrum4_000172; Isoxazolo(5,4-c)pyridin-3(2H)-one, 4,5,6,7-tetrahydro-, hydrate; NCGC00024801-02; Lu 02-030; KBioSS_001964; BPBio1_000420; C6H8N2O2.H2O; Gaboxadol (USAN/INN); EINECS 264-963-0; SPBio_002914; NCGC00015982-02; Spectrum2_001590	64603-91-4	3448	586282	TTDS00019	Gamma-aminobutyric acid A receptor	GABA(A) receptor;GABA-A receptor	N/A	N/A	N/A	agonist
DAP001032	Heptabarbital	5-(cyclohepten-1-yl)-5-ethyl-1,3-diazinane-2,4,6-trione; Heptabarb; Heptabarbo [INN-Spanish]; CID10518; Heptbarbital; Noctyn; 5-(1-CYCLOHEPTEN-1-YL)-5-ETHYLBARBITURIC ACID; Heptadorm; LS-24039; C17725; Heptabarbum; C13H18N2O3; Medapan; Heptabarbum [INN-Latin]; Heptabarbitone; Heptabarbo; 5-(1-Cycloheptenyl)-5-ethylbarbitursaeure; Heptabarbital; Heptabarbe; 17626-60-7 (mono-hydrochloride salt); EINECS 208-107-6; CHEMBL468837; 5-(1-Cyclohepten-1-yl)-5-ethyl-2,4,6(1H,3H,5H)-pyrimidinetrione; G 475; AC1L1VDD; Heptamalum; DB01354; Barbituric acid, 5-(1-cyclohepten-1-yl)-5-ethyl-; 5-Ethyl-5-cycloheptenylbarbituric acid; Cycloheptenylethylmalonylurea; Medomine; 5-Ethyl-5-(1'-cycloheptenyl)-barbituric acid; UNII-V10R70ML23; Heptabarbe [INN-French]; Medomin; 509-86-4; Heptamal; Cycloheptenylethylbarbituric acid; 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-(1-cyclohepten-1-yl)-5-ethyl- (9CI); 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-(1-cyclohepten-1-yl)-5-ethyl-; AC1Q6GAL	509-86-4	10518	10454744	TTDS00019	Gamma-aminobutyric acid A receptor	GABA(A) receptor;GABA-A receptor	N/A	N/A	N/A	antagonist
DPR000160	TPT-43	N/A	N/A	N/A	N/A	TTDS00019	Gamma-aminobutyric acid A receptor	GABA(A) receptor;GABA-A receptor	N/A	N/A	N/A	modulator
DAP000021	Diazepam	LA 111; Amiprol; Valrelease; Caudel; Condition; Valuzepam; Faustan,; Usempax ap; WY-3467; Iazepam; Mentalium; ZINC00006427; LA-111; T-quil; EINECS 207-122-5; Diazepam solution; Calmocitene; Diazepam Desitin; Methyl diazepinone; Ansiolin; Prozepam; Radizepam; Novo-Dipam; CHEBI:49575; Doval; Valaxona; Dipaz; Azedipamin; Metamidol; Sibazon; Kiatrium; Ruhsitus; Spectrum3_001780; Methyldiazepinone; Sipam; Nervium; Placidox 10; Lamra; Winii; Paxel; NSC 169897; 1-Methyl-5-phenyl-7-chloro-1,3-dihydro-2H-1,4-benzodiazepin-2-one; Arzepam; Best [Pharaceutical]; NINDS_000967; Gihitan; 5-24-04-00300 (Beilstein Handbook Reference); Euphorin P; neurolytr il; DB07699; Sonacon; S.a. r.l.; I06-0194; Methyldiazepinone (pharmaceutical); A3662/0155188; HSDB 3057; Diaquel; Diazepamum [INN-Latin]; Seduksen; Diazepan leo; Ro 5-2805; Nivalen; Faustal; Diapax; Diazepam (JP15/USP/INN); Nerozen; Umbrium; SMR000058398; Q-pam; Diazepamu; NSC-77518; MLS000759402; KBioGR_001012; Quetinil; Diazepam-ratiopharm; Paralium; Apaurin; Baogin; Dipam; Saromet; Diazepam Dak; Apo-diazepam; KBio3_002780; Diazetard; Serenack; Quiatril; Lembrol; Paxum; AC1L1EZE; Diapam; 7-Chloro-1-methyl-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one; Mandro-Zep; NCGC00178168-01; Diacepan; 53320-84-6; NSC77518; Liberetas; Servizepam; Unisedil; Neurolytril; Paceum; diazepam; 7-Chloro-1-methyl-5-3H-1,4-benzodiazepin-2(1H)-one; Diazepam [USAN:INN:BAN:JAN]; BRD-K16508793-001-01-8; Ortopsique; Diazepam Nordic; 7-Chloro-1-methyl-5-phenyl-3H-1,4-benzodiazepin-2(1H)-one; Velium; Serenzin; Trazepam; S.A. R.L; Plidan; Serenamin; Diastat Acudial; Eridan; Kratium; Assival; Trankinon; Sico Relax; DZP; Sedipam; Nellium; 7-Chloro-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one; Pms-Diazepam; Anxionil; Evacalm; La-Iii; CB 4261; SAM001246536; Diazemulus; Vival; Placidox 2; 7-chloro-1-methyl-5-phenyl-3H-1,4-benzodiazepin-2-one; Lovium; Vatran; Anxicalm; Stesolid; Reliver; CHEMBL12; D0899_SIGMA; e-Pam; Zipan; Valitran; Wy 3467; Britazepam; Mandro; Diazepam Fabra; Tranimul; Sedapam; Gubex; Vivol; Freudal; NSC169897; Dizac; Dienpax; Dipezona; D-Pam; Novazam; Vazen; Kratium 2; STK735517; Relaminal; Ansiolisina; Metil Gobanal; Methyldiazepinone, pharmaceutical; Valeo; BSPBio_003279; Gradual; Vanconin; Diazepan; Diatran; Faustan; Quievita; Diazepam Rectubes; 11100-37-1; Diazepam-Eurogenerics; Duxen; Nixtensyn; Simasedan; AC-10561; Diazepam-Lipuro; Alboral; Spectrum4_000576; Stesolin; Spectrum5_001890; 7-Chloro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one; Diastat; Valium; Tensium; Setonil; Q-Pam Relanium; Diazepam Elmu; D9900_SIGMA; Seduxen; nchembio747-comp27; Paranten; Dupin; 2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-1-methyl-5-phenyl-; Notense; Jinpanfan; Tranquirit; Domalium; Bialzepam; Alupram; Diazepam Intensol; Kabivitrum; Ansilive; HMS503A15; Psychopax; Relanium; Calmaven; Dialar; CPD000058398; Calmociteno; Tensopam; Benzopin; Tranquase; An-Ding; Medipam; AKOS003367969; Ducene; CID3016; C06948; Diastat (TN); Atilen; Mandrozep; Apozepam; Gewacalm; Cercine; Diazapam; DB00829; Bensedin; nchembio.307-comp2; Dialag; UNII-Q3JTX2Q7TU; BIDD:PXR0158; D00293; Levium; DEA No. 2765; Morosan; IDI1_000967; Ro 5-2807; Renborin; Novodipam; BIDD:GT0105; 7-Chloro-1-methyl-2-oxo-5-phenyl-3H-1,4-benzodiazepine; Disopam; Drenian; Tranqdyn; Valiquid; 439-14-5; Pomin; Lizan; Vazepam; HMS2051N04; Ceregulart; Frustan; Aliseum; ProPAM; Calmpose; LS-122; Betapam; D003975; Tranquo-puren; Eurosan; Desconet; Paxate; D9900_FLUKA; Valium (TN); Elcion CR; Chuansuan; Oprea1_126223; Sibazone; Diazemuls; Diapine; Diazepamum; Diazepamu [Polish]; Antenex; Diazem; Centrazepam; BRN 0754371; Atensine; Zepaxid; Desloneg; Parzam; Placidox 5; Calmod; Diaceplex; Solis; Duksen; LA III; DivK1c_000967; MolPort-001-729-114; CCRIS 6009; Noan; Armonil; Diazepam Stada; Tranquo-tablinen; WLN: T67 GNV JN IHJ CG G1 KR; KBio1_000967; Valium R; Diazepin	439-14-5	3016	153142	TTDS00019	Gamma-aminobutyric acid A receptor	GABA(A) receptor;GABA-A receptor	N/A	N/A	N/A	agonist
DAP001033	Isoflurane	Compound 469; NCGC00181037-01; AC1L1GNN; LS-7462; UNII-CYS9AKD70P; D007530; Isoflurane (JP15/USP/INN); ST51041445; IsoFlo; isoflurane; AC-154802; D00545; R-E 235dal; Isoflurano; EINECS 247-897-7; Isoflurane [USAN:INN:BAN:JAN]; Aerrane; Isoflurane [USAN:BAN:INN:JAN]; MolPort-000-153-606; Forene; Ether, 1-chloro-2,2,2-trifluoroethyl difluoromethyl; 2-Chloro-2-(difluoromethoxy)-1,1,1-trifluoroethane; Ethane, 2-chloro-2-(difluoromethoxy)-1,1,1-trifluoro-; CHEBI:6015; C07518; BRN 1852087; CHEMBL1256; 1-Chloro-2,2,2-trifluoroethyl difluoromethyl ether; CID3763; Forane (TN); CCRIS 3043; Isoflurano [INN-Spanish]; 2-chloro-2-difluoromethoxy-1,1,1-trifluoroethane; Jsp005223; Forane; I14-1303; Isofluranum; DB00753; 26675-46-7; Isofluranum [INN-Latin]; AErrane (Veterinary); Isoflurane [Anaesthetics, volatile]	26675-46-7	3763	175428	TTDS00019	Gamma-aminobutyric acid A receptor	GABA(A) receptor;GABA-A receptor	N/A	N/A	N/A	agonist
DCL001116	Ocinaplon	CID216456; Ocinaplon [USAN:INN]; CL 273547; Ocinaplon; 96604-21-6; Methanone, 2-pyridinyl(7-(4-pyridinyl)pyrazolo(1,5-a)pyrimidin-3-yl)-; AC1L50Q3; LS-178317; D02617; Ocinaplon (USAN/INN); Methanone, 2-pyri(dinyl(7-(4-pyridinyl)pyrazolo(1,5-a)pyrimidin-3-yl)-;; pyridin-2-yl-(7-pyridin-4-ylpyrazolo[1,5-a]pyrimidin-3-yl)methanone; UNII-2H6KVC5E76; 2-Pyridyl 7-(4-pyridyl)pyrazolo(1,5-a)pyrimidin-3-yl ketone; C17H11N5O; 2-Pyridinyl(7-(4-pyridinyl)pyrazolo(1,5-a)pyrimidin-3-yl)methanone	N/A	N/A	N/A	TTDS00019	Gamma-aminobutyric acid A receptor	GABA(A) receptor;GABA-A receptor	N/A	N/A	N/A	modulator
DAP000852	Dihydroergotoxine	NCGC00017400-06; Ergotaman-3',6',18-trione, 9,10-dihydro-12'-hydroxy-2'-methyl-5'-(phenylmethyl)-, (5'alpha,10alpha)-; Orstanorm; Dihidroergotamina; IDI1_000592; Ergont; (10alphaH)-5'alpha-benzyl-12'-hydroxy-2'-methyl-3',6',18-trioxo-9,10-dihydroergotaman; DET MS; DivK1c_000592; Diergo; SPBio_001235; CHEBI:4562; Ambotz511-12-6; DIHYDROERGOTOXINE; 9,10-dihydro-ergotamine; KBio2_006673; Diidroergotamina; CID10531; dihydroergotamine; BSPBio_002209; UNII-436O5HM03C; Dergotamine; Verladyn; 11032-41-0; 9,10-Dihydro-12'-hydroxy-2'-methyl-5'-(phenylmethyl)ergotoman-3',6',18-trione; D07837; NINDS_000592; KBio1_000592; KBio3_001429; LS-61979; Spectrum_001057; Ergot Alkaloids, Hydrogenated; Dihidroergotamina [INN-Spanish]; Migranal; CHEBI:658566; Dirgotarl; Spectrum4_000958; C07798; Spectrum2_001188; Dehydroergotamine; C33H37N5O5; Dihydroergotaminum [INN-Latin]; Seglor; Endophleban; Lopac0_000357; 5'-Benzyl-12'-hydroxy-2'-methyl-3',6',18-trioxo-9,10-dihydroergotaman; CID517557; AC1L1VEA; 511-12-6; Ikaran; BIDD:GT0120; CHEMBL1732; BRD-K72166146-066-02-1; Ergomimet; Angionorm; Morena; LS-64563; Co-Dergocrine; Spectrum3_000395; BRN 5720196; Ergoloid dihydroergotoxine; Ergoloid Mesylates (dihydroergotoxine); Agit; Dihydroergotoxin; AC1LAOVT; KBio2_004105; Ergotamine, 9,10-dihydro-; Dihydroergotamine methanesulfonate; KBio2_001537; DB00320; D.H.E.; KBioSS_001537; Ergotonin; DHE-45; 9,10-Dihydroergotamine; Neomigran; 6190-39-2 (mesylate); Dihydroergotaminum; Spectrum5_000905; KBioGR_001576; Dihydroergotamine (INN); Tonopres; (5'alpha)-12'-Hydroxy-2'-methyl-5'-(phenylmethyl)ergotoman-3',6',18-trione; Ergotamine, dihydro, methanesulfonate (salt); Dihydergot; Neomigran (TN); Diidroergotamina [DCIT]; (5'alpha)-5'-benzyl-12'-hydroxy-2'-methyl-3',6',18-trioxoergotaman; EINECS 208-123-3; Ergotoxine, dihydro-	11032-41-0	6420006	10321698	TTDS00019	Gamma-aminobutyric acid A receptor	GABA(A) receptor;GABA-A receptor	N/A	N/A	N/A	agonist
DAP000427	Zopiclone	Zopiclon-TEVA; Zopiclon beta; Lopac0_001270; C515050; Bio-0528; Biomol-NT_000284; Zopiclon AZU; Zopiclon AbZ; Azupharma brand of zopiclone; Zopitan; Siaten; NCGC00024993-03; 6-(5-chloropyridin-2-yl)-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazin-5-yl 4-methylpiperazine-1-carboxylate; Rhodiapharm brand of zopiclone; Aliud brand of zopiclone; Pinewood brand of zopiclone; Zopiclona [INN-Spanish]; Hormosan brand of zopiclone; RP 27267; CHEBI:324263; Opus brand of zopiclone; AC1L1L0T; Zopiclon TAD; 27267 R.P; Zileze; 138680-07-6; 6-(5-chloropyrid-2-yl)-5-(4-methylpiperazin-1-yl)carbonyloxy-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine; Limovan; Rhone-Poulenc Rorer brand of zopiclone; Amoban; D01372; Stadapharm brand of zopiclone; Zopiclone [BAN:INN:JAN]; Z 4900; Temmler brand of zopiclone; Zimoclone; C17H17ClN6O3; Zopiclonum [INN-Latin]; Zopiclon AL; Amoban (TN); Zopiclone (JAN/INN); 4-Methyl-1-piperazinecarboxylic acid 6-(5-chloro-2-pyridinyl)-6,7-dihydro-7-oxo-5H-pyrrolo[3,4-b]pyrazin-5-yl ester; zopiclodura; Italfarmaco brand of zopiclone; Clonmel brand of zopiclone; Ran-zopiclone; BRD-A34309505-001-08-5; Hexal brand of zopiclone; Gerard brand of zopiclone; Optidorm; Rhovane; S1446_Selleck; Norton brand of zopiclone; 1-Piperazinecarboxylic acid, 4-methyl-, 6-(5-chloro-2-pyridinyl)-6,7-dihydro-7-oxo-5H-pyrrolo(3,4-b)pyrazin-5-yl ester; Zopiclonum; Ratiopharm brand of zopiclone; Imovance; ratio-Zopiclone; ct-Arzneimittel brand of zopiclone; DB01198; STK599439; Nu-Pharm brand of zopiclone; Zopiclona; MLS001201837; Zopiclon-neuraxpharm; Dolorgeit brand of zopiclone; zopiclon von ct; Zorclone; EU-0101270; (+-)-Zopiclone; MLS001304058; AbZ brand of zopiclone; BPBio1_001146; Ciclum brand of zopiclone; Aventis brand of zopiclone; Amovane; Zopi-Puren; Zopiclon Stada; CID5735; 43200-80-2; RP 27 267; 4-Methyl-1-piperazinecarboxylic acid ester with 6-(5-chloro-2-pyridyl)-6,7-dihydro-7-hydroxy-5H-pyrrolo(3,4-b)pyrazin-5-one; MLS000083579; 6-(5-Chloro-2-pyridinyl)-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazin-5-yl 4-methyl-1-piperazinecarboxylate; MolPort-002-507-850; Z4900_SIGMA; Novo-zopiclone; NCGC00024993-04; neuraxpharm brand of zopiclone; Zopicalm; Merck dura brand of zopiclone; CHEBI:32315; Imovane; 1-Piperazinecarboxylic acid, 4-methyl-, 6-(5-chloro-2-pyridinyl)-6,7-dihydro-7-oxo-5H-pyrrolo[3,4-b]pyrazin-5-yl ester; 6-(5-chloro-2-pyridyl)-6,7-dihydro- 7-oxo-5H-pyrrolo(3,4-b)pyrazin-5-yl 4-methyl-1- piperazinecarboxylate; betapharm brand of zopiclone; Ximovan; CHEMBL135400; BRN 0768704; Zopiclone (TN); Sopivan; Aventis Pharma brand of zopiclone; TAD brand of zopiclone; UNII-03A5ORL08Q; Zopicalma; EINECS 256-138-9; Alpharma brand of zopiclone; 27267 R.P.; Zopiclon-ratiopharm; Zimovane; SMR000048685; LS-110937; [6-(5-chloropyridin-2-yl)-5-oxo-7H-pyrrolo[3,4-b]pyrazin-7-yl] 4-methylpiperazine-1-carboxylate; nchembio747-comp16; MLS000028547; Teva brand of zopiclone; RP-27267; Nu-Zopiclone; zopiclone; Zopiclone,  Imovane, Zimovane, Lunesta	43200-80-2	5735	583197	TTDS00019	Gamma-aminobutyric acid A receptor	GABA(A) receptor;GABA-A receptor	N/A	N/A	N/A	binder
DAP001035	Bromazepam	Lekotam; Ro 4-9253; Bromazepam(USAN; Lexomil; 2H-1,4-Benzodiazepin-2-one, 7-bromo-1,3-dihydro-5-(2-pyridinyl)-; CID2441; Durazanil; B4144_FLUKA; Ultramidol; Lexotanil; Pasca;oi,; MolPort-003-940-453; 7-Bromo-5-(2-pyridyl)-3H-1,4-benzodiaxepin-2(1H)-one; Creosedin; Bromazepam [USAN:INN:BAN:JAN]; NSC 140669; DEA No. 2748; 2H-1,4-BENZODIAZEPIN-2-ONE, 7-BROMO-1,3-DIHYDRO-5-(2-PYRIDYL)-; D01245; LA Xvii; 7-Bromo-1,3-dihydro-5-(2-pyridyl)-2H-1,4-benzdiazepin-2-one; DB01558; Nu-Bromazepam; 7-bromo-5-pyridin-2-yl-1,3-dihydro-1,4-benzodiazepin-2-one; ZINC00001051; KL 001; Ro 53350; NSC140669; nchembio747-comp38; Lectopam (TN); 2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-7-bromo-5-(2-pyridyl)-; BRN 0618645; Compedium; 37355-30-9; B4144_SIGMA; Lexaurin; Bromazepamum; 5-26-05-00078 (Beilstein Handbook Reference); AC1L1DON; 7-Bromo-5-(2-pyridyl)-3H-1,4-benzodiazepin-2(1H)-one; 7-Bromo-1,3-dihydro-5-(2-pyridyl)-2H-1,4-benzodiazepin-2-one; LS-34139; KL-001; CHEMBL277062; C14H10BrN3O; Bromazepamum [Latin]; Calmepam; Gen-Bromazepam; Normoc; EINECS 217-322-4; Bromazepam (JP15/USAN/INN); 1,3-Dihydro-7-bromo-5-(2-pyridyl)-2H-1,4-benzodiazepin-2-one; Ro 5-3350; Lexilium; Bromazepamum [INN-Latin]; 1812-30-2; WLN: T67 GMV JN IHJ CE K- BT6NJ; Compendium; bromazepam; Novo-bromazepam; Lectopam; Somalium; Lexotan; Apo-Bromazepam	1812-30-2	2441	10476910	TTDS00019	Gamma-aminobutyric acid A receptor	GABA(A) receptor;GABA-A receptor	N/A	N/A	N/A	binder
DCL001108	ELB-139	N/A	N/A	N/A	N/A	TTDS00019	Gamma-aminobutyric acid A receptor	GABA(A) receptor;GABA-A receptor	N/A	N/A	N/A	modulator
DAP000857	Acamprosate	acamprosate (Campral); 77337-73-6 (calcium[2:1] salt); calcium acetylhomotaurine; HSDB 7358; AC1L2FNA; 77337-70-3 (mono-hydrochloride salt); N-Acetylhomotaurine; Acamprosate [INN:BAN]; EINECS 278-667-4; Acamprosate 6473; 77337-71-4 (mono-potassium salt); Acamprosatum; 3-(Acetylamino)propanesulphonic acid; CHEBI:51041; acamprostate; Aotal (TN); CID71158; C5H11NO4S; AC1Q6X8K; 3-Acetamido-1-propanesulfonic acid; AR-1H6082; UNII-N4K14YGM3J; Acamprosatum [INN-Latin]; Campral; DB00659; Acamprosato [INN-Spanish]; AOTA; Aotal; 77337-74-7 (magnesium[2:1] salt); sodium acetylhomotaurine; 77337-76-9; D07058; LS-120940; 77337-72-5 (mono-lithium salt); Acamprosato; Acamprosate; 3-acetamidopropane-1-sulfonic acid; AC1Q1L6O; calcium acetyl homotaurinate; calcium acetylhomotaurinate; Acamprosate (INN)	77337-76-9	71158	213365	TTDS00019	Gamma-aminobutyric acid A receptor	GABA(A) receptor;GABA-A receptor	N/A	N/A	N/A	agonist
DAP000112	Zolpidem	Imidazo(1,2-a)pyridine-3-acetamide, N,N,6-trimethyl-2-(4-methylphenyl)-; BRD-K44876623-001-01-1; Zolpidem (INN); Zolpidem [INN:BAN]; SPECTRUM1505369; SL-800750-23-N; N,N,6-Trimethyl-2-(4-methylphenyl)-imidazo[1,2-a]pyridine-3-acetamide; CID5732; AC1L1L0K; STK627113; zolpidem; 82626-48-0; Imidazo(1,2-a)pyridine-3-acetamide, 2-(4-methylphenyl)-N,N,6-trimethyl-; Sanval (TN); N,N,6-Trimethyl-2-p-tolylimidazo[1,2-a]pyridine-3-acetamide; LS-187761; N,N,6-trimethyl-2-(4-methylphenyl)imidazo(1,2a)pyridine-3-acetamide hemitartrate; HMS1922F22; DB00425; 2C19H21N3O; NCGC00095179-02; D08690; NCGC00095179-01; SL 80.0750; Zolpidemum; UNII-7K383OQI23; NCGC00095179-03; Z103_SIGMA; CHEMBL911; N,N,6-Trimethyl-2-(4-methylphenyl)imidazo(1,2-a)pyridine-3-acetamide; BSPBio_002278; C07219; LS-80196; N,N-Dimethyl-2-[6-methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridin-3-yl]acetamide; Sanval; CHEBI:10125; NCGC00095179-04; I06-0128; MolPort-003-666-656; SL-800750; Lorex; DEA No. 2783; ZINC00003876; BIDD:GT0785; Zolpidemum [Latin]	82626-48-0	5732	199579	TTDS00019	Gamma-aminobutyric acid A receptor	GABA(A) receptor;GABA-A receptor	N/A	N/A	N/A	binder
DAP001036	Lindane	33376_RIEDEL; nexen-fb; CHEBI:24536; Quellada; TRI-6; CHEBI:39095; Lindafor; AI3-09232; DB00431; Gamacarbatox; HMS1923K17; NSC 11808; HCH (beta); CCRIS 1449; ENT 9,234; AC-11679; Lindosep; .delta.-HCH; C07075; Gamacid; 60291-32-9; Milbol 49; ENT 8,601; HCH (alpha); HSDB 6184; AI3-15109; H.C.H.; 36658_FLUKA; Eso derm; Forlin; NSC8093; d-BHC; Nexit; Kwell; Agrocide; Viton; Aplidal; PLK; Gammasan; C6H6Cl6; Aphtiria; New kotol; Lacco HI lin; Exagama; 39284-22-5; Hexyclan; Hexatox; Submar; Geolin G 3; 33856_FLUKA; Omnitox; MLS001333088; Gamene; Lindano; beta-HCH; Arcotal S; 319-84-6; Lindagam; beta-isomer; BIDD:ER0558; D00360; Entomoxan; Hexachloran; Kwell-R; Heclotox; Benhexol; 45548_RIEDEL; 36584_RIEDEL; 33377_RIEDEL; Gammalin; BIDD:GT0634; Lindanum; Gammex; Hcch; SPBio_001708; hilbeec h; Lindagranox; beta-BHC; gamma BHC; KBio2_005032; nexi t-stark; LS-7426; Hexapoudre; 53529-37-6; Agrocide 7; Lasochron; HMS502D03; ENT 9,233; HCH [BSI]; Scabene; BRN 1907338; 25897-48-7; C15214; Agrocide 2; Lindagrain; Isotox; Benhexachlor; LS-193399; Esoderm; BBH; 6108-12-9; beta-Lindane; 6108-13-0; KBio2_002464; Ovadziak; 20437-97-2; BIDD:ER0449; LS-7425; Lidenal; Agrisol G-20; Novigam; MLS001335969; 6108-11-8; BRN 1907337; HMS2091E05; BRN 1907331; Nexit-stark; Geobilan; KWELL (TN); LS-242; CHEBI:28428; Lindam ul; Gammahexa; Gammexane; SMR000875266; LS-7424; Hexamul; PMS Lindane; Lindatox; ENT 9,232; 8073-23-2; AI3-07796; CHEBI:39096; BRN 1907334; Aficide; Chloresene; Agronexit; AI3-08601; Sang-gamma; NINDS_000701; Hexicide; Lorexane; CCRIS 327; Codechine; Bexol; Mglawik L; 33856_RIEDEL; Trives-T; Gammahexane; Hexcidum; gamma-HCH; Nicochloran; Gammopaz; Isot ox; HSDB 6029; Lindex; Hexa; 608-73-1; alpha- BHC; Hexablanc; Gamacide; Novigan; Owadziak; Agrocide WP; SBB061412; 33377_FLUKA; Gammalin 20; Lintox; CHEMBL15891; gamma-col; KBio2_007600; Agrocide 6G; Hungaria L7; BRN 3195880; ENT 7,796; Aalindan; DOL GRANULE; Gallogama; epsilon-HCH; Isatox; 36756_FLUKA; HSDB 646; Silvanol; Benzex; CHEMBL389022; Arbitex; Lindaterra; SMR000857321; PS71_SUPELCO; KBio3_001979; 319-86-8; Devoran; HCH; delta-HCH; Mszycol; LS-193401; alpha-HCH; Ameisentod; LS-56881; NSC7909; BIDD:PXR0097; Gamiso; Lindamul; Lindalo; .delta.-BHC; BIDD:ER0091; Latka 666; hecoltox; Gyben; 55963-79-6; Pedraczak; Linvur; HSDB 6183; Hexaverm; 8007-42-9; t-HCH; Borer Spray; Jacutin; CCRIS 328; Benzanex; AC1L19VZ; Pflanzol; MLS001361319; 6108-10-7; HSDB 1606; Kokotine; LS-193400; Lendine; Nexol-E; 33376_FLUKA; lindane; Hortex; Lindan; Gamaphex; Streunex; CCRIS 329; IDI1_000701; 45548_FLUKA; 58-89-9; gamma-BHC; NSC11808; am eisenatod; Nexen fb; Aphtitria; 36756_RIEDEL; TAP 85; 36658_RIEDEL; Sang gamma; BIDD:ER0090; Gammaterr; Lentox; Gexane; 36584_FLUKA; H.C.H; CID727; AI3-09233; Gamacide 20; Ameisenatod; delta-BHC; Hexachlor; BHC or HCH; LS-185311; Gamtox; Bentox 10; 89609-19-8; C06988; Hexit; 319-85-7; Lindapoudre; Detox 25; Ben-Hex; Hilbeech; Aparasin; MLS001335970; CHEBI:32888; KBio1_000701; NSC11807; AI3-09234; HCH [ISO]; Inexit; Hexachlorane; Agrocide III; alpha-BHC; Celanex; Forst-nexen; NCI-C00204; Dolmix	58-89-9	727	9201	TTDS00019	Gamma-aminobutyric acid A receptor	GABA(A) receptor;GABA-A receptor	N/A	N/A	N/A	antagonist
DCL000479	AZD7325	N/A	737803-81-5	N/A	3821055	TTDS00019	Gamma-aminobutyric acid A receptor	GABA(A) receptor;GABA-A receptor	N/A	N/A	N/A	agonist
DCL000474	AZD6280	N/A	251922-77-7	475513	42971012	TTDS00019	Gamma-aminobutyric acid A receptor	GABA(A) receptor;GABA-A receptor	N/A	N/A	N/A	agonist
DAP001034	Aprobarbital	AC1L1ML6; 125-88-2 (mono-hydrochloride salt); Aprobarbitalum; C07826; Aprobarbital [INN:DCF]; MolPort-004-285-896; EINECS 200-997-4; 5-(1-Methylethyl)-5-(2-propenyl)-2,4,6(1H,3H,5H)-pyrimidinetrione; HSDB 3290; NSC120769; Aprobarbitale [DCIT]; Allypropymal; 77-02-1; Allylpropymal; 5-Allyl-5-isopropylbarbiturate; LS-23747; Allylisopropylbarbituric acid; Allional; Aprobarbital  (INN); Alurate (TN); WLN: T6VMVMV FHJ FY1&1 F2U1; Isonal (swedish); ZINC18167382; DB01352; Aprobarbitone; Barbituric acid, 5-allyl-5-isopropyl-; CHEMBL7863; Allonal; Aprobarbitalum [INN-Latin]; APROBARBITAL; UNII-Q0YKG9L6RF; Isopropylallylbarbituric acid; 5-Isopropyl-5-allylbarbituric acid; D00698; 5-(propan-2-yl)-5-(prop-2-en-1-yl)pyrimidine-2,4,6(1H,3H,5H)-trione; Aprobarbitale; 5-Allyl-5-isopropylbarbituric acid; 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-(1-methylethyl)-5-(2-propenyl)-; Alurate elixir verdum; 5-allyl-5-isopropylpyrimidine-2,4,6(1H,3H,5H)-trione; BRN 0180858; 5-propan-2-yl-5-prop-2-enyl-1,3-diazinane-2,4,6-trione; Allylisopropylmalonylurea; 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-(1-methylethyl)-5-(2-propenyl)- (9CI); NSC 120769; AC1Q1OAW; Aprobarbita; Allypropymalum; CHEBI:2791; Aprozal; Alurate; CCRIS 7088; AKOS003404772; 5-(1-methylethyl)-5-prop-2-en-1-ylpyrimidine-2,4,6(1H,3H,5H)-trione; ST50511771; CID6464; Numal	77-02-1	31332	10028	TTDS00019	Gamma-aminobutyric acid A receptor	GABA(A) receptor;GABA-A receptor	N/A	N/A	N/A	binder
DAP001459	Barbiturate	Barbiturate; 678184-94-6; 914348-20-2; Pyrimidinetrione; C032232; CHEBI:29745; AC1Q6GAK; 223674-02-0; Malonylurea; 42910-84-9; Barbituric acid (VAN) (8CI); InChI=1/C4H4N2O3/c7-2-1-3(8)6-4(9)5-2/h1H2,(H2,5,6,7,8,9; 16564-27-5; 160336-60-7; 117491-80-2; 888733-51-5; CID3262018; Malonylharnstoff; 4,6-dioxo-1H-pyrimidin-2-olate; 860760-03-8; 253678-06-7; Urea, N,N'-(1,3-dioxo-1,3-propanediyl)-; AC1L1M19; 2,4,6-trioxotetrahydro-2H-pyrimidin-1-ide; MolPort-000-998-466; 774592-06-2; hexahydro-pyrimidine-2,4,6-trione; 253678-08-9; CHEBI:669285; Sodium barbiturate; AG-670/31547005; Barbitursaeure; 11709_FLUKA; BARBITURIC ACID; S03-0134; 4390-16-3 (mono-hydrochloride salt); 408335-37-5; 2,4,6(1H,3H,5H)-Pyrimidinetrione; 32267-40-6; 118738-52-6; 2,4,6-Pyrimidinetriol; CHEMBL574699; 67-52-7; EINECS 200-658-0; Pyrimidinetriol; Barbituric acid (VAN); AR-1H7693; 1,3-diazinane-2,4,6-trione; STK317809; CHEBI:16294; 2,4,6-(1H,3H,5H)-Pyrimidinetrione; 2,4,6-Trioxohexahydropyrimidine; pyrimidine-2,4,6(1H,3H,5H)-trione; 20964-57-2; AI3-02724; AKOS000288853; C00813; 53853-41-1; 1194-23-6; Hexahydropyrimidine-2,4,6-trione; LS-7209; bmse000346; CID6211; 2,4,6-Pyrimidinetrione; AC1MMJIY; 2,4,6-Trihydroxypyrimidine; Hydrouracil, 6-hydroxy-; 944357-77-1; 477705-05-8; 6-Hydroxyuracil; 154254-45-2; 465532-08-5; NSC 7889; 185698_SIAL; 1,2,3,4,5,6-Hexahydro-2,4,6-pyrimidinetrione; 51159-18-3; 158217-19-7; NSC7889; barbiturate anion; 253678-07-8; 4A0BDFFD-9542-4996-A89F-E5A55D03B250	67-52-7	6211	4071	TTDS00019	Gamma-aminobutyric acid A receptor	GABA(A) receptor;GABA-A receptor	N/A	N/A	N/A	agonist
DAP000261	Ivermectin	MLS001333247; MLS002153248; 71827-03-7; AB00513813; CID11957587; EU-0100693; HMS1568O14; CID6427057; MLS001333248; NCGC00094047-03; MK-933; (2aE,4E,5'S,6S,6'R,7S,8E,11R,13R,15S,17aR,20R,20aR,20bS)-20,20b-dihydroxy-5',6,8,19-tetramethyl-6'-[(1S)-1-methylpropyl]-17-oxo-3',4',5',6,6',10,11,14,15,17,17a,20,20a,20b-tetradecahydro-2H,7H-spiro[11,15-methanofuro[4,3,2-pq][2,6]benzodioxacyclooctadecine-13,2'-pyran]-7-yl 2,6-dideoxy-4-O-(2,6-dideoxy-3-O-methyl-alpha-L-arabino-hexopyranosyl)-3-O-methyl-alpha-L-arabino-hexopyranoside; Prestwick_516; HMS2089M09; MolPort-006-394-715; FT-0082656; IVERMECTIN; CID4330618; BPBio1_000322; AC1N7O27; CID6321424; BSPBio_000292; S1351_Selleck; NCGC00094047-02; CHEMBL341047; Prestwick2_000156; NCGC00094047-01; BRD-K24652731-001-02-7; I 8898; Lopac0_000693; Prestwick3_000156; I8898_SIGMA; CID6419971; AC1MJ4GR; SMR000857211	70288-86-7	6474909	10171	TTDS00120	Glutamate-gated chloride channel	GluCl	Q9GQW8	N/A	N/A	activator
DAP000962	Echothiophate Iodide	Iodide, Phospholine; Ethanaminium, 2-((diethoxyphosphinyl)thio)-N,N,N-trimethyl-, iodide; (2-Mercaptoethyl)trimethylammonium iodide S-ester with O,O-diethyl phosphorothioate; 2-Diaethoxyphosphinyl-thioaethyl-trimethyl-ammonium-jodid; 2-((Diethoxyphosphinyl)thio)-N,N,N,-trimethylethanaminium iodide; S-(2-Dimethylaminoethyl)-O.O-diethylphosphorothioate methiodide; 2-[(diethoxyphosphinyl)thio]-N,N,N-trimethylethanaminium iodide; Phospholine (the pharmaceutical); MolPort-005-941-436; S-beta-dimethylaminoethyl-O,O-diethylthionophosphate methiodide; 513-10-0; LS-18625; Iodure d'ecothiopate [INN-French]; D004456; Iodure d'ecothiopate; ECOTHIOPATE IODIDE; AC1L1VFJ; 2-Diaethoxyphosphinyl-thioaethyl-trimethyl-ammonium-jodid [German]; Phospholine; EINECS 208-152-1; Echodide; O,O-Diethyl S-2-trimethylammonium ethylphosphonothiolate iodide; Ammonium, (2-(O,O-diethylphosphorothio)ethyl)trimethyl-, iodide; Ecothiopati iodidum [INN-Latin]; CHEMBL1200367; S-Ester of (2-mercaptoethyl)trimethylammonium iodide with O,O-diethyl phosphorothioate; S-(2-(N,N,N-Trimethylammonio)ethyl) O,O-diethylphosphorothiolate iodide; 217-mi; 217 MI; Phospholine iodide; 2-[(diethoxyphosphoryl)sulfanyl]-N,N,N-trimethylethanaminium iodide; 2-{[bis(ethyloxy)phosphoryl]thio}-N,N,N-trimethylethanaminium iodide; Iodide, Ecothiophate; diethoxyphosphinylthiocholine iodide; N-(2-(Diethoxyphosphinylthio)ethyl)trimethylammonium iodide; UNII-BA9QH3P00T; AC1Q1TM0; D02193; CID10547; Iodide, Echothiophate; (2-mercaptoethyl)trimethylammonium iodidie O,O-diethyl phosphorothioate; Ioduro de ecotiopato; Echothiophate iodide; Iodide, Ecothiopate; Diethoxyphosphoryl-thiocholine iodide; C9H22NO3PS; Ecothiophate iodide; Ioduro de ecotiopato [INN-Spanish]; 2-diethoxyphosphorylsulfanylethyl(trimethyl)azanium iodide; CHEBI:59849; DB01057; Ammonium, (2-mercaptoethyl)trimethyl-, iodide, S-ester with O,O-diethylphosphorothioate; Phospholine iodide (TN); Echothiophate iodide (USP); Ecothiopati iodidum; Ecostigmini jodidum; S-(2-dimethylaminoethyl)-O,O-diethylphosphorothioate methiodide; 2-Diethoxy-phosphinylthioethyl-trimethylammonium iodide; Ecothiopate iodide (JP15/INN)	6736-03-4	10547	7849253	TTDS00143	Cholinesterase	Acylcholine acylhydrolase;BuChE;Butyrylcholine esterase;Butyrylcholinesterase;Choline esterase II;Pseudocholinesterase	P06276	590	ENSG00000114200	inhibitor
DAP000963	Hexafluronium bromide	Bromuro de hexafluronio; AC1L1T17; Mylaxen; LS-18141; NSC-19477; hexafluorenium; Milaxen; CHEMBL1200933; Hexamethylene bis(9-fluorenyldimethylammonium)dibromide; Esafluronio bromuro; Hexafluronii bromidum; Esafluronio bromuro [DCIT]; Hexafluorenium dibromide; DB00941; CID9434; Hexamethylenebis(9-fluorenyldimethylammonium bromide); IN-117; Bromure d'hexafluronium; 1,6-Bis(9 fluorenyldimethyl-ammonium)hexane bromide; UNII-B64NJG83K2; Hexafluronii bromidum [INN-Latin]; Hexafluorenium bromide [USAN]; Bromuro de hexafluronio [INN-Spanish]; Hexamethylenebis(fluoren-9-yldimethylammonium) dibromide; 9H-fluoren-9-yl-[6-[9H-fluoren-9-yl(dimethyl)azaniumyl]hexyl]-dimethylazanium dibromide; Hexafluronium bromide (INN); Hexamethylenebis(dimethyl-9-fluorenylammonium bromide); AMMONIUM, HEXAMETHYLENEBIS(FLUOREN-9-YLDIMETHYL-, DIBROMIDE; Hexafluronium bromide; Hexafluorenium bromide; N,N'-Di(9-fluorenyl)-N,N,N',N'-tetramethyly-hexamethylendi(ammoniumbromid); Bromure d'hexafluronium [INN-French]; EINECS 206-265-0; 1,6-Hexanediaminium, N,N'-di-9H-fluoren-9-yl-N,N,N',N'-tetramethyl-, dibromide; hexafluorenium dibromide salt; Mylaxen (TN); C36H42N2; Ammonium, hexamethylenebis(fluoren-9-yldimethyl-, bromide; D04435; 4844-10-4 (Parent); 317-52-2; Hexafluorenium bromide (USAN)	317-52-2	9434	152643	TTDS00143	Cholinesterase	Acylcholine acylhydrolase;BuChE;Butyrylcholine esterase;Butyrylcholinesterase;Choline esterase II;Pseudocholinesterase	P06276	590	ENSG00000114200	inhibitor
DPR000180	ISIS-PTP1B	N/A	N/A	N/A	N/A	TTDR01437	mRNA of Protein tyrosine phosphatase-1B	mRNA of Tyrosine-protein phosphatase non-receptor type 1;mRNA of Protein-tyrosine phosphatase 1B;mRNA of PTP-1B;mRNA of PTPN1	P18031	5770	ENSG00000196396	antisense
DAP000155	Cefalotin	58-71-9; MLS001048966; Prestwick3_000719; Spectrum2_000121; Cephalothinum; BRN 0945586; D07635; 7-(2-Thienylacetamido)cephalosporanic acid; KBio2_005686; 2073-29-2; KBio2_003118; HSDB 3024; NINDS_000097; (6R,7R)-3-(acetyloxymethyl)-8-oxo-7-[(2-thiophen-2-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; SMR000386987; 7-(Thiophene-2-acetamido)cephalosporanic acid; 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-((acetyloxy)methyl)-8-oxo-7-((2-thienylacetyl)amino)-, (6R-trans)-; KBioSS_000550; 58-71-9 (mono-hydrochloride salt); AC1L1LMU; Cefalothin; Prestwick1_000719; Cefalotina fabra (TN); UNII-R72LW146E6; KBio2_000550; Seffin; Spectrum3_000332; 3-ACETOXYMETHYL-8-OXO-7-(2-THIOPHEN-2-YL-ACETYLAMINO)-5-THIA-1-AZA-BICYCLO[4.2.0]OCT-2-ENE-2-CARBOXYLIC ACID; Spectrum4_000269; 3-(Hydroxymethyl)-8-oxo-7-(2-(2-thienyl)acetamido)-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid acetate; 7-(2-(2-Thienyl)acetylamido)cephalosporanic acid; NCGC00159332-02; C16H16N2O6S2; Cefalotinum; CHEBI:124991; Cefalotin (BAN); Cefalotine [INN-French]; KBioGR_000738; CID6024; Cefalotina; Keflin; BSPBio_000937; Cephalotin; IDI1_000097; 6R-trans-3-((Acetyloxy)methyl)-8-oxo-7-((2-thienylacetyl)amino)-5-thia-1-azabicyclo(4.2.0)-oct-2-ene-2-carboxylic acid; 3-(Acetoxymethyl)-8-oxo-7-(2-(2-thienyl)acetamido)-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-(hydroxymethyl)-8-oxo-7-(2-(2-thienyl)acetamido)-, acetate (ester); 7-(Thiophene-2-acetamido)cephalosporin; DivK1c_000097; cephalothin; LS-150069; Bio-0631; 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 3-[(acetyloxy)methyl]-8-oxo-7-[(2-thienylacetyl)amino]-, (6R,7R)-; Prestwick2_000719; Spectrum5_000669; Cefalotinum [INN-Latin]; 3-Acetoxymethyl-7-(2-thienylacetamido)-3-cephem-4-carboxylic acid; BSPBio_001963; C07761; Coaxin; Spectrum_000110; Cephalothin Monosodium Salt; Cefalotine; SPBio_002858; BPBio1_001031; CHEMBL617; (6R,7R)-3-[(acetyloxy)methyl]-8-oxo-7-[(2-thienylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; Cefalotin; 7beta-(thiophen-2-ylacetamido)-3-acetoxymethyl-3,4-didehydrocepham-4-carboxylic acid; Averon-1; Cefalotina fabra; SPBio_000162; Cemastin; EINECS 205-815-7; Cefalotina [INN-Spanish]; 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-((acetyloxy)methyl)-8-oxo-7-((2-thienylacetyl)amino)-, (6R,7R)-; DB00456; BRD-K28210218-236-05-7; KBio3_001183; Prestwick0_000719; MolPort-002-515-763; Lopac0_000283; KBio1_000097; 153-61-7	153-61-7	6024	9963	TTDS00182	D-alanyl-D-alanine carboxypeptidase	D-alanyl-D-alanine carboxypeptidase-transpeptidase;DD-carboxypeptidase;DD-peptidase	Q47746	N/A	N/A	inhibitor
DAP001461	B-Lactams	N/A	N/A	5280445	49698673	TTDS00182	D-alanyl-D-alanine carboxypeptidase	D-alanyl-D-alanine carboxypeptidase-transpeptidase;DD-carboxypeptidase;DD-peptidase	Q47746	N/A	N/A	inhibitor
DAP001354	Cephalosporin	N/A	73384-59-5	5479530	8908	TTDS00182	D-alanyl-D-alanine carboxypeptidase	D-alanyl-D-alanine carboxypeptidase-transpeptidase;DD-carboxypeptidase;DD-peptidase	Q47746	N/A	N/A	binder
DAP000146	Cefotaxime	cefotaxime; Cefotaxima; AC1OC9NB; Spectrum4_000268; SPBio_000138; Prestwick0_000139; AC1L9UKL; STK383264; BSPBio_000218; Cefotaximum [INN-Latin]; CE3; Claforan; HMS2090M11; SPBio_002157; KBioGR_000736; Cefotaxime (INN); Lopac0_000278; C16H17N5O7S2; BSPBio_001961; AC1NSF5T; CID5742673; Spectrum_000108; BRD-K99586414-236-02-3; DivK1c_000767; 63527-53-7; KBio2_000548; CID6604086; AC1O7G8N; BIDD:GT0681; Cefotaxim; Cephotaxime; AC1NX3QV; CID5916965; MolPort-006-834-754; DB00493; KBio2_003116; Cefotaximum; KBioSS_000548; Prestwick1_000139; AC1NZU9Q; AC1L1E42; Cefotaxim Hikma (TN); Spectrum2_000119; RU 24662; Claforan (*Sodium salt*); Cefotaxim Hikma; CID7566336; AC1O712I; CHEBI:204928; Ru-24756; NCGC00021126-01; KBio3_001181; CID6540461; KBio1_000767; Spectrum3_000331; AC1NUIF8; Klaforan; KBio2_005684; NINDS_000767; Cefotaxime [INN:BAN]; Prestwick2_000139; C06885; EINECS 264-299-1; Spectrum5_000667; D07647; MolPort-002-339-742; LS-187246; Cefotaxima [INN-Spanish]; MolPort-005-934-578; AC1NSF6T; 64485-93-4 (mono-hydrochloride salt); CID9868614; AKOS003286450; LS-149920; AC-217; IDI1_000767; CID5479527; CHEMBL102; Cefotaxime acid; UNII-N2GI8B1GK7; BRD-K78364995-236-03-5; CID5361354; CID2632; CID5361298; 60846-21-1; BPBio1_000240; CID6914272; Cephotaxim; 63527-52-6; Prestwick3_000139; CID456256	63527-52-6	456256	9102	TTDS00182	D-alanyl-D-alanine carboxypeptidase	D-alanyl-D-alanine carboxypeptidase-transpeptidase;DD-carboxypeptidase;DD-peptidase	Q47746	N/A	N/A	inhibitor
DCL000744	Ceftobiprole	(6R,7R)-7-[[(2Z)-2-(5-amino-1,2,4-thiadiazol-3-ylidene)-2-nitrosoacetyl]amino]-8-oxo-3-[(E)-[2-oxo-1-[(3R)-pyrrolidin-3-yl]pyrrolidin-3-ylidene]methyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; CHEMBL407727; 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2Z)-(5-amino-1,2,4-thiadiazol-3-yl)(hydroxyimino)acetyl)amino)-8-oxo-3-((E)-((3'R)-2-oxo(1,3'-bipyrrolidin)-3-ylidene)methyl)-, (6R,7R)-; 209467-52-7; CHEMBL1213115; BAL 9141-000; Ceftobiprole; Ro-63-9141/000; AC1OCFF8; Ro 63-9141; UNII-5T97333YZK; Ro-63-9141; CID6918430; BAL 9141; BAL-9141; CHEMBL520642	209467-52-7	6918430	12015243	TTDS00182	D-alanyl-D-alanine carboxypeptidase	D-alanyl-D-alanine carboxypeptidase-transpeptidase;DD-carboxypeptidase;DD-peptidase	Q47746	N/A	N/A	binder
DAP000145	Ceftriaxone	(6R,7R)-7-(2-(2-Amino-4-thiazolyl)glyoxylamido)-8-oxo-3-(((1,2,5,6-tetrahydro-2-methyl-5,6-dioxo-as-triazin-3-yl)thio)methyl)-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7(sup 2)-(Z)-(O-methyloxime), sesquaterhydrate; ceftriaxone; 104376-79-6 (di-hydrochloride salt); CTRX; C18H18N8O7S3; Longacef; 104376-79-6; Ceftriaxone, Disodium Salt; Ro 139904; D07659; Ceftriazone; CHEMBL161; (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(2-methyl-5,6-dioxo-1H-1,2,4-triazin-3-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; AC-1592; Ceftriaxonum [INN-Latin]; Ceftriaxona; Ro-13-9904; Ro13-9904; DB01212; Rocephine; Ceftriaxone [USAN:JAN]; CEFTRIAXONE SODIUM; CID5479530; Ceftriaxonum; Ceftriaxone (TN); (6R,7R)-7-({(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(methyloxy)imino]acetyl}amino)-3-{[(6-hydroxy-2-methyl-5-oxo-2,5-dihydro-1,2,4-triazin-3-yl)thio]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; Ceftriaxone (INN); (6R,7R)-7-[2-(2-Amino-4-thiazolyl)glyoxylamido]-8-oxo-3-[[(1,2,5,6-tetrahydro-2-methyl-5,6-dioxo-as-triazin-3-yl)thio]methyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7^2-(Z)-(O-; AC1NUIFE; CHEBI:29007; 7beta-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-{[(2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-yl)sulfanyl]methyl}-3,4-didehydrocepham-4-carboxylic acid; Cefatriaxone; Ceftriaxone intravenous; Rocefin; Ceftriaxon; Longaceph; Biotrakson; LS-150031; Ceftriaxone, Disodium Salt, Hemiheptahydrate; C06683; 74578-69-1 (di-hydrochloride salt, hemiheptahydrate); UNII-75J73V1629; 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2Z)-(2-amino-4-thiazolyl)(methoxyimino)acetyl)amino)-8-oxo-3-(((1,2,5,6-tetrahydro-2-methyl-5,6-dioxo-1,2,4-triazin-3-yl)thio)methyl)-, (6R,7R)-; Rocephin; EINECS 277-405-6; 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2-amino-4-thiazolyl)(methoxyimino)acetyl)amino)-8-oxo-3-(((1,2,5,6-tetrahydro-2-methyl-5,6-dioxo-1,2,4-triazin-3-yl)thio)methyl)-, (6R-(6alpha,7beta(Z)))-; (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-{[(2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; DRG-0071; 73384-59-5; MolPort-005-933-495; Ceftriaxona [INN-Spanish]	73384-59-5	5361919	189949	TTDS00182	D-alanyl-D-alanine carboxypeptidase	D-alanyl-D-alanine carboxypeptidase-transpeptidase;DD-carboxypeptidase;DD-peptidase	Q47746	N/A	N/A	inhibitor
DCL001061	LY2181308	N/A	N/A	N/A	N/A	TTDC00285	mRNA of Survivin	N/A	N/A	N/A	N/A	antisense
DCL001183	EZN-3042	N/A	N/A	N/A	N/A	TTDC00285	mRNA of Survivin	N/A	N/A	N/A	N/A	antisense
DCL000955	Reparixin	C490707; Reparixin (INN/USAN); reparixin; 2-(4-isobutylphenyl)propionylmethanesulfonamide; UNII-U604E1NB3K; D08984; Benzeneacetamide, alpha-methyl-4-(2-methylpropyl)-N-(methylsulfonyl)-, (alphaR)-; CID9838712; CHEMBL191413; Reparixin [INN]; repertaxin; 266359-83-5; CHEBI:416774; (R)-2-(4-isobutylphenyl)propionylmethanesulfonamide	266359-93-7	104850	49743862	TTDC00190	High affinity interleukin-8 receptor A	CDw128a;CXCR-1;IL-8 receptor type 1;IL-8R A;Interleukin-8 receptor A	P25024	3577	ENSG00000163464	antagonist
DCL000980	SCH-527123	CID9865554; SCH-527123; CHEBI:464875; CHEMBL216981	N/A	9865554	49684245	TTDC00190	High affinity interleukin-8 receptor A	CDw128a;CXCR-1;IL-8 receptor type 1;IL-8R A;Interleukin-8 receptor A	P25024	3577	ENSG00000163464	antagonist
DAP000272	Pioglitazone	KBio2_007239; 5-(4-(2-(5-ethyl-2-pyridyl)ethoxy)benzyl)-2,4-thiazolidinedione; Pioglitazonum; AC-1021; Pioglitazone [BAN:INN]; 198077-89-3; Spectrum2_001679; 2,4-thiazolidinedione, 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-; D08378; 5-[[4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl]methyl]thiazolidine-2,4-dione; 2,4-Thiazolidinedione, 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]- (9CI); U 72107A; U 72107; HS-0047; Pioglitazona; Spectrum4_001130; KBioSS_002103; NCGC00163128-01; HMS2089H14; 5-[[4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione; 5-[[4-[2-(5-Ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-2,4-thiazolidinedione; Spectrum3_001002; KBio2_004671; LS-151327; 5-[[4-[2-[(5-ethyl-2-pyridyl)]ethoxy]phenyl]methyl]thiazolidine- 2,4-dione; HSDB 7322; Pioglitazona [INN-Spanish]; Duetact; Spectrum5_001480; SPBio_001897; I06-0089; CID4829; Actost; 111025-46-8; 5-[4-[2-(5-Ethyl-2-pyridyl)ethoxy]benzyl]thiazolidine-2,4-dione; (+/-)-5-[p-[2-(ethyl-2-pyridyl)ethoxy]benzyl]-2,4-thiazolidinedione; U-72107; UNII-X4OV71U42S; KBio2_002103; 2,4-Thiazolidinedione, 5-((4-(2-(5-ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-; 5-{4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl}-1,3-thiazolidine-2,4-dione; Actos (TN); NCGC00163128-02; (+/-)-5-[[4-[2-(5-Ethyl-2-pyridinyl)-ethoxy]phenyl]methyl]-2,4-thiazolidinedione; 2,4-Thiazolidinedione, 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-, (+/-)-; AD-4833; 2,4-Thiazolidinedione, 5-((4-(2-(5-ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-, (+-)-; Zactos; Pioglitazone [INN:BAN]; Actos; (+-)-5-((4-(2-(5-ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione; BSPBio_002723; KBioGR_001619; C07675; AB1004597; 5-((4-(2-(5-Ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione; BRD-A48430263-003-02-4; Glustin; C19H20N2O3S; CHEBI:8228; CHEMBL595; 105355-27-9; nchembio790-comp10; Spectrum_001623; MolPort-002-508-211; U72,107A; Pioglitazone; pioglitazone (INN); Spectrum5_002067; DB01132; Pioglitazonum [INN-Latin]; AC1L1J1Q; AD 4833; KBio3_001943	111025-46-8	4829	9877	TTDS00338	Peroxisome proliferator activated receptor gamma	PPARgamma;PPAR-gamma;Transcription factor PPAR gamma receptor	P37231	5468	ENSG00000132170	agonist
DCL000897	Netoglitazone	Netoglitazone (USAN/INN); CID204109; Netoglitazone; Netoglitazone [USAN]; D05150; UNII-QOV2JZ647A; 5-[[6-[(2-fluorophenyl)methoxy]naphthalen-2-yl]methyl]-1,3-thiazolidine-2,4-dione; RWJ-241947; CHEMBL93747; MolPort-005-942-719; MCC 555; AC1L4BXM; 5-({6-[(2-fluorobenzyl)oxy]naphthalen-2-yl}methyl)-1,3-thiazolidine-2,4-dione; C115174; Isaglitazone; 161600-01-7; 2,4-Thiazolidinedione, 5-((6-((2-fluorophenyl)methoxy)-2-naphthalenyl)methyl)-; 5-((6-((2-fluorophenyl)methoxy)-2-naphthalenyl)methyl)-2,4-thiazolidinedione; MCC-555	161599-99-1	204109	47206874	TTDS00338	Peroxisome proliferator activated receptor gamma	PPARgamma;PPAR-gamma;Transcription factor PPAR gamma receptor	P37231	5468	ENSG00000132170	agonist
DCL000632	Rosiglitazone & simvastatin	N/A	N/A	23644561	46509014	TTDS00338	Peroxisome proliferator activated receptor gamma	PPARgamma;PPAR-gamma;Transcription factor PPAR gamma receptor	P37231	5468	ENSG00000132170	agonist
DCL000633	Rosiglitazone XR	SAM001246610; CPD000471612; HMS2051B11; AC1NQXYB; MLS001401426; MolPort-003-850-205; UNII-KX2339DP44; CID5281055; Nyracta; CHEBI:162701; NSC717764; 2,4-Thiazolidinedione,5-((4-(2-(methyl-2-pyridinylamino)ethoxy)phenyl)methyl)-,(2Z)-2-butenedioate; MLS001306472; Rosiglitazone Maleate [USAN]; Avandia; AC-737; Rosiglitazone XR; S2505_Selleck; CHEMBL843; SB-206846; (+-)-5-(p-(2-(Methyl-2-pyridylamino)ethoxy)benzyl)-2,4-thiazolidinedione maleate (1:1); (Z)-but-2-enedioic acid; 5-[[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione; Avandia (TN); BRL 49653-C; Rosiglitazone maleate (JAN/USAN); 5-{[4-({2-[methyl(pyridin-2-yl)amino]ethyl}oxy)phenyl]methyl}-1,3-thiazolidine-2,4-dione (2Z)-but-2-enedioate; BRL-49653C; BRL 49653C; BB_SC-4138; CHEBI:8892; C18H19N3O3S.C4H4O4; Venvia; D00596; Avandia administration for 6-12 weeks; 155141-29-0; SMR000471612; SB-210232; (+ -)-5-[[4-2-(methyl]-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione,(Z)-2-butenedioate (1:1); 2,4-Thiazolidinedione, 5-((4-(2-(methyl-2-pyridinylamino)ethoxy)phenyl)methyl)-, (2Z)-2-butenedioate (1:1); Rosiglitazone maleate; 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino) ethoxy]phenyl]methyl]-, (2Z)-2-butenedioate (1:1)	N/A	N/A	N/A	TTDS00338	Peroxisome proliferator activated receptor gamma	PPARgamma;PPAR-gamma;Transcription factor PPAR gamma receptor	P37231	5468	ENSG00000132170	agonist
DCL000827	GSK-677954	N/A	884324-15-6	N/A	N/A	TTDS00338	Peroxisome proliferator activated receptor gamma	PPARgamma;PPAR-gamma;Transcription factor PPAR gamma receptor	P37231	5468	ENSG00000132170	agonist
DAP000271	Rosiglitazone	Spectrum_001703; Gaudil; UNII-05V02F2KDG; 5-(4-{2-[methyl(pyridin-2-yl)amino]ethoxy}benzyl)-1,3-thiazolidine-2,4-dione; S00306; STOCK6S-23924; MolPort-002-508-212; 2,4-Thiazolidinedione, 5-004-02-((((methyl-2-pyridinylamino)ethoxy)phenyl)methyl)-; Spectrum2_001241; 5-[[4-[2-(methyl-(2-pyridyl)amino)ethoxy]phenyl]methyl] thiazolidine-2,4-dione; HMS1922J11; 5-[[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione; DB00412; rosiglitazona; Rosiglizole; [3H]rosiglitazone; AC1L2U9N; NCGC00095124-03; rosiglitazonum; Spectrum4_001125; Gaudil (TN); TDZ 01; Rosi; Brl 49653; Spectrum5_001464; rosiglitazone (Avandia); HSDB 7555; LS-151340; 2,4-Thiazolidinedione, 5-((4-(2-(methyl-2-pyridinylamino)ethoxy)phenyl)methyl)-; 2,4-thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-; I06-0141; C18H19N3O3S; NCGC00095124-02; rosiglitazone; BRD-A97437073-001-03-1; Rosiglitazone [INN:BAN]; Brl-49653; 122320-73-4; 5-((4-(2-(methyl-2-pyridinylamino)ethoxy)phenyl)methyl)-2,4-thiazolidinedione; Rosiglitazone (INN); KBio2_004751; RSG; 5-((4-(2-Methyl-2-(pyridinylamino)ethoxy)phenyl)methyl)-2,4-thiazolidinedione-2-butenedioate; Spectrum3_000997; D08491; KBio2_007319; Rosigliazone maleate; BRL49653; IDMB (1uM BRL49653, 1uM Dexamethasone, 0.5uM IBMX, 10ug/mL Insulin); Avandia; KBio2_002183; CID77999; KBioGR_001609; Rosigilitazone; KBio3_001913; BRD-A97437073-001-02-3; NCGC00095124-01; KBioSS_002183; SPECTRUM1504263; AC-3459; 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI); 5-[4-[2-(N-Methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione; BSPBio_002693; RGZ; HMS2094O13; SPBio_001142	122320-73-4	77999	7980539	TTDS00338	Peroxisome proliferator activated receptor gamma	PPARgamma;PPAR-gamma;Transcription factor PPAR gamma receptor	P37231	5468	ENSG00000132170	agonist
DCL000631	Rosiglitazone & metformin	N/A	210644-62-5	5329099	39301724	TTDS00338	Peroxisome proliferator activated receptor gamma	PPARgamma;PPAR-gamma;Transcription factor PPAR gamma receptor	P37231	5468	ENSG00000132170	agonist
DCL000330	Genistein	KBio2_007700; KBio2_005132; LMPK12050218; NCGC00025005-04; HSDB 7475; NCGC00025005-05; NCGC00025005-01; NSC36586; NCGC00025005-06; 4',5, 7-Trihydroxyisoflavone; Genestein; Spectrum4_001543; UPCMLD-DP096:001; 4&prime;,5,7-Trihydroxyisoflavone; Bio1_000445; IN1327; ISOFLAVONE, 4',5,7-TRIHYDROXY-; CHEMBL44; C06563; SIPI-9764-I; 446-72-0; G6649_SIGMA; 4 inverted exclamation marka,5,7-Trihydroxyisoflavone; 5,7-Dihydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; BB_NC-1017; GEN; SMP1_000133; KBioGR_002564; DB01645; 5-18-04-00594 (Beilstein Handbook Reference); NCGC00025005-07; CCRIS 7675; cMAP_000086; CID5280961; 4,6,7-Trihydroxyisoflavone; STO514; 5,7-Dihydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; S1342_Selleck; Lactoferrin-genistein; Lopac-G-6649; AKOS001590147; NCI60_003369; genistein; SIPI 807-1; NCGC00015479-01; CHEBI:28088; G6776_SIGMA; 4H-1-Benzopyran-4-one, 5,7-dihydroxy-3-(4-hydroxyphenyl)-; NSC 36586; G10000; SMR000112580; Oprea1_224620; Bio1_001423; UPCMLD-DP096; Spectrum3_000678; C.I. 75610; D019833; 5,7,4'-Trihydroxyisoflavone; GENISTEIN (ENDOCRINE DISRUPTER); KBio3_001595; KBioSS_000800; Differenol A; STK801619; KBio2_000800; EINECS 207-174-9; NPI 031L; MolPort-000-003-911; BRN 0263823; Tocris-1110; Spectrum_000320; nchembio.76-comp6; KBio2_005936; Bio1_000934; 4',5,7-Trihydroxyisoflavone; 5,7-Dihydroxy-3-(4-hydroxyphenyl)-4-benzopyrone; KBioGR_002006; NCGC00169711-01; I06-0431; PTI G4660 (Genistein); KBio1_001345; G0272; Genisterin; AC1NQXT4; BIDD:ER0113; BSPBio_002375; PTI-G4660; Genisteol; 5,7-dihydroxy-3-(4-hydroxyphenyl)chromen-4-one; 4',5,7-Trihydroxy isoflavone; Prunetol; BRD-K43797669-001-02-3; BRD-K43797669-001-03-1; EU-0100520; Spectrum5_000106; Oprea1_437815; ENDOCRINE DISRUPTOR (GENISTEIN) (SEE ALSO GENISTEIN (446-72-0)); NCGC00015479-13; SpecPlus_000305; 1x7r; KBio2_002564; DivK1c_006401; MEGxp0_000568; MolMap_000022; 5,7-dihydroxy-3-(4-hydroxyphenyl)-4H-chromen-4-one; TNP00151; SPECTRUM210296; KBio2_003368; SPBio_000636; K00046; NCGC00025005-03; NCGC00015479-05; Sophoricol; Lopac0_000520; Spectrum2_000638; ZINC18825330; G 6649; NCGC00015479-02; 4,5,7-Trihydroxyiso-flavone; Genistein; 4',5,7-Trihydroxyisoflavone; MLS000738127; nchembio.2007.28-comp32; LS-1266; KBio3_003042; KBioSS_002573; Bonistein; NCGC00025005-02; NCGC00169711-02; nchembio.168-comp7; ACon1_001065; AC-472; AB1004490	446-72-0	5280961	8792	TTDS00338	Peroxisome proliferator activated receptor gamma	PPARgamma;PPAR-gamma;Transcription factor PPAR gamma receptor	P37231	5468	ENSG00000132170	agonist
DAP001337	Troglitazone	2,4-thiazolidinedione, 5-[[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl]-; DB00197; BRD-A13084692-001-02-5; 2,4-Thiazolidinedione, 5-((4-((3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy)phenyl)methyl)-; 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl]- (9CI); C057693; AC1L1KOT; CS 045; Resulin; Rezulin (TN); troglitazone; HMS2093D04; Noscal; AKOS000281116; Warner-Lambert brand of troglitazone; I14-1977; 5-(4-((6-hydroxy-2,5,7,8-tetramethylchroman-2-yl-methoxy)benzyl)-2,4-thiazolidinedione); CS-045; Troglitazone (JAN/USAN/INN); UPCMLD-DP017; BRN 4338399; HMS2089D22; CPD-11439; SMP2_000224; Spectrum5_001973; NCGC00161599-01; (+/-)-5-[4-[(6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)methoxy]benzyl]-2,4-thiazolidinedione; 97322-87-7; D00395; CID5591; CI-991; CHEMBL408; NCGC00161599-03; Ambap97322-87-7; C24H27NO5S; CHEBI:9753; GR 92132X; NCGC00164445-01; Parke Davis brand of troglitazone; troglitazonum; T2573_SIGMA; CI 991; GR-92132X; 5-{4-[(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-chromen-2-yl)methoxy]benzyl}-1,3-thiazolidine-2,4-dione; UNII-I66ZZ0ZN0E; UPCMLD-DP017:001; (+-)-all-rac-5-(p-((6-Hydroxy-2,5,7,8-tetramethyl-2-chromanyl)methoxy)benzyl)-2,4-thiazolidinedione; Troglitazone [USAN:BAN:INN]; Prelay; troglitazona; HSCI1_000037; 5-[(4-{[(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-chromen-2-yl)methyl]oxy}phenyl)methyl]-1,3-thiazolidine-2,4-dione; CCRIS 8969; Romozin; UPCMLD-DP017:002; NCGC00161599-02; LS-151313; Rezulin; 5-(4-(6-Hydroxy-2,5,7,8-tetramethylchroman-2-ylmethoxy)benzyl)thiazolidine-2,4-dione; MolPort-003-666-725; MolPort-000-883-772; 5-[[4-[(3,4-Dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl]-2,4-thiazolidinedione; Romglizone; 5-[[4-[(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydrochromen-2-yl)methoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione	97322-87-7	5591	194350	TTDS00338	Peroxisome proliferator activated receptor gamma	PPARgamma;PPAR-gamma;Transcription factor PPAR gamma receptor	P37231	5468	ENSG00000132170	agonist
DAP000798	Dihydroxyaluminium	N/A	13682-92-3	16683036	179984	TTDS00409	Troponin C	TN-C;TNNC;TNNC1;Troponin C, slow skeletal and cardiac muscles	P63316	7134	ENSG00000114854	stimulator
DAP000797	Levosimendan	((4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazono)propanedinitrile; DB00922; LEVOSIMENDAN; 141505-33-1; D04720; 2-[[4-[(4R)-4-methyl-6-oxo-4,5-dihydro-1H-pyridazin-3-yl]phenyl]hydrazinylidene]propanedinitrile; levosimendanum; TL8000754; Levosimendan (USAN/INN); SBB066085; (R)-((4-(1,4,5,6-Tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazono)propanedinitrile; Simdax; CID3033825; Mesoxalonitrile (p-((R)-1,4,5,6-tetrahydro-4-methyl-6-oxo-pyridazinyl)phenyl)hydrazone; ({4-[(4R)-4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl]phenyl}hydrazono)propanedintrile; Levosimendan [INN]; Simdax (TN); ZINC03915645; AC1MHWDS; LS-120045; Levosimedan; MolPort-003-848-382; (-)-OR-1259; CHEBI:50567; Mesoxalonitrile (-)-(p((R)-1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazone; (R)-((4-(1,4,5,6-Tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazono) propanedintrile; AC-1752	141505-33-1	3033825	197103	TTDS00409	Troponin C	TN-C;TNNC;TNNC1;Troponin C, slow skeletal and cardiac muscles	P63316	7134	ENSG00000114854	stimulator
DAP000325	Cinnarizine	Cero-Aterin; Prestwick_115; Cinazyn; MLS001148649; Prestwick3_000278; Siptazin; Processine; NCGC00021488-05; CHEMBL43064; NCGC00018187-07; Spaderizine; AC1LU5GC; Cinnageron; Zepamol; DB00568; Glanil; cinnarizine; CID1547484; 1-(diphenylmethyl)-4-(3-phenyl-2-propenyl)-piperazine; Katoseran; Cinarizine; Cinnarizine (JAN/USAN/INN); Lazeta; HMS1568H18; NCGC00018187-04; Denapol; 1-Cinnamyl-4-(diphenylmethyl)piperazine; Bio-0747; nchembio790-comp28; 1-(diphenylmethyl)-4-[(2E)-3-phenylprop-2-en-1-yl]piperazine; Eglen; Corathiem; Aplexal; Labyrin; 1-trans-Cinnamyl-4-diphenylmethylpiperazine; Hilactan; NCGC00021488-03; Cinnacet; Senoger; STK216257; Cerebolan; Aplactan; QTL1_000023; Carecin; Sepan; Artate; N-Benzhydryl-N'-cinnamylpiperazine; 7002-58-6 (di-hydrochloride); Lopac0_000314; Olamin; Dimitronal; Cinnarizinum [INN-Latin]; BSPBio_000156; 1-benzhydryl-4-[(E)-3-phenylprop-2-enyl]piperazine; Cinarizina [INN-Spanish]; Prestwick2_000278; Stutgeron; R 1575; Cinnarizine [USAN:INN:BAN:JAN]; MolPort-002-056-760; 1-(Diphenylmethyl)-4-(3-phenyl-2-propenyl)piperazine; Sedatromin; Midronal; Ixertol; Cinnarizinum; C5270_SIGMA; BRN 0626121; Libotasin; MLS002207295; UNII-3DI2E1X18L; EU-0100314; R-516; SMR000058307; LS-111394; Marisan; CHEBI:31403; BPBio1_000172; C 5270; D01295; R 516; Piperazine, 1-(diphenylmethyl)-4-(3-phenyl-2-propenyl)-; Cinaperazine; Toliman; NCGC00021488-04; L001227; 1-Benzhydryl-4-cinnamylpiperazin; 298-57-7; 516 MD; MLS002222167; Dimitron; C26H28N2; Votegol; EINECS 206-064-8; BRD-K07220430-001-03-6; Mitronal; Piperazine, 1-cinnamyl-4-(diphenylmethyl)-; Folcodal; AKOS002134299; MLS000028498; Giganten; Cinnarizine Stugeron; Stugeron; MD 516; I01-3582; Cinarizina; Stutgin; Apotomin	298-57-7	2761	7848358	TTDS00086	Histamine H1 receptor	H1 Histamine receptor;Histamine receptor 1	P35367	3269	ENSG00000196639	antagonist
DAP001373	Antazoline phosphate	NCGC00094590-02; A3766_FLUKA; Antazoline phosphate (USP); HMS2091K05; SMR000058669; MolPort-003-666-124; Antazoline phosphate; N-benzyl-N-(4,5-dihydro-1H-imidazol-2-ylmethyl)aniline; phosphoric acid; CID158798; N-Benzyl-4,5-dihydro-N-phenyl-1H-imidazole-2-methylamine monophosphate; HMS500E05; MLS000028623; D02950; AC-20134; NCGC00094590-01; 91-75-8 (Parent); NCGC00094590-03; EINECS 205-831-4; UNII-VPR5FPH326; SPECTRUM1500126; ST51037133; AC1L4KMX; MLS001148180; HMS1920E05; Antazoline phosphate salt; 154-68-7; CHEMBL1200550; A3766_SIGMA	154-68-7	158798	17397107	TTDS00086	Histamine H1 receptor	H1 Histamine receptor;Histamine receptor 1	P35367	3269	ENSG00000196639	antagonist
DAP000322	Clemastine	NCGC00016710-01; Clemastine [USAN:BAN]; Tavegyl; HS 592; 14976-57-9; Spectrum2_000689; Prestwick2_000306; AC1L1CAE; Clemastina; IDI1_000285; KBio1_000285; NINDS_000285; HMS2089I22; Spectrum3_000353; C21H26ClNO; Prestwick1_000306; (+)-(2R)-2-(2-(((R)-p-Chloro-alpha-methyl-alpha-phenylbenzyl)oxy)ethyl)-1-methylpyrrolidine; (2R)-2-(2-{[(1R)-1-(4-chlorophenyl)-1-phenylethyl]oxy}ethyl)-1-methylpyrrolidine; CHEBI:3738; NCGC00015281-01; BSPBio_002045; clemastine; Clemastinum [INN-Latin]; Prestwick0_000306; Mecloprodin; (+)-(2R)-2-[2-[[(R)-p-Chloro-alpha-methyl-alpha-phenylbenzyl]oxy]ethyl]-1-methylpyrrolidine; Meclastine; DB00283; BSPBio_000272; SPBio_000817; (2R)-2-{2-[(1R)-1-(4-chlorophenyl)-1-phenylethoxy]ethyl}-1-methylpyrrolidine; KBioGR_001570; 15686-51-8; Spectrum5_001520; BPBio1_000300; 2(R)-[2-[(1R)-(4-Chlorophenyl)-1-phenyl-ethoxy]ethyl-1-methylpyrrolidine; Clemastinum; Lopac-C-8903; Meclastin; HS-592; (2R)-2-[2-[(1R)-1-(4-chlorophenyl)-1-phenylethoxy]ethyl]-1-methylpyrrolidine; CAS-14976-57-9; UNII-95QN29S1ID; CID26987; BRD-K30240666-051-05-0; AC1Q3N52; CLEMASTINE FUMARATE; BIDD:GT0391; SPBio_002491; CHEMBL1626; Clemastina [INN-Spanish]; Spectrum4_000955; LS-137531; DivK1c_000285; Tavist (*Fumarate*); Tocris-1453; Tavist; 2-(2-(4-Chlor-alpha-methylbenzhydryloxy)ethyl)-1-methylpyrrolidin; NCGC00025168-01; Prestwick3_000306; KBio3_001265	15686-51-8	26987	9130	TTDS00086	Histamine H1 receptor	H1 Histamine receptor;Histamine receptor 1	P35367	3269	ENSG00000196639	antagonist
DAP000101	Loratadine	I14-0747; Lorastine; Talorat Dy; Lorfast; 4-(8-Chloro-5,6-dihydro-11H-benzo(5,6)cyclohepta(1,2-b)pyridin-11-ylidene)-1-piperidinecarboxylic Acid Ethyl Ester; D00364; L 9664; NCGC00023125-06; Alavert, Claritin, Loratadine; DivK1c_000792; Loratyne; Loranox; EU-0100680; Loraver; Allertidin; Sch 29851; Sch29851; NCGC00023125-05; Loracert; D017336; Lergy; Tadine; Sinhistan Dy; HMS502H14; Loratadinum [Latin]; ZINC00537931; 1-Piperidenecarboxylic acid, 4-(8-chloro-5,6-duhydro-11H-benzo [5,6]cyclohepta[1,2-b]-pyridin-11-ylidene)-, ethyl ester; KBio1_000792; 1-piperidinecarboxylic acid,4-(8-chloro-5,6-dihydro-11H-benzo(5,6)cyclohepta(1,2-b)pyridin-11-ylidene)-,ethyl ester; Restamine; NINDS_000792; NCGC00015619-10; Spectrum2_001584; BIDD:GT0198; Spectrum5_001650; Claritin D; C22H23ClN2O2; Loradex; Lowadina; Bonalerg; Oprea1_027965; Sanelor; Lopac-L-9664; Loratadine [USAN:BAN:INN]; KBio2_004544; Loratadina; Clarinase; KBio2_007112; Claritin reditab; Anhissen; LS-114660; AC-2086; Claratyne; Pylor; NCGC00023125-04; Lopac0_000680; HSDB 3578; SAM001246987; BRD-K82795137-001-02-3; BSPBio_002300; Optimin; MLS000069647; HMS2090O18; Claritin Hives Relief Reditab; Zeos; Tocris-1944; Clarityne-D; 79794-75-5; BRD-K82795137-001-10-6; STK574925; Clarinase Reperabs; NSC721075; Civeran; NCGC00023125-02; Claritin Reditabs; KBio2_001976; Loratadine (JAN/USAN/INN); L0223; IDI1_000792; Histaloran; CPD000058255; Fristamin; KBio3_001520; Loratidine; HMS2051G11; NCGC00015619-06; Claritine; Rinomex; Loratadine Wyeth Brand; Loratadinum; Lisino; Versal; loratadine; 1-Piperidinecarboxylic acid, 4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)-, ethyl ester; Claritin (TN); SMR000058255; Sensibit; Ethyl 4-(8-chloro-5,6-dihydro-11H-benzo(5,6)cyclohepta(1,2-b)pyridin-11-ylidene)-1-piperidinecarboxylate; CID3957; ethyl 4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)piperidine-1-carboxylate; L9664_SIGMA; 4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cycloheptal[1,2-b]pyridin-11-ylidene-1-piperidinecarboxylic acid ethyl ester; Lorantis; Clarityne; Alerpriv; Spectrum3_000740; Spectrum4_000177; NCI60_041473; Clarityn; Sch-29851; Alavert; Sohotin; Biloina; KBioSS_001976; Alarin; DB00455; Nularef; Roletra; Spectrum_001496; BB_SC-2109; Rhinase; NCGC00023125-07; KBioGR_000693; NCGC00015619-02; TL8005389; HMS2093I15; Bedix Loratadina; Clarium; Aerotina; Lertamine; Children's Claritin; MolPort-002-507-846; AC1L1H3E; Loritine; Claratyne Cold; Velodan; Wyeth Brand of Loratadine; S1358_Selleck; Loratadina [Spanish]; MLS000758260; Claritin Hives Relief; Polaratyne; 4-(8-Chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene-1-piperidinecarboxylic acid ethyl ester; Loratadine Redidose; Loradif; NCGC00015619-01; MLS001148466; SPBio_001548; Lesidas; Claritin; Claratyne Decongestant; CHEMBL998; SPECTRUM1503712; UNII-7AJO3BO7QN; L000667; 1-Piperidinecarboxylic acid, 4-(8-chloro-5,6-dihydro-11H-benzo(5,6)cyclohepta(1,2-b)pyridin-11-ylidene)-, ethyl ester; Clarityne Dy Repetabs	79794-75-5	3957	192028	TTDS00086	Histamine H1 receptor	H1 Histamine receptor;Histamine receptor 1	P35367	3269	ENSG00000196639	antagonist
DAP001347	Antazoline	DivK1c_000083; Antazolina; KBioGR_000582; Antazolina [Spanish]; Imidamin; 5512-M; 2-(N-Phenyl-N-benzylaminomethyl)imidazoline; 154-68-7 (phosphate (1:1)); DB08799; KBio2_001269; 91-75-8; KBio1_000083; Tocris-0791; Azalone; IDI1_000083; BPBio1_000084; KBioSS_001269; NCGC00023164-03; Antihistal; KBio3_001366; Spectrum2_001259; Antazolinum [Latin]; Prestwick2_000258; D07458; N-Benzyl-N-(4,5-dihydro-1H-imidazol-2-ylmethyl)aniline; SPBio_002295; NINDS_000083; HSDB 6506; NCGC00016613-01; BRN 0233924; N-(4,5-dihydro-1H-imidazol-2-ylmethyl)-N-(phenylmethyl)aniline; CHEMBL1305; Antistine; CID2200; Antazolinum; antazoline; Antazoline (INN); 2-Phenyl-benzyl-amino-methylimidazolin; AC1L1D5C; 2508-72-7 (hydrochloride); NCGC00016613-03; LS-79572; Spectrum_000789; Spectrum4_000141; Antazoline [INN:BAN]; Antasten; EINECS 202-094-0; 2-Imidazoline, 2-((N-benzylanilino)methyl)-; Phenazoline; Analergine; 2-(N-Benzylanilinomethyl)-2-imidazoline; 1H-Imidazole-2-methanamine, 4,5-dihydro-N-phenyl-N-(phenylmethyl)-; Spectrum5_000818; BSPBio_000076; KBio2_006405; KBio2_003837; Antazolinum [INN-Latin]; ST086981; Imidamine; C17H19N3; Antazolin; Histostab; CAS-2508-72-7; Prestwick1_000258; Antastan; Antazolina [INN-Spanish]; Phenazolin; L000841; UNII-DHA8014SS1; BRD-K99300445-011-02-9; Ben-A-hist; Spectrum3_000303; Prestwick0_000258; NCGC00016613-02; BRD-K99300445-003-03-4; 2-Phenyl-benzyl-amino-methylimidazolin [German]; Prestwick3_000258; 5-25-09-00364 (Beilstein Handbook Reference); 4,5-Dihydro-N-phenyl-N-phenylmethyl-1H-imidazole-2-methanamine; SPBio_001198; Antistin; BSPBio_001866	91-75-8	2200	51091789	TTDS00086	Histamine H1 receptor	H1 Histamine receptor;Histamine receptor 1	P35367	3269	ENSG00000196639	antagonist
DAP001071	Diphenylpyraline	Belfene; 4-benzhydryloxy-1-methylpiperidine; 5-21-01-00053 (Beilstein Handbook Reference); BSPBio_000893; C19H23NO; Histryl; AB00053461; NCGC00016395-01; 4-DIPHENYLMETHOXY-1-METHYLPIPERIDINE; NCGC00178908-01; NINDS_000851; Dayfen; Prestwick3_000707; EINECS 205-686-7; Spectrum3_000401; KBioGR_001121; diphenylpyraline; Hystryl; DB01146; NCIOpen2_007716; Diphenylpyraline (INN); N-Methylpiperidyl-(4)-benzhydrylaether salzsauren salze [German]; AN 1041; 132-18-3 (hydrochloride); KBio3_001142; Diafen; KBio2_004050; Diphenylpyralinum; N-Methylpiperidyl-(4)-benzhydrylaether salzsauren salze; Mepiben; Spectrum5_000917; 4-(benzhydryloxy)-N-methylpiperidine; BRD-K22936972-003-05-3; Spectrum4_000521; Diphenylpyrilene; BPBio1_000983; D07862; AC1L1F6E; 1-Methyl-4-piperidyl benzhydryl ether; diphenylpyraline maleate (2:1); NCGC00178908-02; CHEBI:59788; IDI1_000851; Hispril; SBB063499; DivK1c_000851; KBioSS_001482; Difenilpiralina; Diphenylpyralinum [INN-Latin]; C009871; Spectrum2_000982; Lergobine; 4-(Benzhydryloxy)-1-methylpiperidine; PIPERIDINE, 4-(DIPHENYLMETHOXY)-1-METHYL-; NSC61825; KBio2_001482; I01-1866; SPBio_001043; Diphenylpyraline [INN:BAN]; Histyn; LS-115271; CID3103; CAS-132-18-3; 4-[(diphenylmethyl)oxy]-1-methylpiperidine; Allergen; 147-20-6; 1-methyl-4-hydroxypiperidine benzhydryl ether; KBio1_000851; KBio2_006618; CHEMBL1492; BRN 0245467; Prestwick2_000707; L001180; BSPBio_001922; UNII-33361OE3AV; CHEBI:518482; Spectrum_001002; Prestwick0_000707; Dafen; Neargal; Diphenylpyralamine; Oprea1_289175; Lyssipoll; Difenilpiralina [INN-Spanish]; SPBio_002814; Prestwick1_000707; 4-(Diphenylmethoxy)-1-methylpiperidine	147-20-6	3103	615228	TTDS00086	Histamine H1 receptor	H1 Histamine receptor;Histamine receptor 1	P35367	3269	ENSG00000196639	antagonist
DAP001062	Olopatadine	Dibenz(b,e)oxepin-2-acetic acid, 11-(3-dimethylamino)propylidene)-6,11-dihydro-, hydrochloride, (Z)-; Allelock; Patanol; SMR000469220; Pataday; AC1NR00D; MolPort-003-986-254; CID5281071; 11-((Z)-3-(Dimethylamino)propylidene)-6,11-dihydrodibenz(b,e)oxepin-2-acetic acid, hydrochloride; OLOPATADINE HCl; MLS001401465; 11-((Z)-3-(Dimethylamino)propylidene)-6,11-dihydrodibenz(b,e)oxepin-2-acetic acid hydrochloride; ALO4943A; 2-[(11Z)-11-[3-(dimethylamino)propylidene]-6H-benzo[c][1]benzoxepin-2-yl]acetic acid; L000748; CHEMBL1719; O0361; SAM001246802; AL-4943A; Olopatadine [INN:BAN]; Olopatadine; KW-4943A; 140462-76-6; CID5282402; DB00768; {(11Z)-11-[3-(dimethylamino)propylidene]-6,11-dihydrodibenzo[b,e]oxepin-2-yl}acetic acid; TL8000403; AC1NQXZH; KW 4679; LS-61598; 11-(3-(dimethylamino)propylidene)-6,11-dihydrodibenz(b,e)oxepin-2-acetic acid; S2494_Selleck; 113806-05-6; LS-172239; STK624184; Dibenz(b,e)oxepin-2-acetic acid, 11-(3-(dimethylamino)propylidene)-6,11-dihydro-, hydrochloride, (Z)-; Opatanol; 11-((Z)-3-(Dimethylamino)propylidene)-6,11-dihydrodibenz(b,e)oxepin-2-acetic acid; Patanase; ALO-4943A; 2-[(11Z)-11-[3-(dimethylamino)propylidene]-6H-benzo[c][1]benzoxepin-2-yl]acetic acid hydrochloride; 113806-05-6 (Parent); KW-4679; CPD000469220; OLOPATADINE HYDROCHLORIDE; UNII-2XG66W44KF; 140462-76-6 (hydrochloride); TL8000904; MolPort-003-986-408; FT-0082377; BIDD:GT0285; HMS2089K10; Bio-0072; UNII-D27V6190PM; HCl of KW 4679; SBB066095	113806-05-6	5281071	698647	TTDS00086	Histamine H1 receptor	H1 Histamine receptor;Histamine receptor 1	P35367	3269	ENSG00000196639	antagonist
DAP001074	Epinastine	9,13b-dihydro-1H-dibenzo[c,f]imidazo[1,5-a]azepin-3-amine; 1H-Dibenz(c,f)imidazo(1,5-a)azepin-3-amino, 9,13b-dihydro-; WAL 801CL; Epinastina [Spanish]; 3-amino-9,13b-dihydro-1H-benz(c,f)imidazo(1,5a)azepine; NCGC00165791-03; DB00751; (+-)-Epinastine; L000716; WAL 801; epinastine; LS-177526; Epinastine [INN]; WAL-80 Cl; SBB066107; 3-Amino-9,13b-dihydro-1H-dibenz(c,f)imidazo(1,5-a)azepine; 134507-59-8; CHEBI:51032; Epinastinum; Epinastina; CHEMBL1106; CID3241; Purivist; AC1L1FHQ; AC-15948; Epinastinum [Latin]; NCGC00165791-01; 80012-43-7; D07900; Epinastine (INN); UNII-Q13WX941EF; MolPort-005-935-541; NCGC00165791-02; WAL 80; I06-0349; C16H15N3; 108929-04-0 (hydrochloride); Purivist (TN)	80012-43-7	3241	213455	TTDS00086	Histamine H1 receptor	H1 Histamine receptor;Histamine receptor 1	P35367	3269	ENSG00000196639	antagonist
DAP000334	Promethazine	Phensedyl; PromethazineHcl; N,N,alpha-Trimethyl-10H-phenothiazine-10-ethanamine; Isophenergan; KBio1_000005; Promethegan; 3389 R.p.; Promacot; Prestwick2_000888; Prometasin; NSC 30321; AB00053535; Procit; KBio2_001348; Thiergan; Hiberna; 73745-50-3; Dimethylamino-isopropyl-phenthiazin [German]; KBio3_001997; AC1L1J92; Spectrum3_001019; Diprozin; D00494; Promethazin; NCGC00089735-03; Promethaine; NCI60_001878; 60-87-7; Prothazin; DB01069; Promethiazine; Phenargan; KBio2_006484; WY 509; Oprea1_758749; KBioGR_001697; Camergan; HSDB 3173; Prometazina; CHEMBL643; Histargan; Metaryl; Phargan; 4182 R.p.; N,N-dimethyl-1-(10H-phenothiazin-10-yl)propan-2-amine; KBio2_003916; HMS2089E08; CCRIS 7056; Prestwick1_000888; Genphen; Phenerzine; 10-(2-(Dimethylamino)-2-methylethyl)phenothiazine; AC-15939; Lilly 1516; Diprazin; NCI-C60673; KBioSS_001348; Phenothiazine, 10-[2-(dimethylamino)propyl]-; Vallergine; Prometazina [INN-Spanish]; BRN 0088554; 10-(2-(Dimethylamino)propyl)phenothiazine; Lilly 01516; PROMETHAZINE (SEE ALSO PROMETHAZINE HYDROCHLORIDE 58-33-3); CHEBI:8461; Promethazinum [INN-Latin]; Pyrethiazine; Pyrethia; Proazaimine; Pilpophen; N-Dimethylamino-2-methylethyl thiodiphenylamine; Fargan; C07404; RP 3277; BPBio1_000744; (Dimethylamino-2-propyl-10-phenothiazine hydrochloride; Promazinamide; Spectrum2_000840; A-91033; Protazine; Prometh; (2-Dimethylamino-2-methyl)ethyl-N-dibenzoparathiazine; SPBio_000799; Prometazine; Romergan; Dimethylamino-isopropyl-phenthiazin; NCGC00015817-10; Spectrum5_000977; Pelpica; Promezathine; 10-[2-(Dimethylamino)propyl]phenothiazine; promethazine; NSC30321; 38878-40-9; Zipan-25; Remsed; PWWVAXIEGOYWEE-UHFFFAOYSA-; Diprazine; Prestwick0_000888; Pro-50; Lergigan; Pipolphene; Avomine; Lopac0_000899; DivK1c_000005; CID4927; MolPort-001-783-684; Spectrum4_001149; Isopromethazine; Prometazin; Diphergan; Promergan; Pilothia; LS-264; Dimapp; 3277 RP; Antiallersin; Fenetazina; IDI1_000005; Promethazine (JAN/INN); L000495; SPBio_002895; Lercigan; Aprobit; InChI=1/C17H20N2S/c1-13(18(2)3)12-19-14-8-4-6-10-16(14)20-17-11-7-5-9-15(17)19/h4-11,13H,12H2,1-3H3; 10H-Phenothiazine-10-ethanamine, N,N,alpha-trimethyl-, radical ion(1+); Promethacon; Prorex; N,N-dimethyl-1-phenothiazin-10-ylpropan-2-amine hydrochloride; Fenetazine; SKF 1498; Prothazine; Rumergan; Promesan; Spectrum_000868; Provigan; WLN: T C666 BN ISJ B1Y1&N1&1; 10-(2-Dimethylaminopropyl)phenothiazine; Prestwick3_000888; Valergine; BSPBio_000676; N-(2'-Dimethylamino-2'-methyl)ethylphenothiazine; 10H-Phenothiazine-10-ethanamine, N,N,alpha-trimethyl- (9CI); Fenazil; 10H-Phenothiazine-10-ethanamine, N,N,.alpha.-trimethyl-; Promethazinum; UNII-FF28EJQ494; Phenothiazine, 10-(2-dimethylaminopropyl)-; Promethazine [INN:BAN]; Tanidil; Iergigan; NCGC00089735-02; BSPBio_002777; Proazamine; NINDS_000005; 10H-Phenothiazine-10-ethanamine, N,N,alpha-trimethyl-; EINECS 200-489-2; 4-27-00-01253 (Beilstein Handbook Reference); Phenoject-50; N,N-dimethyl-1-phenothiazin-10-ylpropan-2-amine	60-87-7	4927	7847560	TTDS00086	Histamine H1 receptor	H1 Histamine receptor;Histamine receptor 1	P35367	3269	ENSG00000196639	antagonist
DAP000337	Cyclizine	HMS2091I08; NSC 26608; Wellcome preparation 47-83; Spectrum_000854; BRD-K79501723-001-02-0; HSDB 3309; LS-111945; SPECTRUM1500211; NCGC00094634-02; KBio1_001957; KBioSS_001334; Prestwick2_000510; DivK1c_007013; Valoid; Ciclizina; 1-Diphenylmethyl-4-methylpiperazine; 5-23-01-00232 (Beilstein Handbook Reference); Wellcome; Prestwick3_000510; Spectrum3_000368; Compound 47-83; Marezine hydrochloride; C06930; 1-(Diphenylmethyl)-4-methylpiperazine; KBio2_003902; AC1L1N61; 1-Benzhydryl-4-methylpiperazine; WLN: T6N DNTJ AYR&R& D1; N-Methyl-N'-benzhydrylpiperazine; SpecPlus_000917; BRN 0230441; Cyclizinum [INN-Latin]; BW 47-83; AC1Q3ZTI; Reis-fit; EINECS 201-445-5; Spectrum4_000205; Wellcome prepn. 47-83; Nautazine; Emoquil; BSPBio_000439; Ciclizina [INN-Spanish]; N-Methyl-N'-benzyhydrylpiperazine; Spectrum5_001594; CHEMBL648; NSC26608; CYCLIZINE; CHEBI:3994; 82-92-8; NCGC00016421-01; Neo-devomit; CID6726; DB01176; BSPBio_002095; (+-)-1-diphenylmethyl-4-methylpiperazine; BPBio1_000483; UNII-QRW9FCR9P2; KBioGR_000809; SPBio_001187; Prestwick0_000510; KBio3_001315; KBio2_001334; HMS1920A20; Cyclizine hydrochloride; N-Benzhydryl-N'-methylpiperazine; Cyclizinum; Spectrum2_001174; CAS-303-25-3; KBio2_006470; L000701; Oprea1_429421; NCGC00094634-01; SPBio_002360; Cyclizine [INN:BAN:DCF]; Piperazine, 1-(diphenylmethyl)-4-methyl-; Ne-devomit; D03621; (N-Benzhydryl)(N'-methyl)diethylenediamine; 1-Benzhydryl-4-methylpiperazin; Wellcome prepn 47-83; BRD-K79501723-003-03-4; Marezine; Cyclizine chloride; Prestwick1_000510; ( -)-1-Diphenylmethyl-4-methylpiperazine; MolPort-001-798-137; Cyclizine (INN); AB00053084	82-92-8	6726	9147	TTDS00086	Histamine H1 receptor	H1 Histamine receptor;Histamine receptor 1	P35367	3269	ENSG00000196639	antagonist
DAP000324	Hydroxyzine	Ataraxoid; 2192-20-3 (di-hydrochloride); Hydroxyzin; Traquizine; Marex (TN); NP 212; BPBio1_000228; ST059726; 2-(2-(4-((4-Chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)ethanol; CHEBI:5818; Atarax base; BRD-A62428732-096-02-6; Hydroxyzine (INN); 1-(p-Chlorobenzhydryl)-4-(2-(2-hydroxyethoxy)ethyl)piperazine; Idrossizina; Paxistil; MolPort-002-506-318; C21H27ClN2O2; 10246-75-0 (pamoate); D08054; Orgatrax; Idrossizina [DCIT]; 2-[2-[4-(p-Chloro-.alpha.-phenylbenzyl)-1-piperazinyl]ethoxy]ethanol; Hychotine; Hydroksyzyny; HSDB 3098; Hydroxyzinum; Hydroxyzine hydrochloride; DB00557; N-(4-Chlorobenzhydryl)-N'-(hydroxyethyloxyethyl)piperazine; N-(4-Chlorobenzhydryl)-N'-(hydroxyethoxyethyl)piperazine; 1-(p-Chlorodiphenylmethyl)-4-(2-(2-hydroxyethoxy)ethyl)piperazine; 1-(p-Chloro-alpha-phenylbenzyl)-4-(2-hydroxyethoxyethyl)piperazine; BSPBio_000206; Neurozina; 1-(p-Chlorobenzhydryl)-4-[2-(2-hydroxyethoxy)ethyl]piperazine; UCB 4492; 2-(2-(4-(p-Chloro-alpha-phenylbenzyl)-1-piperazinyl)ethoxy)ethanol; Atarazoid; 1-(p-Chlorodiphenylmethyl)-4-[2-(2-hydroxyethoxy)ethyl]piperazine; Hydroxyzinum [INN-Latin]; AB00053485; EINECS 200-693-1; Hydroksyzyny [Polish]; Prestwick2_000133; WLN: T6N DNTJ AYR&R D6& D2O2Q; hydroxyzine; L000930; Ethanol, 2-(2-(4-((4-chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)-; neo-Calma; Ethanol, 2-[2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-; Atarox; Durrax; NSC 169188; CID3658; Hydroxyzyne; 68-88-2; Atara; Tranquizine; 1-(p-Chloro-alpha-phenylbenzyl)-4-(2-(2-hydroxyethoxy)ethyl)piperazine; 2-(2-{4-[(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethoxy)ethanol; BRN 0321392; U.C.B 4492; LS-66601; U.CB 4492; 1-(p-Chlorobenzhydryl)-4-(2-(2-hydroxyethoxy)ethyl)diethylenediamine; Parenteral; 1-(p-Chlorobenzhydryl)-4-[2-(2-hydroxyethoxy)ethyl]diethylenediamine; C07045; NSC169188; AC1L1GFB; UNII-30S50YM8OG; Hy-Pam 25; Plaxidol; 1-(p-Chloro-.alpha.-phenylbenzyl)-4-[2-[(2-hydroxyethoxy)ethyl]piperazine; CHEMBL896; Vesparaz-Wirkstoff; Prestwick0_000133; BRD-A62428732-300-03-0; Atarax; 5-23-01-00462 (Beilstein Handbook Reference); Nevrolaks; Hidroxizina [INN-Spanish]; Hydroxine; Hydroxycine; Placidol; Ethanol, 2-(2-(4-((4-chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)- (9CI); Vistaril; Pamazone; SPBio_002145; 2-[(2-{4-[(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethyl)oxy]ethanol; Tran-Q; Hydroxyzine Hcl; AKOS003334349; Hidroxizina; Deinait; Prestwick3_000133; Hydroxizine; Atazina; 2-[2-[4-[(4-chlorophenyl)-phenylmethyl]piperazin-1-yl]ethoxy]ethanol; Hydroxyzine base; Prestwick1_000133; Ethanol, 2-[2-[4-(p-chloro-.alpha.-phenylbenzyl)-1-piperazinyl]ethoxy]-; Fenarol; Hydroxizinum; Ethanol, 2-(2-(4-(p-chloro-alpha-phenylbenzyl)-1-piperazinyl)ethoxy)-; Aterax; UCB 492; Hydroxyzine [INN:BAN]	68-88-2	3658	9257	TTDS00086	Histamine H1 receptor	H1 Histamine receptor;Histamine receptor 1	P35367	3269	ENSG00000196639	antagonist
DAP001366	Dimethindene	AC1Q4X0G; 1H-Indene-2-ethanamine, N,N-dimethyl-3-[1-(2-pyridinyl)ethyl]-; Dimetindeno [INN-Spanish]; Z 2001; DIMETHINDENE; TL8003650; Pyridine, 2-(1-(2-(2-(dimethylamino)ethyl)inden-3-yl)ethyl)-; 5-22-11-00123 (Beilstein Handbook Reference); Pecofenil; Dimetindene; Forhistal; Dimethyl{2-[3-(2-pyridylethyl)inden-2-yl]ethyl}amine; Ambap5636-83-9; Fengel; 2-(1-(2-(2-Dimethylaminoethyl)inden-3-yl)ethyl)pyridine; 1H-Indene-2-ethanamine, N,N-dimethyl-3-(1-(2-pyridinyl)ethyl)-; Dimetindenum; EINECS 227-083-8; Dimethpyrindene; LS-131452; Dimethylpyrindene; Dimetindeno; N,N-dimethyl-2-[3-(1-pyridin-2-ylethyl)-1H-inden-2-yl]ethanamine; CID21855; Dimetindene (INN); Dimetindene [INN:BAN]; 1H-Indene-2-ethanamine, N,N-dimethyl-3-(1-(2-pyridinyl)ethyl)- (9CI); (+/-)-Dimethindene; N,N-Dimethyl-N-(3-(1-(2-pyridyl)ethyl)-2-indenylethyl)amin; Fenistil; MolPort-003-986-956; CHEMBL22108; 3614-69-5 (maleate); Dimetindenum [INN-Latin]; N,N-Dimethyl-3-(1-(2-pyridyl)ethyl)inden-2-ethylamin; BRN 0489974; DB08801; Triten; AC1L2J8D; D07853; 5636-83-9; Foristal	5636-83-9	21855	615229	TTDS00086	Histamine H1 receptor	H1 Histamine receptor;Histamine receptor 1	P35367	3269	ENSG00000196639	antagonist
DAP001403	Mizolastine	C24H25FN6O; Mizollen; CID65906; AC-634; Schwarz brand of mizolastine; 108612-45-9; Zolistam; Mistalin; UNII-244O1F90NA; CHEBI:252819; MolPort-002-885-879; ST51052747; Mizolastinum; CCRIS 8410; Mizolastine [INN]; SL 85.0324; Novag brand of mizolastine; Mizolastinum [INN-Latin]; Sanofi Synthelabo brand of mizolastine; ZINC13831810; Mizollen (TN); MKC-431; NCGC00181013-01; I06-0373; CHEMBL94454; 2-((1-(1-(p-Fluorobenzyl)-2-benzimidazolyl)-4-piperidyl)methylamino)-4(3H)-pyrimidinone; LS-135935; AC1L247Z; Zolim; SL-85.0324; Mizolastine (JAN/INN); C076170; Zolistan; AKOS005145756; Allphar brand of mizolastine; Mizolastina; Mizolastine; Mistamine; Mizolastina [INN-Spanish]; 4(1H)-Pyrimidinone, 2-((1-(1-((4-fluorophenyl)methyl)-1H-benzimidazol-2-yl)-4-piperidinyl)methylamino)-; Mizolen; Galderma brand of mizolastine; D01117; 2-[[1-[1-[(4-fluorophenyl)methyl]benzimidazol-2-yl]piperidin-4-yl]-methylamino]-1H-pyrimidin-6-one	108612-45-9	65906	207953	TTDS00086	Histamine H1 receptor	H1 Histamine receptor;Histamine receptor 1	P35367	3269	ENSG00000196639	antagonist
DAP001064	Pemirolast	9-methyl-3-(1H-tetrazol-5-yl)-4H-pyrido(1,2-a)pyrimidin-4-one; ZINC13831144; Pemirolast (INN); Pemirolastum [INN-Latin]; C10H8N6O; Pemirox; HSDB 7291; Pemirolastum; CID57697; 9-TBX; 9-methyl-3-(2H-tetrazol-5-yl)pyrido[1,2-a]pyrimidin-4-one; 4H-Pyrido(1,2-a)pyrimidin-4-one, 9-methyl-3-(1H-tetrazol-5-yl)-; L000978; Pemirolast; UNII-2C09NV773M; AC1L1NHB; Pemiroplast Potassium; DB00885; 100299-08-9 (potassium salt); LS-176743; BIDD:GT0717; Pemirolast [INN]; 69372-19-6; D07476; Pemirox (TN)	100299-08-9	57697	654148	TTDS00086	Histamine H1 receptor	H1 Histamine receptor;Histamine receptor 1	P35367	3269	ENSG00000196639	antagonist
DAP001397	Levocetirizine dihydrochloride	CID9955977; MolPort-003-983-419; Xyzal; Xyzall (TN); Levocetirizine 2HCl; (2-(4-((R)-(4-Chlorophenyl)phenylmethyl)piperazin-1-yl)ethoxy)acetic acid dihydrochloride; KS-1177; Levocetirizine dihydrochloride [USAN]; AC-549; UNII-SOD6A38AGA; D08118; Levocetirizine hydrochloride; Xyzall; 130018-87-0; CHEMBL1201190; Levocetirizine dihydrochloride; Levocetirizine hydrochloride (JAN); Levocetirizine HCl; Acetic acid, (2-(4-((R)-(4-chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)-, dihydrochloride; LS-186529	130018-77-8	9955977	728243	TTDS00086	Histamine H1 receptor	H1 Histamine receptor;Histamine receptor 1	P35367	3269	ENSG00000196639	antagonist
DAP001379	Ergotidine	51-45-6; KBio2_001325; Istamina [Italian]; Istamina; Bio1_001465; 2-Imidazol-4-ylethylamine; .beta.-Imidazolyl-4-ethylamine; Ergotidine; NCGC00015513-01; Lopac0_000595; NCGC00093371-04; Imidazole-4-ethylamine; 2-(1H-imidazol-4-yl)ethan-1-amine; Spectrum5_000796; C00388; SMP1_000151; MLS000069447; KBio2_003025; CHEMBL90; UNII-820484N8I3; STK346752; D08040; 1H-Imidazole-4-ethanamine; NCGC00015513-08; STOCK5S-55669; Ethylamine, 2-imidazol-4-yl-; BSPBio_002124; IDI1_002144; EINECS 200-100-6; KBioGR_001580; Spectrum3_000452; [3H]histamine; AC-13185; 1avn; Spectrum_000845; NINDS_000308; HSDB 3338; KBio1_000308; Spectrum4_000960; NCGC00093371-03; BSPBio_001117; bmse000744; HMS1362G19; L-histamine; nchembio.87-comp54; HMS1990G19; KBio3_000854; 1qft; SDCCGMLS-0066601.P001; Bio1_000976; Bio2_000389; H7125_SIGMA; NSC 33792; histamine; 924364-91-0; AC1Q54BW; Eramin; KBio2_003893; Bio2_000869; KBioSS_000457; MolPort-001-785-597; Histaminum (TN); beta-Imidazolyl-4-ethylamine; 2-[4-Imidazolyl]ethylamine; KBioGR_000457; LS-75835; Imidazole, 4-(2-aminoethyl)-; nchembio714-comp1; AKOS000274386; KBio3_000853; NCGC00093371-05; beta-Aminoethylimidazole; CID774; 53290_FLUKA; CHEBI:18295; F411C768-A159-4FC0-A195-291A08BB03AA; MolPort-002-042-264; ALBB-005968; KBio2_005593; Histamine (DCF); KBio3_001344; Free histamine; Ergamine; ZERO/004089; 5-Imidazoleethylamine; BCBcMAP01_000250; KBioSS_001325; Histamine, Free Base; beta-Aminoethylglyoxaline; 4-Imidazoleethylamine; HMS1792G19; KBio2_000457; IDI1_000308; 2-(1H-Imidazol-4-yl)ethanamine; Histaminum; 2-(4-Imidazolyl)ethylamine; Lopac-H-7250; CCRIS 6535; 2-(1H-imidazol-5-yl)ethanamine; Histamine Base; NSC33792; Spectrum2_000665; SPBio_000729; Theramine; ST073926; NCGC00093371-02; DivK1c_000308; 64422-25-9; AC1Q54BV; Bio1_000487; L000292; WLN: T5M CNJ D2Z; 1H-Imidazole-5-ethanamine; 4-(2-Aminoethyl)-1H-imidazole; beta-aminothethylglyoxaline; SMR000059091; AC1L19ZT; Histamine [USAN]; KBio2_006461; 2-(3H-Imidazol-4-yl)-ethylamine	75614-87-8	774	734025	TTDS00086	Histamine H1 receptor	H1 Histamine receptor;Histamine receptor 1	P35367	3269	ENSG00000196639	agonist
DAP001070	Methdilazine	10-[(1-methylpyrrolidin-3-yl)methyl]-10H-phenothiazine; PDSP1_000149; Methodilazine; EINECS 217-841-6; Methdilazinum [INN-Latin]; Methdilazine (INN); Phenothiazine, 10-((1-methyl-3-pyrrolidinyl)methyl)-; NCI-C60720; Tacryl; Methdilazine [USAN:INN:BAN]; L001130; Disyncram; Methilazine hydrochloride; DB00902; Tacaryl (TN); NCI60_001351; Metodilazina [INN-Spanish]; Tacaryl; 1982-37-2; AC1L24C6; UNII-4Q13LY9Z8X; Methdilazinum; D04979; C18H20N2S; AC1Q7G4W; 10-[(1-Methylpyrrolidin-3-yl)methyl]phenothiazine; NSC169091; 10-((1-methyl-3-pyrrolidinyl)methyl)-10H-phenothiazine; 10-((1-Methyl-3-pyrrolidinyl)methyl)phenothiazine; C07175; Md; Tacazyl; 1229-35-2 (hydrochloride); CHEMBL1200959; CID14677; METHDILAZINE; 10H-Phenothiazine, 10-[(1-methyl-3-pyrrolidinyl)methyl]-; Metodilazina; 10H-Phenothiazine, 10-((1-methyl-3-pyrrolidinyl)methyl)-; LS-979; PDSP2_000148	1982-37-2	14677	9384	TTDS00086	Histamine H1 receptor	H1 Histamine receptor;Histamine receptor 1	P35367	3269	ENSG00000196639	antagonist
DAP000329	Ketotifen	Ketotifeno; Ketotiphene; AC1L1GSZ; UNII-X49220T18G; NCGC00015580-09; 116655-74-4; Ketotifene [INN-French]; BRN 3983897; HMS2090F16; BAS 00444483; Prestwick1_000371; STK048448; Ketotifen (INN); NCGC00022572-05; AKOS000541268; Ketotifene; 4-(1-Methyl-piperidin-4-ylidene)-4,9-dihydro-1-thia-benzo[f]azulen-10-one; HC 20-511; BRD-K28936863-051-05-8; Ketotifene fumarate; L000753; Tocris-0784; NCGC00015580-03; Spectrum3_001382; Oprea1_553550; CHEBI:112957; SPBio_001275; BSPBio_002964; 4-(1-Methyl-4-piperidylidene)-9-hydrobenzo[a]thiopheno[3,2-d][7]annulen-10-one; 10H-Benzo[4,5]cyclohepta[1,2-b]thiophen-10-one, 4,9-dihydro-4-(1-methyl-4-piperidinylidene)-, (2E)-2-butenedioate (1:1); KBio2_006042; CAS-34580-14-8; 10H-Benzo(4,5)cyclohepta(1,2-b)thiophen-10-one, 4,9-dihydro-4-(1-methyl-4-piperidinylidene)-; BSPBio_000521; HSDB 7283; EINECS 252-099-7; BIDD:GT0509; NCGC00022572-04; 4,9-Dihydro-4-(1-methyl-4-piperidylidene)-10H-benzo(4,5)-cyclohepta(1,2-b)thiophen-10-one; Lopac-K-2628; Ketotiphen; Lopac0_000706; Ketotifenum; NINDS_000111; Spectrum2_001198; STOCK1S-14132; AC-15945; 4,9-Dihydro-4-(1-methyl-4-piperidinylidene)-10H-benzo(4,5)cyclohepta(1,2-b)thiophen-10-one; 10H-Benzo[4,5]cyclohepta[1,2-b]thiophen-10-one, 4,9-dihydro-4-(1-methyl-4-piperidinylidene)-; D08105; KBioSS_000906; C19H19NOS; LS-33820; Prestwick2_000371; ketotifen; Ketotifeno [INN-Spanish]; KBioGR_001289; NCGC00015580-02; IDI1_000111; KBio2_003474; CHEMBL534; Spectrum4_000805; Ketotifenum [INN-Latin]; CID3827; Spectrum_000426; Prestwick3_000371; Alaway (TN); Ketotifin; SPBio_002442; Oprea1_335550; 34580-13-7; KBio3_002184; BPBio1_000575; Prestwick0_000371; 4-(1-methylpiperidin-4-ylidene)-4,9-dihydro-10H-benzo[4,5]cyclohepta[1,2-b]thiophen-10-one; KBio2_000906; Spectrum5_001395; NCGC00015580-01; AB00053575; DivK1c_000111; KBio1_000111; MolPort-001-933-278; Ketotifen [INN:BAN]; Zaditor; DB00920; NCGC00022572-02	34580-14-8	3827	7854262	TTDS00086	Histamine H1 receptor	H1 Histamine receptor;Histamine receptor 1	P35367	3269	ENSG00000196639	antagonist
DAP001400	Mepyramine maleate	MolPort-003-666-277; Pyranisamine maleate; N-(p-Methoxybenzyl)-N,N'-dimethyl-N-2-pyridyl-1,2-ethanediamine, maleic acid salt; Mepyramine maleate; Prefrin A; N-(dimethylaminoethyl)-N-(p-methoxyphenyl)-alpha-aminopyridine maleate; AH; N-(4-methoxybenzyl)-N',N'-dimethyl-N-pyridin-2-ylethane-1,2-diamine but-2-enedioate; Histan; EINECS 200-422-7; N-(4-Methoxyphenyl)methyl-N',N'-dimethyl-N-(2-pyridinyl)-1,2-ethanediamine maleate salt; 2-((2-(Dimethylamino)ethyl)(p-methoxybenzyl)amino)pyridine bimaleate; C16H21N3O.C4H4O4; Pyrilamine maleate salt; NSC 3604; NCGC00094209-05; Histavet-P; AB1004850; Renstamin; CHEMBL1201006; Mepyramine maleate salt; Thylogen maleate; Minihist; (Z)-but-2-enedioic acid; N'-[(4-methoxyphenyl)methyl]-N,N-dimethyl-N'-pyridin-2-ylethane-1,2-diamine; HMS1920N10; N-(p-me thoxybenzyl)-N',N'-dimethyl-N-(alpha-pyridyl)ethylenediamine maleate; SPECTRUM1500519; WLN: T6NJ BN1R DO1&2N1&1 &OV1U1VO; NCGC00094209-03; Pyranilamine maleate; CCRIS 1330; Enrumay; MLS000069668; Mepyramine maleate salt; N-(4-Methoxyphenyl)methyl-N inverted exclamation marka,N inverted exclamation marka-dimethyl-N-(2-pyridinyl)-1,2-ethanediamine maleate salt; Pymafed; Pyra-Maleate; 2-((2-(Dimethylamino)ethyl)(p-methoxybenzyl)amino)pyridine maleate; AC1NR4H4; MLS001148634; Pyramal maleate; Pyridine, 2-[[2-(dimethylamino)ethyl](p-methoxybenzyl)amino]-, maleate (1:1); P 5514; 2-[[2-(Dimethylamino)ethyl](p-methoxybenzyl)amino]pyridine maleate; Paramal; Pyraninyl; 1,2-Ethanediamine, N-[(4-methoxyphenyl)methyl]-N',N'-dimethyl-N-2-pyridinyl-, (Z)-2-butenedioate (1:1); N-p-Methoxybenzyl-N',N'-dimethyl-N-alpha-pyridylethylenediamine maleate; Pyra maleate; Kriptin maleate; Histavet-P (veterinary); Dorantamin maleate; N-Dimethylaminoethyl-N-p-methoxy-alpha-aminopyridine maleate; Anisopyradamine; SMR000058495; Anthisan maleate; N-(p-methoxybenzyl)-N',N'-dimethyl-N-(alpha-pyridyl)ethylenediamine maleate; Diaminide maleate; Antihist; NCGC00094209-01; Pyrilamine maleate [USAN]; HMS500I17; CID5284451; LS-251; Neoantergan maleate; Mepiramine maleate; NCGC00094209-04; Stangen maleate; component of Pyrdex; Statomin maleate; Midol Maximum Strength PMS; Neo-Antergan maleate; N,N-dimethyl-N'-{[4-(methyloxy)phenyl]methyl}-N'-pyridin-2-ylethane-1,2-diamine (2Z)-but-2-enedioate; Prestwick_634; N-(p-Methoxybenzyl)-N',N'-dimethyl-N-.alpha.-pyridylethylenediamine maleate; 5572-06-5; Pyrilamine maleate (USP); N,N-Dimethyl-N'-(4-methoxybenzyl)-N'-(2-pyridyl)ethylenediamine maleate; Histine; PYRILAMINE MALEATE; Mepyramine hydrogen maleinate; 2786 R.P. maleate; UNII-R35D29L3ZA; Paraminyl maleate; Pyridine, 2-((2-(dimethylamino)ethyl)(p-methoxybenzyl)amino)-, maleate (1:1); 1,2-Ethanediamine, N1-((4-methoxyphenyl)methyl)-N2,N2-dimethyl-N1-2-pyridinyl-, (2Z)-2-butenedioate (1:1); Histatex; D05660; SMR000653462; 2-((2-(dimethylamino)ethyl )(p-methoxybenzyl)amino)pyridine maleate; Pymafed (TN); 1,2-Ethanediamine, N-((4-methoxyphenyl)methyl)-N',N'-dimethyl-N-2-pyridinyl-, (2Z)-2-butenedioate (1:1); pyranilamine m aleate; PYRILAMINE MALEATE (SEE ALSO PYRILAMINE, CAS 91-84-9); 59-33-6; N-(Dimethylamino)ethyl-N-(p-methoxy)-.alpha.-aminopyridine maleate; component of Endotussin-NN; EU-0100890; NCGC00094209-02; P5514_SIGMA; 1,2-Ethanediamine, N-((4-methoxyphenyl)methyl)-N',N'-dimethyl-N-2-pyridinyl-, (Z)-2-butenedioate (1:1); Histosol; NSC3604; HMS1568J20; 2-[[2-(Dimethylamino)ethyl](p-methoxybenzyl)amino]pyridine bimaleate; HMS2092E11; Pyma; 2-((2-(Dimethylamino)ethyl)(p-methoxybenzyl)amino)pyridine maleate (1:1)	59-33-6	5284451	70057	TTDS00086	Histamine H1 receptor	H1 Histamine receptor;Histamine receptor 1	P35367	3269	ENSG00000196639	antagonist
DAP001343	Acrivastine	BW A825C; ( E,E )-3-[6-[1-(4-methylphenyl)-3-(1-pyrrolidinyl)-1-propenyl]-2-pyridinyl]-2-propenoic acid; Acrivastina; -Propenoic acid, 3-[6-[(1E)-1-(4-methylphenyl)-3-(1-pyrrolidinyl)-1-propenyl]-2-pyridinyl]-, (2; CHEMBL1224; (E)-6-((E)-3-(1-Pyrrolidinyl)-1-p-tolylpropenyl)-2-pyridineacrylic acid; BIDD:GT0209; C22H24N2O2; Acrivastin; Acrivastine (USAN/INN); BW 825C; E)- (9CI); Acrivastinum; CID5284514; 2-Propenoic acid, 3-[6-[(1E)-1-(4-methylphenyl)-3-(1-pyrrolidinyl)-1-propen-1-yl]-2-pyridinyl]-, (2E)-; (E)-6-((E)-3-(1-Pyrrolidinyl-1-p-tolylpropenyl)-2-pyridinacrylsaeure; I14-8671; BW 0270C; BW-825C; (E)-3-[6-[(E)-1-(4-methylphenyl)-3-pyrrolidin-1-ylprop-1-enyl]pyridin-2-yl]prop-2-enoic acid; AC1NR4LM; AC1Q5T9P; 2-Propenoic acid, 3-[6-[1-(4-methylphenyl)-3-(1-pyrrolidinyl)-1-propenyl]-2-pyridinyl]-, (E,E)-; LS-178016; 87848-99-5; UNII-A20F9XAI7W; (2E)-3-{6-[(1E)-1-(4-methylphenyl)-3-pyrrolidin-1-ylprop-1-en-1-yl]pyridin-2-yl}prop-2-enoic acid; AKOS005067182; Acrivastine [USAN:INN:BAN]; Acrivastina [Spanish]; AC-912; D02760; 3-{6-[1-(4-methylphenyl)-3-(pyrrolidin-1-yl)prop-1-en-1-yl]pyridin-2-yl}prop-2-enoic acid; 2-Propenoic acid, 3-(6-(1-(4-methylphenyl)-3-(1-pyrrolidinyl)-1-propenyl)-2-pyridinyl)-, (E,E)-; Acrivastinum [Latin]; Semprex; MolPort-005-942-272; ACRIVASTINE	87848-99-5	5284514	17396918	TTDS00086	Histamine H1 receptor	H1 Histamine receptor;Histamine receptor 1	P35367	3269	ENSG00000196639	antagonist
DAP001075	Aceprometazine	Aceprometazina; Aceprometazina [INN-Spanish]; 10-(2-(Dimethylamino)propyl)phenothiazin-2-yl methyl ketone; AC1Q5GH0; KETONE, 10-(2-(DIMETHYLAMINO)PROPYL)PHENOTHIAZIN-2-YL METHYL; AC1L1A9L; Ethanone, 1-(10-(2-(dimethylamino)propyl)-10H-phenothiazin-2-yl)- (9CI); CHEBI:53770; LS-87167; Aceprometazine [INN:DCF]; Aceprometazinum; 1-{10-[2-(dimethylamino)propyl]-10H-phenothiazin-2-yl}ethanone; CID26035; 4-27-00-02910 (Beilstein Handbook Reference); Ethanone, 1-(10-(2-(dimethylamino)propyl)-10H-phenothiazin-2-yl)-; 1-[10-[2-(dimethylamino)propyl]phenothiazin-2-yl]ethanone; UNII-984N9YTM4Y; Acepromethazine; EINECS 236-661-9; 1-(10-(2-(Dimethylamino)propyl)-10H-phenothiazin-2-yl)ethanone; DB01615; Aceprometazinum [INN-Latin]; 13461-01-3; Aceprometazine; BRN 0038528; 1664 CB	13461-01-3	26035	10487300	TTDS00086	Histamine H1 receptor	H1 Histamine receptor;Histamine receptor 1	P35367	3269	ENSG00000196639	antagonist
DAP000102	Terfenadine	Lopac0_001213; Rapidal; SMR000058260; Stadapharm Brand of Terfenadine; Terfedura; SPBio_002155; Seldane (TN); AC1L1KA8; Triludan; Merck dura Brand of Terfenadine; Wolff Brand of Terfenadine; UNII-7BA5G9Y06Q; T9652_SIGMA; RMI 9918; ratiopharm Brand of Terfenadine; Prestwick0_000138; NCGC00089746-02; DB00342; Teldane; Terfenadin Heumann; Terfemundin; alpha-(p-tert-Butylphenyl)-4-(hydroxydiphenylmethyl)-1-piperidinebutanol; MLS000028499; Bial Brand of Terfenadine; 50679-08-8; 1-(4-tert-butylphenyl)-4-[4-[hydroxy(diphenyl)methyl]piperidin-1-yl]butan-1-ol; Prestwick_460; Cantabria Brand of Terfenadine; NCGC00016064-04; Aliud Brand of Terfenadine; MDL-9918; Oprea1_343139; NCGC00089746-03; Terfenadin Stada; D016593; Cyater; 1-(4-tert-butylphenyl)-4-[4-(hydroxydiphenylmethyl)piperidin-1-yl]butan-1-ol; ct Arzneimittel Brand of Terfenadine; C32H41NO2; Hoechst Brand of Terfenadine; Terfenadin AL; alpha-(4-[1,1-Dimethylethyl]phenyl)-4-[hydroxydiphenylmethyl]-1-piperidinebutanol; MLS001148415; NCGC00016064-08; CID5405; .alpha.-(4-(1,1-dimethylethyl)phenyl)-4-(hydroxydiphenyl-methyl)-1-piperidine butanol; terfenadin von ct; Terfenidine; alpha-(4-(1,1-Dimethylethyl)phenyl)-4-(hydroxydiphenylmethyl)-1-piperidinebutanol; Balkis Saft Spezial; Terfenadin-ratiopharm; Terfenadina; 1-(p-tert-Butylphenyl)-4-(4'-(alpha-hydroxydiphenylmethyl)-1'-piperidyl)butanol; Terfenadina [INN-Spanish]; Hisfedin; Terfenadinum; NSC665802; HMS1568K18; Prestwick2_000138; EU-0101213; CHEMBL17157; BIM-0051180.0001; Terfex; LS-114369; ct-Arzneimittel Brand of Terfenadine; KBio1_001011; NCGC00089746-04; Mundipharma Brand of Terfenadine; Ternadin; T 9652; AB00052367; HSDB 6508; terfenadine; ST50307835; 1-Piperidinebutanol, .alpha.-[4-(1,1-dimethylethyl)phenyl]-4-(hydroxydiphenylmethyl)-; Aldaban; Prestwick1_000138; Terfenadinum [INN-Latin]; Terfenadine [USAN:BAN:INN:JAN]; Teldanex; HMS2089I14; Sigma-Tau Brand of Terfenadine; NCI60_022784; EINECS 256-710-8; Seldane; RMI-9918; alpha-[4-(1,1-Dimethylethyl)phenyl]-4-(hydroxydiphenylmethyl)-1-piperidinebutanol; CHEBI:119569; MolPort-002-904-065; L000888; Prestwick3_000138; DivK1c_001011; 1-(4-tert-Butylphenyl)-4-(4-(alpha-hydroxybenzhydryl)piperidino)-butan-1-ol; Heumann Brand of Terfenadine; BSPBio_000216; 1-[4-(1,1-dimethylethyl)phenyl]-4-{4-[hydroxy(diphenyl)methyl]piperidin-1-yl}butan-1-ol; Sigma Tau Brand of Terfenadine; D00521; alpha-(4-(1,1-Dimethylethyl)phenyl)-4-(hydroxydiphenylmethyl)-1-piperdinebutanol; HMS2093I11; Terfenadine (JAN/USAN/INN); AC1Q1LZA; Allerplus; IDI1_001011; BRN 5857899; AC-15791; Dolorgiet Brand of Terfenadine; C07463; MDL 9918; NINDS_001011; BRD-A06352418-001-03-6; 1-Piperidinebutanol, alpha-(4-(1,1-dimethylethyl)phenyl)-4-(hydroxydiphenylmethyl)-; HMS503K03; Terfen; BPBio1_000238; RMI9918; Terdin	50679-08-8	5405	180732	TTDS00086	Histamine H1 receptor	H1 Histamine receptor;Histamine receptor 1	P35367	3269	ENSG00000196639	antagonist
DAP001531	Tranilast	Rizaben (TN); CID5282230; MK 341; NCGC00018185-05; 53902-12-8; CPD000058373; 3,4-DAA; n-(3',4'-dimethoxycinnamoyl) anthranilic acid; Rizaben; C18H17NO5; DB07615; SBB052710; Tranilast [USAN:INN:JAN]; tranilast; D27; Rizaben, SB 252218, MK 341, Tranpro ,Tranilast; HMS2094I21; NCGC00021458-04; Tranilast (JAN/USAN/INN); MLS001077269; N-(3&prime;,4&prime;-Dimethoxycinnamoyl)anthranilic Acid; D02027; SPECTRUM1505333; AKOS002841076; Lopac0_001193; HSCI1_000076; SB-252218; CHEMBL415324; LS-37150; HMS2051F05; N-(3,4-Dimethoxycinnamoyl)anthranilic acid; NCGC00021458-05; T0318_SIGMA; Tranilastum; SMR000058373; 2-({(2E)-3-[3,4-bis(methyloxy)phenyl]prop-2-enoyl}amino)benzoic acid; T 0318; MLS000028468; MolPort-000-375-102; Anthranilic acid, N-(3,4-dimethoxycinnamoyl)-; NU-3450; BENZOIC ACID, 2-((3-(3,4-DIMETHOXYPHENYL)-1-OXO-2-PROPENYL)AMINO)-; NCGC00021458-07; N 5'; BSPBio_003561; 2-[[(E)-3-(3,4-dimethoxyphenyl)prop-2-enoyl]amino]benzoic acid; AC1NQZP4; Tranilastum [INN-Latin]; HMS2089L07; MLS000759509; MLS002207030; AC-940; EU-0101193; NCGC00018185-09; 2-[[3-(3,4-Dimethoxyphenyl)-1-oxo-2-propenyl]amino] benzoic acid; SAM001246737; BRD-K17849083-001-02-2; MLS001065902; S1439_Selleck; 2-((3-(3,4-Dimethoxyphenyl)-1-oxo-2-propenyl)amino)benzoic acid	53902-12-8	93543	49700724	TTDS00086	Histamine H1 receptor	H1 Histamine receptor;Histamine receptor 1	P35367	3269	ENSG00000196639	antagonist
DAP000103	Cyproheptadine	4-(5H-Dibenzo(a,d)cyclohepten-5-ylidene)-1-methylpiperidine; Ciproheptadina; Viternum; HSDB 3048; nchembio.559-comp10; CHEMBL516; Cyproheptadine (INN); NCGC00015252-03; AKOS004119847; Prestwick3_000103; Cyproheptadinum; Prestwick1_000103; Ciproheptadina [INN-Spanish]; Prestwick0_000103; BPBio1_000096; 5-20-08-00500 (Beilstein Handbook Reference); Tocris-0996; BRD-K28143534-003-03-6; BRN 1685976; L001016; Piperidine, 4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-methyl-; Lopac0_000246; CCRIS 5232; 4-(5-Dibenzo(a,d)cyclohepten-5-ylidine)-1-methylpiperidine; SPBio_002025; Cyproheptadine [INN:BAN]; Cypoheptadine; HMS2090P20; NCGC00024293-02; C06935; NCGC00015252-02; MK 141; 1-Methyl-4-(5-dibenzo(a,e)cycloheptatrienylidene)piperidine; DB00434; Dronactin; D07765; Ciprovit (TN); CHEBI:4046; NCGC00024293-05; MolPort-002-507-777; PDSP2_001213; UNII-2YHB6175DO; EINECS 204-928-9; Eiproheptadine; Biomol-NT_000131; STK802098; 4-(5H-dibenzo[a,d][7]annulen-5-ylidene)-1-methylpiperidine; CYPROHEPTADINE; PDSP1_001229; Prestwick2_000103; BPBio1_000155; Dihexazin; NCGC00015252-09; Cyproheptadine Hcl; Oprea1_498140; 129-03-3; AC1L1ER8; 4-(5H-Dibenzo(a,d)cyclohepten-5-ylidene)-1-methylpiperidene; 41354-29-4; BRD-K28143534-001-01-4; Dibenzosuberonone/Cyproheptadine; Lopac-C-6022; Periactin; Ciprovit; Piperidine, 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-methyl-; BIDD:GT0324; CAS-969-33-5; Cyproheptadiene; 4-(5H-Dibenzo[a,d]cyclohepten-5-ylidene)-1-methylpiperidine; 5-(1-Methylpiperidylidene-4)-5H-dibenzo(a,d)cyclopheptene; LS-114933; Periactinol; CID2913; Periactine; 1-Methyl-4-(5H-dibenzo(a,d)cycloheptenylidene)piperidine; BSPBio_000086; Cyproheptadinum [INN-Latin]; NCGC00024293-04; NCGC00015252-01	129-03-3	2913	597387	TTDS00086	Histamine H1 receptor	H1 Histamine receptor;Histamine receptor 1	P35367	3269	ENSG00000196639	antagonist
DAP000326	Astemizole	Smaller Brand of Astemizole; Laridal; CAS-68844-77-9; HISMANAL (TN); Alermizol; KBio2_000928; ST51014896; Astemizole Alacan Brand; Astemina; DivK1c_000039; QTL1_000010; Histamen; C28H31FN4O; Astemizole Urbion Brand; Lesvi Brand of Astemizole; Rifedot; MJD-30; NCGC00022520-05; Astemizole Elfar Brand; UPCMLD-DP024; BPBio1_000234; Paralergin; McNeil Brand of Astemizole; KBioGR_001686; Astemizol ratiopharm; Simprox; EINECS 272-441-9; HMS500B21; HMS2090F14; Histazol; AC1L1D93; astemizole; Wareezol; Spectrum4_001223; nchembio732-comp2; KBio1_000039; NCGC00022520-06; Medinsa Brand of Astemizole; GNF-PF-2461; Astemizole Merck Brand; Spectrum2_001732; Rimbol; Metodih; Astemizole Medinsa Brand; Emdar; Prestwick3_000136; Novo-mastizol A; R 43 512; CID2247; Prestwick_35; KBio2_003496; MLS000028667; Astemizole ratiopharm Brand; C06832; Metodik; R-43-512; Astemizole Diba Brand; Astemizolum [INN-Latin]; Hestazol, Kelp, Laridal, Retolen, Wareezol, HSBD 6799, BRN 4830190; Senosiain Brand of Astemizole; Waruzol; Astemisan; HMS1568K14; Astemizole Lesvi Brand; CHEMBL296419; Astemizole Esteve Brand; NCGC00016913-01; HSDB 6799; Astemizole (JAN/USP/INN); Astemizolum; Byk Brand of Astemizole; KBioSS_000928; NINDS_000039; Fustery Brand of Astemizole; Spectrum_000448; BRD-K37249724-001-05-9; R 42512; Hubermizol; Retolen; NCGC00018288-01; Astemizole Senosiain Brand; nchembio806-comp1; 68844-77-9; BRN 4830190; R43512; Astemizole [USAN:BAN:INN]; Astemizole ICN Brand; Hismanal; Astemizol [German]; IDI1_000039; NCGC00022520-07; MLS001148073; BSPBio_002684; LS-32978; Astemizole Smaller Brand; Romadin; Urdrim; Janssen Brand of Astemizole; Prestwick0_000136; Elfar Brand of Astemizole; Vita Brand of Astemizole; AKOS005064371; Hestazol; Alonga, Astemizol; Astemizole Septa Brand; Kelp; 1-(p-Fluorobenzyl)-2-((1-(p-methoxyphenethyl)-4-piperidyl)amino)benzimidazole; HMS2093L18; NCGC00022520-03; Reig Jofre Brand of Astemizole; Urbion Brand of Astemizole; D00234; Astemizole Byk Brand; Esteve Brand of Astemizole; L001015; Astemizole Janssen Brand; DB00637; Astemizole McNeil Brand; AB00052413; Nono-Nastizol A; SMR000058911; Esmacen; Astemizole Vita Brand; Prestwick2_000136; CHEBI:2896; R-43512; NCGC00022520-04; Septa Brand of Astemizole; ratiopharm, Astemizol; SPECTRUM2300094; CCRIS 7595; Astemisol; Astemizol [INN-Spanish]; Alonga Brand of Astemizole; Astemison; BSPBio_000212; Histaminos; Astesen; KBio2_006064; Astemizol; Astemizole Alonga Brand; SPBio_001804; SPBio_002151; Spectrum5_001239; Merck Brand of Astemizole; Astemizol Alonga; ratiopharm Brand of Astemizole; NSC329963; MolPort-003-666-765; Fustermizol; UPCMLD-DP024:001; Spectrum3_001072; HMS1922L12; ICN Brand of Astemizole; Diba Brand of Astemizole; KBio3_001904; Astemizole Fustery Brand; [3H]Astemizole; Prestwick1_000136; Alacan Brand of Astemizole; D016589	68844-77-9	2247	188751	TTDS00086	Histamine H1 receptor	H1 Histamine receptor;Histamine receptor 1	P35367	3269	ENSG00000196639	antagonist
DAP000177	Doxepin	AC1LDI5F; Spectrum2_000133; Doxepin (Z)-isomer; CID667477; Doxepinum [INN-Latin]; KBioGR_001131; LS-174582; Doxepina [INN-Spanish]; 11-(3-Dimethylaminopropylidene)-6,11-dihydrodibenz(b,e)oxipin; NCGC00162127-01; Quitaxon; BPBio1_000118; KBio2_006421; Tocris-0508; 11-(3-(Dimethylamino)propylidene)-6H-dibenz(b,e)oxepine; Sinequan; Lopac0_000339; CHEBI:4710; NCGC00024623-02; CID10039438; AKOS001582771; BRD-K36616567-003-01-5; (3Z)-3-(6H-benzo[c][1]benzoxepin-11-ylidene)-N,N-di(methyl)propan-1-amine; SPBio_000206; Zonalon; CHEBI:36692; Prestwick0_000263; AC1L1FAW; Cidoxepin; NINDS_000431; Prestwick1_000263; UNII-5ASJ6HUZ7D; UNII-F96TTB8728; Dibenz(b,e)oxepin-.delta.11(6H),.gamma.-propylamine, N,N-dimethyl-; IDI1_000431; Spectrum4_000526; Dibenz(b,e)oxepin-.delta.(sup 11(6H)),.gamma.-propylamine, N,N-dimethyl-; DivK1c_000431; Doxepin, Hydrochloride; Doxepin (INN); CID5462131; MF 10; MolPort-005-933-834; KBioSS_001285; AC1NUW4A; Spectrum3_000407; CHEMBL101740; doxepin; NCGC00015344-01; NCGC00024623-01; C19H21NO; Doxepina; CID3158; Cidoxepinum; 3-Dibenz[b,e]oxepin-11(6H)-ylidene-N,N-dimethyl-1-propanamine; cis-doxepin; CAS-1229-29-4; D07875; MOLI001594; Doxepinum; HSDB 3069; AC1LDI63; Spectrum5_001051; N,N-Dimethyldibenz(b,e)oxepin-delta(11(6H),gamma)-propylamine; BRD-K37694030-003-02-8; 1-Propanamine, 3-dibenz[b,e]oxepin-11(6H)-ylidene-N,N-dimethyl-; NCGC00015344-02; 11-(3-Dimethylamino-propyliden)-6,11-dihydro-dibenz(b,e)oxipin; 3-(6H-benzo[c][1]benzoxepin-11-ylidene)-N,N-dimethylpropan-1-amine; Dibenz(b,e)oxepin-delta(sup 11(6H)),gamma-propylamine, N,N-dimethyl-; Doxepin Hydrochloride,; BSPBio_001934; CID667468; (3Z)-3-(6H-benzo[c][1]benzoxepin-11-ylidene)-N,N-dimethylpropan-1-amine; (3Z)-3-dibenzo[b,e]oxepin-11(6H)-ylidene-N,N-dimethylpropan-1-amine; CCRIS 9176; Sinequan (TN); MolPort-003-847-024; SPBio_002325; Cidoxepina; Spectrum_000805; L000699; C06971; (3E)-3-dibenzo[b,e]oxepin-11(6H)-ylidene-N,N-dimethylpropan-1-amine; 3607-18-9; BSPBio_000106; cis-N-(3-(6H-Dibenz(b,e)oxepin-11-yliden)propyl)-N,N-dimethylamin; DB01142; KBio1_000431; Doxepine; LS-61638; 1668-19-5; Oprea1_473232; NCGC00015344-04; 3-dibenzo[b,e]oxepin-11(6H)-ylidene-N,N-dimethylpropan-1-amine; Lopac-D-4526; KBio3_001154; KBio2_001285; CHEBI:36691; Triadapin; Doxepin [USAN]; Prestwick2_000263; (Z)-Doxepin; Cidoxepin [INN]; (3E)-3-(6H-benzo[c][1]benzoxepin-11-ylidene)-N,N-dimethylpropan-1-amine; BRD-K54462405-003-03-3; Prestwick3_000263; 1-Propanamine, 3-dibenz(b,e)oxepin-11(6H)-ylidene-N,N-dimethyl-; KBio2_003853	1668-19-5	667477	158785	TTDS00086	Histamine H1 receptor	H1 Histamine receptor;Histamine receptor 1	P35367	3269	ENSG00000196639	inhibitor
DAP000327	Propiomazine	Propiomazine [USAN:BAN:INN]; Propiomazina [INN-Spanish]; Spectrum3_000559; DivK1c_000296; UNII-242Z0PM79Y; NINDS_000296; KBio2_003920; 1-Propanone, 1-[10-[2-(dimethylamino)propyl]-10H-phenothiazin-2-yl]-; Propiomazine (USAN/INN); AC1L1J9S; propiomazine; 10-(2-Dimethylaminopropyl)-2-propionylphenothiazine; Spectrum5_001104; Propionylpromethazine; BRD-A10471441-050-02-8; KBioSS_001352; C07405; Wy-1359; KBio2_006488; 362-29-8; DB00777; Phenoctyl; Spectrum_000872; BSPBio_002237; 2-Propionyl-10-(2-(dimethylamino)propyl)phenothiazine; 1-Propanone, 1-(10-(2-(dimethylamino)propyl)phenothiazin-2-yl)-; Spectrum4_000491; D02361; 3-Propionyl-10-dimethylaminoisopropylphenothiazine; KBio1_000296; 1-(10-(2-(Dimethylamino)propyl)phenothiazin-2-yl)-1-propanone; KBioGR_001001; CID4940; CHEBI:8491; KBio3_001737; 1-{10-[2-(dimethylamino)propyl]-10H-phenothiazin-2-yl}propan-1-one; 10-Dimethylaminoisopropyl-2-propionylphenothiazine; L000807; 1-Propanone, 1-(10-(2-(dimethylamino)propyl)-10H-phenothiazin-2-yl)-; Propiomazinum [INN-Latin]; NCGC00178744-01; HSDB 3275; LS-122934; EINECS 206-646-1; Propiomazinum; IDI1_000296; Propiomazina; SPBio_000840; 1-[10-[2-(dimethylamino)propyl]phenothiazin-2-yl]propan-1-one; Spectrum2_000930; KBio2_001352; Oprea1_617420; Propiomazine [USAN:INN:BAN]	362-29-8	4940	7849420	TTDS00086	Histamine H1 receptor	H1 Histamine receptor;Histamine receptor 1	P35367	3269	ENSG00000196639	antagonist
DAP000330	Fexofenadine	KBio3_002742; STOCK6S-26154; KBio2_007585; L000869; 4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)-1-piperidinyl)butyl)-alpha,alpha-dimethylbenzeneacetic acid; HSDB 7486; CID3348; 76815-58-2; Fexofenadine [INN:BAN]; UNII-E6582LOH6V; NCGC00092389-02; CHEBI:5050; Spectrum4_000204; Terfenidine carboxylate, MDL 16455; Lopac0_000488; D07958; NCGC00015453-06; Fexofenadine (INN); 2-[4-(1-hydroxy-4-{4-[hydroxy(diphenyl)methyl]piperidin-1-yl}butyl)phenyl]-2-methylpropanoic acid; C06999; 2-[4-[1-hydroxy-4-[4-[hydroxy(diphenyl)methyl]piperidin-1-yl]butyl]phenyl]-2-methylpropanoic acid; Carboxyterfenadine; MDL 16455; Terfenadine acid metabolite; fexofenadine; 159389-12-5; KBio2_005017; Spectrum2_001179; CHEMBL914; DB00950; Spectrum_001914; LS-28827; AC1L1FQB; MolPort-002-508-207; KBioSS_002456; F 9427; KBio2_002449; NCGC00092389-03; NCGC00015453-03; EU-0100488; Benzeneacetic acid, 4-(1-hydroxy-4-(4-(hydroxydiphenylmethyl)-1-piperidinyl)butyl)-alpha,alpha-dimethyl-; STK624102; BSPBio_003521; Fexofendine; SPBio_001197; Terfenadine-COOH; Telfast (TN); C32H39NO4; Terfenadine carboxylate; KBioGR_000807; BRD-A73368467-003-02-8; Spectrum5_001474; Spectrum3_001921; 83799-24-0	83799-24-0	3348	205190	TTDS00086	Histamine H1 receptor	H1 Histamine receptor;Histamine receptor 1	P35367	3269	ENSG00000196639	antagonist
DAP001080	Chlophedianol	Dencyl; Tussistop; AC-16003; DB04837; 2-Cloro-alpha-(2-dimetilaminoetil)-benzidrolo; 791-35-5; Abehol; Benzhydrol, 2-chloro-.alpha.-[2-(dimethylamino)ethyl]-; Clofedianolo [Italian]; UNII-42C50P12AP; CID2795; 1-(2-chlorophenyl)-3-dimethylamino-1-phenylpropan-1-ol; CHLOPHEDIANOL; 1-Phenyl-1-(o-chlorophenyl)-3-dimethylaminopropanol; MLS002706537; AC1L1EHH; SMR001573941; alpha-(Dimethylaminoethyl)-o-chlorobenzhydrol; 1-(2-Chlorophenyl)-1-phenyl-3-dimethylaminopropanol; SL 501 base; Clofedanol (INN); Clofedano; Eutus; 2-Chloro-.alpha.-(2-dimethylaminoethyl)benzhydrol; Benzenemethanol, 2-chloro-.alpha.-[2-(dimethylamino)ethyl]-.alpha.-phenyl-; 511-13-7 (hydrochloride); Clofedanolum [INN-Latin]; Clofedanol [INN:BAN]; 2-Chloro-alpha-(2-(dimethylamino)ethyl)benzhydrol; C17H20ClNO; .alpha.-(Dimethylaminoethyl)-o-chlorobenzhydrol; EINECS 212-340-9; Clofedanol; Clofedianolo; AC1Q3WPB; MolPort-005-935-569; Chlofedanol; 1-(2-Chlorophenyl)-3-(dimethylamino)-1-phenyl-1-propanol; D07721; Benzhydrol, 2-chloro-alpha-(2-(dimethylamino)ethyl)-; Clophedianol base; LS-32306; Calmotusin; BRN 2813922; Benzenemethanol, 2-chloro-alpha-(2-(dimethylamino)ethyl)-alpha-phenyl-; 2-Cloro-alpha-(2-dimetilaminoetil)-benzidrolo [Italian]; NSC113595; Benzenemethanol, 2-chloro-alpha-(2-(dimethylamino)ethyl)-alpha-phenyl- (9CI); Antitussin (TN); Ulo base; Antitussin; Clofedanolum; 1-(2-chlorophenyl)-3-(dimethylamino)-1-phenylpropan-1-ol; NSC 113595	791-35-5	2795	10347370	TTDS00086	Histamine H1 receptor	H1 Histamine receptor;Histamine receptor 1	P35367	3269	ENSG00000196639	antagonist
DAP001378	Dimethindene maleate	Dimetindene hydrogen maleate; Pyridine, 2-(1-(2-(2-(dimethylamino)ethyl)inden-3-yl)ethyl)-, maleate (1:1); Dimethinden maleate; Dimethindene Malenate; 1H-Indene-2-ethanamine, N,N-dimethyl-3-(1-(2-pyridinyl)ethyl)-, (Z)-2-butenedioate (1:1); Forhistal maleate (TN); Dimetindene maleate; LS-131453; 5636-83-9 (Parent); MLS002704010; C20H24N2.C4H4O4; 1H-Indene-2-ethanamine, N,N-dimethyl-3-[1-(2-pyridinyl)ethyl]-, (Z)-2-butenedioate (1:1); Pyridine, 2-[1-[2-[2-(dimethylamino)ethyl]inden-3-yl]ethyl]-, maleate (1:1); Forhistal maleate; Forthistal maleate; NSC 107677; Z 820; SMR001570719; AC1NR00Y; Dimetindene maleate (JAN); EINECS 222-789-2; Dimethindene maleate; D01343; Dimethindene maleate (USAN); I14-13956; Dimethindene maleate [USAN]; SU-6518; Dimethpyrindene maleate; UNII-6LL60J9E0O; (Z)-but-2-enedioic acid; N,N-dimethyl-2-[3-(1-pyridin-2-ylethyl)-1H-inden-2-yl]ethanamine; Fenistil; SU 6518; 2-(1-(2-(2-(Dimethylamino)ethyl)inden-3-yl)ethyl)pyridine maleate (1:1); CID5282414; NSC107677; 2-[1-[2-[2-(Dimethylamino)ethyl]inden-3-yl]ethyl]pyridine maleate (1:1); Triten; Fenistil-retard; 2-(1-(2-(2-(Dimethylamino)ethyl)inden-3-yl)ethyl)pyridine maleate; 3614-69-5	3614-69-5	5282414	668296	TTDS00086	Histamine H1 receptor	H1 Histamine receptor;Histamine receptor 1	P35367	3269	ENSG00000196639	antagonist
DAP000859	Doxylamine	HSDB 5184; Ethanamine, N,N-dimethyl-2-(1-phenyl-1-(2-pyridinyl)ethoxy)-; Doxylaminum [INN-Latin]; KBio3_001158; Doxylaminum; NCGC00089789-04; 469-21-6; Phenyl-2-pyridylmethyl-beta-N,N-dimethylaminoethyl ether; CID3162; D004319; Prestwick1_000027; N,N-dimethyl-2-[(1-phenyl-1-pyridin-2-ylethyl)oxy]ethanamine; Pyridine, 2-(alpha-(2-(dimethylamino)ethoxy)-alpha-methylbenzyl)-; SPBio_000130; DB00366; NINDS_000841; NCGC00089789-05; BSPBio_000093; Dossilamina [DCIT]; NCGC00089789-02; Prestwick3_000027; CHEBI:51380; MolPort-005-935-542; Prestwick2_000027; C17H22N2O; NCI C60684; KBio1_000841; KBioSS_001494; Spectrum5_000949; DivK1c_000841; AC-15949; Pyridine, 2-[.alpha.-[2-(dimethylamino)ethoxy]-.alpha.-methylbenzyl]-; EINECS 207-414-2; Spectrum_001014; BRD-A44008656-036-05-0; STL018676; 2-(alpha-(2-(Dimethylamino)ethoxy)-alpha-methylbenzyl)pyridine; AB00053466; Doxylamine [INN:BAN]; UNII-95QB77JKPL; L001076; BPBio1_000103; KBio2_006630; 2-Dimethylaminoethoxyphenylmethyl-2-picoline; SPBio_002014; KBioGR_001135; AC1L1FB8; IDI1_000841; Doxilminio; 5-21-03-00508 (Beilstein Handbook Reference); Prestwick0_000027; N,N-dimethyl-2-[1-phenyl-1-(pyridin-2-yl)ethoxy]ethanamine; Spectrum2_000115; Doxylamine (INN); Dossilamina; D07878; doxylamine; KBio2_001494; Doxilminio [INN-Spanish]; CHEMBL1004; doxilamina; Ethanamine, N,N-dimethyl-2-[1-phenyl-1-(2-pyridinyl)ethoxy]-; KBio2_004062; N,N-Dimethyl-2-(1-phenyl-1-(2-pyridinyl)ethoxy)ethanamine; Spectrum4_000528; BRN 0230379; N,N-dimethyl-2-(1-phenyl-1-pyridin-2-ylethoxy)ethanamine; BSPBio_001938; NCGC00021147-08; Spectrum3_000409; LS-127; Lopac0_000348	469-21-6	3162	7979131	TTDS00086	Histamine H1 receptor	H1 Histamine receptor;Histamine receptor 1	P35367	3269	ENSG00000196639	antagonist
DAP000336	Chlorpheniramine	Clorfeniramina [Italian]; Antagonate; Clorfeniramina; NCGC00162108-01; Chlorphenaminum [INN-Latin]; ISOCLOR; Telachlor; Allergisan; BSPBio_000134; 2-Pyridinepropanamine, .gamma.-(4-chlorophenyl)-N,N-dimethyl-, (S)-; Oprea1_779072; CHEMBL505; 132-22-9; C06905; Prestwick0_000117; Clorfenamina; L000003; KBio1_000596; EINECS 205-054-0; n.-Propanamine, 3-(4-chlorophenyl)-3-(2-pyridyl)-N,N-dimethyl-; 1-(p-Chlorophenyl)-1-(2-pyridyl)-3-dimethylaminopropane; 2-(p-Chloro-alpha-(2-(dimethylamino)ethyl)benzyl)pyridine; Aller-Chlor; Chloroprophenpyridamine; Kloromin; BPBio1_000148; MolPort-002-507-837; Pyridine, 2-(p-chloro-alpha-(2-(dimethylamino)ethyl)benzyl)-; DivK1c_000596; Chlor-Pro; UNII-3U6IO1965U; Prestwick2_000117; NCGC00015227-05; Chloropheniramine; STK736174; 3-(p-Chlorophenyl)-3-(2-pyridyl)-N,N-dimethylpropylamine; NINDS_000596; Chlorpheniraminum; Cloropiril; Chlorphenamine [INN]; Chlorphenaminum; 46970-45-0; CHLORPHENIRAMINE (SEE ALSO: CHLORPHENIRAMINE MALEATE (CAS113-92-8)); Chlorphenamine; Prestwick3_000117; Clofeniramina (TN); Chlor-trimeton; Chlo-amine; PiriIton; Piriton; Gen-Allerate; 3-(4-chlorophenyl)-N,N-dimethyl-3-pyridin-2-ylpropan-1-amine; 113-92-8; 4-Chloropheniramine; C16H19ClN2; HMS2090M21; CID2725; DB01114; 3-(4-chlorophenyl)-N,N-dimethyl-3-(pyridin-2-yl)propan-1-amine; Novo-Pheniram; Teldrin; HSDB 3032; CHEBI:52010; Haynon; gamma-(4-Chlorophenyl)-gamma-(2-pyridyl)propyldimethylamine; IDI1_000596; Allergican; 2-Pyridinepropanamine, .gamma.-(4-chlorophenyl)-N,N-dimethyl-; Histadur; STOCK5S-99837; Pediacare Allergy Formula; SPBio_002073; LS-754; AC1L1EBQ; Prestwick1_000117; D07398; AKOS001650136; Hayon; Chlorophenylpyridamin; Chlorprophenpyridamine; BRD-A04553218-050-03-0; Chloropiril; Chlorphenamine (INN); Chlor-Trimeton Repetabs; 2-Pyridinepropanamine, gamma-(4-chlorophenyl)-N,N-dimethyl-; Clorfenamina [INN-Spanish]; 1-(p-Chlorophenyl)-1-(2-pyridyl)-3-N,N-dimethylpropylamine; Lopac0_000261; Polaronil; Phenetron; Clofeniramina; [3H]Chlorpheniramine; gamma-(4-Chlorophenyl)-N,N-dimethyl-2-pyridinepropanamine; chlorpheniramine; Chlorophenylpyridamine; 42882-96-2	132-22-9	2725	151743	TTDS00086	Histamine H1 receptor	H1 Histamine receptor;Histamine receptor 1	P35367	3269	ENSG00000196639	antagonist
DAP000331	Desloratadine	HMS2052H05; 100643-71-8; Azomyr; Clarinex RediTabs; MLS000759406; Desloratadine [USAN]; CPD000149358; Denosin; CID124087; Descarboethoxyoratidine; Essex brand of desloratadine; Clarinex; Sch-34117; 5H-Benzo(5,6)cyclohepta(1,2-b)pyridine, 8-chloro-6,11-dihydro-11-(4-piperidinylidene)-; AC-1279; STK586537; L001025; D03693; NCGC00159325-02; Desalex; HMS2093F19; Sch 34117; Descarboethoxyloratadine; Claramax; SAM001246545; Opulis; AKOS000280921; DB00967; CHEMBL1172; 8-chloro-11-(piperidin-4-ylidene)-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine; Neoclarityn; Allex; Aerius; NSC675447; MLS001201801; 8-Chloro-11-piperidin-4-ylidene-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine; BB_SC-2104; Schering brand of desloratadine; NCGC00159325-04; I06-1866; Desloratidine; LS-181814; HMS2090C06; TL8000065; C121345; Clarinex (TN); AC1L3XUD; NCGC00159325-03; 8-Chloro-6,11-dihydro-11-(4-piperidinylidene)-5H-benzo(5,6)cyclohepta(1,2-b)pyridine; CHEBI:291342; MolPort-000-883-875; Desloratadine; Schering-Plough brand of desloratadine; Desloratadine (USAN/INN); MLS000559042; 5H-Benzo(5,6)cyclohepta(1,2-b)pyridine,8-chloro-6,11-dihydro-11-(4-piperidinyllidene)-; SMR000149358; UNII-FVF865388R; D3787	100643-71-8	124087	700854	TTDS00086	Histamine H1 receptor	H1 Histamine receptor;Histamine receptor 1	P35367	3269	ENSG00000196639	antagonist
DAP001067	Emedastine	D07890; KB-2413; KG-2413; NCGC00181341-01; DB01084; Emedastinum [INN-Latin]; UNII-9J1H7Y9OJV; C17H26N4O; CHEBI:119712; 87233-61-2; AC1L1FFW; 1-(2-ethoxyethyl)-2-(4-methyl-1,4-diazepan-1-yl)-1H-benzimidazole; L001093; Emedastina [INN-Spanish]; Emedastina; CHEBI:4779; 87233-62-3 (difumarate); Emedastine (INN); CID3219; 1-(2-ethoxyethyl)-2-(4-methyl-1,4-diazepan-1-yl)benzimidazole; Emedastinum; 1-(2-Ethoxyethyl)-2-(4-methyl-1-homopiperazinyl)benzimidazole difumarate; 1-Methyl-4-(1-(2-ethoxyethyl)-1H-benzimidazo)-2-yl)(1,4)diazepane; C07785; 1H-Benzimidazole, 1-(2-ethoxyethyl)-2-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-; Emadine; 1-(2-Ethoxyethyl)-2-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)benzimidazole; emedastine; CHEMBL594; Emadine (TN); Emedastine [INN]; Emedastine difumarate; KB 2413; LS-177979; 1-[2-(ethoxy)ethyl]-2-(4-methyl-1-homopiperazinyl)benzimidazole; Emedastine [INN:BAN]; KG 2413	87233-61-2	3219	9987	TTDS00086	Histamine H1 receptor	H1 Histamine receptor;Histamine receptor 1	P35367	3269	ENSG00000196639	antagonist
DAP001553	Alcaftadine	N/A	N/A	N/A	N/A	TTDS00086	Histamine H1 receptor	H1 Histamine receptor;Histamine receptor 1	P35367	3269	ENSG00000196639	antagonist
DAP001079	Azatadine	5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 6,11-dihydro-11-(1-methyl-4-piperidinylidene)-; UNII-94Z39NID6C; CHEMBL946; L001081; Azatadinum [INN-Latin]; DB00719; Azatadine [INN:BAN]; Azatadina; CHEBI:2946; Azatadinum; D07482; CID19861; C07774; Azatadina [INN-Spanish]; 3964-81-6; 11-(1-methylpiperidin-4-ylidene)-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine; 11-(1-Methyl-4-piperidinylidene)-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine; Azatadine maleate; Azatidine; C20H22N2; LS-174797; AZATADINE; 6,11-Dihydro-11-(1-methyl-4-piperidylidene)-5H-benzo(5,6)cyclohepta(1,2-b)pyridine; 3978-86-7 (maleate); Azatadine (INN); AC1L2F0Z	3964-81-6	19861	9976	TTDS00086	Histamine H1 receptor	H1 Histamine receptor;Histamine receptor 1	P35367	3269	ENSG00000196639	antagonist
DAP001063	Pheniramine	2-(alpha-(2-Dimethylaminoethyl)benzyl)pyridine; NSC 47965; KBio3_001600; 3-Phenyl-3-(2-pyridyl)-N,N-dimethylpropylanine; WLN: T6NJ BYR&2N1&1; IDI1_000235; Prestwick0_000059; Pyriton; NCGC00015831-03; 86-21-5; 2-Pyridinepropanamine, N,N-dimethyl-gamma-phenyl-; Oprea1_875595; Pyridine, 2-(alpha-(2-(dimethylamino)ethyl)benzyl)-; DivK1c_000235; AB00053521; SPBio_002138; SPBio_001274; Spectrum_001075; KBio2_006691; Lopac0_000981; CHEBI:308661; 2-[.alpha.-[2-(Dimethylamino)ethyl]benzyl]pyridine; Prestwick1_000059; BSPBio_000217; Spectrum5_001028; 2-Pyridinepropanamine, N,N-dimethyl-gamma-phenyl- (9CI); Spectrum2_001277; N,N-dimethyl-3-phenyl-3-pyridin-2-ylpropan-1-amine; 2-Pyridinepropanamine, N,N-dimethyl-.gamma.-phenyl-; KBio2_001555; 2-(3-Dimethylamino-1-phenylpropyl)pyridine; Prophenpyridamine; D08355; Dimethyl(3-phenyl-3-(2-pyridyl)propyl)amine; 2-Pyridinepropanamine, N,N-dimethyl-.gamma.-phenyl-; 3-Phenyl-3-(2-pyridyl)-N,N-dimethylpropylamine; Spectrum3_000760; DB01620; Pheniramine Bimaleate; Feniramina; Trimeton; pheniramine; CHEMBL1193; NSC47965; Dimethyl(3-phenyl-3-(2-pyridyl)propyl)amine; MolPort-002-561-441; CID4761; Pheniraminum [INN-Latin]; 132-20-7 (bimaleate); Tripoton; Spectrum4_000966; UNII-134FM9ZZ6M; BRN 0192445; KBio2_004123; Pheniramine [INN:BAN]; NCGC00162306-01; 1-Phenyl-1-(2-pyridyl)-3-dimethylaminopropane; Metron; Prestwick3_000059; STOCK2S-17773; Prestwick2_000059; Avil; Feniramine; Pheniramine (INN); Pheniraminum; LS-1852; KBioGR_001311; NINDS_000235; Histapyridamine; p-Aminosalicylsaures salz; 5-22-10-00487 (Beilstein Handbook Reference); Feniramina [INN-Spanish]; BPBio1_000239; N,N-Dimethyl-3-phenyl-3-(2-pyridyl)propylamine; Pyridine, 2-[.alpha.-[2-(dimethylamino)ethyl]benzyl]-; BSPBio_002380; Propheniramine; PHENIRAMINE (SEE ALSO PHENIRAMINE MALEATE 132-20-7); KBio1_000235; EINECS 201-656-2; AC1L1IW8; NCI-C60695; KBioSS_001555; 2-[.alpha.-(2-Dimethylaminoethyl)benzyl]pyridine; BRD-A23072235-050-05-2	86-21-5	4761	100679	TTDS00086	Histamine H1 receptor	H1 Histamine receptor;Histamine receptor 1	P35367	3269	ENSG00000196639	antagonist
DAP000332	Azelastine	Azelastinum [INN-Latin]; CID2267; L001153; 37932-96-0 (unspecified hydrochloride); DB00972; C07768; Spectrum2_000649; 4-(p-chlorobenzyl)-2-(N-methylperhydroazepinyl-(4))-1-(2H)-phthalazinone; AC1L1DAR; CHEBI:2950; Azelastine (INN); Spectrum3_001984; 4-((4-chlorophenyl)methyl)-2- (hexahydro-1-methyl-1H-azepin-4-yl)-1(2H)- phthalazinone HCl; BSPBio_003584; Azelastine [INN:BAN]; 4-[(4-chlorophenyl)methyl]-2-(1-methylazepan-4-yl)phthalazin-1-one; 1(2H)-Phthalazinone, 4-((4-chlorophenyl)methyl)-2-(hexahydro-1-methyl-1H-azepin-4-yl)-; Azelastina; LS-109214; I14-2736; C22H24ClN3O; NCGC00177979-01; 4-(p-Chlorobenzyl)-2-(hexahydro-1-methyl-1H-azepin-4-yl)-1-(2H)-phthalazinone; UNII-ZQI909440X; Optivar (TN); 4-((4-Chlorophenyl)methyl)-2-(hexahydro-1-methyl-1H-azepin-4-yl)-1(2H)-phthalazinone hydrochloride; D07483; 79307-93-0 (hydrochloride); SPBio_000657; BRN 0900747; 4-(4-chlorobenzyl)-2-(1-methylazepan-4-yl)phthalazin-1(2H)-one; 4-[(4-chlorophenyl)methyl]-2-(1-methylazepan-4-yl)phthalazin-1(2H)-one; Azelastina [INN-Spanish]; BRD-A68888262-003-02-9; Azelastinum; azelastine; CHEMBL639; KBio3_002992; I06-0157; Optivar; 58581-89-8	58581-89-8	2267	9970	TTDS00086	Histamine H1 receptor	H1 Histamine receptor;Histamine receptor 1	P35367	3269	ENSG00000196639	antagonist
DAP000333	Dimenhydrinate	NCGC00017026-01; Prestwick_892; 2-(diphenylmethoxy)-N,N-dimethylethanaminium 8-chloro-1,3-dimethyl-2,6-dioxo-1,2,3,6-tetrahydropurin-7-ide; D00520; CID441281; DB00985; HMS1568F12; CAS-523-87-5; 2-benzhydryloxyethyl(dimethyl)azanium; 8-chloro-1,3-dimethyl-2-oxopurin-6-olate; 8-chloro-1,3-dimethyl-3,7-dihydro-1H-purine-2,6-dione - 2-(diphenylmethoxy)-N,N-dimethylethanamine (1:1); Dimenhydrinate (JP15/USP/INN); AC1L9AVV; CHEBI:4604; Dramamine (TN)	523-87-5	441281	7847586	TTDS00086	Histamine H1 receptor	H1 Histamine receptor;Histamine receptor 1	P35367	3269	ENSG00000196639	antagonist
DAP000335	Levocabastine	AB00514704; NCGC00179240-01; Livostin; Levocabastina [Spanish]; Livostin (TN); Levocabastinum; Levocabastine [INN:BAN]; Prestwick1_001039; levocabastine; Levocabastina; Levocabastine (INN); BSPBio_001257; Levocabastinum [Latin]; Levocabastin; C26H29FN2O2; SPBio_003108; Prestwick2_001039; Prestwick0_001039; AC1L1GWR; Prestwick3_001039; 79516-68-0; 79547-78-7 (hydrochloride); UNII-H68BP06S81; BRD-K33453211-003-03-2; LS-177481; D08117; CHEMBL560041; DB01106; 1-(4-cyano-4-(4-fluorophenyl)cyclohexyl)-3-methyl-4-phenyl-4-piperidinecarboxylic acid; (3S,4R)-1-[4-cyano-4-(4-fluorophenyl)cyclohexyl]-3-methyl-4-phenylpiperidine-4-carboxylic acid; BPBio1_001382; CID54385; 4-Piperidinecarboxylic acid, 1-(4-cyano-4-(4-fluorophenyl)cyclohexyl)-3-methyl-4-phenyl-, (3S-(1(cis),3alpha,4beta))-	79516-68-0	54385	667972	TTDS00086	Histamine H1 receptor	H1 Histamine receptor;Histamine receptor 1	P35367	3269	ENSG00000196639	antagonist
DAP001068	Dexbrompheniramine	NCGC00162100-03; Dexbromfeniramina [INN-Spanish]; EINECS 205-053-5; NCGC00162100-02; Dexbrompheniramine [INN:BAN]; (S)-(+)-brompheniramine; ( )-N,N-Dimethyl-(3-(4-bromphenyl)-3-(2-pyridyl)propyl)amin; CHEBI:59269; Brompheniramine d-; Dexbrompheniramine; Ilvin; AC1Q2610; PDSP2_000134; Dexbrompheniraminum; Parabromodylamine; (S)-brompheniramine; AC1L291B; UNII-75T64B71RP; Dexbromfeniramina; ( )-(3-p-Bromphenyl-3-pyrid-2'-ylpropyl)dimethylamin; Dexbrompheniraminum [INN-Latin]; Lopac0_000232; PDSP1_000134; (+)-brompheniraminum; CID16960; PDSP2_000133; D-Brompheniramine; LS-172813; PDSP1_000135; (3S)-3-(4-bromophenyl)-N,N-dimethyl-3-pyridin-2-ylpropan-1-amine; (3S)-3-(4-bromophenyl)-N,N-dimethyl-3-(pyridin-2-yl)propan-1-amine; NCGC00162100-01; DB00405; 132-21-8	132-21-8	16960	669658	TTDS00086	Histamine H1 receptor	H1 Histamine receptor;Histamine receptor 1	P35367	3269	ENSG00000196639	antagonist
DAP001077	Trimeprazine	Trimeperazine; Trimeprazine (BAN); UNII-76H78MJJ52; Isobutrazine; Phenothiazine, 10-(3-(dimethylamino)-2-methylpropyl)-; Alimezine; AB00053560; HSDB 3197; C07172; N,N,2-trimethyl-3-(10H-phenothiazin-10-yl)propan-1-amine; 10H-Phenothiazine-10-propanamine, N,N,.beta.-trimethyl-; N,N,2-trimethyl-3-phenothiazin-10-ylpropan-1-amine; NSC17476; trimeprazine; L000989; Alimemazinum; D07125; Oxomemazin; N,N,beta-Trimethyl-10H-phenothiazine-10-propanamine; LS-105476; DB01246; Alimemazina; Repeltin (TN); Bayer 1219; AC-19920; MolPort-005-938-362; Trimeprazine Tartrat; CID5574; CHEMBL829; Alimemazine; 10H-Phenothiazine-10-propanamine, N,N,.beta.-trimethyl-; 10-(3-Dimethylamino-2-methylpropyl)phenothiazine; Repetin; Alimemazine (INN); AC1L1KNH; 10-(3-(Dimethylamino)-2-methylpropyl)phenothiazine; Oxomemazine [DCF:INN]; Alimemazine [INN:BAN]; EINECS 201-577-3; 10H-Phenothiazine-10-propanamine, N,N,beta-trimethyl-; Trimeprazine 5,5-dioxide; (+-)-Trimeprazine; (+-)-Alimemazine; Alimemazinum [INN-Latin]; CHEBI:157833; NSC17475; dl-Trimeprazine; Alimemazina [INN-Spanish]; Trimeprazine hemi-(+)tartrate; nchembio.154-comp18; Methylpromazine; 10-(2-Methyl-3-dimethylaminopropyl)-phenothiazine; 84-96-8; Teralen; QTL1_000086	84-96-8	5574	149788	TTDS00086	Histamine H1 receptor	H1 Histamine receptor;Histamine receptor 1	P35367	3269	ENSG00000196639	antagonist
DAP001066	Brompheniramine	gamma-(4-Bromophenyl)-N,N-dimethyl-2-pyridinepropanamine; 3-(4-bromophenyl)-N,N-dimethyl-3-pyridin-2-ylpropan-1-amine; 980-71-2 (maleate (1:1)); HSDB 3017; NCGC00089782-02; 2-(p-Bromo-alpha-(2-dimethylaminoethyl)benzyl)pyridine; SPBio_001619; CHEBI:3183; Prestwick3_000475; CHEMBL811; Bromfeniramina; Prestwick0_000475; Spectrum2_001610; NCGC00015146-07; 2-Pyridinepropanamine, gamma-(4-bromophenyl)-N,N-dimethyl-; KBio3_001861; Oprea1_690847; SPBio_002549; PDSP1_000146; 32188-07-1; KBioSS_002162; Prestwick1_000475; Spectrum_001682; DIMETANE-DX; Spectrum5_001537; 3-(p-Bromophenyl)-3-(2-pyridyl)-N,N-dimethylpropylamine; Bromfenex; BROMFED-DM; KBio2_007298; Spectrum4_001107; KBio2_004730; KBio2_002162; C06857; L001031; UNII-H57G17P2FN; 3-(4-Bromophenyl)-N,N-dimethyl-3-(2-pyridinyl)-1-propanamine; BRD-A68723818-050-05-1; 156428-33-0; LS-187224; BSPBio_002641; p-Bromdylamine; 3-(4-bromophenyl)-N,N-dimethyl-3-(pyridin-2-yl)propan-1-amine; AB00053703; [3-(4-Bromophenyl)-3-(2-pyridyl)propyl]dimethylamine; 2-Pyridinepropanamine, .gamma.-(4-bromophenyl)-N,N-dimethyl-; DB00835; BPBio1_000672; AC1L1NEM; Brotane; 86-22-6; CID6834; BROMPHENIRAMINE; Parabromdylamine; D07543; Brompheniramine Maleate (1:1); PDSP2_000145; Brompheniraminum; DivK1c_006846; LS-130308; 2-Pyridinepropanamine, .gamma.-(4-bromophenyl)-N,N-dimethyl-; Brompheniramine (INN); Brompheniramine [INN:BAN]; C16H19BrN2; LS-177900; Bromfeniramina [INN-Spanish]; 2-Pyridinepropanamine, .gamma.-(4-bromophenyl)-N,N-dimethyl-, (S)-; BSPBio_000610; Spectrum3_000981; Prestwick2_000475; KBio1_001790; Pyridine, 2-(p-bromo-alpha-(2-(dimethylamino)ethyl)benzyl)-; STL058559; 1-(p-Bromophenyl)-1-(2-pyridyl)-3-dimethylaminopropane; Lopac0_000201; para-Bromdylamine; SpecPlus_000750; MolPort-005-935-546; KBioGR_001554; EINECS 201-657-8; Brompheniraminum [INN-Latin]; Bromfed; AC-15955; Brotane (TN)	86-22-6	6834	9075	TTDS00086	Histamine H1 receptor	H1 Histamine receptor;Histamine receptor 1	P35367	3269	ENSG00000196639	antagonist
DAP001399	Mepyramine	Harvamine; NCGC00015822-02; Neo-Bridal; 2-((2-(Dimethylamino)ethyl)-(p-methoxybenzyl)amino)pyridine; Coradon; nchembio714-comp2; KBioSS_001384; [3H]mepyramine; KBio2_006520; D08183; 1,2-Ethanediamine, N-[(4-methoxyphenyl)methyl]-N',N'-dimethyl-N-2-pyridinyl-; DivK1c_000175; IDI1_000175; Nyscaps; [3H]pyrilamine; 102206-59-7; Tocris-0660; Mepiramina; Stamine; Dorantamin; Mepyraminum; AKOS001637059; NCGC00015822-01; Pyranisamine; N-Dimethylamino-aethyl-N-p-methoxy-benzyl-.alpha.-amino-pyridin-maleat; NCGC00023513-04; KBio1_000175; N-(4-methoxybenzyl)-N',N'-dimethyl-N-pyridin-2-ylethane-1,2-diamine; N-para-Methoxybenzyl-N',N'-dimethyl-N-alpha-pyridylethylenediamine; p-Methoxybenzyl-alpha-pyridyl-dimethyl-aethylendiamin [German]; Histasan; Pyramal; Mepyramine; 2-((p-Methoxybenzyl)(2-(dimethylamino)ethyl)amino)pyridine; Statomin; Isamin; BSPBio_000198; Pyridine, 2-[[2-(dimethylamino)ethyl][p-methoxybenzyl)amino]]-; N-((4-Methoxyphenyl)methyl)-N',N'-dimethyl-N-2-pyridinyl-1,2-ethanediamine; NCGC00015822-03; Parmal; KBio2_003952; 2-[(p-Methoxybenzyl)[2-(dimethylamino)ethyl]amino]pyridine; Antalergan; KBio2_001384; Mepiramina [INN-Spanish]; CCRIS 4865; N-[2-(dimethylamino)ethyl]-N-[(4-methoxyphenyl)methyl]pyridin-2-amine; N',N'-Dimethyl-N-(p-methoxybenzyl)-N-(2-pyridyl)ethylenediamine; Mepyramine (INN); BRN 0269019; Stangen; Pyridine, 2-[(p-methoxybenzyl)[2-(dimethylamino)ethyl]amino]-; CAS-59-33-6; Afko-Hist; Pyridine, 2-((p-methoxybenzyl)(2-(dimethylamino)ethyl)amino)-; BIDD:GT0215; Prestwick1_000289; Prestwick0_000289; AC1L1JDF; 2-[[2-(Dimethylamino)ethyl](p-methoxybenzyl)amino]pyridine; Anhistol; N-(p-Methoxybenzyl)-N',N'-dimethyl-N-(.alpha.-pyridyl)ethylenediamine; Lopac-P-5514; Mepyren; NSC 13136; BRD-K97564742-050-05-3; NCGC00015822-10; Antamine; Anhistabs; 5-22-08-00381 (Beilstein Handbook Reference); N-(p-Methoxybenzyl)-N',N'-dimethyl-N-2-pyridyl-1,2-ethanediamine; Thylogen; N-(para-Methoxybenzyl)-N',N'-dimethyl-N-2-pyridylethylenediamine; Pyridine, 2-[[2-(dimethylamino)ethyl](p-methoxybenzyl)amino]-; NCGC00023513-02; p-Methoxy-benzyl-.alpha.-pyridyl-dimethyl-aethylendiamin; N-(p-Methoxybenzyl)-N',N'-dimethyl-N-2-(pyridylethylene)diamine; Ethylenediamine, N',N'-dimethyl-N-(p-methoxybenzyl)-N-(2-pyridyl)-; Copsamine; Prestwick2_000289; N-(p-Methoxybenzyl)-N',N'-dimethyl-N-2-pyridylethylenediamine; MolPort-001-794-651; L000391; 91-84-9; Paraminyl; ST50443109; R.d. 2786; Spectrum2_001306; Pyrilamide; EINECS 202-102-2; N'-[(4-methoxyphenyl)methyl]-N,N-dimethyl-N'-pyridin-2-ylethane-1,2-diamine; Mepyramin; CHEMBL511; N,N-dimethyl-N'-{[4-(methyloxy)phenyl]methyl}-N'-pyridin-2-ylethane-1,2-diamine; N-p-Methoxybenzyl-N',N'-dimethyl-N-alpha-pyridylethylenediamine; Lopac0_000890; NCI-C60651; HSDB 5187; Spectrum_000904; Spectrum3_000605; NCGC00023513-05; Histapyran; Mepiramine; 1,2-Ethanediamine, N-((4-methoxyphenyl)methyl)-N',N'-dimethyl-N-2-pyridinyl-; 2-[[2-(Dimethylamino)ethyl]-(p-methoxybenzyl)amino]pyridine; Dipane; BSPBio_002110; Mepyramin [German]; WLN: T6NJ BN2N1&1&1R DO1; CID4992; KBio3_001610; Maranhist; AC1Q4CO6; C11798; NINDS_000175; SPBio_002417; Antallergan; Spectrum4_000493; 2-dimethylaminoethyl-p-anisyl-(2-pyridyl)amine; PYRA; Anthisan; Spectrum5_001264; Wait's green mountain antihistamine; Histalon; UNII-HPE317O9TL; Mepyraminum [INN-Latin]; NCGC00023513-06; Oprea1_317349; Pyridine, 2-((2-(dimethylamino)ethyl)(p-methoxybenzyl)amino)-; LS-1930; Histacap; KBioGR_001005; pyrilamine; Pyrilamine salt with fine resin; HMS2089M19; BRD-K97564742-050-04-6; WLN: T6NJ DN1R DO1&2N1&1; BPBio1_000218; SPBio_001371; Kriptin; Neobridal; NSC13136; RP 2786; N-(p-Methoxybenzyl)-N',N'-dimethyl-N-(alpha-pyridyl)ethylenediamine; Mepyramine [INN:BAN]; p-Methoxybenzyl-alpha-pyridyl-dimethyl-aethylendiamin; Neoantergan; AB00053539; CHEBI:6762; Prestwick3_000289; N-[(4-methoxyphenyl)methyl]-N',N'-dimethyl-N-2-pyridinyl-1,2-ethanediamine	91-84-9	4992	13962	TTDS00086	Histamine H1 receptor	H1 Histamine receptor;Histamine receptor 1	P35367	3269	ENSG00000196639	antagonist
DCL000393	GSK835726	N/A	N/A	5311268	40722554	TTDS00086	Histamine H1 receptor	H1 Histamine receptor;Histamine receptor 1	P35367	3269	ENSG00000196639	antagonist
DAP001061	Bepotastine	CID2350; Bepotastine; TAU-284DS; AR-1H9724; Betotastine; 1-Piperidinebutanoic acid, 4-((4-chlorophenyl)-2-pyridinylmethoxy)-; AC1L1DHF; UNII-HYD2U48IAS; 4-[4-[(4-chlorophenyl)-pyridin-2-ylmethoxy]piperidin-1-yl]butanoic acid; (S)-4-(4-((4-Chlorophenyl)(2-pyridil)methoxy)piperidino)butylic acid; 4-((4-Chlorophenyl)-2-pyridinylmethoxy)-1-piperidinebutanoic acid; Tau 284; DB04890; AC1Q3NH9	190786-44-8	2350	5424487	TTDS00086	Histamine H1 receptor	H1 Histamine receptor;Histamine receptor 1	P35367	3269	ENSG00000196639	antagonist
DCL000719	Bepotastine besilate	4-((4-Chlorophenyl)-2-pyridinylmethoxy)- (S)-1-piperidinebutanoic acid monobenzenesulfonate; TAU-284; 1-Piperidinebutanoic acid, 4-((4-chlorophenyl)-2-pyridinylmethoxy)- (S)-, monobenzenesulfonate; LS-114358; AR-1G0223; CHEMBL1201759; TAU-284DS; AC1L4UXJ; MolPort-005-938-034; AC-19011; 190786-44-8; Talion; 4-{4-[(s)-(4-chlorophenyl)(pyridin-2-yl)methoxy]piperidin-1-yl}butanoic acid benzenesulfonate; AC1Q6WSY; Bepreve; CID164521; Betotastine besilate; Bepotastine besilate; (+)-(S)-4-(4-((4-Chlorophenyl)(2-pyridyl)methoxy)piperidino)butyric acid monobenzenesulfonate; benzenesulfonic acid; 4-[4-[(S)-(4-chlorophenyl)-pyridin-2-ylmethoxy]piperidin-1-yl]butanoic acid	190786-44-8	2350	46504940	TTDS00086	Histamine H1 receptor	H1 Histamine receptor;Histamine receptor 1	P35367	3269	ENSG00000196639	antagonist
DAP001078	Mequitazine	Quitadrill; MLS000757058; Mequitazine (JP15/INN); Mequitazinum; Mequitazina; Zesulan; 10-(3-Quinuclidinylmethyl)phenothiazine; mequitazine tartrate, (R-(R*,R*))-isomer; Mequitazina [Spanish]; 10-(1-Azabicyclo[2.2.2]oct-3-ylmethyl)-10H-phenothiazine; LM-209; NSC303612; Mequitazinum [INN-Latin]; STK324459; MLS001201790; Mircol; D01324; 10H-Phenothiazine, 10-(1-azabicyclo(2.2.2)oct-3-ylmethyl)- (9CI); EINECS 249-521-7; C12755; LM 209; Virginan; NCI60_002566; 10H-Phenothiazine, 10-(1-azabicyclo(2.2.2)oct-3-ylmethyl)-; MolPort-002-663-305; Primalan; Kitazemin (TN); mequitazine; Vigigan; C20H22N2S; DB01071; Phenothiazine, 10-(3-quinuclidinylmethyl)-; NSC 303612; SMR000528898; 29216-28-2; 10H-Phenothiazine, 10-(1-azabicyclo[2.2.2]oct-3-ylmethyl)-; BRN 1150945; AC1L1HC7; Metaplexan; Instotal; Bio-0800; Butix; Italfarmaco brand of mequitazine; AR-1I1105; LS-105668; 3-Methylquinuclidinyl-10-phenothiazine; Mequitazina [INN-Spanish]; I06-1052; AC-2365; Mequitazine [INN:BAN:DCF:JAN]; 84992-84-7 (hydrochloride); AKOS000424971; L000704; 10-(1-azabicyclo[2.2.2]octan-3-ylmethyl)phenothiazine; CID4066; 10-(1-azabicyclo(2.2.2)oct-8-ylmethyl)phenothiazine; AC1Q7G50; C006069; Kitazemin; CHEMBL73451; mequitazine hydrochloride; Pierre Fabre brand of mequitazine	29216-28-2	4066	583144	TTDS00086	Histamine H1 receptor	H1 Histamine receptor;Histamine receptor 1	P35367	3269	ENSG00000196639	antagonist
DAP000490	Diphenhydramine	Spectrum3_000400; KBio2_004028; CHEBI:127629; NCGC00015335-01; 2-(Benzhydryloxy)-N,N-dimethylethylamine, hydrochloride; NCI60_002916; Antitussive; SMR001307259; Benylan; Nytol Quickcaps; Mephadryl; Dormarex 2; D00300; Allergeval; Benzhydril; Dryistan; Diphenylhydramin; EINECS 200-396-7; N-(Benzhydryloksy-etylo)dwumetyloamina [Polish]; Prestwick0_000065; CAS-147-24-0; Benzhydramine; Baramine; Diphenhist; Diabenyl; BENADRYL HCl; PM 255; Diphenhydraminum; Histaxin; 2-[(diphenylmethyl)oxy]-N,N-dimethylethanamine; 2-(Benzhydryloxy)-N,N-dimethylethylamine; Antistominum; KBioGR_001099; Benadrin; diphenhydramine; STOCK2S-94461; I14-6749; O-Benzhydryldimethylaminoethanol; Betramin; Banophen Caplets; Genahist; STK103720; AKOS003658554; AC-13704; KBio3_001439; Spectrum5_000915; NCGC00015335-10; Bena; HSDB 3066; HMS2089E06; Beldin; Diphenhydraminum [INN-Latin]; Benapon; Dimedryl; Nervine Nighttime Sleep-Aid; Belix; Oprea1_254625; BSPBio_002219; Desentol; Diphenhydramine [INN:BAN:JAN]; Spectrum4_000520; IDI1_000368; Allermax Caplets; 147-24-0; Allergina; Debendrin; Syntedril; Difenhydramin; Dermodrin; BRD-K47278471-003-05-7; Diphenhydramine HCl; CHEMBL657; Allerdryl; Nausen; DIPHENHYDRAMINE, ANTISTOMINUM, BENZHYDRAMINE; NCGC00015335-02; 88637-37-0 (citrate (1:1)); Dihidral; Bagodryl; Ben-allergin; AB00053460; Medidryl; Alledryl; S51; NCI60_022782; Restamin (TN); 2-(diphenylmethoxy)-N,N-dimethylethanamine; NSC665800; beta-Dimethylaminoethylbenzhydrylether; Dabylen; Allergival; Benzantine; 2-(Diphenylmethoxy)-N,N-dimethylethylamine; Ibiodral; SPBio_000961; Compoz; DB01075; Dibenil; BIDD:GT0152; Diphenhydramine (JP15/INN); Difedryl; 2-Diphenylmethoxy-N,N-dimethylethylamine; Spectrum_000980; L000227; Difenidramina; Diphenhydramine Base; Benhydramin; Dimedrol; Benadryl (hydrochloride); N,N-Dimethyl-2-(diphenylmethoxy)-ethylamine hydrochloride; nchembio747-comp18; Diphen Cough; Probedryl; NCGC00024414-03; Benzhydryl; KBioSS_001460; Difenhidramina [INN-Spanish]; Benachlor; TL8003758; CCRIS 1959; Siladryl; Prestwick1_000065; Ethylamine, 2-(diphenylmethoxy)-N,N-dimethyl-; AC1L1F65; Dimedrol base; Amidryl; Difenhidramina; Benadryl; Restamin; 2-benzhydryloxyethyl-N,N-dimethylammonium; Hyrexin; BRN 1914136; alpha-(2-Dimethylaminoethoxy)diphenylmethane; BSPBio_000249; KBio2_001460; MLS002222276; Ethanamine, 2-(diphenylmethoxy)-N,N-dimethyl-; Diphantine; NCGC00024414-04; CPD-10890; KBio1_000368; 2PM; SPBio_002170; Prestwick3_000065; Antomin; Nytol Quickgels; Benadryl Allergy; Dylamon; NCGC00015335-03; FAR 90X2; beta-dimethylaminoethyl benzhydryl ether; DivK1c_000368; Twilite Caplets; Lopac0_000377; Lopac-D-3630; Rigidil; beta-Dimethylaminoethanol diphenylmethyl ether; MolPort-001-783-508; Benodine; Sleep-Eze D; Dibendrin; Drylistan; Aller-Med; Dimehydrinate; N-[2-(BENZHYDRYLOXY)ETHYL]-N,N-DIMETHYLAMINE; Automin; Unisom Sleepgels Maximum Strength; Allergan B; Dibondrin; Etanautine; LS-68208; Diphenhist Captabs; CID3100; CHEBI:4636; Prestwick2_000065; Ethylamine, N,N-dimethyl-2-(diphenylmethoxy)-; Syntodril; N-(2-(Diphenylmethoxy)ethyl)-N,N-dimethylamine; Benzhydraminum; Spectrum2_000961; beta-Dimethylamino-aethyl-benzhydryl-aether; Hydramine; Benylin; Diabylen; 58-73-1; N-(Benzhydryloksy-etylo)dwumetyloamina; 2-diphenylmethoxy-N,N-demthylethanamine; DB06975; Benodin; 2-benzhydryloxy-N,N-dimethylethanamine; UNII-8GTS82S83M; Diphenylhydramine; Dermistina; Sleep-Eze D Extra Strength; 147-24-0 (HYDROCHLORIDE); Hyadrine; Aleryl; beta-Dimethylamino-aethyl-benzhydryl-aether [German]; Difenidramina [Italian]; Benzhydroamina; NINDS_000368; Diphen; Allergical; BPBio1_000275; Novamina; Silphen; Banophen; KBio2_006596	58-73-1	3100	7847366	TTDS00086	Histamine H1 receptor	H1 Histamine receptor;Histamine receptor 1	P35367	3269	ENSG00000196639	antagonist
DAP001414	Oxatomide	Oxatomidum [INN-Latin]; BAS 01509783; Celtect (TN); R 35443; Oxatomida [INN-Spanish]; R 35,443; BIM-0024581.P001; UNII-J31IL9Z2EE; MLS000028549; 60607-34-3; AKOS000507212; McN-JR 35443; NCGC00015774-03; BRN 4724760; CHEMBL13828; D01773; C27H30N4O; Oxatomidum; 2H-Benzimidazol-2-one, 1,3-dihydro-1-(3-(4-(diphenylmethyl)-1-piperazinyl)propyl)-; Bio-0750; C015408; NCGC00015774-01; 1-[3-[4-(Diphenylmethyl)-1-piperazinyl]propyl]-1,3-dihydro-2H-benzimidazol-2-one; R-35443; O 9387; 1-(3-(4-(Diphenylmethyl)-1-piperazinyl)propyl)-2-benzimidazolinone; Lopac-O-9387; EINECS 262-320-9; Lopac0_000924; KW-4354; Oxatomida; KW 4354; EU-0100924; Celtect; LS-33365; NSC309710; 1-[3-(4-Benzhydryl-piperazin-1-yl)-propyl]-1,3-dihydro-benzoimidazol-2-one; CHEBI:112890; Tinset; 2H-Benzimidazol-2-one, 1-[3-[4-(diphenylmethyl)-1-piperazinyl]propyl]-1,3-dihydro-; 1-[3-[4-(Diphenylmethyl)-1-piperazinyl]propyl]-2-benzimidazolinone; Oprea1_338592; NCGC00094235-01; Oxetal; O9387_SIGMA; CID4615; 1-(3-(4-(Diphenylmethyl)-1-piperazinyl)propyl)-1,3-dihydro-2H-benzimidazol-2-one; Oxatomide (JAN/USAN/INN); NCGC00015774-02; R35443; 3-[3-(4-benzhydrylpiperazin-1-yl)propyl]-1H-benzimidazol-2-one; I06-0696; MolPort-001-964-500; HMS2089N07; CBMicro_024634; SMR000058301; 2H-Benzimidazol-2-one, 1-(3-(4-(diphenylmethyl)-1-piperazinyl)propyl)-1,3-dihydro-; AC1L1IKA; Oxatomide (tinset); Oxatomide [USAN:BAN:INN:JAN]; NCGC00094235-02; oxatomide; Oxatimide	60607-34-3	4615	183792	TTDS00086	Histamine H1 receptor	H1 Histamine receptor;Histamine receptor 1	P35367	3269	ENSG00000196639	antagonist
DAP000323	Cetirizine	SAM002589989; Prestwick3_000503; NCGC00167781-02; Cetiderm (TN); AC1L1E7T; Cetirizine (INN); CPD001453715; AKOS003589059; 2-(2-{4-[(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethoxy)acetic acid; MolPort-002-506-309; C21H25ClN2O3; CID2678; Cetirizin; Cetirizine [INN:BAN]; Setir; Virlix; Cetirizina [Spanish]; NCGC00167781-01; AC1Q768B; nchembio714-comp3; D07662; 2-[2-[4-[(4-chlorophenyl)-phenylmethyl]piperazin-1-yl]ethoxy]acetic acid; STK711108; TimTec1_002075; UNII-YO7261ME24; Prestwick1_000503; P-071; Cetirizina; SPBio_002346; BRD-A42571354-300-05-4; NCGC00167781-03; MLS002222268; 83881-52-1 (di-hydrochloride); C07778; Cetirizinum; Zyrlex; STOCK2S-03020; Prestwick2_000503; [(2-{4-[(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethyl)oxy]acetic acid; (2-(4-((4-Chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)acetic acid; cetirizine; Hitrizin Film Tablet; (2-{4-[(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethoxy)acetic acid; BSPBio_000425; Cetryn; L000655; NCGC00167781-04; Prestwick0_000503; 83881-51-0; CHEBI:3561; CHEMBL1000; BSPBio_002302; Ziptek; BPBio1_000469; Acetic acid, (2-(4-((4-chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)-; Cetiderm; SMR000145214; Cetrizine Hcl; Zirtek; I06-0454; (2-{4-[(4-Chloro-phenyl)-phenyl-methyl]-piperazin-1-yl}-ethoxy)-acetic acid; DB00341; AC-5545; HMS1539O07; LS-11409; Cetirizinum [Latin]	83881-51-0	2678	192657	TTDS00086	Histamine H1 receptor	H1 Histamine receptor;Histamine receptor 1	P35367	3269	ENSG00000196639	antagonist
DAP001065	Triprolidine	Spectrum5_001467; HSDB 6316; Histafed; LS-1293; BIDD:GT0569; UNII-YAN7R5L890; Myidyl; 6138-79-0 (mono-hydrochloride, mono-hydrate); Pro-Actidil; 2-[(E)-1-(4-methylphenyl)-3-pyrrolidin-1-ium-1-ylprop-1-enyl]pyridine chloride; Triprolidine Monohydrochloride; CHEBI:165539; Lopac0_001130; CID6433473; L000901; Actidilat; AC1NR02Y; CHEMBL855; 295 C 51; CCRIS 7215; MLS002207213; MLS000028751; FT-0082802; Triprolidine (INN); NCGC00024714-04; BSPBio_000104; IDI1_000297; Pyridine, 2-((1E)-1-(4-methylphenyl)-3-(1-pyrrolidinyl)-1-propenyl)-, monohydrochloride; NCGC00024714-06; C19H22N2.HCl; Pyridine, 2-(1-(4-methylphenyl)-3-(1-pyrrolidinyl)-1-propenyl)-, monohydrochloride, monohydrate, (E)-; 2-[(E)-1-(4-methylphenyl)-3-pyrrolidin-1-ylprop-1-enyl]pyridine; CID5282443; MLS001148254; Prestwick2_000262; trans-1-(4-Methylphenyl)-1-(2-pyridyl)-3-pyrrolidinoprop-1-ene; BSPBio_002255; HMS2089M21; AC-15905; HMS1921I07; Tripolidina [INN-Spanish]; 550-70-9; Triprolidine HCL; SMR000058521; 550-70-9 (mono-hydrochloride); Triprolidinum [INN-Latin]; Tripolidina; Triprolidine [INN:BAN]; 486-12-4; trans-2-(3-(1-Pyrrolidinyl)-1-p-tolylpropenyl)pyridine; Triprolidine hydrochloride; EINECS 208-985-0; CCRIS 7212; EU-0101130; trans-1-(2-Pyridyl)-3-pyrrolidino-1-p-tolylprop-1-ene; HMS1568F06; Pro-Entra; CID5702129; Triprolidinum; NCGC00024714-03; EINECS 207-627-0; UNII-2L8T9S52QM; Entra; 2-[(E)-1-(4-methylphenyl)-3-pyrrolidin-1-ylprop-1-enyl]pyridine hydrochloride; AC1NWAR4; DB00427; Pyridine, 2-((1E)-1-(4-methylphenyl)-3-(1-pyrrolidinyl)-1-propen-1-yl)-, hydrochloride (1:1); Prestwick3_000262; BRD-K11742128-003-05-1; SPECTRUM1500598; NCI-C61450; (E)-2-(1-(4-Methylphenyl)-3-(1-pyrrolidinyl)-1-propenyl)pyridine; NCGC00094397-01; Pyridine, 2-(1-(4-methylphenyl)-3-(1-pyrrolidinyl)-1-propenyl)-, monohydrochloride, (E)-; BPBio1_000116; CHEMBL1200450; BIM-0025383.P001; LS-131942; Actidil; AC1O5G9Y; Triprolidine Monohydrochloride, Monohydrate; Triprolidine hydrochloride anhydrous; NCGC00094397-02; T 6764; Triprolidine Hydrochloride (anhydrous); 486-12-4 (Parent); MolPort-003-182-178; trans-2-(3-(1-Pyrrolidinyl)-1-p-tolylpropenyl)pyridine monohydrochloride; Pyridine, 2-(1-(4-methylphenyl)-3-(1-pyrrolidinyl)-1-propenyl)-, (E)-; NCGC00094397-03; Triprolidin; MLS002222226; Venen (TN); Prestwick_575; C19H22N2; NCGC00024714-05; Venen; (E)-2-[3-(1-Pyrrolidinyl)-1-p-tolylpropenyl]pyridine hydrochloride; Pyridine, 2-(3-(1-pyrrolidinyl)-1-p-tolylpropenyl)-, monohydrochloride, monohydrate, stereoisomer; D08648; 6138-79-0; Pyridine, 2-(3-(1-pyrrolidinyl)-1-p-tolylpropenyl)-, monohydrochloride, (E)-; Pyridine, 2-(3-(1-pyrrolidinyl)-1-p-tolylpropenyl)-, (E)-; MolPort-003-666-303; NCGC00024714-02; triprolidine	486-12-4	5282443	153493	TTDS00086	Histamine H1 receptor	H1 Histamine receptor;Histamine receptor 1	P35367	3269	ENSG00000196639	antagonist
DAP001076	Buclizine	Histabutyzine hydrochloride; Buclizine; DB00354; 1-(4-tert-Butylbenzyl)-4-[(4-chlorophenyl)(phenyl)methyl]piperazine; 4-23-00-00082 (Beilstein Handbook Reference); 129-74-8; NCI60_002006; C07777; Aphilan R; Buclizine (INN); 87994-02-3; Buclizine [INN:BAN]; 1-[(4-chlorophenyl)(phenyl)methyl]-4-{[4-(1,1-dimethylethyl)phenyl]methyl}piperazine; AC1Q3ND3; UNII-0C94V6X681; Buclifen; CID6729; MolPort-003-845-425; Buclizinum [INN-Latin]; Piperazine, 1-[(4-chlorophenyl)phenylmethyl]-4-[[4-(1,1-dimethylethyl)phenyl]methyl]-, dihydrochloride; 82-95-1; 1-[(4-tert-butylphenyl)methyl]-4-[(4-chlorophenyl)-phenylmethyl]piperazine; Buclina (TN); Histabutizine; 1-(p-tert-Butylbenzyl)-4-(4-chloro-alpha-phenylbenzyl)piperazine; NSC25141; PIPERAZINE, 1-(p-tert-BUTYLBENZYL)-4-(p-CHLORO-alpha-PHENYLBENZYL)-; AC-15954; Piperazine, 1-((4-chlorophenyl)phenylmethyl)-4-((4-(1,1-dimethylethyl)phenyl)methyl)- (9CI); Buclizinum; Hitabutyzyne; Buclizine dihydrochloride; CHEBI:3205; L000971; AR-1I0822; C28H33ClN2; Buclizine Hydrochloride  (*dihydrochloride*); Piperazine, 1-((4-chlorophenyl)phenylmethyl)-4-((4-(1,1-dimethylethyl)phenyl)methyl)-; Buclizine hydrochloride; Buclizina [INN-Spanish]; Buclodin; 1-(4-Tert-butylbenzyl)-4-((4-chlorophenyl)(phenyl)methyl)piperazine; Buclizina; EINECS 201-448-1; Vibazine hydrochloride; Piperazine, 1-[(4-chlorophenyl)phenylmethyl]-4-[[4-(1,1-dimethylethyl)phenyl]methyl]-; Buclizine, hydrochloride; Aphilan-R base; 129-74-8 (di-hydrochloride); Softran; Vibazine; Bucladin; AH 2526; UCB 4445; component of Bucladin-S; component of Softran; LS-110571; Histabutyzine dihydrochloride; Histabutyzine; Buclina; Histabuticine; BRN 0349567; Posdel; D07547; AC1L1N6A	82-95-1	6729	9979	TTDS00086	Histamine H1 receptor	H1 Histamine receptor;Histamine receptor 1	P35367	3269	ENSG00000196639	antagonist
DCL000399	GSK1004723	N/A	N/A	5702160	49698346	TTDS00086	Histamine H1 receptor	H1 Histamine receptor;Histamine receptor 1	P35367	3269	ENSG00000196639	antagonist
DAP001073	Phenindamine	2,3,4,9-tetrahydro-2-methyl-9-phenyl-lH-indeno- (2,1-c)pyridine; C07790; CHEBI:130096; 1H-Indeno[2,1-c]pyridine, 2,3,4,9-tetrahydro-2-methyl-9-phenyl-; 82-88-2; D08353; 2,3,4,9-Tetrahydro-2-methyl-9-phenyl-lH-indeno(2,1-c)pyridine; LS-81959; 5-20-08-00420 (Beilstein Handbook Reference); 1H-Indeno(2,1-c)pyridine, 2,3,4,9-tetrahydro-2-methyl-9-phenyl-; 2-Methyl-9-phenyl-2,3,4,9-tetrahydro-1H-indeno[2,1-c]pyridine; PDSP2_000150; CHEMBL278398; NU 1504; Phenindiamine; Phenindaminum; Phenindamine; 5503-08-2 (hydrochloride); BRN 0221083; 569-59-5 (tartrate); Fenindamina; DB01619; EINECS 201-443-4; 2-methyl-9-phenyl-1,3,4,9-tetrahydroindeno[2,1-c]pyridine; Phenindamine (INN); Phenindaminum [INN-Latin]; Thephorin; PDSP1_000151; Phenindamine [INN:BAN]; L001053; Fenindamina [INN-Spanish]; AC1L1X1J; CID11291; 2,3,4,9-Tetrahydro-2-methyl-9-phenyl-1H-indeno(2,1-c)pyridine	82-88-2	11291	9992	TTDS00086	Histamine H1 receptor	H1 Histamine receptor;Histamine receptor 1	P35367	3269	ENSG00000196639	antagonist
DAP001365	Antazoline hydrochloride	2-IMIDAZOLINE, 2-((N-BENZYLANILINO)METHYL)-, HYDROCHLORIDE; AC-20133; 2-(N-Phenyl-N-benzylaminomethyl)imidazoline hydrochloride; HMS1568D18; MLS001148371; Fenazolina; NCGC00180986-01; D07459; Prestwick_82; Phenazolinum (TN); 2-(N-Benzylanilino)methyl-2-imidazoline, hydrochloride; Antazoline hydrochloride; Phenazoline hydrochloride; Antazoline HCl; C17H19N3.HCl; Phenazolinum; 91-75-8 (Parent); Antazolinium chloratum; 2-Phenylbenzylaminomethylimidazoline hydrochloride; A9899_SIGMA; N-benzyl-N-(4,5-dihydro-1H-imidazol-2-ylmethyl)aniline hydrochloride; MLS002153486; 2-(N-Benzylanilinomethyl)-2-imidazoline hydrochloride; MLS000028599; Antistine hydrochloride; MolPort-003-940-371; MLS002222161; LS-79573; AC1L29OE; UNII-FP8Q8F72JH; 2508-72-7; 2-Imidazoline, 2-((N-benzylanilino)methyl)-, monohydrochloride; SBB057007; CID17275; Histazine; SMR000058731; EINECS 219-719-8	2508-72-7	17275	51091790	TTDS00086	Histamine H1 receptor	H1 Histamine receptor;Histamine receptor 1	P35367	3269	ENSG00000196639	antagonist
DAP001072	Bromodiphenhydramine	Bromdiphenhydramine; beta-(p-Bromobenzhydryloxy)ethyldimethylamine; Bromazine [INN:BAN]; Bromdiphenhydraminum; Amodryl; Bromodiphenhydramine hydrochloride; Bromazin; Bromazinum [INN-Latin]; 2-(p-bromo-alpha-phenylbenzyloxy)-N,N-dimethylethylamine; Bromo-Benzdryl; CHEBI:59177; LS-172367; Bromdiphenhydramine hydrochloride; Ethanamine, 2-[(4-bromophenyl)phenylmethoxy]-N,N-dimethyl-; Bromazina [INN-Spanish]; PDSP1_000145; Bromdiphenylhydramine hydrochloride; UNII-T032BI7727; 2-[(4-bromophenyl)-phenylmethoxy]-N,N-dimethylethanamine; Bromazine; Bromo-Benadryl; 2-{[(4-bromophenyl)(phenyl)methyl]oxy}-N,N-dimethylethanamine; L001164; CID2444; 118-23-0; EINECS 204-238-8; AC1L1DOW; bromodiphenhydramine; Bromanautine; DB01237; Bromazina; Neo-Benadryl; 2-[(4-Bromophenyl)(phenyl)methoxy]-N,N-dimethylethanamine; Bromazinum; PDSP2_000144; Histabromamine; beta-dimethylaminoethyl p-bromobenzhydryl ether; Ambodryl hydrochloride; Deserol; 1808-12-4 (hydrochloride); C17H20BrNO	1808-12-4	2444	544844	TTDS00086	Histamine H1 receptor	H1 Histamine receptor;Histamine receptor 1	P35367	3269	ENSG00000196639	antagonist
DAP001340	(S)-(+)-Dimethindene maleate	N/A	121367-05-3	5282414	68529876	TTDS00086	Histamine H1 receptor	H1 Histamine receptor;Histamine receptor 1	P35367	3269	ENSG00000196639	antagonist
DAP001069	Carbinoxamine	CHEBI:3398; DivK1c_000819; Ethanamine, 2-((4-chlorophenyl)-2-pyridinylmethoxy)-N,N-dimethyl-; Allergefon; Prestwick0_000801; 486-16-8; Ethanamine, 2-((4-chlorophenyl)-2-pyridinylmethoxy)-N,N-dimethyl- (9CI); C16H19ClN2O; Carbinoxamina; 3505-38-2 (MALEATE); (+-)-Carbinoxamine; 5-21-03-00492 (Beilstein Handbook Reference); Spectrum4_000264; L000924; KBio2_005656; Ethanamine, 2-[(4-chlorophenyl)-2-pyridinylmethoxy]-N,N-dimethyl-; {2-[(4-Chlorophenyl)-2-pyridylmethoxy]ethyl}dimethylamine; Clistine; Spectrum5_000700; Prestwick3_000801; 59811-38-0; Carbinoxamine base; D07617; Spectrum_000100; Rotoxamine; Carbinoxaminum [INN-Latin]; Spectrum2_001127; UNII-VED9E376NC; AC1L1DYK; 2-[(4-chlorophenyl)(pyridin-2-yl)methoxy]-N,N-dimethylethanamine; BRD-A29426959-050-05-8; Clistin; Paracarinoxamine; BSPBio_001933; AKOS003334261; UNII-982A7M02H5; KBioSS_000520; NCGC00166141-03; AB00053430; IDI1_000819; I14-3528; Carbinoxamine (INN); C06871; SPBio_000993; carbinoxamine; CID2564; Prestwick2_000801; 2-(p-Chloro-alpha-(2-(dimethylamino)ethoxy)benzyl)pyridine; Carbinoxamine [INN:BAN]; Carbinoxaminum; KBio3_001153; DB00748; N,N-Dimethyl-2-(p-chloro-alpha-(2-pyridyl)benzyloxy)ethylamine; KBio2_003088; Ethanamine, 2-[(4-chlorophenyl)-2-pyridinylmethoxy]-N,N-dimethyl-, (-)-; SBB067454; 2-{[(4-chlorophenyl)(pyridin-2-yl)methyl]oxy}-N,N-dimethylethanamine; Pyridine, 2-(p-chloro-alpha-(2-(dimethylamino)ethoxy)benzyl)-; Carbinoxamina [INN-Spanish]; KBioGR_000728; NCGC00166141-01; CHEMBL864; NCGC00166141-02; BSPBio_000661; EINECS 207-628-6; Ethanamine, 2-[(4-chlorophenyl)-2-pyridinylmethoxy]-N,N-dimethyl-; Spectrum3_000327; NINDS_000819; McN-R 73Z; Prestwick1_000801; BRN 0250475; LS-131075; Paracarbinoxamine; AC-5507; KBio1_000819; Oprea1_764868; SPBio_002582; KBio2_000520; 2-[(4-chlorophenyl)-pyridin-2-ylmethoxy]-N,N-dimethylethanamine; BPBio1_000729	486-16-8	2564	9088	TTDS00086	Histamine H1 receptor	H1 Histamine receptor;Histamine receptor 1	P35367	3269	ENSG00000196639	antagonist
DCL000738	Carebastine	AC1L2412; C058251; Carebastine [INN]; Carebastina; CHEMBL67654; CID65820; 90729-42-3; Benzeneacetic acid, 4-(4-(4-(diphenylmethoxy)-1-piperidinyl)-1-oxobutyl)-alpha,alpha-dimethyl-; Carebastinum [Latin]; UNII-75DLN707DO; Carebastina [Spanish]; MolPort-006-391-972; 2-[4-[4-(4-benzhydryloxypiperidin-1-yl)butanoyl]phenyl]-2-methylpropanoic acid; Carebastine; 2-(4-(4-(4-Benzhydryloxypiperidino)butyryl)phenyl)-2-methylpropionsaeure; LS-178123; p-(4-(4-(Diphenylmethoxy)piperidino)butyryl)-alpha-methylhydratropic acid; E00013; Carebastinum; C32H37NO4	90729-42-3	65820	207861	TTDS00086	Histamine H1 receptor	H1 Histamine receptor;Histamine receptor 1	P35367	3269	ENSG00000196639	antagonist
DAP000328	Tripelennamine	HSDB 5191; Pyridine, 2-(benzyl(2-(dimethylamino)ethyl)amino)-; 91-81-6; Tripellenamine; N,N-Dimethyl-N'-benzyl-N'-(2-pyridyl)ethylenediamine; WLN: T6NJ BN1R&2N1&1 &GH; Tripelenamine; BSPBio_003252; KBioGR_000867; C16H21N3; Dehistin; Tripelennamina [Italian]; KBio2_000621; Spectrum2_000957; CID5587; Tripelenamina [INN-Spanish]; beta-Dimethylaminoethyl-2-pyridylbenzylamine; KBio2_003189; N-Benzyl-N',N'-dimethyl-N-(2-pyridyl)ethylenediamine; L000603; N,N-Dimethyl-N'-(phenylmethyl)-N'-2-pyridinyl-1,2-ethanediamine; Cizaron; DivK1c_000534; Benzoxale; KBioSS_000621; LS-130287; Pyridbenzamine; Tripelennamin; nchembio747-comp17; Benzyl-(alpha-pyridyl)-dimethylaethylendiamin; C07180; Tripelennamine (INN); tripelennamine; 5-22-08-00378 (Beilstein Handbook Reference); KBio3_002472; Tripelennamina; 2-[Benzyl(2-dimethylaminoethyl)amino]pyridine; AC1L1KOH; DB00792; Tripelennaminum [INN-Latin]; Pyribenzamin; N,N-dimethyl-N'-(phenylmethyl)-N'-pyridin-2-ylethane-1,2-diamine; 58044-99-8 (maleate (1:1)); Tripelennamine Citrate (1:1); 2750 R.P.; Spectrum_000141; N-Benzyl-N-(2-pyridyl)-N',N'-dimethyl ethylenediamine; BRD-K57033106-048-02-8; N,N-Dimethyl-N'-benzyl-N'-(alpha-pyridyl)ethylenediamine; NCI-C60662; Benzyl-(alpha-pyridyl)-dimethylaethylendiamin [German]; Benzyl-(.alpha.-pyridyl)-dimethylaethylendiamin; 2-(benzyl(2-(dimethylamino)ethyl)amino)pyridine; Tripelennamine [INN]; Oprea1_266730; Pyribenzamine; 6138-56-3 (citrate (1:1)); KBio2_005757; Tripelennaminum; Vetibenzamina; Pyridine, 2-[benzyl[2-(dimethylamino)ethyl]amino]-; Piribenzil; N-Benzyl-N',N'-Dimethyl-N-Pyridin-2-Yl-Ethane-1,2-Diamine Hydrochloride; Spectrum4_000374; Triplennamine; Pyristine (piristina); IDI1_000534; N-Benzyl-N',N'-dimethyl-N-2-(pyridylethylene)diamine; Tonaril; N'-benzyl-N,N-dimethyl-N'-pyridin-2-ylethane-1,2-diamine; N,N-Dimethyl-N'-benzyl-N'-(.alpha.-pyridyl)ethylenediamine; Tripelannamine; CHEMBL1241; Spectrum5_001581; N-Benzyl-N',N'-dimethyl-N-2-pyridylethylenediamine; 2-[N-Benzyl-N-(2-dimethylaminoethyl)amino]pyridine; KBio1_000534; Tripelenamina; Pyrinamine base; UNII-3C5ORO99TY; beta-Dimethylaminoethyl-2-pyridylaminotoluene; D08645; Ethylenediamine, N-benzyl-N',N'-dimethyl-N-(2-pyridyl)-; NINDS_000534; N-benzyl-N-[2-(dimethylamino)ethyl]pyridin-2-amine; EINECS 202-100-1; NCGC00018125-01; BRN 0227074; Tripelennamine [BAN]; MolPort-001-785-598; 2750 R.P; .beta.-Dimethylaminoethyl-2-pyridylaminotoluene; 2-(Benzyl(2-dimethylaminoethyl)amino)pyridine; SPBio_000954; 22306-05-4 (hydrochloride); .beta.-Dimethylaminoethyl-2-pyridylbenzylamine; Resistamine; NSC118946; AC1Q3WSJ; 154-69-8 (mono-hydrochloride); 1,2-Ethanediamine, N,N-dimethyl-N'-(phenylmethyl)-N'-2-pyridinyl-; NSC 118946; Ts and Blues; Benzyl-.alpha.-pyridyl-dimethyl-aethylendiamin; WLN: T6NJ BN1R&2N1&1; AC1Q3WSI; Spectrum3_001696; 1,2-Ethanediamine, N,N-dimethyl-N'-(phenylmethyl)-N'-2-pyridinyl- (9CI); 2-(N-Benzyl-N-(2-dimethylaminoethyl)amino)pyridine	91-81-6	5587	9389	TTDS00086	Histamine H1 receptor	H1 Histamine receptor;Histamine receptor 1	P35367	3269	ENSG00000196639	antagonist
DAP000838	Framycetin	Antibiotic produced by Streptomyces decaris. Neomycin B; NEOMYCIN SULFATE; HSDB 3242; Neomycinum; Myacyne; 4-18-00-07476 (Beilstein Handbook Reference); Neomicina; CID8378; Fraquinol; ST075177; Framycetin [INN:BAN:DCF]; Fradiomycin B; CHEBI:7508; LS-96091; Neobrettin; D05140; EINECS 215-766-3; Antibiotique; Neomycine; Prestwick3_000158; 119-04-0; NMY; DB00994; LS-96095; AC1L1QVH; Neolate; BPBio1_000326; C01737; NEOMYCIN AND POLYMYXIN B SULFATES; Neomas; (2R,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-[(1R,2R,3S,4R,6S)-4,6-diamino-2-[(2S,3R,4S,5R)-4-[(2R,3R,4R,5S,6S)-3-amino-6-(aminomethyl)-4,5-dihydroxyoxan-2-yl]oxy-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-3-hydroxycyclohexyl]oxyoxane-3,4-diol; Myciguent; Actiline; Framycetine [INN-French]; 11025-81-3; Endomixin; neomycin; Framicetina; Tuttomycin; Mycifradin; Framycetinum [INN-Latin]; Myacine; Framygen; Neobiotic; D-Streptamine, O-2,6-diamino-2,6-dideoxy-.beta.-L-idopyranosyl-(1.->3)-O-.beta.-D-ribofuranosyl-(1->5)]-O-[2,6-diamino-2,6-dideoxy-.alpha.-D-glucopyranosyl-(1->4)]-2-deoxy; BDG-(1-4)NEB-(5-1)RIB-(3-1)NED; NCGC00179612-01; AB00443887; Framycetine; D-Streptamine, O-2,6-diamino-2,6-dideoxy-alpha-D-glucopyranosyl-(1-4)-O-(O-2,6-diamino-2,6-dideoxy-beta-L-idopyranosyl-(1-3)-beta-D-ribofuranosyl-(1-5))-2-deoxy-; UNII-I16QD7X297; Vonamycin powder V; 1393-86-8; DB00452; BRN 0101621; Framicetina [INN-Spanish]; EPA Pesticide Chemical Code 006303; PIMAVECORT; C25H50N6O13; Actilin; Neomycin solution; 1405-10-3 (sulfate (salt)); Antibiotic 10676; Neomcin; N1142_SIGMA; 72131_FLUKA; Soframycin; Soframycin Ophthalmic; Neomycinum [INN-Latin]; HMS2089P15; USAF CB-19; EINECS 204-292-2; CCRIS 5462; Neomycin B sulfate; MolPort-003-938-736; BSPBio_000296; Enterfram; UNII-4BOC774388; Neo-Rx; BDG-(1-4)CYY-(5-1)RIB-(3-1)IDG; (1R,2R,3S,4R,6S)-4,6-diamino-2-{[3-O-(2,6-diamino-2,6-dideoxy-beta-L-idopyranosyl)-beta-D-ribofuranosyl]oxy}-3-hydroxycyclohexyl 2,6-diamino-2,6-dideoxy-alpha-D-glucopyranoside; 1404-04-2; Fradiomycin; Framycetin; Framycetin (INN); Neomin; Caswell No. 595; Fradiomycinum; Nivemycin; Neomicina [DCIT]; C23H46N6O13; Framycetinum; Soframycine; VONAMYCIN; Neo-Fradin; NEOMYCIN B; Neomycine [INN-French]	119-04-0	8378	151525	TTDS00216	16S rRNA	Plastid 16S rRNA;RrnS	N/A	N/A	N/A	binder
DAP001527	Tetracyclines	N/A	60-54-8	5280962	48416604	TTDS00216	16S rRNA	Plastid 16S rRNA;RrnS	N/A	N/A	N/A	binder
DPR000123	Gem 92	N/A	N/A	N/A	N/A	TTDR01175	mRNA of HIV-1 Gag	N/A	N/A	N/A	N/A	antisense
DCL000196	Phenoxodiol	Idronoxil; 2H-1-Benzopyran-7-ol, 3-(4-hydroxyphenyl)-; C471183; 2H-1-benzopyran-7-0,1,3-(4-hydroxyphenyl); 7-hydroxy-3-hydroxyphenyl-1H-benzopyran; Idronoxil (USAN/INN); Ambap81267-65-4; 3-(4-Hydroxyphenyl)-2H-chromen-7-ol; MolPort-003-824-273; D04498; Dehydroequol; I14-8946; CID219100; NV-06; CCRIS 8949; 3-(4-Hydroxyphenyl)-2H-1-benzopyran-7-ol; Haginin E; Phenoxodiol; NV 06; LS-182407; ZINC01491943; UNII-995FT1W541; 81267-65-4; AC1L561Y	81267-65-4	219100	791639	TTDC00058	Sphingosine kinase	SK;SPHK;SPK	Q9NYA1	8877	ENSG00000176170	inhibitor
DAP001297	Cysteamine	LS-65761; NCI60_002000; DB00847; AC1Q54NL; NCGC00015691-04; STK315355; Ethanethiolamine; Spectrum_001755; 93965-19-6 (maleate (1:1)); bmse000388; WR 347; Lambraten; L-1573; beta-Mercaptoethylamine; CCRIS 3083; EINECS 200-463-0; 30070_FLUKA; Decarboxycysteine; Mercaptaminum; Mercamine; M9768_SIGMA; 641022_ALDRICH; NSC 647528; Cisteamina [Italian]; Mecramine; Becaptan; KBio2_002235; Cysteamine [USAN:BAN]; Cysteinamine; 3037-04-5; Cysteamine bitartate; Lambratene; Cysteamide; 2DFDA1F8-7010-4225-8280-AB1C4C43F546; Mercamin; KBioSS_002235; 2-Mercaptoethylamine, polymer-bound; (2-Mercaptoethyl)amine; HSDB 7353; NCGC00015691-01; nchembio.315-comp1; Cysteamin; KBio1_001694; beta-Aminoethylthiol; 2-Aminoethyl mercaptan; 2-Aminoethanethiol; 2-Aminoethyl mercaptan; Cystavision; Mercaptamina; 42954-15-4 (hydrobromide); 60-23-1 (Parent); Mercaptoethylamine; MEA; Merkamin; C-9500; CYSTEAMINE; (Mercaptoethyl)ammonium toluene-p-sulphonate; 3037-04-5 (tosylate); UNII-5UX2SD1KE2; Cisteamina; 139720-70-0; DivK1c_006750; 156-57-0 (hydrochloride); Thioethanolamine; beta-MEA; Mercaptamine; 2-Aminoethanethiol; 1-Amino-2-mercaptoethylamine; D03634; A0648; Mercaptamina [INN-Spanish]; NCGC00162236-01; SpecPlus_000654; CHEBI:17141; CID6058; KBio2_004803; AC1L1LPL; beta-Aminoethanethiol; Lopac-M-6500; 60-23-1; EINECS 221-235-7; .beta.-Mercaptoethylamine; KBio2_007371; C2H7NS; MEA (mercaptan); 27761-19-9 (tartrate (1:1)); 16904-32-8 (di-hydrochloride); Mercaptamin; NSC647528; 2-Amino-1-ethanethiol; CHEMBL602; 2-Mercaptoethylamine; AKOS003793343; 2-AMINO-ETHANETHIOL; Riacon; 30070_SIGMA; M9768_ALDRICH; 2-Mercaptoethanamine; C01678; L 1573; nchembio.316-comp1; Cysteamine (USAN); Ethanethiol, 2-amino-; Mercaptamine (INN); Aminoethyl mercaptan; MolPort-001-662-635; Mercaptaminum [INN-Latin]	60-23-1	6058	4821	TTDS00497	Somatostatin	Growth hormone release-inhibiting factor;Somatostatin-14;Somatostatin-28;SST	P61278	6750	ENSG00000157005	binder
DCL000166	Migalastat	UNII-C4XNY919FW; 108147-54-2; AC1L41WN; 1,5-Dideoxy-1,5-iminogalactitol; NSC658776; CHEMBL110458; Migalastat; CHEBI:278290; LS-186039; (2R,3S,4R,5S)-2-(hydroxymethyl)piperidine-3,4,5-triol; DDIG; Tocris-1258; D-Galactitol, 1,5-dideoxy-1,5-imino-; 2-(Hydroxymethyl)-3,4,5-piperidinetriol hydrochloride; D-Galactitol, 1,5-dideoxy-1,5-imino; NCGC00025085-01; CID176077	167933-07-5	11644097	49602865	TTDC00016	Alpha-galactosidase A	Agalsidase;Alpha-D-galactosidase A;Alpha-D-galactoside galactohydrolase;Melibiase	P06280	2717	ENSG00000102393	modulator
DCL000124	GSK-923295	N/A	66569-27-5	39981	47207563	TTDC00064	Centromeric protein E	CENP-E;Centromere-associated protein E	Q02224	1062	ENSG00000138778	inhibitor
DCL000395	GSK923295	N/A	N/A	N/A	N/A	TTDC00064	Centromeric protein E	CENP-E;Centromere-associated protein E	Q02224	1062	ENSG00000138778	inhibitor
DCL001161	BMS 790052	N/A	N/A	N/A	N/A	TTDC00322	HCV NS5A protein	N/A	N/A	N/A	N/A	inhibitor
DCL001222	PPI-461	N/A	N/A	N/A	N/A	TTDC00322	HCV NS5A protein	N/A	N/A	N/A	N/A	inhibitor
DCL001163	BMS-824383	N/A	N/A	N/A	N/A	TTDC00322	HCV NS5A protein	N/A	N/A	N/A	N/A	inhibitor
DCL001149	ARI-3037MO	N/A	N/A	N/A	N/A	TTDC00320	G protein-coupled receptor 110A niacin receptor	N/A	N/A	N/A	N/A	agonist
DAP001300	Antithymocyte globulin	N/A	N/A	184841	46506920	TTDS00472	T-cell surface glycoprotein CD1a	CD1a;hTa1 thymocyte antigen;T-cell surface antigen T6/Leu-6	P06126	909	ENSG00000158477	binder
DCL000789	E-5842	E 5842; 4-(4-fluorophenyl)-1-[4-(1,2,4-triazol-1-yl)butyl]-3,6-dihydro-2H-pyridine; 2-hydroxypropane-1,2,3-tricarboxylic acid; C117757; AC1OCFD2; E-5842; 4-(4-fluorophenil)-1,2,3,4-tetrahydro-1-(4-(1,2,4-triazol-1-il)butyl)pyridine citrate; E5842; CID6918385	177945-46-9	10141	12015160	TTDS00129	Sigma(1)-type opioid receptor	Opioid receptor, sigma 1, isoform 1;OPRS1 protein;SR31747 binding protein 1	Q99720	10280	ENSG00000147955	binder
DPR000170	ANAVEX 1007	N/A	N/A	N/A	N/A	TTDS00129	Sigma(1)-type opioid receptor	Opioid receptor, sigma 1, isoform 1;OPRS1 protein;SR31747 binding protein 1	Q99720	10280	ENSG00000147955	agonist
DPR000111	SR-31742A	[(Z)-3-(3-chloro-4-cyclohexylphenyl)prop-2-enyl]cycloheptane hydrochloride; 3-(Hexahydroazepin-1-yl)-1-(3-chloro-4-cyclohexylphenyl)-1-propene hydrochloride; AC1O5Q87; CID6438730; SR-31742A; 1H-Azepine, 1-(3-(3-chloro-4-cyclohexylphenyl)-2-propenyl)hexahydro-, hydrochloride, (Z)-; 139592-99-7; SR 31742A; (Z)-1-(3-(3-Chloro-4-cyclohexylphenyl)-2-propenyl)hexahydro-1H-azepine hydrochloride	139592-99-7	6913084	703250	TTDS00129	Sigma(1)-type opioid receptor	Opioid receptor, sigma 1, isoform 1;OPRS1 protein;SR31747 binding protein 1	Q99720	10280	ENSG00000147955	binder
DCL000984	Sigma antagonist	N/A	191588-94-0	N/A	47207728	TTDS00129	Sigma(1)-type opioid receptor	Opioid receptor, sigma 1, isoform 1;OPRS1 protein;SR31747 binding protein 1	Q99720	10280	ENSG00000147955	antagonist
DCL000937	PRX-00023	N/A	740873-06-7	11430856	N/A	TTDS00129	Sigma(1)-type opioid receptor	Opioid receptor, sigma 1, isoform 1;OPRS1 protein;SR31747 binding protein 1	Q99720	10280	ENSG00000147955	agonist
DCL000907	OPC-14523	N/A	145969-30-8	66644	48501062	TTDS00129	Sigma(1)-type opioid receptor	Opioid receptor, sigma 1, isoform 1;OPRS1 protein;SR31747 binding protein 1	Q99720	10280	ENSG00000147955	agonist
DCL000893	NE-100	N,N-Dipropyl-2-(4-methoxy-3-(2-phenylethoxy)phenyl)ethylamine monohydrochloride; NE-100; 149409-57-4; N,N-diethyl-2-(4-methoxy-3-phenethyloxyphenyl)ethanamine hydrochloride; AC1L3OPK; C083832; NE 100; Benzeneethanamine, 4-methoxy-3-(2-phenylethoxy)-N,N-dipropyl-, hydrochloride; CID119381	69655-05-6	50599	696061	TTDS00129	Sigma(1)-type opioid receptor	Opioid receptor, sigma 1, isoform 1;OPRS1 protein;SR31747 binding protein 1	Q99720	10280	ENSG00000147955	antagonist
DPR000040	E-6276	N/A	145645-62-1	4515	48185197	TTDS00129	Sigma(1)-type opioid receptor	Opioid receptor, sigma 1, isoform 1;OPRS1 protein;SR31747 binding protein 1	Q99720	10280	ENSG00000147955	binder
DAP000277	Dextromethorphan	BPBio1_000503; Lopac-D-2531; 3-Methoxy-17-methylmorphinan; Methorphan; Benylin Pediatric Cough Suppressant; LS-91837; Cosylan; Morphinan, 3-methoxy-17-methyl-, (9-alpha,13-alpha,14-alpha)- (9CI); Benylin Adult Formula Cough Suppressant; Diabe-Tuss DM Syrup; (+)-3-Methoxy-17-methylmorphinan; 18046-32-7; l-Methorphan; Dextromethorphane [INN-French]; Levometorfano; Prestwick0_000359; HMS2090C08; delta-Methorphan; DB00514; Benylin DM 12 Hour; Demorphan hydrobromide; (-)-3-Methoxy-N-methylmorphinan; Dormetan; Dextromethorphan (USP); EINECS 204-751-7; MolPort-003-940-943; ( )-cis-1,3,4,9,10,10a-Hexahydro-6-methoxy-11-methyl-2H-10,4alpha-iminoethanophenanthren; C06947; AC-13098; 2H-10,4a-Iminoethanophenanthrene, 1,3,4,9,10,10a-hexahydro-6-methoxy-11-methyl-; D03742; Creo-Terpin; Vicks 44 Cough Relief; 9-alpha,13-alpha,14-alpha-Morphinan, 3-methoxy-17-methyl-; Benylin DM for Children 12 Hour; CID3008; 9alpha,13alpha,14alpha-Morphinan, 3-methoxy-17-methyl- (8CI); Morphinan, 3-methoxy-17-methyl-, l-; Dextrometorphan; Triaminic DM Long Lasting for Children; Morphinan, 3-methoxy-17-methyl-, (9alpha,13alpha,14alpha)-; SPBio_002378; MLS000758303; BA 2666; Dextromethorphanum; Benylin DM; dextromethorphan; Novahistine DM; DEA No. 9210; Pertussin DM Extra Strength; NCGC00015333-01; Morphinan, 3-methoxy-17-methyl-, (9.alpha.,13.alpha.,14.alpha.)-; Demorphine; BSPBio_000457; BRD-K33211335-337-03-7; CHEMBL22207; Sucrets 4 Hour Cough Suppressant; Balminil DM Children; AC1L1EYT; NCGC00015333-04; CHEBI:580686; HSDB 3056; Dextromethorphan [USP:INN:BAN]; Robitussin Pediatric; Dextromethorfan; Levomethorphane; CHEBI:128891; Robitussin Pediatric Cough Suppressant; Novahistex DM; Dextromethorfan [Czech]; Cough-X; 125-70-2; 3-Methoxy-17-methyl-9alpha,13alpha,14alpha-morphinan; 18609-21-7 (hydrochloride); (9alpha,13alpha,14alpha)-17-methyl-3-(methyloxy)morphinan; Benylin DM for Children; RACEMETHORPHAN; 32062-10-5; Hold DM; 125-71-3; CHEBI:4470; Levomethorphanum; Dextrometorfano [INN-Spanish]; CHEMBL52440; NCGC00015333-02; 4-21-00-01367 (Beilstein Handbook Reference); Dextromethorphane; Morphinan, 3-methoxy-17-methyl-, (.+/-.)-; Albutussin; ( )-3-Methoxy-N-methylmorphinon; Levomethorphane [INN-French]; Dexyromethorphan; Levometorfano [INN-Spanish]; Trocal; Delsym Cough Formula; Prestwick1_000359; NCGC00162126-01; BRN 0088549; MolPort-004-285-957; Destrometerfano [DCIT]; UNII-7355X3ROTS; LS-91838; Levomethorphan [INN:BAN:DCF]; Dextrometorfano; Morphinan, 3-methoxy-17-methyl-, (9-alpha,13-alpha,14-alpha)-; Robitussin Maximum Strength Cough Suppressant; 9alpha,13alpha,14alpha-Morphinan, 3-methoxy-17-methyl-; Delsym; Prestwick2_000359; CID5362449; d-Methorphan; Levomethorphan; Canfodion; 125-69-9 (hydrobromide); Koffex DM; EINECS 204-752-2; Dextromethorphanum [INN-Latin]; Lopac0_000337; CID5360696; Prestwick3_000359; 6700-34-1 (hydrobromide, mono-hydrate); Levomethorphan [BAN:DCF:INN]; Levomethorphanum [INN-Latin]; Destrometerfano; Balminil DM; Pertussin CS Children's Strength; Dextromethorphan Bromhydrate; Dextromorphan; Hihustan M.; Calmylin #1	125-71-3	5360696	173392	TTDS00129	Sigma(1)-type opioid receptor	Opioid receptor, sigma 1, isoform 1;OPRS1 protein;SR31747 binding protein 1	Q99720	10280	ENSG00000147955	agonist
DPR000171	ANAVEX 1-41	N/A	N/A	N/A	N/A	TTDS00129	Sigma(1)-type opioid receptor	Opioid receptor, sigma 1, isoform 1;OPRS1 protein;SR31747 binding protein 1	Q99720	10280	ENSG00000147955	agonist
DCL001141	ANAVEX 2-73	N/A	N/A	N/A	N/A	TTDS00129	Sigma(1)-type opioid receptor	Opioid receptor, sigma 1, isoform 1;OPRS1 protein;SR31747 binding protein 1	Q99720	10280	ENSG00000147955	agonist
DCL001000	SSR-125047	N/A	82964-04-3	53359	49661446	TTDS00129	Sigma(1)-type opioid receptor	Opioid receptor, sigma 1, isoform 1;OPRS1 protein;SR31747 binding protein 1	Q99720	10280	ENSG00000147955	binder
DCL000888	MS-377	N/A	25546-65-0	5066	46505351	TTDS00129	Sigma(1)-type opioid receptor	Opioid receptor, sigma 1, isoform 1;OPRS1 protein;SR31747 binding protein 1	Q99720	10280	ENSG00000147955	antagonist
DPR000097	Rimcazole	CPD000466293; SMR000466293; Rimcazole [INN]; Tocris-1497; MolPort-001-793-065; LS-177217; 9-[3-(Cis-3,5-Dimethyl-1-Piperazinyl)Propyl]Carbazole Hydrochloride; 346438_ALDRICH; 9-[3-(cis-3,5-Dimethyl-1-piperazinyl)propyl]carbazole dihydrochloride monohydrate; 9-[3-[(3R,5S)-3,5-dimethylpiperazin-1-yl]propyl]carbazole; Rimcazol; 9-[3-[(3S,5R)-3,5-dimethylpiperazin-1-yl]propyl]carbazole; AC1Q29PL; AC1L1ETO; ST50989930; BW-234U; BW 234U; MolPort-004-964-034; CHEBI:110989; cis-9-(3-(3,5-dimethyl-1-piperazinyl)propyl)carbazole; Rimcazolum [INN-Latin]; Rimcazolum; AC1Q29PK; SAM001247094; NCGC00025187-01; CID53389; Rimcazole; C21H27N3; MLS000758976; 9H-Carbazole, 9-(3-(3,5-dimethyl-1-piperazinyl)propyl)-, cis-; CHEMBL275707; MLS001424206; Rimcazol [INN-Spanish]; 75859-04-0; MolPort-003-930-708	75859-04-0	9890801	49681680	TTDS00129	Sigma(1)-type opioid receptor	Opioid receptor, sigma 1, isoform 1;OPRS1 protein;SR31747 binding protein 1	Q99720	10280	ENSG00000147955	antagonist
DCL001217	Moxetumomab Pasudotox	N/A	N/A	N/A	N/A	TTDS00480	B-cell receptor CD22	BL-CAM;B-lymphocyte cell adhesion molecule;CD22;Leu-14;Sialic acid-binding Ig-like lectin 2;Siglec-2	P20273	933	ENSG00000012124	antibody
DCL001142	Anti-CD22	N/A	N/A	N/A	N/A	TTDS00480	B-cell receptor CD22	BL-CAM;B-lymphocyte cell adhesion molecule;CD22;Leu-14;Sialic acid-binding Ig-like lectin 2;Siglec-2	P20273	933	ENSG00000012124	antibody
DCL000799	Epratuzumab	205923-57-5; Epratuzumab (USAN/INN); Lymphocide (TN); D04036; LymphoCide; Epratuzumab	205923-57-5	N/A	47206001	TTDS00480	B-cell receptor CD22	BL-CAM;B-lymphocyte cell adhesion molecule;CD22;Leu-14;Sialic acid-binding Ig-like lectin 2;Siglec-2	P20273	933	ENSG00000012124	antibody
DAP001334	OspA lipoprotein	N/A	N/A	N/A	46504444	TTDS00480	B-cell receptor CD22	BL-CAM;B-lymphocyte cell adhesion molecule;CD22;Leu-14;Sialic acid-binding Ig-like lectin 2;Siglec-2	P20273	933	ENSG00000012124	binder
DCL000714	Balicatib	UNII-E00MVC7O57; 354813-19-7; CHEMBL371064; N-[1-(cyanomethylcarbamoyl)cyclohexyl]-4-(4-propylpiperazin-1-yl)benzamide; Balicatib; CID10201696	354813-19-7	10201696	46519853	TTDC00068	Cathepsin K	Cathepsin O;Cathepsin O2;Cathepsin X	P43235	1513	ENSG00000143387	inhibitor
DCL000568	MK-0822	MK-0822A; D08955; MK0822; 603139-19-1; CID10152654; CHEMBL481611; Odanacatib; Odanacatib (USAN); MK 0822; UNII-N673F6W2VH; CHEBI:574601; CID 10152654; MK-0822	603139-19-1Topotecan	10152654	85149921	TTDC00068	Cathepsin K	Cathepsin O;Cathepsin O2;Cathepsin X	P43235	1513	ENSG00000143387	inhibitor
DCL000214	Relacatib	GSK-462795; CHEMBL203665; Relacatib (USAN/INN); AC1OCFML; 362505-84-8; CID6918602; Relacatib; N-[(2S)-4-methyl-1-[[(4S,7R)-7-methyl-3-oxo-1-pyridin-2-ylsulfonylazepan-4-yl]amino]-1-oxopentan-2-yl]-1-benzofuran-2-carboxamide; D06634; SB-462795; Azepan-3-one compound 10	362505-84-8	6918602	47208285	TTDC00068	Cathepsin K	Cathepsin O;Cathepsin O2;Cathepsin X	P43235	1513	ENSG00000143387	inhibitor
DCL000185	Odanacatib	MK-0822A; D08955; MK0822; 603139-19-1; CID10152654; CHEMBL481611; Odanacatib; Odanacatib (USAN); MK 0822; UNII-N673F6W2VH; CHEBI:574601; CID 10152654; MK-0822	603139-19-1	10152654	85149921	TTDC00068	Cathepsin K	Cathepsin O;Cathepsin O2;Cathepsin X	P43235	1513	ENSG00000143387	inhibitor
DCL000168	MIV-701	N/A	N/A	N/A	N/A	TTDC00068	Cathepsin K	Cathepsin O;Cathepsin O2;Cathepsin X	P43235	1513	ENSG00000143387	inhibitor
DCL001214	MIV-210	N/A	N/A	N/A	N/A	TTDR00970	DNA polymerase/reverse transcriptase	HBV reverse transcriptase;Hepatitis B Virus reverse transcriptase	Q81099	N/A	N/A	inhibitor
DCL001173	Clevudine	N/A	N/A	N/A	N/A	TTDR00970	DNA polymerase/reverse transcriptase	HBV reverse transcriptase;Hepatitis B Virus reverse transcriptase	Q81099	N/A	N/A	inhibitor
DCL001205	LB80380	N/A	N/A	N/A	N/A	TTDR00970	DNA polymerase/reverse transcriptase	HBV reverse transcriptase;Hepatitis B Virus reverse transcriptase	Q81099	N/A	N/A	inhibitor
DAP001084	Emtricitabine	DRG-0208; 524W91; UNII-G70B4ETF4S; (-)-2',3'-Dideoxy-5-fluoro-3'-thiacytidine; 2'-Deoxy-5-fluoro-3'-thiacytidine; 2-FTC; HMS2089I05; (-)-cis-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one; (2R-cis)-4-Amino-5-fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1H)-pyrimidinone; 4-amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one; FTC, (-)-; 2',3'-Dideoxy-5-fluoro-3'-thiacytidine; Coviracil(TM); BW 524W91; 145213-48-5; LS-173184; beta-L-2',3'-dideoxy-5-fluoro-3'-thiacytidine; 2',3',5-FTC; DB00879; 2(1H)-Pyrimidinone, 4-amino-5-fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-, cis-; Emtricitabine; HSDB 7337; TL8000958; 1-(2-(Hydroxymethyl)oxathiolan-5-yl)-5-fluorocytosine; 2(1H)-Pyrimidinone, 4-amino-5-fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-, (2R-cis)-; AC1L1U3I; .beta.-L-(-)-(2R,5S)-5-Fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine; 4-Amino-5-fluoro-1-[(2R,5S)-(hydroxymethyl)-1,3-oxathiolan-5-yl]-2(1H)-pyrimidinone; (-)-.beta.-L-FTC; ZINC03629271; (-)-(2R,5S)-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine; BW524W91; Emtriva (TN); AC1Q4KUB; D01199; NCGC00164564-01; 143491-54-7; Emtriva; 2(1H)-Pyrimidinone, 4-amino-5-fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-, cis-(+-)-; 143491-57-0; 5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)[1,3]oxathiolan-5-yl]cytosine; CHEBI:31536; SBB066061; Coviracil; Emtriva(TM); C12599; (-)-FTC; C122114; FT-0080009; 4-amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2(1H)-one; BW 1592; RCV; C8H10FN3O3S; LS-135838; CHEMBL885; (-)-2'-Deoxy-5-fluoro-3'-thiacytidine; CID60877; Emtricitabine (JAN/USAN/INN); dOTFC; 3'-Thia-2'.3'-dideoxy-5-fluorocytidine; 2'-Deoxy-5-fluoro-3'-oxa-4'-thiocytidine; 5-Fluoro-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine; (-)-beta-2',3'-dideoxy-5-fluoro-3'-thiacytidine; BW-524W91; 2(1H)-Pyrimidinone, 4-amino-5-fluoro-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-, rel-; Racivir; 5-Fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine	143491-57-0	60877	207107	TTDR00970	DNA polymerase/reverse transcriptase	HBV reverse transcriptase;Hepatitis B Virus reverse transcriptase	Q81099	N/A	N/A	inhibitor
DAP000784	Mycophenolic acid	N/A	24280-93-1	446541	602720	TTDS00063	Inosine-5'-monophosphate dehydrogenase 2	IMP dehydrogenase 2;IMPD 2;IMPDH-II	P12268	3615	ENSG00000178035	inhibitor
DAP000783	Mycophenolate mofetil	CHEMBL1456; TM-MMF; NCGC00159459-02; C23H31NO7; MMF CellCept(TM); Munoloc; Mycophenolate mofetil (JAN/USAN); o-5-isobenzofuranyl)-4-methyl-, 2-(4-morpholinyl)ethyl ester, (E)-; ME-MPA; NCGC00159459-03; 2-morpholin-4-ylethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-5-yl)-4-methylhex-4-enoate; S1501_Selleck; 4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-, 2-(4-morpholinyl)ethyl ester, (E)-; C07908; Mycophenylate mofetil; 128794-94-5; CellCept; I01-0898; AR-1J6939; LS-75572; 4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-, 2-(4-morpholinyl)ethyl ester, (4E)-; 2-morpholin-4-ylethyl (4E)-6-[4-hydroxy-7-methyl-6-(methyloxy)-3-oxo-1,3-dihydro-2-benzofuran-5-yl]-4-methylhex-4-enoate; RS 61443; 140401-05-4; Cellcept (TN); RS-61443; RS-61443-190; AC1NQXZW; AC1Q6O6X; 2-Morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate; 115007-34-6; HSDB 7436; Mycophenolic acid morpholinoethyl ester; BB_NC-2566; LS-172272; 2-Morpholinoethyl (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate; mycophenolate mofetil; CellCept, RS 61443, TM-MMF, Mycophenolate mofetil; UNII-9242ECW6R0; 4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl -3-oxo-5-isobenzofuranyl)-4-methyl-, 2-(4-morpholinyl)ethyl ester, (4E); CID5281078; I06-1947; R-99; MMF; TL8000648; DB00688; HMS2090A03; AC-1562; MolPort-000-883-800; NSC724229; ZINC21297660; D00752	128794-94-5	5281078	7847817	TTDS00063	Inosine-5'-monophosphate dehydrogenase 2	IMP dehydrogenase 2;IMPD 2;IMPDH-II	P12268	3615	ENSG00000178035	inhibitor
DAP001217	Bimatoprost	CID5311027; (5Z)-7-{(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxy-5-phenylpent-1-en-1-yl]cyclopentyl}-N-ethylhept-5-enamide; LS-181817; (Z)-7-((1R,2R,3R,5S)-3,5-Dihydroxy-2-((1E,3S)-3-hydroxy-5-phenyl-1-pentenyl)cyclopentyl)-N-ethyl-5-heptenamide; D02724; Lumigan (TN); (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxy-5-phenylpent-1-enyl]cyclopentyl]-N-ethylhept-5-enamide; CHEBI:39562; Bimataprost [USAN:INN:BAN]; AGN-192024; DB06863; CHEBI:51230; NCGC00181745-01; I06-1275; AGN 192024; bimatoprostum; 155206-00-1; Bimatoprost; 5-Heptenamide, 7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((1E,3S)-3-hydroxy-5-phenyl-1-pentenyl)cyclopentyl)-N-ethyl-, (5Z)-; 5-Heptenamide, 7-(3,5-dihydroxy-2-(3-hydroxy-5-phenyl-1-pentenyl)cyclopentyl)-N-ethyl-, (1R-1(alpha(Z),2beta(1E,3S*)3alpha,5alpha))-; I06-1277; Bimatoprost (JAN/USAN/INN); Lumigan; AC1NSJUW; UNII-QXS94885MZ; 5-Heptenamide, 7-(3,5-dihydroxy-2-(3-hydrdoxy-5-phenyl-1-pentenyl)cyclopentyl)-N-ethyl-, (1R-(1alpha(Z),2beta(1E,3S*),3alpha,5alpha))-; Latisse; CHEMBL1200963; DB00905; Bimatoprost [USAN:INN:BAN]; 15M; 267244-98-4; ZINC04474405; 5-Heptenamide,7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((1E,3S)-3-hydroxy-5-phenyl-1-pentenyl)cyclopentyl)-N-ehtyl-,(5Z)	155206-00-1	5311027	7978793	TTDS00169	Prostaglandin F2-alpha receptor	FP prostaglandin receptor;FP prostanoid receptor;PGF receptor;PGF2 alpha receptor;Prostanoid FP receptor	P43088	5737	ENSG00000122420	agonist
DAP001216	Latanoprost	Xalatan; L1167_SIGMA; propan-2-yl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]hept-5-enoate; Isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((3R)-3-hydroxy-5-phenylpentyl)cyclopentyl)-5-heptenoate; AR-202; HMS2051H11; isopropyl (5Z,9alpha,11alpha,15R)-9,11,15-trihydroxy-17-phenyl-18,19,20-trinorprost-5-en-1-oate; PhXA41; CHEBI:6384; AC1NSK8Q; CPD000466354; XA-41; latanoprost; MLS000759468; Isopropyl (5Z,9alpha,11alpha,15R)-9,11,15-trihydroxy-17-phenyl-18,19,20-trinor-prost-5-en-1-oate; CID5311221; XA41; Ambap130209-82-4; TL8000716; CHEMBL1051; HMS2089J17; PhXA34 [as 15(R,S)-isomer]; SMR000466354; latanoprost free acid; Nova-21027; Latanoprost (JAN/USAN/INN); propan-2-yl (5Z)-7-{(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl}hept-5-enoate; Catioprost; MolPort-003-942-862; Xalatan (TN); 130209-82-4; Jsp001835; S1254_Selleck; SAM001246671; D00356; PHXA-41; ZINC12468792; MLS001424106	130209-82-4	5282380	7847422	TTDS00169	Prostaglandin F2-alpha receptor	FP prostaglandin receptor;FP prostanoid receptor;PGF receptor;PGF2 alpha receptor;Prostanoid FP receptor	P43088	5737	ENSG00000122420	agonist
DAP000274	Travoprost	C26H35F3O6; 5-Heptenoic acid, 7-(3,5-dihydroxy-2-(3-hydroxy-4-(3-(trifluoromethyl)phenoxy)-1-butenyl)cyclopentyl)-, 1-methylethyl ester, (1R-(1alpha(Z),2beta(1E,3R*),3alpha,5alpha))-; D01964; (1R-(1alpha(Z),2beta(1E,3R*),3alpha,5alpha))-7-(3,5-Dihydroxy-2-(3-hydroxy-4-(3-(trifluoromethyl)phenoxy)-1-butenyl)cyclopentyl)-5-heptenoic acid, 1-methylethyl ester; CHEMBL1200799; 157283-68-6; 5-Heptenoic acid,7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((1E,3R)-3-hydroxy-4-(3-(trifluoromethyl)phenoxy)-1-butenyl)cyclopentyl)-,1-methylethyl ester,(5Z); CHEBI:746859; AC-6103; ZINC04474682; (Z)-7-((1R,2R,3R,5S)-3,5-Dihydroxy-2-((1E,3R)-3-hydroxy-4-((alpha,alpha,alpha-trifluoro-m-isopropyl-tolyl)oxy)-1-butenyl)cyclopentyl)-5-heptenoate; propan-2-yl (5Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-{(1E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-en-1-yl}cyclopentyl]hept-5-enoate; Travatan; Travatan Alcon; isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-{(1E,3R)-3-hydroxy-4-[(alpha,alpha,alpha-trifluoro-m-tolyl)oxy]-1-butenyl}cyclopentyl)-5-heptenoate; DB00287; AL-6221; Travatan, Travoprost; AC1NQZOS; Travoprost [USAN]; S1554_Selleck; 5-Heptenoic acid, 7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((1E,3R)-3-hydroxy-4-(3-(trifluoromethyl)phenoxy)-1-butenyl)cyclopentyl)-, 1-methylethyl ester, (5Z)-; propan-2-yl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-enyl]cyclopentyl]hept-5-enoate; Travatanz; AL6221; Travatan Z; LS-173521; Travoprost; (+)-Fluprostenol isopropyl ester; (((1R)-(1alpha(Z),2beta(1E,3R*),3alpha,5alpha))-7-(3,5-dihydroxy-2-(3-hydroxy-4-(3-trifluoromethyl)phenoxy)-1-butenyl)cyclopentyl)-5-heptenoic acid, 1-methylethyl ester; Travoprost (JAN/USAN/INN); CID5282226; Travatan (TN)	157283-68-6	5282226	7849026	TTDS00169	Prostaglandin F2-alpha receptor	FP prostaglandin receptor;FP prostanoid receptor;PGF receptor;PGF2 alpha receptor;Prostanoid FP receptor	P43088	5737	ENSG00000122420	agonist
DCL000542	INCB18424	INC-424; INCB-018424; Ruxolitinib phosphate; INCB-18424	N/A	23644203	46506179	TTDC00316	Tyrosine-protein kinase	Protein-tyrosine kinase;PTK	N/A	N/A	N/A	inhibitor
DCL000545	INCB28050	N/A	152811-62-6	177336	47954535	TTDC00316	Tyrosine-protein kinase	Protein-tyrosine kinase;PTK	N/A	N/A	N/A	inhibitor
DAP000772	Acenocoumarol	2-hydroxy-3-[1-(4-nitrophenyl)-3-oxobutyl]-4h-chromen-4-one; Mini Sintrom; MLS001074461; Acenocoumarol Alliance Brand; Sintrom; Synthrom; ACENOCOUMAROL; EINECS 205-807-3; LS-55093; Prestwick3_000110; Ciba-Geigy Brand of Acenocoumarol; Nitrowarfarin; Ascumar; AC1Q1Z5F; Neositron; Sinthrome; Sinthrom; Prestwick1_000110; CHEMBL397420; BPBio1_000110; Sincoumar; 3-(alpha-Acetonyl-para-nitrobenzyl)-4-hydroxy-coumarin; G-23,350; Acenocoumarolum; Acenocoumarol [INN]; 4-Hydroxy-3-(1-(4-nitrophenyl)-3-oxobutyl)-2H-1-benzopyran-2-one; Minisintrom; AB-014/25000129; CHEMBL145253; 3-(alpha-(p-Nitrophenol)-beta-acetylethyl)-4-hydroxycoumarin; Acenokumarin [Czech]; 70897-81-3; CHEBI:53766; Prestwick0_000110; 3-(alpha-Acetonyl-4-nitrobenzyl)-4-hydroxycoumarin; AC1L1S7P; BRD-A65051990-001-03-8; Acenokumarin; Syntrom; HMS1568E22; 3-(alpha-(4'-Nitrophenyl)-beta-acetylethyl)-4-hydroxycoumarin; Sinkumar; Acenocumarolo; Acenocumarolo [DCIT]; Nitrophenylacetylethyl-4-hydroxycoumarine; Novartis Brand of Acenocoumarol; Nitrovarfarian; Sintroma; Syncumar; Prestwick2_000110; 4-Hydroxy-3-[1-(4-nitrophenyl)-3-oxobutyl]-2H-chromen-2-one; CID9052; SPBio_002039; Acenocoumarolum [INN-Latin]; 2H-1-Benzopyran-2-one, 4-hydroxy-3-(1-(4-nitrophenyl)-3-oxobutyl)-; UNII-I6WP63U32H; D000074; Acenocumarolum; D07064; Mini-sintrom; Alliance Brand of Acenocoumarol; 2-hydroxy-3-[1-(4-nitrophenyl)-3-oxobutyl]chromen-4-one; Acenocoumarol (INN); 152-72-7; Jsp002948; Coumarin, 3-(alpha-acetonyl-p-nitrobenzyl)-4-hydroxy-; NCGC00179658-01; Nicumalon; 3-(alpha-Acetonyl-p-nitrobenzyl)-4-hydroxycoumarin; BSPBio_000100; Zotil; Nicoumalone; 2H-1-Benzopyran-2-one, 4-hydroxy-3-[1-(4-nitrophenyl)-3-oxobutyl]-; Ciba Geigy Brand of Acenocoumarol; SMR000162652; Prestwick_773; Syncoumar; Mini-sintrom (TN); G 23350; Acenocoumarol Ciba-Geigy Brand; AB00513804; Acenocoumarin; C19H15NO6; DB01418; Acenocoumarol Novartis Brand; HSDB 3201; MLS000539171; 3-(alpha-p-Nitrophenyl-beta-acetylethyl)-4-hydroxycoumarin; G23350; 2H-1-Benzopyran-2-one, 4-hydroxy-3-(1-(4-nitrophenyl)-3-oxobutyl)-, (+-)-; MolPort-002-798-798; G-23350; AR-1E2350; Acenocumarol	152-72-7	9052	10321722	TTDS00398	Vitamin K epoxide reductase complex subunit 1	MSTP134;MSTP576;UNQ308/PRO351;Vitamin K1 2,3-epoxide reductase subunit 1;VKOR;VKORC1	Q9BQB6	79001	ENSG00000167397	inhibitor
DAP000770	Warfarin	Vampirinip II; Ratorex; Rough & ready mouse mix; Warfarinum; Coumarins; Spectrum2_000935; I14-0958; NSC 59813; Solfarin; Warficide; Warf 42; KBio2_005810; (S)-Warfarin; 81-81-2; Warfarine [INN-French]; BRN 1293536; Ratron G; Rodafarin; 45706_RIEDEL; nchembio.307-comp19; AC1L1N37; Coumaphene; Maag Rattentod Cum; C19H16O4; Rat-Trol; Rat-Kill; Place-pax; Brumolin; Eastern states duocide; Rodex blox; MLS001304042; Warfarin Q; KBio2_000674; Warfarina; Tox-hid; Warfarin [INN:BAN]; Arab rat deth; KBioSS_000674; (-)-Warfarin; Warfarina [INN-Spanish]; MolPort-001-787-822; warfarin; Bio-0586; Warfarine [ISO-French]; Dicusat E; SPBio_000870; SMP1_000316; Warfarine; DivK1c_000444; C01541; CBDivE_013236; Choice (TN); Rat-Gard; Rosex; Sorexa plus; Dethnel; BSPBio_002026; CHEMBL1464; KBio3_001526; NCGC00178855-01; 45706_FLUKA; 5543-57-7; CBKinase1_000192; 5543-56-6; Arab Rat Death; Kumatox; Warfarin(R); HSDB 1786; rac-Warfarin; Warfarat; AC-15978; CBDivE_002127; LS-55083; IDI1_000444; EINECS 201-377-6; SMR000718754; Ro-Deth; Warfarin (INN); BRD-A24514565-236-01-6; Rat-B-gon; W.A.R.F. 42; Ratoxin; Spray-trol brand roden-trol; NCGC00094810-02; Sofarin; Spectrum4_000381; EINECS 226-907-3; EPA Pesticide Chemical Code 086002; PS104_SUPELCO; Liqua-tox; SPECTRUM1500613; Spectrum_000194; WARF compound 42; Rattenstreupulver new schacht; Coumaphen; Dethmor; UNII-5Q7ZVV76EI; HMS501G06; Warfarinum [INN-Latin]; BRD-A24514565-001-02-2; Warfarin plus; Rattunal; NCGC00159398-03; AC1Q6AN3; A2250_FLUKA; Warfarin (and salts of); Warfarin [BSI:ISO]; Spectrum5_001751; Coumafene [French]; Warfarin plus [discontinued]; STK364490; Zoocoumarin; Cov-R-Tox; NSC59813; RCRA waste no. P001; KBioGR_000901; Fasco fascrat powder; A2250_SIGMA; Maveran; Zoocoumarin [Netherlands and USSR]; Athrombine-K; DB00682; Rat-a-way; Warf 10; Choice; Twin light rat away; Rattentraenke; KBio1_000444; Vampirinip iii; Rat-o-cide #2; D-Con; HMS1921K07; CID6691; Mouse pak; Kumadu; CHEBI:10033; NINDS_000444; 200 coumarin; Zoocoumarin [Russian]; RAX; KBio2_003242; D08682; Rodafarin C; Spectrum3_000583; Coumadin; Rat-Mix; Frass-Ratron; Rcra waste number P001; Warfarin titrated to an INR of 2.5-3.0; Latka 42; Compound 42; Mar-Frin; Rat & mice bait; Martin's mar-frin; Kypfarin; HMS2092C20; Coumafen; Rattenstreupulver Neu Schacht; CBKinase1_012592; Prothromadin; Coumefene; CO-Rax; Kumader; Temus W; Ratron; Caswell No. 903; Coumafene; Rats-no-more; Ratten-Koederrohr; Rat-Ola; Latka 42 [Czech]; AR-1E2310; NCGC00094810-01; Panwarfin; WLN: T66 BOVJ DYR&1V1 EQ	81-81-2	6691	4702	TTDS00398	Vitamin K epoxide reductase complex subunit 1	MSTP134;MSTP576;UNQ308/PRO351;Vitamin K1 2,3-epoxide reductase subunit 1;VKOR;VKORC1	Q9BQB6	79001	ENSG00000167397	inhibitor
DAP000768	Dicumarol	AC1Q699Q; 2H-1-Benzopyran-2-one, 3,3'-methylenebis[4-hydroxy- (9CI); uncoupler of oxidative respiration; HMS1570M12; WLN: T66 BOVJ EQ D1- DT66 BOVJ EQ; 3,3'-Methylenebis(4-hydroxycoumarin); 3,3'-methylenebis(4-hydroxy-2H-chromen-2-one); Acavyl; Baracoumin; KBio2_005781; Coumarin, 3,3'-methylenebis(4-hydroxy-; HMS1920E20; 3,3'-Methylenebis[4-hydroxycoumarin]; Dicoumarolum; CHEBI:4513; 3,3'-Methylenebis(4-hydroxy-2H-1-benzopyran-2-one); Dicumaol R; BRN 0335444; NINDS_000896; DivK1c_000896; 3,3'-Methylenebis[4-hydroxy-1,2-benzopyrone]; Spectrum4_000508; Cumid; Dicoumal; BRD-K82236179-001-05-0; 2H-1-Benzopyran-2-one, 3,3'-methylenebis(4-hydroxy)-; Dicumarinum; Prestwick1_000785; NCGC00016296-01; BPBio1_000980; Coumarin, 3,3'-methylenebis[4-hydroxy-; Dwukumarol [Polish]; AC1L19PT; Anathrombase; NCGC00094650-02; Apekumarol; NC 034; C00796; Kumoran; D001728; M0216; SPBio_000248; EINECS 200-632-9; CHEMBL1466; Dikumarol; 3,3'-Methylene-bis(4-hydroxycoumarine) [French]; NSC41834; 3,3'-Methylenebis[4-hydroxy-2H-1-benzopyran-2-one]; NSC 221570; 3,3'-Methylene-bis(4-hydroxycoumarine); 5-19-06-00682 (Beilstein Handbook Reference); Dicumarolum; CCRIS 3713; dicoumarin; KBio1_000896; M1390_SIGMA; NSC 41834; Bis-3,3'-(4-hydroxycoumarinyl)methane; Prestwick0_000785; bis-hydroxycoumarin; KBio2_003213; Trombosan; Prestwick3_000785; HMS1378M04; KBioSS_000645; LS-55258; Di-(4-hydroxy-3-coumarinyl)methane; HSDB 3223; 3,3&prime;-Methylenebis(4-hydroxycoumarin); Dicumarol [INN-Spanish]; 3,3'-Methyleen-bis(4-hydroxy-cumarine); 3,3 -Methylene-bis[4-hydroxycoumarin]; UNII-7QID3E7BG7; 3,3'-methanediylbis(4-hydroxy-2H-chromen-2-one); CHEMBL43154; Dicuman; Dicoumarolum [INN-Latin]; melitoxin; Coumarin, 3,3'-methylenebis[4-hydroxy- (8CI); Dicumarol (TN); NSC221570; Di-4-hydroxy-3,3'-methylenedicoumarin; Bis(4-hydroxycoumarin-3-yl)methane; MolPort-000-422-589; 3,3'-Methylenebis(4-hydroxy-1,2-benzopyrone); HMS502M18; Dicumarol [USAN]; SPBio_002829; KBio3_001393; CAS-66-76-2; KBioGR_001055; 2H-1-Benzopyran-2-one, 3,3'-methylenebis(4-hydroxy-; 3,3'-Methylen-bis(4-hydroxy-cumarin) [German]; nchembio.147-comp9; BSPBio_000890; Prestwick2_000785; CHEBI:166411; Antitrombosin; Spectrum5_000871; Temparin; 66-76-2; KBio2_000645; dicoumarol; ZINC03869855; Bishydroxycoumarin; Acadyl; Bio-0616; IDI1_000896; Spectrum3_000387; D03798; 2H-1-Benzopyran-2-one), 3,3'-methylenebis(4-hydroxy-; Dicumol; 3,3'-Methyleen-bis(4-hydroxy-cumarine) [Dutch]; 3,3'-methylenebis(2-hydroxy-4h-chromen-4-one); Prestwick_90; Spectrum_000165; 3,3'-Metilen-bis(4-idrossi-cumarina) [Italian]; C19H12O6; Oprea1_150990; NSC17860; 3,3'-Methylen-bis(4-hydroxy-cumarin); HMS2091M10; ChemDiv2_003436; Dicumarolo; Dicumarine; SPECTRUM1500239; AR-1E8815; AI3-14546; CID653; STK801287; DB00266; dicumarol; Dicoumerol; NSC 17860; 2-hydroxy-3-[(2-hydroxy-4-oxochromen-3-yl)methyl]chromen-4-one; Dicoumarol (INN); CHEBI:494231; AKOS000520650; 2H-1-Benzopyran-2-one, 3,3'-methylenebis[4-hydroxy-; 3,3'-Methylene-bis(4-hydroxycoumarin); symmetric dicoumarol analogue, 1; CHEBI:469386; NCGC00094650-01; Dufalone; Spectrum2_000144; BSPBio_002173; 3,3'-Metilen-bis(4-idrossi-cumarina); CBDivE_003005; 4,4'-Dihydroxy-3,3'-methylene bis coumarin; Cuma; Dwukumarol; Dicumarolo [DCIT]; Bis-3,3'-(4-oxycoumarinyl)ethylacetate; 2H-1-Benzopyran-2-one], 3,3'-methylenebis[4-hydroxy-; Dicumarol (USAN)	66-76-2	653	4054	TTDS00398	Vitamin K epoxide reductase complex subunit 1	MSTP134;MSTP576;UNQ308/PRO351;Vitamin K1 2,3-epoxide reductase subunit 1;VKOR;VKORC1	Q9BQB6	79001	ENSG00000167397	inhibitor
DAP000771	Phenprocoumon	Fencumar; 3-(1'-Phenyl-propyl)-4-oxycoumarin [German]; Fenprocumone [DCIT]; Phenprogramma; 4-Hydroxy-3-(1-phenylpropyl)-2H-chromen-2-one; 3-(1-Phenylpropyl)-4-hydroxycoumarin; CID9908; D010644; 4-Hydroxy-3-(1-phenylpropyl)-2H-1-benzopyran-2-one; Phenprocoumone; Phenprocumone; CHEBI:117471; CHEBI:50438; Falithrom; Phenprocoumon (USAN/INN); Falithiom; 435-97-2; Fenprocoumona [INN-Spanish]; U29342; BRN 1291115; Phenprocoumarole; S2188_Selleck; PHENPROCOUMON; Phenprocoumalol; 2H-1-Benzopyran-2-one, 4-hydroxy-3-(1-phenylpropyl)-; Phenprocoumon [USAN:INN:BAN]; 2H-Pyran-2-one, 4-hydroxy-3-[[2-(1-methylethyl)phenyl]thio]-6-(3-methylphenyl)-; AKOS002126557; EINECS 207-108-9; 2-hydroxy-3-(1-phenylpropyl)chromen-4-one; LS-55203; Fenprocoumona; 3-(alpha-Phenylpropyl)-4-hydroxycoumarin; Coumarin, 3-(alpha-ethylbenzyl)-4-hydroxy-; Hexal Brand of Phenprocoumon; CHEMBL1465; HSDB 3248; Oprea1_002598; Phenprocoumone [INN-French]; Ro 1-4849; Marcuphen; Marcoumar; Phenprocoumonum; AC1L1U3E; Roche Brand of Phenprocoumon; Marcumar; Liquamar (TN); UNII-Q08SIO485D; Phenylpropylhydroxycumarinum; Worwag Brand of Phenprocoumon; DB00946; 3-(alpha-Ethylbenzyl)-4-hydroxycoumarin; CHEMBL16694; Liquamar; Phenprocumonum; Fenprocumone; Phenprocoumarol; fenprocumon; D05457; 3-(1'-Phenyl-propyl)-4-oxycoumarin; Phenprocoumonum [INN-Latin]; MolPort-005-935-554	435-97-2	9908	153131	TTDS00398	Vitamin K epoxide reductase complex subunit 1	MSTP134;MSTP576;UNQ308/PRO351;Vitamin K1 2,3-epoxide reductase subunit 1;VKOR;VKORC1	Q9BQB6	79001	ENSG00000167397	inhibitor
DAP000769	Phenindione	EINECS 201-454-4; DivK1c_000307; Spectrum4_000476; DB00498; MLS001148439; MLS000069422; SMR000059058; Prestwick2_000538; NCGC00094756-02; 2-phenyl-1,3(2H)-Indenedione; D08354; Indema; Fenindion; WLN: L56 BV DV CHJ CR; Pindione; AC1L1IW5; HMS500P09; Hemolidione; Hedulin; 2-Phenylindan-1,3-dione; KBioSS_001407; CHEMBL711; MolPort-001-783-429; C15H10O2; Phenindionum; Danilon; BSPBio_000555; P26406_ALDRICH; HMS1569L17; SPBio_001097; Theradione; Prestwick3_000538; Phenylindanedione; 2-Phenyl-1,3-diketohydrindene; NCGC00094756-01; Prestwick1_000538; Spectrum3_000710; HMS1920F20; Thrombasal; Cronodione; InChI=1/C15H10O2/c16-14-11-8-4-5-9-12(11)15(17)13(14)10-6-2-1-3-7-10/h1-9,13; Prestwick_872; S1921_Selleck; KBio2_003975; 2-Fenyloindandion-1,3 [Polish]; Indion; Phenyline; HSDB 3155; 1H-Indene-1,3(2H)-dione, 2-phenyl-; Phenylen; Danedion; NSC41693; BPBio1_000611; P1029; Boots Brand of Phenindione; 1,3-Indandione, 2-phenyl-; STK395038; KBio3_001719; AC1Q6DEB; 2-phenyl-2,3-dihydro-1H-indene-1,3-dione; BSPBio_002499; Indon; SPECTRUM1500477; HMS2091N22; LS-81254; Prestwick0_000538; Bindan; C07584; Athrombon; IDI1_000307; Emandione; NSC 41693; Phenindionum [INN-Latin]; Diophindane; Hedulin (TN); Phenylindione; Fenilin; Phenillin; Phenindione [INN:BAN]; D010630; Dineval; KBio1_000307; 2-Phenylindandione; Phenylin; AB00052069; Diadilan; NCGC00094756-04; Fenindiona; Phenhydren; Trombol; Eridione; SPBio_002476; Oprea1_684242; Danilone; Tromazal; 2-phenylindene-1,3-dione; Rectadione; 83-12-5; 2-Fenyloindandion-1,3; Spectrum5_001070; BB_SC-4748; Fenindiona [INN-Spanish]; UNII-5M7Y6274ZE; CID4760; NCGC00016329-01; Phenyllin; KBioGR_000952; Merck Lipha Sante Brand of Phenindione; 2-Phenyl-1,3-indandione; 2-Phenyl-1H-indene-1,3(2H)-dione; NCGC00094756-03; Dindevan; phenindione; AKOS000445019; 2 Phenyl 1,3 indandione; NINDS_000307; CAS-83-12-5; KBio2_006543; 2-Phenyl-1,3-indanedione; Fenhydren; KBio2_001407; CHEBI:8066; Spectrum_000927; Emandion; Spectrum2_000999; Phenindione (INN); Goldshield Brand of Phenindione	83-12-5	4760	9786	TTDS00398	Vitamin K epoxide reductase complex subunit 1	MSTP134;MSTP576;UNQ308/PRO351;Vitamin K1 2,3-epoxide reductase subunit 1;VKOR;VKORC1	Q9BQB6	79001	ENSG00000167397	inhibitor
DCL001055	Antisense TAR and RevM10	N/A	N/A	N/A	N/A	TTDC00308	mRNA of HIV-1 TAR	N/A	N/A	N/A	N/A	antisense
DCL000801	Farampator	D04131; Farampator (USAN/INN); Oprea1_823716; 211735-76-1; Piperidine, 1-(2,1,3-benzoxadiazol-5-ylcarbonyl)-; 1-(Benzofurazan-5-ylcarbonyl)piperidine; Farampator; Org-24448; CID4118151; CX 691; 2,1,3-benzoxadiazol-5-yl(piperidin-1-yl)methanone; CX-691; 224047-75-0; UNII-7X6P5N8K2L; AC1N3TWK; Org 24448	211735-76-1	4118151	47206078	TTDC00250	Glutamate receptor 1	AMPA-selective glutamate receptor 1;GluR-1;GluR-A;GluR-K1;Glutamate receptor ionotropic, AMPA 1	P42261	2890	ENSG00000155511	binder
DCL000473	AZD6244	1H-Benzimidazole-6-carboxamide, 5-((4-bromo-2-chlorophenyl)amino)-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-; S1008_Selleck; 606143-52-6; AZD6244; ARRY 142886; ARRY-142886; AZD-6244; Selumetinib; ARRY142886; 865610-79-3; C517975; AZD 6244; ARRY-142886, Selumetinib, AZD-6244, ARRY142886, AZD6244; ZINC31773258; ARRY-886; NSC741078; CID10127622	N/A	475514	38927383	TTDC00164	Dual specificity mitogen-activated protein kinase kinase	ERK activator kinase;MAP kinase kinase;MAPKK;MEK	N/A	N/A	N/A	inhibitor
DCL001188	GDC-0973	N/A	N/A	N/A	N/A	TTDC00164	Dual specificity mitogen-activated protein kinase kinase	ERK activator kinase;MAP kinase kinase;MAPKK;MEK	N/A	N/A	N/A	inhibitor
DCL000363	PD-0325901	ZINC03938683; S06-0029; 391210-10-9; N-[((R)-2,3-dihydroxypropyl)oxy]-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]benzamide; PD-325901; N-[(2R)-2,3-dihydroxypropoxy]-3,4-difluoro-2-[(2-fluoro-4-iodo-phenyl)amino]benzamide; PD0325901; CID9826528; PD-0325901; PD 0325901; CHEMBL507361; N-{[(2R)-2,3-dihydroxypropyl]oxy}-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]benzamide; PD325901; 870474-62-7; DB07101; S1036_Selleck; C506614; nchembio.282-comp3; 4BM; PD 325901	870474-62-7	9826528	85152673	TTDC00164	Dual specificity mitogen-activated protein kinase kinase	ERK activator kinase;MAP kinase kinase;MAPKK;MEK	N/A	N/A	N/A	inhibitor
DCL000434	Anti-Mek	N/A	144-48-9	3727	48413901	TTDC00164	Dual specificity mitogen-activated protein kinase kinase	ERK activator kinase;MAP kinase kinase;MAPKK;MEK	N/A	N/A	N/A	inhibitor
DCL000403	GSK1120212	N/A	N/A	N/A	N/A	TTDC00164	Dual specificity mitogen-activated protein kinase kinase	ERK activator kinase;MAP kinase kinase;MAPKK;MEK	N/A	N/A	N/A	inhibitor
DCL001187	GDC-0623	N/A	N/A	N/A	N/A	TTDC00164	Dual specificity mitogen-activated protein kinase kinase	ERK activator kinase;MAP kinase kinase;MAPKK;MEK	N/A	N/A	N/A	inhibitor
DCL000483	AZD8330	N/A	N/A	N/A	N/A	TTDC00164	Dual specificity mitogen-activated protein kinase kinase	ERK activator kinase;MAP kinase kinase;MAPKK;MEK	N/A	N/A	N/A	inhibitor
DCL001107	Curcumin I	Hydrastis; AKOS001305497; Turmeric; 4-08-00-03697 (Beilstein Handbook Reference); Turmeric oleoresin (79%-85% curcumin); NSC-32982; PREVENTION 4 (CURCUMIN) (SEE ALSO TUMERIC, OLEORESIN (10105-J)); curouma; Turmeric (>98% curcurmin); SMR000058237; Indian turmeric; Curcuma longa oils; MLS000069631; FEMA No. 3086; 2,7-Nonadiene-4,6-dione, 1,9-bis(4-hydroxy-3-methoxyphenyl)-; AC1LJ6T6; Curcuma longa l. root oleoresin; (E,E)-1,7-bis(4-Hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione; NCGC00023332-05; TURMERIC, OLEORESIN (CURCUMIN) (SEE ALSO CURCURMIN (458-37-7)); Turmeric oil (Curcuma longa L.); Diferaloylmethane; curcumin; NCI-C61325; Curcumin (Natural); CI 75300; Curcurmin; 73729-23-4; Curcumin; 1,7-Bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione; NSC32982; Curcuma longa l. root oil; CI Natural Yellow 3; D003474; CURCUMIN (SEE ALSO TUMERIC, OLEORESIN (10105-J)); Tu rmeric root oil; 8024-37-1; 1,5-Divanillyliden-2,4-pentandion; LS-125; 1,5-Di(vanillyliden)acetylaceton; Turmeric extract; Cucurmin; Kacha haldi; Natural yellow 3; NCGC00023332-03; Turmeric yellow; Curcuma; Gelbwurz; Safran d'Inde; Kurkumin; Turmeric, oleoresin; 1,7-Bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione; CCRIS 3257; LS-2189; 33171-04-9; AC-10434; Yellow, Turmeric; Curcuma oil; Kurkumin [Czech]; Curcuma oil (Curcuma longa); Orange Root; 1,6-Heptadiene-3,5-dione, 1,7-bis(4-hydroxy-3-methoxyphenyl)-; C7727_SIGMA; 91884-86-5; Indian saffron; 15845-47-3; 1,6-Heptadiene-3,5-dione, 1,7-bis(4-hydroxy-3-methoxyphenyl)-, (E,E)-; MLS001148449; Diferulylmethane; nchembio.364-comp3; kachs haldi; Tumeric yellow; BRN 2306965; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; Haldar; Souchet; AC1Q46A0; (1E,6E)-1,7-bis[4-hydroxy-3-(methyloxy)phenyl]hepta-1,6-diene-3,5-dione; Oils, galangal; 458-37-7; Haidr; C.I. Natural Yellow 3; NSC 687842; EINECS 207-280-5; Halud; Zlut prirodni 3; Halad; Turmeric oil; Turmeric root oleoresin; Bio-0677; safra d'inde; C21H20O6; MolPort-001-763-682; Diferuloylmethane; C.I. 75300; Yellow Ginger; NSC 32982; Curcuma longa l. oil; Curcumine; BIDD:ER0479; FEMA No. 3085; C1386_SIGMA; BRD-K07572174-001-02-2; Golden seal; 1,9-Bis(4-hydroxy-3-methoxyphenyl)-2,7-nonadiene-4,6-dione; 1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; CU-01000001305-2; Turmeric root oil; CID969516; Terra Merita; Turmeric extract (Curcuma longa L.); cMAP_000052; Curcumin I; CHEBI:3962; Curcuma longa l. oleoresin; Yo-Kin; Oils, curcuma; 79257-48-0; Oil of turmeric; HSDB 4334; Yellow Root; I06-0010; NCGC00023332-04; NSC687842; CCRIS 5804; E 100; Zlut prirodni 3 [Czech]; 98% curcurmin); Yellow puccoon; 1,6-Heptadiene-3,5-dione, 1,7-bis(4-hydroxy-3-methoxyphenyl)-, (1E,6E)-; Merita earth	N/A	N/A	N/A	TTDS00255	Multidrug resistance protein	P-glycoprotein	N/A	N/A	N/A	inhibitor
DCL001106	CBT-1	N/A	N/A	N/A	N/A	TTDS00255	Multidrug resistance protein	P-glycoprotein	N/A	N/A	N/A	inhibitor
DCL000298	Valspodar	Amdray; Amdray (TN); AC1NQZ8I; Sdz psc 833; CID5281884; Sdz-psc-833; Valspodar; Cyclosporin A, 6-((R-(E))-6,7-didehydro-N,4-dimethyl-3-oxo-L-2-aminooctanoic acid)-7-L-valine-; Valspodar (USAN/INN); 3'-Keto-bmt(1)-val(2)-cyclosporin A; C070272; (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-1,4,7,10,12,15,19,25,28-nonamethyl-33-[(E,2R)-2-methylhex-4-enoyl]-6,9,18,24-tetrakis(2-methylpropyl)-3,21,30-tri(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone; PSC-833; Psc 833; SDZ-PSC 833; 121584-18-7; C11213; PSC833; Cyclosporin D, 6-[(2S,4R,6E)-4-methyl-2-(methylamino)-3-oxo-6-octenoic acid]-; D06277; CHEMBL1086218	121584-18-7	5281884	47207934	TTDS00255	Multidrug resistance protein	P-glycoprotein	N/A	N/A	N/A	modulator
DCL000295	Tariquidar	AC1L3WN5; XR9576; Tariquidar; CID148201; N-(2-((4-(2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)phenyl)carbamoyl)-4,5-dimethoxyphenyl)quinoline-3-carboxamide; D06008; XR 9576; 3-Quinolinecarboxamide, N-(2-(((4-(2-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)ethyl)phenyl)amino)carbonyl)-4,5-dimethoxyphenyl)-; 206873-63-4; tariquidarth; N-[2-[[4-[2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)ethyl]phenyl]carbamoyl]-4,5-dimethoxyphenyl]quinoline-3-carboxamide; C402343; Tariquidar (USAN/INN); CHEBI:359664; UNII-J58862DTVD; CHEMBL348475	206873-63-4	148201	47207666	TTDS00255	Multidrug resistance protein	P-glycoprotein	N/A	N/A	N/A	modulator
DCL000584	Ortataxel	CHEMBL382300; IDN 5109; Bay-59-8862; 186348-23-2; SB-T 101131; 13-(N-tert-butoxycarbonyl-beta-isobutyisoserinyl)-14-hydroxybaccatin-1,14-carbonate; SB-T-101131; BAY59-8862; 13-(N-tert-butoxycarbonyl-beta-isobutyisoserinyl)-14-hydroxy-baccatin-1,14-carbonate; BAY 59-8862; IDN-5109; IND5109; Hexanoic acid, 3-(((1,1-dimethylethoxy)carbonyl)amino)-2-hydroxy-5-methyl-, (3aS,4R,7R,8aS,9S,10aR,12aS,12bR,13S,13aS)-7,12a-bis(acetyloxy)-13-(benzoyloxy)-3a,4,7,8,8a,9,10,10a,12,12a,12b,13-dodecahydro-9-hydroxy-5,8a,14,14-tetramethyl-2,8-dioxo-6,13a-methano-13aH-oxeto(2'',3'':5',6')benzo(1',2':4,5)cyclodeca(1,2-d)-1,3-dioxol-4-yl ester, (2R,3S)-; CID6918412; BAY-59; C404743; Ortataxel	N/A	6918412	12015217	TTDS00255	Multidrug resistance protein	P-glycoprotein	N/A	N/A	N/A	modulator
DAP000713	Benzquinamide	63-12-7; Promecon; NSC 108159; Benzoquinamide; UNII-0475EA27Q3; 2-(Acetyloxy)-N,N-diethyl-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-2H-benzo(a)quinolizine-3-carboxamide; AC1Q5IDP; Benzquinamidum [INN-Latin]; Emeticon; benzquinamide; 2-(acetoxy)-N,N-diethyl-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-2H-benzo[a]quinolizine-3-carboxamide; Quantryl; 2H-Benzo[a]quinolizine-3-carboxamide, 2-(acetyloxy)-N,N-diethyl-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-; P 2647; D00243; P-2647; Benzquinamide [USAN:INN:BAN]; benzquinamida; 2H-Benzo(a)quinolizine-3-carboxamide, 2-(acetyloxy)-N,N-diethyl-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-; 23844-24-8; 3-(diethylcarbamoyl)-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl acetate; 2-Hydroxy-3-diethylcarbamyl-9,10-dimethoxy-1,2,3,4,6,7-hexahydro-11bH-benzoquinolizine acetate; L000844; Benzchinamidum; CID2342; NSC108159; N,N-Diethyl-1,3,4,6,7,11b-hexahydro-2-hydroxy-9,10-dimethoxy-2H-benzo(a)quinolizine-3-carboxamide acetate (ester); N,N-Diethyl-1,3alpha,4,6,7,11bbeta-hexahydro-2beta-hydroxy-9,10-dimethoxy-2H-benzo(a)quinolizine-3-carboxamide acetate (ester); Benzquinamid; Benzchinamide; DB00767; CHEBI:27662; Quantril; NSC169193; 2H-Benzo(a)quinolizine-3-carboxamide, 2-(acetyloxy)-N,N-diethyl-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-, (2alpha,3beta,11balpha)-; 3-[(diethylamino)carbonyl]-9,10-bis(methyloxy)-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl acetate; 2-Acetoxy-3-(N,N-diethylcarboxamido)-9,10-dimethoxy-1,2,3,4,6,7-hexahydro-11bH-benzopyridocoline; 2H-Benzo[a]quinolizine-3-carboxamide, 2-(acetyloxy)-N,N-diethyl-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-, (2.alpha.,3.beta.,11b.alpha.)-; Benzoquinamida; N,N-Diethyl-1,3,4,6,7,11b-hexahydro-2-hydroxy-9,10-dimethoxy-2H-benzo(a)quinolizine-3-carboxamide acetate; 2H-Benzo(a)quinolizine-3-carboxamide, 2-(acetyloxy)-N,N-diethyl-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-, (2R,3R,11bS)-rel-; AR-1L1809; HSDB 3295; AC1L1DGR; LS-176282; 3-Diethylcarbamoyl-2,3,4,6,7,11b-hexahydro-9,10-dimethoxy-1H-benzo(a)chinolizin-2-yl acetat; 2-(acetyloxy)-N,N-diethyl-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-2H-benzo[a]quinolizine-3-carboxamide; Benzquinamide (USAN); Benzochinamide; 2H-Benzo(a)quinolizine-3-carboxamide, N,N-diethyl-1,3alpha,4,6,7,11bbeta-hexahydro-2beta-hydroxy-9,10-dimethoxy-, acetate (ester); C22H32N2O5; Benzoquinamida [INN-Spanish]; [3-(diethylcarbamoyl)-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-benzo[a]quinolizin-2-yl] acetate; NSC64375; Emete-con; 2H-Benzo[a]quinolizine-3-carboxamide, N,N-diethyl-1,3.alpha.,4,6,7,11b.beta.-hexahydro-2.beta.-hydroxy-9,10-dimethoxy-, acetate (ester); Benzchinamid; Benzquinamidum; LS-40205; 2-Acetoxy-3-diethylcarbamyl-9,10-dimethoxy-1,2,3,4,6,7-hexahydro-11b-benzo(a)quinolizine; 2H-Benzo(a)quinolizine-3-carboxamide, 2-(acetyloxy)-N,N-diethyl-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-, (2alpha,3beta,11balpha)- (9CI); 2H-Benzo(a)quinolizine-3-carboxamide, N,N-diethyl-1,3,4,6,7,11b-hexahydro-2-hydroxy-9,10-dimethoxy-, acetate (ester)	63-12-7	2342	9063	TTDS00255	Multidrug resistance protein	P-glycoprotein	N/A	N/A	N/A	inhibitor
DAP001243	Alseroxylon	N/A	8001-95-4	N/A	3730522	TTDS00118	Synaptic vesicle amine transporter	Monoamine transporter;Solute carrier family 18 member 2;VAT;Vesicular amine transporter;Vesicular Monoamine Transporter ;VMAT	Q05940	6571	ENSG00000165646	blocker
DAP000756	Tetrabenazine	9,10-dimethoxy-3-(2-methylpropyl)-1,3,4,6,7,11b-hexahydrobenzo[a]quinolizin-2-one; 2-Oxo-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11-beta-hexahydro-2H-benzoquinolizine; Nitoman; 1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-2H-Benzo[a]quinolizin-2-one; Tetrabenazine [INN:BAN]; HMS1540E17; SMR000718664; Nitoman, Xenazine, Tetrabenazine; 2H-Benzo[a]quinolizin-2-one, 1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-; MLS001249426; Tetrabenazinum; Tetrabenazinum [INN-Latin]; NSC172187; 2H-Benzo[a]quinolizin-2-one, 1,3,4,6,7,11b-hexahydro-3-isobutyl-9,10-dimethoxy-; 2-Oxo-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11.beta.-hexahydro-2H-benzoquinolizine; 5-21-13-00178 (Beilstein Handbook Reference); Tetrabenazina; WLN: T B666 DV GNTT&J E1Y1&1 LO1 MO1; NCGC00160421-02; Xenazine (TN); STK678061; Tetrabenzaine; CHEMBL117785; UNII-Z9O08YRN8O; S1789_Selleck; 1,3,4,6,7,11b-Hexahydro-3-isobutyl-9,10-dimethoxy-2H-benzo(a)quinolizin-2-one; TL8005032; BRD-A47564106-001-01-8; 1,3,4,6,7,11b-Hexahydro-3-isobutyl-9,10-dimethoxy-2H-benzo[a]quinolizin-2-one; MLS001249497; CHEBI:293281; C11168; 2H-Benzo(a)quinolizin-2-one, 1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-; AI3-52046; AC1L1LMF; Tetrabenzine; BRN 0040090; NSC169886; NSC 169886; tetra Benazin; D08575; ST028814; TETRABENAZINE; CID6018; 2H-Benzo(a)quinolizin-2-one, 1,3,4,6,7,11b-hexahydro-3-isobutyl-9,10-dimethoxy-; EINECS 200-383-6; Tetrabenazina [INN-Spanish]; MLS003106727; 58-46-8; LS-40294; MolPort-002-712-672; Ro 1-9569; 2H-Benzo(a)quinolizin-2-one, 1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)- (9CI); Oprea1_264344; Xenazine; NCGC00160421-01; DB04844; Nitoman (TN); Ro 1-9569/12; 9,10-dimethoxy-3-(2-methylpropyl)-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-one; TimTec1_002217; A2708/0115225; Tetrabenazine (INN); Rubigen; 2-Oxo-3-isobutyl-9,10-dimethoxy-1,2,3,4,6,7-hexahydro-11bH-benzo[a]quinolizine; AKOS001681311	58-46-8	6018	13350	TTDS00118	Synaptic vesicle amine transporter	Monoamine transporter;Solute carrier family 18 member 2;VAT;Vesicular amine transporter;Vesicular Monoamine Transporter ;VMAT	Q05940	6571	ENSG00000165646	blocker
DAP000755	Reserpine	Renese R; Reserlor; Serpanray; Rauserpin; Sedaraupina; T-Serp; Hypersil; Serpogen; Raupoid; Key-serpine; V-Serp; Cam-Ap-Es; V Serp; Reserjen; Hydropres 50; Diupres 500; HMS500A14; IDI1_000012; Raunervil; Seominal; 83580_FLUKA; Escaspere; VI XO; KBio2_000549; Neoserp; Serpine; Reserpidefe; Rauwilid; KBio1_000012; Respital; Hydromox R; Austrapine; Supergan; DB00206; Serpyrit; rau sedyl; Eskaserpine; Rauloydin; Carditivo; STK801975; H.R.-50; NCI-C50157; Adelphin; Kitine; Reserutin; VIXO; Serpoid; Diupres-500; loweser p; Carrserp; KBio2_005685; Roxynoid; Sertensin; Rausedyl; Roxel; 1407-38-1; Rausedan; Eserpine; Deserpine; Reserpamed; Tylandril; Maviserpin; Serpaloid; Serfin; Sertina; Raucap; l"-Carpserp; Hexaplin; Resine; Dralserp; Reserpka; R0875_SIGMA; BB_NC-1905; Residin; D012110; Darebon; ENT 50146; Lemiserp; Hydroserp; Regroton; Sandril; Rivasin; Hydrap-ES; SK-Reserpine; C06539; 3P Reserp; Resercen; Raudixoid; Raulen; CHEMBL772; Rivased; Hypercal B; Serpivite; Reserpur; 50-55-5; Hypersine; Sertabs; Rauvlid; Raugal; Triserpin; Veriloid; Benazyl; HMS1570P11; Temposerpine; R 0875; Resaltex; Rauserpine; CHEBI:28487; Rauwasedin; Hydromox-R; Hydrosine 25; Serpiloid; Pressimedin; Serpivate; Rauwoleaf; Rolserp; HMS1920P04; Eberpine; Diupres 250; reserpine; Reserbal; Serpaneurona; Diupres-250; Reserpal; Rese-lar; Mallopress; Modenol; Hiserpia; Abesta; Ascoserpina; Sandron; Tepserpine; D00197; l -Carpserp; Raurine; Serpilum; Gilucard; Diurese-R; KBio3_001808; Resocalm; Hydropres 25; esc aspere; Terbolan; Resedril; Loweserp; Raupasil; EU-0100073; NSC 237659; BRN 0102014; Sedserp; Hydropine; Naquival; Sertens; Recipin; Banisil; Serpen; Resedrex; NSC59272; nembuserpin; Rautrin; Apoplon (TN); Bioserpine; Reserp; Reserpinum; Hiposerpil; Unipres; Sedaraupin; Purserpine; Rauwiloid; gammaserpine; Tensionorme; Rausedil; Tenserpinie; NINDS_000012; Serpate; Serpedin; Tensional; Rauwita; Eskaserp; Sederaupin; Helfoserpin; Mayserpine; Brinderdin; Reserpin; :reserpine; HYDRO-RESERP; AI3-50146; NSC237659; neose rfin; Adelfan; Ryser; Rausan; SPBio_002870; Serpone; Rauserpol; NCI60_004446; Elfanex; Ser-A-Gen; Resercaps; Broserpine; Idoserp; Serpipur; Reserpoid; Ebserpine; Serolfia; LS-1306; Abicol; Reserpanca; Rauwipur; se rpate; R-e-s; Cardioserpin; Serpil; Serpentil; Serpalan; Serpazil; Raumorine; Usaf cb-27; Serpentin; Serpena; Enipresser; Banasil; Rawilid; Serpentina; Orthoserpina; Klimanosid; Residine; H 520; Neoslowten; Resperin; Raunova; Briserine; Serpasil; Serpazol; Reserpil; Diutensen-R; Reserpina; Tefaserpina; Rezerpin; Resperine; Hypertensan; Alkaserp; HMS2092G05; 8048-25-7; Neoserfin; Serpasol; Unilord; Perskleran; Ascoserp; ACon1_000086; Alkarau; Apsical; Reser-ar; Serfolia; Reserpex; Raudixin; AC1L1L3K; Interpina; Rau-Sed; AC-13142; Idsoserp; Carpacil; Transerpin; Quiescin; Resiatric; CCRIS 550; 141099-49-2; Salupres; HSDB 213; MLS002154046; Elserpine; Raunorine; Rausingle; Renese-R; Tensanyl; KBio2_003117; Eberspine; Reserfia; Riserpa; Mephaserpin; CID5770; Restran; Apoplon; rese rpamed; Vio-Serpine; Alserin; Roxinoid; neo-serp; Raudiford; SMR000059122; Reserpene; Serpicon	50-55-5	5770	8769	TTDS00118	Synaptic vesicle amine transporter	Monoamine transporter;Solute carrier family 18 member 2;VAT;Vesicular amine transporter;Vesicular Monoamine Transporter ;VMAT	Q05940	6571	ENSG00000165646	blocker
DCL000927	PG-116800	PGE 530742; 4-Hexynoic acid, 2-(((4-((4-methoxybenzoyl)amino)phenyl)sulfonyl)amino)-6-(4-morpholinyl)-; PG 530742; PGE 7113313; 291533-11-4; 668998-02-5; PG-116800; PG 116800	N/A	N/A	N/A	TTDC00076	92 kDa type IV collagenase	92 kDa gelatinase;Gelatinase B;GELB;Matrix metalloproteinase 9;Matrix metalloproteinase-9;MMP-9	P14780	4318	ENSG00000100985	inhibitor
DCL000008	Neovastat	N/A	305838-77-1	N/A	3820640	TTDC00076	92 kDa type IV collagenase	92 kDa gelatinase;Gelatinase B;GELB;Matrix metalloproteinase 9;Matrix metalloproteinase-9;MMP-9	P14780	4318	ENSG00000100985	inhibitor
DAP000796	Methoxamine	Methoxaminum; Methoxamin; Methoxamedrin; Prestwick0_000535; Prestwick1_000535; KBioGR_000541; EINECS 206-867-3; Spectrum_001021; 390-28-3; Methoxamine (BAN); CID6082; CHEBI:111775; methoxamine; BSPBio_001995; KBio3_001495; Benzenemethanol, .alpha.-(1-aminoethyl)-2,5-dimethoxy-; Spectrum2_000776; CHEMBL524; DB00723; Benzenemethanol, alpha-(1-aminoethyl)-2,5-dimethoxy-; SPBio_000852; DL-2-Amino-1-(2,5-dimethoxyphenyl)propanol; Spectrum5_001821; alpha-(1-Aminoethyl)-2,5-dimethoxybenzyl alcohol; KBioSS_001501; Prestwick2_000535; KBio2_006637; BSPBio_000549; 2-Amino-1-(2,5-dimethoxyphenyl)-1-propanol; NCGC00015692-06; Metossamina; KBio2_001501; Methoxaminum [INN-Latin]; UNII-HUQ1KC1YLI; MolPort-002-052-010; Methoxamedrine; 61-16-5 (hydrochloride); 2-amino-1-[2,5-bis(methyloxy)phenyl]propan-1-ol; LS-42641; KBio2_004069; NCGC00089793-02; AC1L1LRI; Metoxamina; AB00053731; Benzyl alcohol, alpha-(1-aminoethyl)-2,5-dimethoxy-; Methoxamine [INN:BAN]; 2-amino-1-(2,5-dimethoxyphenyl)propan-1-ol; Pseudomethoxamine; Metoxamina [INN-Spanish]; 2-Amino-1-(2,5-dimethoxyphenyl)propanol; Benzyl alcohol, .alpha.-(1-aminoethyl)-2,5-dimethoxy-; Vasoxine; Spectrum4_000051; BPBio1_000605; Metossamina [DCIT]; Lopac0_000769; Vasoxin; SPBio_002470; C07513; L000757; AQ-387/40213491; Spectrum3_000498; D08201; Prestwick3_000535	390-28-3	6082	9716	TTDS00029	Alpha-1B adrenergic receptor	Alpha 1B-adrenoceptor;Alpha 1B-adrenoreceptor	P35368	147	ENSG00000170214	stimulator
DAP000571	Lisdexamfetamine	D08130; Lisdexamfetamine (INN); MolPort-004-285-960; CID11597698; UNII-H645GUL8KJ; DB01255; LS-187377; Lisdexamfetamine; 608137-32-2; NRP104	608137-32-2	11597697	16700339	TTDS00029	Alpha-1B adrenergic receptor	Alpha 1B-adrenoceptor;Alpha 1B-adrenoreceptor	P35368	147	ENSG00000170214	antagonist
DAP000572	Dextroamphetamine	dextroamphetamine; D-Amphetamine; (2S)-(+)-Amphetamine; Desamfetamina [DCIT]; Dexamfetamina; (+/-)-beta-Phenylisopropylamine; (+/-)-Desoxynorephedrine; DB01576; Benzeneethanamine, alpha-methyl-, (alphaS)-; CID5826; AC1L1L85; (S)-alpha-Phenylethylamine; (+/-)-Benzedrine; Dephadren; beta-phenyl-isopropylamine; Psychedrine; NCGC00168247-01; (+)-Phenaminum; S(+)-Amphetamine; DEA No. 1100; PDSP1_001511; Simpatedrin; Dexamfetamine (INN); (S)-alpha-Methylphenethylamine; Raphetamine; Fenylo-izopropylaminyl; Sympamin; D-AM; Benzeneethanamine, alpha-methyl-, (aS)- (9CI); HSDB 3055; BRN 2205872; (S)-1-Phenyl-2-propylamine; Rhinalator; Phenethylamine, alpha-methyl-, d-; Propisamine; Dexadrine; Benzedrine; dextro-Amphetamine; (+)-alpha-Methylphenylethylamine; NSC 73713; Dexedrine; Amsustain; CHEMBL612; (S)-Amphetamine; Dextroamphetamine [USAN]; D-2-Amino-1-phenylpropane; D-1-Phenyl-2-aminopropane; Dexacaps; Dexamfetamina [INN-Spanish]; LS-187774; Dexamphetamine; C07884; EINECS 200-112-1; Sympatedrine; Dexamfetaminum; D-alpha-methylphenethylamine; Dexamfetamine; d-1-Phenyl-2-aminopropan [German]; alpha-Methylphenethylamine, d-form; Sympamine; Benzeneethanamine, alpha-methyl-, (S)-; Dextro-Amphetamine Sulfate; D-(+)-Amphetamine; Dexamphetaminum; (alphaS)-alpha-methylbenzeneethanamine; (S)-(+)-Amphetamine; PDSP2_001495; Dexidrine; 4-12-00-02587 (Beilstein Handbook Reference); (2S)-1-phenylpropan-2-amine; Dextroamphetamine (USAN); Dexanfetamina [INN-Spanish]; Desamfetamina; CHEBI:4469; Phenethylamine, alpha-methyl-, (+)-; (+)-(S)-Amphetamine; dl-1-Phenyl-2-aminopropane; D03740; Dexanfetamina; Dextroamphetamine resin complex; (S)-alpha-methylbenzeneethanamine; Weckamine; Dexamfetaminum [INN-Latin]; MolPort-004-285-839; Isoamycin; 51-64-9; (S)-1-Phenyl-2-propanamine; (S)-1-Phenyl-2-aminopropane; (+)-Amphetamine; D-(S)-Amphetamine; Dexamphetaminum [INN-Latin]; (+)-alpha-Methylphenethylamine; D-1-Phenyl-2-aminopropan; dl-Benzedrine; (S)-(+)-beta-Phenylisopropylamine; DB00182; Phenethylamine, alpha-methyl-, (+)- (8CI); Dexedrine Spansule; LS-103617; UNII-TZ47U051FI; dl-Amphetamine	51-64-9	5826	10086	TTDS00029	Alpha-1B adrenergic receptor	Alpha 1B-adrenoceptor;Alpha 1B-adrenoreceptor	P35368	147	ENSG00000170214	antagonist
DAP000573	Methamphetamine	METHAMPHETAMINE; Metamfetamina [INN-Spanish]; d-Desoxyephedrine; (alphaS)-N,alpha-dimethylbenzeneethanamine; Benzeneethanamine, N,alpha-dimethyl-, (alphaS)- (9CI); N-Methyl-beta-phenylisopropylamin [German]; (S)-N,alpha-Dimethylbenzeneethanoamine; Benzeneethanamine, N,alpha-dimethyl-, (S)-; AC1Q4SVR; Speed [Street Name]; (S)-(+)-Methamphetamine; D-N,alpha-dimethylphenethylamine; N-Methylamphetamine; Benzeneethanamine, N,.alpha.-dimethyl-, (+)-; Benzeneethanamine, N,alpha-dimethyl-, (+)-; desohyephedrine; ICE [Street Name]; Phenethylamine, N,.alpha.-dimethyl-, (+)-; Crystal Meth [Street Name]; (+)-(S)-N-alpha-Dimethylphenethylamine; PDSP2_001389; Phenethylamine, N,alpha-dimethyl-, (S)-(+)-; Methamphetamine, its salts, isomers, and salts of its isomers; EINECS 208-668-7; Metanfetamina [INN-Spanish]; Benzeneethanamine, N,alpha-dimethyl-, (S)- (9CI); D-1-Phenyl-2-methylaminopropan; WLN: 1MY1&1R -D; N-Methyl-beta-phenylisopropylamine; AC1L1W1Z; (+)-Methylamphetamine; Metanfetamina [Spanish]; Phenethylamine, N,alpha-dimethyl-, (S)-(+)- (8CI); Metamphetamine; 1-Phenyl-2-methylamino-propan; C10H15N; Metamfetamina; 139-47-9; UNII-44RAL3456C; S-(+)-Methamphetamine; Crystal Meth; 1690-86-4; d-Methamphetamine; Methamphetaminum [INN-Latin]; 2S-(+)-Methamphetamine; Benzeneethanamine, N,alpha-dimethyl-, (alphaS)-; (+)-methamphetamine; (S)-(+)-Deoxyephedrine; NSC25115; Methyl-beta-phenylisopropylamine; (S)-(+)-N,alpha,dimethylphenethylamine; 1-Phenyl-2-methylamino-propan [German]; Metamfetamine; Norodin; Metamfetaminum [Latin]; Metamfetamine [INN]; CHEBI:6809; Crank; (+)-(S)-Deoxyephedrine; Methamphetaminum; Phenethylamine, N,alpha-dimethyl-, (+)-; Methamphetaminum [JP]; Crank [Street Name]; L-Methamphetamine; 45952-89-4; C07164; PDSP2_001388; d-Phenylisopropylmethylamine; Metamfetamine-m; d-(S)-Methamphetamine; 14611-50-8; d-Deoxyephedrine; (S)-Methylamphetamine; (+ )-Methylamphetamine; Desyphed hydrochloride; d-N-Methylamphetamine; (+)-2-(N-Methylamino)-1-phenylpropane; d-1-Phenyl-2-methylaminopropan [German]; Desyphed; LS-103331; CHEMBL1201201; Methyl-.beta.-phenylisopropylamine; Speed; (S)-N,alpha-Dimethylbenzeneethanamine; Meth (Street Name); CID10836; (+)-N-Methylamphetamine; PDSP1_001405; DEA No. 1105; Metamfetamine (INN); (+)-N,alpha-Dimethylphenethylamine; N-Methyl-beta-phenylisopropylamin; DB01577; HSDB 3359; d-Methylamphetamine; Metamfetaminum; (+)-N,alpha-Dimethyl-beta-phenylethylamine; Meth; (2S)-N-methyl-1-phenylpropan-2-amine; D-1-Phenyl-2-methylaminopropane; 1-Phenyl-2-methylaminopropane; d-N,.alpha.-Dimethylphenethylamine; N-Methyl-1-phenyl-2-propanamine; (S)-Methamphetamine; NSC 25115; Methylamphetamine; B40; MolPort-001-794-405; Stimulex; 537-46-2; PDSP1_001404; Metamfetaminum [INN-Latin]; D08187	537-46-2	10836	10318874	TTDS00029	Alpha-1B adrenergic receptor	Alpha 1B-adrenoceptor;Alpha 1B-adrenoreceptor	P35368	147	ENSG00000170214	antagonist
DAP000574	Phendimetrazine	(2S,3S)-3,4-Dimethyl-2-phenylmorpholine; Mephenmetrazine; DB01579; CID12460; NSC 169187; (+)-3,4-Dimethyl-2-phenylmorpholine; LS-92783; CID30487; 634-03-7; 16311-86-7; Morpholine, 3,4-dimethyl-2-phenyl-, (+)-; Fendimetrazina [INN-Spanish]; d-2-Phenyl-3,4-dimethylmorpholine; Phendimetrazine (INN); 21784-30-5; Wehless; CHEMBL1744; UNII-AB2794W8KV; hyrex; (2R-trans)-3,4-Dimethyl-2-phenylmorpholine; LS-173902; EINECS 211-204-6; 3-Phenyl-2-methylmorpholine; Adphen (base); Sedafamen; 3,4-Dimethyl-2-phenyltetrahydro-1,4-oxazine; AC1L1JNO; x-Trozine; phendimetrazine; D08347; Phendimetrazinum; Adphen; 17140-98-6 (hydrochloride); NSC169187; phendimetrazine, (2S-trans)-isomer; DEA No. 1615; Morpholine, 3,4-dimethyl-2-phenyl-, ( )-; 711-71-7; Morpholine, 3,4-dimethyl-2-phenyl-, (2S-trans)-; MolPort-000-003-187; (+)-Phendimetrazine; Phendimetrazinum [INN-Latin]; Morpholine, 3,4-dimethyl-2-phenyl-; Dyrexan; 3,4-Dimethyl-2-phenylmorpholine; Fendimetrazina; Antapentan; AC1L1ZN6; HSDB 3381; ZINC22010387; C07904; Phendimetrazine [INN:BAN]	634-03-7	12460	10106	TTDS00029	Alpha-1B adrenergic receptor	Alpha 1B-adrenoceptor;Alpha 1B-adrenoreceptor	P35368	147	ENSG00000170214	antagonist
DAP000413	Propericiazine	C21H23N3OS; 10-[3-(4-hydroxypiperidin-1-yl)propyl]-10H-phenothiazine-2-carbonitrile; propericiazine(jan); 6909 RP; NCGC00095086-02; BRD-K89669299-001-02-7; HMS502L16; CID4747; 2-Cyano-10-(3-(4-hydroxypiperidino)propyl)phenothiazine; Spectrum4_000210; CHEBI:31981; Periciazinum; NCGC00095086-03; KBio2_002094; IC 6002; Spectrum3_000748; Neuleptil; KBioSS_002094; Periciazine [INN]; Phenothiazine-2-carbonitrile, 10-(3-(4-hydroxypiperidino)propyl)-; Spectrum_001614; Piperocyanomazine; AC1Q4RQI; Nemactil; MolPort-003-981-163; Spectrum5_001747; SPBio_001607; Periciazinum [INN-Latin]; Periciazina; EINECS 220-071-3; Cyano-3 ((hydroxy-4 piperidyl-1)-3 propyl)-10 phenothiazine; DivK1c_000874; Spectrum2_001604; Cyano-3 ((hydroxy-4 piperidyl-1)-3 propyl)-10 phenothiazine [French]; Periciazina [INN-Spanish]; 2-Cyano-10-(3-(4-hydroxy-1-piperidyl)propyl)phenothiazine; BRN 0576739; 2622-26-6; RP 8908; UNII-3405M6FD73; Neuleptil (TN); D01485; Aolept; KBio3_001556; KBio2_007230; Propericiazine (JAN); Bayer 1409; F.I. 6145; LS-105273; Propericiazine; Neulactil; KBio1_000874; 10-(3-(4-Hydroxypiperidino)propyl)phenothiazine-2-carbonitrile; WH 7508; SKF 20,716; KBioGR_000819; 4-Piperidinol, 1-(3-(2-cyano-10-phenothiazinyl)propyl)-; IDI1_000874; CHEMBL251940; AR-1L2302; DB01608; PERICYAZINE; periciazine; KBio2_004662; HMS1922M18; NINDS_000874; BSPBio_002336; 10-[3-(4-hydroxypiperidin-1-yl)propyl]phenothiazine-2-carbonitrile; SPECTRUM1503936; AC1L1IV8; NCGC00095086-01	2622-26-6	4747	10391833	TTDS00029	Alpha-1B adrenergic receptor	Alpha 1B-adrenoceptor;Alpha 1B-adrenoreceptor	P35368	147	ENSG00000170214	binder
DAP000876	Menthol	(1r,2s,5r)-(-)-menthol; M0321; D008610; Menthol, trans-1,3,trans-1,4-; NSC 62788; rac-Menthol; LS-57201; Menthol, (1alpha,2beta,5alpha)-Isomer; dl-Menthol; Menthol, trans-1,3,cis-1,4-; Menthol, cis-1,3,trans-1,4-; Hexahydrothymol; NCGC00159382-02; d-Menthol; BRN 3194263; 89-78-1; 6C6A4A8C-A054-468C-A1F0-F29E39838CF2; Menthol, (.+/-.)-; (+/-)-Menthol; LS-89531; NCI-C50000; CCRIS 9231; MolPort-001-793-392; nchembio862-comp1; Racementol [INN-Spanish]; MENTHOL; NSC62788; Levomentholum; D-p-Menthan-3-ol; HMS1922G13; NCGC00164247-01; l-Menthol (natural); l-Menthol; Levomenthol; Levomenthol [INN:BAN]; NSC2603; UNII-L7T10EIP3A; (-)-menthol; HMS2092L14; SPECTRUM1503134; 20747-49-3; CHEBI:545611; BRN 1902288; KBio3_002562; CHEBI:15409; 15785_SIAL; AI3-08161; 551376_FLUKA; MolPort-000-849-729; Menthol racemique [French]; (1S,2R,5R)-(+)-Isomenthol; Menthol (USP); Headache crystals; MENTHOL, (+)-neo-; (+)-p-Menthan-3-ol; EINECS 201-939-0; AC1L1B2E; MLS002207256; W266523_ALDRICH; (+-)-(1R*,3R*,4S*)-Menthol; (1S,2R,5S)-Menthol; l-(-)-Menthol; D04849; 588733_ALDRICH; Racementhol [INN:BAN]; Neoisomenthol; ()-Menthol; KBio2_005921; LS-89533; Spectrum2_000855; l-Menthol (TN); EINECS 218-690-9; AC1Q1NQ2; cis-1,3-trans-1,4-(+-)-menthol; Tra-kill tracheal mite killer; Racementholum; p-Menthan-3-ol; 63975-60-0; Racemic menthol; d,l-Menthol; 5-Methyl-2-(1-methylethyl)cyclohexanol; (R)-(-)-Menthol; (1R,2S,5R)-Menthol; UNII-BZ1R15MTK7; Levomentholum [INN-Latin]; 5-methyl-2-propan-2-ylcyclohexan-1-ol; 5-methyl-2-(propan-2-yl)cyclohexanol; Menthol, (1S,3S,4R)-(+)-; 2-Isopropyl-5-methylcyclohexanol; Menthacamphor; I14-7371; (+)-Neo-menthol; UNII-YS08XHA860; Menthol solution; dl-Menthol (JP15); --MENTHOL; AC1L28FR; CCRIS 3728; LMPR0102090001; Menthol, (1R,3R,4S)-(-)-; 15356-60-2; EPA Pesticide Chemical Code 051601; NINDS_000820; NSC 2603; NOOLISFMXDJSKH-KXUCPTDWSA-; I06-1216; SDCCGMLS-0066659.P001; DivK1c_000820; LS-2353; Cyclohexanol, 2-isopropyl-5-methyl-; D00064; BB_NC-0057; dl-3-p-Menthanol; 551376_ALDRICH; 4-Isopropyl-1-methylcyclohexan-3-ol; BSPBio_003062; 19863P; Spectrum3_001561; (-)-Menthyl alcohol; CHEMBL470670; 15785_RIEDEL; CID1254; Robitussin Cough Drops; Menthol racemique; (&#8722;)-Menthol; ZINC01482164; NCGC00164247-02; EINECS 216-074-4; EINECS 207-724-8; Racementhol; Fisherman's friend lozenges (TN); Menthomenthol; Fisherman's friend lozenges; EINECS 239-387-8; Menthol, cis-1,3,cis-1,4-; C10H20O; HSDB 5662; 613290_ALDRICH; CCRIS 4666; (1S, 2S, 5R)-(+)-Neomenthol; LS-886; WLN: L6TJ AY1&1 DQ D1 -L; AR-1J3337; AC1Q2QQM; Menthol natural, brazilian; Menthol, dl-; Menthol natural; NOOLISFMXDJSKH-KXUCPTDWBX; AKOS000119740; d-Neomenthol; Spectrum5_001060; cis-1 ,3-trans-1,4-(+-)-menthol; (1R)-(-)-Menthol; Menthol, l-; DB00825; U.S.P. Menthol; M2772_SIAL; 63660_FLUKA; 491-02-1; Racementol; 63670_ALDRICH; HMS502I22; 98167-53-4; C00400; (+-)-Menthol; 613290_FLUKA; 15356-70-4; KBio1_000820; SPBio_000869; (L)-MENTHOL; KBioSS_000785; (1S,2R,5S)-(+)-Menthol; RACEMIC MENTHOL U.S.P.; Menthyl alcohol; WLN: L6TJ AY1&1 BQ D1; Peppermint camphor; CHEMBL256087; CCRIS 375; HSDB 593; (1R,3R,4S)-(-)-MENTHOL; EINECS 239-388-3; Menthol racemic; Spectrum_000305; 1490-04-6; IDI1_000820; (-)-p-Menthan-3-ol; W266507_ALDRICH; 2216-51-5; AI3-52408; NCGC00159382-03; (+/-)-p-Menthan-3-ol; KBio2_000785; Racementholum [INN-Latin]; D-(-)-Menthol; l-Menthol (JP15); Menthol (VAN); 3-p-Menthol; SMR001306785; KBio2_003353; (-)-trans-p-Menthan-cis-ol; STK802468; W266590_ALDRICH; 5-Methyl-2-(1-methylethyl)-cyclohexanol; M0545; 63670_FLUKA; FEMA No. 2665; D04918; (-)-(1R,3R,4S)-Menthol; CID16666; Caswell No. 540	2216-51-5	16666	3690	TTDS00507	Transient receptor potential cation channel subfamily M member 8	Long transient receptor potential channel 6;LTrpC6;Transient receptor potential-p8;TRPM8;TRPP8;Trp-p8	Q7Z2W7	79054	ENSG00000144481	activator
DAP000632	Cilastatin	EINECS 279-875-8; BIDD:GT0782; CHEBI:3697; (Z)-7-[(2R)-2-amino-3-hydroxy-3-oxopropyl]sulfanyl-2-[[(1S)-2,2-dimethylcyclopropanecarbonyl]amino]hept-2-enoic acid; 81129-83-1 (mono-hydrochloride salt); Cilastatine [French]; (2Z)-7-{[(2R)-2-amino-2-carboxyethyl]sulfanyl}-2-({[(1S)-2,2-dimethylcyclopropyl]carbonyl}amino)hept-2-enoic acid; LS-74560; Cilastatin; TL8005438; CHEMBL766; UNII-141A6AMN38; Cilastatinum; Cilastatin acid; D07698; AC-268; Cilastatine; MK0791; 2-Heptenoic acid, 7-((2-amino-2-carboxyethyl)thio)-2-(((2,2-dimethylcyclopropyl)carbonyl)amino)-, (R-(R*,S*-(Z)))-; DB01597; CID6435415; NCGC00181346-01; Cilastatinum [Latin]; 82009-34-5; Cilastatina [Spanish]; AC1O5JQX; MK-791; (Z)-(S)-6-carboxy-6-[(S)-2,2-dimethylcyclopropanecarboxamido]hex-5-enyl-L-cysteine; Cilastatin [INN:BAN]; C01675; Cilastatina; Cilastatin (INN); MolPort-003-987-260; Cilastatin Monosodium Salt; C16H26N2O5S	82009-34-5	5280454	4819	TTDS00230	Dehydropeptidase I	Dehydropeptidase-I;MDP;RDP;Renal dipeptidase	P16444	1800	ENSG00000015413	inhibitor
DAP001480	GMA-161	N/A	N/A	N/A	N/A	TTDS00518	Fc gamma receptor III	CD16;Fc-gamma RIII;FcgammaRIIIb;FcR-10;FcRIII;IgG FC receptor III;Low affinity immunoglobulin gamma Fc region receptor III	N/A	N/A	N/A	antagonist
DCL000641	SPI-1620	N/A	N/A	N/A	N/A	TTDS00199	Endothelin B receptor	Endothelin receptor B;Endothelin receptor Non-selective type;ET-B	P24530	1910	ENSG00000136160	agonist
DAP000030	Bosentan	174227-18-0; TL8001039; -5-(o-methoxyphenoxy)-2-(2-pyrimidinyl)-4-pyrimidinyl]benzenesulfonamide; Bosentan [USAN:INN:BAN]; Bosentan (INN); Benzenesulfonamide, 4-(1,1-dimethylethyl)-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)(2,2'-bipyrimidin)-4-yl)-; Bosentan; Benzenesulfonamide, 4-(1,1-dimethylethyl)-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)[2,2'-bipyrimidin]-4-yl]-; AC1L2XN2; LS-31532; PDSP1_001731; I06-1873; Tracleer; AC-148; UNII-XUL93R30K2; 4-(1,1-Dimethylethyl)-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-(2,2'-bipyrimidin)-4-yl)benzenesulfornamide; bosentanum; p-tert-Butyl-N-[6-(2-hydroxyethoxy); p-tert-Butyl-N-(6-(2-hydroxyethoxy)-5-(o-methoxyphenoxy)-2-(2-pyrimidinyl)-4-pyrimidinyl)benzenesulfonamide; NCGC00167440-01; 4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-pyrimidin-2-ylpyrimidin-4-yl]benzenesulfonamide; Ro-47-0203/029; PDSP2_001714; CHEBI:51450; Ro 47-0203; CHEMBL957; 4-t-butyl-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2,2'-bipyrimidin-4-yl)benzenesulfonamide; 4-(1,1-Dimethylethyl)-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-(2,2'-bipyrimidin)-4-yl) benzenesulfornamide; CID104865; 4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2,2'-bipyrimidin-4-yl]benzenesulfonamide; D07538; 147536-97-8; KS-5062; DB00559; Ro-47-0203; MolPort-003-845-300; Actelion; C27H29N5O6S; L001086; EN002863; HMS2090N14; Ro-47-0203/039; Ro 47-0203/039	147536-97-8	104865	682323	TTDS00199	Endothelin B receptor	Endothelin receptor B;Endothelin receptor Non-selective type;ET-B	P24530	1910	ENSG00000136160	antagonist
DCL000494	Beta-Lapachone	NCGC00094066-01; 2H-Naphtho(1,2-b)pyran-5,6-dione, 3,4-dihydro-2,2-dimethyl-; L2037_SIGMA; NSC26326; BSPBio_001306; .beta.-Lapachone; 3,4-Dihydro-2,2-dimethyl-2H-naphtho(1,2-b)pyran-5,6-dione; LS-95515; ZINC01531790; 4707-32-8; NCGC00094066-02; |A-lapachone; HMS1989B08; C10367; KBio3_000052; EU-0100717; Lopac0_000717; AC1L1GXE; NCI60_009665; HMS1361B08; BCBcMAP01_000055; NSC629749; ARQ 501; KBio3_000051; Lopac-L-2037; KBio2_002594; 500587-45-1; NCGC00094066-05; BRN 0181499; Bio2_000506; KBioGR_000026; NSC 26326; KBio2_005162; NCGC00015598-01; HMS1791B08; KBio2_000026; 2,2-dimethyl-3,4-dihydrobenzo[h]chromene-5,6-dione; Bio2_000026; CHEMBL15192; SL 11001; LAPACHONE, BETA; QTL1_000048; Lapachone, beta-; NCGC00015598-02; 2H-Naphtho[1,2-b]pyran-5,6-dione, 3,4-dihydro-2,2-dimethyl-; NCGC00015598-08; NSC 629749; IDI1_033776; MolPort-003-946-081; beta-Lapachone; 5-17-11-00459 (Beilstein Handbook Reference); NCGC00094066-03; 3,4-Dihydro-2,2-dimethyl-2H-naphtho[1,2-B]pyran-5,6-dione; CID3885; HSCI1_000182; KBioSS_000026; C014638; AR-1L8716; NCGC00094066-04; AK-693/21096016; AC1Q6JBS	N/A	497540	793803	TTDS00079	DNA topoisomerase I	Topoisomerase-I	Q00313	N/A	N/A	inhibitor
DAP000648	Topotecan	(S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; NChemBio.2007.10-comp24; BSPBio_002348; SKF-S 104864; topotecan; C23H23N3O5; HSCI1_000228; SKF 104864; 1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline- 3,14(4H,12H)-dione, 10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-, (4S)-; Topotecane [INN-French]; MLS000759456; Topotecanum [INN-Latin]; Topotecan lactone; Hycamtin; NCIStruc2_001796; Topotecanum; Topotecan [INN:BAN]; 1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, 10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-, (4S)-; TOPOTECAN, HYCAMTIN; CHEBI:107501; C11158; Topotecane; D08618; NCI60_004771; Topotecan (BAN); NCGC00178695-01; AC1L1TQZ; SMR000466344; (S)-10-[(DIMETHYLAMINO)METHYL]-4-ETHYL-4,9-DIHYDROXY-1H-PYRANO[3',4':6,7]INOLIZINO[1,2-B]-QUINOLINE-3,14(4H,12H)-DIONE; SK&F-104864-A; (S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]-quinoline-3,14(4H,12H)-dione; AC1Q6APZ; 1H-Pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione, 10-((dimethylamino)methyl)-4-ethyl-4,9-dihydroxy-, (S)-; CCRIS 8163; Topotecan Monohydrochloride, (S)-Isomer; AC-11592; CHEBI:46035; CHEMBL84; 123948-87-8; SKF-104864-A; CID60700; SMP2_000312; LS-127395; 9-Dimethylaminomethyl-10-hydroxycamptothecin; Hycamtamine; Hycamptamine; UNII-7M7YKX2N15; Hycamtin (TN); NCIStruc1_001659; HMS2090B20; DB01030; Hycamptin; (4S)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; NSC609699; (S)-10-((Dimethylamino)methyl)-4-ethyl-4,9-dihydroxy-1H-pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione; SMP2_000327	119413-54-6	60700	606579	TTDS00079	DNA topoisomerase I	Topoisomerase-I	Q00313	N/A	N/A	inhibitor
DAP000647	Irinotecan	S1198_Selleck; 1u65; (1,4'-Bipiperidine)-1'-carboxylic acid, 4,11-diethyl-3,4,12-14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano(3',4':6,7)indolizino(1,2-b)quinolin-9-yl ester, (S)-; CHEBI:105985; Camptosar, Campto, CPT-11, Irinotecan; Irinotecan hydrochloride; CID60838; C33H38N4O6; C16641; (+)-Irinotecan; D08086; TL8006026; FT-0083650; HSDB 7607; (4S)-4,11-DIETHYL-4-HYDROXY-3,14-DIOXO-3,4,12,14-TETRAHYDRO-1H-PYRANO[3',4':6,7]INDOLIZINO[1,2-B]QUINOLIN-9-YL 1,4'-BIPIPERIDINE-1'-CARBOXYLATE; NCI60_005051; BRD-K08547377-003-02-4; Irinotecanum; UNII-7673326042; Biotecan (TN); Irinotecan [INN:BAN]; AC1L1U0Z; IRINOTECAN HYDROCHLORIDE Trihydrate; Biotecan; CP0; Irinotecan (INN); (4S)-4,11-Diethyl-4-hydroxy-3,14-dioxo-4,12-dihydro-1H-pyrano[3,4-f]quinolino[2,3-a]indolizin-9-yl 4-piperidylpiperidinecarboxylate; Bio-0054; AC1Q6PGI; NSC728073; BSPBio_002346; LS-44589; AC-7469; Irinotecan Hcl; IRINOTECAN, CPT-11; Camptosar; DB00762; Irinotecanum [INN-Latin]; CHEMBL481; 97682-44-5; irinotecan	100286-90-6	60838	217212	TTDS00079	DNA topoisomerase I	Topoisomerase-I	Q00313	N/A	N/A	inhibitor
DAP001449	Topetecan	N/A	N/A	N/A	N/A	TTDS00079	DNA topoisomerase I	Topoisomerase-I	Q00313	N/A	N/A	inhibitor
DAP000842	Aminoglutethimide	AC1L1D0R; alpha-(p-Aminophenyl)-alpha-ethylglutarimide; HMS2090I05; Prestwick3_000244; Prestwick2_000244; Aminoglutetimida; A1947; Prestwick0_000244; Ba 16038; Cytadren (TN); NCGC00093615-02; KBio1_000884; NCGC00015110-02; KBioSS_000400; (+/-)-p-AMINOGLUTETHIMIDE; Novartis Brand of Aminoglutethimide; BSPBio_001832; HMS1920C09; Prestwick_243; dl-Aminoglutethimide; NCGC00093615-03; Spectrum5_000802; BRD-A25234499-001-05-0; AB00051935; CHEMBL488; STK802074; Spectrum4_000144; CPD000326785; SPBio_002247; Ba-16038; UNII-0O54ZQ14I9; BPBio1_000032; DB00357; CID2145; Aminoglutethimidum; AG-1; CPD-10532; Aminoglutethimide (USP/INN); EINECS 204-756-4; Aminoglutethimidum [INN-Latin]; SAM002589964; NSC330915; AC-12456; NCGC00093615-04; Spectrum3_000296; KBio2_000400; NINDS_000884; SPECTRUM1500115; Lopac0_000124; 2,6-Piperidinedione, 3-(4-aminophenyl)-3-ethyl-; HMS2091I09; C 16038-BA; 3-(4-Aminophenyl)-3-ethyl-2,6-piperidinedione; Aminoglutethimide [INN:BAN]; Glutarimide, 2-(p-aminophenyl)-2-ethyl-; DivK1c_000884; NCGC00093615-05; NCI60_002900; CCRIS 7562; Elipten; Aminoglutetimida [INN-Spanish]; 3-(p-Aminophenyl)-3-ethylpiperidine-2,6-dione; MolPort-001-828-287; D00574; aminoglutethimide; HMS1568B10; MLS000859924; KBio3_001332; SMP1_000017; Glutethimide, para-amino; BB_SC-1153; SPBio_000046; AKOS004120070; 3-Ethyl-3-(p-aminophenyl)-2,6-dioxopiperidine; A 9657; LS-72014; HSDB 7494; CHEBI:2654; KBioGR_000588; 3-(4-Aminophenyl)-3-ethyl-2,6-piperidindion; Spectrum2_000093; Prestwick1_000244; KBio2_002968; C07617; Cytadren; NCGC00015110-07; 2-(p-Aminophenyl)-2-ethylglutarimide; Spectrum_000040; SMR000326785; AC1Q2SPJ; MLS001213216; Ciba Vision Brand of Aminoglutethimide; HMS502M06; KBio2_005536; aminoglutethimide (AG); S1672_Selleck; IDI1_000884; ( inverted question mark)-p-Aminoglutethimide; (+-)-3-(p-Aminophenyl)-3-ethyl-2,6-piperidinedione; .alpha.-(p-Aminophenyl)-.alpha.-ethylglutarimide; BSPBio_000028; p-Aminoglutethimide; 3-(4-aminophenyl)-3-ethylpiperidine-2,6-dione; A9657_SIGMA; NCGC00093615-01; EU-0100124; D000616; Orimeten; BRN 0210656; (?)-p-Aminoglutethimide; VU0243029-3; 125-84-8	125-84-8	2145	9819	TTDS00419	Cytochrome P450 11A1, mitochondrial	Cholesterol desmolase;CYP11A;CYP11A1;CYPXIA1;Cytochrome P450 11A1;P450(scc)	P05108	1583	ENSG00000140459	inhibitor
DCL000092	CP-690,550	MI1; CID9818231; 3-Piperidinamine, 1-(cyanoacetyl)-4-methyl-N-methyl-N-1H-pyrrolo(2,3-d)pyrimidin-4-yl-, (3R,4R)-; CHEBI:668341; CID 9926791; CID9926791; CHEMBL221959; 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile; CP-690550; DB08183; Kinome_3438; CHEBI:467860; CP 690550; S5001_Selleck; FT-0083764; CP-690,550; MolPort-006-393-346; AKOS005145814; 477600-75-2	N/A	N/A	N/A	TTDC00084	Tyrosine-protein kinase JAK3	JAK-3;Janus kinase 3;Leukocyte janus kinase;L-JAK	P52333	3718	ENSG00000105639	inhibitor
DCL000945	R348	N/A	N/A	5360545	49746451	TTDC00084	Tyrosine-protein kinase JAK3	JAK-3;Janus kinase 3;Leukocyte janus kinase;L-JAK	P52333	3718	ENSG00000105639	inhibitor
DAP000128	Sodium bicarbonate	SODIUM BICARBONATE; Sodium bicarbonate (JP15/USP); 31437_RIEDEL; 5006-97-3; S8875_SIAL; D017693; S8761_SIGMA; AC1LANJA; NaHCO3; Sodium bicarbonate solution; Col-evac; S4019_SIGMA; 13433_SIAL; Sodium hydrocarbonate; Meylon (TN); E-Z-EM Prep Lyte; Sodium bicarbonate in plastic container; 151127-72-9; UNII-8MDF5V39QO; 246180-97-2; Carbonic acid, monosodium salt; Soludal; Gripe water; Sodium acid carbonate; S7277_SIGMA; Monosodium hydrogen carbonate; Meylon; 7542-12-3 (unspecified hydrochloride salt); Sandoz sodium bicarbonate; Natron; Sodium hydrogen carbonate; 196216-68-9; 144-55-8; Golytely; MolPort-003-926-303; Peg-lyte; Natrii hydrogencarbonas; Baking soda; Natrium bicarbonicum; Nulytely; Natrium hydrogencarbonicum; Sodium carbonate (Na(HCO3)); LS-2380; BSS plus; D01203; S5761_SIGMA; Sodium bicarbonate (1:1); Go-evac; 88208_FLUKA; C12603; Carbonic acid sodium salt (1:1); Soda (van); Caswell No. 747; Natrum bicarbonicum; Bicarbonate, Sodium; Glycoprep; Sodium bicarbonate liquid concentrate; S3817_SIGMA; CID8953; 13433_RIEDEL; HSDB 697; S6297_SIAL; Sodium bicarbonate [USAN:JAN]; Lithium bicarbonate; CHEBI:32139; 36486_FLUKA; DB01390; Hydrogen Carbonate, Sodium; 172672-17-2; 31437_SIAL; Sodium hydrogencarbonate; CID516892; EPA Pesticide Chemical Code 073505; EINECS 205-633-8; Carbonic acid monosodium salt; 800 Sodium Bicarbonate Powder; Monosodium carbonate; NSC 134031; CHEMBL1353; Sel De vichy; Hema BP-38; S4019_SIAL; Neut (TN); Natriumhydrogenkarbonat; Neut; Colovage; Jusonin; CCRIS 3064; Co-lav; 401676_SIAL; 199723-76-7; Soda Mint; Bicarbonate of soda; AC1Q1W5G; Soda, Baking; S6014_SIAL; Acidosan	144-55-8	8953	7848266	TTDS00412	Potassium voltage-gated channel subfamily D member 3	KCND3;Voltage-gated potassium channel subunit Kv4.3	Q9UK17	3752	ENSG00000171385	blocker
DCL000560	MEDI-563	N/A	N/A	N/A	N/A	TTDC00217	Interleukin-5 receptor	IL-5R	Q14633	N/A	N/A	antibody
DCL000561	Mepolizumab	CID177399; SB 240563; Mepolizumab; 196078-29-2; 195971-48-3; (2S,3S,4S,5R,6R)-6-[[(3S,4aR,6aR,6bS,8aS,14aR,14bR)-8a-carboxy-4,4,6a,6b,11,11,14b-heptamethyl-1,2,3,4a,5,6,7,8,9,10,12,13,14,14a-tetradecahydropicen-3-yl]oxy]-3,5-dihydroxy-4-[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxyoxane-2-carboxylic acid; Bosatria; AC1L42Q2; beta-D-Glucopyranosiduronic acid, (3beta)-17-carboxy-28-norolean-13(18)-en-3-yl 3-O-beta-D-xylopyranosyl-; Scoparianoside C; Immunoglobulin G1, anti-(human interleukin 5) (human-mouse monoclonal SB-240563 gamma1-chain), disulfide with human-mouse monoclonal SB-240563 kappa-chain, dimer	196078-29-2	477579	47206675	TTDC00217	Interleukin-5 receptor	IL-5R	Q14633	N/A	N/A	antibody
DAP000894	Demecarium bromide	Benzenaminium, 3,3'-(1,10-decanediylbis((methylimino)carbonyloxy))bis(N,N,N-trimethyl-, dibromide; AR-1I3519; (m-Hydroxyphenyl)trimethylammonium bromide decamethylenebis(methylcarbamate); Frumtosnil; Decamethylenebis(N-methylcarbamic acid m-dimethylaminophenyl ester) bromomethylate; LS-18445; Demecarium bromide [INN:BAN]; D00667; demecastigmine; Bromure de demecarium [INN-French]; 56-94-0; HSDB 2168; CHEBI:4391; N,N'-Bis(3-trimethylammoniumphenoxycarbonyl)-N,N'-dimethyldecamethylenediamine dibromide; BC 48; Demecarium; Ammonium, (m-hydroxyphenyl)trimethyl-, bromide, decamethylenebis(methylcarbamate) (2:1); Humorsol (TN); Bromuro de demecario; CHEMBL1200514; Bromuro de demecario [INN-Spanish]; DEMECARIUM BROMIDE; (m-Hydroxyphenyl)trimethylammonium bromide decamethylenebis(methylcarbamate) (2:1); 3,3'-{decane-1,10-diylbis[(methylcarbamoyl)oxy]}bis(N,N,N-trimethylanilinium) dibromide; C21H36N2O2.C12H18N2O2; trimethyl-[3-[methyl-[10-[methyl-[3-(trimethylazaniumyl)phenoxy]carbonylamino]decyl]carbamoyl]oxyphenyl]azanium dibromide; AC1L1LIL; Demecarii bromidum; UNII-61D5V4OKTP; Ammonium, (m-hydroxyphenyl)trimethyl-, bromide, decamethylenebis(methylcarbamate); Visumatic; Tosmicil; decamethylenebis(m-dimethylaminophenyl-N-methylcarbamate)dimethobromide; Bromure de demecarium; Demecarii bromidum [INN-Latin]; Tosmilene; CID5965; Demekastigmine bromide; decamethylenebis[m-dimethylaminophenyl n-methylcarbamate] dimethobromide; Humorsol; (m-Hydroxyphenyl)trimethylammonium bromide decamethylenebis(methylcarbamate) (7CI); Demekarium bromide; EINECS 200-301-9; I06-2187; Tonilen; MolPort-005-943-446; AC1Q1R6E; Demecarium bromide (USP/INN); Tosmilen; AC-305; Visumiotic; Decamethylenebis(m-dimethylaminophenyl-N-methylcarbamate) dimethobromide; DB00944	56-94-0	5965	7847733	TTDS00140	Acetylcholinesterase	AChE	P22303	43	ENSG00000087085	inhibitor
DAP000149	Rivastigmine	MolPort-003-666-662; HMS2089H18; C11766; (S)-3-(1-(Dimethylamino)ethyl)phenyl ethylmethylcarbamate; AB1004572; Carbamic acid, N-ethyl-N-methyl-, 3-[(1S)-1-(dimethylamino)ethyl]phenyl ester; ENA 713 free base; 123441-03-2; D03822; Carbamic acid, ethylmethyl-, 3-(1-(dimethylamino)ethyl)phenyl ester, (S)-; BIDD:GT0316; 3-[(1S)-1-(dimethylamino)ethyl]phenyl ethyl(methyl)carbamate; Exelon; Rivastigmine hydrogen tartrate; 3-((1S)-1-(Dimethylamino)ethyl)phenyl N-ethyl-N-methylcarbamate; Ethylmethylcarbamic acid 3-((1S)-1-(dimethylamino)ethyl)phenyl ester; 3-((1S)-1-(Dimethylamino)ethyl)phenyl ethylmethylcarbamate; DB00989; Carbamic acid, ethylmethyl-, 3-((1S)-1-(dimethylamino)ethyl)phenyl ester; NCGC00167531-01; SDZ 212-713; Rivastigmine (JAN/USAN/INN); UNII-PKI06M3IW0; CHEMBL636; LS-172571; 3-((1S)-1-(Dimethylamino)ethyl)phenyl ethylmethylcarbamate; AC1L2U92; I06-2037; rivastigmine; [3-[(1S)-1-(dimethylamino)ethyl]phenyl] N-ethyl-N-methylcarbamate; m-((S)-1-(Dimethylamino)ethyl)phenyl ethylmethylcarbamate; CID77991; Rivastigmine [USAN:INN]	123441-03-2	77991	655049	TTDS00140	Acetylcholinesterase	AChE	P22303	43	ENSG00000087085	inhibitor
DAP000561	Physostigmine	Eserolein, methylcarbamate (ester); Spectrum2_001283; NSC 30782; Physostigmine [USAN:BAN]; NCGC00093889-01; Physostigmine (USP); Pyrrolo(2,3-b)indol-5-ol, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-, methylcarbamate (ester), (3aS-cis)-; EU-0100483; CCRIS 3422; KBio2_007414; KBioSS_001396; NIH 10421; RCRA waste no. P204; Prestwick3_000566; MolPort-001-683-926; SPBio_000774; Ezerin; Prestwick0_000566; Spectrum4_001631; Spectrum2_000330; 45710_FLUKA; NSC30782; NCGC00093889-04; Fysostigmin [Czech]; WLN: T B556 EN GNTT&J B1 E1 G1 KOVM1; KBio3_001689; MLS001304022; C06535; BSPBio_000352; Lopac0_000483; Spectrum3_000901; Spectrum_000916; Spectrum_001789; (3aS,8aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl methylcarbamate; CPD-12048; NCGC00093889-05; KBio2_002278; HMS2089M11; KBio2_003964; Pyrrolo[2,3-b]indol-5-ol, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-, methylcarbamate (ester), (3aS-cis)-; 511-49-9; DB00981; Spectrum2_000757; SPECTRUM1500753; KBio2_001396; Pyrrolo(2,3-b)indol-5-ol, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-, 5-(N-methylcarbamate), (3aS,8aR)-; Esromiotin; Eserine (TN); BRD-K25650355-001-02-5; KBioGR_002533; UNII-9U1VM840SP; CHEBI:27953; SPBio_002571; 50975-37-6; KBio1_001421; KBio3_001842; NCGC00093889-06; Spectrum5_001672; KBioGR_001433; Calabarine; Eserine; AC1L1LJL; [(3aR,8bS)-3,4,8b-trimethyl-2,3a-dihydro-1H-pyrrolo[2,3-b]indol-7-yl] N-methylcarbamate; MEGxp0_001872; NCGC00093889-02; MCV 4484; (3aS-cis)-1,2,3,3a,8,8a-Hexahydro-1,3a,8-trimethylpyrrolo(2,3-b)indol-5-ol methylcarbamate (ester); Spectrum4_001913; Spectrum4_000997; Eserine sulfate; SDCCGMLS-0066585.P001; KBioGR_002061; DivK1c_006477; STOCK1N-03554; Fysostigmin; Methyl-carbamic acid, ester with eseroline; 1,2,3,3abeta,8abeta-Hexahydro-1,3a,8-trimethylpyrrolo(2,3-b)-indol-5-yl methylcarbamate; NCGC00093889-03; Erserine; CID5983; BPBio1_000388; AC-15983; P0406; BRD-K25650355-059-02-3; HSDB 3161; SMR000718753; Physostol; E8375_SIGMA; Carbamic acid, methyl-, ester with eseroline; Eserolein, methylcarbamate; E 8375; CS 58525; KBio2_006532; EINECS 200-332-8; SpecPlus_000381; BSPBio_002189; HMS1921G06; KBio2_004846; Spectrum5_000626; Spectrum3_000545; KBioSS_002279; SPBio_001285; physostigmine; Pyrrolo(2,3-b)indol-5-ol, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-, methylcarbamate (ester), (3aS,8aR)-; (-)-physostigmine; D010830; ACon1_000097; LS-109562; Antilirium; Prestwick2_000566; NCGC00093889-08; SPBio_000339; 57-47-6; D00196; CHEMBL94; Pyrrolo(2,3-b)indol-5-ol, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-, methylcarbamate (ester), (3aS-cis); Spectrum5_000441; Prestwick1_000566	57-47-6	5983	7847264	TTDS00140	Acetylcholinesterase	AChE	P22303	43	ENSG00000087085	inhibitor
DAP000893	Ambenonium	CHEBI:2627; Ambenonum; AC1L1CZL; DB01122; NCGC00163221-01; 7648-98-8; ambenonium; NCGC00024567-01; Benzenemethanaminium, N,N'-((1,2-dioxo-1,2-ethanediyl)bis(imino-2,1-ethanediyl))bis(2-chloro-N,N-diethyl-; C07773; 2,2'-[(1,2-dioxoethane-1,2-diyl)diimino]bis[n-(2-chlorobenzyl)-n,n-diethylethanaminium]; (2-chlorophenyl)methyl-[2-[[2-[2-[(2-chlorophenyl)methyl-diethylazaniumyl]ethylamino]-2-oxoacetyl]amino]ethyl]-diethylazanium; UNII-L16PUN799N; CHEMBL1652; AR-1D0811; Ambenonium Base; CID2131; AC1Q3PBF; AC1Q2C8X; Ambenonium kation; Tocris-0388; CHEBI:609190	7648-98-8	2131	9975	TTDS00140	Acetylcholinesterase	AChE	P22303	43	ENSG00000087085	inhibitor
DAP000896	Isoflurophate	Fluophosphoric acid, diisopropyl ester; Floropryl (TN); Fluorodiisopropyl phosphate; Diisopropyl phosphofluoridate; T-1703; O,O-Diisopropyl fluorophosphate; Phosphorofluoridic acid, diisopropyl ester; dipropan-2-yl phosphorofluoridoate; Diisopropylfluorfosfat [Czech]; PDSP2_000464; HSCI1_000366; Diisopropyl phosphorofluoridate; Diisopropylphosphorofluoridate; diisopropyl fluorophosphate; Fluoropryl; Isoflurophate (USP); CHEBI:17941; Diflupyl; LS-108313; 38399_FLUKA; Isoflurophate [USP]; 37209-35-1; Fluostigmine; Diisopropylfluorfosfat; nchembio.70-comp11; Diflurophate; Dyflos; Fluorophosphoric acid, diisopropyl ester; Bis(1-methylethyl) Phosphorofluoridate; 55-91-4; Fluropryl; CID5936; Isoflurophate; Phosphoric acid diisopropyl ester fluoride; PDSP1_000466; Di-isopropylphosphorofluoridate; RCRA waste no. P043; 2-[fluoro(propan-2-yloxy)phosphoryl]oxypropane; Isofluorphate; Diisopropoxyphosphoryl fluoride; PF-3; Diisopropylphosphofluoridate; Diisopropylfluorophosphate; EA 1152; EINECS 200-247-6; Merck Brand of Isoflurophate; HSDB 2133; D0879_SIGMA; DB00677; Isofluorophate; Diisopropyl fluoridophosphate; Isoflurophosphate; TL 466; Fluorostigmine; MolPort-003-846-790; C6H14FO3P; D00043; DFP; Diisopropylfluorophosphoric acid ester; DIFP; Disiopropyl fluorophosphonate; DIISOPROPYL-FLUOROPHOSPHATE; AC1L1LGC; UNII-12UHW9R67N; D007531; Diisopropyl fluorophosphonate; Neoglaucit; Isopropyl fluophosphate; NCGC00168783-01; Floropryl; C00202; Di isopropylphosphorofluoridate; Diisopropylfluorphosphorsaeureester; O,O'-Diisopropyl phosphoryl fluoride; bis(propan-2-yl) fluorophosphate; Phosphorofluoridic acid, bis(1-methylethyl) ester; Diisopropylfluorphosphorsaeureester [German]; CHEMBL1025; Rcra waste number P043; BRN 1723307; Isopropyl phosphorofluoridate	55-91-4	5936	3502	TTDS00140	Acetylcholinesterase	AChE	P22303	43	ENSG00000087085	inhibitor
DAP000895	Malathion	Taskil; DivK1c_006482; Spectrum2_001228; SPBio_001076; Spectrum3_000813; Camathion; TM-4049; LS-654; Ovide; MolPort-003-665-439; EINECS 204-497-7; Malmed; NSC 6524; Malation [Polish]; Malathion-2,3-14C; KBio3_001805; Malaphele; Siptox I; TAK; D00534; NCGC00091902-07; ENT 17,034; Mercaptosuccinic acid diethyl ester; Paladin; Spectrum4_000653; Malamar; Four thousand forty-nine; UNII-U5N7SU872W; Spectrum5_001936; Spectrum_001795; Kop-thion; KBio2_004854; Malphos; Vegfru malatox; WLN: 2OV1YVO2 & SPS & O1 & O1; American cyanamid 4,049; Malathion E50; Malaphos; AC 26691; Extermathion; CCRIS 368; Cythion; Malathion (old ID); Insecticide no. 4049; SpecPlus_000386; NCGC00091902-06; 121-75-5; Ethiolacar; Forthion; Kop-Thionkypfosmalacide; EL 4049; malathion; D008294; detm ol ma; Mercaptothion; NCGC00091902-02; Malathion LV Concentrate; Calmathion; KBio1_001426; Malathione; Sadofos; Hilthion; Malamar 50; NSC6524; Malathion (USP); CHEBI:6651; Malatox; CHEMBL1200468; Latka 4049; Malagran; NCGC00091902-01; Carbethoxy malathion; BRN 1804525; Malataf; Latka 4049 [Czech]; Maltox MLT; KBio2_002286; Malasol; Kill-A-Mite; Maltox; Compound 4049; AI3-17034; KBioSS_002288; Carbafos; Dorthion; SF 60; Karbofos; Fosfotion; Mercaptotion [Spanish]; Malathiazol; 8059HC; KBio2_007422; Vetiol; Fog 3; BSPBio_002305; KBioGR_001025; C10H19O6PS2; Celthion; MALATHION, 96%; Malacide; Zithiol; Organoderm; Malathion 60; I09-0505; Flair; Malathyl; Emmatos extra; MET86C_SUPELCO; Malathon; OMS 1; Carbophos; IFO 13140; CID4004; Detmol MA; Sadofos 30; Malafor; 36143_RIEDEL; DB00772; Fosfothion; 11096-67-6; 36143_FLUKA; Kypfos; Cimexan; Chemathion; NCI-C00215; Malakill; NCGC00091902-03; Prioderm; Carbofos; Derbac-M; PS86_SUPELCO; Etiol; Sumitox; Malathion [USP]; Phosphothion; C07497; Malation; Suleo-M; L001138; Emmatos; Fyfanon; HSDB 665; Carbetox; Fosfotion 550; Mercaptotion; NCGC00091902-05; M1912_SIGMA; Oleophosphothion; Maldison; Hilthion 25wdp; Malatol; Lice Rid; Sadophos; Staeubol-Puder; Carbetovur; Experimental insecticide 4049; Malathiozoo; Ovide (TN); Ortho Malathion; AC1L1H72; Moscarda; JXSJBGJIGXNWCI-UHFFFAOYSA-; Cleensheen; Malaspray	121-75-5	4004	9700	TTDS00140	Acetylcholinesterase	AChE	P22303	43	ENSG00000087085	inhibitor
DAP000563	Neostigmine	Spectrum_001061; KBioGR_000623; AC1L1I7G; 59-99-4; ZINC00001792; 3-[(dimethylcarbamoyl)oxy]-N,N,N-trimethylanilinium; NINDS_000198; CAS-114-80-7; IDI1_000165; KBio1_000198; nchembio.188-comp33; DivK1c_000165; Prostigmin; CID4456; 51-60-5 (methyl sulfate); Lopac0_000816; UNII-3982TWQ96G; SPBio_002515; AB00053807; Neostigmine (BAN); 3-Trimethylammoniumphenyl N,N-dimethylcarbamate; KBio2_004109; BPBio1_000634; Synstigmin; NINDS_000165; Benzenaminium, 3-(((dimethylamino)carbonyl)oxy)-N,N,N-trimethyl- (9CI); STL058953; [3-(dimethylcarbamoyloxy)phenyl]-trimethyl-azanium; sulfonatooxymethane; InChI=1/C12H19N2O2/c1-13(2)12(15)16-11-8-6-7-10(9-11)14(3,4)5/h6-9H,1-5H3/q+1; IDI1_000198; KBio1_000165; Vagostigmin; NCGC00015730-01; HSDB 3921; DivK1c_000198; KBio2_006677; [3-(dimethylcarbamoyloxy)phenyl]-trimethyl-azanium bromide; Benzenaminium, 3-(((dimethylamino)carbonyl)oxy)-N,N,N-trimethyl-; BRD-K18922609-004-04-1; (m-Hydroxyphenyl)trimethylammonium dimethylcarbamate (ester); CHEBI:7514; HMS2089A22; Neostigmine [BAN]; Prestwick2_000468; Ammonium, (m-hydroxyphenyl)trimethyl-, dimethylcarbamate (ester); 3-{[(dimethylamino)carbonyl]oxy}-N,N,N-trimethylanilinium; NCGC00015730-04; NCGC00021658-03; SPBio_001276; Eustigmine; Spectrum5_001234; Prostigmin (TN); Prostigmine; NCGC00163240-01; Intrastigmina; BRN 3615946; LS-18452; bmse000762; Vagostigmine; C07258; Lopac-N-2001; NCGC00015730-03; Prestwick3_000468; (m-Hydroxyphenyl)trimethylammonium dimethylcarbamate; D08261; NCGC00015730-08; Neostigminum; CCRIS 3079; NEOSTIGMINE; Prozerin; KBioSS_001541; BSPBio_000576; [3-(dimethylcarbamoyloxy)phenyl]-trimethylazanium; NCGC00015730-02; Prestwick1_000468; KBio2_001541; 114-80-7 (bromide); Juvastigmin; ALWKGYPQUAPLQC-UHFFFAOYSA-; Neostigmine omega; Eustigmin; Syntostigmine; Spectrum4_000072; Prestwick0_000468; DB01400; Spectrum2_001278; m-Trimethylammoniumphenyldimethylcarbamate; Neostigmin	59-99-4	4456	9467	TTDS00140	Acetylcholinesterase	AChE	P22303	43	ENSG00000087085	inhibitor
DAP000562	Edrophonium	AR-1H8213; Ethyl-(3-hydroxy-phenyl)-dimethyl-ammonium; AC1L1FEK; N-ethyl-3-hydroxy-N,N-dimethylbenzenaminium; KBio2_000922; NINDS_000809; CID3202; KBio1_000809; SPBio_001945; Spectrum_000442; BSPBio_002386; KBioGR_001032; NCGC00015409-01; C06976; Prestwick2_000083; N-ethyl-3-hydroxy-N,N-dimethylanilinium; ENLON-PLUS; Lopac-E-3256; Edrophonum; Enlon Plus; UNII-70FP3JLY7N; MolPort-005-942-309; Benzenaminium, N-ethyl-3-hydroxy-N,N-dimethyl-; Spectrum5_001531; BSPBio_000006; KBio2_006058; AB00053796; Edrophone Chloride; Prestwick1_000083; CHEBI:251408; EDR; DivK1c_000809; C10H16NO.Cl; IDI1_000809; AC1Q7AIY; NCGC00015409-02; CHEMBL1104; NCGC00023975-03; Lopac0_000511; KBioSS_000922; edrophonium; 312-48-1; ethyl-(3-hydroxyphenyl)-dimethylazanium; Prestwick3_000083; DB01010; NCGC00015409-07; 116-38-1 (cloride); Tensilon; Edroponium; LS-174330; KBio2_003490; Spectrum4_000736; BPBio1_000008; Prestwick0_000083; (3-hydroxyphenyl)dimethylethylammonium; EDROPHONIUM ION; Reversol; ZINC00001341; Spectrum2_001110; 3-hydroxy-N,N-dimethyl-N-ethylanilinium; SPBio_001220; NCGC00015409-03; CAS-116-38-1	116-38-1	3202	9190	TTDS00140	Acetylcholinesterase	AChE	P22303	43	ENSG00000087085	inhibitor
DAP000809	Pyridostigmine	Spectrum_001603; MolPort-003-803-842; AQ-776/42801589; Spectrum5_001046; UNII-19QM69HH21; KBio2_004651; DB00545; CHEMBL1115; Pyridinium, 3-(((dimethylamino)carbonyl)oxy)-1-methyl- (9CI); LS-132643; (1-methylpyridin-1-ium-3-yl) N,N-dimethylcarbamate; NCGC00015862-06; NCGC00015862-02; Spectrum2_000861; NCGC00015862-01; Spectrum3_001909; KBio2_007219; NCGC00023921-03; KBioSS_002083; pyridostigmine; 3-(((Dimethylamino)carbonyl)oxy)-1-methylpyridinium; 155-97-5; NCI60_028530; KBio2_002083; C07410; Pyridostigminum; Lopac-P-9797; KBio1_000207; Pyridostigmine Bromine; SPBio_000901; C9H13N2O2; NINDS_000207; ZINC00002009; BIDD:GT0384; 1-methyl-3-pyridiniumyl dimethylcarbamate; Regonol; DivK1c_000207; KBio3_002982; BSPBio_003478; Mestinon-SR; 5-21-02-00078 (Beilstein Handbook Reference); BRN 1428269; CID4991; Pyridinium, 3-hydroxy-1-methyl-, dimethylcarbamate (ester); AC1L1JDC; Lopac0_001035; Pyridinium, 3-(((dimethylamino)carbonyl)oxy)-1-methyl-; IDI1_000207	155-97-5	4991	9614	TTDS00140	Acetylcholinesterase	AChE	P22303	43	ENSG00000087085	inhibitor
DAP000559	Galantamine	ASUTZQLVASHGKV-JDFRZJQESA-; BSPBio_000436; (-)-Galanthamine; Reminyl (TN); Galantamine [USAN:INN]; 4-27-00-02184 (Beilstein Handbook Reference); BRD-K49481516-004-03-5; Prestwick2_000588; Prestwick3_000588; 6H-Benzofuro(3a,3,2-ef)(2)benzazepin-6-ol, 4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-, (4aS,6R,8aS)-; AC1L1TIM; CHEMBL659; Spectrum3_001738; BRD-K49481516-004-04-3; CID9651; Galantaminum; galanthamine; SMP1_000131; AC-20240; SDCCGMLS-0066737.P001; InChI=1/C17H21NO3/c1-18-8-7-17-6-5-12(19)9-14(17)21-16-13(20-2)4-3-11(10-18)15(16)17/h3-6,12,14,19H,7-10H2,1-2H3/t12-,14-,17-/m0/s1; SPBio_002655; KBioGR_001417; Galantamin; Razadyne ER; Prestwick1_000588; BSPBio_003416; KBio2_001751; STOCK1N-46108; Galantamine (USAN/INN); (4aS,6R,8aS)-4a,5,9,10,11,12-Hexahydro-3-methoxy-11-methyl-6H-benzofuro(3a,3,2-ef)(2)benzazepin-6-ol; KBio3_002636; D04292; 1qti; NSC 100058; Prestwick0_000588; GNT; LS-71039; C08526; Galantamine; NINDS_000590; KBio2_004319; 6H-Benzofuro[3a,3,2-ef][2]benzazepin-6-ol, 4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-, (4aS,6R,8aS)-; 357-70-0; 736-79-8; DivK1c_000590; Spectrum4_000839; BIDD:GT0517; BPBio1_000480; KBioSS_001751; HSDB 7361; Reminyl; Lycoremine; KBio1_000590; Galantamina; UNII-0D3Q044KCA; BRN 0093736; Galanthaminum; NCGC00024731-02; 1953-04-4; KBio2_006887; Probes2_000395; MolPort-002-521-885; 1dx6; HMS2089H03; CHEBI:42944; Jilkon; 1551-02-6; Spectrum_001271; IDI1_000590; Galantamina [INN-Spanish]; Galantaminum [INN-Latin]; Spectrum5_001673; Probes1_000055; Lycoremin	357-70-0	9651	10719	TTDS00140	Acetylcholinesterase	AChE	P22303	43	ENSG00000087085	inhibitor
DAP000560	Donepezil	DB00843; Eranz; KBio2_002144; AC-6969; KBioSS_002144; Donepezil (INN); I06-0343; ( inverted exclamation markA)-E 2020; 1-Benzyl-4-[(5,6-dimethoxy-1-oxoindan-2-yl)methyl]piperidine; Donepezil; D07869; Spectrum5_001662; KBio2_004712; Donaz (TN); donepezil; CHEMBL502; AC1L1FAE; 2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxyindan-1-one; 120014-06-4; AB1004836; MolPort-003-847-014; Spectrum_001664; UNII-8SSC91326P; Donaz; MolPort-000-881-588; 1H-Inden-1-one, 2,3-dihydro-5,6-dimethoxy-2-((1-(phenylmethyl)-4-piperidinyl)methyl)-; 2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxy-2,3-dihydroinden-1-one; TL8000531; AKOS000277311; NCGC00167537-01; C24H29NO3; KBio2_007280; Oprea1_188452; LS-81819; 1H-Inden-1-one, 2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]-; CHEBI:53289; CID3152; Donepezil [INN:BAN]	120014-06-4	3152	207105	TTDS00140	Acetylcholinesterase	AChE	P22303	43	ENSG00000087085	inhibitor
DAP000558	Tacrine	1,2,3,4-TETRAHYDRO-9-ACRIDINAMINE; NCGC00024908-04; 321-64-2; Acridine, 1,2,3,4-tetrahydro-9-amino-; Tetrahydroaminacrine; AKOS000277493; 1,2,3,4-tetrahydroacridin-9-amine; AC1Q51C5; HMS2089F19; AC1L1CK0; EU-0010966; AB00053524; BIDD:GT0090; Tacrinum [INN-Latin]; BAS 00232275; CS 12602; D08555; Tacrina [INN-Spanish]; BSPBio_000337; Tacrine hydrochloride; NCIOpen2_003667; Tetrahydroaminocrine; 1,2,3,4-TETRAHYDRO-9-ACRIDINAMINE (SEE ALSO 1684-40-8); NCGC00024908-05; Prestwick1_000329; 9-Amino-1,2,3,4-Tetrahydroacridine Hydrate Hydrochloride Hydrate; CPD-10887; C01453; Tacrina; BRD-K81473089-003-03-0; 1mx1; BSPBio_003298; Prestwick3_000329; Lopac0_000036; Tocris-0965; CID1935; STK101308; 5-Amino-6,7,8,9-tetrahydroacridine (European); 9-amino-1,2,3,4-tetrahydroacridine; ZINC19014866; Prestwick2_000329; KBio3_002518; KBio2_000896; BRN 0147610; Spectrum_000416; Tacrine (INN); BPBio1_000371; Spectrum4_000819; Spectrum3_001709; NCGC00015054-01; KBioSS_000896; Prestwick0_000329; nchembio.188-comp31; 1,2,3,4-Tetrahydro-acridin-9-ylamine; FT-0083001; Lopac-A-3773; PDSP1_000330; CHEBI:45980; KBio2_006032; Tacrinum; UNII-4VX7YNB537; KBioGR_001337; BRD-K81473089-003-04-8; MLS000758202; 2aox; BBL001044; SPBio_002258; NCGC00024908-01; CHEMBL95; Spectrum5_001402; DB00382; Spectrum2_001812; EINECS 206-291-2; Tacrine [INN:BAN]; SPBio_001823; Tacrinal; Tacrinal (TN); Oprea1_008681; Romotal; Cognex; NINDS_000936; KBio2_003464; 1,2,3,4-Tetrahydroaminoacridine; NCGC00024908-03; LS-1191; ST083243; Tetrahydroaminocrin; 1,2,3,4-Tetrahydro-9-acridineamine; 9-Acridinamine, 1,2,3,4-tetrahydro-; NCGC00015054-07; DivK1c_000936; 2aow; PDSP2_000328; C13H14N2; 9-Acridinamine, 1,2,3,4-tetrahydro- (9CI); nchembio.2007.55-comp2; Tetrahydroaminoacridine; MolPort-000-881-472; Tacrine; IDI1_000936; tha; KBio1_000936; 9-AMINOTETRAHYDROACRIDINE; Tenakrin; 1684-40-8 (hydrochloride)	321-64-2	1935	4630	TTDS00140	Acetylcholinesterase	AChE	P22303	43	ENSG00000087085	inhibitor
DAP001248	Thyrotropin Alfa	N/A	9002-71-5	9571004	46505696	TTDS00452	Thyrotropin receptor	Thyroid stimulating hormone receptor;TSH receptor;TSH-R	P16473	7253	ENSG00000165409	binder
DCL000051	APD668	N/A	N/A	56971	49602934	TTDC00050	Glucose-dependent insulinotropic receptor	G-protein coupled receptor 119	Q8TDV5	139760	ENSG00000147262	agonist
DCL001226	PSN821	N/A	N/A	N/A	N/A	TTDC00050	Glucose-dependent insulinotropic receptor	G-protein coupled receptor 119	Q8TDV5	139760	ENSG00000147262	agonist
DCL001171	CF102	N/A	N/A	N/A	N/A	TTDS00189	Adenosine A3 receptor	A3 Adenosine receptor;A3AR;Adenosine 3 receptor;Adenosine receptor A3A	P33765	140	ENSG00000121933	agonist
DPR000174	CF502	N/A	N/A	N/A	N/A	TTDS00189	Adenosine A3 receptor	A3 Adenosine receptor;A3AR;Adenosine 3 receptor;Adenosine receptor A3A	P33765	140	ENSG00000121933	agonist
DAP000223	Adenosine	(2R,3R,4S,5R)-2-(6-Aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol; NCGC00023673-05; UNII-K72T3FS567; SR 96225; Adenoscan; AC1L1U8O; beta-D-Ribofuranose, 1-(6-amino-9H-purin-9-yl)-1-deoxy-; nchembio.64-comp4; Spectrum3_000288; 2gl0; USAF CB-10; NSC7652; SDCCGMLS-0003108.P003; Adenoscan (TN); Adenosine, homopolymer; Adenosine (JAN/USP); EA6C60C2-6AFB-4264-A2F0-541373DB950E; CHEBI:16335; A4036_SIGMA; Adenocard (TN); Bio1_000926; beta-D-Ribofuranoside, adenine-9; HMS1920A13; 46946-45-6; Spectrum2_001257; 9H-Purin-6-amine, 9beta-D-ribofuranosyl-; NCGC00023673-04; 4-Aminopyrazolo[3,4-d]pyrimidine ribonucleoside; Adenocor; V0098; Polyadenosine; 58-61-7; adenosine; KBio3_001296; BB_NC-0565; Pallacor; beta-D-Adenosine; NSC 627048; EINECS 200-389-9; AC1Q1ID3; Bio1_000437; Adensoine; CCRIS 2557; AI3-52413; NCGC00023673-03; Adenine nucleoside; NSC 7652; C00212; Adenine 9-beta-D-arabinofuranoside; MLS000069638; bmse000061; Adenine riboside; CHEMBL477; A0152; 9beta-D-Ribofuranosyladenine; Boniton; ADN; Bio1_001415; S1647_Selleck; HMS2091G13; 9-(beta-D-Arabinofuranosyl)adenine; NCGC00023673-07; TL8003749; Sandesin; FT-0082881; SPECTRUM1500107; D000241; 9-beta-D-Ribofuranosyladenine; MLS002153227; BSPBio_001796; 46969-16-8; Adenosin [German]; Adenocard, Adenosine; DB00640; nchembio.2007.56-comp13; LS-15085; Adenine-9-beta-D-ribofuranoside; 9-beta-D-Ribofuranosyl-9H-purin-6-amine; A9251_SIGMA; 6-Amino-9beta-D-ribofuranosyl-9H-purine; 6-Amino-9-.beta.-ribofuranosyl-9H-purine; 2fqy; nchembio.143-comp9; 30143-02-3; 1odi; Caswell No. 010B; NCGC00023673-06; nchembio706-5; (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol; 9-beta-D-Ribofuranosidoadenine; nchembio.186-comp109; CID60961; MEDR-640; adenine-D-ribose; Nucleocardyl; D00045; 6-Amino-9-beta-D-ribofuranosyl-9H-purine; Ade-Rib; SR-96225; Adenosin; Adenocard; SPBio_001194; Myocol; NSC627048; SUN-Y4001; beta-Adenosine; Vidarabine; MolPort-001-838-229; SMR000058216; AC1Q52XU; ZINC02169830; Adenosine [USAN:BAN]; Polyriboadenosine	58-61-7	60961	3512	TTDS00189	Adenosine A3 receptor	A3 Adenosine receptor;A3AR;Adenosine 3 receptor;Adenosine receptor A3A	P33765	140	ENSG00000121933	agonist
DCL000749	CF101	MolPort-003-941-777; I-146; CID123683; AC1O7G3W; CID6604809; SI-615; (2S,3S,4S,5S)-3,4-dihydroxy-5-[6-[(3-iodophenyl)methylamino]purin-9-yl]-N-methyloxolane-2-carboxamide; CID3668; NCGC00024978-02; CID6603878; NCGC00024978-03; (2S,3S,4R,5R)-3,4-dihydroxy-5-[6-[(3-iodophenyl)methylamino]purin-9-yl]-N-methyloxolane-2-carboxamide; MLS002153391; C084956; 1-Deoxy-1-[6-[((3-Iodophenyl)methyl)amino]-9H-purin-9-yl]-N-methyl-beta-D-ribofuranuronamide; Lopac0_000675; N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine; EU-0100675; 3,4-dihydroxy-5-[6-[(3-iodophenyl)methylamino]purin-9-yl]-N-methyloxolane-2-carboxamide; methyl]amino]-9H-purin-9-yl]-N-methyl-beta-D-ribofuranuronamide; NCGC00024978-05; SMR001230772; HMS1989J20; HMS1791J20; NCGC00179190-01; RPR-113090; I146_SIGMA; NCGC00015539-01; beta-D-Ribofuranuronamide, 1-deoxy-1-(6-(((3-iodophenyl)methyl)amo)-9H-purin-9-yl)-N-methyl-; N(6)-(3-Iodobenzyl)adenosine-5'-N-methyluronamide; NCGC00024978-04; BSPBio_001478; BRD-A20527803-001-01-2; IBMECA; (2R,3S,4R,5R)-3,4-dihydroxy-5-[6-[(3-iodophenyl)methylamino]purin-9-yl]-N-methyloxolane-2-carboxamide; CHEBI:120397; LS-184434; Tocris-1066; CHEBI:294619; CID11957586; CHEMBL119709; 152918-18-8; Cf101; 215462-30-9; AC1O7GWM; AC1L3X3V; N6-(3-Iodobenzyl)adenosine-5'-N-methyluronamide; Lopac-I-146; L000303; NCGC00024978-01; AC1L1GG2; CF-101; N(6)-Ibamu; CF 101; 1-Deoxy-1-[6-[[(3-iodophenyl); 1-Deoxy-1-(6-(((3-iodophenyl)methyl)amino)-9H-purin-9-yl)-N-methyl-beta-D-ribofuranuronamide; BRD-A48809242-001-02-9; IB-MECA; Adenosine, N(6)-[3-iodobenzyl]-4'-methylcarbamoyl-4'-dehydroxymethyl-; 3-IB-Meca	196078-29-2	N/A	47206675	TTDS00189	Adenosine A3 receptor	A3 Adenosine receptor;A3AR;Adenosine 3 receptor;Adenosine receptor A3A	P33765	140	ENSG00000121933	agonist
DPR000175	CF602	N/A	N/A	N/A	N/A	TTDS00189	Adenosine A3 receptor	A3 Adenosine receptor;A3AR;Adenosine 3 receptor;Adenosine receptor A3A	P33765	140	ENSG00000121933	agonist
DPR000054	GSK-326416	N/A	N/A	N/A	N/A	TTDC00155	Motilin receptor	N/A	O43193	2862	ENSG00000102539	agonist
DCL000564	Mitemcinal fumarate	Mitemcinal fumarate; AC1OCF7Z; CID6918266; D05053; CID11513721; CID10123676; CID 11513721; (E)-but-2-enedioic acid; (2S,4R,5R,8R,9S,10S,11R,12R)-5-ethyl-9-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-11-[(2S,3R,4S,6R)-3-hydroxy-6-methyl-4-[methyl(propan-2-yl)amino]oxan-2-yl]oxy-4-methoxy-2,4,8,10,12,14-hexamethyl-6,15-dioxabicyclo[10.2.1]pentadec-1(14)-ene-3,7-dione	154802-96-7	6475540	47206780	TTDC00155	Motilin receptor	N/A	O43193	2862	ENSG00000102539	agonist
DCL000398	GSK962040	CHEBI:554842; GSK-962040; CHEMBL489095	223652-82-2	124093	46233248	TTDC00155	Motilin receptor	N/A	O43193	2862	ENSG00000102539	agonist
DCL000167	Mitemcinal	N/A	150586-58-6	6918266	14767358	TTDC00155	Motilin receptor	N/A	O43193	2862	ENSG00000102539	agonist
DCL000144	KOS-2187	N/A	N/A	N/A	N/A	TTDC00155	Motilin receptor	N/A	O43193	2862	ENSG00000102539	agonist
DAP000819	Cromoglicate	N/A	16110-51-3	27686	170250	TTDS00274	Heat shock protein 90	Heat shock protein HSP 90;Heat-shock protein 90 molecular chaperone;HSP90;Hsp90 chaperone;HSP90 molecular chaperone	Q8III6	N/A	N/A	inhibitor
DCL001179	Debio 0932	N/A	N/A	N/A	N/A	TTDS00274	Heat shock protein 90	Heat shock protein HSP 90;Heat-shock protein 90 molecular chaperone;HSP90;Hsp90 chaperone;HSP90 molecular chaperone	Q8III6	N/A	N/A	inhibitor
DCL000559	MEDI-561	N/A	N/A	N/A	N/A	TTDS00274	Heat shock protein 90	Heat shock protein HSP 90;Heat-shock protein 90 molecular chaperone;HSP90;Hsp90 chaperone;HSP90 molecular chaperone	Q8III6	N/A	N/A	inhibitor
DPR000161	VER 49009	CHEBI:47273; CID5327095; CHEMBL365617; (5Z)-5-(3-chloro-4-hydroxy-6-oxocyclohexa-2,4-dien-1-ylidene)-N-ethyl-4-(4-methoxyphenyl)-1,2-dihydropyrazole-3-carboxamide; BSM; 5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-N-ETHYL-4-(4-METHOXYPHENYL)-1H-PYRAZOLE-3-CARBOXAMIDE; VER-49009; DB07495; AC1NS1N4	N/A	N/A	N/A	TTDS00274	Heat shock protein 90	Heat shock protein HSP 90;Heat-shock protein 90 molecular chaperone;HSP90;Hsp90 chaperone;HSP90 molecular chaperone	Q8III6	N/A	N/A	inhibitor
DAP000321	Amlexanox	MolPort-005-934-117; 5H-(1)Benzopyrano(2,3-b)pyridine-3-carboxylic acid, 2-amino-7-(1-methylethyl)-5-oxo-; 2-amino-5-oxo-7-propan-2-ylchromeno[2,3-b]pyridine-3-carboxylic acid; Amoxanox; LS-39875; Amlexanox [USAN:INN:JAN]; Amlexanoxum; Aptheal; AA-673; BIDD:GT0709; MLS001424059; amlexanox; Solfa; HMS2051F13; ANW; Amlexanoxo; Amlenanox; AC1L1D23; AA 673; 2-amino-7-isopropyl-5-oxo-5H-(1)benzopyrano(2,3b)pyridine-3-carboxylic acid; D01828; DB01025; NCGC00167472-01; CHEBI:31205; C16H14N2O4; 2-Amino-7-isopropyl-5-oxo-5H-(1)benzopyrano(2,3-b)pyridine-3-carboxylic acid; CCRIS 2686; Aphthasol (TN); 2-amino-7-(1-methylethyl)-5-oxo-5H-chromeno[2,3-b]pyridine-3-carboxylic acid; OraDisc; 68302-57-8; GlaxoSmithKline brand of amlexanox; Amlexanox (JAN/USAN/INN); CHX 3673; SAM001246669; I14-0660; MLS000759466; Elics; AC-1192; OraDisc A; C045742; L001037; CID2161; CPD000466352; Amlexanoxo [Spanish]; Solfa (TN); CHX-3673; Amlexanoxum [Latin]; Apthera; Aphthasol; OraRinse; UNII-BRL1C2459K; BRN 0556384; SMR000466352; 2-amino-5-oxo-7-(propan-2-yl)-5H-chromeno[2,3-b]pyridine-3-carboxylic acid; CHEMBL1096; SBB067036	68302-57-8	2161	7848890	TTDS00274	Heat shock protein 90	Heat shock protein HSP 90;Heat-shock protein 90 molecular chaperone;HSP90;Hsp90 chaperone;HSP90 molecular chaperone	Q8III6	N/A	N/A	inhibitor
DCL001115	NVP-AUY922	S1069_Selleck; VER-52296/NVP-AUY922; 2GJ; CHEMBL252164; CID10096043; AUY922, VER-52296, NVP-AUY922; CID 10096043; NVP-AUY922; VER-52296	N/A	N/A	N/A	TTDS00274	Heat shock protein 90	Heat shock protein HSP 90;Heat-shock protein 90 molecular chaperone;HSP90;Hsp90 chaperone;HSP90 molecular chaperone	Q8III6	N/A	N/A	inhibitor
DCL000547	IPI-493	N/A	172521-94-7	213022	47158075	TTDS00274	Heat shock protein 90	Heat shock protein HSP 90;Heat-shock protein 90 molecular chaperone;HSP90;Hsp90 chaperone;HSP90 molecular chaperone	Q8III6	N/A	N/A	inhibitor
DPR000130	CCT-018159	AKOS002164043; CHEMBL399530; 4-[4-(2,3-dihydro-1,4-benzodioxin-6-yl)-5-methyl-1H-pyrazol-3-yl]-6-ethylbenzene-1,3-diol; BRD-K65503129-001-01-4; MolPort-000-424-874; (6Z)-6-[4-(2,3-dihydro-1,4-benzodioxin-6-yl)-5-methyl-1,2-dihydropyrazol-3-ylidene]-4-ethyl-3-hydroxycyclohexa-2,4-dien-1-one; AC1NS1MS; CCT 018159; EC-000.2389; CHEBI:41656; CID5327091; AC1Q2T5O; ST50039568; NCGC00161410-01; CCT018159; DB07594	N/A	N/A	N/A	TTDS00274	Heat shock protein 90	Heat shock protein HSP 90;Heat-shock protein 90 molecular chaperone;HSP90;Hsp90 chaperone;HSP90 molecular chaperone	Q8III6	N/A	N/A	inhibitor
DCL000325	Geldanamycin	2-Azabicyclo[16.3.1]docosane, geldanamycin deriv.; Geldanamycin, Streptomyces hygroscopicus; KBioSS_000413; HMS1792E15; AC1NS4EZ; CBiol_001845; CID5281885; [(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-6-hydroxy-5,11,21-trimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; geldanomycin; AC-6794; Antibiotic (U-29,135); A00271; AC1NUEYU; [(3R,5R,6S,7R,10R,11R)-6-hydroxy-5,11,21-trimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; CID5702269; [(3R,5S,6R,7S,10S,11S)-6-hydroxy-5,11,21-trimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; CHEMBL408672; BRN 1633093; CID644250; KBio2_000413; KBio2_005549; Geldanamycin (9CI); I06-2304; KBio3_000786; Bio1_001109; Antibiotic U 29135; [(3R,5S,6R,7S,10R,11R)-6-hydroxy-5,11,21-trimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; CID5288382; NSC212518; AC1L1FZK; [(8E,12E,14Z)-6-hydroxy-5,11,21-trimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; KBio2_002981; CID65378; AC1NSHIL; Bio2_000367; Bio1_000620; IDI1_000256; GDM; nchembio.83-comp18; KBio3_000785; 2-Azabicyclo[16.3.1]docosa-4,6,10,18,21-pentaene-3,20,22-trione, 9,13-dihydroxy-8,14,19-trimethoxy-4,10,12,16-tetramethyl-, 9-carbamate (8CI); AC1L235A; 2-Azabicyclo[16.3.1]docosa-4,6,10,18,21-pentaene-3,20,22-trione, 9-[(aminocarbonyl)oxy]-13-hydroxy-8,14,19-trimethoxy-4,10,12,16-tetramethyl-, [8S-(4E,6Z,8R*,9R*,10E,12R*,13S*,14R*,16S*)]-; AC1LD8UU; CID3460; [(3S,5S,6R,7S,8E,10S,11S,12Z,14E)-6-hydroxy-5,11,21-trimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; (6-hydroxy-5,11,21-trimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl) carbamate; C29H40N2O9; [8S-(4E,6Z,8R*,9R*,10E,12R*,13S*,14R*,16S*)]-9-[(Aminocarbonyl)oxy]-13-hydroxy-8,14,19-trimethoxy-4,10,12,16-tetramethyl-2-azabicyclo[16.3.1]docosa-4,6,10,18,21-pentaene-3,20,22-trione; AC1NWAXS; CID5363342; Geldaramycin; BODIPY-labeled Geldanamycin; 30562-34-6; HMS1362E15; NCGC00163449-01; NINDS_000256; AC1NQZ8L; AC1NRBJT; [(3S,5S,6R,7S,8E,10R,11S,12Z,14E)-6-Hydroxy-5,11,21-trimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-8,12,14,18,21-pentaen-10-yl] carbamate; G0334; KBio1_000256; IDI1_002122; Bio2_000847; CID5353642; NCGC00163449-02; geldanamycin; AC1NRBEH; KBioGR_000413; CHEMBL278315; CID5476289; Bio1_000131; [(8Z,12Z,14Z)-6-hydroxy-5,11,21-trimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; BSPBio_001073; CID10793124; CID5288451; NSC 122750; U-29135; SMP1_000132; AC1O8F8Y; BRD-A33132503-001-01-9; Geldanamicin; CID6708467; 2-azabicyclo[16.3.1]docosa-4,6,10,18,21-pentaene-3,20,22-trione, 9-[(aminocarbonyl)oxy]-13-hydroxy-8,14,19-trimethoxy-4,10,12,16-tetramethyl-, (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-; [(3R,5S,6R,7S,8E,10R,11R,12Z,14E)-6-hydroxy-5,11,21-trimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; GMY; [(3R,5S,6R,7S,8E,10S,11S,12Z,14E)-6-hydroxy-5,11,21-trimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; [(8E,12Z,14E)-6-hydroxy-5,11,21-trimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; NCI60_000537; LS-71125; NChemBio.2007.10-comp1; (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-13-hydroxy-8,14,19-trimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl carbamate; HMS1990E15; BRD-A33132503-001-02-7; HMS500M18; DivK1c_000256; NSC122750; C11222	30562-34-6	5281885	13401	TTDS00274	Heat shock protein 90	Heat shock protein HSP 90;Heat-shock protein 90 molecular chaperone;HSP90;Hsp90 chaperone;HSP90 molecular chaperone	Q8III6	N/A	N/A	inhibitor
DCL001057	AVI4126	N/A	N/A	N/A	N/A	TTDC00271	Myc proto-oncogene protein	C-myc;C-myc oncogene	P01106	4609	ENSG00000136997	antisense
DCL000425	AMG 386	N/A	N/A	5360545	49746451	TTDC00247	Angiopoietin-1	ANG-1	Q15389	284	ENSG00000154188	inhibitor
DCL000001	Sodium stibogluconate	CHEBI:28148; trisodium 1-{[3-carboxylato-5-(1,2-dihydroxyethyl)-1-hydroxy-2,6,7-trioxa-1lambda(5)-stibabicyclo[2.2.1]hept-1-yl]oxy}-5-(1,2-dihydroxyethyl)-1-oxido-2,6,7-trioxa-1lambda(5)-stibabicyclo[2.2.1]heptane-3-carboxylate--water (1/9); D00582; Lenocta; Pentostam (TN); Sodium stibogluconate (INN); DB05630; trisodium 1-{[3-carboxylato-5-(1,2-dihydroxyethyl)-1-hydroxy-2,6,7-trioxa-1lambda(5)-stibabicyclo[2.2.1]hept-1-yl]oxy}-5-(1,2-dihydroxyethyl)-1-oxido-2,6,7-trioxa-1lambda(5)-stibabicyclo[2.2.1]heptane-3-carboxylate nonahydrate	16037-91-5	16685683	24712274	TTDC00032	Tyrosine-protein phosphatase non-receptor type 6	Hematopoietic cell protein-tyrosine phosphatase;Protein-tyrosine phosphatase 1C;Protein-tyrosine phosphatase SHP-1;PTP-1C;SH-PTP1	P29350	5777	ENSG00000111679	inhibitor
DPR000120	YM-344031	N/A	N/A	N/A	N/A	TTDC00207	C-C chemokine receptor type 3	C-C CKR-3;CC-CKR-3;CCR3;CCR-3;Chemokine receptor CCR3;CKR3;Eosinophil eotaxin receptor	P51677	1232	ENSG00000183625	antagonist
DCL000720	Bertilimumab??	iCo-008; CAT-213	375348-49-5	5486198	47206551	TTDC00207	C-C chemokine receptor type 3	C-C CKR-3;CC-CKR-3;CCR3;CCR-3;Chemokine receptor CCR3;CKR3;Eosinophil eotaxin receptor	P51677	1232	ENSG00000183625	antagonist
DPR000121	YM-355179	N/A	N/A	N/A	N/A	TTDC00207	C-C chemokine receptor type 3	C-C CKR-3;CC-CKR-3;CCR3;CCR-3;Chemokine receptor CCR3;CKR3;Eosinophil eotaxin receptor	P51677	1232	ENSG00000183625	antagonist
DAP000006	Sorafenib	BAY-54-9085; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide; BAY-43-0006; Sorafenib [INN]; NCGC00167488-01; CID216239; D08524; CHEBI:50924; 4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]AMINO}CARBONYL)AMINO]PHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE; Kinome_766; Bio-0100; sorafenibum; BAY 439006; Sorafenib; AC-1674; BAY 54-9085 (tosylate salt); LS-187788; DB00398; ZINC01493878; 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-; LS-186067; MolPort-003-850-270; Nexavar; DB07438; BAY-43-9006; 4-(4-{3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; NSC-724772; K00597a; AB1004622; BRD-K23984367-001-01-8; STK627350; N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea; I06-0856; 4(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; BAY 43-9006 (free base); CHEBI:47228; N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcar bamoyl)-4-pyridyloxy)phenyl)urea; nchembio.117-comp17; CHEMBL1336; N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea; 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide; 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide; BAX; EN002709; AC1L50CF; Sorafenib (INN); 4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide; 2-Pyridinecarboxamide, 4-(4-((((4-chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-; NSC747971; LS-187021; 4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate; UNII-9ZOQ3TZI87; BAY 43-9006; BAY43-9006; 284461-73-0; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide	284461-73-0	216239	789424	TTDS00007	Vascular endothelial growth factor receptor 1	Flt-1;Fms-like tyrosine kinase 1;Tyrosine-protein kinase FRT;Tyrosine-protein kinase receptor FLT;Vascular permeability factor receptor;VEGFR-1	P17948	2321	ENSG00000102755	inhibitor
DCL001016	Telbermin	Telbermin; Telbermin (USAN/INN); 205887-54-3; D06058	205887-54-3	N/A	47207716	TTDS00007	Vascular endothelial growth factor receptor 1	Flt-1;Fms-like tyrosine kinase 1;Tyrosine-protein kinase FRT;Tyrosine-protein kinase receptor FLT;Vascular permeability factor receptor;VEGFR-1	P17948	2321	ENSG00000102755	activator
DAP001260	Ranibizumab	Ranibizumab (genetical recombination) (JAN); Ranibizumab (USAN/INN); D05697; Lucentis; 347396-82-1; Ranibizumab (genetical recombination); Ranibizumab; Lucentis (TN)	347396-82-1	459903	47207358	TTDS00007	Vascular endothelial growth factor receptor 1	Flt-1;Fms-like tyrosine kinase 1;Tyrosine-protein kinase FRT;Tyrosine-protein kinase receptor FLT;Vascular permeability factor receptor;VEGFR-1	P17948	2321	ENSG00000102755	inhibitor
DAP000174	Acarbose	AC1L9HYX; CID444254; MLS000759506; 1ukt; acarbose; AC1L26GM; 1k1y; AC1NAU1X; SAM001246733; SPECTRUM1505172; Acarbose (JAN/USAN/INN); Bay g 5421; Beta-Acarbose; AC1L9APL; NCGC00096061-01; CID41774; CHEMBL1566; CPD000466376; Acarbose [USAN:BAN:INN:JAN]; CHEBI:2376; ACI-(1-4)GLD-(1-4)GLC-(1-4)GLB; HMC-(1-4)AGL-(1-4)GLC-(1-4)GLC; LS-71702; Bay-g-5421; Prandase, Precose, Glucobay, Bay-g 5421, Acarbose; CID10627975; CHEBI:506767; CHEMBL569486; SMR000466376; AC1L9G0J; CHEMBL394434; HMS2051F03; Prandase; MolPort-002-507-369; NCGC00160515-01; Acarbosum; S1271_Selleck; Acarbosa [INN-Spanish]; 56180-94-0; HMS2093I22; Acarbosa; 1gah; Glucobay; 1agm; MLS001424056; BB_NC-1311; Precose; D00216; CID4432690; DB00284; STK801930; C06802; C25H43NO18; BAY-g 5421; CID445421; 1lf9; UNII-T58MSI464G; NCGC00096061-02; Acarbosum [INN-Latin]; Precose (TN); CID441184; 1,4-DEOXY-4-((5-HYDROXYMETHYL-2,3,4-TRIHYDROXYCYCLOHEX-5,6-ENYL)AMINO)FRUCTOSE; MolPort-003-844-373; EINECS 260-030-7; Glucor; AC1OCEJZ; Alpha-Acarbose	56180-94-0	441184	7847283	TTDS00291	Maltase-glucoamylase, intestinal	Alpha-glucosidase	O43451	8972	ENSG00000257335; ENSG00000259858	inhibitor
DAP001104	Voglibose	Glustat; MolPort-003-987-271; (1S,2S,3R,4S,5S)-5-{[2-hydroxy-1-(hydroxymethyl)ethyl]amino}-1-(hydroxymethyl)cyclohexane-1,2,3,4-tetrol; CHEMBL476960; 83480-29-9; Vocarb; voglibose; TL8005479; AB1004883; CID444020; Basen OD; CHEBI:590151; Ambap83480-29-9; Voglibose (JP15/USAN/INN); 3,4-Dideoxy-4-{[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-2-D-epi-inositol; N-(1,3-Dihydroxyprop-2-yl)valiolamine; (1S,2S,3R,4S,5S)-5-(1,3-dihydroxypropan-2-ylamino)-1-(hydroxymethyl)cyclohexane-1,2,3,4-tetrol; Basen (Takeda Chemical Industries); AO-128; D01665; AC1L9FKA; Volix (Ranbaxy labs); Basen (TN); DB04878; A-71100; Basen	83480-29-9	444020	10299466	TTDS00291	Maltase-glucoamylase, intestinal	Alpha-glucosidase	O43451	8972	ENSG00000257335; ENSG00000259858	inhibitor
DAP000712	Miglitol	Plumarol; AC1L9AYD; Bio-0159; (2R,3R,4R,5S)-1-(2-hydroxyethyl)-2-(hydroxymethyl)piperidine-3,4,5-triol; 72432-03-2; HMS2051D05; CID441314; CHEBI:545681; SMR000466381; SK-983; Seibule; Miglitol (JAN/USAN/INN); MIGLITOL; SAM001246745; CPD000466381; BIDD:GT0732; MLS001424128; D00625; C07708; Diastabol; Glyset (TN); MLS000759514; CHEMBL1561; Glyset; DB00491; Bay-m-1099	72432-03-2	441314	9910	TTDS00291	Maltase-glucoamylase, intestinal	Alpha-glucosidase	O43451	8972	ENSG00000257335; ENSG00000259858	inhibitor
DAP001238	Sulfadiazine	CAS-68-35-9; Lipo-Diazine; 141582-64-1; DB00359; Sulfanilamide, N1-2(1H)-pyrimidinylidene-; Trisem; CRL-8131 & Sulfadiazine; HMS2092I15; Solfadiazina [DCIT]; Spectrum5_000992; 4-Amino-N-2-pyrimidinyl- benzenesulfonamide; KBio1_000543; Oprea1_081078; Sulfapyrimidin; UNII-0N7609K889; Spectrum_000986; A-306; N(1)-2-pyrimidylsulfanilamide; HMS1568E07; sulfadiazine; BSPBio_000085; Sulfapyrimidin [German]; Sulfadiazina [INN-Spanish]; NCGC00016305-02; WLN: T6N CNJ BMSWR DZ; Liquadiazine; Honey diazine; 4-Amino-N-(2-pyrimidinyl)benzenesulfonamide; NSC 35600; Adiazine; KBio2_001466; KBio2_006602; Diazolone; Recombinant bactericidal/permeability-increasing protein & Sulfadiazine; Sulfanilamide, N1-2-pyrimidinyl- (8CI); N1-(Pyrimidin-2-yl)sulfanilamide; Truozine; SPBio_001417; Theradiazine; Thi-Di-Mer; Prestwick_428; Di-Azo-Mul; Spofadrizine; IDI1_000543; S1770_Selleck; NCGC00023291-03; 4-AMINO-N-2-PYRIMIDINYLBENZENESULFONAMIDE; Sulfadiazine (JAN/USP/INN); BB_SC-0628; Sulfadiazinum; Piridisir; N(sup 1)-2-Pyrimidinylsulfanilamide; Sulfazine; Sanodiazine; LS-147838; KBio2_004034; 4-amino-N-pyrimidin-2-ylbenzenesulfonamide; S.N. 112; Spectrum2_001319; Diazovit; DivK1c_000543; SPECTRUM1500546; CHEMBL439; AC1L1JUR; Sulfadiazine, Zinc; A-306 (VAN); HMS501L05; S0579; BRN 0235192; Thermazene; Metha-Meridiazine; Sulfatryl; Cremodiazine; Diazyl; CID5215; AC1Q6W1E; Sulfadiazine (TN); Sulfose; D00587; HMS2090P09; EINECS 200-685-8; Tri-Sulfameth; Spectrum3_001362; Sulfanilamide, N1-2-pyrimidinyl-; SPBio_002006; Coco-Diazine; N(sup1)-2-Pyrimidinylsulfanilamide; KBio3_002104; Benzenesulfonamide, 4-amino-N-2-pyrimidinyl-; Sulfapyrimidine; AB00052095; Terfonyl; RP 2616; Neazine; NSC117870; Silvadene; 35033_RIEDEL; N-(2-Pyrimidinyl)sulfanilamide; Deltazina; Prestwick2_000023; Sulfadiazin; STK317797; BPBio1_000095; 4-Amino-N-2-pyrimidinyl-benzenesulfonamide; Pecta-Diazine; 68-35-9; A 306; AC-12001; Mixture of sulfadiazine, sulfamerazine, and sulfamethazine; BRD-K32273377-001-05-4; Microsulfon; Pyrimal; Prestwick3_000023; Sulfonsol; 2-Sulfanilamido-pyrimidine; 2-Sulfanilamidopyrimidin [German]; AI3-01047; SSD; Sulfanilamidopyrimidine; AC1Q51XM; 5-25-10-00067 (Beilstein Handbook Reference); CHEBI:9328; Sildaflo; AR-1L4215; BSPBio_002884; Prestwick1_000023; NSC35600; Zinc Sulfadiazine; MLS000069423; Adiazin; S8626_SIGMA; Sterazine; C10H10N4O2S; Sulfadiazene; KBioSS_001466; Sulphadiazine; D013411; SMR000059113; Sulfanilamide, N(sup 1)-2-pyrimidinyl-; Sulphadiazine E; NINDS_000543; Quadetts; Solfadiazina; Neotrizine; Eskadiazine; 2-Sulfapyrimidine; Sulfadiazina; KBioGR_000743; Sulfapirimidin; Cremotres; 4-amino-N-(pyrimidin-2-yl)benzenesulfonamide; Trisulfapyrimidine, oral suspension; Spectrum4_000342; Sulfadiazine [USAN:INN:JAN]; N(sup1)-2-Pyrimidylsulfanilamide; 2-Sulfanilamidopyrimidine; Prestwick0_000023; C07658; Sulfonamides Duplex; Quadramoid; CocoDiazine; rBPI21 & Sulfa; Pecta-diazine, suspension; Codiazine; MolPort-000-629-738; Lipo-Levazine; Adiazin, Adiazine, Debenal, Liquadiazine, Microsulfon, Sulfazine, Sulfolex, Sulfadiazine; Triple Sulfas; NCGC00016305-01; HMS1921A13; 2-Sulfanilylaminopyrimidine; AKOS000119073; Palatrize; Debenal; Trifonamide; N(1)-2-pyrimidinylsulfanilamide; Pirimal; Pyrimidine, 2-sulfanilamido-; Sulfolex; NCGC00023291-04; TL80073596; Diazin; ZINC00120319; S. N. 112; Sulfadiazinum [INN-Latin]; 35033_FLUKA; 2-Sulfanilamidopyrimidin	68-35-9	5215	9860	TTDS00237	Dihydropteroate synthetase	DHPS;Dihydropteroate pyrophosphorylase;Dihydropteroate synthase;H2Pte synthase	Q9BIX9	N/A	N/A	inhibitor
DAP001201	Sulfacytine	NSC356717; Sulfacitina; 4-amino-N-(1-ethyl-2-oxopyrimidin-4-yl)benzenesulfonamide; 1-Ethyl N4-sulfanilylcytosin; sulfacytine; Sulfacitina [INN-Spanish]; 1401-49-6; Renoquid (TN); 4-amino-N-(1-ethyl-2-oxo-1,2-dihydropyrimidin-4-yl)benzenesulfonamide; Sulfanilamide, N1-(1-ethyl-1,2-dihydro-2-oxo-4-pyrimidinyl)- (8CI); Sulfanilamide, N(1)-(1-ethyl-1,2-dihydro-2-oxo-4-pyrimidinyl)-; AC1Q6C6O; HSDB 3272; CHEMBL1201056; Sulfacitinum; CI-636; D02519; N(sup1)-(1-Ethyl-1,2-dihydro-2-oxo-4-pyrimidinyl)sulfanilamide; CL 636; LS-173691; CID5322; Sulfacitinum [INN-Latin]; DB01298; Nl-sulfanilyl-1-ethylcytosine; Sulfacytine [USAN:BAN]; Sulfacitine; N(sup 1)-(1-Ethyl-1,2-dihydro-2-oxo-4-pyrimidinyl)sulfanilamide; Sulfanilamide, N1-(1-ethyl-1,2-dihydro-2-oxo-4-pyrimidinyl)-; UNII-T795873AJP; Renoquid; Benzenesulfonamide, 4-amino-N-(1-ethyl-1,2-dihydro-2-oxo-4-pyrimidinyl)-; AR-1L5715; NSC 356717; N-Sulfanilyl-l-ethylcytosine; 17784-12-2; CI 636; 1-Ethyl-N-sulfanilylcytosine; AC1L1K3H; Sulfacytine (USAN)	17784-12-2	5322	10349273	TTDS00237	Dihydropteroate synthetase	DHPS;Dihydropteroate pyrophosphorylase;Dihydropteroate synthase;H2Pte synthase	Q9BIX9	N/A	N/A	inhibitor
DAP001523	Sulfonamides	CHEBI:35358; Sulfonamides; Mixtures, Sulfonamide; Sulfonamide Mixtures; D013449; CHEBI:425355	26914-52-3	N/A	3736898	TTDS00237	Dihydropteroate synthetase	DHPS;Dihydropteroate pyrophosphorylase;Dihydropteroate synthase;H2Pte synthase	Q9BIX9	N/A	N/A	binder
DAP001199	Sulfametopyrazine	5175-55-3; Sulphametopyrazine; Sulfaleno [INN-Spanish]; Kelfizina (TN); ARONIS23883; SULFALENE; Sulfalene [USAN:INN]; NCGC00160482-01; N(sup1)-(3-Methoxy-2-pyrazinyl)sulfanilamide; Polycidal; Sulfaleno; Solfametopirazina [DCIT]; 152-47-6; Sulfametoxypyridazin; NSC 110433; SMP2; 2-(p-Aminobenzenesulfanamide)-3-methoxypyrazine; 2-Methoxy-3-sulfanilamidopyrazine; AS 18908; EINECS 205-804-7; AC1L1S7A; CID9047; Kelfizine; Dalysep; WLN: T6N DNJ BO1 CMSWR DZ; 2-Sulfanilamido-3-methoxypyrazine; UNII-T6BL4ZC15G; 4-amino-N-(3-methoxypyrazin-2-yl)benzenesulfonamide; 2-(p-Aminobenzenesulfonamido)-3-methoxypyrazine; MLS001304170; Sulfanilamide, N(sup 1)-(3-methoxy-2-pyrazinyl)-; Sulfanilamide, N1-(3-methoxypyrazinyl)-; BIM-0013167.P001; Sulfalen; Sulfapyrazinemethoxyine; AC-750; Sulfanilamide, N1-(3-methoxypyrazinyl)- (8CI); N(sup 1)-(3-Methoxy-2-pyrazinyl)sulfanilamide; MLS001304101; Solfametopirazina; 2-Sulfanilamide 3-methoxy-pyrazine; SMR000011031; FI 5978; Sulfamethopyrazine; 3-Methoxy-2-sulfanilamidopyrazine; Sulphalene; NSC110433; CBMicro_013257; Sulfalene (USAN); Longum; Sulfamethoxysuccinate; AKOS000538590; N(sup 1)-(3-Methoxypyrazinyl)sulfanilamide; D01216; 3-Methoxypyrazine sulfanilamide; 4-Amino-N-(3-methoxypyrazinyl)-benzenesulfonamide; Benzenesulfonamide, 4-amino-N-(3-methoxypyrazinyl)-; Sulfametopyrazine; Pyrazine, 2-sulfanilamido-3-methoxy-; Sulfapyrazinmethoxine; Sulfapyrazinemethoxine; Bio-0403; ZINC00002097; Sulfalenum [INN-Latin]; Sulfamethopyrazine (JAN); SMP; Farmitalia 204/122; Sulfanilamide, N(sup 1)-(3-methoxypyrazinyl)-; STK386859; Sulfalenum; Kelfizina; N1-(3-Methoxypyrazinyl)sulfanilamide; WR 4629; Kelfizin; 4-Amino-N-(3-methoxypyrazinyl)benzenesulfonamide; Sulfapyrazinemethoxyne; F.I. 5978; NSC-110433; MolPort-002-320-006; Sulfanilamide, N'-(3-methoxypyrazinyl)-; 3-Methoxy-2-sulfapyrazine; Sulfamethoxypyrazine; Oprea1_010520; DB00664; N(sup1)-(3-Methoxypyrazinyl)sulfanilamide; C12616; LS-147805; Kelfizine W; 4-Amino-N-(3-methoxy-pyrazin-2-yl)-benzenesulfonamide; 5-25-12-00574 (Beilstein Handbook Reference); BRN 0622512	152-47-6	9047	583006	TTDS00237	Dihydropteroate synthetase	DHPS;Dihydropteroate pyrophosphorylase;Dihydropteroate synthase;H2Pte synthase	Q9BIX9	N/A	N/A	inhibitor
DAP000638	Sulfadoxine	HMS2094C19; Prestwick0_001094; EINECS 219-504-9; Sulfadoxina; AB00514044; Sulphormethoxine; CHEBI:9329; NCGC00016612-02; MolPort-003-850-341; S2511_Selleck; Prestwick3_001094; 2447-57-6; D00580; NCGC00016612-01; Fanasil; Solfadossina [DCIT]; Sulphadoxine; S7821_SIGMA; Sulfadoxina [INN-Spanish]; CID17134; 46810_RIEDEL; N(sup 1)-(5,6-Dimethoxy-4-pyrimidinyl)sulfanilamide; Sulfadoxin; CHEMBL1539; Ambap2447-57-6; BRN 0625453; N'-(5,6-Dimethoxy-4-pyrimidyl)sulfanilamide; ZINC00002094; HMS2090P07; Sulfadoxine [USAN:INN:BAN:JAN]; WR 4073; BSPBio_001168; 4-amino-N-(5,6-dimethoxypyrimidin-4-yl)benzenesulfonamide; WR 4873; MLS002154150; BPBio1_001286; Sulphormetoxin; 5-25-13-00306 (Beilstein Handbook Reference); Benzenesulfonamide, 4-amino-N-(5,6-dimethoxy-4-pyrimidinyl)-; Sulforthomidine; Sanasil: Sulfadoxine: Sulformetoxin; Sulfadoxine (JAN/USP/INN); Ro-4-4393; Fanzil; BRD-K55250441-001-03-1; 4-Amino-N-(5,6-dimethoxy-4-pyrimidinyl)benzenesulfonamide; Sulformetoxine; HMS1571K10; Sulfadoxinum; AC1Q46GG; Ro 4-4393; Sulformethoxine; I09-0529; SPBio_003054; Prestwick1_001094; Sulphorthodimethoxine; 4-amino-N-[5,6-bis(methyloxy)pyrimidin-4-yl]benzenesulfonamide; AC-11921; DB01299; N1-(5,6-Dimethoxy-4-pyrimidinyl)sulfanilamide; 4-Sulfanilamido-5,6-dimethoxypyrimidine; Sulfadoxinum [INN-Latin]; Orthosulfin; LS-31247; C07630; SMR000857259; 6-(4-Aminobenzenesulfonamido)-4,5-dimethoxypyrimidine; CAS-2447-57-6; Prestwick2_001094; Solfadossina; UNII-88463U4SM5; AC1L29DT; SULFADOXINE	2447-57-6	17134	10462311	TTDS00237	Dihydropteroate synthetase	DHPS;Dihydropteroate pyrophosphorylase;Dihydropteroate synthase;H2Pte synthase	Q9BIX9	N/A	N/A	inhibitor
DAP000637	Dapsone	SPBio_002050; 4,4'-diaminophenyl sulfone; DB00250; AC1L1EUH; Croysulphone; 32960_FLUKA; Aniline, 4,4'-sulfonyldi-; Sulfona; Araldite HT 976; HT 976; CID2955; AKOS000119322; Sulfadione; DSS (VAN); CCRIS 192; 4,4'-Sulfonylbisbenzamine; p,p-Sulphonyldianiline; Bis(4-aminophenyl)sulphone; LS-1790; Eporal; Avlosulfone; ALBB-005917; Sulphonyldianiline; Di(4-aminophenyl)sulfone; IDI1_000573; Sulphadione; D0089; AB1004833; Sulphon-mere; Dapson; SPECTRUM1500222; p,p-Sulfonylbisbenzenamine; Disulone; p,p'-Diaminodiphenyl sulfone; Atrisone; Avlosulfon; IN-201; HY 976; Dapsoderm-X; HMS1920C14; HSDB 5073; 4,4'-Sulphonylbisbenzamine; 4,4' Diaminophenyl Sulfone; KBio1_000573; Sulfone ucb; 4,4'-Diaminodiphenyl suphone; ZINC00006310; DDS (pharmaceutical); Di(p-aminophenyl) sulfone; BIDD:GT0770; Aczone (TN); Fatol Brand of Dapsone; Novophone; 4-Aminophenylsulfone; 4,4'-Diaminodiphenyl sulfone; NSC 6091; Di(4-aminophenyl)sulphone; NCI-C01718; 4,4'-Diaminodiphenylsulfone; 1,1'-Sulfonylbis(4-aminobenzene); p,p-Sulfonylbisbenzamine; 4,4-Sulfonyldianiline; Benzenamine, 4,4'-sulfonylbis-; 4-Aminophenyl sulfone; Sulfanona-mae; Dubronaz; Bis(p-aminophenyl) sulfone; Prestwick2_000035; Avsulfor; DivK1c_000573; NCGC00016322-02; SMR000059064; NSC6091; AC1Q51WN; BRD-K62363391-001-05-8; Dapsonum; CAS-80-08-0; NCGC00023946-06; I01-3640; A74807_ALDRICH; STK387118; KBio2_006504; Metabolite C; N, N'-Diphenyl sulfondiamide; SPBio_001025; 4-(4-aminophenyl)sulfonylaniline; NCGC00023946-05; 80-08-0; N,N'-Diphenyl sulfondiamide; Oprea1_143052; Prestwick3_000035; Bis(4-aminophenyl)sulfone; p,p-Diaminodiphenyl sulphone; Spectrum2_001133; Orsade Brand of Dapsone; Diamino-4,4'-diphenyl sulphone; Sulfon-mere; CHEMBL1043; 4-Aminop henyl sulfone; DDS; MolPort-001-780-172; Diaminodifenilsulfona; p,p-Sulphonylbisbenzamine; Aczone; Dapsone (USP); 4,4-Diaminodifenylsulfon [Czech]; DDS, pharmaceutical; BSPBio_000129; DADPS; Protogen; D00592; Dapsona [INN-Spanish]; KBioSS_001368; p-Aminophenyl sulfone; Diaphenylsulphone; 46158_RIEDEL; NSC-6091; 4,4'-Sulfonyldianiline; Dapsonum [INN-Latin]; Diaphenylsulfone; SAM002554879; MLS001055349; W R 448; 4,4'-Sulfonyldianiline (Dapsone); p, p'-Sulfonyldianiline; 4,4'-Sulphonylbisbenzenamine; HMS501M15; AZT + Dapsone cominbation; NCGC00023946-04; NCGC00016322-01; Diamino-diphenyl sulphone; 1,1'-Sulphonylbis(4-aminobenzene); Diaminodifenilsulfona [Spanish]; 1358F; Diaminodiphenyl sulfone; KBioGR_000900; Prestwick_152; AC1Q51WM; Diaphenylsulphon; Sulfonyldianiline; EINECS 201-248-4; Diaphenylsulfone (JAN); p,p'-sulfonyldianiline; KBio2_001368; AC-10922; WLN: ZR DSWR DZ; Dubronax; Ambap80-08-0; 4-[(4-aminophenyl)sulfonyl]aniline; Dapsone [USAN:BAN]; NINDS_000573; 4,4'-Dapsone; Udolac; MLS001076146; Prestwick0_000035; 4,4'-Sulfonylbisbenzenamine; BRN 0788055; Mex-America Brand of Dapsone; Sulfona-MAE; Hardener HT 976; BSPBio_002129; F 1358; Dapsona; Sulfone, 4,4'-Diaminophenyl; Sulfone, diphenyl, 4,4'-diamino-; AB00051962; Prestwick1_000035; Bis(p-aminophenyl)sulphone; Spectrum4_000310; Sumicure S; KBio3_001349; HMS1568G11; Dapson-Fatol; Spectrum3_000375; Avlosulphone; CHEBI:4325; 4,4-Diaminodifenylsulfon; ICI; AI3-08087; Araldite HT; Croysulfone; (4-sulfanilylphenyl)amine; p,p-Sulphonylbisbenzenamine; KBio2_003936; D003622; WR 448; MLS000069409; 4,4'-Sulphonyldianiline; Diamino-4,4'-diphenyl sulfone; CPD000059064; Spectrum5_000825; NCGC00023946-03; 46158_FLUKA; Spectrum_000888; Diaminodiphenylsulfone; Bis(4-aminophenyl) sulfone; DDS; Dapsone; TL8005401; CBDivE_013582; Diphenasone; 4-[(4-aminobenzene)sulfonyl]aniline; 1,1'-Sulfonylbis[4-aminobenzene]; Diaphenylsulfon; Di(p-aminophenyl)sulphone; Bis(4-aminophenyl) sulfone; UNII-8W5C518302; DDS, diaphenylsulfone; Dumitone; dapsone; Diphone; D SS; 4,4'-Sulfonylbisaniline; Di(4-aminophenyl) sulfone; NSC 6091D; HMS2091K04; C07666; BPBio1_000143; Tarimyl	80-08-0	2955	7847658	TTDS00237	Dihydropteroate synthetase	DHPS;Dihydropteroate pyrophosphorylase;Dihydropteroate synthase;H2Pte synthase	Q9BIX9	N/A	N/A	inhibitor
DAP001524	Sulphadoxine	Prestwick0_001094; Sulphormethoxine; NCGC00016612-02; MolPort-003-850-341; Prestwick3_001094; NCGC00016612-01; Fanasil; Sulfadoxina [INN-Spanish]; CID17134; 46810_RIEDEL; N(sup 1)-(5,6-Dimethoxy-4-pyrimidinyl)sulfanilamide; CHEMBL1539; BRN 0625453; ZINC00002094; Sulfadoxine [USAN:INN:BAN:JAN]; BSPBio_001168; 4-amino-N-(5,6-dimethoxypyrimidin-4-yl)benzenesulfonamide; MLS002154150; 5-25-13-00306 (Beilstein Handbook Reference); Sulforthomidine; Fanzil; 4-Amino-N-(5,6-dimethoxy-4-pyrimidinyl)benzenesulfonamide; Sulformetoxine; HMS1571K10; Sulfadoxinum; AC1Q46GG; SPBio_003054; Prestwick1_001094; 4-amino-N-[5,6-bis(methyloxy)pyrimidin-4-yl]benzenesulfonamide; AC-11921; Sulfadoxinum [INN-Latin]; LS-31247; CAS-2447-57-6; Prestwick2_001094; AC1L29DT; SULFADOXINE; HMS2094C19; EINECS 219-504-9; Sulfadoxina; AB00514044; CHEBI:9329; S2511_Selleck; 2447-57-6; D00580; Solfadossina [DCIT]; Sulphadoxine; S7821_SIGMA; Sulfadoxin; Ambap2447-57-6; N'-(5,6-Dimethoxy-4-pyrimidyl)sulfanilamide; HMS2090P07; WR 4073; WR 4873; BPBio1_001286; Sulphormetoxin; Benzenesulfonamide, 4-amino-N-(5,6-dimethoxy-4-pyrimidinyl)-; Sanasil: Sulfadoxine: Sulformetoxin; Sulfadoxine (JAN/USP/INN); Ro-4-4393; BRD-K55250441-001-03-1; Ro 4-4393; Sulformethoxine; I09-0529; Sulphorthodimethoxine; DB01299; N1-(5,6-Dimethoxy-4-pyrimidinyl)sulfanilamide; 4-Sulfanilamido-5,6-dimethoxypyrimidine; Orthosulfin; C07630; SMR000857259; 6-(4-Aminobenzenesulfonamido)-4,5-dimethoxypyrimidine; Solfadossina; UNII-88463U4SM5	2447-57-6	17134	160328	TTDS00237	Dihydropteroate synthetase	DHPS;Dihydropteroate pyrophosphorylase;Dihydropteroate synthase;H2Pte synthase	Q9BIX9	N/A	N/A	binder
DAP001202	Sulfamethizole	Renasul; C08050; KBio1_000141; 46842_RIEDEL; IDI1_000141; RP 2145; 46842_FLUKA; MLS002303066; 2-Sulfanilamido-5-methyl-1,3,4-thiadiazole; SPECTRUM1500549; Spectrum4_000640; Sulfa gram; Sulfamethizolum [INN-Latin]; Sulfamethizole [USAN:INN:JAN]; Salimol; Prestwick_114; AI3-50149; 4-Amino-N-(5-methyl-1,3,4-thiadiazol-2-yl)benzenesulfonamide; N(1)-(5-Methyl-1,3,4-thiadiazol-2-yl)sulfanilamide; Thidicur; BSPBio_001960; SPBio_001443; Thiosulfil-A-Forte; UNII-25W8454H16; VK 53; KBio3_001460; Thiosulfil; 4-Amino-N-(5-methyl-1,3,4-thiadiazol-2-yl)benzenesulfonamide; 2-Methyl-5-sulfanilamido-1,3,4-thiadiazole; BRD-K31682896-001-05-9; HSDB 4379; Proklar; Thiosulfil (TN); Tetracid; N1-(5-Methyl-1,3,4-thiadiazol-2-yl)sulfanilamide; HMS500H03; 2-(p-Aminobenzenesulfonamido)-5-methylthiadiazole; AB00052098; BSPBio_000724; KBioSS_001472; Sulfstat; Famet; Ayerlucil; KBio2_006608; BPBio1_000798; KBio2_004040; Urosulfin; S1957_Selleck; KBio2_001472; Microsul; Prestwick3_000742; sulfamethizole; 5-Methyl-2-sulfanilamido-1,3,4-thiadiazole; Urolucosil; AKOS002666345; CHEBI:9331; NCGC00016407-02; Rufol; Prestwick0_000742; AC1L1K3Z; Sulfamethizol; D00870; MolPort-000-876-475; CCRIS 756; Sulphamethizole; SMR000058666; S0360; Sulfametizol [INN-Spanish]; 4-Amino-N-(5-Methyl-1,3,4-Thiadiazol-2-Yl)Benzene-1-Sulfonamide; KBioGR_001260; EINECS 205-641-1; Lucosil; HMS1570E06; S5632_FLUKA; ZINC00057493; NINDS_000141; DB00576; 4-Amino-N-[5-methyl-1,3,4-thiadiazol-2-yl]benzenesulfonamide; NCGC00024107-05; NCGC00016407-01; Sulfamethylthiadiazole; Sulfamethazole; Sulfametizol; Urodiaton; Sulfurine; Sulamethizole; Spectrum3_000570; SMP1_000284; AC1Q2PXR; CHEMBL1191; Sulphamethyltiadiazole; SBB058179; Sulfapyelon; SULFAMETHIAZOLE; NCGC00024107-04; S5632_SIGMA; Prestwick2_000742; Thiosulfil Forte; Uroz; SPBio_002663; N(sup 1)-(5-Methyl-1,3,4-thiadiazol-2-yl)-sulfanilamide; Urocydal; Sulfamethizolum; Sulfanilamide, N(sup 1)-(5-methyl-1,3,4-thiadiazol-2-yl)-; Methazol; NCGC00024107-03; N(sup 1)-(5-Methyl-1,3,4-thiadiazol-2-yl)sulfanilamide; HMS1921A19; CAS-144-82-1; HMS2092I21; Solfametizolo; Spectrum5_001078; Solfametizolo [DCIT]; Prestwick1_000742; DivK1c_000141; LS-853; Spectrum_000992; Ultrasul; CID5328; Sulfamethizole (JP15/USP/INN); 144-82-1; MLS000028603; Spectrum2_001322; C9H10N4O2S2	144-82-1	5328	10250	TTDS00237	Dihydropteroate synthetase	DHPS;Dihydropteroate pyrophosphorylase;Dihydropteroate synthase;H2Pte synthase	Q9BIX9	N/A	N/A	inhibitor
DAP001240	Sulfamerazine	4-amino-N-(4-methylpyrimidin-2-yl)benzenesulfonamide; 2-Sulfanilamido-4-methylpyrimidine; Sulfamerazinum; NSC 27259; 4-Amino-N-(4-methyl-2-pyrimidinyl)-benzenesulfonamide (9CI); N(sup1)-(4-Methyl-2-pyrimidinyl)sulfanilamide; Spectrum4_000343; KBio2_002911; A-310; HMS2092I17; N-(4-Methyl-2-pyrimidyl)sulfanilamide; UNII-UR1SAB295F; Methylsulfadiazine; Bio-0519; KBioGR_000745; Sulfamerazine (INN); BSPBio_002886; 99482-27-6; SPBio_002768; Pyralcid; sulfamerazine; N(1)-(4-Methyl-2-pyrimidinyl)sulfanilamide; S8876_SIGMA; Debenal-M; ZINC00057501; NSC27259; Methylsulfazin; CHEMBL438; Spectrum2_001320; Mesulfa; BRN 0249133; Sulfamerazine [USAN:INN:BAN]; 4-Amino-N-(4-methyl-pyrimidin-2-yl)-benzenesulfonamide; KBio1_000563; AC1Q2NY3; Methylpyrimal; HMS501M05; 2-(4-Aminobenzenesulfonamido)-4-methylpyrimidine; MolPort-001-783-537; Benzenesulfonamide, 4-amino-N-(4-methyl-2-pyrimidinyl)-; Sulfanilamide, N1-(4-methyl-2-pyrimidinyl)- (8CI); Metilsulfazin; RP 2632; EINECS 204-866-2; Sulfamerazin; Solfamerazina [DCIT]; Prestwick1_000694; IDI1_000563; Sulfanilamide, N(sup 1)-(4-methyl-2-pyrimidinyl)-; Sulfamerazina; Methylsulfazine; Kelamerazine; Spectrum_000003; AI3-08026; NCGC00094787-02; KBio2_005479; 2(p-Aminobenzolsulfonamido)-4-methylpyrimidin; DB01581; 127-79-7; SPECTRUM1500547; SMR000145672; LS-147821; DivK1c_000563; Sumedine; NINDS_000563; Sulfamerazina [INN-Spanish]; 5-25-10-00167 (Beilstein Handbook Reference); Sulphamerazine; Spectrum3_001363; 2-Sulfa-4-methylpyrimidine; Septacil; BRD-K93524252-001-05-6; Sulfanilamide, N1-(4-methyl-2-pyrimidinyl)-; MLS000551747; Spectrum5_001413; 46826_RIEDEL; HMS1570K09; D02435; N1-(4-Methylpyrimidin-2-yl)sulfanilamide; AB00052096; Prestwick2_000694; CID5325; AKOS005143010; 4-Amino-N-(4-methyl-2-pyrimidinyl)-benzenesulfonamide; Prestwick_17; 4-Amino-N-(4-methyl-2-pyrimidinyl)benzenesulfonamide; Percoccide; 2643-RP; N1-(4-Methyl-2-pyrimidinyl)sulfanilamide; AC1L1K3Q; Solumedin; KBio3_002106; Prestwick3_000694; BSPBio_000847; CAS-127-79-7; MLS001201765; Metilsulfadiazin; (p-Aminobenzolsulfonyl)-2-amino-4-methylpyrimidin; C11H12N4O2S; NCGC00094787-01; S8876_ALDRICH; AC1Q2P0R; CHEBI:102130; 4-amino-N-(4-methylpyrimidin-2-yl)benzene-1-sulfonamide; KBio2_000343; 46826_FLUKA; Sulfamethyldiazine; KBioSS_000343; Sulfamerazinum [INN-Latin]; N(sup 1)-(4-Methyl-2-pyrimidinyl)sulfanilamide; Cremomerazine; Pyrimal M; 2632 R. P.; Septosyl; HMS1921A15; STK520614; NCGC00016386-01; Mebacid; Sulfameradine; Pirimal-M; (p-Aminobenzolsulfonyl)-2-amino-4-methylpyrimidin [German]; Romezin; 2632 R. P; SPBio_001419; 2-(p-Aminobenzolsulfonamido)-4-methylpyrimidine; Veta-Merazine; BPBio1_000933; Solfamerazina; Prestwick0_000694; 2-(Sulfanilamido)-4-methylpyrimidine	127-79-7	5325	10321119	TTDS00237	Dihydropteroate synthetase	DHPS;Dihydropteroate pyrophosphorylase;Dihydropteroate synthase;H2Pte synthase	Q9BIX9	N/A	N/A	inhibitor
DAP001239	Sulfamethoxazole	CHEMBL443; DB01015; EINECS 211-963-3; SULFAMETHOXAZOLE (8064-90-2 (TRIMETHOPRIM/SULFAMETHOXAZOLE); TMP/SMX (MIXTURE)); 4-amino-N-(5-methylisoxazol-3-yl)benzenesulfonamide; Radonil; N1-(5-Methylisoxazol-3-yl)sulfanilamide; TL8005058; Benzenesulfonamide, 4-amino-N-(5-methyl-3-isoxazolyl)-; 4-Amino-N-(5-methyl-3-isoxazolyl)benzenesulfonamide; Maybridge1_007190; AC1Q2J5R; Sulphamethoxazol; S1915_Selleck; Prestwick3_000177; Azo-gantanol; Spectrum_000994; Septran; SMR000058223; Sulfamethalazole; 5-Methyl-3-sulfanylamidoisoxazole; S7507_FLUKA; N(sup 1)-(5-Methyl-3-isoxazolyl)sulphanilamide; 4-Amino-N-(5-methyl-isoxazol-3-yl)-benzenesulfonamide; Spectrum2_000788; HMS502A11; ZINC00089763; 3-(p-Aminophenylsulfonamido)-5-methylisoxazole; ALBB-002089; BB_SC-1251; SPBio_001994; DivK1c_000649; sulfamethoxazole; Ro 4-2130; Sulfanilamide, N1-(5-methyl-3-isoxazolyl)-; KBioSS_001474; Benzenesulfonamide, 4-amino-N-(5-methyl-3-isoxazolyl)-; Prestwick2_000177; Oprea1_285680; AC1L1K42; Gantanol; Prestwick0_000177; MLS001055354; 129378-89-8; D00447; Sulpha-methoxizole; MLS000069732; Sulfamethoxazolum; IDI1_000649; 3-Sulfanilamido-5-methylisoxazole; 4-amino-N-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide; Spectrum3_000584; MS 53; 723-46-6; S7507_SIGMA; Sulfisomezole; Spectrum4_000345; Ro 6-2580/11; Sulphisomezole; NCGC00021995-03; CAS-723-46-6; 3-(para-Aminophenylsulphonamido)-5-methylisoxazole; ARONIS018156; Sulfamethoxazole sodium; NINDS_000649; I01-0154; N'-(5-Methyl-3-isoxazolyl)sulfanilamide; Solfametossazolo [DCIT]; Sulfamethoxizole; 5-Methyl-3-sulphanil-amidoisoxazole; nchembio.221-comp24; UNII-JE42381TNV; C07315; KBio1_000649; Sulphamethalazole; N'-(5-Methylisoxazol-3-yl)sulphanilamide; Metoxal; NCGC00021995-04; JLKIGFTWXXRPMT-UHFFFAOYSA-; WLN: T5NOJ C1 EMSWR DZ; Sulfametoxazol [INN-Spanish]; HMS2092K03; AKOS000200952; BSPBio_000073; Trib; NCGC00021995-05; N(sup1)-(5-Methyl-3-isoxazolyl)sulfanilamide; Sulfametoxazol; Sulphamethylisoxazole; Simsinomin; 4-Amino-N-(5-methyl-3-isoxazolyl)benzenesulfonamide; BAS 00836086; NCGC00016533-01; Sulfamethoxazol; Sulfanilamide, N1-(5-methyl-3-isoxazolyl)- (8CI); Gantanol-DS; A047; KBio3_001528; Solfametossazolo; KBio2_006610; BRN 0226453; NSC 147832; HMS1568D15; BPBio1_000081; MolPort-000-145-787; N1-(5-Methyl-3-isoxazolyl)sulfanilamide; MLS001074165; Sulfamethoxazolum [INN-Latin]; AC-11118; Sinomin; SMX; Gamazole; HMS1921A21; Urobak; Sulphamethoxazole; Sulfamethylisoxazole; 4-Amino-N-[5-methyl-3- isoxazolyl]benzenesulfonamide; 3-Sulphanilamido-5-methylisoxazole; Sulfanilamide, N'-(5-methyl-3-isoxazolyl)-; 46850_RIEDEL; Sulfamethoxazole [USAN:INN:JAN]; HMS561O18; Oprea1_114486; KBioGR_000749; Prestwick_453; CCRIS 567; Sulfanilamide, N(1)-(5-methyl-3-isoxazolyl)-; HSDB 3186; LS-1620; CHEBI:9332; SPBio_000896; C10H11N3O3S; CID5329; SAM002554930; Sulphamethoxazole BP 98; D013420; KBio2_004042; BRD-K28494619-001-05-0; Bactrimel; KBio2_001474; Sulfamethoxazole (JP15/USP/INN); BIDD:GT0731; STK007988; 5-Methyl-3-sulfanilamidoisoxazole; AB00052099; Prestwick1_000177; N'-(5-Methyl-3-isoxazole)sulfanilamide; NCGC00016533-02; S0361; BSPBio_002028; N(sup 1)-(5-Methyl-3-isoxazolyl)sulfanilamide; InChI=1/C10H11N3O3S/c1-7-6-10(12-16-7)13-17(14,15)9-4-2-8(11)3-5-9/h2-6H,11H2,1H3,(H,12,13); Spectrum5_000982; Apo-Sulfamethoxazole; NSC147832; Ro-4-2130; CPD000058223; SPECTRUM1500550	723-46-6	5329	156228	TTDS00237	Dihydropteroate synthetase	DHPS;Dihydropteroate pyrophosphorylase;Dihydropteroate synthase;H2Pte synthase	Q9BIX9	N/A	N/A	inhibitor
DAP001241	Sulfamethazine	NCGC00018243-01; [(4-Aminophenyl)sulfonyl](4,6-dimethylpyrimidin-2-yl)amine; 4-Amino-N-(4,6-dimethyl-2-pyrimidyl)benzenesulfonamide; Sulphadimethylpyrimidine; DivK1c_000293; Sulfanilamide, N(sup 1)-(4,6-dimethyl-2-pyrimidinyl)-; Sulfadimidina [INN-Spanish]; MolPort-000-887-465; NINDS_000293; Prestwick0_000775; Oprea1_142608; BRD-K11640013-001-02-6; NSC683529; 57-68-1; Bio-0716; NSC67457; 4-Amino-N- [4,6-dimethyl-2-pyrimidinyl]- benzenesulfonamide; SPBio_002789; Neazina; MLS002454449; Sulfanilamide, N(sup1)-(2,6-dimethyl-4-pyrimidinyl)-; BRD-K11640013-236-03-6; 4-amino-N-(4,6-dimethylpyrimidin-2-yl)benzene-1-sulfonamide; BIDD:PXR0093; BSPBio_000850; MLS000103403; Mermeth; Spectrum3_001700; MLS001077331; 46802_FLUKA; Sulfadimezin; Prestwick2_000775; HC210279; DB01582; Prestwick3_000775; Sulfadimethyldiazine; Sulfametazina; 4-amino-N-(4,6-dimethylpyrimidin-2-yl)benzenesulfonamide; Spectrum2_001321; N(sup 1)-(4,6-Dimethyl-2-pyrimidinyl)sulfanilamide; Cremomethazine; KBio2_001470; Sulfadimidine; Intradine; Sulphadimidine; Calfspan Tablets; KBioGR_000747; Dimidin-R; KBio2_006606; Primazin; KBio1_000293; Sulphamidine; A-502; sulfamethazine; AC1Q2ID9; D013418; NSC 67457; ASWVTGNCAZCNNR-UHFFFAOYSA-; (p-Aminobenzolsulfonyl)-2-amino-4,6-dimethylpyrimidin [German]; Vertolan; CHEMBL446; ARONIS018080; 4-Amino-N-(4,6-dimethyl-pyrimidin-2-yl)-benzenesulfonamide; CID5327; NCGC00021490-06; WLN: T6N CNJ BMSWR DZ& D1 F1; Sulphodimezine; Superseptil; AKOS000119894; SPECTRUM1500548; Sulfamethazine (USP); CBDivE_012932; BN 2409; N(1)-(4,6-Dimethyl-2-pyrimidinyl)sulfanilamide; HMS1921A17; N(sup 1)-(4,6-Dimethyl-2-pyrimidyl)sulfanilamide; (p-Aminobenzolsulfonyl)-2-amino-4,6-dimethylpyrimidin; Sulfadimerazine; Sulfanilamide, N1-(4,6-dimethyl-2-pyrimidinyl)-; Sulphamezathine; EINECS 200-346-4; CHEBI:102265; Spectrum5_001270; LS-232; Oprea1_677935; Sulfadimethylpyrimidine; Superseptyl; Sulfodimezine; STK097514; Sulfadimidin; Sulfadimidine solution; NCI-C56600; Sulfamezathine (TN); KBio2_004038; NCGC00021490-05; Sulfadimidinum; MLS000069711; S0586; S6256_SIGMA; Sulfadimidinum [INN-Latin]; Sulfanilamide, N(1)-(4,6-dimethyl-2-pyrimidinyl)-; 4,6-Dimethylsulfadiazine; KBioSS_001470; 2-(p-Aminobenzenesulfonamido)-4,6-dimethylpyrimidine; Sa III; Hava-Span; BRN 0261304; Sulka S Boluses; AI3-26817; Sulfadimidine [INN:BAN]; BPBio1_000936; Sulfamethiazine; Spectrum_000990; Sulfadine; Solfadimidina; Sulfanilamide, N(sup1)-(4,6-dimethyl-2-pyrimidinyl)-; Sulfa-Isodimerazine; 4-Amino-N-(2,6-dimethyl-4-pyrimidinyl)benzenesulfonamide; 4-Amino-N-(4,6-dimethyl-2-pyrimidinyl)benzenesulfonamide; n(sup1)-(2,6-Dimethylpyrimid-4-yl)sulfanilamide; Prestwick1_000775; N(Sup1)-(4,6-Dimethyl-2-pyrimidinyl)sulfanilamide; Diazil (the sulfanilamide); CCRIS 3701; Dimezathine; N(Sup1)-(4,6-Dimethyl-2-pyrimidyl)sulfanilamide; NCGC00021490-04; 2-(4-Aminobenzenesulfonamido)-4,6-dimethylpyrimidine; KBio3_002480; 4,6-Dimethyl-2-sulfanilamidopyrimidine; Sulphamethasine; AC1L1K3W; Neasina; Azolmetazin; Spanbolet; NCGC00021490-03; Sulfadimesine; Sulfadimidine (INN); N-(4,6-Dimethyl-2-pyrimidyl)sulfanilamide; Sulfametazyny; HMS500O15; IDI1_000293; Sulfamethazine solution; Sulfadimidina; BSPBio_003260; NCIOpen2_003489; Kelametazine; Sulfametazyny [Polish]; HSDB 4157; N(1)-(4,6-Dimethyl-2-pyrimidyl)sulfanilamide; Solfadimidina [DCIT]; Pirmazin; Sulfamezathine; D02436; 6-(4'-Aminobenzol-sulfonamido)-2,4-dimethylpyrimidin; AC-16126; HMS2092I19; Sulfodimesin; UNII-48U51W007F; Sulphamethazine; ZINC00057494; 2-Sulfanilamido-4,6-dimethylpyrimidine; Sulfadimezinum; Diazil; Sulfadimesin; 6-(4'-Aminobenzol-sulfonamido)-2,4-dimethylpyrimidin [German]; SPBio_001441; SMR000017409; 00189_FLUKA; Benzenesulfonamide, 4-amino-N-(4,6-dimethyl-2-pyrimidinyl)-; SulfaSURE SR Bolus; Spectrum4_000344; 46802_RIEDEL; Sulfametazina [Italian]; 5-25-10-00250 (Beilstein Handbook Reference); Sulfadimezine	57-68-1	5327	10452360	TTDS00237	Dihydropteroate synthetase	DHPS;Dihydropteroate pyrophosphorylase;Dihydropteroate synthase;H2Pte synthase	Q9BIX9	N/A	N/A	inhibitor
DAP001200	Sulfapyridine	Pyriamid; Dagenan; N1-2-Pyridylsulfanilamide; 2-Sulfanilamidopyridin; 4-[(2-Pyridylamino)sulfonyl]aniline; 2-(p-Aminobenzenesulphonamido)pyridine; Spectrum2_001323; DivK1c_000216; Piridazol; Adiplon; Spectrum3_001773; A-499; BSPBio_000804; 4-Amino-N,2-pyridinylbenzenesulfonamide; MLS000069725; M+B 693; KBio1_000216; M&B 693; KBio2_004044; AI3-01049; N(1)-Pyridylsulfanilamide; 2-(4-Aminobenzenesulfonamido)pyridine; Trianon; S0071; Sulfidin; AO-801/41077453; C11H11N3O2S; NINDS_000216; Sulfapyridinum; Spectrum4_000346; InChI=1/C11H11N3O2S/c12-9-4-6-10(7-5-9)17(15,16)14-11-3-1-2-8-13-11/h1-8H,12H2,(H,13,14); AC-10730; CID5336; HMS500K18; BRD-K41406082-001-05-5; 2-Sulfanilamidopyridin [German]; BSPBio_003265; Haptocil; N-2-Pyridylsulfanilamide; NSC41791; Solfapiridina [DCIT]; N1-(Pyridin-2-yl)sulfanilamide; NCGC00022008-04; Sulfapyridinum [INN-Latin]; CHEMBL700; MolPort-000-883-306; Eubasinum; 4-amino-N-pyridin-2-ylbenzenesulfonamide; S6252_FLUKA; UPCMLD0ENAT5889155:001; Sulfanilamide, N(sup 1)-2-pyridyl-; N(1)-2-Pyridylsulfanilamide; KBioSS_001476; Spectrum5_001182; N(sup 1)-2-Pyridylsulfanilamide; Sulfapiridina [INN-Spanish]; ALBB-006215; HMS1570I06; AC1L1K4N; 4-amino-N-(pyridin-2-yl)benzenesulfonamide; Streptosilpyridine; N'-2-Pyridylsulfanilide; WLN: T6NJ BMSWR DZ; I14-1461; STK292439; Sulphapyridin; BPBio1_000886; Sulfapiridina; Sulfapyridine [USAN:INN:BAN]; 144-83-2; SMR000058213; 4-AMINO-N-2-PYRIDINYLBENZENESULFONAMIDE; 4-Amino-N-[2-pyridyl]benzene sulfonamide; NSC 41791; Ronin; KBio3_002766; Sulfanilamide, N1-2-pyridyl-; Solfapiridina; Sulfanilamide, N1-2-pyridyl- (8CI); AB00052100; D013427; M + B 693; NSC4753; LS-854; SPBio_001445; M and B 693; 2-Sulfapyridine; CHEBI:132842; 2-Sulfanilyl aminopyridine; EINECS 205-642-7; Pyridazol; DB00891; GECHUMIMRBOMGK-UHFFFAOYSA-; NCGC00022008-03; Oprea1_344996; KBioGR_000751; Septipulmon; Sulfapyridine (TN); Prestwick3_000762; UNII-Y5V2N1KE8U; Prestwick1_000762; Prestwick_1015; AC1Q51XL; Relbapiridina; NCGC00016408-02; Thioseptal; Spectrum_000996; Sulfidine; S6252_SIGMA; 4-Amino-N-2-pyridinyl- benzenesulfonamide; 2-Sulfanilylaminopyridine; NCGC00016408-01; Plurazol; Benzenesulfonamide, 4-amino-N-2-pyridinyl-; SPBio_002743; 4-amino-N-pyridin-2-yl-benzenesulfonamide; NSC 4753; SPECTRUM1500551; Sulfapyridine (USP/INN); Coccoclase; HMS1921C03; AKOS000121424; Prestwick2_000762; KBio2_006612; Sulphapyridine; 4-(2-Pyridinylsulfonyl)aniline; sulfapyridine; N(sup1)-Pyridylsulfanilamide; HMS2092K05; D02434; IDI1_000216; KBio2_001476; ZINC00002105; Benzenesulfonamide, 4-amino-N-(2-pyridinyl)-; Eubasin; 2-Sulfanilamidopyridine; CAS-144-83-2; Prestwick0_000762	144-83-2	5336	152111	TTDS00237	Dihydropteroate synthetase	DHPS;Dihydropteroate pyrophosphorylase;Dihydropteroate synthase;H2Pte synthase	Q9BIX9	N/A	N/A	inhibitor
DAP001203	Sulfisoxazole	US-67; Prestwick0_000334; Soxazole; 3,4-Dimethyl-5-sulphonamidoisoxazole; AB00052104; Sulfazin (VAN); Sulfafurazolum; BIDD:GT0322; Gantrisin; NCI-C50022; G-sox; Sulfisoxazolum; KBio1_000579; Neoxazol; V-Sul; Sulfisonazole; Vagilia; Sulfagan; IDI1_000579; CHEBI:102484; Bactesulf; Sulphisoxazol; 3,4-dimethylisoaxazole-5-sulfanilimide; KBio2_006640; Sulfapolar; Oprea1_828173; MLS000028495; Entusil; DB00263; Sulphafurazole; Roxosul tablets; 5-Sulphanilamido-3,4-dimethyl-isoxazole; Sulphaisoxazole; 6155-81-3 (mono-lithium salt); Sulfisin; UNII-740T4C525W; 5-Sulfanilamido-3,4-dimethyl-isoxazole; NSC 683536; Solfafurazolo; Azo Gantrisin; SPBio_002288; Astrazolo; 207522-06-3; AKOS000119074; Prestwick2_000334; MLS000037737; CHEMBL453; SPBio_001449; STK400452; Soxisol; Isoxamin; Norilgan-S; AKOS000310021; Barazae; KBio2_001504; Sulfizole; Gantrosan; Sulfisoxasole; Component of Azo Gantrisin Accuzole; NCGC00023116-06; Sulfaisoxazole; Sulsoxin; component of Azo-Sulfizin; Prestwick_726; NCGC00023116-08; HSDB 797; Sulfafuraz ole; DivK1c_000579; HMS1569C09; NCGC00023116-05; Sulfasoxizole; Sulfafurazolum [INN-Latin]; SPECTRUM1500555; Neazolin; KBioSS_001504; NINDS_000579; Suloxsol; Thiasin; KBio2_004072; Alphazole; 3,4-Dimethyl-5-sulphanilamidoisoxazole; Renosulfan; Gantrisona; Sulfafurazol; CPD000037657; KBioGR_000757; D00450; SOXO; Ganda; U.S.-67; Sulfisoxazole [USAN]; NSC38588; Spectrum5_001222; ERYZOLE; NCGC00016384-02; Entusul; Sulfizin; MolPort-000-422-016; Urogan; BSPBio_003376; Sulphofurazole; Spectrum3_001728; Sulphisoxazole; Azosulfizin; Sulfoxol; Sulfisoxazole dialamine; Bio-0765; Soxitabs; LS-713; Soxamide; Sosol; SAM002554929; Sulbio; Soxomide; BRN 0263871; SMR000037657; Dorsulfan; Spectrum_001024; AI3-24003; Sulfadimethylisoxazole; Prestwick3_000334; Sulfisoxazol; Sulfasoxazole; 3,4-Dimethylisoxale-5-sulfanilamide; Tocris-0731; Sulfafurazole; Urisoxin; EINECS 204-858-9; Sodizole; component of Azo Gantrisin; Sulfisoxazole - Carc; J-Sul; NSC33807; Uritrisin; 3,4-Dimethylisoxazole-5-sulfanilamide; Sulfazin; Sulphafuraz; Tl-azole; Amidoxal; Resoxol; CID5344; 3,4-Dimethyl-5-sulfanilamidoisoxazole; HMS501M21; Sulphadimethylisoxazole; sulfisoxazole; Prestwick1_000334; KBio3_002596; 127-69-5; BRD-K50859149-001-05-4; Gantrisine; 2200-44-4 (mono-hydrochloride salt); Stansin; Sulfizol; Sulphafurazol; Accuzole; Pancid; Unisulf; NCGC00016384-01; NCGC00023116-02; WLN: T5NOJ CMSWR DZ& D1 E1; 5-Sulfanilamido-3,4-dimethylisoxazole; NU 445; Sulfisoxazole (JP15/USP); MolPort-004-288-290; HMS2092K13; C07318; S1916_Selleck; SK-Soxazole; NSC13120; Sulfagen; Oprea1_680668; S6377_SIGMA; Saxosozine; Neoxazoi; Koro-sulf; BPBio1_000405; Spectrum4_000349; AC-1941; NCGC00023116-07; BSPBio_000367; BAS 00531889; Gantrisin (TN); Sulfasol; MLS000563718; Sulphafurazolum; NSC683536; Novosaxazole; Roxoxol; CAS-127-69-5; Sulfafurazole (INN); AC1L1K55; Chemouag; 3,4-Dimethyl-5-sulfonamidoisoxazole; UPCMLD00X127-69-5:001; Sulfalar; CCRIS 568; Solfafurazolo [DCIT]; NSC 13120; Spectrum2_001325; Novazolo; Roxosul; Cosoxazole; Dorsulfan warthausen; 3,4-Dimethylisoxazole-5-sulphanilamide; Sulfofurazole	127-69-5	5344	9526	TTDS00237	Dihydropteroate synthetase	DHPS;Dihydropteroate pyrophosphorylase;Dihydropteroate synthase;H2Pte synthase	Q9BIX9	N/A	N/A	inhibitor
DAP001291	NADH	Adenosine 5'-(trihydrogen pyrophosphate), 5'->5'-ester with 1,4-dihydro-1-beta-D-ribofuranosylnicotinamide (8CI); AC1L96RW; CHEBI:57945; CID439153; Reduced nicotinamide-adenine dinucleotide; 58-68-4; CHEBI:16908; [[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2R,3S,4R,5R)-5-(3-carbamoyl-4H-pyridin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate; NAD-reduced; diphosphopyridine nucleotide reduced; 2fsv; nchembio.150-comp50; DB00157; Diphosphopyridine nucleotide, reduced form; N4505_SIGMA; MolPort-003-958-998; nchembio.94-comp28; NChemBio.2007.9-comp15; Adenosine 5'-(trihydrogen diphosphate), P'->5'-ester with 1,4-dihydro-1-beta-D-ribofuranosyl-3-pyridinecarboxamide (9CI); Cozymase I, reduced; NADH+H+; beta-Nicotinamide adenine dinucleotide, reduced dipotassium salt; Nicotinamide adenine dinucleotide, reduced form; nchembio.62-comp9; dihydrodiphosphopyridine nucleotide; CHEMBL1234616; beta-DPNH; nchembio.186-comp5; Coenzyme I, reduced; dihydronicotinamide adenine dinucleotide; beta-NADH; Adenosine pyrophosphate, 5'->5'-ester with 1,4-dihydro-1-beta-D-ribofuranosylnicotinamide (7CI); nchembio.135-comp3; NADH dianion; NADH2; [(2R,3S,4R,5R)-5-(6-Aminopurin-9-yl)-3,4-dihydroxy-oxolan-2-yl]methoxy-[[(2R,3S,4R,5R)-5-(3-carbamoyl-4H-pyridin-1-yl)-3,4-dihydroxy-oxolan-2-yl]methoxy-hydroxy-phosphoryl]oxy-phosphinic acid; DPNH; nicotinamide adenine dinucleotide reduced; nchembio.121-comp31; NADH; adenosine 5'-{3-[1-(3-carbamoyl-1,4-dihydropyridin-1-yl)-1,4-anhydro-D-ribitol-5-yl] diphosphate}; bmse000054; Reduced Nicotinamide Adenine Dinucleotide; Nicotinaminde-Adenine-Dinucleotide; [5-(6-Aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl [[5-(3-carbamoyl-4H-pyridin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] hydrogen phosphate; adenosine 5'-{3-[1-(3-carbamoyl-1,4-dihydropyridin-1-yl)-1,4-anhydro-D-ribitol-5-yl] dihydrogen diphosphate}	606-68-8	439153	3306	TTDS00469	NADH dehydrogenase	MTND;MT-ND;NADH;NADH-ubiquinone oxidoreductase;ND	P03897	4537	ENSG00000198840	binder
DAP000151	Drotrecogin alfa	Drotrecogin alfa (activated); Drotrecogin alfa; Xigris (TN); Xigris; 98530-76-8; Drotrecogin alfa (activated) (USAN); D03918	60202-16-6	121850	47205907	TTDS00204	Coagulation Factor Va	Factor Va	P12259	2153	ENSG00000198734	inhibitor
DAP000166	Lithium	444456_ALDRICH; MolPort-003-927-072; 248827_ALDRICH; UN1415; 62500_FLUKA; 7580-67-8; UN2805; 64975-42-4; Normothymin-E; 159577-72-7; 278327_ALDRICH; Lithium atomic absorption standard solution; LS-88066; Lithium monohydride; Lithium compounds; MolPort-003-926-239; Lithium [UN1415] [Dangerous when wet]; Lithium hydride [UN1414]  [Dangerous when wet]; 3Li; Lithium hydride [UN1414] [Dangerous when wet]; UN1414; 320080_ALDRICH; LITHIUM HYDRIDE; litio; HSDB 549; Hydrure de lithium [French]; 207241_FLUKA; Lithium, elemental; Lithium hydride, fused solid [UN2805] [Dangerous when wet]; CID3028194; 220914_ALDRICH; 266000_ALDRICH; Normothymin-E (TN); LTBB002851; 340421_ALDRICH; D08133; Lithium hydride (LiH); 7439-93-2; Lithium, metallic; 265969_ALDRICH; HSDB 647; Lithium-6Li; 265977_ALDRICH; Lithium [UN1415]  [Dangerous when wet]; CHEBI:30145; D008094; LITHIUM HYDRIDE, 98.6%; HSD690000; AC1MHL68; 265985_ALDRICH; 265993_ALDRICH; HSDB 6900; EINECS 231-102-5; 207241_ALDRICH; 201049_ALDRICH; C15473; LITHIUM; AB1003835; 499811_ALDRICH; EINECS 231-484-3; LS-88055; Lithium hydride, fused solid [UN2805]  [Dangerous when wet]	7439-93-2	28486	11538471	TTDS00136	Glycogen synthase kinase-3	Glycogen synthase kinase 3;GSK-3	N/A	N/A	N/A	inhibitor
DCL001031	Valproate	nchembio.79-comp4; Deproic; Myproic Acid; MLS001076682; Acide valproique [INN-French]; Vupral; KBio2_007413; G2M-777; I04-0211; Novo-Valproic; Acido valproico; Acido valproico [INN-Spanish]; NCGC00091149-01; Valproic acid USP; Di-n-propylacetic acid; Ergenyl; Med Valproic; CID3121; KBioGR_002277; Kyselina 2-propylvalerova [Czech]; MolPort-001-791-895; 2-Propylvaleric acid; Valproate; DB00313; SAM002564230; HSDB 3582; SBB065764; VPA; Acidum valproicum; KBio3_002757; KBio2_003569; Valproinsaeure; Mylproin; Valproic acid USP24; Avugane; Valproic acid (USP); KBio2_002277; 2-n-Propyl-n-valeric acid; Di-n-propylessigsaure [German]; Di-n-propylessigsaure; Valproic acid [USAN:INN:BAN]; NCGC00091149-04; 2 PP (base); MLS001335928; Nu-Valproic; P0823; Propylvaleric acid; Valproic Acid, Sodium Salt (2:1); MLS002415770; BIDD:GT0858; AC1Q2ULA; NINDS_000273; n-Dipropylacetic acid; KBio1_000273; KBioSS_001001; KBioSS_002278; CPD000499581; Convulsofin; Dipropylacetic acid; AI3-10500; Valeric acid, 2-propyl-; Spectrum3_001733; EINECS 202-777-3; KBio2_001001; PMS-Valproic Acid; 4-Heptanecarboxylic acid; Dipropyl Acetate; Di-n-propylessigsaeure; nchembio815-comp21; CHEMBL109; Depakin chrono; 76584-70-8 (hydrochloride salt (2:1)); SPBio_000912; Abbott 44090; Depakin; Pentanoic acid, 2-propyl-; Penta-Valproic; Spectrum_000521; Savicol; KBioGR_000871; NSC93819; 99-66-1; MLS001335927; WLN: QVY3 & 3; P6273_SIGMA; SMR000499581; InChI=1/C8H16O2/c1-3-5-7(6-4-2)8(9)10/h7H,3-6H2,1-2H3,(H,9,10); Alti-Valproic; Convulex; UNII-614OI1Z5WI; Depakine chrono; HMS2089J06; NCGC00091149-02; KBio2_004845; VALPROIC ACID; DivK1c_000273; LS-2068; C07185; NCGC00091149-03; Dom-Valproic; Depakene; D00399; KBio3_002626; Semisodium Valproate; Depakote (TM); Acide valproique; Acidum valproicum [INN-Latin]; Spectrum2_000946; Stavzor; NSC 93819; Depakene (TN); Dipropylacetate; n-DPA; 2-Propylpentanoic acid; Depakine; Kyselina 2-propylvalerova; BRN 1750447; Acetic acid, dipropyl-; AC1L1F7T; Spectrum4_000376; Baceca; LS-161170; NIJJYAXOARWZEE-UHFFFAOYSA-; CHEBI:39867; KBio2_006137	76584-70-8	5310969	150523	TTDS00136	Glycogen synthase kinase-3	Glycogen synthase kinase 3;GSK-3	N/A	N/A	N/A	inhibitor
DCL000147	Lapaquistat acetate	Lapaquistat acetate; 1-((1-(3-Acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl)acetyl)piperidine-4-acetic acid; TAK-475; Lapaquistat acetate (USAN); CHEMBL435224; UNII-IUH3AY74O3; CID 9874248; CID9874248; 189060-13-7; D06609; CHEBI:335143	189060-13-7	9874248	47208260	TTDC00106	Farnesyl-diphosphate farnesyltransferase	FPP:FPP farnesyltransferase;SQS;Squalene synthase;Squalene synthetase;SS	P37268	2222	ENSG00000079459	inhibitor
DCL000193	Pasireotide	N/A	396091-73-9	N/A	10549826	TTDC00112	Somatostatin receptor type 1	Somatostatin receptor 1;SRIF-2;SS1R;Sst(1)	P30872	6751	ENSG00000139874	agonist
DCL000018	CAP-232	CID6918265; TLN-232; AC1OCF7X; CAP-232; (4R,7S,10R,13S,16R)-7-(4-aminobutyl)-N-[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]-16-[[(2R)-2-amino-3-phenylpropanoyl]amino]-13-[(4-hydroxyphenyl)methyl]-10-(1H-indol-3-ylmethyl)-6,9,12,15-tetraoxo-1,2-dithia-5,8,11,14-tetrazacycloheptadecane-4-carboxamide; CHEMBL539934	N/A	6918265	12014851	TTDC00112	Somatostatin receptor type 1	Somatostatin receptor 1;SRIF-2;SS1R;Sst(1)	P30872	6751	ENSG00000139874	agonist
DAP001024	Methyl aminolevulinate	UNII-585NM85KYM; AC1L4IXN; CID157922; Levulinic acid, 5-amino-, methyl ester; Methyl aminolevulinate; D08204; CHEBI:724125; LS-187769; 5-Aminolevulinic acid methyl ester; DB00992; Pentanoic acid, 5-amino-4-oxo-, methyl ester; CHEMBL1096562; NCGC00018251-01; Aminolevulinic acid methyl ester; methyl 5-amino-4-oxopentanoate; LS-187024; 33320-16-0; methyl 5-aminolevulinate; Metvix; methyl delta-aminolevulinate	33320-16-0	157922	791577	TTDS00437	Ferrochelatase	Heme synthetase;Protoheme ferro-lyase	P22830	2235	ENSG00000066926	activator
DAP001434	Tinzaparin	Reviparin; EINECS 232-681-7; HSDB 3094; Heparin sodium 5,000 units in sodium chloride 0.9%; FR 860; 12656-11-0; Eparina; Vetren; Liquaemin Sodium; Sandoparin; cis-Cinnamic acid; Lioton 1000; Hepathrom; Heparin sodium 25,000 units and dextrose 5% in plastic container; Heparin sodium 10,000 units in sodium chloride 0.45%; 91449-79-5; Parnaparin; Heparin sodium 5,000 units and sodium chloride 0.9% in plastic container; NSC174025; 2-Propenoic acid, 3-phenyl-, (Z)-; Fragmin IV; Heparin sodium; Allocinnamic acid; Heparin sodium 5,000 units in sodium chloride 0.9% in plastic container; Heparin sodium preservative Free; Nadroparin; Clivarin; OP 386; alpha-Heparin; Heparin CY 216; Heparinate; Heparinic acid; Clivarine; Tinzaparin; Heparin sodium 20,000 units and dextrose 5% in plastic container; Ro 11; Fraxiparin; Heparinum natricum; 104521-37-1; Subeparin; 9045-22-1; ALFA 87-163; 11078-24-3; 9041-08-1; Heparin sodium 10,000 units in dextrose 5% in plastic container; Heparin sulfate; Bemiparin; Ardeparin; Heparin sodium 1,000 units in dextrose 5% in plastic container; Heparina; KB 101; 9075-96-1; Heparin sodium 12,500 units in sodium chloride 0.9%; Liquaemin; Liquaemin Lock Flush; Eparina [DCIT]; Heparin sodium 25,000 units in dextrose 5%; Sublingula; Fragmin A; Heparin sodium 12,500 units in dextrose 5%; Heparine [INN-French]; UNII-3S182ET3UA; Heparinum; Fragmin B; Novoheparin; Triofiban; Hepflush-10; Reviparin sodium; Cy 222; WY 90493RD; Liquaemin sodium preservative free; UNII-ZZ45AB24CA; Heparin, sodium salt; Liquemin; Heparin Lock Flush preservative free; Heparin sodium 12,500 units in dextrose 5% in plastic container; Heparin sodium 5,000 units in sodium chloride 0.45%; Isocinnamic acid; 37324-73-5; Heparin sodium in plastic container; 101921-26-0; Vitrum AB; ALFA 87-120; ALFA 88-247; Tinzaparin sodium; AC1L1ROY; Heparin sodium 2,000 units in dextrose 5% in plastic container; Parvoparin; Heparin sodium 10,000 units in dextrose 5%; Minolteparin sodium; Nadroparine; Logiparin; Heparin sodium 1,000 units in sodium chloride 0.9% in plastic container; MolPort-003-760-257; Heparin sodium 1,000 units and sodium chloride 0.9% in plastic container; LHN 1; 913079-23-9; Heparin sodium 5,000 units in dextrose 5% in plastic container; Heparin sodium 10,000 units in sodium chloride 0.9%; Thromboliquine; Cinnamic acid, (Z)-; cis-.beta.-Carboxystyrene; Kabi 2165; heparin; Heparin Lock Flush; Sodium acid heparin; Depo-Heparin; Sodium heparinate; Hep-Lock; Certoparin; Heparina [INN-Spanish]; OP 622; Heparin natrium; Hed-heparin; Ardeparin sodium; Multiparin; 102785-31-9; Pabyrin; Parnaparin sodium; Dalteparin; Heparin sodium 12,500 units in sodium chloride 0.45% in plastic container; Panheprin; Heparin Lock Flush in plastic container; Heparin sodium 25,000 units in sodium chloride 0.9% in plastic container; Octaparin; 11129-39-8; UNII-E47C0NF7LV; Heparin sodium 25,000 units in sodium chloride 0.45% in plastic container; CID8784; Inno-Hep; Dalteparin sodium; Heparin sodium 25,000 units in dextrose 5% in plastic container; Heparin sodium 2,000 units in sodium chloride 0.9% in plastic container; 102-94-3; Bemiparin sodium; Heparin sodium 25,000 units in sodium chloride 0.9%; Heparinum [INN-Latin]; ALFA 87-198; ALFA 87-81; CY 216; Pularin; Fluxum; UNII-12M44VTJ7B; Heparin sodium 20,000 units in dextrose 5% in plastic container; Heparine; Heparin Lock Flush preservative free in plastic container; Sodium heparin; H 2149; Innohep; UNII-T2410KM04A; Hep-Lock U/P; Lipo-hepin; Arteven; Heparin sodium 2,000 units and sodium chloride 0.9% in plastic container; Hep Flush Kit in plastic container; Enoxaparin sodium	9005-49-6	25244225	2789	TTDS00467	Antithrombin-III	AT3;ATIII;SERPINC1	P01008	462	ENSG00000117601	cofactor
DAP000189	Heparin	Heparin sodium 5,000 units in sodium chloride 0.45%; Isocinnamic acid; Reviparin; EINECS 232-681-7; 37324-73-5; HSDB 3094; Heparin sodium in plastic container; 101921-26-0; Heparin sodium 5,000 units in sodium chloride 0.9%; FR 860; 12656-11-0; Vitrum AB; Eparina; Vetren; ALFA 87-120; Liquaemin Sodium; ALFA 88-247; Sandoparin; cis-Cinnamic acid; Tinzaparin sodium; AC1L1ROY; Lioton 1000; Heparin sodium 2,000 units in dextrose 5% in plastic container; Parvoparin; Hepathrom; Heparin sodium 25,000 units and dextrose 5% in plastic container; Heparin sodium 10,000 units in sodium chloride 0.45%; 91449-79-5; Parnaparin; Heparin sodium 5,000 units and sodium chloride 0.9% in plastic container; NSC174025; 2-Propenoic acid, 3-phenyl-, (Z)-; Heparin sodium 10,000 units in dextrose 5%; Minolteparin sodium; Fragmin IV; Heparin sodium; Nadroparine; Logiparin; Heparin sodium 1,000 units in sodium chloride 0.9% in plastic container; Allocinnamic acid; MolPort-003-760-257; Heparin sodium 5,000 units in sodium chloride 0.9% in plastic container; Heparin sodium 1,000 units and sodium chloride 0.9% in plastic container; LHN 1; 913079-23-9; Heparin sodium 5,000 units in dextrose 5% in plastic container; Heparin sodium preservative Free; Nadroparin; Clivarin; OP 386; alpha-Heparin; Heparin sodium 10,000 units in sodium chloride 0.9%; Heparin CY 216; Thromboliquine; Cinnamic acid, (Z)-; Heparinate; cis-.beta.-Carboxystyrene; Heparinic acid; Kabi 2165; heparin; Heparin Lock Flush; Sodium acid heparin; Clivarine; Tinzaparin; Heparin sodium 20,000 units and dextrose 5% in plastic container; Depo-Heparin; Sodium heparinate; Ro 11; Fraxiparin; Hep-Lock; Certoparin; Heparina [INN-Spanish]; OP 622; Heparin natrium; Heparinum natricum; 104521-37-1; Subeparin; 9045-22-1; Hed-heparin; Ardeparin sodium; Multiparin; ALFA 87-163; 102785-31-9; 11078-24-3; 9041-08-1; Pabyrin; Heparin sodium 10,000 units in dextrose 5% in plastic container; Parnaparin sodium; Dalteparin; Heparin sulfate; Heparin sodium 12,500 units in sodium chloride 0.45% in plastic container; Panheprin; Bemiparin; Heparin Lock Flush in plastic container; Heparin sodium 25,000 units in sodium chloride 0.9% in plastic container; Ardeparin; Heparin sodium 1,000 units in dextrose 5% in plastic container; Heparina; KB 101; Octaparin; 9075-96-1; Heparin sodium 12,500 units in sodium chloride 0.9%; Liquaemin; Liquaemin Lock Flush; 11129-39-8; UNII-E47C0NF7LV; Heparin sodium 25,000 units in sodium chloride 0.45% in plastic container; CID8784; Eparina [DCIT]; Inno-Hep; Dalteparin sodium; Heparin sodium 25,000 units in dextrose 5% in plastic container; Heparin sodium 2,000 units in sodium chloride 0.9% in plastic container; 102-94-3; Heparin sodium 25,000 units in dextrose 5%; Bemiparin sodium; Heparin sodium 25,000 units in sodium chloride 0.9%; Heparinum [INN-Latin]; ALFA 87-198; Sublingula; ALFA 87-81; CY 216; Pularin; Fragmin A; Heparin sodium 12,500 units in dextrose 5%; Fluxum; Heparine [INN-French]; UNII-3S182ET3UA; UNII-12M44VTJ7B; Heparinum; Heparin sodium 20,000 units in dextrose 5% in plastic container; Fragmin B; Heparine; Heparin Lock Flush preservative free in plastic container; Sodium heparin; Novoheparin; Triofiban; H 2149; Innohep; UNII-T2410KM04A; Hepflush-10; Reviparin sodium; Hep-Lock U/P; Cy 222; Lipo-hepin; Arteven; WY 90493RD; Heparin sodium 2,000 units and sodium chloride 0.9% in plastic container; Hep Flush Kit in plastic container; Enoxaparin sodium; Liquaemin sodium preservative free; UNII-ZZ45AB24CA; Heparin, sodium salt; Liquemin; Heparin Lock Flush preservative free; Heparin sodium 12,500 units in dextrose 5% in plastic container	9005-49-6	772	2789	TTDS00467	Antithrombin-III	AT3;ATIII;SERPINC1	P01008	462	ENSG00000117601	cofactor
DAP000866	Sulodexide	N/A	57821-29-1	123047	46477239	TTDS00467	Antithrombin-III	AT3;ATIII;SERPINC1	P01008	462	ENSG00000117601	activator
DCL000756	CNTF	N/A	444069-80-1	N/A	17397746	TTDC00257	Ciliary neurotrophic factor receptor alpha	CNTFR alpha	P26992	1271	ENSG00000122756	agonist
DCL000921	PegCNTF	N/A	117796-52-8	60680	43118039	TTDC00257	Ciliary neurotrophic factor receptor alpha	CNTFR alpha	P26992	1271	ENSG00000122756	agonist
DCL001146	Anti-LT alpha	N/A	N/A	N/A	N/A	TTDC00327	Lymphotoxin alpha	Lymphotoxin-alpha;LT-alpha;TNF-beta;Tumor necrosis factor ligand superfamily member 1	P01374	4049	ENSG00000230279; ENSG00000226979; ENSG00000231408	antibody
DCL000810	Gabapentin ER	N/A	60142-96-3	3446	48416046	TTDC00240	Voltage-dependent calcium channel subunit alpha-2/delta-2	Voltage-dependent calcium channel subunit alpha-2-2;Voltage-dependent calcium channel subunit delta-2;Voltage-gated calcium channel subunit alpha-2/delta-2	Q9NY47	9254	ENSG00000007402	blocker
DAP000489	Famciclovir	1,3-Propanediol, 2-(2-(2-amino-9H-purin-9-yl)ethyl)-, diacetate (ester); CPD000466375; Bio-0039; KBio3_002709; C14H19N5O4; Spectrum5_001548; Famciclovir [USAN:BAN:INN]; I03-0096; 2-[(acetyloxy)methyl]-4-(2-amino-9H-purin-9-yl)butyl acetate; SPBio_001202; UNII-QIC03ANI02; 104227-87-4; ZINC01530635; CHEMBL880; 2-(2-(2-Amino-9H-purin-9-yl)ethyl)-1,3-propanediol diacetate (ester); KBioSS_000946; KBioGR_001162; SMR000466375; HMS1922L09; KBio2_006082; Diacetyl 6-deoxy-9-(4-hydroxy-3-hydroxymethyl-but-1-yl)guanine; BSPBio_003489; HMS2093K12; Famciclovirum [INN-Latin]; 2-(acetoxymethyl)-4-(2-amino-4,5-dihydro-9H-purin-9-yl)butyl acetate; STK623204; Spectrum_000466; MLS001424115; HMS2090G10; Famciclovir (JAN/USAN/INN); 2-(2-(2-amino-9H-purin-9-yl)ethyl)-1,3-propanediol diacetate; BRD-K45033733-001-02-3; HMS2051G22; Famciclovirum; famciclovir; LS-120147; SAM001246732; CID3324; Famvir (TN); 9-[4-acetoxy-3-(acetoxymethyl)but-1-yl]-2-aminopurine; D00317; SPECTRUM1505201; BRL-42810; IN1338; 2-[2-(2-amino-9H-purin-9-yl)ethyl]-1,3-propanediol diacetate; FCV; 9-(4-acetoxy-3-(acetoxymethyl)but-1-yl)-2-aminopurine; S2467_Selleck; BRL 42810; Spectrum3_001675; Famvir; DB00426; KBio2_000946; NCGC00095133-01; KBio2_003514; AC-11064; Spectrum4_000611; NCGC00095133-03; Anti-Farnesyl Rabbit pAb; MolPort-003-666-602; NCGC00095133-02; Spectrum2_001101; [2-(acetyloxymethyl)-4-(2-aminopurin-9-yl)butyl] acetate; MLS000759505; AC1L1FOB; CHEBI:4974; Oravir	104227-87-4	3324	196284	TTDS00316	DNA polymerase (HSV-2)	DNA polymerase;Herpes simplex virus type 2 DNA polymerase	P07918	N/A	N/A	inhibitor
DCL001182	EZN-2968	N/A	N/A	N/A	N/A	TTDR01423	mRNA of HIF2-alpha	N/A	Q99814	2034	ENSG00000116016	antisense
DCL000636	SAR164877	N/A	N/A	N/A	N/A	TTDC00189	Tumor necrosis factor receptor superfamily member 16	75kD-neurotrophin receptor;Gp80-LNGFR;Low affinity neurotrophin receptor p75NTR;Low-affinity nerve growth factor receptor;NGF receptor;NGF-P75 receptor;P75 ICD;P75 neurotrophin receptor (p75(NTR));P75NTR	P08138	4804	ENSG00000064300	antagonist
DCL000598	PF-4383119	N/A	N/A	N/A	N/A	TTDC00189	Tumor necrosis factor receptor superfamily member 16	75kD-neurotrophin receptor;Gp80-LNGFR;Low affinity neurotrophin receptor p75NTR;Low-affinity nerve growth factor receptor;NGF receptor;NGF-P75 receptor;P75 ICD;P75 neurotrophin receptor (p75(NTR));P75NTR	P08138	4804	ENSG00000064300	antagonist
DCL000618	R7334	86311-67-3; CID55489; CHEMBL7261; R 7334; 2-Nitro-6,7,8,9-tetrahydronaphtho(1,2-b)furan; 2-nitro-6,7,8,9-tetrahydrobenzo[g][1]benzofuran; BRN 5040167; NAPHTHO(1,2-b)FURAN, 6,7,8,9-TETRAHYDRO-2-NITRO-; LS-95336; 6,7,8,9-Tetrahydro-2-nitronaphtho(1,2-b)furan; AC1L1J6Y	86311-67-3	55489	192924	TTDC00176	Placenta growth factor	PlGF-131	P49763	5228	ENSG00000119630	antibody
DCL001074	P276-00	N/A	N/A	N/A	N/A	TTDC00095	Cell division protein kinase 9	C-2K;CDC2-related kinase;Cyclin-dependent kinase 9;Cyclin-dependent protein kinase Cdk9;Serine/threonine-protein kinase PITALRE;Similar to cyclin-dependent kinase 9	P50750	1025	ENSG00000136807	inhibitor
DCL000007	SNS-032	CID3025986; S1145_Selleck; BMS-387032; Kinome_3820; AC-5242; I09-1579; CID6918586; LS-186036; BMS-387032, SNS-032; N-(5-(((5-(1,1-Dimethylethyl)-2-oxazolyl)methyl)thio)-2-thiazolyl)-4-piperidinecarboxamide; SNS-032; N-[5-[(5-tert-butyl-1,3-oxazol-2-yl)methylsulfanyl]-1,3-thiazol-2-yl]piperidine-4-carboxamide; (2R,3R)-2,3-dihydroxybutanedioic acid; MolPort-005-942-660; 345627-80-7; N-[5-[(5-tert-butyl-1,3-oxazol-2-yl)methylsulfanyl]-1,3-thiazol-2-yl]piperidine-4-carboxamide; AC1OCFM7; AC1MHGD4; CHEMBL296468; N-[5-[[[5-(1,1-Dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4-piperidinecarboxamide L-tartaric acid salt (2:1); 4-Piperidinecarboxamide, N-(5-(((5-(1,1-dimethylethyl)-2-oxazolyl)methyl)thio)-2-thiazolyl)-; BMS-387072	N/A	6918586	12015560	TTDC00095	Cell division protein kinase 9	C-2K;CDC2-related kinase;Cyclin-dependent kinase 9;Cyclin-dependent protein kinase Cdk9;Serine/threonine-protein kinase PITALRE;Similar to cyclin-dependent kinase 9	P50750	1025	ENSG00000136807	inhibitor
DCL001084	ZK 304709	N/A	N/A	N/A	N/A	TTDC00095	Cell division protein kinase 9	C-2K;CDC2-related kinase;Cyclin-dependent kinase 9;Cyclin-dependent protein kinase Cdk9;Serine/threonine-protein kinase PITALRE;Similar to cyclin-dependent kinase 9	P50750	1025	ENSG00000136807	inhibitor
DCL001081	SCH 727965	Dinaciclib; SCH-727965	N/A	N/A	N/A	TTDC00095	Cell division protein kinase 9	C-2K;CDC2-related kinase;Cyclin-dependent kinase 9;Cyclin-dependent protein kinase Cdk9;Serine/threonine-protein kinase PITALRE;Similar to cyclin-dependent kinase 9	P50750	1025	ENSG00000136807	inhibitor
DCL001143	Anti-Factor D	N/A	N/A	N/A	N/A	TTDC00326	Complement factor D	Adipsin;C3 convertase activator;Properdin factor D	P00746	1675	ENSG00000197766	antibody
DCL000838	Ibudilast	EU-0100599; I 0157; NCGC00025261-03; 1-Propanone, 2-methyl-1-(2-(1-methylethyl)pyrazolo(1,5-a)pyridin-3-yl)-; 2-Isopropyl-3-isobutyrylpyrazolo(1,5-a)pyridine; Bio-0127; Ibudilast (JAN/INN); Eyevinal; 1-(2-Isopropylpyrazolo(1,5-a)pyridin-3-yl)-2-methyl-1-propanone; CID3671; Ke Tas; CHEBI:123745; C038366; 2-methyl-1-(2-propan-2-ylpyrazolo[1,5-a]pyridin-3-yl)propan-1-one; I0157_SIGMA; NCGC00025261-02; AV-411; I0740; KC-404; NCGC00025261-01; KC 404; SMR000326961; Ibudilastum; Tocris-1694; 2-Methyl-1-[2-(1-methylethyl)pyrazolo[1,5-a]pyridin-3-yl] 1-propanone; DB05266; Ketas (TN); MN-166; 50847-11-5; NCGC00015542-06; Ibudilast [INN:JAN]; Lopac-I-0157; I06-0361; AC-1044; AV 411; Ibudilastum [Latin]; BRN 0656579; CHEMBL19449; ZINC00004234; ibudilast; D01385; Pyrazolo(1,5-a)pyridine, 3-isobutyryl-2-isopropyl-; NCGC00015542-03; 3-Isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine; BRD-K16444452-001-03-4; LS-129153; Lopac0_000599; UNII-M0TTH61XC5; 3-Isobutyryl-2-isopropylpyrazolo(1,5-a)pyridine; AC1L1GGB; L003042; Ketas; MolPort-003-848-127; 5-24-03-00396 (Beilstein Handbook Reference); HMS2089B21; NCGC00015542-01; MLS000862198	50847-11-5	3671	46500478	TTDC00080	Interleukin-6	B-cell stimulatory factor 2;BSF-2;CDF;CTL differentiation factor;Hybridoma growth factor;IL-6;Interferon beta-2	P05231	3569	ENSG00000136244	inhibitor
DCL000076	C326	N/A	N/A	N/A	N/A	TTDC00080	Interleukin-6	B-cell stimulatory factor 2;BSF-2;CDF;CTL differentiation factor;Hybridoma growth factor;IL-6;Interferon beta-2	P05231	3569	ENSG00000136244	inhibitor
DCL001048	TPI ASM8	N/A	N/A	N/A	N/A	TTDC00278	mRNA of Inflammatory cytokines	N/A	N/A	N/A	N/A	antisense
DCL001252	Vidofludimus	N/A	N/A	N/A	N/A	TTDS00059	Dihydroorotate dehydrogenase, mitochondrial	DHOD;DHODase;DHOdehase;DHODH;Dihydroorotate dehydrogenase ;Dihydroorotate oxidase;Mitochondrially bound dihydroorotate-ubiqui oxidoreductase	Q12610	N/A	N/A	inhibitor
DAP000636	Leflunomide	BPBio1_000930; AP-501/42475599; NCGC00022625-07; Prestwick3_000772; Lefunomide [Inn-Spanish]; CHEMBL960; 5-methyl-N-[4-(trifluoromethyl)phenyl]-4-isoxazolecarboxamide; SU 101 (pharmaceutical); NCGC00015610-02; CAS-75706-12-6; Isoxazole-4-carboxamide, 5-methyl-N-[4-(trifluoromethyl)phenyl]-; 5-methyl-N-[4-(trifluoromethyl)phenyl]-1,2-oxazole-4-carboxamide; Aventis Behring Brand of Leflunomide; SU101; 4-Isoxazolecarboxamide, 5-methyl-N-(4-(trifluoromethyl)phenyl)-; 5-Methylisoxazole-4-(4-trifluoromethyl)carboxanilide; HWA 486; Spectrum_000322; CID3899; AC-6796; DB01097; KBio1_000916; Leflunomide (JAN/USAN/INN); lefunamide; 210165-51-8; 5-methyl-N-[4-(trifluoromethyl)phenyl]isoxazole-4-carboxamide; NCGC00022625-06; Aventis Brand of Leflunomide; CHEBI:6402; NSC677411; Leflunomide [USAN:INN]; SPBio_002783; S1247_Selleck; NCGC00015610-03; 5-Methylisoxazole-4-carboxylic acid (4-trifluoromethyl)anilide; C045463; BIDD:PXR0189; 5-Methyl-N-(4-(trifluoromethyl)phenyl)-4-isoxazolecarboxamide; Lopac-L-5025; AC1Q2EVA; L 5025; 75706-12-6; HSDB 7289; Arava (TN); EU-0100649; D00749; KBioSS_000802; RS-34821; NCGC00015610-07; alpha,alpha,alpha-Trifluoro-5-methyl-4-isoxazolecarboxy-p-toluidide; MLS001076267; Spectrum5_000850; Prestwick0_000772; DivK1c_000916; N-(4'-Trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide; BSPBio_000844; Hoechst Brand of Leflunomide; C07905; KBio2_005938; N-(4-trifluoromethyphenyl)-5-methylisoxazole-4-carboxamide; 5-Methylisoxazole-4-(4-trifluoromethylcarboxanilide); MLS000069648; Leflunomidum; HMS1922M06; TL8005179; KBio2_003370; NCGC00015610-12; Prestwick_87; NCGC00015610-01; NCGC00022625-05; AC1L1GYK; UNII-G162GK9U4W; leflunomide; Arava, Leflunomide; HMS1570K06; LS-86580; Prestwick1_000772; Prestwick2_000772; HMS502N18; Lopac0_000649; 4-isoxazolecarboxamide,5-methyl-N-(4-(trifluoromethyl)phenyl); SU 101; SMR000058209; MLS-0003109.0001; SU-101; BRD-K78692225-001-03-9; AKOS000265193; NCGC00022625-03; HMS2090O12; Leflunomida; NCGC00022625-08; NINDS_000916; Arava; Leflunomida [INN-Spanish]; MolPort-002-345-613; NCGC00022625-04; I06-2131; Leflunomidum [INN-Latin]; AB00052389; IDI1_000916; Aventis Pharma Brand of Leflunomide; Leflunomid; ZINC00004840; 4-Isoxazolecarboxamide, 5-methyl-N-(4-(trifluoromethyl)phenyl; L5025_SIGMA; HWA-486; SPECTRUM1503927; A77 1486; KBio2_000802	75706-12-6	3899	191162	TTDS00059	Dihydroorotate dehydrogenase, mitochondrial	DHOD;DHODase;DHOdehase;DHODH;Dihydroorotate dehydrogenase ;Dihydroorotate oxidase;Mitochondrially bound dihydroorotate-ubiqui oxidoreductase	Q12610	N/A	N/A	inhibitor
DCL000272	Brequinar sodium	96201-88-6; NCI60_003391; DB03523; Dup-785; C23H15F2NO2; CID57030; UNII-49EEF6HRUS; Neuro_000208; Brequinar [INN]; Brequinar; 96201-88-6 (hydrochloride salt); NSC368390; Brequiner; CHEMBL38434; BRF; brequinar potassium; 4-Quinolinecarboxylic acid, 6-fluoro-2-(2'-fluoro(1,1'-biphenyl)-4-yl)-3-methyl-; LS-178286; 6-Fluoro-2-(2'-fluoro-[1,1'-biphenyl]-4-yl)-3-methyl-4-quinolinecarboxylic acid, (*Sodium sal*); 4-Quinolinecarboxylic acid, 6-fluoro-2-(2'-fluoro- [1,1'-biphenyl]-4-yl)-3-methyl-, sodium salt; 96187-53-0 (Parent); 6-FLUORO-2-(2'-FLUORO-1,1'-BIPHENYL-4-YL)-3-METHYLQUINOLINE-4-CARBOXYLIC ACID; Brequinar sodium (USAN); UNII-5XL19F49H6; Brequinar sodium salt; CID57029; Biphenquinate; CHEBI:174555; BREQUINAR SODIUM; 6-fluoro-2-[4-(2-fluorophenyl)phenyl]-3-methylquinoline-4-carboxylic acid; Dup 785; 96187-53-0; 4-Quinolinecarboxylic acid, 6-fluoro-2-(2'-fluoro[1,1'-biphenyl]-4-yl)-3-methyl-; 4-Quinolinecarboxylic acid, 6-fluoro-2-(2'-fluoro(1,1'-biphenyl)-4-yl)-3-methyl-, sodium salt; NSC 368390; brequinarum; Brequinarum [INN-Latin]; brequinarum [Latin]; D03154; AC1L1M61; 6-fluoro-2-(2'-fluoro-1,1'-biphenyl-4-yl)-3-methyl-4-quinolinecarboxylic acid; NSC-368390; CHEMBL300058	96201-88-6	23663964	17397308	TTDS00059	Dihydroorotate dehydrogenase, mitochondrial	DHOD;DHODase;DHOdehase;DHODH;Dihydroorotate dehydrogenase ;Dihydroorotate oxidase;Mitochondrially bound dihydroorotate-ubiqui oxidoreductase	Q12610	N/A	N/A	inhibitor
DCL000314	Teriflunomide	CHEMBL973; HMR-1726; (2Z)-2-[hydroxy-[4-(trifluoromethyl)anilino]methylidene]-3-oxobutanenitrile; 108605-62-5; (Z)-2-Cyano-alpha'alpha'alpha-trifluoro-3-hydroxy-p-crotonotoluidide; Teriflunomide; A 771726; 2-Butenamide, 2-cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-; 2-Butenamide, 2-cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)-; 2-Cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)-2-butenamide; Active metabolite of leflunomide; UNII-1C058IKG3B; Flucyamide; LS-46899; AC1NUIOH; RS 61980; A77 1726; RS-61980; A771726; 2-hydroxyethylidene-cyanoacetic acid-4-trifluoromethyl anilide; MolPort-005-943-824; HMR 1726; A-771726; N-(4-Trifluoromethylphenyl)-2-cyano-2-hydroxycrotonamide; Teriflunomide [INN]; CID5479847; SU-0020; SU 20	163451-81-8	5479847	12014666	TTDS00059	Dihydroorotate dehydrogenase, mitochondrial	DHOD;DHODase;DHOdehase;DHODH;Dihydroorotate dehydrogenase ;Dihydroorotate oxidase;Mitochondrially bound dihydroorotate-ubiqui oxidoreductase	Q12610	N/A	N/A	inhibitor
DAP001454	Artemisinin	KBio2_006967; KBioSS_001831; A0854/0040033; CHEMBL77; AKOS004119830; (#43;)-Artemisinin; NCGC00161634-03; HMS1569D17; Ambap63968-64-9; Qing Hau SU; 3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin-10(3H)-one, octahydro-3,6,9-trimethyl-; Spectrum4_000721; (3R,5aS,6R,8aS,9R,12S,12aR)-Octahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano(4,3-j)-1,2-benzodioxepin-10(3H)-one; 63968-64-9; ST056292; DivK1c_000656; CID641602; AC1L9Q59; AC1LD383; MLS001304036; TL8004521; NCGC00161634-02; Artemisinine [French]; CID9838675; HMS1607A03; (+)-Arteannuin; SPBio_001583; MLS001097650; LMPR0103190003; C09538; Prestwick1_000498; Spectrum_001351; KBioGR_000982; MolPort-002-493-751; MolPort-002-692-529; NSC 369397; KBio2_004399; SMR000578089; Prestwick2_000498; AC1L2AIV; AC1Q6O1J; 2AB44F63-5D0F-424A-AA3F-24062F9C1CED; NSC369397; CID5458876; Quing Hau Sau; Spectrum2_001512; AR-1E9905; BSPBio_000395; Artemisininum [Latin]; 1,5,9-trimethyl-(1R,4S,5R,9R,12S,13R)-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-one; Artemisinina; AC1Q6O6P; BPBio1_000435; HMS502A18; ZINC08143788; CHEMBL345083; CID452191; C15H22O5; Artesin; LS-64242; IDI1_000656; MLS002153846; BRN 4194670; Arteannuin; Qinghaosu; 3,6,9-trimethyloctahydro-3,12-epoxy[1,2]dioxepino[4,3-i]isochromen-10(3H)-one; Spectrum3_001549; Qinghaosu [Chinese]; CID2240; 3,12-Epoxy-12H-pyranol(4,3-j)-1,2-benzodioxepin-10(3H)-one, octahydro-3,6,9-trimethyl-, (3-alpha,5a-beta,6-beta,8a-beta,9-alpha,12-beta,12aR*)-(+)-; AC1L1D8I; GNF-PF-5671; KBio1_000656; (+)-Artemisinin; Prestwick0_000498; Artemisinin [INN]; 3,12-Epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin-10(3H)-one, octahydro-3,6,9-trimethyl-, (3R,5aS,6R,8aS,9R,12S,12aR)-; artemisinin; BB_NC-0820; SPECTRUM1503042; CPD-7561; InChI=1/C15H22O5/c1-8-4-5-11-9(2)12(16)17-13-15(11)10(8)6-7-14(3,18-13)19-20-15/h8-11,13H,4-7H2,1-3H; NINDS_000656; Qing Hau Sau; UPCMLD-DP074:001; (5aS,6R,8aS,9R,12S,12aR)-3,6,9-trimethyloctahydro-3,12-epoxy[1,2]dioxepino[4,3-i]isochromen-10(3H)-one; Qinghosu; SPBio_002316; nchembio806-comp6; Coartem, Artemisinin; Qing Hau Sau [Chinese]; SMR000554414; Spectrum5_001098; MLS001195096; SDCCGMLS-0066721.P001; CHEBI:223316; Huanghuahaosu; I06-0006; nchembio.215-comp2; 91487-93-3; HMS2090I17; CHEBI:106677; CID68827; Artemisininum; Artemisia annua L., extract; S1282_Selleck; NCGC00161634-01; quinghaosu; 361593_ALDRICH; Artemisinina [Spanish]; FT-0082854; UNII-9RMU91N5K2; KBio3_002498; NCGC00142461-01; nchembio875-comp2; Artemisine; Prestwick3_000498; HMS1923O03; D02481; UPCMLD-DP074; (3R,5aS,6R,8aS,9R,12S,12aR)-3,6,9-trimethyloctahydro-3,12-epoxypyrano[4,3-j][1,2]benzodioxepin-10(3H)-one; nchembio.87-comp18; Octahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano(4,3-j)-1,2-benzodioxepin-10(3H)-one; Prestwick_818; Artemisinin (INN); AKOS001483011; AC-2064; BSPBio_002998; GNF-Pf-5341; NCGC00160207-01; 361593_SIGMA; KBio2_001831; Artemisinine	63968-64-9	148184	49720288	TTDS00059	Dihydroorotate dehydrogenase, mitochondrial	DHOD;DHODase;DHOdehase;DHODH;Dihydroorotate dehydrogenase ;Dihydroorotate oxidase;Mitochondrially bound dihydroorotate-ubiqui oxidoreductase	Q12610	N/A	N/A	inhibitor
DAP000156	Atovaquone	AB00513855; Spectrum2_001665; STK636160; Prestwick1_000534; NCGC00016961-02; DivK1c_006782; SPBio_002468; 566C80, hydroxynaphthoquinone; pron; CRL-8131 & Atovaquone; BW 556C-80; Compound 566; ATOVAQUONE; Wellvone; Malarone Pediatric; 1,4-Naphthalenedione, 2-(trans-4-(4-chlorophenyl)cyclohexyl)-3-hydroxy-; 2-[trans-4-(p-Chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthoquinone; KBio2_002223; Atovaquone & Interleukin 12; atovaquone GlaxoSmithKline brand; C06835; AC1L2MZG; 2-[trans-4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthoquinone; Spectrum4_001117; D00236; BSPBio_000547; Mepron (antipneumocystic); HMS1569L09; BW 566C80; BPBio1_000603; KBio2_007359; GlaxoSmithKline brand of atovaquone; 94015-53-9; SPECTRUM1504210; C22H19ClO3; HSDB 7083; SMR001233220; Bio-0115; Atovaquone (USP/INN); 1,4-Naphthalenedione, 2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-, trans-; SpecPlus_000686; Mepron (TN); MLS002153863; 2-(4-(4'-chlorophenyl)cyclohexyl)-3-hydroxy-1,4-naphthoquinone; I06-0872; 566C80; 3-(4-(4-chlorophenyl)cyclohexyl)-4-hydroxy-naphthalene-1,2-dione; D053626; BW 566C; Mepron; KBio2_004791; Glaxo Wellcome brand of atovaquone; 1,4-Naphthalenedione, 2-(4-(4-chlorophenyl)cyclohexyl)-3-hydroxy-, trans-; BW-A 566C; 2-(trans-4-(4-chlorophenyl)cyclohexyl)-3-hydroxy-1,4-naphthoquinone; CHEMBL1450; Spectrum5_001382; Prestwick0_000534; SPBio_001849; BIDD:GT0849; 566C80 hydroxynaphthoquinone; Prestwick2_000534; KBioSS_002223; HMS1922F19; Spectrum_001743; 2-[trans-4-(4-chlorophenyl)cyclohexyl]-3-hydroxynaphthalene-1,4-dione; BW 566C-80; 566C; HMS2093C10; HMS2089M14; 1,4-Naphthalenedione, 2-(4-(4-chlorophenyl)cyclohexyl)-3-hydroxy-; Prestwick3_000534; CHEBI:478315; CAS-95233-18-4; NCGC00095113-02; 2-(trans-4-(p-Chlorophenyl)cyclohexyl)-3-hydroxy-1,4-naphthoquinone; AC1Q6E9K; AC-15237; MolPort-003-666-542; NCGC00016961-01; NCGC00095113-01; BSPBio_002681; hydroxynaphthoquinone 566C80; 95233-18-4; FT-0081084; Atovaquone [USAN:BAN:INN]; DB01117; LS-178256; KBio3_001901; CID74989; KBio1_001726; Atavaquone; 1,4-Naphthalenedione, 2-[trans-4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-; AR-1H7607; MolPort-003-844-665; 1,4-naphthalenedione,2-(trans-4-(4-chlorophenyl)cyclohexyl)-3-hydroxy-; DRG-0084; CHEBI:575568; 2-(4-(4-Chlorophenyl)cyclohexyl)-3-hydroxy-1,4-naphthoquinone; KBioGR_001594; Spectrum3_000991; ATO & IL-12; 3-[4-(4-chlorophenyl)cyclohexyl]-4-hydroxynaphthalene-1,2-dione; hydroxynaphthoquinone, 566C80; Acuvel; MolPort-006-666-289	95233-18-4	74989	9053	TTDS00059	Dihydroorotate dehydrogenase, mitochondrial	DHOD;DHODase;DHOdehase;DHODH;Dihydroorotate dehydrogenase ;Dihydroorotate oxidase;Mitochondrially bound dihydroorotate-ubiqui oxidoreductase	Q12610	N/A	N/A	inhibitor
DPR000045	FK778	FK778; HMR-1715; 2-Hepten-6-ynamide, 2-cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)-, (Z)-; MNA-715; C115284; FK 778; malononitrilamide-715; Malononitrilamide 715; AC1OCF7L; FK-778; 2-Hepten-6-ynamide, 2-cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)-; MNA 715; 152418-67-2; 2-cyano-3-hydroxy-N-(4--(trifluoromethyl)phenyl)-2-hepten-6-ynoic acid; MNA-X 920715; 202057-76-9; X-920715; Manitimus; 185915-33-7; CID6918253; 2-cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)-2-hepten-6-ynamide; (2Z)-2-[hydroxy-[4-(trifluoromethyl)anilino]methylidene]-3-oxohept-6-ynenitrile; X 920715; HMR 1715	152418-67-2	4593	43529434	TTDS00059	Dihydroorotate dehydrogenase, mitochondrial	DHOD;DHODase;DHOdehase;DHODH;Dihydroorotate dehydrogenase ;Dihydroorotate oxidase;Mitochondrially bound dihydroorotate-ubiqui oxidoreductase	Q12610	N/A	N/A	inhibitor
DCL000965	Rolofylline	MK-7418; 8-(3-Noradamantyl)-1,3-dipropylxanthine; AC1Q6LCF; 8-(Hexahydro-2,5-methanopentalen-3a(1H)-yl)-3,7-dihydro-1,3-dipropyl-1H-purine-2,6-dione; KW 3902; Rolofylline (USAN); CID64627; 8-(hexahydro-2,5-methanopentalen-3a(1h)-yl)-1,3-dipropyl-3,7-dihydro-1h-purine-2,6-dione; 1H-Purine-2,6-dione, 8-(hexahydro-2,5-methanopentalen-3a(1H)-yl)-3,7-dihydro-1,3-dipropyl-; 1,3-Dipropyl-8-(3-noradamantyl)xanthine; Rolofylline; CHEBI:176666; AC1L21M5; HMR-4902; D08989; 136199-02-5; 8-(Noradamantan-3-yl)-1,3-dipropylxanthine; KW-3902; LS-126967; CHEMBL52333; L001406; 1,3-Dnax	136199-02-5	8530	12014585	TTDS00186	Adenosine A1 receptor	A(1) adenosine receptor	P30542	134	ENSG00000163485	antagonist
DCL000573	MK-7418	MK-7418; 8-(3-Noradamantyl)-1,3-dipropylxanthine; AC1Q6LCF; 8-(Hexahydro-2,5-methanopentalen-3a(1H)-yl)-3,7-dihydro-1,3-dipropyl-1H-purine-2,6-dione; KW 3902; Rolofylline (USAN); CID64627; 8-(hexahydro-2,5-methanopentalen-3a(1h)-yl)-1,3-dipropyl-3,7-dihydro-1h-purine-2,6-dione; 1H-Purine-2,6-dione, 8-(hexahydro-2,5-methanopentalen-3a(1H)-yl)-3,7-dihydro-1,3-dipropyl-; 1,3-Dipropyl-8-(3-noradamantyl)xanthine; Rolofylline; CHEBI:176666; AC1L21M5; HMR-4902; D08989; 136199-02-5; 8-(Noradamantan-3-yl)-1,3-dipropylxanthine; KW-3902; LS-126967; CHEMBL52333; L001406; 1,3-Dnax	N/A	64627	12014585	TTDS00186	Adenosine A1 receptor	A(1) adenosine receptor	P30542	134	ENSG00000163485	antagonist
DCL000313	Tecadenoson	CVT-510; Tecadenoson (USAN/INN); CHEBI:502091; Tecadenoson; D06019; N-(3-Tetrahydrofuranyl)-6-aminopurine riboside; UNII-GZ1X96601Z; AC1L4KMO; (2R,3S,4R,5R)-2-(hydroxymethyl)-5-[6-[[(3R)-oxolan-3-yl]amino]purin-9-yl]oxolane-3,4-diol; CID158795; 204512-90-3; LS-190860; CHEMBL392149	204512-90-3	158795	47207677	TTDS00186	Adenosine A1 receptor	A(1) adenosine receptor	P30542	134	ENSG00000163485	agonist
DAP000099	Caffeine	MLS001056714; Stim; NCGC00090699-03; Caffine; Quick Pep; Theophylline, 7-methyl; nchembio774-comp2; 3,7-dihydro-1,3,7-trimethyl-1H-purine; Cafecon; Passauer Brand of Caffeine; Caffeine (USP); AC-12774; BSPBio_001921; Coffeine; DivK1c_000730; NCGC00168808-02; Coffein; Caffedrine Caplets; KBio1_000730; NCGC00015208-02; Caffeine Pure; Bio1_001451; Seid Brand of Caffeine; Theobromine, 1-methyl-; CHEMBL113; C1778_SIAL; Nodaca; Methylxanthine theophylline; SMR000326667; KBio2_001781; CCRIS 1314; nchembio.243-comp7; NINDS_000730; LS-237; Caffeine (natural); Vivarin; NCGC00090699-06; Caffeine solution; DB00201; No-Doz; Republic Drug Brand of Caffeine; Bio-0579; Pierre Fabre Brand of Caffeine; Lopac0_000228; C2042; Refresh'n; 1,3,7-Trimethyl-2,6-dioxopurine; NCGC00015208-14; C6035_SIGMA; Spectrum3_000321; MolPort-000-730-850; Natural Caffeinum; Anhydrous caffeine (TN); 1-methyltheobromine; Caffeine, synthetic; CFF; NCIOpen2_008255; Quick-Pep; C8960_SIAL; DHC Plus; Bio1_000473; Spectrum4_001782; Diurex; caffeine; BIDD:PXR0172; 1l5q; Tri-Aqua; CHEBI:27732; P-A-C Analgesic Tablets; D00528; Methyltheobromine; Coffeinum; A.S.A. and Codeine Compound; 27602_FLUKA; Caffeine [BAN:JAN]; KBio2_004349; 1gfz; Mateina; Coffeinum Purrum; Durvitan; caffenium; PDSP2_001000; EINECS 200-362-1; Thompson Brand 1 of Caffeine; Caffein; Coffeinum N; Probes2_000128; Spectrum_001301; HSDB 36; 07E4FB58-FD79-4175-8E3D-05BF96954522; Midol Maximum Strength; 2a3b; KBioSS_001781; UNII-3G6A5W338E; PDSP2_001219; 71701-02-5; AI3-20154; Propoxyphene Compound-65; Anacin Maximum Strength; Anhydrous caffeine (JP15); BIM-0050216.0001; 95789-13-2; NCGC00090699-04; C7731_SIAL; KBio3_001141; 1l7x; Eldiatric C; component of Cafergot; NCGC00090699-08; Pep-Back; CU-01000012617-3; HMS2091O11; FEMA No. 2224; 7-Methyltheophylline; NCGC00090699-07; Xanthine, 1,3,7-trimethyl; Organex; BIDD:ER0554; cafeine; Compound 65; No Doz; KBioGR_002325; Cafamil; NSC 5036; Hycomine; Theobromine Me; SPECTRUM1500155; NCGC00090699-01; Dasin; Lopac-C-0750; Cafeina; Caffeina [Italian]; Merck dura Brand of Caffeine; Alert-pep; SPBio_001222; NCGC00090699-05; SDCCGMLS-0064595.P002; Thompson Brand 2 of Caffeine; SDCCGMLS-0064595.P001; Thein; IDI1_000730; Coffein [German]; MLS001066409; teina; Enerjets; Koffein; AC1Q3Z23; Caffeine, Monohydrate; TNP00310; Bristol-Myers Squibb Brand of Caffeine; 58-08-2; NCI-C02733; Probes1_000150; Wake-Up; HMS1920I09; D002110; BRD-K02404261-001-03-5; Keep Alert; PDSP1_001016; AKOS000121334; Spectrum5_000423; Propoxyphene Compound 65; Kofein [Czech]; C6035_FLUKA; ACon1_000085; NCGC00015208-04; BRD-K02404261-001-02-7; EU-0100228; MLS001055341; Dexitac; Hycomine Compound; Spectrum2_001261; 1,3,7-Trimethylpurine-2,6-dione; Nodoz Maximum Strength Caplets; Ultra Pep-Back; BRN 0017705; SK 65 Compound; Caffeine, anhydrous; HMS502E12; bmse000206; Cafipel; NCGC00168808-01; SK-65 Compound; Phensal; Miudol; Methyltheobromide; 75035_FLUKA; Tirend; 5-26-13-00558 (Beilstein); Percoffedrinol N; Theine; AC1L1DV2; Monomethyl derivative of Theophylline; Koffein [German]; nchembio.63-comp5; Bio1_000962; ZINC00001084; L000155; C07481; Theophylline Me; BIDD:GT0632; Guaranine; C0750_SIAL; KBio2_006917; MolMap_000054; Kofein; W222402_ALDRICH; CID2519; NCGC00015208-01; I14-4386; Ercatab; Dexitac Stay Alert Stimulant; WLN: T56 BN DN FNVNVJ B1 F1 H1; Caffeina; NCGC00090699-09; MEGxp0_001350; 1-3-7-TRIMETHYLXANTHINE; Caffedrine; STK177283; Berlin-Chemie Brand of Caffeine; GlaxoSmithKline Brand of Caffeine; Anhydrous caffeine; NCGC00090699-02; Percutafeine; Nix Nap; PDSP1_001235; NSC5036; C 0750; 1,3,7-Trimethylxanthine; DHCplus	58-08-2	2519	148854	TTDS00186	Adenosine A1 receptor	A(1) adenosine receptor	P30542	134	ENSG00000163485	antagonist
DCL000285	CVT-124	CVT-124; BG 9719; 166374-49-8; 1,3-ENX; BG9719; BG-9719; Adentri; ENX cpd; Naxifylline; CVT 124; 1,3-dipropyl-8-(2-(5,6-epoxy)norbornyl)xanthine; 8-((2S,5,6-Exo)-5,6-epoxy-2-norbonyl)-1,3-dipropylxanthine; C097280	166374-49-8	158540	735979	TTDS00186	Adenosine A1 receptor	A(1) adenosine receptor	P30542	134	ENSG00000163485	antagonist
DCL000992	SLV320	SLV320; CHEBI:697839; CID9953065; 251945-92-3; SLV-320; 4-[(4-phenyl-3,5,7-triazabicyclo[4.3.0]nona-2,4,8,10-tetraen-2-yl)amino]cyclohexan-1-ol; Cyclohexanol, 4-((2-phenyl-1H-pyrrolo(2,3-d)pyrimidin-4-yl)amino)-, trans-; CHEMBL592435	685561-51-7	5437	48433653	TTDS00186	Adenosine A1 receptor	A(1) adenosine receptor	P30542	134	ENSG00000163485	antagonist
DAP001559	Pneumococcal 13-valent conjugate vaccine	N/A	N/A	N/A	N/A	TTDS00532	Corynebacterium diphtheriae CRM197 protein	N/A	N/A	N/A	N/A	binder
DAP001558	Meningococcal groups A, C, Y and W-135 conjugate vaccine	N/A	N/A	N/A	N/A	TTDS00532	Corynebacterium diphtheriae CRM197 protein	N/A	N/A	N/A	N/A	binder
DAP001026	Palifermin	Palifermin (USAN/INN); Kepivance (TN); 162394-19-6; Kepivance; Palifermin; D05338	162394-19-6	2536	47207024	TTDS00171	Fibroblast growth factor receptor 2	FGF-2 receptor;FGFR-2;Keratinocyte growth factor receptor 2	P21802	2263	ENSG00000066468	binder
DCL001020	Trafermin	Fiblast; Fiblast (TN); D03362; Trafermin (genetical recombination); 131094-16-1; Trafermin (genetical recombination) (JAN); Trafermin; Trafermin (USAN/INN)	131094-16-1	2020	17397511	TTDS00171	Fibroblast growth factor receptor 2	FGF-2 receptor;FGFR-2;Keratinocyte growth factor receptor 2	P21802	2263	ENSG00000066468	activator
DCL000361	AEE-788	CID10297043; CHEMBL587723; AEE-788, NVP-AEE 788, AEE788; GNF-Pf-5343; CHEBI:40629; 497839-62-0; 1H-Pyrrolo(2,3-d)pyrimidin-4-amine, 6-(4-((4-ethyl-1-piperazinyl)methyl)phenyl)-N-((1R)-1-phenylethyl)-; CID 11578515; CID11578515; S1486_Selleck; AEE788; AEE; AEE 788	N/A	10297043	56464542	TTDS00171	Fibroblast growth factor receptor 2	FGF-2 receptor;FGFR-2;Keratinocyte growth factor receptor 2	P21802	2263	ENSG00000066468	inhibitor
DAP001025	Pentosan Polysulfate	Polypentose sulfate; 39432-58-1; LS-187046; 37300-21-3; CID37720; AC1L1YAW; UNII-F59P8B75R4; Xylan, hydrogen sulfate; [(2R,3R,4S,5R)-2-hydroxy-5-[(2S,3R,4S,5R)-5-hydroxy-3,4-disulfooxyoxan-2-yl]oxy-3-sulfooxyoxan-4-yl] hydrogen sulfate; 42613-02-5; pentosan polysulfate; 11096-31-4; Pentosan sulfuric polyester; Elmiron; DB00686; LS-187658	37300-21-3	37720	179048	TTDS00171	Fibroblast growth factor receptor 2	FGF-2 receptor;FGFR-2;Keratinocyte growth factor receptor 2	P21802	2263	ENSG00000066468	inhibitor
DAP000801	Interferon Alfa-2a, Recombinant	N/A	77907-69-8	N/A	3770499	TTDS00171	Fibroblast growth factor receptor 2	FGF-2 receptor;FGFR-2;Keratinocyte growth factor receptor 2	P21802	2263	ENSG00000066468	binder
DCL000986	Sivelestat sodium hydrate	sodium 2-[[2-[[4-(2,2-dimethylpropanoyloxy)phenyl]sulfonylamino]benzoyl]amino]acetate tetrahydrate; 201677-61-4; Sivelestat sodium hydrate (JAN); MolPort-005-935-338; CID158792; LY544349 Sodium Hydrate; EI-546; Elaspol (TN); UNII-737RR8Y409; Sivelestat sodium (USAN); Ono 5046; AC1L4KMF; D01918; AC-1291; Sivelestat sodium; Elaspol; Sodium  ((2-(((4-((2,2-dimethylpropanoyl)oxy)phenyl)sulfonyl)amino)benzoyl)amino)acetate  tetrahydrate; ONO-5046.Na; sivelestat sodium hydrate; Glycine, N-(2-(((4-(2,2-dimethyl-1-oxopropoxy)phenyl)sulfonyl)amino)benzoyl)-, monosodium salt, tetrahydrate	201677-61-4	5360545	12014432	TTDS00448	Leukocyte elastase	Bone marrow serine protease;Medullasin;Neutrophil elastase;PMN elastase	P08246	1991	ENSG00000197561	inhibitor
DCL000019	Dermolastin	N/A	N/A	N/A	N/A	TTDS00448	Leukocyte elastase	Bone marrow serine protease;Medullasin;Neutrophil elastase;PMN elastase	P08246	1991	ENSG00000197561	inhibitor
DPR000039	DX-890	N/A	10024-97-2	948	48414241	TTDS00448	Leukocyte elastase	Bone marrow serine protease;Medullasin;Neutrophil elastase;PMN elastase	P08246	1991	ENSG00000197561	inhibitor
DCL000489	AZD9668	N/A	64952-97-2	47499	48416297	TTDS00448	Leukocyte elastase	Bone marrow serine protease;Medullasin;Neutrophil elastase;PMN elastase	P08246	1991	ENSG00000197561	inhibitor
DAP001102	Alpha-1-proteinase inhibitor	N/A	9041-92-3	N/A	46506364	TTDS00448	Leukocyte elastase	Bone marrow serine protease;Medullasin;Neutrophil elastase;PMN elastase	P08246	1991	ENSG00000197561	inhibitor
DAP000875	Ranolazine	NCGC00095177-03; RANOLAZINE; HMS2090L09; 95635-55-5; LS-187267; Ranexa; MLS002154149; RS-43285-003; BRD-A97674275-001-01-9; (-)-Ranolazine; SMR000857382; D05700; CHEMBL1404; NCGC00095177-02; MolPort-003-666-653; RS-43285; Ranolazine 2HCl; Ranexa, Ranolazine; CVT-303; HMS2093D21; BSPBio_002276; NCGC00015897-05; AC1Q5LYD; AC-1673; Ran4; I06-0160; RAN D; DB00243; AC1L1M17; HMS1922F16; Ranolazine dihydrochloride; 1-Piperazineacetamide, N-(2,6-dimethylphenyl)-4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]-; Lopac0_001062; NCGC00095177-01; Ranexa (TN); 142387-99-3; N-(2,6-dimethylphenyl)-2-[4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl]acetamide; Latixa; KEG-1295; CID56959; Ranolazine (USAN/INN); UNII-A6IEZ5M406; 1-Piperazineacetamide, N-(2,6-dimethylphenyl)-4-(2-hydroxy-3-(2-methoxyphenoxy)propyl)-; SPECTRUM1505366; S1799_Selleck; ( -)-Ranolazine; I01-2008	142387-99-3	56959	194150	TTDS00514	Sodium channel protein type 10 subunit alpha	hPN3;Peripheral nerve sodium channel 3;Sodium channel protein type X subunit alpha;Voltage-gated sodium channel subunit alpha Nav1.8	Q9Y5Y9	6336	ENSG00000185313	blocker
DAP000547	Caspofungin	UNII-F0XDI6ZL63; N-{(2R,6S,9S,11R,12S,14aS,15S,20S,23S,25aS)-12-[(2-aminoethyl)amino]-20-[(1R)-3-amino-1-hydroxypropyl]-23-[(1S2S)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-2,11,15-trihydroxy-6-[(1R)-1-hydroxyethyl]-5,8,14,19,22,25-hexaoxotetracosahydro-1H-dipyrrolo[2,1-c:2',1'-l][1,4,7,10,13,16]hexaazacyclohenicosin-9-yl}-10,12-dimethyltetradecanamide; (4R,5S)-5-((2-aminoethyl)amino)-N(2)-(10,12-dimethyltetradecanoyl)-4-hydroxy-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-(p-hydroxyphenyl)-L-threonyl-threo-3-hydroxy-L-ornithyl-trans-3-hydroxy-L-proline cyclic (6-1)-peptide; Pneumocandin B0, 1-[(4R,5S)-5-[(2-aminoethyl)amino]-N2-(10,12-dimethyl-1-oxotetradecyl)-4-hydroxy-L-ornithine]-5-[(3R)-3-hydroxy-L-ornithine]- (9CI); Cancidas; Caspofungin (INN); CHEMBL374999; MK-0991; LS-187303; [1(R)-hydroxyethyl]-1,4,7,13,16,22-hexaazatricyclo[22.3.0.0(9,13)]heptacosane-2,5,8,14,17,23-hexaone diacetate; CID468682; AR-1K4318; 1-[(4R,5S)-5-[(2-aminoethyl)amino]-N(2)-(10,12-dimethyl-1-oxotetradecyl)-4-hydroxy-L-ornithine]-5-[(3R)-3-hydroxy-L-ornithine]-pneumocandin B0; 162808-62-0; AC1LAHR5; M991; AC1MCVUN; Pneumocandin B0, 1-[(4R,5S)-5-[(2-aminoethyl)amino]-N2-(10,12-dimethyl-1-oxotetradecyl)-4-hydroxy-L-ornithine]-5-(threo-3-hydroxy-L-ornithine)-; (3S,6S,9S,11R,15S,18S,20R,21S,24S,25S)-21-(2-Aminoethylamino)-3-[3-amino-1(R)-hydroxypropyl]-6-[1(S),2(S)-dihydroxy-2-(4-hydroxyphenyl)ethyl]-18-(10,12-dimethyltetradecanamido)-11,20,25-trihydroxy-15-; Caspofungin [INN]; LS-187635; HSDB 7476; CHEMBL499808; n-{(2r,6s,9s,11r,12s,14as,15s,20s,23s,25as)-12-[(2-aminoethyl)amino]-20-[(1r)-3-amino-1-hydroxypropyl]-23-[(1s,2s)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-2,11,15-trihydroxy-6-[(1r)-1-hydroxyethyl]-5,8,14,19,22,25-hexaoxotetracosahydro-1h-dipyrrolo[2,1-c:2',1'-l][1,4,7,10,13,16]hexaazacyclohenicosin-9-yl}-10,12-dimethyltetradecanamide; Caspofungin; nchembio.184-comp7; CHEBI:474180; AC1L45LR; Capsofungin; L-743,872; (4R,5S)-5-((2-Aminoethyl)amino)-N(sup 2)-(10,12-dimethyltetradecanoyl)-4-hydroxy-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-(p-hydroxyphenyl)-L-threonyl-threo-3-hydroxy-L-ornithyl-trans-3-hydroxy-L-proline cyclic (6-1)-peptide; CID151068; CASPO; DB00520; D07626; CID2826718; LS-186994; Cancidas (TM); Cancidas (TN)	179463-17-3	468682	622847	TTDS00299	1,3-Beta-Glucan synthase	(1,3)-beta-D-glucan synthase;1,3-beta-D-glucan-UDP glucosyltransferase;Beta-1,3-glucan synthase;Beta-1,3-glucan synthetase;CND1 protein;CWN53 protein;FKS1;FKS1 protein;Glucan synthase;Papulacandin B sensitivity protein 1;UDP-glucose-1,3-beta-D-glucan glucosyltransferase	P38678	N/A	N/A	inhibitor
DCL000331	Cilofungin	LY-121019; AC1L2GRJ; L-649,991; CHEMBL438650; AR-1K2954; CID6918120; AC1Q2WBJ; D03500; Cilofungin; N-{(2R,6S,9S,11R,12R,14aS,15S,16S,20S,23S,25aS)-23-[(1S,2S)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-2,11,12,15-tetrahydroxy-6,20-bis[(1R)-1-hydroxyethyl]-16-methyl-5,8,14,19,22,25-hexaoxotetracosahydro-1H-dipyrrolo[2,1-c:2',1'-l][1,4,7,10,13,16]hexaazacyclohenicosin-9-yl}-4-(octyloxy)benzamide; 1-[(4R,5R)-4,5-Dihydroxy-N2-[4-(octyloxy)benzoyl]-L-ornithine]echinocandin B; Cilofungin (USAN/INN); Cilofungina; L-646991; CID71762; CHEBI:315019; AC1L9UU3; 5.1:6-anhydro{(4R,5R)-4,5-dihydroxy-N(2)-[4-(octyloxy)benzoyl]-L-ornithyl-L-threonyl-(4R)-4-hydroxy-L-prolyl-(4S)-4-hydroxy-4-(4-hydroxyphenyl)-L-threonyl-L-threonyl-(3S,4S)-3-hydroxy-4-methyl-L-proline}; 79404-91-4; Cilofunginum; n-[(2r,11r,12r,15s,16s)-23-[(1s,2s)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-2,11,12,15-tetrahydroxy-6,20-bis(1-hydroxyethyl)-16-methyl-5,8,14,19,22,25-hexaoxotetracosahydro-1h-dipyrrolo[2,1-c:2',1'-l][1,4,7,10,13,16]hexaazacyclohenicosin-9-yl]-4-(octyloxy)benzamide; CID456395	79404-91-4	71762	47205843	TTDS00299	1,3-Beta-Glucan synthase	(1,3)-beta-D-glucan synthase;1,3-beta-D-glucan-UDP glucosyltransferase;Beta-1,3-glucan synthase;Beta-1,3-glucan synthetase;CND1 protein;CWN53 protein;FKS1;FKS1 protein;Glucan synthase;Papulacandin B sensitivity protein 1;UDP-glucose-1,3-beta-D-glucan glucosyltransferase	P38678	N/A	N/A	inhibitor
DAP000546	Anidulafungin	Anidulafungin; Ecalta; Anidulafungin [USAN:INN]; UNII-9HLM53094I; (4R,5R)-4,5-Dihydroxy-N(sup 2)-((4'-(pentyloxy)-p-terphenyl-4-yl)carbonyl)-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-(p-hydroxyphenyl)-L-threonyl-L-threonyl-(3S,4S)-3-hydroxy-4-methyl-L-proline cyclic (6-1)-peptide; LY-303366; Eraxis; DB00362; 166663-25-8; CID166548; Echinocandin B, 1-((4R,5R)-4,5-dihydroxy-N2-((4"-(pentyloxy)(1,1':4',1"-terphenyl)-4-yl)carbonyl)-L-ornithine); VER-002; V-Echinocandin; CHEBI:55346; LS-63738; AC1L4YAI; N-{(2R,6S,9S,11R,12R,14aS,15S,16S,20S,23S,25aS)-23-[(1S,2S)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-2,11,12,15-tetrahydroxy-6,20-bis[(1R)-1-hydroxyethyl]-16-methyl-5,8,14,19,22,25-hexaoxotetracosahydro-1H-dipyrrolo[2,1-c:2',1'-l][1,4,7,10,13,16]hexaazacyclohenicosin-9-yl}-4''-(pentyloxy)-1,1':4',1''-terphenyl-4-carboxamide; Echinocandin B, 1-((4R,5R)-4,5-dihydroxy-N(sup 2)-((4'-(pentyloxy)(1,1':4',1'-terphenyl)-4-yl)carbonyl)-L-ornithine)-	166663-25-8	166548	743929	TTDS00299	1,3-Beta-Glucan synthase	(1,3)-beta-D-glucan synthase;1,3-beta-D-glucan-UDP glucosyltransferase;Beta-1,3-glucan synthase;Beta-1,3-glucan synthetase;CND1 protein;CWN53 protein;FKS1;FKS1 protein;Glucan synthase;Papulacandin B sensitivity protein 1;UDP-glucose-1,3-beta-D-glucan glucosyltransferase	P38678	N/A	N/A	inhibitor
DCL000522	Eraxis/Vfend	N/A	254751-28-5	N/A	3820489	TTDS00299	1,3-Beta-Glucan synthase	(1,3)-beta-D-glucan synthase;1,3-beta-D-glucan-UDP glucosyltransferase;Beta-1,3-glucan synthase;Beta-1,3-glucan synthetase;CND1 protein;CWN53 protein;FKS1;FKS1 protein;Glucan synthase;Papulacandin B sensitivity protein 1;UDP-glucose-1,3-beta-D-glucan glucosyltransferase	P38678	N/A	N/A	inhibitor
DAP000548	Micafungin	Mycamine; AC-6107; DB01141; 5.1:6-anhydro{(4R,5R)-4,5-dihydroxy-N(2)-(4-{5-[4-(pentyloxy)phenyl]isoxazol-3-yl}benzoyl)-L-ornithyl-L-threonyl-(4R)-4-hydroxy-L-prolyl-(4S)-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]-L-threonyl-(3R)-3-hydroxy-L-glutaminyl-(3S,4S)-3-hydroxy-4-methyl-L-proline}; AC1MIXSV; 5-[(1S,2S)-2-{(2R,6S,9S,11R,12R,14aS,15S,16S,20S,23S,25aS)-20-[(1R)-3-amino-1-hydroxy-3-oxopropyl]-2,11,12,15-tetrahydroxy-6-[(1R)-1-hydroxyethyl]-16-methyl-5,8,14,19,22,25-hexaoxo-9-[(4-{5-[4-(pentyloxy)phenyl]isoxazol-3-yl}benzoyl)amino]tetracosahydro-1H-dipyrrolo[2,1-c:2',1'-l][1,4,7,10,13,16]hexaazacyclohenicosin-23-yl}-1,2-dihydroxyethyl]-2-hydroxyphenyl hydrogen sulfate; I14-11710; CID11804463; Mycamine(TM); AC1L9WY8; CID6602291; Micafungin; UNII-R10H71BSWG; FK463; LS-184079; CID3081921; CHEBI:600520; CID477468; FK-463; LS-187369; Pneumocandin A0, 1-((4R,5R)-4,5-dihydroxy-N2-(4-(5-(4-(pentyloxy)phenyl)-3-isoxazolyl)benzoyl]-L-ornithine)-4-((4S)-4-hydroxy-4-(4-hydroxy-3-(sulfooxy)phenyl)-L-threonine)-; CHEMBL1201351	235114-32-6	3081921	3884856	TTDS00299	1,3-Beta-Glucan synthase	(1,3)-beta-D-glucan synthase;1,3-beta-D-glucan-UDP glucosyltransferase;Beta-1,3-glucan synthase;Beta-1,3-glucan synthetase;CND1 protein;CWN53 protein;FKS1;FKS1 protein;Glucan synthase;Papulacandin B sensitivity protein 1;UDP-glucose-1,3-beta-D-glucan glucosyltransferase	P38678	N/A	N/A	inhibitor
DAP000314	Aminolevulinic acid	KBio2_002062; 5-ALA; delta-aminolevulinic acid; Pentanoic acid, 5-amino-4-oxo- (9CI); Spectrum_001582; delta-ALA; AC-054; LMFA01100055; 106-60-5; CPD000857229; Aminolevulinic; KBio3_002627; Spectrum5_001505; SpecPlus_000858; ST50819610; SMR000857229; 35BEC718-C970-426A-9859-BF58284C60B4; Spectrum2_001662; D07567; DivK1c_006954; CCRIS 8958; BIDD:GT0260; AC1L18K9; SAM002589919; KBio2_004630; BSPBio_003407; Levulinic acid, 5-amino-; AKOS003587520; SPBio_001843; Pentanoic acid, 5-amino-4-oxo-; KBioGR_001176; NCGC00178086-01; 5-Aminolevulinic acid; CHEBI:17549; 5-Aminolevulinate; Kerastick; EINECS 203-414-1; 5-Amino-4-oxovaleric acid; Spectrum3_001654; 5-Amino-4-oxopentanoic acid; I14-10101; MLS001333098; MolPort-001-788-423; Aminolevulinate; 5451-09-2; MLS001333097; 5-amino-levulinate; UNII-88755TAZ87; 5-Amino-4-oxopentanoate; LS-101793; Aladerm; CHEMBL601; C00430; CID137; KBio2_007198; Levulinic acid, 5-amino- (8CI); Spectrum4_000618; KBioSS_002062; Aminolevulinic acid; KBio1_001898; DB00855	106-60-5	137	3719	TTDS00342	Delta-aminolevulinic acid dehydratase	ALAD;ALADH;Delta-aminolevulinate dehydratase;Porphobilinogen synthase	P13716	210	ENSG00000148218	inhibitor
DAP000116	Gentamicin	Gentamar; AR-1F8593; Gentavet; 1403-66-3; D08013; Gentamycinum; HSDB 3087; Gentamicina; O-2-amino-2,3,4,6,7-pentadeoxy-6-(methylamino)-alpha-D-ribo-heptopyranosyl-(1-4)-O-(3-deoxy-4-C-methyl-3-(methylamino)-beta-L-arabinopyranosyl-(1-6))-2-deoxy-D-streptamine; UNII-T6Z9V48IKG; 2-[4,6-diamino-3-[3-amino-6-[1-(methylamino)ethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol; 4,6-diamino-3-{[3-deoxy-4-c-methyl-3-(methylamino)pentopyranosyl]oxy}-2-hydroxycyclohexyl 2-amino-2,3,4,6,7-pentadeoxy-6-(methylamino)heptopyranoside; Gentak; LS-71146; MolPort-005-934-296; Genoptic Liquifilm; Gentamicine [INN-French]; G-Myticin; Gentamicin (TN); CHEBI:27412; CID441305; (1R,2S,3S,4R,6S)-4,6-diamino-3-{[3-deoxy-4-C-methyl-3-(methylamino)-beta-L-arabinopyranosyl]oxy}-2-hydroxycyclohexyl (6x)-2-amino-2,3,4,6,7-pentadeoxy-6-(methylamino)-alpha-D-erythro-heptopyranoside; gentamicin; Refobacin; Gentamicinum; DB00798; Gentamicins; Uromycine; Ocu-Mycin; EINECS 215-765-8; Apogen; GENTAMYCIN; AC1Q57VC; U-Gencin; C21H43N5O7; Gentamicinum [INN-Latin]; Gentacidin; Bristagen; Gentamycin-creme [German]; Gentamycin-creme; (1R,2S,3S,4R,6S)-4,6-diamino-3-[3-deoxy-4-C-methyl-3-(methylamino)-beta-L-arabinopyranosyloxy]-2-hydroxycyclohexyl 2-amino-2,3,4,6,7-pentadeoxy-6-(methylamino)-beta-L-lyxo-heptopyranoside; Cidomycin; Gentamicin (BAN); Gentamicin C1; Refobacin TM; Gentamicine; AC-13386; AC1L1G02; Spectro-Genta; Garamycin Otic Solution; Garamycin; Garasol; 25876-10-2; Gentocin; CHEMBL195892; Gentamcin Sulfate; (2R,3R,4R,5R)-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2R,3R,6S)-3-amino-6-[1-(methylamino)ethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol; G-Mycin; Gentamicina [INN-Spanish]; nchembio.274-comp5; Gentacycol; Gentafair; AC1L9AXS; CID3467; Alcomicin; Jenamicin; Genoptic S.O.P.; Gentamicin sulphate sterile	1403-66-3	3467	3788	TTDS00234	73-kDa molecular chaperone HSP73	Heat shock protein 73;HSP73	P11142	3312	ENSG00000109971	inhibitor
DCL000950	Rambazole	Talarozole (USAN/INN); 851811-31-9; N-(4-(2-ethyl-1-(1H-1,2,4-triazol-1-yl)butyl)phenyl)-2-benzothiazolamine; C406527; R115866; CHEMBL459505; D09385; 201410-53-9; R 115866; CID9799888; Rambazole (TN); Rambazole; Talarozole; CHEBI:570953; R-115866; AKOS005067289	25122-46-7	6918520	49684199	TTDC00232	Cytochrome P450 26	Cytochrome P450RAI;HP450RAI;P450 retinoic acid-inactivating 1;P450RAI;Retinoic acid 4-hydroxylase;Retinoic acid inducible enzyme;Retinoic acid-metabolizing cytochrome	O43174	1592	ENSG00000095596	inhibitor
DAP001419	Quercetin	CHEBI:16243; 49643640-FD4C-4B93-BD28-0D7C2021CC52; EU-0100999; QUE; KBioGR_001293; HMS1990F09; CCRIS 1639; KUC104418N; BRD-K97399794-001-02-1; NCGC00025016-07; Prestwick3_000507; Spectrum2_000059; C.I. 75670; Xanthaurine; S00057; Spectrum5_001389; 3',4',5,7-Tetrahydroxyflavan-3-ol; HMS1792F09; LS-69030; NCI60_042036; Maybridge1_008992; SGCUT00001; KBioSS_000584; NCGC00015870-03; 3,5,7,3',4'-Pentahydroxyflavone; Lopac0_000999; UPCMLD-DP081:001; AC1NQWX8; Tocris-1125; Lopac-Q-0125; Natural Yellow 10; Quercetin dihydrate; NCGC00168962-03; 74893-81-5; C00389; BRD-K97399794-001-07-0; BIDD:PXR0007; nchembio.65-comp4; 2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one; UNII-9IKM0I5T1E; NCGC00025016-01; KBioGR_000408; NCGC00168962-02; 5-18-05-00494 (Beilstein Handbook Reference); NSC9219; to_000078; CI Natural Yellow 10; Prestwick2_000507; AC-19596; Quercitin; AKOS000511724; Spectrum3_000642; C.I. Natural yellow 10 & 13; SMP1_000252; AC1Q795T; KBio3_001463; BiomolKI2_000068; NCIOpen2_007882; BAS 00649429; 3,5,7-Trihydroxy-2-(3,4-dihydroxyphenyl)-4H-chromen-4-on; NCGC00168962-01; KBio2_000408; NCGC00015870-05; SPBio_002354; 73123-10-1; Quercetin content; Flavone, 3,4',5,5',7-pentahydroxy-; 2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4H-1-benzopyran-4-one; Quercetol; Bio1_001347; Spectrum_000124; 3,3',4,5,7-Pentahydroxyflavone; NCGC00025016-02; NSC 9219; Prestwick1_000507; BRD-K97399794-335-03-1; AC1Q795S; 7255-55-2; KSC-23-76; CHEMBL50; NSC58588; CID5280343; NCIOpen2_007628; SPECTRUM1500672; Quercetine; KBio2_000584; C.I . natural yellow 10; K00029; LIM-5662; AI3-26018; WLN: T66 BO EVJ CR CQ DQ & DQ GQ IQ; NSC324608; SPBio_000217; NSC-9219; NCGC00025016-03; STK365650; P0042; quercetin; 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-; Quertin; CU-01000012502-3; NINDS_000485; LS-589; Cyanidelonon 1522; C.I. Natural red 1; HMS501I07; KBio2_005720; Bio1_000369; NCGC00015870-17; 2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4H-1-benzopyran-4-one dihydrate; UPCMLD-DP081; KBio2_005544; NCGC00025016-08; HSDB 3529; TNP00089; NCGC00015870-01; Flavone, 3,3',4',5,7-pentahydroxy-; LNS-5662; NCGC00025016-04; 2-(3,4-Dihydroxy-phenyl)-3,5,7-trihydroxy-chromen-4-one; KSC-10-126; 3cf8; MolPort-001-740-557; Prestwick0_000507; KBio2_002976; BiomolKI_000062; DB04216; BSPBio_001068; D011794; BIDD:ER0315; KBio1_000485; KUC107684N; Bio1_000858; 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxychromen-4-one; 3',4',5,7-tetrahydroxyflavon-3-ol; A1784/0075599; 3,3',4',5,7-Pentahydroxyflavone dihydrate; Spectrum4_000807; KBio2_003152; BSPBio_000433; C.I. Natural Yellow 10; NCGC00025016-05; NCGC00015870-02; Quertine; Flavin meletin; NSC57655; KBio3_000776; HMS1923O19; BRN 0317313; HMS1362F09; DivK1c_000485; IDI1_002129; MEGxp0_000381; Kvercetin; T-Gelb bzw. grun 1; Sophoretin; STOCK1N-04222; BSPBio_002243; Meletin; LMPK12110004; MixCom3_000183; 3,3',4',5,7-Pentahydroxyflavone; BPBio1_000477; NChemBio.2007.10-comp11; nchembio.117-comp3; Bio2_000374; KBio3_000775; ACon1_000560; Quercetin; 3,3',4',5,7-Pentahydroxyflavone; Kvercetin [Czech]; IDI1_000485; NCGC00168962-04; CI 75670; TNP00070; NCGC00025016-06; Bio2_000854; 3,5,7-trihydroxy-2-(3,4-dihydroxyphenyl)-4H-chromen-4-one; 117-39-5; EINECS 204-187-1; KBioSS_000408; Q 0125	117-39-5	5280343	151474	TTDS00133	Lyso-PAF: acetyl-CoA acetyltransferase 	Acetyl-CoA: 1-alkyl-2-lyso-sn-glycero-3-phosphocholine acetyltransferase;LysoPAF acetyltransferase	N/A	N/A	N/A	inhibitor
DCL001045	ISIS 104838	N/A	N/A	N/A	N/A	TTDC00268	mRNA of TNF alpha	N/A	N/A	N/A	N/A	antisense
DCL000256	Urocortin 2	N/A	N/A	312145	47646136	TTDC00074	Corticotropin releasing factor receptor 2	Corticotropin-releasing hormone receptor 2;CRF2;CRF-R 2;CRH2 receptor;CRH-R 2	Q13324	1395	ENSG00000106113	antagonist
DCL000758	CRF-R2 antagonists	N/A	358-086-15	4261	49738862	TTDC00074	Corticotropin releasing factor receptor 2	Corticotropin-releasing hormone receptor 2;CRF2;CRF-R 2;CRH2 receptor;CRH-R 2	Q13324	1395	ENSG00000106113	antagonist
DAP000366	Methysergide	NCGC00024027-04; D02357; EINECS 206-644-0; N-(1-(Hydroxymethyl)propyl)-1-methyl-dextro-(+)-lysergamide; 29987-97-1; Ergoline-8-beta-carboxamide, 9,10-didehydro-N-(1-(hydroxymethyl)propyl)-1,6-dimethyl-; C07199; Methysergidum [INN-Latin]; 9,10-Didehydro-N-(1-(hydroxymethyl)propyl)-1,6-dimethylergoline-8-carboxamide; Desril; CHEBI:238605; DB00247; Methysergid; 1-Methyl-D-lysergic acid butanolamide; Metisergido; Methysergidum; Lysergamide, N-(1-(hydroxymethyl)propyl)-1-methyl-, D-; Desernil; BPBio1_000486; Desernyl; Methysergide (USAN/INN); Metisergide [DCIT]; UNII-XZA9HY6Z98; 1-Methylmethylergonovine; 47478-64-8; Metisergide; CHEMBL1065; 156558-44-0; Ergoline-8beta-carboxamide, 9,10-didehydro-N-(1-(hydroxymethyl)propyl)-1,6-dimethyl-; Methysergide [USAN:INN:BAN]; Methyllysergic acid butanolamide; BRD-K35941380-001-01-7; Sansert; Ergoline-8-carboxamide, 9,10-didehydro-N-(1-(hydroxymethyl)propyl)-1,6-dimethyl-, (8beta(S))-; Biomol-NT_000155; 361-37-5; HSDB 3237; UML-491; methysergide; NCGC00024027-06; BRN 0765985; 1-Methyl-dextro-lysergic acid (+)-1-hydroxy-2-butylamide; 2016-33-3; LS-64361; Lopac0_000863; CID9681; Methylmethylergonovine; NCGC00024027-05; Deseryl; (+)-9,10-Didehydro-N-(1-(hydroxymethyl)propyl)-1,6-dimethylergoline-8beta-carboxamide; AC1L1TKV; HMS2090P04; Metisergido [INN-Spanish]; 746-51-0; N-(alpha-(Hydroxymethyl)propyl)-1-methyl-dextro-lysergamide; (+)-N-(1-(Hydroxymethyl)propyl)-1-methyl-D-lysergamide; (8beta)-N-[(1S)-1-(hydroxymethyl)propyl]-1,6-dimethyl-9,10-didehydroergoline-8-carboxamide; UML 491; Ergoline-8-carboxamide, 9,10-didehydro-N-(1-(hydroxymethyl)propyl)-1,6-dimethyl-, (8beta)-; Deseril; Dimethylergometrin; C21H27N3O2	361-37-5	9681	7849416	TTDS00105	5-hydroxytryptamine 2C receptor	5HT-1C;5-HT-2C;5-HT2C receptor;Serotonin receptor;Serotonin receptor 2C	P28335	3358	ENSG00000147246	antagonist
DCL000872	Lorcaserin	Lorcaserin; (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine; TL80074203; 10-chloro-2-methyl-4-azabicyclo[5.4.0]undeca-8,10,12-triene; LS-193332; APD356; 616202-92-7; AR-10A; AC-553; CHEBI:401194; MolPort-005-942-408; CID11658860; CHEMBL360328; UNII-637E494O0Z; APD 356	616202-92-7	N/A	N/A	TTDS00105	5-hydroxytryptamine 2C receptor	5HT-1C;5-HT-2C;5-HT2C receptor;Serotonin receptor;Serotonin receptor 2C	P28335	3358	ENSG00000147246	agonist
DPR000004	5-HT2C agonist	N/A	N/A	N/A	N/A	TTDS00105	5-hydroxytryptamine 2C receptor	5HT-1C;5-HT-2C;5-HT2C receptor;Serotonin receptor;Serotonin receptor 2C	P28335	3358	ENSG00000147246	agonist
DCL001223	PRX00933	N/A	N/A	N/A	N/A	TTDS00105	5-hydroxytryptamine 2C receptor	5HT-1C;5-HT-2C;5-HT2C receptor;Serotonin receptor;Serotonin receptor 2C	P28335	3358	ENSG00000147246	agonist
DAP000010	Mirtazapine	MLS000759460; 6-Azamianserin; SAM001246659; Mirtazepine; Axit; (N-methyl-11C)mirtazapine; 85650-52-8; L001294; 5-methyl-2,5,19-triazatetracyclo[13.4.0.0^{2,7}.0^{8,13}]nonadeca-1(15),8(13),9,11,16,18-hexaene; EINECS 288-060-6; NCGC00025346-02; Mirtazapinum [INN-Latin]; Mirtabene; CHEMBL654; Norset; Mundogen brand of mirtazapine; Remeron SolTab; AC1Q3ZYM; PDSP1_001529; I06-0606; MLS001076676; Azamianserin; ME-2040; Pyrazino[2,1-a]pyrido[2,3-c][2]benzazepine, 1,2,3,4,10,14b-hexahydro-2-methyl-; M0443_SIGMA; BRD-A64977602-001-01-9; Mirtazon; Mepirzepine; Zispin; UNII-A051Q2099Q; Mirtazapine [USAN:INN:BAN]; Mirtazapina; AC1L1HND; Remergil; Remeron; CHEBI:6950; Remeron (TN); C035133; D00563; MolPort-003-849-233; CPD000466347; I01-1882; STK711107; SMR000466347; HMS2052H03; 1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine; Mirtazapina [INN-Spanish]; 2-Methyl-1,2,3,4,10,14b-hexahydropyrazino[2,1-a]pyrido[2,3-c][2]benzazepine; Rexer; LS-127703; Mirtazapinum; Mirtazapine (JAN/USAN/INN); Mepirzapin; PDSP2_001513; 1,2,3,4,10,14b-Hexahydro-2-methylpyrazino(2,1-a)pyrido(2,3-c)benzazepine; AC-15480; (1)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino(2,1-a)pyrido(2,3-c)(2)benzazepine; Organon brand of mirtazapine; 61337-67-5; DB00370; mirtazapine; CID4205; 82601-27-2; Org-3770; Pyrazino(2,1-a)pyrido(2,3-c)(2)benzazepine, 1,2,3,4,10,14b-hexahydro-2-methyl-; Avanza; Promyrtil; Celltech brand of mirtazapine; LS-185067; Mirtazapine [USAN:BAN:INN]; Mirtazipine; C07570; ORG 3770; Mirtaz; Remergon	61337-67-5	4205	183976	TTDS00105	5-hydroxytryptamine 2C receptor	5HT-1C;5-HT-2C;5-HT2C receptor;Serotonin receptor;Serotonin receptor 2C	P28335	3358	ENSG00000147246	antagonist
DCL000999	SR46349B	(E)-but-2-enedioic acid; 4-[(E)-3-(2-dimethylaminoethyloxyamino)-3-(2-fluorophenyl)prop-2-enylidene]cyclohexa-2,5-dien-1-one; 4-((3Z)-3-(2-Dimethylaminoethyl)oxyimino-3-(2-fluorophenyl)propen-1-yl)phenol hemifumarate; 2-Propen-1-one, 1-(2-fluorophenyl)-3-(4-hydroxyphenyl)-, O-(2-(dimethylamino)ethyl)oxime, (Z,E)-, (E)-2-butenedioate (2:1) (salt); SR 46349B; CID6438382; SR-46349B; Eplivanserin fumarate; AC1O5PLB; 130580-02-8; LS-184149; SR 46349	36951-72-1	4234	49742601	TTDS00105	5-hydroxytryptamine 2C receptor	5HT-1C;5-HT-2C;5-HT2C receptor;Serotonin receptor;Serotonin receptor 2C	P28335	3358	ENSG00000147246	binder
DAP000042	Nefazodone	HMS2090D17; DB01149; Nefazodonum; MolPort-003-849-346; Nefazodonum [Latin]; NCGC00165846-01; 2-[3-[4-(3-chlorophenyl)piperazin-1-yl]propyl]-5-ethyl-4-(2-phenoxyethyl)-1,2,4-triazol-3-one; 83366-66-9; D08257; Nefazodona [Spanish]; C25H32ClN5O2; L001196; NCGC00165846-02; Nefazodona; Nefazodone Hcl; CHEBI:7494; 2-{3-[4-(3-chlorophenyl)piperazin-1-yl]propyl}-5-ethyl-4-[2-(phenyloxy)ethyl]-2,4-dihydro-3H-1,2,4-triazol-3-one; SMR000550487; Nefazodone [INN:BAN]; MLS001195657; BRD-K90789829-003-03-3; C07256; MLS000759458; 3H-1,2,4-Triazol-3-one, 2-(3-(4-(3-chlorophenyl)-1-piperazinyl)propyl)-5-ethyl-2,4-dihydro-4-(2-phenoxyethyl)-; MolPort-002-885-843; 2-{3-[4-(3-chlorophenyl)piperazin-1-yl]propyl}-5-ethyl-4-(2-phenoxyethyl)-2,4-dihydro-3H-1,2,4-triazol-3-one; CID4449; 1-(3-(4-(3-Chlorpheyl-1-piperazinylpropyl)-3-ethyl-4,5-dihydro-4-(2-phenoxyethyl)-1,2,4-triazol-5-on; 3H-1,2,4-Triazol-3-one, 2,4-dihydro-2-3-(4-(3-chlorophenyl)-1-piperazinyl)propyl)-5-ethyl-4-(2-phenoxyethyl)-; BIDD:GT0789; CHEMBL623; Nefazodone (INN); LS-156497; 82752-99-6 (hydrochloride); AC1L1I6V; MLS001165769; 2-[3-[4-(3-Chlorophenyl)-1-piperazinyl]propyl]-5-ethyl-2,4-dihydro-4-(2-phenoxyethyl)-3H-1,2,4-triazol-3-one; 1-(3-(4-(m-Chlorophenyl)-1-piperazinyl)propyl)-3-ethyl-4-(2-phenoxyethyl)-delta2-1,2,4-triazolin-5-one; UNII-59H4FCV1TF; nefazodone	83366-66-9	4449	205126	TTDS00105	5-hydroxytryptamine 2C receptor	5HT-1C;5-HT-2C;5-HT2C receptor;Serotonin receptor;Serotonin receptor 2C	P28335	3358	ENSG00000147246	antagonist
DAP001462	Bromocryptine mesylate	EINECS 244-881-1; C32H40BrN5O5.CH4O3S; 2-Bromoergocryptine Mesylate; (5'alpha)-2-bromo-12'-hydroxy-5'-(2-methylpropyl)-2'-(propan-2-yl)-3',6',18-trioxoergotaman methanesulfonate; 2-Bromo-alpha-ergocryptine mesylate; NSC169774; CB 154 methanesulfonate (salt); 25614-03-3 (Parent); LS-7234; 2-Bromo-alpha-ergocryptine methanesulfonate; CHEBI:3182; Parlodel (TN); (5xi,5'alpha)-2-bromo-12'-hydroxy-5'-isobutyl-2'-isopropyl-3',6',18-trioxoergotaman methanesulfonate (salt); Bromocriptine methanesulfonate; Parlodel; 2-Bromo-alpha-ergokryptine-mesilate; (5xi,5'alpha)-2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-3',6',18-trioxoergotaman methanesulfonate (salt); Bromocriptine mesylate [USAN]; alpha-Ergocryptine, 2-bromo-, methanesulfonate; Bromocryptine mesylate; (5'alpha)-2-bromo-12'-hydroxy-5'-(2-methylpropyl)-3',6',18-trioxo-2'-(propan-2-yl)ergotaman methanesulfonate (salt); Bagren; 2-Bromo-.alpha.-ergocryptine monomethanesulfonate; HMS1568I04; 2-Bromo-alpha-ergokryptine-mesilate [German]; (+)-Bromocriptine methanesulfonate; BROMOCRIPTINE MESYLATE; Bromocriptine mesilate; CHEMBL1200503; (5'alpha)-2-bromo-12'-hydroxy-5'-isobutyl-2'-isopropyl-3',6',18-trioxoergotaman methanesulfonate; I06-2158; Ergotaman-3',6',18-trione, 2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-, monomethanesulfonate (salt), (5'alpha)-; Bromocriptine mesilate (JP15); Bromocriptine mesylate (USP); UNII-FFP983J3OD; 22260-51-1; EU-0100171; 2-Bromo-12'-hydroxy-5'alpha-isobutyl-2'-isopropylergotaman-3',6',18-trione monomethanesulphonate; B 2134; CID31100; Bromergon; .alpha.-Ergocryptine, 2-bromo-, methanesulfonate; Bromocryptine methanesulfonate; D00780; 2-Bromine-alpha-ergocryptine methanesulfonate; Prestwick_771; 2-Bromoergocryptine monomethanesulfonate (salt); CB 154; Pravidel; AC1L1KXP	22260-51-1	31101	10321720	TTDS00010	Dopamine receptor	N/A	N/A	N/A	N/A	agonist
DAP000317	Domperidone	KBio2_006007; UNII-5587267Z69; R-33,812; 5-Chloro-1-[1-[3-(2-oxo-1-benzimidazolinyl)propyl]-4-piperidyl]-2-benzimidazolinone; Spectrum4_000087; NCI299589; NSC299589; NCGC00021472-07; 2H-Benzimidazol-2-one, 1,3-dihydro-5-chloro-1-(1-(3-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)propyl)-4-piperidinyl)-; AB00052423; BPBio1_001185; Biomol-NT_000022; I14-14161; NCIStruc2_001819; 6-chloro-3-[1-[3-(2-oxo-3H-benzimidazol-1-yl)propyl]piperidin-4-yl]-1H-benzimidazol-2-one; CHEMBL219916; R-33812; DB01184; 5-chloro-1-{1-[3-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)propyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one; LS-33301; KW-5338; 4-(5-Chloro-2-oxo-1-benzimidazolinyl)-1-[3-(2-oxobenzimidazolinyl)propyl]piperidine; 5-chloro-1-(1-(3-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)propyl)-4-piperidinyl)-1,3-dihydro-2H-benzimidazol-2-one; AC1L1FAB; STK622843; Lopac0_000427; Prestwick3_000461; Prestwick0_000461; Motilium (TN); Domperidona [INN-Spanish]; Domperidonum; C22H24ClN5O2; D122_SIGMA; KBio2_003439; R 33,812; Domperidona; 5-24-02-00402 (Beilstein Handbook Reference); NCGC00021472-02; SMR000326802; NCGC00014670; HS-0067; MLS001306482; SPECTRUM2300212; SPBio_002501; KW 5338; NCGC00021472-06; I01-0054; KBioSS_000871; 2H-Benzimidazol-2-one, 5-chloro-1-(1-(3-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)propyl)-4-piperidinyl)-1,3-dihydro-; KBioGR_000354; Domperidonum [INN-Latin]; HMS2089C14; NCIStruc1_001686; NCGC00021472-08; SpecPlus_000825; 99497-03-7 (maleate); NCGC00021472-05; EU-0100427; Prestwick2_000461; HMS2093N22; BSPBio_002350; 83898-65-1 (maleate (1:1)); S2461_Selleck; NSC-299589; BRD-K38305202-001-02-6; MLS002222324; MLS000859942; CHEBI:31515; HMS1922N04; Domperidon; DivK1c_006921; Prestwick_794; Lopac-D-122; NCGC00014670-05; NCGC00015306-01; 2H-Benzimidazol-2-one, 5-chloro-1-[1-[3-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)propyl]-4-piperidinyl]-1,3-dihydro-; NCI60_002512; BRN 0903774; BPBio1_000620; L000230; NCGC00014670-13; NCGC00097773-01; AC-2037; NCGC00021472-04; CID3151; KBio2_000871; Domperidone (JAN/USAN/INN); NCGC00021472-03; EINECS 260-968-7; D-122; Nauzelin; D01745; KBio1_001865; Prestwick1_000461; 5-Chloro-1-[1-[3-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)propyl]-4-piperidinyl]- 1,3-dihydro-2H-benzimidazol-2-one; 57808-66-9; CHEBI:464745; 5-Chloro-1-(1-(3-(2-oxo-1-benzimidazolinyl)propyl)-4-piperidyl)-2-benzimidazolinone; domperidone; Motilium; Domperidone [USAN:BAN:INN:JAN]; Spectrum_000391	57808-66-9	3151	183089	TTDS00010	Dopamine receptor	N/A	N/A	N/A	N/A	antagonist
DAP001007	Fencamfamine	AC1Q4TUX; LS-97058; DB01463; Fencamfaminum [INN-Latin]; C15H21N; 2-NORBORNANAMINE, N-ETHYL-3-PHENYL-; Fencamfamin (INN); Reactivan; Euvitol; AC1L2453; Fencanfamina [INN-Spanish]; Bicyclo(2.2.1)heptan-2-amine, N-ethyl-3-phenyl-; DEA No. 1760; Fencamfamina; CHEMBL7010; 2240-14-4 (hydrochloride); 2-Phenyl-3-ethylaminobicyclo(2.2.1)heptane; Fencamfamina [DCIT]; Fencanfamina; N-ethyl-2-phenylbicyclo[2.2.1]heptan-3-amine; 2-ethylamino-3-phenylnorcamphane; D07343; 3-Phenyl-N-ethyl-2-norbornanamine; Fencamfaminum; Fencamfamin; 1209-98-9; Fencamfamin [INN:BAN]; Fenacamfamin; Fencamfamine [INN-French]; Fencamfamine; CID14584; MolPort-004-285-857; N-ethyl-3-phenylbicyclo(2.2.1)heptan-2-amine; 2-Ethylamino-3-phenylnorbornane	1209-98-9	14584	10452544	TTDS00010	Dopamine receptor	N/A	N/A	N/A	N/A	agonist
DAP000255	Lisuride	HMS1568E14; EINECS 241-925-1; UNII-E0QN3D755O; Prestwick_525; AC1L1G87; Prestwick0_000106; BSPBio_000092; Lisuride Maleate (1:1); N'-((8alpha)-9,10-Didehydro-6-methylergolin-8-yl)-N,N-diethylurea; 3-(9,10-Didehydro-6-methylergolin-8alpha-yl)-1,1-diethylurea; C20H26N4O; Lisuridum [INN-Latin]; Prestwick2_000106; Lisuride (INN); 18016-80-3; Lisuride (S)(-); Lysuride; Lisurida [INN-Spanish]; Lisuride [INN]; LISURIDE; Lysuride Hydrogen Maleate; CHEBI:51164; LS-159312; Lisuridum; CHEMBL157138; Methylergol Carbamide; D08132; Prestwick1_000106; 19875-60-6 (maleate (1:1)); Prestwick3_000106; 1,1-diethyl-3-[(8alpha)-6-methyl-9,10-didehydroergolin-8-yl]urea; Lysurid; SPBio_002031; Lopac0_000751; Lisurida; CID28864; BPBio1_000102; Urea, N'-((8alpha)-9,10-didehydro-6-methylergolin-8-yl)-N,N-diethyl-; DB00589; MolPort-003-943-009	18016-80-3	28864	171280	TTDS00010	Dopamine receptor	N/A	N/A	N/A	N/A	agonist
DPR000023	BL-1020	955400-87-0; BL 1020; Perphenazine 4-aminobutyrate; Butanoic acid, 4-amino-, 2-(4-(3-(2-chloro-10H-phenothiazin-10-yl)propyl)-1-piperazinyl)ethyl ester; BL-1020; 751477-01-7	1027512-25-9	213046	47362895	TTDS00010	Dopamine receptor	N/A	N/A	N/A	N/A	antagonist
DCL000726	BIM23A760	N/A	N/A	N/A	N/A	TTDS00010	Dopamine receptor	N/A	N/A	N/A	N/A	antagonist
DAP001515	Ropinirole HCl	91374-20-8; UNII-D7ZD41RZI9; Ropinirole HCl; MolPort-003-987-439; Requip (TN); SKF 101468; 4-[2-(dipropylamino)ethyl]-1,3-dihydro-2H-indol-2-one hydrochloride; JZP-7; 4-[2-(dipropylamino)ethyl]-1,3-dihydroindol-2-one hydrochloride; SKF 101468-A; AC-735; Ropinirole hydrochloride [USAN]; NCGC00094373-01; 2(H)-Indol-2-one, 4-(2-(dipropylamino)ethyl)-1,3-dihydro-, monohydrochloride; AC1Q3EQJ; Repreve; 2H-Indol-2-one, 1,3-dihydro-4-(2-(dipropylamino)ethyl)-, monohydrochloride; AR-1L3132; AC1L2ABS; Ropinirole hydrochloride (JAN/USAN); 4-(2-(Dipropylamino)ethyl)-2-indolinone monohydrochloride; ST51051236; I06-0693; ReQuip CR; R 4152; Ropinirole hydrochloride; 1,3-Dihydro-4-(2-(dipropylamino)ethyl)-2H-indol-2-one monohydrochloride; SK&F-101468A; 2H-Indol-2-one, 4-[2-(dipropylamino)ethyl]-1,3-dihydro-, hydrochloride (1:1); ReQuip; CID68727; TL8005858; SK&F-101468-A; CHEMBL1200411; ReQuip XL; LS-83828; 91374-21-9 (Parent); SK&F 101468-A; ReQuip XR; ReQuip LP; Adartrel; D00784; EU-0101101; NVD-434	91374-21-9	497540	46507918	TTDS00010	Dopamine receptor	N/A	N/A	N/A	N/A	agonist
DCL000987	SLV-308	SLV 308; D09366; 7-(4-methylpiperazin-1-yl)-3H-1,3-benzoxazol-2-one hydrochloride; 2(3H)-Benzoxazolone, 7-(4-methyl-1-piperazinyl)-, monohydrochloride; AC1OCFJC; SLV-308; Pardoprunox hydrochloride (USAN); 269718-83-4; DU-126891; SME-308; CID6918524; MolPort-005-942-398; Pardoprunox hydrochloride; UNII-U40903X6V8	N/A	6918525	12015433	TTDS00010	Dopamine receptor	N/A	N/A	N/A	N/A	antagonist
DAP000209	Levodopa	1E83F927-C221-46AA-B90A-81B33C5F3868; Dopasol; Veldopa; D9628_SIGMA; DB01235; Dopaston SE; MolPort-000-856-937; Dopaston; KBio2_006070; NCGC00016270-06; Eldopal; CHEBI:15765; Laradopa; L-O-Dihydroxyphenylalanine; 59-92-7; CAS-59-92-7; Brocadopa; L-beta-(3,4-Dihydroxyphenyl)-alpha-alanine; BPBio1_000059; DivK1c_000452; ne; L-(3, 4-Dihydroxyphenyl)alanine; L-.Beta.-(3,4-Dihydroxyphenyl)alanine; 25525-15-9; NINDS_000452; NCGC00016270-01; L Dopa; 90638-38-3; L-3-(3,4-Dihydroxyphenyl)alanine; Helfo-Dopa; Sobiodopa; Dopar; Dopaflex; Levodopa [USAN:INN:BAN:JAN]; L-DOPA; Levodopa; Maipedopa; AC1Q4U7F; l)-L-alanine; 3, 4-Dihydroxy-L-phenylalanine; Alanine, 3-(3, 4-dihydroxyphenyl)-, (-)-; Alanine, 3-(3,4-dihydroxyphenyl)-; Alanine, 3-(3,4-dihydroxyphenyl)-, L-; L-(3, 4-Dihydroxyphenyl)-.alpha.-alani; NCGC00015384-01; L-dopa; DAH; 37830_FLUKA; KBio2_000934; KBio2_003502; Prestwick0_000017; L-3,4-Dihydroxyphenylalanine; L-3-Hydroxytyrosine; Dopalina; Larodopa; Spectrum4_000539; nchembio.89-comp9; KBioSS_000934; SDCCGMLS-0066924.P001; CID6047; LS-255; 23734-74-9; SPBio_001974; alanine, 3-(3,4-dihydroxyphenyl)-, L-; HMS1922J14; Dopar (TN); Weldopa; NCGC00093869-04; 72572-99-7; Spectrum2_000496; Bendopa; (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid; D00059; Helfo DOPA; 3,4-Dihydroxyphenyl-L-alanine; Doprin; (-)-Dopa; C9H11NO4; Levodopa (JP15/USP); Ledopa; 3, 4-Dihydroxyphenylalanine; D0600; 88250-23-1; Prestwick1_000017; Prodopa; PDSP2_001525; D 9628; beta-(3,4-Dihydroxyphenyl)-alpha-alanine; L-Tyrosine, 3-hydroxy-; 3-(3,4-Dihydroxyphenyl)-L-alanine; Dopaidan; Deadopa; Ro 4-6316; 3,4-Dihydroxyphenylalanine; (-)-(3,4-Dihydroxyphenyl)alanine; (-)-3-(3,4-Dihydroxyphenyl)-L-alanine; .Beta.-(3, 4-Dihydroxyphenyl)alanine; .Beta.-(3,4-Dihydroxyphenyl)-L-alanine; 3-(3,4-Dihydroxypheny; Lopac0_000454; BSPBio_002354; Levodopum; 3,4-dihydroxy-L-phenylalanine; Levopa; Dopastral; 72573-00-3; Eurodopa; MLS000028514; Tyrosine, 3-hydroxy-; 587-45-1; Prestwick_185; HMS501G14; InChI=1/C9H11NO4/c10-6(9(13)14)3-5-1-2-7(11)8(12)4-5/h1-2,4,6,11-12H,3,10H2,(H,13,14; Dihydroxy-L-phenylalanine; SMR000058312; IV Levodopa; CHEMBL1009; HMS1568C15; Parda; CCRIS 3766; Doparkine; EU-0100454; Prestwick3_000017; Bio-0575; SPECTRUM2300205; UNII-46627O600J; L-beta-(3,4-Dihydroxyphenyl)alanine; Cidandopa; levodopa; 3,4-Dihydroxyphenylalanine (VAN); L-(-)-Dopa; bmse000322; HSDB 3348; BSPBio_000053; Alanine, 3-(3,4-dihydroxyphenyl)-, (-)-; PDSP1_001541; component of Sinemet; beta-(3,4-Dihydroxyphenyl)-L-alanine; Dopal-fher; Prestwick2_000017; KBio1_000452; KBioGR_001177; Cerepap; Levedopa; HMS2090O08; HMS2093N04; Levodopum [INN-Latin]; (-)-3-(3,4-Dihydroxyphenyl)-L-alanine; D9628; Syndopa; SPBio_000391; Levodopa (JP15/USP/INN); S1726_Selleck; L-(o-Dihydroxyphenyl)alanine; Doparl; L-DOPA, Parcopa, Atamet, Stalevo, Madopar, Prolopa, Dopar, 3,4-Dihydroxyphenylalanine, Levodopa; nchembio.2007.55-comp26; beta-(3,4-Dihydroxyphenyl)-alpha-L-alanine; AC1L1LOR; 3-Hydroxy-L-tyrosine; Eldopar; beta-(3,4-Dihydroxyphenyl)alanine; Lopac-D-9628; NSC 118381; Spectrum_000454; Eldopatec; Insulamina; Pardopa; NSC118381; Dopa; C00355; EINECS 200-445-2; Biodopa; BIDD:GT0158; 34241-25-3; L(-)-Dopa; L-o-Hydroxytyrosine; IDI1_000452; Spectrum5_001899; 2-Amino-3-(3,4-dihydroxyphenyl)propanoic acid; L-Dihydroxyphenylalanine; AC-11686	59-92-7	6047	7847127	TTDS00010	Dopamine receptor	N/A	N/A	N/A	N/A	agonist
DCL000785	DU-127090	CID208951; D06566; CHEBI:467160; D06567; DU127090; Bifeprunox mesylate (USAN); DU 127090; Bifeprunox (USAN/INN); 350992-10-8; L001659; Bifeprunoxum [INN-Latin]; Bifeprunoxum; CHEMBL218166; Bifeprunox mesilate; Bifeprunox; 7-[4-[(3-phenylphenyl)methyl]piperazin-1-yl]-3H-1,3-benzoxazol-2-one; 350992-13-1; 362524-71-8; 7-(4-(Biphenyl-3-ylmethyl)piperazin-1-yl)benzoxazol-2(3H)-one; DU-127090; CID6918587; AC1OCFM9; MolPort-005-943-082; Bifeprunox [INN]; AC1L4LOA; UNII-AP69E83Z79; methanesulfonic acid; 7-[4-[(3-phenylphenyl)methyl]piperazin-1-yl]-3H-1,3-benzoxazol-2-one; Bifeprunox mesylate	362524-71-8	208951	12015562	TTDS00010	Dopamine receptor	N/A	N/A	N/A	N/A	antagonist
DCL000795	Entacapone+levodopa+carbidopa	N/A	130929-57-6 + 59-92-7	N/A	10550026	TTDS00010	Dopamine receptor	N/A	N/A	N/A	N/A	agonist
DAP001418	Prolixin decanoate	NSC169510; Flufenazine decanoate; Fluphenazine O-decanoate; EINECS 225-672-4; AC1Q4K03; D00793; Prolixin decanoate (TN); NSC 169510; Modecate; CCRIS 3954; CHEMBL1200854; AKOS003589045; Dapotum D; Moditen depot; Fluphenazine decanoate (JAN/USP); MolPort-001-728-034; BRN 0599852; UNII-FMU62K1L3C; CID3388; AR-1J0863; Decanoic acid, 2-(4-(3-(2-(trifluoromethyl)phenothiazin-10-yl)propyl)-1-piperazinyl)ethyl ester; Fluphenazine depot; 5002-47-1; Decanoic acid, 2-[4-[3-[2-(trifluoromethyl)phenothiazin-10-yl]propyl]-1-piperazinyl]ethyl ester; Fluphenaline decanoate; Moditen-depo; SQ 10,733; WLN: T C666 BN ISJ EXFFF B3- AT6N DNTJ D2OV9; LS-59383; C32H44F3N3O2S; 2-(4-{3-[2-(trifluoromethyl)-10H-phenothiazin-10-yl]propyl}piperazin-1-yl)ethyl decanoate; AC1L1FTN; Decanoic acid, 2-(4-(3-(2-(trifluoromethyl)-10H-phenothiazin-10-yl)propyl)-1-piperazinyl)ethyl ester; Fluphenazine decanoate; 2-(4-(3-(2-(Trifluoromethyl)phenothiazin-10-yl)propyl)-1-piperazinyl)ethyl decanoate; Fluorophenazine decanoate; 2-[4-[3-[2-(trifluoromethyl)phenothiazin-10-yl]propyl]piperazin-1-yl]ethyl decanoate; Decanoic acid, 2-[4-[3-[2-(trifluoromethyl)-10H-phenothiazin-10-yl]propyl]-1-piperazinyl]ethyl ester	5002-47-1	11191402	163878	TTDS00010	Dopamine receptor	N/A	N/A	N/A	N/A	antagonist
DAP000315	Thiethylperazine	Thiethylperazine (USAN/INN); Thiethylperazinum [INN-Latin]; AB00514742; CHEMBL1378; ETHYLTHIOPERAZINE; 52239-63-1 (malate (1:2)); AC1L1KCZ; NSC130044; 3-Ethylmercapto-10-(1'-methylpiperazinyl-4'-propyl)phenothiazine; UNII-8ETK1WAF6R; Norzine (*Dimaleate*); DB00372; L000871; Thiethylperazinum; LS-105543; Thiethylpipezazine; GS-95 (*Dimaleate*); HSDB 3400; EINECS 215-819-0; D02354; 1179-69-7 (maleate (1:2)); Phenothiazine, 2-(ethylthio)-10-(3-(4-methyl-1-piperazinyl)propyl)-; 2-(ethylsulfanyl)-10-[3-(4-methylpiperazin-1-yl)propyl]-10H-phenothiazine; Torecan; Thiethylperazine [USAN:INN:BAN]; CID5440; Theithylperazine; Tietilperazina; C07132; 1420-55-9; Tietilperazina [DCIT]; 10H-Phenothiazine, 2-(ethylthio)-10-[3-(4-methyl-1-piperazinyl)propyl]-; 2-ethylsulfanyl-10-[3-(4-methylpiperazin-1-yl)propyl]phenothiazine; Thioethylperazine; 10H-Phenothiazine, 2-(ethylthio)-10-(3-(4-methyl-1-piperazinyl)propyl)-; CHEBI:9544; C22H29N3S2; 2-(Ethylthio)-10-(3-(4-methyl-1-piperazinyl)propyl)phenothiazine; 2-(ethylthio)-10-[3-(4-methylpiperazin-1-yl)propyl]-10H-phenothiazine; 10H-Phenothiazine, 2-(ethylthio)-10-[3-(4-methyl-1-piperazinyl)propyl]-, (Z)-2-butenedioate (1:2); thiethylperazine	1420-55-9	5440	618292	TTDS00010	Dopamine receptor	N/A	N/A	N/A	N/A	antagonist
DAP000318	Thiothixene	Thiothixene Hydrochloride (base); PDSP2_000622; Navaron; SPBio_001485; KBio2_004116; PDSP2_000168; Spectrum5_001150; PDSP1_000038; DB01623; MolPort-000-006-316; D00374; N,N-Dimethyl-9-(3-(4-methylpiperazin-1-yl)propylidene)-9H-thioxanthene-2-sulphonamide; NSC 108165; AC1LJ0FD; P 4657B; HSDB 3402; PDSP2_000548; CID941650; SMR000058396; PDSP1_000169; Orbinamon; Tiotixenum [INN-Latin]; HMS1921E13; MLS000028463; Thioxanthene-2-sulfonamide, N,N-dimethyl-9-(3-(4-methyl-1-piperazinyl)propylidene)-, (E)-; DivK1c_000335; Tiotixeno [INN-Spanish]; NCGC00162353-01; Spectrum2_001333; N,N-Dimethyl-9-(3-(4-methyl-1-piperazinyl)propylidene)thioxanthene-2-sulfonamide; MolPort-000-006-315; PDSP1_000626; 5591-45-7; Tiotixene (JAN); BIDD:PXR0153; T4937_SIAL; Tiotixeno; CID5454; NCGC00094793-04; T15560; ST060258; 9H-Thioxanthene-2-sulfonamide, N,N-dimethyl-9-[3-(4-methyl-1-piperazinyl)propylidene]-; AR-1H5778; Tiotixene; LS-153666; (9E)-N,N-dimethyl-9-[3-(4-methylpiperazin-1-yl)propylidene]thioxanthene-2-sulfonamide; cis-Thiothixene; KBio2_001548; NSC-108165; P-4657A; CID941651; P-4657 B; PDSP2_000038; HMS2092M15; NCGC00015998-01; KBio3_001522; AC1Q6V49; EINECS 227-001-0; N,N-Dimethyl-9-[3-(4-methyl-1-piperazinyl)propylidene]thioxanthene-2-sulfonamide; Thiothixene hydrochloride; CP-12,252-1 base; P-4657B; Spectrum3_000581; WLN: T C666 BS IYJ FSWN1&1 IU3- AT6N DNTJ D1; Navan; CHEMBL1201; PDSP1_000625; MLS001146956; Spectrum_001068; SMR000653538; LS-153663; NINDS_000335; 2-(Dimethylsulfamoyl)-(9-(4-methyl-1-piperazinyl)propylidene)thioxanthene; UNII-7318FJ13YJ; KBioSS_001548; 9H-Thioxanthene-2-sulfonamide, N, {N-dimethyl-9-[3-(4-methyl-1-piperazinyl)propylidene]-,} (Z)-; {2-(Dimethylsulfamoyl)-[9-(4-methyl-1-piperazinyl)propylidene]thiox} anthene; 9H-Thioxanthene-2-sulfonamide, N,N-dimethyl-9-(3-(4-methyl-1-piperazinyl)propylidene)-, (Z)-; MLS001360493; P-4657-B; Thioxanthene-2-sulfonamide, N,N-dimethyl-9-(3-(4-methyl-1-piperazinyl)propylidene)-; KBio2_006684; CP 12252-1; Tiotixenum; 9H-Thioxanthene-2-sulfonamide, N,N-dimethyl-9-[3-(4-methyl-1-piperazinyl)propylidene]-, (Z)-; KBio1_000335; PDSP1_000550; Oprea1_774264; Lopac0_001144; (9E)-N,N-dimethyl-9-[3-(4-methylpiperazin-1-yl)propylidene]-9H-thioxanthene-2-sulfonamide; trans-N,N-Dimethyl-9-(3-(4-methyl-piperazinyl)propylidene)thioxanthene-2-sulfonamide; AC1L1KDT; LS-153667; HMS501A17; SPECTRUM1500576; Thiothixine; thiothixene; Thiothixene [USAN:BAN]; CP-12,252-1; Thiothixene (USP); N,N-Dimethyl-9-[3-(4-methyl-1-piperazinyl)propylidene]thiaxanthene-2-sulfonamide; N,N-dimethyl-9-[3-(4-methylpiperazin-1-yl)propylidene]thioxanthene-2-sulfonamide; (9Z)-N,N-dimethyl-9-[3-(4-methylpiperazin-1-yl)propylidene]thioxanthene-2-sulfonamide; cis-N,N-Dimethyl-9-(3-(4-methyl-1-piperazinyl)propylidene)thioxanthene-2-sulfonamide; AC1LJ0FG; 9H-Thioxanthene-2-sulfonamide, N,N-dimethyl-9-(3-(4-methyl-1-piperazinyl)propylidene)-; Navane; 3313-26-6; trans-Thiothixene; IDI1_000335; BRD-K97309399-001-02-9; Thiothixene (Z); T15550; Thioxanthene-2-sulfonamide, N,N-dimethyl-9-(3-(4-methyl-1-piperazinyl)propylidene)-, (Z)-; BSPBio_002022; L001204; Navane (TN); NCGC00094793-01; (E)-Thiothixene; C23H29N3O2S2; NCGC00094793-02; 3313-27-7; Lopac-T-0780; NSC108165	5591-45-7	941651	10391422	TTDS00010	Dopamine receptor	N/A	N/A	N/A	N/A	antagonist
DCL000442	ATL1103	N/A	N/A	N/A	N/A	TTDC00345	mRNA of growth hormone receptor	mRNA of GH receptor;mRNA of Somatotropin receptor;mRNA of GHR	P10912	2690	ENSG00000112964	antisense
DAP000157	Enfuvirtide	peptide T20; L-Phenylalaninamide, N-acetyl-L-tyrosyl-L-threonyl-L-seryl-L-leucyl-L-isoleucyl-L-histadyl-L-seryl-L-leucyl-L-isoleucyl-L-alpha-glutamyl-L-alpha-glutamyl-L-seryl-L-glutaminyl-L-asparaginyl-L-glutaminyl-L-glutaminyl-L-alpha-glutamyl-L-lysyl-L-asparaginyl-L-alpha-glutamyl-L-glutaminyl-L-alpha-glutamyl-L-leucyl-L-leucyl-L-alpha-glutamyl-L-leucyl-L-alpha-aspartyl-L-lysyl-L-tryptophyl-L-alanyl-L-seryl-L-leucyl-L-tryptophyl-L-asparaginyl-L-tryptophyl-; N-Acetyl-L-tyrosyl-L-threonyl-L-seryl-L-leucyl-L-isoleucyl-L-histadyl-L-seryl-L-leucyl-L-isoleucyl-L-alpha-glutamyl-L-alpha-glutamyl-L-seryl-L-glutaminyl-L-asparaginyl-L-glutaminyl-L-glutaminyl-L-alpha-glutamyl-L-lysyl-L-asparaginyl-L-alpha-glutamyl-L-glutaminyl-L-alpha-glutamyl-L-leucyl-L-leucyl-L-alpha-glutamyl-L-leucyl-L-alpha-aspartyl-L-lysyl-L-tryptophyl-L-alanyl-L-seryl-L-leucyl-L-tryptophyl-L-asparaginyl-L-tryptophyl-L-phenylalaninamide; T20 peptide; T-20 cpd; Pentafuside; Dp 178; DP178; Fuzeon; Enfuvirtide; Enfuvirtide [USAN]; LS-183961; HSDB 7341; L-Phenylalaninamide, N-acetyl-L-tyrosyl-L-threonyl-L-seryl-L-leucyl-L-isoleucyl-L-histidyl-L-seryl-L-leucyl-L-isoleucyl-L-alpha-glutamyl-L-alpha-glutamyl-L-seryl-L-glutaminyl-L-asparaginyl-L-glutaminyl-L-glutaminyl-L-alpha-glutamyl-L-lysyl-L-asparaginyl-L-alpha-glutamyl-L-glutaminyl-L-alpha-glutamyl-L-leucyl-L-leucyl-L-alpha-glutamyl-L-leucyl-L-alpha-aspartyl-L-lysyl-L-tryptophyl-L-alanyl-L-seryl-L-leucyl-L-tryptophyl-L-asparaginyl-L-tryptophyl-; 262434-79-7; UNII-19OWO1T3ZE; C105196; T 20 (peptide); Roche brand of pentafuside; T-20; T 20	159519-65-0	16130199	623635	TTDS00325	Transmembrane glycoprotein gp41	Glycoprotein gp41;HIV-1 gp41;HIV-1 gp41 envelope glycoprotein	O40239	N/A	N/A	inhibitor
DAP000123	Pancuronium	Pavulon; AB00384328; NCGC00023037-03; NA 97; Pancuronii bromidum; Prestwick3_001034; 15500-66-0; EU-0100887; DB01337; Mioblock; HMS2089M07; NSC293162; CHEMBL185073; Piperidinium, 1,1'-[(2.beta.,3.alpha.,5.alpha.,16.beta.,17.beta.)-3,17-bis(acetyloxy)androstane-2,16-diyl]bis[1-methyl-, dibromide; HMS1571O09; Prestwick2_001034; Piperidinium, 1,1'-((2beta,3alpha,5alpha,16beta,17beta)-3,17-bis(acetyloxy)androstane-2,16-diyl)bis(1-methyl)-, dibromide; Piperidinium, 1,1'-(3alpha,17beta-dihydroxy-5alpha-androstan-2beta,16beta-ylene)bis(1-methyl-, dibromide, diacetate (8CI); Piperidinium, 1,1'-(3alpha,17beta-dihydroxy-5alpha-androstan-2beta,16beta-ylene)bis(1-methyl-, dibromide, diacetate; pancuronium; 5alpha-Androstan-3alpha,17beta-diol, 2beta,16beta-dipipecolinio-, dibromide, diacetate; Piperidinium, 1,1'-(2-beta,16-beta-(3-alpha,17-beta-dihydroxy-5-alpha-androstanylene))bis(1-methyl-, dibromide, diacetate; Pavulon (TN); Bromuro de pancuronio; EINECS 239-532-5; ORG NA 97; UNII-U9LY9Y75X2; Pancuronii bromidum [INN-Latin]; 1,1'-(3,17-Bis(acetyloxy)androstane-2,16-diyl)bis(1-methylpiperidinium) dibromide; PANCURONIUM BROMIDE; BPBio1_001372; CID27350; CID441289; Lopac0_000887; 2beta,16beta-Dipiperidino-5alpha-androstane-3alpha,17beta-dioldiacetatedimethobromide; Bromure de pancuronium [INN-French]; BSPBio_001247; C07551; 3alpha,17beta-diacetoxy-2beta,16beta-bis(1-methylpiperidinium-1-yl)-5alpha-androstane dibromide; Pancuronium bromide [USAN:BAN:INN:JAN]; Bromure de pancuronium; HSDB 3244; P 1918; NCGC00023037-05; SPBio_003098; [(2S,3S,5S,8R,9S,10S,13S,14S,16S,17R)-17-acetyloxy-10,13-dimethyl-2,16-bis(1-methylpiperidin-1-ium-1-yl)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl] acetate dibromide; Prestwick0_001034; NSC 293162; P1918_SIGMA; CHEBI:7907; ORG-NA 97; CHEBI:7908; CHEMBL1200757; 3alpha,17beta-diacetoxy-2beta,16beta-bis(1-methylpiperidinium-1-yl)-5alpha-androstane; Bromuro de pancuronio [INN-Spanish]; 3alpha,17beta-Diacetoxy-2beta,16beta-dipiperidino-5alpha-androstane dimethobromide; AC1L9AWJ; Ambap15500-66-0; Pancuronium dibromide; 1,1'-(3alpha,17beta-Dihydroxy-5alpha-androstan-2beta,16beta-ylene)bis(1-methylpiperidinium) dibromide diacetate; [(2S,3S,5S,8R,9S,10S,13S,14S,16S,17R)-17-acetyloxy-10,13-dimethyl-2,16-bis(1-methylpiperidin-1-ium-1-yl)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl] acetate; LS-116480; S2497_Selleck; (2beta,3alpha,5alpha,16beta,17beta)-3,17-bis(acetyloxy)-2,16-bis(1-methylpiperidinium-1-yl)androstane dibromide; NCGC00023037-04; Piperidinium, 1,1'-((2beta,3alpha,5alpha,16beta,17beta)-3,17-bis(acetyloxy)androstane-2,16-diyl)bis(1-methyl-, dibromide; Prestwick1_001034; 1,1'-(3alpha,17beta-Bis(acetyloxy)-5alpha-androstane-2beta,16beta-diyl)bis(1-methylpiperidinium) dibromide; 3-alpha,17-beta-Diacetoxy-2-beta,16-beta-dipiperidino-5-alpha-androstane dimethobromide; AC1L1D1A; 2beta,16beta-Dipiperidino-5alpha-androstane-3alpha,17beta-diol diacetate dimethobromide; 1,1'-([2beta,3alpha,5alpha,16beta,17beta]-3,17-Bis[acetyloxy]androstane-2,16-diyl)bis(1-methylpiperidinium) dibromide; Pancuronium bromide (JP15/USAN/INN); MolPort-003-938-961; 1,1'-[(2beta,3alpha,5alpha,16beta,17beta)-3,17-bis(Acetyloxy)androstane-2,16-diyl]bis(1-methylpiperidinium) dibromide; C35H60N2O4; D00492; Poncuronium bromide	15500-66-0	27350	169954	TTDS00303	Nicotinic acetylcholine receptor	nAChR;Nicotinergic acetylcholine receptor	N/A	N/A	N/A	antagonist
DPR000078	NAChRs agonist	N/A	N/A	N/A	N/A	TTDS00303	Nicotinic acetylcholine receptor	nAChR;Nicotinergic acetylcholine receptor	N/A	N/A	N/A	agonist
DAP000196	Cisatracurium Besylate	LS-178337; C53H72N2O12.2C6H5O3S; (1R-cis,1'R-cis)-Atracurium besylate; D00759; Atracurium besylate 1R-cis,1R'-cis form; Nimbex Forte; Cisatracurium besilate; benzenesulfonate; 5-[3-[(1R,2R)-1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propanoyloxy]pentyl 3-[(1R,2R)-1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propanoate; Cisatracurium; UNII-80YS8O1MBS; Cisatracurium besylate (USAN); CHEBI:3721; (1R,2R)-2-(2-Carboxyethyl)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-veratrylisoquinolinium benzenesulfonate, pentamethylene ester; NCGC00017127-01; MolPort-003-987-490; AC1L1XZG; Nimbium; Cisatracurium besylate [USAN:BAN]; CAS-64228-81-5; AC1Q22ND; TL8006016; Cisatracurium besilate (INN); CID62886; Nimbex; DB00565; Isoquinolinium, 2,2'-(1,5-pentanediylbis(oxy(3-oxo-3,1-propanediyl)))bis(1-((3,4-dimethoxyphenyl)methyl)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-, dibenzenesulfonate, (1R-(1alpha,2alpha(1'R(sup *),2'R(sup *))))-; cisatracurium besylate(usan); CHEMBL1200641; 51W89; NIMBEX PRESERVATIVE FREE; 96946-42-8; Nimbex (TN); Cisatracurium besylate	96946-42-8	62886	7847824	TTDS00303	Nicotinic acetylcholine receptor	nAChR;Nicotinergic acetylcholine receptor	N/A	N/A	N/A	antagonist
DPR000037	Dianicline+rimonabant	N/A	292634-27-6	8378	49703385	TTDS00303	Nicotinic acetylcholine receptor	nAChR;Nicotinergic acetylcholine receptor	N/A	N/A	N/A	agonist
DCL001024	TRIDMAC	N/A	1142-43-4	1054	49737753	TTDS00303	Nicotinic acetylcholine receptor	nAChR;Nicotinergic acetylcholine receptor	N/A	N/A	N/A	antagonist
DAP000027	Mecamylamine	Spectrum_000304; EINECS 200-476-1; Spectrum4_001257; AKOS003662515; N,2,3,3-Tetramethylbicyclo[2.2.1]heptan-2-amine; Mevasin hydrochloride; KBio1_001776; Prestwick2_001111; 3-Methylaminoisokamfan; Mecamylamine [INN:BAN]; Mecamine; CHEBI:100880; AB00053764; C07511; Spectrum5_001616; 3-Methylaminoisokamfan [Czech]; Mecamylaminum [INN-Latin]; 2-Methylaminoisocamphane; KBio3_001512; (-)-Mecamylamine; Mecamilamina [DCIT]; KBio2_003352; Spectrum3_000736; 3-Methylaminoisocamphane; BSPBio_002292; Mecamilamina; 3-beta-Methylamino-2,2,3-trimethylbicyclo(2.2.1)heptane; 2-Methylamino-2,3,3-trimethylnorbornane; AC1L1H9E; KBio2_000784; UNII-6EE945D3OK; SpecPlus_000736; Bicyclo(2.2.1)heptan-2-amine, N,2,3,3-tetramethyl-; BSPBio_001242; CHEMBL267936; C11H21N; Inversine hydrochloride; Mekamine; DivK1c_006832; NCGC00162272-01; 60-40-2; Versamine; Mevasine; mecamylamine; Mecamylaminum; BPBio1_001367; KBioSS_000784; LS-97063; NCGC00162272-02; CID4032; Mecamilamina [Italian]; KBioGR_001814; 2-Norbornanamine, N,2,3,3-tetramethyl-; AR-1J2400; N,2,3,3-Tetramethyl-2-norcamphanamine; Bicyclo[2.2.1]heptan-2-amine, N,2,3,3-tetramethyl-; Prestwick3_001111; Lopac0_000841; MolPort-002-052-009; Revertina; ST088032; D008464; N-Methyl-2-isocamphanamine; DB00657; Prestwick0_001111; NCGC00015703-04; Prestwick1_001111; N,2,3,3-Tetramethyl-2-norbornamine; KBio2_005920; SPBio_003111; (+)-Mecamylamine; N,2,2,3-tetramethylbicyclo[2.2.1]heptan-3-amine	60-40-2	4032	9714	TTDS00303	Nicotinic acetylcholine receptor	nAChR;Nicotinergic acetylcholine receptor	N/A	N/A	N/A	antagonist
DAP001535	Varenicline tartrate	AC1L55H3; AC1Q5QUE; D06282; 6,10-Methano-6H-pyrazino(2,3-h)(3)benzazepine, 7,8,9,10-tetrahydro-, (2R,3R)-2,3-dihydroxybutanedioate (1:1); Chantix; AR-1H2912; Chantix, Champix, Varenicline tartrate; UNII-82269ASB48; CP-526555-18; 7,8,9,10-tetrahydro-6h-6,10-methanoazepino[4,5-g]quinoxaline 2,3-dihydroxybutanedioate(1:1); S1440_Selleck; LS-186594; 375815-87-5; 7,8,9,10-Tetrahydro-6,10-methano-6H-pyrazino(2,3-h)(3)benzazepine (2R,3R)-2,3-dihydroxybutanedioate; CP 526555-18; CHEMBL1201135; CID6918678; AKOS005146509; Varenicline tartrate (USAN); Champix; Chantix (TN); Varenicline tartrate [USAN]; Varenicline tartrate; I14-8434; CID170362; CID9906942	375815-87-5	444305	47207939	TTDS00303	Nicotinic acetylcholine receptor	nAChR;Nicotinergic acetylcholine receptor	N/A	N/A	N/A	agonist
DCL000675	ABT-089	2-methyl-3-[[(2S)-pyrrolidin-2-yl]methoxy]pyridine; 2-methyl-3-[[(2R)-pyrrolidin-2-yl]methoxy]pyridine; Pozanicline; CID127922; 161417-03-4; AC1L2SVN; Pozanicline (USAN); Abt-089; PDSP2_001311; Pyridine, 2-methyl-3-(2-pyrrolidinylmethoxy)-, (R)-; CHEMBL126692; CHEMBL127071; AC1L434V; D09367; PDSP2_001310; PDSP1_001327; Pyridine, 2-methyl-3-((2S)-2-pyrrolidinylmethoxy)-; CID178052; UNII-CL2002R563; PDSP1_001326; 2-Methyl-3-(2-pyrrolidinylmethoxy)pyridine; ABT 089; 161417-20-5; 2-Methyl-3-(2S-pyrrolidinylmethoxy)pyridine; CHEBI:309696; (R)-2-Methyl-3-(2-pyrrolidinylmethoxy)pyridine; Pyridine, 2-methyl-3-(2-pyrrolidinylmethoxy)-, (S)-; A 94224; CHEBI:310037	161417-03-4	178052	755276	TTDS00303	Nicotinic acetylcholine receptor	nAChR;Nicotinergic acetylcholine receptor	N/A	N/A	N/A	agonist
DCL000771	Dexefaroxan	Dexefaroxan; 2-Imidazoline, 2-(2-ethyl-2,3-dihydro-2-benzofuranyl)-, ( )-(R)-; NCGC00015410-01; KST-1A1946; AR-1A0132; Lopac-E-3263; CID208820; UNII-F751MO69EV; AC1Q4UEV; AC1L4LF7; (+)-(r)-2-(2-ethyl-2,3-dihydro-2-benzofuranyl)-2-imidazoline; NCGC00024793-01; Tocris-0792; 2-[(2R)-2-ethyl-3H-1-benzofuran-2-yl]-4,5-dihydro-1H-imidazole; Dexefaroxan [INN]; 16950-79-1	143249-88-1	208820	783638	TTDS00303	Nicotinic acetylcholine receptor	nAChR;Nicotinergic acetylcholine receptor	N/A	N/A	N/A	agonist
DAP000175	Nicotine	1uw6; 46343_FLUKA; beta-Pyridyl-alpha-N-methyl pyrrolidine; (-)-Nicotine; MLS001335905; PDSP1_000465; SAM002564224; LS-202; PDSP2_000555; ENT 3,424; Nikotin [German]; nicotine; Nikotyna [Polish]; N5511_FLUKA; Nicotine (compounds related to); NCGC00090693-03; (-)-Nicotine solution; AC1L3I79; MLS001055457; NCGC00090693-06; CHEBI:17688; Nicotine [UN1654] [Poison]; Caswell No. 597; EPA Pesticide Chemical Code 056702; Nicotine (USP); 36733_RIEDEL; 36733_FLUKA; 3-(N-Methylpyrrolidino)pyridine; Nicotina [Italian]; NCGC00090693-02; (2S) 3-(1-Methyl-pyrrolidin-2-yl)-pyridine; (S)-Nicotine; 434F7990-3240-4A43-ACEC-E6CC1E495FA0; Habitrol (TN); NCT; EINECS 200-193-3; NCGC00090693-05; CID89594; SDCCGMLS-0066911.P001; CPD000059074; bmse000105; L(-)-nicotine; CCRIS 1637; Nicoderm Patch; (S)-3-(1-methylpyrrolidin-2-yl)pyridine; PDSP2_000463; Nicotine [BSI:ISO]; 3-(2-(N-methylpyrrolidinyl))pyridine; (S)-3-(N-methylpyrrolidin-2-yl)pyridine; RCRA waste number P075; (&#8722;)-Nicotine; N3876_SIGMA; BIDD:GT0599; (&#8722;)-1-Methyl-2-(3-pyridyl)pyrrolidine; 46343_RIEDEL; 54-11-5; NCGC00090693-01; Nictoine patch; (S)-(-)-Nicotine; BRD-K05395900-322-02-1; Nicotine Patch; MolPort-000-744-731; BB_NC-0777; Pyridine, 3-((2S)-1-methyl-2-pyrrolidinyl)-; CHEMBL3; AC1Q3ZOC; SMR000059074; D03365; NSC97238; PDSP1_000113; 3-[(2S)-1-methylpyrrolidin-2-yl]pyridine; C00745; NSC 5065; AI3-03424; NICOTINE AND SALTS; NCGC00090693-04; (S)-(-)-NICOTINE, 3-[(2S)-1-METHYL-2-PYRROLIDINYL] PYRIDINE; N5511_SIGMA; Micotine; 3-(N-Methylpyrollidino)pyridine; Nicotine [USAN]; (&#8722;)-Nicotine solution; Habitrol; RCRA waste no. P075; UN1654; HSDB 1107; NCGC00090693-07; nicotine replacement patch; Transdermal Nicotine	54-11-5	942	148704	TTDS00303	Nicotinic acetylcholine receptor	nAChR;Nicotinergic acetylcholine receptor	N/A	N/A	N/A	antagonist
DAP000105	Atracurium	Isoquinolinium, 2,2'-(1,5-pentanediylbis(oxy(3-oxo-3,1-propanediyl)))bis(1-((3,4-dimethoxyphenyl)methyl)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-; DB00732; AC1L2HUF; CHEBI:2914; AB00514743; SPBio_001930; LS-86151; 64228-79-1; 2,2'-{pentane-1,5-diylbis[oxy(3-oxopropane-3,1-diyl)]}bis[1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolinium]; Isoquinolinium, 1,2,3,4-tetrahydro-2,2'-(1,5-pentanediylbis(oxy(3-oxo-3,1-propanediyl)))bis(1-((3,4-dimethoxyphenyl)methyl)-6,7-dimethoxy-2-methyl-; CID47319; 64228-81-5 (besylate); Prestwick2_000005; 5-[3-[1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propanoyloxy]pentyl 3-[1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propanoate; BRN 1523633; UNII-2GQ1IRY63P; AC1Q67HR; C53H70N2O12; BPBio1_000011; Atracurium; Prestwick1_000005; CHEMBL1360; Atracurium Dibesylate; MolPort-005-932-641; HMS2090I21; C07548; Isoquinolinium, 2,2'-(1,5-pentanediylbis(oxy(3-oxo-3,1-propanediyl)))bis(1-((3,4-dimethoxyphenyl)methyl))-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-; BSPBio_000009; Prestwick3_000005	64228-79-1	47319	9751	TTDS00303	Nicotinic acetylcholine receptor	nAChR;Nicotinergic acetylcholine receptor	N/A	N/A	N/A	antagonist
DAP001460	Benztropine mesylate	SMR000394012; AC1MMXWK; Cogentin (TN); NCGC00016118-02; (1R,5S)-3-benzhydryloxy-8-methyl-8-azabicyclo[3.2.1]octane; methanesulfonic acid; WLN: T56 A ANTJ A1 GOYR & R & OSW1; (1R,5R)-3-benzhydryloxy-8-methyl-8-azabicyclo[3.2.1]octane; methanesulfonic acid; 3-(diphenylmethoxy)-8-methyl-8-azabicyclo[3.2.1]octane; methanesulfonic acid; 1alphaH,5alphaH-Tropane, 3alpha-(diphenylmethoxy)-, methanesulfonate; N-methylbenztropine; AC1L1RAS; 8-Azabicyclo(3.2.1)octane, 3-(diphenylmethoxy)-8-methyl-, endo-, methanesulfonate (9CI); LS-157781; NCGC00016118-01; 3-benzhydryloxy-8-methyl-8-azabicyclo[3.2.1]octane; methanesulfonic acid; SAM002548938; (5R)-3-benzhydryloxy-8-methyl-8-azabicyclo[3.2.1]octane; methanesulfonic acid; NSC42199; Benztropine mesilate (JAN); NSC 169913; EU-0100194; benzatropine mesylate; Benztropine mesilate; CPD000394012; 132-17-2; Tropine benzohydryl ether methanesulfonate; CID8584; BENZTROPINE MESYLATE; Benztropine methanesulfonate; 8-Azabicyclo(3.2.1)octane, 3-(diphenylmethoxy)-8-methyl-, endo-, methanesulfonate; NCGC00013495; Benztropine mesylate (USP); AR-1E7617; AC1L604T; endo-3-(Diphenylmethoxy)-8-methyl-8-azoniabicyclo(3.2.1)octane methanesulphonate; CHEMBL1200383; MolPort-003-844-725; AC1Q4GST; 1-alpha-H,5-alpha-H-Tropane, 3-alpha-(diphenylmethoxy)-, methanesulfonate; 1.alpha.H,5.alpha.H-Tropane, 3.alpha.-(diphenylmethoxy)-, methanesulfonate; Benzotropine mesylate; AC1L9B11; 3alpha-(Diphenylmethoxy)-1alphaH,5alphaH-tropane methanesulfonate; I01-0267; Cogentin; 3-Diphenylmethoxytropane methanesulfonate; Benztropine mesylate [USP]; 1alphaH,5alphaH-Tropane, 3alpha-(diphenylmethoxy)-, methanesulfonate (8CI); Benzotropinemesylate; CID3246155; NCGC00093670-01; Cogentin mesylate; UNII-WMJ8TL7510; MLS000737056; EINECS 205-048-8; Benzotropine methanesulfonate; ST50997629; NCGC00096609-01; C21H25NO; 8-Azabicyclo[3.2.1]octane, 3-(diphenylmethoxy)-8-methyl-, endo-, methanesulfonate; benzhydryl 8-methyl-8-azabicyclo[3.2.1]oct-3-yl ether methanesulfonate; 3-(diphenylmethoxy)-8-methyl-8-azabicyclo[3.2.1]octane methanesulfonate(1:1); CID441352; Lopac-B-8262; AC1Q6WCX; 3-Diphenyl methoxytropane methanesulfonate; MK 02; CHEMBL85236; NSC169913; Cogentin methanesulfonate; CID238053; B 8262; NSC-42199; Cobrentin methanesulfonate; NCI42199; D00778; 3-alpha-(Diphenylmethoxy)-1-alpha-H, 5-alpha-H-tropane methanesulfonate; 3-(Diphenylmethoxy)-8-methyl-8-azabicyclo[3.2.1]octane methane sulfonate; Benzatropine methanesulfonate; 3-Diphenylmethoxytropane mesylate	132-17-2	73303	7847843	TTDS00303	Nicotinic acetylcholine receptor	nAChR;Nicotinergic acetylcholine receptor	N/A	N/A	N/A	antagonist
DPR000036	Dianicline	CID 9816447; SSR591813; 292634-27-6; SSR591813L; UNII-Y0SNM34C6O; 5a,6,9,10-Tetrahydro-7H,11H-8,10a-methanopyrido(2',3'-5,6)pyrano(2,3-d)azepine; CID9816447; Dianicline	292634-27-6	72392	48416317	TTDS00303	Nicotinic acetylcholine receptor	nAChR;Nicotinergic acetylcholine receptor	N/A	N/A	N/A	agonist
DCL000450	AZD0328	Spiro[1-azabicyclo[2.2.2]octane-8,8'-7-oxa-5-azabicyclo[4.3.0]nona-2,4,10-triene]; CID9794392; AR-R23465XX; AZD-0328	N/A	5312125	39341745	TTDS00303	Nicotinic acetylcholine receptor	nAChR;Nicotinergic acetylcholine receptor	N/A	N/A	N/A	agonist
DCL000407	GSK1292263	N/A	N/A	N/A	N/A	TTDC00230	Gastrin-releasing peptide receptor	Bombesin/gastrin-releasing peptide receptor;GRP-preferring bombesin receptor;GRP-R	P30550	2925	ENSG00000126010	agonist
DCL000507	CP-800569	CHEMBL67129; CID 9829416; CID6918520; CHEBI:207624; CP-800569; AC1OCFJ8; (2R)-3-[3-(4-chloro-3-ethylphenoxy)-N-[[3-(1,1,2,2-tetrafluoroethoxy)phenyl]methyl]anilino]-1,1,1-trifluoropropan-2-ol	N/A	6918520	12015419	TTDC00124	Cholesteryl ester transfer protein	CETP;Cholesterol ester transfer protein;Lipid transfer protein I	P11597	1071	ENSG00000087237	inhibitor
DCL000617	R7232	N/A	N/A	N/A	N/A	TTDC00124	Cholesteryl ester transfer protein	CETP;Cholesterol ester transfer protein;Lipid transfer protein I	P11597	1071	ENSG00000087237	inhibitor
DCL000597	PF-3185043	N/A	N/A	N/A	N/A	TTDC00124	Cholesteryl ester transfer protein	CETP;Cholesterol ester transfer protein;Lipid transfer protein I	P11597	1071	ENSG00000087237	inhibitor
DCL000048	Anacetrapib	D08855; 875446-37-0; Anacetrapib; CID 11556427; Anacetrapib (USAN); UNII-P7T269PR6S; MK0859; MK-0859; CID11556427	875446-37-0	N/A	N/A	TTDC00124	Cholesteryl ester transfer protein	CETP;Cholesterol ester transfer protein;Lipid transfer protein I	P11597	1071	ENSG00000087237	inhibitor
DCL000252	Torcetrapib	Torcetrapib (USAN/INN); CP-529,414; CP 529414; CHEBI:617982; CP-529414; LS-187027; Torcetrapib [USAN]; LS-187649; CHEBI:49203; 1(2H)-Quinolinecarboxylic acid, 4-(((3,5-bis(trifluoromethyl)phenyl)methyl) (methoxycarbonyl)amino)-2-ethyl-3,4-dihydro-6-(trifluoromethyl)-, ethyl ester, (2R,4S)-; AC1L4LN3; Torcetrapib; ethyl (2R,4S)-4-[[3,5-bis(trifluoromethyl)phenyl]methyl-methoxycarbonylamino]-2-ethyl-6-(trifluoromethyl)-3,4-dihydro-2H-quinoline-1-carboxylate; CID159325; ethyl (2R,4S)-4-{[3,5-bis(trifluoromethyl)benzyl](methoxycarbonyl)amino}-2-ethyl-6-(trifluoromethyl)-3,4-dihydroquinoline-1(2H)-carboxylate; Ethyl (2R,4S)-4-((3,5-bis(trifluoromethyl)benzyl)(methoxycarbonyl)amino)-2-ethyl-6-(trifluoromethyl)-3,4-dihydroquinoline-1(2H)-carboxylate; D06195; (2R,4S)-4-((3,5-Bis-trifluoromethylbenzyl)methoxycarbonylamino)-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester; CHEMBL479527; 262352-17-0	262352-17-0	159325	47207853	TTDC00124	Cholesteryl ester transfer protein	CETP;Cholesterol ester transfer protein;Lipid transfer protein I	P11597	1071	ENSG00000087237	inhibitor
DCL000513	Dalcetrapib	RG-1658; UNII-3D050LIQ3H; RO-4607381; CHEBI:240637; S-[2-[[1-(2-ethylbutyl)cyclohexanecarbonyl]amino]phenyl] 2-methylpropanethioate; JTT 705; CID6918540; Dalcetrapib; CHEMBL313006; JTT-705; AC1OCFK8; R-1658	N/A	6918540	12015448	TTDC00124	Cholesteryl ester transfer protein	CETP;Cholesterol ester transfer protein;Lipid transfer protein I	P11597	1071	ENSG00000087237	inhibitor
DAP001263	Nitrendipine	CHEBI:135534; KBio3_001795; C07713; EINECS 254-513-1; Baypress; KSK, Nitrend; KBio3_000238; N-144; Nitre AbZ; SMR000058366; Gericin; AC1L1IBM; Nitrendepat; BSPBio_000792; Deiten; Spectrum3_000968; SAM001246531; Nitrepin; Jutapress; von ct, nitrendipin; KBioSS_000119; LS-131286; STK368903; Nitrensal; HMS2051B04; Niprina; NCGC00015713-04; Oprea1_472855; MLS001148149; 1A Pharma, Nitren; Nitrendipinum; Bio1_000609; CHEMBL475534; I06-0052; Oprea1_703261; KBio3_000237; EU-0100881; KBio2_002426; Nitrendipino; Bio-0179; Prestwick3_000916; SpecPlus_000742; Nitrendipin beta; NCGC00024676-07; HMS2089H15; KBioGR_001476; Baylotensin; Atid, Nitrendipin; Prestwick1_000916; Bio2_000599; SPBio_002981; BAY e 5009; KBio2_002687; MolPort-001-827-314; Stada, Nitrendipin; Nidrel; Baypress (TN); DB01054; HMS1361F21; Vastensium; Prestwick2_000916; Nitrendidoc; BSPBio_001399; MLS000759400; Bio1_000120; Nitren 1A Pharma; Nitrendi Biochemie; Bio2_000119; Nitrendipin Heumann; KBio2_005255; Spectrum_001901; Nitrend KSK; SPBio_001470; Bylotensin; KBioSS_002432; Nitrendipin Atid; MLS002154060; Nitren acis; AbZ, Nitre; Nitrendipin AL; Spectrum5_001655; AKOS000622913; Bio1_001098; NCGC00024676-06; Nitrendipin Stada; N144_SIGMA; Nitrendipin Apogepha; KBio2_004994; Trendinol; D00629; KBio1_001782; D009568; KBio2_007562; Nitrendipin Lindo; MLS002153303; BPBio1_000872; Nitre-Puren; Nitrendipino Bayvit; nitrendipine; Lich, Nitren; BSPBio_002575; nitrendipincorax; AB00513962; DivK1c_006838; Bayvit, Nitrendipino; Spectrum2_001565; CPD000058366; Bayotensin; Nitre Puren; CHEMBL28123; NCGC00024676-04; S2491_Selleck; HMS1570H14; CID4507; Nitrendipin Basics; CHEBI:553570; nitrendipin-corax; HMS1791F21; Lindo, Nitrendipin; beta, Nitrendipin; CBiol_001834; Basics, Nitrendipin; BRN 0498823; Nitrepress; Prestwick0_000916; NCGC00015713-10; Nitrendipin; BAS 00087504; nchembio.79-comp8; KBioGR_000119; HMS2093G17; IDI1_033869; Tensogradal; Bay-e-5009; MLS000069349; NCGC00024676-02; AL, Nitrendipin; SPECTRUM1503609; 39562-70-4; AC-648; HMS1989F21; NCGC00024676-05; KBio2_000119; nitrendipin corax; Nitregamma; acis, Nitren; FT-0082867; Nitrendimerck; Heumann, Nitrendipin; nitrendipin von ct; Spectrum4_001088; ct, nitrendipin von; C18H20N2O6; Pharma, Nitren 1A; AC1Q32RF; NCGC00024676-03; Biochemie, Nitrendi; Lopac0_000881; NitrePuren; Nitren Lich	39562-70-4	4507	179531	TTDS00415	Voltage-dependent calcium channel subunit alpha-2/delta-1	CACNA2D1;CACNL2A;CCHL2A;MHS3;Voltage-dependent calcium channel subunit alpha-2-1;Voltage-dependent calcium channel subunit delta-1;Voltage-gated calcium channel subunit alpha-2/delta-1	Q06432	786	ENSG00000108878	blocker
DAP001262	Diltiazem	Cardil; d-cis-Diltiazem; Tocris-0685; STOCK1N-03672; Cardizen LA; 1,5-Benzothiazepin-4(5H)-one, 3-(acetyloxy)-5-(2-(dimethylamino)ethyl)-2,3-dihydro-2-(4-methoxyphenyl)-, (2S-cis)-; NCGC00024309-06; BRN 3573079; DB00343; HMS2089H09; UNII-EE92BBP03H; Viazem; Tiazac Tildiem; (2S,3S)-5-[2-(dimethylamino)ethyl]-2-[4-(methyloxy)phenyl]-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate; Dilren; Prestwick2_000134; Cardizem (Hydrochloride); Apo-Diltiaz; Dilta-Hexal; 33286-22-5; Citizem; [(2S,3S)-5-(2-dimethylaminoethyl)-2-(4-methoxyphenyl)-4-oxo-2,3-dihydro-1,5-benzothiazepin-3-yl] acetate; Diltzac; NCGC00024309-07; 42399-41-7; CID39186; BPBio1_000230; Lopac0_000327; Diltiazemum; AC1Q6LHX; BIDD:GT0548; Diltia; Prestwick3_000134; Anoheal; BSPBio_001311; NCGC00024309-08; NCGC00024309-02; diltiazem; (2S,3S)-5-(2-(dimethylamino)ethyl)-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepin-3-yl acetate; Diltiazem [INN:BAN]; Diltiazem (INN); 144604-00-2; 1,5-Benzothiazepin-4(5H)-one, 3-(acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-, (2S,3S)-; Incoril AP; Dilticard; Bio1_000860; Adizem; NCGC00024309-09; (2S-cis)-3-(acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-1,5-benzothiazepin-4(5H)-one; Bio1_000371; Surazem (TN); C22H26N2O4S; LS-40510; Tiazac XC; HMS1791B13; BSPBio_000208; AC1L2181; Aldizem; BRD-K24023109-001-02-5; Prestwick0_000134; RG 83606 (Hydrochloride); (+)-cis-5-[2-(dimethylamino)ethyl]-2,3-dihydro-3-hydroxy-2-(p-methoxyphenyl)-1,5-benzothiazepin-4(5H)-one acetate ester; NCGC00024309-10; (2S,3S)-5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate; Bio1_001349; CHEBI:101278; Dilzen; Diltiazemum [INN-Latin]; CHEMBL23; SPBio_002147; Prestwick1_000134; EINECS 255-796-4; AC-936; MK-793 (Malate); NCGC00024309-04; Dilacor; BRD-K24023109-003-03-9; Dilacor-XR; FT-0081415; Dilt-cd; Endrydil; Acalix; Cardizem; Dilcontin; C06958; HSDB 6528; nchembio.368-comp1; Acetic acid (2S,3S)-5-(2-dimethylamino-ethyl)-2-(4-methoxy-phenyl)-4-oxo-2,3,4,5-tetrahydro-benzo[b][1,4]thiazepin-3-yl ester; MolPort-002-509-369; D07845; Nu-Diltiaz; HMS1989B13; NCGC00024309-05	42399-41-7	39186	180243	TTDS00415	Voltage-dependent calcium channel subunit alpha-2/delta-1	CACNA2D1;CACNL2A;CCHL2A;MHS3;Voltage-dependent calcium channel subunit alpha-2-1;Voltage-dependent calcium channel subunit delta-1;Voltage-gated calcium channel subunit alpha-2/delta-1	Q06432	786	ENSG00000108878	blocker
DAP001261	Lercanidipine	100427-26-7; 5-O-[1-[3,3-diphenylpropyl(methyl)amino]-2-methylpropan-2-yl] 3-O-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; 1-[(3,3-diphenylpropyl)(methyl)amino]-2-methylpropan-2-yl methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; CHEMBL250270; C36H41N3O6; Lercanil; (+-)-2-((3,3-Diphenylpropyl)methylamino)-1,1-dimethylethyl methyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate; Lercanidipine; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 3-[2-[(3,3-diphenylpropyl)methylamino]-1,1-dimethylethyl] 5-methyl ester; AC-15409; REC-15-2375; methyl-1,1-dimethyl-2-(N-(3,3-diphenylpropyl)-N-methylamino)ethyl-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; Lercanil (TN); DB00528; Lercanidipine (INN); NCGC00167492-02; LS-130876; CID65866; Lercanidipine [INN]; NCGC00167492-01; REC 15-2375; MolPort-005-935-354; I06-0228; STK639861; masnidipine; UNII-V7XTJ4R0BH; D08111; AC1L244Q; AC1Q1ZXR	100427-26-7	65866	207908	TTDS00415	Voltage-dependent calcium channel subunit alpha-2/delta-1	CACNA2D1;CACNL2A;CCHL2A;MHS3;Voltage-dependent calcium channel subunit alpha-2-1;Voltage-dependent calcium channel subunit delta-1;Voltage-gated calcium channel subunit alpha-2/delta-1	Q06432	786	ENSG00000108878	blocker
DAP000139	Amlodipine	Amlodipine Free Base; KBio3_001947; AC1Q32ZS; HMS2052N03; LS-131183; 3-O-ethyl 5-O-methyl 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate; Lipinox; Amlor; KBioGR_001643; NCGC00165957-01; CHEMBL1491; Amlodis; amlodipine; NCGC00165957-02; 3-Ethyl-5-methyl ( -)-2-((2-aminoethoxy)methyl)-4-(2-chlorphenyl)-1,4-dihydro-6-methyl-3,5-pyridindicarboxylat; Spectrum2_000486; D07450; AMLODIPINE BASE; 3,5-Pyridinedicarboxylic acid, 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-, 3-ethyl 5-methyl ester; Amlodipino [Spanish]; AC1L1D26; Amlodipino; -3-(ethoxycarbonyl)-5-(methoxycarbonyl)-6-methyl-1,4-dihydropyridine; Amlodipinum; Intervask; I14-0798; SPBio_000351; Racemic Amlodipine; BIDD:GT0810; UNII-1J444QC288; BRD-A22032524-074-03-2; Spectrum4_001132; Amlocard; MolPort-001-792-963; Amlodipine [INN:BAN]; NCGC00165957-03; Amlodipine (INN); CPD000469198; 3-Ethyl-5-methyl ( -)-2-((2-aminoethoxymethyl)-4-(o-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate; SAM001246705; AC-4535; 88150-42-9; Ambap88150-42-9; BSPBio_002727; 3-ethyl 5-methyl 2-{[(2-aminoethyl)oxy]methyl}-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate; R,S)-Amlodipine; ()-Amlodipine; 2-[(2-Aminoethoxy)methyl]-4-(2-chlorophenyl); HMS2089H07; SMR000469198; MLS001401409; 3-Ethyl-5-methyl (.+/-.)-2-[(2-aminoethoxy)methyl]-4-(o-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate; 3,5-Pyridinedicarboxylic acid, 2-((2-aminoethoxy)methyl)-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-, 3-ethyl 5-methyl ester; Spectrum3_001004; C06825; Norvasc (TN); Coroval; DB00381; 3-Ethyl-5-methyl (+-)-2-(2-aminoethoxymethyl)-4-(o-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate; 88150-47-4 (maleate (1:1)); Amlopres; 3-ethyl 5-methyl 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate; UK-4834011; CID2162; CHEBI:2668; BRD-A22032524-074-02-4; Spectrum5_001550; Amlodipinum [Latin]	88150-42-9	2162	193166	TTDS00415	Voltage-dependent calcium channel subunit alpha-2/delta-1	CACNA2D1;CACNL2A;CCHL2A;MHS3;Voltage-dependent calcium channel subunit alpha-2-1;Voltage-dependent calcium channel subunit delta-1;Voltage-gated calcium channel subunit alpha-2/delta-1	Q06432	786	ENSG00000108878	blocker
DAP000529	Nifedipine	Calcibloc; KBioGR_002400; AC1L1I9V; Dilafed; Adalat CC; Aprical long; ARONIS24171; Adalat 20; Nifidine; Alfadal; Introcar; Anifed; CHEBI:7565; Bay1040; N7634_SIGMA; Nifebene; Procardia; Monohydrochloride, Nifedipine; CPD000058291; HMS2051O03; BIDD:GT0442; Bio-0733; Sepamit; BSPBio_001391; Nifangin; N 7634; Nifecor; AWD Pharma Brand of Nifedipine; Nifedepat; D00437; Adalat Crono; Pfizer Brand of Nifedipine; Adalat LP; Adalat Oros; Fenihidin; Nifedicor; KBioGR_000627; IDI1_000313; NCGC00024983-07; Adalat CR; NCGC00015748-02; Nifecard; Hexadilat; Nifedipinum; Bay-a-1040; Adalat 10; Cordaflex; SPECTRUM1500431; NCGC00015748-03; Nifedical XL; SPBio_001016; AC1Q4254; Coracten XL; KBio3_002879; C17H18N2O6; NCGC00091707-01; KBio1_000313; Tibricol; HMS2091H20; Prestwick_357; Emaberin; Coracten; S1808_Selleck; Tocris-1075; EU-0100819; Spectrum_000979; Adcock Ingram Brand of Nifedipine; Prestwick2_000063; CBiol_001826; KBio2_007536; Nifedipine [USAN:BAN:INN:JAN]; Nifedipino [INN-Spanish]; Adalat GITS 30; 101539-70-2; D009543; Citilat; Nifedipine Orion Brand; I06-1286; HMS1568M07; SMR000058291; NCGC00024983-04; Fortipine LA; KRKA Brand of Nifedipine; HMS500P15; BSPBio_002071; 60299-11-8 (mono-hydrochloride); EINECS 244-598-3; Oprea1_788617; NINDS_000313; Fedcor; Nifediac; Tensipine MR; KBio2_002400; Bay-1040; CHEMBL193; Bio2_000111; KBio2_005247; L001054; Nificard; Cardilat; Adalat; KBioSS_000111; Glopir; Lopac-N-7634; NCGC00024983-03; Spectrum4_000074; Spectrum2_001058; DB01115; Prestwick3_000063; 5-22-04-00268 (Beilstein Handbook Reference); nifedipine; NCGC00024983-08; N0528; Orion Brand of Nifedipine; Cordicant; Angipec; Nifedipine Bayer Brand; Ecodipin E; Bonacid; STK735567; Infedipin; Adalat PA; Adalate LP; Bio1_000112; Nifelat; Macorel; Spectrum5_001278; LS-1012; Calcilat; Fenamon; Nifedin; Ecodipin; Procardia XL; Adalat Retard; Chronadalate; Nifedipino; Adapine; CCRIS 6074; Afeditab; Duranifin; 21829-25-4; Adalat XL; Bio2_000591; BSPBio_000245; Nifedine; Alonix; Adipine XL; Nifelat Q; Kordafen; Bayer Brand of Nifedipine; Myogard; Prestwick0_000063; CAS-21829-25-4; cMAP_000042; Fenigidin; KBio2_002679; N1fedilat; Spectrum3_000516; Nifedipine Retard; NCGC00015748-01; BAY-a 1040; HMS1989F13; Korinfar; Corynphar; BAY 1040; Adalat 5; Apo-Nifed; DivK1c_000313; AC-11618; Nifedical; C07266; Corotrend; Nifdemin; Dignokonstant; Nifedipine-GTIS; Niphedipine; Adapress; Nifipen; Pidilat; HMS1791F13; NCGC00024983-02; Adalat GITS; MolPort-006-822-492; I06-0051; Cordipine; Nifedipinum [INN-Latin]; Orix; NCGC00024983-05; Lopac0_000819; Nedipin; KBio3_000222; ZINC19594578; BPBio1_000271; MLS001401371; UNII-I9ZF7L6G2L; Chronadalate LP; Dipinkor; BIDD:PXR0034; Corinfar; Cordipin; KBio2_006595; SPBio_002166; KBioSS_002405; Fenihidine; Cordilan; HMS2089H11; BAYa1040; Nifelan; BRN 0497773; Nifedipres; NCGC00015748-13; Calcigard; Cordalat; Ecodipi; HMS1920P19; KBio2_004968; nchembio.95-comp13; Nifensar XL; KBio3_000221; Nicardia; MLS001148146; Afeditab CR; Fenamon SR; Cardionorm; NCGC00024983-06; Alonix S; Coral; KBio2_004027; Megalat; IDI1_033861; KBioSS_001459; Nifar; BCBcMAP01_000046; MolPort-000-787-707; Cordafen; NCGC00015748-06; Bio1_000601; MLS000028521; Adalat (TN); Nifedipine GTIS; KB-1712P; Nifedirex LP; Aprical; Camont; CID4485; Vascard; Slofedipine XL; Alat; Depin; HMS1361F13; Adalat FT; Afeditab CR (TN); Aldipin; Bio1_001090; Nifedipine Pfizer Brand; 101554-38-5; Nifelate; Procardia (TN); KBio3_001571; Zenusin; NCGC00024983-01; Cardifen; Fedcor Retard; Hadipin; Adalate; SAM001246963; Adalat LA; Anpine; MLS000758222; Alpha-Nifedipine Retard; Nifedipine Monohydrochloride; KBio2_001459; Nifedipine (JP15/USP/INN); KBio2_000111; Prestwick1_000063; Nifedipine KRKA Brand; KBioGR_000111; BAY A 1040; Oxcord; BIM-0050796.0001; AKOS002942507	21829-25-4	4485	172894	TTDS00415	Voltage-dependent calcium channel subunit alpha-2/delta-1	CACNA2D1;CACNL2A;CCHL2A;MHS3;Voltage-dependent calcium channel subunit alpha-2-1;Voltage-dependent calcium channel subunit delta-1;Voltage-gated calcium channel subunit alpha-2/delta-1	Q06432	786	ENSG00000108878	blocker
DAP000134	Isradipine	PN 205034; 4-(4-Benzofurazanyl)-1,4-dihydro-2,-6-dimethyl-3,5-pyridinedicarboxylic acid methyl 1-methylethyl ester; Icaz; HMS1571M03; I6658_SIGMA; 3,5-Pyridinedicarboxylic acid, 4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-2,6-dimethyl-, methyl 1-methylethyl ester (9CI); DynaCirc, Prescal, PN-200-110, Clivoten, Esradin, Isradipine; KBioSS_000698; 2,1,3-Benzoxadiazole, 3,5-pyridinedicarboxylic acid deriv.; Isradipine, (R)-Isomer; 75695-93-1; 3,5-Pyridinedicarboxylic acid, 4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-2,6-dimethyl-, 3-methyl 5-(1-methylethyl) ester; PN-205-034; D017275; Prestwick3_001021; Rebriden; Isradipine, (+-)-Isomer; NCGC00025341-02; SMR000466320; Dynacirc CR; isopropyl 4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-5-methoxycarbonyl-2,6-dimethyl-3-pyridinecarboxylate; DynaCirc (TN); 3,5-Pyridinedicarboxylic acid, 4-(4-benzofurazanyl)-1,4-dihydro-2,6-dimethyl-, methyl 1-methylethyl ester, (+-)-; Spectrum_000218; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-4-(4-benzofurazanyl)-2,6-dimethyl-, methyl 1-methylethyl ester, (+-)-; I06-0364; CID3784; Esradin; PN 200-110; Isradipine (USP/INN); BRD-A90799790-001-03-3; Prestwick1_001021; LS-131190; Isradipine [USAN:INN:BAN]; PN-205-033; (+/-)-Isradipine; CHEMBL315436; PN 205033; SAM001246584; Prescal; MLS001424076; HMS2051J12; 4-(4-Benzofurazanyl)-1,-4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid methyl 1-methylethyl ester; 4-(4-Benzofurazanyl)-1,-4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid methyl 1-methhylethyl ester; PN205033; C19H21N3O5; KBio2_003266; 4-(2,1,3-Benzooxadiazol-4-yl)-2.6-dimethyl-1,4-dihydro-3-isopropyloxycarbonylpyridine-5-carboxylic Acid Methyl Ester; PN 205-034; Isradipinum [Latin]; Isradipino [Spanish]; AB00514007; Prestwick2_001021; 3,5-Pyridinedicarboxylic acid, 4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-2,6-dimethyl-, methyl 1-methylethyl ester; CPD000466320; PN 205 034; PN 200; CHEMBL1648; D00349; Isradipino; Isrodipine; BPBio1_001323; UNII-YO1UK1S598; MLS002154106; Isradipin; SPBio_003062; PN-200-110; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-4-(4-benzofurazanyl)-2,6-dimethyl-,methyl 1-methylethyl ester, (+-)-; LS-177211; DynaCire CR; isradipine; Dynacrine; Isopropyl methyl (+-)-4-(4-benzofurazanyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate; Isradipinum; KBio2_005834; (+-)-Isradipine; Clivoten; PN205034; BSPBio_001201; AC1L1GPE; O5-methyl O3-propan-2-yl 4-(2,1,3-benzoxadiazol-7-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate; 3,5-Pyridinedicarboxylic acid, 4-(4-benzofurazanyl)-1,4-dihydro-2,6-dimethyl-, methyl 1-methylethyl ester; DynaCirc; methyl 1-methylethyl 4-(2,1,3-benzoxadiazol-4-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate; NCGC00025341-03; S1662_Selleck; Prestwick0_001021; DynaCire; DB00270; 3,5-Pyridinedicarboxylic acid, 4-(4-benzofurazanyl)-1,4-dihydro-2,6-dimethyl-, methyl 1-methylethyl ester, (.+/-.)-; PN-200110; 3-O-methyl 5-O-propan-2-yl 4-(2,1,3-benzoxadiazol-4-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate; Lomir; PN 205-033; AC1Q426L; MolPort-003-848-292; 88977-22-4; KBio2_000698; MLS000759425; Isradipine, (S)-Isomer; PN 205 033	75695-93-1	3784	191160	TTDS00415	Voltage-dependent calcium channel subunit alpha-2/delta-1	CACNA2D1;CACNL2A;CCHL2A;MHS3;Voltage-dependent calcium channel subunit alpha-2-1;Voltage-dependent calcium channel subunit delta-1;Voltage-gated calcium channel subunit alpha-2/delta-1	Q06432	786	ENSG00000108878	blocker
DAP001305	Glutethimide	glutethimide; CHEMBL1102; 3-ethyl-3-phenylpiperidine-2,6-dione; Glutethimidum; 3-Phenyl-3-ethyl-2,6-dioxopiperidine; Dorimide; AC-16077; NCGC00159407-03; AC1L1G1N; MolPort-004-285-846; AC1Q2SPK; Doriden (TN); D005984; Phenyl-aethyl-glutarsaeureimid [German]; 2-Ethyl-2-phenylglutarimide; Doriden; 77-21-4; EINECS 201-012-0; Noxiron; Doriden-sed; Glutethimidum [INN-Latin]; alpha-Phenyl-alpha-ethylglutaric acid imide; CC 11511; HSDB 3088; 2-Phenyl-2-ethylglutaric acid imide; DB01437; Gluthetimide; UNII-C8I4BVN78E; Glutethimid; Rigenox; NSC95239; LS-72074; AI3-50601; NCGC00159407-02; .alpha.-Ethyl-.alpha.-phenylglutarimide; DEA No. 2550; Ondasil; Glutethimide [INN:BAN]; Glutetimidu; 3-Phenyl-3-ethyl-2,6-diketopiperidine; CID3487; C07489; 3-Ethyl-3-phenyl-2,6-piperidinedione; .alpha.-Phenyl-.alpha.-ethylglutaric acid imide; Sarodormin; WLN: T6VMVTJ D2 DR; alpha-Ethyl-alpha-phenylglutarimide; 3-Ethyl-3-phenyl-2,6-diketopiperidine; Gimid; D00532; Alfimid; LT00114358; Elrodorm; Glimid; Glutarimide, 2-ethyl-2-phenyl-; Glutetimide; 3-Ethyl-3-phenyl-2,6-dioxopiperidine; Noxyron; Glutetimide [DCIT]; Glutetimidu [Polish]; .alpha.-Phenyl-.alpha.-ethylglutarimide; Glutathimid; alpha-Phenyl-alpha-ethylglutarimide; 2,6-Piperidinedione, 3-ethyl-3-phenyl-; Phenyl-aethyl-glutarsaeureimid; Glutetimid; Glutetimida; Glutetimida [INN-Spanish]; Glutethimide (JAN/INN); NSC 95239	77-21-4	3487	7847598	TTDS00475	Cytochrome P450 2D6	CYP2D6;CYP2DL1;CYPIID6;Debrisoquine 4-hydroxylase;P450-DB1	P10635	N/A	ENSG00000100197	inducer
DPR000090	PD-160170	5-nitro-6-(2-propan-2-ylphenyl)sulfonyl-quinolin-8-amine; BRD-K12079898-001-01-8; CHEMBL422942; PD-160170; MolPort-003-983-659; NCGC00092332-01; CID9820766; CHEBI:180003	181468-88-2	N/A	N/A	TTDC00193	Neuropeptide Y receptor type 1	Neuropeptide Y receptor Y1;Neuropeptide Y Y(1) receptor;Neuropeptide Y-Y1 receptor;NPY1-R	P25929	4886	ENSG00000164128	antagonist
DPR000052	GI-264879A	N/A	181110-62-3	N/A	N/A	TTDC00193	Neuropeptide Y receptor type 1	Neuropeptide Y receptor Y1;Neuropeptide Y Y(1) receptor;Neuropeptide Y-Y1 receptor;NPY1-R	P25929	4886	ENSG00000164128	antagonist
DCL000718	Benzylamine derivative	N/A	100-46-9	7504	48415031	TTDC00193	Neuropeptide Y receptor type 1	Neuropeptide Y receptor Y1;Neuropeptide Y Y(1) receptor;Neuropeptide Y-Y1 receptor;NPY1-R	P25929	4886	ENSG00000164128	antagonist
DAP000401	Oxytetracycline	DB00595; 105145-10-6; Oxitetracyclin; UNII-SLF0D9077S; Oxytetracycline [INN]; Ursocycline; HSDB 3145; Oxymykoin; Unimycin; AC1NQZMP; 15251-48-6; CID5282186; Ossitetraciclina [DCIT]; CHEBI:27701; 7179-50-2 (calcium (1:1) salt); LS-93860; SPBio_001055; Geomycin (Streptomyces vimosus); Oxytetracycline (internal use); STOCK1N-50853; (4S,4aR,5S,5aR,6S,12aS)-4-(dimethylamino)-3,5,6,10,12,12a-hexahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide; Oxymycin; MLS000069429; AC1O52HP; 2058-46-0 (mono-hydrochloride); NCGC00091268-04; Terramycin, Liquamycin,  Oxytetracycline; Tetracycline, 5-hydroxy-; MolPort-002-524-946; Oxyterracyne; Prestwick1_000307; CHEMBL1517; Ursocyclin; Oxytetracycline (anhydrous); Oxytetracycline amphoteric; 6153-64-6 (di-hydrate); (2Z,4S,4aR,5S,5aR,6S,12aS)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,6,10,11,12a-pentahydroxy-6-methyl-4,4a,5,5a-tetrahydrotetracene-1,3,12-trione; Tarocyn; 21645-09-0; Prestwick3_000307; Solkaciclina; Pennox 200; Oxytetracyclinum [INN-Latin]; BSPBio_002151; 106216-57-3; CID6426716; (2E,4S,6S,12aS)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,6,10,11,12a-pentahydroxy-6-methyl-4,4a,5,5a-tetrahydrotetracene-1,3,12-trione; 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,6,10,12,12a-hexahydroxy-6-methyl-1,11-dioxo-, (4S,4aR,5S,5aR,6S,12aS)-; AKOS001632631; 64038-91-1 (sulfate (2:1)); BRN 2714587; C06624; MolPort-005-934-326; Macocyn; AC-12777; 69766-62-7 (hydrochloride salt); OTC; 52214-46-7; Ryomycin; DivK1c_000225; KBio1_000225; 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,6,10,12,12a-hexahydroxy-6-methyl-1,11-dioxo-, [4S-(4.alpha.,4a.alpha.,5.alpha.,5a.alpha.,6.beta.,12a.alpha.)]-; 79-57-2; 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,6,10,12,12a-hexahydroxy-6-methyl-1,11-dioxo-, (4S-(4alpha,4aalpha,5alpha,5aalpha,6beta,12aalpha))-; SPBio_002493; NCI-C56473; NSC-9169; 103351-03-7; Oxitetraciclina; SMR000059000; Oxytetracid; KBio2_001535; Oxitetraciclina [INN-Spanish]; Oxytetracyclin; OTC (antibiotic); 856305-69-6; Terramitsin; Teravit; Geomycin; Ossitetraciclina; Tarosin; Biostat PA; Adamycin; Spectrum5_001148; 4-14-00-02633 (Beilstein Handbook Reference); Oxyterracin; 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,6,10,12,12a-hexahydroxy-6-methyl-1,11-dioxo-, (4S-(4-alpha,4a-alpha,5-alpha,5a-alpha,6-beta,12a-alpha))-; Oxyterracine; KBio3_001651; Dabicycline; 102287-29-6; Oxytetracyclinum; 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,6,10,12,12a-hexahydroxy-6-methyl-1,11-dioxo-; oxytetracycline; S1773_Selleck; Spectrum2_000988; Hydroxytetracycline; Terramycin im; Imperacin; Oxytetracycline HCl; KBioSS_001535; Spectrum4_000466; Mycoshield TMQTHC 20; Oxitetracycline; Antibiotic TM 25; Fanterrin; Lenocycline; 6153-65-7 (di-hydrochloride salt, di-hydrate); Dalimycin; LA 200; KBio2_006671; TM 5; AC1NS4NE; Oxytetracycline anhydrous; Prestwick0_000307; Oxypam; Terramycin Q50; KBioGR_000912; Spectrum3_000536; CID5280972; Biostat; CID5353856; (2Z)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,6,10,11,12a-pentahydroxy-6-methyl-4,4a,5,5a-tetrahydrotetracene-1,3,12-trione; UNII-X20I9EN955; Riomitsin; Oxitetracyclinum; 1405-95-4; Tetran; Proteroxyna; NCGC00091268-05; NINDS_000225; BSPBio_000274; Oxytetracycline calcium; AC1NQXTY; Geotilin; Vendarcin; IDI1_000225; EINECS 201-212-8; KBio2_004103; Liquamycin LA 200; BPBio1_000302; Prestwick2_000307; Oksisyklin; 5-Hydroxytetracycline; C22H24N2O9; Terramycin; Oxacycline; 96310-42-8; Terrafungine; (2E,4S,4aR,5S,5aR,6S,12aS)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,6,10,11,12a-pentahydroxy-6-methyl-4,4a,5,5a-tetrahydrotetracene-1,3,12-trione; LMPK07000005; Spectrum_001055	79-57-2	5280972	8850	TTDS00219	30S ribosomal subunit	30S ribosome subunit	N/A	N/A	N/A	binder
DAP000883	Methacycline	Methacyclin; Methacycline [USAN:BAN]; DB00931; (2Z,4S,4aR,5S,5aR,12aS)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methylidene-4,4a,5,5a-tetrahydrotetracene-1,3,12-trione; Methacycline (USAN); GS-2876; Bialatan; Metacycline; Metacycline (INN); STOCK1N-51719; 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methylene-1,11-dioxo-; CHEBI:304538; AC1NQXY8; C07654; NCGC00179358-01; LS-93875; Metaciclina [INN-Spanish]; CID5281054; 3963-95-9 (mono-hydrochloride); 6-Methylene-5-hydroxytetracycline; 6-Methyleneoxytetracycline; 6-Methylene-5-oxytetracycline; Methacycline amphoteric; C22H22N2O8; Metaciclina; Metacyclinum [INN-Latin]; Methyleneoxytetracycline; Methacyclinum; GS 2876; Oxytetracycline, 6-methylene-; AC-13213; Methacycline base; 4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methylene-1,11-dioxo-2-naphthacenecarboxamide; (4S,4aR,5S,5aR,12aS)-4-(dimethylamino)-3,5,10,12,12a-pentahydroxy-6-methylidene-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide; methacycline; Rondomycin; AB00514707; CHEMBL124506; D04972; 914-00-1; UNII-IR235I7C5P; 6-Demethyl-6-deoxy-5-hydroxy-6-methylenetetracycline; Metacyclinum; Methylenecycline; HSDB 3118; MolPort-002-525-541; CHEMBL249837; Tri-methacycline; 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methylene-1,11-dioxo-, (4S-(4alpha,4aalpha,5alpha,5aalpha,12aalpha))-; 6-Deoxy-6-demethyl-6-methylene-5-oxytetracycline; EINECS 213-017-5	914-00-1	5281054	9856	TTDS00219	30S ribosomal subunit	30S ribosome subunit	N/A	N/A	N/A	binder
DAP000144	Streptomycin	HMS2090P05; CHEBI:405369; 2-[(1S,2S,3R,4S,5S,6R)-3-(diaminomethylideneamino)-4-[(2R,3R,4R,5S)-3-[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy-2,5,6-trihydroxycyclohexyl]guanidine; Streptomyzin [German]; Streptomycin Sesquisulfate Hydrate; NCGC00179603-02; MolPort-002-525-998; O-2-Deoxy-2-(methylamino)-.alpha.-L-glucopyranosyl-(1->2)-O-5-deoxy-3-C-formyl-.alpha.-L-lyxofuranosyl-(1->4)-N,N'-bis(aminoiminomethyl)-D-streptamine and Liposome; AC1O7EO6; Streptomycin, Sulfate Salt; CID6426892; EPA Pesticide Chemical Code 006306; 3810-74-0; Streptomycin & Propolis; ACon1_001297; Strepcen; AC1Q29OE; NSC 14083; CHEMBL1201194; N,N'''-[(1R,2R,3S,4R,5R,6S)-4-{5-deoxy-2-O-[2-deoxy-2-(methylamino)-alpha-L-glucopyranosyl]-3-C-formyl-alpha-L-lyxofuranosyloxy}-2,5,6-trihydroxycyclohexane-1,3-diyl]diguanidine; SPBio_002242; NSC14083; STREPTOMYCIN SULFATE (2:3) SALT; D-Streptamine, O-2-deoxy-2-(methylamino)-.alpha.-L-glucopyranosyl-(1->2)-O-5-deoxy-3-C-formyl-.alpha.-L-lyxofuranosyl-(1->4)-N,N'-bis(aminoiminomethyl)-; 57-92-1; NCGC00179603-01; CID6602485; Streptomicina; Agrimycin; NCGC00159339-02; UNII-Y45QSO73OB; 4-18-00-07540 (Beilstein Handbook Reference); Prestwick2_000321; HSDB 1768; Streptomycin (INN); 82958-69-8; AC1O52TO; Estreptomicina [INN-Spanish]; CHEBI:17076; N,N'''-[(1R,2R,3S,4R,5R,6S)-4-({5-deoxy-2-O-[2-deoxy-2-(methylamino)-alpha-L-glucopyranosyl]-3-C-formyl-alpha-L-lyxofuranosyl}oxy)-2,5,6-trihydroxycyclohexane-1,3-diyl]diguanidine; Streptomycin A sulfate; 3810-74-0 (sulfate (2:3) salt); Bio-0644; Streptomycin A; D-Streptamine, O-2-deoxy-2-(methylamino)-alpha-L-glucopyranosyl-(1-2)-O-5-deoxy-3-C-formyl-alpha-L-lyxofuranosyl-(1-4)-N,N'-bis(aminoiminomethyl)-; AC1L2EK8; Streptomycin sulfate; Hokko-mycin; 2,4-Diguanidino-3,5,6-trihydroxycyclohexyl 5-deoxy-2-O-(2-deoxy-2-methylamino-alpha-L-glucopyranosyl)-3-C-formyl-beta-L-lyxopentanofuranoside; CID19649; Streptomicina [Italian]; AC1L1LKU; Agrept; D-Streptamine, O-2-deoxy-2-(methylamino)-alpha-L-glucopyranosyl-(1.fwdarw.2)-O-5-deoxy-3-C-formyl-alpha-L-lyxofuranosyl-(1.fwdarw.4)-N,N'-bis(aminoiminomethyl)-; Gerox; Prestwick3_000321; DB01082; Prestwick1_000321; Streptomycin sulphate; streptomycin; D08531; BSPBio_000321; CHEMBL173; C00413; CCRIS 5730; Streptomycin (TN); Streptomycinum; BRN 0074498; LS-187084; Streptomycin [INN:BAN]; Streptomycine; C21H39N7O12; [2-deoxy-2-(dimethylamino)-alpha-L-glucopyranosyl]-(1->2)-[5-deoxy-3-C-formyl-alpha-L-lyxofuranosyl]-(1->4)-{N',N'''-[(1,3,5/2,4,6)-2,4,5,6-tetrahydroxycyclohexane-1,3-diyl]diguanidine}; 12672-24-1; Streptomyzin; 2-[(1S,4S)-5-(diaminomethylideneamino)-2-[(2R,5S)-3-[(2S,5R)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy-3,4,6-trihydroxycyclohexyl]guanidine; 47816-81-9; LS-147053; Prestwick0_000321; Neodiestreptopab; CID5999; Caswell No. 804; BPBio1_000355; 2-[(1R,2R,3S,4R,5R,6S)-3-(diaminomethylideneamino)-4-[(2R,3R,4R,5S)-3-[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy-2,5,6-trihydroxycyclohexyl]guanidine; EINECS 200-355-3; 2-[(1R,2R,3S,4R,5R,6S)-3-(diaminomethylideneamino)-4-[(2S,3S,4S,5R)-3-[(2R,3R,4R,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy-2,5,6-trihydroxycyclohexyl]guanidine; Streptomycin & EEP; Liposomal Streptomycin; SRY; 47814-83-5	57-92-1	19649	3703	TTDS00219	30S ribosomal subunit	30S ribosome subunit	N/A	N/A	N/A	binder
DAP000882	Clomocycline	Chlormethylenecycline; 7-Chloro-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-N-(hydroxymethyl)-6-methyl-1,11-dioxo-2-naphthacenecarboxamide; CHEBI:59589; D06885; 1181-54-0; clomocyclina; Clomocycline (INN); Clomociclina; (2Z,4S,4aS,5aS,6S,12aS)-7-chloro-4-(dimethylamino)-6,10,11,12a-tetrahydroxy-2-[hydroxy-(hydroxymethylamino)methylidene]-6-methyl-4,4a,5,5a-tetrahydrotetracene-1,3,12-trione; N-2-Hydroxymethylchlortetracycline; LS-93854; DB00453; Clomocycline [INN:BAN]; Clomocyclinum; UNII-YP0241BU76; Clomocycline; N'-Methylolo-chlortetracycline; C23H25ClN2O9; Clomocyclinum [INN-Latin]; 2-Naphthacenecarboxamide, 7-chloro-4-(dimethylamino)-1,2,3,4,4a,5,5a,6,11,12a-decahydro-1,11-dioxo-N-(hydroxymethyl)-6-methyl-3,6,10,12,12a-pentahydroxy-; (4S,4aS,5aS,6S,12aS)-7-chloro-4-(dimethylamino)-3,6,10,12,12a-pentahydroxy-N-(hydroxymethyl)-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide; CID5464321; Clomociclina [INN-Spanish]; AC1NUZ4S; BRN 2715004	1181-54-0	5464321	214075	TTDS00219	30S ribosomal subunit	30S ribosome subunit	N/A	N/A	N/A	binder
DAP000400	Amikacin	BPBio1_000671; 37517-28-5; NCGC00093350-02; Amikin (Disulfate); NSC 177001; Arikace; Amikavet; Amikacin [USAN:BAN:INN]; amikacin; O-3-Amino-3-deoxy-alpha-D-glucopyranosyl-(1-4)-O-(6-amino-6-deoxy-alpha-D-glucopyranosyl-(1-6))-N(sup 3)-(4-amino-L-2-hydroxybutyryl)-2-deoxy-L-streptamine; O-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1->4)-O-(6-amino-6-deoxy-alpha-D-glucopyranosyl-(1->6))-N(3)-(4-amino-L-2-hydroxybutyryl)-2-deoxy-L-streptamine; Amikin; 108914-65-4; D02543; D-Streptamine, O-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1->6)-O-(6-amino-6-deoxy-alpha-D-glucopyranosyl-(1->4))-N(sup 1)-(4-amino-2-hydroxy-1-oxobutyl)-2-deoxy-, (S)-; STK039706; Amikacinum [INN-Latin]; CID37768; HSDB 3583; D-Streptamine, O-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1-6)-O-(6-amino-6-deoxy-alpha-D-glucopyranosyl-(1-4))-N1-(4-amino-2-hydroxy-1-oxobutyl)-2-deoxy-, (S)-; Amicacin; AB00513828; NSC177001; Lukadin; Mikavir; BSPBio_000609; Amikacin Base; (2S)-4-amino-N-[(1R,2S,3S,4R,5S)-5-amino-2-[(2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4-[(2R,3R,4S,5S,6R)-6-(aminomethyl)-3,4,5-trihydroxyoxan-2-yl]oxy-3-hydroxycyclohexyl]-2-hydroxybutanamide; BB-K 8; D-Streptamine, O-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1-6)-O-(6-amino-6-deoxy-alpha-D-glucopyranosyl-(1,4))-N(sup 1)-(4-amino-2-hydroxy-1-oxobutyl)-2-deoxy-, (S)-; Prestwick3_000395; LS-146896; NCGC00093350-03; CHEMBL177; AMIKACIN SULFATE; EINECS 253-538-5; Kaminax; C06820; Amikacina; Amikacin (USP); BB-K8; 110660-81-6; AC1L1YE8; Amikacin & Tumor Necrosis Factor; amikacine; 38859-32-4; 111319-93-8; (2S)-4-amino-N-[(1R,2S,3S,4R,5S)-5-amino-2-(3-amino-3-deoxy-alpha-D-glucopyranosyloxy)-4-(6-amino-6-deoxy-alpha-D-glucopyranosyloxy)-3-hydroxycyclohexyl]-2-hydroxybutanamide; Amikacin (USP/INN); AC1Q5JTM; UNII-84319SGC3C; CHEBI:2637; Antibiotic BB-K 8; Amikacine [INN-French]; Amikacin Dihydrate; (2S)-4-amino-N-{(1R,2S,3S,4R,5S)-5-amino-2-[(3-amino-3-deoxy-alpha-D-glucopyranosyl)oxy]-4-[(6-amino-6-deoxy-alpha-D-glucopyranosyl)oxy]-3-hydroxycyclohexyl}-2-hydroxybutanamide; Briclin; ANTIBIOTIC BB-K8; D-Streptamine, O-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1-6)-O-(6-amino-6-deoxy-alpha-D-glucopyranosyl-(1-4))-N(sup 1)-(4-amino-2-hydroxy-1-oxobutyl)-2-deoxy-, (S)-; DB00479; O-3-Amino-3-deoxy-.alpha.-D-glucopyranosyl-(1->6)-O-[6-amino-6-deoxy-.alpha.-D-glucopyranosyl-(1->4)]-1-(4-amino-2-hydroxy-1-oxobutyl)-2-deoxy-D-streptamine; Amiglyde-V; D-Streptamine, O-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1.fwdarw.6)-O-(6-amino-6-deoxy-alpha-D-glucopyranosyl-(1.fwdarw.4))-N1-((2S)-4-amino-2-hydroxy-1-oxobutyl)-2-deoxy-; 1-N-(L(-)-gamma-Amino-alpha-hydroxybutyryl)kanamycin A; Amikacina [INN-Spanish]; 110660-83-8; C22H43N5O13; MolPort-000-761-900; Amikacinum	37517-28-5	37768	9038	TTDS00219	30S ribosomal subunit	30S ribosome subunit	N/A	N/A	N/A	binder
DAP000880	Tigecycline	WAY-GAR-936; Tygacil, GAR-936, WAY-GAR-936, TBG-MINO, Tigecycline; TBG-MINO; (4S,4aS,5aR,12aS)-9-(2-(tert-butylamino)acetamido)-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide; Tigecycline [USAN]; 220620-09-7; S1403_Selleck; Tigecycline (JAN/USAN); DB00560; N-[(5aR,6aS,7S,9Z,10aS)-9-[amino(hydroxy)methylidene]-4,7-bis(dimethylamino)-1,10a,12-trihydroxy-8,10,11-trioxo-5a,6,6a,7-tetrahydro-5H-tetracen-2-yl]-2-(tert-butylamino)acetamide; GAR-936; LS-187002; GAR 936; Tigecycline; (4S,12aS)-4,7-Bis(dimethylamino)-9-{2-[(tert-butyl)amino]acetylamino}-3,10,12,12a-tetrahydroxy-1,11-dioxo-4,5,6,12a,4a,5a-hexahydronaphthacene-2-carboxamide; (4S,4aS,5aR,12aS)-9-[(N-tert-butylglycyl)amino]-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide; 2-Naphthacenecarboxamide, 4,7-bis(dimethylamino)-9-((((1,1-dimethylethyl)amino)acetyl)amino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)-; CHEMBL1212946; D01079; Tygacil(TM); Tigilcycline; UNII-70JE2N95KR; C12012; Tygacil (TN); CHEMBL376140; AC-1798; LS-186580; CHEBI:149836; AC1NQZEU; LS-187782; 9-t-Butylglycylamido minocycline; CID5282044; Tygacil; 121GE002; GAR-936,Tigecycline	220620-09-7	5282044	14170	TTDS00219	30S ribosomal subunit	30S ribosome subunit	N/A	N/A	N/A	binder
DAP000403	Spectinomycin	AC1L21W5; BPBio1_000735; Spectinomicina; 1695-77-8 (Parent); CHEMBL1167; LS-127328; Prestwick0_000804; EINECS 216-911-3; Spectrum5_001407; KBioGR_001425; KBio1_000137; CID15541; MolPort-004-947-049; Spectam; UNII-93AKI1U6QF; STOCK1N-24271; 1695-77-8; Spectrum3_000898; MLS001032090; M 141; XK 43-1; Prospec (TN); NSC 132679; 4H-Pyrano(2,3-b)(1,4)benzodioxin-4-one, decahydro-4a,7,9-trihydroxy-2-methyl-6,8-bis(methylamino)-, (2R-(2alpha,4abeta,5abeta,6beta,7beta,8beta,9alpha,9aalpha,10abeta))-; KBio3_001816; 4H-Pyrano(2,3-b)(1,4)benzodioxin-4-one, decahydro-4a,7,9-trihydroxy-2-methyl-6,8-bis(methylamino)-, dihydrochloride, (2R,4aR,5aR,6S,7S,8R,9S,9aR,10aS)-; Antibiotic 2233wp; SMP1_000276; 21736-83-4 (di-hydrochloride, anhydrous); SPBio_001409; MolPort-002-513-665; Prestwick2_000804; NSC248616; HMS2089C03; Actinospectacina [Italian]; (2R,4aR,5aR,6S,7S,8R,9S,9aR,10aS)-4a,7,9-trihydroxy-2-methyl-6,8-bis(methylamino)decahydro-4H-pyrano[2,3-b][1,4]benzodioxin-4-one; BSPBio_000667; Actinospectacina; 21736-83-4; M-141; Spectrum4_000993; ACTINOSPECTACIN, ESPECTINOMICINA, CHX-3101; Trobicin; Spectinomycin Hydrochloride (anhydrous); KBio2_004002; Spectinomycin sulfate; Spectinomycine; 4H-Pyrano(2,3-b)(1,4)benzodioxin-4-one, decahydro-4a,7,9-trihydroxy-2-methyl-6,8-bis(methylamino)-, (2R,4aR,5aR,6S,7S,8R,9S,9aR,10aS)-; Spectinomycin HCl; Stanilo; AC1L21VZ; AC-13570; SPBio_002588; CID64771; AC1MHWL1; Spectrum2_001315; NCGC00142531-02; U 18409; 4H-Pyrano[2,3-b][1,4]benzodioxin-4-one, decahydro-4a,7,9-trihydroxy-2-methyl-6,8-bis(methylamino)-, (2R,4aR,5aR,6S,7S,8R,9S,9aR,10aS)-; 4H-Pyrano(2,3-b)(1,4)benzodioxin-4-one, decahydro-4a,7,9-trihydroxy-2-methyl-6,8-bis(methylamino)-, monohydrochloride, (2R-(2alpha,4abeta,5abeta,6beta,7beta,8beta,9alpha,9aalpha,10abeta))-; Spectinomycin hydrochloride anhydrous; Espectinomicina; Spectam Scour Halt; CHEBI:45551; Spectinomicina [Italian]; Spectinomycin (INN); U-18409AE; Spectinomycinum; Spectinomycinum [INN-Latin]; Adspec (TN); Togamycin; Spectinomycin [INN:BAN]; Togamycin sulfate (1:1); Espectinomicina [INN-Spanish]; IDI1_000137; (2R-(2alpha,4abeta,5abeta,6beta,7beta,8beta,9alpha,9aalpha,10abeta))-Decahydro-4a,7,9-trihydroxy-2-methyl-6,8-bis(methylamino)-4H-pyrano(2,3-b)(1,4)benzodioxin-4-one monohydrochloride; Spectinomycin monohydrochloride; 4H-Pyrano[2,3-b][1,4]benzodioxin-4-one, decahydro-4a,7,9-trihydroxy-2-methyl-6,8-bis(methylamino)-, [2R-(2.alpha.,4a.beta.,5a.beta.,6.beta.,7.beta.,8.beta.,9.alpha.,9a.alpha.,10a.beta.)]-, sulfate (1:1) (salt); actinospectacin; Spectinomycin dihydrochloride; NCGC00180937-01; Spectinomycin Di HCl; AC1L263X; 23312-56-3; AC1Q3EJ7; NCI60_000023; KBioSS_001434; 4H-Pyrano(2,3-b)(1,4)benzodioxin-4-one, decahydro-4a,7,9-trihydroxy-2-methyl-6,8-bis(methylamino)-, dihydrochloride, (2R-(2-alpha,4a-beta,5a-beta,6-beta,7-beta,8-beta,9-alpha,9a-alpha,10a-beta))-; DivK1c_000137; 22189-32-8 (di-hydrochloride, pentahydrate); Prospec; EINECS 245-578-7; Spectinomycin; 22189-32-8; CID64769; DB00919; D08526; U 18409 E; NINDS_000137; BRN 2171701; CID3033928; CHEMBL1200407; SCM; SPCM; KBio2_001434; KBio2_006570; NCGC00142531-01; NSC132679; C02078; NSC100859; Prestwick3_000804; Spectinomycin Dihydrochloride, Anhydrous; Spectinomycin HCl/ Sulphate; C14H24N2O7; Spectrum_000954; Spectogard; Spectinomycin Dihydrochloride, Pentahydrate; EINECS 244-554-3; C14H24N2O7.2HCl; Spectinomycin hydrochloride; Actinospectacin, hydrochloride; AC1Q6CAT; LS-127327; Prestwick1_000804; NSC 248616; ST057253; 22193-75-5; Adspec; Spectinomycine [INN-French]	1695-77-8	15541	5164	TTDS00219	30S ribosomal subunit	30S ribosome subunit	N/A	N/A	N/A	binder
DAP000881	Lymecycline	Tetrlysal 300; N(2)-(((+)-5-Amino-5-carboxypentylamino)methyl)tetracycline; Orospray; Limeciclina; CHEBI:59040; Biovetin; Chrusomykine; Lymecycline (INN); Acronize PD; D06884; N(6)-[({[(4S,4aS,5aS,6S,12aS)-4-(dimethylamino)-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracen-2-yl]carbonyl}amino)methyl]-L-lysine; Chlortetracyclin; Centraureo; Aureomicina; 992-21-2; (+)-N-(5-Amino-5-carboxypentylaminomethyl)-4-dimethylamino-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxonaphthacene-2-carboxamide; Aurofac 10; DB00256; Lymecyclinum; Aurofac; Aureociclin	992-21-2	5280963	605300	TTDS00219	30S ribosomal subunit	30S ribosome subunit	N/A	N/A	N/A	binder
DAP000404	Netilmicin	CID6604416; Netilmicina [INN-Spanish]; AC1L1I7S; O-(2,6-Diamino-2,3,4,6-tetradesoxy-alpha-glycero-4-hexenopyranosyl-(1-4)-O-(3-desoxy-4-C-methyl-3-methylamino-beta-L-arabinopyranosyl-(1-6)-2-desoxy-N1-ethyl-D-streptamin; 1-N-Aethylsisomicin; C21H41N5O7; Prestwick3_001101; D08268; UNII-4O5J85GJJB; C07657; BRN 5316582; NETILMICIN SULFATE; NCGC00016881-01; Netira; NCGC00179265-01; AB00514048; LS-147005; CID4460; Netilyn; D-Streptamine, O-3-deoxy-4-C-methyl-3-(methylamino)-beta-L-arabinopyranosyl-(1-6)-O-(2,6-diamino-2,3,4,6-tetradeoxy-alpha-D-glycero-hex-4-enopyranosyl-(1-4))-2-deoxy-N1-ethyl-; AR-1G0648; Nettacin; BSPBio_001202; Netilmicine [INN-French]; Netilmicin (INN); CID41859; MolPort-003-849-357; Netilmicinum [INN-Latin]; (2R,3R,4R,5R)-2-[(1S,2S,3R,4S,6R)-4-amino-3-[[3-amino-6-(aminomethyl)-3,4-dihydro-2H-pyran-2-yl]oxy]-6-(ethylamino)-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol; CAS-56931-57-2; AC1O7GGT; EINECS 260-146-8; SPBio_003081; D-Streptamine, O-3-deoxy-4-C-methyl-3-(methylamino)-.beta.-L-arabinopyranosyl-(1->6)-O-[2,6-diamino-2,3,4,6-tetradeoxy-.alpha.-D-glycero-hex-4-enopyranosyl-(1->4)]-2-deoxy-N1-ethyl-; Vectacin; Prestwick2_001101; AC-13442; Sch 20569; 56391-57-2 (sulfate (2:5) salt); (2R,3S,4S,5S)-2-[(1S,2R,3S,4S,6R)-4-amino-3-[[(2S,3R)-3-amino-6-(aminomethyl)-3,4-dihydro-2H-pyran-2-yl]oxy]-6-(ethylamino)-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol; 2-[4-amino-3-[[3-amino-6-(aminomethyl)-3,4-dihydro-2H-pyran-2-yl]oxy]-6-(ethylamino)-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol; Netilmicine; AC1Q59OC; Netira (TN); Netilmicinum; 56391-56-1; Sch-20569; AC1L9AXV; (2R,3R,4R,5R)-2-[(1S,2S,3R,4S,6R)-4-amino-3-[[(2S,3R)-3-amino-6-(aminomethyl)-3,4-dihydro-2H-pyran-2-yl]oxy]-6-(ethylamino)-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol; Prestwick0_001101; NTL; 4-amino-3-{[3-amino-6-(aminomethyl)-3,4-dihydro-2h-pyran-2-yl]oxy}-6-(ethylamino)-2-hydroxycyclohexyl 3-deoxy-4-c-methyl-3-(methylamino)pentopyranoside; AC1L26N7; CID10480069; CID441306; BPBio1_001324; Prestwick1_001101; CHEMBL1572; HSDB 3584; netilmicin; Netilmicin [INN:BAN]; Netilmicina; D-Streptamine, O-3-deoxy-4-C-methyl-3-(methylamino)-beta-L-arabinopyranosyl(1-6)-O-(2,6-diamino-2,3,4,6-tetradeoxy-alpha-D-glycero-hex-4-enopyranosyl(1-4))-2-deoxy-N(sup 1)-ethyl-; AC1Q57VA; 1-N-Ethylsisomicin	56391-56-1	441306	9859	TTDS00219	30S ribosomal subunit	30S ribosome subunit	N/A	N/A	N/A	binder
DAP000407	Paromomycin	MolPort-002-510-747; Aminosidine, sulfate; 84420-34-8; PAROMOMYCIN I, AMMINOSIDIN, CATENULIN, CRESTOMYCIN, MONOMYCIN A, NEOMYCIN E; Paromomycin sulfate Rx346208; Paromomycin (complex); CHEMBL370143; O-2-Amino-2-deoxy-.alpha.-D-glucopyranosyl-(1->4)-O-[O-2,6-diamino-2,6-dideoxy-.beta.-L-idopyranosyl-(1->3)-.beta.D-ribofuranosyl(1->5)]-2-deoxy-D-streptamine; Human .alpha.-1-antitrypsin & Paromomyin; hATT & Paromomycin; PA1-PA2-PA3-PA4; STOCK1N-08708; 7542-37-2; D07467; AC1L4WW9; catenulin; paromomycin; NSC227228; Hydroxymycin sulfate; DB01421; Paromomycin (INN); CID165580; (2S,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-[(2R,3S,4R,5S)-5-[(1R,2R,3S,5R,6S)-3,5-diamino-2-[(2S,3R,4R,5S,6R)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol; Neomycin E; Humatin; Aminosidin; (1R,2R,3S,4R,6S)-4,6-diamino-2-{[3-O-(2,6-diamino-2,6-dideoxy-beta-L-idopyranosyl)-beta-D-ribofuranosyl]oxy}-3-hydroxycyclohexyl 2-amino-2-deoxy-alpha-D-glucopyranoside; C00832; Paromomycin (TN); Paramomycin Sulfate; Paromomycin I	1263-89-4	165580	10255961	TTDS00219	30S ribosomal subunit	30S ribosome subunit	N/A	N/A	N/A	binder
DAP000032	Tetracycline	NINDS_000827; Tetrazyklin; MLS000069728; KBio2_004082; Achromycin, naphthacene derivative; T-125; CID5289435; Bristaciclina; BSPBio_000220; Tetrachel; C06570; CID5497101; SPBio_001457; 64-75-5 (mono-hydrochloride); Amycin; KBio1_000827; 6-Methyl-1,11-dioxy-2-naphthacenecarboxamide; Purocyclina; Ambramicina; Criseociclina; Tetraverine; Vetacyclinum; Micycline; MolPort-003-983-460; DB00759; NSC 108579; CID12309720; Topicycline; UPCMLD-DP127; Cefracycline suspension; Tetracycline (JAN/USP/INN); methyl-1,11-dioxo-2-naphthacenecarboxamide; Spectrum4_000352; Tetracyclinum [INN-Latin]; Robitet; Sumycin (TN); Bio-tetra; AC1L1KAT; LS-93869; CHEBI:27902; Sumycin syrup; SMR000058220; D00201; Cytome; Tetraciclina [INN-Spanish]; Biocycline; CID5388997; HSDB 3188; CID5280962; AC1NSDX8; Dumocyclin; KBioGR_000783; Lexacycline; WLN: L E6 C666 BV FV CU GUTTT&J DQ EQ GVZ HQ IN1&1 MQ M1 RQ; Liquamycin, veterinary; CHEMBL1440; DivK1c_000827; Bristaciclin .alpha.; Cyclomycin; Enterocycline; AC1NRDAM; Medocycline; Copharlan; Tetracycline I; CID5353990; nchembio.289-comp1; HMS2090B04; Liquamycin (Veterinary); Polycycline, antibiotic; BIDD:GT0653; UPCMLD-DP127:002; Tetracyn; Tetraciclina; Abricycline; Cyclopar; Democracin; Deschlorobiomycin; IDI1_000827; Tsiklomistsin; Tetracycline & VRC3375; Prestwick0_000140; CID5359245; BPBio1_000242; SPBio_002159; Ciclibion; Sanclomycine; Tetracyclinum; Solvocin; Spectrum5_001112; STOCK1N-42738; KBioSS_001514; EINECS 200-481-9; Veracin; SK-Tetracycline; CID5412; Polycycline (VAN); AC1NUZHL; nchembio.273-comp1; Spectrum3_000565; MolPort-005-934-198; Tetracycline (internal use); Omegamycin; AC1NQXT7; MolPort-001-794-633; Vetquamycin-324 (free base); Tetracycline Free Base; Tsiklomitsin; T3258_SIGMA; tetracycline; Ambramycin; NCGC00161665-01; (-)-Tetracycline; KBio2_006650; Tetracycline II; Bristaciclin; Agromicina; Abramycin; Piracaps (base); 87128_FLUKA; Resteclin; component of Tetrastatin; Cefracycline; Sumycin; Panmycin; Prestwick1_000140; 60-54-8; AC-13151; Tetra-Co; Spectrum2_001329; Mericycline; 6591-49-7; AC1NS4RQ; Limecycline; Spectrum_001034; Polycycline; Prestwick2_000140; Tetracyclin; LS-187078; KBio2_001514; Achromycin (naphthacene derivative); Prestwick3_000140; BSPBio_001950; UPCMLD-DP127:001; Centet (base); Neocycline; UNII-F8VB5M810T; Tetrabon; NSC108579; AC1O52HS; Hostacyclin; Tetracycline Monohydrochloride; AC1NTUT2; Tetrafil; Tetracycl; Tetradecin; 87128_SIGMA; Polycycline (antibiotic); Orlycycline; Achromycin; Roviciclina; CID6426717; Lemtrex (base); Achromycin V; KBio3_001450; Bristacycline; Tetracycline [USAN:INN:BAN:JAN]; Polyotic	60-54-8	5353990	407983	TTDS00219	30S ribosomal subunit	30S ribosome subunit	N/A	N/A	N/A	binder
DAP000884	Rolitetracycline	Tetracycline, pyrrolidinomethyl-; CHEMBL1214184; (2Z,4S,4aS,5aS,6S,12aS)-4-(dimethylamino)-6,10,11,12a-tetrahydroxy-2-[hydroxy-(pyrrolidin-1-ylmethylamino)methylidene]-6-methyl-4,4a,5,5a-tetrahydrotetracene-1,3,12-trione; Bristacin; SQ 15659; SQ 15,659; HMS2052O05; Synotodecin; Prestwick_1045; BSPBio_000837; Rolitetracycline [USAN:INN:BAN:JAN]; (4S,4aS,6S,12aS)-4-(dimethylamino)-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-N-(pyrrolidin-1-ylmethyl)-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide; Velacycline; Rolitetracycline (JAN/USAN/INN); UNII-GH9IW85221; LS-93872; Synterin (TN); (2Z,4S,4aS,6S,12aS)-4-(dimethylamino)-6,10,11,12a-tetrahydroxy-2-[hydroxy-(pyrrolidin-1-ylmethylamino)methylidene]-6-methyl-4,4a,5,5a-tetrahydrotetracene-1,3,12-trione; NCGC00179407-01; D02282; 20685-78-3 (mononitrate); Prestwick1_000849; Prestwick3_000849; AAT 4; CID5282179; Rolitetracyclinum; Kinteto; BPBio1_000921; 751-97-3; Pirrolidinometil-tetraciclina [Italian]; Rolitetracyclinum [INN-Latin]; EINECS 212-031-9; Rolitetraciclina; SMR000058701; Tetracycline, N-(pyrrolidinylmethyl)-; R2253_SIGMA; Prestwick2_000849; Syntetrex; 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-N-(1-pyrrolidinylmethyl)-; Tetraverin; Rolitetraciclina [INN-Spanish]; Pirrolidinometil-tetraciclina; 68060-64-0; N-(1-Pyrrolidinylmethyl)-tetracycline; Pyrrolidinomethyltetracycline; C27H33N3O8; Prm-TC; 4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-N-(1-pyrrolidinylmethyl)-2-naphthacenecarboxamide; (2Z,4S,6S,12aS)-4-(dimethylamino)-6,10,11,12a-tetrahydroxy-2-[hydroxy-(pyrrolidin-1-ylmethylamino)methylidene]-6-methyl-4,4a,5,5a-tetrahydrotetracene-1,3,12-trione; Velacicline; CHEMBL436221; ROLITETRACYCLINE; Transcycline; ST075203; AC1NR4RN; Superciclin; R2253_FLUKA; Pyrrolidino-methyl-tetracycline; 7681-32-5 (nitrate); HMS1570J19; Solvocillin; n-Pyrrolidino-methyl-tetracycline; AC1O4WIV; MLS000028710; CPD000058701; Syntetrin; Synterin; Prestwick0_000849; SAM001246892; AC1NQZM8; Revrin; CID5284615; 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-N-(1-pyrrolidinylmethyl)-, (4S-(4alpha,4aalpha,5aalpha,6beta,12aalpha))-; SPBio_002758; Reverin; DB01301; CID6420073; N-(Pyrrolidinomethyl)tetracycline	751-97-3	5282179	14811900	TTDS00219	30S ribosomal subunit	30S ribosome subunit	N/A	N/A	N/A	binder
DAP000406	Kanamycin	Kanamicina; DB01172; CHEBI:58214; 4,6-diamino-2-hydroxy-1,3-cyclohexylene 3,6'-diamino-3,6'-dideoxydi-D-glucopyranoside; Kanamycin sulfate (TN); (1S,2R,3R,4S,6R)-4,6-diazaniumyl-3-(6-azaniumyl-6-deoxy-alpha-D-glucopyranosyloxy)-2-hydroxycyclohexyl 3-azaniumyl-3-deoxy-alpha-D-glucopyranoside; D03262; D-Streptamine, O-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1->6)-O-(6-amino-6-deoxy-alpha-D-glucopyranosyl-(1->4))-2-deoxy-; BSPBio_000607; nchembio.244-comp4; Kanamycinum [INN-Latin]; Kantrex; 11025-65-3; (2R,3S,4S,5R,6R)-2-(aminomethyl)-6-[(1R,2R,3S,4R,6S)-4,6-diamino-3-[(2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxyoxane-3,4,5-triol; sulfuric acid; Kanamicina [Italian]; KANAMYCIN A; (1S,2R,3R,4S,6R)-4,6-diamino-3-[(6-amino-6-deoxy-alpha-D-glucopyranosyl)oxy]-2-hydroxycyclohexyl 3-amino-3-deoxy-alpha-D-glucopyranoside; UNII-RUC37XUP2P; CID6032; SMP2_000007; Glucopyranoside, 4,6-diamino-2-hydroxy-1,3-cyclohexylene 3,6'-diamino-3,6'-dideoxydi-, D-; CHEBI:17630; Kanamycin [INN:BAN]; HMS500B06; Kanamycine; Prestwick3_000394; Kanamycin Base; IDI1_000024; CHEMBL1384; AC1L9B21; NINDS_000024; CHEBI:6109; Kenamycin A; kanamycin A tetracation; BPBio1_000669; Kanamycin sulfate; O-3-Amino-3-deoxy-.alpha.-D-glucopyranosyl-(1->6)-O-[6-amino-6-deoxy-.alpha.-D-glucopyranosyl-(1->4)]-2-deoxy-D-streptamine; Kanamycin sulfate (JP15); C18H36N4O11; Kanamycin monosulfate; Kanamycinum; (1S,2R,3R,4S,6R)-4,6-diamino-3-(6-amino-6-deoxy-alpha-D-glucopyranosyloxy)-2-hydroxycyclohexyl 3-amino-3-deoxy-alpha-D-glucopyranoside; Kantrex (TN); 19079-03-9; C01822; 25389-94-0; EINECS 200-411-7; KM (the Antibiotic); 64013-69-0; DivK1c_000024; D-Streptamine, O-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1-6)-O-(6-amino-6-deoxy-alpha-D-glucopyranosyl-(1,4))-2-deoxy-; 59-01-8; Kanamycin sulfate (USP); KBio1_000024; C08046; NCGC00179506-01; Klebcil (1:1 sulfate); O-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1->6)-O-(6-amino-6-deoxy-alpha-D-glucopyranosyl-(1->4))-2-deoxy-D-streptamine; HSDB 3107; (2R,3S,4S,5R,6R)-2-(aminomethyl)-6-[(1R,2R,3S,4R,6S)-4,6-diamino-3-[(2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxyoxane-3,4,5-triol; CPD-4821; LS-146900; D-Streptamine, O-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1.fwdarw.6)-O-(6-amino-6-deoxy-alpha-D-glucopyranosyl-(1.fwdarw.4))-2-deoxy-; D00866; AC1L1LNI; nchembio.274-comp1; D-Streptamine, O-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1-6)-O-(6-amino-6-deoxy-alpha-D-glucopyranosyl-(1-4))-2-deoxy-; UNII-EQK9Q303C5; Liposomal Kanamycin; KAN; S2315_Selleck; 4,6-Diamino-2-hydroxy-1,3-cyclohexane 3,6'diamino-3,6'-dideoxydi-alpha-D-glucoside; AB00513827; Kanamycine [INN-French]; Aspidium; Kanamycin monosulfate (JP15); Kantrex (1:1 sulfate); Klebcil; CHEMBL1446; 936337-76-7; CID441374; 8063-07-8; BRN 0061647; kanamycin; Ambap133-92-6	8063-07-8	6032	3598	TTDS00219	30S ribosomal subunit	30S ribosome subunit	N/A	N/A	N/A	binder
DAP000838	Framycetin	Antibiotic produced by Streptomyces decaris. Neomycin B; NEOMYCIN SULFATE; HSDB 3242; Neomycinum; Myacyne; 4-18-00-07476 (Beilstein Handbook Reference); Neomicina; CID8378; Fraquinol; ST075177; Framycetin [INN:BAN:DCF]; Fradiomycin B; CHEBI:7508; LS-96091; Neobrettin; D05140; EINECS 215-766-3; Antibiotique; Neomycine; Prestwick3_000158; 119-04-0; NMY; DB00994; LS-96095; AC1L1QVH; Neolate; BPBio1_000326; C01737; NEOMYCIN AND POLYMYXIN B SULFATES; Neomas; (2R,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-[(1R,2R,3S,4R,6S)-4,6-diamino-2-[(2S,3R,4S,5R)-4-[(2R,3R,4R,5S,6S)-3-amino-6-(aminomethyl)-4,5-dihydroxyoxan-2-yl]oxy-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-3-hydroxycyclohexyl]oxyoxane-3,4-diol; Myciguent; Actiline; Framycetine [INN-French]; 11025-81-3; Endomixin; neomycin; Framicetina; Tuttomycin; Mycifradin; Framycetinum [INN-Latin]; Myacine; Framygen; Neobiotic; D-Streptamine, O-2,6-diamino-2,6-dideoxy-.beta.-L-idopyranosyl-(1.->3)-O-.beta.-D-ribofuranosyl-(1->5)]-O-[2,6-diamino-2,6-dideoxy-.alpha.-D-glucopyranosyl-(1->4)]-2-deoxy; BDG-(1-4)NEB-(5-1)RIB-(3-1)NED; NCGC00179612-01; AB00443887; Framycetine; D-Streptamine, O-2,6-diamino-2,6-dideoxy-alpha-D-glucopyranosyl-(1-4)-O-(O-2,6-diamino-2,6-dideoxy-beta-L-idopyranosyl-(1-3)-beta-D-ribofuranosyl-(1-5))-2-deoxy-; UNII-I16QD7X297; Vonamycin powder V; 1393-86-8; DB00452; BRN 0101621; Framicetina [INN-Spanish]; EPA Pesticide Chemical Code 006303; PIMAVECORT; C25H50N6O13; Actilin; Neomycin solution; 1405-10-3 (sulfate (salt)); Antibiotic 10676; Neomcin; N1142_SIGMA; 72131_FLUKA; Soframycin; Soframycin Ophthalmic; Neomycinum [INN-Latin]; HMS2089P15; USAF CB-19; EINECS 204-292-2; CCRIS 5462; Neomycin B sulfate; MolPort-003-938-736; BSPBio_000296; Enterfram; UNII-4BOC774388; Neo-Rx; BDG-(1-4)CYY-(5-1)RIB-(3-1)IDG; (1R,2R,3S,4R,6S)-4,6-diamino-2-{[3-O-(2,6-diamino-2,6-dideoxy-beta-L-idopyranosyl)-beta-D-ribofuranosyl]oxy}-3-hydroxycyclohexyl 2,6-diamino-2,6-dideoxy-alpha-D-glucopyranoside; 1404-04-2; Fradiomycin; Framycetin; Framycetin (INN); Neomin; Caswell No. 595; Fradiomycinum; Nivemycin; Neomicina [DCIT]; C23H46N6O13; Framycetinum; Soframycine; VONAMYCIN; Neo-Fradin; NEOMYCIN B; Neomycine [INN-French]	119-04-0	8378	151525	TTDS00219	30S ribosomal subunit	30S ribosome subunit	N/A	N/A	N/A	binder
DAP001398	Meclocycline	2-Naphthacenecarboxamide, 7-chloro-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methylene-1,11-dioxo-, (4S-(4alpha,4aalpha,5alpha,5aalpha,12aalpha))-; Meclociclina [Italian]; Samil; 2-[amino(hydroxy)methylidene]-7-chloro-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methylidene-4,4a,5,5a-tetrahydrotetracene-1,3,12-trione; CID5359674; Meclocycline (USAN/INN); CID5353747; 7-Chloro-6-methylene-5-oxytetracycline; (2E,4aR,5S,5aS,12aS)-2-[amino(hydroxy)methylidene]-7-chloro-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methylidene-4,4a,5,5a-tetrahydrotetracene-1,3,12-trione; EINECS 217-938-3; meclocycline; AC1L1H9N; UNII-23Q8M2HE6S; 7-Cloro-6-metilene-5-ossitetraciclina [Italian]; CID11972607; GS-2989; 7-Cloro-6-metilene-5-ossitetraciclina; AC1NS4JB; 2-Naphthacenecarboxamide, 7-chloro-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methylene-1,11-dioxo-, [4S-(4.alpha.,4aal; LS-93859; 2-Naphthacenecarboxamide, 7-chloro-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methylene-1,11-dioxo-, [4S-(4.alpha.,4a.alpha.,5.alpha.,5a.alpha.,12a.alpha.)]-; 7-chloro-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methylene-1,11-dioxo-2-naphthacene carboxamide; AC1NUJKU; Meclosorb; (2Z,4S,4aR,5S,5aR,12aS)-2-[amino(hydroxy)methylidene]-7-chloro-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methylidene-4,4a,5,5a-tetrahydrotetracene-1,3,12-trione; 2-Naphthacenecarboxamide, 7-chloro-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methylene-1,11-dioxo-, [4S-(4.alpha.,4a.alpha.,5.alpha.,5a.alpha.,12a.alpha.)]- (9CI); Meclocyclinum [INN-Latin]; C22H21ClN2O8; Meclociclina [INN-Spanish]; CID4035; D02476; Meclocycline [USAN:INN:BAN]; (2E,4S,4aR,5S,5aR,12aS)-2-[amino(hydroxy)methylidene]-7-chloro-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methylidene-4,4a,5,5a-tetrahydrotetracene-1,3,12-trione; Meclocyclinum; NSC78502; AC1NR077; CID5282519; 7-Chloro-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methylene-1,11-dioxo-2-naphthacenecarboxamide; Meclocycline(USAN); 2-Naphthacenecarboxamide, 7-chloro-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methylene-1,11-dioxo-; (2Z)-2-[amino(hydroxy)methylidene]-7-chloro-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methylidene-4,4a,5,5a-tetrahydrotetracene-1,3,12-trione; GS 2989; NSC 78502; CID5480760; 2013-58-3; Meclociclina; AC1NSE5G	2013-58-3	5480760	617806	TTDS00219	30S ribosomal subunit	30S ribosome subunit	N/A	N/A	N/A	binder
DAP000036	Neomycin	Antibiotic produced by Streptomyces decaris. Neomycin B; NEOMYCIN SULFATE; D-Streptamine, O-2,6-diamino-2,6-dideoxy-.beta.-L-idopyranosyl-(1.->3)-O-.beta.-D-ribofuranosyl-(1->5)]-O-[2,6-diamino-2,6-dideoxy-.alpha.-D-glucopyranosyl-(1->4)]-2-deoxy; BDG-(1-4)NEB-(5-1)RIB-(3-1)NED; HSDB 3242; Neomycinum; NCGC00179612-01; AB00443887; Framycetine; Myacyne; D-Streptamine, O-2,6-diamino-2,6-dideoxy-alpha-D-glucopyranosyl-(1-4)-O-(O-2,6-diamino-2,6-dideoxy-beta-L-idopyranosyl-(1-3)-beta-D-ribofuranosyl-(1-5))-2-deoxy-; 4-18-00-07476 (Beilstein Handbook Reference); UNII-I16QD7X297; Vonamycin powder V; Neomicina; 1393-86-8; DB00452; CID8378; Fraquinol; BRN 0101621; Framicetina [INN-Spanish]; EPA Pesticide Chemical Code 006303; ST075177; Framycetin [INN:BAN:DCF]; PIMAVECORT; C25H50N6O13; Actilin; Neomycin solution; 1405-10-3 (sulfate (salt)); Fradiomycin B; Antibiotic 10676; CHEBI:7508; Neomcin; N1142_SIGMA; LS-96091; Neobrettin; 72131_FLUKA; Soframycin; Soframycin Ophthalmic; Neomycinum [INN-Latin]; HMS2089P15; D05140; EINECS 215-766-3; Antibiotique; USAF CB-19; EINECS 204-292-2; CCRIS 5462; Neomycine; Prestwick3_000158; 119-04-0; Neomycin B sulfate; MolPort-003-938-736; BSPBio_000296; NMY; DB00994; LS-96095; Enterfram; AC1L1QVH; UNII-4BOC774388; Neo-Rx; BDG-(1-4)CYY-(5-1)RIB-(3-1)IDG; (1R,2R,3S,4R,6S)-4,6-diamino-2-{[3-O-(2,6-diamino-2,6-dideoxy-beta-L-idopyranosyl)-beta-D-ribofuranosyl]oxy}-3-hydroxycyclohexyl 2,6-diamino-2,6-dideoxy-alpha-D-glucopyranoside; Neolate; BPBio1_000326; 1404-04-2; C01737; NEOMYCIN AND POLYMYXIN B SULFATES; Neomas; (2R,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-[(1R,2R,3S,4R,6S)-4,6-diamino-2-[(2S,3R,4S,5R)-4-[(2R,3R,4R,5S,6S)-3-amino-6-(aminomethyl)-4,5-dihydroxyoxan-2-yl]oxy-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-3-hydroxycyclohexyl]oxyoxane-3,4-diol; Fradiomycin; Framycetin; Framycetin (INN); Neomin; Myciguent; Caswell No. 595; Fradiomycinum; Actiline; Nivemycin; Framycetine [INN-French]; 11025-81-3; Endomixin; neomycin; Framicetina; Neomicina [DCIT]; C23H46N6O13; Framycetinum; Soframycine; VONAMYCIN; Neo-Fradin; NEOMYCIN B; Tuttomycin; Mycifradin; Framycetinum [INN-Latin]; Myacine; Neomycine [INN-French]; Framygen; Neobiotic	1404-04-2	8378	158283	TTDS00219	30S ribosomal subunit	30S ribosome subunit	N/A	N/A	N/A	binder
DAP000402	Demeclocycline	SPBio_002705; KBioGR_000926; NCGC00162149-04; (2Z,4S,4aS,5aS,6S,12aS)-2-[amino(hydroxy)methylidene]-7-chloro-4-(dimethylamino)-6,10,11,12a-tetrahydroxy-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; SAM002589921; (4S,4aS,5aS,6S,12aS)-7-chloro-4-(dimethylamino)-3,6,10,12,12a-pentahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide; DMCT; DMCTC; Demeclocycline [USAN:BAN]; Novotriclina; CID5311063; SMP1_000091; NCGC00015359-01; Spectrum3_000378; CHEMBL1591; RP 10192; CID5281009; 7-Chloro-4-dimethylamino-3,6,10,12,12a-pentahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydro-naphthacene-2-carboxylic acid amide; 2-Naphthacenecarboxamide, 7-chloro-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-1,11-dioxo-; Prestwick1_000753; C21H21ClN2O8; Ledermycin; 6-Demethyl-7-chlorotetracycline; Demethylchlortetracycline base; Demethylchlortetracycline; Spectrum5_000831; Demethylchlorotetracycline; Clortetrin; Demeclociclina; AC1NSQ1X; 8059-70-9; 2-[amino(hydroxy)methylidene]-7-chloro-4-(dimethylamino)-6,10,11,12a-tetrahydroxy-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; HSDB 3051; LS-187188; Demethylchlortetracycline (JAN); 2-Naphthacenecarboxamide, 7-chloro-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-1,11-dioxo-, (4S-(4alpha,4aalpha,5aalpha,6beta,12aalpha))-; CID5367858; (2E,4S,4aS,5aS,6S,12aS)-2-[amino(hydroxy)methylidene]-7-chloro-4-(dimethylamino)-6,10,11,12a-tetrahydroxy-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; CID2983; DMCT (antibiotic); KBio3_001355; CPD001496930; AC1O7G2H; D03680; Perciclina; 16204-02-7; Demeclocyclinum [INN-Latin]; UNII-5R5W9ICI6O; Demeclocycline Monohydrochloride; 6-Demethylchlortetracycline; AC1NSJXH; Deganol; 6-Demetil-7-clorotetraciclina; BSPBio_002135; Lopac0_000421; Demethylchlortetracyclin; Ledermycin hydrochloride; demeclocycline; NINDS_000863; Tri-demethylchlortetracycline; KBio2_003944; (2E,4S,4aS,5aS,6R,12aR)-2-[amino(hydroxy)methylidene]-7-chloro-4-(dimethylamino)-6,10,11,12a-tetrahydroxy-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; Chlortetracycline, 6-demethyl-; Demethylchlortetracyclinum; 7-Chloro-6-demethyltetracycline; 64-73-3 (mono-hydrochloride); CHEBI:4392; AC1L1EWT; LS-93855; [4S-(4alpha,4aalpha,5aalpha,6beta,12aalpha)]-7-chloro-4-(dimethylamino)1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-1,11-dioxo-2-naphthacenecarboxamide; Spectrum_000896; Spectrum2_001132; DivK1c_000863; NCGC00162149-03; KBio2_006512; Demeclocycline (USP); Mexocine; Demeclociclina [INN-Spanish]; AC1NQXW1; BPBio1_000844; Diuciclin; Prestwick0_000753; KBio1_000863; EINECS 204-834-8; Tetracycline, 7-chloro-6-demethyl-; 6-Demethylchlorotetracycline; 2-Naphthacenecarboxamide, 7-chloro-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-1,11-dioxo-, (4S,4aS,5aS,6S,12aS)-; Sumaclina; 2-Naphthacenecarboxamide, 7-chloro-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-1,11-dioxo-, [4S-(4.alpha.,4a.alpha.,5a.alpha.,6.beta.,12a.alpha.)]-; 6-Demethyl-7-chlortetracycline; Declomycin; IDI1_000863; BSPBio_000766; NCGC00015359-02; 6-Demetil-7-clorotetraciclina [Italian]; KBio2_001376; NCGC00162149-02; Prestwick2_000753; Bioterciclin; Demeclor; 64-73-3; Demeclocyclinum; Demetraclin; CID6603821; Methylchlorotetracycline; Spectrum4_000313; Lopac-D-6140; Prestwick3_000753; (2E)-2-[amino(hydroxy)methylidene]-7-chloro-4-(dimethylamino)-6,10,11,12a-tetrahydroxy-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; KBioSS_001376; NCGC00016290-01; SPBio_001023; 7-Chloro-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-1,11-dioxo-2-naphthacenecarboxamide; CAS-64-73-3; DB00618; 127-33-3	127-33-3	5311063	173448	TTDS00219	30S ribosomal subunit	30S ribosome subunit	N/A	N/A	N/A	binder
DAP000405	Minocycline	CHEMBL259172; NSC 141993; Minociclina [INN-Spanish]; MIY; (4S,4AS,5AR,12AS)-4,7-BIS(DIMETHYLAMINO)-3,10,12,12A-TETRAHYDROXY-1,11-DIOXO-1,4,4A,5,5A,6,11,12A-OCTAHYDROTETRACENE-2-CARBOXAMIDE; CRL-1605 & Minocycline; CID5281021; (2Z,4S,4aS,5aR,12aS)-2-[amino(hydroxy)methylidene]-4,7-bis(dimethylamino)-10,11,12a-trihydroxy-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; Minociclina; NSC141993; Minocycline [USAN:BAN:INN]; Minocycline (USAN/INN); CHEBI:529981; Borymycin; 10118-90-8; LMPK07000002; AC1NQXWM; nchembio.559-comp1; Lactoferrin B & Minocycline; CHEBI:50694; MINO; CL 59806; Minocycline Monohydrochloride; Bio-0062; Minocline; Minocyclinum; 2-Naphthacenecarboxamide, 4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S-(4alpha,4aalpha,5aalpha,12aalpha))-; 2-Naphthacenecarboxamide, 4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)-; NCGC00178854-01; Minocin (Hydrochloride); UNII-FYY3R43WGO; 4708-96-7; Lactoferrin H & Minocycline; Minocyclin; LS-93850; minociclinum; Minocyclinum [INN-Latin]; minocycline; BRN 3077644; C23H27N3O7; Minocin; 4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide; CHEMBL1434; 13614-98-7 (mono-hydrochloride); HSDB 3130; 7-Dimethylamino-6-demethyl-6-deoxytetracycline; D05045; C07225; Vectrin (Hydrochloride); HMS2090D03	10118-90-8	5281021	167749	TTDS00219	30S ribosomal subunit	30S ribosome subunit	N/A	N/A	N/A	binder
DAP001510	Raltegravir	AC-2062; MK-0518; CHEMBL254316; S2005_Selleck; K-0518; 518048-05-0; Raltegravir; MK 0518; AB1004864; Raltegravir (INN); N-((4-Fluorophenyl)methyl)-1,6-dihydro-5-hydroxy-1-methyl-2-(1-methyl-1-(((5-methyl-1,3,4-oxadiazol-2-yl)carbonyl)amino)ethyl)-6-oxo-4-pyrimidinecarboxamide; -5-hydroxy-1-methyl-6-oxo-1, 6-dihydropyrimidin-2-yl)propan-2-yl) -5-methyl-1,3,4-oxadiazole-2- carboxamide; UNII-22VKV8053U; Isentress(TM); RGV; CID11598201; D06676; N-(2-(4-(4-fluorobenzylcarbamoyl); CHEMBL1162988; I14-1973	871038-72-1	11598201	47208327	TTDS00519	HIV-1 integrase	HIV 1 Integrase;HIV Integration Protein;Integrase, HIV-1;Integration Protein, HIV	O56072	N/A	N/A	inhibitor
DCL001212	MEDI-578	N/A	N/A	N/A	N/A	TTDR00553	Nerve growth factor	NGF	P30894	N/A	N/A	antibody
DCL000487	AZD9056	N/A	847254-30-2	N/A	85153111	TTDC00218	P2X purinoceptor 7	Adenosine P2X7 receptor;ATP receptor;P2X7;P2Z receptor;Purinergic receptor	Q99572	5027	ENSG00000089041	antagonist
DCL000410	GSK1482160	N/A	N/A	N/A	N/A	TTDC00218	P2X purinoceptor 7	Adenosine P2X7 receptor;ATP receptor;P2X7;P2Z receptor;Purinergic receptor	Q99572	5027	ENSG00000089041	antagonist
DAP000467	Aluminium	7784-21-6; 266957_ALDRICH; Caswell No. 028A; 338788_ALDRICH; IRMM528RA_FLUKA; CHEBI:33629; Emanay atomized aluminum powder; JISC 3108; IRMM530RA_FLUKA; AO A1; 37425_FLUKA; 326852_ALDRICH; Aluminum soluble salts; IRMM528RC_FLUKA; 11009_ALDRICH; NA9260; Metana; AV00; A999; LS-16478; Aluminum metal; AD1M; Aluminum production; 433705_ALDRICH; AE; PAP-1; Aa1193; A 99; Aluminum powder, uncoated [UN1396] [Dangerous when wet]; Aluminum powder, coated [UN1309] [Flammable solid]; 37465_RIEDEL; Aluminum, pyro powders/welding fumes; IRMM533C_FLUKA; L16; 113962-66-6; AQUANAL-plus aluminum (Al) 0.02-0.2 mg/L; AC1NSDXQ; IRMM532A_FLUKA; 37425_RIEDEL; CHEBI:28984; IRMM533A_FLUKA; 11009_RIEDEL; 356859_ALDRICH; IRMM528RB_FLUKA; IRMM530RC_FLUKA; 518573_ALDRICH; CI 77000; ALUMINUM (SEE ALSO ALUMINUM OXIDE 1344-28-1); Aluminum metal, total dust; AO Al; Aluminium bronze; IRMM523B_FLUKA; EPA Pesticide Chemical Code 000111; Noral Extra Fine Lining Grade; 39332-62-2; 202576_ALDRICH; 266515_ALDRICH; A 995; Aluminum dust; Aluminum welding fumes; Allbri aluminum paste and powder; Noral non-leafing grade; 12766-45-9; EINECS 231-072-3; 326941_ALDRICH; ALUMINUM; CID5359268; A999V; Aluminum metal, alkyls; 11008_ALDRICH; Metana aluminum paste; 37505_RIEDEL; IRMM534A_FLUKA; Alaun [German]; Al alloy; Aluminum powder; 182260-45-3; 185464-37-3; Aluminum, pyro powders; 37465_FLUKA; AV000; UN1396; IRMM532C_FLUKA; Aluminum powder, coated [UN1309]  [Flammable solid]; AQUANAL(R)-plus aluminum (Al) 0.02-0.2 mg/L; 11010_RIEDEL; C-Pigment 1; IRMM527RC_FLUKA; Aluminum metal, soluble salts; Aluminum pyro powders; D000535; IRMM533B_FLUKA; AD 1; AA1199; A 999; IRMM532B_FLUKA; Aluminum metal, welding fumes; 298688-47-8; Noral ink grade aluminium; Aluminum alloy; Aluminum (dust or fume); Aluminium, elementar; Aluminium; LS-16450; 266523_SIAL; AA 1099; Al; 326860_ALDRICH; MolPort-003-927-740; 326925_ALDRICH; 37202-64-5; aluminium(0); MolPort-003-925-507; Aluminum, elemental; Aluminum hydride [UN2463]  [Dangerous when wet]; 7429-90-5; Aluminum dehydrated; 214752_SIAL; Aluminum, molten [NA9260] [Class 9]; 326887_ALDRICH; Pigment metal 1; 356859_SIAL; C-Pigment 1 [German]; A 00; 11008_RIEDEL; Aluminum 27; Noral aluminum; ALUMINUM, 99.999%; Al(0); Adom; ALUMINUM, ATOMIZED; 202584_ALDRICH; Aluminum powder, uncoated [UN1396]  [Dangerous when wet]; IRMM534B_FLUKA; IRMM523A_FLUKA; Aluminum (fume or dust); 257888-99-6; Aluminum metal, respirable fraction; Aluminum, welding fumes; 310360_SIAL; Aluminum metal, pyro powders; Noral Ink Grade Aluminum; 653608_ALDRICH; HSDB 507; Noral aluminium; Alumina fibre; 266558_ALDRICH; UN1309; Aluminum, molten [NA9260]  [Class 9]; 91728-14-2; aluminio; DB01370; 13Al; IRMM527RA_FLUKA; JISC 3110; Aluminum (metal); Aluminium flake; C.I. 77000; IRMM527RB_FLUKA; Aluminum, soluble salts; 39302-71-1; 266574_ALDRICH; IRMM523C_FLUKA; IRMM534C_FLUKA; 80341-19-1; 11010_ALDRICH; LS-1637; A 95; Aluminum A00	7429-90-5	5359268	10534431	TTDS00045	Sodium/potassium-transporting ATPase alpha-1 chain	Na+/K+ ATPase 1;Sodium pump 1;Sodium/potassium-transporting ATPase alpha1	P05023	476	ENSG00000163399	binder
DAP001453	Artemether	3,12-Epoxy-12H-pyrano(4,3-j)-1,2-benzodioxepin, decahydro-10-methoxy-3,6,9-trimethyl-, (3R,5aS,6R,8aS,9R,10R,12R,12aR)-; 3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin, decahydro-10-methoxy-3,6,9-trimethyl-, (3S,5aS,6R,8aS,9R,10R,12R)-; 3,12-Epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin, decahydro-10-methoxy-3,6,9-tri; Artemether; Artmether; 71963-77-4; Artesaph; KST-1A8041; Artemetero; CID6712286; AC1Q6Z7V; beta-Artemether; CID456408; (3r,5as,6r,8as,9r,10r,12r,12ar)-10-methoxy-3,6,9-trimethyldecahydro-3,12-epoxy[1,2]dioxepino[4,3-i]isochromene; rither; (3R,5aS,6R,8aS,9R,10S,12R,12aR)-Decahydro-10-methoxy-3,6,9-trimethyl-3,12-epoxy-12H-pyrano(4,3-j)-1,2-benzodioxepin; SM 229; 3,12-Epoxy-12H-pyrano(4,3-j)-1,2-benzodioxepin, decahydro-10-methoxy-3,6,9-trimethyl-, (3alpha,5alphabeta,6beta,8alphabeta,9alpha,10beta,12beta,12aR*)-; HMS2052L09; Artemetheri; LS-176935; AR-1A4424; SM-224; SM 224; ( )-alpha-Artemether; (3R,5aS,6R,8aS,9R,10S,12R,12aR)-10-methoxy-3,6,9-trimethyldecahydro-3,12-epoxypyrano[4,3-j][1,2]benzodioxepine; Methyl-dihydroartemisinine; Artemetero [INN-Spanish]; CID6483308; artemether[inn]; Dihydroquinghaosu methyl ether; 93787-85-0; beta-Dihydroartemisinin methyl ether; Malartem; Artemether (INN); UNII-C7D6T3H22J; Artimist; SMR000469218; BRN 5948416; AC1L9UV0; .beta.-Dihydroartemisinin methyl ether; AC1L2XO8; Gvither; 3,12-Epoxy-12H-pyrano(4,3-j)-1,2-benzodioxepin, decahydro-10-methoxy-3,6,9-trimethyl-,(3-alpha,5a-beta,6-beta,8a-beta,9-alpha,12-beta,12aR)-, (+)-; CID9796294; 3,12-Epoxy-12H-pyrano(4,3-j)-1,2-benzodioxepin, decahydro-10-methoxy-3,6,9-trimethyl-, (3R-(3-alpha,5a-beta,6-beta,8a-alpha,9-alpha,10-beta,12-beta,12aR*))-; DB06697; MLS001424249; Artemos; 159573-83-8; LS-64237; 3,12-Epoxy-12H-pyrano(4,3-j)-1,2-benzodioxepin, decahydro-10-methoxy-3,6,9-trimethyl-, (3-alpha,5a-beta,6-beta,8a-beta,9-alpha,12-beta,12aR)-, (+)-; 71939-51-0; Artesian; CID9796295; Artemetherum [INN-Latin]; artemether, (3R-(3alpha,5abeta,6beta,8abeta,9alpha,10alpha,12beta,12aR*))-isomer; alpha-Artemether; Paluther; I06-0205; Artenam; Artemisininelactol methyl ether; 80286-56-2; HSDB 7456; Artemetherum; .beta.-Methylether of 11-epi-dihydroartemisinin; D02483; CHEMBL411864; AC1L2APD; CPD000469218; 10-methoxy-1,5,9-trimethyl-(1R,4S,5R,8S,9R,10S,12R,13R)-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecane; CID68911; C16H26O5; 3,12-Epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin, decahydro-10-methoxy-3,6,9-trimethyl-, (3R,5aS,6R,8aS,9R,10S,12R,12aR)-; NSC 665970; (3alpha,5abeta,6beta,8abeta,9alpha,10beta,12beta,12aR*)-isomer of artemether; AC1L9SH2; NCI60_022891; .beta.-Artemether; CHEBI:195280; O-Methyldihydroartemisinine; Arteannuin ether; methyl-, [3R-(3.alpha.,5a.beta.,6.beta.,8a.beta.,9.alpha.,10.alpha.,12.beta.,12aR*)]-; AC1MI2ZX; S2264_Selleck; Artemether [INN]; SAM001246799; CID10266705; CID104888; Dihydroartemisinin methyl ether; CID500199; CHEMBL512315; Falcidol; AC1Q6Z74; CID3062122; (5aS,6R,8aS,9R,10S,12R,12aR)-10-methoxy-3,6,9-trimethyldecahydro-3,12-epoxy[1,2]dioxepino[4,3-i]isochromene; 74784-06-8; NSC665970; alpha-Dihydroartemisinin methyl ether	71963-77-4	119380	17396662	TTDS00045	Sodium/potassium-transporting ATPase alpha-1 chain	Na+/K+ ATPase 1;Sodium pump 1;Sodium/potassium-transporting ATPase alpha1	P05023	476	ENSG00000163399	binder
DAP000464	Deslanoside	3beta-(O-beta-D-Glucopyranosyl-(1-4)-O-beta-D-digitoxosyl-(1-4)-O-beta-D-digitoxosyl-(1-4)-beta-D-digitoxosyloxy-12beta,14-dihydroxy-5beta,14beta-card-20(22)-enolid; Deacetyllanatoside C; 3-[(3S,5R,8R,9S,10S,12R,13S,14S,17R)-12,14-dihydroxy-3-[(2R,4S,5S,6R)-4-hydroxy-5-[(2S,4S,5S,6R)-4-hydroxy-5-[(2S,4S,5S,6R)-4-hydroxy-6-methyl-5-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-6-methyloxan-2-yl]oxy-6-methyloxan-2-yl]oxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2H-furan-5-one; Deslanosidum [INN-Latin]; Cedilanid-d (TN); LS-87553; Lekozid; CID28620; UNII-YGY317RK75; EINECS 241-568-1; 11029-69-9; Desacetyl Lanatoside; Desacetyllanatoside C; Deslanosidum; 17598-65-1; Ambap17598-65-1; CHEBI:31468; Lanatosid C; Card-20(22)-enolide, 3-((O-beta-D-glucopyranosyl-(1-4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy)-12,14-dihydroxy-, (3beta,5beta,12beta)-; Deslanosido; Desacetyl-Lanatoside C; deslanoside; Ceglunat; Cedilanid-D; Deslanosido [INN-Spanish]; 1329-81-3; (3beta,5beta,12beta)-3-{[beta-D-glucopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl]oxy}-12,14-dihydroxycard-20(22)-enolide; Deslanoside (JP15/USP/INN); CHEMBL1614; Lanatoside C, deacetyl-; 3beta-{[beta-D-glucopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl]oxy}-12beta,14-dihydroxy-5beta-card-20(22)-enolide; Deslanosidum C; Deslanatoside C; 11004-41-4; glucodigoxin; 3-[(O-beta-D-glucopyranosyl-(1->4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy]-12,14-dihydroxy-3beta,5beta,12beta-card-20(22)-enolide; Deslanoside [USAN:BAN:INN:JAN]; Sediranido; Card-20(22)-enolide, 3-((O-beta-D-glucopyranosyl-(1->4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy)-12,14-dihydroxy-, (3beta,5beta,12beta)-; Desacetyldigilanide C; 3beta-(O-beta-D-Glucopyranosyl-(1-4)-O-beta-D-digitoxosyl-(1-4)-O-beta-D-digitoxosyl-(1-4)-beta-D-digitoxosyloxy=12beta.14=dihydroxy-5beta,14beta-card-20(22)-enolid; AC1L1FPG; D01240; Desace; 4-18-00-02455 (Beilstein Handbook Reference); BRN 0078187; 35-58-5	17598-65-1	443932	7848303	TTDS00045	Sodium/potassium-transporting ATPase alpha-1 chain	Na+/K+ ATPase 1;Sodium pump 1;Sodium/potassium-transporting ATPase alpha1	P05023	476	ENSG00000163399	binder
DAP000131	Chloroprocaine	4-amino-2-chlorobenzoic acid 2-(diethylamino)ethyl ester; Nesacaine; UNII-5YVB0POT2H; C13H19ClN2O2; DB01161; CHLOROPROCAINE; Chloroprocainum [INN-Latin]; Cloroprocaina [INN-Spanish]; Chloroprocain; LS-35706; 133-16-4; 2-(Diethylaminoethyl)-4-amino-2-chlorobenzoate; 2-Chloroprocaine; BRN 2808071; Benzoic acid, 4-amino-2-chloro-, 2-(diethylamino)ethyl ester; CHEBI:3636; 2-diethylaminoethyl 4-amino-2-chlorobenzoate; Chlorprocainum; D07678; Chloroprocaine [INN]; Halestyn; Chloroprocaine hydrochloride; Chloroprocaine (INN); 3858-89-7 (hydrochloride); AC1L1RCM; Chlorprocaine; 2-(Diethylamino)ethyl 4-amino-2-chlorobenzoate; Chlor-procaine; 4-14-00-01273 (Beilstein Handbook Reference); Piocaine; CID8612; HSDB 3301; Chloroprocainum; Nesacaine MPF; Nesacaine-Ce; Cloroprocaina; C07877	133-16-4	8612	10079	TTDS00045	Sodium/potassium-transporting ATPase alpha-1 chain	Na+/K+ ATPase 1;Sodium pump 1;Sodium/potassium-transporting ATPase alpha1	P05023	476	ENSG00000163399	blocker
DAP000466	Ciclopirox	KBio3_001261; 6-cyclohexyl-1-hydroxy-4-methylpyridin-2(1H)-one; 2(1H)-Pyridinone, 6-cyclohexyl-1-hydroxy-4-methyl-; AC-13011; Ciclopiroxum; UNII-19W019ZDRJ; Spectrum2_000146; TL8002303; AC1L1EDN; Loprox Gel; C12H17NO2; HOE-296b; Penlac (TN); Loprox (TN); KBioGR_000816; NCGC00178850-02; BIDD:GT0080; (6-Cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridone); 6-Cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridinone; 6-cyclohexyl-1-hydroxy-4-methyl-2(1 H )-pyridinone; BSPBio_000581; Prestwick1_000541; Loprox; SPBio_000252; LS-174247; CICLOPIROX; Ciclopirox (USP/INN); Penlac nail lacquer; Loprox Shampoo; DB01188; 2(1H)-Pyridone, 6-cyclohexyl-1-hydroxy-4-methyl-; HOE 296b; Ciclopirox [USAN:BAN:INN]; SPBio_002502; CHEMBL1413; Prestwick0_000541; Dafnegin-CSC; EINECS 249-577-2; 29342-05-0; Spectrum5_000747; cyclopirox; BPBio1_000641; Spectrum3_000351; Stieprox; Penlac; Ciclopirox-Olamin; 6-cyclohexyl-1-hydroxy-4-methylpyridin-2-one; D03488; Prestwick3_000541; Ciclopiroxum [INN-Latin]; CHEBI:453011; Terit; 6-Cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridone; Loprox cream; cyclopyroxolamine; 6-Cyclohexyl-1-hydroxy-4-methyl-2-(1H)-pyridone; Spectrum4_000288; Prestwick2_000541; CID2749; BSPBio_002041; NCGC00178850-01; I06-0862; HOE-296; Ciclopirox Olamin; Ciclopirox gel	29342-05-0	2749	213640	TTDS00045	Sodium/potassium-transporting ATPase alpha-1 chain	Na+/K+ ATPase 1;Sodium pump 1;Sodium/potassium-transporting ATPase alpha1	P05023	476	ENSG00000163399	binder
DAP000468	Almitrine	Almitrin; 2,4-Bis(allylamino)-6-(4-(bis(p-fluorophenyl)methyl)-1-piperazinyl)-s-triazine; Almitrine (INN); 2,4-bis[allylamino]-6-[4-[bis(p-fluorophenyl)methyl]-1-piperazinyl]-s-triazine; LS-174185; Almitrina; Almitrine [INN:BAN]; UNII-9A1222NBG4; AC1L1QHF; CID33887; Almitrine bismesylate; Almitrinum [INN-Latin]; Almitrine [BAN:INN]; CHEBI:53778; AC1Q4NMG; 1,3,5-Triazine-2,4-diamine, 6-(4-(bis(4-fluorophenyl)methyl)-1-piperazinyl)-N,N'-di-2-propenyl-; Almitrine Bis(methanesulfonate); ALMITRINE; D07126; Almitrina [INN-Spanish]; N,N'-diallyl-6-{4-[bis(4-fluorophenyl)methyl]piperazin-1-yl}-1,3,5-triazine-2,4-diamine; DB01430; Almitrinum; C26H29F2N7; Vectarion; EINECS 248-475-5; Almitrine dimesylate; 6-(4-(Bis(4-fluorphenyl)methyl)-1-piperazinyl)-N,N'-di-2-propenyl-1,3,5-triazin-2,4-diamin; S 2620; 29608-49-9 (dimesylate); 6-[4-[bis(4-fluorophenyl)methyl]piperazin-1-yl]-2-N,4-N-bis(prop-2-enyl)-1,3,5-triazine-2,4-diamine; 27469-53-0	27469-53-0	33887	16862494	TTDS00045	Sodium/potassium-transporting ATPase alpha-1 chain	Na+/K+ ATPase 1;Sodium pump 1;Sodium/potassium-transporting ATPase alpha1	P05023	476	ENSG00000163399	binder
DAP000465	Ouabain	Oubain; Strophalen; CID439501; EINECS 211-139-3; HMS502N07; AC1Q6AXD; NSC-25485; NCGC00017394-07; Strodival; IDI1_000905; KBioGR_002272; DB01092; HMS1921A22; C01443; Ouabagenin-L-rhamnosid [German]; WLN: L E5 B666TJ A1Q CQ E1 IQ MQ QQ F- DT5OV EHJ& OO- BT6OTJ CQ DQ EQ F1; BRD-A46747628-001-01-9; Quabain; CID637579; MolPort-003-938-921; BPBio1_000664; 3-[(6-Deoxyhexopyranosyl)oxy]-1,5,11,14,19-pentahydroxycard-20(22)-enolide; LMST01120022; G-Strophanthin; Ouabagenin L-Rhamnoside; Ouabagenin-L-rhamnosid; Ouabain; Ouabain anhydrous; Ouabaine; Oubain; Ouabain, Octahydrate; Astrobain; C29H44O12; 5-18-05-00625 (Beilstein Handbook Reference); HSDB 3519; Solufantina; Strophanthin-G; BSPBio_002774; MLS002702983; CHEBI:472805; Strophosan; KBio3_001994; Acocantherine; G-Strophanthin; Prestwick3_000471; Strophanthin G; SR-01000721848; Ouabain octahydrate; Uabaina; BRN 0101712; 36-06-6; Rectobaina; O 3125; MolPort-003-922-984; Ouabagenin-L-rhamnosid; SR-01000721848-2; Spectrum5_000849; 630-60-4; Gratibain; CID12420; nchembio.476-comp7; NCI60_002047; BRD-K35708212-331-03-1; AC1L97H2; NINDS_000905; Prestwick0_000471; SMR001551689; NCGC00094248-03; SPBio_001128; BRD-A68930007-001-02-3; ouabain; Gratus strophanthin; Strophoperm; Acocantherin; DivK1c_000905; card-20(22)-enolide, 3-[(6-deoxyhexopyranosyl)oxy]-1,5,11,14,19-pentahydroxy-; 11018-89-6; D00112; CID9829825; Prestwick1_000471; AC1L1ZK6; 1ibg; HMS2089J19; NSC 25485; Prestwick2_000471; CID4605; OBN; NCGC00094248-02; SPBio_002541; NCGC00178479-01; NCGC00017394-02; Uabanin; Ouabain anhydrous; Ouabagenin L-rhamnoside; Spectrum3_001097; Ouabaine; Purostrophan; Spectrum2_001084; KBio1_000905; SMR000058492; SMP1_000142; S0091; AC1LCUIW; MLS000069786; LS-98533; Kombetin; NCGC00094248-04; Lopac0_000943; Acolongifloroside K; EU-0100943; NCGC00094248-01; SPECTRUM1500676; 3-((6-deoxyhexopyranosyl)oxy)-1,5,11,14,19-pentahydroxycard-20(22)-enolide; G-Strophicor; nchembio.2007.53-comp10; AR-1F0680; BSPBio_000602; Spectrum4_001926; CCRIS 965; MolPort-003-665-540; SR-01000721848-4; TL8004371; CHEMBL222863; O3125_SIGMA; G-Strophanthin (JAN); AC1L1IJG; HMS2092I06; ST085767; Ouabain (anhydrous); NSC25485; SDCCGMLS-0066608.P001	630-60-4	439501	4621	TTDS00045	Sodium/potassium-transporting ATPase alpha-1 chain	Na+/K+ ATPase 1;Sodium pump 1;Sodium/potassium-transporting ATPase alpha1	P05023	476	ENSG00000163399	binder
DAP001491	Lumefantrine	AC-4542; 120583-69-9; 82186-77-4; UNII-F38R0JR742; CID6437380; HSDB 7210; NCGC00167490-01; (+-)-2,7-Dichloro-9-((Z)-p-chlorobenzylidene)-alpha((dibutylamino)methyl)fluorene-4-methanol; CHEBI:156095; CHEMBL38827; LS-177674; 2-Dibutylamino-1-{2,7-dichloro-9-[1-(4-chloro-phenyl)-meth-(Z)-ylidene]-9H-fluoren-4-yl}-ethanol; 2-(dibutylamino)-1-[(9Z)-2,7-dichloro-9-[(4-chlorophenyl)methylidene]fluoren-4-yl]ethanol; 9H-Fluorene-4-methanol, 2,7-dichloro-9-((4-chlorophenyl)methylene)-alpha-((dibutylamino)methyl)-, (Z)-; D03821; AC1O5NKD; Bio-0132; Coartem; C30H32Cl3NO; Lumefantrine; dl-Benflumelol; 2-(dibutylamino)-1-[(9Z)-2,7-dichloro-9-(4-chlorobenzylidene)-9H-fluoren-4-yl]ethanol; Lumefantrine (INN); I14-7746; DB06708; 2-Dibutylamino-1-[2,7-dichloro-9-(4-chloro-benzylidene)-9H-fluoren-4-yl]-ethanol; MolPort-006-394-826; Lumefantrine [INN:BAN]; Benflumetol; (+-)-2,7-Dichloro-9-((Z)-p-chlorobenzylidene)-alpha-((dibutylamino)methyl)fluorene-4-methanol	82186-77-4	N/A	47205892	TTDS00045	Sodium/potassium-transporting ATPase alpha-1 chain	Na+/K+ ATPase 1;Sodium pump 1;Sodium/potassium-transporting ATPase alpha1	P05023	476	ENSG00000163399	binder
DCL000406	GSK1278863	N/A	N/A	N/A	N/A	TTDC00054	Hypoxia-inducible factor-prolyl hydroxylase	Egl nine homolog 2;EGLN2;EIT6;Estrogen-induced tag 6;HIF-PH;HIF-PH1;HIF-prolyl hydroxylase 1;HPH-3;Hypoxia-inducible factor prolyl hydroxylase 1;PHD1;Prolyl hydroxylase domain-containing protein 1	Q96KS0	112398	ENSG00000171570	inhibitor
DCL000111	FG-2216	N/A	N/A	N/A	N/A	TTDC00054	Hypoxia-inducible factor-prolyl hydroxylase	Egl nine homolog 2;EGLN2;EIT6;Estrogen-induced tag 6;HIF-PH;HIF-PH1;HIF-prolyl hydroxylase 1;HPH-3;Hypoxia-inducible factor prolyl hydroxylase 1;PHD1;Prolyl hydroxylase domain-containing protein 1	Q96KS0	112398	ENSG00000171570	inhibitor
DCL000112	FG-4592	N/A	637334-45-3	N/A	47206937	TTDC00054	Hypoxia-inducible factor-prolyl hydroxylase	Egl nine homolog 2;EGLN2;EIT6;Estrogen-induced tag 6;HIF-PH;HIF-PH1;HIF-prolyl hydroxylase 1;HPH-3;Hypoxia-inducible factor prolyl hydroxylase 1;PHD1;Prolyl hydroxylase domain-containing protein 1	Q96KS0	112398	ENSG00000171570	inhibitor
DAP000132	Glimepiride	Glimepiride [USAN:BAN:INN]; NCGC00181757-01; Prestwick2_000651; TL8005924; MolPort-003-847-587; CPD000466368; Bio-0049; Glimepirida [Spanish]; LS-136752; AC1L1G0T; 93479-97-1; Glimepirida; Ratio-glimepiride; Glimepiride (JAN/USP/INN); MLS001076674; BRN 5365754; I06-2285; MolPort-005-941-721; SMR000466368; G2295_SIGMA; Prestwick0_000651; Glimer; Amaryl, Glista OD, Glimepiride; Glymepirid; glimepiride; 4-ethyl-3-methyl-N-[2-[4-[(4-methylcyclohexyl)carbamoylsulfamoyl]phenyl]ethyl]-5-oxo-2H-pyrrole-1-carboxamide; S1344_Selleck; Oprea1_382896; Prestwick3_000651; MolPort-003-987-461; CCRIS 7083; Hoe-490; 1-{[4-(2-{[(3-ethyl-4-methyl-2-oxo-2,5-dihydro-1H-pyrrol-1-yl)carbonyl]amino}ethyl)phenyl]sulfonyl}-3-(trans-4-methylcyclohexyl)urea; NCGC00161404-01; NCGC00016960-01; 64598P; Endial; HMS1570C03; BPBio1_000751; CHEBI:5383; SAM001246710; BSPBio_000681; Glimepride; Solosa; Glimepirid; Amaryl; MLS000759495; Amarel; Sandoz glimepiride; HOE 490; UNII-6KY687524K; D00593; Amaryl (TN); PMS-glimepiride; C07669; HMS2052L03; Glimepiridum; DB00222; 1H-Pyrrole-1-carboxamide, 3-ethyl-2,5-dihydro-4-methyl-N-(2-(4-(((((4-methylcyclohexyl)amino)carbonyl)amino)sulfonyl)phenyl)ethyl)-2-oxo-, trans-; ZINC00537791; CHEMBL1481; 1H-Pyrrole-1-carboxamide, 2,5-dihydro-3-ethyl-4-methyl-N-(2-(4-(((((4-methylcyclohexyl)amino)carbonyl)amino)sulfonyl)phenyl)ethyl)-2-oxo-, trans-; Glimepiridum [Latin]; BRD-K34776109-001-03-4; NCGC00161404-02; AB00513874; HMS2090K18; Roname; Novo-glimepiride; 1-((p-(2-(3-Ethyl-4-methyl-2-oxo-3-pyrroline-1-carboxamido)ethyl)phenyl)sulfonyl)-3-(trans-4-methylcyclohexyl)urea; C24H34N4O5S; BRD-K42693031-001-01-8; Prestwick1_000651; CAS-93479-97-1; 3-ethyl-4-methyl-N-[2-(4-{[(trans-4-methylcyclohexyl)carbamoyl]sulfamoyl}phenyl)ethyl]-2-oxo-2,5-dihydro-1H-pyrrole-1-carboxamide; SPBio_002602; AC-476; 3-ethyl-4-methyl-n-(4-(n-((1r,4r)-4-methylcyclohexylcarbamoyl)sulfamoyl)phenethyl)-2-oxo-2,5-dihydro; I06-0029; MLS001401419; CID3476	93479-97-1	3476	193913	TTDS00331	SUR1-type K(ATP) channel	Kir6.2/SUR1	N/A	N/A	N/A	blocker
DAP000133	Repaglinide	SAM001246546; NCGC00016978-01; Novo Nordisk brand of repaglinide; Glaxo Wellcome brand of replaginide; D00594; 135062-02-1; AC-726; C27H36N2O4; 2-ethoxy-N-(alpha-(2-methyl-1-propyl)-2-piperidinobenzyl)-4-carbamoylmethylbenzoic acid; MLS001076684; MolPort-003-850-140; Repaglinida [INN-Spanish]; AC1L24D5; (+)-2-Ethoxy-alpha-(((S)-alpha-isobutyl-o-piperidinobenzyl)carbamoyl)-p-toluic acid; CAS-135062-02-1; AG-EE 388; (S)-(+)-2-Ethoxy-4-[N-[1-(2-piperidinophenyl)-3-methyl-1-butyl]aminocarbonylmethyl]benzoic acid; Prestwick0_001046; GlucoNorm; AGEE-623ZW; Actulin; 2-ethoxy-4-[2-[[(1S)-3-methyl-1-(2-piperidin-1-ylphenyl)butyl]amino]-2-oxoethyl]benzoic acid; Repaglinide; SMP-508; AG-EE-388; (S)-2-Ethoxy-4-(2-((methyl-1-(2-(1-piperidinyl)phenyl)butyl)amino)-2-oxoethyl)-benzoic acid; MLS000759407; CID65981; AC1Q5TZW; Prestwick3_001046; SMR000466305; Repaglinidum; BPBio1_001070; Prandin, GlucoNorm, NovoNorm, Repaglinide; AG-EE-623 ZW; NCGC00016978-02; C07670; Repaglinide [USAN]; STK629501; LS-38509; Prestwick1_001046; NovoNorm; UNII-668Z8C33LU; repa-glinide; Prestwick2_001046; CHEBI:348669; DB00912; AG-EE 623 ZW; AG-EE 388 ZW; 2-ethoxy-4-(2-{[(1S)-3-methyl-1-(2-piperidin-1-ylphenyl)butyl]amino}-2-oxoethyl)benzoic acid; HMS2051N08; Bio-0087; Novo Nordisk brand 2 of repaglinide; BSPBio_000972; HMS1571A14; repaglinide, (+-)-isomer; 2-ethoxy-4-(2-((3-methyl-1-(2-(1-piperidinyl)phenyl)butyl)amino)-2-oxoethyl)benzoic acid; 2-ethoxy-4-[2-({(1S)-3-methyl-1-[2-(piperidin-1-yl)phenyl]butyl}amino)-2-oxoethyl]benzoic acid; HMS2094C07; Prandin; C072379; NN-623; Repaglinidum [INN-Latin]; Repaglinide (JAN/USP/INN); BIDD:GT0338; S1426_Selleck; CPD000466305; AB00514019; CHEMBL1272; R9028_SIGMA; SPBio_002906; (S)-2-ethoxy-4-(2-((3-methyl-1-(2-(1-piperidinyl)-phenyl)butyl)amino)-2-oxoethyl)-benzoic acid; 111GE012; BRD-K82846253-001-03-0; Prandin (TN); Benzoic acid, 2-ethoxy-4-(2-((3-methyl-1-(2-(1-piperidinyl)phenyl)butyl)amino)-2-oxoethyl)-, (S)-; Repaglinida	135062-02-1	65981	208038	TTDS00331	SUR1-type K(ATP) channel	Kir6.2/SUR1	N/A	N/A	N/A	blocker
DAP000522	Gliclazide	KBio1_001910; 1-(3-Azabicyclo(3.3.0)oct-3-yl)-3-(p-tolylsulfonyl)urea; N-[(hexahydrocyclopenta[c]pyrrol-2(1H)-ylamino)carbonyl]-4-methylbenzenesulfonamide; 1-(Hexahydrocyclopenta(c)pyrrol-2(1H)-yl)-3-(p-tolylsulfonyl)urea; S 1702; Diamicron; SMR000542971; DB01120; STK803142; NCGC00095107-01; Gliclazidum [INN-Latin]; KBio2_004526; S-1702; Gliclazida [INN-Spanish]; AB1004595; SPECTRUM1505013; Urea, 1-(hexahydrocyclopenta(c)pyrrol-2(1H)-yl)-3-(p-tolylsulfonyl)-; KBio2_001958; BRD-A61154809-001-04-3; 1-(3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrol-2-yl)-3-(4-methylphenyl)sulfonylurea; NCGC00095107-02; LS-160299; Spectrum_001478; Gliclazide [BAN:INN:DCF:JAN]; SPBio_002556; KBioGR_001096; N-(hexahydrocyclopenta[c]pyrrol-2(1H)-ylcarbamoyl)-4-methylbenzenesulfonamide; S-852; Prestwick3_000558; Prestwick2_000558; Diaikron; KBio2_007094; Nordialex; C15H21N3O3S; MolPort-002-507-779; 21187-98-4; SPECTRUM1504145; MLS001304118; AC1L1G0Q; NCGC00095107-03; KBio3_002806; Prestwick0_000558; EINECS 244-260-5; BPBio1_000699; Gliclazidum; AB00053165; N-(4-Methylbenzenesulfonyl)-N'-(3-azabicyclo(3.3.0)oct-3-yl)urea; Glimicron (TN); G2167_SIGMA; HMS2090K16; 1-(3-Azabicyclo[3.3.0]oct-3-yl)-3-p-tolylsulphonylurea; BRN 1657836; SE 1702; NCGC00095107-04; NCGC00095107-05; Spectrum4_000598; CHEMBL427216; MLS001215197; Spectrum5_000753; Gliclazida; KBioSS_001958; BSPBio_000635; CID3475; Gliklazid; D01599; AC-12045; Prestwick_869; Spectrum3_001862; BSPBio_003304; SpecPlus_000870; I06-0117; MLS001304077; DivK1c_006966; Prestwick1_000558; gliclazide; NCGC00095107-06; Glimicron; Glyclazide; HMS1922D15; HMS1569P17; AKOS003237903; CHEBI:31654; Benzenesulfonamide, N-(((hexahydrocyclopenta(c)pyrrol-2(1H)-yl)amino)carbonyl)-4-methyl-; Gliclazide (JAN/INN); S 852; Bio-0502	21187-98-4	3475	585123	TTDS00331	SUR1-type K(ATP) channel	Kir6.2/SUR1	N/A	N/A	N/A	blocker
DAP000136	Tolbutamide	NCGC00015999-01; Tarasina; N-(4-Methylbenzenesulfonyl)-N'-butylurea; Urea, 1-butyl-3-(p-tolylsulfonyl)-; LS-278; KBioGR_000795; TL8000121; CHEBI:27999; KBio3_002755; NCGC00022721-05; D014044; Tolbutamide Aventis Brand; Toluvan; Mobenol; Tolylsulfonylbutylurea; Prestwick0_000190; toluran; KBio2_004843; NCGC00015999-14; N-(4-Methylphenylsulfonyl)-N'-butylurea; Apotex Brand of Tolbutamide; HMS501B03; NCGC00022721-08; NCGC00022721-04; NCGC00022721-09; KBio2_007411; N-4-Methylbenzolsulfonyl-N-butylurea; Orinaz; cMAP_000008; AB00052110; Tolbutamidum; U 2043; HSDB 3393; 100735-34-0; Diabuton; BRN 1984428; Glyconon; NSC23813; NCGC00015999-02; HMS1791L09; Tolbutamidum [INN-Latin]; N-Butyl-N'-(p-tolylsulfonyl)urea; Berlin-Chemie Brand of Tolbutamide; Bio1_000206; Tolbutamida; CCRIS 592; TOLBUTAMIDE USP; Lopac0_001154; KBio2_002795; Dolipol; KBio2_006063; T 0891; Drabet; Oramide; Tolbutamid R.A.N.; BPBio1_000131; NCGC00015999-07; Novo-Butamide; Valdecasas Brand of Tolbutamide; N-Butyl-N'-toluene-p-sulfonylurea; Pramidex; MLS001148399; 1-butyl-3-(4-methylphenyl)sulfonylurea; CAS-64-77-7; SPBio_002040; KBio2_000227; Lopac-T-0891; 3-(p-Tolyl-4-sulfonyl)-1-butylurea; KBio3_000454; tolbutamide; Prestwick2_000190; 1-Butyl-3-(4-methylphenylsulfonyl)urea; CPD000058363; Spectrum_000447; Tolbutamida [INN-Spanish]; Butamidum; MLS000028399; Berlin Chemie Brand of Tolbutamide; 3-[p-Tolyl-4-sulfonyl]-1-butylurea; BRD-K85119730-001-06-5; Arkozal; NCIOpen2_009592; Yamanouchi Brand of Tolbutamide; Willbutamide; NINDS_000341; Butamid; Toluina; Aglicid; CID5505; CBiol_001920; Diasulfon; SAM002554936; 1-Butyl-3-tosylurea; KBio3_000453; AC1L1KHP; Oralin; N-4-(Methylbenzolsulfonyl)-n-butylurea; Pfizer Brand of Tolbutamide; Restinon; BSPBio_001507; 1-Butyl-3-(p-methylphenylsulfonyl)urea; NSC 23813; 1-Butyl-3-(p-tolylsulfonyl)urea; D 860; Prestwick_471; Diabesan; KBioSS_002276; 46968_FLUKA; Tolbutamide Pfizer Brand; HMS1989L09; Spectrum5_001272; NCGC00022721-06; R.A.N. Brand of Tolbutamide; KBio2_005363; KBio2_003495; KBioSS_000927; KBioGR_000227; MLS002152944; Tolbutamide Butamide Brand; Diaval; IDI1_000341; KBioGR_002275; Prestwick1_000190; BSPBio_000119; Butamide; Orinase (TN); Tolbet; WLN: 4MVMSWR D1; HLS 831; Apo-Tolbutamide; SPBio_001000; Spectrum4_000358; DB01124; Sk-tolbutamide; KBio1_000341; Arcosal; N-(p-tolylsulfonyl)-N'-n-butylurea; AC-12490; ZINC01530703; HMS2089C17; Beglucin; AB1004876; NCI-C01763; Tolbutamide Hoechst Brand; BIM-0051121.0001; Tolumid; BSPBio_002078; NCGC00022721-10; KBio2_000927; AC1Q2X3T; Orabet; Artozin; Spectrum2_001210; D00380; Diaben; Hoechst Brand of Tolbutamide; HMS1361L09; SPECTRUM1500581; C12H18N2O3S; IDI1_033977; N-Butyl-N'-(4-methylphenylsulfonyl)urea; NCGC00022721-07; T0891_FLUKA; Prestwick3_000190; Rastinon; 1-p-Toluenesulfonyl-3-butylurea; Diabetamid; Butamide Brand of Tolbutamide; Bio2_000227; 64-77-7; N-Butyl-N'-p-toluenesulfonylurea; Spectrum3_000599; N-(p-Tolylsulfonyl)-N'-butylcarbamide; Bio1_000695; Tolbutamide [INN:BAN:JAN]; C07148; Bio2_000707; Tol-Tab; KBio3_001578; Tolbutone; Orinase; Diabetol; CHEMBL782; Tolbusal; 1-Butyl-3-(para-tolylsulfonyl) urea; EU-0101154; T0891_SIGMA; Orezan; Bio1_001184; Aventis Brand of Tolbutamide; NCGC00015999-03; UNII-982XCM1FOI; DivK1c_000341; NCGC00022721-03; Ipoglicone; N-n-Butyl-N'-tosylurea; KBioSS_000227; 46968_RIEDEL; 3-(p-tolylsulfonyl)-1-butylurea; Tolbutamide (JP15/USP/INN); HMS1568F21; Dirastan; KBio2_002275; Tolbutamid; EINECS 200-594-3; SMR000058363; Oterben; BIDD:PXR0179; HMS2092M21; MolPort-001-783-540; Artosin	64-77-7	5505	149066	TTDS00331	SUR1-type K(ATP) channel	Kir6.2/SUR1	N/A	N/A	N/A	blocker
DPR000063	Iptakalim	2,3-dimethyl-N-propan-2-yl-butan-2-amine; iptakalim; C502260; N-(1-methylethyl)-1,1,2-trimethylpropylamine; CID10057607	N/A	N/A	N/A	TTDR01270	ATP-sensitive inward rectifier potassium channel 11	IKATP;Inward rectifier K+ channel Kir6.2;KATP channel (Kir6.2/SUR2A);Potassium channel, inwardly rectifying, subfamily J, member 11	Q14654	N/A	ENSG00000187486	N/A
DCL000099	CYT 99007	N/A	N/A	N/A	N/A	TTDC00136	Interleukin-7 receptor alpha chain	CD127 antigen;CDw127;IL-7R alpha chain;IL-7R-alpha	P16871	3575	ENSG00000168685	binder
DAP000695	Praziquantel	SPBio_001295; EINECS 260-741-2; Bay-8440; AC-11670; AKOS000541869; 2-(cyclohexanecarbonyl)-3,6,7,11b-tetrahydro-1H-pyrazino[2,1-a]isoquinolin-4-one; CCRIS 4114; KBio2_006735; NCGC00089733-04; CPD000037139; Drontsit; Cysticide; Droncit; Cesol; STK030186; LS-23174; Prasiquantel; HMS1568D22; 135526-78-2; NINDS_000130; HMS1920J06; P4668_SIGMA; IDI1_000130; P 4668; CID4891; MLS001304085; 46648_RIEDEL; Prestwick_402; EU-0100909; Praziquantel [USAN:INN:BAN:JAN]; 8440, EMBAY; D011223; SPECTRUM1500494; HMS2092A09; KBioSS_001599; (11bS)-2-(cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1-a]isoquinolin-4-one; HMS2090J19; 4H-Pyrazino[2,1-a]isoquinolin-4-one, 2-(cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-; HMS500G12; Praziquantel (JAN/USP/INN); BRN 0761557; MLS000028528; Biliricide; 2-(Cyclohexylcarbonyl)-1,2,3,6,7-11b-hexahydro-4H-pyrazino(2,1a)isoquinolin-4-one; Prestwick2_000260; KBio2_001599; BPBio1_000088; UNII-6490C9U457; Praziquantel, (S)-Isomer; Bio-0456; 57452-31-0; Pyquiton; Azinox; Embay 8440; Biltricide (TN); NCGC00089733-03; EINECS 259-559-6; SAM002264632; 55268-74-1; Spectrum2_001288; 2-Cyclohexanecarbonyl-1,2,3,6,7,11b-hexahydro-pyrazino[2,1-a]isoquinolin-4-one; 5-24-03-00361 (Beilstein Handbook Reference); (.+-)-2-(Cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-4H-pyrazino(2,1a)isoquinolin-4-one; MLS000038419; Spectrum4_000482; DB01058; KBio2_004167; KBioGR_000963; NCGC00015818-05; MolPort-001-926-470; AC1L1J6N; Oprea1_163497; 2-(Cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro- 4H-pyrazino[2,1-a]-isoquinolin-4-one; Cutter; NPFAPI-02; 2-(Cyclohexylcarbonyl)-1,2,3,6,7-11b-hexahydro-4H-pyrazinoe(2,1a)isoquinolin-4-one; KBio3_001699; Praziquantel, (+-)-Isomer; D00471; praziquantel; NCGC00015818-11; Cutter Tape Tabs; NCGC00089733-02; BAS 00347357; EMBAY-8440; BSPBio_000080; Praziquantel, (R)-Isomer; Spectrum_001119; SPBio_002299; Prestwick3_000260; 2-(Cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-4H-pyrazino(2,1-a)isoquinolin-4-one; DivK1c_000130; C07367; NCGC00089733-05; S1691_Selleck; Praziquantelum; Cisticid; Biltricide, Droncit, Praziquantel; Traziquantel; 46648_FLUKA; Prestwick0_000260; 4H-Pyrazino(2,1-a)isoquinolin-4-one, 2-(cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-; 2-(cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1-a]isoquinolin-4-one; I06-0088; KBio1_000130; Praziquantelum [INN-Latin]; CHEMBL976; InChI=1/C19H24N2O2/c22-18-13-20(19(23)15-7-2-1-3-8-15)12-17-16-9-5-4-6-14(16)10-11-21(17)18/h4-6,9,15,17H,1-3,7-8,10-13H; Bayer Brand of Praziquantel; SMR000037139; Merck Brand of Praziquantel; BRD-A21858158-001-05-2; Spectrum5_001064; BSPBio_002199; Biltricide; Prestwick1_000260; Lopac0_000909; 2-Cyclohexylcarbonyl-1,2,3,6,7,11b-hexahydro-4H-pyrazino(2,1-a) isoquinolin-4-one; MLS001201812; Spectrum3_000550; AB00052075; LS-7155	55268-74-1	4891	9571	TTDS00192	Glutathione S-transferase	Glutathione-S-transferase;GST class-alpha	Q8MU52	N/A	N/A	inhibitor
DCL000350	Vandetanib	DB08764; UNII-YO460OQ37K; 338992-00-0; CHEMBL24828; AC1MIWRU; Zactima, ZD6474; ||Zactima; CH 331; ZD 6474|; Vandetanib; Quinazolin-4-amine, N-(4-bromo-2-fluorophenyl)-6-mthoxy-7-[(1-methyl-4-piperidinyl)methoxy]-; C452423; Kinome_3316; LS-184394; N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methyl-4-piperidinyl)methoxy)-4-quinazolinamine; 4-Quninazolinamine, N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methyl-4-piperidinyl)methoxy)-; EN002713; NCGC00167513-01; CID3081361; N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-amine; NSC744325; ZD 6474; N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine; Zactima; EC-000.2359; AZD-6474; 443913-73-3; Vandetanib, Zactima, ZD6474; MolPort-005-942-399; S1046_Selleck; ZD-6474; F9995-0087; 4-(4-Bromo-2-fluoroanilino)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazoline; Vandetanib [INN]; AC-5251; CH-331; CHEBI:49960; 4-Quinazolinamine, N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-; I14-1942; Vandetanib (JAN/INN); D06407; 2ivu; ZD6474	443913-73-3	3081361	3882431	TTDS00348	Proto-oncogene tyrosine-protein kinase receptor ret	C-ret;RET receptor tyrosine kinase	P07949	5979	ENSG00000165731	inhibitor
DAP000006	Sorafenib	BAY-54-9085; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide; BAY-43-0006; Sorafenib [INN]; NCGC00167488-01; CID216239; D08524; CHEBI:50924; 4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]AMINO}CARBONYL)AMINO]PHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE; Kinome_766; Bio-0100; sorafenibum; BAY 439006; Sorafenib; AC-1674; BAY 54-9085 (tosylate salt); LS-187788; DB00398; ZINC01493878; 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-; LS-186067; MolPort-003-850-270; Nexavar; DB07438; BAY-43-9006; 4-(4-{3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; NSC-724772; K00597a; AB1004622; BRD-K23984367-001-01-8; STK627350; N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea; I06-0856; 4(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; BAY 43-9006 (free base); CHEBI:47228; N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcar bamoyl)-4-pyridyloxy)phenyl)urea; nchembio.117-comp17; CHEMBL1336; N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea; 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide; 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide; BAX; EN002709; AC1L50CF; Sorafenib (INN); 4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide; 2-Pyridinecarboxamide, 4-(4-((((4-chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-; NSC747971; LS-187021; 4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate; UNII-9ZOQ3TZI87; BAY 43-9006; BAY43-9006; 284461-73-0; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide	284461-73-0	216239	789424	TTDS00348	Proto-oncogene tyrosine-protein kinase receptor ret	C-ret;RET receptor tyrosine kinase	P07949	5979	ENSG00000165731	inhibitor
DCL000036	ALX-0081	N/A	N/A	N/A	N/A	TTDC00108	Von Willebrand factor	VWF	P04275	7450	ENSG00000110799	binder
DAP001308	Tetrahydrofolic acid	glutamic acid, N-[4-[[(2-amino-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-; CID91443; T3125_SIGMA; Tetrahydropteroylglutamic acid; CHEBI:20506; MolPort-001-684-176; EINECS 205-181-1; CID11442178; AC1NUT77; AC1L1ASH; (6S)-THFA; N-[4-{[(2-amino-4-oxo-3,4,5,6,7,8-hexahydropteridin-6-yl)methyl]amino}benzoyl]-L-glutamic acid; AC1Q5SG4; AC1L3M37; BIT3012; (6S)-5,6,7,8-TETRAHYDROFOLATE; CHEBI:15635; CHEMBL91866; tetrahydrofolate; N-[4-({[(6S)-2-AMINO-4-OXO-1,4,5,6,7,8-HEXAHYDROPTERIDIN-6-YL]METHYL}AMINO)BENZOYL]-L-GLUTAMIC ACID; C00101; DL-Glutamic acid, N-(4-(((2-amino-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-; FH4; tetrahydropteroylglutamate; tetrahydropteroyl mono-L-glutamate; Glutamic acid, N-(p-(((2-amino-3,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-, L-; LS-71775; folate-H4; DB00116; nchembio.108-comp12; N-(4-(((2-Amino-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid; 5,6,7,8-tetrahydrofolate; 2-[[4-[(2-amino-4-oxo-5,6,7,8-tetrahydro-1H-pteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid; 5,6,7,8-Tetrahydropteroyl-L-glutamic acid; CHEMBL1236287; N-[4-({[(6S)-2-amino-4-oxo-3,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)benzoyl]-L-glutamic acid; th-folate; (6S)-tetrahydrofolate; (2S)-2-[[4-[(2-amino-4-oxo-5,6,7,8-tetrahydro-1H-pteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid; 135-16-0; CID1129; 5,6,7,8-tetrahydrofolic acid; (2S)-2-[[4-[[(6S)-2-amino-4-oxo-5,6,7,8-tetrahydro-1H-pteridin-6-yl]methylamino]benzoyl]amino]pentanedioic acid; CID9826590; CHEBI:250731; N-(4-(((2-Amino-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)glutamic acid; AR-1J1194; (6S)-Tetrahydrofolic acid; N-(5,6,7,8-tetrahydropteroyl)-L-glutamic acid; CID5460413; tetrahydrafolate; L-Glutamic acid, N-(4-(((2-amino-1,4,5,6,7,8-hexahydro-4-oxopteridinyl)methyl)amino)benzoyl)-; 29347-89-5; (6S)-5,6,7,8-tetrahydropteroylglutamate; tetrahydrofolic acid; MolPort-004-964-617; (6S)-H4folate; H4PteGlu; L-glutamic acid, N-[4-[[(2-amino-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-; tetra-H-folate	135-16-0	91443	8146989	TTDS00489	Folate receptor	FOLR;FR	P41439	2352	ENSG00000110203	binder
DCL000802	Farletuzumab	N/A	896723-44-7	N/A	85154520	TTDS00489	Folate receptor	FOLR;FR	P41439	2352	ENSG00000110203	antagonist
DAP001309	Folic Acid	Kyselina listova; Acido folico [INN-Spanish]; SAM002264616; DB00158; Glutamic acid, N-(p-(((2-amino-4-hydroxy-6-pteridinyl)methyl)amino)benzoyl)-, l-; Foliamin; Folacid; Folbal; N-(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid; F8758_SIGMA; Acfol (Spain); Acidum folicum; Folcysteine; C00504; Folvite; F8890_SIGMA; Folic acid (TN); SPECTRUM1502020; Prestwick3_000627; Usaf cb-13; BPBio1_000654; Kyselina listova [Czech]; Folipac; Acifolic; SPBio_001357; InChI=1/C19H19N7O6/c20-19-25-15-14(17(30)26-19)23-11(8-22-15)7-21-10-3-1-9(2-4-10)16(29)24-12(18(31)32)5-6-13(27)28/h1-4,8,12,21H,5-7H2,(H,24,29)(H,27,28)(H,31,32)(H3,20,22,25,26,30)/t12-/m0/s; Folaemin; L-Glutamic acid, N-(4-(((2-amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-; Vitamin Bc; BIDD:ER0563; BSPBio_000594; Pteroylglutamic acid; Pteroylmonoglutamate; Nifolin; (2S)-2-[[4-[(2-amino-4-oxo-1H-pteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid; Pteroyl-L-monoglutamic acid; HSDB 2002; SMP2_000137; Facid; KBio2_006997; MLS001335861; CID6037; Spectrum2_001459; KBioSS_001861; SMR000471860; KBio1_000494; Folcidin; CAS-59-30-3; 36653-55-1 (mono-potassium salt); F7876_SIAL; IDI1_000494; NCGC00016265-01; CHEMBL1622; Folettes; Folsav; Liver Lactobacillus casei factor; 6484-89-5 (mono-hydrochloride salt); Vitamin Be; L-glutamic acid, N-[4-[[(2-amino-4,8-dihydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-; Folvron; Spectrum5_000602; Vitamin B11; Novofolacid [Canada]; PteGlu; Nifolin [Denmark]; Mission prenatal; Apo-Folic; LS-2157; Spectrum_001381; Folcidin (VAN); C20H20N6O6; Folsaeure; Acido folico; PGA (VAN); BIF0608; Spectrum4_001751; AKOS000503224; Folic acid [INN:BAN:JAN]; MLS001304016; Acide folique; Folina (Italy); AC1L1LNX; FOL; L-Glutamic acid, N-(4-(((2-amino-3,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-; KBioGR_002222; Folan; AI3-26387; Serum Folate Level; Antianemia factor; F8798_SIAL; D00070; Dosfolat B activ; Cytofol; Pteroyl-L-glutamic acid; L-Glutamic acid, N-(4-((2-amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-; Millafol; HMS501I16; Vitamin M; Folic acid (JP15/USP/INN); Folic acid [BAN:INN:JAN]; Vitamin B9; N-(4-(((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzo- yl)-L-glutamic acid; Novofolacid; Glutamic acid, pteroyl-, l-; KBio3_001558; F0043; CCRIS 666; Folico; Folasic (Australia); Folic acid dihydrate; EINECS 200-419-0; Incafolic; BIDD:GT0641; Acidum folicum [INN-Latin]; ARONIS014410; Folina; Folic; SDCCGMLS-0066738.P001; Folaemin [Netherlands]; 01769_FLUKA; Folsan; UNII-935E97BOY8; NSC 3073; Glutamic acid, N-(p-(((2-amino-4-hydroxypyrimido(4,5-b)pyrazin-6-yl)methyl)amino)benzoyl)-, L; 59-30-3; Folico (Italy); Acide folique [INN-French]; Prestwick_230; nchembio.108-comp10; Foldine [France]; MolPort-004-285-551; Folsaure; bmse000299; KBio2_001861; DivK1c_000494; Folicet; BSPBio_002338; Folacin; Folicet (TN); NINDS_000494; F7876_SIGMA; Foldine; N-(4-((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid; L-Glutamic acid, N-(4-(((2-amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzo- yl)-; N-(p-(((2-Amino-4-hydroxy-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid; HMS1921D20; CHEBI:27470; 2d0k; Pteroylmonoglutamic acid; AC-11682; CPD000471860; HMS2092N17; folic acid; Folate; Factor U; NCGC00142391-01; Spectrum3_000749; KBio2_004429; Mittafol; 33609-88-0; 4-Pteridinol, 2-amino-6-((p-((1,3-dicarboxypropyl)carbamoyl)anilino)methyl)-	59-30-3	6037	3787	TTDS00489	Folate receptor	FOLR;FR	P41439	2352	ENSG00000110203	binder
DAP001404	Mizoribine	Bredinine; Bredinin (TN); 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-hydroxyimidazole-4-carboxamide; NCGC00094087-01; AC-5266; 1H-Imidazole-4-carboxamide, 5-hydroxy-1-beta-D-ribofuranosyl-; Spectrum5_001671; Spectrum2_001559; AC1Q5G14; BRN 4151713; AR-1G1414; Mizoribinum [INN-Latin]; M 3047; SMR000058473; Bredinin; Mizoribine [INN:JAN]; Mizoribina; MLS001076272; 5-Hydroxy-1-beta-D-ribofuranosylimidazole-4-carboxamide; KBio1_000948; CHEMBL245019; KBio3_001518; mizoribine; Anhydro-4-carbamoyl-5-hydroxy-1-beta-D-ribofuranosyl-imidazolium hydroxide; 50924-49-7; Spectrum3_000739; IDI1_000948; CPD-12504; DivK1c_000948; Lopac0_000745; BSPBio_002298; HS-0046; KBioGR_000859; 4-Carbamoyl-1-beta-D-ribofuranosyl-imidazolium-5-olate; Mizoribine (JAN/INN); Mizoribinum; M3047_SIGMA; ZINC03812887; MZR; SPBio_001438; NCGC00094087-02; 4-carbamoyl-1-b-d-ribofuranosylimidazolium-5-olate; NINDS_000948; S1384_Selleck; Spectrum4_000220; NCGC00094087-04; AC1L2XG8; NCGC00094087-03; MolPort-003-665-578; Bredinin, HE 69, NSC 289637, MZB, Mizoribine; LS-78195; UNII-4JR41A10VP; N'-(beta-D-Ribofuranosyl)-5-hydroxyimidazole-4-carboxamide; N'-(beta-D-Ribofuranosyl)-5-hydroxy-?imida-?zole-4-carboxamide; D01392; HE-69; 5-Hydroxy-1-beta-D-ribofuranosyl-1H-imidazole-4-carboxamide; MLS000028813; HMS502P10; Mizoribina [INN-Spanish]; SMP1_000195; CID104762; EU-0100745	50924-49-7	104762	815565	TTDS00062	Inosine-5'-monophosphate dehydrogenase	IMP dehydrogenase;IMPD;IMPDH;Inosine dehydrogenase;NAD-dependent inosine monophosphate dehydrogenase;Probable inosine-5'-monophosphate dehydrogenase IMD1;SOI12;Superoxide-inducible protein 12	P50097	N/A	N/A	inhibitor
DAP001433	Tiazofurin	Tiazole; 2-beta-D-Ribofuranosyl-4-thiazolecarboxamide; 2-ribofuranosylthiazole-4-carboxamide; Tiazofurine; TIAZOFURIN; CI-909; NSC-286193; TIZ; Tiazofurine (INN); 4-Thiazolecarboxamide, 2-beta-D-ribofuranosyl-; Tiazofurin [USAN]; NSC 286193; 60084-10-8; Tiazofurinum [Latin]; TCAR; Tiazofurina; AC1L9XI3; CHEMBL108358; Cpd-5825; Tiazofurina [Spanish]; C9H12N2O5S; LS-150859; Tiazofurinum; Riboxamide; Tiazofurin (USAN); BRN 1084555; D06130; CID457954; 2-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3-thiazole-4-carboxamide	60084-10-8	457954	606015	TTDS00062	Inosine-5'-monophosphate dehydrogenase	IMP dehydrogenase;IMPD;IMPDH;Inosine dehydrogenase;NAD-dependent inosine monophosphate dehydrogenase;Probable inosine-5'-monophosphate dehydrogenase IMD1;SOI12;Superoxide-inducible protein 12	P50097	N/A	N/A	inhibitor
DCL000278	Viramidine	ICN-3142; 1-beta-D-Ribofuranosyl-1,2,4-triazole-3-carboximidine; AC1L9PND; 119567-79-2; Ribamidine; 1H-1,2,4-Triazole-3-carboximidamide, 1-beta-D-ribofuranosyl-; 40372-00-7; CID451447; 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,4-triazole-3-carboximidamide; AVS-206; D06651; Taribavirin hydrochloride (USAN); 1-.Beta.-D-Ribofuranosyl-1,2,4-triazole-3-carboximidine hydrochloride; UNII-R3B1994K2E; Viramidine; Viramidine (TN); Prodrug of Ribavirin; NSC627433; Ribavirin amidine; CID451448; Taribavirin hydrochloride; 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,4-triazole-3-carboximidamide hydrochloride; 132425-32-2; AVS-000206; ICN 3142; AC1L9PNE	119567-79-2	451448	47208302	TTDS00062	Inosine-5'-monophosphate dehydrogenase	IMP dehydrogenase;IMPD;IMPDH;Inosine dehydrogenase;NAD-dependent inosine monophosphate dehydrogenase;Probable inosine-5'-monophosphate dehydrogenase IMD1;SOI12;Superoxide-inducible protein 12	P50097	N/A	N/A	inhibitor
DAP000173	Ribavirin	Virazole (Ribavirin) Inhalation Solution; KBio2_002328; Cotronak; Ribav; D00423; Ro-20-9963; NCGC00090726-06; RTC; Ribavirinum; EU-0101063; 1-beta-D-Ribofuranosyl-1H-1,2,4-triazole-3-carboxamide; Copegus; 1-beta-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide; Ribavirine; Ro 20-9963/000; MolPort-002-885-856; LS-1241; KBioSS_002331; C-Virin; DivK1c_000782; NCGC00090726-03; Ribavirine [INN-French]; HMS502H04; Virazole (TN); ICN-1229; MLS000028486; KBio3_002854; 66510-90-5; MLS002222317; Varazid; 1H-1,2,4-Triazole-3-carboxamide, 1-beta-D-ribofuranosyl-; Tribavirin; KBio2_007464; 36791-04-5; R-964; Copegus (TN); HMS2094O09; UNII-49717AWG6K; Virazide; BSPBio_001085; AB00430481; Ribavirina; Ravanex; AC1Q4ZGS; BRN 0892462; Vilona; Rebetol (TN); NCGC00090726-04; CID37542; AA-504/07617051; Rebetol; Ribavirinum [INN-Latin]; Rebetron; SCH 18908; 1-beta-D-ribofuranosyl-1-H-1,2,4-triazole-3-carboxamide; AKOS001715163; KS-1104; NCGC00090726-01; Ribacine; 1H-1,2,4-Triazole-3-carboxamide, 1-.beta.-D-ribofuranosyl-; Spectrum5_002075; DB00811; NCGC00090726-07; IDI1_000782; ZINC01035331; Prestwick3_000993; KBio2_004896; SMP1_000261; HMS2090L15; Viramid; Ribamidil; Spectrum3_001876; SPECTRUM1503938; SMR000058315; S2504_Selleck; HSDB 6513; KBioGR_001804; R9644_SIGMA; NINDS_000782; Lopac0_001063; Viramide; RTCA; Ribavirina [INN-Spanish]; RBV; Rebretron; SR-01000076112-3; NSC 163039; 437710-49-1; Ribavirin (JAN/USP/INN); Ribamidyl; Ribasphere; Ribamide; NSC163039; MolPort-002-507-104; FT-0082885; 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,4-triazole-3-carboxamide; Spectrum_001826; Spectrum4_001252; NCGC00090726-05; BPBio1_001195; KBio1_000782; Virazole; AC1Q1IDC; Virazid; AC1L1XXZ; ribavirin; 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-1,2,4-triazole-3-carboxamide; Ribavirin Capsules; Ribovirin; RG-964; Ribavirin [USAN:INN]; R 9644; Drug:  Ribavirin; DRG-0028; 1-.beta.-D-Ribofuranosyl-1,2,4-triazolo-3-carboxamide; CHEMBL1643; 1,2,4-Triazole-3-carboxamide, 1-beta-D-ribofuranosyl-; BB_NC-0567; BSPBio_003352; Ribasphere (TN)	36791-04-5	37542	178906	TTDS00062	Inosine-5'-monophosphate dehydrogenase	IMP dehydrogenase;IMPD;IMPDH;Inosine dehydrogenase;NAD-dependent inosine monophosphate dehydrogenase;Probable inosine-5'-monophosphate dehydrogenase IMD1;SOI12;Superoxide-inducible protein 12	P50097	N/A	N/A	inhibitor
DAP000147	Mercaptopurine	6H-Purine-6-thione, 1,7-dihydro-; AKOS000275858; NCI-C04886; 7-Mercapto-1,3,4,6-tetrazaindene; MP; Wellcome Brand of 6-Mercaptopurine; Leukerin, 99% - Carc; LS-141; HMS2091B20; WLN: T56 BM DN FN HNJ ISH; 9H-Purin-6-yl hydrosulfide; 6-MP; AG-670/31547064; Ismipur; U-4748; KBio1_000493; KBio2_003969; FT-0083571; 5818-33-7; CCRIS 2761; UNII-PKK6MUZ20G; S1305_Selleck; GlaxoSmithKline Brand of 6-Mercaptopurine; AC-11464; 6 Mercaptopurine Monohydrate; Spectrum2_000060; 1,9-dihydro-6H-purine-6-thione; NCIMech_000025; KBio3_001481; PM6; Leupu rin; GlaxoSmithKline Brand of 6 Mercaptopurine; 50-44-2; SPECTRUM1500387; NCGC00094717-03; M0063; 6-Merkaptopurin [Czech]; 3,7-dihydropurine-6-thione; mercaptopurine; 6-Merkaptopurin; Leukerin; C01756; 3H-Purine-6-thiol; Merkaptopuryna [Polish]; C5H4N4S; Purinethol; KBio2_004931; Mercaptopurin; CHEBI:50667; C02380; Spectrum4_000857; 63810_FLUKA; CID667490; DivK1c_000493; 6-Thiopurine; 6H-Purine-6-thione, 1,7-dihydro-; 7-Mercapto-1,3,4,6-tetrazaindene; Glaxo Wellcome Brand of 6 Mercaptopurine; 9H-Purine-6(1H)-thione; Purinethol (TN); CHEBI:2208; 6-MERCAPTOPURINE MONOHYDRATE; cMAP_000033; NSC755; KBio3_002842; KBio2_007499; HMS501I15; MLS001304020; MolPort-001-815-626; KBioGR_001493; 1,7-Dihydro-6H-purine-6-thione; Mercaptopurin [German]; Puri Nethol; 6-Thiohypoxanthine; 6-Mercaptopurine; Purinethiol; 6 Thiohypoxanthine; Leupurin; 5818-60-0; SPBio_000219; Mercaptopurine (VAN); DB01033; Spectrum_000921; D04931; Mercaptopurina Wellcome; 6-Thioxopurine; Mercapurin; Glaxo Wellcome Brand of 6-Mercaptopurine; MolPort-001-783-696; D015122; Purine-6-thiol; Purinethol, 6-mercaptopurine, 6-MP, Mercaptopurine; Purine-6(1H)-thione; Wellcome Brand of 6 Mercaptopurine; CHEMBL1425; Mercaptopurina [INN-Spanish]; KBioSS_001401; BB_SC-0064; Mercaptopurinum [INN-Latin]; Mercaleukim; MLS001304953; NINDS_000493; STK727062; NSC 755; EINECS 200-037-4; KBioSS_002366; 39454-94-9; 6 MP; BW 57 323H; 1H-Purine, 6-mercapto-; 6 Mercaptopurine; Purine, 6-mercapto-; CPD000544948; KBio2_001401; Puri-Nethol; 6-Purinethiol; AC1LDI73; NCI60_041653; F3329-0452; Hypoxanthine, thio-; Mercaptopurinum; NCGC00094717-01; KBio2_002363; MolPort-003-846-751; AKOS000170222; 6-Mercaptopurin; purine antimetabolite: inhibits nucleic acid replication; Mercaptopurine, 6-; NCGC00094717-02; Mern; IDI1_000493; HSDB 3235; I14-1716; 7H-purine-6-thiol; MLS001066623; SMR000544948; Spectrum5_000950; 5759-99-9; Mercaleukin; Thiopurine; Merkaptopuryna; Ambap50-44-2; 6112-76-1; Mercaptopurina; 6 Thiopurine; SAM002589937; NSC-755; KBio2_006537; 6112-76-1 (monohydrate); Mercaptopurine (INN); BSPBio_001981; Mercaptopurine anhydrous; Mercaptopurine (anhydrous); Purimethol; HMS1920L07; Spectrum3_000491; KBioGR_002363	50-44-2	667490	5422	TTDS00062	Inosine-5'-monophosphate dehydrogenase	IMP dehydrogenase;IMPD;IMPDH;Inosine dehydrogenase;NAD-dependent inosine monophosphate dehydrogenase;Probable inosine-5'-monophosphate dehydrogenase IMD1;SOI12;Superoxide-inducible protein 12	P50097	N/A	N/A	inhibitor
DAP001298	Botulinum Toxin Type A	Botulinum toxin type A (JAN); 93384-43-1; Botulinum toxin type A; Botox; Botox (TN); D00783	93384-43-1	N/A	7847848	TTDS00496	Synaptosomal-associated protein 25	SNAP;SNAP25;SNAP-25;SUP;Super protein;Synaptosomal-associated 25 kDa protein	P60880	6616	ENSG00000132639	inhibitor
DCL000259	VX-680	VX-680; MK 0457; Cyclopropanecarboxylic acid N-(4-((4-(4-methylpiperazin-1-yl)-6-(5-methyl-2H-pyrazol-3-ylamino)pyrimidin-2-yl)sulfanyl)phenyl)amide; Cyclopropanecarboxylic Acid {4-[4-(4-Methyl-Piperazin-1-Yl)-6-(5-Methyl-2h-Pyrazol-3-Ylamino)-Pyrimidin-2-Ylsulfanyl]-Phenyl}-Amide; VX6; Tozasertib (USAN); AC1NUV5F; VX-68; Cyclopropanecarboxamide, N-(4-((4-(4-methyl-1-piperazinyl)-6-((5-methyl-1H-pyrazol-3-yl)amino)-2-pyrimidinyl)thio)phenyl)-; MLS001065920; CID5494449; CHEMBL572878; L-001281814; Kinome_3803; S1048_Selleck; Tozasertib; ST51054127; Cyclopropane carboxylic acid{4-[4-(4-methyl-piperazin-1-yl)-6-(5-methyl-2H-pyrazol-3-ylamino)-pyrimidin-2-ylsulphanyl]-phenyl}-amide; 2f4j; MK-0457, Tozasertib, VX680, VX-680; NSC745967; EC-000.2365; MK-045; SMR000486395; D08279; VX 680; 639089-54-6; MK-0457; I14-1964; N-[4-[4-(4-methylpiperazin-1-yl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl]sulfanylphenyl]cyclopropanecarboxamide; N-(4-(4-(3-methyl-1H-pyrazol-5-ylamino)-6-(4-methylpiperazin-1-yl)pyrimidin-2-ylthio)phenyl)cyclopropanecarboxamide	N/A	5494449	46513935	TTDS00407	Proto-oncogene tyrosine-protein kinase LCK	FYN;p59-Fyn;Protooncogene Syn;SLK	P06239	3932	ENSG00000182866	inhibitor
DAP000004	Dasatinib	302962-49-8; LS-186641; MolPort-003-846-143; EC-000.2122; LS-187773; BCB03_000715; CHEBI:49375; 1N1; UNII-X78UG0A0RN; BMS-354825, Sprycel, BMS354825, Dasatinib; 2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)-N-(2-chloro-6-methylphenyl)thiazole-5-carboxamide; SPRYCEL (TN); nchembio.117-comp11; Sprycel; Dasatinib anhydrous; S1021_Selleck; NSC-732517; CHEMBL1421; LS-187028; N-(2-CHLORO-6-METHYLPHENYL)-2-({6-[4-(2-HYDROXYETHYL)PIPERAZIN-1-YL]-2-METHYLPYRIMIDIN-4-YL}AMINO)-1,3-THIAZOLE-5-CARBOXAMIDE; N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)thiazole-5-carboxamide; FT-0084503; Dasatinib (USAN); CID3062316; N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carboxamide; Kinome_3650; I14-1972; BMS354825; dasatinibum; 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-; AC1MI3ET; BMS 354825; N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide; AC1Q2P0C; D03658; Dasatinib, BMS 354825; EN002710; C488369; nchembio.162-comp4; 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-; (18F)-N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide; DB01254; N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide, monohydrate; Spyrcel; NCGC00181129-01; Dasatinib; BMS-354825; AmbotzLS-1203; nchembio.332-comp1; NSC732517; Dasatinib [USAN]	302962-49-8	3062316	10061134	TTDS00407	Proto-oncogene tyrosine-protein kinase LCK	FYN;p59-Fyn;Protooncogene Syn;SLK	P06239	3932	ENSG00000182866	inhibitor
DAP000469	Ridogrel	Ibidel; L001350; CHEBI:127439; AC1NSFY9; EC-000.2105; 5-[(E)-[pyridin-3-yl-[3-(trifluoromethyl)phenyl]methylidene]amino]oxypentanoic acid; 110140-89-1; CID5362391; Ridogrel (USAN/INN); D05727; RIDOGREL; DB01207; CHEMBL280728; R-68070	110140-89-1	5362391	196719	TTDS00395	Thromboxane A2 receptor	Prostanoid TP receptor;TXA2 receptor;TXA2-R	P21731	6915	ENSG00000006638	binder
DCL000316	BIBV 308	N/A	N/A	N/A	N/A	TTDS00395	Thromboxane A2 receptor	Prostanoid TP receptor;TXA2 receptor;TXA2-R	P21731	6915	ENSG00000006638	antagonist
DCL000326	Seratrodast	Bronica; MolPort-003-850-233; AA 2414; Abbott-73001; ABT-001; (+-)-7-(3,5,6-Trimethyl-1,4-benzoquinon-2-yl)-7-phenylheptanoic acid; NCGC00181296-01; A 73001; AC1Q691M; A-73001; Benzeneheptanoic acid, zeta-(2,4,5-trimethyl-3,6-dioxo-1,4-cyclohexadien-1-yl)-, (+-)-; CID2449; AR-1H3923; Seratrodast [USAN:INN]; CHEMBL71921; CHEBI:211798; LS-30374; L001973; 103186-19-2; TL8000143; CHEMBL70972; D01123; AC1L1DPB; Seratrodast (JAN/USAN/INN); CHEMBL71879; STOCK1N-72590; 7-phenyl-7-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dien-1-yl)heptanoic acid; ABT 001; SERATRODAST; 112665-43-7; Bronica (TN); 7-(3,5,6-trimethyl-1,4-benzoquinon-2-yl)-7-phenylheptanoic acid; Abbott 73001; CCRIS 8939; (+-)-2,4,5-Trimethyl-3,6-dioxo-zeta-phenyl-1,4-cyclohexadiene-1-heptanoic acid; C22H26O4; AA-2414	N/A	2449	12013832	TTDS00395	Thromboxane A2 receptor	Prostanoid TP receptor;TXA2 receptor;TXA2-R	P21731	6915	ENSG00000006638	antagonist
DCL000318	Ramatroban	9H-Carbazole-9-propanoic acid, 3-(((4-fluorophenyl)sulfonyl)amino)-1,2,3,4-tetrahydro-, (R)-; CHEBI:402297; D01128; MolPort-005-943-701; 3-(4-Fluorophenylsulfonamido)-1,2,3,4-tetrahydro-9-carbazole propanoic acid; C21H21FN2O4S; 116649-85-5; Bay u 3406; Baynas; Bay u-3405; FT-0080313; C063119; CHEMBL361812; Bay u 3405; LS-172326; AC-719; Ramatroban (JAN/INN); UNII-P1ALI72U6C; Bay-u-3405; Ramatroban; NCGC00167519-01; Baynas (TN); AC1L3XGV; BAY u3405; CID123879; 3-[(3R)-3-[(4-fluorophenyl)sulfonylamino]-1,2,3,4-tetrahydrocarbazol-9-yl]propanoic acid; (+)-(3R)-3-(p-Fluorobenzenesulfonamido)-1,2,3,4-tetrahydrocarbazole-9-propionic acid	116649-85-5	123879	12014153	TTDS00395	Thromboxane A2 receptor	Prostanoid TP receptor;TXA2 receptor;TXA2-R	P21731	6915	ENSG00000006638	antagonist
DCL000275	Ifetroban sodium	Ifetroban sodium; BMS-180291-02; BMS-180291 sodium salt; 156715-37-6; Ifetroban sodium [USAN]; CID3037232; UNII-48IJA0E92C; Benzenepropanoic acid, 2-((3-(4-((pentylamino)carbonyl)-2-oxazolyl)-7-oxabicyclo(2.2.1)hept-2-yl)methyl)-, monosodium salt, (1S-(exo,exo))-	156715-37-6	3037232	47206349	TTDS00395	Thromboxane A2 receptor	Prostanoid TP receptor;TXA2 receptor;TXA2-R	P21731	6915	ENSG00000006638	antagonist
DCL000762	Cyclosporin A	KBioSS_000780; KBio2_003348; 59865-13-3; CID5280754; Modusik-A; AC1L1EQW; Sandimmune; Spectrum5_001628; Sang-35; GNF-Pf-2808; C1832_SIGMA; Neoplanta; Sandimmun; CsA & IFN.alpha.; Nova-22007; Sandimmun Neoral; S-Neoral; 1c5f; Equoral; CYCLOSPORIN A (SEE ALSO TRANSGENIC MODEL EVALUATION (CYCLOSPORIN A)); ST-603; Restasis; MolPort-000-760-988; OLO-400; NCGC00093704-02; Cyclosporin A, Tolypocladium inflatum; KBioGR_001898; SPECTRUM1502202; Zyclorin; Gengraf; Ciclosporin (JP15); BMT-ABA-SAR-MLE-VAL-MLE-ALA-ALA-MLE-MLE-MVA; Spectrum_000300; Papilock; BRD-A64290322-001-01-6; AC1NR4C4; BSPBio_001596; Ambap59865-13-3; LS-257; AC1NUZNC; Prestwick3_000435; Vekacia; Antibiotic S 7481F1; NeuroSTAT; NCGC00093704-03; Lopac0_000242; Mitogard; CHEMBL386389; EU-0100242; Pulminiq; nchembio.342-comp1; 30024_SIGMA; LMPK14000003; HMS2092F06; Cyclosporin A & IFN.alpha.; CID5458585; Prestwick2_000435; cyclophorine; HMS1989P18; Spectrum4_001279; nonamethyl-3,21-bis(1-methylethyl)-6,9,18,24-tetrakis(2-methylpropyl)-; NSC290193; AC1NUQK3; Spectrum3_001593; Spectrum2_001484; Prestwick_731; Cyclosporine [USAN]; Sang-2000; I06-0966; BPBio1_000496; HMS2089A09; IDI1_000871; Consupren S; BSPBio_003186; NCGC00164258-01; SDZ-OXL 400; NCGC00093704-08; Neoral (TN); D00184; Helv Chim Acta 60: 1568 (1977); KBio2_005916; CHEBI:328305; cyclosporine; CHEBI:106343; NCGC00093704-01; CHEBI:4031; NCGC00093704-06; I06-0379; MLS002153454; Cyclokat; OL-27400; CHEMBL532318; cyclosporin A; MolPort-006-705-994; C62H111N11O12; MLS001333756; Cyclosporin A Implant; NINDS_000871; from Tolypocladium inflatum (Trichoderma polysporin); Sigmasporin; BSPBio_000450; NCGC00093704-07; SMR000058578; SPBio_001467; CHEMBL160; Cipol N; CID2909; Restasis (TN); KBio2_000780; BRD-K13533483-001-03-0; Cyclosporine (USP); Sigmasporin Microoral; CID5284373; HMS1569G12; DivK1c_000871; Ambotz59865-13-3; 30024_FLUKA; OL 27-400; MLS000028376; Cyclosporin; CYCLOSPORIN A, USP; KBio3_002686; NCGC00093704-04; KBio1_000871; BMT-ABA-SAR-MLE-VAL-MLE-ALA-DAL-MLE-MLE-MVA; C3662_SIGMA; SangCyA; DE-076; Sandimmune (TN); MLS002207033; CB-01-09 MMX; NCGC00164258-02; Ciclosporin; BRD-A69815203-001-04-3; 1cyn; Gengraf (TN); NCGC00093704-05; TRANSGENIC MODEL EVALUATION (CYCLOSPORIN A); HMS502L13; CID5497195; HMS1921L20; nchembio.301-comp5; Ramihyphin A; C05086; Neoral; HMS1791P18; Cyclosporine A; Consupren; Cipol-N; C 3662; CSA; AC1NQXJE	59865-13-3	5284373	48423197	TTDS00363	Calcineurin	Serine/threonine protein phosphatase	N/A	N/A	N/A	inhibitor
DAP000162	Tacrolimus	Tacrolimus (anhydrous); NCGC00163470-01; KBio3_001098; BSPBio-001279; Modigraf; Prograf (TN); 109581-93-3 (Hydrate); DB00864; Prograf; MLS001424054; KBio2_003187; CID6912836; CPD-10016; Bio2_000950; IDI1_002225; IDI1_001040; 15,19-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclotricosine-1,7,20,21(23H)-tetrone,; Protopy; CID6536850; CID9853905; BRD-K35452788-001-02-1; 4,5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-heptadecahydro-5,19-dihydroxy-3-; NINDS_001040; KBio2_005755; CID9940643; AKOS005145901; MolPort-003-666-518; CID6436007; DivK1c_001040; 3S-[3R*[E(1S*,3S*,4S*)],4S*,5R*,8S*,9E,12R*,14R*,15S*,16R*,18S*,19S*,26aR*]]-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5, 19-dihydroxy-3-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methylethenyl]-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(2-propenyl)-15,19-epoxy-3H-pyrido[2,1-c] [1,4] oxaazacyclotricosine-1,7,20,21(4H,23H)-tetrone; dimethoxy-4,10,12,18-tetramethyl-8-(2-propenyl)-,(3S,4R,5S,8R,12S,14S,15R,16S,18R,19R,26aS)-; Tsukubaenolide; LCP-Tacro; K506; HMS2093M19; Graceptor; LMPK04000003; HMS1792O21; Ambap104987-11-3; 8-DEETHYL-8-[BUT-3-ENYL]-ASCOMYCIN; AC1L97GB; CID9832283; C01375; (-)-FK 506; CID11158639; NCGC00163470-02; FR 900506; Bio2_000470; CHEBI:61049; FT-0082660; Fk-506; KBioSS_000619; BCBcMAP01_000194; Ambap5429; KBioGR_000619; NChemBio.2007.16-comp1; 15,19-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclotricosine-1,7,20,21(4H,23H)-tetrone, 5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5,19-dihydroxy-3-(2-(4-hydroxy-3-methoxycyclohexyl)-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(2-propenyl)-, (3S-(3R*(E(1S*,3S*,4S*)),4S*,5R*,8S*,9E,12R*,14R*,15S*,16R*,18S*,19S*,26aR*))-; HMS2051C18; CID5472317; Tacrolimus (Prograf?); tacrolimus; FR-900506; FR900506; L 679934; Bio-0921; CPD000466356; CID6610362; CID445643; 104987-11-3; AC1L9IBU; FK5; C44H69NO10; CID9918805; AC-1182; CID11556866; NCGC00163470-03; CID6426916; KBio1_001040; Tacrolimus (INN); L-679934; CID5372; [(E)-2-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethenyl]-14,16-; CID6473866; CID9963169; Tacrolimus anhydrous; SMR000466356; NSC717865; S5003_Selleck; FK506; CHEBI:100924; CID439492; UNII-Y5L2157C4J; Fujimycin; CHEMBL1200738; AC1L1K7H; SAM001246677; Advagraf; CCRIS 7124; BSPBio_001279; MLS000759471; NCGC00163470-04; (3S,4R,5S,8R,9E,12S,14S,15R,16S,18R,19R,26aS)-5,19-dihydroxy-3-{(1E)-1-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl}-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(prop-2-en-1-yl)-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-3H-15,19-epoxypyrido[2,1-c][1,4]oxazacyclotricosine-1,7,20,21(4H,23H)-tetrone; KBio2_000619; D08556; HMS1990O21; Tacarolimus; FK 506; HMS1362O21; KBio3_001097; NCGC00179232-01; LS-64247; nchembio.2007.23-comp2; [3S-[3R*[E(1S*,3S*,4S*)],4S*,5R*,8S*,9E,12R*, 14R*,15S*,16R*,18S*,19S*,26aR*]]-5,6,8,11,12,13, 14,15,16,17,18,19,24,25,26,26a-Hexadecahydro-5, 19-dihydroxy-3-[2-(4-hydroxy-3-methoxycyclohexyl)-1-; HMS503O21; Protopic	104987-11-3	439492	4572	TTDS00363	Calcineurin	Serine/threonine protein phosphatase	N/A	N/A	N/A	inhibitor
DCL001037	Voclosporin	368455-04-3; LX-211; Voclosporin [USAN]; AC1OCFHS; Voclosporin (USAN/INN); R-1524; CID6918486; 515814-00-3; Cyclosporin A, 6-((2S,3R,4R)-3-hydroxy-4-methyl-2-(methylamino)-6,8-nonadienoic acid)-; ISA247; ISA 247; trans-ISA 247; Voclosporin; ISA-247; LX-214; R 1524; ISATX247; (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(1R,2R,4E)-1-hydroxy-2-methylhepta-4,6-dienyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone; LX211; Luveniq; trans-ISA-247; 515814-01-4; ISAtx-247; D09033	515814-01-4	6918486	12015362	TTDS00363	Calcineurin	Serine/threonine protein phosphatase	N/A	N/A	N/A	inhibitor
DAP000594	Pimecrolimus	D05480; NCGC00167506-01; SDZ-ASM 981; S5004_Selleck; UNII-7KYV510875; CID6447131; SDZ-ASM-981; CID6509979; Pimecrolimus (JAN/USAN/INN); 15,19-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclotricosine-1,7,20,21(4H,23H)-tetrone, 3-((1E)-2-((1R,3R,4S)-4-chloro-3-methoxycyclohexyl)-1-methylethenyl)-8-ethyl-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5,19-dihydroxy-14,16-dimethoxy-4,10,12,18-tetramethyl-, (3S,4R,5S,8R,9E,12S,14S,15R,16S,18R,19R,26aS)-; ASM-998; 33-epi-Chloro-33-desoxyascomycin; ASM 981; LS-181798; 15,19-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclotricosine-1,7,20,21(4H,23H)-tetrone, 3-(2-(4-chloro-3-methoxycyclohexyl)-1-methylethenyl)-8-ethyl-, 5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5,19-dihydroxy-14,16-dimethoxy-4,10,12,18-tetramethyl-, (3S-(3R*(E(1S*,3S*,4R*)),4S*,5R*,8S*,9E,12R*,14R*,15S*,16R*,18S*,19S*,26aR*))-; 137071-32-0; CID6916008; Elidel (TN); MolPort-003-666-749; Pimecrolimus [USAN:INN:BAN]; ASM-981; CHEMBL1200686; Pimecrolimus; I06-1252; (3S,4R,5S,8R,9E,12S,14S,15R,16S,18R,19R,26aS)-3-((E)-2-((1R,3R,4S)-4-chloro-3-methoxycyclohexyl)-1-methylvinyl)-8-ethyl-5,6,8,11,12,13,14,15,16,17,18,19,24,26,26a-hexadecahydro-5,19-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclotricosine-1,17,20,21(4H,23H)-tetrone; SDZ ASM 981; Elidel; DB00337	137071-32-0	6447131	3859844	TTDS00363	Calcineurin	Serine/threonine protein phosphatase	N/A	N/A	N/A	inhibitor
DAP000014	Cyclosporine	CHEBI:328305; cyclosporine; CHEBI:106343; NCGC00093704-01; 59865-13-3; CHEBI:4031; CID5280754; NCGC00093704-06; Modusik-A; Sandimmune; Spectrum5_001628; I06-0379; Sang-35; GNF-Pf-2808; C1832_SIGMA; Neoplanta; MLS002153454; Sandimmune, Gengraf, Restasis, Atopica, Sangcya, Cyclosporine; Cyclokat; OL-27400; Sandimmun; CsA & IFN.alpha.; CHEMBL532318; Nova-22007; Sandimmun Neoral; cyclosporin A; MolPort-006-705-994; S-Neoral; 1c5f; Equoral; CYCLOSPORIN A (SEE ALSO TRANSGENIC MODEL EVALUATION (CYCLOSPORIN A)); C62H111N11O12; MLS001333756; ST-603; Cyclosporin A Implant; Restasis; AC1Q2UDG; from Tolypocladium inflatum (Trichoderma polysporin); MolPort-000-760-988; OLO-400; NCGC00093704-02; Sigmasporin; Cyclosporin A, Tolypocladium inflatum; BSPBio_000450; NCGC00093704-07; SMR000058578; CHEMBL160; Cipol N; SPECTRUM1502202; Zyclorin; Gengraf; Ciclosporin (JP15); Restasis (TN); BRD-K13533483-001-03-0; 79217-60-0; Cyclosporine (USP); BMT-ABA-SAR-MLE-VAL-MLE-ALA-ALA-MLE-MLE-MVA; Sigmasporin Microoral; CID5284373; Papilock; BRD-A64290322-001-01-6; AC1NR4C4; BSPBio_001596; MolPort-005-934-008; Ambap59865-13-3; LS-257; HMS1569G12; AC1NUZNC; Prestwick3_000435; Ambotz59865-13-3; Vekacia; 30024_FLUKA; Antibiotic S 7481F1; OL 27-400; NeuroSTAT; NCGC00093704-03; Lopac0_000242; MLS000028376; Cyclosporin; Mitogard; CHEMBL386389; NCGC00093704-04; BMT-ABA-SAR-MLE-VAL-MLE-ALA-DAL-MLE-MLE-MVA; EU-0100242; C3662_SIGMA; Pulminiq; nchembio.342-comp1; SangCyA; DE-076; 30024_SIGMA; LS-58836; LMPK14000003; HMS2092F06; Cyclosporin A & IFN.alpha.; Prestwick2_000435; Sandimmune (TN); MLS002207033; cyclophorine; HMS1989P18; CB-01-09 MMX; NCGC00164258-02; nonamethyl-3,21-bis(1-methylethyl)-6,9,18,24-tetrakis(2-methylpropyl)-; Ciclosporin; NSC290193; S1514_Selleck; CID6435893; BRD-A69815203-001-04-3; Prestwick_731; Cyclosporine [USAN]; 1cyn; Sang-2000; Gengraf (TN); NCGC00093704-05; TRANSGENIC MODEL EVALUATION (CYCLOSPORIN A); AC1O5KOG; HMS502L13; I06-0966; BPBio1_000496; CID5497195; nchembio.184-comp6; HMS1921L20; nchembio.301-comp5; HMS2089A09; IDI1_000871; Consupren S; BSPBio_003186; Ramihyphin A; NCGC00164258-01; C05086; SDZ-OXL 400; Neoral; NCGC00093704-08; HMS1791P18; Cyclosporine A; Consupren; Neoral (TN); D00184; Cipol-N; C 3662; CSA; Helv Chim Acta 60: 1568 (1977); AC1NQXJE	59865-13-3	6435893	199551	TTDS00363	Calcineurin	Serine/threonine protein phosphatase	N/A	N/A	N/A	inhibitor
DCL000691	Amediplase	trans,trans-3,4:12,13-Tetrahydroxy-3,4,12,13-tetrahydro-dibenz(a,h)anthracene; 151910-75-7; CCRIS 8205; AC1L4CPU; LS-189263; 151912-11-7; Amediplase; CID154656; (3S,4S,12S,13S)-3,4,12,13-tetrahydronaphtho[1,2-b]phenanthrene-3,4,12,13-tetrol; Amediplase [INN]	151912-11-7	3108	3817181	TTDC00312	Urokinase-type plasminogen activator	UPA;U-plasminogen activator	P00749	5328	ENSG00000122861	activator
DAP001357	Chloroquinium	(+)-Chloroquine; Artrichin; KBio2_003160; KBioGR_000778; (R)-(-)-Chloroquine; IDI1_000404; Chloroquinum [INN-Latin]; Nivachine; Bemasulph; 58175-87-4; Sanoquin; CCRIS 3439; Chloroquine, D-; Ipsen 225; Elestol; LS-141726; Chloroquine (USP/INN); UNII-886U3H6UFF; Gontochin phosphate; BSPBio_000595; nchembio.215-comp4; Prestwick0_000548; Amokin; Chloroquine [USAN:INN:BAN]; Clorochina [DCIT]; Quinercyl; NSC14050; NCGC00015256-04; 7-Chloro-4-[[4-(diethylamino)-1-methylbutyl]amino]quinoline; Spectrum4_000279; Bemaphate; Bemaco; Benaquin; Prestwick2_000548; Khingamin; WLN: T66 BNJ EMY1&3N2&2 IG; Chloroquinium; Spectrum_000132; Cocartrit; Cloroquina [INN-Spanish]; nchembio.368-comp8; Chloroquina; Chlorochinum; N4-(7-Chloro-4-quinolinyl)-N1,N1-diethyl-1,4-pentanediamine; Siragan; KBio3_001221; MolMap_000009; Arolen; Chloroin; KBioSS_000592; BPBio1_000655; Lapaquin; SN 6718; AC1Q2ZA7; Delagil; Malaquin (*Diphosphate*); BSPBio_002001; DB00608; Resoquine; Cidanchin; 50-63-5; Malaren; Sopaquin; HSDB 3029; CID2719; MolPort-001-783-623; AB00053436; Prestwick1_000548; SPBio_000174; CU-01000012392-2; Ro 01-6014/N2; Capquin; Imagon; 7-Chloro-4-((4-(diethylamino)-1-methylbutyl)amino)quinoline; Neochin; Resoquina; 3377 RP opalate; Malarex; Arthrochin; Dichinalex; Tanakan; Avloclor; Chlorochin; Reumaquin; Quinoscan; C18H26ClN3; Lopac0_000296; KBio2_000592; AC1Q2ZA8; Resochin; Spectrum5_000707; BRD-A91699651-065-01-1; Quinagamin; RP-3377; Chloroquine (VAN); Chlorquin; Chloroquin; Prestwick3_000548; SPBio_002516; NCI60_000894; {4-[(7-chloroquinolin-4-yl)amino]pentyl}diethylamine; 54-05-7; W 7618; CHEBI:3638; Quinoline, 7-chloro-4-(4-diethylamino-1-methyl-butylamino)-; Chingamin; CQ; Trochin; Nivaquine B; Heliopar; Reumachlor; Roquine; BRN 0482809; EINECS 200-191-2; NSC 187208; Chloroquine Bis-Phosphoric Acid; Ronaquine; NSC187208; CHEMBL76; AC1L1EB8; Malaquin; Aralen; ( -)-Chloroquine; Silbesan; Klorokin; Solprina; Resochen; Spectrum2_000127; Chloroquinum; KBio1_000404; Spectrum3_000341; Chloroquine phosphate; Bipiquin; DivK1c_000404; NINDS_000404; 58175-86-3; Chemochin; N4-(7-chloroquinolin-4-yl)-N1,N1-diethylpentane-1,4-diamine; Gontochin; HMS2090O03; ST 21; Arechine; Arechin; WIN 244; (-)-Chloroquine; SMP2_000034; Miniquine; Cloroquina; Chloraquine; nchembio.87-comp17; Rivoquine; 3545-67-3; Mesylith; Tanakene; Tresochin; NCGC00162120-01; 56598-66-4; ST 21 (pharmaceutical); Aralen HCl; Avlochlor; Quingamine; C07625; Pfizerquine; Quinilon; RP 3377; Clorochina; Quinagamine; KBio2_005728; Quinachlor; SN-7618; D02366; Iroquine; Chlorochine; Arequin; chloroquine	56598-66-4	2719	148702	TTDS00310	DNA polymerase	N/A	O39644	N/A	N/A	inhibitor
DAP000642	Vidarabine	Vidarabin; HMS1570I18; NCGC00023673-05; UNII-K72T3FS567; NCGC00094579-02; SR 96225; Adenoscan; EU-0100123; AC1L1U8O; NSC80832; IDI1_000191; nchembio.64-comp4; Araadenosine; Spectrum3_000288; Arabinosyladenine; MolPort-003-666-308; 2gl0; USAF CB-10; Armes (TN); AI3-52821; NCGC00179417-01; CCRIS 3383; NSC91041; NSC7652; NCI60_037192; Adenine arabinoside; Adenoscan (TN); Adenosine (JAN/USP); CHEBI:16335; Arabinoside adenine; A4036_SIGMA; Adenocard (TN); 9-Arabinosyladenine; ARA-A NSC 247519; KBio1_000191; Bio1_000926; Vidarabine (JAN); KBio3_001500; HMS1920A13; 46946-45-6; S1784_Selleck; Spectrum4_000782; LS-15059; CI 673; Spectrum2_001257; NINDS_000191; beta-Ara A; SPBio_001491; NCGC00023673-04; Adenocor; V0098; Polyadenosine; NSC247519; SMP1_000312; 58-61-7; adenosine; KBio3_001296; alpha-Ara A; BB_NC-0565; Pallacor; .beta.-D-Adenosine; CPD000471872; Ara A; Spectrum5_001429; HMS1921K05; CID21704; Vira ATM; NSC404241; NSC 247519; beta-D-Adenosine; PDSP1_001036; NCIOpen2_003303; NCGC00094579-01; NSC 627048; EINECS 200-389-9; Prestwick3_000768; CID102198; I01-1121; BSPBio_000816; AC1Q1ID3; Bio1_000437; Adensoine; KBioGR_001224; SMR000225041; Arabinosyl adenine; Vira-A, Vidarabine; CCRIS 2557; Vidarabinum; MolPort-001-785-903; Adenine xyloside; Arasena-A; AI3-52413; NCGC00023673-03; ZINC00970363; NSC70422; Spectrum3_000580; CAS-5536-17-4; AC1L18OL; Prestwick0_000768; Adenine nucleoside; MLS001066352; NSC 7652; C00212; CHEBI:45327; MLS000069638; .beta.-Adenosine; Arabinosyl-adenine; NSC 404241; 3228-71-5; Prestwick2_000768; EINECS 217-911-6; MLS000699527; CID6420052; bmse000061; NSC 7359; NSC7359; Adenine riboside; CHEMBL477; AC1Q4Y1Z; ADENOSINE, U.S.P.; A0152; HMS2092C16; Boniton; ADN; NSC-404241; Bio1_001415; NCGC00178869-01; Ara-A; AC1O4WIN; L000094; S1647_Selleck; HMS2091G13; HMS500J13; NCGC00094579-04; NCIOpen2_005376; NCGC00023673-07; TL8003749; KBio2_002418; Sandesin; FT-0082881; Vidarabine anhydrous; Xylosyl A; NCI60_003823; SPECTRUM1500107; CHEMBL20247; CHEBI:136932; CID6713976; VIRDARABINE; Xylosyladenine; D000241; NCGC00016656-01; MLS002153227; EINECS 226-893-9; MLS001333134; BSPBio_001796; (+)-Cyclaradine; SMR001233326; 46969-16-8; Adenosin [German]; D06298; A5762_SIGMA; SAM002564191; Adenocard, Adenosine; DB00640; Adenosine-8-14C; LS-15085; SPECTRUM1500609; UNII-3XQD2MEW34; 4005-33-8; A4676_SIGMA; A9251_SIGMA; SPBio_002755; Spongoadenosine; Ambap5536-17-4; NCGC00094579-03; A 9251; NSC87676; 2fqy; Prestwick_983; DivK1c_000191; nchembio.143-comp9; 30143-02-3; Spectrum2_001336; AR-1H6029; Armes; 1odi; HMS2090F06; Caswell No. 010B; NCGC00023673-06; nchembio706-5; Vidarabina; 3080-29-3; Lopac0_000123; Vidarabina [DCIT]; BSPBio_002000; KBioSS_002424; KBio2_004986; STK361815; nchembio.186-comp109; CID60961; 5536-17-4; XA; MLS001333133; AC1O8PY7; Prestwick1_000768; MEDR-640; adenine-D-ribose; Nucleocardyl; D00045; Spectrum_001894; CI-673; MLS002153992; KBio2_007554; CHEMBL1090; Ade-Rib; SR-96225; Adenosin; Adenocard; SPBio_001194; Myocol; RAB; PDSP2_001020; NSC627048; Adenosine arabinose; BPBio1_000898; SUN-Y4001; beta-Adenosine; AC1L2SCM; Vira-A; AC1L2IWM; Vidarabine; 2946-52-3; MolPort-001-838-229; HSDB 6514; CID191; 524-69-6; SMR000471872; BRN 0624881; SMR000058216; AC1Q52XU; ZINC02169830; Adenosine [USAN:BAN]; Polyriboadenosine	24356-66-9	32326	174304	TTDS00310	DNA polymerase	N/A	O39644	N/A	N/A	inhibitor
DAP000645	Ganciclovir	HHEMG; BW 759; MB3795; 2-amino-9-((1,3-dihydroxypropan-2-yloxy)methyl)-3H-purin-6(9H)-one; CAS-82410-32-0; NCGC00015471-06; GCV & MSL; 2'-Nor-2'-deoxyguanosine; Zirgan; 82410-32-0; AC1L1FZ2; Hydroxyacyclovir; 9-((1,3-Dihydroxy-2-propoxy)methyl)guanine; 9-[(1,3-Dihydroxy-2-propoxy)methyl]guanine; EU-0100539; 2-amino-9-((1,3-dihydroxypropan-2-yloxy)methyl)-9H-purin-6-ol; Vitrasert (TN); Ganciclovirum; CHEBI:465284; Ganciclovir [USAN:INN:BAN:JAN]; 2'-NDG; DRG-0018; 107910-75-8 (mono-hydrochloride salt); AC1Q52OB; MLS001077349; Prestwick1_000839; MolPort-002-507-301; BW-B 759U; NCGC00015471-03; I07-0010; nchembio.87-comp3; Cytovene; Prestwick_1068; Ganciclovir & C34-dgA immunotoxin; 6H-Purin-6-one, 2-amino-1,9-dihydro-9-((2-hydroxy-1-(hydroxymethyl)ethoxy)methyl)-; AKOS004119898; BW-795; BIDD:GT0783; Prestwick0_000839; HSDB 6512; HMS2090K08; Prestwick2_000839; Cymeven; SMR000058324; D00333; CID3454; 9-(1,3-DIHYDROXY-PROPOXYMETHANE)GUANINE; Lopac-G-2536; 96551-29-0; Guanine, 9-((2-hydroxy-1-(hydroxymethyl)ethoxy)methyl)- and MSL, neutralizing monoclonal antibody; 2-amino-9-((1,3-dihydroxypropan-2-yloxy)methyl)-1H-purin-6(9H)-one; STK801910; UNII-P9G3CKZ4P5; NCGC00015471-02; BW-759U; Prestwick3_000839; IN1478; ST-605; Citovirax; NCGC00015471-01; 9-((2-Hydroxy-1-(hydroxymethyl)ethoxy)methyl)guanine; PDSP1_000816; Cytovene-IV; Biolf 62; DB01004; BPBio1_000877; Gancyclovir; PDSP2_000803; SAM002548936; GANCICLOVIR SODIUM; SMP2_000038; BSPBio_000797; HMS1570H19; 2-Amino-9-(2-hydroxy-1-hydroxymethyl-ethoxymethyl)-1,9-dihydro-purin-6-one; G2536_SIGMA; BW 759U; G 2536; Cytovene (TN); 2-amino-9-{[(1,3-dihydroxypropan-2-yl)oxy]methyl}-1,9-dihydro-6H-purin-6-one; CPD000058324; NCGC00093928-01; 2-Amino-1,9-((2-hydroxy-1-(hydroxymethyl)ethoxy)methyl)-6-H-purin-6-one; 2-amino-9-(1,3-dihydroxypropan-2-yloxymethyl)-3H-purin-6-one; 106931-35-5; NCGC00093928-02; Virgan; Ganciclovirum [Latin]; Ganciclovir & D5-dgA immunotoxin; AC-12604; CHEMBL182; LS-73939; MLS000028481; Lopac0_000539; RS-21592; BB_NC-1042; 86357-12-2; ganciclovir; GA2; 2-amino-9-(2-hydroxy-1-hydroxymethylethoxymethyl)-6,9-dihydro-1H-6-purinone; BIOLF-62; Cymevan; Ganciclovir (JAN/USP/INN); GCV & 1110U81; Cymevene; ZINC00001505; Vitrasert; 2-(6-Amino-purin-9-ylmethoxy)-propane-1,3-diol; Guanine, 9-((2-hydroxy-1-(hydroxymethyl)ethoxy)methyl)-; CCRIS 9212; 2-amino-9-{[(1,3-dihydroxypropan-2-yl)oxy]methyl}-6,9-dihydro-3H-purin-6-one; SPBio_002718; NCGC00168567-01; MolPort-000-758-398	82410-32-0	3454	192372	TTDS00310	DNA polymerase	N/A	O39644	N/A	N/A	inhibitor
DAP001083	Cidofovir	LS-106432; (S)-1-(3-Hydroxy-2-phosphonomethoxypropyl)cytosine; CID60613; (S)-HPMPC; Cidofovir (anhydrous); [(2S)-1-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxypropan-2-yl]oxymethylphosphonic acid; S1516_Selleck; Forvade; Cidofovir (Vistide); ({[(2S)-1-(4-amino-2-oxopyrimidin-1(2H)-yl)-3-hydroxypropan-2-yl]oxy}methyl)phosphonic acid; Cidofovir; 113852-37-2; AC1Q6C68; 149394-66-1; Cidofovir anhydrous; UNII-768M1V522C; Phosphonic acid, ((2-(4-amino-2-oxo-1(2H)-pyrimidinyl)-1-(hydroxymethyl)ethoxy)methyl)-, (S)-; CDV; Cidofovirum; HPMPC; HSDB 7115; AC1L1TLB; AKOS005145721; 1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine; (S)-1-[3-hydroxy-2-(phosphonylmethoxy)-propyl]cytosine; C8H14N3O6P; GS-504; (S)-2-(4-Amino-2-oxo-1(2H)-pyrimidinyl-1-(hydroxymethyl)ethoxy)methyl phosphonic acid; DB00369; NSC742135; GS 504; AC-1666; 1-[(S)-3-Hydroxy-2-(phosphonomethoxy)propyl]-cytosine dihydrate; 120362-37-0 (hydrochloride salt); MolPort-005-935-597; (2S)-3-Hydroxy-2-phosphonylmethoxypropyl-cytosine; CHEMBL152; Vistide, Cidofovir; GS-0504; Vistide; GS504; GS 0504; CHEBI:3696; Phosphonic acid, [[(1S)-2-(4-amino-2-oxo-1(2H)-pyrimidinyl)-1-(hydroxymethyl)ethoxy]methyl]-; (s)-[[2-(4-amino-2-oxo-1(2h)-pyrimidinyl)-1-(hydroxymethyl)ethoxy]methyl]phosphonic acid	113852-37-2	60613	196891	TTDS00310	DNA polymerase	N/A	O39644	N/A	N/A	inhibitor
DAP000643	Valaciclovir	Talavir; L -valine, 2-[(2-amino-1,6-dihydro-6-oxo-9 H -purin-9-yl)methoxy]ethyl ester, monohydrochloride; Zelitrex; CHEBI:397372; Valaciclovir, Valtrex; Valaciclovir; 256U87; HMS2090D20; CHEMBL1349; Valtrex; TBB067866; ValACV; SBB065727; Valaciclovir Hcl; L-Valine, 2-((2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy)ethyl ester; LS-161293; Acyclovir-valine; BSPBio_002474; Valaciclovir [INN:BAN]; Valaciclovir (INN); 124832-26-4; BW256U87; L-Valine ester with 9-((2-hydroxyethoxy)methyl)guanine; AC1L1TW5; BW-256U; AC1Q68HP; 2-[(2-amino-6-oxo-3H-purin-9-yl)methoxy]ethyl (2S)-2-amino-3-methylbutanoate; Valacyclover Hydrochloric; AC-11128; BRD-K46435977-003-01-2; valacyclovir, (L)-isomer; Virval; D08664; C13H20N6O4; 2-[(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)methoxy]ethyl L-valinate; SMR000752514; 2-{[(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)methyl]oxy}ethyl L-valinate; NCGC00159520-02; MLS001304747; DB00577; Valacyclover Hydrochloride; MolPort-002-885-872; valacyclovir; STK802272; CHEBI:35854; VACV; CID60773; Valtrex (TN)	124832-27-5	60773	215420	TTDS00310	DNA polymerase	N/A	O39644	N/A	N/A	inhibitor
DAP000644	Cytarabine	1-beta-D-Arabinosylcytosine; AR3; HMS2051K19; MLS001066340; Cytosine-beta-arabinoside; 2(1H)-Pyrimidinone, 4-amino-1-  -D-arabinofuranosyl- [CAS]; 1beta-D-Arabinofuranosylcytosine; C9H13N3O5; BIDD:PXR0139; NCGC00093356-03; Cytosine beta-D-arabinofuranoside hydrochloride; Depocyt (TN); UNII-04079A1RDZ; Arabitin; Depocyt (liposomal); 4-amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one; U 19920A; 1-beta-D-Arabinofuranosylcytosine; Cytarabina; Beta-cytosine arabinoside; Iretin; Citarabina [INN-Spanish]; 1-beta-D-Arabinofaranosylcytosine; Ara-C; Spongocytidine; Cytarabin; Cytosine, 1-beta-D-arabinosyl-; Intrathecal (injected into the spinal fluid) DepoCyt; DepoCyte; 147-94-4; D00168; cytarabine liposome injection; Alexan; Cytosine arabinofuranoside; CHEMBL803; Arafcyt; Udicil; CYTARABINE (SEE ALSO CYTARABINE HYDROCHLORIDE 69-74-9); AC-1075; Aracytine; FT-0082880; 1beta-D-Arabinosylcytosine; Cytosine-1-beta-D-arabinofuranoside; Arabinosyl Cytosine; LS-860; Cytosine arabinoside; beta-D-Arabinosylcytosine; MolPort-001-792-509; Cytosinearabinoside; Arabinosylcytosine; NSC 287459; Cytarabinum; U-19,920; 1-beta-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone; Lopac0_000316; Cytosine-beta-D-arabinofuranoside; MLS000758310; NCGC00093356-04; C02961; C1768_SIGMA; (beta-D-Arabinofuranosyl)cytosine; SR-01000075773-3; 4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone; 4-amino-1-beta-D-arabinofuranosylpyrimidin-2(1H)-one; C2035; Citarabina; 4-Amino-1-b-D-arabinofuranosyl-2-(1H)-pyrimidinone; HMS2090A18; Cytarabinoside; Cytarbel; SAM001247012; beta-Arabinosylcytosine; Cytosine beta-D-arabinofuranoside; Intrathecal cytarabine (also known as ara-C); beta-Ara C; ZINC03795098; 4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin; CPD000449317; Aracytidine; AraC; TL8001048; BIDD:GT0371; Ara-C, Cytosine Arabinoside, Cytosar-U, Cytarabine; Cytosine, 1-beta-D-arabinofuranosyl-; BTB15125; U-19920; Arabinocytidine; CHEBI:28680; Cytonal; CCRIS 913; CID6253; 4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidine; 30399_FLUKA; NCGC00093356-05; 2(1H)-Pyrimidinone, 4-amino-1-.beta.-D-arabinofuranosyl-; AC1L1M4F; Ara-Cytidine; Cytosine arabinoside (VAN); AC1Q52OJ; Tarabine; NCI-C04728; SMR000449317; Aracytin; cytarabine; AI3-52329; Cytarabinum [INN-Latin]; Cytosar; 1beta-Arabinofuranasylcytosine; NSC287459; Cytosine 1-beta-D-arabinofuranoside; 2(1H)-Pyrimidinone, 4-amino-1-beta-D-arabinofuranosyl-; Arabinofuranosylcytosine; Cytosine arabinose; Cytosine, beta-D-arabinoside; Cytosar-U; HSDB 3049; EINECS 205-705-9; 4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinon [Czech]; S1648_Selleck; Cytarabine (JP15/USP/INN); Depocyt; 4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinon; 1-.beta.-D-arabinofuranosyl-cytosine; Cytosine beta-D-arabinoside; CHX 3311; Cytarabine [USAN:INN:BAN:JAN]; 4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin [Czech]; DB00987; 1-Arabinofuranosylcytosine; 69-74-9 (hydrochloride); Erpalfa; 1-beta-D-Arabinofuranosylcytosine, Cytosine Arabinoside	147-94-4	6253	7847236	TTDS00310	DNA polymerase	N/A	O39644	N/A	N/A	inhibitor
DAP001383	Foscavir	Foscarnet sodico [Spanish]; Spectrum3_001484; Foscarnetum natricum [Latin]; Spectrum2_000668; Foscarnet sodico; KBio2_001839; 34156-56-4; Foscarnetum natricum [INN-Latin]; CHEMBL754; Foscarnet sodique [INN-French]; MSL & PFA; KBioSS_001839; KBio2_006975; 63585-09-1; Phosphinecarboxylic acid, dihydroxy-, oxide, trisodium salt, hexahydrate; HMS502N17; LS-105953; AR-1L5079; Phosphinecarboxylic acid, dihydroxy-, oxide; Trisodium phosphonoformate hexahydrate; Phosphonoformate; DRG-0017; Foscarnet sodium hydrate (JAN); Phosphonoformic acid, trisodium salt; Forscarnet sodium; Trisodium carboxyphosphate; PFA & rIFN.alpha.A; 63585-09-1 (tri-hydrochloride salt); Spectrum4_000840; AC-2085; trisodium phosphonatoformate; DB00529; BSPBio_003067; Trisodium phosphonoformte hexahydrate; sodium dioxidophosphanecarboxylate oxide hydrate(3:1:6); EHB 776; AC1L5400; CID3415; Foscavir (TN); Foscavir; A 29622; D00579; Foscarnet sodique; phosphonomethanoic acid; HMS1921D18; trisodium carboxyphosphate (anhydrous); KBio2_004407; foscarnet sodium hexahydrate; Foscarneto sodico; AC1L2C37; trisodium dioxidophosphanecarboxylate oxide; Phosphonoformate(trisodium) & Recombinant Alpha-A Interferon; Foscarnet sodium hydrate; LS-187063; NINDS_000915; KBio3_002567; Prestwick_1024; KBioGR_001419; C06456; 4428-95-9 (Parent); Formic acid, phosphono-; Triapten; Carboxyphosphonic acid; Foscarnet sodium (USAN/INN); AC1NB82R; Spectrum_001359; Foscarmet; 1nki; CHEBI:60269; dihydroxyphosphanecarboxylic acid oxide; Dihydroxyphosphinecarboxylic acid oxide and MSL, neutralizing monoclonal antibody; Dihydroxyphosphinecarboxylic acid oxide trisodium salt hexahydrate; foscarnet; Phosphonoformic acid; FOSCARNET SODIUM; AC1L1FVT; NChemBio.2007.9-comp7; 4428-95-9; D02267; SPECTRUM1502019; trisodium dioxidophosphinecarboxylate oxide; A-29622; UNII-964YS0OOG1; CHEBI:141644; Foscarneto sodico [INN-Spanish]; LS-105952; Ambap63585-09-1; Foscarnet & IFN-.ALPHA.; Foscarnet sodique [French]; CID44561; CHEBI:127780; Dihydroxyphosphinecarboxylic acid oxide; KBio1_000915; Dihydroxyphosphinecarboxylic acid oxide trisodium salt; NCGC00094941-02; CID169569; UNII-364P9RVW4X; IDI1_000915; SPBio_000735; LS-183979; Foscarnet sodium [USAN:INN:BAN]; Formic acid, phosphono-, trisodium salt, hexahydrate; Phosphinecarboxylic acid, dihydroxy-, oxide, trisodium salt; Phosphonoformic acid & IFN-.ALPHA.; Phosphonoformic acid, trisodium salt, hexahydrate; MolPort-003-665-560; Phgosphonocarboxylic acid; CHEMBL666; Spectrum5_000932; DivK1c_000915; Virudin; NCGC00094941-01; trisodium phosphonoformate (anhydrous); Trisodium phosphonoformate; trisodium phosphonatoformate hexahydrate; NSC313410; LS-187793; EHB-776; HS-0008; Foscarnetum natricum; HMS2092N15; AC1Q1UNV	4428-95-9	44561	8689	TTDS00310	DNA polymerase	N/A	O39644	N/A	N/A	inhibitor
DAP000646	Valganciclovir	RO1079070/194; Cymeval; Valganciclovir; AC1Q63EV; Valganciclovir (INN); D02495; RS 79070; AC1L20JF; LS-173677; [2-[(2-amino-6-oxo-3H-purin-9-yl)methoxy]-3-hydroxypropyl] (2S)-2-amino-3-methylbutanoate; C14H22N6O5; Valganciclovir (Oral); L-Valine, ester with ganciclovir; CID64147; NCGC00168779-01; L-Valine, 2-((2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy)-3-hydroxypropyl ester; 175865-60-8; UNII-GCU97FKN3R; I06-1704; 5-Amino-3-[1-(hydroxymethyl)-2-(L-valyloxy)ethoxymethyl]-6,7-dihydro-3H-imidazo[4,5-d]pyrimidin-7-one; DB01610; Valganciclovir [INN:BAN]	175865-60-8	64147	11068227	TTDS00310	DNA polymerase	N/A	O39644	N/A	N/A	inhibitor
DAP000816	Aciclovir	CHEBI:2453; 9-[(2-Hydroxyethoxy)- methyl]guanine; KBioSS_002219; NSC 645011; 1pwy; Zovirax; TL8003779; NCGC00015061-01; Zovirax (TN); NCGC00022426-03; Spectrum_001739; ACV & Pluronic F-68; NCGC00093555-04; EINECS 261-685-1; HSDB 6511; FT-0082883; 9-(2-Hydroxyethoxy)methylguanine; Aciclovier; NCGC00015061-04; 6H-Purin-6-one, 2-amino-1,9-dihydro-9-((2-hydroxyethoxy)methyl)-; W-248-U; NCGC00093555-01; 9-((2-Hydroxyethoxy)methyl)guanine; IDI1_000185; 2-Amino-9-[(2-hydroxyethoxy)methyl]-1,9-dihydro-6H-purin-6-one; Prestwick2_000086; NCGC00015061-03; CID2022; S1807_Selleck; UNII-X4HES1O11F; CAS-59277-89-3; Prestwick1_000086; A1562_SIGMA; NCGC00167756-01; Lopac-A-4669; KBio3_002850; NINDS_000185; Zovir; STK796771; CPD000058225; BAS 00485787; KBioGR_000889; LS-127209; BB_NC-0569; DivK1c_000185; Genvir; HMS2090G09; HMS1568A14; Avirax; NSC645011; NCGC00015061-02; HMS500J07; BPBio1_000014; BW-248U74; 2-amino-9-{[(2-hydroxyethyl)oxy]methyl}-1,9-dihydro-6H-purin-6-one; 6H-Purin-6-one, 2-amino-1,9-dihydro-9-((2-hydroxyethoxy)-methyl)-; Acyclovir (USP); C06810; Virorax; SPECTRUM1503603; A 4669; AC2; ZINC01530555; EU-0100037; KBio2_004787; 9-[(2-Hydroxyethoxy)-methyl]guanine; NCGC00093555-03; MLS000069633; KBio2_002219; Lopac0_000037; SAM002589967; BIDD:GT0646; Aciclovir (JAN/INN); Bovine lactoferrin & 2-Amino-1,9-dihydro-9-[(2-hydroxyethoxy)methyl]-6H-purin-6-one; MolPort-001-889-834; Spectrum2_001563; DRG-0008; Vipral; acyclovir; 2-Amino-1,9-dihydro-9-[(2-hydroxyethoxy)methyl]-6H-purin-6-one; 9-[(2-Hydroxyethoxy)-methyl]guanine; AcycloFoam; Aciclovirum [Latin]; Wellcome-248U; Zovirax Oral Acyclovir (ACV) Suspension; InChI=1/C8H11N5O3/c9-8-11-6-5(7(15)12-8)10-3-13(6)4-16-2-1-14/h3,14H,1-2,4H2,(H3,9,11,12,15; Aciclovirum [INN-Latin]; SPBio_001951; C8H11N5O3; 6H-Purin-6-one, 1,9-dihydro-2-amino-9-((2-hydroxyethoxy)methyl)-; Acyclovir Lauriad; Acyclovir [USAN]; DB00787; CHEMBL184; 9-HYROXYETHOXYMETHYLGUANINE; BSPBio_000012; BW-248-U; Prestwick3_000086; Aciclovir; Maynar; Acycloguanosine; MolPort-000-768-994; Spectrum3_001874; Virolex; A4669_SIGMA; 2-amino-9-(2-hydroxyethoxymethyl)-3H-purin-6-one; Prestwick_6; 2-Amino-9-(2-hydroxy-ethoxymethyl)-1,9-dihydro-purin-6-one; Acyclovir & Pluronic F-68; NCGC00015061-10; 9-[(2-Hydroxyethoxy)methyl]guanine; SPBio_001466; Prestwick0_000086; D00222; Spectrum5_001093; 6H-Purin-6-one, 2-amino-1,9-dihydro-9-[(2-hydroxyethoxy)methyl]-; BW-248U; 2-Amino-1,9-dihydro-9-((2-hydroxyethoxy)methyl)-6H-purin-6-one; CCRIS 1953; Viropump; I01-1122; AKOS000656213; HMS1922E08; 59277-89-3; Activir; NCGC00093555-02; Hascovir; SMR000058225; Acyclovir-side chain-2-3H; SMP1_000007; AC-11038; Alti-Acyclovir; B-LF& ACV; 6H-Purin-6-one,2-amino-1,9-dihydro-9-((2-hydroxyethoxy)mehtyl); BSPBio_003348; KBio2_007355; KBio1_000185; Aciclovirum; Aciclovir, Acycloguanosine, Zovirax, Acyclovir; AC1L1CR6; Spectrum4_000225	59277-89-3	2022	7847289	TTDS00310	DNA polymerase	N/A	O39644	N/A	N/A	inhibitor
DAP001090	Insulin-detemir	N/A	169148-63-4	5311023	46508877	TTDS00292	Insulin receptor	CD220 antigen;IR	P06213	3643	ENSG00000171105	binder
DAP001089	Insulin, porcine	Insulin (Ox), 8A-L-threonine-10A-L-isoleucine- (9CI); Insulin,pig; Insulin (ox), 8(sup A)-L-threonine-10(sup A)-L-isoleucine-; Insulin (sperm whale); L-Alanine, L-phenylalanyl-L-valyl-L-asparaginyl-L-glutaminyl-L-histidyl-L-leucyl-L-cysteinylglycyl-L-seryl-L-histidyl-L-leucyl-L-valyl-L-alpha-glutamyl-L-alanyl-L-leucyl-L-tyrosyl-L-leucyl-L-valyl-L-cysteinylglycyl-L-alpha-glutamyl-L-arginylglycyl-L-phenylalanyl-L-phenylalanyl-L-tyrosyl-L-threonyl-L-prolyl-L-lysyl-, cyclic (7-7'),(19-20')-bis(disulfide) with glycyl-L-isoleucyl-L-valyl-L-alpha-glutamyl-L-glytaminyl-L-cysteinyl-L-cysteinyl-L-threonyl-L-seryl-L-isolucyl-L-cysteinyl-L-seryl-L-leucyl-L-tyrosyl-L-glutaminyl-L-leucyl-L-alpha-glutamyl-L-asparaginyl-L-tyrosyl-L-cysteinyl-L-asparagine cyclic (6'-11')-disulfide; Porcine insulin; LS-84079; 184890-24-2; Insulin [pig]; Pig insulin; 12584-58-6; EINECS 235-703-3; Insulin [USAN:JAN]; Neutral insulin; Insulin porcine; Insulin (pig); Insulin (ox), 8A-l-threonine-10A-l-isoleucine-; Insulin (Canis familiaris); Swine insulin; Insulin, 8A-L-threonine-10A-L-isoleucine-; Insulin (Alopex lagopus); A neutral, buffered solution of pork insulin; Hog insulin; Insulin (swine); 97380-49-9; Insulin (ox); UNII-AVT680JB39; Insulin (porcine); Insulin, neutral; 8A-L-Threonine-10A-L-isoleucineinsulin (ox); 9004-14-2; Velosulin; Insulin (Physeter catodon); Insulin (dog)	9004-14-2	N/A	46508925	TTDS00292	Insulin receptor	CD220 antigen;IR	P06213	3643	ENSG00000171105	binder
DAP001088	Insulin Glargine recombinant	N/A	160337-95-1	N/A	46507981	TTDS00292	Insulin receptor	CD220 antigen;IR	P06213	3643	ENSG00000171105	binder
DAP001091	Insulin-glargine	Lantus; SoloStar [Insulin delivery pen]; A21-Gly-B31-Arg-B32-Arg-insulin; UNII-2ZM8CX04RZ; SoloStar; Insulin, glycyl(A21)-arginyl(B31,B32)-; Insulin glargine; Glargine; 160337-95-1	160337-95-1	44146714	46505513	TTDS00292	Insulin receptor	CD220 antigen;IR	P06213	3643	ENSG00000171105	binder
DAP001092	Insulin-aspart	B28-Asp-insulin; NovoMix 30; Insulin aspart; LS-185932; NovoRapid 30 Mix; Insulin, Asp(B28)-; 139532-40-4; Aspart insulin; NovoRapid; INA-X 14; UNII-D933668QVX; Insulin (human), 28B-L-aspartic acid-; 28(sup B)-L-Aspartic acid-insulin (human); AspB28-insulin (human); Insulin X14; (AspB28)-human insulin; 1024611-56-0; 116094-23-6; NovoLog; Insulin aspart [USAN]; Aspart; Novolog mix 70/30; 877034-90-7; Insulin (ox), 8A-L-threonine-10A-L-isoleucine-28B-L-aspartic acid-30B-L-threonine-	116094-23-6	16132418	46507309	TTDS00292	Insulin receptor	CD220 antigen;IR	P06213	3643	ENSG00000171105	binder
DAP001495	Meglitinides	N/A	N/A	3033769	49681662	TTDS00292	Insulin receptor	CD220 antigen;IR	P06213	3643	ENSG00000171105	stimulator
DAP000802	Insulin recombinant	N/A	9004-10-8	N/A	3989	TTDS00292	Insulin receptor	CD220 antigen;IR	P06213	3643	ENSG00000171105	binder
DAP001093	Insulin-glulisine	N/A	207748-29-6	N/A	46504450	TTDS00292	Insulin receptor	CD220 antigen;IR	P06213	3643	ENSG00000171105	binder
DAP000803	Insulin Lyspro recombinant	N/A	133107-64-9	N/A	46507498	TTDS00292	Insulin receptor	CD220 antigen;IR	P06213	3643	ENSG00000171105	binder
DAP000822	Insulin-lispro	N/A	133107-64-9	16132438	46508737	TTDS00292	Insulin receptor	CD220 antigen;IR	P06213	3643	ENSG00000171105	binder
DAP000875	Ranolazine	NCGC00095177-03; RANOLAZINE; HMS2090L09; 95635-55-5; LS-187267; Ranexa; MLS002154149; RS-43285-003; BRD-A97674275-001-01-9; (-)-Ranolazine; SMR000857382; D05700; CHEMBL1404; NCGC00095177-02; MolPort-003-666-653; RS-43285; Ranolazine 2HCl; Ranexa, Ranolazine; CVT-303; HMS2093D21; BSPBio_002276; NCGC00015897-05; AC1Q5LYD; AC-1673; Ran4; I06-0160; RAN D; DB00243; AC1L1M17; HMS1922F16; Ranolazine dihydrochloride; 1-Piperazineacetamide, N-(2,6-dimethylphenyl)-4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]-; Lopac0_001062; NCGC00095177-01; Ranexa (TN); 142387-99-3; N-(2,6-dimethylphenyl)-2-[4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl]acetamide; Latixa; KEG-1295; CID56959; Ranolazine (USAN/INN); UNII-A6IEZ5M406; 1-Piperazineacetamide, N-(2,6-dimethylphenyl)-4-(2-hydroxy-3-(2-methoxyphenoxy)propyl)-; SPECTRUM1505366; S1799_Selleck; ( -)-Ranolazine; I01-2008	142387-99-3	56959	194150	TTDS00503	Voltage-gated sodium channel subunit alpha Nav1.7	hNE-Na;Neuroendocrine sodium channel;Peripheral sodium channel 1;Sodium channel protein type 9 subunit alpha;Sodium channel protein type IX subunit alpha	Q15858	6335	ENSG00000169432	blocker
DAP001275	Phytonadione	Phytylmenadione; Phytomenadione (INN); 1,4-Naphthalenedione, 2-methyl-3-((2E,7R,11R)-3,7,11,15-tetramethyl-2-hexadecen-1-yl)-; Phythyl-menadion (GERMAN); Vitamin K1 (VAN); K-Ject; Fitomenadiona; Mephyton; 27696-10-2; Phylloquinone (8CI); LT00452032; Mephyton (TN); Vitamin K 1; 1,4-Naphthalenedione, 2-methyl-3-((2E,7R,11R)-3,7,11,15-tetramethyl-2-hexadecenyl)-; Vitamin K1(20); MLS001332660; .alpha.-Phylloquinone; Phytonadionum; 1,4-Naphthalenedione, 2-methyl-3-((2E,7R,11R)-3,7,11,15-tetramethyl-2-hexadecenyl)-, radical ion(1-); NSC 270681; Aqua mephyton; 2-Methyl-3-phytyl-1,4-naphthoquinone; C02059; 2-Methyl-3-phytyl-1,4-naphthochinon [German]; Antihemorrhagic vitamin; 1,4-Naphthalenedione, 2-methyl-3-(3,7,11,15-tetramethyl-2-hexadecenyl)-; Kephton; Kinadion; 2-methyl-3-[(E)-3,7,11,15-tetramethylhexadec-2-enyl]naphthalene-1,4-dione; EINECS 201-564-2; 1,4-Naphthalenedione, 2-methyl-3-(3,7,11,15-tetramethyl-2-hexadecenyl)-, radical ion(1-), (R-(R*,R*-(E)))-; 11104-38-4; C31H46O2; Combinal K1; AR-1E3503; NCGC00159423-02; HSDB 3162; Phytomenadionum; 2-METHYL-3-PHYTYL-14-NAPHTHOQUINONE; DB01022; 2-Methyl-3-phytyl-1,4-naphthochinon; 10485-69-5; SMR000059144; 3-Phytylmenadione; Vitamin K1 (generic); 2-methyl-3-(3,7,11,15-tetramethylhexadec-2-en-1-yl)naphthalene-1,4-dione; 50926-17-5; 1,4-Naphthalenedione, 2-methyl-3-(3,7,11,15-tetramethyl-2-hexadecenyl)-, [R-[R*,R*-(E)]]-; 2', 3'-trans-Vitamin K1; Vitamin K1 (TN); LS-94617; MLS001332659; VITAMIN K; Phytonadione [USAN:JAN]; NSC270681; Aquamephyton; ST075162; Fitomenadione [DCIT]; D00148; Monodion; Kativ N; Fitomenadione; 15973-57-6; trans-Phylloquinone; Synthex P; UNII-A034SE7857; phytonadione; Phyllochinon; Phyllochinonum; EINECS 279-833-9; P0642; Phytomenadione; 2-Methyl-3-(3,7,11,15-tetramethylhexadec-2-enyl)-1,4-naphthoquinone; 2',3'-trans-Vitamin K1; Mono-Kay; AC1Q6B3J; VITAMIN K1; 2-(3,7,11,15-Tetramethylhexadec-2-enyl)-3-methylnaphthalene-1,4-dione; Phytomenadionum [INN-Latin]; Phytonadione (JP15/USP); AC1NQX34; Konakion; phyllohydroquinone; 2-Methyl-3-phythyl-1,4-naphthochinon; Phythyl-menadion; MolPort-001-785-978; Aqua-Mephytin; 2-Methyl-3-(3,7,11,15-tetramethyl-2-hexadecenyl)-1,4-naphthalened- ione; 1,4-Naphthalenedione, 2-methyl-3-(3,7,11,15-tetramethyl-2-hexadecenyl)-, (R-(R*,R*-(E)))-; alpha-Phylloquinone; 1,4-Naphthoquinone, 2-methyl-3-phytyl-; EINECS 234-330-3; Fitomenadiona [INN-Spanish]; CID5280483; Phylloquinone; Phyllochinon [German]; 2-Methyl-3-(3,7,11,15-tetramethyl-2-hexadecenyl)-1,4-naphthalenedione; 84-80-0	84-80-0	4812	5148	TTDS00486	Vitamin K-dependent gamma-carboxylase	Gamma-glutamyl carboxylase;GC;GGCX;Vitamin K gamma glutamyl carboxylase	P38435	2677	ENSG00000115486	cofactor
DAP001274	Anisindione	D07457; KBioGR_000986; Anisindionum [INN-Latin]; anisindione; EINECS 204-186-6; 2-(4-Methoxyphenyl)indan-1,3-dione; LS-81215; AKOS000987728; Anisindiona [INN-Spanish]; CID2197; STK363125; 2-(4-methoxyphenyl)indene-1,3-dione; HMS1921L18; 2-(4-Methoxy-phenyl)-indan-1,3-dione; NCGC00094969-01; KBio3_002410; 2-[4-(methyloxy)phenyl]-1H-indene-1,3(2H)-dione; Anisindione [INN:BAN]; Miradon (TN); NINDS_000336; Spectrum_001355; HSDB 3205; 2-para-Anisyl-1,3-indandione; Anisin indandione; SMR000146452; 1H-Indene-1,3(2H)-dione, 2-(4-methoxyphenyl)-; DivK1c_000336; 1,3-Indandione, 2-(p-methoxyphenyl)-; 2-(p-Methoxyphenyl)-1,3-indandione; C16H12O3; KBioSS_001835; CHEBI:133809; KBio1_000336; BSPBio_002910; MLS001201835; 1,3-Indanedione, 2-(4-methoxyphenyl)-; 2-(4-Methoxyphenyl)-1H-indene-1,3(2H)-dione; Bio-0735; KBio2_001835; CHEMBL712; Spectrum3_001525; 3-08-00-02931 (Beilstein Handbook Reference); DB01125; HMS2092F04; 2-(p-Methoxyphenyl)indane-1,3-dione; Spectrum2_000427; SR-01000642873-1; Spectrum5_000960; UNII-S747T1ERAJ; IDI1_000336; 2-p-Anisyl-1,3-indandione; A2429/0102869; MLS000554135; Spectrum4_000723; NCGC00094969-02; BRN 1880681; 117-37-3; Anisindione (INN); AC1L1D53; MolPort-002-318-562; SPE 2792; Unidone; KBio2_004403; Anisindiona; Anisindionum; NCGC00094969-03; HMS501A18; SPECTRUM1502198; Oprea1_729452; SPBio_000414; KBio2_006971; Miradon	117-37-3	2197	151473	TTDS00486	Vitamin K-dependent gamma-carboxylase	Gamma-glutamyl carboxylase;GC;GGCX;Vitamin K gamma glutamyl carboxylase	P38435	2677	ENSG00000115486	inhibitor
DCL000807	Fontolizumab	Fontolizumab (USAN/INN); Fontolizumab; D04242; 326859-36-3	326859-36-3	N/A	47206188	TTDC00096	Interferon gamma	IFN-gamma;Immune interferon	P01579	3458	ENSG00000111537	antibody
DCL000809	Fumaric acid	(E)-2-Butenedioic acid; LS-500; Fumaric acid (NF); F8509_SIGMA; 2-Butenedioic acid (2E)- (9CI); Acidum fumaricum; Allomalenic acid; MolPort-001-780-031; Lichenic acid (VAN); EINECS 203-743-0; trans-1,2-Ethylenedicarboxylic acid; 2-butenedioic acid, (2E)-; DB04299; 2-Butenedioic acid (2E)-; F0067; NSC-2752; FC 33 (acid); U-1149; MLS002454406; 240745_SIAL; SMR000112117; fumarate; Allomaleic acid; MolPort-004-288-293; Butenedioic acid, (E)-; CID444972; nchembio.2007.47-comp1; CHEBI:22958; ammonium fumarate; HSDB 710; AB1002616; trans-but-2-enedioic acid; FEMA No. 2488; OR17920; USAF EK-P-583; AKOS000118896; C00122; AC1Q5T7Y; CHEBI:18012; S04-0167; nchembio.186-comp71; 2-(E)-Butenedioic acid; 240745_ALDRICH; NSC2752; CHEMBL503160; FEMA Number 2488; Boletic acid; (2E)-but-2-enedioic acid; D02308; UNII-88XHZ13131; fum; bmse000083; AC1Q71EM; trans-Butenedioic acid; 2-Butenedioic acid (E)-; 03761_FLUKA; 623158-97-4; 1,2-Ethylenedicarboxylic acid, (E); 2-Butenedioic acid; Lichenic acid; fumarate, 10; 110-17-8; 1,2-Ethenedicarboxylic acid, trans-; Kyselina fumarova [Czech]; Fumaric acid (8CI); W248800_ALDRICH; E-2-Butenedioic acid; AR-1D9767; Caswell No. 465E; I04-1070; AC1L9H76; Kyselina fumarova; fumaric acid; Tumaric acid; BRN 0605763; WLN: QV1U1VQ-T; 4-02-00-02202 (Beilstein Handbook Reference); NCGC00091192-01; Fumarsaeure; trans-2-Butenedioic acid; 26B3632D-E93F-4655-90B0-3C17855294BA; 2-Butenedioic acid, (E)-; LMFA01170106; Butenedioic acid; C4H4O4; EPA Pesticide Chemical Code 051201; CCRIS 1039; (E)-but-2-enedioic acid; (2E)-2-butenedioic acid; AI3-24236; But-2-enedioic acid	110-17-8	444972	48425155	TTDC00096	Interferon gamma	IFN-gamma;Immune interferon	P01579	3458	ENSG00000111537	binder
DCL000095	CRx-191	N/A	N/A	N/A	N/A	TTDC00096	Interferon gamma	IFN-gamma;Immune interferon	P01579	3458	ENSG00000111537	inhibitor
DCL000056	AT-101	Isosorbide (JP15/USP/INN); 1,4:3,6-dianhydrohexitol; Sorbid; CHEMBL1200660; Bio-0643; 50974-60-2; NCGC00160508-01; 1,4:3,6-Dianhydro-D-sorbitol; Isosorbida [INN-Spanish]; EINECS 211-492-3; Vascardin dinitrate; BRN 0080510; 652-67-5; Glucitol, 1,4:3,6-dianhydro-, D-; Oprea1_439690; Ismotic (TN); 2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3,6-diol; AC1Q79SL; 42750-75-4; Isosorbide [USAN:INN:BAN:JAN]; TL8004635; 67803-92-3; STK801813; I0407; HSDB 3105; AC1L4190; Isobide; SMP1_000177; EINECS 248-906-7; AR-1B7417; NSC 40725; EINECS 211-374-1; BIDD:GT0695; Devicoran; 49871-92-3; Isosorbidum [INN-Latin]; D-Sorbitol, 1,4:3,6-dianhydro(furo[3,2-b]furan-3,6-diol, hexahydro-); 24332-71-6; MolPort-001-783-404; I14-6752; 1,4:3,6-Dianhydroglucitol; LS-71370; Isobide (TN); NSC40725; D00347; UNII-WXR179L51S; D-Glucitol, 1,4:3,6-dianhydro-; D-Sorbitol, {1,4:3,6-dianhydro(furo[3,2-b]furan-3,6-diol,} hexahydro-); LS-89261; Hydronol; Sorbitol, 1,4:3,6-dianhydro-; Isosorbidum; 1,4:3,6-Dianhydromannitol; 151380-60-8; A912284D-27E1-4FB0-91B8-86C8AB905297; 5-19-03-00201 (Beilstein Handbook Reference); 641-74-7; NSC270938; 152881-21-5; Hydronol (VAN); Isomannide; D-1,4:3,6-Dianhydroglucitol; isosorbide; 1,4:3,6-Dianhydro-D-glucitol; (3S,3aR,6R,6aR)-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3,6-diol; Ismotic; (+)-D-Isosorbide; AT-101; CID99937; AC1L1ZXO; Dianhydrosorbitol; D-Mannitol, 1,4:3,6-dianhydro-; KST-1B7297; CID12597; AT 101; ZINC18284778; Isosorbida; D-Glucitol, 1,4:3,6-dianhydro-; 28218-68-0; MolPort-000-812-960; Mannitol, 1,4:3,6-dianhydro-; NSC231906; Dianhydro-D-glucitol; 1,4:3,6-Dianhydrosorbitol; 1,4-Dianhydrosorbitol	652-67-5	12597	26683984	TTDC00048	Induced myeloid leukemia cell differentiation protein Mcl-1	Bcl-2-related protein EAT/mcl1;mcl1/EAT	Q07820	4170	ENSG00000143384	inhibitor
DCL000866	LGD-4665	N/A	N/A	N/A	N/A	TTDS00524	Thrombopoietin Receptor	CD110 antigen;C-mpl;MPL;Myeloproliferative leukemia protein;TPOR;TPO-R	P40238	4352	ENSG00000117400	agonist
DCL000960	RhTPO	N/A	N/A	N/A	N/A	TTDS00524	Thrombopoietin Receptor	CD110 antigen;C-mpl;MPL;Myeloproliferative leukemia protein;TPOR;TPO-R	P40238	4352	ENSG00000117400	agonist
DCL000792	Eltrombopag	SB-497115; CHEBI:591033; Eltrombopag; Promacta; thylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy- (9CI); SB497115; UNII-S56D65XJ9G; [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[(2Z)-1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy-; (1,1'-Biphenyl)-3-carboxylic acid, 3'-((2Z)-(1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene)hydrazino)-2'-hydroxy-; [1,1'-Biphenyl]-3-carboxylic acid, 3'-[(2Z)-[1-(3,4-dime; SB 497115; CHEBI:557398; EN002876; 496775-61-2; Eltrombopag [INN]; (E)-3\'-(2-(1-(3,4-Dimethylphenyl)-3-methyl-5-oxo-1H-pyrazol-4(5H)-ylidene)hydrazinyl)-2\'-hydroxybiphenyl-3-carboxylic acid; CHEMBL461101; MolPort-006-393-918; CID9846180	443130-00-5	3033962	22395450	TTDS00524	Thrombopoietin Receptor	CD110 antigen;C-mpl;MPL;Myeloproliferative leukemia protein;TPOR;TPO-R	P40238	4352	ENSG00000117400	agonist
DCL000247	Thrombopoietin	N/A	N/A	N/A	7980783	TTDS00524	Thrombopoietin Receptor	CD110 antigen;C-mpl;MPL;Myeloproliferative leukemia protein;TPOR;TPO-R	P40238	4352	ENSG00000117400	agonist
DCL000659	Totrombopag	N/A	851606-62-7 	N/A	N/A	TTDS00524	Thrombopoietin Receptor	CD110 antigen;C-mpl;MPL;Myeloproliferative leukemia protein;TPOR;TPO-R	P40238	4352	ENSG00000117400	agonist
DCL000686	AKR-501	N/A	N/A	54459	49699309	TTDS00524	Thrombopoietin Receptor	CD110 antigen;C-mpl;MPL;Myeloproliferative leukemia protein;TPOR;TPO-R	P40238	4352	ENSG00000117400	agonist
DCL000222	SB-559448	N/A	387867-13-2	3038522	48426754	TTDS00524	Thrombopoietin Receptor	CD110 antigen;C-mpl;MPL;Myeloproliferative leukemia protein;TPOR;TPO-R	P40238	4352	ENSG00000117400	agonist
DAP001447	Revolade/Promacta	N/A	139592-99-7	N/A	N/A	TTDS00524	Thrombopoietin Receptor	CD110 antigen;C-mpl;MPL;Myeloproliferative leukemia protein;TPOR;TPO-R	P40238	4352	ENSG00000117400	agonist
DAP000231	Clonidine	2-(2,6-Dichlorophenylamino)-2-imidazoline; Clonidine [USAN:BAN:INN]; 2-IMIDAZOLINE, 2-(2,6-DICHLOROPHENYLAMINO)-; Clonidine (JAN/USAN/INN); KBio2_004389; NCGC00024734-01; Prestwick0_000248; Clonidinum [INN-Latin]; 2,6-dichloro-N-2-imidazolidinylidenebenzenamide; Bio2_000788; Catapres-TTS; Clonidinhydrochlorid; KBioSS_001821; HMS1791P10; AC1L1EI5; CATAPRES-TTS-1; Clonidinum; BSPBio_001588; KBioSS_000308; CHEBI:46632; M-5041T; NCGC00024734-05; 2-Imidazoline, 2-(2,6-dichloroanilino)-; 2,6-dichloro-N-(2-imidazolidinylidene)aniline; Bio2_000308; nchembio705-10; DivK1c_000774; D00281; Prestwick2_000248; KBio2_000308; CCRIS 7787; 2-[(2,6-dichlorophenyl)imino]-2-imidazoline; Catapresan; 57066-25-8; NCGC00015268-08; CAS-4205-91-8; Prestwick1_000248; BIDD:GT0547; NCGC00024734-04; ST-155BS; KBioGR_000308; 2-Imidazoline, 2-(2,6-dichloroanilino)- (7CI,8CI); BSPBio_002055; L000193; nchembio.79-comp11; Chlornidinum; Isoglaucon; Clofenil; Lopac0_000268; Dixarit; 2,6-Dichloro-N-2-imidazolidinylidenebenzenamine; 2-(2,6-Dichloroanilino)-1,3-diazacyclopentene-(2); Catapressan; SPBio_001233; 2-((2,6-Dichlorophenyl)imino)imidazolidine; SKF 34427; IDI1_000774; 734571A; EINECS 224-119-4; NCGC00015268-01; UNII-MN3L5RMN02; SPBio_002255; Gemiton; KBio2_002876; clonidine; Clonidina; Tocris-0690; AB00514634; HMS1361P10; Catapres- TTS; Klofelin; T171; Duraclon; 2-(2,6-Dichlorophenylimino)imidazolidine; BSPBio_000036; Spectrum3_000358; HMS2089G11; 1H-Imidazol-2-amine, N-(2,6-dichlorophenyl)-4,5-dihydro-; BRD-K98530306-001-02-1; CHEMBL134; KBio2_005444; CATAPRES-TTS-3; IDI1_034058; Clopheline; ZINC00896484; AC1Q3K6V; NINDS_000774; M 5041T; Clonidina [INN-Spanish]; 2-(2,6-Dichloroanilino)-2-imidazoline; BRD-K98530306-003-05-0; Spectrum4_000956; Lopac-C-7897; Catarpres; CID2803; Spectrum5_000759; Benzenamine, 2,6-dichloro-N-2-imidazolidinylidene-; ST-155-BS; KBio2_001821; Spectrum_001341; HSDB 3040; Bio1_001448; NCGC00015268-02; HMS1989P10; LS-79606; CATAPRES-TTS-2; 4205-91-8 (mono-hydrochloride); KBio3_000616; Prestwick3_000248; NCGC00024734-02; 1H-Imidazol-2-amine, N-(2,6-dichlorophenyl)-4,5-dihydro- (9CI); CHEBI:3757; ST 155BS; DB07566; Clonidin; Bio1_000470; KBio2_006957; MolPort-001-779-668; KBio3_001275; Tenso-Timelets; BPBio1_000040; 2,6-dichloro-N-imidazolidin-2-ylideneaniline; AKOS001595470; 4205-90-7; Bio1_000959; Klofenil; Spectrum2_001187; DB00575; Catarpresan; Catarpres-TTS (TN); NCGC00179680-01; N-(2,6-Dichlorophenyl)-4,5-dihydro-1H-imidazol-2-amine; Duraclont; Adesipress; Hemiton; KBio1_000774; Catarpres-TTS; C9H9Cl2N3; KBio3_000615; 2-[(2,6-Dichlorophenyl)imino]imidazoline; MolPort-005-932-374; NCGC00024734-03; KBioGR_001572	4205-90-7	2803	163008	TTDS00031	Alpha-2 adrenergic receptor	Alpha(2)-adrenoceptor	N/A	N/A	N/A	agonist
DAP001481	Guanfacine extended release	N/A	29110-47-2	4671	49681174	TTDS00031	Alpha-2 adrenergic receptor	Alpha(2)-adrenoceptor	N/A	N/A	N/A	agonist
DAP000232	Guanabenz	5051-62-7; Hydrazinecarboximidamide, 2-((2,6-dichlorophenyl)methylene)-; GBZ; NCGC00024846-03; Guanidine, [(2,6-dichlorobenzylidene)amino]-; CID5702063; 2-[(E)-(2,6-dichlorophenyl)methylideneamino]guanidine; HMS2089G13; 2,6-Dichlorobenzylideneaminoguanidine; EINECS 225-750-8; C07034; Guanidine, ((2,6-dichlorobenzylidene)amino)- (8CI); NSC68982; NSC-68982; BRD-K67847053-015-08-8; LS-175166; Wy-8678; Wy 8678 base; Guanabenz [USAN:INN]; BSPBio_000052; N-((2,6-Dichlorobenzylidene)amino)guanidine; 23256-50-0 (monoacetate); Prestwick3_000096; Prestwick2_000096; N-(2,6-Dichlorobenzylidene)-N'-amidinohydrazine; T6332738; LS-187161; CHEMBL420; NCGC00024846-04; Guanabenz monoacetate; AR-1J2045; Guanabenz acetate; [(2,6-Dichlorobenzylidene)amino]guanidine; Guanabenzo [INN-Spanish]; DB00629; C8H8Cl2N4; D04375; BR-750; ((2,6-Dichlorobenzylidene)amino)guanidine; Guanabenzum; CHEBI:101202; L000834; Hydrazinecarboximidamide, 2-[(2,6-dichlorophenyl)methylene]-; AC1NWAN0; Wytensin; NCGC00024846-05; AC1Q3P2X; Guanabenz (USAN/INN); Guanidine, ((2,6-dichlorobenzylidene)amino)-; Guanabenzo; MolPort-001-835-432; BPBio1_000058; NCGC00024846-02; guanabenz; Guanabenzum [INN-Latin]; 2-((2,6-Dichlorophenyl)methylene)-hydrazinecarboximidamide; Wy 8678; Guanabenz(USAN); Lopac0_000601	5051-62-7	3517	9246	TTDS00031	Alpha-2 adrenergic receptor	Alpha(2)-adrenoceptor	N/A	N/A	N/A	agonist
DAP001470	Dexamfetamine	dextroamphetamine; D-Amphetamine; (2S)-(+)-Amphetamine; (+/-)-beta-Phenylisopropylamine; DB01576; CID5826; (S)-alpha-Phenylethylamine; S(+)-Amphetamine; DEA No. 1100; Simpatedrin; Dexamfetamine (INN); (S)-alpha-Methylphenethylamine; Raphetamine; Fenylo-izopropylaminyl; Sympamin; (S)-1-Phenyl-2-propylamine; Rhinalator; Phenethylamine, alpha-methyl-, d-; Propisamine; Benzedrine; dextro-Amphetamine; (+)-alpha-Methylphenylethylamine; CHEMBL612; (S)-Amphetamine; Dexamfetamina [INN-Spanish]; LS-187774; EINECS 200-112-1; Dexamfetaminum; D-alpha-methylphenethylamine; Dexamfetamine; alpha-Methylphenethylamine, d-form; Sympamine; Benzeneethanamine, alpha-methyl-, (S)-; D-(+)-Amphetamine; Dexamphetaminum; (S)-(+)-Amphetamine; PDSP2_001495; Dexidrine; (2S)-1-phenylpropan-2-amine; Phenethylamine, alpha-methyl-, (+)-; dl-1-Phenyl-2-aminopropane; D03740; Dextroamphetamine resin complex; MolPort-004-285-839; Isoamycin; (S)-1-Phenyl-2-propanamine; D-(S)-Amphetamine; Dexamphetaminum [INN-Latin]; dl-Benzedrine; (S)-(+)-beta-Phenylisopropylamine; Dexedrine Spansule; dl-Amphetamine; Desamfetamina [DCIT]; Dexamfetamina; (+/-)-Desoxynorephedrine; Benzeneethanamine, alpha-methyl-, (alphaS)-; AC1L1L85; (+/-)-Benzedrine; Dephadren; beta-phenyl-isopropylamine; Psychedrine; NCGC00168247-01; (+)-Phenaminum; PDSP1_001511; D-AM; Benzeneethanamine, alpha-methyl-, (aS)- (9CI); HSDB 3055; BRN 2205872; Dexadrine; NSC 73713; Dexedrine; Amsustain; Dextroamphetamine [USAN]; D-2-Amino-1-phenylpropane; D-1-Phenyl-2-aminopropane; Dexacaps; Dexamphetamine; C07884; Sympatedrine; d-1-Phenyl-2-aminopropan [German]; Dextro-Amphetamine Sulfate; (alphaS)-alpha-methylbenzeneethanamine; 4-12-00-02587 (Beilstein Handbook Reference); Dextroamphetamine (USAN); Dexanfetamina [INN-Spanish]; Desamfetamina; CHEBI:4469; (+)-(S)-Amphetamine; Dexanfetamina; (S)-alpha-methylbenzeneethanamine; Weckamine; Dexamfetaminum [INN-Latin]; 51-64-9; (S)-1-Phenyl-2-aminopropane; (+)-Amphetamine; (+)-alpha-Methylphenethylamine; D-1-Phenyl-2-aminopropan; DB00182; Phenethylamine, alpha-methyl-, (+)- (8CI); LS-103617; UNII-TZ47U051FI	51-63-8	16077373	46506252	TTDS00031	Alpha-2 adrenergic receptor	Alpha(2)-adrenoceptor	N/A	N/A	N/A	agonist
DAP000902	Nicergoline	BPBio1_000280; HMS2092F07; Spectrum2_001414; Nicergoline [USAN:BAN:INN:JAN]; KBio3_002787; QTL1_000060; Nargoline; Nicergolinum; HMS1568M16; Ergoline-8beta-methanol, 10-methoxy-1,6-dimethyl-, 5-bromonicotinate (ester); NSC 150531; HMS1923O09; BSPBio_000254; Nimergoline base; KBioSS_001850; RP 19651; 10-Methoxy-1,6-dimethylergoline-8beta-methanol 5-bromonicotinate (ester); LS-64447; Ergoline-8beta-methanol, 10-methoxy-1,6-dimethyl-, 5-bromonicotinate (ester) (8CI); BSPBio_003533; Ergoline-8-methanol, 10-methoxy-1,6-dimethyl-, 5-bromo-3-pyridinecarboxylate (ester), (8beta)-; Sermion (TN); AC1L1QT0; HMS2089I03; Spectrum_001370; Spectrum3_001933; N7889_FLUKA; 8-beta-((5-Bromonicotinoyloxy)methyl)-1,6-dimethyl-10-alpha-methoxyergoline; CID34040; 5-Bromonicotinic acid 10-methoxy-1,6-dimethylergoline-8-methyl ester; 10-Methoxy-1,6-dimethyl-ergolin-8-beta-methanol-(5-bromnicotinat); Nicergolina; 27848-84-6; Prestwick1_000147; I06-1875; BRD-K76810206-001-05-7; Nicergoline (JP15/USAN/INN); Nicergolin; AKOS005067888; Spectrum5_001352; SPBio_002193; Prestwick0_000147; D01290; HMS500G06; EINECS 248-694-6; Ergoline-8-beta-methanol, 10-methoxy-1,6-dimethyl-, 5-bromo-3-pyridinecarboxylate (ester); 1-Methyl-lumilysergol 8-(5-bromonicotinate) 10-methyl ether; KBio2_004418; 10-Methoxy-1,6-dimethyl-ergolin-8-beta-methanol-(5-bromnicotinat) [German]; NCGC00024678-02; 10-Methoxy-1,6-dimethylergoline-8-methanol 5-bromo-3-pyrindinecarboxylate (ester); Nimergoline; Nicergolin [German]; N7889_SIGMA; Nicotergoline; Nicergolina [DCIT]; IDI1_000124; SPBio_001488; Ergoline-8-beta-methanol, 10-methoxy-1,6-dimethyl-, 5-bromonicotinate (ester); nicergoline; C24H26BrN3O3; Ergoline-8-methanol, 10-methoxy-1,6-dimethyl-, (8beta)-, 5-bromo-3-pyridinecarboxylate (ester); Prestwick3_000147; KBio1_000124; BRN 4828393; Nicergolinum [INN-Latin]; (+)-10-Methoxy-1,6-dimethylergoline-8-beta-methanol 5-bromonicotinate; F.I. 6714; Prestwick2_000147; DivK1c_000124; Bio-0069; 10-Methoxy-1,6-dimethylergoline-8beta-methanol 5-bromonicotinate; Spectrum4_000440; KBio2_006986; DB00699; KBio2_001850; MolPort-002-513-778; Sermion; MNE; NINDS_000124; KBioGR_000800; FI 6714; SPECTRUM1501133; NCGC00024678-03	27848-84-6	34040	175827	TTDS00031	Alpha-2 adrenergic receptor	Alpha(2)-adrenoceptor	N/A	N/A	N/A	antagonist
DAP000087	Yohimbine	Aphrosol; NCGC00025018-05; Johimbin; Yohimban-16-alpha-carboxylic acid, 17-alpha-hydroxy-, methyl ester; SPBio_002647; Yocon; methyl (16alpha,17alpha)-17-hydroxyyohimban-16-carboxylate; (16alpha,17alpha)-17-Hydroxy-yohimban-16-carboxylic acid methyl ester; CID8969; Baron-X; Prestwick0_000584; KBio3_001032; Yohimban-16-carboxylic acid, 17-hydroxy-, methyl ester, (16alpha,17alpha)- (9CI); C09256; Bio1_000455; APHRODINE; KBio2_000576; BPBio1_000472; KBio3_001031; KBio2_005712; NCGC00025018-06; AC1L1S1D; 4-25-00-01237 (Beilstein Handbook Reference); Yohimban-16alpha-carboxylic acid, 17alpha-hydroxy-, methyl ester (8CI); CHEBI:10093; Yohimbine; SMR000058527; Benz[g]indolo[2,3-a]quinolizine, yohimban-16-carboxylic acid deriv.; HMS1990N17; IDI1_002213; Dayto himbin; HMS2089G19; (16alpha,17alpha)-17-hydroxyyohimban-16-carboxylic acid methyl ester; 146-48-5; DB01392; Yohimbine (DCF); CHEMBL15245; Prestwick1_000584; nchembio705-2; I14-13374; SMR000470778; Bio1_000944; 65-19-0; BRD-K35586044-001-02-6; InChI=1/C21H26N2O3/c1-26-21(25)19-15-10-17-20-14(13-4-2-3-5-16(13)22-20)8-9-23(17)11-12(15)6-7-18(19)24/h2-5,12,15,17-19,22,24H,6-11H2,1H3/t12?,15?,17?,18-,19+/m0/s; (+)-Yohimbin; Actibine; BRN 0097276; MLS001333983; (+)-Yohimbine; EINECS 205-672-0; 17alpha-hydroxyyohimban-16alpha-carboxylic acid methyl ester; STOCK1N-51304; LS-162738; Yoman; Bio2_000458; HMS1792N17; 2-Hydroxy-1,2,3,4,4a,5,7,8,13,13b,14,14a-dodecahydro-indolo[2',3':3,4]pyrido[1,2-b]isoquinoline-1-carboxylic acid methyl ester; NSC19509; MolPort-001-794-653; Yohimbic acid methyl ester; Thybine; KBioSS_000576; BRD-K35586044-003-03-0; nchembio.188-comp13; Yovital; KBio2_003144; Yohimban-16-.alpha.-carboxylic acid, 17-.alpha.-hydroxy-, methyl ester; BCBcMAP01_000032; Bio1_001433; Yohimar; Quebrachine; Aphrodyne; Prestwick3_000584; HMS1362N17; SMP1_000320; methyl 17alpha-hydroxyyohimban-16alpha-carboxylate; Prestwick2_000584; KBioGR_000576; 17-Hydroxyyohimban-16-carboxylic acid methyl ester; Corynine; Yohimbol-16alpha-carboxylic acid, methyl ester (6CI); UNII-2Y49VWD90Q; BSPBio_000428; 17-Hydroxy-yohimbane-16-carboxylic acid methyl ester; Lopac0_001210; Bio2_000938; NCGC00025018-07; Yohimex; trans-Quinolizidine yohimbine; Yohimban-16-carboxylic acid, 17-hydroxy-, methyl ester, (16alpha,17alpha)-; D08685; Quebrachin; MLS000728591; BSPBio_001236; Yohimbin	146-48-5	8969	11447	TTDS00031	Alpha-2 adrenergic receptor	Alpha(2)-adrenoceptor	N/A	N/A	N/A	antagonist
DAP000064	Lofexidine	AC1L1K1D; DB04948; Lofexidinum; CHEMBL17860; Lofexidinum [INN-Latin]; CID30668; Britlofex; 2-Imidazoline 2-(1-(2,6-dichlorophenoxy)ethyl)-; Lofexidine [INN:BAN]; CHEBI:51368; D08141; AC1Q3Q8L; 1H-Imidazole, 2-(1-(2,6-dichlorophenoxy)ethyl)-4,5-dihydro-; 2-(a-(2,6-dichlorophenoxy)ethyl)2-imidazoline; Lofexidina; 1H-Imidazole, 2-(1-(2,6-dichlorophenoxy)ethyl)-4,5-dihydro- (9CI); Lofexidine; 2-[1-(2,6-dichlorophenoxy)ethyl]-4,5-dihydro-1H-imidazole; MolPort-003-848-405; 2-(alpha-(2,6-dichlorophenoxy)ethyl) delta-2-imidazoline; 21498-08-8 (mono-hydrochloride); 31036-80-3; 2-(1-(2,6-Dichlorophenoxy)ethyl)-4,5-dihydro-1H-imidazole; HMS2090C03; 2-{1-[(2,6-dichlorophenyl)oxy]ethyl}-4,5-dihydro-1H-imidazole; LS-79612; 2-(alpha-(2,6-Dichlorophenoxy)ethyl)2-imidazoline; Lofexidina [INN-Spanish]; C11H12Cl2N2O; Lofexidine (INN)	31036-80-3	30668	14774610	TTDS00031	Alpha-2 adrenergic receptor	Alpha(2)-adrenoceptor	N/A	N/A	N/A	agonist
DAP000901	Ergoloid mesylate	Hydergin; Dihydroergotoxine methanesulphonate; CID592735; Trigot; Dihydroergotoxin methanesulfonate; AC1LC1K5; Ergoloid mesylate; Dihydroergotoxin mesylate; Alkergot; Ischelium; Redergin; Dihydroergotoxine methanesulfonate; Hydergine LC; Deapril-ST; Dihydroergotoxin Mesilat; DB01049; Circanol; Ergoloid Mesylates [USAN]; Hydrogenated Ergot Alkaloids; Gerimal	8067-24-1	592735	10422210	TTDS00031	Alpha-2 adrenergic receptor	Alpha(2)-adrenoceptor	N/A	N/A	N/A	antagonist
DAP000234	Tizanidine	STK711168; AC1L1KGE; STOCK6S-26959; NCGC00160529-04; BRN 0618691; 5-Chloro-4-(2-imidazolin-2-ylamino)-2,1,3-benzothiadiazole; I01-2529; C07452; 2,1,3-Benzothiadiazole-4-amine, 5-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-; Tizanidine [INN:BAN]; tizanidine; CHEMBL1079; 2,1,3-Benzothiadiazole, 5-chloro-4-(2-imidazolin-2-ylamino)-; Tizanidinum; 5-chloro-4-(2-imidazolin-2-yl-amino)-2,1,3-benzothiadiazole; 2,1,3-Benzothiadiazol-4-amine, 5-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-; 5-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-2,1,3-benzothiadiazol-4-amine; HMS2089B03; NCGC00160529-05; NCGC00160529-01; DB00697; Tizanidinum [INN-Latin]; LS-40470; Sirdalud (TN); L001084; MolPort-002-508-203; Tizanidina; Tizanidina [INN-Spanish]; CHEBI:240117; NCGC00160529-02; C9H8ClN5S; Ternelin; 51322-75-9; CID5487; BIDD:GT0580; ZINC19702309; NCGC00160529-03; 64461-82-1 (mono-hydrochloride); D08611; Sirdalud; Tizanidine (INN); UNII-6AI06C00GW	51322-75-9	5487	180932	TTDS00031	Alpha-2 adrenergic receptor	Alpha(2)-adrenoceptor	N/A	N/A	N/A	agonist
DCL001136	ADX415	N/A	N/A	N/A	N/A	TTDS00031	Alpha-2 adrenergic receptor	Alpha(2)-adrenoceptor	N/A	N/A	N/A	antagonist
DCL000841	Idazoxan	Idazoxano [Spanish]; 2-(2,3-dihydro-1,4-benzodioxin-3-yl)-4,5-dihydro-1H-imidazole; Idazoxan [BAN:INN]; 4,5-dihydro-2-(2,3-dihydro-1,4-benzodioxin-2-yl)-1H-imidazole; NCGC00024794-03; Potassium dicopper trichloride; AB00514632; Idazoxanum; Prestwick1_000926; nchembio705-12; 79944-58-4; AC1L1H1U; BPBio1_000916; ST51055467; C10968; I14-6697; Prestwick0_000926; CID54459; Prestwick2_000926; (+-)-2-(1,4-Benzodioxan-2-yl)-2-imidazoline; Idazoxane; L000808; BSPBio_000832; CHEBI:5862; LS-78447; SPBio_003011; NCGC00024794-04; NCGC00015560-08; Idazoxane [French]; Prestwick3_000926; 2-(2,3-Dihydro-1,4-benzodioxin-2-yl)-4,5-dihydro-1H-imidazole; CHEMBL10316; 1H-Imidazole, 4,5-dihydro-2-(2,3-dihydro-1,4-benzodioxin-2-yl)-; Idazoxano; IDAZOXAN; BRD-A18696154-003-03-6; Lopac0_000652; HMS2089E14; RX-781094; Idazoxanum [Latin]	79944-56-2	54459	10486812	TTDS00031	Alpha-2 adrenergic receptor	Alpha(2)-adrenoceptor	N/A	N/A	N/A	antagonist
DAP000900	Guanfacine	Prestwick3_000339; NCGC00024950-03; DB01018; D08031; C9H9Cl2N3O; G1043_SIGMA; EINECS 249-442-8; LS-174236; UNII-30OMY4G3MK; SPD 503; Lopac-G-1043; L013430; Guanfacina; 29110-48-3 (mono-hydrochloride); Intuniv; CID3519; Prestwick1_000339; CHEMBL862; BPBio1_000415; NCGC00024950-02; N (Aminoiminomethyl)-2,6-dichlorobenzeneacetamide; NCGC00015469-02; Lopac0_000519; BRD-K32830106-003-03-0; NCGC00015469-01; Lon798; C07037; Tocris-1030; CAS-29110-48-3; Benzeneacetamide, N-(aminoiminomethyl)-2,6-dichloro-; Prestwick2_000339; Estulic (TN); GUANFACINE; ZINC03872738; Guanfacina [INN-Spanish]; Estulic; Prestwick0_000339; Guanfacinum [INN-Latin]; Guanfacine (INN); BSPBio_000377; L000286; Guanfacine Monohydrochloride; 29110-47-2; AC1L1G4B; N-(diaminomethylidene)-2-(2,6-dichlorophenyl)acetamide; NCGC00024950-01; NCGC00015469-06; MolPort-003-941-447; SPBio_002298; Guanfacine [INN:BAN]; Guanfacinum	29110-47-2	3519	176213	TTDS00031	Alpha-2 adrenergic receptor	Alpha(2)-adrenoceptor	N/A	N/A	N/A	agonist
DAP000236	Apraclonidine	MolPort-005-933-986; Lopac-A-0779; C07668; 2-(4-amino-2,6-dichloro)phenyliminoimidazolidine; Iopidine Eye; Apraclonidine [INN:BAN]; Iopidine (TN); ZINC00020231; MolPort-003-940-020; Lopac0_000033; CHEBI:2788; Apraclonidina; DB00964; D07461; CHEBI:127495; L013394; 4-Aminoclonidine; C9H10Cl2N4; 2-(4-Amino-2,6-dichloroanilino)-2-imidazoline hydrochloride; 2,6-dichloro-N(1)-(4,5-dihydro-1H-imidazol-2-yl)benzene-1,4-diamine; CID2216; NCGC00015033-03; 1,4-Benzenediamine, 2,6-dichloro-N'-(4,5-dihydro-1H-imidazol-2-yl)-; 66711-21-5; AC1L1D6L; UNII-843CEN85DI; Apraclonidine (INN); ALO 2145; NCGC00162050-01; AC-12697; Apraclonidinum [INN-Latin]; CHEMBL647; PDSP2_000778; 2,6-dichloro-1-N-(4,5-dihydro-1H-imidazol-2-yl)benzene-1,4-diamine; NCGC00015033-01; SMP1_000016; para-aminoclonidine; Apraclonidinum; LS-176536; apraclonidine; Aplonidine; Iopidine; A0779_SIGMA; PDSP1_000790; Apraclonidina [INN-Spanish]; L000686; p-aminoclonidine	66711-21-5	2216	9870	TTDS00031	Alpha-2 adrenergic receptor	Alpha(2)-adrenoceptor	N/A	N/A	N/A	agonist
DAP000235	Oxymetazoline	Afrin Original 12 Hour Pump Mist; oxymeta zoline; NCGC00022345-04; NCGC00022345-05; D08322; KBio2_006667; Visine L.R; IDI1_000567; KBioSS_001531; DB00935; UNII-8VLN5B44ZY; Spectrum5_001114; Oxymetazoline (INN); Prestwick3_000224; Vicks Sinex 12 Hour Ultra Fine Mist for Sinus Relief; FT-0082560; Afrin Extra Moisturizing 12 Hour Nasal Spray; Spectrum_001051; BRD-K16195444-001-01-7; Iliadin; NINDS_000567; 3-[(4,5-Dihydro-1H-imidazol-2-yl)methyl]-6-(1,1-dimethylethyl)-2,4-dimethylphenol; Oxymethazoline; Afrin Original 12 Hour Nasal Spray; AC-6370; NCGC00015766-02; Oximetazolina [INN-Spanish]; 3-(4,5-dihydro-1H-imidazol-2-ylmethyl)-2,4-dimethyl-6-tert-butyl-phenol; Phenol, 6-tert-butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethyl- (7CI,8CI); CAS-151615; BSPBio_000267; NCGC00015766-03; Vicks Sinex 12 Hour Nasal Spray; SPBio_001095; Genasal Nasal Spray Up to 12 Hour Relief; Drixoral Nasal Solution; Lopac0_000903; KBioGR_000908; Operil (TN); Neo-Synephrine 12 Hour Spray; Afrin Sinus 12 Hour Nasal Spray; Phenol, 3-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-6-(1,1-dimethylethyl)-2,4-dimethyl- (9CI); Hazol; Nasal Relief 12 Hour Nasal Spray; EINECS 216-079-1; Oxymetazolinum; Phenol, 6-t-butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethyl-; 6-tert-Butyl-3-(4,5-dihydro-1H-imidazol-2-ylmethyl)-2,4-dimethylphenol; Oximetazolinum; BSPBio_002145; KBio3_001645; 1491-59-4; Navisin; SPBio_002188; D010109; Tocris-1142; CID4636; Phenol, 6-tert-butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethyl-; oxymetazoline hydrochloride crystalline; Oxylazine; HMS2089G03; 2-(4-tert-Butyl-2,6-dimethyl-3-hydroxybenzyl)-2-imidazoline; CHEMBL762; Duramist Plus Up To 12 Hour Nasal Decongestant Spray; Oximetazolina; Dristan Long Lasting Nasal Mist; Navasin; BPBio1_000419; KBio2_001531; Nostrilla 12 Hour Nasal Decongestant; Afrin Cherry 12 Hour Nasal Spray; NCGC00022345-06; BPBio1_000295; Sinerol; H 990; LS-104146; KBio1_000567; 6-tert-Butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethylphenol; Prestwick0_000224; NCGC00022345-02; Oxymetazolinum [INN-Latin]; Nafrine; Lopac-O-2378; Spectrum3_000533; BRN 0886303; CHEBI:142520; Oxymetazoline [INN:BAN]; Dristan Long Lasting Mentholated Nasal Spray; Spectrum2_000998; Prestwick2_000224; Prestwick1_000224; MolPort-002-538-313; L000459; Visine L.R.; KBio2_004099; NCGC00015766-10; 6-t-Butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethylphenol; Rhinolitan; nchembio705-11; Afrin Original 12 Hour Nose Drops; Rhinofrenol; C07363; Nezeril; NCGC00015766-01; Spectrum4_000464; Phenol, 3-((4,5-dihydro-1H-imidazol-2-yl)methyl)-6-(1,1-dimethylethyl)-2,4-dimethyl-; DivK1c_000567; oxymetazoline; Oxymetozoline; HSDB 3143; AC1L1IM1; Phenol, 3-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-6-(1,1-dimethylethyl)-2,4-dimethyl-; Biomol-NT_000161	1491-59-4	4636	9567	TTDS00031	Alpha-2 adrenergic receptor	Alpha(2)-adrenoceptor	N/A	N/A	N/A	agonist
DAP000230	Meperidine	D008614; IDI1_000983; HSDB 3116; Pethidinum; Ethyl 1-methyl-4-phenylisonipecotate; LS-85121; Pethidine (INN); 610593_ALDRICH; 1-Methyl-4-phenylpiperidine-4-carboxylic acid ethyl ester; CID4058; Meperidol; Operidine EPJ-I; Ethyl 1-methyl-4-phenylpiperidine-4-carboxylate; 1-Methyl-4-phenyl-piperidin-4-carbon-saeure-aethylester [German]; Pethidineter; Pethanol; Dolosal; C07128; 50-13-5 (hydrochloride); meperidine; 610593_FLUKA; Operidine EPJ I; DB00454; Piperosal; DivK1c_000983; Methyl phenylpiperidine carbonic acid ethyl ester; Lydol; Demarol; 1-Methyl-4-phenyl-4-piperidinecarboxylic acid ethyl ester; EINECS 200-329-1; Dolsin; Pipersal; Isonipecain; YIsonipecotic acid, 1-methyl-4-phenyl-, ethyl ester (8CI); 57-42-1; AC1L1HBJ; Demerol; Petidina [INN-Spanish]; Pethidine DBL (TN); N-Methyl-4-phenyl-4-carbethoxypiperidine; MolPort-001-785-564; Phetidine; CHEBI:122528; 4-Piperidinecarboxylic acid, 1-methyl-4-phenyl-, ethyl ester; KBio1_000983; NINDS_000983; Pethidine; D08343; UNII-9E338QE28F; DEA No. 9230; 4-Carbethoxy-1-methyl-4-phenylpiperidine; Meperidine solution; Pethidinum [INN-Latin]; Nemerol; Lidol; 1-Methyl-4-phenyl-piperidin-4-carbon-saeure-aethylester; Pethidine DBL; Petydyna [Polish]; Petydyna; L000908; 1-Methyl-4-phenylisonipecotic acid, ethyl ester; CHEMBL607; Isonipecotic acid, 1-methyl-4-phenyl-, ethyl ester; Dolcontral; Petidina; Pethidin; Isonipecaine	57-42-1	4058	148822	TTDS00031	Alpha-2 adrenergic receptor	Alpha(2)-adrenoceptor	N/A	N/A	N/A	agonist
DAP000233	Dexmedetomidine	Tocris-2023; MPV-1440; Dexmedetomidinum; CHEMBL778; C07450; (+)-4-((S)-alpha,2,3-Trimethylbenzyl)imidazole; Dexmedetomidine (USAN/INN); DEXMEDETOMIDINE; ZINC04632106; Dexmedetomidina; 4-[(1S)-1-(2,3-dimethylphenyl)ethyl]-1H-imidazole; D00514; 113775-47-6; AC1NSJXT; CID5311068; MPV 1440; NCGC00025347-01; Precedex (TN); 5-[(1S)-1-(2,3-dimethylphenyl)ethyl]-1H-imidazole; CHEBI:4466	113775-47-6	68602	9653	TTDS00031	Alpha-2 adrenergic receptor	Alpha(2)-adrenoceptor	N/A	N/A	N/A	agonist
DAP000965	Collagenase	N/A	9001-12-1	N/A	4074	TTDS00434	Collagen	N/A	N/A	N/A	N/A	N/A
DAP000966	Vitamin C	88845-26-5; Planavit C; BPBio1_000363; Semidehydroascorbate; Catavin C; Proscorbin; A0278_SIGMA; Colascor; 47863_SUPELCO; NSC 33832; Vitacee; A7506_SIGMA; Ce-Mi-Lin; Ascorbajen; Ascorbicap (TN); ascorbic acid; ascor-b.i.d; 2-(1,2-Dihydroxyethyl)-4,5-dihydroxyfuran-3-one; NCI-C54808; Cetane-Caps TC; Sunkist; Natrascorb; C-Span; C-Level; C-Vimin; component of Endoglobin Forte; Viforcit; nchembio821-comp9; A2218_SIGMA; Ascoltin (TN); Iron(II) ascorbate; l-threo-hex-1-eofuranos-3-ulose; 95212_FLUKA; Liqui-Cee; Ascorbicap; C-Long; AC1Q77S6; Ascorbicin; (2R)-2-[(1S)-1,2-dihydroxyethyl]-4,5-dihydroxyfuran-3-one; Acide ascorbique [INN-French]; DB00126; Vicomin C; nchembio.92-comp2; L-threo-hex-2-enono-1,4-lactone; Cantan; Viscorin; AB00376923; Cegiolan; CHEBI:29073; Cevex; 33034_RIEDEL; NCGC00164357-01; 885512-24-3; Xitix; l-ascorbic acid; Ascorb; 33034_SIAL; Cantaxin; Cetamid; Laroscorbine; FEMA No. 2109; 95210_SIAL; Cetane-Caps TD; 882690-91-7; Duoscorb; Ceglion; 95210_FLUKA; 47A605F0-4187-47A8-B0CE-F9E7DA1B0076; Kyselina askorbova; Cecon; Acidum ascorbinicum; 14536-17-5; Cemagyl; Cevitamin; Ambap36431-82-0; L-Ascorbic acid; L-threo-ascorbic acid; 50-81-7; (2R)-2-[(1S)-1,2-Dihydroxyethyl]-4,5-dihydroxy-furan-3-one; D00018; C6H8O6; component of Ferancee; EINECS 200-066-2; vitamin C; 89924-69-6; Ascorbutina; UNII-PQ6CK8PD0R; L-Ascorbic acid, free radical form; 129940-97-2; Cergona; Ascorteal; Scorbacid; L-Xyloascorbic acid; Hicee; C-Quin; Ascorbinsaeure; Dora-C-500; 56172-55-5; AC1L1L4T; Meri-C; ascorbate; A5960_SIGMA; component of E and C-Level; A92902_SIAL; Cevi-Bid; Cebion; Sodascorbate; nchembio.89-comp1; Vitamisin; Vitace; L-3-ketothreohexuronic acid; Caswell No. 061B; 57304-74-2; Stuartinic; Vicelat; HSDB 818; AR-1J3435; Cee-Vite; Arco-cee; Cevalin; Concemin; 95209_FLUKA; Cevitan; Vicin; Magnorbin; Cebid; Acid Ascorbic; AB1002440; Xyloascorbic acid, L-; A92902_ALDRICH; L-Threoascorbic acid; Cevitamic acid; Sodium Ascorbate (Ascorbic Acid); Lemascorb; Ascorin; CCRIS 57; 57606-40-3; Ascorbicab; L-ascorbate; Acido ascorbico [INN-Spanish]; 884381-69-5; Vitamin-?C; Ascorbic Acid, Monosodium Salt; Secorbate; L-3-Ketothreohexuronic acid lactone; Ascorbic acid (JP15/USP/INN); 50976-75-5; 95209_SIGMA; Cipca; Prestwick3_000325; CE-VI-Sol; Ascorvit; A4403_SIGMA; W210901_ALDRICH; A2343_SIGMA; Cevimin; Celin; Natrascorb injectable; L-(+)-Ascorbic Acid; Cewin; Adenex; Acidum ascorbicum [INN-Latin]; Cevital; Ascoltin; cevibid; NCGC00091517-01; antiscorbic vita min; Tolfrinic; Vitamin- C; Cevitex; Cevatine; Cetemican; NCGC00091517-02; L-Lyxoascorbic acid; 3-Oxo-L-gulofuranolactone (enol form); Roscorbic; Antiscorbutic factor; Hybrin; Citriscorb; L-threo-Hex-2-enonic acid, gamma-lactone; SMR001233160; Kyselina askorbova [Czech]; 259133-78-3; Allercorb; Antiscorbic vitamin; Cenetone; Ferrous ascorbate; Celaskon; LS-145; 56533-05-2; Magnesium Ascorbicum; 30208-61-8; 623158-95-2; C00072; CID5785; Ascor-B.I.D.; 6730-29-6; Vitacin; Ascorbyl radical; Acido ascorbico; Scorbu-C; A2174_SIGMA; BSPBio_000329; 134-03-2 (monosodium salt); Cebicure; 3-Keto-L-gulofuranolactone; Cemill; Cenolate; 255564_SIAL; MLS002153776; Cereon; Acide ascorbique; IDO-C; cee-caps  td; Davitamon C; bmse000182; roscorbi c; Testascorbic; Cebione; Vitacimin; (5R)-5-[(1S)-1,2-dihydroxyethyl]-3,4-dihydroxyfuran-2(5H)-one; Ciamin; Hex-2-enonic acid gamma-lactone, L-threo-; Acidum ascorbicum; L(+)-Ascorbic acid; L-Threoascorbic acid; Antiscorbutic factor; Vitamin C; 3-Oxo-L-gulofuranolactone; Cescorbat; Ascorbic acid [BAN:INN:JAN]; MolPort-001-792-501; Vitascorbol; Ribena; 154170-90-8; Cee-Caps TD; Iron-ascorbic acid complexes; Redoxon; Ascorbic acid [INN:BAN:JAN]; CHEMBL196; Cortalex; Cetebe; Monodehydroascorbic acid; nchembio.174-comp5; Ce lent; Ferancee; A0537; component of Cortalex; A4544_SIGMA; Antiscorbutic vitamin; Oral Vitamin C	50-81-7	5785	597821	TTDS00434	Collagen	N/A	N/A	N/A	N/A	activator
DCL001258	XL652/XL014	N/A	N/A	N/A	N/A	TTDR00911	Oxysterols receptor LXR	Liver x receptor;Nuclear orphan receptor LXR	N/A	N/A	N/A	modulator
DAP001315	Glatiramer Acetate	Glatiramer acetate [USAN]; LS-71889; Copolymer-1; Aventis brand of copolymer 1; CID3081884; TV5010; TV-5010; C089995; Copolymer 1; Glatiramer acetate; LS-186971; L-Glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt); 147245-92-9; acetic acid; (2S)-2-amino-3-(4-hydroxyphenyl)propanoic acid; (2S)-2-aminopentanedioic acid; (2S)-2-aminopropanoic acid; (2S)-2,6-diaminohexanoic acid; UNII-5M691HL4BO; Teva brand of copolymer 1; AC1MIXQC; TV 5010; COP-1; Copaxone; L-Glutamic acid peptide with L-alanine, L-lysine and L-tyrosine, acetate (salt)	147245-92-9	3081884	14863134	TTDS00471	HLA class II histocompatibility antigen, DRB1-1	DR1;DR-1;HLA-DRB1;MHC class I antigen DRB1*1	P04229	N/A	ENSG00000196126	binder
DAP000060	Adefovir Dipivoxil	AC-1693; DB00718; CHEMBL922; 9-(2-((-Bis((pivaloyloxy)methoxy)phosphinyl)methoxy)ethyl)adenine; ZINC03930376; Adefovir dipivoxil (USAN); Propanoic acid, 2,2-dimethyl-, (((2-(6-amino-9H-purin-9-yl)ethoxy)methyl)phosphinylidene)bis(oxymethylene) ester; Hepsera; Propanoic acid,2,2-dimethyl-(((2-(6-amino-9H-purin-9-yl)ehtoxy)mehtyl)phosphinyldiene)bis(oxymehtylene)ester; Preveon; GS-840; Hepsera (TM); MolPort-003-986-417; GS 840; Hepsera (TN); [2-(6-aminopurin-9-yl)ethoxymethyl-(2,2-dimethylpropanoyloxymethoxy)phosphoryl]oxymethyl 2,2-dimethylpropanoate; LS-173141; adefovir depivoxil; Adefovir pivoxil; Bis(pivaloyloxymethyl)-9-(2-phosphonylmethoxyethyl)adenine; Bis-POM PMEA, Preveon, Hepsera, Adefovir Dipivoxil; AKOS005145737; Bis-POM PMEA, Adefovir Dipivoxil; YouHeDing; 142340-99-6; (((2-(6-Amino-9H-purin-9-yl)ethoxy)methyl)phosphinylidene)bis(oxymethylene) 2,2-dimethylpropanoate; AC1L1U36; 9-(2-((Bis((pivaloyloxy)methoxy)phosphinyl)methoxy)ethyl)adenine; CID60871; bis-POM PMEA; ADEFOVIR DIPIVOXIL; Bis(POM)-PMEA; UNII-U6Q8Z01514; I06-1150; Bis(pom)PMEA; GS 0840; NCGC00164624-01; GS-0840; C20H32N5O8P; ((2-(6-Amino-9H-purin-9-yl)ethoxy)methyl)phosphonic acid, diester with hydroxymethyl pivalate; FT-0082875; Adefovirdipivoxl; Ambap142340-99-6; D01655; I14-3234; Adefovir pivoxil (JAN); TL8000938; Piv2PMEA; S1718_Selleck	142340-99-6	60871	7848718	TTDS00309	HBV polymerase	N/A	Q67889	N/A	N/A	inhibitor
DAP000697	Entecavir	MolPort-005-942-963; 209216-23-9; SBB066120; DB00442; FT-0083013; AB1004838; SQ-34676; 142217-69-4; AC1L4BEC; CID153941; CHEBI:473990; AC-1593; ZINC03802690; Entecavir hydrate; D07896; S2128_Selleck; Baraclude (TN); Entecavir (USAN); ETV; Entecavir; Entecavir hydrate (JAN); TL8000933; BMS-200475; 2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl]-1,9-dihydro-6H-purin-6-one--water (1/1); Entecavir (INN); CHEBI:59902; Baraclude; D04008; 2-amino-1,9-dihydro-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one; entecavir monohydrate; CHEMBL713; 2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl]-3H-purin-6-one; 6-H-Purin-6-one-,2-amino-1,9-dihydro-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]; 9-((1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl)guanine monohydrate; 2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl]-1,9-dihydro-6H-purin-6-one	142217-69-4	153941	641041	TTDS00309	HBV polymerase	N/A	Q67889	N/A	N/A	inhibitor
DAP000698	Telbivudine	CID159269; LLT; NV 02B; Telbivudine (USAN/INN); LdT; ZINC00002159; AC1L4LJI; Telbivudine [USAN]; S1651_Selleck; L-Thymidine; CHEMBL374731; L-Deoxythymidine; Tyzeka; CHEBI:17748; LDT-600; Epavudine; 2'-Deoxy-L-thymidine; LDT600; Tyzeka, Sebivo, Telbivudine; L-dT; Tyzeka (TN); 1-[(2S,4R,5S)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione; 2,4(1H,3H)-Pyrimidinedione, 1-(2-deoxy-b-L-erythro-pentofuranosyl)-5-methyl-; Telbivudin; Telbivudine; DB01265; beta-L-Thymidine; AC-5632; 1-(2-Deoxy-beta-L-erythro-pentofuranosyl)-5-methylpyrimidine-2,4(1H,3H)-dione; I14-8810; UNII-2OC4HKD3SF; Sebivo; NB 02B; Thymine, 1-(2-deoxy-.beta.-L-erythro-pentofuranosyl)-; D06675; NV-02B; LS-187347; Thymine, 1-(2-deoxy-beta-L-erythro-pentofuranosyl)-; 3424-98-4; LS-186402; 1-(2-Deoxy-beta-L-erythropentafuranosyl)-5-methyl-2,4(1H,3H)-pyrimidinedione	3424-98-4	159269	15220961	TTDS00309	HBV polymerase	N/A	Q67889	N/A	N/A	inhibitor
DAP000167	Lamivudine	HSDB 7155; MLS001424097; HHA & Lamivudine; (-)-BCH-189; (-)-1-[(2R,5S)-2-(Hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine; STK801940; 3TC & SST; Lamivudine [USAN:BAN:INN]; UNII-2T8Q726O95; Epivir(TM); GR 109714X; Lamivudine (JAN/USP/INN); BCH-790; Zefix; SAM002589994; 4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one; LMV; NSC620753; (-)-(2'R,5'S)-1-[2'-Hydroxymethyl-5'-(1,3-oxathiolanyl)]cytosine; 2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (-)(2R,5S) & Galanthus Nivalis Agglutinin (GNA); Lamivir; beta-L-2',3'-Dideoxy-3'-thiacytidine; CHEMBL141; SMR000466319; (-)-BCH 189; GR109714X; (+/-) (Cis)-1-[2-(Hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine; 2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (+/-) (Cis); 3TC, Zeffix, Heptovir, Epivir, Epivir-HBV, Lamivudine; lamivudine; beta-L-3'-Thia-2',3'-dideoxycytidine; Epivir (TN); Epivir-HBV; DTHC; 2(1H)-Pyrimidinone, 4-amino-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-, (2R-cis)-; C8H11N3O3S; Heptovir; DRG-0126; CHEBI:133986; NCGC00159341-04; D019259; NCGC00159341-03; D00353; Lamivudine [USAN:INN:BAN]; DB00709; 3TC & GNA; 3TC and NV-01; (-)-(2'R,5'S)-1-[2'-Hydroxymethyl-5'-(1,3-oxathiolanyl)]cytosine; 2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (-)(2R,5S); (-)-beta-L-2',3'-Dideoxy-3'-thiacytidine; (-)-SddC; AC1L1TZZ; C07065; (-)-(2'R,5'S)-1-[2'-Hydroxymethyl-5'-(1,3-oxathiolanyl)]cytosine; 2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (-)(2R,5S) & Hippeastrum hybrid agglutinin( HHA); GR-109714X; BIDD:GT0033; (-)NGPB-21; 3TC; 2',3' Dideoxy 3' thiacytidine; L0217; AC1Q6C34; Bio-0652; S1706_Selleck; SAM001246582; (-)-1-((2R,5S)-2-(Hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine; MLS000759424; Heptodin; GG-714; Zeffix; Epivir; BCH 189, (-)-; MolPort-002-507-347; LS-2107; CCRIS 9274; 3TC (AIDS INITIATIVE) (AIDS INITIATIVE); 134678-17-4; (-)-2'-Deoxy-3'-thiacytidine; Heptivir; FT-0082667; AC-1416; 4-Amino-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1H)-pyrimidinone; (2R,cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one; 2(1H)-Pyrimidinone, 4-amino-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-; 2(1H)-Pyrimidinone, 4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-; BCH189; HMS2051D21; BCH-189; .beta.-L-(-)-2',3'-dideoxy-3'-thiacytidine & Sho-Saiko-To; Lamivudine & GNA; Lamivudine, (2S-cis)-Isomer; 2',3'-Dideoxy-3'-thiacytidine; ZINC00012346; HHA & 3TC; (+/-)-SddC; CID60825; Hepitec; BCH 189; (+/-)-BCH-189; 480434-79-5; 4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2(1H)-one; 3'-Thia-2',3'-dideoxycytidine; CPD000466319; (+/-)-3TC	134678-17-4	60825	197069	TTDS00309	HBV polymerase	N/A	Q67889	N/A	N/A	inhibitor
DAP000936	Arbutamine	Arbutamine [INN:BAN]; AC1Q7ABI; LS-187279; Genesa; AC1L1TXH; CID60789; LS-172776; 4-[(1R)-1-hydroxy-2-[4-(4-hydroxyphenyl)butylamino]ethyl]benzene-1,2-diol; 130783-37-8; 1,2-Benzenediol, 4-(1-hydroxy-2-((4-(4-hydroxyphenyl)butyl)amino)ethyl)-; DB01102; Arbutaminum [INN-Latin]; CHEBI:50580; CID123639; Arbutamina [INN-Spanish]; ARBUTAMINE; 4-[1-hydroxy-2-[4-(4-hydroxyphenyl)butylamino]ethyl]benzene-1,2-diol; Arbutamina; L001303; 128470-16-6; UNII-B07L15YAEV; AC1L3X0S; 4-[(1R)-1-hydroxy-2-{[4-(4-hydroxyphenyl)butyl]amino}ethyl]benzene-1,2-diol; Arbutaminum	128470-16-6	60789	197034	TTDS00035	Beta adrenergic receptor	Beta-Adrenoceptor	N/A	N/A	N/A	stimulator
DAP000080	Isoproterenol	1,2-Benzenediol, 4-(1-hydroxy-2-((1-methylethyl)amino)ethyl)-, (+-)-; Asiprenol; Isoproterenol Chloride; Aludrine; KBio1_000894; Isopropylnorepinephrine; IDI1_000894; Isonorene; Spectrum2_001061; NSC 9975; Prestwick2_001097; nchembio801-comp2; Neodrenal; KBioSS_001429; Lopac0_000711; .alpha.-(Isopropylaminomoethyl)protocatechuyl alcohol; Dihydroxyphenylethanolisopropylamine; AC1L1GOZ; KBio2_001429; ISOPROP; (+-)-Isoprenaline; 1-(3,4-Dihydroxyphenyl)-2-isopropylaminoethanol; dl-Isopropylnoradrenaline; alpha-(Isopropylaminomethyl)protocatechuyl alcohol; dl-N-Isopropylnoradrenaline; SPBio_001042; 4-(1-Hydroxy-2(isopropylamino)ethyl)-benzene 1,2-diol; isoproterenol; 3,4-Dihydroxy-.alpha.-(isopropylaminomethyl)-benzyl alcohol; Isopropylnoradrenaline; CID3779; 149-53-1; Isoprenalinum [INN-Latin]; NCGC00025274-03; NSC33791; Oprea1_009434; 46388-38-9; (S)-Isoprenaline; l-Isoproterenol; SGCUT00015; KBio3_001428; Isoprenalina [INN-Spanish]; WIN 5162; Bellasthman; Isoprenaline (INN); Epinephrine isopropyl homolog; 1,2-Benzenediol, 4-[1-hydroxy-2-[(1-methylethyl)amino]ethyl]-; EINECS 231-687-7; KBio2_006565; 4-{1-hydroxy-2-[(1-methylethyl)amino]ethyl}benzene-1,2-diol; Spectrum3_000474; Isupren; BENZYL ALCOHOL, 3,4-DIHYDROXY-alpha-((ISOPROPYLAMINO)METHYL)-, (+-)-; NCGC00025274-04; 2964-04-7; (+)-Isoproterenol; 1,2-Benzenediol, 4-(1-hydroxy-2-((1-methylethyl)amino)ethyl)- (9CI); CHEMBL434; neo-Epinine; DivK1c_000894; d-N-Isopropylnorepinephrine; KBio2_003997; (+)-Isoprenaline; Isoprenaline hydrochloride; PDSP2_001409; Isopropylaminomethyl-3,4-dihydroxyphenyl carbinol; DL-Isopropylnorepinephrine; Isuprel Mistometer; Assiprenol; nchembio.307-comp1; Novodrin; Izadrin; Isorenin; Vapo-N-iso; WLN: QR BQ DYQ1MY1&1; Benzyl alcohol, 3,4-dihydroxy-alpha-((isopropylamino)methyl)-; NCGC00015558-08; N-Isopropylnoradrenaline; d-Isopropylarterenol; nchembio882-comp6; Isoprenaline; STOCK1N-00740; BENZYL ALCOHOL, 3,4-DIHYDROXY-alpha-((ISOPROPYLAMINO)METHYL)-, (+)-; Spectrum5_000880; HMS2089A12; NSC9975; (+-)-Isoproterenol; MolPort-001-783-449; LS-42868; Bronkephrine; Aleudrine; 1,2-Benzenediol, 4-(1-hydroxy-2-((1-methylethyl)amino)ethyl)-; Racemic isoproterenol; CCRIS 3081; l-Isopropylnoradrenaline; PDSP1_001425; 1,2-Benzenediol, 4-(1-hydroxy-2-((1-methylethyl)amino)ethyl)-, (S)-; Isopropyl noradrenaline; Protocatechuyl alcohol,.alpha.-(isopropylamino-methyl),-; Isadrine; 3,4-Dihydroxy-.alpha.-[(isopropylamino)methyl]benzyl alcohol; DB01064; D08090; L000936; (S)-(+)-Isoproterenol; DL(+-)-Isoproterenol; dl-Ipr; Norisodrine; 7683-59-2; Vapo-Iso; Racemic isoprenaline; Lomupren; Spectrum4_000024; Aerolone; Isuprel; Aludrin; Prestwick0_001097; BSPBio_002208; Respifral; Isonorin; Prestwick1_001097; NINDS_000894; LS-42866; Isoproterenolum; 1,2-Benzenediol, 4-(1-hydroxy-2-((1-methylethyl)amino)ethyl)-, (S)- (9CI); C07056; d-Isoproterenol; UNII-L628TT009W; 1-(3,4-Dihydroxyphenyl)-2-(isopropylamino)ethanol; LS-42869; 3-13-00-02387 (Beilstein Handbook Reference); Isoproterenol [JAN]; KBioGR_000427; Benzyl alcohol, 3,4-dihydroxy-.alpha.-[(isopropylamino)methyl]-; 4-(1-Hydroxy-2-((1-methylethyl)amino)ethyl)-1,2-benzenediol; AC1Q1QBS; dl-Isadrine; N-Isopropylnorepinephrine; NCGC00162220-01; Spectrum_000949; Asmalar; Proternol; Isoprenalin; Saventrine; d-Isoprenaline; SPBio_003057; Isadrin; Protocatechuyl alcohol, alpha-(isopropylaminomethyl)-; Isopropylarterenol; (-)-Isoproterenol hydrochloride; Medihaler-ISO; ICI 46399; Euspiran; Isopropyladrenaline; Isopropydrin; 3,4-Dihydroxy-alpha-((isopropylamino)methyl)benzyl alcohol; NSC 33791; to_000062; Isopropylaminomethyl(3,4-dihydroxyphenyl)carbinol; N-Isopropyl-beta-dihydroxyphenyl-beta-hydroxyethylamine; (S)-Isoproterenol; BRN 2213857	7683-59-2	3779	9268	TTDS00035	Beta adrenergic receptor	Beta-Adrenoceptor	N/A	N/A	N/A	agonist
DAP000938	Penbutolol	C18H29NO2; Levatolol; CCRIS 2855; (-)-Penbutolol; Betapressin; DB01359; Penbutolol [INN:BAN]; HOE 893d; Paginol; PENBUTOLOL SULFATE; 38363-32-5 (sulfate (2:1) salt); AC1Q59G2; 1-(tert-Butylamino)-3-(o-cyclopentylphenoxy)propan-2-ol; Penbutolol Sulfate (2:1); l-Penbutolol; Levatol; penbutolol; 2-Propanol, 1-(2-cyclopentylphenoxy)-3-((1,1-dimethylethyl)amino)-; BRN 4484348; CHEMBL1290; PDSP1_000056; CID37464; (2S)-1-(tert-butylamino)-3-(2-cyclopentylphenoxy)propan-2-ol; CHEMBL87418; C07416; UNII-78W62V43DY; Penbutololum; Levopenbutol; 2-Propanol, 1-(2-cyclopentylphenoxy)-3-((1,1-dimethylethyl)amino)-, (S)-; Penbutololum [INN-Latin]; AC1L1XS5; Penbutolol (INN); LS-122000; 61914-98-5; LS-174602; Lobeta; D08074; PDSP2_000056; HOE 893; EINECS 253-074-3; 38363-40-5; S(-)-Penbutolol	36507-48-9	37464	15902888	TTDS00035	Beta adrenergic receptor	Beta-Adrenoceptor	N/A	N/A	N/A	antagonist
DAP000935	Isoetharine	1,2-Benzenediol, 4-[1-hydroxy-2-[(1-methylethyl)amino]butyl]-; Dey-Lute Isoetharine; 3,4-Dihydroxy-alpha-(1-(isopropylamino)propyl)benzyl alcohol; Isoetharine Hcl; Neoisuprel; Bronkosol; LS-175412; Dilabron; Etyprenalinum; 530-08-5; Isoetarin; Isoetarinum; Isoetarine; Prestwick0_000749; C07053; Prestwick2_000749; BSPBio_000738; BPBio1_000812; 4-[1-hydroxy-2-(propan-2-ylamino)butyl]benzene-1,2-diol; 1,2-Benzenediol, 4-(1-hydroxy-2-((1-methylethyl)amino)butyl)-; UNII-YV0SN3276Q; Isoetarina [INN-Spanish]; Etyprenaline; isoetharine; Lopac0_000671; Isoetharine (USP); NCGC00018239-06; AR-1I5329; Prestwick3_000749; Isoetarina; EINECS 208-472-1; D04625; NCGC00089806-02; Prestwick1_000749; CID3762; SPBio_002677; Isoetarine (INN); Isoetarinum [INN-Latin]; Isoetharine HCl S/F; Isoetharine [USAN:BAN]; BRD-A24587114-066-03-5; L001043; AC1L1GNK; NCGC00089806-03; Win 3406; AC1Q7AC0; DB00221	530-08-5	3762	9265	TTDS00035	Beta adrenergic receptor	Beta-Adrenoceptor	N/A	N/A	N/A	agonist
DAP000937	Ritodrine	L000737; 4-[2-[[1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]phenol; LS-187116; CID31729; CAS-23239-51-2; EINECS 247-879-9; Prestwick0_000349; Utopar; BRD-K51465424-003-03-6; KBio2_001898; AC1LEMBZ; Benzenemethanol, 4-hydroxy-alpha-(1-((2-(4-hydroxyphenyl)ethyl)amino)ethyl)-, (R*,S*)-; D02359; Prestwick3_000349; Prestwick2_000349; RITODRINE HCL; NCGC00016773-01; Spectrum4_000438; Ritodrinium; AC1LEMBT; Spectrum_001418; Ritodrinium [INN-Latin]; CID688570; KBio2_007034; NCGC00162324-02; Ritodrina [INN-Spanish]; AC1L1PV2; Lopac0_001041; AC1L1M7Q; 4-Hydroxy-alpha-(1-((2-(4-hydroxyphenyl)ethyl)amino)ethyl)benzenemethanol (R*,S*)-; Spectrum3_001458; KBio3_002455; NCGC00015887-01; BPBio1_000459; KBio2_004466; KBioGR_000796; Ritodrine [USAN:BAN:INN]; 4-[2-[[(1R,2S)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]phenol; BRD-A59174698-003-02-9; CHEMBL83063; 2-(4-Hydroxyphenethylamino)-1-(4-hydroxyphenyl)propanol; Yutopar; SPBio_001526; CHEMBL785; NCGC00179566-01; DB00867; 4-[2-[[(1S,2S)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]phenol; AC1LEMBW; Spectrum2_001423; LS-30764; Ritodrina; erythro-p-Hydroxy-alpha-(1-((p-hydroxyphenethyl)amino)ethyl)benzyl alcohol; 4-[2-[[(1S,2R)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]phenol; UNII-I0Q6O6740J; Ritodrine (USAN/INN); AC1Q59PF; BSPBio_000417; Yutopar S.R; NCGC00162324-01; Benzyl alcohol, p-hydroxy-alpha-(1-((p-hydroxyphenethyl)amino)ethyl)-, erythro-; SPBio_002338; CID688568; Prepar; Prestwick1_000349; DU-21220; Benzenemethanol, 4-hydroxy-.alpha.-[1-[[2-(4-hydroxyphenyl)ethyl]amino]ethyl]-, (R*,S*)-; AC1Q76UV; Lopac-R-0758; 4-[2-[[(1R,2R)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]phenol; Spectrum5_001225; BSPBio_002955; NCGC00015887-02; 26652-09-5; CID33572; p-Hydroxy-alpha-(1-((p-hydroxyphenethyl)amino)ethyl)benzyl alcohol; KBioSS_001898; CID688569; ritodrine; BRN 2388728; C07239	26652-09-5	33572	9448	TTDS00035	Beta adrenergic receptor	Beta-Adrenoceptor	N/A	N/A	N/A	agonist
DAP000047	Bethanidine	Bethanidine Sulfate (2:1); 1-Benzyl-2,3-dimethylguanidine sulfate; 1-Benzyl-2,3-dimethylguanidine sulfate (1:1/2); 1-Benzyl-2,3-dimethylguanidinium sulfate; Bethanidine Sulfate (2:1) (USAN); Guanidine, 1-benzyl-2,3-dimethyl-, s; LS-73260; BW467C60; Bethanidine hemisulfate; 114-85-2 (sulfate (2:1)); Tenathan; LS-73259; Esbatal; BW-467-C-60; 55-73-2; 2-Benzyl-1,3-dimethylguanidine; CHEBI:37937; Betanidole; 1,2-dimethyl-3-(phenylmethyl)guanidine; Bethanidine; AC1L1DIW; Guanidine, 1-benzyl-2,3-dimethyl-; BW 467C60; Guanidine, 1-benzyl-2,3-dimethyl- (8CI); Bethanidine, Sulfate (2:1); Bethanid; CID2368; AR-1C1712; Betanidinum; L001022; 1-BENZYL-2,3-DIMETHYLGUANIDINE; Bethanidine sulfate; Guanidine, N,N'-dimethyl-N''-(phenylmethyl)-; N,N'-dimethyl-N''-(phenylmethyl)-guanidine; ulfate (2:1); Guanidine, N, N'-dimethyl-N''-(phenylmethyl)-, sulfate (2:1); N-Benzyl-N',N''-dimethylguanidine sulfate; Sulfuric acid compound with N''-benzyl-N,N'-dimethylguanidine (1:1); UNII-W8S3YM7AUU; Betanidina [INN-Spanish]; NSC106563; Betanidina; Betanidine; Regulin; Guanidine, 2-benzyl-1,3-dimethyl-; Betanidine [INN:BAN]; Betanidinum [INN-Latin]; AC1Q4SZ3	2181-76-2	6324770	10732	TTDS00035	Beta adrenergic receptor	Beta-Adrenoceptor	N/A	N/A	N/A	antagonist
DAP000480	Metipranolol	VUFB-6453; D014290; C07915; Turoptin; D02374; Phenol, 4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)-2,3,6-trimethyl-, 1-acetate (9CI); (RS)-4-(2-Hydroxy-3-isopropylaminopropoxy)-2,3,6-trimethylphenyl acetat; CHEMBL1291; 1-(4-Hydroxy-2,3,5-trimethylphenoxy)-3-(isopropylamino)-2-propanol 4-acetate; (+-)-1-(4-Hydroxy-2,3,5-trimethylphenoxy)-3-(isopropylamino)-2-propanol 4-acetate; MolPort-001-801-890; AC1Q60JH; CHEBI:6897; BRN 2152010; NCGC00159498-02; 22664-55-7; L001291; Disorat; DB01214; UNII-X39AL81KEB; Metipranolol [USAN:BAN:INN]; 4-[2-hydroxy-3-(isopropylamino)propoxy]-2,3,6-trimethylphenyl acetate; Phenol, 4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)-2,3,6-trimethyl-, 1-acetate; Metipranololum [INN-Latin]; AC1L1LOH; Metipranololum; 62164P; NCGC00159498-03; EINECS 245-151-5; Trimepranol; BM-01004; 4-(2-Hydroxy-3-((1-methylethyl)-amino)propoxy)-2,3,6-trimethylphenol 1-acetate; Phenol, 4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)-2,3,6-trimethyl-, (+-)-, 1-acetate; LS-122351; VUAB-6453; Methypranol; 1-(4-Acetoxy-2,3,5-Trimethylphenoxy)-3-Isopropylamino-2-Propanol; CID31477; [4-[2-hydroxy-3-(propan-2-ylamino)propoxy]-2,3,6-trimethylphenyl] acetate; Metipranolol (USAN/INN); Metipranolol; 2-Propanol, 1-(4-hydroxy-2,3,5-trimethylphenoxy)-3-(isopropylamino)-, 4-acetate; 38202-74-3	22664-55-7	31477	10117	TTDS00035	Beta adrenergic receptor	Beta-Adrenoceptor	N/A	N/A	N/A	antagonist
DAP000016	Norepinephrine	(-)-NORADRENALINE; 1,2-Benzenediol, 4-((1R)-2-amino-1-hydroxyethyl)-; noradrenaline; LT4; PDSP2_001095; 66197-73-7; Norepinephrinum [INN-Latin]; Noradrenalina [Italian]; L-Norepinephrine; HMS2089E18; (R)-Norepinephrine; 1,2-Benzenediol, 4-[(1R)-2-amino-1-hydroxyethyl]-; Norepinephrine Noradrenalin; (R)-4-(2-Amino-1-hydroxyethyl)-1,2-benzenediol; NCGC00159406-04; HMS500L12; NCGC00159406-03; LS-42676; Noradrenalin; Levarterenol; norepinephrine; norepinefrina; SPBio_001048; CID439260; Sympathin E; (-)-(R)-Norepinephrine; L-3,4-dihydroxyphenylethanolamine; Levarterenolo [DCIT]; A7257_SIGMA; AC1L96ZT; Adrenor; Norepirenamine; KBio2_004057; KBio2_006625; LT03330026; Spectrum5_001068; 4-[(1R)-2-Amino-1-hydroxyethyl]-1,2-benzenediol; L-Noradrenaline; Noradrenalina; KBioSS_001489; 1,2-Benzenediol, 4-(2-amino-1-hydroxyethyl)-, (R)-; l-2-Amino-1-(3,4-dihydroxyphenyl)ethanol; Norepinephrine (INN); DB00368; EINECS 200-096-6; (R)-Noradrenaline; to_000024; Noradrenaline (JP15); Aktamin; (-)-Arterenol free base; SGCUT00123; BRN 4231961; Noradrenalin, l-; HMS1920B08; 4899-05-2; Noreinefrina; Norepinephrine [INN:JAN]; DivK1c_000230; Levoarterenol; CHEBI:18357; ALBB-006229; NCGC00159406-06; 1,2-Benzenediol, 4-(2-amino-1-hydroxyethyl)-, (R)- (9CI); 51-41-2; Arterenol; Nor adrenalin (TN); KBio2_001489; nchembio705-1; BSPBio_002079; nchembio.284-comp2; Levonor; Spectrum_001009; NCGC00159406-05; Norepinephrine l-Tartrate (1:1); nchembio.64-comp2; NCGC00159406-09; (-)-Norepinephrine; Levophed; (-)-Arterenol; STK503776; Benzyl alcohol, alpha-(aminomethyl)-3,4-dihydroxy-, (-)-; Spectrum2_001064; 1,2-Benzenediol, 4-((R)-2-amino-1-hydroxyethyl)-; 4-[(1R)-2-amino-1-hydroxyethyl]benzene-1,2-diol; CHEMBL1437; 51-40-1 (l-tartrate (1:1)); Levonoradrenaline; norepinephrinum; KBioGR_000635; (R)-(-)-Norepinephrine; Noradrenalinum; UNII-X4W3ENH1CV; Levarterenolo; NINDS_000230; Levonorepinephrine; KBio3_001579; Spectrum3_000520; D-(-)-Noradrenaline; NCGC00159406-07; (-)-alpha-(Aminomethyl)protocatechuyl alcohol; l-1-(3,4-Dihydroxyphenyl)-2-aminoethanol; bmse000404; KBio1_000230; HMS2091J08; L-alpha-(aminomethyl)-3,4-dihydroxybenzyl alcohol; Spectrum4_000078; NCGC00159406-02; 1,2-Benzenediol, 4-(2-amino-1-hydroxyethyl)-, (R)-(-)-; C00547; IDI1_000230; Noreinefrina [INN-Spanish]; D53D5E3A-2360-4CA9-8031-6C2CD4062FD5; Nor adrenalin; SPECTRUM1500436; PDSP1_001111; D00076; L-arterenol	51-41-2	439260	10298272	TTDS00035	Beta adrenergic receptor	Beta-Adrenoceptor	N/A	N/A	N/A	stimulator
DAP000122	Nadolol	AC1L2151; D00432; DB01203; VU0239635-6; Spectrum_001643; BSPBio_003152; DivK1c_000427; HMS501F09; MLS000028580; BRD-A87606379-001-03-4; SQ-11725; 2,3-Naphthalenediol, 5-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)-1,2,3,4-tetrahydro-, cis-; SMP1_000203; Spectrum3_001586; CCRIS 1048; Spectrum5_001255; Prestwick_108; (2R,3S)-5-({3-[(1,1-dimethylethyl)amino]-2-hydroxypropyl}oxy)-1,2,3,4-tetrahydronaphthalene-2,3-diol; NCGC00089811-02; Prestwick1_000818; Corgaretic; Solgol; CPD000058975; HMS1570D17; 42200-33-9; IDI1_000427; 2,3-cis-1,2,3,4-Tetrahydro-5-((2-hydroxy-3-tert-butylamino)propoxy)-2,3-naphthalenediol; Nadolol (JP15/USP/INN); HSDB 6532; SAM002264627; Nadic; nadolol; LS-94578; 2,3-Naphthalenediol, 5-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)-1,2,3,4-tetrahydro-; (2R,3S)-5-(3-(tert-Butylamino)-2-hydroxypropoxy)-1,2,3,4-tetrahydronaphthalene-2,3-diol; CHEMBL649; 5-(3-((1,1-Dimethylethyl)amino)-2-hydroxypropoxy)-1,2,3,4-tetrahydro-2,3-naphthalenediol; Corgard (TN); HMS2093A15; SMR000058975; KBio2_007259; KBioGR_000765; AC1Q77IZ; Nadololum [INN-Latin]; Anabet; NINDS_000427; SPECTRUM1503260; UNII-FEN504330V; KBio3_002652; MLS001148087; KBio2_002123; Spectrum2_001546; AC1Q1MO3; Prestwick2_000818; Nadololum; HMS1922O05; Prestwick0_000818; D009248; Corgard; KBio1_000427; SPBio_002636; CID39147; Nadolol [USAN:BAN:INN:JAN]; Spectrum4_000193; SPBio_001392; EINECS 255-706-3; KBioSS_002123; MolPort-003-666-474; KBio2_004691; (2R,3S)-5-[3-(tert-butylamino)-2-hydroxypropoxy]-1,2,3,4-tetrahydronaphthalene-2,3-diol; SQ11725; SQ 11725	42200-33-9	39147	180211	TTDS00035	Beta adrenergic receptor	Beta-Adrenoceptor	N/A	N/A	N/A	antagonist
DAP000025	Pindolol	HMS502J19; PDSP1_000772; Prestwick_397; Durapindol; Glauco-Viskin; KBio2_001589; LS-122385; 1-(1H-Indol-4-yloxy)-3-[(1-methylethyl)amino]-2-propanol; 5-21-03-00017 (Beilstein Handbook Reference); L000006; SMR000059120; PDSP2_000760; 1-(1H-indol-4-yloxy)-3-(isopropylamino)propan-2-ol; SAM002264631; 1-(1H-Indol-4-yloxy)-3-(isopropylamino)-2-propanol; P0778_SIGMA; BRD-A97701745-001-05-3; DL-Pindolol; DL-LB 46; HSDB 6539; 4-(3-(Isopropylamino)-2-hydroxypropoxy)indole; Spectrum3_000547; Pectobloc; Oprea1_770884; Glauco-visken; C07445; 1-(1H-indol-4-yloxy)-3-[(1-methylethyl)amino]propan-2-ol; Spectrum4_000479; PDSP2_000759; CPD000059120; 2-Propanol, 1-(1H-indol-4-yloxy)-3-(1-methylethyl)amino-; CCRIS 9215; Blocklin-L (TN); NCGC00024925-03; 1-(1H-Indol-4-yloxy)-3-((1-methylethyl)amino)-2-propanol; CHEMBL500; Carvisken (TN); P-6820; Blocklin-L; 28813-39-0; AC1L1J1N; PDSP1_000771; LB-46; BSPBio_002193; Prestwick0_000090; NCGC00024925-04; KBio2_004157; SPECTRUM1500488; LB 46; AC1Q1QC1; SPBio_001959; DB00960; EINECS 244-623-8; Pindololum [INN-Latin]; 13523-86-9; 1-(1H-indol-4-yloxy)-3-(propan-2-ylamino)-propan-2-ol; 2-Propanol, 1-(1H-indol-4-yloxy)-3-[(1-methylethyl)amino]-; DL-4-[2-Hydroxy-3-(isopropylamino)propoxy]indole; Betapindol; Spectrum5_001266; Spectrum2_001285; UNII-BJ4HF6IU1D; KBio2_006725; 21870-06-4; 4-(2-Hydroxy-3-isopropylaminopropoxy)-indole; BSPBio_000020; NINDS_000837; Prestwick1_000090; MLS000069496; HMS2089I21; Prestwick3_000090; CID4828; (+-)-Pindolol; Blockin L; NCGC00024925-06; NCGC00024925-05; Bio-0642; 1-(Indol-4-yloxy)-3-(isopropylamino)-2-propanol; 2-Propanol, 1-(4-indolyloxy)-3-(isopropylamino)-; EU-0100955; 2-Propanol, 1-(indol-4-yloxy)-3-(isopropylamino)-, (+-)-; Blocklin L; MolPort-001-792-503; NCGC00015786-07; D010869; D00513; Spectrum_001109; 2-Propanol, 1-(1H-indol-4-yloxy)-3-((1-methylethyl)amino)-; Visken (TN); Carvisken; Pynastin; KBioSS_001589; IDI1_000837; Blocklin; BPBio1_000022; KBio3_001693; Prindolol; BRN 1536506; Pindolol [USAN:INN:BAN:JAN]; HMS1568A22; DivK1c_000837; Decreten; CHEBI:8214; P 0778; Lopac0_000955; Calvisken; AB00052072; 2-Propanol, 1-(1H-indol-4-yloxy)-3-[(1-methylethyl)amino]-; NCGC00015786-13; HMS1920H16; 1-(1H-indol-4-yloxy)-3-[(propan-2-yl)amino]propan-2-ol; LB46; NCGC00024925-07; SPBio_001289; Visken; pindolol; Pinbetol; Pindolol (JP15/USP/INN); HMS2091P20; (1)-1-(1H-Indol-4-yloxy)-3-(isopropylamino)propan-2-ol; 1-((1-Methylethyl)amino)-3-(4-indolyloxy)-2-propanol; 1-(1H-indol-4-yloxy)-3-(propan-2-ylamino)propan-2-ol; Pindololum; Prestwick2_000090; EINECS 236-867-9; Prinodolol; KBio1_000837; KBioGR_000958	13523-86-9	4828	168830	TTDS00035	Beta adrenergic receptor	Beta-Adrenoceptor	N/A	N/A	N/A	antagonist
DAP000066	Epinephrine	Stryptirenal; Drenamist; l-1-(3,4-Dihydroxyphenyl)-2-methylaminoethanol; l-Methylaminoethanolcatechol; Sindrenina; Adrenaline (JP15); Adrenal; Renostyptin; Adrine; NCGC00015417-01; MolPort-002-051-368; Tonogen; Micronephrine; Suprarenin; (R)-Adrenaline; (-)-Epinephrine; Adrin; Epiglaufrin; R-Adrenaline; R-(-)-Epinephrine; (R)-4-[1-Hydroxy-2-(methylamino)ethyl]-1,2-benzenediol; Corisol; Epinephran; Vasodrine; L-Adrenaline Base; 1,2-Benzenediol, 4-(1-hydroxy-2-(methylamino)ethyl)-; NSC62786; Bosmin; Adrenalina [DCIT]; EPI E Z PEN JR; Adrenalin; Micronefrin; BIDD:GT0119; Isoptoepinal; 4-[(1R)-1-Hydroxy-2-(methylamino)ethyl]-1,2-benzenediol; 1-Adrenalin; L-epinephrine; DB00668; 4-(1-hydroxy-2-methylamino-ethyl)benzene-1,2-diol; Vasotonin; Citanest Forte; Surenine; (R)-(-)-Adnephrine; Haemostatin; NCGC00142615-03; Paranephrin; HSCI1_000215; Renagladin; Sphygmogenin; Rcra waste number P042; Asthma meter mist; (R)-Epinephrine; Nephridine; Suprel; Glauposine; 1,2-Benzenediol, 4-((1R)-1-hydroxy-2-(methylamino)ethyl)-; Adrenosan; (-)-R-Epinephrine; ADROP; Asthma-nefrin; A0173; Chelafrin; 1,2-Benzenediol, 4-(1-hydroxy-2-(methylamino)ethyl)-, (R)-; Medihaler-Epi; Levorenine; Epirenan; AC-13188; CHEBI:28918; PDSP2_001104; Epinephrine hydrochloride; Primatene Mist; Epinephrine [USAN:INN:JAN]; Twinject 0.3; Hemisine; E4250_SIGMA; (R)-(-)-Adrenaline; L-Epinehphrine; Epinefrin [Czech]; Simplene; Bronkaid; Suprarenaline; (-)-Adrenaline; Hemostasin; Asthmahaler Mist; EINECS 200-098-7; Twinject 0.30; 02252_FLUKA; Adrenalina; Tokamina; Renalina; AI3-19015; NSC 62786; Biorenine; D-Epifrin; Adrenaline/Epinephrine; (-)-(R)-Epinephrine; Styptirenal; Glaucosan; Levoadrenaline; Adrenamine; Mytrate; Renaleptine; Sympathin I; CCRIS 4812; NCGC00142615-04; Levorenin; Epipen; Surrenine; Racemic Epinephrine; Renaglandulin; Scurenaline; Myosthenine; Adrenine; Epinephrine (USP/INN); Septocaine; Astminhal; Supradin; Esphygmogenina; 4-(1-Hydroxy-2-(methylamino)ethyl)-1,2-benzenediol; Takamine; Glycirenan; Adrenalinum; Epipen Jr.; Lopac-E-4642; Haemostasin; Supracapsulin; Hyporenin; Hektalin; ST069368; Intranefrin; bmse000316; Levoepinephrine; D-Epinephrine; l-Epinephrine (synthetic); Twinject; Mucidrina; d-Adrenaline; Epinephrinum [INN-Latin]; Epirenin; Iontocaine; l-Adrenaline; Asmatane Mist; Lyophrin; Sus-Phrine; Astmahalin; Vasoton; 4-[(1R)-1-hydroxy-2-(methylamino)ethyl]benzene-1,2-diol; Epinephrinum; PDSP1_001120; Supranefran; Adrenan; NCGC00142615-06; Methylaminoethanolcatechol; NCGC00142615-05; Adrenapax; Takamina; 1-Epinephrine; Epinefrin; Adrenatrate; Exadrin; (R)-(-)-Epirenamine; HSDB 4289; Hemostatin; Epinefrina [INN-Spanish]; Kidoline; Twinject 0.15; IOP; AC1L1L7B; Adrenalin-Medihaler; Epirenamine; Ana-Guard; C00788; Nieraline; Epitrate; SMP1_000227; Vasoconstrictor; Renaglandin; Bupivacaine Hcl and Epinephrine; nchembio747-comp9; EPIPEN JR; SUS-PHRINE SULFITE-FREE; Adrenutol; Dyspne-Inhal; Asthmanefrin; Adrenohorma; Brevirenin; D00095; LS-156; Eppy; Epi EZ Pen Jr; CHEMBL679; Epifrin; CID5816; l-Epirenamine; Balmadren; Racepinephrine; Dylephrin; Epipen Jr. Auto-Injector; 1-1-(3,4-Dihydroxyphenyl)-2-methylaminoethanol; Epipen (TN); Epinephrin; Supranephrane; Primatene; Adnephrine; 51-43-4; Renoform; Hypernephrin; Soladren; UNII-YKH834O4BH; Supranol; Bronkaid Mist; Renostypticin; Susphrine; Epinefrina; Bernarenin; l-Epinephine; (-)-3,4-Dihydroxy-alpha-((methylamino)methyl)benzyl alcohol; NCGC00142615-01; Supranephrine; 51028-73-0; Levo-Methylaminoethanolcatechol; Adrenasol; Adrenalin (TN); EPIPEN E Z PEN; ADR ADRENALINE; Antiasthmatique; (R)-(-)-Epinephrine; NCGC00142615-07; Epinephrine (USP); Adrenalin in Oil; Metanephrin; Vaponefrin; RCRA waste no. P042; l-Adrenalin; adrenaline; Epipen Auto-Injector; epinephrine; Bronkaid Suspension Mist; Renostypricin; Glaucon; Levorenen; Methylarterenol; Vasoconstrictine; 51-43-4 (FREE BASE); (-)-Adrenalin; Adrenodis; Epipen EZ Pen	51-43-4	5816	7847163	TTDS00035	Beta adrenergic receptor	Beta-Adrenoceptor	N/A	N/A	N/A	agonist
DAP000303	Levobunolol	CAS-27912-14-7; BRD-K31812033-003-03-7; Levobunololum [INN-Latin]; Levobunolol (INN); CHEBI:6438; 5-[(2S)-3-(tert-butylamino)-2-hydroxypropoxy]-3,4-dihydro-2H-naphthalen-1-one; Prestwick1_000847; D08115; NCGC00016801-03; BPBio1_000917; CAS-47141-41-3; Akbeta; Prestwick0_000847; NCGC00016801-02; 47141-42-4; AC1Q6JRH; LEVOBUNOLOL; CID39468; Levobunolol HCl; Betagan; UNII-G6317AOI7K; SPBio_002754; AC1L21RP; 5-[(2S)-3-(tert-butylamino)-2-hydroxypropoxy]-3,4-dihydronaphthalen-1(2H)-one; NCGC00016801-01; Levobunolol [INN:BAN]; BSPBio_000833; W-7000A; C07914; W-6412A; DB01210; (-)-Bunolol; LS-175034; Prestwick2_000847; Levobunololum; CCRIS 4375; Prestwick3_000847; (S)-5-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)-3,4-dihydro-1(2H)-naphthalenone; 1(2H)-Naphthalenone, 5-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)-3,4-dihydro-, (S)-	47141-42-4	39468	10116	TTDS00035	Beta adrenergic receptor	Beta-Adrenoceptor	N/A	N/A	N/A	antagonist
DAP000593	Dipivefrin	LS-121419; 2,2-Dimethylpropanoic acid 4-[1-hydroxy-2-(methylamino)ethyl]-1,2-phenylene ester; 4-[1-hydroxy-2-(methylamino)ethyl]-o-phenylene divavalate; (+-)-4-[1-hydroxy-2-(methylamino)ethyl]-o-phenylene divavalate; Propine; dipivefrin; dipivalyl epinephrine; Prestwick0_000632; NCGC00179499-01; Dipivefrin (USAN); Dipivefrinum; UNII-8Q1PVL543G; ( -)-4-(1-Hydroxy-2-methylaminoethyl)-o-phenylendipivalat; 4-[1-hydroxy-2-(methylamino)ethyl]benzene-1,2-diyl bis(2,2-dimethylpropanoate); AB00514686; Dipivefrina [INN-Spanish]; Prestwick1_000632; Ophtho-Dipivefrin; 1-(3',4'-dipivaloyloxyphenyl)-2-methylamino-1-ethanol; Dipivefrine; (RS)-4-(1-Hydroxy-2-(methylamino)ethyl)-1,2-phenylen dipivalat; AKOS003662293; K 30081; Dipivefrin HCL; CHEBI:4646; (+-)-3,4-Dihydroxy-alpha-((methylamino)methyl)benzyl alcohol 3,4-dipivalate; C06963; Dipivefrina; BPBio1_000688; [2-(2,2-dimethylpropanoyloxy)-4-[1-hydroxy-2-(methylamino)ethyl]phenyl] 2,2-dimethylpropanoate; Dipivefrin [USAN]; C19H29NO5; AKPro; 52365-63-6; SPBio_002843; Dipivefrine (INN); Prestwick2_000632; Dipivefrinum [INN-Latin]; BRD-A47494775-003-03-0; DB00449; Propanoic acid, 2,2-dimethyl-, 4-(1-hydroxy-2-(methylamino)ethyl)-1,2-phenylene ester, (+-)-; BSPBio_000624; ( -)-2,2-Dimethylpropansaeure-4-(1-hydroxy-2-(methylamino)ethyl)-1,2-phenylenester; AC1L1F6K; 4-(1-Hydroxy-2-(methylamino)ethyl)-1,2-phenylen dipivalat; Prestwick3_000632; D02349; CID3105; Propine C Cap B.I.D.; nchembio747-comp3; L000915	52365-63-6	3105	9177	TTDS00035	Beta adrenergic receptor	Beta-Adrenoceptor	N/A	N/A	N/A	antagonist
DAP000088	Timolol	Betimol; NCGC00016038-01; (2S)-1-[(1,1-dimethylethyl)amino]-3-[(4-morpholin-4-yl-1,2,5-thiadiazol-3-yl)oxy]propan-2-ol; Timacar; C07141; MK-950; AB00513729; Istalol; SAM002564238; Tenopt; Prestwick3_000948; Prestwick1_000948; DB08625; Timoptic-XE; Tim-AK; Timololum; (-)-3-Morpholino-4-(3-tert-butylamino-2-hydroxypropoxy)-1,2,5-thiadiazole; Proflax; S(-)-Timolol maleate; Optimol; TIM; Prestwick2_000948; HSDB 6533; Tocris-0649; LS-122231; Timolol [USAN]; Timolol (INN); Lopac-T-6394; BPBio1_001008; HMS2089I11; 26921-17-5 (maleate (1:1) salt); Timoptol; Prestwick0_000948; NCGC00022033-04; CHEMBL499; Timolol GFS; BSPBio_000916; L-714,465; Blocadren; Timopic; Oprea1_640981; 26839-75-8; ST072193; NCGC00022033-05; (S)-timolol; DB00373; timolol; Betimol (TN); BRD-K08806317-050-03-6; Phoxal-timolol; NCGC00016798-07; CID33624; Timololum [INN-Latin]; Temserin; NCGC00016798-01; (2S)-1-(tert-butylamino)-3-[(4-morpholin-4-yl-1,2,5-thiadiazol-3-yl)oxy]propan-2-ol; Apo-Timop; CHEBI:9599; Timolol (TN); NCGC00016038-02; (S)-1-(1,1-(Dimethylethyl)amino)-3-((4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl)oxy)-2-propanol; Timolol Maleate, (1:1) Salt; 2-Propanol, 1-((1,1-dimethylethyl)amino)-3-((4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl)oxy)-, (2S)-; Timoptic OcuDose; D08600; Lopac0_001189; EINECS 248-032-6; 194288-09-0; (S)-1-(tert-Butylamino)-3-((4-morpholino-1,2,5-thiadiazol-3-yl)oxy)propan-2-ol; C13H24N4O3S; UNII-817W3C6175; NCGC00022033-02; (2S)-1-((1,1-dimethylethyl)amino)-3-((4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl)oxy)-2-propanol; Aquanil; CAS-26921-17-5; AC1Q59QM; Apo-Timol; BIDD:GT0073; Betim; Novo-Timol; SPBio_003075; 131628-37-0; S-(-)-3-(3-tert-Butylamino-2-hydroxypropoxy)-4-morpholino-1,2,5-thiadiazole; CPD001456519; AC1L1PYN; Nu-Timolol; 2-Propanol, 1-((1,1-dimethylethyl)amino)-3-((4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl)oxy)-, (S)-	26839-75-8	33624	175467	TTDS00035	Beta adrenergic receptor	Beta-Adrenoceptor	N/A	N/A	N/A	antagonist
DAP000479	Cryptenamine	N/A	1356-18-9	N/A	3728148	TTDS00035	Beta adrenergic receptor	Beta-Adrenoceptor	N/A	N/A	N/A	antagonist
DAP000089	Propranolol	Propanolol [INN-Spanish]; SPBio_001361; Euprovasin; 2-Propanol, 1-((1-methylethyl)amino)-3-(1-naphthalenyloxy)-, (+-)-; 1-Isopropylamino-3-(1-naphthyloxy)-2-propanol; Propranololo [DCIT]; Inderex; cMAP_000071; Inderol; Berkolol; propranolol; 2-Propanol, 1-((1-methylethyl)amino)-3-(1-naphthalenyloxy)-; IDI1_000023; Sawatal; Spectrum4_000974; BPBio1_001040; 525-66-6; Propanalol; 1-naphthalen-1-yloxy-3-(propan-2-ylamino)propan-2-ol; ICI 45520; KBioSS_002523; Bio-0732; KBio1_000023; PDSP2_000755; Spectrum5_000751; KBio3_001766; 1-(isopropylamino)-3-(1-naphthyloxy)propan-2-ol; Propranolol [INN:BAN]; Naprilin; Servanolol; Prestwick0_000952; Efektolol; SPBio_001658; Reducor; Lopac0_000896; D08443; etalong; KBio2_005083; KBio2_007651; 2-Propanol, 1-[(1-methylethyl)amino]-3-(1-naphthalenyloxy)-; KBioGR_001347; Reducor line; CHEMBL27; BSPBio_002682; AC1Q1QC0; 1-((1-Methylethyl)amino)-3-(1-naphthalenyloxy)-2-propanol; 1-[(1-methylethyl)amino]-3-(naphthalen-1-yloxy)propan-2-ol; Propranolol Hcl Intensol; BSPBio_000944; Intermigran; EINECS 235-867-6; Bedranol; DivK1c_000023; 2-Propanol, 1-((1-methylethyl)amino)-3-(1-naphthalenyloxy)-, (+-)- (9CI); 2-Propanol, 1-((1-methylethyl)amino)-3-(1-naphthalenyloxy)-  (9CI); Spectrum3_001071; 4199-09-1; LS-184129; 1-(Isopropylamino)-3-(1-naphthyloxy)-2-propanol; 2-Propanol, 1-(isopropylamino)-3-(1-naphthyloxy)-; AB00053537; PDSP2_001591; KBioGR_002515; 4199-10-4; Herzbase; SPBio_003093; Betachron; Propanix; Corpendol; Propranololum; Spectrum2_001699; NINDS_000023; NSC91523; 2-Propanol, 1-[(1-methylethyl)amino]-3-(1-naphthalenyloxy)-, (R)-; Avlocardyl; Oprea1_304193; Propanolol; CCRIS 3082; Propranalol; Ikopal; PDSP1_000767; Dociton; D,L-Propranolol; AKOS000588816; KBio3_001902; MolPort-001-794-623; CID4946; AY-20694; Anaprilin; STK735510; (1)-1-(Isopropylamino)-3-(naphthyloxy)propan-2-ol; CBDivE_006180; DL-Propranolol hydrochloride; Sumial; Spectrum3_000883; 3-(naphthalen-1-yloxy)-1-(propan-2-ylamino)propan-2-ol; Pranolol; KBioGR_001684; Betalong; Pronovan; Prestwick1_000952; Migrastat; KBio2_002515; Obzidan; (R)-(+)-propranolol; Prestwick2_000952; Inderalici; PDSP1_001607; CHEBI:8499; Kemi; Inderal; LS-122410; R,S-Propranolol Hydrochloride; NCGC00024690-03; NCGC00015798-07; Proprasylyt; Anapriline; propranololo; (S)-(-)-PROPRANOLOL; Spectrum2_001301; DB00571; 13013-17-7; Caridolol; Propranololum [INN-Latin]; INDERIDE-80/25; 1-(naphthalen-1-yloxy)-3-(propan-2-ylamino)propan-2-ol; Bio1_000856; C07407; INDERIDE-40/25; Bio1_001345; Kemi S; Betadren; HMS2090L21; Prestwick3_000952; AC1L1JA4; BRD-A10070317-003-06-9; Beta-Timelets; L000679; 1-(1-Naphthyloxy)-2-hydroxy-3-(isopropylamino)propane; 1-(Isopropylamino)-3-(1-naphthoxy)-propan-2-ol; Beta Neg; AC1Q1QBV; AY 64043; KBio3_002993; PDSP2_001592; Racemic propranolol; (+-)-Propranolol; C16H21NO2; Propranolol (TN); Bio1_000367; PDSP1_001608; Beta-Tablinen; Obsidan; 2-Propanol, 1-(isopropylamino)-3-(1-naphthyloxy)-, (+-)-; Propranolol (INN); Inderal hydrochloride; UNII-9Y8NXQ24VQ; Spectrum4_001222; beta-Propranolol; EINECS 208-378-0; NCGC00024690-02	525-66-6	4946	153977	TTDS00035	Beta adrenergic receptor	Beta-Adrenoceptor	N/A	N/A	N/A	antagonist
DAP000065	Carteolol	C06874; D07624; Prestwick0_000446; BSPBio_000492; CID2583; Prestwick3_000446; 5-[3-(tert-butylamino)-2-hydroxypropoxy]-3,4-dihydro-1H-quinolin-2-one; Carteolol Monohydrochloride; Carteololum [INN-Latin]; LS-142779; L000777; I14-8021; C16H24N2O3; Prestwick1_000446; 5-({3-[(1,1-dimethylethyl)amino]-2-hydroxypropyl}oxy)-3,4-dihydroquinolin-2(1H)-one; Carteolol (INN); 51781-21-6 (mono hydrochloride); DB00521; Carteolol [INN:BAN]; Carteolol HCl; AB00514682; AC1L1E05; 51781-06-7; Prestwick2_000446; CHEBI:3437; 2(1H)-Quinolinone, 5-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)-3,4-dihydro-; BPBio1_000542; NCGC00179541-01; CHEMBL839; CARTEOLOL; 5-[3-(tert-butylamino)-2-hydroxypropoxy]-3,4-dihydroquinolin-2(1H)-one; SPBio_002431; Carteololum; Oprea1_672850; BRD-A42167015-003-03-7; UNII-8NF31401XG	51781-06-7	2583	9091	TTDS00035	Beta adrenergic receptor	Beta-Adrenoceptor	N/A	N/A	N/A	agonist
DAP000939	Bretylium	2-bromo-N-ethyl-N,N-dimethylbenzenemethanaminium; Bretylium tolsylate; DB01158; N-ethyl-N,N-dimethyl-2-bromobenzenemethanaminium; Prestwick2_000942; Bretylium; AC1L1DNT; BSPBio_000904; (2-bromophenyl)methyl-ethyl-dimethylazanium; NCGC00168463-02; Bretylum; L000814; Bretylium tosylate(USAN); SPBio_003063; CID2431; NCGC00168463-01; 59-41-6; Prestwick1_000942; BPBio1_000996; LS-175977; AB00383047; CHEBI:3172; (o-Bromobenzyl)ethyldimethylammonium p-toluenesulfonate; Benzenemethanaminium, 2-bromo-N-ethyl-N,N-dimethyl-, salt with 4-methylbenzenesulfonic acid (1:1); Prestwick3_000942; Benzenemethanaminium, 2-bromo-N-ethyl-N,N-dimethyl-; UNII-RZR75EQ2KJ; 3170-72-7 (bromide); C11H17BrN; C06855; (2-bromobenzyl)ethyldimethylaminium; N-(2-bromobenzyl)-N,N-dimethylethanaminium	59-41-6	2431	794516	TTDS00035	Beta adrenergic receptor	Beta-Adrenoceptor	N/A	N/A	N/A	antagonist
DPR000048	FSA2	N/A	N/A	N/A	N/A	TTDS00295	Fatty acid synthase	FAS;Fatty acyl-CoA synthetase enzyme;Fatty-acyl-CoA synthase;Yeast fatty acid synthase	P49327	2194	ENSG00000169710	inhibitor
DPR000044	FAS1	N/A	N/A	N/A	N/A	TTDS00295	Fatty acid synthase	FAS;Fatty acyl-CoA synthetase enzyme;Fatty-acyl-CoA synthase;Yeast fatty acid synthase	P49327	2194	ENSG00000169710	inhibitor
DAP000659	Cerulenin	NCGC00163492-02; (2R,3S,E,E)-2,3-Epoxy-4-oxo-7,10-dodecadienamide; Bio2_000478; (2R,3S)-3-nona-4,7-dienoyloxirane-2-carboxamide; C12058; KBioSS_000616; LS-63388; KBio3_001091; 3-nona-4,7-dienoyloxirane-2-carboxamide; cerulenin; Helicocerin; AC1L1FI4; AC1L6R79; 2,3-Epoxy-4-oxo-7,10-dodecadienoylamide; C2389_SIGMA; NCI60_000363; 7,10-DODECADIENAMIDE, 2,3-EPOXY-4-OXO-; KBio2_000616; (2R-(2alpha,3alpha(4E,7E)))-3-(1-Oxonona-4,7-dienyl)oxirane-2-carboxamide; KBio2_003184; 17397-89-6; KBio2_005752; NSC116069; CID28517; (2S)(3R)-2,3-Epoxy-4-oxo-7,10-dodecadienoylamide; NCGC00163492-01; AC1NQZF4; HMS1990P17; CID5352018; Bio2_000958; AC1Q5H5H; (2S,3R)-2,3-epoxy-4-oxy-7,10-dodecadienoylamide; Cerulenin, Cephalosporium caerulens; (2R,3S)-2,3-Epoxy-4-oxo-7E,10E-dodecadienamide; CID5282054; SMP1_000098; 2,3-Epoxy-4-oxo-7,10-dodecadienamide; BRD-K52075040-001-02-2; (2r,3s)-3-(nona-4,7-dienoyl)oxirane-2-carboxamide; QTL1_000017; 3-[(4E,7E)-nona-4,7-dienoyl]oxirane-2-carboxamide; Oxiranecarboxamide, 3-(1-oxo-4,7-nonadienyl)-, (2R-(2alpha,3alpha(4E,7E)))-; Oxiranecarboxamide, 3-[(4E,7E)-1-Oxo-4,7-nonadienyl]-, (2R,3S)-; DB01034; AC1NS1LT; NSC 116069; CHEMBL45627; Ambotz17397-89-6; CID272023; CHEBI:171741; KBioGR_000616; IDI1_002233; Oxiranecarboxamide, 3-(1-oxo-4,7-nonadienyl)-, (2R-(2-alpha,3-alpha(4E,7E)))-; (2R,3S)-3-((4E,7E)-nona-4,7-dienoyl)oxirane-2-carboxamide; MolPort-003-928-099; KBio3_001092; CPD-6901; (2R,3S)-3-[(4E,7E)-nona-4,7-dienoyl]oxirane-2-carboxamide; HMS1362P17; EINECS 241-424-8; BSPBio_001276; (2R,3S)-3-((4E,7E)-Nona-4,7-dienoyl)-oxirane-2-carboxylic acid amide; HMS1792P17; 3-(1-Oxo-4,7-nonadienyl)oxiranecarboxamide; Oxiranecarboxamide, 3-(1-oxo-4,7-nonadienyl)-, (2R-(2-alpha,3-alpha(4E,7E)))- (9CI)	17397-89-6	28517	14213	TTDS00295	Fatty acid synthase	FAS;Fatty acyl-CoA synthetase enzyme;Fatty-acyl-CoA synthase;Yeast fatty acid synthase	P49327	2194	ENSG00000169710	inhibitor
DAP001448	Tocilizumab	D02596; Tocilizumab (genetical recombination); Actemra (TN); 375823-41-9; Tocilizumab; Tocilizumab (genetical recombination) (JAN); Tocilizumab (USAN/INN); Actemra	375823-41-9	N/A	17396767	TTDS00521	Interleukin-6 receptor	CD126;gp80;IL6R;IL-6R;Membrane glycoprotein 80	P40189	3572	ENSG00000134352	antibody
DCL000635	SAR153191	N/A	N/A	N/A	N/A	TTDS00521	Interleukin-6 receptor	CD126;gp80;IL6R;IL-6R;Membrane glycoprotein 80	P40189	3572	ENSG00000134352	antagonist
DAP000110	Tobramycin	CID9934285; Brulamycin; SMR000058793; Gotabiotic; Tenemycin; MolPort-003-665-548; KBioGR_001104; BAS 00463364; Nebramycin factir 6; Nebramycin VI; Tobralex; LS-187329; Obracin; HMS2090B16; SPBio_002508; CHEBI:533587; 54330-95-9; 11098-01-4; CHEBI:28864; Tobramycine; Prestwick1_000544; Tobracin (TN); KBio2_006688; 34337-51-4; BIDD:GT0503; Nebcin; Nebramycin 6; SPBio_000295; BSPBio_002036; C00397; Tobramicin; Distobram; Spectrum4_000752; Tobramycine [INN-French]; 49842-07-1 (Sulfate); AC1L1VI0; TOA-(1-6)2TB-(4-1)TOC; D00063; HMS1569N09; AKOS000715235; Tobracin; NSC180514; AC1Q2AOW; UNII-VZ8RRZ51VK; C18H37N5O9; Lilly 47663; Nebcin (Sulfate); Tobramycin, Free Base; Tobrasone; CID36294; Spectrum3_000588; Prestwick_850; DB00684; Tobradistin; Tobi; S2514_Selleck; SAM001246911; EINECS 251-322-5; Obramycin; Tobramycinum [INN-Latin]; CID11340303; CAS-32986-56-4; BPBio1_000647; KBio2_004120; Spectrum2_000078; Tobramicina [INN-Spanish]; Prestwick3_000544; BRN 1357507; TOBRAMYCIN SULFATE; Tobramycetin; LS-146940; Spectrum5_001038; NEBRAMYCIN; KBioSS_001552; Tobramaxin; Tobramycin [USAN:BAN:INN:JAN]; A 12253A; tobramycin solution for inhalation; Tobrex; SPECTRUM1500579; SPRC-AB01; STK182610; Aktob; Tobacin; MolPort-001-934-131; Tenebrimycin; AC1L1KGY; CID5496; T4014_SIGMA; NCGC00016814-01; AB00513858; NSC 180514; 70322-33-7; TOA-(1-6)TOB-(4-1)TOC; CID6604388; NCGC00178852-01; 37321-13-4; Tobramycinum; CPD000058793; Prestwick0_000544; Tobrex (TN); KBio3_001536; Tobradex; 32986-56-4; AC1O7GFJ; Nebicin; HMS2092M17; 1-Epitobramycin; NF 6; KBio2_001552; Tobrased; Sybryx; Tobramycin for Inhalation; TOY; 79645-27-5; MLS000069544; Tobramitsetin; MolPort-003-939-629; NCGC00178852-02; BSPBio_000587; CID9804613; Tobramicina; 11111-45-8; Deoxykanamycin B; Spectrum_001072; Prestwick2_000544; CHEMBL1747; Tobramycin (JP15/USP); HSDB 3259; 3'-Deoxykanamycin B; tobramycin; Nebramycin factor 6	32986-56-4	5496	447098	TTDS00220	50S ribosomal subunit	50S ribosome subunit	N/A	N/A	N/A	binder
DAP000887	Josamycin	JM; Josacine; josamycin; CID6419972; 39416-64-3; CHEMBL329011; 16846-24-5; Kitasamycin A3; Josamicina; Antibiotic yl-704 A3; C12662; EN 141; CID3804; Josamycin (JP15/USAN/INN); Leucomycin V, 3-acetate 4B-(3-methylbutanoate); ST075007; AC1NV9EJ; CID6713920; Josamycine; CID5353695; Prestwick0_000154; Turimycin A5; SPBio_002227; D01235; Josamycinum [INN-Latin]; Leucomycin V, 3-acetate 4(sup B)-(3-methylbutanoate); CAS-16846-24-5; Prestwick1_000154; LS-185083; DB01321; AC1NQZL5; 35414-05-2; dro-2H-pyran-3-yl 3-methylbutanoate; Josamycin (TN); Leucomycin V, 3-acetate 4(sup beta)-(3-methylbutanoate); AC1O8PVD; Prestwick2_000154; 56689-45-3; CID5474986; AC1L1GR2; Josamycine [INN-French]; AC1NS4H2; CID6604350; Yl-704 A3; HMS1568O10; NSC122223; Josamicina [INN-Spanish]; AC1O4WH7; Josamycin [USAN:INN:JAN]; CHEMBL224436; CCRIS 8511; AC1NR4PM; CID5284579; 59983_SIGMA; Leucomycin A3; LS-87883; MolPort-003-937-666; CID5282165; Prestwick_517; AC1O7GE3; EINECS 240-871-6; 11033-18-4; Josamycinum; NCGC00016725-01; 59983_FLUKA	16846-24-5	5282165	7848298	TTDS00220	50S ribosomal subunit	50S ribosome subunit	N/A	N/A	N/A	binder
DAP001388	Gentamicine sulfate	CHEMBL1200643; Gentamicine sulfate; AC1O4WGI; CID6419933; HMS1568O22; Prestwick_240; SCH-9724; (2R,3R,4R,5R)-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2R,3R,6S)-3-amino-6-[(1R)-1-aminoethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol; (2R,3R,4R,5R)-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2R,3R,6S)-3-amino-6-(aminomethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol; (2R,3R,4R,5R)-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2R,3R,6S)-3-amino-6-[(1R)-1-(methylamino)ethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol; sulfuric acid	1405-41-0	6419933	10321340	TTDS00220	50S ribosomal subunit	50S ribosome subunit	N/A	N/A	N/A	binder
DAP001356	Chlornitromycin	85666-84-8; Cidocetine; Comycetin; Chloramfenikol [Czech]; Chloromycetny [Polish]; Novomycetin; Halomycetin; Ertilen; BSPBio_000121; Kemicetina; Chlorocid; Catilan; SMP1_000065; Sno-Phenicol; Mycinol; BPBio1_000135; Chemicetin; Levomycetin; AKOS005111001; Clorosintex; Amphenicol; Isopto fenicol; BIDD:GT0145; Chlorocol; MLS001055372; Chloramphenicol, d-; Emetren; NCGC00091011-02; Alficetyn; Amphicol; Clorocyn; Chloroject L; Mastiphen; D-(-)-threo-Chloramphenicol; Chloromycetin (TN); C.A.F; Levomicetina; NCI60_002620; Cloranfenicol; LS-225; D002701; Cloramfenicol; Syntomycin; BRN 2225532; Ophtochlor; Intramyctin; HMS2090M15; Dextromycetin; MolPort-001-794-646; AI3-25003; Juvamycetin; Biophenicol; Sintomicetina; Kamaver; I 337A; Synthomycine; Isicetin; D-(-)-Chloramphenicol; C2255; D(-)-threo-2-dichloroacetamido-1-p-nitrophenyl-propanediol; Klorocid S; Viceton; D(-)-threo-Chloramphenicol; Opclor; Embacetin; Micochlorine; Detreomycin; Vice ton; Sintomicetine R; Cloromissan; Anacetin; Myscel; MLS001332385; Cloramfenicolo; Enicol; Austracol; Ak-chlor; Chlorocidin C; Biocetin; Erbaplast; Intramycetin; Doctamicina; IDI1_000544; Paraxin; Tea-Cetin; Elase-Chloromycetin; Mychel; Chlorocaps; Novophenicol; NCGC00091011-03; Oleomycetin; Tifomycin; Micoclorina; Quemicetina; Chloramphenicolum; ST024743; NSC3069; Chloramphenicol & VRC3375; Cloramfenicol [INN-Spanish]; Chloromyxin; Chlora-tabs; D(-)-threo-2-dichloroacetamido-1-p-nitrophen yl-propanediol; Chloramficin; Chlorocidin C tetran; D-Chloramphenicol; KBio1_000544; C7795_SIGMA; Cloramficin; CID5959; Prestwick3_000031; Micloretin; Chloro-25 vetag; Tifomycine; Econochlor (TN); Duphenicol; Enteromycetin; Detreomycine; Fenicol; Chloricol; Tevcocin; Cloroamfenicolo [Italian]; Chloroptic; Klorita; Chlorocid S; Amseclor; CHEBI:17698; 2787-09-9; Chlorasol; Septicol; Chlorocide; Chlorofair; 15313-32-3; ARONIS23913; Desphen; MLS002222155; Chloromycetin; Chloramsaar; Ismicetina; Cloroamfenicolo; NCGC00091011-04; Chloramex; Ambofen; Cloramfenicolo [DCIT]; Isophenicol; 4-13-00-02742 (Beilstein Handbook Reference); Leukomyan; Pantovernil; Cylphenicol; Cloramical; C00918; AB00374860; Ronphenil; Tevcosin; Laevomycetinum; Synthomycetine; Stanomycetin; CHLOROPTIC S.O.P; Pentamycetin; Mychel-Vet; Kemicetine; Globenicol; Normimycin V; Amphicol (TN); NINDS_000544; C1919_SIGMA; Opelor; Kloramfenikol; Loromicetina; Chemicetina; 55172-72-0; Cloramidina; Oftalent; 23276_FLUKA; Chlorbiotic (Veterinary); 442513_SUPELCO; S1677_Selleck; Mediamycetine; Leukomycin; F armicetina; D00104; HSDB 3027; AC1L1LI3; CCRIS 3922; C0378_SIGMA; Econochlor; HMS501L06; Chloramphenicolum [INN-Latin]; chloramphenicol; Synthomycetin; Chloramfilin; Ciplamycetin; Cloromisan; Chloromycetny; Chloramphenicol (JP15/USP/INN); Chloromycetin&#174; DivK1c_000544; 137731-90-9; Sificetina; Loromisan; 59112-59-3; MLS001332386; Chloroamphenicol; Treomicetina; Chlomin; Austracil; Hortfenicol; Chlornitromycin; Chloronitrin; Chloroptic S.O.P.; EINECS 200-287-4; Unimycetin; Aquamycetin; UNII-66974FR9Q1; Chloramphenicol [INN:BAN:JAN]; Tega-Cetin; Alficetyn, Chlornitromycin, Chloromycetin, Chloramphenicol; NSC 3069; CAF (pharmaceutical); Rivomycin; CLM; SMR000471851; Veticol; Chloramphenicol crystalline; Optomycin; Microcetina; Chloramfenikol; Loromisin; Cloramicol; Chlorovules; CHEMBL130; Leukamycin; Chlorsig; Medichol; Ronfenil; BRD-K08111712-001-02-7; D-threo-Chloramphenicol; NCI-C55709; Glorous; Romphenil; C0857_SIGMA; NCGC00091011-01; Otophen; Otachron; MLS001066397; Chloromax; Tiromycetin; 56-75-7; Ophthochlor; nchembio.244-comp5; U-6062; Interomycetine; Chlomycol; Farmicetina; NSC 16331; Sno Phenicol; Chlormycetin R; Ch loramex; WLN: WNR DYQY1QMVYGG; C1863_SIGMA; ZINC00113382; CAF; Cloramfen; Novochlorocap; C11H12Cl2N2O5; Chemiceticol; Levomitsetin	56-75-7	298	4172	TTDS00220	50S ribosomal subunit	50S ribosome subunit	N/A	N/A	N/A	binder
DAP000888	Dirithromycin	BPBio1_000697; Dirithromycinum [Latin]; AC1O8PX4; 62013-04-1; Spectrum4_000597; MLS001074061; AS-E 136; Prestwick1_000557; AC1NDR4M; DB00954; Noriclan; Dynabac; Spectrum3_001630; Dirithromycin (USP/INN); HMS1922D13; KBioSS_001956; SPECTRUM1504144; HMS1569P15; Prestwick0_000557; KBio1_001908; AC1OCDP6; Diritromicina; KBio2_001956; BSPBio_003299; AB00513862; DivK1c_006964; I06-0179; Dirithromycin; Ambap62013-04-1; Dirithromycine; CID4580358; -methyl-3-O-methylhexopyranoside; SpecPlus_000868; CID5464388; LY 237216; NCGC00016900-01; CID6713946; KBio2_007092; Dirithromycin [USAN:BAN:INN]; (9S)-9-deoxo-11-deoxy-9,11-[imino[2-(2-methoxyethoxy)ethylidene]erythromycin; CID9988071; UNII-1801D76STL; D03865; SPBio_002554; SPBio_001809; AC1O7GH5; Dynabac (TN); CHEBI:474014; MLS000028564; NCGC00178154-02; AC1O6F4R; CID6604422; BSPBio_000633; CHEMBL1200505; NCGC00178154-01; Prestwick3_000557; KBioGR_001094; HMS2093A06; Spectrum5_000715; AC1LA66D; ASE-136; CID9811215; CID462481; CID6473883; CAS-62013-04-1; LS-176227; Prestwick2_000557; CID6917067; STL008572; Spectrum2_001655; LY-237216; C42H78N2O14; KBio3_002519; Dirithromycine [French]; KBio2_004524; AC1NUZ6Y; MolPort-003-666-531; Valodin; SMR000058954; Dirithromycinum; Spectrum_001476; Divitross; Diritromicina [Spanish]	62013-04-1	5464388	214716	TTDS00220	50S ribosomal subunit	50S ribosome subunit	N/A	N/A	N/A	binder
DAP000839	Lincomycin	NINDS_000361; Spectrum4_000033; CID1597155; NCGC00016545-01; lincomycin; CID1777615; AC1Q5JT8; AC1OFCLO; Lincolnensin; BIM-0021730.P001; AC1L1H0Z; Lincomix; BPBio1_000292; methyl 6,8-dideoxy-6-[(1-methyl-4-propylprolyl)amino]-1-thiooctopyranoside; CID5702079; Lincomycinum; Spectrum3_000481; Lincomycin (USAN/INN); AC1NWAO9; D00223; HSDB 3109; Prestwick0_000302; AC1LV2ZC; Lincomycinum [INN-Latin]; SPBio_000090; 859-18-7 (mono-hydrochloride); CBMicro_021584; CID656509; EINECS 205-824-6; IDI1_000361; CID5388973; Spectrum2_000105; UNII-BOD072YW0F; Lincomicina [INN-Spanish]; Lincocin; KBio2_006499; STOCK1N-50613; AR-1J5605; C18H34N2O6S; BRD-K81447180-003-03-2; MolPort-002-323-205; KBio1_000361; LS-174532; AC1LWJX1; Epilincomycin; Lincomicina; LS-98136; Lincomycin, (2S-cis)-Isomer; NCGC00159326-02; CID9911258; Prestwick1_000302; CID9063; Jiemycin; Lincomycine [French]; NCGC00024307-03; CID7048702; Spectrum5_000914; AC1O7GCP; AC1OFCLI; CAS-859-18-7; Lincomycin A; CID3928; BSPBio_000264; CHEBI:6472; AC1L1S8J; MolPort-002-507-379; 154-21-2; 7179-49-9 (mono-hydrochloride, hemi.hydrate); CID11418330; BRD-K08033334-003-02-7; Prestwick3_000302; Lincocine; KBioSS_001363; AC1OF50G; DB01627; 12768-69-3; Lincomycine [INN-French]; KBio2_001363; BSPBio_001941; Lincomycin [USAN:INN:BAN]; KBioGR_000465; CID7048696; BRN 0707677; Lincolcina; Pura Ject 100; Lincomix 20; NCGC00178902-01; Lincomyocin; U 10,149A; LCM; AC1NTUSE; SMP1_000178; AC1LCV3Y; CID6604285; C06812; NSC-70731; CHEMBL1447; KBio3_001441; SPBio_002483; CID7048698; AC1OFCLC; AC1MHD7X; AC1OFCL6; HMS2089A13; NSC70731; Lincorex; CID7092851; Lincomycine; Spectrum_000883; CID7048700; Prestwick2_000302; STK177245; DivK1c_000361; CID3000540; Cillimycin; Mycivin; KBio2_003931	154-21-2	656509	7847290	TTDS00220	50S ribosomal subunit	50S ribosome subunit	N/A	N/A	N/A	inhibitor
DAP000409	Clindamycin	Clindamicina; AC1OFCJ7; CID3032758; Dalacin T Topical Solution; 7-Chloro-7-deoxylincomycin; NCGC00179636-01; HMS2089A05; Chlolincocin; AC1MHUOE; AC1OFCIP; 24620-78-8; 7-CDL; Clindamycine [French]; Prestwick3_000137; NINDS_000464; CID9812677; AC1OIBYN; Clinimycin; SMP2_000295; LS-187128; MLS001183714; CID7276016; Spectrum2_000885; KBio1_000464; BSPBio_002049; SPBio_000670; CID7048644; AC1OFCJ1; 58207-19-5; CID446598; KBioSS_000638; CID3034218; IDI1_000464; D00277; C18H33ClN2O5S; Dalacin C; Spectrum_000158; Clindamycin & VRC3375; Dalacin C Flavored Granules; SPBio_002153; ClindaDerm; AC1L1GLA; Dalacin C Phosphate; CID7048642; clindamycin; 7(S)-Chloro-7-deoxylincomycin; 16669-21-9; AC1O7ENS; Clindamycine [INN-French]; STOCK1N-31150; LS-98131; CID7048648; MolPort-002-964-479; Klimicin; DivK1c_000464; Chlorodeoxylincomycin; BPBio1_000236; STK177246; Cleocin; Prestwick0_000137; CID6604361; HSDB 3037; UNII-3U02EL437C; AC1MHX4G; MolPort-002-323-206; KBio2_005774; AC1OIBYJ; Clindamycin & Interleukin 12; Klindan 300; Clindamycinum [INN-Latin]; Clindamycinum; Cleocin T Gel; BSPBio_000214; Cleocin (TN); BIDD:GT0418; Zindaclin; CHEBI:3745; CID5702026; CID6602476; BRD-A23034328-003-03-4; Cleocin HCl; Clindamycin [USAN:BAN:INN]; AC1MHD7N; CLINDA & IL-12; Prestwick2_000137; Dalacine; DB01190; AC1L1EGQ; 7-Chlorolincomycin; ResiDerm A; EINECS 242-209-1; CLDM; CID7276018; Chlorlincocin; 21462-39-5 (mono-hydrochloride); Spectrum3_000355; AC1OFCIV; CID7048646; U 21251; CID7276014; AC1Q2V4O; KBio3_001269; AC1OIBYL; Prestwick1_000137; Clindamycine; CID2786; Sobelin; Clindamicina [INN-Spanish]; KBio2_003206; NCGC00178843-01; C06914; NCGC00016752-01; HMS2089N16; 13441-63-9; Spectrum4_000292; U-21,251; Chlorolincomycin; CID29029; CLY; Cleocin T Lotion; 24696-19-3; Clindamycin (USAN/INN); AC1MHE1M; AC1O7GED; CID3001928; SMR000677917; CAS-21462-39-5; Antirobe; U-21251; I06-0826; Spectrum5_001525; 7-Deoxy-7(S)-chlorolincomycin; KBioGR_000844; 18323-44-9; CID3000512; AC1L9JV8; CHEMBL187; Cleocin T Topical Solution; KBio2_000638; AC1NWAKO	18323-44-9	29029	171415	TTDS00220	50S ribosomal subunit	50S ribosome subunit	N/A	N/A	N/A	binder
DAP000411	Troleandomycin	NSC 108166; Oleandocetin; HMS2092F08; Troleandomycin [USAN:INN]; AC1O8FBS; AC1L483V; Troleandomycine; Troleandomycinum [INN-Latin]; KBio3_002010; 2751-09-9; KBio2_004190; Prestwick1_000036; Prestwick3_000036; HMS1921L22; Tao (TN); KBio2_001622; DivK1c_006136; Spectrum4_001053; HMS1568G13; KBioSS_001622; Prestwick0_000036; Treis-Micina; AC1L2AG5; Troleandomicina [INN-Spanish]; Triolan; DB01361; TROLEANDOMYCIN; TAO; Spectrum3_000945; C41H67NO14; BPBio1_000145; Wytrion; CHEBI:45735; Spectrum5_001132; AC1NRDAP; BSPBio_000131; Troleandomycine [INN-French]; AI3-50166; Prestwick_594; SpecPlus_000040; UNII-C4DZ64560D; Oleandomycin triacetate; CID6604456; Matromicina; CHEMBL564085; Aovine; T.A.O; Triacetyloleandomycin; CID418931; Oleandomycin triacetyl ester; CID6708521; Triacetyloleandomycinum; CID17675; Oleandomycin, triacetyl-; Evramicina; NSC108166; CID6713914; SPBio_002052; WY 651; EINECS 220-392-9; Triacetyloleandomycin (JAN); KBio1_001080; AC1L9GO5; MolPort-003-666-419; Troleandomycin (USP/INN); CHEMBL553636; HMS2089B10; Matromycin T; T.A.O.; Tribiocillina; FT-0082364; CHEMBL1200719; CHEBI:662206; SPBio_001469; Spectrum_001142; KBioGR_001346; CID5289436; Treolmicina; BIDD:PXR0043; NCGC00179654-01; C12753; AC1O8PUY; Cyclamycin; Viamicina; Spectrum2_001485; Troleandomicina; Troleandomycinum; AC1O7GIN; Triacetyl ester of oleandomycin; LMPK04000042; Triocetin; AB00513798; troleandomycin (TAO); LS-98282; AC1NR4SQ; CID5284630; Prestwick2_000036; Oleandomycin, triacetate (ester); SPECTRUM1502203; D01322; Oleandocetine; KBio2_006758; Tao (VAN); CHEMBL1236187; CID202225	2751-09-9	202225	583142	TTDS00220	50S ribosomal subunit	50S ribosome subunit	N/A	N/A	N/A	binder
DAP000410	Clarithromycin	Clarith; hydro-2H-pyran-2-yl]oxy}-7-methoxy-3,5,7,9,11,13-hexame; BSPBio_003453; Clarithromycin (JP15/USP/INN); Cyllind; MolPort-003-845-969; CHEBI:136451; D00276; AC1NSJWH; Biaxin xl filmtab; Clambiotic; SAM001246748; 116836-41-0; Kofron; Claritromicina [INN-Spanish]; BIDD:GT0200; Spectrum_000089; Maclar; Clarithromycinum; Clarithromycin suspension or tablets; TE031; Klax; CID9810688; Klaricid Pediatric; AC-6813; Klaricid; HMS2090O11; Mabicrol; C30H54O11.C9H19NO2; CID10328822; Claricide; Clarithromycine [INN-French]; TE-031; Klaricid H.P.; Erythromycin, 6-O-methyl-; Clarithromycin [USAN:INN:BAN:JAN]; CID54688; LMPK04000014; LS-1812; MolPort-005-934-146; Helas; CTY; SPBio_001855; AC1L36NJ; KBio2_000509; Claritromicina; 6-O-Methylerythromycin; CID5284534; MLS000759516; AC1O52DV; MolPort-002-507-425; Clarithromycin & Interleukin-12; Biaxin (TN); CRL-1605 & Clarithromycin; Spectrum4_000629; ANX-015; KBio2_003077; Mavid; Bicrolid; SDP-015; Naxy; KBio3_002673; 81103-11-9; HMS2094M05; Abbott-56268; Veclam; Clarithromycin extended release; Astromen; CID9811194; KBio1_001599; Klacid; Claribid; CID6426662; clarithromycina; HMS1922H09; CID5311050; KBioGR_001218; Klaciped; SMR000466382; CHEMBL143; SPECTRUM1504231; MolPort-005-910-192; Spectrum2_001668; (14R)-14-Hydroxyclarithromycin; CPD000466382; CCRIS 8833; HMS2051G18; AC1NFSZE; CID489010; O(6)-methylerythromycin; A-56268; Biaxin HP; Bio-0020; CID4663848; Biaxin; AC1NR4MY; CHEBI:3732; CID11828745; Spectrum3_001667; Macladin; Heliclar; Klaricid XL; 6-O-Methylerythromycin a; Clarithromycine; AC1Q6O1T; Biaxin XL; DivK1c_006655; NSC643733; CID11969952; Klaricid H.P; Klarin; C2220; UNII-H1250JIK0A; CID10147055; Clacine; CID11814635; SpecPlus_000559; Biaxin filmtab; MLS001424066; Klarid; NCGC00178054-01; CLM & IL-12; CID84029; Spectrum5_001729; MLS001201751; Zeclar; C06912; STK801952; clarithromycin; I05-0074; KBio2_005645; Abbotic; DRG-0099; Lactoferrin H & Clarithromycin; Clathromycin; Clarithromycinum [INN-Latin]; Cyllid; AC1L1HJO; Lactoferrin B & Clarithromycin; BB_NC-1450; KBioSS_000509; CHEMBL1741; Adel	81103-11-9	84029	602963	TTDS00220	50S ribosomal subunit	50S ribosome subunit	N/A	N/A	N/A	binder
DAP000109	Telithromycin	(1R,2R,4R,6R,7R,8R,10R,13R,14S)-7-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-13-ethyl-6-methoxy-2,4,6,8,10,14-hexamethyl-17-[4-(4-pyridin-3-ylimidazol-1-yl)butyl]-12,15-dioxa-17-azabicyclo[12.3.0]heptadecane-3,9,11,16-tetrone; CID5462516; CPD000469222; (1R,2S,4R,6R,7R,8R,10R,13R,14S)-7-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-13-ethyl-6-methoxy-2,4,6,8,10,14-hexamethyl-17-[4-(4-pyridin-3-ylimidazol-1-yl)butyl]-12,15-dioxa-17-azabicyclo[12.3.0]heptadecane-3,9,11,16-tetrone; CID3002190; HMR-3647; Ketek (TN); MolPort-005-935-303; CHEMBL1215848; HSDB 7359; LS-182988; RU66647; TEL; MolPort-006-666-261; 191114-48-4; (3R,5S,6S,7R,8S,11S,12R,13S,14R,15S)-12- [(4-O-ACETYL-2,6-DIDEOXY-3-O-METHYL-ALPHA-L-ARABINO-HEXOPYRANOSYL) OXY] -14-{[2-O-ACETYL-3,4,6-TRIDEOXY-3-(DIMETHYLAMINO) BETA-D-XYLO-HEXOPYRANOSYL]OXY} -5,7,8,11,13,15-HEXAMETHYL-4,10-DIOXO-1,9-DIOXASPIRO[2.13]HEXADEC-6-YL ACETATE; CHEMBL1136; Erythromycin, 3-de[(2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribo-hexopyranosyl)oxy]-11,12-dideoxy-6-O-methyl-3-oxo-12,11-[oxycarbonyl[[4-[4-(3-pyridinyl)-1H-imidazol-1-yl]butyl]imino]]-; 173838-31-8; Telithromycin (JAN/USAN/INN); CHEMBL1236249; (1R,2R,4R,6S,7R,8R,10R,13R,14S)-7-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-13-ethyl-6-methoxy-2,4,6,8,10,14-hexamethyl-17-[4-(4-pyridin-3-ylimidazol-1-yl)butyl]-12,15-dioxa-17-azabicyclo[12.3.0]heptadecane-3,9,11,16-tetrone; Telithromycin; RU 66647; CID5496803; CID11693521; UNII-KI8H7H19WL; D01078; AC1NUWEH; AC-1692; Ketek; Levviax; AC1L2K8V; Erythromycin, 3-de((2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl)oxy)-11,12-dideoxy-6-O-methyl-3-oxo-12,11-(oxycarbonyl((4-(4-(3-pyridinyl)-1H-imidazol-1-yl)butyl)imino))-; DB00976; SAM001246805; RU-66647; HMR 3647; CHEBI:46029; C12009; AC1MHE79; HMS2052B11; 11,12-Dideoxy-3-des(2,6-dideoxy-3-C,3-O-dimethyl-alpha-L-altropyranosyloxy)-6-O-methyl-3-oxo-12,11-(oxycarbonylimino)-N11-[4-[4-(3-pyridyl)imidazol-1-yl]butyl]erythromycin A; AC1NUZ37; (1R,2R,4R,6R,7R,8R,10S,13R,14S)-7-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-13-ethyl-6-methoxy-2,4,6,8,10,14-hexamethyl-17-[4-(4-pyridin-3-ylimidazol-1-yl)butyl]-12,15-dioxa-17-azabicyclo[12.3.0]heptadecane-3,9,11,16-tetrone; CID9918852; Telithromycin [USAN:BAN:INN]; HMR3647; NCGC00167967-01	191114-48-4	5462516	14168	TTDS00220	50S ribosomal subunit	50S ribosome subunit	N/A	N/A	N/A	binder
DAP000408	Azithromycin	1-Oxa-6-azacyclopentadecan-15-one, 13-((2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl)oxy)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-((3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl)oxy)-, (2R-(2R*,3S*,4R*,5R*,8R*,10R*,11R*,12S*,13S*,14R*))-; Zithromax IV; DCH3; MLS001201763; Zentavion; SMR000471864; 1-Oxa-6-azacyclopentadecan-15-one, 13-((2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl)oxy)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-((3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl)oxy)-,(2R-(2R*,3S*; Aritromicina; Hemomycin; (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-15-oxo-11-{[3,4,6-trideoxy-3-(dimethylamino)-b-D-xylo-hexopyranosyl]oxy}-1-oxa-6-azacyclopentadecan-13-yl 2,6-dideoxy-3-C-methyl-3-O-methyl-a-L-ribo-hexopyranoside; Azithromycin & Tumor Necrosis Factor; 1-Oxa-6-azacyclopentadecan-15-one, 13-((2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl)oxy)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-((3,4,6-trideoxy-3-     (dimethylamino)-beta-D-xylo-hexopyranosyl)oxy)-, monohydrate,     (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-; MLS001055353; Azifast; AC1L9KEG; Spectrum_000307; DRG-0104; HMS1922G12; KBio2_000787; CP62,993; Z-Pak; KBioSS_000787; DivK1c_000233; Zmax; HMS500L15; CCRIS 1961; Sumamed; (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-13-((2,6-Dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl)oxy)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-((3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl)oxy)-1-oxa-6-azacyclopentadecan-15-one; (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-15-oxo-11-{[3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl]oxy}-1-oxa-6-azacyclopentadecan-13-yl 2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranoside; Zitromax; Azithromycin (anhydrous); Azigram; Zithromycin; MLS001304005; Azitromin; NCGC00090753-02; [2R-(2R*,3S*,4R*,5R*,8R*,10R*,11R*,12S*,13S*,14R*)]-13-[(2,6-Dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-; Misultina; ZIT; Zithromax; KBio1_000233; NSC643732; KBio2_005923; Spectrum3_000653; azithromycin; CP-62993; Spectrum2_001582; UNII-JTE4MNN1MD; MolPort-002-507-426; BRN 5387583; 121470-24-4; CHEBI:2955; IDI1_000233; NINDS_000233; Zithromac; SPECTRUM1503679; KBio2_003355; Tromix; Azimakrol; MLS001332499; NCGC00090753-01; SPBio_001544; BSPBio_002285; Azithromycin (AIDS Initiative); Azithromycin Monohydrate; AC-16014; Zitromax Avium 600; MLS001066331; 75199_FLUKA; Spectrum5_001867; HSDB 7205; Azasite; C38H72N2O12; Azithromycinum; (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)13-((2,6-Dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl)oxy)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-((3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl)oxy)-1-oxa-6-azacyclopentadecan-15-one; Spectrum4_000186; Azitromax; LS-1834; MLS001332500; CHEMBL529; SAM002589961; Azythromycin; HMS2094M11; 9-Deoxo-9a-aza-9a-methyl-9a-homoerythromycin A; Zmas; CID447043; Azithromycine; Bio-0676; 83905-01-5; Azenil; CPD000471864; KBio3_001505; Azitrocin; (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-11-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-2-ethyl-3,4,10-trihydroxy-13-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,6,8,10,12,14-heptamethyl-1-oxa-6-azacyclopentadecan-15-one; XZ-450; BIDD:GT0792; KBioGR_000731	83905-01-5	55185	9056	TTDS00220	50S ribosomal subunit	50S ribosome subunit	N/A	N/A	N/A	binder
DCL000492	Azithromycin/chloroquine	N/A	83905-01-5	N/A	N/A	TTDS00220	50S ribosomal subunit	50S ribosome subunit	N/A	N/A	N/A	binder
DAP000111	Erythromycin	Erycen; N-Methylerythromycin A; STK249736; Erygel; NSC55929; CID3255; ERY; AC-12744; Erytop; MolPort-003-933-429; Ery-Tab; Ilotycin; Paediathrocin; ERYTHROMYCIN STEARATE; SPECTRUM1500280; Erythromycinum [INN-Latin]; Erythromycin [INN:BAN:JAN]; Aknin; AustriaS; E0751; Erythromycin Lactate; Eryacnen; Eryc 125; Robimycin; Staticin; E-Glades; Romycin; KBio2_003123; Eritromicina [INN-Spanish]; AR-1H0723; Erythrogran; erythro; PCE Dispertab (base); Latotryd; MolPort-000-772-161; Tiprocin; Stiemicyn; NCGC00179619-01; Erimycin-T; Eritomicina; KBioGR_001175; Erythromycin A, T-Stat, Pantomicina, HSDB 3074, Erytab, DRG-0279; Iloticina; IDI1_000397; Propiocine; Erythromid; BSPBio_002480; Erymax; Spectrum5_001596; Sans-acne; Akne Cordes Losung; ERYC (base); E-Mycin; Emu-V; CHEBI:42355; Erymed; KBioSS_000555; HMS500O16; Erythromycin & VRC3375; Benzamycin Pak; IDI1_000294; Acnesol; KBio2_001139; Inderm Gel; SPBio_000778; SMP1_000119; Retcin; Endoeritrin; Erythromycin sodium lauryl sulfate; Abomacetin; AC1Q2UA1; Akne-Mycin; Erecin; E-Base; Erytrociclin; Ak-Mycin; Oftalmolosa Cusi Eritromicina; Acneryne; Erisone; Erythromast 36; CHEMBL532; HMS1920M04; Oftamolets; CID12560; Erythroguent; Erythra-Derm; SPBio_001226; Ery-Sol; Eryderm; DivK1c_000397; Eryacne; Erydermer; Mercina; SPBio_002221; DivK1c_000702; Emgel; LMPK04000006; Deripil; adecane-2,10-dione (non-preferred name); Eros; Tiloryth; BB_NC-1332; Proterytrin; KBio2_005691; Sansac; Prestwick3_000151; D00140; Akne-mycin (TN); T-Stat; Erytab; AC1Q6O1S; KBioSS_001139; Aknederm Ery Gel; 45673_FLUKA; Theramycin Z; DivK1c_000294; Erythromycine [INN-French]; UNII-63937KV33D; Skid Gel E; LS-64648; Pantomicina; Eryc Sprinkles; nchembio.285-comp13; Erythromycin A; Spectrum_000659; AC1L1FIQ; Erythroderm; Prestwick1_000151; KBio1_000702; CID8233; E- mycin, Erycin, Robimysin; E7904_SIGMA; Erythro-Teva; Ilosone (estolate); Lederpax; BPBio1_000312; Aknemycin; Prestwick2_000151; I06-0245; Erythromycine; 114-07-8; 374700-25-1; E6376_SIAL; Erycinum; 45674_FLUKA; Del-Mycin; Ilotycin T.S.; Derimer; KBio1_000397; KBio2_006275; ERYC; Emycin; NINDS_000397; NINDS_000294; Ery-Diolan; Dumotrycin; AC1L1ZUR; IndermRetcin; Erycin; bmse000664; BSPBio_000282; Ermycin; EINECS 204-040-1; R-P Mycin; Prestwick0_000151; C-Solve-2; E-Base (base); NINDS_000702; A/T/S; MolPort-002-507-378; 82343-12-2; Erysafe; DB00199; Udima Ery Gel; Ilotycin T.S; AC1L1QK7; MLS001066618; HMS2091D05; Erythromycin (JP15/USP/INN); Erythro-Statin; Prestwick_205; Kesso-Mycin; Abboticin; AC1O8PVA; T-stat (TN); C01912; Erythromycinum; BIDD:GT0017; Erythromycin intravenous; Erythromycin base; SMR000544946; KBio1_000294; Erythromycin, compd. with monododecyl sulfate, sodium salt; Stiemycin; erythromycin; LS-187077; E0774_SIAL; Eryhexal; Spectrum_000115; Erythromycin, N-demethyl-N-(methyl-11C)-; Emuvin; Taimoxin-F; Spectrum2_000759; EM; Ilocaps; Torlamicina; Pantodrin; Ery-B; Erycette; Emu-Ve; SBB057401; Wemid; KST-1A8261; NSC 55929; Eritromicina; 79235-06-6; Staticin (TN); Pharyngocin; Erythromycin Ointment; C37H67NO13; Dotycin; Pce (TN); HMS1568O04; Eritrocina; Primacine; NCI-C55674; E-Mycin (base); Eryc-125; AI3-50138; Benzamycin; Eryc (TN); Sulfuric acid, monododecyl ester, sodium salt, compd. with erythromycin; Erygel (TN); Ery-Tab (base); Mephamycin; ,10-dione; Ery-maxin; KBio2_003707; IDI1_000702; E-Solve 2; CID6713919; Spectrum2_001263; E5389_SIGMA; CCRIS 9078; HSDB 3074; KBio2_000555; AR-1A4414; Pantoderm; Spectrum4_000538; Eryc-250; Inderm	114-07-8	12560	5020	TTDS00220	50S ribosomal subunit	50S ribosome subunit	N/A	N/A	N/A	binder
DAP000885	Roxithromycin	Erythromycin, 9-(O-((2-methoxyethoxy)methyl)oxime), (9E)-; Surlid; SPECTRUM1503276; Prestwick_1046; CID5106; R4393_SIGMA; 80214-83-1; C13173; SPBio_001422; C41H76N2O15; CID9604450; Rulide (TN); HMS501D04; CHEBI:32109; Spectrum3_001159; BCBcMAP01_000131; KBio2_007269; RU 28965; Prestwick2_000854; SPBio_002788; HMS2093C11; KBio3_002217; RU-28965; FT-0084508; Roxithromycinum [Latin]; Assoral; Roxithromycin [USAN:INN:JAN]; HMS2090N05; RC2952; Spectrum2_001551; Erythromycin 9-(O-((2-methoxyethoxy)methyl)oxime); KBio2_004701; MLS001304008; CHEMBL1214185; 9-[O-[(2-Methoxyethoxy)methyl]oxime]erythromycin, (9E)-; AC1OCCUC; TL8005408; Roxithromycin (JP15/USAN/INN); KBioGR_000779; Spectrum_001653; KBio2_002133; Rulid; CID9604982; MolPort-000-788-289; Overall; AC1L9FLG; Roxitromicina [Spanish]; KBio1_000382; BSPBio_002717; CHEBI:48935; BRN 4286925; Prestwick0_000854; KBioSS_002133; CID9567573; D01710; Roxithromycine; HMS1570L09; Roxitromicina; AC1L1JMI; Bio-0657; HMS1922O19; LS-64684; SMP1_000054; RU-965; NCGC00178510-01; S2506_Selleck; IDI1_000382; Prestwick1_000854; Rossitrol; DivK1c_000382; CID54548; CID5480431; RU 965; CID5353933; CAS-80214-83-1; AC1NUJ9L; 9-[O-(2-methoxyethoxymethyl)-oxime] of erythromycin; SMR001233360; 9-(O-((2-Methoxyethoxy)methyl)oxime)erythromycin; AC1NS4PZ; NCGC00016942-01; SMR000718779; Erythromycin, 9-(O-((2-methoxyethoxy)methyl)oxime); CID444037; Roxithromycine [French]; CID9574581; CHEBI:48844; MLS002154033; Roxithromycin & Tumor Necrosis Factor; Rulide; AC1L1H8O; RXM; CCRIS 3461; Spectrum5_001058; Roxithromycinum; Spectrum4_000200; ST51015117; NINDS_000382; DB00778; CID6915744; Erythromycin 9-(-O-[2-methoxyethoxy]methyloxime); roxithromycin; MolPort-003-959-451	80214-83-1	444037	585237	TTDS00220	50S ribosomal subunit	50S ribosome subunit	N/A	N/A	N/A	inhibitor
DAP000886	Retapamulin	Altabax (Glaxo); 345632-67-9; SB 275833; Retapamulin; CID6918462; Altargo; CHEMBL1658; 224452-66-8; UNII-4MG6O8991R; DB01256; D05720; Altabax; Retapamulin (USAN/INN); Altabax (TN)	224452-66-8	6918462	16578667	TTDS00220	50S ribosomal subunit	50S ribosome subunit	N/A	N/A	N/A	inhibitor
DCL000482	AZD8075	N/A	N/A	N/A	N/A	TTDC00237	Putative G-protein coupled receptor 44	CD294;Chemoattractant receptor-homologous molecule expressed on Th2 cells	Q9Y5Y4	11251	ENSG00000183134	antagonist
DCL000460	AZD1981	N/A	155270-99-8	5311037	47206484	TTDC00237	Putative G-protein coupled receptor 44	CD294;Chemoattractant receptor-homologous molecule expressed on Th2 cells	Q9Y5Y4	11251	ENSG00000183134	antagonist
DCL000472	AZD5985	N/A	N/A	65002	44847056	TTDC00237	Putative G-protein coupled receptor 44	CD294;Chemoattractant receptor-homologous molecule expressed on Th2 cells	Q9Y5Y4	11251	ENSG00000183134	antagonist
DCL001241	SGN-70	N/A	N/A	N/A	N/A	TTDC00337	CD70	CD70 antigen;CD27 ligand;CD27-L;Tumor necrosis factor ligand superfamily member 7	P32970	970	ENSG00000125726	antibody
DCL001242	SGN-75	N/A	N/A	N/A	N/A	TTDC00337	CD70	CD70 antigen;CD27 ligand;CD27-L;Tumor necrosis factor ligand superfamily member 7	P32970	970	ENSG00000125726	antibody
DAP000082	Liothyronine	KBioSS_001925; CHEMBL1544; T3; Spectrum5_001793; CHEBI:18258; SR-01000003143; KBio2_001925; Tri-Thyrotope; triothyrone; 5714-08-9; Tresitope; Spectrum4_000326; 3,3',5-Triiodothyronine; SR-01000003143-4; KBio2_005136; 3,3'5-Triiodo-L-thyronine; Liothyronin; T3 (amino acid); BPBio1_000953; BSPBio_000865; L-3,3',5-TriioDOThyronine; Spectrum3_001887; CHEBI:533015; BCBcMAP01_000192; SMP1_000179; Liothyronine (INN); Lyothyronine; DB00279; 57164-27-9; NCGC00096669-01; Euthroid-1; NSC 80203; T3 (Triiodothyronine); 3,5,3'TRIIODOTHYRONINE; MLS000028458; Triiodothyronine (T3); Liothyronine [INN:BAN]; Liothyronine I 131 [USAN]; Liothyroninum [INN-Latin]; Liothyronine I 131; L-3,5,3'-Triiodothyronine; SMR000058402; BRD-K89152108-001-03-3; Prestwick0_000853; triiodothyronine; 3,5,3'-triiodothyronine; THYROID HORMONE; 20196-64-9; Alanine, 3-(4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl)-, L-; KBio2_007061; T3 (VAN); Euthroid-3; KBio2_007704; 4-(4-Hydroxy-3-iodophenoxy)-3,5-diiodophenylalanine; L-Tyrosine, O-(4-hydroxy-3-iodophenyl)-3,5-diiodo- (9CI); Prestwick3_000853; HSDB 3110; SPBio_002167; AC1L1LF0; Thyrolar-2; KBioGR_000671; Liotironina; NSC-46046; NCGC00096669-02; KBio3_002897; T3 (Hormone); Prestwick1_000853; nchembio.106-comp8; L-T3; Prestwick2_000853; UNII-86AZ0G22V2; 3,5,3'-Triiodo-L-thyronine; Thyrolar-3; KBio2_004493; Triiodo-L-thyronine; Spectrum2_001984; SPBio_002786; CID5920; Thyronine, 3,3',5-triiodo-, L-; KBioSS_002577; Spectrum_001445; Euthroid-2; C02465; 1xzx; T0453; O-(4-Hydroxy-3-iodophenyl)-3,5-diiodo-L-tyrosine; KBioGR_002568; InChI=1/C15H12I3NO4/c16-9-6-8(1-2-13(9)20)23-14-10(17)3-7(4-11(14)18)5-12(19)15(21)22/h1-4,6,12,20H,5,19H2,(H,21,22; 7013-53-8; TRIIODOTHYRONINE (T3 OR LIOTHYRONINE, ACTIVE) (6-11%); Euthroid-0.5; 6893-02-3; BRN 2710227; Liothyroninum; cMAP_000088; Liotironina [INN-Spanish]; 3,3',5-Triiodothyronine, L-; KBio3_003046; Thyronine, 3,3',5-triiodo-, L- (6CI); (2S)-2-amino-3-[4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl]propanoic acid; L-3-(4-(4-Hydroxy-3-iodophenoxy)-3,5-diiodophenyl)alanine; UNII-06LU7C9H1V; HMS1570L07; 4-(3-Iodo-4-hydroxyphenoxy)-3,5-diiodophenylalanine; T3 liothyronine; D08128; 3,5,3'-Tri-iodo-L-thyronine; Triiodothyronine, l-; liothyronine; Thyrolar-0.5; T2877_SIGMA; C15H12I3NO4; Prestwick_135; 4-(4-hydroxy-3-iodophenoxy)-3,5-diiodo-L-phenylalanine; KBio2_002568; NCGC00013556; 3,3',5-Triiodo-L-thyronine; MolPort-003-850-717; EINECS 229-999-3; L-Liothyronine; L-Tyrosine, O-(4-hydroxy-3-iodophenyl)-3,5-diiodo-; Thyrolar-1; BSPBio_003394; Thyrolar-0.25; Rathyronine; NCIStruc1_000449; Triomet-131; LS-16137	6893-02-3	5920	5481	TTDS00381	Thyroid hormone receptor alpha	C-erbA-1;C-erbA-alpha;EAR7;EAR-7	P10827	7067	ENSG00000126351	antagonist
DAP000083	Levothyroxine	Spectrum3_000611; Thyrax; MolPort-003-666-820; BPBio1_000360; 1hk1; Prestwick0_000403; Oroxine; LT00440967; SPECTRUM1500774; Levothroid (*Sodium salt*); 3,5,3',5'-Tetraiodo-L-thyronine; T2376_SIGMA; 3,5,3'5'-Tetraiodo-L-thyronine; EINECS 200-101-1; SAM002264651; BSPBio_002142; beta-((3,5-Diiodo-4-hydroxyphenoxy)-3,5-diiodophenyl)alanine; Thyroxevan; Synthroid sodium; BRD-K30685142-001-05-5; SPBio_002265; NSC 36397; L-Thyroxin; 3-(4-(4-Hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl)alanine; L-Tyrosine, O-(4-hydroxy-3,5-diiodophenyl)-3,5-diiodo-; Prestwick1_000403; 1y0x; Spectrum5_001500; Synthroid (*Sodium salt*); NCGC00164336-01; eltroxin; MLS000028647; levothyroxine; BRN 2228515; Thryroxine, l-; Levo-T; Levothyroxine (BAN); Spectrum2_000573; 55-03-8; Forthyron (TN); HMS2090P18; CHEMBL1624; Prestwick2_000403; 3,3',5,5'-Tetraiodo-L-thyronine; Thyroxinal; 1hk5; Levothyroxine Sodium (L-thyroxine); 587-29-1; 24486-40-6; BIDD:PXR0161; NCGC00164336-03; Laevothyroxinum; D08125; T-3850; 74-16-8; Levothyrox; 51-48-9; t4; SPBio_000386; KBio1_001911; HMS1921I06; SpecPlus_000871; 3,3',5,5''-Tetraiodo-L-thyronine; DL-Thyroxin; Euthyrox; BSPBio_000326; AC-7504; Thyroxine [BAN]; Levothyroxinum (acid); Thyreoideum; 1hk3; L-Thryoxin; KBio3_001642; (125I)T4; 587-30-4; Thyroxine, L- (8CI); 3,5,3',5'-Tetraiodothyronine; synthroid; DivK1c_006967; Spectrum4_000128; Thyroxine (VAN); 3,3',5,5"-Tetraiodo-L-thyronine; O-(4-Hydroxy-3,5-diidophenyl)-3,5-diiodo-L-tyrosine; DB00451; thyroxin; L-thyroxine; CCRIS 6739; O-(4-Hydroxy-3,5-diiodophenyl)-3,5-diiodotyrosine; Laevothyroxinum (acid); T4 (Hormone); AC1L1L7K; 2ceo; KBioSS_001556; Levothyroxine sodium; Levoxyl; (-)-Thyroxine; KBio2_004124; Prestwick3_000403; KBio2_006692; Tetraiodothyronine; 4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodo-L-phenylalanine; 1hk2; C01829; Forthyron; O-(4-hydroxy-3,5-diiodophenyl)-3,5-diiodo-L-tyrosine; C15H11I4NO4; KBioGR_000516; Thyroxine iodine; THX; (2S)-2-amino-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]propanoic acid; UNII-Q51BO43MG4; HMS1569A08; Levolet; CHEBI:18332; SMR000059176; 7200-84-2; Prestwick_548; L-T4; SDCCGMLS-0066571.P001; CID5819; 1hk4; NCGC00164336-02; Thyroxine, L-; LS-158291; CPD000059176; KBio2_001556; Spectrum_001076; Thyratabs; 2-amino-3-[4-(4-hydroxy-3,5-diiodo-phenoxy)-3,5-diiodo-phenyl]-propanoic acid; Laevoxin; HMS2092K12; T1775_SIGMA; T4 levothyroxine; L-3,5,3',5'-Tetraiodothyronine; 3-[4-(4-Hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]-L-alanine; InChI=1/C15H11I4NO4/c16-8-4-7(5-9(17)13(8)21)24-14-10(18)1-6(2-11(14)19)3-12(20)15(22)23/h1-2,4-5,12,21H,3,20H2,(H,22,23; levothroid; HSDB 3108; Thyroxine (l); Levothyroxin	51-48-9	5819	7854286	TTDS00381	Thyroid hormone receptor alpha	C-erbA-1;C-erbA-alpha;EAR7;EAR-7	P10827	7067	ENSG00000126351	antagonist
DCL001138	ALN-TTR01	N/A	N/A	N/A	N/A	TTDC00329	mRNA of transthyretin	mRNA of ATTR;mRNA of Prealbumin;mRNA of TBPA	P02766	7276	ENSG00000118271	N/A
DCL001204	ISIS-TTR	N/A	N/A	N/A	N/A	TTDC00329	mRNA of transthyretin	mRNA of ATTR;mRNA of Prealbumin;mRNA of TBPA	P02766	7276	ENSG00000118271	antisense
DCL000218	RX-0201	N/A	N/A	N/A	N/A	TTDC00132	RAC-alpha serine/threonine kinase	Akt;C-AKT;PKB;Protein kinase B;RAC-PK-alpha;Serine/threonine protein kinase PKB	P31749	207	ENSG00000142208	inhibitor
DCL000570	MK-2206	N/A	133652-38-7	N/A	47207382	TTDC00132	RAC-alpha serine/threonine kinase	Akt;C-AKT;PKB;Protein kinase B;RAC-PK-alpha;Serine/threonine protein kinase PKB	P31749	207	ENSG00000142208	inhibitor
DCL001186	GDC-0068	N/A	N/A	N/A	N/A	TTDC00132	RAC-alpha serine/threonine kinase	Akt;C-AKT;PKB;Protein kinase B;RAC-PK-alpha;Serine/threonine protein kinase PKB	P31749	207	ENSG00000142208	inhibitor
DCL000109	Enzastaurin	3-(1-methylindol-3-yl)-4-[1-[1-(pyridin-2-ylmethyl)piperidin-4-yl]indol-3-yl]pyrrole-2,5-dione; CHEMBL300138; UNII-UC96G28EQF; 1H-Pyrrole-2,5-dione, 3-(1-methyl-1H-indol-3-yl)-4-(1-(1-(2-pyridinylmethyl)-4-piperidinyl)-1H-indol-3-yl)-; 170364-57-5; LY317615; 3-(1-methyl-1H-indol-3-yl)-4-{1-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1H-indol-3-yl}-1H-pyrrole-2,5-dione; AC-5900; CID176167; AC1L41YQ; LY317615, Enzastaurin; LE-0014; S1055_Selleck; CHEBI:183217; Enzastaurin	170364-57-5	176167	3891570	TTDC00132	RAC-alpha serine/threonine kinase	Akt;C-AKT;PKB;Protein kinase B;RAC-PK-alpha;Serine/threonine protein kinase PKB	P31749	207	ENSG00000142208	inhibitor
DCL000009	XL418	N/A	N/A	N/A	N/A	TTDC00132	RAC-alpha serine/threonine kinase	Akt;C-AKT;PKB;Protein kinase B;RAC-PK-alpha;Serine/threonine protein kinase PKB	P31749	207	ENSG00000142208	inhibitor
DCL001093	VQD-002	N/A	N/A	N/A	N/A	TTDC00132	RAC-alpha serine/threonine kinase	Akt;C-AKT;PKB;Protein kinase B;RAC-PK-alpha;Serine/threonine protein kinase PKB	P31749	207	ENSG00000142208	inhibitor
DCL000194	Perifosine	CHEMBL372764; C105905; FT-0083490; ST51054138; (1,1-dimethylpiperidin-1-ium-4-yl) octadecyl phosphate; KRX-0401, NSC 639966; Perifosine; octadecyl-(1,1-dimethyl-4-piperidylio)phosphate; Piperidinium, 4-((hydroxy(octadecyloxy)phosphinyl)oxy)-1,1-dimethyl-, inner salt; CID148177; UNII-2GWV496552; AKOS005146344; I14-1991; NSC 639966; KRX-0401; D-21266; NKA17; Piperidinium, 4-[[hydroxy(octadecyloxy)phosphinyl]oxy]-1,1-dimethyl-, inner salt; NSC-639966; 4-((Hydroxy(octadecyloxy)phosphinyl)oxy)-1,1-dimethylpiperidinium inner salt; D 21266; S1037_Selleck; AC1L3WLE; 157716-52-4; MolPort-005-943-222	N/A	148177	12014848	TTDC00132	RAC-alpha serine/threonine kinase	Akt;C-AKT;PKB;Protein kinase B;RAC-PK-alpha;Serine/threonine protein kinase PKB	P31749	207	ENSG00000142208	inhibitor
DCL001092	MK2206	N/A	N/A	N/A	N/A	TTDC00132	RAC-alpha serine/threonine kinase	Akt;C-AKT;PKB;Protein kinase B;RAC-PK-alpha;Serine/threonine protein kinase PKB	P31749	207	ENSG00000142208	inhibitor
DCL000086	CI-1033	S1019_Selleck; N-(4-((3-Chloro-4-fluorophenyl)amino)-7-(3-(morpholin-4-yl)propoxy)quinazolin-6-yl)prop-2-enamide; Canertinib HCl; N-[4-(3-chloro-4-fluoroanilino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]prop-2-enamide dihydrochloride; 2-Propenamide, N-(4-((3-chloro-4-fluorophenyl) amino)-7-(3-(4-morpholinyl) propoxy)-6-quinazolinyl)-, dihydrochloride; CI-1033; UNII-C78W1K5ASF; D03350; AC1L4G5R; I14-8433; 2-Propenamide, N-(4-((3-chloro-4-fluorophenyl)amino)-7-(3-(4-morpholinyl)propoxy)-6-quinazolinyl)-, dihydrochloride; EC-000.2258; 267243-28-7; CI1033; PD-0183805; 289499-45-2; CHEMBL545315; PD 183805; CHEMBL31965; CID156413; CHEBI:61399; N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(morpholin-4-yl)propoxy]quinazolin-6-yl}prop-2-enamide; LS-185636; Canertinib dihydrochloride; N-[4-(3-Chloro-4-fluorophenylamino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]acrylamide dihydrochloride; N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl]-2-propenamide dihydrochloride; Canertinib, PD-183805, CI1033, PD183805; AKOS005145818; Canertinib dihydrochloride [USAN]; Canertinib; CID156414; AC-2414; I06-1255; CI 1033; N-[4-(3-chloro-4-fluoroanilino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]prop-2-enamide; Canertinib dihydrochloride (USAN); AB1004832; Canertinib dihydrochloride; PD-183805; AC1L4G5O; UNII-ICJ93X8X90; N-(4-(3-chloro-4-fluorophenyl)amino)-7-(3-morpholin-4-yl)propoxy)quinazolin-6-yl)prop-2-enamide dihydrochloride	289499-45-2	156414	12015296	TTDC00132	RAC-alpha serine/threonine kinase	Akt;C-AKT;PKB;Protein kinase B;RAC-PK-alpha;Serine/threonine protein kinase PKB	P31749	207	ENSG00000142208	inhibitor
DCL000985	Siplizumab	288392-69-8; Siplizumab; D05847; Siplizumab (USAN/INN)	288392-69-8	N/A	47207508	TTDS00368	T-cell surface antigen CD2	CD2;Erythrocyte receptor;LFA-2;LFA-3 receptor;Rosette receptor;T-cell surface antigen T11/Leu-5	P06729	914	ENSG00000116824	antibody
DAP000540	Alefacept	N/A	222535-22-0	N/A	46505772	TTDS00368	T-cell surface antigen CD2	CD2;Erythrocyte receptor;LFA-2;LFA-3 receptor;Rosette receptor;T-cell surface antigen T11/Leu-5	P06729	914	ENSG00000116824	inhibitor
DCL000411	GSK1521498	GSK-1521498B; GSK-1521498	N/A	447379	49603820	TTDS00126	Mu-type opioid receptor	MOR-1;MOR1A;Mu opioid receptor	P35372	4988	ENSG00000112038	agonist
DAP001140	Alvimopan	Glycine, N-((2S)-2-(((3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl)methyl)-1-oxo-3-phenylpropyl)-; ]-, [3R-[1(S*),3.alpha.,4.alpha.]]-; DB06274; CID5488548; 2-[[(2S)-2-benzyl-3-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethylpiperidin-1-yl]propanoyl]amino]acetic acid; Glycine, N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl; Glycine, N-[(2S)-2-[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-; trans-3,4-dimethyl-4-(3-hydroxyphenyl) piperidine; CHEMBL270190; Adl 8-2698; LY 246736; LY246736; Alvimopan; AC1NUQN6; 170098-38-1 (dihydrate); UNII-Q153V49P3Z; Alvimopan anhydrous; I06-1921; 156053-89-3	156053-89-3	5488548	17397035	TTDS00126	Mu-type opioid receptor	MOR-1;MOR1A;Mu opioid receptor	P35372	4988	ENSG00000112038	antagonist
DAP001353	Buprenex	DB00921; CID40400; 52485-79-7; AC1L9B1P; 6,14-ethenomorphinan-3-ol, 17-(cyclopropylmethyl)-4,5-epoxy-18,19-dihydro-7-[(1S)-1-hydroxy-1,2,2-trimethylpropyl]-6-methoxy-, (5alpha,7alpha)-; ETI-311; (-)-buprenorphine; BEMA long acting analgesic; CID11969480; AC1LD8IH; 6,14-Ethenomorphinan-7-methanol, 17-(cyclopropylmethyl)-alpha-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-alpha-methyl-, hydrochloride, (5-alpha,7-alpha(S))-; 52485-79-7 (Parent); Buprenorfina; RX-6029-M; Temgesic; CL 112302; NIH 8805; AC1L23NL; MolPort-003-983-827; C08007; Buprenophine; TSN-09; Buprenorphine hydrochloride [USAN:JAN]; Subutex; EINECS 257-950-6; 6,14-Ethenomorphinan-7-methanol, 17-(cyclopropylmethyl)-alpha-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-alpha-methyl-, (5-alpha,7-alpha-(S))-; 21-Cyclopropyl-7alpha-((S)-1-hydroxy-1,2,2-trimethylpropyl)-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine hydrochloride; 2-(N-Cyclopropylmethyl-4,5alpha-epoxy-3-hydroxy-6-methoxy-6,14-endo-ethanomorphinan-7alpha-yl)-3,3-dimethyl-2-butanol; CL 112,302; 17-cyclopropylmethyl-4,5alpha-epoxy-7alpha-((S)-1-hydroxy-1,2,2-trimethylpropyl)-6-methoxy-6,14-endo-ethanomorphinan-3-ol; IX-1005; LS-67682; [5alpha,7alpha(S)]-17-(Cyclopropylmethyl)-alpha-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-alpha-methyl-6,14-ethenomorphinan-7-methanol; Finibron; DEA No. 9064; (5alpha,6beta,14beta,18R)-17-(cyclopropylmethyl)-18-[(2S)-2-hydroxy-3,3-dimethylbutan-2-yl]-6-methoxy-18,19-dihydro-4,5-epoxy-6,14-ethenomorphinan-3-ol; RX 6029M; [5alpha,7alpha(S)]-; 53187-13-6; Buprex; C29H41NO4.HCl; Buprenorphinum; AC1MHV55; MolPort-004-285-844; 2-(N-cyclopropylmethyl-4,5alpha-epoxy-3-hydroxy-6-methoxy-6,14-endo-ethanomorphinan-6alpha-yl)-3,3-dimethyl-2-butanol; Buprenorphine [INN:BAN]; Transtec; LS-67683; Buprenex; MR 56; UNII-56W8MW3EN1; Buprenorphine hydrochloride (JAN/USP); 21-cyclopropyl-7alpha-(2-hydroxy-3,3-dimethyl-2-butyl)-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine; 6,14-Ethenomorphinan-7-methanol, 17-(cyclopropylmethyl)-alpha-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-alpha-methyl-,; UM-952; D00836; 21-cyclopropyl-7alpha-[(S)-1-hydroxy-1,2,2-trimethylpropyl]-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine; 6,14-Ethenomorphinan-7-methanol, 17-(cyclopropylmethyl)-alpha-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-alpha-methyl-, hydrochloride, (5alpha,7alpha(S))-; IX-1003; EINECS 258-396-8; BEMA-buprenorphine; MolPort-006-393-069; CHEMBL1200401; RX 6029-M; (5alpha,7alpha(S))-alpha-tert-Butyl-17-(cyclopropylmethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-alpha-methyl-6,14-ethenomorphinan-7-methanol hydrochloride; 6,14-Ethenomorphinan-7-methanol, 17-(cyclopropylmethyl)-alpha-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-alpha-methyl-, (alphaS,5alpha,7alpha)- (9CI); IX-1004; CID644073; CID441364; 17-Cyclopropylmethyl-4,5alpha-epoxy-7alpha-((S)-1-hydroxy-1,2,2-trimethylpropyl-6-methoxy-6,14-endo-ethanomorphinan-3-ol; Butrans; Norspan; V-1005; 21-(Cyclopropyl-7alpha-((S)-1-hydroxy-1,2,2-trimethylpropyl-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine; 6029-M; 64425-21-4; CL-112302; CHEBI:3216; C29H41NO4; V-1004; NIH-8805; Buprel; 55327-62-3; UNII-40D3SCR4GZ; Buprenorphine Depot; CID3033050; Buprenorphinum [INN-Latin]; 53152-21-9; BUPRENORPHINE HYDROCHLORIDE; 6,14-Ethenomorphinan-7-methanol, 17-(cyclopropylmethyl)-alpha-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-alpha-methyl-, (5alpha,7alpha(S))-; BEMA LA; Buprenorfina [INN-Spanish]; 53152-21-9 (hydrochloride); UM 952; Buprenorphine Hcl; Buprenex (TN); Probuphine; V-1003; buprenorphine	52485-79-7	40400	181274	TTDS00126	Mu-type opioid receptor	MOR-1;MOR1A;Mu opioid receptor	P35372	4988	ENSG00000112038	agonist
DAP001136	Diphenoxylate	2,2-Diphenyl-4-(4-carbethoxy-4-phenylpiperidino)butyronitrile; EINECS 213-020-1; 1-(3-Cyano-3,3-diphenylpropyl)-4-phenylisonipecotic acid ethyl ester hydrochloride; 3810-80-8 (mono-hydrochloride); diphenoxylate hydrochloride(usp); AC1L21V6; 1-(3-Cyano-3,3-diphenylpropyl)-4-phenyl-4-piperidinecarboxylic acid ethyl ester; 5-22-02-00487 (Beilstein Handbook Reference); AC1Q4QOH; 3810-80-8; Diphenoxylatum; FT-0080160; ethyl 1-(3-cyano-3,3-diphenylpropyl)-4-phenylpiperidine-4-carboxylate hydrochloride; 4-Piperidinecarboxylic acid, 1-(3-cyano-3,3-diphenylpropyl)-4-phenyl-, ethyl ester (9CI); Isonipecotic acid, 1-(3-cyano-3,3-diphenylpropyl)-4-phenyl-, ethyl ester; Difenoxilato; LS-85078; EINECS 223-287-6; AC1L2EKB; C30H32N2O2.HCl; 1-(3-cyano-3,3-diphenylpropyl)-4-(ethoxycarbonyl)-4-phenylpiperidinium chloride; 4-Piperidinecarboxylic acid, 1-(3-cyano-3,3-diphenylpropyl)-4-phenyl-, ethyl ester; SMR000469140; 915-30-0 (Parent); CHEMBL1200665; R 1132; BRN 0503374; R-1132; D07861; NCGC00167963-01; ethyl 1-(3-cyano-3,3-diphenylpropyl)-4-phenylpiperidin-1-ium-4-carboxylate chloride; Difenossilato [DCIT]; Diphenoxylate HCl; HSDB 3067; UNII-W24OD7YW48; Diphenoxalate; Isonipecotic acid, 1-(3-cyano-3,3-diphenylpropyl)-4-phenyl-, ethyl ester, hydrochloride; Diphenoxylate hydrochloride; DIPHENOXYLATE; Diphenoxylate hydrochloride (USP); ethyl 1-(3-cyano-3,3-diphenylpropyl)-4-phenylpiperidine-4-carboxylate; 4-Ethoxycarbonyl-alpha,alpha,4-triphenyl-1-piperidinebutyronitrile, hydrochloride; C30H32N2O2; Ethyl 1-(3-cyano-3,3-diphenylpropyl)-4-phenyl-4-piperidinecarboxylate; Diphenoxylatum [INN-Latin]; NIH 7562; AC1O5E7B; Difenossilato; CID6432394; MLS001401383; L001046; C07872; AC1Q1SJB; DB01081; Ethyl 1-(3-cyano-3,3-diphenylpropyl)-4-phenylisonipecotate monohydrochloride; MolPort-004-285-933; AKOS005065925; D03860; SAM001246532; LS-85079; Diphenoxylate Monohydrochloride; 4-Piperidinecarboxylic acid, 1-(3-cyano-3,3-diphenylpropyl)-4-phenyl-, ethyl ester, monohydrochloride; Diphenoxylatum [Latin]; Ethyl 1-(3-cyano-3,3-diphenylpropyl)-4-phenylisonipecotate; 915-30-0; CHEBI:59784; Difenoxilato [Spanish]; CID19650; DEA No. 9170; Diphenoxylate (INN); R 1132 (antiperistaltic); UNII-73312P173G; 1-(3-Cyano-3,3-diphenylpropyl)-4-phenyl-isonipecotic acid ethyl ester; Diphenoxylate [INN:BAN]; Difenoxilato [INN-Spanish]; 4-ethoxycarbonyl-alpha,alpha,4-triphenyl-1-piperidinebutyronitrile hydrochloride; CID13505; CPD000469140	915-30-0	13505	10074	TTDS00126	Mu-type opioid receptor	MOR-1;MOR1A;Mu opioid receptor	P35372	4988	ENSG00000112038	agonist
DCL000881	Methylnaltrexone	Naltrexone MB; methyl-naltrexone hydrobromide; C21H26NO4; CID5361918; 83387-25-1; MRZ 2663BR; LS-177749; Quaternary ammonium naltrexone; UNII-0RK7M7IABE; naltrexonium methiodide; N-Methylnaltrexone; 17-(Cyclopropylmethyl)-4,5alpha-epoxy-3,14-dihydroxy-17-methyl-6-oxomorphinanium; Mrz-2663; Methylnaltrexone; CID11639740; CID11992464; NALTREXONE METHYLBROMIDE; Methylnaltrexonium; 17-(Cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinanium-6-one; Morphinanium, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-17-methyl-6-oxo-, (5alpha)-	83387-25-1	6603824	685076	TTDS00126	Mu-type opioid receptor	MOR-1;MOR1A;Mu opioid receptor	P35372	4988	ENSG00000112038	antagonist
DAP001137	Methadyl Acetate	Methadyl acetate [USAN:BAN]; 509-74-0; LS-74433; Methadyl acetate; LS-175186; MolPort-004-285-886; LS-74437; Acetylmethadolum [INN-Latin]; DB01433; LS-74436; Acetilmetadol [INN-Spanish]; N-LAMM; Acetylmethadol (INN); L000758; LS-74435; DEA No. 9601; Acetylmethadol; race-Acetylmethadol; 3-Acetoxy-6-dimethylamino-4,4-diphenylheptane; Benzeneethanol, .beta.-[2-(dimethylamino)propyl]-.alpha.-ethyl-.beta.-phenyl-, acetate; D04973; Acetylmethadolum; Methadyl acetate (USAN); [6-(dimethylamino)-4,4-diphenylheptan-3-yl] acetate; CHEBI:385936; Acetilmetadol; (R,S)-4-Dimethylamino-1-ethyl-2,2-diphenylpentyl acetat; 4-(Dimethylamino)-1-ethyl-2,2-diphenylpentyl acetate; Levamethadyl; CHEMBL170179; CID10517; Benzeneethanol, .beta.-[2-(dimethylamino)propyl]-.alpha.-ethyl-.beta.-phenyl-, acetate (ester), [S-(R*,R*)]-; Amidolacetate; Acemethadone; 6-(Dimethylamino)-4,4-Diphenyl-3-Heptanol Acetate; 6-(Dimethylamino)-4,4-diphenyl-3-heptanol acetate (ester); Benzeneethanol, beta-(2-(dimethylamino)propyl)-alpha-ethyl-beta-phenyl-, acetate (ester); AC1L1VDA; LS-74434; EINECS 208-103-4; 1-Ethyl-4-dimethylamino-2,2-diphenylpentylacetat; ALPHACETYLMETHADOL	509-74-0	10517	10354601	TTDS00126	Mu-type opioid receptor	MOR-1;MOR1A;Mu opioid receptor	P35372	4988	ENSG00000112038	agonist
DAP000072	Fentanyl	Fentanylum; PDSP1_000860; Sublimase; Propanamide, N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)- (9CI); BRN 0494484; Fentanylum [INN-Latin]; Duragesic-75; CHEMBL596; PDSP2_000846; 5-22-08-00049 (Beilstein Handbook Reference); N-(1-Phenethyl-piperidin-4-yl)-N-phenyl-propionamide; BIDD:GT0555; CHEBI:119915; Propanamide, N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-; N-Phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide; Fentanyl (JAN/USAN/INN); Sentonil; N-(1-Phenethylpiperidin-4-yl)-N-phenylpropionamide; N-(1-Phenethyl-4-piperidinyl)-N-phenylpropionamide; 437-38-7; 1-Phenethyl-4-N-propionylanilinopiperidine; R 4263; Duragesic; Fentanyl-25; 80832-90-2; Fentanyl-75; Fentanila; Duragesic (TN); LS-124439; Oprea1_207148; Duragesic-25; Fentanil [DCIT]; Fentanyl [INN:BAN]; fentanyl; Nasalfent; Phentanyl; NCGC00168252-01; Duragesic-100; HSDB 3329; N-(1-Phenethyl-4-piperidyl)propionanilide; N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide; 990-73-8 (citrate); N-Phenethyl-4-(N-propionylanilino)piperidine; CID3345; Fentanyl-100; Fentanyl-12; Durogesic; Rapinyl; Oprea1_152073; Propionanilide, N-(1-phenethyl-4-piperidyl)-; N-(1-phenethylpiperidin-4-yl)-N-phenylpropanamide; MolPort-003-847-369; Fentanyl-50; Propanamide, N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)-; D00320; Fentanest; Duragesic-12; IONSYS; JNS020QD; UNII-UF599785JZ; Fentanila [INN-Spanish]; L001275; Fentanil; 1-Phenethyl-4-(N-phenylpropionamido)piperidine; Matrifen; AC1L1FQ2; DB00813; Duragesic-50; EINECS 207-113-6	437-38-7	3345	153132	TTDS00126	Mu-type opioid receptor	MOR-1;MOR1A;Mu opioid receptor	P35372	4988	ENSG00000112038	agonist
DAP001134	Alfentanil	UNII-1N74HM2BS7; Propanamide, N-(1-(2-(4-ethyl-4,5-dihydro-5-oxo-1H-tetrazol-1-yl)ethyl)-4-(methoxymethyl)-4-piperidinyl)-N-phenyl-; HSDB 6789; N-(1-(2-(4-Ethyl-4,5-dihydro-5-oxotetrazolyl)ethyl)-4-(methoxymethyl)-4-piperidyl)-N-phenylpropionamid; Alfentanilum [INN-Latin]; N-{1-[2-(4-ethyl-5-oxo-4,5-dihydro-1H-tetrazol-1-yl)ethyl]-4-(methoxymethyl)piperidin-4-yl}-N-phenylpropanamide; CHEBI:2569; MolPort-004-285-887; LS-119259; ALFENTANIL; CHEMBL634; D07122; CHEBI:127190; 71195-58-9; N-{1-[2-(4-ethyl-5-oxo-4,5-dihydro-1H-tetrazol-1-yl)ethyl]-4-[(methyloxy)methyl]piperidin-4-yl}-N-phenylpropanamide; Alfentanyl; N-(1-(2-(4-Ethyl-4,5-dihydro-5-oxotetrazolyl)ethyl)-4-(methoxymethyl)-4-piperidyl)propionanilid; 5-26-13-00110 (Beilstein Handbook Reference); N-[1-[2-(4-Ethyl-5-oxo-2-tetrazolin-1-yl)ethyl]-4-(methoxymethyl)-4-piperidyl]propionanilide; N-[1-[2-(4-ethyl-5-oxotetrazol-1-yl)ethyl]-4-(methoxymethyl)piperidin-4-yl]-N-phenylpropanamide; C08005; Alfentanil (INN); L001231; N-(1-(2-(4-Ethyl-5-oxo-2-tetrazolin-1-yl)ethyl)-4-(methoxymethyl)-4-piperidyl)propionanilide; AC1Q6F0S; DB00802; Rapifen (TN); Alfentanilum; DEA No. 9737; Alfenta; Alfentanil [INN:BAN]; AC1L1ARM; 70879-28-6 (hydrochloride); CID51263; BRN 1188293	71195-58-9	51263	189496	TTDS00126	Mu-type opioid receptor	MOR-1;MOR1A;Mu opioid receptor	P35372	4988	ENSG00000112038	agonist
DAP000073	Buprenorphine	CHEMBL47085; PDSP2_000111; CID6321408; DB00921; CID40400; 21-cyclopropyl-7alpha-(2-hydroxy-3,3-dimethyl-2-butyl)-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine; 6,14-Ethenomorphinan-7-methanol, 17-(cyclopropylmethyl)-alpha-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-alpha-methyl-,; 52485-79-7; 6,14-ethenomorphinan-3-ol, 17-(cyclopropylmethyl)-4,5-epoxy-18,19-dihydro-7-[(1S)-1-hydroxy-1,2,2-trimethylpropyl]-6-methoxy-, (5alpha,7alpha)-; 21-cyclopropyl-7alpha-[(S)-1-hydroxy-1,2,2-trimethylpropyl]-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine; (-)-buprenorphine; AC1LD8IH; D07132; AC1L9B1M; Buprenorfina; RX-6029-M; Temgesic; AC1L23NL; C08007; 6,14-Ethenomorphinan-7-methanol, 17-(cyclopropylmethyl)-alpha-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-alpha-methyl-, (alphaS,5alpha,7alpha)- (9CI); Buprenophine; CID644073; 17-Cyclopropylmethyl-4,5alpha-epoxy-7alpha-((S)-1-hydroxy-1,2,2-trimethylpropyl-6-methoxy-6,14-endo-ethanomorphinan-3-ol; EINECS 257-950-6; 6,14-Ethenomorphinan-7-methanol, 17-(cyclopropylmethyl)-alpha-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-alpha-methyl-, (5-alpha,7-alpha-(S))-; 2-(N-Cyclopropylmethyl-4,5alpha-epoxy-3-hydroxy-6-methoxy-6,14-endo-ethanomorphinan-7alpha-yl)-3,3-dimethyl-2-butanol; 21-(Cyclopropyl-7alpha-((S)-1-hydroxy-1,2,2-trimethylpropyl-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine; 17-cyclopropylmethyl-4,5alpha-epoxy-7alpha-((S)-1-hydroxy-1,2,2-trimethylpropyl)-6-methoxy-6,14-endo-ethanomorphinan-3-ol; 6029-M; CHEBI:3216; C29H41NO4; LS-67682; CHEMBL1201894; CID5311033; Buprel; [5alpha,7alpha(S)]-17-(Cyclopropylmethyl)-alpha-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-alpha-methyl-6,14-ethenomorphinan-7-methanol; UNII-40D3SCR4GZ; DEA No. 9064; (5alpha,6beta,14beta,18R)-17-(cyclopropylmethyl)-18-[(2S)-2-hydroxy-3,3-dimethylbutan-2-yl]-6-methoxy-18,19-dihydro-4,5-epoxy-6,14-ethenomorphinan-3-ol; RX 6029M; Buprenorphine (JAN/INN); [5alpha,7alpha(S)]-; Temgesic (TN); Buprenorphinum [INN-Latin]; (5alpha,6beta,14beta,18R)-17-(cyclopropylmethyl)-18-[(1S)-1-hydroxy-1,2,2-trimethylpropyl]-6-(methyloxy)-18,19-dihydro-4,5-epoxy-6,14-ethenomorphinan-3-ol; 6,14-Ethenomorphinan-7-methanol, 17-(cyclopropylmethyl)-alpha-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-alpha-methyl-, (5alpha,7alpha(S))-; Buprenorfina [INN-Spanish]; CID441363; 53152-21-9 (hydrochloride); Buprenorphinum; MolPort-004-285-844; 2-(N-cyclopropylmethyl-4,5alpha-epoxy-3-hydroxy-6-methoxy-6,14-endo-ethanomorphinan-6alpha-yl)-3,3-dimethyl-2-butanol; Buprenorphine Hcl; Probuphine; Buprenorphine [INN:BAN]; buprenorphine; Buprenex	52485-79-7	40400	181274	TTDS00126	Mu-type opioid receptor	MOR-1;MOR1A;Mu opioid receptor	P35372	4988	ENSG00000112038	agonist
DCL001021	Tramadol ER	N/A	27203-92-5	33741	48416650	TTDS00126	Mu-type opioid receptor	MOR-1;MOR1A;Mu opioid receptor	P35372	4988	ENSG00000112038	agonist
DAP001135	Anileridine	Ethyl 1-(p-aminophenethyl)-4-phenylisonipecotate; Ethyl 1-(4-aminophenethyl)-4-phenylisonipecotate; HSDB 3288; Apodol; UNII-71Q1A3O279; 1-(p-Aminophenethyl)-4-phenylisonipecotic acid ethyl ester; Adopol; LS-114624; Anileridina [INN-Spanish]; N-(beta-(p-Aminophenyl)ethyl)-4-phenyl-4-carbethoxypiperidine; Anileridine (USP/INN); 126-12-5 (di-hydrochloride); CID8944; 144-14-9; ethyl 1-[2-(4-aminophenyl)ethyl]-4-phenylpiperidine-4-carboxylate; Anileridine [INN:BAN]; N-beta-(p-Aminophenyl)ethylnormeperidine; Ethyl 1-(2-(4-aminophenyl)ethyl)-4-phenyl-4-piperidinecarboxylate; 53421-22-0 (mono-hydrochloride); CHEBI:61203; DEA No. 9020; Apidol; AC1L1RZS; Alidine; MolPort-004-285-895; 1-[2-(4-Aminophenyl)ethyl]-4-phenyl-4-piperidinecarboxlic acid ethyl ester; D02941; 1-(p-Aminophenethyl)-4-phenylpiperidine-4-carboxylic acid ethyl ester; ANILERIDINE; Leritin; Isonipecotic acid, 1-(p-aminophenethyl)-4-phenyl-, ethyl ester; Anileridina; DB00913; Anileridinum; Nipecotan; Anileridinum [INN-Latin]; L000700; 1-(2-(4-Aminophenyl)ethyl)-4-phenyl-4-piperidinecarboxylic acid ethyl ester; 4-Piperidinecarboxylic acid, 1-[2-(4-aminophenyl)ethyl]-4-phenyl-, ethyl ester; 4-Piperidinecarboxylic acid, 1-(2-(4-aminophenyl)ethyl)-4-phenyl-, ethyl ester	144-14-9	8944	152095	TTDS00126	Mu-type opioid receptor	MOR-1;MOR1A;Mu opioid receptor	P35372	4988	ENSG00000112038	agonist
DAP000097	Naloxone	UNII-36B82AMQ7N; Naloxonum [INN-Latin]; N-Allyl-4,5alpha-epoxy-3,14-dihydroxy-6-morphinanon; (5alpha)-3,14-dihydroxy-17-prop-2-en-1-yl-4,5-epoxymorphinan-6-one; Naloxona; CID5284596; Narcanti; l-N-Allyl-7,8-dihydro-14-hydroxynormorphinone; Prestwick2_000111; EN 1530 base; 17-allyl-3,14-dihydroxy-4,5alpha-epoxymorphinan-6-one; Naloxone [INN:BAN]; Morphinan-6-one, 4,5-alpha-epoxy-3,14-dihydroxy-17-(2-propenyl)-; CHEBI:7459; l-N-Allyl-14-hydroxynordihydromorphinone; 357-08-4 (hydrochloride); Morphinan-6-one, 4,5-epoxy-3,14-dihydroxy-17-(2-propenyl)-, (5.alpha.)-; Narcon; (-)-Naloxone; 1-N-Allyl-14-hydroxynordihydromorphinone; Naloxonum; CHEMBL80; DB01183; BRD-K67511046-003-03-7; Naloxone (INN); NCGC00024674-02; Morphinan-6-one, 4,5.alpha.-epoxy-3,14-dihydroxy-17-(2-propenyl)-; Narcan; SMP1_000205; Nalone; NSC 70413; Morphinan-6-one, 17-allyl-4,5.alpha.-epoxy-3,14-dihydroxy-; EINECS 207-365-7; HSDB 3279; NSC70413; SPBio_002061; 3,14-dihydroxy-17-(prop-2-en-1-yl)-4,5alpha-epoxymorphinan-6-one; Morphinan-6-one, 17-allyl-4,5alpha-epoxy-3,14-dihydroxy-; Normorphinone, N-allyl-7,8-dihydro-14-hydroxy-, (-)-; 1-N-Allyl-7,8-dihydro-14-hydroxynormorphinone; Prestwick3_000111; Naloxone HCl; HMS2090F20; 17-Allyl-4,5alpha-epoxy-3,14-dihydroxymorphinan-6-one; LS-187184; 465-65-6; BRN 1089071; BIDD:GT0110; Prestwick1_000111; C07252; l-Naloxone; Morphinan-6-one, 4,5-epoxy-3,14-dihydroxy-17-(2-propenyl)-, (5alpha)-; BPBio1_000136; Normorphinone, N-allyl-dihydro-14-hydroxy-; N-Allyl-noroxymorphone; 12-Allyl-7,7a,8,9-tetrahydro-3,7a-dihydroxy-4aH-8,9c-iminoethanophenanthro(4,5-bcd)furanone; naloxone; STOCK1N-69923; n-Allylnoroxymorphone; D08249; Morphinan-6-one, 4,5-epoxy-3,14-dihydroxy-17-(2-propenyl)-, (5alpha)- (9CI); Morphinan-6-one, 4,5alpha-epoxy-3,14-dihydroxy-17-(2-propenyl)-; 12-Allyl-7,7a,8,9-tetrahydro-3,7a-dihydroxy-4aH-8,9c-iminoethanophenanthro[4,5-bcd]furan-5(6H)-one; Morphinan-6-one, 17-allyl-4,5alpha-epoxy-3,14-dihydroxy- (8CI); LS-92141; Prestwick0_000111; DBL Naloxone; 17-Allyl-4,5-alpha-epoxy-3,14-dihydroxymorphinan-6-one; 4aH-8,9c-Iminoethanophenanthro[4,5-bcd]furan-5(6H)-one, N-allyl-7,7a,8,9-tetrahydro-3,7a-dihydroxy-; Naloxona [INN-Spanish]; BSPBio_000122; MolPort-002-536-640; DBL Naloxone (TN); (5alpha)-4,5-Epoxy-3,14-dihydroxy-17-(2-propenyl)morphinan-6-one; Nalossone; Nalossone [DCIT]; (-)-N-allyl-14-hydroxynordihydroxymorphinan-6-one; PDSP2_001520	465-65-6	5284596	9461	TTDS00126	Mu-type opioid receptor	MOR-1;MOR1A;Mu opioid receptor	P35372	4988	ENSG00000112038	antagonist
DAP001138	Oxymorphone	Oxymorphone (INN); oxymorphone; DB01192; 76-41-5; NSC19045; (5alpha)-3,14-dihydroxy-17-methyl-4,5-epoxymorphinan-6-one; Dihydroxymorphinone; CHEMBL963; MolPort-003-849-766; C08019; CID5284604; (-)-Oxymorphone; (5alpha)-4,5-Epoxy-3,14-dihydroxyl-17-methylmorphinan-6-one; Dihydro-14-hydroxymorphinone; Oxymorphine; Morphinan-6-one, 4,5.alpha.-epoxy-3,14-dihydroxy-17-methyl-; Morphinan-6-one, 4,5alpha-epoxy-3,14-dihydroxy-17-methyl- (8CI); Dihydrohydroxymorphinone; D08323; 14-Hydroxydihydromorphinone; 7,8-Dihydro-14-hydroxymorphinone; Morphinan-6-one, 4,5-epoxy-3,14-dihydroxy-17-methyl-, (5alpha)- (9CI); 4,5-Epoxy-3,14-dihydroxy-N-methyl-6-oxomorphinan; (14S)-14-Hydroxydihydromorphinone; Morphinone, dihydro-14-hydroxy-; EN3202; Oximorphonum; FT-0080194; Numorphan; AC-16042; Morphinone, 7,8-dihydro-14-hydroxy- (6CI,7CI); Morphinan-6-one, 4,5-epoxy-3,14-dihydroxy-17-methyl-, (5alpha)-; CHEBI:194484	76-41-5	5284604	10219	TTDS00126	Mu-type opioid receptor	MOR-1;MOR1A;Mu opioid receptor	P35372	4988	ENSG00000112038	agonist
DPR000068	LY-25582	N/A	N/A	N/A	N/A	TTDS00126	Mu-type opioid receptor	MOR-1;MOR1A;Mu opioid receptor	P35372	4988	ENSG00000112038	antagonist
DPR000053	GNTI	G 3416; G3416_SIGMA; CID9853099; GNTI di-trifluoroacetate; SMR001338894; 5'-Guanidinonaltrindole di(trifluoroacetate) salt hydrate; Guanidinyl-naltrindole di-trifluoroacetate; NCGC00093944-01; 5'-Guanidinylnaltrindole dihydrochloride; EU-0100559; GNTI; MLS002320748	219655-56-8	9826034	24278454	TTDS00126	Mu-type opioid receptor	MOR-1;MOR1A;Mu opioid receptor	P35372	4988	ENSG00000112038	antagonist
DAP000264	Remifentanil	UNII-P10582JYYK; D08473; 1-Piperidinepropanoic acid, 4-(methoxy-carbonyl)-4-((1-oxopropyl)phenylamino)-, methyl ester; CHEMBL1005; GI87084B; Ultiva (TN); 3-(4-methoxycarbonyl-4-((1-oxopropyl)phenylamino)-1-piperidine)propanoic acid methyl ester; REMIFENTANIL; DEA No. 9739; AC1Q5ZGR; CID60815; Remifentanil [INN:BAN]; AC1L1TZ8; MolPort-004-286-006; GI 87084B; BIDD:GT0029; Remifentanil (INN); GI 87084X; CHEBI:8802; 4-carboxy-4-(n-phenylpropionamido)-1-piperidinepropionic acid dimethyl ester; LS-115982; DB00899; 132539-07-2 (mono-hydrochloride); L001266; Ultiva; methyl 1-(3-methoxy-3-oxopropyl)-4-(N-propanoylanilino)piperidine-4-carboxylate; Remifentanyl; C08021; 132875-61-7	132875-61-7	60815	10221	TTDS00126	Mu-type opioid receptor	MOR-1;MOR1A;Mu opioid receptor	P35372	4988	ENSG00000112038	agonist
DAP001139	Levomethadyl Acetate	BIDD:PXR0155; D04716; LS-74438; DB01227; 3-Heptanol, 6-(dimethylamino)-4,4-diphenyl-, acetate (ester), (3S,6S)-(-)- (8CI); 34433-66-4; Levacetylmethadolum; alpha-(-)-Acetylmethadol; Benzeneethanol, beta-((2S)-2-(dimethylamino)propyl)-alpha-ethyl-beta-phenyl-, acetate (ester), (alphaS)-; DEA No. 9648; Benzeneethanol, beta-[(2S)-2-(dimethylamino)propyl]-alpha-ethyl-beta-phenyl-, acetate (ester), (alphaS)- (9CI); CHEBI:6441; MolPort-004-285-956; AC1L2582; AC1Q5X3P; 1-alpha-Acetylmethadol; Levomethadyl acetate (USAN); LS-187090; Benzeneethanol, beta-(2-(dimethylamino)propyl)-alpha-ethyl-beta-phenyl-, acetate (ester), (S-(R*,R*))-; levo-Alphacetylmethadol; LAAM; C08012; Orlaam; BIDD:GT0373; Levomethadyl acetate; [(3S,6S)-6-(dimethylamino)-4,4-diphenylheptan-3-yl] acetate; a-l-acetylmethadol; levo-alpha-Acetylmethadol; [S-(R*,R*)]-beta-[2-Dimethylamino)propyl]-alpha-ethyl-beta-phenylbenzeneethanol acetate (ester); 3-HEPTANOL, 6-(DIMETHYLAMINO)-4,4-DIPHENYL-, ACETATE (ester), (3S,6S)-(-)-; levo-Methadyl acetate; benzeneethanol, beta-[(2S)-2-(dimethylamino)propyl]-alpha-ethyl-beta-phenyl-, acetate (ester), (alphaS)-; Levacetylmethadol; Levacetylmethadol (INN); l-alpha-Acetylmethadol; Benzeneethanol, beta-[2-(dimethylamino)propyl]-alpha-ethyl-beta-phenyl-, acetate (ester), [S-(R*,R*)]-; Levacetilmetadol [INN-Spanish]; Levacetylmethadolum [INN-Latin]; N-alpha-Acetylmethadol; 1477-40-3; CHEMBL1514; (-)-6-(Dimethylamino)-4,4-diphenyl-3-heptanol acetate (ester); (1S,4S)-4-(dimethylamino)-1-ethyl-2,2-diphenylpentyl acetate; Benzeneethanol, beta-(2-(dimethylamino)propyl)-alpha-ethyl-beta-phenyl-, acetate (ester), (-)-; CID15130; Levomethadyl; alpha-l-Acetylmethadol; Levacetylmethadol [INN]; (3S,6S)-6-(dimethylamino)-4,4-diphenylheptan-2-yl acetate; (-)-alpha-Acetylmethadol; Levacetilmetadol	1477-40-3	15130	158449	TTDS00126	Mu-type opioid receptor	MOR-1;MOR1A;Mu opioid receptor	P35372	4988	ENSG00000112038	agonist
DAP000555	Rosuvastatin	CHEMBL1496; AKOS000280777; AZD-4522; Rosuvastatin [INN]; 147098-20-2 (Calcium); AC1NR03S; Spectrum5_001695; CID446157; Rosumed; Rosuvast; CID5282455; Creston (TN); (E,3R,5S)-7-[4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-propan-2-ylpyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid; 147098-20-2; HSDB 7317; AKOS005145896; Rosvel; 6-Heptenoic acid, 7-(4-(4-fluorophenyl)-6-(1-methylethyl)-2-(ethyl(methylsulfonyl)amino)-5-pyrimidinyl)-3,5-dihydroxy-, (3R,5S,6E); TL8006179; AC1L9J7O; Vivacor; Astende; Rosuvas; I06-044; bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino] pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhelpt-6-enoic acid] calcium salt; ZD 4522; Creston; I06-1902; ZD 4522, calcium salt; SPECTRUM1505213; Rosedex; UNII-413KH5ZJ73; AC1O5R1T; ZD-4522; Rosuvastatin calcium; NCGC00178070-01; Pyrimidine Compound, 26; Rovartal; CHEMBL1200361; Rosustatin; S-4522; DB01098; Sinlip; D01915; CID6439133; Crestor; (3R,5S,6E)-7-{4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-(propan-2-yl)pyrimidin-5-yl}-3,5-dihydroxyhept-6-enoic acid; (S-(R*,S*-(E)))-7-(4-(4-Fluorophenyl)-6-(1-methylethyl)-2-(methyl(methylsulfonyl)amino)-5-pyrimidinyl)-3,5-dihydroxy-6-heptenoic acid, calcium salt (2:1); CHEBI:38545; Razel; Rosuvastatin hemicalcium; Rosuvastatin; Rosuvastatin calcium (JAN/USAN); Rosuvastatin calcium [USAN]; HMS2093M08; (S-((R*,S*-(E)))- 7-(4-(4-fluorophenyl)-6-(1-methylethyl)-2-(methyl(methylsulfonyl) amino)-5-pyrimidinyl)-3,5-dihydroxy-6-heptenoic acid, calcium salt (2:1); Provisacor; Crestor (TN); 6-Heptenoic acid, 7-(4-(4-fluorophenyl)-6-(1-methylethyl)-2-(methyl(methylsulfonyl)amino)-5-pyrimidinyl)-3,5-dihydroxy-, calcium salt (2:1), (3R,5S,6E)-; S 4522; LS-181805; HMS1922N09; Simestat; 6-Heptenoic acid, 7-(4-(4-fluorophenyl)-6-(1-methylethyl)-2-(methyl(methylsulfonyl)amino)-5-pyrimidinyl)-3,5-dihydroxy-, calcium salt (2:1), (3R,5S,6E); ZD4522; Rosuvastatin (INN); (E,3R,5R)-7-[4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-propan-2-ylpyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid; Bio-0143; (3R,5S,6E)-7-(4-(4-fluorophenyl)-6-(1-methylethyl)-2-(ethyl(methylsulfonyl)amino)-5-pyrimidinyl)-3,5-dihydroxy-6-heptenoic acid; calcium (E,3R,5S)-7-[4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-propan-2-ylpyrimidin-5-yl]-3,5-dihydroxyhept-6-enoate; MolPort-000-883-884; Cirantan; (3R,5S,6E)-7-{4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl}-3,5-dihydroxyhept-6-enoic acid; Cresadex; BSPBio_003429; 287714-41-4; Rosimol; LS-187345; D08492; MolPort-003-987-534	287714-41-4	6439133	706341	TTDS00195	3-hydroxy-3-methylglutaryl-coenzyme A reductase	HMG coA reductase;HMG-CoA reductase	P04035	3156	ENSG00000113161	inhibitor
DCL000509	Crestor/TriLipix	N/A	N/A	N/A	N/A	TTDS00195	3-hydroxy-3-methylglutaryl-coenzyme A reductase	HMG coA reductase;HMG-CoA reductase	P04035	3156	ENSG00000113161	inhibitor
DAP000551	Lovastatin	ZINC03812841; 81739-26-6; 6 Methylcompactin; HMS1990O07; BRN 3631989; ACon0_000534; Mevacor; Lovastatin, (1 alpha(S*))-Isomer; BIDD:GT0749; Lovastatin (USP/INN); Altocor; Lovastatin [USAN:BAN:INN]; Liposcler; HMS2093O03; Lipivas; HMS1792O07; SMR000058779; MK-803; Lovastatine [French]; Rodatin; Lestatin; HMS1923O13; Prestwick_819; Colevix; NCGC00023509-08; STK801953; Lovastin; nchembio869-comp12; Lovasterol; Sivlor; 71949-96-7; MK803; KBio1_001032; 6-alpha-Methylcompactin; NCGC00023509-03; KBio3_002848; AC1L1EI6; Lozutin; SAM002589963; ARONIS24208; MEGxm0_000398; mevinolin; BSPBio_003346; DB00227; C07074; Tecnolip; HMS1569H13; MLS000069585; I06-1876; Lovastatin & Primycin; Mevinolin from Aspergillus sp.; MSD 803; Hipolip; D00359; NCGC00023509-07; Hipovastin; CCRIS 8092; AC1Q2C7T; Prestwick1_000516; BIDD:PXR0113; Prestwick2_000516; M2147_SIGMA; Teroltrat; MLS001055358; CID53232; BSPBio_000471; Nergadan; DivK1c_001032; BPBio1_000519; HMS2089M06; nchembio742-comp5; Lovastatina [Spanish]; CHEBI:40303; NCGC00023509-06; Paschol; Taucor; Rovacor; SPECTRUM1503977; 6alpha-Methylcompactin; Mevlor; Artein; Lovalord; Rextat; Monakolin K; Monacolin K; C24H36O5; BB_NC-1457; Lipdip; SPBio_002392; 2beta,6alpha-Dimethyl-8alpha-(2-methyl-1-oxobutoxy)-mevinic acid lactone; CPD000673570; HMS503O05; CPD-5561; UNII-9LHU78OQFD; Cholestra; Lovastatin, 1 alpha-Isomer (without R*/S* notation); NINDS_001032; MK 803; CHEMBL503; Lovalip; Mevacor (TN); 75330-75-5; D008148; AC-13961; Mevinacor; nchembio790-comp14; ML-530B; NCGC00023509-05; BSPBio_001265; Lovastatinum; Lovastatinum [Latin]; MolPort-001-739-990; ACon1_000390; 6-Methylcompactin; SMR000673570; Spectrum5_001294; 74133-25-8; Belvas; Prestwick3_000516; BRD-K09416995-001-06-8; L0214; Lovastatina; Prestwick0_000516; HSDB 6534; Lovastatine; Spectrum3_001873; Lipofren; NCGC00023509-04; IDI1_001032; Altoprev; LS-46359; 1cqp; 6 alpha-Methylcompactin; lovastatin; Closterol; L-154803	75330-75-5	53232	191104	TTDS00195	3-hydroxy-3-methylglutaryl-coenzyme A reductase	HMG coA reductase;HMG-CoA reductase	P04035	3156	ENSG00000113161	inhibitor
DAP000552	Simvastatin	Sinvacor; Zocor (TN); SpecPlus_000895; simvastatin; KBio2_002197; Simvastatin (JAN/USP/INN); ZINC03780893; AC-1530; MolPort-002-507-345; BCBcMAP01_000007; MLS001304029; NCGC00017324-02; Synvinolin; ARONIS24119; S1792_Selleck; BSPBio_002337; MolPort-002-885-862; Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-((2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester; RYMZZMVNJRMUDD-HGQWONQESA-; CID54454; DRG-0320; MLS002154038; KBioSS_002197; UNII-AGG2FN16EV; Prestwick1_000865; InChI=1/C25H38O5/c1-6-25(4,5)24(28)30-21-12-15(2)11-17-8-7-16(3)20(23(17)21)10-9-19-13-18(26)14-22(27)29-19/h7-8,11,15-16,18-21,23,26H,6,9-10,12-14H2,1-5H3/t15-,16-,18+,19+,20-,21-,23-/m0/s1; Prestwick_171; Simvastatina [Spanish]; C25H38O5; Labistatin; Spectrum2_001671; KBio1_001935; DivK1c_006991; SPBio_001881; Simvastatin, Compactin; S6196_SIGMA; BRN 4768037; Prestwick2_000865; Butanoic acid, 2,2-dimethyl-, 1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester, (1S-(1alpha,3alpha,7beta,8beta(2S*,4S*),8abeta))-; STK801938; MK-733; Zocor, Simlup, Simcard, Simvacor, Simvoget, Zorced, Simvastatin; Prestwick0_000865; Simvastatine; Rendapid; Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,*aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-((2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester; AKOS005111006; SMR000718785; Vasotenal; HMS2089D12; nchembio790-comp16; NCGC00017324-01; Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester; KS-1113; Simovil; SAM002589969; Simvastatina; [(1S,3R,7S,8S,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] 2,2-dimethylbutanoate; Nivelipol; Coledis; MK733; KBio2_004765; Sivastin; butanoic acid, 2,2-dimethyl-,1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)-ethyl]-1-naphthalenyl ester, [1S-[1 alpha,3 alpha,7 beta,8 beta(2S*,4S*),-8a beta; MK 0733; Lodales; HMS1570N11; Zocor; AC1L1H1F; 2,2-Dimethylbutanoic acid (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester; KBio3_001557; MK-0733; Bio-0672; Denan; CPD000718785; Cholestat; L 644128-000U; MLS001333078; BSPBio_000909; HSDB 7208; SPBio_002830; MK 733; Simvastatin & Primycin; Spectrum4_000632; Simvastatin [USAN:INN:BAN]; D00434; BPBio1_001001; Lipex; CHEMBL1064; CHEBI:9150; Colemin; Simvastatinum [Latin]; Simvastatine [French]; HMS1922H13; MLS001333077; Prestwick3_000865; TNP00259; Spectrum_001717; CCRIS 7558; NCGC00017324-03; LS-46264; BIDD:GT0769; KBioGR_001244; HMS2093E06; SPECTRUM1504236; BRD-K22134346-001-05-8; Zocord; Corolin; KBio2_007333; Pantok; D019821; Simvastatinum; Medipo; Simvast CR; Spectrum3_000669; 2,2-Dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one; Spectrum5_001428; Lipovas; (1S,3R,7S,8S,8aR)-8-{2-[(2R,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2,2-dimethylbutanoate; 79902-63-9	79902-63-9	54454	7847500	TTDS00195	3-hydroxy-3-methylglutaryl-coenzyme A reductase	HMG coA reductase;HMG-CoA reductase	P04035	3156	ENSG00000113161	inhibitor
DCL001003	Statins	N/A	145599-86-6	446156	48415746	TTDS00195	3-hydroxy-3-methylglutaryl-coenzyme A reductase	HMG coA reductase;HMG-CoA reductase	P04035	3156	ENSG00000113161	inhibitor
DCL000565	MK-0524B	N/A	N/A	N/A	N/A	TTDS00195	3-hydroxy-3-methylglutaryl-coenzyme A reductase	HMG coA reductase;HMG-CoA reductase	P04035	3156	ENSG00000113161	inhibitor
DAP000554	Fluvastatin	Fluvastatinum; T6624179; 93957-54-1; (E)-7-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-3,5-dihydroxyhept-6-enoic acid; Fluvas (TN); (3S,5R,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; Fluvas; HMS2089P06; BPBio1_000965; (3S,5R,6E)-7-[3-(4-fluorophenyl)-1-isopropyl-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; 7-(3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl)-3,5-dihydroxy-6-heptenoate; (3R,5S,6E)-7-[3-(4-fluorophenyl)-1-isopropyl-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; Fluvastatin [INN:BAN]; (3R,5S)-7-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-3,5-dihydroxyhept-6-enoic acid; CID446155; CHEBI:38562; CID146801; XU 62320; BSPBio_000877; BRD-K03602135-236-02-1; I06-2297; CID5353627; nchembio.301-comp9; CID6914285; C24H26FNO4; 6-Heptenoic acid, 7-(3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl)- 3,5-dihydroxy-, (3R,5S,6E)-rel-; CHEBI:38565; Fluvastatin & Primycin; CID1548972; CID3403; CID10501876; Fluvastatine; AC1L9J7I; (+)-(3R,5S)-fluvastatin; (E,3S,5R)-7-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (E,3R,5S)-7-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (3R,5R,6E)-7-[3-(4-fluorophenyl)-1-isopropyl-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; XU-62320; Prestwick1_000859; Fluvastatinum [INN-Latin]; Fluvastatine [INN-French]; AC1NS4EB; CHEBI:38567; 6-Heptenoic acid, 7-(3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl)-3,5-dihydroxy-, (R*,S*-(E))-(+-)-; CHEMBL1078; CPD001453708; Prestwick3_000859; Fluvastatin (INN); (6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; CHEBI:5136; MolPort-003-847-470; Cranoc; Prestwick0_000859; AC1Q1PZO; D07983; nchembio790-comp18; BIDD:GT0839; (Z,3R,5S)-7-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-3,5-dihydroxyhept-6-enoic acid; Lescol XL; Fluindostatin; UNII-4L066368AS; CID9887837; (6E)-7-[3-(4-fluorophenyl)-1-isopropyl-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; LS-7404; (3R,5R,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; TL8005940; (-)-(3S,5R)-fluvastatin; 7-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-3,5-dihydroxyhept-6-enoic acid; AC1LU7LJ; SPBio_002798; (3R,5S,6E)-rel-7-[3-(4-Fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxy-6-heptenoic acid; AC1L3TXK; Fluvastatina; (3R,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; CHEMBL170417; 6-Heptenoic acid, 7-(3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl)- 3,5-dihydroxy-, (R*,S*-(E))-(+-)-; C07014; DB01095; Fluvastatina [INN-Spanish]; (3R,5S,6E)-7-[3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; fluvastatin; Lescol; Prestwick2_000859; 6-Heptenoic acid, 7-[3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxy-, (3R,5S,6E)-; AC1L1FUW; SAM002548940; Canef; AC1OC9O5	93957-54-1	1548972	206649	TTDS00195	3-hydroxy-3-methylglutaryl-coenzyme A reductase	HMG coA reductase;HMG-CoA reductase	P04035	3156	ENSG00000113161	inhibitor
DPR000058	HMG-CoA reductase inhibitor	N/A	N/A	N/A	N/A	TTDS00195	3-hydroxy-3-methylglutaryl-coenzyme A reductase	HMG coA reductase;HMG-CoA reductase	P04035	3156	ENSG00000113161	inhibitor
DCL000933	Pitavastatin	CID5282452; Pitavastatin [INN]; P-872441; Itavastatin; Bis((3R,5S,6E)-7-(2-cyclopropyl-4-(4-fluorophenyl)-3-quinolyl)-3,5-dihydroxy-6-heptenoate), monocalcium salt; LS-190698; AC1NR03G; ( )-(3R,5S,6E)-7-(2-Cyclopropyl-4-(4-fluorophenyl)-3-quinolyl)-3,5-dihydroxy-6-heptenoic acid; Nisvastatin; 6-Heptenoic acid, 7-(2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl)-3,5-dihydroxy-, (3R,5S,6E)-; S1759_Selleck; KS-1220; LS-74594; MolPort-006-822-984; Itavastatin calcium; Pitavastatin calcium; 6-Heptenoic acid, 7-(2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl)-3,5-dihydroxy-,calcium salt (2:1), (3R,5S,6E)-; Livalo; CCRIS 8652; C13334; Pitavastatin calcium (JAN); NK-104; CID5282451; Pitavastatin hemicalcium; Livalo (TN); P 872441; (E,3R,5S)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-6-enoic acid; (3R,5S,6E)-7-(2-Cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl)-3,5-dihydroxyhept-6-enoic acid; ZINC01534965; NK 104; 147511-69-1; 2C25H23FNO4.Ca; 6-Heptenoic acid, 7-(2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl)-3,5-dihydroxy-, (S-(R*,S*-(E)))-; Alipza; AC1NR03J; (3R,5S,6E)-7-(2-Cyclopropyl-4-(p-fluorophenyl)-3-quinolyl)-3,5-dihydroxy-6-heptenoic acid; Livazo; 147526-32-7; LS-74595; NKS-104; Livalo, Pitavastatin calcium; 6-Heptenoic acid, 7-(2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl)-3,5-dihydroxy-, calcium salt (2:1), (S-(R*,S*-(E)))-; Pitavastatin; (3R,5S,E)-7-(2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl)-3,5-dihydroxyhept-6-enoate; 111GE002; D01862; AKOS005145916; calcium (E,3R,5S)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-6-enoate	147526-32-7	6366718	3816026	TTDS00195	3-hydroxy-3-methylglutaryl-coenzyme A reductase	HMG coA reductase;HMG-CoA reductase	P04035	3156	ENSG00000113161	inhibitor
DAP001519	Simvistatin	N/A	79902-63-9	5479847	46515042	TTDS00195	3-hydroxy-3-methylglutaryl-coenzyme A reductase	HMG coA reductase;HMG-CoA reductase	P04035	3156	ENSG00000113161	inhibitor
DAP001506	Pravigard	N/A	98201-60-6	2244	148573	TTDS00195	3-hydroxy-3-methylglutaryl-coenzyme A reductase	HMG coA reductase;HMG-CoA reductase	P04035	3156	ENSG00000113161	inhibitor
DAP000553	Atorvastatin	atorvastatine; atorvastatinium; UNII-A0JWA85V8F; (3R,5R)-7-[3-(anilinocarbonyl)-5-(4-fluorophenyl)-2-isopropyl-4-phenyl-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid; (betaR,deltaR)-2-(p-Fluorophenyl)-beta,delta-dihydroxy-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)pyrrole-1-heptanoic acid; Atorvastatin [INN:BAN]; Faboxim; (R-(R*,R*))-2-(4-Fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoic acid; Sotis; BIDD:GT0336; atorvastatina; DB01076; AC-15611; CHEBI:39548; (3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid; Sortis; 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-, (betaR,deltaR)-; 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-beta,delta-dihydroxy-; atorvastatin; Tozalip; Lowden; Torvacard; Xarator; Zurinel; 134523-00-5; 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-, (R-(R*,R*))-; Atorvastatin (INN); MolPort-000-883-773; Torvast; C33H35FN2O5; CHEMBL1487; CCRIS 7159; 7-[2-(4-FLUORO-PHENYL)-5-ISOPROPYL-3-PHENYL-4-PHENYLCARBAMOYL-PYRROL-1-YL]- 3,5-DIHYDROXY-HEPTANOIC ACID; Atorpic; AKOS000281127; AC1L1TZT; CI 981; NCGC00159458-02; AC1Q1OZQ; 134523-03-8; 5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-, (R-(R*,R*))-; C06834; Sincol; Lipitor (TN); Xavator; Totalip; Atogal; HSDB 7039; atrovastin; Vastina; Lipotropic; Atorlip; nchembio.301-comp8; Cardyl; Xanator; Sortis (TN); D07474; Lipitor(TM); Lipovastatinklonal; CID60823; Liprimar; Tulip; LS-136975	134523-00-5	60823	205162	TTDS00195	3-hydroxy-3-methylglutaryl-coenzyme A reductase	HMG coA reductase;HMG-CoA reductase	P04035	3156	ENSG00000113161	inhibitor
DAP000550	Pravastatin	BRD-K60511616-236-01-4; AC1Q5T3M; Pravator; (3R,5R)-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-[(2S)-2-methylbutanoyl]oxy-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid; SQ-31,000; BIDD:GT0773; RMS-431; 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-beta,delta,6-trihydroxy-2-methyl-8-((2S)-2-methyl-1-oxobutoxy)-, (betaR,deltaR,1S,2S,6S,8S,8aR)-; pravastatin; KS-5015; Vasten; (3R,5R)-3,5-dihydroxy-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-{[(2S)-2-methylbutanoyl]oxy}-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]heptanoic acid; C01844; LS-94713; 81131-70-6 (hydrochloride salt); C23H36O7; nchembio790-comp15; Pravastatinum [Latin]; Pravastatine; Pravastatin tert-Octylamine Salt; nchembio.301-comp7; Eptastatin; DB00175; Pravastatin [INN:BAN]; Pravastatina; FT-0082682; 1,2,6,7,8,8a-hexahydro-beta,delta,6-trihydroxy-2-methyl-8-(2-methyl-1-oxobutoxy)-, (1S-(1alpha(betaS*,deltaS*),2alpha,6alpha,8beta(R*),8aalpha))-1-Naphthaleneheptanoic acid; Pravastatin (INN); Oliprevin; 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-beta,delta,6-trihydroxy-2-methyl-8-(2-methyl-1-oxobutoxy)-, (1S-(1alpha(betas*,deltas*),2alpha,6alpha,8beta(R*),8aalpha))-; AC1L1HJL; CHEMBL1144; Pravastatina [Spanish]; Pravator (TN); Pravastatine [French]; CID54687; 81093-37-0; D08410; UNII-KXO2KT9N0G; Pravastatinum; CCRIS 7557; Pravastatin Sodium Salt	81093-37-0	54687	192211	TTDS00195	3-hydroxy-3-methylglutaryl-coenzyme A reductase	HMG coA reductase;HMG-CoA reductase	P04035	3156	ENSG00000113161	inhibitor
DAP001272	Botulinum Toxin Type B	N/A	93384-44-2	N/A	46504750	TTDS00483	Vesicle-associated membrane protein	SYB1;Synaptobrevin-1;VAMP1;VAMP-1	P63027	6844	ENSG00000220205	binder
DAP001041	Prednisone	MLS002154191; HMS1568O15; 1-Dehydrocortisone; Parmenison; MLS001335908; Panasol; HSDB 3168; .delta.sone; NCGC00090766-02; SPBio_002214; Supercortil; Ultracorten; Sone; Zenadrid (veterinary); Prednicen-M; Nurison; Zenadrid; Enkortolon; delta-1-Cortisone; Predeltin; CID5865; ACon0_000082; Orasone; Sterapred; Precort; SMR001227202; Dekortin; delta cortelan; 1,4-Pregnadiene-17alpha,21-diol-3,11,20-trione; Ancortone; Encorton; Decortisyl; BSPBio_000293; Apo-Prednisone; .delta. E; Prednisone Intensol; Metrevet (Veterinary); NCGC00090766-01; Pregna-1,4-diene-3,11,20-trione, 17,21-hydroxy-; Ultracortene; Prednisonum [INN-Latin]; .delta.-Cortelan; .delta.-Cortisone; P6254_SIGMA; 1,2-Dehydrocortisone; 1,4-Pregnadiene-17alpha,21-diol-3,11,20-trione; 17,21-Dihydroxypregna-1,4-diene-3,11,20-trione; Prednisone; P1276; SK-Prednisone; .delta.1-Cortisone; CHEBI:8382; AC1Q29EZ; Prednilonga; Zenadrid [veterinary]; Presone; Prestwick3_000077; (8xi,9xi,14xi)-17,21-dihydroxypregna-1,4-diene-3,11,20-trione; Bio-0649; BRD-K85883481-001-04-2; Incocortyl; Wojtab; (1S,2R,10S,11S,14R,15S)-14-hydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-diene-5,17-dione; Prestwick1_000077; ZINC03875357; Novoprednisone; delta(sup 1)-Cortisone; Prednisona [INN-Spanish]; Deltasone, Liquid Pred, Orasone, Adasone, Deltacortisone,Prednisone; CPD001227202; 81552_FLUKA; Prednisone [INN:BAN]; MLS001335907; Servisone; Prednicorm; Cartancyl; Prednitone; Bicortone; 1,2-Dehydrocortisone; Fiasone; AI3-52939; 17alpha,21-Dihydroxy-1,4-pregnadiene-3,11,20-trione; U 6020; MolPort-001-740-041; Metacortandracin; Juvason; delta-1-Dehydrocortisone; In-Sone; delta-Cortisone; Nisona; Cortan; BPBio1_000323; Dacorten; Enkorton; Prestwick0_000077; Deltisone; .delta.-Cortone; 1,4-Pregnadiene-17-alpha,21-diol-3,11,20-trione; Dacortin; AC-11112; Pregna-1,4-diene-3,11,20-trione, 17,21-dihydroxy-; Pehacort; Panafcort; C21H26O5; Paracort; Adasone; UNII-VB0R961HZT; Decortancyl; WLN: L E5 B666 CV OV AHTTT&J A1 E1 FV1Q FQ; Di-Adreson; Diadreson; MLS001061265; MLS002207083; delta(sup 1)-Dehydrocortisone; delta-Cortone; Prednovister; .delta.-E; Prednicot; Econosone; Prestwick_405; DB00635; 53-03-2; Winpred; prednisone; Cotone; Meticorten (Veterinary); Lisacort; Dellacort A; Prestwick2_000077; Origen Prednisone; Delta-Cortelan; NSC 10023; 1,4-Pregnadiene-17.alpha.,21-diol-3,11,20-trione; Prednicort; Cortidelt; LMST02030180; (8S,9S,10R,13S,14S,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,9,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,11-dione; Deltison; Retrocortine; Prednison; Kortancyl; Prednidib; Me-Korti; EINECS 200-160-3; Decortin; Colisone; NCGC00090766-03; Delta E.; Deltasone; 1-Cortisone; Pronisone; 68-59-7; HMS2090J13; MLS001304073; Deltacortisone; Deltacortone; Prednisonum; Delta E; MEGxm0_000443; NSC10023; Encortone; Deltisona; Lodotra; CCRIS 2646; CHEMBL635; Prednizon; NCI-C04897; C07370; Deltra; Liquid Pred; S1622_Selleck; .delta.(sup1)-Cortisone; Pronison; SMR000718760; Dehydrocortisone; Prednisona; Pregna-1,4-diene-3,11,20-trione monohydrate, 17,21-dihydroxy-; Delta-Dome; Meticorten; Deltacortene; 17,21-Dihydroxypregna-1,4-diene-3,11,20-trione; LS-1325; AC1L1LB2; ACon1_000297; Nizon; Rectodelt; NCI60_000008; Dellacort; Hostacortin; .delta.1-Dehydrocortisone; SAM002264641	53-03-2	5865	148670	TTDS00283	Glucocorticoid receptor	Alpha-A;GR	P04150	2908	ENSG00000113580	agonist
DAP001380	Fluticasone	MolPort-006-666-449; fluticasone; AC-456; CID5311101; D07981; Fluticaps; AC1NSJZT; Fluticaps (TN); S-(fluoromethyl) (6S,8S,9R,10S,11S,13S,14S,16R,17R)-6,9-difluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-17-carbothioate; BIDD:GT0819; 90566-53-3; Fluticasone (INN); C07815; CHEMBL1201396	90566-53-3	62924	205110	TTDS00283	Glucocorticoid receptor	Alpha-A;GR	P04150	2908	ENSG00000113580	antagonist
DAP001039	Fluticasone Propionate	CPD000469159; SAM001246583; Cutivate (TN); Flixotide Inhaler; Prestwick3_000997; 6alpha,9-difluoro-17beta-{[(fluoromethyl)sulfanyl]carbonyl}-11beta-hydroxy-16-methyl-3-oxoandrosta-1,4-dien-17alpha-yl propanoate; Fluticasonpropionat Allen; Flonase (TN); Fluticasone propionate [USAN]; Trialona; Flutivate; Flixonase; Flixonase Nasal Spray; SBB071021; BSPBio_001093; Rinosone; HMS1571G15; AC1L9FLD; FLUTICASONE PROPIONATE; ZINC03920027; Skyron; CHEBI:31441; CCI-18781; Fluticasone propionate (JAN/USAN); DB00588; Zoflut; Asmatil; atemur; BRD-K62310379-001-03-0; 80474-14-2; AB00513992; Androsta-1,4-diene-17-carbothioic acid, 6,9-difluoro-11-hydroxy-16-methyl-3-oxo-17-(1-oxopropoxy)-, S-(fluoromethyl) ester, (6-alpha,11-beta,16-alpha,17-alpha)-; Prestwick0_000997; Flovent (TN); BPBio1_001203; [(6S,8S,9R,10S,11S,13S,14S,16R,17R)-6,9-difluoro-17-(fluoromethylsulfanylcarbonyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] propanoate; Flovent HFA; Flusonal; Flixotide; S-(Fluoromethyl) 6alpha,9-difluoro-11beta,17-dihydroxy-16alpha-methyl-3-oxoandrosta-1,4-diene-17beta-carbothioate, 17-propionate; SMR000469159; Fluxonal; MolPort-003-847-468; Prestwick2_000997; Axotide; Flixotide Disk; FT-0082893; Flovent; CID444036; LS-19323; Flonase; Flonase Aq; Flunase; FN-25; CCI 18781; Prestwick1_000997; Flovent Diskus 250; Flutide; Cutivate; NCGC00179308-01; HMS2051N19; Fluspiral; Ubizol; Brethal; Fluinol; Flixotide Disks; Inalacor; AC-457; Flovent Diskus 50; Flovent Diskus; Androsta-1,4-diene-17-carbothioic acid, 6,9-difluoro-11-hydroxy-16-methyl-3-oxo-17-(1-oxopropoxy)-, (6alpha,11beta,16alpha,17alpha)-S-(fluoromethyl) ester; Flovent Diskus 100; SPBio_002984; MLS001424085; CHEMBL1473; C25H31F3O5S; D01708	80474-14-2	444036	585235	TTDS00283	Glucocorticoid receptor	Alpha-A;GR	P04150	2908	ENSG00000113580	antagonist
DAP000320	Budesonide	Prestwick3_000518; Bio-0010; UDB; Dexbudesonide [INN]; Pregna-1,4-diene-3,20-dione, 16,17-(butylidenebis(oxy))-11,21-dihydroxy-, (11-beta,16-alpha)-; SPBio_000586; Miflonide; C25H34O6; Entocort; SPECTRUM1500813; IDI1_000475; Prestwick0_000518; BRD-A82238138-001-01-7; NCGC00178789-01; Pulmicort Flexhaler; DB01222; B7777_SIGMA; UNII-2HI1006KPH; Budesonidum; Budenofalk; KBio1_000475; Pulmaxan; Budesonide MMX; Prestwick_840; DivK1c_000475; ZINC04097286; CID40000; NINDS_000475; Rhinocort; Pulmicort Respules; EINECS 257-160-1; CHEBI:3207; NCGC00089747-02; BPBio1_000523; Pulmicort (TN); Spectrum5_001738; (S)-16alpha,17-(Butylidenedioxy)-11beta,21-dihydroxypregna-1,4-diene-3,20-dione; Cortivent; 16-alpha,17-alpha-Butylidenedioxy-11-beta,21-dihydroxy-1,4-pregnadiene-3,20-dione; Rhinocort Aqua; EINECS 257-139-7; 11beta,21-dihydroxy-16alpha,17alpha-(butane-1,1-diyldioxy)pregna-1,4-diene-3,20-dione; budesonide; Spirocort; Inflammide; S-1320; Giona Easyhaler; CID3033890; Pregna-1,4-diene-3,20-dione,16,17-(butylidenebis(oxy))-11,21-dihydroxy-, (11beta,16alpha)-; MolPort-003-666-332; TL8003397; Pregna-1,4-diene-3,20-dione, 16,17-butylidenebis(oxy)-11,21-dihydroxy-, (11beta,16alpha(R))-, and 16alpha,17-((S)-Butylidenebis(oxy))-11beta,21-dihydroxypregna-1,4-diene-3,20-dione; Entocort EC; MLS001077323; MAP-0010; MLS000028507; AC-4697; 16,17-Butylidenebis(oxy)-11,21-dihydroxypregna-1,4-diene-3,20-dione; BSPBio_000475; HMS501H17; 16alpha(R),17-(Butylidenebis(oxy))-11beta,21-dihydroxypregna-1,4-diene-3,20-dione; Rhinocort, Pulmicort , Entocort, Symbicort, Noex. Entocort EC, Budesonide; HMS1921I22; Pulmicort turbuhaler; Budecort Inhaler; NCGC00089747-04; AC1L1Y6Y; (11-beta,16-alpha)-16,17-(Butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione; 16alpha-,17alpha--butylidenedioxypregna-1,4-diene-11beta-,21-diol-3,20-dione; AC1L1DQE; Dexbudesonide; Pulmicort Topinasal; CID5281004; 16,17-Butylidenebis(oxy)-11-,21-dihydroxypregna-1,4-diene-3,20-dione; Pulmicort; Horacort; LS-187734; Bidien; Budesonido; MolPort-002-529-265; CPD000058337; Preferid; KBio3_001660; Unit dose budesonide; LS-7235; HMS1569H17; Pulmaxan turbohaler; AC1MHWI7; NCGC00015165-03; (4aR,4bS,5S,6aS,6bS,8R,9aR,10aS,10bS)-5-hydroxy-6b-(hydroxyacetyl)-4a,6a-dimethyl-8-propyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one; AC1L22VC; CID63006; Budesonide Easyhaler; BSPBio_002160; ST51039033; KBioGR_001361; CID2462; Budeson; SMR000058337; EU-0100174; S1286_Selleck; Budesonido [INN-Spanish]; Prestwick2_000518; NCGC00021318-06; Entocort EC (TN); CCRIS 5230; UNII-168L5HT37P; HMS2094I13; NCGC00021318-03; (RS)-(11beta,16alpha)-16,17-[Butylidenebis(oxy)]-11,21-dihydroxypregna-1,4-diene-3,20-dione; Micronyl; (R,S)-11b,16a,17,21,tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with buty raldehyde; D00246; Rhinocort alpha; Rhinocort Turbuhaler; Budesonide [USAN:INN:BAN:JAN]; Budesonide (JAN/USAN/INN); BRD-A34299591-001-03-4; Budiair; Budesonidum [INN-Latin]; Spectrum2_000623; S 1320; SPBio_002396; UNII-Q3OKS62Q6X; B 7777; Lopac0_000174; CHEBI:656601; (4aR,4bS,5S,6aS,6bS,9aR,10aS,10bS)-5-hydroxy-6b-(hydroxyacetyl)-4a,6a-dimethyl-8-propyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one; Respules; 51333-22-3; ZINC03938751; Spectrum4_000821; (RS)-11beta,16alpha,17,21-Tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with butyraldehyde; Pulmicort Nebuamp; MolPort-003-986-909; SAM002699898; NCGC00089747-03; EINECS 257-161-7; MLS002207112; CHEMBL1370; Spectrum3_000620; (11beta,16alpha)-16,17-(Butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione; Prestwick1_000518	51333-22-3	63006	7847312	TTDS00283	Glucocorticoid receptor	Alpha-A;GR	P04150	2908	ENSG00000113580	antagonist
DAP001040	Methylprednisolone	Reactenol; Methylprednisolon; delta(sup 1)-6-alpha-Methylhydrocortisone; Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy-6alpha-methyl- (8CI); Methylprednisolonum; EINECS 201-476-4; Artisone-wyeth; Medesone; Prestwick2_000279; LMST02030178; 11beta,17alpha,21-Trihydroxy-6alpha-methyl-1,4-pregnadiene-3,20-dione; UNII-X4W7ZR7023; Methylprednisolonum [INN-Latin]; (6a,11b)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione; Medlone 21; Bio-0658; Prednol- L; Metastab; Summicort; Lemod; Medrol (TN); Medrol adt pak; methylprenisolone; Promacortine; Prestwick_622; Methylprednisolone [USAN:INN:BAN:JAN]; SMR000058330; Besonia; Mesopren; Methylprednisolone, 6-alpha; Metysolon; Metilprednisolona [INN-Spanish]; Urbasone; Nirypan; 11-beta,17,21-Trihydroxy-6-alpha-methylpregna-1,4-diene-3,20-dione; 6 Methylprednisolone; M1665; NCGC00022735-03; Metrocort; 11beta,17,21-Trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione; HMS2090B13; D00407; S1733_Selleck; CPD000058330; Metilprednisolone; 570-35-4; Sieropresol; Firmacort; BRD-K35240538-001-03-1; (6alpha,11beta)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione; Prestwick3_000279; CHEMBL650; MLS000028541; Solomet; AC1L1N7A; Metilprednisolone [DCIT]; delta(1)-6alpha-Methylhydrocortisone; MLS001148159; 6alpha-Methylprednisolone; Methyleneprednisolone; 1-Dehydro-6alpha-methylhydrocortisone; NSC-19987; Dopomedrol; Medixon; U 7532; Pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-6-methyl-, (6.alpha.,11.beta.)-; Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy-6alpha-methyl-; (6alpha,11beta)-11,17,21-trihydroxy-6-methylpregna-1,4-diene-3,20-dione; 1-dehydro-6alpha-methylhydrocortisone; 6alpha-methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione; Delta(1)-6alpha-methylhydrocortisone; Methylprednisolon; .DELTA.1-6.alpha.-Methylhydrocortisone; CID6741; MEPRDL; HMS1568H20; Pregna-1,4-diene-3,20-dione, 6.alpha.-methyl-11.beta.-17,21-trihydroxy-; Medrone; BRN 2340300; DB00959; 83-43-2; LS-118498; Predni N Tablinen; BPBio1_000174; Prednisolone, methyl-; Moderin; SAM002589984; Metilbetasone; 46436_RIEDEL; Wyacort; 6alpha-Methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione; 46436_FLUKA; Noretona; M0639_SIGMA; Medrol dosepak; MLS002207191; D008775; Prednisolone, 6.alpha.-methyl-; HSDB 3127; Prestwick1_000279; SPBio_002377; (6S,8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-6,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one; Esametone; Metrisone; Medrol, Solu-Medrol, Medrone, Methylprednisolone; CHEBI:6888; Prestwick0_000279; 6.alpha.-Methylprednisolone; Pregna-1,4-diene-3,20-dione, 11.beta.,17,21-trihydroxy-6.alpha.-methyl-; 6-Methylprednisolone; Pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-6-methyl-, (6alpha,11beta)-; 121673-01-6; 11beta,17alpha,21-Trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione; 4-08-00-03498 (Beilstein Handbook Reference); methylprednisolone; Metilprednisolona; Depo-Medrol (acetate); Metipred; Medrol; MolPort-002-528-554; 6alpha-Methyl-11beta,17alpha,21-trihydroxy-1,4-pregnadiene-3,20-dione; ZINC03875560; Medrate; NCI60_001657; NSC19987; Methylprednisolone (JP15/USP/INN); BSPBio_000158; Summicort;; Prednisolone, 6alpha-methyl-; 6-alpha-Methylprednisolone; Pregna-1,4-diene-3,20-dione, 6-alpha-methyl-11-beta-17,21-trihydroxy-; Suprametil; 6923-42-8; Urbason	83-43-2	6741	149724	TTDS00283	Glucocorticoid receptor	Alpha-A;GR	P04150	2908	ENSG00000113580	agonist
DAP000007	Dexamethasone	NSC34521; Methylfluorprednisolone; AC-11056; HMS1792A17; Aeroseb-D; Dexa-Cortidelt; MLS001332508; BRD-K38775274-001-02-3; D00292; D1756_SIGMA; CCRIS 7067; C15643; 16.alpha.-Methyl-9.alpha.-fluoro-1-dehydrocortisol; Corson; LS-7300; Azium; Lokalison F; Dexamethasone (JP15/USP/INN); Dexa Mamallet; Gammacorten; Corsone; Aeroseb-Dex; Decameth; Dexpak; 16alpha-Methyl-9alpha-fluoroprednisolone; Dexacen-4; Visumetazone; 9.alpha.-Fluoro-16.alpha.-methylprednisolone; delta(sup 1)-9-alpha-Fluoro-16-alpha-methylcortisol; Dexamethasone Base; Dinormon; Luxazone; 1-Dehydro-16.alpha.-methyl-9.alpha.-fluorohydrocortisone; Merz Brand 2 of Dexamethasone; S1322_Selleck; Dexair; HMS2089N13; Hexadrol; Decaject; Hexadrol Elixir; C22H29FO5; CPD001227192; dexamethasone; 8054-59-9; Maxidex; IontoDex; D8893_SIGMA; BRD-K38775274-001-06-4; Prednisolone, 9alpha-fluoro-16alpha-methyl-; Isopto-Dex; FT-0080377; Decalix; Prodex; nchembio809-comp2; Dexametasona; Dexone 0.75; Mexidex; Deronil; OTO-104; Alcon Brand of Dexamethasone; Dexa-sine; Dexone; Decadron (TN); Dexone 1.5; Decaspray; SMR000857119; 46165_RIEDEL; Pet-Derm Iii; ST50307091; Cortisumman; Spoloven; Fluormethylprednisolone; Millicorten; Superprednol; ICN Brand of Dexamethasone; 9A-FLUORO-16BETA-METHYLPREDNISOLONE; to_000038; Dexaltin; SMP1_000092; Decadron-LA; Dexasone; BIDD:ER0494; Dexamethansone; Fortecortin; Dexamethasonum [INN-Latin]; D9184_SIGMA; SK-Dexamethasone; BSPBio_000995; Dexadeltone; Decacort; Decadron Tablets, Elixir; Dexametasona [INN-Spanish]; Decasone; EINECS 200-003-9; Sunia Sol D; Desameton; Dexone 4; Dexalona; NSC 34521; Mymethasone; Dexason; ZINC03875332; NCGC00091019-01; Hexadrol Tablets; Mediamethasone; Spectrum5_002019; Turbinaire; Dexafarma; Decadron, Dexamethasone; TL8003317; Decagel; Calonat; Hl-dex; AC1Q29DM; Fluorocort; CID5743; 16alpha-Methyl-9alpha-fluoro-1-dehydrocortisol; Dexonium; WLN: L E5 B666 OV KU MUTJ A1 BF CQ E1 FV1Q FQ G1; Dexamethasone alcohol; Oradexon; Desametasone [DCIT]; SGCUT00126; Loverine; Dexacortal; BIDD:PXR0060; Decaderm; Dxms; NCGC00091019-02; 16-alpha-Methyl-9-alpha-fluoroprednisolone; Dexamethasone [INN:BAN:JAN]; NCI60_003067; Fluormone; 137098-19-2; SMR001227192; CHEBI:41879; Prednisolone, 9.alpha.-fluoro-16.alpha.-methyl-; 16-alpha-Methyl-9-alpha-fluoro-1-dehydrocortisol; Dexinolon; 906422-84-2; Dexamonozon; 16.alpha.-Methyl-9.alpha.-fluoroprednisolone; 46165_FLUKA; 31375_FLUKA; Policort; 1-Dehydro-16alpha-methyl-9alpha-fluorohydrocortisone; Dexa-Cortisyl; UNII-7S5I7G3JQL; D003907; NCGC00091019-05; .delta.(sup 1)-9-.alpha.-Fluoro-16-.alpha.-methylcortisol; 9-alpha-Fluoro-16-alpha-methylprednisolone; Foy Brand of Dexamethasone; MolMap_000018; Decadron; Dexaprol; SAM002548948; Decaject L.A.; Aphthasolone; NCGC00091019-03; Dezone; MolPort-003-846-433; MK 125; Dexa-Scheroson; Deseronil; Dexamethasone Intensol; Dexa-Mamallet; CHEMBL384467; AC1L1L1H; ECR Brand of Dexamethasone; Dexacortin; Hexadecadrol; HSDB 3053; Desadrene; Dex-ide; D6645_SIGMA; 16-alpha-Methyl-9-alpha-fluoro-delta1-hydrocortisone; Prednisolon F; Ocu-trol; Dexinoral; Aphtasolon; Deltafluorene; MLS001055412; MLS001332507; Dekacort; Anaflogistico; Merz Brand 1 of Dexamethasone; CPD-10549; 50-02-2; Pet Derm III; Dergramin; Desametasone; Decacortin; Dexacort; DXM; Decaject-L.A.; DB01234; Auxiron; 9alpha-Fluoro-16alpha-methylprednisolone; delta1-9alpha-Fluoro-16alpha-methylcortisol; (3H)-Dexamethasone; Dectancyl; Dexameth; Dexamethazone; AI3-50934; Merck Brand of Dexamethasone; I06-1196; 23495-06-9; 16alpha-Methyl-9alpha-fluoro-delta(sup 1)-hydrocortisone; Bisu DS; NCGC00091019-04; Dexone 0.5; Dextelan; 16-alpha-Methyl-9-alpha-fluoro-delta(sup 1)-hydrocortisone; Azium (Veterinary); Posurdex; D4902_SIGMA; Prednisolone F; Dexamethasonum; .gamma.corten; HMS1990A17; Adexone; Dexapolcort; Desamethasone	50-02-2	5743	9160	TTDS00283	Glucocorticoid receptor	Alpha-A;GR	P04150	2908	ENSG00000113580	agonist
DAP001048	Medrysone	Prestwick3_000743; WLN: L E5 B666 OV MUTJ A1 CQ E1 FV1 L1; SMR000058693; 11beta-Hydroxy-6alpha-methylpregn-4-ene-3,20-dione; AC1L6L4H; HMS1570E08; M0388_SIGMA; 6.alpha.-Methyl-11.beta.-hydroxyprogesterone; MLS002207230; 11.beta.-Hydroxy-6.alpha.-methylpregn-4-ene-3,20-dione; Medrifar; ZINC03977945; MLS000028714; D02289; Pregn-4-ene-3,20-dione, 11.beta.-hydroxy-6.alpha.-methyl-; CHEMBL1201173; CPD000058693; HMS; SAM002564258; BSPBio_000726; 11beta-Hydroxy-6alpha-methyl-4-pregnene-3,20-dione; NCGC00179460-01; BPBio1_000800; Progesterone, 11.beta.-hydroxy-6.alpha.-methyl-; Medrocort; CID247839; medrysone; SMP1_000061; Medritonic; Visudrisone; SPBio_002665; MLS001076155; Medrysone (USAN); U-8471; BCBcMAP01_000088; MolPort-003-958-619; Prestwick_89; BRD-K56515112-001-03-4; (6S,8S,9S,10R,11S,13S,14S,17S)-17-acetyl-11-hydroxy-6,10,13-trimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one; 11.beta.-Hydroxy-6.alpha.-methylprogesterone; Prestwick0_000743; MLS002222162; Pregn-4-ene-3,20-dione, 11-hydroxy-6-methyl-, (6.alpha.,11.beta.)-; Hydroxymesterone; HMS Liquifilm; 2668-66-8; Prestwick1_000743; NSC63278; HMS (TN); ST082266; C14643; Prestwick2_000743; DB00253	2668-66-8	247839	7849348	TTDS00283	Glucocorticoid receptor	Alpha-A;GR	P04150	2908	ENSG00000113580	binder
DAP001047	Fluorometholone	Flucon; Fluoro Ophtal; HMS1570O17; D005469; 426-13-1; Fluormetholonum; PMS-Fluorometholone; (6S,8S,9R,10S,11S,13S,14S,17R)-17-acetyl-9-fluoro-11,17-dihydroxy-6,10,13-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; Progesterone, 1-dehydro-9-fluoro-11.beta., 17-dihydroxy-6.alpha.-methyl-; AC-3520; 11beta,17alpha-Dihydroxy-9-fluoro-6-methyl-1,4-pregnadiene-3,20-dione; Pregna-1,4-diene-3,20-dione, 9-fluoro-11beta,17-dihydroxy-6alpha-methyl- (8CI); Pregna-1,4-diene-3,20-dione, 9-fluoro-11beta,17-dihydroxy-6alpha-methyl-; Trilcin; CHEMBL1200600; DB00324; U 8614; Fluormetholon; Isdin Brand of Fluorometholone; Cortisdin; Fluorometolona; NCGC00021575-03; SMR000058598; EINECS 207-041-5; 9-Fluoro-11,17-dihydroxy-6-methylpregna-1,4-diene-3,20-dione; Pregna-1, 4-diene-3,20-dione, 9-fluoro-11,17-dihydroxy-6-methyl-, (6.alpha., 11.beta.)-; Pregna-1,4-diene-3,20-dione, 9-fluoro-11.beta.,17; Cortilet; Ursnon; Pregna-1,4-diene-3,20-dione, 9-fluoro-11-beta,17-dihydroxy-6-alpha-methyl-; Fluorometholonum; CID9878; BSPBio_000935; Flumetholon; Delmeson; PMS Fluorometholone; MolPort-003-941-413; 9-Fluoro-11-beta,17-dihydroxy-6-alpha-methylpregna-1,4-diene-3,20-dione; Loticort; BPBio1_001029; component of Neo-Oxylone; LS-118455; Pharm-Allergan Brand of Fluorometholone; 9-Fluoro-11beta,17-dihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione; Fluorometholone (JP15/USP/INN); Prestwick3_000718; -dihydroxy-6.alpha.-methyl-; Progesterone, 1-dehydro-9-fluoro-11.beta., 17-dihydroxy-6.alpha.-methyl-; Pregna-1,4-diene-3,20-dione, 9-fluoro-11,17-dihydroxy-6-methyl-, (6.alpha.,11.beta.)-; Fluorometolone; MLS000069537; Fluoromethalone; AC1L1U0Y; Efflumidex; ZINC03876158; Fluorometholone [INN:BAN:JAN]; Fluorometolone [DCIT]; Fluoropos; Pharmascience Brand of Fluorometholone; Fluorometolona [INN-Spanish]; Prestwick0_000718; FML Liquifilm; Fluor-op (TN); fluorometholone; Prestwick1_000718; Fluormetholone; Alcon Brand of Fluorometholone; Oxylone (TN); FML Forte; NCI60_002886; AI3-52813; Fluorometholonum [INN-Latin]; Winzer Brand of Fluorometholone; Pregna-1,4-diene-3,20-dione, 9-fluoro-11,17-dihydroxy-6-methyl-, (6-alpha,11-beta)-; SPBio_002856; Fluoro-Ophtal; Neo-Oxylone; Fluaton; NSC-33001; FML; F9381_SIGMA; Pregna-1,4-diene-3,20-dione, 9-fluoro-11,17-dihydroxy-6-methyl-, (6alpha,11beta)-; Allergan Brand 1 of Fluorometholone; D01367; Pregna-1,4-diene-3,20-dione, 9-fluoro-11.beta.,17-dihydroxy-6.alpha.-methyl-; FML-S Liquifilm; Prestwick2_000718; Pharm Allergan Brand of Fluorometholone; BRD-K64862097-001-03-9; Ursapharm Brand of Fluorometholone; NSC33001; FML S.O.P; Allergan Brand 3 of Fluorometholone; Flucon, Isopto; Fml (TN); Fluor-Op; Allergan Brand 2 of Fluorometholone; F0414; MLS001076157; NSC 33001; Fluor Op; UNII-SV0CSG527L; Novartis Brand of Fluorometholone; Oxylone; Prestwick_227; Isopto Flucon	426-13-1	9878	7848430	TTDS00283	Glucocorticoid receptor	Alpha-A;GR	P04150	2908	ENSG00000113580	binder
DAP001043	Betamethasone	Celeston; Prestwick_703; B7005_SIAL; Betametasone; Betamethasone Valearate; 9alpha-Fluoro-16beta-methylprednisolone; Betnelan; Betamethazone; KST-1A3042; B7005_SIGMA; C22H29FO5; SPBio_002404; Betafluorene; Desacort-Beta; EINECS 206-825-4; DB00443; 9-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione; 34166_RIEDEL; Prestwick1_000362; AKOS001582690; Prednisolone, 9-fluoro-16.beta.-methyl-; Betamethasonum; MolPort-003-845-025; AC1L1EYE; Betacortril; ZINC03876136; Celestone Syrup and Tablets; 1,4-Pregnadiene-3,20-dione-9alpha-fluoro-16 beta-methyl-11 beta,17alpha,21-triol; AC1Q5HJZ; Betamethasone alcohol; BPBio1_000533; 24024-03-1; Rinderon (TN); MLS001066413; 9-Fluoro-16.beta.-methylprednisolone; Betamethasone Base; MLS002153244; 9alpha-Fluoro-16 beta-methyl-prednisolone; Betsolan; SMR000339803; Celestona; 378-44-9; CHEMBL632; AR-1A7284; Rinderon A; Betadexamethasone; Corticosterone, 1-dehydro-9-fluoro-17-hydroxy-16.beta.-methyl-; HMS1569I05; HSDB 3015; Luxiq; Betamethasonum [INN-Latin]; SCH-4831; BRD-A35108200-001-04-7; SMP1_000043; NCGC00164401-02; BRN 3176546; Cellestoderm; Rinderon; NSC 39470; Betamethasone (JP15/USP/INN); UNII-9842X06Q6M; NSC-39470; 34166_FLUKA; 16beta-Methyl-1,4-pregnadiene-9alpha-fluoro-11beta,17alpha,21-triol-3,20-dione; Hormezon; Bebate; Corticosterone, 1-dehydro-9-fluoro-17-hydroxy-16beta-methyl-; BSPBio_000483; CID9782; betamethasone; Bedifos; AC1L1TT4; Prednisolone, 9-fluoro-16beta-methyl-; CID3003; Betacorlan; I06-0121; Celestone; Betasolon; Becort; Valisone; D00244; MLS001332616; Cidoten; Methazon; S1500_Selleck; 9-Fluoro-16beta-methylprednisolone; SMR000058601; CHEBI:3077; NCGC00164401-01; 9-Fluoro-11-beta,17,21-trihydroxy-16-beta-methylpregna-1,4-diene-3,20-dione; Betapredol; Betamethasone [USAN:BAN:INN:JAN]; Pregna-1,4-diene-3,20-dione, 9-fluoro-11beta,17,21-trihydroxy-16beta-methyl-; SAM002589959; Betamethasone [USAN:INN:BAN:JAN]; .beta.-Methasone alcohol; Betametasona; Betamethasonvalerat Mikron; Prestwick2_000362; B9675_SIAL; Prestwick0_000362; Betamethasone cream; BIDD:PXR0047; 9.alpha.-Fluoro-16.beta.-methylprednisolone; Prestwick3_000362; D1961; beta-Methasone alcohol; B1837; LT00441022; Visubeta; beta-Methasone; Celestone, Betadexamethasone, Flubenisolone, Sch-4831, NCS-39470, Betamethasone; Betamamallet; Celestene; Betametasona [INN-Spanish]; BRD-K39188321-001-03-9; Flubenisolone; LS-118466; MLS000859943; .beta.-Methasone; MLS-0310139.0001; 9-Fluoro-11.beta.,17,21-trihydroxy-16.beta.-methylpregna-1,4-diene-3,20-dione; Pregna-1,4-diene-3,20-dione, 9-fluoro-11-beta,17,21-trihydroxy-16-beta-methyl-; CPD000339803; Pregna-1,4-diene-3,20-dione, 9-fluoro-11.beta.,17,21-trihydroxy-16.beta.-methyl-; 4-08-00-03501 (Beilstein Handbook Reference); Betametasone [DCIT]; MolPort-007-981-051; MLS000686794; 9-Fluoro-11beta,17,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione; AR-1H5595; Luxiqo; SCH 4831; 9-alpha-Fluoro-16-beta-methylprednisolone; NSC39470	378-44-9	9782	152998	TTDS00283	Glucocorticoid receptor	Alpha-A;GR	P04150	2908	ENSG00000113580	agonist
DAP001046	Flunisolide	BRD-K49577446-001-03-1; CID82153; BSPBio_000645; CHEMBL1512; MLS002153928; AeroBid, Nasalide, Nasarel,Flunisolide; C07005; SPBio_002566; Flunisolide [anhydrous]; DB00180; Rhinalar; HMS1570A07; Flunisolide HFA; Flunisolide anhydrous; Flunisolida; CPD001233272; Pregna-1,4-diene-3,20-dione, 6-alpha-fluoro-11-beta,16-alpha,17,21-tetrahydroxy-,cyclic 16,17-acetal with acetone; Lunis; 6alpha-fluoro-11beta,21-dihydroxy-16alpha,17alpha-(isopropylidenedioxy)pregna-1,4-diene-3,20-dione; Prestwick3_000643; Prestwick0_000643; Flunisolide (anhydrous); Soluzione; SMR001233272; Rhinolar; SAM002589966; Nisolid; Aerobid; Pregna-1,4-diene-3,20-dione, 6-fluoro-11,21-dihydroxy-16,17-((1-methylethylidene)bis(oxy))-, (6alpha,11beta,16alpha)-; 6 alpha-fluoro-11 beta,16 alpha,17,21- tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16, 17-acetal with acetone; Bronalide; CHEBI:5106; Prestwick1_000643; BPBio1_000711; Prestwick_223; 77326-96-6; F0437; Synaclyn; Nasalide; S1513_Selleck; MolPort-005-943-434; Flunisolida [INN-Spanish]; Flunisolide [INN]; 6-Fluoro-11,21-dihydroxy-16,17-(isopropylidenedioxy)pregna-1,4-diene-3,20-dione; flunisolide; NCGC00179492-01; LS-118464; AC-3514; 3385-03-3; Prestwick2_000643; RS-3999; Pregna-1,4-diene-3,20-dione, 6-alpha-fluoro-11-beta,16-alpha,17,21-tetrahydroxy-, cyclic 16,17-acetal with acetone; AC1L32UV; EINECS 222-193-2; 6 alpha-fluorodihydroxy-16 alpha,17 alpha-isopropylidenedioxy-1,4-pregnadiene-3,20- dione; ZINC04097305; Flunisolidum; RS 3999; Nasarel; Syntaris; Aerobid M; 6alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16, 17-acetal with acetone; Flunisolidum [INN-Latin]; Aerospan HFA; Aerospan	3385-03-3	82153	659083	TTDS00283	Glucocorticoid receptor	Alpha-A;GR	P04150	2908	ENSG00000113580	agonist
DCL000388	GW685698X	Fluticasone furoate; GW-685698; Androsta-1,4-diene-17-carbothioic acid, 6,9-difluoro-17-((2- furanylcarbonyl)oxy)-11-hydroxy-16-methyl-3-oxo-, S-(fluoromethyl) ester, (6alpha,11beta,16alpha,17alpha)-; (6alpha,11beta,16alpha,17alpha)-6,9-Difluoro-17-(((fluoromethyl)thio)carbonyl)-11-hydroxy-16-methyl-3-oxoandrosta-1,4-dien-17-yl-2-furancarboxylate; GW6; LS-186596; 6alpha,9-Difluoro-17-(((fluoromethyl)sulfanyl)carbonyl)-11beta-hydroxy-16alpha-methyl-3-oxoandrosta-1,4-dien-17alpha-yl furan-2-carboxylate; 397864-44-7; Androsta-1,4-diene-17-carbothioic acid, 6,9-difluoro-17-((2-     furanylcarbonyl)oxy)-11-hydroxy-16-methyl-3-oxo-, S-(fluoromethyl) ester, (6alpha,11beta,16alpha,17alpha)-; UNII-JS86977WNV; D06315; Fluticasone furoate (JAN/USAN/INN); Veramyst (TN); GW-685698X; Veramyst; LS-187376; Allermist; GW 685698X; CID9854489; Avamys; CHEMBL1676	N/A	7419	49601035	TTDS00283	Glucocorticoid receptor	Alpha-A;GR	P04150	2908	ENSG00000113580	agonist
DAP001044	Amcinonide	CHEMBL1200732; HMS2093K09; CPD001491664; MLS001146959; BRD-A36010170-001-02-4; Amcinonidum [INN-Latin]; CL 34,699; CID2133; AC1L22LU; Spectrum3_001915; amcinonida; MolPort-003-940-103; DivK1c_000870; Spectrum5_001489; C28H35FO7; KBioGR_000777; CHEBI:31199; Amcinonido [INN-Spanish]; AC-13190; CID443958; MLS000028656; DB00288; Pregna-1,4-diene-3,20-dione, 21-(acetyloxy)-16,17-(cyclopentylidenebis(oxy))-9-fluoro-11-hydroxy-, (11beta,16alpha)-; CID39858; MLS001333715; Triamcinolonacetatcyclopentanonid; Amcinonide (JAN/USP/INN); Cyclocort; HMS502L12; MLS002695893; KBio2_007138; UNII-423W026MA9; IDI1_000870; KBio3_003015; A2428_FLUKA; CL-34699; 1,4-Pregnadiene-2,20-dione-16,17-cyclopentylidenedioxy-9-fluoro-11,21-dihydroxy-21-acetate; 19alpha-Fluor-11beta,21-dihydroxy-16alpha,17alpha-(tetramethylen)methylendioxy-1,4-pregnadien-3,20-dion 21-acetat; AC1L9FH1; BSPBio_003510; Spectrum2_001588; Amcinonido; NINDS_000870; LS-118421; Amcinonide [USAN:INN:BAN:JAN]; Spectrum_001522; 51022-69-6; SAM002699903; AC1L1CZR; MolPort-003-666-502; triamcinolone 16,17-cyclopentylidenedioxy-21-acetate; SPECTRUM1503816; Cyclort; 16alpha,17alpha-(cyclopentane-1,1-diyldioxy)-9-fluoro-11beta-hydroxy-3,20-dioxopregna-1,4-dien-21-yl acetate; ZINC03977777; amcinonide; CID5702266; NCGC00178020-01; Pregna-1,4-diene-3,20-dione, 21-(acetyloxy)-16,17-[cyclopentylidenebis(oxy)]-9-fluoro-11-hydroxy-, (11.beta.,16.alpha.)-; Pregna-1,4-diene-3,20-dione, 21-(acetyloxy)-16,17-(cyclopentylidenebis(oxy))-9-fluoro-11-hydroxy-, (11-beta,16-alpha)-; Spectrum4_000199; SMR000058920; Cyclocort (TN); CL 34699; SPBio_001556; A2428_SIGMA; D01387; 9-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with cyclopentanone, 21-acetate; KBio1_000870; KBio2_002002; Amcinonidum; HMS1922I10; EINECS 256-915-2; KBio2_004570; Visderm; KBioSS_002002	51022-69-6	443958	7848450	TTDS00283	Glucocorticoid receptor	Alpha-A;GR	P04150	2908	ENSG00000113580	agonist
DCL000394	GW870086X	N/A	552858-79-4	N/A	47208221	TTDS00283	Glucocorticoid receptor	Alpha-A;GR	P04150	2908	ENSG00000113580	agonist
DAP001045	Loteprednol Etabonate	Lotemax; CHEMBL1200865; chloromethyl (8S,9S,10R,11S,13S,14S,17R)-17-ethoxycarbonyloxy-11-hydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthrene-17-carboxylate; IDR-90102; Alrex; chloromethyl 17alpha-[(ethoxycarbonyl)oxy]-11beta-hydroxy-3-oxoandrosta-1,4-diene-17beta-carboxylate; MLS001424221; Alrex, Lotemax, Loteprednol etabonate; 82034-46-6; AKOS005145741; IDR-90103; ZINC03920673; Loteprednol etabonate; NCGC00164594-01; Locort; CID444025; Loteprednol etabonate (JAN/USAN); MolPort-003-848-424; SMR000469178; Lotemax (TN); Loteflam; CHEBI:31784; S1669_Selleck; P-5604; CDDD-5604; CPD000469178; D01689; SAM001246630; Loterox; HGP-1; AC1L9FKJ; DB00873; HMS2051F16	82034-46-6	444025	7848752	TTDS00283	Glucocorticoid receptor	Alpha-A;GR	P04150	2908	ENSG00000113580	binder
DAP001042	Mometasone	C07816; Mometasona; MolPort-003-986-193; CID123620; DB00764; 105102-22-5; (8S,9R,10S,11S,13S,14S,16R,17R)-9-chloro-17-(2-chloroacetyl)-11,17-dihydroxy-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; UNII-8HR4QJ6DW8; D08227; Mometasone; (+)-Mometasone; Mometasona [Spanish]; (9R,10S,11S,13S,14S,16R,17R)-9-chloro-17-(2-chloroacetyl)-11,17-dihydroxy-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; CID441335; TL8000198; Elocom; Mometasonum; 9,21-dichloro-11beta,17-dihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione; AC1L3WZP; Mometasone (INN); AC1L9AZP; Mometasonum [Latin]; CHEBI:6970; ZINC04097440	105102-22-5	123620	700342	TTDS00283	Glucocorticoid receptor	Alpha-A;GR	P04150	2908	ENSG00000113580	agonist
DCL000910	ORG 34517/34850	N/A	189035-07-2	9576789	44714787	TTDS00283	Glucocorticoid receptor	Alpha-A;GR	P04150	2908	ENSG00000113580	antagonist
DCL000932	Pirfenidone	5-21-07-00197 (Beilstein Handbook Reference); Lopac0_000907; BRD-K96862998-001-03-1; I01-1466; BRN 1526549; Esbriet; Pirfenidonum [INN-Latin]; Pirfenidona; 5-methyl-1-phenylpyridin-2-one; S-7701; Lopac-P-2116; Bio1_001375; 5-Methyl-1-phenyl-2-(1H)-pyridone; 2(1H)-Pyridinone, 5-methyl-1-phenyl-; C093844; NCGC00015806-05; SMR000326900; AMR-69; 53179-13-8; 5-Methyl-1-phenyl-2(1H)-pyridone; LS-133834; 5-methyl-1-phenylpyridin-2(1H)-one; ZINC00001958; NCGC00024992-02; MLS000860042; PIRFENIDONE; Deskar; 5-Methyl-1-phenyl-1H-pyridin-2-one; CID40632; AC1L2454; NCGC00015806-03; Bio1_000886; EN000704; EU-0100907; FT-0082541; AC-6797; Pirfenidonum; Pirfenidone (JAN/USAN/INN); KS-5041; P 2116; Pirespa; Pirfenidone [USAN:INN]; AMR 69; NCGC00024992-01; Tocris-1093; Pirfenidona [INN-Spanish]; D01583; F-647; NCGC00024992-03; C12H11NO; Bio1_000397; P2116_SIGMA; Pirfenidone (Deskar); 2(1H)-Pyridone, 5-methyl-1-phenyl-; NCGC00015806-01	53179-13-8	40632	46500438	TTDC00203	Transforming growth factor-beta	TGF-beta	N/A	N/A	N/A	inhibitor
DCL001133	ACE-011	N/A	N/A	N/A	N/A	TTDC00203	Transforming growth factor-beta	TGF-beta	N/A	N/A	N/A	inhibitor
DCL000812	GC-1008	N/A	N/A	N/A	N/A	TTDC00203	Transforming growth factor-beta	TGF-beta	N/A	N/A	N/A	inhibitor
DAP001294	Dalfopristin	DALFOPRISTIN; CHEMBL1200937; CHEBI:42127; 5-(2-DIETHYLAMINO-ETHANESULFONYL)-21-HYDROXY-10-ISOPROPYL-11,19-DIMETHYL-9,26-DIOXA-3,15,28-TRIAZA-TRICYCLO[23.2.1.00,255]OCTACOSA-1(27),12,17,19,25(28)-PENTAENE-2,8,14,23-TETRAONE	112362-50-2	6435782	10233	TTDS00456	Peptidyl-transferase domain of the bacterial ribosome	N/A	N/A	N/A	N/A	binder
DCL000038	AM-111	N/A	543726-73-4	N/A	3821033	TTDC00102	Mitogen-activated protein kinase 8	C-Jun N-terminal kinase 1;JNK1;JNK-46;Stress-activated protein kinase JNK1	P45983	5599	ENSG00000107643	inhibitor
DCL000079	CC-401	N/A	N/A	N/A	N/A	TTDC00102	Mitogen-activated protein kinase 8	C-Jun N-terminal kinase 1;JNK1;JNK-46;Stress-activated protein kinase JNK1	P45983	5599	ENSG00000107643	inhibitor
DAP000500	Zonisamide	Excegran; Trerief; BRN 1077076; zonisamide monosodium; CPD000596519; CHEMBL750; 1-(1,2-Benzoxazol-3-Yl)methanesulfonamide; MLS001306491; Elan brand of zonisamide; Zonisamida; SPR_2; Excegran (TN); S1445_Selleck; 1,2-Benzisoxazole-3-methanesulfonamide; MolPort-002-507-855; C8H8N2O3S; BIDD:GT0708; D00538; 1-(1,2-benzisoxazol-3-yl)methanesulfonamide; CHEBI:10127; E-2090; AC1Q55GQ; I06-0495; ZINC00004321; MLS001195632; SAM002548957; Zonisamidum; 3-(Sulfamoylmethyl)-1,2-benzisoxazole; Bio-0532; Exceglan; AC1L1L0Q; PD 110843; C022189; Zonisamide (JAN/USAN/INN); NCGC00159319-03; Tremode; LS-33637; STK711131; zonisamide; UNII-459384H98V; 3-sulfamoylmethyl-1,2-benzisoxazole; BIDD:PXR0183; FT-0082702; Zonegran, Zonisamide; PD-110843; AD 810; Excegram; Zonegran; SMR000596519; HMS2089O07; NCGC00159319-02; DB00909; AD-810; Zonisamida [Spanish]; AD-810N; C07504; BRD-K48300629-001-03-8; Zonisamide [USAN:BAN:INN:JAN]; AC-1413; 1,2-benzoxazol-3-ylmethanesulfonamide; CI-912; Zonisamidum [Latin]; CID5734; 68291-97-4; HSDB 7293; CI 912; Zonisamide (ZNS); AKOS001312269	68291-97-4	5734	188654	TTDS00404	Sodium channel protein type 1 subunit alpha	NAC1;SCN1;SCN1A;Sodium channel protein type I subunit alpha;Sodium channel protein, brain I subunit alpha;Voltage-gated sodium channel subunit alpha Nav1.1	P35498	6323	ENSG00000144285	blocker
DAP000502	Levetiracetam	HMS2051D07; UCB-L 059; 102767-28-2; C8H14N2O2; (S)-alpha-Ethyl-2-oxo-1-pyrrolidineacetamide; CID5284583; SMR000466303; ucb L060; Keppra; Levetiracetam; Levetiracetam [INN]; SBB070161; MLS000759403; 1-Pyrrolidineacetamide, alpha-ethyl-2-oxo-, (S)-; BIDD:GT0242; FT-0082600; CPD000466303; Levetiracetamum [INN-Latin]; 1-Pyrrolidineacetamide, alpha-ethyl-2-oxo-, (alphaS)-; etiracetam, S-isomer; Levetiractam; MLS001424069; TL8000131; MolPort-003-848-377; (-)-(S)-alpha-Ethyl-2-oxo-1-pyrrolidineacetamide; LS-137054; Torleva; 1-Pyrrolidineacetamide, .alpha.-ethyl-2-oxo-, (.alpha.S)-; AC-1479; Keppra XR; SAM001246539; HMS2089L20; Keppra, Keppra XR),Levetiracetam; NCGC00186028-01; Etiracetam levo-isomer; SIB-S1; CHEMBL1286; (2S)-2-(2-oxopyrrolidin-1-yl)butanamide; UCB-L059; ZINC01547851; S1356_Selleck; UCB-22059; Leviteracetam; L-059; AC1NR4PY	102767-28-2	441341	10043	TTDS00404	Sodium channel protein type 1 subunit alpha	NAC1;SCN1;SCN1A;Sodium channel protein type I subunit alpha;Sodium channel protein, brain I subunit alpha;Voltage-gated sodium channel subunit alpha Nav1.1	P35498	6323	ENSG00000144285	blocker
DAP000501	Phenacemide	Spectrum4_000473; Epheron; .alpha.-Phenylacetylurea; KBio1_000320; Fenacetil-karbamide; Phenicarb; Fenacetamide; DivK1c_000320; N-(Aminocarbonyl)benzeneacetamide; Spectrum2_001019; Spectrum5_001240; Carbamide phenylacetate; Fenylacetylmocovina [Czech]; Benzeneacetamide, N-(aminocarbonyl)-; KBioGR_000946; KBio2_006539; Fenurone; Fenurea; Phetylureum; IDI1_000320; Phenuron; N-carbamoyl-2-phenylacetamide; NSC 39458; NCGC00094754-01; Phenylacetylurea; Phenacetylcarbamide; Phenacemidum [INN-Latin]; CID4753; Carbanmide; C9H10N2O2; Fenacemide; Efron; (2-phenylacetyl)urea; SBB057962; Phenacalum; Epiclase; BSPBio_002377; D00504; Fenytan; HMS2091N16; MolPort-003-666-257; KBio3_001597; Phenylacetyluree [French]; Neophenal; Phenylacetyluree; Fenylacetylmocovina; EINECS 200-570-2; KBio2_003971; NCGC00094754-03; HMS1920F16; Phenacemide (JAN/INN); Phenyrit; Eferon; 4-09-00-01636 (Beilstein Handbook Reference); SPECTRUM1500472; N-(aminocarbonyl)-2-phenylacetamide; NCGC00094754-02; Fenacemide [DCIT]; Fenacemid; Phenacemide [INN:BAN]; Phenacemidum; Phenacetylurea; Fenised; KBio2_001403; SPBio_001177; BRD-K40905133-001-02-3; Phenurone; Felurea; A-1348; AC1Q4ZTX; DB01121; Phenurone (TN); Phenarone; UNII-PAI7J52V09; HSDB 3380; C07428; ZINC00001916; Neophedan; (Phenylacetyl)urea; Cetylureum; BRN 2048735; WLN: ZVMV1R; Fenural; CHEMBL918; 63-98-9; AC1L1IVK; NSC39458; Fenostenyl; Phenacereum; HMS500P22; sym-PHENYLACETYLUREA; phenacemide; Urea, (phenylacetyl)-; Phacetur; Acetylureum; Fenilep; NINDS_000320; Fenacemida; Phenacetur; Spectrum_000923; KBioSS_001403; Fenacemida [INN-Spanish]; Phenutal; Comitiadone; Phenacerum; LS-160628; Spectrum3_000679	63-98-9	4753	9632	TTDS00404	Sodium channel protein type 1 subunit alpha	NAC1;SCN1;SCN1A;Sodium channel protein type I subunit alpha;Sodium channel protein, brain I subunit alpha;Voltage-gated sodium channel subunit alpha Nav1.1	P35498	6323	ENSG00000144285	blocker
DAP000821	Penicillamine	Bio-0578; BSPBio_002181; Metalcaptase (*Hydrochloride*); (-)-Penicillamine; D-Penicillamine; Cuprimine; (2S)-2-Amino-3-methyl-3-sulfanylbutanoic acid; AC1Q1NPA; Spectrum3_000541; D-Mercaptovaline; CCRIS 2904; Reduced D-penicillamine; Mercaptyl; Valine, 3-mercapto-, D-; D-Valine, 3-mercapto-; KBioSS_000763; Sufirtan; 76400_FLUKA; KBio2_003331; D-beta-Mercaptovaline; penicillamine; Dimethylcysteine; Penicillaminate, Copper; D-3-Mercaptovaline; D 3 Mercaptovaline; Mercaptovaline; 3-sulfanyl-D-valine; Spectrum_000283; HSDB 3378; KBio3_001681; beta-Thiovaline; DivK1c_000314; (2S)-2-amino-3-methyl-3-sulfanyl-butanoic acid; D-(-)-Penicillamine; (S)-Penicillamin; Spectrum5_001196; Metalcaptase; P-1280; 16414-54-3; 3,3-Dimethyl-D-cysteine; D-Penicyllamine; NINDS_000314; CPD-7702; C07418; SMP1_000042; KBioGR_000920; Penicillamine [USAN:INN:BAN:JAN]; NCGC00024359-04; Cupripen; Penicillamina [DCIT]; Penicillamina; 52-67-5; D010396; IDI1_000314; DB00859; Sufortan; EINECS 200-148-8; Copper penicillaminate; (S)-3,3-Dimethylcysteine; LS-161321; D-beta,beta-Dimethylcysteine; 2-Amino-3-mercapto-3-methylbutanoic acid; CID5852; UNII-GNN1DV99GX; Penicillamine (JAN/USP/INN); P4875_SIGMA; InChI=1/C5H11NO2S/c1-5(2,9)3(6)4(7)8/h3,9H,6H2,1-2H3,(H,7,8; Depamine; Depen; NCGC00024359-05; Penicilamina; Emtexate; Artamine; S1853_Selleck; 3-Mercaptovaline; Pendramine; NSC 81549; D Penicillamine; (S)-Penicillamine; TBB068824; Spectrum2_001029; Distamine (*Hydrochloride*); Penicillaminum; beta,beta Dimethylcysteine; d,3-Mercaptovaline; Penicilllamine; Penicillaminum [INN-Latin]; 3-Mercapto-D-valine; KBio1_000314; beta,beta-Dimethylcysteine; CHEMBL1430; KBio2_000763; Spectrum4_000470; Cuprenil; AC1L1L9Z; NCGC00018283-01; CHEBI:7959; KBio2_005899; Trolovol; Reduced penicillamine; NSC81549; D-(-)-2-Amino-3-mercapto-3-methylbutanoic acid; D-Penamine; AC1Q1NP9; Kuprenil; Penicilamina [INN-Spanish]; Cuprimine (TN); Penicillamin; D-Penicilamine; Depen (TN); P0147; MolPort-001-792-382; Perdolat; D-(-)-Penicillamine; D00496; (D)-PENICILLAMINE; alpha-Amino-beta-methyl-beta-mercaptobutyric acid; SPBio_001217	52-67-5	5852	9622	TTDS00322	HIV-1 Tat protein	TAT protein;Transactivating regulatory protein	P04612	N/A	N/A	inhibitor
DAP000460	Chloramphenicol	Desphen; 85666-84-8; Cidocetine; MLS002222155; Comycetin; Chloromycetin; Chloramsaar; Chloramfenikol [Czech]; Ismicetina; Cloroamfenicolo; NCGC00091011-04; Chloromycetny [Polish]; Chloramex; Ambofen; Novomycetin; Cloramfenicolo [DCIT]; Halomycetin; Isophenicol; Ertilen; BSPBio_000121; 4-13-00-02742 (Beilstein Handbook Reference); Leukomyan; Pantovernil; Kemicetina; Chlorocid; Cylphenicol; Cloramical; C00918; AB00374860; Catilan; SMP1_000065; Sno-Phenicol; Mycinol; BPBio1_000135; Chemicetin; Ronphenil; Tevcosin; Laevomycetinum; Levomycetin; Synthomycetine; Stanomycetin; CHLOROPTIC S.O.P; AKOS005111001; Pentamycetin; Mychel-Vet; Clorosintex; Amphenicol; Kemicetine; Globenicol; Normimycin V; Isopto fenicol; BIDD:GT0145; Chlorocol; MLS001055372; Amphicol (TN); NINDS_000544; C1919_SIGMA; Opelor; Chloramphenicol, d-; Kloramfenikol; Emetren; Loromicetina; NCGC00091011-02; Alficetyn; Chemicetina; Amphicol; Clorocyn; Chloroject L; 55172-72-0; Cloramidina; Mastiphen; D-(-)-threo-Chloramphenicol; Chloromycetin (TN); C.A.F; Oftalent; 23276_FLUKA; Levomicetina; NCI60_002620; Chlorbiotic (Veterinary); Cloranfenicol; 442513_SUPELCO; LS-225; S1677_Selleck; Mediamycetine; Leukomycin; F armicetina; D00104; HSDB 3027; D002701; AC1L1LI3; CCRIS 3922; C0378_SIGMA; Cloramfenicol; Syntomycin; Econochlor; HMS501L06; BRN 2225532; Chloramphenicolum [INN-Latin]; chloramphenicol; Ophtochlor; Intramyctin; Synthomycetin; Chloramfilin; HMS2090M15; Dextromycetin; Ciplamycetin; Cloromisan; Chloromycetny; Chloramphenicol (JP15/USP/INN); Chloromycetin&#174; DivK1c_000544; MolPort-001-794-646; AI3-25003; Juvamycetin; Biophenicol; 137731-90-9; Sificetina; Sintomicetina; Kamaver; I 337A; Synthomycine; Loromisan; 59112-59-3; MLS001332386; Isicetin; D-(-)-Chloramphenicol; C2255; Chloroamphenicol; D(-)-threo-2-dichloroacetamido-1-p-nitrophenyl-propanediol; Treomicetina; Chlomin; Klorocid S; Austracil; Hortfenicol; Viceton; D(-)-threo-Chloramphenicol; Chlornitromycin; Chloronitrin; Opclor; Embacetin; Micochlorine; Detreomycin; Vice ton; Chloroptic S.O.P.; EINECS 200-287-4; Unimycetin; Aquamycetin; Sintomicetine R; Cloromissan; UNII-66974FR9Q1; Anacetin; Chloramphenicol [INN:BAN:JAN]; Myscel; Tega-Cetin; MLS001332385; Cloramfenicolo; Enicol; Austracol; Ak-chlor; Chlorocidin C; Alficetyn, Chlornitromycin, Chloromycetin, Chloramphenicol; NSC 3069; Biocetin; Erbaplast; CAF (pharmaceutical); Rivomycin; Intramycetin; CLM; SMR000471851; Veticol; Chloramphenicol crystalline; Doctamicina; IDI1_000544; Optomycin; Paraxin; Tea-Cetin; Microcetina; Elase-Chloromycetin; Mychel; Chloramfenikol; Chlorocaps; Loromisin; Cloramicol; Chlorovules; Novophenicol; CHEMBL130; NCGC00091011-03; Leukamycin; Oleomycetin; Chlorsig; Tifomycin; Micoclorina; Medichol; Ronfenil; BRD-K08111712-001-02-7; D-threo-Chloramphenicol; NCI-C55709; Quemicetina; Chloramphenicolum; ST024743; NSC3069; Glorous; Romphenil; C0857_SIGMA; Chloramphenicol & VRC3375; Cloramfenicol [INN-Spanish]; Chloromyxin; NCGC00091011-01; Otophen; Otachron; Chlora-tabs; D(-)-threo-2-dichloroacetamido-1-p-nitrophen yl-propanediol; MLS001066397; Chloramficin; Chlorocidin C tetran; D-Chloramphenicol; KBio1_000544; C7795_SIGMA; Chloromax; Cloramficin; CID5959; Prestwick3_000031; Micloretin; Tiromycetin; Chloro-25 vetag; 56-75-7; Tifomycine; Ophthochlor; nchembio.244-comp5; U-6062; Interomycetine; Econochlor (TN); Duphenicol; Chlomycol; Enteromycetin; Detreomycine; Farmicetina; Fenicol; NSC 16331; Sno Phenicol; Chlormycetin R; Chloricol; Tevcocin; Ch loramex; WLN: WNR DYQY1QMVYGG; Cloroamfenicolo [Italian]; C1863_SIGMA; ZINC00113382; CAF; Chloroptic; Klorita; Cloramfen; Novochlorocap; C11H12Cl2N2O5; Chlorocid S; Amseclor; Chemiceticol; CHEBI:17698; Levomitsetin; 2787-09-9; Chlorasol; Septicol; Chlorocide; Chlorofair; 15313-32-3; ARONIS23913	56-75-7	298	4172	TTDS00229	Peptidyl tranferase	N/A	N/A	N/A	N/A	binder
DAP000641	Decitabine	4-amino-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one; A3656_SIGMA; NCGC_5ADOC; 5A2dc; FT-0082622; 5-aza-2-deoxycytidine; S1200_Selleck; MLS001332588; 2353-33-5; CID451668; 2'-Deoxy-5-azacytidine; 1,3, 5-Triazin-2(1H)-one, 4-amino-1-(2-deoxy--D-erythro-pentofuranosyl)-; SMR000857076; SBB066121; TL8001944; Decitabine; Dacogen; D03665; Dacogen (TN); 5-aza-dC; 5-Aza-2&prime;-Deoxycytidine; 5-Azadeoxycytidine; NSC-127716; Dezocitidine; 4-Amino-1-(2-deoxy-beta-D-erythro-pentofuranosyl)-1,3,5-triazin-2(1H)-one; NSC127716; 4-Amino-1-(2-deoxy-beta-D-ribofuranosyl)-1,3,5-triazin-2(1H)-one; Decitabine (USAN/INN); 5-Deoxy-2&prime;-azacytidine; 5-AZAdC; CHEBI:50131; 5-aza-CdR; Dacogen, 5-aza-2'-deoxycytidine,NSC 127716, Dacogen, DAC, Decitabine; AC1L9PS9; 5-Aza-2'-deoxycytidine; DB01262; MolMap_000063; E-7373; MLS001332587; CHEMBL1201129; 4-Amino-1-(2-deoxy-beta-D-erythro-pentofuranosyl)-s-triazin-2(1H)-one; AC-1135; AzadC	2353-33-5	451668	17397761	TTDS00312	DNA (cytosine-5)-methyltransferase	DNA methyltransferase;DNA MTase;M.EcoDcm	P11876	N/A	N/A	inhibitor
DAP000640	Azacitidine	IDI1_000125; KBio3_002657; Azacitidine [USAN:INN]; Spectrum3_001509; MLS001333121; 4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triaz; InChI=1/C8H12N4O5/c9-7-10-2-12(8(16)11-7)6-5(15)4(14)3(1-13)17-6/h2-6,13-15H,1H2,(H2,9,11,16)/t3-,4-,5-,6-/m1/s1; Azacitidina; HMS500G07; 4-Amino-1-beta-D-ribofuranosyl-1,3,5-traizin-2(1H)-one; 5AzaC; 4-Amino-1-(beta-D-ribofuranosyl)-1,3,5-triazin-2(1H)-one; Jsp005945; BRN 0620461; NCGC00090851-01; TL80073599; cMAP_000082; HSDB 6879; pyrimidine antimetabolite: inhibits nucleic acid replication; MLS002153249; Antibiotic U 18496; NINDS_000125; MolMap_000062; NSC 102816; 2-(beta-D-Ribofuranosyl)-4-amino-1,3,5-triazin-2-one; KBioSS_002565; Azacitidinum [INN-Latin]; NCGC00090851-04; NSC102816; SPBio_000892; KBio1_000125; 5-AZAC; 5-azacytidine, Mylosar, Ladakamycin, Vidaza, Azacitidine; U 18496; 4-Amino-1-(beta-D-ribofuranosyl)-1,3,5-triazin-2(1H)-one; Ladakamycin; CID9444; 4-amino-1-beta-L-ribofuranosyl-1,3,5-triazin-2(1H)-one; SPECTRUM1502111; CHEMBL1489; WR-183027; KBio2_006878; 1,3,5-Triazin-2(1H)-one, 4-amino-1-beta-D-ribofuranosyl-; NCGC00090851-08; mylo sar; Azacitidine; ZINC03861768; SAM002264595; Ladakamycin; NCGC00090851-02; SMR000857239; DivK1c_000125; KBioGR_001444; D001374; Vidaza; Mylosar; HMS2092D08; 4-Amino-1-beta-D-ribofuranosyl-1,3,5-triazine-2(1H)-one; 5-AZCR; 4-Amino-1-beta-D-ribofuranosyl-s-triazin-2(1H)-one; C11262; Pharmion Brand of Azacitidine; Azacitidina [INN-Spanish]; KBioGR_002556; Azacitidinum; Spectrum_001262; KBio2_005124; CPD000857239; BCBcMAP01_000083; KBio2_002556; EU-0100035; s-Triazin-2(1H)-one, 4-amino-1-beta-D-ribofuranosyl- (8CI); KBioSS_001742; MLS001333122; LS-1189; KBio2_007692; UNII-M801H13NRU; NCGC00178234-01; 5-azacytidine; FT-0081170; Spectrum2_000786; 5-azacitidine; NCI-C01569; NCGC00090851-03; Vidaza (TN); 5-AC; Azacitidine (JAN/USAN/INN); U-18496; ST056940; 4-Amino-1-beta-d-ribofuranosyl-1,3,5-triazin-2(1H)-one; s-Triazin-2(1H)-one, 4-amino-1-beta-D-ribofuranosyl-; A2385_SIGMA; AC1L1T1Y; EINECS 206-280-2; wr 183027; BSPBio_003157; KBio2_004310; Azacytidine, 5-; HMS1921J22; A 2385; D03021; CCRIS 60; 5 Azacytidine; DB00928; NSC-102816; 5 AZC; 5-aza-CR; Spectrum4_000922; NS-17; Azacytidine; S1782_Selleck; Lopac0_000035; A1287_SIGMA; KBio3_003034; CHEBI:2038; 4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one; KBio2_001742; NMUSYJAQQFHJEW-KVTDHHQDSA-; Spectrum5_001166; 320-67-2	320-67-2	9444	13439	TTDS00312	DNA (cytosine-5)-methyltransferase	DNA methyltransferase;DNA MTase;M.EcoDcm	P11876	N/A	N/A	inhibitor
DCL000467	AZD4017	N/A	116507-04-1	121963	29302450	TTDC00070	Corticosteroid 11-beta-dehydrogenase, isozyme 1	11 beta-hydroxysteroid dehydrogenase type 1;11-beta-HSD1;11beta-HSD1A;11beta-HSD2;11-beta-hydroxysteroid dehydrogenase 1;11-DH;11HSD1	P28845	3290	ENSG00000117594	inhibitor
DCL000134	INCB13739	N/A	N/A	N/A	N/A	TTDC00070	Corticosteroid 11-beta-dehydrogenase, isozyme 1	11 beta-hydroxysteroid dehydrogenase type 1;11-beta-HSD1;11beta-HSD1A;11beta-HSD2;11-beta-hydroxysteroid dehydrogenase 1;11-DH;11HSD1	P28845	3290	ENSG00000117594	inhibitor
DCL001156	AZD8329	N/A	N/A	N/A	N/A	TTDC00070	Corticosteroid 11-beta-dehydrogenase, isozyme 1	11 beta-hydroxysteroid dehydrogenase type 1;11-beta-HSD1;11beta-HSD1A;11beta-HSD2;11-beta-hydroxysteroid dehydrogenase 1;11-DH;11HSD1	P28845	3290	ENSG00000117594	inhibitor
DCL000369	Bosutinib	xy]-3-quinolinecarbonitrile; K00615a; SKI606; 3-Quinolinecarbonitrile, 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-; 380843-75-4; SKI-606; CHEBI:39112; 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile; AC-2413; ST51054132; C471992; 3-Quinolinecarbonitrile, 4-((2,4-dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methyl-1-piperazinyl)propoxy)-; Bosutinib (USAN); UNII-5018V4AEZ0; I14-1974; PF-5208763; Bosutinib; EC-000.2261; CHEMBL288441; 4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile; CID5328940; 4-((2,4-dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile; SKI 606; AC1NS5P1; D03252; 4-((2,4-dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methyl-1-piperazinyl)propoxy)-3-quinolinecarbonitrile; 4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propo; 380443-75-4	N/A	5328940	26746630	TTDS00247	Proto-oncogene tyrosine-protein kinase SRC	C-Src;C-src TK;C-SRC tyrosine kinase;P60-Src;Pp60(src);Src tyrosine kinase;Tyrosine kinase;Tyrosine kinase (pp60(src))	P12931	6714	ENSG00000197122	inhibitor
DAP001390	Herbimycin A	CID5311102; MolPort-003-941-703; H6649_SIGMA; AC1L1G9T; CID6436247; NSC305978; Geldanamycin, 17-demethoxy-15-methoxy-11-O-methyl-, (15R)-; herbimycin a; AC1O5LAW; ACon0_000819; AC1NSJZW; (2,5,6,11-tetramethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl) carbamate; [(2R,3S,5S,6R,7S,8E,10S,11S,12E,14E)-2,5,6,11-tetramethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; [(2R,3S,5S,6R,7S,8E,10S,11S,12Z,14E)-2,5,6,11-tetramethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; MEGxm0_000417; NSC 305978; CID3591; LS-71126; C11225; Herbimycin A from Streptomyces hygroscopicus; Antibiotic Tan 420F; Herbimycin; 70563-58-5	70563-58-5	6436247	627068	TTDS00247	Proto-oncogene tyrosine-protein kinase SRC	C-Src;C-src TK;C-SRC tyrosine kinase;P60-Src;Pp60(src);Src tyrosine kinase;Tyrosine kinase;Tyrosine kinase (pp60(src))	P12931	6714	ENSG00000197122	inhibitor
DAP000004	Dasatinib	302962-49-8; LS-186641; MolPort-003-846-143; EC-000.2122; LS-187773; BCB03_000715; CHEBI:49375; 1N1; UNII-X78UG0A0RN; BMS-354825, Sprycel, BMS354825, Dasatinib; 2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)-N-(2-chloro-6-methylphenyl)thiazole-5-carboxamide; SPRYCEL (TN); nchembio.117-comp11; Sprycel; Dasatinib anhydrous; S1021_Selleck; NSC-732517; CHEMBL1421; LS-187028; N-(2-CHLORO-6-METHYLPHENYL)-2-({6-[4-(2-HYDROXYETHYL)PIPERAZIN-1-YL]-2-METHYLPYRIMIDIN-4-YL}AMINO)-1,3-THIAZOLE-5-CARBOXAMIDE; N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)thiazole-5-carboxamide; FT-0084503; Dasatinib (USAN); CID3062316; N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carboxamide; Kinome_3650; I14-1972; BMS354825; dasatinibum; 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-; AC1MI3ET; BMS 354825; N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide; AC1Q2P0C; D03658; Dasatinib, BMS 354825; EN002710; C488369; nchembio.162-comp4; 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-; (18F)-N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide; DB01254; N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide, monohydrate; Spyrcel; NCGC00181129-01; Dasatinib; BMS-354825; AmbotzLS-1203; nchembio.332-comp1; NSC732517; Dasatinib [USAN]	302962-49-8	3062316	10061134	TTDS00247	Proto-oncogene tyrosine-protein kinase SRC	C-Src;C-src TK;C-SRC tyrosine kinase;P60-Src;Pp60(src);Src tyrosine kinase;Tyrosine kinase;Tyrosine kinase (pp60(src))	P12931	6714	ENSG00000197122	inhibitor
DCL000368	AZD0530	4-Quinazolinamine, N-(5-chloro-1,3-benzodioxol-4-yl)-7-(2-(4-methyl-1-piperazinyl)ethoxy)-5-((tetrahydro-2H-pyran-4-yl)oxy)-; 4-(6-Chloro-2,3-methylenedioxyanilino)-7-(2-(4-methylpiperazin-1-yl)ethoxy)-5-tetrahydropyran-4-yloxyquinazoline; AZD0530; N-(5-Chloro-1,3-benzodioxol-4-yl)-7-(2-(4-methylpiperazin-1-yl)ethoxy)-5-(tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine; ST51054135; I14-1980; CHEMBL217092; CID10302451; 379231-04-6; AC-5249; nchembio866-comp19; LS-193231; Saracatinib; AZD-0530; Saracatinib, AZD-0530, AZD0530; 2h8h; AKOS005145757; H8H; S1006_Selleck; CHEBI:47458	N/A	10302451	46512739	TTDS00247	Proto-oncogene tyrosine-protein kinase SRC	C-Src;C-src TK;C-SRC tyrosine kinase;P60-Src;Pp60(src);Src tyrosine kinase;Tyrosine kinase;Tyrosine kinase (pp60(src))	P12931	6714	ENSG00000197122	inhibitor
DCL000682	AEB07	N/A	159634-47-6	178024	46059961	TTDC00181	Protein kinase C	N/A	N/A	N/A	N/A	inhibitor
DPR000101	Rottlerin	(E)-1-[6-[(3-acetyl-2,4,6-trihydroxy-5-methylphenyl)methyl]-5,7-dihydroxy-2,2-dimethylchromen-8-yl]-3-phenylprop-2-en-1-one; BSPBio_001080; LS-13446; NCGC00025228-06; HMS1792F21; R5648_SIGMA; NCGC00025228-07; BiomolKI_000058; CHEBI:150547; 1-[6-[(3-Acetyl-2,4,6-trihydroxy-5-methylphenyl)methyl]-5,7-dihydroxy-2,2-dimethyl-2H-1-benzopyran-8-yl]-3-phenyl-2-propen-1-one; NSC 56346; NCGC00025228-04; HMS1362F21; BiomolKI2_000064; NCGC00025228-05; nchembio.2007.59-comp22; ZINC03874886; (E)-1-(6-((3-Acetyl-2,4,6-trihydroxy-5-methylphenyl)methyl)-5,7-dihydroxy-2,2-dimethyl-2H-1-benzopyran-8-yl)-3-phenyl-2-propen-1-one; BRD-K39256324-001-01-5; Mallotoxin; EINECS 201-395-4; BRD-K03816923-001-03-9; R 5648; Acetophenone, 3'-((8-cinnamoyl-5,7-dihydroxy-2,2-dimethyl-2H-1-benzopyran-6-yl)methyl)-2',4',6'-trihydroxy-5'-methyl-; MolPort-003-959-457; BMK1-F10; NSC 94525; 82-08-6; BRN 0070757; 1-[6-(3-Acetyl-2,4,6-trihydroxy-5-methyl-benzyl)-5,7-dihydroxy-2,2-dimethyl-2H-chromen-8-yl]-3-phenyl-propenone; BCBcMAP01_000019; AC1NQZ6C; CID5281847; EU-0101052; C085746; NCGC00025228-02; LMPK12120428; 1-[6-[(3-Acetyl-2,4,6-trihydroxy-5-methylphenyl)methyl]-5,7-dihydroxy-2,2-dimethylchromen-8-yl]-3-phenylprop-2-en-1-one; C30H28O8; HMS1990F21; C10721; NCGC00025228-08; rottlerin; NCGC00025228-03; ST056358; Lopac0_001052; Kamalin; 5-18-05-00695 (Beilstein Handbook Reference); IDI1_002135; nchembio.65-comp12; CHEMBL34241	82-08-6	5281847	29204544	TTDC00181	Protein kinase C	N/A	N/A	N/A	N/A	inhibitor
DCL000484	AZD8529	N/A	N/A	N/A	N/A	TTDC00220	Metabotropic glutamate receptor 1	Glutamate receptor mGLU1;mGLUR1	Q13255	2911	ENSG00000152822	agonist
DCL000594	PF-1913539	N/A	N/A	N/A	N/A	TTDC00220	Metabotropic glutamate receptor 1	Glutamate receptor mGLU1;mGLUR1	Q13255	2911	ENSG00000152822	antagonist
DCL000712	AZD-9272	N/A	N/A	11434515	49684225	TTDC00220	Metabotropic glutamate receptor 1	Glutamate receptor mGLU1;mGLUR1	Q13255	2911	ENSG00000152822	modulator
DCL000387	SB-656933	SB-656933	N/A	N/A	N/A	TTDC00087	High affinity interleukin-8 receptor B	CDw128b;CXCR-2;GRO/MGSA receptor;IL-8 receptor type 2;IL-8R B;Interleukin-8 receptor B	P25025	3579	ENSG00000180871	antagonist
DCL000955	Reparixin	C490707; Reparixin (INN/USAN); reparixin; 2-(4-isobutylphenyl)propionylmethanesulfonamide; UNII-U604E1NB3K; D08984; Benzeneacetamide, alpha-methyl-4-(2-methylpropyl)-N-(methylsulfonyl)-, (alphaR)-; CID9838712; CHEMBL191413; Reparixin [INN]; repertaxin; 266359-83-5; CHEBI:416774; (R)-2-(4-isobutylphenyl)propionylmethanesulfonamide	266359-93-7	104850	49743862	TTDC00087	High affinity interleukin-8 receptor B	CDw128b;CXCR-2;GRO/MGSA receptor;IL-8 receptor type 2;IL-8R B;Interleukin-8 receptor B	P25025	3579	ENSG00000180871	antagonist
DCL000977	SB-656933	SB-656933	N/A	10479502	49684247	TTDC00087	High affinity interleukin-8 receptor B	CDw128b;CXCR-2;GRO/MGSA receptor;IL-8 receptor type 2;IL-8R B;Interleukin-8 receptor B	P25025	3579	ENSG00000180871	antagonist
DCL000980	SCH-527123	CID9865554; SCH-527123; CHEBI:464875; CHEMBL216981	N/A	9865554	49684245	TTDC00087	High affinity interleukin-8 receptor B	CDw128b;CXCR-2;GRO/MGSA receptor;IL-8 receptor type 2;IL-8R B;Interleukin-8 receptor B	P25025	3579	ENSG00000180871	antagonist
DCL000975	SB-265610	N/A	211096-49-0	9841667	49684220	TTDC00087	High affinity interleukin-8 receptor B	CDw128b;CXCR-2;GRO/MGSA receptor;IL-8 receptor type 2;IL-8R B;Interleukin-8 receptor B	P25025	3579	ENSG00000180871	antagonist
DCL000200	PS-938285	N/A	N/A	N/A	N/A	TTDC00087	High affinity interleukin-8 receptor B	CDw128b;CXCR-2;GRO/MGSA receptor;IL-8 receptor type 2;IL-8R B;Interleukin-8 receptor B	P25025	3579	ENSG00000180871	antagonist
DAP000596	Dyphylline	COR-theophylline; 7-(2,3-Dihydroxypropyl)-1,3-dimethylxanthine; Silbephylline; KBioGR_001139; Glyfyllin; Prestwick0_000033; dyphylline; Circair; 7-(beta,gamma-Dihydroxypropyl)theophylline; D3600; Diprophylline; Isophyllen; Propyphyllin; Glyphyllinum; NSC40844; Glyphyllin; KSCFJBIXMNOVSH-UHFFFAOYSA-; BSPBio_000125; AC-11186; DivK1c_000022; 37910_FLUKA; NCGC00089736-03; Dyphylline (USP); NCGC00178894-02; Teofen; Lufyllin; EINECS 207-526-1; 52756-53-3; Spectrum_000809; 1H-Purine-2,6-dione, 7-(2,3-dihydroxypropyl)-3,7-dihydro-1,3-dimethyl-, (+-)-; Prestwick2_000033; Astrophyllin; Spectrum2_000090; Oprea1_363458; InChI=1/C10H14N4O4/c1-12-8-7(9(17)13(2)10(12)18)14(5-11-8)3-6(16)4-15/h5-6,15-16H,3-4H2,1-2H3; Neutraphylline; 7-(2,3-dihydroxypropyl)-1,3-dimethylpurine-2,6-dione; (+-)-dyphylline; STK796769; Purifilin; BB_NC-1985; NSC 14305; KBioSS_001289; CHEMBL1752; Diprofilline; Solufyllin; Theal ampules; 479-18-5; LS-149505; Aristophyllin; Dihydroxypropyl theophylline; Diprophylline (JAN/INN); DB00651; SMR000059068; Coronarin; Neophylline; NSC14305; Diprophyllinum; SMP1_000108; Neophyllin M; (1,2-Dihydroxy-3-propyl)thiophyllin; Dihydroxypropyl theopylin; KBio2_006425; Tefilan; 5-26-14-00070 (Beilstein Handbook Reference); KBio2_003857; MLS000069403; Diprofillin; MolPort-001-783-701; Thefylan; Lufyllin (TN); Hiphyllin; Tesfen; I14-5830; Prestwick1_000033; Diprofillina; Theophylline, 7-(2,3-dihydroxypropyl)-; BSPBio_001962; HSDB 3322; Astmamasit; D00691; 7-(2,3-Dihydroxypropyl)-1,3-dimethyl-3,7-dihydro-1H-purine-2,6-dione; AB00051977; Diprophyllinum [INN-Latin]; Solufilin; Droxine; Dyflex; Dyphylline [USAN]; Prestwick_465; Neufil; 7-DIHYDROXYPROPYLTHEOPHYLLINE; Diprofilina; Theal; Diphyllin (VAN); Spectrum5_000953; Coronal; AC1Q3Z7Q; 1H-Purine-2,6-dione, 7-(2,3-dihydroxypropyl)-3,7-dihydro-1,3-dimethyl; Diprophyllin; Neutrafil; WLN: T56 BN DN FNVNVJ B1YQ1Q F1 H1; HMS2091B13; SPECTRUM1500269; CID3182; SPBio_000020; AR-1I7082; AC1L1FCW; AC1Q6LEB; Hyphylline; Neothylline; Dipropylline; Dilor-400; 7-[2,3-Dihydroxypropyl]-theophylline; KBio2_001289; Spectrum3_000411; HMS1920K08; 7-(2,3-Dihydroxypropyl)-3,7-dihydro-1,3-dimethyl-1H-purine-2,6-dione; Neo-Vasophylline; Neutroxantina; Corphyllin; Synthophylline; Hidroxiteofillina; NCGC00089736-02; HMS500B04; 7-(.beta.,.gamma.-Dihydroxypropyl)theophylline; UNII-263T0E9RR9; KBio3_001182; IDI1_000022; C10H14N4O4; Soluphyllin; SPBio_002046; BRN 0284563; AFI-Phyllin; Neutraphyllin; Iphyllin; Silbephyllin; S1504_Selleck; (+-)-diprophylline; Neostenovasan; Dihydroxypropyltheophylline; MLS001076466; NCGC00178894-01; Circain; Asthmolysin; D0633_SIGMA; 1H-Purine-2,6-dione, 7-(2,3-dihydroxypropyl)-3,7-dihydro-1,3-dimethyl-; KBio1_000022; Dihydroxypropyl theopylin (german); 7-(2,3-dihydroxypropyl)-1,3-dimethyl-2,3,6,7-tetrahydro-1H-purine-2,6-dione; Liactemin; 7-(2,3-Dioxypropyl)theophylline; Spectrum4_000530; Neothylline, Lufyllin, diprophylline,Dyphylline; Neophyl; C07819; Neophyllin; Prestwick3_000033; Protheophylline; Glyphylline; BPBio1_000139; NINDS_000022; 7-(2,3-Dihydroxypropyl)theophylline; CHEBI:4728; Diprofilina [INN-Spanish]; (+-)-7-(2,3-Dihydroxypropyl)theophylline; 1,3-Dimethyl-7-(2,3-dihydroxypropyl)xanthine; Neutrafillina; BRD-A00827783-001-05-5; HMS1568G07; Diprofillina [DCIT]; Neotilina; Dilor G; SR-01000002972-2	479-18-5	3182	10021	TTDS00280	CAMP-specific 3',5'-cyclic phosphodiesterase 4A	DPDE2;PDE46;Type 4A cAMP phosphodiesterase	P27815	5141	ENSG00000065989	inhibitor
DCL000752	Cilomilast	Cilomilast; DB03849; 1xom; 153259-65-5; PDSP2_001271; CHEMBL511115; S1455_Selleck; Cilomilast (JAN/USAN/INN); D01704; Cilomilast [USAN:INN]; Ariflo; LS-56637; AC1L45SU; cis-4-Cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)cyclohexanecarboxylic acid; SB207499; CIO; CID151170; Ariflo (TN); C433247; Ariflo, SB-207499,Cilomilast; cis-4-Cyano-4-(3-(cyclopentyloxy)-4-methoxyphenyl)cyclohexanecarboxylic acid; NCGC00167520-01; 1xlx; CHEBI:221895; cis-4-(3-(Cyclopentyloxy)-4-methoxyphenyl)-4-cyanocyclohexane-1-carboxylic acid; SB 207499; CIS-4-CYANO-4-[3-(CYCLOPENTYLOXY)-4-METHOXYPHENYL]CYCLOHEXANECARBOXYLIC ACID; PDSP1_001287; Cyclohexanecarboxylic acid, 4-cyano-4-(3-(cyclopentyloxy)-4-methoxyphenyl)-, cis-; 4-cyano-4-(3-cyclopentoxy-4-methoxy-phenyl)-cyclohexane-1- carboxylic acid; MolPort-005-940-870; MolPort-005-943-371; SB-207499; 4-cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)cyclohexane-1-carboxylic acid	153259-65-5	151170	46515098	TTDS00280	CAMP-specific 3',5'-cyclic phosphodiesterase 4A	DPDE2;PDE46;Type 4A cAMP phosphodiesterase	P27815	5141	ENSG00000065989	inhibitor
DAP000597	Enprofylline	Enprofyllinum; CHEMBL279898; PDSP1_001202; D-4028; 3-n-Propylxanthine; 3-propyl-7H-purine-2,6-dione; PDSP2_001003; AC1L1BZI; Enprofilina; NCGC00015824-05; 41078-02-8; NCGC00022716-05; Lopac-P-5679; CHEBI:126237; AC1Q6LGE; MLS000069700; Lopac0_000910; AR-1F4712; Oxeze; P 5679; NCGC00015824-02; 3-Propyl-3,7-dihydro-purine-2,6-dione; PDSP1_001019; 3-propyl-3,7-dihydro-1H-purine-2,6-dione; NCGC00015824-08; EU-0100910; D04006; ZINC00403567; UNII-DT7DT5E518; 1H-Purine-2,6-dione, 3,7-dihydro-3-propyl-; L000242; NCGC00022716-03; Enprofyllinum [INN-Latin]; Enprofylline (USAN/INN); P5679_SIGMA; SMR000058496; PDSP2_001186; Enprofilina [INN-Spanish]; LS-127057; EINECS 255-201-8; Nilyph; DB00824; NCGC00022716-04; NCGC00015824-01; CID1676; ENPROFYLLINE; Enprofylline [USAN:INN]; 3-Propylxanthine; 3,7-Dihydro-3-propyl-1H-purine-2,6-dione	41078-02-8	1676	179921	TTDS00280	CAMP-specific 3',5'-cyclic phosphodiesterase 4A	DPDE2;PDE46;Type 4A cAMP phosphodiesterase	P27815	5141	ENSG00000065989	inhibitor
DCL000375	GSK256066	CID 9827968; CHEMBL570015; CID9827968; GSK-256066	326859-36-3	N/A	47206188	TTDS00280	CAMP-specific 3',5'-cyclic phosphodiesterase 4A	DPDE2;PDE46;Type 4A cAMP phosphodiesterase	P27815	5141	ENSG00000065989	inhibitor
DCL000820	GPI-16072	N/A	N/A	N/A	N/A	TTDS00441	Glutamate carboxypeptidase II	FGCP;Folate hydrolase 1;Folylpoly-gamma-glutamate carboxypeptidase;Membrane glutamate carboxypeptidase;MGCP;NAALADase I;N-acetylated-alpha-linked acidic dipeptidase I;Prostate-specific membrane antigen;PSM;PSMA;Pteroylpoly-gamma-glutamate carboxypeptidase	Q04609	2346	ENSG00000086205	inhibitor
DAP001049	Capromab	N/A	145464-28-4	N/A	46506263	TTDS00441	Glutamate carboxypeptidase II	FGCP;Folate hydrolase 1;Folylpoly-gamma-glutamate carboxypeptidase;Membrane glutamate carboxypeptidase;MGCP;NAALADase I;N-acetylated-alpha-linked acidic dipeptidase I;Prostate-specific membrane antigen;PSM;PSMA;Pteroylpoly-gamma-glutamate carboxypeptidase	Q04609	2346	ENSG00000086205	antibody
DCL001033	Vasoactive intestinal peptide	N/A	40077-57-4	N/A	47205429	TTDC00204	Vasoactive intestinal polypeptide receptor 1	PACAP type II receptor;PACAP-R-2;Pituitary adenylate cyclase activating polypeptide type II receptor;Vasoactive intestinal peptide receptor 1;Vasoactive intestinal peptide/pituitary adenylate cyclase activating polypeptide receptor-1;VIP-R-1;VPAC1;VPAC-1	P32241	7433	ENSG00000114812	antagonist
DPR000026	BVT-A	N/A	N/A	N/A	N/A	TTDS00076	Growth hormone receptor	GH receptor;Serum binding protein;Somatotropin receptor	P10912	2690	ENSG00000112964	antagonist
DCL000797	EP-51389	N/A	N/A	N/A	N/A	TTDS00076	Growth hormone receptor	GH receptor;Serum binding protein;Somatotropin receptor	P10912	2690	ENSG00000112964	agonist
DCL000697	AOD-9604	386264-39-7; AOD9604; Somatostatin (177-191), Tyr-; L-Tyrosine, L-leucyl-L-arginyl-L-isoleucyl-L-valyl-L-glutaminyl-L-cysteinyl-L-arginyl-L-seryl-L-valyl-L-alpha-glutamylglycyl-L-seryl-L-cysteinylglycyl-L-phenylalanyl-; Human GH (hGH) lipolytic fragment; Somatostatin (177-191), tyrosyl-; Tyr-somatostatin (177-191); AOD 9604	386264-39-7	16131447	791578	TTDS00076	Growth hormone receptor	GH receptor;Serum binding protein;Somatotropin receptor	P10912	2690	ENSG00000112964	agonist
DAP001054	Somatropin recombinant	N/A	12629-01-5	491941	46506010	TTDS00076	Growth hormone receptor	GH receptor;Serum binding protein;Somatotropin receptor	P10912	2690	ENSG00000112964	binder
DAP000286	Pegvisomant	Pegvisomant (genetical recombination); Somavent; 218620-50-9; Pegvisomant (USAN/INN); Somavent (TN); Pegvisomant; D05394; Pegvisomant (genetical recombination) (JAN)	218620-50-9	2540	47207070	TTDS00076	Growth hormone receptor	GH receptor;Serum binding protein;Somatotropin receptor	P10912	2690	ENSG00000112964	antagonist
DCL000796	EP-51216	(2S)-6-amino-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-(4-aminobutanoylamino)-3-(2-methyl-1H-indol-3-yl)propanoyl]amino]-3-(2-methyl-1H-indol-3-yl)propanoyl]amino]-3-(2-methyl-1H-indol-3-yl)propanoyl]amino]hexanamide; CID6918424; EP-51216; AC1OCFEW; CHEMBL324218	703-95-7	69711	12015234	TTDS00076	Growth hormone receptor	GH receptor;Serum binding protein;Somatotropin receptor	P10912	2690	ENSG00000112964	agonist
DAP001483	Ibutamoren	MK-677; 159634-47-6; MK-0667; CHEBI:112850; AC1L4346; Propanamide, 2-amino-N-((1R)-2-(1,2-dihydro-1-(methylsulfonyl)spiro(3H-indole-3,4'-piperidin)-1'-yl)-2-oxo-1-((phenylmethoxy)methyl)ethyl)-2-methyl-; Propanamide, 2-amino-N-(2-(1,2-dihydro-1-(methylsulfonyl)spiro(3H-indole-3,4'-piperidin)-1'-yl)-2-oxo-1-((phenylmethoxy)methyl)ethyl)-2-methyl-, (R)-; CID178024; Ibutamoren; CHEMBL13817; 2-amino-2-methyl-N-[(2R)-1-(1-methylsulfonylspiro[2H-indole-3,4'-piperidine]-1'-yl)-1-oxo-3-phenylmethoxypropan-2-yl]propanamide; L 163191; S1151_Selleck	159634-47-6	178024	755250	TTDS00076	Growth hormone receptor	GH receptor;Serum binding protein;Somatotropin receptor	P10912	2690	ENSG00000112964	binder
DPR000017	ATL-1103	N/A	N/A	N/A	N/A	TTDS00076	Growth hormone receptor	GH receptor;Serum binding protein;Somatotropin receptor	P10912	2690	ENSG00000112964	antagonist
DCL000848	INS-37217	INS-37217; Uridine 5'-(pentahydrogen tetraphosphate), P'''-5'-ester with 2'-deoxycytidine, tetrasodium salt; Denufosol tetrasodium; INS 37217; AR-1L6614; AC1Q1UNF; CID192707; tetrasodium[[[[(3s,5r)-5-(4-amino-2-oxo-pyrimidin-1-yl)-3-hydroxy-tetrahydrofuran-2-yl]methoxy-hydroxy-phosphoryl]oxy-hydroxy-phosphoryl]oxy-hydroxy-phosphoryl][(2r,3s,4r,5r)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxy-tetrahydrofuran-2-yl]methyl hydrogen phosphate; tetrasodium [[(3S,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate; Denufosol tetrasodium (USAN); dCp4U; INS37217; CID10219163; Up4dC; D03685; AC1L4USO	318250-11-2	6366718	42986251	TTDC00179	P2Y purinoceptor 2	Adenosine P2Y2 receptor;ATP receptor;P2U nucleotide receptor;P2U purinoceptor 1;P2U receptor;P2U1;P2Y2;Purinergic receptor	P41231	5029	ENSG00000175591	agonist
DCL000774	Diquafosol	KPY 998; Diquafosol; CHEMBL221326; Diquafosol [INN:BAN]; 59985-21-6; [[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate; INS-365; UppppU; P1,P4-Bis(5'-uridyl) tetrahydrogen tetraphosphate; Diquafosol [INN]; AC1L3WMW; CHEBI:27791; UNII-7828VC80FJ; P1,P4-Bis(5'-uridyl) tetraphosphate; C06198; CID148197	59985-21-6	148197	789436	TTDC00179	P2Y purinoceptor 2	Adenosine P2Y2 receptor;ATP receptor;P2U nucleotide receptor;P2U purinoceptor 1;P2U receptor;P2U1;P2Y2;Purinergic receptor	P41231	5029	ENSG00000175591	agonist
DCL001206	LFA102	N/A	N/A	N/A	N/A	TTDC00333	Prolactin receptor	PRL-R	P16471	5618	ENSG00000113494	antibody
DCL000193	Pasireotide	N/A	396091-73-9	N/A	10549826	TTDC00253	Somatostatin receptor type 5	SS5R	P35346	6755	ENSG00000162009	agonist
DCL001064	7-hydroxystaurosporine	(5s,6r,7r,9r,16r)-16-hydroxy-6-methoxy-5-methyl-7-(methylamino)-6,7,8,9,15,16-hexahydro-5h,14h-5,9-epoxy-4b,9a,15-triazadibenzo[b,h]cyclonona[1,2,3,4-jkl]cyclopenta[e]-as-indacen-14-one; KW-2401; UCN; AR-1A6540; 8,12-Epoxy-1H,8H-2,7b,12a-triazadibenzo(a,g)cyclonona(cde)triinden-1-one, 2,3,9,10,11,12-hexahydro-3-hydroxy-9-methoxy-8-methyl-10-(methylamino)-; KRX-0601; AC1Q6PB4; Ucn 01; NSC-638850; CPD-11911; LS-64044; 1okz; 98290-92-7; 9,13-Epoxy-1H,9H-diindolo(1,2,3-gh:3',2',1'-lm)pyrrolo(3,4-j)(1,7)benzodiazonin-1-one,2,3,10,11,12,13-hexahydro-3-hydroxy-10-methoxy-9-methyl-11-(methylamino)-, (3-alpha,9-beta,10-alpha,11-alpha,13-beta)-(+)-; C28H26N4O4; NSC 638850; UCN01; NSC638850; 7-hydroxystaurosporine (UCN-01); CHEBI:46153; NCI60_012974; 9,13-Epoxy-1H,9H-diindolo(1,2,3-gh:3',2',1'-lm)pyrrolo(3,4-j)(1,7)benzodiazonin-1-one, 2,3,10,11,12,13-hexahydro-3-hydroxy-10-methoxy-9-methyl-11-(methylamino)-, (3-alpha,9-beta,10-alpha,11-alpha,13-beta)-(+)-; CHEMBL1236539; UCN-02; KST-1A9223; UCN-01; 7-Hydroxystaurosporine; 112953-11-4; 9,13-Epoxy-1H,9H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one, 2,3,10,11,12,13-hexahydro-3-hydroxy-10-methoxy-9-methyl-11-(methylamino)-, (3R,9S,10R,11R,13R)-	N/A	72271	49965093	TTDC00281	MARK3	Cdc25C-associated protein kinase 1;cTAK1;C-TAK1;MAP/microtubule affinity-regulating kinase 3;Protein kinase STK10);Ser/Thr protein kinase PAR-1;Serine/threonine-protein kinase p78	P27448	4140	ENSG00000075413	inhibitor
DCL000773	Dextromethorphan+quinidine	N/A	6700-34-1	5360696	10321646	TTDS00252	Cytochrome P450 19	Aromatase;CYPXIX;Estrogen synthetase;P-450AROM	P11511	1588	ENSG00000137869	inhibitor
DAP000625	Exemestane	Aromasin, Exemestane; Exemestano [INN-Spanish]; ZINC03973334; LS-19329; FCE-24304; C08162; Exemestanum [INN-Latin]; SMR000466314; 107868-30-4; S1196_Selleck; Ambap107868-30-4; CID60198; MLS000759419; HSDB 7463; 6-Methyleneandrosta-1,4-diene-3,17-dione; Aromasin (TN); 6-Methylenandrosta-1,4-diene-3,17-dione; Androsta-1,4-diene-3,17-dione, 6-methylene-; Fce 24304; Aromasine; 6-methylideneandrosta-1,4-diene-3,17-dione; C056516; AC1Q6AAZ; Nikidess; D00963; Aromasil; DB00990; CPD000466314; MolPort-003-847-343; UNII-NY22HMQ4BX; SAM001246574; AC-2171; CHEBI:4953; S1196_Sellek; MLS001424062; PNU-155971; Exemestane [USAN:INN:BAN]; Curator_000009; Aromasin; Exemestano; EXEMESTANE; CHEMBL1200374; (8R,9S,10R,13S,14S)-10,13-dimethyl-6-methylidene-7,8,9,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,17-dione; Exemestance; Pfizer brand of exemestane; Exemestane (JAN/USP/INN); Exemestanum; AC1L1SRB; EXE; NSC713563; HMS2051J04	107868-30-4	60198	196561	TTDS00252	Cytochrome P450 19	Aromatase;CYPXIX;Estrogen synthetase;P-450AROM	P11511	1588	ENSG00000137869	inhibitor
DAP000842	Aminoglutethimide	AC1L1D0R; alpha-(p-Aminophenyl)-alpha-ethylglutarimide; HMS2090I05; Prestwick3_000244; Prestwick2_000244; Aminoglutetimida; A1947; Prestwick0_000244; Ba 16038; Cytadren (TN); NCGC00093615-02; KBio1_000884; NCGC00015110-02; KBioSS_000400; (+/-)-p-AMINOGLUTETHIMIDE; Novartis Brand of Aminoglutethimide; BSPBio_001832; HMS1920C09; Prestwick_243; dl-Aminoglutethimide; NCGC00093615-03; Spectrum5_000802; BRD-A25234499-001-05-0; AB00051935; CHEMBL488; STK802074; Spectrum4_000144; CPD000326785; SPBio_002247; Ba-16038; UNII-0O54ZQ14I9; BPBio1_000032; DB00357; CID2145; Aminoglutethimidum; AG-1; CPD-10532; Aminoglutethimide (USP/INN); EINECS 204-756-4; Aminoglutethimidum [INN-Latin]; SAM002589964; NSC330915; AC-12456; NCGC00093615-04; Spectrum3_000296; KBio2_000400; NINDS_000884; SPECTRUM1500115; Lopac0_000124; 2,6-Piperidinedione, 3-(4-aminophenyl)-3-ethyl-; HMS2091I09; C 16038-BA; 3-(4-Aminophenyl)-3-ethyl-2,6-piperidinedione; Aminoglutethimide [INN:BAN]; Glutarimide, 2-(p-aminophenyl)-2-ethyl-; DivK1c_000884; NCGC00093615-05; NCI60_002900; CCRIS 7562; Elipten; Aminoglutetimida [INN-Spanish]; 3-(p-Aminophenyl)-3-ethylpiperidine-2,6-dione; MolPort-001-828-287; D00574; aminoglutethimide; HMS1568B10; MLS000859924; KBio3_001332; SMP1_000017; Glutethimide, para-amino; BB_SC-1153; SPBio_000046; AKOS004120070; 3-Ethyl-3-(p-aminophenyl)-2,6-dioxopiperidine; A 9657; LS-72014; HSDB 7494; CHEBI:2654; KBioGR_000588; 3-(4-Aminophenyl)-3-ethyl-2,6-piperidindion; Spectrum2_000093; Prestwick1_000244; KBio2_002968; C07617; Cytadren; NCGC00015110-07; 2-(p-Aminophenyl)-2-ethylglutarimide; Spectrum_000040; SMR000326785; AC1Q2SPJ; MLS001213216; Ciba Vision Brand of Aminoglutethimide; HMS502M06; KBio2_005536; aminoglutethimide (AG); S1672_Selleck; IDI1_000884; ( inverted question mark)-p-Aminoglutethimide; (+-)-3-(p-Aminophenyl)-3-ethyl-2,6-piperidinedione; .alpha.-(p-Aminophenyl)-.alpha.-ethylglutarimide; BSPBio_000028; p-Aminoglutethimide; 3-(4-aminophenyl)-3-ethylpiperidine-2,6-dione; A9657_SIGMA; NCGC00093615-01; EU-0100124; D000616; Orimeten; BRN 0210656; (?)-p-Aminoglutethimide; VU0243029-3; 125-84-8	125-84-8	2145	9819	TTDS00252	Cytochrome P450 19	Aromatase;CYPXIX;Estrogen synthetase;P-450AROM	P11511	1588	ENSG00000137869	inhibitor
DAP000626	Letrozole	SAM001246649; AC-1193; Prestwick0_001025; AKOS005145822; DB01006; 4,4'-(1H-1,2,4-triazol-1-ylmethanediyl)dibenzonitrile; Prestwick3_001025; Benzonitrile, 4,4'-(1H-1,2,4-triazol-1-ylmethylene)bis-; 4,4'-(1H-1,2,4-Triazol-1-ylmethylene)dibenzonitrile; letrozole; NCGC00016973-02; Letrozole [USAN:INN]; 4,4'-((1h-1,2,4-triazol-1-yl)methylene)dibenzonitrile; FEM-345; CCRIS 8822; Bio-0057; Femara (TN); 1-[bis(4-cyanophenyl)methyl]-1,2,4-triazole; C08163; 4,4'-(1H-1,2,4-triazol-1-ylmethylene)bis-Benzonitrile Letrozole; C17H11N5; Prestwick2_001025; HMS2089L22; CGS 20267, Femara, Piroxicam, Letrozole; HMS1571M11; 1-[Bis-(4-cyanophenyl)methyl]-1,2,4-triazole; CGS 20267; CGS-20267; TL8000371; AB00514009; BSPBio_001209; Letrozol; CHEMBL1444; UNII-7LKK855W8I; NSC719345; I06-0022; C067431; LS-38788; ZINC03778874; SMR000466343; Prestwick1_001025; MLS002584991; CID3902; BIDD:PXR0130; 4,4'-(1h-1,2,4-triazol-1-ylmethylene) bis-benzonitrile; MLS001424038; Letoval; CPD000466343; CAS-112809-51-5; CHEBI:6413; SPBio_003070; Letrozole (JAN/USP/INN); MolPort-003-848-373; Novartis Brand of Letrozole; Femera; AC1L1GYT; 4,4'-(1h-1,2,4-triazol-1-ylmethylene)bisbenzonitrile; 4,4'-(1H-1,2,4-triazol-1-yl-methylene)-bis(benzonitrile); BRD-K88789588-001-03-2; 4-[(4-cyanophenyl)-(1,2,4-triazol-1-yl)methyl]benzonitrile; 112809-51-5; BPBio1_001331; BIDD:GT0015; NCGC00016973-01; Femara; D00964; MLS000759455; 4,4'-(1h-1,2,4-triazol-1-ylmethylene)bis-benzonitrile; S1235_Selleck; HSDB 7461; HMS2051E08	112809-51-5	3902	10363	TTDS00252	Cytochrome P450 19	Aromatase;CYPXIX;Estrogen synthetase;P-450AROM	P11511	1588	ENSG00000137869	inhibitor
DAP000627	Anastrozole	SAM001246525; Arimidex (Zeneca); Astra brand of anastrozole; .alpha.,alpha.,.alpha.',.alpha.'-tetramethyl-5(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile; 1,3-benzenediacetonitrile, a, a, a', a'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl); MLS000759396; Zeneca brand of anastrozole; Arimidex (TN); C08159; Zeneca ZD 1033; Anastrozol; NSC719344; ZD1033; Anastrole; ZD-1033; 2,2'-[5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-phenylene]bis(2-methylpropanenitrile); AstraZeneca brand of anastrozole; HMS2089N10; NCGC00164619-01; D00960; C17H19N5; MolPort-005-933-078; alpha,alpha,alpha',alpha'-Tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile; 2,2'-[5-(1H-1,2,4-triazol-1-ylmethyl)benzene-1,3-diyl]bis(2-methylpropanenitrile); ICI-D 1033; C090450; Anastrozole (JAN/USAN/INN); ICI-D1033; HSDB 7462; Anastrozole [USAN:INN:BAN]; CID2187; LS-29563; UNII-2Z07MYW1AZ; SBB066057; 120511-73-1; ICI D1033; anastrazole; ZD 1033; I06-0021; Arimidex, Anastrozole; HMS2052M11; 1,3-Benzenediacetonitrile,.alpha.,alpha.,alpha.',.alpha.'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-; Arimidex; DB01217; AC-4234; MLS001424217; CPD000466301; S1188_Selleck; CHEMBL1399; SMR000466301; 2-[3-(2-cyanopropan-2-yl)-5-(1,2,4-triazol-1-ylmethyl)phenyl]-2-methylpropanenitrile; 2,2'-(5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-phenylene)bis(2-methylpropionitrile); AC1L1D49; CHEBI:2704; 1,3-Benzenediacetonitrile, alpha,alpha,alpha',alpha'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-; ZINC00000941; Asiolex; anastrozole	120511-73-1	2187	196979	TTDS00252	Cytochrome P450 19	Aromatase;CYPXIX;Estrogen synthetase;P-450AROM	P11511	1588	ENSG00000137869	inhibitor
DAP000624	Testolactone	DB00894; Testololactone, 1,2-didehydro-; .DELTA.1-Dehydrotestolactone; CHEBI:9460; 1-Dehydrotestolactone; 17alpha-Oxo-D-homo-1,4-androstadiene-3,17-dione; Testolattone; 13-Hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid delta-lactone; (4aS,4bR,10aR,10bS,12aS)-10a,12a-dimethyl-4,4a,4b,5,6,10b,11,12-octahydro-3H-naphtho[2,1-f]chromene-2,8-dione; Testolattone [DCIT]; 3-oxo-13,17-secoandrosta-1,4-dieno-17,13alpha-lactone; HSDB 3255; D-Homo-17A-oxaandrosta-1,4-diene-3,17-dione; 1,2,3,4,4a,4b,7,9,10,10a-Decahydro-2-hydroxy-2,4b-dimethyl-7-oxo-1-phenanthrenepropionic acid delta-lactone; (4aS,4bR,10aR,10bS,12aS)-10a,12a-dimethyl-3,4,4a,5,6,10a,10b,11,12,12a-decahydro-2H-naphtho[2,1-f]chromene-2,8(4bH)-dione; 1,2-didehydrotestololactone; 1-dehydrotestololactone; 13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid delta-lactone; D-homo-17a-oxaandrosta-1,4-diene-3,17-dione; Delta(1)-testololactone; Teslac; Testolactone; 13,17-Secoandrosta-1,4-dien-17-oic acid, 13-hydroxy-3-oxo-, delta-lactone (8CI); SQ-9538; D013738; LS-102968; C02197; Delta-1-testololactone; MolPort-004-286-011; 13,17-Secoandrosta-1,4-dien-17-oic acid, 13-hydroxy-3-oxo-, .delta.-lactone; Bristol-Myers Squibb Brand of Testolactone; Teslak; Testolactona [INN-Spanish]; UNII-6J9BLA949Q; Bristol Myers Squibb Brand of Testolactone; D00153; LMST02020084; Testolactone [USAN:INN]; 13-Hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid .delta.-lactone; Teolit; 13,17-Secoandrosta-1,4-dien-17-oic acid, 13.alpha.-hydroxy-3-oxo-, .delta.-lactone; Fludestrin; NCI60_001908; CID13769; delta(1)-Testololactone; Testolactone (USP/INN); 2H-Phenanthro[2,1-b]pyran-2,8(4bH)-dione, 3,4,4a,5,6,10a,10b,11,12,12a-decahydro-10a,12a-dimethyl-, lactone; 13,17-Secoandrosta-1,4-dien-17-oic acid, 13-hydroxy-3-oxo-, delta-lactone; 17a-Oxa-D-homoandrosta-1,4-diene-3,17-dione; .DELTA.1-Testololactone; Testolactonum; 13,17-Secoandrosta-1,4-dien-17-oic acid, 13-hydroxy-3-oxo-, lactone; C19H24O3; Teslac; delta(1)-Dehydrotestolactone; ZINC04081771; NSC 23759; Testolacton; Testolactona; 1 Dehydrotestolactone; 968-93-4; 1-Dehydrotestololactone; Testololactone, 1-dehydro-; delta(1)-Testolactone; testolactone; 1,2-Didehydrotestololactone; AC1L22FS; .DELTA.1-Dehydrotestololactone; Testolactonum [INN-Latin]; 1,2-Dehydrotestololactone; EINECS 213-534-6; SQ 9538; NSC-12173; TESLAC (TN); NSC23759; CHEMBL1571; (4aS,4bR,10aR,10bS,12aS)-10a,12a-dimethyl-3,4,4a,5,6,10a,10b,11,12,12a-decahydro-2H-naphtho[2,1-f]chromene-2,8(4bH)-dione	968-93-4	13769	157104	TTDS00252	Cytochrome P450 19	Aromatase;CYPXIX;Estrogen synthetase;P-450AROM	P11511	1588	ENSG00000137869	inhibitor
DAP001478	Fenfluramine	Ponderax (TN); MolPort-001-794-054; 2-Ethylamino-1-(3-trifluoromethylphenyl)propane; DEA No. 1670; Pesos; (+/-)-Fenfluramine hydrochloride; Adipomin; AC-16024; LS-103506; DB00574; Dextrofenfluramine; fenfluramine; NCGC00159473-03; Phenethylamine, N-ethyl-alpha-methyl-m-(trifluoromethyl)-, (+-)-; 3-(Trifluoromethyl)-N-ethyl-alpha-methylphenethylamine; Fenfluramine, (+-)-Isomer; Prestwick_868; Benzeneethanamine, N-ethyl-alpha-methyl-3-(trifluoromethyl)-, (+-)- (9CI); Obedrex; 1-(meta-Trifluoromethyl-phenyl)-2 ethylaminopropane; Phenethylamine, N-ethyl-.alpha.-methyl-m-(trifluoromethyl)-; LS-103505; Dexfenfluramina [Spanish]; DivK1c_000980; Adifax; S 768; (+-)-Fenfluramine; NINDS_000980; NCGC00159473-04; Dexfenfluraminum; 458-24-2; HSDB 7356; CID3337; LS-103507; EINECS 207-276-3; N-Ethyl-alpha-methyl-3-trifluoromethylphenethylamine; Dexfenfluraminum [Latin]; 404-82-0 (hydrochloride); 1-(m-trifluoromethyl-phenyl)-2-ethylaminopropane; N-Ethyl-alpha-methyl-3-(trifluoromethyl)benzeneethanamine; L000742; UNII-2DS058H2CF; d-Fenfluramine; (S)-Fenfluramine; Fenfluraminum; HSDB 3080; NCGC00159473-02; AC1Q31F0; IDI1_000980; Ponderex; Fenfluramina [DCIT]; Rotondin; N-ethyl-1-[3-(trifluoromethyl)phenyl]propan-2-amine; (+)-Fenfluramine; Phenethylamine, N-ethyl-alpha-methyl-m-(trifluoromethyl)-; Fenfluramina; Fenfluramine (INN); d-N-Ethyl-alpha-methyl-m-trifluoromethylphenethylamine; Phenethylamine, N-ethyl-alpha-methyl-m-(trifluoromethyl)-, (S)-; C12H16F3N; Benzeneethanamine, N-ethyl-alpha-methyl-3-(trifluoromethyl)-; DB01191; 5220-89-3; Isomeride; Benzeneethanamine, N-ethyl-alpha-methyl-3-(trifluoromethyl)-, (S)-; BRN 4783711; N-Ethyl-alpha-methyl-m-(trifluoromethyl)phenethylamine; D07945; AC1L1FPE; Levofenfluramine [INN]; Dexafenfluramine; Fenfluramine [INN:BAN]; Ponderax PA; Acino; Benzeneethanamine, N-ethyl-.alpha.-methyl-3-(trifluoromethyl)-; AC1Q31EZ; ()-Fenfluramine hydrochloride; Dexfenfluramina; Benzeneethanamine, N-ethyl-alpha-methyl-3-(trifluoromethyl)-, (+-)-; Benzeneethanamine, N-ethyl-alpha-methyl-3-(trifluoromethyl)- (9CI); Benzeneethanamine, N-ethyl-alpha-methyl-3-(trifluoromethyl)-, (S)- (9CI); Fenfluraminum [INN-Latin]; Dexfenfluramine [INN:BAN]; Dexfenfluramine; 3239-44-9; KBio1_000980; C06996; CHEBI:5000; CHEMBL87493	458-24-2	3337	48416003	TTDS00097	5-hydroxytryptamine receptor	5-HT receptor	N/A	N/A	N/A	antagonist
DCL000836	HMR-2934	N/A	N/A	5330286	46394060	TTDS00097	5-hydroxytryptamine receptor	5-HT receptor	N/A	N/A	N/A	antagonist
DCL000785	DU-127090	CID208951; D06566; CHEBI:467160; D06567; DU127090; Bifeprunox mesylate (USAN); DU 127090; Bifeprunox (USAN/INN); 350992-10-8; L001659; Bifeprunoxum [INN-Latin]; Bifeprunoxum; CHEMBL218166; Bifeprunox mesilate; Bifeprunox; 7-[4-[(3-phenylphenyl)methyl]piperazin-1-yl]-3H-1,3-benzoxazol-2-one; 350992-13-1; 362524-71-8; 7-(4-(Biphenyl-3-ylmethyl)piperazin-1-yl)benzoxazol-2(3H)-one; DU-127090; CID6918587; AC1OCFM9; MolPort-005-943-082; Bifeprunox [INN]; AC1L4LOA; UNII-AP69E83Z79; methanesulfonic acid; 7-[4-[(3-phenylphenyl)methyl]piperazin-1-yl]-3H-1,3-benzoxazol-2-one; Bifeprunox mesylate	362524-71-8	208951	12015562	TTDS00097	5-hydroxytryptamine receptor	5-HT receptor	N/A	N/A	N/A	agonist
DCL000182	NXN-188	N/A	64815-81-2	123853	29304035	TTDS00097	5-hydroxytryptamine receptor	5-HT receptor	N/A	N/A	N/A	antagonist
DCL000555	Lu AA21004	N/A	N/A	N/A	N/A	TTDS00097	5-hydroxytryptamine receptor	5-HT receptor	N/A	N/A	N/A	modulator
DCL000646	Sunitinib malate	SU010398; N-(2-diethylaminoethyl)-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; (2S)-2-hydroxybutanedioic acid; PNU-290940AD; SU011248; SU-010398; PHA-290940AD; AKOS005145765; FT-0083555; Sunitinib malate [USAN]; Sutent, SU-11248; D06402; SU-011248 L-malate salt; Sunitinib malate; N-(2-(Diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (2S)-hydroxybutanedioate; ST51053712; Sutent (TN); AC1O5CMQ; CHEMBL1567; 341031-54-7; LS-186078; 1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-,     (2S)-hydroxybutanedioate (1:1); CHEBI:550864; MolPort-003-986-763; 1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1); SU011248 L-malate salt; TL8002546; Sunitinib malate (JAN/USAN); UNII-LVX8N1UT73; CID6456015; Butanedioic acid, hydroxy-, (2S)-, compd. with N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (1:1); SU-11248 L-malate salt; SU 011248; S1042_Selleck	557795-19-4	5329102	14830382	TTDS00090	FL cytokine receptor	CD135 antigen;FLT3 tyrosine kinase ;Receptor tyrosine kinase FLT3;Stem cell tyrosine kinase 1;STK-1;Tyrosine-protein kinase receptor FLT3	P36888	2322	ENSG00000122025	inhibitor
DCL000165	Midostaurin	PKC412; 120685-11-2; C411007; Midostaurin; CHEMBL608533; Midostaurin (USAN/INN); CHEMBL338448; CID9829523; NSC656576; N-Benzoylstaurosporine; CPG 41251; D05029; Benzamide, N-[(9S,10R,11R,13R)-2,3,10,11,12,13- hexahydro-10-methoxy-9-methyl-1-oxo-9,13-epoxy-1H,9H- diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazonin-11-yl]-N-methyl-; PKC-412; HMS3229K17	120685-11-2	9829523	48426267	TTDS00090	FL cytokine receptor	CD135 antigen;FLT3 tyrosine kinase ;Receptor tyrosine kinase FLT3;Stem cell tyrosine kinase 1;STK-1;Tyrosine-protein kinase receptor FLT3	P36888	2322	ENSG00000122025	inhibitor
DCL000367	Tandutinib	MLN-0518; CT53518; CT-53518; NSC726292; CT 53518; Tandutinib; 387867-13-2; (4-(6-Methoxy-7-(3-piperidylpropoxy)quinazolin-4-yl)piperazinyl)-N-(4-(methylethoxy)phenyl)carboxamide; MLN-518; 4-[6-methoxy-7-(3-piperidin-1-ylpropoxy)quinazolin-4-yl]-N-(4-propan-2-yloxyphenyl)piperazine-1-carboxamide; D06005; 4-(6-Methoxy-7-(3-piperidin-1-ylpropoxy)quinazolin-4-yl)piperazine-1-carboxylic acid (4-isopropoxyphenyl)amide; MLN518, CT53518; Kinome_3320; I14-1975; EC-000.2262; MLN 518; S1043_Selleck; UNII-E1IO3ICJ9A; CID3038522; CHEMBL124660; AC1MI50F; 1-Piperazinecarboxamide, 4-(6-methoxy-7-(3-(1-piperidinyl)propoxy)-4-quinazolinyl)-N-(4-(1-methylethoxy)phenyl)-; AC-1659; Tandutinib (USAN/INN)	387867-13-2	9933475	47207663	TTDS00090	FL cytokine receptor	CD135 antigen;FLT3 tyrosine kinase ;Receptor tyrosine kinase FLT3;Stem cell tyrosine kinase 1;STK-1;Tyrosine-protein kinase receptor FLT3	P36888	2322	ENSG00000122025	inhibitor
DCL001128	4SC-203	N/A	N/A	N/A	N/A	TTDS00090	FL cytokine receptor	CD135 antigen;FLT3 tyrosine kinase ;Receptor tyrosine kinase FLT3;Stem cell tyrosine kinase 1;STK-1;Tyrosine-protein kinase receptor FLT3	P36888	2322	ENSG00000122025	inhibitor
DCL000292	SU5614	MolPort-006-389-303; su5614; SU-5614; CID6536806; (3Z)-5-chloro-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-1H-indol-2-one; C416849; 5-Chloro-3-[(3,5-dimethylpyrrol-2-yl)methylene]-2-indolinone; SU 5614; AC1O6W2Q	186611-56-3	6536806	26759569	TTDS00090	FL cytokine receptor	CD135 antigen;FLT3 tyrosine kinase ;Receptor tyrosine kinase FLT3;Stem cell tyrosine kinase 1;STK-1;Tyrosine-protein kinase receptor FLT3	P36888	2322	ENSG00000122025	inhibitor
DAP000005	Sunitinib	PDGF TK antagonist; 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-; AC1NS62J; SU 11248; 5-(5-FLUORO-2-OXO-1,2-DIHYDRO-INDOL-3-YLIDENEMETHYL)-2,4-DIMETHYL-1H-PYRROLE-3-CARBOXYLIC ACID (2-DIETHYLAMINO-ETHYL)-AMIDE; NSC736511; SU-11248J; 326914-13-0; NSC750690; K00588a; Su-011248; Sunitinib; SU-12662; KS-5022; CHEMBL535; UNII-V99T50803M; Sunitanib; 557795-19-4; N-(2-diethylaminoethyl)-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; NCGC00164631-01; SU11248; 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)- (5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-; LS-187023; DB01268; I01-1229; CID5329102; SU-11248; CHEBI:38940; sunitinibum; DB07417; LS-187648; N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; FT-0083556; Sutent; D08552; Sunitinib (free base); Sunitinib (INN); EN002687; 1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-	557795-19-4	5329102	14830382	TTDS00090	FL cytokine receptor	CD135 antigen;FLT3 tyrosine kinase ;Receptor tyrosine kinase FLT3;Stem cell tyrosine kinase 1;STK-1;Tyrosine-protein kinase receptor FLT3	P36888	2322	ENSG00000122025	inhibitor
DAP001422	Retigabine	Ethyl 2-amino-4-((p-fluorobenzyl)amino)carbanilate; Potiga; 150812-12-7; I06-0810; AC-6908; ethyl N-(2-amino-4-(4-fluorobenzylamino)phenyl)carbamate hydrochloride; CID121892; C16H18FN3O2; [2-Amino-4-[[(4-fluorophenyl)methyl]amino]phenyl]-carbamate; AC1L3TLD; D 20443; LS-48932; D 23129; ethyl N-[2-amino-4-[(4-fluorophenyl)methylamino]phenyl]carbamate; UNII-12G01I6BBU; Retigabine; ZINC00016154; TL80090034; CHEBI:161945; Trobalt; CHEMBL41355; Ezogabine; Carbamic acid, (2-amino-4-(((4-fluorophenyl)methyl)amino)phenyl)-, ethyl ester; ADD-230001; N-(2-Amino-4-(4-fluorobenzylamino)-phenyl) carbamic acid ethyl ester; nchembio874-comp3; C13826; N-(2-Amino-4-(4-fluorobenzylamino)phenyl)carbamic acid ethyl ester; C101866; FT-0080801; D-23129; Ethyl (2-amino-4-(((4-fluorophenyl)methyl)amino)phenyl)carbamate; D-20443; MolPort-003-850-148; KE-0201; Retigabine [USAN]; GKE-841	150812-12-7	121892	698390	TTDS00149	Potassium voltage-gated channel subfamily KQT member 4	KQT-like 4;Potassium channel alpha subunit KvLQT4;Voltage-gated potassium channel subunit Kv7.4	P56696	9132	ENSG00000117013	activator
DAP001126	Methylscopolamine	N-Methylscopolamine; UNII-VDR09VTQ8U; AC1LCVBJ; CID656633; 6106-46-3 (Nitrate); Metylskopolamin; Methylscopolamine; 18905-44-7; 3-Oxa-9-azoniatricyclo(3.3.1.0(2,4))nonane, 7-(3-hydroxy-1-oxo-2-phenylpropoxy)-9,9-dimethyl-, (7(S)-(1alpha,2beta,4beta,5alpha,7beta))-; methscopolamine; 13265-10-6; 18067-13-5 (Methylsulfate); 52211-64-0; 155-41-9 (Bromide); 53832-46-5	155-41-9	4120	5557592	TTDS00003	Muscarinic acetylcholine receptor M2	M2 receptor	P08172	1129	ENSG00000181072	antagonist
DAP000343	Scopolamine	SDCCGMLS-0066589.P001; BPBio1_001049; Hyoscine bromide; Scopolaminhydrobromid; CAS-55-16-3; Atroscine Hydrobromide; IDI1_000291; AC1MIXH6; CHEBI:16794; Tropane alkaloid; CID2723877; NCI60_005415; Hyosol; Scop; Scopolammonium bromide; Spectrum4_000992; UNII-DL48G20X8X; 81D34684-E0B2-4B3A-A36C-FB916BBC90F7; HMS2090N13; BRD-A14566392-004-03-5; NCGC00024357-02; Scopine (-)-tropate; Atroquin; SCOPOLAMINE BROMIDE; NCI61806; LS-194418; MolPort-002-506-902; AKOS001581155; 6-beta,7-beta-Epoxy-3-alpha-tropanyl S-(-)-tropate; KBio1_000291; CID3000322; Scopine tropate; NCGC00024357-04; Prestwick0_000877; Spectrum_000950; CID10267087; Scopolamine Hyoscine; KBio2_003998; NSC-61806; CID5702114; 6,7-Epoxytropine tropate; CHEBI:111434; CID3081743; KBioGR_001423; SEE; SPBio_001405; MLS000758270; 58670-87-4; LS-144659; Hyocine F hydrobromide; CID6325382; (+)-Scopolamine; Isopto Hyoscine; NCGC00096833-01; nchembio.78-comp19; Scopolamine (INN); AC1L9QO2; CID10267079; KBioGR_001853; Tropic acid, 9-methyl-3-oxa-9-azatricyclo(3.3.1.0(sup 2,4))non-7-yl ester; Transderm scop (TN); CID153311; D00138; NCGC00016245-01; Skopolamin; Prestwick2_000877; Spectrum5_001142; Atrochin; 6beta,7beta-Epoxy-1alpha,5alpha-tropan-3alpha-ol; Hyosceine; CID673473; CID11968014; CHEMBL253569; EINECS 200-090-3; Hydroscine hydrobromide; Tocris-1414; CID5184; KBio2_001430; CID452977; Transderm-V; Hysco; 28901-63-5; Isoscopil; CID6432494; 14797-94-5; Tranaxine; HSDB 4074; (+)-Hyoscine; Prestwick3_000877; AC-968; 138-12-5; BSPBio_000953; Tropic acid, ester with scopine; AC1L1L6Q; MolPort-005-938-576; CID638340; CHEMBL1201069; Prestwick1_000877; Scopamin; 3-Oxa-9-azatricyclo(3.3.1.0(sup 2,4))nonan-7-ol, 9-methyl-, tropate (ester); 226562-00-1; CID450840; 9-methyl-3-oxa-9-azatricyclo[3.3.1.0~2,4~]non-7-yl tropate; NCGC00162334-01; CID6451257; NCGC00015932-02; KBio2_006566; Scopolaminium bromide; 51-34-3; Transcop; CID3246242; Oscine; 3-Oxa-9-azatricyclo(3.3.1.O(sup 2,4))nonan-7-ol, 9-methyl-, tropate (ester); CID5809; Beldavrin; C01851; NINDS_000291; Epoxytropine tropate; NCGC00015932-01; (-)-Scopolamine; AR-1J2195; L001096; Spectrum4_001187; DivK1c_000291; Atroscine; SMR000449327; AC1L1JSC; CID6713754; BRD-K89923877-003-02-4; Scopos; 6beta,7beta-Epoxy-3alpha-tropanyl S-(-)-tropate; AC1MC3SI; DB00747; Lopac-S-1875; (-)-Hyoscine; AC1LDRGW; Hyoscine; NCGC00024357-05; AC1L4A4J; Euscopol; ZINC19796020; MOLI001381; 114-49-8; (1S,3S,5R,6R,7S)-6,7-epoxytropan-3-yl (2S)-3-hydroxy-2-phenylpropanoate; KBioSS_001430; scopolamine; l-Scopolamine; CHEMBL608810; AC1Q60XM; NCGC00162334-02; NCGC00013722; Sereen; SMP1_000270; CID9916237; Triptone; Scopoderm-TTS; 97991-84-9; AC1LCW6T; Transderm scop; KBio3_001814; (-)-Scopolamine hydrobromide trihydrate; AC1MMY38; 1alphaH,5alphaH-Tropan-3alpha-ol, 6beta,7beta-epo; AC1L9P7Q; Spectrum2_001313; CID9808333; SPBio_002874; CID6604698; Transderm-Scop; AB00429689; CID10017965; Spectrum3_000897; xy-, (-)-tropate (ester); AC1MHD40; Kwells; Hyoscyine hydrobromide; LS-144660; MolPort-002-052-054; Lopac0_001076; l-Hyoscine hydrobromide; 1alphaH,5alphaH-Tropan-3alpha-ol, 6beta,7beta-epoxy-, (-)-tropate (ester); 65319-33-7	6533-68-2	5184	548858	TTDS00003	Muscarinic acetylcholine receptor M2	M2 receptor	P08172	1129	ENSG00000181072	antagonist
DAP001127	Gallamine Triethiodide	Triethiodure de gallamine; 2,2',2''-[benzene-1,2,3-triyltris(oxy)]tris(N,N,N-triethylethanaminium) triiodide; Pyrogallol 1,2,3-(diethylaminoethyl ether) tris(ethyliodide); 1,2,3-Tris(2-diethylaminoethoxy)benzene tris(ethyliodide); CID6172; Gallamina triodoetilato [DCIT]; Triiodoethylate de gallamine; Triiodoethylate de gallamine [French]; F 2559; UNII-Q3254X40X2; Gallaminum triaethoiodatum; 2,2',2''-(1,2,3-Benzenetriyltris(oxy))tris(N,N,N-triethylethanaminium) triiodide; (v-Phenenyltris(oxyethylene))tris(triethylammonium iodide); Gallamine triethiodide [INN]; Tri(beta-diethylaminoethoxy)-1,2,3-benzene tri-iodoethylate; 1,2,3-Tris(2-triethylammonium ethoxy)benzene triiodide; Remyolan; Triiodure de tri(beta-triethylammoniumethoxy)-1,2,3 benzene; CHEMBL1200993; 3697 R.P; Sincurarine; Relaxan; 1,2,3-Tri(beta-diethylaminoethoxy)benzene triethiodide; 153-76-4 (parent); 1,2,3-Tris(diethylaminoethoxy)benzene triethiodide; G8134_SIGMA; Gallaflex; 3.697 R.P; 3.697 R.P.; HL 8583; (v-Phenenyltris(oxyethylene))tris(triethylammoniumiodide); Gallamone triethiodide; Pyrogallol 1,2,3-(diethylaminoethyl ether) trisethyl iodide; Gallamina triodoetilato; Miowas G; D02292; AC1L1LY0; Flaxedil; Tri(iodoethylate) de tri (beta diethylaminoethoxy)-1,2,3 benzene [French]; Ethanaminium, 2,2',2'-(1,2,3-benzenetriyltris(oxy))tris(N,N,N-triethyl)-, triiodide; G 8134; NCGC00093937-01; Gallamini triethiodidum; Gallamine triethiodide (USP); Parexyl; RP 3697; 1,2,3-Tris(2-diethylaminoethoxy)benzene triethiodide; EU-0100550; EINECS 200-605-1; Ammonium, (v-phenenyltris(oxyethylene)tris(triethyl-, triiodide; Triethioduro de galamina; 3697 R.P.; NSC 102690; HMS502A12; Pirolakson; Gallaminum triaethjodidum; Benzkurin; Benzcurine iodide; Tri(iodoethylate) de tri (beta diethylaminoethoxy)-1,2,3 benzene; HSDB 3229; Gallamine triiodoethylate; LS-18834; (v-Phenenyltris(oxyethylene))tris(triethylammonium) triiodide; HMS1568O16; Gallamini triethiodidum [INN-Latin]; Prestwick_237; Retensin; GALLAMINE TRIETHIODIDE; MolPort-003-666-195; Tricuran; Gallamin triethiodide; 2-[2,3-bis[2-(triethylazaniumyl)ethoxy]phenoxy]ethyl-triethylazanium triiodide; Flaxedil (TN); Gallaminii iodidum; Triethioduro de galamina [INN-Spanish]; 65-29-2; Gallamine iodide; Triethiodure de gallamine [INN-French]; Fourneau 2559; Ethanaminium, 2,2',2''-(1,2,3-benzenetriyltris(oxy))tris(N,N,N-triethyl-, triiodide; Syncurarine; Pyrolaxon; Triiodure de tri(beta-triethylammoniumethoxy)-1,2,3 benzene [French]; Ammonium, (v-phenenyltris(oxyethylene))tris(triethyl-, triiodide; Gallamoni jodidum; Triiodoethylate of tri(diethylaminoethyloxy)-1,2,3-benzene; HMS2091H09; Gallamine-3ETI; Ethanaminium, 2,2',2''-(1,2,3-benzenetriyltris(oxy))tris(N,N,N-triethyl)-, triiodide	65-29-2	67425	209540	TTDS00003	Muscarinic acetylcholine receptor M2	M2 receptor	P08172	1129	ENSG00000181072	antagonist
DAP000148	Trilostane	Win-24540; D01180; Modrenal (TN); CHEMBL1200907; Desopan; 13647-35-3; Vetoryl, Trilostane; (4alpha,5alpha,17beta)-3,17-dihydroxy-4,5-epoxyandrost-2-ene-2-carbonitrile; MolPort-003-850-727; DB01108; CHEBI:32260; Trilostane (JAN/USAN); S1404_Selleck; 3,17beta-dihydroxy-4alpha,5-epoxy-5alpha-androst-2-ene-2-carbonitrile; Desopan (TN); AC1LCV8M; AC-927; CID656583	13647-35-3	656583	7848243	TTDS00055	3-beta-hydroxysteroid dehydrogenase	N/A	P19871	N/A	N/A	inhibitor
DAP100399	Doxycycline	Vibramycin Novum; Spectrum2_000143; DivK1c_000345; CHEBI:50845; NSC633557; Doxycycline (INN); 6-Deoxyoxytetracycline; Doxycyclin; AC1O8PYM; alpha-Doxycycline; 94088-85-4 (calcium salt (1:2)); 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S,4aR,5S,5aR,6R,12aS)-; 7264-10-0; DOXYCYCLINE MONOHYDRATE; Hydramycin; Doxitard; Doxycyclinum; KBioGR_001133; SMP1_000107; Lopac0_000405; doxycycline; LS-187766; Supracyclin; BCBcMAP01_000024; AC1NQXW7; CID5463943; Doxivetin; Doxycycline (200mg/day) or Placebo; SPBio_002784; Doxycycline hyclate; Monodox; Spectrum5_000947; Doxiciclina; KBio2_003855; Apo-Doxy; 24390-14-5; HMS2090E06; BSPBio_001936; Vibramycin; Doxy-Puren; Doxytec; DB00254; Prestwick3_000852; Liviatin; Prestwick2_000852; NCGC00179395-01; CID5281011; DOXCYCLINE ANHYDROUS; Doxytetracycline; (2Z,4S,4aR,5S,5aR,6R,12aS)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; Doxycycline (anhydrous); 6-Deoxytetracycline; 6alpha-Deoxy-5-oxytetracycline; Azudoxat; Vibravenos; DOXYCYCLINE CALCIUM; BMY-28689; NINDS_000345; Prestwick0_000852; Doxychel (TN); 69935-17-7 (mono-hydrochloride, di-hydrate); NCGC00161602-01; Doxiciclina [INN-Spanish]; (2Z,4S,4aR,5S,5aR,6R)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; Vivox (*Hyclate); EINECS 209-271-1; KBio1_000345; LS-93868; 564-25-0; 7164-70-7; DMSC (*Fosfatex); Spectrum_000807; KBio2_001287; HSDB 3071; Oracea; Doxychel; 6-alpha-Deoxy-5-oxytetracycline; Doxycycline anhydrous; (2E,4S,4aR,5S,5aR,6R,12aS)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; Doxysol; CID6713981; Jenacyclin; UPCMLD-DP021:001; BIDD:GT0146; Novo-Doxylin; C06973; Doxy-Caps; Deoxymykoin; 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S,4aR,5S,5aR,6R,12aS); Doxycen; Ronaxan; STOCK1N-34341; alpha-6-Deoxyoxytetracycline; BU-3839T; 5-Hydroxy-alpha-6-deoxytetracycline; Alti-Doxycycline; Doxycycline (internal use); Vibra-tabs; NCGC00167961-01; 10597-92-9; NCGC00161602-03; CID5353597; IDI1_000345; GS-3065 (*monohydrate); KBio2_006423; BSPBio_000863; alpha-6-Deoxy-5-hydroxytetracycline; Doxycyclinum [INN-Latin]; Spectrum3_000408; Dossiciclina [DCIT]; BPBio1_000951; Doxycin; Doxiciclina [Italian]; Vibramycine; KBioSS_001287; Doxycycline-Chinoin; 2-Naphthacenecarboxamide, 4-alpha-S-(dimethylamino)-1,4,4a-alpha-5,5a-alpha,6,11,12a-octahydro-3,5-alpha,10,12,12a-alpha-pentahydroxy-6-alpha-methyl-1,11-dioxo-; SPBio_000246; Vibramycin (*monohydrate); AB08 (*Fosfatex); Dossiciclina; KBio3_001156; CHEMBL1433; Investin; Oxytetracycline, 6-deoxy-; UPCMLD-DP021; MolPort-002-507-423; D07876; Doxycycline (TN); Prestwick1_000852; 41411-66-9 (6-epimer, mono-hydrochloride); Atridox; AC1NS4CW; Doxy-Tabs; AC1NUYS8; CPD001550033; DOXY; UNII-334895S862; NCGC00161602-04; 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S-(4alpha,4aalpha,5alpha,5aalpha,6alpha,12aalpha))-; (2Z)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; Monodox (*monohydrate); (4S,4aR,5S,5aR,6R,12aS)-4-(dimethylamino)-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide; 17086-28-1 (mono-hydrate); Spectrum4_000527; Spanor; SAM002589932; Nu-Doxycycline	N/A	N/A	N/A	TTDR01266	Neutrophil collagenase	Matrix metalloproteinase-8;MMP-8;PMNL collagenase;PMNL-CL	P22894	4317	ENSG00000118113	inhibitor
DAP001276	Sodium Tetradecyl Sulfate	EINECS 214-737-2; CID14492; Tesapon K 14; Tetradecyl sulfate, sodium salt; Tetradecilsulfato sodico [INN-Spanish]; Sulfuric acid, monotetradecyl ester, sodium salt; STDS; Sulfuric acid, myristyl ester, sodium salt; Tetradecyl sulfate de sodium [INN-French]; Texapon K 14; Natrii tetradecyclis sulfas [INN-Latin]; NSC 139032; Myristyl sulfate, sodium salt; 1-Tetradecanol, 1-(hydrogen sulfate), sodium salt (1:1); Sodium tetradecyl sulphate; Sotradecol Sodium; S.T.D.; Niaproof 4; C14H28O5S; Trombavar; 1191-50-0; Natri tetradecylsulfas; CHEMBL541505; 22088-37-5; 1-Tetradecanol, hydrogen sulfate, sodium salt; S.T.D; Sodium tetradecylsulfate; Natrii tetradecyclis sulfas; Sodium myristyl sulfate; LS-148911; Monotetradecylsulfate sodium salt; Tetradecyl sodium sulfate	1191-50-0	14492	14874529	TTDS00470	Vitamin K-dependent protein C	Activation peptide;Anticoagulant protein C;Autoprothrombin IIA;Blood coagulation factor XIV;PROC;Vitamin K-dependent protein C heavy chain;Vitamin K-dependent protein C light chain	P04070	5624	ENSG00000115718	inhibitor
DPR000140	HC-Toxin	C15676; Cyclo(L-alanyl-D-alanyl-(alphaS,2S)-alpha-amino-eta-oxooxiraneoctanoyl-D-prolyl); 83209-65-8; (3S,6R,9S,12R)-6,9-dimethyl-3-[6-(oxiran-2-yl)-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone; AC1L32W5; Cyclo(aoe-pro-ala-ala); CID107864; HC Toxin; Cyclic(L-alanyl-D-alanyl-eta-oxo-L-alpha-aminooxiraneoctanoyl-D-prolyl); Cyclo(2-amino-8-oxo-9,10-epoxydecanoic acid-prolyl-alanyl-alanine); HC-Toxin	N/A	N/A	N/A	TTDS00095	Histone deacetylase 1	HDAC1	Q13547	3065	ENSG00000116478	inhibitor
DCL000172	MS-275	NCI60_038022; Entinostat, SNDX-275, MS-27-275, MS-275; CID4261; N-(2-aminophenyl)-4-(N-(pyridin-3-ylmethoxycarbonyl)aminomethyl)benzamide; 3-Pyridinylmethyl ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)carbamate; Entinostat; Entinostat (USAN/INN); MolPort-005-942-713; AC1L1HRM; CHEMBL27759; EC-000.2117; pyridin-3-ylmethyl{4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; NCGC00165833-01; NSC-706995; nchembio.275-comp4; ZINC01488870; S1053_Selleck; AC1Q5NOI; SNDX 275; IN1470; NSC706995; LS-185285; MS-27-275; pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate; 209783-80-2; Histone Deacetylase Inhibitor I; NCGC00165833-02; MS 275; N-(2-Aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)aminomethyl]benzamide; Carbamic acid, ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)-, 3-pyridinylmethyl ester; SNDX-275; pyridin-3-ylmethyl 4-(2-aminophenylcarbamoyl)benzylcarbamate; MS 27-275; Carbamic acid, [[4-[[(2-aminophenyl)carbaonyl]phenyl]methyl]-, 3-pyridinylmethyl ester; ms-275; AR-1L2666; nchembio.313-comp19; pyridin-3-ylmethyl {4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; C118739; D09338; Carbamic acid, [[4-[[(2-aminophenyl)amino]carbonyl]phenyl] methyl]-, 3-pyridinylmethyl ester	209783-80-2	4261	46519433	TTDS00095	Histone deacetylase 1	HDAC1	Q13547	3065	ENSG00000116478	inhibitor
DPR000137	FFF2	N/A	N/A	N/A	N/A	TTDS00095	Histone deacetylase 1	HDAC1	Q13547	3065	ENSG00000116478	inhibitor
DCL001122	Tacedinaline	Tacedinalina [INN-Spanish]; C15H15N3O2; PD-123654; CHEMBL235191; Tacedinalina; AR-1G0333; UNII-UMF554N5FG; AC1L1EDE; 4-(Acetylamino)-N-(2-aminophenyl)benzamide; 4-acetamido-n-(2-aminophenyl)benzamid; ST51052145; AC1Q5NOJ; 4-acetylamino-N-(2'-aminophenyl)benzamide; EC-000.2116; CID2746; Benzamide, 4-(acetylamino)-N-(2-aminophenyl)-; CI 994; Acetyldinaline; 4-acetamido-N-(2-aminophenyl)benzamide; D05988; LS-25188; Tacedinaline; C.I. 994; Goe-5549; nchembio.313-comp20; Tacedinaline (USAN/INN); ci-994; Tacedinaline [USAN:INN]; I01-6962; Goe 5549; PD 123654	N/A	N/A	N/A	TTDS00095	Histone deacetylase 1	HDAC1	Q13547	3065	ENSG00000116478	inhibitor
DCL000852	ITF2357	Carbamic acid, N-(4-((hydroxyamino)carbonyl)phenyl)-, (6-((diethylamino)methyl)-2-naphthalenyl)methyl ester, hydrochloride (1:1); ITF2357; EC-000.2471; 383198-22-9; 199657-29-9; Givinostat	N/A	N/A	N/A	TTDS00095	Histone deacetylase 1	HDAC1	Q13547	3065	ENSG00000116478	inhibitor
DCL001117	PDX-101	N/A	N/A	N/A	N/A	TTDS00095	Histone deacetylase 1	HDAC1	Q13547	3065	ENSG00000116478	inhibitor
DCL001114	MGCD-0103	N-(2-Aminophenyl)-4-((4-pyridin-3-ylpyrimidin-2-ylamino)methyl)benzamide; 726169-73-9; MG0103; N-(2-aminophenyl)-4-[[(4-pyridin-3-ylpyrimidin-2-yl)amino]methyl]benzamide; Mocetinostat, MGCD0103; MG 4915; C523184; MGCD-0103; MG5206; MG-4230; MGCD 0103; MG-5026; MGCD0103; MG 0103; MG 4230; UNII-A6GWB8T96J; CHEMBL272980; MG-0103; CID9865515; EC-000.2284; MG-4915; MG4915; nchembio.313-comp18; S1122_Selleck; MG 5026; Mocetinostat; MG4230; Benzamide, N-(2-aminophenyl)-4-(((4-(3-pyridinyl)-2-pyrimidinyl)amino)methyl)-	N/A	N/A	N/A	TTDS00095	Histone deacetylase 1	HDAC1	Q13547	3065	ENSG00000116478	inhibitor
DPR000154	SB-639	(E)-N-hydroxy-3-[2-phenethyl-1-(2-pyrrolidin-1-ylethyl)benzimidazol-5-yl]prop-2-enamide; CHEBI:557921; AC1OCG09; CID6918877; SB-639; CHEMBL491316	N/A	N/A	N/A	TTDS00095	Histone deacetylase 1	HDAC1	Q13547	3065	ENSG00000116478	inhibitor
DPR000153	SB-6241	N/A	N/A	N/A	N/A	TTDS00095	Histone deacetylase 1	HDAC1	Q13547	3065	ENSG00000116478	inhibitor
DPR000139	FFF4	N/A	N/A	N/A	N/A	TTDS00095	Histone deacetylase 1	HDAC1	Q13547	3065	ENSG00000116478	inhibitor
DPR000150	Oxamflatin	151720-43-3; NSC729360; oxamflatin; C100692; CID5353852; (2E)-5-[3-(Phenylsulfonylamino)phenyl]pent-2-en-4-ynohydroxamic Acid; CHEBI:258842; AC1NS4N2; 2-Penten-4-ynamide, N-hydroxy-5-[3-[(phenylsulfonyl)amino] phenyl]-, (2E)-; (2E)-5-(3-(phenylsulfonylamino)phenyl)pent-2-ene-4-ynohydroxamic acid; NCGC00165855-01; (E)-5-[3-(benzenesulfonamido)phenyl]-N-hydroxypent-2-en-4-ynamide; I14-11718	N/A	N/A	N/A	TTDS00095	Histone deacetylase 1	HDAC1	Q13547	3065	ENSG00000116478	inhibitor
DAP001082	Vorinostat	ZINC01543873; NSC701852; UNII-58IFB293JI; N-Hyrdroxy-N'-phenyloctanediamide; Vorinostat; N-hydroxy-N'-phenyloctanediamide; Merck brand of Vorinostat; WIN64652; Vorinostat [USAN]; N-hydroxy-N'-phenyl-octane-1,8-diotic acid diamide; NSC-701852; NHNPODA; Zolinza; m344; SAHA, Suberoylanilide hydroxamic acid; N-Hydroxy-N'-phenyl octanediamide; SMR000486344; Zolinza (TN); CID5311; CHEMBL98; Zolinza, MK-0683, SAHA; S1047_Selleck; suberoylanilide hydroxamic acid; nchembio815-comp18; OCTANEDIOIC ACID HYDROXYAMIDE PHENYLAMIDE; D06320; SKI390; LS-187780; AC-1923; N'-hydroxy-N-phenyloctanediamide; EC-000.2057; CCRIS 8456; nchembio.275-comp2; 1zz1; MLS001065855; MK0683; SHH; N1-hydroxy-N8-phenyloctanediamide; SAHA; LS-186997; NCGC00168085-02; MK-0683; SAHA cpd; AC1L1K2K; Vorinostat MSD; C111237; LS-186548; Suberanilohydroxamic acid; Octanediamide, N-hydroxy-N'-phenyl-; Vorinostat (JAN/USAN); FT-0082592; CHEBI:45716; SW-064652; DB02546; nchembio.313-comp1; MolPort-003-850-293; BRD-K81418486-001-10-3; 149647-78-9	149647-78-9	5311	12015019	TTDS00095	Histone deacetylase 1	HDAC1	Q13547	3065	ENSG00000116478	inhibitor
DCL001111	LAQ824	(E)-N-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide; NVP-LAQ824, Dacinostat, LAQ824; CHEMBL356066; AC1O62SB; NVP-LAQ 824; NVP-LAQ824; I14-11726; Dacinostat; UNII-V10P524501; EC-000.2469; 404951-53-7; LAQ-824; LS-192513; S1095_Selleck; CID6445533; 2-Propenamide, N-hydroxy-3-(4-(((2-hydroxyethyl)(2-(1H-indol-3-yl)ethyl)amino)methyl)phenyl)-, (2E)-; (2E)-N-hydroxy-3-[4-({(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enamide; nchembio.313-comp12	N/A	N/A	N/A	TTDS00095	Histone deacetylase 1	HDAC1	Q13547	3065	ENSG00000116478	inhibitor
DCL001119	Pyroxamide	CHEMBL353581; AR-1K7219; NSC-696085; pyroxamide; I14-11725; AC1L1JDR; S2190_Selleck; n-hydroxy-n'-(pyridin-3-yl)octanediamide; nchembio.313-comp13; POLAR HYBRID COMPOUND; CHEBI:373911; AC1Q5NR5; Octanediamide, N-hydroxy-N'-3-pyridinyl-; NCI60_034337; N-Hydroxy-N'-(3-pyridyl)-1,8-octanediamide; N-Hydroxy-N'-3-pyridinyloctanediamide; CID4996; N'-hydroxy-N-pyridin-3-yloctanediamide; NSC696085; suberoyl-3-aminopyridineamide hydroxamic acid	N/A	N/A	N/A	TTDS00095	Histone deacetylase 1	HDAC1	Q13547	3065	ENSG00000116478	inhibitor
DPR000136	FFF1	N/A	N/A	N/A	N/A	TTDS00095	Histone deacetylase 1	HDAC1	Q13547	3065	ENSG00000116478	inhibitor
DCL000914	Panobinostat	2-Propenamide, N-hydroxy-3-(4-(((2-(2-methyl-1H-indol-3-yl)ethyl)amino)methyl)phenyl)-, (2E)-; (E)-N-HYDROXY-3-(4-{[2-(2-METHYL-1H-INDOL-3-YL)-ETHYLAMINO]-METHYL}-PHENYL)-ACRYLAMIDE; FT-0083488; LBH 589; AC1OCFY8; Panobinostat, NVP-LBH589, LBH589; NVP-LBH589; ZINC22010649; LBH589; AKOS005146046; Faridak; NVP-LBH-589; 404950-80-7; LBH-589B; nchembio.313-comp11; C496932; MolPort-005-933-338; EC-000.2287; CID6918837; LBH-589; Panobinostat; CHEMBL483254; S1030_Selleck; (E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide	404950-80-7	6918837	12015928	TTDS00095	Histone deacetylase 1	HDAC1	Q13547	3065	ENSG00000116478	inhibitor
DPR000143	JNS-16241199	N/A	N/A	N/A	N/A	TTDS00095	Histone deacetylase 1	HDAC1	Q13547	3065	ENSG00000116478	inhibitor
DPR000104	Scriptaid	AC1Q6JL7; CBDivE_004422; 6-(1,3-dioxobenzo[de]isoquinolin-2-yl)-N-hydroxyhexanamide; GNF-PF-2024; EC-000.2460; SBB039068; AC1L1JSF; CGK1026; BRD-K22503835-001-05-2; nchembio.275-comp3; CID5186; N-Hydroxy-1,3-dioxo-1H-benz(de)isoquinoline-2(3H)-hexan amide; C410733; BAS 00383114; NCGC00159564-01; SB-556629; I14-11722; CHEMBL96051; ZINC03873638; AKOS000267387; nchembio.313-comp14; BRD-K22503835-001-03-7; 1h-benz[de]isoquinoline-2(3h)-hexanamide, n-hydroxy-1,3-dioxo-; IN1099; 6-(1,3-Dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)-N-hydroxyhexanamide; scriptaid; 6-(1,3-Dioxo-1H,3H-benzo[de]isoquinolin-2-yl)-hexanoic acid hydroxyamide; AR-1C3260; MolPort-000-434-144	287383-59-9	609483	26759501	TTDS00095	Histone deacetylase 1	HDAC1	Q13547	3065	ENSG00000116478	inhibitor
DPR000132	Chlamydocin	AmbotzLS-1109; 53342-16-8; AC1Q5H7X; AC1L3XWY; (3s,9s,14ar)-9-benzyl-6,6-dimethyl-3-{6-[(2s)-oxiran-2-yl]-6-oxohexyl}decahydropyrrolo[1,2-a][1,4,7,10]tetraazacyclododecine-1,4,7,10-tetrone; Cyclic(2-methylalanyl-L-phenylalanyl-D-propyl-L-alpha-amino-eta-oxooxiraneoctanoyl); AR-1A4679; (3S,9S,12R)-3-benzyl-6,6-dimethyl-9-[6-[(2S)-oxiran-2-yl]-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone; KST-1A5678; CID124134; C006963; HDInhib_000038; 5424-27-1; chlamydocin	N/A	N/A	N/A	TTDS00095	Histone deacetylase 1	HDAC1	Q13547	3065	ENSG00000116478	inhibitor
DPR000141	HDAC-42	NSC-D-731438; N-hydroxy-4-[(3-methyl-2-phenylbutanoyl)amino]benzamide; CHEBI:417828; HDAC-42; NSC-731438; CHEMBL191091; CID6918801; AC1OCFWJ	N/A	N/A	N/A	TTDS00095	Histone deacetylase 1	HDAC1	Q13547	3065	ENSG00000116478	inhibitor
DCL001227	Resminostat	N/A	N/A	N/A	N/A	TTDS00095	Histone deacetylase 1	HDAC1	Q13547	3065	ENSG00000116478	inhibitor
DPR000134	Depudecin 	CID6438725; 139508-73-9; (1R)-1-[(2S,3S)-3-[(E)-2-[(3S)-3-[(1R)-1-hydroxyethyl]oxiran-2-yl]ethenyl]oxiran-2-yl]prop-2-en-1-ol; depudecin; CBChromo1_000044; Oxiranemethanol, alpha-ethenyl-3-(2-(3-(1-hydroxyethyl)oxiranyl)ethenyl)-, (2S-(2R*(E(2R*(S*),3R*)),3R*(S*)))-; AC1O5Q7V	N/A	N/A	N/A	TTDS00095	Histone deacetylase 1	HDAC1	Q13547	3065	ENSG00000116478	inhibitor
DCL001100	Sodium butyrate	Butyric acid, sodium salt; CCRIS 7068; Butanoic acid, sodium salt; Sodium butyrate (USP); SODIUM BUTYRATE; Butyric acid sodium salt; Jsp003080; CHEMBL62381; CHEBI:200479; Sodium butanoate; AKOS003051490; AB1002593; Tetradecanoyl phorbol acetate/ sodium butyrate; AC1Q1V79; AR-1L5048; S1999_Selleck; Sodium propanecarboxylate; Sodium n-butyrate; MolPort-001-770-270; FT-0085069; CID9080; nchembio.275-comp12; NSC 174280; CID5222465; HSDB 5655; B5887_SIAL; tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA); OR8783; 62327-34-8; 303410_ALDRICH; I14-11038; D08998; TPA/BA; 156-54-7; LS-48173; AC1NQILT; EINECS 205-857-6; Butyric Acid, Na; Butyrate sodium; S0519; Butanoic acid, sodium salt (1:1); NSC174280	N/A	N/A	N/A	TTDS00095	Histone deacetylase 1	HDAC1	Q13547	3065	ENSG00000116478	inhibitor
DPR000183	RG2833	N/A	N/A	N/A	N/A	TTDS00095	Histone deacetylase 1	HDAC1	Q13547	3065	ENSG00000116478	inhibitor
DPR000152	SB-623	AC1OCG07; SB-623; CHEMBL491491; CID6918876; (E)-3-[1-(2-diethylaminoethyl)-2-phenethylbenzimidazol-5-yl]-N-hydroxyprop-2-enamide; CHEBI:557920	N/A	N/A	N/A	TTDS00095	Histone deacetylase 1	HDAC1	Q13547	3065	ENSG00000116478	inhibitor
DPR000157	SK-7068	CHEMBL152543; CID9799221; N-[[4-[(E)-2-(hydroxycarbamoyl)ethenyl]phenyl]methyl]-4-pyrrolidin-1-yl-benzamide; CHEBI:356088; SK-7068	N/A	N/A	N/A	TTDS00095	Histone deacetylase 1	HDAC1	Q13547	3065	ENSG00000116478	inhibitor
DPR000156	SK-7041	4-(dimethylamino)-N-[[4-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]phenyl]methyl]benzamide; SK-7041; IN-2001; CHEBI:356339; C497103; CHEMBL152133; AC1OCFS1; CID6918714	N/A	N/A	N/A	TTDS00095	Histone deacetylase 1	HDAC1	Q13547	3065	ENSG00000116478	inhibitor
DCL000207	PXD101	(2E)-N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]acrylamide; ZINC03818726; CHEMBL408513; EC-000.2286; 414864-00-9; S1085_Selleck; NSC726630; PXD 101; CHEBI:61076; 2-Propenamide, N-hydroxy-3-(3-((phenylamino)sulfonyl)phenyl)-; D08870; N-hydroxy-3-(3-(phenylsulfamoyl)phenyl)prop-2-enamide; (E)-N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide; PX-105684; PXD101; C487081; nchembio.313-comp10; PXD101, PX105684,  Belinostat; AC1OCFO7; PXD-101; CID6918638; PX 105684; (2E)-N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide; N-Hydroxy-3-(3-phenylsulphamoylphenyl)acrylamide; Belinostat; Belinostat (USAN/INN)	N/A	6918525	46525764	TTDS00095	Histone deacetylase 1	HDAC1	Q13547	3065	ENSG00000116478	inhibitor
DPR000138	FFF3	N/A	N/A	N/A	N/A	TTDS00095	Histone deacetylase 1	HDAC1	Q13547	3065	ENSG00000116478	inhibitor
DCL000994	SNDX-275	NCI60_038022; Entinostat, SNDX-275, MS-27-275, MS-275; CID4261; N-(2-aminophenyl)-4-(N-(pyridin-3-ylmethoxycarbonyl)aminomethyl)benzamide; 3-Pyridinylmethyl ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)carbamate; Entinostat; Entinostat (USAN/INN); MolPort-005-942-713; AC1L1HRM; CHEMBL27759; EC-000.2117; pyridin-3-ylmethyl{4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; NCGC00165833-01; NSC-706995; nchembio.275-comp4; ZINC01488870; S1053_Selleck; AC1Q5NOI; SNDX 275; IN1470; NSC706995; LS-185285; MS-27-275; pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate; 209783-80-2; Histone Deacetylase Inhibitor I; NCGC00165833-02; MS 275; N-(2-Aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)aminomethyl]benzamide; Carbamic acid, ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)-, 3-pyridinylmethyl ester; SNDX-275; pyridin-3-ylmethyl 4-(2-aminophenylcarbamoyl)benzylcarbamate; MS 27-275; Carbamic acid, [[4-[[(2-aminophenyl)carbaonyl]phenyl]methyl]-, 3-pyridinylmethyl ester; ms-275; AR-1L2666; nchembio.313-comp19; pyridin-3-ylmethyl {4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; C118739; D09338; Carbamic acid, [[4-[[(2-aminophenyl)amino]carbonyl]phenyl] methyl]-, 3-pyridinylmethyl ester	703-95-7	69711	12015232	TTDS00095	Histone deacetylase 1	HDAC1	Q13547	3065	ENSG00000116478	inhibitor
DPR000166	4SC-202	N/A	N/A	N/A	N/A	TTDS00095	Histone deacetylase 1	HDAC1	Q13547	3065	ENSG00000116478	inhibitor
DCL000317	Romidepsin	Probes2_000337; CID5352062; HDInhib_000006; CHEMBL343448; L-Valine, N-(3-hydroxy-7-mercapto-1-oxo-4-heptenyl)-D-valyl-D-cysteinyl-(Z)-2,3-didehydro-2-aminobutanoyl-, xi-lactone, cyclic (1-2)-disulfide, (S-(E))-; Chromadax (TN); Istodax; CHEBI:61080; Cyclo((2Z)-2-amino-2-butenoyl-L-valyl-(3S,4E)-3-hydroxy-7-mercapto-4-heptenoyl-D-valyl-D-cysteinyl), cyclic (3?5)-disulfide"; AC1NS1N3; FR901228; NSC630176; NSC 630176; C087123; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone; Probes1_000153; FR-901228; FK 228; Chromadax; nchembio.313-comp2; D06637; (1S,4S,7Z,10S,16E,21R)-7-Ethylidene-4,21-bis(1-methylethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo(8.7.6)tricos-16-ene-3,6,9,19,22-pentone; FK-901228; LS-161318; Romidepsin (USAN); FK228; Antibiotic FR 901228; C24H36N4O6S2; L-Valine, N-((3S,4E)-3-hydroxy-7-mercapto-1-oxo-4-heptenyl)-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoxyl-, (4-1)-lactone, cyclic (1-2)-disulfide; Romidepsin; NSC-630176; 128517-07-7; FK-228; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone; FR 901228	128517-07-7	5352062	47208288	TTDS00095	Histone deacetylase 1	HDAC1	Q13547	3065	ENSG00000116478	inhibitor
DPR000147	M-carboxycinnamic acid bishydroxamide	m-Carboxycinnamic Acid bis-Hydroxamide; N-hydroxy-3-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]benzamide; HDInhib_000062; cbha; AC1NS49A; Histone Deacetylase Inhibitor II; EC-000.2467; I14-11719; MolPort-006-391-953; CID5353484	N/A	N/A	N/A	TTDS00095	Histone deacetylase 1	HDAC1	Q13547	3065	ENSG00000116478	inhibitor
DPR000131	CHAP-15	N/A	N/A	N/A	N/A	TTDS00095	Histone deacetylase 1	HDAC1	Q13547	3065	ENSG00000116478	inhibitor
DCL001103	AN-9	C070441; CID60748; ((2,2-Dimethylpropanoyl)oxy)methyl butanoate; C10H18O4; AN 9; NSC39949; AN 9 (ion exchanger); butanoyloxymethyl 2,2-dimethylpropanoate; Pivalyloxymethyl butyrate; AC1L1TUK; 1,5-BIS[3-(DIETHYLAMINO)PROPIONAMIDO]ANTHRACENE-9,10-DIONE; CID236909; BRN 4861411; AC1L5XNF; 37380-45-3; AN-9; Butanoic acid, (2,2-dimethyl-1-oxopropoxy)methyl ester; Pivanex; AN9; LS-46268; AR-1J9462; 122110-53-6; AC1Q6JG6; CHEMBL100014; N-(5-amino-9,10-dioxoanthracen-1-yl)acetamide; n-(5-amino-9,10-dioxo-9,10-dihydroanthracen-1-yl)acetamide	N/A	N/A	N/A	TTDS00095	Histone deacetylase 1	HDAC1	Q13547	3065	ENSG00000116478	inhibitor
DCL000902	NVP-LAQ824	(E)-N-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide; NVP-LAQ824, Dacinostat, LAQ824; CHEMBL356066; AC1O62SB; NVP-LAQ 824; NVP-LAQ824; I14-11726; Dacinostat; UNII-V10P524501; EC-000.2469; 404951-53-7; LAQ-824; LS-192513; S1095_Selleck; CID6445533; 2-Propenamide, N-hydroxy-3-(4-(((2-hydroxyethyl)(2-(1H-indol-3-yl)ethyl)amino)methyl)phenyl)-, (2E)-; (2E)-N-hydroxy-3-[4-({(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enamide; nchembio.313-comp12	84371-65-3	55245	48416281	TTDS00095	Histone deacetylase 1	HDAC1	Q13547	3065	ENSG00000116478	inhibitor
DCL000929	Phenylbutyrate	Spectrum4_000092; 4-phenylbutyrate; Spectrum5_001003; CID20354; CPD000059104; AC1L2G3A; Spectrum2_001798; BRD-K67102207-236-01-0; I01-3326; DB02000; SAM002264634; NSC 295; .gamma.-Phenylbutyric acid; KBio1_001854; GAMMA-PHENYL-BUTYRIC ACID; FT-0082934; ZINC02037928; BSPBio_002484; AC-3254; Benzenebutanoic acid; AI3-12065; SPBio_001755; gamma-Phenylbutyric acid; TL8001458; AI3-11761; AC1Q5W0X; Phenylbutyrate; Butyric acid, 4-phenyl- (8CI); 4-PHENYLBUTYRIC ACID; NSC295; 2ay7; 4-phenylbutans; Butanoic acid, phenyl ester; Benzenebutyric acid; NCGC00018113-01; Butyric acid, 4-phenyl-; LS-173716; SpecPlus_000814; bmse000701; Spectrum3_000782; EINECS 217-341-8; CID4775; 4-Phenylbutanoic acid; DivK1c_006910; 4346-18-3; KBio2_001811; AKOS002952627; P0643; 1821-12-1; KBioGR_000384; OBKXEAXTFZPCHS-UHFFFAOYSA-; EINECS 224-405-9; InChI=1/C10H12O2/c11-10(12)8-4-7-9-5-2-1-3-6-9/h1-3,5-6H,4,7-8H2,(H,11,12); 2-methyl-1-phenyl-propan-2-amine; AKOS000154540; MLS000069408; AC1L1IXE; KBio2_006947; P21005_ALDRICH; MolPort-000-871-587; Spectrum_001331; MLS001076482; SBB008452; NCI60_002455; 4-PHENYL-BUTANOIC ACID; CHEBI:41500; phenyl butanoate; LS-46421; HDInhib_000004; 1716-12-7 (hydrochloride); NCI60_020145; AC1Q75DT; .omega.-Phenylbutanoic acid; phenyl butyrate; BRD-K67102207-001-02-6; AR-1G4411; AB1001924; CHEMBL1469; KBioSS_001811; SMR000059104; Butyric acid, phenyl ester; omega-Phenylbutanoic acid; AC1Q75DU; 1-Phenylbutyric acid; KBio2_004379; FR-2080; KBio3_001704	90315-82-5	2733848	12051860	TTDS00095	Histone deacetylase 1	HDAC1	Q13547	3065	ENSG00000116478	inhibitor
DAP000428	Ardeparin	Heparin sodium 5,000 units in sodium chloride 0.45%; Isocinnamic acid; Reviparin; EINECS 232-681-7; 37324-73-5; HSDB 3094; Heparin sodium in plastic container; 101921-26-0; Heparin sodium 5,000 units in sodium chloride 0.9%; FR 860; 12656-11-0; Vitrum AB; Eparina; Vetren; ALFA 87-120; Liquaemin Sodium; ALFA 88-247; Sandoparin; cis-Cinnamic acid; Tinzaparin sodium; AC1L1ROY; Lioton 1000; Heparin sodium 2,000 units in dextrose 5% in plastic container; Parvoparin; Hepathrom; Heparin sodium 25,000 units and dextrose 5% in plastic container; Heparin sodium 10,000 units in sodium chloride 0.45%; 91449-79-5; Parnaparin; Heparin sodium 5,000 units and sodium chloride 0.9% in plastic container; NSC174025; 2-Propenoic acid, 3-phenyl-, (Z)-; Heparin sodium 10,000 units in dextrose 5%; Minolteparin sodium; Fragmin IV; Heparin sodium; Nadroparine; Logiparin; Heparin sodium 1,000 units in sodium chloride 0.9% in plastic container; Allocinnamic acid; MolPort-003-760-257; Heparin sodium 5,000 units in sodium chloride 0.9% in plastic container; Heparin sodium 1,000 units and sodium chloride 0.9% in plastic container; LHN 1; 913079-23-9; Heparin sodium 5,000 units in dextrose 5% in plastic container; Heparin sodium preservative Free; Nadroparin; Clivarin; OP 386; alpha-Heparin; Heparin sodium 10,000 units in sodium chloride 0.9%; Heparin CY 216; Thromboliquine; Cinnamic acid, (Z)-; Heparinate; cis-.beta.-Carboxystyrene; Heparinic acid; Kabi 2165; heparin; Heparin Lock Flush; Sodium acid heparin; Clivarine; Tinzaparin; Heparin sodium 20,000 units and dextrose 5% in plastic container; Depo-Heparin; Sodium heparinate; Ro 11; Fraxiparin; Hep-Lock; Certoparin; Heparina [INN-Spanish]; OP 622; Heparin natrium; Heparinum natricum; 104521-37-1; Subeparin; 9045-22-1; Hed-heparin; Ardeparin sodium; Multiparin; ALFA 87-163; 102785-31-9; 11078-24-3; 9041-08-1; Pabyrin; Heparin sodium 10,000 units in dextrose 5% in plastic container; Parnaparin sodium; Dalteparin; Heparin sulfate; Heparin sodium 12,500 units in sodium chloride 0.45% in plastic container; Panheprin; Bemiparin; Heparin Lock Flush in plastic container; Heparin sodium 25,000 units in sodium chloride 0.9% in plastic container; Ardeparin; Heparin sodium 1,000 units in dextrose 5% in plastic container; Heparina; KB 101; Octaparin; 9075-96-1; Heparin sodium 12,500 units in sodium chloride 0.9%; Liquaemin; Liquaemin Lock Flush; 11129-39-8; UNII-E47C0NF7LV; Heparin sodium 25,000 units in sodium chloride 0.45% in plastic container; CID8784; Eparina [DCIT]; Inno-Hep; Dalteparin sodium; Heparin sodium 25,000 units in dextrose 5% in plastic container; Heparin sodium 2,000 units in sodium chloride 0.9% in plastic container; 102-94-3; Heparin sodium 25,000 units in dextrose 5%; Bemiparin sodium; Heparin sodium 25,000 units in sodium chloride 0.9%; Heparinum [INN-Latin]; ALFA 87-198; Sublingula; ALFA 87-81; CY 216; Pularin; Fragmin A; Heparin sodium 12,500 units in dextrose 5%; Fluxum; Heparine [INN-French]; UNII-3S182ET3UA; UNII-12M44VTJ7B; Heparinum; Heparin sodium 20,000 units in dextrose 5% in plastic container; Fragmin B; Heparine; Heparin Lock Flush preservative free in plastic container; Sodium heparin; Novoheparin; Triofiban; H 2149; Innohep; UNII-T2410KM04A; Hepflush-10; Reviparin sodium; Hep-Lock U/P; Cy 222; Lipo-hepin; Arteven; WY 90493RD; Heparin sodium 2,000 units and sodium chloride 0.9% in plastic container; Hep Flush Kit in plastic container; Enoxaparin sodium; Liquaemin sodium preservative free; UNII-ZZ45AB24CA; Heparin, sodium salt; Liquemin; Heparin Lock Flush preservative free; Heparin sodium 12,500 units in dextrose 5% in plastic container	9005-49-6	772	3664	TTDS00378	Heparin cofactor II	HC-II;HLS2;Protease inhibitor leuserpin 2	P05546	3053	ENSG00000099937	binder
DCL000415	ABT-263	Navitoclax; ABT 263; 1000696-69-4; 923564-51-6; Benzamide, 4-(4-((2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohexen-1-yl)methyl)-1-piperazinyl)-N-((4-(((1R)-3-(4-morpholinyl)-1-((phenylthio)methyl)propyl)amino)-3-((trifluoromethyl)sulfonyl)phenyl)sulfonyl)-; CHEMBL443684; CHEBI:608147; ABT263, Navitoclax; I06-2050; S1001_Selleck; BRD-K82746043-001-03-7; BRD-K82746043-001-02-9; MolPort-006-391-499; 4-(4-{[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({4-({(1R)-3-morpholin-4-yl-1-[(phenylsulfanyl)methyl]propyl}amino)-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)benzamide; BRD-K82746043-001-01-1; ABT-263	119229-65-1	3081185	44854467	TTDC00244	Bcl-2-like protein 2	Apoptosis regulator Bcl-W;Bcl2-L-2	Q92843	599	ENSG00000129473; ENSG00000258643	inhibitor
